PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Guerrieri, M; Francavilla, B; Fiorelli, D; Nuccetelli, M; Passali, FM; Coppeta, L; Somma, G; Bernardini, S; Magrini, A; Di Girolamo, S				Guerrieri, Mariapia; Francavilla, Beatrice; Fiorelli, Denise; Nuccetelli, Marzia; Passali, Francesco Maria; Coppeta, Luca; Somma, Giuseppina; Bernardini, Sergio; Magrini, Andrea; Di Girolamo, Stefano			Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection	VACCINES			English	Article						IgA; nasal; salivary; SARS-CoV-2; vaccine; mucosal; immunity; BNT162b2; COVID-19; IgG-RBD	IGA; ANTIBODIES; PROTEIN	SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic. Approved mRNA COVID-19 vaccines are well known to induce a serum antibody responses against the spike protein and its RBD. Mucosal immunity plays a major role in the fight against COVID-19 directly at the site of virus entry; however, vaccine abilities to elicit mucosal immune responses have not been reported. We detected anti-SARS-CoV-2 IgA-S1 and IgG-RBD in three study populations (healthy controls, vaccinated subjects, and subjects recovered from COVID-19 infection) on serum, saliva, and nasal secretions using two commercial immunoassays (ELISA for IgA-S1 and chemiluminescent assay for IgG-RBD). Our results show that the mRNA BNT162b2 vaccine Comirnaty (Pfizer/BioNTech, New York, NY, USA) determines the production of nasal and salivary IgA-S1 and IgG-RBD against SARS-CoV-2. This mucosal humoral immune response is stronger after the injection of the second vaccine dose compared to subjects recovered from COVID-19. Since there is a lack of validated assays on saliva and nasal secretions, this study shows that our pre-analytical and analytical procedures are consistent with the data. Our findings indicate that the mRNA COVID-19 vaccine elicits antigen-specific nasal and salivary immune responses, and that mucosal antibody assays could be used as candidates for non-invasive monitoring of vaccine-induced protection against viral infection.	[Guerrieri, Mariapia; Francavilla, Beatrice; Passali, Francesco Maria; Di Girolamo, Stefano] Univ Roma Tor Vergata, Dept Otorhinolaryngol, I-00100 Rome, Italy; [Fiorelli, Denise; Nuccetelli, Marzia; Bernardini, Sergio] Univ Roma Tor Vergata, Dept Expt Med, I-00100 Rome, Italy; [Coppeta, Luca; Somma, Giuseppina; Magrini, Andrea] Univ Roma Tor Vergata, Dept Occupat Med, I-00100 Rome, Italy; [Bernardini, Sergio] Tor Vergata Univ Hosp, Dept Lab Med, I-00100 Rome, Italy		Francavilla, B (通讯作者)，Univ Roma Tor Vergata, Dept Otorhinolaryngol, I-00100 Rome, Italy.	Mariapia.guerrieri@ptvonline.it; beatrice.francavilla@ptvonline.it; denise.fiorelli@ptvonline.it; Marzia.nuccetelli@ptvonline.it; passali@med.uniroma2.it; luca.coppeta@ptvonline.it; giuseppina.somma@ptvonline.it; sergio.bernardini@ptvonline.it; andrea.magrini@ptvonline.it; stefano.di.girolamo@uniroma2.it	Francavilla, Beatrice/AAC-8105-2022	PASSALI, Francesco Maria/0000-0003-4032-8230			Aita A, 2020, CLIN CHIM ACTA, V510, P717, DOI 10.1016/j.cca.2020.09.018; Anand P, 2021, PATIENT SAF SURG, V15, DOI 10.1186/s13037-021-00291-9; Bagga B, 2015, J INFECT DIS, V212, P1719, DOI 10.1093/infdis/jiv281; Bar-Zeev N, 2020, LANCET, V396, P448, DOI 10.1016/S0140-6736(20)31611-1; Brandtzaeg P, 2013, J ORAL MICROBIOL, V5, DOI 10.3402/jom.v5i0.20401; Cervia C, 2021, J ALLERGY CLIN IMMUN, V147, P545, DOI 10.1016/j.jaci.2020.10.040; Chao YX, 2020, BRAIN BEHAV IMMUN, V87, P182, DOI 10.1016/j.bbi.2020.05.057; Clements JD, 2016, CLIN VACCINE IMMUNOL, V23, P438, DOI 10.1128/CVI.00214-16; Cristiano A, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108215; Deeks JJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013652; Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090; Flament H, 2021, EUR J IMMUNOL, V51, P298, DOI 10.1038/s41590-021-00870-z; Froberg J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25949-x; Froberg J, 2021, CURR OPIN INFECT DIS, V34, P181, DOI 10.1097/QCO.0000000000000724; Galipeau Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.610688; Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; Infantino M, 2021, INT IMMUNOPHARMACOL, V100, DOI 10.1016/j.intimp.2021.108095; Infantino M, 2021, J MED VIROL, V93, P1436, DOI 10.1002/jmv.26422; Isho B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe5511; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441; Ketas Thomas J, 2021, bioRxiv, DOI [10.20411/pai.v6i1.441, 10.1101/2021.03.11.434841]; Li LT, 2021, INT J BIOL MACROMOL, V190, P409, DOI 10.1016/j.ijbiomac.2021.08.232; Lippi G, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11060941; Ma H, 2020, CELL MOL IMMUNOL, V17, P773, DOI 10.1038/s41423-020-0474-z; Meng T., 2020, BIORXIV, DOI 10.1101/2020.02.08.926006; Mortari EP, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10102541; Orellana B., 2020, CIMEL, V27, P35, DOI [10.23961/cimel.v27i2.1663, DOI 10.23961/CIMEL.V27I2.1663]; Paces J, 2020, PHYSIOL RES, V69, P379, DOI 10.33549/physiolres.934492; Park JG, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102941; Pearson Claire F, 2021, Oxf Open Immunol, V2, piqab002, DOI 10.1093/oxfimm/iqab002; Pereira NL, 2021, MAYO CLIN PROC, V96, P446, DOI 10.1016/j.mayocp.2020.11.024; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Randad PR, 2021, J CLIN MICROBIOL, V59, DOI [10.1101/2020.05.24.20112300, 10.1128/JCM.02204-20]; Roda A, 2021, BIOSENS BIOELECTRON, V172, DOI 10.1016/j.bios.2020.112765; Russell MW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611337; Saad-Roy CM, 2021, SCIENCE, V372, P363, DOI 10.1126/science.abg8663; Samrat SK, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198141; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Varadhachary Atul, 2020, medRxiv, DOI 10.1101/2020.08.07.20170258; Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI [10.1172/JCI138759, 10.1172/JCI138759.]	42	2	2	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1499	10.3390/vaccines9121499			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YF0OA	34960244	Green Published, gold			2022-04-29	WOS:000741514800001
J	Gupta, KH; Nowicki, C; Giurini, EF; Marzo, AL; Zloza, A				Gupta, Kajal H.; Nowicki, Christina; Giurini, Eileena F.; Marzo, Amanda L.; Zloza, Andrew			Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy	VACCINES			English	Article						bacterial therapy; bacteriotherapy; tumor targeting bacteria; cancer immunotherapy; therapeutic bacteria	ATTENUATED SALMONELLA-TYPHIMURIUM; ENTERICA SEROVAR TYPHIMURIUM; III SECRETION SYSTEM; IN-SITU DELIVERY; LISTERIA-MONOCYTOGENES; ESCHERICHIA-COLI; GENE-THERAPY; PHASE-I; LACTOCOCCUS-LACTIS; ANAEROBIC-BACTERIA	Currently approximately 10 million people die each year due to cancer, and cancer is the cause of every sixth death worldwide. Tremendous efforts and progress have been made towards finding a cure for cancer. However, numerous challenges have been faced due to adverse effects of chemotherapy, radiotherapy, and alternative cancer therapies, including toxicity to non-cancerous cells, the inability of drugs to reach deep tumor tissue, and the persistent problem of increasing drug resistance in tumor cells. These challenges have increased the demand for the development of alternative approaches with greater selectivity and effectiveness against tumor cells. Cancer immunotherapy has made significant advancements towards eliminating cancer. Our understanding of cancer-directed immune responses and the mechanisms through which immune cells invade tumors have extensively helped us in the development of new therapies. Among immunotherapies, the application of bacteria and bacterial-based products has promising potential to be used as treatments that combat cancer. Bacterial targeting of tumors has been developed as a unique therapeutic option that meets the ongoing challenges of cancer treatment. In comparison with other cancer therapeutics, bacterial-based therapies have capabilities for suppressing cancer. Bacteria are known to accumulate and proliferate in the tumor microenvironment and initiate antitumor immune responses. We are currently well-informed regarding various methods by which bacteria can be manipulated by simple genetic engineering or synthetic bioengineering to induce the production of anti-cancer drugs. Further, bacterial-based cancer therapy (BBCT) can be either used as a monotherapy or in combination with other anticancer therapies for better clinical outcomes. Here, we review recent advances, current challenges, and prospects of bacteria and bacterial products in the development of BBCTs.	[Gupta, Kajal H.; Nowicki, Christina; Giurini, Eileena F.; Marzo, Amanda L.; Zloza, Andrew] Rush Univ, Med Ctr, Dept Internal Med, Div Hematol Oncol & Cell Therapy, Chicago, IL 60612 USA; [Gupta, Kajal H.; Nowicki, Christina; Giurini, Eileena F.; Marzo, Amanda L.; Zloza, Andrew] Rush Univ, Med Ctr, Dept Internal Med, Div Translat & Precis Med, Chicago, IL 60612 USA		Zloza, A (通讯作者)，Rush Univ, Med Ctr, Dept Internal Med, Div Hematol Oncol & Cell Therapy, Chicago, IL 60612 USA.; Zloza, A (通讯作者)，Rush Univ, Med Ctr, Dept Internal Med, Div Translat & Precis Med, Chicago, IL 60612 USA.	Kajal_Gupta@rush.edu; Christina_A_Nowicki@rush.edu; Eileena_F_Giurini@rush.edu; Amanda_Marzo@rush.edu; andrew_zloza@rush.edu		Gupta, Kajal/0000-0002-0665-1539			Abdolalipour E, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104207; Afkhami F, 2011, IEEE ENG MED BIO, P6668, DOI 10.1109/IEMBS.2011.6091644; Ahmad S, 2011, J UROLOGY, V186, P687, DOI 10.1016/j.juro.2011.03.139; Akin D, 2007, NAT NANOTECHNOL, V2, P441, DOI 10.1038/nnano.2007.149; Akoachere JFTK, 2009, J HEALTH POPUL NUTR, V27, P612; Al-Ani AW, 2019, NANOMED-NANOTECHNOL, V20, DOI 10.1016/j.nano.2019.04.008; Al-Ramadi BK, 2009, CLIN IMMUNOL, V130, P89, DOI 10.1016/j.clim.2008.08.021; Antonelli AC, 2020, P NATL ACAD SCI USA, V117, P18627, DOI 10.1073/pnas.2004421117; Asoudeh-Fard A, 2017, BIOIMPACTS, V7, P193, DOI 10.15171/bi.2017.22; Bahey-El-Din M, 2010, CURR GENE THER, V10, P34, DOI 10.2174/156652310790945557; Bakardjiev AI, 2004, INFECT IMMUN, V72, P489, DOI 10.1128/IAI.72.1.489-497.2004; Barbe S, 2005, FEMS MICROBIOL LETT, V246, P67, DOI 10.1016/j.femsle.2005.03.037; Barbe S, 2006, J APPL MICROBIOL, V101, P571, DOI 10.1111/j.1365-2672.2006.02886.x; Basu P, 2018, INT J GYNECOL CANCER, V28, P764, DOI 10.1097/IGC.0000000000001235; Bazylinski DA, 2013, INT J SYST EVOL MICR, V63, P801, DOI 10.1099/ijs.0.038927-0; Biot C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003586; Brockstedt DG, 2004, P NATL ACAD SCI USA, V101, P13832, DOI 10.1073/pnas.0406035101; Brown JM, 1998, CANCER RES, V58, P1408; CAMILLI A, 1993, MOL MICROBIOL, V8, P143, DOI 10.1111/j.1365-2958.1993.tb01211.x; Cano-Garrido O, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0313-6; Carlisle R, 2013, THER DELIV, V4, P1213, DOI [10.4155/TDE.13.94, 10.4155/tde.13.94]; Carvalho F, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00048; Casadevall A, 2009, J WATER HEALTH, V7, pS2, DOI 10.2166/wh.2009.036; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; CHAGNON A, 1972, CANCER, V29, P431, DOI 10.1002/1097-0142(197202)29:2<431::AID-CNCR2820290226>3.0.CO;2-Z; Chakrabarty AM, 2003, J BACTERIOL, V185, P2683, DOI 10.1128/JB.185.9.2683-2686.2003; Chang WH, 2002, NUTR CANCER, V43, P214, DOI 10.1207/S15327914NC432_12; Chen WF, 2018, ACS NANO, V12, P5995, DOI 10.1021/acsnano.8b02235; Cheng X, 2016, ONCOTARGET, V7, P77916, DOI 10.18632/oncotarget.12844; Cheong I, 2006, SCIENCE, V314, P1308, DOI 10.1126/science.1130651; Cheong I, 2009, METHOD ENZYMOL, V465, P251, DOI 10.1016/S0076-6879(09)65013-8; Chiang CJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97457-3; Chowdhury S, 2019, NAT MED, V25, P1057, DOI 10.1038/s41591-019-0498-z; Clairmont C, 2000, J INFECT DIS, V181, P1996, DOI 10.1086/315497; Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015; Coley WB, 1893, AM J MED SCI, V105, P487; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; Connell HC, 1935, CAN MED ASSOC J, V33, P364; Cronin M, 2010, MOL THER, V18, P1397, DOI 10.1038/mt.2010.59; Cross AS, 2008, CRIT CARE, V12, DOI 10.1186/cc7127; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Decatur AL, 2000, SCIENCE, V290, P992, DOI 10.1126/science.290.5493.992; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Drozdz M, 2020, LIFE SCI, V261, DOI 10.1016/j.lfs.2020.118296; Elsayad K, 2015, INT J RADIAT ONCOL, V93, P1077, DOI 10.1016/j.ijrobp.2015.08.041; Epaulard O, 2006, MOL THER, V14, P656, DOI 10.1016/j.ymthe.2006.06.011; Farley MM, 2016, J BACTERIOL, V198, P1186, DOI 10.1128/JB.00901-15; Felfoul O, 2016, NAT NANOTECHNOL, V11, P941, DOI [10.1038/nnano.2016.137, 10.1038/NNANO.2016.137]; Felgner Sebastian, 2016, Int J Microbiol, V2016, P8451728, DOI 10.1155/2016/8451728; Felgner S, 2016, MBIO, V7, DOI 10.1128/mBio.01220-16; Fensterle J, 2008, CANCER GENE THER, V15, P85, DOI 10.1038/sj.cgt.7701109; Forbes NS, 2010, NAT REV CANCER, V10, P784, DOI 10.1038/nrc2934; Fox ME, 1996, GENE THER, V3, P173; Frahm M, 2015, MBIO, V6, DOI 10.1128/mBio.00254-15; Fritz SE, 2016, VET MED SCI, V2, P179, DOI 10.1002/vms3.32; Fronzes R, 2009, NAT REV MICROBIOL, V7, P703, DOI 10.1038/nrmicro2218; Fujimori Minoru, 2006, Breast Cancer, V13, P27, DOI 10.2325/jbcs.13.27; Ganai S, 2009, BRIT J CANCER, V101, P1683, DOI 10.1038/sj.bjc.6605403; Gao S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60396-6; Gardlik R, 2010, IDRUGS, V13, P701; Gilert A, 2016, BIOMED MICRODEVICES, V18, DOI 10.1007/s10544-016-0050-6; Glomski IJ, 2003, INFECT IMMUN, V71, P6754, DOI 10.1128/IAI.71.12.6754-6765.2003; Glomski IJ, 2002, J CELL BIOL, V156, P1029, DOI 10.1083/jcb.200201081; Gniadek TJ, 2020, J IMMUNOTHER, V43, P217, DOI 10.1097/CJI.0000000000000325; Griffin ME, 2021, SCIENCE, V373, P1040, DOI 10.1126/science.abc9113; Grillot-Courvalin C, 2002, CELL MICROBIOL, V4, P177, DOI 10.1046/j.1462-5822.2002.00184.x; Groot AJ, 2006, LAB INVEST, V86, P345, DOI 10.1038/labinvest.3700395; Gunn GR, 2001, J IMMUNOL, V167, P6471, DOI 10.4049/jimmunol.167.11.6471; Heimann DM, 2003, J IMMUNOTHER, V26, P179, DOI 10.1097/00002371-200303000-00011; Hense M, 2001, CELL MICROBIOL, V3, P599, DOI 10.1046/j.1462-5822.2001.00138.x; HEPPNER F, 1978, ACTA NEUROCHIR, V42, P123, DOI 10.1007/BF01406639; Hibberd AA, 2017, BMJ OPEN GASTROENTER, V4, DOI 10.1136/bmjgast-2017-000145; Huang TX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110826; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; Jain RK, 2001, P NATL ACAD SCI USA, V98, P14748, DOI 10.1073/pnas.261606598; Jellbauer S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034214; Jiang SN, 2010, MOL THER, V18, P635, DOI 10.1038/mt.2009.295; Johnson PV, 2011, MICROBIOL IMMUNOL, V55, P304, DOI 10.1111/j.1348-0421.2011.00322.x; Kalaora S, 2021, NATURE, V592, P138, DOI 10.1038/s41586-021-03368-8; Kamarajan P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131008; Kikuchi T, 2017, BIOCHEM BIOPH RES CO, V493, P306, DOI 10.1016/j.bbrc.2017.09.026; Kim SH, 2008, BRIT J CANCER, V99, P741, DOI 10.1038/sj.bjc.6604526; Kim YJ, 2019, ARTIF CELL NANOMED B, V47, P30, DOI 10.1080/21691401.2018.1541900; Kitagawa K, 2019, MOL CANCER THER, V18, P980, DOI 10.1158/1535-7163.MCT-18-1105; KIYOKAWA T, 1989, CANCER RES, V49, P4042; Kono M, 2017, J ORAL MAXIL SURG, V75, P336, DOI 10.1016/j.joms.2016.08.013; Kreitman RJ, 2009, CLIN CANCER RES, V15, P5274, DOI 10.1158/1078-0432.CCR-09-0062; Kullberg M, 2014, NANOMED-NANOTECHNOL, V10, P1253, DOI 10.1016/j.nano.2014.02.013; Le DT, 2015, J CLIN ONCOL, V33, P1325, DOI 10.1200/JCO.2014.57.4244; Lee CH, 2014, GENE THER, V21, P309, DOI 10.1038/gt.2013.86; Leshem Y, 2019, TOXINS, V11, DOI 10.3390/toxins11010020; Leventhal DS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16602-0; Lewen S, 2008, CANCER IMMUNOL IMMUN, V57, P507, DOI 10.1007/s00262-007-0389-x; Li T, 2015, LIVER INT, V35, P1416, DOI 10.1111/liv.12644; Li X, 2003, CANCER GENE THER, V10, P105, DOI 10.1038/sj.cgt.7700530; Li YM, 2010, TOXINS, V2, P2645, DOI 10.3390/toxins2112645; Li Z, 2013, MOL MED REP, V7, P1215, DOI 10.3892/mmr.2013.1308; Liang K, 2018, CANCER GENE THER, V25, P167, DOI 10.1038/s41417-018-0021-6; Lim D, 2017, ONCOTARGET, V8, P37550, DOI 10.18632/oncotarget.17197; Lin IYC, 2015, VACCINES-BASEL, V3, P940, DOI 10.3390/vaccines3040940; Liu CF, 2010, J FOOD DRUG ANAL, V18, P77; Loeffler M, 2008, J NATL CANCER I, V100, P1113, DOI 10.1093/jnci/djn205; Lukasiewicz K, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2397808; Luo M, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.109929; Duong MTQ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0297-0; Mann K, 2016, CANCER GENE THER, V23, P221, DOI 10.1038/cgt.2016.21; Mansour M, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-020-00995-8; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; McCarthy Edward F, 2006, Iowa Orthop J, V26, P154; Meng JZ, 2010, CLIN VACCINE IMMUNOL, V17, P889, DOI 10.1128/CVI.00044-10; Mengesha A, 2007, FRONT BIOSCI-LANDMRK, V12, P3880, DOI 10.2741/2357; Mesa-Pereira B, 2015, MICROB BIOTECHNOL, V8, P169, DOI 10.1111/1751-7915.12153; Mi Z, 2019, J CANCER, V10, P4765, DOI 10.7150/jca.32650; Michalska M, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00963; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Miyake K, 2019, ARCH GYNECOL OBSTET, V299, P1683, DOI 10.1007/s00404-019-05147-3; Miyazaki M, 2015, J CONTROL RELEASE, V213, pE73, DOI 10.1016/j.jconrel.2015.05.122; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; Na HS, 2006, VACCINE, V24, P2027, DOI 10.1016/j.vaccine.2005.11.031; Nallar SC, 2017, CYTOKINE, V89, P160, DOI 10.1016/j.cyto.2016.01.002; Nemunaitis J, 2003, CANCER GENE THER, V10, P737, DOI 10.1038/sj.cgt.7700634; Ngo N, 2019, FUTURE ONCOL, V15, P3861, DOI 10.2217/fon-2019-0374; Nguyen VH, 2010, CANCER RES, V70, P18, DOI 10.1158/0008-5472.CAN-09-3453; Nishikawa H, 2006, J CLIN INVEST, V116, P1946, DOI 10.1172/JCI28045; O'Callaghan A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00925; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ogita S, 1996, J PEDIATR SURG, V31, P477, DOI 10.1016/S0022-3468(96)90478-9; Oh NS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192021; Ohta N, 2010, LARYNGOSCOPE, V120, P2193, DOI 10.1002/lary.21141; Ohta N, 2010, ACTA OTO-LARYNGOL, V130, P1287, DOI 10.3109/00016489.2010.483480; Ohta T, 2000, CARCINOGENESIS, V21, P937, DOI 10.1093/carcin/21.5.937; Olino K, 2012, ANN SURG ONCOL, V19, pS597, DOI 10.1245/s10434-011-2037-0; Panthel K, 2006, MICROBES INFECT, V8, P2539, DOI 10.1016/j.micinf.2006.07.004; Park BW, 2017, ACS NANO, V11, P8910, DOI 10.1021/acsnano.7b03207; Park D, 2014, BIOTECHNOL BIOENG, V111, P134, DOI 10.1002/bit.25007; Park J, 2020, MOLECULES, V25, DOI 10.3390/molecules25173895; Park SJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep03394; PARKER RC, 1947, P SOC EXP BIOL MED, V66, P461; Paton AW, 2012, TRENDS MOL MED, V18, P417, DOI 10.1016/j.molmed.2012.05.006; Pawelek JM, 1997, CANCER RES, V57, P4537; Radoshevich L, 2018, NAT REV MICROBIOL, V16, P32, DOI 10.1038/nrmicro.2017.126; Rafelski SM, 2006, MOL MICROBIOL, V59, P1262, DOI 10.1111/j.1365-2958.2006.05025.x; Raj R, 2017, APPL MICROBIOL BIOT, V101, P5439, DOI 10.1007/s00253-017-8298-1; Rajoka MSR, 2019, FOOD RES INT, V123, P286, DOI 10.1016/j.foodres.2019.05.002; Roberts NJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008982; Roider E, 2011, CANCER IMMUNOL IMMUN, V60, P371, DOI 10.1007/s00262-010-0950-x; Russmann H, 1998, SCIENCE, V281, P565, DOI 10.1126/science.281.5376.565; Ryan RM, 2009, GENE THER, V16, P329, DOI 10.1038/gt.2008.188; Schmitz-Winnenthal FH, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1303584; Sedighi M, 2019, CANCER MED-US, V8, P3167, DOI 10.1002/cam4.2148; Semenov AV, 2011, J ENVIRON MANAGE, V92, P780, DOI 10.1016/j.jenvman.2010.10.031; Sewell DA, 2004, CANCER RES, V64, P8821, DOI 10.1158/0008-5472.CAN-04-1958; Shafiee F, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02340; Shahabi V, 2008, CANCER IMMUNOL IMMUN, V57, P1301, DOI 10.1007/s00262-008-0463-z; Shapira A, 2010, TOXINS, V2, P2519, DOI 10.3390/toxins2112519; Shi L, 2016, AMB EXPRESS, V6, DOI 10.1186/s13568-016-0226-8; Shida K, 2013, INDIAN J MED RES, V138, P808; Singer HM, 2012, MBIO, V3, DOI 10.1128/mBio.00115-12; Song SY, 2018, INFECT AGENTS CANCER, V13, DOI 10.1186/s13027-018-0180-y; Sorenson BS, 2008, CLIN ORTHOP RELAT R, V466, P1285, DOI 10.1007/s11999-008-0243-2; St Jean AT, 2008, CURR OPIN BIOTECH, V19, P511, DOI 10.1016/j.copbio.2008.08.004; St Jean AT, 2014, MOL THER, V22, P1266, DOI 10.1038/mt.2014.36; Steidler L, 2003, NAT BIOTECHNOL, V21, P785, DOI 10.1038/nbt840; Takagi A, 2015, INT J MOL SCI, V16, P10907, DOI 10.3390/ijms160510907; Tamang J.P., 2014, ENCY FOOD MICROBIOLO, V2nd ed., P250, DOI [10.1016/B978-0-12-384730-0.00038-0, DOI 10.1016/B978-0-12-384730-0.00038-0]; TANNOCK IF, 1989, CANCER RES, V49, P4373; Theys J, 1999, APPL ENVIRON MICROB, V65, P4295; Theys J, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.39; Toso JF, 2002, J CLIN ONCOL, V20, P142, DOI 10.1200/JCO.2002.20.1.142; Nguyen VD, 2016, SENSOR ACTUAT B-CHEM, V224, P217, DOI 10.1016/j.snb.2015.09.034; van Geel-Schutten GH, 1998, APPL MICROBIOL BIOT, V50, P697, DOI 10.1007/s002530051353; Van Mellaert L, 2006, TRENDS MICROBIOL, V14, P190, DOI 10.1016/j.tim.2006.02.002; van Pijkeren JP, 2010, HUM GENE THER, V21, P405, DOI 10.1089/hum.2009.022; Veena VK, 2015, APOPTOSIS, V20, P1281, DOI 10.1007/s10495-015-1162-9; Wang L, 2017, GENE THER, V24, P699, DOI 10.1038/gt.2017.74; Wang Q, 2020, APPL MICROBIOL BIOT, V104, P5915, DOI 10.1007/s00253-020-10621-z; Wei C, 2016, TECHNOL CANCER RES T, V15, P498, DOI 10.1177/1533034615581977; Wei MQ, 2008, CANCER LETT, V259, P16, DOI 10.1016/j.canlet.2007.10.034; Wei MQ, 2007, EUR J CANCER, V43, P490, DOI 10.1016/j.ejca.2006.10.005; Wolf P, 2009, INT J MED MICROBIOL, V299, P161, DOI 10.1016/j.ijmm.2008.08.003; Wood LM, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00051; Wood LM, 2008, IMMUNOL RES, V42, P233, DOI 10.1007/s12026-008-8087-0; Xiong GS, 2010, INT J CANCER, V126, P2622, DOI 10.1002/ijc.24957; Yazawa K, 2000, CANCER GENE THER, V7, P269, DOI 10.1038/sj.cgt.7700122; Yazdi MH, 2013, DARU, V21, DOI 10.1186/2008-2231-21-33; Yoon WS, 2011, APPL MICROBIOL BIOT, V89, P1807, DOI 10.1007/s00253-010-3006-4; Yu B, 2012, SCI REP-UK, V2, DOI 10.1038/srep00436; Zahaf NI, 2017, TOXINS, V9, DOI 10.3390/toxins9080236; Zhang Y, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0010498, 10.1371/journal.pone.0012559, 10.1371/journal.pone.0015300, 10.1371/journal.pone.0015570]; Zhang YL, 2018, THERANOSTICS, V8, P1690, DOI 10.7150/thno.21575; Zhao M, 2005, P NATL ACAD SCI USA, V102, P755, DOI 10.1073/pnas.0408422102; Zheng JH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aak9537; Zheng Jin Hai, 2016, Chonnam Med J, V52, P173, DOI 10.4068/cmj.2016.52.3.173; Zheng Q, 2017, MOL ONCOL, V11, P584, DOI 10.1002/1878-0261.12056; Zu C, 2014, CRIT REV MICROBIOL, V40, P225, DOI 10.3109/1040841X.2013.776511	195	1	1	11	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1497	10.3390/vaccines9121497			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0VR	34960243	Green Published, gold			2022-04-29	WOS:000737380800001
J	Sidanin, I; Njegovan, BR; Sokolovic, B				Sidanin, Iva; Njegovan, Biljana Ratkovic; Sokolovic, Bojana			Students' Views on Vaccination against COVID-19 Virus and Trust in Media Information about the Vaccine: The Case of Serbia	VACCINES			English	Article						COVID-19 vaccinations; vaccines; students; media; Republic of Serbia	INTENTIONS	Mass immunization of the citizens of the Republic of Serbia began in January 2021. Information on the significance, manner, advantages and consequences of this process was intensively distributed through all communication channels, with the media playing a key role. According to the data of the official institutions for the public health of Serbia, by July 2021 the lowest percentage of vaccinated population was among those between the ages of 18 and 24-only 15% of this demographic had received the vaccine by this point. Given the low turnout of young people for vaccination, in this paper we investigated the general attitude of students in Serbia, as a special category of young people, towards the vaccine against the COVID-19 virus, as well as their attitude regarding information about vaccination in the media. Research was conducted on a sample of 345 students at the University of Novi Sad. The results of the research showed that 42% of students had not been vaccinated and did not plan to do so, 37.4% had received at least one dose of vaccine and 20.6% had not been vaccinated even though they planned to do so. Students who were vaccinated had more confidence in information provided through media channels than those who were not vaccinated. Therefore, it can be concluded that encouraging students to decide in favor of vaccination against the COVID-19 virus should come from the universities where they study as well as the media.	[Sidanin, Iva; Njegovan, Biljana Ratkovic; Sokolovic, Bojana] Univ Novi Sad, Fac Tech Sci, Dept Ind Engn & Engn Management, Novi Sad 21000, Serbia		Njegovan, BR; Sokolovic, B (通讯作者)，Univ Novi Sad, Fac Tech Sci, Dept Ind Engn & Engn Management, Novi Sad 21000, Serbia.	iva.sidjanin@uns.ac.rs; njegovan@uns.ac.rs; bojana.sokolovic985@gmail.com					Al-Amer R, 2022, J CLIN NURS, V31, P62, DOI 10.1111/jocn.15951; [Anonymous], 2018, STATE VACCINE CONFID; Bai W, 2021, INT J BIOL SCI, V17, P1469, DOI 10.7150/ijbs.58835; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647; Cardo AEF, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18157772; CINS, NUMBER VACCINATED SE; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Freeman D., COVID 19 VACCINE HES; Godlee F, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l4044; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Gruner S, 2021, APPL ECON LETT, V28, P1847, DOI 10.1080/13504851.2020.1854445; Holt E, 2021, LANCET, V397, P1793, DOI 10.1016/S0140-6736(21)01097-7; Jain J, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001205; Karlsson LC, 2021, PERS INDIV DIFFER, V172, DOI 10.1016/j.paid.2020.110590; Klapper JosephT., 1960, EFFECTS MASS COMMUNI; Lim LJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101141; Lin YL, 2020, J MED INTERNET RES, V22, DOI 10.2196/19982; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Mant M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255447; Margolis MA, 2019, PREV MED, V118, P251, DOI 10.1016/j.ypmed.2018.11.005; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Piltch-Loeb R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251095; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Sahin TT, 2020, WORLD J GASTROENTERO, V26, P2987, DOI 10.3748/wjg.v26.i22.2987; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Sandler K, 2020, J AM COLL HEALTH, V68, P593, DOI 10.1080/07448481.2019.1583660; Taha SA, 2013, J HEALTH COMMUN, V18, P278, DOI 10.1080/10810730.2012.727960; Thunstrom L, 2021, ECOHEALTH, V18, P44, DOI 10.1007/s10393-021-01524-0; Toplu SA, 2021, INT J CLIN PRACT, DOI 10.1111/ijcp.14668; Velikonja NK, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9070781; WHO, SERB WHO COR DIS COV; World Health Organization, COR DIS COVID 19; Yang GL, 2020, HEALTH EDUC RES, V35, P110, DOI 10.1093/her/cyaa002; Rivas DRZ, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245859; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	38	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1430	10.3390/vaccines9121430			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1KU	34960176	Green Published, gold			2022-04-29	WOS:000737420100001
J	Alamer, E; Hakami, F; Hamdi, S; Alamer, A; Awaf, M; Darraj, H; Abutalib, Y; Madkhali, E; Alamer, R; Bakri, N; Qadri, M; Algaissi, A; Alhazmi, A				Alamer, Edrous; Hakami, Faisal; Hamdi, Sulaiman; Alamer, Afnan; Awaf, Mohammed; Darraj, Hussam; Abutalib, Yumna; Madkhali, Ebtisam; Alamer, Rahaf; Bakri, Nawaf; Qadri, Marwa; Algaissi, Abdullah; Alhazmi, Abdulaziz			Knowledge, Attitudes and Perception toward COVID-19 Vaccines among Adults in Jazan Province, Saudi Arabia	VACCINES			English	Article						vaccine; hesitancy; SARS-CoV-2; Saudi Arabia	INFLUENZA VACCINATION; ACCEPTANCE	Background: Saudi Arabia is one of the countries that initiated early vaccination programs despite the global challenges concerning the availability of COVID-19 vaccines. Massive vaccination campaigns have been undertaken in the country; however, negative perception and hesitancy toward vaccines may exist which could reduce public response to vaccination. Further, studies evaluating the current perception and attitude toward COVID-19 vaccines are scarce. Thus, this study aims to assess the community attitudes and perceptions toward COVID-19 vaccines in Jazan Province, Saudi Arabia. Methods: A cross-sectional, retrospective study using an online questionnaire was conducted among the public in Jazan, the southern region of Saudi Arabia. General and demographic data were collected, and perception and attitude toward COVID-19 vaccines were evaluated. Results: Most participants in this study were female (67%) with a median age of 23 years. The majority held a bachelor's degree, and they trusted the Saudi healthcare system. Our survey showed that 67% of the study participants had positive perceptions toward COVID-19 vaccines, a finding that is significantly associated with receiving the influenza vaccine in the past, the existence of trust on the current healthcare system and holding positive beliefs toward the effectiveness of the current COVID-19 vaccines in reducing the risk of infection, complication, and mortality. Conclusions: The proportion of the public in Jazan who believed in the COVID-19 vaccine effectiveness is not inferior from similar international reports. Thus, national awareness programs toward the effectiveness of the vaccine could be enhanced to accelerate vaccination coverage. Further, nationwide surveys are warranted to include larger populations from different communities to assess the overall perception toward COVID-19 vaccines in the whole country.	[Alamer, Edrous; Algaissi, Abdullah] Jazan Univ, Dept Med Labs Technol, Coll Appl Med Sci, Jazan 45142, Saudi Arabia; [Alamer, Edrous; Alamer, Rahaf; Qadri, Marwa; Algaissi, Abdullah; Alhazmi, Abdulaziz] Jazan Univ, Emerging & Epidem Infect Dis Res Unit, Med Res Ctr, Jazan 45142, Saudi Arabia; [Hakami, Faisal; Hamdi, Sulaiman; Alamer, Afnan; Awaf, Mohammed; Darraj, Hussam; Abutalib, Yumna; Madkhali, Ebtisam; Alamer, Rahaf; Bakri, Nawaf] Jazan Univ, Coll Med, Jazan 45142, Saudi Arabia; [Qadri, Marwa] Jazan Univ, Dept Pharmacol & Toxicol, Coll Pharm, Jazan 45142, Saudi Arabia; [Alhazmi, Abdulaziz] Jazan Univ, Dept Microbiol & Parasitol, Coll Med, Jazan 45142, Saudi Arabia		Alhazmi, A (通讯作者)，Jazan Univ, Emerging & Epidem Infect Dis Res Unit, Med Res Ctr, Jazan 45142, Saudi Arabia.; Alhazmi, A (通讯作者)，Jazan Univ, Dept Microbiol & Parasitol, Coll Med, Jazan 45142, Saudi Arabia.	ealamer@jazanu.edu.sa; faisalhakami1420@gmail.com; sulaiman.hamdi27@gmail.com; AAlgaissi@jazanu.edu.sa; hamod6141@gmail.com; hosamdarraj25@gmail.com; none69991@gmail.com; 1ebtisamahmed@gmail.com; rahafalamer99@gmail.com; nawafbakri@hotmail.com; mqadri@jazanu.edu.sa; AAlgaissi@jazanu.edu.sa; abalhazmi@jazanu.edu.sa		Algaissi, Abdullah/0000-0002-5386-406X; Alamer, Afnan/0000-0002-4990-0507; Madkhali, Ebtisam/0000-0001-7987-4015; Barakat, Yumna/0000-0001-8822-5586; Awaf, Mohammed/0000-0001-6098-9306; , abdulaziz/0000-0002-4260-6540; ALAMER, EDROUS/0000-0002-9700-1610	Jazan University, Jazan, Saudi Arabia	This research was funded by the Deanship of Scientific Research, Jazan University, Jazan, Saudi Arabia (Project number: Cov19-56).	Al-Qerem WA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.632914; Alfageeh EI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030226; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; ANDERSON RM, 1985, NATURE, V318, P323, DOI 10.1038/318323a0; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; CDC, 2021, INT GUID US SARS COV; Cornwall W, 2020, SCIENCE, V369, P14, DOI 10.1126/science.369.6499.14; Davis CJ, 2022, BRIT J HEALTH PSYCH, V27, P300, DOI 10.1111/bjhp.12546; Eastwood K, 2010, MED J AUSTRALIA, V192, P33, DOI 10.5694/j.1326-5377.2010.tb03399.x; El-Elimat T, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250555; Elgendy MO, 2021, J MED VIROL, V93, P6535, DOI 10.1002/jmv.27199; Eurosurveillance Editorial Team, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2101211; Fadda M, 2020, INT J PUBLIC HEALTH, V65, P711, DOI 10.1007/s00038-020-01404-4; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; General Authority for Statistics, 2019, POP JAZ REG GEND AGE; Kim HW, 2021, JAMA CARDIOL, V6, P1196, DOI 10.1001/jamacardio.2021.2828; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Manuel DG, 2002, INFECT CONT HOSP EP, V23, P609, DOI 10.1086/501980; Maurer J, 2009, VACCINE, V27, P5732, DOI 10.1016/j.vaccine.2009.07.080; Nehal KR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101071; Nguyen Trang, 2011, Infect Drug Resist, V4, P197, DOI 10.2147/IDR.S23174; Ofri D, 2009, NEW ENGL J MED, V361, P2594, DOI 10.1056/NEJMp0911047; Rubin GJ, 2010, HEALTH TECHNOL ASSES, V14, P183, DOI 10.3310/hta14340-03; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schwarzinger M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010199; Seale H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-99; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Sypsa V, 2009, EUROSURVEILLANCE, V14, P2; Tregoning JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/s41577-021-00592-1; Vindrola-Padros C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040503; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Waldrip, 2011, VA EVIDENCE SYNTHESI; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; WHO, 2012, VACC BIOL; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization, 2021, WEEKLY EPIDEMIOLOGIC; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Zijtregtop EAM, 2009, VACCINE, V28, P207, DOI 10.1016/j.vaccine.2009.09.099	43	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1259	10.3390/vaccines9111259			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH1WV	34835190	gold, Green Published			2022-04-29	WOS:000725233300001
J	Allan, FK; Peters, AR				Allan, Fiona K.; Peters, Andrew R.			Safety and Efficacy of the East Coast Fever Muguga Cocktail Vaccine: A Systematic Review	VACCINES			English	Review						East Coast fever; cattle; Muguga cocktail; vaccine; safety; efficacy	TICKBORNE DISEASE-CONTROL; THEILERIA-PARVA SPOROZOITES; CYTOTOXIC T-LYMPHOCYTES; PAPER SUSTAINABLE TICK; LIVESTOCK IMPROVEMENT; LIVE IMMUNIZATION; CATTLE PRODUCTION; ECONOMIC-IMPACT; INFECTION; BUFFALO	Immunisation of livestock with high quality vaccines is considered an essential approach to controlling many animal diseases. The only currently available commercial vaccine to protect cattle from East Coast fever (ECF), a tick-borne disease caused by Theileria parva, is an unconventional "infection and treatment method" (ITM) involving administration of a combination of live T. parva isolates, referred to as the "Muguga cocktail", and simultaneous treatment with long-acting oxytetracycline. Veterinary vaccine research and development typically involves studies designed to demonstrate vaccine quality, safety, and efficacy; however, as there were no such purpose-designed registration studies conducted for the Muguga cocktail, evidence for safety and efficacy is solely based on that which is available in the clinical literature. An extensive systematic review was conducted to analyse the evidence available in the literature in order to establish the safety and efficacy of the Muguga cocktail vaccine. A combination of meta-analyses and narrative summaries was conducted. A total of 61 studies met the criteria to be included in the systematic review. The majority of studies demonstrated or reported in favour of the vaccine with regards to safety and efficacy of the Muguga cocktail vaccine. Proximity to buffalo often resulted in reduced vaccine efficacy, and reports of shed and transmission of vaccine components affected the overall interpretation of safety. Better understanding of control options for this devastating livestock disease is important for policymakers and livestock keepers, enabling them to make informed decisions with regards to the health of their animals and their livelihoods.	[Allan, Fiona K.; Peters, Andrew R.] Univ Edinburgh, Ctr Supporting Evidence Based Intervent Livestock, Royal Dick Sch Vet Studies, Roslin EH25 9RG, Midlothian, Scotland		Peters, AR (通讯作者)，Univ Edinburgh, Ctr Supporting Evidence Based Intervent Livestock, Royal Dick Sch Vet Studies, Roslin EH25 9RG, Midlothian, Scotland.	andy.peters@ed.ac.uk		Peters, Andrew/0000-0001-6273-2862; Allan, Fiona/0000-0002-1391-0519			Akoolo L, 2008, VET IMMUNOL IMMUNOP, V121, P216, DOI 10.1016/j.vetimm.2007.09.012; Allan FK, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.684127; Amzati GS, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3848-2; [Anonymous], 2005, TUR TECHN M INF TREA; [Anonymous], 1999, EVALUATION EFFICACY; [Anonymous], 1998, EVALUATION EFFICACY; [Anonymous], 2007, APPLYING ITM IMMUNIS; [Anonymous], 2020, REV MAN REVMAN VERS; [Anonymous], 1999, INFECTIVITY VIABILIT; Atuhaire DK, 2020, VET PARASITOL, V288, DOI 10.1016/j.vetpar.2020.109304; Atuhaire DK, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04322-9; Berkvens DL, 1998, VET PARASITOL, V77, P211, DOI 10.1016/S0304-4017(98)00096-X; Bishop RP, 2015, INT J PARASITOL-PAR, V4, P333, DOI 10.1016/j.ijppaw.2015.08.006; Chatanga E, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050334; Clarke CR, 1999, J VET PHARMACOL THER, V22, P65, DOI 10.1046/j.1365-2885.1999.00181.x; Clements CJ, 2004, VACCINE, V22, P2054, DOI 10.1016/j.vaccine.2004.01.008; CONRAD PA, 1989, PARASITOLOGY, V98, P179, DOI 10.1017/S0031182000062089; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; de Castro JJ, 1998, VET PARASITOL, V77, P213; De Deken R, 2007, VET PARASITOL, V143, P245, DOI 10.1016/j.vetpar.2006.08.018; de Vries RBM., 2015, EVID BASED PRECLIN M, V2, DOI 10.1002/ebm2.7; deCastro JJ, 1997, VET PARASITOL, V71, P77, DOI 10.1016/S0304-4017(97)00033-2; Di Giulio G, 2000, 3RD INTERNATIONAL CONFERENCE ON TICKS AND TICK-BORNE PATHOGENS: INTO THE 21ST CENTURY, PROCEEDINGS, P121; Di Giulio G, 2009, TRENDS PARASITOL, V25, P85, DOI 10.1016/j.pt.2008.11.007; Dolan T.T., 1989, THEILERIOSIS E CENTR, P187; DOLAN TT, 1980, VET PARASITOL, V6, P325, DOI 10.1016/0304-4017(80)90077-1; Dolan TT, 1999, TROP MED INT HEALTH, V4, pA3, DOI 10.1046/j.1365-3156.1999.00445.x; Elisa M, 2015, PARASITOLOGY, V142, P698, DOI 10.1017/S0031182014001784; Geysen D, 1999, TROP MED INT HEALTH, V4, pA21, DOI 10.1046/j.1365-3156.1999.00447.x; Green S., PREPARING COCHRANE R; Greenhalgh T, 1997, BRIT MED J, V315, P672, DOI 10.1136/bmj.315.7109.672; Grindlay DJC, 2012, J VET MED EDUC, V39, P404, DOI 10.3138/jvme.1111.109R; Gwakisa P, 2020, TRANSBOUND EMERG DIS, V67, P79, DOI 10.1111/tbed.13405; Head JR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42714-9; Hemmink JD, 2018, INT J PARASITOL, V48, P287, DOI 10.1016/j.ijpara.2017.10.006; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Homewood K, 2006, AGR SYST, V89, P248, DOI 10.1016/j.agsy.2005.09.004; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; ILRI, 1996, TITR FAO 1 STAB; Kazungu YEM, 2015, TICKS TICK-BORNE DIS, V6, P587, DOI 10.1016/j.ttbdis.2015.04.014; Kerario II, 2019, TICKS TICK-BORNE DIS, V10, P1003, DOI 10.1016/j.ttbdis.2019.05.007; Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824; Kiraithe Z.N., 2015, THESIS U NAIROBI NAI; Kivaria FM, 2007, VET J, V173, P384, DOI 10.1016/j.tvjl.2005.08.013; Lankinen KS, 2004, B WORLD HEALTH ORGAN, V82, P828; Lynen G., 1999, ANIMAL HLTH PRODUCTI, V1, P367; Lynen G., 2005, ROLE BIOTECHNOLOGY A, P193; Lynen G, 2012, TROP ANIM HEALTH PRO, V44, P567, DOI 10.1007/s11250-011-9936-8; Magulu E, 2019, VET PARASITOL REG ST, V17, DOI 10.1016/j.vprsr.2019.100312; Magwisha H. B., 2011, Journal of Commonwealth Veterinary Association, V27, P87; Martins SB, 2010, PREV VET MED, V97, P175, DOI 10.1016/j.prevetmed.2010.09.018; Mbassa GK, 1998, VET PARASITOL, V77, P41, DOI 10.1016/S0304-4017(97)00138-6; Mbyuzi Albano O., 2013, Research Opinions in Animal & Veterinary Sciences, V3, P92; McHardy N., 1989, International Symposium on Mycoplasmosis and Theileriosis, 11-13 October, 1989, Pendik, Turkey,., P114; McKeever DJ, 2007, TRENDS PARASITOL, V23, P565, DOI 10.1016/j.pt.2007.09.002; Melewas J., 1999, P FAO ILRI OAU IBAR, P13; Morrison WI, 2006, PARASITOLOGY, V133, pS169, DOI 10.1017/S0031182006001867; Mutugi J., 1997, AGGCPRAF291DEN FAO; Mutugi J., REV SAFETY EFFIACY E; Nambota A., 1989, THEILERIOSIS E CENTR, P87; Nambota AM, 1997, J VET MED SCI, V59, P1, DOI 10.1292/jvms.59.1; Nene V, 2016, TICKS TICK-BORNE DIS, V7, P549, DOI 10.1016/j.ttbdis.2016.02.001; Nsubuga-Mutaka R., 1999, P FAO ILRI OAU IBAR, P21; Nsubuga-Mutaka R.C., 2000, UGANDA J AGR SCI, V5, P1; Obara I, 2015, PARASITOL RES, V114, P1729, DOI 10.1007/s00436-015-4358-6; Ocaido M, 2009, TROP ANIM HEALTH PRO, V41, P731, DOI 10.1007/s11250-008-9245-z; Onono JO, 2013, TROP ANIM HEALTH PRO, V45, P1415, DOI 10.1007/s11250-013-0379-2; Oura CAL, 2007, PARASITOLOGY, V134, P1205, DOI 10.1017/S0031182007002557; Oura CAL, 2004, PARASITOLOGY, V129, P27, DOI 10.1017/S003118200400513X; Oura CAL, 2011, PARASITOL RES, V108, P1365, DOI 10.1007/s00436-010-2030-8; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n71; Patel E, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1787-y; Patel E, 2016, TICKS TICK-BORNE DIS, V7, P306, DOI 10.1016/j.ttbdis.2015.11.006; Pelle R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019015; Perry BD, 2016, ONE HEALTH, V2, P103, DOI 10.1016/j.onehlt.2016.07.002; Peters A.R., 2020, GATES OPEN RES, V4, P100, DOI [10.21955/gatesopenres.1116653.1, DOI 10.21955/GATESOPENRES.1116653.1]; Pound P, 2004, BMJ-BRIT MED J, V328, P514, DOI 10.1136/bmj.328.7438.514; RADLEY D E, 1975, Veterinary Parasitology, V1, P51, DOI 10.1016/0304-4017(75)90007-2; RADLEY D E, 1975, Veterinary Parasitology, V1, P43, DOI 10.1016/0304-4017(75)90006-0; RADLEY D E, 1975, Veterinary Parasitology, V1, P35, DOI 10.1016/0304-4017(75)90005-9; Radley D.E., 1985, P IMM THEIL AFR NAIR, P58; RADLEY DE, 1979, VET PARASITOL, V5, P117, DOI 10.1016/0304-4017(79)90003-7; Rashid A, 2009, J ANIM PLANT SCI, V19, P22; Rowlands GJ, 2000, PARASITOLOGY, V120, P371, DOI 10.1017/S0031182099005600; Rukambile E. J., 2014, Tanzania Veterinary Journal, V29, P27; Sargeant JM, 2014, ZOONOSES PUBLIC HLTH, V61, P3, DOI 10.1111/zph.12128; Schreuder B.E.C., 1976, TROPENMED PARASITOL, V27, P26; Sitt T, 2015, INT J PARASITOL-PAR, V4, P244, DOI 10.1016/j.ijppaw.2015.04.006; Steinaa Lucilla, 2018, BMC Res Notes, V11, P44, DOI 10.1186/s13104-018-3145-8; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Stryhn H., 2009, VET EPIDEMIOLOGIC RE; Tawfik GM, 2019, TROP MED HEALTH, V47, DOI 10.1186/s41182-019-0165-6; Tenesi M.G., 2015, THESIS U NAIROBI NAI; Theiler A, 1912, ONDERSTEPOORT J VET, V2, P266, DOI [10.1016/S0368-1742(13)80049-5, DOI 10.1016/S0368-1742(13)80049-5]; Thrusfield M., 2005, VET EPIDEMIOLOGY, V2nd; Turasha G.K., 2011, PROJECT REPORT; Uilenberg G., 1978, Tick-borne diseases and their vectors., P307; UILENBERG G, 1977, TROPENMED PARASITOL, V28, P499; van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245; Vesterinen HM, 2014, J NEUROSCI METH, V221, P92, DOI 10.1016/j.jneumeth.2013.09.010; Wesonga F., 2013, E COAST FEVER ECF VA	102	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1318	10.3390/vaccines9111318			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XT6NW	34835249	Green Published, gold			2022-04-29	WOS:000733702800001
J	Go, HJ; Park, BJ; Ahn, HS; Kim, DH; Kim, D; Kim, JH; Lee, JB; Park, SY; Song, CS; Lee, SW; Choi, YK; Choi, IS				Go, Hyeon-Jeong; Park, Byung-Joo; Ahn, Hee-Seop; Kim, Dong-Hwi; Kim, Da-Yoon; Kim, Jae-Hyeong; Lee, Joong-Bok; Park, Seung-Yong; Song, Chang-Seon; Lee, Sang-Won; Choi, Yang-Kyu; Choi, In-Soo			Pigs Immunized with the Virus-like Particle Vaccine Are Protected against the Hepatitis E-3 Virus	VACCINES			English	Article						Hepatitis E virus; virus-like particle; 239 amino acids; viremia; fecal viral shedding; liver fibrosis; baculovirus expression system	EXPRESSION; SEQUENCES; EFFICACY; SAFETY	In this study, we generated the HEV virus-like particle (VLP) vaccine expressing 239 amino acids (367-605 aa) of the HEV-3 ORF2 using the baculovirus expression system. The HEV-3-239-VLP vaccine efficacy was evaluated by dividing 12 pathogen-free pigs into four groups: negative control, positive control, 100 mu g VLP-, and 200 mu g VLP-vaccinated groups for 10 weeks. The pigs in either of the vaccinated groups were administered the corresponding first and booster doses on weeks 0 and 2. At week 4, the positive control and two vaccinated groups were challenged with 10(6) HEV-3 genomic equivalent copies; viremia and fecal shedding of the virus were identified in pigs in the positive control and 100 mu g VLP-vaccinated pigs showed transient viremia and fecal viral shedding. However, no viruses were detected in the serum or fecal samples of the 200 mu g VLP-vaccinated pigs. The 100 and 200 mu g VLP-vaccinated pigs had significantly higher (p < 0.01) anti-HEV antibodies than the negative control pigs from weeks 6-10 with normal levels of liver enzymes. The 200 mu g VLP-vaccinated pigs showed statistically less liver tissue fibrosis (p < 0.05) than that of the positive control pigs. Thus, the novel baculovirus expression system-generated VLP vaccine dose-dependently protects against HEV-3 challenge and may be useful in other animal species, including humans.	[Go, Hyeon-Jeong; Park, Byung-Joo; Ahn, Hee-Seop; Kim, Dong-Hwi; Kim, Da-Yoon; Kim, Jae-Hyeong; Lee, Joong-Bok; Song, Chang-Seon; Lee, Sang-Won; Choi, In-Soo] Konkuk Univ, Dept Infect Dis, Coll Vet Med, 120 Neundong Ro, Seoul 05029, South Korea; [Choi, Yang-Kyu] Konkuk Univ, Dept Lab Anim Med, Coll Vet Med, 120 Neundong Ro, Seoul 05029, South Korea		Choi, IS (通讯作者)，Konkuk Univ, Dept Infect Dis, Coll Vet Med, 120 Neundong Ro, Seoul 05029, South Korea.	goluffy@konkuk.ac.kr; twilight@konkuk.ac.kr; frequency0@konkuk.ac.kr; opeean0@konkuk.ac.kr; kimda68@konkuk.ac.kr; mirine2u@konkuk.ac.kr; virus@konkuk.ac.kr; paseyo@konkuk.ac.kr; songcs@konkuk.ac.kr; odssey@konkuk.ac.kr; yangkyuc@konkuk.ac.kr; ischoi@konkuk.ac.kr		Song, Chang-Seon/0000-0002-4158-6402	Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [HI18C1836]	This research was supported by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C1836).	Ahmad I, 2011, VIRUS RES, V161, P47, DOI 10.1016/j.virusres.2011.02.011; Blasco-Perrin H, 2016, LIVER INT, V36, P130, DOI 10.1111/liv.13014; Cao YF, 2017, VACCINE, V35, P5073, DOI 10.1016/j.vaccine.2017.05.072; Cheng XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051616; Colson P, 2010, J INFECT DIS, V202, P825, DOI 10.1086/655898; Dalton HR, 2014, FUTURE MICROBIOL, V9, P1361, DOI 10.2217/fmb.14.89; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992; Kamar N, 2012, LANCET, V379, P2477, DOI 10.1016/S0140-6736(11)61849-7; Kannan H, 2009, J VIROL, V83, P6375, DOI 10.1128/JVI.02571-08; Khuroo MS, 2003, J VIRAL HEPATITIS, V10, P61, DOI 10.1046/j.1365-2893.2003.00398.x; Kumar A, 2005, INT J GYNECOL OBSTET, V89, P7, DOI 10.1016/j.ijgo.2005.01.016; Li SW, 2005, VACCINE, V23, P2893, DOI 10.1016/j.vaccine.2004.11.064; Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997; Li TC, 2004, VACCINE, V22, P370, DOI 10.1016/j.vaccine.2003.08.004; Liu FX, 2013, PROTEIN EXPRES PURIF, V90, P104, DOI 10.1016/j.pep.2013.05.009; Lu L, 2006, REV MED VIROL, V16, P5, DOI 10.1002/rmv.482; Mizuo H, 2002, J CLIN MICROBIOL, V40, P3209, DOI 10.1128/JCM.40.9.3209-3218.2002; Park BJ, 2019, VACCINE, V37, P5972, DOI 10.1016/j.vaccine.2019.08.029; Rein DB, 2012, HEPATOLOGY, V55, P988, DOI 10.1002/hep.25505; Shrestha MP, 2007, NEW ENGL J MED, V356, P895, DOI 10.1056/NEJMoa061847; Sinclair SM, 2017, DRUG SAFETY, V40, P1205, DOI 10.1007/s40264-017-0566-6; Smith DB, 2016, J GEN VIROL, V97, P537, DOI 10.1099/jgv.0.000393; Smith DB, 2014, J GEN VIROL, V95, P2223, DOI 10.1099/vir.0.068429-0; Perez-Gracia MT, 2013, REV MED VIROL, V23, P384, DOI 10.1002/rmv.1759; Tsarev SA, 1997, VACCINE, V15, P1834, DOI 10.1016/S0264-410X(97)00145-X; Wu T, 2012, HUM VACC IMMUNOTHER, V8, P823, DOI 10.4161/hv.20042; Zhang J, 2015, NEW ENGL J MED, V372, P914, DOI 10.1056/NEJMoa1406011; Zhang J, 2009, VACCINE, V27, P1869, DOI 10.1016/j.vaccine.2008.12.061; Zhao QJ, 2013, J GASTROENTEROL, V48, P159, DOI 10.1007/s00535-012-0701-1; Zheng MH, 2018, VACCINE, V36, P2104, DOI 10.1016/j.vaccine.2018.03.005; Zhou YH, 2005, VACCINE, V23, P3157, DOI 10.1016/j.vaccine.2004.12.020; Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6	33	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1265	10.3390/vaccines9111265			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG4FH	34835195	Green Published, gold			2022-04-29	WOS:000724709800001
J	Singh, AA; Pillay, P; Tsekoa, TL				Singh, Advaita Acarya; Pillay, Priyen; Tsekoa, Tsepo Lebiletsa			Engineering Approaches in Plant Molecular Farming for Global Health	VACCINES			English	Review						plant-made pharmaceutical; molecular farming; vaccine; glycoengineering; tyrosine sulfation; proteases inactivation	CAULIFLOWER MOSAIC VIRUS-35S; ANTI-HIV ANTIBODIES; NICOTIANA-BENTHAMIANA; AGROBACTERIUM-TUMEFACIENS; HYPERSENSITIVE RESPONSE; PROTEOLYTIC DEGRADATION; THERAPEUTIC ANTIBODIES; MONOCLONAL-ANTIBODIES; RECOMBINANT PROTEINS; TRANSFORMED TOBACCO	Since the demonstration of the first plant-produced proteins of medical interest, there has been significant growth and interest in the field of plant molecular farming, with plants now being considered a viable production platform for vaccines. Despite this interest and development by a few biopharmaceutical companies, plant molecular farming is yet to be embraced by 'big pharma'. The plant system offers a faster alternative, which is a potentially more cost-effective and scalable platform for the mass production of highly complex protein vaccines, owing to the high degree of similarity between the plant and mammalian secretory pathway. Here, we identify and address bottlenecks in the use of plants for vaccine manufacturing and discuss engineering approaches that demonstrate both the utility and versatility of the plant production system as a viable biomanufacturing platform for global health. Strategies for improving the yields and quality of plant-produced vaccines, as well as the incorporation of authentic posttranslational modifications that are essential to the functionality of these highly complex protein vaccines, will also be discussed. Case-by-case examples are considered for improving the production of functional protein-based vaccines. The combination of all these strategies provides a basis for the use of cutting-edge genome editing technology to create a general plant chassis with reduced host cell proteins, which is optimised for high-level protein production of vaccines with the correct posttranslational modifications.	[Singh, Advaita Acarya; Pillay, Priyen; Tsekoa, Tsepo Lebiletsa] CSIR, Future Prod, Chem Cluster, ZA-0001 Pretoria, South Africa		Tsekoa, TL (通讯作者)，CSIR, Future Prod, Chem Cluster, ZA-0001 Pretoria, South Africa.	ASingh4@csir.co.za; PPillay3@csir.co.za; TTsekoa@csir.co.za		Singh, Advaita Acarya/0000-0002-9749-9260			Arzola L, 2011, INT J MOL SCI, V12, P4975, DOI 10.3390/ijms12084975; Bagdonaite I, 2018, GLYCOBIOLOGY, V28, P443, DOI 10.1093/glycob/cwy021; BARTA A, 1986, PLANT MOL BIOL, V6, P347, DOI 10.1007/BF00034942; Baum LL, 1996, J IMMUNOL, V157, P2168; Benchabane M, 2008, PLANT BIOTECHNOL J, V6, P633, DOI 10.1111/j.1467-7652.2008.00344.x; Bendandi M, 2010, ANN ONCOL, V21, P2420, DOI 10.1093/annonc/mdq256; Bombarely A, 2012, MOL PLANT MICROBE IN, V25, P1523, DOI 10.1094/MPMI-06-12-0148-TA; Brodersen P, 2006, TRENDS GENET, V22, P268, DOI 10.1016/j.tig.2006.03.003; Buyel JF, 2021, TRANSGENIC RES, V30, P401, DOI 10.1007/s11248-021-00236-z; Buyel JF, 2015, BIOTECHNOL ADV, V33, P902, DOI 10.1016/j.biotechadv.2015.04.010; Castilho A, 2018, PLANT BIOTECHNOL J, V16, P1700, DOI 10.1111/pbi.12906; Castilho A, 2014, PLANT PHYSIOL, V166, P1839, DOI 10.1104/pp.114.250720; Castilho A, 2012, BIOTECHNOL J, V7, DOI 10.1002/biot.201200032; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; Chu L, 2001, CURR OPIN BIOTECH, V12, P180, DOI 10.1016/S0958-1669(00)00197-X; De Martinis D, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01148; De Muynck B, 2010, PLANT BIOTECHNOL J, V8, P529, DOI 10.1111/j.1467-7652.2009.00494.x; Doran PM, 2006, TRENDS BIOTECHNOL, V24, P426, DOI 10.1016/j.tibtech.2006.06.012; Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036; Duwadi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130556; Faye L, 2005, VACCINE, V23, P1770, DOI 10.1016/j.vaccine.2004.11.003; Fischer R, 2000, TRANSGENIC RES, V9, P279, DOI 10.1023/A:1008975123362; Garabagi F, 2012, PLANT BIOTECHNOL J, V10, P1118, DOI 10.1111/j.1467-7652.2012.00742.x; Giddings G, 2001, CURR OPIN BIOTECH, V12, P450, DOI 10.1016/S0958-1669(00)00244-5; Girard C, 2007, NEW PHYTOL, V173, P841, DOI 10.1111/j.1469-8137.2007.01968.x; Giritch A, 2006, P NATL ACAD SCI USA, V103, P14701, DOI 10.1073/pnas.0606631103; Goritzer K, 2019, J BIOL CHEM, V294, P13995, DOI 10.1074/jbc.RA119.009954; Goulet C, 2010, PROTEOMICS, V10, P2536, DOI 10.1002/pmic.200900382; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; Grosse-Holz F, 2018, PLANT BIOTECHNOL J, V16, P1068, DOI 10.1111/pbi.12852; Gu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032422; Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006; Hehle VK, 2015, PLANT BIOTECHNOL J, V13, P235, DOI 10.1111/pbi.12266; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Hortensteiner S, 2002, J EXP BOT, V53, P927, DOI 10.1093/jexbot/53.370.927; Houdebine LM, 2000, TRANSGENIC RES, V9, P305, DOI 10.1023/A:1008934912555; Jansing J, 2019, PLANT BIOTECHNOL J, V17, P350, DOI 10.1111/pbi.12981; Jeong IS, 2018, PLANT J, V94, P131, DOI 10.1111/tpj.13847; Jutras PV, 2015, BIOTECHNOL J, V10, P1478, DOI 10.1002/biot.201500056; Kallolimath S, 2016, P NATL ACAD SCI USA, V113, P9498, DOI 10.1073/pnas.1604371113; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; Komori R, 2009, P NATL ACAD SCI USA, V106, P15067, DOI 10.1073/pnas.0902801106; LAWTON MA, 1987, PLANT MOL BIOL, V9, P315, DOI 10.1007/BF00014906; Lewis GK, 2013, CURR HIV RES, V11, P354, DOI 10.2174/1570162X113116660060; Li W, 2017, MOL PLANT PATHOL, V18, P489, DOI 10.1111/mpp.12411; Lin HL, 2009, APPL ECON, V41, P1191, DOI 10.1080/00036840601019224; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Loos A, 2015, P NATL ACAD SCI USA, V112, P12675, DOI 10.1073/pnas.1509090112; Mahalik S, 2014, MICROB CELL FACT, V13, DOI 10.1186/s12934-014-0177-1; Mandal MK, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00267; Mandal MK, 2014, BIOTECHNOL J, V9, P1065, DOI 10.1002/biot.201300424; Margolin E, 2020, PLANT BIOTECHNOL J, V18, P2109, DOI 10.1111/pbi.13369; Montero-Morales L, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00242; Montero-Morales L, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00081; Moore KL, 2009, P NATL ACAD SCI USA, V106, P14741, DOI 10.1073/pnas.0908376106; Nadakuduti SS, 2018, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01607; Nandi S, 2016, MABS-AUSTIN, V8, P1456, DOI 10.1080/19420862.2016.1227901; Gonzalez MN, 2020, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.01649; Niemer M, 2014, BIOTECHNOL J, V9, P493, DOI 10.1002/biot.201300207; Nolke G, 2003, EXPERT OPIN BIOL TH, V3, P1153; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; Paireder M, 2017, BBA-PROTEINS PROTEOM, V1865, P444, DOI 10.1016/j.bbapap.2017.02.007; Peyret H, 2019, PLANT METHODS, V15, DOI 10.1186/s13007-019-0494-9; Peyret H, 2013, PLANT MOL BIOL, V83, P51, DOI 10.1007/s11103-013-0036-1; Pillay P, 2012, APPL BIOCHEM BIOTECH, V168, P1608, DOI 10.1007/s12010-012-9882-6; Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008; Pitzschke A, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00519; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Rawlings ND, 2018, NUCLEIC ACIDS RES, V46, pD624, DOI 10.1093/nar/gkx1134; Rico A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008977; Rivard D, 2006, PLANT BIOTECHNOL J, V4, P359, DOI 10.1111/j.1467-7652.2006.00187.x; ROBINETTE D, 1990, J BACTERIOL, V172, P5742, DOI 10.1128/jb.172.10.5742-5749.1990; Rosenberg Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120451; Sahoo Satyabrata, 2019, Gene, V721S, P100012, DOI 10.1016/j.gene.2019.100012; Sainsbury F, 2009, PLANT BIOTECHNOL J, V7, P682, DOI 10.1111/j.1467-7652.2009.00434.x; Salazar-Gonzalez JA, 2015, PLANT MOL BIOL, V87, P203, DOI 10.1007/s11103-014-0279-5; Schaller A, 2004, PLANTA, V220, P183, DOI 10.1007/s00425-004-1407-2; Schillberg S, 2021, J PLANT PHYSIOL, V258, DOI 10.1016/j.jplph.2020.153359; Schillberg S, 2013, CURR PHARM DESIGN, V19, P5531, DOI 10.2174/1381612811319310008; Sheikh AH, 2014, MOL PLANT MICROBE IN, V27, P1175, DOI 10.1094/MPMI-04-14-0114-R; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Singh AA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63052-1; Spiegel H., 2018, MOL PHARM APPL CHALL, P1, DOI 10.1002/9781118801512.ch1; Stelter S, 2020, PLANT BIOTECHNOL J, V18, P402, DOI 10.1111/pbi.13207; Stone MJ, 2009, NEW BIOTECHNOL, V25, P299, DOI 10.1016/j.nbt.2009.03.011; Strasser R, 2008, PLANT BIOTECHNOL J, V6, P392, DOI 10.1111/j.1467-7652.2008.00330.x; Strasser R, 2018, ANNU REV PLANT BIOL, V69, P147, DOI 10.1146/annurev-arplant-042817-040331; Strasser R, 2016, GLYCOBIOLOGY, V26, P926, DOI 10.1093/glycob/cww023; Strasser R, 2009, J BIOL CHEM, V284, P20479, DOI 10.1074/jbc.M109.014126; Swartz JR, 2001, CURR OPIN BIOTECH, V12, P195, DOI 10.1016/S0958-1669(00)00199-3; Tsekoa TL, 2020, CURR OPIN BIOTECH, V61, P89, DOI 10.1016/j.copbio.2019.11.005; Twyman Richard M, 2005, Expert Opin Emerg Drugs, V10, P185, DOI 10.1517/14728214.10.1.185; Twyman RM, 2003, TRENDS BIOTECHNOL, V21, P570, DOI 10.1016/j.tibtech.2003.10.002; van der Hoorn RAL, 2004, CURR OPIN PLANT BIOL, V7, P400, DOI 10.1016/j.pbi.2004.04.003; van der Hoorn RAL, 2008, ANNU REV PLANT BIOL, V59, P191, DOI 10.1146/annurev.arplant.59.032607.092835; Van der Vyver C, 2003, PLANT BIOTECHNOL J, V1, P101, DOI 10.1046/j.1467-7652.2003.00010.x; Wakasa Y, 2011, PLANT J, V65, P675, DOI 10.1111/j.1365-313X.2010.04453.x; Webster GR, 2017, BIOTECHNOL BIOENG, V114, P492, DOI 10.1002/bit.26183; Whaley KJ, 2011, HUM VACCINES, V7, P349, DOI 10.4161/hv.7.3.14266; Wohlschlager T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04061-7; Zauner FB, 2018, PLANT CELL, V30, P686, DOI 10.1105/tpc.17.00963; Zhou YY, 2017, PLANT BIOTECHNOL REP, V11, P161, DOI 10.1007/s11816-017-0439-6	103	0	0	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1270	10.3390/vaccines9111270			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XL0NR	34835201	gold, Green Published			2022-04-29	WOS:000727850900001
J	Staempfli, D; de la Torre, A; Simi, E; Du Pasquier, S; Berger, J; Burden, AM				Staempfli, Dominik; de la Torre, Adrian; Simi, Elodie; Du Pasquier, Sophie; Berger, Jerome; Burden, Andrea M.			Community Pharmacist-Administered COVID-19 Vaccinations: A Pilot Customer Survey on Satisfaction and Motivation to Get Vaccinated	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccination; satisfaction; survey; community pharmacy		In response to the coronavirus disease 2019 (COVID-19) pandemic, Swiss health authorities approved and ordered two mRNA vaccines in 2021. The canton of Zurich was the second in Switzerland to allow community pharmacists to administer the COVID-19 mRNA Vaccine Moderna to the adult population. We aimed to pilot a customer satisfaction questionnaire regarding COVID-19 vaccinations in Zurich pharmacies. Questions focused on satisfaction with different aspects of the service, motivation for getting the vaccination, and reasons for being vaccinated in a pharmacy. Zurich pharmacies administered 68,169 COVID-19 doses until June 2021, and 421 questionnaires were filled. Respondents' mean age was 43.5 (& PLUSMN;13.2) years, with 42.3% reporting being women and 46.1% being men. Of the 372 complete questionnaires, 98.7% of the respondents would have recommended the service to others. High levels of satisfaction were reported concerning pre-vaccination discussion (98.9%), pharmacies' information level on COVID-19 vaccines (98.9%), general comfort with receiving the vaccination in a pharmacy (99.5%), injection technique (99.2%), and premises used (98.1%). Most respondents (57.3%) would have had the option of another vaccination provider, but the pharmacies were chosen for their opening hours, ease of access, and perceived trust. The availability of pharmacist-administered services may be an important contributor to a successful vaccination programme in Switzerland.	[Staempfli, Dominik; de la Torre, Adrian; Burden, Andrea M.] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, Pharmacoepidemiol, CH-8093 Zurich, Switzerland; [Simi, Elodie; Du Pasquier, Sophie; Berger, Jerome] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Community Pharm, CH-1011 Lausanne, Switzerland; [Simi, Elodie; Berger, Jerome] Univ Lausanne, Lausanne Univ Hosp, Ctr Res & Innovat Clin Pharmaceut Sci, CH-1011 Lausanne, Switzerland; [Simi, Elodie; Berger, Jerome] Univ Geneva, Sch Pharmaceut Sci, CH-1206 Geneva, Switzerland; [Simi, Elodie; Berger, Jerome] Univ Lausanne, Inst Pharmaceut Sci Western Switzerland, CH-1011 Lausanne, Switzerland		Staempfli, D (通讯作者)，Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, Pharmacoepidemiol, CH-8093 Zurich, Switzerland.	dominik.staempfli@pharma.ethz.ch; adrian.martinez@pharma.ethz.ch; elodie.simi@unisante.ch; sophie.du-pasquier@unisante.ch; jerome.berger@unisante.ch; andrea.burden@pharma.ethz.ch	Berger, Jérôme/L-1033-2019; Stämpfli, Dominik/AAT-7229-2020; /B-3004-2016	Berger, Jérôme/0000-0003-1177-5453; Stämpfli, Dominik/0000-0001-5293-134X; /0000-0001-7082-8530; Martinez-De la Torre, Adrian/0000-0002-3155-7421; Du Pasquier, Sophie/0000-0003-2082-7251	Swiss Federal Institute of Technology ETH ZurichETH Zurich	Funding The study was enabled by funds from the Swiss Federal Institute of Technology ETH Zurich.	[Anonymous], Vaccin Contre le COVID-19 de Johnson Johnson: Swissmedic Autorise un Troisieme Vaccin Contre le COVID-19; Burt S, 2018, INT J CLIN PHARM-NET, V40, P1519, DOI 10.1007/s11096-018-0738-1; Isabelle B, 2019, SWISS MED WKLY, V149, DOI 10.4414/smw.2019.20161; Isenor JE, 2018, HUM VACC IMMUNOTHER, V14, P706, DOI 10.1080/21645515.2018.1423930; Leuthold C, 2018, PHARMACY, V6, DOI 10.3390/pharmacy6040125; Merks P, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020599; Papastergiou John, 2014, Can Pharm J (Ott), V147, P359, DOI 10.1177/1715163514552557; Paudyal V, 2021, INT J CLIN PHARM-NET, V43, P1139, DOI 10.1007/s11096-021-01301-7; R Core Team, 2020, R LANGUAGE ENV STAT; Stampfli D, 2020, J PHARM POLICY PRACT, V13, DOI 10.1186/s40545-020-00259-7; The Swiss Confederation, 2015, 81111 SR; Wickham H., 2016, GGPLOT2 CREATE ELEGA; Zhang Yanjie, 2021, Glob Health J, V5, P51, DOI 10.1016/j.glohj.2021.02.005	13	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1320	10.3390/vaccines9111320			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG0AV	34835251	Green Published, gold			2022-04-29	WOS:000724425600001
J	Wang, ZX; Fang, Y; Chan, PSF; Chidgey, A; Fong, F; Ip, M; Lau, JTF				Wang, Zixin; Fang, Yuan; Chan, Paul Shing-fong; Chidgey, Andrew; Fong, Francois; Ip, Mary; Lau, Joseph T. F.			Effectiveness of a Community-Based Organization-Private Clinic Service Model in Promoting Human Papillomavirus Vaccination among Chinese Men Who Have Sex with Men	VACCINES			English	Article						HPV vaccination; men who have sex with men; online health promotion; outcome and process evaluation	BISEXUAL MEN; PREVALENCE; HEALTH; WOMEN; GAY; ACCEPTABILITY; CLEARANCE; INFECTION	This study evaluated the effectiveness of the community-based organization (CBO)-private clinic service model in increasing human papillomavirus (HPV) vaccination uptake among unvaccinated men who have sex with men (MSM) in Hong Kong during a 12-month follow-up period. A CBO-private clinic model was implemented to promote HPV vaccination among Chinese MSM. A CBO with good access to MSM approached MSM aged 18-45 years who had never received an HPV vaccination, invited them to receive an online health promotion, and referred them to receive HPV vaccination at gay-friendly private clinics. A baseline survey and a follow-up evaluation at Month 12 were conducted. A total of 350 participants completed the baseline survey. Among 274 participants who were followed up at Month 12, 46 (16.8%) had taken up at least one dose of HPV vaccination. After adjusting for significant baseline characteristics, the perceived susceptibility (AOR:1.25, p = 0.002) and perceived severity (AOR:1.21, p = 0.003) of HPV and HPV-related diseases, perceived benefits (AOR:1.16, p = 0.03), self-efficacy to receive HPV vaccination (AOR:1.37, p = 0.001), and behavioral intention to take up HPV vaccination at baseline (AOR:6.99, p < 0.001) significantly predicted HPV vaccination uptake. The process evaluation of the program was positive. The CBO-private clinic service model was helpful in increasing HPV vaccination uptake among MSM.	[Wang, Zixin; Chan, Paul Shing-fong; Ip, Mary; Lau, Joseph T. F.] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Fac Med, Hong Kong, Peoples R China; [Fang, Yuan] Educ Univ Hong Kong, Dept Early Childhood Educ, Hong Kong, Peoples R China; [Chidgey, Andrew] AIDS Concern, Hong Kong, Peoples R China; [Fong, Francois] Neohealth, Hong Kong, Peoples R China		Wang, ZX; Lau, JTF (通讯作者)，Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Fac Med, Hong Kong, Peoples R China.	wangzx@cuhk.edu.hk; lunajoef@gmail.com; pchan@link.cuhk.edu.hk; andrew.childgey@aidsconcern.org.hk; drfong@neohealth.com.hk; mitk@cuhk.edu.hk; jlau@cuhk.edu.hk	Chan, Paul Shing-fong/AAI-9366-2021	Chan, Paul Shing-fong/0000-0002-6916-4957; Fang, Yuan/0000-0003-1154-5076; Lau, Joseph/0000-0003-2344-7107	Knowledge Transfer Project Fund; Chinese University of Hong KongChinese University of Hong Kong [KPF18HLF22]	This research was funded by the Knowledge Transfer Project Fund, the Chinese University of Hong Kong (grant number: KPF18HLF22).	[Anonymous], 2017, Wkly Epidemiol Rec, V92, P241; Centers for Disease Control and Prevention (CDC), HPV VACC REC; Centers for Disease Control and Prevention (CDC), EV REC HPV VACC AD 2; Checchi M, 2019, SEX TRANSM INFECT, V95, P608, DOI 10.1136/sextrans-2018-053923; D'Souza G, 2016, JAIDS-J ACQ IMM DEF, V71, P570, DOI 10.1097/QAI.0000000000000910; De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116; Dunne EF, 2012, JAMA-J AM MED ASSOC, V307, P557; Fontenot HB, 2020, J MED INTERNET RES, V22, DOI 10.2196/22878; Gerend MA, 2021, ANN BEHAV MED, V55, P321, DOI 10.1093/abm/kaaa056; Geskus RB, 2016, AIDS, V30, P37, DOI 10.1097/QAD.0000000000000874; Hebnes JB, 2014, J SEX MED, V11, P2630, DOI 10.1111/jsm.12652; Hildesheim A, 2007, JAMA-J AM MED ASSOC, V298, P743, DOI 10.1001/jama.298.7.743; Hildesheim A, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.02.021; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Jiang J, 2006, SEX TRANSM DIS, V33, P118, DOI 10.1097/01.olq.0000199763.14766.2b; Kang M, 2012, HIV MED, V13, P372, DOI 10.1111/j.1468-1293.2011.00979.x; Lau JTF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057204; Lin A, 2017, CLIN INFECT DIS, V64, P580, DOI 10.1093/cid/ciw845; Liu FF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15637; Loretan C, 2019, SEX TRANSM DIS, V46, P465, DOI 10.1097/OLQ.0000000000001008; Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3; McGrath L, 2019, SEX TRANSM INFECT, V95, P181, DOI 10.1136/sextrans-2018-053619; Milkman KL, 2011, P NATL ACAD SCI USA, V108, P10415, DOI 10.1073/pnas.1103170108; National Cancer Institute, HUMAN PAPILLOMAVIRUS; Noar SM, 2007, PSYCHOL BULL, V133, P673, DOI 10.1037/0033-2909.133.4.673; Pollock KG, 2019, VACCINE, V37, P5513, DOI 10.1016/j.vaccine.2018.11.081; Public Health England, HPV VACC MEN WHO HAV; Qin QQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep31081; Redding CA, 2011, AIDS CARE, V23, P10, DOI 10.1080/09540121.2010.498858; Reiter PL, 2020, JMIR RES PROTOC, V9, DOI 10.2196/16294; Reiter PL, 2018, LGBT HEALTH, V5, P325, DOI 10.1089/lgbt.2018.0059; Scott M, 2001, CLIN DIAGN LAB IMMUN, V8, P209, DOI 10.1128/CDLI.8.2.209-220.2001; Suen YT, 2021, INT J INFECT DIS, V106, P358, DOI 10.1016/j.ijid.2021.04.005; Tucker JD, 2018, LANCET HIV, V5, pE113, DOI 10.1016/S2352-3018(18)30027-4; Tugizov SM, 2013, VIROLOGY, V446, P378, DOI 10.1016/j.virol.2013.08.018; VERNON SD, 1993, VIRUS RES, V27, P133, DOI 10.1016/0168-1702(93)90077-Z; Wang ZX, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05024-4; Wang ZX, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040705; Wang ZX, 2021, J MED INTERNET RES, V23, DOI 10.2196/21465; Wang ZX, 2020, J MED INTERNET RES, V22, DOI 10.2196/17894; Wang ZX, 2018, VACCINE, V36, P2657, DOI 10.1016/j.vaccine.2018.03.057; Wang ZX, 2018, AIDS CARE, V30, P95, DOI 10.1080/09540121.2017.1338659; Wang ZX, 2013, VACCINE, V31, P4675, DOI 10.1016/j.vaccine.2013.06.090; Wong HTH, 2015, AIDS BEHAV, V19, P505, DOI 10.1007/s10461-014-0881-1; Zhang XJ, 2013, AIDS BEHAV, V17, P1129, DOI 10.1007/s10461-011-0085-x	45	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1218	10.3390/vaccines9111218			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF5UB	34835149	Green Published, gold			2022-04-29	WOS:000724134400001
J	Zona, S; Partesotti, S; Bergomi, A; Rosafio, C; Antodaro, F; Esposito, S				Zona, Stefano; Partesotti, Simonetta; Bergomi, Andrea; Rosafio, Cristiano; Antodaro, Francesco; Esposito, Susanna			Anti-COVID Vaccination for Adolescents: A Survey on Determinants of Vaccine Parental Hesitancy	VACCINES			English	Article						adolescents; COVID-19; COVID-19 vaccines; pediatric infectious diseases; vaccine hesitancy	UNITED-STATES; CHILDREN	Vaccine hesitancy has been considered one of the most severe threats to global health, as it represents an obstacle to achieving adequate vaccination coverage. Recent research studies aimed at investigating the propensity for anti-COVID vaccination among adults have found a high prevalence of vaccine hesitancy, but few data are available on parental vaccine hesitancy. We therefore built an anonymous online survey to investigate the factors related to the vaccine hesitancy of parents of adolescents between 12 and 17 years of age, with a special focus on demographic factors and the domains of confidence and complacency. The online survey was conducted by using the Crowd Signal platform from 15 July to 16 August 2021, in Italy. A total of 1799 analyzable questionnaires were analyzed. Overall, Favorable and Doubtful parents declared a higher level of confidence on safety and efficacy of pediatric vaccines and on confidence in health institutions than Hesitant/Reluctant ones (p-values < 0.001). The univariate multinomial logistic regression analysis and the multivariate multinomial logistic regression analysis showed that the Hesitant/Reluctant parents were younger than 40 years of age, with a secondary-school or three-year degree, free-lance, with a family income below euro28,000, with an erroneous perception of the risk of COVID-19 as disease and with fear of anti-COVID vaccination. These results, which should be confirmed in a larger population and in different geographical areas, should lead Institutions and stakeholders to identify targeted communication tools to improve trust in health institutions, especially by younger parents.	[Zona, Stefano; Partesotti, Simonetta; Esposito, Susanna] Local Hlth Agcy Modena, Primary Hlth Care Dept, I-41121 Modena, Italy; [Bergomi, Andrea; Rosafio, Cristiano; Antodaro, Francesco] Local Hlth Agcy Modena, I-41121 Modena, Italy; [Esposito, Susanna] Univ Parma, Pietro Barilla Childrens Hosp, Pediat Clin, I-43126 Parma, Italy		Zona, S (通讯作者)，Local Hlth Agcy Modena, Primary Hlth Care Dept, I-41121 Modena, Italy.	s.zona@ausl.mo.it; si.partesotti@ausl.mo.it; nao.bergomi@gmail.com; cristiano.rosafio@gmail.com; francesco.antodaro@gmail.com; susannamariaroberta.esposito@unipr.it	Esposito, Susanna/AAA-8275-2022	Zona, Stefano/0000-0003-3451-2744			ANDERSON R M, 1991; [Anonymous], 2020, VACCINAZIONE ANTI SA; Bagateli LE, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101115; CENSIS, 2014, CULT VACC IT IND GEN; Colgrove J, 2016, NEW ENGL J MED, V375, P1316, DOI 10.1056/NEJMp1608967; Del Riccio M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060633; Di Pietro ML, 2017, ANN I SUPER SANITA, V53, P157, DOI 10.4415/ANN_17_02_13; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2017, CLIN MICROBIOL INFEC, V23, P279, DOI 10.1016/j.cmi.2016.11.007; Emilia-Romagna, REP VACC ANT COVID 1; Esposito S, 2021, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.628072; European Medicine Agency, COM; European Medicine Agency, COVID 19 VACC JANSS; European Medicines Agency, SPIK PREV COVID 19 V; European Medicines Agency, 1 COVID 19 VACC APPR; European Medicines Agency, COVID 19 VACC SPIK A; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Greco A., VARIANTE DELTA RADDO; Handy LK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180759; Istituto Superiore di Sanita, VACC IT COP VACC IT; Jennings W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060593; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Ke RA, 2021, J THEOR BIOL, V517, DOI 10.1016/j.jtbi.2021.110621; Liu Y, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab124; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mann JA, 2021, J INFECTION, V83, P266, DOI 10.1016/j.jinf.2021.05.002; Milani GP, 2021, JAMA PEDIATR, V175, P193, DOI 10.1001/jamapediatrics.2020.3595; Ministero della salute, 2017, PIAN NAZ PREV VACC P; Montalti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040366; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Odone A, 2020, ACTA BIOMED, V91; Plotkin SA, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2021-050531; Principi N, 2016, EXPERT OPIN DRUG SAF, V15, P825, DOI 10.1517/14740338.2016.1167869; Raz A, 2021, VACCINE, V39, P4027, DOI 10.1016/j.vaccine.2021.06.004; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Sabbatucci M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122540; Seale H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235112; Shih SF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.558270; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; Stoddard M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254734; Stojanovic J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060661; Szilagyi PG, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-052335; Teasdale CA, 2021, J PEDIATR-US, V237, P292, DOI 10.1016/j.jpeds.2021.07.021; Trent Mallory, 2022, Vaccine, V40, P2498, DOI 10.1016/j.vaccine.2021.06.048; Wake AD, 2021, RISK MANAG HEALTHC P, V14, P2609, DOI 10.2147/RMHP.S311074; WHO, WHO COR COVID 19 DAS; World Health Organization, 2020, GLOBAL TUBERCULOSIS; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	50	1	1	13	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1309	10.3390/vaccines9111309			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH3PL	34835239	Green Published, gold			2022-04-29	WOS:000725350400001
J	Barbaro, AD; Palano, MT; Cucchiara, M; Gallazzi, M; Mortara, L; Bruno, A				De Lerma Barbaro, Andrea; Palano, Maria Teresa; Cucchiara, Martina; Gallazzi, Matteo; Mortara, Lorenzo; Bruno, Antonino			Metabolic Rewiring in the Tumor Microenvironment to Support Immunotherapy: A Focus on Neutrophils, Polymorphonuclear Myeloid-Derived Suppressor Cells and Natural Killer Cells	VACCINES			English	Review						neutrophils; PMN-MDSCs; natural killer cells; tumor metabolism; tumor microenvironment	MHC CLASS-I; NK CELLS; IMMUNE-RESPONSE; CANCER; IMMUNOMETABOLISM; POLARIZATION; INHIBITION; HALLMARKS	Leukocytes often undergo rapid changes in cell phenotype, for example, from a resting to an activated state, which places significant metabolic demands on the cell. These rapid changes in metabolic demand need to be tightly regulated to support immune cell effector functions during the initiation and downregulation of an immune response. Prospects for implementing cancer immunotherapy also rest on the idea of optimizing the metabolic profile of immune cell effectors. Here, we examine this issue by focusing on neutrophils and NK cells as cells of increasing interest in cancer immunology and tumor immunometabolism, because they can be targeted or, in the case of NK, used as effectors in immunotherapy. In addition, neutrophils and NK cells have been shown to functionally interact. In the case of neutrophils, we also extended our interest to polymorphonuclear MDSC (PMN-MDSCs), since the granulocytic subset of MDSCs share many phenotypes and are functionally similar to pro-tumor neutrophils. Finally, we reviewed relevant strategies to target tumor metabolism, focusing on neutrophils and NK cells.</p>	[De Lerma Barbaro, Andrea] Univ Insubria, Dept Biotechnol & Life Sci, Lab Comparat Physiopathol, I-21100 Varese, Italy; [Palano, Maria Teresa; Cucchiara, Martina; Bruno, Antonino] IRCCS MultiMed, Lab Innate Immun, Unit Mol Pathol Biochem & Immunol, I-20100 Milan, Italy; [Gallazzi, Matteo; Mortara, Lorenzo] Univ Insubria, Dept Biotechnol & Life Sci, Lab Immunol & Gen Pathol, I-21100 Varese, Italy		Barbaro, AD (通讯作者)，Univ Insubria, Dept Biotechnol & Life Sci, Lab Comparat Physiopathol, I-21100 Varese, Italy.; Bruno, A (通讯作者)，IRCCS MultiMed, Lab Innate Immun, Unit Mol Pathol Biochem & Immunol, I-20100 Milan, Italy.	a.delermabarbaro@uninsubria.it; mariateresa.palano@multimedica.it; martina.cucchiara@multimedica.it; matteo.gallazzi@uninsubria.it; lorenzo.mortara@uninsubria.it; antonino.bruno@multimedica.it	PALANO, MARIA TERESA/AAB-2990-2022; Bruno, Antonino/J-7066-2016	PALANO, MARIA TERESA/0000-0002-0867-9527; GALLAZZI, Matteo/0000-0001-6662-9352; CUCCHIARA, MARTINA/0000-0003-0030-5149; MORTARA, LORENZO/0000-0002-4757-7101; Bruno, Antonino/0000-0002-4790-0861	Italian Association for Cancer Research (AIRC)Fondazione AIRC per la ricerca sul cancro [MFAG2019-ID-22818]; Cariplo FoundationFondazione Cariplo [ID-2019-1609]; Italian Ministry of Health Ricerca Corrente-IRCCS MultiMedica; University of Insubria, Fondi di Ateneo per la Ricerca; assegno di ricerca, by the Italian Ministry of University and Research PRIN 2017 grant [2017NTK4HY]	A.B. received funds from the Italian Association for Cancer Research (AIRC), MFAG2019-ID-22818 and the Cariplo Foundation (ID-2019-1609). This work has been supported by the Italian Ministry of Health Ricerca Corrente-IRCCS MultiMedica (AB, DN) and the University of Insubria, Fondi di Ateneo per la Ricerca 2019 and 2020 (L.M). M.G. is a participant in the PhD course in Life Sciences and Biotechnology at the University of Insubria, Varese, Italy and is funded by an assegno di ricerca, by the Italian Ministry of University and Research PRIN 2017 grant 2017NTK4HY.	Andzinski L, 2016, INT J CANCER, V138, P1982, DOI 10.1002/ijc.29945; Assmann N, 2017, NAT IMMUNOL, V18, P1197, DOI 10.1038/ni.3838; Bahr I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00245; Bassani B, 2019, CANCERS, V11, DOI 10.3390/cancers11040461; Bi JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01999; Blois SM, 2011, J REPROD IMMUNOL, V88, P86, DOI 10.1016/j.jri.2010.11.002; Bosi A, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2438598; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Bruno A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00771; Bruno A, 2018, FASEB J, V32, P5365, DOI 10.1096/fj.201701103R; Bruno A, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju200; Bruno A, 2013, NEOPLASIA, V15, P133, DOI 10.1593/neo.121758; Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004; Butler LM, 2020, ADV DRUG DELIVER REV, V159, P245, DOI 10.1016/j.addr.2020.07.013; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cao YQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00348-8; Caputa G, 2019, NAT IMMUNOL, V20, P793, DOI 10.1038/s41590-019-0407-0; Cassim S, 2020, CANCERS, V12, DOI 10.3390/cancers12051119; Catalan E, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985924; Cerezo-Wallis D, 2021, FEBS J, DOI 10.1111/febs.16022; Charni S, 2010, J IMMUNOL, V185, P3498, DOI 10.4049/jimmunol.1001250; Chiossone L, 2018, NAT REV IMMUNOL, V18, P671, DOI 10.1038/s41577-018-0061-z; Chiu DKC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00530-7; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Condamine T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8943; Cong JJ, 2018, CELL METAB, V28, P243, DOI 10.1016/j.cmet.2018.06.021; Costantini C, 2011, J LEUKOCYTE BIOL, V89, P221, DOI 10.1189/jlb.0510250; Daher M, 2021, BLOOD, V137, P624, DOI 10.1182/blood.2020007748; Danhier P, 2017, BBA-BIOENERGETICS, V1858, P556, DOI 10.1016/j.bbabio.2017.02.001; Di Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0; Dong Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00235-2; Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473; Ferlazzo G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00159; Fu YJ, 2017, ONCOTARGET, V8, P57813, DOI 10.18632/oncotarget.18175; Furumaya C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02100; Gallazzi M, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586126; Ganeshan K, 2014, ANNU REV IMMUNOL, V32, P609, DOI 10.1146/annurev-immunol-032713-120236; Gerbec ZJ, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101454; Gnanaprakasam JNR, 2017, CYTOKINE GROWTH F R, V35, P63, DOI 10.1016/j.cytogfr.2017.03.004; Groth C, 2019, BRIT J CANCER, V120, P16, DOI 10.1038/s41416-018-0333-1; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Guo CQ, 2019, ADV CANCER RES, V143, P195, DOI 10.1016/bs.acr.2019.03.004; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanna J, 2006, NAT MED, V12, P1065, DOI 10.1038/nm1452; Hasmim M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00482; He W, 2016, SCI REP-UK, V6, DOI 10.1038/srep24506; Hossain F, 2015, CANCER IMMUNOL RES, V3, P1236, DOI 10.1158/2326-6066.CIR-15-0036; Hsu BE, 2019, CELL REP, V27, P3902, DOI 10.1016/j.celrep.2019.05.091; Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702; Injarabian L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010287; Jaillon S, 2020, NAT REV CANCER, V20, P485, DOI 10.1038/s41568-020-0281-y; Jian SL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.192; Jung J, 2019, NAT CELL BIOL, V21, P85, DOI 10.1038/s41556-018-0217-x; Karre K, 2002, SCAND J IMMUNOL, V55, P221, DOI 10.1046/j.1365-3083.2002.01053.x; Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1; Knudsen NH, 2020, IMMUNITY, V53, P1131, DOI 10.1016/j.immuni.2020.11.018; Kobayashi T, 2020, BLOOD, V136, P3004, DOI 10.1182/blood.2020005602; Krishnamoorthy M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051170; Kumar S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02099; Lanuza PM, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03010; Laubichler Manfred D, 2007, Novartis Found Symp, V284, P20; Li PS, 2020, NAT IMMUNOL, V21, P1444, DOI 10.1038/s41590-020-0783-5; Li PS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18125-0; Li S, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.112; Lim AR, 2020, ELIFE, V9, DOI 10.7554/eLife.55185; Linke M, 2017, FEBS LETT, V591, P3089, DOI 10.1002/1873-3468.12711; Makowski L, 2020, IMMUNOL REV, V295, P5, DOI 10.1111/imr.12858; Mao YM, 2014, CLIN CANCER RES, V20, P4096, DOI 10.1158/1078-0432.CCR-14-0635; Martinez-Reyes I, 2021, NAT REV CANCER, V21, P669, DOI 10.1038/s41568-021-00378-6; Masucci MT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01146; Maurer S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608849; Mehla K, 2019, TRENDS CANCER, V5, P822, DOI 10.1016/j.trecan.2019.10.007; Mehmeti-Ajradini M, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000893; Meng G, 2020, BRIT J CANCER, V122, P111, DOI 10.1038/s41416-019-0639-7; Michelet X, 2018, NAT IMMUNOL, V19, P1330, DOI 10.1038/s41590-018-0251-7; Molgora M, 2018, SCAND J IMMUNOL, V88, DOI 10.1111/sji.12705; Molon B, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00020; Niavarani SR, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6045-y; Nissen SE, 2010, ARCH INTERN MED, V170, P1191, DOI 10.1001/archinternmed.2010.207; O'Brien KL, 2019, NAT REV IMMUNOL, V19, P282, DOI 10.1038/s41577-019-0139-2; O'Sullivan D, 2019, NAT REV IMMUNOL, V19, P324, DOI 10.1038/s41577-019-0140-9; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Paudel BB, 2019, P NATL ACAD SCI USA, V116, P3370, DOI 10.1073/pnas.1900169116; Paul S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01124; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Poznanski SM, 2018, INFLAMM RES, V67, P813, DOI 10.1007/s00011-018-1174-3; Radomska-Lesniewska DM, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071621; Raulet DH, 2006, NAT REV IMMUNOL, V6, P520, DOI 10.1038/nri1863; Rice CM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07505-2; Sadiku P, 2021, CELL METAB, V33, DOI 10.1016/j.cmet.2020.11.016; Sanchez-Pino MD, 2021, CELL IMMUNOL, V362, DOI 10.1016/j.cellimm.2021.104302; Schuster IS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00235; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Slattery K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02915; Sun R, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100825; Tai LH, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1431082; Terren I, 2020, SEMIN HEMATOL, V57, P213, DOI 10.1053/j.seminhematol.2020.10.003; Terren I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02278; Uehara T, 2019, INT IMMUNOL, V31, P187, DOI 10.1093/intimm/dxy079; Ugolini A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138581; Uribe-Querol E, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/983698; van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072; Veglia F, 2021, J EXP MED, V218, DOI 10.1084/jem.20201803; Veglia F, 2021, NAT REV IMMUNOL, V21, P485, DOI 10.1038/s41577-020-00490-y; Veglia F, 2019, NATURE, V569, P73, DOI 10.1038/s41586-019-1118-2; Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884; Vitale I, 2019, CELL METAB, V30, P36, DOI 10.1016/j.cmet.2019.06.001; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Waldhauer I, 2008, ONCOGENE, V27, P5932, DOI 10.1038/onc.2008.267; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Wang WJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.605154; Wang X, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20447-y; Wang X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02456; Wensveen FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00441; Xia LZ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01316-8; Yazdani HO, 2019, CANCER RES, V79, P5626, DOI 10.1158/0008-5472.CAN-19-0800; Yin ZP, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1409-3; Young A, 2018, CANCER RES, V78, P1003, DOI 10.1158/0008-5472.CAN-17-2826; Zaiatz-Bittencourt V, 2018, J IMMUNOL, V200, P3934, DOI 10.4049/jimmunol.1701461; Zecca A, 2020, CANCER IMMUNOL IMMUN, V69, P1589, DOI 10.1007/s00262-020-02561-4; Zheng XH, 2019, NAT IMMUNOL, V20, P1656, DOI 10.1038/s41590-019-0511-1; Zhou J, 2018, SEMIN IMMUNOL, V35, P19, DOI 10.1016/j.smim.2017.12.004; Zhu H, 2020, CELL STEM CELL, V27, P224, DOI 10.1016/j.stem.2020.05.008; Zuo HQ, 2020, ACS APPL MATER INTER, V12, P55723, DOI 10.1021/acsami.0c18180	125	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1178	10.3390/vaccines9101178			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ2EV	34696286	Green Published			2022-04-29	WOS:000713634300001
J	Li, XG; Liang, C; Xiao, XM				Li, Xiaoguang; Liang, Chao; Xiao, Xiumei			SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration	VACCINES			English	Article						SARS-CoV-2; COVID-19 vaccine; neutralizing antibody detection; enzyme-linked immunosorbent assay		This study investigated the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies following inoculation with the coronavirus disease (COVID-19) vaccine. From June to July 2021, 127 participants who had completed COVID-19 vaccination (inactivated SARS-CoV-2 vaccine, 64; CoronaVac, 61; CanSino, 2) were recruited and tested using SARS-CoV-2 neutralizing antibody kits. The positive detection rate (inhibition of neutralizing antibodies & GE; 30%) was calculated and stratified according to population characteristics and inoculation time. The positive rate of neutralizing antibody was 47.22% (17/36) in men and 53.85% (49/91) in women, and 54.55% (24/44) in BMI & GE; 24 and 50.60% (42/83) in BMI < 24. Age was stratified as 20-29, 30-39, 40-49, and & GE;50; positive detection rates of SARS-CoV-2 neutralizing antibodies were observed in 60.00% (24/40), 50.00% (21/42), 48.39% (15/31), and 42.86% (6/14), respectively, but with no significant difference (x(2) = 1.724, p = 0.632). Among 127 vaccinated participants, 66 (51.97%) were positive. The positive detection rate was 63.93% (39/61) with CoronaVac and 42.19% (27/64) with the inactivated SARS-CoV-2 vaccine (significance x(2) = 5.927, p = 0.015). Multivariate analysis revealed a significant difference in vaccination times, with average vaccination weeks in the positive and negative groups of 11.57 & PLUSMN; 6.48 and 17.87 & PLUSMN; 9.17, respectively (t= -4.501, p < 0.001). The positive neutralizing antibody rate was 100.00%, 60.00%, 58.33%, 55.56%, 43.14%, 28.57%, and 0.00% at 2-4, 5-8, 9-12, 13-16,17-20, 21-24, and > 24 weeks, respectively (x(2) = 18.030, p = 0.006). Neutralizing antibodies were detected after COVID-19 inoculation, with differences relating to inoculation timing. This study provides a reference for vaccine evaluation and follow-up immunization strengthening.</p>	[Li, Xiaoguang; Liang, Chao] Peking Univ Third Hosp, Dept Infect Dis, Beijing 100191, Peoples R China; [Xiao, Xiumei] Peking Univ Third Hosp, Dept Lab Med, Beijing 100191, Peoples R China		Li, XG (通讯作者)，Peking Univ Third Hosp, Dept Infect Dis, Beijing 100191, Peoples R China.	xxmlza@163.com		Li, Xiaoguang/0000-0002-9438-5313	National Major Science and Technology Projects [2018ZX10732401-003]	This work was funded by the National Major Science and Technology Projects (project no. 2018ZX10732401-003).	Assadiasl Sara, 2020, Human Antibodies, V28, P287, DOI 10.3233/HAB-200429; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Caini S, 2020, EUROSURVEILLANCE, V25, P9, DOI 10.2807/1560-7917.ES.2020.25.23.2000980; Chang FY, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00663-w; Chen XH, 2022, CLIN INFECT DIS, V74, P734, DOI 10.1093/cid/ciab646; Deeks JJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013652; Gao GF., 2021, BIORXIV; Garcia-Beltran WF, 2021, CELL, V184, P476, DOI 10.1016/j.cell.2020.12.015; GeurtsvanKessel CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17317-y; Ho MS, 2005, EMERG INFECT DIS, V11, P1730, DOI 10.3201/eid1111.040659; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Ke ZL, 2020, NATURE, V588, P498, DOI 10.1038/s41586-020-2665-2; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Meyer B, 2020, CLIN MICROBIOL INFEC, V26, P1386, DOI 10.1016/j.cmi.2020.06.024; Meyer B, 2020, EMERG MICROBES INFEC, V9, P2394, DOI 10.1080/22221751.2020.1835448; Nielsen, 2020, EVALUATION 9 COMMERC, DOI [10.1101/2020.04.09.20056325, DOI 10.1101/2020.04.09.20056325]; Normark J, 2021, NEW ENGL J MED, V385, P1049, DOI 10.1056/NEJMc2110716; Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421; Rogliani P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030227; Sil BK, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246346; Taylor SC, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02438-20; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang GL, 2021, NEW ENGL J MED, V384, P2354, DOI 10.1056/NEJMc2103022; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wu F., 2020, medRxiv, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]; Zainol Rashid Z, 2020, MALAYS J PATHOL, V42, P13; Zhou RH, 2020, IMMUNITY, V53, P864, DOI 10.1016/j.immuni.2020.07.026	29	0	0	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1139	10.3390/vaccines9101139			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ0VB	34696247	gold, Green Published			2022-04-29	WOS:000713539500001
J	Nikolova, KA; Andersson, M; Slotved, HC; Koch, A				Nikolova, Kristiana Alexandrova; Andersson, Mikael; Slotved, Hans-Christian; Koch, Anders			Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland	VACCINES			English	Article						invasive pneumococcal disease; PCV13; pneumococcal conjugate vaccine; Greenland; pneumococcal serotypes; non-vaccine serotype; vaccine serotype; streptococcal infection; herd protection; Inuit	CHILDREN; EPIDEMIOLOGY; SURVEILLANCE; POPULATION; SEROTYPES; ADULTS; IMPACT; CARRIAGE; RISK	The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in 2010 to the childhood vaccination program in Greenland. This study aimed to estimate the effectiveness of the PCV13 on the incidence of invasive pneumococcal disease (IPD) in children and in adults in Greenland. IPD cases from the pre-PCV13 period (January 1995-September 2010) were compared with the post-PCV13 period (September 2010-October 2020). Register data were collected from laboratory records, IPD reports, the national registry on admissions, and medical files. A total of 295 IPD cases were identified in the study period. Overall IPD incidence rate (IR) declined from the pre-PCV13 period to the post-PCV13 period (IR 23.3 to 15.3 per 100,000 person years). Overall IPD incidence among children decreased significantly, whereas overall IPD incidence among the elderly increased significantly. During the post-PCV13 period, the incidence of vaccine serotype (VT) IPD decreased in all ages, while the incidence of non-vaccine serotype (NVT) IPD increased. This increase was most substantial among elderly >= 60 years. In conclusion, the PCV13 has reduced incidence rates of IPD in Greenland. However, the increase in NVT IPD among the elderly is noteworthy, and sup-ports continued surveillance of IPD in the population of Greenland.	[Nikolova, Kristiana Alexandrova; Andersson, Mikael; Koch, Anders] Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark; [Nikolova, Kristiana Alexandrova; Koch, Anders] Univ Hosp, Rigshosp, Dept Infect Dis, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark; [Slotved, Hans-Christian] Statens Serum Inst, Dept Bacteria Parasites & Fungi, Artillerivej 5, DK-2300 Copenhagen S, Denmark; [Koch, Anders] Statens Serum Inst, Dept Infect Dis Epidemiol & Prevent, Artillerivej 5, DK-2300 Copenhagen S, Denmark; [Koch, Anders] Ilisimatusarfik Univ Greenland, Manutooq 1, Nuuk 3900, Greenland; [Koch, Anders] Queen Ingrids Hosp, Dept Internal Med, Nuuk 3900, Greenland		Nikolova, KA (通讯作者)，Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark.; Nikolova, KA (通讯作者)，Univ Hosp, Rigshosp, Dept Infect Dis, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.	KRIN@ssi.dk; ASO@ssi.dk; HCS@ssi.dk; AKO@ssi.dk	Slotved, Hans-Christian/H-7476-2019	Slotved, Hans-Christian/0000-0002-7294-4911	Independent Research Fund Denmark; Grosserer L.F. Foghts Fond grant; Dagmar Marshall Fond grant [500020]; Fonden af 1870 grant; Ville Heise Legat grant; Aase og Ejnar Danielsens Fond grant; Holms Mindelegat grant; Rigshospitalet University Hospital	This research was funded by Independent Research Fund Denmark grant number 0168-0019B, the Grosserer L.F. Foghts Fond grant number 21.778, the Dagmar Marshall Fond grant number J.nr.-500020 and J.nr.-131120, the Fonden af 1870 grant number RL-WSDOCS.FID1290380, the Ville Heise Legat grant number M18-19, the Aase og Ejnar Danielsens Fond grant number 20100179, the Holms Mindelegat grant number 20064, and Rigshospitalet University Hospital grant number E-23997-01.	Albertsen N, 2020, INT J CIRCUMPOL HEAL, V79, DOI 10.1080/22423982.2020.1721983; Albertsen N, 2018, INT J CIRCUMPOL HEAL, V77, DOI 10.1080/22423982.2018.1426948; Baxter R, 2021, J PEDIAT INF DIS SOC, V10, P141, DOI 10.1093/jpids/piaa035; Bruce M, 2016, PUBLIC HEALTH, V137, P5, DOI 10.1016/j.puhe.2016.06.014; Bruce MG, 2008, EMERG INFECT DIS, V14, P25, DOI 10.3201/eid1401.071315; Bruce MG, 2015, VACCINE, V33, P4813, DOI 10.1016/j.vaccine.2015.07.080; Christiansen J, 2004, SCAND J INFECT DIS, V36, P325, DOI 10.1080/00365540410020460; Dalcin D, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3531-9; de Miguel S, 2021, CLIN INFECT DIS, V73, pE3778, DOI 10.1093/cid/ciaa1483; Demczuk WHB, 2018, VACCINE, V36, P4701, DOI 10.1016/j.vaccine.2018.06.018; Eton V, 2017, INT J INFECT DIS, V65, P27, DOI 10.1016/j.ijid.2017.09.016; Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517; Garcia-Rodriguez JA, 2002, J ANTIMICROB CHEMOTH, V50, P59, DOI 10.1093/jac/dkf506; Gonzalez-Diaz A, 2020, CLIN MICROBIOL INFEC, V26, P753, DOI 10.1016/j.cmi.2019.10.034; Gounder PP, 2015, J INFECTION, V71, P179, DOI 10.1016/j.jinf.2015.04.001; Hanquet G, 2019, THORAX, V74, P473, DOI 10.1136/thoraxjnl-2018-211767; Hansen H.L., 2020, VEJLEDNING UDVIDEDE; Harboe ZB, 2014, CLIN INFECT DIS, V59, P1066, DOI 10.1093/cid/ciu524; Henckaerts L, 2021, ACTA CLIN BELG, V76, P272, DOI 10.1080/17843286.2020.1721131; Htar MTT, 2019, EXPERT REV VACCINES, V18, P1145, DOI 10.1080/14760584.2019.1688149; Kathy H.N., 2009, IMMUNOLOGICAL BASIS, P1; Kleist F.S., 2010, USI LANDSLAEGEEMBEDE; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; LeMeur JB, 2019, CAN J PUBLIC HEALTH, V110, P36, DOI 10.17269/s41997-018-0138-2; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; Meyer A, 2008, EMERG INFECT DIS, V14, P76, DOI 10.3201/eid1401.071240; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Navne J., 2014, THESIS U COPENHAGEN; Navne JE, 2016, EPIDEMIOL INFECT, V144, P3226, DOI 10.1017/S0950268816001461; Navne JE, 2017, INT J CIRCUMPOL HEAL, V76, DOI 10.1080/22423982.2017.1309504; Nordholm AC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171094; Ouldali N, 2021, LANCET INFECT DIS, V21, P137, DOI 10.1016/S1473-3099(20)30165-1; Parkinson AJ, 2008, EMERG INFECT DIS, V14, P18, DOI 10.3201/eid1401.070717; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Regev-Yochay G, 2017, VACCINE, V35, P2449, DOI 10.1016/j.vaccine.2017.03.031; Rudolph K, 2013, INT J CIRCUMPOL HEAL, V72, P611, DOI 10.3402/ijch.v72i0.20854; Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0; Singleton R, 2013, PEDIATR INFECT DIS J, V32, P257, DOI 10.1097/INF.0b013e3182748ada; Singleton RJ, 2007, JAMA-J AM MED ASSOC, V297, P1784, DOI 10.1001/jama.297.16.1784; Slotved HC, 2016, VACCINE, V34, P769, DOI 10.1016/j.vaccine.2015.12.056; Statistics Greenland, 2020, GREENL FIG 2020, V17th; Steens A, 2013, VACCINE, V31, P6232, DOI 10.1016/j.vaccine.2013.10.032; Torres A, 2015, THORAX, V70, P984, DOI 10.1136/thoraxjnl-2015-206780; Vadlamudi NK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239848; Vadlamudi NK, 2019, CLIN INFECT DIS, V69, P34, DOI 10.1093/cid/ciy872; van der Linden M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220453; Wijayasri S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226353; World Health Organization & International Diabetes Federation, 2006, DEV POL REV DPR, P1	48	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1123	10.3390/vaccines9101123			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP6YD	34696230	gold, Green Published			2022-04-29	WOS:000713273600001
J	Ueda, Y; Miyagi, E				Ueda, Yutaka; Miyagi, Etsuko			Importance of Education about Cervical Cancer and Its Preventive Measures for the Promotion of HPV Vaccine According to the WHO Strategies	VACCINES			English	Editorial Material									[Ueda, Yutaka] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, Osaka 5650871, Japan; [Miyagi, Etsuko] Yokohama City Univ, Sch Med, Dept Obstet & Gynecol, Yokohama, Kanagawa 2360004, Japan		Ueda, Y (通讯作者)，Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, Osaka 5650871, Japan.	y.ueda@gyne.med.osaka-u.ac.jp; emiyagi@yokohama-cu.ac.jp		Miyagi, Etsuko/0000-0002-5492-0844; Ueda, Yutaka/0000-0001-8760-6379			Brisson M, 2020, LANCET, V395, P575, DOI 10.1016/S0140-6736(20)30068-4; Bruni L, 2021, PREV MED, V144, DOI 10.1016/j.ypmed.2020.106399; Njuguna DW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101099; Sukegawa A, 2021, J OBSTET GYNAECOL RE, V47, P3618, DOI 10.1111/jog.14949; Suzuki Y, 2021, J MED INTERNET RES, V23, DOI 10.2196/28355	5	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1199	10.3390/vaccines9101199			2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS5XV	34696307	Green Published, gold			2022-04-29	WOS:000715254500001
J	Ticona, JPA; Nery, N; Victoriano, R; Fofana, MO; Ribeiro, GS; Giorgi, E; Reis, MG; Ko, AI; Costa, F				Aguilar Ticona, Juan P.; Nery, Nivison; Victoriano, Renato; Fofana, Mariam O.; Ribeiro, Guilherme S.; Giorgi, Emanuele; Reis, Mitermayer G.; Ko, Albert, I; Costa, Federico			Willingness to Get the COVID-19 Vaccine among Residents of Slum Settlements	VACCINES			English	Article						COVID-19; vaccine; vaccine hesitancy	MEASLES OUTBREAK; HESITANCY	Slum residents are more vulnerable to COVID-19 infection. Without a specific treatment, vaccination became the main strategy against COVID-19. In this study, we determined the rate and factors associated with the willingness to get vaccinated against COVID-19 among slum residents and their main reasons associated with the vaccine intention. The study was conducted in Pau da Lima, a slum community in Salvador Brazil. In total, 985 residents were interviewed. Among them 66.0% (650/985) were willing to get vaccinated, 26.1% (257/985) were hesitant to take the vaccine and 7.9% (78/285) were not sure. The main reasons cited for vaccine hesitancy or being unsure were concerns about vaccine efficacy and potential side effects. In contrast, the main reasons cited for wanting the vaccine were the high incidence of COVID-19 cases and participants' self-perception of their own health history. Multivariate analysis identified that COVID-19 vaccine hesitancy was associated with younger age and low social capital, summarized as low perceived importance of vaccination to protect one's family, friends and community. Slum residents have been less willing to vaccinate than the general population. Social capital presents a critical opportunity in the design of communication campaigns to increase COVID-19 vaccine acceptance in slum settings.	[Aguilar Ticona, Juan P.; Nery, Nivison; Costa, Federico] Univ Fed Bahia, Inst Saude Colet, Rua Basilio da Gama S-N, BR-40110040 Salvador, BA, Brazil; [Aguilar Ticona, Juan P.; Nery, Nivison; Victoriano, Renato; Ribeiro, Guilherme S.; Reis, Mitermayer G.; Ko, Albert, I; Costa, Federico] Minist Saude, Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil; [Fofana, Mariam O.; Reis, Mitermayer G.; Ko, Albert, I; Costa, Federico] Yale Univ, Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, 60 Coll St,POB 208034, New Haven, CT 06520 USA; [Ribeiro, Guilherme S.; Reis, Mitermayer G.] Univ Fed Bahia, Fac Med Bahia, Praca 15 Novembro S-N, BR-40026010 Salvador, BA, Brazil; [Giorgi, Emanuele] Univ Lancaster, Sch Hlth & Med, Lancaster LAI 4YB, England		Costa, F (通讯作者)，Univ Fed Bahia, Inst Saude Colet, Rua Basilio da Gama S-N, BR-40110040 Salvador, BA, Brazil.; Ko, AI; Costa, F (通讯作者)，Minist Saude, Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.; Ko, AI; Costa, F (通讯作者)，Yale Univ, Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, 60 Coll St,POB 208034, New Haven, CT 06520 USA.	juanpat@ufba.br; nivison.nery@fiocruz.br; renato.victoriano@fiocruz.br; mariam.fofana@yale.edu; guilherme.ribeiro@fiocruz.br; e.giorgi@lancaster.ac.uk; miter@bahia.fiocruz.br; albert.ko@yale.edu; federico.costa@ufba.br	Aguilar Ticona, Juan Pablo/AAE-3068-2021; Ribeiro, Guilherme/B-6624-2008; Ko, Albert Icksang/P-2343-2015; Fofana, Mariam O./H-5208-2019	Aguilar Ticona, Juan Pablo/0000-0002-6971-2677; Ribeiro, Guilherme/0000-0002-6798-2059; Ko, Albert Icksang/0000-0001-9023-2339; Fofana, Mariam O./0000-0002-2874-471X; Giorgi, Emanuele/0000-0003-0640-181X; Reis, Mitermayer/0000-0002-3051-9060	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIAID R01 AI052473, R25 U01AI088752, FIC R01 TW009504, R25 TW009338, F31 AI114245, R01 AI121207]; Wellcome TrustWellcome TrustEuropean Commission [218987/Z/19/Z]; Coordination for the Improvement of Higher Education (CAPES) from BrazilCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); National Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This research was funded by grants from the National Institutes of Health (NIAID R01 AI052473 (A.I.K.), R25 U01AI088752 (A.I.K.), FIC R01 TW009504 (A.I.K.), R25 TW009338 (A.I.K.), F31 AI114245 (A.I.K.), R01 AI121207 (A.I.K.)), Wellcome Trust (218987/Z/19/Z (F.C.)), Coordination for the Improvement of Higher Education (CAPES) from Brazil, and National Council for Scientific and Technological Development (CNPq) (research scholarship to G.S.R. and F.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arghittu A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115642; Corburn J, 2020, J URBAN HEALTH, V97, P348, DOI 10.1007/s11524-020-00438-6; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Felzemburgh RDM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002927; George CE, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821000273; Goldani LZ, 2018, BRAZ J INFECT DIS, V22, P359, DOI 10.1016/j.bjid.2018.11.001; Horton R, 2020, LANCET, V396, P1474, DOI 10.1016/S0140-6736(20)32315-1; IBGE, EST POP 2017 CIT BAH; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Makridis CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245135; Malani A, 2021, LANCET GLOB HEALTH, V9, pE110, DOI 10.1016/S2214-109X(20)30467-8; McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003; Nelson R, 2019, LANCET INFECT DIS, V19, P248, DOI 10.1016/S1473-3099(19)30074-X; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618; Winter K., 2010, Morbidity and Mortality Weekly Report, V59, P817; Wong ASY, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-020-00615-x; Worldbank D., POPULATION LIVING SL; Zhao YX, 2020, J MED INTERNET RES, V22, DOI 10.2196/18825	22	1	1	5	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							951	10.3390/vaccines9090951			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3PE	34579188	Green Published, gold			2022-04-29	WOS:000702119600001
J	Bonito, B; Balzi, D; Boccalini, S; Bonanni, P; Mereu, G; Santini, MG; Bechini, A				Bonito, Benedetta; Balzi, Daniela; Boccalini, Sara; Bonanni, Paolo; Mereu, Giovanna; Santini, Maria Grazia; Bechini, Angela			Descriptive Observational Study of Tdap Vaccination Adhesion in Pregnant Women in the Florentine Area (Tuscany, Italy) in 2019 and 2020	VACCINES			English	Article						COVID-19; pandemic; pregnancy; newborn; pertussis; vaccination; vaccination coverage; Florence; Italy	PERTUSSIS VACCINATION; UNITED-STATES; COVERAGE; INFLUENZA; INFANTS	Background: Tdap (Tetanus-Diphtheria-acellular Pertussis) vaccination is nowadays a worldwide-recommended practice to immunize pregnant women. The vaccine administration at the third trimester of pregnancy (as recommended by the WHO) would ensure antibody protection to both the mother and the newborn and has contributed to the significant drop of pertussis cases in infants. The aim of this observational study was to describe for the first time the socio-demographic characteristics and determinants of Tdap vaccination adhesion of pregnant women in the Florentine area. Methods: Information about parents' vaccination status, their citizenship, employment type and mothers' previous pregnancies and/or abortions were collected at the time of birth through the assistance birth certificates (CedAP) both for the years 2019 and 2020. This archive and the regional SISPC (Collective Prevention Healthcare Information System) linked using an anonymous unique personal identifier to retrieve the mother's vaccination status. Results: We found an overall Tdap vaccination adhesion of 43% in 2019 and 47.3% in 2020. Several socio-demographic parameters would determine an increased vaccination adhesion, including parents' geographical origin, mothers' age and educational background, as well as the number of previous deliveries, abortions or voluntary termination of pregnancy. Conclusions: Since not much data are available on this topic in Italy, this study may constitute the baseline information for Tdap vaccination adhesion in pregnant women in the Florentine area (Italy). Thus, future successful vaccination strategies may be designed accordingly.	[Bonito, Benedetta; Boccalini, Sara; Bonanni, Paolo; Bechini, Angela] Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy; [Balzi, Daniela; Mereu, Giovanna; Santini, Maria Grazia] AUSL Toscana Ctr, I-50122 Florence, Italy		Bechini, A (通讯作者)，Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy.	benedetta.bonito@unifi.it; daniela.balzi@uslcentro.toscana.it; sara.boccalini@unifi.it; paolo.bonanni@unifi.it; giovanna.mereu@uslcentro.toscana.it; mariagrazia.santini@uslcentro.toscana.it; angela.bechini@unifi.it		Bonanni, Paolo/0000-0003-2875-3744; Bonito, Benedetta/0000-0002-6116-8777; Bechini, Angela/0000-0002-6013-8779; Boccalini, Sara/0000-0002-9695-7549			Agricola E, 2016, HUM VACC IMMUNOTHER, V12, P1982, DOI 10.1080/21645515.2016.1188242; [Anonymous], ECDC PERTUSSIS ANN E; [Anonymous], EPICENTRO VACCINAZIO; [Anonymous], TUSCANY REGION VACCI; [Anonymous], HIST VACCINES ED RES; ARS Toscana, SORV EP MAL INF TOSC; Barchitta M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020168; CDC, PREGN WHOOP COUGH; D'Alessandro A, 2018, HUM VACC IMMUNOTHER, V14, P1573, DOI 10.1080/21645515.2018.1483809; Dudley MZ, 2021, PUBLIC HEALTH REP, V136, P699, DOI 10.1177/0033354920974660; Fiasca F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16224531; Istat, BIL DEM ANN 2019; Kharbanda EO, 2016, VACCINE, V34, P968, DOI 10.1016/j.vaccine.2015.12.046; Krishnaswamy S, 2018, HUM VACC IMMUNOTHER, V14, P1591, DOI 10.1080/21645515.2018.1445455; Laenen J, 2015, VACCINE, V33, P2125, DOI 10.1016/j.vaccine.2015.03.020; Leuridan E.E., 2020, MATERNAL IMMUNIZATIO, DOI [10.1016/C2016-0-05288-9, DOI 10.1016/C2016-0-05288-9]; Lichty JA, 1938, J CLIN INVEST, V17, P613, DOI 10.1172/JCI100987; Lu PJ, 2017, VACCINE, V35, P3104, DOI 10.1016/j.vaccine.2017.04.028; Maertens K, 2016, VACCINE, V34, P142, DOI 10.1016/j.vaccine.2015.10.100; Marchetti F, 2021, J MATERN-FETAL NEO M, V34, P2132, DOI 10.1080/14767058.2019.1659240; Ministry of Health, 33045 MIN HLTH; Ministry of Health, 0034074 MIN HLTH; Ministry of Health, NAT IMM PLAN 2017 20; Ravaldi C, 2021, WOMEN BIRTH, V34, P335, DOI 10.1016/j.wombi.2020.07.002; Razzaghi H, 2020, MMWR-MORBID MORTAL W, V69, P1391, DOI 10.15585/mmwr.mm6939a2; Salehi L, 2020, BRAIN BEHAV, V10, DOI 10.1002/brb3.1835; Scatigna M, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1894061; Tuscany Region, LIBR GRAV; WHO, PERT VACC PREV DIS; WHO, VACC PREV DIS MON SY; WHO, SAF IMM PREGN REV EV; Wiley KE, 2013, VACCINE, V31, P618, DOI 10.1016/j.vaccine.2012.11.052	32	1	1	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							955	10.3390/vaccines9090955			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2RT	34579192	Green Published, gold			2022-04-29	WOS:000702058200001
J	Fu, Y; Chen, F; Cui, LF; Zhao, Y; Zhang, HN; Fu, S; Zhang, JH				Fu, Yu; Chen, Fang; Cui, Lifen; Zhao, Yue; Zhang, Henan; Fu, Shuang; Zhang, Jihong			Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection	VACCINES			English	Article						SARS-CoV-2; inactivated vaccines; lymphocyte subsets; cytokines; neutralizing antibodies	COVID-19; IMMUNITY; LESSONS	Clarifying changes in the immune microenvironment caused by vaccination is crucial for the development and application of vaccines. In this study, we analyzed seroconversion of antibodies, 12 key cytokines, and 34 lymphocyte subsets at three time points (D-1, D14, and D42) around vaccination and differences between two inactivated vaccines (Sinopharm and Sinovas) to understand the immune response induced by inactivated vaccines in the real world. The results showed that 62.5% and 75% of the participants achieved neutralizing antibody seroconversion on D14 and D42, respectively. After vaccination, IL-5 and IL-6 increased, and INF-gamma decreased. IL6, IL-1B, INF-gamma, IL-8, and IL-12p70 showed statistical significance in the comparison of different groups. In terms of lymphocyte subsets, CD3 +, CD56 +, CD3 + CD8 +, CD8 + CD71 +, and CD56 + CD71 + showed upward trend, while CD19 +, CD4 + CD8 +, CD8 + CD45RA +, CD4 + HLA-DR +, CD8 + HLA-DR +, and CD8 + CD38 + showed downward trend. Additionally, we found certain differences between the two vaccines in neutralizing antibodies, cytokines, and lymphocyte subsets. This research is a clinical observation on the immune response after vaccination through detecting various immune indicators, which showed that the inactivated vaccines induced both humoral immunity by producing neutralizing antibodies and cellular immunity. The cellular immunity induced by these two vaccines was a Th2-biased response, and it may also lead to a mild Th1-type response.	[Fu, Yu; Chen, Fang; Cui, Lifen; Zhao, Yue; Zhang, Henan; Fu, Shuang; Zhang, Jihong] China Med Univ, Shengjing Hosp, Hematol Lab, Shenyang 110022, Peoples R China		Zhang, JH (通讯作者)，China Med Univ, Shengjing Hosp, Hematol Lab, Shenyang 110022, Peoples R China.	fuyu_727@126.com; chenfang020117@163.com; cuilf@sj-hospital.org; zy_3026@126.com; cmunancy9226428@126.com; coolerfspretty@126.com; zhangjh96615@126.com			Department of Science and Technology of Liaoning Province [2019JH1/10300005]; National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [82070165]	This work was supported by the Department of Science and Technology of Liaoning Province (Grant Number: 2019JH1/10300005) and the National Natural Science Foundation of China (NSFC) (Grant number: 82070165).	[Anonymous], WHO Coronavirus Disease (COVID-19): Vaccines.; [Anonymous], WHO STATUS COVID 19; [Anonymous], DRAFT LANDSCAPE COVI; Bozzano F, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009448; Ella R, 2021, LANCET INFECT DIS, V21, P950, DOI 10.1016/S1473-3099(21)00070-0; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Ganneru B, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102298; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Kreps S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00335-2; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sariol A, 2020, IMMUNITY, V53, P248, DOI 10.1016/j.immuni.2020.07.005; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Su S, 2021, NAT REV MICROBIOL, V19, P211, DOI 10.1038/s41579-020-00462-y; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Wang C, 2021, VACCINE, V39, P2833, DOI 10.1016/j.vaccine.2021.04.020; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	28	3	3	7	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1028	10.3390/vaccines9091028			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3CC	34579267	gold, Green Published			2022-04-29	WOS:000702085300001
J	Mustafa, A				Mustafa, Abu Salim			Adjuvants and Antigen-Delivery Systems for Subunit Vaccines against Tuberculosis	VACCINES			English	Editorial Material						tuberculosis; subunit vaccines; antigens; adjuvants; delivery systems	DOUBLE-BLIND; BCG; IMMUNOGENICITY; SAFETY; ADULTS; ID93+GLA-SE; INFECTION	The only licensed vaccine against tuberculosis is BCG. However, BCG has failed to provide consistent protection against tuberculosis, especially pulmonary disease in adults. Furthermore, the use of BCG is contraindicated in immunocompromised subjects. The research towards the development of new vaccines against TB includes the use of Mycobacterium tuberculosis antigens as subunit vaccines. Such vaccines may be used either alone or in the prime-boost model in BCG-vaccinated people. However, the antigens for subunit vaccines require adjuvants and/or delivery systems to induce appropriate and protective immune responses against tuberculosis and other diseases. Articles published in this Special Issue have studied the pathogenesis of BCG in children and the use of BCG and recombinant BCG as potential vaccines against asthma. Furthermore, the use of different adjuvants and delivery systems in inducing the protective immune responses after immunization with subunit vaccines has been described.	[Mustafa, Abu Salim] Kuwait Univ, Fac Med, Dept Microbiol, Safat 13110, Kuwait		Mustafa, A (通讯作者)，Kuwait Univ, Fac Med, Dept Microbiol, Safat 13110, Kuwait.	abu.mustafa@ku.edu.kw		Mustafa, AbuSalim/0000-0002-6074-1041	Kuwait University, Research Sector [MI02/12, SRUL02/13, GM01/15]	This research was funded by Kuwait University, Research Sector grant nos. MI02/12, SRUL02/13, and GM01/15.	Agger EM, 2016, ADV DRUG DELIVER REV, V102, P73, DOI 10.1016/j.addr.2015.11.012; Ahmed A, 2021, IMMUNOL REV, V301, P98, DOI 10.1111/imr.12968; Al Busaidi N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020150; [Anonymous], 2017, BCG VACCINES; Bekker LG, 2020, ECLINICALMEDICINE, V21, DOI 10.1016/j.eclinm.2020.100313; Biet F, 2005, ALLERGY, V60, P1065, DOI 10.1111/j.1398-9995.2005.00826.x; Biet F, 2002, INFECT IMMUN, V70, P6549, DOI 10.1128/IAI.70.12.6549-6557.2002; Coler RN, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0057-5; Day TA, 2021, LANCET RESP MED, V9, P373, DOI 10.1016/S2213-2600(20)30319-2; Dockrell HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01134; Drick N, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0689-2; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Franco AR, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010078; Han JY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020126; Hussein J, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2354-0; Ji NF, 2014, INT IMMUNOPHARMACOL, V21, P76, DOI 10.1016/j.intimp.2014.04.015; Kowalewicz-Kulbat M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030277; Mearns H, 2017, VACCINE, V35, P132, DOI 10.1016/j.vaccine.2016.11.023; Mustafa A.S., 2016, TXB BIOCH BIOTECHNOL, P1347; Mustafa A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010027; Mustafa A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040736; Mustafa A, 2020, MED PRIN PRACT, V29, P404, DOI 10.1159/000508719; Mustafa AS, 2009, EXPERT REV VACCINES, V8, P1309, DOI [10.1586/erv.09.93, 10.1586/ERV.09.93]; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]; Norrby M, 2017, VACCINE, V35, P1652, DOI 10.1016/j.vaccine.2017.01.055; Penn-Nicholson A, 2018, LANCET RESP MED, V6, P287, DOI 10.1016/s2213-2600(18)30077-8; Safar HA, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00402-x; Safar HA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228381; Sivakumaran D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.673532; Stewart E, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7080255; Suliman S, 2019, AM J RESP CRIT CARE, V199, P220, DOI 10.1164/rccm.201802-0366OC; Syggelou A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103224; Szpakowski P, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/359153; Thomas ZRM, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002790; Ullah I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01806; Vasina DV, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040166; Weerasuriya CK, 2020, J INTERN MED, V288, P661, DOI 10.1111/joim.13197; Whitlow E, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040586; Wilkie M, 2020, VACCINE, V38, P779, DOI 10.1016/j.vaccine.2019.10.102; World Health Organization, GLOBAL TUBERCULOSIS; World Health Organization, 2019, MULT ACC FRAM ACC PR; Ying WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094485; Zimmermann P, 2018, J INFECT DIS, V218, P679, DOI 10.1093/infdis/jiy207	43	0	0	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							972	10.3390/vaccines9090972			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2WH	34579209	Green Published, gold			2022-04-29	WOS:000702070100001
J	Singhatiraj, E; Pongpirul, K; Jongkaewwattana, A; Hirankarn, N				Singhatiraj, Ekachai; Pongpirul, Krit; Jongkaewwattana, Anan; Hirankarn, Nattiya			Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report	VACCINES			English	Article						COVID-19 vaccines; ChAdOx1-S; CoronaVac; intradermal injections; intramuscular injections		Inactivated SARS-CoV-2 vaccines are used in many countries with uncertain immunogenicity. Intradermal ChAdOx1 has been proposed as a resource-efficient heterologous third booster shot. A 52-year-old healthy male healthcare professional had received two intramuscular CoronaVac shots on 21 April and 23 May 2021, and volunteered to take a 0.1 mL ChAdOx1 vaccine intradermally on 29 June 2021, with minimal local reactions. The declining IgG levels against spike protein from the two CoronaVac shots increased to higher than 10,000 AU/mL two weeks after the intradermal ChAdOx1. Moreover, the neutralizing antibody increased from 66.77% to almost 100%. A ratio of 6.6:9.7 of IgA:IgG was observed. The 50% pseudovirus neutralization titer (PVNT50) against lentiviral pseudovirus bearing a codon-optimized spike gene (wild type, alpha, beta, and delta) were 1812.42, 822.99, 1025.42, 1347.13, respectively. The SARS-CoV-2-specific T cells to spike protein-peptide pools (532-788 SFU/10(6) PBMCs) were detected. In conclusion, the antibody and cellular responses to the intradermal ChAdOx1, as a third booster dose in a healthy volunteer who received two intramuscular CoronaVac shots, revealed a dramatic increase in the total antibodies, including IgG, IgA, as well as T cell responses against spike protein. The immune response from intradermal ChAdOx1 should be further investigated in a larger population.	[Singhatiraj, Ekachai; Pongpirul, Krit] Bumrungrad Int Hosp, Dept Med, Bangkok 10110, Thailand; [Pongpirul, Krit] Chulalongkorn Univ, Fac Med, Dept Prevent & Social Med, Bangkok 10330, Thailand; [Pongpirul, Krit] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Jongkaewwattana, Anan] Natl Sci & Technol Dev Agcy NSTDA, Natl Ctr Genet Engn & Biotechnol BIOTEC, Pathum Thani 12120, Thailand; [Hirankarn, Nattiya] Chulalongkorn Univ, Fac Med, Ctr Excellence Immunol & Immune Mediated Dis, Dept Microbiol, Bangkok 10330, Thailand		Pongpirul, K (通讯作者)，Bumrungrad Int Hosp, Dept Med, Bangkok 10110, Thailand.; Pongpirul, K (通讯作者)，Chulalongkorn Univ, Fac Med, Dept Prevent & Social Med, Bangkok 10330, Thailand.; Pongpirul, K (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	ekachai.singhatiraj@gmail.com; doctorkrit@gmail.com; anan.jon@biotec.or.th; nattiya.h@chula.ac.th	Pongpirul, Krit/H-4064-2019	Pongpirul, Krit/0000-0003-3818-9761; Jongkaewwattana, Anan/0000-0003-2354-9883			Borobia AM, 2021, LANCET, V398, P121, DOI 10.1016/S0140-6736(21)01420-3; Carter D, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aas9930; Department of Disease Control Ministry of Public Health of Thailand, 2021, DAIL COR VIR DIS COV; Dey A, 2021, VACCINE, V39, P4108, DOI 10.1016/j.vaccine.2021.05.098; Egunsola O, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.35693; Ferrara F, 2018, METHOD PROTOCOL, V1, DOI 10.3390/mps1010008; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Maeda K, 2021, SCI REP-UK, V11, DOI [10.1038/s41598-021-01930-y, 10.1101/2021.07.27.21261237]; Migliore A, 2021, RISK MANAG HEALTHC P, V14, P2079, DOI 10.2147/RMHP.S309707; Momin T, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101020; Nicolai L., 2021, THROMBOCYTOPENIA SPL, DOI [10.1101/2021.06.29.450356, DOI 10.1101/2021.06.29.450356]; Roozen GVT, 2021, TOLERABILITY SAFETY, DOI [10.1101/2021.07.27.21261116, DOI 10.1101/2021.07.27.21261116]; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Souza WM, 2021, LANCET MICROBE, V2, pE527, DOI 10.1016/S2666-5247(21)00129-4; Tebas P, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100689; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Zhang H., 2021, STUDIES LEVEL NEUTRA, P2214, DOI [10.1101/2021.08.18.21262214, DOI 10.1101/2021.08.18.21262214]	17	2	2	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							990	10.3390/vaccines9090990			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2WX	34579227	gold, Green Published			2022-04-29	WOS:000702071700001
J	Yuan, Y; Deng, ZM; Chen, MS; Yin, D; Zheng, JZ; Liu, YJ; Liu, XL; Zou, HC; Zhang, CH; Sun, CJ				Yuan, Yue; Deng, Zhaomin; Chen, Musha; Yin, Di; Zheng, Jiazhen; Liu, Yajie; Liu, Xinglai; Zou, Huachun; Zhang, Chunhuan; Sun, Caijun			Changes in Mental Health and Preventive Behaviors before and after COVID-19 Vaccination: A Propensity Score Matching (PSM) Study	VACCINES			English	Article						COVID-19 vaccine; mass vaccination; health belief; mental health; preventive behavior; propensity score matching (PSM)	BELIEF MODEL; POPULATION; RISK	Mass vaccination against the COVID-19 pandemic is ongoing worldwide to achieve herd immunity among the general population. However, little is known about how the COVID-19 vaccination would affect mental health and preventive behaviors toward the COVID-19 pandemic. In this study, we conducted a cross-sectional survey to address this issue among 4244 individuals at several COVID-19 vaccination sites in Guangzhou, China. Using univariate analysis and multiple linear regression models, we found that major demographic characteristics, such as biological sex, age, education level, and family per capita income, are the dominant influencing factors associated with health beliefs, mental health, and preventive behaviors. After propensity score matching (PSM) treatment, we further assessed the changes in the scores of health belief, mental health, and preventive behaviors between the pre-vaccination group and the post-vaccination group. When compared to individuals in the pre-vaccination group, a moderate but statistically significant lower score was observed in the post-vaccination group (p = 0.010), implying possibly improved psychological conditions after COVID-19 vaccination. In addition, there was also a moderate but statistically higher score of preventive behaviors in the post-vaccination group than in the pre-vaccination group (p < 0.001), suggesting a higher probability to take preventive measures after COVID-19 vaccination. These findings have implications for implementing non-pharmaceutical interventions combined with mass vaccination to control the rebound of COVID-19 outbreaks.	[Yuan, Yue; Deng, Zhaomin; Chen, Musha; Yin, Di; Zheng, Jiazhen; Liu, Yajie; Liu, Xinglai; Zou, Huachun; Sun, Caijun] Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen Campus, Shenzhen 518107, Peoples R China; [Zhang, Chunhuan; Sun, Caijun] Guangzhou Ctr Dis Control & Prevent, Guangzhou 510440, Peoples R China; [Sun, Caijun] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou 510080, Peoples R China		Sun, CJ (通讯作者)，Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen Campus, Shenzhen 518107, Peoples R China.; Sun, CJ (通讯作者)，Guangzhou Ctr Dis Control & Prevent, Guangzhou 510440, Peoples R China.; Sun, CJ (通讯作者)，Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou 510080, Peoples R China.	yuany263@mail2.sysu.edu.cn; dengzhm8@mail2.sysu.edu.cn; chenmsh28@mail2.sysu.edu.cn; yind6@mail2.sysu.edu.cn; 429zjz@smu.edu.cn; liuyj237@mail2.sysu.edu.cn; liuxlai@mail2.sysu.edu.cn; zouhuachun@mail.sysu.edu.cn; gzcdc_zhangch@gz.gov.cn; suncaijun@mail.sysu.edu.cn		Sun, Caijun/0000-0002-2000-7053; Zou, Huachun/0000-0002-8161-7576	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81971927]; Science and Technology Planning Project of Shenzhen City [JSGG20200225152008136, 20190804095916056]	This study was supported by grants from the National Natural Science Foundation of China (81971927) and the Science and Technology Planning Project of Shenzhen City (JSGG20200225152008136, 20190804095916056). All funding parties did not have any role in the design of the study or in the explanation of the data.	Ames-Guerrero RJ, 2021, BMC PSYCHIATRY, V21, DOI 10.1186/s12888-021-03326-8; Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Campbell F, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100509; Chemaitelly H, 2021, NAT MED, V27, P1614, DOI 10.1038/s41591-021-01446-y; Chen MS, 2021, INFECT DIS POVERTY, V10, DOI 10.1186/s40249-021-00878-5; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; Chodick G, 2022, CLIN INFECT DIS, V74, P472, DOI 10.1093/cid/ciab438; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Gazibara T, 2020, J GEN INTERN MED, V35, P2647, DOI 10.1007/s11606-020-05845-8; Gomes ACR, 2020, P ROY SOC B-BIOL SCI, V287, DOI 10.1098/rspb.2020.0525; Goularte JF, 2021, J PSYCHIATR RES, V132, P32, DOI 10.1016/j.jpsychires.2020.09.021; Government Council, PRESS C JOINT PREV C; Guangzhou Statistics Bureau, ADM DIVISION; Hannah Ritchie E.O.-O., COR COVID 19 VACC; Harper JA, 2017, GEN HOSP PSYCHIAT, V48, P56, DOI 10.1016/j.genhosppsych.2017.07.005; Hirschtritt ME, 2017, JAMA-J AM MED ASSOC, V318, P745, DOI 10.1001/jama.2017.9820; Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954; Inauen J, 2017, APPL PSYCHOL-HLTH WE, V9, P303, DOI 10.1111/aphw.12093; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Lai SJ, 2020, NATURE, V585, P410, DOI 10.1038/s41586-020-2293-x; [黎国威 Li Guowei], 2021, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V21, P469; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Liu L., VACCINATION COVERAGE; Mercadante AR, 2021, RES SOC ADMIN PHARM, V17, P1596, DOI 10.1016/j.sapharm.2020.12.012; Morsky B, 2019, P NATL ACAD SCI USA, V116, P8834, DOI 10.1073/pnas.1817095116; Nochaiwong S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89700-8; Saeed H, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13886; Santos AJ, 2017, EPIDEMIOL INFECT, V145, P1786, DOI 10.1017/S0950268817000814; Scholz U, 2019, APPL PSYCHOL-HLTH WE, V11, P173, DOI 10.1111/aphw.12156; Shahnazi H, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00776-2; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Simpson CR, 2021, NAT MED, V27, P1290, DOI 10.1038/s41591-021-01408-4; Tam CC, 2021, CURR PSYCHOL, DOI 10.1007/s12144-021-01942-x; Wang RK, 2021, IMMUNITY, V54, P1611, DOI 10.1016/j.immuni.2021.06.003; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; Wu J, 2020, J MED INTERNET RES, V22, DOI 10.2196/21980; Xia Juntao W.X, 2020, CHIN J WOMAN CHILD H, V31, P399; Yang J, 2021, NAT HUM BEHAV, V5, P1009, DOI 10.1038/s41562-021-01155-z; Zhang KC, 2021, J MED INTERNET RES, V23, DOI 10.2196/24673; Zhang WW, 2021, ECON RES-EKON ISTRAZ, DOI 10.1080/1331677X.2021.1930091	42	1	1	7	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1044	10.3390/vaccines9091044			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UW1YU	34579281	Green Published, gold			2022-04-29	WOS:000699961100001
J	Bignucolo, A; Scarabel, L; Mezzalira, S; Polesel, J; Cecchin, E; Toffoli, G				Bignucolo, Alessia; Scarabel, Lucia; Mezzalira, Silvia; Polesel, Jerry; Cecchin, Erika; Toffoli, Giuseppe			Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis	VACCINES			English	Review						SARS-CoV-2; COVID-19; vaccines; sex; gender; immune system	RECURRENT VENOUS THROMBOEMBOLISM; RISK; VACCINATION; RESPONSES	Sex differences in adaptive and innate immune responses have been shown to occur and anecdotal reports suggest that vaccine efficacy and safety may be sex-dependent. We investigated the influence of sex on the efficacy of COVID-19 vaccines through a systematic review and meta-analysis of clinical trials on COVID-19 vaccines. The safety profile of COVID-19 vaccines was also investigated. A systematic review included eligible articles published in three databases and three websites. A meta-analysis of available data, stratified by sex, was conducted. Statistical analysis was performed using the Hartung-Knapp-Sidik-Jonkman method, as well as influence and heterogeneity analysis. Pooled analysis showed significantly higher efficacy, measured as the rate of new COVID-19 cases, in men compared to women in the vaccine group (OR = 0.67, 95% CI 0.48-0.94). No sex differences were found in the rate of new cases in the control group (OR = 0.92, 95% CI 0.78-1.09). Safety profiles derived from pharmacovigilance reports appear to indicate increased toxicity in women. In conclusion, evidence of a potential role of sex in COVID-19 vaccine efficacy was described. It strengthens the need to include sex as a core variable in the clinical trial design of COVID-19 vaccines.	[Bignucolo, Alessia; Scarabel, Lucia; Mezzalira, Silvia; Cecchin, Erika; Toffoli, Giuseppe] IRCCS, Ctr Riferimento Oncol Aviano CRO, Expt & Clin Pharmacol, Via Franco Gallini 2, I-33081 Aviano, Italy; [Polesel, Jerry] IRCCS, Ctr Riferimento Oncol Aviano CRO, Unit Canc Epidemiol, Via Franco Gallini 2, I-33081 Aviano, Italy		Toffoli, G (通讯作者)，IRCCS, Ctr Riferimento Oncol Aviano CRO, Expt & Clin Pharmacol, Via Franco Gallini 2, I-33081 Aviano, Italy.	alessia.bignucolo@cro.it; lucia.scarabel@cro.it; silvia.mezzalira@cro.it; polesel@cro.it; ececchin@cro.it; gtoffoli@cro.it	Scarabel, Lucia/Q-3556-2019; Cecchin, Erika/K-2448-2018; Toffoli, Giuseppe/F-6642-2018; Mezzalira, Silvia/AAZ-6699-2020; bignucolo, alessia/AAZ-5587-2020; Polesel, Jerry/AAA-5750-2019	Scarabel, Lucia/0000-0002-8556-0140; Cecchin, Erika/0000-0001-7517-7490; Toffoli, Giuseppe/0000-0002-5323-4762; Mezzalira, Silvia/0000-0001-5279-5181; bignucolo, alessia/0000-0003-4379-291X; Polesel, Jerry/0000-0001-9381-1520	Italian Ministry of HealthMinistry of Health, Italy	This work was supported by the Italian Ministry of Health (Ricerca Corrente).	[Anonymous], 2020, FDA BRIEF VACC REL B, P54; [Anonymous], 2021, FDA BRIEF VACC REL B, P62; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Chang WH, 2020, TAIWAN J OBSTET GYNE, V59, P812, DOI 10.1016/j.tjog.2020.09.006; Fink AL, 2015, PHYSIOLOGY, V30, P408, DOI 10.1152/physiol.00035.2015; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Honig PK, 2021, CLIN PHARMACOL THER, V109, P1169, DOI 10.1002/cpt.2230; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167; Kyrle PA, 2004, NEW ENGL J MED, V350, P2558, DOI 10.1056/NEJMoa032959; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Mauvais-Jarvis F, 2020, LANCET, V396, P565, DOI 10.1016/S0140-6736(20)31561-0; McCartney PR, 2020, JOGNN-J OBST GYN NEO, V49, P405, DOI 10.1016/j.jogn.2020.08.001; McNeil MM, 2016, J ALLERGY CLIN IMMUN, V137, P868, DOI 10.1016/j.jaci.2015.07.048; Mcrae S, 2006, LANCET, V368, P371, DOI 10.1016/S0140-6736(06)69110-1; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rover C, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0091-1; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8; See I, 2021, JAMA-J AM MED ASSOC, V325, P2448, DOI 10.1001/jama.2021.7517; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Vijayasingham L, 2021, LANCET, V397, P966, DOI 10.1016/S0140-6736(21)00384-6; Watson S, 2019, ECLINICALMEDICINE, V17, DOI 10.1016/j.eclinm.2019.10.001; Zekarias A, 2020, DRUG SAFETY, V43, P1309, DOI 10.1007/s40264-020-01000-8	26	11	11	6	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							825	10.3390/vaccines9080825			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7LE	34451950	gold, Green Published			2022-04-29	WOS:000690106600001
J	Boikos, C; Imran, M; Nguyen, V; Ducruet, T; Sylvester, GC; Mansi, JA				Boikos, Constantina; Imran, Mahrukh; Nguyen, Van Hung; Ducruet, Thierry; Sylvester, Gregg C.; Mansi, James A.			Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications	VACCINES			English	Article						MF59-adjuvanted influenza vaccine; relative vaccine effectiveness; high-risk; influenza-related medical encounters; older adults	UNITED-STATES; SEASONAL INFLUENZA; IMMUNOSENESCENCE; MF59	MF59(R)-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent inactivated influenza vaccine (HD-IIV3) elicit an enhanced immune response in older adults compared to standard, quadrivalent inactivated influenza vaccines (IIV4). We sought to determine the relative vaccine effectiveness (rVE) of aIIV3 versus IIV4 and HD-IIV3 in preventing influenza-related medical encounters in this retrospective cohort study involving adults >= 65 years with >= 1 health condition during the 2017-2018 and 2018-2019 influenza seasons. Data were obtained from primary and specialty care electronic medical records linked with pharmacy and medical claims. Adjusted odds ratios (OR) were derived from an inverse probability of treatment-weighted sample adjusted for age, sex, race, ethnicity, geographic region, vaccination week, and health status. rVE was determined using the formula (% rVE = 1 - ORadjusted) x 100. Analysis sets included 1,755,420 individuals for the 2017-2018 season and 2,055,012 for the 2018-2019 season. Compared to IIV4, aIIV3 was 7.1% (95% confidence interval 3.3-10.8) and 20.4% (16.2-24.4) more effective at preventing influenza-related medical encounters in the 2017-2018 and 2018-2019 seasons, respectively. Comparable effectiveness was observed with HD-IIV3 across both seasons. Our results support improved effectiveness of aIIV3 vs IIV4 in a vulnerable population of older adults at high risk of influenza and its complications.	[Boikos, Constantina; Imran, Mahrukh; Mansi, James A.] Seqirus Inc, Kirkland, PQ H9H 4M7, Canada; [Nguyen, Van Hung; Ducruet, Thierry] VHN Consulting, Montreal, PQ H2V 3L8, Canada; [Sylvester, Gregg C.] Seqirus USA Inc, Summit, NJ 07901 USA		Boikos, C (通讯作者)，Seqirus Inc, Kirkland, PQ H9H 4M7, Canada.	constantina.boikos@seqirus.com; Mahrukh.Imran@seqirus.com; vhnguyen@vhnconsulting.com; thierryducruet@vhnconsulting.com; Gregg.Sylvester@Seqirus.com; James.Mansi@modernatx.com			Seqirus Inc.	C. Gordon Beck and Amanda M. Justice provided editorial support in the preparation of this manuscript, which was funded by Seqirus Inc.	Ansaldi F, 2008, VACCINE, V26, P1525, DOI 10.1016/j.vaccine.2008.01.019; Ansaldi F, 2010, VACCINE, V28, P4123, DOI 10.1016/j.vaccine.2010.04.030; Armed Forces Health Surveillance Center (AFHSC), 2015, AFHSC STAND CAS DEF; Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Bella A, 2019, EXPERT REV VACCINES, V18, P671, DOI 10.1080/14760584.2019.1627206; Belongia EA, 2019, CLIN INFECT DIS, V69, P1817, DOI 10.1093/cid/ciz411; Beyer WEP, 2013, VACCINE, V31, P6030, DOI 10.1016/j.vaccine.2013.09.063; Boikos C, 2021, CLIN INFECT DIS, V73, P816, DOI 10.1093/cid/ciab152; Castrucci MR, 2018, HUM VACC IMMUNOTHER, V14, P637, DOI 10.1080/21645515.2017.1338547; Centers for Disease Control and Prevention, SEASONAL INFLUENZA V; Centers for Disease Control and Prevention, ESTIMATED INFLUENZA; Crooke SN, 2019, EXP GERONTOL, V124, DOI 10.1016/j.exger.2019.110632; Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011; Eick-Cost Angelia A, 2015, MSMR, V22, P2; Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960; Garten R, 2018, MMWR-MORBID MORTAL W, V67, P634, DOI 10.15585/mmwr.mm6722a4; Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Grubeck-Loebenstein B, 2009, AGING CLIN EXP RES, V21, P201, DOI 10.1007/BF03324904; Hak E, 2002, CLIN INFECT DIS, V35, P370, DOI 10.1086/341403; Izurieta HS, 2020, J INFECT DIS, V222, P278, DOI 10.1093/infdis/jiaa080; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; Lapi F, 2019, EXPERT REV VACCINES, V18, P663, DOI 10.1080/14760584.2019.1622418; Mannino S, 2012, AM J EPIDEMIOL, V176, P527, DOI 10.1093/aje/kws313; McConeghy K.W., 2021, CLIN INFECT DIS, V73, P4237, DOI [10.1093/cid/ciaa1233, DOI 10.1093/CID/CIAA1233]; Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Pebody RG, 2010, EUROSURVEILLANCE, V15; Pebody R, 2020, VACCINE, V38, P173, DOI 10.1016/j.vaccine.2019.10.032; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Restivo V, 2018, HUM VACC IMMUNOTHER, V14, P724, DOI 10.1080/21645515.2017.1321722; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Sellers SA, 2017, INFLUENZA OTHER RESP, V11, P372, DOI 10.1111/irv.12470; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057; Vajo Z, 2019, VACCINE, V37, P258, DOI 10.1016/j.vaccine.2018.11.039; Vajo Z, 2017, BRIT J CLIN PHARMACO, V83, P1912, DOI 10.1111/bcp.13289; van Aalst R, 2020, VACCINE, V38, P372, DOI 10.1016/j.vaccine.2019.09.105; Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059; Weinberger B, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0107-2; World Health Organization, VACC US; World Health Organization, REC COMP INFL VIR VA; World Health Organization (WHO), 2019, GLOB INFL STRAT 2019; Xu XY, 2019, MMWR-MORBID MORTAL W, V68, P544, DOI 10.15585/mmwr.mm6824a3; Yang J, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019095	47	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							862	10.3390/vaccines9080862			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5VF	34451987	Green Published, gold			2022-04-29	WOS:000689997500001
J	Dego, OK; Almeida, R; Ivey, S; Agga, GE				Kerro Dego, Oudessa; Almeida, Raul; Ivey, Susan; Agga, Getahun E.			Evaluation of Streptococcus uberis Surface Proteins as Vaccine Antigens to Control S. uberis Mastitis in Dairy Cows	VACCINES			English	Article						Streptococcus uberis; dairy cow; intramammary infection; surface proteins; immune response; immune reactive; western blot; protein electrophoresis	MAMMARY EPITHELIAL-CELLS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PLASMINOGEN-ACTIVATOR; SCHISTOSOMA-MANSONI; BACTERIAL ADHERENCE; CONFERS PROTECTION; ADHESION MOLECULE; T-CELL; IDENTIFICATION; VIRULENCE	There is no effective vaccine against Streptococcus uberis mastitis in dairy cows. Objectives of this study were (1) to extract S. uberis surface proteins (SUSP) and determine immunoreactivity in vitro and (2) immunogenicity and efficacy in vivo. SUSP was extracted from S. uberis, and their immunoreactivity was tested by western blot. In total, 26 Jersey dairy cows were randomly divided into four groups. Groups 1, 2, and 3 were vaccinated subcutaneously with 4 mg, 1 mg, and 100 mu g of SUSP, respectively, with Freund's incomplete adjuvant. Group 4 (control) was injected with placebo. S. uberis UT888 was infused into two contralateral quarters of each cow during early lactation. Somatic cell count (SCC), bacteria count in milk, and mastitis were monitored. Our results show that SUSP contains multiple protein bands, that ranged from 10 to 100 kDa. All vaccinates showed an increased anti-SUSP IgG antibody. The SCC of all experimentally infected quarters increased after challenge but slightly decreased after day 3 with no significant difference among groups. Milk bacterial count was significantly (p < 0.05) reduced in high and medium doses vaccinated groups than low and control groups. In conclusion, SUSP vaccine is immunogenic and showed a promising efficacy to control bovine S. uberis mastitis.	[Kerro Dego, Oudessa; Almeida, Raul; Ivey, Susan] Univ Tennessee, Dept Anim Sci, Knoxville, TN 37996 USA; [Agga, Getahun E.] ARS, Food Anim Environm Syst Res Unit, USDA, Bowling Green, KY 42101 USA		Dego, OK (通讯作者)，Univ Tennessee, Dept Anim Sci, Knoxville, TN 37996 USA.	okerrode@utk.edu; ralmeida@utk.edu; ivey@utk.edu; getahun.agga@usda.gov	dego, Oudessa Kerro/L-5286-2018	dego, Oudessa Kerro/0000-0003-2108-8905; Agga, Getahun/0000-0002-9903-5283			Abdi RD, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02528; Almeida RA, 2006, VET MICROBIOL, V115, P183, DOI 10.1016/j.vetmic.2006.02.005; Almeida RA, 1996, J VET MED B, V43, P385, DOI 10.1111/j.1439-0450.1996.tb00330.x; Almeida RA, 2001, J VET MED B, V48, P759, DOI 10.1046/j.1439-0450.2001.00506.x; Almeida RA, 1999, FEMS MICROBIOL LETT, V177, P313, DOI 10.1111/j.1574-6968.1999.tb13748.x; Almeida RA, 2006, MICROB PATHOGENESIS, V41, P80, DOI 10.1016/j.micpath.2006.04.007; Almeida RA, 2015, VET RES, V46, DOI 10.1186/s13567-015-0271-3; Almeida RA, 2015, VET MICROBIOL, V179, P332, DOI 10.1016/j.vetmic.2015.07.005; Almeida Raul A, 2010, Vet Med Int, V2010, P319192, DOI 10.4061/2010/319192; Amblee V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130575; Barbano DM, 2006, J DAIRY SCI, V89, pE15, DOI 10.3168/jds.S0022-0302(06)72360-8; Barbano DM, 2006, J DAIRY SCI, V89, P1189, DOI 10.3168/jds.S0022-0302(06)72188-9; Boel G, 2005, INFECT IMMUN, V73, P6237, DOI 10.1128/IAI.73.10.6237-6248.2005; Chen XY, 2011, VET MICROBIOL, V147, P426, DOI 10.1016/j.vetmic.2010.07.006; Clinical and Laboratory Standards Institute, 2018, M100S28 CLSI; Collado R, 2018, J DAIRY SCI, V101, P10290, DOI 10.3168/jds.2018-14840; Crowley RC, 2011, APPL ENVIRON MICROB, V77, P382, DOI 10.1128/AEM.01099-10; Dego OK, 2018, MICROB PATHOGENESIS, V115, P304, DOI 10.1016/j.micpath.2017.12.046; Egan SA, 2012, MICROBIOL-SGM, V158, P1581, DOI 10.1099/mic.0.055863-0; El Ridi R, 2001, SCAND J IMMUNOL, V53, P24, DOI 10.1046/j.1365-3083.2001.00835.x; El Ridi R, 2001, SCAND J IMMUNOL, V54, P477, DOI 10.1046/j.1365-3083.2001.00992.x; El Ridi R, 2001, INFECT IMMUN, V69, P237, DOI 10.1128/IAI.69.1.237-244.2001; FINCH JM, 1994, INFECT IMMUN, V62, P3599, DOI 10.1128/IAI.62.9.3599-3603.1994; Finch JM, 1997, VACCINE, V15, P1138, DOI 10.1016/S0264-410X(96)00307-6; Fontaine MC, 2002, VACCINE, V20, P2278, DOI 10.1016/S0264-410X(02)00114-7; Gillespie BE, 2012, J DAIRY SCI, V95, P4275, DOI 10.3168/jds.2011-4881; Gozalbo D, 1998, INFECT IMMUN, V66, P2052, DOI 10.1128/IAI.66.5.2052-2059.1998; Gunther J, 2016, VET RES, V47, DOI 10.1186/s13567-015-0287-8; Jayarao BM, 1996, J FOOD PROTECT, V59, P615, DOI 10.4315/0362-028X-59.6.615; Jayarao BM, 2004, J DAIRY SCI, V87, P3561, DOI 10.3168/jds.S0022-0302(04)73493-1; Jin H, 2005, J MOL BIOL, V350, P27, DOI 10.1016/j.jmb.2005.04.063; Kaczorek E, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1322-y; Kinoshita H, 2008, J APPL MICROBIOL, V104, P1667, DOI 10.1111/j.1365-2672.2007.03679.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leigh JA, 2002, VACCINE, V20, P3047, DOI 10.1016/S0264-410X(02)00263-3; Leigh JA, 1997, FEMS MICROBIOL LETT, V154, P123, DOI 10.1111/j.1574-6968.1997.tb12633.x; Leigh JA, 1999, VACCINE, V17, P851, DOI 10.1016/S0264-410X(98)00270-9; Lincoln RA, 1997, ADV EXP MED BIOL, V418, P643; Madureira P, 2007, J IMMUNOL, V178, P1379, DOI 10.4049/jimmunol.178.3.1379; Maeda K, 2004, INFECT IMMUN, V72, P5475, DOI 10.1128/IAI.72.9.5475-5477.2004; MATTHEWS KR, 1994, INFECT IMMUN, V62, P5641, DOI 10.1128/IAI.62.12.5641-5646.1994; MATTHEWS KR, 1993, J VET MED B, V40, P597, DOI 10.1111/j.1439-0450.1993.tb00181.x; Merrill C, 2019, VET IMMUNOL IMMUNOP, V214, DOI 10.1016/j.vetimm.2019.109890; Oliver S.P., 2004, MICROBIOLOGICAL PROC; Parodi PW, 2004, AUST J DAIRY TECHNOL, V59, P3; Patel D, 2009, VET MICROBIOL, V137, P297, DOI 10.1016/j.vetmic.2009.01.013; Perez-Casal J, 2016, VACCINE, V34, P1012, DOI 10.1016/j.vaccine.2015.11.072; Prado ME, 2011, VET IMMUNOL IMMUNOP, V141, P201, DOI 10.1016/j.vetimm.2011.02.023; Rosinha GMS, 2002, J MED MICROBIOL, V51, P661, DOI 10.1099/0022-1317-51-8-661; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tallima H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005443; Tassi R, 2013, J DAIRY SCI, V96, P5129, DOI 10.3168/jds.2013-6741; Varhimo E, 2011, VET MICROBIOL, V149, P381, DOI 10.1016/j.vetmic.2010.11.010; Wang KC, 2007, BERL MUNCH TIERARZTL, V120, P207, DOI 10.2376/0005-9366-120-207; Ward PN, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-54; Ward PN, 2003, INFECT IMMUN, V71, P7193, DOI 10.1128/IAI.71.12.7193-7196.2003; Ward PN, 2001, INFECT IMMUN, V69, P392, DOI 10.1128/IAI.69.1.392-399.2001; Zadoks RN, 2003, EPIDEMIOL INFECT, V130, P335, DOI 10.1017/S0950268802008221	58	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							868	10.3390/vaccines9080868			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3VS	34451993	Green Published, gold			2022-04-29	WOS:000689863600001
J	Milecki, T; Michalak, M; Milecki, J; Michalak, M; Kadziszewski, R; Kuncman, L; Jarzemski, P; Milecki, P; Antczak, A				Milecki, Tomasz; Michalak, Maciej; Milecki, Jakub; Michalak, Michal; Kadziszewski, Radoslaw; Kuncman, Lukasz; Jarzemski, Piotr; Milecki, Piotr; Antczak, Andrzej			Polish Medical Students' Knowledge Regarding Human Papillomavirus's Ways of Transmission, Risk of Cancer Development and Vaccination, and Their Intention to Recommend Vaccination	VACCINES			English	Article						HPV (human papillomavirus); medical education student; vaccination	HPV INFECTION; CERVICAL-CANCER; MEN; ACCEPTABILITY	Introduction: Human papillomavirus (HPV) is associated with six types of cancer in men and women. A vaccine against HPV, preferably administered before initial sexual intercourse, has been proven to be highly effective in preventing these cancers. An effective healthcare provider recommendation has significant influence on HPV vaccine uptake; therefore, it is critical that medical students receive comprehensive training in this area. Aim: The aim of the study was to assess the knowledge of medical students regarding Human Papillomavirus's (HPV) ways of transmission, risk of cancer development, and vaccination against HPV. This study also investigated factors among medical students that would affect their intention to recommend HPV vaccination to others. Materials and Methods: The study was conducted among 1061 (678 women and 383 men) medical students who filled in our questionnaire. The medical students were divided into two subgroups: (1) pre-clinical medical students (MS pre-clinical; first-to third-year students; n = 683) and (2) clinical medical students (MS clinical; fourth-to six-year students; n = 378). Results: A total259 (24.41%) of the 1061 medical students were vaccinated against HPV. We found a significant improvement in the general level of knowledge in the later years of education (4-6) compared to the early years of education (1-3). However, it was demonstrated that, despite medical education advancements, there are still significant gaps of knowledge about the relationship between HPV infection and cancers other than cervical cancer, as well as in relation to the routes by which HPV is transmitted. Medical students' intentions to recommend HPV vaccine to others were related to their own HPV-related knowledge and their own vaccination status. Conclusion: Medical students have gaps of knowledge regarding particular issues and aspects of HPV. It is necessary to further educate medical students in the field of prevention and in the treatment of lesions caused by HPV infection. Medical students' intention to recommend the HPV vaccine can be improved by including them and members of their families in the HPV vaccination program.	[Milecki, Tomasz; Michalak, Maciej; Milecki, Jakub; Kadziszewski, Radoslaw; Antczak, Andrzej] Poznan Univ Med Sci, Dept Urol, PL-61701 Poznan, Poland; [Michalak, Michal] Univ Med Sci, Dept Comp Sci & Stat, PL-61701 Poznan, Poland; [Kuncman, Lukasz] Med Univ Lodz, Dept Radiotherapy, PL-90419 Lodz, Poland; [Jarzemski, Piotr] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Dept Radiotherapy, PL-87100 Torun, Poland; [Milecki, Piotr] Univ Med Sci, Dept Electro Radiol, PL-61701 Poznan, Poland; [Milecki, Piotr] Greater Poland Canc Ctr, Radiotherapy Dept, PL-61866 Poznan, Poland		Milecki, T (通讯作者)，Poznan Univ Med Sci, Dept Urol, PL-61701 Poznan, Poland.	tomasz.milecki@student.ump.edu.pl; maciekmichalak@op.pl; jakub.milecki@gmail.com; michal@ump.edu.pl; radek_kadziszewski@o2.pl; lukaszkuncnaan@gmail.com; piotr@jarzemski.pl; piotr.milecki@wco.pl; aa26@poczta.onet.pl	; Michalak, Michal/I-4215-2016	Krzysztof, Maciej/0000-0002-8466-1273; Kuncman, Lukasz/0000-0003-3568-269X; Michalak, Michal/0000-0002-2852-3984; Kadziszewski, Radoslaw/0000-0001-5017-3477	Poznan University of Medical Sciences	The APC was funded by Poznan University of Medical Sciences. Check carefully that the details given are accurate and use the standard spelling of funding agency names at https://search.crossref.org/funding.Any errors may affect your future funding.	Afonso NM, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3969-x; Bonkat G., 2021, EUR ASS UROL, P42; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Burger EA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089974; Cartmell KB, 2018, PAPILLOMAVIRUS RES, V5, P21, DOI 10.1016/j.pvr.2017.11.003; Chido-Amajuoyi OG, 2021, HUM VACC IMMUNOTHER, V17, P420, DOI 10.1080/21645515.2020.1783952; Cogliano V, 2005, LANCET ONCOL, V6, P204, DOI 10.1016/S1470-2045(05)70086-3; Dunne EF, 2006, J INFECT DIS, V194, P1044, DOI 10.1086/507432; Dyda A, 2019, HUM VACC IMMUNOTHER, V15, P1488, DOI 10.1080/21645515.2019.1596712; Evans L, 2020, J CANCER EDUC, V35, P774, DOI 10.1007/s13187-019-01529-y; Kotarski J., 2009, GINEKOL POL, V80, P139; Kreimer AR, 2013, LANCET, V382, P877, DOI 10.1016/S0140-6736(13)60809-0; Liddon N, 2010, J ADOLESCENT HEALTH, V46, P113, DOI 10.1016/j.jadohealth.2009.11.199; Liu A, 2018, J PAEDIATR CHILD H, V54, P302, DOI 10.1111/jpc.13693; Majewski S., 2007, PULS MED, V11, P222; Newman PA, 2013, SEX TRANSM INFECT, V89, P568, DOI 10.1136/sextrans-2012-050980; Okunade KS, 2019, J OBSTET GYNAECOL, DOI [10.1080/01443615.2019.1634030, 10.1080/01443615.2019.1674261]; Owsianka Barbara, 2015, Przegl Epidemiol, V69, P53; Palefsky JM, 2005, AIDS, V19, P1407, DOI 10.1097/01.aids.0000181012.62385.4a; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Rerucha CM, 2018, AM FAM PHYSICIAN, V97, P441; Shetty S, 2019, HUM VACC IMMUNOTHER, V15, P1656, DOI 10.1080/21645515.2019.1565260; Smith JS, 2007, SEX TRANSM DIS, V34, P928, DOI 10.1097/OLQ.0b013e318065b8ef; Smolarczyk K, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020551; Wen Y, 2014, ASIAN PAC J CANCER P, V15, P5773, DOI 10.7314/APJCP.2014.15.14.5773; Wiley R., 2019, TEX MED, V115, P1; World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069; Wysocki J., 2012, PEDIAT POL, V87, P637, DOI [10.1016/j.pepo.2012.11.001, DOI 10.1016/J.PEPO.2012.11.001]	28	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							776	10.3390/vaccines9070776			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6YL	34358192	gold, Green Published			2022-04-29	WOS:000677054200001
J	Pinon, M; Giugliano, L; Nicastro, E; Kakaa, O; Coscia, A; Carbonara, C; D'Antiga, L; Calvo, PL				Pinon, Michele; Giugliano, Laura; Nicastro, Emanuele; Kakaa, Omar; Coscia, Alessandra; Carbonara, Caterina; D'Antiga, Lorenzo; Calvo, Pier Luigi			Timely Birth Dose Vaccine to Prevent Vertical Transmission of Hepatitis B: A Single Center Experience on the Road to the WHO Elimination Goals in Italy	VACCINES			English	Article						hepatitis B virus; vertical transmission; timely vaccination; immunoprophylaxis; prevention strategies	POSITIVE MOTHERS; SURFACE-ANTIGEN; VIRUS; IMMUNOPROPHYLAXIS; RECOMMENDATIONS; INFECTION; INFANTS; STATE; HBSAG; BORN	Italy was one of the first industrialized countries to implement a program of routine vaccination against hepatitis B virus (HBV) infection. However, currently, no HBV vaccine is administered at birth if the screened mother is HBsAg negative, whilst babies born to HBsAg positive mothers are given vaccine and hepatitis B immunoglobulin, within 12-24 post-delivery hours. A single center retrospective analysis of policies and practices to prevent mother-to-child transmission of HBV was carried out, to evaluate their adherence to HBV care guidelines. Paired maternal-infant medical records for consecutive live births, between January 2015 and December 2019, were reviewed at the AOU Citta della Salute e Scienza di Torino, where a total of 235/35,506 babies (0.7%) were born to HBsAg positive mothers. Markers of active viral replication, i.e., HBV DNA level and/or HBeAg, were reported in only 66/235 (28%) of the mothers' medical records. All newborns had immunoprophylaxis at birth: 61% at <12 h, 31% between 12 and 24 h, 7% between 24 and 36 h and 1% at >36 h. In 2019, two cases of vertical HBV transmission occurred, despite timely immunoprophylaxis, as their mothers' viral load was detected too late for antiviral prophylaxis. Missed early identification of pregnant women with high viremia levels or late vaccinations may contribute to perinatal HBV infection. Immunoprophylaxis should be given to babies born to HBsAg positive mothers at the latest within 12 h. In Italy, policies aimed at achieving the WHO 2030 goal of eliminating viral hepatitis should be further implemented.	[Pinon, Michele; Giugliano, Laura; Calvo, Pier Luigi] Univ Turin, AOU Citta Salute & Sci Torino, Pediat Gastroenterol Unit, I-10126 Turin, Italy; [Nicastro, Emanuele; D'Antiga, Lorenzo] ASST Osped Papa Giovanni XXIII, Paediat Hepatol Gastroenterol & Transplantat, I-24127 Bergamo, Italy; [Kakaa, Omar] Univ Turin, Dept Pediat & Publ Hlth Sci, I-10126 Turin, Italy; [Coscia, Alessandra; Carbonara, Caterina] Univ Turin, AOU Citta Salute & Sci Torino, Neonatol Unit, I-10126 Turin, Italy		Pinon, M (通讯作者)，Univ Turin, AOU Citta Salute & Sci Torino, Pediat Gastroenterol Unit, I-10126 Turin, Italy.	mpinon@cittadellasalute.to.it; l.giugliano91@gmail.com; enicastro@asst-pg23.it; omar.kakaa@unito.it; alessandra.coscia@unito.it; ccarbonara@cittadellasalute.to.it; ldantiga@asst-pg23.it; pierluigi.calvo@unito.it	D'Antiga, Lorenzo/AAU-6924-2020; D'Antiga, Lorenzo/AAH-4485-2019; coscia, alessandra/AFR-8018-2022; Nicastro, Emanuele/K-1260-2018	D'Antiga, Lorenzo/0000-0001-7150-3148; coscia, alessandra/0000-0001-5094-1077; Giugliano, Laura/0000-0001-6073-6608; Pinon, Michele/0000-0001-5077-5531; Nicastro, Emanuele/0000-0002-4518-9375			[Anonymous], 2002, GLOBAL ALERT RESPONS; [Anonymous], 2015, GUIDELINES PREVENTIO; [Anonymous], 2015, 2015 ASSESSMENT REPO; [Anonymous], 2020, PREVENTION MOTHER TO; Beasley RP, 2009, ANN EPIDEMIOL, V19, P231, DOI 10.1016/j.annepidem.2009.01.017; Boccalini S, 2013, HUM VACC IMMUNOTHER, V9, P1119, DOI 10.4161/hv.23827; Calvo PL, 2021, J PEDIATR GASTR NUTR, V72, P597, DOI 10.1097/MPG.0000000000003042; Campagna M, 2011, HEPAT MON, V11, P750, DOI 10.5812/kowsar.1735143X.723; Coppola N, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-016-0228-4; Cornberg M., 2018, ANNEX C HEPATITIS B; de Villiers MJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237525; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Fasano M, 2013, INFECTION, V41, P53, DOI 10.1007/s15010-012-0384-9; Ghany M.G., 2020, AASLD IDSA HEPAT C G, V71, P10, DOI [10.1002/hep.31060, DOI 10.1002/HEP.31060]; Goldstein ST, 2005, INT J EPIDEMIOL, V34, P1329, DOI 10.1093/ije/dyi206; Harder KM, 2011, VACCINE, V29, P9303, DOI 10.1016/j.vaccine.2011.10.028; Indolfi G, 2020, J PEDIATR GASTR NUTR, V70, P527, DOI 10.1097/MPG.0000000000002628; Indolfi G, 2019, LANCET GASTROENTEROL, V4, P466, DOI 10.1016/S2468-1253(19)30042-1; Jourdain G, 2018, NEW ENGL J MED, V378, P911, DOI 10.1056/NEJMoa1708131; Kang WY, 2014, VACCINE, V32, P3362, DOI 10.1016/j.vaccine.2014.04.045; Komatsu H, 2014, WORLD J GASTROENTERO, V20, P8998, DOI 10.3748/wjg.v20.i27.8998; Kushner T, 2021, J VIRAL HEPATITIS, V28, P582, DOI 10.1111/jvh.13459; Lai A, 2018, J MED VIROL, V90, P786, DOI 10.1002/jmv.25027; Linea Guida Gravidanza Fisiologica, 2011, SIST NAZ LIN GUID I; LO KJ, 1985, J INFECT DIS, V152, P817, DOI 10.1093/infdis/152.4.817; Luman ET, 2005, AM J PUBLIC HEALTH, V95, P1367, DOI 10.2105/AJPH.2004.046284; Mele A, 2001, J INFECT DIS, V184, P905, DOI 10.1086/323396; Sagnelli E, 2014, WORLD J GASTROENTERO, V20, P7635, DOI 10.3748/wjg.v20.i24.7635; Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1; Sistema Epidemiologico Integrato dell'Epatite Virale Acuta (SEIEVA) Istituto Superiore di Sanita, SEIEVA B ANN 2019; Soeung SC, 2012, VACCINE, V31, P149, DOI 10.1016/j.vaccine.2012.10.079; Terrault Norah A, 2018, Clin Liver Dis (Hoboken), V12, P33, DOI 10.1002/cld.728; Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156; Wang C, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004390; Weinbaum Cindy M., 2008, Morbidity and Mortality Weekly Report, V57, P1, DOI 10.1002/hep.22882; WHO, 2012, WORLD MALARIA REPORT 2012, P1; Willis BC, 2010, PEDIATRICS, V125, P704, DOI 10.1542/peds.2009-1831; WONG VCW, 1984, LANCET, V1, P921	38	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							801	10.3390/vaccines9070801			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6NP	34358216	Green Published, gold			2022-04-29	WOS:000677026000001
J	Rhoda, DA; Prier, ML; Clary, CB; Trimner, MK; Velandia-Gonzalez, M; Danovaro-Holliday, MC; Cutts, FT				Rhoda, Dale A.; Prier, Mary L.; Clary, Caitlin B.; Trimner, Mary Kay; Velandia-Gonzalez, Martha; Danovaro-Holliday, M. Carolina; Cutts, Felicity T.			Using Household Surveys to Assess Missed Opportunities for Simultaneous Vaccination: Longitudinal Examples from Colombia and Nigeria	VACCINES			English	Article						missed opportunities for vaccination; Vaccination Coverage Surveys; Demographic and Health Surveys; Nigeria; Colombia; Vaccination Coverage Quality Indicators; immunization	EXPANDED PROGRAM; IMMUNIZATION; WORLDWIDE; COVERAGE; IMPROVE; URBAN	One important strategy to increase vaccination coverage is to minimize missed opportunities for vaccination. Missed opportunities for simultaneous vaccination (MOSV) occur when a child receives one or more vaccines but not all those for which they are eligible at a given visit. Household surveys that record children's vaccination dates can be used to quantify occurrence of MOSVs and their impact on achievable vaccination coverage. We recently automated some MOSV analyses in the World Health Organization's freely available software: Vaccination Coverage Quality Indicators (VCQI) making it straightforward to study MOSVs for any Demographic & Health Survey (DHS), Multi-Indicator Cluster Survey (MICS), or Expanded Programme on Immunization (EPI) survey. This paper uses VCQI to analyze MOSVs for basic vaccine doses among children aged 12-23 months in four rounds of DHS in Colombia (1995, 2000, 2005, and 2010) and five rounds of DHS in Nigeria (1999, 2003, 2008, 2013, and 2018). Outcomes include percent of vaccination visits MOSVs occurred, percent of children who experienced MOSVs, percent of MOSVs that remained uncorrected (that is, the missed vaccine had still not been received at the time of the survey), and the distribution of time-to-correction for children who received the MOSV dose at a later visit.	[Rhoda, Dale A.; Prier, Mary L.; Clary, Caitlin B.; Trimner, Mary Kay] Biostat Global Consulting, Worthington, OH 43085 USA; [Velandia-Gonzalez, Martha] Pan Amer Hlth Org, Comprehens Family Immunizat Unit, Washington, DC 20037 USA; [Danovaro-Holliday, M. Carolina] World Hlth Org, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland; [Cutts, Felicity T.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England		Rhoda, DA (通讯作者)，Biostat Global Consulting, Worthington, OH 43085 USA.	Dale.Rhoda@biostatglobal.com; Mary.Prier@biostatglobal.com; Caitlin.Clary@biostatglobal.com; MaryKay.Trimner@biostatglobal.com; velandiam@paho.org; danovaroc@who.int; Felicity.Cutts@lshtm.ac.uk		Rhoda, Dale/0000-0003-0948-1368; Clary, Caitlin/0000-0001-7283-749X	World Health OrganizationWorld Health Organization [001] Funding Source: Medline		Acharya K., 2019, FACTORS AFFECTING VA; Adamu A.A., 2019, USING QUALITY IMPROV; Adamu AA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218572; [Anonymous], 2021, LANCET, V397, P1519, DOI 10.1016/S0140-6736(21)00900-4; Baptiste A.E.J., 2021, VACCINE, DOI [10.1016/j.vaccine.2021.03.095, DOI 10.1016/J.VACCINE.2021.03.095]; Biostat Global Consulting, VACCINATION COVERAGE; Boyle E.H., 2020, DOI 10.18128/D080.V8; Chang Winston, 2021, CRAN; Chard AN, 2020, MMWR-MORBID MORTAL W, V69, P1706, DOI 10.15585/mmwr.mm6945a7; Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2; Clary C.B., MISSED OPPORTUNITIES; CUTTS F, 1990, B WORLD HEALTH ORGAN, V68, P199; CUTTS FT, 1991, INT J EPIDEMIOL, V20, P1099, DOI 10.1093/ije/20.4.1099; CUTTS FT, 1991, J TROP PEDIATRICS, V37, P153, DOI 10.1093/tropej/37.4.153; CUTTS FT, 1989, INT J EPIDEMIOL, V18, P427, DOI 10.1093/ije/18.2.427; DAMMANN DF, 1992, S AFR MED J, V82, P118; Desve G., 1991, COVERAGE SURVEY ANAL; EPI in the Americas, 1991, EPI NEWSL, V13, P3; Federal Office of Statistics/Nigeria Institute for Resource Development-IRD/Macro International, 1992, NIG DEM HLTH SURV 19; GALAZKA AM, 1984, B WORLD HEALTH ORGAN, V62, P357; Garib Z, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4721836; GINDLER JS, 1993, PEDIATRICS, V91, P315; Giuffrida A., 2009, FEW MANY 10 YEARS HL; Hanson CM, 2018, VACCINE, V36, P3260, DOI 10.1016/j.vaccine.2018.04.070; HUTCHINS SS, 1993, B WORLD HEALTH ORGAN, V71, P549; ICF, DHS PROGR 2020 DHS PROGR 2020; Kabore L, 2020, VACCINE, V38, P7603, DOI 10.1016/j.vaccine.2020.10.021; Kabore L, 2020, VACCINE, V38, P2808, DOI 10.1016/j.vaccine.2020.02.023; KAHN JG, 1995, B WORLD HEALTH ORGAN, V73, P47; Li AJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237913; Li AJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230783; Li AJ, 2019, VACCINE, V37, P4281, DOI 10.1016/j.vaccine.2019.06.041; Mandomando I, 2021, VACCINE, V39, P3111, DOI 10.1016/j.vaccine.2021.03.021; Mansour Z, 2019, VACCINE, V37, P4177, DOI 10.1016/j.vaccine.2019.05.032; National Department of Health and ICF, 2019, S AFR DEM HLTH SURV; National Population Commission ICF, 2019, NIG DEM HLTH SURV 20; National Population Commission Nigeria, 2000, NIG DEM HLTH SURV 19; National Population Commission (Nigeria) and ICF International, 2014, NIG DEM HLTH SURV 20; National Population Commission [Nigeria] and ICF Macro, 2009, NIG DEM HLTH SURV 20; National Population Commission of Nigeria, 2004, NIG DEM HLTH SURV 20; Ndwandwe D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040705; Ogbuanu IU, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210648; Ojeda G., 2005, RESULTADOS ENCUESTA; Ojeda G, 2011, COLOMBIA ENCUESTA NA; Pan American Health Organization, 2013, METHODOLOGY EVALUATI; Pan American Health Organization, 2017, VACC DEW SOIL TRANSM VACC DEW SOIL TRANSM; Patel MK, 2020, MMWR-MORBID MORTAL W, V69, P1700, DOI 10.15585/mmwr.mm6945a6; Profamilia, 2000, RES ENC NAC DEM SAL RES ENC NAC DEM SAL; Profamilia Macro International, 1995, COL ENC NAC DEM SAL COL ENC NAC DEM SAL; R Core Team, 2020, R LANGUAGE ENV STAT; Rhoda D.A., 2021, VCQI FORMS VARIABLE; Rhoda D.A., 2021, VCQI INDICATOR LIST; Rhoda D.A., 2021, VCQI USERS GUIDE DRA; Sato P., 1988, PROTOCOL ASSESSMENT; Sridhar S, 2014, VACCINE, V32, P6870, DOI 10.1016/j.vaccine.2014.10.063; StataCorp, 2019, STAT STAT SOFTW REL; UNICEF, NEW PARTNP IPUM 2018 NEW PARTNP IPUM 2018; Wagai JN, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247415; WHO, MISSED OPPORTUNITIES; WHO, 1984, WKLY EPIDEMIOL REC, V59, P341; WHO, 2020, LEAV NO ON GUID PLAN; WHO, 2020, IMM AG 2030 GLOB STR; WHO, 2005, WHOIVB0423; World Bank, 2009, COL DEC OPT INC EFF COL DEC OPT INC EFF; World Health Organization, 2019, INT GUID IMPL MON AC; World Health Organization, VACC POS PAP 2020 VACC POS PAP 2020; World Health Organization, SUMM WHO POS PAP REC; World Health Organization, 2015, WKLY EPIDEMIOL REC, V90, P477; World Health Organization, 2017, PLANN GUID RED MISS; World Health Organization,, 2018, WHOIVB1809; World Health Organization, 2017, METH ASS MISS OPP VA	71	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							795	10.3390/vaccines9070795			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5XO	34358211	gold, Green Published			2022-04-29	WOS:000676984300001
J	Rotondo, C; Cantatore, FP; Fornaro, M; Colia, R; Busto, G; Rella, V; Sciacca, S; Lops, L; Cici, D; Maruotti, N; D'Onofrio, F; Iannone, F; Corrado, A				Rotondo, Cinzia; Cantatore, Francesco Paolo; Fornaro, Marco; Colia, Ripalta; Busto, Giuseppe; Rella, Valeria; Sciacca, Stefania; Lops, Lucia; Cici, Daniela; Maruotti, Nicola; D'Onofrio, Francesca; Iannone, Florenzo; Corrado, Addolorata			Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study	VACCINES			English	Article						rheumatic diseases; relapse; flare; disease activity; DMARDs; biologic drugs; safety; efficacy; anti-COVID-19 vaccine; comirnaty; vaxzevria; SARs-COV-2	INFECTIONS; VACCINATION; RISK	An increased risk of developing severe infections has been evidenced in rheumatic disease (RD) patients, and anti-COVID-19 vaccination is strictly recommended for RD patients. However, up to now, no data are available on safety, immunogenicity and efficacy of COVID-19 vaccinations in RD patients. The possible development of adverse events (AEs), including the flare-up of underlying RD, represents a matter of growing importance. The aim of our study is to assess, in RD patients, the safety profile of different types of approved vaccines and the possible influence of immunosuppressive therapies and clinical or demographic characteristics of RD patients on development of AEs. Participants (n = 185; 30.7%) received anti-COVID-19 vaccinations, 137 with autoimmune/chronic inflammatory RD (Au/cIn-RD) and 48 with nonautoimmune/chronic inflammatory RD (no-Au/cIn-RD). AEs were recorded in 42% of patients after the first dose of vaccine, and in 26% of patients after the second dose. The most common reported AEs after anti-COVID 19 vaccines were site injection pain (17%), headache (12%), fever (12%), myalgia (10%) and fatigue (10%). Relapses of the underlying Au/c-In-RD were recorded in 2.2% of patients after the first dose of vaccine. In Au/c-In-RD the risk of developing AEs after the first dose of vaccine was lower in older patients (OR = 0.95; p = 0.001), and in the group of patients with complete control of RD (OR: 0.2; p = 0.010). A lower percentage of AEs was observed in patients with complete control of their Au/cIn-RD (29%) compared to those with low (57%) or moderate-high disease activity (63%) (p = 0.002 and p = 0.006 respectively). In this study all types of COVID-19 vaccines in use in Italy seemed safe in RD patients. The results of this study might provide reassuring information for Au/cIn RD patients and clinicians and could strengthen the data on vaccine safety to guide the use of COVID-19 vaccines in Au/cIn-RD on immunosuppressive agents.	[Rotondo, Cinzia; Cantatore, Francesco Paolo; Colia, Ripalta; Busto, Giuseppe; Rella, Valeria; Sciacca, Stefania; Lops, Lucia; Cici, Daniela; Maruotti, Nicola; D'Onofrio, Francesca; Corrado, Addolorata] Osped Riuniti Foggia, Rheumatol Unit, Dept Med & Surg Sci, Viale Luigi Pinto 1, I-71122 Foggia, Italy; [Fornaro, Marco; Iannone, Florenzo] Policlinico, Rheumatol Unit, Dept Emergency & Organ Transplantat, Piazza G Cesare 11, I-70124 Bari, Italy		Rotondo, C (通讯作者)，Osped Riuniti Foggia, Rheumatol Unit, Dept Med & Surg Sci, Viale Luigi Pinto 1, I-71122 Foggia, Italy.	cinzia.rotondo@gmail.com; francescopaolo.cantatore@unifg.it; marco3987@hotmail.it; ripaltacolia@gmail.com; giuseppe.busto@unifg.it; valeria.rella92@gmail.com; stefania.sciacca@hotmail.it; lucialops85@gmail.com; daniela.cici@gmail.com; nicola.maruotti@unifg.it; drfrancesca.donofrio@gmail.com; florenzolannone@uniba.it; ada.corrado@unifg.it	Rotondo, Cinzia/AAP-1621-2020	Rotondo, Cinzia/0000-0003-1356-8423; Cantatore, Francesco Paolo/0000-0001-9929-9177; Busto, Giuseppe/0000-0002-6412-2256; Cici, Daniela/0000-0002-3532-5791; Fornaro, Marco/0000-0003-1716-7432	Dept. of Medical and Surgical Sciences of the University of Foggia	This paper has been published with the financial support of the Dept. of Medical and Surgical Sciences of the University of Foggia.	Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P63, DOI 10.1016/S0162-3109(00)00186-7; Bernatsky S, 2007, RHEUMATOLOGY, V46, P1157, DOI 10.1093/rheumatology/kem076; Buhler S, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14159; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Chau CYC, 2021, OPHTHALMOL THER, V10, P201, DOI 10.1007/s40123-021-00338-1; Crowe SR, 2011, ARTHRITIS RHEUM-US, V63, P2396, DOI 10.1002/art.30388; Curtis JR, 2007, ARTHRITIS RHEUM-US, V56, P1125, DOI 10.1002/art.22504; Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, P1093, DOI 10.1002/art.41734; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524; Dutta S., 2021, SERIOUS ADVERSE EVEN, DOI [10.1101/2021.03.23.21253433, DOI 10.1101/2021.03.23.21253433]; Fathizadeh Hadis, 2020, Infez Med, V28, P185; Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Gluck T, 2005, J RHEUMATOL, V32, P1473; Gluck T, 2008, CLIN INFECT DIS, V46, P1459, DOI 10.1086/587063; Listing J, 2005, ARTHRITIS RHEUM-US, V52, P3403, DOI 10.1002/art.21386; Maillefert JF, 1999, RHEUMATOLOGY, V38, P978, DOI 10.1093/rheumatology/38.10.978; Nazarenko Y, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020049; Petri M, 2007, ANN RHEUM DIS, V66, P61, DOI 10.1136/ard.2007.078477; Teslya A, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003166; van Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216; WHO, 2013, GLOB VACC ACT PLAN 2; Wraith DC, 2003, LANCET, V362, P1659, DOI 10.1016/S0140-6736(03)14802-7; Yuan Ping, 2020, medRxiv, DOI 10.1101/2020.11.03.20224998; Zandman-Goddard G, 2005, AUTOIMMUNITY, V38, P473, DOI 10.1080/08916930500285352; Zink A, 2010, ENTZUNDLICH RHEUMATI	26	7	8	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							730	10.3390/vaccines9070730			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8OF	34358147	Green Published, gold			2022-04-29	WOS:000677162800001
J	Ferrari, C; Aurilio, MT; Mazza, A; Pietroiusti, A; Magrini, A; Balbi, O; Bolcato, M; Coppeta, L				Ferrari, Cristiana; Aurilio, Marco Trabucco; Mazza, Andrea; Pietroiusti, Antonio; Magrini, Andrea; Balbi, Ottavia; Bolcato, Matteo; Coppeta, Luca			Evaluation of Immunity for Mumps among Vaccinated Medical Students	VACCINES			English	Article						mumps; outbreak; vaccination; health care workers; students	HEALTH-CARE WORKERS; MMR VACCINE; MEASLES; RUBELLA; IMMUNIZATION; OUTBREAK; RISK; IGG	Healthcare workers are considered at higher risk for mumps infection than the general population. Since 2017, the national immunization plan recommended the administration of a dose of measles-mumps-rubella (MMR) vaccine to the healthcare operators who are unable to demonstrate a complete vaccination history or that are seronegative for at least one of the three agents. Regarding mumps infection, based on actual concerns regarding the loss of protection over the years after vaccination, the Advisory Committee on Immunization Practices (ACIP) recommended to administer a third dose of vaccine to operators previously vaccinated with two doses of MMR vaccine who belong to a group at increased risk of mumps infection in the event of an epidemic. This guideline, however, is not currently followed in Italy, resulting in a potential risk for vaccinated operators to become unprotected from mumps over the years. The aim of our study is to evaluate the persistence of a protective antibody level for mumps among medical students vaccinated during infancy or adolescence, at the start of their hospital internship. We retrospectively evaluated mumps-specific IgG levels in a group of medical students, in the period from 1 January to 31 December 2020. We evaluated the persistence of the detectable level of mumps-specific antibodies in relation to their vaccinal status, gender and time elapsed from vaccination. We found that 17.4% (65 subjects) of our sample were seronegative for mumps. The univariate analysis showed a significant difference in serological protection between male and female gender (77.0% vs. 86.2%; p < 0.05 with chi(2) test) and between age classes (86.5% vs. 76.4%; p < 0.05 for subjects aged 18-23 years and over 23 years, respectively). Female gender was significantly related to higher serological protection even after adjusting for age classes and number of vaccine doses administered in a multivariate analysis model. Our study shows a substantial percentage of subjects lacking a protective mumps titer among medical students who were vaccinated in childhood. Given the higher risk of infection among those subjects, routine pre-employment screening should be performed among those operators regardless of their vaccination history and a third dose of MMR should be offered to unprotected students.	[Ferrari, Cristiana; Mazza, Andrea; Pietroiusti, Antonio; Magrini, Andrea; Balbi, Ottavia; Coppeta, Luca] Univ Roma Tor Vergata, Dept Occupat Med, Viale Oxford 81, I-00133 Rome, Italy; [Aurilio, Marco Trabucco] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, I-86100 Campobasso, Italy; [Bolcato, Matteo] Univ Padua, Legal Med, Via Falloppio 50, I-35121 Padua, Italy		Bolcato, M (通讯作者)，Univ Padua, Legal Med, Via Falloppio 50, I-35121 Padua, Italy.	cristiana.ferrari@ptvonline.it; marco.trabuccoaurilio@unimol.it; andrea.mazza@ptvonline.it; pietroiu@uniroma2.it; andrea.magrini@uniroma2.it; ottaventidue@hotmail.it; matteo.bolcato@unipd.it; lcoppeta@gmail.com	coppeta, luca/X-6052-2019	coppeta, luca/0000-0003-2470-6107; Trabucco Aurilio, Marco/0000-0003-2327-1455; , Matteo Bolcato/0000-0002-8784-8463	HCWs of Occupational Medicine of PTV	The authors would like to thank all HCWs of Occupational Medicine of PTV for supporting this study.	[Anonymous], 2019, NAT MICROBIOL, V4, P725, DOI 10.1038/s41564-019-0450-5; Bonebrake AL, 2010, EMERG INFECT DIS, V16, P426, DOI 10.3201/eid1603.090198; Campins M, 2013, AM J INFECT CONTROL, V41, P378, DOI 10.1016/j.ajic.2012.04.327; Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309; Chen SY, 2011, J INFECT DIS, V203, P1517, DOI 10.1093/infdis/jir115; Connell AR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02089; Coppeta L, 2019, OCCUP MED-OXFORD, V69, P143, DOI 10.1093/occmed/kqy132; Coppeta L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217992; Coppeta L, 2021, HUM VACC IMMUNOTHER, V17, P1342, DOI 10.1080/21645515.2020.1818523; Coppeta L, 2019, HUM VACC IMMUNOTHER, V15, P1135, DOI 10.1080/21645515.2018.1564442; Eriksen J, 2013, EPIDEMIOL INFECT, V141, P651, DOI 10.1017/S0950268812001136; European Centre for Disease Prevention and Control, 2019, SEXUAL TRANSMISSION; Fedeli U, 2002, J HOSP INFECT, V51, P133, DOI 10.1053/jhin.2002.1222; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Fortunato F, 2015, HUM VACC IMMUNOTHER, V11, P133, DOI 10.4161/hv.34415; Genovese C, 2019, J Prev Med Hyg, V60, pE12, DOI 10.15167/2421-4248/jpmh2019.60.1.1097; Haywood B, 2014, J VIROL METHODS, V196, P15, DOI 10.1016/j.jviromet.2013.10.027; Kitano T, 2021, HUM VACC IMMUNOTHER, V17, P1313, DOI 10.1080/21645515.2020.1826799; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Kontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568; Marin M, 2018, MMWR-MORBID MORTAL W, V67, P33, DOI 10.15585/mmwr.mm6701a7; Ministero Della Salute Piano Nazionale Prevenzione Vaccinale, 2017 2019 PNPV; Porru S., 2008, G ITAL MED LAV ERGON, V29, P407; Rubin S, 2015, J PATHOL, V235, P242, DOI 10.1002/path.4445; Shirts BH, 2013, CLIN VACCINE IMMUNOL, V20, P443, DOI 10.1128/CVI.00503-12; Taddei C, 2014, HUM VACC IMMUNOTHER, V10, P2612, DOI 10.4161/21645515.2014.970879; Trabucco Aurilio M., 2020, OPEN PUBLIC HLTH J, V13, P692; Vygen S, 2016, EUROSURVEILLANCE, V21, P12, DOI 10.2807/1560-7917.ES.2016.21.10.30156; World Health Organization, WHO IMMUNIZATION VAC	29	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							599	10.3390/vaccines9060599			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ0FX	34199971	Green Published			2022-04-29	WOS:000666253700001
J	Hanan, N; Doud, RL; Park, IW; Jones, HP; Mathew, SO				Hanan, Nicholas; Doud, Ronnie L., Jr.; Park, In-Woo; Jones, Harlan P.; Mathew, Stephen O.			The Many Faces of Innate Immunity in SARS-CoV-2 Infection	VACCINES			English	Review						SARS-CoV-2; COVID-19; innate immunity; cytokines	CONVERTING ENZYME 2; RACIAL DISPARITIES; I INTERFERON; CORONAVIRUS; COVID-19; SARS; RECEPTOR; ACE2; RESPONSES; REPLICATION	The innate immune system is important for initial antiviral response. SARS-CoV-2 can result in overactivity or suppression of the innate immune system. A dysregulated immune response is associated with poor outcomes; with patients having significant Neutrophil-to-Lymphocyte ratios (NLR) due to neutrophilia alongside lymphopenia. Elevated interleukin (IL)-6 and IL-8 leads to overactivity and is a prominent feature of severe COVID-19 patients. IL-6 can result in lymphopenia; where COVID-19 patients typically have significantly altered lymphocyte subsets. IL-8 attracts neutrophils; which may play a significant role in lung tissue damage with the formation of neutrophil extracellular traps leading to cytokine storm or acute respiratory distress syndrome. Several factors like pre-existing co-morbidities, genetic risks, viral pathogenicity, and therapeutic efficacy act as important modifiers of SARS-CoV-2 risks for disease through an interplay with innate host inflammatory responses. In this review, we discuss the role of the innate immune system at play with other important modifiers in SARS-CoV-2 infection.	[Hanan, Nicholas; Doud, Ronnie L., Jr.; Park, In-Woo; Jones, Harlan P.; Mathew, Stephen O.] Univ North Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Ft Worth, TX 76107 USA; [Park, In-Woo; Jones, Harlan P.; Mathew, Stephen O.] Univ North Texas, Hlth Sci Ctr, Dept Microbiol Immunol & Genet, Ft Worth, TX 76107 USA		Mathew, SO (通讯作者)，Univ North Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Ft Worth, TX 76107 USA.; Mathew, SO (通讯作者)，Univ North Texas, Hlth Sci Ctr, Dept Microbiol Immunol & Genet, Ft Worth, TX 76107 USA.	NicholasHanan@my.unthsc.edu; RonnieDoud@my.unthsc.edu; Inwoo.Park@unthsc.edu; Harlan.Jones@unthsc.edu; Stephen.mathew@unthsc.edu		Mathew, Stephen/0000-0001-5784-224X; Hanan, Nicholas/0000-0002-8005-1291			Aguirre AA, 2020, WORLD MED HEALTH POL, V12, P256, DOI 10.1002/wmh3.348; Alcendor DJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082442; Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008; Amraei Razie, 2021, bioRxiv, DOI [10.1021/acscentsci.0c01537, 10.1101/2020.06.22.165803]; Anguiano L, 2017, CURR MED CHEM, V24, P3231, DOI 10.2174/0929867324666170414162841; [Anonymous], COVID 19 RACIAL ETHN; [Anonymous], WHO COR DIS COVID 19; Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652; Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Brandt EB, 2020, J ALLERGY CLIN IMMUN, V146, P61, DOI 10.1016/j.jaci.2020.04.035; Brook CE, 2020, ELIFE, V9, DOI 10.7554/eLife.48401; Broszeit F, 2019, CELL REP, V27, P3284, DOI 10.1016/j.celrep.2019.05.048; Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707; Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2; Carbo EC, 2020, J CLIN VIROL, V131, DOI 10.1016/j.jcv.2020.104594; Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902; Chan YK, 2015, CURR OPIN VIROL, V12, P7, DOI 10.1016/j.coviro.2015.01.004; Chang FY, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00663-w; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Cheng H, 2020, J MED VIROL, V92, P726, DOI 10.1002/jmv.25785; Chhabra KH, 2013, AM J PHYSIOL-ENDOC M, V304, pE874, DOI 10.1152/ajpendo.00490.2012; Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E; Dalan R, 2020, HORM METAB RES, V52, P257, DOI 10.1055/a-1155-0501; Daly JL, 2020, SCIENCE, V370, P861, DOI 10.1126/science.abd3072; Datta PK, 2020, THERANOSTICS, V10, P7448, DOI 10.7150/thno.48076; Davis ME, 2015, VIROLOGY, V479, P52, DOI 10.1016/j.virol.2015.02.033; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Demaria O, 2020, CELL MOL IMMUNOL, V17, P995, DOI 10.1038/s41423-020-0493-9; Dhochak N, 2020, INDIAN J PEDIATR, V87, P537, DOI 10.1007/s12098-020-03322-y; Donnik IM, 2021, BIOL BULL+, V48, P26, DOI 10.1134/S1062359021010052; Dosch SF, 2009, VIRUS RES, V142, P19, DOI 10.1016/j.virusres.2009.01.005; Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1; Feng Z., 2020, NOVEL SEVERE ACUTE R, V2, P1, DOI [10.1101/2020.03.27.20045427, DOI 10.1101/2020.03.27.20045427]; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Gawlik KS, 2019, AM J HEALTH PROMOT, V33, P1063, DOI 10.1177/0890117119847619; Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Gil C, 2020, J MED CHEM, V63, P12359, DOI 10.1021/acs.jmedchem.0c00606; Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10; Golonka RM, 2020, PHYSIOL GENOMICS, V52, P217, DOI 10.1152/physiolgenomics.00033.2020; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386; Grandi G, 2020, EUR J CONTRACEP REPR, V25, P233, DOI 10.1080/13625187.2020.1766017; Grimaud M, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00690-8; Hawkins D, 2020, AM J IND MED, V63, P817, DOI 10.1002/ajim.23145; He RY, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104361; He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18; Izda V, 2021, CLIN IMMUNOL, V222, DOI 10.1016/j.clim.2020.108634; Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633; Jimenez-Alcazar M, 2017, SCIENCE, V358, P1202, DOI 10.1126/science.aam8897; Johnson BA, 2021, NATURE, V591, P293, DOI 10.1038/s41586-021-03237-4; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kim OY, 2010, CRIT CARE, V14, DOI 10.1186/cc8959; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Kumar H, 2009, BIOCHEM J, V420, P1, DOI 10.1042/BJ20090272; Kuri-Cervantes Leticia, 2020, bioRxiv, DOI 10.1101/2020.05.18.101717; Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819; Lei XB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17665-9; Li LH, 2008, COPD, V5, P291, DOI 10.1080/15412550802363329; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Maelfait J, 2012, MICROBIOL MOL BIOL R, V76, P33, DOI 10.1128/MMBR.05012-11; McKechnie JL, 2020, CELL HOST MICROBE, V27, P863, DOI 10.1016/j.chom.2020.05.009; Mudd Philip A, 2020, medRxiv, DOI 10.1101/2020.05.28.20115667; Nabi G, 2021, SCI TOTAL ENVIRON, V754, DOI 10.1016/j.scitotenv.2020.142372; Panesar NS, 2008, MED HYPOTHESES, V71, P298, DOI 10.1016/j.mehy.2008.03.019; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P2386, DOI 10.1001/jama.2020.8946; Phillips N, 2021, J RACIAL ETHN HEALTH, V8, P1153, DOI 10.1007/s40615-020-00871-y; Prajapat M, 2020, INDIAN J PHARMACOL, V52, P142, DOI 10.4103/ijp.IJP_338_20; Priyadarsini S Lakshmi, 2020, Glob Transit, V2, P202, DOI 10.1016/j.glt.2020.09.003; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Qin L, 2020, J MED VIROL, V92, P2684, DOI 10.1002/jmv.26137; Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005; Roth GA, 2018, JAMA CARDIOL, V3, P375, DOI 10.1001/jamacardio.2018.0385; Schijns V, 2020, EUR J IMMUNOL, V50, P932, DOI 10.1002/eji.202048693; Schroeder S, 2021, LANCET MICROBE, V2, pE210, DOI 10.1016/S2666-5247(21)00027-6; Shah M, 2020, J AM ACAD DERMATOL, V83, pE35, DOI 10.1016/j.jaad.2020.04.046; Shekhar S, 2020, HORM METAB RES, V52, P471, DOI 10.1055/a-1172-1352; Song JW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17240-2; Spagnolo P, 2020, LANCET RESP MED, V8, P750, DOI 10.1016/S2213-2600(20)30222-8; Sridharan GK, 2020, AM J THER, V27, pE400, DOI 10.1097/MJT.0000000000001196; Suleyman G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.12270; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Thwaites G., 2021, TOCILIZUMAB PATIENTS, DOI [10.1101/2021.02.11.21249258, DOI 10.1101/2021.02.11.21249258]; Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069; [王科雯 Wang Kewen], 2020, [测绘通报, Bulletin of Surveying and Mapping], P1; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007; Watsa M, 2020, SCIENCE, V369, P145, DOI 10.1126/science.abc0017; Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xia HJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108234; Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363; Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504; Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999	121	1	1	4	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							596	10.3390/vaccines9060596			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5EK	34199761	gold, Green Published			2022-04-29	WOS:000665910900001
J	Javier, PRF; Ramon, DL; Ana, EG; Alves, MVCM; Julia, ABM				Javier, Perez-Rivas Francisco; Ramon, Del Gallego-Lastra; Ana, Esteban-Garcimartin; Alves, Marques-Vieira Cristina Maria; Julia, Ajejas Bazan Maria			Attitude towards Vaccination among Health Science Students before the COVID-19 Pandemic	VACCINES			English	Article						attitudes; beliefs; health occupations; influenza vaccination; students; vaccination	INFLUENZA VACCINATION; SEASONAL INFLUENZA; KNOWLEDGE; HESITANCY; BELIEFS; PARENTS	Health science students are tomorrow's health professionals, the duties of whom could include vaccination. This work examines the general attitude towards vaccination in students attending the Faculty of Nursing, Physiotherapy and Chiropody at a university in Madrid, Spain, using the 'Attitudes and Behaviour With Regard To Vaccination Among Health Science Students Questionnaire'. The results were subjected to multivariate analysis to identify the influence of sex, the degree being pursued, and 'course year'. The number of students vaccinated against influenza in the campaign preceding the present study was also recorded, as were the factors that influenced decision-making in this regard. A total of 934 students completed the questionnaire. Their beliefs regarding vaccination were positive (mean score 3.23 points out of 4), as was their behaviour (3.35/4). Their general attitude (all variables taken together) was therefore also good (3.27/4). Only 26.8% of the students had been vaccinated against influenza. Beliefs scores among the students of nursing in their more senior course years were significantly better than those recorded for all other groups. These students also showed the best general attitude towards vaccination and formed the largest group vaccinated against influenza. The results obtained are encouraging since nursing students are the most likely of future healthcare professionals to be involved in vaccination programmes.	[Javier, Perez-Rivas Francisco; Ramon, Del Gallego-Lastra; Julia, Ajejas Bazan Maria] Univ Complutense Madrid, Dept Enfermeria, Fac Enfermeria Fisioterapia & Podol, Plaza Ramon y Cajal 3,Ciudad Univ, Madrid 28040, Spain; [Ana, Esteban-Garcimartin] Univ Complutense Madrid, Fac Enfermeria Fisioterapia & Podol, Estudiante Grado Enfermeria, Madrid 28040, Spain; [Alves, Marques-Vieira Cristina Maria] Univ Catolica Portuguesa, Nursing Sch Lisbon, Inst Hlth Sci, Ctr Interdisciplinary Res Hlth, P-1649023 Lisbon, Portugal; [Julia, Ajejas Bazan Maria] Minist Def, Escuela Mil Sanidad, Acad Cent Def, Madrid 28040, Spain		Javier, PRF (通讯作者)，Univ Complutense Madrid, Dept Enfermeria, Fac Enfermeria Fisioterapia & Podol, Plaza Ramon y Cajal 3,Ciudad Univ, Madrid 28040, Spain.	frjperez@ucm.es; rgallego@ucm.es; aneste01@ucm.es; cristina_marques@ucp.pt; majejas@ucm.es	Pérez-Rivas, Francisco-Javier/H-8960-2016; AJEJAS BAZAN, MARIA JULIA/I-3586-2016	Pérez-Rivas, Francisco-Javier/0000-0003-4294-8417; Marques-Vieira, Cristina/0000-0002-4409-7911; AJEJAS BAZAN, MARIA JULIA/0000-0001-5343-3377	Universidad Complutense de Madrid via the 'Ayudas Economicas a los Grupos de Investigacion UCM' [G/6400100/3000]	This work was funded by the Universidad Complutense de Madrid via the `Ayudas Economicas a los Grupos de Investigacion UCM (Aplicacion presupuestaria G/6400100/3000)'.	Afonso NM, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3969-x; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Picchio CA, 2019, EUROSURVEILLANCE, V24, P20, DOI 10.2807/1560-7917.ES.2019.24.6.1800117; Berera D., 2012, J VACCINES VACCIN, P6, DOI [10.4172/2157-7560.1000268, DOI 10.4172/2157-7560.1000268]; Berry NJ, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0783-2; Bonaccorsi G, 2013, Ann Ig, V25, P181, DOI 10.7416/ai.2013.1920; Cornally Nicola, 2013, Br J Nurs, V22, P1207; Cvjetkovic SJ, 2017, J INFECT PUBLIC HEAL, V10, P649, DOI 10.1016/j.jiph.2017.05.008; de Ministerio S., VACUNACI N FRENTE GR; Dube E, 2017, CLIN MICROBIOL INFEC, V23, P279, DOI 10.1016/j.cmi.2016.11.007; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Dybsand LL, 2019, BMC MED EDUC, V19, DOI 10.1186/s12909-019-1678-8; Ethgen O, 2018, HUM VACC IMMUNOTHER, V14, P2911, DOI 10.1080/21645515.2018.1504528; European Centre for Disease Prevention and Control, 2016, LETS TALK HES ENH CO; European Centre for Disease Prevention and Control, 2015, VACCINE HESITANCY HE; Fernandez-Prada M, 2016, REV ESP SALUD PUBLIC, V7, P1; Forcada J.A., 2014, VACUNAS, V15, P272, DOI [10.1016/S1576-9887(14)70088-3, DOI 10.1016/S1576-9887(14)70088-3]; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Hernández-García Ignacio, 2015, Rev. Esp. Salud Publica, V89, P615, DOI 10.4321/S1135-57272015000600009; Herzog R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-154; Hough-Telford C, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2127; Kelly DA, 2014, HUM VACC IMMUNOTHER, V10, P1930, DOI 10.4161/hv.29071; Kin C, 2017, VACCINE, V35, P1482, DOI 10.1016/j.vaccine.2017.02.001; La Fauci V, 2019, CLIN TER, V170, pE448, DOI 10.7417/CT.2019.2174; Larson S., 2018, STATE VACCINE CONFID; Lehmann BA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0929-5; Mergler MJ, 2013, VACCINE, V31, P4591, DOI 10.1016/j.vaccine.2013.07.039; Ministerio de Sanidad Consumo y Bienestar Social, 2019, CARACTER STICAS INDI; O'Leary ST, 2013, PREV MED, V56, P231, DOI 10.1016/j.ypmed.2013.01.001; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Pelly LP, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-86; Pelullo CP, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16101770; Remy Vanessa, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27041; Rogers CJ, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6041-1; Schmitt HJ, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-11; Shahrabani S, 2009, EUR J HEALTH ECON, V10, P227, DOI 10.1007/s10198-008-0124-3; Shrestha R, 2019, J UNIVERSAL COLL MED, V7, P46; Suryadevara M, 2015, VACCINE, V33, P6629, DOI 10.1016/j.vaccine.2015.10.096; Villanueva S, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16224507; Walker L, 2016, VACCINE, V34, P6193, DOI 10.1016/j.vaccine.2016.10.074; World Health Organization, 2014, REP STRAT ADV GROUP; World Health Organization, 2019, 10 CUESTIONES SALUD; Wozniak-Kosek A, 2014, ACTA BIOCHIM POL, V61, P829; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018; Zarobkiewicz MK, 2017, HUM VACC IMMUNOTHER, V13, P2654, DOI 10.1080/21645515.2017.1365994	45	1	1	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							644	10.3390/vaccines9060644			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6NM	34204741	gold, Green Published, Green Accepted			2022-04-29	WOS:000666002300001
J	Moccia, G; Carpinelli, L; Savarese, G; Borrelli, A; Boccia, G; Motta, O; Capunzo, M; De Caro, F				Moccia, Giuseppina; Carpinelli, Luna; Savarese, Giulia; Borrelli, Anna; Boccia, Giovanni; Motta, Oriana; Capunzo, Mario; De Caro, Francesco			Perception of Health, Mistrust, Anxiety, and Indecision in a Group of Italians Vaccinated against COVID-19	VACCINES			English	Article						COVID-19; vaccination; psychological perception	HESITANCY; INTENTION; FRANCE; ADULTS; CARE	The objectives of this study were to evaluate the psychological factors of health perception, mistrust, anxiety, fear, and indecision of Italians vaccinated against COVID-19, and conduct an analysis of the relationships between these factors and other variables: sex, vaccine priority ministerial categories, and the type and dose of vaccine. The participants included 1564 subjects who joined the vaccination campaign at the COVID-19 Vaccination Center in Salerno, Italy. A survey was conducted in the reference period March-April 2021 using a brief anamnestic questionnaire. In addition, the following standardized scales were used: the State-Trait Anxiety Inventory (STAI-Y) and the Short Form Health Survey (SF-12). The results showed that, in terms of the type of vaccine received, the interviewees felt more confident in having received the Comirnaty (Pfizer-BioNTech, 23.5%) and Vaxzevria (AstraZeneca, 18.6%) vaccines-feeling less tense (2.1%; Vaxzevria (AstraZeneca) = 3.2%), frightened (1%; Vaxzevria (AstraZeneca) = 1.4%), not at all nervous (61.1%; Vaxzevria (AstraZeneca), 43.6%), and not at all/undecided (67.9%; Vaxzevria (AstraZeneca), 58.6%). Regarding the mood and psychological states considered at the different vaccine administration times, other important differences emerged as the interviewees reported higher levels of tension, nervousness, and fear during the first phase of vaccine administration. Specifically, 40.7% (second dose, 32.7%) felt somewhat tense at the first dose, 26.4% felt frightened (second dose, 21.8%), and 33.8% felt nervous (second dose, 26.8%). The perceived state of health also increased at the end of the vaccination cycle, as, at the second dose, 15.4% of the sample reported an evaluation of "excellent" (first dose, 12.4%).	[Moccia, Giuseppina; Carpinelli, Luna; Savarese, Giulia; Boccia, Giovanni; Motta, Oriana; Capunzo, Mario; De Caro, Francesco] Univ Salerno, Dept Med Surg & Dent, Scuola Med Salernitana, I-84081 Baronissi, Italy; [Moccia, Giuseppina; Borrelli, Anna; Boccia, Giovanni; Motta, Oriana; Capunzo, Mario; De Caro, Francesco] AUO San Giovanni Dio & Ruggi dAragona, I-84121 Salerno, Italy		Savarese, G (通讯作者)，Univ Salerno, Dept Med Surg & Dent, Scuola Med Salernitana, I-84081 Baronissi, Italy.	gmoccia@unisa.it; lcarpinelli@unisa.it; gsavarese@unisa.it; direzione.sanitaria@sangiovannieruggi.it; gboccia@unisa.it; omotta@unisa.it; mcapunzo@unisa.it; fdecaro@unisa.it	Savarese, Giulia GS/H-4722-2012; Motta, Oriana/ABC-8897-2021; BOCCIA, GIOVANNI/J-9496-2016	Savarese, Giulia GS/0000-0002-0974-6429; Carpinelli, Luna/0000-0001-7265-8504; Motta, Oriana/0000-0003-1088-6741; MOCCIA, GIUSEPPINA/0000-0002-7017-7413; BOCCIA, GIOVANNI/0000-0002-7757-6855; DE CARO, Francesco/0000-0001-9659-9940			Barello S, 2021, PSYCHOL MED, DOI 10.1017/S003329172100101X; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Beaudoin-Bussieres G, 2020, MBIO, V11, DOI 10.1128/mBio.02590-20; Bener A., 2020, INT J CLIN PSYCHIAT, V8, P16, DOI [10.12970/2310-8231.2020.08.04, DOI 10.12970/2310-8231.2020.08.04]; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Byrne T., 2021, TRENDS PATTERNS PSYC, DOI [10.1101/2021.03.22.21254130, DOI 10.1101/2021.03.22.21254130]; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Cohen S, 2021, PERSPECT PSYCHOL SCI, V16, P161, DOI 10.1177/1745691620942516; Davin-Casalena B, 2021, REV EPIDEMIOL SANTE, V69, P105, DOI 10.1016/j.respe.2021.04.135; Depoux A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa031; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Fisher A, 2021, ACAD PEDIATR, V21, pS3, DOI 10.1016/j.acap.2021.03.013; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lang R, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10790-0; Madison AA, 2021, PERSPECT PSYCHOL SCI, V16, P191, DOI 10.1177/1745691621989243; Manning ML, 2021, NURS OUTLOOK, V69, P565, DOI 10.1016/j.outlook.2021.01.019; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Palgi Y, 2021, J AFFECT DISORDERS, V287, P352, DOI 10.1016/j.jad.2021.03.064; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Shim E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040591; Shrotri M, 2021, LANCET GLOB HEALTH, V9, pE590, DOI 10.1016/S2214-109X(21)00043-7; Spielberger CD., 1970, MANUAL STATE TRAIT A; Sun SF, 2021, PREV MED REP, V22, DOI 10.1016/j.pmedr.2021.101350; Trujillo K.L., CONVERSATION; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	30	7	7	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							612	10.3390/vaccines9060612			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ8EA	34200347	gold, Green Published			2022-04-29	WOS:000666790100001
J	Orsi, A; Domnich, A; De Pace, V; Ricucci, V; Caligiuri, P; Bottiglieri, L; Vagge, R; Cavalleri, MA; Orlandini, F; Bruzzone, B; Icardi, G				Orsi, Andrea; Domnich, Alexander; De Pace, Vanessa; Ricucci, Valentina; Caligiuri, Patrizia; Bottiglieri, Livio; Vagge, Rosanna; Cavalleri, Maurizio A.; Orlandini, Francesco; Bruzzone, Bianca; Icardi, Giancarlo			Outbreak of SARS-CoV-2 Lineage 20I/501Y.V1 in a Nursing Home Underlines the Crucial Role of Vaccination in Both Residents and Staff	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccination; nursing home; elderly; Italy	COVID-19; MORTALITY; IMPACT; RATES	Elderly residents in nursing homes are at very high risk of life-threatening COVID-19-related outcomes. In this report, an epidemiological and serological investigation of a SARS-CoV-2 outbreak in an Italian nursing home is described. Among the residents, all but one (19/20) were regularly vaccinated against SARS-CoV-2. In mid-February 2021, a non-vaccinated staff member of the nursing home was diagnosed with the SARS-CoV-2 infection. Following the outbreak investigation, a total of 70% (14/20) of residents aged 77-100 years were found positive. The phylogenetic analysis showed that the outbreak was caused by the SARS-CoV-2 variant of concern 202012/01 (the so-called "UK variant"). However, all but one positive subjects (13/14) were fully asymptomatic. The only symptomatic patient was a vaccinated 86-year-old female with a highly compromised health background and deceased approximately two weeks later. The subsequent serological investigation showed that the deceased patient was the only vaccinated subject that did not develop the anti-spike protein antibody response, therefore being likely a vaccine non-responder. Although the available mRNA SARS-CoV-2 vaccine was not able to prevent several asymptomatic infections, it was able to avert most symptomatic disease cases caused by the SARS-CoV-2 variant of concern 202012/01 in nursing home residents.	[Orsi, Andrea; Icardi, Giancarlo] Univ Genoa, Dept Hlth Sci DISSAL, I-16132 Genoa, Italy; [Orsi, Andrea; Domnich, Alexander; De Pace, Vanessa; Ricucci, Valentina; Caligiuri, Patrizia; Bruzzone, Bianca; Icardi, Giancarlo] San Martino Policlin Hosp, Hyg Unit, IRCCS Oncol & Neurosci, I-16132 Genoa, Italy; [Bottiglieri, Livio] San Martino Policlin Hosp, Lab Med, IRCCS Oncol & Neurosci, I-16132 Genoa, Italy; [Vagge, Rosanna; Cavalleri, Maurizio A.; Orlandini, Francesco] Local Hlth Unit 4, I-16043 Chiavari, Italy		Domnich, A (通讯作者)，San Martino Policlin Hosp, Hyg Unit, IRCCS Oncol & Neurosci, I-16132 Genoa, Italy.	andrea.orsi@unige.it; alexander.domnich@hsanmartino.it; Vanessa.DePace@hsanmartino.it; valentina.ricucci@hsanmartino.it; patrizia.caligiuri@hsanmartino.it; livio.bottiglieri@hsanmartino.it; rosanna_vagge@libero.it; maurizioalessandro.cavalleri@as14.ligurialt; francesco.orlandini@as14.liguria.it; bianca.bruzzone@hsanmartino.it; icardi@unige.it	De Pace, Vanessa/AAG-7431-2020; Orsi, Andrea/AAC-7431-2022	Orsi, Andrea/0000-0002-2433-9610; cavalleri, maurizio alessandro/0000-0002-1529-1280			Karim SAS, 2021, NEW ENGL J MED, V384, P1866, DOI 10.1056/NEJMc2100362; Bagchi S, 2021, MMWR-MORBID MORTAL W, V70, P52, DOI 10.15585/mmwr.mm7002e2; Bernadou A, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05890-6; Brown KA, 2021, JAMA INTERN MED, V181, P229, DOI 10.1001/jamainternmed.2020.6466; Chen MK, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2015455118; Cherubini A, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2011.04.001; Chirumbolo S, 2021, J MED VIROL, V93, P4049, DOI 10.1002/jmv.26922; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; de Girolamo G, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.586524; European Centre for Disease Prevention and Control (ECDC), SURV COVID 19 LONGT; GISAID Initiative, EPICOV; Gur-Arie R, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004877; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Heras E, 2021, EUR GERIATR MED, V12, P601, DOI 10.1007/s41999-020-00432-w; Italian Institute of Statistics, DEM NUMB; Italian Ministry of Health, NAT COVID 19 VACC PL; Italian National Institute of Health, INT IND PREV CONTR S; Italian National Institute of Health, 2021, TEMP TREND COVID 19; Kennelly SP, 2021, AGE AGEING, V50, P49, DOI 10.1093/ageing/afaa220; Kirby T, 2021, LANCET RESP MED, V9, pE20, DOI 10.1016/S2213-2600(21)00005-9; Krammer F, 2021, LANCET, V397, P1421, DOI 10.1016/S0140-6736(21)00782-0; Levine-Tiefenbrun M., DECREASED SARS COV 2, DOI [10.1101/2021.02.06.21251283v1, DOI 10.1101/2021.02.06.21251283V1]; Li J, 2021, J MED VIROL, V93, P1449, DOI 10.1002/jmv.26424; Lo Menzo S, 2021, INFECTION, V49, P1341, DOI 10.1007/s15010-021-01609-6; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n597; Mallapaty Smriti, 2021, Nature, DOI 10.1038/d41586-021-00450-z; Moore KL, 2012, J AM GERIATR SOC, V60, P756, DOI 10.1111/j.1532-5415.2012.03909.x; Mousten-Helms I.R., VACCINE EFFECTIVENES, DOI [10.1101/2021.03.08.21252200v1.full.pdf, DOI 10.1101/2021.03.08.21252200V1.FULL.PDF]; Ouslander JG, 2020, J AM GERIATR SOC, V68, P2153, DOI 10.1111/jgs.16784; Parohan M, 2020, AGING MALE, V23, P1416, DOI 10.1080/13685538.2020.1774748; Patel Urvish, 2020, SN Compr Clin Med, V2, P1740, DOI 10.1007/s42399-020-00476-w; Paterlini M, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n905; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ribbe MW, 1997, AGE AGEING, V26, P3, DOI 10.1093/ageing/26.suppl_2.3; Rondinone V, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020276; Sugg MM, 2021, SCI TOTAL ENVIRON, V752, DOI 10.1016/j.scitotenv.2020.141946; Tande AJ, 2022, CLIN INFECT DIS, V74, P59, DOI 10.1093/cid/ciab229; White EM, 2021, NEW ENGL J MED, V385, P474, DOI 10.1056/NEJMc2104849; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021	40	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							591	10.3390/vaccines9060591			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6ZH	34199663	gold, Green Published			2022-04-29	WOS:000666710200001
J	Santos, TM; Cata-Preta, BO; Victora, CG; Barros, AJD				Santos, Thiago M.; Cata-Preta, Bianca O.; Victora, Cesar G.; Barros, Aluisio J. D.			Finding Children with High Risk of Non-Vaccination in 92 Low- and Middle-Income Countries: A Decision Tree Approach	VACCINES			English	Article						vaccination; immunization; prenatal care; decision trees	REACHING EVERY DISTRICT; IMMUNIZATION; INEQUALITIES; COVERAGE; EQUITY	Reducing vaccination inequalities is a key goal of the Immunization Agenda 2030. Our main objective was to identify high-risk groups of children who received no vaccines (zero-dose children). A decision tree approach was used for 92 low- and middle-income countries using data from Demographic and Health Surveys and Multiple Indicator Cluster Surveys, allowing the identification of groups of children aged 12-23 months at high risk of being zero dose (no doses of the four basic vaccines-BCG, polio, DPT and measles). Three high-risk groups were identified in the analysis combining all countries. The group with the highest zero-dose prevalence (42%) included 4% of all children, but almost one in every four zero-dose children in the sample. It included children whose mothers did not receive the tetanus vaccine during and before the pregnancy, who had no antenatal care visits and who did not deliver in a health facility. Separate analyses by country presented similar results. Children who have been missed by vaccination services were also left out by other primary health care interventions, especially those related to antenatal and delivery care. There is an opportunity for better integration among services in order to achieve high and equitable immunization coverage.	[Santos, Thiago M.; Cata-Preta, Bianca O.; Victora, Cesar G.; Barros, Aluisio J. D.] Univ Fed Pelotas, Int Ctr Equ Hlth, Marechal Deodoro 1160, BR-96020220 Pelotas, RS, Brazil		Santos, TM (通讯作者)，Univ Fed Pelotas, Int Ctr Equ Hlth, Marechal Deodoro 1160, BR-96020220 Pelotas, RS, Brazil.	tmelo@equidade.org; bcatapreta@equidade.org; cvictora@equidade.org; abarros@equidade.org	Victora, Cesar Gomes/Y-2455-2019	Victora, Cesar Gomes/0000-0002-2465-2180; Barros, Aluisio/0000-0002-2022-8729; Cata-Preta, Bianca O/0000-0002-5632-7016; Santos, Thiago M/0000-0002-4572-5297	Wellcome TrustWellcome TrustEuropean Commission [101815/Z/13/Z]; Bill and Melinda Gates FoundationBill & Melinda Gates Foundation [OPP1199234]; Associacao Brasileira de Saude Coletiva; Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]	This research was funded by the Wellcome Trust (Grant Number: 101815/Z/13/Z), Bill and Melinda Gates Foundation (Grant Number: OPP1199234), Associacao Brasileira de Saude Coletiva, and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Finance Code 001).	[Anonymous], 2018, Wkly Epidemiol Rec, V93, P73; Arroyave L, 2021, INT J EQUITY HEALTH, V20, DOI 10.1186/s12939-021-01440-3; Atkinson Beth, 2019, CRAN; Ayalneh AA, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0561-7; Bishai D, 2003, HEALTH ECON, V12, P415, DOI 10.1002/hec.732; Blewitt ME, 2008, NAT GENET, V40, P663, DOI 10.1038/ng.142; Bosch-Capblanch X, 2012, TROP MED INT HEALTH, V17, P697, DOI 10.1111/j.1365-3156.2012.02989.x; Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053; da Silva ICM, 2018, J NUTR, V148, P254, DOI 10.1093/jn/nxx050; Duclos P, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S2; Enkhtuya B, 2009, RURAL REMOTE HEALTH, V9; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.1353/dem.2001.0003; Francis MR, 2018, VACCINE, V36, P6559, DOI 10.1016/j.vaccine.2017.08.026; Hajizadeh M, 2018, J EPIDEMIOL COMMUN H, V72, P719, DOI 10.1136/jech-2017-210296; Hancioglu A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001391; Kelso N.V., NATURAL EARTH VECTOR; Patel MK, 2019, MMWR-MORBID MORTAL W, V68, P1105, DOI 10.15585/mmwr.mm6848a1; Roy P, 2019, LANCET GLOB HEALTH, V7, pE1655, DOI 10.1016/S2214-109X(19)30444-9; Rutstein S., 2004, DHS WEALTH INDEX COM, V6; Rutstein SO, 2008, DHS WEALTH INDEX APP; Ryman T, 2010, J PUBLIC HEALTH-UK, V32, P18, DOI 10.1093/pubmed/fdp048; Shenton LM, 2018, MATERN CHILD HLTH J, V22, P419, DOI 10.1007/s10995-017-2409-6; Soeung SC, 2013, HEALTH POLICY PLANN, V28, P526, DOI 10.1093/heapol/czs096; Vandelaer Jos, 2008, Bull World Health Organ, V86, pA; WHO, 2020, IMM AG 2030 GLOB STR; WHO, 2019, GLOB VACC ACT PLAN 2; WHO UNICEF, 2009, MICR IMM SERV DEL US; Wolfson J, 2018, CURR EPIDEMIOL REP, V5, P221, DOI 10.1007/s40471-018-0163-y; World Health Organization, 2019, EXP PROGR IMM EPI HA; World Health Organization, 2019, PROT ALL TET GUID SU	30	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							646	10.3390/vaccines9060646			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5RK	34199179	gold, Green Published			2022-04-29	WOS:000665944700001
J	Zdanowski, W; Wasniewski, T				Zdanowski, Wojciech; Wasniewski, Tomasz			Evaluation of SARS-CoV-2 Spike Protein Antibody Titers in Cord Blood after COVID-19 Vaccination during Pregnancy in Polish Healthcare Workers: Preliminary Results	VACCINES			English	Article						COVID-19; pregnancy; vaccine	2019-NCOV; VACCINES; ACE2	Background: The coronavirus disease 2019 (COVID-19) pandemic has given rise to the need to develop a vaccine as quickly as possible. As pregnant women are at increased risk of contracting severe COVID-19, with higher mortality, it is essential to assess the safety of the vaccines administered during pregnancy. Methods: The aim of this study was to determine the titer of specific maternal and cord antibodies against severe acute respiratory syndrome coronavirus 2 S protein after antenatal vaccination. The secondary objective was to evaluate the ratio of the umbilical cord to the maternal antibody titers. Patients included in the study were enrolled after undergoing voluntary vaccination against COVID-19 during pregnancy at different weeks of gestation. All patients analyzed in our initial study were vaccinated with the BNT162b2 mRNA COVID-19 vaccine. Results: The results of the current study document high anti-S total IgG antibody titers in cord serum at birth in all mother-infant pairs analyzed. The mean umbilical cord blood sample IgG antibody titer anti-S protein was 1026.51 U/mL (+/- SD 769.25). The mean cord-to-maternal anti-S IgG antibody ratio was 1.28 (+/- SD 0.798). A significant positive correlation was observed between the week of gestation at which the first dose was administered and the week of gestation at which the second dose was administered, and the respective cord-to-maternal ratio (r = 0.48; p = 0.0029) for the first dose and (r = 0.39; p = 0.0102) for the second dose. Conclusions: To date, despite the prevalence of COVID-19 vaccination, there is a lack of conclusive evidence supporting the safety and efficacy of vaccination of pregnant women. Therefore, the results we present are complementary. Our study suggests that maternal immunization may provide neonatal protection through the transplacental transfer of antibodies. Of particular importance is the demonstration that antibody transfer is correlated with the time from vaccination to delivery, which may allow future determination of the optimal timing of COVID-19 vaccination in pregnant women.	[Zdanowski, Wojciech; Wasniewski, Tomasz] Reg Specialist Hosp, Gynaecol Oncol Clin Ward, Dept Gynaecol & Obstet, Ul Zolnierska 18, PL-10561 Olsztyn, Poland; [Zdanowski, Wojciech; Wasniewski, Tomasz] Univ Warmia & Mazury, Coll Med, Sch Med, Dept Obstet & Gynaecol, PL-10561 Olsztyn, Poland		Zdanowski, W (通讯作者)，Reg Specialist Hosp, Gynaecol Oncol Clin Ward, Dept Gynaecol & Obstet, Ul Zolnierska 18, PL-10561 Olsztyn, Poland.; Zdanowski, W (通讯作者)，Univ Warmia & Mazury, Coll Med, Sch Med, Dept Obstet & Gynaecol, PL-10561 Olsztyn, Poland.	wojciech.zdanowski@uwm.edu.pl; tomasz.wasniewski@uwm.edu.pl	Zdanowski, Wojciech/AAD-3065-2022	Zdanowski, Wojciech/0000-0003-0460-1658	Ministry of Science and Higher Education Republic of PolandMinistry of Science and Higher Education, Poland [61.610.009-110]	This study is conducted with funding from Ministry of Science and Higher Education Republic of Poland, (grant number: 61.610.009-110).	Abu Raya B, 2017, LANCET INFECT DIS, V17, pE209, DOI 10.1016/S1473-3099(17)30190-1; American College of Obstetricians and Gynecologist, 2020, VACC PREGN LACT PAT; Edlow AG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.30455; Esposito S, 2012, CLIN MICROBIOL INFEC, V18, P85, DOI 10.1111/j.1469-0691.2012.03936.x; European Medicines Agency, EMEAHC0057350000 EUR; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; Higgins V, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.03149-20; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Klein SL, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI147553; L'Huillier AG, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.01.005; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI 10.1038/s41564-020-0688-y; Masmejan Sophie, 2020, Rev Med Suisse, V16, P944; Omer SB, 2020, LANCET RESP MED, V8, P597, DOI 10.1016/S2213-2600(19)30479-5; Rasmussen SA, 2021, OBSTET GYNECOL, V137, P408, DOI 10.1097/AOG.0000000000004290; Roberts JN, 2015, VACCINE, V33, P966, DOI 10.1016/j.vaccine.2014.12.068; Royal College of Obstetricians Gynaecologists, UPD ADV COVID 19 VAC; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1056/NEJMx210016, 10.1097/01.ogx.0000802676.57373.17]; Society for Maternal-Fetal Medicine (SMFM) Statement, SARS CO V 2 VACC PRE; Stafford IA, 2021, AM J OBSTET GYNECOL, V224, P484, DOI 10.1016/j.ajog.2021.01.022; Vilajeliu A, 2015, VACCINE, V33, P1056, DOI 10.1016/j.vaccine.2014.12.062; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Xu H, 2020, INT J ORAL SCI, V12, DOI [10.1038/s41368-020-0074-X, 10.1038/s41368-020-0074-x]	23	12	12	1	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							675	10.3390/vaccines9060675			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3FJ	34205434	Green Published, gold			2022-04-29	WOS:000666455100001
J	Tay, BQ; Wright, Q; Ladwa, R; Perry, C; Leggatt, G; Simpson, F; Wells, JW; Panizza, BJ; Frazer, IH; Cruz, JLG				Tay, Ban Qi; Wright, Quentin; Ladwa, Rahul; Perry, Christopher; Leggatt, Graham; Simpson, Fiona; Wells, James W.; Panizza, Benedict J.; Frazer, Ian H.; Cruz, Jazmina L. G.			Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions	VACCINES			English	Review						vaccine; cancer; antigens; ICIs; immunotherapies; T-cells; tumour; neoantigens	EPSTEIN-BARR-VIRUS; ACTIVE SPECIFIC IMMUNOTHERAPY; PROSTATIC ACID-PHOSPHATASE; BACILLUS-CALMETTE-GUERIN; LONG PEPTIDE VACCINE; HEPATITIS-B-VACCINE; TUMOR-CELL VACCINE; P53-SPECIFIC IMMUNE-RESPONSES; HUMAN-PAPILLOMAVIRUS VACCINES; TESTIS ANTIGEN NY-ESO-1	The development of cancer vaccines has been intensively pursued over the past 50 years with modest success. However, recent advancements in the fields of genetics, molecular biology, biochemistry, and immunology have renewed interest in these immunotherapies and allowed the development of promising cancer vaccine candidates. Numerous clinical trials testing the response evoked by tumour antigens, differing in origin and nature, have shed light on the desirable target characteristics capable of inducing strong tumour-specific non-toxic responses with increased potential to bring clinical benefit to patients. Novel delivery methods, ranging from a patient's autologous dendritic cells to liposome nanoparticles, have exponentially increased the abundance and exposure of the antigenic payloads. Furthermore, growing knowledge of the mechanisms by which tumours evade the immune response has led to new approaches to reverse these roadblocks and to re-invigorate previously suppressed anti-tumour surveillance. The use of new drugs in combination with antigen-based therapies is highly targeted and may represent the future of cancer vaccines. In this review, we address the main antigens and delivery methods used to develop cancer vaccines, their clinical outcomes, and the new directions that the vaccine immunotherapy field is taking.	[Tay, Ban Qi; Wright, Quentin; Leggatt, Graham; Simpson, Fiona; Wells, James W.; Frazer, Ian H.; Cruz, Jazmina L. G.] Univ Queensland, Diamantina Inst, Fac Med, Brisbane, Qld 4102, Australia; [Ladwa, Rahul] Princess Alexandra Hosp, Dept Med Oncol, Brisbane, Qld 4102, Australia; [Ladwa, Rahul; Perry, Christopher; Panizza, Benedict J.] Univ Queensland, Fac Med, Woolloongabba, Qld 4102, Australia; [Perry, Christopher; Panizza, Benedict J.] Princess Alexandra Hosp, Dept Otolaryngol, Brisbane, Qld 4102, Australia		Cruz, JLG (通讯作者)，Univ Queensland, Diamantina Inst, Fac Med, Brisbane, Qld 4102, Australia.	b.tay@uq.net.au; q.wright@uq.edu.au; rahul.ladwa@health.qld.gov.au; c.perry@uq.edu.au; g.leggatt@uq.edu.au; f.simpson@uq.edu.au; j.wells3@uq.edu.au; ben.panizza@health.qld.gov.au; i.frazer@uq.edu.au; j.gonzalezcruz@uq.edu.au	Ladwa, Rahul/AAW-5861-2021; Simpson, Fiona/ABE-1276-2020; Wells, James W./C-7480-2011; Leggatt, Graham/G-1924-2010	Simpson, Fiona/0000-0002-0271-781X; Wells, James W./0000-0002-9618-6940; Leggatt, Graham/0000-0002-4078-5653; Wright, Quentin/0000-0001-9628-0200; Tay, Ban Qi/0000-0002-2644-8001; Ladwa, Rahul/0000-0002-4196-0177; Gonzalez Cruz, Jazmina Libertad/0000-0003-2671-7408	Garnet Passe and RodneyWilliams Memorial Foundation Cojoint grant (2019_CG_Gonzalez Cruz_Perry); Princess Alexandra Research Foundation; NHMRCNational Health and Medical Research Council (NHMRC) of Australia	This research was funded by Garnet Passe and RodneyWilliams Memorial Foundation Cojoint grant (2019_CG_Gonzalez Cruz_Perry), Princess Alexandra Research Foundation 2021 Research Award and NHMRC Investigator grant (Frazer_2020).	Abd Hamid M, 2020, CELL MOL IMMUNOL, V17, P684, DOI 10.1038/s41423-020-0468-x; ABRAHAMSSON PA, 1988, PROSTATE, V12, P39, DOI 10.1002/pros.2990120106; Aggarwal C, 2019, CLIN CANCER RES, V25, P110, DOI 10.1158/1078-0432.CCR-18-1763; Ahluwalia MS, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2016; Amon W, 2005, REV MED VIROL, V15, P149, DOI 10.1002/rmv.456; Anassi Enock, 2011, P T, V36, P197; [Anonymous], 2017, NAT BIOTECHNOL, V35, P97, DOI 10.1038/nbt.3800; Arlen PM, 2009, FUTURE ONCOL, V5, P187, DOI 10.2217/14796694.5.2.187; Atsmon J, 2021, VACCINE, V39, P1328, DOI 10.1016/j.vaccine.2020.12.050; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bagarazzi ML, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004414; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Banerjee A, 2010, VIRUSES-BASEL, V2, P2108, DOI 10.3390/v2092108; Barthel FP, 2017, NAT GENET, V49, P349, DOI 10.1038/ng.3781; Bauman J, 2020, J IMMUNOTHER CANCER, V8, pA477, DOI 10.1136/jitc-2020-SITC2020.0798; Bentzen AK, 2016, NAT BIOTECHNOL, V34, P1037, DOI 10.1038/nbt.3662; BERD D, 1990, J CLIN ONCOL, V8, P1858, DOI 10.1200/JCO.1990.8.11.1858; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Blagovic K, 2020, J IMMUNOTHER CANCER, V8, pA98, DOI 10.1136/jitc-2020-SITC2020.0165; Blass E, 2021, NAT REV CLIN ONCOL, V18, P215, DOI 10.1038/s41571-020-00460-2; Bonehill A, 2009, CLIN CANCER RES, V15, P3366, DOI 10.1158/1078-0432.CCR-08-2982; Booty M, 2020, J IMMUNOTHER CANCER, V8, pA86, DOI 10.1136/jitc-2020-SITC2020.0141; Bright RK, 2014, HUM VACC IMMUNOTHER, V10, P3297, DOI 10.4161/hv.29475; Brisse M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583077; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Buschmann MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010065; Butts C, 2014, LANCET ONCOL, V15, P59, DOI 10.1016/S1470-2045(13)70510-2; Cai Y, 2009, EXPERT REV VACCINES, V8, P1277, DOI [10.1586/erv.09.84, 10.1586/ERV.09.84]; Caldeira JC, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050488; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Cebon JS, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000410; Chandra J, 2021, CANCER IMMUNOL IMMUN, V70, P743, DOI 10.1007/s00262-020-02720-7; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Cheng LQ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030391; Chia WK, 2012, ANN ONCOL, V23, P997, DOI 10.1093/annonc/mdr341; Cho Hearn J, 2006, Cancer Immun, V6, P12; Cho H, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-LB-093; Cohen EEW, 2019, LANCET, V393, P156, DOI 10.1016/S0140-6736(18)31999-8; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cooper CL, 2004, J CLIN IMMUNOL, V24, P693, DOI 10.1007/s10875-004-6244-3; Costa RLB, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-0153-3; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Cunha AC, 2006, CANCER LETT, V236, P229, DOI 10.1016/j.canlet.2005.05.021; De Keersmaecker B, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000329; DEPLAEN E, 1988, P NATL ACAD SCI USA, V85, P2274; Dijkgraaf EM, 2015, ONCOTARGET, V6, P32228, DOI 10.18632/oncotarget.4772; Dillon PM, 2020, BREAST CANCER-TARGET, V12, P69, DOI 10.2147/BCTT.S224758; Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dreno B, 2018, LANCET ONCOL, V19, P916, DOI 10.1016/S1470-2045(18)30254-7; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Farrell PJ, 2019, ANNU REV PATHOL-MECH, V14, P29, DOI 10.1146/annurev-pathmechdis-012418-013023; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fenstermaker RA, 2016, CANCER IMMUNOL IMMUN, V65, P1339, DOI 10.1007/s00262-016-1890-x; Fernandez JG, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-209; Fijak M, 2006, IMMUNOL REV, V213, P66, DOI 10.1111/j.1600-065X.2006.00438.x; Fowler DM, 2007, TRENDS BIOCHEM SCI, V32, P217, DOI 10.1016/j.tibs.2007.03.003; Garg H, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0326-1; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Gjerstorff MF, 2007, HUM REPROD, V22, P953, DOI 10.1093/humrep/del494; GOLDFARB DA, 1986, J UROLOGY, V136, P1266, DOI 10.1016/S0022-5347(17)45310-9; Gridelli C, 2020, BRIT J CANCER, V122, P1461, DOI 10.1038/s41416-020-0785-y; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; Guevara ML, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.589959; Gulley JL, 2019, J CLIN ONCOL, V37, P1051, DOI 10.1200/JCO.18.02031; Gupta R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020446; Haen SP, 2020, NAT REV CLIN ONCOL, V17, P595, DOI 10.1038/s41571-020-0387-x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanna MG, 2001, VACCINE, V19, P2576, DOI 10.1016/S0264-410X(00)00485-0; Hao YH, 2013, CELL, V152, P1051, DOI 10.1016/j.cell.2013.01.051; Hardwick NR, 2018, CLIN CANCER RES, V24, P1315, DOI 10.1158/1078-0432.CCR-17-2709; Harper DM, 2017, GYNECOL ONCOL, V146, P196, DOI 10.1016/j.ygyno.2017.04.004; Harris JE, 2000, J CLIN ONCOL, V18, P148, DOI 10.1200/JCO.2000.18.1.148; Hassan MI, 2010, EXPERT REV ANTICANC, V10, P1055, DOI 10.1586/ERA.10.46; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Heffernan ME, 2010, SEX HEALTH, V7, P383, DOI 10.1071/SH09134; Heldenbrand JR, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3169-7; Hemminger JA, 2013, MODERN PATHOL, V26, P282, DOI 10.1038/modpathol.2012.133; Higano C., 2009, P 2009 GEN CANC S 26; Higano CS, 2009, CANCER-AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoerr I, 2000, EUR J IMMUNOL, V30, P1; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hui EP, 2013, CANCER RES, V73, P1676, DOI 10.1158/0008-5472.CAN-12-2448; Iqbal Nida, 2014, Mol Biol Int, V2014, P852748, DOI 10.1155/2014/852748; Ishihara M, 2020, CANCER IMMUNOL IMMUN, V69, P663, DOI 10.1007/s00262-020-02483-1; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Jiang T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0787-5; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kang SM, 2009, MOL CELLS, V27, P5, DOI 10.1007/s10059-009-0015-1; Kantoff PW, 2017, J CLIN ONCOL, V35, P124, DOI 10.1200/JCO.2016.69.7748; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Karpanen T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01718; Keenan BP, 2012, SEMIN ONCOL, V39, P276, DOI 10.1053/j.seminoncol.2012.02.007; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Kisseleva-Romanova E, 2006, EMBO J, V25, P3576, DOI 10.1038/sj.emboj.7601235; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kong HY, 2013, BIOMOL THER, V21, P10, DOI 10.4062/biomolther.2012.095; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kumai T, 2017, CURR OPIN IMMUNOL, V45, P1, DOI 10.1016/j.coi.2016.11.001; Larocca C, 2011, CANCER J, V17, P359, DOI 10.1097/PPO.0b013e3182325e63; Laus R., 2001, CANCER RES THER CONT, V11, P1; Le DT, 2019, CLIN CANCER RES, V25, P5493, DOI 10.1158/1078-0432.CCR-18-2992; Le DT, 2015, J CLIN ONCOL, V33, P1325, DOI 10.1200/JCO.2014.57.4244; Leao R, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0422-8; Lee GH, 2021, EXPERT REV VACCINES, V20, P487, DOI 10.1080/14760584.2021.1908133; Leffers N, 2009, INT J CANCER, V125, P2104, DOI 10.1002/ijc.24597; Lennerz V, 2014, CANCER IMMUNOL IMMUN, V63, P381, DOI 10.1007/s00262-013-1516-5; Li FZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1362-1; Li L, 2017, ANN ONCOL, V28, P11, DOI 10.1093/annonc/mdx681; Lilleby W, 2017, CANCER IMMUNOL IMMUN, V66, P891, DOI 10.1007/s00262-017-1994-y; Liu S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0629-6; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; LUCHTERW.E, 1974, BIOCHIM BIOPHYS ACTA, V365, P349, DOI 10.1016/0005-2795(74)90008-7; Luckey Alison M, 2015, Mult Scler J Exp Transl Clin, V1, p2055217315583385, DOI 10.1177/2055217315583385; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473; Maestroni L, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020055; Maloney M, 2020, J IMMUNOTHER CANCER, V8, pA102, DOI 10.1136/jitc-2020-SITC2020.0169; Martins KA, 2015, EXPERT REV VACCINES, V14, P447, DOI 10.1586/14760584.2015.966085; Middleton G, 2014, LANCET ONCOL, V15, P829, DOI 10.1016/S1470-2045(14)70236-0; Miles D, 2011, ONCOLOGIST, V16, P1092, DOI 10.1634/theoncologist.2010-0307; Mittendorf EA, 2014, ANN ONCOL, V25, P1735, DOI 10.1093/annonc/mdu211; Mittendorf EA, 2019, CLIN CANCER RES, V25, P4248, DOI 10.1158/1078-0432.CCR-18-2867; Mittrucker HW, 2014, ARCH IMMUNOL THER EX, V62, P449, DOI 10.1007/s00005-014-0293-y; Mizukoshi E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081823; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Mohsen MO, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1579; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; Morelli AB, 2012, J MED MICROBIOL, V61, P935, DOI 10.1099/jmm.0.040857-0; Morton DL, 2007, J CLIN ONCOL, V25; Morton DL, 2002, ANN SURG, V236, P438, DOI 10.1097/00000658-200210000-00006; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; Muniyan S, 2013, INT J MOL SCI, V14, P10438, DOI 10.3390/ijms140510438; Nagatomo D, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/471468; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Newman AM, 2014, BIOINFORMATICS, V30, P3390, DOI 10.1093/bioinformatics/btu549; Nicholaou T, 2006, IMMUNOL CELL BIOL, V84, P303, DOI 10.1111/j.1440-1711.2006.01446.x; NUNBERG JH, 1989, P NATL ACAD SCI USA, V86, P4240, DOI 10.1073/pnas.86.11.4240; Odumade OA, 2011, CLIN MICROBIOL REV, V24, P193, DOI 10.1128/CMR.00044-10; OLD LJ, 1959, NATURE, V184, P291, DOI 10.1038/184291a0; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pal A, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03116; Pallerla S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020779; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardoll DM, 1998, NAT MED, V4, P525, DOI 10.1038/nm0598supp-525; Parks RJ, 2018, P NATL ACAD SCI USA, V115, P9652, DOI 10.1073/pnas.1813461115; Perez CR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13368-y; Peshwa MV, 1998, PROSTATE, V36, P129, DOI 10.1002/(SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D; Petrulio CA, 2006, EXPERT REV VACCINES, V5, P9, DOI 10.1586/14760584.5.1.9; Pineda CT, 2015, CELL, V160, P715, DOI 10.1016/j.cell.2015.01.034; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; PREHN RT, 1957, J NATL CANCER I, V18, P769; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; Riedel Stefan, 2005, Proc (Bayl Univ Med Cent), V18, P21; Roake CM, 2020, NAT REV MOL CELL BIO, V21, P384, DOI 10.1038/s41580-020-0234-z; Robert C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17670-y; RONNBERG L, 1981, INT J ANDROL, V4, P372, DOI 10.1111/j.1365-2605.1981.tb00721.x; Rosales R, 2014, HUM GENE THER, V25, P1035, DOI 10.1089/hum.2014.024; Sabado RL, 2017, CELL RES, V27, P74, DOI 10.1038/cr.2016.157; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Saini SK, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau9039; Samy KP, 2018, TRANSPLANTATION, V102, P1593, DOI 10.1097/TP.0000000000002238; Saxena M, 2021, NAT REV CANCER, V21, P360, DOI 10.1038/s41568-021-00346-0; Scheetz L, 2019, NAT BIOMED ENG, V3, P768, DOI 10.1038/s41551-019-0436-x; Schenck RO, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2876-4; Schuetz T, 2005, J CLIN ONCOL, V23, p184S; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Schwartzentruber DJ, 2011, NEW ENGL J MED, V364, P2119, DOI 10.1056/NEJMoa1012863; Montoto SS, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.587997; Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Serrano B, 2018, BEST PRACT RES CL OB, V47, P14, DOI 10.1016/j.bpobgyn.2017.08.006; Sharei A, 2013, JOVE-J VIS EXP, DOI 10.3791/50980; Shi YF, 2006, CELL RES, V16, P126, DOI 10.1038/sj.cr.7310017; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slingluff CL, 2016, CANCER IMMUNOL IMMUN, V65, P25, DOI 10.1007/s00262-015-1770-9; Small E., 2009, P 2009 GEN CANC S 26; Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Sosman JA, 2002, J CLIN ONCOL, V20, P2067, DOI 10.1200/JCO.2002.08.072; Speetjens FM, 2009, CLIN CANCER RES, V15, P1086, DOI 10.1158/1078-0432.CCR-08-2227; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Stauber RH, 2007, CANCER RES, V67, P5999, DOI 10.1158/0008-5472.CAN-07-0494; Surget S, 2014, ONCOTARGETS THER, V7, P57, DOI 10.2147/OTT.S53876; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173; Tanji H, 2015, NAT STRUCT MOL BIOL, V22, P109, DOI 10.1038/nsmb.2943; Tashiro H, 2017, CELL RES, V27, P59, DOI 10.1038/cr.2016.153; Tatsumi T, 2002, J EXP MED, V196, P619, DOI 10.1084/jem.20012142; Taylor GS, 2014, CLIN CANCER RES, V20, P5009, DOI 10.1158/1078-0432.CCR-14-1122-T; Taylor-Papadimitriou J, 2018, BIOCHEM SOC T, V46, P659, DOI 10.1042/BST20170400; Thomas R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00947; Thompson MP, 2004, CLIN CANCER RES, V10, P803, DOI 10.1158/1078-0432.CCR-0670-3; Tovey MG, 2010, METHODS MOL BIOL, V626, P287, DOI 10.1007/978-1-60761-585-9_19; Trimble CL, 2015, LANCET, V386, P2078, DOI 10.1016/S0140-6736(15)00239-1; Valentijn LJ, 2015, NAT GENET, V47, P1411, DOI 10.1038/ng.3438; van der Burg SH, 2002, CLIN CANCER RES, V8, P1019; van Doorn E, 2016, HUM VACC IMMUNOTHER, V12, P159, DOI 10.1080/21645515.2015.1071455; Van Lint S, 2012, CANCER RES, V72, P1661, DOI 10.1158/0008-5472.CAN-11-2957; van Poelgeest MIE, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-88; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P3038, DOI 10.1002/eji.1830241218; Vansteenkiste JF, 2016, LANCET ONCOL, V17, P822, DOI 10.1016/S1470-2045(16)00099-1; Vermeij R, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/702146; Vermeij R, 2012, INT J CANCER, V131, pE670, DOI 10.1002/ijc.27388; Vermorken JB, 1999, LANCET, V353, P345, DOI 10.1016/S0140-6736(98)07186-4; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang YQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.577823; Watt B, 2013, PIGM CELL MELANOMA R, V26, P300, DOI 10.1111/pcmr.12067; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z; Welters MJP, 2008, CLIN CANCER RES, V14, P178, DOI 10.1158/1078-0432.CCR-07-1880; Weon JL, 2015, CURR OPIN CELL BIOL, V37, P1, DOI 10.1016/j.ceb.2015.08.002; Wheatley SP, 2019, J CELL SCI, V132, DOI 10.1242/jcs.223826; Wilson JB, 2018, CANCERS, V10, DOI 10.3390/cancers10040109; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wood LM, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00051; Xu SQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186582; Yan WL, 2017, IMMUNOTHERAPY-UK, V9, P347, DOI 10.2217/imt-2016-0141; Yang B, 2014, HUM VACC IMMUNOTHER, V10, P3153, DOI 10.4161/21645515.2014.980686; Yarchoan M, 2017, NAT REV CANCER, V17, P209, DOI 10.1038/nrc.2016.154; Yutani S, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/473909; Zarour HM, 2000, CANCER RES, V60, P4946; ZHOU J, 1993, J GEN VIROL, V74, P763, DOI 10.1099/0022-1317-74-4-763; Zhu Daming, 2016, Nat Prod Chem Res, V3; ZimberStrobl U, 1996, EMBO J, V15, P7070, DOI 10.1002/j.1460-2075.1996.tb01098.x	234	5	5	10	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							535	10.3390/vaccines9050535			44	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1FY	34065557	Green Published, gold			2022-04-29	WOS:000654573200001
J	Jager, L; Senn, O; Rosemann, T; Plate, A				Jaeger, Levy; Senn, Oliver; Rosemann, Thomas; Plate, Andreas			Awareness, Attitudes and Clinical Practices Regarding Human Papillomavirus Vaccination among General Practitioners and Pediatricians in Switzerland	VACCINES			English	Article						human papillomavirus; vaccine; primary care providers; survey	KNOWLEDGE; COVERAGE; WOMEN	In Switzerland, the human papillomavirus vaccination (HPVv) coverage rate lies below a desirable threshold. General practitioners (GPs) and pediatricians have been recognized as important providers of the HPVv, but there is little known about their self-attributed role and its relationship with their actual HPVv behavior. Therefore, the objective of this study was to explore the awareness, attitudes, and clinical practices of Swiss GPs and pediatricians concerning HPVv by means of a web-based questionnaire. We analyzed the responses of 422 physicians (72% GPs, 28% pediatricians). A substantial proportion of respondents considered the HPVv "absolutely essential" (54.2% of pediatricians, 30.6% of GPs). GPs indicated spending more time and effort on HPVv counseling for female rather than male patients more often compared to pediatricians (44.0% versus 13.9%, p < 0.001). The weekly number of patients aged 18-26 years seen in practice (p = 0.002) and whether the HPVv was deemed "absolutely essential" (adjusted odds ratio 2.39, 95% confidence interval 1.12-5.08) were factors associated with GPs administering HPVv in their practice. Shortcomings in terms of awareness, effort in the identification of potential vaccination candidates, and the role of male patients were revealed. By addressing these gaps, Swiss primary care providers could contribute to an increase in the national HPVv coverage rate.	[Jaeger, Levy; Senn, Oliver; Rosemann, Thomas; Plate, Andreas] Univ Hosp Zurich, Inst Primary Care, CH-8091 Zurich, Switzerland		Jager, L (通讯作者)，Univ Hosp Zurich, Inst Primary Care, CH-8091 Zurich, Switzerland.	levy.jaeger@usz.ch; oliver.senn@usz.ch; thomas.rosemann@usz.ch; andreas.plate@usz.ch		Jager, Levy/0000-0002-7749-6759; Senn, Oliver/0000-0003-4422-7250; Plate, Andreas/0000-0001-6143-5479; Rosemann, Thomas/0000-0002-6436-6306	Association of Swiss General Practitioners and Pediatricians (mfe)	We acknowledge all participating primary care providers for survey participation and support of health services research. We thank all volunteer colleagues for piloting the survey and, finally, we thank the Association of Swiss General Practitioners and Pediatricians (mfe) for their support concerning survey distribution and advertisement.	Allison MA, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2488; Association of Swiss General Practitioners and Pediatricians (mfe), 2020, JAHR 2019; Ball HL, 2019, J HUM LACT, V35, P413, DOI 10.1177/0890334419848734; Barnack JL, 2010, WOMEN HEALTH ISS, V20, P28, DOI 10.1016/j.whi.2009.08.007; Bihr S., 2009, SWISS FDN SEXUAL REP; Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764; Bryer J., 2016, LIKERT ANAL VISUALIZ; Cartier T., 2015, BUILDING PRIMARY CAR; Collange F, 2016, VACCINE, V34, P762, DOI 10.1016/j.vaccine.2015.12.054; Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3; Elam-Evans LD, 2020, MMWR-MORBID MORTAL W, V69, P1109, DOI 10.15585/mmwr.mm6933a1; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354; Gilkey MB, 2015, CANCER EPIDEM BIOMAR, V24, P1673, DOI 10.1158/1055-9965.EPI-15-0326; Hartwig S, 2017, INFECT AGENTS CANCER, V12, DOI 10.1186/s13027-017-0129-6; Hopfer S, 2019, HUM VACC IMMUNOTHER, V15, P1776, DOI 10.1080/21645515.2018.1560771; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Huh WK, 2017, LANCET, V390, P2143, DOI 10.1016/S0140-6736(17)31821-4; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; McRee AL, 2014, J PEDIATR HEALTH CAR, V28, P541, DOI 10.1016/j.pedhc.2014.05.003; McSherry LA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208482; Nguyen-Huu NH, 2020, VACCINE, V38, P1315, DOI 10.1016/j.vaccine.2019.11.081; Nilsen K, 2017, SCAND J PRIM HEALTH, V35, P387, DOI 10.1080/02813432.2017.1358433; R Core Team, 2018, R LANG ENV STAT COMP; Rosen BL, 2018, ACAD PEDIATR, V18, pS53, DOI 10.1016/j.acap.2017.10.007; Swiss Federal Office of Public Health, 2020, KANT DURCH SCHWEIZ D; Swiss Federal Office of Public Health, 2018, BAG B; Swiss Federal Office of Public Health, 2015, BAG B; Swiss Federal Office of Public Health, 2010, BAG B; Swiss Federal Office of Public Health and Federal Vaccination Commission, 2007, GUID REC NO 21 STAT; Swiss Federal Office of Public Health and Federal Vaccination Commission, 2020, SWISS VACC SCHED STA; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Ward BJ, 2006, J TRAVEL MED, V13, P300, DOI 10.1111/j.1708-8305.2006.00061.x; WHO, 2016, GLOB HLTH SECT STRAT; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wong MCS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071827; Zeller A, 2020, PRIM HOSP CARE, V20, P325, DOI [10.4414/phc-d.2020.10311, DOI 10.4414/PHCD.2020.10311.2297-7163, 10.4414/phcd.2020.10311.2297-7163]; Zimet GD, 2010, GYNECOL ONCOL, V117, pS26, DOI 10.1016/j.ygyno.2010.01.028	38	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							332	10.3390/vaccines9040332			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4PU	33915931	gold, Green Published, Green Accepted			2022-04-29	WOS:000643763800001
J	Joma, M; Fovet, CM; Seddiki, N; Gressens, P; Laforge, M				Joma, Mohamed; Fovet, Claire-Maelle; Seddiki, Nabila; Gressens, Pierre; Laforge, Mireille			COVID-19 and Pregnancy: Vertical Transmission and Inflammation Impact on Newborns	VACCINES			English	Review						COVID-19; fetus; newborn; transmission; immunity; inflammation; preterm delivery; central nervous system; neurodevelopmental disorders	SARS-COV-2; INFECTION; MOTHERS; BORN	The COVID-19 pandemic is ongoing and we are still compiling new findings to decipher and understand SARS-CoV-2 infection during pregnancy. No reports encompass any conclusive confirmation of vertical transmission. Nevertheless, cases of fetal distress and multiple organ failure have been reported, as well as rare cases of fetal demise. While clinicians and scientists continue to seek proof of vertical transmission, they miss the greater point, namely the cause of preterm delivery. In this review, we suggest that the cause might not be due to the viral infection but the fetal exposure to maternal inflammation or cytokine storm that translates into a complication of COVID-19. This statement is extrapolated from previous experience with infections and inflammation which were reported to be fatal by increasing the risk of preterm delivery and causing abnormal neonatal brain development and resulting in neurological disorders like atypical behavioral phenotype or autistic syndrome. Given the potentially fatal consequences on neonate health, we highlight the urgent need for an animal model to study vertical transmission. The preclinical model will allow us to make the link between SARS-COV-2 infection, inflammation and long-term follow-up of child brain development.	[Joma, Mohamed; Gressens, Pierre; Laforge, Mireille] Univ Paris, INSERM, NeuroDiderot, F-75019 Paris, France; [Fovet, Claire-Maelle; Seddiki, Nabila] Univ Paris Saclay, IDMIT Dept Immunol Viral Autoimmune Hematol & Bac, CEA, INSERM U1184, F-92265 Fontenay Aux Roses, France		Laforge, M (通讯作者)，Univ Paris, INSERM, NeuroDiderot, F-75019 Paris, France.	mohamed.joma@st.ul.edu.lb; daire-maelle.fovet@cea.fr; nabila.seddiki@cea.fr; pierre.gressens@inserm.fr; mireille.laforge@inserm.fr	; mireille, laforge/H-5472-2018	Fovet, Claire-Maelle/0000-0001-8976-5584; mireille, laforge/0000-0002-1892-5250; /0000-0002-0909-4221	Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS)ANRSFrench National Research Agency (ANR); Institut National de la Sante et de la Recherche Medicale (INSERM)Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Paris (UP)	M.L. receives financial support from the Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) and from The Institut National de la Sante et de la Recherche Medicale (INSERM) and Universite de Paris (UP), PG receives financial support from the Institut National de la Sante et de la Recherche Medicale (INSERM) and the Universite de Paris (UP).	Abdallah MW, 2012, J NEUROIMMUNOL, V252, P75, DOI 10.1016/j.jneuroim.2012.07.013; Angelone DF, 2006, PEDIATR RES, V60, P205, DOI 10.1203/01.pdr.0000228319.10481.ea; [Anonymous], 2007, Paediatr Child Health, V12, P798; ARIAS RA, 2003, J CLIN ENDOCR METAB, V307, P266, DOI DOI 10.1016/S0042-6822(02)00040-5; ARMSTRONGWELLS J, 2015, PEDIATR RES, V212, DOI DOI 10.1016/J.AJOG.2014.09.016; Bahadur G, 2021, FACTS VIEWS VIS OBGY, V13, P53, DOI 10.52054/FVVO.13.1.001; Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; BAUD D, 2020, MMWR-MORBID MORTAL W, DOI DOI 10.1001/JAMA.2020.7233; BAUMAN MD, 2014, AM J OBSTET GYNECOL, V75, P332, DOI DOI 10.1016/J.BIOPSYCH.2013.06.025; BLOT M, 2020, VIRUS RES, V18, P1, DOI DOI 10.1186/S12967-020-02646-9; Carbonne B, 1998, AM J OBSTET GYNECOL, V178, P150, DOI 10.1016/S0002-9378(98)70643-X; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; CHEN H, 2020, BMJ-BRIT MED J, V395, P809, DOI DOI 10.1016/S0140-6736(20)30360-3; CHEN Y, 2020, CLIN INFECT DIS, V8, P104, DOI DOI 10.3389/FPED.2020.00104; Alzamora MC, 2020, AM J PERINAT, V37, P861, DOI 10.1055/s-0040-1710050; Coomes EA, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2141; Cosma S, 2021, AM J OBSTET GYNECOL, V224, DOI [10.1016/j.ajog.2020.10.OO5, 10.1016/j.ajog.2020.10.005]; DANDO SJ, 2014, NAT COMMUN, V27, P691, DOI DOI 10.1128/CMR.00118-13; DELPECH JC, 2015, J CLIN INVEST, V96, P19, DOI DOI 10.1016/J.NEUROPHARM.2014.12.034; Denis M., 2020, TRANSDISCIPL INSIGHT, DOI [10.11116/TDI2020.4.10.SI.Covipendium, DOI 10.11116/TDI2020.4.10.SI.COVIPENDIUM]; Dong L, 2020, JAMA-J AM MED ASSOC, V323, P1846, DOI 10.1001/jama.2020.4621; ELIEZER M, 2020, EUR ARCH OTO-RHINO-L, DOI DOI 10.1001/JAMAOTO.2020.0832; ESTES ML, 2016, BIOCHEM SOC T, V353, P772, DOI DOI 10.1126/SCIENCE.AAG3194; Feng Z., 2020, NOVEL SEVERE ACUTE R, V2, P1, DOI [10.1101/2020.03.27.20045427, DOI 10.1101/2020.03.27.20045427]; FOULON I, 2008, PEDIATR RES, V122, DOI DOI 10.1542/PEDS.2008-0770; Freiesleben NL, 2021, HUM REPROD, V36, P40, DOI 10.1093/humrep/deaa311; FUCHS R, 2004, NEUROPHARMACOLOGY, V5, P725, DOI DOI 10.1111/J.1600-0854.2004.00221.X; GIAVRIDIS T, 2018, MICROBIOL MOL BIOL R, V24, P731, DOI DOI 10.1038/S41591-018-0041-7; GINSBERG Y, 2017, TRAFFIC, V8, DOI DOI 10.5041/RMMJ.10305; Gu HJ, 2020, SCIENCE, V369, P1603, DOI 10.1126/science.abc4730; GUO T, 2020, INT J INFECT DIS, DOI DOI 10.1001/JAMACARDIO.2020.1017; GURUNG S, 2019, J INFECT DIS, V15, DOI DOI 10.1371/JOURNAL.PPAT.1007507; HAGBERG H, 2015, AM J OBSTET GYNECOL, V11, P192, DOI DOI 10.1038/NRNEUROL.2015.13; HAGBERG H, 2012, NEUROIMAGE, V71, P444, DOI DOI 10.1002/ANA.22620; Hanson LA, 1998, ANN ALLERG ASTHMA IM, V81, P523, DOI 10.1016/S1081-1206(10)62704-4; Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011; HEGEWALD MJ, 2011, TRANSL PEDIATR, V32, P1, DOI DOI 10.1016/J.CCM.2010.11.001; HIRANO T, 2020, LANCET RESP MED, V52, P731, DOI DOI 10.1016/J.IMMUNI.2020.04.003; HOANG TN, 2021, NATURE, V184, P460, DOI DOI 10.1016/J.CELL.2020.11.007; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hughes, 2020, WALTHAM MA UPTODATE, V12, P5128; IMAI M, 2020, VIRUSES-BASEL, V117, P16587, DOI DOI 10.1073/PNAS.2009799117; Johnston SC, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246366; Jones CA, 2002, J REPROD IMMUNOL, V56, P45, DOI 10.1016/S0165-0378(02)00022-0; Karami Parisa, 2020, Travel Med Infect Dis, P101665, DOI 10.1016/j.tmaid.2020.101665; Kim C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20602-5; KIM JA, 2020, CELL, V27, P704, DOI DOI 10.1016/J.CHOM.2020.03.023; Kirtsman M, 2020, CAN MED ASSOC J, V192, pE647, DOI 10.1503/cmaj.200821; KNIGHT M, 2020, AM J OBSTET GYNECOL, V369, P2107, DOI DOI 10.1136/BMJ.M2107; La Cour Freiesleben N., 2020, SARS COV 2 1 TRIMEST, DOI [10.1101/2020.06.08.20125195, DOI 10.1101/2020.06.08.20125195]; Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1; [雷帝 Lei Di], 2020, [中华围产医学杂志, Chinese Journal of Perinatal Medicine], V23, P159; Lempriere S, 2021, NAT REV NEUROL, V17, P63, DOI 10.1038/s41582-020-00449-6; LEVITT P, 2003, NEUROBIOL LEARN MEM, V143, pS35, DOI DOI 10.1067/S0022-3476(03)00400-1; Li N, 2020, CLIN INFECT DIS, V71, P2035, DOI 10.1093/cid/ciaa352; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; LI W, 2004, CELL, V89, P2897, DOI DOI 10.1210/JC.2003-032048; Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728; Liu HH, 2020, J INFECTION, V80, pE7, DOI 10.1016/j.jinf.2020.03.007; Liu W., 2020, PREPRINTS 2020020373; Liu WL, 2021, CRIT REV FOOD SCI, V61, P2742, DOI 10.1080/10408398.2020.1784841; LOCHT C, 2017, SCI ADV, V216, P117, DOI DOI 10.1093/INFDIS/JIX254; Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073; Machado C, 2020, NEUROL INDIA, V68, P989, DOI 10.4103/0028-3886.299165; MAHMUDPOUR M, 2020, IMMUNITY, V133, P55151, DOI DOI 10.1016/J.CYTO.2020.155151; MAISONNASSE P, 2020, SCIENCE, V585, P584, DOI DOI 10.1038/S41586-020-2558-4; Makvandi Somayeh, 2020, Gastroenterol Hepatol Bed Bench, V13, P305; Malek A, 1996, AM J REPROD IMMUNOL, V36, P248; MCGONAGLE D, 2020, NATL SCI REV, V19, P2537, DOI DOI 10.1016/J.AUTREV.2020.102537; MELVAN JN, 2010, ANN ALLERG ASTHMA IM, V29, P315, DOI DOI 10.3109/08830181003792803; Montagutelli X., 2021, B1 351 P1 VARIANTS E, p2021.03.18.436013, DOI [10.1101/2021.03.18.436013, DOI 10.1101/2021.03.18.436013]; Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062; Mullins E, 2021, ULTRASOUND OBST GYN, V57, P573, DOI 10.1002/uog.23619; Munster VJ, 2020, NATURE, V585, P268, DOI 10.1038/s41586-020-2324-7; NARA K, 2011, PLOS ONE, V31, P9179, DOI DOI 10.1523/JNEUROSCI.1282-11.2011; NGUYEN AW, 2020, AM J OBSTET GYNECOL, V6, DOI DOI 10.1126/SCIADV.AAY9258; O'Loughlin E, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0981-8; OLIN A, 2018, VACCINE, V174, P1277, DOI DOI 10.1016/J.CELL.2018.06.045; Osterrieder N, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070779; Palma G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02094; Pellegrini L, 2020, CELL STEM CELL, V27, P951, DOI 10.1016/j.stem.2020.10.001; Pierce-Williams RAM, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100134; RASMUSSEN JM, 2019, SCIENCE, V185, P825, DOI DOI 10.1016/J.NEUROIMAGE.2018.04.020; RASMUSSEN SA, 2012, NAT REV IMMUNOL, V207, pS3, DOI DOI 10.1016/J.AJOG.2012.06.068; Redline Raymond W, 2004, Semin Neonatol, V9, P265, DOI 10.1016/j.siny.2003.09.005; Richard M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17367-2; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI 10.1001/jama.2020.7681; Rockx Barry, 2020, Science, V368, P1012, DOI 10.1126/science.abb7314; RYAN AM, 2019, BIOL PSYCHIAT, V165, P6950, DOI DOI 10.1016/J.NLM.2018.10.006; Ryan KA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20439-y; SADOWSKY DW, 2006, PLOS ONE, V195, P1578, DOI DOI 10.1016/J.AJOG.2006.06.072; Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791; SANCHEZFELIPE L, 2021, SCIENCE, V590, P320, DOI DOI 10.1038/S41586-020-3035-9; SASIDHAR MV, 2017, CELL STEM CELL, V12, DOI DOI 10.1371/JOURNAL.PONE.0189701; SAVMAN K, 1998, J NEUROIMMUNOL, V43, P746, DOI DOI 10.1203/00006450-199806000-00006; Selvaraj P, 2021, LIFE SCI ALLIANCE, V4, DOI 10.26508/lsa.202000886; SHAH PS, 2020, JAMA-J AM MED ASSOC, V99, P565, DOI DOI 10.1111/AOGS.13870; Shende P, 2021, HUM REPROD, V36, P899, DOI 10.1093/humrep/deaa367; SHI L, 2005, BIRTH DEFECTS RES B, V23, P299, DOI DOI 10.1016/J.IJDEVNEU.2004.05.005; Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3; SHORT SJ, 2010, J NEUROSCI, V67, P965, DOI DOI 10.1016/J.BIOPSYCH.2009.11.026; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; SIMISTER NE, 2003, JAMA-J AM MED ASSOC, V21, P3365, DOI DOI 10.1016/S0264-410X(03)00334-7; Singh DK, 2021, NAT MICROBIOL, V6, P73, DOI 10.1038/s41564-020-00841-4; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; Soma-Pillay P, 2016, CARDIOVASC J AFR, V27, P89, DOI 10.5830/CVJA-2016-021; SONG E, 2021, CLIN MICROBIOL REV, V218, DOI DOI 10.1084/JEM.20202135; Steinbach RJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227676; Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020; Tahaghoghi-Hajghorbani S, 2020, VIRUS RES, V290, DOI 10.1016/j.virusres.2020.198197; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11; VANSTEENWINCKEL J, 2014, RAMBAM MAIMONIDES ME, V42, P557, DOI DOI 10.1042/BST20130284; VIVANTI A, 2020, VIROLOGY, V11, P3572, DOI DOI 10.1038/S41467-020-17436-6; WALDORF KMA, 2011, NATURE, V118, P136, DOI DOI 10.1111/J.1471-0528.2010.02728.X; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; [王科雯 Wang Kewen], 2020, [测绘通报, Bulletin of Surveying and Mapping], P1; WANG Y, 2020, LANCET, V92, P568, DOI DOI 10.1002/JMV.25748; WATSON RE, 2006, J PEDIATR-US, V77, P471, DOI DOI 10.1002/BDRB.20090; Willoughby, 2018, RABIES VIRUS PRINCIP; Wood SL, 2003, BIRTH DEFECTS RES B, V68, P391, DOI 10.1002/bdrb.10037; Wu WL, 2017, BRAIN BEHAV IMMUN, V62, P11, DOI 10.1016/j.bbi.2016.11.007; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yee J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75096-4; Yin M, 2020, SEVERE ACUTE RESP SY, DOI [10.1101/2020.04.07.20053744., DOI 10.1101/2020.04.07.20053744, 10.1101/2020.04.07.20053744]; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Yu P, 2020, ANIM MODEL EXP MED, V3, P93, DOI 10.1002/ame2.12108; ZAIGHAM M, 2020, J INFECTION, DOI DOI 10.1111/AOGS.13867; ZENG H, 2020, CAN MED ASSOC J, DOI DOI 10.1001/JAMA.2020.4861; Zhang, 2020, ZHONGHUA ER KE ZA ZH, V58, DOI DOI 10.3760/CMA.J.ISSN.0578-1310.2020.03.003; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; ZHOU Y, 2020, LANCET, DOI DOI 10.1093/NSR/NWAA041; Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zhu Y., 2020, SINGLE CELL ANAL ACE, DOI [10.20944/preprints202002.0221.v1, DOI 10.20944/PREPRINTS202002.0221.V1]	141	5	5	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							391	10.3390/vaccines9040391			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5IC	33921113	Green Published, gold			2022-04-29	WOS:000643811700001
J	Royston, L; Royston, E; Masouridi-Levrat, S; Vernaz, N; Chalandon, Y; Van Delden, C; Neofytos, D				Royston, Lena; Royston, Eva; Masouridi-Levrat, Stavroula; Vernaz, Nathalie; Chalandon, Yves; Van Delden, Christian; Neofytos, Dionysios			Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study	VACCINES			English	Article						letermovir; cytomegalovirus (CMV); prophylaxis; allogeneic hematopoietic cell transplant recipients; recurrent CMV infection	CYTOMEGALOVIRUS REACTIVATION; CURRENT ERA; DISEASE; DEFINITIONS; INFECTION	Background: Real-life data on the administration of letermovir as cytomegalovirus (CMV) primary prophylaxis after allogeneic hematopoietic cell transplantation (HCT) remain limited. Methods: We conducted a retrospective single-center matched cohort study, comparing consecutive high-risk allogeneic HCT recipients (cases) receiving primary prophylaxis with letermovir and untreated matched historical controls, during a study period of 180 days. The primary outcome was the incidence of clinically significant (cs) CMV infection. Secondary outcomes included duration and costs of CMV-antiviral treatments, hospital resource utilization, hematology and laboratory parameters. Results: Letermovir prophylaxis decreased csCMV infection incidence from 82.7% (controls) to 34.5% (cases; p-value < 0.0001). Controls were more likely to have >1 episode of csCMV infection (59.6%) compared to cases (11.5%; p-value < 0.0001). Letermovir was associated with: shorter overall CMV-associated treatment duration (49 days vs. 77.8 days; p-value: 0.02) and a trend for lower costs of CMV-associated treatments ($4096 vs. $9736; p-value: 0.07) and reduced length of stay (44.8 days vs. 59.8 days; p-value: 0.16). Letermovir administration was associated with significantly shorter duration (27.3 days vs. 57.1 days; p-value: 0.008) and lower costs ($1089 vs. $2281; p-value: 0.008) of valganciclovir treatment. Compared to controls, higher platelet counts were observed in cases (138 G/L vs. 92 G/L; p-value: 0.03) and renal function was improved (94 mL/min/1.73 m(2) vs. 74 mL/min/1.73 m(2); p-value: 0.006). Conclusions: Primary anti-CMV letermovir prophylaxis decreased the incidence of csCMV infection and the administration of CMV-associated treatments and costs, particularly those associated with valganciclovir. An effect of letermovir on platelet reconstitution and renal function of csCMV post-HCT was observed and needs further investigation.	[Royston, Lena; Van Delden, Christian; Neofytos, Dionysios] Univ Hosp Geneva, Div Infect Dis, CH-1205 Geneva, Switzerland; [Royston, Eva; Masouridi-Levrat, Stavroula; Chalandon, Yves] Univ Hosp Geneva, Div Hematol, Bone Marrow Transplant Unit, CH-1205 Geneva, Switzerland; [Vernaz, Nathalie] Univ Hosp Geneva, Med Directorate, CH-1205 Geneva, Switzerland		Neofytos, D (通讯作者)，Univ Hosp Geneva, Div Infect Dis, CH-1205 Geneva, Switzerland.	lena.royston@hcuge.ch; royston.eva@gmail.com; stavroula.masouridi@hcuge.ch; nathalie.vernaz@hcuge.ch; yves.chalandon@hcuge.ch; christian.vandelden@hcuge.ch; dionysios.neofytos@hcuge.ch		Royston, Lena/0000-0003-2367-7682; Vernaz, Nathalie/0000-0002-1371-5510; Neofytos, Dionysios/0000-0001-6970-2869; Chalandon, Yves/0000-0001-9341-8104			Anderson A, 2020, CLIN TRANSPLANT, V34, DOI 10.1111/ctr.13866; Boeckh M, 2003, BIOL BLOOD MARROW TR, V9, P543, DOI 10.1016/S1083-8791(03)00287-8; Chen GL, 2020, BIOL BLOOD MARROW TR, V26, P2147, DOI 10.1016/j.bbmt.2020.07.024; El Haddad L, 2020, J MED VIROL, V92, P86, DOI 10.1002/jmv.25574; Fang JQ, 2020, BIOL BLOOD MARROW TR, V26, P1937, DOI 10.1016/j.bbmt.2020.06.025; Green ML, 2016, LANCET HAEMATOL, V3, pE119, DOI 10.1016/S2352-3026(15)00289-6; Lin A, 2019, TRANSPL INFECT DIS, DOI 10.1111/tid.13187; Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329; Ljungman P, 2017, CLIN INFECT DIS, V64, P87, DOI 10.1093/cid/ciw668; Ljungman P, 2014, CURR OPIN HEMATOL, V21, P466, DOI 10.1097/MOH.0000000000000085; Marty FM, 2017, NEW ENGL J MED, V377, P2433, DOI 10.1056/NEJMoa1706640; Marty FM, 2020, AM J TRANSPLANT, V20, P1703, DOI 10.1111/ajt.15764; Masouridi-Levrat S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00362; Nakamae H, 2011, HAEMATOL-HEMATOL J, V96, P1838, DOI 10.3324/haematol.2011.044966; Navarro D, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw107; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Royston L., 2021, IMMUN INFLAMM DIS; Sperotto A., 2021, TRANSPLANT CELL THER; Studer U, 2020, ANTICANCER RES, V40, P5909, DOI 10.21873/anticanres.14611; Teira P, 2016, BLOOD, V127, P2427, DOI 10.1182/blood-2015-11-679639; Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019; Yong MK, 2017, BIOL BLOOD MARROW TR, V23, P1961, DOI 10.1016/j.bbmt.2017.07.025; Zamora D., 2021, BLOOD	23	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							372	10.3390/vaccines9040372			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4QG	33921218	gold, Green Published			2022-04-29	WOS:000643765000001
J	Sundstrom, B; Cartmell, KB; White, AA; Well, H; Pierce, JY; Brandt, HM				Sundstrom, Beth; Cartmell, Kathleen B.; White, Ashley A.; Well, Henry; Pierce, Jennifer Young; Brandt, Heather M.			Correcting HPV Vaccination Misinformation Online: Evaluating the HPV Vaccination NOW Social Media Campaign	VACCINES			English	Article						HPV vaccination; campaign; misinformation; parents; social media		The human papillomavirus (HPV) vaccine provides protection from six HPV-related cancers. Approximately half of South Carolina adolescents have not completed the vaccination series, representing a missed opportunity to prevent cancer. The HPV Vaccination NOW: This is Our Moment social media campaign is an initiative of the South Carolina Cancer Alliance (SCCA) and Hollings Cancer Center at the Medical University of South Carolina (MUSC). This statewide social media campaign aimed to increase parental awareness of and build vaccine confidence around HPV vaccination in S.C. The ten-week campaign was strategically implemented between June and August 2019 to encourage HPV vaccination at back-to-school medical appointments. A process evaluation showed that the campaign resulted in over 370,000 total impressions, reached over 33,000 individuals, and culminated with over 1122 followers. There were over 2700 engagements on Facebook and Twitter. A qualitative content analysis indicated that pro-vaccine and anti-vaccine comments were dominated by personal stories. Comments promoting misinformation about the HPV vaccine were often countered through peer-to-peer dialogue. Findings suggest that creating opportunities for the target audience to engage with campaign messages effectively corrected misinformation.	[Sundstrom, Beth] Coll Charleston, Dept Commun, Charleston, SC 29424 USA; [Cartmell, Kathleen B.] Clemson Univ, Dept Publ Hlth Sci, Clemson, SC 29634 USA; [White, Ashley A.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA; [Well, Henry] South Carolina Canc Alliance, Columbia, SC 29204 USA; [Pierce, Jennifer Young] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36604 USA; [Brandt, Heather M.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA; [Brandt, Heather M.] Comprehens Canc Ctr, Memphis, TN 38105 USA		Sundstrom, B (通讯作者)，Coll Charleston, Dept Commun, Charleston, SC 29424 USA.	BLS@cofc.edu; kcartme@clemson.edu; whitashl@musc.edu; henry.well@sccancer.org; jypierce@health.southalabama.edu; Heather.Brandt@STJUDE.ORG		White, Ashley/0000-0003-1256-0809; Sundstrom, Beth/0000-0002-6306-2941; Brandt, Heather M./0000-0003-1066-2879	Medical University of South Carolina Hollings Cancer Center; South Carolina Cancer Alliance	This project was funded through institutional support from the Medical University of South Carolina Hollings Cancer Center and the South Carolina Cancer Alliance (SCCA) and through the HCC's NCI-funded P30 CA138313 cancer center support grant.	Beavis A, 2018, J ADOLESCENT HEALTH, V63, P652, DOI 10.1016/j.jadohealth.2018.06.024; Bogani G, 2021, GYNECOL ONCOL, V160, P346, DOI 10.1016/j.ygyno.2020.08.034; Bogani G, 2019, INT J GYNECOL OBSTET, V147, P233, DOI 10.1002/ijgo.12934; Bogani G, 2018, INT J GYNECOL OBSTET, V142, P338, DOI 10.1002/ijgo.12546; Bonnevie E, 2020, AM J PUBLIC HEALTH, V110, pS326, DOI 10.2105/AJPH.2020.305901; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Cartmell KB, 2019, J CANCER EDUC, V34, P1014, DOI 10.1007/s13187-018-1405-x; Corbin J.S., 2008, BASICS QUALITATIVE R, DOI DOI 10.4135/9781452230153; Elam-Evans LD, 2020, MMWR-MORBID MORTAL W, V69, P1109, DOI 10.15585/mmwr.mm6933a1; Fox S., 2013, HLTH TECHNOLOGY US P; Fu LY, 2014, VACCINE, V32, P1901, DOI 10.1016/j.vaccine.2014.01.091; Gilkey MB, 2020, J ADOLESCENT HEALTH, V67, P633, DOI 10.1016/j.jadohealth.2020.08.013; Hall MT, 2019, LANCET PUBLIC HEALTH, V4, pE19, DOI 10.1016/S2468-2667(18)30183-X; Hull P., 2021, PRACTICAL STRATEGIES; Jamison A, 2020, AM J PUBLIC HEALTH, V110, pS331, DOI 10.2105/AJPH.2020.305940; Jang SM, 2019, HEALTH COMMUN, V34, P110, DOI 10.1080/10410236.2017.1384433; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Loft LH, 2020, VACCINE, V38, P4901, DOI 10.1016/j.vaccine.2020.04.032; Luisi MLR, 2021, VACCINE, V39, P303, DOI 10.1016/j.vaccine.2020.11.065; Luvero D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040597; Maher CA, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.2952; Margolis MA, 2019, PREV MED, V118, P251, DOI 10.1016/j.ypmed.2018.11.005; Massey PM, 2020, J MED INTERNET RES, V22, DOI 10.2196/21451; McClung NM, 2019, CANCER EPIDEM BIOMAR, V28, P602, DOI 10.1158/1055-9965.EPI-18-0885; Mehrotra A., 2020, IMPACT COVID 19 PAND, DOI [10.26099/ds9e-jm36, DOI 10.26099/DS9E-JM36]; Neiger BL, 2012, HEALTH PROMOT PRACT, V13, P159, DOI 10.1177/1524839911433467; Ortiz RR, 2019, HUM VACC IMMUNOTHER, V15, P1465, DOI 10.1080/21645515.2019.1581543; Pagoto S, 2019, J MED INTERNET RES, V21, DOI 10.2196/16661; Pedersen EA, 2020, VACCINE, V38, P4909, DOI 10.1016/j.vaccine.2020.05.061; Perrin A., 2019, SHARE US ADULTS USIN; Reiter PL, 2018, ACAD PEDIATR, V18, pS14, DOI 10.1016/j.acap.2017.04.023; Simms KT, 2019, LANCET ONCOL, V20, P394, DOI 10.1016/S1470-2045(18)30836-2; Sonawane K, 2020, LANCET PUBLIC HEALTH, V5, pE484, DOI 10.1016/S2468-2667(20)30139-0; Sundstrom B., 2018, Journal of Communication in Healthcare, V11, P205, DOI 10.1080/17538068.2018.1484984; Sundstrom B, 2019, SOC SCI MED, V232, P289, DOI 10.1016/j.socscimed.2019.05.010; Van Dyne EA, 2018, MMWR-MORBID MORTAL W, V67, P918, DOI 10.15585/mmwr.mm6733a2; World Health Organization, 2020, LAUNCH GLOBAL STRATE; Zhao YH, 2017, HEALTH INFO LIBR J, V34, P268, DOI 10.1111/hir.12192	38	5	5	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							352	10.3390/vaccines9040352			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS4TH	33917512	gold, Green Published			2022-04-29	WOS:000643773000001
J	Rohl, M; Tjernlund, A; Lajoie, J; Edfeldt, G; Bradley, F; Bergstrom, S; Kaldhusdal, V; Ahlberg, A; Manberg, A; Omollo, K; Boily-Larouche, G; Asghar, M; Kwon, DS; Oyugi, J; Kimani, J; Nilsson, P; Fowke, KR; Broliden, K				Rohl, Maria; Tjernlund, Annelie; Lajoie, Julie; Edfeldt, Gabriella; Bradley, Frideborg; Bergstrom, Sofia; Kaldhusdal, Vilde; Ahlberg, Alexandra; Manberg, Anna; Omollo, Kenneth; Boily-Larouche, Genevieve; Asghar, Muhammad; Kwon, Douglas S.; Oyugi, Julius; Kimani, Joshua; Nilsson, Peter; Fowke, Keith R.; Broliden, Kristina			HIV-Exposed Seronegative Sex Workers Express Low T-Cell Activation and an Intact Ectocervical Tissue Microenvironment	VACCINES			English	Article						HIV; mucosa; female genital tract; RNA sequencing; microbiome; image analysis; protein profiling; HIV-exposed seronegative; HESN		Immunological correlates of natural resistance to HIV have been identified in HIV-exposed seronegative (HESN) individuals and include a low-inflammatory genital mucosal status. The cervicovaginal epithelium has not been studied for such correlates despite constituting an important barrier against sexual HIV transmission. To fill this gap in knowledge, we collected samples of blood, cervical mononuclear cells, cervicovaginal lavage, and ectocervical tissue from Kenyan HESN sex workers (n = 29) and controls (n = 33). The samples were analyzed by flow cytometry, protein profiling, 16S rRNA gene sequencing, in situ image analysis, and tissue-based RNA sequencing. A significantly higher relative proportion of regulatory T cells in blood (B7(+)CD25(hi)FoxP3(+)CD127(lo)CD4(+) and B7(+)Helios(+)FoxP3(+)CD4(+)), and a significantly lower proportion of activated cervical T cells (CCR5(+)CD69(+)CD4(+) and CCR5(+)CD69(+)CD8(+)), were found in the HESN group compared with the controls. In contrast, there were no statistically significant differences between the study groups in cervicovaginal protein and microbiome compositions, ectocervical epithelial thickness, E-cadherin expression, HIV receptor expression, and tissue RNA transcriptional profiles. The identification of an intact ectocervical microenvironment in HESN individuals add new data to current knowledge about natural resistance to sexual transmission of HIV.	[Rohl, Maria; Tjernlund, Annelie; Edfeldt, Gabriella; Bradley, Frideborg; Kaldhusdal, Vilde; Ahlberg, Alexandra; Asghar, Muhammad; Broliden, Kristina] Karolinska Inst, Ctr Mol Med, Karolinska Univ Hosp, Dept Infect Dis,Dept Med Solna,Div Infect Dis, S-17164 Stockholm, Sweden; [Lajoie, Julie; Omollo, Kenneth; Oyugi, Julius; Kimani, Joshua; Fowke, Keith R.] Univ Nairobi, Dept Med Microbiol, Nairobi 00100, Kenya; [Lajoie, Julie; Boily-Larouche, Genevieve; Kimani, Joshua; Fowke, Keith R.] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB R3A 1R9, Canada; [Bergstrom, Sofia; Manberg, Anna; Nilsson, Peter] KTH Royal Inst Technol, Div Affin Prote, Dept Prot Sci, SciLifeLab, S-17164 Stockholm, Sweden; [Kwon, Douglas S.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA; [Kimani, Joshua; Fowke, Keith R.] Partners Hlth & Dev Africa, Nairobi 00100, Kenya; [Fowke, Keith R.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3A 1R9, Canada		Broliden, K (通讯作者)，Karolinska Inst, Ctr Mol Med, Karolinska Univ Hosp, Dept Infect Dis,Dept Med Solna,Div Infect Dis, S-17164 Stockholm, Sweden.	maria.rohl@ki.se; annelie.tjernlund@ki.se; julie.lajoie1@gmail.com; gabriella.edfeldt@ki.se; frideborg.bradley@ki.se; sofia.bergstrom@scilifelab.se; vilde.kaldhusdal@ki.se; alexandra.ahlberg@ki.se; anna.manberg@scilifelab.se; oduorkenneth@gmail.com; genevieve.boily.larouche@gmail.com; asghar.muhammad@ki.se; dkwon@mgh.harvard.edu; julias.oyugi9@gmail; jkimani@csrtkenya.org; peter.nilsson@scilifelab.se; keith.fowke@umanitoba.ca; kristina.broliden@ki.se	Asghar, Muhammad/C-6730-2013	Asghar, Muhammad/0000-0002-9017-2206; Edfeldt, Gabriella/0000-0003-0366-5588	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [86721]; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Physician Against AIDS Foundation; Olle Engkvist Byggmastare [188-0156]; KTH Center for AppliedPrecision Medicine (KCAP)	This research was funded by grants from the Canadian Institutes of Health Research (CIHR) (MOP #86721) (K.R.F.), the Swedish Research Council (K.B.), the Swedish Physician Against AIDS Foundation (M.R.), Olle Engkvist Byggmastare (#188-0156) (A.T.), and the KTH Center for AppliedPrecision Medicine (KCAP) (P.N.).	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anahtar MN, 2016, JOVE-J VIS EXP, DOI 10.3791/53939; Anahtar MN, 2015, IMMUNITY, V42, P965, DOI 10.1016/j.immuni.2015.04.019; Serna-Ortega PA, 2020, MICROBES INFECT, V22, P371, DOI 10.1016/j.micinf.2019.11.002; Arnold KB, 2016, MUCOSAL IMMUNOL, V9, P194, DOI 10.1038/mi.2015.51; Birse K, 2015, J VIROL, V89, P8793, DOI 10.1128/JVI.00756-15; Birse KD, 2017, J INFECT DIS, V215, P590, DOI 10.1093/infdis/jiw590; Borgdorff H, 2016, MUCOSAL IMMUNOL, V9, P621, DOI 10.1038/mi.2015.86; Bradley F, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.12863; Burgener A, 2011, J PROTEOME RES, V10, P5139, DOI 10.1021/pr200596r; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Card CM, 2009, J INFECT DIS, V199, P1318, DOI 10.1086/597801; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Cole JR, 2005, NUCLEIC ACIDS RES, V33, pD294, DOI 10.1093/nar/gki038; de Jong MAWP, 2008, J CLIN INVEST, V118, P3440, DOI 10.1172/JCI34721; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dupont HA, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13019; Edfeldt G, 2022, J INFECT DIS, V225, P1151, DOI 10.1093/infdis/jiaa514; Fenizia C, 2020, EXPERT REV CLIN IMMU, V16, P429, DOI 10.1080/1744666X.2020.1732820; Florez-Alvarez L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.537044; Fourcade L, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007840; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; Girard A, 2019, AIDS, V33, P411, DOI 10.1097/QAD.0000000000002099; Gu J, 2017, CELL MOL IMMUNOL, V14, P521, DOI 10.1038/cmi.2016.30; Hasselrot K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047570; Houshdaran S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072625; Jiang J., 2020, Front. Immunol, V11, P1050, DOI 10.3389/fimmu.2020.01050; Juno JA, 2014, JOVE-J VIS EXP, DOI 10.3791/51906; Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095; Kaul R, 2015, CURR HIV-AIDS REP, V12, P216, DOI 10.1007/s11904-015-0269-5; Khamassi M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009103; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Lajoie J, 2012, MUCOSAL IMMUNOL, V5, P277, DOI 10.1038/mi.2012.7; Lajoie J, 2016, AM J REPROD IMMUNOL, V76, P82, DOI 10.1111/aji.12520; Manberg A, 2019, MOL CELL PROTEOMICS, V18, P461, DOI 10.1074/mcp.RA118.000757; Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298; Mbuya W, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240154; McKinnon LR, 2015, AIDS BEHAV, V19, P2204, DOI 10.1007/s10461-015-1118-7; McLaren PJ, 2010, J INFECT DIS, V202, pS339, DOI 10.1086/655968; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Naranbhai V, 2012, J INFECT DIS, V206, P993, DOI 10.1093/infdis/jis465; Pattacini L, 2013, AIDS RES HUM RETROV, V29, P1321, DOI [10.1089/aid.2013.0075, 10.1089/AID.2013.0075]; Posavad CM, 2017, MUCOSAL IMMUNOL, V10, P1259, DOI 10.1038/mi.2016.118; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Saulle I, 2020, AIDS, V34, P1593, DOI 10.1097/QAD.0000000000002591; Saylor J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02925; Schellenberg JJ, 2011, APPL ENVIRON MICROB, V77, P4066, DOI 10.1128/AEM.02943-10; Scott ME, 2006, J CLIN IMMUNOL, V26, P222, DOI 10.1007/s10875-006-9010-x; Shacklett BL, 2020, CURR HIV-AIDS REP, V17, P109, DOI 10.1007/s11904-020-00481-7; Stassen M, 2004, EUR J IMMUNOL, V34, P1303, DOI 10.1002/eji.200324656; Thibodeau V, 2017, SCI REP-UK, V7, DOI 10.1038/srep43857; Weisberg E, 2000, CONTRACEPTION, V62, P83, DOI 10.1016/S0010-7824(00)00137-2; Wickham H., 2019, J OPEN SOURCE SOFTWA, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/joss.01686]; Wickham Hadley, 2009, GGPLOT2; Woods MW, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12781; Zalenskaya IA, 2018, J CLIN INVEST, V128, P4622, DOI 10.1172/JCI120583; Zevin AS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005889; Zhao NQ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238347	59	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							217	10.3390/vaccines9030217			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5NB	33806390	Green Published, gold			2022-04-29	WOS:000634199500001
J	Sanchez-Aleman, MA; Gutierrez-Perez, IA; Diaz-Salgado, N; Zaragoza-Garcia, O; Olamendi-Portugal, M; Castro-Alarcon, N; Parra-Rojas, I; Guzman-Guzman, IP				Sanchez-Aleman, Miguel A.; Gutierrez-Perez, Ilse A.; Diaz-Salgado, Nayeli; Zaragoza-Garcia, Oscar; Olamendi-Portugal, Maria; Castro-Alarcon, Natividad; Parra-Rojas, Isela; Guzman-Guzman, Iris P.			Low Seroprevalence of Measles-Specific IgG in Children of Three Ethnic Groups from Mexico: Influence of Age, Sex, Malnutrition and Family Size	VACCINES			English	Article						measles; vaccine; IgG antibodies; children; ethnic groups; Mexico	VACCINATION COVERAGE; ANTIBODY-RESPONSE; NATIONAL-HEALTH; MUMPS	Background: The reemergence of measles represents a public health problem. The aim of the study was to determine the seroprevalence of IgG antibodies against measles in children of three ethnic groups in southern Mexico and the nutritional status and demographic risk factors associated. Methods: A cross-sectional study in 416 school-age children, 207 belonging to the Tlapaneco ethnic group, 101 to the Mixteco group and 108 were considered Mestizo. Sociodemographic data were collected, an anthropometric evaluation of the children was performed and a fasting blood sample was obtained from each child for the measurement of measles IgG antibodies by Enzyme-Linked Immunosorbent Assay (ELISA). Results: From the total sample, 59% of the children were seropositive for IgG antibodies against measles; in contrast, 41% lacked IgG antibodies. Measles antibody seropositivity was higher in girls (64%). 90.5% of 6-year-old children had higher antibodies seroprevalence, compared to the children between 10 and 13 years old (45.5%). In the three ethnic groups, age was negatively correlated with the index standard ratio (ISR) of measles antibody levels and the families with >= 8 members showed less seropositivity. According to the antibodies levels, most of the positive cases remained around 1 Standard Deviation (SD) of the ISR values and no underweight children had antibody levels above 2 SD. Conclusions: The Anti-Measles serological coverage is low in children of three ethnic groups from Southern Mexico and the age, sex, malnutrition and family size are associated factors. Therefore, it is important to strengthen immunization campaigns, principally in vulnerable groups.	[Sanchez-Aleman, Miguel A.; Olamendi-Portugal, Maria] Natl Inst Publ Hlth, Ctr Infect Dis Res, Cuernavaca 62100, Morelos, Mexico; [Gutierrez-Perez, Ilse A.; Zaragoza-Garcia, Oscar; Castro-Alarcon, Natividad; Parra-Rojas, Isela; Guzman-Guzman, Iris P.] Autonomous Univ Guerrero, Fac Chem Sci, Chilpancingo 39087, Guerrero, Mexico; [Diaz-Salgado, Nayeli] Autonomous Univ Morelos, Fac Nat Sci, Cuernavaca 62209, Morelos, Mexico; [Gutierrez-Perez, Ilse A.; Zaragoza-Garcia, Oscar] PhD Program Biomed Sci, Cuernavaca, Morelos, Mexico		Guzman-Guzman, IP (通讯作者)，Autonomous Univ Guerrero, Fac Chem Sci, Chilpancingo 39087, Guerrero, Mexico.	msanchez@insp.mx; 20389360@uagro.mx; nayely.diaz@uaem.edu.mx; 15158700@uagro.mx; molamendi@insp.mx; natividadcastro@uagro.mx; iselaparra@uagro.mx; irisguzman@uagro.mx		Zaragoza-Garcia, Oscar/0000-0001-9006-2165; Guzman Guzman, Iris Paola/0000-0003-1535-4226; Olamendi-Portugal, Maria/0000-0002-5227-7541			Anichini G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010066; Bester JC, 2016, JAMA PEDIATR, V170, P1209, DOI 10.1001/jamapediatrics.2016.1787; Bloss E, 2004, J TROP PEDIATRICS, V50, P260, DOI 10.1093/tropej/50.5.260; Burgos-Pelaez R., 2013, NUTR HOSP SUPPL, V6, P10; Navarro RC, 2017, SALUD COLECT, V13, P443, DOI 10.18294/sc.2017.1115; Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309; Cediel G, 2015, FOOD NUTR BULL, V36, pS98, DOI 10.1177/0379572115585743; Chowdhury F, 2006, ACTA PAEDIATR, V95, P44, DOI 10.1080/08035250500286987; Colson KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130697; Cuevas-Nasu L, 2012, ENCUESTA NACL SALUD; Diaz-Quinonez Jose Alberto, 2019, Gac Med Mex, V155, P421, DOI 10.24875/GMM.M20000326; Direccion General de Epidemiologia, 2019, SECR SAL SAR; European Centre for Disease Prevention and Control, 2018, MEASL OUTBR STILL ON; European Centre for Disease Prevention and Control, 2020, MONTHL MEASL RUB MON; GARFIELD E, 1986, CURR CONTENTS, P3; GREENWOOD BM, 1986, ANN TROP MED PARASIT, V80, P537, DOI 10.1080/00034983.1986.11812062; Griffin D, 2013, FIELDS VIROLOGY, VVolume 1; Haralambieva IH, 2017, HUM GENET, V136, P421, DOI 10.1007/s00439-017-1768-9; Jimenez-Aguilar A, 2014, SALUD PUBLICA MEXICO, V56, pS103; Kizito D, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-619; Kremer JR, 2006, VACCINE, V24, P2594, DOI 10.1016/j.vaccine.2005.12.015; Lewnard JA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5945; Diaz-Ortega JL, 2018, SALUD PUBLICA MEXICO, V60, P338, DOI 10.21149/8812; Diaz-Ortega JL, 2013, SALUD PUBLICA MEXICO, V55, pS289; Barcenas-Lopez RM, 2012, SALUD PUBLICA MEXICO, V54, P361, DOI 10.1590/S0036-36342012000400001; Moss WJ, 2017, LANCET, V390, P2490, DOI 10.1016/S0140-6736(17)31463-0; Mundo-Rosas V, 2009, SALUD PUBLICA MEXICO, V51, pS530; Organizacion Panamericana de Salud, 2019, ACT EP SAR 2019; Pan American Health Organization, 2019, MEASL EP AL UPD; Pan American Health Organization, 2016, 55 DIR COUNC 68 SESS; Rodriguez-Martin A, 2010, NUTR HOSP, V25, P67; Ruiz-Gomez J, 2007, SALUD PUBLICA MEXICO, V49, pS370, DOI 10.1590/S0036-36342007000900008; Rytter MJH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105017; Sanchez-Perez HJ, 2007, AM J PUBLIC HEALTH, V97, P229, DOI 10.2105/AJPH.2005.070409; Santos JI, 2004, J INFECT DIS, V189, pS243, DOI 10.1086/378520; Seagle EE, 2018, VACCINE, V36, P818, DOI 10.1016/j.vaccine.2017.12.075; Secretaria de Gobernacion, 2020, TAL RES CAS CONF SAR; Secretaria de Salud y Asistencia, CO VAC CON ESQ COMPL; Shamah-Levy T., 2015, REV DIG U UNAM, V6, P1; Siani A, 2019, PREV MED, V121, P99, DOI 10.1016/j.ypmed.2019.02.011; Situacion Epidemiologica de Sarampion Aviso, EP CONVAVE 01 2019 S; Uzicanin A., 2011, J INFECT DIS, V204, pS133, DOI [10.1093/infdis/jir102, DOI 10.1093/infdis/jir102]; World Health Organization, 2019, MEASL GLOB SIT MEASL GLOB SIT	43	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							295	10.3390/vaccines9030295			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE5GR	33810023	Green Published, gold			2022-04-29	WOS:000634182900001
J	Yeh, YC; Chen, IH; Ahorsu, DK; Ko, NY; Chen, KL; Li, PC; Yen, CF; Lin, CY; Griffiths, MD; Pakpour, AH				Yeh, Ya-Chin; Chen, I-Hua; Ahorsu, Daniel K.; Ko, Nai-Ying; Chen, Kuan-Lin; Li, Ping-Chia; Yen, Cheng-Fang; Lin, Chung-Ying; Griffiths, Mark D.; Pakpour, Amir H.			Measurement Invariance of the Drivers of COVID-19 Vaccination Acceptance Scale: Comparison between Taiwanese and Mainland Chinese-Speaking Populations	VACCINES			English	Article						confirmatory factor analysis; COVID-19; measurement invariance; vaccine; university students; Drivers of COVID-19 Vaccination Acceptance Scale	CONFIRMATORY FACTOR-ANALYSIS; MENTAL-HEALTH; FIT INDEXES; SELF-REPORT; IMPACT; GENDER; INTENTION	The impacts of novel coronavirus disease-2019 (COVID-19) on human life continue to be serious. To control the spread of COVID-19, the production of effective vaccines is likely to be one of the best solutions. However, vaccination hesitancy may decrease individuals' willingness to get vaccinated. The Drivers of COVID-19 Vaccination Acceptance Scale (DrVac-COVID19S) was recently developed to help healthcare professionals and researchers better understand vaccination acceptance. The present study examined whether DrVac-COVID19S is measurement invariant across different subgroups (Taiwanese vs. mainland Chinese university students; males vs. females; and health-related program majors vs. non-health-related program majors). Taiwanese (n = 761; mean age = 25.51 years; standard deviation (SD) = 6.42; 63.5% females) and mainland Chinese university students (n = 3145; mean age = 20.72 years; SD = 2.06; 50.2% females) were recruited using an online survey between 5 January and 21 February 2021. Factor structure and measurement invariance of the two DrVac-COVID19S scales (nine-item and 12-item) were tested using confirmatory factor analysis (CFA). The findings indicated that the DrVac-COVID19S had a four-factor structure and was measurement invariant across the subgroups. The DrVac-COVID19S's four-factor structure was supported by the CFA results is a practical and valid instrument to quickly capture university students' willingness to get COVID-19 vaccination. Moreover, the DrVac-COVID19S can be used to compare university students' underlying reasons to get COVID-19 vaccination among different subgroups.	[Yeh, Ya-Chin; Chen, Kuan-Lin; Lin, Chung-Ying] Natl Cheng Kung Univ, Inst Allied Hlth Sci, Coll Med, Tainan 701401, Taiwan; [Yeh, Ya-Chin] Shu Zen Jr Coll Med & Management, Dept Occupat Therapy, Kaohsiung 82144, Taiwan; [Chen, I-Hua] Minnan Normal Univ, Sch Educ Sci, Zhangzhou 363000, Peoples R China; [Ahorsu, Daniel K.] Hong Kong Polytech Univ, Dept Rehabil Sci, Fac Hlth & Social Sci, Hung Hom, Hong Kong, Peoples R China; [Ko, Nai-Ying] Natl Cheng Kung Univ, Dept Nursing, Natl Cheng Kung Univ Hosp, Coll Med, Tainan 701401, Taiwan; [Ko, Nai-Ying] Natl Cheng Kung Univ, Dept Nursing, Coll Med, Int Doctoral Program Nursing, Tainan 701401, Taiwan; [Chen, Kuan-Lin; Lin, Chung-Ying] Natl Cheng Kung Univ, Dept Occupat Therapy, Coll Med, Tainan 701401, Taiwan; [Chen, Kuan-Lin] Natl Cheng Kung Univ, Dept Phys Med & Rehabil, Natl Cheng Kung Univ Hosp, Coll Med, Tainan 701401, Taiwan; [Li, Ping-Chia] I Shou Univ, Dept Occupat Therapy, Kaohsiung 824005, Taiwan; [Yen, Cheng-Fang] Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 807378, Taiwan; [Yen, Cheng-Fang] Kaohsiung Med Univ, Sch Med, Coll Med, Kaohsiung 807378, Taiwan; [Lin, Chung-Ying] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Publ Hlth, Tainan 701401, Taiwan; [Griffiths, Mark D.] Nottingham Trent Univ, Dept Psychol, Int Gaming Res Unit, Nottingham NG14FQ, England; [Pakpour, Amir H.] Jonkoping Univ, Dept Nursing, Sch Hlth & Welf, S-55318 Jonkoping, Sweden		Lin, CY (通讯作者)，Natl Cheng Kung Univ, Inst Allied Hlth Sci, Coll Med, Tainan 701401, Taiwan.; Lin, CY (通讯作者)，Natl Cheng Kung Univ, Dept Occupat Therapy, Coll Med, Tainan 701401, Taiwan.; Yen, CF (通讯作者)，Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 807378, Taiwan.; Yen, CF (通讯作者)，Kaohsiung Med Univ, Sch Med, Coll Med, Kaohsiung 807378, Taiwan.; Lin, CY (通讯作者)，Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Publ Hlth, Tainan 701401, Taiwan.	yehyachin@ms.szmc.edu.tw; ahole.chen@gmail.com; daniel.ahorsu@connect.polyu.hk; nyko@mail.ncku.edu.tw; klchen@mail.ncku.edu.tw; pingchia@isu.edu.tw; chfaye@kmu.edu.tw; cylin36933@gmail.com; mark.griffiths@ntu.ac.uk; pakpour_amir@yahoo.com	Pakpour, Amir H./C-6160-2014; Griffiths, Mark D./AAY-3546-2021; Lin, Chung-Ying/I-5434-2016	Pakpour, Amir H./0000-0002-8798-5345; Griffiths, Mark D./0000-0001-8880-6524; Lin, Chung-Ying/0000-0002-2129-4242; Ko, Nai-Ying/0000-0002-3007-2537; chen, i hua/0000-0001-6999-6406	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST109-2327-B-006-005, 110-swf-01]	This study was supported in part by a research grant from the Ministry of Science and Technology, Taiwan (MOST109-2327-B-006-005) and in part by a research grant from the Taipei MunicipalWanfang Hospital Cross-Institutions Fund (110-swf-01).	Ahorsu DK, 2020, GERONTOL GERIATR MED, V6, DOI 10.1177/2333721420966081; Ahorsu DK, 2022, INT J MENT HEALTH AD, V20, P68, DOI 10.1007/s11469-020-00340-x; Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8; Chang CC, 2018, ASSESSMENT, V25, P777, DOI 10.1177/1073191116658547; Chen FF, 2007, STRUCT EQU MODELING, V14, P464, DOI 10.1080/10705510701301834; Craxi L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030189; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Du FX, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030201; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Dubey S, 2020, DIABETES METAB SYND, V14, P779, DOI 10.1016/j.dsx.2020.05.035; Fazeli Sara, 2020, Addict Behav Rep, V12, P100307, DOI [10.1016/j.abrep.2020.100322, 10.1016/j.abrep.2020.100307]; Gregorich SE, 2006, MED CARE, V44, pS78, DOI 10.1097/01.mlr.0000245454.12228.8f; Hashemi SGS, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05135; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jain S. M., 2021, CONT ED DIALOGUE, V18, P58, DOI 10.1177/0973184920976433; Kassianos G, 2018, VACCINE, V36, P6546, DOI 10.1016/j.vaccine.2018.02.031; Kayikcioglu M, 2020, J CLIN LIPIDOL, V14, P751, DOI 10.1016/j.jacl.2020.09.002; Keogh-Brown MR, 2020, SSM-POPUL HLTH, V12, DOI 10.1016/j.ssmph.2020.100651; Lee K, 2009, GLOB INST, P1; Leung H, 2020, ADDICT BEHAV, V101, DOI 10.1016/j.addbeh.2019.04.027; Leung TYM, 2020, EMERG MICROBES INFEC, V9, P2190, DOI 10.1080/22221751.2020.1825914; Limbers CA, 2008, VALUE HEALTH, V11, P659, DOI 10.1111/j.1524-4733.2007.00289.x; Lin CY, 2020, BRIT J HEALTH PSYCH, V25, P981, DOI 10.1111/bjhp.12465; Lin CY, 2017, INT PSYCHOGERIATR, V29, P1841, DOI 10.1017/S1041610217001417; Lin CY, 2014, EUR J PSYCHOL ASSESS, V30, P100, DOI 10.1027/1015-5759/a000175; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Lu S, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02064; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Mamun MA, 2021, J AFFECT DISORDERS, V279, P462, DOI 10.1016/j.jad.2020.10.036; Naser AY, 2021, INT J SOC PSYCHIATR, V67, P664, DOI 10.1177/0020764020966631; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Picconi L, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01164; Pramukti I, 2020, J MED INTERNET RES, V22, DOI 10.2196/24487; Prati G, 2020, HEALTH EDUC RES, V35, P505, DOI 10.1093/her/cyaa043; Reuben RC, 2021, J COMMUN HEALTH, V46, P457, DOI 10.1007/s10900-020-00881-1; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Shaukat N, 2020, INT J EMERG MED, V13, DOI 10.1186/s12245-020-00299-5; Sun SF, 2021, GLOBALIZATION HEALTH, V17, DOI 10.1186/s12992-021-00663-x; Sundarasen S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176206; THOMAS KW, 1990, ACAD MANAGE REV, V15, P666, DOI 10.2307/258687; Vallee-Tourangeau G, 2018, VACCINE, V36, P6540, DOI 10.1016/j.vaccine.2017.08.025; Wang JH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030191; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong SYS, 2020, BRIT J GEN PRACT, V70, pE817, DOI 10.3399/bjgp20X713021; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; Wu TH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117592; Xiong JQ, 2020, J AFFECT DISORDERS, V277, P55, DOI 10.1016/j.jad.2020.08.001	51	18	18	3	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							297	10.3390/vaccines9030297			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE5MD	33810036	Green Accepted, gold, Green Published			2022-04-29	WOS:000634197100001
J	Keikha, R; Daliri, K; Jebali, A				Keikha, Reza; Daliri, Karim; Jebali, Ali			The Use of Nanobiotechnology in Immunology and Vaccination	VACCINES			English	Article						nanotechnology; nanostructures; immunology; vaccination		Nanotechnology uses the unique properties of nanostructures with a size of 1 to 200 nanometers. Different nanoparticles have shown great promise for the production of new vaccines and drugs. Nanostructures can be used to deliver immunological compounds more effectively than microstructures to target sites. Different nanostructures can be applied to form a new generation of vaccines, adjuvants, and immune system drugs. The goal of nanotechnology is to better respond to a wide range of infectious and non-infectious diseases.	[Keikha, Reza] Zahedan Univ Med Sci, Resistant TB Inst, Infect Dis & Trop Med Res Ctr, Zahedan 9816743463, Iran; [Keikha, Reza] Zahedan Univ Med Sci, Fac Med, Dept Pathol, Zahedan 9816743463, Iran; [Daliri, Karim] Shiraz Univ Med Sci, Dept Genet, Shiraz 1433671348, Iran; [Jebali, Ali] Rafsanjan Univ Med Sci, Res Inst Basic Med Sci, Mol Med Res Ctr, Rafsanjan 7717933777, Iran		Jebali, A (通讯作者)，Rafsanjan Univ Med Sci, Res Inst Basic Med Sci, Mol Med Res Ctr, Rafsanjan 7717933777, Iran.	rezakeikha.md@gmail.com; karimdaliri@gmail.com; alijebal2011@gmail.com	jebali, ali/AAN-4546-2021	jebali, ali/0000-0002-1353-3864			Ayatollahi M, 2018, COLLOID INTERFAC SCI, V24, P45, DOI 10.1016/j.colcom.2018.03.006; Azimi A, 2020, BIOLOGICALS, V68, P60, DOI 10.1016/j.biologicals.2020.08.007; Bafghi AF, 2015, COLLOID SURFACE B, V136, P300, DOI 10.1016/j.colsurfb.2015.09.029; Bafghi AF, 2015, COLLOID SURFACE B, V136, P323, DOI 10.1016/j.colsurfb.2015.09.028; Barnowski C, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050204; Boato F, 2007, ANGEW CHEM INT EDIT, V46, P9015, DOI 10.1002/anie.200702805; Buonaguro L, 2011, EXPERT REV VACCINES, V10, P1569, DOI [10.1586/ERV.11.135, 10.1586/erv.11.135]; Chang LJ, 2014, LANCET, V384, P2046, DOI 10.1016/S0140-6736(14)61185-5; Christensen D, 2007, EXPERT REV VACCINES, V6, P785, DOI 10.1586/14760584.6.5.785; Cubas R, 2009, J IMMUNOTHER, V32, P118, DOI 10.1097/CJI.0b013e31818f13c4; Damm D, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9101389; Das SC, 2012, VACCINE, V30, P6871, DOI 10.1016/j.vaccine.2012.09.007; Doll TAPF, 2015, NANOMED-NANOTECHNOL, V11, P1705, DOI 10.1016/j.nano.2015.05.003; Douglas RG, 1996, JAMA-J AM MED ASSOC, V276, P1796, DOI 10.1001/jama.276.22.1796; El Sahly H, 2010, EXPERT REV VACCINES, V9, P1135, DOI [10.1586/erv.10.111, 10.1586/ERV.10.111]; Elsayed H, 2018, J VIROL, V92, DOI 10.1128/JVI.00141-18; Feng L, 2006, J CONTROL RELEASE, V112, P35, DOI 10.1016/j.jconrel.2006.01.012; Ferreira SA, 2013, NANOMED-NANOTECHNOL, V9, P159, DOI 10.1016/j.nano.2012.06.001; Goldinger SM, 2012, EUR J IMMUNOL, V42, P3049, DOI 10.1002/eji.201142361; He B, 2018, NANOMED-NANOTECHNOL, V14, P365, DOI 10.1016/j.nano.2017.11.002; HILLEMAN MR, 1983, J INFECTION, V7, P3, DOI 10.1016/S0163-4453(83)96465-4; Ilinskaya A.N., 2016, HDB IMMUNOLOGICAL PR, P139; Ishii N, 1997, AIDS RES HUM RETROV, V13, P1421, DOI 10.1089/aid.1997.13.1421; Jebali A, 2017, ADV COLLOID INTERFAC, V240, P1, DOI 10.1016/j.cis.2016.11.002; Jennings GT, 2009, ANNU REV PHARMACOL, V49, P303, DOI 10.1146/annurev-pharmtox-061008-103129; Johansen P, 2000, EUR J PHARM BIOPHARM, V50, P129, DOI 10.1016/S0939-6411(00)00079-5; Karpenko LI, 2004, VACCINE, V22, P1692, DOI 10.1016/j.vaccine.2003.09.050; Kool M, 2012, J MED MICROBIOL, V61, P927, DOI 10.1099/jmm.0.038943-0; KREUTER J, 1991, J CONTROL RELEASE, V16, P169, DOI 10.1016/0168-3659(91)90040-K; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Letchford K, 2007, EUR J PHARM BIOPHARM, V65, P259, DOI 10.1016/j.ejpb.2006.11.009; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Marasini N, 2014, EXPERT REV VACCINES, V13, P1361, DOI 10.1586/14760584.2014.936852; McClements DJ, 2018, ADV COLLOID INTERFAC, V253, P1, DOI 10.1016/j.cis.2018.02.002; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Negandaripour M, 2017, BIOTECHNOL ADV, V35, P575, DOI 10.1016/j.biotechadv.2017.05.002; Ngobili TA, 2016, EXP BIOL MED, V241, P1064, DOI 10.1177/1535370216650053; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; O'Hagan DT, 2007, EXPERT REV VACCINES, V6, P699, DOI 10.1586/14760584.6.5.699; Park Yeong-Min, 2013, Immune Netw, V13, P177, DOI 10.4110/in.2013.13.5.177; Podda A, 2001, VACCINE, V19, P2673, DOI 10.1016/S0264-410X(00)00499-0; Podda Audino, 2003, Expert Rev Vaccines, V2, P197, DOI 10.1586/14760584.2.2.197; Purwar M, 2018, VACCINE, V36, P6345, DOI 10.1016/j.vaccine.2018.07.032; Raman S, 2006, NANOMED-NANOTECHNOL, V2, P95, DOI 10.1016/j.nano.2006.04.007; Rashidi M, 2019, J NEUROIMMUNOL, V326, P75, DOI 10.1016/j.jneuroim.2018.11.014; Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI 10.1038/nbtl332; Reth M, 2013, NAT IMMUNOL, V14, P765, DOI 10.1038/ni.2621; Saslow D, 2007, CA-CANCER J CLIN, V57, P7, DOI 10.3322/canjclin.57.1.7; Shehata MM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020046; Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488; Stanberry LR, 2012, VACCINE, V30, P307, DOI 10.1016/j.vaccine.2011.10.094; Suleiman E, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11110619; Tannig P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010027; Uenaka A., 2007, CANC IMMUN ARCH, V7, P7; van der Pol L, 2015, BIOTECHNOL J, V10, P1689, DOI 10.1002/biot.201400395; Vogel FR, 2009, EXPERT REV VACCINES, V8, P483, DOI [10.1586/erv.09.5, 10.1586/ERV.09.5]; Wang BZ, 2007, J VIROL, V81, P10869, DOI 10.1128/JVI.00542-07; Wang H., 2018, J IMMUNOLOGICAL SCI, V2, P36, DOI [10.29245/2578-3009/2018/2.1118, DOI 10.29245/2578-3009/2018/2.1118]; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zilker C, 2017, NANOMED-NANOTECHNOL, V13, P173, DOI 10.1016/j.nano.2016.08.028; Zolnik BS, 2010, ENDOCRINOLOGY, V151, P458, DOI 10.1210/en.2009-1082	62	5	5	6	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							74	10.3390/vaccines9020074			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7KN	33494441	Green Published, gold			2022-04-29	WOS:000623318900001
J	Rzymski, P; Borkowski, L; Drag, M; Flisiak, R; Jemielity, J; Krajewski, J; Mastalerz-Migas, A; Matyja, A; Pyrc, K; Simon, K; Sutkowski, M; Wysocki, J; Zajkowska, J; Fal, A				Rzymski, Piotr; Borkowski, Leszek; Drag, Marcin; Flisiak, Robert; Jemielity, Jacek; Krajewski, Jacek; Mastalerz-Migas, Agnieszka; Matyja, Andrzej; Pyrc, Krzysztof; Simon, Krzysztof; Sutkowski, Michal; Wysocki, Jacek; Zajkowska, Joanna; Fal, Andrzej			The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation	VACCINES			English	Review						COVID-19; vaccine; science communication; vaccine hesitancy; misinformation		COVID-19 vaccinations are about to begin in various countries or are already ongoing. This is an unprecedented operation that is also met with a loud response from anti-vaccine communities-currently using all available channels to manipulate public opinion. At the same time, the strategy to educate on vaccinations, explain their mechanism of action, and build trust in science is subdued in different world parts. Such actions should go much beyond campaigns promoting the COVID-19 vaccines solely on the information provided by the health institutions and national authorities. In this paper, actions provided by independent expert groups needed to counteract the anti-vaccine propaganda and provide scientific-based information to the general public are offered. These actions encompass organizing groups continuously communicating science on COVID-19 vaccines to the general public; tracking and tackling emerging and circulating fake news; and equipping celebrities and politicians with scientific information to ensure the quality of messages they communicate, as well as public letters, and statements of support for vaccination by healthcare workers, recognized scientists, VIPs, and scientific societies; and no tolerance to false and manipulated claims on vaccination spread via traditional and social media as well as by health professionals, scientists, and academics. These activities should be promptly implemented worldwide, regardless of the current status and availability of the COVID-19 vaccine in a particular region. If we are about to control the pandemic for the sake of public benefit, it is high time to collectively speak out as academic and medical societies with support from decision-makers. Otherwise, the battle will be lost to those who stand against scientific evidence while offering no feasible solution to the problem.	[Rzymski, Piotr] Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland; [Rzymski, Piotr] Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland; [Borkowski, Leszek] Fdn Together Dis, PL-05252 Dabrowka, Poland; [Drag, Marcin] Wroclaw Univ Sci & Technol, Dept Chem Biol & Bioimaging, PL-50370 Wroclaw, Poland; [Flisiak, Robert] Med Univ Bialystok, Dept Infect Dis & Hepatol, PL-15540 Bialystok, Poland; [Jemielity, Jacek] Univ Warsaw, Ctr New Technol, PL-02097 Warsaw, Poland; [Krajewski, Jacek] Federat Healthcare Employers Unions Porozumienie, PL-65048 Zielona Gora, Poland; [Mastalerz-Migas, Agnieszka] Wroclaw Med Univ, Dept Family Med, PL-50367 Wroclaw, Poland; [Matyja, Andrzej] Polish Supreme Chamber Phys & Dentists, Supreme Med Council, PL-00764 Warsaw, Poland; [Matyja, Andrzej] Jagiellonian Univ, Med Coll Krakow, Dept Gen Surg 2, PL-30688 Krakow, Poland; [Pyrc, Krzysztof] Jagiellonian Univ, Malopolska Ctr Biotechnol, Virogenet Lab Virol, PL-30387 Krakow, Poland; [Simon, Krzysztof] Wroclaw Med Univ, Dept Infect Dis & Hepatol, PL-51149 Wroclaw, Poland; [Sutkowski, Michal] Coll Family Phys Poland, PL-00209 Warsaw, Poland; [Sutkowski, Michal] Lazarski Univ, Fac Med, PL-02662 Warsaw, Poland; [Wysocki, Jacek] Poznan Univ Med Sci, Dept Prevent Med, PL-60179 Poznan, Poland; [Zajkowska, Joanna] Med Univ Bialystok, Dept Infect Dis & Neuroinfect, PL-15540 Bialystok, Poland; [Fal, Andrzej] Cardinal Stefan Wyszynski Univ, Coll Med, Warsaw Fac Med, PL-01938 Warsaw, Poland		Rzymski, P (通讯作者)，Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland.; Rzymski, P (通讯作者)，Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland.; Fal, A (通讯作者)，Cardinal Stefan Wyszynski Univ, Coll Med, Warsaw Fac Med, PL-01938 Warsaw, Poland.	rzymskipiotr@ump.edu.pl; c@data.pl; marcin.drag@pwr.edu.pl; robert.flisiak1@gmail.com; j.jemielity@cent.uw.edu.pl; jkrajewski52@gmail.com; agnieszka.mastalerz-migas@umed.wroc.pl; andrzej.matyja@hipokrates.org; k.a.pyrc@gmail.com; krzysztof.simon@umed.wroc.pl; doktormjs@gmail.com; jawysocki@pro.onet.pl; zajkowsk@umb.edu.pl; amfal@wp.pl	Fal, Andrzej/ABB-7181-2021; Rzymski, Piotr/I-2240-2012; Jemielity, Jacek/E-2635-2013; Flisiak, Robert/S-5356-2018; Mastalerz-Migas, Agnieszka/W-5453-2018	Fal, Andrzej/0000-0002-9675-7942; Rzymski, Piotr/0000-0002-4713-0801; Simon, Krzysztof/0000-0002-8040-0412; Jemielity, Jacek/0000-0001-7633-788X; Flisiak, Robert/0000-0003-3394-1635; Mastalerz-Migas, Agnieszka/0000-0001-6600-2760; Pyrc, Krzysztof/0000-0002-3867-7688			Alwan NA, 2020, LANCET, V396, pE71, DOI 10.1016/S0140-6736(20)32153-X; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], 2020, LANCET INFECT DIS, V20, P875, DOI 10.1016/S1473-3099(20)30565-X; Anwar A, 2020, CUREUS, V12, DOI 10.7759/cureus.10453; Ball P, 2021, NATURE, V589, P16, DOI 10.1038/d41586-020-03626-1; Bendau A, 2021, EUR ARCH PSY CLIN N, V271, P283, DOI 10.1007/s00406-020-01171-6; Brandtzaeg PB, 2017, COMMUN ACM, V60, P65, DOI 10.1145/3122803; Brownell Sara E, 2013, J Undergrad Neurosci Educ, V12, pE6; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Burki T, 2020, LANCET INFECT DIS, V20, P292, DOI 10.1016/S1473-3099(20)30076-1; Butler T., 2020, BR J CARDIOL, V27, P79; Calisher C, 2020, LANCET, V395, pE42, DOI 10.1016/S0140-6736(20)30418-9; Caulfield Timothy, 2020, Nature, DOI 10.1038/d41586-020-01266-z; Cheah JH, 2019, INTERNET RES, V29, P552, DOI 10.1108/IntR-12-2017-0530; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; Cusinato J, 2021, EXPERT OPIN THER PAT, V31, P295, DOI 10.1080/13543776.2021.1861248; Dong MY, 2020, HEALTH EXPECT, V23, P259, DOI 10.1111/hex.13055; Dubey MJ, 2020, DIABETES METAB SYND, V14, P817, DOI 10.1016/j.dsx.2020.06.008; Eise Jessica, 2019, Nature, DOI 10.1038/d41586-019-03869-7; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gianola S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240123; Gruber M.F., 2018, PLOTKINS VACCINES, V7th, P1547, DOI DOI 10.1016/B978-0-323-35761-6.00079-1; Gwenzi W, 2021, ENVIRON RES, V194, DOI 10.1016/j.envres.2020.110637; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Islam MS, 2020, AM J TROP MED HYG, V103, P1621, DOI 10.4269/ajtmh.20-0812; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Kadkhoda K, 2021, AM J CLIN PATHOL, V155, P471, DOI 10.1093/ajcp/aqaa272; KLEE AJ, 1972, AICHE J, V18, P1107, DOI 10.1002/aic.690180604; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Lenzen M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235654; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Meshi D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049748; Miller IF, 2020, NAT MED, V26, P1212, DOI 10.1038/s41591-020-0952-y; Moraes M, 2019, J MARKET MANAG-UK, V35, P1159, DOI 10.1080/0267257X.2019.1632373; Mullard Asher, 2020, Nature, DOI 10.1038/d41586-020-03370-6; Nkengasong JN, 2020, NATURE, V586, P197, DOI 10.1038/d41586-020-02774-8; Nowakowska J, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110451; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2; Orso D, 2020, EUR J EMERG MED, V27, P327, DOI 10.1097/MEJ.0000000000000713; Petzold MB, 2020, BRAIN BEHAV, V10, DOI 10.1002/brb3.1745; Phizackerley David, 2021, Drug Ther Bull, V59, P2, DOI 10.1136/dtb.2020.000071; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Porter C., 2020, NEW YORK TIMES; Rapanta C., 2020, POSTDIGIT SCI ED, V2, P923, DOI [10.1007/s42438-020-00155-y, DOI 10.1007/S42438-020-00155-Y]; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Rimoin A.W., 2020, ASSESSMENT COVID 19, DOI [10.1101/2020.11.18.20234468, DOI 10.1101/2020.11.18.20234468]; Rzymski P, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106711; Rzymski P, 2020, J INFECT PUBLIC HEAL, V13, P873, DOI 10.1016/j.jiph.2020.04.013; Rzymski P, 2020, SCIENCE, V367, P1313, DOI 10.1126/science.abb4870; Sasaki N, 2020, PSYCHIAT CLIN NEUROS, V74, P501, DOI 10.1111/pcn.13095; Science Against Pandemic Initiative, POL WHIT BOOK; Sidor A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061657; Simonovich VA, 2021, NEW ENGL J MED, V384, P619, DOI 10.1056/NEJMoa2031304; Singh TU, 2020, PHARMACOL REP, V72, P1479, DOI 10.1007/s43440-020-00155-6; Sridhar D, 2021, SCIENCE, V371, P230, DOI 10.1126/science.abf7921; Sternberg A, 2020, CURR TOP MED CHEM, V20, P1423, DOI 10.2174/1568026620999200517043137; Sun MY, 2020, INT J INFECT DIS, V98, P334, DOI 10.1016/j.ijid.2020.06.107; van Der Linden S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.566790; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wondmkun YT, 2020, BIOL-TARGETS THER, V14, P77, DOI [10.2147/BTT.S266487, 10.2147/STT.S266487]	62	33	33	18	41	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							109	10.3390/vaccines9020109			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6SC	33535716	Green Published, gold			2022-04-29	WOS:000623270400001
J	Wang, ZF; Guo, MT; Kong, LC; Gao, Y; Ma, JJ; Cheng, YQ; Wang, HN; Yan, YX; Sun, JH				Wang, Zhaofei; Guo, Mengting; Kong, Licheng; Gao, Ya; Ma, Jingjiao; Cheng, Yuqiang; Wang, Henan; Yan, Yaxian; Sun, Jianhe			TLR4 Agonist Combined with Trivalent Protein JointS of Streptococcus suis Provides Immunological Protection in Animals	VACCINES			English	Article						Streptococcus suis; JointS; zebrafish; mice; piglet; subunit vaccine		Streptococcus suis (S. suis) serotype 2 (SS2) is the causative agent of swine streptococcosis and can cause severe diseases in both pigs and humans. Although the traditional inactive vaccine can protect pigs from SS2 infection, novel vaccine candidates are needed to overcome its shortcomings. Three infection-associated proteins in S. suis-muramidase-released protein (MRP), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and DLD, a novel putative dihydrolipoamide dehydrogenase-have been previously identified by immunoproteomic assays. In this study, the effective immune protection of the recombinant trivalent protein GAPDH-MRP-DLD (JointS) against SS2, SS7, and SS9 was determined in zebrafish. To improve the immune efficacy of JointS, monophosphoryl lipid A (MPLA) as a TLR4 agonist adjuvant, which induces a strong innate immune response in the immune cells of mice and pigs, was combined with JointS to immunize the mice. The results showed that immunized mice could induce the production of a high titer of anti-S. suis antibodies; as a result, 100% of mice survived after SS2 infection. Furthermore, JointS provides good protection against virulent SS2 strain infections in piglets. Given the above, there is potential to develop JointS as a novel subunit vaccine for piglets to prevent infection by SS2 and other S. suis serotypes.	[Wang, Zhaofei; Guo, Mengting; Kong, Licheng; Gao, Ya; Ma, Jingjiao; Cheng, Yuqiang; Wang, Henan; Yan, Yaxian; Sun, Jianhe] Shanghai Jiao Tong Univ, Shanghai Key Lab Vet Biotechnol, Shanghai 200240, Peoples R China; [Wang, Zhaofei; Guo, Mengting; Kong, Licheng; Gao, Ya; Ma, Jingjiao; Cheng, Yuqiang; Wang, Henan; Yan, Yaxian; Sun, Jianhe] Shanghai Jiao Tong Univ, Key Lab Urban Agr South, Minist Agr, Shanghai 200240, Peoples R China		Sun, JH (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Key Lab Vet Biotechnol, Shanghai 200240, Peoples R China.; Sun, JH (通讯作者)，Shanghai Jiao Tong Univ, Key Lab Urban Agr South, Minist Agr, Shanghai 200240, Peoples R China.	wzfxlzjx@sjtu.edu.cn; guomengting1994@sjtu.edu.cn; klc0713@163.com; ele.gaoya@sjtu.edu.cn; majingjiao@sjtu.edu.cn; 19871ccyq@163.com; hawang@sjtu.edu.cn; yanyaxian@sjtu.edu.cn; sunjhe@sjtu.edu.cn		MA, JINGJIAO/0000-0003-1187-7249; Sun, JianHe/0000-0002-4005-6071	National Key Research and Development Program of China [2018YFE0101300]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31772744, 31902237]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [18391901900]; Shanghai Jiao Tong University Fund [Agri-X2017007]	This study was funded by the National Key Research and Development Program of China (2018YFE0101300), the National Natural Science Foundation of China (31772744 and 31902237), the Science and Technology Commission of Shanghai Municipality (18391901900); and Shanghai Jiao Tong University Fund (Agri-X2017007).	AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Baums CG, 2009, CLIN VACCINE IMMUNOL, V16, P200, DOI 10.1128/CVI.00371-08; Bharucha T, 2017, HUM VACC IMMUNOTHER, V13, P1789, DOI 10.1080/21645515.2017.1317410; Celis E, 2007, CANCER RES, V67, P7945, DOI 10.1158/0008-5472.CAN-07-1652; Choi JH, 2020, J VET SCI, V21, DOI 10.4142/jvs.2020.21.e74; Dai F, 2019, VIRULENCE, V10, P839, DOI 10.1080/21505594.2019.1682761; Devasundaram S, 2017, J LEUKOCYTE BIOL, V102, P135, DOI 10.1189/jlb.4A0916-067RR; Estrada AA, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00377-19; Geng HR, 2008, J PROTEOME RES, V7, P4132, DOI 10.1021/pr800196v; Hallstrom T, 2012, J IMMUNOL, V189, P4939, DOI 10.4049/jimmunol.1200386; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Li Q, 2018, VET MICROBIOL, V216, P198, DOI 10.1016/j.vetmic.2018.02.013; Meng XP, 2011, APPL ENVIRON MICROB, V77, P8272, DOI 10.1128/AEM.05151-11; Neely MN, 2002, INFECT IMMUN, V70, P3904, DOI 10.1128/IAI.70.7.3904-3914.2002; Pang HY, 2016, VACCINE, V34, P1225, DOI 10.1016/j.vaccine.2015.11.001; Patterson H, 2012, DEV COMP IMMUNOL, V38, P447, DOI 10.1016/j.dci.2012.07.007; Reed SG, 2020, CURR OPIN IMMUNOL, V65, P97, DOI 10.1016/j.coi.2020.08.008; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Segura M, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090707; Segura M, 2015, EXPERT REV VACCINES, V14, P1587, DOI 10.1586/14760584.2015.1101349; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; STANIC M, 1963, PATHOL MICROBIOL, V26, P298, DOI 10.1159/000161378; Staton GJ, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00050-20; Tan C, 2019, CURR ISSUES MOL BIOL, V32, P473, DOI 10.21775/cimb.032.473; Tang JQ, 2006, PLOS MED, V3, P668, DOI 10.1371/journal.pmed.0030151; Vreman S, 2019, VET IMMUNOL IMMUNOP, V212, P27, DOI 10.1016/j.vetimm.2019.04.008; Wang HR, 2019, CURR ISSUES MOL BIOL, V32, P645, DOI 10.21775/cimb.032.645; Wang KC, 2007, BERL MUNCH TIERARZTL, V120, P207, DOI 10.2376/0005-9366-120-207; Wang Y, 2019, VIRULENCE, V10, P588, DOI 10.1080/21505594.2019.1631661; Wang YQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00256; Wei ZG, 2009, VET MICROBIOL, V137, P196, DOI 10.1016/j.vetmic.2008.12.015; Weir H, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00606; WETHERALL BL, 1980, J CLIN MICROBIOL, V11, P573, DOI 10.1128/JCM.11.6.573-578.1980; Wilk MM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01860; Wisselink HJ, 2001, VET REC, V148, P473, DOI 10.1136/vr.148.15.473; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831; Xing XX, 2019, J INFECT DIS, V220, P1679, DOI 10.1093/infdis/jiz352; Yamamoto M, 1996, ANN NY ACAD SCI, V778, P64, DOI 10.1111/j.1749-6632.1996.tb21115.x; Yi L, 2021, J APPL MICROBIOL, V130, P1075, DOI 10.1111/jam.14874; Zhang W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021234; Zhang YB, 2020, GENES-BASEL, V11, DOI 10.3390/genes11091065; Zhu YC, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00274	42	0	0	3	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							184	10.3390/vaccines9020184			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7AA	33671673	Green Published, gold			2022-04-29	WOS:000623291300001
J	Choi, H; Lee, SM; Lim, S; Shin, KH; Kim, T; Kim, WJ; Yun, M; Oh, SH				Choi, Hyunji; Lee, Sun-Min; Lim, Seungjin; Shin, Kyung-Hwa; Kim, Taeyun; Kim, Won-joo; Yun, Misook; Oh, Seung-Hwan			Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle	VACCINES			English	Article						SARS-CoV-2; vaccines; adverse effect; neutralizing antibody; cellular immune response; BMI	SEX-DIFFERENCES; SARS-COV-2; RESPONSES; EXERCISE; IMMUNITY; INFLAMMATION	The immune-acquired responses after vaccination vary depending on the type of vaccine and the individual. The purpose of this study was to investigate the relationship between the acquisition of immunity and the side effects, health status, and lifestyle after completion of the second dose of AZD1222. Blood samples were collected after a second dose of AZD1222. The Euroimmun Anti-SARS-CoV-2 ELISA (IgG) for anti-S1 antibody, the cPASS SARS-CoV-2 neutralizing antibody detection kit for the surrogate virus neutralization test, and the T-spot Discovery SARS-CoV-2 kit were used to identify cellular immunogenicity. Patient experience of adverse effects was investigated using questionnaires. Information on health status and lifestyle were collected from the most recent health checkup data. Generally, females experience more reactogenicity in both intensity and duration. The rash of the first shot and chills of the second shot were associated with humoral immunity. However, comprehensive adverse effects had no correlation with humoral and cellular immunity. The T-spot-positive group had a higher creatinine level, which reflects muscle mass, than the T-spot-negative group. Males presented a higher level of T-spot assays. Body mass index and age were negatively correlated with the T-spot assay and anti-S1 antibody, respectively. Immune acquisition after the second AZD1222 shot was not associated with reactogenicity. However, individuals' sex, age, and BMI were found to be associated with immunogenicity after vaccination.	[Choi, Hyunji; Lee, Sun-Min; Kim, Won-joo; Oh, Seung-Hwan] Pusan Natl Univ, Yangsan Hosp, Dept Lab Med, Yangsan 50612, South Korea; [Lee, Sun-Min; Shin, Kyung-Hwa] Pusan Natl Univ, Sch Med, Dept Lab Med, Yangsan 50612, South Korea; [Lim, Seungjin] Pusan Natl Univ, Sch Med, Div Infect Dis, Yangsan 50612, South Korea; [Shin, Kyung-Hwa] Pusan Natl Univ Hosp, Dept Lab Med, Busan 49241, South Korea; [Kim, Taeyun] Armed Forces Goyang Hosp, Dept Internal Med, Goyang 10271, South Korea; [Yun, Misook] Pusan Natl Univ, Yangsan Hosp, Res Inst Convergence Biomed Sci & Technol, Div Biostat, Yangsan 50612, South Korea		Lee, SM (通讯作者)，Pusan Natl Univ, Yangsan Hosp, Dept Lab Med, Yangsan 50612, South Korea.; Lee, SM (通讯作者)，Pusan Natl Univ, Sch Med, Dept Lab Med, Yangsan 50612, South Korea.	woojukirin@naver.com; yaong97@paran.com; babopm@naver.com; skh2009pnuh@gmail.com; jimsb89@naver.com; sweethome01@naver.com; msyun@pusan.ac.kr; paracelsus@hanmail.net	Lee, Sun-Min/AAV-7695-2021	Lee, Sun-Min/0000-0002-2896-3365; Lim, Seungjin/0000-0001-7939-9744; Kim, Taeyun/0000-0001-7786-5051; Choi, Hyunji/0000-0002-6453-7099			An KY, 2019, EPIDEMIOL HEALTH, V41, DOI 10.4178/epih.e2019047; Bertoletti A, 2021, CELL MOL IMMUNOL, V18, P2307, DOI 10.1038/s41423-021-00743-3; Bull FC, 2009, J PHYS ACT HEALTH, V6, P790, DOI 10.1123/jpah.6.6.790; Chia WN, 2021, LANCET MICROBE, V2, pE240, DOI 10.1016/S2666-5247(21)00025-2; Falsey AR, 2021, NEW ENGL J MED, V385, P2348, DOI 10.1056/NEJMoa2105290; Favaloro EJ, 2022, CLIN CHEM LAB MED, V60, P7, DOI 10.1515/cclm-2021-1039; Favaloro EJ, 2021, INT J LAB HEMATOL, V43, P559, DOI 10.1111/ijlh.13629; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; GROSS PA, 1994, CLIN DIAGN LAB IMMUN, V1, P134, DOI 10.1128/CDLI.1.2.134-138.1994; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Hwang YH, 2021, KOREAN J INTERN MED, V36, P1486, DOI 10.3904/kjim.2021.210; Jeon M, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e114; Jeong S, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.01105-21; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Jung Jin-Gyu, 2021, Korean Journal of Family Practice, V11, P14, DOI 10.21215/kjfp.2021.11.1.14; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kohut ML, 2002, J GERONTOL A-BIOL, V57, pM557, DOI 10.1093/gerona/57.9.M557; Li HF, 2011, AGING DIS, V2, P466; Luk TT, 2021, VACCINE, V39, P3602, DOI 10.1016/j.vaccine.2021.05.036; McDonald I, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00336-1; Montgomery RR, 2015, J LEUKOCYTE BIOL, V98, P937, DOI 10.1189/jlb.5MR0315-104R; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Park JY, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132844; Pascoe AR, 2014, BRAIN BEHAV IMMUN, V39, P33, DOI 10.1016/j.bbi.2013.10.003; Patel SS, 2013, J CACHEXIA SARCOPENI, V4, P19, DOI 10.1007/s13539-012-0079-1; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Prendecki M, 2021, ANN RHEUM DIS, V80, P1322, DOI 10.1136/annrheumdis-2021-220626; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Ruggieri Anna, 2016, Ann Ist Super Sanita, V52, P198, DOI 10.4415/ANN_16_02_11; Schoenborn Charlotte A, 2013, Vital Health Stat 10, P1; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Stankov M.V., 2021, CLIN INFECT DIS PUBL, DOI [10.1093/cid/ciab555, DOI 10.1093/CID/CIAB555, 10.1101/2021.04.16.21255412]; Tan AT, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108728; von Hundelshausen P, 2021, THROMB HAEMOSTASIS, V121, P1395, DOI 10.1055/a-1481-3039; Woods JA, 2009, IMMUNOL ALLERGY CLIN, V29, P381, DOI 10.1016/j.iac.2009.02.011; Young KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082779; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	40	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1473	10.3390/vaccines9121473			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9JV	34960219	gold, Green Published			2022-04-29	WOS:000737281600001
J	Ibrahim, D; Kis, Z; Tak, K; Papathanasiou, MM; Kontoravdi, C; Chachuat, B; Shah, N				Ibrahim, Dauda; Kis, Zoltan; Tak, Kyungjae; Papathanasiou, Maria M.; Kontoravdi, Cleo; Chachuat, Benoit; Shah, Nilay			Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK	VACCINES			English	Article						SARS-CoV-2 vaccines; vaccination campaign; vaccine availability; demand stratification; economic analysis; mathematical programming	VACCINES; NETWORK; IMPACT; BENIN	Vaccination plays a key role in reducing morbidity and mortality caused by infectious diseases, including the recent COVID-19 pandemic. However, a comprehensive approach that allows the planning of vaccination campaigns and the estimation of the resources required to deliver and administer COVID-19 vaccines is lacking. This work implements a new framework that supports the planning and delivery of vaccination campaigns. Firstly, the framework segments and priorities target populations, then estimates vaccination timeframe and workforce requirements, and lastly predicts logistics costs and facilitates the distribution of vaccines from manufacturing plants to vaccination centres. The outcomes from this study reveal the necessary resources required and their associated costs ahead of a vaccination campaign. Analysis of results shows that by integrating demand stratification, administration, and the supply chain, the synergy amongst these activities can be exploited to allow planning and cost-effective delivery of a vaccination campaign against COVID-19 and demonstrates how to sustain high rates of vaccination in a resource-efficient fashion.	[Ibrahim, Dauda; Kis, Zoltan; Tak, Kyungjae; Papathanasiou, Maria M.; Kontoravdi, Cleo; Chachuat, Benoit; Shah, Nilay] Imperial Coll London, Sargent Ctr Proc Syst Engn, Dept Chem Engn, London SW7 2AZ, ON, Canada; [Kis, Zoltan] Univ Sheffield, Dept Chem & Biol Engn, Sheffield S1 3JD, S Yorkshire, England		Ibrahim, D (通讯作者)，Imperial Coll London, Sargent Ctr Proc Syst Engn, Dept Chem Engn, London SW7 2AZ, ON, Canada.	d.ibrahim@imperial.ac.uk; z.kis10@imperial.ac.uk; k.tak@imperial.ac.uk; maria.papathanasiou11@imperial.ac.uk; cleo.kontoravdi98@imperial.ac.uk; b.chachuat@imperial.ac.uk; n.shah@imperial.ac.uk	Chachuat, Benoit/J-6899-2012; Kis, Zoltan/H-3611-2016	Chachuat, Benoit/0000-0003-4780-9686; Kis, Zoltan/0000-0002-6598-8369; Kontoravdi, Cleo/0000-0003-0213-4830	UK Research and Innovation (UKRI) via the Engineering and Physical Science Research Council (EPSRC) [EP/V01479X/1]; Future Vaccine Manufacturing Research Hub at UCL-Oxford [EP/R013756/1]; Department of Health and Social Care using UK Aid [EP/R01374/1]	This research is partly funded by UK Research and Innovation (UKRI) via the Engineering and Physical Science Research Council (EPSRC) grant on COVID-19/SARS-CoV-2 vaccine manufacturing and supply chain optimisation (EP/V01479X/1) and the Future Vaccine Manufacturing Research Hub at UCL-Oxford (EP/R013756/1). Additional financial support from the Department of Health and Social Care using UK Aid funding as managed by the EPSRC (EP/R01374/1) is also gratefully acknowledged. The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care.	Acharya KP, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00323-6; Alvarez MM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83697-w; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Asselah T, 2021, J HEPATOL, V74, P168, DOI 10.1016/j.jhep.2020.09.031; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baraniuk C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n743; Becker AD, 2021, LANCET DIGIT HEALTH, V3, pE41, DOI 10.1016/S2589-7500(20)30268-5; Beddingfield BJ, 2021, JACC-BASIC TRANSL SC, V6, P1, DOI 10.1016/j.jacbts.2020.10.003; Bertozzi AL, 2020, P NATL ACAD SCI USA, V117, P16732, DOI 10.1073/pnas.2006520117; Brown ST, 2014, VACCINE, V32, P4097, DOI 10.1016/j.vaccine.2014.04.090; Brown ST, 2014, VACCINE, V32, P2518, DOI 10.1016/j.vaccine.2014.02.060; Carcione JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00230; Chen SI, 2014, IIE TRANS, V46, P853, DOI 10.1080/0740817X.2013.813094; Choi EM, 2021, T ROY SOC TROP MED H, V115, P447, DOI 10.1093/trstmh/trab045; Crocker-Buque T, 2019, HUM VACC IMMUNOTHER, V15, P3016, DOI 10.1080/21645515.2019.1619403; Crocker-Buque T, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6228-5; Crocker-Buque T, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0824-8; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; De Carvalho M.I., 2019, PHARM SUPPLY CHAINS; Emmerich MTM, 2018, NAT COMPUT, V17, P585, DOI 10.1007/s11047-018-9685-y; Georgiadis GP, 2021, VACCINE, V39, P5302, DOI 10.1016/j.vaccine.2021.07.068; Global Partnership to Make Available 120M Affordable, QUAL COVID 19 RAP TE; Guignard A, 2019, EXPERT REV VACCINES, V18, P119, DOI 10.1080/14760584.2019.1574224; Haidari LA, 2015, VACCINE, V33, P3242, DOI 10.1016/j.vaccine.2015.04.018; Hall S., NONE ARE SAFE ALL AR; Hung IFN, 2021, LANCET, V397, P854, DOI 10.1016/S0140-6736(21)00528-6; James LP, 2021, MED DECIS MAKING, V41, P379, DOI 10.1177/0272989X21990391; Joint Committee on Vaccination and Immunisation, 2020, ADV PRIOR GROUPS COV; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Kis Z., 2019, J ADV MANUF PROCESS, V1, pe10025, DOI [10.1002/amp2.10025, DOI 10.1002/AMP2.10025]; Kis Z, ENHANCING VACCINE PL; Kis Zoltan, 2020, J Adv Manuf Process, V2, pe10060, DOI 10.1002/amp2.10060; Kis Z, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010003; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Lee BY, 2015, VACCINE, V33, P2858, DOI 10.1016/j.vaccine.2015.04.022; Lee BY, 2012, AM J PUBLIC HEALTH, V102, P269, DOI 10.2105/AJPH.2011.300218; Liu YC, 2020, BIOMED J, V43, P328, DOI 10.1016/j.bj.2020.04.007; Livingston Edward H, 2021, JAMA, V325, P1575, DOI 10.1001/jama.2021.2927; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n296; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rauch S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00311-w; Reader D., MODELLING MANUFACTUR; Sadjadi SJ, 2019, J MODEL MANAG, V14, P841, DOI 10.1108/JM2-07-2018-0093; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Tanne JH, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1079; Thompson RN, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01628-4; van de Berg D, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00322-7; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; West S., IS WORLD READY PRODU; World Health Organization, 2020, FRAM DEC MAK IMPL MA FRAM DEC MAK IMPL MA; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	54	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1460	10.3390/vaccines9121460			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0MU	34960206	gold, Green Accepted, Green Published			2022-04-29	WOS:000737357700001
J	Al-Lahham, A				Al-Lahham, Adnan			Prevalence of Pneumococcal Carriage among Jordanian Infants in the First 6 Months of Age, 2008-2016	VACCINES			English	Article						infants; Streptococcus pneumoniae; PCVs; carriage; resistance	STREPTOCOCCUS-PNEUMONIAE COLONIZATION; NASOPHARYNGEAL CARRIAGE; ANTIBIOTIC-RESISTANCE; CHILDREN; POPULATION; VACCINES; ADULTS	Background: Streptococcus pneumoniae is an opportunistic human-adapted pathogen driven by nasopharyngeal carriage. Aims: To find the pneumococcal carriage rate, resistance, serotypes, and coverage of pneumococcal conjugate vaccines (PCVs) among infants in the first six months of age in the period from March 2008 to April 2016. Methods: Nasopharyngeal swabs (NP) were taken from healthy infants from the northern part of Jordan. Swabs were processed for cultivation, identification, resistance testing and serotyping according to standard methods. Results: During the surveillance period, 484 infants of this age group were tested, with a total carriage rate of 56.2%. 96.2% of infants one to two months of age got one PCV7 injection and were 58% carriers at the time of the first injection. At age three to four months, 84.9% had received two injections, with a carriage rate of 54.9% at the time of the second injection. At ages five to six months, 12.5% had received one to three injections, with a carriage rate of 43.8%. Predominant serotypes in all age groups were 19F (12.5%), 6A (11.4%), 11A (8.4%), 19A (7.0%), 6B (6.6%), 23F (5.9%), 15B (5.1%), 15A and 23A (4.0% each). Coverage of PCV7, PCV13 and the future PCV20 among all cases were 30.5%, 50.7% and 70.6%, respectively. The highest coverage rate of 78.6% was noticed in the age group at five to six months with the future PCV20. Antibiotic resistance was the highest in the first age group. Conclusions: Pneumococcal carriage starts from the first month of the infant's life. The highest coverage was noticed for PCV20, which implies the necessity for inoculation with future vaccines.	[Al-Lahham, Adnan] German Jordanian Univ, Sch Appl Med Sci, Dept Biomed Engn, Amman 11180, Jordan		Al-Lahham, A (通讯作者)，German Jordanian Univ, Sch Appl Med Sci, Dept Biomed Engn, Amman 11180, Jordan.	adnan.lahham@gju.edu.jo		Al-Lahham, Adnan/0000-0002-5661-3426	deanship of scientific research at the GERMAN JORDANIAN UNIVERSITY [SAMS 22/2015]	This research was funded by the deanship of scientific research at the GERMAN JORDANIAN UNIVERSITY under the research grant number SAMS 22/2015.	Adegbola RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103293; Al-Bakri AG, 2005, INT J ANTIMICROB AG, V26, P389, DOI 10.1016/j.ijantimicag.2005.07.014; Al-Lahham A., 2014, INT ARAB J ANTIMICRO, V4, P1, DOI [10.3823/752, DOI 10.3823/752]; Al-Lahham A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070789; Al-Lahham A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237247; Apte A, 2021, J GLOB HEALTH, V11, DOI 10.7189/jogh.11.04054; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Bosch AATM, 2016, VACCINE, V34, P531, DOI 10.1016/j.vaccine.2015.11.060; Chaguza C, 2021, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.587730; CLSI, 2021, PERFORMANCE STANDARD, V31st; Croucher NJ, 2018, ANNU REV MICROBIOL, V72, P521, DOI 10.1146/annurev-micro-090817-062338; Darboe MK, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-195; Dunne EM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224392; Ekdahl K, 1997, CLIN INFECT DIS, V25, P1113, DOI 10.1086/516103; Gamez G, 2021, J PEDIAT INF DIS-GER, V16, P205, DOI 10.1055/s-0041-1731343; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524; Goyal R, 2007, Indian J Med Microbiol, V25, P256; GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923; Huang WH, 2004, AM J RHINOL, V18, P387, DOI 10.1177/194589240401800609; Jacobs Michael R, 2004, Semin Pediatr Infect Dis, V15, P5, DOI 10.1053/j.spid.2004.01.003; Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348; Kayhty H, 2006, EXPERT REV VACCINES, V5, P651, DOI 10.1586/14760584.5.5.651; Laval CB, 2006, CLIN MICROBIOL INFEC, V12, P50, DOI 10.1111/j.1469-0691.2005.01304.x; Malfroot A, 2004, CLIN MICROBIOL INFEC, V10, P797, DOI 10.1111/j.1198-743X.2004.00926.x; Marangu D, 2019, PAEDIATR RESPIR REV, V32, P3, DOI 10.1016/j.prrv.2019.06.001; Marchisio P, 2002, EMERG INFECT DIS, V8, P479; Mulholland K, 2007, LANCET, V370, P285, DOI 10.1016/S0140-6736(07)61130-1; Nisar MI, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3733-9; Otsuka T, 2013, PEDIATR INFECT DIS J, V32, P709, DOI 10.1097/INF.0b013e31828701ea; Pallares R, 2003, INT J ANTIMICROB AG, V22, pS15, DOI 10.1016/j.ijantimicag.2003.08.004; Schaumburg F, 2013, T ROY SOC TROP MED H, V107, P105, DOI 10.1093/trstmh/trs018; Schranz J, 2009, PROCEDIA VACCINOL, V1, P189, DOI 10.1016/j.provac.2009.07.032; Shakl JR, 2013, TRENDS MICROBIOL, V21, P129, DOI 10.1016/j.tim.2012.11.005; Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/ERV.12.53, 10.1586/erv.12.53]; Swedan SF, 2016, INDIAN J MED MICROBI, V34, P159, DOI 10.4103/0255-0857.176840; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Verani JR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191113; Voysey M, 2017, VACCINE, V35, P5850, DOI 10.1016/j.vaccine.2017.09.002; Wardlaw TM, 2006, PNEUMONIA FORGOTTEN; Weinberger DM, 2008, J INFECT DIS, V197, P1511, DOI 10.1086/587941	42	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1283	10.3390/vaccines9111283			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG0ID	34835213	Green Published, gold			2022-04-29	WOS:000724444600001
J	Beni, A; Mazzilli, S; Bellino, E; Costagliola, G; Ferretti, E; Lopalco, PL; Tavoschi, L; Peroni, DG				Beni, Alessandra; Mazzilli, Sara; Bellino, Elisabetta; Costagliola, Giorgio; Ferretti, Elena; Lopalco, Pier Luigi; Tavoschi, Lara; Peroni, Diego Giampietro			Uptake of Vaccinations among Children with Chronic Diseases Is Affected by Knowledge Gaps and Implementation Challenges in Italy	VACCINES			English	Article						immunization; child; pediatrician; knowledge; practice; vaccination attitude; chronic disease; vaccine; guidelines	INFLUENZA IMMUNIZATION; ILL CHILDREN; COVERAGE; ASTHMA	(1) Background: Children with chronic medical conditions may be at increased risk for severe complications related to vaccine-preventable infections. Therefore, additional booster doses or supplementary vaccines are recommended, over and above the routine immunization schedule for healthy children. The aim of this study was to investigate attitude, knowledge, and practices toward additional vaccinations for children affected by chronic conditions among pediatricians and parents. (2) Methods: This study is based on two surveys: (i) a national cross-sectional survey, targeting pediatrician working in hospitals or in the primary health sector; (ii) a local cross-sectional survey, targeting parents of children with a previous diagnosis of chronic disease. (3) Results: Despite the fact that most of the health professionals and parents interviewed had an overall positive vaccine attitude, most pediatricians did not show an adequate knowledge of additional vaccinations for children affected by chronic diseases. Moreover, the coverage of additional recommended vaccinations in chronic pediatric patients was low. (4) Conclusions: This research highlighted important existing challenges hampering optimal vaccination coverage among pediatric chronic patients, including knowledge gaps on tailored vaccination schedules among pediatricians and organizational issues. The ongoing review of the Italian national immunization plan is a not-to-be-missed-opportunity to include evidence-based, detailed, and comprehensive recommendations on vaccinations for children affected by chronic conditions.	[Beni, Alessandra; Bellino, Elisabetta; Costagliola, Giorgio; Ferretti, Elena; Peroni, Diego Giampietro] Univ Pisa, Dept Clin & Expt Med, Sect Pediat, I-56126 Pisa, Italy; [Mazzilli, Sara] Scuola Normale Super Pisa, I-56126 Pisa, Italy; [Mazzilli, Sara; Tavoschi, Lara] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Via San Zeno 35, I-56124 Pisa, Italy; [Lopalco, Pier Luigi] Univ Salento, Dept Sci Biol Technol & Environm, Piazza Tancredi 7, I-73100 Lecce, Italy		Peroni, DG (通讯作者)，Univ Pisa, Dept Clin & Expt Med, Sect Pediat, I-56126 Pisa, Italy.; Tavoschi, L (通讯作者)，Univ Pisa, Dept Translat Res & New Technol Med & Surg, Via San Zeno 35, I-56124 Pisa, Italy.	alessandrabeni95@gmail.com; sara.mazzill@gmail.com; elisabettabellino@libero.it; giorgio.costagliola@hotmail.com; e.ferretti@hotmail.it; p.lopalco@regione.puglia.it; lara.tavoschi@unipi.it; diego.peroni@unipi.it	Tavoschi, Lara/K-1729-2018; Peroni, Diego/K-8795-2016	Tavoschi, Lara/0000-0002-2217-4664; Mazzilli, Sarah/0000-0002-9187-2722; Costagliola, Giorgio/0000-0002-4160-3727; Peroni, Diego/0000-0002-0234-1373			Alauzet P, 2021, EUR J PEDIATR, V180, P303, DOI 10.1007/s00431-020-03751-z; Azienda Ospedaliero Universitaria Pisana, AZIENDA OSPEDALIERO; Calendario Vaccinale Della Regione Toscana e Direttive in Materia di Vaccinazioni, AGG 2019 VACC PLAN T; Crawford NW, 2011, EXPERT REV VACCINES, V10, P175, DOI 10.1586/ERV.10.157; Dati Statistici per il Territorio, REG TOSC STAT DAT LO; Dube E, 2014, HUM VACC IMMUNOTHER, V10, P2935, DOI 10.4161/21645515.2014.970498; Esposito S, 2006, VACCINE, V24, P5251, DOI 10.1016/j.vaccine.2006.03.059; Ferre F, 2014, HEALT SYST TRANSIT, V16, P1; Filia A, 2019, EUROSURVEILLANCE, V24, P8, DOI 10.2807/1560-7917.ES.2019.24.6.1800275; Gaglani M, 2001, PEDIATR INFECT DIS J, V20, P1155, DOI 10.1097/00006454-200112000-00012; Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074; Kaya A, 2017, ALLERGOL IMMUNOPATH, V45, P240, DOI 10.1016/j.aller.2016.08.003; Merckx J, 2016, VACCINE, V34, P750, DOI 10.1016/j.vaccine.2015.12.055; Ministero della Salute, PIAN NAZ PREV VACC 2; Napolitano F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040560; Pandolfi E, 2012, VACCINE, V30, P5172, DOI 10.1016/j.vaccine.2011.02.099; Pandolfi E, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-984; Pittet LF, 2021, EUR J PEDIATR, V180, P2035, DOI 10.1007/s00431-021-03997-1; Remy Vanessa, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27041	19	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1217	10.3390/vaccines9111217			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH9UK	34835148	gold, Green Published			2022-04-29	WOS:000725770300001
J	Haruyama, R; Okawa, S; Akaba, H; Obara, H; Fujita, N				Haruyama, Rei; Okawa, Sumiyo; Akaba, Hiroki; Obara, Hiromi; Fujita, Noriko			A Review of the Implementation Status of and National Plans on HPV Vaccination in 17 Middle-Income Countries of the WHO Western Pacific Region	VACCINES			English	Review						cervical cancer; HPV vaccination; Western Pacific Region	HUMAN-PAPILLOMAVIRUS VACCINATION; CERVICAL-CANCER PREVENTION; INTERVENTIONS	The World Health Organization's Western Pacific Region is responsible for one-fourth of the global cervical cancer burden, and nearly 90% of that burden is concentrated in middle-income countries (MICs). Applying a conceptual model of implementation of population-based interventions, we synthesized the current implementation status of human papillomavirus (HPV) vaccination and national plans that form the basis of its implementation in 17 MICs. We gathered information from a range of governmental documents, published studies, and global databases. For all available national cancer-related plans and immunization plans, we examined the description of HPV vaccination. We found that, as of July 2021, only four countries (24%) had a mature HPV vaccination program with a high first-dose coverage; three (18%) had introduced HPV vaccination, but needed further efforts to scale it up, seven (41%) had not been able to introduce it after conducting demonstration projects, and three (18%) did not have any experience in HPV vaccination. In the national plans, most of the countries recognized the importance of HPV vaccination, but only 10 (59%) provided an implementation strategy on how it would be introduced or scaled up. Countries with a mature program were more likely to have their implementation strategy detailed in their national cancer control plan. Successful implementation of HPV vaccination requires overcoming known challenges and having a clear national plan. Positioning HPV vaccination clearly in the overall national cancer control plan may be key to accelerating its nationwide implementation.	[Haruyama, Rei; Obara, Hiromi; Fujita, Noriko] Natl Ctr Global Hlth & Med, Bur Int Hlth Cooperat, Tokyo 1628655, Japan; [Okawa, Sumiyo] Natl Ctr Global Hlth & Med, Inst Global Hlth Policy Res, Tokyo 1628655, Japan; [Akaba, Hiroki] WHO, Dept Immunizat Vaccines & Biol, Life Course & Integrat EPI, CH-1211 Geneva, Switzerland		Haruyama, R (通讯作者)，Natl Ctr Global Hlth & Med, Bur Int Hlth Cooperat, Tokyo 1628655, Japan.	rharuyama@it.ncgm.go.jp; sokawa@it.ncgm.go.jp; akabah@who.int; h-obara@it.ncgm.go.jp; norikof@it.ncgm.go.jp		Obara, Hiromi/0000-0003-4789-4972	National Center for Global Health and Medicine Intramural Research Fund [20A08]	This research was funded by National Center for Global Health and Medicine Intramural Research Fund, grant number 20A08.	Aarons GA, 2011, ADM POLICY MENT HLTH, V38, P4, DOI 10.1007/s10488-010-0327-7; Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; Batmunkh T, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100175; Black E, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030061; Brisson M, 2020, LANCET, V395, P575, DOI 10.1016/S0140-6736(20)30068-4; Broutet N, 2013, J ADOLESCENT HEALTH, V53, P6, DOI 10.1016/j.jadohealth.2013.02.022; Bruni L, 2021, PREV MED, V144, DOI 10.1016/j.ypmed.2020.106399; Buang SN, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4602; Department of Health, 2017, PHIL STRAT PLAN PREV; Ferlay J, GLOBAL CANC OBSERVAT; Ferlay J., 2020, GLOBAL CANC OBSERVAT; Gallagher KE, 2018, VACCINE, V36, P4761, DOI 10.1016/j.vaccine.2018.02.003; Gallagher KE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177773; Garon J, 2019, VACCINE, V37, P1202, DOI 10.1016/j.vaccine.2018.12.052; Gavi the Vaccine Alliance, COUNT HUB; Government of Federated States of Micronesia, 2019, NATL STRAT PLAN ACT; Hanson CM, 2015, VACCINES-BASEL, V3, P408, DOI 10.3390/vaccines3020408; Harry T.J., 2017, CERVICAL CANC CARE H; Heffelfinger J, 2018, HPV VACCINATION W PA; Hindin MJ, 2015, J ADOLESCENT HEALTH, V56, P10, DOI 10.1016/j.jadohealth.2014.08.004; Minh HV, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2297-x; International Cancer Control Partnership, ICCP PORT THE ON STO; Jhpiego, 2016, IGN CHANG LANDSC HLT; Kumar S, 2021, INT J GYNECOL OBSTET, V152, P32, DOI 10.1002/ijgo.13482; La Vincente SF, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2579-3; Ladner J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-670; Ladner J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-370; LaMontagne DS, 2011, B WORLD HEALTH ORGAN, V89, P821, DOI [10.2471/BLT.11.08986, 10.2471/BLT.11.089862]; Ministry of Health, 2013, NCD EM RESP HLTH RMI; Ministry of Health, 2016, NATL STRAT PLAN CANC; Ministry of Health, 2018, NATL MULT ACT PLAN P; Ministry of Health, 2016, NATL IMM PROGR STRAT; Ministry of Health, 2018, UN JOINT GLOB PROGR; Ministry of Health, 2016, MED TERM STRAT PLAN; Ministry of Health, 2013, NATL IMM POL PROC MA; Ministry of Health, 2019, NATL ACT PLAN CERV C; Ministry of Health, 2016, NATL ACT PLAN PREV C; Ministry of Health, 2015, NATL STRAT PREV CONT; Ministry of Health, 2017, NATL INF DIS PREV CO; Ministry of Health, 2018, NATL NONC DIS CONTR; Ministry of Health, 2017, NATL NONC DIS STRAT; Ministry of Health, 2015, SUBPR CANC PREV CONT; Ministry of Health, 2014, NATL MULT ACT PLAN P; Ministry of Health, 2016, NONC DIS POL STRAT P; Ministry of Health, 2017, NATL PROGR NCD CONTR; Ministry of Health, 2016, COMPR MULT PLAN EXT; Ministry of Health and Human Services, 2017, NATL COMPR CANC CONT; Ministry of Health and Medical Services, 2015, NONC DIS STRAT PLAN; Ministry of Health and Medical Services, 2015, CERVICAL CANC SCREEN; Ministry of Health and Medical Services, 2019, MULT NATL NONC DIS S; Ministry of Health Medical Services, 2019, COMPR MULT PLAN IMM; Muhamad NA, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6316-6; Murillo R, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9607803; National Comprehensive Cancer Control Program Department of Health and Social Affairs, 2019, COMPR CANC CONTR PLA; National Department of Health, 2017, CANC ACT PRIOR 2017; National Department of Health, 2015, NATL MULT STRAT PLAN; National Department of Health, 2016, COMPR EPI MULT PLAN; National Health Commission, 2019, HLTH CHIN ACT CANC C; Obel J, 2015, Asian Pac J Cancer Prev, V16, P3435; Office of the People's Government of Ordos City China, 2020, NOT OFF PEOPL GOV OR; Office of the State Council, 2017, LONG TERM PLAN PREV; Philippines Department of Health, NATL CANC PREV CONTR; Philippines Department of Health, 2015, GUIDELINES IMPLEMENT; Philippines Department of Health, 2016, NATL IMM PROGR MAN O; Pineros M, 2021, PREV MED, V144, DOI 10.1016/j.ypmed.2020.106237; Romero Y, 2018, LANCET ONCOL, V19, pE546, DOI 10.1016/S1470-2045(18)30681-8; Sankaranarayanan R, 2019, LANCET ONCOL, V20, pE637, DOI 10.1016/S1470-2045(19)30531-5; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0; Simms KT, 2019, LANCET ONCOL, V20, P394, DOI 10.1016/S1470-2045(18)30836-2; Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001; Solomon Islands, COMPR MULT PLAN IMM; Tervonen H, 2017, CANCER EPIDEMIOL, V50, P184, DOI 10.1016/j.canep.2017.09.002; The World Bank, NEW COUNTR CLASS INC; Toh ZQ, 2021, JNCI CANCER SPECT, V5, DOI 10.1093/jncics/pkab011; Tsu VD, 2021, PREV MED, V144, DOI 10.1016/j.ypmed.2020.106335; UNAIDS, 2021, HIV EST UNC BOUNDS 1; UNICEF Supply Division, 2021, VACC PRIC DATA; United Nations Children's Fund, 2021, WHO UNICEF HUM PAP H; United Nations Department of Economic and Social Affairs population division, 2019, WORLD POP PROSP; United States Agency for International Development, 2018, NATL IMM PROGR UPD C; Vanska S, 2020, J INFECT DIS, V222, P948, DOI 10.1093/infdis/jiaa099; Waramin E.N.P., 2017, HPV VACCINATION PILO; WHO, WHO VACC PREV DIS MO; WHO, 2016, GUID INTR HPV VACC N; World Health Organization, GLOB HLTH OBS; World Health Organization, 2014, WHO UN GUID COMPR MU; World Health Organization, PREQ MED PROD IVDS M; World Health Organization, 2020, GLOB MARK STUD HPV V; World Health Organization, NONC DIS DOC REP; World Health Organization, 2018, VACC PRIC GAV FULL S; World Health Organization, 2020, GLOB STRAT ACC EL CE; World Health Organization, 2020, GLOB HLTH EST 2019 D; World Health Organization, 2020, WHO REP CANC SETT PR; World Health Organization (WHO), COUNTR; Xiamen Municipal Health Commission, 2020, NOT IMPL PLAN DOM BI; Zhao FH, 2019, LANCET, V393, P969, DOI 10.1016/S0140-6736(18)32849-6	96	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1355	10.3390/vaccines9111355			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XG5VZ	34835286	Green Published, gold			2022-04-29	WOS:000724821700001
J	Jeong, CG; Khatun, A; Nazki, S; Kim, SC; Noh, YH; Kang, SC; Lee, DU; Yang, MS; Shabir, N; Yoon, IJ; Kim, B; Won-Il Kim				Jeong, Chang-Gi; Khatun, Amina; Nazki, Salik; Kim, Seung-Chai; Noh, Yun-Hee; Kang, Sang-Chul; Lee, Dong-Uk; Yang, Myeon-Sik; Shabir, Nadeem; Yoon, In-Joong; Kim, Bumseok; Won-Il Kim			Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model	VACCINES			English	Article						porcine reproductive and respiratory syndrome; PRRSV; reproductive model; reproductive failure; PRRS vaccine; chimeric vaccine	RESPIRATORY SYNDROME VIRUS; RANDOM MUTAGENESIS LIBRARIES; BIOLOGICAL CHARACTERISTICS; NEUTRALIZATION EPITOPE; PROTEIN-REQUIREMENTS; STRUCTURAL GENES; INFECTIOUS CLONE; ENVELOPE PROTEIN; MEGAPRIMER PCR; EXPRESSING GP5	Despite the routine use of porcine reproductive and respiratory syndrome (PRRS)-modified live vaccines, serious concerns are currently being raised due to their quick reversion to virulence and limited cross-protection against divergent PRRS virus (PRRSV) strains circulating in the field. Therefore, a PRRS chimeric vaccine (JB1) was produced using a DNA-launched infectious clone by replacing open reading frames (ORFs) 3-6 with those from a mixture of two genetically different PRRSV2 strains (K07-2273 and K08-1054) and ORF1a with that from a mutation-resistant PRRSV strain (RVRp22) exhibiting an attenuated phenotype. To evaluate the safety and cross-protective efficacy of JB1 in a reproductive model, eight PRRS-negative pregnant sows were purchased and divided into four groups. Four sows in two of the groups were vaccinated with JB1, and the other 4 sows were untreated at gestational day 60. At gestational day 93, one vaccinated group and one nonvaccinated group each were challenged with either K07-2273 or K08-1054. All of the sows aborted or delivered until gestation day 115 (24 days post challenge), and the newborn piglets were observed up to the 28th day after birth, which was the end of the experiment. Overall, pregnant sows of the JB1-vaccinated groups showed no meaningful viremia after vaccination and significant reductions in viremia with K07-2273 and K08-1054, exhibiting significantly higher levels of serum virus-neutralizing antibodies than non-vaccinated sows. Moreover, the JB1-vaccinated groups did not exhibit any abortion due to vaccination and showed improved piglet viability and birth weight. The piglets from JB1-vaccinated sows displayed lower viral concentrations in serum and fewer lung lesions compared with those of the piglets from the nonvaccinated sows. Therefore, JB1 is a safe and effective vaccine candidate that confers simultaneous protection against two genetically different PRRSV strains.	[Jeong, Chang-Gi; Khatun, Amina; Nazki, Salik; Kim, Seung-Chai; Yang, Myeon-Sik; Shabir, Nadeem; Kim, Bumseok; Won-Il Kim] Jeonbuk Natl Univ, Coll Vet Med, Iksan 54596, South Korea; [Khatun, Amina] Sher E Bangla Agr Univ, Fac Anim Sci & Vet Med, Dept Pathol, Dhaka 1207, Bangladesh; [Nazki, Salik] Pirbright Inst, Pirbright GU24 0NF, England; [Noh, Yun-Hee; Lee, Dong-Uk; Yoon, In-Joong] ChoongAng Vaccine Lab, Daejeon 34055, South Korea; [Kang, Sang-Chul] Optipharm Inc, Anim Clin Evaluat Ctr, Cheongju 28158, South Korea; [Shabir, Nadeem] Sher E Kashmir Univ Agr Sci & Technol Kashmir, Fac Vet Sci & Anim Husb, Div Anim Biotechnol, Srinagar 190006, India		Won-Il Kim (通讯作者)，Jeonbuk Natl Univ, Coll Vet Med, Iksan 54596, South Korea.	jcg0102@gmail.com; amina.vet.sau.bd@gmail.com; saliknazki@gmail.com; leesor2@jbnu.ac.kr; sdocter@cavac.co.kr; supervet@naver.com; showsh233@gmail.com; 111@jbnu.ac.kr; drnadurose@gmail.com; jyoon@cavac.co.kr; bskims@jbnu.ac.kr; kwi0621@jbnu.ac.kr	Khatun, Amina/U-7070-2017; Shabir, Nadeem/AAY-9151-2020	Khatun, Amina/0000-0002-8384-1854; Shabir, Nadeem/0000-0001-6358-5251; Lee, Donguk/0000-0002-9431-0303; Kim, Won-Il/0000-0002-0465-0794; Nazki, Salik/0000-0002-2837-3365	"Cooperative Research Program for Agriculture Science and Technology Development" Rural Development Administration and Animal Disease Management Technology Development Program of the Ministry of Agriculture, Food and Rural Affairs, Republic of Korea [PJ01561102, 320060-02]	This research was carried out with the support of the "Cooperative Research Program for Agriculture Science and Technology Development (Project No. PJ01561102)" Rural Development Administration and Animal Disease Management Technology Development Program (320060-02) of the Ministry of Agriculture, Food and Rural Affairs, Republic of Korea.	Barranco I, 2012, VET IMMUNOL IMMUNOP, V149, P262, DOI 10.1016/j.vetimm.2012.07.011; Bautista EM, 1999, ARCH VIROL, V144, P1191, DOI 10.1007/s007050050578; Brinton MA, 2021, J GEN VIROL, V102, DOI 10.1099/jgv.0.001632; Cancel-Tirado SM, 2004, VET IMMUNOL IMMUNOP, V102, P249, DOI 10.1016/j.vetimm.2004.09.017; Cao QM, 2018, J VIROL, V92, DOI [10.1128/JVI.00007-18, 10.1128/jvi.00007-18]; Cavanagh D, 1997, ARCH VIROL, V142, P629; Charerntantanakul Wasin, 2012, World J Virol, V1, P23, DOI 10.5501/wjv.v1.i1.23; Choi HY, 2021, RES VET SCI, V135, P143, DOI 10.1016/j.rvsc.2021.01.012; CHRISTIANSON WT, 1993, CAN J VET RES, V57, P262; Chung HK, 2003, J COMP PATHOL, V129, P205, DOI 10.1016/S0021-9975(03)00036-7; CONZELMANN KK, 1993, VIROLOGY, V193, P329, DOI 10.1006/viro.1993.1129; Das PB, 2011, VIROLOGY, V410, P385, DOI 10.1016/j.virol.2010.12.002; Dwivedi V, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-45; Fang Y, 2010, VIRUS RES, V154, P61, DOI 10.1016/j.virusres.2010.07.030; Feigelstock DA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-402; Fix JS, 2010, LIVEST SCI, V132, P98, DOI 10.1016/j.livsci.2010.05.007; Gonin P, 1999, J VET DIAGN INVEST, V11, P20, DOI 10.1177/104063879901100103; Han K, 2013, VET J, V195, P313, DOI 10.1016/j.tvjl.2012.06.035; Han MY, 2014, VET MICROBIOL, V174, P279, DOI 10.1016/j.vetmic.2014.10.007; Harding JCS, 2017, VET MICROBIOL, V209, P114, DOI 10.1016/j.vetmic.2017.02.019; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; Jeong J, 2018, VET REC, V182, P485, DOI 10.1136/vr.104397; Jeong J, 2017, VET MICROBIOL, V208, P47, DOI 10.1016/j.vetmic.2017.07.016; Jiang WM, 2006, VET IMMUNOL IMMUNOP, V113, P169, DOI 10.1016/j.vetimm.2006.05.001; Jiang YB, 2006, VACCINE, V24, P2869, DOI 10.1016/j.vaccine.2005.12.049; Kang H, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1480-6; Khatun A, 2016, J VIROL, V90, P4454, DOI 10.1128/JVI.02836-15; Khatun A, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0330-z; Kim HK, 2012, TRANSBOUND EMERG DIS, V59, P62, DOI 10.1111/j.1865-1682.2011.01243.x; Kim WI, 2008, VIRUS GENES, V37, P380, DOI 10.1007/s11262-008-0278-1; Kim WI, 2008, J CLIN MICROBIOL, V46, P1758, DOI 10.1128/JCM.01927-07; Kim WI, 2013, VET MICROBIOL, V162, P10, DOI 10.1016/j.vetmic.2012.08.005; Ladinig A, 2015, VET RES, V46, DOI 10.1186/s13567-015-0251-7; Ladinig A, 2015, VIRUS RES, V203, P24, DOI 10.1016/j.virusres.2015.03.005; Lee CH, 2004, VET IMMUNOL IMMUNOP, V102, P189, DOI 10.1016/j.vetimm.2004.09.020; Lee JA, 2016, INFECT GENET EVOL, V40, P288, DOI 10.1016/j.meegid.2015.11.001; Lee JA, 2014, J MICROBIOL, V52, P345, DOI 10.1007/s12275-014-4074-4; Levi LI, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001163; Li X, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/416727; Lopez-Fuertes L, 2000, VIRUS RES, V69, P41, DOI 10.1016/S0168-1702(00)00172-6; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008; Miyazaki K, 2002, BIOTECHNIQUES, V33, P1033, DOI 10.2144/02335st03; Miyazaki K, 2011, METHOD ENZYMOL, V498, P399, DOI 10.1016/B978-0-12-385120-8.00017-6; Murtaugh MP, 2002, VIRAL IMMUNOL, V15, P533, DOI 10.1089/088282402320914485; Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635; Nielsen HS, 2003, J VIROL, V77, P3702, DOI 10.1128/JVI.77.6.3702-3711.2003; Nielsen HS, 2001, J GEN VIROL, V82, P1263, DOI 10.1099/0022-1317-82-6-1263; Okuda Y, 2008, J VET MED SCI, V70, P1017, DOI 10.1292/jvms.70.1017; Opriessnig T, 2002, J VIROL, V76, P11837, DOI 10.1128/JVI.76.23.11837-11844.2002; Park C, 2015, VET MICROBIOL, V177, P87, DOI 10.1016/j.vetmic.2015.02.020; Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100; Plagemann PGW, 2002, ARCH VIROL, V147, P2327, DOI 10.1007/s00705-002-0887-2; Ruedas-Torres I, 2021, VET MICROBIOL, V260, DOI 10.1016/j.vetmic.2021.109168; Shabir N, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8080240; Shi M, 2010, VIRUS RES, V154, P7, DOI 10.1016/j.virusres.2010.08.014; Sierra M, 2007, J VIROL, V81, P2012, DOI 10.1128/JVI.01606-06; Sun D, 2016, VACCINE, V34, P4335, DOI 10.1016/j.vaccine.2016.06.069; Tian DB, 2017, VACCINE, V35, P2427, DOI 10.1016/j.vaccine.2017.03.046; Truong HM, 2004, VIROLOGY, V325, P308, DOI 10.1016/j.virol.2004.04.046; Vanhee M, 2011, VACCINE, V29, P4794, DOI 10.1016/j.vaccine.2011.04.071; Vanhee M, 2009, VET RES, V40, DOI 10.1051/vetres/2009046; Wieringa R, 2004, J VIROL, V78, P13019, DOI 10.1128/JVI.78.23.13019-13027.2004; Wissink EHJ, 2005, J VIROL, V79, P12495, DOI 10.1128/JVI.79.19.12495-12506.2005; Wissink EHJ, 2003, J GEN VIROL, V84, P1535, DOI 10.1099/vir.0.18957-0; Yang Myeon-Sik, 2019, [Korean Journal of Veterinary Service, 한국가축위생학회지], V42, P201, DOI 10.7853/kjvs.2019.42.4.201; Yang S, 2020, COMP IMMUNOL MICROB, V69, DOI 10.1016/j.cimid.2020.101423; Zhou L, 2012, VIROLOGY, V434, P96, DOI 10.1016/j.virol.2012.09.005; Zhou YJ, 2006, VIRUS RES, V118, P98, DOI 10.1016/j.virusres.2005.11.019	69	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1258	10.3390/vaccines9111258			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XE5KE	34835189	gold, Green Published			2022-04-29	WOS:000723425600001
J	Rzymski, P; Camargo, CA; Fal, A; Flisiak, R; Gwenzi, W; Kelishadi, R; Leemans, A; Nieto, JJ; Ozen, A; Perc, M; Poniedzialek, B; Sedikides, C; Sellke, F; Skirmuntt, EC; Stashchak, A; Rezaei, N				Rzymski, Piotr; Camargo, Carlos A., Jr.; Fal, Andrzej; Flisiak, Robert; Gwenzi, Willis; Kelishadi, Roya; Leemans, Alexander; Nieto, Juan J.; Ozen, Ahmet; Perc, Matjaz; Poniedzialek, Barbara; Sedikides, Constantine; Sellke, Frank; Skirmuntt, Emilia C.; Stashchak, Anzhela; Rezaei, Nima			COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly	VACCINES			English	Article						immunology; pandemic; massive vaccinations; vaccine inequity; SARS-CoV-2	DELTA VARIANT PREDOMINANCE; HOSPITALIZATIONS; BNT162B2; DEATHS; HEALTH; STATES	Pursuing vaccinations against COVID-19 brings hope to limit the spread of SARS-CoV-2 and remains the most rational decision under pandemic conditions. However, it does not come without challenges, including temporary shortages in vaccine doses, significant vaccine inequity, and questions regarding the durability of vaccine-induced immunity that remain unanswered. Moreover, SARS-CoV-2 has undergone evolution with the emergence of its novel variants, characterized by enhanced transmissibility and ability to at least partially evade neutralizing antibodies. At the same time, serum antibody levels start to wane within a few months after vaccination, ultimately increasing the risk of breakthrough infections. This article discusses whether the administration of booster doses of COVID-19 vaccines is urgently needed to control the pandemic. We conclude that, at present, optimizing the immunity level of wealthy populations cannot come at the expense of low-income regions that suffer from vaccine unavailability. Although the efficiency of vaccination in protecting from infection may decrease over time, current data show that efficacy against severe disease, hospitalization, and death remains at a high level. If vaccine coverage continues at extremely low levels in various regions, including African countries, SARS-CoV-2 may sooner or later evolve into variants better adapted to evade natural and vaccine-induced immunity, ultimately bringing a global threat that, of course, includes wealthy populations. We offer key recommendations to increase vaccination rates in low-income countries. The pandemic is, by definition, a major epidemiological event and requires looking beyond one's immediate self-interest; otherwise, efforts to contain it will be futile.	[Rzymski, Piotr; Poniedzialek, Barbara] Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland; [Rzymski, Piotr; Camargo, Carlos A., Jr.; Fal, Andrzej; Kelishadi, Roya; Leemans, Alexander; Nieto, Juan J.; Ozen, Ahmet; Perc, Matjaz; Poniedzialek, Barbara; Sedikides, Constantine; Sellke, Frank; Stashchak, Anzhela; Rezaei, Nima] Universal Sci Educ & Res Network USERN, Tehran 1417614411, Iran; [Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Fal, Andrzej] Cardinal Stefan Wyszynski Univ, Coll Med, Warsaw Fac Med, PL-01938 Warsaw, Poland; [Flisiak, Robert] Med Univ Bialystok, Dept Infect Dis & Hepatol, PL-15540 Bialystok, Poland; [Gwenzi, Willis] Univ Zimbabwe, Dept Agr & Biosyst Engn, Biosyst & Environm Engn Res Grp, POB MP167, Harare, Zimbabwe; [Kelishadi, Roya] Isfahan Univ Med Sci, Child Growth & Dev Res Ctr, Res Inst Primordial Prevent Noncommunicable Dis, Dept Pediat, Esfahan 8174673441, Iran; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, PROVIDI Lab, NL-3584 CX Utrecht, Netherlands; [Nieto, Juan J.] Univ Santiago de Compostela, Inst Matemat, Santiago De Compostela 15782, Spain; [Ozen, Ahmet] Marmara Univ, Dept Pediat Allergy & Immunol, Sch Med, TR-34854 Istanbul, Turkey; [Perc, Matjaz] Univ Maribor, Fac Nat Sci & Math, Maribor 2000, Slovenia; [Perc, Matjaz] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung 404332, Taiwan; [Sedikides, Constantine] Univ Southampton, Ctr Res Self & Ident, Sch Psychol, Southampton SO17 1BJ, Hants, England; [Sellke, Frank] Brown Univ, Rhode Isl Hosp, Div Cardiothorac Surg, Alpert Med Sch, Providence, RI 02905 USA; [Skirmuntt, Emilia C.] Univ Oxford, Dept Zool, Peter Medawar Bldg Pathogen Res, Oxford OX1 3SY, England; [Stashchak, Anzhela] Kharkiv Natl Med Univ, Int Relat Off, UA-61000 Kharkiv, Ukraine; [Rezaei, Nima] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran 1417614411, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran 1417614411, Iran		Rzymski, P (通讯作者)，Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland.; Rzymski, P; Rezaei, N (通讯作者)，Universal Sci Educ & Res Network USERN, Tehran 1417614411, Iran.; Rezaei, N (通讯作者)，Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran 1417614411, Iran.; Rezaei, N (通讯作者)，Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran 1417614411, Iran.	rzymskipiotr@ump.edu.pl; ccamargo@partners.org; amfal@wp.pl; robert.flisiakl@gmail.com; wgwenzi@agric.uz.ac.zw; roya.kelishadi@gmail.com; aleemans@umcutrecht.nl; juanjose.nieto.roig@usc.es; ahmetozen_md@yahoo.com; matjaz.perc@gmail.com; bpon@ump.edu.pl; c.sedikides@soton.ac.uk; fsellke@lifespan.org; emilia.skirmuntt@zoo.ox.ac.uk; khnmu_stashchak@ukr.net; rezaei_nima@tums.ac.ir	Camargo, Carlos A./C-2145-2008; Perc, Matjaz/A-5148-2009; Rzymski, Piotr/I-2240-2012; Kelishadi, Roya/E-6154-2012; Flisiak, Robert/S-5356-2018; Rezaei, Nima/B-4245-2008; /R-6749-2017	Camargo, Carlos A./0000-0002-5071-7654; Perc, Matjaz/0000-0002-3087-541X; Rzymski, Piotr/0000-0002-4713-0801; Sedikides, Contantine/0000-0003-4036-889X; Kelishadi, Roya/0000-0001-7455-1495; sellke, frank/0000-0002-8886-801X; Flisiak, Robert/0000-0003-3394-1635; Fal, Andrzej/0000-0002-9675-7942; Poniedzialek, Barbara/0000-0002-1601-1703; Skirmuntt, Emilia/0000-0002-7302-0665; Rezaei, Nima/0000-0002-3836-1827; Gwenzi, Willis/0000-0003-3149-1052; /0000-0002-9065-1901	Slovenian Research AgencySlovenian Research Agency - Slovenia [P1-0403, J1-2457]	M.P. is supported by the Slovenian Research Agency (Grantt P1-0403 and J1-2457).	Ahmad T, 2021, HUM VACC IMMUNOTHER, V17, P2367, DOI 10.1080/21645515.2021.1886806; Amran MS, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.639041; Ayass M.A., 2021, IMPACT NEW SARS COV, DOI [10.1101/2021.09.21.21263898, DOI 10.1101/2021.09.21.21263898]; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bajema KL, 2021, MMWR-MORBID MORTAL W, V70, P1294, DOI 10.15585/mmwr.mm7037e3; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Benotmane I, 2021, JAMA-J AM MED ASSOC, V326, P1063, DOI 10.1001/jama.2021.12339; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Brosh-Nissimov T, 2021, CLIN MICROBIOL INFEC, V27, P1652, DOI 10.1016/j.cmi.2021.06.036; Burki TK, 2021, LANCET RESP MED, V9, pE83, DOI 10.1016/S2213-2600(21)00328-3; Centers for Disease Control and Prevention, RAT COVID 19 CAS DEA; Chia Po Ying, 2022, Clin Microbiol Infect, V28, DOI 10.1016/j.cmi.2021.11.010; Choi A, 2021, NAT MED, V27, P2025, DOI 10.1038/s41591-021-01527-y; Cobey S, 2021, NAT REV IMMUNOL, V21, P330, DOI 10.1038/s41577-021-00544-9; Contreras, 2021, FULL VACCINATION IMP, DOI [10.1101/2021.08.08.21261768, DOI 10.1101/2021.08.08.21261768]; De Gier B., 2021, RIVM COVID 19 EPIDEM, DOI [10.1101/2021.09.15.21263613, DOI 10.1101/2021.09.15.21263613]; Dyer O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2282; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; European Medicine Agency, SARS COV 2 DELT VAR; European Medicine Agency, ECDC EMA HIGHL CONS; European Medicine Agency, SARS COV 2 VAR 21 OC; European Medicine Agency, SPIK EMA REC BOOST; European Medicines Agency, COM SPIK EMA REC EXT; Flaxman A, 2021, LANCET, V398, P981, DOI 10.1016/S0140-6736(21)01699-8; Fowlkes A, 2021, MMWR-MORBID MORTAL W, V70, P1167, DOI 10.15585/mmwr.mm7034e4; Gaveniak T., 2021, MEDRXIV, DOI [10.1101/2021.06.10.21258647, DOI 10.1101/2021.06.10.21258647]; Gazit S., 2021, COMP SARS COV 2 NATU, DOI [10.1101/2021.08.24.21262415, DOI 10.1101/2021.08.24.21262415]; Grannis SJ, 2021, MMWR-MORBID MORTAL W, V70, P1291, DOI 10.15585/mmwr.mm7037e2; Gwenzi W, 2021, ENVIRON RES, V194, DOI 10.1016/j.envres.2020.110637; Haas EJ, 2022, LANCET INFECT DIS, V22, P357, DOI 10.1016/S1473-3099(21)00566-1; Hall VG, 2021, NEW ENGL J MED, V385, P1244, DOI 10.1056/NEJMc2111462; Hassan F, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2027; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; KFF, US INT COVID 19 VACC; Kozlov Max, 2021, Nature, DOI 10.1038/d41586-021-02516-4; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Lee J, 2020, LANCET CHILD ADOLESC, V4, P421, DOI 10.1016/S2352-4642(20)30109-7; Liu Y, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab124; Lockhart, 2021, 6 MONTH SAFETY EFFIC, DOI [10.1101/2021.07.28.21261159, DOI 10.1101/2021.07.28.21261159]; Mahase E, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2082; Martinez-Baz I, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.39.2100894; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Moghadas S.M., 2021, COVID 19 DEATHS HOSP, V2021, DOI [10.1101/2021.07.07.21260156, DOI 10.1101/2021.07.07.21260156]; Nanduri S, 2021, MMWR-MORBID MORTAL W, V70, P1163, DOI 10.15585/mmwr.mm7034e3; Nowakowska J, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110451; Our world in data, COR COVID 19 VACC; Pan H., 2021, IMMUNOGENICITY SAFET, DOI [10.1101/2021.07.23.21261026, DOI 10.1101/2021.07.23.21261026]; Phillips N, 2021, NATURE, V590, P382, DOI 10.1038/d41586-021-00396-2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pouwels KB., 2021, IMPACT DELTA VIRAL B, DOI [DOI 10.1101/2021.08.18.21262237V1, 10.1101/2021.08.18.21262237v1]; Purver, 2021, IMPACT SARS COV 2 VA, DOI [10.1101/2021.09.28.21264260, DOI 10.1101/2021.09.28.21264260]; Reardon S., WILL GIVING COVID BO; Riemersma K.K., 2021, SHEDDING INFECTIOUS, DOI [10.1101/2021.07.31.21261387, DOI 10.1101/2021.07.31.21261387]; Rouw A., TRACKING GLOBAL COVI; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070781; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Sadarangani M, 2021, NAT REV IMMUNOL, V21, P475, DOI 10.1038/s41577-021-00578-z; Sadoff J., 2021, DURABILITY ANTIBODY, DOI [10.1101/2021.08.25.21262569, DOI 10.1101/2021.08.25.21262569]; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Scobie HM, 2021, MMWR-MORBID MORTAL W, V70, P1284, DOI 10.15585/mmwr.mm7037e1; Shrotri M, 2021, LANCET, V398, P385, DOI 10.1016/S0140-6736(21)01642-1; Ssentongo P, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026664118; Tang P., 2021, BNT162B2 MRNA 1273 C, DOI [10.1101/2021.08.11.21261885, DOI 10.1101/2021.08.11.21261885V1, DOI 10.1101/2021.08.11.21261885]; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Tenforde MW, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab687, 10.1101/2021.07.08.21259776]; Teyssou E, 2021, J INFECTION, V83, pE1, DOI 10.1016/j.jinf.2021.08.027; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang Panpan, 2021, J Biosaf Biosecur, V3, P4, DOI 10.1016/j.jobb.2020.12.002; WHO, COVAX ANN NEW AGR PL; Yamayoshi S, 2021, ECLINICALMEDICINE, V32, DOI 10.1016/j.eclinm.2021.100734; Zahid MN, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105350	71	8	8	17	17	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1299	10.3390/vaccines9111299			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG7KN	34835230	Green Accepted, gold, Green Published			2022-04-29	WOS:000724927900001
J	Samel-Kowalik, P; Jankowski, M; Lisiecka-Bielanowicz, M; Ostrowska, A; Gujski, M; Kobuszewski, B; Pinkas, J; Raciborski, F				Samel-Kowalik, Piotr; Jankowski, Mateusz; Lisiecka-Bielanowicz, Mira; Ostrowska, Aurelia; Gujski, Mariusz; Kobuszewski, Bartosz; Pinkas, Jaroslaw; Raciborski, Filip			Factors Associated with Attitudes towards Seasonal Influenza Vaccination in Poland: A Nationwide Cross-Sectional Survey in 2020	VACCINES			English	Article						influenza; influenza vaccine; vaccine hesitancy; vaccines; Poland		We aimed to assess attitudes towards the influenza vaccine and factors associated with a willingness to vaccinate against seasonal influenza in Poland during the COVID-19 pandemic (flu season 2020/2021). This cross-sectional questionnaire-based study was carried out between 5 and 15 November 2020 on a representative nationwide sample of 1052 individuals aged 18+ in Poland. Of the respondents, 5.5% (95% CI: 4.3-7.0%) declared that they had already got vaccinated against influenza and 13.4% (95% CI: 11.4-15.6%) declared a willingness to vaccinate against influenza during the 2020/2021 season. Out of nine different factors analyzed in this study, only three were significantly associated with attitudes towards influenza vaccination. Participants aged 75 years and over (OR = 5.82; 95% CI: 2.63-12.85), as well as participants aged 60-74 years (OR = 2.43; 95% CI: 1.30-4.54), compared to those aged 19-29, had significantly higher odds of having a positive attitude towards seasonal influenza vaccination. Respondents who define themselves as completely religious unbelievers (OR = 4.34; 95% CI: 1.79-10.55), as well as Internet users (OR = 2.12; 95% CI: 1.30-3.47), had higher odds of having a positive attitude towards influenza vaccination. Despite the COVID-19 pandemic, the percentage of adults in Poland who already got vaccinated or declared a willingness to vaccinate against influenza remains low. This also applies to high-risk groups.	[Samel-Kowalik, Piotr; Lisiecka-Bielanowicz, Mira; Raciborski, Filip] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, PL-02091 Warsaw, Poland; [Jankowski, Mateusz; Ostrowska, Aurelia; Kobuszewski, Bartosz; Pinkas, Jaroslaw] Ctr Postgrad Med Educ, Sch Publ Hlth, PL-01826 Warsaw, Poland; [Gujski, Mariusz] Med Univ Warsaw, Dept Publ Hlth, PL-02097 Warsaw, Poland		Jankowski, M (通讯作者)，Ctr Postgrad Med Educ, Sch Publ Hlth, PL-01826 Warsaw, Poland.	piotr.samel@wum.edu.pl; mjankowski@cmkp.edu.pl; mira.bielanowicz@wum.edu.pl; aostrowska@cmkp.edu.pl; mariusz.gujski@wum.edu.pl; bkobuszewski@cmkp.edu.pl; jpinkas@cnakp.edu.pl; filip.raciborski@wum.edu.pl	Samel-Kowalik, Piotr/M-3239-2018; Gujski, Mariusz/A-3222-2019; Jankowski, Mateusz/N-7536-2018	Samel-Kowalik, Piotr/0000-0002-9047-0414; Gujski, Mariusz/0000-0002-2938-4795; Jankowski, Mateusz/0000-0002-7142-5167; Kobuszewski, Bartosz/0000-0001-5828-1341; Raciborski, Filip/0000-0003-0562-0260	National Center for Research and Development as part of the Strategic Program of Scientific Research and Development "Social and economic development of Poland in the conditions of globalizing markets" [GOSPOSTRATEG-II/0007/2020-00]	This research was funded by the National Center for Research and Development as part of the Strategic Program of Scientific Research and Development "Social and economic development of Poland in the conditions of globalizing markets", grant number GOSPOSTRATEG-II/0007/2020-00.	Anderson ML, 2020, ANN INTERN MED, V172, P445, DOI 10.7326/M19-3075; [Anonymous], 2021, J LAWS MINIST HLTH, V65; Arnold-Forster A, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1888; Bell DM, 2009, EMERG INFECT DIS, V15, P1963, DOI 10.3201/eid1512.091232; Centers for Disease Control and Prevention (CDC), HOW FLU SPREADS; Centre for Public Opinion Research, 1722016 CTR PUBL OP; Centre for Public Opinion Research, BS1692013 CTR PUBL O; Cheng Hui G, 2014, Shanghai Arch Psychiatry, V26, P371, DOI 10.11919/j.issn.1002-0829.214171; Czajka H, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124461; Czech M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217945; European Centre for Disease Prevention and Control, 2018, SEASONAL INFLUENZA V; European Centre for Disease Prevention and Control (ECDC), VACC SCHED POL REC V; European Centre for Disease Prevention and Control (ECDC), SEASONAL INFLUENZA V; Fournet N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5103-8; Kalucka S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18042105; Kalucka S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030516; Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y; Nessler K, 2014, VACCINE, V32, P7122, DOI 10.1016/j.vaccine.2014.10.026; Official website of the Government of Poland, OBT PESEL NUMB SERV; Opel DJ, 2009, ARCH PEDIAT ADOL MED, V163, P432, DOI 10.1001/archpediatrics.2009.42; Raciborski F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091000; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Shen SX, 2019, CAN FAM PHYSICIAN, V65, P175; The National Institute of Public Health-National Institute of Hygiene, JAK JEST POZ ZASZ PR; The National Institute of Public Health-National Institute of Hygiene, INFL INFL ILLN POL; The Polish National Program for Influenza Prevention, EXP CONS NEED INFL V; The Public Opinion Research Center, MAT METHODS; The Public Opinion Research Center, INF REL POL INH; Vemula SV, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8040096; Vrdelja M, 2018, EUR J PUBLIC HEALTH, V28, P934, DOI 10.1093/eurpub/cky114; WHO, INFL SEAS; World Health Organization, INFLUENZA; World Health Organization (WHO) Regional Office for Europe, INFL VACC COV EFF; Cuan-Baltazar JY, 2020, JMIR PUBLIC HLTH SUR, V6, P176, DOI 10.2196/18444	34	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1336	10.3390/vaccines9111336			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG6XC	34835267	Green Published, gold			2022-04-29	WOS:000724892400001
J	Sugawara, N; Yasui-Furukori, N; Fukushima, A; Shimoda, K				Sugawara, Norio; Yasui-Furukori, Norio; Fukushima, Atsuhito; Shimoda, Kazutaka			Attitudes of Medical Students toward COVID-19 Vaccination: Who Is Willing to Receive a Third Dose of the Vaccine?	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccine; hesitancy; medical student; attitudes		Medical students may come in contact with individuals infected with COVID-19 in their clinical rotations. A high level of acceptance of vaccination is needed for them to protect their health and the health of patients from this disease. The objectives of this study were to (1) obtain information on medical students' attitudes toward COVID-19 vaccination, (2) assess factors associated with students' attitudes, and (3) identify predictors of their willingness to receive a third dose of the COVID-19 vaccine. Using a cross-sectional design, we conducted a questionnaire survey of medical students in July 2021. For this survey, we employed a 15-item questionnaire specifically developed to assess the students' attitudes toward COVID-19 vaccination. Of the 742 distributed questionnaires, 496 (294 males and 202 females) were completed. Among all the participants, 89.1% (442/496) received the second dose of the vaccine, and 90.7% (450/496) indicated that they would hypothetically receive the COVID-19 vaccine in the future. Furthermore, 84.5% (419/496) of all the participants were willing to receive a third dose of the vaccine. Regarding willingness to receive a third dose of the COVID-19 vaccine, multiple logistic regression models showed that students' grade and their responses to Q1 (positive attitude toward vaccination), Q9 (belief in the protection offered by COVID-19 vaccination), Q10 (concern about the excessively rapid development of COVID-19 vaccines), Q12 (need for aspects of pre-pandemic life), and Q14 (concern about the sustainability of immunity) had significant associations with this outcome. Confidence in vaccines, relaxation of mobility restrictions, and concern about the sustainability of immunity motivate willingness to receive a third dose of the COVID-19 vaccine in medical students.	[Sugawara, Norio] Dokkyo Med Univ, Hlth Serv Ctr Students & Staff, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan; [Sugawara, Norio; Yasui-Furukori, Norio; Shimoda, Kazutaka] Dokkyo Med Univ, Sch Med, Dept Psychiat, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan; [Fukushima, Atsuhito] Dokkyo Med Univ, Sch Med, Dept Infect Control & Clin Lab Med, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan		Sugawara, N (通讯作者)，Dokkyo Med Univ, Hlth Serv Ctr Students & Staff, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.; Sugawara, N (通讯作者)，Dokkyo Med Univ, Sch Med, Dept Psychiat, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	nsuga3@dokkyomed.ac.jp; furukori@dokkyomed.ac.jp; atsufuku@dokkyomed.ac.jp; shimoda@dokkyomed.ac.jp		Sugawara, Norio/0000-0001-7058-664X			Azuma K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248935; Balan A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080854; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Graupensperger S, 2021, VACCINE, V39, P2060, DOI 10.1016/j.vaccine.2021.03.018; Harries AJ, 2021, BMC MED EDUC, V21, DOI 10.1186/s12909-020-02462-1; Herzog R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-154; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Kanyike AM, 2021, TROP MED HEALTH, V49, DOI 10.1186/s41182-021-00331-1; Kelekar AK, 2021, J AM DENT ASSOC, V152, P596, DOI 10.1016/j.adaj.2021.03.006; Krause PR, 2021, LANCET, V398, P1377, DOI 10.1016/S0140-6736(21)02046-8; Lancet Infect Dis, 2021, LANCET INFECT DIS, V21, P1193, DOI 10.1016/S1473-3099(21)00486-2; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Mahase E, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1659; Murayama H, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18168238; Nagasu M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247705; Okubo R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060662; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Petravic L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030247; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Rosental H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070783; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Sakai H, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.655022; Sovicova M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18136815; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Talarek E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070709; Tezuka M., 2021, J OCCUP ENVIRON MED, DOI [10.1097/JOM.0000000000002367, DOI 10.1097/JOM.0000000000002367]; World Health Organization, COVID 19 DASHB; Xu BY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070704; Yue L, 2022, J MED VIROL, V94, P35, DOI 10.1002/jmv.27334; Zhang JL, 2021, EMERG MICROBES INFEC, V10, P1598, DOI 10.1080/22221751.2021.1957401	32	7	7	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1295	10.3390/vaccines9111295			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH4EZ	34835226	Green Published, gold			2022-04-29	WOS:000725391000001
J	Suleman, M; ul Qamar, MT; Kiran; Rasool, S; Rasool, A; Albutti, A; Alsowayeh, N; Alwashmi, ASS; Aljasir, MA; Ahmad, S; Hussain, Z; Rizwan, M; Ali, SS; Khan, A; Wei, DQ				Suleman, Muhammad; ul Qamar, Muhammad Tahir; Kiran; Rasool, Samreen; Rasool, Aneela; Albutti, Aqel; Alsowayeh, Noorah; Alwashmi, Ameen S. S.; Aljasir, Mohammad Abdullah; Ahmad, Sajjad; Hussain, Zahid; Rizwan, Muhammad; Ali, Syed Shujait; Khan, Abbas; Wei, Dong-Qing			Immunoinformatics and Immunogenetics-Based Design of Immunogenic Peptides Vaccine against the Emerging Tick-Borne Encephalitis Virus (TBEV) and Its Validation through In Silico Cloning and Immune Simulation	VACCINES			English	Article						Tick-borne encephalitis (TBE); proteome mining; vaccine construct; in silico cloning; immune simulation	TOLL-LIKE RECEPTOR; MYCOBACTERIUM-TUBERCULOSIS; IXODES-RICINUS; PROTEINS; EPITOPE; FLAVIVIRUSES; RECOGNITION; PREVENTION; PREDICTION; PROTECTION	Pegivirus, HPgV, earlier known as Gb virus and hepatitis G virus, is an enveloped, positive-stranded RNA and lymphotropic virus classified into the Flaviviridae family. The transmission routes primarily involve blood products, with infections worldwide, leading up to 25% of persistent infections. To date, no effective therapeutic means are available to resolve Pegivirus infections. Effective vaccine therapeutics are the best alternative to manage this disease and any associated potential pandemic. Thus, whole proteome-based mining of immunogenic peptides, i.e., CTL (cytotoxic T lymphocytes), HTL (helper T lymphocytes) and B cell epitopes were mapped to design a vaccine ensemble. Our investigation revealed that 29 different epitopes impart a critical role in immune response induction, which was also validated by exploring its physiochemical properties and experimental feasibility. In silico expression and host immune simulation using an agent-based modeling approach confirmed the induction of both primary and secondary immune factors such as IL, cytokines and antibodies. The current study warrants further lab experiments to demonstrate its efficacy and safety.	[Suleman, Muhammad; Hussain, Zahid; Rizwan, Muhammad; Ali, Syed Shujait] Univ Swat, Ctr Biotechnol & Microbiol, Swat 19200, Pakistan; [ul Qamar, Muhammad Tahir] Guangxi Univ, Coll Life Sci & Technol, Nanning 530004, Peoples R China; [Kiran] Univ Agr Faisalabad, Dept Plant Breeding & Genet, Faisalabad 38000, Pakistan; [Rasool, Samreen] Govt Coll Univ, Dept Biochem, Lahore 54000, Pakistan; [Rasool, Aneela] Univ Okara, Dept Bot, Okara 56300, Pakistan; [Albutti, Aqel] Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, Buraydah 51452, Saudi Arabia; [Alsowayeh, Noorah] Majmaah Univ, Coll Educ, Dept Biol, Al Majmaah 15341, Saudi Arabia; [Alwashmi, Ameen S. S.; Aljasir, Mohammad Abdullah] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 51452, Saudi Arabia; [Ahmad, Sajjad] Abasyn Univ, Dept Hlth & Biol Sci, Peshawar 25120, Pakistan; [Khan, Abbas; Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biol Stat, Shanghai 200240, Peoples R China; [Wei, Dong-Qing] Shanghai Jiao Tong Univ, Shanghai Islamabad Belgrade Joint Innovat Ctr Ant, Joint Lab Int Cooperat Metab & Dev Sci, Minist Educ,State Key Lab Microbial Metab, Shanghai 200030, Peoples R China; [Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China; [Wei, Dong-Qing] Peng Cheng Lab, Vanke Cloud City Phase 1,Bldg 8,Xili St, Shenzhen 518055, Peoples R China		Albutti, A (通讯作者)，Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, Buraydah 51452, Saudi Arabia.; Wei, DQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biol Stat, Shanghai 200240, Peoples R China.; Wei, DQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Islamabad Belgrade Joint Innovat Ctr Ant, Joint Lab Int Cooperat Metab & Dev Sci, Minist Educ,State Key Lab Microbial Metab, Shanghai 200030, Peoples R China.; Wei, DQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China.; Wei, DQ (通讯作者)，Peng Cheng Lab, Vanke Cloud City Phase 1,Bldg 8,Xili St, Shenzhen 518055, Peoples R China.	m.tahirulqamar@hotmail.com; kiranzahra9999@gmail.com; samaruaf@yahoo.com; aneelarasool3@gmail.com; as.albutti@qu.edu.sa; n.alsowayeh@mu.edu.sa; sahmad@bs.qau.edu.pk	Khan, Abbas/AAF-2409-2020; Tahir ul Qamar, Muhammad/E-5803-2015	Tahir ul Qamar, Muhammad/0000-0003-4832-4250; Albutti, Aqel/0000-0001-8697-5340; Alwashmi, Ameen/0000-0002-7290-8945; Suleman, Muhammad/0000-0003-2914-1862	Deanship of Scientific Research, Qassim University; Key Research Area Grant of the Ministry of Science and Technology of China [2016YFA0501703]; National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32070662, 61832019, 32030063]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [19430750600]; SJTU JiRLMDS Joint Research Fund; Joint Research Funds for Medical and Engineering and Scientific Research at Shanghai Jiao Tong University [YG2021ZD02]	The researchers would like to thank the Deanship of Scientific Research, Qassim University, for funding the publication of this project. "Dong-Qing Wei is supported by grants from the Key Research Area Grant 2016YFA0501703 of the Ministry of Science and Technology of China, the National Science Foundation of China (Grant No. 32070662, 61832019, 32030063), the Science and Technology Commission of Shanghai Municipality (Grant No.: 19430750600), as well as SJTU JiRLMDS Joint Research Fund and Joint Research Funds for Medical and Engineering and Scientific Research at Shanghai Jiao Tong University (YG2021ZD02)".	Ahmad I., 2020, COMPUTATIONAL VACCIN, DOI [10.1080/07391102.2020.1845799, DOI 10.1080/07391102.2020.1845799]; Ali A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37070-z; Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495; Apellaniz B, 2015, ADV PROTEIN CHEM STR, V99, P15, DOI 10.1016/bs.apcsb.2015.03.002; Barrett PN, 2003, VACCINE, V21, pS41, DOI 10.1016/S0264-410X(02)00814-9; Baseer S, 2017, BIOLOGICALS, V50, P87, DOI 10.1016/j.biologicals.2017.08.004; Ben Beard C, 2012, EMERG INFECT DIS, V18, P1918, DOI 10.3201/eid1811.120675; Bhardwaj VK, 2021, J BIOMOL STRUCT DYN, V39, P3882, DOI 10.1080/07391102.2020.1772109; Biotech G, SNAPGENE VIEWER GLIC; Black M, 2010, EXPERT REV VACCINES, V9, P157, DOI [10.1586/erv.09.160, 10.1586/ERV.09.160]; Bogovic P, 2015, WORLD J CLIN CASES, V3, P430, DOI 10.12998/wjcc.v3.i5.430; Dai XY, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0081-6; Danielova V, 2010, VECTOR-BORNE ZOONOT, V10, P223, DOI 10.1089/vbz.2009.0020; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Gould EA, 2008, LANCET, V371, P500, DOI 10.1016/S0140-6736(08)60238-X; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Gul H, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104551; Heinze DM, 2012, J VIROL, V86, P8663, DOI 10.1128/JVI.01013-12; Heo L, 2018, P NATL ACAD SCI USA, V115, P13276, DOI 10.1073/pnas.1811364115; Hollingsworth SA, 2018, NEURON, V99, P1129, DOI 10.1016/j.neuron.2018.08.011; Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a; Hussain I, 2020, GENES IMMUN, V21, P409, DOI 10.1038/s41435-020-00120-6; Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201; Kathwate G. H., 2020, BIORXIV; Khan Abd Ullah, 2020, Journal of Network and Computer Applications, V164, P37, DOI 10.1016/j.jnca.2020.102686; Khan A, 2021, COMPUT BIOL MED, V133, DOI 10.1016/j.compbiomed.2021.104420; Khan A, 2021, J CELL PHYSIOL, V236, P7045, DOI 10.1002/jcp.30367; Khan A, 2021, PHYTOTHER RES, V35, P2841, DOI 10.1002/ptr.6998; Khan A, 2020, COMPUT STRUCT BIOTEC, V18, P2174, DOI 10.1016/j.csbj.2020.08.006; Khan A, 2020, INTERDISCIP SCI, V12, P335, DOI 10.1007/s12539-020-00381-9; Khan A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196484; Khan M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49354-z; Khan S, 2022, J BIOMOL STRUCT DYN, V40, P833, DOI 10.1080/07391102.2020.1819423; Khan SZ, 2019, INFECT GENET EVOL, V73, P390, DOI 10.1016/j.meegid.2019.06.006; Khatoon N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08842-w; Kollaritsch H, 2012, EXPERT REV VACCINES, V11, P1103, DOI [10.1586/ERV.12.86, 10.1586/erv.12.86]; Kovalev SY, 2017, INFECT GENET EVOL, V55, P159, DOI 10.1016/j.meegid.2017.09.014; Kubinski M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030451; Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424; Lee SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104351; Lengths MC, 2018, QUICK GUIDELINE COMP, V16, P75; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Lin WJ, 2005, SHOCK, V24, P206, DOI 10.1097/01.shk.0000180074.69143.77; Lindquist L, 2008, LANCET, V371, P1861, DOI 10.1016/S0140-6736(08)60800-4; Lu Z, 2008, VECTOR-BORNE ZOONOT, V8, P713, DOI 10.1089/vbz.2008.0028; Mansfield KL, 2009, J GEN VIROL, V90, P1781, DOI 10.1099/vir.0.011437-0; McGowin CL, 2017, J INFECT DIS, V216, pS382, DOI 10.1093/infdis/jix172; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Olsen AW, 2000, EUR J IMMUNOL, V30, P1724; Pandey M, 2015, J IMMUNOL, V194, P5915, DOI 10.4049/jimmunol.1500157; Peng J, 2011, PROTEINS, V79, P161, DOI 10.1002/prot.23175; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Proutski V, 1997, NUCLEIC ACIDS RES, V25, P1194, DOI 10.1093/nar/25.6.1194; RADDA A, 1969, ACTA VIROL, V13, P74; Rahlenbeck S, 2016, BRIT J GEN PRACT, V66, P492, DOI 10.3399/bjgp16X687013; Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862; Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p; Sabourin M, 2007, YEAST, V24, P39, DOI 10.1002/yea.1431; Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343; Saha Sudipto, 2007, V409, P387, DOI 10.1007/978-1-60327-118-9_29; Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y; Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Singh Shailza, 2007, J Bioinform Comput Biol, V5, P135, DOI 10.1142/S0219720007002564; Suleman M, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.692835; Suss J, 2008, Euro Surveill, V13; Taba P, 2017, EUR J NEUROL, V24, P1214, DOI 10.1111/ene.13356; ul Qamar MT, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00752-w; Uddin R, 2018, EUR J PHARM SCI, V114, P13, DOI 10.1016/j.ejps.2017.11.014; ul Qamar MT, 2021, COMPUT BIOL MED, V132, DOI 10.1016/j.compbiomed.2021.104389; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Wilkins MR, 1999, METH MOL B, V112, P531; Zaharieva N, 2019, CURR COMPUT-AID DRUG, V15, P398, DOI 10.2174/1573409915666190318121838	73	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1210	10.3390/vaccines9111210			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF2WP	34835141	Green Published, gold			2022-04-29	WOS:000723936700001
J	Colucci, M; De Santis, E; Totti, B; Miroballo, M; Tamiro, F; Rossi, G; Piepoli, A; De Vincentis, G; Greco, A; Mangia, A; Cianci, R; Di Mauro, L; Miscio, G; Giambra, V				Colucci, Mattia; De Santis, Elisabetta; Totti, Beatrice; Miroballo, Mattia; Tamiro, Francesco; Rossi, Giovanni; Piepoli, Ada; De Vincentis, Gabriella; Greco, Antonio; Mangia, Alessandra; Cianci, Rossella; Di Mauro, Lazzaro; Miscio, Giuseppe; Giambra, Vincenzo			Associations between Allelic Variants of the Human IgH 3 ' Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine	VACCINES			English	Article						COVID-19; vaccine; HS1.2 & nbsp;; IgH locus & nbsp;; antigen-specific B cells	INCREASED FREQUENCY; ANTIBODY-RESPONSE; T-CELLS; IMMUNOGLOBULIN; PSORIASIS; HS1.2; HS1,2	The escalation of Coronavirus disease 2019 (COVID-19) has required the development of safe and effective vaccines against the severe acute respiratory syndrome coronavirus 2-associated (SARS-CoV-2), which is the causative agent of the disease. Here, we determined the levels of antibodies, antigen-specific B cells, against a recombinant GFP-tagged SARS-CoV-2 spike (S) protein and total T and NK cell subsets in subjects up to 20 days after the injection of the BNT162b2 (Pfizer-BioNTech) vaccine using a combined approach of serological and flow cytometry analyses. In former COVID-19 patients and highly responsive individuals, a significant increase of antibody production was detected, simultaneous with an expansion of antigen-specific B cell response and the total number of NK-T cells. Additionally, through a genetic screening of a specific polymorphic region internal to the 3' regulatory region 1 (3'RR1) of human immunoglobulin constant-gene (IgH) locus, we identified different single-nucleotide polymorphic (SNP) variants associated with either highly or lowly responsive subjects. Taken together, these results suggest that favorable genetic backgrounds and immune profiles support the progression of an effective response to BNT162b2 vaccination.</p>	[Colucci, Mattia; De Santis, Elisabetta; Totti, Beatrice; Miroballo, Mattia; Tamiro, Francesco; Giambra, Vincenzo] Fdn IRCCS Casa Sollievo Sofferenza, Inst Stem Cell Biol Regenerat Med & Innovat Thera, I-71013 San Giovanni Rotondo, Italy; [Rossi, Giovanni] Fdn IRCCS Casa Sollievo Sofferenza, Dept Hematol, I-71013 San Giovanni Rotondo, Italy; [Rossi, Giovanni] Fdn IRCCS Casa Sollievo Sofferenza, Stem Cell Transplant Unit, I-71013 San Giovanni Rotondo, Italy; [Piepoli, Ada; De Vincentis, Gabriella] Fdn IRCCS Casa Sollievo Sofferenza, Hosp Hlth Dept, I-71013 San Giovanni Rotondo, Italy; [Greco, Antonio] Fdn IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Complex Struct Geriatr, I-71013 San Giovanni Rotondo, Italy; [Mangia, Alessandra] Fdn IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Liver Unit, I-71013 San Giovanni Rotondo, Italy; [Cianci, Rossella] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, IRCCS, Dipartimento Med & Chirurg Traslaz, I-00168 Rome, Italy; [Di Mauro, Lazzaro; Miscio, Giuseppe] Fdn IRCCS Casa Sollievo Sofferenza, Clin Lab Anal & Transfus Med, I-71013 San Giovanni Rotondo, Italy		Giambra, V (通讯作者)，Fdn IRCCS Casa Sollievo Sofferenza, Inst Stem Cell Biol Regenerat Med & Innovat Thera, I-71013 San Giovanni Rotondo, Italy.	m.colucci@operapadrepio.it; e.desantis@operapadrepio.it; beatrice.totti9@gmail.com; m.miroballo@css-mendel.it; f.tamiro@operapadrepio.it; giovannirossi.fr@gmail.com; a.piepoli@operapadrepio.it; g.devincentis@operapadrepio.it; a.greco@operapadrepio.it; a.mangia@operapadrepio.it; rossellacianci@gmail.com; l.dimauro@operapadrepio.it; g.miscio@operapadrepio.it; v.giambra@operapadrepio.it	Giambra, Vincenzo/ABG-8306-2021; colucci, mattia/AAD-5997-2022; De Santis, Elisabetta/AAB-5290-2022; colucci, mattia/AAD-5999-2022; Mangia, A/AAL-5357-2020; Greco, Antonio/C-1100-2017	Giambra, Vincenzo/0000-0003-2607-2080; colucci, mattia/0000-0001-5772-7313; Mangia, A/0000-0002-2600-3555; Greco, Antonio/0000-0001-6674-5468; Cianci, Rossella/0000-0001-5378-8442	Italian Ministry of HealthMinistry of Health, Italy [GR-2016-02361287]	This research was funded by the Italian Ministry of Health, grant number GR-2016-02361287.	Chan KK, 2020, SCIENCE, V369, P1261, DOI 10.1126/science.abc0870; Chew KL, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.05.036; Cianci R, 2016, EUR REV MED PHARMACO, V20, P3618; Cianci R, 2008, J INVEST DERMATOL, V128, P1920, DOI 10.1038/jid.2008.40; Cocomazzi G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080913; D'Addabbo P, 2018, GENE, V669, P47, DOI 10.1016/j.gene.2018.05.090; D'Addabbo P, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-71; Davila S, 2010, GENES IMMUN, V11, P232, DOI 10.1038/gene.2010.1; DiMuzio JM, 2021, VACCINE-X, V8, DOI 10.1016/j.jvacx.2021.100098; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Ebinger Joseph E, 2021, medRxiv, DOI 10.1101/2021.02.23.21252230; Fabricius D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080918; Frezza D, 2004, SCAND J GASTROENTERO, V39, P1083, DOI 10.1080/00365520410007999; Giambra V, 2005, GENE, V346, P105, DOI 10.1016/j.gene.2004.10.009; Giambra V, 2008, MOL CELL BIOL, V28, P6123, DOI 10.1128/MCB.00233-08; Giambra V, 2018, CELL STEM CELL, V23, P714, DOI 10.1016/j.stem.2018.08.018; Giambra V, 2009, J IMMUNOL, V183, P8280, DOI 10.4049/jimmunol.0902426; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Jones NK, 2021, ELIFE, V10, DOI 10.7554/eLife.68808; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Le Noir S, 2017, NUCLEIC ACIDS RES, V45, P5829, DOI 10.1093/nar/gkx203; Leadbetter EA, 2008, P NATL ACAD SCI USA, V105, P8339, DOI 10.1073/pnas.0801375105; Li JX, 2021, NAT MED, V27, P1062, DOI 10.1038/s41591-021-01330-9; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Lombardi A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.657711; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Ma XC, 2020, IMMUNITY, V53, P1315, DOI 10.1016/j.immuni.2020.11.015; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Miyasaka T, 2012, VACCINE, V30, P3304, DOI 10.1016/j.vaccine.2012.03.007; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Ovsyannikova IG, 2020, IMMUNOL REV, V296, P205, DOI 10.1111/imr.12897; Ovsyannikova IG, 2012, VACCINE, V30, P4182, DOI 10.1016/j.vaccine.2012.04.055; Pape KA, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109823; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2018, VACCINE, V36, P5350, DOI 10.1016/j.vaccine.2017.07.062; Poland GA, 2008, VACCINE, V26, P6183, DOI 10.1016/j.vaccine.2008.06.057; Puget N, 2015, MOL CELL BIOL, V35, P529, DOI 10.1128/MCB.00235-14; Reyes Raphael A, 2021, bioRxiv, DOI 10.1101/2021.09.24.461732; Rogers CH, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.633705; Sakharkar M, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abg6916; Tauzin Alexandra, 2021, bioRxiv, DOI 10.1101/2021.03.18.435972; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Xie JJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.715464; Xu ZM, 2012, NAT REV IMMUNOL, V12, P517, DOI 10.1038/nri3216; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	47	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1207	10.3390/vaccines9101207			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WT9NE	34696315	Green Published, gold			2022-04-29	WOS:000716182800001
J	Fakhroo, A; AlKhatib, HA; Al Thani, AA; Yassine, HM				Fakhroo, Aisha; AlKhatib, Hebah A.; Al Thani, Asmaa A.; Yassine, Hadi M.			Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity	VACCINES			English	Review						reinfection; antibodies; variants; coronavirus; SARS-CoV-2	SARS-COV-2 INFECTION; RESPONSES	The COVID-19 pandemic is still posing a devastating threat to social life and economics. Despite the modest decrease in the number of cases during September-November 2020, the number of active cases is on the rise again. This increase was associated with the emergence and spread of the new SARS-CoV-2 variants of concern (VOCs), such as the U.K. (B1.1.7), South Africa (B1.351), Brazil (P1), and Indian (B1.617.2) strains. The rapid spread of these new variants has raised concerns about the multiple waves of infections and the effectiveness of available vaccines. In this review, we discuss SARS-CoV-2 reinfection rates in previously infected and vaccinated individuals in relation to humoral responses. Overall, a limited number of reinfection cases have been reported worldwide, suggesting long protective immunity. Most reinfected patients were asymptomatic during the second episode of infection. Reinfection was attributed to several viral and/or host factors, including (i) underlying immunological comorbidities; (ii) low antibody titers due to the primary infection or vaccination; (iii) rapid decline in antibody response after infection or vaccination; and (iv) reinfection with a different SARS-CoV-2 variant/lineage. Infections after vaccination were also reported on several occasions, but mostly associated with mild or no symptoms. Overall, findings suggest that infection- and vaccine-induced immunity would protect from severe illness, with the vaccine being effective against most VOCs.	[Fakhroo, Aisha] Barzan Holdings, Res & Dev Dept, Doha 7178, Qatar; [AlKhatib, Hebah A.; Al Thani, Asmaa A.; Yassine, Hadi M.] Qatar Univ, Biomed Res Ctr, Doha 2713, Qatar		Yassine, HM (通讯作者)，Qatar Univ, Biomed Res Ctr, Doha 2713, Qatar.	asfakhroo@barzanholdings.com	YASSINE, HADI M./AAW-6475-2020	YASSINE, HADI M./0000-0001-7592-2788	QNRF [NPRP11S-1212-170092, QUHI-BRC20/21-1]	Funds were provided through QNRF, grant #NPRP11S-1212-170092 AND QUHI-BRC20/21-1.	Abu-Raddad LJ, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab083; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Abu-Raddad LJ, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100861; Bertollini R, 2021, JAMA-J AM MED ASSOC, V326, P185, DOI 10.1001/jama.2021.9970; CDC, COVID 19 BREAKTHR CA; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Chia WN, 2021, LANCET MICROBE, V2, pE240, DOI 10.1016/S2666-5247(21)00025-2; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Deng XD, 2021, CELL, V184, P3426, DOI 10.1016/j.cell.2021.04.025; dos Santos LA, 2021, J INFECTION, V82, P399, DOI 10.1016/j.jinf.2021.01.020; Elrashdy F, 2021, J BIOMOL STRUCT DYN, V39, P5831, DOI 10.1080/07391102.2020.1790426; Eyal Nir, 2021, Hum Vaccin Immunother, P1, DOI 10.1080/21645515.2021.1917240; Fontanet A, 2021, LANCET, V397, P952, DOI 10.1016/S0140-6736(21)00370-6; Guallar MP, 2020, INT J INFECT DIS, V97, P290, DOI 10.1016/j.ijid.2020.06.035; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Hao SR, 2020, J INFECT DIS, V222, P367, DOI 10.1093/infdis/jiaa311; Huynh A, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040697; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Keehner J, 2021, NEW ENGL J MED, V384, P1774, DOI 10.1056/NEJMc2101927; Kim YI, 2021, EMERG MICROBES INFEC, V10, P152, DOI 10.1080/22221751.2021.1872352; Lee PH, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1160; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Liu L, 2020, EMERG MICROBES INFEC, V9, P1664, DOI 10.1080/22221751.2020.1791738; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Lumley SF, 2021, CLIN INFECT DIS, V73, pE699, DOI 10.1093/cid/ciab004; Lynch KL, 2021, CLIN INFECT DIS, V72, P301, DOI 10.1093/cid/ciaa979; Ma H, 2021, SCI CHINA LIFE SCI, V64, P482, DOI 10.1007/s11427-020-1805-0; Mathew S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010011; Molina LP, 2020, OBSTET GYNECOL, V136, P838, DOI 10.1097/AOG.0000000000004086; Mulder M, 2021, CLIN INFECT DIS, V73, pE2841, DOI 10.1093/cid/ciaa1538; Park WB, 2015, EMERG INFECT DIS, V21, P2186, DOI 10.3201/eid2112.151421; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Resende PC, 2021, VIROL, V10; Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Singanayagam A, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.32.2001483; Tegally H., 2020, EMERGENCE RAPID SPRE, DOI [10.1101/2020.12.21.20248640, DOI 10.1101/2020.12.21.20248640]; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; To Kelvin Kai-Wang, 2021, Clin Infect Dis, V73, pe2946, DOI 10.1093/cid/ciaa1275; Van Elslande J, 2021, CLIN INFECT DIS, V73, P354, DOI 10.1093/cid/ciaa1330; Nonaka CKV, 2021, EMERG INFECT DIS, V27, P1522, DOI 10.3201/eid2705.210191; Volz E., 2021, TRANSMISSION SARS CO, DOI [10.1101/2020.12.30.20249034, DOI 10.1101/2020.12.30.20249034]; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Younuskunju, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1846, DOI 10.1093/CID/CIAA1846]; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037	51	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1168	10.3390/vaccines9101168			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP5FE	34696276	Green Published, gold			2022-04-29	WOS:000713156600001
J	Alvarez-Manzo, HS; Badillo-Davila, R; Olaya-Gomez, A; Gonzalez-de-Cossio-Tello, B; Cardoso-Arias, R; Gamboa-Balzaretti, ES; Baranzini-Rogel, CD; Garcia-Garnica, G; Hernandez-Corrales, LE; Linares-Koloffon, CA				Alvarez-Manzo, Hector S.; Badillo-Davila, Rafael; Olaya-Gomez, Alejandro; Gonzalez-de-Cossio-Tello, Barbara; Cardoso-Arias, Rafael; Gamboa-Balzaretti, Emilio S.; Baranzini-Rogel, Carlos D.; Garcia-Garnica, Gabriel; Hernandez-Corrales, Luis E.; Linares-Koloffon, Carlos A.			COVID-19 Vaccine Intention among Rural Residents in Mexico: Validation of a Questionnaire	VACCINES			English	Article						COVID-19; COVID-19 vaccine; vaccine intention; vaccine hesitancy; questionnaire validation; rural population; pilot study; Mexico; Latin America		The COVID-19 pandemic forced the scientific community and the pharmaceutical industry to develop new vaccines, in an attempt to reach herd immunity and stop the SARS-CoV-2 from spreading. However, to ensure vaccination among the general population, COVID-19 vaccine intention must be measured. So far, no studies have focused on rural residents in Latin America, which represent approximately 20% of the population of this geographical region. In this study, we present the validation of a self-developed questionnaire, which was validated in a pilot study with 40 Spanish-speaking Mexican rural residents in the state of Guerrero, Mexico. In this study, we describe the chronological validation of the questionnaire, including the assessment of its internal consistency and temporal reliability, which we measured with the Cronbach's alpha and Spearman's rank correlation coefficient, respectively. After the psychometrical analysis, we were able to validate a 20-item questionnaire, which intends to assess vaccine intention among the rural population. Aiming to develop a comprehensive policy and vaccination strategies, we hope this instrument provides valuable insight regarding COVID-19 vaccination willingness across rural communities in Mexico and Latin America. Finally, if we want to reach worldwide herd immunity, it is important to understand rural residents' position towards COVID-19 vaccination.	[Alvarez-Manzo, Hector S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Alvarez-Manzo, Hector S.; Badillo-Davila, Rafael; Gonzalez-de-Cossio-Tello, Barbara; Cardoso-Arias, Rafael; Linares-Koloffon, Carlos A.] Invest Comunitaria & Implementac Salud AC, Mexico City 01900, DF, Mexico; [Alvarez-Manzo, Hector S.; Cardoso-Arias, Rafael; Gamboa-Balzaretti, Emilio S.; Baranzini-Rogel, Carlos D.; Garcia-Garnica, Gabriel; Hernandez-Corrales, Luis E.; Linares-Koloffon, Carlos A.] Clin MAS Med & Asistencia Social AC, Tlapa 41304, Mexico; [Olaya-Gomez, Alejandro] Univ Washington, Dept Stat, Seattle, WA 98195 USA; [Gamboa-Balzaretti, Emilio S.; Baranzini-Rogel, Carlos D.; Garcia-Garnica, Gabriel; Hernandez-Corrales, Luis E.] Univ Panamer, Sch Med, Mexico City 03920, DF, Mexico; [Linares-Koloffon, Carlos A.] Univ New Mexico, Coll Populat Hlth, Albuquerque, NM 87131 USA		Alvarez-Manzo, HS (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.; Alvarez-Manzo, HS (通讯作者)，Invest Comunitaria & Implementac Salud AC, Mexico City 01900, DF, Mexico.; Alvarez-Manzo, HS (通讯作者)，Clin MAS Med & Asistencia Social AC, Tlapa 41304, Mexico.	halvare3@jhu.edu; rafa4554@gmail.com; olaya19@uw.edu; barbara.bgdc@gmail.com; rcardoso@mas.org.mx; esgb.1995@gmail.com; carlos_baranzini4@hotmail.com; gagg1710@hotmail.com; eliuduisa@hotmail.com; clinareskoloffon@salud.unm.edu		Badillo-Davila, Rafael/0000-0002-7174-6198; Alvarez Manzo, Hector Salvador/0000-0002-6118-1066			Akarsu B, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13891; Ali I, 2020, MED ANTHROPOL, V39, P376, DOI 10.1080/01459740.2020.1745481; [Anonymous], 2021, KFF COVID 19 VACC MO; [Anonymous], 2020, CENSO POBLACION VIVI; Boparai JK, 2018, CURR CLIN PHARMACOL, V13, P210, DOI 10.2174/1574884713666180807151328; Burki T, 2021, LANCET INFECT DIS, V21, P33, DOI 10.1016/S1473-3099(20)30949-X; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; de Leon-Martinez LD, 2020, SCI TOTAL ENVIRON, V733, DOI 10.1016/j.scitotenv.2020.139357; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fisk RJ, 2021, GHJ, V5, P51, DOI [10.1016/j.glohj.2021.02.005, DOI 10.1016/J.GLOHJ.2021.02.005]; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Guzman-Holst A, 2020, VACCINE, V38, P470, DOI 10.1016/j.vaccine.2019.10.088; Harrison AG, 2020, TRENDS IMMUNOL, V41, P1100, DOI 10.1016/j.it.2020.10.004; Ho HY, 2020, INTERNET INTERV, V22, DOI 10.1016/j.invent.2020.100350; Instituto Nacional de Estadistica y Geografia (INEGI), LENGUA INDIGENA; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Liu YZ, 2020, J MED ETHICS, V46, P499, DOI 10.1136/medethics-2020-106516; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Olagoke AA, 2021, J RELIG HEALTH, V60, P65, DOI 10.1007/s10943-020-01090-9; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Polit DF, 2006, RES NURS HEALTH, V29, P489, DOI 10.1002/nur.20147; Prion S, 2014, CLIN SIMUL NURS, V10, P535, DOI 10.1016/j.ecns.2014.07.005; Rattray J, 2007, J CLIN NURS, V16, P234, DOI 10.1111/j.1365-2702.2006.01573.x; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Urrunaga-Pastor D, 2021, TRAVEL MED INFECT DI, V41, DOI 10.1016/j.tmaid.2021.102059; World Health Organization, TIMEL WHOS RESP COVI; World Health Organization (WHO), 2020, WHO CORONAVIRUS COVI; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	38	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							952	10.3390/vaccines9090952			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ3FR	34579189	Green Published, gold			2022-04-29	WOS:000702094700001
J	Guzman-Martinez, O; Guardado, K; de Guevara, EL; Navarro, S; Hernandez, C; Zenteno-Cuevas, R; Montero, H				Guzman-Martinez, Oscar; Guardado, Kathia; Ladron de Guevara, Elsa; Navarro, Saturnino; Hernandez, Crescencio; Zenteno-Cuevas, Roberto; Montero, Hilda			IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population	VACCINES			English	Article						SARS-CoV-2; vaccines; BNT162b2; Ad5-nCoV; antibodies; adverse effects		SARS-CoV-2 has rapidly generated a pandemic. Vaccines are currently being rolled out to control the viral spread and prevent deaths. Emergency vaccines, using new platforms, have been approved. Their effectiveness, safety and immunogenicity in different populations are not fully known. This study aimed to discover the immunogenicity of the messenger ribonucleic acid (mRNA) BNT162b2 and adenovirus vector Ad5-nCoV vaccines through IgG antibody generation against subunit 1 of protein S (S1 IgG) and assess the side effects of the vaccines. A total of 115 vaccinated people were included, 61 of whom received the BNT162b2 vaccine, while 54 received Ad5-nCoV. Measurements of S1 IgG antibodies were carried out using the enzyme-linked immunosorbent assay (ELISA) technique. The BNT162b2 vaccine generated S1 IgG antibodies in 80.3% of the participants after the first dose. The number of seropositive participants increased to 98.36% with the administration of the second dose. The Ad5-nCoV vaccine generated S1 IgG antibodies in 88.89% of those vaccinated. Women generated more antibodies when administered either vaccine. There were no serious adverse effects from vaccination. In conclusion, not all participants had detectable S1 IgG antibodies. The Ad5-nCoV vaccine presented the most seronegative cases. The studied vaccines were shown to be safe.	[Guzman-Martinez, Oscar; Guardado, Kathia; Ladron de Guevara, Elsa; Zenteno-Cuevas, Roberto; Montero, Hilda] Univ Veracruzana, Inst Salud Publ, Xalapa 91190, Veracruz, Mexico; [Guzman-Martinez, Oscar; Guardado, Kathia] Univ Veracruzana, Ctr Invest Biomed, Xalapa 91190, Veracruz, Mexico; [Navarro, Saturnino; Hernandez, Crescencio] Univ Veracruzana, Fac Med, Xalapa 91010, Veracruz, Mexico		Montero, H (通讯作者)，Univ Veracruzana, Inst Salud Publ, Xalapa 91190, Veracruz, Mexico.	oscarguzmanmtz@yahoo.com; kathia.aguardado@gmail.com; elsaladron@uv.mx; snavarro@uv.mx; cosorio@uv.mx; rzenteno@uv.mx; hmontero@uv.mx	ZENTENO-CUEVAS, ROBERTO/A-7152-2012	ZENTENO-CUEVAS, ROBERTO/0000-0001-9597-127X; Aguilar Guardado, Kathia Liliana/0000-0003-4658-0787; Montero, Hilda/0000-0001-8090-4103	CONACYT, MexicoConsejo Nacional de Ciencia y Tecnologia (CONACyT) [312487]; Direccion General de Investigaciones, Direccion General de Desarrollo Academico e Innovacion Educativa and Direccion General del Area Academica de Ciencias de la Salud at the Universidad Veracruzana	This research was partially funded by CONACYT, Mexico (grant number 312487). The APC was funded by Direccion General de Investigaciones, Direccion General de Desarrollo Academico e Innovacion Educativa and Direccion General del Area Academica de Ciencias de la Salud at the Universidad Veracruzana.	Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Angeles C.M., HAN MUERTO 1183 PERS; Bajaj V, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.571416; Birhane M, 2021, MMWR-MORBID MORTAL W, V70, P792, DOI 10.15585/mmwr.mm7021e3; Bradley T, 2021, NEW ENGL J MED, V384, P1959, DOI 10.1056/NEJMc2102051; (CDC) Centros para el Control y la Prevencoin de Enfermedades, VIS GEN SEG VAC CONT; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Chen J, 2021, BIOSCI TRENDS, V15, P126, DOI 10.5582/bst.2021.01092; Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Elezkurtaj S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82862-5; FDA, EUR ANTI SARS COV 2; Figueiredo-Campos P, 2020, EUR J IMMUNOL, V50, P2025, DOI 10.1002/eji.202048970; Garcia LF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01441; Gostin LO, 2020, LANCET INFECT DIS, V20, pE11, DOI 10.1016/S1473-3099(19)30558-4; Grigoryan L, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101422; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Harvala H, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.28.2001260; Keehner J, 2021, NEW ENGL J MED, V384, P1774, DOI 10.1056/NEJMc2101927; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Mehew J, 2020, EUROSURVEILLANCE, V25, DOI 10.2807/1560-7917.ES.2020.25.45.2001754; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Salud O.M.D.L., OMS INCLUYE OTRA VAC; Salud S.D., CALENDARIO VACUNACIO; Salud S.D., ESTATUS REGULATORIO; Valdivia A, 2021, EUR J CLIN MICROBIOL, V40, P485, DOI 10.1007/s10096-020-04128-8; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; WHO, WHO COR COVID 19 DAS; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	34	2	2	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							999	10.3390/vaccines9090999			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3EI	34579236	gold, Green Published			2022-04-29	WOS:000702091100001
J	Lim, XR; Leung, BP; Ng, CYL; Tan, JWL; Chan, GYL; Loh, CM; Tan, GL; Goh, VHH; Wong, LT; Chua, CR; Tan, SC; Lee, SSM; Howe, HS; Thong, BYH; Leong, KP				Lim, Xin Rong; Leung, Bernard Pui; Ng, Carol Yee Leng; Tan, Justina Wei Lynn; Chan, Grace Yin Lai; Loh, Chien Mei; Tan, Gwendolyn Li Xuan; Goh, Valerie Hui Hian; Wong, Lok To; Chua, Chong Rui; Tan, Sze Chin; Lee, Samuel Shang Ming; Howe, Hwee Siew; Thong, Bernard Yu Hor; Leong, Khai Pang			Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination	VACCINES			English	Article						COVID-19; vaccine; anaphylaxis; antibodies; cytokines		Anaphylactic reactions were observed after Singapore's national coronavirus disease 2019 (COVID-19) vaccination programme started in December 2020. We report the clinical and laboratory features of three patients in our institution who developed anaphylactic reactions after receiving the Pifzer BNT162b2 vaccine. IgM and IgG antibodies, but not IgE antibodies to the Pfizer BNT162b2 vaccine, were detected in all subjects. Similarly, mild to high elevated levels of anti-polyethylene glycol (PEG) IgG (1035-19709 U/mL, vs. vaccine-naive < 265 U/mL, vaccine-tolerant < 785 U/mL) and IgM (1682-5310 U/mL, vs. vaccine-naive < 1011 U/mL, vaccine-tolerant < 1007 U/mL) were detected in two out of three patients via commercial ELISA. High levels of serum anaphylatoxin C3a (79.0 +/- 6.3 mu g/mL, mean +/- SD, vs. normal < 10 mu g/mL) were observed in all three patients during the acute phase of the reaction, while tryptase levels, a marker of mast cell activation, were not elevated. Finally, one patient with the highest levels of anti-PEG IgG, IgM, and anti-Pfizer BNT162b2 IgG and IgM exhibited an enhanced Th2 cytokine serum profile during an acute reaction, with high levels of IL-4 (45.7 pg/mL, vs. vaccine-naive/tolerant < 2.30 pg/mL), IL-33 (86.4 pg/mL, vs. vaccine-naive/tolerant < 5.51 pg/mL) and IL-10 (22.9 pg/mL, vs. vaccine-naive/tolerant < 12.49 pg/mL) diminishing over time following corticosteroid treatment. Taken together, we propose these cases of anaphylaxis described are driven by a complement activation-related pseudoallergy (CAPRA), rather than classical IgE-mediated mechanisms.	[Lim, Xin Rong; Leung, Bernard Pui; Tan, Justina Wei Lynn; Chan, Grace Yin Lai; Tan, Sze Chin; Lee, Samuel Shang Ming; Howe, Hwee Siew; Thong, Bernard Yu Hor; Leong, Khai Pang] Tan Tock Seng Hosp, Dept Rheumatol Allergy & Immunol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore; [Leung, Bernard Pui] Singapore Inst Technol, Hlth & Social Sci, Singapore 138683, Singapore; [Ng, Carol Yee Leng; Loh, Chien Mei; Tan, Gwendolyn Li Xuan; Goh, Valerie Hui Hian; Wong, Lok To; Chua, Chong Rui; Leong, Khai Pang] Tan Tock Seng Hosp, Clin Immunol Lab, Singapore 308433, Singapore		Lim, XR (通讯作者)，Tan Tock Seng Hosp, Dept Rheumatol Allergy & Immunol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	xin_rong_lim@ttsh.com.sg; bernard.p.leung@gmail.com; carol_ng@ttsh.com.sg; justina_tan@ttsh.com.sg; grace_yl_chan@ttsh.com.sg; chien_mei_loh@ttsh.com.sg; Gwendolyn_TAN@ttsh.com.sg; Hui_Hian_Valerie_GOH@ttsh.com.sg; Lok_To_WONG@ttsh.com.sg; Chong_Rui_CHUA@ttsh.com.sg; sze_chin_tan@ttsh.com.sg; samuel_lee@ttsh.com.sg; Howe_hwee_siew@ttsh.com.sg; bernard_thong@ttsh.com.sg; khai_pang_leong@ttsh.com.sg	Leung, Bernard/O-2409-2013	Leung, Bernard/0000-0002-1119-4934; Lim, Xin Rong/0000-0002-1167-353X	Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital; National Centre for Infectious Diseases, Singapore [FY2021LXR]	\This work is supported by the research fund of the Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, and a research grant from the National Centre for Infectious Diseases, Singapore, Catalyst Grant #FY2021LXR.	Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Health Sciences Authority Singapore, INT AUTH PFIZ BIONTE; Health Sciences Authority Singapore, MICR WORD HSAS SAF U; Health Sciences Authority Singapore, HSA GRANTS INT AUTH; Hong L, 2020, J PHARMACOL TOX MET, V102, DOI 10.1016/j.vascn.2020.106678; Klimek L, 2021, ALLERGY, V76, P3307, DOI 10.1111/all.14794; Mohamed M, 2019, SCI TECHNOL ADV MAT, V20, P710, DOI 10.1080/14686996.2019.1627174; Risma KA, 2021, J ALLERGY CLIN IMMUN, V147, P2075, DOI 10.1016/j.jaci.2021.04.002; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Stone SF, 2009, J ALLERGY CLIN IMMUN, V124, P786, DOI 10.1016/j.jaci.2009.07.055	12	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							974	10.3390/vaccines9090974			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3LE	34579211	Green Published, gold			2022-04-29	WOS:000702109100001
J	Mitra, T; Bramberger, B; Bilic, I; Hess, M; Liebhart, D				Mitra, Taniya; Bramberger, Beatrice; Bilic, Ivana; Hess, Michael; Liebhart, Dieter			Vaccination against the Protozoan Parasite Histomonas meleagridis Primes the Activation of Toll-like Receptors in Turkeys and Chickens Determined by a Set of Newly Developed Multiplex RT-qPCRs	VACCINES			English	Article						pro-inflammatory cytokines; extracellular pathogen; innate immune response; poultry; blackhead disease; histomonosis	EXPERIMENTAL-INFECTION; EXPRESSION; MACROPHAGES; LIGANDS; CELLS; CECUM; PCR; OLD	Histomonosis in turkeys and chickens is caused by the extracellular parasite Histomonas meleagridis, but the outcome of the disease varies depending on the host species. So far, studies on the immune response against histomonosis focus mainly on different traits of the adaptive immune system. Activation of toll like receptors (TLR) leads to the interplay between cells of innate and adaptive immunity with consequences on B and T cell clonal expansion. Therefore, the present investigation focused on the interaction of virulent and/or attenuated histomonads with the innate immune system of turkeys and chickens at 4, 10, 21 days post inoculation. The expression of TLRs (TLR1A, 1B, 2A, 2B, 3, 4, 5, 6(Tu), 7, 13(Tu) and 21(Ch)) and pro-inflammatory cytokines (IL1 beta and IL6) were analysed in caecum and spleen samples by RT-qPCR. Most frequent significant changes in expression levels of TLRs were observed in the caecum following infection with virulent parasites, an effect noticed to a lower degree in tissue samples from birds vaccinated with attenuated parasites. TLR1B, 2B and 4 showed a continuous up-regulation in the caecum of both species during infection or vaccination, followed by challenge with virulent parasites. Vaccinated birds of both species showed a significant earlier change in TLR expression following challenge than birds kept non-vaccinated but challenged. Expression of TLRs and pro-inflammatory cytokines were associated with severe inflammation of diseased birds in the local organ caecum. In the spleen, changes in TLRs and pro-inflammatory cytokines were less prominent and mainly observed in turkey samples. In conclusion, a detailed comparison of TLRs and pro-inflammatory cytokines of the innate immune system following inoculation with attenuated and/or virulent H. meleagridis of two avian host species provides an insight into regulative mechanisms of TLRs in the development of protection and limitation of the disease.	[Mitra, Taniya; Bramberger, Beatrice; Bilic, Ivana; Hess, Michael; Liebhart, Dieter] Univ Vet Med, Dept Farm Anim & Vet Publ Hlth, Clin Poultry & Fish Med, A-1210 Vienna, Austria; [Hess, Michael] Univ Vet Med, Christian Doppler Lab Innovat Poultry Vaccines IP, A-1210 Vienna, Austria		Mitra, T (通讯作者)，Univ Vet Med, Dept Farm Anim & Vet Publ Hlth, Clin Poultry & Fish Med, A-1210 Vienna, Austria.	taniya.mitra@vetmeduni.ac.at; 1245157@students.vetmeduni.ac.at; ivana.bilic@vetmeduni.ac.at; michael.hess@vetmeduni.ac.at; dieter.liebhart@vetmeduni.ac.at		Mitra, Taniya/0000-0003-0214-0755; Hess, Michael/0000-0002-6991-0120	INPOMED (Innovations in Poultry Medicine) project, which is funded by the European Regional Development Fund, Cross-border Cooperation Programme Austria-Czech Republic 2014-2020 [ATCZ194]	This study was financed by a grant from the INPOMED (Innovations in Poultry Medicine) project, which is funded by the European Regional Development Fund, Cross-border Cooperation Programme Austria-Czech Republic 2014-2020. Project No: ATCZ194.	Becker I, 2003, MOL BIOCHEM PARASIT, V130, P65, DOI 10.1016/S0166-6851(03)00160-9; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Cabral ES, 2006, J INFECT DIS, V193, P849, DOI 10.1086/500467; Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x; Fouzder C., 2019, TOLL LIKE RECEPTORS; Hawn TR, 2002, MICROBES INFECT, V4, P763, DOI 10.1016/S1286-4579(02)01596-4; Hess M, 2006, AVIAN PATHOL, V35, P280, DOI 10.1080/03079450600815507; Hess M., 2020, DIS POULTRY, P1223; Hess M, 2008, VACCINE, V26, P4187, DOI 10.1016/j.vaccine.2008.05.071; Hess M, 2015, VET PARASITOL, V208, P67, DOI 10.1016/j.vetpar.2014.12.018; Hug H, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020203; Kaufman EH, 2012, BRIT J PHARMACOL, V166, P569, DOI 10.1111/j.1476-5381.2011.01758.x; Kim JH, 2020, CANCER PREV RES, V13, P25, DOI 10.1158/1940-6207.CAPR-19-0286; Krishnan J, 2007, EXP MOL MED, V39, P421, DOI 10.1038/emm.2007.47; Lagler J, 2021, DEV COMP IMMUNOL, V116, DOI 10.1016/j.dci.2020.103949; Liebhart D, 2020, AVIAN PATHOL, V49, P1, DOI 10.1080/03079457.2019.1654087; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mitra T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02518; Mitra T, 2017, VACCINE, V35, P4184, DOI 10.1016/j.vaccine.2017.06.035; Mitra T, 2016, VET RES, V47, DOI 10.1186/s13567-016-0388-z; Nawab A, 2019, INT REV IMMUNOL, V38, P284, DOI 10.1080/08830185.2019.1659258; Oliveira-Nascimento L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00079; Powell FL, 2009, PARASITE IMMUNOL, V31, P312, DOI 10.1111/j.1365-3024.2009.01113.x; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Ramasamy KT, 2012, MOL BIOL REP, V39, P8539, DOI 10.1007/s11033-012-1709-6; Ray A, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00052; Smith T., 1895, USDA BUR ANIM IND B, V8, P3; St Paul M, 2013, VET IMMUNOL IMMUNOP, V152, P191, DOI 10.1016/j.vetimm.2012.10.013; Sumners LH, 2011, EXP PARASITOL, V127, P714, DOI 10.1016/j.exppara.2010.12.002; Temperley ND, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-62; Windisch M, 2010, PARASITE IMMUNOL, V32, P29, DOI 10.1111/j.1365-3024.2009.01159.x; Yilmaz A, 2005, IMMUNOGENETICS, V56, P743, DOI 10.1007/s00251-004-0740-8; Zahoor MA, 2011, AVIAN DIS, V55, P29, DOI 10.1637/9508-082110-Reg.1; Zhang L, 2012, EXP PARASITOL, V130, P442, DOI 10.1016/j.exppara.2012.01.013; Zhou ZY, 2014, J INTEGR AGR, V13, P904, DOI 10.1016/S2095-3119(13)60384-6; Zhou ZY, 2013, EXP PARASITOL, V133, P427, DOI 10.1016/j.exppara.2013.01.002	36	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							960	10.3390/vaccines9090960			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2VK	34579197	gold, Green Published			2022-04-29	WOS:000702067800001
J	Pilewski, KA; Kramer, KJ; Georgiev, IS				Pilewski, Kelsey A.; Kramer, Kevin J.; Georgiev, Ivelin S.			Simultaneous Immunization with Multiple Diverse Immunogens Alters Development of Antigen-Specific Antibody-Mediated Immunity	VACCINES			English	Article						immunization; antibodies; subunit vaccines; humoral immunity; bacterial pathogens	HEPARIN-BINDING HEMAGGLUTININ; MYCOBACTERIUM-TUBERCULOSIS; VIRULENCE; VACCINES; PROTECT	Vaccination remains one of the most successful medical interventions in history, significantly decreasing morbidity and mortality associated with, or even eradicating, numerous infectious diseases. Although traditional immunization strategies have recently proven insufficient in the face of many highly mutable and emerging pathogens, modern strategies aim to rationally engineer a single antigen or cocktail of antigens to generate a focused, protective immune response. However, the effect of cocktail vaccination (simultaneous immunization with multiple immunogens) on the antibody response to each individual antigen within the combination, remains largely unstudied. To investigate whether immunization with a cocktail of diverse antigens would result in decreased antibody titer against each unique antigen in the cocktail compared to immunization with each antigen alone, we immunized mice with surface proteins from uropathogenic Escherichia coli, Mycobacterium tuberculosis, and Neisseria meningitides, and monitored the development of antigen-specific IgG antibody responses. We found that antigen-specific endpoint antibody titers were comparable across immunization groups by study conclusion (day 70). Further, we discovered that although cocktail-immunized mice initially elicited more robust antibody responses, the rate of titer development decreases significantly over time compared to single antigen-immunized mice. Investigating the basic properties that govern the development of antigen-specific antibody responses will help inform the design of future combination immunization regimens.	[Pilewski, Kelsey A.; Kramer, Kevin J.; Georgiev, Ivelin S.] Vanderbilt Univ, Vanderbilt Vaccine Ctr, Med Ctr, Nashville, TN 37232 USA; [Pilewski, Kelsey A.; Kramer, Kevin J.; Georgiev, Ivelin S.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Georgiev, Ivelin S.] Vanderbilt Univ, Vanderbilt Inst Infect Immunol & Inflammat, Med Ctr, Nashville, TN 37232 USA; [Georgiev, Ivelin S.] Vanderbilt Univ, Dept Elect Engn & Comp Sci, Med Ctr, Nashville, TN 37232 USA; [Georgiev, Ivelin S.] Vanderbilt Univ, Program Computat Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA		Georgiev, IS (通讯作者)，Vanderbilt Univ, Vanderbilt Vaccine Ctr, Med Ctr, Nashville, TN 37232 USA.; Georgiev, IS (通讯作者)，Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA.; Georgiev, IS (通讯作者)，Vanderbilt Univ, Vanderbilt Inst Infect Immunol & Inflammat, Med Ctr, Nashville, TN 37232 USA.; Georgiev, IS (通讯作者)，Vanderbilt Univ, Dept Elect Engn & Comp Sci, Med Ctr, Nashville, TN 37232 USA.; Georgiev, IS (通讯作者)，Vanderbilt Univ, Program Computat Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA.	kelsey.a.pilewski@vanderbilt.edu; kevinj.kramer@vanderbilt.edu; Ivelin.Georgiev@Vanderbilt.edu		Kramer, Kevin/0000-0001-8451-9018; Pilewski, Kelsey/0000-0003-0916-4098			Alteri CJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000586; Andreano E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01722; Delany I, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012476; Donald RGK, 2017, HUM VACC IMMUNOTHER, V13, P255, DOI 10.1080/21645515.2017.1264750; Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473; Galli V, 2013, CLIN VACCINE IMMUNOL, V20, P1370, DOI 10.1128/CVI.00140-13; Gebre MS, 2021, CELL, V184, P1589, DOI 10.1016/j.cell.2021.02.030; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Hagan EC, 2007, INFECT IMMUN, V75, P3941, DOI 10.1128/IAI.00337-07; Hart P, 2018, MOL THER, V26, P822, DOI 10.1016/j.ymthe.2017.12.016; Hussein IH, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/fpubh.2015.00269; Jones D, 2020, LANCET, V396, P810, DOI 10.1016/S0140-6736(20)31924-3; Kwong PD, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007278; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Mascola JR, 2020, NAT REV IMMUNOL, V20, P87, DOI 10.1038/s41577-019-0243-3; McNeil LK, 2013, MICROBIOL MOL BIOL R, V77, P234, DOI 10.1128/MMBR.00056-12; Nandi A, 2020, HUM VACC IMMUNOTHER, V16, P1900, DOI 10.1080/21645515.2019.1708669; Parra M, 2004, INFECT IMMUN, V72, P6799, DOI 10.1128/IAI.72.12.6799-6805.2004; Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083; Piot P, 2019, NATURE, V575, P119, DOI 10.1038/s41586-019-1656-7; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Rodrigues CMC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01526; Russo TA, 2001, INFECT IMMUN, V69, P6209, DOI 10.1128/IAI.69.10.6209-6216.2001; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Scarselli M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002234; Sette A, 2010, IMMUNITY, V33, P530, DOI 10.1016/j.immuni.2010.09.017; Swanson KA, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba6466; Zhang L, 2015, EXPERT REV VACCINES, V14, P1509, DOI 10.1586/14760584.2015.1081067	30	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							964	10.3390/vaccines9090964			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3PD	34579201	Green Published, gold			2022-04-29	WOS:000702119500001
J	Tsai, CS; Hsiao, RC; Chen, YM; Yen, CF				Tsai, Ching-Shu; Hsiao, Ray C.; Chen, Yu-Min; Yen, Cheng-Fang			Factors Related to Caregiver Intentions to Vaccinate Their Children with Attention-Deficit/Hyperactivity Disorder against COVID-19 in Taiwan	VACCINES			English	Article						attention-deficit; hyperactivity disorder; caregiver; COVID-19; vaccine	OPPOSITIONAL DEFIANT DISORDER; PROTECTION MOTIVATION THEORY	The aims of this study were to examine the proportion of caregivers who were hesitant to vaccinate their children with attention-deficit/hyperactivity disorder (ADHD) against coronavirus disease 2019 (COVID-19) and the factors related to caregiver intentions to vaccinate their children against COVID-19. In total, 161 caregivers of children with ADHD were recruited in this study. The caregivers completed an online questionnaire to provide data regarding their intention to vaccinate their children against COVID-19, concerns about the effectiveness and safety of vaccines, unfavorable family attitudes toward vaccines, and children's medication use for ADHD and comorbid psychopathology. The factors related to caregiver intentions to vaccinate their child were examined using linear regression analysis. The results indicated that 25.5% of caregivers were hesitant to vaccinate their children with ADHD, and 11.8% refused to vaccinate their children against COVID-19. The caregivers' concerns about the safety of vaccines and children's regular use of medication for ADHD were negatively associated with caregiver intentions to vaccinate, whereas the children's comorbid conduct or oppositional defiant problems were positively associated with the caregiver intentions to vaccinate. An intervention that enhances caregiver intentions to vaccinate their children with ADHD against COVID-19 by addressing the related factors found in this study is warranted.	[Tsai, Ching-Shu] Kaohsiung Chang Gung Mem Hosp, Dept Child & Adolescent Psychiat, Kaohsiung 833401, Taiwan; [Tsai, Ching-Shu] Chang Gung Univ, Coll Med, Taoyuan 33302, Taiwan; [Hsiao, Ray C.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Hsiao, Ray C.] Childrens Hosp & Reg Med Ctr, Dept Psychiat, Seattle, WA 98105 USA; [Chen, Yu-Min; Yen, Cheng-Fang] Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 80708, Taiwan; [Yen, Cheng-Fang] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Psychiat, Kaohsiung 80708, Taiwan; [Yen, Cheng-Fang] Natl Pingtung Univ Sci & Technol, Coll Profess Studies, Pingtung 91201, Taiwan		Chen, YM; Yen, CF (通讯作者)，Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 80708, Taiwan.; Yen, CF (通讯作者)，Kaohsiung Med Univ, Coll Med, Sch Med, Dept Psychiat, Kaohsiung 80708, Taiwan.; Yen, CF (通讯作者)，Natl Pingtung Univ Sci & Technol, Coll Profess Studies, Pingtung 91201, Taiwan.	jingshu@cgmh.org.tw; rhsiao@u.washington.edu; bluepooh79@msn.com; chfaye@cc.kmu.edu.tw		Tsai, Ching-Shu/0000-0002-7371-1757; Hsiao, Ray Chih-Jui/0000-0003-2351-2335; Yen, Cheng-Fang/0000-0003-1156-4939	Kaohsiung Medical University Hospital [KMUH109-M911]; Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST 110-2635-B-182A-001]	This study was supported by grants awarded by Kaohsiung Medical University Hospital (KMUH109-M911) and the Ministry of Science and Technology, Taiwan (MOST 110-2635-B-182A-001). The funding agencies did not have a role in this study.	Ajzen I., 1985, ACTION CONTROL, P11, DOI 10.1007/978-3-642-69746-3_2; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bhuiyan MU, 2021, VACCINE, V39, P667, DOI 10.1016/j.vaccine.2020.11.078; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX; Camerini AL, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.11.005; Centers for Disease control Prevention, COVID 19 VACC CHILDR; Chang CC, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18147532; Chang CC, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17020576; Chen IH, 2021, VACCINE, V39, P4510, DOI 10.1016/j.vaccine.2021.06.044; Chen YL, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18137042; Chen YL, 2021, J AFFECT DISORDERS, V279, P59, DOI 10.1016/j.jad.2020.09.121; Deater-Deckard K, 2004, PARENTING STRESS; European Medicines Agency, 1 COVID 19 VACC APPR; Fan CW, 2021, HUM VACC IMMUNOTHER, V17, P3413, DOI 10.1080/21645515.2021.1933687; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7; Hetherington Erin, 2021, CMAJ Open, V9, pE548, DOI 10.9778/cmajo.20200302; Honein MA, 2020, MMWR-MORBID MORTAL W, V69, P1860, DOI 10.15585/mmwr.mm6949e2; Leitch S, 2019, INT J QUAL STUD HEAL, V14, DOI 10.1080/17482631.2019.1690091; Masi G, 2017, J CLIN PSYCHOPHARM, V37, P590, DOI 10.1097/JCP.0000000000000747; Masi G, 2016, PSYCHIAT RES, V238, P8, DOI 10.1016/j.psychres.2016.02.010; Maughan B, 2004, J CHILD PSYCHOL PSYC, V45, P609, DOI 10.1111/j.1469-7610.2004.00250.x; Mehta NS, 2020, CLIN INFECT DIS, V71, P2469, DOI 10.1093/cid/ciaa556; Melegari MG, 2021, PSYCHIAT RES, V296, DOI 10.1016/j.psychres.2020.113692; Merzon E, 2022, J ATTEN DISORD, V26, P491, DOI 10.1177/10870547211003659; Merzon E, 2021, J ATTEN DISORD, V25, P1783, DOI 10.1177/1087054720943271; Montalti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040366; Nonweiler J, 2020, CHILDREN-BASEL, V7, DOI 10.3390/children7090128; Pollak Y, 2022, J ATTEN DISORD, V26, P735, DOI 10.1177/10870547211027934; Rhodes ME, 2020, J HEALTH COMMUN, V25, P831, DOI 10.1080/10810730.2021.1871986; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; Shon EJ, 2021, AM J HEALTH PROMOT, V35, P708, DOI 10.1177/0890117120985833; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; Taiwan Centers for Disease Control, 1 BATCH ASTRAZENECAS; The World Health Organization,, WHO LISTS ADD COVID; Theule J, 2013, J EMOT BEHAV DISORD, V21, P3, DOI 10.1177/1063426610387433; Tsankov BK, 2021, INT J INFECT DIS, V103, P246, DOI 10.1016/j.ijid.2020.11.163; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380; Wang QQ, 2021, WORLD PSYCHIATRY, V20, P124, DOI 10.1002/wps.20806; WHO, WHO COR COVID 19 DAS; World Health Organization, COR DIS COVID 19 VAC; World Health Organization, WHO SAG ROADM PRIOR; Yeh YC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030297; Yigit M, 2021, PEDIATR INFECT DIS J, V40, pE134, DOI 10.1097/INF.0000000000003042; Zhang JS, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102077; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827	47	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							983	10.3390/vaccines9090983			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ3IE	34579219	gold, Green Published			2022-04-29	WOS:000702101200001
J	White, AD; Sibley, L; Gullick, J; Sarfas, C; Clark, S; Fagrouch, Z; Verschoor, E; Salguero, FJ; Dennis, M; Sharpe, S				White, Andrew D.; Sibley, Laura; Gullick, Jennie; Sarfas, Charlotte; Clark, Simon; Fagrouch, Zahra; Verschoor, Ernst; Salguero, Francisco J.; Dennis, Mike; Sharpe, Sally			TB and SIV Coinfection; a Model for Evaluating Vaccine Strategies against TB Reactivation in Asian Origin Cynomolgus Macaques: A Pilot Study Using BCG Vaccination	VACCINES			English	Article						tuberculosis; SIV; macaques; coinfection; reactivation	MYCOBACTERIUM-TUBERCULOSIS; AEROSOL CHALLENGE; PERIPHERAL-BLOOD; RHESUS MACAQUES; LYMPHOCYTES; MONOCYTES; RATIO; METAANALYSIS; PROTECTION; INFECTION	This pilot study aimed to determine the utility of a cynomolgus macaque model of coinfection with simian immunodeficiency virus (SIV) for the assessment of vaccines designed to prevent reactivation of TB. Following infection caused by aerosol exposure to an ultralow dose of Mycobacterium tuberculosis (M. tb), data trends indicated that subsequent coinfection with SIVmac32H perturbed control of M. tb infection as evidenced by the increased occurrence of progressive disease in this group, higher levels of pathology and increased frequency of progressive tuberculous granulomas in the lung. BCG vaccination led to improved control of TB-induced disease and lower viral load in comparison to unvaccinated coinfected animals. The M. tb-specific IFN gamma response after exposure to M. tb, previously shown to be associated with bacterial burden, was lower in the BCG-vaccinated group than in the unvaccinated groups. Levels of CD4+ and CD8+ T cells decreased in coinfected animals, with counts recovering more quickly in the BCG-vaccinated group. This pilot study provides proof of concept to support the use of the model for evaluation of interventions against reactivated/exacerbated TB caused by human immunodeficiency virus (HIV) infection.	[White, Andrew D.; Sibley, Laura; Gullick, Jennie; Sarfas, Charlotte; Clark, Simon; Salguero, Francisco J.; Dennis, Mike; Sharpe, Sally] Natl Infect Serv, Publ Hlth England, Salisbury SP4 0JG, Wilts, England; [Fagrouch, Zahra; Verschoor, Ernst] Biomed Primate Res Ctr, Dept Virol, Lange Kleiweg 161, NL-2288 GJ Rijswijk, Netherlands		Sibley, L (通讯作者)，Natl Infect Serv, Publ Hlth England, Salisbury SP4 0JG, Wilts, England.	Andrew.White@phe.gov.uk; Laura.Sibley@phe.gov.uk; J.Gullick@soton.ac.uk; Charlotte.Sarfas@phe.gov.uk; Simon.Clark@phe.gov.uk; Fagrouch@bprc.nl; Verschoor@bprc.nl; Javier.Salguero@phe.gov.uk; Mike.Dennis@phe.gov.uk; Sally.Sharpe@phe.gov.uk		White, Andrew/0000-0001-9481-0079; Salguero, Francisco Javier/0000-0002-5315-3882; Verschoor, Ernst/0000-0003-0912-2074	European Union (EU-FP7) [TBVAC2020]	This research was supported by the European Union (EU-FP7, TBVAC2020).	Abubakar I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17370; Atkinson G.F., BU141M; Capuano SV, 2003, INFECT IMMUN, V71, P5831, DOI 10.1128/IAI.71.10.5831-5844.2003; Cardona PJ, 2006, TUBERCULOSIS, V86, P273, DOI 10.1016/j.tube.2006.01.024; Chaisson RE, 2010, J INFECT DIS, V201, P653, DOI 10.1086/650531; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Cranage M, 2008, PLOS MED, V5, P1238, DOI 10.1371/journal.pmed.0050157; Cranage MP, 1997, VIROLOGY, V229, P143, DOI 10.1006/viro.1996.8419; Diedrich CR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009611; Fletcher HA, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0617-3; Flynn JL, 2015, IMMUNOL REV, V264, P60, DOI 10.1111/imr.12258; Ji ZH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02089; KITCHIN PA, 1990, ANIM MODELS, V1, P115; La Manna MP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171358; Leutenegger CM, 2001, AIDS RES HUM RETROV, V17, P243, DOI 10.1089/088922201750063160; Lin PL, 2012, J CLIN INVEST, V122, P303, DOI 10.1172/JCI46252; Mitchell JL, 2012, IMMUNOGENETICS, V64, P123, DOI 10.1007/s00251-011-0567-z; Naranbhai V, 2014, JAIDS-J ACQ IMM DEF, V67, P573, DOI 10.1097/QAI.0000000000000353; Naranbhai V, 2014, J INFECT DIS, V209, P500, DOI 10.1093/infdis/jit494; Nell AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089612; Okamura T, 2016, J GEN VIROL, V97, P3413, DOI 10.1099/jgv.0.000641; Rayner EL, 2015, J COMP PATHOL, V152, P217, DOI 10.1016/j.jcpa.2014.10.002; Sharpe S, 2016, TUBERCULOSIS, V101, P174, DOI 10.1016/j.tube.2016.09.004; Sharpe SA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171906; Sharpe SA, 2010, CLIN VACCINE IMMUNOL, V17, P1170, DOI 10.1128/CVI.00079-10; Sharpe SA, 2009, TUBERCULOSIS, V89, P405, DOI 10.1016/j.tube.2009.09.002; Sharpe S, 2016, TUBERCULOSIS, V96, P1, DOI 10.1016/j.tube.2015.10.004; Sharpe SA, 2018, LAB ANIM-UK, V52, P599, DOI 10.1177/0023677218757815; Sibley L., 2021, SCI REP-UK, DOI [10.21203/rs.3.rs-296520/v1, DOI 10.21203/RS.3.RS-296520/V1]; Tait DR, 2019, NEW ENGL J MED, V381, P2429, DOI 10.1056/NEJMoa1909953; Unis G, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0548-6; Vordermeier HM, 2002, INFECT IMMUN, V70, P3026, DOI 10.1128/IAI.70.6.3026-3032.2002; Wang J, 2015, BRAZ J INFECT DIS, V19, P125, DOI 10.1016/j.bjid.2014.10.008; White AD, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00262-8; White AD, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12050394	35	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							945	10.3390/vaccines9090945			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3DQ	34579182	Green Published, gold			2022-04-29	WOS:000702089300001
J	Chang, CY; Wang, YS; Wu, JF; Yang, TJ; Chang, YC; Chae, C; Chang, HW; Hsu, STD				Chang, Chia-Yu; Wang, Yong-Sheng; Wu, Jou-Fei; Yang, Tzu-Jing; Chang, Yen-Chen; Chae, Chanhee; Chang, Hui-Wen; Hsu, Shang-Te Danny			Generation and Characterization of a Spike Glycoprotein Domain A-Specific Neutralizing Single-Chain Variable Fragment against Porcine Epidemic Diarrhea Virus	VACCINES			English	Article						porcine epidemic diarrhea virus; single-chain variable fragment (scFv); neutralizing antibody	MONOCLONAL-ANTIBODY; UNITED-STATES; CHALLENGES; VACCINES; DISEASE; DESIGN	The emergence of the genotype (G) 2 and re-emergence of the G1 porcine epidemic diarrhea virus (PEDV) has caused severe economic impacts in the past decade. Developments of efficient vaccines against new variants of PEDV have been challenging, not least because of the difficulties in eliciting mucosal and lactogenic immunity. A single-chain fragment variable (scFv) capable of efficient antigen recognition is an alternative to vaccination and treatment of a viral infection. In the present study, the variable regions of the light chain and the heavy chain of a G2b PEDV spike domain A (S1(A))-specific neutralizing monoclonal antibody (mAb) were sequenced, constructed with a (G4S) x3 linker, and produced by a mammalian protein expression system. Our results demonstrated that the PEDV S1(A) domain scFv was able to bind to S proteins of both G1 and G2b PEDVs. Nevertheless, the scFv was only capable of neutralizing the homologous G2b PEDV but not the G1 PEDV. The binding ability of the G2b-specific neutralizing scFv was not able to predict the neutralizing ability toward heterologous PEDV. The anti-PEDV S1(A) scFv presented herein serves as a potential therapeutic candidate against the virulent G2b PEDV.	[Chang, Chia-Yu; Wang, Yong-Sheng; Yang, Tzu-Jing; Hsu, Shang-Te Danny] Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; [Wang, Yong-Sheng; Yang, Tzu-Jing; Hsu, Shang-Te Danny] Natl Taiwan Univ, Inst Biochem Sci, Taipei 10617, Taiwan; [Wu, Jou-Fei; Chang, Yen-Chen; Chang, Hui-Wen] Natl Taiwan Univ, Grad Inst Mol & Comparat Pathobiol, Sch Vet Med, Taipei 10617, Taiwan; [Chae, Chanhee] Seoul Natl Univ, Dept Vet Pathol, Coll Vet Med, Seoul 151742, South Korea		Hsu, STD (通讯作者)，Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan.; Hsu, STD (通讯作者)，Natl Taiwan Univ, Inst Biochem Sci, Taipei 10617, Taiwan.	flywinds11@gmail.com; willywang13@gate.sinica.edu.tw; a10153018@gmail.com; jing0526@gate.sinica.edu.tw; jing0526@gate.sinica.edu.tw; swine@snu.ac.kr; huiwenchang@ntu.edu.tw; sthsu@gate.sinica.edu.tw	Hsu, Shang-Te Danny/L-2826-2014; CHANG, HUI-WEN/C-9058-2017	Hsu, Shang-Te Danny/0000-0002-7231-0185; Chang, Chia-Yu/0000-0001-5132-1654; CHANG, HUI-WEN/0000-0001-8877-1886; Wang, Yong-Sheng/0000-0002-4868-4507	Academia Sinica intramural fund; Academia Sinica Career Development Award, Academia Sinica [AS-CDA-109-L08]; Ministry of Science and Technology (MOST), TaiwanMinistry of Science and Technology, Taiwan [MOST 109-3114-Y-001001, MOST106-2311-B-002-028-MY3]	This work was supported by Academia Sinica intramural fund to S.-T.D.H., an Academia Sinica Career Development Award, Academia Sinica to S.-T.D.H. (grant number: AS-CDA-109-L08) , and the Ministry of Science and Technology (MOST), Taiwan (grant number: MOST 109-3114-Y-001001 to S.-T.D.H. and grant number: MOST106-2311-B-002-028-MY3 to H.-W.C.).	Antas M, 2019, J VET RES, V63, P465, DOI 10.2478/jvetres-2019-0064; Beirao BCB, 2016, VET J, V218, P40, DOI 10.1016/j.tvjl.2016.11.005; Bustamante-Cordova L, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00175; Chai Z, 2014, FEMS MICROBIOL LETT, V354, P85, DOI 10.1111/1574-6968.12437; Chang CY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39844-5; Chang SH, 2002, MOL CELLS, V14, P295; Chang YC, 2018, APPL MICROBIOL BIOT, V102, P7499, DOI 10.1007/s00253-018-9110-6; Chattha KS, 2015, ANNU REV ANIM BIOSCI, V3, P375, DOI 10.1146/annurev-animal-022114-111038; Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039; Chiou HY, 2017, TRANSBOUND EMERG DIS, V64, P157, DOI 10.1111/tbed.12357; Crawford K, 2016, VIRUS RES, V226, P108, DOI 10.1016/j.virusres.2016.08.005; Gaudinski MR, 2019, LANCET, V393, P889, DOI 10.1016/S0140-6736(19)30036-4; Guo JH, 2019, TRANSBOUND EMERG DIS, V66, P111, DOI 10.1111/tbed.12991; Harmsen MM, 2008, VET MICROBIOL, V132, P56, DOI 10.1016/j.vetmic.2008.04.030; Huang YW, 2013, MBIO, V4, DOI 10.1128/mBio.00737-13; Jangra P., 2010, ASIAN PACIFIC J TROP, V3, P1, DOI [10.1016/S1995-7645(10)60020-X, DOI 10.1016/S1995-7645(10)60020-X]; Jung K, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198045; Jung K, 2015, VET J, V204, P134, DOI 10.1016/j.tvjl.2015.02.017; Karte C, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02548-4; Khalafalla RE, 2010, PARASITOL RES, V107, P983, DOI 10.1007/s00436-010-1964-1; Langel SN, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020130; Langel SN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00727; Lee C, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0421-2; Li CH, 2017, J VIROL, V91, DOI [10.1128/JVI.00273-17, 10.1128/jvi.00273-17]; Low JGH, 2017, J INFECT DIS, V215, pS96, DOI 10.1093/infdis/jiw423; Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z; Meyer L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218717; Michels GM, 2016, VET DERMATOL, V27, P478, DOI 10.1111/vde.12376; Miquel-Clopes A, 2019, CLIN EXP IMMUNOL, V196, P205, DOI 10.1111/cei.13285; Morales JO, 2017, AAPS J, V19, P652, DOI 10.1208/s12248-017-0054-z; Nachbagauer R, 2017, CLIN MICROBIOL INFEC, V23, P222, DOI 10.1016/j.cmi.2017.02.009; Niederwerder MC, 2018, TRANSBOUND EMERG DIS, V65, P660, DOI 10.1111/tbed.12823; Okda FA, 2017, VIROLOGY, V509, P185, DOI 10.1016/j.virol.2017.06.013; Park K, 2011, REACT FUNCT POLYM, V71, P280, DOI 10.1016/j.reactfunctpolym.2010.10.002; PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606; Pereira EPV, 2019, INT IMMUNOPHARMACOL, V73, P293, DOI 10.1016/j.intimp.2019.05.015; Pinto FL, 2010, ANAL BIOCHEM, V397, P227, DOI 10.1016/j.ab.2009.10.022; Sahagun-Ruiz A, 2015, VET RES COMMUN, V39, P229, DOI 10.1007/s11259-015-9646-1; Salazar G, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0019-3; Sparrow E, 2017, B WORLD HEALTH ORGAN, V95, P235, DOI [10.2471/BLT.16.178061, 10.2471/blt.16.178061]; Sun DB, 2007, ACTA VIROL, V51, P149; Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657; Wang M, 2015, RES VET SCI, V100, P109, DOI 10.1016/j.rvsc.2015.02.012; Wang QH, 2019, CURR OPIN VIROL, V34, P39, DOI 10.1016/j.coviro.2018.12.001; Won H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040642; Wrapp D, 2019, J VIROL, V93, DOI 10.1128/JVI.00923-19; Zhang FQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010058	47	1	1	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							833	10.3390/vaccines9080833			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2TX	34451958	gold, Green Published			2022-04-29	WOS:000689791300001
J	King, RG; Silva-Sanchez, A; Peel, JN; Botta, D; Dickson, AM; Pinto, AK; Meza-Perez, S; Allie, SR; Schultz, MD; Liu, MY; Bradley, JE; Qiu, SH; Yang, G; Zhou, F; Zumaquero, E; Simpler, TS; Mousseau, B; Killian, JT; Dean, B; Shang, Q; Tipper, JL; Risley, CA; Harrod, KS; Feng, TW; Lee, Y; Shiberu, B; Krishnan, V; Peguillet, I; Zhang, JF; Green, TJ; Randall, TD; Suschak, JJ; Georges, B; Brien, JD; Lund, FE; Roberts, MS				King, R. Glenn; Silva-Sanchez, Aaron; Peel, Jessica N.; Botta, Davide; Dickson, Alexandria M.; Pinto, Amelia K.; Meza-Perez, Selene; Allie, S. Rameeza; Schultz, Michael D.; Liu, Mingyong; Bradley, John E.; Qiu, Shihong; Yang, Guang; Zhou, Fen; Zumaquero, Esther; Simpler, Thomas S.; Mousseau, Betty; Killian, John T., Jr.; Dean, Brittany; Shang, Qiao; Tipper, Jennifer L.; Risley, Christopher A.; Harrod, Kevin S.; Feng, Tsungwei; Lee, Young; Shiberu, Bethlehem; Krishnan, Vyjayanthi; Peguillet, Isabelle; Zhang, Jianfeng; Green, Todd J.; Randall, Troy D.; Suschak, John J.; Georges, Bertrand; Brien, James D.; Lund, Frances E.; Roberts, M. Scot			Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge	VACCINES			English	Article						COVID-19; SARS-CoV-2; receptor binding domain; vaccine; adenovirus vector; viral vector; intranasal; mucosal immunity; IgA	INFLUENZA-VIRUS; T-CELLS; TRANSMISSION; IMMUNIZATION; VACCINATION; ADENOVIRUS; CANDIDATE; COVID-19; SPIKE	The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry. The current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity. Here, we tested a single intranasal dose of our candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (AdCOVID) in inbred, outbred, and transgenic mice. A single intranasal vaccination with AdCOVID elicited a strong and focused immune response against RBD through the induction of mucosal IgA in the respiratory tract, serum neutralizing antibodies, and CD4(+) and CD8(+) T cells with a T(h)1-like cytokine expression profile. A single AdCOVID dose resulted in immunity that was sustained for over six months. Moreover, a single intranasal dose completely protected K18-hACE2 mice from lethal SARS-CoV-2 challenge, preventing weight loss and mortality. These data show that AdCOVID promotes concomitant systemic and mucosal immunity and represents a promising vaccine candidate.	[King, R. Glenn; Peel, Jessica N.; Botta, Davide; Schultz, Michael D.; Qiu, Shihong; Yang, Guang; Zhou, Fen; Zumaquero, Esther; Simpler, Thomas S.; Mousseau, Betty; Killian, John T., Jr.; Dean, Brittany; Shang, Qiao; Risley, Christopher A.; Green, Todd J.; Lund, Frances E.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Silva-Sanchez, Aaron; Meza-Perez, Selene; Allie, S. Rameeza; Liu, Mingyong; Bradley, John E.; Randall, Troy D.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; [Dickson, Alexandria M.; Pinto, Amelia K.; Brien, James D.] St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; [Tipper, Jennifer L.; Harrod, Kevin S.] Univ Alabama Birmingham, Dept Anesthesiol & Perioperat Med, Birmingham, AL 35294 USA; [Feng, Tsungwei; Lee, Young; Shiberu, Bethlehem; Krishnan, Vyjayanthi; Peguillet, Isabelle; Zhang, Jianfeng; Suschak, John J.; Georges, Bertrand; Roberts, M. Scot] Altimmune Inc, Gaithersburg, MD 20878 USA		Lund, FE (通讯作者)，Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.; Roberts, MS (通讯作者)，Altimmune Inc, Gaithersburg, MD 20878 USA.	rgking@uab.edu; aaronsilvasanchez@uabmc.edu; jnpeel@uab.edu; dbotta@uab.edu; alexandria.dickson@slu.edu; akpintolab@gmail.com; selenemezaperez@uabmc.edu; sallie@pennstatehealth.psu.edu; mschul20@uab.edu; miliu@uab.edu; johnbradley@uabmc.edu; qiaoshang@uabmc.edu; gyang@uab.edu; fzhou@uab.edu; ezm@uab.edu; ssimpler@uab.edu; mousseau@uab.edu; jtkillian@uabmc.edu; bdean819@uab.edu; qiaoshang@uabmc.edu; jennifertipper@uabmc.edu; crisley@uab.edu; kevinharrod@uabmc.edu; rfeng@altimmune.com; ylee@altimmune.com; bshiberu@altimmune.com; vkrishnan@altimmune.com; ipeguillet@altimmune.com; zhang@altimmune.com; tgreen@uab.edu; troyrandall@uabmc.edu; jsuschak@altimmune.com; bgeorges@altimmune.com; brienlab@gmail.com; flund@uab.edu; sroberts@altimmune.com	Suschak, John/ABE-5854-2021; Silva-Sanchez, Aaron/AAI-8572-2021; Pinto, Amelia/O-6658-2018	Suschak, John/0000-0002-2867-8265; Silva-Sanchez, Aaron/0000-0002-1882-2534; Botta, Davide/0000-0003-3926-0662; Green, Todd/0000-0003-1158-4710; Brien, James/0000-0002-1670-8041; Pinto, Amelia/0000-0002-7147-3978; Schultz, Michael/0000-0002-6741-4115; Killian, John/0000-0002-3702-9005; King, Rodney/0000-0001-6522-0053; Harrod, Kevin/0000-0003-0780-9470	Altimmune Inc.; Barbara Ingalls Shook Foundation; NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [1U01CA260541-01];  [U19 3U19AI142737]	Altimmune Inc. and the Barbara Ingalls Shook Foundation (to FEL) provided funding for the work reported in this article. Support for the development and validation of SARS-CoV-2 spike cytometric bead arrays was provided by U19 3U19AI142737 (to F.E.L., R.G.K., T.J.G., T.D.R.). Support for the development of the SARS-CoV-2 challenge model and FRNT was provided by NIH/NCI 1U01CA260541-01 (to J.D.B).	Amanat F, 2021, PLASMABLAST RESPONSE, DOI [10.1101/2021.03.07.21253098, DOI 10.1101/2021.03.07.21253098]; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Belshe RB, 2000, J INFECT DIS, V181, P1133, DOI 10.1086/315323; Boari GEM, 2021, HIGH BLOOD PRESS CAR, V28, P373, DOI 10.1007/s40292-021-00454-w; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; Brann DH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc5801; CDC, COR DIS 2019 COVID 1; Croyle MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003548; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Funk CD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00937; Gould VMW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00900; Greaney Allison J, 2021, bioRxiv, DOI 10.1101/2021.04.14.439844; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Krishnan V, 2015, CLIN VACCINE IMMUNOL, V22, P430, DOI 10.1128/CVI.00690-14; Laidlaw BJ, 2014, IMMUNITY, V41, P633, DOI 10.1016/j.immuni.2014.09.007; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Letko Michael, 2020, bioRxiv, DOI 10.1101/2020.01.22.915660; Li HJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00618; Li LH, 2002, TECHNOL CANCER RES T, V1, P341, DOI 10.1177/153303460200100504; Liu J, 2021, CURR OPIN CARDIOL, V36, P234, DOI 10.1097/HCO.0000000000000832; Lowen AC, 2009, J VIROL, V83, P2803, DOI 10.1128/JVI.02424-08; Ma CQ, 2014, VACCINE, V32, P6170, DOI 10.1016/j.vaccine.2014.08.086; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Pizzolla A, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam6970; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Price GE, 2014, J VIROL, V88, P6019, DOI 10.1128/JVI.03101-13; Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Seydoux Emilie, 2020, bioRxiv, DOI 10.1101/2020.05.12.091298; Shafi AMA, 2020, J CARDIAC SURG, V35, P1988, DOI 10.1111/jocs.14808; Shen Y, 2020, JAMA INTERN MED, V180, P1665, DOI 10.1001/jamainternmed.2020.5225; Sonnweber T, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.03481-2020; Starr Tyler N, 2021, bioRxiv, DOI 10.1101/2021.04.06.438709; Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Taddio A, 2012, VACCINE, V30, P4807, DOI 10.1016/j.vaccine.2012.05.011; Takamura S, 2017, VIRAL IMMUNOL, V30, P438, DOI 10.1089/vim.2017.0016; Tang DCC, 2009, EXPERT REV VACCINES, V8, P469, DOI 10.1586/ERV.09.1; Tasker S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030224; Thatte J, 2003, BLOOD, V101, P4916, DOI 10.1182/blood-2002-10-3159; van Doremalen Neeltje, 2021, bioRxiv, DOI 10.1101/2021.01.09.426058; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; van Ginkel FW, 2000, EMERG INFECT DIS, V6, P123, DOI 10.3201/eid0602.000204; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651; Wold WSM, 2013, CURR GENE THER, V13, P421; World Health Organization (WHO), Coronavirus disease 2019 (COVID-19) weekly epidemiological update-5 October 2021; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu SP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17972-1; Yinda CK, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009195; Yusuf H, 2017, HUM VACC IMMUNOTHER, V13, P34, DOI 10.1080/21645515.2016.1239668; Zhang C, 2016, HUM VACC IMMUNOTHER, V12, P2064, DOI 10.1080/21645515.2016.1165908; Zhang JF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022605; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zhuang Z, 2021, J EXP MED, V218, DOI 10.1084/jem.20202187; Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.22.111005	65	10	11	4	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							881	10.3390/vaccines9080881			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9IX	34452006	Green Published, gold			2022-04-29	WOS:000690235900001
J	Nautrup, BP; Van Vlaenderen, I; Mah, C; Angulo, J				Poulsen Nautrup, Barbara; Van Vlaenderen, Ilse; Mah, Choewkong; Angulo, Jose			Do High Levels of Maternally Derived Antibodies Interfere with the Vaccination of Piglets against Porcine Circovirus Type 2? A Literature Review and Data Analysis	VACCINES			English	Review						porcine circovirus type 2; maternally derived antibodies; vaccination; production parameters; viremia; immunological parameters	PRODUCTION PARAMETERS; PCV2 VACCINATION; IMPROVEMENT; PIGS; AGE	Vaccination against porcine circovirus type 2 (PCV2) is commonly performed in piglets worldwide, and increasingly also in sows. We conducted a literature search and review to assess the potential interference of maternally derived antibodies (MDA) in piglets with vaccination against PCV2. The effectiveness of vaccination was compared to no vaccination in the presence of high levels of MDA (>= 8 log(2) IPMA titer), as reported in field studies. In total, 13 papers fulfilled the predefined inclusion criteria, allowing up to 24 comparisons per parameter. In the presence of high levels of MDA, vaccinated pigs had, on average, a 20 g/d higher mean daily weight gain and a 34% lower mortality compared to non-vaccinates. The maximum percentage of viremic pigs was reduced by 63% and the maximum viral load in serum was 0.72 log(10) PCV2 DNA copies lower. Vaccination at 3 weeks of age was associated with the highest improvements in production parameters and reductions in viremia. Our findings suggest that the vaccination of piglets is effective with respect to production parameters and viremia even in the presence of high MDA, with an age of 3 weeks at vaccination being most beneficial.	[Poulsen Nautrup, Barbara] EAH Consulting, D-52064 Aachen, Germany; [Van Vlaenderen, Ilse] CHESS, B-2820 Bonheiden, Belgium; [Mah, Choewkong; Angulo, Jose] Zoetis, Parsippany, NJ 07054 USA		Nautrup, BP (通讯作者)，EAH Consulting, D-52064 Aachen, Germany.	bpn@EAH-Consulting.de; ivanvlaenderen@chessinhealth.com; ck.mah@zoetis.com; Jose.Angulo@zoetis.com			Zoetis	This study was supported by an unrestricted grant from Zoetis.	Balasch M, 2019, PORCINE HEALTH MANAG, V5, DOI 10.1186/s40813-018-0112-7; Base I., LOG VALUE CONVERSION; Beller EM, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-36; Borenstein M., 2011, INTRO META ANAL, DOI DOI 10.1002/9780470743386; Csank T, 2013, APMIS, V121, P1207, DOI 10.1111/apm.12069; Feng H, 2016, VACCINE, V34, P3044, DOI 10.1016/j.vaccine.2016.04.088; Figueras-Gourgues S, 2019, PORCINE HEALTH MANAG, V5, DOI 10.1186/s40813-019-0128-7; Fort M, 2009, VACCINE, V27, P4031, DOI 10.1016/j.vaccine.2009.04.028; Fraile L, 2012, VET MICROBIOL, V161, P229, DOI 10.1016/j.vetmic.2012.07.021; Fraile L, 2012, VACCINE, V30, P1986, DOI 10.1016/j.vaccine.2012.01.008; Haake M, 2014, VET MICROBIOL, V168, P272, DOI 10.1016/j.vetmic.2013.11.012; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; Karuppannan AK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050099; Li WH, 2018, BMC GASTROENTEROL, V18, DOI 10.1186/s12876-018-0847-2; Lin CN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020339; Lopez-Soria S, 2014, VET MICROBIOL, V174, P296, DOI 10.1016/j.vetmic.2014.09.016; Martelli P, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0700-1; Opriessnig T, 2007, J VET DIAGN INVEST, V19, P591, DOI 10.1177/104063870701900601; Paphavasit T, 2009, THAI J VET MED, V39, P145; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Segales J, 2012, VIRUS RES, V164, P10, DOI 10.1016/j.virusres.2011.10.007; Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2; Stevancevic O, 2014, KAFKAS UNIV VET FAK, V20, P465, DOI 10.9775/kvfd.2013.10373; Tassis PD, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1014-7; Tzika ED, 2015, PORCINE HEALTH MANAG, V1, DOI 10.1186/s40813-015-0006-x; Vargas-Bermudez D.S., 2018, F1000RES, V7, P42, DOI [10.12688/f1000research.13160.2, DOI 10.12688/F1000RESEARCH.13160.2]; Villa-Mancera A, 2016, LIVEST SCI, V190, P10, DOI 10.1016/j.livsci.2016.05.013; Wilson S, 2012, VACCINE, V30, P7625, DOI 10.1016/j.vaccine.2012.10.028	28	2	2	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							923	10.3390/vaccines9080923			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3KL	34452048	gold, Green Published			2022-04-29	WOS:000689834300001
J	Wiest, NE; Johns, GS; Edwards, E				Wiest, Nathaniel E.; Johns, Gretchen S.; Edwards, Eric			A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccination; pulmonary embolus; adverse event		Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is a critical strategy to overcome the COVID-19 pandemic. Multiple SARS-CoV-2 vaccines have been developed in a rapid timeframe to combat the pandemic. While generally safe and effective, rare cases of venous thromboembolism (VTE) have been reported after two adenovirus-based vaccines, the AstraZeneca ChAdOx1 nCoV-19 vaccine and the Janssen Ad.26.COV2.S vaccine, as well as after the Pfizer-BioNTech BNT162b2 mRNA vaccine. Here, we present the case of a patient who developed acute pulmonary emboli (PE) shortly after his second dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine. We report the results of an extensive thrombophilia workup that was normal except for the identification of positive lupus anticoagulant (LA) signals. It is our goal to contribute to the body of knowledge regarding SARS-CoV-2 vaccines and encourage vaccine adverse event reporting so that clinicians can have a full appreciation and awareness of the possible adverse events related to these critical vaccines.	[Wiest, Nathaniel E.] Mayo Clin, Dept Internal Med, 4500 San Pablo Rd, Jacksonville, FL 32224 USA; [Johns, Gretchen S.] Mayo Clin, Div Lab Med & Pathol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA; [Edwards, Eric] Mayo Clin, Dept Hosp Internal Med, 4500 San Pablo Rd, Jacksonville, FL 32224 USA		Edwards, E (通讯作者)，Mayo Clin, Dept Hosp Internal Med, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	wiest.nathaniel@mayo.edu; johns.gretchen@mayo.edu; edwards.eric@mayo.edu		Wiest, Nathaniel/0000-0002-6211-2716			Al-Maqbali JS, 2021, AM J CASE REP, V22, DOI 10.12659/AJCR.932946; [Anonymous], COVID-19 Dashboard by the Center for Systems Science and Engineering (CSEE) at Johns Hopkins University (JHU); ARNOUT J, 1994, BRIT J HAEMATOL, V87, P94, DOI 10.1111/j.1365-2141.1994.tb04876.x; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bowles L, 2020, NEW ENGL J MED, V383, P288, DOI 10.1056/NEJMc2013656; Carli G, 2021, INTERN EMERG MED, V16, P803, DOI 10.1007/s11739-021-02685-0; De Kesel PMM, 2020, RES PRACT THROMB HAE, V4, P161, DOI 10.1002/rth2.12264; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; (HHS) USDoHaHS, VACC ADV EV REP SYST; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; Lee GM, 2013, HEMATOL-AM SOC HEMAT, P668, DOI 10.1182/asheducation-2013.1.668; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; MacNeil JR, 2021, MMWR-MORBID MORTAL W, V70, P651, DOI 10.15585/mmwr.mm7017e4; Mahase E, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1046; Malas MB, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100639; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Nevzorova TA, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0188-0; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Radic M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00969; SCHJETLEIN R, 1995, AM J CLIN PATHOL, V103, P108, DOI 10.1093/ajcp/103.1.108; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Smadja DM, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.00956-2021; Taquet M., 2021, CEREBRAL VENOUS THRO, DOI [10.1101/2021.04.27.21256153v1, DOI 10.1101/2021.04.27.21256153V1]; Thachil J, 2020, J THROMB HAEMOST, V18, P2408, DOI 10.1111/jth.14956; Toom S, 2021, AM J HEMATOL, V96, pE134, DOI 10.1002/ajh.26128; Tung ML, 2021, RHEUMATOL ADV PRACT, V5, DOI 10.1093/rap/rkaa081	27	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							903	10.3390/vaccines9080903			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4QH	34452028	Green Published, gold			2022-04-29	WOS:000689917100001
J	Atanackovic, D; Luetkens, T; Avila, SV; Hardy, NM; Lutfi, F; Sanchez-Petitto, G; Vander Mause, E; Glynn, N; Mannuel, HD; Alkhaldi, H; Hankey, K; Baddley, J; Dahiya, S; Rapoport, AP				Atanackovic, Djordje; Luetkens, Tim; Avila, Stephanie, V; Hardy, Nancy M.; Lutfi, Forat; Sanchez-Petitto, Gabriela; Vander Mause, Erica; Glynn, Nicole; Mannuel, Heather D.; Alkhaldi, Hanan; Hankey, Kim; Baddley, John; Dahiya, Saurabh; Rapoport, Aaron P.			Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant	VACCINES			English	Article						allogeneic stem cell transplant; COVID-19; SARS-CoV-2; antibody responses; T cells; vaccine; immunology; immunotherapy		Patients after autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) are at an increased risk of COVID-19-related morbidity and mortality, compounded by an immune system weakened by the underlying malignancy and prior treatments. Allogeneic transplantation, including stem cell and solid organ transplants, requires intensive immunosuppressive prophylaxis, which may further undermine the development of a protective vaccine-induced anti-viral immunity. Herein, we report on short- and long-term antiviral immune responses in two peri-stem cell transplant recipients and a third patient who received a COVID-19 vaccination after kidney transplantation. Our data indicate that: (1) patients post-alloSCT may be able to mount an anti-COVID-19 immune response; however, a sufficient time interval between transplant and exposure may be of critical importance; (2) alloSCT recipients with preexisting anti-SARS-CoV-2 immunity are at risk for losing protective humoral immunity following transplantation, particularly if the stem-cell donor lacks antiviral immunity, e.g., vaccine-derived immunity; and (3) some post-transplant patients are completely unable to build an immune response to a COVID-19 vaccine, perhaps based on the prophylactic suppression of T cell immunity.	[Atanackovic, Djordje; Luetkens, Tim; Avila, Stephanie, V; Hardy, Nancy M.; Vander Mause, Erica; Glynn, Nicole; Hankey, Kim; Dahiya, Saurabh; Rapoport, Aaron P.] Univ Maryland, Dept Med, Transplant & Cellular Therapy Program, Sch Med, Baltimore, MD 21201 USA; [Atanackovic, Djordje; Luetkens, Tim; Avila, Stephanie, V; Hardy, Nancy M.; Vander Mause, Erica; Glynn, Nicole; Hankey, Kim; Baddley, John; Dahiya, Saurabh; Rapoport, Aaron P.] Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Atanackovic, Djordje; Luetkens, Tim] Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; [Lutfi, Forat; Sanchez-Petitto, Gabriela; Alkhaldi, Hanan] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Lutfi, Forat; Sanchez-Petitto, Gabriela; Alkhaldi, Hanan] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Mannuel, Heather D.] Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Hematol Oncol, Baltimore, MD 21201 USA; [Mannuel, Heather D.] Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA; [Baddley, John] Univ Maryland, Div Infect Dis, Sch Med, Baltimore, MD 21201 USA		Atanackovic, D (通讯作者)，Univ Maryland, Dept Med, Transplant & Cellular Therapy Program, Sch Med, Baltimore, MD 21201 USA.; Atanackovic, D (通讯作者)，Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA.; Atanackovic, D (通讯作者)，Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.	datanackovic@som.umaryland.edu; tluetkens@som.umaryland.edu; savila@som.umaryland.edu; nhardyl@umm.edu; FLutfi@som.umaryland.edu; gabriela.sanchez@umm.edu; EVanderMause@som.umaryland.edu; nglynn@umm.edu; hmannuel@umm.edu; HananAlkhaldi@umm.edu; KHankey@som.umaryland.edu; jbaddley@ilivumaryland.edu; SDahiya@som.umaryland.edu; ARapoport@som.umaryland.edu		Baddley, John/0000-0001-9111-625X	Kahlert Foundation	This research was supported by a grant from The Kahlert Foundation to D.A.	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Aries JA, 2020, BRIT J HAEMATOL, V190, pE64, DOI 10.1111/bjh.16852; Atanackovic D, 2020, LEUKEMIA, V34, P317, DOI 10.1038/s41375-019-0536-3; Cattaneo C, 2020, CANCER-AM CANCER SOC, V126, P5069, DOI 10.1002/cncr.33160; Chari A, 2020, BLOOD, V136, P3033, DOI 10.1182/blood.2020008150; Coll E, 2021, AM J TRANSPLANT, V21, P1825, DOI 10.1111/ajt.16369; Du Z, 2020, J MED VIROL, V92, P1735, DOI 10.1002/jmv.25820; Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711; Harvey Raymond A, 2020, medRxiv, DOI 10.1101/2020.12.18.20248336; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Luetkens T, 2020, BLOOD ADV, V4, P4864, DOI 10.1182/bloodadvances.2020002595; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rabinowich L, 2021, J HEPATOL, V75, P435, DOI 10.1016/j.jhep.2021.04.020; Sahu Kamal Kant, 2021, Ther Adv Infect Dis, V8, p20499361211013252, DOI 10.1177/20499361211013252; Thevarajan I, 2020, NAT MED, V26, P453, DOI 10.1038/s41591-020-0819-2; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wei J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000862; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	21	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							737	10.3390/vaccines9070737			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6AD	34358153	Green Published, gold			2022-04-29	WOS:000676991000001
J	Cazzato, G; Romita, P; Foti, C; Cimmino, A; Colagrande, A; Arezzo, F; Sablone, S; Barile, A; Lettini, T; Resta, L; Ingravallo, G				Cazzato, Gerardo; Romita, Paolo; Foti, Caterina; Cimmino, Antonietta; Colagrande, Anna; Arezzo, Francesca; Sablone, Sara; Barile, Angela; Lettini, Teresa; Resta, Leonardo; Ingravallo, Giuseppe			Purpuric Skin Rash in a Patient Undergoing Pfizer-BioNTech COVID-19 Vaccination: Histological Evaluation and Perspectives	VACCINES			English	Article						SARS-CoV-2; COVID-19; skin; rash; purpuric; vaccines		The COVID-19 pandemic has affected the entire planet, and within about a year and a half, has led to 174,502,686 confirmed cases of COVID-19 worldwide, with 3,770,361 deaths. Although it is now clear that SARS-CoV-2 can affect various different organs, including the lungs, brain, skin, vessels, placenta and others, less is yet known about adverse reactions from vaccines, although more and more reports are starting to emerge. Among the adverse events, we focused particularly on skin rashes. In this short report, we describe the case of a patient vaccinated with Comirnaty, who developed a purpuric rash resistant to oral steroid therapy after 2 weeks. To date, this is one of the very few cases in which skin biopsy was performed to better characterize the histopathological picture of this rash. Finally, we conduct a literature review of the cases of rashes from SARS-CoV-2 vaccines described in the literature, with the aim of laying foundations for future, larger case studies.	[Cazzato, Gerardo; Foti, Caterina; Cimmino, Antonietta; Colagrande, Anna; Barile, Angela; Lettini, Teresa; Resta, Leonardo; Ingravallo, Giuseppe] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat DETO, Sect Pathol, I-70124 Bari, Italy; [Romita, Paolo] Univ Bari, Dept Biomed Sci & Human Oncol, Dermatol Clin, I-70124 Bari, Italy; [Arezzo, Francesca] Gynecol & Obstet Clin, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy; [Sablone, Sara] Univ Bari, Polidin Bari Hosp, Dept Interdisciplinary Med, Sect Legal Med, I-70124 Bari, Italy		Cazzato, G (通讯作者)，Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat DETO, Sect Pathol, I-70124 Bari, Italy.	gerycazzato@hotmail.it; paolo.romita@uniba.it; caterina.foti@uniba.it; micasucci@inwind.it; anna.colagrande@gmail.com; francesca.arezzo@uniba.it; sarasabloneml@gmail.com; angela.barile66@libero.it; lettinit@yahoo.com; leonardo.resta@uniba.it; giuseppe.ingravallo@uniba.it	Cazzato, Gerardo/AAH-7941-2021; INGRAVALLO, Giuseppe/Q-1477-2016	Cazzato, Gerardo/0000-0003-0325-4316; INGRAVALLO, Giuseppe/0000-0002-4792-3545; Sablone, Sara/0000-0002-2864-3521; Lettini, Teresa/0000-0003-0860-3044; Resta, Leonardo/0000-0003-4335-4776			Ackerman M, 2021, J EUR ACAD DERMATOL, V35, pE423, DOI 10.1111/jdv.17248; Blumenthal KG, 2021, NEW ENGL J MED, V384, P1273, DOI 10.1056/NEJMc2102131; Cazzato G, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11060838; Cazzato G, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081566; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; CLARK PS, 1971, CALIF MED, V115, P7; Corbeddu M, 2021, J EUR ACAD DERMATOL, V35, pE483, DOI 10.1111/jdv.17268; Fernandez-Nieto D, 2021, J EUR ACAD DERMATOL, V35, pE425, DOI 10.1111/jdv.17250; Fotuhi M, 2020, J ALZHEIMERS DIS, V76, P3, DOI 10.3233/JAD-200581; Grandolfo M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13499; Gronbeck C, 2021, CLIN DERMATOL, V39, P674, DOI 10.1016/j.clindermatol.2021.05.027; Hashizume Hideo, 2021, Arerugi, V70, P1, DOI 10.15036/arerugi.70.1; Hendaus MA, 2021, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2021.1927847; Ingravallo G, 2021, PEDIATRIC REP, V13, P181, DOI 10.3390/pediatric13020025; Johnston MS, 2021, JAMA DERMATOL, V157, P716, DOI 10.1001/jamadermatol.2021.1214; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; McMahon DE, 2021, J AM ACAD DERMATOL, V85, P46, DOI 10.1016/j.jaad.2021.03.092; MILIAUSKAS JR, 1993, AM J SURG PATHOL, V17, P516, DOI 10.1097/00000478-199305000-00012; Mohamadian M, 2021, J GENE MED, V23, DOI 10.1002/jgm.3303; Ohsawa R, 2021, J DERMATOL SCI, V103, P124, DOI 10.1016/j.jdermsci.2021.06.006; ONWUKWE M F, 1973, International Journal of Dermatology, V12, P290, DOI 10.1111/j.1365-4362.1973.tb00057.x; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Resta L, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13060995; Resta L, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050723; Ring J, 2021, J EUR ACAD DERMATOL, V35, pE362, DOI 10.1111/jdv.17237; Rutkowski K, 2021, CLIN EXP ALLERGY, V51, P770, DOI 10.1111/cea.13880; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Silveira MM, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118919; Wolf ME, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081599; Wollenberg A, 2020, J EUR ACAD DERMATOL, V34, P2717, DOI 10.1111/jdv.16892; World Health Organization (WHO), DASHBOARD; Xu SQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186582; Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533	33	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							760	10.3390/vaccines9070760			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5SP	34358176	gold, Green Published			2022-04-29	WOS:000676971400001
J	Lampo, M; Hernandez-Villena, JV; Cascante, J; Vincenti-Gonzalez, MF; Forero-Pena, DA; Segovia, MJ; Hampson, K; Castro, J; Grillet, ME				Lampo, Margarita; Hernandez-Villena, Juan V.; Cascante, Jaime; Vincenti-Gonzalez, Maria F.; Forero-Pena, David A.; Segovia, Maikell J.; Hampson, Katie; Castro, Julio; Grillet, Maria Eugenia			Signatures of the Venezuelan Humanitarian Crisis in the First Wave of COVID-19: Fuel Shortages and Border Migration	VACCINES			English	Article						SEI models; metapopulations; Venezuela; SARS-CoV-2; drivers of transmission; spatial incidence		Testing and isolation have been crucial for controlling the COVID-19 pandemic. Venezuela has one of the weakest testing infrastructures in Latin America and the low number of reported cases in the country has been attributed to substantial underreporting. However, the Venezuelan epidemic seems to have lagged behind other countries in the region, with most cases occurring within the capital region and four border states. Here, we describe the spatial epidemiology of COVID-19 in Venezuela and its relation to the population mobility, migration patterns, non-pharmaceutical interventions and fuel availability that impact population movement. Using a metapopulation model of SARS-CoV-2 transmission dynamics, we explore how movement patterns could have driven the observed distribution of cases. Low within-country connectivity most likely delayed the onset of the epidemic in most states, except for those bordering Colombia and Brazil, where high immigration seeded outbreaks. NPIs slowed early epidemic growth and subsequent fuel shortages appeared to be responsible for limiting the spread of COVID-19 across the country.	[Lampo, Margarita; Grillet, Maria Eugenia] Acad Ciencias Fis Matemat & Nat, Palacio Acad, Av Univ, Caracas 1030, Venezuela; [Hernandez-Villena, Juan V.; Grillet, Maria Eugenia] Univ Cent Venezuela, Fac Ciencias, Inst Zool & Ecol Trop, Lab Biol Vectores & Parasitos, Caracas 1058, Venezuela; [Cascante, Jaime] Univ Los Andes, Dept Ingn Biomed, Grp Biol Matemat & Computac, Bogota 111711, Colombia; [Vincenti-Gonzalez, Maria F.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, NL-9713 GZ Groningen, Netherlands; [Forero-Pena, David A.] Biomed Res & Therapeut Vaccines Inst, Ciudad Bolivar 8001, Venezuela; [Segovia, Maikell J.; Castro, Julio] Univ Cent Venezuela, Fac Med, Inst Med Trop, Caracas 1058, Venezuela; [Hampson, Katie] Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow G12 8QQ, Lanark, Scotland		Lampo, M (通讯作者)，Acad Ciencias Fis Matemat & Nat, Palacio Acad, Av Univ, Caracas 1030, Venezuela.	mlampo@gmail.com; juanv.hernandezv@gmail.com; je.cascante10@uniandes.edu.co; mfvg87@gmail.com; davidnica1991@hotmail.com; segoviamaikell@gmail.com; Katie.Hampson@glasgow.ac.uk; juliocastrom@gmail.com; mariaeugenia.grillet@gmail.com		Vincenti-Gonzalez, Maria/0000-0003-1364-1774; Lampo, Margarita/0000-0002-3669-701X; Segovia, Maikell/0000-0002-6015-8120; Hampson, Katie/0000-0001-5392-6884; Forero, David/0000-0002-8065-8464; Hernandez Villena, Juan Vicente/0000-0001-9006-8380	COVID Rapid Response (GCRF Grant, Engagement Network, Small Grant Funds University of Glasgow); Scottish Funding Council; Global Challenges Research Fund; United Kingdom Embassy in Caracas [INT 2021/VEC C19]; Wellcome TrustWellcome TrustEuropean Commission [095787/Z/11/Z]; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/T003782/1] Funding Source: UKRI	This research was funded by the COVID Rapid Response (GCRF Grant, Engagement Network, Small Grant Funds University of Glasgow), Scottish Funding Council, Global Challenges Research Fund and the United Kingdom Embassy in Caracas (Project INT 2021/VEC C19). KH was supported by Wellcome Trust (095787/Z/11/Z).	Abbott S., 2020, WELLCOME OPEN RES, V5, P112, DOI [DOI 10.12688/WELLCOMEOPENRES.16006.1, 10.12688/wellcomeopenres.16006.1]; ACFIMAN, 2020, EST ACT EP COVID 19; [Anonymous], 2021, DIESEL SHORTAGE ONCE; [Anonymous], 2021, VENEZUELA INFLATION; [Anonymous], 2020, VENEZUELA TRAVEL RES; Badr HS, 2020, LANCET INFECT DIS, V20, P1247, DOI 10.1016/S1473-3099(20)30553-3; Balcan D, 2009, P NATL ACAD SCI USA, V106, P21484, DOI 10.1073/pnas.0906910106; Besson ESK, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004564; Burki T, 2020, LANCET INFECT DIS, V20, P547, DOI 10.1016/S1473-3099(20)30303-0; Chen YL, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83166-4; Daniels JP, 2020, LANCET, V395, P1023, DOI 10.1016/S0140-6736(20)30718-2; Du ZW, 2020, EMERG INFECT DIS, V26, P1341, DOI [10.3201/eid2606.200357, 10.1101/2020.02.19.20025452]; Feng YJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244351; Grillet ME, 2019, LANCET INFECT DIS, V19, pE149, DOI 10.1016/S1473-3099(18)30757-6; Gu Y., 2020, ESTIMATING TRUE INFE; Instituto de Investigaciones Economicas y Sociales UCAB, 2020, IND SOC INSO ENCOVI; Jombart T., 2020, Wellcome Open Research, V5, DOI 10.12688/wellcomeopenres.15786.1; Kang D, 2020, INT J INFECT DIS, V94, P96, DOI 10.1016/j.ijid.2020.03.076; Li RY, 2020, SCIENCE, V368, P489, DOI [10.1126/science.abb3221, 10.1101/2020.02.14.20023127]; Loureiro CL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247196; Mwananyanda L., COVID 19 DEATHS DETE, DOI [10.1101/2020.12.22.20248327, DOI 10.1101/2020.12.22.20248327]; Nouvellet P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21358-2; OAS, 2020, SIT REP VEN MIGR REF; OCHA, 2020, VEN JUN 2020 INF SIT; Paniz-Mondolfi AE, 2020, LANCET, V395, pE85, DOI 10.1016/S0140-6736(20)31053-9; Phung P., 2020, EVALUATION UNHCR REG; Roser M., 2020, CORONAVIRUS PANDEMIC; Salyer SJ, 2021, LANCET, V397, P1265, DOI 10.1016/S0140-6736(21)00632-2; Saravia A., 2021, VENEZUELA POLITICS O; Trujillo V.E.C., 2020, CARACAS, V128, P273; Watson O., 2020, 39 IMP COLL LOND, DOI [10.25561/84283, DOI 10.25561/84283]; Yapur N., 2020, BLOOMBERG	32	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							719	10.3390/vaccines9070719			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7HN	34358135	Green Published, gold, Green Accepted			2022-04-29	WOS:000677077800001
J	Savoia, E; Piltch-Loeb, R; Goldberg, B; Miller-Idriss, C; Hughes, B; Montrond, A; Kayyem, J; Testa, MA				Savoia, Elena; Piltch-Loeb, Rachael; Goldberg, Beth; Miller-Idriss, Cynthia; Hughes, Brian; Montrond, Alberto; Kayyem, Juliette; Testa, Marcia A.			Predictors of COVID-19 Vaccine Hesitancy: Socio-Demographics, Co-Morbidity, and Past Experience of Racial Discrimination	VACCINES			English	Article						COVID-19; vaccine hesitancy; discrimination	INFLUENZA VACCINATION; DISPARITIES; TRUST	The goal of this study is to explore predictors of COVID-19 vaccine hesitancy, including socio-demographic factors, comorbidity, risk perception, and experience of discrimination, in a sample of the U.S. population. We used a cross-sectional online survey study design, implemented between 13-23 December 2020. The survey was limited to respondents residing in the USA, belonging to priority groups for vaccine distribution. Responses were received from 2650 individuals (response rate 84%) from all 50 states and Puerto Rico, American Samoa, and Guam. The five most represented states were California (13%), New York (10%), Texas (7%), Florida (6%), and Pennsylvania (4%). The majority of respondents were in the age category 25-44 years (66%), male (53%), and working in the healthcare sector (61%). Most were White and non-Hispanic (66%), followed by Black and non-Hispanic (14%) and Hispanic (8%) respondents. Experience with racial discrimination was a predictor of vaccine hesitancy. Those reporting racial discrimination had 21% increased odds of being at a higher level of hesitancy compared to those who did not report such experience (OR = 1.21, 95% C.I. 1.01-1.45). Communication and logistical aspects during the COVID-19 vaccination campaign need to be sensitive to individuals' past-experience of racial discrimination in order to increase vaccine coverage.	[Savoia, Elena; Piltch-Loeb, Rachael; Montrond, Alberto; Testa, Marcia A.] Harvard TH Chan Sch Publ Hlth, Emergency Preparedness Res Evaluat & Practice EPR, Div Policy Translat & Leadership Dev, 90 Smith St, Boston, MA 02115 USA; [Savoia, Elena; Testa, Marcia A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, 677 Huntington Ave, Boston, MA 02115 USA; [Goldberg, Beth] Google LLC, Jigsaw, 82th 10th Ave, New York, NY 10024 USA; [Miller-Idriss, Cynthia; Hughes, Brian] Amer Univ, Ctr Univ Excellence CUE, 4400 Massachusetts Ave NW, Washington, DC 20016 USA; [Miller-Idriss, Cynthia; Hughes, Brian] Amer Univ, Polarizat & Extremism Res & Innovat Lab PERIL, 4400 Massachusetts Ave NW, Washington, DC 20016 USA; [Kayyem, Juliette] Harvard Univ, Belfer Ctr Sci & Int Affairs, Harvard Kennedy Sch, 79 John F Kennedy St, Cambridge, MA 02138 USA; [Testa, Marcia A.] Massachusetts Assoc Hlth Boards, 20 Walnut St,Suite 110, Wellesley, MA 02481 USA		Savoia, E (通讯作者)，Harvard TH Chan Sch Publ Hlth, Emergency Preparedness Res Evaluat & Practice EPR, Div Policy Translat & Leadership Dev, 90 Smith St, Boston, MA 02115 USA.; Savoia, E (通讯作者)，Harvard TH Chan Sch Publ Hlth, Dept Biostat, 677 Huntington Ave, Boston, MA 02115 USA.	esavoia@hsph.harvard.edu; piltch-loeb@hsph.harvard.edu; bethgoldberg@google.com; cynthia@american.edu; bhughes@american.edu; amontrond@hsph.harvard.edu; Juliette_Kayyem@hks.harvard.edu; testa@hsph.harvard.edu		Miller-Idriss, Cynthia/0000-0002-2849-0799	Jigsaw Google LLC [37088-A210057-S001]	Research reported in this publication was supported by Jigsaw Google LLC under award number 37088-A210057-S001. The content is solely the responsibility of the authors and does not necessarily represent the official views of Jigsaw Google LLC.	[Anonymous], 2018, PUBL HLTH EM PREP RE PUBL HLTH EM PREP RE; [Anonymous], 2020, COVID 19 VACC PROGR; Artiga S., RACIAL DISPARITIES F; Bajaj SS, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMpv2035827; Blendon RJ, 2003, J HEALTH COMMUN, V8, P83, DOI 10.1080/10810730390224884; Bleser WK, 2016, MED CARE, V54, P570, DOI 10.1097/MLR.0000000000000544; Centers for disease control and prevention (CDC), 2016, FLU VACCINATION COVE; Dooling K, 2021, MMWR-MORBID MORTAL W, V69, P1657, DOI 10.15585/mmwr.mm695152e2; Hand DJ, 2001, MACH LEARN, V45, P171, DOI 10.1023/A:1010920819831; Jamison AM, 2019, SOC SCI MED, V221, P87, DOI 10.1016/j.socscimed.2018.12.020; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Lin L, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-484; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033; Savoia E, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-328; SteelFisher GK, 2021, NEW ENGL J MED, V384, P1483, DOI 10.1056/NEJMp2100351; Sternthal MJ, 2011, DU BOIS REV, V8, P95, DOI 10.1017/S1742058X11000087; Taylor-Clark KA, 2010, HEALTH COMMUN, V25, P221, DOI 10.1080/10410231003698895; Warren RC, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2030033; Woko C, 2020, J HEALTH COMMUN, V25, P819, DOI 10.1080/10810730.2020.1864521	20	15	15	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							767	10.3390/vaccines9070767			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7BS	34358184	Green Submitted, gold, Green Published			2022-04-29	WOS:000677062700001
J	Wang, JL; Zhang, Y; Long, SG; Fu, X; Zhang, XX; Zhao, SY; Xiu, SX; Wang, XW; Lu, B; Jin, H				Wang, Jianli; Zhang, Yan; Long, Sigui; Fu, Xin; Zhang, Xiaoxuan; Zhao, Shuangyu; Xiu, Shixin; Wang, Xuwen; Lu, Bing; Jin, Hui			Non-EPI Vaccine Hesitancy among Chinese Adults: A Cross-Sectional Study	VACCINES			English	Article						Chinese adults; vaccine hesitancy; non-EPI vaccine; COVID-19 vaccine	COVID-19 VACCINATION; PERCEPTIONS; BEHAVIORS; NURSES	Vaccination against coronavirus disease 2019 (COVID-19) is paramount to curtailing the pandemic. However, the impact of the Non-Expanded Program on Immunization (non-EPI) and COVID-19 vaccine hesitancy on vaccine uptake among Chinese adults remain unclear. This study was an online survey performed in Eastern, Central, and Western China between February 2021 and March 2021 using proportional sampling (n = 7381). Adults aged >= 18 years were included, especially younger people (aged < 65). Vaccine hesitancy was assessed using the 3C model and relative scales; logistic regression was used to explore the factors affecting vaccination uptake; structural equation modeling was used to evaluate the correlations between variables. Overall, 67.6% and 24.7% of adults reported vaccine hesitancy toward the non-EPI and COVID-19 vaccines, respectively. Participants (66.3%) reported taking the vaccine mainly based on recommendations from medical staff. Vaccine-hesitant participants (60.5%) reported a fear of side effects as the deciding factor in vaccine rejection. Vaccine hesitancy interacted negatively with confidence (beta = -0.349, p < 0.001) and convenience (beta = -0.232, p < 0.001), and positively with complacence (beta = 0.838, p < 0.001). Nonmedical personnel, adults who had previously received the influenza vaccine, and older people had lower vaccine hesitancy than their counterparts. Most Chinese adults have non-EPI but not COVID-19 vaccine hesitancy. Vaccine safety remains a concern.	[Wang, Jianli; Zhang, Yan; Long, Sigui; Fu, Xin; Zhang, Xiaoxuan; Zhao, Shuangyu; Jin, Hui] Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Nanjing 210009, Peoples R China; [Wang, Jianli; Zhang, Yan; Long, Sigui; Fu, Xin; Zhang, Xiaoxuan; Zhao, Shuangyu; Jin, Hui] Southeast Univ, Sch Publ Hlth, Key Lab Environm Med Engn, Minist Educ, Nanjing 210009, Peoples R China; [Xiu, Shixin; Wang, Xuwen; Lu, Bing] Wuxi Ctr Dis Control & Prevent, Wuxi 214023, Jiangsu, Peoples R China		Jin, H (通讯作者)，Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Nanjing 210009, Peoples R China.; Jin, H (通讯作者)，Southeast Univ, Sch Publ Hlth, Key Lab Environm Med Engn, Minist Educ, Nanjing 210009, Peoples R China.	213171070@seu.edu.cn; 213171093@seu.edu.cn; 213180365@seu.edu.cn; 213180456@seu.edu.cn; 213181280@seu.edu.cn; 213181074@seu.edu.cn; wxcdcsx@163.com; wxmgwang@163.com; Lub19661023@163.com; jinhuihld@seu.edu.cn			General Program of National Natural Science Fund [81573258]; COVID-19 Fund of Southeast University [3225002001c1]	This research was supported by the General Program of National Natural Science Fund (No. 81573258) and COVID-19 Fund of Southeast University (No. 3225002001c1).	Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826; Bogart L.M., 2021, WHAT CONTRIBUTES COV, DOI [10.7249/rra1110-1, DOI 10.7249/RRA1110-1]; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Carter S., 2020, HUMANITARIAN PROGRAM; Choi MJ, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e166; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008; He Q, 2020, VACCINE, V38, P6751, DOI 10.1016/j.vaccine.2020.08.039; Horne Z, 2015, P NATL ACAD SCI USA, V112, P10321, DOI 10.1073/pnas.1504019112; Iten A., 2013, ANTIMICROB RESIST IN, V2, DOI [10.1186/2047-2994-2-S1-P37, DOI 10.1186/2047-2994-2-S1-P37]; Jama A, 2019, PEDIATR HEALTH MED T, V10, P177, DOI 10.2147/PHMT.S212921; Krueger P, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-44; Kumar D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0062-y; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2014, HUM VACC IMMUNOTHER, V10, P2543, DOI 10.4161/21645515.2014.969618; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin L, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003599; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Liu XJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17197170; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Miton H, 2015, TRENDS COGN SCI, V19, P633, DOI 10.1016/j.tics.2015.08.007; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; Opel DJ, 2009, ARCH PEDIAT ADOL MED, V163, P432, DOI 10.1001/archpediatrics.2009.42; Rashid H, 2016, HEALTH AFFAIR, V35, P284, DOI 10.1377/hlthaff.2015.1087; Riphagen-Dalhuisen J, 2013, EUROSURVEILLANCE, V18, P10, DOI 10.2807/1560-7917.ES2013.18.26.20512; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Sun SF, 2021, PREV MED REP, V22, DOI 10.1016/j.pmedr.2021.101350; Wang C, 2021, VACCINE, V39, P2833, DOI 10.1016/j.vaccine.2021.04.020; Wang W, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4704; Wilson R, 2020, VACCINE, V38, P1144, DOI 10.1016/j.vaccine.2019.11.018; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P1511, DOI 10.1080/21645515.2019.1706935; Wyatt JC, 2000, J AM MED INFORM ASSN, V7, P426, DOI 10.1136/jamia.2000.0070426; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2; Zizzo J, 2021, HUM VACC IMMUNOTHER, V17, P1326, DOI 10.1080/21645515.2020.1831859	39	6	7	15	25	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							772	10.3390/vaccines9070772			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7FG	34358188	Green Published, gold			2022-04-29	WOS:000677071900001
J	Casale, M; Di Maio, N; Verde, V; Scianguetta, S; Di Girolamo, MG; Tomeo, R; Roberti, D; Misso, S; Perrotta, S				Casale, Maddalena; Di Maio, Nicoletta; Verde, Valentina; Scianguetta, Saverio; Di Girolamo, Maria Grazia; Tomeo, Rita; Roberti, Domenico; Misso, Saverio; Perrotta, Silverio			Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients	VACCINES			English	Article						transfusion; red blood cells; measles; mumps; rubella; live attenuated vaccine	IMMUNE GLOBULIN; THALASSEMIA; IMMUNOMODULATION; PERSISTENCE; ANTIBODIES; CHILDREN; INFANTS	Measles, mumps and rubella (MMR) still determine significant morbidity and mortality, although a highly effective vaccine is available. Postponing the MMR vaccination until 6 months after the last red blood cell (RBC) transfusion is recommended, but this delay is incompatible with chronic transfusions. The present study aimed at investigating the impact of blood transfusions on the immunogenicity of the MMR vaccine. In this observational study, a group of 45 transfusion- dependent (TD) patients was compared to 24 non-transfusion-dependent (NTD) patients. Immunity to measles was achieved in 35 (78%) TD and 21 (88%) NTD subjects (p = 0.7), to mumps in 36 (80%) TD and 21 (88%) NTD subjects (p = 0.99), and to rubella in 40 (89%) TD and 23 (96%) NTD subjects (p = 0.99). No significant difference was observed in the number of non-immune individuals or those with doubtful protection between the two groups (p > 0.05). The mean IgG value, assayed in 50 pre-storage leukoreduced RBC units, was 0.075 +/- 0.064 mg/mL, ten times lower than the level assumed in blood units and considered detrimental to the immune response in TD patients. This work shows a favorable response to MMR vaccination in TD and NTDT patients and paves the way for further larger studies assessing the impact of chronic transfusions on vaccine response.	[Casale, Maddalena; Di Maio, Nicoletta; Verde, Valentina; Scianguetta, Saverio; Roberti, Domenico; Perrotta, Silverio] Univ Luigi Vanvitelli, Dept Women Child & Gen & Specialized Surg, I-80138 Naples, Italy; [Di Girolamo, Maria Grazia; Tomeo, Rita; Misso, Saverio] ASL Caserta, Immunotransfus Serv, I-81031 Aversa, Italy		Casale, M (通讯作者)，Univ Luigi Vanvitelli, Dept Women Child & Gen & Specialized Surg, I-80138 Naples, Italy.	maddalena.casale@unicampania.it; nicolettadimaio@virgilio.it; valentina.verde@unicampania.it; saverio.scianguetta@unicampania.it; mg.digirolamo@gmail.com; ritatomeo@libero.it; Domenico.Roberti@nyumc.org; saveriomisso@libero.it; silverio.perrotta@unicampania.it		Di Maio, Nicoletta/0000-0002-1224-0242; casale, maddalena/0000-0003-4740-2421; Perrotta, Silverio/0000-0001-6149-6845; VERDE, VALENTINA/0000-0001-6540-096X	University of Campania "Luigi Vanvitelli" (VALERE Project); American Society of Hematology (ASH Global Research Award 2019)	This work was supported by a grant from the University of Campania "Luigi Vanvitelli" (VALERE Project) and from the American Society of Hematology (ASH Global Research Award 2019). Authors thank Anne Freckleton for her help in the preparation of this paper.	ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4; Amendola A, 2021, EMERG INFECT DIS, V27, P648, DOI 10.3201/eid2702.204632; Anichini G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010066; Arvas A, 2014, TURK PEDIATR ARSIVI, V49, P181, DOI 10.5152/tpa.2014.2206; Bianchi FP, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7829-3; Bockelman C, 2018, J EMERG MED, V54, P207, DOI 10.1016/j.jemermed.2017.08.037; Borgna-Pignatti C, 2004, HAEMATOLOGICA, V89, P1187; Bouthry E, 2014, PRENATAL DIAG, V34, P1246, DOI 10.1002/pd.4467; Buchanan R, 2012, SEMIN PEDIATR NEUROL, V19, P107, DOI 10.1016/j.spen.2012.02.003; Cappellini MD, 2014, GUIDELINES MANAGEMEN; Carryn S, 2019, VACCINE, V37, P5323, DOI 10.1016/j.vaccine.2019.07.049; Casale M, 2019, BLOOD TRANSFUS-ITALY, V17, P165, DOI 10.2450/2018.0092-18; Casale M, 2019, AM J HEMATOL, V94, P312, DOI 10.1002/ajh.25370; Casale M, 2011, EXPERT REV HEMATOL, V4, P627, DOI 10.1586/EHM.11.51; Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993; De Franceschi L, 2019, BLOOD, V133, P2100, DOI 10.1182/blood-2018-09-876508; Demicheli V, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004407.pub3; Di Pietrantonj C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004407.pub4; Franchini M, 2019, BLOOD TRANSFUS-ITALY, V17, P4, DOI 10.2450/2019.0229-18; Gianesin B, 2020, ANN HEMATOL, V99, P2047, DOI 10.1007/s00277-020-04188-y; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; KAPLAN JE, 1984, B WORLD HEALTH ORGAN, V62, P585; Kroger Andrew T., 2006, Morbidity and Mortality Weekly Report, V55, P1; Lombardo D, 2020, ADV RESPIR MED, V88, P197, DOI 10.5603/ARM.2020.0118; Ma SJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001721; Mancusi S, 2013, J NEPHROL, V26, P207, DOI 10.5301/jn.5000126; McLean HQ, 2013, MMWR RECOMM REP, V62, P1; Mina MJ, 2015, SCIENCE, V348, P694, DOI 10.1126/science.aaa3662; Ministero della Sanita, 12 MIN SAN; Miura M, 2004, EUR J PEDIATR, V163, P25, DOI 10.1007/s00431-003-1335-3; Modell B, 2008, B WORLD HEALTH ORGAN, V86, P480, DOI 10.2471/BLT.06.036673; Orenstein WA, 2018, VACCINE, V36, pA35, DOI 10.1016/j.vaccine.2017.10.065; Public Health England, 2013, GREENB IMM INF DIS; RUDERMAN JW, 1991, AM J DIS CHILD, V145, P425; Russo G, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1099-0; SIBER GR, 1993, J PEDIATR-US, V122, P204, DOI 10.1016/S0022-3476(06)80114-9; Tacke CE, 2013, J ALLERGY CLIN IMMUN, V131, P1701, DOI 10.1016/j.jaci.2013.01.045; Tischer A, 2000, VACCINE, V18, P1382, DOI 10.1016/S0264-410X(99)00397-7; Velasquez Daniel E, 2018, Expert Rev Vaccines, V17, P145, DOI 10.1080/14760584.2018.1418665; Wanachiwanawin W, 2000, J PEDIAT HEMATOL ONC, V22, P581, DOI 10.1097/00043426-200011000-00027; Youssef LA, 2017, CURR OPIN HEMATOL, V24, P551, DOI 10.1097/MOH.0000000000000376; Zabeida A, 2019, TRANSFUSION, V59, P2806, DOI 10.1111/trf.15433	42	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							561	10.3390/vaccines9060561			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY4TT	34072263	Green Published, gold			2022-04-29	WOS:000665883200001
J	Hedges, JF; Thompson, MA; Snyder, DT; Robison, A; Taylor, MP; Jutila, MA				Hedges, Jodi F.; Thompson, Macy A.; Snyder, Deann T.; Robison, Amanda; Taylor, Matthew P.; Jutila, Mark A.			Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination	VACCINES			English	Article						anti-RBD IgG; antibodies; SARS-CoV-2; COVID-19; neutralization; duration; asymptomatic; vaccine	PERSISTENT	Information concerning the development of neutralizing antibodies and their duration will be critical to establishing herd immunity for COVID-19. We sought to evaluate SARS-CoV-2 spike protein receptor-binding domain (RBD)-specific antibodies, their duration, and capacity for SARS-CoV-2 neutralization in volunteers while the pandemic spread within our community starting in March 2020. Those participants with the highest starting titers had the longest-lasting response, up to 12 months post-diagnosis. SARS-CoV-2 neutralization capacity was correlated with anti-RBD antibody levels. The majority of our participants with confirmed COVID-19 diagnosis had very mild or asymptomatic infections. We also detected low and largely non-neutralizing anti-RBD IgG titers in a few participants with no known COVID-19 diagnosis. Finally, we found that antibody responses induced by vaccination were significantly higher than those induced by natural infection. Thus, our study suggests that vaccination is still critical even for those naturally infected or diagnosed with COVID-19.	[Hedges, Jodi F.; Thompson, Macy A.; Snyder, Deann T.; Robison, Amanda; Taylor, Matthew P.; Jutila, Mark A.] Montanta State Univ, Dept Microbiol & Cell Biol, Bozeman, MT 59717 USA		Hedges, JF (通讯作者)，Montanta State Univ, Dept Microbiol & Cell Biol, Bozeman, MT 59717 USA.	jodi.hedges@montana.edu; 14macythompson@gmail.com; deann.snyder@montana.edu; amanda.robison@montana.edu; mptaylor@montana.edu; mark.jutila@montana.edu		Snyder, Deann/0000-0003-3087-7260; Hedges, Jodi/0000-0002-7461-3972; Taylor, Matthew/0000-0003-0199-7175	Montana State University Vice President of Research, Economic Development and Graduate Education; NIH/NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3U01EB029242-02S1]; Montana Agricultural Experiment Station, USDA/NIFA Hatch; USDA/NIFA Multi-State	This work was supported by funding from the Montana State University Vice President of Research, Economic Development and Graduate Education. Partial funding was provided by NIH/NIBIB Grant 3U01EB029242-02S1, Montana Agricultural Experiment Station, USDA/NIFA Hatch and USDA/NIFA Multi-State.	Addetia Amin, 2020, medRxiv, DOI 10.1101/2020.08.13.20173161; Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1038/s41591-020-0913-5, 10.1101/2020.03.17.20037713]; Anand S, 2020, LANCET, V396, P1335, DOI 10.1016/S0140-6736(20)32009-2; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Brochot E, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.584251; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011; Hedges JF, 1999, J VIROL, V73, P3672, DOI 10.1128/JVI.73.5.3672-3681.1999; Higgins RL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247797; Jardine J.G., 2020, SARS COV 2 ANTIBODY, DOI [10.1101/2020.07.27.20162321, DOI 10.1101/2020.07.27.20162321]; Lau EHY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20247-4; Lei Q, 2021, ALLERGY, V76, P551, DOI 10.1111/all.14622; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Loveday EK., 2020, BIORXIV BIORXIV, P2020, DOI [10.1101/2020.11.14.383026, DOI 10.1101/2020.11.14.383026]; Malfertheiner SF, 2020, J CLIN VIROL, V130, DOI 10.1016/j.jcv.2020.104575; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Roltgen K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0240; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100; Wang XL, 2020, CLIN INFECT DIS, V71, P2688, DOI 10.1093/cid/ciaa721; Wang ZF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22036-z; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Wolf J, 2021, J PEDIAT INF DIS SOC, V10, P629, DOI 10.1093/jpids/piaa175; Yu XC, 2008, NATURE, V455, P532, DOI 10.1038/nature07231; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	32	0	0	1	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							587	10.3390/vaccines9060587			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5OL	34199357	gold, Green Published			2022-04-29	WOS:000665937000001
J	Kulus, J; Kulus, M; Stefanska, K; Sobolewski, J; Piotrowska-Kempisty, H; Mozdziak, P; Kempisty, B				Kulus, Jakub; Kulus, Magdalena; Stefanska, Katarzyna; Sobolewski, Jaroslaw; Piotrowska-Kempisty, Hanna; Mozdziak, Paul; Kempisty, Bartosz			SARS-CoV-2 Genetic Variability and Non-Specific Immunity Associated with the Use of Different BCG Strains-A Molecular and Clinical Approach	VACCINES			English	Review						SARS-CoV-2; COVID-19; BCG vaccinations; genetic variability; WHO recommendation; variants; tuberculosis	RESPIRATORY SYNDROME CORONAVIRUS; CALMETTE-GUERIN BCG; SPIKE PROTEIN; FUNCTIONAL RECEPTOR; CRUCIAL ROLE; VACCINATION; INFECTION; COVID-19; PATHOGENESIS; VARIANT	The effect of BCG vaccination against tuberculosis on the reduction in COVID-19 infection is related to the effect of the BCG vaccine on the immunomodulation of non-specific immunity. In the early stages of the pandemic, countries with universal BCG vaccination programs registered a low number of new cases of COVID-19, with the situation now reversed, as exemplified by India. The high genetic variability of SARS-CoV-2, a known characteristic of RNA viruses, causing the occurrence of SARS-CoV-2 variants may have led to the virus adapting to overcome the initial immune protection. The strains from the United Kingdom (B1.1.7), Brazil (B1.1.28 and B1.1.33), South Africa (B.1.351), and India (B.1.617) are characterized by a greater ability to spread in the environment, in comparison with the original infectious agent of SARS-CoV-2. It should be remembered that the large variation in the genetic makeup of SARS-CoV-2 may result in future changes in its pathogenicity, immunogenicity and antigenicity, and therefore it is necessary to carefully study the mutations occurring within the virus to determine whether the current vaccines will remain effective. However, most studies show that monoclonal antibodies produced after vaccination against COVID-19 are effective against the newly developed variants.	[Kulus, Jakub] Nicolaus Copernicus Univ Torun, Dept Diagnost & Clin Sci, Inst Vet Med, PL-87100 Torun, Poland; [Kulus, Magdalena; Kempisty, Bartosz] Nicolaus Copernicus Univ Torun, Dept Vet Surg, Inst Vet Med, PL-87100 Torun, Poland; [Stefanska, Katarzyna; Kempisty, Bartosz] Poznan Univ Med Sci, Dept Histol & Embryol, PL-60781 Poznan, Poland; [Sobolewski, Jaroslaw] Nicolaus Copernicus Univ Torun, Dept Publ Hlth Protect & Anim Welf, Inst Vet Med, PL-87100 Torun, Poland; [Piotrowska-Kempisty, Hanna] Poznan Univ Med Sci, Dept Toxicol, PL-60631 Poznan, Poland; [Piotrowska-Kempisty, Hanna] Nicolaus Copernicus Univ Torun, Dept Basic & Preclin Sci, Inst Vet Med, PL-87100 Torun, Poland; [Mozdziak, Paul; Kempisty, Bartosz] North Carolina State Univ, Prestage Dept Poultry Sci, Coll Agr & Life Sci, Raleigh, NC 27695 USA; [Kempisty, Bartosz] Poznan Univ Med Sci, Dept Anat, PL-60781 Poznan, Poland		Kempisty, B (通讯作者)，Nicolaus Copernicus Univ Torun, Dept Vet Surg, Inst Vet Med, PL-87100 Torun, Poland.; Kempisty, B (通讯作者)，Poznan Univ Med Sci, Dept Histol & Embryol, PL-60781 Poznan, Poland.; Kempisty, B (通讯作者)，North Carolina State Univ, Prestage Dept Poultry Sci, Coll Agr & Life Sci, Raleigh, NC 27695 USA.; Kempisty, B (通讯作者)，Poznan Univ Med Sci, Dept Anat, PL-60781 Poznan, Poland.	jakub.kulus@umk.pl; magdalena.kulus@umk.pl; k.stefanska94@o2.pl; jsobolewski@umk.pl; hpiotrow@ump.edu.pl; pemozdzi@ncsu.edu; bkempisty@ump.edu.pl		Stefanska, Katarzyna/0000-0002-8814-4935; Kulus, Magdalena/0000-0003-1098-5627; Sobolewski, Jaroslaw/0000-0002-0044-6956; Kulus, Jakub/0000-0003-0694-8006; mozdziak, paul/0000-0002-1575-3123			Alsaadi EAJ, 2019, FUTURE VIROL, V14, P275, DOI 10.2217/fvl-2018-0144; Amor S, 2020, CLIN EXP IMMUNOL, V202, P193, DOI 10.1111/cei.13523; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; Andersen P, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018523; Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Behr MA, 2002, LANCET INFECT DIS, V2, P86, DOI 10.1016/S1473-3099(02)00182-2; BELLIN E, 1994, JAMA-J AM MED ASSOC, V272, P765, DOI 10.1001/jama.1994.03520100029014; Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106; Bhutta ZA, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1190; Bianchi M, 2021, INT J BIOL MACROMOL, V170, P820, DOI 10.1016/j.ijbiomac.2020.12.142; Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7; Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1; Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055; Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x; Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380; Chu H, 2014, VIROLOGY, V454, P197, DOI 10.1016/j.virol.2014.02.018; Ciarlo E, 2020, J INFECT DIS, V222, P1869, DOI 10.1093/infdis/jiz692; Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19; Conti P, 2021, J Biol Regul Homeost Agents, V35, P1, DOI 10.23812/21-3-E; Covian C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00970; Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4; Daniloski Z, 2021, CELL, V184, P92, DOI 10.1016/j.cell.2020.10.030; Deniz M, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1793322; dos Santos JC, 2019, CELL REP, V28, P2659, DOI 10.1016/j.celrep.2019.08.004; Escobar Luis E, 2020, medRxiv, DOI [10.1073/pnas.2008410117, 10.1101/2020.05.05.20091975]; Fritschi N, 2020, PAEDIATR RESPIR REV, V36, P57, DOI 10.1016/j.prrv.2020.08.004; Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13; Group W., SAGE EV REC FRAM 1; Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088; Guo Y, 2008, VIRUS RES, V133, P4, DOI 10.1016/j.virusres.2007.01.022; Gupta PK, 2020, CELL IMMUNOL, V356, DOI 10.1016/j.cellimm.2020.104187; Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189; Hashemian SMR, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02165-4; Hensel J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75491-x; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20; Hou YXJ, 2020, SCIENCE, V370, P1464, DOI 10.1126/science.abe8499; Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005; Kin N, 2015, VIRUSES-BASEL, V7, P2358, DOI 10.3390/v7052358; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Levillain F, 2020, VACCINE, V38, P1416, DOI 10.1016/j.vaccine.2019.11.085; Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012; Li SM, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03022; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Makoni M, 2021, LANCET, V397, P267, DOI 10.1016/S0140-6736(21)00144-6; Mallapaty S, 2021, NATURE, V592, P667, DOI 10.1038/d41586-021-01059-y; McAloose D, 2020, MBIO, V11, DOI 10.1128/mBio.02220-20; Meng FP, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00286-5; Meselson M, 2020, NEW ENGL J MED, V382, P2063, DOI 10.1056/NEJMc2009324; Miyasaka M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012661; Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730; Muller C, 2018, ANTIVIR RES, V150, P123, DOI 10.1016/j.antiviral.2017.12.010; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878; O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y; Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005; Rivas MN, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145157; Tazerji SS, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02534-2; Paiva MHS, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121414; Schrager LK, 2020, LANCET INFECT DIS, V20, pE28, DOI 10.1016/S1473-3099(19)30625-5; Sharma AR, 2020, ALLERGOL IMMUNOPATH, V48, P507, DOI 10.1016/j.aller.2020.05.002; Sharma A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2720-9; Shi L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00488-5; Shu L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01875-5; Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102; Singla R, 2020, VET RES COMMUN, V44, P119, DOI 10.1007/s11259-020-09781-0; Sit THC, 2020, NATURE, V586, P776, DOI 10.1038/s41586-020-2334-5; Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003; Sun J, 2020, EMERG MICROBES INFEC, V9, P991, DOI 10.1080/22221751.2020.1760144; Sun K, 2020, ATLAS ACE2 GENE EXPR, p20200330015644, DOI [10.1101/2020.03.30.015644, DOI 10.1101/2020.03.30.015644]; Tang JLW, 2021, J INFECTION, V82, pE8, DOI 10.1016/j.jinf.2021.01.007; Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792; Tarancon R, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008404; Tegally H., 2020, EMERGENCE RAPID SPRE, DOI [10.1101/2020.12.21.20248640, DOI 10.1101/2020.12.21.20248640]; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222; Vabret A, 2006, J GEN VIROL, V87, P3349, DOI 10.1099/vir.0.82065-0; Vivanti AJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17436-6; Volz Erik, 2021, Cell, V184, P64, DOI 10.1016/j.cell.2020.11.020; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang MY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.587269; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Weinberger DM, 2020, JAMA INTERN MED, V180, P1336, DOI 10.1001/jamainternmed.2020.3391; Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94; Woolf SH, 2020, JAMA-J AM MED ASSOC, V324, P510, DOI 10.1001/jama.2020.11787; World Health Organization, 2018, Vaccine, V36, P3408, DOI 10.1016/j.vaccine.2018.03.009; World Health Organization, 2020, GLOBAL TUBERCULOSIS; World Health Organization, 2017, IEEE T POWER SYSTEMS; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xia XH, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010109; Xiao KP, 2020, NATURE, V583, P286, DOI 10.1038/s41586-020-2313-x; Xie Xuping, 2021, bioRxiv, DOI 10.1101/2021.01.07.425740; Xu Y, 2020, NAT MED, V26, P502, DOI 10.1038/s41591-020-0817-4; Yadav PD, 2022, CLIN INFECT DIS, V74, P366, DOI 10.1093/cid/ciab411; Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16; Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472; Yitbarek K, 2020, VACCINE, V38, P6374, DOI 10.1016/j.vaccine.2020.08.018; Yurkovetskiy Leonid, 2020, bioRxiv, DOI 10.1101/2020.07.04.187757; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022; Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035; Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504; Zhou P., 2020, NATURE, V579, P270, DOI [10.1038/s41586-020-2012-7, DOI 10.1038/s41586-020-2012-7]; Zhou P, 2018, NATURE, V556, P255, DOI 10.1038/s41586-018-0010-9; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035; Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012	114	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							639	10.3390/vaccines9060639			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY7AO	34200951	Green Published, gold			2022-04-29	WOS:000666036400001
J	Sliker, BH; Campbell, PM				Sliker, Bailee H.; Campbell, Paul M.			Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment	VACCINES			English	Review						tumor microenvironment; cancer-associated fibroblasts; immunotherapy; cancer vaccines; chemokines; cytokines	ENDOTHELIAL GROWTH-FACTOR; TUMOR-INFILTRATING LYMPHOCYTES; PHASE-II TRIAL; SQUAMOUS-CELL CARCINOMA; ONCOLYTIC HERPES-VIRUS; ACTIVATION PROTEIN; T-CELLS; TGF-BETA; STROMAL FIBROBLASTS; METASTATIC MELANOMA	Tumors are composed of not only epithelial cells but also many other cell types that contribute to the tumor microenvironment (TME). Within this space, cancer-associated fibroblasts (CAFs) are a prominent cell type, and these cells are connected to an increase in tumor progression as well as alteration of the immune landscape present in and around the tumor. This is accomplished in part by their ability to alter the presence of both innate and adaptive immune cells as well as the release of various chemokines and cytokines, together leading to a more immunosuppressive TME. Furthermore, new research implicates CAFs as players in immunotherapy response in many different tumor types, typically by blunting their efficacy. Fibroblast activation protein (FAP) and transforming growth factor beta (TGF-beta), two major CAF proteins, are associated with the outcome of different immunotherapies and, additionally, have become new targets themselves for immune-based strategies directed at CAFs. This review will focus on CAFs and how they alter the immune landscape within tumors, how this affects response to current immunotherapy treatments, and how immune-based treatments are currently being harnessed to target the CAF population itself.	[Sliker, Bailee H.; Campbell, Paul M.] Fox Chase Canc Ctr, Canc Signaling & Epigenet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Sliker, Bailee H.; Campbell, Paul M.] Fox Chase Canc Ctr, Marvin & Concetta Greenberg Pancreat Canc Inst, 7701 Burholme Ave, Philadelphia, PA 19111 USA		Campbell, PM (通讯作者)，Fox Chase Canc Ctr, Canc Signaling & Epigenet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.; Campbell, PM (通讯作者)，Fox Chase Canc Ctr, Marvin & Concetta Greenberg Pancreat Canc Inst, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	Bailee.Sliker@fccc.edu; Paul.Campbell@fccc.edu		Sliker, Bailee/0000-0002-4686-4221	NCI T32 FellowshipUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [NCI 5T32CA009035-43]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA006927]	BHS is supported by an NCI T32 Fellowship, NCI 5T32CA009035-43. This publication was supported by grant number P30 CA006927 from the National Cancer Institute.	Adams S, 2004, CANCER RES, V64, P5471, DOI 10.1158/0008-5472.CAN-04-0447; Aghi M, 2008, ONCOGENE, V27, P4249, DOI 10.1038/onc.2008.53; Ahmadzadeh M, 2005, J IMMUNOL, V174, P5215, DOI 10.4049/jimmunol.174.9.5215; Akhurst RJ, 2004, NAT GENET, V36, P790, DOI 10.1038/ng0804-790; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Alard E, 2020, CANCERS, V12, DOI 10.3390/cancers12071826; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Balsamo M, 2009, P NATL ACAD SCI USA, V106, P20847, DOI 10.1073/pnas.0906481106; Barnas JL, 2010, CANCER MICROENVIRON, V3, P29, DOI 10.1007/s12307-010-0044-5; Barnas JL, 2010, J IMMUNOL, V185, P2681, DOI 10.4049/jimmunol.1000896; Barrett RL, 2020, ELIFE, V9, DOI 10.7554/eLife.57243; Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bhatt D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040596; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Bollard CM, 2018, J CLIN ONCOL, V36, P1128, DOI 10.1200/JCO.2017.74.3179; Bollard CM, 2002, BLOOD, V99, P3179, DOI 10.1182/blood.V99.9.3179; Calmeiro J, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020158; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Chakravarthy A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06654-8; Chen R, 2019, BLOOD, V134, P1144, DOI 10.1182/blood.2019000324; Cheng JD, 2002, CANCER RES, V62, P4767; Chiarugi P, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25563; Cho YA, 2011, ORAL ONCOL, V47, P1148, DOI 10.1016/j.oraloncology.2011.08.007; Chu GC, 2007, J CELL BIOCHEM, V101, P887, DOI 10.1002/jcb.21209; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Cohen EEW, 2019, LANCET, V393, P156, DOI 10.1016/S0140-6736(18)31999-8; Cohen SJ, 2008, PANCREAS, V37, P154, DOI 10.1097/MPA.0b013e31816618ce; Constantino J, 2016, TRANSL RES, V168, P74, DOI 10.1016/j.trsl.2015.07.008; Couzin-Frankel J, 2013, Cancer Immunother. Sci, V342, P1432, DOI 10.1126/science.342.6165.1432; Devapatla B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139237; Dikov MM, 2005, J IMMUNOL, V174, P215, DOI 10.4049/jimmunol.174.1.215; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Ene-Obong A, 2013, GASTROENTEROLOGY, V145, P1121, DOI 10.1053/j.gastro.2013.07.025; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Erkan M, 2012, NAT REV GASTRO HEPAT, V9, P454, DOI 10.1038/nrgastro.2012.115; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; Fassnacht M, 2005, CLIN CANCER RES, V11, P5566, DOI 10.1158/1078-0432.CCR-05-0699; Fearon DT, 2014, CANCER IMMUNOL RES, V2, P187, DOI 10.1158/2326-6066.CIR-14-0002; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; Ford K, 2020, CANCER RES, V80, P1846, DOI 10.1158/0008-5472.CAN-19-3158; Fujii N, 2012, J ORAL PATHOL MED, V41, P444, DOI 10.1111/j.1600-0714.2012.01127.x; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Garber K, 2009, J NATL CANCER I, V101, P1110, DOI 10.1093/jnci/djp266; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Geng F, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1747350; Giaccone G, 2015, EUR J CANCER, V51, P2321, DOI 10.1016/j.ejca.2015.07.035; Giraldo NA, 2014, CURR OPIN IMMUNOL, V27, P8, DOI 10.1016/j.coi.2014.01.001; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Goscinski MA, 2008, ULTRASTRUCT PATHOL, V32, P89, DOI 10.1080/01913120802034934; Guo CQ, 2013, ADV CANCER RES, V119, P421, DOI 10.1016/B978-0-12-407190-2.00007-1; Haniffa MA, 2007, J IMMUNOL, V179, P1595, DOI 10.4049/jimmunol.179.3.1595; HANNA MG, 1978, CANCER RES, V38, P204; Hartmann N, 2014, CLIN CANCER RES, V20, P3422, DOI 10.1158/1078-0432.CCR-13-2972; Helms E, 2020, CANCER DISCOV, V10, P648, DOI 10.1158/2159-8290.CD-19-1353; Henry LR, 2007, CLIN CANCER RES, V13, P1736, DOI 10.1158/1078-0432.CCR-06-1746; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herrera M, 2013, CANCER SCI, V104, P437, DOI 10.1111/cas.12096; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Kakarla S, 2013, MOL THER, V21, P1611, DOI 10.1038/mt.2013.110; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Kaufman HL, 2010, FUTURE ONCOL, V6, P941, DOI 10.2217/FON.10.66; Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183; Kieffer Y, 2020, CANCER DISCOV, V10, P1330, DOI 10.1158/2159-8290.CD-19-1384; Kim HJ, 2014, CANCER IMMUNOL RES, V2, P91, DOI 10.1158/2326-6066.CIR-13-0216; Kim JH, 2012, BIOCHEM BIOPH RES CO, V423, P60, DOI 10.1016/j.bbrc.2012.05.081; Kloss CC, 2018, MOL THER, V26, P1855, DOI 10.1016/j.ymthe.2018.05.003; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Kuen J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182039; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lan Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan5488; Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; LeBeau AM, 2009, MOL CANCER THER, V8, P1378, DOI 10.1158/1535-7163.MCT-08-1170; Lee J, 2005, CANCER RES, V65, P11156, DOI 10.1158/0008-5472.CAN-05-2805; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Li TJ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0663-z; Li TJ, 2012, CANCER LETT, V318, P154, DOI 10.1016/j.canlet.2011.12.020; Li ZQ, 2019, INT J CANCER, V145, P1946, DOI 10.1002/ijc.32278; Liao D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007965; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Lo A, 2015, CANCER RES, V75, P2800, DOI 10.1158/0008-5472.CAN-14-3041; Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532; Lopes A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1154-7; Mace TA, 2013, CANCER RES, V73, P3007, DOI 10.1158/0008-5472.CAN-12-4601; Malchiodi ZX, 2021, CANCERS, V13, DOI 10.3390/cancers13030405; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Monteran L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01835; Morales A, 2017, J UROLOGY, V197, pS142, DOI 10.1016/j.juro.2016.10.101; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874; Nazareth MR, 2007, J IMMUNOL, V178, P5552, DOI 10.4049/jimmunol.178.9.5552; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Nemunaitis J, 2009, CANCER GENE THER, V16, P620, DOI 10.1038/cgt.2009.15; Nemunaitis J, 2006, J CLIN ONCOL, V24, P4721, DOI 10.1200/JCO.2005.05.5335; Nurmik M, 2020, INT J CANCER, V146, P895, DOI 10.1002/ijc.32193; Nywening TM, 2018, GUT, V67, P1112, DOI 10.1136/gutjnl-2017-313738; O'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8; Ocana A, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0707-7; Ogasawara M, 2019, THER APHER DIAL, V23, P279, DOI 10.1111/1744-9987.12831; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Ohshio Y, 2015, CANCER SCI, V106, P134, DOI 10.1111/cas.12584; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ostermann E, 2008, CLIN CANCER RES, V14, P4584, DOI 10.1158/1078-0432.CCR-07-5211; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Oyama T, 1998, J IMMUNOL, V160, P1224; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Park JR, 2007, MOL THER, V15, P825, DOI 10.1038/sj.mt.6300104; Pease JE, 2009, EXPERT OPIN THER PAT, V19, P199, DOI 10.1517/13543770802641353; Pease JE, 2009, EXPERT OPIN THER PAT, V19, P39, DOI 10.1517/13543770802641346; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Piersma B, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2020.188356; Pinchuk IV, 2008, GASTROENTEROLOGY, V135, P1228, DOI 10.1053/j.gastro.2008.07.016; Poeta VM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00379; Pol J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1115641; Powell DR, 2016, TRENDS IMMUNOL, V37, P41, DOI 10.1016/j.it.2015.11.008; Raker VK, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00569; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Roma-Rodrigues C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040840; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Rosenblatt J, 2013, CLIN CANCER RES, V19, P3640, DOI 10.1158/1078-0432.CCR-13-0282; Rous P, 1910, J EXP MED, V12, P344, DOI 10.1084/jem.12.3.344; Rybinski B, 2014, PHYSIOL GENOMICS, V46, P223, DOI 10.1152/physiolgenomics.00158.2013; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Salmon H, 2012, J CLIN INVEST, V122, P899, DOI 10.1172/JCI45817; Sanjabi S, 2009, IMMUNITY, V31, P131, DOI 10.1016/j.immuni.2009.04.020; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; Schuberth PC, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-187; Scott AM, 2003, CLIN CANCER RES, V9, P1639; Sharma B, 2013, MOL CANCER THER, V12, P799, DOI 10.1158/1535-7163.MCT-12-0529; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shaul ME, 2017, J LEUKOCYTE BIOL, V102, P343, DOI 10.1189/jlb.5MR1216-508R; Sherman MH, 2018, ANNU REV CELL DEV BI, V34, P333, DOI 10.1146/annurev-cellbio-100617-062855; Shi M, 2012, WORLD J GASTROENTERO, V18, P840, DOI 10.3748/wjg.v18.i8.840; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Stromnes IM, 2015, CANCER CELL, V28, P638, DOI 10.1016/j.ccell.2015.09.022; Tanyi JL, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5931; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tel J, 2013, CANCER RES, V73, P1063, DOI 10.1158/0008-5472.CAN-12-2583; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Tran E, 2013, J EXP MED, V210, P1125, DOI 10.1084/jem.20130110; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Van Tendeloo VF, 2010, P NATL ACAD SCI USA, V107, P13824, DOI 10.1073/pnas.1008051107; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Wang H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.122; Wang LCS, 2014, CANCER IMMUNOL RES, V2, P154, DOI 10.1158/2326-6066.CIR-13-0027; Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wells TNC, 2006, TRENDS PHARMACOL SCI, V27, P41, DOI 10.1016/j.tips.2005.11.001; Wen YA, 2010, CANCER SCI, V101, P2325, DOI 10.1111/j.1349-7006.2010.01695.x; Wong PF, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0675-0; Wu Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00930; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Young HL, 2017, J EXP MED, V214, P1691, DOI 10.1084/jem.20160855; Yu PF, 2017, ONCOGENE, V36, P482, DOI 10.1038/onc.2016.217; Zhang Y, 2016, ONCOTARGET, V7, P23282, DOI 10.18632/oncotarget.7818; Zhao F, 2018, CANCER IMMUNOL RES, V6, P1459, DOI 10.1158/2326-6066.CIR-18-0086; Ziani L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00414; Zigler M, 2008, AM J CLIN DERMATOL, V9, P307, DOI 10.2165/00128071-200809050-00004	179	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							634	10.3390/vaccines9060634			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6NZ	34200702	Green Published, gold			2022-04-29	WOS:000666680800001
J	Walker, AN; Zhang, T; Peng, XQ; Ge, JJ; Gu, H; You, H				Walker, Anita Nyarkoa; Zhang, Ting; Peng, Xue-Qing; Ge, Jin-Jin; Gu, Hai; You, Hua			Vaccine Acceptance and Its Influencing Factors: An Online Cross-Sectional Study among International College Students Studying in China	VACCINES			English	Article						vaccine acceptance; health behavior theory; cross-sectional study; China	CORONAVIRUS; HESITANCY	Background: With the continuous large-scale development of the COVID-19 vaccine, the acceptance of vaccination and its influencing factors at the individual level have become crucial to stemming the pandemic. This study aims to explore the factors that influence the acceptance of the COVID-19 vaccine among international college students. Methods: The target population constituted international students pursuing various degrees in Jiangsu Province through an online cross-sectional study. A cluster random sampling was performed using a self-administered questionnaire. The Health Belief Model and Knowledge, Attitude/Beliefs, and Practice Theory served as the underlying theories to understanding the factors that influence vaccine acceptance. Results: We received 330 responses. About 36.4% intended to accept the vaccine. The acceptance varied across respondents' place of residence, program of study, continent of origin, knowledge, susceptibility, severity, benefits, and cues to action (p < 0.05). A multivariable logistics regression revealed cues to action (p < 0.001), the perception of COVID-19 vaccination benefits (p = 0.002), and the perception of barriers (p < 0.001) that were associated with vaccine acceptance. Conclusions: The acceptance of the COVID-19 vaccine was low among international students. The correct and comprehensive beliefs of the target groups regarding the benefits and barriers of the vaccination must be raised. Various effective social strategies must be adopted to trigger the intention of COVID-19 vaccination. The study findings will inform the decisions of public health campaigners, aimed at reducing vaccine hesitation when the COVID-19 vaccine is widely available.	[Walker, Anita Nyarkoa; Peng, Xue-Qing; Ge, Jin-Jin; You, Hua] Nanjing Med Univ, Sch Publ Hlth, Nanjing 211166, Peoples R China; [Zhang, Ting] Zhejiang Gongshang Univ, Sch Publ Adm, Hangzhou 310018, Peoples R China; [Gu, Hai] Nanjing Univ, Sch Govt, Nanjing 210093, Peoples R China		You, H (通讯作者)，Nanjing Med Univ, Sch Publ Hlth, Nanjing 211166, Peoples R China.	walkeranita30@gmail.com; zhting1978@sina.com; Pengxueqing1230@163.com; gejjin@163.com; ghai1008@nju.edu.cn; youhua98@163.com		Peng, Xueqing/0000-0002-3296-3472; you, hua/0000-0002-0004-0470	NSFC (National Natural Science Foundation of China)National Natural Science Foundation of China (NSFC) [72074122]; Philosophy and Social Science Research of Jiangsu Higher Education Institutions of China [2020SJA0306]	This study was supported by the NSFC (National Natural Science Foundation of China) (No. 72074122), Philosophy and Social Science Research of Jiangsu Higher Education Institutions of China (No. 2020SJA0306).	Afshan Y., 2021, HINDU; Al-Qerem WA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.632914; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565; Barewar SD, 2021, EXP HEAT TRANSFER, V34, P531, DOI 10.1080/08916152.2020.1792587; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Centers for Disease Control and Prevention, WHO SHOULD WHO SHOUL; Centers for Disease Control and Prevention, FREQUENTLY ASKED QUE; Champion V.L., 2008, HLTH BEHAV HLTH ED T, V4, P45; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Children's Hospital of Philadephia, VACC SAF IMM SYST HL; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007; Graupensperger S, 2021, VACCINE, V39, P2060, DOI 10.1016/j.vaccine.2021.03.018; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Johnson, 2020, ABC NEWS; Jorgensen F, 2021, BRIT J HEALTH PSYCH, V26, P679, DOI 10.1111/bjhp.12519; Kaliyaperumal K., 2004, AECS ILLUMINATION, V4, P7; Kwok KO, 2020, EMERG INFECT DIS, V26, P1575, DOI 10.3201/eid2607.200500; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Manning ML, 2021, NURS OUTLOOK, V69, P565, DOI 10.1016/j.outlook.2021.01.019; Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310; Meier BP, 2021, J PUBLIC HEALTH-UK, DOI [10.1093/pubmed/fdab013, 10.1080/00224545.2021.1935830]; Mullard A, 2020, LANCET, V395, P1751, DOI 10.1016/S0140-6736(20)31252-6; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Palache A, 2011, VACCINE, V29, P9459, DOI 10.1016/j.vaccine.2011.10.030; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Riley S, 2020, COMMUNITY PREVALENCE, DOI [10.1101/2020.07.10.20150524, DOI 10.1101/2020.07.10.20150524]; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; The World Bank, GLOB EC OUTL COVID 1; Thunstrom L., 2020, HESITANCY COVID 19 V, V94, DOI [DOI 10.2139/SSRN.3593098, 10.2139/ssrn.3593098]; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083	36	11	11	7	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							585	10.3390/vaccines9060585			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6OW	34199331	gold, Green Published			2022-04-29	WOS:000666683100001
J	Densumite, J; Phanthong, S; Seesuay, W; Sookrung, N; Chaisri, U; Chaicumpa, W				Densumite, Jaslan; Phanthong, Siratcha; Seesuay, Watee; Sookrung, Nitat; Chaisri, Urai; Chaicumpa, Wanpen			Engineered Human Monoclonal scFv to Receptor Binding Domain of Ebolavirus	VACCINES			English	Article						human single-chain antibodies (HuscFvs); cell-penetrating antibodies; Ebolavirus; Ebolavirus-like particles; Glycoprotein (GP); Cleaved GP (GPcl); Thermolysin; receptor-binding domain (RBD); receptor binding site (RBS); Niemann-Pick C1	ANTIBODY-MEDIATED NEUTRALIZATION; VIRUS GLYCOPROTEIN; PROTEIN-STRUCTURE; WEB SERVER; INFECTION; REPLICATION; PEPTIDES; CELLS	(1) Background: Ebolavirus (EBOV) poses as a significant threat for human health by frequently causing epidemics of the highly contagious Ebola virus disease (EVD). EBOV glycoprotein (GP), as a sole surface glycoprotein, needs to be cleaved in endosomes to fully expose a receptor-binding domain (RBD) containing a receptor-binding site (RBS) for receptor binding and genome entry into cytoplasm for replication. RBDs are highly conserved among EBOV species, so they are an attractive target for broadly effective anti-EBOV drug development. (2) Methods: Phage display technology was used as a tool to isolate human single-chain antibodies (HuscFv) that bind to recombinant RBDs from a human scFv (HuscFv) phage display library. The RBD-bound HuscFvs were fused with cell-penetrating peptide (CPP), and cell-penetrating antibodies (transbodies) were made, produced from the phage-infected E. coli clones and characterized. (3) Results: Among the HuscFvs obtained from phage-infected E. coli clones, HuscFvs of three clones, HuscFv4, HuscFv11, and HuscFv14, the non-cell-penetrable or cell-penetrable HuscFv4 effectively neutralized cellular entry of EBOV-like particles (VLPs). While all HuscFvs were found to bind cleaved GP (GPcl), their presumptive binding sites were markedly different, as determined by molecular docking. (4) Conclusions: The HuscFv4 could be a promising therapeutic agent against EBOV infection.	[Densumite, Jaslan; Phanthong, Siratcha; Seesuay, Watee] Mahidol Univ, Fac Med, Dept Immunol, Grad Program Immunol,Siriraj Hosp, Bangkok 10700, Thailand; [Densumite, Jaslan; Phanthong, Siratcha; Seesuay, Watee; Chaicumpa, Wanpen] Mahidol Univ, Ctr Res Excellence Therapeut Prot & Antibody Engn, Fac Med, Dept Parasitol,Siriraj Hosp, Bangkok 10700, Thailand; [Sookrung, Nitat] Mahidol Univ, Fac Med, Dept Res, Biomed Res Incubat Unit,Siriraj Hosp, Bangkok 10700, Thailand; [Chaisri, Urai] Mahidol Univ, Fac Top Med, Dept Trop Pathol, Bangkok 10400, Thailand		Chaicumpa, W (通讯作者)，Mahidol Univ, Ctr Res Excellence Therapeut Prot & Antibody Engn, Fac Med, Dept Parasitol,Siriraj Hosp, Bangkok 10700, Thailand.	jaslan.den@student.mahidol.ac.th; siratcha.pha@student.mahidol.edu; watee.see@student.mahidol.ac.th; nitat.soo@mahidol.ac.th; urai.cha@mahidol.ac.th; wanpen.cha@mahidol.ac.th			NSTDA Chair Professor grant of the National Science and Technology Development Agency - Crown Property Bureau of Thailand [P-1450624]	J.D. is a Ph.D.-M.D. candidate of the Medical Scholar Program of Mahidol University. The work was supported by the NSTDA Chair Professor grant (P-1450624) of the National Science and Technology Development Agency funded by the Crown Property Bureau of Thailand toW.C.	Aleksandrowicz P, 2011, J INFECT DIS, V204, pS957, DOI 10.1093/infdis/jir326; Baize S, 2014, NEW ENGL J MED, V371, P1418, DOI 10.1056/NEJMoa1404505; Bornholdt ZA, 2016, MBIO, V7, DOI 10.1128/mBio.02154-15; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Commisso C, 2014, NAT PROTOC, V9, P182, DOI 10.1038/nprot.2014.004; Du Y, 2016, ONCOTARGET, V7, P58418, DOI 10.18632/oncotarget.11170; Dube D, 2010, P NATL ACAD SCI USA, V107, P16637, DOI 10.1073/pnas.1008509107; Dube D, 2009, J VIROL, V83, P2883, DOI 10.1128/JVI.01956-08; Flyak AI, 2015, CELL, V160, P893, DOI 10.1016/j.cell.2015.01.031; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Golding CG, 2016, SCI REP-UK, V6, DOI 10.1038/srep26516; Goldstein T, 2018, NAT MICROBIOL, V3, P1084, DOI 10.1038/s41564-018-0227-2; Hashiguchi T, 2015, CELL, V160, P904, DOI 10.1016/j.cell.2015.01.041; Howell KA, 2016, CELL REP, V15, P1514, DOI 10.1016/j.celrep.2016.04.026; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Kondratowicz AS, 2011, P NATL ACAD SCI USA, V108, P8426, DOI 10.1073/pnas.1019030108; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Kulkeaw K, 2009, J PROTEOMICS, V72, P270, DOI 10.1016/j.jprot.2008.12.007; Kuzmina NA, 2018, CELL REP, V24, P1802, DOI 10.1016/j.celrep.2018.07.035; Lee JE, 2008, NATURE, V454, P177, DOI 10.1038/nature07082; Lennemann NJ, 2014, MBIO, V5, DOI 10.1128/mBio.00862-13; Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y; Misasi J, 2016, SCIENCE, V351, P1343, DOI 10.1126/science.aad6117; Murin CD, 2014, P NATL ACAD SCI USA, V111, P17182, DOI 10.1073/pnas.1414164111; Najjar K, 2017, BIOCONJUGATE CHEM, V28, P2932, DOI 10.1021/acs.bioconjchem.7b00560; Negredo A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002304; Pettitt J, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006608; Phanthong S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.562768; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; Qiu XG, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003876; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Rugarabamu S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2019-001955; Saeed MF, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001110; Santajit S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01172; Schornberg K, 2006, J VIROL, V80, P4174, DOI 10.1128/JVI.80.8.4174-4178.2006; Shedlock DJ, 2010, VIROLOGY, V401, P228, DOI 10.1016/j.virol.2010.02.029; Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730; Takada A, 2004, J VIROL, V78, P2943, DOI 10.1128/JVI.78.6.2943-2947.2004; Thueng-In K, 2014, MABS-AUSTIN, V6, P1327, DOI 10.4161/mabs.29978; Tina KG, 2007, NUCLEIC ACIDS RES, V35, pW473, DOI 10.1093/nar/gkm423; Tscherne DM, 2010, J VIROL METHODS, V163, P336, DOI 10.1016/j.jviromet.2009.10.020; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762; Wang H, 2016, CELL, V164, P258, DOI 10.1016/j.cell.2015.12.044; Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024; Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514; Yang XL, 2019, NAT MICROBIOL, V4, P390, DOI 10.1038/s41564-018-0328-y; Yu DS, 2017, ONCOTARGET, V8, P55750, DOI 10.18632/oncotarget.18498; Yuan S, 2015, PROTEIN CELL, V6, P814, DOI 10.1007/s13238-015-0220-y; Zhang J, 2011, STRUCTURE, V19, P1784, DOI 10.1016/j.str.2011.09.022	50	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							457	10.3390/vaccines9050457			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI7MM	34064480	Green Published, gold			2022-04-29	WOS:000655012700001
J	Di Resta, C; Ferrari, D; Vigano, M; Moro, M; Sabetta, E; Minerva, M; Ambrosio, A; Locatelli, M; Tomaiuolo, R				Di Resta, Chiara; Ferrari, Davide; Vigano, Marco; Moro, Matteo; Sabetta, Eleonora; Minerva, Massimo; Ambrosio, Alberto; Locatelli, Massimo; Tomaiuolo, Rossella			The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination-An Analysis of Serological Response and Side Effects	VACCINES			English	Article						COVID-19; side effects; vaccination coverage; gender impact assessment	COVID-19 VACCINES; IMMUNE-RESPONSES; SEX; TESTOSTERONE; ANDROGENS; CELLS; WOMEN; AGE	Healthcare professionals are considered to be at high risk of exposure and spread of SARS-CoV-2, and have therefore been considered a priority group in COVID-19 vaccination campaign strategies. However, it must be assumed that the immune response is influenced by numerous factors, including sex and gender. The analysis of these factors is an impact element for stratifying the population and targeting the vaccination strategy. Therefore, a large cohort of healthcare workers participating in the Italian vaccination campaign against SARS-CoV-2 has been studied to establish the impact of sex and gender on vaccination coverage using the Gender Impact Assessment approach. This study shows a significant difference in the antibody titers among different age and sex groups, with a clear decreasing trend in antibody titers in the older age groups. Overall, the serological values were significantly higher in females; the reported side effects are more frequent in females than in males. Therefore, disaggregated data point out how the evaluation of gender factors could be essential in COVID-19 vaccination strategies. On this biomedical and social basis, suggestions are provided to improve the SARS-CoV-2 vaccination campaign in healthcare professionals. Still, they could be adapted to other categories and contexts.	[Di Resta, Chiara; Moro, Matteo; Ambrosio, Alberto; Locatelli, Massimo] IRCCS San Raffaele Hosp, I-20132 Milan, Italy; [Ferrari, Davide] Univ Parma, I-43121 Parma, Italy; [Vigano, Marco] IRCCS Galeazzi Orthopaed Inst, I-20161 Milan, Italy; [Sabetta, Eleonora; Minerva, Massimo; Tomaiuolo, Rossella] Univ Vita Salute San Raffaele, I-20132 Milan, Italy		Di Resta, C (通讯作者)，IRCCS San Raffaele Hosp, I-20132 Milan, Italy.	diresta.chiara@hsr.it; davide.ferrari@unipr.it; marco.vigano@grupposandonato.it; moro.matteo@hsr.it; e.sabetta@studenti.unisr.it; m.minerva3@studenti.unisr.it; ambrosio.alberto@hsr.it; locatelli.massimo@hsr.it; tomaiuolo.rossella@hsr.it	; Vigano, Marco/H-2559-2013	moro, matteo/0000-0001-5398-6000; Tomaiuolo, Rossella/0000-0002-2828-782X; DI RESTA, Chiara/0000-0003-2880-6631; ferrari, davide/0000-0001-7084-6800; Vigano, Marco/0000-0002-6463-6564	Ministero della SaluteMinistry of Health, Italy [COVID-2020-12371619]	The study was funded by Ministero della Salute (COVID-2020-12371619).	Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053; Arnold CR, 2011, J CLIN IMMUNOL, V31, P137, DOI 10.1007/s10875-010-9499-x; Baggio G, 2013, CLIN CHEM LAB MED, V51, P713, DOI 10.1515/cclm-2012-0849; Bali S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002595; Buitrago-Garcia D, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003346; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chia WN, 2021, LANCET MICROBE, V2, pE179, DOI 10.1016/S2666-5247(21)00088-4; Davies SE, 2016, INT AFF, V92, P1041, DOI 10.1111/1468-2346.12704; Day S, 2016, HEALTH RES POLICY SY, V14, DOI 10.1186/s12961-016-0147-7; Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790; Foo YZ, 2017, BIOL REV, V92, P551, DOI 10.1111/brv.12243; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Gavazzi G, 2002, LANCET INFECT DIS, V2, P659, DOI 10.1016/S1473-3099(02)00437-1; Geller SE, 2011, J WOMENS HEALTH, V20, P315, DOI 10.1089/jwh.2010.2469; Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166; Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326; GIGLIO T, 1994, LIFE SCI, V54, P1305, DOI 10.1016/0024-3205(94)00508-7; Gracia CR, 2018, OBSTET GYN CLIN N AM, V45, P585, DOI 10.1016/j.ogc.2018.07.002; Grubeck-Loebenstein B, 1998, NAT MED, V4, P870, DOI 10.1038/nm0898-870b; Harman S, 2021, LANCET, V397, P357, DOI 10.1016/S0140-6736(20)32727-6; Hewagama A, 2009, GENES IMMUN, V10, P509, DOI 10.1038/gene.2009.12; Hirokawa K, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-19; Khan D, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00635; Kissick HT, 2014, P NATL ACAD SCI USA, V111, P9887, DOI 10.1073/pnas.1402468111; Klein SL, 2012, J LEUKOCYTE BIOL, V92, P67, DOI 10.1189/jlb.0811427; Kovats S, 2010, SEX HORMONES AND IMMUNITY TO INFECTION, P53, DOI 10.1007/978-3-642-02155-8_3; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Mahbub Shegufta, 2011, Current Immunology Reviews, V7, P104, DOI 10.2174/157339511794474181; Mathioudakis AG, 2021, LIFE-BASEL, V11, DOI 10.3390/life11030249; Mazure CM, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0251-9; Napolitano F, 2019, VACCINE, V37, P6900, DOI 10.1016/j.vaccine.2019.09.053; Nielsen MW, 2021, BIOL SEX DIFFER, V12, DOI 10.1186/s13293-021-00366-3; Ovseiko PV, 2016, HEALTH RES POLICY SY, V14, DOI 10.1186/s12961-016-0126-z; Park HJ, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030410; Patin E, 2018, NAT IMMUNOL, V19, P302, DOI 10.1038/s41590-018-0049-7; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Perkmann T, 2020, CLIN CHEM, V66, P1405, DOI 10.1093/clinchem/hvaa198; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Restivo V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168546; Ruggieri Anna, 2016, Ann Ist Super Sanita, V52, P198, DOI 10.4415/ANN_16_02_11; Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013; Scholz JL, 2013, CURR OPIN IMMUNOL, V25, P504, DOI 10.1016/j.coi.2013.07.006; Seillet C, 2012, BLOOD, V119, P454, DOI 10.1182/blood-2011-08-371831; Simon V, 2005, SCIENCE, V308, P1517, DOI 10.1126/science.1115616; Trigunaite A, 2015, CELL IMMUNOL, V294, P87, DOI 10.1016/j.cellimm.2015.02.004; Weinberger B, 2012, CLIN MICROBIOL INFEC, V18, P100, DOI 10.1111/j.1469-0691.2012.03944.x; Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2; World Health Organization, 2020, WHO POS PAP IMM HEAL; Zeng FF, 2020, J MED VIROL, V92, P2050, DOI 10.1002/jmv.25989	49	17	17	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							522	10.3390/vaccines9050522			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1WK	34070196	gold, Green Published			2022-04-29	WOS:000654616100001
J	Leone, P; Solimando, AG; Fasano, R; Argentiero, A; Malerba, E; Buonavoglia, A; Lupo, LG; De Re, V; Silvestris, N; Racanelli, V				Leone, Patrizia; Solimando, Antonio Giovanni; Fasano, Rossella; Argentiero, Antonella; Malerba, Eleonora; Buonavoglia, Alessio; Lupo, Luigi Giovanni; De Re, Valli; Silvestris, Nicola; Racanelli, Vito			The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment	VACCINES			English	Review						hepatocellular carcinoma; immune checkpoint molecules; immune checkpoint inhibitors; immune microenvironment	CD8(+) T-CELL; ANTITUMOR-ACTIVITY; POSTOPERATIVE RECURRENCE; OPEN-LABEL; PHASE-III; PD-L1; EXPRESSION; THERAPY; HCC; LIVER	Hepatocellular carcinoma (HCC) is one of most common cancers and the fourth leading cause of death worldwide. Commonly, HCC development occurs in a liver that is severely compromised by chronic injury or inflammation. Liver transplantation, hepatic resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), and targeted therapies based on tyrosine protein kinase inhibitors are the most common treatments. The latter group have been used as the primary choice for a decade. However, tumor microenvironment in HCC is strongly immunosuppressive; thus, new treatment approaches for HCC remain necessary. The great expression of immune checkpoint molecules, such as programmed death-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), lymphocyte activating gene 3 protein (LAG-3), and mucin domain molecule 3 (TIM-3), on tumor and immune cells and the high levels of immunosuppressive cytokines induce T cell inhibition and represent one of the major mechanisms of HCC immune escape. Recently, immunotherapy based on the use of immune checkpoint inhibitors (ICIs), as single agents or in combination with kinase inhibitors, anti-angiogenic drugs, chemotherapeutic agents, and locoregional therapies, offers great promise in the treatment of HCC. This review summarizes the recent clinical studies, as well as ongoing and upcoming trials.	[Leone, Patrizia; Solimando, Antonio Giovanni; Fasano, Rossella; Malerba, Eleonora; Buonavoglia, Alessio; Silvestris, Nicola; Racanelli, Vito] Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, Unit Internal Med Guido Baccelli, I-70124 Bari, Italy; [Solimando, Antonio Giovanni; Fasano, Rossella; Argentiero, Antonella; Silvestris, Nicola] IRCCS Ist Tumori Giovanni Paolo II, I-70124 Bari, Italy; [Malerba, Eleonora] Univ Bologna, Dept Expt Diagnost & Specialty Med L&A Seragnoli, I-40138 Bologna, Italy; [Lupo, Luigi Giovanni] Univ Bari, Dept Gen Surg & Liver Transplantat, I-70124 Bari, Italy; [De Re, Valli] CRO Aviano Natl Canc Inst, Immunopathol & Canc Biomarkers Bioprote Facil, I-33081 Aviano, Italy		Racanelli, V (通讯作者)，Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, Unit Internal Med Guido Baccelli, I-70124 Bari, Italy.	patrizia.leone@uniba.it; antonio.solimando@uniba.it; rossella.fasano.93@gmail.com; argentieroantonella@gmail.com; ele94.malerba@gmail.com; alessio.buonavoglia85@gmail.com; luigig.lupo@gmail.com; vdere@cro.it; n.silvestris@oncologico.bari.it; vito.racanelli1@uniba.it	SOLIMANDO, ANTONIO GIOVANNI/U-7152-2018; FASANO, ROSSELLA/AAB-8565-2022; DE RE, VALLI/AAA-1374-2019; RACANELLI, Vito/J-8511-2018	SOLIMANDO, ANTONIO GIOVANNI/0000-0002-2293-9698; FASANO, ROSSELLA/0000-0003-4123-7234; DE RE, VALLI/0000-0001-6100-9373; Buonavoglia, Alessio/0000-0002-1044-2027; RACANELLI, Vito/0000-0002-8639-1940	Ministry of Health, Italian Government	This research was supported by the Ministry of Health, Italian Government, Funds from R.C. 2021.	Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; Abou-Alfa GK, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.TPS4144; Batra SA, 2020, CANCER IMMUNOL RES, V8, P309, DOI 10.1158/2326-6066.CIR-19-0293; Benson AB, 2017, J NATL COMPR CANC NE, V15, P563, DOI 10.6004/jnccn.2017.0059; Berasain C, 2007, LIVER INT, V27, P174, DOI 10.1111/j.1478-3231.2006.01424.x; Bishayee A, 2014, ADV EXP MED BIOL, V816, P401, DOI 10.1007/978-3-0348-0837-8_16; Bruix J, 2016, GASTROENTEROLOGY, V150, P835, DOI 10.1053/j.gastro.2015.12.041; Brunetti O, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55100707; Cardoso H, 2016, J HEPATOL, V65, P1070, DOI 10.1016/j.jhep.2016.07.027; Cast AE, 2015, DEV DYNAM, V244, P497, DOI 10.1002/dvdy.24222; Conti F, 2016, J HEPATOL, V65, P727, DOI 10.1016/j.jhep.2016.06.015; Cui TM, 2020, ONCOTARGETS THER, V13, P11725, DOI 10.2147/OTT.S279858; Dimitroulis D, 2017, WORLD J GASTROENTERO, V23, P5282, DOI 10.3748/wjg.v23.i29.5282; Dooley S, 2012, CELL TISSUE RES, V347, P245, DOI 10.1007/s00441-011-1246-y; Duffy AG, 2017, J HEPATOL, V66, P545, DOI 10.1016/j.jhep.2016.10.029; Eggert T, 2017, PHARMACOL THERAPEUT, V173, P47, DOI 10.1016/j.pharmthera.2017.02.005; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Finn RS, 2020, J CLIN ONCOL, V38, P2960, DOI 10.1200/JCO.20.00808; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Finn RS, 2020, J CLIN ONCOL, V38, P193, DOI 10.1200/JCO.19.01307; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gao Q, 2009, CLIN CANCER RES, V15, P971, DOI 10.1158/1078-0432.CCR-08-1608; Garmpis N, 2021, J PERS MED, V11, DOI 10.3390/jpm11030223; Guo CL, 2014, ASIAN PAC J CANCER P, V15, P2613, DOI 10.7314/APJCP.2014.15.6.2613; Guo MZ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02469-8; Guo XL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01118; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Han YP, 2004, J BIOL CHEM, V279, P4820, DOI 10.1074/jbc.M310999200; Harding JJ, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.TPS4146; Innovent Biologics (Suzhou) Co. Ltd, STUD EV EFF SAF SINT; Jiang Y, 2019, WORLD J GASTROENTERO, V25, P3151, DOI 10.3748/wjg.v25.i25.3151; Jiangsu HengRui Medicine Co. Ltd, TRIAL SHR 1210 ANT P; Jung HI, 2017, CANCER RES TREAT, V49, P246, DOI 10.4143/crt.2016.066; Kelley RK, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4073; Kitaoka S, 2003, HEPATO-GASTROENTEROL, V50, P1569; Kleponis J, 2015, CANCER BIOL MED, V12, P201, DOI 10.7497/j.issn.2095-3941.2015.0046; Kole C, 2020, CANCERS, V12, DOI 10.3390/cancers12102859; Kuang DM, 2009, J EXP MED, V206, P1327, DOI 10.1084/jem.20082173; Kudo M, 2019, WORLD J GASTROENTERO, V25, P789, DOI 10.3748/wjg.v25.i7.789; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Lai XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178479; Lee HW, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e11; Lee MS, 2020, LANCET ONCOL, V21, P808, DOI 10.1016/S1470-2045(20)30156-X; Li FJ, 2013, IMMUNOL LETT, V150, P116, DOI 10.1016/j.imlet.2012.12.004; Li Y, 2016, J IMMUNOL, V196, P1617, DOI 10.4049/jimmunol.1501737; Lindsted T, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-5629; Liu FF, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0667-4; Liu X, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920910347; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Longo V, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55100698; Marra F, 2014, GASTROENTEROLOGY, V147, P577, DOI 10.1053/j.gastro.2014.06.043; Merck Sharp Dohme Corp, MK7902002E7080G00031; Meringer H, 2019, WORLD J GASTROENTERO, V25, P3929, DOI 10.3748/wjg.v25.i29.3929; Moghaddam Y, 2018, PATHOL RES PRACT, V214, P1482, DOI 10.1016/j.prp.2018.07.019; Muhlbauer M, 2006, J HEPATOL, V45, P520, DOI 10.1016/j.jhep.2006.05.007; Murtaza A, 2016, EUR J CANCER, V69, pS102, DOI 10.1016/S0959-8049(16)32903-3; Nakagawa H, 2012, WORLD J GASTROENTERO, V18, P4071, DOI 10.3748/wjg.v18.i31.4071; Nakagawa H, 2009, INT J CANCER, V125, P2264, DOI 10.1002/ijc.24720; Natri HM, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6167-2; Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492; Pfizer, STUD AV COMB AX ADV; Pinato DJ, 2019, ANN ONCOL, V30, P288; Porta C, 2008, ANN ONCOL, V19, P353, DOI 10.1093/annonc/mdm448; Qin S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1091-2; Qin SK, 2020, LANCET ONCOL, V21, P571, DOI 10.1016/S1470-2045(20)30011-5; Qin SK, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4074; Qin SK, 2019, FUTURE ONCOL, V15, P1811, DOI 10.2217/fon-2019-0097; Racanelli V, 2006, HEPATOLOGY, V43, pS54, DOI 10.1002/hep.21060; Ramakrishna G, 2013, LIVER CANCER, V2, P367, DOI 10.1159/000343852; Ramos-Casals M, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0160-6; Reig M, 2016, J HEPATOL, V65, P719, DOI 10.1016/j.jhep.2016.04.008; Richani M, 2016, ANN HEPATOL, V15, P82, DOI 10.5604/16652681.1184233; Robinson MW, 2016, CELL MOL IMMUNOL, V13, P267, DOI 10.1038/cmi.2016.3; Rossetto A, 2019, CANCERS, V11, DOI 10.3390/cancers11111731; Sangro B, 2020, J HEPATOL, V72, P320, DOI 10.1016/j.jhep.2019.10.021; Sangro B, 2013, J HEPATOL, V59, P81, DOI 10.1016/j.jhep.2013.02.022; Savitsky D, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-3819; Schutte K, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-117; Shi F, 2011, INT J CANCER, V128, P887, DOI 10.1002/ijc.25397; Sung PS, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00266; Tan SY, 2020, CANCER RES, V80, P1130, DOI 10.1158/0008-5472.CAN-19-2332; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Vogel A, 2019, ANN ONCOL, V30, P871, DOI 10.1093/annonc/mdy510; Wainberg ZA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4071; Wang F, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00886-2; Wang P, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.09.009; Weinhold B, 1997, BIOCHEM J, V327, P425, DOI 10.1042/bj3270425; Wu K, 2009, CANCER RES, V69, P8067, DOI 10.1158/0008-5472.CAN-09-0901; Wu XQ, 2019, MOL THER, V27, P1483, DOI 10.1016/j.ymthe.2019.04.020; Xiao X, 2016, CANCER DISCOV, V6, P546, DOI 10.1158/2159-8290.CD-15-1408; Xu JM, 2019, CLIN CANCER RES, V25, P515, DOI 10.1158/1078-0432.CCR-18-2484; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yau T, 2019, ANN ONCOL, V30, P874; Yau T, 2020, JAMA ONCOL, V6, DOI 10.1001/jamaoncol.2020.4564; Yin ZY, 2020, CANCER LETT, V470, P8, DOI 10.1016/j.canlet.2019.12.002; Zhou GY, 2017, GASTROENTEROLOGY, V153, P1107, DOI 10.1053/j.gastro.2017.06.017; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6; Zong ZY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01643	98	3	4	11	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							532	10.3390/vaccines9050532			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1QZ	34065489	gold, Green Published			2022-04-29	WOS:000654602000001
J	Steffen, A; Rieck, T; Siedler, A				Steffen, Annika; Rieck, Thorsten; Siedler, Anette			Monitoring of Influenza Vaccination Coverage among Pregnant Women in Germany Based on Nationwide Outpatient Claims Data: Findings for Seasons 2014/15 to 2019/20	VACCINES			English	Article						claims data; Germany; influenza; pregnancy; vaccination coverage	UNITED-STATES; IMMUNIZATION	Pregnant women and their infants are at increased risk for severe influenza-related complications. A decade has passed since influenza vaccination was first recommended for pregnant women in Germany in 2010; however, monitoring of vaccination coverage (VC) has not yet been implemented for this target group. Using nationwide outpatient claims data, we here provide results on influenza VC among pregnant women in Germany for seasons 2014/15 to 2019/20. For any given season, pregnant women were defined as women who had undergone prenatal health care in at least two consecutive quarters within a season. VC increased from 9.0% in season 2014/15 to 16.6% in 2019/20 (+84%), while most of the increase occurred from season 2016/17 (VC: 9.9%) onwards (+68%). Consistently across seasons, women in east Germany were 40 to 60% more likely to be vaccinated compared to women residing in west Germany. According to age, the highest VC was observed among women aged 35 to <40 years (2019/20: 18.2%). Despite noticeable increases in influenza VC during recent years, overall coverage remains low among pregnant women. Starting with this analysis, VC among pregnant women in Germany will be monitored on a yearly basis in order to detect trends and identify immunization gaps.	[Steffen, Annika; Rieck, Thorsten; Siedler, Anette] Robert Koch Inst, Immunizat Unit, D-13353 Berlin, Germany		Steffen, A (通讯作者)，Robert Koch Inst, Immunizat Unit, D-13353 Berlin, Germany.	steffena@rki.de; rieckt@rki.de; siedlera@rki.de	Steffen, Annika/H-7709-2018	Steffen, Annika/0000-0003-4072-9245; Rieck, Thorsten/0000-0002-8799-8744			Advisory Committee on Immunization Practices (ACIP), INFL ACIP VACC REC; Akmatov MK, 2021, VACCINE, V39, P952, DOI 10.1016/j.vaccine.2020.12.081; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Australian Immunisation Handbook, PREGN WOM AR STRONGL; Bartolo S, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2628-5; Batzing-Feigenbaum J., 2017, VACCINATION SEASONAL, DOI [10.20364/VA-17.06, DOI 10.20364/VA-17.06]; Baum S, 2017, GEBURTSH FRAUENHEILK, V77, P340, DOI 10.1055/s-0043-103970; Blanchard-Rohner G, 2012, J MATERN-FETAL NEO M, V25, P1800, DOI 10.3109/14767058.2012.663835; Bodeker B, 2015, BMC PUBLIC HEALTH, V15, DOI [10.1186/s12889-015-2621-5, 10.1186/S12889-015-2621-5]; Bodeker B, 2014, VACCINE, V32, P4131, DOI 10.1016/j.vaccine.2014.06.007; Ding H, 2017, MMWR-MORBID MORTAL W, V66, P1016, DOI 10.15585/mmwr.mm6638a2; Eppes C, 2013, VACCINE, V31, P2874, DOI 10.1016/j.vaccine.2013.04.031; European Centre for Disease Prevention and Control, 2018, SEASONAL INFLUENZA V; European Centre for Disease Prevention and Control (ECDC), 2017, SEAS INFL IMM EUR VA; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; Kerr S, 2016, MMWR-MORBID MORTAL W, V65, P1370, DOI 10.15585/mmwr.mm6548a3; Poehling KA, 2011, AM J OBSTET GYNECOL, V204, pS141, DOI 10.1016/j.ajog.2011.02.042; Professional Association of Gynecologists (BVF), 2021, INT INF CAMP I UNPUB; Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068; Razzaghi H, 2020, MMWR-MORBID MORTAL W, V69, P1391, DOI 10.15585/mmwr.mm6939a2; Rieck T., 2020, EPIDEMIOL B, V32, P9; Rieck T., 2020, EPIDEMIOL B, V47, P3, DOI [10.25646/7658, DOI 10.25646/7658]; Robert Koch Institute, 2010, EPIDEMIOLOGISCHES B, V31, P299; Robert Koch Institute, 2019, EPID B, V34, P13, DOI [10.25646/6233.5, DOI 10.25646/6233.5]; Sheffield JS, 2012, OBSTET GYNECOL, V120, P532, DOI 10.1097/AOG.0b013e318263a278; Siedler A, 2012, EUROSURVEILLANCE, V17, P23; Vetter K, 2013, BUNDESGESUNDHEITSBLA, V56, P1679, DOI 10.1007/s00103-013-1858-3; Wiley KE, 2013, MED J AUSTRALIA, V198, P373, DOI 10.5694/mja12.11849; World Health Organization, PREV CONTR INFL PAND, P56; Yudin MH, 2009, J OBSTET GYNAECOL CA, V31, P120, DOI 10.1016/S1701-2163(16)34095-6; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630	31	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							485	10.3390/vaccines9050485			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1FC	34064546	gold, Green Published			2022-04-29	WOS:000654570900001
J	Valero, Y; Olveira, JG; Lopez-Vazquez, C; Dopazo, CP; Bandin, I				Valero, Yulema; Olveira, Jose G.; Lopez-Vazquez, Carmen; Dopazo, Carlos P.; Bandin, Isabel			BEI Inactivated Vaccine Induces Innate ad Adaptive Responses and Elicits Partial Protection upon Reassortant Betanodavirus Infection in Senegalese Sole	VACCINES			English	Article						Senegalese sole; inactivated vaccine; BEI; formalin; nervous necrosis virus; immune response; antibodies; gene expression	EUROPEAN SEA BASS; NERVOUS NECROSIS VIRUS; EPINEPHELUS-SEPTEMFASCIATUS THUNBERG; CELL-MEDIATED CYTOTOXICITY; SEVENBAND GROUPER; T-CELL; MOLECULAR CHARACTERIZATION; VERTICAL TRANSMISSION; VIRAL ENCEPHALOPATHY; EXPRESSION	Nervous necrosis virus (NNV), the causative agent of viral encephalopathy and retinopathy (VER), is one of the most threatening viruses affecting marine and freshwater fish species worldwide. Senegalese sole is a promising fish species in Mediterranean aquaculture but also highly susceptible to NNV and VER outbreaks, that puts its farming at risk. The development of vaccines for aquaculture is one of best tools to prevent viral spread and sudden outbreaks, and virus inactivation is the simplest and most cost-effective method available. In this work, we have designed two inactivated vaccines based on the use of formalin or binary ethylenimine (BEI) to inactivate a reassortant NNV strain. After vaccination, the BEI-inactivated vaccine triggered the production of specific IgM-NNV antibodies and stimulated innate and adaptive immune responses at transcriptional level (rtp3, mx, mhcii and tcrb coding genes). Moreover, it partially improved survival after an NNV in vivo challenge, reducing the mid-term viral load and avoiding the down-regulation of immune response post-challenge. On the other hand, the formalin-inactivated vaccine improved the survival of fish upon infection without inducing the production of IgM-NNV antibodies and only stimulating the expression of herc4 and mhcii genes (in head-kidney and brain, respectively) during the vaccination period; this suggests that other immune-related pathways may be involved in the partial protection provoked. Although these vaccines against NNV showed encouraging results, further studies are needed to improve sole protection and to fully understand the underlying immune mechanism.	[Valero, Yulema; Olveira, Jose G.; Lopez-Vazquez, Carmen; Dopazo, Carlos P.; Bandin, Isabel] Univ Santiago de Compostela, Dept Microbiol & Parasitol, Inst Acuicultura, Campus Vida, Santiago De Compostela 15782, Spain		Valero, Y (通讯作者)，Univ Santiago de Compostela, Dept Microbiol & Parasitol, Inst Acuicultura, Campus Vida, Santiago De Compostela 15782, Spain.	yulema.valero@usc.es; jose.olveira@usc.es; mdelcarmen.lopez.vazquez@usc.es; carlos.pereira@usc.es; isabel.bandin@usc.es	Valero, Yulema/H-6694-2015	Valero, Yulema/0000-0002-5432-4903	MICIU (Spain) - FEDER [RTI2018-094687-B-C21]	This work was supported by grant RTI2018-094687-B-C21 from MICIU (Spain) co-funded by FEDER.	Alvarez-Torres D, 2017, FISH SHELLFISH IMMUN, V66, P423, DOI 10.1016/j.fsi.2017.05.040; Arimoto M, 1996, AQUACULTURE, V143, P15, DOI 10.1016/0044-8486(96)01261-6; Bandin I, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020106; Carballo C, 2016, VET RES, V47, DOI 10.1186/s13567-015-0304-y; Cheng YK, 2017, DEV COMP IMMUNOL, V67, P385, DOI 10.1016/j.dci.2016.08.013; Chien MH, 2018, VET IMMUNOL IMMUNOP, V197, P69, DOI 10.1016/j.vetimm.2018.01.012; Coeurdacier JL, 2003, FISH SHELLFISH IMMUN, V14, P435, DOI 10.1006/fsim.2002.0449; Delrue I, 2012, EXPERT REV VACCINES, V11, P695, DOI [10.1586/erv.12.38, 10.1586/ERV.12.38]; Eslamloo K, 2016, DEV COMP IMMUNOL, V63, P187, DOI 10.1016/j.dci.2016.05.021; FAO, 2012, STATE WORLD FISHERIE; Frerichs GN, 2000, AQUACULTURE, V185, P13, DOI 10.1016/S0044-8486(99)00337-3; Gemez-Mata J, 2021, GENE, V774, DOI 10.1016/j.gene.2021.145430; Gonzalez-Fernandez C, 2021, FISH SHELLFISH IMMUN, V109, P106, DOI 10.1016/j.fsi.2020.12.006; Gonzalez-Silvera D, 2019, FISH SHELLFISH IMMUN, V88, P458, DOI 10.1016/j.fsi.2019.03.013; Gye HJ, 2018, AQUACULTURE, V485, P93, DOI 10.1016/j.aquaculture.2017.11.039; Huang Sue-Min, 2017, Taiwan Veterinary Journal, V43, P171, DOI 10.1142/S1682648517500032; Kai YH, 2008, VACCINE, V26, P1450, DOI 10.1016/j.vaccine.2007.12.043; Kai YH, 2014, FISH SHELLFISH IMMUN, V40, P563, DOI 10.1016/j.fsi.2014.08.005; Kai YH, 2010, VACCINE, V28, P996, DOI 10.1016/j.vaccine.2009.10.132; Kim JO, 2015, J MICROBIOL BIOTECHN, V25, P1761, DOI 10.4014/jmb.1507.07004; Krasnov A, 2011, MOL IMMUNOL, V49, P163, DOI 10.1016/j.molimm.2011.08.007; Lama R, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030094; Lin CF, 2018, FISH SHELLFISH IMMUN, V74, P551, DOI 10.1016/j.fsi.2018.01.029; Liu P, 2017, FISH SHELLFISH IMMUN, V61, P61, DOI 10.1016/j.fsi.2016.12.021; Liu P, 2016, FISH SHELLFISH IMMUN, V54, P342, DOI 10.1016/j.fsi.2016.04.029; Lopez-Munoz A, 2012, DEV COMP IMMUNOL, V37, P429, DOI 10.1016/j.dci.2012.02.007; Nunez-Ortiz N, 2016, VET RES, V47, DOI 10.1186/s13567-016-0376-3; Olveira JG, 2009, J GEN VIROL, V90, P2940, DOI 10.1099/vir.0.013912-0; Overgard AC, 2013, VACCINE, V31, P2395, DOI 10.1016/j.vaccine.2013.01.034; Overgard AC, 2012, DEV COMP IMMUNOL, V37, P139, DOI 10.1016/j.dci.2011.10.003; Pakingking R, 2009, J FISH DIS, V32, P457, DOI 10.1111/j.1365-2761.2009.01040.x; Pakingking R, 2018, VACCINE, V36, P5002, DOI 10.1016/j.vaccine.2018.07.015; Pakingking R, 2010, FISH SHELLFISH IMMUN, V28, P525, DOI 10.1016/j.fsi.2009.12.004; Panzarin V, 2012, INFECT GENET EVOL, V12, P63, DOI 10.1016/j.meegid.2011.10.007; Pascoli F, 2019, FISH SHELLFISH IMMUN, V85, P85, DOI 10.1016/j.fsi.2017.10.033; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poisa-Beiro L, 2008, MOL IMMUNOL, V45, P218, DOI 10.1016/j.molimm.2007.04.016; Qin YH, 2021, AQUACULTURE, V536, DOI 10.1016/j.aquaculture.2021.736488; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rise ML, 2010, PHYSIOL GENOMICS, V42, P266, DOI 10.1152/physiolgenomics.00168.2009; Souto S, 2015, VET MICROBIOL, V177, P53, DOI 10.1016/j.vetmic.2015.02.030; Souto S, 2015, VET MICROBIOL, V179, P162, DOI 10.1016/j.vetmic.2015.07.004; Tanaka S, 2001, J FISH DIS, V24, P15, DOI 10.1046/j.1365-2761.2001.00259.x; Thwaite R, 2020, FISH SHELLFISH IMMUN, V99, P578, DOI 10.1016/j.fsi.2020.02.029; Toffan A, 2017, SCI REP-UK, V7, DOI 10.1038/srep46755; Valero Y, 2018, DEV COMP IMMUNOL, V86, P171, DOI 10.1016/j.dci.2018.05.013; Valero Y, 2018, FISH SHELLFISH IMMUN, V74, P627, DOI 10.1016/j.fsi.2018.01.034; Valero Y, 2016, DEV COMP IMMUNOL, V65, P64, DOI 10.1016/j.dci.2016.06.021; Valero Y, 2015, J GEN VIROL, V96, P2176, DOI 10.1099/vir.0.000164; Volpe E, 2020, AQUACULTURE, V523, DOI 10.1016/j.aquaculture.2020.735155; Yamashita H, 2005, FISH PATHOL, V40, P15, DOI 10.3147/jsfp.40.15; Yamashita H, 2009, J FISH DIS, V32, P767, DOI 10.1111/j.1365-2761.2009.01054.x	52	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							458	10.3390/vaccines9050458			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3AZ		gold, Green Published			2022-04-29	WOS:000654699300001
J	Narasimhan, M; Mahimainathan, L; Araj, E; Clark, AE; Wilkinson, K; Yekkaluri, S; Tiro, J; Lee, FM; Balani, J; Sarode, R; Singal, AG; Muthukumar, A				Narasimhan, Madhusudhanan; Mahimainathan, Lenin; Araj, Ellen; Clark, Andrew E.; Wilkinson, Kathleen; Yekkaluri, Sruthi; Tiro, Jasmin; Lee, Francesca M.; Balani, Jyoti; Sarode, Ravi; Singal, Amit G.; Muthukumar, Alagarraju			Expanding COVID-19 Vaccine Availability: Role for Combined Orthogonal Serology Testing (COST)	VACCINES			English	Article						COVID-19; SARS-CoV-2; IgG; IgM; spike; nucleocapsid; orthogonal antibody testing; vaccine; vaccine prioritization		Background: The persisting Coronavirus disease 2019 (COVID-19) pandemic and limited vaccine supply has led to a shift in global health priorities to expand vaccine coverage. Relying on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) molecular testing alone cannot reveal the infection proportion, which could play a critical role in vaccination prioritization. We evaluated the utility of a combination orthogonal serological testing (COST) algorithm alongside RT-PCR to quantify prevalence with the aim of identifying candidate patient clusters to receive single and/or delayed vaccination. Methods: We utilized 108,505 patients with suspected COVID-19 in a retrospective analysis of SARS-CoV-2 RT-PCR vs. IgG-nucleocapsid (IgG(NC)) antibody testing coverage in routine practice for the estimation of prevalence. Prospectively, an independent cohort of 21,388 subjects was simultaneously tested by SARS-CoV-2 RT-PCR and IgG(NC) to determine the prevalence. We used 614 prospective study subjects to assess the utility of COST (IgG(NC), IgM-spike (IgM(SP)), and IgG-spike (IgG(SP))) in establishing the infection proportion to identify a single-dose vaccination cohort. Results: Retrospectively, we observed a 6.3% (6871/108,505) positivity for SARS-CoV-2 RT-PCR, and only 2.3% (2533/108,505) of cases had paired IgG(NC) serology performed. Prospectively, IgG(NC) serology identified twice the number of COVID-positive cases in relation to RT-PCR alone. COST further increased the number of detected positive cases: IgG(NC)+ or IgM(SP)+ (18.0%); IgG(NC)+ or IgG(SP)+ (23.5%); IgM(SP)+ or IgG(SP)+ (23.8%); and IgG(NC)+ or IgM(SP)+ or IgG(SP)+ (141/584 = 24.1%). Conclusion: COST may be an effective tool for the evaluation of infection proportion and thus could define a cohort for a single dose and/or delayed vaccination.	[Narasimhan, Madhusudhanan; Mahimainathan, Lenin; Araj, Ellen; Clark, Andrew E.; Lee, Francesca M.; Balani, Jyoti; Sarode, Ravi; Muthukumar, Alagarraju] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Wilkinson, Kathleen; Yekkaluri, Sruthi; Tiro, Jasmin; Lee, Francesca M.; Sarode, Ravi; Singal, Amit G.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA		Muthukumar, A (通讯作者)，Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.; Singal, AG (通讯作者)，Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.	madhusudhanan.narasimhan@utsouthwestern.edu; lenin.mahimainathan@utsouthwestern.edu; ellen.araj@utsouthwestern.edu; andrew.clark@utsouthwestern.edu; kathleen.wilkinson@utsouthwestern.edu; sruthi.yekkaluri@utsouthwestern.edu; jasmin.tiro@utsouthwestern.edu; francescalee@utsouthwestern.edu; jyoti.balani@utsouthwestern.edu; ravi.sarode@utsouthwestern.edu; amit.singal@utsouthwestern.edu; Alagarraju.Muthukumar@UTSouthwestern.edu	Singal, Amit/ABD-5344-2021; Lee, Francesca/ABC-5955-2021	Singal, Amit/0000-0002-1172-3971; Lee, Francesca/0000-0002-1462-4119; Clark, Andrew/0000-0002-0722-0482	State of Texas; Tarrant County; Dallas County; City of FortWorth; City of Dallas; Lyda Hill Philanthropies; Communities Foundation of Texas	The State of Texas, Tarrant County, Dallas County, the City of FortWorth, and the City of Dallas, as well as private philanthropy including Lyda Hill Philanthropies and W.W. Caruth, Fund at Communities Foundation of Texas generously funded this research.	Bavaro DF, 2021, J MED VIROL, V93, P3158, DOI 10.1002/jmv.26878; Bubar KM, 2021, SCIENCE, V371, P916, DOI 10.1126/science.abe6959; Burgos Rodrigo M, 2021, Drugs Context, V10, DOI 10.7573/dic.2020-12-2; Cai XF, 2020, J INFECT DIS, V222, P189, DOI 10.1093/infdis/jiaa243; CDC, 2020, INT GUID COV 19 ANT; Chew KL, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.05.036; Eyre DW, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05878-2; Mazzoni A., 2021, 1 DOSE MRNA VACCINAT, DOI [10.1101/2021.03.05.21252590, DOI 10.1101/2021.03.05.21252590]; Mlcochova P, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100099; Narasimhan M, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.00388-21; Peeling RW, 2020, LANCET INFECT DIS, V20, pE245, DOI 10.1016/S1473-3099(20)30517-X; Phipps WS, 2020, AM J CLIN PATHOL, V154, P459, DOI 10.1093/ajcp/aqaa123; Ripperger TJ, 2020, IMMUNITY, V53, P925, DOI 10.1016/j.immuni.2020.10.004; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786	14	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							376	10.3390/vaccines9040376			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4UQ	33924340	gold, Green Published			2022-04-29	WOS:000643776500001
J	Strohmeier, S; Carreno, JM; Brito, RN; Krammer, F				Strohmeier, Shirin; Carreno, Juan Manuel; Brito, Ruhi Nichalle; Krammer, Florian			Introduction of Cysteines in the Stalk Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice	VACCINES			English	Article						neuraminidase; N1; vaccine; stalk domain; cysteine mutant		Influenza virus surface glycoproteins represent the main targets of the immune system during infection and vaccination. Current influenza virus vaccines rely mostly on the hemagglutinin, requiring a close match between the vaccine and circulating strains. Recently, the neuraminidase (NA) has become an attractive target; however low immunogenicity and stability in vaccine preparations remain an obstacles. Here, we took advantage of the hypervariable stalk domain of the NA to introduce cysteines at different positions and to produce more stable multimeric forms of the protein. We generated 11 N1 constructs and characterized the proteins by performing sodium dodecyl sulfate polyacrylamide gel electrophoresis and by testing their enzymatic activity and representation of antigenic epitopes. Moreover, we evaluated their potential to induce a protective immune response in vivo and characterized the polyclonal antibody responses of immunized mice. We observed that the introduction of cysteines at certain positions led to the formation of stable N1 dimers, which are capable of inducing a strong antibody response characterized by neuraminidase inhibiting activity and protection of mice from high dose viral challenge. Overall, our results provide evidence for the feasibility of introducing stalk modifications to enhance the stability and immunogenicity of NA-based recombinant antigens.	[Strohmeier, Shirin; Carreno, Juan Manuel; Brito, Ruhi Nichalle; Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Strohmeier, Shirin] Univ Nat Resources & Life Sci, Dept Biotechnol, A-1190 Vienna, Austria		Krammer, F (通讯作者)，Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.	shirin.strohmeier@mssm.edu; jm.carreno@mssm.edu; brito.n.ruhi@gmail.com; florian.krammer@mssm.edu		Krammer, Florian/0000-0003-4121-776X; Carreno Quiroz, Juan Manuel/0000-0002-9039-9275	National Institute of Allergy and Infectious Disease (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00051]; NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]	This work was supported in part by the National Institute of Allergy and Infectious Disease (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 and NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C.	Amanat F, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00189-18; Arunkumar GA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26409-2; BLOK J, 1982, BIOCHEMISTRY-US, V21, P4001, DOI 10.1021/bi00260a015; CASTRUCCI MR, 1993, J VIROL, V67, P759, DOI 10.1128/JVI.67.2.759-764.1993; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Cohen M, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-321; Couch RB, 2013, J INFECT DIS, V207, P974, DOI 10.1093/infdis/jis935; da Silva DV, 2013, J BIOL CHEM, V288, P644, DOI 10.1074/jbc.M112.424150; Das SR, 2013, CELL HOST MICROBE, V13, P314, DOI 10.1016/j.chom.2013.02.008; Eichelberger MC, 2019, J INFECT DIS, V219, pS75, DOI 10.1093/infdis/jiz017; ELS MC, 1985, VIROLOGY, V142, P241, DOI 10.1016/0042-6822(85)90332-0; JOHANSSON BE, 1987, P NATL ACAD SCI USA, V84, P6869, DOI 10.1073/pnas.84.19.6869; Johansson BE, 2011, EXPERT REV VACCINES, V10, P1683, DOI [10.1586/ERV.11.130, 10.1586/erv.11.130]; KILBOURNE ED, 1968, J VIROL, V2, P281, DOI 10.1128/JVI.2.4.281-288.1968; KILBOURNE ED, 1990, P NATL ACAD SCI USA, V87, P786, DOI 10.1073/pnas.87.2.786; Krammer F., 2020, FIELDS VIROLOGY, V1, P596; Krammer F, 2019, CELL HOST MICROBE, V26, P712, DOI 10.1016/j.chom.2019.11.006; Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y; Krammer F, 2018, MBIO, V9, DOI 10.1128/mBio.02332-17; Krammer F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043603; Madsen A, 2020, IMMUNITY, V53, P852, DOI 10.1016/j.immuni.2020.08.015; Maier HE, 2020, CLIN INFECT DIS, V70, P2290, DOI 10.1093/cid/ciz639; Margine I, 2013, JOVE-J VIS EXP, DOI 10.3791/51112; McAuley JL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00039; McMahon M, 2020, VACCINE, V38, P7129, DOI 10.1016/j.vaccine.2020.08.067; Memoli MJ, 2016, MBIO, V7, DOI 10.1128/mBio.00417-16; Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195; Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4; Nguyen-Van-Tam JS, 2015, CLIN MICROBIOL INFEC, V21, P222, DOI 10.1016/j.cmi.2014.11.020; PALESE P, 1976, J GEN VIROL, V33, P159, DOI 10.1099/0022-1317-33-1-159; Park S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11348-0; Stadlbauer D, 2019, SCIENCE, V366, P499, DOI 10.1126/science.aay0678; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WARD CW, 1983, FEBS LETT, V153, P29, DOI 10.1016/0014-5793(83)80113-6; Wohlbold TJ, 2015, VACCINE, V33, P3314, DOI 10.1016/j.vaccine.2015.05.038; Wohlbold TJ, 2015, MBIO, V6, DOI 10.1128/mBio.02556-14; Wohlbold TJ, 2014, VIRUSES-BASEL, V6, P2465, DOI 10.3390/v6062465; Xu XJ, 2008, J VIROL, V82, P10493, DOI 10.1128/JVI.00959-08	38	4	4	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							404	10.3390/vaccines9040404			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5LZ	33921722	gold, Green Published			2022-04-29	WOS:000643821800001
J	Cui, XL; Cao, ZH; Ishikawa, Y; Cui, S; Imadome, KI; Snapper, CM				Cui, Xinle; Cao, Zhouhong; Ishikawa, Yuriko; Cui, Sara; Imadome, Ken-Ichi; Snapper, Clifford M.			Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge	VACCINES			English	Article						Epstein-Barr virus; infectious mononucleosis; EBV-associated lymphoma and epithelial cancer; EBV vaccine development; core fusion machinery; envelope glycoprotein; gH/gL; gB; neutralizing antibody		Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers. EBV core fusion machinery envelope proteins gH/gL and gB coordinately mediate EBV fusion and entry into its target cells, B lymphocytes and epithelial cells, suggesting these proteins could induce antibodies that prevent EBV infection. We previously reported that the immunization of rabbits with recombinant EBV gH/gL or trimeric gB each induced markedly higher serum EBV-neutralizing titers for B lymphocytes than that of the leading EBV vaccine candidate gp350. In this study, we demonstrated that immunization of rabbits with EBV core fusion machinery proteins induced high titer EBV neutralizing antibodies for both B lymphocytes and epithelial cells, and EBV gH/gL in combination with EBV trimeric gB elicited strong synergistic EBV neutralizing activities. Furthermore, the immune sera from rabbits immunized with EBV gH/gL or trimeric gB demonstrated strong passive immune protection of humanized mice from lethal dose EBV challenge, partially or completely prevented death respectively, and markedly decreased the EBV load in peripheral blood of humanized mice. These data strongly suggest the combination of EBV core fusion machinery envelope proteins gH/gL and trimeric gB is a promising EBV prophylactic vaccine.	[Cui, Xinle; Cao, Zhouhong; Cui, Sara; Snapper, Clifford M.] Uniformed Serv Univ Hlth Sci, Inst Vaccine Res, Dept Pathol, Bethesda, MD 20814 USA; [Cui, Xinle] NCI, Ctr Canc Res, Bethesda, MD 20892 USA; [Ishikawa, Yuriko; Imadome, Ken-Ichi] Natl Ctr Child Hlth & Dev, Dept Adv Med Infect, Tokyo 1570074, Japan		Cui, XL (通讯作者)，Uniformed Serv Univ Hlth Sci, Inst Vaccine Res, Dept Pathol, Bethesda, MD 20814 USA.; Cui, XL (通讯作者)，NCI, Ctr Canc Res, Bethesda, MD 20892 USA.	xinle.cui@nih.gov; zhouhong.cao@nih.gov; ishikawa-yu@ncchd.go.jp; scui567@gmail.com; imadome-k@ncchd.go.jp; clifford.snapper@usuhs.edu			Dean's Research and Education Endowment Fund from Uniformed Services University of the Health Sciences (USUHS)	This study was supported by the Dean's Research and Education Endowment Fund from Uniformed Services University of the Health Sciences (USUHS). USUHS had no involvement in design of study, data analysis or interpretation, nor manuscript preparation or study publication.	Al-Mansour Z, 2013, CURR HEMATOL MALIG R, V8, P173, DOI 10.1007/s11899-013-0162-5; AlDabbagh MA, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14020; Ambinder Richard F, 2007, Hematology Am Soc Hematol Educ Program, P204, DOI 10.1182/asheducation-2007.1.204; ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; Backovic M, 2009, P NATL ACAD SCI USA, V106, P2880, DOI 10.1073/pnas.0810530106; Berges BK, 2014, J GEN VIROL, V95, P2106, DOI 10.1099/vir.0.067793-0; BIRKENBACH M, 1992, J EXP MED, V176, P1405, DOI 10.1084/jem.176.5.1405; Bornkamm GW, 2009, INT J CANCER, V124, P1745, DOI 10.1002/ijc.24223; Bu W, 2019, IMMUNITY, V50, P1305, DOI 10.1016/j.immuni.2019.03.010; Chen XZ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000792; Chiuppesi F, 2018, J VIROL, V92, DOI 10.1128/JVI.01012-18; Cocco M, 2008, AM J PATHOL, V173, P1369, DOI 10.2353/ajpath.2008.071186; Cohen JI, 2018, ADV EXP MED BIOL, V1045, P477, DOI 10.1007/978-981-10-7230-7_22; Cohen JI, 2013, VACCINE, V31, pB194, DOI 10.1016/j.vaccine.2012.09.041; Cohen JI, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002878; Connolly SA, 2011, NAT REV MICROBIOL, V9, P369, DOI 10.1038/nrmicro2548; Cox C, 1998, J MED VIROL, V55, P255, DOI 10.1002/(SICI)1096-9071(199808)55:4<255::AID-JMV1>3.0.CO;2-#; Cu XL, 2019, HUM VACC IMMUNOTHER, V15, P2673, DOI 10.1080/21645515.2019.1593729; Cui XL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020179; Cui XL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133158; Cui XL, 2018, VACCINE, V36, P5580, DOI 10.1016/j.vaccine.2018.07.056; Cui XL, 2016, VACCINE, V34, P4050, DOI 10.1016/j.vaccine.2016.06.021; Cui XL, 2013, VACCINE, V31, P3039, DOI 10.1016/j.vaccine.2013.04.071; Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095; DAMBAUGH T, 1986, J VIROL, V59, P453, DOI 10.1128/JVI.59.2.453-462.1986; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; de Oliveira DE, 2016, TRENDS MICROBIOL, V24, P649, DOI 10.1016/j.tim.2016.03.008; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Dharnidharka VR, 2018, AM J TRANSPLANT, V18, P537, DOI 10.1111/ajt.14603; Diamond DJ, 2018, EXPERT REV VACCINES, V17, P889, DOI 10.1080/14760584.2018.1526085; Draper SJ, 2015, VACCINE, V33, P7433, DOI 10.1016/j.vaccine.2015.09.093; FINERTY S, 1992, J GEN VIROL, V73, P449, DOI 10.1099/0022-1317-73-2-449; Fingeroth JD, 1999, J VIROL, V73, P2115, DOI 10.1128/JVI.73.3.2115-2125.1999; Fukayama M, 2010, PATHOL INT, V60, P337, DOI 10.1111/j.1440-1827.2010.02533.x; Gottschalk S, 2015, CURR TOP MICROBIOL, V391, P427, DOI 10.1007/978-3-319-22834-1_15; HALLEE TJ, 1974, YALE J BIOL MED, V47, P182; Heldwein EE, 2008, CELL MOL LIFE SCI, V65, P1653, DOI 10.1007/s00018-008-7570-z; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Heslop HE, 2010, BLOOD, V115, P925, DOI 10.1182/blood-2009-08-239186; Heuts F, 2014, J VIROL, V88, P3235, DOI 10.1128/JVI.02885-13; Hjalgrim H, 2000, J NATL CANCER I, V92, P1522, DOI 10.1093/jnci/92.18.1522; Hjerrild KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep30357; Hutt-Fletcher LM, 2007, J VIROL, V81, P7825, DOI 10.1128/JVI.00445-07; Hutt-Fletcher LM, 2014, P NATL ACAD SCI USA, V111, P16242, DOI 10.1073/pnas.1418974111; IEZZONI JC, 1995, AM J CLIN PATHOL, V103, P308, DOI 10.1093/ajcp/103.3.308; Janz A, 2000, J VIROL, V74, P10142, DOI 10.1128/JVI.74.21.10142-10152.2000; Jiang R, 2008, J ORAL PATHOL MED, V37, P626, DOI 10.1111/j.1600-0714.2008.00681.x; Kimura H, 1999, J CLIN MICROBIOL, V37, P132, DOI 10.1128/JCM.37.1.132-136.1999; Kimura H, 2012, BLOOD, V119, P673, DOI 10.1182/blood-2011-10-381921; Kuwana Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026630; Lal H, 2015, NEW ENGL J MED, V373, P1576, DOI 10.1056/NEJMc1508392; Lee JH, 2009, J GASTROEN HEPATOL, V24, P354, DOI 10.1111/j.1440-1746.2009.05775.x; LI QX, 1992, NATURE, V356, P347, DOI 10.1038/356347a0; Luzuriaga K, 2010, NEW ENGL J MED, V362, P1993, DOI 10.1056/NEJMcp1001116; Mackett M, 1996, J MED VIROL, V50, P263, DOI 10.1002/(SICI)1096-9071(199611)50:3<263::AID-JMV9>3.3.CO;2-U; Majji S, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2264-y; Majji S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28093; Maruo S, 2001, J GEN VIROL, V82, P2373, DOI 10.1099/0022-1317-82-10-2373; Mawson AR, 2017, INT J CANCER, V141, P1849, DOI 10.1002/ijc.30885; McVoy MA, 2015, VACCINE, V33, P7328, DOI 10.1016/j.vaccine.2015.10.078; Mendoza M, 2018, HUM VACC IMMUNOTHER, V14, P345, DOI 10.1080/21645515.2017.1403703; MORGAN AJ, 1989, J MED VIROL, V29, P74, DOI 10.1002/jmv.1890290114; MORGAN AJ, 1988, J MED VIROL, V25, P189, DOI 10.1002/jmv.1890250209; MORGAN AJ, 1984, J MED VIROL, V13, P281, DOI 10.1002/jmv.1890130310; Moutschen M, 2007, VACCINE, V25, P4697, DOI 10.1016/j.vaccine.2007.04.008; Neparidze Natalia, 2014, Clin Adv Hematol Oncol, V12, P358; Neuhierl B, 2002, P NATL ACAD SCI USA, V99, P15036, DOI 10.1073/pnas.232381299; NIEDERMAN JC, 1968, J AMER MED ASSOC, V203, P205; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Perez EM, 2017, ONCOTARGET, V8, P19255, DOI 10.18632/oncotarget.13770; RAGOT T, 1993, J GEN VIROL, V74, P501, DOI 10.1099/0022-1317-74-3-501; Rea T D, 2001, J Am Board Fam Pract, V14, P234; Rochford R, 2015, CURR TOP MICROBIOL, V390, P267, DOI 10.1007/978-3-319-22822-8_11; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; Sashihara J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002308; Sashihara J, 2009, VIROLOGY, V391, P249, DOI 10.1016/j.virol.2009.06.013; Sato K, 2011, BLOOD, V117, P5663, DOI 10.1182/blood-2010-09-305979; Schleiss MR, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00268-17; Seung E, 2013, J INFECT DIS, V208, pS155, DOI 10.1093/infdis/jit448; Shanbhag S, 2018, CA-CANCER J CLIN, V68, P116, DOI 10.3322/caac.21438; Shannon-Lowe C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00713; Shannon-Lowe C, 2014, CURR OPIN VIROL, V4, P78, DOI 10.1016/j.coviro.2013.12.001; Sokal EM, 2007, J INFECT DIS, V196, P1749, DOI 10.1086/523813; Song SY, 2002, HAEMATOLOGICA, V87, P1343; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Tsao SW, 2012, SEMIN CANCER BIOL, V22, P137, DOI 10.1016/j.semcancer.2012.02.004; Vetsika Eleni-Kyriaki, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404008440; Villegas E, 2010, MINI-REV MED CHEM, V10, P914, DOI 10.2174/138955710792007150; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; Yajima M, 2008, J INFECT DIS, V198, P673, DOI 10.1086/590502	93	3	3	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							285	10.3390/vaccines9030285			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6CW	33808755	Green Published, gold			2022-04-29	WOS:000634240600001
J	Dzinamarira, T; Nachipo, B; Phiri, B; Musuka, G				Dzinamarira, Tafadzwa; Nachipo, Brian; Phiri, Bright; Musuka, Godfrey			COVID-19 Vaccine Roll-Out in South Africa and Zimbabwe: Urgent Need to Address Community Preparedness, Fears and Hesitancy	VACCINES			English	Article						COVID-19; vaccine; hesitancy; Africa	HEALTH	South Africa became one of the first African countries to receive the COVID-19 vaccine. As the rest of Africa prepares to receive COVID-19 vaccines, most countries in Africa have set up national-level coordination committees for developing national vaccination deployment plans. While the main focus of these committees has been on setting up strategies that facilitate the swift distribution of COVID-19 vaccines once they are available, the role of effective public health awareness should not be ignored. Countries must devise strategies on how best to enhance public understanding and curb misinformation about the vaccines. With this viewpoint, we unpack the threat of COVID-19 vaccine hesitancy and offer recommendations for COVID-19 vaccine communication strategies in the South African and Zimbabwean contexts.	[Dzinamarira, Tafadzwa] Univ KwaZulu Natal, Dept Publ Hlth Med, ZA-4001 Durban, South Africa; [Dzinamarira, Tafadzwa; Phiri, Bright] Columbia Univ, ICAP, ZA-0157 Pretoria, South Africa; [Nachipo, Brian] Minist Hlth & Child Care, AIDS & TB Unit, Harare, Zimbabwe; [Musuka, Godfrey] Columbia Univ, ICAP, Harare, Zimbabwe		Dzinamarira, T (通讯作者)，Univ KwaZulu Natal, Dept Publ Hlth Med, ZA-4001 Durban, South Africa.; Dzinamarira, T (通讯作者)，Columbia Univ, ICAP, ZA-0157 Pretoria, South Africa.	td2581@cumc.columbia.edu; bnachipo@gmail.com; bp2483@cumc.columbia.edu; gm2660@cumc.columbia.edu	Dzinamarira, Tafadzwa/AAK-5667-2020	Dzinamarira, Tafadzwa/0000-0002-9929-5739; Musuka, Godfrey/0000-0001-9077-4429			Afolabi AA, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.3.27401; [Anonymous], OPERA NEWS; [Anonymous], DAILY MAVERICK; [Anonymous], WHO NEWS; [Anonymous], ANURADHA GUPTA; [Anonymous], 2021, COLUMBUS MAVHUNGA VO; [Anonymous], UN NEWS; [Anonymous], 2021, PETER MWAI BBC NEWS; [Anonymous], 2021, SABC NEWS; [Anonymous], 2020, ICAP NEWS; [Anonymous], 2020, BBC NEWS CORONAVIRUS; [Anonymous], NEWS18; [Anonymous], 2021, BBC NEWS; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Catalan-Matamoros D, 2019, PERSPECT PUBLIC HEAL, V139, P34, DOI 10.1177/1757913918780142; CDC, COR COVID 19; Desmon S., STIGMA RELATED COVID; Dodzo MK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181771; Duke Global Health Institute, 2021, ENS EV WORLD GETS CO; Dzinamarira T., 2020, AFRICA PUBLIC HLTH P, V1, DOI [10.1016/j.puhip.2020.100038, DOI 10.1016/J.PUHIP.2020.100038]; Dzinamarira T, 2021, CLIN INFECT DIS, V72, pE667, DOI 10.1093/cid/ciaa1301; Eghtessadi R, 2020, INT J INFECT DIS, V100, P286, DOI 10.1016/j.ijid.2020.08.086; GAVI, S AFR IS PREP COVID; Gavi The Vaccine Alliance, COVAX EXPL; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Grossman S, 2018, COMP POLIT STUD, V51, P979, DOI 10.1177/0010414017720706; Haider N, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003319; Heywood M., S AFRICA FACES SER B; Islam AKMN, 2020, TECHNOL FORECAST SOC, V159, DOI 10.1016/j.techfore.2020.120201; Kilanowski JF, 2017, J AGROMEDICINE, V22, P295, DOI 10.1080/1059924X.2017.1358971; Lahijani AY, 2021, SOC SCI MED, V268, DOI 10.1016/j.socscimed.2020.113375; Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239; Magamela MR, 2021, SAJP-S AFR J PSYCHI, V27, DOI 10.4102/sajpsychiatry.v27i0.1611; Mapingure M, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10405-8; Mhango M, 2020, AIDS BEHAV, V24, P3014, DOI 10.1007/s10461-020-02939-6; MoHCC, 2021, ZIMB COVID 19 SITREP; MoHCC, COMPR NAT HIV COMM S; MoHCC, 2015, CREAT DEM VMMC NEW M; Mukandavire Z, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236003; Mukwenha S, 2020, INT J INFECT DIS, V100, P394, DOI 10.1016/j.ijid.2020.09.1425; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Newman A, 2020, MMWR-MORBID MORTAL W, V69, P710, DOI 10.15585/mmwr.mm6923e3; Nhari L.G., 2020, PUBLIC HLTH PRACT, V1, DOI [10.1016/j.puhip.2020.100058, DOI 10.1016/J.PUHIP.2020.100058]; ParkerWhite, 2019, IMP BRAND POS AG HEA; Peretti-Watel Patrick, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289; Pierre G, 2020, AIDS BEHAV, V24, P3299, DOI 10.1007/s10461-020-02956-5; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Renne EP, 2014, AFRICA, V84, P466, DOI 10.1017/S0001972014000369; Rzymski P., STRATEGIES SUPPORT C; Salama P, 2019, B WORLD HEALTH ORGAN, V97, P443, DOI 10.2471/BLT.19.238279; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Stadnytskyi V, 2020, P NATL ACAD SCI USA, V117, P11875, DOI 10.1073/pnas.2006874117; Taylor S, 2017, VACCINE, V35, P6438, DOI 10.1016/j.vaccine.2017.09.075; Tozivepi S.N., 2020, COVID 19 VACCINE HES; UNICEF Collaborating Centre for Operational Research and Evaluation (CCORE), 2011, APOSTOLIC RELIG HLTH; USAID PSI, 2020, COVID IS CLOS YOU TH; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1056/NEJMc2004973, 10.1101/2020.03.09.20033217]; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786; Ward JK, 2016, HUM VACC IMMUNOTHER, V12, P1924, DOI 10.1080/21645515.2016.1146430; WHO, NOV COR COVID 19; World Health Organisation (WHO), 2020, MAN COVID 19 INF PRO; World Health Organization, COVID 19 WHO AFR REG; Xiao F, 2020, EMERG INFECT DIS, V26, P1920, DOI 10.3201/eid2608.200681; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	65	31	31	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							250	10.3390/vaccines9030250			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE4YK	33809002	Green Published, gold			2022-04-29	WOS:000634161400001
J	Flynn, O; Dillane, K; Lanza, JS; Marshall, JM; Jin, J; Silk, SE; Draper, SJ; Moore, AC				Flynn, Olivia; Dillane, Kate; Lanza, Juliane Sousa; Marshall, Jennifer M.; Jin, Jing; Silk, Sarah E.; Draper, Simon J.; Moore, Anne C.			Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection	VACCINES			English	Article						adenovirus; virus vector vaccine; microneedle; skin; dose; stability; antibody; anti-vector immunity	PROTECTIVE EFFICACY; EBOLA VACCINE; T-CELLS; DELIVERY; IMMUNITY; SAFETY; IMMUNIZATION; STABILITY; RESPONSES; POTENCY	Adenovirus-based vaccines are demonstrating promising clinical potential for multiple infectious diseases, including COVID-19. However, the immunogenicity of the vector itself decreases its effectiveness as a boosting vaccine due to the induction of strong anti-vector neutralizing immunity. Here we determined how dissolvable microneedle patches (DMN) for skin immunization can overcome this issue, using a clinically-relevant adenovirus-based Plasmodium falciparum malaria vaccine, AdHu5-PfRH5, in mice. Incorporation of vaccine into patches significantly enhanced its thermostability compared to the liquid form. Conventional high dose repeated immunization by the intramuscular (IM) route induced low antigen-specific IgG titres and high anti-vector immunity. A low priming dose of vaccine, by the IM route, but more so using DMN patches, induced the most efficacious immune responses, assessed by parasite growth inhibitory activity (GIA) assays. Administration of low dose AdHu5-PfRH5 using patches to the skin, boosted by high dose IM, induced the highest antigen-specific serum IgG response after boosting, the greatest skewing of the antibody response towards the antigen and away from the vector, and the highest efficacy. This study therefore demonstrates that repeated use of the same adenovirus vaccine can be highly immunogenic towards the transgene if a low dose is used to prime the response. It also provides a method of stabilizing adenovirus vaccine, in easy-to-administer dissolvable microneedle patches, permitting storage and distribution out of cold chain.	[Flynn, Olivia; Dillane, Kate; Lanza, Juliane Sousa; Moore, Anne C.] Univ Coll Cork, Sch Pharm, Cork T12 XF62, Ireland; [Lanza, Juliane Sousa; Marshall, Jennifer M.; Jin, Jing; Silk, Sarah E.; Draper, Simon J.] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England; [Moore, Anne C.] Univ Coll Cork, Sch Biochem & Cell Biol, Cork T12 XF62, Ireland		Moore, AC (通讯作者)，Univ Coll Cork, Sch Pharm, Cork T12 XF62, Ireland.; Moore, AC (通讯作者)，Univ Coll Cork, Sch Biochem & Cell Biol, Cork T12 XF62, Ireland.	olivia.flynn@cit.ie; kdillane@ucc.ie; julianelanza@gmail.com; jennifer.marshall@ndm.ox.ac.uk; jing.jin@ndm.ox.ac.uk; sarah.silk@ndm.ox.ac.uk; simon.draper@ndm.ox.ac.uk; anne.moore@ucc.ie		Draper, Simon/0000-0002-9415-1357; Moore, Anne/0000-0003-3656-4230	Health Research Board, Ireland, Patient Oriented Research grant [POR/2012/95]; Wellcome TrustWellcome TrustEuropean Commission [106917/Z/15/Z]	This work was supported by Health Research Board, Ireland, Patient Oriented Research grant POR/2012/95. S.J.D. is a Jenner Investigator, a Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow [106917/Z/15/Z]; for the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.	Alanine DGW, 2019, CELL, V178, P216, DOI 10.1016/j.cell.2019.05.025; Alcock R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000490; Allen EA, 2016, INT J PHARMACEUT, V500, P1, DOI 10.1016/j.ijpharm.2015.12.052; Bachy V, 2013, P NATL ACAD SCI USA, V110, P3041, DOI 10.1073/pnas.1214449110; Baden LR, 2016, ANN INTERN MED, V164, P313, DOI 10.7326/M15-0880; Bajrovic I, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aau4819; Barnes E, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003155; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Bernelin-Cottet C, 2019, J CONTROL RELEASE, V308, P14, DOI 10.1016/j.jconrel.2019.06.041; Billeskov R, 2017, J IMMUNOL, V198, P3494, DOI 10.4049/jimmunol.1600965; Bliss CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21630-4; Callendret B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192312; Carey JB, 2014, SCI REP-UK, V4, DOI 10.1038/srep06154; Carey JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022442; Croyle M A, 1998, Pharm Dev Technol, V3, P373, DOI 10.3109/10837459809009865; de Cassan SC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00348; DeMuth PC, 2013, NAT BIOTECHNOL, V31, P1082, DOI 10.1038/nbt.2759; Dolzhikova IV, 2017, HUM VACC IMMUNOTHER, V13, P613, DOI 10.1080/21645515.2016.1238535; Donadei A., 2019, Patent, Patent No. [2019/238779, 2019238779]; Douglas AD, 2015, CELL HOST MICROBE, V17, P130, DOI 10.1016/j.chom.2014.11.017; Douglas AD, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1615; Draper SJ, 2008, NAT MED, V14, P819, DOI 10.1038/nm.1850; Draper SJ, 2018, CELL HOST MICROBE, V24, P43, DOI 10.1016/j.chom.2018.06.008; EMEA, 2006, ICH TOP Q 1 R2 STAB; Ewer K, 2016, NEW ENGL J MED, V374, P1635, DOI 10.1056/NEJMoa1411627; Fazilleau N, 2009, NAT IMMUNOL, V10, P375, DOI 10.1038/ni.1704; Folegatti PM, 2020, LANCET INFECT DIS, V20, P816, DOI 10.1016/S1473-3099(20)30160-2; Hamid MMA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020547; Hirobe S, 2015, BIOMATERIALS, V57, P50, DOI 10.1016/j.biomaterials.2015.04.007; Hirobe S, 2012, VACCINE, V30, P1847, DOI 10.1016/j.vaccine.2011.12.130; Hodgson SH, 2014, MOL THER, V22, P2142, DOI 10.1038/mt.2014.157; Jin J, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0071-7; Lanza JS, 2020, INT J PHARMACEUT, V586, DOI 10.1016/j.ijpharm.2020.119390; Malkin EM, 2005, INFECT IMMUN, V73, P3677, DOI 10.1128/IAI.73.6.3677-3685.2005; Marshall S, 2016, HUM VACC IMMUNOTHER, V12, P2975, DOI 10.1080/21645515.2016.1171440; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Milligan ID, 2016, JAMA-J AM MED ASSOC, V315, P1610, DOI 10.1001/jama.2016.4218; Moore A., 2012, Patent, Patent No. [2012153266 A3, 2012153266]; Norman JJ, 2014, VACCINE, V32, P1856, DOI 10.1016/j.vaccine.2014.01.076; Payne RO, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93683; Pearson FE, 2015, VACCINE, V33, P3248, DOI 10.1016/j.vaccine.2015.03.039; Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993; Quinn KM, 2015, J CLIN INVEST, V125, P1129, DOI 10.1172/JCI78280; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Reyes-Sandoval A, 2008, EUR J IMMUNOL, V38, P732, DOI 10.1002/eji.200737672; Rouphael NG, 2017, LANCET, V390, P649, DOI 10.1016/S0140-6736(17)30575-5; Salisch NC, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0150-4; Sheehy SH, 2011, MOL THER, V19, P2269, DOI 10.1038/mt.2011.176; Singh S, 2006, INFECT IMMUN, V74, P4573, DOI 10.1128/IAI.01679-05; Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419; Sridhar S, 2008, J VIROL, V82, P3822, DOI 10.1128/JVI.02568-07; Tamminga C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025868; van Zyl-Smit RN, 2017, AM J RESP CRIT CARE, V195, P1171, DOI 10.1164/rccm.201603-0654OC; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Vrdoljak A, 2016, J CONTROL RELEASE, V225, P192, DOI 10.1016/j.jconrel.2016.01.019; Vrdoljak A, 2012, J CONTROL RELEASE, V159, P34, DOI 10.1016/j.jconrel.2011.12.026; Wolfson LJ, 2008, B WORLD HEALTH ORGAN, V86, P27, DOI 10.2471/BLT.07.045096; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/S0140-6736(16)32617-4, 10.1016/s0140-6736(16)32617-4]	59	4	4	6	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							299	10.3390/vaccines9030299			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6DY	33810085	gold, Green Submitted, Green Published			2022-04-29	WOS:000634243400001
J	Hajikhezri, Z; Roohvand, F; Maleki, M; Shahmahmoodi, S; Amirzargar, AA; Keshavarz, A; Seyed, N; Farahmand, M; Samimi-Rad, K				Hajikhezri, Zamaneh; Roohvand, Farzin; Maleki, Monireh; Shahmahmoodi, Shohreh; Amirzargar, Ali Akbar; Keshavarz, Abolfazl; Seyed, Negar; Farahmand, Mohammad; Samimi-Rad, Katayoun			HCV Core/NS3 Protein Immunization with "N-Terminal Heat Shock gp96 Protein (rNT (gp96))" Induced Strong and Sustained Th1-Type Cytokines in Immunized Mice	VACCINES			English	Article						Hepatitis C virus; rNT (gp96); vaccine; Core-Ns3; prime-boost		Feeble cellular responses induced by T cell-based vaccines are a major challenge for the development of an effective vaccine against Hepatitis C virus (HCV) infection. To address this challenge, the potential of N-terminal fragment of gp96 heat shock protein (rNT (gp96) as an adjuvant was evaluated and compared to that of the CpG (as a recognized Th1-type adjuvant) in the formulation of HCV core/NS3 antigens in three immunization strategies of protein/protein, DNA/DNA, and DNA/protein. Immunized mice were evaluated for elicited immune responses in week 3 (W3) and 11 post-immunizations. Our results demonstrated that the protein (subunit) vaccine formulated with rNT (gp96) in protein/protein strategy (core/NS3 + gp96) was significantly more efficient than CpG oligodeoxynucleotides (CpG ODN) formulation and all other immunization strategies in the induction of Th1-type cytokines. This group of mice (core/NS3 + gp96) also elicited a high level of anti-Core-NS3 total immunoglobulin G (IgG) with dominant IgG2a isotype at W3. Thus, the co-administration of recombinant NT (gp96) protein with rHCV proteins might be a promising approach in the formulation of HCV subunit vaccine candidates for induction of high levels of Th1 cytokines and humoral responses.	[Hajikhezri, Zamaneh; Shahmahmoodi, Shohreh; Keshavarz, Abolfazl; Farahmand, Mohammad; Samimi-Rad, Katayoun] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran 1449614535, Iran; [Roohvand, Farzin] Pasteur Inst Iran, Dept Virol, Tehran 1316943551, Iran; [Maleki, Monireh] Islamic Azad Univ Tehran, Dept Clin Biochem, Fac Med Sci, Tehran 1477893855, Iran; [Shahmahmoodi, Shohreh] Univ Tehran Med Sci, Food Microbiol Res Ctr, Tehran 1449614535, Iran; [Amirzargar, Ali Akbar] Univ Tehran Med Sci, Mol Immunol Res Ctr, Tehran 1449614535, Iran; [Amirzargar, Ali Akbar] Univ Tehran Med Sci, Dept Immunol, Immunogenet Lab, Fac Med, Tehran 1449614535, Iran; [Seyed, Negar] Pasteur Inst Iran, Dept Immunotherapy & Leishmania Vaccine Res, Tehran 1316943551, Iran		Samimi-Rad, K (通讯作者)，Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran 1449614535, Iran.	z-hajikhezri@razi.tums.ac.ir; farzin.roohvand2@gmail.com; Monireh.maleki@gmail.com; Shahmahmoodi@tums.ac.ir; amirzara@sina.tums.ac.ir; a-keshavarz@farabi.tums.ac.ir; negarse@gmail.com; Farahmandm@outlook.com; ksamimirad@sina.tums.ac.ir		/0000-0002-9648-9298	Tehran university of medical sciences (TUMS)Tehran University of Medical Sciences [95-02-27-31344]	This research was part of a Ph.D. dissertation supported by Tehran university of medical sciences (TUMS); Grant no: 95-02-27-31344.	Alekseeva Ekaterina, 2009, Genet Vaccines Ther, V7, P7, DOI 10.1186/1479-0556-7-7; Ansari N, 2019, MOL IMMUNOL, V111, P152, DOI 10.1016/j.molimm.2019.04.009; Bailey JR, 2019, GASTROENTEROLOGY, V156, P418, DOI 10.1053/j.gastro.2018.08.060; Bastola R, 2017, ARCH PHARM RES, V40, P1238, DOI 10.1007/s12272-017-0969-z; Bolhassani A, 2008, VACCINE, V26, P3362, DOI 10.1016/j.vaccine.2008.03.082; Chen CW, 2012, VIRUS RES, V167, P162, DOI 10.1016/j.virusres.2012.04.011; Conti F, 2016, J HEPATOL, V65, P727, DOI 10.1016/j.jhep.2016.06.015; Cox AL, 2015, SCIENCE, V349, P790, DOI 10.1126/science.aad1302; Dale C. Jane, 2006, V127, P171; Donnison T, 2020, VACCINE, V38, P5036, DOI 10.1016/j.vaccine.2020.05.042; Fauvelle C, 2016, EXPERT REV VACCINES, V15, P1535, DOI 10.1080/14760584.2016.1194759; Fernando GJP, 1998, J IMMUNOL, V161, P2421; Garmory Helen S, 2003, Genet Vaccines Ther, V1, P2, DOI 10.1186/1479-0556-1-2; Geissler M, 1997, J IMMUNOL, V158, P1231; Gummow J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010053; Habersetzer F, 2009, CURR OPIN MOL THER, V11, P456; Ju Y, 2014, VACCINE, V32, P2703, DOI 10.1016/j.vaccine.2014.03.045; Klinman Dennis M, 2003, Expert Rev Vaccines, V2, P305, DOI 10.1586/14760584.2.2.305; Lin YL, 2008, J VIROL, V82, P7492, DOI 10.1128/JVI.02743-07; Logvinoff C, 2004, P NATL ACAD SCI USA, V101, P10149, DOI 10.1073/pnas.0403519101; Manickan E, 1997, CRIT REV IMMUNOL, V17, P139, DOI 10.1615/CritRevImmunol.v17.i2.20; Masavuli MG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01145; Olivera S, 2020, ARCH VIROL, V165, P593, DOI 10.1007/s00705-019-04464-x; Pishraft-Sabet L, 2015, ARCH VIROL, V160, P141, DOI 10.1007/s00705-014-2243-8; Qiu Q, 2008, VACCINE, V26, P5527, DOI 10.1016/j.vaccine.2008.07.034; Sambrook J., 2006, CONDENSED PROTOCOLS; Samimi-Rad K, 2015, J MED VIROL, V87, P1565, DOI 10.1002/jmv.24211; Semmo N, 2006, BLOOD, V107, P4570, DOI 10.1182/blood-2005-11-4522; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Sugauchi F, 2006, J INFECT DIS, V193, P563, DOI 10.1086/499823; Suwanthawornkul T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145953; Tabata K, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a037093; Takeuchi A, 2016, J EXP MED, V213, P123, DOI 10.1084/jem.20150519; Wang SF, 2011, VACCINE, V29, P6342, DOI 10.1016/j.vaccine.2011.05.008; World Health Organization, 2017, GLOBAL HEPATITIS REP; zur Wiesch JS, 2005, J IMMUNOL, V175, P3603, DOI 10.4049/jimmunol.175.6.3603	36	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							215	10.3390/vaccines9030215			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5TO	33802466	gold, Green Published			2022-04-29	WOS:000634216400001
J	Kandeil, A; Mostafa, A; Hegazy, RR; El-Shesheny, R; El Taweel, A; Gomaa, MR; Shehata, M; Elbaset, MA; Kayed, AE; Mahmoud, SH; Moatasim, Y; Kutkat, O; Yassen, NN; Shabana, ME; GabAllah, M; Kamel, MN; Shama, NAM; El Sayes, M; Ahmed, AN; Elalfy, ZS; Mohamed, BM; Abd El-Fattah, SN; El Hariri, HM; Kader, MA; Azmy, O; Kayali, G; Ali, MA				Kandeil, Ahmed; Mostafa, Ahmed; Hegazy, Rehab R.; El-Shesheny, Rabeh; El Taweel, Ahmed; Gomaa, Mokhtar R.; Shehata, Mahmoud; Elbaset, Marawan A.; Kayed, Ahmed E.; Mahmoud, Sara H.; Moatasim, Yassmin; Kutkat, Omnia; Yassen, Noha N.; Shabana, Marwa E.; GabAllah, Mohamed; Kamel, Mina Nabil; Abo Shama, Noura M.; El Sayes, Mohamed; Ahmed, Amira N.; Elalfy, Zahraa S.; Mohamed, Bassim M. S. A.; Abd El-Fattah, Safa N.; El Hariri, Hazem Mohamed; Abdel Kader, Mona; Azmy, Osama; Kayali, Ghazi; Ali, Mohamed A.			Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies	VACCINES			English	Article						SARS-CoV-2; pre-clinical study; vaccine safety; immunogenicity; efficacy	INFLAMMATORY RESPONSE; D-DIMER; FEVER	Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in clinical development and 173 are in the pre-clinical phase. Five types of vaccines are currently approved for emergency use in many countries (Inactivated, Sinopharm; Viral-vector, Astrazeneca, and Gamaleya Research Institute; mRNA, Moderna, and BioNTech/Pfizer). The main challenge in this pandemic was the availability to produce an effective vaccine to be distributed to the world's population in a short time. Herein, we developed a whole virus NRC-VACC-01 inactivated candidate SARS-CoV-2 vaccine and tested its safety and immunogenicity in laboratory animals. In the preclinical studies, we used four experimental animals (mice, rats, guinea pigs, and hamsters). Antibodies were detected as of week three post vaccination and continued up to week ten in the four experimental models. Safety evaluation of NRC-VACC-01 inactivated candidate vaccine in rats revealed that the vaccine was highly tolerable. By studying the effect of booster dose in the immunological profile of vaccinated mice, we observed an increase in neutralizing antibody titers after the booster shot, thus a booster dose was highly recommended after week three or four. Challenge infection of hamsters showed that the vaccinated group had lower morbidity and shedding than the control group. A phase I clinical trial will be performed to assess safety in human subjects.	[Kandeil, Ahmed; Mostafa, Ahmed; El-Shesheny, Rabeh; El Taweel, Ahmed; Gomaa, Mokhtar R.; Shehata, Mahmoud; Kayed, Ahmed E.; Mahmoud, Sara H.; Moatasim, Yassmin; Kutkat, Omnia; GabAllah, Mohamed; Kamel, Mina Nabil; Abo Shama, Noura M.; El Sayes, Mohamed; Ali, Mohamed A.] Natl Res Ctr, Environm Res Div, Ctr Sci Excellence Influenza Virus, Giza 12622, Egypt; [Hegazy, Rehab R.; Elbaset, Marawan A.; Mohamed, Bassim M. S. A.] Natl Res Ctr, Med Div, Dept Pharmacol, Giza 12622, Egypt; [Yassen, Noha N.; Shabana, Marwa E.; Elalfy, Zahraa S.] Natl Res Ctr, Med Div, Dept Pathol, Giza 12622, Egypt; [Ahmed, Amira N.; Abd El-Fattah, Safa N.; Abdel Kader, Mona] Natl Res Ctr, Med Div, Dept Clin & Chem Pathol, Giza 12622, Egypt; [El Hariri, Hazem Mohamed] Natl Res Ctr, Med Div, Dept Community Med, Giza 12622, Egypt; [Azmy, Osama] Natl Res Ctr, Med Res Div, Reprod Hlth Dept, Giza 12622, Egypt; [Kayali, Ghazi] Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA		Ali, MA (通讯作者)，Natl Res Ctr, Environm Res Div, Ctr Sci Excellence Influenza Virus, Giza 12622, Egypt.; Kayali, G (通讯作者)，Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.	Ahmed.Kandeil@human-link.org; ahmed_nrc2000@hotmail.com; rehab_hegazy@hotmail.com; rabeh.elshesheny@stjude.org; Ahmed.Nageh@human-link.org; Mokhtar.Rizk@human-link.org; Mahmoud.Shehata@human-link.org; dr.marawan@gmail.com; Ahmed.Elsayed@human-link.org; Sarah.Hussein@human-link.org; Yasmin.Moatasim@human-link.org; Omnia.Abdelaziz@human-link.org; nn.yassin@nrc.sci.eg; me.shabana@nrc.sci.eg; gaballah09@gmail.com; minanabil56@yahoo.com; noura.mahrous1995@gmail.com; mohameddiaaelsayes@outlook.com; amira.koraitim@yahoo.com; zs.el-alfy@nrc.sci.eg; bassim.mohamed@umontreal.ca; sn.abdelfattah@nrc.sci.eg; dochzm@gmail.com; dr.monaabdelkader@hotmail.com; osamaazmy@nrc.sci.eg; ghazi@human-link.org; Mohamed.Ali@human-link.org	Elbaset, Marawan/M-8214-2019; Mostafa, Ahmed/S-7462-2016; Gomaa, Mokhtar Rizk/N-9125-2018; Mohamed, Bassim/AFW-4110-2022; El-Taweel, Ahmed/ABG-8828-2021; Kandeil, Ahmed/N-5473-2019; Moatasim, Yassmin/AAQ-8426-2020; kutkat, omnia/AAU-5582-2020; Shehata, Mahmoud/R-7703-2016; El-Shesheny, Rabeh/S-7927-2016	Elbaset, Marawan/0000-0002-0861-6251; Mostafa, Ahmed/0000-0002-2878-5714; El-Taweel, Ahmed/0000-0002-7051-1389; Kandeil, Ahmed/0000-0003-3253-6961; Moatasim, Yassmin/0000-0003-2159-2511; kutkat, omnia/0000-0003-2256-2816; Shehata, Mahmoud/0000-0001-7556-9398; Mohamed, Bassim/0000-0003-0536-8261; El-Shesheny, Rabeh/0000-0002-8798-2240; El Hariri, Hazem/0000-0001-9886-2087; Kayed, Ahmed/0000-0002-0439-3476; Hegazy, Rehab/0000-0002-2586-2104	National Research CentreNational Research Centre (NRC) [MP120810]; National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human ServicesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)NIH National Institute of Neurological Disorders & Stroke (NINDS) [HHSN272201400006C]	This work was funded by the National Research Centre, under contract number MP120810. Initial virus sequencing and isolation and assay development were funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services (under contract HHSN272201400006C).	Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; Barrett PN, 2017, EXPERT REV VACCINES, V16, P883, DOI 10.1080/14760584.2017.1357471; Borowiec A, 2020, ADV MED SCI-POLAND, V65, P97, DOI 10.1016/j.advms.2019.12.007; Brill-Edwards P, 1999, THROMB HAEMOSTASIS, V82, P688; Chowdhury P, 2015, ADV VIROL, V2015, DOI 10.1155/2015/616898; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gomaa MR, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.596851; Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; ICTV, VIRUS TAXONOMY; Kajon AE, 2003, J MED VIROL, V71, P233, DOI 10.1002/jmv.10475; Kohl KS, 2004, CLIN INFECT DIS, V39, P389, DOI 10.1086/422454; Kulacoglu Hakan, 2005, Asian J Surg, V28, P131, DOI 10.1016/S1015-9584(09)60277-3; Kulkarni OP, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/2856213; Li H, 2017, AME MED J, V2, P27, DOI DOI 10.21037/AMJ.2017.02.07; Nakayama T, 2016, VACCINE, V34, P5815, DOI 10.1016/j.vaccine.2016.08.051; PEY K, 2020, TRANSBOUND EMERG DIS, DOI DOI 10.1111/TBED.13907; Roberts A, 2010, VIRAL IMMUNOL, V23, P509, DOI 10.1089/vim.2010.0028; Rosenke Kyle, 2020, bioRxiv, DOI 10.1101/2020.09.25.314070; Sarkar J, 2020, VET RES COMMUN, V44, P101, DOI 10.1007/s11259-020-09778-9; Smit PM, 2011, J THROMB HAEMOST, V9, P1659, DOI 10.1111/j.1538-7836.2011.04413.x; Tapiainen T, 2005, EXPERT REV VACCINES, V4, P419, DOI 10.1586/14760584.4.3.419; Tostanoski LH, 2020, NAT MED, V26, P1694, DOI 10.1038/s41591-020-1070-6; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wellington D, 2013, J AM ASSOC LAB ANIM, V52, P481; Yahalom-Ronen Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20228-7	26	7	7	3	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							214	10.3390/vaccines9030214			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5TJ	33802467	gold, Green Published			2022-04-29	WOS:000634215900001
J	Principi, N; Esposito, S				Principi, Nicola; Esposito, Susanna			Why It Is Important to Develop an Effective and Safe Pediatric COVID-19 Vaccine	VACCINES			English	Article						children; COVID-19; pediatric infectious diseases; SARS-CoV-2; vaccine	CHILDREN	The need to cope with the medical, social, and economic storm due to the new coronavirus 2019 (COVID-19) pandemic as quickly as possible has led to the very rapid development of a huge number of vaccines. All these vaccines have been mainly developed in healthy adults and, in some cases, in the elderly. Children were marginally involved as, according to the clinical trial registry Clinical Trials.gov, only very few studies have included children among subjects to enroll, although just a few weeks after the pandemic declaration, the US Food and Drug Administration had highlighted the importance of vaccine evaluation in pediatrics. Availability of an effective and safe pediatric COVID-19 vaccine appears mandatory for several clinical and epidemiological reasons. However, as the development of an effective and safe pediatric vaccine seems far from easy, strong cooperation among governments, researchers, and pharmaceutical companies is highly desirable.	[Principi, Nicola] Univ Milan, I-20122 Milan, Italy; [Esposito, Susanna] Univ Parma, Pietro Barilla Childrens Hosp, Pediat Clin, I-43126 Parma, Italy		Esposito, S (通讯作者)，Univ Parma, Pietro Barilla Childrens Hosp, Pediat Clin, I-43126 Parma, Italy.	nicola.principi@unimi.it; susannamariaroberta.esposito@unipr.it	Esposito, Susanna/AAA-8275-2022	Principi, Nicola/0000-0002-3468-5568			American Academy of Pediatrics, CHILDR COVID 19 STAT; Anastassopoulou C, 2020, FUTURE MICROBIOL, V15, P1201, DOI 10.2217/fmb-2020-0195; [Anonymous], THE GUARDIAN; Burke RM, 2019, CURR OPIN INFECT DIS, V32, P435, DOI 10.1097/QCO.0000000000000572; Centers for Disease Control and Prevention, COR DIS 2019 COVID 1; Conte C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020309; Esposito S, 2015, FUTURE MICROBIOL, V10, P1599, DOI 10.2217/fmb.15.81; Kao Carol M, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa712; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Park YJ, 2020, EMERG INFECT DIS, V26, P2465, DOI 10.3201/eid2610.201315; Principi N, 2018, VACCINE, V36, P5391, DOI 10.1016/j.vaccine.2017.09.016; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Song XY, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.20495; STAT, WILL COV 19 VACC BE; U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, DEV LICENSURE VACCIN; Viner RM, 2021, JAMA PEDIATR, V175, P143, DOI 10.1001/jamapediatrics.2020.4573; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Zeichner SL, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-032888	19	10	10	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							127	10.3390/vaccines9020127			4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6VJ	33562619	Green Published, gold			2022-04-29	WOS:000623279000001
J	Zhang, Y; Yuan, Y; Zhang, LH; Zhu, D; Wang, L; Wei, LP; Fan, WS; Zhao, CR; Su, YJ; Liao, JQ; Yong, L; Wei, TC; Wei, P; Mo, ML				Zhang, Yu; Yuan, Yuan; Zhang, Li-Hua; Zhu, Dan; Wang, Lu; Wei, Lan-Ping; Fan, Wen-Sheng; Zhao, Chang-Run; Su, Yan-Jing; Liao, Jian-Qi; Yong, Lu; Wei, Tian-Chao; Wei, Ping; Mo, Mei-Lan			Construction and Immunogenicity Comparison of Three Virus-Like Particles Carrying Different Combinations of Structural Proteins of Avian Coronavirus Infectious Bronchitis Virus	VACCINES			English	Article						infectious bronchitis virus; virus-like particles; construction; immunogenicity		Infectious bronchitis virus (IBV) poses massive economic losses in the global poultry industry. Here, we firstly report the construction and immunogenicity comparison of virus-like particles (VLPs) carrying the S, M and E proteins (SME-VLPs); VLPs carrying the S and M proteins (SM-VLPs); and VLPs carrying the M and E proteins (ME-VLPs) from the dominant serotype representative strain GX-YL5 in China. The neutralizing antibody response induced by the SME-VLPs was similar to that induced by the inactivated oil vaccine (OEV) of GX-YL5, and higher than those induced by the SM-VLPs, ME-VLPs and commercial live vaccine H120. More importantly, the SME-VLPs elicited higher percentages of CD4(+) and CD8(+) T lymphocytes than the SM-VLPs, ME-VLPs and OEV of GX-YL5. Compared with the OEV of GX-YL5, higher levels of IL-4 and IFN-gamma were also induced by the SME-VLPs. Moreover, the mucosal immune response (sIgA) induced by the SME-VLPs in the tear and oral swabs was comparable to that induced by the H120 vaccine and higher than that induced by the OEV of GX-YL5. In the challenge experiment, the SME-VLPs resulted in significantly lower viral RNA levels in the trachea and higher protection scores than the OEV of GX-YL5 and H120 vaccines, and induced comparable viral RNA levels in the kidneys, and tear and oral swabs to the OEV of GX-YL5. In summary, among the three VLPs, the SME-VLPs carrying the S, M and E proteins of IBV could stimulate the strongest humoral, cellular and mucosal immune responses and provide effective protection, indicating that it would be an attractive vaccine candidate for IB.	[Zhang, Yu; Yuan, Yuan; Zhang, Li-Hua; Zhu, Dan; Wang, Lu; Wei, Lan-Ping; Fan, Wen-Sheng; Zhao, Chang-Run; Su, Yan-Jing; Liao, Jian-Qi; Yong, Lu; Wei, Tian-Chao; Wei, Ping; Mo, Mei-Lan] Guangxi Univ, Coll Anim Sci & Technol, Nanning 530004, Peoples R China		Wei, P; Mo, ML (通讯作者)，Guangxi Univ, Coll Anim Sci & Technol, Nanning 530004, Peoples R China.	1818303038@st.gxu.edu.cn; 1618305016@alu.gxu.edu.cn; 1418305025@alu.gxu.edu.cn; 1818393058@alu.gxu.edu.cn; 1818393037@alu.gxu.edu.cn; 1818403007@st.gxu.edu.cn; 1618403001@st.gxu.edu.cn; 1718305023@alu.gxu.edu.cn; 1634130106@alu.gxu.edu.cn; 2018302019@st.gxu.edu.cn; 1918302036@st.gxu.edu.cn; weitianchao@gxu.edu.cn; weiping@gxu.edu.cn; momeilan@gxu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31860715]; Guangxi Special Funding on Science and Technology Research [AA17204057]; Guangxi Natural Science FoundationNational Natural Science Foundation of Guangxi Province [2018GXNSFAA281009, 2020GXNSFDA297004]; Nanning Scientific Research and Technology Development Project [20182024-1]	This work was supported by the National Natural Science Foundation of China (31860715), Guangxi Special Funding on Science and Technology Research (AA17204057), Guangxi Natural Science Foundation Grants (2018GXNSFAA281009 and 2020GXNSFDA297004), and a Nanning Scientific Research and Technology Development Project (20182024-1).	Bande F, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/424860; Beyer Thomas, 2001, Current Drug Targets - Infectious Disorders, V1, P287, DOI 10.2174/1568005014605973; Casais R, 2003, J VIROL, V77, P9084, DOI 10.1128/JVI.77.16.9084-9089.2003; CAVANAGH D, 1992, AVIAN PATHOL, V21, P33, DOI 10.1080/03079459208418816; Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055; Chroboczek J, 2014, ACTA BIOCHIM POL, V61, P531; Collisson EW, 2000, DEV COMP IMMUNOL, V24, P187, DOI 10.1016/S0145-305X(99)00072-5; Cook JKA, 2012, AVIAN PATHOL, V41, P239, DOI 10.1080/03079457.2012.680432; Cook JKA, 1999, AVIAN PATHOL, V28, P477, DOI 10.1080/03079459994506; de Haan CAM, 2000, J VIROL, V74, P4967, DOI 10.1128/JVI.74.11.4967-4978.2000; de Wit JJ, 2014, AVIAN PATHOL, V43, P485, DOI 10.1080/03079457.2014.974504; Fan WS, 2018, J VET MED SCI, V80, P1438, DOI 10.1292/jvms.18-0249; Fan WS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100898; Feng KY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06987-2; He YN, 2016, VIROL SIN, V31, P57, DOI 10.1007/s12250-015-3696-y; Ho Y, 2004, BIOCHEM BIOPH RES CO, V318, P833, DOI 10.1016/j.bbrc.2004.04.111; Kato T, 2019, J BIOTECHNOL, V306, P177, DOI 10.1016/j.jbiotec.2019.10.007; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Ladman BS, 2002, AVIAN DIS, V46, P938, DOI 10.1637/0005-2086(2002)046[0938:POCALA]2.0.CO;2; Lee SW, 2012, SCIENCE, V337, P188, DOI 10.1126/science.1217134; Leyson C, 2016, VIROLOGY, V498, P218, DOI 10.1016/j.virol.2016.08.030; Li M, 2013, ARCH VIROL, V158, P1783, DOI 10.1007/s00705-013-1656-0; Li M, 2012, ARCH VIROL, V157, P467, DOI 10.1007/s00705-011-1206-6; Liu GM, 2013, VACCINE, V31, P5524, DOI 10.1016/j.vaccine.2013.09.024; Liu XL, 2013, VET MICROBIOL, V162, P429, DOI 10.1016/j.vetmic.2012.10.027; Lu BJ, 2010, IMMUNOLOGY, V130, P254, DOI 10.1111/j.1365-2567.2010.03231.x; Lv LS, 2014, J VET SCI, V15, P209, DOI 10.4142/jvs.2014.15.2.209; Masters PS, 2006, ADV EXP MED BIOL, V581, P163; McKinley ET, 2008, VACCINE, V26, P1274, DOI 10.1016/j.vaccine.2008.01.006; McMullin PF, 2020, AVIAN PATHOL, V49, P526, DOI 10.1080/03079457.2020.1794237; Meeusen ENT, 2007, CLIN MICROBIOL REV, V20, P489, DOI 10.1128/CMR.00005-07; Mo ML, 2013, VIRUSES-BASEL, V5, P3007, DOI 10.3390/v5123007; Nguyen VP, 1997, J VIROL, V71, P9278, DOI 10.1128/JVI.71.12.9278-9284.1997; NIESTERS HGM, 1987, VIROLOGY, V161, P511, DOI 10.1016/0042-6822(87)90145-0; Qin Li-Li, 2014, Bing Du Xue Bao, V30, P162; Ruch TR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002674; Shapouri MRS, 2004, ACTA VET HUNG, V52, P163, DOI 10.1556/AVet.52.2004.2.4; Shi XM, 2011, VACCINE, V29, P1576, DOI 10.1016/j.vaccine.2010.12.102; Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08; Tarpey I, 2006, VACCINE, V24, P6830, DOI 10.1016/j.vaccine.2006.06.040; van Santen VL, 2008, AVIAN PATHOL, V37, P293, DOI 10.1080/03079450802043783; Wang C, 2017, ONCOTARGET, V8, P12686, DOI 10.18632/oncotarget.8475; Wang JW, 2013, EXPERT REV VACCINES, V12, P129, DOI [10.1586/erv.12.151, 10.1586/ERV.12.151]; Wu X, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030254; Wu X, 2016, VIRUS GENES, V52, P509, DOI 10.1007/s11262-016-1337-7; Xu PW, 2016, BIOTECHNOL LETT, V38, P299, DOI 10.1007/s10529-015-1973-3; Yuan Y, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070347; Zhang J, 2014, VACCINE, V32, P664, DOI 10.1016/j.vaccine.2013.12.006; Zhang TT, 2015, INFECT GENET EVOL, V32, P377, DOI 10.1016/j.meegid.2015.03.034; Zhu WZ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030465	50	0	0	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							146	10.3390/vaccines9020146			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7AL	33670249	gold, Green Published			2022-04-29	WOS:000623292500001
J	Miguelez, SA; Guirao, GY; Ruiz, AIM; Sanchez-Solis, M; Lucas, MD; Camacho, FG; Romero, MMO; Garcia, PE; Gomez, CG; de Arce, AI; Parrado, LM; Andrada, RSM; Alcolea, EC; Garcia, SL; Reyes, PP; Barcelo, AC; Yepes, MLL; Abellan, JJV; Mateo, GS				Alfayate Miguelez, Santiago; Yague Guirao, Genoveva; Menasalvas Ruiz, Ana I.; Sanchez-Solis, Manuel; Domenech Lucas, Mirian; Gonzalez Camacho, Fernando; Ortiz Romero, M. Mar; Espejo Garcia, Pilar; Guerrero Gomez, Carmen; Iofrio de Arce, Antonio; Moreno Parrado, Laura; Sanchez Andrada, Rosa M.; Cascales Alcolea, Eva; Lorente Garcia, Sebastian; Paredes Reyes, Pedro; Casquet Barcelo, Angela; Lopez Yepes, M. Luisa; Vigueras Abellan, Juan Jose; Sanz Mateo, Gonzalo			Impact of Pneumococcal Vaccination in the Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children of the Murcia Region in Spain	VACCINES			English	Article						Streptococcus pneumoniae nasopharyngeal carriage; conjugate vaccines; antimicrobial susceptibility	ANTIMICROBIAL SUSCEPTIBILITY; SEROTYPE DISTRIBUTION; CONJUGATE VACCINES; COLONIZATION; DISEASE; EPIDEMIOLOGY; RESISTANCE; COUNTRIES; DENSITY; TRENDS	Background: An epidemiological study of Streptococcus pneumoniae nasopharyngeal carriage in healthy children was carried out five years after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13). Objectives: Study the impact of pediatric vaccination with PCV13, and other associated epidemiological factors on the status of nasopharyngeal carriage, the circulating pneumococcal serotypes, and the antibiotic susceptibility to more frequently used antibiotics. Methods: A multi-center study was carried out in Primary Health Care, which included 1821 healthy children aged 1 to 4 years old. All isolates were sent to the Spanish Pneumococcal Reference Laboratory for serotyping and antimicrobial susceptibility testing. Results: At least one dose of PCV13 had been received by 71.9% of children and carriage pneumococcal prevalence was 19.7%. The proportion of PCV13 serotypes was low (14.4%), with an observed predominance of non-vaccine serotypes, 23B, 11A, 10A, 35B/F, and 23A were the five most frequent. A high rate of resistance to penicillin, erythromycin, and trimethoprim sulfamethoxazole was found. Conclusions: A low proportion of PCV13 serotypes were detected, confirming the impact of pediatric vaccination for reducing the serotypes vaccine carriage. High resistance rates to clinically important antibiotics were observed.	[Alfayate Miguelez, Santiago; Menasalvas Ruiz, Ana I.; Sanchez-Solis, Manuel] Pediat Infect Dis & Virgen Arrixaca Hosp, Murcia 30120, Spain; [Yague Guirao, Genoveva; Paredes Reyes, Pedro] Virgen Arrixaca Hosp, Dept Microbiol, Murcia 30120, Spain; [Domenech Lucas, Mirian; Gonzalez Camacho, Fernando] Pneumoccocal Reference Lab CNM ISCIII, Madrid 28220, Spain; [Ortiz Romero, M. Mar] Lucia Hosp, Microbiol Dept S, Cartagena 30202, Spain; [Espejo Garcia, Pilar] Barrio Peral Hlth Care Ctr, Cartagena 30300, Spain; [Guerrero Gomez, Carmen] Morales Meseguer Hosp, Microbiol Dept, Murcia 30008, Spain; [Iofrio de Arce, Antonio] El Ranero Hlth Care Ctr, Murcia 30009, Spain; [Moreno Parrado, Laura] Parrado Moreno L Los Arcos Mar Menor Hosp, San Javier 30739, Spain; [Sanchez Andrada, Rosa M.] San Javier Hlth Care Ctr, San Javier 30730, Spain; [Cascales Alcolea, Eva] Rafael Mendez Hosp, Dept Microbiol, San Javier 30739, Spain; [Lorente Garcia, Sebastian] Totana Hlth Care Ctr, Murcia 30850, Spain; [Casquet Barcelo, Angela] Ronda Sur Hlth Care Ctr, Murcia 30010, Spain; [Lopez Yepes, M. Luisa] Castillo Hosp, Microbiol Dept 5, Yecla 30510, Spain; [Vigueras Abellan, Juan Jose] Ctr Salud Mariano Yago, Yecla 30510, Spain; [Sanz Mateo, Gonzalo] Santa Maria Gracia Hlth Care Ctr, Murcia 30009, Spain		Miguelez, SA (通讯作者)，Pediat Infect Dis & Virgen Arrixaca Hosp, Murcia 30120, Spain.; Guirao, GY (通讯作者)，Virgen Arrixaca Hosp, Dept Microbiol, Murcia 30120, Spain.	santiagoalfayatem@gmail.com; gyague@um.es; amenasalvas@hotmail.com; msolis@um.es; mdomenech@isciii.es; fgonzalezc@isciii.es; mmar.ortiz2@carm.es; mpespejo@hotmail.com; carsmile@hotmail.com; aiofrio@gmail.com; lauramorenoparrado@hotmail.com; rosandrada@yahoo.es; eva.cascales@carm.es; sebastian.lorente@carm.es; pedror.paredes@carm.es; angelacasquet_barcelo@hotmail.com; mluisa.lopez3@carm.es; jjva70@hotmail.com; gzmateo@hotmail.com	González-Camacho, Fernando/P-1610-2014	Sanchez-Solis, Manuel/0000-0001-9642-0613; ORTIZ-ROMERO, MARIA DEL MAR/0000-0003-1594-7849; Gonzalez-Camacho, Fernando/0000-0003-3175-9004; , Antonio Iofrio de Arce/0000-0002-0525-0995	Ministerio de Economia, Industria y Competitividad (MINECO)Spanish Government [SAF2017-83388]	This work was supported by Ministerio de Economia, Industria y Competitividad (MINECO) [grant SAF2017-83388].	Abu Seir R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206927; [Anonymous], 2019, SEXUAL TRANSMISSION; [Anonymous], 2020, PERFORMANCE STANDARD, V30 edn; [Anonymous], 2019, ANTIMICROBIAL CONSUM; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Dagan R, 2017, VACCINE, V35, P945, DOI 10.1016/j.vaccine.2016.12.052; Danino D, 2019, CLIN INFECT DIS, V69, P648, DOI 10.1093/cid/ciy926; de Miguel S, 2021, CLIN INFECT DIS, V73, pE3778, DOI 10.1093/cid/ciaa1483; Dunais B, 2015, PEDIATR INFECT DIS J, V34, P286, DOI 10.1097/INF.0000000000000559; Elberse KEM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020390; Fenoll A, 2015, VACCINE, V33, P5691, DOI 10.1016/j.vaccine.2015.08.009; Garcia Vera C., 2011, MED 150 N, V137, P1; Gaviria-Agudelo CL, 2017, J PEDIAT INF DIS SOC, V6, P253, DOI 10.1093/jpids/piw005; Gebre T, 2017, CHILDREN-BASEL, V4, DOI 10.3390/children4040027; Hadjipanayis A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163269; Harboe Zitta B, 2012, Open Microbiol J, V6, P40, DOI 10.2174/1874285801206010040; Hauser C, 2016, EUROSURVEILLANCE, V21, P12, DOI 10.2807/1560-7917.ES.2016.21.21.30239; Hjalmarsdottir MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230332; Instituto Nacional de Estadistica, INS NAC EST; Kaur R, 2021, CLIN INFECT DIS, V72, P797, DOI 10.1093/cid/ciaa157; Kaur R, 2016, PEDIATR INFECT DIS J, V35, P901, DOI 10.1097/INF.0000000000001206; Koliou MG, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1119-6; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Lee GM, 2014, J PEDIATR INFECT DIS, V3, P23, DOI 10.1093/jpids/pit057; Lee JK, 2017, J KOREAN MED SCI, V32, P1431, DOI 10.3346/jkms.2017.32.9.1431; Linares J, 2010, CLIN MICROBIOL INFEC, V16, P402, DOI 10.1111/j.1469-0691.2010.03182.x; Lopez B, 1999, EUR J CLIN MICROBIOL, V18, P771, DOI 10.1007/s100960050399; Lovlie A, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-019-4754-0; Lynch JP, 2010, CURR OPIN PULM MED, V16, P217, DOI 10.1097/MCP.0b013e3283385653; Mayanskiy N, 2019, DIAGN MICR INFEC DIS, V94, P385, DOI 10.1016/j.diagmicrobio.2019.02.010; Mendes RE, 2014, DIAGN MICR INFEC DIS, V80, P19, DOI 10.1016/j.diagmicrobio.2014.05.020; Obando I, 2011, ENFERM INFEC MICR CL, V29, P581, DOI 10.1016/j.eimc.2011.05.010; Ouldali N, 2021, LANCET INFECT DIS, V21, P137, DOI 10.1016/S1473-3099(20)30165-1; Reinert RR, 2005, ANTIMICROB AGENTS CH, V49, P2903, DOI 10.1128/AAC.49.7.2903-2913.2005; Richter L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210081; Ricketson LJ, 2014, PEDIATR INFECT DIS J, V33, P724, DOI 10.1097/INF.0000000000000267; Sanchez-Tatay D, 2008, CLIN MICROBIOL INFEC, V14, P797, DOI 10.1111/j.1469-0691.2008.02025.x; Savulescu C, 2017, LANCET RESP MED, V5, P648, DOI [10.1016/S2213-2600(17)30110-8, 10.1016/s2213-2600(17)30110-8]; Sigurdsson S, 2017, VACCINE, V35, P5242, DOI 10.1016/j.vaccine.2017.08.020; Southern J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195799; The European Committee on Antimicrobial Susceptibility Testing, BREAKPOINT TABLES IN; Htar MTT, 2019, EXPERT REV VACCINES, V18, P1069, DOI 10.1080/14760584.2019.1676155; Wouters I, 2018, VACCINE, V36, P15, DOI 10.1016/j.vaccine.2017.11.052; Yildirim I, 2017, VACCINE, V35, P4002, DOI 10.1016/j.vaccine.2017.05.077; Zhou JY, 2015, INT J INFECT DIS, V39, P50, DOI 10.1016/j.ijid.2015.08.010	45	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							14	10.3390/vaccines9010014			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6TU	33379235	gold, Green Published			2022-04-29	WOS:000610805300001
J	Mara, K; Dai, ML; Brice, AM; Alexander, MR; Tribolet, L; Layton, DS; Bean, AGD				Mara, Kostlend; Dai, Meiling; Brice, Aaron M.; Alexander, Marina R.; Tribolet, Leon; Layton, Daniel S.; Bean, Andrew G. D.			Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production	VACCINES			English	Review						NSV vaccines; RNA viruses; host immune response; host&#8211; pathogen interaction; vaccine design; vaccine manufacturing		The current pandemic has highlighted the ever-increasing risk of human to human spread of zoonotic pathogens. A number of medically-relevant zoonotic pathogens are negative-strand RNA viruses (NSVs). NSVs are derived from different virus families. Examples like Ebola are known for causing severe symptoms and high mortality rates. Some, like influenza, are known for their ease of person-to-person transmission and lack of pre-existing immunity, enabling rapid spread across many countries around the globe. Containment of outbreaks of NSVs can be difficult owing to their unpredictability and the absence of effective control measures, such as vaccines and antiviral therapeutics. In addition, there remains a lack of essential knowledge of the host-pathogen response that are induced by NSVs, particularly of the immune responses that provide protection. Vaccines are the most effective method for preventing infectious diseases. In fact, in the event of a pandemic, appropriate vaccine design and speed of vaccine supply is the most critical factor in protecting the population, as vaccination is the only sustainable defense. Vaccines need to be safe, efficient, and cost-effective, which is influenced by our understanding of the host-pathogen interface. Additionally, some of the major challenges of vaccines are the establishment of a long-lasting immunity offering cross protection to emerging strains. Although many NSVs are controlled through immunisations, for some, vaccine design has failed or efficacy has proven unreliable. The key behind designing a successful vaccine is understanding the host-pathogen interaction and the host immune response towards NSVs. In this paper, we review the recent research in vaccine design against NSVs and explore the immune responses induced by these viruses. The generation of a robust and integrated approach to development capability and vaccine manufacture can collaboratively support the management of outbreaking NSV disease health risks.	[Mara, Kostlend; Dai, Meiling; Brice, Aaron M.; Alexander, Marina R.; Tribolet, Leon; Layton, Daniel S.; Bean, Andrew G. D.] CSIRO Hlth & Biosecur, Australian Ctr Dis Preparedness, Geelong, Vic 3220, Australia		Mara, K (通讯作者)，CSIRO Hlth & Biosecur, Australian Ctr Dis Preparedness, Geelong, Vic 3220, Australia.	kostlend.mara@csiro.au; meiling.dai@csiro.au; aaron.brice@csiro.au; marina.alexander@csiro.au; leon.tribolet@csiro.au; daniel.layton@csiro.au; andrew.bean@csiro.au	Layton, Daniel S/J-6117-2017; Alexander, Marina/AAK-9995-2021	Alexander, Marina/0000-0003-0745-7903; Brice, Aaron/0000-0002-2999-186X; Tribolet, Leon/0000-0002-2093-9678; MARA, KOSTLEND/0000-0003-0055-6212			Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15; Afrough B, 2019, CLIN EXP IMMUNOL, V196, P157, DOI 10.1111/cei.13295; Ahmed-Hassan H, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0954-2; ALEXANDROVA G. I., 1965, REV ROUMAINE INFRAMICROBIOL, V2, P179; Ambrose CS, 2008, INFLUENZA OTHER RESP, V2, P193, DOI 10.1111/j.1750-2659.2008.00056.x; Ana-Sosa-Batiz F, 2017, VACCINE, V35, P6451, DOI 10.1016/j.vaccine.2017.09.062; Ana-Sosa-Batiz F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154461; Atsmon J, 2014, VACCINE, V32, P5816, DOI 10.1016/j.vaccine.2014.08.031; Audet J, 2015, VIRAL IMMUNOL, V28, P10, DOI 10.1089/vim.2014.0066; Baloul L, 2004, J NEUROVIROL, V10, P372, DOI 10.1080/13550280490521122; Barr IG, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0079-z; Bellini WJ, 2005, J INFECT DIS, V192, P1686, DOI 10.1086/497169; Betakova T, 2013, ACTA VIROL, V57, P91, DOI 10.4149/av_2013_02_91; BLOCH AB, 1985, PEDIATRICS, V76, P524; Bonjardim CA, 2009, IMMUNOL LETT, V122, P1, DOI 10.1016/j.imlet.2008.11.002; Bourhy H, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000839; Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303; Brunker K, 2018, TRENDS MICROBIOL, V26, P886, DOI 10.1016/j.tim.2018.07.001; Brzozka K, 2006, J VIROL, V80, P2675, DOI 10.1128/JVI.80.6.2675-2683.2006; Caignard G, 2009, VIROLOGY, V383, P112, DOI 10.1016/j.virol.2008.10.014; Cao RG, 2014, J INFECT DIS, V210, P224, DOI 10.1093/infdis/jiu079; Cardenas WB, 2006, J VIROL, V80, P5168, DOI 10.1128/JVI.02199-05; Carragher DM, 2008, J IMMUNOL, V181, P4168, DOI 10.4049/jimmunol.181.6.4168; Carrasco-Hernandez R, 2017, ILAR J, V58, P343, DOI 10.1093/ilar/ilx026; Cenna J, 2009, J INFECT DIS, V200, P1251, DOI 10.1086/605949; Cespedes PF, 2014, P NATL ACAD SCI USA, V111, pE3214, DOI 10.1073/pnas.1400760111; Chen XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00320; Childs K, 2007, VIROLOGY, V359, P190, DOI 10.1016/j.virol.2006.09.023; Chinnakannan SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057063; Clifford HD, 2011, VACCINE, V29, P5407, DOI 10.1016/j.vaccine.2011.05.068; Co MDT, 2009, VACCINE, V27, P319, DOI 10.1016/j.vaccine.2008.09.092; Costantino C, 2016, J Prev Med Hyg, V57, pE13; Coughlin MM, 2013, REV MED VIROL, V23, P126, DOI 10.1002/rmv.1735; Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595; D'Aoust MA, 2010, PLANT BIOTECHNOL J, V8, P607, DOI 10.1111/j.1467-7652.2009.00496.x; Davis ME, 2014, CELL HOST MICROBE, V16, P19, DOI 10.1016/j.chom.2014.06.007; den Haan JMM, 2014, IMMUNOL LETT, V162, P103, DOI 10.1016/j.imlet.2014.10.011; Devaux P, 2007, VIROLOGY, V360, P72, DOI 10.1016/j.virol.2006.09.049; Devaux P, 2011, J VIROL, V85, P348, DOI 10.1128/JVI.00802-10; Dhiman N, 2007, J ALLERGY CLIN IMMUN, V120, P666, DOI 10.1016/j.jaci.2007.04.036; Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011; Dougan SK, 2013, NATURE, V503, P406, DOI 10.1038/nature12637; Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2; Duan S, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00025; Dudek T, 2006, VIROLOGY, V344, P230, DOI 10.1016/j.virol.2005.09.020; Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323; Durbin JE, 2002, J IMMUNOL, V168, P2944, DOI 10.4049/jimmunol.168.6.2944; Durmus S, 2017, FEBS OPEN BIO, V7, P96, DOI 10.1002/2211-5463.12167; Edri A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01428; Eggink D, 2014, J VIROL, V88, P699, DOI 10.1128/JVI.02608-13; Elliott J, 2007, J VIROL, V81, P3428, DOI 10.1128/JVI.02303-06; EMENY JM, 1979, J GEN VIROL, V43, P247, DOI 10.1099/0022-1317-43-1-247; Evans JS, 2012, VACCINE, V30, P7447, DOI 10.1016/j.vaccine.2012.10.015; Faber M, 2002, J VIROL, V76, P3374, DOI 10.1128/JVI.76.7.3374-3381.2002; Faber M, 2009, P NATL ACAD SCI USA, V106, P11300, DOI 10.1073/pnas.0905640106; Feldmann H, 2011, LANCET, V377, P849, DOI 10.1016/S0140-6736(10)60667-8; Fernandez-Sesma A, 2006, J VIROL, V80, P6295, DOI 10.1128/JVI.02381-05; Fisher CR, 2018, REV SCI TECH OIE, V37, P657, DOI 10.20506/rst.37.2.2831; Fooks AR, 2009, VACCINES FOR BIODEFENSE AND EMERGING AND NEGLECTED DISEASES, P609, DOI 10.1016/B978-0-12-369408-9.00033-0; Forero A, 2016, J VIROL, V90, P2240, DOI 10.1128/JVI.02974-15; Fries L, 2020, J INFECT DIS, V222, P572, DOI 10.1093/infdis/jiz518; Fries LF, 2013, NEW ENGL J MED, V369, P2564, DOI 10.1056/NEJMc1313186; Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010; Gack MU, 2009, CELL HOST MICROBE, V5, P439, DOI 10.1016/j.chom.2009.04.006; Garcia-Leon ML, 2015, HUM VACC IMMUNOTHER, V11, P1762, DOI 10.1080/21645515.2015.1032488; Garcia-Maurino C, 2019, J INFECT DIS, V219, P1207, DOI 10.1093/infdis/jiy655; Gonzalez PA, 2008, P NATL ACAD SCI USA, V105, P14999, DOI 10.1073/pnas.0802555105; GREENBERG SB, 1977, J IMMUNOL, V119, P2100; Griffin DE, 2010, IMMUNOL REV, V236, P176, DOI 10.1111/j.1600-065X.2010.00925.x; Habibi MS, 2015, AM J RESP CRIT CARE, V191, P1040, DOI 10.1164/rccm.201412-2256OC; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; Han T, 2011, ANN NY ACAD SCI, V1217, P178, DOI 10.1111/j.1749-6632.2010.05829.x; Hannaman D, 2016, VACCINE, V34, P3607, DOI 10.1016/j.vaccine.2016.04.077; Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008; Heinonen S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw0268; Henao-Restrepo AM, 2015, LANCET, V386, P857, DOI 10.1016/S0140-6736(15)61117-5; Hirota Y, 1996, VACCINE, V14, P1597, DOI 10.1016/S0264-410X(96)00153-3; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Holmes EC, 2009, ANNU REV ECOL EVOL S, V40, P353, DOI 10.1146/annurev.ecolsys.110308.120248; Hooper DC, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000535; Hooper DC, 1998, J VIROL, V72, P3711, DOI 10.1128/JVI.72.5.3711-3719.1998; Iampietro M, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006397; Ito N, 2005, MICROBIOL IMMUNOL, V49, P973, DOI 10.1111/j.1348-0421.2005.tb03692.x; Ito N, 2016, J VET MED SCI, V78, P1089, DOI 10.1292/jvms.16-0092; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; Janssen R, 2007, J INFECT DIS, V196, P826, DOI 10.1086/520886; Johansson BE, 2011, EXPERT REV VACCINES, V10, P1683, DOI [10.1586/ERV.11.130, 10.1586/erv.11.130]; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Jonker EFF, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax033; Jounai N, 2017, EBIOMEDICINE, V16, P124, DOI 10.1016/j.ebiom.2017.01.014; Jozwik A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10224; Kaminski DA, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00076; Kiesslich S, 2020, J BIOTECHNOL, V310, P32, DOI 10.1016/j.jbiotec.2020.01.015; Kiseleva Irina, 2017, Open Microbiol J, V11, P316, DOI 10.2174/1874285801711010316; KISSLING RE, 1958, P SOC EXP BIOL MED, V98, P223, DOI 10.3181/00379727-98-23997; Kolpe A, 2017, EXPERT REV VACCINES, V16, P123, DOI 10.1080/14760584.2017.1240041; KONDO A, 1965, VIROLOGY, V27, P199, DOI 10.1016/0042-6822(65)90160-1; Kopf M, 2002, NAT MED, V8, P373, DOI 10.1038/nm0402-373; Krug RM, 2015, CURR OPIN VIROL, V12, P1, DOI 10.1016/j.coviro.2015.01.007; KRUGMAN S, 1971, AM J DIS CHILD, V121, P380, DOI 10.1001/archpedi.1971.02100160050003; Lafon M, 2008, J IMMUNOL, V180, P7506, DOI 10.4049/jimmunol.180.11.7506; Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0; Lebrun A, 2015, J IMMUNOL, V195, P4358, DOI 10.4049/jimmunol.1501274; Lee JKH, 2018, EXPERT REV VACCINES, V17, P435, DOI 10.1080/14760584.2018.1471989; Lifland AW, 2012, J VIROL, V86, P8245, DOI 10.1128/JVI.00215-12; Ling Z, 2009, J VIROL, V83, P3734, DOI 10.1128/JVI.02434-08; Liu J, 2017, AUTOPHAGY, V13, P739, DOI 10.1080/15548627.2017.1280220; Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2; Lodmell DL, 2006, VACCINE, V24, P412, DOI 10.1016/j.vaccine.2005.08.003; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Loomis RJ, 2015, VACCINES-BASEL, V3, P429, DOI 10.3390/vaccines3020429; Mahl P, 2014, VET RES, V45, DOI 10.1186/s13567-014-0077-8; Maki J, 2017, VET RES, V48, DOI 10.1186/s13567-017-0459-9; Mallajosyula VVA, 2014, P NATL ACAD SCI USA, V111, pE2514, DOI 10.1073/pnas.1402766111; Manini I, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5030018; Marzi A, 2015, SCIENCE, V349, P739, DOI 10.1126/science.aab3920; Masatani T, 2010, J VIROL, V84, P4002, DOI 10.1128/JVI.02220-09; Megret F, 2007, HUM IMMUNOL, V68, P294, DOI 10.1016/j.humimm.2006.12.003; Miyake K, 2018, INT IMMUNOL, V30, P43, DOI 10.1093/intimm/dxy016; Morimoto K, 2005, VIRUS RES, V111, P61, DOI 10.1016/j.virusres.2005.03.011; Moseley GW, 2009, J CELL SCI, V122, P3652, DOI 10.1242/jcs.045542; Muller TF, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003953; Mullarkey CE, 2013, EUR J IMMUNOL, V43, P1940, DOI 10.1002/eji.201242922; Munir S, 2008, J VIROL, V82, P8780, DOI 10.1128/JVI.00630-08; Nakaya HI, 2015, IMMUNITY, V43, P1186, DOI 10.1016/j.immuni.2015.11.012; Niewiesk S, 1999, J GEN VIROL, V80, P2023, DOI 10.1099/0022-1317-80-8-2023; Niewiesk S, 2000, P NATL ACAD SCI USA, V97, P4251, DOI 10.1073/pnas.060012097; Ning YJ, 2017, VIROL SIN, V32, P3, DOI 10.1007/s12250-016-3850-1; O'Donnell K, 2020, EXPERT REV VACCINES, V19, P267, DOI 10.1080/14760584.2020.1738225; Openshaw PJM, 2017, ANNU REV IMMUNOL, V35, P501, DOI 10.1146/annurev-immunol-051116-052206; Orr-Burks N, 2019, VACCINE-X, V3, DOI 10.1016/j.jvacx.2019.100045; Oshansky CM, 2009, FUTURE MICROBIOL, V4, P279, DOI [10.2217/fmb.09.1, 10.2217/FMB.09.1]; Ovsyannikova I, 2011, HUM GENET, V130, P547, DOI 10.1007/s00439-011-0977-x; Pauli EK, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000196; Payne S, 2017, VIRUSES: FROM UNDERSTANDING TO INVESTIGATION, P97, DOI 10.1016/B978-0-12-803109-4.00010-6; Pearce JMS, 2002, J NEUROL NEUROSUR PS, V73, P82, DOI 10.1136/jnnp.73.1.82; Pfeffermann K, 2018, ADV VIRUS RES, V100, P75, DOI 10.1016/bs.aivir.2017.12.003; Piedra FA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172953; Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008; Pillet S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216533; Pleet ML, 2018, J INFECT DIS, V218, pS365, DOI 10.1093/infdis/jiy472; Pleet ML, 2017, DNA CELL BIOL, V36, P243, DOI 10.1089/dna.2017.3639; Pleguezuelos O, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0174-9; Pleguezuelos O, 2020, ANN INTERN MED, V172, P453, DOI 10.7326/M19-0735; Plummer JR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007800; Rarnachandran A, 2008, J VIROL, V82, P8330, DOI 10.1128/JVI.00831-08; Raymond J, 2011, J INFECT DIS, V204, pS986, DOI 10.1093/infdis/jir335; Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216; Reid SP, 2007, J VIROL, V81, P13469, DOI 10.1128/JVI.01097-07; Richetta C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003599; Rimmelzwaan GF, 2004, VIRUS RES, V103, P97, DOI 10.1016/j.virusres.2004.02.020; Roberts A, 1999, J VIROL, V73, P3723, DOI 10.1128/JVI.73.5.3723-3732.1999; Rocca S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004738; Rose J.K., 2015, RHABDOVIRUSES VACCIN, P199, DOI [10.1142/9789814635349_0009, DOI 10.1142/9789814635349_0009]; Rudenko L, 2016, VACCINE, V34, P5436, DOI 10.1016/j.vaccine.2016.08.018; Rupprecht Charles, 2017, F1000Res, V6, P184, DOI 10.12688/f1000research.10416.1; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Schlender J, 1996, P NATL ACAD SCI USA, V93, P13194, DOI 10.1073/pnas.93.23.13194; Schmidt ME, 2020, MUCOSAL IMMUNOL, V13, P507, DOI 10.1038/s41385-019-0243-4; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Schutsky K, 2013, J VIROL, V87, P1834, DOI 10.1128/JVI.02589-12; Sesterhenn F, 2020, SCIENCE, V368, P730, DOI 10.1126/science.aay5051; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Shingai M, 2007, J IMMUNOL, V179, P6123, DOI 10.4049/jimmunol.179.9.6123; Shuai L, 2015, ANTIVIR RES, V121, P9, DOI 10.1016/j.antiviral.2015.06.011; Siegrist CA, 1998, EUR J IMMUNOL, V28, P4138, DOI 10.1002/(SICI)1521-4141(199812)28:12<4138::AID-IMMU4138>3.3.CO;2-C; Singanayagam A, 2018, LANCET INFECT DIS, V18, pE25, DOI [10.1016/S1473-3099(17)30360-2, 10.1016/s1473-3099(17)30360-2]; Singh S, 2020, ARCH PHYSIOL BIOCHEM, V126, P348, DOI 10.1080/13813455.2018.1538249; Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Smith SE, 2013, J VIROL, V87, P12957, DOI 10.1128/JVI.01443-13; Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023; Spitaels J, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040033; Stoloff GA, 2007, EUR J IMMUNOL, V37, P2441, DOI 10.1002/eji.200737254; Sullivan N, 2003, J VIROL, V77, P9733, DOI 10.1128/JVI.77.18.9733-9737.2003; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; SUNTHARASAMAI P, 1986, LANCET, V2, P129; Suschak JJ, 2016, J IMMUNOL, V196, P310, DOI 10.4049/jimmunol.1501836; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Takayama I, 2012, VIROLOGY, V424, P45, DOI 10.1016/j.virol.2011.12.011; Talbot HK, 2015, CLIN INFECT DIS, V60, P1170, DOI 10.1093/cid/civ019; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; Tebas P, 2019, J INFECT DIS, V220, P400, DOI 10.1093/infdis/jiz132; Tetsutani K, 2012, VACCINE, V30, P7658, DOI 10.1016/j.vaccine.2012.10.007; Tognarelli EI, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00810; van der Sanden SMG, 2016, J VIROL, V90, P1694, DOI 10.1128/JVI.01464-15; Vanderven HA, 2017, CURR OPIN VIROL, V22, P89, DOI 10.1016/j.coviro.2016.12.002; Vidy A, 2007, J VIROL, V81, P4255, DOI 10.1128/JVI.01930-06; Von Holle TA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01457; Wang JY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071537; Wang YF, 2014, VIROLOGY, V468, P621, DOI 10.1016/j.virol.2014.09.010; Warfield KL, 2007, J INFECT DIS, V196, pS421, DOI 10.1086/520612; Warfield KL, 2018, J INFECT DIS, V218, pS553, DOI 10.1093/infdis/jiy316; Warfield KL, 2003, P NATL ACAD SCI USA, V100, P15889, DOI 10.1073/pnas.2237038100; Wei HT, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003845; Weyer J, 2009, VACCINE, V27, P7198, DOI 10.1016/j.vaccine.2009.09.033; Whelan JN, 2016, J VIROL, V90, P6453, DOI 10.1128/JVI.00423-16; WHO, 2018, WHO TECH REP SER, V1012, P1; WIKTOR TJ, 1964, J IMMUNOL, V93, P353; Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760; Wiltzer L, 2014, J INFECT DIS, V209, P1744, DOI 10.1093/infdis/jit829; Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12; Xu W, 2014, CELL HOST MICROBE, V16, P187, DOI 10.1016/j.chom.2014.07.008; Yen B, 2014, J VIROL, V88, P12500, DOI 10.1128/JVI.02163-14; Yokota S, 2011, VIROLOGY, V414, P74, DOI 10.1016/j.virol.2011.03.010; Zhang APP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002550; Zhirnov OP, 2013, J VIROL, V87, P13107, DOI 10.1128/JVI.02148-13; Zhivaki D, 2017, IMMUNITY, V46, P301, DOI 10.1016/j.immuni.2017.01.010; Zhou M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063384	212	0	0	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							59	10.3390/vaccines9010059			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VX	33477334	gold, Green Published			2022-04-29	WOS:000610810900001
J	van der Weken, H; Cox, E; Devriendt, B				van der Weken, Hans; Cox, Eric; Devriendt, Bert			Advances in Oral Subunit Vaccine Design	VACCINES			English	Review						oral vaccination; subunit vaccines; mucosal immunity; secretory IgA; adjuvants; targeted delivery; Micro; and nanoparticles	RECOMBINANT LACTOCOCCUS-LACTIS; MUCOSAL IMMUNE-RESPONSES; VIRUS-LIKE PARTICLES; PATTERN-RECOGNITION RECEPTORS; THYMUS-EXPRESSED CHEMOKINE; CHOLERA-TOXIN ADJUVANT; NEONATAL FC-RECEPTOR; M CELLS; DENDRITIC CELLS; RETINOIC ACID	Many pathogens invade the host at the intestinal surface. To protect against these enteropathogens, the induction of intestinal secretory IgA (SIgA) responses is paramount. While systemic vaccination provides strong systemic immune responses, oral vaccination is the most efficient way to trigger protective SIgA responses. However, the development of oral vaccines, especially oral subunit vaccines, is challenging due to mechanisms inherent to the gut. Oral vaccines need to survive the harsh environment in the gastrointestinal tract, characterized by low pH and intestinal proteases and need to reach the gut-associated lymphoid tissues, which are protected by chemical and physical barriers that prevent efficient uptake. Furthermore, they need to surmount default tolerogenic responses present in the gut, resulting in suppression of immunity or tolerance. Several strategies have been developed to tackle these hurdles, such as delivery systems that protect vaccine antigens from degradation, strong mucosal adjuvants that induce robust immune responses and targeting approaches that aim to selectively deliver vaccine antigens towards specific immune cell populations. In this review, we discuss recent advances in oral vaccine design to enable the induction of robust gut immunity and highlight that the development of next generation oral subunit vaccines will require approaches that combines these solutions.	[van der Weken, Hans; Cox, Eric; Devriendt, Bert] Univ Ghent, Dept Virol Parasitol & Immunol, Salisburylaan 133, B-9820 Merelbeke, Belgium		Devriendt, B (通讯作者)，Univ Ghent, Dept Virol Parasitol & Immunol, Salisburylaan 133, B-9820 Merelbeke, Belgium.	hans.vanderweken@ugent.be; eric.cox@ugent.be; b.devriendt@ugent.be	Van der Weken, Hans/AAB-8168-2022; Devriendt, Bert/AAM-6666-2021	Van der Weken, Hans/0000-0002-3104-9355; Devriendt, Bert/0000-0002-3222-8769; Cox, Eric/0000-0003-4281-2990	concerted research action (GOA) from Ghent University [BOF15/GOA/031]; research Foundation Flanders (FWO-Vlaanderen)FWO	This research was funded by a concerted research action (GOA) from Ghent University, grant number BOF15/GOA/031. Bert Devriendt holds a postdoctoral grant of the research Foundation Flanders (FWO-Vlaanderen).	Ahmed B, 2014, VACCINE, V32, P3909, DOI 10.1016/j.vaccine.2014.05.054; Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-102; Akhtar M, 2019, VACCINE, V37, P5645, DOI 10.1016/j.vaccine.2018.11.040; Auray G, 2016, J IMMUNOL, V197, P4791, DOI 10.4049/jimmunol.1600672; Azevedo MSP, 2010, CLIN VACCINE IMMUNOL, V17, P420, DOI 10.1128/CVI.00395-09; Baert K, 2016, INT J NANOMED, V11, P2463, DOI 10.2147/IJN.S101881; Baert K, 2015, J CONTROL RELEASE, V220, P149, DOI 10.1016/j.jconrel.2015.10.025; Baker K, 2014, FRONT IMMUNOL, V5, DOI [10.3389/fimmu.2014.00664, 10.3389/fimmu.2014.00408]; Bakshi S, 2020, J CONTROL RELEASE, V321, P416, DOI 10.1016/j.jconrel.2020.01.033; Baldrick P, 2002, REGUL TOXICOL PHARM, V35, P398, DOI 10.1006/rtph.2002.1541; Barouch DH, 2010, CURR OPIN HIV AIDS, V5, P386, DOI 10.1097/COH.0b013e32833cfe4c; Basak S, 2020, MICROB PATHOGENESIS, V149, DOI 10.1016/j.micpath.2020.104495; Baumann J, 2010, IMMUNOL LETT, V131, P59, DOI 10.1016/j.imlet.2010.03.005; Berg MG, 2014, CLIN VACCINE IMMUNOL, V21, P1224, DOI 10.1128/CVI.00197-14; Bernasconi V, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5482087; Bode C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067991; Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639; Caminschi I, 2008, BLOOD, V112, P3264, DOI 10.1182/blood-2008-05-155176; Cao AT, 2015, MUCOSAL IMMUNOL, V8, P1072, DOI 10.1038/mi.2014.134; Carreno LJ, 2014, IMMUNOTHERAPY-UK, V6, P309, DOI 10.2217/imt.13.175; Carter RW, 2006, J IMMUNOL, V177, P2276, DOI 10.4049/jimmunol.177.4.2276; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Chen G, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001313; Chen H, 2010, J VIROL, V84, P10522, DOI 10.1128/JVI.00450-10; Chen XJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep24152; Choi Y, 2013, CLIN EXP VACCINE RES, V2, P97, DOI 10.7774/cevr.2013.2.2.97; Chorny A, 2010, ADV IMMUNOL, V107, P31, DOI [10.1016/B978-0-12-381300-8.00002-2, 10.1016/S0065-2776(10)07006-9]; Christensen D, 2019, ACS NANO, V13, P1116, DOI 10.1021/acsnano.8b05209; CHRISTY C, 1995, PEDIATRICS, V96, P584; Ciabattini A, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01305; CLEMENTS JD, 1988, VACCINE, V6, P269, DOI 10.1016/0264-410X(88)90223-X; Clements JD, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00215-18; Courtney AN, 2009, VACCINE, V27, P3335, DOI 10.1016/j.vaccine.2009.01.083; Cui BF, 2018, EXPERT REV VACCINES, V17, P335, DOI 10.1080/14760584.2018.1457443; da Silva AJ, 2014, BRAZ J MICROBIOL, V45, P1117, DOI 10.1590/S1517-83822014000400001; Davitt CJH, 2019, MUCOSAL IMMUNOL, V12, P1055, DOI 10.1038/s41385-019-0159-z; Davitt CJH, 2015, ADV DRUG DELIVER REV, V91, P52, DOI 10.1016/j.addr.2015.03.007; de Jong SE, 2020, CELL HOST MICROBE, V28, P169, DOI 10.1016/j.chom.2020.06.014; Devriendt B, 2009, VET RES, V40, DOI 10.1051/vetres/2009023; Diehl SA, 2012, IMMUNOL CELL BIOL, V90, P802, DOI 10.1038/icb.2012.17; Doherty TM, 2002, INFECT IMMUN, V70, P3111, DOI 10.1128/IAI.70.6.3111-3121.2002; Duan QD, 2020, VET RES, V51, DOI 10.1186/s13567-020-00818-5; Duan Qiangde, 2017, J Vaccines Vaccin, V8, DOI 10.4172/2157-7560.1000367; Duran-Lobato M, 2014, BIOMACROMOLECULES, V15, P2725, DOI 10.1021/bm500588x; Duran-Lobato M, 2014, J BIOMED NANOTECHNOL, V10, P1068, DOI 10.1166/jbn.2014.1806; Duverger A, 2006, J IMMUNOL, V176, P1776, DOI 10.4049/jimmunol.176.3.1776; Ebbo M, 2017, NAT REV IMMUNOL, V17, P665, DOI 10.1038/nri.2017.86; Feng LQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18077-5; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Flanagan KL, 2017, EXPERT REV VACCINES, V16, P5, DOI 10.1080/14760584.2016.1203260; Florence AT, 1997, PHARM RES-DORDR, V14, P259, DOI 10.1023/A:1012029517394; Frazer IH, 2004, NAT REV IMMUNOL, V4, P46, DOI 10.1038/nri1260; Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Gao J, 2019, FEBS LETT, V593, P3609, DOI 10.1002/1873-3468.13691; Gehad A, 2012, J IMMUNOL, V189, P337, DOI 10.4049/jimmunol.1102315; Ghosh Mallika, 2012, Bio Protoc, V2, pe305; Giannasca PJ, 1999, INFECT IMMUN, V67, P946, DOI 10.1128/IAI.67.2.946-953.1999; Gil M, 2009, J IMMUNOL, V183, P6808, DOI 10.4049/jimmunol.0900364; Girard A, 2011, VACCINE, V29, P6695, DOI 10.1016/j.vaccine.2011.06.092; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477; GREENBERG DP, 1994, J INFECT DIS, V170, P76, DOI 10.1093/infdis/170.1.76; Greene SA, 2019, MMWR-MORBID MORTAL W, V68, P458, DOI 10.15585/mmwr.mm6820a3; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Gregor CE, 2017, ADV IMMUNOL, V135, P119, DOI 10.1016/bs.ai.2017.03.001; Guo SG, 2015, VACCINE, V33, P1586, DOI 10.1016/j.vaccine.2015.02.006; Guo SJ, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1582; Gurwith M, 2013, LANCET INFECT DIS, V13, P238, DOI 10.1016/S1473-3099(12)70345-6; Guthridge S, 2000, VACCINE, V18, P2584, DOI 10.1016/S0264-410X(99)00549-6; Gutjahr A, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125107; Habtezion A, 2016, GASTROENTEROLOGY, V150, P340, DOI 10.1053/j.gastro.2015.10.046; Hammerschmidt SI, 2011, J CLIN INVEST, V121, P3051, DOI 10.1172/JCI44262; Haralambieva IH, 2013, HUM IMMUNOL, V74, P1263, DOI 10.1016/j.humimm.2013.06.031; Haralambieva LH, 2014, VACCINE, V32, P1946, DOI 10.1016/j.vaccine.2014.01.090; Hardison SE, 2012, NAT IMMUNOL, V13, P817, DOI 10.1038/ni.2369; Harris VC, 2018, CELL HOST MICROBE, V24, P197, DOI 10.1016/j.chom.2018.07.005; Harro C, 2019, VACCINE, V37, P1978, DOI 10.1016/j.vaccine.2019.02.025; Hase K, 2009, NATURE, V462, P226, DOI 10.1038/nature08529; Hatayama T, 2018, J IMMUNOL, V200, P2670, DOI 10.4049/jimmunol.1701276; He LZ, 2007, J IMMUNOL, V178, P6259, DOI 10.4049/jimmunol.178.10.6259; Henderson H, 2009, VACCINE, V27, P7194, DOI 10.1016/j.vaccine.2009.09.030; Henrick BM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00482; Hernandez-Adame L, 2019, EXPERT REV VACCINES, V18, P951, DOI 10.1080/14760584.2019.1647783; Hjelm BE, 2014, HUM VACC IMMUNOTHER, V10, P410, DOI 10.4161/hv.27147; Ho HT, 2014, RESPIROLOGY, V19, P109, DOI 10.1111/resp.12191; Hoelzer K, 2018, VET RES, V49, DOI 10.1186/s13567-018-0561-7; Hoelzer K, 2018, VET RES, V49, DOI 10.1186/s13567-018-0560-8; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Huda MN, 2014, PEDIATRICS, V134, pE362, DOI 10.1542/peds.2013-3937; Hutton G, 2006, AM J TROP MED HYG, V75, P119, DOI 10.4269/ajtmh.2006.75.119; Jahan ST, 2018, INT J NANOMED, V13, P367, DOI 10.2147/IJN.S144266; Jain S, 2014, NANOMED-NANOTECHNOL, V10, P431, DOI 10.1016/j.nano.2013.08.012; Joyce C, 2018, VACCINE, V36, P4265, DOI 10.1016/j.vaccine.2018.05.112; Kajikawa A, 2007, VACCINE, V25, P3599, DOI 10.1016/j.vaccine.2007.01.055; Kawane K, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016394; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328; Kennedy RB, 2014, IMMUNOGENETICS, V66, P493, DOI 10.1007/s00251-014-0776-3; Kim KJ, 2013, CELL IMMUNOL, V285, P92, DOI 10.1016/j.cellimm.2013.09.006; Kim L, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121077; Kim L, 2016, SCI REP-UK, V6, DOI 10.1038/srep37295; Kim SH, 2013, MICROBES INFECT, V15, P895, DOI 10.1016/j.micinf.2013.07.006; Kim SH, 2011, EUR J IMMUNOL, V41, P3219, DOI 10.1002/eji.201141592; Klein Sabra L, 2010, Biol Sex Differ, V1, P5, DOI 10.1186/2042-6410-1-5; Kolb AF, 1998, ADV EXP MED BIOL, V440, P61; Kour P, 2018, ARTIF CELL NANOMED B, V46, pS1102, DOI 10.1080/21691401.2018.1533842; Kretz-Rommel A, 2007, J IMMUNOTHER, V30, P715, DOI 10.1097/CJI.0b013e318135472c; Kumar A, 2015, Cell Mol Biol (OMICS), V61; Kunkel EJ, 2000, J EXP MED, V192, P761, DOI 10.1084/jem.192.5.761; Kurupati R, 2016, ONCOTARGET, V7, P62898, DOI 10.18632/oncotarget.11704; Langermann S, 2000, J INFECT DIS, V181, P774, DOI 10.1086/315258; Latvala S, 2017, J HISTOCHEM CYTOCHEM, V65, P321, DOI 10.1369/0022155417705095; Lauer KB, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00298-16; Lavelle Ed C, 2006, Expert Opin Drug Deliv, V3, P747, DOI 10.1517/17425247.3.6.747; Lebens M, 2016, VACCINE, V34, P2121, DOI 10.1016/j.vaccine.2016.03.002; Lee CS, 2017, GENES DIS, V4, P43, DOI 10.1016/j.gendis.2017.04.001; Lee P, 2009, MICROBES INFECT, V11, P20, DOI 10.1016/j.micinf.2008.10.002; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; Li WT, 2018, P NATL ACAD SCI USA, V115, pE5135, DOI 10.1073/pnas.1802879115; Li XY, 2014, PATHOG DIS, V72, P78, DOI 10.1111/2049-632X.12173; Li Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2032057; Liebowitz D, 2020, LANCET INFECT DIS, V20, P435, DOI 10.1016/S1473-3099(19)30584-5; Lin RQ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00417; Liu J, 2014, J MED VIROL, V86, P886, DOI 10.1002/jmv.23768; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lu T, 2020, APPL ENVIRON MICROB, V86, DOI 10.1128/AEM.00274-20; Lycke N, 2018, CURR OPIN PHARMACOL, V41, P42, DOI 10.1016/j.coph.2018.03.015; Mabbott NA, 2013, MUCOSAL IMMUNOL, V6, P666, DOI 10.1038/mi.2013.30; Mann JFS, 2009, VACCINE, V27, P3643, DOI 10.1016/j.vaccine.2009.03.040; Mann JFS, 2004, VACCINE, V22, P2425, DOI 10.1016/j.vaccine.2003.11.067; Mantis NJ, 2011, MUCOSAL IMMUNOL, V4, P603, DOI 10.1038/mi.2011.41; Marasini N, 2016, NANOMEDICINE-UK, V11, P1223, DOI 10.2217/nnm.16.36; Marasini N, 2014, EXPERT REV VACCINES, V13, P1361, DOI 10.1586/14760584.2014.936852; Marelli B, 2011, J VIROL METHODS, V175, P28, DOI 10.1016/j.jviromet.2011.04.011; Marks E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00643; McCluskie MJ, 2000, VACCINE, V19, P950, DOI 10.1016/S0264-410X(00)00215-2; McDermott AJ, 2014, IMMUNOLOGY, V142, P24, DOI 10.1111/imm.12231; McQuillan GM, 2007, J INFECT DIS, V196, P1459, DOI 10.1086/522866; Melkebeek V, 2012, MUCOSAL IMMUNOL, V5, P635, DOI 10.1038/mi.2012.37; Mestecky J, 2007, J IMMUNOL, V179, P5633, DOI 10.4049/jimmunol.179.9.5633; Mina-Osorio P, 2008, TRENDS MOL MED, V14, P361, DOI 10.1016/j.molmed.2008.06.003; Mirza Z, 2017, METHODS MOL BIOL, V1625, P143, DOI 10.1007/978-1-4939-7104-6_11; Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156; Monteil M, 2000, VACCINE, V18, P1738, DOI 10.1016/S0264-410X(99)00545-9; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Mudie DM, 2010, MOL PHARMACEUT, V7, P1388, DOI 10.1021/mp100149j; Mwanza-Lisulo M, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0145; Naili I, 2019, VACCINE, V37, P314, DOI 10.1016/j.vaccine.2018.10.008; Nandre R, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00550-17; Naylor C, 2015, EBIOMEDICINE, V2, P1759, DOI 10.1016/j.ebiom.2015.09.036; Neal MD, 2006, J IMMUNOL, V176, P3070, DOI 10.4049/jimmunol.176.5.3070; Nomura R, 2004, J VIROL, V78, P8701, DOI 10.1128/JVI.78.16.8701-8708.2004; O'Neill LAJ, 2009, CELL, V138, P428, DOI 10.1016/j.cell.2009.07.021; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Ohno H, 2010, GUT MICROBES, V1, P407, DOI 10.4161/gmic.1.6.14078; Pang Y, 2013, AVIAN DIS, V57, P627, DOI 10.1637/10427-101812-Reg.1; Papadakis KA, 2000, J IMMUNOL, V165, P5069, DOI 10.4049/jimmunol.165.9.5069; Parmo-Cabanas M, 2007, J LEUKOCYTE BIOL, V82, P380, DOI 10.1189/jlb.1206726; Pavlovic N, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01283; Pavot V, 2012, VACCINE, V30, P142, DOI 10.1016/j.vaccine.2011.11.003; Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036; Pham GH, 2014, VACCINE, V32, P5212, DOI 10.1016/j.vaccine.2014.07.050; Philipps J, 1996, WIEN KLIN WOCHENSCHR, V108, P615; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.iy.10.040192.003021; Pierron A, 2016, ANIM NUTR, V2, P63, DOI 10.1016/j.aninu.2016.03.001; Pirahmadi S, 2019, INFECT IMMUN, V87, DOI [10.1128/IAI.00911-18, 10.1128/iai.00911-18]; Plapied L, 2011, CURR OPIN COLLOID IN, V16, P228, DOI 10.1016/j.cocis.2010.12.005; Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111; Poland GA, 1999, VACCINE, V17, P1525, DOI 10.1016/S0264-410X(98)00362-4; Premanand B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055536; Price AE, 2018, IMMUNITY, V49, P560, DOI 10.1016/j.immuni.2018.07.016; Pridgen EM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007049; Pumpens P.U.R., 2009, CONSTRUCTION NOVEL V; Qadri F, 2020, LANCET INFECT DIS, V20, P208, DOI 10.1016/S1473-3099(19)30571-7; Ramirez JEV, 2017, ADV DRUG DELIVER REV, V114, P116, DOI 10.1016/j.addr.2017.04.008; Rampelli S, 2013, AGING-US, V5, P902, DOI 10.18632/aging.100623; Rawool DB, 2008, J IMMUNOL, V180, P5548, DOI 10.4049/jimmunol.180.8.5548; Rehwinkel J, 2010, SCIENCE, V327, P284, DOI 10.1126/science.1185068; Ricobaraza A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103643; Robinson K, 1997, NAT BIOTECHNOL, V15, P653, DOI 10.1038/nbt0797-653; Rochereau N, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001658; Roeder PL, 2011, PREV VET MED, V102, P98, DOI 10.1016/j.prevetmed.2011.04.004; Ruan XS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121623; Sahoo M, 2011, THESCIENTIFICWORLDJO, V11, P2037, DOI 10.1100/2011/212680; Salman HH, 2009, VACCINE, V27, P4784, DOI 10.1016/j.vaccine.2009.05.091; Sanchez J, 2005, CURR OPIN IMMUNOL, V17, P388, DOI 10.1016/j.coi.2005.06.007; Sancho D, 2008, J CLIN INVEST, V118, P2098, DOI 10.1172/JCI34584; Sanders MT, 2005, IMMUNOL CELL BIOL, V83, P119, DOI 10.1111/j.1440-1711.2005.01319.x; Saxena M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00327; Sayedahmed EE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040574; Sayedahmed EE, 2018, MOL THER-METH CLIN D, V10, P210, DOI 10.1016/j.omtm.2018.07.007; Scallan CD, 2013, CLIN VACCINE IMMUNOL, V20, P85, DOI 10.1128/CVI.00552-12; Schwendener Reto A, 2014, Ther Adv Vaccines, V2, P159, DOI 10.1177/2051013614541440; Seo H, 2020, HUM VACC IMMUNOTHER, V16, P419, DOI 10.1080/21645515.2019.1649555; Serradell MC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08265-9; Shah R, 2018, ARCH DIS CHILDHOOD-E, V103, P109, DOI 10.1136/archdischild-2017-313391; Shao LL, 2016, VET IMMUNOL IMMUNOP, V171, P7, DOI 10.1016/j.vetimm.2016.01.008; Shelly A, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101150; Shibasaki Seiji, 2014, Sci Pharm, V82, P697, DOI 10.3797/scipharm.1404-07; Shukla A, 2016, DRUG DISCOV TODAY, V21, P888, DOI 10.1016/j.drudis.2016.03.013; Shukla A, 2010, INT J PHARMACEUT, V385, P47, DOI 10.1016/j.ijpharm.2009.10.027; Singh P, 2004, INT J PHARMACEUT, V278, P379, DOI 10.1016/j.ijpharm.2004.03.014; Sirisinha S, 2015, ASIAN PAC J ALLERGY, V33, P71; Snider DP, 2017, CRIT REV IMMUNOL, V37, P499, DOI 10.1615/CritRevImmunol.v37.i2-6.150; Snoeck V, 2008, VET IMMUNOL IMMUNOP, V124, P29, DOI 10.1016/j.vetimm.2006.10.014; SODERBERG C, 1993, J VIROL, V67, P6576; Stephenson KE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205139; Stirling CMA, 2005, IMMUNOLOGY, V114, P542, DOI 10.1111/j.1365-2567.2004.02121.x; Subiza JL, 2015, RECENT PATENTS INFLA, V9, P4, DOI 10.2174/1872213X09666150211122313; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tan XF, 2011, J VIROL, V85, P8316, DOI 10.1128/JVI.00781-11; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; Taylor DN, 2011, VACCINE, V29, P4897, DOI 10.1016/j.vaccine.2011.05.001; Tezuka H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01891; Thakral S, 2013, EXPERT OPIN DRUG DEL, V10, P131, DOI 10.1517/17425247.2013.736962; Thompson MR, 2011, VIRUSES-BASEL, V3, P920, DOI 10.3390/v3060920; TOP FH, 1975, YALE J BIOL MED, V48, P185; Tordesillas L, 2018, CLIN REV ALLERG IMMU, V55, P107, DOI 10.1007/s12016-018-8680-5; Treanor JJ, 2010, VACCINE, V28, P8268, DOI 10.1016/j.vaccine.2010.10.009; Trovato Maria, 2015, World J Virol, V4, P156, DOI 10.5501/wjv.v4.i3.156; Tucker S.N, 2020, PRECLINICAL STUDIES, DOI [10.1101/2020.09.04.283853, DOI 10.1101/2020.09.04.283853]; Tvinnereim AR, 2002, INFECT IMMUN, V70, P153, DOI 10.1128/IAI.70.1.153-162.2002; Ugolini M, 2018, NAT IMMUNOL, V19, P386, DOI 10.1038/s41590-018-0068-4; Umlauf BJ, 2012, VIRAL IMMUNOL, V25, P29, DOI 10.1089/vim.2011.0051; Upham JW, 2002, J ALLERGY CLIN IMMUN, V109, P307, DOI 10.1067/mai.2002.121527; VAJDY M, 1992, IMMUNOLOGY, V75, P488; Van den Broeck W, 1999, VACCINE, V17, P2020, DOI 10.1016/S0264-410X(98)00406-X; Verdonck F, 2005, J CONTROL RELEASE, V104, P243, DOI 10.1016/j.jconrel.2005.02.007; Verdonck F, 2004, FEMS IMMUNOL MED MIC, V41, P243, DOI 10.1016/j.femsim.2004.03.009; Vetvicka V, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12833; Villasenor-Cardoso MI, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/562984; Vlasova AN, 2019, CURR OPIN VIROL, V37, P16, DOI 10.1016/j.coviro.2019.05.001; Volckmar J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43985; Wang DA, 2010, VACCINE, V28, P3134, DOI 10.1016/j.vaccine.2010.02.058; Wang J, 2011, J IMMUNOL, V187, P5277, DOI 10.4049/jimmunol.1102077; Wang M, 2014, HUM VACC IMMUNOTHER, V10, P3544, DOI 10.4161/hv.36174; Wang SH, 2018, J CELL BIOL, V217, P2799, DOI 10.1083/jcb.201710022; Ward ES, 2018, TRENDS PHARMACOL SCI, V39, P892, DOI 10.1016/j.tips.2018.07.007; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Wen LJ, 2012, VACCINE, V30, P3339, DOI 10.1016/j.vaccine.2011.08.036; Wenink MH, 2009, J IMMUNOL, V183, P4509, DOI 10.4049/jimmunol.0900153; Williams A, 2010, CURR OPIN IMMUNOL, V22, P34, DOI 10.1016/j.coi.2010.01.004; Xia PP, 2016, VET RES, V47, DOI 10.1186/s13567-016-0313-5; Xiang ZQ, 2014, VIROLOGY, V450, P243, DOI 10.1016/j.virol.2013.12.029; Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277; Yang L, 2008, NAT BIOTECHNOL, V26, P326, DOI 10.1038/nbt1390; Yang WT, 2017, APPL MICROBIOL BIOT, V101, P8475, DOI 10.1007/s00253-017-8600-2; Ye LL, 2011, NAT BIOTECHNOL, V29, P158, DOI 10.1038/nbt.1742; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zhang LH, 2008, VACCINE, V26, P224, DOI 10.1016/j.vaccine.2007.10.058; Zhang ZH, 2005, WORLD J GASTROENTERO, V11, P6975, DOI 10.3748/wjg.v11.i44.6975; Zhao D, 2018, POLYMERS, V10, P1, DOI [DOI 10.3390/P0LYM10010031, DOI 10.3390/polym10010031]; Zhu XP, 2001, J IMMUNOL, V166, P3266, DOI 10.4049/jimmunol.166.5.3266; Zimmermann P, 2018, VACCINE, V36, P207, DOI 10.1016/j.vaccine.2017.08.069	255	7	7	6	22	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							1	10.3390/vaccines9010001			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VF	33375151	Green Published, gold			2022-04-29	WOS:000610809100001
J	Karyal, C; Palazi, P; Hughes, J; Griffiths, RC; Persaud, RR; Tighe, PJ; Mitchell, NJ; Griffin, R				Karyal, Cansu; Palazi, Panayiota; Hughes, Jaime; Griffiths, Rhys C.; Persaud, Ruby R.; Tighe, Patrick J.; Mitchell, Nicholas J.; Griffin, Ruth			Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against Clostridioides difficile	VACCINES			English	Article						oral vaccine; Clostridioides difficile; recombinant protein; sIgA; IgG; lipidation; liposomes	ANTIBODY-RESPONSE; FUSION PROTEIN; LIPOPROTEINS; MUCOSAL; ADJUVANTS; PROMOTES; SUBUNIT; IMMUNE; MODEL; TLR2	Mucosal vaccination aims to prevent infection mainly by inducing secretory IgA (sIgA) antibody, which neutralises pathogens and enterotoxins by blocking their attachment to epithelial cells. We previously demonstrated that encapsulated protein antigen CD0873 given orally to hamsters induces neutralising antibodies locally as well as systemically, affording partial protection against Clostridioides difficile infection. The aim of this study was to determine whether displaying CD0873 on liposomes, mimicking native presentation, would drive a stronger antibody response. The recombinant form we previously tested resembles the naturally cleaved lipoprotein commencing with a cysteine but lacking lipid modification. A synthetic lipid (DHPPA-Mal) was designed for conjugation of this protein via its N-terminal cysteine to the maleimide headgroup. DHPPA-Mal was first formulated with liposomes to produce MalLipo; then, CD0873 was conjugated to headgroups protruding from the outer envelope to generate CD0873-MalLipo. The immunogenicity of CD0873-MalLipo was compared to CD0873 in hamsters. Intestinal sIgA and CD0873-specific serum IgG were induced in all vaccinated animals; however, neutralising activity was greatest for the CD0873-MalLipo group. Our data hold great promise for development of a novel oral vaccine platform driving intestinal and systemic immune responses.	[Karyal, Cansu; Hughes, Jaime; Griffin, Ruth] Univ Nottingham, Sch Life Sci, Synthet Biol Res Ctr, Biodiscovery Inst, Nottingham NG7 2RD, England; [Palazi, Panayiota; Griffiths, Rhys C.; Mitchell, Nicholas J.] Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England; [Persaud, Ruby R.] Univ Birmingham, Inst Immunol & Immunotherapy, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Tighe, Patrick J.] Univ Nottingham, Sch Life Sci, Nottingham NG7 2RD, England; [Griffin, Ruth] Univ Nottingham, Nottingham Univ Hosp NHS Trust, NIHR Nottingham Biomed Res Ctr, Nottingham NG7 2UH, England		Griffin, R (通讯作者)，Univ Nottingham, Sch Life Sci, Synthet Biol Res Ctr, Biodiscovery Inst, Nottingham NG7 2RD, England.; Griffin, R (通讯作者)，Univ Nottingham, Nottingham Univ Hosp NHS Trust, NIHR Nottingham Biomed Res Ctr, Nottingham NG7 2UH, England.	cansu.karyal@nottingham.ac.uk; panayiota.palazi@nottingham.ac.uk; jaime.hughes@nottingham.ac.uk; rhys.griffiths@nottingham.ac.uk; MRP813@student.bham.ac.uk; paddy.tighe@nottingham.ac.uk; nicholas.mitchell@nottingham.ac.uk; ruth.griffin1@nottingham.ac.uk		Tighe, Patrick/0000-0001-8326-093X; Mitchell, Nicholas/0000-0002-9041-1852			Abdel-Aal AM, 2014, CHEMBIOCHEM, V15, P1508, DOI 10.1002/cbic.201402077; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Arnon R, 2011, VACCINE DESIGN: INNOVATIVE APPROACHES AND NOVEL STRATEGIES, P1; Bates JT, 2011, J IMMUNOL, V186, P6255, DOI 10.4049/jimmunol.1001855; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Bofinger R, 2018, J PEPT SCI, V24, DOI 10.1002/psc.3131; Brito LA, 2013, SEMIN IMMUNOL, V25, P130, DOI 10.1016/j.smim.2013.05.007; CHILDERS N K, 1990, Regional Immunology, V3, P8; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Czerkinsky C, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2015.0142; da Silva RAG, 2017, BRIT J PHARMACOL, V174, P2247, DOI 10.1111/bph.13660; da Silva RAG, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02847; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Fletcher LD, 2004, INFECT IMMUN, V72, P2088, DOI 10.1128/IAI.72.4.2088-2100.2004; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Han M, 1997, J VET MED SCI, V59, P1109, DOI 10.1292/jvms.59.1109; Harokopakis E, 1998, INFECT IMMUN, V66, P4299; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoft DF, 2011, CELL MICROBIOL, V13, P934, DOI 10.1111/j.1462-5822.2011.01609.x; Huang QR, 2016, BIOCONJUGATE CHEM, V27, P1165, DOI 10.1021/acs.bioconjchem.6b00116; Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101; Jansen KU, 2018, NAT MED, V24, P10, DOI 10.1038/nm.4465; Kang SH, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10090948; Karch CP, 2016, BIOCHEM PHARMACOL, V120, P1, DOI 10.1016/j.bcp.2016.05.001; Karyal C, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9020306; Kastenmuller W, 2014, NAT REV IMMUNOL, V14, P705, DOI 10.1038/nri3727; Kovacs-Simon A, 2011, INFECT IMMUN, V79, P548, DOI 10.1128/IAI.00682-10; Kovacs-Simon A, 2014, J INFECT DIS, V210, P274, DOI 10.1093/infdis/jiu070; Lavelle EC, 2022, NAT REV IMMUNOL, V22, P236, DOI 10.1038/s41577-021-00583-2; Lee CC, 2012, NAT REV IMMUNOL, V12, P168, DOI 10.1038/nri3151; Lee Y, 2018, NAT MATER, V17, P834, DOI 10.1038/s41563-018-0106-5; Leher HF, 1998, INVEST OPHTH VIS SCI, V39, P2666; Lu BL, 2020, ORG BIOMOL CHEM, V18, P5073, DOI 10.1039/d0ob00942c; Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251; Mak T.W., 2013, PRIMER IMMUNE RESPON; Moyle PM, 2014, BIOCONJUGATE CHEM, V25, P965, DOI 10.1021/bc500108b; Moyle PM, 2013, NANOMED-NANOTECHNOL, V9, P935, DOI 10.1016/j.nano.2013.01.009; Moyle PM, 2017, BIOTECHNOL ADV, V35, P375, DOI 10.1016/j.biotechadv.2017.03.005; Naaber P, 1996, FEMS IMMUNOL MED MIC, V14, P205, DOI 10.1016/0928-8244(96)00031-4; Naciute M, 2020, EUR J PHARM BIOPHARM, V152, P183, DOI 10.1016/j.ejpb.2020.04.020; Nakayama H, 2012, FEBS J, V279, P4247, DOI 10.1111/febs.12041; Nisini R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00155; PAPPO J, 1989, CLIN EXP IMMUNOL, V76, P144; Ramirez JEV, 2017, ADV DRUG DELIVER REV, V114, P116, DOI 10.1016/j.addr.2017.04.008; Roberts AP, 2018, ANAEROBE, V53, P2, DOI [10., 10.1016/j.anaerobe.2018.04.015]; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; Savelkoul HFJ, 2015, VACCINES-BASEL, V3, P148, DOI 10.3390/vaccines3010148; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sebaihia M, 2006, NAT GENET, V38, P779, DOI 10.1038/ng1830; Suzuki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037551; Svindland SC, 2012, INFLUENZA OTHER RESP, V6, P90, DOI 10.1111/j.1750-2659.2011.00271.x; Tokuda H, 2009, BIOSCI BIOTECH BIOCH, V73, P465, DOI 10.1271/bbb.80778; Watarai S, 1998, J VET MED SCI, V60, P1047, DOI 10.1292/jvms.60.1047; Zeng WG, 2015, VACCINE, V33, P3526, DOI 10.1016/j.vaccine.2015.05.053	55	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1453	10.3390/vaccines9121453			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0VE	34960199	Green Published, gold			2022-04-29	WOS:000737379500001
J	Smith, PL; Piadel, K; Dalgleish, AG				Smith, Peter Lawrence; Piadel, Katarzyna; Dalgleish, Angus George			Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy	VACCINES			English	Article						immunotherapy; T-cell; vaccine; cancer; checkpoint inhibition; microbiome; metabolism	ACTIVATED PROTEIN-KINASE; RETINOIC ACID; VITAMIN-D; GUT MICROBIOTA; PHASE-I; BLOCKADE IMMUNOTHERAPY; TARGETED INHIBITION; METASTATIC MELANOMA; ANTI-PD-1 EFFICACY; ANTITUMOR RESPONSE	Cancer vaccination and immunotherapy revolutionised the treatment of cancer, a result of decades of research into the immune system in health and disease. However, despite recent breakthroughs in treating otherwise terminal cancer, only a minority of patients respond to cancer immunotherapy and some cancers are largely refractive to immunotherapy treatment. This is due to numerous issues intrinsic to the tumour, its microenvironment, or the immune system. CD4(+) and CD8(+) alpha beta T-cells emerged as the primary effector cells of the anti-tumour immune response but their function in cancer patients is often compromised. This review details the mechanisms by which T-cell responses are hindered in the setting of cancer and refractive to immunotherapy, and details many of the approaches under investigation to direct T-cell function and improve the efficacy of cancer vaccination and immunotherapy.	[Smith, Peter Lawrence; Piadel, Katarzyna; Dalgleish, Angus George] St Georges Univ London, Inst Infect & Immun, London SW17 0RE, England		Smith, PL (通讯作者)，St Georges Univ London, Inst Infect & Immun, London SW17 0RE, England.	plsmith@sgul.ac.uk; kpiadel@sgul.ac.uk; dalgleis@sgul.ac.uk					Aguirre M, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657-015-0256-x; Allegrezza MJ, 2016, CANCER RES, V76, P2561, DOI 10.1158/0008-5472.CAN-15-2808; Moro-Garcia MA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00107; Araujo DV, 2020, J CLIN ONCOL, V38; Arranz-Nicolas J, 2021, CANCER IMMUNOL IMMUN, V70, P3277, DOI 10.1007/s00262-021-02924-5; Arruga F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051825; Bachem A, 2019, IMMUNITY, V51, P285, DOI 10.1016/j.immuni.2019.06.002; Bajor DL, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468956; Baldini C, 2020, EUR J CANCER, V129, P71, DOI 10.1016/j.ejca.2020.01.013; Barnstorf I, 2020, IMMUN INFLAMM DIS, V8, P249, DOI 10.1002/iid3.300; Barnstorf I, 2019, J EXP MED, V216, P571, DOI 10.1084/jem.20181589; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Berezhnoy A, 2014, J CLIN INVEST, V124, P188, DOI 10.1172/JCI69856; Bergerot PG, 2020, J CLIN ONCOL, V38; Beziaud L, 2018, INT J CANCER, V143, P3008, DOI 10.1002/ijc.31842; Beziaud L, 2016, CANCER RES, V76, P4100, DOI 10.1158/0008-5472.CAN-15-2452; Bhattacharya N, 2016, IMMUNITY, V45, P641, DOI 10.1016/j.immuni.2016.08.008; Bolesta E, 2006, J IMMUNOL, V177, P177, DOI 10.4049/jimmunol.177.1.177; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Borgoni S, 2021, AGEING RES REV, V70, DOI 10.1016/j.arr.2021.101410; Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008-0004; Brown CC, 2015, IMMUNITY, V42, P499, DOI 10.1016/j.immuni.2015.02.003; Brownlie RJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127847; Brownlie RJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01427-1; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Butler M, 2021, TRENDS ENDOCRIN MET, V32, P367, DOI 10.1016/j.tem.2021.03.003; Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175; Cannons JL, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109804; Carbonero F, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00448; Casey KA, 2007, J IMMUNOL, V178, P7640, DOI 10.4049/jimmunol.178.12.7640; Castro-Sanchez P, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.608747; Chambers E.S., 2021, NAT AGING, V1, P101, DOI [10.1038/s43587-020-00010-6, DOI 10.1038/S43587-020-00010-6]; Chaoul N, 2015, CANCER RES, V75, P3279, DOI 10.1158/0008-5472.CAN-15-0454; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chen LM, 2018, CANCER DISCOV, V8, P1156, DOI 10.1158/2159-8290.CD-17-1033; Chen SH, 2015, CANCER IMMUNOL RES, V3, P149, DOI 10.1158/2326-6066.CIR-14-0118; Cheng Y, 2017, MOLECULES, V22, DOI 10.3390/molecules22101551; Choi HJ, 2015, MOL CELLS, V38, P918, DOI 10.14348/molcells.2015.0168; Cieri N, 2013, BLOOD, V121, P573, DOI 10.1182/blood-2012-05-431718; Cohen AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010436; Comin-Anduix B, 2010, CLIN CANCER RES, V16, P6040, DOI 10.1158/1078-0432.CCR-10-1911; Cope AP, 2002, ARTHRITIS RES THER, V4, pS197, DOI 10.1186/ar557; Croft M, 2009, IMMUNOL REV, V229, P173, DOI 10.1111/j.1600-065X.2009.00766.x; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Cubas R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001439; Cui GL, 2015, CELL, V161, P750, DOI 10.1016/j.cell.2015.03.021; Curti BD, 2013, CANCER RES, V73, P7189, DOI 10.1158/0008-5472.CAN-12-4174; Cusi Maria Grazia, 2010, Immun Ageing, V7, P14, DOI 10.1186/1742-4933-7-14; Damasio MP, 2021, BIOCHEM J, V478, P79, DOI 10.1042/BCJ20200661; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; Decman V, 2010, J IMMUNOL, V184, P5151, DOI 10.4049/jimmunol.0902063; Deken MA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1238557; Denlinger CS, 2018, ANN ONCOL, V29, P411; Devalaraja S, 2020, CELL, V180, P1098, DOI 10.1016/j.cell.2020.02.042; Diab A, 2020, CANCER DISCOV, V10, P1158, DOI 10.1158/2159-8290.CD-19-1510; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Diken M, 2013, CANCER IMMUNOL RES, V1, P386, DOI 10.1158/2326-6066.CIR-13-0046; Dillon TJ, 2005, MOL CELL BIOL, V25, P4117, DOI 10.1128/MCB.25.10.4117-4128.2005; Dushyanthen S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00728-9; Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024; El-Khoueiry AB, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3027; Erkelens MN, 2017, TRENDS IMMUNOL, V38, P168, DOI 10.1016/j.it.2016.12.006; Ersek B, 2012, J IMMUNOL, V189, P1602, DOI 10.4049/jimmunol.1102365; Esfahani K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12628-1; Feng J, 2016, PROTEIN CELL, V7, P391, DOI 10.1007/s13238-016-0245-x; Ferreira C, 2020, NAT IMMUNOL, V21, P766, DOI 10.1038/s41590-020-0674-9; Ferrere G, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145207; Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2; Flores C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00588; Francisco-Anderson L, 2021, CANCER RES, V81; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Freen-van Heeren Julian J, 2021, Cytokine X, V3, P100049, DOI 10.1016/j.cytox.2020.100049; French RR, 1999, NAT MED, V5, P548, DOI 10.1038/8426; Frohlich A, 2009, SCIENCE, V324, P1576, DOI 10.1126/science.1172815; Gao ND, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.9536; Gardner HA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e14241; Garrison K, 2012, CANCER IMMUNOL IMMUN, V61, P511, DOI 10.1007/s00262-011-1119-y; Gauttier V, 2014, INT J CANCER, V135, P2857, DOI 10.1002/ijc.28943; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Gellrich FF, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010223; Geva R, 2020, CANCER-AM CANCER SOC, V126, P4926, DOI 10.1002/cncr.33133; Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560; Glisson BS, 2020, CLIN CANCER RES, V26, P5358, DOI 10.1158/1078-0432.CCR-19-3070; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Graham JB, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009287; Grant WB, 2008, PEDIATR INFECT DIS J, V27, P853, DOI 10.1097/INF.0b013e3181817bc1; Grasso CS, 2020, CANCER CELL, V38, P500, DOI 10.1016/j.ccell.2020.08.005; Greer RM, 2013, PEDIATR DIABETES, V14, P31, DOI 10.1111/j.1399-5448.2012.00890.x; Grover S, 2020, CANCER-AM CANCER SOC, V126, P3758, DOI 10.1002/cncr.32966; Gu YZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32351; Gurusamy D, 2020, CANCER CELL, V37, P818, DOI 10.1016/j.ccell.2020.05.004; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hall JA, 2011, IMMUNITY, V34, P435, DOI 10.1016/j.immuni.2011.03.003; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hasegawa K, 2004, SCIENCE, V303, P685, DOI 10.1126/science.1092138; He JL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24619-2; He S, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020107, 10.1371/journal.pone.0028291]; He TZ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01556; Hebeisen M, 2013, J CLIN INVEST, V123, P1044, DOI 10.1172/JCI65325; Henson SM, 2015, EUR J IMMUNOL, V45, P1441, DOI 10.1002/eji.201445312; Hinrichs CS, 2008, BLOOD, V111, P5326, DOI 10.1182/blood-2007-09-113050; Ho WJ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146950; Hooijkaas AI, 2012, ONCOIMMUNOLOGY, V1, P609, DOI 10.4161/onci.20226; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Huemer HP, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/349176; Infante JR, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.101; Inomata M, 2019, ANTICANCER RES, V39, P6887, DOI 10.21873/anticanres.13908; Jansen CS, 2019, NATURE, V576, P465, DOI 10.1038/s41586-019-1836-5; Jeninga EH, 2010, ONCOGENE, V29, P4617, DOI 10.1038/onc.2010.206; Jeon SM, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0038-9; Ji M., 2021, DIETARY METHIONINE R, DOI [10.1101/2021.08.27.457955, DOI 10.1101/2021.08.27.457955]; Jing N, 2021, CANCERS, V13, DOI 10.3390/cancers13163987; Joseph RW, 2012, HUM IMMUNOL, V73, P693, DOI 10.1016/j.humimm.2012.04.019; Jung J, 2019, NAT CELL BIOL, V21, P85, DOI 10.1038/s41556-018-0217-x; Kauffmann-Guerrero D, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90397-y; Kim CH, 2018, IMMUNOLOGY, V154, P220, DOI 10.1111/imm.12930; Kim JH, 2021, BMB REP, V54, P21, DOI 10.5483/BMBRep.2021.54.1.257; Kim S, 2005, J BONE MINER RES, V20, P305, DOI 10.1359/JBMR.041112; Kogkopoulou O, 2006, J LEUKOCYTE BIOL, V79, P1052, DOI 10.1189/jlb.0705418; Kourko O, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00969; Kuehm LM, 2019, CANCER IMMUNOL IMMUN, V68, P1095, DOI 10.1007/s00262-019-02346-4; Kusnadi A, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe4782; Ladomersky E, 2020, CLIN CANCER RES, V26, P5232, DOI 10.1158/1078-0432.CCR-19-3874; Laidlaw BJ, 2015, NAT IMMUNOL, V16, P871, DOI 10.1038/ni.3224; Larange A, 2016, ANNU REV IMMUNOL, V34, P369, DOI 10.1146/annurev-immunol-041015-055427; Laute-Caly DL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36926-8; Lazuardi L, 2005, IMMUNOLOGY, V114, P37, DOI 10.1111/j.1365-2567.2004.02006.x; Leone RD, 2019, SCIENCE, V366, P1013, DOI 10.1126/science.aav2588; Lhuillier C, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0653-7; Li Chan, 2018, Oncotarget, V9, P35293, DOI 10.18632/oncotarget.24293; Li C, 2011, IMMUNOLOGY, V132, P104, DOI 10.1111/j.1365-2567.2010.03345.x; Li Y, 2020, CELL REP, V30, P1753, DOI 10.1016/j.celrep.2020.01.035; Li Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21241-0; Lian JY, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00986-z; Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y; Liu JJ, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22964; Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339; Liu QJ, 2020, PROTEIN CELL, V11, P549, DOI 10.1007/s13238-020-00707-9; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Lu L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-36; Mabalirajan U, 2010, INT IMMUNOPHARMACOL, V10, P1514, DOI 10.1016/j.intimp.2010.08.025; Mager LF, 2020, SCIENCE, V369, P1481, DOI 10.1126/science.abc3421; Martinez-Limon A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061913; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]; McDermott DF, 2016, J CLIN ONCOL, V34, P833, DOI 10.1200/JCO.2015.63.7421; McKee AM, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103012; Melchionda F, 2005, J CLIN INVEST, V115, P1177, DOI 10.1172/JCI200523134; Messenheimer DJ, 2017, CLIN CANCER RES, V23, P6165, DOI 10.1158/1078-0432.CCR-16-2677; Michaelson JS, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-SY03-02; Miller JS, 2018, CLIN CANCER RES, V24, P1525, DOI 10.1158/1078-0432.CCR-17-2451; Miyajima M, 2017, NAT IMMUNOL, V18, P1342, DOI 10.1038/ni.3867; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Murayama A, 1999, ENDOCRINOLOGY, V140, P2224, DOI 10.1210/en.140.5.2224; Naing A, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3018; Nomura M, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2895; O'Shea M, 2004, AM J CLIN NUTR, V79, p1199S, DOI 10.1093/ajcn/79.6.1199S; Ohkusu-Tsukada K, 2010, EUR J IMMUNOL, V40, P1011, DOI 10.1002/eji.200939513; Ohnishi H, 2009, J ALLERGY CLIN IMMUN, V123, P249, DOI 10.1016/j.jaci.2008.10.054; Ostiguy V, 2007, J LEUKOCYTE BIOL, V82, P645, DOI 10.1189/jlb.0806494; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Pan J, 2019, EBIOMEDICINE, V49, P72, DOI 10.1016/j.ebiom.2019.10.044; Papadopoulos KP, 2021, CLIN CANCER RES, V27, P1904, DOI 10.1158/1078-0432.CCR-20-2886; Park J, 2015, MUCOSAL IMMUNOL, V8, P80, DOI 10.1038/mi.2014.44; Patsoukis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7692; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097; Pellegrini M, 2009, NAT MED, V15, P528, DOI 10.1038/nm.1953; Pelly VS, 2021, CANCER DISCOV, V11, P2602, DOI 10.1158/2159-8290.CD-20-1815; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; Pereira Felipe V, 2018, Oncotarget, V9, P25808, DOI 10.18632/oncotarget.25380; Petersen CT, 2018, BLOOD ADV, V2, P210, DOI 10.1182/bloodadvances.2017011254; Petrella TM, 2012, J CLIN ONCOL, V30, P3396, DOI 10.1200/JCO.2011.40.0655; Piechutta M, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000510; Pieper AA, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002715; Pollizzi KN, 2015, J CLIN INVEST, V125, P2090, DOI 10.1172/JCI77746; Quinn KM, 2018, CELL REP, V23, P3512, DOI 10.1016/j.celrep.2018.05.057; Rajilic-Stojanovic M, 2014, FEMS MICROBIOL REV, V38, P996, DOI 10.1111/1574-6976.12075; Ribas A, 2019, NAT MED, V25, P936, DOI 10.1038/s41591-019-0476-5; Richard C, 2020, J IMMUNOTHER CANCER, V8, pA408, DOI 10.1136/jitc-2020-SITC2020.0679; Rischin D, 2019, ANN ONCOL, V30, DOI [DOI 10.1093/ANNONC/MDZ252.011, 10.1093/annonc/mdz252.011]; Robinson TO, 2017, IMMUNOL LETT, V190, P159, DOI 10.1016/j.imlet.2017.08.010; Rossini M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3195; Routy B, 2018, NAT REV CLIN ONCOL, V15, P382, DOI 10.1038/s41571-018-0006-2; Roy DG, 2020, CELL METAB, V31, P250, DOI 10.1016/j.cmet.2020.01.006; Ruby CE, 2009, J IMMUNOL, V183, P4853, DOI 10.4049/jimmunol.0901112; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Salah A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.686544; Sapkota B, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22890; Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893, DOI 10.4049/jimmunol.168.11.5893; Sceneay J, 2019, CANCER DISCOV, V9, P1208, DOI 10.1158/2159-8290.CD-18-1454; Scharping NE, 2016, IMMUNITY, V45, P374, DOI 10.1016/j.immuni.2016.07.009; Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011; Schulthess J, 2019, IMMUNITY, V50, P432, DOI 10.1016/j.immuni.2018.12.018; Segal NH, 2018, CLIN CANCER RES, V24, P1816, DOI 10.1158/1078-0432.CCR-17-1922; Segal NH, 2017, CLIN CANCER RES, V23, P1929, DOI 10.1158/1078-0432.CCR-16-1272; Seo H, 2019, P NATL ACAD SCI USA, V116, P12410, DOI 10.1073/pnas.1905675116; Seo W, 2021, EXP MOL MED, V53, P202, DOI 10.1038/s12276-021-00568-0; Shang J, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.585271; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shiba T, 2014, TOXICOL APPL PHARM, V274, P191, DOI 10.1016/j.taap.2013.10.016; Singh M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01572-7; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Sneller MC, 2011, BLOOD, V118, P6845, DOI 10.1182/blood-2011-09-377804; Snook JP, 2020, CANCER IMMUNOL RES, V8, P506, DOI 10.1158/2326-6066.CIR-19-0690; Spencer CN, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-2838; Sportes C, 2008, J EXP MED, V205, P1701, DOI 10.1084/jem.20071681; Stelekati E, 2014, IMMUNITY, V40, P801, DOI 10.1016/j.immuni.2014.04.010; Stevenson A, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e15006; Sun L, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00099; Sznol M, 2008, J CLIN ONCOL, V26; Takahashi H, 2012, NAT IMMUNOL, V13, P587, DOI 10.1038/ni.2286; Takeuchi A, 1998, J IMMUNOL, V160, P209; Takeuchi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016089; Tamanna N, 2018, MECH AGEING DEV, V176, P9, DOI 10.1016/j.mad.2018.10.004; Tan XF, 2011, J VIROL, V85, P8316, DOI 10.1128/JVI.00781-11; Tang KH, 2022, CANCER DISCOV, V12, P47, DOI 10.1158/2159-8290.CD-21-0369; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Thaker PH, 2019, FUTURE ONCOL, V15, P421, DOI 10.2217/fon-2018-0423; Thompson HL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00706; Timerman D, 2017, ONCOTARGET, V8, P6873, DOI 10.18632/oncotarget.14316; Tolcher AW, 2017, CLIN CANCER RES, V23, P5349, DOI 10.1158/1078-0432.CCR-17-1243; Toti E, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4637861; Tran B, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0407-x; Tredan O, 2015, ANN ONCOL, V26, P1353, DOI 10.1093/annonc/mdv173; Trompette A, 2018, IMMUNITY, V48, P992, DOI 10.1016/j.immuni.2018.04.022; Twumasi-Boateng K, 2018, NAT REV CANCER, V18, P419, DOI 10.1038/s41568-018-0009-4; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; Verma V, 2019, NAT IMMUNOL, V20, P1231, DOI 10.1038/s41590-019-0441-y; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Vidal M, 2002, MOL CELL BIOL, V22, P2777, DOI 10.1128/MCB.22.8.2777-2787.2002; Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036; von Essen MR, 2010, NAT IMMUNOL, V11, P344, DOI 10.1038/ni.1851; Waldmann TA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00868; Wanders D, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030684; Wang DY, 2020, ONCOLOGIST, V25, pE602, DOI 10.1634/theoncologist.2019-0518; Wang TT, 2020, NAT METAB, V2, P635, DOI 10.1038/s42255-020-0219-4; Wang Y, 2011, BRIT J CANCER, V104, P643, DOI 10.1038/bjc.2011.15; Wang Y., 2020, POTENTIATING ANTITUM, DOI [10.1101/2020.03.21.001123, DOI 10.1101/2020.03.21.001123]; Wang YP, 2014, CANCER RES, V74, P2217, DOI 10.1158/0008-5472.CAN-13-2928; Wei HF, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28248; Wei Z, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.603837; Wiede F, 2020, EMBO J, V39, DOI 10.15252/embj.2019103637; Wrangle JM, 2018, LANCET ONCOL, V19, P694, DOI 10.1016/S1470-2045(18)30148-7; Xu A., 2019, WORLD J VACCINES, V9, P1, DOI [10.4236/wjv.2019.91001, DOI 10.4236/WJV.2019.91001]; Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025; Yang MX, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106876; Yang W, 2016, NATURE, V531, P651, DOI 10.1038/nature17412; Yap TA, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3000; Yu YR, 2020, NAT IMMUNOL, V21, P1540, DOI 10.1038/s41590-020-0793-3; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057; Zhang SL, 2021, THERANOSTICS, V11, P4155, DOI 10.7150/thno.54476; Zhang YC, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1957605; Zhang Z, 2020, J IMMUNOL, V204, P2575, DOI 10.4049/jimmunol.1901213; Zhang Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00017; Zhao LX, 2014, J IMMUNOL, V193, P735, DOI 10.4049/jimmunol.1400004; Zhao MQ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108677; Zizzari IG, 2020, J PERS MED, V10, DOI 10.3390/jpm10040208	259	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1392	10.3390/vaccines9121392			42	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9MI	34960140	Green Published, gold, Green Accepted			2022-04-29	WOS:000737288100001
J	Baldi, I; Azzolina, D; Francavilla, A; Bartolotta, P; Lorenzoni, G; Vanuzzo, D; Gregori, D				Baldi, Ileana; Azzolina, Danila; Francavilla, Andrea; Bartolotta, Patrizia; Lorenzoni, Giulia; Vanuzzo, Diego; Gregori, Dario			Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy	VACCINES			English	Article						claims data; COVID-19; Vaxzevria; safety; adverse events; Italy	IMMUNE THROMBOCYTOPENIC PURPURA; THROMBOEMBOLISM	Several European countries suspended or changed recommendations for the use of Vaxzevria (AstraZeneca) for suspected adverse effects due to atypical blood-clotting. This research aims to identify a reference point towards the number of thrombotic events expected in the Italian population over 50 years of age who received Vaxzevria from 22 January to 12 April 2021. The venous thromboembolism (VT) and immune thrombocytopenia (ITP) event rates were estimated from a population-based cohort. The overall VT rate was 1.15 (95% CI 0.93-1.42) per 1000 person-years, and the ITP rate was 2.7 (95% CI 0.7-11) per 100,000 person-years. These figures translate into 83 and two expected events of VT and ITP, respectively, in the 15 days following the first administration of Vaxzevria. The number of thrombotic events reported from the Italian Medicines Agency does not appear to have increased beyond that expected in individuals over 50 years of age.	[Baldi, Ileana; Francavilla, Andrea; Bartolotta, Patrizia; Lorenzoni, Giulia; Gregori, Dario] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Unit Biostat Epidemiol & Publ Hlth, I-35121 Padua, Italy; [Azzolina, Danila] Univ Ferrara, Dept Med Sci, I-44100 Ferrara, Italy; [Vanuzzo, Diego] Cardiovasc Prevent Ctr, I-33100 Udine, Italy		Baldi, I (通讯作者)，Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Unit Biostat Epidemiol & Publ Hlth, I-35121 Padua, Italy.	ileana.baldi@unipd.it; danila.azzolina@unife.it; andrea.francavilla@studenti.unipd.it; patrizia.bartolotta@studenti.unipd.it; giulia.lorenzoni@unipd.it; diego50rdc@gmail.com; dario.gregori@unipd.it	Azzolina, Danila/M-5100-2019; Gregori, Dario/F-9974-2012	Azzolina, Danila/0000-0002-8185-5742; Gregori, Dario/0000-0001-7906-0580; BALDI, ILEANA/0000-0002-8578-9164			European Medicine Agency, 2021, SIGN ASS REP EMB THR; Helfand BKI, 2020, JAMA INTERN MED, V180, P1546, DOI 10.1001/jamainternmed.2020.5084; Italia/Covid19-Opendata-Vaccini, DEV IT 2021; Ledford H, 2021, NATURE, V592, P15, DOI 10.1038/d41586-021-00785-7; Lorenzoni G, 2018, INT J CARDIOL, V271, P195, DOI 10.1016/j.ijcard.2018.05.132; Magnani C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103452; Ostergaard SD, 2021, LANCET, V397, P1441, DOI 10.1016/S0140-6736(21)00762-5; Puska P., 1988, COMPREHENSIVE CARDIO; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Segal JB, 2004, AM J HEMATOL, V75, P12, DOI 10.1002/ajh.10445; Tamariz L, 2012, PHARMACOEPIDEM DR S, V21, P154, DOI 10.1002/pds.2341; Vanuzzo D, 2007, EUR HEART J, V28, P484, DOI 10.1093/eurheartj/ehl470; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wu SC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53165-7	14	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1307	10.3390/vaccines9111307			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH7CU	34835237	gold, Green Published			2022-04-29	WOS:000725588900001
J	Chbib, C; Shah, SRM; Gala, RP; Uddin, MN				Chbib, Christiane; Shah, Sarthak M.; Gala, Rikhav P.; Uddin, Mohammad N.			Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and Syphilis	VACCINES			English	Review						antibiotic; chlamydia; gonorrhea; syphilis; sexually transmitted diseases (STDs); microparticulate; vaccine; outer membrane vesicles (OMV)	GRAM-NEGATIVE BACTERIA; PLASMID DNA; DELIVERY; RELEASE; ANTIGEN; PURIFICATION; BIOGENESIS; STRATEGIES; PROTECTION; ANTIBODIES	Sexually transmitted diseases (STDs) are a major global health issue. Approximately 250 million new cases of STDs occur each year globally. Currently, only three STDs (human papillomavirus (HPV), hepatitis A, and hepatitis B) are preventable by vaccines. Vaccines for other STDs, including gonorrhea, chlamydia, and syphilis, await successful development. Currently, all of these STDs are treated with antibiotics. However, the efficacy of antibiotics is facing growing challenge due to the emergence of bacterial resistance. Therefore, alternative therapeutic approaches, including the development of vaccines against these STDs, should be explored to tackle this important global public health issue. Mass vaccination could be more efficient in reducing the spread of these highly contagious diseases. Bacterial outer membrane vesicle (OMV) is a potential antigen used to prevent STDs. OMVs are released spontaneously during growth by many Gram-negative bacteria. They present a wide range of surface antigens in native conformation that possess interesting properties such as immunogenicity, adjuvant potential, and the ability to be taken up by immune cells, all of which make them an attractive target for application as vaccines against pathogenic bacteria. The major challenge associated with the use of OMVs is its fragile structure and stability. However, a particulate form of the vaccine could be a suitable delivery system that can protect the antigen from degradation by a harsh acidic or enzymatic environment. The particulate form of the vaccine can also act as an adjuvant by itself. This review will highlight some practical methods for formulating microparticulate OMV-based vaccines for STDs.	[Chbib, Christiane] Larkin Univ, Coll Pharm, Dept Pharmaceut Sci, Miami, FL 33169 USA; [Shah, Sarthak M.; Uddin, Mohammad N.] Mercer Univ, Coll Pharm, Dept Pharmaceut Sci, Atlanta, GA 30341 USA; [Gala, Rikhav P.] Fraunhofer USA, Ctr Midatlantic, Biotechnol Div, Newark, DE 19702 USA		Uddin, MN (通讯作者)，Mercer Univ, Coll Pharm, Dept Pharmaceut Sci, Atlanta, GA 30341 USA.	cchbib@ularkin.org; sarthak.modi.shah@live.mercer.edu; Rgala@fraunhofer.org; uddin_mn@mercer.edu					Ahmed AAQ, 2021, LIFE SCI, V279, DOI 10.1016/j.lfs.2021.119644; Ali OA, 2016, CANCER IMMUNOL RES, V4, P95, DOI 10.1158/2326-6066.CIR-14-0126; Alves NJ, 2017, RES MICROBIOL, V168, P139, DOI 10.1016/j.resmic.2016.10.001; [Anonymous], 2019, NATL OVERVIEW SEXUAL; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Balmert SC, 2012, ADV MATER, V24, P3757, DOI 10.1002/adma.201200224; Bartolini E, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20181; Bauman SJ, 2006, MICROBES INFECT, V8, P2400, DOI 10.1016/j.micinf.2006.05.001; Bhowmik T, 2012, J DRUG TARGET, V20, P364, DOI 10.3109/1061186X.2012.662686; Bielinska AU, 1997, BBA-GENE STRUCT EXPR, V1353, P180, DOI 10.1016/S0167-4781(97)00069-9; Blanco DR, 2005, FEMS MICROBIOL LETT, V249, P171, DOI 10.1016/j.femsle.2005.06.007; Blanco DR, 2005, INFECT IMMUN, V73, P3083, DOI 10.1128/IAI.73.5.3083-3095.2005; Bonnington KE, 2014, BBA-MOL CELL RES, V1843, P1612, DOI 10.1016/j.bbamcr.2013.12.011; Davenport V, 2008, J INFECT DIS, V198, P731, DOI 10.1086/590669; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Elwell C, 2016, NAT REV MICROBIOL, V14, P385, DOI 10.1038/nrmicro.2016.30; Fattom A., DEV NANOEMULSION BAS; Fredriksen BN, 2012, VACCINE, V30, P656, DOI 10.1016/j.vaccine.2011.10.105; Gaspar EB, 2021, HUM VACC IMMUNOTHER, V17, P2965, DOI 10.1080/21645515.2021.1920272; Gnopo YMD, 2017, ADV DRUG DELIVER REV, V114, P132, DOI 10.1016/j.addr.2017.05.003; Gong YK, 2012, NANOSCALE, V4, P360, DOI 10.1039/c1nr11297j; Gulati S, 2019, MBIO, V10, DOI 10.1128/mBio.02552-19; Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021; Harrell JE, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10050616; Hashimoto M, 2018, J BIOSCI BIOENG, V125, P425, DOI 10.1016/j.jbiosc.2017.11.006; Jan AT, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01053; Janes KA, 2001, ADV DRUG DELIVER REV, V47, P83, DOI 10.1016/S0169-409X(00)00123-X; Kaparakis-Liaskos M, 2015, NAT REV IMMUNOL, V15, P375, DOI 10.1038/nri3837; Kim SH, 2009, BBA-BIOMEMBRANES, V1788, P2150, DOI 10.1016/j.bbamem.2009.08.001; Kirkcaldy RD, 2019, SEX HEALTH, V16, P401, DOI 10.1071/SH19061; Kulp A, 2010, ANNU REV MICROBIOL, V64, P163, DOI 10.1146/annurev.micro.091208.073413; Liu T, 2016, P NATL ACAD SCI USA, V113, P5910, DOI 10.1073/pnas.1605363113; Mallapragada SK, 2008, INT J PHARMACEUT, V364, P265, DOI 10.1016/j.ijpharm.2008.06.030; Manning AJ, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-258; Maredia R, 2012, SCI WORLD J, P1, DOI 10.1100/2012/402919; McBroom AJ, 2007, MOL MICROBIOL, V63, P545, DOI 10.1111/j.1365-2958.2006.05522.x; McBroom AJ, 2006, J BACTERIOL, V188, P5385, DOI 10.1128/JB.00498-06; McIntosh Edwin David G, 2020, Ther Adv Vaccines Immunother, V8, p2515135520923887, DOI 10.1177/2515135520923887; Monkare J, 2018, EUR J PHARM BIOPHARM, V129, P111, DOI 10.1016/j.ejpb.2018.05.031; Nokleby H, 2007, VACCINE, V25, P3080, DOI 10.1016/j.vaccine.2007.01.022; O'Hagan DT, 1998, ADV DRUG DELIVER REV, V34, P305, DOI 10.1016/S0169-409X(98)00045-3; OHAGAN DT, 1991, IMMUNOLOGY, V73, P239; Parker ML, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166274; Paynter J, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010005; Perez O, 2009, VACCIMONITOR, V18, P53; Petousis-Harris H, 2018, HUM VACC IMMUNOTHER, V14, P1058, DOI 10.1080/21645515.2017.1381810; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Schautteet Katelijn, 2011, Infect Dis Obstet Gynecol, V2011, P963513, DOI 10.1155/2011/963513; Schooling SR, 2006, J BACTERIOL, V188, P5945, DOI 10.1128/JB.00257-06; Schooling SR, 2009, J BACTERIOL, V191, P4097, DOI 10.1128/JB.00717-08; Schwechheimer C, 2015, NAT REV MICROBIOL, V13, P605, DOI 10.1038/nrmicro3525; Schwechheimer C, 2013, BIOCHEMISTRY-US, V52, P3031, DOI 10.1021/bi400164t; Silhavy TJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000414; Slutter B, 2010, J CONTROL RELEASE, V143, P207, DOI 10.1016/j.jconrel.2010.01.007; Solanki KS, 2016, J PURE APPL MICROBIO, V10, P2121; St Cyr S, 2020, MMWR-MORBID MORTAL W, V69, P1911, DOI 10.15585/mmwr.mm6950a6; Thomasin C, 1996, J CONTROL RELEASE, V41, P131, DOI 10.1016/0168-3659(96)01363-6; Toyofuku M, 2019, NAT REV MICROBIOL, V17, P13, DOI 10.1038/s41579-018-0112-2; Uddin MN, 2015, J PHARM PHARM SCI, V18, P220, DOI 10.18433/J3RS3V; van der Pol L, 2015, BIOTECHNOL J, V10, P1689, DOI 10.1002/biot.201400395; Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2; Wu GX, 2020, NANOMED-NANOTECHNOL, V24, DOI 10.1016/j.nano.2019.102148; Wu X, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-87; Xu XY, 2015, TRENDS MOL MED, V21, P223, DOI 10.1016/j.molmed.2015.01.001; Zeng Q, 2017, BIOMATERIALS, V122, P105, DOI 10.1016/j.biomaterials.2017.01.010; Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069	66	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1245	10.3390/vaccines9111245			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF2UN	34835176	Green Published, gold			2022-04-29	WOS:000723931300001
J	Gurrieri, F; Corbellini, S; Piccinelli, G; Turra, A; Morello, E; Malagola, M; Russo, D; Caruso, A; De Francesco, MA				Gurrieri, Francesca; Corbellini, Silvia; Piccinelli, Giorgio; Turra, Alessandro; Morello, Enrico; Malagola, Michele; Russo, Domenico; Caruso, Arnaldo; De Francesco, Maria Antonia			Management of Invasive Infections due to a Rare Arthroconidial Yeast, Saprochaete capitata, in Two Patients with Acute Hematological Malignancies	VACCINES			English	Article						immunosuppression; fungal infection; neutropenia; bone marrow transplantation	DESORPTION IONIZATION-TIME; BLASTOSCHIZOMYCES-CAPITATUS; GEOTRICHUM-CAPITATUM; MAGNUSIOMYCES-CAPITATUS; OPPORTUNISTIC YEAST; FUNGAL DISEASE; LEUKEMIA; SEPTICEMIA; EMERGENCE; CLUSTER	Saprochaete capitata is an arthroconidial yeast, found principally in the environment, even if it belongs also to the normal microbial flora that colonize human subjects. This yeast is increasingly associated with invasive infections in hematological patients, in particular in those affected by acute leukemia. An important risk factor that predisposes to this infection is the profound neutropenia present in such immunocompromised patients. Saprochaete spp. were found resistant to both echinocandins and fluconazole so the treatment is often difficult. Here, we report two cases of sepsis in two patients with acute leukemia. All of them had fatal events, due to the worsening of their clinical condition. An early diagnosis and appropriate management of these pathogens is important in consideration of the poor prognosis associated to these fungal invasive infections.	[Gurrieri, Francesca; Corbellini, Silvia; Piccinelli, Giorgio; Caruso, Arnaldo; De Francesco, Maria Antonia] Univ Brescia, ASST Spedali Civili, Dept Mol & Translat Med, Inst Microbiol, I-25123 Brescia, Italy; [Turra, Alessandro; Morello, Enrico; Malagola, Michele; Russo, Domenico] Univ Brescia, ASST Spedali Civili, Chair Hematol, Unit Blood Dis & Stem Cells Transplantat, I-25123 Brescia, Italy		De Francesco, MA (通讯作者)，Univ Brescia, ASST Spedali Civili, Dept Mol & Translat Med, Inst Microbiol, I-25123 Brescia, Italy.	silvia.corbellini@gmail.com; giorgio.piccinelli@gmail.com; enrico.morello@asst-spedalicivili.it; michele.malagola@unibs.it; domenico.russo@unibs.it; arnaldo.caruso@unibs.it; maria.defrancesco@unibs.it	De Francesco, Maria Antonia/H-3456-2019	De Francesco, Maria Antonia/0000-0003-2221-6286			Arendrup MC, 2014, CLIN MICROBIOL INFEC, V20, P76, DOI 10.1111/1469-0691.12360; Armstrong-James D, 2017, TRENDS MICROBIOL, V25, P428, DOI 10.1016/j.tim.2017.02.013; Arrieta-Aguirre I, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01246-17; Birrenbach T, 2012, EMERG INFECT DIS, V18, P98, DOI 10.3201/eid1801.111192; Buchta V, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02196; Garcia-Ruiz JC, 2013, REV IBEROAM MICOL, V30, P248, DOI 10.1016/j.riam.2013.02.004; Chagas-Neto TC, 2009, J CLIN MICROBIOL, V47, P1074, DOI 10.1128/JCM.01614-08; Chakrabarti A, 2014, CLIN MICROBIOL INFEC, V20, pO83, DOI 10.1111/1469-0691.12337; CHANG WWL, 1964, ARCH INTERN MED, V113, P356, DOI 10.1001/archinte.1964.00280090042007; Christakis G, 2005, MYCOSES, V48, P216, DOI 10.1111/j.1439-0507.2005.01098.x; Colombo AL, 2017, LANCET INFECT DIS, V17, pE344, DOI 10.1016/S1473-3099(17)30304-3; Cornely OA, 2019, MYCOSES, V62, P716, DOI 10.1111/myc.12960; de Hoog GS, 2004, STUD MYCOL, P489; de Jong AW, 2019, MYCOPATHOLOGIA, V184, P353, DOI 10.1007/s11046-019-00351-w; De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; Del Principe MI, 2016, MYCOSES, V59, P594, DOI 10.1111/myc.12508; Desnos-Ollivier M, 2014, J CLIN MICROBIOL, V52, P2196, DOI 10.1128/JCM.00039-14; Diekema DJ, 2005, J CLIN MICROBIOL, V43, P476, DOI 10.1128/JCM.43.1.476-478.2005; Erman B, 2020, J CLIN IMMUNOL, V40, P466, DOI 10.1007/s10875-020-00759-w; Esposto MC, 2019, MED MYCOL, V57, P909, DOI 10.1093/mmy/myy133; Gadea I, 2004, J CLIN MICROBIOL, V42, P1832, DOI 10.1128/JCM.42.4.1832-1836.2004; Girmenia C, 2005, J CLIN MICROBIOL, V43, P1818, DOI 10.1128/JCM.43.4.1818-1828.2005; Graeff LD, 2017, MYCOSES, V60, P273, DOI 10.1111/myc.12595; Gulcan A, 2016, COMP IMMUNOL MICROB, V46, P47, DOI 10.1016/j.cimid.2016.04.004; Kaplan E, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01427-17; Kolecka A, 2013, J CLIN MICROBIOL, V51, P2491, DOI 10.1128/JCM.00470-13; Leoni M, 2019, MED MYCOL CASE REP, V23, P65, DOI 10.1016/j.mmcr.2018.12.005; Li HT, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001624; Lo Cascio Giuliana, 2020, Frontiers in Microbiology, V11, P84, DOI 10.3389/fmicb.2020.00084; MARTINO P, 1990, REV INFECT DIS, V12, P570; Martino R, 2004, CLIN INFECT DIS, V38, P335, DOI 10.1086/380643; Mazzocato S, 2015, INFECTION, V43, P211, DOI 10.1007/s15010-014-0668-3; Miceli MH, 2011, LANCET INFECT DIS, V11, P142, DOI 10.1016/S1473-3099(10)70218-8; Pamidimukkala U, 2017, J CLIN DIAGN RES, V11, pDC36, DOI 10.7860/JCDR/2017/30339.10669; Pande A, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12664; Pfaller MA, 2013, J CLIN MICROBIOL, V51, P2571, DOI 10.1128/JCM.00308-13; Potenza L, 2019, MYCOSES, V62, P223, DOI 10.1111/myc.12875; Saghrouni F, 2012, MED MYCOL CASE REP, V1, P88, DOI 10.1016/j.mmcr.2012.09.003; Fernandez IS, 2019, ENFERM INFEC MICR CL, V37, P283, DOI 10.1016/j.eimc.2018.05.003; Schuermans C, 2011, MED MYCOL, V49, P414, DOI 10.3109/13693786.2010.535179; Supram HS, 2016, MED MYCOL, V54, P103, DOI 10.1093/mmy/myv075; Trabelsi H, 2015, MYCOPATHOLOGIA, V179, P465, DOI 10.1007/s11046-015-9869-2; Ulu-Kilic A, 2015, MYCOSES, V58, P491, DOI 10.1111/myc.12347; Vallabhaneni S, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-016-0572-1; Vallabhaneni S, 2016, INFECT DIS CLIN N AM, V30, P1, DOI 10.1016/j.idc.2015.10.004; Vaux S, 2014, MBIO, V5, DOI 10.1128/mBio.02309-14	46	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1289	10.3390/vaccines9111289			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF0KD	34835220	Green Published, gold			2022-04-29	WOS:000723767400001
J	Umar, A; Haque, A; Alghamdi, YS; Mashraqi, MM; Rehman, A; Shahid, F; Khurshid, M; Ashfaq, UA				Umar, Ahitsham; Haque, Asma; Alghamdi, Youssef Saeed; Mashraqi, Mutaib M.; Rehman, Abdur; Shahid, Farah; Khurshid, Mohsin; Ashfaq, Usman Ali			Development of a Candidate Multi-Epitope Subunit Vaccine against Klebsiella aerogenes: Subtractive Proteomics and Immuno-Informatics Approach	VACCINES			English	Article						subtractive proteomics; subunit vaccine; Klebsiella aerogenes; molecular docking	CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; PEPTIDE VACCINE; RISK-FACTORS; PROTEIN; EPIDEMIOLOGY; BACTEREMIA; EXPRESSION; PREDICTION; PROGRESS; DESIGN	Klebsiella aerogenes is a Gram-negative bacterium which has gained considerable importance in recent years. It is involved in 10% of nosocomial and community-acquired urinary tract infections and 12% of hospital-acquired pneumonia. This organism has an intrinsic ability to produce inducible chromosomal AmpC beta-lactamases, which confer high resistance. The drug resistance in K. aerogenes has been reported in China, Israel, Poland, Italy and the United States, with a high mortality rate (~50%). This study aims to combine immunological approaches with molecular docking approaches for three highly antigenic proteins to design vaccines against K. aerogenes. The synthesis of the B-cell, T-cell (CTL and HTL) and IFN-gamma epitopes of the targeted proteins was performed and most conserved epitopes were chosen for future research studies. The vaccine was predicted by connecting the respective epitopes, i.e., B cells, CTL and HTL with KK, AAY and GPGPG linkers and all these were connected with N-terminal adjuvants with EAAAK linker. The humoral response of the constructed vaccine was measured through IFN-gamma and B-cell epitopes. Before being used as vaccine candidate, all identified B-cell, HTL and CTL epitopes were tested for antigenicity, allergenicity and toxicity to check the safety profiles of our vaccine. To find out the compatibility of constructed vaccine with receptors, MHC-I, followed by MHC-II and TLR4 receptors, was docked with the vaccine. Lastly, in order to precisely certify the proper expression and integrity of our construct, in silico cloning was carried out. Further studies are needed to confirm the safety features and immunogenicity of the vaccine.	[Umar, Ahitsham; Haque, Asma; Rehman, Abdur; Shahid, Farah; Ashfaq, Usman Ali] Govt Coll Univ Faisalabad, Dept Bioinformat & Biotechnol, Faisalabad 38000, Pakistan; [Alghamdi, Youssef Saeed] Taif Univ, Turabah Univ Coll, Dept Biol, At Taif 21944, Saudi Arabia; [Mashraqi, Mutaib M.] Najran Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Najran 61441, Saudi Arabia; [Khurshid, Mohsin] Govt Coll Univ Faisalabad, Dept Microbiol, Faisalabad 38000, Pakistan		Ashfaq, UA (通讯作者)，Govt Coll Univ Faisalabad, Dept Bioinformat & Biotechnol, Faisalabad 38000, Pakistan.	ahitshamumar85@gmail.com; asma@gcuf.edu.pk; ysghamdi@tu.edu.sa; mmmashraqi@nu.edu.sa; abdurrehman93@gcuf.edu.pk; farahshahid24@gcuf.edu.pk; mohsinkhurshid@gcuf.edu.pk; ashfaqua@gcuf.edu.pk	Mashraqi‬‏, Mutaib M/AGY-7690-2022; Ashfaq, usman ali/D-7792-2013; Khurshid, Mohsin/N-8135-2013	Mashraqi‬‏, Mutaib M/0000-0002-2931-296X; Rehman, Abdur/0000-0003-0570-6224; Ashfaq, usman ali/0000-0002-5495-805X; Khurshid, Mohsin/0000-0002-3196-2857	Taif University, Taif, Saudi Arabia	Taif University Researchers Supporting Project number (TURSP-2020/258), Taif University, Taif, Saudi Arabia.	Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010; Aldakheel FM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101079; Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529; Ashfaq UA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245072; Aslam S, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10100997; Azhagesan K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208722; Brennan MJ, 2017, INFECT IMMUN, V85, DOI [10.1128/IAI.00969-16, 10.1128/iai.00969-16]; Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153; Cherryholmes GA, 2015, VACCINE, V33, P7408, DOI 10.1016/j.vaccine.2015.06.116; Cooper MD, 2015, NAT REV IMMUNOL, V15, P191, DOI 10.1038/nri3801; Corona F, 2016, FUTURE MED CHEM, V8, P1133, DOI 10.4155/fmc-2016-0027; Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346; CRYZ SJ, 1983, EUR J CLIN MICROBIOL, V2, P523, DOI 10.1007/BF02016559; Dar HA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030088; Davin-Regli A, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00392; Dhanda SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/263952; Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30; Dheenadhayalan V, 2006, MICROBES INFECT, V8, P262, DOI 10.1016/j.micinf.2005.06.021; Diene SM, 2013, MOL BIOL EVOL, V30, P369, DOI 10.1093/molbev/mss236; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Franolic I, 2019, CEN CASE REP, V8, P38, DOI 10.1007/s13730-018-0360-z; Gomez-Simmonds A, 2018, MBIO, V9, DOI [10.1128/mBio.00542-18, 10.1128/mbio.00542-18]; Grazziotin Ana Laura, 2016, Front Microbiol, V7, P1649; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Guh AY, 2015, JAMA-J AM MED ASSOC, V314, P1479, DOI 10.1001/jama.2015.12480; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; HENGEN PN, 1995, TRENDS BIOCHEM SCI, V20, P285, DOI 10.1016/S0968-0004(00)89045-3; Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Kalita P, 2019, INT J BIOL MACROMOL, V138, P224, DOI 10.1016/j.ijbiomac.2019.07.024; Kazi A, 2018, PATHOG GLOB HEALTH, V112, P123, DOI 10.1080/20477724.2018.1446773; Khajuria Atul, 2014, Chemother Res Pract, V2014, P972646, DOI 10.1155/2014/972646; Khalid H, 2020, J BIOMED INFORM, V108, DOI 10.1016/j.jbi.2020.103498; Khatoon N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08842-w; Kovacs JA, 2004, PROTEINS, V56, P661, DOI 10.1002/prot.20151; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860; Lee HJ, 2016, INFECT CHEMOTHER, V48, P166, DOI 10.3947/ic.2016.48.3.166; Lengths MC, 2018, QUICK GUIDELINE COMP, V16, P75; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Lin XY, 2016, CELL MOL IMMUNOL, V13, P492, DOI 10.1038/cmi.2015.29; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Martinez JL, 2009, FEMS MICROBIOL REV, V33, P44, DOI 10.1111/j.1574-6976.2008.00142.x; Lund FE, 2008, CURR OPIN IMMUNOL, V20, P332, DOI 10.1016/j.coi.2008.03.003; Ma DY, 2020, INFECT DRUG RESIST, V13, P577, DOI 10.2147/IDR.S235975; Mahmood M, 2021, INFECT GENET EVOL, V91, DOI 10.1016/j.meegid.2021.104795; Mahram Atabak, 2010, 24th ACM International Conference on Supercomputing 2010, P73; Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215; Nagpal G, 2017, SCI REP-UK, V7, DOI 10.1038/srep42851; Nain Z, 2020, J BIOMOL STRUCT DYN, V38, P4850, DOI 10.1080/07391102.2019.1692072; Nezafat N, 2016, COMPUT BIOL CHEM, V62, P82, DOI 10.1016/j.compbiolchem.2016.04.006; Nezafat N, 2014, J THEOR BIOL, V349, P121, DOI 10.1016/j.jtbi.2014.01.018; Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238; Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1; Passarelli-Araujo H, 2019, AN ACAD BRAS CIENC, V91, DOI 10.1590/0001-376520182018762; Phillips RO, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003457; Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Raines RT, 2000, METHOD ENZYMOL, V326, P362; Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339; Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862; Rehman A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060658; Robert J, 2014, J ANTIMICROB CHEMOTH, V69, P2706, DOI 10.1093/jac/dku208; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Shahid F, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104199; Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x; Tindall BJ, 2017, INT J SYST EVOL MICR, V67, P502, DOI 10.1099/ijsem.0.001572; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; VanAalten DMF, 1997, J COMPUT CHEM, V18, P169; Walker JM, 2005, PROTEOMICS PROTOCOLS; Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568; WUTHRICH K, 1980, BIOPHYS J, V32, P549; Wyres KL, 2016, TRENDS MICROBIOL, V24, P944, DOI 10.1016/j.tim.2016.09.007; Yin DH, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1552-9; YOUNG SEJ, 1982, J INFECTION, V5, P19, DOI 10.1016/S0163-4453(82)93149-8; Zheng W, 2019, PROTEINS, V87, P1149, DOI 10.1002/prot.25792; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; Zinner S., 1983, MED MICROBIOL, V2, P71	79	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1373	10.3390/vaccines9111373			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG5PC	34835304	Green Published, gold			2022-04-29	WOS:000724803800001
J	Hall, RN; King, T; O'Connor, TW; Read, AJ; Vrankovic, S; Piper, M; Strive, T				Hall, Robyn N.; King, Tegan; O'Connor, Tiffany W.; Read, Andrew J.; Vrankovic, Sylvia; Piper, Melissa; Strive, Tanja			Passive Immunisation against RHDV2 Induces Protection against Disease but Not Infection	VACCINES			English	Article						RHDV2; lagovirus; rabbit calicivirus; maternal antibody; passive immunity; biocontrol	RABBIT HEMORRHAGIC-DISEASE; WILD RABBITS; NEW-ZEALAND; VIRUS 2; RT-PCR; RESISTANCE; ISLAND	Rabbit haemorrhagic disease virus 2 (RHDV2) is a lagovirus in the family Caliciviridae. The closely related Rabbit haemorrhagic disease virus (RHDV, termed RHDV1 throughout this manuscript for clarity) has been used extensively as a biocontrol agent in Australia since the mid-1990s to manage wild rabbit populations, a major economic and environmental pest species. Releasing RHDV1 into populations with a high proportion of rabbits less than 8-10 weeks of age leads to non-lethal infection in many of these young animals, with subsequent seroconversion and long-term immunity against reinfection. In contrast, RHDV2 causes lethal disease even in young rabbits, potentially offering substantial benefits for rabbit management programs over RHDV1. However, it is not clear how acquired resistance from maternal antibodies may influence immunity after RHDV2 infection. In this study, we assessed serological responses after RHDV2 challenge in young rabbits of three different ages (5-, 7-, or 9-weeks-old) that were passively immunised with either high- (titre of 2560 by RHDV IgG ELISA; 2.41 mg/mL total protein) or low- (titre of 160-640 by RHDV IgG ELISA; 1.41 mg/mL total protein) dose RHDV2 IgG to simulate maternal antibodies. All rabbits treated with a high dose and 75% of those treated with a low dose of RHDV2 IgG survived virus challenge. Surviving animals developed robust lagovirus-specific IgA, IgM, and IgG responses within 10 days post infection. These findings demonstrate that the protection against RHDV2 conferred by passive immunisation is not sterilising. Correspondingly, this suggests that the presence of maternal antibodies in wild rabbit populations may impede the effectiveness of RHDV2 as a biocontrol.</p>	[Hall, Robyn N.; King, Tegan; Strive, Tanja] CSIRO, Hlth & Biosecur, Acton, ACT 2601, Australia; [Hall, Robyn N.; Strive, Tanja] Ctr Invas Species Solut, Bruce, ACT 2617, Australia; [O'Connor, Tiffany W.; Read, Andrew J.; Vrankovic, Sylvia] NSW Dept Primary Ind, Elizabeth Macarthur Agr Inst, Menangle, NSW 2568, Australia; [Piper, Melissa] CSIRO, Agr & Food, Acton, ACT 2601, Australia		Hall, RN (通讯作者)，CSIRO, Hlth & Biosecur, Acton, ACT 2601, Australia.; Hall, RN (通讯作者)，Ctr Invas Species Solut, Bruce, ACT 2617, Australia.	Robyn.Hall@csiro.au; tegan.king4891@gmail.com; Tiffany.OConnor@dpi.nsw.gov.au; andrew.j.read@dpi.nsw.gov.au; sylvia.vrankovic@dpi.nsw.gov.au; Melissa.Piper@csiro.au; Tanja.Strive@csiro.au	Strive, Tanja/C-1486-2008; O'Connor, Tiffany/ACF-8908-2022; O'Connor, Tiffany/AAE-9467-2022; Read, Andrew/I-6999-2012; Hall, Robyn/E-3121-2017	O'Connor, Tiffany/0000-0003-1252-0591; O'Connor, Tiffany/0000-0003-1252-0591; Read, Andrew/0000-0002-2421-4287; Hall, Robyn/0000-0002-5836-2990; Strive, Tanja/0000-0003-2971-8406	Centre for Invasive Species Solutions [P-01-B-001]	This research and the APC was funded by the Centre for Invasive Species Solutions, grant number P-01-B-001.	AUGUST DA, 1985, CANCER-AM CANCER SOC, V55, P1490, DOI 10.1002/1097-0142(19850401)55:7<1490::AID-CNCR2820550712>3.0.CO;2-N; Baratelli M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030484; Borchers H.W., 2019; Camarda A, 2014, RES VET SCI, V97, P642, DOI 10.1016/j.rvsc.2014.10.008; Capucci L, 1997, VET REC, V140, P647, DOI 10.1136/vr.140.25.647; Commonwealth of Australia, 2016, THREAT AB PLAN COMP; Cooke BD, 2018, TRANSBOUND EMERG DIS, V65, pe470, DOI 10.1111/tbed.12786; Cooke BD, 2000, EPIDEMIOL INFECT, V124, P563, DOI 10.1017/S0950268899003994; Decaro N, 2020, VET MICROBIOL, V247, DOI 10.1016/j.vetmic.2020.108760; Ferreira PG, 2008, VET IMMUNOL IMMUNOP, V121, P364, DOI 10.1016/j.vetimm.2007.09.005; Forrester NL, 2007, VIROLOGY, V358, P18, DOI 10.1016/j.virol.2006.09.011; Forrester NL, 2003, J GEN VIROL, V84, P3079, DOI 10.1099/vir.0.19213-0; Hall RN, 2018, TRANSBOUND EMERG DIS, V65, pe444, DOI 10.1111/tbed.12779; Hall RN, 2017, VET REC, V180, DOI 10.1136/vr.104034; Hall RN, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13061184; Hall RN, 2015, EMERG INFECT DIS, V21, P2276, DOI 10.3201/eid2112.151210; Kassambara A., 2017; Kearney Stephen G., 2019, Pacific Conservation Biology, V25, P231, DOI 10.1071/PC18024; KNIGHT KL, 1994, ADV IMMUNOL, V56, P179, DOI 10.1016/S0065-2776(08)60452-6; Lankton JS, 2021, J WILDLIFE DIS, V57, P694, DOI 10.7589/JWD-D-20-00207; Lavazza A., 2021, CHAPTER 372 RABBIT H; Le Gall-Recule G, 2017, VET RES, V48, DOI 10.1186/s13567-017-0473-y; Le Gall-Recule G, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-81; Le Gall-Recule G, 2011, VIROLOGY, V410, P395, DOI 10.1016/j.virol.2010.12.001; Le Pendu J, 2017, J GEN VIROL, V98, P1658, DOI 10.1099/jgv.0.000840; Lemaitre E, 2018, ARCH VIROL, V163, P2921, DOI 10.1007/s00705-018-3901-z; Liu JE, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-182; Liu JN, 2012, VET MICROBIOL, V157, P345, DOI 10.1016/j.vetmic.2012.01.018; Marques RM, 2012, VET IMMUNOL IMMUNOP, V150, P181, DOI 10.1016/j.vetimm.2012.09.038; Marques RM, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-14; Matthaei M, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-109; Neave MJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090512; Neimanis AS, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1694-7; Nicholson LJ, 2017, APPL ENVIRON MICROB, V83, DOI 10.1128/AEM.00090-17; Parkes JP, 2002, WILDLIFE RES, V29, P543, DOI 10.1071/WR00108; Peacock D, 2017, VET REC, V180, DOI 10.1136/vr.104135; Puggioni G, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-96; R Core Team, 2020, R LANGUAGE ENV STAT; Robinson AJ, 2002, WILDLIFE RES, V29, P663, DOI 10.1071/WR00119; Strive T, 2020, TRANSBOUND EMERG DIS, V67, P822, DOI 10.1111/tbed.13403; Strive T, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-51; Taggart PL, 2021, TRANSBOUND EMERG DIS, DOI 10.1111/tbed.14071; Velarde R, 2017, TRANSBOUND EMERG DIS, V64, P1750, DOI 10.1111/tbed.12562; Wickham H., 2019, **DATA OBJECT**; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wilke C., 2020; Zehnder AM, 2012, AM J VET RES, V73, P1859, DOI 10.2460/ajvr.73.12.1859	47	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1197	10.3390/vaccines9101197			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WU0SO	34696305	gold, Green Published			2022-04-29	WOS:000716264600001
J	McAbee, L; Tapera, O; Kanyangarara, M				McAbee, Lauren; Tapera, Oscar; Kanyangarara, Mufaro			Factors Associated with COVID-19 Vaccine Intentions in Eastern Zimbabwe: A Cross-Sectional Study	VACCINES			English	Article						COVID-19 vaccine; vaccine intentions; COVID-19 pandemic; Zimbabwe; Sub-Saharan Africa	HESITANCY	Vaccines are one of the most effective public health strategies to protect against infectious diseases, yet vaccine hesitancy has emerged as a global health threat. Understanding COVID-19 knowledge and attitudes and their association with vaccine intentions can help the targeting of strategies to increase vaccination uptake and achieve herd immunity. The goal of this study was to assess COVID-19 knowledge, attitudes, and behaviors, and identify factors associated with COVID-19 vaccine intentions among heads of households in Manicaland Province, Zimbabwe. A cross-sectional survey was conducted in May 2021 among 551 randomly selected households. Data were collected on socio-demographic characteristics, and knowledge, attitudes, and behaviors regarding COVID-19 and the vaccines. More than half (55.7%) of the respondents reported intending to vaccinate themselves or their households. Multivariate logistic regression indicated that the likelihood of vaccine intentions was most strongly associated with confidence in vaccine safety. Additionally, the odds of intending to get vaccinated were significantly higher among heads of households who were male, had a higher level of education, and identified vaccination and face mask usage as prevention measures. Among perceived motivators to vaccinate, recommendations from the World Health Organization and availability of the vaccine free of charge increased the likelihood of vaccine intentions, while country of vaccine manufacturer posed a barrier to vaccine intentions. As the vaccine rollout in Zimbabwe continues, efforts to increase COVID-19 vaccination coverage and achieve herd immunity should target females and less educated populations and be tailored to address concerns about vaccine safety and country of manufacturer.</p>	[McAbee, Lauren; Kanyangarara, Mufaro] Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA; [Tapera, Oscar] SADTAP Hlth Res Inst, Harare 00263, Zimbabwe		Kanyangarara, M (通讯作者)，Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA.	lgmcabee@email.sc.edu; oscar.tapera@gmail.com; mufaro@mailbox.sc.edu		Kanyangarara, Mufaro/0000-0002-1367-1546; Tapera, Oscar/0000-0001-5916-4745; McAbee, Lauren/0000-0001-7479-5000			Acheampong T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080814; Adamu AA, 2021, EXPERT REV VACCINES, V20, P611, DOI 10.1080/14760584.2021.1899819; [Anonymous], 2021, LANCET, V397, P941, DOI 10.1016/S0140-6736(21)00617-6; [Anonymous], 2019, UN 2019 REV WORLD PO; [Anonymous], 2021, WHO CORONAVIRUS COVI; Chigevenga R., 2021, J BIOMED RES ENV SCI, V2, P174, DOI [10.37871/jbres1206, DOI 10.37871/JBRES1206]; Matos CCDA, 2021, GLOB PUBLIC HEALTH, DOI 10.1080/17441692.2021.1912138; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Dula J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080828; Dzinamarira T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030250; Ekwebelem OC, 2021, PUBLIC HEALTH, V197, pE18, DOI 10.1016/j.puhe.2021.01.010; Garcia LL, 2021, J PUBLIC HEALTH-UK, V43, pE529, DOI 10.1093/pubmed/fdab192; Heidari S., 2021, CRITICAL SEX GENDER; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kriss JL, 2016, PAN AFR MED J, V24, DOI 10.11604/pamj.2016.24.47.8663; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loembe MM, 2021, IMMUNITY, V54, P1353, DOI 10.1016/j.immuni.2021.06.017; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machekanyanga Z, 2017, J RELIG HEALTH, V56, P1683, DOI 10.1007/s10943-017-0428-7; Mavhunga C., 2021, GOVT URGES ZIMBABWEA; Mundagowa P.T., 2021, ASSESSMENT COVID 19, DOI [10.1101/2021.06.24.21259505, DOI 10.1101/2021.06.24.21259505]; Nachega JB, 2021, LANCET GLOB HEALTH, V9, pE746, DOI 10.1016/S2214-109X(21)00097-8; Our World In Data, COVID 19 DAT EXPL; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Seydou A, WHO WANTS COVID 19 V; Tozivepi S.N., 2020, COVID 19 VACCINE HES; UNICEF, 2021, COVID 19 VACC MARK D; Voice of America, ZIMB CHIN ALL SIN CO; Wagner AL, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040155; World Health Organization, 2020, WHO2019NCOVIPCPPEUSE; World Health Organization, WHO VAL SIN COVID 19; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	33	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1109	10.3390/vaccines9101109			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN6DI	34696215	Green Published, gold			2022-04-29	WOS:000711856600001
J	Piltch-Loeb, R; Harriman, NW; Healey, J; Bonetti, M; Toffolutti, V; Testa, MA; Su, MX; Savoia, E				Piltch-Loeb, Rachael; Harriman, Nigel Walsh; Healey, Julia; Bonetti, Marco; Toffolutti, Veronica; Testa, Marcia A.; Su, Max; Savoia, Elena			COVID-19 Vaccine Concerns about Safety, Effectiveness, and Policies in the United States, Canada, Sweden, and Italy among Unvaccinated Individuals	VACCINES			English	Article						vaccine hesitancy; COVID-19; vaccine beliefs		Despite the effectiveness of the COVID-19 vaccine, global vaccination distribution efforts have thus far had varying levels of success. Vaccine hesitancy remains a threat to vaccine uptake. This study has four objectives: (1) describe and compare vaccine hesitancy proportions by country; (2) categorize vaccine-related concerns; (3) rank vaccine-related concerns; and (4) compare vaccine-related concerns by country and hesitancy status in four countries-the United States, Canada, Sweden, and Italy. Using the Pollfish survey platform, we sampled 1000 respondents in Canada, Sweden, and Italy and 750 respondents in the United States between 21-28 May 2021. Results showed vaccine-related concerns varied across three topical areas-vaccine safety and government control, vaccine effectiveness and population control, and freedom. For each thematic area, the top concern was statistically significantly different in each country and among the hesitant and non-hesitant subsamples within each county. Concerns related to freedom were the most universal. Understanding the specific concerns among individuals when it comes to the COVID-19 vaccine can help to inform public communications and identify which, if any, salient narratives are global.	[Piltch-Loeb, Rachael; Testa, Marcia A.; Su, Max; Savoia, Elena] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02120 USA; [Piltch-Loeb, Rachael; Harriman, Nigel Walsh; Healey, Julia; Testa, Marcia A.; Su, Max; Savoia, Elena] Harvard TH Chan Sch Publ Hlth, Emergency Preparedness Res Evaluat & Practice EPR, Div Policy Translat & Leadership Dev, Boston, MA 02120 USA; [Bonetti, Marco] Bocconi Univ, Carlo F Dondena Res Ctr, I-20136 Milan, Italy; [Bonetti, Marco] Bocconi Univ, COVID Crisis Lab, I-20136 Milan, Italy; [Toffolutti, Veronica] Imperial Coll London, Dept Econ & Publ Policy, London SW7 2AZ, England		Piltch-Loeb, R (通讯作者)，Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02120 USA.; Piltch-Loeb, R (通讯作者)，Harvard TH Chan Sch Publ Hlth, Emergency Preparedness Res Evaluat & Practice EPR, Div Policy Translat & Leadership Dev, Boston, MA 02120 USA.	piltch-loeb@hsph.harvard.edu; nharriman@hsph.harvard.edu; uliahealey@hsph.harvard.edu; marco.bonetti@unibocconi.it; v.toffolutti@imperial.ac.uk; testa@hsph.harvard.edu; masu@hsph.harvard.edu; esavoia@hsph.harvard.edu		Bonetti, Marco/0000-0003-2304-4180; Toffolutti, Veronica/0000-0003-3753-3559; Harriman, Nigel/0000-0003-2545-0174	NATO Science for Peace and Security Programme [SPS.MYPG5556]; US Department of Homeland Security (DHS), Science and Technology DirectorateUnited States Department of Homeland Security (DHS) [2015-ST-108-FRG005]; Swedish Contingency Agency (MSB)	This project received funding from the NATO Science for Peace and Security Programme (grant number SPS.MYPG5556), the US Department of Homeland Security (DHS), Science and Technology Directorate (Cooperative Agreement Number: 2015-ST-108-FRG005) and Swedish Contingency Agency (MSB). The content of this manuscript as well as the views and discussions expressed are solely those of the authors and do not necessarily represent the official views of any of the above institutions, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the US government.	Collis H, 2021, POLITICO EUROPE 0316; Dettmer J, 2021, VOA VOICE AM 0322; Giles-Vernick T., 2021, RECOVER RAPID EUROPE; Government of Canada, COR DIS COVID 19; Griffith J, 2021, J MED INTERNET RES, V23, DOI 10.2196/26874; Hamel L., 2021, KFF COVID 19 VACCINE; Horowitz J., 2021, NEW YORK TIMES; Kirzinger A., 2021, KFF COVID 19 VACCINE; Lazarus JV, 2020, J HEALTH COMMUN, V25, P799, DOI 10.1080/10810730.2020.1868630; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; McCulloch C., 2021, VOA VOICE AM 0731; Romer D, 2021, J MED INTERNET RES, V23, DOI 10.2196/25215; Rozek LS, 2021, INT J PUBLIC HEALTH, V66, DOI 10.3389/ijph.2021.636255; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; World Health Organization, 2020, GLOBAL TUBERCULOSIS	15	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1138	10.3390/vaccines9101138			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN3OC	34696245	gold, Green Submitted, Green Published			2022-04-29	WOS:000711680400001
J	Theocharopoulos, C; Lialios, PP; Samarkos, M; Gogas, H; Ziogas, DC				Theocharopoulos, Charalampos; Lialios, Panagiotis-Petros; Samarkos, Michael; Gogas, Helen; Ziogas, Dimitrios C.			Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond	VACCINES			English	Review						antibody-drug conjugates; immunoconjugates; bispecific antibodies; dual-drug ADCs; targeted therapy	IN-VIVO EFFICACY; ANTIBIOTIC CONJUGATE; STAPHYLOCOCCUS-AUREUS; MONOCLONAL-ANTIBODIES; RESISTANCE MECHANISMS; RHEUMATOID-ARTHRITIS; CYTOTOXIC PAYLOADS; ANTITUMOR-ACTIVITY; TARGETED DELIVERY; OPEN-LABEL	In the era of precision medicine, antibody-based therapeutics are rapidly enriched with emerging advances and new proof-of-concept formats. In this context, antibody-drug conjugates (ADCs) have evolved to merge the high selectivity and specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of attached payloads. So far, ten ADCs have been approved by FDA for oncological indications and many others are currently being tested in clinical and preclinical level. This paper summarizes the essential components of ADCs, from their functional principles and structure up to their limitations and resistance mechanisms, focusing on all latest bioengineering breakthroughs such as bispecific mAbs, dual-drug platforms as well as novel linkers and conjugation chemistries. In continuation of our recent review on anticancer implication of ADC's technology, further insights regarding their potential usage outside of the oncological spectrum are also presented. Better understanding of immunoconjugates could maximize their efficacy and optimize their safety, extending their use in everyday clinical practice.	[Theocharopoulos, Charalampos; Lialios, Panagiotis-Petros; Samarkos, Michael; Gogas, Helen; Ziogas, Dimitrios C.] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Sch Med, Dept Med 1, Athens 11527, Greece		Ziogas, DC (通讯作者)，Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Sch Med, Dept Med 1, Athens 11527, Greece.	hartheoch@gmail.com; lialiospeter@gmail.com; msamarkos@gmail.com; helgogas@gmail.com; ziogasdc@gmail.com	Samarkos, Michael/Q-5104-2019	Samarkos, Michael/0000-0001-9630-9712; Ziogas, Dimitrios C./0000-0003-2620-4004; Gogas, Helen/0000-0002-0451-2885			Ackerman ME, 2008, MOL CANCER THER, V7, P2233, DOI 10.1158/1535-7163.MCT-08-0067; Adams GP, 2001, CANCER RES, V61, P4750; Anami Y, 2017, ORG BIOMOL CHEM, V15, P5635, DOI 10.1039/c7ob01027c; Andreev J, 2017, MOL CANCER THER, V16, P681, DOI 10.1158/1535-7163.MCT-16-0658; Andrikopoulou A, 2021, CLIN BREAST CANCER, V21, pE212, DOI 10.1016/j.clbc.2020.08.006; Balendiran GK, 2004, CELL BIOCHEM FUNCT, V22, P343, DOI 10.1002/cbf.1149; Bander NH, 2013, METHODS MOL BIOL, V1045, P29, DOI 10.1007/978-1-62703-541-5_2; Bargh JD, 2021, CHEM COMMUN, V57, P3457, DOI 10.1039/d1cc00957e; Bargh JD, 2019, CHEM SOC REV, V48, P4361, DOI 10.1039/c8cs00676h; Bay AP, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-233; Beck A, 2017, NAT REV DRUG DISCOV, V16, P315, DOI 10.1038/nrd.2016.268; Beerli RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131177; Bethell R., 2020, P AACR ANN M 2020 PH, V80, DOI [10.1158/1538-7445.am2020-2887, DOI 10.1158/1538-7445.AM2020-2887]; Bird M, 2020, METHODS MOL BIOL, V2078, P113, DOI 10.1007/978-1-4939-9929-3_8; Bodyak ND, 2021, MOL CANCER THER, V20, P896, DOI 10.1158/1535-7163.MCT-20-0183; Bogen JP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01892; Brandish PE, 2018, BIOCONJUGATE CHEM, V29, P2357, DOI 10.1021/acs.bioconjchem.8b00312; Brinkmann U, 2017, MABS-AUSTIN, V9, P182, DOI 10.1080/19420862.2016.1268307; Bruhns P, 2009, BLOOD, V113, P3716, DOI 10.1182/blood-2008-09-179754; Bryden F, 2018, ORG BIOMOL CHEM, V16, P1882, DOI 10.1039/c7ob02780j; Burton JK, 2019, AAPS J, V22, DOI 10.1208/s12248-019-0390-2; Bussing D, 2021, AAPS J, V23, DOI 10.1208/s12248-021-00584-y; Buttgereit F, 2021, ANN RHEUM DIS, V80, P64, DOI 10.1136/annrheumdis-2021-eular.221; Cai H, 2020, DRUG METAB DISPOS, V48, P1161, DOI 10.1124/dmd.120.000092; Caimi PF, 2021, LANCET ONCOL, V22, P790, DOI 10.1016/S1470-2045(21)00139-X; Chen R, 2020, CLIN CANCER RES, V26, P1034, DOI 10.1158/1078-0432.CCR-19-1768; Chen R, 2015, MOL CANCER THER, V14, P1376, DOI 10.1158/1535-7163.MCT-15-0036; Chung SW, 2018, ADV SCI, V5, DOI 10.1002/advs.201800368; Cilliers C, 2016, AAPS J, V18, P1117, DOI 10.1208/s12248-016-9940-z; Collins DM, 2019, CANCERS, V11, DOI 10.3390/cancers11030394; Comer F, 2018, CANCER DRUG DISCOV D, P267, DOI 10.1007/978-3-319-78154-9_11; Conilh L, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14030247; Czechowicz A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08201-x; Dahlgren D, 2020, MOLECULES, V25, DOI 10.3390/molecules25122861; Dan N, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11020032; de Goeij BECG, 2016, MOL CANCER THER, V15, P2688, DOI 10.1158/1535-7163.MCT-16-0364; de Taeye SW, 2019, ANTIBODIES, V8, DOI 10.3390/antib8020030; Deng CC, 2013, CLIN CANCER RES, V19, P22, DOI 10.1158/1078-0432.CCR-12-0290; Dennler P, 2014, BIOCONJUGATE CHEM, V25, P569, DOI 10.1021/bc400574z; Doronina SO, 2006, BIOCONJUGATE CHEM, V17, P114, DOI 10.1021/bc0502917; Dovgan I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64518-y; Drago JZ, 2021, NAT REV CLIN ONCOL, V18, P327, DOI 10.1038/s41571-021-00470-8; Drake PM, 2014, BIOCONJUGATE CHEM, V25, P1331, DOI 10.1021/bc500189z; Ducry L, 2010, BIOCONJUGATE CHEM, V21, P5, DOI 10.1021/bc9002019; Duvall J.R., 2019, P AACR ANN M 2019 AT, V79, DOI [10.1158/1538-7445.am2019-232, DOI 10.1158/1538-7445.AM2019-232]; Ellestad GA, 2011, CHIRALITY, V23, P660, DOI 10.1002/chir.20990; Erickson HK, 2010, BIOCONJUGATE CHEM, V21, P84, DOI 10.1021/bc900315y; Everts M, 2002, J IMMUNOL, V168, P883, DOI 10.4049/jimmunol.168.2.883; Fernandez-Codina A, 2021, ANN RHEUM DIS, V80, P103, DOI 10.1136/annrheumdis-2021-eular.2115; Garcia-Alonso S, 2018, CANCER RES, V78, P2159, DOI 10.1158/0008-5472.CAN-17-3671; Gebleux R, 2017, INT J CANCER, V140, P1670, DOI 10.1002/ijc.30569; Goldmacher VS, 2011, THER DELIV, V2, P397, DOI 10.4155/TDE.10.98; Graversen JH, 2012, MOL THER, V20, P1550, DOI 10.1038/mt.2012.103; Hamblett KJ, 2015, CANCER RES, V75, P5329, DOI 10.1158/0008-5472.CAN-15-1610; Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641; Harper J., 2016, SELECTING OPTIMAL AN, P33; Hartley JA, 2004, CANCER RES, V64, P6693, DOI 10.1158/0008-5472.CAN-03-2941; Hartley JA, 2011, EXPERT OPIN INV DRUG, V20, P733, DOI 10.1517/13543784.2011.573477; Hochberg J, 2019, RESIST TARGET ANTI-C, V21, P57, DOI 10.1007/978-3-030-24424-8_3; Hoffmann RM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1395127; Huang J, 2020, ADV SCI, V7, DOI 10.1002/advs.202002852; Ibtehaj N, 2017, CLIN IMMUNOL, V176, P122, DOI 10.1016/j.clim.2017.01.005; Jeffrey SC, 2006, BIOCONJUGATE CHEM, V17, P831, DOI 10.1021/bc0600214; Jeger S, 2010, ANGEW CHEM INT EDIT, V49, P9995, DOI 10.1002/anie.201004243; Junutula JR, 2008, NAT BIOTECHNOL, V26, P925, DOI 10.1038/nbt.1480; Kern JC, 2016, BIOCONJUGATE CHEM, V27, P2081, DOI 10.1021/acs.bioconjchem.6b00337; Kern JC, 2016, J AM CHEM SOC, V138, P1430, DOI 10.1021/jacs.5b12547; Khera E, 2021, NEOPLASIA, V23, P210, DOI 10.1016/j.neo.2020.12.001; Khera E, 2018, MOL SYST DES ENG, V3, P73, DOI 10.1039/c7me00093f; Koganemaru S, 2021, EXPERT OPIN BIOL TH, V21, P923, DOI 10.1080/14712598.2020.1802423; Kolodych S, 2017, EUR J MED CHEM, V142, P376, DOI 10.1016/j.ejmech.2017.08.008; Kovtun YV, 2007, CANCER LETT, V255, P232, DOI 10.1016/j.canlet.2007.04.010; Kumar A, 2018, BIOORG MED CHEM LETT, V28, P3617, DOI 10.1016/j.bmcl.2018.10.043; Lazzerini L, 2020, ARCH GYNECOL OBSTET, V302, P1255, DOI 10.1007/s00404-020-05734-9; Lee H, 2017, BIOCONJUGATE CHEM, V28, P1084, DOI 10.1021/acs.bioconjchem.7b00008; Lehar SM, 2015, NATURE, V527, P323, DOI 10.1038/nature16057; Levengood MR, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-982; Levengood MR, 2017, ANGEW CHEM INT EDIT, V56, P733, DOI 10.1002/anie.201608292; Li F, 2016, CANCER RES, V76, P2710, DOI 10.1158/0008-5472.CAN-15-1795; Li GM, 2018, MOL CANCER THER, V17, P1441, DOI 10.1158/1535-7163.MCT-17-0296; Li JG, 2021, BIOORG CHEM, V111, DOI 10.1016/j.bioorg.2020.104475; Li JY, 2019, CANCER CELL, V35, P948, DOI 10.1016/j.ccell.2019.05.010; Lim RKV, 2015, BIOCONJUGATE CHEM, V26, P2216, DOI 10.1021/acs.bioconjchem.5b00203; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Loganzo F, 2015, MOL CANCER THER, V14, P952, DOI 10.1158/1535-7163.MCT-14-0862; Ma Y, 2016, DRUG METAB DISPOS, V44, P1958, DOI 10.1124/dmd.116.073031; MAIESE WM, 1989, J ANTIBIOT, V42, P558, DOI 10.7164/antibiotics.42.558; Maimaitili Y, 2018, LEUKEMIA RES, V74, P68, DOI 10.1016/j.leukres.2018.09.017; Maruani Antoine, 2018, Drug Discov Today Technol, V30, P55, DOI 10.1016/j.ddtec.2018.09.003; McCombs JR, 2015, AAPS J, V17, P339, DOI 10.1208/s12248-014-9710-8; Mehta G, 2015, J IMMUNOL, V194, P5446, DOI 10.4049/jimmunol.1403012; Merkul E, 2019, EXPERT OPIN DRUG DEL, V16, P783, DOI 10.1080/17425247.2019.1645118; Moller LNO, 2015, ANN MED SURG, V4, P331, DOI 10.1016/j.amsu.2015.09.001; Muchekehu R, 2013, TRANSL ONCOL, V6, P562, DOI 10.1593/tlo.13409; Nagai T, 2006, ARTHRITIS RHEUM-US, V54, P3126, DOI 10.1002/art.22082; Nilchan Napon, 2019, Antib Ther, V2, P71, DOI 10.1093/abt/tbz009; Nolting B, 2013, METHODS MOL BIOL, V1045, P71, DOI 10.1007/978-1-62703-541-5_5; Ogitani Y, 2016, CANCER SCI, V107, P1039, DOI 10.1111/cas.12966; Pak Y, 2012, CANCER RES, V72, P3143, DOI 10.1158/0008-5472.CAN-11-3925; Palchaudhuri R, 2016, NAT BIOTECHNOL, V34, P738, DOI 10.1038/nbt.3584; Peck M, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.02588-18, 10.1128/aac.02588-18]; Pegram MD, 2021, MOL CANCER THER, V20, P1442, DOI 10.1158/1535-7163.MCT-20-0014; Perrino E, 2014, CANCER RES, V74, P2569, DOI 10.1158/0008-5472.CAN-13-2990; Peters C, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150089; Polson AG, 2009, CANCER RES, V69, P2358, DOI 10.1158/0008-5472.CAN-08-2250; Rios-Luci C, 2017, CANCER RES, V77, P4639, DOI 10.1158/0008-5472.CAN-16-3127; Ritchie M, 2015, AAPS ADV PHARM SCI, V17, P23, DOI 10.1007/978-3-319-13081-1_3; Rosellini M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041551; Rosen DB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053518; Rossin R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03880-y; Rudnick SI, 2009, CANCER BIOTHER RADIO, V24, P155, DOI 10.1089/cbr.2009.0627; Saatci O, 2018, ONCOGENE, V37, P2251, DOI 10.1038/s41388-017-0108-9; Sharma S, 2020, DRUG METAB DISPOS, V48, P368, DOI 10.1124/dmd.119.089276; Singh AP, 2020, J PHARMACOL EXP THER, V374, P184, DOI 10.1124/jpet.119.262287; Singh AP, 2020, AAPS J, V22, DOI 10.1208/s12248-019-0387-x; Singh AP, 2016, J PHARMACOKINET PHAR, V43, P567, DOI 10.1007/s10928-016-9495-8; Spangler B, 2018, MOL PHARMACEUT, V15, P2054, DOI 10.1021/acs.molpharmaceut.8b00242; Staudacher AH, 2017, BRIT J CANCER, V117, P1736, DOI 10.1038/bjc.2017.367; Stewart R, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425-014-0029-x; Stoffel B, 2021, ANN RHEUM DIS, V80, P412, DOI 10.1136/annrheumdis-2021-eular.2213; Strop P, 2013, CHEM BIOL, V20, P161, DOI 10.1016/j.chembiol.2013.01.010; Sugo T, 2016, J CONTROL RELEASE, V237, P1, DOI 10.1016/j.jconrel.2016.06.036; Svendsen P, 2017, MOL THER-METH CLIN D, V4, P50, DOI 10.1016/j.omtm.2016.11.004; Tang F, 2019, METHODS MOL BIOL, V2033, P221, DOI 10.1007/978-1-4939-9654-4_15; Theocharopoulos C, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920962997; Tian F, 2014, P NATL ACAD SCI USA, V111, P1766, DOI 10.1073/pnas.1321237111; Trudeau KM, 2016, J CELL BIOL, V214, P25, DOI 10.1083/jcb.201511042; Tsuchikama K, 2018, PROTEIN CELL, V9, P33, DOI 10.1007/s13238-016-0323-0; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Vollmar BS, 2021, MOL CANCER THER, V20, P1112, DOI 10.1158/1535-7163.MCT-20-0035; Waight AB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160890; Waldmann H, 2019, METHODS MOL BIOL, V1904, P1, DOI 10.1007/978-1-4939-8958-4_1; Walter RB, 2004, BLOOD, V103, P4276, DOI 10.1182/blood-2003-11-3825; Wang HB, 2017, CANCER SCI, V108, P1458, DOI 10.1111/cas.13253; Wang L, 2018, CANCER SCI, V109, P3305, DOI 10.1111/cas.13761; Wang Q, 2019, ANTIBODIES, V8, DOI 10.3390/antib8030043; Wang RSE, 2015, J AM CHEM SOC, V137, P3229, DOI 10.1021/jacs.5b00620; Yamazaki CM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23793-7; Yasunaga M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11255-4; Yu JF, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00876-4; Yu S, 2016, MOL THER, V24, P2078, DOI 10.1038/mt.2016.175; Yurkovetskiy AV, 2021, MOL CANCER THER, V20, P885, DOI 10.1158/1535-7163.MCT-20-0166; Zhang YJ, 2008, CLIN CANCER RES, V14, P7981, DOI 10.1158/1078-0432.CCR-08-0324; Zhou CG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224096; Zhou CG, 2016, MABS-AUSTIN, V8, P1612, DOI 10.1080/19420862.2016.1229722; Zhou Q, 2014, BIOCONJUGATE CHEM, V25, P510, DOI 10.1021/bc400505q; Zimmerman ES, 2014, BIOCONJUGATE CHEM, V25, P351, DOI 10.1021/bc400490z	147	2	2	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1111	10.3390/vaccines9101111			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ0KV	34696218	Green Published, gold			2022-04-29	WOS:000713512800001
J	Tong, KK; He, M; Wu, AMS; Dang, L; Chen, JH				Tong, Kwok Kit; He, Mu; Wu, Anise M. S.; Dang, Le; Chen, Juliet Honglei			Cognitive Factors Influencing COVID-19 Vaccination Intentions: An Application of the Protection Motivation Theory Using a Probability Community Sample	VACCINES			English	Article						COVID-19; protection motivation theory; intention; vaccine efficacy; vaccine acceptance	SELF-EFFICACY; METAANALYSIS; HESITANCY; BEHAVIOR	COVID-19 vaccines have been shown to provide protection against severe disease and death. However, substantial individual differences in vaccination intentions have hindered achieving optimal vaccination rates across the population. To look for efficient strategies to promote vaccination, this study tested whether the protection motivation theory (PMT), a cognitive model based upon threat and coping appraisals, would account for the differences in vaccination intentions under three scenarios (i.e., in the context of getting vaccinated in general, and in the context of high- and low- efficacy for reducing COVID-19 transmission risk). A phone survey was conducted in early 2021 and obtained a probability community sample (n = 472; 49.2% men) in Macao, China. We found that 54.0% of respondents indicated their relatively strong intention to receive COVID-19 vaccination for high-efficacy vaccines, compared to 29.5% for low-efficacy vaccines and 31.0% for vaccines in general. After adjusting for demographics, self-efficacy (i.e., the perceived capability of receiving COVID-19 vaccines) and maladaptive response reward (i.e., the perceived benefits of not receiving COVID-19 vaccines) were consistently associated with COVID-19 vaccination intentions under all three scenarios. The perceived severity of COVID-19 infection and response cost (i.e., the perceived costs of receiving COVID-19 vaccines) were significantly associated with vaccination intention for high-efficacy vaccines, while the response efficacy of lowering the COVID-19 impact with COVID-19 vaccination was positively associated with vaccination intention for general and low-efficacy vaccines. Given that the relative strength of PMT constructs depends on perceived vaccine efficacy, we recommend taking PMT constructs and vaccine efficacy into account for encouraging vaccination.	[Tong, Kwok Kit; He, Mu; Wu, Anise M. S.; Dang, Le; Chen, Juliet Honglei] Univ Macau, Fac Social Sci, Dept Psychol, Macau, Peoples R China; [Wu, Anise M. S.; Dang, Le; Chen, Juliet Honglei] Univ Macau, Ctr Cognit & Brain Sci, Inst Collaborat Innovat, Macau, Peoples R China; [Dang, Le] Pingdingshan Univ, Fac Teacher Educ, Pingdingshan 467000, Peoples R China		Chen, JH (通讯作者)，Univ Macau, Fac Social Sci, Dept Psychol, Macau, Peoples R China.; Chen, JH (通讯作者)，Univ Macau, Ctr Cognit & Brain Sci, Inst Collaborat Innovat, Macau, Peoples R China.	kktong@um.edu.mo; yc07309@um.edu.mo; anisewu@um.edu.mo; yb97304@um.edu.mo; JulietChen@um.edu.mo	Tong, Kwok Kit/J-3253-2019	Tong, Kwok Kit/0000-0001-8594-9300; Wu, Anise M.S./0000-0001-8174-6581; Chen, Juliet Honglei/0000-0002-6564-5390	University of Macau [MYRG2019-00125-FSS]	FundingThis research was funded by the University of Macau, grant number MYRG2019-00125-FSS.	Al-Amer R, 2022, J CLIN NURS, V31, P62, DOI 10.1111/jocn.15951; Alvarado-Socarras JL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030287; American Association for Public Opinion Research, 2016, STAND DEF FIN DISP C; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Camerini AL, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.11.005; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd ed; Dyer O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2282; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Floyd DL, 2000, J APPL SOC PSYCHOL, V30, P407, DOI 10.1111/j.1559-1816.2000.tb02323.x; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Hoeppner BB, 2011, J SUBST ABUSE TREAT, V41, P305, DOI 10.1016/j.jsat.2011.04.005; Hotez P, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100780; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lavrakas PJ, 2008, ENCY SURVEY RES METH, P417, DOI DOI 10.4135/9781412963947.N267; Li L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050445; Ling M, 2019, SOC SCI MED, V233, P87, DOI 10.1016/j.socscimed.2019.06.002; Liu C, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09292-2; Mak DB, 2010, MED J AUSTRALIA, V193, P401, DOI 10.5694/j.1326-5377.2010.tb03969.x; McClendon BT, 2002, HLTH ED, V102, P76, DOI [DOI 10.1108/09654280210419009, 10.1108/09654280210419009]; McNeill A, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00026; Milne S, 2000, J APPL SOC PSYCHOL, V30, P106, DOI 10.1111/j.1559-1816.2000.tb02308.x; Nicoll A, 2013, LANCET INFECT DIS, V13, P7, DOI 10.1016/S1473-3099(12)70313-4; Ong G, 2005, J INFECTION, V51, P294, DOI 10.1016/j.jinf.2004.10.001; RIPPETOE PA, 1987, J PERS SOC PSYCHOL, V52, P596, DOI 10.1037/0022-3514.52.3.596; Rogers R.W., 1983, SOCIAL PSYCHOPHYSIOL, P153; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; SAGE Working Group, DEAL VACC HES REP SA; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schulz PJ, 2021, HEALTH COMMUN, V36, P1505, DOI 10.1080/10410236.2020.1771119; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Skegg D, 2021, LANCET, V397, P777, DOI 10.1016/S0140-6736(21)00424-4; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Tong KK, 2020, APPL PSYCHOL-HLTH WE, V12, P1205, DOI 10.1111/aphw.12230; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380; WHO, WHO COR COVID 19 DAS; WHO, COVID 19 ADV PUBL GE; Witte K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506; World Health Organization, COR DIS COVID 19 VAC; World Health Organization [WHO], VACC EFF EFF PROT; Wu AMS, 2020, J INFECT PUBLIC HEAL, V13, P970, DOI 10.1016/j.jiph.2020.04.009	46	1	1	19	20	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1170	10.3390/vaccines9101170			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI8XI	34696278	Green Published, gold			2022-04-29	WOS:000726386600001
J	Wang, ZW; Ran, L; Chen, CX; Shi, RR; Dong, Y; Li, YB; Zhou, XM; Qi, YM; Zhu, PP; Gao, YF; Wu, YH				Wang, Zhiwei; Ran, Ling; Chen, Chunxia; Shi, Ranran; Dong, Yu; Li, Yubing; Zhou, Xiuman; Qi, Yuanming; Zhu, Pingping; Gao, Yanfeng; Wu, Yahong			Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma	VACCINES			English	Article						esophageal squamous cell carcinoma; cytotoxic T lymphocytes; mutant peptide; neoantigen; immunotherapy	T-CELLS; CANCER; BLOCKADE; IMMUNOTHERAPY; MELANOMA; VACCINES; IMMUNITY; PEPTIDE; BURDEN	Esophageal squamous cell carcinoma (ESCC), one of the deadliest gastrointestinal cancers, has had limited effective therapeutic strategies up to now. Accumulating evidence suggests that effective immunotherapy in cancer patients has been associated with T cells responsive to mutant peptides derived from neoantigens. Here, we selected 35 human leukocyte antigen-A2 (HLA-A2)-restricted mutant (MUT) peptides stemmed from neoantigens of ESCC. Among them, seven mutant peptides had potent binding affinity to HLA-A*0201 molecules and could form a stable peptide/HLA-A*0201 complex. Three mutant peptides (TP53-R267P, NFE2L2-D13N, and PCLO-E4090Q) of those were immunogenic and could induce the cytotoxic T lymphocytes (CTLs) recognizing mutant peptides presented on transfected cells in an HLA-A2-restricted and MUT peptide-specific manner. In addition, the CTL response in immunized HLA-A2.1/K-b transgenic (Tg) mice was enhanced by coupling MUT peptides to peptide WH, a peptide delivery carrier targeting Clec9a(+) DCs. Then, the possible binding model conversions between the WT and MUT candidate peptides were analyzed by docking with the pockets of HLA-A*0201 molecule. We therefore propose a novel strategy and epitopes for immunotherapy of ESCC based on neoantigens.</p>	[Wang, Zhiwei; Ran, Ling; Chen, Chunxia; Shi, Ranran; Dong, Yu; Li, Yubing; Zhou, Xiuman; Qi, Yuanming; Zhu, Pingping; Wu, Yahong] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Peoples R China; [Qi, Yuanming; Wu, Yahong] Zhengzhou Univ, Int Joint Lab Prot & Peptide Drugs Henan Prov, Zhengzhou 450001, Peoples R China; [Zhu, Pingping] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent Treatment, Zhengzhou 450052, Peoples R China; [Gao, Yanfeng] Sch Pharmaceut Sci Shenzhen, Sun Yat Sen Univ, Shenzhen 510080, Peoples R China		Wu, YH (通讯作者)，Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Peoples R China.; Wu, YH (通讯作者)，Zhengzhou Univ, Int Joint Lab Prot & Peptide Drugs Henan Prov, Zhengzhou 450001, Peoples R China.; Gao, YF (通讯作者)，Sch Pharmaceut Sci Shenzhen, Sun Yat Sen Univ, Shenzhen 510080, Peoples R China.	202011161010131@gs.zzu.edu.cn; 18039215962@163.com; chunxiachen@gs.zzu.edu.cn; srr@gs.zzu.edu.cn; 16637144372@163.com; liyubing7788@gs.zzu.edu.cn; zhouxm36@mail.sysu.edu.cn; qym@zzu.edu.cn; zhup@zzu.edu.cn; gaoyf29@mail.sysu.edu.cn; yahongwu@zzu.edu.cn		Zhou, Xiuman/0000-0002-5938-450X; yahong, Wu/0000-0001-6381-611X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81822043, 81601448, U20A20369]	This work was supported by the National Natural Science Foundation of China (81822043, 81601448, U20A20369).	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cafri G, 2020, J CLIN INVEST, V130, P5976, DOI 10.1172/JCI134915; Chen WQ, 2019, LANCET GLOB HEALTH, V7, pE257, DOI 10.1016/S2214-109X(18)30488-1; Chen Y, 2017, CLIN CANCER RES, V23, P6178, DOI 10.1158/1078-0432.CCR-17-1185; Ciemny M, 2018, DRUG DISCOV TODAY, V23, P1530, DOI 10.1016/j.drudis.2018.05.006; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Dotto GP, 2016, CANCER CELL, V29, P622, DOI 10.1016/j.ccell.2016.04.004; Filby A, 2015, METHODS, V82, P29, DOI 10.1016/j.ymeth.2015.02.016; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Hoos A, 2016, NAT REV DRUG DISCOV, V15, P235, DOI 10.1038/nrd.2015.35; Ito H, 2015, IMMUNOLOGY, V144, P621, DOI 10.1111/imm.12413; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Kuai R, 2017, NAT MATER, V16, P489, DOI [10.1038/NMAT4822, 10.1038/nmat4822]; Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Lu YC, 2014, CLIN CANCER RES, V20, P3401, DOI 10.1158/1078-0432.CCR-14-0433; Mennonna D, 2017, GUT, V66, P454, DOI 10.1136/gutjnl-2015-309453; Nakagawa Y, 2011, BIOMED RES-TOKYO, V32, P159, DOI 10.2220/biomedres.32.159; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Plebanski M, 1999, NAT MED, V5, P565, DOI 10.1038/8444; Prickett TD, 2016, CANCER IMMUNOL RES, V4, P669, DOI 10.1158/2326-6066.CIR-15-0215; Restifo NP, 2016, NAT REV CANCER, V16, P121, DOI 10.1038/nrc.2016.2; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sancho D, 2008, J CLIN INVEST, V118, P2098, DOI 10.1172/JCI34584; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shi RR, 2022, SCI CHINA LIFE SCI, V65, P572, DOI 10.1007/s11427-021-1944-5; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; van Rossum PSN, 2018, NAT REV GASTRO HEPAT, V15, P235, DOI 10.1038/nrgastro.2017.162; Wu YH, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2942679; Xie XL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0420-5; Xu ZH, 2013, J CONTROL RELEASE, V172, P259, DOI 10.1016/j.jconrel.2013.08.021; Yan ZY, 2016, ONCOTARGET, V7, P40437, DOI 10.18632/oncotarget.9624; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zeng BJ, 2018, J CLIN INVEST, V128, P1971, DOI 10.1172/JCI96791; Zhang L, 2015, AM J HUM GENET, V96, P597, DOI 10.1016/j.ajhg.2015.02.017; Zhu B, 2003, CLIN CANCER RES, V9, P1850	44	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1118	10.3390/vaccines9101118			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN9AU	34696226	Green Published, gold			2022-04-29	WOS:000712059000001
J	Huang, PC; Hung, CH; Kuo, YJ; Chen, YP; Ahorsu, DK; Yen, CF; Lin, CY; Griffiths, MD; Pakpour, AH				Huang, Po-Ching; Hung, Ching-Hsia; Kuo, Yi-Jie; Chen, Yu-Pin; Ahorsu, Daniel Kwasi; Yen, Cheng-Fang; Lin, Chung-Ying; Griffiths, Mark D.; Pakpour, Amir H.			Expanding Protection Motivation Theory to Explain Willingness of COVID-19 Vaccination Uptake among Taiwanese University Students	VACCINES			English	Article						coping appraisal; COVID-19 vaccination; intention; perceived knowledge; protection motivation theory; vaccine hesitancy	FEAR APPEALS; INTENTION	Vaccination appears to be one of the effective strategies to control the COVID-19 pandemic. However, the challenge of vaccine hesitancy may lower the uptake rate and affect overall vaccine efficacy. Being a low-risk group in terms of serious consequences of infection, university students may possess low motivation to get vaccinated. Therefore, an expanded Protection Motivation Theory (PMT) incorporating perceived knowledge, adaptive response, and maladaptive response was proposed to investigate the COVID-19 vaccination intention among Taiwanese university students. University students (n = 924; 575 males; mean age = 25.29 years) completed an online survey during January to February 2021. The proposed expanded PMT model was examined using structural equation modeling (SEM). The results showed that perceived knowledge was significantly associated with coping appraisal (standardized coefficient (beta) = 0.820; p < 0.001), and coping appraisal was significantly associated with adaptive response (beta = 0.852; p < 0.001), maladaptive response (beta = 0.300; p < 0.001) and intention (beta = 0.533; p = 0.009). Moreover, maladaptive response (beta = -0.173; p = 0.001) but not adaptive response (beta = 0.148; p = 0.482) was significantly and negatively associated with intention. The present study's results demonstrated a positive path between perceived knowledge, coping appraisal, and intention among university students. Therefore, improving knowledge among this population may increase the intention to uptake the vaccine.	[Huang, Po-Ching; Hung, Ching-Hsia; Lin, Chung-Ying] Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan 701401, Taiwan; [Hung, Ching-Hsia] Natl Cheng Kung Univ, Coll Med, Dept Phys Therapy, Tainan 701401, Taiwan; [Kuo, Yi-Jie; Chen, Yu-Pin] Taipei Med Univ, Wan Fang Hosp, Dept Orthoped Surg, Taipei 116081, Taiwan; [Kuo, Yi-Jie; Chen, Yu-Pin] Taipei Med Univ, Coll Med, Sch Med, Dept Orthoped Surg, Taipei 106339, Taiwan; [Ahorsu, Daniel Kwasi] Hong Kong Polytech Univ, Dept Rehabil Sci, Hung Hom, Hong Kong, Peoples R China; [Yen, Cheng-Fang] Kaohsiung Med Univ, Sch Med, Coll Med, Dept Psychiat, Kaohsiung 807377, Taiwan; [Yen, Cheng-Fang] Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 807377, Taiwan; [Yen, Cheng-Fang] Natl Pingtung Univ Sci & Technol, Coll Profess Studies, Pingtung 91201, Taiwan; [Lin, Chung-Ying] Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan 701401, Taiwan; [Lin, Chung-Ying] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Publ Hlth, Tainan 701401, Taiwan; [Griffiths, Mark D.] Nottingham Trent Univ, Psychol Dept, Int Gaming Res Unit, Nottingham NG1 4FQ, England; [Pakpour, Amir H.] Qazvin Univ Med Sci, Social Determinants Hlth Res Ctr, Res Inst Prevent Noncommunicable Dis, Qazvin 3419759811, Iran; [Pakpour, Amir H.] Jonkoping Univ, Sch Hlth & Welf, Dept Nursing, SE-55111 Jonkoping, Sweden		Lin, CY (通讯作者)，Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan 701401, Taiwan.; Yen, CF (通讯作者)，Kaohsiung Med Univ, Sch Med, Coll Med, Dept Psychiat, Kaohsiung 807377, Taiwan.; Yen, CF (通讯作者)，Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 807377, Taiwan.; Yen, CF (通讯作者)，Natl Pingtung Univ Sci & Technol, Coll Profess Studies, Pingtung 91201, Taiwan.; Lin, CY (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan 701401, Taiwan.; Lin, CY (通讯作者)，Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Publ Hlth, Tainan 701401, Taiwan.	hh780705@hotmail.com; chhung@mail.ncku.edu.tw; benkuo5@tmu.edu.tw; 99231@w.tmu.edu.tw; daniel.ahorsu@connect.polyu.hk; chfaye@kmu.edu.tw; cylin36933@gmail.com; mark.griffiths@ntu.ac.uk; apakpour@qums.ac.ir	Ahorsu, Daniel Kwasi/AAE-3760-2020; Pakpour, Amir H./C-6160-2014; Lin, Chung-Ying/I-5434-2016; Huang, Po-Ching/ABA-2896-2021	Ahorsu, Daniel Kwasi/0000-0003-0530-8138; Pakpour, Amir H./0000-0002-8798-5345; Lin, Chung-Ying/0000-0002-2129-4242; Yen, Cheng-Fang/0000-0003-1156-4939; Griffiths, Mark/0000-0001-8880-6524; Chen, Yu-Pin/0000-0002-9729-6375	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST109-2327-B-006-005, 110-swf-01]	This study was supported in part by a research grant from the Ministry of Science and Technology, Taiwan (MOST109-2327-B-006-005) and in part by a research grant from the Taipei MunicipalWanfang Hospital Cross-Institutions Fund (110-swf-01).	Al-Hasan A, 2020, J MED INTERNET RES, V22, DOI 10.2196/23019; Bashirian S, 2020, J HOSP INFECT, V105, P430, DOI 10.1016/j.jhin.2020.04.035; Biasio LR, 2021, HUM VACC IMMUNOTHER, V17, P1304, DOI 10.1080/21645515.2020.1829315; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bubar KM, 2021, SCIENCE, V371, P916, DOI 10.1126/science.abe6959; Cameron KA, 2009, PATIENT EDUC COUNS, V74, P309, DOI 10.1016/j.pec.2008.12.003; Carlos W Graham, 2020, Am J Respir Crit Care Med, V202, pP15, DOI 10.1164/rccm.2025P15; Chang KC, 2020, J FORMOS MED ASSOC, V119, P1772, DOI 10.1016/j.jfma.2020.07.032; Cheng Y., 2020, SOCIAL HLTH BEHAV, V3, P72, DOI [10.4103/shb.Shb_18_20, DOI 10.4103/SHB.SHB_18_20]; DiBonaventura MD, 2005, PSYCHOL HEALTH, V20, P761, DOI 10.1080/14768320500183368; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Elhadi M, 2020, PAN AFR MED J, V35, DOI 10.11604/pamj.supp.2020.35.2.23586; Eppright David R, 2002, Health Mark Q, V20, P51; Felten-Barentsz KM, 2020, PHYS THER, V100, P1444, DOI 10.1093/ptj/pzaa114; Frydenberg E, 2009, PSYCHOL REP, V104, P745, DOI 10.2466/PR0.104.3.745-758; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Kok G, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-174; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kukreti S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030246; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Landau S., 2003, HDB STAT ANAL USING; Levin AT, 2020, EUR J EPIDEMIOL, V35, P1123, DOI 10.1007/s10654-020-00698-1; Li JB, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09695-1; Li L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050445; Lin CY, 2021, NURS OPEN, V8, P1892, DOI 10.1002/nop2.855; Ling M, 2019, SOC SCI MED, V233, P87, DOI 10.1016/j.socscimed.2019.06.002; MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9; Murray CJL, 2021, JAMA-J AM MED ASSOC, V325, P1249, DOI 10.1001/jama.2021.2828; Nguyen KH, 2021, AM J TRANSPLANT, V21, P1650, DOI 10.1111/ajt.16560; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Plotnikoff RC, 2010, EXERC SPORT SCI REV, V38, P91, DOI 10.1097/JES.0b013e3181d49612; Rad RE, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10500-w; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; RIPPETOE PA, 1987, J PERS SOC PSYCHOL, V52, P596, DOI 10.1037/0022-3514.52.3.596; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; Rosseel Y, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i02; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Shrotri M, 2021, LANCET GLOB HEALTH, V9, pE590, DOI 10.1016/S2214-109X(21)00043-7; Tan G, 2011, CLIN J PAIN, V27, P769, DOI 10.1097/AJP.0b013e31821d8f5a; Teasdale E, 2012, BRIT J HEALTH PSYCH, V17, P44, DOI 10.1111/j.2044-8287.2011.02017.x; Thomas P, 2020, J PHYSIOTHER, V66, P73, DOI 10.1016/j.jphys.2020.03.011; Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380	45	9	9	15	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1046	10.3390/vaccines9091046			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ2SX	34579283	Green Published, Green Accepted, gold			2022-04-29	WOS:000702061200001
J	Perego, G; Vigezzi, GP; Cocciolo, G; Chiappa, F; Salvati, S; Balzarini, F; Odone, A; Signorelli, C; Gianfredi, V				Perego, Giulia; Vigezzi, Giacomo Pietro; Cocciolo, Giulia; Chiappa, Federica; Salvati, Stefano; Balzarini, Federica; Odone, Anna; Signorelli, Carlo; Gianfredi, Vincenza			Safety and Efficacy of Spray Intranasal Live Attenuated Influenza Vaccine: Systematic Review and Meta-Analysis	VACCINES			English	Review						intranasal live attenuated influenza vaccine; inactivated influenza vaccine; adult; infant; immunogenicity; immune response; antibody response; safety	DOUBLE-BLIND; CANDIDATE VACCINE; VIRUS VACCINE; CHILDREN; ADULTS; TRIVALENT; IMMUNOGENICITY; H1N1; MORTALITY; RESPONSES	Although influenza is a major public health concern, little is known about the use of spray live attenuated influenza vaccine (LAIV) among adults. For this reason, we conducted a systematic review and meta-analysis to investigate the efficacy and safety of LAIV, especially in adults with/without clinical conditions and children <2 years, with the final aim of possibly extending the clinical indications. PubMed/MEDLINE and Scopus were the two databases consulted through February 2021. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. A critical appraisal was conducted. Analyses were performed by using ProMeta3 software. Twenty-two studies were included, showing that LAIV was associated with a higher probability of seroconversion when compared with a placebo and considering the A/H1N1 serotype (pooled OR = 2.26 (95% CI = 1.12-4.54), p-value = 0.022; based on 488 participants, without heterogeneity (I2 = 0.0%)). The meta-analysis also confirmed no significant association with systemic adverse events. Only rhinorrhea, nasal congestion, and sore throat were significantly associated with LAIV compared to the placebo. Despite limited available evidence, LAIV has proved to be a safe and effective flu vaccination, also due to its very low invasiveness, and our review's results can be considered a starting point for guiding future research and shaping forthcoming vaccination campaigns.	[Perego, Giulia; Vigezzi, Giacomo Pietro; Cocciolo, Giulia; Chiappa, Federica; Salvati, Stefano; Signorelli, Carlo; Gianfredi, Vincenza] Univ Vita Salute San Raffaele, Sch Med, Via Olgettina 58, I-20132 Milan, Italy; [Balzarini, Federica] Agenzia Tutela Salute ATS Bergamo, Serv Autorizzaz & Accreditamento, Dipartimento Programmaz Accreditamento Acquisto P, Via Galliccioli 4, I-24121 Bergamo, Italy; [Odone, Anna] Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy; [Gianfredi, Vincenza] Maastricht Univ, CAPHRI Care & Publ Hlth Res Inst, NL-6200 MD Maastricht, Netherlands		Gianfredi, V (通讯作者)，Univ Vita Salute San Raffaele, Sch Med, Via Olgettina 58, I-20132 Milan, Italy.; Gianfredi, V (通讯作者)，Maastricht Univ, CAPHRI Care & Publ Hlth Res Inst, NL-6200 MD Maastricht, Netherlands.	perego.giulia@hsr.it; vigezzi.giacomopietro@hsr.it; cocciolo.giulia@hsr.it; chiappa.federica@hsr.it; salvati.stefano@hsr.it; federica.balzarini@ats-bg.it; anna.odone@unipv.it; signorelli.carlo@hsr.it; gianfredi.vincenza@hsr.it	Signorelli, Carlo/AAC-7630-2022; Odone, Anna/AAC-4715-2022; Gianfredi, Vincenza/W-1408-2017	Gianfredi, Vincenza/0000-0003-3848-981X; Vigezzi, Giacomo Pietro/0000-0001-6425-2926; Chiappa, Federica/0000-0002-5259-2250; SIGNORELLI, Carlo/0000-0002-0960-9563; Odone, Anna/0000-0002-5657-9774			Ambrose CS, 2013, VACCINE, V31, P857, DOI 10.1016/j.vaccine.2012.12.028; Ambrose CS, 2012, VACCINE, V30, P886, DOI 10.1016/j.vaccine.2011.11.104; Belshe RB, 2010, INFLUENZA OTHER RESP, V4, P141, DOI 10.1111/j.1750-2659.2009.00124.x; Brady RC, 2018, VACCINE, V36, P4663, DOI 10.1016/j.vaccine.2018.06.036; Brown P, 2006, BRIT MED J, V333, P804, DOI 10.1136/bmj.38987.492014.94; Carr S, 2011, J INFECT DIS, V204, P1475, DOI 10.1093/infdis/jir561; Cella Paola, 2020, J Prev Med Hyg, V61, pE340, DOI 10.15167/2421-4248/jpmh2020.61.3.1448; Centers for Disease Control and Prevention, ACIP VOT US LAIV 201; Dhere R, 2011, VACCINE, V29, pA16, DOI 10.1016/j.vaccine.2011.04.119; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; European Medicines Agency, FLUENZ INFL VACC LIV; Food and Drugs Administration, FDA INF REG FLUMIST; Forrest BD, 2011, VACCINE, V29, P3633, DOI 10.1016/j.vaccine.2011.03.029; Friedman L, 2019, VACCINE, V37, P7213, DOI 10.1016/j.vaccine.2019.09.086; Gianfredi V, 2018, J Prev Med Hyg, V59, pE14, DOI 10.15167/2421-4248/jpmh2018.59.1.806; Gianfredi V., 2019, J PREV MED HYG, V60, pE108; Gianfredi Vincenza, 2021, Acta Biomed, V92, pe2021318, DOI 10.23750/abm.v92i4.11558; Gianfredi Vincenza, 2021, Acta Biomed, V92, pe2021056, DOI 10.23750/abm.v92i1.9790; Gianfredi V, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103738; Gianfredi V, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071579; Gianfredi Vincenza, 2018, Recenti Prog Med, V109, P374, DOI 10.1701/2955.29706; Gianfredi V, 2017, NUTR CANCER, V69, P969, DOI 10.1080/01635581.2017.1359322; Glezen WP, 2008, PEDIATR INFECT DIS J, V27, pS104, DOI 10.1097/INF.0b013e318168b729; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; GRUBER WC, 1993, J INFECT DIS, V168, P1282, DOI 10.1093/infdis/168.5.1282; Hammitt LL, 2009, VACCINE, V27, P7359, DOI 10.1016/j.vaccine.2009.09.041; Herzog R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-154; Italian Ministry of Health, INFL VACC VACC COV C; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Julian PT, 2019, COCHRANE HDB SYSTEMA; King JC, 2000, J INFECT DIS, V181, P725, DOI 10.1086/315246; Kiseleva I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020296; Lo CKL, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-45; Lund FE, 2021, SCIENCE, V373, P397, DOI 10.1126/science.abg9857; Mallory RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013755; Manenti A, 2017, VACCINE, V35, P191, DOI 10.1016/j.vaccine.2016.10.024; Nichol KL, 1999, JAMA-J AM MED ASSOC, V282, P137, DOI 10.1001/jama.282.2.137; Nucci D, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18084168; Nucci D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17186686; Odone A, 2015, EPIDEMIOL PREV, V39, P139; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Page MJ, 2021, INT J SURG, V88, DOI 10.1016/j.ijsu.2021.105906; Phonrat B, 2013, VACCINE, V31, P1503, DOI 10.1016/j.vaccine.2012.12.082; Pitisuttithum P, 2017, LANCET INFECT DIS, V17, P833, DOI [10.1016/s1473-3099(17)30240-2, 10.1016/S1473-3099(17)30240-2]; Plans-Rubio P, 2012, PREV MED, V55, P72, DOI 10.1016/j.ypmed.2012.02.015; Preaud E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-813; Rhorer J, 2009, VACCINE, V27, P1101, DOI 10.1016/j.vaccine.2008.11.093; Rudenko L, 2016, LANCET INFECT DIS, V16, P303, DOI 10.1016/S1473-3099(15)00378-3; Rudenko L, 2015, VACCINE, V33, P5110, DOI 10.1016/j.vaccine.2015.08.019; Rudenko L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087962; Signorelli C, 2016, SCAND J PUBLIC HEALT, V44, P549, DOI 10.1177/1403494816649833; Signorelli C, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h116; Speroni Karen Gabel, 2005, AAOHN J, V53, P477; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Treanor JJ, 1999, VACCINE, V18, P899, DOI 10.1016/S0264-410X(99)00334-5; Troeger CE, 2019, LANCET RESP MED, V7, P69, DOI [10.1016/S2213-2600(18)30496-X, 10.1016/s2213-2600(18)30496-x]; VANVOORTHUIZEN F, 1981, ANTIVIR RES, V1, P107, DOI 10.1016/0166-3542(81)90037-1; Vesikari T, 2008, PEDIATRICS, V121, pE568, DOI 10.1542/peds.2007-1405; Walker M., ACIP REINSTATES FLUM; Wang Z, 2009, JAMA-J AM MED ASSOC, V301, P945, DOI 10.1001/jama.2009.265; White W G, 1976, Dev Biol Stand, V33, P202; WHO (World Health Organization), 2018, INFL SEAS; World Health Organization, TYP SEAS INFL VACC	66	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							998	10.3390/vaccines9090998			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3PJ	34579235	gold, Green Published			2022-04-29	WOS:000702120100001
J	Wolfe, DN; Sabourin, CL; Merchlinsky, MJ; Florence, WC; Wolfraim, LA; Taylor, KL; Ward, LA				Wolfe, Daniel N.; Sabourin, Carol L.; Merchlinsky, Michael J.; Florence, William C.; Wolfraim, Larry A.; Taylor, Kimberly L.; Ward, Lucy A.			Selection of Filovirus Isolates for Vaccine Development Programs	VACCINES			English	Editorial Material						ebola; Sudan; Marburg; filovirus; animal rule; viral isolate; challenge strain	PROTECTS NONHUMAN-PRIMATES; EBOLA-VIRUS; MARBURG VIRUS; HEMORRHAGIC-FEVER; GUINEA-PIGS; INFECTION; OUTBREAK; DISEASE; EVOLUTION; MACAQUES	The continuing outbreaks of ebola virus disease highlight the ongoing threat posed by filoviruses. Fortunately, licensed vaccines and therapeutics are now available for Zaire ebolavirus. However, effective medical countermeasures, such as vaccines for other filoviruses such as Sudan ebolavirus and the Marburg virus, are presently in early stages of development and, in the absence of a large outbreak, would require regulatory approval via the U.S. Food and Drug Administration (FDA) Animal Rule. The selection of an appropriate animal model and virus challenge isolates for nonclinical studies are critical aspects of the development program. Here, we have focused on the recommendation of challenge isolates for Sudan ebolavirus and Marburg virus. Based on analyses led by the Filovirus Animal and Nonclinical Group (FANG) and considerations for strain selection under the FDA Guidance for the Animal Rule, we propose prototype virus isolates for use in nonclinical challenge studies.	[Wolfe, Daniel N.; Merchlinsky, Michael J.] US Dept Hlth & Human Serv DHHS, Biomed Adv Res & Dev Author BARDA, Preparedness & Response ASPR, Washington, DC 20201 USA; [Sabourin, Carol L.] US Dept Hlth & Human Serv DHHS, Tunnell Govt Serv Inc, Preparedness & Response ASPR, Supporting Biomed Adv Res & Dev Author BARDA, Washington, DC 20201 USA; [Florence, William C.; Wolfraim, Larry A.; Taylor, Kimberly L.] NIAID, US Dept Hlth & Human Serv DHHS, NIH, Rockville, MD 20852 USA; [Ward, Lucy A.] US Dept Def DOD, Joint Program Execut Off Chem Biol Radiol & Nucl, Chem Biol Radiol & Nucl Med GPM CBRN Med, Ft Detrick, MD 21702 USA		Wolfe, DN (通讯作者)，US Dept Hlth & Human Serv DHHS, Biomed Adv Res & Dev Author BARDA, Preparedness & Response ASPR, Washington, DC 20201 USA.	Daniel.wolfe2@hhs.gov; carol.sabourin@hhs.gov; Michael.merchlinsky@hhs.gov; clint.florence@nih.gov; larry.wolfraim@nih.gov; Kimberly.taylor3@nih.gov; lucy.a.ward.civ@mail.mil		Wolfe, Daniel/0000-0002-8392-9506			Alfson KJ, 2015, J VIROL, V89, P6773, DOI 10.1128/JVI.00649-15; Baize S, 2014, NEW ENGL J MED, V371, P1418, DOI 10.1056/NEJMoa1404505; Blair PW, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110658; Callendret B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192312; Carroll SA, 2013, J VIROL, V87, P2608, DOI 10.1128/JVI.03118-12; Centers for Disease Control and Prevention, 2014, OUTBR CHRON MARB HEM; Dulin N, 2021, VACCINE, V39, P202, DOI 10.1016/j.vaccine.2020.11.042; Dye JM, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8040094; Geisbert TW, 2009, J VIROL, V83, P7296, DOI 10.1128/JVI.00561-09; Glaze ER, 2015, COMPARATIVE MED, V65, P241; Goldstein T, 2018, NAT MICROBIOL, V3, P1084, DOI 10.1038/s41564-018-0227-2; Grant-Klein RJ, 2015, HUM VACC IMMUNOTHER, V11, P1991, DOI 10.1080/21645515.2015.1039757; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Herbert AS, 2013, J VIROL, V87, P4952, DOI 10.1128/JVI.03361-12; Hevey M, 1998, VIROLOGY, V251, P28, DOI 10.1006/viro.1998.9367; Kugelman JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050316; Kuhn JH, 2019, NAT REV MICROBIOL, V17, P261, DOI 10.1038/s41579-019-0187-4; Ledgerwood JE, 2010, VACCINE, V29, P304, DOI 10.1016/j.vaccine.2010.10.037; MacNeil A, 2010, EMERG INFECT DIS, V16, P1969, DOI 10.3201/eid1612.100627; Martin JE, 2006, CLIN VACCINE IMMUNOL, V13, P1267, DOI 10.1128/CVI.00162-06; Marzi A, 2015, SCIENCE, V349, P739, DOI 10.1126/science.aab3920; Mire CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094355; Muyembe-Tamfum JJ, 1999, J INFECT DIS, V179, pS259, DOI 10.1086/514302; Okware SI, 2002, TROP MED INT HEALTH, V7, P1068, DOI 10.1046/j.1365-3156.2002.00944.x; Park DJ, 2015, CELL, V161, P1516, DOI 10.1016/j.cell.2015.06.007; Peterson AT, 2012, ECOL EVOL, V2, P1826, DOI 10.1002/ece3.297; Rojas M, 2020, J AUTOIMMUN, V106, DOI 10.1016/j.jaut.2019.102375; Roozendaal R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00261-9; Ruedas JB, 2018, J VIROL, V92, DOI [10.1128/JVI.00820-18, 10.1128/jvi.00820-18]; Sanchez A, 2004, J VIROL, V78, P10370, DOI 10.1128/JVI.78.19.10370-10377.2004; Swenson DL, 2008, EXPERT REV VACCINES, V7, P417, DOI 10.1586/14760584.7.4.417; Towner JS, 2006, J VIROL, V80, P6497, DOI 10.1128/JVI.00069-06; Trefry JC, 2015, VIRUSES-BASEL, V7, P6739, DOI 10.3390/v7122969; U.S. Food and Drug Administration, 2015, PROD DEV ANIM RUL; Warfield KL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118881; WHO, 2019, PREL RES EFF RVSV ZE; Wolf J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030190; Wolfe DN, 2020, HUM VACC IMMUNOTHER, V16, P2855, DOI 10.1080/21645515.2020.1741313; Wolfe DN, 2019, VACCINE, V37, P7178, DOI 10.1016/j.vaccine.2017.10.111	39	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1045	10.3390/vaccines9091045			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3ID	34579282	Green Published, gold			2022-04-29	WOS:000702101100001
J	Basile, M; Calabro, GE; Ghelardi, A; Ricciardi, R; De Vincenzo, R; Cicchetti, A				Basile, Michele; Calabro, Giovanna Elisa; Ghelardi, Alessandro; Ricciardi, Roberto; De Vincenzo, Rosa; Cicchetti, Americo			HPV Vaccination in Women Treated for Cervical Intraepithelial Neoplasia: A Budget Impact Analysis	VACCINES			English	Article						adjuvant HPV vaccination; cervical intraepithelial neoplasia; budget impact analysis; health technology assessment		Human Papillomavirus (HPV) is the most common sexually transmitted infection. Its progression is related to the development of malignant lesions, particularly cervical intraepithelial neoplasias (CINs). CINs correlate with a higher risk of premature births, and their excisional and ablative treatment further increases this risk in pregnant women. These complications are also correlated with higher healthcare costs for their management. In Italy, more than 26,000 new cases of CINs are estimated to occur yearly and their economic burden is significant. Therefore, the management of these conditions is a public health priority. Since HPV vaccination is associated with a reduced risk of relapse in women surgically treated for HPV-related injuries, we estimated the economic impact of extending HPV vaccination to this target population. This strategy would result in a significant reduction in the general costs of managing these women, resulting in an overall saving for the Italian Health Service of euro155,596.38 in 5 years. This lower cost is due not only to the reduced incidence of CINs following vaccination, but also to the lower occurrence of preterm births. Extending HPV vaccination to this target population as part of a care path to be offered to women treated for HPV injuries is therefore desirable.	[Basile, Michele; Cicchetti, Americo] Univ Cattolica Sacro Cuore, Grad Sch Hlth Econ & Management ALTEMS, I-00168 Rome, Italy; [Calabro, Giovanna Elisa] Univ Cattolica Sacro Cuore, Univ Dept Life Sci & Publ Hlth, Sect Hyg, I-00168 Rome, Italy; [Calabro, Giovanna Elisa; Ricciardi, Roberto] Spin Off Univ Cattolica Sacro Cuore, VIHTALI Value Hlth Technol & Acad Leadership & In, I-00168 Rome, Italy; [Ghelardi, Alessandro] Osped Apuane, UOC Ostetricia & Ginecol, Azienda USL Toscana Nord Ovest, Via Enrico Mattei 21, I-54100 Massa, Italy; [De Vincenzo, Rosa] Fdn Policlin Univ A Gemelli, IRCCS, Gynecol Oncol Unit, Dipartimento Sci Salute Donna Bambino & Sanita Pu, I-00168 Rome, Italy; [De Vincenzo, Rosa] Univ Cattolica Sacro Cuore, Dipartimento Sci Vita & Sanita Pubbl, I-00168 Rome, Italy		Calabro, GE (通讯作者)，Univ Cattolica Sacro Cuore, Univ Dept Life Sci & Publ Hlth, Sect Hyg, I-00168 Rome, Italy.; Calabro, GE (通讯作者)，Spin Off Univ Cattolica Sacro Cuore, VIHTALI Value Hlth Technol & Acad Leadership & In, I-00168 Rome, Italy.	michele.basile@unicatt.it; alisacalabro@icloud.com; ghelardi.alessandro@gmail.com; ghelardi.alessandro@gmail.com; rosa.devincenzo@unicatt.it; americo.cicchetti@unicatt.it		Basile, Michele/0000-0002-1098-2648; de vincenzo, rosa/0000-0001-7408-0435; Calabro, Giovanna Elisa/0000-0003-0259-3797; Cicchetti, Americo/0000-0002-4633-9195	MSD Italia S.r.l.	This Budget Impact Analysis was part of a project that received an unconditional grant from MSD Italia S.r.l.	Acampora A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217997; Agenzia Italiana del Farmaco (AIFA), TAR PRES ASS SPEC AC; Agenzia Italiana del Farmaco (AIFA), TAR PREST SPEC AMB; Aiom-Airtum, 2020, NUM CANCR IT; [Anonymous], 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.29414; Bartels HC, 2020, INT J GYNECOL CANCER, V30, P777, DOI 10.1136/ijgc-2020-001197; Bloom DE, 2011, ADV EXP MED BIOL, V697, P1, DOI 10.1007/978-1-4419-7185-2_1; Bloom DE, 2017, VACCINE, V35, pA29, DOI 10.1016/j.vaccine.2016.12.001; Byun JM, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013606; Calabro GE, 2020, EPIDEMIOL BIOSTAT PU, V17, DOI 10.2427/13302; Cavallo MC, 2015, ITAL J PEDIATR, V41, DOI 10.1186/s13052-015-0165-z; EUnetHTA, HTA COR MOD; European Centre for Disease Prevention and Control, ECDC SCHED; Expert Panel on Effective Ways of Investing in Health, VACC PROGR HLTH SYST; Ghelardi A, 2018, GYNECOL ONCOL, V151, P229, DOI 10.1016/j.ygyno.2018.08.033; Hartwig S, 2015, PAPILLOMAVIRUS RES, V1, P90, DOI 10.1016/j.pvr.2015.06.003; Ho GYF, 2011, J LOW GENIT TRACT DI, V15, P268, DOI 10.1097/LGT.0b013e3182216fef; Italian Ministry of Health, PIAN NAZ PREV VACC 2; Jentschke M, 2020, VACCINE, V38, P6402, DOI 10.1016/j.vaccine.2020.07.055; Kristensen FB, 2009, INT J TECHNOL ASSESS, V25, P107, DOI 10.1017/S0266462309990754; Kyrgiou M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012847; Kyrgiou M, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3633; Largeron Nathalie, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27043; Linee Guida SIGO (Societa Italiana di Ginecologia e Ostetricia), GEST PART PRET; Molet L, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100169; Rossi PG, 2009, BMC PUBLIC HEALTH, V9, DOI [10.1186/1471-2458-9-71, 10.1186/1471-2407-9-69]; Sideri M.-G., 2014, PRINCIPI RACCOMANDAZ; Sistema Nazionale Linee Guida Istituto Superiore di Sanita, 2020, LIN GUID COND PREV C; Weinmann S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0165276; World Health Organization, CERV CANC; World Health Organization, 2020, HUMAN PAPILLOMAVIRUS; World Health Organization, 2020, GLOB STRAT ACC EL CE; World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069	33	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							816	10.3390/vaccines9080816			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7EQ	34451941	Green Published			2022-04-29	WOS:000690089600001
J	Benning, L; Tollner, M; Hidmark, A; Schaier, M; Nusshag, C; Kalble, F; Reichel, P; Buylaert, M; Grenz, J; Ponath, G; Klein, K; Zeier, M; Susal, C; Schnitzler, P; Morath, C; Speer, C				Benning, Louise; Toellner, Maximilian; Hidmark, Asa; Schaier, Matthias; Nusshag, Christian; Kaelble, Florian; Reichel, Paula; Buylaert, Mirabel; Grenz, Julia; Ponath, Gerald; Klein, Katrin; Zeier, Martin; Susal, Caner; Schnitzler, Paul; Morath, Christian; Speer, Claudius			Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers	VACCINES			English	Article						COVID-19; COVID-19 vaccination; heterologous vaccination; humoral response; mRNA vaccine; BNT162b2; adenovirus-vectored vaccine; ChAdOx1 nCoV-19; SARS-CoV-2		Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups. In this prospective, single-center study we included 166 health care workers from Heidelberg University Hospital who received either heterologous ChAdOx1 nCoV-19/BNT162b2, homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination between December 2020 and May 2021. We measured anti-S1 IgG, SARS-CoV-2 specific neutralizing antibodies, and antibodies against different SARS-CoV-2 fragments 0-3 days before and 19-21 days after boost vaccination. Before boost, 55/70 (79%) ChAdOx1 nCoV-19-primed compared with 44/45 (98%) BNT162b2-primed individuals showed positive anti-S1 IgG with a median (IQR) anti-S1 IgG index of 1.95 (1.05-2.99) compared to 9.38 (6.26-17.12). SARS-CoV-2 neutralizing antibodies exceeded the threshold in 24/70 (34%) of ChAdOx1 nCoV-19-primed and 43/45 (96%) of BNT162b2-primed individuals. After boosting dose, median (IQR) anti-S1 IgG index in heterologous ChAdOx1 nCoV-19/BNT162b2 vaccinees was 116.2 (61.84-170), compared to 13.09 (7.03-29.02) in homologous ChAdOx1 nCoV-19 and 145.5 (100-291.1) in homologous BNT162b2 vaccinees. All boosted vaccinees exceeded the threshold for neutralization, irrespective of their vaccination scheme. Vaccination was well-tolerated overall. We show that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.	[Benning, Louise; Toellner, Maximilian; Hidmark, Asa; Schaier, Matthias; Nusshag, Christian; Kaelble, Florian; Reichel, Paula; Buylaert, Mirabel; Grenz, Julia; Ponath, Gerald; Klein, Katrin; Zeier, Martin; Morath, Christian; Speer, Claudius] Univ Heidelberg Hosp, Dept Nephrol, D-69120 Heidelberg, Germany; [Susal, Caner] Univ Heidelberg Hosp, Inst Immunol, D-69120 Heidelberg, Germany; [Schnitzler, Paul] Univ Heidelberg Hosp, Dept Infect Dis Virol, D-69120 Heidelberg, Germany; [Speer, Claudius] EMBL, Mol Med Partnership Unit Heidelberg, D-69117 Heidelberg, Germany		Benning, L; Speer, C (通讯作者)，Univ Heidelberg Hosp, Dept Nephrol, D-69120 Heidelberg, Germany.; Speer, C (通讯作者)，EMBL, Mol Med Partnership Unit Heidelberg, D-69117 Heidelberg, Germany.	louise.benning@med.uni-heidelberg.de; maximilian.toellner@googlemail.com; asa.hidmark@gmail.com; matthias.schaier@med.uni-heidelberg.de; christian.nusshag@med.uni-heidelberg.de; florian.kaelble@med.uni-heidelberg.de; paulareichel@web.de; mirabel.buylaert@med.uni-heidelberg.de; julia.grenz@med.uni-heidelberg.de; gerald.ponath@gmail.com; katrin.klein@med.uni-heidelberg.de; Martin.Zeier@med.uni-heidelberg.de; caner.suesal@med.uni-heidelberg.de; paul.schnitzler@med.uni-heidelberg.de; christian.morath@med.uni-heidelberg.de; claudius.speer@med.uni-heidelberg.de	Morath, Christian/ABC-5091-2021	Benning, Louise/0000-0002-8366-2100; Nusshag, Christian/0000-0001-7776-3784; Schaier, Matthias/0000-0003-1040-1150	Rahel Goitein-Straus Program of the Heidelberg Faculty of Medicine; Physician Scientist Program of the Heidelberg Faculty of Medicine	Louise Benning is funded by the Rahel Goitein-Straus Program of the Heidelberg Faculty of Medicine. Claudius Speer is funded by the Physician Scientist Program of the Heidelberg Faculty of Medicine.	Barros-Martins J, 2021, NAT MED, V27, P1525, DOI 10.1038/s41591-021-01449-9; Bray RA, 2021, TRANSPLANTATION, V105, P79, DOI 10.1097/TP.0000000000003524; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Gross R., 2021, HETEROLOGOUS CHADOX1, DOI [10.1101/2021.05.30.21257971, DOI 10.1101/2021.05.30.21257971]; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Hillus D, 2021, LANCET RESP MED, V9, P1255, DOI 10.1016/S2213-2600(21)00357-X; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Liu X., SAFETY IMMUNOGENICIT; Olmeda P, REACTOGENICITY IMMUN; Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines, COVID 19 VACC VAXZ A; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Pritchard E., 2021, IMPACT VACCINATION N, DOI [10.1101/2021.04.22.21255913, DOI 10.1101/2021.04.22.21255913]; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Sattler A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150175; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Shaw RH, 2021, LANCET, V397, P2043, DOI [10.1016/S0140-6736(21)01115-6, 10.1016/S0140-6736(21)01158-2]; Speer C, 2021, CLIN J AM SOC NEPHRO, V16, P1073, DOI 10.2215/CJN.03700321; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z	22	18	18	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							857	10.3390/vaccines9080857			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4QI	34451982	gold, Green Published			2022-04-29	WOS:000689917200001
J	Buja, A; Manfredi, M; De Luca, G; Zampieri, C; Zanovello, S; Perkovic, D; Scotton, F; Minnicelli, A; De Polo, A; Cristofori, V; Biasi, L; Baldovin, T; Bertoncello, C; Cocchio, S; Baldo, V				Buja, Alessandra; Manfredi, Mariagiovanna; De Luca, Giuseppe; Zampieri, Chiara; Zanovello, Sofia; Perkovic, Davor; Scotton, Francesca; Minnicelli, Anil; De Polo, Anna; Cristofori, Vittorio; Biasi, Laura; Baldovin, Tatjana; Bertoncello, Chiara; Cocchio, Silvia; Baldo, Vincenzo			Using Failure Mode, Effect and Criticality Analysis to Improve Safety in the COVID Mass Vaccination Campaign	VACCINES			English	Article						patient safety; proactive management; vaccination campaign; SARS-COV-2	ERRORS	Vaccination against SARS-CoV-2 will likely be the most promising way to combat the pandemic. Even if mass vaccination is urgent, it should still always be supported by appropriate patient safety management. The aim of this study, based on failure mode, effects and criticality analysis (FMECA), was to identify possible failures and highlight measures that can be adopted to prevent their occurrence. A team of resident doctors in public health from the University of Padua and specialists in risk analysis in public health examined the mass vaccination process. A diagram was drafted to illustrate the various phases of mass vaccination, analyze the process, and identify all failure modes. Criticalities were ascertained by rating the severity, frequency and likelihood of failure detection on a scale of 1 to 10. We identified a total of 71 possible faults distributed over the various phases of the process, and 34 of them were classified as carrying a high risk. For the potentially high-risk failure modes, we identified 63 recommended actions to contain the cause of their occurrence or improve their detection. For the purpose of detecting potential failures, FMECA can be successfully applied to mass vaccination, which should be considered a high-risk process.	[Buja, Alessandra; Manfredi, Mariagiovanna; De Luca, Giuseppe; Zampieri, Chiara; Zanovello, Sofia; Perkovic, Davor; Scotton, Francesca; Minnicelli, Anil; De Polo, Anna; Cristofori, Vittorio; Biasi, Laura; Baldovin, Tatjana; Bertoncello, Chiara; Cocchio, Silvia; Baldo, Vincenzo] Univ Padua IT, Dept Cardiol Thorac Vasc Sci & Publ Hlth, I-35131 Padua, Italy		Zampieri, C (通讯作者)，Univ Padua IT, Dept Cardiol Thorac Vasc Sci & Publ Hlth, I-35131 Padua, Italy.	alessandra.buja@unipd.it; mariagiovanna.manfredi@studenti.unipd.it; giuseppe.deluca.2@studenti.unipd.it; chiara.zampieri.8@studenti.unipd.it; sofia.zanovello@studenti.unipd.it; davor.perkovic.1@studenti.unipd.it; francesca.scotton.1@studenti.unipd.it; anil.minnicelli@studenti.unipd.it; anna.depolo@studenti.unipd.it; vittorio.cristofori@studenti.unipd.it; laura.biasi@studenti.unipd.it; tatjana.baldovin@unipd.it; chiara.bertoncello@unipd.it; silvia.cocchio@unipd.it; vincenzo.baldo@unipd.it	De Luca, Giuseppe/ABG-9353-2021; Baldo, Vincenzo/D-7822-2018	De Luca, Giuseppe/0000-0002-3970-3286; Buja, Alessandra/0000-0003-2216-3807; Baldo, Vincenzo/0000-0001-6012-9453; Bertoncello, Chiara/0000-0003-4040-8601; De Polo, Anna/0000-0002-6171-7625; Zampieri, Chiara/0000-0002-1946-5882; CRISTOFORI, VITTORIO/0000-0002-4286-7062			Adil MT, 2021, POSTGRAD MED J, V97, P110, DOI 10.1136/postgradmedj-2020-138386; Villafranca JJA, 2014, AM J HEALTH-SYST PH, V71, P1210, DOI 10.2146/ajhp130640; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P2938, DOI 10.1080/21645515.2020.1842683; Frederiksen LSF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01817; Gilliam ML, 2014, CONTRACEPTION, V90, P542, DOI 10.1016/j.contraception.2014.06.036; Rodriguez-Gonzalez CG, 2015, J EVAL CLIN PRACT, V21, P549, DOI 10.1111/jep.12314; Lago P, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001249; Ministero della Salute, COV 19 SIT IT; Morens DM, 2020, MBIO, V11, DOI 10.1128/mBio.00812-20; Morse-Brady J, 2020, VACCINE, V38, P1623, DOI 10.1016/j.vaccine.2019.11.078; Paparella SF, 2015, J EMERG NURS, V41, P428, DOI 10.1016/j.jen.2015.05.010; Public Health England, GID HEALTHC PRACT CO; Pupo A., 2021, B UFFICIALE REGIONE; Snee R.D., 2008, NSES012775370 WEST E; Stolzer AJ, 2011, ASHGATE STUD HUM, P1; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; World Health Organization, FRAM DEC MAK IMPL MA	18	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							866	10.3390/vaccines9080866			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4ZW	34451990	Green Published, gold			2022-04-29	WOS:000689942000001
J	Kosinska, AD; Festag, J; Muck-Hausl, M; Festag, MM; Asen, T; Protzer, U				Kosinska, Anna D.; Festag, Julia; Muck-Hausl, Martin; Festag, Marvin M.; Asen, Theresa; Protzer, Ulrike			Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection	VACCINES			English	Article						hepatitis B virus; chronic hepatitis B; therapeutic vaccination; prime/boost vaccination; hepatitis B virus e antigen; pre-core mutation	T-CELLS; VIRUS-DNA; E-ANTIGEN; PRECORE REGION; MUTATIONS; SEROCONVERSION; EXPRESSION; CLEARANCE; FULMINANT; PROTEIN	During the natural course of chronic hepatitis B virus (HBV) infection, the hepatitis B e antigen (HBeAg) is typically lost, while the direct transmission of HBeAg-negative HBV may result in fulminant hepatitis B. While the induction of HBV-specific immune responses by therapeutic vaccination is a promising, novel treatment option for chronic hepatitis B, it remains unclear whether a loss of HBeAg may influence its efficacy or tolerability. We therefore generated an adeno-associated virus (AAV)-vector that carries a 1.3-fold overlength HBV genome with a typical stop-codon mutation in the pre-core region and initiates the replication of HBeAg(-) HBV in mouse livers. Infection of C57BL/6 mice established persistent HBeAg(-) HBV-replication without any detectable anti-HBV immunity or liver damage. HBV-carrier mice were immunized with TherVacB, a therapeutic hepatitis B vaccine that uses a particulate HBV S and a core protein for prime vaccination, and a modified vaccinia Ankara (MVA) for boost vaccination. The TherVacB immunization of HBeAg(+) and HBeAg(-) HBV carrier mice resulted in the effective induction of HBV-specific antibodies and the loss of HBsAg but only mild liver damage. Intrahepatic, HBV-specific CD8 T cells induced in HBeAg(-) mice expressed more IFN gamma but showed similar cytolytic activity. This indicates that the loss of HBeAg improves the performance of therapeutic vaccination by enhancing non-cytolytic effector functions.	[Kosinska, Anna D.; Festag, Julia; Muck-Hausl, Martin; Festag, Marvin M.; Asen, Theresa; Protzer, Ulrike] Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, D-81675 Munich, Germany; [Kosinska, Anna D.; Protzer, Ulrike] German Ctr Infect Res DZIF, Munich Partner Site, D-81675 Munich, Germany		Protzer, U (通讯作者)，Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, D-81675 Munich, Germany.; Protzer, U (通讯作者)，German Ctr Infect Res DZIF, Munich Partner Site, D-81675 Munich, Germany.	anna.kosinska@tum.de; julia.festag@gmx.de; martin.mueck-haeusl@tum.de; marvin.festag@gmail.com; theresa.asen@tum.de; protzer@tum.de	; Protzer, Ulrike/D-5915-2015	Festag, Marvin/0000-0003-1294-8336; Protzer, Ulrike/0000-0002-9421-1911; Festag, Julia/0000-0001-6159-8286	German research foundation (DFG)German Research Foundation (DFG) [TRR179]; German Center for Infection research (DZIF) [TTU05.803]; EU Horizon 2020 consortium TherVacB; proof-of-concept initiative by the Helmholtz Association; proof-of-concept initiative by the Fraunhofer Association	This research was funded by the German research foundation (DFG) via TRR179, project TP18, the German Center for Infection research (DZIF) via project TTU05.803 "HBV Cure", the proof-of-concept initiative by the Helmholtz and Fraunhofer Associations, and the EU Horizon 2020 consortium TherVacB.	Backes S, 2016, VACCINE, V34, P923, DOI 10.1016/j.vaccine.2015.12.060; Bayliss J, 2017, GUT, V66, P2013, DOI 10.1136/gutjnl-2015-309300; Boni C, 2007, J VIROL, V81, P4215, DOI 10.1128/JVI.02844-06; BRUNETTO MR, 1993, GASTROENTEROLOGY, V105, P845, DOI 10.1016/0016-5085(93)90903-P; Burton AR, 2018, J CLIN INVEST, V128, P4588, DOI [10.1172/JCI121960, 10.1172/jci121960]; CARMAN WF, 1989, LANCET, V2, P588; Chen MT, 2004, P NATL ACAD SCI USA, V101, P14913, DOI 10.1073/pnas.0406282101; Fisicaro P, 2010, GASTROENTEROLOGY, V138, P682, DOI 10.1053/j.gastro.2009.09.052; Fried MW, 2008, HEPATOLOGY, V47, P428, DOI 10.1002/hep.22065; Gehring AJ, 2019, GASTROENTEROLOGY, V156, P325, DOI 10.1053/j.gastro.2018.10.032; HASEGAWA K, 1991, VIROLOGY, V185, P460, DOI 10.1016/0042-6822(91)90799-H; Hsu YS, 2002, HEPATOLOGY, V35, P1522, DOI 10.1053/jhep.2002.33638; Hur GM, 1996, J MED VIROL, V48, P38, DOI 10.1002/(SICI)1096-9071(199601)48:1<38::AID-JMV6>3.0.CO;2-M; Isogawa M, 2005, IMMUNITY, V23, P53, DOI 10.1016/j.immuni.2005.05.005; Kosinska AD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47149-w; Kosinska AD, 2017, CURR OPIN VIROL, V23, P75, DOI 10.1016/j.coviro.2017.03.011; LIAW YF, 1991, HEPATOLOGY, V13, P627, DOI 10.1002/hep.1840130403; LIAW YF, 1987, HEPATOLOGY, V7, P20, DOI 10.1002/hep.1840070106; LIAW YF, 1987, HEPATOLOGY, V7, P1, DOI 10.1002/hep.1840070102; Lok ASF, 2016, HEPATOLOGY, V63, P284, DOI 10.1002/hep.28280; LOK ASF, 1994, P NATL ACAD SCI USA, V91, P4077, DOI 10.1073/pnas.91.9.4077; Maini MK, 1999, GASTROENTEROLOGY, V117, P1386, DOI 10.1016/S0016-5085(99)70289-1; Michler T, 2020, GASTROENTEROLOGY, V158, P1762, DOI 10.1053/j.gastro.2020.01.032; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; Pallett LJ, 2017, J EXP MED, V214, P1567, DOI 10.1084/jem.20162115; Penaud-Budloo M, 2018, MOL THER-METH CLIN D, V8, P166, DOI 10.1016/j.omtm.2018.01.002; Protzer U, 2012, NAT REV IMMUNOL, V12, P201, DOI 10.1038/nri3169; Rehermann B, 1996, NAT MED, V2, P1104, DOI 10.1038/nm1096-1104; Thimme R, 2003, J VIROL, V77, P68, DOI 10.1128/JVI.77.1.68-76.2003; Tian YJ, 2016, IMMUNITY, V44, P1204, DOI 10.1016/j.immuni.2016.04.008; Tong SP, 2016, J HEPATOL, V64, pS4, DOI 10.1016/j.jhep.2016.01.027; Tseng TC, 2015, GUT, V64, P292, DOI 10.1136/gutjnl-2014-306977; Webster GJM, 2004, J VIROL, V78, P5707, DOI 10.1128/JVI.78.11.5707-5719.2004; Xia YC, 2016, GASTROENTEROLOGY, V150, P194, DOI 10.1053/j.gastro.2015.09.026; Zhang Z, 2008, GASTROENTEROLOGY, V134, P1938, DOI 10.1053/j.gastro.2008.03.037	35	1	1	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							841	10.3390/vaccines9080841			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8TT	34451966	Green Published, gold			2022-04-29	WOS:000690196500001
J	Lukaszuk, K; Kiewisz, J; Rozanska, K; Dabrowska, M; Podolak, A; Jakiel, G; Woclawek-Potocka, I; Lukaszuk, A; Rabalski, L				Lukaszuk, Krzysztof; Kiewisz, Jolanta; Rozanska, Karolina; Dabrowska, Malgorzata; Podolak, Amira; Jakiel, Grzegorz; Woclawek-Potocka, Izabela; Lukaszuk, Aron; Rabalski, Lukasz			Usefulness of IVD Kits for the Assessment of SARS-CoV-2 Antibodies to Evaluate the Humoral Response to Vaccination	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccination; Pfizer/BioNTech; Roche; DiaSorin; Abbott; assay comparison	ASSAYS; COVID-19	Background: The introduction of the vaccination against SARS-CoV-2 infection creates the need for precise tools for the quality control of vaccination procedures, detection of poor humoral response, and estimation of the achieved protection against the disease. Thus, the study aimed to compare the results of the anti-SARS-CoV-2 tests to evaluate the application of the WHO standard unitage (the binding antibody units; BAU/mL) for a measurement of response to the vaccination. Methods: Patients undergoing vaccination against SARS-CoV-2 with Pfizer/BioNTech BNT162b2 (BNT162b2) (n = 79), referred for SARS-CoV-2 antibody measurement prior to vaccination and 21 days after dose 1, and 8, 14, and 30 days after dose 2 were included. The sera were tested with three assays: Elecsys SARS-CoV-2 S (Roche), LIAISON (R) SARS-CoV-2 TrimericS IgG (DiaSorin), and SARS-CoV-2 IgG II Quant (Abbott). Results: The three assays showed varying correlations at different time points in the study. The overall agreement for all samples was moderate to high (rho = 0.663-0.902). We observed the most uniform agreement for the day of dose 2 (rho = 0.775-0.825), while it was least consistent for day 8 (rho = -0.131-0.693) and 14 (rho = -0.247-0.603) after dose 2. The dynamics of changes of the SARS-CoV-2 antibody levels in patients without history of prior SARS-CoV-2 infection appears homogenous based on the Roche results, more heterogenous when considering the DiaSorin results, and in between for the Abbott results. Conclusions: The results highlight the need for further work on the international standard of measurement of SARS-CoV-2 Ig, especially in the era of vaccination. The serological assays can be useful to detect IgG/IgM antibodies to assess the response to the vaccination. However, they cannot be used interchangeably. In terms of the evaluation of the immune response to the BNT162b2 vaccine, Roche and Abbott kits appear to be more useful.	[Lukaszuk, Krzysztof; Rozanska, Karolina; Podolak, Amira; Lukaszuk, Aron] Invicta Res & Dev Ctr, PL-81740 Sopot, Poland; [Lukaszuk, Krzysztof] Med Univ Gdansk, Dept Obstet & Gynecol Nursing, PL-80210 Gdansk, Poland; [Kiewisz, Jolanta] Univ Warmia & Mazury, Fac Med, Dept Human Histol & Embryol, Coll Med, PL-10082 Olsztyn, Poland; [Dabrowska, Malgorzata] Univ Clin Ctr, Cent Clin Lab, PL-80214 Gdansk, Poland; [Jakiel, Grzegorz; Lukaszuk, Aron] Univ Gdansk, Dept Obstet & Gynecol 1, Ctr Postgrad Med Educ, PL-01004 Warsaw, Poland; [Woclawek-Potocka, Izabela] Polish Acad Sci, Inst Anim Reprod & Food Res, Dept Gamete & Embryo Biol, PL-10748 Olsztyn, Poland; [Rabalski, Lukasz] Univ Gdansk, Intercollegiate Fac Biotechnol, Lab Recombinant Vaccines, PL-80307 Gdansk, Poland		Lukaszuk, A (通讯作者)，Invicta Res & Dev Ctr, PL-81740 Sopot, Poland.; Lukaszuk, A (通讯作者)，Univ Gdansk, Dept Obstet & Gynecol 1, Ctr Postgrad Med Educ, PL-01004 Warsaw, Poland.	krzysztof.lukaszuk@invicta.pl; jolanta.kiewisz@uwm.edu.pl; karolina.rozanska@invicta.pl; mdabrowska@uck.gda.pl; amira.podolak@invicta.pl; grzegorz.jakiel1@o2.pl; i.woclawek-potocka@pan.olsztyn.pl; lukaszuk.aron@gmail.com; lukasz.rabalski@biotech.ug.edu.pl	Lukaszuk, Krzysztof/ABD-1103-2021; Rabalski, Lukasz/ABG-9936-2020; WOCLAWEK-POTOCKA, Izabela/H-7266-2017	Lukaszuk, Krzysztof/0000-0001-5996-6991; Rabalski, Lukasz/0000-0002-5292-9263; WOCLAWEK-POTOCKA, Izabela/0000-0002-1270-3438; Jakiel, Grzegorz/0000-0002-6094-2273; Podolak, Amira/0000-0002-1942-5522; Kiewisz, Jolanta/0000-0002-2738-8952	Invicta Research and Development Center	The study has been financed by the Invicta Research and Development Center. This research received no external funding.	Adams E. R., 2020, Wellcome Open Research, V5, DOI 10.12688/wellcomeopenres.15927.1; Bajaj V, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.571416; Deeks JJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013652; Egger M, 2020, CLIN CHIM ACTA, V509, P18, DOI 10.1016/j.cca.2020.05.049; Fons S, 2021, PATHOG DIS, V79, DOI 10.1093/femspd/ftaa069; Grzelak L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3103; Jahrsdorfer B, 2021, J INFECT DIS, V223, P796, DOI 10.1093/infdis/jiaa656; James J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040713; Kontou PI, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050319; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; Kruttgen A, 2021, J VIROL METHODS, V287, DOI 10.1016/j.jviromet.2020.113978; Kruttgen A, 2020, J CLIN VIROL, V128; Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020; Manuilova E, CRAN PACKAGE MCR; Mattiuzzo G, 2020, ESTABLISHMENT WHO IN, P9; Mueller T, 2021, CLIN CHIM ACTA, V518, P9, DOI 10.1016/j.cca.2021.03.007; Naaber P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237548; NIBSC, 2020, WHO INT STAND 1 WHO; Nilsson AC, 2021, INT J INFECT DIS, V103, P381, DOI 10.1016/j.ijid.2020.12.017; Padoan A, 2020, CLIN CHIM ACTA, V507, P164, DOI 10.1016/j.cca.2020.04.026; Paiva KJ, 2021, J MED VIROL, V93, P916, DOI 10.1002/jmv.26341; Perkmann T, 2020, CLIN CHEM, V66, P1405, DOI 10.1093/clinchem/hvaa198; Perkmann-Nagele N., 2021, ANTISPIKE PROTEIN AS, V383, P1782, DOI [10.1101/2021.03.05.21252977, DOI 10.1101/2021.03.05.21252977]; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; R Core Team, R R PROJ STAT COMP; Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259; Stoesser N, 2020, LANCET INFECT DIS, V20, P1390, DOI 10.1016/S1473-3099(20)30634-4; Theel ES, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00797-20; Trabaud MA, 2020, J CLIN VIROL, V132, DOI 10.1016/j.jcv.2020.104613; Verkerke H, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02026-20; Wakita M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246536; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; Weidner L, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104540; Weissleder R, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc1931; Wickham H., 2019, J OPEN SOURCE SOFTWA, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/joss.01686]	35	8	8	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							840	10.3390/vaccines9080840			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4GQ	34451965	Green Published, gold			2022-04-29	WOS:000689892000001
J	Noushad, M; Nassani, MZ; Alsalhani, AB; Koppolu, P; Niazi, FH; Samran, A; Rastam, S; Alqerban, A; Barakat, A; Almoallim, HS				Noushad, Mohammed; Nassani, Mohammad Zakaria; Alsalhani, Anas B.; Koppolu, Pradeep; Niazi, Fayez Hussain; Samran, Abdulaziz; Rastam, Samer; Alqerban, Ali; Barakat, Ali; Almoallim, Hesham S.			COVID-19 Vaccine Intention among Healthcare Workers in Saudi Arabia: A Cross-Sectional Survey	VACCINES			English	Article						COVID-19; vaccine intention; herd immunity; Saudi Arabia; healthcare workers		The COVID-19 pandemic has caused largescale morbidity and mortality and a tremendous burden on the healthcare system. Healthcare workers (HCWs) require adequate protection to avoid onward transmission and minimize burden on the healthcare system. Moreover, HCWs can also influence the general public into accepting the COVID-19 vaccine. Therefore, determining COVID-19 vaccine intention among HCWs is of paramount importance to plan tailor-made public health strategies to maximize vaccine coverage. A structured questionnaire was administered in February and March 2021 among HCWs in Saudi Arabia using convenience sampling, proceeding the launch of the vaccination campaign. HCWs from all administrative regions of Saudi Arabia were included in the study. In total, 674 out of 1124 HCWs responded and completed the survey (response rate 59.9%). About 65 percent of the HCWs intended to get vaccinated. The intention to vaccinate was significantly higher among HCWs 50 years of age or older, Saudi nationals and those who followed the updates about COVID-19 vaccines (p < 0.05). The high percentage (26 percent) of those who were undecided in getting vaccinated is a positive sign. As the vaccination campaign gathers pace, the attitude is expected to change over time. Emphasis should be on planning healthcare strategies to convince the undecided HCWs into accepting the vaccine in order to achieve the coverage required to achieve herd immunity.	[Noushad, Mohammed; Nassani, Mohammad Zakaria; Niazi, Fayez Hussain; Samran, Abdulaziz; Barakat, Ali] Dar Al Uloom Univ, Dept Restorat & Prosthet Dent Sci, Coll Dent, Riyadh 11512, Saudi Arabia; [Noushad, Mohammed; Niazi, Fayez Hussain] Univ Sains Malaysia, Sch Dent Sci, Biomat Unit, Hlth Campus, Kubang Kerian 16150, Malaysia; [Alsalhani, Anas B.] Vis Coll, Vis Coll Dent & Nursing, Dept Oral Med & Diagnost Sci, Riyadh 11691, Saudi Arabia; [Koppolu, Pradeep; Alqerban, Ali] Dar Al Uloom Univ, Dept Prevent Dent Sci, Coll Dent, Riyadh 13313, Saudi Arabia; [Samran, Abdulaziz] Ibb Univ, Dept Prosthodont, Coll Dent, Ibb 70270, Yemen; [Rastam, Samer] Vis Coll, Vis Coll Med, Dept Biomed Sci, Riyadh 11691, Saudi Arabia; [Alqerban, Ali] Prince Sattam Bin Abdulaziz Univ, Dept Prevent Dent Sci, Coll Dent, Al Kharj 11942, Saudi Arabia; [Almoallim, Hesham S.] Dar Al Uloom Univ, Dept Surg & Diagnost Sci, Coll Dent, Riyadh 13313, Saudi Arabia; [Almoallim, Hesham S.] King Saud Univ, Dept Oral & Maxillofacial Surg, Coll Dent, Riyadh 11545, Saudi Arabia		Noushad, M (通讯作者)，Dar Al Uloom Univ, Dept Restorat & Prosthet Dent Sci, Coll Dent, Riyadh 11512, Saudi Arabia.; Noushad, M (通讯作者)，Univ Sains Malaysia, Sch Dent Sci, Biomat Unit, Hlth Campus, Kubang Kerian 16150, Malaysia.	m.noushad@dau.edu.sa; mznassani@dau.edu.sa; Dr.anas_salhany@hotmail.com; pradeep@dau.edu.sa; fayez.h@dau.edu.sa; asamran@dau.edu.sa; mrastam@gmail.com; a.alqerban@psau.edu.sa; ali.ab@dau.edu.sa; halmoallim@dau.edu.sa	Rastam, M. Samer/N-6365-2017; Almoallim, Hesham S Khalil/H-7795-2014; koppolu, Pradeep/AAJ-6106-2021; Alqerban, Ali/AAE-5487-2021	Rastam, M. Samer/0000-0002-4004-7773; Almoallim, Hesham S Khalil/0000-0002-1455-1095; koppolu, Pradeep/0000-0001-8226-6926; Alqerban, Ali/0000-0002-8145-5466; Noushad, Mohammed/0000-0002-0157-3666; Alsalhani, Anas/0000-0002-5158-7222; Nassani, Mohammad Zakaria/0000-0003-0927-895X; Samran, Abdulaziz/0000-0002-2934-4830	Deanship of Postgraduate and Scientific Research at Dar Al UIoom University	The authors extend their appreciation to the Deanship of Postgraduate and Scientific Research at Dar Al UIoom University for their support for this work.	Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alagoz O, 2021, ANN INTERN MED, V174, P50, DOI 10.7326/M20-4096; Alfageeh EI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030226; Alshamrani MM, 2021, INT J INFECT DIS, V109, P238, DOI 10.1016/j.ijid.2021.07.009; Alzeer AA, 2021, SAUDI PHARM J, V29, P188, DOI 10.1016/j.jsps.2021.01.001; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; [Anonymous], 2021, SAUDI GAZETTE; Arab News, 2021, ARAB NEWS; Aslaner H, 2021, IRAN J PUBLIC HEALTH, V50, P721, DOI 10.18502/ijph.v50i4.5996; Awadhi EA, 2021, RISK MANAG HEALTHC P, V14, P1413, DOI 10.2147/RMHP.S300602; Bashir S, 2021, ONE HEALTH-AMSTERDAM, V12, DOI 10.1016/j.onehlt.2021.100229; Coe AB, 2022, RES SOC ADMIN PHARM, V18, P2593, DOI 10.1016/j.sapharm.2021.04.023; European Centre for Disease Prevention and Control, 2015, VACC HES HEALTHC WOR; Ferrari M., 2021, ALMOST 1 5 MLN WORSH; Friedrich MJ, 2019, JAMA-J AM MED ASSOC, V321, P1041, DOI 10.1001/jama.2019.1934; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Huang B, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06313-2; Kaplan AK, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14226; Kumari A, 2021, DIABETES METAB SYND, V15, P679, DOI 10.1016/j.dsx.2021.03.021; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Ledda C, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052703; MOH News, 2021, MOH BEG VACC 12 18 A; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Noh EB, 2021, INFECT CHEMOTHER, V53, P261, DOI 10.3947/ic.2021.0029; Palache A, 2014, VACCINE, V32, P6369, DOI 10.1016/j.vaccine.2014.07.012; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Sage Working Group, 2014, REP SAG WORK GROUP V; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Yan E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070696; Yu YQ, 2021, HUM VACC IMMUNOTHER, V17, P2894, DOI 10.1080/21645515.2021.1909327; Zimmer C., 2020, NEW YORK TIMES	32	4	4	10	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							835	10.3390/vaccines9080835			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5DV	34451960	gold, Green Published			2022-04-29	WOS:000689952300001
J	Petras, M; Lesna, IK; Danova, J; Celko, AM				Petras, Marek; Lesna, Ivana Kralova; Danova, Jana; Celko, Alexander M.			Can Vaccination Trigger Autoimmune Disorders? A Meta-Analysis	VACCINES			English	Review						vaccine-associated autoimmune disease; immunization; meta-analysis; vaccine safety	HEPATITIS-B VACCINATION; MULTIPLE-SCLEROSIS; DEMYELINATING DISEASES; RISK; POWER; VACCINES	Vaccination as an important tool in the fight against infections has been suggested as a possible trigger of autoimmunity over the last decades. To confirm or refute this assumption, a Meta-analysis of Autoimmune Disorders Association With Immunization (MADAWI) was conducted. Included in the meta-analysis were a total of 144 studies published in 1968-2019 that were available in six databases and identified by an extensive literature search conducted on 30 November 2019. The risk of bias classification of the studies was performed using the Newcastle-Ottawa Quality Assessment Scale. The strength of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation. While our primary analysis was conducted in terms of measures of association employed in studies with a low risk of bias, the robustness of the MADAWI outcome was tested using measures independent of each study risk of bias. Additionally, subgroup analyses were performed to determine the stability of the outcome. The pooled association of 0.99 (95% confidence interval, 0.97-1.02), based on a total of 364 published estimates, confirmed an equivalent occurrence of autoimmune disorders in vaccinated and unvaccinated persons. The same level of association reported by studies independently of the risk of bias was supported by a sufficient number of studies, and no serious limitation, inconsistency, indirectness, imprecision, and publication bias. A sensitivity analysis did not reveal any discrepancy in the primary result. Current common vaccination is not the cause of any of the examined autoimmune disorders in the medium and long terms.	[Petras, Marek; Danova, Jana; Celko, Alexander M.] Charles Univ Prague, Fac Med 3, Dept Epidemiol & Biostat, Prague 10000, Czech Republic; [Lesna, Ivana Kralova] Inst Clin & Expt Med, Ctr Med Expt, Lab Atherosclerosis Res, Prague 14021, Czech Republic		Petras, M (通讯作者)，Charles Univ Prague, Fac Med 3, Dept Epidemiol & Biostat, Prague 10000, Czech Republic.	marek.petras@lf3.cuni.cz; ivka@ikem.cz; jana.danova@lf3.cuni.cz; martin.celko@lf3.cuni.cz	Petras, Marek/G-8739-2019	Petras, Marek/0000-0003-2913-1736	UK PROGRES Q16-Environmental research project, Charles University in Prague, Czech Republic	This research was funded by UK PROGRES Q16-Environmental research project, Charles University in Prague, Czech Republic.	Albert LJ, 1999, NEW ENGL J MED, V341, P2068, DOI 10.1056/NEJM199912303412707; ALTER M, 1968, NEUROLOGY, V18, P109, DOI 10.1212/WNL.18.2.109; Chaimani A, 2014, EVID-BASED MENT HEAL, V17, P111, DOI 10.1136/eb-2014-101967; de Chambrun GP, 2015, CLIN GASTROENTEROL H, V13, P1405, DOI 10.1016/j.cgh.2015.04.179; DUKE RC, 1989, J EXP MED, V170, P59, DOI 10.1084/jem.170.1.59; Elwood JM, 2018, VACCINE, V36, P5796, DOI 10.1016/j.vaccine.2018.07.074; Farez MF, 2011, J NEUROL, V258, P1197, DOI 10.1007/s00415-011-5984-2; Genovese C, 2018, J Prev Med Hyg, V59, pE194, DOI 10.15167/2421-4248/jpmh2018.59.3.998; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Hedges LV, 2001, PSYCHOL METHODS, V6, P203, DOI 10.1037/1082-989X.6.3.203; Hernan MA, 2006, NEUROLOGY, V67, P212, DOI 10.1212/01.wnl.0000225079.51201.f9; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jackson D, 2017, RES SYNTH METHODS, V8, P290, DOI 10.1002/jrsm.1240; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jiang HY, 2019, VACCINE, V37, P3031, DOI 10.1016/j.vaccine.2019.04.049; Langridge WHR, 2000, SCI AM, V283, P66; Lerner A., 2016, INT J CELIAC DIS, V3, P151, DOI [10.12691/ijcd-3-4-8, DOI 10.12691/IJCD-3-4-8]; Mailand MT, 2017, J NEUROL, V264, P1035, DOI 10.1007/s00415-016-8263-4; Mantadakis E, 2010, J PEDIATR-US, V156, P623, DOI 10.1016/j.jpeds.2009.10.015; Arias LHM, 2015, VACCINE, V33, P3773, DOI 10.1016/j.vaccine.2015.05.013; Martinez-Sernandez V, 2013, J NEUROL, V260, P1951, DOI 10.1007/s00415-012-6716-y; Meggiolaro A, 2018, HUM VACC IMMUNOTHER, V14, P1266, DOI 10.1080/21645515.2017.1423155; Mellone NG, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01075; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Morgan E, 2016, DIABETOLOGIA, V59, P237, DOI 10.1007/s00125-015-3800-8; Mouchet J, 2018, PHARMACOL RES, V132, P108, DOI 10.1016/j.phrs.2018.04.007; Mouchet J, 2018, VACCINE, V36, P1548, DOI 10.1016/j.vaccine.2018.02.036; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Petras M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020150; Regner M, 2001, NAT IMMUNOL, V2, P185, DOI 10.1038/85228; Sestili C, 2021, HUM VACC IMMUNOTHER, V17, P2273, DOI 10.1080/21645515.2018.1528835; Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2; STRATTON KR, 1994, JAMA-J AM MED ASSOC, V271, P1602, DOI 10.1001/jama.271.20.1602; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Todd JA, 2001, IMMUNITY, V15, P387, DOI 10.1016/S1074-7613(01)00202-3; Valentine JC, 2010, J EDUC BEHAV STAT, V35, P215, DOI 10.3102/1076998609346961; Wells G.A., NEWCASTLE OTTAWA SCA; Wraith DC, 2003, LANCET, V362, P1659, DOI 10.1016/S0140-6736(03)14802-7; Xie S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116517	39	3	3	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							821	10.3390/vaccines9080821			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6NE	34451946	Green Published			2022-04-29	WOS:000690044200001
J	Salomoni, MG; Di Valerio, Z; Gabrielli, E; Montalti, M; Tedesco, D; Guaraldi, F; Gori, D				Salomoni, Maria Giulia; Di Valerio, Zeno; Gabrielli, Elisa; Montalti, Marco; Tedesco, Dario; Guaraldi, Federica; Gori, Davide			Hesitant or Not Hesitant? A Systematic Review on Global COVID-19 Vaccine Acceptance in Different Populations	VACCINES			English	Review						coronavirus; COVID-19; global vaccination; healthcare workers; SARS-CoV-2; vaccination attitude; vaccine acceptance rate; vaccine hesitancy; vaccine intention; vaccine rejection	HEALTH-CARE WORKERS; INFLUENZA VACCINATION; SOCIOECONOMIC-STATUS; WILLINGNESS; INTENTION; DISEASE; ACCEPTABILITY; SARS-COV-2; ATTITUDES; CHILDREN	Vaccination currently appears to be the only strategy to contain the spread of COVID-19. At the same time, vaccine hesitancy (VH) could limit its efficacy and has, therefore, attracted the attention of Public Health Systems. This systematic review aimed at assessing anti-COVID-19 vaccine acceptance rates worldwide and at identifying populations more prone to vaccine hesitancy, for which specific interventions should be planned. PubMed database was searched using a purposely formulated string. One hundred out of the 9243 studies retrieved were considered pertinent and thus included in the analyses. VH rate was analyzed according to patient geographical origin, ethnicity, age, study setting, and method used for data collection; data from specific populations were separately analyzed. Overall, this study demonstrated significant differences in terms of VH in the general population and in the specific subgroups examined according to geographical, demographic factors, as well as associated comorbidities, underlining the need for purposely designed studies in specific populations from the different countries, to design targeted programs aimed at increasing awareness for confidence and complacency toward COVID-19 vaccines.	[Salomoni, Maria Giulia; Di Valerio, Zeno; Gabrielli, Elisa; Montalti, Marco; Gori, Davide] Univ Bologna, Dept Biomed & Neuromotor Sci, Unit Hyg, Publ Hlth & Med Stat, I-40126 Bologna, Italy; [Tedesco, Dario] Reg Author Healthcare & Welf, I-40126 Bologna, Emilia Romagna, Italy; [Guaraldi, Federica] IRCCS Ist Sci Neurol Bologna, Pituitary Unit, I-40139 Bologna, Italy		Montalti, M (通讯作者)，Univ Bologna, Dept Biomed & Neuromotor Sci, Unit Hyg, Publ Hlth & Med Stat, I-40126 Bologna, Italy.	mariagiulia.salomoni@studio.unibo.it; zeno.divalerio@studio.unibo.it; elisa.gabrielli4@studio.unibo.it; marco.montalti7@studio.unibo.it; dario.tedesco@regione.emilia-romagna.it; federica.guaraldi@yahoo.it; davide.gori4@unibo.it	Tedesco, Dario/AAD-8342-2022; Gori, Davide/AAC-3486-2022; Montalti, Marco/AAQ-2494-2021	Gori, Davide/0000-0003-4954-9419; Montalti, Marco/0000-0001-7276-0277; Guaraldi, Federica/0000-0001-8416-1669; TEDESCO, DARIO/0000-0002-5027-5446			Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Al-Qerem WA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.632914; Alabdulla M, 2021, INFLUENZA OTHER RESP, V15, P361, DOI 10.1111/irv.12847; Allen JD, 2021, TRANSL BEHAV MED, V11, P785, DOI 10.1093/tbm/ibab014; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; Amin DP, 2021, AM J EMERG MED, V48, P372, DOI 10.1016/j.ajem.2021.01.089; [Anonymous], EC DISADVANTAGE; Barello S, 2021, PSYCHOL MED, DOI 10.1017/S003329172100101X; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Barriere J, 2021, ANN ONCOL, V32, P673, DOI 10.1016/j.annonc.2021.01.066; Batty GD, 2021, BRAIN BEHAV IMMUN, V96, P100, DOI 10.1016/j.bbi.2021.05.016; Bello AK, 2008, CLIN J AM SOC NEPHRO, V3, P1316, DOI 10.2215/CJN.00680208; Bocquier A, 2020, HUM VACC IMMUNOTHER, V16, P2565, DOI 10.1080/21645515.2020.1729628; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810; Caban-Martinez AJ, 2021, J OCCUP ENVIRON MED, V63, P369, DOI 10.1097/JOM.0000000000002152; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Castaneda-Vasquez DE, 2021, J OCCUP ENVIRON MED, V63, P633, DOI 10.1097/JOM.0000000000002205; Chew NWS, 2021, INT J INFECT DIS, V106, P52, DOI 10.1016/j.ijid.2021.03.069; Daly M, 2021, AM J PREV MED, V60, P766, DOI 10.1016/j.amepre.2021.01.008; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Di Gennaro F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030371; Dinga JN, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020175; Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Eguia H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020170; Ehde DM, 2021, MULT SCLER RELAT DIS, V49, DOI 10.1016/j.msard.2021.102788; Faasse K, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.551004; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gan L, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18041993; Gatwood J, 2021, AM J HEALTH-SYST PH, V78, P879, DOI 10.1093/ajhp/zxab099; Gerayeli FV, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100789; Gerussi V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020172; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Gori D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070752; Gori D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020173; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Graupensperger S, 2021, VACCINE, V39, P2060, DOI 10.1016/j.vaccine.2021.03.018; Green MS, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00458-w; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Jackson SE, 2021, NICOTINE TOB RES, V23, P1623, DOI 10.1093/ntr/ntab039; Jordan Rachel E, 2020, BMJ, V368, pm1198, DOI 10.1136/bmj.m1198; Karlsson LC, 2021, PERS INDIV DIFFER, V172, DOI 10.1016/j.paid.2020.110590; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kociolek LK, 2021, INFECT CONT HOSP EP, V42, P775, DOI [10.1017/ice.2021.58, 10.1017/ice.2021.415]; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kuter BJ, 2021, VACCINE, V39, P1693, DOI 10.1016/j.vaccine.2021.02.029; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Latkin C, 2021, VACCINE, V39, P2237, DOI 10.1016/j.vaccine.2021.02.058; Lazarus JV, 2021, NAT MED, V27, P354, DOI 10.1038/s41591-020-01226-0; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100495; MANNING ML, 2021, NURS OUTLOOK, P233; McGurnaghan SJ, 2021, LANCET DIABETES ENDO, V9, P82, DOI 10.1016/S2213-8587(20)30405-8; Meier BP, 2021, J PUBLIC HEALTH-UK, DOI [10.1093/pubmed/fdab013, 10.1080/00224545.2021.1935830]; Mellis AM, 2021, DRUG ALCOHOL DEPEN, V220, DOI 10.1016/j.drugalcdep.2021.108519; Meyer MN, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.5344; Mo PKH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020129; Montagni I, 2021, J PUBLIC HEALTH-UK, V43, P695, DOI 10.1093/pubmed/fdab028; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Pamplona GM, 2021, KIDNEY INT REP, V6, P1192, DOI 10.1016/j.ekir.2021.02.001; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Parajuli Janaki, 2020, J Nepal Health Res Counc, V18, P466, DOI 10.33314/jnhrc.v18i3.2816; Paris C, 2021, INFECT DIS NOW, V51, P484, DOI 10.1016/j.idnow.2021.04.001; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Patrick ME, 2012, J STUD ALCOHOL DRUGS, V73, P772, DOI 10.15288/jsad.2012.73.772; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Piltch-Loeb R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251095; Plans-Rubio P, 2012, HUM VACC IMMUNOTHER, V8, DOI 10.4161/hv.18444; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Prati G, 2020, HEALTH EDUC RES, V35, P505, DOI 10.1093/her/cyaa043; Priori R, 2021, ANN RHEUM DIS, V80, P893, DOI [10.1136/annrheumdis-2021-eular.2622, 10.1136/annrheumdis-2021-220059]; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Razai MS, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1138; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Rungkitwattanakul D, 2021, HEMODIAL INT, V25, P410, DOI 10.1111/hdi.12922; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Salmon DA, 2021, VACCINE, V39, P2698, DOI 10.1016/j.vaccine.2021.03.034; Schrading WA, 2021, ACAD EMERG MED, V28, P455, DOI 10.1111/acem.14236; Serrazina F, 2021, MULT SCLER RELAT DIS, V51, DOI 10.1016/j.msard.2021.102880; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Shaw J, 2021, CLIN INFECT DIS, V73, P1776, DOI 10.1093/cid/ciab054; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Talbot TR, 2005, INFECT CONT HOSP EP, V26, P882, DOI 10.1086/502512; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Unroe KT, 2021, J AM GERIATR SOC, V69, P593, DOI 10.1111/jgs.17022; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Williams L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010017; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Yigit M, 2021, PEDIATR INFECT DIS J, V40, pE134, DOI 10.1097/INF.0000000000003042; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Yu YW, 2022, IEEE-ASME T MECH, V27, P928, DOI [10.34172/ijhpm.2021.02, 10.1109/TMECH.2021.3075057]; Zhang KC, 2021, J MED INTERNET RES, V23, DOI 10.2196/24673; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2; Zigron A, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.618403	122	14	14	3	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							873	10.3390/vaccines9080873			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UH2MZ	34452000	Green Published, gold			2022-04-29	WOS:000689773300001
J	Kohl, C; Nitsche, A; Kurth, A				Kohl, Claudia; Nitsche, Andreas; Kurth, Andreas			Update on Potentially Zoonotic Viruses of European Bats	VACCINES			English	Review						bats; virome; metagenomics; Issyk-Kul virus; SARS-like CoV; zoonoses; Zwiesel bat banyangvirus; Mammalian orthoreovirus; Lloviu virus	RESPIRATORY SYNDROME CORONAVIRUS; WEST-NILE-VIRUS; THROMBOCYTOPENIA SYNDROME VIRUS; MAMMALIAN ORTHOREOVIRUS TYPE-3; MARBURG HEMORRHAGIC-FEVER; ISSYK-KUL VIRUS; INFECTIOUS-DISEASES; LYSSAVIRUS TYPE-1; FRUIT BATS; MOLECULAR CHARACTERIZATION	Bats have been increasingly gaining attention as potential reservoir hosts of some of the most virulent viruses known. Numerous review articles summarize bats as potential reservoir hosts of human-pathogenic zoonotic viruses. For European bats, just one review article is available that we published in 2014. The present review provides an update on the earlier article and summarizes the most important viruses found in European bats and their possible implications for Public Health. We identify the research gaps and recommend monitoring of these viruses.	[Kohl, Claudia; Nitsche, Andreas; Kurth, Andreas] Robert Koch Inst, Ctr Biol Threats & Special Pathogens, D-13353 Berlin, Germany		Kohl, C (通讯作者)，Robert Koch Inst, Ctr Biol Threats & Special Pathogens, D-13353 Berlin, Germany.	KohlC@rki.de; NitscheA@rki.de; kurtha@rki.de		kohl, claudia/0000-0002-1480-8911; Nitsche, Andreas/0000-0001-8185-3176			Adjemian J, 2011, J INFECT DIS, V204, pS796, DOI 10.1093/infdis/jir312; Ain-Najwa MY, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10122367; Al-Salihi KA, 2021, VET WORLD, V14, P190, DOI 10.14202/vetworld.2021.190-199; ALLEN R, 1970, AM J TROP MED HYG, V19, P851, DOI 10.4269/ajtmh.1970.19.851; Amman BR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002877; Amorim F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087291; Amoroso MG, 2018, ZOONOSES PUBLIC HLTH, V65, P702, DOI 10.1111/zph.12484; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503; Appleton BR, 2004, MOL PHYLOGENET EVOL, V31, P431, DOI 10.1016/j.ympev.2003.08.017; Arai S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030228; Arai S, 2013, EMERG INFECT DIS, V19, P1159, DOI 10.3201/eid1907.121549; Ceballos NA, 2013, EMERG INFECT DIS, V19, P793, DOI 10.3201/eid1905.121071; August TA, 2012, VECTOR-BORNE ZOONOT, V12, P530, DOI 10.1089/vbz.2011.0829; Aznar-Lopez C, 2013, J GEN VIROL, V94, P69, DOI 10.1099/vir.0.046490-0; Badrane H, 2001, J VIROL, V75, P3268, DOI 10.1128/JVI.75.7.3268-3276.2001; Baggieri M, 2015, VIRUS RES, V200, P35, DOI 10.1016/j.virusres.2015.01.013; Balboni A, 2011, EPIDEMIOL INFECT, V139, P216, DOI 10.1017/S0950268810001147; Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041; Banyai K, 2017, INFECT GENET EVOL, V48, P19, DOI 10.1016/j.meegid.2016.12.002; Banyard AC, 2018, J GEN VIROL, V99, P1590, DOI 10.1099/jgv.0.001068; Bell D, 2021, SCI REP-UK, DOI [10.21203/rs.3.rs-358285/v1, DOI 10.21203/RS.3.RS-358285/V1]; Beyer RM, 2021, SCI TOTAL ENVIRON, V767, DOI 10.1016/j.scitotenv.2021.145413; BOIRO I, 1987, B SOC PATHOL EXOT, V80, P62; Boklund A, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11010164; BOURHY H, 1992, J CLIN MICROBIOL, V30, P2419, DOI 10.1128/JCM.30.9.2419-2426.1992; Boyles JG, 2011, SCIENCE, V332, P41, DOI 10.1126/science.1201366; Brauburger K, 2012, VIRUSES-BASEL, V4, P1878, DOI 10.3390/v4101878; Brinkmann A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79468-8; Brinkmann A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006075; Bunde JM, 2006, J WILDLIFE DIS, V42, P455, DOI 10.7589/0090-3558-42.2.455; Cadar D, 2014, EMERG INFECT DIS, V20, P1771, DOI 10.3201/eid2010.140909; Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06; Calvelage S, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010069; CANARD B, 1994, GENE, V148, P1, DOI 10.1016/0378-1119(94)90226-7; Carroll MW, 2015, NATURE, V524, P97, DOI 10.1038/nature14594; Charrel RN, 2005, EMERG INFECT DIS, V11, P1657, DOI 10.3201/eid1111.050869; Chen LH, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau021; Cheng P, 2009, J CLIN VIROL, V45, P79, DOI 10.1016/j.jcv.2009.03.001; Choisy M, 2006, P ROY SOC B-BIOL SCI, V273, P2025, DOI 10.1098/rspb.2006.3554; Chua KB, 2007, P NATL ACAD SCI USA, V104, P11424, DOI 10.1073/pnas.0701372104; Chua KB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025434; Chua KB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003803; Cirkovic V, 2016, TROP BIOMED, V33, P780; Cisneros LM, 2014, J ANIM ECOL, V83, P1124, DOI 10.1111/1365-2656.12201; Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001; Cui R, 2008, AM J TROP MED HYG, V78, P1007, DOI 10.4269/ajtmh.2008.78.1007; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; Dacheux L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087194; Dacheux L, 2010, J VIROL, V84, P9557, DOI 10.1128/JVI.00771-10; Davis A, 2005, AM J TROP MED HYG, V73, P467, DOI 10.4269/ajtmh.2005.73.467; de Araujo Jansen, 2012, BMC Research Notes, V5, P690, DOI 10.1186/1756-0500-5-690; De Benedictis P, 2014, VIRUS GENES, V48, P366, DOI 10.1007/s11262-013-1008-x; De Sabato L, 2019, VIRUS RES, V260, P60, DOI 10.1016/j.virusres.2018.11.007; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Decaro N, 2005, VET MICROBIOL, V109, P19, DOI 10.1016/j.vetmic.2005.05.014; Delmas O, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002057; Diakoudi G, 2020, ARCH VIROL, V165, P1019, DOI 10.1007/s00705-020-04548-z; Diakoudi G, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060523; DIETZ C., 2007, HDB FLEDERMAUSE EURO; Drexler JF, 2015, P NATL ACAD SCI USA, V112, P15190, DOI 10.1073/pnas.1516992112; Drexler JF, 2012, J VIROL, V86, P9134, DOI 10.1128/JVI.00800-12; Drexler JF, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1796; Drexler JF, 2011, EMERG INFECT DIS, V17, P449, DOI 10.3201/eid1703.100526; Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Du LF, 2010, ARCH VIROL, V155, P1295, DOI 10.1007/s00705-010-0690-4; Dubovi E.J., 2016, FENNERS VET VIROLOGY, DOI [10.1016/C2013-0-06921-6, DOI 10.1016/C2013-0-06921-6]; Dufkova L, 2015, VECTOR-BORNE ZOONOT, V15, P518, DOI 10.1089/vbz.2015.1813; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; Epstein JH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000972; Falcon A, 2011, ARCH VIROL, V156, P1883, DOI 10.1007/s00705-011-1057-1; Fereidouni S, 2015, ZOONOSES PUBLIC HLTH, V62, P187, DOI 10.1111/zph.12131; Fischer K, 2016, INFECT GENET EVOL, V37, P108, DOI 10.1016/j.meegid.2015.11.010; Fooks AR, 2003, EPIDEMIOL INFECT, V131, P1029, DOI 10.1017/S0950268803001481; Fooks AR, 2003, J MED VIROL, V71, P281, DOI 10.1002/jmv.10481; Forbes KM, 2019, EMERG INFECT DIS, V25, P955, DOI 10.3201/eid2505.181666; Formenty P, 2003, Med Trop (Mars), V63, P291; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Freuling CM, 2013, VIRUS RES, V177, P201, DOI 10.1016/j.virusres.2013.07.021; Freuling CM, 2011, EMERG INFECT DIS, V17, P1519, DOI 10.3201/eid1708.110201; Frutos R, 2020, NEW MICROB NEW INFEC, V38, DOI 10.1016/j.nmni.2020.100816; Garcia-Perez R, 2014, GENOME BIOL EVOL, V6, P94, DOI 10.1093/gbe/evt211; GARD GP, 1973, ARCH GES VIRUSFORSCH, V43, P34, DOI 10.1007/BF01249346; Ge XY, 2016, VIROL SIN, V31, P31, DOI 10.1007/s12250-016-3713-9; Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711; Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439; Goffard A, 2015, VIRUSES-BASEL, V7, P6279, DOI 10.3390/v7122937; Goldstein T, 2018, NAT MICROBIOL, V3, P1084, DOI 10.1038/s41564-018-0227-2; Gouilh MA, 2018, VIROLOGY, V517, P88, DOI 10.1016/j.virol.2018.01.014; Grange ZL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2002324118; Grobbelaar AA, 2011, EMERG INFECT DIS, V17, P2270, DOI 10.3201/eid1712.111035; Guo WP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003159; Halfmann PJ, 2020, NEW ENGL J MED, V383, P592, DOI 10.1056/NEJMc2013400; Hall JS, 2021, TRANSBOUND EMERG DIS, V68, P3443, DOI 10.1111/tbed.13949; Halpin K, 2000, J GEN VIROL, V81, P1927, DOI 10.1099/0022-1317-81-8-1927; Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698; Hutterer R., 2005, BAT MIGRATIONS EUROP; ICTV, 2021, INT COMM TAX VIR ICT; IFUKUBE T, 1991, IEEE T BIO-MED ENG, V38, P461, DOI 10.1109/10.81565; Iglesias-Caballero M, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080443; Jakava-Viljanen M, 2010, EPIDEMIOL INFECT, V138, P1581, DOI 10.1017/S0950268810000373; Janoska M, 2011, VET J, V189, P118, DOI 10.1016/j.tvjl.2010.06.020; Jayme SI, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0331-3; Johara MY, 2001, EMERG INFECT DIS, V7, P439; Johnson CK, 2020, P ROY SOC B-BIOL SCI, V287, DOI 10.1098/rspb.2019.2736; Johnson N, 2010, VET MICROBIOL, V142, P151, DOI 10.1016/j.vetmic.2010.02.001; Kapoor A, 2013, J GEN VIROL, V94, P1051, DOI 10.1099/vir.0.046748-0; Karan LS, 2019, EMERG INFECT DIS, V25, P1774, DOI 10.3201/eid2509.190581; Kemenesi G, 2014, ACTA VIROL, V58, P95, DOI 10.4149/av_2014_01_95; Kemenesi G, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0067-4; Kemenesi G, 2018, ARCH VIROL, V163, P671, DOI 10.1007/s00705-017-3678-5; Kemenesi G, 2015, INFECT GENET EVOL, V33, P288, DOI 10.1016/j.meegid.2015.05.017; Kemenesi G, 2015, J GEN VIROL, V96, P815, DOI 10.1099/jgv.0.000028; Kemenesi G, 2014, VECTOR-BORNE ZOONOT, V14, P846, DOI 10.1089/vbz.2014.1637; KISSI B, 1995, VIROLOGY, V209, P526, DOI 10.1006/viro.1995.1285; Kivisto I, 2020, VECTOR-BORNE ZOONOT, V20, P155, DOI 10.1089/vbz.2018.2367; Kohl C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86435-4; Kohl C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58466-w; Kohl C, 2014, VIRUSES-BASEL, V6, P3110, DOI 10.3390/v6083110; Kohl C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043106; Kohl C, 2012, J VIROL, V86, P1888, DOI 10.1128/JVI.05974-11; Kruger DH, 2011, HUM VACCINES, V7, P685, DOI 10.4161/hv.7.6.15197; Kuemmerle T, 2016, ENVIRON RES LETT, V11, DOI 10.1088/1748-9326/11/6/064020; Kuhn JH, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060164; Kuno G, 2006, AM J TROP MED HYG, V75, P1165, DOI 10.4269/ajtmh.2006.75.1165; Kurth A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038688; Kuzmin IV, 2005, VIRUS RES, V111, P28, DOI 10.1016/j.virusres.2005.03.008; Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0; Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102; Lazov CM, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090486; Lecis R, 2020, VIRUS GENES, V56, P325, DOI 10.1007/s11262-020-01747-3; Lecis R, 2019, VIRUS GENES, V55, P60, DOI 10.1007/s11262-018-1614-8; Lelli D, 2013, ZOONOSES PUBLIC HLTH, V60, P84, DOI 10.1111/zph.12001; Lelli D, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060568; Lelli D, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0949-z; Lelli D, 2015, VIRUSES-BASEL, V7, P5844, DOI 10.3390/v7112908; Lelli D, 2013, VIRUSES-BASEL, V5, P2679, DOI 10.3390/v5112679; Leopardi S, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010004; Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a; Lewandowska DW, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2946-7; Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391; Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006; Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640; LUMIO J, 1986, LANCET, V1, P378; LVOV DK, 1984, VOP VIRUSOL+, P89; LVOV DK, 1973, ARCH GES VIRUSFORSCH, V42, P207, DOI 10.1007/BF01270841; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; McCain CM, 2007, GLOBAL ECOL BIOGEOGR, V16, P1, DOI 10.1111/j.1466-8238.2006.00263.x; McMullan LK, 2012, NEW ENGL J MED, V367, P834, DOI 10.1056/NEJMoa1203378; Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172; Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985; Mikheyev AS, 2014, MOL ECOL RESOUR, V14, P1097, DOI 10.1111/1755-0998.12324; Mingo-Casas P, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006290; Mohd HA, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0544-0; Moldal T, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1135-z; Molnar V, 2008, ACTA VET HUNG, V56, P529, DOI 10.1556/AVet.56.2008.4.10; Moreno A, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0907-1; Mourya DT, 2014, J VIROL, V88, P3605, DOI 10.1128/JVI.02617-13; Muhldorfer K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029773; Muller MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26637; Muller T, 2007, ARCH VIROL, V152, P273, DOI 10.1007/s00705-006-0853-5; Muise KA, 2018, PHYSIOL BEHAV, V194, P356, DOI 10.1016/j.physbeh.2018.06.003; Muller T, 2004, J VET MED B, V51, P49, DOI 10.1111/j.1439-0450.2003.00725.x; Munnink Bas B. Oude, 2021, Science (Washington D C), V371, P172, DOI 10.1126/science.abe5901; Naglic T, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1585-y; Negredo A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002304; Neuweiler G., 2000, BIOL BATS; Nobach D, 2020, VIROL J, V17, DOI 10.1186/s12985-020-1289-3; Nokireki T, 2018, TRANSBOUND EMERG DIS, V65, P593, DOI 10.1111/tbed.12833; Nokireki T, 2017, ACTA VET SCAND, V59, DOI 10.1186/s13028-017-0331-y; Normile D, 2004, SCIENCE, V304, P659, DOI 10.1126/science.304.5671.659; Normile D, 2004, SCIENCE, V303, P26, DOI 10.1126/science.303.5654.26; Normile D, 2003, SCIENCE, V301, P1642; Olival KJ, 2017, NATURE, V546, P646, DOI 10.1038/nature22975; Onyango CO, 2007, J INFECT DIS, V196, pS193, DOI 10.1086/520609; Oreshkova N, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.23.2001005; Paez DJ, 2017, EPIDEMIOL INFECT, V145, P3143, DOI 10.1017/S0950268817002138; Park SW, 2014, EMERG INFECT DIS, V20, P1880, DOI 10.3201/eid2011.140888; PAUL SD, 1970, INDIAN J MED RES, V58, P1169; Pauly M, 2017, APPL ENVIRON MICROB, V83, DOI [10.1128/AEM.01326-17, 10.1128/aem.01326-17]; Peterson AT, 2004, EMERG INFECT DIS, V10, P2073, DOI 10.3201/eid1012.040346; Phan TG, 2012, J VIROL, V86, P11024, DOI 10.1128/JVI.01427-12; Picard-Meyer E, 2004, VET REC, V154, P589, DOI 10.1136/vr.154.19.589; Picard-Meyer E, 2019, ZOONOSES PUBLIC HLTH, V66, P254, DOI 10.1111/zph.12535; Picard-Meyer E, 2013, ARCH VIROL, V158, P2333, DOI 10.1007/s00705-013-1747-y; Pilipski JD, 2004, J WILDLIFE DIS, V40, P335, DOI 10.7589/0090-3558-40.2.335; Plowright RK, 2017, NAT REV MICROBIOL, V15, P502, DOI 10.1038/nrmicro.2017.45; Plowright RK, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004796; Plowright RK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.2124; Poon LLM, 2004, LANCET INFECT DIS, V4, P663, DOI 10.1016/S1473-3099(04)01172-7; Pourrut X, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-159; Pozo F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169153; Pritchard LI, 2006, ARCH VIROL, V151, P229, DOI 10.1007/s00705-005-0644-4; QUILLIEN MC, 1986, ACTA VIROL, V30, P418; Racey PA, 2013, ZOONOSES PUBLIC HLTH, V60, P58, DOI 10.1111/j.1863-2378.2012.01533.x; Ramezani A, 2017, SCI ROBOT, V2, DOI 10.1126/scirobotics.aal2505; de Arellano ER, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040360; Rebelo H, 2010, GLOBAL CHANGE BIOL, V16, P561, DOI 10.1111/j.1365-2486.2009.02021.x; Reusken CBEM, 2010, VECTOR-BORNE ZOONOT, V10, P785, DOI 10.1089/vbz.2009.0173; Rihtaric D, 2010, ARCH VIROL, V155, P507, DOI 10.1007/s00705-010-0612-5; Rizzo F, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1307-x; Rydell J, 2010, EUR J WILDLIFE RES, V56, P823, DOI 10.1007/s10344-010-0444-3; Saez AM, 2015, EMBO MOL MED, V7, P17, DOI 10.15252/emmm.201404792; Savage HM, 2013, AM J TROP MED HYG, V89, P445, DOI 10.4269/ajtmh.13-0209; Schatz J, 2013, ZOONOSES PUBLIC HLTH, V60, P22, DOI 10.1111/zph.12002; Schlottau K, 2020, LANCET MICROBE, V1, pE218, DOI 10.1016/S2666-5247(20)30089-6; Senior K, 2003, LANCET INFECT DIS, V3, P679, DOI 10.1016/S1473-3099(03)00815-6; Serra-Cobo J, 2002, EMERG INFECT DIS, V8, P413, DOI 10.3201/eid0804.010263; Sherwin HA, 2013, MAMMAL REV, V43, P171, DOI 10.1111/j.1365-2907.2012.00214.x; Siegert R, 1968, Ger Med Mon, V13, P514; Simic I, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080891; Simic I, 2019, MICROBIOL RESOUR ANN, V8, DOI 10.1128/MRA.00280-19; Simmonds P, 2019, NAT REV MICROBIOL, V17, P321, DOI 10.1038/s41579-018-0120-2; Simsek C, 2021, MBIO, V12, DOI 10.1128/mBio.02755-20; Sit THC, 2020, NATURE, V586, P776, DOI 10.1038/s41586-020-2334-5; Slenczka W, 2007, J INFECT DIS, V196, pS131, DOI 10.1086/520551; Smreczak M, 2018, ZOONOSES PUBLIC HLTH, V65, P1015, DOI 10.1111/zph.12519; Sohayati A R, 2011, Epidemiol Infect, V139, P1570, DOI 10.1017/S0950268811000550; Sonntag M, 2009, EMERG INFECT DIS, V15, P2052, DOI 10.3201/eid1512.090646; Steyer A, 2013, J CLIN MICROBIOL, V51, P3818, DOI 10.1128/JCM.01531-13; Strakova P, 2017, INFECT GENET EVOL, V48, P127, DOI 10.1016/j.meegid.2016.12.025; Sumibcay L, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-34; Tajima S, 2005, VIROLOGY, V332, P38, DOI 10.1016/j.virol.2004.06.052; Tang XY, 2013, J INFECT DIS, V207, P736, DOI 10.1093/infdis/jis748; Taubenberger JK, 2010, CELL HOST MICROBE, V7, P440, DOI 10.1016/j.chom.2010.05.009; Thalmann CM, 2010, VIROLOGY, V402, P26, DOI 10.1016/j.virol.2009.11.048; Timen A, 2009, EMERG INFECT DIS, V15, P1171, DOI [10.3201/eid1508.090051, 10.3201/eid1508.090015]; Tjornehoj K, 2006, J COMP PATHOL, V134, P190, DOI 10.1016/j.jcpa.2005.10.005; Torres-Castro M, 2021, ZOONOSES PUBLIC HLTH, V68, P834, DOI 10.1111/zph.12834; Towner JS, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000536; Tuttle Merlin D., 2013, P363; Urbanowicz RA, 2016, CELL, V167, P1079, DOI 10.1016/j.cell.2016.10.013; Van der Poel WHM, 2005, EMERG INFECT DIS, V11, P1854, DOI 10.3201/eid1112.041200; van Doremalen N, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120727; Vazquez-Moron S, 2011, EMERG INFECT DIS, V17, P520, DOI 10.3201/eid1703.100894; Vidovszky MZ, 2020, J GEN VIROL, V101, P1119, DOI 10.1099/jgv.0.001467; Vidovszky MZ, 2015, ACTA VET HUNG, V63, P508, DOI 10.1556/004.2015.047; Voigt Christian C., 2016, P427; Walker PJ, 2020, ARCH VIROL, V165, P2737, DOI 10.1007/s00705-020-04752-x; Walker PJ, 2016, AM J TROP MED HYG, V94, P1107, DOI 10.4269/ajtmh.15-0917; Wang HZ, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101737; Wang LF, 2006, EMERG INFECT DIS, V12, P1834; Wang QH, 2014, CELL HOST MICROBE, V16, P328, DOI 10.1016/j.chom.2014.08.009; Watanabe S, 2010, COMP IMMUNOL MICROB, V33, P25, DOI 10.1016/j.cimid.2008.07.008; Weaver SC, 2004, NAT REV MICROBIOL, V2, P789, DOI 10.1038/nrmicro1006; Weiss S, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0843-0; Weiss S, 2012, EMERG INFECT DIS, V18, P159, DOI 10.3201/eid1801.111026; Weissenbock H, 2013, EMERG INFECT DIS, V19, P274, DOI 10.3201/eid1902.121191; Wibbelt G, 2007, J GEN VIROL, V88, P2651, DOI 10.1099/vir.0.83045-0; Wolf RC, 2020, NEUROPSYCHOBIOLOGY, V79, P335, DOI 10.1159/000505601; World Health Organization, 2021, WHO DIRECTOR GEN OPE; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wurtz N, 2016, EUR J CLIN MICROBIOL, V35, P1247, DOI 10.1007/s10096-016-2657-1; Yahiro T, 2014, EMERG INFECT DIS, V20, P1037, DOI 10.3201/eid2006.131430; Yang XL, 2017, EMERG INFECT DIS, V23, P482, DOI 10.3201/eid2303.161119; Yu XJ, 2011, NEW ENGL J MED, V364, P1523, DOI 10.1056/NEJMoa1010095; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zhang T., 2020, PANGOLIN HOMOLOGY AS, DOI [10.1101/2020.02.19.950253, DOI 10.1101/2020.02.19.950253]; Zhang YZ, 2012, CLIN INFECT DIS, V54, P527, DOI 10.1093/cid/cir804; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	261	5	5	6	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							690	10.3390/vaccines9070690			41	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5EF	34201666	Green Published			2022-04-29	WOS:000676934000001
J	Ahmed, EH; Brooks, E; Sloan, S; Schlotter, S; Jeney, F; Hale, C; Mao, C; Zhang, XL; McLaughlin, E; Shindiapina, P; Shire, S; Das, M; Prouty, A; Lozanski, G; Mamuye, AT; Abebe, T; Alinari, L; Caligiuri, MA; Baiocchi, RA				Ahmed, Elshafa Hassan; Brooks, Eric; Sloan, Shelby; Schlotter, Sarah; Jeney, Frankie; Hale, Claire; Mao, Charlene; Zhang, Xiaoli; McLaughlin, Eric; Shindiapina, Polina; Shire, Salma; Das, Manjusri; Prouty, Alexander; Lozanski, Gerard; Mamuye, Admasu T.; Abebe, Tamrat; Alinari, Lapo; Caligiuri, Michael A.; Baiocchi, Robert A.			Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease	VACCINES			English	Article						Epstein-Barr virus; BZLF1; BZLF1-specific cytotoxic T-cells; vaccine; post-transplant lymphoproliferative disease (PTLD); Hu-PBL-SCID model	EPSTEIN-BARR-VIRUS; CYTOTOXIC T-LYMPHOCYTES; RENAL-TRANSPLANTATION; NASOPHARYNGEAL CARCINOMA; ADOPTIVE IMMUNOTHERAPY; ORGAN-TRANSPLANTATION; CELLULAR-IMMUNITY; PERIPHERAL-BLOOD; UNITED-STATES; GP350 VACCINE	Epstein-Barr virus (EBV) is a human herpes virus that infects over 90% of the world's population and is linked to development of cancer. In immune-competent individuals, EBV infection is mitigated by a highly efficient virus-specific memory T-cell response. Risk of EBV-driven cancers increases with immune suppression (IS). EBV-seronegative recipients of solid organ transplants are at high risk of developing post-transplant lymphoproliferative disease (PTLD) due to iatrogenic IS. While reducing the level of IS may improve EBV-specific immunity and regression of PTLD, patients are at high risk for allograft rejection and need for immune-chemotherapy. Strategies to prevent PTLD in this vulnerable patient population represents an unmet need. We have previously shown that BZLF1-specific cytotoxic T-cell (CTL) expansion following reduced IS correlated with immune-mediated PTLD regression and improved patient survival. We have developed a vaccine to bolster EBV-specific immunity to the BZLF1 protein and show that co-culture of dendritic cells (DCs) loaded with a alpha DEC205-BZLF1 fusion protein with peripheral blood mononuclear cells (PMBCs) leads to expansion and increased cytotoxic activity of central-effector memory CTLs against EBV-transformed B-cells. Human-murine chimeric Hu-PBL-SCID mice were vaccinated with DCs loaded with alpha DEC205-BZLF1 or control to assess prevention of fatal human EBV lymphoproliferative disease. Despite a profoundly immunosuppressive environment, vaccination with alpha DEC205-BZLF1 stimulated clonal expansion of antigen-specific T-cells that produced abundant IFN gamma and significantly prolonged survival. These results support preclinical and clinical development of vaccine approaches using BZLF1 as an immunogen to harness adaptive cellular responses and prevent PTLD in vulnerable patient populations.	[Ahmed, Elshafa Hassan; Sloan, Shelby] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA; [Ahmed, Elshafa Hassan; Brooks, Eric; Sloan, Shelby; Schlotter, Sarah; Jeney, Frankie; Mao, Charlene; Shindiapina, Polina; Das, Manjusri; Prouty, Alexander; Alinari, Lapo; Baiocchi, Robert A.] Ohio State Univ, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Ahmed, Elshafa Hassan; Brooks, Eric; Sloan, Shelby; Schlotter, Sarah; Jeney, Frankie; Mao, Charlene; Shindiapina, Polina; Das, Manjusri; Prouty, Alexander; Alinari, Lapo; Baiocchi, Robert A.] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA; [Hale, Claire] Ohio State Univ, Coll Engn, Dept Biomed Engn, Columbus, OH 43210 USA; [Zhang, Xiaoli; McLaughlin, Eric] Ohio State Univ, Dept Biomed Informat, Ctr Biostat, Columbus, OH 43210 USA; [Shindiapina, Polina; Alinari, Lapo; Baiocchi, Robert A.] Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA; [Shire, Salma] Ohio State Univ, Coll Educ & Human Ecol, Columbus, OH 43210 USA; [Lozanski, Gerard] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Mamuye, Admasu T.] Addis Ababa Univ, Black Lion Hosp, Dept Internal Med, Addis Ababa 3614, Ethiopia; [Abebe, Tamrat] Addis Ababa Univ, Black Lion Hosp, Dept Microbiol, Addis Ababa 3614, Ethiopia; [Caligiuri, Michael A.] City Hope Natl Med Ctr, Duarte, CA 91010 USA		Baiocchi, RA (通讯作者)，Ohio State Univ, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH 43210 USA.; Baiocchi, RA (通讯作者)，Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.; Baiocchi, RA (通讯作者)，Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA.; Caligiuri, MA (通讯作者)，City Hope Natl Med Ctr, Duarte, CA 91010 USA.	elshafa.ahmed@osumc.edu; eric.brooks@osumc.edu; Shelby.Sloan@osumc.edu; Sarah.schlotter@osumc.edu; frankiej336@gmail.com; claire.hale1@outlook.com; Charlene.mao@osumc.edu; Xiaoli.zhang@osumc.edu; eric.mclaughlin@osumc.edu; Polina.shindiapina@osumc.edu; Salma.shire@case.edu; dasmanjusri7@gmail.com; Ap2794@mynsu.nova.edu; Gerard.lozanski@osumc.edu; kadmasen@gmail.com; tamrat.abebe@aau.edu.et; Lapo.Alinari@osumc.edu; mcaligiuri@coh.org; Robert.Baiocchi@osumc.edu		ZHANG, XIAOLI/0000-0002-2495-4568; Abebe, Tamrat/0000-0002-6100-9303	Friends of Jason Gould Foundation; Leukemia Lymphoma Society Translational Research ProgramLeukemia and Lymphoma Society; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1RC2CA148348-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32CA090223]; Minority Hematology Fellow Award - American Society of Hematology Minority Recruitment Initiative	This work was supported by The Friends of Jason Gould Foundation, the Leukemia Lymphoma Society Translational Research Program (to R.A.B. and M.A.C.), the National Institutes of Health (to R.A.B. and M.A.C., 1RC2CA148348-01), and NIH grant T32CA090223 (E.H.A., P.S.). E.H.A. is supported by the Minority Hematology Fellow Award sponsored by the American Society of Hematology Minority Recruitment Initiative.	Abbas Fedaey, 2020, World J Transplant, V10, P29, DOI 10.5500/wjt.v10.i2.29; Ahmed EH, 2016, ILAR J, V57, P55, DOI 10.1093/ilar/ilv074; AlDabbagh MA, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14020; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Babcock GJ, 1999, J EXP MED, V190, P567, DOI 10.1084/jem.190.4.567; BAIOCCHI RA, 1994, P NATL ACAD SCI USA, V91, P5577, DOI 10.1073/pnas.91.12.5577; BAIOCCHI RA, 1995, BLOOD, V85, P1063, DOI 10.1182/blood.V85.4.1063.bloodjournal8541063; Baiocchi RA, 2001, J CLIN INVEST, V108, P887, DOI 10.1172/JCI12932; Balfour HH, 2014, CURR OPIN VIROL, V6, P1, DOI 10.1016/j.coviro.2014.02.005; Bian Z, 2017, BONE MARROW TRANSPL, V52, P264, DOI 10.1038/bmt.2016.238; Bollard CM, 2014, J CLIN ONCOL, V32, P798, DOI 10.1200/JCO.2013.51.5304; Bollard CM, 2004, J EXP MED, V200, P1623, DOI 10.1084/jem.20040890; Bollard CM, 2003, ACTA HAEMATOL-BASEL, V110, P139, DOI 10.1159/000072463; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Brooks JM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005549; Chia WK, 2014, MOL THER, V22, P132, DOI 10.1038/mt.2013.242; Cockfield S M, 2001, Transpl Infect Dis, V3, P70; Cohen JI, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2014.27; Curtis RE, 1999, BLOOD, V94, P2208; DHHS U.S, ORGANDONOR GOV; Doubrovina E, 2012, BLOOD, V119, P2644, DOI 10.1182/blood-2011-08-371971; Elliott SL, 2008, J VIROL, V82, P1448, DOI 10.1128/JVI.01409-07; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Faull RJ, 2005, TRANSPLANTATION, V80, P193, DOI 10.1097/01.TP.0000165098.49658.F3; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; FINERTY S, 1992, J GEN VIROL, V73, P449, DOI 10.1099/0022-1317-73-2-449; Frahm MA, 2012, J IMMUNOL, V188, P4289, DOI 10.4049/jimmunol.1103701; Gottschalk S, 2005, ANNU REV MED, V56, P29, DOI 10.1146/annurev.med.56.082103.104727; GU SY, 1995, DEV BIOL STAND, V84, P171; Guo M, 2000, HUM IMMUNOL, V61, P729, DOI 10.1016/S0198-8859(00)00144-0; Gurer C, 2008, BLOOD, V112, P1231, DOI 10.1182/blood-2008-03-148072; Habib M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09798-7; Haque T, 2001, TRANSPLANTATION, V72, P1399, DOI 10.1097/00007890-200110270-00012; Hartlage AS, 2015, CANCER IMMUNOL RES, V3, P787, DOI 10.1158/2326-6066.CIR-14-0242; Henle W, 1976, Adv Pathobiol, P5; Heslop HE, 2010, BLOOD, V115, P925, DOI 10.1182/blood-2009-08-239186; Heslop HE, 2009, BLOOD, V114, P4002, DOI 10.1182/blood-2009-07-143545; Hislop AD, 2005, J CLIN INVEST, V115, P2546, DOI 10.1172/JCI24810; Hislop AD, 2001, J IMMUNOL, V167, P2019, DOI 10.4049/jimmunol.167.4.2019; Hosseini-Moghaddam SM, 2016, TRANSPL INFECT DIS, V18, P423, DOI 10.1111/tid.12533; Hui-Yuen J, 2011, JOVE-J VIS EXP, DOI 10.3791/3321; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Jedema I, 2004, BLOOD, V103, P2677, DOI 10.1182/blood-2003-06-2070; KASAI M, 1981, NATURE, V291, P334, DOI 10.1038/291334a0; Khan G, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037505; Krueger KM, 2020, AM J KIDNEY DIS, V75, P417, DOI 10.1053/j.ajkd.2019.06.014; LEBLOND V, 1995, J CLIN ONCOL, V13, P961, DOI 10.1200/JCO.1995.13.4.961; Lehmann CHK, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020008; Leipold MD, 2015, METHODS MOL BIOL, V1343, P81, DOI 10.1007/978-1-4939-2963-4_7; Lewin K J, 1997, Pathol Oncol Res, V3, P177, DOI 10.1007/BF02899918; Loren AW, 2003, BONE MARROW TRANSPL, V31, P145, DOI 10.1038/sj.bmt.1703806; Lucas KG, 1996, BLOOD, V87, P2594, DOI 10.1182/blood.V87.6.2594.bloodjournal8762594; Martin SI, 2011, AM J TRANSPLANT, V11, P1058, DOI 10.1111/j.1600-6143.2011.03478.x; Matas AJ, 2015, AM J TRANSPLANT, V15, DOI 10.1111/ajt.13195; McDonald RA, 2008, AM J TRANSPLANT, V8, P984, DOI 10.1111/j.1600-6143.2008.02167.x; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Miyashita EM, 1997, J VIROL, V71, P4882, DOI 10.1128/JVI.71.7.4882-4891.1997; Moutschen M, 2007, VACCINE, V25, P4697, DOI 10.1016/j.vaccine.2007.04.008; Mundo L, 2020, MODERN PATHOL, V33, P2407, DOI 10.1038/s41379-020-0575-3; MURRAY JE, 1968, ANN SURG, V168, P416, DOI 10.1097/00000658-196809000-00010; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; Nourse JP, 2011, AM J TRANSPLANT, V11, P888, DOI 10.1111/j.1600-6143.2011.03499.x; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; Opelz G, 2004, AM J TRANSPLANT, V4, P222, DOI 10.1046/j.1600-6143.2003.00325.x; ORTOLANI C, 1993, BIOCHEM BIOPH RES CO, V191, P601, DOI 10.1006/bbrc.1993.1260; Ou SHI, 2007, ANN ONCOL, V18, P29, DOI 10.1093/annonc/mdl320; Porcu P, 2002, BLOOD, V100, P2341, DOI 10.1182/blood-2002-01-0210; Prockop S, 2020, J CLIN INVEST, V130, P733, DOI 10.1172/JCI121127; Rees L, 2009, TRANSPLANTATION, V88, P1025, DOI 10.1097/TP.0b013e3181b9d918; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Rickinson AB, 1997, ANNU REV IMMUNOL, V15, P405, DOI 10.1146/annurev.immunol.15.1.405; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; Roskrow MA, 1998, BLOOD, V91, P2925, DOI 10.1182/blood.V91.8.2925.2925_2925_2934; Savoldo B, 2006, BLOOD, V108, P2942, DOI 10.1182/blood-2006-05-021782; Shindiapina P, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01723; Smith JM, 2006, TRANSPLANTATION, V81, P175, DOI 10.1097/01.tp.0000188687.18972.a8; Sokal EM, 2007, J INFECT DIS, V196, P1749, DOI 10.1086/523813; Straathof KCM, 2005, BLOOD, V105, P1898, DOI 10.1182/blood-2004-07-2975; TARYLEHMANN M, 1992, J EXP MED, V175, P503, DOI 10.1084/jem.175.2.503; TARYLEHMANN M, 1995, IMMUNOL TODAY, V16, P529, DOI 10.1016/0167-5699(95)80046-8; Thorley-Lawson DA, 2015, CURR TOP MICROBIOL, V390, P151, DOI 10.1007/978-3-319-22822-8_8; Trappe RU, 2017, J CLIN ONCOL, V35, P536, DOI 10.1200/JCO.2016.69.3564; Tsuji T, 2011, J IMMUNOL, V186, P1218, DOI 10.4049/jimmunol.1000808; van Beek J, 2004, J CLIN ONCOL, V22, P664, DOI 10.1200/JCO.2004.08.061; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; van Zyl DG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00104; Walti LN, 2021, AM J TRANSPLANT, V21, P2532, DOI 10.1111/ajt.16423; Wen WR, 2007, J VIROL, V81, P1037, DOI 10.1128/JVI.01416-06; Yamaguchi M, 2018, BLOOD, V131, P2528, DOI 10.1182/blood-2017-12-791418	89	0	0	6	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							555	10.3390/vaccines9060555			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ7LK	34073261	Green Published, gold			2022-04-29	WOS:000666741700001
J	Donninger, H; Li, C; Eaton, JW; Yaddanapudi, K				Donninger, Howard; Li, Chi; Eaton, John W.; Yaddanapudi, Kavitha			Cancer Vaccines: Promising Therapeutics or an Unattainable Dream	VACCINES			English	Review						cancer vaccines; preventative vaccines; therapeutic vaccines; immunotherapy; personalized vaccines	COLONY-STIMULATING FACTOR; CELL LUNG-CANCER; PHASE-I TRIAL; RESISTANT PROSTATE-CANCER; EMBRYONIC ANTIGEN-EXPRESSION; METASTATIC MELANOMA PATIENTS; AUGMENTS ANTITUMOR IMMUNITY; SECRETING TUMOR VACCINE; DENDRITIC CELLS; GM-CSF	The advent of cancer immunotherapy has revolutionized the field of cancer treatment and offers cancer patients new hope. Although this therapy has proved highly successful for some patients, its efficacy is not all encompassing and several cancer types do not respond. Cancer vaccines offer an alternate approach to promote anti-tumor immunity that differ in their mode of action from antibody-based therapies. Cancer vaccines serve to balance the equilibrium of the crosstalk between the tumor cells and the host immune system. Recent advances in understanding the nature of tumor-mediated tolerogenicity and antigen presentation has aided in the identification of tumor antigens that have the potential to enhance anti-tumor immunity. Cancer vaccines can either be prophylactic (preventative) or therapeutic (curative). An exciting option for therapeutic vaccines is the emergence of personalized vaccines, which are tailor-made and specific for tumor type and individual patient. This review summarizes the current standing of the most promising vaccine strategies with respect to their development and clinical efficacy. We also discuss prospects for future development of stem cell-based prophylactic vaccines.	[Donninger, Howard; Li, Chi] Univ Louisville, Expt Therapeut Grp, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; [Donninger, Howard; Eaton, John W.] Univ Louisville, Dept Med, Louisville, KY 40202 USA; [Li, Chi] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; [Eaton, John W.; Yaddanapudi, Kavitha] Univ Louisville, Immunooncol Grp, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; [Yaddanapudi, Kavitha] Univ Louisville, Div Immunotherapy, Dept Surg, Louisville, KY 40202 USA; [Yaddanapudi, Kavitha] Univ Louisville, Dept Microbiol Immunol, Louisville, KY 40202 USA		Yaddanapudi, K (通讯作者)，Univ Louisville, Immunooncol Grp, James Graham Brown Canc Ctr, Louisville, KY 40202 USA.; Yaddanapudi, K (通讯作者)，Univ Louisville, Div Immunotherapy, Dept Surg, Louisville, KY 40202 USA.; Yaddanapudi, K (通讯作者)，Univ Louisville, Dept Microbiol Immunol, Louisville, KY 40202 USA.	howard.donninger@louisville.edu; chi.li@louisville.edu; eatonredox@aol.com; kavitha.yaddanapudi@louisville.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21CA198249]; Free to Breathe Grant; Department of Defense Lung Cancer Research Program [LC180452]; Kentucky Lung Cancer Research Program; Commonwealth of Kentucky Research Challenge Trust Fund	NIH Grant R21CA198249 (K.Y.), Free to Breathe Grant (K.Y.), Department of Defense Lung Cancer Research Program Grant LC180452 (C.L., K.Y.), Kentucky Lung Cancer Research Program (H.D. and K.Y.) and J.W.E. is supported by the Commonwealth of Kentucky Research Challenge Trust Fund.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; ALEXANDER P, 1972, NATURE, V235, P137, DOI 10.1038/235137a0; ALEXANDER P, 1967, BRIT MED BULL, V23, P86, DOI 10.1093/oxfordjournals.bmb.a070523; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; AMBROSE KR, 1969, P SOC EXP BIOL MED, V132, P1013; AMBROSE KR, 1971, NATURE, V233, P194, DOI 10.1038/233194a0; Hernandez-Luna MA, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2984247; Arlen PM, 2007, J UROLOGY, V178, P1515, DOI 10.1016/j.juro.2007.05.117; Armstrong CA, 1996, CANCER RES, V56, P2191; Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205; BALDWIN RW, 1972, ANN I PASTEUR PARIS, V122, P715; BALDWIN RW, 1972, INT J CANCER, V10, P233, DOI 10.1002/ijc.2910100202; Baumgaertner P, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1216290; Beg S, 2020, NANOMEDICINE-UK, V15, P1527, DOI 10.2217/nnm-2020-0046; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENDICH A, 1973, J IMMUNOL, V111, P284; Bezu L, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1511506; Bol KF, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0580-6; Bos R, 2005, CANCER RES, V65, P6443, DOI 10.1158/0008-5472.CAN-05-0666; Bowen WS, 2018, EXPERT REV VACCINES, V17, P207, DOI 10.1080/14760584.2018.1434000; BRAWN RJ, 1970, INT J CANCER, V6, P245, DOI 10.1002/ijc.2910060211; Brayer J, 2015, AM J HEMATOL, V90, P602, DOI 10.1002/ajh.24014; Breckpot K, 2005, J LEUKOCYTE BIOL, V78, P898, DOI 10.1189/jlb.0105052; Brewer BG, 2009, EXP MOL PATHOL, V86, P192, DOI 10.1016/j.yexmp.2008.12.002; Burris HA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2523; BUTTLE GAH, 1967, NATURE, V215, P1495, DOI 10.1038/2151495a0; Butts C, 2014, LANCET ONCOL, V15, P59, DOI 10.1016/S1470-2045(13)70510-2; Calmeiro J, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020158; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Castle PE, 2016, EPIDEMIOL INFECT, V144, P449, DOI 10.1017/S0950268815002198; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chaput N, 2005, EXPERT OPIN BIOL TH, V5, P737, DOI 10.1517/14712598.5.6.737; Chen PF, 2016, HUM VACC IMMUNOTHER, V12, P612, DOI 10.1080/21645515.2015.1105415; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Chesney JA, 2017, J LEUKOCYTE BIOL, V102, P727, DOI 10.1189/jlb.5VMR1116-458RRR; Chianese-Bullock KA, 2005, J IMMUNOL, V174, P3080, DOI 10.4049/jimmunol.174.5.3080; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Cho H, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-LB-093; Cho HI, 2013, CANCER IMMUNOL IMMUN, V62, P787, DOI 10.1007/s00262-012-1382-6; Chodon T, 2018, HEMATOL ONCOL CLIN N, V32, P1025, DOI 10.1016/j.hoc.2018.07.011; COGGIN JH, 1969, P SOC EXP BIOL MED, V130, P246; COLNAGHI MI, 1973, J NATL CANCER I, V50, P173, DOI 10.1093/jnci/50.1.173; Conry RM, 2018, HUM VACC IMMUNOTHER, V14, P839, DOI 10.1080/21645515.2017.1412896; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Coveler AL, 2016, IMMUNOTHERAPY-UK, V8, P117, DOI 10.2217/imt.15.113; Cutts F T, 2004, Expert Rev Vaccines, V3, P349, DOI 10.1586/14760584.3.4.349; Cuzzubbo S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615240; Dillman RO, 2020, MELANOMA MANAG, V7, DOI 10.2217/mmt-2020-0011; DiPaola RS, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-1; Dong W, 2010, CANCER IMMUNOL IMMUN, V59, P1697, DOI 10.1007/s00262-010-0899-9; Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Dranoff G, 2002, IMMUNOL REV, V188, P147, DOI 10.1034/j.1600-065X.2002.18813.x; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240; Dreno B, 2018, LANCET ONCOL, V19, P916, DOI 10.1016/S1470-2045(18)30254-7; Duan F, 2014, J EXP MED, V211, P2231, DOI 10.1084/jem.20141308; Dunussi-Joannopoulos K, 1998, BLOOD, V91, P222, DOI 10.1182/blood.V91.1.222.222_222_230; Engelhard VH, 2002, IMMUNOL REV, V188, P136, DOI 10.1034/j.1600-065X.2002.18812.x; Fenstermaker RA, 2016, CANCER IMMUNOL IMMUN, V65, P1339, DOI 10.1007/s00262-016-1890-x; Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148; Flickinger JC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030048; FOLEY EJ, 1953, CANCER RES, V13, P835; Frazer IH, 2007, EUR J IMMUNOL, V37, pS148, DOI 10.1002/eji.200737820; Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306; GALILI U, 1993, BLOOD, V82, P2485, DOI 10.1182/blood.V82.8.2485.bloodjournal8282485; Galluzzi L, 2016, CANCER IMMUNOL RES, V4, P895, DOI 10.1158/2326-6066.CIR-16-0197; Gardner TA, 2012, HUM VACC IMMUNOTHER, V8, P534, DOI 10.4161/hv.19795; Giaccone G, 2015, EUR J CANCER, V51, P2321, DOI 10.1016/j.ejca.2015.07.035; Gibney GT, 2015, CLIN CANCER RES, V21, P712, DOI 10.1158/1078-0432.CCR-14-2468; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; GRANT JP, 1974, J SURG RES, V16, P533, DOI 10.1016/0022-4804(74)90080-8; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Gulley JL, 2019, J CLIN ONCOL, V37, P1051, DOI 10.1200/JCO.18.02031; Gunn GR, 2001, J IMMUNOL, V167, P6471, DOI 10.4049/jimmunol.167.11.6471; Hammerich L, 2019, NAT MED, V25, P814, DOI 10.1038/s41591-019-0410-x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardacre JM, 2013, J GASTROINTEST SURG, V17, P94, DOI 10.1007/s11605-012-2064-6; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoeller C, 2016, CANCER IMMUNOL IMMUN, V65, P1015, DOI 10.1007/s00262-016-1860-3; HogenEsch H, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00406; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Hulett TW, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0331-0; Jacouton E, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03355; Jaffee EM, 2001, J CLIN ONCOL, V19, P145, DOI 10.1200/JCO.2001.19.1.145; Jaini R, 2010, NAT MED, V16, P799, DOI 10.1038/nm.2161; Jaroslawski S, 2015, BIODRUGS, V29, P301, DOI 10.1007/s40259-015-0140-7; Kantoff PW, 2017, J CLIN ONCOL, V35, P124, DOI 10.1200/JCO.2016.69.7748; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597; Karbach J, 2011, CLIN CANCER RES, V17, P861, DOI 10.1158/1078-0432.CCR-10-1811; Kaufman HL, 2008, CLIN CANCER RES, V14, P4843, DOI 10.1158/1078-0432.CCR-08-0276; Kelly RJ, 2011, CANCER J, V17, P302, DOI 10.1097/PPO.0b013e318233e6b4; KLAVINS JV, 1971, NATURE-NEW BIOL, V234, P153, DOI 10.1038/newbio234153a0; Klein L, 2009, NAT REV IMMUNOL, V9, P833, DOI 10.1038/nri2669; Kooreman NG, 2018, CELL STEM CELL, V22, P501, DOI 10.1016/j.stem.2018.01.016; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Kruit WHJ, 2013, J CLIN ONCOL, V31, P2413, DOI 10.1200/JCO.2012.43.7111; Laheru D, 2008, CLIN CANCER RES, V14, P1455, DOI 10.1158/1078-0432.CCR-07-0371; Lapenta C, 2019, CANCER IMMUNOL IMMUN, V68, P1791, DOI 10.1007/s00262-019-02411-y; Larocca C, 2011, CANCER J, V17, P359, DOI 10.1097/PPO.0b013e3182325e63; LaTemple DC, 1999, CANCER RES, V59, P3417; LAURENCE DJ, 1972, BRIT J CANCER, V26, P335, DOI 10.1038/bjc.1972.45; Le DT, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.345; Le DT, 2015, J CLIN ONCOL, V33, P1325, DOI 10.1200/JCO.2014.57.4244; Le DT, 2013, J IMMUNOTHER, V36, P382, DOI 10.1097/CJI.0b013e31829fb7a2; Le DT, 2010, CANCER J, V16, P304, DOI 10.1097/PPO.0b013e3181eb33d7; Le Gall CM, 2018, NAT MATER, V17, P474, DOI 10.1038/s41563-018-0093-6; LEMEVEL BP, 1973, NATURE-NEW BIOL, V244, P183, DOI 10.1038/newbio244183a0; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li FZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1362-1; Li Y, 2009, STEM CELLS, V27, P3103, DOI 10.1002/stem.234; Link CJ, 1998, ANTICANCER RES, V18, P2301; Lipson EJ, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0572-3; Liu HP, 2014, NATURE, V507, P519, DOI 10.1038/nature12978; Lowy DR, 2006, J CLIN INVEST, V116, P1167, DOI 10.1172/JCI28607; Luiten RM, 2005, J CLIN ONCOL, V23, P8978, DOI 10.1200/JCO.2005.01.6816; Lutz E, 2011, ANN SURG, V253, P328, DOI 10.1097/SLA.0b013e3181fd271c; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003; Madan RA, 2012, LANCET ONCOL, V13, P501, DOI 10.1016/S1470-2045(12)70006-2; Madan RA, 2009, EXPERT OPIN INV DRUG, V18, P1001, DOI 10.1517/13543780902997928; Makkouk A, 2015, CANCER RES, V75, P5, DOI 10.1158/0008-5472.CAN-14-2538; Marroquin CE, 2002, J IMMUNOTHER, V25, P278, DOI 10.1097/00002371-200205000-00011; Maver PJ, 2018, VACCINE, V36, P5416, DOI 10.1016/j.vaccine.2017.07.113; Mazumder S, 2017, CANCER PREV RES, V10, P612, DOI 10.1158/1940-6207.CAPR-17-0154; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; MENARD S, 1973, CANCER RES, V33, P478; Michael A, 2005, CLIN CANCER RES, V11, P4469, DOI 10.1158/1078-0432.CCR-04-2337; Min YZ, 2017, NAT NANOTECHNOL, V12, P877, DOI [10.1038/nnano.2017.113, 10.1038/NNANO.2017.113]; Mitchell P, 2015, ANN ONCOL, V26, P1134, DOI 10.1093/annonc/mdv104; Mohsen MO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01015; Mohseni AH, 2020, MOL CANCER THER, V19, P717, DOI 10.1158/1535-7163.MCT-19-0375; Morse MA, 2000, J CLIN ONCOL, V18, P3883, DOI 10.1200/JCO.2000.18.23.3883; Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576-019-0151-1; Nemunaitis J, 2009, CANCER GENE THER, V16, P620, DOI 10.1038/cgt.2009.15; Nemunaitis J, 2006, J CLIN ONCOL, V24, P4721, DOI 10.1200/JCO.2005.05.5335; Ohno S, 2012, ANTICANCER RES, V32, P2263; Onodi F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00517; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Ott PA, 2016, CLIN CANCER RES, V22, P3127, DOI 10.1158/1078-0432.CCR-15-2709; Patel JM, 2016, BIOMATERIALS, V74, P231, DOI 10.1016/j.biomaterials.2015.09.031; Pavlick A, 2020, CANCER IMMUNOL RES, V8, P70, DOI 10.1158/2326-6066.CIR-19-0545; PEARSON G, 1968, CANCER RES, V28, P1665; Pedersen SR, 2013, J IMMUNOL, V191, P3955, DOI 10.4049/jimmunol.1300555; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Prue RL, 2015, J IMMUNOTHER, V38, P71, DOI 10.1097/CJI.0000000000000063; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15; REES RC, 1975, NATURE, V255, P329, DOI 10.1038/255329a0; Reimers MA, 2019, CURR UROL REP, V20, DOI 10.1007/s11934-019-0931-3; Rittig SM, 2011, MOL THER, V19, P990, DOI 10.1038/mt.2010.289; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Sabado RL, 2017, CELL RES, V27, P74, DOI 10.1038/cr.2016.157; Sahin IH, 2017, ANN ONCOL, V28, P2950, DOI 10.1093/annonc/mdx503; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Saiag P, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw291; Saif MW., 2020, J CANC METASTASIS TR, V6, P43, DOI DOI 10.20517/2394-4722.2020.90; Sakamaki I, 2014, LEUKEMIA, V28, P329, DOI 10.1038/leu.2013.177; Salgia R, 2003, J CLIN ONCOL, V21, P624, DOI 10.1200/JCO.2003.03.091; Samaik AA, 2011, CLIN CANCER RES, V17, P896, DOI 10.1158/1078-0432.CCR-10-2463; Sampson JH, 2010, J CLIN ONCOL, V28, P4722, DOI 10.1200/JCO.2010.28.6963; SANDA MG, 1994, J UROLOGY, V151, P622, DOI 10.1016/S0022-5347(17)35032-2; Sanderson K, 2005, J CLIN ONCOL, V23, P741, DOI 10.1200/JCO.2005.01.128; Sasso E, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101430; Scholz M, 2017, IMMUNOTARGETS THER, V6, P11, DOI 10.2147/ITT.S122497; Schreibelt G, 2016, CLIN CANCER RES, V22, P2155, DOI 10.1158/1078-0432.CCR-15-2205; Schuler G, 2003, CURR OPIN IMMUNOL, V15, P138, DOI 10.1016/S0952-7915(03)00015-3; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sewell DA, 2004, CANCER RES, V64, P8821, DOI 10.1158/0008-5472.CAN-04-1958; Simons JW, 2006, UROL ONCOL-SEMIN ORI, V24, P419, DOI 10.1016/j.urolonc.2005.08.021; Singer CF, 2020, EUR J CANCER, V132, P43, DOI 10.1016/j.ejca.2020.03.018; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Slingluff CL, 2016, CANCER IMMUNOL IMMUN, V65, P25, DOI 10.1007/s00262-015-1770-9; Small EJ, 2007, CLIN CANCER RES, V13, P3883, DOI 10.1158/1078-0432.CCR-06-2937; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Soares S, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00360; Soiffer R, 1998, P NATL ACAD SCI USA, V95, P13141, DOI 10.1073/pnas.95.22.13141; Soiffer R, 2003, J CLIN ONCOL, V21, P3343, DOI 10.1200/JCO.2003.07.005; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Spaner DE, 2006, CANCER, V106, P890, DOI 10.1002/cncr.21669; Stebbing J, 2012, ANN ONCOL, V23, P1314, DOI 10.1093/annonc/mdr363; STONEHILL EH, 1970, NATURE, V228, P370, DOI 10.1038/228370a0; Sultan H, 2019, CANCER IMMUNOL IMMUN, V68, P455, DOI 10.1007/s00262-018-02294-5; Takeoka T, 2017, J IMMUNOTHER, V40, P140, DOI 10.1097/CJI.0000000000000162; Tardon MC, 2019, CURR OPIN PHARMACOL, V47, P20, DOI 10.1016/j.coph.2019.01.007; Tel J, 2013, CANCER RES, V73, P1063, DOI 10.1158/0008-5472.CAN-12-2583; Temizoz B, 2016, INT IMMUNOL, V28, P329, DOI 10.1093/intimm/dxw015; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Tuohy VK, 2020, SEMIN IMMUNOL, V47, DOI 10.1016/j.smim.2020.101392; Tuohy VK, 2016, CANCERS, V8, DOI 10.3390/cancers8060056; Tyzzer EE, 1916, J CANCER RES CLIN, V1, P125; van den Hende M, 2008, INT J CANCER, V123, P146, DOI 10.1002/ijc.23502; van der Burg SH, 2016, NAT REV CANCER, V16, P219, DOI 10.1038/nrc.2016.16; van Doorn E, 2016, HUM VACC IMMUNOTHER, V12, P159, DOI 10.1080/21645515.2015.1071455; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; van Steenwijk PJD, 2014, CANCER IMMUNOL IMMUN, V63, P147, DOI 10.1007/s00262-013-1499-2; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vansteenkiste J, 2013, J CLIN ONCOL, V31, P2396, DOI 10.1200/JCO.2012.43.7103; Vansteenkiste JF, 2016, LANCET ONCOL, V17, P822, DOI 10.1016/S1470-2045(16)00099-1; Verma V, 2019, NAT IMMUNOL, V20, P1231, DOI 10.1038/s41590-019-0441-y; von Mehren M, 2001, CLIN CANCER RES, V7, P1181; Wang ZB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010128; Weber JS, 2013, J CLIN ONCOL, V31, P4311, DOI 10.1200/JCO.2013.51.4802; Welters MJP, 2010, P NATL ACAD SCI USA, V107, P11895, DOI 10.1073/pnas.1006500107; Westdorp H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0787-6; Wilgenhof S, 2016, J CLIN ONCOL, V34, P1330, DOI 10.1200/JCO.2015.63.4121; Wu AA, 2020, CLIN CANCER RES, V26, P5129, DOI 10.1158/1078-0432.CCR-20-1025; Wurz GT, 2014, HUM VACC IMMUNOTHER, V10, P3383, DOI 10.4161/hv.29836; Xia L, 2016, CELL CHEM BIOL, V23, P1515, DOI 10.1016/j.chembiol.2016.10.012; Xia WJ, 2014, J THORAC DIS, V6, P1513, DOI 10.3978/j.issn.2072-1439.2014.08.17; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Xing Y, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006957; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001; Yaddanapudi K, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1561119; Yaddanapudi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042289; Yan WL, 2017, IMMUNOTHERAPY-UK, V9, P347, DOI 10.2217/imt-2016-0141; Yang GY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00751; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zeng G, 2001, P NATL ACAD SCI USA, V98, P3964, DOI 10.1073/pnas.061507398; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhou JW, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00188	230	2	2	22	25	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							668	10.3390/vaccines9060668			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6JH	34207062	gold, Green Published			2022-04-29	WOS:000665991400001
J	Jennings, W; Stoker, G; Bunting, H; Valgardsson, VO; Gaskell, J; Devine, D; McKay, L; Mills, MC				Jennings, Will; Stoker, Gerry; Bunting, Hannah; Valgardsson, Viktor Orri; Gaskell, Jennifer; Devine, Daniel; McKay, Lawrence; Mills, Melinda C.			Lack of Trust, Conspiracy Beliefs, and Social Media Use Predict COVID-19 Vaccine Hesitancy	VACCINES			English	Article						COVID-19; vaccination; trust; misinformation	HEALTH INFORMATION; ACCEPTANCE; SCALE	As COVID-19 vaccines are rolled out across the world, there are growing concerns about the roles that trust, belief in conspiracy theories, and spread of misinformation through social media play in impacting vaccine hesitancy. We use a nationally representative survey of 1476 adults in the UK between 12 and 18 December 2020, along with 5 focus groups conducted during the same period. Trust is a core predictor, with distrust in vaccines in general and mistrust in government raising vaccine hesitancy. Trust in health institutions and experts and perceived personal threat are vital, with focus groups revealing that COVID-19 vaccine hesitancy is driven by a misunderstanding of herd immunity as providing protection, fear of rapid vaccine development and side effects, and beliefs that the virus is man-made and used for population control. In particular, those who obtain information from relatively unregulated social media sources-such as YouTube-that have recommendations tailored by watch history, and who hold general conspiratorial beliefs, are less willing to be vaccinated. Since an increasing number of individuals use social media for gathering health information, interventions require action from governments, health officials, and social media companies. More attention needs to be devoted to helping people understand their own risks, unpacking complex concepts, and filling knowledge voids.	[Jennings, Will; Stoker, Gerry; Bunting, Hannah; Valgardsson, Viktor Orri; Gaskell, Jennifer; McKay, Lawrence] Univ Southampton, Sch Econ Social & Polit Sci, Southampton SO17 1BJ, Hants, England; [Devine, Daniel] Univ Oxford, St Hildas Coll, Oxford OX4 1DY, England; [Mills, Melinda C.] Univ Oxford, Leverhulme Ctr Demog Sci, Oxford OX1 1NF, England; [Mills, Melinda C.] Univ Oxford, Nuffield Coll, Oxford OX1 1NF, England		Mills, MC (通讯作者)，Univ Oxford, Leverhulme Ctr Demog Sci, Oxford OX1 1NF, England.; Mills, MC (通讯作者)，Univ Oxford, Nuffield Coll, Oxford OX1 1NF, England.	w.j.jennings@soton.ac.uk; g.stoker@soton.ac.uk; h.j.b.willis@soton.ac.uk; v.o.valgardsson@soton.ac.uk; j.gaskell@soton.ac.uk; daniel.devine@st-hildas.ox.ac.uk; l.a.mckay@soton.ac.uk; melinda.mills@nuffield.ox.ac.uk	Bunting, Hannah/AAC-7618-2022	Bunting, Hannah/0000-0002-9701-3064; Jennings, Will/0000-0001-9007-8896; Mckay, Lawrence/0000-0002-2071-3943; Gaskell, Jennifer/0000-0003-1702-6234	ESRC's UK in a Changing Europe programmeUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC); ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/S009809/1]; Leverhulme Trust (Leverhulme Centre for Demographic Science);  [ERC-2018-ADG-835079]	Research Funding support has been provided by the ESRC's UK in a Changing Europe programme and ESRC research award ES/S009809/1, the Leverhulme Trust (Leverhulme Centre for Demographic Science), and ERC-2018-ADG-835079.	Allington D, 2021, PSYCHOL MED, DOI 10.1017/S0033291721001434; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Basch CH, 2017, CHILD CARE HLTH DEV, V43, P499, DOI 10.1111/cch.12442; Battiston Pietro, 2021, SSM Popul Health, V13, P100721, DOI 10.1016/j.ssmph.2020.100721; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bode L, 2021, SOC MEDIA SOC, V7, DOI 10.1177/20563051211008829; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Devine D, 2021, POLIT STUD REV, V19, P274, DOI 10.1177/1478929920948684; Dickson E.J., 2020, ROLL STONE; Donzelli G, 2018, HUM VACC IMMUNOTHER, V14, P1654, DOI 10.1080/21645515.2018.1454572; Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Ehsan A, 2019, SSM-POPUL HLTH, V8, DOI 10.1016/j.ssmph.2019.100425; Elgar FJ, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113365; Featherstone JD, 2019, VACCINE, V37, P2993, DOI 10.1016/j.vaccine.2019.04.063; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Gieysztor S., 2020, COVID 19 VACCINE DEP; Hornsey MJ, 2020, J EXP SOC PSYCHOL, V88, DOI 10.1016/j.jesp.2019.103947; Hussein Eslam, 2020, Proceedings of the ACM on Human-Computer Interaction, V4, DOI 10.1145/3392854; Jackson Kuha, 2020, LSE COVID 19 BLOG; Jacobs W, 2017, COGENT SOC SCI, V3, DOI 10.1080/23311886.2017.1302785; Jennings W, 2021, J EUR PUBLIC POLICY, V28, P1174, DOI 10.1080/13501763.2021.1942151; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Kahneman D., 2011, THINKING FAST SLOW; Kreps SE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd4563; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Massey PM, 2016, J HEALTH COMMUN, V21, P118, DOI 10.1080/10810730.2015.1058444; Mills, 2021, FINANC TIMES; Mills M.C., 2020, LCDS BLOG; Mills MC, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100674; Murphy, 2020, FINANC TIMES; Ohlheiser A., 2020, MIT TECHNOL REV; Oladejo O, 2016, VACCINE, V34, P4964, DOI 10.1016/j.vaccine.2016.08.046; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Seale H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-99; Smith N, 2019, INFORM COMMUN SOC, V22, P1310, DOI 10.1080/1369118X.2017.1418406; Sturgis P, 2021, NAT HUM BEHAV, V5, P1528, DOI 10.1038/s41562-021-01115-7	37	30	30	31	53	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							593	10.3390/vaccines9060593			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SZ3YW	34204971	Green Accepted, Green Published, gold			2022-04-29	WOS:000666505800001
J	Oh, Y; Park, Y; Choi, BH; Park, S; Gu, S; Park, J; Kim, JK; Sohn, EJ				Oh, Yeonsu; Park, Youngmin; Choi, Bo-Hwa; Park, Soohong; Gu, Sungmin; Park, Jungae; Kim, Jong-Kook; Sohn, Eun-Ju			Field Application of a New CSF Vaccine Based on Plant-Produced Recombinant E2 Marker Proteins on Pigs in Areas with Two Different Control Strategies	VACCINES			English	Article						classical swine fever virus; E2 glycoprotein; DIVA vaccine; plant-made vaccine; field application	CLASSICAL SWINE-FEVER; CIRCOVIRUS TYPE-2 PCV2; VIRUS; ANTIBODIES	A classical swine fever virus (CSFV)-modified live LOM (low-virulence strain of Miyagi) vaccine (MLV-LOM) to combat CSF has been used in places where the disease is prevalent around the world, including in Korea, except in Jeju Island. In general, modified live virus-based vaccines (MLV) are known to be highly effective in inducing immune responses. At the same time, MLVs also have potential dangers such as a circulation in the field. There is still a need for safer and more effective vaccines to control CSF in the field. In this study, we applied a new CSF vaccine based on plant-produced recombinant E2 marker proteins at two different locations, Jeju Island and a suburb of Pohang, using different CSF control strategies. The result suggested that vaccinated sows in Jeju Island highly developed immunogenicity and maintained stably until 102 days post-vaccination (dpv). Its piglets that received maternal antibodies were shown to carry high serological values and maintained them until 40 days of age, which was the end of the follow-up. Naive piglets vaccinated at 40 days of age showed high serological values and these were maintained until 100 days of age (60 dpv), which was the end of the follow-up. The vaccine was also effective in inducing immune responses in newborn piglets that carried maternal antibodies received from MLV-LOM vaccine-immunized mother sows.	[Oh, Yeonsu] Kangwon Natl Univ, Coll Vet Med, Chunchon 24341, South Korea; [Oh, Yeonsu] Kangwon Natl Univ, Inst Vet Sci, Chunchon 24341, South Korea; [Park, Youngmin; Choi, Bo-Hwa; Park, Soohong; Gu, Sungmin; Park, Jungae; Kim, Jong-Kook; Sohn, Eun-Ju] BioApplications Inc, Pohang Techno Pk Complex,394 Jigok Ro, Pohang 37668, South Korea		Sohn, EJ (通讯作者)，BioApplications Inc, Pohang Techno Pk Complex,394 Jigok Ro, Pohang 37668, South Korea.	yeonoh@kangwon.ac.kr; ympark86@postech.ac.kr; bhchoi@bioapp.co.kr; saysh13@bioapp.co.kr; gusungmin@bioapp.co.kr; oh@bioapp.co.kr; bio2020@bioapp.co.kr; ejsohn@bioapp.co.kr		Oh, Yeonsu/0000-0001-5743-5396; Park, Youngmin/0000-0003-1174-3793	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the Animal Disease Management Technology Development Program - Ministry of Agriculture, Food and Rural Affairs (MAFRA) [320064-2]	This work was supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the Animal Disease Management Technology Development Program, funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) (No. 320064-2).	Aguirreburualde M.S.P., 2016, CURR MOL BIOL REP, V2, P171, DOI [10.1007/s40610-016-0047-1, DOI 10.1007/S40610-016-0047-1]; Choe S, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9010018; Francis MJ, 2018, VET CLIN N AM-SMALL, V48, P231, DOI 10.1016/j.cvsm.2017.10.002; Jang G, 2020, ARCH VIROL, V165, P1691, DOI 10.1007/s00705-020-04651-1; Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536; Kim B, 2008, VET REC, V162, P12, DOI 10.1136/vr.162.1.12; Lico C, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.609910; Lomonossoff GP, 2016, SCIENCE, V353, P1237, DOI 10.1126/science.aaf6638; Madera R, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0823-4; Moennig V, 2003, VET J, V165, P11, DOI 10.1016/S1090-0233(02)00112-0; Oh Y, 2014, VET MICROBIOL, V172, P371, DOI 10.1016/j.vetmic.2014.05.028; Opriessnig T, 2010, VET MICROBIOL, V142, P177, DOI 10.1016/j.vetmic.2009.09.056; Owczarek B, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4216060; Park Y, 2021, NEW BIOTECHNOL, V63, P29, DOI 10.1016/j.nbt.2021.02.005; Park Y, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00624; Rybicki EP, 2017, HUM VACC IMMUNOTHER, V13, P2912, DOI 10.1080/21645515.2017.1356497; SATO U, 1969, ARCH GES VIRUSFORSCH, V26, P1, DOI 10.1007/BF01241171; Smith DB, 2017, J GEN VIROL, V98, P2106, DOI 10.1099/jgv.0.000873; TERPSTRA C, 1984, VET MICROBIOL, V9, P113, DOI 10.1016/0378-1135(84)90026-9; Wang JC, 2020, APPL MICROBIOL BIOT, V104, P3847, DOI 10.1007/s00253-020-10483-5; Zhang HW, 2014, VACCINE, V32, P6607, DOI 10.1016/j.vaccine.2014.10.003	21	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							537	10.3390/vaccines9060537			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ9YP	34063818	Green Published, gold			2022-04-29	WOS:000666913000001
J	Tall, H; Adam, P; Tiendrebeogo, ASE; Vincent, JP; Schaeffer, L; von Platen, C; Fernandes-Pellerin, S; Sawadogo, F; Bokoum, A; Bouda, G; Ouattara, S; Ouedraogo, I; Herrant, M; Boucheron, P; Sawadogo, A; Betsem, E; Essoh, A; Kabore, L; Ouattara, A; Meda, N; Hien, H; Gosset, A; Giles-Vernick, T; Boyer, S; Kania, D; Vray, M; Shimakawa, Y				Tall, Haoua; Adam, Pierrick; Tiendrebeogo, Abdoul Salam Eric; Vincent, Jeanne Perpetue; Schaeffer, Laura; von Platen, Cassandre; Fernandes-Pellerin, Sandrine; Sawadogo, Francois; Bokoum, Alkadri; Bouda, Ghislain; Ouattara, Seydou; Ouedraogo, Issa; Herrant, Magali; Boucheron, Pauline; Sawadogo, Appolinaire; Betsem, Edouard; Essoh, Alima; Kabore, Lassane; Ouattara, Amariane; Meda, Nicolas; Hien, Herve; Gosset, Andrea; Giles-Vernick, Tamara; Boyer, Sylvie; Kania, Dramane; Vray, Muriel; Shimakawa, Yusuke			Impact of Introducing Hepatitis B Birth Dose Vaccines into the Infant Immunization Program in Burkina Faso: Study Protocol for a Stepped Wedge Cluster Randomized Trial (NeoVac Study)	VACCINES			English	Article						hepatitis B vaccine; mother-to-child transmission; birth dose vaccination; complex intervention; mixed method; stepped wedge cluster randomized trial; implementation science; sub-Saharan Africa	TO-CHILD TRANSMISSION; VIRUS-INFECTION; PREGNANT-WOMEN; VIRAL-HEPATITIS; E-ANTIGEN; HBEAG; WEST; METAANALYSIS; ELIMINATION; MANAGEMENT	To achieve global hepatitis elimination by 2030, it is critical to prevent the mother-to-child transmission (MTCT) of hepatitis B virus (HBV). Since 2009, the WHO has recommended administering hepatitis B vaccine to all neonates within 24 h of birth to prevent MTCT. However, many countries in sub-Saharan Africa only provide hepatitis B immunization at the age of 6, 10, and 14 weeks or 8, 12, and 16 weeks using a combined vaccine. To accelerate the introduction of the hepatitis B birth dose vaccine (HepB-BD) into sub-Saharan Africa, it is critical to establish to what extent the addition of HepB-BD can further reduce HBV transmission in areas where three-dose infant vaccination has been implemented. We therefore designed a study to evaluate the impact, acceptability, and cost-effectiveness of incorporating the HepB-BD into the routine immunization program in a real-life field condition in Burkina Faso, where the hepatitis B vaccination is currently scheduled at 8-12-16 weeks. Through a multidisciplinary approach combining epidemiology, anthropology, and health economics, the Neonatal Vaccination against Hepatitis B in Africa (NeoVac) study conducts a pragmatic stepped wedge cluster randomized controlled trial in rural areas of the Hauts-Bassins Region. The study was registered in ClinicalTrials.gov (identifier: NCT04029454). A health center is designated as a cluster, and the introduction of HepB-BD will be rolled out sequentially in 24 centers. Following an initial period in which no health center administers HepB-BD, one center will be randomly allocated to incorporate HepB-BD. Then, at a regular interval, another center will be randomized to cross from the control to the intervention period, until all 24 centers integrate HepB-BD. Pregnant women attending antenatal care will be systematically invited to participate. Infants born during the control period will follow the conventional immunization schedule (8-12-16 weeks), while those born in the interventional period will receive HepB-BD in addition to the routine vaccines (0-8-12-16 weeks). The primary outcome, the proportion of hepatitis B surface antigen (HBsAg) positivity in infants aged at 9 months, will be compared between children born before and after HepB-BD introduction. The study will generate data that may assist governments and stakeholders in sub-Saharan Africa to make evidence-based decisions about whether to add HepB-BD into the national immunization programs.	[Tall, Haoua; Tiendrebeogo, Abdoul Salam Eric; Vincent, Jeanne Perpetue; Sawadogo, Francois; Betsem, Edouard; Essoh, Alima; Kabore, Lassane] Agence Med Prevent AMP, Epidemiol Malad Evitables Vaccinat, BP 638, Ouagadougou, Burkina Faso; [Adam, Pierrick; Vincent, Jeanne Perpetue; Schaeffer, Laura; Boucheron, Pauline; Vray, Muriel; Shimakawa, Yusuke] Inst Pasteur, Unite Epidemiol Malad Emergentes, F-75015 Paris, France; [von Platen, Cassandre; Fernandes-Pellerin, Sandrine] Inst Pasteur, Ctr Rech Translat, F-75015 Paris, France; [Bokoum, Alkadri] Minist Hlth, Dist Sanitaire Dafra, BP 1508, Bobo Dioulasso, Burkina Faso; [Bouda, Ghislain] Minist Hlth, Dist Sanitaire Do, BP 1508, Bobo Dioulasso, Burkina Faso; [Ouattara, Seydou] Minist Hlth, Direct Reg Sante Hauts Bassins, BP 1508, Bobo Dioulasso, Burkina Faso; [Ouedraogo, Issa] Minist Hlth, Direct Prevent Vaccinat DPV, BP 7009, Ouagadougou, Burkina Faso; [Herrant, Magali] Inst Pasteur, Direct Int, F-75015 Paris, France; [Sawadogo, Appolinaire] CHU Souro Sanou, Dept Med, BP 676, Bobo Dioulasso, Burkina Faso; [Ouattara, Amariane; Meda, Nicolas; Hien, Herve; Kania, Dramane] Ctr Muraz, Lab Virol, BP 390, Bobo Dioulasso, Burkina Faso; [Gosset, Andrea; Boyer, Sylvie] Aix Marseille Univ, INSERM, IRD, Sci Econom & Sociales Sante & Traitement Informat, F-13385 Marseille, France; [Giles-Vernick, Tamara] Inst Pasteur, Unite Anthropol & Ecol Emergence Malad, F-75015 Paris, France; [Vray, Muriel] INSERM, F-75013 Paris, France		Shimakawa, Y (通讯作者)，Inst Pasteur, Unite Epidemiol Malad Emergentes, F-75015 Paris, France.	htall@aamp.org; adam.pierrick@gmail.com; tiendraseric@gmail.com; jeanne.vincent@pasteur.fr; laura.schaeffer@pasteur.fr; cassandre.von-platen@pasteur.fr; sandrine.fernandes-pellerin@pasteur.fr; fsawadogo@aamp.org; alkadria1@yahoo.fr; ghislainbouda@yahoo.com; seydououatf@gmail.com; issayann09@yahoo.fr; magali.herrant@pasteur.fr; boucheronp@fellows.iarc.fr; drsawadogo.appolinaire@yahoo.fr; edouardbetsem@gmail.com; tae@aamp.org; lassane.kabore1@yahoo.fr; koneama@yahoo.fr; nicolas.meda@gmail.com; hien_herve@hotmail.com; andrea.gosset@inserm.fr; tamara.giles-vernick@pasteur.fr; sylvie.boyer@inserm.fr; draka3703@yahoo.fr; muriel.vray@pasteur.fr; yusuke.shimakawa@gmail.com		Boyer, Sylvie/0000-0002-7567-5200; ADAM, Pierrick/0000-0002-2986-4641; Gosset, Andrea/0000-0003-0743-2458; VINCENT, Jeanne/0000-0003-2448-2908; Shimakawa, Yusuke/0000-0002-4198-4785; Boucheron, Pauline/0000-0001-8896-0740	Total FoundationTotal SA; Gilead SciencesGilead Sciences; AbbottAbbott Laboratories; Institut PasteurEuropean Commission; Fondation Pasteur Japon; Ambassade de France au Japon	The NeoVac study was funded by the Total Foundation. The PREDICT-B study was funded by the Gilead Sciences and Abbott. JPV was funded by the Institut Pasteur, Ambassade de France au Japon, and Fondation Pasteur Japon. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.	Akanmu A S, 2006, Afr J Med Med Sci, V35, P5; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P369; [Anonymous], 2009, Wkly Epidemiol Rec, V84, P405; Avellon A, 2020, J MED VIROL, V92, P3403, DOI 10.1002/jmv.25862; Bassoum O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020301; Boucheron P, 2021, LANCET INFECT DIS, V21, P85, DOI 10.1016/S1473-3099(20)30593-4; Boye S, 2020, AM J TROP MED HYG, V102, P637, DOI 10.4269/ajtmh.19-0477; Boyer S, 2018, P AFR VIH 2018 9 C I, P115; Brown RS, 2016, HEPATOLOGY, V63, P319, DOI 10.1002/hep.28302; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Chang MH, 2008, HEPATOL INT, V2, pS28, DOI 10.1007/s12072-008-9050-9; Clement F, 2002, J CLIN MICROBIOL, V40, P4603, DOI 10.1128/JCM.40.12.4603-4606.2002; Collenberg E, 2006, J MED VIROL, V78, P683, DOI 10.1002/jmv.20593; de Villiers MJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237525; Demolis R, 2018, VACCINE, V36, P6497, DOI 10.1016/j.vaccine.2017.10.087; EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197, DOI 10.1098/rspb.1993.0102; Ekra D, 2008, VACCINE, V26, P2753, DOI 10.1016/j.vaccine.2008.03.018; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Funk AL, 2021, LANCET INFECT DIS, V21, P70, DOI 10.1016/S1473-3099(20)30586-7; GAVI the Vaccine Alliance, GAV BOARD STARTS FRA; Giles M, 2015, GUT, V64, P1810, DOI 10.1136/gutjnl-2014-308211; Giles-Vemick T, 2016, AM J TROP MED HYG, V95, P1368, DOI 10.4269/ajtmh.16-0398; Giles-Vernick T, 2016, MED ANTHROPOL Q, V30, P203, DOI 10.1111/maq.12187; Hagan JE, 2019, AM J TROP MED HYG, V101, P891, DOI 10.4269/ajtmh.18-0926; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Hayes RJ, 2009, INTERD STAT, P3; Hemming K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h391; Hemming K, 2014, STATA J, V14, P363, DOI 10.1177/1536867X1401400208; HYAMS KC, 1995, CLIN INFECT DIS, V20, P992, DOI 10.1093/clinids/20.4.992; Keane E, 2016, ALIMENT PHARM THER, V44, P1005, DOI 10.1111/apt.13795; Lau DTY, 2003, J VIRAL HEPATITIS, V10, P331, DOI 10.1046/j.1365-2893.2003.00418.x; Lee C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004790.pub2; LEE SD, 1986, HEPATOLOGY, V6, P369, DOI 10.1002/hep.1840060306; Lingani M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5432-7; Machaira M, 2015, J ANTIMICROB CHEMOTH, V70, P396, DOI 10.1093/jac/dku404; Mainet-González Damián, 2009, Biotecnol Apl, V26, P143; MARION SA, 1994, AM J EPIDEMIOL, V140, P734, DOI 10.1093/oxfordjournals.aje.a117321; Maylin S, 2013, J CLIN VIROL, V56, P306, DOI 10.1016/j.jcv.2012.12.022; McNaughton AL, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003068; Ministere de la Sante du Burkina Faso, 2015, PLAN ACT 2016 DISTR; Ministere de la Sante du Burkina Faso, 2014, PLAN ACT 2015 DISTR; Moher David, 2012, Int J Surg, V10, P28, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869, 10.1016/j.ijsu.2011.10.001]; Moturi Edna, 2018, J Immunol Sci, VSuppl, P31; Murayama A, 2019, J CLIN VIROL, V117, P37, DOI 10.1016/j.jcv.2019.05.011; Nayagam S, 2016, LANCET INFECT DIS, V16, P1399, DOI 10.1016/S1473-3099(16)30204-3; Sarin SK, 2016, HEPATOL INT, V10, P1, DOI 10.1007/s12072-015-9675-4; Seck A, 2018, AM J TROP MED HYG, V99, P428, DOI 10.4269/ajtmh.18-0116; Segeral O, 2020, CLIN INFECT DIS, V71, pE587, DOI 10.1093/cid/ciaa282; Segeral O, 2018, J CLIN VIROL, V109, P29, DOI 10.1016/j.jcv.2018.10.007; Shimakawa Y, 2021, J VIRAL HEPATITIS, V28, P837, DOI 10.1111/jvh.13489; Shimakawa Y, 2020, CLIN INFECT DIS, V70, P1442, DOI 10.1093/cid/ciz412; Shimakawa Y, 2017, LANCET INFECT DIS, V17, P688, DOI 10.1016/S1473-3099(17)30339-0; Shimakawa Y, 2016, GUT, V65, P2007, DOI 10.1136/gutjnl-2015-309892; Shimakawa Y, 2016, LANCET INFECT DIS, V16, P19, DOI 10.1016/S1473-3099(15)00469-7; Shimakawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069430; Sosler S., 2021, UPDATE GAVIS SUPPORT, P1; Spearman CW, 2017, LANCET GASTROENTEROL, V2, P900, DOI 10.1016/S2468-1253(17)30295-9; Stanaway JD, 2016, LANCET, V388, P1081, DOI 10.1016/S0140-6736(16)30579-7; Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800; Vanhomwegen J, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.03.014; White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40; WHO, 2012, PRACT IMPR COV HEP B; WHO, 2020, VACC PREV DIS MON SY; WHO, 2016, GLOB HLTH SECT STRAT; WHO, 2016, SYST REV SAF EFF CHI; World Health Organization, 2019, WHO GUID STAND EC EV; World Health Organization, 2017, GLOBAL HEPATITIS REP; World Health Organization, 2020, PREV MOTH TO CHILD T; Yang YT, 2021, EXPERT REV ANTI-INFE, V19, P649, DOI 10.1080/14787210.2021.1845652; Yoshida K, 2021, CLIN GASTROENTEROL H, V19, P46, DOI 10.1016/j.cgh.2020.04.045	71	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							583	10.3390/vaccines9060583			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5RB	34206058	Green Published, gold			2022-04-29	WOS:000665943800001
J	Chun, JH; Jung, JW; Kim, YR; Lazarte, JMS; Kim, SW; Kim, J; Thompson, KD; Kim, HJ; Jung, TS				Chun, Jin Hong; Jung, Jae Wook; Kim, Young Rim; Lazarte, Jassy Mary S.; Kim, Si Won; Kim, Jaesung; Thompson, Kim D.; Kim, Hyoung Jun; Jung, Tae Sung			Poly (I:C)-Potentiated Vaccination Enhances T Cell Response in Olive Flounder (Paralichthys olivaceus) Providing Protection against Viral Hemorrhagic Septicemia Virus (VHSV)	VACCINES			English	Article						viral haemorrhagic septicaemia (VHS); poly (I:C); vaccination; T cell responses; flow cytometry; olive flounder (Paralichthys olivaceus)	RAINBOW-TROUT; IMMUNE-RESPONSE; SEVENBAND GROUPER; LIVE VACCINE; FISH; IMMUNIZATION; EXPRESSION; ANTIBODY; INNATE; LIPOPOLYSACCHARIDE	Viral hemorrhagic septicemia (VHS), caused by viral hemorrhagic septicemia virus (VHSV), is a viral disease affecting teleosts, and is the major cause of virus-related deaths in olive flounder (Paralichthys olivaceus). Research has focused on ways to control VHS, and recently, the use of polyinosinic-polycytidylic acid poly (I:C)-potentiated vaccination has been investigated, whereby fish are injected with poly (I:C) and then with live pathogenic virus, resulting in a significant decrease in VHSV-related mortality. T cell responses were investigated in the present study after vaccinating olive flounder with poly (I:C)-potentiated vaccination to understand the ability of poly (I:C) to induce T cell immunity. Stimulation of T cell responses with the poly (I:C)-potentiated vaccination was confirmed by examining levels of CD3(+) T cells, CD4-1(+) T cells and CD4-2(+) T cells. Higher levels of CD4-2(+) T cells were found in vaccinated fish than CD4-1(+) T cells, believed to result from a synergistic effect between poly (I:C) administration and pathogenic VHSV immunization. More importantly, the role of CD4-2(+) T cells in the antiviral response was clearly evident. The results of this study suggest that the outstanding protection obtained with the poly (I:C)-potentiated vaccination is due to the robust immune response initiated by the CD4-2(+) T cells.	[Chun, Jin Hong; Jung, Jae Wook; Kim, Young Rim; Lazarte, Jassy Mary S.; Kim, Si Won; Kim, Jaesung; Jung, Tae Sung] Gyeongsang Natl Univ, Lab Aquat Anim Dis, Res Inst Nat Sci, Coll Vet Med, 501-201,501 Jinju Daero, Jinju Si 52828, South Korea; [Thompson, Kim D.] Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland; [Kim, Hyoung Jun] Natl Inst Fisheries Sci, Pathol Res Div, OIE Reference Lab Viral Haemorrhag Septicaemia VH, 216 Gijanghaean Ro, Busan 46083, South Korea; [Jung, Tae Sung] Flinders Univ S Australia, Ctr Marine Bioprod Dev, Bedford Pk, SA 5042, Australia		Jung, TS (通讯作者)，Gyeongsang Natl Univ, Lab Aquat Anim Dis, Res Inst Nat Sci, Coll Vet Med, 501-201,501 Jinju Daero, Jinju Si 52828, South Korea.	hilanamang@naver.com; wjdwodnr0605@gmail.com; yl0808@nate.com; jassylazarte@yahoo.com; ksw0017@hanmail.net; afteru70@gmail.com; Kim.Thompson@moredun.ac.uk; hjkim1882@korea.kr; jungts@gnu.ac.kr	Thompson, Kim/O-7707-2015	Thompson, Kim/0000-0003-3550-4842	Korea Research FoundationKorea Research Foundation [NRF-2021R1A2B5B02002220]; National Institute of Fisheries Science [P2021040]	This research was supported by the Korea Research Foundation grant (NRF-2021R1A2B5B02002220) and by the National Institute of Fisheries Science (P2021040).	Ashfaq H, 2019, VET RES, V50, DOI 10.1186/s13567-018-0620-0; AVTALION RR, 1981, CRIT REV ENV CONTR, V11, P163, DOI 10.1080/10643388109381687; Avunje S, 2017, FISH SHELLFISH IMMUN, V71, P338, DOI 10.1016/j.fsi.2017.10.032; Bird S, 2005, IMMUNOGENETICS, V56, P909, DOI 10.1007/s00251-004-0741-7; Bolton DL, 2009, EXPERT REV VACCINES, V8, P779, DOI 10.1586/ERV.09.41; Castro R, 2011, FISH SHELLFISH IMMUN, V31, P644, DOI 10.1016/j.fsi.2010.08.016; Castro R., 2015, MUCOSAL HLTH AQUACUL, P3; Castro R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111084; Diaz-Rosales P, 2009, FISH SHELLFISH IMMUN, V27, P414, DOI 10.1016/j.fsi.2009.06.008; Fischer U, 2013, FISH SHELLFISH IMMUN, V35, P197, DOI 10.1016/j.fsi.2013.04.018; Ganassin RC, 1999, IN VITRO CELL DEV-AN, V35, P80; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; Jorgensen P. E. V., 1980, Fish diseases--third COPRAQ session, P3; Jung JW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114180; Jung JW, 2020, DEV COMP IMMUNOL, V103, DOI 10.1016/j.dci.2019.103518; Jung JW, 2017, FISH SHELLFISH IMMUN, V65, P179, DOI 10.1016/j.fsi.2017.04.016; Ke Q, 2017, J VIROL, V91, DOI 10.1128/JVI.00279-17; Kim HJ, 2016, FISH SHELLFISH IMMUN, V48, P206, DOI 10.1016/j.fsi.2015.11.035; Kim HJ, 2009, DIS AQUAT ORGAN, V83, P105, DOI 10.3354/dao02000; Kim Su-Mi, 2003, [JOURNAL OF FISH PATHOLOGY, 한국어병학회지], V16, P1; Kim Wi Sik, 2011, Journal of Fish Pathology, V24, P1; Kim WS, 2009, AQUACULTURE, V296, P165, DOI 10.1016/j.aquaculture.2009.07.019; Kobayashi I, 2016, DEV COMP IMMUNOL, V58, P86, DOI 10.1016/j.dci.2016.01.003; Kole S, 2019, AQUACULTURE, V503, P51, DOI 10.1016/j.aquaculture.2018.12.085; Liu Y, 2004, FISH SHELLFISH IMMUN, V16, P621, DOI 10.1016/j.fsi.2003.10.001; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247; Lorenzen N, 1999, FISH SHELLFISH IMMUN, V9, P345, DOI 10.1006/fsim.1999.0194; Lorenzen N, 1997, DEV BIOLOGICALS, V90, P201; Lorenzen N, 2005, REV SCI TECH OIE, V24, P201, DOI 10.20506/rst.24.1.1565; Midtlyng PJ, 2016, BIRKHAUSER ADV INFEC, P119, DOI 10.1007/978-3-0348-0980-1_6; Moller AM, 2014, DEV COMP IMMUNOL, V46, P518, DOI 10.1016/j.dci.2014.03.020; Monath TP, 2010, VACCINE, V28, P3827, DOI 10.1016/j.vaccine.2010.03.023; Mu PF, 2018, FISH SHELLFISH IMMUN, V81, P309, DOI 10.1016/j.fsi.2018.07.040; Nakanishi Teruyuki, 2015, Biology-Basel, V4, P640, DOI 10.3390/biology4040640; Nishizawa T, 2011, VACCINE, V29, P8397, DOI 10.1016/j.vaccine.2011.08.032; Nishizawa T, 2011, AQUACULTURE, V311, P100, DOI 10.1016/j.aquaculture.2010.12.009; Nishizawa T, 2009, DIS AQUAT ORGAN, V83, P115, DOI 10.3354/dao02001; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Oh MJ, 2013, J FISH DIS, V36, P159, DOI 10.1111/j.1365-2761.2012.01451.x; Oh MJ, 2012, J FISH DIS, V35, P187, DOI 10.1111/j.1365-2761.2011.01334.x; Philip AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129299; Philip AM, 2014, DEV COMP IMMUNOL, V45, P133, DOI 10.1016/j.dci.2014.02.012; Philip AM, 2012, DEV COMP IMMUNOL, V38, P360, DOI 10.1016/j.dci.2012.07.005; RASMUSSEN CJ, 1965, ANN NY ACAD SCI, V126, P427, DOI 10.1111/j.1749-6632.1965.tb14293.x; Robertsen B, 2006, FISH SHELLFISH IMMUN, V20, P172, DOI 10.1016/j.fsi.2005.01.010; Roederer M, 2004, CLIN IMMUNOL, V110, P199, DOI 10.1016/j.clim.2003.11.015; Rombout JHWM, 2014, FISH SHELLFISH IMMUN, V40, P634, DOI 10.1016/j.fsi.2014.08.020; Shepherd BS, 2018, FISH SHELLFISH IMMUN, V74, P410, DOI 10.1016/j.fsi.2018.01.003; Smail DA, 1999, FISH DISEASES AND DISORDERS, VOL 3, P123; Sommerset I, 2005, EXPERT REV VACCINES, V4, P89, DOI 10.1586/14760584.4.1.89; Swiecki M, 2011, J LEUKOCYTE BIOL, V90, P691, DOI 10.1189/jlb.0311166; Takami I, 2010, DIS AQUAT ORGAN, V89, P109, DOI 10.3354/dao02185; Tang XQ, 2019, FISH SHELLFISH IMMUN, V93, P55, DOI 10.1016/j.fsi.2019.07.023; Tordo N., 2004, 8 REPORT INT COMMITT; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Tubo NJ, 2014, TRENDS IMMUNOL, V35, P591, DOI 10.1016/j.it.2014.09.008; Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548; Winton JR, 1997, DEV BIOLOGICALS, V90, P211; Xing J, 2019, FISH SHELLFISH IMMUN, V84, P979, DOI 10.1016/j.fsi.2018.11.004; Xing J, 2018, MOL IMMUNOL, V96, P19, DOI 10.1016/j.molimm.2018.02.007; 김진우, 2012, [JOURNAL OF FISH PATHOLOGY, 한국어병학회지], V25, P271, DOI 10.7847/jfp.2012.25.3.271; Zou J, 2011, DEV COMP IMMUNOL, V35, P1376, DOI 10.1016/j.dci.2011.07.001	63	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							482	10.3390/vaccines9050482			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1XT	34068522	Green Published, gold			2022-04-29	WOS:000654619600001
J	Han, KY; Francis, MR; Zhang, RY; Wang, Q; Xia, AC; Lu, LY; Yang, BY; Hou, ZY				Han, Kaiyi; Francis, Mark R.; Zhang, Ruiyun; Wang, Qian; Xia, Aichen; Lu, Linyao; Yang, Bingyi; Hou, Zhiyuan			Confidence, Acceptance and Willingness to Pay for the COVID-19 Vaccine among Migrants in Shanghai, China: A Cross-Sectional Study	VACCINES			English	Article						COVID-19; vaccine; acceptance; intention; confidence; China	HEALTH; ATTITUDES; HESITANCY; OUTBREAK	Understanding the public's attitude towards COVID-19 vaccination and their acceptance could help facilitate the COVID-19 rollout. This study aimed to assess the acceptance and willingness to pay (WTP) for the COVID-19 vaccine among migrants in Shanghai, China. A cross-sectional study was conducted among 2126 migrants in Shanghai for the period 1-20 November 2020. Convenience sampling was used to recruit respondents in workplaces with large numbers of migrant workers. Multivariable (ordered) logistic regressions were used to examine factors associated with acceptance and WTP of the COVID-19 vaccine. Most (89.1%) migrants would accept COVID-19 vaccination. Over 90.0% perceived the COVID-19 vaccine as important, while only 75.0% and 77.7% perceived vaccines safe and effective. Socio-demographic factors were not significantly associated with vaccine acceptance, but confidence in the importance (OR 8.71, 95% CI 5.89-12.89), safety (OR 1.80, 95% CI 1.24-2.61) and effectiveness (OR 2.66, 95% CI 1.83-3.87) of COVID-19 vaccine was significantly positively associated with vaccine acceptance. The top reasons for vaccine hesitancy were lack of vaccine information and confidence. The proportion of those definitely willing to get the COVID-19 vaccine was 20% lower if paid by themselves than free vaccination. Migrants were willing to pay a median amount of USD 46 for the COVID-19 vaccine. Results show that a high acceptance of the COVID-19 vaccine was universal among migrants in Shanghai. Concerns about vaccine safety, effectiveness and high costs of the COVID-19 vaccine may hinder their uptake. Effective health communication to build confidence in the COVID-19 vaccine and subsidies toward the costs of these vaccines are needed to improve uptake.	[Han, Kaiyi; Zhang, Ruiyun; Wang, Qian; Xia, Aichen; Lu, Linyao; Hou, Zhiyuan] Fudan Univ, Sch Publ Hlth, Shanghai 200032, Peoples R China; [Han, Kaiyi] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England; [Francis, Mark R.] Tampere Univ, Fac Social Sci, Hlth Sci Unit, Tampere 33014, Finland; [Yang, Bingyi] Univ Hong Kong, Div Epidemiol & Biostat, Hong Kong 999077, Peoples R China; [Hou, Zhiyuan] Fudan Univ, NHC Key Lab Hlth Technol Assessment, Shanghai 200032, Peoples R China		Hou, ZY (通讯作者)，Fudan Univ, Sch Publ Hlth, Shanghai 200032, Peoples R China.	kaiyi.han@lshtm.ac.uk; mark.francis@tuni.fi; 17301020124@fudan.edu.cn; 19211020072@fudan.edu.cn; 16301050086@fudan.edu.cn; 17301020062@fudan.edu.cn; yangby@hku.hk; zyhou@fudan.edu.cn		Zhang, Ruiyun/0000-0003-1993-8042; Francis, Mark Rohit/0000-0001-8428-4298; XIA, AICHEN/0000-0001-9655-1680; Hou, Zhiyuan/0000-0003-3413-0076	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71874034]; National Key R&D Program of China [2018YFC1312600, 2018YFC1312604]; National Institute for Health Research from the UK Government [EPIDZL9012]	Zhiyuan Hou acknowledges financial support from the National Natural Science Foundation of China (No. 71874034), the National Key R&D Program of China (No. 2018YFC1312600 and 2018YFC1312604), and the National Institute for Health Research (EPIDZL9012) using UK aid from the UK Government to support global health research. The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.	Acter T, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.138996; [Anonymous], 2019, 10 THREATS GLOBAL HL; De Serres G, 2013, J INFECT DIS, V207, P990, DOI 10.1093/infdis/jis923; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; du Chatelet IP, 2010, EUROSURVEILLANCE, V15, P2; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Falagas ME, 2008, CURR MED RES OPIN, V24, P1719, DOI 10.1185/03007990802085692; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fishman Jessica, 2020, Implement Sci Commun, V1, P81, DOI 10.1186/s43058-020-00050-4; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Glaeser Edward L, 2022, J Urban Econ, V127, P103292, DOI 10.1016/j.jue.2020.103292; Haque A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040739; Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154; Leask J, 2011, NATURE, V473, P443, DOI 10.1038/473443a; Mahase E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2815; Malik AA, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100495; Mheidly N, 2020, J PUBLIC HEALTH POL, V41, P410, DOI 10.1057/s41271-020-00247-w; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nuno M, 2007, J R SOC INTERFACE, V4, P505, DOI 10.1098/rsif.2006.0186; OOSTVOGEL PM, 1994, LANCET, V344, P665, DOI 10.1016/S0140-6736(94)92091-5; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Tu SY, 2020, VACCINE, V38, P6882, DOI 10.1016/j.vaccine.2020.08.063; Wang B, 2010, SOC SCI MED, V71, P84, DOI 10.1016/j.socscimed.2010.03.021; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wen M, 2017, ASIAN POPUL STUD, V13, P5, DOI 10.1080/17441730.2016.1233655; WHO, 2020, WHO TIMELINE COVID 1; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Yang M, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122671; Yu CY, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6661-0; Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221	35	12	12	8	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							443	10.3390/vaccines9050443			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1KA	34063182	Green Published, gold			2022-04-29	WOS:000654583800001
J	Jahn, B; Sroczynski, G; Bicher, M; Rippinger, C; Muhlberger, N; Santamaria, J; Urach, C; Schomaker, M; Stojkov, I; Schmid, D; Weiss, G; Wiedermann, U; Redlberger-Fritz, M; Druml, C; Kretzschmar, M; Paulke-Korinek, M; Ostermann, H; Czasch, C; Endel, G; Bock, W; Popper, N; Siebert, U				Jahn, Beate; Sroczynski, Gaby; Bicher, Martin; Rippinger, Claire; Muehlberger, Nikolai; Santamaria, Julia; Urach, Christoph; Schomaker, Michael; Stojkov, Igor; Schmid, Daniela; Weiss, Guenter; Wiedermann, Ursula; Redlberger-Fritz, Monika; Druml, Christiane; Kretzschmar, Mirjam; Paulke-Korinek, Maria; Ostermann, Herwig; Czasch, Caroline; Endel, Gottfried; Bock, Wolfgang; Popper, Nikolas; Siebert, Uwe			Targeted COVID-19 Vaccination (TAV-COVID) Considering Limited Vaccination Capacities-An Agent-Based Modeling Evaluation	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccination; prioritization; vaccination strategy; optimization; decision-analytic modeling; agent-based simulation; health policy decision making; policy guidance		(1) Background: The Austrian supply of COVID-19 vaccine is limited for now. We aim to provide evidence-based guidance to the authorities in order to minimize COVID-19-related hospitalizations and deaths in Austria. (2) Methods: We used a dynamic agent-based population model to compare different vaccination strategies targeted to the elderly (65 >= years), middle aged (45-64 years), younger (15-44 years), vulnerable (risk of severe disease due to comorbidities), and healthcare workers (HCW). First, outcomes were optimized for an initially available vaccine batch for 200,000 individuals. Second, stepwise optimization was performed deriving a prioritization sequence for 2.45 million individuals, maximizing the reduction in total hospitalizations and deaths compared to no vaccination. We considered sterilizing and non-sterilizing immunity, assuming a 70% effectiveness. (3) Results: Maximum reduction of hospitalizations and deaths was achieved by starting vaccination with the elderly and vulnerable followed by middle-aged, HCW, and younger individuals. Optimizations for vaccinating 2.45 million individuals yielded the same prioritization and avoided approximately one third of deaths and hospitalizations. Starting vaccination with HCW leads to slightly smaller reductions but maximizes occupational safety. (4) Conclusion: To minimize COVID-19-related hospitalizations and deaths, our study shows that elderly and vulnerable persons should be prioritized for vaccination until further vaccines are available.	[Jahn, Beate; Sroczynski, Gaby; Muehlberger, Nikolai; Santamaria, Julia; Schomaker, Michael; Stojkov, Igor; Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Eduard Wallnoefer Zentrum 1, A-6060 Hall In Tirol, Austria; [Bicher, Martin; Rippinger, Claire; Urach, Christoph; Popper, Nikolas] Dwh GmbH, Dwh Simulat Serv, Neustiftgasse 57-59, A-1070 Vienna, Austria; [Bicher, Martin; Popper, Nikolas] TU Wien, Inst Informat Syst Engn, Favoritenstr 11, A-1050 Vienna, Austria; [Schomaker, Michael] Univ Cape Town, Ctr Infect Dis Epidmiol & Res, Barnard Fuller Bldg,Anzio Rd, ZA-7935 Cape Town, South Africa; [Schmid, Daniela] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Div Quant Methods Publ Hlth & Hlth Serv Res, Eduard Wallnoefer Zentrum 1, A-6060 Hall In Tirol, Austria; [Weiss, Guenter] Med Univ Innsbruck, Dept Internal Med 2, Anichstr 35, A-6020 Innsbruck, Austria; [Wiedermann, Ursula] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol OEL, Inst Specif Prophylaxis & Trop Med, Kinderspitalgasse 15, A-1090 Vienna, Austria; [Redlberger-Fritz, Monika] Med Univ Vienna, Ctr Virol, Kinderspitalgasse 15, A-1090 Vienna, Austria; [Druml, Christiane] Med Univ Vienna, UNESCO Chair Bioeth, Waehringerstr 25, A-1090 Vienna, Austria; [Kretzschmar, Mirjam] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [Paulke-Korinek, Maria] Minist Social Affairs Hlth Care & Consumer Protec, Stubenring 1, A-1010 Vienna, Austria; [Ostermann, Herwig; Czasch, Caroline] Gesundheit Osterreich GmbH, Austrian Natl Publ Hlth Inst, Stubenring 6, A-1010 Vienna, Austria; [Endel, Gottfried] Austrian Federat Social Insurances, Kundmanngasse 21, A-1030 Vienna, Austria; [Bock, Wolfgang] TU Kaiserslautern, Dept Math, Gottlieb Daimler Str 48, D-67663 Kaiserslautern, Germany; [Popper, Nikolas] Assoc Decis Support Hlth Policy & Planning, DEXHELPP, Neustiftgasse 57-59, A-1070 Vienna, Austria; [Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St, Boston, MA 02114 USA; [Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, 101 Merrimac St, Boston, MA 02114 USA; [Siebert, Uwe] Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Dept Epidemiol, 718 Huntington Ave, Boston, MA 02115 USA; [Siebert, Uwe] Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Dept Hlth Policy & Management, 718 Huntington Ave, Boston, MA 02115 USA		Siebert, U (通讯作者)，UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Eduard Wallnoefer Zentrum 1, A-6060 Hall In Tirol, Austria.; Siebert, U (通讯作者)，Harvard Med Sch, Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St, Boston, MA 02114 USA.; Siebert, U (通讯作者)，Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, 101 Merrimac St, Boston, MA 02114 USA.; Siebert, U (通讯作者)，Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Dept Epidemiol, 718 Huntington Ave, Boston, MA 02115 USA.; Siebert, U (通讯作者)，Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Dept Hlth Policy & Management, 718 Huntington Ave, Boston, MA 02115 USA.	beate.jahn@umit.at; gaby.sroczynski@umit.at; martin.bicher@tuwien.ac.at; claire.rippinger@dwh.at; nikolai.muehlberger@umit.at; julia.santamaria-navarro@umit.at; christoph.urach@dwh.at; michael.schomaker@umit.at; igor.stojkov@umit.at; daniela.schmid@umit.at; guenter.weiss@i-med.ac.at; ursula.wiedermann-schmidt@meduniwein.ac.at; monika.redlberger@meduniwien.ac.at; christiane.druml@meduniwien.ac.at; m.e.e.kretzschmar@umcutrecht.nl; Maria.Paulke-Korinek@gesundheitsministerium.gv.at; herwig.ostermann@goeg.at; caroline.czasch@goeg.at; Gottfried.Endel@sozialversicherung.at; bock@mathematik.uni-kl.de; nikolas.popper@tuwien.ac.at; uwe.siebert@umit.at	Popper, Niki/AAL-6464-2021; Schomaker, Michael/K-3840-2019; Bock, Wolfgang/I-7454-2017	Popper, Niki/0000-0003-4615-2774; Schomaker, Michael/0000-0002-8475-0591; Bock, Wolfgang/0000-0002-8400-0416; Czasch, Caroline/0000-0001-7569-1668; Weiss, Guenter/0000-0003-0709-2158; Kretzschmar, Mirjam/0000-0002-4394-7697; Sroczynski, Gaby/0000-0001-5193-0492; Siebert, Uwe/0000-0001-6425-7671; Stojkov, Igor/0000-0001-6788-7986; Endel, Gottfried/0000-0003-2071-4572; Jahn, Beate/0000-0002-6764-6362	Gordon and Betty Moore FoundationGordon and Betty Moore Foundation [GBMF9634]; Austrian Federal Ministry for Digital and Economic Affairs BMDW; Austrian Research Promotion Agency (FFG) [881665]; Vienna Science and Technology Fund WWTF [COV20-035]; Medical-Scientific Fund of the Mayor of Vienna [CoVid002]	This research was funded by the Gordon and Betty Moore Foundation through Grant (GBMF9634) to Johns Hopkins University to support the work of the Society for Medical Decision Making COVID-19 Decision Modeling Initiative and partially funded by the Austrian Federal Ministry for Digital and Economic Affairs BMDW and handled by the Austrian Research Promotion Agency (FFG) within the Emergency Call for research into COVID-19 in response to the Sars-CoV-2 outbreak (CIDS-Concurrent Infectious Disease Simulation) (881665), Vienna Science and Technology Fund WWTF within the Call COVID-19 Rapid Response Funding (COV20-035), and the Medical-Scientific Fund of the Mayor of Vienna (CoVid002). The authors had complete and independent control over study design, data collection and analysis, interpretation of data, report writing, decision to publish, and preparation of the manuscript.	[Anonymous], 2021, GESUNDHEITSBERICHTER; [Anonymous], 2020, POSITIONSPAPIER GEME; Arora M, 2021, BEST PRACT RES CL OB, V76, P23, DOI 10.1016/j.bpobgyn.2021.02.002; Bellou V, 2020, RISK FACTORS ADVERSE, DOI [DOI 10.1101/2020.05.13.20100495, 10.1101/2020.05.13.20100495]; Bicher M., 2020, EVALUATION CONTACT T, DOI [10.1101/2020.05.12.20098970v3, DOI 10.1101/2020.05.12.20098970V3]; Bicher M., 2021, AGENT BASED COVID 19; Bicher M., 2020, SUPPORTING AUSTRIA C, DOI [10.1101/2020.10.18.20214767v2, DOI 10.1101/2020.10.18.20214767V2]; Bicher M, 2018, WINT SIMUL C PROC, P2656, DOI 10.1109/WSC.2018.8632170; Bubar Kate M, 2021, medRxiv, DOI [10.1101/2020.09.08.20190629, 10.1126/science.abe6959]; Bundesministerium fur Soziales Gesundheit Pflege und Konsumentenschutz Bundesministerium fur Soziales Gesundheit Pflege und Konsumentenschutz, 2021, COVID 19 IMPF ANW NA; Caro JJ, 2012, MED DECIS MAKING, V32, P667, DOI 10.1177/0272989X12454577; Centers for Disease Control and Prevention (CDC) Centers for Disease Control and Prevention (CDC), 2020, WHO GETS VACC 1; Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9; Cohen SA, 2011, J AM GERIATR SOC, V59, P327, DOI 10.1111/j.1532-5415.2010.03271.x; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Eddy DM, 2012, MED DECIS MAKING, V32, P733, DOI 10.1177/0272989X12454579; Eubank S, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00726-x; European Medicines Agency European Medicines Agency, 2021, COVID 19 VACC MOD 57; Fitzpatrick MC, 2021, SCIENCE, V371, P890, DOI 10.1126/science.abg2334; Foy BH, 2021, INT J INFECT DIS, V103, P431, DOI 10.1016/j.ijid.2020.12.075; Hall V, 2021, DO ANTIBODY POSITIVE, DOI [10.1101/2021.01.13.21249642v1, DOI 10.1101/2021.01.13.21249642V1]; Kim DS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.571481; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Lee KW, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073554; Marshall DA, 2015, VALUE HEALTH, V18, P147, DOI 10.1016/j.jval.2015.01.006; Matrajt Laura, 2020, medRxiv, DOI 10.1101/2020.08.14.20175257; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; Nussbaumer-Streit B, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013574; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Osterreichisches Rotes Kreuz Initiative Osterreichisches Rotes Kreuz Initiative, 2021, OST IMPFT; Pitman R, 2012, MED DECIS MAKING, V32, P712, DOI 10.1177/0272989X12454578; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rappold E., 2020, JAHRESBERICHT GESUND; Rechtsinformationssystem des Bundes Rechtsinformationssystem des Bundes, BUND KONS GES RECHTS; Rippinger C, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-020-05737-6; Robert Koch-Institut, 2015, GES DEUTSCHL GES BUN; Robert Koch-Institut, 2021, EP STECKBR SARS COV; Roberts M, 2012, MED DECIS MAKING, V32, P678, DOI [10.1177/0272989X12454941, 10.1016/j.jval.2012.06.016]; Sahu Kamal Kant, 2020, Blood Cells Mol Dis, V83, P102439, DOI 10.1016/j.bcmd.2020.102439; Siebert U., 2003, EUR J HEALTH ECON, V4, P143, DOI [10.1007/s10198-003-0205-2, DOI 10.1007/S10198-003-0205-2]; Statistik Austria Statistik Austria, 2014, OST GES HAUPT AUSTR; Statistik Austria Statistik Austria, 2020, BEV NACH ALT GESCHL; Szczerbinska K, 2020, EUR GERIATR MED, V11, P639, DOI 10.1007/s41999-020-00362-7; The National Academies of Sciences Engineering and Medicine., 2020, FRAM EQ ALL COVID 19; Viswanathan M, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013718; WHO, 2021, DRAFT LANDSC COVID 1	46	8	8	6	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							434	10.3390/vaccines9050434			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1KH	33925650	gold, Green Published			2022-04-29	WOS:000654584500001
J	Lee, NK; Kothandan, VK; Kothandan, S; Byun, Y; Hwang, SR				Lee, Na-Kyeong; Kothandan, Vinoth Kumar; Kothandan, Sangeetha; Byun, Youngro; Hwang, Seung-Rim			Exosomes and Cancer Stem Cells in Cancer Immunity: Current Reports and Future Directions	VACCINES			English	Review						exosome; cancer stem cell; cancer stem cell-derived exosome; immunotherapy; exosome engineering	COLON-CANCER; RESISTANCE; IDENTIFICATION; PROMOTE; HETEROGENEITY; ANGIOGENESIS; MIGRATION; RNAS	Cancer stem cells (CSCs), which have the capacity to self-renew and differentiate into various types of cells, are notorious for their roles in tumor initiation, metastasis, and therapy resistance. Thus, underlying mechanisms for their survival provide key insights into developing effective therapeutic strategies. A more recent focus has been on exosomes that play a role in transmitting information between CSCs and non-CSCs, resulting in activating CSCs for cancer progression and modulating their surrounding microenvironment. The field of CSC-derived exosomes (CSCEXs) for different types of cancer is still under exploration. A deeper understanding and further investigation into CSCEXs' roles in tumorigenicity and the identification of novel exosomal components are necessary for engineering exosomes for the treatment of cancer. Here, we review the features of CSCEXs, including surface markers, cargo, and biological or physiological functions. Further, reports on the immunomodulatory effects of CSCEXs are summarized, and exosome engineering for CSC-targeting is also discussed.	[Lee, Na-Kyeong; Byun, Youngro] Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 08826, South Korea; [Kothandan, Vinoth Kumar; Hwang, Seung-Rim] Chosun Univ, Grad Sch, Dept Biomed Sci, 309 Pilmun Daero, Gwangju 61452, South Korea; [Kothandan, Sangeetha] Saveetha Inst Med & Tech Sci, Saveetha Sch Engn, Dept Biotechnol, Chennai 600073, Tamil Nadu, India; [Hwang, Seung-Rim] Chosun Univ, Coll Pharm, 309 Pilmun Daero, Gwangju 61452, South Korea		Hwang, SR (通讯作者)，Chosun Univ, Grad Sch, Dept Biomed Sci, 309 Pilmun Daero, Gwangju 61452, South Korea.; Hwang, SR (通讯作者)，Chosun Univ, Coll Pharm, 309 Pilmun Daero, Gwangju 61452, South Korea.	enklee8@gmail.com; vino2787@ymail.com; sangeethak.sse@saveetha.com; yrbyun@snu.ac.kr; srhwang@chosun.ac.kr		Lee, Na Kyeong/0000-0002-6461-4445; Hwang, Seung Rim/0000-0002-3250-3396	National Research Foundation of Korea (NRF) - Ministry of Science and ICT [NRF-2019R1F1A1057702]	This research was supported by a National Research Foundation of Korea (NRF) grant, funded by the Ministry of Science and ICT (grant number NRF-2019R1F1A1057702).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Sowayan BS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00384; Alzahrani FA, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8058979; Aramini B, 2020, WORLD J STEM CELLS, V12, P406, DOI 10.4252/wjsc.v12.i6.406; Baran J, 2010, CANCER IMMUNOL IMMUN, V59, P841, DOI 10.1007/s00262-009-0808-2; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Besse B, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1071008; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Brocco D, 2019, J ONCOL, V2019, DOI 10.1155/2019/5879616; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Chen PW, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108597; Cheng WC, 2019, INT J CANCER, V145, P2209, DOI 10.1002/ijc.32338; Cheng ZJ, 2019, MOL CARCINOGEN, V58, P1389, DOI 10.1002/mc.23022; Clayton SM, 2020, STEM CELLS DEV, V29, P327, DOI 10.1089/scd.2019.0197; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Dai S, 2008, MOL THER, V16, P782, DOI 10.1038/mt.2008.1; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dandawate PR, 2016, SEMIN CANCER BIOL, V40-41, P192, DOI 10.1016/j.semcancer.2016.09.001; Domenis R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169932; Du Q, 2021, J GASTROINTEST ONCOL, V12, P52, DOI 10.21037/jgo-20-513; Eguchi T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191109; Escudier B, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-10; Falcone G, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0148-3; Felicetti F, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0811-2; Feng ZY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00500; Francipane MG, 2008, CANCER RES, V68, P4022, DOI 10.1158/0008-5472.CAN-07-6874; Gabrusiewicz K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412909; Garcia-Mayea Y, 2020, SEMIN CANCER BIOL, V60, P166, DOI 10.1016/j.semcancer.2019.07.022; Gernapudi R, 2015, BREAST CANCER RES TR, V150, P685, DOI 10.1007/s10549-015-3326-2; Goto K, 2006, STEM CELLS, V24, P1859, DOI 10.1634/stemcells.2005-0585; Grange C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-2025-z; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Hardin H, 2018, LAB INVEST, V98, P1133, DOI 10.1038/s41374-018-0065-0; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625; Huang RX, 2017, ONCOTARGET, V8, P35351, DOI 10.18632/oncotarget.10169; Hwang WL, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0699-4; Kaur G, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864-018-0533-1; Kyuno D, 2019, INT J CANCER, V145, P2182, DOI 10.1002/ijc.32312; Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923; Lecerf C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122613; Lee CJ, 2008, J CLIN ONCOL, V26, P2806, DOI 10.1200/JCO.2008.16.6702; Li JJ, 2021, CANCER RES, V81, P114, DOI 10.1158/0008-5472.CAN-20-2270; Li QL, 2014, J BIOL CHEM, V289, P1303, DOI 10.1074/jbc.M113.502278; Li W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0949-7; Liao J, 2016, INT J ONCOL, V48, P2567, DOI 10.3892/ijo.2016.3453; Lin RZ, 2013, MOL CELL BIOCHEM, V383, P13, DOI 10.1007/s11010-013-1746-z; Lin XJ, 2018, MOL THER-NUCL ACIDS, V11, P243, DOI 10.1016/j.omtn.2018.02.014; Lu Z, 2017, J HEPATOL, V67, P739, DOI 10.1016/j.jhep.2017.05.019; Lugini L, 2012, J IMMUNOL, V189, P2833, DOI 10.4049/jimmunol.1101988; Maccalli C, 2018, SEMIN CANCER BIOL, V53, P189, DOI 10.1016/j.semcancer.2018.09.006; Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; McNamara MA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/794528; Mimeault M, 2007, J CELL MOL MED, V11, P981, DOI 10.1111/j.1582-4934.2007.00088.x; Mirzaei R, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1478647; Morse MA, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-9; Muller L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00140; Naseri M, 2021, J CELL MOL MED, V25, P3312, DOI 10.1111/jcmm.16401; Nawaz Muhammad, 2017, Stem Cell Investig, V4, P83, DOI 10.21037/sci.2017.10.04; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Otvos B, 2016, STEM CELLS, V34, P2026, DOI 10.1002/stem.2393; Pasto A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093352; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Philip R, 2015, ONCOTARGET, V6, P2046, DOI 10.18632/oncotarget.2858; Raimondo S, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0086-x; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rodriguez M, 2015, ONCOTARGET, V6, P40575, DOI 10.18632/oncotarget.5818; Rossi F, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-02018-6; Sanchez CA, 2016, ONCOTARGET, V7, P3993, DOI 10.18632/oncotarget.6540; Santos P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061450; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Scheele CLGJ, 2016, TRENDS CANCER, V2, P205, DOI 10.1016/j.trecan.2016.03.001; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Seo N, 2018, CANCER SCI, V109, P2998, DOI 10.1111/cas.13735; Shoff M., 2020, EXRNA, V2, P1, DOI [10.1186/s41544-019-0045-6, DOI 10.1186/S41544-019-0045-6]; Singh SK, 2003, CANCER RES, V63, P5821; Sreepadmanabh M, 2018, BIOTECHNOL ADV, V36, P1094, DOI 10.1016/j.biotechadv.2018.03.009; Steinbichler TB, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0970-x; Su CY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00499-2; Sun HX, 2019, J ONCOL, V2019, DOI 10.1155/2019/3516973; Sun W, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01255-w; Sun X, 2017, ONCOTARGET, V8, P36137, DOI 10.18632/oncotarget.16661; Sun ZP, 2017, ONCOTARGET, V8, P93839, DOI 10.18632/oncotarget.21288; Sun Z, 2020, CELL MOL NEUROBIOL, V40, P767, DOI 10.1007/s10571-019-00771-8; Sutherland KD, 2015, TRENDS CANCER, V1, P15, DOI 10.1016/j.trecan.2015.07.003; Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281-010-0234-8; Turdo A, 2020, CANCERS, V12, DOI 10.3390/cancers12061436; Valcz G, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0071-9; van der Goot FG, 2006, TRENDS CELL BIOL, V16, P514, DOI 10.1016/j.tcb.2006.08.003; Wang JH, 2017, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00533; Wang KX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120593; Wang L, 2020, J CELL MOL MED, V24, P6324, DOI 10.1111/jcmm.15274; Wang L, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118024; Wang L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01261-y; Wang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0997-z; Wang Z, 2019, CANCER METAST REV, V38, P259, DOI 10.1007/s10555-019-09793-6; Wang Z, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1129-8; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Wolfson Benjamin, 2014, World J Stem Cells, V6, P591, DOI 10.4252/wjsc.v6.i5.591; Xu JS, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4837370; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yang ZY, 2020, CELL ONCOL, V43, P123, DOI 10.1007/s13402-019-00476-6; Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022; Zhang D, 2020, ONCOL REP, V43, P1125, DOI 10.3892/or.2020.7496; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhao H, 2020, J CELL BIOCHEM, V121, P3286, DOI 10.1002/jcb.29600; Zhou XX, 2020, CELL MOL IMMUNOL, V17, P323, DOI 10.1038/s41423-020-0391-1	111	4	4	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							441	10.3390/vaccines9050441			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3CW	34062950	Green Published, gold			2022-04-29	WOS:000654704200001
J	Maltezou, HC; Pavli, A; Tsakris, A				Maltezou, Helena C.; Pavli, Androula; Tsakris, Athanasios			Post-COVID Syndrome: An Insight on Its Pathogenesis	VACCINES			English	Review						COVID-19; SARS-CoV-2; inflammation; post-infectious; complications; long term; pathogenesis	FATIGUE; SYMPTOMS	Post-COVID syndrome is increasingly recognized as a new clinical entity in the context of SARS-CoV-2 infection. Symptoms persisting for more than three weeks after the diagnosis of COVID-19 characterize the post-COVID syndrome. Its incidence ranges from 10% to 35%, however, rates as high as 85% have been reported among patients with a history of hospitalization. Currently, there is no consensus on the classification of post-COVID syndrome. We reviewed the published information on post-COVID syndrome, putting emphasis on its pathogenesis. The pathogenesis of post-COVID syndrome is multi-factorial and more than one mechanism may be implicated in several clinical manifestations. Prolonged inflammation has a key role in its pathogenesis and may account for some neurological complications, cognitive dysfunction, and several other symptoms. A multisystem inflammatory syndrome in adults (MIS-A) of all ages has been also described recently, similarly to multisystem inflammatory syndrome in children (MIS-C). The post-infectious inflammatory pathogenetic mechanism of MIS-A is supported by the fact that its diagnosis is established through serology in up to one third of cases. Other pathogenetic mechanisms that are implicated in post-COVID syndrome include immune-mediated vascular dysfunction, thromboembolism, and nervous system dysfunction. Although the current data are indicating that the overwhelming majority of patients with post-COVID syndrome have a good prognosis, registries to actively follow them are needed in order to define the full clinical spectrum and its long-term outcome. A consensus-based classification of post-COVID syndrome is essential to guide clinical, diagnostic, and therapeutic management. Further research is also imperative to elucidate the pathogenesis of post-COVID syndrome.	[Maltezou, Helena C.] Natl Publ Hlth Org, Directorate Res Studies & Documentat, Athens 11523, Greece; [Pavli, Androula] Natl Publ Hlth Org, Dept Travel Med, Athens 11523, Greece; [Tsakris, Athanasios] Natl & Kapodistrian Univ Athens, Sch Med, Dept Microbiol, Athens 15772, Greece		Maltezou, HC (通讯作者)，Natl Publ Hlth Org, Directorate Res Studies & Documentat, Athens 11523, Greece.	helen-maltezou@ath.forthnet.gr; androulapavli2017@gmail.com; atsakris@gmail.com		Maltezou, Helena/0000-0003-0264-3547			Abrams JY, 2020, J PEDIATR-US, V226, P45, DOI 10.1016/j.jpeds.2020.08.003; Addison AB, 2021, J ALLERGY CLIN IMMUN, V147, P1704, DOI 10.1016/j.jaci.2020.12.641; Al-Jahdhami Issa, 2021, Oman Med J, V36, pe220, DOI 10.5001/omj.2021.91; Alemanno F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246590; Alpert Orna, 2020, Brain Behav Immun Health, V9, P100173, DOI 10.1016/j.bbih.2020.100173; Amenta E.M., 2020, OPEN FORUM INFECT DI, DOI DOI 10.1093/ofid/ofaa509; Becker RC, 2021, J THROMB THROMBOLYS, V51, P587, DOI 10.1007/s11239-021-02375-w; Bellan M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.36142; Boumaza A, 2021, J INFECT DIS, V224, P395, DOI 10.1093/infdis/jiab044; Brodard J, 2021, J THROMB HAEMOST, V19, P1294, DOI 10.1111/jth.15262; Camdessanche JP, 2020, REV NEUROL-FRANCE, V176, P516, DOI 10.1016/j.neurol.2020.04.003; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Carroll E, 2020, EPILEPSIA, V61, pE135, DOI 10.1111/epi.16683; Carvalho-Schneider C, 2021, CLIN MICROBIOL INFEC, V27, P258, DOI 10.1016/j.cmi.2020.09.052; Chang MC, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040373; Chopra V, 2021, ANN INTERN MED, V174, P576, DOI 10.7326/M20-5661; Dani M, 2021, CLIN MED, V21, pE63, DOI 10.7861/clinmed.2020-0896; Davido B, 2020, CLIN MICROBIOL INFEC, V26, P1448, DOI 10.1016/j.cmi.2020.07.028; Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019; Dennis A, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-048391; Dicpinigaitis PV, 2020, LUNG, V198, P863, DOI 10.1007/s00408-020-00406-6; E.U, WASH POST; Emamikhah M, 2021, J NEUROVIROL, V27, P26, DOI 10.1007/s13365-020-00941-1; Eythorsson E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4529; Fernandez-de-las-Penas C, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052621; Garcia-Oscos F, 2012, BIOL PSYCHIAT, V71, P574, DOI 10.1016/j.biopsych.2011.11.018; Garg P, 2021, J MED VIROL, V93, P673, DOI 10.1002/jmv.26465; Garrigues E, 2020, J INFECTION, V81, pE4, DOI 10.1016/j.jinf.2020.08.029; Gautret P, 2020, EXPERT REV CLIN IMMU, V16, P1159, DOI 10.1080/1744666X.2021.1847640; Greenhalgh T, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3026; Halpin SJ, 2021, J MED VIROL, V93, P1013, DOI 10.1002/jmv.26368; Havervall S, 2021, JAMA-J AM MED ASSOC, V325, P2015, DOI 10.1001/jama.2021.5612; Hayden MR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112475; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Kilbertus S, 2021, CAN J EMERG MED, V23, P551, DOI 10.1007/s43678-021-00104-z; Konig MF, 2020, J CLIN INVEST, V130, P3345, DOI 10.1172/JCI139642; Koumpa FS, 2020, BMJ CASE REP, V13, DOI 10.1136/bcr-2020-238419; Kumar MA, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2020-241059; Ladds E, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-06001-y; Lagier JC, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101791; Le Bon Serge-Daniel, 2021, Eur Arch Otorhinolaryngol, V278, P101, DOI 10.1007/s00405-020-06267-2; Leta V, 2021, MOVEMENT DISORD, V36, P1287, DOI 10.1002/mds.28622; Liang LM, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e418; Maltezou HC, 2021, J INFECT DIS, V223, P1132, DOI 10.1093/infdis/jiaa804; Medscape Pediatrics, SOM LONG COVID SEE R; Mitrani RD, 2020, HEART RHYTHM, V17, P1984, DOI 10.1016/j.hrthm.2020.06.026; Moldofsky H, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-37; Moreno-Perez O, 2021, J INFECTION, V82, P378, DOI 10.1016/j.jinf.2021.01.004; Morin L, 2021, JAMA-J AM MED ASSOC, V325, P1525, DOI 10.1001/jama.2021.3331; Morris SB, 2020, MMWR-MORBID MORTAL W, V69, P1450, DOI 10.15585/mmwr.mm6940e1; Muller JA, 2021, NAT METAB, V3, P149, DOI 10.1038/s42255-021-00347-1; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Nazy I, 2021, J THROMB HAEMOST, V19, P1342, DOI 10.1111/jth.15283; Novak Peter, 2020, eNeurologicalSci, V21, P100276, DOI 10.1016/j.ensci.2020.100276; Nuzzo D, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11040454; Ortelli P, 2021, J NEUROL SCI, V420, DOI 10.1016/j.jns.2020.117271; Patient-Led Research Collaborative, REP WHAT DOES COVID; Pavli A, 2021, ARCH MED RES, V52, P575, DOI 10.1016/j.arcmed.2021.03.010; Raahimi MM, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2020-240178; Ritchie K, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa069; Saeed S, 2021, J HYPERTENS, V39, P1282, DOI 10.1097/HJH.0000000000002819; Sathish T, 2021, DIABETES METAB, V47, DOI 10.1016/j.diabet.2020.10.002; Scoppettuolo Pasquale, 2020, Brain Behav Immun Health, V5, P100094, DOI 10.1016/j.bbih.2020.100094; Scordo KA, 2021, AACN ADV CRIT CARE, V32, P188, DOI 10.4037/aacnacc2021492; Shahali H, 2021, J NEUROVIROL, V27, P354, DOI 10.1007/s13365-021-00957-1; Simani L, 2021, J NEUROVIROL, V27, P154, DOI 10.1007/s13365-021-00949-1; Soloveva NV, 2020, EUR J TRANSL MYOL, V30, DOI 10.4081/ejtm.2020.9302; Stratton CW, 2021, J MED VIROL, V93, P1320, DOI 10.1002/jmv.26610; Sun B, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020386; Tale S, 2020, QJM-INT J MED, V113, P837, DOI 10.1093/qjmed/hcaa255; Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P993, DOI [10.15585/mmwr.mm6930e1, 10.15585/mmwr.mm6930e1externalicon]; Townsend L, 2021, J THROMB HAEMOST, V19, P1064, DOI 10.1111/jth.15267; Trougakos IP, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929-020-00703-5; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Willi S, 2021, TRAVEL MED INFECT DI, V40, DOI 10.1016/j.tmaid.2021.101995; World Health Organization, COR DIS COVID 19 SIT; Wostyn P, 2021, MED HYPOTHESES, V146, DOI 10.1016/j.mehy.2020.110469; Xia XH, 2021, TRANSL NEURODEGENER, V10, DOI 10.1186/s40035-021-00237-2	78	23	26	7	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							497	10.3390/vaccines9050497			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3DN	34066007	gold, Green Published			2022-04-29	WOS:000654705900001
J	Taghinezhad-S, S; Mohseni, AH; Bermudez-Humaran, LG; Casolaro, V; Cortes-Perez, NG; Keyvani, H; Simal-Gandara, J				Taghinezhad-S, Sedigheh; Mohseni, Amir Hossein; Bermudez-Humaran, Luis G.; Casolaro, Vincenzo; Cortes-Perez, Naima G.; Keyvani, Hossein; Simal-Gandara, Jesus			Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease	VACCINES			English	Review						coronavirus; SARS-CoV-2; COVID-19; probiotics; vaccines; mucosal immunization	RECOMBINANT LACTOBACILLUS-PLANTARUM; LACTIC-ACID BACTERIA; HUMAN-PAPILLOMAVIRUS TYPE-16; SYSTEMIC IMMUNE-RESPONSES; ORAL IMMUNIZATION; SPIKE PROTEIN; EXPRESSING HEMAGGLUTININ; IMMUNOLOGICAL EVALUATION; GASTROINTESTINAL-TRACT; MUCOSAL IMMUNITY	Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, the causative agent of COVID-19, now represents the sixth Public Health Emergency of International Concern (PHEIC)-as declared by theWorld Health Organization (WHO) since 2009. Considering that SARS-CoV-2 is mainly transmitted via the mucosal route, a therapy administered by this same route may represent a desirable approach to fight SARS-CoV-2 infection. It is now widely accepted that genetically modified microorganisms, including probiotics, represent attractive vehicles for oral or nasal mucosal delivery of therapeutic molecules. Previous studies have shown that the mucosal administration of therapeutic molecules is able to induce an immune response mediated by specific serum IgG and mucosal IgA antibodies along with mucosal cell-mediated immune responses, which effectively concur to neutralize and eradicate infections. Therefore, advances in the modulation of mucosal immune responses, and in particular the use of probiotics as live delivery vectors, may encourage prospective studies to assess the effectiveness of genetically modified probiotics for SARS-CoV-2 infection. Emerging trends in the ever-progressing field of vaccine development re-emphasize the contribution of adjuvants, along with optimization of codon usage (when designing a synthetic gene), expression level, and inoculation dose to elicit specific and potent protective immune responses. In this review, we will highlight the existing pre-clinical and clinical information on the use of genetically modified microorganisms in control strategies against respiratory and non-respiratory viruses. In addition, we will discuss some controversial aspects of the use of genetically modified probiotics in modulating the cross-talk between mucosal delivery of therapeutics and immune system modulation.	[Taghinezhad-S, Sedigheh; Mohseni, Amir Hossein] Islamic Azad Univ, Dept Microbiol, Fac Basic Sci, Sci & Res Branch, Tehran 1477893855, Iran; [Bermudez-Humaran, Luis G.] Univ Paris Saclay, INRAE, AgroParisTech, Micalis Inst, F-78350 Jouy En Josas, France; [Casolaro, Vincenzo] Univ Salerno, Dept Med Surg & Dent, Scuola Med Salernitana, I-84081 Salerno, Italy; [Cortes-Perez, Naima G.] Univ Paris Saclay, AgroParisTech, INRAE, UMR 0496, F-78350 Jouy En Josas, France; [Keyvani, Hossein] Iran Univ Med Sci, Dept Virol, Fac Med, Tehran 1449614535, Iran; [Simal-Gandara, Jesus] Univ Vigo, Fac Food Sci & Technol, Nutr & Bromatol Grp, Dept Analyt Chem & Food Sci, Ourense Campus, E-32004 Orense, Spain		Mohseni, AH (通讯作者)，Islamic Azad Univ, Dept Microbiol, Fac Basic Sci, Sci & Res Branch, Tehran 1477893855, Iran.	taghinezhad.m@gmail.com; amho.mohseni@gmail.com; luis.bermudez@inrae.fr; vcasolaro@unisa.it; naima.cortes-perez@inrae.fr; keyvani.h@iums.ac.ir; jsimal@uvigo.es	Cortes-Perez, Naima/AAG-7100-2022; Simal-Gandara, Jesus/A-9533-2009; Casolaro, Vincenzo/E-9144-2010; Mohseni, Amir Hossein/I-6084-2016	Cortes-Perez, Naima/0000-0003-4189-7304; Simal-Gandara, Jesus/0000-0001-9215-9737; Casolaro, Vincenzo/0000-0001-9810-0488; Bermudez Humaran, Luis G./0000-0001-7525-3131; Mohseni, Amir Hossein/0000-0003-0320-9523			Adachi K, 2010, VACCINE, V28, P2810, DOI 10.1016/j.vaccine.2010.02.005; Asahi-Ozaki Y, 2004, J MED VIROL, V74, P328, DOI 10.1002/jmv.20173; Azegami T, 2018, J HYPERTENS, V36, P387, DOI 10.1097/HJH.0000000000001519; Bahey-El-Din M, 2012, VACCINE, V30, P685, DOI 10.1016/j.vaccine.2011.11.098; Bermudez-Humaran LG, 2005, J IMMUNOL, V175, P7297, DOI 10.4049/jimmunol.175.11.7297; Bermudez-Humaran LG, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-S1-S4; Cai RP, 2016, J MICROBIOL BIOTECHN, V26, P421, DOI 10.4014/jmb.1509.09030; Cao YJ, 2020, J IMMUNOL, V205, P842, DOI 10.4049/jimmunol.1901000; Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399; Chowdhury MYE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094051; Cui LC, 2015, VACCINE, V33, P3092, DOI 10.1016/j.vaccine.2015.05.002; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; Daniel C, 2011, TRENDS BIOTECHNOL, V29, P499, DOI 10.1016/j.tibtech.2011.05.002; Davidson LE, 2011, EUR J CLIN NUTR, V65, P501, DOI 10.1038/ejcn.2010.289; del Rio B, 2008, CLIN VACCINE IMMUNOL, V15, P1429, DOI 10.1128/CVI.00169-08; Dicks LMT, 2010, BENEF MICROBES, V1, P11, DOI 10.3920/BM2009.0012; Dieye Y, 2001, J BACTERIOL, V183, P4157, DOI 10.1128/JB.183.14.4157-4166.2001; Dong HL, 2012, BRIT J NUTR, V108, P459, DOI 10.1017/S0007114511005824; Duan KX, 2018, FISH SHELLFISH IMMUN, V83, P223, DOI 10.1016/j.fsi.2018.09.034; Ellebedy AH, 2011, VACCINE, V29, P3335, DOI 10.1016/j.vaccine.2010.08.067; Enomoto M, 2009, BIOSCI BIOTECH BIOCH, V73, P457, DOI 10.1271/bbb.80438; Temprana CF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203700; Fuglsang A, 2003, BIOCHEM BIOPH RES CO, V312, P285, DOI 10.1016/j.bbrc.2003.10.120; Gao SY, 2015, INT IMMUNOPHARMACOL, V24, P140, DOI 10.1016/j.intimp.2014.10.032; Geriletu, 2011, CURR MICROBIOL, V62, P1573, DOI 10.1007/s00284-011-9894-4; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; LeBlanc JG, 2013, FEMS MICROBIOL LETT, V344, P1, DOI 10.1111/1574-6968.12159; Hanniffy SB, 2007, J INFECT DIS, V195, P185, DOI 10.1086/509807; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Huang C, 2020, Lancet, V395, P497; Hugentobler F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030945; Jiang XP, 2016, APPL MICROBIOL BIOT, V100, P7457, DOI 10.1007/s00253-016-7424-9; Jiang YL, 2017, J BIOTECHNOL, V259, P6, DOI 10.1016/j.jbiotec.2017.08.011; Jiang YL, 2015, J BIOTECHNOL, V216, P82, DOI 10.1016/j.jbiotec.2015.09.033; Jin YB, 2018, APPL MICROBIOL BIOT, V102, P8403, DOI 10.1007/s00253-018-9205-0; Joan SSX, 2016, BIOTECHNOL LETT, V38, P793, DOI 10.1007/s10529-016-2034-2; Kajikawa A, 2012, CLIN VACCINE IMMUNOL, V19, P1374, DOI 10.1128/CVI.00049-12; Kathania M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055143; Kawana K, 2014, VACCINE, V32, P6233, DOI 10.1016/j.vaccine.2014.09.020; Kikuchi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086416; Komatsu A, 2018, VACCINE, V36, P3423, DOI 10.1016/j.vaccine.2018.05.009; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; LeCureux JS, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00061-18; Lee JS, 2006, J VIROL, V80, P4079, DOI 10.1128/JVI.80.8.4079-4087.2006; Lee YN, 2013, ANTIVIR RES, V98, P284, DOI 10.1016/j.antiviral.2013.03.013; Lei H, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0287-4; Lei H, 2015, VIROLOGY, V476, P189, DOI 10.1016/j.virol.2014.12.017; Lei H, 2011, CLIN VACCINE IMMUNOL, V18, P1046, DOI 10.1128/CVI.00050-11; Li R, 2015, VET MICROBIOL, V179, P250, DOI 10.1016/j.vetmic.2015.07.020; Li YJ, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/708460; Li YJ, 2014, ONCOL LETT, V7, P576, DOI 10.3892/ol.2013.1743; Liu DQ, 2012, APPL MICROBIOL BIOT, V93, P2437, DOI 10.1007/s00253-011-3734-0; Liu DQ, 2011, CAN J MICROBIOL, V57, P392, DOI [10.1139/W11-027, 10.1139/w11-027]; Liu YY, 2017, J VET SCI, V18, P159, DOI 10.4142/jvs.2017.18.2.159; Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251; Landete JM, 2017, CRIT REV BIOTECHNOL, V37, P296, DOI 10.3109/07388551.2016.1144044; Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004; Michon C, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-016-0468-9; Mierau I, 2005, APPL MICROBIOL BIOT, V68, P705, DOI 10.1007/s00253-005-0107-6; Mitragotri S, 2005, NAT REV IMMUNOL, V5, P905, DOI 10.1038/nri1728; Mohamadzadeh M, 2009, P NATL ACAD SCI USA, V106, P4331, DOI 10.1073/pnas.0900029106; Mohseni A.H., 2020, BIORXIV; Mohseni AH, 2021, GUT MICROBES, V13, P1, DOI 10.1080/19490976.2021.1886844; Mohseni AH, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00337-7; Mohseni AH, 2020, MOL CANCER THER, V19, P717, DOI 10.1158/1535-7163.MCT-19-0375; Mohseni AH, 2019, BMC BIOTECHNOL, V19, DOI 10.1186/s12896-019-0499-5; Mohseni AH, 2019, J MED VIROL, V91, P296, DOI 10.1002/jmv.25303; Mohseni AH, 2017, MICROB PATHOGENESIS, V110, P554, DOI 10.1016/j.micpath.2017.07.039; Mohseni Amir Hossein, 2017, Asian Pac J Cancer Prev, V18, P783; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Ohkouchi K, 2012, J BIOSCI BIOENG, V113, P536, DOI 10.1016/j.jbiosc.2011.11.025; Pant N, 2006, J INFECT DIS, V194, P1580, DOI 10.1086/508747; Park YC, 2019, J GYNECOL ONCOL, V30, DOI 10.3802/jgo.2019.30.e88; Peiroten A, 2020, APPL MICROBIOL BIOT, V104, P3797, DOI 10.1007/s00253-020-10426-0; Petrarca C., 2015, J VACCINES VACCIN, V1; Plant LJ, 2002, FEMS IMMUNOL MED MIC, V34, P105, DOI 10.1111/j.1574-695X.2002.tb00610.x; Qiao XY, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-249; Ramirez K, 2010, MUCOSAL IMMUNOL, V3, P159, DOI 10.1038/mi.2009.131; Reese Kaleb A, 2013, Vet Med Int, V2013, P316926, DOI 10.1155/2013/316926; Renegar KB, 2004, J IMMUNOL, V173, P1978, DOI 10.4049/jimmunol.173.3.1978; Ricci A, 2018, EFSA J, V16, DOI 10.2903/j.efsa.2018.5131; Rosales-Mendoza S, 2016, TRENDS BIOTECHNOL, V34, P124, DOI 10.1016/j.tibtech.2015.11.007; Rose MA, 2012, EXPERT REV VACCINES, V11, P595, DOI [10.1586/erv.12.31, 10.1586/ERV.12.31]; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Seegers JFML, 2002, TRENDS BIOTECHNOL, V20, P508, DOI 10.1016/S0167-7799(02)02075-9; Sehgal K, 2014, IMMUNOL LETT, V162, P59, DOI 10.1016/j.imlet.2014.07.004; Shi SH, 2016, VIRUS RES, V211, P46, DOI 10.1016/j.virusres.2015.09.005; Shi SH, 2014, VIROLOGY, V464, P166, DOI 10.1016/j.virol.2014.07.011; Sim ACN, 2008, VACCINE, V26, P1145, DOI 10.1016/j.vaccine.2007.12.047; Suebwongsa N, 2013, INT MICROBIOL, V16, P93, DOI 10.2436/20.1501.01.184; Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010; Sundararaman A, 2020, APPL MICROBIOL BIOT, V104, P8089, DOI 10.1007/s00253-020-10832-4; Taghinezhad S, 2017, FUTURE VIROL, V12, P499, DOI 10.2217/fvl-2017-0032; Taghinezhad S, 2021, CELL MOL LIFE SCI, V78, P1191, DOI 10.1007/s00018-020-03652-2; Taghinezhad-S S, 2019, MOL THER-METH CLIN D, V15, P40, DOI 10.1016/j.omtm.2019.08.005; Taghinezhad-S S, 2018, FUTURE VIROL, V13, P697, DOI 10.2217/fvl-2018-0026; Taghinezhad-S S, 2019, MICROB PATHOGENESIS, V126, P149, DOI 10.1016/j.micpath.2018.10.043; Taguchi A, 2012, VACCINE, V30, P5368, DOI 10.1016/j.vaccine.2012.06.027; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Tang LJ, 2009, VIRUS GENES, V39, P238, DOI 10.1007/s11262-009-0390-x; Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; van Roosmalen ML, 2006, METHODS, V38, P144, DOI 10.1016/j.ymeth.2005.09.015; Vijayakumar PP, 2015, BIOMOLECULES, V5, P1178, DOI 10.3390/biom5021178; Vitini E, 2000, BIOCELL, V24, P223; Walter J, 2008, APPL ENVIRON MICROB, V74, P4985, DOI 10.1128/AEM.00753-08; Wang GH, 2009, AGR SCI CHINA, V8, P231, DOI 10.1016/S1671-2927(09)60031-6; Wang MP, 2020, INT J BIOL MACROMOL, V160, P736, DOI 10.1016/j.ijbiomac.2020.05.239; Wang ZS, 2012, FUTURE MICROBIOL, V7, P1003, DOI [10.2217/FMB.12.69, 10.2217/fmb.12.69]; Wang ZS, 2012, CLIN VACCINE IMMUNOL, V19, P174, DOI 10.1128/CVI.05618-11; Wypych TP, 2019, NAT IMMUNOL, V20, P1279, DOI 10.1038/s41590-019-0451-9; Xin KQ, 2003, BLOOD, V102, P223, DOI 10.1182/blood-2003-01-0110; Xu YG, 2011, CLIN VACCINE IMMUNOL, V18, P1979, DOI 10.1128/CVI.05204-11; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8; Yang WT, 2018, APPL MICROBIOL BIOT, V102, P5077, DOI 10.1007/s00253-018-8924-6; Yang WT, 2017, ANTIVIR RES, V138, P9, DOI 10.1016/j.antiviral.2016.11.025; Yang WT, 2016, SCI REP-UK, V6, DOI 10.1038/srep39665; Yoon SW, 2012, VACCINE, V30, P3286, DOI 10.1016/j.vaccine.2012.03.009; Yotpanya Panjamaporn, 2016, Journal of the Medical Association of Thailand, V99, pS9; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhao LL, 2012, VACCINE, V30, P1823, DOI 10.1016/j.vaccine.2011.12.132; Zhen-guo W., 2005, VIROL SIN, V20, P607	124	5	5	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							466	10.3390/vaccines9050466			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1RU	34066443	Green Published, gold			2022-04-29	WOS:000654604100001
J	Alfageeh, EI; Alshareef, N; Angawi, K; Alhazmi, F; Chirwa, GC				Alfageeh, Eman Ibrahim; Alshareef, Noor; Angawi, Khadijah; Alhazmi, Fahad; Chirwa, Gowokani Chijere			Acceptability of a COVID-19 Vaccine among the Saudi Population	VACCINES			English	Article						COVID-19; hesitancy; public; intention; Saudi Arabia; vaccine		To investigate the associated factors underlying vaccination intentions for Coronavirus Disease 2019 (COVID-19), an online cross-sectional survey was conducted among adults 18 years or over in the Kingdom of Saudi Arabia. Data were collected between 8 and 14 December 2020. A logistic regression analysis was employed to examine and identify the variables associated with vaccination intentions for COVID-19, with the odds ratio (OR) and 95% confidence interval (CI) also calculated. A total of 2137 respondents completed the questionnaire. Overall, about 48% of Saudi adults were willing to receive the COVID-19 vaccine. Participants had stronger intentions to receive a vaccination if they resided in the southern region (OR: 1.95; 95% CI: 1.21-3.14), received the seasonal influenza vaccination in the past (OR: 1.52; 95% CI: 1.17-1.97), believed in mandatory COVID-19 vaccination (OR: 45.07; 95% CI: 31.91-63.65), or reported high levels of concern about contracting COVID-19 (OR: 1.91; 95% CI: 1.29-2.81). Participants were less likely to have an intention to be vaccinated if they had a history of vaccine refusal (OR: 0.28; 95% CI: 0.19-0.40). The low acceptance rate among the Saudi population should be targeted with multifaceted interventions aimed at raising awareness and emphasizing the safety and efficacy of the COVID-19 vaccine.	[Alfageeh, Eman Ibrahim] East Jeddah Gen Hosp, Primary Hlth Care Ctr Affairs Adm, Jeddah 22253, Saudi Arabia; [Alshareef, Noor; Angawi, Khadijah; Alhazmi, Fahad] King Abdulaziz Univ, Fac Econ & Adm, Dept Hlth Serv & Hosp Adm, Jeddah 80200, Saudi Arabia; [Chirwa, Gowokani Chijere] Univ Malawi, Econ Dept, Chancellor Coll, Zomba, Malawi		Alshareef, N (通讯作者)，King Abdulaziz Univ, Fac Econ & Adm, Dept Hlth Serv & Hosp Adm, Jeddah 80200, Saudi Arabia.	Emanfageeh@gmail.com; naalshareef@kau.edu.sa; kkangawi@kau.edu.sa; fnalhazmi@kau.edu.sa; gowokani@gmail.com	Chirwa, Gowokani Chijere/AAB-3310-2020	Chirwa, Gowokani Chijere/0000-0003-0199-779X; Alhazmi, Fahad/0000-0002-0271-7166; Angawi, Khadijah/0000-0002-7625-1813			Al-Hanawi MK, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00217; Al-Hanawi MK, 2020, RISK MANAG HEALTHC P, V13, P733, DOI 10.2147/RMHP.S264037; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136; Cameron A. C., 2010, MICROECONOMETRICS US; Chirwa GC, 2020, SCI AFR, V7, DOI 10.1016/j.sciaf.2019.e00213; Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039; Halpin Carmel, 2019, Nurs Older People, V31, P32, DOI 10.7748/nop.2019.e1154; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Jayasooriya S, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4713; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Muthukrishnan S, 2005, FOUND TRENDS THEOR C, V1, P1, DOI 10.1561/0400000002; Nguyen Trang, 2011, Infect Drug Resist, V4, P197, DOI 10.2147/IDR.S23174; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Ofri D, 2009, NEW ENGL J MED, V361, P2594, DOI 10.1056/NEJMp0911047; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Rubin GJ, 2010, HEALTH TECHNOL ASSES, V14, P183, DOI 10.3310/hta14340-03; Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054; Sharpe HR, 2020, IMMUNOLOGY, V160, P223, DOI 10.1111/imm.13222; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wooldridge JM, 2010, ECONOMETRIC ANALYSIS OF CROSS SECTION AND PANEL DATA, 2ND EDITION, P1	29	32	32	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							226	10.3390/vaccines9030226			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5MK	33807732	Green Published, gold			2022-04-29	WOS:000634197800001
J	Rahman, MM; Zhou, N; Huang, JD				Rahman, Md. Motiar; Zhou, Nan; Huang, Jiandong			An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo	VACCINES			English	Review						IVT mRNA; mRNA vaccine; electroporation; protamine; LNPs		The mRNA-based vaccine approach is a promising alternative to traditional vaccines due to its ability for prompt development, high potency, and potential for secure administration and low-cost production. Nonetheless, the application has still been limited by the instability as well as the ineffective delivery of mRNA in vivo. Current technological improvements have now mostly overcome these concerns, and manifold mRNA vaccine plans against various forms of malignancies and infectious ailments have reported inspiring outcomes in both humans and animal models. This article summarizes recent mRNA-based vaccine developments, advances of in vivo mRNA deliveries, reflects challenges and safety concerns, and future perspectives, in developing the mRNA vaccine platform for extensive therapeutic use.	[Rahman, Md. Motiar; Zhou, Nan; Huang, Jiandong] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Synthet Biol, Shenzhen 518055, Peoples R China; [Huang, Jiandong] Univ Hong Kong, Sch Biomed Sci, Fac Med, Hong Kong 999077, Peoples R China		Rahman, MM (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Synthet Biol, Shenzhen 518055, Peoples R China.	md_motiar@siat.ac.cn; nan.zhou@siat.ac.cn; jdhuang@hku.hk	/C-4277-2009	/0000-0001-7531-2816; ZHOU, Nan/0000-0003-1669-1830	Shenzhen Peacock project [KQTD2015033-117210153]; Shenzhen Science and Technology Innovation Committee Basic Science Research Grant [JCYJ20150629151046896]; Health and Medical Research Fund [COVID190117]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32001040]; L & T Charitable Foundation	The work was supported by Shenzhen Peacock project (KQTD2015033-117210153), Shenzhen Science and Technology Innovation Committee Basic Science Research Grant (JCYJ20150629151046896), the Health and Medical Research Fund (COVID190117) to J.H. and National Natural Science Foundation of China (32001040) to N.Z. J.H. is supported by the L & T Charitable Foundation. The funders had no role in the design of the study.	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Alizargar J, 2020, J FORMOS MED ASSOC, V119, P1123, DOI 10.1016/j.jfma.2020.04.013; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Arya S, 2020, MOL THER-NUCL ACIDS, V19, P1098, DOI 10.1016/j.omtn.2019.12.044; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Bao YJ, 2013, PHARM RES-DORDR, V30, P342, DOI 10.1007/s11095-012-0874-6; da Silva FLB, 2018, BIOCHEM BIOPH RES CO, V498, P264, DOI 10.1016/j.bbrc.2017.07.027; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Bonehill A, 2009, CLIN CANCER RES, V15, P3366, DOI 10.1158/1078-0432.CCR-08-2982; Brown DM, 2006, J IMMUNOL, V177, P2888, DOI 10.4049/jimmunol.177.5.2888; Buhr F, 2016, MOL CELL, V61, P341, DOI 10.1016/j.molcel.2016.01.008; Caruso DA, 2004, NEURO-ONCOLOGY, V6, P236, DOI 10.1215/S1152851703000668; Chahal JS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00193-w; Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113; Chulalongkorn University, 2020, CHULACOV19 MRNA VACC; CONRY RM, 1995, CANCER RES, V55, P1397; Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312; Creusot RJ, 2010, MOL THER, V18, P2112, DOI 10.1038/mt.2010.146; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; De Temmerman ML, 2011, BIOMATERIALS, V32, P9128, DOI 10.1016/j.biomaterials.2011.08.024; Deering RP, 2014, EXPERT OPIN DRUG DEL, V11, P885, DOI 10.1517/17425247.2014.901308; Deming ME, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2020076; Deng X, 2014, J VIROL, V88, P11886, DOI 10.1128/JVI.01528-14; Dewitte H, 2014, J CONTROL RELEASE, V194, P28, DOI 10.1016/j.jconrel.2014.08.011; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; Farzan, 2020, SARS COV 2 RECEPTOR, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fotin-Mleczek M, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-180; Fotin-Mleczek M, 2011, J IMMUNOTHER, V34, P1, DOI 10.1097/CJI.0b013e3181f7dbe8; Garber K, 2020, NAT BIOTECHNOL, V38, P773, DOI 10.1038/d41587-020-00016-w; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Grohskopf L, 2011, AM J TRANSPLANT, V11, P2250, DOI 10.1111/j.1600-6143.2011.03793.x; Guan S, 2017, GENE THER, V24, P133, DOI 10.1038/gt.2017.5; Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006; Harvie P, 2000, J PHARM SCI, V89, P652, DOI 10.1002/(SICI)1520-6017(200005)89:5<652::AID-JPS11>3.0.CO;2-H; Hatakeyama H, 2007, GENE THER, V14, P68, DOI 10.1038/sj.gt.3302843; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Heiser A, 2002, J CLIN INVEST, V109, P409, DOI 10.1172/JCI200214364; Heyes J, 2006, J CONTROL RELEASE, V112, P280, DOI 10.1016/j.jconrel.2006.02.012; Hirsch-Lerner D, 2005, BBA-BIOMEMBRANES, V1714, P71, DOI 10.1016/j.bbamem.2005.04.008; Hoerr I, 2000, EUR J IMMUNOL, V30, P1; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Islam MA, 2015, BIOMATER SCI-UK, V3, P1519, DOI 10.1039/c5bm00198f; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jacobson JM, 2016, JAIDS-J ACQ IMM DEF, V72, P31, DOI 10.1097/QAI.0000000000000926; Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9; JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298; Kallen K.-J., 2013, THE J, V1, P219, DOI [10.1186/2051-1426-1-S1-P219, DOI 10.1186/2051-1426-1-S1-P219]; Kallen Karl-Josef, 2014, Ther Adv Vaccines, V2, P10, DOI 10.1177/2051013613508729; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 1999, GENE THER, V6, P1092, DOI 10.1038/sj.gt.3300930; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2012, MOL THER, V20, P948, DOI 10.1038/mt.2012.7; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kauffman KJ, 2016, BIOMATERIALS, V109, P78, DOI 10.1016/j.biomaterials.2016.09.006; Kauffman KJ, 2016, J CONTROL RELEASE, V240, P227, DOI 10.1016/j.jconrel.2015.12.032; Koido S, 2000, J IMMUNOL, V165, P5713, DOI 10.4049/jimmunol.165.10.5713; Kormann MSD, 2011, NAT BIOTECHNOL, V29, P154, DOI 10.1038/nbt.1733; Kowalczyk A, 2016, VACCINE, V34, P3882, DOI 10.1016/j.vaccine.2016.05.046; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kudla G, 2006, PLOS BIOL, V4, P933, DOI 10.1371/journal.pbio.0040180; Kudla G, 2009, SCIENCE, V324, P255, DOI 10.1126/science.1170160; Kubler H, 2011, EUR J CANCER, V47, pS498; Kyte JA, 2005, CANCER GENE THER, V12, P579, DOI 10.1038/sj.cgt.7700837; Levy O, 2013, BLOOD, V122, pE23, DOI 10.1182/blood-2013-04-495119; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Mandl CW, 1998, NAT MED, V4, P1438, DOI 10.1038/4031; Markov OO, 2012, J CONTROL RELEASE, V160, P200, DOI 10.1016/j.jconrel.2011.11.034; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Mauro VP, 2014, TRENDS MOL MED, V20, P604, DOI 10.1016/j.molmed.2014.09.003; Mays LE, 2013, J CLIN INVEST, V123, P1216, DOI 10.1172/JCI65351; McLenachan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083596; McNamara MA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/794528; Meyer M, 2018, J INFECT DIS, V217, P451, DOI 10.1093/infdis/jix592; Miao L, 2019, NAT BIOTECHNOL, V37, P1174, DOI 10.1038/s41587-019-0247-3; Midoux P, 2015, EXPERT REV VACCINES, V14, P221, DOI 10.1586/14760584.2015.986104; Mitchell DA, 2008, HUM GENE THER, V19, P511, DOI 10.1089/hum.2007.115; Mockey M, 2007, CANCER GENE THER, V14, P802, DOI 10.1038/sj.cgt.7701072; Morris KV, 2020, MOL THER, V28, P1548, DOI 10.1016/j.ymthe.2020.06.005; Morse MA, 2002, J GASTROINTEST CANC, V32, P1, DOI 10.1385/IJGC:32:1:1; Morse MA, 2003, CANCER INVEST, V21, P341, DOI 10.1081/CNV-120018224; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Nair SK, 1999, INT J CANCER, V82, P121, DOI 10.1002/(SICI)1097-0215(19990702)82:1<121::AID-IJC20>3.0.CO;2-X; Nair SK, 2002, ANN SURG, V235, P540, DOI 10.1097/00000658-200204000-00013; Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878; Nencioni A, 2008, CRIT REV ONCOL HEMAT, V65, P191, DOI 10.1016/j.critrevonc.2007.10.002; Oberli MA, 2017, NANO LETT, V17, P1326, DOI 10.1021/acs.nanolett.6b03329; Okumura K, 2008, J GENE MED, V10, P910, DOI 10.1002/jgm.1214; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Perche F, 2011, NANOMED-NANOTECHNOL, V7, P445, DOI 10.1016/j.nano.2010.12.010; Phua KKL, 2014, NANOSCALE, V6, P7715, DOI 10.1039/c4nr01346h; Phua KKL, 2013, J CONTROL RELEASE, V166, P227, DOI 10.1016/j.jconrel.2012.12.029; Plotkin SA, 2009, CLIN VACCINE IMMUNOL, V16, P1709, DOI 10.1128/CVI.00290-09; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ponsaerts P, 2003, CLIN EXP IMMUNOL, V134, P378, DOI 10.1046/j.1365-2249.2003.02286.x; Puerta-Guardo H, 2010, J GEN VIROL, V91, P394, DOI 10.1099/vir.0.015420-0; Qiu P, 1996, GENE THER, V3, P262; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Rejman J, 2010, J CONTROL RELEASE, V147, P385, DOI 10.1016/j.jconrel.2010.07.124; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Rittig SM, 2011, MOL THER, V19, P990, DOI 10.1038/mt.2010.289; Rodrigues CMC, 2017, J INFECTION, V74, pS2, DOI 10.1016/S0163-4453(17)30184-6; Roy Sayak, 2020, SN Compr Clin Med, V2, P710, DOI 10.1007/s42399-020-00335-8; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Scheel B, 2005, EUR J IMMUNOL, V35, P1557, DOI 10.1002/eji.200425656; Schirrmacher V, 2000, GENE THER, V7, P1137, DOI 10.1038/sj.gt.3301220; Schmidt ST, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8010007; Schnee M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004746; Schuurhuis DH, 2009, CANCER RES, V69, P2927, DOI 10.1158/0008-5472.CAN-08-3920; Schwendener Reto A, 2014, Ther Adv Vaccines, V2, P159, DOI 10.1177/2051013614541440; Sebastian M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-748; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Sharpe HR, 2020, IMMUNOLOGY, V160, P223, DOI 10.1111/imm.13222; Silveira MM, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118919; Song LY, 2002, BBA-BIOMEMBRANES, V1558, P1, DOI 10.1016/S0005-2736(01)00399-6; Su Z, 2005, J IMMUNOL, V174, P3798, DOI 10.4049/jimmunol.174.6.3798; Su Z, 2003, CANCER RES, V63, P2127; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; Tavernier G, 2011, J CONTROL RELEASE, V150, P238, DOI 10.1016/j.jconrel.2010.10.020; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Thran M, 2017, EMBO MOL MED, V9, P1434, DOI 10.15252/emmm.201707678; To Kelvin Kai-Wang, 2021, Clin Infect Dis, V73, pe2946, DOI 10.1093/cid/ciaa1275; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang XW, 2005, J VIROL METHODS, V126, P171, DOI 10.1016/j.jviromet.2005.02.005; Wang YH, 2013, MOL THER, V21, P358, DOI 10.1038/mt.2012.250; Wasungu L, 2006, J CONTROL RELEASE, V116, P255, DOI 10.1016/j.jconrel.2006.06.024; Wasungu L, 2006, BBA-BIOMEMBRANES, V1758, P1677, DOI 10.1016/j.bbamem.2006.06.019; Weide B, 2008, J IMMUNOTHER, V31, P180, DOI 10.1097/CJI.0b013e31815ce501; Weide B, 2009, J IMMUNOTHER, V32, P498, DOI 10.1097/CJI.0b013e3181a00068; Wilgenhof S, 2013, ANN ONCOL, V24, P2686, DOI 10.1093/annonc/mdt245; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Woodle MC, 1998, ADV DRUG DELIVER REV, V32, P139, DOI 10.1016/S0169-409X(97)00136-1; Younger DS, 2016, NEUROL CLIN, V34, P1035, DOI 10.1016/j.ncl.2016.05.004; Yu CH, 2015, MOL CELL, V59, P744, DOI 10.1016/j.molcel.2015.07.018; Zangi L, 2013, NAT BIOTECHNOL, V31, P898, DOI 10.1038/nbt.2682; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhong ZF, 2018, NANO TODAY, V23, P16, DOI 10.1016/j.nantod.2018.10.005; Zhou WZ, 1999, HUM GENE THER, V10, P2719, DOI 10.1089/10430349950016762; Zimmermann O, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.003293; Zohra FT, 2007, BIOCHEM BIOPH RES CO, V358, P373, DOI 10.1016/j.bbrc.2007.04.059; Zohra FT, 2009, BIOMATERIALS, V30, P4006, DOI 10.1016/j.biomaterials.2009.02.050; Zohra FT, 2012, BIOL PHARM BULL, V35, P111, DOI 10.1248/bpb.35.111; Zohra FT, 2005, ANAL BIOCHEM, V345, P164, DOI 10.1016/j.ab.2005.06.031; Zou S, 2010, INT J PHARMACEUT, V389, P232, DOI 10.1016/j.ijpharm.2010.01.019	152	3	3	16	34	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							244	10.3390/vaccines9030244			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5LF	33799516	gold, Green Published			2022-04-29	WOS:000634194700001
J	Barchitta, M; Maugeri, A; San Lio, RM; La Rosa, MC; La Mastra, C; Favara, G; Giunta, G; Cianci, A; Agodi, A				Barchitta, Martina; Maugeri, Andrea; San Lio, Roberta Magnano; La Rosa, Maria Clara; La Mastra, Claudia; Favara, Giuliana; Giunta, Giuliana; Cianci, Antonio; Agodi, Antonella			Vaccination Status of Mothers and Children from the 'Mamma & Bambino' Cohort	VACCINES			English	Article						birth cohort; communicable diseases; pregnancy; vaccine hesitancy; public health	PREGNANT-WOMEN; INFLUENZA VACCINATION; IMMUNIZATION; KNOWLEDGE; PERTUSSIS; HESITANCY; COVERAGE; ATTITUDES; VACCINES; BELIEFS	According to the evidence demonstrating vaccines' safety and effectiveness in anticipation of and during pregnancy, several countries have established immunization programs during the periconceptional period. Here, we evaluated vaccination status among 220 mother-child pairs, using data from the 'Mamma & Bambino' cohort. The self-reported data were evaluated at delivery, and with planned follow-ups at 1-2 years after delivery. In general, we noted that the vaccination status among the women was heterogeneous, ranging from 8.3% (vaccine against Human Papillomavirus, HPV) to 65.6% (vaccine against Diphtheria Tetanus and Pertussis, DTaP). Excluding the women who contracted the diseases in the past, the main ground for refusal was the lack of information. We also demonstrated that increasing age was associated with higher odds of not being vaccinated against Measles-Mumps-Rubella (MMR; OR = 1.12; 95% CI = 1.04-1.21; p = 0.004), HPV (OR = 1.20; 95% CI = 1.08-1.33; p = 0.001) and DTaP (OR =1.09; 95% CI = 1.01-1.18; p = 0.040). As expected, we showed that the proportion of newborns vaccinated with the Hexavalent and Pneumococcal vaccines was high (99.5% and 98.6%, respectively), while the vaccination coverage against MMRV did not reach the auspicated threshold (84.1%). Overall, these results underlined the need for the improvement of women's knowledge about the recommendations for vaccination, especially during pregnancy.	[Barchitta, Martina; Maugeri, Andrea; San Lio, Roberta Magnano; La Rosa, Maria Clara; La Mastra, Claudia; Favara, Giuliana; Agodi, Antonella] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, I-95123 Catania, Italy; [Giunta, Giuliana; Cianci, Antonio] Univ Catania, Dept Gen Surg & Med Surg Specialties, Obstet & Gynecol Unit, I-95123 Catania, Italy		Agodi, A (通讯作者)，Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, I-95123 Catania, Italy.	martina.barchitta@unict.it; andrea.maugeri@unict.it; roberta.magnanosanlio@phd.unict.it; mariaclara.larosa@unict.it; daudia.lamastra@unict.it; giuliana.favara@unict.it; giunta.giuliana@studium.unict.it; acianci@unict.it; agodia@unict.it	Favara, Giuliana/AAC-9931-2022; Favara, Giuliana/AAD-6561-2022; Cianci, Antonio/AAO-3996-2021; Magnano San Lio, Roberta/AAC-9932-2022; Barchitta, Martina/A-1362-2015	Favara, Giuliana/0000-0003-0812-8386; Magnano San Lio, Roberta/0000-0003-2023-2135; Agodi, Antonella/0000-0002-4405-8162; Maugeri, Andrea/0000-0003-2655-8574; Barchitta, Martina/0000-0002-0905-5003	University of Catania, Italy, Department of Medical and Surgical Science and Advanced Technologies 'GF Ingrassia' (Programma ricerca di ateneo UNICT 2020-22 linea 2, PIAno di inCEntivi per la RIcerca di Ateneo 2020/2022); Department of Medical and Surgical Science and Advanced Technologies 'GF Ingrassia', University of Catania, Italy (Piano Triennale di sviluppo delle Attivita di Ricerca Scientifica del Dipartimento 2016-18)	The research 'La coorte Mamma & Bambino: un approccio Multisettoriale Alla salute Materno-Infantile Mediante valutazione dell'Esposoma nelle Donne, MAMI-MED' was funded by the University of Catania, Italy, Department of Medical and Surgical Science and Advanced Technologies 'GF Ingrassia' (Programma ricerca di ateneo UNICT 2020-22 linea 2, PIAno di inCEntivi per la RIcerca di Ateneo 2020/2022). This work was also supported by the Department of Medical and Surgical Science and Advanced Technologies 'GF Ingrassia', University of Catania, Italy (Piano Triennale di sviluppo delle Attivita di Ricerca Scientifica del Dipartimento 2016-18).	Ammon Andrea, 2018, Euro Surveill, V23, DOI 10.2807/1560-7917.ES.2018.23.17.18-00210; [Anonymous], 2018, LANCET, V391, P1638, DOI [10.1016/S0140-6736(18)30942-5, 10.1016/S0140-6736(18)30943-7]; [Anonymous], 2018, PROGR CHALL ACH UN I; [Anonymous], 2020, IM AG 2030 GLOB STRA; Bandyopadhyay AS, 2015, FUTURE MICROBIOL, V10, P791, DOI [10.2217/FMB.15.19, 10.2217/fmb.15.19]; Barchitta M, 2019, FUTURE MICROBIOL, V14, P15, DOI 10.2217/fmb-2018-0237; Barchitta M, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16132253; Barchitta M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091172; Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091; Chamberlain Allison T, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.d37b61bceebae5a7a06d40a301cfa819; D'Alessandro A, 2018, HUM VACC IMMUNOTHER, V14, P1573, DOI 10.1080/21645515.2018.1483809; D'Ancona F, 2019, EUROSURVEILLANCE, V24, P31, DOI 10.2807/1560-7917.ES.2019.24.25.1900371; D'Ancona F, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.22.1800238; de Figueiredo A, 2015, LANCET GLOB HEALTH, V3, P20; Delamater PL, 2017, JAMA-J AM MED ASSOC, V318, P863, DOI 10.1001/jama.2017.9242; Ding HL, 2019, AM J PREV MED, V56, P477, DOI 10.1016/j.amepre.2018.11.020; Ditsungnoen D, 2016, VACCINE, V34, P2141, DOI 10.1016/j.vaccine.2016.01.056; Donaldson B, 2015, VACCINE, V33, P5822, DOI 10.1016/j.vaccine.2015.08.093; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027; European Center for Disease Prevention and Control, ENH CONF VACC UPD 20; European Centre for Disease Prevention and Control, VACC SCHED ALL COUNT; European Commission, VACC; Geraldine BR, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14526; Glatman-Freedman Aharona, 2012, Hum Vaccin Immunother, V8, P293, DOI 10.4161/hv.19003; Haralambieva IH, 2020, VACCINE, V38, P1249, DOI 10.1016/j.vaccine.2019.11.004; Healy CM, 2015, VACCINE, V33, P5445, DOI 10.1016/j.vaccine.2015.08.028; Italian Ministry of Health, VACC RACC PER DONN F; Laenen J, 2015, VACCINE, V33, P2125, DOI 10.1016/j.vaccine.2015.03.020; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; MacDonald NE, 2018, VACCINE, V36, P5811, DOI 10.1016/j.vaccine.2018.08.042; MacDougall DM, 2016, HUM VACC IMMUNOTHER, V12, P879, DOI 10.1080/21645515.2015.1130193; Maugeri A, 2019, ANN IG MED PREV COMU, V31, P81, DOI 10.7416/ai.2019.2280; McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003; Nunes MC, 2017, CLIN INFECT DIS, V65, P1066, DOI 10.1093/cid/cix497; Odone A, 2015, HUM VACC IMMUNOTHER, V11, P1268, DOI 10.1080/21645515.2015.1019980; Rezza G, 2019, PATHOG GLOB HEALTH, V113, P291, DOI 10.1080/20477724.2019.1705021; Ricciardi W, 2018, EUR J PUBLIC HEALTH, V28, P2, DOI 10.1093/eurpub/ckx214; Sheikh S, 2018, VACCINE, V36, P4979, DOI 10.1016/j.vaccine.2018.06.044; Signorelli C, 2018, ANN IG MED PREV COMU, V30, P1, DOI 10.7416/ai.2018.2227; Signorelli C, 2017, ANN I SUPER SANITA, V53, P231, DOI 10.4415/ANN_17_03_09; Signorelli Carlo, 2014, Epidemiol Prev, V38, P88; Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724; Takla A, 2015, EUROSURVEILLANCE, V20, P16, DOI 10.2807/1560-7917.ES2015.20.9.21049; Tavoschi L, 2019, FUTURE MICROBIOL, V14, P9, DOI 10.2217/fmb-2018-0236; Theves C, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.PoH-0004-2014; Ward JK, 2018, VACCINE, V36, P1801, DOI 10.1016/j.vaccine.2018.02.095; WHO, 2013, GLOB VACC ACT PLAN 2; World Health Organization, MEASL RUB SURV DAT S; World Health Organization, 2020, IM VACC BIOL VACC DI; World Health Organization, 2017, ASS REP GLOB VACC AC; Zacharis K, 2018, MEDICINA-LITHUANIA, V54, DOI 10.3390/medicina54040050; Zerbo O, 2017, VACCINE, V35, P3186, DOI 10.1016/j.vaccine.2017.04.074	53	4	4	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							168	10.3390/vaccines9020168			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6YD	33671412	gold, Green Published			2022-04-29	WOS:000623286400001
J	Sangesland, M; Lingwood, D				Sangesland, Maya; Lingwood, Daniel			Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for 'Universal' Influenza Vaccines	VACCINES			English	Review						influenza virus; antibody response; universal vaccine; immunodominance; broadly neutralizing antibodies; B cell immunology	RECEPTOR-BINDING SITE; BROADLY NEUTRALIZING ANTIBODIES; B-CELL IMMUNODOMINANCE; A VIRUS HEMAGGLUTININ; MONOCLONAL-ANTIBODY; PANDEMIC H1N1; SEASONAL INFLUENZA; STRUCTURAL-CHARACTERIZATION; NEURAMINIDASE ANTIBODY; REACTIVE ANTIBODIES	Influenza virus remains a serious public health burden due to ongoing viral evolution. Vaccination remains the best measure of prophylaxis, yet current seasonal vaccines elicit strain-specific neutralizing responses that favor the hypervariable epitopes on the virus. This necessitates yearly reformulations of seasonal vaccines, which can be limited in efficacy and also shortchange pandemic preparedness. Universal vaccine development aims to overcome these deficits by redirecting antibody responses to functionally conserved sites of viral vulnerability to enable broad coverage. However, this is challenging as such antibodies are largely immunologically silent, both following vaccination and infection. Defining and then overcoming the immunological basis for such subdominant or 'immuno-recessive' antibody targeting has thus become an important aspect of universal vaccine development. This, coupled with structure-guided immunogen design, has led to proof-of-concept that it is possible to rationally refocus humoral immunity upon normally 'unseen' broadly neutralizing antibody targets on influenza virus.	[Sangesland, Maya; Lingwood, Daniel] Ragon Inst MGH MIT & Harvard, 400 Technology Sq, Cambridge, MA 02139 USA		Lingwood, D (通讯作者)，Ragon Inst MGH MIT & Harvard, 400 Technology Sq, Cambridge, MA 02139 USA.	msangesland@mgh.harvard.edu; dlingwood@mgh.harvard.edu		Lingwood, Daniel/0000-0001-5631-9238; Sangesland, Maya/0000-0001-8316-039X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI137057, DP2DA042422, R01AI124378, R01AI153098, R01AI155447, F31Al138368]; Harvard University Milton Award; Gilead Research Scholars Program Institute	D.L. was supported by the NIH (R01AI137057, DP2DA042422, R01AI124378, R01AI153098, R01AI155447), the Harvard University Milton Award, and The Gilead Research Scholars Program Institute. M.S. was supported by an NIH fellowship (F31Al138368).	Abbott RK, 2020, IMMUNOL REV, V296, P120, DOI 10.1111/imr.12861; Abbott RK, 2018, IMMUNITY, V48, P133, DOI 10.1016/j.immuni.2017.11.023; Abed Y, 2002, J MED VIROL, V67, P589, DOI 10.1002/jmv.10143; Abreu RB, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132155; Altman MO, 2018, VIRAL IMMUNOL, V31, P142, DOI 10.1089/vim.2017.0129; Altman MO, 2015, ELIFE, V4, DOI 10.7554/eLife.07467; Amitai A, 2020, CELL SYST, V11, P573, DOI 10.1016/j.cels.2020.09.005; Andrews SF, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan2676; Andrews SF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0522; Angeletti D, 2019, P NATL ACAD SCI USA, V116, P13474, DOI 10.1073/pnas.1816300116; Angeletti D, 2017, NAT IMMUNOL, V18, P456, DOI 10.1038/ni.3680; ARCHETTI I, 1950, J EXP MED, V92, P441, DOI 10.1084/jem.92.5.441; Avnir Y, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004103; Bajic G, 2020, ACS INFECT DIS, V6, P1182, DOI 10.1021/acsinfecdis.0c00008; Bajic G, 2019, CELL HOST MICROBE, V25, P827, DOI 10.1016/j.chom.2019.04.003; Balazs AB, 2013, NAT BIOTECHNOL, V31, P647, DOI 10.1038/nbt.2618; Bangaru S, 2019, CELL, V177, P1136, DOI 10.1016/j.cell.2019.04.011; Bangaru S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04704-9; BLACK RA, 1993, J GEN VIROL, V74, P143, DOI 10.1099/0022-1317-74-1-143; Bournazos S, 2020, NATURE, V588, P485, DOI 10.1038/s41586-020-2838-z; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Boyoglu-Barnum S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14579-4; Broecker F, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0126-4; Carrat F, 2007, VACCINE, V25, P6852, DOI 10.1016/j.vaccine.2007.07.027; Chai N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14234; Chambers BS, 2015, CELL REP, V12, P1, DOI 10.1016/j.celrep.2015.06.005; Chen YQ, 2019, J VIROL, V93, DOI 10.1128/JVI.01526-18; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Cheung CSF, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108088; Cirelli KM, 2019, CELL, V177, P1153, DOI 10.1016/j.cell.2019.04.012; Corbett KS, 2019, MBIO, V10, DOI 10.1128/mBio.02810-18; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Corti D, 2010, J CLIN INVEST, V120, P1663, DOI 10.1172/JCI41902; COUCH RB, 1974, J INFECT DIS, V129, P411, DOI 10.1093/infdis/129.4.411; Cox F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00399; Das DK, 2018, CELL, V174, P926, DOI 10.1016/j.cell.2018.05.050; de Jong JC, 2000, J MED VIROL, V61, P94, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;94::AID-JMV15&gt;3.0.CO;2-C; Deng L, 2015, VACCINES-BASEL, V3, P105, DOI 10.3390/vaccines3010105; Dhakal S, 2019, J VIROL, V93, DOI 10.1128/JVI.00797-19; DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Dosenovic P, 2018, P NATL ACAD SCI USA, V115, P4743, DOI 10.1073/pnas.1803457115; Doyle TM, 2013, ANTIVIR RES, V100, P567, DOI 10.1016/j.antiviral.2013.09.018; Dreyfus C, 2012, SCIENCE, V337, P1343, DOI 10.1126/science.1222908; Dugan HL, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abd3601; Dunand CJH, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0238; Dunand CJH, 2015, J CLIN INVEST, V125, P1255, DOI 10.1172/JCI74374; Eggink D, 2014, J VIROL, V88, P699, DOI 10.1128/JVI.02608-13; Eichelberger MC, 2019, J INFECT DIS, V219, pS75, DOI 10.1093/infdis/jiz017; Ekiert DC, 2012, NATURE, V489, P526, DOI 10.1038/nature11414; Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Ellebedy AH, 2014, P NATL ACAD SCI USA, V111, P13133, DOI 10.1073/pnas.1414070111; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Ermler ME, 2017, J VIROL, V91, DOI 10.1128/JVI.00286-17; Feng JQ, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-102; Fiore AE, 2009, CURR TOP MICROBIOL, V333, P43, DOI 10.1007/978-3-540-92165-3_3; Flyak AI, 2018, CELL HOST MICROBE, V24, P703, DOI 10.1016/j.chom.2018.10.009; Francis ME, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020122; Friesen RHE, 2014, P NATL ACAD SCI USA, V111, P445, DOI 10.1073/pnas.1319058110; Fu Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12780; Gao RY, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030276; Golsaz-Shirazi F, 2015, VIRAL IMMUNOL, V28, P425, DOI 10.1089/vim.2015.0023; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Guthmiller JJ, 2018, CURR OPIN IMMUNOL, V53, P187, DOI 10.1016/j.coi.2018.05.010; Hamilton BS, 2012, VIRUSES-BASEL, V4, P1144, DOI 10.3390/v4071144; He WQ, 2016, P NATL ACAD SCI USA, V113, P11931, DOI 10.1073/pnas.1609316113; Hehle V, 2020, J EXP MED, V217, DOI 10.1084/jem.20200840; Henry C, 2018, TRENDS IMMUNOL, V39, P70, DOI 10.1016/j.it.2017.08.003; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Hong MS, 2013, J VIROL, V87, P12471, DOI 10.1128/JVI.01388-13; Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012; Hsieh YC, 2006, J FORMOS MED ASSOC, V105, P1, DOI 10.1016/S0929-6646(09)60102-9; Hu HX, 2012, J VIROL, V86, P2978, DOI 10.1128/JVI.06665-11; Huang DL, 2020, P NATL ACAD SCI USA, V117, P22920, DOI 10.1073/pnas.2004489117; Huang KYA, 2015, J CLIN INVEST, V125, P2631, DOI 10.1172/JCI81104; Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263; Jiang LL, 2016, J VIROL, V90, P117, DOI 10.1128/JVI.01756-15; Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043; Kallewaard NL, 2016, CELL, V166, P596, DOI 10.1016/j.cell.2016.05.073; Kanekiyo M, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a038448; Kanekiyo M, 2019, NAT IMMUNOL, V20, P362, DOI 10.1038/s41590-018-0305-x; Kashyap AK, 2008, P NATL ACAD SCI USA, V105, P5986, DOI 10.1073/pnas.0801367105; Kato Y, 2020, IMMUNITY, V53, P548, DOI 10.1016/j.immuni.2020.08.001; Kelly HG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136653; KILBOURNE ED, 1990, P NATL ACAD SCI USA, V87, P786, DOI 10.1073/pnas.87.2.786; Knossow M, 2002, VIROLOGY, V302, P294, DOI 10.1006/viro.2002.1625; Kolpe A, 2017, EXPERT REV VACCINES, V16, P123, DOI 10.1080/14760584.2017.1240041; Koopman G, 2019, J GEN VIROL, V100, P738, DOI 10.1099/jgv.0.001251; Kosik I, 2019, J EXP MED, V216, P304, DOI 10.1084/jem.20181624; Koutsakos M, 2019, J IMMUNOL, V202, P360, DOI 10.4049/jimmunol.1800986; Krammer F, 2019, J INFECT DIS, V219, pS62, DOI 10.1093/infdis/jiy711; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Krammer F, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028845; Krammer F, 2016, CURR OPIN VIROL, V17, P95, DOI 10.1016/j.coviro.2016.02.002; Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529; Krammer F, 2013, J VIROL, V87, P6542, DOI [10.1128/JVI.00641-13, 10.1128/JVI.03183-13]; Krause JC, 2012, J VIROL, V86, P6334, DOI 10.1128/JVI.07158-11; Kuroda D, 2008, PROTEINS, V73, P608, DOI 10.1002/prot.22087; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAMB RA, 1981, VIROLOGY, V112, P729, DOI 10.1016/0042-6822(81)90317-2; Ledgerwood JE, 2013, J INFECT DIS, V208, P418, DOI 10.1093/infdis/jit180; Lee PS, 2015, CURR TOP MICROBIOL, V386, P323, DOI 10.1007/82_2014_413; Lee PS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4614; Lee PS, 2012, P NATL ACAD SCI USA, V109, P17040, DOI 10.1073/pnas.1212371109; Leon PE, 2016, P NATL ACAD SCI USA, V113, pE5944, DOI 10.1073/pnas.1613225113; Lerner RA, 2011, MOL BIOSYST, V7, P1004, DOI 10.1039/c0mb00310g; Lingwood D, 2012, NATURE, V489, P566, DOI 10.1038/nature11371; Liu WC, 2015, J VIROL, V89, P7224, DOI 10.1128/JVI.00585-15; LUCAS AH, 1991, J CLIN INVEST, V88, P1811, DOI 10.1172/JCI115502; Madsen A, 2020, IMMUNITY, V53, P852, DOI 10.1016/j.immuni.2020.08.015; Mallajosyula VVA, 2014, P NATL ACAD SCI USA, V111, pE2514, DOI 10.1073/pnas.1402766111; Marcelin G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026335; Margine I, 2013, J VIROL, V87, P10435, DOI 10.1128/JVI.01715-13; Matrosovich MN, 2004, J VIROL, V78, P12665, DOI 10.1128/JVI.78.22.12665-12667.2004; Medina RA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005996; Memoli MJ, 2016, MBIO, V7, DOI 10.1128/mBio.00417-16; MONTO AS, 1973, LANCET, V1, P623, DOI 10.1016/S0140-6736(73)92196-X; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Morens DM, 2010, CRIT CARE MED, V38, pE10, DOI 10.1097/CCM.0b013e3181ceb25b; Nabel GJ, 2010, NAT MED, V16, P1389, DOI 10.1038/nm1210-1389; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nachbagauer R, 2018, CURR OPIN IMMUNOL, V53, P51, DOI 10.1016/j.coi.2018.04.001; Nachbagauer R, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.15; Nakamura G, 2013, CELL HOST MICROBE, V14, P93, DOI 10.1016/j.chom.2013.06.004; Nobusawa E, 2006, J VIROL, V80, P3675, DOI 10.1128/JVI.80.7.3675-3678.2006; North B, 2011, J MOL BIOL, V406, P228, DOI 10.1016/j.jmb.2010.10.030; Ohshima N, 2011, J VIROL, V85, P11048, DOI 10.1128/JVI.05397-11; OKUNO Y, 1993, J VIROL, V67, P2552, DOI 10.1128/JVI.67.5.2552-2558.1993; Oliva B, 1998, J MOL BIOL, V279, P1193, DOI 10.1006/jmbi.1998.1847; PALESE P, 1976, J GEN VIROL, V33, P159, DOI 10.1099/0022-1317-33-1-159; PALESE P, 1974, VIROLOGY, V59, P490, DOI 10.1016/0042-6822(74)90458-9; Pappas L, 2014, NATURE, V516, P418, DOI 10.1038/nature13764; Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0; Paules CI, 2018, NEW ENGL J MED, V378, P7, DOI 10.1056/NEJMp1714916; Pauthner MG, 2019, IMMUNITY, V50, P241, DOI 10.1016/j.immuni.2018.11.011; Peterhoff D, 2017, CURR OPIN HIV AIDS, V12, P257, DOI 10.1097/COH.0000000000000356; Petrie JG, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020017; Poovorawan Y, 2013, PATHOG GLOB HEALTH, V107, P217, DOI 10.1179/2047773213Y.0000000103; Raymond DD, 2018, P NATL ACAD SCI USA, V115, P168, DOI 10.1073/pnas.1715471115; Raymond DD, 2016, NAT MED, V22, P1465, DOI 10.1038/nm.4223; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; Ren HH, 2016, CURR OPIN IMMUNOL, V42, P83, DOI 10.1016/j.coi.2016.06.002; Saada R, 2007, IMMUNOL CELL BIOL, V85, P323, DOI 10.1038/sj.icb.7100055; Sandbulte MR, 2011, P NATL ACAD SCI USA, V108, P20748, DOI 10.1073/pnas.1113801108; Sangesland M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108065; Sangesland M, 2019, IMMUNITY, V51, P735, DOI 10.1016/j.immuni.2019.09.001; Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227; Schmidt AG, 2015, CELL, V161, P1026, DOI 10.1016/j.cell.2015.04.028; Schmidt AG, 2013, P NATL ACAD SCI USA, V110, P264, DOI 10.1073/pnas.1218256109; Schneemann A, 2012, J VIROL, V86, P11686, DOI 10.1128/JVI.01694-12; Schnell JR, 2008, NATURE, V451, P591, DOI 10.1038/nature06531; Schotsaert M, 2009, EXPERT REV VACCINES, V8, P499, DOI 10.1586/ERV.09.6; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Shirai H, 1999, FEBS LETT, V455, P188, DOI 10.1016/S0014-5793(99)00821-2; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; SKEHEL JJ, 1984, P NATL ACAD SCI-BIOL, V81, P1779, DOI 10.1073/pnas.81.6.1779; Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182; Stadlbauer D, 2019, SCIENCE, V366, P499, DOI 10.1126/science.aay0678; Steichen JM, 2019, SCIENCE, V366, P1216, DOI 10.1126/science.aax4380; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Sun WN, 2019, J VIROL, V93, DOI 10.1128/JVI.00333-19; Sutton TC, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090461; Tam HH, 2016, P NATL ACAD SCI USA, V113, pE6639, DOI 10.1073/pnas.1606050113; Tan GS, 2014, J VIROL, V88, P13580, DOI 10.1128/JVI.02289-14; Tan HX, 2019, J CLIN INVEST, V129, P850, DOI 10.1172/JCI123366; Tan J, 2018, CURR OPIN IMMUNOL, V53, P45, DOI 10.1016/j.coi.2018.04.002; Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942; TREANOR JJ, 1990, J VIROL, V64, P1375, DOI 10.1128/JVI.64.3.1375-1377.1990; Trifonov V, 2009, NEW ENGL J MED, V361, P115, DOI 10.1056/NEJMp0904572; Tzarum N, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav1882; Vanderven HA, 2017, CURR OPIN VIROL, V22, P89, DOI 10.1016/j.coviro.2016.12.002; Villar RF, 2016, SCI REP-UK, V6, DOI 10.1038/srep36298; Wan HQ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7114; Wan HQ, 2013, J VIROL, V87, P9290, DOI 10.1128/JVI.01203-13; Wang XS, 2021, EMBO J, V40, DOI 10.15252/embj.2020105926; Watanabe A, 2019, CELL, V177, P1124, DOI 10.1016/j.cell.2019.03.048; Weaver GC, 2016, NAT PROTOC, V11, P193, DOI 10.1038/nprot.2016.009; Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424; Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; Wei CJ, 2020, NAT REV DRUG DISCOV, V19, P239, DOI 10.1038/s41573-019-0056-x; Wei CJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004273; Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517; Wei CJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000799; Weidenbacher PA, 2019, P NATL ACAD SCI USA, V116, P9947, DOI 10.1073/pnas.1822062116; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; Westgeest KB, 2012, J GEN VIROL, V93, P1996, DOI 10.1099/vir.0.043059-0; Wheatley AK, 2015, J IMMUNOL, V195, P602, DOI 10.4049/jimmunol.1402835; Whittle JRR, 2014, J VIROL, V88, P4047, DOI 10.1128/JVI.03422-13; Whittle JRR, 2011, P NATL ACAD SCI USA, V108, P14216, DOI 10.1073/pnas.1111497108; WHO, WHO REC COMP INFL VI; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wohlbold TJ, 2017, NAT MICROBIOL, V2, P1415, DOI 10.1038/s41564-017-0011-8; Wohlbold TJ, 2015, MBIO, V6, DOI 10.1128/mBio.02556-14; Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352; Wu NC, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12091053; Wu NC, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a038778; Wu NC, 2017, J MOL BIOL, V429, P2694, DOI 10.1016/j.jmb.2017.06.015; Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532; Wu Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8708; Wyrzucki A, 2014, J VIROL, V88, P7083, DOI 10.1128/JVI.00178-14; Xie H, 2015, SCI REP-UK, V5, DOI 10.1038/srep15279; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6; Xu R, 2013, NAT STRUCT MOL BIOL, V20, P363, DOI 10.1038/nsmb.2500; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Yewdell JW, 2011, CURR OPIN VIROL, V1, P177, DOI 10.1016/j.coviro.2011.05.005; Yoshida R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000350; Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321; Yusuf M, 2013, J CHEM INF MODEL, V53, P2423, DOI 10.1021/ci400421e; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; Zhong WM, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw102; Zhong WM, 2014, J INFECT DIS, V209, P986, DOI 10.1093/infdis/jit811; Zhou TQ, 2015, CELL, V161, P1280, DOI 10.1016/j.cell.2015.05.007; Zhou TQ, 2013, IMMUNITY, V39, P245, DOI 10.1016/j.immuni.2013.04.012; Zost SJ, 2019, J INFECT DIS, V219, pS38, DOI 10.1093/infdis/jiy696	216	7	7	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							125	10.3390/vaccines9020125			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6QV	33562627	Green Published			2022-04-29	WOS:000623267100001
J	Buschmann, MD; Carrasco, MJ; Alishetty, S; Paige, M; Alameh, MG; Weissman, D				Buschmann, Michael D.; Carrasco, Manuel J.; Alishetty, Suman; Paige, Mikell; Alameh, Mohamad Gabriel; Weissman, Drew			Nanomaterial Delivery Systems for mRNA Vaccines	VACCINES			English	Review						mRNA; lipid nanoparticle; ionizable lipid; vaccine; SARS-CoV-2		The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We present an overview of mRNA delivery systems and then focus on the lipid nanoparticles used in the current SARS-CoV-2 vaccine clinical trials. The review concludes with an analysis of the determinants of the performance of lipid nanoparticles in mRNA vaccines.	[Buschmann, Michael D.; Carrasco, Manuel J.; Alishetty, Suman] George Mason Univ, Dept Bioengn, 4400 Univ Dr,MS 1J7, Fairfax, VA 22030 USA; [Paige, Mikell] George Mason Univ, Dept Chem & Biochem, 4400 Univ Dr, Fairfax, VA 22030 USA; [Alameh, Mohamad Gabriel] Univ Penn, Perelman Sch Med, 130 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA; [Weissman, Drew] Univ Penn, Perelman Sch Med, 410B Hill Pavil,380 S Univ Ave, Philadelphia, PA 19104 USA		Buschmann, MD (通讯作者)，George Mason Univ, Dept Bioengn, 4400 Univ Dr,MS 1J7, Fairfax, VA 22030 USA.	mbuschma@gmu.edu; mcarras@masonlive.gmu.edu; salishet@GMU.EDU; mpaige3@gmu.edu; Mg.Alameh@pennmedicine.upenn.edu; dreww@pennmedicine.upenn.edu	Alameh, Mohamad Gabriel/ABA-5345-2021; ALISHETTY, SUMAN/AAR-4906-2021	Alameh, Mohamad Gabriel/0000-0002-5672-6930; Alishetty, Suman/0000-0002-7491-0280; Carrasco, Manuel J/0000-0002-8253-2937; Buschmann, Michael/0000-0001-7555-8189			Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Akinc A, 2019, NAT NANOTECHNOL, V14, P1084, DOI 10.1038/s41565-019-0591-y; Akinc A, 2010, MOL THER, V18, P1357, DOI 10.1038/mt.2010.85; Alameh Mohamad-Gabriel, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_202; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007; Alwis R.d., 2020, 280446 BIORXIV, DOI [10.1101/2020.09.03.280446, DOI 10.1101/2020.09.03.280446]; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Andries O, 2015, J CONTROL RELEASE, V217, P337, DOI 10.1016/j.jconrel.2015.08.051; [Anonymous], NIH DEVISING STUDY R; Armbruster N, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040132; Arteta MY, 2018, P NATL ACAD SCI USA, V115, pE3351, DOI 10.1073/pnas.1720542115; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Baiersdorfer M, 2019, MOL THER-NUCL ACIDS, V15, P26, DOI 10.1016/j.omtn.2019.02.018; Barros SA, 2012, ADV DRUG DELIVER REV, V64, P1730, DOI 10.1016/j.addr.2012.06.007; Behlke MA, 2008, OLIGONUCLEOTIDES, V18, P305, DOI 10.1089/oli.2008.0164; Belliveau NM, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.28; Blakney AK, 2020, ACS NANO, V14, P5711, DOI 10.1021/acsnano.0c00326; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113; Chen NH, 2017, IUBMB LIFE, V69, P297, DOI 10.1002/iub.1625; Chen S, 2016, J CONTROL RELEASE, V235, P236, DOI 10.1016/j.jconrel.2016.05.059; Cheng Q, 2020, NAT NANOTECHNOL, V15, P313, DOI 10.1038/s41565-020-0669-6; Cheng Q, 2018, ADV MATER, V30, DOI 10.1002/adma.201805308; Cheng XW, 2016, ADV DRUG DELIVER REV, V99, P129, DOI 10.1016/j.addr.2016.01.022; Choi JH, 2018, NAT STRUCT MOL BIOL, V25, P208, DOI 10.1038/s41594-018-0030-z; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Cullis PR, 2017, MOL THER, V25, P1467, DOI 10.1016/j.ymthe.2017.03.013; Derosa F., CYSTINE CATIONIC LIP; DeRosa F, 2019, MOL THER, V27, P878, DOI 10.1016/j.ymthe.2019.03.001; Devoldere J, 2016, DRUG DISCOV TODAY, V21, P11, DOI 10.1016/j.drudis.2015.07.009; Diken M, 2011, GENE THER, V18, P702, DOI 10.1038/gt.2011.17; Erasmus JH, 2018, MOL THER, V26, P2507, DOI 10.1016/j.ymthe.2018.07.010; Evans BC, 2015, ACS NANO, V9, P5893, DOI 10.1021/acsnano.5b00491; Evers MJW, 2018, SMALL METHODS, V2, DOI 10.1002/smtd.201700375; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fenton OS, 2017, ADV MATER, V29, DOI 10.1002/adma.201606944; FERNANDEZ MS, 1977, J PHYS CHEM-US, V81, P1755, DOI 10.1021/j100533a009; Fotin-Mleczek M, 2011, J IMMUNOTHER, V34, P1, DOI 10.1097/CJI.0b013e3181f7dbe8; Freyn AW, 2020, MOL THER, V28, P1569, DOI 10.1016/j.ymthe.2020.04.018; Gabor, 2020, PHASE 1 ASSESSMENT S, DOI [10.1101/2020.11.09.20228551, DOI 10.1101/2020.11.09.20228551]; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Gilleron J, 2013, NAT BIOTECHNOL, V31, P638, DOI 10.1038/nbt.2612; Gindy ME, 2014, MOL PHARMACEUT, V11, P4143, DOI 10.1021/mp500367k; Gomez G, 2001, PHARM RES-DORDR, V18, P90, DOI 10.1023/A:1011082911917; Gomez-Aguado I, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10020364; GRUNER SM, 1985, ANNU REV BIOPHYS BIO, V14, P211, DOI 10.1146/annurev.biophys.14.1.211; Hajj KA, 2020, NANO LETT, V20, P5167, DOI 10.1021/acs.nanolett.0c00596; Hajj KA, 2019, SMALL, V15, DOI 10.1002/smll.201805097; Hajj KA, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.56; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Heyes J, 2005, J CONTROL RELEASE, V107, P276, DOI 10.1016/j.jconrel.2005.06.014; Hoerr I, 2000, EUR J IMMUNOL, V30, P1; Islam MA, 2018, NAT BIOMED ENG, V2, P850, DOI 10.1038/s41551-018-0284-0; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jayaraman M, 2012, ANGEW CHEM INT EDIT, V51, P8529, DOI 10.1002/anie.201203263; Jiang YH, 2020, NANO LETT, V20, P1117, DOI 10.1021/acs.nanolett.9b04426; Jiang YH, 2018, BIOMATERIALS, V176, P122, DOI 10.1016/j.biomaterials.2018.05.043; Kaczmarek JC, 2016, ANGEW CHEM INT EDIT, V55, P13808, DOI 10.1002/anie.201608450; Kalnin KV, 2020, IMMUNOGENICITY NOVEL, DOI [10.1101/2020.10.14.337535., DOI 10.1101/2020.10.14.337535]; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kauffman KJ, 2015, NANO LETT, V15, P7300, DOI 10.1021/acs.nanolett.5b02497; Kedmi R, 2018, NAT NANOTECHNOL, V13, P214, DOI 10.1038/s41565-017-0043-5; Kilchrist KV, 2019, ACS NANO, V13, P1136, DOI 10.1021/acsnano.8b05482; Kim J, 2020, CELL MOL BIOENG, V13, P463, DOI 10.1007/s12195-020-00619-y; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kulkarni JA, 2019, NANOSCALE, V11, P9023, DOI 10.1039/c9nr02004g; Kulkarni JA, 2018, ACS NANO, V12, P4787, DOI 10.1021/acsnano.8b01516; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Lallana E, 2017, MOL PHARMACEUT, V14, P2422, DOI 10.1021/acs.molpharmaceut.7b00320; Li B, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1530; Li JH, 2017, ANGEW CHEM INT EDIT, V56, P13709, DOI 10.1002/anie.201707466; Li JH, 2017, ACS NANO, V11, P2531, DOI 10.1021/acsnano.6b08447; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Lorenz C, 2011, RNA BIOL, V8, P627, DOI 10.4161/rna.8.4.15394; Love KT, 2010, P NATL ACAD SCI USA, V107, P1864, DOI 10.1073/pnas.0910603106; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; Mai YP, 2020, CELL IMMUNOL, V354, DOI 10.1016/j.cellimm.2020.104143; Maier MA, 2013, MOL THER, V21, P1570, DOI 10.1038/mt.2013.124; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Marcos-Contreras OA, 2020, P NATL ACAD SCI USA, V117, P3405, DOI 10.1073/pnas.1912012117; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Maugeri M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12275-6; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; McKinlay CJ, 2018, P NATL ACAD SCI USA, V115, pE5859, DOI 10.1073/pnas.1805358115; Miao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16248-y; Mulligan MJ, 2020, PHASE 1 2 STUDY DESC, DOI [10.1101/2020.06.30. 20142570., DOI 10.1101/2020.06.30.20142570, 10.1038/s41586-020-2639-4]; Muskula PR, 2017, CIRC-CARDIOVASC IMAG, V10, DOI 10.1161/CIRCIMAGING.116.005459; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Oberli MA, 2017, NANO LETT, V17, P1326, DOI 10.1021/acs.nanolett.6b03329; Pardi N, 2020, CURR OPIN IMMUNOL, V65, P14, DOI 10.1016/j.coi.2020.01.008; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14630; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Parhiz H, 2018, J CONTROL RELEASE, V291, P106, DOI 10.1016/j.jconrel.2018.10.015; Parhiz H, 2018, ADV DRUG DELIVER REV, V130, P90, DOI 10.1016/j.addr.2018.06.023; Patel AK, 2019, ADV MATER, V31, DOI 10.1002/adma.201805116; Patel S, 2019, ADV DRUG DELIVER REV, V144, P90, DOI 10.1016/j.addr.2019.08.004; Patel S, 2017, NANO LETT, V17, P5711, DOI 10.1021/acs.nanolett.7b02664; Perche F, 2011, J DRUG TARGET, V19, P315, DOI 10.3109/1061186X.2010.504262; Rajappan K, 2020, J MED CHEM, V63, P12992, DOI 10.1021/acs.jmedchem.0c01407; Rauch S, 2020, MRNA BASED SARS COV2, V2020, DOI [10.23.351775, 10.1101/2020.10.23.351775., DOI 10.1101/2020.10.23.351775, 10.1101/2020.10.23.351775]; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Robinson E, 2018, MOL THER, V26, P2034, DOI 10.1016/j.ymthe.2018.05.014; Sabnis S, 2018, MOL THER, V26, P1509, DOI 10.1016/j.ymthe.2018.03.010; Sahay G, 2013, NAT BIOTECHNOL, V31, P653, DOI 10.1038/nbt.2614; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Scheel B, 2004, EUR J IMMUNOL, V34, P537, DOI 10.1002/eji.200324198; Schlake T, 2019, CELL MOL LIFE SCI, V76, P301, DOI 10.1007/s00018-018-2935-4; Schnee M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004746; Sedic M, 2018, VET PATHOL, V55, P341, DOI 10.1177/0300985817738095; Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602; Soliman OY, 2020, J PHARM SCI-US, V109, P1581, DOI 10.1016/j.xphs.2019.12.020; Stadler CR, 2017, NAT MED, V23, P815, DOI 10.1038/nm.4356; Swaminathan G, 2016, SCI REP-UK, V6, DOI 10.1038/srep34215; Swaminathan G, 2016, VACCINE, V34, P110, DOI 10.1016/j.vaccine.2015.10.132; Swartz MA, 2001, ADV DRUG DELIVER REV, V50, P3, DOI 10.1016/S0169-409X(01)00150-8; Tang XL, 2004, PHARM RES-DORDR, V21, P191, DOI 10.1023/B:PHAM.0000016234.73023.75; Tatematsu M, 2018, J INNATE IMMUN, V10, P398, DOI 10.1159/000494034; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Thran M, 2017, EMBO MOL MED, V9, P1434, DOI 10.15252/emmm.201707678; U.S. Dep. Health Hum. Serv. Food Drug Adm. Cent. Biol. Eval. Res, 2020, DEV LICENSURE VACCIN; Uchida H, 2016, J AM CHEM SOC, V138, P1478, DOI 10.1021/jacs.5b11726; Van Hoecke L, 2020, MOL THER-NUCL ACIDS, V20, P777, DOI 10.1016/j.omtn.2020.04.015; Van Hoecke L, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1804-8; Veiga N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06936-1; Vogel A.B., 2020, BIORXIV, V370, P1022, DOI 10.1101/2020.09.08.280818; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Wadman M, 2020, SCIENCE, V370, P1022, DOI 10.1126/science.370.6520.1022; Wahane A, 2020, MOLECULES, V25, DOI 10.3390/molecules25122866; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang Y, 2020, ANGEW CHEM INT EDIT, V59, P23374, DOI 10.1002/anie.202003545; Wang Y, 2020, ANGEW CHEM INT EDIT, V59, P2695, DOI 10.1002/anie.201914264; Wheeler JJ, 1999, GENE THER, V6, P271, DOI 10.1038/sj.gt.3300821; Witzigmann D, 2020, ADV DRUG DELIVER REV, V159, P344, DOI 10.1016/j.addr.2020.06.026; Yan XD, 2005, BIOCHEM BIOPH RES CO, V328, P57, DOI 10.1016/j.bbrc.2004.12.137; Yang Y, 2019, J MOL CELL BIOL, V11, P911, DOI 10.1093/jmcb/mjz091; Yoshinaga N, 2019, ANGEW CHEM INT EDIT, V58, P11360, DOI 10.1002/anie.201905203; Yoshinaga N, 2019, BIOMATERIALS, V197, P255, DOI 10.1016/j.biomaterials.2019.01.023; Yuki Y, 2003, REV MED VIROL, V13, P293, DOI 10.1002/rmv.398; Zhao PX, 2020, BIOACT MATER, V5, P358, DOI 10.1016/j.bioactmat.2020.03.001; Zhao WY, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119291; Zhou KJ, 2016, P NATL ACAD SCI USA, V113, P520, DOI 10.1073/pnas.1520756113; Zhuang XY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010123; Zimmer C., 2020, NEW YORK TIMES	155	97	98	149	285	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							65	10.3390/vaccines9010065			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6WY	33478109	gold, Green Published	Y	N	2022-04-29	WOS:000610813700001
J	Karwaciak, I; Salkowska, A; Karas, K; Dastych, J; Ratajewski, M				Karwaciak, Iwona; Salkowska, Anna; Karas, Kaja; Dastych, Jaroslaw; Ratajewski, Marcin			Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce IL6 in Monocytes and Macrophages-Potential Implications for Cytokine Storm Syndrome	VACCINES			English	Article						SARS-COV-2; COVID-19; monocytes; macrophages; IL-6; cytokine storm	RESPIRATORY SYNDROME SARS; INFLAMMATORY MONOCYTE; TH1 DIFFERENTIATION; GLOBAL HEALTH; PATHOGENESIS; ALPHA; INTERLEUKIN-6; EXPRESSION; RESPONSES; OUTBREAK	The pandemic of the new coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has led to the deaths of more than 1.5 million people worldwide. SARS-CoV-2 causes COVID-19, which exhibits wide variation in the course of disease in different people, ranging from asymptomatic and mild courses to very severe courses that can result in respiratory failure and death. Despite the rapid progression of knowledge, we still do not know how individual cells of the immune system interact with the virus or its components, or how immune homeostasis becomes disrupted, leading to the rapid deterioration of a patient's condition. In the present work, we show that SARS-CoV-2 proteins induce the expression and secretion of IL-6 by human monocytes and macrophages, the first line cells of antiviral immune responses. IL-6 may play a negative role in the course of COVID-19 by inhibiting Th1-dependent immunity and stimulating Th17 lymphocytes, thus leading to an increased probability of a cytokine storm.	[Karwaciak, Iwona] Polish Acad Sci, Inst Med Biol, Lab Transcript Regulat, PL-93232 Lodz, Poland; [Salkowska, Anna; Karas, Kaja; Ratajewski, Marcin] Polish Acad Sci, Inst Med Biol, Lab Epigenet, PL-93232 Lodz, Poland; [Dastych, Jaroslaw] Polish Acad Sci, Inst Med Biol, Lab Cellular Immunol, PL-93232 Lodz, Poland		Ratajewski, M (通讯作者)，Polish Acad Sci, Inst Med Biol, Lab Epigenet, PL-93232 Lodz, Poland.	isachrajda@cbm.pan.pl; asalkowska@cbm.pan.pl; kkaras@cbm.pan.pl; jdastych@cbm.pan.pl; mratajewski@cbm.pan.pl	Ratajewski, Marcin/I-4657-2019	Ratajewski, Marcin/0000-0001-5391-5843	National Science Center Grant [2015/18/E/NZ5/00733]; Institute of Medical Biology PAS	This work was supported in part by a National Science Center Grant 2015/18/E/NZ5/00733 and by statutory funds from the Institute of Medical Biology PAS.	Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4; Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071; Bonam SR, 2021, NANO TODAY, V36, DOI 10.1016/j.nantod.2020.101051; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen N., 2020, The Lancet, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Dhall A, 2021, BRIEF BIOINFORM, V22, P936, DOI 10.1093/bib/bbaa259; Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9; Dosch SF, 2009, VIRUS RES, V142, P19, DOI 10.1016/j.virusres.2009.01.005; Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3; Fajnzylber J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19057-5; Feng Z., 2020, NOVEL SEVERE ACUTE R, V2, P1, DOI [10.1101/2020.03.27.20045427, DOI 10.1101/2020.03.27.20045427]; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; Gabay C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1917; Gomez-Rial J, 2020, INFECT DRUG RESIST, V13, P2485, DOI 10.2147/IDR.S258639; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; Hojyo S, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232-020-00146-3; Hou WQ, 2009, J EXP MED, V206, P313, DOI 10.1084/jem.20082030; Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009; Ivanova EA, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4789279; Jafarzadeh A, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118102; Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC; Karwaciak I, 2017, ONCOTARGET, V8, P54243, DOI 10.18632/oncotarget.17342; Lai Y., 2020, COVID 19 INFECT INDU, DOI [10.1101/2020.03.24.20042655, DOI 10.1101/2020.03.24.20042655]; Leisman DE, 2020, LANCET RESP MED, V8, P1233, DOI 10.1016/S2213-2600(20)30404-5; Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374; Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74; Liu YL, 2021, CYTOKINE, V138, DOI 10.1016/j.cyto.2020.155365; McElvaney OJ, 2020, AM J RESP CRIT CARE, V202, P812, DOI 10.1164/rccm.202005-1583OC; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Nikitina E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092821; Paciolla M, 2011, HUM REPROD, V26, P1191, DOI 10.1093/humrep/der040; Patra T, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009128; Ping Z, 2019, LEUKEMIA, V33, P536, DOI 10.1038/s41375-018-0267-x; Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446; Roschewski M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd0110; Salkowska A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040673; Salkowska A, 2017, J LEUKOCYTE BIOL, V102, P1487, DOI 10.1189/jlb.6A0617-217R; Strohbehn GW, 2021, CLIN PHARMACOL THER, V109, P688, DOI 10.1002/cpt.2117; Tsukamoto H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7702; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; Wang P., 2020, IMPAIRED CELLULAR IM, DOI 10.1101/2020.08.10.20171371; Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007; Wilson JG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140289; Wise J, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4530; Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1; Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037; Ye Q, 2020, J MED VIROL, V92, P755, DOI 10.1002/jmv.25813; Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08; Zhang X, 2007, VIROLOGY, V365, P324, DOI 10.1016/j.virol.2007.04.009; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2	53	14	14	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							54	10.3390/vaccines9010054			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6UU	33467724	Green Published, gold			2022-04-29	WOS:000610808000001
J	Babicki, M; Malchrzak, W; Hans-Wytrychowska, A; Mastalerz-Migas, A				Babicki, Mateusz; Malchrzak, Wojciech; Hans-Wytrychowska, Anna; Mastalerz-Migas, Agnieszka			Impact of Vaccination on the Sense of Security, the Anxiety of COVID-19 and Quality of Life among Polish. A Nationwide Online Survey in Poland	VACCINES			English	Article						COVID-19 vaccination; mental health; GAD-7; quality of life; attitudes towards vaccination	SARS-COV-2; VACCINES; FUTURE	The pandemic state has a destructive effect on the human psyche and induces fear for one's own health. By reducing the risk of severe COVID-19, vaccination may indirectly improve the mental state. This study aims to assess the effects of vaccination on respondents' mental well-being, their attitudes towards adherence to government recommendations limiting viral transmission, and to identify factors that may influence the decision to get vaccinated. The survey took the form of the authors' own, fully voluntary, anonymous, online questionnaire. Standardised psychometric tools were used in the survey: Generalised Anxiety Disorder Assessment (GAD-7) and Manchester Short Assessment of Quality of Life (MANSA). The survey involved 1696 respondents, the vast majority of whom were women, and were aged 18-29. The vaccination status was declared by 1677 respondents (98.9%), 430 (25.4%) of whom were vaccinated with at least one dose of vaccine, while 303 (17.9%) respondents were not only unvaccinated at all, and declared no intention to get vaccinated in the future. Fully vaccinated individuals were found to have lower levels of anxiety, higher MANSA scores and lower subjective anxiety about being infected with COVID-19 than those awaiting vaccination or those with an incomplete vaccination regimen (one dose). Those who are not willing to get vaccinated have the lowest sense of anxiety and fear of being infected and they have the lowest adherence to government recommendations limiting SARS-CoV-2 transmission. Conclusions: COVID-19 vaccination reduces the level of anxiety about being infected and anxiety due to COVID-19 disease in people from the immediate environment. Those who are not willing to get vaccinated have extreme attitudes that negate the pandemic as a whole, including the need for COVID-19 vaccination. Fully vaccinated individuals still adhere to the SARS-CoV-2 prevention policies in place.	[Babicki, Mateusz; Malchrzak, Wojciech; Hans-Wytrychowska, Anna; Mastalerz-Migas, Agnieszka] Wroclaw Med Univ, Dept Family Med, PL-51141 Wroclaw, Poland		Babicki, M (通讯作者)，Wroclaw Med Univ, Dept Family Med, PL-51141 Wroclaw, Poland.	ma.babicki@gmail.com; wojciech.malchrzak@gmail.com; anna.hans-wytrychowska@umw.edu.pl; agnieszka.migas@gmail.com	Babicki, Mateusz/AAG-9558-2020; Mastalerz-Migas, Agnieszka/W-5453-2018	Babicki, Mateusz/0000-0002-7719-6959; Malchrzak, Wojciech/0000-0002-3738-7822; Hans-Wytrychowska, Anna/0000-0003-4842-5262; Mastalerz-Migas, Agnieszka/0000-0001-6600-2760	Wroclaw Medical University [SUB.C290.21.010]	This research was founded by the Wroclaw Medical University SUB.C290.21.010.	Akarsu B, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13891; Al-Amer R, 2022, J CLIN NURS, V31, P62, DOI 10.1111/jocn.15951; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Bleier BS, 2021, OTOLARYNG HEAD NECK, V164, P305, DOI 10.1177/0194599820982633; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Chan EYY, 2015, VACCINE, V33, P4737, DOI 10.1016/j.vaccine.2015.07.046; Coe Antoinette B, 2012, Innov Pharm, V3, P1; Cohn BA, 2022, SCIENCE, V375, P331, DOI 10.1126/science.abm0620; Collier DA, 2021, NATURE, V593, P136, DOI 10.1038/s41586-021-03412-7; Elharake JA, 2021, INT J INFECT DIS, V109, P286, DOI 10.1016/j.ijid.2021.07.004; Eysenbach G, 2020, J MED INTERNET RES, V22, DOI 10.2196/21820; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Georgiou N, 2020, PERS INDIV DIFFER, V166, DOI 10.1016/j.paid.2020.110201; Giorgi G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217857; Glanville D, COVID 19 VACCINES AU; Hernandez Antonio F, 2021, Toxicol Rep, V8, P871, DOI 10.1016/j.toxrep.2021.04.003; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Liu CH, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113172; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Priebe S, 1999, INT J SOC PSYCHIATR, V45, P7, DOI 10.1177/002076409904500102; Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066; Ritchie H., 2020, CORONAVIRUS PANDEMIC; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Sheahan TP, 2020, CURR OPIN VIROL, V40, P37, DOI 10.1016/j.coviro.2020.05.010; Simione L, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.683684; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Szilagyi PG, 2021, PREV MED, V153, DOI 10.1016/j.ypmed.2021.106727; Tahir AI., 2021, MIDDLE E CURR PSYCHI, V28, P46, DOI [10.1186/s43045-021-00126-4, DOI 10.1186/S43045-021-00126-4]; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Troyer EA, 2020, BRAIN BEHAV IMMUN, V87, P34, DOI 10.1016/j.bbi.2020.04.027; Ullah I, 2021, Vacunas, V22, P93, DOI 10.1016/j.vacun.2021.01.001; Vindegaard N, 2020, BRAIN BEHAV IMMUN, V89, P531, DOI 10.1016/j.bbi.2020.05.048; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wright L, 2022, J EPIDEMIOL COMMUN H, V76, P109, DOI 10.1136/jech-2021-217179; Xiao CF, 2020, PSYCHIAT INVEST, V17, P175, DOI 10.30773/pi.2020.0047	42	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1444	10.3390/vaccines9121444			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1YE	34960190	gold, Green Published			2022-04-29	WOS:000737454900001
J	Guha, J; Chari, R				Guha, June; Chari, Raj			Disc Large Homolog 1 Is Critical for Early T Cell Receptor Micro Cluster Formation and Activation in Human T Cells	VACCINES			English	Article						Dlg1; TCR-microcluster; T cell	SIGNALING PATHWAYS; PROTEINS; PHOSPHATASE; INHIBITION; ZAP-70; DLGH1; POLARITY	T cell activation by antigen involves multiple sequential steps, including T cell receptor-microcluster TCR-(MC) formation, immunological synapse formation, and phosphorylation of mediators downstream of the TCR. The adaptor protein, Disc Large Homolog 1 (DLG1), is known to regulate proximal TCR signaling and, in turn, T cell activation, acting as a molecular chaperone that organizes specific kinases downstream of antigen recognition. In this study, we used knockdown and knockout technologies in human primary T cells and a human T cell line to demonstrate the role of DLG1 in proximal T cell signaling. High-end confocal microscopy was used for pictorial representation of T cell micro-clusters and colocalization studies. From all these studies, we could demonstrate that DLG1 functions even earlier than immunological synapse formation, to regulate T cell activation by promoting TCR-MC formation. Moreover, we found that DLG1 can act as a bridge between the TCR-zeta chain and ZAP70 while inhibiting binding of the phosphatase SHP1 to TCR-zeta. Together, these effects drive dysregulation of T cell activation in DLG1-deficient T cells. Overall, the activation and survival status of T cell is a critical determinant of effective vaccine response, and DLG1-mediated T cell signaling events can be a driving factor for improving vaccine-designing strategies.	[Guha, June] NCI, Lab Immune Cell Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Chari, Raj] NCI, Genome Modificat Core, Lab Anim Sci Program, Frederick Natl Lab Canc Res,NIH, Bethesda, MD 20892 USA; [Guha, June] NIAID, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA		Guha, J (通讯作者)，NIAID, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA.	june.guha@nih.gov; raj.chari@nih.gov		Guha, June/0000-0001-5325-8476			Azoulay-Alfaguter I, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal2880; Balagopalan L, 2011, NAT REV IMMUNOL, V11, P21, DOI 10.1038/nri2903; Bilder D, 2001, TRENDS GENET, V17, P511, DOI 10.1016/S0168-9525(01)02407-6; Brockdorff J, 1999, EUR J IMMUNOL, V29, P2539, DOI 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M; Brownlie RJ, 2013, NAT REV IMMUNOL, V13, P257, DOI 10.1038/nri3403; Choi S, 2017, NAT IMMUNOL, V18, P433, DOI 10.1038/ni.3692; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Hashimoto-Tane A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00255; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Humphries LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045276; Lorenz U, 2009, IMMUNOL REV, V228, P342, DOI 10.1111/j.1600-065X.2008.00760.x; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Nagaishi T, 2006, IMMUNITY, V25, P769, DOI 10.1016/j.immuni.2006.08.026; Rebeaud F, 2007, TRENDS IMMUNOL, V28, P196, DOI 10.1016/j.it.2007.03.004; Round JL, 2005, J EXP MED, V201, P419, DOI 10.1084/jem.20041428; Round JL, 2007, NAT IMMUNOL, V8, P154, DOI 10.1038/ni1422; Roy NH, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00116; Torchia MLG, 2018, P NATL ACAD SCI USA, V115, P2174, DOI 10.1073/pnas.1713301115; Wange R L, 2000, Sci STKE, V2000, pre1; Xavier R, 2004, J CELL BIOL, V166, P173, DOI 10.1083/jcb.200309044; Yamasaki S, 2001, J BIOL CHEM, V276, P45175, DOI 10.1074/jbc.M105384200; Zanin-Zhorov A, 2012, P NATL ACAD SCI USA, V109, P1625, DOI 10.1073/pnas.1110120109; Zheng CY, 2011, NEUROSCIENTIST, V17, P493, DOI 10.1177/1073858410386384	25	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1446	10.3390/vaccines9121446			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9TQ	34960191	Green Published, gold			2022-04-29	WOS:000737307800001
J	Imhof, D; Pownall, WR; Monney, C; Oevermann, A; Hemphill, A				Imhof, Dennis; Pownall, William Robert; Monney, Camille; Oevermann, Anna; Hemphill, Andrew			A Listeria monocytogenes-Based Vaccine Formulation Reduces Vertical Transmission and Leads to Enhanced Pup Survival in a Pregnant Neosporosis Mouse Model	VACCINES			English	Article						Neospora caninum; Listeria monocytogenes; vaccine; vertical transmission; abortion; neosporosis mouse model	CANINUM INFECTIONS; LIVE TACHYZOITES; MICE; PROTECTION; ANTIGENS; PROTEIN; CATTLE; PCR	The apicomplexan parasite Neospora caninum is the worldwide leading cause of abortion and stillbirth in cattle. An attenuated mutant Listeria monocytogenes strain (Lm3Dx) was engineered by deleting the virulence genes actA, inlA, and inlB in order to avoid systemic infection and to target the vector to antigen-presenting cells (APCs). Insertion of sag1, coding for the major surface protein NcSAG1 of N. caninum, yielded the vaccine strain Lm3Dx_NcSAG1. The efficacy of Lm3Dx_NcSAG1 was assessed by inoculating 1 x 10(5), 1 x 10(6), or 1 x 10(7) CFU of Lm3Dx_NcSAG1 into female BALB/c mice by intramuscular injection three times at two-week intervals, and subsequent challenge with 1 x 10(5) N. caninum tachyzoites of the highly virulent NcSpain-7 strain on day 7 of pregnancy. Dose-dependent protective effects were seen, with a postnatal offspring survival rate of 67% in the group treated with 1 x 10(7) CFU of Lm3Dx_NcSAG1 compared to 5% survival in the non-vaccinated control group. At euthanasia (25 days post-partum), IgG antibody titers were significantly decreased in the groups receiving the two higher doses and cytokines recall responses in splenocyte culture supernatants (IFN-gamma, IL-4, and IL-10) were increased in the vaccinated groups. Thus, Lm3Dx_NcSAG1 induces immune-protective effects associated with a balanced Th1/Th2 response in a pregnant neosporosis mouse model and should be further assessed in ruminant models.	[Imhof, Dennis; Hemphill, Andrew] Univ Bern, Inst Parasitol, Vetsuisse Fac, Langgassstr 122, CH-3012 Bern, Switzerland; [Imhof, Dennis; Pownall, William Robert] Univ Bern, Grad Sch Cellular & Biomed Sci, Mittelstr 43, CH-3012 Bern, Switzerland; [Pownall, William Robert] Univ Bern, Vetsuisse Fac, Dept Surg, Small Anim Clin, Langgassstr 128, CH-3012 Bern, Switzerland; [Monney, Camille; Oevermann, Anna] Univ Bern, Vetsuisse Fac, Div Neurol Sci, DCR VPH, Bremgartenstr 109A, CH-3012 Bern, Switzerland		Hemphill, A (通讯作者)，Univ Bern, Inst Parasitol, Vetsuisse Fac, Langgassstr 122, CH-3012 Bern, Switzerland.	dennis.imhof@vetsuisse.unibe.ch; william.pownall@vetsuisse.unibe.ch; camille.monney@vetsuisse.unibe.ch; anna.oevermann@vetsuisse.unibe.ch; andrew.hemphill@vetsuisse.unibe.ch		Hemphill, Andrew/0000-0002-0622-2128; Pownall, William/0000-0001-9571-9824			Aguado-Martinez A, 2019, VACCINE, V37, P473, DOI 10.1016/j.vaccine.2018.11.060; Aguado-Martinez A, 2017, INT J PARASITOL, V47, P723, DOI 10.1016/j.ijpara.2017.09.001; Aguado-Martinez A, 2016, PARASITOLOGY, V143, P606, DOI 10.1017/S0031182016000056; Arranz-Solis D, 2015, VET PARASITOL, V211, P133, DOI 10.1016/j.vetpar.2015.05.021; Bengoa-Luoni SA, 2019, ACTA TROP, V198, DOI 10.1016/j.actatropica.2019.105094; Cannas A, 2003, PARASITOLOGY, V126, P303, DOI 10.1017/S0031182002002895; Chavez-Arroyo A, 2020, CELL MICROBIOL, V22, DOI 10.1111/cmi.13175; Cho Jung-Hwa, 2005, Korean Journal of Parasitology, V43, P19, DOI 10.3347/kjp.2005.43.1.19; D'Orazio SEF, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0065-2019; Debache K, 2008, INT J PARASITOL, V38, P1455, DOI 10.1016/j.ijpara.2008.04.001; Debache K, 2009, INT J PARASITOL, V39, P1373, DOI 10.1016/j.ijpara.2009.04.006; Dubey JP., 2017, NEOSPOROSIS ANIMALS, DOI [10.1201/9781315152561, DOI 10.1201/9781315152561]; Dunbar SA, 2006, CLIN CHIM ACTA, V363, P71, DOI 10.1016/j.cccn.2005.06.023; Eperon S, 1999, PARASITE IMMUNOL, V21, P225, DOI 10.1046/j.1365-3024.1999.00223.x; Flickinger JC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030048; Hemphill A, 2006, PARASITOLOGY, V133, P261, DOI 10.1017/S0031182006000485; Hemphill A, 2016, PARASITOLOGY, V143, P245, DOI 10.1017/S0031182015001596; Hemphill Andrew, 2013, Front Biosci (Elite Ed), V5, P23; Horcajo P, 2016, PARASITE IMMUNOL, V38, P709, DOI 10.1111/pim.12342; Howe DK, 1998, INFECT IMMUN, V66, P5322, DOI 10.1128/IAI.66.11.5322-5328.1998; Lecuit M, 1997, INFECT IMMUN, V65, P5309, DOI 10.1128/IAI.65.12.5309-5319.1997; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; Marugan-Hernandez V, 2017, J COMP PATHOL, V157, P193, DOI 10.1016/j.jcpa.2017.08.001; Marugan-Hernandez V, 2011, VACCINE, V29, P7867, DOI 10.1016/j.vaccine.2011.07.091; Monney T, 2011, ANIMALS-BASEL, V1, P306, DOI 10.3390/ani1030306; Monney T, 2014, EXP PARASITOL, V140, P52, DOI 10.1016/j.exppara.2014.02.015; Monney T, 2012, VACCINE, V30, P6588, DOI 10.1016/j.vaccine.2012.08.024; Muller N, 2002, J CLIN MICROBIOL, V40, P252, DOI 10.1128/JCM.40.1.252-255.2002; Muller N, 1996, J CLIN MICROBIOL, V34, P2850; Penarete-Vargas DM, 2010, INFECT IMMUN, V78, P651, DOI 10.1128/IAI.00703-09; Pownall WR, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.675219; Radoshevich L, 2018, NAT REV MICROBIOL, V16, P32, DOI 10.1038/nrmicro.2017.126; Reichel MP, 2015, VACCINE, V33, P1299, DOI 10.1016/j.vaccine.2015.01.064; Reichel MP, 2013, INT J PARASITOL, V43, P133, DOI 10.1016/j.ijpara.2012.10.022; Rojo-Montejo S, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-106; Rojo-Montejo S, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-62; Sonda S, 1998, MOL BIOCHEM PARASIT, V97, P97, DOI 10.1016/S0166-6851(98)00133-9; Weber FH, 2013, CLIN VACCINE IMMUNOL, V20, P99, DOI 10.1128/CVI.00225-12; WHITTEN MK, 1957, NATURE, V180, P1436, DOI 10.1038/1801436a0; Williams DJL, 2007, INFECT IMMUN, V75, P1343, DOI 10.1128/IAI.00777-06; Xu J, 2019, VACCINE, V37, P6426, DOI 10.1016/j.vaccine.2019.09.002; Yin YL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00407	42	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1400	10.3390/vaccines9121400			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YI7GD	34960146	Green Published, gold			2022-04-29	WOS:000744012300001
J	Juncker, HG; Mulleners, SJ; van Gils, MJ; Bijl, TPL; de Groot, CJM; Pajkrt, D; Korosi, A; van Goudoever, JB; van Keulen, BJ				Juncker, Hannah G.; Mulleners, Sien J.; van Gils, Marit J.; Bijl, Tom P. L.; de Groot, Christianne J. M.; Pajkrt, Dasja; Korosi, Aniko; van Goudoever, Johannes B.; van Keulen, Britt J.			Comparison of SARS-CoV-2-Specific Antibodies in Human Milk after mRNA-Based COVID-19 Vaccination and Infection	VACCINES			English	Article						breastmilk; immunization (vaccination); SARS-CoV-2; immunoglobulin A; BNT162b2 mRNA COVID-19 vaccine; COVID-19		SARS-CoV-2-specific antibodies are secreted into human milk of infected or vaccinated lactating women and might provide protection to the breastfed infant against COVID-19. Differences in antibody response after these types of exposure are unknown. In this longitudinal cohort study, we compared the antibody response in human milk following SARS-CoV-2 vaccination or infection. We analyzed 448 human milk samples of 28 lactating women vaccinated with the SARS-CoV-2 vaccine BNT162b2 as well as 82 human milk samples of 18 lactating women with a prior SARS-CoV-2 infection. The levels of SARS-CoV-2-specific IgA in human milk were determined over a period of 70 days both after vaccination and infection. The amount of SARS-CoV-2-specific IgA in human milk was similar after SARS-CoV-2 vaccination and infection. After infection, the variability in IgA levels was higher than after vaccination. Two participants with detectable IgA prior to vaccination were analyzed separately and showed higher IgA levels following vaccination compared to both groups. In conclusion, breastfed infants of mothers who have been vaccinated with the BNT162b2 vaccine receive human milk with similar amounts of SARS-CoV-2-specific antibodies compared to infants of previously infected mothers.	[Juncker, Hannah G.; Mulleners, Sien J.; Pajkrt, Dasja; van Goudoever, Johannes B.; van Keulen, Britt J.] Amsterdam UMC, Dept Pediat, Emma Childrens Hosp, Amsterdam Reprod & Dev Res Inst, NL-1081 HV Amsterdam, Netherlands; [Juncker, Hannah G.; Korosi, Aniko] Univ Amsterdam, Ctr Neurosci, Swammerdam Inst Life Sci, NL-1098 XH Amsterdam, Netherlands; [van Gils, Marit J.; Bijl, Tom P. L.] Univ Amsterdam, Amsterdam Infect & Immun Inst, Dept Med Microbiol & Infect Prevent, Amsterdam UMC, NL-1105 AZ Amsterdam, Netherlands; [de Groot, Christianne J. M.] Vrije Univ, Amsterdam Reprod & Dev Res Inst, Dept Obstet & Gynaecol, Amsterdam UMC, NL-1081 HV Amsterdam, Netherlands		van Goudoever, JB (通讯作者)，Amsterdam UMC, Dept Pediat, Emma Childrens Hosp, Amsterdam Reprod & Dev Res Inst, NL-1081 HV Amsterdam, Netherlands.	cj.degroot@amsterdamumc.nl		van Goudoever, Johannes (Hans)/0000-0003-3960-1703; Pajkrt, Dasja/0000-0002-5232-8206; van Gils, Marit J./0000-0003-3422-8161	Stichting Steun Emma Kinderziekenhuis; Amsterdam Infection and Immunity Institute [24175];  [COVID-19]	This research was funded by Stichting Steun Emma Kinderziekenhuis. M.J.v.G. acknowledges the Amsterdam Infection and Immunity Institute for funding this work through the COVID-19 grant (24175).	Andre MC, 2020, PEDIATR PULM, V55, P2842, DOI 10.1002/ppul.25030; Appelman B, 2021, EBIOMEDICINE, V72, DOI 10.1016/j.ebiom.2021.103589; Brandtzaeg P, 2010, J PEDIATR-US, V156, pS8, DOI 10.1016/j.jpeds.2009.11.014; Chambers C, 2020, JAMA-J AM MED ASSOC, V324, P1347, DOI 10.1001/jama.2020.15580; Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563; Fox A., 2020, EVIDENCE SIGNIFICANT, DOI [10.1101/2020.05.04.20089995, DOI 10.1101/2020.05.04.20089995]; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; Grimaud E, 2020, PEDIATR PULM, V55, P2211, DOI 10.1002/ppul.24946; Juncker HG, 2021, J HUM LACT, V37, P477, DOI 10.1177/08903344211027112; Juncker HG, 2021, J HUM LACT, V37, P469, DOI 10.1177/08903344211018185; Kim L, 2020, MMWR-MORBID MORTAL W, V69, P1081, DOI 10.15585/mmwr.mm6932e3; Lamberti LM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S18; Lebrao CW, 2020, J HUM LACT, V36, P609, DOI 10.1177/0890334420960433; Liu XH, 2020, J INFECT DIS, V222, P1293, DOI 10.1093/infdis/jiaa472; Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020; Low JM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00370-z; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Mark EG, 2021, J PEDIATR-US, V228, P94, DOI 10.1016/j.jpeds.2020.09.008; Mosca Fabio, 2017, Pediatr Med Chir, V39, P155, DOI 10.4081/pmc.2017.155; Perl SH, 2021, JAMA-J AM MED ASSOC, V325, P2013, DOI 10.1001/jama.2021.5782; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; Schlaudecker EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070867; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Sui ZW, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00596-2; Van Gils M.J., 2021, SINGLE DOSE SARS COV, DOI [10.1101/2021.05.25.21257797v1.full-text, DOI 10.1101/2021.05.25.21257797V1.FULL-TEXT]; van Keulen BJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051645; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; Wang ZJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1555; World Health Organization, BREASTF COVID 19 SCI	30	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1475	10.3390/vaccines9121475			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0QR	34960222	Green Published, gold			2022-04-29	WOS:000737367800001
J	Klugar, M; Riad, A; Mohanan, L; Pokorna, A				Klugar, Miloslav; Riad, Abanoub; Mohanan, Lekshmi; Pokorna, Andrea			COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study	VACCINES			English	Article						booster immunization; COVID-19 vaccines; Czechia; decision making; health personnel	INFECTION; B.1.617.2; EMPLOYEES; SYSTEM	The emerging SARS-CoV-2 variants and waning vaccine-elicited immunity are two public health challenges that occurred simultaneously and synergistically during the summer of 2021 and led to a surging demand for COVID-19 vaccine booster dose (BD) rollout. This study aimed to evaluate the COVID-19 vaccine booster hesitancy (VBH) among Czech healthcare workers to explore the potential determinants of VBH. A national cross-sectional survey-based study was carried out between 3 and 11 November 2021, using an online self-administered questionnaire (SAQ) that explored the participants' demographic characteristics, COVID-19 infection and vaccine anamneses, willingness to receive COVID-19 vaccine BD, and the psychosocial drivers of VBH. A total of 3454 HCW properly responded to the online SAQ, of which 80.9% were females, 30.3% were medical professionals, and 50.5% were <= 47 years old. Most of the participants were already inoculated against SARS-CoV-2 (95.2%), and BTN162b2 was the most commonly administered vaccine (90.7%). As the study sample was planned to represent the target population, it revealed a high level of BD acceptance (71.3%) among Czech HCW, while 12.2% were still hesitant and 16.6% were against the currently available BD. These results are consistent with other recent results from central Europe. Medical professional, male, and older participants were more likely to accept BD rather than allied health professional, female, and younger participants. The BDs' perceived effectiveness against severe illness, symptomatic infection, and community transmission was a significant and strong predictor for BD acceptance, while the effectiveness against the circulating variants was not that important for our target population. The BDs' perceived safety and ethical dilemmas of vaccine justice should be addressed sufficiently while communicating with HCW and other population groups. The altruistic reasons for BD acceptance, i.e., family protection, patient protection, and community health protection, underpin the recommendation of postponing the COVID-19 vaccine mandating in favour of stressing these altruistic concerns amid public health messaging.	[Klugar, Miloslav; Riad, Abanoub; Mohanan, Lekshmi; Pokorna, Andrea] Masaryk Univ, Inst Biostat & Anal, Fac Med, GRADE Ctr,Czech EBHC JBI Ctr Excellence,Czech Nat, Brno 62500, Czech Republic; [Klugar, Miloslav; Pokorna, Andrea] Masaryk Univ, Fac Med, Dept Hlth Sci, Brno 62500, Czech Republic; [Klugar, Miloslav; Pokorna, Andrea] Inst Hlth Informat & Stat Czech Republ, Prague 12801, Czech Republic; [Riad, Abanoub] Masaryk Univ, Fac Med, Dept Publ Hlth, Brno 62500, Czech Republic		Riad, A (通讯作者)，Masaryk Univ, Inst Biostat & Anal, Fac Med, GRADE Ctr,Czech EBHC JBI Ctr Excellence,Czech Nat, Brno 62500, Czech Republic.; Riad, A (通讯作者)，Masaryk Univ, Fac Med, Dept Publ Hlth, Brno 62500, Czech Republic.	klugar@med.muni.cz; abanoub.riad@med.muni.cz; lekshmi.mohanan@mail.muni.cz; apokorna@med.muni.cz	Riad, Abanoub/AAU-7046-2020; Klugar, Miloslav/E-5748-2018; Pokorna, Andrea/E-5483-2019	Riad, Abanoub/0000-0001-5918-8966; Klugar, Miloslav/0000-0002-2804-7295; Pokorna, Andrea/0000-0002-1305-6455	Masaryk University [MUNI/IGA/1543/2020, MUNI/A/1608/2020]; INTER-EXCELLENCE [LTC20031]	This study was funded by Masaryk University, grant number MUNI/IGA/1543/2020 and MUNI/A/1608/2020. The work of M.K., A.R. and A.P. was supported by the INTER-EXCELLENCE grant number LTC20031-"Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic".	Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Alhazmi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060674; Almufty HB, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.102207; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Ashinyo ME, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248282; Atwell JE, 2014, PEDIATRICS, V134, P602, DOI 10.1542/peds.2014-1883; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Barda N, 2021, LANCET, V398, P2093, DOI 10.1016/S0140-6736(21)02249-2; Berg S., WHAT DOCTORS WISH PA; Berg S., WHICH COVID 19 VACCI; Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038; CDC, COVID 19 VACC BOOST; Centers for Disease Control and Prevention (CDC), VACC ADV EV REP SYST; Centers for Disease Control and Prevention (CDC), EP INF WIND; Centers for Disease Control Prevention (CDC), POP SURV DESCR STUD; Chen Xinhua, 2021, medRxiv, DOI 10.1101/2021.08.26.21262699; Crescitelli MED, 2020, PUBLIC HEALTH, V180, P38, DOI 10.1016/j.puhe.2019.10.027; Czech Statistical Office (CZSO), ZAOSTR ZEN MUZ 2018; Czech Statistical Office (CZSO), ODM ZDRAV PRAC; Dasgupta P, 2018, INDIAN J PUBLIC HLTH, V62, P253, DOI 10.4103/ijph.IJPH_397_17; Dziedzic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10225338; Facciola A, 2019, J PUBLIC HEALTH RES, V8, P13, DOI 10.4081/jphr.2019.1436; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Fowlkes A, 2021, MMWR-MORBID MORTAL W, V70, P1167, DOI 10.15585/mmwr.mm7034e4; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Gohil SK, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.15980; Goldberg Y., 2021, WANING IMMUNITY BNT1, DOI [10.1101/2021.08.24.21262423, DOI 10.1101/2021.08.24.21262423]; Government of Canada (Canada.ca), CAN ADV EV FOLL IMM; Gur-Arie R, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004877; Hollmeyer HG, 2009, VACCINE, V27, P3935, DOI 10.1016/j.vaccine.2009.03.056; Hotez PJ, 2021, ECLINICALMEDICINE, V39, DOI 10.1016/j.eclinm.2021.101053; Institute of Health Information and Statistics of the Czech Republic (UZIS), 2017, HLTH YB CZECH REP; Jarkovsky J, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-045442; Jayasundara D., 2021, INT J EPIDEMIOL, V50, DOI [10.1093/ije/dyab168.321, DOI 10.1093/IJE/DYAB168.321]; Jeskowiak I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050502; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Kateeb E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090954; Keehner J, 2021, NEW ENGL J MED, V384, P1774, DOI 10.1056/NEJMc2101927; Keske S, 2020, VACCINE, V38, P8357, DOI 10.1016/j.vaccine.2020.11.003; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Klugar M., COVID 19 VACCINES SA; Klugar M, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10080752; Komenda M, 2020, J MED INTERNET RES, V22, DOI 10.2196/19367; Kuter BJ, 2021, VACCINE, V39, P1693, DOI 10.1016/j.vaccine.2021.02.029; Lai XQ, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-00746-1; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Lange B, 2021, NEW ENGL J MED, V385, P1145, DOI 10.1056/NEJMc2108076; Lee JT, 2021, MMWR-MORBID MORTAL W, V70, P1036, DOI [10.15585/mmwr.mm7030a2externalicon, 10.15585/mmwr.mm7030a2, 10.1101/2021.05.14.21257224v1]; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Marion O, 2021, ANN INTERN MED, V174, P1336, DOI 10.7326/M21-1341; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Medicines and Healthcare Products Regulatory Agency (MHRA), COR COVID 19 VACC AD; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Ministerstvo zdravotnictvi Ceske republiky (MZCR), DOT PRUZK POST ZDRAV; Ministerstvo Zdravotnictvi CR (MZCR), COVID 19 PREHL VYK O; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nasreen S., 2021, EFFECTIVENESS COVID, DOI [10.1101/2021.06.28.21259420, DOI 10.1101/2021.06.28.21259420]; NHMRC N.H., MRC AUSTR GUID CLIN; Parente DJ, 2021, J AM BOARD FAM MED, V34, P498, DOI 10.3122/jabfm.2021.03.200541; Patalon T., 2021, CORRELATION SARS COV, DOI [10.1101/ 2021.07.29.21261317, DOI 10.1101/2021.07.29.21261317]; Pless A, 2017, BMC NURS, V16, DOI 10.1186/s12912-017-0215-5; Proton Technologies AG, GEN DAT PROT REG GDP; Rey D, 2018, EUROSURVEILLANCE, V23, P30, DOI [10.2807/1560-7917.ES.23.17.17-00816, 10.2807/1560-7917.ES.2018.23.17.17-00816]; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101158; Riad A, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14101049; Riad A, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14090873; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090948; Riad A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18157859; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122629; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060673; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060566; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111286; Salerno L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080927; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schernhammer E, 2022, J PUBLIC HEALTH-UK, V44, pE106, DOI 10.1093/pubmed/fdab122; Shatnawi NJ, 2022, FUTUR SCI OA, V8, DOI 10.2144/fsoa-2021-0094; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Silva-Cayetano A, 2021, MED-CAMBRIDGE, V2, P243, DOI 10.1016/j.medj.2020.12.006; SPSS Inc, IBM SPSS STAT; Stepanek L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080863; Strategic Advisory Group of Experts on Immunization (SAGE), 2014, REP SAG WORK GROUP V; Sugawara N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111295; Surgo Ventures, 6 WAYS BETT UND COVI; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Trent Mallory, 2022, Vaccine, V40, P2498, DOI 10.1016/j.vaccine.2021.06.048; Ustav Zdravotnickych Informaci a Statistiky CR (UZIS), ROZL LEK NEL ZDRAV P; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120, 10.1371/journal.pmed.0040296]; Wall EC, 2021, LANCET, V397, P2331, DOI 10.1016/S0140-6736(21)01290-3; Williams JL, 2001, VACCINE, V19, P4081, DOI 10.1016/S0264-410X(01)00112-8; World Economic Forum (WEF), WOULD YOU GET COVID; World Health Organization (WHO), MED BRIEF COVID 19; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	98	8	8	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1437	10.3390/vaccines9121437			29	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	0G9SH	34960183	Green Published, gold			2022-04-29	WOS:000778380900001
J	Malave, CM; Lopera-Madrid, J; Medina-Magues, LG; Rocke, TE; Osorio, JE				Malave, Carly M.; Lopera-Madrid, Jaime; Medina-Magues, Lex G.; Rocke, Tonie E.; Osorio, Jorge E.			Impact of Molecular Modifications on the Immunogenicity and Efficacy of Recombinant Raccoon Poxvirus-Vectored Rabies Vaccine Candidates in Mice	VACCINES			English	Article						rabies; rabies virus; RABV; raccoon poxvirus; recombinant; vaccine; A; J mice	VAMPIRE BATS; VIRUS; INFECTION; LYSSAVIRUSES; IMMUNIZATION; EXPRESSION; EMERGENCE; HUMANS	Rabies is an ancient disease that is responsible for approximately 59,000 human deaths annually. Bats (Order Chiroptera) are thought to be the original hosts of rabies virus (RABV) and currently account for most rabies cases in wildlife in the Americas. Vaccination is being used to manage rabies in other wildlife reservoirs like fox and raccoon, but no rabies vaccine is available for bats. We previously developed a recombinant raccoonpox virus (RCN) vaccine candidate expressing a mosaic glycoprotein (MoG) gene that protected mice and big brown bats when challenged with RABV. In this study, we developed two new recombinant RCN candidates expressing MoG (RCN-tPA-MoG and RCN-SS-TD-MoG) with the aim of improving RCN-MoG. We assessed and compared in vitro expression, in vivo immunogenicity, and protective efficacy in vaccinated mice challenged intracerebrally with RABV. All three candidates induced significant humoral immune responses, and inoculation with RCN-tPA-MoG or RCN-MoG significantly increased survival after RABV challenge. These results demonstrate the importance of considering molecular elements in the design of vaccines, and that vaccination with either RCN-tPA-MoG or RCN-MoG confers adequate protection from rabies infection, and either may be a sufficient vaccine candidate for bats in future work.	[Malave, Carly M.; Rocke, Tonie E.] US Geol Survey, Natl Wildlife Hlth Ctr, Madison, WI 53711 USA; [Malave, Carly M.; Lopera-Madrid, Jaime; Medina-Magues, Lex G.; Osorio, Jorge E.] Univ Wisconsin Madison, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA		Rocke, TE (通讯作者)，US Geol Survey, Natl Wildlife Hlth Ctr, Madison, WI 53711 USA.; Osorio, JE (通讯作者)，Univ Wisconsin Madison, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.	malave@usgs.gov; loperamadrid@wisc.edu; medinamagues@wisc.edu; rocke@usgs.gov; jorge.osorio@wisc.edu		OSORIO, JORGE/0000-0002-7474-6150; Medina Magues, Lex Guillermo/0000-0002-4242-6945	U.S. Geological Survey and the University of Wisconsin-Madison	FundingThis research was funded by the U.S. Geological Survey and the University of Wisconsin-Madison (NSF award no. 2011069).	Banyard AC, 2014, VIRUSES-BASEL, V6, P2974, DOI 10.3390/v6082974; Barber RD, 2005, PHYSIOL GENOMICS, V21, P389, DOI 10.1152/physiolgenomics.00025.2005; Blackwood JC, 2013, P NATL ACAD SCI USA, V110, P20837, DOI 10.1073/pnas.1308817110; Calisher CH, 2012, TRAVEL MED INFECT DI, V10, P69, DOI 10.1016/j.tmaid.2012.01.003; Cardenas-Canales EM, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5010034; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; Dato V., 2009, Morbidity and Mortality Weekly Report, V58, P1204; Dean D.J., 1996, LAB TECHNIQUES RABIE, P83; Earl P L, 2001, Curr Protoc Mol Biol, VChapter 16, DOI [10.1002/0471142727.mb1616s43, 10.1002/0471142727.mb1617s43]; Fisher CR, 2018, NAT REV MICROBIOL, V16, P241, DOI 10.1038/nrmicro.2018.11; Haddad D, 1997, FEMS IMMUNOL MED MIC, V18, P193, DOI 10.1016/S0928-8244(97)00039-4; Hwa SH, 2010, AVIAN DIS, V54, P1157, DOI 10.1637/9315-032410-Reg.1; Johnson N, 2010, VET MICROBIOL, V142, P151, DOI 10.1016/j.vetmic.2010.02.001; Kou YM, 2017, IMMUNOL LETT, V190, P51, DOI 10.1016/j.imlet.2017.07.007; Lui YLE, 2013, BIOCHEM BIOPH RES CO, V433, P607, DOI 10.1016/j.bbrc.2013.03.044; Ma XY, 2018, JAVMA-J AM VET MED A, V253, P1555, DOI 10.2460/javma.253.12.1555; Malave C.M., 2021, IN VITRO EXPRESSION; Megid J, 2008, AM J TROP MED HYG, V79, P647, DOI 10.4269/ajtmh.2008.79.647; Meza D.K., 2020, PREDICTING PRESENCE, DOI [10.1111/tbed.13826, DOI 10.1111/TBED.13826]; Moore SM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000595; Osorio JE, 2003, VACCINE, V21, P1232, DOI 10.1016/S0264-410X(02)00557-1; Rasband W.S., IMAGEJ; REED L. J., 1938, AMER JOUR HYG, V27, P493; RUPPRECHT CE, 1986, P NATL ACAD SCI USA, V83, P7947, DOI 10.1073/pnas.83.20.7947; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider MC, 2009, REV PANAM SALUD PUBL, V25, P260, DOI 10.1590/S1020-49892009000300010; Setien AA, 1998, VACCINE, V16, P1122, DOI 10.1016/S0264-410X(98)80108-4; Sidwa TJ, 2005, JAVMA-J AM VET MED A, V227, P785, DOI 10.2460/javma.2005.227.785; Slate D, 2005, VIRUS RES, V111, P68, DOI 10.1016/j.virusres.2005.03.012; Smith J.S., 1996, RAPID FLUORESCENT FO, V4; Smith TG, 2017, TROP MED INFECT DIS, V2, DOI 10.3390/tropicalmed2030024; Stading B, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005958; Streicker DG, 2012, P ROY SOC B-BIOL SCI, V279, P3384, DOI 10.1098/rspb.2012.0538; Thomas Philip, 2005, Journal of Pharmacological and Toxicological Methods, V51, P187, DOI 10.1016/j.vascn.2004.08.014; Wallace RM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107539; Wang JY, 2011, APPL MICROBIOL BIOT, V91, P731, DOI 10.1007/s00253-011-3297-0; WHO, 2005, WHO TECH REP SER, V931, P1; Wyatt LS, 1996, VACCINE, V14, P1451, DOI 10.1016/S0264-410X(96)00072-2; Zhao RQ, 2020, PROTEIN EXPRES PURIF, V168, DOI 10.1016/j.pep.2019.105567; Zhu JW, 2012, BIOTECHNOL ADV, V30, P1158, DOI 10.1016/j.biotechadv.2011.08.022	40	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1436	10.3390/vaccines9121436			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0WE	34960182	Green Published, gold			2022-04-29	WOS:000737382100001
J	Murewanhema, G; Mukwenha, S; Dzinamarira, T; Mukandavire, Z; Cuadros, D; Madziva, R; Chingombe, I; Mapingure, M; Herrera, H; Musuka, G				Murewanhema, Grant; Mukwenha, Solomon; Dzinamarira, Tafadzwa; Mukandavire, Zindoga; Cuadros, Diego; Madziva, Roda; Chingombe, Innocent; Mapingure, Munyaradzi; Herrera, Helena; Musuka, Godfrey			Optimising COVID-19 Vaccination Policy to Mitigate SARS-CoV-2 Transmission within Schools in Zimbabwe	VACCINES			English	Article						COVID-19; vaccination; schools; Zimbabwe		The COVID-19 pandemic has disrupted the learning of millions of children across the world. Since March 2020 when the first cases of COVID-19 were reported in Zimbabwe, the country, like many others, has gone through periods of closing and re-opening of schools as part of the national COVID-19 control and mitigation measures. Schools promote the social, mental, physical, and moral development of children. With this viewpoint, the authors argue that schools should not be closed to provide a measured and efficient response to the threats posed by the COVID-19 epidemic. Rather, infection prevention and control strategies, including vaccination of learners and teachers, and surveillance in schools should be heightened. The use of multiple prevention strategies discussed in this viewpoint has shown that when outbreaks in school settings are adequately managed, the transmission usually is low. The information presented here suggests that schools should remain open due to the preponderance of evidence indicating the overriding positive impacts of this policy on the health, development, and wellbeing of children.	[Murewanhema, Grant] Univ Zimbabwe, Fac Med & Hlth Sci, Unit Obstet & Gynecol, Harare, Zimbabwe; [Mukwenha, Solomon; Dzinamarira, Tafadzwa; Chingombe, Innocent; Mapingure, Munyaradzi; Musuka, Godfrey] Columbia Univ, ICAP, Harare, Zimbabwe; [Dzinamarira, Tafadzwa] Univ Pretoria, Sch Hlth Syst & Publ Hlth, ZA-0002 Pretoria, South Africa; [Mukandavire, Zindoga] Emirates Aviat Univ, Ctr Data Sci & Artificial Intelligence, POB 53044, Dubai, U Arab Emirates; [Cuadros, Diego] Univ Cincinnati, Dept Geog & Geog Informat Sci, Cincinnati, OH 45221 USA; [Madziva, Roda] Univ Nottingham, Sch Sociol & Social Policy, Nottingham NG7 2RD, England; [Herrera, Helena] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth PO1 2UP, Hants, England		Dzinamarira, T (通讯作者)，Columbia Univ, ICAP, Harare, Zimbabwe.; Dzinamarira, T (通讯作者)，Univ Pretoria, Sch Hlth Syst & Publ Hlth, ZA-0002 Pretoria, South Africa.	gmurewanhema@yahoo.com; sm4803@cumc.columbia.edu; td2581@cumc.columbia.edu; zindoga.mukandavire@emirates.com; cuadrodo@ucmail.uc.edu; roda.madziva@nottingham.ac.uk; zindoga.mukandavire@emirates.com; cuadrodo@ucmail.uc.edu; helena.herrera@port.ac.uk; gm2660@cumc.columbia.edu		Herrera, Helena/0000-0003-0107-8128; Musuka, Godfrey/0000-0001-9077-4429; Mukwenha, Solomon/0000-0001-6260-8247; Murewanhema, Grant/0000-0001-7531-730X			[Anonymous], COVERSATION; [Anonymous], NEW YORK TIMES; Delahoy MJ, 2021, MMWR-MORBID MORTAL W, V70, P1255, DOI 10.15585/mmwr.mm7036e2; Dzinamarira T, 2021, LANCET GLOB HEALTH, V9, pE1624, DOI 10.1016/S2214-109X(21)00451-4; Dzinamarira Tafadzwa, 2021, Public Health Pract (Oxf), V2, P100070, DOI 10.1016/j.puhip.2020.100070; Dzinamarira T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030250; Dzinamarira T, 2021, CLIN INFECT DIS, V72, pE667, DOI 10.1093/cid/ciaa1301; Dzobo M, 2021, IJID REG, V2021, DOI [10.1016/j.ijregi.2021.09.004, DOI 10.1016/J.IJREGI.2021.09.004]; Dzobo M, 2020, PAN AFR MED J, V35, DOI 10.11604/pamj.2020.35.2.23059; Fan A, VACCINATION CHILDREN; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Hassounah M, 2020, J MED INTERNET RES, V22, DOI 10.2196/19338; Irfan O, 2021, J GLOB HEALTH, V11, DOI 10.7189/jogh.11.05013; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Kitano T, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246326; Ledford H, 2021, NATURE, V595, P639, DOI 10.1038/d41586-021-01897-w; Mavhunga C, ZIMBABWE REIMPOSES L; Mavhunga C., ZIMBABWE STARTS VACC; Mukwenha S, 2022, ADDICTION, V117, P1177, DOI 10.1111/add.15729; Murewanhema G, 2021, PAN AFR MED J, V40, DOI 10.11604/pamj.2021.40.46.31237; Murewanhema Grant, 2021, Public Health Pract (Oxf), V2, P100200, DOI 10.1016/j.puhip.2021.100200; Murewanhema G, 2021, DISASTER MED PUBLIC, DOI 10.1017/dmp.2021.295; Murewanhema G, 2021, PAN AFR MED J, V39, DOI 10.11604/pamj.2021.39.125.28794; Murewanhema G, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.336.28953; Murewanhema G, 2020, PAN AFR MED J, V37, DOI 10.11604/pamj.supp.2020.37.41.26970; Musuka G, 2021, SAMJ S AFR MED J, V111, P816, DOI 10.7196/SAMJ.2021.v111i9.15923; Newsday,, SCH DEM COVID 19 CER; Pray IW, 2020, MMWR-MORBID MORTAL W, V69, P1600, DOI 10.15585/mmwr.mm6943a4; Stein-Zamir C, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.29.2001352; UNESCO, ED DISR REC; UNICEF,, ZIMB CHILDR RET SCH; UNICEF Education Disrupted,, 2 YEAR COVID 19 PAND	32	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1481	10.3390/vaccines9121481			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YG3WB	34960227	gold, Green Published			2022-04-29	WOS:000742422200001
J	Suah, JL; Tok, PSK; Ong, SM; Husin, M; Tng, BH; Sivasampu, S; Thevananthan, T; Appannan, MR; Zin, FM; Zin, SM; Yahaya, H; Rusli, N; Ujang, MF; Ibrahim, HM; Abdullah, NH; Peariasamy, KM				Suah, Jing Lian; Tok, Peter Seah Keng; Ong, Su Miin; Husin, Masliyana; Tng, Boon Hwa; Sivasampu, Sheamini; Thevananthan, Thevesh; Appannan, Maheshwara Rao; Muhamad Zin, Faizah; Mohd Zin, Shahanizan; Yahaya, Hazlina; Rusli, Norhayati; Ujang, Mohd Fikri; Mohd Ibrahim, Hishamshah; Abdullah, Noor Hisham; Peariasamy, Kalaiarasu M.			PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio	VACCINES			English	Article						COVID-19; SARS-CoV-2; COVID-19 vaccines; vaccine effectiveness; cohort study; Malaysia		Malaysia rolled out a diverse portfolio of predominantly three COVID-19 vaccines (AZD1222, BNT162b2, and CoronaVac) beginning 24 February 2021. We evaluated vaccine effectiveness with two methods, covering 1 April to 15 September 2021: (1) the screening method for COVID-19 (SARS-CoV-2) infection and symptomatic COVID-19; and (2) a retrospective cohort of confirmed COVID-19 cases for COVID-19 related ICU admission and death using logistic regression. The screening method estimated partial vaccination to be 48.8% effective (95% CI: 46.8, 50.7) against COVID-19 infection and 33.5% effective (95% CI: 31.6, 35.5) against symptomatic COVID-19. Full vaccination is estimated at 87.8% effective (95% CI: 85.8, 89.7) against COVID-19 infection and 85.4% effective (95% CI: 83.4, 87.3) against symptomatic COVID-19. Among the cohort of confirmed COVID-19 cases, partial vaccination with any of the three vaccines is estimated at 31.3% effective (95% CI: 28.5, 34.1) in preventing ICU admission, and 45.1% effective (95% CI: 42.6, 47.5) in preventing death. Full vaccination with any of the three vaccines is estimated at 79.1% effective (95% CI: 77.7, 80.4) in preventing ICU admission and 86.7% effective (95% CI: 85.7, 87.6) in preventing deaths. Our findings suggest that full vaccination with any of the three predominant vaccines (AZD1222, BNT162b2, and CoronaVac) in Malaysia has been highly effective in preventing COVID-19 infection, symptomatic COVID-19, COVID-19-related ICU admission, and death.	[Suah, Jing Lian; Tng, Boon Hwa; Thevananthan, Thevesh] Govt Malaysia, COVID 19 Immunisat Task Force, Putrajaya 62000, Malaysia; [Tok, Peter Seah Keng; Ong, Su Miin; Husin, Masliyana; Sivasampu, Sheamini; Peariasamy, Kalaiarasu M.] Minist Hlth Malaysia, Inst Clin Res, Natl Inst Hlth, Setia Alam 40170, Malaysia; [Appannan, Maheshwara Rao; Yahaya, Hazlina; Rusli, Norhayati] Minist Hlth Malaysia, Dis Control Div, Putrajaya 62590, Malaysia; [Muhamad Zin, Faizah; Mohd Zin, Shahanizan; Ujang, Mohd Fikri] Minist Hlth Malaysia, Med Dev Div, Putrajaya 62590, Malaysia; [Mohd Ibrahim, Hishamshah; Abdullah, Noor Hisham] Minist Hlth Malaysia, Off Director Gen, Putrajaya 62590, Malaysia		Suah, JL (通讯作者)，Govt Malaysia, COVID 19 Immunisat Task Force, Putrajaya 62000, Malaysia.	suahjinglian@bnm.gov.my; petertok.crc@gmail.com; smongium1984@gmail.com; masliyana@crc.gov.my; boonhwa@bnm.gov.my; sheamini@crc.gov.my; thevesh@bnm.gov.my; mahesh@moh.gov.my; faizahmz@moh.gov.my; dr.shahanizan@moh.gov.my; dr_hazlina@moh.gov.my; dr_norhayati@moh.gov.my; drmdfikri@moh.gov.my; tkpkpst@moh.gov.my; anhisham@moh.gov.my; drkalai@moh.gov.my	Tok, Peter Seah Keng/ABE-6489-2021	Tok, Peter Seah Keng/0000-0003-3663-450X; M Peariasamy, Kalaiarasu/0000-0001-9279-3498; Suah, Jing Lian/0000-0003-0908-3597; Sivasampu, Sheamini/0000-0003-2314-6048			Alimohamadi Yousef, 2020, J Prev Med Hyg, V61, pE304, DOI 10.15167/2421-4248/jpmh2020.61.3.1530; [Anonymous], 45 WHO; [Anonymous], COVID 19 VACCINE TRA; Araki K, 2016, HUM VACC IMMUNOTHER, V12, P1244, DOI 10.1080/21645515.2015.1121337; Baraniuk C, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n912; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Campbell F, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100509; Cascella M, 2021, STATPEARLS; Centers for Disease Control and Prevention, SCI BRIEF EV US UPD; Cohen AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041785; COVID-19 Immunisation Task Force (CITF), OP DAT MAL NAT COVID; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Department of Statistics Malaysia, 2020, CURRENT POPULATION E; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; Falsey AR, 2021, NEW ENGL J MED, V385, P2348, DOI 10.1056/NEJMoa2105290; Falzone L, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4933; Government of Chile, EFF SARS COV 2 VACC; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hak E, 2002, J EPIDEMIOL COMMUN H, V56, P951, DOI 10.1136/jech.56.12.951; Hale T, 2021, NAT HUM BEHAV, V5, P529, DOI 10.1038/s41562-021-01079-8; Hashim JH, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.560592; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Krause PR, 2021, LANCET, V398, P1377, DOI 10.1016/S0140-6736(21)02046-8; Mathieu E., CORONAVIRUS PANDEMIC; Mazagatos C, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100452; Ministry of Health Malaysia, 2020, NATL HLTH MORB SURV; Ministry of Health Malaysia, OP DAT COVID 19 EP M; National Pharmaceutical Regulatory Agency (NPRA), MIN HLTH MAL FREQ AS; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Prime Minister Office of Malaysia, KEN MED PEJ PERD MEN; Rampal L, 2021, Med J Malaysia, V76, P1; Ranzani O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2015; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; Van Rossum G., 2009, PYTHON 3 REFERENCE M; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; WHO, COVID 19 VACC TRACK; WHO, EV ASS SIN CORONAVAC; World Health Organization, COVID 19 SIT REP W P; World Health Organization, CONS EV COVID 19 VAC; World Health Organization, COVID 19 WEEKL EP UP; World Health Organization, TRACK SARS COV 2 VAR	46	1	1	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1381	10.3390/vaccines9121381			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1XA	34960126	Green Published, gold			2022-04-29	WOS:000737451900001
J	Al-Karmalawy, AA; Soltane, R; Elmaaty, AA; Tantawy, MA; Antar, SA; Yahya, G; Chrouda, A; Pashameah, RA; Mustafa, M; Abu Mraheil, M; Mostafa, A				Al-Karmalawy, Ahmed A.; Soltane, Raya; Abo Elmaaty, Ayman; Tantawy, Mohamed A.; Antar, Samar A.; Yahya, Galal; Chrouda, Amani; Pashameah, Rami Adel; Mustafa, Muhamad; Abu Mraheil, Mobarak; Mostafa, Ahmed			Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview	VACCINES			English	Review						COVID-19; SARS-CoV-2; management; vaccines; drug repurposing; clinical trials	IN-VITRO; TANSHINONE IIA; CYTOKINE STORM; SARS-COV-2; VACCINES; INFECTION; HYDROXYCHLOROQUINE; PHARMACOKINETICS; METAANALYSIS; FAVIPIRAVIR	Respiratory viruses represent a major public health concern, as they are highly mutated, resulting in new strains emerging with high pathogenicity. Currently, the world is suffering from the newly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is the cause of coronavirus disease 2019 (COVID-19), a mild-to-severe respiratory tract infection with frequent ability to give rise to fatal pneumonia in humans. The overwhelming outbreak of SARS-CoV-2 continues to unfold all over the world, urging scientists to put an end to this global pandemic through biological and pharmaceutical interventions. Currently, there is no specific treatment option that is capable of COVID-19 pandemic eradication, so several repurposed drugs and newly conditionally approved vaccines are in use and heavily applied to control the COVID-19 pandemic. The emergence of new variants of the virus that partially or totally escape from the immune response elicited by the approved vaccines requires continuous monitoring of the emerging variants to update the content of the developed vaccines or modify them totally to match the new variants. Herein, we discuss the potential therapeutic and prophylactic interventions including repurposed drugs and the newly developed/approved vaccines, highlighting the impact of virus evolution on the immune evasion of the virus from currently licensed vaccines for COVID-19.	[Al-Karmalawy, Ahmed A.] Horus Univ Egypt, Fac Pharm, Dept Pharmaceut Med Chem, New Damietta 34518, Egypt; [Soltane, Raya; Pashameah, Rami Adel] Umm Al Qura Univ, Adham Univ Coll, Dept Basic Sci, Mecca 21955, Saudi Arabia; [Soltane, Raya] Tunis El Manar Univ, Fac Sci, Dept Biol, Tunis 1068, Tunisia; [Abo Elmaaty, Ayman] Port Said Univ, Fac Pharm, Dept Med Chem, Port Said 42526, Egypt; [Tantawy, Mohamed A.] Natl Res Ctr, Med Res & Clin Studies Res Inst, Hormones Dept, Dokki 12622, Egypt; [Tantawy, Mohamed A.] Natl Res Ctr, Ctr Excellence Adv Sci, Stem Cells Lab, Dokki 12622, Egypt; [Antar, Samar A.] Horus Univ Egypt, Fac Pharm, Dept Pharmacol, New Damietta 34518, Egypt; [Yahya, Galal] Zagazig Univ, Fac Pharm, Microbiol & Immunol Dept, Zagazig 44519, Egypt; [Chrouda, Amani] Majmaah Univ, Coll Sci Al Zulfi, Dept Chem, Al Majmaah 11932, Saudi Arabia; [Chrouda, Amani] Monastir Univ, Fac Sci, Lab Interfaces & Adv Mat, Monastir 5000, Tunisia; [Chrouda, Amani] UCBL, CNRS, Inst Analyt Sci, ENS,UMR 5280, 5 Rue Doua, F-69100 Villeurbanne, France; [Mustafa, Muhamad] Deraya Univ, Dept Med Chem, Al Minya 61111, Egypt; [Abu Mraheil, Mobarak; Mostafa, Ahmed] Justus Liebig Univ, Inst Med Microbiol, German Ctr Infect Res DZIF, D-35392 Giessen, Germany; [Mostafa, Ahmed] Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Dokki 12622, Egypt		Al-Karmalawy, AA (通讯作者)，Horus Univ Egypt, Fac Pharm, Dept Pharmaceut Med Chem, New Damietta 34518, Egypt.; Mostafa, A (通讯作者)，Justus Liebig Univ, Inst Med Microbiol, German Ctr Infect Res DZIF, D-35392 Giessen, Germany.; Mostafa, A (通讯作者)，Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Dokki 12622, Egypt.	akarmalawy@horus.edu.eg; ayman.mohamed@pharm.psu.edu.eg; mohamed_tantawy@daad-alumni.de; santar@horus.edu.eg; galalmetwally2020@gmail.com; amain.c@mu.edu.sa; muhamad_mustafa99@yahoo.com	A. Antar, Samar/AFL-6674-2022; Al-Karmalawy, Ahmed A./AAE-3311-2021; Mustafa, Muhamad/AAX-1021-2020; Antar, Samar/AFL-6788-2022; Elsayed, Ahmed Moustafa Mohamed/S-7462-2016	Al-Karmalawy, Ahmed A./0000-0002-8173-6073; Mustafa, Muhamad/0000-0002-1384-7556; Antar, Samar/0000-0002-1223-3579; Abo Elmaaty, Ayman/0000-0002-4634-3039; Elsayed, Ahmed Moustafa Mohamed/0000-0002-2878-5714; Soltane, Raya/0000-0002-3211-4630; METWALLY, GALAL/0000-0002-9466-7863; chrouda, Amani/0000-0003-0939-9890; Pashameah, Rami/0000-0002-6813-5863	Umm Al-Qura University [20-SCI-4-13-0001]; NRCNational Research Centre (NRC) [12010126]; Egyptian Academy of Scientific Research and Technology (ASRT) within the Ideation Fund program [7303]; German Center for Infection Research (DZIF); German Research FoundationGerman Research Foundation (DFG) [SFB-TR 84]	FundingThis research was funded by the Deanship of Scientific Research at Umm Al-Qura University, grant code 20-SCI-4-13-0001. It was also partially funded by the NRC under contract number 12010126 and the Egyptian Academy of Scientific Research and Technology (ASRT) within the Ideation Fund program under contract number 7303 (to A.M). The study was also funded by the German Center for Infection Research (DZIF), Partner Site GiessenMarburgLangen Application of recombinant bacterial membrane vesicles (BMVs) in vaccination against MERS-CoV, H1N1 Influenza Virus, and SARS-CoV-2 (to M.A.M. and A.M.). M.A.M. is further funded by German Research Foundation SFB-TR 84 Innate Immunity of the Lung: Mechanisms of Pathogen Attack and Host Defense in Pneumonia.	Abdallah AE, 2021, NEW J CHEM, V45, P16557, DOI 10.1039/d1nj02710g; Abdelnabi R, 2021, J INFECT DIS, V224, P749, DOI 10.1093/infdis/jiab361; Abdulamir A.S., 2021, EFFECTIVENESS SAFETY, DOI [10.1101/2021.06.10.21258709, DOI 10.1101/2021.06.10.21258709]; Elmaaty AA, 2021, MOLECULES, V26, DOI 10.3390/molecules26123772; Al-Karmalawy AA, 2021, MOLECULES, V26, DOI 10.3390/molecules26216559; Al-Karmalawy AA, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.661230; Al-Karmalawy AA, 2021, PHARM SCI-IRAN, V27, pS109, DOI 10.34172/PS.2021.3; Al-Karmalawy AA, 2020, NEW J CHEM, V44, P13990, DOI 10.1039/d0nj02844d; Almadhi MA, 2021, INT J INFECT DIS, V105, P656, DOI 10.1016/j.ijid.2021.02.100; Alnajjar R, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05641; Alshahrani MS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-017-0350-x; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; Perez MA, 2010, PEDIATR INFECT DIS J, V29, P1052, DOI 10.1097/INF.0b013e3181e6c69b; Aucoin M, 2020, ADV INTEGR MED, V7, P203, DOI 10.1016/j.aimed.2020.07.004; Axfors C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22446-z; Backer V, 2021, LANCET REG HEALTH-EU, V4, DOI 10.1016/j.lanepe.2021.100084; Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475; Baruah C, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7234961; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Beyer Daniel K, 2022, J Mol Biol, V434, P167265, DOI 10.1016/j.jmb.2021.167265; Blum VF, 2021, ECLINICALMEDICINE, V37, DOI 10.1016/j.eclinm.2021.100981; Boson B, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016175; Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; Bozkurt B, 2021, CIRCULATION, V144, P471, DOI 10.1161/CIRCULATIONAHA.121.056135; Braga L, 2021, NATURE, V594, P88, DOI 10.1038/s41586-021-03491-6; Bryant A, 2021, AM J THER, V28, pE434, DOI 10.1097/MJT.0000000000001402; Budweiser S, 2021, RESP RES, V22, DOI 10.1186/s12931-021-01756-2; Butler CC, 2021, LANCET, V397, P1063, DOI 10.1016/S0140-6736(21)00461-X; Cai QX, 2020, ENGINEERING-PRC, V6, P1192, DOI 10.1016/j.eng.2020.03.007; Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Carstens EB., 2011, VIRUS TAXONOMY; Castelli M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081514; Chen JH, 2021, J MOL BIOL, V433, DOI [10.1016/j.jmb.2021.167155, 10.1101/2021.04.12.439473]; Chen RC, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05672; Lee CC, 2021, ANTIBIOTICS-BASEL, V10, DOI 10.3390/antibiotics10111294; Coenen S, 2020, BRIT J GEN PRACT, V70, pE444, DOI 10.3399/bjgp20X711941; Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003; Costela-Ruiz VJ, 2020, CYTOKINE GROWTH F R, V54, P62, DOI 10.1016/j.cytogfr.2020.06.001; Cubuk J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21953-3; Davoudi-Monfared E, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01061-20; de Oliveira S, EMPIRICAL TREATMENT; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; del Amo J, 2020, ANN INTERN MED, V173, P536, DOI 10.7326/M20-3689; Delamater PL, 2019, EMERG INFECT DIS, V25, P1, DOI 10.3201/eid2501.171901; Delaney JW, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1230-8; Deng XD, 2021, CELL, V184, P3426, DOI 10.1016/j.cell.2021.04.025; Derington CG, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248080; Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938; Dhouib W, 2021, SYST REV-LONDON, V10, DOI 10.1186/s13643-021-01648-y; Ding CC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.693775; Dobano C, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02032-2; Doerfler W, 2021, VIRUS RES, V302, DOI 10.1016/j.virusres.2021.198466; Drozdzal S, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10070465; Duke T, 2010, INT J TUBERC LUNG D, V14, P1362; El Gizawy HA, 2021, MOLECULES, V26, DOI 10.3390/molecules26195844; El-Demerdash A, 2021, RSC ADV, V11, P31339, DOI 10.1039/d1ra05817g; Elebeedy D, 2021, RSC ADV, V11, P29267, DOI 10.1039/d1ra05268c; Eliaa SG, 2020, ACS PHARMACOL TRANSL, V3, P1330, DOI 10.1021/acsptsci.0c00144; Elmaaty AA, 2021, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2021.1918256; Elmaaty AA, 2021, RSC ADV, V11, P10027, DOI 10.1039/d0ra10674g; Elshal M, 2022, PHARM SCI-IRAN, V28, P76, DOI 10.34172/PS.2021.22; European Medicines Agency (EMA), COVID 19 VACC ASTRAZ; European Society of Cardiology, 2020, SCIENCEDAILY; Fan LC, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000023923; Fara A, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200160; Farthing M, 2020, J CLIN GASTROENTEROL, V54, P747, DOI 10.1097/MCG.0000000000001369; Fernandez J., 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.09.01.20184390, DOI 10.1101/2020.09.01.20184390]; Fitton A, 1992, Clin Pharmacokinet, V22 Suppl 1, P1; Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104; Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Gaspar EB, 2021, HUM VACC IMMUNOTHER, V17, P2965, DOI 10.1080/21645515.2021.1920272; Ghanem A, 2020, NEW J CHEM, V44, P17374, DOI 10.1039/d0nj04088f; Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015; Gluck V, 2021, INFECTION, V49, P739, DOI 10.1007/s15010-021-01598-6; Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Gordon CJ, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100770; Greenhalgh T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1182; Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Harrington WE, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100253; Hartikainen TS, 2020, EUR HEART J, V41, P2209, DOI 10.1093/eurheartj/ehaa035; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Hernandez A.V, 2020, ASS ACEIS ARBS USE C, DOI [10.1101/2020.06.03.20120261, DOI 10.1101/2020.06.03.20120261]; Hinks TSC, 2021, LANCET RESP MED, V9, P1130, DOI 10.1016/S2213-2600(21)00263-0; Hippisley-Cox J, 2021, HEART, V107, P170, DOI [10.1136/heartjnl-2020-318312, 10.1136/heartjnl-2020-317393]; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang D, 2021, J MED VIROL, V93, P481, DOI 10.1002/jmv.26256; Huang LN, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.710946; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001; Islam MS, 2016, EMERG INFECT DIS, V22, P664, DOI 10.3201/eid2204.151747; Jan JT, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021579118; Jensen LA, 1998, HEART LUNG, V27, P387, DOI 10.1016/S0147-9563(98)90086-3; Jiang X, 2020, J MED VIROL, V92, P476, DOI 10.1002/jmv.25708; Jung JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24377-1; Kandeil A, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10060758; Kandeil A, 2020, MICROBIOL RESOUR ANN, V9, DOI 10.1128/MRA.00489-20; Kasuga Y, 2021, EXP MOL MED, V53, P723, DOI 10.1038/s12276-021-00602-1; Khan WH, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.690621; Khan Z, 2020, NEW MICROB NEW INFEC, V38, DOI 10.1016/j.nmni.2020.100770; Khattab M, 2021, FUTURE MED CHEM, V13, P1623, DOI 10.4155/fmc-2020-0273; Khattab M, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.628398; Khiali S, 2020, J CLIN PHARMACOL, V60, P1131, DOI 10.1002/jcph.1693; Klein S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19619-7; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kumar A, 2021, J MED VIROL, V93, P1343, DOI 10.1002/jmv.26615; Kunnumakkara AB, 2021, LIFE SCI, V284, DOI 10.1016/j.lfs.2021.119201; Kuriya B, 2017, THER ADV MUSCULOSKEL, V9, P37, DOI 10.1177/1759720X16687481; Lakkireddy M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90189-4; Lamontagne F, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3284; Lansbury L., 2019, Cochrane Database of Systematic Reviews, pCD010406; Latinne A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17687-3; Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028; Lee MK, 2018, CLIN RESPIR J, V12, P2046, DOI 10.1111/crj.12772; Li CS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24230-5; Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3; Li MF, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248652; Li RY, 2020, SCIENCE, V368, P489, DOI [10.1126/science.abb3221, 10.1101/2020.02.14.20023127]; Liang ST, 2021, POSTGRAD MED J, V97, P273, DOI 10.1136/postgradmedj-2020-139070; Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08; Liu CH, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.616595; Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006; liu Y, 2020, TREATMENT ARBIDOL MO, DOI [10.1101/2020.05.30.20117598, DOI 10.1101/2020.05.30.20117598]; Liu Y, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab124; Liu YN, 2021, J CANCER EDUC, V36, P1014, DOI 10.1007/s13187-019-01682-4; Llor C, 2014, THER ADV DRUG SAF, V5, P229, DOI 10.1177/2042098614554919; Lopez-Medina E, 2021, JAMA-J AM MED ASSOC, V325, P1426, DOI 10.1001/jama.2021.3071; Lou Y, 2021, EUR J PHARM SCI, V157, DOI 10.1016/j.ejps.2020.105631; Luo P, 2020, J MED VIROL, V92, P814, DOI 10.1002/jmv.25801; Mahase E, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2422; Mahmoud A, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e07962; Mahmoud DB, 2021, J DRUG DELIV SCI TEC, V66, DOI 10.1016/j.jddst.2021.102845; Mahmoud Dina B., 2020, Journal of Genetic Engineering and Biotechnology, V18, P35, DOI 10.1186/s43141-020-00055-5; Mahyuddin AP, 2020, PRENATAL DIAG, V40, P1655, DOI 10.1002/pd.5765; Mariano G, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.605236; Mazzon M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020176; McCallum M, 2021, SCIENCE, V373, P648, DOI 10.1126/science.abi7994; McFee RB, 2020, DM-DIS MON, V66, DOI 10.1016/j.disamonth.2020.101068; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Miorin L, 2020, P NATL ACAD SCI USA, V117, P28344, DOI 10.1073/pnas.2016650117; Mostafa A, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13120443; Mostafa A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8070991; Moustaqil M, 2021, EMERG MICROBES INFEC, V10, P178, DOI 10.1080/22221751.2020.1870414; Muir KL, 2021, NEW ENGL J MED, V384, P1964, DOI 10.1056/NEJMc2105869; Murgolo N, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009225; Nagata T, 2015, DISASTER MED PUBLIC, V9, P79, DOI 10.1017/dmp.2014.151; NIH, CLIN SPECTR SARS COV; Nimavat N, 2021, ANN MED SURG, V68, DOI 10.1016/j.amsu.2021.102661; Oh SJ, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030530; Oldenburg CE, 2021, JAMA-J AM MED ASSOC, V326, P490, DOI 10.1001/jama.2021.11517; Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; Munnink BBO, 2021, NAT MED, V27, P1518, DOI 10.1038/s41591-021-01472-w; Oyedeji O.O, 2020, ANTIBIOTIC MAT HEALT, P11; Padhi AK, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101992; Papali A, 2019, SEPSIS MANAGEMENT IN RESOURCE-LIMITED SETTINGS, P31, DOI 10.1007/978-3-030-03143-5_3; Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI [10.1016/S1473-3099(20)30484-9, 10.1016/S1473-3099(20)30648-4]; Pettoello-Mantovani M, 2021, J PEDIATR-US, V239, P250, DOI 10.1016/j.jpeds.2021.09.013; Pinna SM, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108200; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Pott-Junior Henrique, 2021, Toxicol Rep, V8, P505, DOI 10.1016/j.toxrep.2021.03.003; Poudel A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256744; Pruijssers AJ, 2019, CURR OPIN VIROL, V35, P57, DOI 10.1016/j.coviro.2019.04.002; Rappazzo CG, 2016, VACCINE, V34, P1252, DOI 10.1016/j.vaccine.2016.01.028; Razonable RR, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101102; Rehwinkel J, 2020, NAT REV IMMUNOL, V20, P537, DOI 10.1038/s41577-020-0288-3; Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722; Riad A, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14090873; Ribero MS, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008737; Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4; Robson F, 2020, MOL CELL, V79, P710, DOI 10.1016/j.molcel.2020.07.027; Royer P.-J, 2021, XAV 19 SWINE GLYCO H, DOI [10.1101/2021.04.02.437747, DOI 10.1101/2021.04.02.437747]; Saadaoui M, 2021, J PERS MED, V11, DOI 10.3390/jpm11060483; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI 10.1056/NEJMoa2030340; Salter A, 2021, JAMA NEUROL, V78, P699, DOI 10.1001/jamaneurol.2021.0688; Samra RM, 2021, S AFR J BOT, V139, P210, DOI 10.1016/j.sajb.2021.02.007; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Saraste J, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030503; Sarhan Amany A, 2021, Inform Med Unlocked, V24, P100604, DOI 10.1016/j.imu.2021.100604; Sarosiek S, 2016, THER ADV HEMATOL, V7, P360, DOI 10.1177/2040620716653745; Satarker S, 2021, POSTGRAD MED, V133, P489, DOI 10.1080/00325481.2020.1855921; Schiff MH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3455; Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529; Self WH, 2020, JAMA-J AM MED ASSOC, V324, P2165, DOI 10.1001/jama.2020.22240; Shafran N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92220-0; Sharun K, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00368-w; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Shehata MM, 2021, MOLECULES, V26, DOI 10.3390/molecules26206182; Shehata MM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020046; Shuchi N.S., 2019, THESIS BRAC U DHAKA; SIDDIQUI AJ, 2020, J BIOMOL STRUCT DYN, V39, P1, DOI DOI 10.1080/07391102.2020.1852117; Simpson CR, 2021, NAT MED, V27, P1290, DOI 10.1038/s41591-021-01408-4; Singh A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83761-5; Soleimani A, 2020, AM J HYPERTENS, V33, P1102, DOI 10.1093/ajh/hpaa149; Soltan MA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179330; Soltan MA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060669; Soltane R, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10050623; Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059; Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; Tegally H, 2021, NAT MED, V27, P440, DOI 10.1038/s41591-021-01255-3; Teoh SL, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01857; Thomas S, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0369; Titanji BK, 2021, CLIN INFECT DIS, V72, P1247, DOI 10.1093/cid/ciaa879; Tito A, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.638187; Tong S, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106114; Tregoning JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/s41577-021-00592-1; Tsatsakis A, 2020, FOOD CHEM TOXICOL, V141, DOI 10.1016/j.fct.2020.111418; Turtle CJ, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3020; van Eeden C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176351; Verma AK, 2021, NEW ENGL J MED, V385, P1332, DOI 10.1056/NEJMc2109975; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; Vivanti AJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17436-6; Wahl A, 2021, NATURE, V591, P451, DOI 10.1038/s41586-021-03312-w; Wang SS, 2020, CLIN INFECT DIS, V71, P853, DOI 10.1093/cid/ciaa225; Wilkinson Eduan, 2021, Science, V374, P423, DOI 10.1126/science.abj4336; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wirz Y, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2125-7; Witberg G, 2021, NEW ENGL J MED, V385, P2132, DOI 10.1056/NEJMoa2110737; Wolf JS, 2008, J UROLOGY, V179, P1379, DOI 10.1016/S0022-5347(08)62119-9; World Health Organization, COVID 19 WEEKL EP; World Health Organization, CLIN MAN COVID 19 LI; Wrobel AG, 2020, NAT STRUCT MOL BIOL, V27, P763, DOI 10.1038/s41594-020-0468-7; Wu J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22034-1; Wu XK, 2020, ENGINEERING-PRC, V6, P1185, DOI 10.1016/j.eng.2020.08.011; Xiao KH, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.684864; Xiao X, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91470-2; Rojas-Reyes MX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005975.pub3; Xiong XM, 2021, THROMB J, V19, DOI 10.1186/s12959-021-00284-9; Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Yadav R, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040821; Yang G, 2020, HYPERTENSION, V76, P51, DOI 10.1161/HYPERTENSIONAHA.120.15143; Yang JS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18319-6; Yang L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00679-0; Yousef A., 2019, THESIS U LIVERPOOL L; Yousefi M, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05194-9; Yuan S, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.752214; Yuen CK, 2020, EMERG MICROBES INFEC, V9, P1418, DOI 10.1080/22221751.2020.1780953; Zaki AA, 2022, S AFR J BOT, V144, P115, DOI 10.1016/j.sajb.2021.08.006; Zaki AA, 2022, J TRADIT COMPL MED, V12, P16, DOI 10.1016/j.jtcme.2021.05.001; Zaki AA, 2020, NEW J CHEM, V44, P16752, DOI 10.1039/d0nj03611k; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zaki N, 2021, J INFECT PUBLIC HEAL, V14, P638, DOI 10.1016/j.jiph.2021.01.019; Zeng FF, 2021, J MED VIROL, V93, P6506, DOI 10.1002/jmv.27152; Zhang LS, 2020, CLIN INFECT DIS, V71, P882, DOI 10.1093/cid/ciaa112; Zhang YW, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024202118; Zhao HM, 2020, CHINESE MED J-PEKING, V133, P1595, DOI 10.1097/CM9.0000000000000848; Zheng KI, 2021, J MED VIROL, V93, P323, DOI 10.1002/jmv.26294; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou P., 2020, NATURE, V579, P270, DOI [10.1038/s41586-020-2012-7, DOI 10.1038/s41586-020-2012-7]; Zotta A, 2021, NAT CELL BIOL, V23, P682, DOI 10.1038/s41556-021-00712-y	257	6	6	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1317	10.3390/vaccines9111317			40	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF1OO	34835248	gold, Green Published			2022-04-29	WOS:000723847200001
J	Pariano, M; Costantini, C; Santarelli, I; Puccetti, M; Giovagnoli, S; Talesa, VN; Romani, L; Antognelli, C				Pariano, Marilena; Costantini, Claudio; Santarelli, Ilaria; Puccetti, Matteo; Giovagnoli, Stefano; Talesa, Vincenzo N.; Romani, Luigina; Antognelli, Cinzia			Defective Glyoxalase 1 Contributes to Pathogenic Inflammation in Cystic Fibrosis	VACCINES			English	Article						glyoxalase 1; cystic fibrosis; anakinra	RECEPTOR; DISEASE	Cystic fibrosis (CF) is an autosomal recessive disorder that affects multiple organs, although a decline in respiratory function represents the major cause of morbidity and mortality. The airways of CF patients are characterized by a chronic inflammatory state to which the receptor for advanced glycation end-products greatly contributes. Glyoxalase 1 (GLO1) is the major enzyme metabolizing methylglyoxal, a potent precursor of advanced glycation end-products. Its role in CF has never been investigated. We herein resorted to murine and human preclinical models of CF to define the contribution of GLO1 to inflammatory pathology. We found that the expression and activity of GLO1, measured by real-time PCR and Western blot or a specific spectrophotometric assay, respectively, are defective in mice and human bronchial cells from CF patients exposed to Aspergillus fumigatus, a common pathogen in CF, but could be restored upon blockade of interleukin-1 receptor signaling by anakinra in mice. This study suggests that GLO1 contributes to pathology in CF and may be potentially targeted to mitigate inflammation.	[Pariano, Marilena; Costantini, Claudio; Santarelli, Ilaria; Talesa, Vincenzo N.; Romani, Luigina; Antognelli, Cinzia] Univ Perugia, Dept Med & Surg, I-06132 Perugia, Italy; [Puccetti, Matteo; Giovagnoli, Stefano] Univ Perugia, Dept Pharmaceut Sci, I-06132 Perugia, Italy		Antognelli, C (通讯作者)，Univ Perugia, Dept Med & Surg, I-06132 Perugia, Italy.	marilena.pariano@gmail.com; claudio.costantini@unipg.it; ilasanta@libero.it; matteo.puccetti@gmail.com; stefano.giovagnoli@unipg.it; vincenzo.talesa@unipg.it; luigina.romani@unipg.it; cinzia.antognelli@unipg.it	giovagnoli, stefano/N-1064-2018	giovagnoli, stefano/0000-0001-5043-7233; Puccetti, Matteo/0000-0003-3007-0475; Romani, Luigina/0000-0002-1356-525X; ANTOGNELLI, Cinzia/0000-0002-8259-680X; pariano, marilena/0000-0002-9896-171X; Costantini, Claudio/0000-0002-1433-7830	Italian Cystic Fibrosis Research FoundationMinistry of Health, ItalyItalian Cystic Fibrosis Research Foundation [FFC 22/2014, FFC 17/2020]	This research was funded by the Italian Cystic Fibrosis Research Foundation (Research Projects number FFC#22/2014 to L.R. and FFC#17/2020 to S.G.). Marilena Pariano gratefully acknowledges a fellowship from the Italian Cystic Fibrosis Research Foundation.	Antognelli C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060547; Antognelli C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020415; Antognelli C, 2018, FREE RADICAL BIO MED, V115, P292, DOI 10.1016/j.freeradbiomed.2017.11.014; Bell SC, 2020, LANCET RESP MED, V8, P65, DOI 10.1016/S2213-2600(19)30337-6; Beucher J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041913; Borcherding DC, 2019, J CLIN INVEST, V129, P3448, DOI 10.1172/JCI96273; Borghi M, 2015, CELL HOST MICROBE, V18, P198, DOI 10.1016/j.chom.2015.07.004; Chen G, 2019, J CLIN INVEST, V129, P4433, DOI 10.1172/JCI125669; Corvol H, 2012, J CYST FIBROS, V11, P63, DOI 10.1016/j.jcf.2011.09.006; Costantini C, 2020, EUR J MED CHEM, V206, DOI 10.1016/j.ejmech.2020.112717; de Luca A, 2014, P NATL ACAD SCI USA, V111, P3526, DOI 10.1073/pnas.1322831111; Favia M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111890; Fritzsching B, 2015, AM J RESP CRIT CARE, V191, P902, DOI 10.1164/rccm.201409-1610OC; Gresnigt MS, 2016, SCI REP-UK, V6, DOI 10.1038/srep26490; He YJ, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110663; Hudson BI, 2018, ANNU REV MED, V69, P349, DOI 10.1146/annurev-med-041316-085215; Hudson VM, 2001, FREE RADICAL BIO MED, V30, P1440, DOI 10.1016/S0891-5849(01)00530-5; Iannitti RG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10791; Iannitti RG, 2013, AM J RESP CRIT CARE, V188, P1338, DOI 10.1164/rccm.201305-0986OC; Pariano M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126531; Petrasek J, 2012, J CLIN INVEST, V122, P3476, DOI 10.1172/JCI60777; Rabbani N, 2016, CLIN SCI, V130, P1677, DOI 10.1042/CS20160025; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343; VANDOORNINCK JH, 1995, EMBO J, V14, P4403, DOI 10.1002/j.1460-2075.1995.tb00119.x	24	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1311	10.3390/vaccines9111311			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF9RV	34835243	Green Published, gold			2022-04-29	WOS:000724402200001
J	Lukaszuk, K; Woclawek-Potocka, I; Jakiel, G; Malinowska, P; Wdowiak, A; Rozanska, K; Rabalski, L				Lukaszuk, Krzysztof; Woclawek-Potocka, Izabela; Jakiel, Grzegorz; Malinowska, Paulina; Wdowiak, Artur; Rozanska, Karolina; Rabalski, Lukasz			Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring	VACCINES			English	Article						COVID-19; vaccination; methotrexate; TNFis; autoimmune disease; AIIRD	COVID-19	We report a case of monitoring the antibody response to the BioNTech-Pfizer vaccine of a 50-year-old female diagnosed with rheumatoid arthritis undergoing treatment with methotrexate (MTX). Antibody levels were measured 21 days after dose 1 (i.e., on the day of dose 2) and then 8, 14 and 30 days after dose 2 with Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics). Patient showed a negative result after dose 1 and had the serum sample retested using a LIAISON(R) SARS-CoV-2 TrimericS IgG assay (DiaSorin), which showed a positive result. Subsequent samples were tested using both assays. Antibody levels kept increasing but at a much slower rate than in patients not receiving any immunomodulatory therapies. Other research indicates that among patients with autoimmune diseases, those receiving disease-modifying antirheumatic drugs (DMARDs) have higher COVID-19 mortality than those treated with tumor necrosis factor inhibitors (TNFis). These results indicate the need for people with autoimmune diseases to be carefully observed following vaccinations, including testing of antibody levels, and treated as potentially at risk until the effect of vaccination is confirmed. The different available vaccines should also be tested to verify their usefulness in the case of people with autoimmune diseases and those who take different immunomodulatory medications.</p>	[Lukaszuk, Krzysztof] Med Univ Gdansk, Dept Obstet & Gynecol Nursing, PL-80211 Gdansk, Poland; [Lukaszuk, Krzysztof; Malinowska, Paulina; Rozanska, Karolina] Invicta Res & Dev Ctr, PL-81740 Sopot, Poland; [Woclawek-Potocka, Izabela] Polish Acad Sci, Inst Anim Reprod & Food Res, Dept Gamete & Embryo Biol, PL-10243 Olsztyn, Poland; [Jakiel, Grzegorz] Ctr Postgrad Med Educ, Dept Obstet & Gynecol 1, PL-01004 Warsaw, Poland; [Wdowiak, Artur] Med Univ Lublin, Diagnost Tech Unit, PL-20081 Lublin, Poland; [Rabalski, Lukasz] Univ Gdansk, Intercollegiate Fac Biotechnol, Lab Recombinant Vaccines, PL-80307 Gdansk, Poland; [Rabalski, Lukasz] Med Univ Gdansk, PL-80307 Gdansk, Poland		Malinowska, P (通讯作者)，Invicta Res & Dev Ctr, PL-81740 Sopot, Poland.; Rabalski, L (通讯作者)，Univ Gdansk, Intercollegiate Fac Biotechnol, Lab Recombinant Vaccines, PL-80307 Gdansk, Poland.; Rabalski, L (通讯作者)，Med Univ Gdansk, PL-80307 Gdansk, Poland.	krzysztof.lukaszuk@invicta.pl; i.woclawek-potocka@pan.olsztyn.pl; grzegorz.jakiel1@o2.pl; malinowskap@invicta.pl; artur.wdowiak@umlub.com; karolina.rozanska@invicta.pl; lukasz.rabalski@ug.edu.pl	Rabalski, Lukasz/ABG-9936-2020; WOCLAWEK-POTOCKA, Izabela/H-7266-2017	Rabalski, Lukasz/0000-0002-5292-9263; WOCLAWEK-POTOCKA, Izabela/0000-0002-1270-3438; Jakiel, Grzegorz/0000-0002-6094-2273			[Anonymous], British Society for Rheumatology COVID-19 Guidance; [Anonymous], DIASORIN LIAISON SAR; [Anonymous], ROCHE DIAGNOSTIC ELE; [Anonymous], Canadian Rheumatology Association COVID-19 Resource Centre; [Anonymous], METHOTREXATE GLUCOCO; [Anonymous], WHO WHO COVID 19 VAC; [Anonymous], American College of Rheumatology ACR Announcements: Coronavirus Disease (COVID-19); Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Connolly CM, 2021, LANCET RHEUMATOL, V3, pE607, DOI 10.1016/S2665-9913(21)00217-4; Favresse J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071364; Furer V, 2021, ANN RHEUM DIS, V80, P1330, DOI 10.1136/annrheumdis-2021-220647; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Haberman RH, 2021, ANN RHEUM DIS, V80, P1339, DOI 10.1136/annrheumdis-2021-220597; Haidar G., 2021, MEDRXIV2021101101, DOI [10.1101/2021.06.28.21259576, DOI 10.1101/2021.06.28.21259576]; Hall VG, 2021, NEW ENGL J MED, V385, P1244, DOI 10.1056/NEJMc2111462; Lombardi A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.657711; Lukaszuk K, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080840; Mahil SK, 2021, LANCET RHEUMATOL, V3, pE627, DOI 10.1016/S2665-9913(21)00212-5; Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Subesinghe S, 2018, J RHEUMATOL, V45, P733, DOI 10.3899/jrheum.170710; Turner JS, 2021, NATURE, V596, P109, DOI 10.1038/s41586-021-03738-2; Winthrop KL, 2021, ANN RHEUM DIS, V80, P269, DOI 10.1136/annrheumdis-2020-218580; Yousaf A, 2021, J AM ACAD DERMATOL, V84, P70, DOI 10.1016/j.jaad.2020.09.009	25	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1151	10.3390/vaccines9101151			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP3FQ	34696259	Green Published, gold			2022-04-29	WOS:000713022300001
J	Silva, DSD; da Fonseca, FG				Silva, Danielle Soares de Oliveira; da Fonseca, Flavio Guimaraes			The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis	VACCINES			English	Review						vaccine; SARS-CoV-2; COVID-19; recombinant viral vectors; immunization	VIRAL VECTORS; VIRUS ANKARA; DENDRITIC CELLS; IMMUNOGENICITY; SAFETY; SPIKE; INFLUENZA; VACCINATION; SARS-COV-2; PROTECTION	The COVID-19 pandemic represents a milestone in vaccine research and development in a global context. A worldwide effort, as never seen before, involved scientists from all over the world in favor of the fast, accurate and precise construction and testing of immunogens against the new coronavirus, SARS-CoV-2. Among all the vaccine strategies put into play for study and validation, those based on recombinant viral vectors gained special attention due to their effectiveness, ease of production and the amplitude of the triggered immune responses. Some of these new vaccines have already been approved for emergency/full use, while others are still in pre- and clinical trials. In this article we will highlight what is behind adeno-associated vectors, such as those presented by the immunogens ChaAdOx1, Sputnik, Convidecia (CanSino, Tianjin, China), and Janssen (Johnson & Johnson, New Jersey, EUA), in addition to other promising platforms such as Vaccinia virus MVA, influenza virus, and measles virus, among others.</p>	[Silva, Danielle Soares de Oliveira; da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, Lab Virol Basica & Aplicada, Dept Microbiol, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil; [da Fonseca, Flavio Guimaraes] Univ Fed Minas Gerais, CT Vacinas, BH TEC Inst Ciencias Biol, BR-31310260 Belo Horizonte, MG, Brazil		Silva, DSD (通讯作者)，Univ Fed Minas Gerais, Lab Virol Basica & Aplicada, Dept Microbiol, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil.	danydaian@ufmg.br; dafonsecaflavio@gmail.com			CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Brazilian Ministry of Science and Innovation; FINEPFinanciadora de Inovacao e Pesquisa (Finep); CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); FAPEMIGFundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)	We are grateful to all scientists who dedicated themselves, body and soul, to the development of vaccines, therapies and treatments for COVID-19. In particular, the authors thank the professors and students at the CT-Vacinas and Laboratorio de Virologia Basica e Aplicada, both at the Universidade Federal de Minas Gerais, who bravely resisted the havoc brought by COVID-19 Brazil and went on working to produce good science. Da Fonseca FG is a CNPq fellowship recipient, and Daian e Silva DSO is a CAPES Post-Doc fellow. We thank the following financing agencies for their continuous support in studies related to the COVID-19: Rede Virus (Brazilian Ministry of Science and Innovation), CNPq, FINEP, CAPES and FAPEMIG. No writing assistance was utilized during preparation of this manuscript.	Afrough B, 2019, CLIN EXP IMMUNOL, V196, P157, DOI 10.1111/cei.13295; Alharbi NK, 2019, HUM VACC IMMUNOTHER, V15, P203, DOI 10.1080/21645515.2018.1513439; Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032; An D, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abi5246; Astrazeneca Media Center, 2021, AZD1222 US PHAS 3 PR; Bangari DS, 2006, VACCINE, V24, P849, DOI 10.1016/j.vaccine.2005.08.101; Barouch DH, 2021, NEW ENGL J MED, V385, P951, DOI 10.1056/NEJMc2108829; Bertran K, 2013, VACCINE, V31, P3572, DOI 10.1016/j.vaccine.2013.05.039; Bos R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00243-x; Bouard D, 2009, BRIT J PHARMACOL, V157, P153, DOI 10.1038/bjp.2008.349; Brave A, 2007, MOL PHARMACEUT, V4, P18, DOI 10.1021/mp060098+; Callaway E, 2019, NATURE, V575, P425, DOI 10.1038/d41586-019-03490-8; Capone S, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00240-0; Carson C, 2009, VACCINE, V27, P1080, DOI 10.1016/j.vaccine.2008.11.094; Case JB, 2020, CELL HOST MICROBE, V28, P465, DOI 10.1016/j.chom.2020.07.018; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; Chavda VP, 2021, DRUG DISCOV TODAY, V26, P2619, DOI 10.1016/j.drudis.2021.07.021; Chiuppesi F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19819-1; Claro F, 2021, INT J INFECT DIS, V111, P261, DOI 10.1016/j.ijid.2021.07.070; Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385; Escriou N, 2014, VIROLOGY, V452, P32, DOI 10.1016/j.virol.2014.01.002; Ewer KJ, 2016, CURR OPIN IMMUNOL, V41, P47, DOI 10.1016/j.coi.2016.05.014; Flaxman A, 2021, LANCET, V398, P981, DOI 10.1016/S0140-6736(21)01699-8; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Frantz PN, 2018, MICROBES INFECT, V20, P493, DOI 10.1016/j.micinf.2018.01.005; Garcia-Arriaza J, 2021, J VIROL, V95, DOI 10.1128/JVI.02260-20; Garcia-Arriaza J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066894; GARCIASASTRE A, 1995, BIOLOGICALS, V23, P171, DOI 10.1006/biol.1995.0028; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Gilbert S., 2020, NEW SCI, V247, P8, DOI [10.1016/S0262-4079(20)31303-8, DOI 10.1016/S0262-4079(20)31303-8]; Gushchin VA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070779; He J, 2021, J MED VIROL, V93, P1923, DOI 10.1002/jmv.26769; Humphreys IR, 2018, IMMUNOLOGY, V153, P1, DOI 10.1111/imm.12829; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jackson LA, 2017, VACCINE, V35, P1675, DOI 10.1016/j.vaccine.2017.02.032; Johnson & Johnson Johnson & Johnson, JOHNS JOHNS COVID 19; Kiesslich S, 2020, BIOTECHNOL ADV, V44, DOI 10.1016/j.biotechadv.2020.107608; Ko EJ, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010024; Ku MW, 2021, CELL HOST MICROBE, V29, P236, DOI 10.1016/j.chom.2020.12.010; Ledford H, 2021, NATURE, V592, P495, DOI 10.1038/d41586-021-00998-w; Ledford H, 2021, NATURE, V592, P334, DOI 10.1038/d41586-021-00940-0; Ledford H, 2021, NATURE, V590, P375, DOI 10.1038/d41586-021-00315-5; Loes AN, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12090987; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lu MJ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026153118; Lundstrom K, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111324; Malczyk AH, 2015, J VIROL, V89, P11654, DOI 10.1128/JVI.01815-15; Matchett WE, 2021, J IMMUNOL, V207, P376, DOI [10.4049/jimmunol.2100421, 10.1101/2021.04.26.441518]; Mayr A, 2003, COMP IMMUNOL MICROB, V26, P423, DOI 10.1016/S0147-9571(03)00025-0; Morenweiser R, 2005, GENE THER, V12, pS103, DOI 10.1038/sj.gt.3302624; Mosaheb MM, 2020, CURR OPIN VIROL, V44, P73, DOI 10.1016/j.coviro.2020.07.012; Nogrady B, 2021, NATURE, V595, P339, DOI 10.1038/d41586-021-01813-2; Osada T, 2009, CANCER GENE THER, V16, P673, DOI 10.1038/cgt.2009.17; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pardi N, 2020, NAT BIOMED ENG, V4, P1128, DOI 10.1038/s41551-020-00658-w; Pettini E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030289; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Pollard AJ, 2021, LANCET INFECT DIS, V21, P493, DOI 10.1016/S1473-3099(20)30476-X; Quinan BR, 2014, FUTURE VIROL, V9, P173, DOI 10.2217/fvl.13.129; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Robert-Guroff M, 2007, CURR OPIN BIOTECH, V18, P546, DOI 10.1016/j.copbio.2007.10.010; Rollier CS, 2011, CURR OPIN IMMUNOL, V23, P377, DOI 10.1016/j.coi.2011.03.006; Rossi AH, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100359; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Sasso E, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101430; Saxena M, 2013, MICROBIOL-SGM, V159, P1, DOI 10.1099/mic.0.049601-0; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Sun W., 2021, NEWCASTLE DIS VIRUS, DOI [10.1101/2021.07.06.451301v1, DOI 10.1101/2021.07.06.451301V1]; Tan WG, 2013, J VIROL, V87, P1359, DOI 10.1128/JVI.02055-12; Thiele F, 2015, J VIROL, V89, P2698, DOI 10.1128/JVI.03244-14; Tscherne A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026207118; U.S. National Institutes of Health, OFF TITL SYNTH MVA B; U.S. National Institutes of Health, OFF TITL SAF TOL IMM; U.S. National Institutes of Health, OFF TITL PHAS 1 INTR; U.S. National Institutes of Health, OFF TITL PHAS 2 CLIN; U.S. National Institutes of Health, OFF TITL SAF IMM INT; U.S. National Institutes of Health, OFF TITL ASS SAF IMM; U.S. National Institutes of Health, OFF TITL IMM SAF COV; U.S. National Institutes of Health, OFF TITL OP STUD SAF; U.S. National Institutes of Health, OFF TITL STUD AD26 C; U.S. National Institutes of Health, OFF TITL CLIN TRIAL; U.S. National Institutes of Health, OFF TITL PHAS 3 DOUB; U.S. National Institutes of Health, OFF TITL STUD LIV RN; U.S. National Institutes of Health, OFF TITL PHAS 3 TRIA; U.S. National Institutes of Health, OFF TITL SAF TOL IMM; U.S. National Institutes of Health, OFF TITL EV SAF IMM; U.S. National Institutes of Health, OFF TITL STUD EV SA; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y; van Doremalen N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8399; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Verardi PH, 2012, HUM VACC IMMUNOTHER, V8, P961, DOI 10.4161/hv.21080; Verdier F, 2002, TOXICOLOGY, V174, P37, DOI 10.1016/S0300-483X(02)00055-0; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wacheck V, 2010, J INFECT DIS, V201, P354, DOI 10.1086/649428; Wang P, 2019, MBIO, V10, DOI 10.1128/mBio.02180-19; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Yahalom-Ronen Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20228-7; Zavala F, 2001, VIROLOGY, V280, P155, DOI 10.1006/viro.2000.0792; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	104	2	2	10	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1101	10.3390/vaccines9101101			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN4BH	34696209	Green Published, gold			2022-04-29	WOS:000711714700001
J	Showalter, LE; Czerniecki, BJ; Kodumudi, K; Koski, GK				Showalter, Loral E.; Czerniecki, Brian J.; Kodumudi, Krithika; Koski, Gary K.			Murine Dendritic Cells Grown in Serum-Free Culture Show Potent Therapeutic Activity when Loaded with Novel Th Epitopes in an Orthotopic Model of HER2(pos) Breast Cancer	VACCINES			English	Article						dendritic cell; vaccine; peptide; epitope; breast cancer; ErbB2/HER2	FETAL CALF SERUM; BONE-MARROW; GENERATION; PEPTIDE; HER-2/NEU; ANTIGEN; DIFFERENTIATION; VACCINATION; MONOCYTES; INDUCE	Preferred methods for generating mouse dendritic cells (DC) would encompass qualities of consistency, high yield, and potent function. Serum-free culture is also highly desirable, since this is the standard for cell-based therapies used in humans. We report here a serum-free modification of a culture method generating mature, activated DCs from bone marrow precursors. This is achieved through a two-stage culture comprised of 6-day expansion in Flt3 ligand and IL-6 followed by brief differentiation in a medium containing GM-CSF and IL-4, with subsequent activation using TLR ligands ODN1826 and LPS. The serum-free DCs achieve yields and surface phenotype including IL-12p70 secretion similar to standard serum-replete cultures, display a capacity to sensitize in vivo against both MHC class I- and Class II-restricted antigens, and exhibit some aspects of "killer DC" function against tumor cells. We used these DCs to help identify novel CD4(pos) Th epitopes on the rat ErbB2/HER-2 protein and demonstrated a subset of these as effective immunogens in a DC-based therapeutic model of HER-2(pos) breast cancer in Balb/c mice, where they induced powerful Th1-polarized immune responses. This method represents a useful way to efficiently produce large numbers of murine dendritic cells with excellent in vivo function well-suited for use in experimental vaccine studies.	[Showalter, Loral E.; Koski, Gary K.] Kent State Univ, Sch Biomed Sci, Dept Biol Sci, Kent, OH 44242 USA; [Czerniecki, Brian J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Breast Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Kodumudi, Krithika] H Lee Moffitt Canc Ctr & Res Inst, Clin Sci Lab Dept, 12902 Magnolia Dr, Tampa, FL 33612 USA		Koski, GK (通讯作者)，Kent State Univ, Sch Biomed Sci, Dept Biol Sci, Kent, OH 44242 USA.	lshowal1@kent.edu; Brian.Czerniecki@moffitt.org; krithika.kodumudi@moffitt.org; dendritic_cell@hotmail.com			US Department of DefenseUnited States Department of Defense [W81XH-16-110385]; Pennies in Action foundation; Gertrude Henle Charitable Trust	This research was funded by the US Department of Defense, (http://cdmrp.army.mil/; Grant number W81XH-16-110385) and by support from Pennies in Action foundation and theWerner and Gertrude Henle Charitable Trust.	BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0; Cohen PA, 2008, BLOOD, V112, P1832, DOI 10.1182/blood-2007-12-130138; Czerniecki BJ, 1997, J IMMUNOL, V159, P3823; Czerniecki BJ, 2007, CANCER RES, V67, P1842, DOI 10.1158/0008-5472.CAN-06-4038; Dauer M, 2003, J IMMUNOL, V170, P4069, DOI 10.4049/jimmunol.170.8.4069; Disis ML, 1999, CLIN CANCER RES, V5, P1289; Ghimirey N, 2021, INT J BREAST CANCER, V2021, DOI 10.1155/2021/8818393; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Jonuleit H, 2000, ARCH DERMATOL RES, V292, P325, DOI 10.1007/s004030000144; Kadri N, 2007, IMMUNOL LETT, V108, P129, DOI 10.1016/j.imlet.2006.11.007; Kaisho T, 2003, CURR MOL MED, V3, P759, DOI 10.2174/1566524033479366; Kim SJ, 2007, J IMMUNOL METHODS, V323, P101, DOI 10.1016/j.jim.2007.03.005; Koski GK, 2001, EUR J IMMUNOL, V31, P3773, DOI 10.1002/1521-4141(200112)31:12<3773::AID-IMMU3773>3.0.CO;2-W; Larmonier N, 2010, CANCER IMMUNOL IMMUN, V59, P1, DOI 10.1007/s00262-009-0736-1; Lowenfeld L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1207032; Lowenfeld L, 2017, CLIN CANCER RES, V23, P2961, DOI 10.1158/1078-0432.CCR-16-1924; LU L, 1995, IMMUNOLOGY, V84, P127; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mackensen A, 2000, CANCER IMMUNOL IMMUN, V49, P152, DOI 10.1007/s002620050614; Menges M, 2005, J LEUKOCYTE BIOL, V77, P535, DOI 10.1189/jlb.0804473; Nava-Parada P, 2007, CANCER RES, V67, P1326, DOI 10.1158/0008-5472.CAN-06-3290; Nicolas A, 2007, J IMMUNOL, V179, P812, DOI 10.4049/jimmunol.179.2.812; Ostler T, 2002, J IMMUNOL METHODS, V268, P211, DOI 10.1016/S0022-1759(02)00191-6; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; Sadeghzadeh M, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117580; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Saxena M, 2018, TRENDS CANCER, V4, P119, DOI 10.1016/j.trecan.2017.12.007; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.iy.11.040193.003501; Sharma A, 2012, CANCER-AM CANCER SOC, V118, P4354, DOI 10.1002/cncr.26734; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; Showalter Loral, 2020, Oncotarget, V11, P2873, DOI 10.18632/oncotarget.27556; Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Toldbod HE, 2003, SCAND J IMMUNOL, V58, P43, DOI 10.1046/j.1365-3083.2003.01267.x; Warncke M, 2006, J IMMUNOL METHODS, V310, P1, DOI 10.1016/j.jim.2005.09.012; WEIGLE WO, 1962, J IMMUNOL, V88, P121; Wesa AK, 2008, CELL DEATH DIFFER, V15, P51, DOI 10.1038/sj.cdd.4402243	42	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1037	10.3390/vaccines9091037			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3WG	34579275	gold, Green Published			2022-04-29	WOS:000702138300001
J	Aw, J; Seng, JJB; Seah, SSY; Low, LL				Aw, Junjie; Seng, Jun Jie Benjamin; Seah, Sharna Si Ying; Low, Lian Leng			COVID-19 Vaccine Hesitancy-A Scoping Review of Literature in High-Income Countries	VACCINES			English	Review						scoping review; coronavirus disease-19 (COVID-19); COVID-19 pandemic; SARS-CoV-2 infection; 2019 novel coronavirus disease; vaccines; COVID-19 vaccines; vaccine hesitancy; vaccine acceptance	UNITED-STATES; WILLINGNESS; INTENTION; ACCEPTABILITY; INFLUENZA; ATTITUDES; ACCEPTANCE; SARS-COV-2; SEPTEMBER; CHILDREN	Vaccine hesitancy forms a critical barrier to the uptake of COVID-19 vaccine in high-income countries or regions. This review aims to summarize rates of COVID-19 hesitancy and its determinants in high-income countries or regions. A scoping review was conducted in Medline(R), Embase(R), CINAHL(R), and Scopus(R) and was reported in accordance with the PRISMA-SCr checklist. The search was current as of March 2021. Studies which evaluated COVID-19 vaccine hesitancy and its determinants in high-income countries (US$12,536 or more GNI per capita in 2019) were included. Studies conducted in low, lower-middle, and upper-middle income countries or regions were excluded. Factors associated with vaccine hesitancy were grouped into four themes (vaccine specific, individual, group, or contextual related factors). Of 2237 articles retrieved, 97 articles were included in this review. Most studies were conducted in U.S. (n = 39) and Italy (n = 9). The rates of vaccine hesitancy across high-income countries or regions ranged from 7-77.9%. 46 studies (47.4%) had rates of 30% and more. Younger age, females, not being of white ethnicity and lower education were common contextual factors associated with increased vaccine hesitancy. Lack of recent history of influenza vaccination, lower self-perceived risk of contracting COVID-19, lesser fear of COVID-19, believing that COVID-19 is not severe and not having chronic medical conditions were most frequently studied individual/group factors associated with increased vaccine hesitancy. Common vaccine-specific factors associated with increased vaccine hesitancy included beliefs that vaccine are not safe/effective and increased concerns about rapid development of COVID-19 vaccines. Given the heterogeneity in vaccine hesitancy definitions used across studies, there is a need for standardization in its assessment. This review has summarized COVID-19 vaccine hesitancy determinants that national policymakers can use when formulating health policies related to COVID-19 vaccination.	[Aw, Junjie; Seah, Sharna Si Ying; Low, Lian Leng] SingHlth Community Hosp, Outram Community Hosp, 10 Hosp Blvd, Singapore 168582, Singapore; [Seng, Jun Jie Benjamin; Low, Lian Leng] MOH Holdings Pte Ltd, 1 Maritime Sq, Singapore 099253, Singapore; [Low, Lian Leng] Singapore Gen Hosp, Dept Family Med & Continuing Care, Outram Rd, Singapore 169608, Singapore; [Low, Lian Leng] SingHlth Duke NUS Family Med Acad Clin Program, Outram Rd, Singapore 169608, Singapore; [Low, Lian Leng] Singapore Hlth Serv, SingHlth Reg Hlth Syst PULSES Ctr, Outram Rd, Singapore 169608, Singapore		Aw, J (通讯作者)，SingHlth Community Hosp, Outram Community Hosp, 10 Hosp Blvd, Singapore 168582, Singapore.	aw.junjie@singhealth.com.sg; benjamin.seng@u.duke.nus.edu; sharna.seah.s.y@singhealthch.com.sg; low.lian.leng@singhealth.com.sg	Seng, Jun Jie Benjamin/L-9282-2019	Seng, Jun Jie Benjamin/0000-0002-3039-3816; Aw, Junjie/0000-0002-9169-1702			Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alabdulla M, 2021, INFLUENZA OTHER RESP, V15, P361, DOI 10.1111/irv.12847; AlHajri B, 2021, J PEDIATR-US, V231, P298, DOI 10.1016/j.jpeds.2020.11.059; Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; Amin DP, 2021, AM J EMERG MED, V48, P372, DOI 10.1016/j.ajem.2021.01.089; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], WHO COR DIS COVID 19; [Anonymous], 2020, KFF UNDEFEATED SURVE; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Attwell K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245907; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Barriere J, 2021, ANN ONCOL, V32, P673, DOI 10.1016/j.annonc.2021.01.066; Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Beesley RP, 2021, RHEUMATOLOGY, V60, P3474, DOI 10.1093/rheumatology/keab169; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Benham JL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246941; Bhopal S, 2021, ARCH DIS CHILD, V106, P113, DOI 10.1136/archdischild-2020-318988; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Bokemper SE, 2021, VACCINE, V39, P825, DOI 10.1016/j.vaccine.2020.12.048; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Boulton ML, 2018, INT J INFECT DIS, V69, P35, DOI 10.1016/j.ijid.2018.01.035; Caban-Martinez AJ, 2021, J OCCUP ENVIRON MED, V63, P369, DOI 10.1097/JOM.0000000000002152; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Campochiaro C, 2021, ANN RHEUM DIS, V80, P816, DOI 10.1136/annrheumdis-2020-219811; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Chu HR, 2021, PATIENT EDUC COUNS, V104, P1878, DOI 10.1016/j.pec.2021.02.031; Crocker-Buque T, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4473-7; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dror AA, 2021, EUR J EPIDEMIOL, V36, P709, DOI 10.1007/s10654-021-00758-0; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Editorial A.B., WHY MILLENNIALS GEN; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Ehde DM, 2021, MULT SCLER RELAT DIS, V49, DOI 10.1016/j.msard.2021.102788; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Faasse K, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.551004; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gandhi P., 2021, WHAT CONTRIBUTES COV; Goldman RD, 2020, CLIN THER, V42, P2124, DOI 10.1016/j.clinthera.2020.09.012; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Gruner S, 2021, APPL ECON LETT, V28, P1847, DOI 10.1080/13504851.2020.1854445; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Hiscott J, 2020, CYTOKINE GROWTH F R, V53, P1, DOI 10.1016/j.cytogfr.2020.05.010; Hoke AM, 2021, J SCH NURS, V37, P292, DOI 10.1177/1059840521992054; Hughes S, 2021, PERS INDIV DIFFER, V171, DOI 10.1016/j.paid.2020.110559; Hursh SR, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.608852; International Labor Organization, ALM 25 MILL JOBS COU; Jeffs E, 2021, J PAEDIATR CHILD H, V57, P403, DOI 10.1111/jpc.15234; Jung H, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2007538118; Karlsson LC, 2021, PERS INDIV DIFFER, V172, DOI 10.1016/j.paid.2020.110590; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Klein JK, 2021, J ADOLESCENT HEALTH, V68, pS6; Kociolek LK, 2021, INFECT CONT HOSP EP, V42, P775, DOI [10.1017/ice.2021.58, 10.1017/ice.2021.415]; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kuter BJ, 2021, VACCINE, V39, P1693, DOI 10.1016/j.vaccine.2021.02.029; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Largent EA, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.33324; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Malik AA, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100495; Manning ML, 2021, NURS OUTLOOK, V69, P565, DOI 10.1016/j.outlook.2021.01.019; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; McCaffery KJ, 2020, PUBLIC HEALTH RES PR, V30, DOI 10.17061/phrp30342012; McPhedran R, 2021, ECON LETT, V200, DOI 10.1016/j.econlet.2021.109747; Mercadante AR, 2021, RES SOC ADMIN PHARM, V17, P1596, DOI 10.1016/j.sapharm.2020.12.012; Mohan S, 2021, J PERINAT MED, V49, P678, DOI 10.1515/jpm-2021-0069; Morgul E, 2021, INT J SOC PSYCHIATR, V67, P128, DOI 10.1177/0020764020941889; Morley, 2021, ASSESSMENT US HLTH C, DOI [10.1093/cid/ciab054/6118651, DOI 10.1093/CID/CIAB054/6118651]; Motta M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113642; Muqattash R, 2020, DATA BRIEF, V33, DOI 10.1016/j.dib.2020.106446; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; Niankara I., 2020, J OPEN INNOV-TECHNOL, V6, P132, DOI [10.3390/joitmc6040132, DOI 10.3390/JOITMC6040132]; Nkwihoreze H., 2021, CLIN INFECT DIS, pCIAB102, DOI [10.1093/cid/ciab102, DOI 10.1093/CID/CIAB102]; Olagoke AA, 2021, J RELIG HEALTH, V60, P65, DOI 10.1007/s10943-020-01090-9; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Prati G, 2020, HEALTH EDUC RES, V35, P505, DOI 10.1093/her/cyaa043; Priori R, 2021, ANN RHEUM DIS, V80, P893, DOI [10.1136/annrheumdis-2021-eular.2622, 10.1136/annrheumdis-2021-220059]; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Roser, 2021, CORONAVIRUS COVID 19; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243264; Schmelz K, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2016385118; Schoch-Spana M, 2021, VACCINE, V39, P6004, DOI 10.1016/j.vaccine.2020.10.059; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Seale H, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05833-1; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Shore DA, 2003, J HEALTH COMMUN, V8, P13, DOI 10.1080/10810730390224839; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Sprengholz P, 2021, J MED ETHICS, V47, P547, DOI 10.1136/medethics-2020-107122; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Tremblay S, 2021, INT J QUAL METH, V20, DOI 10.1177/16094069211009679; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Underschultz JG, 2021, UNIV TOR MED J, V98, P35; Unroe KT, 2021, J AM GERIATR SOC, V69, P593, DOI 10.1111/jgs.17022; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Webber-Ritchey KJ, 2021, NURS SCI QUART, V34, P13, DOI 10.1177/0894318420965225; Wellcome, WELLC GLOB MON 2018; Williams L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010017; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Wiysonge CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037905; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Bank Blogs, 2019, NEW COUNTR CLASS INC; World Health Organisation, 2014, REP SAGE WORK GROUP; World Tourism Organization, 2020, UNWTO WORLD TOUR BAR, DOI [10.18111/9789284421817, DOI 10.18111/9789284421817]; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Wright KB, 2005, J COMPUT-MEDIAT COMM, V10; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	131	34	34	19	32	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							900	10.3390/vaccines9080900			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UH9UO	34452026	gold, Green Published			2022-04-29	WOS:000690266200001
J	Douxfils, J; Gillot, C; De Gottal, E; Vandervinne, S; Bayart, JL; Dogne, JM; Favresse, J				Douxfils, Jonathan; Gillot, Constant; De Gottal, Emilie; Vandervinne, Stephanie; Bayart, Jean-Louis; Dogne, Jean-Michel; Favresse, Julien			Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature	VACCINES			English	Article						neonates; infant; COVID-19; vaccine; antibodies; pregnancy; immunity	PREGNANT-WOMEN; UNITED-STATES; COVID-19; INFLUENZA; VACCINES; IMMUNIZATION; INFECTION; INFANTS; MOTHERS; SAFETY	This case reports on the successful maternal to fetal transfer of neutralizing antibodies after vaccination with BNT162b2 in a pregnant woman at 25 weeks of gestation. The levels of neutralizing antibodies were approximately 5-fold higher in the umbilical cord than in the maternal blood while the level of total antibodies showed only a 2-fold increase. This suggest that the antibodies that crossed the syncytiotrophoblast cell barrier have specific characteristics that correlate to functional neutralizing capacity. Although pregnant and lactating women have been excluded from clinical trials for several reasons including ethical concerns about fetal exposure, accumulating evidence has now revealed that these vaccines are safe and efficient for both the fetus and the woman. Vaccination against COVID-19 in pregnancy is vital to control disease burden and to decrease morbidity in the ante-, peri- and post-natal periods. Inclusion of pregnant women in research programs for the development of SARS-CoV-2 vaccines should be mandatory to provide this population with the equitable benefits of vaccine research.	[Douxfils, Jonathan] Qualiblood Sa, B-5000 Namur, Belgium; [Douxfils, Jonathan; Gillot, Constant; Dogne, Jean-Michel; Favresse, Julien] Univ Namur, Namur Res Inst Life Sci, Dept Pharm, Namur Thrombosis & Hemostasis Ctr,Fac Med, B-5000 Namur, Belgium; [De Gottal, Emilie] Ctr Hosp Reg Huy, Dept Gynecol, B-4500 Liege, Belgium; [Vandervinne, Stephanie] Ctr Hosp Reg Huy, Lab Biol Clin, B-4500 Liege, Belgium; [Bayart, Jean-Louis] Clin St Pierre Ottignies, Dept Lab Med, B-1340 Ottignies, Belgium; [Favresse, Julien] Clin St Luc Bouge, Dept Lab Med, B-5004 Namur, Belgium		Douxfils, J (通讯作者)，Qualiblood Sa, B-5000 Namur, Belgium.; Douxfils, J (通讯作者)，Univ Namur, Namur Res Inst Life Sci, Dept Pharm, Namur Thrombosis & Hemostasis Ctr,Fac Med, B-5000 Namur, Belgium.	jonathan.douxfils@unamur.be; constant.gillot@unamur.be; emilie.degottal@gmail.com; stevdv25@gmail.com; jean-louis.bayart@cspo.be; jean-michel.dogne@unamur.be; j.favresse@labstluc.be	Douxfils, Jonathan/C-8483-2014	Douxfils, Jonathan/0000-0002-7644-5298; Gillot, Constant/0000-0002-4151-9760			Atyeo Caroline, 2021, bioRxiv, DOI 10.1101/2021.04.04.438404; Atyeo C, 2021, CELL, V184, P628, DOI 10.1016/j.cell.2020.12.027; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bayart JL, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9061340; BEHARIER O, 2021, J CLIN INVEST, V131, DOI [DOI 10.1172/JCI150319, 10.1172/JCI150319]; Chakraborty S, 2021, NAT IMMUNOL, V22, P67, DOI [10.1038/s41590-020-00828-7, 10.1101/2020.05.15.20103341]; Craig AM, 2021, AM J OBST GYNEC MFM, V3, DOI 10.1016/j.ajogmf.2020.100295; Donders GGG, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132902; Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702; Ellington S, 2020, MMWR-MORBID MORTAL W, V69, P769, DOI [10.15585/mmwr.mm6925a1, 10.15585/mmwr.mm6925a1externalicon]; Estes ML, 2016, SCIENCE, V353, P772, DOI 10.1126/science.aag3194; Favresse J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071364; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Favresse J, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.05.004; Favresse J, 2020, CLIN CHEM, V66, P1104, DOI 10.1093/clinchem/hvaa131; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; Gerretsen HE, 2017, J INFECTION, V74, pS143, DOI 10.1016/S0163-4453(17)30205-0; Gill L, 2021, OBSTET GYNECOL, V137, P894, DOI 10.1097/AOG.0000000000004367; Gray Kathryn J, 2021, medRxiv, DOI 10.1101/2021.03.07.21253094; Gurol-Urganci I, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.05.016; Jennewein MF, 2019, CELL, V178, P202, DOI 10.1016/j.cell.2019.05.044; Kim L, 2020, MMWR-MORBID MORTAL W, V69, P1081, DOI 10.15585/mmwr.mm6932e3; Levy AT, 2021, AM J OBST GYNEC MFM, V3, DOI 10.1016/j.ajogmf.2021.100399; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Martinez DR, 2019, CELL, V178, P190, DOI 10.1016/j.cell.2019.05.046; Maykin MM, 2021, VACCINE, V39, P171, DOI 10.1016/j.vaccine.2020.12.007; Mithal LB, 2021, AM J OBSTET GYNECOL, V225, P192, DOI 10.1016/j.ajog.2021.03.035; Mithal LB, 2020, J PEDIATR-US, V224, P150, DOI 10.1016/j.jpeds.2020.06.047; Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633; Ory S, 2021, HUM REPROD OPEN, V2021, DOI 10.1093/hropen/hoab016; Peretz SB, 2021, ULTRASOUND OBST GYN, V58, P450, DOI 10.1002/uog.23729; Pettirosso E, 2020, AUST NZ J OBSTET GYN, V60, P640, DOI 10.1111/ajo.13204; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prochaska E, 2020, AM J REPROD IMMUNOL, V84, DOI 10.1111/aji.13306; Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068; Razzaghi H, 2020, MMWR-MORBID MORTAL W, V69, P1391, DOI 10.15585/mmwr.mm6939a2; Richtmann R., 2020, CASE REP WOMENS HLTH, V27, DOI [10.1016/j.crwh.2020.e00243, DOI 10.1016/J.CRWH.2020.E00243]; Riley LE, 2021, NEW ENGL J MED, V384, P2342, DOI 10.1056/NEJMe2107070; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194; Society for Maternal-Fetal Medicine, SOC MAT FET MED SMFM; Toner LE, 2020, AM J PERINAT, V37, P1280, DOI 10.1055/s-0040-1715643; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang TT, 2015, CELL, V162, P160, DOI 10.1016/j.cell.2015.06.026; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630; Zambrano LD, 2020, MMWR-MORBID MORTAL W, V69, P1641, DOI 10.15585/mmwr.mm6944e3; Zdanowski W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060675; Zeng H, 2020, JAMA-J AM MED ASSOC, V323, P1848, DOI 10.1001/jama.2020.4861; Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P469, DOI 10.1097/INF.0000000000002700	50	4	4	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							907	10.3390/vaccines9080907			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5OY	34452032	gold, Green Published			2022-04-29	WOS:000689981200001
J	Hineno, A; Ikeda, SI				Hineno, Akiyo; Ikeda, Shu-Ichi			A Long-Term Observation on the Possible Adverse Effects in Japanese Adolescent Girls after Human Papillomavirus Vaccination	VACCINES			English	Article						human papillomavirus vaccination; adverse effects; orthostatic dysregulation; chronic regional pain syndrome; cognitive dysfunction	POSTURAL TACHYCARDIA SYNDROME; REGIONAL PAIN SYNDROME; CHRONIC-FATIGUE; ORTHOSTATIC INTOLERANCE; HPV VACCINATION; DYSFUNCTION; ANTIBODIES; AUTOANTIBODIES; DYSAUTONOMIA; AUTOIMMUNITY	In Japan, a significant number of adolescent females noted unusual symptoms after receiving the human papillomavirus (HPV) vaccination, of which the vast majority of them were initially diagnosed with psychiatric illnesses because of the absence of pathologic radiological images and specific abnormalities in laboratory test results. Later these symptoms were thought to be adverse effects of HPV vaccination. However, a causal link between HPV vaccination and the development of these symptoms has not been demonstrated. Between June 2013 and March 2021, we examined 200 patients who noted various symptoms after HPV vaccination. In total, 87 were diagnosed with HPV vaccination-related symptoms based on our proposed diagnostic criteria. The clinical histories of these 87 patients were analyzed. The age at initial vaccination ranged from 11 to 19 years old (mean +/- SD: 13.5 +/- 1.5 years old), and the age at the first appearance of symptoms ranged from 12 to 20 years old (mean +/- SD: 14.3 +/- 1.6 years old). The patients received an initial HPV vaccine injection between May 2010 and May 2013, but the first affected patient developed symptoms in October 2010, and the last affected developed symptoms in October 2015. A cluster of patients with a post-HPV vaccination disorder has not appeared in Japan during the last five years. Our study shows that, in Japan, the period of HPV vaccination considerably overlapped with that of a unique post-HPV vaccination disorder development. This disorder appears as a combination of orthostatic intolerance, chronic regional pain syndrome, and cognitive dysfunction, but its exact pathogenesis remains unclear.	[Hineno, Akiyo; Ikeda, Shu-Ichi] Shinshu Univ Hosp, Intractable Dis Care Ctr, Matsumoto, Nagano 3900802, Japan; [Hineno, Akiyo] Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, Matsumoto, Nagano 3908621, Japan; [Ikeda, Shu-Ichi] Ikeda Med & Neurol Clin, Azumino 3998205, Japan		Ikeda, SI (通讯作者)，Shinshu Univ Hosp, Intractable Dis Care Ctr, Matsumoto, Nagano 3900802, Japan.; Ikeda, SI (通讯作者)，Ikeda Med & Neurol Clin, Azumino 3998205, Japan.	hineno@shinshu-u.ac.jp; shu-ichi@ikeda-mnc.jp			Health and Labour Science Research Grant on Emerging and Re-emerging Infectious Diseases from the Ministry of Public Health, Labour and Welfare, Japan [19HA1006]	This work was supported by the grant from a Health and Labour Science Research Grant on Emerging and Re-emerging Infectious Diseases (Establishment of Diagnosis and Treatment System on Symptoms after HPV vaccination, grant number 19HA1006) to S.-I.I. from the Ministry of Public Health, Labour and Welfare, Japan.	Blitshteyn S, 2014, EUR J NEUROL, V21, P135, DOI 10.1111/ene.12272; Blitshteyn S, 2018, IMMUNOL RES, V66, P744, DOI 10.1007/s12026-018-9036-1; Blitshteyn S, 2017, IMMUNOL RES, V65, P282, DOI 10.1007/s12026-016-8855-1; Brinth L, 2015, DAN MED J, V62; Brinth LS, 2015, VACCINE, V33, P2602, DOI 10.1016/j.vaccine.2015.03.098; Cervantes JL, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760180063; Chambuso RS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00548; Chandler RE, 2017, DRUG SAFETY, V40, P1167, DOI 10.1007/s40264-017-0593-3; Dubuis E, 2014, PAIN, V155, P2408, DOI 10.1016/j.pain.2014.09.022; Halicka M, 2020, BEHAV NEUROL, V2020, DOI 10.1155/2020/4561831; Hendrickson JE, 2016, VACCINE, V34, P4468, DOI 10.1016/j.vaccine.2016.05.029; Hendrickson JE, 2016, J CLIN APHERESIS, V31, P368, DOI 10.1002/jca.21407; Hineno A, 2019, ANN ARTHRITIS CLIN R, V2, P1014; Hirai T., 2016, AUTON NERV SYST, V53, P49, DOI [10.1016/j.autneu.2016.09.011, DOI 10.1016/J.AUTNEU.2016.09.011]; Hviid A, 2018, J INTERN MED, V283, P154, DOI 10.1111/joim.12694; Jeurissen S, 2009, INT J GYNECOL CANCER, V19, P761, DOI 10.1111/IGC.0b013e3181a130c0; Karas B, 2000, PACE, V23, P344, DOI 10.1111/j.1540-8159.2000.tb06760.x; Kinoshita T, 2014, INTERNAL MED, V53, P2185, DOI 10.2169/internalmedicine.53.3133; Kohr D, 2011, PAIN, V152, P2690, DOI 10.1016/j.pain.2011.06.012; Larson H, 2015, NATURE, V528, P9, DOI 10.1038/528009a; Loebel M, 2016, BRAIN BEHAV IMMUN, V52, P32, DOI 10.1016/j.bbi.2015.09.013; Martinez P, MOTOR SENSORY CLIN F; Martinez-Lavin M, 2017, CLIN RHEUMATOL, V36, P2169, DOI 10.1007/s10067-017-3768-5; Martinez-Lavin M, 2014, JCR-J CLIN RHEUMATOL, V20, P392, DOI 10.1097/RHU.0000000000000165; Matsudaira T, 2016, NEUROL CLIN NEUROSCI, V4, P220, DOI 10.1111/ncn3.12083; Meyer C, 2018, FRONT BIOSCI-LANDMRK, V23, P2177, DOI 10.2741/4698; Ocon AJ, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00063; Ozawa K, 2017, DRUG SAFETY, V40, P1219, DOI 10.1007/s40264-017-0574-6; Palmieri B, 2017, IMMUNOL RES, V65, P106, DOI 10.1007/s12026-016-8820-z; Phillips A, 2020, VACCINE, V38, P6038, DOI 10.1016/j.vaccine.2020.06.039; Phillips A, 2018, DRUG SAFETY, V41, P329, DOI 10.1007/s40264-017-0625-z; Ruzieh M, 2017, SCAND CARDIOVASC J, V51, P243, DOI 10.1080/14017431.2017.1355068; Schofield JR, 2018, CLIN PEDIATR, V57, P603, DOI 10.1177/0009922817728701; Simms KT, 2020, LANCET PUBLIC HEALTH, V5, pE223, DOI 10.1016/S2468-2667(20)30010-4; Stewart JM, 2000, PEDIATR RES, V48, P218, DOI 10.1203/00006450-200008000-00016; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wick G, ALLOWING OPEN DISCUS; Yu XC, 2012, J AM SOC HYPERTENS, V6, P40, DOI 10.1016/j.jash.2011.10.003	39	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							856	10.3390/vaccines9080856			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6TZ	34451981	Green Published, gold			2022-04-29	WOS:000690061900001
J	Osterloh, A				Osterloh, Anke			Vaccine Design and Vaccination Strategies against Rickettsiae	VACCINES			English	Review						rickettsiae; orientia; immunity; vaccination	MOUNTAIN-SPOTTED-FEVER; SCRUB TYPHUS IMMUNOGENS; MEMBRANE PROTEIN ANTIGEN; CENTRAL-NERVOUS-SYSTEM; ORIENTIA-TSUTSUGAMUSHI; PROTECTIVE IMMUNITY; MURINE TYPHUS; EPIDEMIC TYPHUS; MONOCLONAL-ANTIBODIES; GAMMA-INTERFERON	Rickettsioses are febrile, potentially lethal infectious diseases that are a serious health threat, especially in poor income countries. The causative agents are small obligate intracellular bacteria, rickettsiae. Rickettsial infections are emerging worldwide with increasing incidence and geographic distribution. Nonetheless, these infections are clearly underdiagnosed because methods of diagnosis are still limited and often not available. Another problem is that the bacteria respond to only a few antibiotics, so delayed or wrong antibiotic treatment often leads to a more severe outcome of the disease. In addition to that, the development of antibiotic resistance is a serious threat because alternative antibiotics are missing. For these reasons, prophylactic vaccines against rickettsiae are urgently needed. In the past years, knowledge about protective immunity against rickettsiae and immunogenic determinants has been increasing and provides a basis for vaccine development against these bacterial pathogens. This review provides an overview of experimental vaccination approaches against rickettsial infections and perspectives on vaccination strategies.	[Osterloh, Anke] Res Ctr Borstel, Parkallee 22, D-23845 Borstel, Germany		Osterloh, A (通讯作者)，Res Ctr Borstel, Parkallee 22, D-23845 Borstel, Germany.	aosterloh@fz-borstel.de	Osterloh, Anke/ABA-8626-2021		German Research Foundation (Deutsche Forschungsgemeinschaft DFG)German Research Foundation (DFG) [OS583/1-1]	The author is funded by the German Research Foundation (Deutsche Forschungsgemeinschaft DFG; No OS583/1-1).	Abarca K, 2020, EMERG INFECT DIS, V26, P2148, DOI 10.3201/eid2609.200918; Abdad MY, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/jcm.01728-17, 10.1128/JCM.01728-17]; Acuna-Soto R, 2000, T ROY SOC TROP MED H, V94, P45, DOI 10.1016/S0035-9203(00)90432-2; Adjemian J, 2010, EMERG INFECT DIS, V16, P412, DOI 10.3201/eid1603.091028; Alhassan A, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00628-18; Anacker R.L., 1981, RICKETTSIAE RICKETTS, P71; ANACKER RL, 1985, J INFECT DIS, V151, P1052, DOI 10.1093/infdis/151.6.1052; ANACKER RL, 1987, INFECT IMMUN, V55, P825, DOI 10.1128/IAI.55.3.825-827.1987; Andre E, 1998, Acta Med Port, V11, P81; Armenteros JJA, 2019, NAT BIOTECHNOL, V37, P420, DOI 10.1038/s41587-019-0036-z; Bacellar F, 1998, Euro Surveill, V3, P18; Badiaga S, 2012, COMP IMMUNOL MICROB, V35, P39, DOI 10.1016/j.cimid.2011.09.008; BAILEY CA, 1948, J IMMUNOL, V60, P431; Bendtsen JD, 2004, PROTEIN ENG DES SEL, V17, P349, DOI 10.1093/protein/gzh037; BERGE TO, 1949, AM J HYG, V50, P337, DOI 10.1093/oxfordjournals.aje.a119366; Bernabeu-Wittel M, 2006, EUR J CLIN MICROBIOL, V25, P375, DOI 10.1007/s10096-006-0147-6; Bise G, 1997, T ROY SOC TROP MED H, V91, P133, DOI 10.1016/S0035-9203(97)90198-X; BUCKLAND FE, 1945, LANCET, V249, P734; Campbell J., 2009, Morbidity and Mortality Weekly Report, V58, P1267; CARD WI, 1947, LANCET, V252, P481; Caro-Gomez E, 2014, VACCINE, V32, P4968, DOI 10.1016/j.vaccine.2014.06.089; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P1224; Chaliotis G, 2012, INT J INFECT DIS, V16, pE591, DOI 10.1016/j.ijid.2012.03.010; Chan YGY, 2011, INFECT IMMUN, V79, P2303, DOI 10.1128/IAI.01324-10; Chattopadhyay S, 2005, INFECT IMMUN, V73, P5039, DOI 10.1128/IAI.73.8.5039-5047.2005; Chen HW, 2011, CLIN VACCINE IMMUNOL, V18, P1021, DOI 10.1128/CVI.00017-11; Chen NH, 2017, IUBMB LIFE, V69, P297, DOI 10.1002/iub.1625; Chen WJ, 2003, INFECT IMMUN, V71, P4772, DOI 10.1128/IAI.71.8.4772-4779.2003; Ching WM, 1996, INFECT IMMUN, V64, P1413, DOI 10.1128/IAI.64.4.1413-1419.1996; Ching WM, 1993, TECHNIQUES PROTEIN C, P307; Cho JH, 2001, J IMMUNOL, V167, P5549, DOI 10.4049/jimmunol.167.10.5549; Choi S, 2014, J MICROBIOL BIOTECHN, V24, P1728, DOI 10.4014/jmb.1407.07048; Choi Y, 2006, VACCINE, V24, P1438, DOI 10.1016/j.vaccine.2005.07.113; Chung MH, 2012, J KOREAN MED SCI, V27, P231, DOI 10.3346/jkms.2012.27.3.231; CLEMENTS ML, 1983, J INFECT DIS, V148, P922, DOI 10.1093/infdis/148.5.922; Croquet-Valdes PA, 2001, VACCINE, V20, P979; Curto P, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00097; Dhimal M, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05866-6; Diaz-Montero CM, 2001, AM J TROP MED HYG, V65, P371, DOI 10.4269/ajtmh.2001.65.371; Dittrich S, 2015, LANCET GLOB HEALTH, V3, pE104, DOI 10.1016/S2214-109X(14)70289-X; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Drevets DA, 2004, CLIN MICROBIOL REV, V17, P323, DOI 10.1128/CMR.17.2.323-347.2004; Driskell LO, 2009, INFECT IMMUN, V77, P3244, DOI 10.1128/IAI.00395-09; DUMLER JS, 1991, JAMA-J AM MED ASSOC, V266, P1365, DOI 10.1001/jama.266.10.1365; DUPONT HL, 1973, J INFECT DIS, V128, P340, DOI 10.1093/infdis/128.3.340; DUPONT HT, 1995, CLIN INFECT DIS, V21, P1126, DOI 10.1093/clinids/21.5.1126; ECKE RS, 1945, AM J TROP MED, V25, P447; Edwards DK, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-016-1111-6; EISENBERG GHG, 1977, INFECT IMMUN, V15, P124, DOI 10.1128/IAI.15.1.124-131.1977; EISENBERG GHG, 1978, INFECT IMMUN, V22, P80, DOI 10.1128/IAI.22.1.80-86.1978; EISENBERG GHG, 1979, INFECT IMMUN, V26, P131, DOI 10.1128/IAI.26.1.131-136.1979; Espinosa N, 2010, ENFERM INFEC MICR CL, V28, P416, DOI 10.1016/j.eimc.2009.07.014; Feng HM, 1997, J IMMUNOL, V158, P5314; Feng HM, 2004, INFECT IMMUN, V72, P3524, DOI 10.1128/IAI.72.6.3524-3530.2004; Feng HM, 2004, INFECT IMMUN, V72, P2222, DOI 10.1128/IAI.72.4.2222-2228.2004; FENG HM, 1994, INFECT IMMUN, V62, P1952, DOI 10.1128/IAI.62.5.1952-1960.1994; Feng HM, 2000, INFECT IMMUN, V68, P6729, DOI 10.1128/IAI.68.12.6729-6736.2000; Fish AI, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00061; Fournier PE, 2002, CLIN DIAGN LAB IMMUN, V9, P324, DOI 10.1128/CDLI.9.2.324-328.2002; FOX JP, 1957, J IMMUNOL, V79, P348; Gardy JL, 2003, NUCLEIC ACIDS RES, V31, P3613, DOI 10.1093/nar/gkg602; Garza DA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179544; Gazi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076253; Gharaibeh M, 2016, INFECT IMMUN, V84, P3379, DOI 10.1128/IAI.00185-16; GONDER JC, 1979, J CLIN MICROBIOL, V10, P719, DOI 10.1128/JCM.10.5.719-723.1979; Gong WP, 2018, HUM VACC IMMUNOTHER, V14, P1697, DOI 10.1080/21645515.2018.1458806; Gong WP, 2015, HUM VACC IMMUNOTHER, V11, P642, DOI 10.1080/21645515.2015.1011572; Gong WP, 2015, VACCINE, V33, P985, DOI 10.1016/j.vaccine.2015.01.017; Gong WP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100253; Gong WP, 2014, VACCINE, V32, P2027, DOI 10.1016/j.vaccine.2014.02.057; Guan Pingping, 2003, Appl Bioinformatics, V2, P63; Ha NY, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0229-2; Ha NY, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003585; Ha NY, 2012, CLIN VACCINE IMMUNOL, V19, P1442, DOI 10.1128/CVI.00285-12; Hackstadt T, 1996, INFECT AGENT DIS, V5, P127; Harro C, 2009, CLIN VACCINE IMMUNOL, V16, P1285, DOI 10.1128/CVI.00144-09; Hauptmann M, 2016, PLOS NEGLECT TROP D, V10, DOI [10.1371/journal.pntd.0004991, 10.137]; He YQ, 2014, NUCLEIC ACIDS RES, V42, pD1124, DOI 10.1093/nar/gkt1133; HICKMAN CJ, 1991, MICROB PATHOGENESIS, V11, P19, DOI 10.1016/0882-4010(91)90090-W; Hill AVS, 2010, HUM VACCINES, V6, P78, DOI 10.4161/hv.6.1.10116; HOVE MGM, 1995, ARCH PATHOL LAB MED, V119, P429; Imai K, 2008, BIOINFORMATION, V2, P417, DOI 10.6026/97320630002417; Izzard L, 2010, J CLIN MICROBIOL, V48, P4404, DOI 10.1128/JCM.01526-10; Jiao YM, 2005, ANN NY ACAD SCI, V1063, P261, DOI 10.1196/annals.1355.042; Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181; Karla DR, 2017, J VECTOR DIS, V54, P317, DOI 10.4103/0972-9062.225836; Kawamura R, 1940, TROP DIS B, V37, P269; KENYON RH, 1975, J CLIN MICROBIOL, V2, P300; KENYON RH, 1975, J CLIN MICROBIOL, V1, P500, DOI 10.1128/JCM.1.6.500-503.1975; Kheirollahpour Mehdi, 2020, Pharmaceutical Nanotechnology, V8, P6, DOI 10.2174/2211738507666191024162042; Kim HI, 2019, EMERG MICROBES INFEC, V8, P946, DOI 10.1080/22221751.2019.1632676; Kim MJ, 2013, MICROB PATHOGENESIS, V63, P37, DOI 10.1016/j.micpath.2013.06.002; Koliou M, 2007, EUR J CLIN MICROBIOL, V26, P491, DOI 10.1007/s10096-007-0310-8; Koo JE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039042; Kowalczyk A, 2016, VACCINE, V34, P3882, DOI 10.1016/j.vaccine.2016.05.046; Kuloglu F., 2013, DIS MOL MED, V1, P39, DOI [10.5455/dmm.20130704110837, DOI 10.5455/DMM.20130704110837]; Kutzler MA, 2004, J CLIN INVEST, V114, P1241, DOI 10.1172/JCI200423467; LANGE JV, 1984, INFECT IMMUN, V46, P289, DOI 10.1128/IAI.46.2.289-294.1984; Li H, 1998, MICROB PATHOGENESIS, V24, P289, DOI 10.1006/mpat.1997.0197; Li Z, 2003, INFECT IMMUN, V71, P3920, DOI 10.1128/IAI.71.7.3920-3926.2003; Li ZJ, 2020, EMERG INFECT DIS, V26, P1091, DOI 10.3201/eid2606.191168; Lin HH, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-8; Lledo L, 2005, VECTOR-BORNE ZOONOT, V5, P157, DOI 10.1089/vbz.2005.5.157; Lutwick LI, 2001, LANCET, V357, P1198, DOI 10.1016/S0140-6736(00)04339-7; Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551; Mansueto P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/967852; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Maude RR, 2014, AM J TROP MED HYG, V91, P580, DOI 10.4269/ajtmh.13-0570; MAUGH TH, 1978, SCIENCE, V201, P604, DOI 10.1126/science.97783; McCoy K, 2007, J VIROL, V81, P6594, DOI 10.1128/JVI.02497-06; Meng YF, 2015, SCI CHINA LIFE SCI, V58, P287, DOI 10.1007/s11427-014-4720-4; Moderzynski K, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005404; Moderzynski K, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005089; Ni YS, 2005, AM J TROP MED HYG, V73, P936, DOI 10.4269/ajtmh.2005.73.936; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Nielsen M, 2004, BIOINFORMATICS, V20, P1388, DOI 10.1093/bioinformatics/bth100; Nogueras MM, 2006, AM J TROP MED HYG, V74, P123, DOI 10.4269/ajtmh.2006.74.123; Noriea NF, 2015, MBIO, V6, DOI 10.1128/mBio.00323-15; Ogawa M, 2017, MICROB PATHOGENESIS, V107, P335, DOI 10.1016/j.micpath.2017.04.012; Osterloh A, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008704; Osterloh A, 2016, INFECT IMMUN, V84, P1615, DOI 10.1128/IAI.00034-16; Papp S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004935; Park H, 2011, J BIOL CHEM, V286, P35096, DOI 10.1074/jbc.M111.263855; PARKER RT, 1954, J IMMUNOL, V73, P383; Parola P, 2003, EMERG INFECT DIS, V9, P592, DOI 10.3201/eid0905.020511; Peter JV, 2014, J GLOB INFECT DIS, V6, P195, DOI 10.4103/0974-777X.145260; Phongmany S, 2006, EMERG INFECT DIS, V12, P256; Pichla-Gollon SL, 2009, J VIROL, V83, P5567, DOI 10.1128/JVI.00405-09; Psaroulaki A, 2012, T ROY SOC TROP MED H, V106, P489, DOI 10.1016/j.trstmh.2012.02.010; Qi Y, 2013, VACCINE, V31, P5643, DOI 10.1016/j.vaccine.2013.09.064; Qi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070440; Radosevic K, 2007, INFECT IMMUN, V75, P4105, DOI 10.1128/IAI.00004-07; Radulovic S, 2002, INFECT IMMUN, V70, P2576, DOI 10.1128/IAI.70.5.2576-2582.2002; Ramaiah A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196240; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Raoult D, 1997, EMERG INFECT DIS, V3, P357, DOI 10.3201/eid0303.970313; Raoult D, 1998, LANCET, V352, P353, DOI 10.1016/S0140-6736(97)12433-3; Raoult D, 2004, INFECT DIS CLIN N AM, V18, P127, DOI 10.1016/S0891-5520(03)00093-X; Rauch J, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253084; Rauch S, 2017, METHODS MOL BIOL, V1499, P89, DOI 10.1007/978-1-4939-6481-9_5; Reche Pedro A., 2007, V409, P185, DOI 10.1007/978-1-60327-118-9_13; Regan JJ, 2015, CLIN INFECT DIS, V60, P1659, DOI 10.1093/cid/civ116; Renesto P, 2005, FEMS MICROBIOL LETT, V245, P231, DOI 10.1016/j.femsle.2005.03.004; RIGHTS FL, 1948, J EXP MED, V87, P339, DOI 10.1084/jem.87.4.339; Riley SP, 2014, CELL MICROBIOL, V16, P849, DOI 10.1111/cmi.12243; Saade F, 2012, EXPERT REV VACCINES, V11, P189, DOI [10.1586/ERV.11.188, 10.1586/erv.11.188]; Safar HA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228381; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Sahni SK, 2009, FUTURE MICROBIOL, V4, P323, DOI 10.2217/FMB.09.6; Scheel B, 2005, EUR J IMMUNOL, V35, P1557, DOI 10.1002/eji.200425656; Schlessinger A, 2006, NUCLEIC ACIDS RES, V34, pD777, DOI 10.1093/nar/gkj053; Sears KT, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002856; Seong SY, 1997, INFECT IMMUN, V65, P1541, DOI 10.1128/IAI.65.4.1541-1545.1997; Seong SY, 1997, INFECT IMMUN, V65, P5250, DOI 10.1128/IAI.65.12.5250-5256.1997; Seong SY, 1997, VACCINE, V15, P1741, DOI 10.1016/S0264-410X(97)00112-6; SILVERMAN DJ, 1984, J INFECT DIS, V149, P201, DOI 10.1093/infdis/149.2.201; Skinner MA, 1997, INFECT IMMUN, V65, P4525, DOI 10.1128/IAI.65.11.4525-4530.1997; SPENCER R. R., 1925, Public Health Reports, V40, P2159, DOI 10.2307/4577679; SUMNER JW, 1995, VACCINE, V13, P29, DOI 10.1016/0264-410X(95)80007-Z; Suputtamongkol Y, 2009, ANN NY ACAD SCI, V1166, P172, DOI 10.1111/j.1749-6632.2009.04514.x; Tantibhedhyangkul W, 2013, MICROB PATHOGENESIS, V55, P55, DOI 10.1016/j.micpath.2012.10.001; Tantibhedhyangkul W, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001028; Tarasevich I, 1998, LANCET, V352, P1151, DOI 10.1016/S0140-6736(05)79799-3; TEYSSEIRE N, 1992, J CLIN MICROBIOL, V30, P455, DOI 10.1128/JCM.30.2.455-460.1992; TURCO J, 1986, INFECT IMMUN, V53, P38, DOI 10.1128/IAI.53.1.38-46.1986; Veintemillas F, 1939, J IMMUNOL, V36, P339; VISHWANATH S, 1990, INFECT IMMUN, V58, P646, DOI 10.1128/IAI.58.3.646-653.1990; Walker DH, 2009, VACCINE, V27, pD52, DOI 10.1016/j.vaccine.2009.07.045; Walker DH, 2000, LAB INVEST, V80, P1361, DOI 10.1038/labinvest.3780144; Walker DH, 2001, INFECT IMMUN, V69, P1841, DOI 10.1128/IAI.69.3.1841-1846.2001; Wang PC, 2017, VACCINE, V35, P7204, DOI 10.1016/j.vaccine.2017.09.068; WEIGL R, 1947, TEX REP BIOL MED, V5, P177; Weigl R.L., 1930, B INT ACAD POL SCI L, V7, P25; Whitworth T, 2005, INFECT IMMUN, V73, P6668, DOI 10.1128/IAI.73.10.6668-6673.2005; Wisseman C L Jr, 1972, Adv Exp Med Biol, V31, P97; Xiang ZQ, 2006, EMERG INFECT DIS, V12, P1596, DOI 10.3201/eid1210.060078; Xu G, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005763; Yoon HJ, 2010, VECTOR-BORNE ZOONOT, V10, P231, DOI 10.1089/vbz.2008.0149; Yu YF, 2005, AM J TROP MED HYG, V72, P458, DOI 10.4269/ajtmh.2005.72.458; Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479; Zhang Guang Lan, 2006, Immunome Res, V2, P3, DOI 10.1186/1745-7580-2-3; Zhang JZ, 2006, VACCINE, V24, P2317, DOI 10.1016/j.vaccine.2005.11.044; Zhang LJ, 2016, J VET SCI, V17, P505, DOI 10.4142/jvs.2016.17.4.505; ZINSSER HANS, 1931, JOUR EXP MED, V53, P493, DOI 10.1084/jem.53.4.493	184	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							896	10.3390/vaccines9080896			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7SB	34452021	Green Published, gold			2022-04-29	WOS:000690124500001
J	Morales-Nunez, JJ; Munoz-Valle, JF; Meza-Lopez, C; Wang, LF; Sulbaran, ACM; Torres-Hernandez, PC; Bedolla-Barajas, M; De la O-Gomez, B; Balcazar-Felix, P; Hernandez-Bello, J				Javier Morales-Nunez, Jose; Francisco Munoz-Valle, Jose; Meza-Lopez, Carlos; Wang, Lin-Fa; Machado Sulbaran, Andrea Carolina; Carolina Torres-Hernandez, Paola; Bedolla-Barajas, Martin; De la O-Gomez, Brenda; Balcazar-Felix, Paulina; Hernandez-Bello, Jorge			Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection	VACCINES			English	Article						COVID-19; BNT162b2; neutralizing antibodies; vaccine side effects		The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the first to be authorized in the USA and Mexico (11 December 2020). This study evaluated the efficacy of this vaccine on antibody production with neutralizing capacity and its side effects in healthcare workers with and without prior SARS-CoV-2 infection and in a group of unvaccinated individuals with prior COVID-19. The main findings are the production of 100% neutralizing antibodies in both groups after the second dose, well-tolerated adverse effects, the possible presence of immunosenescence, and finally, we support that a single dose of this vaccine in individuals with prior COVID-19 would be sufficient to achieve an immunization comparable to people without prior COVID-19 with a complete vaccination program (2 doses).	[Javier Morales-Nunez, Jose; Francisco Munoz-Valle, Jose; Hernandez-Bello, Jorge] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Inst Res Biomed Sci, Guadalajara 44340, Jalisco, Mexico; [Meza-Lopez, Carlos] Univ Guadalajara, Nuevo Hosp Civil Guadalajara Dr Juan I Menchaca, Pediat Serv, Guadalajara 44340, Jalisco, Mexico; [Wang, Lin-Fa] Duke NUS Med Sch, Programmed Emerging Infect Dis, Singapore 169857, Singapore; [Machado Sulbaran, Andrea Carolina] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Inst Res Canc Childhood & Adolescence, Guadalajara 44340, Jalisco, Mexico; [Carolina Torres-Hernandez, Paola; Balcazar-Felix, Paulina] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Immunol Lab, Guadalajara 44340, Jalisco, Mexico; [Bedolla-Barajas, Martin] Univ Guadalajara, Nuevo Hosp Civil Guadalajara Dr Juan I Menchaca, Allergy & Clin Immunol Serv, Guadalajara 44340, Jalisco, Mexico; [De la O-Gomez, Brenda] Univ Guadalajara, Univ Ctr Exact Sci & Engn CUCEI, Guadalajara 44340, Jalisco, Mexico		Munoz-Valle, JF; Hernandez-Bello, J (通讯作者)，Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Inst Res Biomed Sci, Guadalajara 44340, Jalisco, Mexico.	pepejavis_15@hotmail.com; biologiamolecular@hotmail.com; pedmeza70@hotmail.com; linfa.wang@duke-nus.edu.sg; andrecaroms@gmail.com; carolina.torres.h@hotmail.com; drmbedbar@gmail.com; brenda.delao@alumnos.udg.mx; paufe97@gmail.com; jorge89_5@hotmail.com	Torres Hernández, Paola Carolina Carolina Torres/AAX-7383-2021	De la O Gomez, Brenda/0000-0002-3482-4695; Bedolla-Barajas, Martin/0000-0003-4915-1582; Hernandez-Bello, Jorge/0000-0001-8004-1811; Morales Nunez, Jose Javier/0000-0001-5062-0310; Munoz-Valle, Jose Francisco/0000-0002-2272-9260; Machado-Sulbaran, Andrea Carolina/0000-0001-7879-9316; Meza-Lopez, Carlos/0000-0002-8720-4289; Wang, Lin-Fa/0000-0003-2752-0535	Likewise	The authors thank all the contributors to this work. Likewise, the support provided by Gabriela Rosario Molina Cuevas and Maria Patricia Aceves Cuevas in the sampling.	Ali MG, 2020, IMMUNOL RES, V68, P325, DOI 10.1007/s12026-020-09159-z; Bachmann MF, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00264-6; Bereshchenko O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01332; Chia WN, 2021, LANCET MICROBE, V2, pE240, DOI 10.1016/S2666-5247(21)00025-2; Deshpande GR, 2020, INDIAN J MED RES, V152, P82, DOI 10.4103/ijmr.IJMR_2382_20; Dorrington MG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00171; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Ejaz H, 2020, J INFECT PUBLIC HEAL, V13, P1833, DOI 10.1016/j.jiph.2020.07.014; Galipeau Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.610688; Ghaffari A, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10070453; Gobbi F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030422; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Grubeck-Loebenstein B, 2009, AGING CLIN EXP RES, V21, P201, DOI 10.1007/BF03324904; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Khoury DS, 2021, WHAT LEVEL NEUTRALIS, DOI [10.1101/2021.03.09.21252641, DOI 10.1101/2021.03.09.21252641]; Krammer F., 2021, ROBUST SPIKE ANTIBOD, DOI [10.1101/2021.01.29.21250653, DOI 10.1101/2021.01.29.21250653]; Liu X, 2020, THERANOSTICS, V10, P7821, DOI 10.7150/thno.47987; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Manian DV, 2021, ANN ALLERG ASTHMA IM, V126, P206, DOI 10.1016/j.anai.2020.11.009; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Martinez-Liu C, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11010124; Meyer B, 2020, EMERG MICROBES INFEC, V9, P2394, DOI 10.1080/22221751.2020.1835448; Moghadas Seyed M, 2021, medRxiv, DOI [10.1101/2021.01.27.21250619, 10.1371/journal.pbio.3001211]; Patruno C, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109852; Pieper K, 2013, J ALLERGY CLIN IMMUN, V131, P959, DOI 10.1016/j.jaci.2013.01.046; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Redondo-Sendino A, 2020, MED CLIN-BARCELONA, V155, P414, DOI 10.1016/j.medcli.2020.04.057; Riggioni C, 2020, ALLERGY, V75, P2503, DOI 10.1111/all.14449; Sanyaolu Adekunle, 2020, SN Compr Clin Med, V2, P1069, DOI 10.1007/s42399-020-00363-4; Sprent J, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj9256; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Taylor SC, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02438-20; U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 2020, DEV LIC VACC PREV CO, P24; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; Wibawa T, 2021, TROP MED INT HEALTH, V26, P14, DOI 10.1111/tmi.13503	37	16	16	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							742	10.3390/vaccines9070742			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7GV	34358158	gold, Green Published			2022-04-29	WOS:000677076000001
J	Subramanian, R; Liyanapathirana, V; Barua, N; Sun, R; Wang, MH; Ng, R; Nelson, EAS; Hui, DS; Ip, M				Subramanian, Reema; Liyanapathirana, Veranja; Barua, Nilakshi; Sun, Rui; Wang, Maggie Haitian; Ng, Rita; Nelson, Edmund A. S.; Hui, David S.; Ip, Margaret			Persistence of Pneumococcal Serotype 3 in Adult Pneumococcal Disease in Hong Kong	VACCINES			English	Article						pneumococcal disease; pneumonia; adults; risk factors; serotype 3	STREPTOCOCCUS-PNEUMONIAE; VACCINATION; MORTALITY	The epidemiology of hospitalised pneumococcal disease in adults following the introduction of universal childhood pneumococcal immunisation in 2009 was assessed. Culture-confirmed Streptococcus pneumoniae (SP) from adults hospitalised between 2009 to 2017 were examined. The cases were categorised into invasive pneumococcal disease (IPD) and pneumonia (bacteraemic, non-bacteraemic, and that associated with other lung conditions). The isolates were serotyped and antimicrobial susceptibilities were determined by microbroth dilution. Patient characteristics, comorbidities, and outcomes were analysed. Seven hundred and seventy-four patients (mean age, 67.7 years, SD +/- 15.6) were identified, and IPD was diagnosed in 110 (14.2%). The most prevalent serotype, 19F, was replaced by serotype 3 over time. Penicillin and cefotaxime non-susceptibilities were high at 54.1% and 39.5% (meningitis breakpoints), 19.9% and 25.5% (non-meningitis breakpoints), respectively. The overall 30-day mortality rate was 7.8% and 20.4% for IPD. Age >= 75 years (OR:4.6, CI:1.3-17.0, p < 0.02), presence of any complications (OR:4.1, CI:1.02-16.3, p < 0.05), pleural effusion (OR:6.7, CI:1.2-39.4, p < 0.03) and intensive care unit (ICU) admission (OR:9.0, CI:1.3-63.4, p < 0.03) were independent predictors of 30-day mortality. Pneumococcal disease by PCV 13 covered serotypes; in particular, 19F and 3 are still prominent in adults. Strengthening targeted adult vaccination may be necessary in order to reduce disease burden.	[Subramanian, Reema; Liyanapathirana, Veranja; Barua, Nilakshi; Ng, Rita; Ip, Margaret] Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Dept Microbiol, Hong Kong, Peoples R China; [Liyanapathirana, Veranja] Univ Peradeniya, Fac Med, Dept Microbiol, Peradeniya 20400, Sri Lanka; [Sun, Rui; Wang, Maggie Haitian] Chinese Univ Hong Kong, Ctr Clin Res & Biostat, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China; [Sun, Rui] Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen 518107, Peoples R China; [Nelson, Edmund A. S.] Chinese Univ Hong Kong, Fac Med, Dept Paediat, Hong Kong, Peoples R China; [Hui, David S.] Chinese Univ Hong Kong, Fac Med, Dept Med & Therapeut, Hong Kong, Peoples R China		Ip, M (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Dept Microbiol, Hong Kong, Peoples R China.	reema@link.cuhk.edu.hk; veranjad@pdn.ac.lk; nilakshibarua@cuhk.edu.hk; rsun@gmail.com; maggiew@cuhk.edu.hk; ritang@cuhk.edu.hk; tony-nelson@cuhk.edu.hk; dschui@cuhk.edu.hk; margaretip@cuhk.edu.hk	Ng, Wai Yin/AAY-8826-2020; Ip, Margaret/K-1096-2013	Ng, Wai Yin/0000-0003-4966-3350; Ip, Margaret/0000-0003-1291-6537; Nelson, Edmund Anthony Severn/0000-0002-2521-3403; Barua, Nilakshi/0000-0002-7007-5433	Pfizer Corp (Hong Kong) Ltd. (PIM.I.) [TP1712042]	This study was supported as investigator-initiated research from Pfizer Corp (Hong Kong) Ltd. (PIM.I., Grant number TP1712042).	Alanee SRJ, 2007, CLIN INFECT DIS, V45, P46, DOI 10.1086/518538; Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; Anon JB, 2004, OTOLARYNG HEAD NECK, V130, P1, DOI 10.1016/j.otohns.2003.12.003; [Anonymous], PNEUMOCOCCAL VACCINA PNEUMOCOCCAL VACCINA; Centers for Disease Control and Prevention, PROT MULT PCR S PNEU PROT MULT PCR S PNEU; Centre for Health Protection Department of Health Hong Kong., DEATH RAT LEAD CAUS DEATH RAT LEAD CAUS; Chan D, 2018, REV PNEUMOCOCCAL VAC, V15, P4; Chan KCC, 2016, VACCINE, V34, P3867, DOI 10.1016/j.vaccine.2016.05.047; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Choi EH, 2016, CLIN VACCINE IMMUNOL, V23, P162, DOI 10.1128/CVI.00591-15; CLSI (Clinical and Laboratory Standards Institute), 2006, M100S16 CLSI; EUCAST, BREAKP INT MICS ZON BREAKP INT MICS ZON; Gonzalez-Diaz A, 2020, CLIN MICROBIOL INFEC, V26, P753, DOI 10.1016/j.cmi.2019.10.034; Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165; Harboe ZB, 2014, CLIN INFECT DIS, V59, P1066, DOI 10.1093/cid/ciu524; Horacio AN, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01616; Hurley D, 2021, CLIN INFECT DIS, V73, pE1489, DOI 10.1093/cid/ciaa1045; Hyndman RJ, 2008, J STAT SOFTW, V27, P1, DOI 10.18637/jss.v027.i03; Jacobs MR, 2003, J ANTIMICROB CHEMOTH, V52, P229, DOI 10.1093/jac/dkg321; LeBlanc JJ, 2017, VACCINE, V35, P3647, DOI 10.1016/j.vaccine.2017.05.049; Liyanapathirana V, 2015, DIAGN MICR INFEC DIS, V81, P66, DOI 10.1016/j.diagmicrobio.2014.09.028; Lui G, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa146; Marrie TJ, 2011, MEDICINE, V90, P171, DOI 10.1097/MD.0b013e31821a5a76; McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312; Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3; Ridda Iman, 2014, Infectious Disorders - Drug Targets, V14, P133; Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273; Scelfo C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050420; Slotved HC, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00198; Song JH, 2012, VACCINE, V30, P2728, DOI 10.1016/j.vaccine.2012.01.091; Torumkuney D, 2020, J ANTIMICROB CHEMOTH, V75, P19, DOI 10.1093/jac/dkaa082; Wagenvoort GHJ, 2017, VACCINE, V35, P1749, DOI 10.1016/j.vaccine.2017.02.037	32	2	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							756	10.3390/vaccines9070756			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8GA	34358172	Green Published, gold			2022-04-29	WOS:000677141500001
J	van Oosterwijk, JG; Wikel, SK				van Oosterwijk, Jolieke G.; Wikel, Stephen K.			Resistance to Ticks and the Path to Anti-Tick and Transmission Blocking Vaccines	VACCINES			English	Review						tick; host resistance; anti-tick vaccine; transmission blocking vaccine; immune response	AMBLYOMMA-AMERICANUM ACARI; MAST CELL-DEFICIENT; DERMACENTOR-ANDERSONI STILES; HISTAMINE-BINDING LIPOCALIN; RESERVOIR TARGETED VACCINE; HOST IMMUNOGLOBULIN-G; BOOPHILUS-MICROPLUS; LYME-DISEASE; CATTLE TICK; BORNE DISEASES	The medical and veterinary public health importance of ticks and tick-borne pathogens is increasing due to the expansion of the geographic ranges of both ticks and pathogens, increasing tick populations, growing incidence of tick-borne diseases, emerging tick transmitted pathogens, and continued challenges of achieving effective and sustained tick control. The past decades show an increasing interest in the immune-mediated control of tick infestations and pathogen transmission through the use of vaccines. Bovine tick resistance induced by repeated infestations was reported over a century ago. This review addresses the phenomena and immunological underpinning of resistance to tick infestation by livestock and laboratory animals; the scope of tick countermeasures to host immune defenses; and the impact of genomics, functional genomics, and proteomics on dissecting complex tick-host-pathogen interactions. From early studies utilizing tick tissue extracts to salivary gland derived molecules and components of physiologically important pathways in tick gut and other tissues, an increased understanding of these relationships, over time, impacted the evolution of anti-tick vaccine antigen selection. Novel antigens continue to emerge, including increased interest in the tick microbiome. Anti-tick and transmission blocking vaccines targeting pathogen reservoirs have the potential to disrupt enzootic cycles and reduce human, companion, domestic animal, and wildlife exposure to infected ticks.	[van Oosterwijk, Jolieke G.; Wikel, Stephen K.] US Biol Inc, 20 Dudley St, Memphis, TN 38103 USA; [Wikel, Stephen K.] Quinnipiac Univ, Sch Med, Dept Med Sci, Hamden, CT 06518 USA		Wikel, SK (通讯作者)，US Biol Inc, 20 Dudley St, Memphis, TN 38103 USA.; Wikel, SK (通讯作者)，Quinnipiac Univ, Sch Med, Dept Med Sci, Hamden, CT 06518 USA.	jolieke.vanoosterwijk@usbiologic.com; stephenwikel@gmail.com					Abbas RZ, 2014, VET PARASITOL, V203, P6, DOI 10.1016/j.vetpar.2014.03.006; ACKERMAN S, 1980, J MED ENTOMOL, V17, P391, DOI 10.1093/jmedent/17.5.391; ACKERMAN S, 1981, J PARASITOL, V67, P737, DOI 10.2307/3280459; Adrion ER, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116767; Agina OA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090697; Alarcon-Chaidez FJ, 2007, INSECT BIOCHEM MOLEC, V37, P48, DOI 10.1016/j.ibmb.2006.10.002; Ali A, 2015, VET PARASITOL, V207, P107, DOI 10.1016/j.vetpar.2014.11.007; Aljamali MN, 2009, INSECT MOL BIOL, V18, P129, DOI 10.1111/j.1365-2583.2009.00863.x; ALLEN J R, 1973, International Journal for Parasitology, V3, P195, DOI 10.1016/0020-7519(73)90024-6; ALLEN JR, 1979, NATURE, V280, P491, DOI 10.1038/280491a0; ALLEN JR, 1989, EXP APPL ACAROL, V7, P5, DOI 10.1007/BF01200448; ALLEN JR, 1979, J IMMUNOL, V122, P563; ALLEN JR, 1977, CAN J COMP MED, V41, P26; Allsopp BA, 2015, REV SCI TECH OIE, V34, P557, DOI 10.20506/rst.34.2.2379; Almazan C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030475; Almazan C, 2018, FRONT BIOSCI-LANDMRK, V23, P1535, DOI 10.2741/4659; Costa GCA, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611104; Andreotti R, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-6; Anguita J, 2002, IMMUNITY, V16, P849, DOI 10.1016/S1074-7613(02)00325-4; Araman S.F., 1979, P385; Artigas-Jeronimo S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01612; Baneth G, 2014, INT J PARASITOL, V44, P591, DOI 10.1016/j.ijpara.2014.03.011; Barnett KM, 2020, TRENDS PARASITOL, V36, P970, DOI 10.1016/j.pt.2020.08.006; Beard CB, 2019, J MED ENTOMOL, V56, P1199, DOI 10.1093/jme/tjz074; BELL JF, 1979, AM J TROP MED HYG, V28, P876, DOI 10.4269/ajtmh.1979.28.876; BENNETT GF, 1969, EXP PARASITOL, V26, P323, DOI 10.1016/0014-4894(69)90125-8; Bensaoud C, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6042-1; BENYAKIR D, 1989, J MED ENTOMOL, V26, P243, DOI 10.1093/jmedent/26.4.243; BENYAKIR D, 1987, PARASITOL RES, V73, P284, DOI 10.1007/BF00578519; Bernard Q, 2020, TRENDS PARASITOL, V36, P304, DOI 10.1016/j.pt.2019.12.017; Beugnet F, 2015, REV SCI TECH OIE, V34, P627, DOI 10.20506/rst.34.2.2385; Bhattacharya D, 2011, VACCINE, V29, P7818, DOI 10.1016/j.vaccine.2011.07.100; Bhowmick B, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00319; Bishopp F. C., 1913, Parasitology Cambridge, V6, DOI 10.1017/S0031182000003012; Bogovic P, 2015, WORLD J CLIN CASES, V3, P430, DOI 10.12998/wjcc.v3.i5.430; Bonnet SI, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00236; Bonnet SI, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12813; Boulanger N, 2019, MED MALADIES INFECT, V49, P87, DOI 10.1016/j.medmal.2019.01.007; Boulanger N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.625993; Bowman AS, 2004, PARASITOLOGY, V129, pS67, DOI 10.1017/S0031182004006468; BROSSARD M, 1984, EXPERIENTIA, V40, P561, DOI 10.1007/BF01982330; Brown CGD, 1997, TROP ANIM HEALTH PRO, V29, p1S, DOI 10.1007/BF02632905; BROWN SJ, 1981, J IMMUNOL, V127, P2163; Burke GS, 2005, EMERG INFECT DIS, V11, P36; Campbell EM, 2008, J COMP PHYSIOL B, V178, P935, DOI 10.1007/s00360-008-0288-2; Canales M, 2009, VACCINE, V27, P7244, DOI 10.1016/j.vaccine.2009.09.123; Carpi G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025604; CHINERY WA, 1977, NATURE, V265, P366, DOI 10.1038/265366a0; Chmelar J, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00812; Chmelar J, 2016, TRENDS PARASITOL, V32, P368, DOI 10.1016/j.pt.2016.01.004; Chmelar J, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-233; Colwell DD, 2011, VET PARASITOL, V182, P14, DOI 10.1016/j.vetpar.2011.07.012; Contreras M, 2017, VACCINE, V35, P1323, DOI 10.1016/j.vaccine.2017.01.052; Cooley R. A, 1944, AMER MIDLAND NAT MONOGR, V1, P1; Dai JF, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001205; Dai JF, 2009, CELL HOST MICROBE, V6, P482, DOI 10.1016/j.chom.2009.10.006; Dantas-Torres F, 2015, INT J PARASITOL-PAR, V4, P452, DOI 10.1016/j.ijppaw.2015.07.001; Dantas-Torres F, 2012, TRENDS PARASITOL, V28, P437, DOI 10.1016/j.pt.2012.07.003; de la Fuente J, 2016, PARASITE IMMUNOL, V38, P754, DOI 10.1111/pim.12339; de la Fuente J, 2020, EXPERT REV VACCINES, V19, P217, DOI 10.1080/14760584.2020.1745635; de la Fuente J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00114; de la Fuente J, 2015, EXPERT REV VACCINES, V14, P1367, DOI 10.1586/14760584.2015.1076339; de la Fuente J, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-372; DECASTRO JJ, 1993, PARASITOL TODAY, V9, P13, DOI 10.1016/0169-4758(93)90154-8; DENHOLLANDER N, 1985, EXP PARASITOL, V59, P169, DOI 10.1016/0014-4894(85)90069-4; Destoumieux-Garzon D, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00014; Diaz-Martin V, 2015, TICKS TICK-BORNE DIS, V6, P211, DOI 10.1016/j.ttbdis.2015.03.006; Domingues R, 2014, GENET MOL RES, V13, P4013, DOI 10.4238/2014.May.23.12; Dong XT, 2018, NEURON, V98, P482, DOI 10.1016/j.neuron.2018.03.023; Eisen L, 2021, TICKS TICK-BORNE DIS, V12, DOI 10.1016/j.ttbdis.2021.101649; Eisen L, 2021, J MED ENTOMOL, V58, P1588, DOI 10.1093/jme/tjaa079; Eisen L, 2020, EMERG INFECT DIS, V26, P641, DOI 10.3201/eid2604.191629; Eisen L, 2016, J MED ENTOMOL, V53, P1063, DOI 10.1093/jme/tjw103; Eisen RJ, 2021, J MED ENTOMOL, V58, P1490, DOI 10.1093/jme/tjaa087; Eisen RJ, 2017, ILAR J, V58, P319, DOI 10.1093/ilar/ilx005; Eisen RJ, 2018, TRENDS PARASITOL, V34, P295, DOI 10.1016/j.pt.2017.12.006; Quiroz-Castaneda RE, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9032085; Esteves E, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00476; Estrada-Pena A, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9040309; Estrada-Pena A, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00236; Evora PM, 2017, REV BRAS PARASITOL V, V26, P60, DOI [10.1590/S1984-29612017005, 10.1590/s1984-29612017005]; Fan GH, 2015, J MATH BIOL, V71, P1017, DOI 10.1007/s00285-014-0845-0; Finn RN, 2015, BIOL BULL-US, V229, P6, DOI 10.1086/BBLv229n1p6; Fogaca AC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.628054; Francischetti IMB, 2002, BLOOD, V99, P3602, DOI 10.1182/blood-2001-12-0237; Franzin AM, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-016-1945-z; Galay RL, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0482-x; Garcia-Garcia JC, 2000, VACCINE, V18, P2275, DOI 10.1016/S0264-410X(99)00548-4; Garg R, 2006, J IMMUNOL, V177, P6579, DOI 10.4049/jimmunol.177.10.6579; Giachetto PF, 2020, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00477; Glatz M, 2017, EXP DERMATOL, V26, P263, DOI 10.1111/exd.13207; Gray J S, 2009, Interdiscip Perspect Infect Dis, V2009, P593232, DOI 10.1155/2009/593232; Greay TL, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-017-2550-5; Grubhoffer Libor, 2014, P258; Guerrero FD, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0475-9; Guinat C, 2016, VET REC, V178, DOI 10.1136/vr.103593; Hajdusek O, 2016, TICKS TICK-BORNE DIS, V7, P565, DOI 10.1016/j.ttbdis.2016.01.006; Hart BL, 2000, ANN NY ACAD SCI, V916, P565, DOI 10.1111/j.1749-6632.2000.tb05337.x; Hassan IA, 2020, VACCINE, V38, P907, DOI 10.1016/j.vaccine.2019.10.076; HEWETSON RW, 1968, AUST J AGR RES, V19, P497, DOI 10.1071/AR9680497; HEWETSON RW, 1971, AUST J AGR RES, V22, P331, DOI 10.1071/AR9710331; Heyman P, 2010, EXPERT REV ANTI-INFE, V8, P33, DOI [10.1586/eri.09.118, 10.1586/ERI.09.118]; HOEPPLI R., 1931, NAT MED JOUR CHINA, V17, P541; Huercha, 2020, VET PARASITOL, V279, DOI 10.1016/j.vetpar.2020.109043; Hunt J.S, 1899, QLD AGR J, V4, P216; Hussein HE, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1226-2; Imamura S, 2005, VACCINE, V23, P1301, DOI 10.1016/j.vaccine.2004.08.041; Jasinskas A, 2005, J MED ENTOMOL, V42, P359, DOI 10.1603/0022-2585(2005)042[0359:TFFMTU]2.0.CO;2; JELLISON W. L., 1938, JOUR PARASITOL, V24, P143, DOI 10.2307/3272493; Jennings R, 2019, J MATH BIOL, V78, P1331, DOI 10.1007/s00285-018-1311-1; Jeschke P, 2021, PEST MANAG SCI, V77, P64, DOI 10.1002/ps.6084; Johnston T. H., 1918, R SOC QUEENSLAND PRO, V32, P219; Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967; Jonsson NN, 2014, PARASITE IMMUNOL, V36, P551, DOI 10.1111/pim.12140; Juncadella IJ, 2007, FEMS IMMUNOL MED MIC, V49, P433, DOI 10.1111/j.1574-695X.2007.00223.x; Juncadella IJ, 2009, ADV EXP MED BIOL, V666, P121; Karasuyama H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601504; Karasuyama H, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01769; Karesh WB, 2012, LANCET, V380, P1936, DOI 10.1016/S0140-6736(12)61678-X; Karim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131292; Kasaija PD, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020319; KAUFMAN WR, 1973, J EXP BIOL, V58, P523; KAUFMAN WR, 1989, PARASITOL TODAY, V5, P47; Kazimirova M, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00043; Keesing F, 2006, ECOL LETT, V9, P485, DOI 10.1111/j.1461-0248.2006.00885.x; KILPATRICK AM, 2017, PHILOS T R SOC B, V372, DOI DOI 10.1098/RSTB.2016.0117; Kimura R, 2017, J CUTAN PATHOL, V44, P1091, DOI 10.1111/cup.13045; Knorr S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01696; Kolb P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136180; Kotal J, 2015, J PROTEOMICS, V128, P58, DOI 10.1016/j.jprot.2015.07.005; KOUDSTAAL D, 1978, PARASITOLOGY, V76, P379, DOI 10.1017/S0031182000048241; Krause PJ, 2009, VECTOR-BORNE ZOONOT, V9, P603, DOI 10.1089/vbz.2008.0091; Kugeler KJ, 2021, EMERG INFECT DIS, V27, P616, DOI 10.3201/eid2702.202731; Kullberg BJ, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1041; Kumar B, 2012, PARASITE IMMUNOL, V34, P297, DOI 10.1111/j.1365-3024.2012.01356.x; Kurtenbach K, 1997, VACCINE, V15, P1670, DOI 10.1016/S0264-410X(97)00086-8; Lew-Tabor AE, 2016, TICKS TICK-BORNE DIS, V7, P573, DOI 10.1016/j.ttbdis.2015.12.012; Little EAH, 2020, EXP APPL ACAROL, V80, P127, DOI 10.1007/s10493-019-00452-7; Liu T, 2013, PFLUG ARCH EUR J PHY, V465, P1671, DOI 10.1007/s00424-013-1284-2; Luo J, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9040284; Mac S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210280; Madison-Antenucci S, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00083-18; Manzano-Roman R, 2007, VET PARASITOL, V145, P314, DOI 10.1016/j.vetpar.2007.01.011; Maritz-Olivier C, 2007, TRENDS PARASITOL, V23, P397, DOI 10.1016/j.pt.2007.07.005; Martin PAW, 1998, J ECON ENTOMOL, V91, P864, DOI 10.1093/jee/91.4.864; Martins LA, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12807; Mateos-Hernandez L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040702; MATSUDA H, 1985, J PARASITOL, V71, P443, DOI 10.2307/3281535; MCGOWAN MJ, 1981, J MED ENTOMOL, V18, P328, DOI 10.1093/jmedent/18.4.328; McNeil B, 2012, NEUROSCI BULL, V28, P100, DOI 10.1007/s12264-012-1202-1; Medlock JM, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-1; Mierzejewska EJ, 2017, EXP APPL ACAROL, V72, P399, DOI 10.1007/s10493-017-0160-8; MINOURA H, 1985, EXP PARASITOL, V60, P355, DOI 10.1016/0014-4894(85)90042-6; Mitchell RD, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00618; Mota RR, 2018, ANIMAL, V12, P205, DOI 10.1017/S1751731117001562; Narasimhan S, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12808; Narasimhan S, 2020, TICKS TICK-BORNE DIS, V11, DOI 10.1016/j.ttbdis.2019.101369; Narasimhan S, 2019, TICKS TICK-BORNE DIS, V10, P386, DOI 10.1016/j.ttbdis.2018.12.001; Narasimhan S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00208-0; Narasimhan S, 2015, TRENDS PARASITOL, V31, P315, DOI 10.1016/j.pt.2015.03.010; Narladkar BW, 2018, VET WORLD, V11, P151, DOI 10.14202/vetworld.2018.151-160; Nazario S, 1998, AM J TROP MED HYG, V58, P780, DOI 10.4269/ajtmh.1998.58.780; Ndawula C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030457; Ndekezi C, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00236; Neelakanta G, 2018, INSECT MOL BIOL, V27, P177, DOI 10.1111/imb.12362; Neelakanta G, 2015, ARCH IMMUNOL THER EX, V63, P169, DOI 10.1007/s00005-014-0324-8; Nijhof AM, 2010, INT J PARASITOL, V40, P1587, DOI 10.1016/j.ijpara.2010.06.003; Novikov V. N., 2008, Doklady, Biological Sciences, V420, P209, DOI 10.1134/S0012496608030204; Nuttall Patricia A, 2019, Wien Klin Wochenschr, DOI 10.1007/s00508-019-1500-y; Ogden NH, 2005, INT J PARASITOL, V35, P375, DOI 10.1016/j.ijpara.2004.12.013; Ogden NH, 2016, TRENDS PARASITOL, V32, P646, DOI 10.1016/j.pt.2016.04.015; Ohta T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01348; Olds CL, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1774-0; Oliveira CJF, 2011, J BIOL CHEM, V286, P10960, DOI 10.1074/jbc.M110.205047; Ostfeld RS, 2009, CLIN MICROBIOL INFEC, V15, P40, DOI 10.1111/j.1469-0691.2008.02691.x; Paesen GA, 2000, BBA-PROTEIN STRUCT M, V1482, P92, DOI 10.1016/S0167-4838(00)00168-0; Paesen GC, 1999, MOL CELL, V3, P661, DOI 10.1016/S1097-2765(00)80359-7; PAINE SH, 1983, PARASITOLOGY, V86, P419, DOI 10.1017/S0031182000050617; Parizi LF, 2012, VET J, V194, P158, DOI 10.1016/j.tvjl.2012.05.023; Parizi LF, 2020, TICKS TICK-BORNE DIS, V11, DOI 10.1016/j.ttbdis.2020.101378; Paules CI, 2018, NEW ENGL J MED, V379, P701, DOI 10.1056/NEJMp1807870; Perez-Sanchez R, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3768-1; Pfaffle M, 2013, INT J PARASITOL, V43, P1059, DOI 10.1016/j.ijpara.2013.06.009; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; Piper EK, 2009, CLIN VACCINE IMMUNOL, V16, P1074, DOI 10.1128/CVI.00157-09; Piper EK, 2008, VET IMMUNOL IMMUNOP, V126, P110, DOI 10.1016/j.vetimm.2008.06.011; Ramamoorthi N, 2005, NATURE, V436, P573, DOI 10.1038/nature03812; Aguirre ADR, 2016, VET PARASITOL, V221, P30, DOI 10.1016/j.vetpar.2016.02.032; Rego ROM, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3468-x; Ribeiro JMC, 2006, INSECT BIOCHEM MOLEC, V36, P111, DOI 10.1016/j.ibmb.2005.11.005; Richer LM, 2014, J INFECT DIS, V209, P1972, DOI 10.1093/infdis/jiu005; Richer LM, 2011, CLIN VACCINE IMMUNOL, V18, P1809, DOI 10.1128/CVI.05226-11; RIEK RF, 1962, AUST J AGR RES, V13, P532, DOI 10.1071/AR9620532; Rizzoli A, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00251; Robbertse L, 2018, TICKS TICK-BORNE DIS, V9, P976, DOI 10.1016/j.ttbdis.2018.03.034; ROBERTS JA, 1968, J PARASITOL, V54, P657, DOI 10.2307/3277013; Rochlin I, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7069-6; Mallon AR, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060513; Rodriguez-Mallon A, 2016, METHODS MOL BIOL, V1404, P243, DOI 10.1007/978-1-4939-3389-1_17; Rodriguez-Vivas RI, 2018, PARASITOL RES, V117, P3, DOI 10.1007/s00436-017-5677-6; Rosa R, 2007, MATH BIOSCI, V208, P216, DOI 10.1016/j.mbs.2006.10.002; Sangamnatdej S, 2002, INSECT MOL BIOL, V11, P79, DOI 10.1046/j.0962-1075.2001.00311.x; SAUER JR, 1995, ANNU REV ENTOMOL, V40, P245, DOI 10.1146/annurev.en.40.010195.001333; Scheckelhoff MR, 2006, VACCINE, V24, P1949, DOI 10.1016/j.vaccine.2005.10.044; SCHLEGER AV, 1976, AUST J BIOL SCI, V29, P499, DOI 10.1071/BI9760499; SCHLEIN Y, 1976, ANN TROP MED PARASIT, V70, P227, DOI 10.1080/00034983.1976.11687116; Schulze T. L., 1988, Annals of the New York Academy of Sciences, V539, P204, DOI 10.1111/j.1749-6632.1988.tb31854.x; Simo L, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00281; Snowball G. J., 1956, Australian Journal of Agricultural Research, V7, P227; Sokol CL, 2010, MUCOSAL IMMUNOL, V3, P129, DOI 10.1038/mi.2009.137; Stafford KC, 2020, EXP APPL ACAROL, V80, P257, DOI 10.1007/s10493-019-00458-1; STEEVES EBT, 1990, INT J PARASITOL, V20, P655, DOI 10.1016/0020-7519(90)90124-6; Strnad M, 2020, APPL MICROBIOL BIOT, V104, P1915, DOI 10.1007/s00253-020-10375-8; Suppan J, 2018, BIOL REV, V93, P1056, DOI 10.1111/brv.12384; Tabakawa Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01540; Tabor AE, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00506; Talagrand-Reboul E, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00098; TATCHELL RJ, 1970, SCIENCE, V167, P1002, DOI 10.1126/science.167.3920.1002; Telford SR, 2011, TICKS TICK-BORNE DIS, V2, P151, DOI 10.1016/j.ttbdis.2011.06.001; Tellam Ross L., 1992, P303; THEIS JH, 1974, EXP PARASITOL, V36, P77, DOI 10.1016/0014-4894(74)90115-5; Tijsse-Klasen E, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00073; Tokarz R, 2018, MSPHERE, V3, DOI [10.1128/mSphere.00614-17, 10.1128/msphere.00614-17]; TRAGER WILLIAM, 1939, JOUR PARASITOL, V25, P137, DOI [10.1016/S0033-3506(39)80097-X, 10.2307/3272354]; TRAGER WILLIAM, 1939, JOUR PARASITOL, V25, P57, DOI 10.2307/3272160; Trentelman JJA, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3616-3; Trimnell AR, 2002, VACCINE, V20, P3560, DOI 10.1016/S0264-410X(02)00334-1; Tsao JI, 2004, P NATL ACAD SCI USA, V101, P18159, DOI 10.1073/pnas.0405763102; Ullmann AJ, 2013, TICKS TICK-BORNE DIS, V4, P160, DOI 10.1016/j.ttbdis.2012.08.006; Valenzuela JG, 2000, J BIOL CHEM, V275, P18717, DOI 10.1074/jbc.M001486200; van Oosterwijk JG, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12831; Vaz ID, 1996, VET PARASITOL, V62, P155, DOI 10.1016/0304-4017(95)00851-9; Voehringer D, 2013, NAT REV IMMUNOL, V13, P362, DOI 10.1038/nri3427; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Walker AR, 2011, PARASITOLOGY, V138, P945, DOI 10.1017/S0031182011000709; WANG H, 1994, PARASITOLOGY, V109, P525, DOI 10.1017/S0031182000080781; Wang H, 1999, CELL MOL LIFE SCI, V56, P286, DOI 10.1007/s000180050430; WIKEL SK, 1982, ANN TROP MED PARASIT, V76, P179, DOI 10.1080/00034983.1982.11687525; WIKEL SK, 1986, VET PARASITOL, V20, P149, DOI 10.1016/0304-4017(86)90098-1; Wikel SK, 1999, INT J PARASITOL, V29, P851, DOI 10.1016/S0020-7519(99)00042-9; WIKEL SK, 1982, ANNU REV ENTOMOL, V27, P21, DOI 10.1146/annurev.en.27.010182.000321; WIKEL SK, 1979, AM J TROP MED HYG, V28, P586, DOI 10.4269/ajtmh.1979.28.586; WIKEL SK, 1977, IMMUNOLOGY, V32, P457; WIKEL SK, 1976, IMMUNOLOGY, V30, P311; Wikel SK, 1996, ANNU REV ENTOMOL, V41, P1, DOI 10.1146/annurev.en.41.010196.000245; WIKEL SK, 1976, IMMUNOLOGY, V30, P479; Wikel S, 2017, ARTHROPOD VECTOR: CONTROLLER OF DISEASE TRANSMISSION, VOL 2: VECTOR SALIVA-HOST-PATHOGEN INTERACTIONS, P13, DOI 10.1016/B978-0-12-805360-7.00002-2; Wikel S, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00337; Wikel SK, 2018, FRONT BIOSCI-LANDMRK, V23, P265, DOI 10.2741/4590; WILKINSON P R, 1983, Journal of the Entomological Society of British Columbia, V80, P37; Willadsen P, 1999, PARASITOL TODAY, V15, P258, DOI 10.1016/S0169-4758(99)01472-6; Willadsen P, 1980, Adv Parasitol, V18, P293, DOI 10.1016/S0065-308X(08)60402-9; Willadsen P, 2004, PARASITOLOGY, V129, pS367, DOI 10.1017/S0031182003004657; WILLADSEN P, 1979, Z PARASITENKD, V59, P87, DOI 10.1007/BF00927849; WILLADSEN P, 1988, PARASITOL TODAY, V4, P196, DOI 10.1016/0169-4758(88)90084-1; Williams SC, 2020, VECTOR-BORNE ZOONOT, V20, P603, DOI 10.1089/vbz.2019.2612; Yoshikawa S, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12804; Zhu KC, 1997, J PARASITOL, V83, P38, DOI 10.2307/3284314	258	6	6	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							725	10.3390/vaccines9070725			28	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8AJ	34358142	Green Published			2022-04-29	WOS:000677126800001
J	Chudasama, R; Phung, Q; Hsu, A; Almhanna, K				Chudasama, Rani; Phung, Quan; Hsu, Andrew; Almhanna, Khaldoun			Vaccines in Gastrointestinal Malignancies: From Prevention to Treatment	VACCINES			English	Review						gastrointestinal cancer; vaccines	METASTATIC COLORECTAL-CANCER; TRANSITIONAL-CELL CARCINOMA; BACILLUS-CALMETTE-GUERIN; PHASE-I TRIAL; HEPATOCELLULAR-CARCINOMA; PEPTIDE VACCINE; DENDRITIC CELLS; SIPULEUCEL-T; ADJUVANT TREATMENT; ALPHA-FETOPROTEIN	Gastrointestinal (GI) malignancies are some of the most common and devastating malignancies and include colorectal, gastric, esophageal, hepatocellular, and pancreatic carcinomas, among others. Five-year survival rates for many of these malignancies remain low. The majority presents at an advanced stage with limited treatment options and poor overall survival. Treatment is advancing but not at the same speed as other malignancies. Chemotherapy and radiation treatments are still only partially effective in GI malignancies and cause significant side effects. Thus, there is an urgent need for novel strategies in the treatment of GI malignancies. Recently, immunotherapy and checkpoint inhibitors have entered as potential new therapeutic options for patients, and thus, cancer vaccines may play a major role in the future of treatment for these malignancies. Further advances in understanding the interaction between the tumor and immune system have led to the development of novel agents, such as cancer vaccines.	[Chudasama, Rani; Hsu, Andrew; Almhanna, Khaldoun] Brown Univ, Rhode Isl Hosp, Div Hematol Oncol, Alpert Med Sch, Providence, RI 02903 USA; [Phung, Quan] Brown Univ, Rhode Isl Hosp, Dept Med, Alpert Med Sch, Providence, RI 02903 USA		Almhanna, K (通讯作者)，Brown Univ, Rhode Isl Hosp, Div Hematol Oncol, Alpert Med Sch, Providence, RI 02903 USA.	RChudasama@lifespan.org; QPhung@lifespan.org; AHsu2@lifespan.org; Kalmhanna@lifespan.org		Hsu, Andrew/0000-0002-6325-5479			Abdul-Latif M, 2020, CANCER TREAT REV, V88, DOI 10.1016/j.ctrv.2020.102030; Ajani JA, 2006, CANCER-AM CANCER SOC, V106, P1908, DOI 10.1002/cncr.21814; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; [Anonymous], TRIAL BOOST VACCINAT; [Anonymous], PERSONALIZED VACCINE; [Anonymous], EPACADOSTAT PEMBROLI; [Anonymous], STUDY CRS 207 NIVOLU; [Anonymous], PHASE 1B STUDY EVALU; [Anonymous], TRIAL PERIOPERATIVE; [Anonymous], 600 VACCINE COLORECT; [Anonymous], NEOANTIGEN PEPTIDE V; [Anonymous], 600 VACCINE PANCREAT; [Anonymous], **NON-TRADITIONAL**; [Anonymous], COCKTAIL THERAPY HEP; [Anonymous], GVAX COLORECTAL CANC; [Anonymous], DNAJB1 PRKACA FUSION; [Anonymous], Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (with CY) with or without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer; [Anonymous], MAINTENANCE THERAPY; [Anonymous], CLIN TRIAL PERSONALI; [Anonymous], STUDY PERSONALIZED T; [Anonymous], TRIAL NEOADJUVANT AD; [Anonymous], NIVOLUMAB IPILIMUMAB; [Anonymous], GNOS PV02 PERSONALIZ; [Anonymous], STUDY IMU 131 HER VA; [Anonymous], TRIAL PALLOV 200 COL; [Anonymous], INTRATUMORAL INFLUEN; [Anonymous], GVAX PANCREAS VACCIN; [Anonymous], VACCINATION AUTOLOGO; Aurisicchio L, 2012, EXPERT OPIN BIOL TH, V12, P1043, DOI 10.1517/14712598.2012.689279; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bassani-Sternberg M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01832; Berger M, 2007, J PHARM PHARM SCI, V10, P144; Butterfield LH, 2006, CLIN CANCER RES, V12, P2817, DOI 10.1158/1078-0432.CCR-05-2856; Butterfield LH, 2003, CLIN CANCER RES, V9, P5902; Chang MH, 2016, GASTROENTEROLOGY, V151, P472, DOI 10.1053/j.gastro.2016.05.048; Cho HI, 2009, CANCER RES, V69, P9012, DOI 10.1158/0008-5472.CAN-09-2019; Correale P, 1997, JNCI-J NATL CANCER I, V89, P293, DOI 10.1093/jnci/89.4.293; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Finn OJ, 2018, NAT REV IMMUNOL, V18, P183, DOI 10.1038/nri.2017.140; Fujiwara Y, 2017, YONAGO ACTA MED, V60, P101, DOI 10.33160/yam.2017.06.005; Gnjatic S, 2010, P NATL ACAD SCI USA, V107, P5088, DOI 10.1073/pnas.0914213107; Greten TF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-209; Guo CQ, 2013, ADV CANCER RES, V119, P421, DOI 10.1016/B978-0-12-407190-2.00007-1; Harris JE, 2000, J CLIN ONCOL, V18, P148, DOI 10.1200/JCO.2000.18.1.148; Hazama S, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-63; Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011; Higano CS, 2009, CANCER-AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429; Higashihara Y, 2014, INT J ONCOL, V44, P662, DOI 10.3892/ijo.2013.2242; Hofmann O, 2008, P NATL ACAD SCI USA, V105, P20422, DOI 10.1073/pnas.0810777105; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Hurez V, 2017, CLIN EXP IMMUNOL, V187, P53, DOI 10.1111/cei.12875; Jacobs JJL, 2014, ANTICANCER RES, V34, P2689; Jou J, 2021, CLIN CANCER RES, V27, P689, DOI 10.1158/1078-0432.CCR-20-0245; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597; Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062; Kariko K, 2007, CURR OPIN DRUG DISC, V10, P523; Kavanagh B, 2007, J IMMUNOTHER, V30, P762, DOI 10.1097/CJI.0b013e318133451c; Kawamura J, 2018, ONCOL LETT, V15, P4241, DOI 10.3892/ol.2018.7905; Kim MN, 2015, SEMIN ONCOL, V42, P316, DOI 10.1053/j.seminoncol.2014.12.018; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; LAMM DL, 1991, NEW ENGL J MED, V325, P1205, DOI 10.1056/NEJM199110243251703; Lamm DL, 2000, J UROLOGY, V163, P1124, DOI 10.1016/S0022-5347(05)67707-5; Lesterhuis WJ, 2006, ANN ONCOL, V17, P974, DOI 10.1093/annonc/mdl072; Lollini PL, 2006, NAT REV CANCER, V6, P204, DOI 10.1038/nrc1815; Mehrotra S, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0459-2; Miyazawa M, 2017, INT J CANCER, V140, P973, DOI 10.1002/ijc.30510; Mogensen MB, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4639-4; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; Nakagawa H, 2017, GASTROENTEROLOGY, V152, P1395, DOI 10.1053/j.gastro.2017.02.001; Ogasawara M, 2018, ANN ONCOL, V29, P21; Orlandi F, 2011, VACCINE, V29, P3646, DOI 10.1016/j.vaccine.2011.03.017; Pan L, 2019, AM J CANCER RES, V9, P562; Pan RY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4325874; Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272; PETERS LC, 1979, CANCER RES, V39, P1353; Rahma OE, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-55; Rahma Osama E, 2011, Gastroenterol Hepatol (N Y), V7, P517; Rivoltini L, 2003, J IMMUNOL, V171, P3467, DOI 10.4049/jimmunol.171.7.3467; Rizell M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00019; Rong YF, 2012, CLIN EXP MED, V12, P173, DOI 10.1007/s10238-011-0159-0; Sato Y, 2004, BRIT J CANCER, V90, P1334, DOI 10.1038/sj.bjc.6601711; Sawada Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1129483; Sawada Y, 2012, CLIN CANCER RES, V18, P3686, DOI 10.1158/1078-0432.CCR-11-3044; Schwartzentruber DJ, 2011, NEW ENGL J MED, V364, P2119, DOI 10.1056/NEJMoa1012863; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Sondak VK, 2006, CLIN CANCER RES, V12, p2337S, DOI 10.1158/1078-0432.CCR-05-2555; Toubaji A, 2008, CANCER IMMUNOL IMMUN, V57, P1413, DOI 10.1007/s00262-008-0477-6; TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982; Wagner S, 2018, WORLD J GASTROENTERO, V24, P5418, DOI 10.3748/wjg.v24.i48.5418; Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648; Ward JP, 2016, ADV IMMUNOL, V130, P25, DOI 10.1016/bs.ai.2016.01.001; Weitzenfeld P, 2019, J CLIN INVEST, V129, P3952, DOI 10.1172/JCI128437; Zom GGP, 2012, ADV IMMUNOL, V114, P177, DOI 10.1016/B978-0-12-396548-6.00007-X	94	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							647	10.3390/vaccines9060647			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA0RY	34199248	gold, Green Published			2022-04-29	WOS:000666963800001
J	Del Riccio, M; Boccalini, S; Rigon, L; Biamonte, MA; Albora, G; Giorgetti, D; Bonanni, P; Bechini, A				Del Riccio, Marco; Boccalini, Sara; Rigon, Lisa; Biamonte, Massimiliano Alberto; Albora, Giuseppe; Giorgetti, Duccio; Bonanni, Paolo; Bechini, Angela			Factors Influencing SARS-CoV-2 Vaccine Acceptance and Hesitancy in a Population-Based Sample in Italy	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccine acceptance; vaccine hesitancy; survey	COVID-19	Vaccination against SARS-CoV-2 represents an effective and safe tool to protect the population against the disease; however, COVID-19 vaccine hesitancy could be a major barrier to achieving herd immunity. Despite the severity of the current pandemic, the population's intention to get vaccinated against COVID-19 is still not clear. The aim of this study was to evaluate the intention to get vaccinated against COVID-19 among a convenience sample of the general population resident in Italy and the factors associated with hesitancy and acceptance of the vaccine in the context of the current pandemic before the rolling out of COVID-19 vaccines. An anonymous online survey was diffused among a general adult population living in Italy. Participants aged 18 or older and living in Italy were considered eligible. Incomplete questionnaires were excluded. Overall, 7605 valid questionnaires were collected. Most of the participants (81.9%) were inclined to get vaccinated; male sex (OR 1.38, 95% CI 1.12-1.71), a high level of trust in institutions (OR 3.93, 95% CI 2.04-7.83), and personal beliefs about high safety of COVID-19 vaccines (OR 56.33, 95% CI 31.57-105.87) were found to be among the significant predictors of COVID-19 acceptance. These data could help design larger studies to address the problem of COVID-19 vaccine hesitancy in the current pandemic.	[Del Riccio, Marco; Rigon, Lisa; Biamonte, Massimiliano Alberto; Albora, Giuseppe; Giorgetti, Duccio] Univ Florence, Med Specializat Sch Hyg & Prevent Med, I-50134 Florence, Italy; [Boccalini, Sara; Bonanni, Paolo; Bechini, Angela] Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy		Del Riccio, M (通讯作者)，Univ Florence, Med Specializat Sch Hyg & Prevent Med, I-50134 Florence, Italy.	marco.delriccio@unifi.it; sara.boccalini@unifi.it; lisa.rigon@unifi.it; massimilianoalberto.biamonte@unifi.it; giuseppe.albora@unifi.it; duccio.giorgetti@unifi.it; paolo.bonanni@unifi.it; angela.bechini@unifi.it	DEL RICCIO, MARCO/ABB-3559-2020	DEL RICCIO, MARCO/0000-0002-2742-0297; Bechini, Angela/0000-0002-6013-8779; Boccalini, Sara/0000-0002-9695-7549; Bonanni, Paolo/0000-0003-2875-3744			Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Biasio LR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030268; Carrieri V, 2019, HEALTH ECON, V28, P1377, DOI 10.1002/hec.3937; Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987; Dorman C, 2021, J COMMUN HEALTH, V46, P1013, DOI 10.1007/s10900-021-00987-0; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Habersaat KB, 2020, NAT HUM BEHAV, V4, P677, DOI 10.1038/s41562-020-0906-x; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Montalti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040366; Moscadelli A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165850; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Newbold S., 2020, HESITANCY COVID 19 V; Nguyen Trang, 2011, Infect Drug Resist, V4, P197, DOI 10.2147/IDR.S23174; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rey D, 2018, EUROSURVEILLANCE, V23, P30, DOI [10.2807/1560-7917.ES.23.17.17-00816, 10.2807/1560-7917.ES.2018.23.17.17-00816]; SAGE Working Group on Vaccine Hesitancy, REP SAGE WORK GROUP; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sartor G, 2020, INT J INFECT DIS, V98, P188, DOI 10.1016/j.ijid.2020.06.060; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Weintraub RL, 2021, HEALTH AFFAIR, V40, P33, DOI 10.1377/hlthaff.2020.01523; World Health Organization, DRAFT LANDSC COVID 1; World Health Organization, IMPR VACC DEM ADDR H; World Health Organization, DIR GEN OP REM MED B	32	14	14	6	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							633	10.3390/vaccines9060633			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6QM	34200656	Green Published, gold			2022-04-29	WOS:000666010100001
J	Radwanska, M; Nguyen, HTT; Magez, S				Radwanska, Magdalena; Nguyen, Hang Thi Thu; Magez, Stefan			African Trypanosomosis Obliterates DTPa Vaccine-Induced Functional Memory So That Post-Treatment Bordetella pertussis Challenge Fails to Trigger a Protective Recall Response	VACCINES			English	Article						trypanosomosis; treatment; DTPa; Bordetella pertussis	VARIANT SURFACE GLYCOPROTEIN; NECROSIS-FACTOR-ALPHA; EVANSI INFECTION; MECHANICAL TRANSMISSION; GLOBAL DISTRIBUTION; BRUCEI-GAMBIENSE; IMMUNE-RESPONSE; ARMS-RACE; CONGOLENSE; IMMUNIZATION	Salivarian trypanosomes are extracellular parasites causing anthroponotic and zoonotic infections. Anti-parasite vaccination is considered the only sustainable method for global trypanosomosis control. Unfortunately, no single field applicable vaccine solution has been successful so far. The active destruction of the host's adaptive immune system by trypanosomes is believed to contribute to this problem. Here, we show that Trypanosome brucei brucei infection results in the lasting obliteration of immunological memory, including vaccine-induced memory against non-related pathogens. Using the well-established DTPa vaccine model in combination with a T. b. brucei infection and a diminazene diaceturate anti-parasite treatment scheme, our results demonstrate that while the latter ensured full recovery from the T. b. brucei infection, it failed to restore an efficacious anti-B. pertussis vaccine recall response. The DTPa vaccine failure coincided with a shift in the IgG1/IgG2a anti-B. pertussis antibody ratio in favor of IgG2a, and a striking impact on all of the spleen immune cell populations. Interestingly, an increased plasma IFN gamma level in DTPa-vaccinated trypanosome-infected mice coincided with a temporary antibody-independent improvement in early-stage trypanosomosis control. In conclusion, our results are the first to show that trypanosome-inflicted immune damage is not restored by successful anti-parasite treatment.	[Radwanska, Magdalena] Univ Ghent, Dept Biomed Mol Biol, Technol Pk Zwijnaarde 71, B-9000 Ghent, Belgium; [Radwanska, Magdalena; Nguyen, Hang Thi Thu; Magez, Stefan] Univ Ghent, Lab Biomed Res, Dept Mol Biotechnol Environm Technol & Food Techn, Global Campus,Songdomunhwa Ro 119-5, Incheon 406840, South Korea; [Nguyen, Hang Thi Thu; Magez, Stefan] Univ Ghent, Dept Biochem & Microbiol, Ledeganckstr 35, B-9000 Ghent, Belgium; [Nguyen, Hang Thi Thu; Magez, Stefan] Vrije Univ Brussel, Dept Bioengn Sci, Lab Cellular & Mol Immunol, Pl Laan 2, B-1050 Brussels, Belgium		Radwanska, M (通讯作者)，Univ Ghent, Dept Biomed Mol Biol, Technol Pk Zwijnaarde 71, B-9000 Ghent, Belgium.; Radwanska, M (通讯作者)，Univ Ghent, Lab Biomed Res, Dept Mol Biotechnol Environm Technol & Food Techn, Global Campus,Songdomunhwa Ro 119-5, Incheon 406840, South Korea.	magdalena.radwanska@UGent.be; hang.nguyenthithu@ugent.be; Stefan.Magez@vub.ac.be		Nguyen, Hang/0000-0002-1642-4700	Fonds voor Wetenschappelijk Onderzoek-VlaanderenFWO [G013518N]; Universiteit Gent [BOF.STG.2018.0009.01/01N01518/UGent-BOF]; Vrije Universiteit Brussel [SRP63]; Ghent University Global Campus RC5 Research Center	This research was funded by the Fonds voorWetenschappelijk Onderzoek-Vlaanderen (G013518N), the Universiteit Gent (BOF.STG.2018.0009.01/01N01518/UGent-BOF `Startkrediet') the Vrije Universiteit Brussel (SRP63) and Ghent University Global Campus RC5 Research Center core funding.	Aregawi WG, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3311-4; Bangs JD, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201800181; Barkhuizen M, 2008, J INFECT DIS, V198, P1284, DOI 10.1086/592048; Black SJ, 2016, PARASITE IMMUNOL, V38, P735, DOI 10.1111/pim.12387; Blom-Potar MC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000793; Bockstal V, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002089; Buscher P, 2018, TRENDS PARASITOL, V34, P197, DOI 10.1016/j.pt.2017.11.008; Buscher P, 2017, LANCET, V390, P2397, DOI 10.1016/S0140-6736(17)31510-6; Capewell P, 2015, PARASITOLOGY, V142, pS108, DOI 10.1017/S0031182014000602; Chowdhury AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001226; Cnops J, 2015, PARASITE IMMUNOL, V37, P479, DOI 10.1111/pim.12208; Cnops J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004964; Dagenais TR, 2009, INFECT IMMUN, V77, P141, DOI 10.1128/IAI.00729-08; Daulouede S, 2001, J INFECT DIS, V183, P988, DOI 10.1086/319257; Dean SD, 2007, CELL HOST MICROBE, V2, P279, DOI 10.1016/j.chom.2007.10.006; Deleeuw V, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12664; Desquesnes M, 2003, EXP PARASITOL, V105, P226, DOI 10.1016/j.exppara.2003.12.014; Desquesnes M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/194176; Desquesnes M, 2009, INT J PARASITOL, V39, P333, DOI 10.1016/j.ijpara.2008.07.004; DEVINE DV, 1986, INFECT IMMUN, V52, P223, DOI 10.1128/IAI.52.1.223-229.1986; Dickie EA, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5010029; DIFFLEY P, 1983, J IMMUNOL, V131, P1983; Drennan MB, 2005, J IMMUNOL, V175, P2501, DOI 10.4049/jimmunol.175.4.2501; Engstler M, 2007, CELL, V131, P505, DOI 10.1016/j.cell.2007.08.046; Feunou PF, 2014, VACCINE, V32, P4281, DOI 10.1016/j.vaccine.2014.06.019; Franco JR, 2014, CLIN EPIDEMIOL, V6, P257, DOI 10.2147/CLEP.S39728; Frenkel D, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005733; Gomez-Rodriguez J, 2009, J INFECT DIS, V200, P1849, DOI 10.1086/648374; Hall JPJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003502; Hertz CJ, 1998, J IMMUNOL, V161, P6775; Holland WG, 2003, VET PARASITOL, V111, P115, DOI 10.1016/S0304-4017(02)00363-1; Holland WG, 2001, VET PARASITOL, V102, P225, DOI 10.1016/S0304-4017(01)00534-9; KAZYUMBA G, 1986, CLIN EXP IMMUNOL, V65, P10; Krafsur ES, 2018, INFECT GENET EVOL, V64, P185, DOI 10.1016/j.meegid.2018.05.033; Lavigne MV, 2004, MICROBES INFECT, V6, P481, DOI 10.1016/j.micinf.2004.01.004; Lavigne MV, 2002, MICROBES INFECT, V4, P815, DOI 10.1016/S1286-4579(02)01601-5; Lejon V, 2010, J CLIN MICROBIOL, V48, P2836, DOI 10.1128/JCM.00456-10; Lejon V, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003947; LIU EW, 1993, VET IMMUNOL IMMUNOP, V38, P169, DOI 10.1016/0165-2427(93)90121-J; Magez S, 1997, J CELL BIOL, V137, P715, DOI 10.1083/jcb.137.3.715; Magez S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00382; Magez S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000122; McCulloch R, 2017, EMERG TOP LIFE SCI, V1, P585, DOI 10.1042/ETLS20170104; Morel S, 2011, VACCINE, V29, P3449, DOI 10.1016/j.vaccine.2011.02.062; Chau NVV, 2016, CLIN INFECT DIS, V62, P1002, DOI 10.1093/cid/ciw052; Obishakin E, 2014, PARASITE IMMUNOL, V36, P187, DOI 10.1111/pim.12099; Onah DN, 1997, J COMP PATHOL, V117, P73, DOI 10.1016/S0021-9975(97)80067-9; Onyilagha C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02738; Pan WL, 2006, MICROBES INFECT, V8, P1209, DOI 10.1016/j.micinf.2005.11.009; PAYS E, 1981, NUCLEIC ACIDS RES, V9, P4225, DOI 10.1093/nar/9.17.4225; Pays E, 2014, NAT REV MICROBIOL, V12, P575, DOI 10.1038/nrmicro3298; Radwanska M, 2000, INFECT IMMUN, V68, P848, DOI 10.1128/IAI.68.2.848-860.2000; Radwanska M, 2000, PARASITE IMMUNOL, V22, P639, DOI 10.1046/j.1365-3024.2000.00348.x; Radwanska M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02253; Radwanska M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000078; Raeven RHM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63998-2; Roduit C, 2002, INFECT IMMUN, V70, P3521, DOI 10.1128/IAI.70.7.3521-3528.2002; RURANGIRWA FR, 1980, INFECT IMMUN, V27, P832, DOI 10.1128/IAI.27.3.832-836.1980; SCHLEIFER KW, 1993, J IMMUNOL, V151, P5492; Schwede A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005259; Singla LD, 2010, TROP ANIM HEALTH PRO, V42, P589, DOI 10.1007/s11250-009-9461-1; Stijlemans B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00582; Trindade S, 2016, CELL HOST MICROBE, V19, P837, DOI 10.1016/j.chom.2016.05.002; Truc P, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002256; Vanhollebeke B, 2006, NEW ENGL J MED, V355, P2752, DOI 10.1056/NEJMoa063265; Wamwiri FN, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6201350; Wu H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01105; Zoll S, 2018, NAT MICROBIOL, V3, P295, DOI 10.1038/s41564-017-0085-3	68	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							603	10.3390/vaccines9060603			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ4FW	34200074	Green Published, Green Submitted			2022-04-29	WOS:000666524000001
J	Vignier, N; Brureau, K; Granier, S; Breton, J; Michaud, C; Gaillet, M; Agostini, C; Ballet, M; Nacher, M; Valdes, A; Abboud, P; Adenis, A; Djossou, F; Epelboin, L; Douine, M				Vignier, Nicolas; Brureau, Kepha; Granier, Sybille; Breton, Jacques; Michaud, Celine; Gaillet, Melanie; Agostini, Camille; Ballet, Mathilde; Nacher, Mathieu; Valdes, Audrey; Abboud, Philippe; Adenis, Antoine; Djossou, Felix; Epelboin, Loic; Douine, Maylis			Attitudes towards the COVID-19 Vaccine and Willingness to Get Vaccinated among Healthcare Workers in French Guiana: The Influence of Geographical Origin	VACCINES			English	Article						COVID-19 vaccines; health personnel; vaccine hesitancy; willingness to get vaccinated; French Guiana; South America	HESITANCY; INTENTION	Background: In the context of the global COVID-19 pandemic and the expansion of the more transmissible 20J/501Y.V3 (Gamma) variant of concern (VOC), mRNA vaccines have been made available in French Guiana, an overseas French territory in South America, from mid-January 2021. This study aimed to estimate the willingness to be vaccinated and the socio-demographic and motivational correlates among Health Care Workers (HCWs) in French Guiana. Methods: A cross-sectional survey was conducted from January 22 to March 26, 2021 among a sample of HCWs in French Guiana. They were asked about their willingness to get vaccinated against COVID-19 and vaccine hesitancy, vaccine uptake and vaccines attitudes. Factors associated with willingness to get vaccinated have been analyzed with ordinal logistic regression, using Stata software. Results: A total of 579 HCWs were interviewed, including 220 physicians and 200 nurses most often working in hospital (54%) or in the liberal sector (22%). Overall, 65.6% of respondents reported that they were willing or had already been vaccinated against COVID-19, while 24.3% of respondents reported that they did not want to get vaccinated against COVID-19 and 11.2% were unsure. HCWs were more willing to get vaccine if they were older, were worried about COVID-19 and were confident in the management of epidemic. Conversely, participants were less likely to have been vaccinated or willing to if they were nurses or of another non-medical profession, born in French Guiana, feared adverse effects, or if they did not trust pharmaceutical companies and management of the epidemic by authorities. Conclusion: Negative attitudes towards vaccines are a major public health concern among HCWs in French Guiana when considering the current active epidemic with Gamma VOC. General vaccine hesitancy and concerns about future side effects in particular represent important barriers. Low confidence in government and science are significant in COVID-19 vaccine refusal among non-medical staffs. Public health messaging with information on vaccine safety should be tailored to address these concerns. The specific challenges of HCWs from French Guiana must be taken into account.	[Vignier, Nicolas; Brureau, Kepha; Granier, Sybille; Nacher, Mathieu; Adenis, Antoine; Douine, Maylis] Ctr Hosp Cayenne, Ctr Invest Clin Antilles Guyane, CIC Inserm 1424, DRISP, Av Flamboyants, F-97300 Cayenne, France; [Vignier, Nicolas] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ IPLESP, Dept Social Epidemiol, F-75012 Paris, France; [Vignier, Nicolas] Univ Sorbonne Paris Nord, Fac Med, UFR SMBH, F-97300 Bobigny, France; [Brureau, Kepha] Univ Antilles, Dept Univ Med Gen, F-97145 Pointe A Pitre, Guadeloupe, France; [Granier, Sybille] Univ Montpellier, Dept Univ Med Gen Montpellier Nimes, F-34090 Montpellier, France; [Breton, Jacques] Union Reg Profess Sante Med Liberaux Guyane, F-97300 Cayenne, France; [Michaud, Celine; Gaillet, Melanie] Ctr Hosp Cayenne Andree Rosemon, Ctr Delocalises Prevent & Soins, F-97300 Cayenne, France; [Agostini, Camille] Ctr Hosp Ouest Guyanais, F-97320 St Laurent Du Maroni, France; [Ballet, Mathilde] Agence Reg Sante Guyane, F-97300 Cayenne, France; [Nacher, Mathieu; Adenis, Antoine; Djossou, Felix; Epelboin, Loic] Univ Guyane, DFR Sante, Campus Troubiran, F-97337 Cayenne, France; [Valdes, Audrey] Ctr Hosp Cayenne Andree Rosemon, Dept Hyg, F-97306 Cayenne, France; [Abboud, Philippe; Djossou, Felix; Epelboin, Loic] Ctr Hosp Cayenne Andree Rosemon, Unite Malad Infect & Trop, F-97306 Cayenne, France		Vignier, N (通讯作者)，Ctr Hosp Cayenne, Ctr Invest Clin Antilles Guyane, CIC Inserm 1424, DRISP, Av Flamboyants, F-97300 Cayenne, France.; Vignier, N (通讯作者)，Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ IPLESP, Dept Social Epidemiol, F-75012 Paris, France.; Vignier, N (通讯作者)，Univ Sorbonne Paris Nord, Fac Med, UFR SMBH, F-97300 Bobigny, France.	dr.vignier@gmail.com; k97.brureau@gmail.com; graniersibylle@gmail.com; jacques.14@icloud.com; celine.michaud@ch-cayenne.fr; melanie.gaillet@ch-cayenne.fr; c.agostini@ch-ouestguyane.fr; mathilde.ballet@ars.sante.fr; mathieu.nacher66@gmail.com; audrey.valdes@ch-cayenne.fr; philippe.abboud@ch-cayenne.fr; antoine.adenis@ch-cayenne.fr; felix.djossou@ch-cayenne.fr; epelboincrh@hotmail.fr; maylis.douine@ch-cayenne.fr	nacher, mathieu/AAH-4796-2021; Vignier, Nicolas/AAH-8382-2021	nacher, mathieu/0000-0001-9397-3204; Vignier, Nicolas/0000-0002-9410-9327; adenis, antoine/0000-0003-4000-4981; Douine, Maylis/0000-0003-4616-6690			Andronico A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21944-4; [Anonymous], 1995, NATURE, V373, P546, DOI [10.1038/373546a0, DOI 10.1038/373546A0]; Basurko C., 2020, Bulletin Epidemiologique Hebdomadaire, P582; Collaborative T.O., 2021, TRENDS CLIN CHARACTE, DOI [10.1101/2021.01.25.21250356, DOI 10.1101/2021.01.25.21250356]; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Epelboin L., EPIDEMIE COVID 19 CO; Faria N.R., SCIENCE, V372, P815, DOI [10.1126/science.abh2644, DOI 10.1126/SCIENCE.ABH2644]; Fedele F, 2021, HUM VACC IMMUNOTHER, V17, P3348, DOI 10.1080/21645515.2021.1928460; Flamand C, 2020, SEROPREVALENCE ANTIS, DOI [10.1101/2020.09.27.20202465, DOI 10.1101/2020.09.27.20202465]; Flamand C., SE PROTEGER SOI MEME; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Galanis PA, 2020, INTENTION HLTH CARE, DOI [10.1101/2020.12.08.20246041, DOI 10.1101/2020.12.08.20246041]; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Le Marechal M, 2018, CLIN MICROBIOL INFEC, V24, P858, DOI 10.1016/j.cmi.2017.10.021; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Mignot A, 2020, HUM VACC IMMUNOTHER, V16, P1125, DOI 10.1080/21645515.2019.1694328; Mouchet J, 2019, VACCINE, V37, P2142, DOI 10.1016/j.vaccine.2019.02.046; Mueller J., CROSS SECTIONAL STUD; Nacher M, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.586299; Nacher M, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008426; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Singh R, 2021, FASEB J, V35, DOI 10.1096/fj.202002662R; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Ward JK, 2019, NAT IMMUNOL, V20, P1257, DOI 10.1038/s41590-019-0488-9; Ward JK, 2016, SOC SCI MED, V159, P48, DOI 10.1016/j.socscimed.2016.05.003; WHO Organization, 2020, WHO SAGE VAL FRAM AL; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Woodhead C., 2021, ETHNIC HEALTH, P1, DOI [10.1080/13557858.2021.1936464, DOI 10.1080/13557858.2021.1936464]; World Health Organization, 2014, SAGE WORK GROUP VACC; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	44	6	7	12	21	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							682	10.3390/vaccines9060682			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SY5PH	34205613	Green Published, gold			2022-04-29	WOS:000665939200001
J	Yu, SC; Che, KD; Fang, L; Mao, HY; Lou, XY; Li, CN; Zhang, YJ				Yu, Sicong; Che, Keda; Fang, Lei; Mao, Haiyan; Lou, Xiuyu; Li, Chaonan; Zhang, Yanjun			Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans	VACCINES			English	Review						SARS-CoV-2; MERS-CoV; SARS-CoV; vaccine; neutralizing antibody	DNA VACCINE; IMMUNOGENICITY; SAFETY	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV) pose a great threat to humanity. Every pandemic involving these coronaviruses has seriously affected human health and economic development. Currently, there are no approved therapeutic drugs against their infections. Therefore, the development of vaccines is particularly important to combat these coronaviruses. In this review, we summarized and analyzed the progress of vaccines against SARS-CoV, MERS-CoV, and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, nucleic acid vaccines, and viral vector vaccines. In addition, we compared the levels of neutralizing antibodies in the serum of patients with these three kinds of coronaviruses at different stages, and their ability and effects against SARS-CoV-2, MERS-CoV, and SARS-CoV. This review provides useful information for vaccine evaluation and analysis.	[Yu, Sicong] Zhejiang Chinese Med Univ, Sch Med Technol & Informat Engn, Hangzhou 310053, Peoples R China; [Yu, Sicong; Fang, Lei; Mao, Haiyan; Lou, Xiuyu; Zhang, Yanjun] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou 310051, Peoples R China; [Che, Keda; Li, Chaonan] Zhejiang Shuren Univ, Shulan Int Med Coll, Hangzhou 310015, Peoples R China		Zhang, YJ (通讯作者)，Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou 310051, Peoples R China.	yu.sicong@foxmail.com; chenkd@zjsru.edu.cn; lfang@cdc.zj.cn; hymao@cdc.zj.cn; xylou@cdc.zj.cn; 201930001207@stu.zjsru.edu.cn; zhangyjtt@163.com		Li, Chaonan/0000-0002-5514-842X; Chen, Keda/0000-0002-9469-0991	Chinese Foundation for Key Research and Development Program of Zhejiang Province [2021C03044]; Major Health Science and Technology Projects of Zhejiang Province [WKJ-ZJ-2105]; Health Leading Talents Program of Zhejiang Province [CX-9]	Yanjun Zhang was supported by the Chinese Foundation for Key Research and Development Program of Zhejiang Province, program number 2021C03044; Major Health Science and Technology Projects of Zhejiang Province, projects number WKJ-ZJ-2105; Health Leading Talents Program of Zhejiang Province, program number CX-9.	Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; [Anonymous], INTERIM REPORT SAFET, DOI [10.1101/2021.03.31.21254494v1, DOI 10.1101/2021.03.31.21254494V1]; [Anonymous], CORONAVIRUS DIS COVI; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Custers J, 2021, VACCINE, V39, P3081, DOI 10.1016/j.vaccine.2020.09.018; Danese E, 2021, CLIN CHEM LAB MED, V59, P1585, DOI 10.1515/cclm-2021-0339; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Favresse J, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.05.004; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Folegatti PM, 2020, LANCET INFECT DIS, V20, P816, DOI 10.1016/S1473-3099(20)30160-2; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Goepfert PA, 2021, LANCET INFECT DIS, V21, P1257, DOI [10.1016/S1473-3099(21)00147-X, 10.1016/S1473-3099(21)00227-9]; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682; Koch T, 2020, LANCET INFECT DIS, V20, P827, DOI 10.1016/S1473-3099(20)30248-6; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Lin JT, 2007, ANTIVIR THER, V12, P1107; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; MacNeil JR, 2021, MMWR-MORBID MORTAL W, V70, P651, DOI 10.15585/mmwr.mm7017e4; Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026; Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X; Mohamadian M, 2021, J GENE MED, V23, DOI 10.1002/jgm.3303; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0; Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878; Neerukonda SN, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248348; Neerukonda SN, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060426; Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421; Pinto Dora, 2020, bioRxiv, DOI 10.1101/2020.04.07.023903; Rauch S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00311-w; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; See I, 2021, JAMA-J AM MED ASSOC, V325, P2448, DOI 10.1001/jama.2021.7517; Singh J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030439; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Solforosi L, 2021, J EXP MED, V218, DOI 10.1084/jem.20202756; Tebas P, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100689; van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y; Voss D, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-79; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang MY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.587269; WHO, SUMM POSS SARS CAS; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Xiong HL, 2020, EMERG MICROBES INFEC, V9, P2105, DOI 10.1080/22221751.2020.1815589; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	60	1	1	5	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							588	10.3390/vaccines9060588			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3XE	34199384	gold, Green Published			2022-04-29	WOS:000666501400001
J	Bono, SA; Villela, EFD; Siau, CS; Chen, WS; Pengpid, S; Hasan, MT; Sessou, P; Ditekemena, JD; Amodan, BO; Hosseinipour, MC; Dolo, H; Fodjo, JNS; Low, WY; Colebunders, R				Bono, Suzanna Awang; Faria de Moura Villela, Edlaine; Siau, Ching Sin; Chen, Won Sun; Pengpid, Supa; Hasan, M. Tasdik; Sessou, Philippe; Ditekemena, John D.; Amodan, Bob Omoda; Hosseinipour, Mina C.; Dolo, Housseini; Siewe Fodjo, Joseph Nelson; Low, Wah Yun; Colebunders, Robert			Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low-and Middle-Income Countries	VACCINES			English	Article						COVID-19; vaccine acceptance; LMICs; healthcare worker; psychological distress; Brazil; Malaysia; Thailand; Bangladesh; Africa	UNITED-STATES; ACCEPTABILITY; HESITANCY; ADULTS	Vaccination is fast becoming a key intervention against the ongoing COVID-19 pandemic. We conducted cross-sectional online surveys to investigate COVID-19 vaccine acceptance across nine Low- and Middle-Income Countries (LMICs; N = 10,183), assuming vaccine effectiveness at 90% and 95%. The prevalence of vaccine acceptance increased from 76.4% (90% effectiveness) to 88.8% (95% effectiveness). Considering a 90% effective vaccine, Malaysia, Thailand, Bangladesh, and five African countries (Democratic Republic of Congo, Benin, Uganda, Malawi, and Mali) had lower acceptance odds compared to Brazil. Individuals who perceived taking the vaccine as important to protect themselves had the highest acceptance odds (aOR 2.49) at 95% effectiveness.Vaccine acceptance was also positively associated with COVID-19 knowledge, worry/fear regarding COVID-19, higher income, younger age, and testing negative for COVID-19. However, chronic disease and female gender reduced the odds for vaccine acceptance. The main reasons underpinning vaccine refusal were fear of side effects (41.2%) and lack of confidence in vaccine effectiveness (15.1%). Further research is needed to identify country-specific reasons for vaccine hesitancy in order to develop mitigation strategies that would ensure high and equitable vaccination coverage across LMICs.	[Bono, Suzanna Awang] Univ Sains Malaysia, Sch Social Sci, Gelugor 11800, Malaysia; [Faria de Moura Villela, Edlaine] Sao Paulo State Hlth Dept, Dis Control Coordinat, BR-01246000 Sao Paulo, Brazil; [Faria de Moura Villela, Edlaine] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, BR-74690900 Goiania, Go, Brazil; [Siau, Ching Sin] Univ Kebangsaan Malaysia, Ctr Community Hlth Studies ReaCH, Fac Hlth Sci, Kuala Lumpur 50300, Malaysia; [Chen, Won Sun] Swinburne Univ Technol, Dept Hlth Sci & Biostat, Fac Hlth Arts & Design, Hawthorn, Vic 3122, Australia; [Pengpid, Supa] Mahidol Univ, ASEAN Inst Hlth Dev, Nakhon Pathom 73170, Thailand; [Hasan, M. Tasdik] Publ Hlth Fdn Bangladesh PHF BD, Dhaka 1217, Bangladesh; [Hasan, M. Tasdik] Univ Liverpool, Dept Primary Care & Mental Hlth, Liverpool L69 3BX, Merseyside, England; [Sessou, Philippe] Univ Abomey Calavi, Res Unit Communicable Dis, Polytech Sch Abomey Calavi, 01 BP 526, Cotonou, Benin; [Ditekemena, John D.] Univ Kinshasa, Kinshasa Sch Publ Hlth, Kinshasa 7948, DEM REP CONGO; [Amodan, Bob Omoda] Uganda Publ Hlth Fellowship Program, Loudel Towers,Level 4, Kampala, Uganda; [Hosseinipour, Mina C.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Hosseinipour, Mina C.] Univ North Carolina UNC Project Malawi, Lilongwe, Malawi; [Dolo, Housseini] Fac Med & OdontoStomatol, Int Ctr Excellence Res, Bamako, Mali; [Siewe Fodjo, Joseph Nelson; Colebunders, Robert] Univ Antwerp, Global Hlth Inst, B-2000 Antwerp, Belgium; [Siewe Fodjo, Joseph Nelson] Brain Res Africa Initiat BRAIN, POB 25625, Yaounde, Cameroon; [Low, Wah Yun] Univ Malaya, Fac Med, Kuala Lumpur 50603, Malaysia; [Low, Wah Yun] Univ Malaya, Asia Europe Inst, Kuala Lumpur 50603, Malaysia		Siau, CS (通讯作者)，Univ Kebangsaan Malaysia, Ctr Community Hlth Studies ReaCH, Fac Hlth Sci, Kuala Lumpur 50300, Malaysia.	suzanna.bono@usm.my; edlaine@alumni.usp.br; chingsin.siau@ukm.edu.my; wchen@swin.edu.au; supa.pen@mahidol.ac.th; tasdikhdip@yahoo.com; sessouphilippe@yahoo.fr; jditekemena@hotmail.fr; bomoda@musph.ac.ug; mina_hosseinipour@med.unc.edu; dolohousseini@yahoo.fr; josephnelson.siewefodjo@uantwerpen.be; lowwy@um.edu.my; robert.colebunders@uantwerpen.be	Bono, Suzanna/ABB-9182-2020; Low, Wah Yun/B-1775-2009; Sessou, Philippe/M-5107-2017	Bono, Suzanna/0000-0003-2143-2622; Low, Wah Yun/0000-0003-4409-1509; Sessou, Philippe/0000-0003-4154-9211; Colebunders, Robert/0000-0002-1919-1340; Siau, Ching Sin/0000-0001-7612-6839; Chen, Won Sun/0000-0001-9077-3530; Siewe Fodjo, Joseph Nelson/0000-0003-3544-1239; Hasan, M. Tasdik/0000-0002-3256-093X; Amodan, Bob Omoda/0000-0002-4561-1337; Faria de Moura Villela, Edlaine/0000-0002-7043-2007	VLIRUOS (Flemish Interuniversity Council for University Development Cooperation)	This research was funded by VLIRUOS (Flemish Interuniversity Council for University Development Cooperation).	[Anonymous], 2020, LANCET, V395, P1461, DOI 10.1016/S0140-6736(20)31095-3; Bethlehem J, 2010, INT STAT REV, V78, P161, DOI 10.1111/j.1751-5823.2010.00112.x; Christ S.L, 2008, INT HDB SURVEY METHO; Dash S, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004671; De Man J, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-043866; Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153; Dooling K, 2020, MMWR-MORBID MORTAL W, V69, P1857, DOI 10.15585/mmwr.mm6949e1; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Hacquin AS, 2020, PSYARXIV, DOI [10.31234/osf.io/r8h6z, DOI 10.31234/OSF.IO/R8H6Z]; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; He JY, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0619-8; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jay J, 2020, NAT HUM BEHAV, V4, DOI 10.1038/s41562-020-00998-2; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Malik AA, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100495; Marcel S, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20225; Mein SA, 2020, J GEN INTERN MED, V35, P2439, DOI 10.1007/s11606-020-05880-5; Mo PKH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020129; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Our World in Data, 2021, CORONAVIRUS COVID 19; Peck J., 2011, EXTENSION COMMANDS R; Persad G, 2020, JAMA-J AM MED ASSOC, V324, P1601, DOI 10.1001/jama.2020.18513; Peter Mwa, BBC NEWS 0423; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Torjesen I, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3226; WHO, COR DIS COVID 19 DAS; WHO, COVID 19 VACC; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wu DC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240778; Yansaneh I.S., 2003, CONSTRUCTION USE SAM; Yeung MPS, 2016, J PUBLIC HEALTH-UK, V38, P746, DOI 10.1093/pubmed/fdv194	45	46	46	8	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							515	10.3390/vaccines9050515			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1YQ	34067682	Green Published, gold			2022-04-29	WOS:000654621900001
J	Deignan, C; Swartz, A; Cooper, S; Colvin, CJ				Deignan, Caroline; Swartz, Alison; Cooper, Sara; Colvin, Christopher J.			Stakeholders' Understandings of Human Papillomavirus (HPV) Vaccination in Sub-Saharan Africa: A Rapid Qualitative Systematic Review	VACCINES			English	Review						Human Papillomavirus (HPV); vaccination; Sub-Saharan Africa (SSA); stakeholder understandings; rapid qualitative systematic review; thematic analysis	SOUTH-AFRICA; ACCEPTABILITY; KNOWLEDGE	Cervical cancer rates in Sub-Saharan Africa (SSA) are amongst the highest worldwide. All three of the Human Papillomavirus (HPV) vaccines (9-valent, quadrivalent and bivalent HPV vaccine) provide primary protection against the most common cancer-causing strains of HPV (types 16 and 18) that are known to cause 70% of cervical cancers. Over the last five years, there has been an increase in Sub-Saharan African countries that have introduced the HPV vaccine. The majority of research has been conducted on supply-side barriers and facilitators to HPV vaccination uptake in SSA, yet little research has been conducted on demand-side or end-user perspectives of, and decisions around, HPV vaccination. In order to complement existing research, and inform current and future HPV vaccination implementation approaches, this qualitative systematic review explored Stakeholders' understandings of HPV vaccination in SSA. This review searched the following databases: Embase (via Scopus), Scopus, MEDLINE (via PubMed), PubMed, EBSCOhost, Academic Search Premier, Africa-Wide Information, CINAHL, PsycARTICLES, PsycINFO, SocINDEX, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL) and found a total of 259 articles. Thirty-one studies were found eligible for inclusion and were analyzed thematically using Braun and Clarke's methods for conducting a thematic analysis. The quality of included studies was assessed using the Critical Appraisal Skills Programme (CASP) checklist. Three major themes emerged from this analysis; knowledge of HPV vaccination and cervical cancer is intertwined with misinformation; fear has shaped contradictory perceptions about HPV vaccination and gender dynamics are relevant in how stakeholders understand HPV vaccination in SSA.	[Deignan, Caroline; Swartz, Alison; Colvin, Christopher J.] Univ Cape Town, Sch Publ Hlth & Family Med, Div Social & Behav Sci, ZA-7935 Cape Town, South Africa; [Cooper, Sara] South African Med Res Council, ZA-7501 Cape Town, South Africa		Deignan, C (通讯作者)，Univ Cape Town, Sch Publ Hlth & Family Med, Div Social & Behav Sci, ZA-7935 Cape Town, South Africa.	dgncar001@myuct.ac.za; alison.swartz@uct.ac.za; Sara.cooper@mrc.ac.za; cj.colvin@uct.ac.za		Cooper, Sara/0000-0001-9894-236X; Deignan, Caroline/0000-0003-0417-4844			Abdullahi LH, 2014, SYST REV, V3, DOI 10.1186/2046-4053-3-100; Altman D.G., 2009, PRISMA STATEMENT PLO, V6, DOI [10.1371/journal.pmed.1000097, DOI 10.1371/JOURNAL.PMED.1000097]; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P241; Balogun F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203950; Bingham A, 2009, ARCH PEDIAT ADOL MED, V163, P455, DOI 10.1001/archpediatrics.2009.50; Black E, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030061; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI DOI 10.1191/1478088706QP063OA; Brewer NT, 2018, PEDIATRICS, V141, DOI 10.1542/peds.141.1_MeetingAbstract.110; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; CDC CDC, WHAT IS HPV; Chido-Amajuoyi OG, 2019, LANCET GLOB HEALTH, V7, pE20, DOI 10.1016/S2214-109X(18)30405-4; Crann SE, 2016, J PSYCHOSOM OBST GYN, V37, P147, DOI 10.1080/0167482X.2016.1199544; Daley EM, 2017, PAPILLOMAVIRUS RES, V3, P142, DOI 10.1016/j.pvr.2017.04.004; Melo BAD, 2021, BRAZ J OTORHINOLAR, V87, P346, DOI 10.1016/j.bjorl.2020.10.017; de Sanjos? S., HUMAN PAPILLOMAVIRUS; Dochez C, 2017, PAPILLOMAVIRUS RES, V4, P66, DOI 10.1016/j.pvr.2017.08.003; Dyer SJ, 2002, HUM REPROD, V17, P1657, DOI 10.1093/humrep/17.6.1657; Feller Liviu, 2009, Infect Agent Cancer, V4, P16, DOI 10.1186/1750-9378-4-16; Francis SA, 2013, MATERN CHILD HLTH J, V17, P1222, DOI 10.1007/s10995-012-1116-6; Francis Shelley A, 2013, Afr J Reprod Health, V17, P158; Francis SA, 2011, VACCINE, V29, P8760, DOI 10.1016/j.vaccine.2011.07.116; Friedman AL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-855; Gallagher KE, 2018, VACCINE, V36, P4761, DOI 10.1016/j.vaccine.2018.02.003; GAVI GAVI, GAV VACC ALL; Gopichandran Vijayaprasad, 2017, Indian J Med Ethics, V2, P98; Gorjana R, 2017, PREV MED, V95, P26, DOI 10.1016/j.ypmed.2016.11.019; GRADE-CERQual GRADE-CERQual, WHAT IS GRADE CERQUA; Graham Suzanne, 2008, Perm J, V12, P67; Greenfield LS, 2015, J ADOLESCENT HEALTH, V56, pS47, DOI 10.1016/j.jadohealth.2014.10.274; Harden A, 2004, J EPIDEMIOL COMMUN H, V58, P794, DOI 10.1136/jech.2003.014829; Harries J, 2009, VACCINE, V27, P38, DOI 10.1016/j.vaccine.2008.10.033; Hasahya O.T., 2016, GLOBAL HEALTH ACTION, V9, P29336, DOI [10.3402/gha.v9.29336, DOI 10.3402/gha.v9.29336]; Inhorn MC, 2015, HUM REPROD UPDATE, V21, P411, DOI 10.1093/humupd/dmv016; Islam JY, 2018, CANCER CAUSE CONTROL, V29, P1115, DOI 10.1007/s10552-018-1085-1; Katahoire A, 2013, INT J CHILD ADOL HLT, V6, P211; Katahoire R A, 2008, Afr J Reprod Health, V12, P159; Katz IT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072094; Kisaakye E, 2018, PAN AFR MED J, V31, DOI 10.11604/pamj.2018.31.184.14801; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Marshall S, 2019, RES SOC ADMIN PHARM, V15, P331, DOI 10.1016/j.sapharm.2018.05.013; Masika MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135563; Moodley J, 2009, SAMJ S AFR MED J, V99, P128; Nelson JA, 2010, SEX REPROD HEALTHC, V1, P195, DOI 10.1016/j.srhc.2010.07.004; Newman PA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019206; Nyambe A, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5164-1; Obol JH, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09482-y; Odendaal W.A., 2015, COCHRANE DB SYST REV, V2015, P011942, DOI [10.1002/14651858.CD011942, DOI 10.1002/14651858.CD011942]; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Perlman S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090912; Ports KA, 2013, WOMEN HEALTH, V53, P630, DOI 10.1080/03630242.2013.809046; Remes P, 2012, VACCINE, V30, P5363, DOI 10.1016/j.vaccine.2012.06.025; Soi C, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0846-2; Turiho Andrew Kampikaho, 2017, BMC Res Notes, V10, P431, DOI 10.1186/s13104-017-2749-8; Turiho AK, 2014, AFR J REPROD HEALTH, V18, P45; Venturas C, 2017, VACCINE, V35, P1886, DOI 10.1016/j.vaccine.2017.02.052; Vermandere H., 2016, AFR FOCUS, V29, P117, DOI [10.1163/2031356X-02902010, DOI 10.1163/2031356X-02902010, 10.21825/af.v29i2.4851, DOI 10.21825/AF.V29I2.4851]; Vermandere H, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2219-y; Watson-Jones D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123701; Watson-Jones D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045231; WHO WHO, CERV CANC COMM AM AF; World Health Organization, HUMAN PAPILLOMAVIRUS	61	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							496	10.3390/vaccines9050496			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1YE	34065961	gold, Green Published			2022-04-29	WOS:000654620700001
J	Kvisgaard, LK; Larsen, LE; Kristensen, CS; Paboeuf, F; Renson, P; Bourry, O				Kvisgaard, Lise K.; Larsen, Lars E.; Kristensen, Charlotte S.; Paboeuf, Frederic; Renson, Patricia; Bourry, Olivier			Challenge of Naive and Vaccinated Pigs with a Vaccine-Derived Recombinant Porcine Reproductive and Respiratory Syndrome Virus 1 Strain (Horsens Strain)	VACCINES			English	Article						porcine reproductive and respiratory syndrome virus; recombination; vaccines; swine; PRRSV; vaccine efficacy	ANTIGENIC CHARACTERIZATION; INFECTION; DISEASE	In July 2019, a vaccine-derived recombinant Porcine reproductive and respiratory syndrome virus 1 strain (PRRSV-1) (Horsens strain) infected more than 40 Danish sow herds, resulting in severe losses. In the present study, the pathogenicity of the recombinant Horsens strain was assessed and compared to a reference PRRSV-1 strain using a well-characterized experimental model in young SPF pigs. Furthermore, the efficacies of three different PRRSV-1 MLV vaccines to protect pigs against challenge with the recombinant strain were assessed. Following challenge, the unvaccinated pigs challenged with the Horsens strain had significant increased viral load in serum compared to all other groups. No macroscopic changes were observed at necropsy, but tissue from the lungs and tonsils from almost all pigs were PRRSV-positive. The viral load in serum was lower in all vaccinated groups compared to the unvaccinated group challenged with the Horsens strain, and only small differences were seen among the vaccinated groups. The findings in the present study, combined with two other recent reports, indicate that this recombinant "Horsens" strain indeed is capable of inducing infection in growing pigs as well as in pregnant sows that is comparable to or even exceeding those induced by typical PRRSV-1, subtype 1 strains. However, absence of notable clinical signs and lack of significant macroscopic changes indicate that this strain is less virulent than previously characterized highly virulent PRRSV-1 strains.	[Kvisgaard, Lise K.; Larsen, Lars E.] Univ Copenhagen, Inst Vet & Anim Sci, Sect Vet Clin Microbiol, DK-1870 Frederiksberg C, Denmark; [Kristensen, Charlotte S.] Danish Pig Res Ctr, SEGES, DK-8200 Aarhus N, Denmark; [Paboeuf, Frederic; Renson, Patricia; Bourry, Olivier] Agence Natl Secur Sanit Alimentat Environm & Trav, Lab Ploufragan Plouzane Niort, F-22440 Ploufragan, France		Kvisgaard, LK (通讯作者)，Univ Copenhagen, Inst Vet & Anim Sci, Sect Vet Clin Microbiol, DK-1870 Frederiksberg C, Denmark.	likik@sund.ku.dk; lael@sund.ku.dk; csk@seges.dk; frederic.paboeuf@anses.fr; Patricia.RENSON@anses.fr; Olivier.BOURRY@anses.fr	; Larsen, Lars Erik/G-3827-2015	BOURRY, Olivier/0000-0003-0220-0922; Patricia, RENSON/0000-0001-8329-8479; Larsen, Lars Erik/0000-0003-0730-5555	SEGES	This work was partly funded by a grant provided by SEGES.	Afonso CL, 2016, ARCH VIROL, V161, P2351, DOI 10.1007/s00705-016-2880-1; Canelli E, 2018, VET MICROBIOL, V226, P89, DOI 10.1016/j.vetmic.2018.10.001; Dortmans JCFM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218481; Eclercy J, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030296; Frossard JP, 2013, VET MICROBIOL, V162, P507, DOI 10.1016/j.vetmic.2012.11.011; Frydas IS, 2015, VET RES, V46, DOI 10.1186/s13567-015-0166-3; Genis S, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090772; Karniychuk UU, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-30; Kristensen CS, 2020, PORCINE HEALTH MANAG, V6, DOI 10.1186/s40813-020-00165-z; Kvisgaard LK, 2017, VET MICROBIOL, V211, P74, DOI 10.1016/j.vetmic.2017.10.001; Kvisgaard LK, 2013, VIRUS RES, V178, P197, DOI 10.1016/j.virusres.2013.10.009; Kvisgaard LK, 2020, TRANSBOUND EMERG DIS, V67, P1786, DOI 10.1111/tbed.13555; Liu JK, 2017, VET MICROBIOL, V204, P110, DOI 10.1016/j.vetmic.2017.04.017; Martin-Valls GE, 2014, J VIROL, V88, P3170, DOI 10.1128/JVI.02858-13; Marton S, 2019, ARCH VIROL, V164, P2605, DOI 10.1007/s00705-019-04338-2; Murtaugh MP, 2011, VACCINE, V29, P8192, DOI 10.1016/j.vaccine.2011.09.013; Renson P, 2017, MICROBIOL RESOUR ANN, V5, DOI [10.1128/genomeA.00454-17, 10.1128/genomea.00454-17]; Renson P, 2017, VET RES, V48, DOI 10.1186/s13567-017-0420-y; Rose N, 2015, VACCINE, V33, P2493, DOI 10.1016/j.vaccine.2015.03.040; Sinn LJ, 2016, PORCINE HEALTH MANAG, V2, DOI 10.1186/s40813-016-0044-z; Sinn LJ, 2016, VET RES, V47, DOI 10.1186/s13567-015-0293-x; Stadejek T, 2017, VET MICROBIOL, V209, P13, DOI 10.1016/j.vetmic.2017.05.011; van Geelen AGM, 2018, VIROLOGY, V513, P168, DOI 10.1016/j.virol.2017.10.002; Weesendorp E, 2013, VET MICROBIOL, V163, P1, DOI 10.1016/j.vetmic.2012.09.013; Wernike K, 2012, J VET DIAGN INVEST, V24, P855, DOI 10.1177/1040638712452724; Zhao HJ, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0735-3	26	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							417	10.3390/vaccines9050417			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1UF	33921958	Green Published			2022-04-29	WOS:000654610400001
J	Speziale, P; Pietrocola, G				Speziale, Pietro; Pietrocola, Giampiero			Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci	VACCINES			English	Review						Staphylococcus aureus; Staphylococcus epidermidis; virulence factor; infectious diseases; monoclonal antibody; passive immunization	FACTOR-BINDING-PROTEIN; CLUMPING FACTOR-B; CHEMOTAXIS INHIBITORY PROTEIN; ACCUMULATION-ASSOCIATED PROTEIN; EPIDERMIDIS BIOFILM FORMATION; ADHESIVE MATRIX MOLECULES; AUREUS COLLAGEN ADHESIN; VIRULENCE DETERMINANT; FIBRONECTIN-BINDING; SEPTIC ARTHRITIS	Staphylococci (specifically Staphylococcus aureus and Staphylococcus epidermidis) are the causative agents of diseases ranging from superficial skin and soft tissue infections to severe conditions such as fatal pneumonia, bacteremia, sepsis and endocarditis. The widespread and indiscriminate use of antibiotics has led to serious problems of resistance to staphylococcal disease and has generated a renewed interest in alternative therapeutic agents such as vaccines and antibodies. Staphylococci express a large repertoire of surface and secreted virulence factors, which provide mechanisms (adhesion, invasion and biofilm development among others) for both bacterial survival in the host and evasion from innate and adaptive immunity. Consequently, the development of antibodies that target specific antigens would provide an effective protective strategy against staphylococcal infections. In this review, we report an update on efforts to develop anti-staphylococci monoclonal antibodies (and their derivatives: minibodies, antibody-antibiotic conjugates) and the mechanism by which such antibodies can help fight infections. We also provide an overview of mAbs used in clinical trials and highlight their therapeutic potential in various infectious contexts.	[Speziale, Pietro; Pietrocola, Giampiero] Univ Pavia, Biochem Unit, Dept Mol Med, I-27100 Pavia, Italy		Speziale, P (通讯作者)，Univ Pavia, Biochem Unit, Dept Mol Med, I-27100 Pavia, Italy.	pspeziale@unipv.it; giampiero.pietrocola@unipv.it		PIETROCOLA, GIAMPIERO/0000-0002-7069-8155			Aguilar JL, 2017, VIRULENCE, V8, P741, DOI 10.1080/21505594.2016.1231295; Anderson AS, 2012, J INFECT DIS, V205, P1688, DOI 10.1093/infdis/jis272; Anderson MJ, 2018, TOXINS, V10, DOI 10.3390/toxins10040157; Arciola CR, 2018, NAT REV MICROBIOL, V16, P397, DOI 10.1038/s41579-018-0019-y; Baker M, 2006, NAT BIOTECHNOL, V24, P1491, DOI 10.1038/nbt1206-1491; Bartual SG, 2018, INT J MED MICROBIOL, V308, P692, DOI 10.1016/j.ijmm.2017.10.003; Bispo M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139512; Bjerketorp J, 2004, FEMS MICROBIOL LETT, V234, P309, DOI 10.1016/j.femsle.2004.03.040; Bjerketorp J, 2002, MICROBIOL-SGM, V148, P2037, DOI 10.1099/00221287-148-7-2037; Bowden MG, 2002, J BIOL CHEM, V277, P43017, DOI 10.1074/jbc.M207921200; Brown M, 2009, CLIN VACCINE IMMUNOL, V16, P1095, DOI 10.1128/CVI.00085-09; Brusselmans K, 2007, J BIOL CHEM, V282, P18777, DOI 10.1074/jbc.M611763200; Buttner H, 2020, MBIO, V11, DOI 10.1128/mBio.01612-20; Burnie JP, 2000, INFECT IMMUN, V68, P3200, DOI 10.1128/IAI.68.6.3200-3209.2000; Caiazza NC, 2003, J BACTERIOL, V185, P3214, DOI 10.1128/JB.185.10.3214-3217.2003; Chen XH, 2020, P NATL ACAD SCI USA, V117, P22992, DOI 10.1073/pnas.2003621117; Chen XH, 2019, J INFECT DIS, V219, P884, DOI 10.1093/infdis/jiy597; Cheung GYC, 2021, VIRULENCE, V12, P547, DOI 10.1080/21505594.2021.1878688; Christner M, 2010, MOL MICROBIOL, V75, P187, DOI 10.1111/j.1365-2958.2009.06981.x; de Haas CJC, 2004, J EXP MED, V199, P687, DOI 10.1084/jem.20031636; De Jong NWM, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0061-2019; Descotes J, 2009, MABS, V1, P104, DOI 10.4161/mabs.1.2.7909; Elasri MO, 2002, BONE, V30, P275, DOI 10.1016/S8756-3282(01)00632-9; Estelles A, 2016, ANTIMICROB AGENTS CH, V60, P2292, DOI 10.1128/AAC.02588-15; Falugi F, 2013, MBIO, V4, DOI 10.1128/mBio.00575-13; Foster TJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01829; Foster TJ, 2019, TRENDS MICROBIOL, V27, P927, DOI 10.1016/j.tim.2019.06.007; Foster TJ, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0046-2018; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Ganesh VK, 2011, J BIOL CHEM, V286, P25963, DOI 10.1074/jbc.M110.217414; Ganesh VK, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000226; Georgoutsou-Spyridonos M, 2015, J IMMUNOL, V195, P3946, DOI 10.4049/jimmunol.1500966; Gomez MI, 2006, J BIOL CHEM, V281, P20190, DOI 10.1074/jbc.M601956200; Goodman SD, 2011, MUCOSAL IMMUNOL, V4, P625, DOI 10.1038/mi.2011.27; Haas PJ, 2004, J IMMUNOL, V173, P5704, DOI 10.4049/jimmunol.173.9.5704; Hall AE, 2003, INFECT IMMUN, V71, P6864, DOI 10.1128/IAI.71.12.6864-6870.2003; Hall AE, 2007, HYBRIDOMA, V26, P28, DOI 10.1089/hyb.2006.039; Heilmann C, 2003, MICROBIOL-SGM, V149, P2769, DOI 10.1099/mic.0.26527-0; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; Herman-Bausier P, 2016, MBIO, V7, DOI 10.1128/mBio.01529-16; Hoekstra H, 2018, VIRULENCE, V9, P70, DOI 10.1080/21505594.2017.1294297; Horsburgh MJ, 2002, MOL MICROBIOL, V44, P1269, DOI 10.1046/j.1365-2958.2002.02944.x; Hua L, 2014, ANTIMICROB AGENTS CH, V58, P1108, DOI 10.1128/AAC.02190-13; Janeway C.A, 2001, IMMUNO BIOL, V5th ed., P123; Jongerius I, 2007, J EXP MED, V204, P2461, DOI 10.1084/jem.20070818; Kang MS, 2013, J BIOL CHEM, V288, P20520, DOI 10.1074/jbc.M113.454462; Karau MJ, 2017, VIRULENCE, V8, P1148, DOI 10.1080/21505594.2016.1267894; Khodaparast L, 2016, INFECT GENET EVOL, V43, P222, DOI 10.1016/j.meegid.2016.05.037; Kim HK, 2012, INFECT IMMUN, V80, P3460, DOI 10.1128/IAI.00230-12; Kim HK, 2010, J EXP MED, V207, P1863, DOI 10.1084/jem.20092514; Kirchdoerfer RN, 2011, J BIOL CHEM, V286, P17351, DOI 10.1074/jbc.M111.231258; Ko YP, 2011, J BIOL CHEM, V286, P9865, DOI 10.1074/jbc.M110.199687; Kroh HK, 2009, P NATL ACAD SCI USA, V106, P7786, DOI 10.1073/pnas.0811750106; Kuby J, 1994, IMMUNOLOGY, V2nd ed., P109; Kukita K, 2013, INFECT IMMUN, V81, P1870, DOI 10.1128/IAI.00011-13; Lehar SM, 2015, NATURE, V527, P323, DOI 10.1038/nature16057; Liu Y, 2018, NAT MICROBIOL, V3, P622, DOI 10.1038/s41564-018-0146-2; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Mariathasan S, 2017, TRENDS MOL MED, V23, P135, DOI 10.1016/j.molmed.2016.12.008; Mariotti P, 2013, BIOCHEM J, V449, P683, DOI 10.1042/BJ20121426; Millenbaugh NJ, 2015, INT J NANOMED, V10, P1953, DOI 10.2147/IJN.S76150; Moldenhauer G., 2010, HDB THERAPEUTIC ANTI, P19; Mulcahy ME, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003092; Nguyen HTT, 2020, COMPUT STRUCT BIOTEC, V18, P3324, DOI 10.1016/j.csbj.2020.10.027; Nguyen MT, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.582582; O'Seaghdha M, 2006, FEBS J, V273, P4831, DOI 10.1111/j.1742-4658.2006.05482.x; Oganesyan V, 2014, J BIOL CHEM, V289, P29874, DOI 10.1074/jbc.M114.601328; Ortines RV, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.02288-17, 10.1128/aac.02288-17]; Otto M, 2010, EXPERT OPIN BIOL TH, V10, P1049, DOI 10.1517/14712598.2010.495115; Otto M, 2009, NAT REV MICROBIOL, V7, P555, DOI 10.1038/nrmicro2182; Paharik AE, 2017, MOL MICROBIOL, V103, P860, DOI 10.1111/mmi.13594; Panizzi P, 2006, J BIOL CHEM, V281, P1169, DOI 10.1074/jbc.M507955200; Park J, 2007, CHEM BIOL, V14, P1119, DOI 10.1016/j.chembiol.2007.08.013; Patti JM, 2004, VACCINE, V22, pS39, DOI 10.1016/j.vaccine.2004.08.015; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; Perkins S, 2001, J BIOL CHEM, V276, P44721, DOI 10.1074/jbc.M106741200; Pietrocola G, 2020, J BIOL CHEM, V295, P10008, DOI 10.1074/jbc.RA120.013510; Pietrocola G, 2019, J BIOL CHEM, V294, P3588, DOI 10.1074/jbc.RA118.005707; Pietrocola G, 2016, J BIOL CHEM, V291, P18148, DOI 10.1074/jbc.M116.731125; Ponnuraj K, 2003, CELL, V115, P217, DOI 10.1016/S0092-8674(03)00809-2; Postma B, 2005, J BIOL CHEM, V280, P2020, DOI 10.1074/jbc.M412230200; Rhem MN, 2000, INFECT IMMUN, V68, P3776, DOI 10.1128/IAI.68.6.3776-3779.2000; Rohde H, 2005, MOL MICROBIOL, V55, P1883, DOI 10.1111/j.1365-2958.2005.04515.x; Rooijakkers SHM, 2006, CELL MICROBIOL, V8, P1282, DOI 10.1111/j.1462-5822.2006.00709.x; Rouha H, 2015, MABS-AUSTIN, V7, P243, DOI 10.4161/19420862.2014.985132; Rukkawattanakul T, 2017, TOXINS, V9, DOI 10.3390/toxins9020050; Ruzin A, 2018, CLIN TRANSL IMMUNOL, V7, DOI 10.1002/cti2.1009; Schaffer AC, 2006, INFECT IMMUN, V74, P2145, DOI 10.1128/IAI.74.4.2145-2153.2006; Scherr TD, 2015, MBIO, V6, DOI 10.1128/mBio.01021-15; Shahrooei M, 2009, INFECT IMMUN, V77, P3670, DOI 10.1128/IAI.01464-08; SPEZIALE P, 1984, J BACTERIOL, V157, P420, DOI 10.1128/JB.157.2.420-427.1984; Speziale P, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02054; Speziale P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121516; Speziale P, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00171; Stapels DAC, 2014, P NATL ACAD SCI USA, V111, P13187, DOI 10.1073/pnas.1407616111; Stulik L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41826-6; Sun DQ, 2005, CLIN DIAGN LAB IMMUN, V12, P93, DOI 10.1128/CDLI.12.1.93-100.2005; SWERLICK RA, 1986, J INVEST DERMATOL, V87, P367, DOI 10.1111/1523-1747.ep12524838; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; Tam K, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0039-2018; Thammavongsa V, 2015, VACCINE, V33, P523, DOI 10.1016/j.vaccine.2014.11.051; Thomas MG, 1999, J INFECT DIS, V179, P291, DOI 10.1086/314576; Thomas S, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00106; Thomer L, 2016, J EXP MED, V213, P293, DOI 10.1084/jem.20150074; Thomer L, 2013, J BIOL CHEM, V288, P28283, DOI 10.1074/jbc.M113.493122; Torres VJ, 2006, J BACTERIOL, V188, P8421, DOI 10.1128/JB.01335-06; Towell AM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2014444118; Tribelli PM, 2020, CELL MICROBIOL, V22, DOI 10.1111/cmi.13111; Valotteau C, 2017, ACS NANO, V11, P2160, DOI 10.1021/acsnano.6b08404; Varshney AK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190537; Varshney AK, 2014, J INFECT DIS, V210, P973, DOI 10.1093/infdis/jiu198; Viela F, 2019, MBIO, V10, DOI 10.1128/mBio.00555-19; Visai L, 2000, J BIOL CHEM, V275, P39837, DOI 10.1074/jbc.M005297200; Vor L., 2021, HUMAN MONOCLONAL ANT, DOI [10.1101/2021.02.09.429966, DOI 10.1101/2021.02.09.429966]; Walsh EJ, 2004, J BIOL CHEM, V279, P50691, DOI 10.1074/jbc.M408713200; Walsh EJ, 2008, MICROBIOL-SGM, V154, P550, DOI 10.1099/mic.0.2007/010868-0; Wang Y, 2017, P NATL ACAD SCI USA, V114, pE5094, DOI 10.1073/pnas.1703427114; Weems JJ, 2006, ANTIMICROB AGENTS CH, V50, P2751, DOI 10.1128/AAC.00096-06; Woehl JL, 2014, J IMMUNOL, V193, P6161, DOI 10.4049/jimmunol.1401600; Xiong YQ, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00904-17; Yang YH, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004169; Yang YL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149460; Yu XQ, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01020-16, 10.1128/aac.01020-16]; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhou TT, 2021, J MICROBIOL IMMUNOL, V54, P420, DOI 10.1016/j.jmii.2019.08.019	125	3	3	5	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							459	10.3390/vaccines9050459			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1IQ	34064471	Green Published, gold			2022-04-29	WOS:000654580200001
J	Calzetta, L; Ritondo, BL; Coppola, A; Matera, MG; Di Daniele, T; Rogliani, P				Calzetta, Luigino; Ritondo, Beatrice Ludovica; Coppola, Angelo; Matera, Maria Gabriella; Di Daniele, TNicola; Rogliani, Paola			Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials	VACCINES			English	Article						COVID-19; efficacy; meta-regression; modifying factors; SARS-Cov-2; vaccine	INCONSISTENCY; METAANALYSIS	To date, there is still a paucity of data from Phase III trials concerning the efficacy of vaccines against COVID-19. Furthermore, no studies investigated the variables that may modulate the efficacy of vaccination. The aim of this analysis was to assess whether there are modifying factors that may potentially influence the clinical efficacy of COVID-19 vaccines. A quantitative synthesis of data from Phase III trials was performed via pairwise and network meta-analyses, along with meta-regression analysis. Data from Phase III trials are currently available only for AZD1222, BNT162b2, mRNA-1237, and Sputnik V. Vaccination resulted to be generally effective (90.0%, 95%CI 72.6-96.4; p < 0.001), although the efficacy of AZD1222 (62.1%) introduced a significant level of heterogeneity in the meta-analysis (I-2 92.17%, p < 0.001). No significant modifying factors resulted from the meta-regression analysis. However, considering the mRNA-based vaccines, a trend toward significance (p = 0.081) resulted for age. The network meta-analysis provided the following rank of effectiveness: BNT162b2 similar or equal to mRNA-1273 > Sputnik V >> AZD1222. In conclusion, no modifying factors seem to modulate the efficacy of vaccines against COVID-19. This quantitative synthesis will need to be updated as soon as further clinical results on the efficacy profile are available from Phase III trials for further licensed COVID-19 vaccines.	[Calzetta, Luigino] Univ Parma, Dept Med & Surg, Resp Dis & Lung Funct Unit, I-43125 Parma, Italy; [Ritondo, Beatrice Ludovica; Coppola, Angelo; Rogliani, Paola] Univ Roma Tor Vergata, Dept Expt Med, Unit Resp Med, I-00133 Rome, Italy; [Matera, Maria Gabriella] Univ Campania Luigi Vanvitelli, Dept Expt Med, I-80138 Naples, Italy; [Di Daniele, TNicola] Univ Roma Tor Vergata, Dept Syst Med, I-00133 Rome, Italy		Calzetta, L (通讯作者)，Univ Parma, Dept Med & Surg, Resp Dis & Lung Funct Unit, I-43125 Parma, Italy.	luigino.calzetta@unipr.it; beatriceritondo@gmail.com; coppolangelo@gmail.com; mariagabriella.matera@unicampania.it; didaniele@med.uniroma2.it; paola.rogliani@uniroma2.it	Calzetta, Luigino/K-4516-2016	Calzetta, Luigino/0000-0003-0456-069X; Ritondo, Beatrice Ludovica/0000-0002-9071-2006			[Anonymous], WHO COR DIS COVID 19; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Borenstein M., 2011, INTRO METAANALYSIS; Borenstein M., 2009, INTRO METAANALYSIS; Calzetta L, 2017, EQUINE VET J, V49, P710, DOI 10.1111/evj.12680; Calzetta L, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0043-2016; Calzetta L, 2016, CHEST, V149, P1181, DOI 10.1016/j.chest.2016.02.646; Cazzola M, 2017, COPD, V14, P552, DOI 10.1080/15412555.2017.1347918; Citrome L., 2011, TYRANNY P VALUE EFFE; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dias S, 2013, MED DECIS MAKING, V33, P641, DOI 10.1177/0272989X12455847; Dobler CC, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00525-2018; Doshi P., PETER DOSHI PFIZER M; European centre for disease prevention and control, MAPS SUPP COUNC REC; Gianinazzi ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124290; Guarascio F., EU LOCKS HORNS ASTRA; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Higgins J., 2019, COCHRANE HDB SYSTEMA, V2nd; Hu DT, 2021, WIEN KLIN WOCHENSCHR, V133, P321, DOI 10.1007/s00508-021-01816-z; INOVIO Pharmaceuticals, INOVIO ADV ANN 1 DOS; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kershner I., ISRAELS VACCINATION; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lu GB, 2006, J AM STAT ASSOC, V101, P447, DOI 10.1198/016214505000001302; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Mallapaty S., VACCINES ARE CURBING; Martin-Moreno J.M., COVID 19 VACCINES AR; McGuinness L.A., ROBVIS R PACKAGE WEB; Miller J., EUROPEAN COUNTRIES S; Parodi E., MODERNA COVID VACCIN; Pedder H, 2016, SYST REV, V5, DOI 10.1186/s13643-016-0368-4; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Reuters Staff, CHIN APPR 2 MOR DOM; Rogliani P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030227; Rossman H, 2021, PATTERNS COVID 19 PA, V27, P1055, DOI [10.1038/s41591-021-01337-2, DOI 10.1101/2021.02.08.21251325, 10.1101/2021.02.08.21251325]; Russell FM, 2021, HUM VACC IMMUNOTHER, V17, P1317, DOI 10.1080/21645515.2020.1827882; Schardt C, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-16; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Spiegelhalter D.J., 2004, BAYESIAN APPROACHES, VVolume 13; Stang A, 2010, EUR J EPIDEMIOL, V25, P225, DOI 10.1007/s10654-010-9440-x; Stein-Zamir C, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.29.2001352; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Szablewski CM, 2020, MMWR-MORBID MORTAL W, V69, P1023, DOI 10.15585/mmwr.mm6931e1; Tatsioni Aathina., 2017, INT ENCY PUBLIC HLTH, P117, DOI [10.1016/B978-0-12-803678-5.00291-5, DOI 10.1016/B978-0-12-803678-5.00291-5]; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; van Valkenhoef G, 2016, RES SYNTH METHODS, V7, P80, DOI 10.1002/jrsm.1167; van Valkenhoef G, 2012, RES SYNTH METHODS, V3, P285, DOI 10.1002/jrsm.1054; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wallace BC, 2012, J STAT SOFTW, V49, P1, DOI 10.18637/jss.v049.i05; WHO, DRAFT LANDSCAPE COVI; Yonker LM, 2020, J PEDIATR-US, V227, P45, DOI 10.1016/j.jpeds.2020.08.037	55	11	11	6	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							341	10.3390/vaccines9040341			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4SP	33916222	gold, Green Published			2022-04-29	WOS:000643771200001
J	Hagens, A; Inkaya, AC; Yildirak, K; Sancar, M; van der Schans, J; Sancar, AA; Unal, S; Postma, M; Yegenoglu, S				Hagens, Arnold; Inkaya, Ahmet Cagkan; Yildirak, Kasirga; Sancar, Mesut; van der Schans, Jurjen; Sancar, Aylin Acar; Unal, Serhat; Postma, Maarten; Yegenoglu, Selen			COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey	VACCINES			English	Article						COVID-19; cost-effectiveness; vaccination; Turkey; dynamic modeling		As of March 2021, COVID-19 has claimed the lives of more than 2.7 million people worldwide. Vaccination has started in most countries around the world. In this study, we estimated the cost-effectiveness of strategies for COVID-19 vaccination for Turkey compared to a baseline in the absence of vaccination and imposed measures by using an enhanced SIRD (Susceptible, Infectious, Recovered, Death) model and various scenarios for the first year after vaccination. The results showed that vaccination is cost-effective from a health care perspective, with an incremental cost-effectiveness ratio (ICER) of 511 USD/QALY and 1045 USD/QALY if vaccine effectiveness on transmission is equal or reduced to only 50% of effectiveness on disease, respectively, at the 90% baseline effectiveness of the vaccine. From a societal perspective, cost savings were estimated for both scenarios. Other results further showed that the minimum required vaccine uptake to be cost-effective would be at least 30%. Sensitivity and scenario analyses, as well as the iso-ICER curves, showed that the results were quite robust and that major changes in cost-effectiveness outcomes cannot be expected. We can conclude that COVID-19 vaccination in Turkey is highly cost-effective or even cost-saving.	[Hagens, Arnold; van der Schans, Jurjen; Postma, Maarten] Univ Groningen RUG, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9713 AV Groningen, Netherlands; [Inkaya, Ahmet Cagkan; Unal, Serhat] Hacettepe Univ, Fac Med, Dept Infect Dis & Clin Microbiol, TR-06230 Ankara, Turkey; [Yildirak, Kasirga] Hacettepe Univ, Fac Sci, Dept Actuarial Sci, TR-06800 Ankara, Turkey; [Sancar, Mesut] Marmara Univ, Fac Pharm, Dept Clin Pharm, TR-34854 Istanbul, Turkey; [van der Schans, Jurjen; Postma, Maarten] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, NL-9747 AE Groningen, Netherlands; [Sancar, Aylin Acar] Marmara Univ, Fac Pharm, Pharmaceut Care Unit, TR-34854 Istanbul, Turkey; [Postma, Maarten] Univ Padjadjaran, Ctr Excellence Higher Educ Pharmaceut Care Innova, Bandung 40132, Indonesia; [Postma, Maarten] Univ Airlangga, Dept Pharmacol & Therapy, Surabaya 60115, Indonesia; [Yegenoglu, Selen] Hacettepe Univ, Fac Pharm, Dept Pharm Management, TR-06230 Ankara, Turkey		Hagens, A (通讯作者)，Univ Groningen RUG, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9713 AV Groningen, Netherlands.	a.j.j.hagens@umcg.nl; inkaya@hacettepe.edu.tr; kasirgayildirak@gmail.com; sancarmesut@yahoo.com; j.van.der.schans@rug.nl; ecz.aylin@gmail.com; unalserhat57@gmail.com; m.j.postma@rug.nl; selen.yegen@gmail.com		Inkaya, Ahmet Cagkan/0000-0001-7943-8715; Postma, Maarten/0000-0002-6306-3653; Hagens, Arnold/0000-0002-9087-8719; YEGENOGLU, SELEN/0000-0002-5217-8797	EU-project VITAL [806776]	This research received no external funding. This project benefited from our cooperation within the EU-project VITAL (#806776) analyzing vaccination for respiratory infections in older adults.	[Anonymous], Hacettepe Universitesi Aktuerya Bilimleri Bolumu Turkey Life Tables; [Anonymous], WORLD BANK GROUP TUR; [Anonymous], BLOOMBERG; [Anonymous], The Economist GitHub-TheEconomist/Covid-19-Excess-Deaths-Tracker: Source Code and Data for The Economist's Covid-19 Excess Deaths Tracker; [Anonymous], NICE Covid-19 op de IC; [Anonymous], ECDC QUESTIONS ANSWE; [Anonymous], ECONOMIST; [Anonymous], TURKSTAT DEATH CAUSE; [Anonymous], POPULATIONPYRAMIDNET; [Anonymous], JCVI JOINT COMMITTEE; [Anonymous], WHO COR DIS COVID 19; [Anonymous], TURKISH OFFICIAL GAZ; [Anonymous], Turkey Statistical Institute (TURKSTAT); Avorn J, 2020, JAMA-J AM MED ASSOC, V324, P1284, DOI 10.1001/jama.2020.17101; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bollyky TJ, 2020, JAMA-J AM MED ASSOC, V323, P2462, DOI 10.1001/jama.2020.6641; Bosely S., GUARDIAN; Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; Deb Paroma, 2021, Biosaf Health, V3, P87, DOI 10.1016/j.bsheal.2021.02.001; Demiralp S., EC IMPACT COVID 19 T; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Hall VJ., 2021, SSRN ELECT J, DOI [10.2139/ssrn.3790399, DOI 10.2139/SSRN.3790399]; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; JCVI, JCVI INT STAT PHAS 2; Jo YJ, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab040; Kohli M, 2021, VACCINE, V39, P1157, DOI 10.1016/j.vaccine.2020.12.078; Koopmanschap MA, 1996, PHARMACOECONOMICS, V10, P460, DOI 10.2165/00019053-199610050-00003; Levin AT, 2020, EUR J EPIDEMIOL, V35, P1123, DOI 10.1007/s10654-020-00698-1; Liu YW, 2020, J AM STAT ASSOC, DOI 10.1080/01621459.2020.1831926; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Makhoul M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040668; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Our World in Data, COR COVID 19 VACC ST; Peirlinck M, 2020, BIOMECH MODEL MECHAN, V19, P2179, DOI 10.1007/s10237-020-01332-5; Pike J, 2018, APPL HEALTH ECON HEA, V16, P765, DOI 10.1007/s40258-018-0416-4; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Portnoy A, 2020, PHARMACOECONOMICS, V38, P995, DOI 10.1007/s40273-020-00930-6; Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6; Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697; RIVM, RIVM DAT CAT; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Shah A, 2020, JAMA-J AM MED ASSOC, V324, P931, DOI 10.1001/jama.2020.15725; Shapiro MB, 2021, J MED INTERNET RES, V23, DOI 10.2196/24389; Terry, UPDATED COMP COVID 1; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Trogen B, 2020, JAMA-J AM MED ASSOC, V323, P2460, DOI 10.1001/jama.2020.8917; Turkish Ministry of Health, SAG BILG SIST GEN MU; Turkish Ministry of Health, COVID 19 INF PLATF; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Vynnycky E., 2010, INTRO INFECT DIS MOD; World Bank Group, GDP PER CAP CURR US; World Health Organization, 2020, BACKGR PAP COV 19 DI; World Health Organization, 2003, MAKING CHOICES HLTH; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Yetim B, 2020, HEALTH SOC CARE COMM, V28, P431, DOI 10.1111/hsc.12875; Younuskunju, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1846, DOI 10.1093/CID/CIAA1846]	57	5	5	7	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							399	10.3390/vaccines9040399			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS4VF	33919586	Green Published, gold			2022-04-29	WOS:000643778000001
J	Olajiga, O; Holguin-Rocha, AF; Rippee-Brooks, M; Eppler, M; Harris, SL; Londono-Renteria, B				Olajiga, Olayinka; Holguin-Rocha, Andres F.; Rippee-Brooks, Meagan; Eppler, Megan; Harris, Shanice L.; Londono-Renteria, Berlin			Vertebrate Responses against Arthropod Salivary Proteins and Their Therapeutic Potential	VACCINES			English	Review						vector-borne; salivary proteins; arbovirus; vaccines	IGG ANTIBODY-RESPONSE; YELLOW-FEVER VACCINE; NILE VIRUS-INFECTION; AEDES-AEGYPTI; MOSQUITO SALIVA; TICK PROTEIN; DENGUE VIRUS; MALARIA ELIMINATION; GLAND PROTEINS; DISEASE	The saliva of hematophagous arthropods contains a group of active proteins to counteract host responses against injury and to facilitate the success of a bloodmeal. These salivary proteins have significant impacts on modulating pathogen transmission, immunogenicity expression, the establishment of infection, and even disease severity. Recent studies have shown that several salivary proteins are immunogenic and antibodies against them may block infection, thereby suggesting potential vaccine candidates. Here, we discuss the most relevant salivary proteins currently studied for their therapeutic potential as vaccine candidates or to control the transmission of human vector-borne pathogens and immune responses against different arthropod salivary proteins.	[Olajiga, Olayinka; Holguin-Rocha, Andres F.; Eppler, Megan; Harris, Shanice L.; Londono-Renteria, Berlin] Kansas State Univ, Dept Entomol, Vector Biol Lab, Manhattan, KS 66506 USA; [Rippee-Brooks, Meagan] Missouri State Univ, Dept Biol, Springfield, MO 65897 USA		Londono-Renteria, B (通讯作者)，Kansas State Univ, Dept Entomol, Vector Biol Lab, Manhattan, KS 66506 USA.	olayinkajiga@ksu.edu; aholguin@ksu.edu; mrippeebrooks@gmail.com; megeppler96@ksu.edu; harrissl@vet.k-state.edu; blondono@ksu.edu		Rippee-Brooks, Meagan/0000-0002-9265-4655; Londono-Renteria, Berlin/0000-0001-5956-5274; Holguin, Andres/0000-0002-1030-0969	USDA National Institute of Food and Agriculture, Hatch-Multistate [1021430]; COBRE-NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P20GM103638-08]	This research was funded by the USDA National Institute of Food and Agriculture, HatchMultistate, project 1021430 and the COBRE-NIH 5P20GM103638-08, BLR.	Anguita J, 2002, IMMUNITY, V16, P849, DOI 10.1016/S1074-7613(02)00325-4; Arca B, 2018, CURR OPIN INSECT SCI, V29, P102, DOI 10.1016/j.cois.2018.07.012; Bakhshi H, 2018, INFECT GENET EVOL, V63, P195, DOI 10.1016/j.meegid.2018.05.023; Benelli G, 2017, ACTA TROP, V174, P91, DOI 10.1016/j.actatropica.2017.06.028; Bowman LR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004551; Briant L, 2014, VIROLOGY, V464, P26, DOI 10.1016/j.virol.2014.06.023; BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4; Cabezon C, 2008, MOL IMMUNOL, V45, P1431, DOI 10.1016/j.molimm.2007.08.022; Calvo E, 2006, J BIOL CHEM, V281, P1935, DOI 10.1074/jbc.M510359200; Cardenas JC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0208455; Chagas AC, 2014, P NATL ACAD SCI USA, V111, P6946, DOI 10.1073/pnas.1404179111; Chisenhall DM, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-252; Chisenhall DM, 2014, AM J TROP MED HYG, V90, P431, DOI 10.4269/ajtmh.13-0412; Collins ND, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0566-9; Conway MJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004941; Conway MJ, 2014, J VIROL, V88, P164, DOI 10.1128/JVI.02235-13; Cotte V, 2014, J PROTEOMICS, V96, P29, DOI 10.1016/j.jprot.2013.10.033; Cottin P, 2013, EXPERT REV VACCINES, V12, P1351, DOI 10.1586/14760584.2013.836320; Coutinho-Abreu IV, 2015, CURR OPIN INSECT SCI, V10, P98, DOI 10.1016/j.cois.2015.04.014; Dai JF, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001205; Dai JF, 2009, CELL HOST MICROBE, V6, P482, DOI 10.1016/j.chom.2009.10.006; Das S, 2001, J INFECT DIS, V184, P1056, DOI 10.1086/323351; Dhiman S, 2019, INFECT DIS POVERTY, V8, DOI 10.1186/s40249-019-0524-x; Donovan MJ, 2007, INFECT IMMUN, V75, P2523, DOI 10.1128/IAI.01928-06; Espinal MA, 2019, AM J PUBLIC HEALTH, V109, P387, DOI 10.2105/AJPH.2018.304849; Bardach AE, 2019, TROP MED INT HEALTH, V24, P530, DOI 10.1111/tmi.13217; Firbas C, 2015, HUM VACC IMMUNOTHER, V11, P411, DOI 10.4161/21645515.2014.983412; Fong SW, 2018, J VIROL, V92, DOI [10.1128/jvi.01004-17, 10.1128/JVI.01004-17]; Fontaine A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029107; Frierson J. Gordon, 2010, Yale Journal of Biology and Medicine, V83, P77; Gao JL, 2008, PARASITOL RES, V102, P737, DOI 10.1007/s00436-007-0826-y; Garg R, 2006, J IMMUNOL, V177, P6579, DOI 10.4049/jimmunol.177.10.6579; Gari T, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2607-8; Gold LI, 2006, J INVEST DERM SYMP P, V11, P57, DOI 10.1038/sj.jidsymp.5650011; Hastings AK, 2019, J VIROL, V93, DOI 10.1128/JVI.00395-19; Hennessy S, 1996, LANCET, V347, P1583, DOI 10.1016/S0140-6736(96)91075-2; Hopp CS, 2015, ANN NY ACAD SCI, V1342, P37, DOI 10.1111/nyas.12661; Izmirly AM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01055; Jablonka W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41848-0; Jin L, 2018, NAT IMMUNOL, V19, P342, DOI 10.1038/s41590-018-0063-9; Kotsyfakis M, 2006, J BIOL CHEM, V281, P26298, DOI 10.1074/jbc.M513010200; KUNZ C, 1980, WIEN KLIN WOCHENSCHR, V92, P809; Kurokawa C, 2020, NAT REV MICROBIOL, V18, P587, DOI 10.1038/s41579-020-0400-5; Labuda M, 2006, PLOS PATHOG, V2, P251, DOI 10.1371/journal.ppat.0020027; Londono-Renteria B, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1802-0; Londono-Renteria B, 2015, BIOMEDICA, V35, P572, DOI 10.7705/biomedica.v35i4.2530; Londono-Renteria B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081211; Londono-Renteria BL, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00111; Londono-Renteria BL, 2010, J MED ENTOMOL, V47, P1156, DOI 10.1603/ME09240; Maldonado-Ruiz LP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01996; Manning JE, 2020, LANCET, V395, P1998, DOI 10.1016/S0140-6736(20)31048-5; Manning JE, 2018, J INFECT DIS, V218, P7, DOI 10.1093/infdis/jiy179; Martin-Martin I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16665-z; Maruyama SR, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0145-1; Maruyama SR, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2136-2; McCracken MK, 2014, VIROLOGY, V468, P133, DOI 10.1016/j.virol.2014.07.019; Montero SB, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00377; Narasimhan S, 2007, CELL HOST MICROBE, V2, P7, DOI 10.1016/j.chom.2007.06.001; Ndille EE, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005109; Ndille EE, 2014, TROP MED INT HEALTH, V19, P576, DOI 10.1111/tmi.12280; Ndille EE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001905; Nuttall P, 2020, LANCET, V395, P1953, DOI 10.1016/S0140-6736(20)31319-2; Olson D, 2018, PEDIATR INFECT DIS J, V37, P1184, DOI 10.1097/INF.0000000000002169; Parizi LF, 2009, VET PARASITOL, V164, P282, DOI 10.1016/j.vetpar.2009.05.023; PENNEYS NS, 1988, J AM ACAD DERMATOL, V18, P87, DOI 10.1016/S0190-9622(88)70013-4; Piesman J, 2004, PARASITOLOGY, V129, pS191, DOI 10.1017/S0031182003004694; Pingen M, 2016, IMMUNITY, V44, P1455, DOI 10.1016/j.immuni.2016.06.002; Ramamoorthi N, 2005, NATURE, V436, P573, DOI 10.1038/nature03812; Reagan KL, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001935; Rego ROM, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3468-x; REUNALA T, 1994, INT ARCH ALLERGY IMM, V104, P366, DOI 10.1159/000236693; Rizzo C, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0549-8; Rosa P, 2005, NAT MED, V11, P831, DOI 10.1038/nm0805-831; Sankar S, 2017, BIOINFORMATION, V13, P366, DOI 10.6026/97320630013366; Schneider BS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011704; Schuijt TJ, 2011, CELL HOST MICROBE, V10, P136, DOI 10.1016/j.chom.2011.06.010; Styer LM, 2011, J VIROL, V85, P1517, DOI 10.1128/JVI.01112-10; Sun P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14115-z; Surasombatpattana P, 2014, J INVEST DERMATOL, V134, P281, DOI 10.1038/jid.2013.251; Tabor AE, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00506; Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503; Trimnell AR, 2005, VACCINE, V23, P4329, DOI 10.1016/j.vaccine.2005.03.041; Uraki R, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0120-x; Uraki R, 2019, NAT MICROBIOL, V4, P948, DOI 10.1038/s41564-019-0385-x; Valenzuela JG, 2002, INSECT MOL BIOL, V11, P149, DOI 10.1046/j.1365-2583.2002.00319.x; Vannavong N, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2107-7; Vogt Megan B, 2018, PLoS Negl Trop Dis, V12, pe0006439, DOI 10.1371/journal.pntd.0006439; Wagemakers A, 2016, VECTOR-BORNE ZOONOT, V16, P223, DOI 10.1089/vbz.2015.1901; Wang XW, 2016, INFECT IMMUN, V84, P1796, DOI 10.1128/IAI.01526-15; Wang YC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020145; WHO, 2017, GLOB VECT CONTR RESP; Wilson AL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007831; World Health Organization, 2020, DENG SEV DENG FACT S; Yu YX, 2010, VACCINE, V28, P3635, DOI 10.1016/j.vaccine.2010.02.105	94	1	1	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							347	10.3390/vaccines9040347			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4NT	33916367	gold, Green Published			2022-04-29	WOS:000643758500001
J	Plant, EP; Xie, H				Plant, Ewan P.; Xie, Hang			Research Updates for Influenza Virus and Vaccine Development	VACCINES			English	Editorial Material									[Plant, Ewan P.; Xie, Hang] US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA		Plant, EP; Xie, H (通讯作者)，US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA.	ewan.plant@fda.hhs.gov; hang.xie@fda.hhs.gov	Plant, Ewan/AAB-1911-2020	Plant, Ewan/0000-0003-0166-5939; Xie, Hang/0000-0001-8318-5554			Ambati A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040630; Bazhan S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030448; Carnell GW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020100; Chen Po-Ling, 2020, Vaccines, V8, P626, DOI 10.3390/vaccines8040626; Ito T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020149; Kiseleva I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020296; Rockman S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020211; Tannig P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040570	8	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							383	10.3390/vaccines9040383			2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5BH	33919751	Green Published, gold			2022-04-29	WOS:000643793900001
J	Rayner, JO; Kim, JH; Roberts, RW; Wood, RR; Fouty, B; Solodushko, V				Rayner, Jonathan O.; Kim, Jin Hyun; Roberts, Rosemary W.; Wood, Raphael Ryan; Fouty, Brian; Solodushko, Victor			Evaluation of DNA-Launched Virus-Like Particle Vaccines in an Immune Competent Mouse Model of Chikungunya Virus Infection	VACCINES			English	Article						chikungunya virus; immune competent; mouse model; DNA vaccine; virus-like particle		Chikungunya virus (CHIKV) infection can result in chronic and debilitating arthralgia affecting humans in tropical and subtropical regions around the world, yet there are no licensed vaccines to prevent infection. DNA launched virus like particle (VLP) vaccines represent a potentially safer alternative to traditional live-attenuated vaccines; however, fully characterized immunocompetent mouse models which appropriately include both male and female animals for preclinical evaluation of these, and other, vaccine platforms are lacking. Utilizing virus stocks engineered to express mutations reported to enhance CHIKV virulence in mice, infection of male and female immunocompetent mice was evaluated, and the resulting model utilized to assess the efficacy of candidate DNA launched CHIKV VLP vaccines. Results demonstrate the potential utility of DNA launched VLP vaccines in comparison to a live attenuated CHIKV vaccine and identify gender differences in viral RNA loads that impact interpretation of vaccine efficacy and may have important implications for future CHIKV vaccine development.	[Rayner, Jonathan O.; Kim, Jin Hyun; Roberts, Rosemary W.; Wood, Raphael Ryan] Univ S Alabama, Dept Microbiol & Immunol, Mobile, AL 36688 USA; [Fouty, Brian] Univ S Alabama, Dept Internal Med, Mobile, AL 36688 USA; [Fouty, Brian; Solodushko, Victor] Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA; [Fouty, Brian; Solodushko, Victor] Univ S Alabama, Ctr Lung Biol, Mobile, AL 36688 USA		Rayner, JO (通讯作者)，Univ S Alabama, Dept Microbiol & Immunol, Mobile, AL 36688 USA.	jrayner@southalabama.edu; jinkim@southalabama.edu; rroberts@southalabama.edu; rrwood@southalabama.edu; bfouty@health.southalabama.edu; vsolodushko@southalabama.edu		Solodushko, Victor/0000-0002-3137-8650; Kim, Jin/0000-0001-7902-4571	University of South Alabama College of Medicine Intramural Grants Program	Funding for this project was provided in part by the University of South Alabama College of Medicine Intramural Grants Program.	Arnegard ME, 2020, J WOMENS HEALTH, V29, P858, DOI 10.1089/jwh.2019.8247; Berry IM, 2019, AM J TROP MED HYG, V100, P1249, DOI 10.4269/ajtmh.18-0980; Blum JS, 2013, ANNU REV IMMUNOL, V31, P443, DOI 10.1146/annurev-immunol-032712-095910; Chaiwatpongsakorn S, 2011, J VIROL, V85, P3968, DOI 10.1128/JVI.01813-10; Council, 2011, GUIDE CARE USE LAB A, P246, DOI DOI 10.17226/12910; Deeba IM, 2019, AM J TROP MED HYG, V100, P1545, DOI 10.4269/ajtmh.19-0122; Donnelly JJ, 2000, AM J RESP CRIT CARE, V162, pS190, DOI 10.1164/ajrccm.162.supplement_3.15tac10; Essackjee K, 2013, POSTGRAD MED J, V89, P440, DOI 10.1136/postgradmedj-2012-131477; Gerardin P, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4137; Haese NN, 2016, J INFECT DIS, V214, pS482, DOI 10.1093/infdis/jiw284; Halstead SB, 2015, EMERG INFECT DIS, V21, P557, DOI 10.3201/eid2104.141723; Hawman DW, 2017, J VIROL, V91, DOI 10.1128/JVI.00816-17; Huits R, 2018, CLIN MICROBIOL INFEC, V24, P78, DOI 10.1016/j.cmi.2017.06.004; Islam MA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218281; Jain J, 2020, AM J TROP MED HYG, V102, P857, DOI 10.4269/ajtmh.19-0481; Lu YL, 2020, MICROB PATHOGENESIS, V143, DOI 10.1016/j.micpath.2020.104130; Mascarenhas M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207554; Mordecai EA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005568; Payyappilly R.J., 2017, J INT MED DENT, V4, P27, DOI [10.18320/JIMD/201704.0127, DOI 10.18320/JIMD/201704.0127]; Powers AM, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00104-16; Ramachandran V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051519; Schilte C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002137; Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263; Schwameis M, 2016, HUM VACC IMMUNOTHER, V12, P716, DOI 10.1080/21645515.2015.1101197; Smalley C, 2016, VACCINE, V34, P2976, DOI 10.1016/j.vaccine.2016.03.076; Solodushko V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02411; Tsetsarkin KA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-376; Tsetsarkin KA, 2011, P NATL ACAD SCI USA, V108, P7872, DOI 10.1073/pnas.1018344108; Uddin M, 2019, J PHARM PHARM SCI, V22, P536, DOI 10.18433/jpps30768; Wahid B, 2017, INT J INFECT DIS, V58, P69, DOI 10.1016/j.ijid.2017.03.006	30	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							345	10.3390/vaccines9040345			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4RO	33918409	Green Published, gold			2022-04-29	WOS:000643768400001
J	Du, FX; Chantler, T; Francis, MR; Sun, FY; Zhang, X; Han, KY; Rodewald, L; Yu, HJ; Tu, SY; Larson, H; Hou, ZY				Du, Fanxing; Chantler, Tracey; Francis, Mark R.; Sun, Fiona Yueqian; Zhang, Xuan; Han, Kaiyi; Rodewald, Lance; Yu, Hongjie; Tu, Shiyi; Larson, Heidi; Hou, Zhiyuan			Access to Vaccination Information and Confidence/Hesitancy towards Childhood Vaccination: A Cross-Sectional Survey in China	VACCINES			English	Article						vaccine; confidence; hesitancy; vaccination information; China		Access to vaccination information could influence public attitudes towards vaccination. This study investigated the number and types of vaccination-related information sources, and estimated their associations with vaccine confidence and hesitancy in China. In January 2019, we conducted a cross-sectional survey in China, and 2122 caregivers with children <6 years completed self-administered questionnaires. Logistic regressions were used to assess associations between caregivers' primary information sources and vaccine confidence/hesitancy. A majority (72%) of caregivers had multiple sources of vaccination-related information. The proportions of caregivers reporting professional sources, media, and peers as primary information sources were 81%, 63%, and 26%. Internal migrants were less likely to get information from professional sources; more educated and wealthier caregivers reported more information sources and were more likely to get information from media and peers. Caregivers who reported professional information sources had significantly higher odds of being confident about the safety of vaccines and lower odds of being hesitant toward vaccination than those who did not. Caregivers who reported the media as a primary information source had significantly higher odds of being hesitant toward vaccination than those who did not. To address vaccine hesitancy, it is essential to promote universal access to professional vaccination-related information sources, and to use the media to disseminate evidence-based information and clarify misinformation. Health communication should target internal migrants, and more educated and wealthier caregivers.	[Du, Fanxing; Han, Kaiyi; Yu, Hongjie; Tu, Shiyi; Hou, Zhiyuan] Fudan Univ, Sch Publ Hlth, NHC Key Lab Hlth Technol Assessment, Shanghai 200032, Peoples R China; [Chantler, Tracey] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Global Hlth & Dev, London WC1H 9SH, England; [Francis, Mark R.; Sun, Fiona Yueqian; Han, Kaiyi; Larson, Heidi] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England; [Zhang, Xuan; Rodewald, Lance] Chinese Ctr Dis Control & Prevent, Beijing 102200, Peoples R China; [Yu, Hongjie] Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Shanghai 200032, Peoples R China		Hou, ZY (通讯作者)，Fudan Univ, Sch Publ Hlth, NHC Key Lab Hlth Technol Assessment, Shanghai 200032, Peoples R China.	fdu18@fudan.edu.cn; Tracey.Chantler@lshtm.ac.uk; Mark.Francis@lshtm.ac.uk; Fiona.Sun@lshtm.ac.uk; zhangxuan@chinacdc.cn; Kaiyi.Han@lshtm.ac.uk; rodewaldl@chinacdc.cn; yhj@fudan.edu.cn; sytu@fudan.edu.cn; Heidi.Larson@lshtm.ac.uk; zyhou@fudan.edu.cn	; Larson, Heidi J./N-1018-2017	Hou, Zhiyuan/0000-0003-3413-0076; Rodewald, Lance/0000-0003-2593-542X; Francis, Mark Rohit/0000-0001-8428-4298; Chantler, Tracey/0000-0001-7776-7339; Larson, Heidi J./0000-0002-8477-7583	National Institute for Health Research using UK aid from the UK government [EPIDZL9012]; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Immunisation at London School of Hygiene and Tropical Medicine; Public Health England (PHE)	This research was funded by the National Institute for Health Research using UK aid from the UK government to support global health research under grant EPIDZL9012. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. This research was supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Immunisation at London School of Hygiene and Tropical Medicine in partnership with Public Health England (PHE). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, or PHE. The funders had no role in the design or conduct of the study.	Ames HMR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011787.pub2; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; [Anonymous], 2019, NATURE, V568, P5, DOI 10.1038/d41586-019-01031-x; [Anonymous], 2014, Wkly Epidemiol Rec, V89, P561; Aquino F, 2017, VACCINE, V35, P4494, DOI 10.1016/j.vaccine.2017.07.029; Ashkenazi S, 2020, VACCINE, V38, P7292, DOI 10.1016/j.vaccine.2020.09.044; Babalola S, 2011, J PAEDIATR CHILD H, V47, P276, DOI 10.1111/j.1440-1754.2010.01956.x; Bianco A, 2019, VACCINE, V37, P984, DOI 10.1016/j.vaccine.2018.12.062; Braczkowska Bogumila, 2017, Przegl Epidemiol, V71, P227; Bystrom E, 2020, VACCINE, V38, P3909, DOI 10.1016/j.vaccine.2020.01.078; Cao L, 2018, HUM VACC IMMUNOTHER, V14, P1672, DOI 10.1080/21645515.2018.1473697; Casciotti DM, 2014, J ADOLESCENCE, V37, P133, DOI 10.1016/j.adolescence.2013.11.004; Catalan-Matamoros D, 2019, PERSPECT PUBLIC HEAL, V139, P34, DOI 10.1177/1757913918780142; Charron J, 2020, MED MALADIES INFECT, V50, P727, DOI 10.1016/j.medmal.2020.01.010; Chen B, 2015, VACCINE, V33, P1780, DOI 10.1016/j.vaccine.2015.02.046; Chow MYK, 2017, AUST FAM PHYSICIAN, V46, P145; Succi RCD, 2018, J PEDIAT-BRAZIL, V94, P574, DOI 10.1016/j.jped.2018.01.008; Du FX, 2020, VACCINE, V38, P7464, DOI 10.1016/j.vaccine.2020.09.075; Firenze A, 2015, HUM VACC IMMUNOTHER, V11, P240, DOI 10.4161/hv.36158; Gao Q, 2018, SOC POLICY SOC, V17, P227, DOI 10.1017/S1474746417000100; [郭静 Guo Jing], 2014, [中国卫生政策研究, Chinese Journal of Health Policy], V7, P51; Hagerman TK, 2020, J PEDIATR-US, V220, P254, DOI 10.1016/j.jpeds.2019.12.059; Han BF, 2019, VACCINE, V37, P5270, DOI 10.1016/j.vaccine.2019.07.052; Handy LK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180759; He Q, 2020, VACCINE, V38, P6751, DOI 10.1016/j.vaccine.2020.08.039; Hofstetter AM, 2014, VACCINE, V32, P1616, DOI 10.1016/j.vaccine.2013.06.035; Hu D, 2020, VACCINE, V38, P2764, DOI 10.1016/j.vaccine.2020.02.027; Hwang J, 2019, HEALTH COMMUN, V34, P1279, DOI 10.1080/10410236.2018.1481707; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jing Y, 2019, HEALTH RISK SOC, V21, P284, DOI 10.1080/13698575.2019.1619672; Jones Abbey M, 2012, Adv Prev Med, V2012, P932741, DOI 10.1155/2012/932741; Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112; Kennedy A, 2011, HEALTH AFFAIR, V30, P1151, DOI 10.1377/hlthaff.2011.0396; Kim J, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040673; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lin W, 2020, CANCER RES TREAT, V52, P207, DOI 10.4143/crt.2019.053; Liu K, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13080780; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Moorhead SA, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.1933; Moussaid M, 2015, P NATL ACAD SCI USA, V112, P5631, DOI 10.1073/pnas.1421883112; Omer SB, 2017, JAMA PEDIATR, V171, P929, DOI 10.1001/jamapediatrics.2017.2219; Pagoto S, 2019, J MED INTERNET RES, V21, DOI 10.2196/16661; Smith PJ, 2010, PUBLIC HEALTH REP, V125, P534, DOI 10.1177/003335491012500408; Sohn M, 2018, MEDICINA-LITHUANIA, V54, DOI 10.3390/medicina54060105; Tu SY, 2020, VACCINE, V38, P6882, DOI 10.1016/j.vaccine.2020.08.063; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P1511, DOI 10.1080/21645515.2019.1706935; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018; Zhang JY, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14091002; Zhang S., 2010, CHIN J PUBLIC HLTH M, V26, P578	51	7	7	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							201	10.3390/vaccines9030201			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE6GJ	33670971	gold, Green Published			2022-04-29	WOS:000634249700001
J	Martin-Galiano, AJ; Escolano-Martinez, MS; Corsini, B; de la Campa, AG; Yuste, J				Martin-Galiano, Antonio J.; Escolano-Martinez, Maria S.; Corsini, Bruno; de la Campa, Adela G.; Yuste, Jose			Immunization with SP_1992 (DiiA) Protein of Streptococcus pneumoniae Reduces Nasopharyngeal Colonization and Protects against Invasive Disease in Mice	VACCINES			English	Article						Streptococcus pneumoniae; reverse vaccinology; hypothetical protein; DiiA; sepsis; carrier state; protein vaccine; SPD_1789; Spr1806	B VACCINE; PREDICTION; IMMUNOGENICITY; IDENTIFICATION; CANDIDATES; ANTIBODIES; VIRULENCE; CARRIAGE; GENOME; SAFETY	Knowledge-based vaccinology can reveal uncharacterized antigen candidates for a new generation of protein-based anti-pneumococcal vaccines. DiiA, encoded by the sp_1992 locus, is a surface protein containing either one or two repeats of a 37mer N-terminal motif that exhibits low interstrain variability. DiiA belongs to the core proteome, contains several conserved B-cell epitopes, and is associated with colonization and pathogenesis. Immunization with DiiA protein via the intraperitoneal route induced a strong IgG response, including different IgG subtypes. Vaccination with DiiA increased bacterial clearance and induced protection against sepsis, conferring 70% increased survival at 48 h post-infection when compared to the adjuvant control. The immunogenic response and survival rates in mice immunized with a truncated DiiA version lacking 119 N-terminal residues were remarkably lower, confirming the relevance of the repeat zone in the immunoprotection by DiiA. Intranasal immunization of mice with the entire recombinant protein elicited mucosal IgG and IgA responses that reduced bacterial colonization of the nasopharynx, confirming that this protein might be a vaccine candidate for reducing the carrier rate. DiiA constitutes an example of how functionally unannotated proteins may still represent promising candidates that can be used in prophylactic strategies against the pneumococcal carrier state and invasive disease.	[Martin-Galiano, Antonio J.; Escolano-Martinez, Maria S.; Corsini, Bruno; de la Campa, Adela G.; Yuste, Jose] Inst Salud Carlos III ISCIII, Ctr Nacl Microbiol, Madrid 28220, Spain; [de la Campa, Adela G.] CSIC, Madrid 28006, Spain; [Yuste, Jose] CIBER Enfermedades Resp CIBERES, Madrid 28029, Spain		Martin-Galiano, AJ; Yuste, J (通讯作者)，Inst Salud Carlos III ISCIII, Ctr Nacl Microbiol, Madrid 28220, Spain.; Yuste, J (通讯作者)，CIBER Enfermedades Resp CIBERES, Madrid 28029, Spain.	mgaliano@isciii.es; memartinez@alumni.unav.es; bcorsini@ucm.es; agcampa@isciii.es; jyuste@isciii.es		YUSTE, JOSE/0000-0001-7996-0837	Ministerio de Economia y CompetitividadSpanish Government [SAF2017-83388, BIO2017-82951-R]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [MPY 509/19]	This research was funded by Ministerio de Economia y Competitividad (grant numbers SAF2017-83388 and BIO2017-82951-R) and Instituto de Salud Carlos III (grant number MPY 509/19).	Adamou JE, 2001, INFECT IMMUN, V69, P949, DOI 10.1128/IAI.69.2.949-958.2001; Aguinagalde L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137565; Ali A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/139580; Andam CP, 2017, J CLIN MICROBIOL, V55, P1104, DOI 10.1128/JCM.02453-16; Barocchi MA, 2006, P NATL ACAD SCI USA, V103, P2857, DOI 10.1073/pnas.0511017103; Bergmann S, 2006, MICROBIOL-SGM, V152, P295, DOI 10.1099/mic.0.28610-0; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Bologa M, 2012, VACCINE, V30, P7461, DOI 10.1016/j.vaccine.2012.10.076; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Brueggemann AB, 2007, PLOS PATHOG, V3, P1628, DOI 10.1371/journal.ppat.0030168; Cafini F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012041; Chiang MH, 2015, HUM VACC IMMUNOTHER, V11, P1065, DOI 10.1080/21645515.2015.1010910; Corsini B, 2016, VACCINE, V34, P6148, DOI 10.1016/j.vaccine.2016.11.001; Davydov Ia I, 2009, Mol Biol (Mosk), V43, P166; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Escolano-Martinez MS, 2016, J INFECTION, V73, P71, DOI 10.1016/j.jinf.2016.04.010; Feldman C, 2014, J INFECTION, V69, P309, DOI 10.1016/j.jinf.2014.06.006; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; Giefing C, 2008, J EXP MED, V205, P117, DOI 10.1084/jem.20071168; Gonzalez-Diaz A, 2020, EUROSURVEILLANCE, V25, P42, DOI 10.2807/1560-7917.ES.2020.25.16.1900457; Heath CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142773; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; Iannelli F, 2002, GENE, V284, P63, DOI 10.1016/S0378-1119(01)00896-4; Jefferies JMC, 2011, TRENDS MICROBIOL, V19, P377, DOI 10.1016/j.tim.2011.06.001; Jomaa M, 2005, INFECT IMMUN, V73, P6852, DOI 10.1128/IAI.73.10.6852-6859.2005; Kamtchoua T, 2013, VACCINE, V31, P327, DOI 10.1016/j.vaccine.2012.11.005; Kelly DF, 2005, ADV EXP MED BIOL, V568, P217; Kilian M, 2019, MBIO, V10, DOI 10.1128/mBio.01985-19; Kohler S, 2016, FEBS LETT, V590, P3820, DOI 10.1002/1873-3468.12352; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Ladhani SN, 2020, NEW ENGL J MED, V382, P309, DOI 10.1056/NEJMoa1901229; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Lottenbach KR, 1999, INFECT IMMUN, V67, P4935, DOI 10.1128/IAI.67.9.4935-4938.1999; Mann B, 2006, INFECT IMMUN, V74, P821, DOI 10.1128/IAI.74.2.821-829.2006; Marshall HS, 2020, NEW ENGL J MED, V382, P318, DOI 10.1056/NEJMoa1900236; Martin-Galiano AJ, 2017, INFECT GENET EVOL, V49, P283, DOI 10.1016/j.meegid.2017.02.002; McAllister LJ, 2004, MOL MICROBIOL, V53, P889, DOI 10.1111/j.1365-2958.2004.04164.x; Monterrubio-Lopez GP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/483150; O'Brien KL, 2006, LANCET, V368, P1469, DOI 10.1016/S0140-6736(06)69614-1; Pan XY, 2020, BIOINFORMATICS, V36, P5159, DOI 10.1093/bioinformatics/btaa656; Ramos-Sevillano E, 2015, INFECT IMMUN, V83, P591, DOI 10.1128/IAI.02811-14; Ramos-Sevillano E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023626; Read RC, 2017, VACCINE, V35, P427, DOI 10.1016/j.vaccine.2016.11.071; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Rolo D, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-80; Rosch JW, 2009, MOL MICROBIOL, V72, P12, DOI 10.1111/j.1365-2958.2009.06638.x; Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Salva-Serra F, 2018, DIAGN MICR INFEC DIS, V90, P248, DOI 10.1016/j.diagmicrobio.2017.12.003; Saravanan V, 2015, OMICS, V19, P648, DOI 10.1089/omi.2015.0095; Shelly MA, 1997, INFECT IMMUN, V65, P242, DOI 10.1128/IAI.65.1.242-247.1997; Sidney J, 2010, J IMMUNOL, V184, P2492, DOI 10.4049/jimmunol.0903655; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1; Uddin S, 2006, VACCINE, V24, P5637, DOI 10.1016/j.vaccine.2006.03.088; Wuorimaa T, 2001, VACCINE, V19, P1863, DOI 10.1016/S0264-410X(00)00441-2; Yao B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045152	59	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							187	10.3390/vaccines9030187			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5JW	33668195	gold, Green Published			2022-04-29	WOS:000634191200001
J	Prescott, MJ; Clark, C; Dowling, WE; Shurtleff, AC				Prescott, Mark J.; Clark, Carolyn; Dowling, William E.; Shurtleff, Amy C.			Opportunities for Refinement of Non-Human Primate Vaccine Studies	VACCINES			English	Review						3Rs; animal welfare; biocontainment; biologics; COVID-19; drugs; infectious disease; nonhuman primates; therapeutics; vaccines	MACAQUES MACACA-MULATTA; RHESUS MACAQUES; ANIMALS; SCIENCE; MODELS; FACILITIES; HUSBANDRY; KETAMINE; PROGRAMS; SURVIVAL	Non-human primates (NHPs) are used extensively in the development of vaccines and therapeutics for human disease. High standards in the design, conduct, and reporting of NHP vaccine studies are crucial for maximizing their scientific value and translation, and for making efficient use of precious resources. A key aspect is consideration of the 3Rs principles of replacement, reduction, and refinement. Funders of NHP research are placing increasing emphasis on the 3Rs, helping to ensure such studies are legitimate, ethical, and high-quality. The UK's National Centre for the 3Rs (NC3Rs) and the Coalition for Epidemic Preparedness Innovations (CEPI) have collaborated on a range of initiatives to support vaccine developers to implement the 3Rs, including hosting an international workshop in 2019. The workshop identified opportunities to refine NHP vaccine studies to minimize harm and improve welfare, which can yield better quality, more reproducible data. Careful animal selection, social housing, extensive environmental enrichment, training for cooperation with husbandry and procedures, provision of supportive care, and implementation of early humane endpoints are features of contemporary good practice that should and can be adopted more widely. The requirement for high-level biocontainment for some pathogens imposes challenges to implementing refinement but these are not insurmountable.	[Prescott, Mark J.] Natl Ctr Replacement Refinement & Reduct Anim Res, London NW1 2BE, England; [Clark, Carolyn; Dowling, William E.; Shurtleff, Amy C.] Coalit Epidem Preparedness Innovat CEPI, N-0473 Oslo, Norway		Prescott, MJ (通讯作者)，Natl Ctr Replacement Refinement & Reduct Anim Res, London NW1 2BE, England.	mark.prescott@nc3rs.org.uk; carolyn.clark@cepi.net; william.dowling@cepi.net; amy.c.shurtleff@cepi.net		Prescott, Mark/0000-0002-8814-0512	NC3RsUK Research & Innovation (UKRI)National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs); CEPI	M.J.P. was supported by the NC3Rs. A.C.S., C.C. and W.E.D. were supported by CEPI.	Alfson KJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110642; [Anonymous], 2020, J AM ASSOC LAB ANIM, V59, P6; [Anonymous], 2010, OFF J EUR UNION, V276, P33; Baillet N, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01543-7; Baker KC, 2016, AM J PRIMATOL, V78, P780, DOI 10.1002/ajp.22543; Baker KC, 2012, APPL ANIM BEHAV SCI, V137, P148, DOI 10.1016/j.applanim.2011.09.010; Benton CG, 2013, J AM ASSOC LAB ANIM, V52, P240; Bernasconi V, 2020, BUNDESGESUNDHEITSBLA, V63, P65, DOI 10.1007/s00103-019-03061-2; Bertrand HGMJ, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0721-9; Blair PW, 2021, J INFECT DIS, V224, P632, DOI 10.1093/infdis/jiaa781; Blair PW, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110658; Brown M, P LASA WINT M BRIGHT; Buchanan-Smith HM, 2004, ANIM WELFARE, V13, pS197; Capitanio JP, 2006, ILAR J, V47, P294, DOI 10.1093/ilar.47.4.294; Capitanio JP, 1998, P NATL ACAD SCI USA, V95, P4714, DOI 10.1073/pnas.95.8.4714; Chapman K, 2016, MABS-AUSTIN, V8, P427, DOI 10.1080/19420862.2016.1145331; Chapman KL, 2012, REGUL TOXICOL PHARM, V62, P347, DOI 10.1016/j.yrtph.2011.10.016; Colby LA, 2017, COMPARATIVE MED, V67, P222; Coleman K, 2017, ILAR J, V58, P295, DOI 10.1093/ilar/ilx008; Copps J, 2005, ILAR J, V46, P34, DOI 10.1093/ilar.46.1.34; Couch J., 2012, CHALLENGES NONHUMAN, P47; Daly MB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225146; DiVincenti L, 2011, J AM ASSOC LAB ANIM, V50, P856; du Sert NP, 2020, EXP PHYSIOL, V105, P1459, DOI [10.1113/JP280389, 10.1111/bph.15193, 10.1113/EP088870, 10.1177/0271678X20943823, 10.1371/journal.pbio.3000410, 10.1371/journal.pbio.3000411]; Estes JD, 2018, NAT REV IMMUNOL, V18, P390, DOI 10.1038/s41577-018-0005-7; Food and Drug Administration, 2012, GUID IND S6 ADD PREC, P1; Food and Drug Administration, AN RUL INF; Gardner MB, 2008, ILAR J, V49, P220, DOI 10.1093/ilar.49.2.220; Gilbert MH, 2011, J MED PRIMATOL, V40, P71, DOI 10.1111/j.1600-0684.2010.00447.x; Graham ML, 2015, EUR J PHARMACOL, V759, P19, DOI 10.1016/j.ejphar.2015.03.040; Graham ML, 2012, J MED PRIMATOL, V41, P89, DOI 10.1111/j.1600-0684.2011.00525.x; Guina T, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00099; Guler A., 2020, BNT162B VACCINES ARE, DOI [10.1101/2020.12.11.421008X, DOI 10.1101/2020.12.11.421008X]; Hannibal DL, 2017, AM J PRIMATOL, V79, DOI 10.1002/ajp.22528; Harris SA, 2018, TUBERCULOSIS, V108, P99, DOI 10.1016/j.tube.2017.11.006; Hirschberg R, 2014, VIRUSES-BASEL, V6, P2673, DOI 10.3390/v6072673; Jennings M, 2009, Lab Anim, V43 Suppl 1, P1, DOI 10.1258/la.2008.007143; Jennings M, 2010, BIOLOGICALS, V38, P684, DOI 10.1016/j.biologicals.2010.04.004; Kemp C, 2017, APPL ANIM BEHAV SCI, V197, P90, DOI 10.1016/j.applanim.2017.08.006; Kilgore N, 2012, VIRUSES-BASEL, V4, P2312, DOI 10.3390/v4102312; Kortepeter MG, 2011, J INFECT DIS, V204, pS1000, DOI 10.1093/infdis/jir337; Laule Gail E., 2003, Journal of Applied Animal Welfare Science, V6, P163, DOI 10.1207/S15327604JAWS0603_02; Lilly AA, 1999, AM J PRIMATOL, V48, P197, DOI 10.1002/(SICI)1098-2345(1999)48:3&lt;197::AID-AJP3&gt;3.0.CO;2-Y; Ling BH, 2002, AIDS, V16, P1489, DOI 10.1097/00002030-200207260-00005; Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4; McKinley Jean, 2003, Journal of Applied Animal Welfare Science, V6, P209, DOI 10.1207/S15327604JAWS0603_06; Morton D B, 2000, ILAR J, V41, P80; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; National Research Council, 2011, GUIDE CARE USE LAB A, V8th, DOI 10.17226/12910; National Research Council, 1998, PSYCH WELL BEING NON, DOI [10.17226/4909, DOI 10.17226/4909]; NC3Rs, 2017, NONH PRIM ACC CAR US, V2nd, P1; NC3Rs, PEER REV ADV SERV; NC3Rs, MAC WEBS; Nehete PN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188694; Nelson M, 2015, INT J EXP PATHOL, V96, P414, DOI 10.1111/iep.12161; Nelson M, 2010, ANTIMICROB AGENTS CH, V54, P3922, DOI 10.1128/AAC.00390-10; Novak MA, 2013, APPL ANIM BEHAV SCI, V143, P135, DOI 10.1016/j.applanim.2012.10.012; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; OECD, 2000, ASS US CLIN SIGNS HU; Olfert E D, 2000, ILAR J, V41, P99; Pahar B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565746; Perlman JE, 2012, APPL ANIM BEHAV SCI, V137, P114, DOI 10.1016/j.applanim.2011.11.003; Poole T, 1997, LAB ANIM-UK, V31, P116, DOI 10.1258/002367797780600198; Powell DS, 2014, PATHOG DIS, V71, P217, DOI 10.1111/2049-632X.12140; Prescott M. J., 2005, Animal Technology and Welfare, V4, P133; Prescott M.J., INT SURVEY BEH UNPUB; Prescott MJ, 2017, LAB ANIMAL, V46, P152, DOI 10.1038/laban.1217; Prescott Mark J., 2003, Journal of Applied Animal Welfare Science, V6, P157, DOI 10.1207/S15327604JAWS0603_01; Reinhardt V., 1990, PRIM NEWS, V29, P7; Rennie AE, 2006, ANIM WELFARE, V15, P215; Rivera-Hernandez T, 2014, DISCOV MED, V18, P313; Rommeck I, 2009, J APPL ANIM WELF SCI, V12, P61, DOI 10.1080/10888700802536798; Russell WMS, 1959, PRINCIPLES HUMANE EX; Schapiro SJ, 2005, LAB ANIMAL, V34, P37, DOI 10.1038/laban0505-37; Sharpe SA, 2020, LAB ANIM-UK, V54, P386, DOI 10.1177/0023677220913328; Sharpe SA, 2018, LAB ANIM-UK, V52, P599, DOI 10.1177/0023677218757815; Shurtleff A.C., 2019, WORKSHOP REPORT REFI, P1; Sibal L R, 2001, ILAR J, V42, P74; Sibley L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39819-6; Smither SJ, 2012, VIRUSES-BASEL, V4, P1305, DOI 10.3390/v4081305; Springer DA, 2007, AM J PRIMATOL, V69, P1080, DOI 10.1002/ajp.20421; Stone LH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81953-7; Tanner R, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02983; Tanner R, 2017, ALTEX-ALTERN ANIM EX, V34, P157, DOI [10.14573/altex.1607281human, 10.14573/altex.1607281]; Toth L A, 2000, ILAR J, V41, P72; Trichel AM, 2002, J MED PRIMATOL, V31, P171, DOI 10.1034/j.1600-0684.2002.02003.x; Vermeire T., 2017, FINAL OPINION NEED N, P1; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Warren TK, 2014, VIRUSES-BASEL, V6, P4666, DOI 10.3390/v6114666; Westlund K., 2015, PRIMATE BIOL, V2, P119, DOI [10.5194/pb-2-119-2015, DOI 10.5194/PB-2-119-2015]; Zhang S., 2020, ATLANTIC	91	1	1	0	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							284	10.3390/vaccines9030284			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6HW	33808708	gold, Green Published			2022-04-29	WOS:000634253600001
J	Richi, P; Yuste, J; Navio, T; Gonzalez-Hombrado, L; Salido, M; Thuissard-Vasallo, I; Jimenez-Diaz, A; Llorente, J; Cebrian, L; Lojo, L; Steiner, M; Cobo, T; Martin, MD; Garcia-Castro, M; Castro, P; Munoz-Fernandez, S				Richi, Patricia; Yuste, Jose; Navio, Teresa; Gonzalez-Hombrado, Laura; Salido, Marina; Thuissard-Vasallo, Israel; Jimenez-Diaz, Ana; Llorente, Jesus; Cebrian, Laura; Lojo, Leticia; Steiner, Martina; Cobo, Tatiana; Martin, Maria Dolores; Garcia-Castro, Marta; Castro, Patricia; Munoz-Fernandez, Santiago			Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases	VACCINES			English	Article						PPV23; PCV13; OPKA titers; invasive pneumococcal disease; biological therapy; anti-TNF alpha; rituximab; tocilizumab; autoimmune inflammatory diseases		Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNF alpha, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol.	[Richi, Patricia; Jimenez-Diaz, Ana; Steiner, Martina; Cobo, Tatiana; Munoz-Fernandez, Santiago] Hosp Univ Infanta Sofia San Sebastian Reyes, Rheumatol Unit, Madrid 28702, Spain; [Richi, Patricia; Steiner, Martina; Cobo, Tatiana; Munoz-Fernandez, Santiago] Univ Europea, Sch Med, Madrid 28670, Spain; [Yuste, Jose] Inst Salud Carlos III, Natl Ctr Microbiol, Spanish Pneumococcal Reference Lab, Madrid 28220, Spain; [Yuste, Jose] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid 28029, Spain; [Navio, Teresa; Cebrian, Laura; Lojo, Leticia] Hosp Univ Infanta Leonor, Rheumatol Unit, Madrid 28031, Spain; [Gonzalez-Hombrado, Laura; Garcia-Castro, Marta] Hosp Tajo, Rheumatol Unit, Madrid 28300, Spain; [Salido, Marina; Castro, Patricia] Hosp Univ Infanta Cristina, Rheumatol Unit, Madrid 28981, Spain; [Thuissard-Vasallo, Israel] Univ Europea, Sch Doctoral Studies & Res, Madrid 28670, Spain; [Llorente, Jesus] Hosp Univ Infanta Sofia, Pharm Dept, Madrid 28702, Spain; [Martin, Maria Dolores] Bacteriol Dept, BR Salud Labs, Madrid 28702, Spain		Richi, P (通讯作者)，Hosp Univ Infanta Sofia San Sebastian Reyes, Rheumatol Unit, Madrid 28702, Spain.; Richi, P (通讯作者)，Univ Europea, Sch Med, Madrid 28670, Spain.; Yuste, J (通讯作者)，Inst Salud Carlos III, Natl Ctr Microbiol, Spanish Pneumococcal Reference Lab, Madrid 28220, Spain.; Yuste, J (通讯作者)，Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid 28029, Spain.	patricia.richi@salud.madrid.org; jyuste@isciii.es; mteresa.navio@salud.madrid.org; lgonzalez.hdoc@salud.madrid.org; marina.salido@salud.madrid.org; israeljohn.thuissard@universidadeuropea.es; ajimenezd@salud.madrid.org; jesus.llorente@salud.madrid.org; laura.cebrian@salud.madrid.org; leticia.lojo@salud.madrid.org; martina.steiner@salud.madrid.org; mtatiana.cobo@salud.madrid.org; dmrodrigo@salud.madrid.org; gamarta@hotmail.com; patricia.castro@salud.madrid.org; santiago.munoz@salud.madrid.org		Thuissard Vasallo, Israel John/0000-0002-6990-0619; YUSTE, JOSE/0000-0001-7996-0837; Cebrian-Mendez, Laura/0000-0003-2475-7924; Richi, Patricia/0000-0003-2277-6814; Cobo-Ibanez, Tatiana/0000-0002-9220-1867	Sociedad Madrilena de Reumatologia (SORCOM)/MSD; PfizerPfizer; Ministerio de Economia, Industria y Competitividad [SAF2017-83388]	This research was funded by Sociedad Madrilena de Reumatologia (SORCOM)/MSD and, Pfizer. This study was also supported by Ministerio de Economia, Industria y Competitividad (grant number SAF2017-83388).	Backhaus E, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1648-2; Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034; Brocq O, 2016, JOINT BONE SPINE, V83, P155, DOI 10.1016/j.jbspin.2015.11.005; Cafini F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012041; Chiricozzi A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040769; Choi EH, 2016, CLIN VACCINE IMMUNOL, V23, P162, DOI 10.1128/CVI.00591-15; Craft JE, 2012, NAT REV RHEUMATOL, V8, P337, DOI 10.1038/nrrheum.2012.58; de Miguel S, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1483, DOI 10.1093/cid/ciaa1483]; Domenech M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02700; Fernandez-Martinez S, 2016, EXPERT OPIN BIOL TH, V16, P1317, DOI 10.1080/14712598.2016.1218844; Fischer L, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0663-9; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Glaesener S, 2014, ARTHRITIS RHEUMATOL, V66, P2590, DOI 10.1002/art.38736; Gonzalez-Romo F, 2017, REV ESP QUIM, V30, P142; Kaine JL, 2007, J RHEUMATOL, V34, P272; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Lee H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-60; Loubet P, 2015, VACCINE, V33, P3703, DOI 10.1016/j.vaccine.2015.06.012; Manoff SB, 2010, J INFECT DIS, V201, P525, DOI 10.1086/651131; Mease PJ, 2004, J RHEUMATOL, V31, P1356; Nguyen MTT, 2017, SCAND J RHEUMATOL, V46, P446, DOI 10.1080/03009742.2016.1242774; Pham Thao, 2008, Joint Bone Spine, V75 Suppl 1, pS1, DOI 10.1016/S1297-319X(08)73620-0; Rakoczi E, 2016, JOINT BONE SPINE, V83, P675, DOI 10.1016/j.jbspin.2015.10.017; Ramos-Sevillano E, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005500; Ramos-Sevillano E, 2012, ANTIMICROB AGENTS CH, V56, P5534, DOI 10.1128/AAC.01470-12; Ramos-Sevillano E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044135; Shea KM, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu024; Subesinghe S, 2018, J RHEUMATOL, V45, P733, DOI 10.3899/jrheum.170710; van Aalst M, 2018, VACCINE, V36, P5832, DOI 10.1016/j.vaccine.2018.07.039; van Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216; Visser Leo G, 2011, Curr Infect Dis Rep, V13, P243, DOI 10.1007/s11908-011-0183-y; Wotton CJ, 2012, J EPIDEMIOL COMMUN H, V66, P1177, DOI 10.1136/jech-2011-200168	32	10	11	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							203	10.3390/vaccines9030203			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5MZ	33671007	Green Published, gold			2022-04-29	WOS:000634199300001
J	Salcines-Cuevas, D; Teran-Navarro, H; Calderon-Gonzalez, R; Torres-Rodriguez, P; Tobes, R; Fresno, M; Calvo-Montes, J; Del Molino-Bernal, ICP; Yanez-Diaz, S; Alvarez-Dominguez, C				Salcines-Cuevas, David; Teran-Navarro, Hector; Calderon-Gonzalez, Ricardo; Torres-Rodriguez, Paula; Tobes, Raquel; Fresno, Manuel; Calvo-Montes, Jorge; Del Molino-Bernal, I. Concepcion Perez; Yanez-Diaz, Sonsoles; Alvarez-Dominguez, Carmen			Glyceraldehyde-3-phosphate Dehydrogenase Common Peptides of Listeria monocytogenes, Mycobacterium marinum and Streptococcus pneumoniae as Universal Vaccines	VACCINES			English	Article						adjuvants; glyceraldehyde-3-phosphate-dehydrogenase; listeriosis; pneumonia; tuberculosis; vaccines		Universal vaccines can be prepared with antigens common to different pathogens. In this regard, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a common virulence factor among pathogenic bacteria of the genera Listeria, Mycobacterium and Streptococcus. Their N-terminal 22 amino acid peptides, GAPDH-L1 (Listeria), GAPDH-M1 (Mycobacterium) and GAPDH-S1 (Streptococcus), share 95-98.55% sequence homology, biochemical and MHC binding abilities and, therefore, are good candidates for universal vaccine designs. Here, we used dendritic cells (DC) as vaccine platforms to test GAPDH epitopes that conferred protection against Listeria monocytogenes, Mycobacterium marinum or Streptococcus pneumoniae in our search of epitopes for universal vaccines. DC loaded with GAPDH-L1, GAPDH-M1 or GAPDH-S1 peptides show high immunogenicity measured by the cellular DTH responses in mice, lacked toxicity and were capable of cross-protection immunity against mice infections with each one of the pathogens. Vaccine efficiency correlated with high titers of anti-GAPDH-L1 antibodies in sera of vaccinated mice, a Th1 cytokine pattern and high frequencies of GAPDH-L1-specific CD4+ and CD8+ T cells and IFN-gamma producers in the spleens. We concluded that GAPDH-L1 peptide was the best epitope for universal vaccines in the Listeria, Mycobacterium or Streptococcus taxonomic groups, whose pathogenic strains caused relevant morbidities in adults and especially in the elderly.	[Salcines-Cuevas, David; Teran-Navarro, Hector; Calderon-Gonzalez, Ricardo; Torres-Rodriguez, Paula] Inst Invest Marques Valdecilla, Grp Oncol & Nanovacunas, Santander 39011, Cantabria, Spain; [Tobes, Raquel] Alamo Blanco, Granada 18110, Andalucia, Spain; [Fresno, Manuel] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain; [Calvo-Montes, Jorge; Del Molino-Bernal, I. Concepcion Perez] Hosp Univ Marques Valdecilla, Serv Microbiol, Santander 39008, Cantabria, Spain; [Yanez-Diaz, Sonsoles] Hosp Univ Marques Valdecilla, Serv Dermatol, Santander 39008, Cantabria, Spain; [Alvarez-Dominguez, Carmen] Univ Int La Rioja, Fac Educ, Avda La Paz 137, Logrono 26006, La Rioja, Spain; [Alvarez-Dominguez, Carmen] Univ Int La Rioja, Fac Ciencias Salud, Avda La Paz 137, Logrono 26006, La Rioja, Spain		Alvarez-Dominguez, C (通讯作者)，Univ Int La Rioja, Fac Educ, Avda La Paz 137, Logrono 26006, La Rioja, Spain.; Alvarez-Dominguez, C (通讯作者)，Univ Int La Rioja, Fac Ciencias Salud, Avda La Paz 137, Logrono 26006, La Rioja, Spain.	davidsalcines@gmail.com; hteran35@hotmail.com; ricardocalderongonzalez@hotmail.com; paulatr98@hotmail.com; raquel.tobes@alamoblanco.org; mfresno@cbm.csic.es; jorge.calvo@scsalud.es; inmaculadaconcepc.perezdelmolino@scsalud.es; sonsolesjuana.yanez@scsalud.es; carmen.alvarez@unir.net	González, Ricardo Calderón/N-6863-2013; Alvarez-Dominguez, Carmen/J-4675-2014	González, Ricardo Calderón/0000-0003-0841-3814; Alvarez-Dominguez, Carmen/0000-0002-4585-6959; Tobes, Raquel/0000-0001-7032-8720; Salcines-Cuevas, David/0000-0003-2627-0597; Teran Navarro, Hector/0000-0001-8227-9030	CICYT program of the Ministry of Science and Innovation [SAF2012-34203]; European FEDER funds "A new way of making Europe"; COST European action ENOVA; Instituto de Salud Carlos III (ISCIII)Instituto de Salud Carlos IIIEuropean Commission [DTS18-00022, PI19-01580]; Bio-Health Research Program of Cantabria Government [INNVAL19/26, INNVAL20/01]; Comunidad de MadridComunidad de Madrid [SAF2016-75988-R, S2017/BMD-3671]; "Fondo de Investigaciones Sanitarias" (BIOIMID); intramural CIBER-BNN [CIB16NM009]	This research was funded by the CICYT program of the Ministry of Science and Innovation, grant number SAF2012-34203, co-funded in part with European FEDER funds "A new way of making Europe", the COST European action ENOVA, the Instituto de Salud Carlos III (ISCIII) grant numbers, DTS18-00022 and PI19-01580 to C.A.-D., the intramural CIBER-BNN grant number, CIB16NM009 to C.A.-D., to the Bio-Health Research Program of Cantabria Government, gran number INNVAL19/26 to S.Y.-D., I.C.P.D.M.-B. and C.A.-D. and INNVAL20/01 to C.A.-D.; SAF2016-75988-R "Comunidad de Madrid (S2017/BMD-3671. INFLAMUNE-CM) and Fondo de Investigaciones Sanitarias" (BIOIMID) to M.F. and a Predoctoral contract to D.S.-C. by Bio-Health research program of Cantabria government.	Alvarez-Dominguez C, 1999, J BIOL CHEM, V274, P11459, DOI 10.1074/jbc.274.17.11459; Alvarez-Dominguez C., Patent Number, Patent No. [2008020108A1, 2008020108]; Alvarez-Dominguez C., Patent Number, Patent No. 2019243647; Alvarez-Dominguez C, 2008, TRAFFIC, V9, P325, DOI 10.1111/j.1600-0854.2007.00683.x; Alvarez-Dominguez C, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.573348; Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; Barbieri AM, 2001, INFECT IMMUN, V69, P5329, DOI 10.1128/IAI.69.9.5329-5334.2001; Bienert S, 2017, NUCLEIC ACIDS RES, V45, pD313, DOI 10.1093/nar/gkw1132; Blum M, 2021, NUCLEIC ACIDS RES, V49, pD344, DOI 10.1093/nar/gkaa977; Calderon-Gonzalez R, 2017, ONCOTARGET, V8, P53916, DOI 10.18632/oncotarget.19405; Calderon-Gonzalez R, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6080151; Calderon-Gonzalez R, 2015, J IMMUNOL METHODS, V424, P111, DOI 10.1016/j.jim.2015.05.009; Calderon-Gonzalez R, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00022; Cohen N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039193; Cordoba EV, 2013, NANOMED-NANOTECHNOL, V9, P972, DOI 10.1016/j.nano.2013.03.004; Fromen CA, 2015, P NATL ACAD SCI USA, V112, P488, DOI 10.1073/pnas.1422923112; Godshall CE, 2013, J CLIN MICROBIOL, V51, P3591, DOI 10.1128/JCM.01974-13; Gonzalez-Santiago TM, 2015, DERMATOL CLIN, V33, P563, DOI 10.1016/j.det.2015.03.017; Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140; Han J, 2021, INT J MED SCI, V18, P406, DOI 10.7150/ijms.47706; Herrador Z, 2019, EUROSURVEILLANCE, V24, P22, DOI 10.2807/1560-7917.ES.2019.24.21.1800271; Johansson L, 2010, CLIN INFECT DIS, V51, P58, DOI 10.1086/653116; Kawasaki N, 2014, J IMMUNOL, V193, P1560, DOI 10.4049/jimmunol.1303278; Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438; Kono M, 2012, VACCINE, V30, P2633, DOI 10.1016/j.vaccine.2012.02.026; Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329; Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202; Marais BJ, 2017, CLIN INFECT DIS, V64, P501, DOI 10.1093/cid/ciw757; Martin-Moreno A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070656; McGill F, 2016, LANCET, V388, P3036, DOI 10.1016/S0140-6736(16)30654-7; Mekonnen ZA, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.559105; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Ovejero-Guisasola J.I., Patent Number, Patent No. [2010139352A1, 2010139352]; Pagliano Pasquale, 2017, Infez Med, V25, P210; Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132; Rey-Ladino J, 2014, HUM VACC IMMUNOTHER, V10, P2664, DOI 10.4161/hv.29683; Sanchez-Ramon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02936; Sidney John, 2008, Immunome Res, V4, P2, DOI 10.1186/1745-7580-4-2; Solana R, 2006, IMMUNITY, V24, P491, DOI 10.1016/j.immuni.2006.05.003; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; Weinberger B, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0107-2	42	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							269	10.3390/vaccines9030269			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6FU	33802959	Green Published, gold			2022-04-29	WOS:000634248200001
J	Torelli, A; Gianchecchi, E; Monti, M; Piu, P; Barneschi, I; Bonifazi, C; Coluccio, R; Ganfini, L; La Magra, LM; Marconi, S; Marzucchi, G; Pace, R; Palladino, L; Biagi, B; Montomoli, E				Torelli, Alessandro; Gianchecchi, Elena; Monti, Martina; Piu, Pietro; Barneschi, Irene; Bonifazi, Carolina; Coluccio, Rosa; Ganfini, Luisa; La Magra, Luciano Michele; Marconi, Silvia; Marzucchi, Ginevra; Pace, Ramona; Palladino, Laura; Biagi, Bernardo; Montomoli, Emanuele			Effect of Repeated Freeze-Thaw Cycles on Influenza Virus Antibodies	VACCINES			English	Article						Serum; stability; storage; serological test; influenza vaccine		Background: Vaccine effectiveness relies on various serological tests, whose aim is the measurement of antibody titer in serum samples collected during clinical trials before and after vaccination. Among the serological assays required by the regulatory authorities to grant influenza vaccine release there are: Hemagglutination inhibition (HAI), microneutralization (MN), and Single Radial Hemolysis (SRH). Although antibodies are regarded to be relatively stable, limited evidences on the effect of multiple freeze-thaw cycles on the stability of antibodies in frozen serum samples are available so far. In view of this, the present paper aimed to evaluate the impact of multiple freeze-thaw cycles on influenza antibody stability, performing HAI, MN and SRH assays. Methods: Ten serum samples were divided into 14 aliquots each, stored at -20 degrees C and taken through a total of 14 freeze-thaw cycles to assess influenza antibody stability. Each assay measurement was carried out following internal procedures based on World Health Organization (WHO) guidelines. Results: No statistically significant effect of 14 freeze-thaw cycles on antibody stability, measured through three different assays, was observed. Conclusions: Collectively, these data demonstrated that specific influenza antibody present in serum samples are stable up to 14 freeze-thaw cycles.	[Torelli, Alessandro; Gianchecchi, Elena; Monti, Martina; Piu, Pietro; Barneschi, Irene; Bonifazi, Carolina; Coluccio, Rosa; Ganfini, Luisa; La Magra, Luciano Michele; Marconi, Silvia; Marzucchi, Ginevra; Pace, Ramona; Palladino, Laura; Biagi, Bernardo; Montomoli, Emanuele] VisMederi Srl, I-53100 Siena, Italy; [Bonifazi, Carolina] Univ Siena, Dept Life Sci, I-53100 Siena, Italy; [Montomoli, Emanuele] Univ Siena, Dept Mol & Dev Med, I-53100 Siena, Italy		Torelli, A (通讯作者)，VisMederi Srl, I-53100 Siena, Italy.	Alessandro.Torelli@vismederi.com; Elena.Gianchecchi@vismederi.com; Martina.Monti@vismederi.com; Pietro.Piu@vismederi.com; Irene.Barneschi@vismederi.com; Carolina.Bonifazi@vismederi.com; Rosa.Coluccio@vismederi.com; Luisa.Ganfini@vismederi.com; Luciano.LaMagra@vismederi.com; Silvia.Marconi@vismederi.com; Ginevra.Marzucchi@vismederi.com; Ramona.Pace@vismederi.com; laurapalladino_2013@libero.it; bernardo.biagi@vismederi.com; emanuele.montomoli@unisi.it		Piu, Pietro/0000-0002-7504-1822; Monti, Martina/0000-0002-2173-7269; TORELLI, ALESSANDRO/0000-0003-3629-5149			Cao EH, 2003, BIOTECHNOL BIOENG, V82, P684, DOI 10.1002/bit.10612; Castro AR, 2013, SEX TRANSM DIS, V40, P870, DOI 10.1097/OLQ.0000000000000036; Cuhadar S, 2013, BIOCHEM MEDICA, V23, P70, DOI 10.11613/BM.2013.009; Gislefoss RE, 2017, CLIN CHEM LAB MED, V55, P967, DOI 10.1515/cclm-2016-0892; Hillebrand JJ, 2017, ANN CLIN BIOCHEM, V54, P289, DOI 10.1177/0004563216657361; Horber S, 2019, CLIN LAB, V65, P845, DOI 10.7754/Clin.Lab.2018.181107; Keshavan Ashvini, 2018, Alzheimers Dement (Amst), V10, P448, DOI 10.1016/j.dadm.2018.06.001; Kisand K, 2011, CLIN CHEM LAB MED, V49, P229, DOI 10.1515/CCLM.2011.049; Lee Jae-Eun, 2016, Osong Public Health Res Perspect, V7, P351, DOI 10.1016/j.phrp.2016.11.004; Michaut L, 2014, BIOANALYSIS, V6, P1395, DOI 10.4155/bio.14.97; Montomoli E, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010014; Naz S, 2017, ANN CLIN BIOCHEM, V54, P348, DOI 10.1177/0004563216662074; Pinsky NA, 2003, CLIN DIAGN LAB IMMUN, V10, P19, DOI 10.1128/CDLI.10.1.19-21.2003; Rastawicki Waldemar, 2012, Medycyna Doswiadczalna i Mikrobiologia, V64, P79; Rebholz Sandra L, 2017, J Clin Lab Med, V2, DOI 10.16966/2572-9578.107; Reyna R, 2001, FERTIL STERIL, V76, P823, DOI 10.1016/S0015-0282(01)01986-0; SCHILD GC, 1975, B WORLD HEALTH ORGAN, V52, P43; Trombetta CM, 2018, INFLUENZA OTHER RESP, V12, P675, DOI 10.1111/irv.12591; Trombetta CM, 2018, HUM VACC IMMUNOTHER, V14, P657, DOI 10.1080/21645515.2017.1423153; Trombetta CM, 2016, EXPERT REV VACCINES, V15, P967, DOI 10.1586/14760584.2016.1164046; Trombetta CM, 2015, J IMMUNOL METHODS, V422, P95, DOI 10.1016/j.jim.2015.04.009; U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research Guidance for Industry, CLIN DAT NEED SUPP L; World Health Organization (WHO), GLOB INFL SURV NETW; World Health Organization (WHO), SER DIAGN INFL MICR	24	2	2	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							267	10.3390/vaccines9030267			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE4YD	33802846	gold, Green Published			2022-04-29	WOS:000634160700001
J	Deal, CE; Carfi, A; Plante, OJ				Deal, Cailin E.; Carfi, Andrea; Plante, Obadiah J.			Advancements in mRNA Encoded Antibodies for Passive Immunotherapy	VACCINES			English	Review						mRNA; antibody; immunotherapy	IN-VIVO; GENE-TRANSFER; MONOCLONAL-ANTIBODIES; DELIVERY; EXPRESSION; TRANSLATION; STABILITY; CELLS; MICE; TRAFFICKING	Monoclonal antibodies are the fastest growing therapeutic class in medicine today. They hold great promise for a myriad of indications, including cancer, allergy, autoimmune and infectious diseases. However, the wide accessibility of these therapeutics is hindered by manufacturing and purification challenges that result in high costs and long lead times. Efforts are being made to find alternative ways to produce and deliver antibodies in more expedient and cost-effective platforms. The field of mRNA has made significant progress in the last ten years and has emerged as a highly attractive means of encoding and producing any protein of interest in vivo. Through the natural role of mRNA as a transient carrier of genetic information for translation into proteins, in vivo expression of mRNA-encoded antibodies offer many advantages over recombinantly produced antibodies. In this review, we examine both preclinical and clinical studies that demonstrate the feasibility of mRNA-encoded antibodies and discuss the remaining challenges ahead.	[Deal, Cailin E.; Carfi, Andrea; Plante, Obadiah J.] Moderna Inc, 200 Technol Sq, Cambridge, MA 02114 USA		Carfi, A; Plante, OJ (通讯作者)，Moderna Inc, 200 Technol Sq, Cambridge, MA 02114 USA.	Cailin.Deal@modernatx.com; andrea.carfi@modernatx.com; obadiah.plante@modernatx.com			Moderna, Inc.	All research was funded by Moderna, Inc.	Alvarez RD, 2000, CLIN CANCER RES, V6, P3081; Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660; Beissert T, 2020, MOL THER, V28, P119, DOI 10.1016/j.ymthe.2019.09.009; Ben Mkaddem S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00811; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Brandenberg OF, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006313; Casazza J.P., 2020, P C RETR OPP INF CRO; Chippaux JP, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0003-1; Chng J, 2015, MABS-AUSTIN, V7, P403, DOI 10.1080/19420862.2015.1008351; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Cymer F, 2017, BIOLOGICALS, V50, P125, DOI 10.1016/j.biologicals.2017.09.006; Dangi AK, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00630; De BP, 2008, MOL THER, V16, P203, DOI 10.1038/sj.mt.6300344; De Vlieger D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02920; Deal CE, 2015, CURR OPIN IMMUNOL, V35, P113, DOI 10.1016/j.coi.2015.06.014; Deyle DR, 2009, CURR OPIN MOL THER, V11, P442; Diken M, 2011, GENE THER, V18, P702, DOI 10.1038/gt.2011.17; Ecker DM, 2015, MABS-AUSTIN, V7, P9, DOI 10.4161/19420862.2015.989042; Erasmus JH, 2020, MOL THER-METH CLIN D, V18, P402, DOI 10.1016/j.omtm.2020.06.011; Evers MJW, 2018, SMALL METHODS, V2, DOI 10.1002/smtd.201700375; Fausther-Bovendo H, 2014, HUM VACC IMMUNOTHER, V10, P2875, DOI 10.4161/hv.29594; Gao GP, 2004, BLOOD, V103, P3300, DOI 10.1182/blood-2003-11-3852; Gao GP, 2009, HUM GENE THER, V20, P930, DOI 10.1089/hum.2009.060; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Gholamalipour Y, 2018, NUCLEIC ACIDS RES, V46, P9253, DOI 10.1093/nar/gky796; Gilleron J, 2013, NAT BIOTECHNOL, V31, P638, DOI 10.1038/nbt.2612; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hajj KA, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.56; Hale G, 2006, ADV DRUG DELIVER REV, V58, P633, DOI 10.1016/j.addr.2006.03.010; Ho SCL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063247; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Hoogenboom HR, 2005, NAT BIOTECHNOL, V23, P1105, DOI 10.1038/nbt1126; Jain R, 2018, NUCLEIC ACID THER, V28, P285, DOI 10.1089/nat.2018.0734; Jennewein MF, 2017, TRENDS IMMUNOL, V38, P358, DOI 10.1016/j.it.2017.02.004; Kaplon H, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2019.1703531; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kauffman KJ, 2015, NANO LETT, V15, P7300, DOI 10.1021/acs.nanolett.5b02497; Khoshnejad M, 2019, MOL THER, V27, P188, DOI 10.1016/j.ymthe.2018.10.016; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Kozma GT, 2019, ACS NANO, V13, P9315, DOI 10.1021/acsnano.9b03942; KRIEG PA, 1990, NUCLEIC ACIDS RES, V18, P6463, DOI 10.1093/nar/18.21.6463; Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103; Lindsay KE, 2020, MOL THER, V28, P805, DOI 10.1016/j.ymthe.2020.01.002; Lorenz C, 2011, RNA BIOL, V8, P627, DOI 10.4161/rna.8.4.15394; Lu XJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57184-2; Mauger DM, 2019, P NATL ACAD SCI USA, V116, P24075, DOI 10.1073/pnas.1908052116; Maximiano S, 2016, BIODRUGS, V30, P75, DOI 10.1007/s40259-016-0162-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Molnar MJ, 2004, MOL THER, V10, P447, DOI 10.1016/j.ymthe.2004.06.642; Mukherjee J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029941; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; Nidetz NF, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107453; Nimmerjahn F, 2007, CURR OPIN IMMUNOL, V19, P239, DOI 10.1016/j.coi.2007.01.005; Pardi N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14630; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Priddy FH, 2019, LANCET HIV, V6, pE230, DOI 10.1016/S2352-3018(19)30003-7; Probst J, 2007, GENE THER, V14, P1175, DOI 10.1038/sj.gt.3302964; Pyzik M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01540; Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551; Resch B, 2017, HUM VACC IMMUNOTHER, V13, P2138, DOI 10.1080/21645515.2017.1337614; Rouet R, 2014, FEBS LETT, V588, P269, DOI 10.1016/j.febslet.2013.11.029; Russell DW, 2007, MOL THER, V15, P1740, DOI 10.1038/sj.mt.6300299; Rybakova Y, 2019, MOL THER, V27, P1415, DOI 10.1016/j.ymthe.2019.05.012; Sabnis S, 2018, MOL THER, V26, P1509, DOI 10.1016/j.ymthe.2018.03.010; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Salles G, 2017, ADV THER, V34, P2232, DOI 10.1007/s12325-017-0612-x; Samaranayake H, 2009, ANN MED, V41, P322, DOI 10.1080/07853890802698842; Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564; Schone D, 2017, J VIROL, V91, DOI 10.1128/JVI.01184-17; Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; Somiari S, 2000, MOL THER, V2, P178, DOI 10.1006/mthe.2000.0124; Sparrow E, 2019, VACCINE, V37, pA132, DOI 10.1016/j.vaccine.2018.11.004; Stadler CR, 2017, NAT MED, V23, P815, DOI 10.1038/nm.4356; Svitkin YV, 2017, NUCLEIC ACIDS RES, V45, P6023, DOI 10.1093/nar/gkx135; Szebeni J, 2005, TOXICOLOGY, V216, P106, DOI 10.1016/j.tox.2005.07.023; Tabrizi MA, 2006, DRUG DISCOV TODAY, V11, P81, DOI 10.1016/S1359-6446(05)03638-X; Thran M, 2017, EMBO MOL MED, V9, P1434, DOI 10.15252/emmm.201707678; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Tiwari PM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06508-3; Tjelle TE, 2006, VACCINE, V24, P4667, DOI 10.1016/j.vaccine.2005.08.068; Tjelle TE, 2004, MOL THER, V9, P328, DOI 10.1016/j.ymthe.2003.12.007; Tremblay JM, 2013, INFECT IMMUN, V81, P4592, DOI 10.1128/IAI.01033-13; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; Van Hoecke L, 2020, MOL THER-NUCL ACIDS, V20, P777, DOI 10.1016/j.omtn.2020.04.015; Van Hoecke L, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1804-8; Vandenberghe LH, 2006, NAT MED, V12, P967, DOI 10.1038/nm1445; von Niessen AGO, 2019, MOL THER, V27, P824, DOI 10.1016/j.ymthe.2018.12.011; Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213; Welles HC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007395; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xu L, 2017, SCIENCE, V358, P85, DOI 10.1126/science.aan8630; Zaks T., ANTIBODY CHIKUNGUNYA; Zalevsky J, 2010, NAT BIOTECHNOL, V28, P157, DOI 10.1038/nbt.1601	97	7	7	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							108	10.3390/vaccines9020108			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UG	33572679	gold, Green Published			2022-04-29	WOS:000623276000001
J	Eguia, H; Vinciarelli, F; Bosque-Prous, M; Kristensen, T; Saigi-Rubio, F				Eguia, Hans; Vinciarelli, Franco; Bosque-Prous, Marina; Kristensen, Troels; Saigi-Rubio, Francesc			Spain's Hesitation at the Gates of a COVID-19 Vaccine	VACCINES			English	Article						vaccination hesitancy; COVID-19; perception; socio-cultural factors	HESITANCY	(1) Background: This study aims to delineate a pattern on vaccine hesitancy in a sample of the Spanish population, considering age groups and status as healthcare workers. (2) Methods: Participants were recruited using Twitter (R) as a dissemination tool to reach as many respondents as possible in different parts of the Spanish territory. The participants were recruited in a cross-sectional study, which included answering an online questionnaire. Data were collected from 10 September through 23 November 2020. Respondents answered questions asking whether they intended to be vaccinated and provided the main reason for their answers. To estimate associations between vaccination hesitancy and independent variables, we fit Poisson regression models with robust variance. (3) Results: One thousand and two responses were obtained, of which only 731 were validated. One hundred and sixty-four participants stated that they would not be vaccinated (22.43%), of which 20-24% were non-health workers or unemployed, 17.5% physicians, 31.5% other health workers, and almost 35% nurses. Concerns about lack of effectiveness of the vaccination, lack of safety when vaccinating and possibly dangerous adverse effects were the main causes provided. (4) Conclusions: This study indicates that more interventions are needed to achieve better communication with the population and health professionals. Receptiveness to the message of the importance and security of the COVID-19 vaccination could be an important strategy for improving these results.	[Eguia, Hans; Bosque-Prous, Marina; Saigi-Rubio, Francesc] Univ Oberta Catalunya UOC, Fac Hlth Sci, Barcelona 08018, Spain; [Eguia, Hans; Vinciarelli, Franco] SEMERGEN New Technol Working Grp, Madrid 28009, Spain; [Vinciarelli, Franco] Emergency Hosp Clemente Alvarez, RA-2002 Rosario S, Argentina; [Kristensen, Troels] Univ Southern DaCHE, Danish Ctr Hlth Econ, DK-5230 Odense, Denmark		Saigi-Rubio, F (通讯作者)，Univ Oberta Catalunya UOC, Fac Hlth Sci, Barcelona 08018, Spain.	heguia@uoc.edu; fvincia0@rosario.gov.ar; mbosquep@uoc.edu; trkristensen@health.sdu.dk; fsaigi@uoc.edu	Bosque-Prous, Marina/AAE-1562-2020	Bosque-Prous, Marina/0000-0002-8830-8880; Kristensen, Troels/0000-0001-5232-6895; Eguia, Hans/0000-0001-6315-8559			Andre F.E., 2008, B WORLD HEALTH ORGAN, V86; [Anonymous], SMALLPOX; [Anonymous], Telediario-21 Horas-04/12/20-RTVE.es; [Anonymous], DIFTERIA CONFIRMAN P; [Anonymous], COVID 19 ONLY HALF B; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Catalan-Matamoros D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218136; Danchin M, 2020, AUST J GEN PRACT, V49, P625, DOI 10.31128/AJGP-08-20-5559; de Noordhout CM, 2018, EUR J PUBLIC HEALTH, V28, P124, DOI 10.1093/eurpub/ckx090; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2016, CAN MED ASSOC J, V188, pE17, DOI 10.1503/cmaj.150707; Espelt A, 2017, ADICCIONES, V29, P105, DOI 10.20882/adicciones.823; Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; George DR, 2013, CLIN OBSTET GYNECOL, V56, P453, DOI 10.1097/GRF.0b013e318297dc38; Henrikson NB, 2015, PEDIATRICS, V136, P70, DOI 10.1542/peds.2014-3199; Ihm J, 2018, J BEHAV ADDICT, V7, P473, DOI 10.1556/2006.7.2018.48; Jain S, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110037; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141; McGough SF, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005295; Megget K, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2184; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Peretti-Watel P, 2019, SOCIOL HEALTH ILL, V41, P1192, DOI 10.1111/1467-9566.12902; Perry C., 2020, SW RESP CRITICAL CAR, V8, P32, DOI [10.12746/swrccc.v8i36.749, DOI 10.12746/SWRCCC.V8I36.749]; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Pujazon-Zazik M, 2010, AM J MENS HEALTH, V4, P77, DOI 10.1177/1557988309360819; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Shetty P, 2010, LANCET, V375, P970, DOI 10.1016/S0140-6736(10)60421-7; Taddio A, 2015, CAN MED ASSOC J, V187, P975, DOI 10.1503/cmaj.150391; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065; Veinot Tiffany C, 2011, AMIA Annu Symp Proc, V2011, P1436; Weber TP, 2010, EMERG INFECT DIS, V16, P664, DOI 10.3201/eid1604.090434; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; World Health Organization World Health Organization, 10 THREATS GLOB HLTH	40	17	17	5	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							170	10.3390/vaccines9020170			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6PT	33670621	Green Published, gold			2022-04-29	WOS:000623264300001
J	Gerussi, V; Peghin, M; Palese, A; Bressan, V; Visintini, E; Bontempo, G; Graziano, E; De Martino, M; Isola, M; Tascini, C				Gerussi, Valentina; Peghin, Maddalena; Palese, Alvisa; Bressan, Valentina; Visintini, Erica; Bontempo, Giulia; Graziano, Elena; De Martino, Maria; Isola, Miriam; Tascini, Carlo			Vaccine Hesitancy among Italian Patients Recovered from COVID-19 Infection towards Influenza and Sars-Cov-2 Vaccination	VACCINES			English	Article						COVID-19; vaccination; influenza; pandemic; vaccine hesitancy; SARS-CoV-2		We aimed to assess the attitude towards influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations among coronavirus disease 2019 (COVID-19) recovered patients. We performed a cross-sectional study consisting of a standardized telephone interview carried out between September and November 2020 targeting a cohort of adult in- and out-patients that had recovered from COVID-19 after the first wave (March-May 2020) at Udine Hospital (Italy). Overall, 599 people participated (320 female, median age 53 years) and most had experienced an acute COVID-19 with mild illness (409, 68.3%). The majority were hesitant or undecided towards influenza (327, 54.6%) and SARS-CoV-2 (353, 59.2%) vaccines. Older age, public work exposure, and previous 2019 flu shots were the main factors associated with a positive attitude toward both vaccinations (p < 0.05). Being hospitalized during the acute COVID-19 phase was associated with the willingness to get a flu shot (94/272, 34.5%) but not SARS-CoV-2 vaccine (70/244, 28.7%). Vaccine hesitancy is diffuse and multifactorial also among COVID-19 recovered.	[Gerussi, Valentina; Peghin, Maddalena; Bontempo, Giulia; Graziano, Elena; Tascini, Carlo] Santa Maria Misericordia Univ Hosp, Infect Dis Div, I-33100 Udine, Italy; [Palese, Alvisa; Bressan, Valentina; Visintini, Erica] Univ Udine, Sch Nursing, Dept Med Sci, I-33100 Udine, Italy; [De Martino, Maria; Isola, Miriam] Univ Udine, Dept Med, I-33100 Udine, Italy		Peghin, M (通讯作者)，Santa Maria Misericordia Univ Hosp, Infect Dis Div, I-33100 Udine, Italy.	valentina.gerussi@gmail.com; maddalena.peghin@gmail.com; alvisa.palese@uniud.it; valentina.bressan@uniud.it; visintini.erica001@spes.uniud.it; bontempo.giulia@gmail.com; elenagraziano22@gmail.com; maria.demartino@uniud.it; miriam.isola@uniud.it; c.tascini@gmail.com	Palese, Alvisa/J-9427-2015; De Martino, Maria/AAM-2236-2021; ISOLA, Miriam/AAM-1191-2021; Tascini, Carlo/L-5942-2017	Palese, Alvisa/0000-0002-3508-844X; De Martino, Maria/0000-0002-0445-9578; ISOLA, Miriam/0000-0002-6391-1720; Gerussi, Valentina/0000-0003-4527-2758; Peghin, Maddalena/0000-0002-4640-679X; Tascini, Carlo/0000-0001-9625-6024	PRINMinistry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN) [20178S4EK9]	This research was funded by PRIN 2017 n.20178S4EK9-"Innovative Statistical methods in biomedical research on biomarkers: from their identification to their use in clinical practice".	Abramson ZH, 2000, ISRAEL MED ASSOC J, V2, P902; Aknin LB, 2013, J PERS SOC PSYCHOL, V104, P635, DOI 10.1037/a0031578; Belongia EA, 2020, SCIENCE, V368, P1163, DOI 10.1126/science.abd2220; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Centers for Disease Control and Prevention, 2021, INT CLIN CONS US MRN; Chiatti C, 2010, PREV MED, V51, P332, DOI 10.1016/j.ypmed.2010.06.008; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Determann D, 2016, VACCINE, V34, P803, DOI 10.1016/j.vaccine.2015.12.035; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; EpiCentro, 2021, 20202021 STAGIONE; EpiCentro, 2018, INFLUENZA COPERTURE; European Centre for Disease Prevention and Control, 2020, GUIDELINES IMPLEMENT; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fournet N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5103-8; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Grech Victor, 2020, Early Hum Dev, P105213, DOI 10.1016/j.earlhumdev.2020.105213; Han E, 2020, LANCET, V396, P1525, DOI 10.1016/S0140-6736(20)32007-9; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Matsui D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-149; Millner VS, 2010, SOUTH MED J, V103, P993, DOI 10.1097/SMJ.0b013e3181eda3d5; Nagata JM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-388; Nowalk MP, 2004, J AM GERIATR SOC, V52, P25, DOI 10.1111/j.1532-5415.2004.52006.x; O'Malley AS, 2006, AM J PREV MED, V31, P150, DOI 10.1016/j.amepre.2006.03.021; Obradovich N, 2016, CLIMATIC CHANGE, V137, P307, DOI 10.1007/s10584-016-1670-9; Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur, PROJETS RECHERCH; Odone A., 2020, ACTA BIOMED, V91; Peiris M, 2020, LANCET, V396, P1467, DOI 10.1016/S0140-6736(20)31976-0; Pena-Rey I, 2004, PUBLIC HEALTH, V118, P582, DOI 10.1016/j.puhe.2004.04.010; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Sticchi L, 2021, HUM VACC IMMUNOTHER, V17, P1664, DOI 10.1080/21645515.2020.1829413; Turner Cathy, 2003, Inj Control Saf Promot, V10, P123, DOI 10.1076/icsp.10.3.123.14560; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; WHO, 2020, CLIN MAN COVID 19 IN; WHO, 2021, DRAFT LANDSC TRACK C; Wilson R, 2020, VACCINE, V38, P1144, DOI 10.1016/j.vaccine.2019.11.018; World Health Organization, 2020, COVID 19 CAS DEFI; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Yeoh DK, 2021, CLIN INFECT DIS, V72, P2199, DOI 10.1093/cid/ciaa1475	41	23	23	4	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							172	10.3390/vaccines9020172			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6SA	33670661	gold, Green Published			2022-04-29	WOS:000623270200001
J	Gorun, F; Malita, D; Ciohat, I; Vilibic-Cavlek, T; Feier, H; Tabain, I; Craina, M; Cretu, O; Navolan, D				Gorun, Florin; Malita, Daniel; Ciohat, Ioana; Vilibic-Cavlek, Tatjana; Feier, Horea; Tabain, Irena; Craina, Marius; Cretu, Octavian; Navolan, Dan			Prevalence of Rubella Antibodies among Fertile Women in the West of Romania, 18 Years after the Implementation of Immunization	VACCINES			English	Article						rubella virus; epidemiology; vaccine; pregnant women; Romania	SEROPREVALENCE; MEASLES	Seronegative women are susceptible to primary rubella virus (RV) infection during pregnancy, which can cause fetal damage. Vaccination represents the main strategy in rubella prevention. The aim of this study was to analyze changes in the rubella seroprevalence and identify populations with a high susceptibility to RV. A cross-sectional study was performed on 6914 Caucasian fertile women who had Toxoplasma gondii, other viruses, Rubella, Cytomegalovirus, and the herpes simplex virus (TORCH) screening in two distinct periods-1452 at the Timis,oara Municipal Hospital, Romania (Group 1: 2008-2010) and 5462 at the laboratory Bioclinica S.A., Timis,oara, Romania (Group 2: 2015-2018). The RV seroprevalence decreased (Group 1 versus Group 2; 94.1% (92.7-95.2) versus 91.4% (90.6-92.1), OR = 0.76 (p = 0.0007)). According to the year of birth and eligibility to vaccination program, RV seroprevalence rates were 82.4% (76.8-86.8)/1997-2004, 85.4% (80.5-89.3)/1995-1996, 90.1% (89.0-91.1)/<1989, and 95.8% (94.7-96.6)/1989-1994. No significant difference in the RV seropositivity according to the place of residence was found. The overall RV susceptibility increased from 2008-2010 to 2015-2018. The highest susceptibility was found in women born between 19972004 eligible for measles-mumps-rubella (MMR) vaccine through the family practice system and the lowest in women born between 1989-1994 eligible for monovalent rubella vaccine conducted in schools.	[Gorun, Florin; Craina, Marius; Navolan, Dan] Victor Babes Univ Med & Pharm Timisoara, Dept Obstet Gynecol, Eftimie Murgu Sq 2, Timisoara 300041, Romania; [Malita, Daniel] Victor Babes Univ Med & Pharm Timisoara, Dept Radiol, Eftimie Murgu Sq 2, Timisoara 300041, Romania; [Ciohat, Ioana] City Unversitary Emergency Hosp Timisoara, Lab Antenatal Med, Str Odobescu 1-3, Timisoara 300202, Romania; [Vilibic-Cavlek, Tatjana; Tabain, Irena] Croatian Inst Publ Hlth, Dept Virol, Rockefeller Str 12, Zagreb 10000, Croatia; [Vilibic-Cavlek, Tatjana] Univ Zagreb, Sch Med, Salata 3, Zagreb 10000, Croatia; [Feier, Horea] Victor Babes Univ Med & Pharm Timisoara, Dept Cardiovasc Surg, Eftimie Murgu Sq 2, Timisoara 300041, Romania; [Cretu, Octavian] Victor Babes Univ Med & Pharm Timisoara, Dept Surg, Eftimie Murgu Sq 2, Timisoara 300041, Romania		Vilibic-Cavlek, T (通讯作者)，Croatian Inst Publ Hlth, Dept Virol, Rockefeller Str 12, Zagreb 10000, Croatia.; Vilibic-Cavlek, T (通讯作者)，Univ Zagreb, Sch Med, Salata 3, Zagreb 10000, Croatia.	gorun.florin@umft.ro; malita.daniel@umft.ro; ioana.ciohat@umft.ro; tatjana.vilibic-cavlek@hzjz.hr; horea.feier@umft.ro; irena.tabain@hzjz.hr; craina.marius@umft.ro; octavian.cretu@umft.ro; navolan@umft.ro	GORUN, FLORIN/ABB-4540-2020; Vilibić-Čavlek, Tatjana/AAI-2010-2019	GORUN, FLORIN/0000-0002-8882-7381; Feier, Horea/0000-0002-4870-8249; Vilibic-Cavlek, Tatjana/0000-0002-1877-5547; Malita, Daniel/0000-0002-8158-8947			[Anonymous], 2019, LANCET CHILD ADOLESC, V3, P281, DOI 10.1016/S2352-4642(19)30092-6; Bouthry E, 2014, PRENATAL DIAG, V34, P1246, DOI 10.1002/pd.4467; Demicheli V, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004407.pub3; DeStefano F, 2019, ANNU REV VIROL, V6, P585, DOI 10.1146/annurev-virology-092818-015515; Dontigny L, 2018, J OBSTET GYNAECOL CA, V40, pE615, DOI 10.1016/j.jogc.2018.05.009; European Centre for Disease Prevention and Control, 2020, MONTHLY MEASLES RUBE; European Centre for Disease Prevention and Control, MONTHLY MEASLES RUBE; European Centre for Disease Prevention and Control, 2016, MEASLES RUBELLA MONI; Godlee F, 2011, BRIT MED J, V342, DOI 10.1136/bmj.c7452; Gorun F, 2020, EXP THER MED, V20, P2439, DOI 10.3892/etm.2020.8945; Kaushik A, 2018, INDIAN J PUBLIC HLTH, V62, P52, DOI 10.4103/ijph.IJPH_275_16; Kirby T, 2015, LANCET INFECT DIS, V15, P768, DOI 10.1016/S1473-3099(15)00102-4; Lambert N, 2015, LANCET, V385, P2297, DOI 10.1016/S0140-6736(14)60539-0; Leung AKC, 2019, HONG KONG MED J, V25, P134, DOI 10.12809/hkmj187785; Lo Giudice D, 2009, J Prev Med Hyg, V50, P236; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Motoi S, 2020, EXP THER MED, V20, P3536, DOI 10.3892/etm.2020.9012; Nardone A, 2008, B WORLD HEALTH ORGAN, V86, P118, DOI 10.2471/BLT.07.042010; National Institute of Public Health Romania National Center for Surveillance and Control of Communicable Diseases, DROPPED REF; Pandolfi E, 2017, EUR J PUBLIC HEALTH, V27, P530, DOI 10.1093/eurpub/ckw259; Spencer JP, 2017, AM FAM PHYSICIAN, V95, P786; Tabacchi G, 2016, HUM VACC IMMUNOTHER, V12, P1909, DOI 10.1080/21645515.2016.1151990; The Sage Working Group, REPORT SAGE WORKING; Vilibic-Cavlek T, 2011, J MATERN-FETAL NEO M, V24, P280, DOI 10.3109/14767058.2010.485233; Warnecke JM, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820002629; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WHO, MEASLES RUBELLA GLOB; WHO, **NON-TRADITIONAL**; WHO, MEASLES RUBELLA ELIM; WHO Regional Office for Europe, 7 M EUR REG VER COMM	30	1	1	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							104	10.3390/vaccines9020104			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7IS	33572943	Green Published			2022-04-29	WOS:000623314100001
J	Rus, M; Groselj, U				Rus, Meta; Groselj, Urh			Ethics of Vaccination in Childhood-A Framework Based on the Four Principles of Biomedical Ethics	VACCINES			English	Review						vaccination; children; bioethics; principles of biomedical ethics; autonomy; nonmaleficence; beneficence; justice; common good; herd immunity		Although vaccination is recognised as the top public health achievement of the twentieth century, unequivocal consensus about its beneficence does not exist among the general population. In countries with well-established immunisation programmes, vaccines are "victims of their own success", because low incidences of diseases now prevented with vaccines diminished the experience of their historical burdens. Increasing number of vaccine-hesitant people in recent years threatens, or even effectively disables, herd immunity levels of the population and results in outbreaks of previously already controlled diseases. We aimed to apply a framework for ethical analysis of vaccination in childhood based on the four principles of biomedical ethics (respect for autonomy, nonmaleficence, beneficence and justice) to provide a comprehensive and applicable model on how to address the ethical aspects of vaccination at both individual and societal levels. We suggest finding an "ethical equilibrium", which means that the degree of respect for parents' autonomy is not constant, but variable; it shall depend on the level of established herd immunity and it is specific for every society. When the moral obligation of individuals to contribute to herd immunity is not fulfilled, mandatory vaccination policies are ethically justified, because states bear responsibility to protect herd immunity as a common good.	[Rus, Meta] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Bohoriceva 20, Ljubljana 1000, Slovenia; [Groselj, Urh] Univ Childrens Hosp, Univ Med Ctr Ljubljana, Dept Endocrinol Diabet & Metab Dis, Bohoriceva 20, Ljubljana 1000, Slovenia; [Groselj, Urh] Univ Ljubljana, Fac Med, Vrazov Trg 2, Ljubljana 1000, Slovenia; [Groselj, Urh] Minist Hlth, Natl Med Eth Comm Republ Slovenia, Stefanova 5, Ljubljana 1000, Slovenia		Groselj, U (通讯作者)，Univ Childrens Hosp, Univ Med Ctr Ljubljana, Dept Endocrinol Diabet & Metab Dis, Bohoriceva 20, Ljubljana 1000, Slovenia.; Groselj, U (通讯作者)，Univ Ljubljana, Fac Med, Vrazov Trg 2, Ljubljana 1000, Slovenia.; Groselj, U (通讯作者)，Minist Hlth, Natl Med Eth Comm Republ Slovenia, Stefanova 5, Ljubljana 1000, Slovenia.	meta.rus9@gmail.com; urh.groselj@kclj.si		Groselj, Urh/0000-0002-5246-9869	Slovenian research agency programSlovenian Research Agency - Slovenia [J3-2356]	The research and publication was partially funded by the Slovenian research agency program J3-2356.	Angelo KM, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0414; Beauchamp TL C.J., 2009, PRINCIPLES BIOMEDICA, V6th ed.; Beauchamp T, 2019, AM J BIOETHICS, V19, P9, DOI 10.1080/15265161.2019.1665402; Beauchamp TL, 2020, J MED PHILOS, V45, P560, DOI 10.1093/jmp/jhaa011; Bechini A, 2019, EXPERT REV VACCINES, V18, P693, DOI 10.1080/14760584.2019.1639502; Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004; Bedford HE, 2020, ARCH DIS CHILDHOOD-E, V105, P194, DOI 10.1136/archdischild-2019-316927; Bennett B, 2018, GLOB PUBLIC HEALTH, V13, P519, DOI 10.1080/17441692.2017.1296172; Bester JC, 2018, BIOETHICS, V32, P611, DOI 10.1111/bioe.12511; Blunden CT, 2019, J MED ETHICS, V45, P71, DOI 10.1136/medethics-2018-104752; Braun C, 2020, CURR OPIN PEDIATR, V32, P601, DOI 10.1097/MOP.0000000000000929; Browne K, 2016, CAMB Q HEALTHC ETHIC, V25, P472, DOI 10.1017/S0963180116000116; Centers for Disease Control and Prevention, 2020, REC CHILD AD IMM SCH; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P241; Chadwick R, 2018, MED LAW REV, V26, P183, DOI 10.1093/medlaw/fwy011; Chantler T, 2019, VACCINE, V37, P5218, DOI 10.1016/j.vaccine.2019.07.061; Clarke S, 2017, BIOETHICS, V31, P155, DOI 10.1111/bioe.12326; Cocanour CS, 2017, AM J SURG, V214, P993, DOI 10.1016/j.amjsurg.2017.09.015; Cohen R, 2019, MED MALADIES INFECT, V49, P34, DOI 10.1016/j.medmal.2018.10.004; Danchin Margie, 2014, Aust Fam Physician, V43, P690; Davidson AJ, 2009, PEDIATR ANESTH, V19, P994, DOI 10.1111/j.1460-9592.2009.03117.x; Davies B, 2019, PUBLIC HEALTH ETH-UK, V12, P133, DOI 10.1093/phe/phz008; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025; Dube E, 2017, CLIN MICROBIOL INFEC, V23, P279, DOI 10.1016/j.cmi.2016.11.007; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Dzansi D.Y., 2013, J SOCIOL SOC ANTHR, V4, DOI [10.31901/24566764.2013/04.03.08, DOI 10.31901/24566764.2013/04.03.08]; Eberl JT, 2019, THEOR MED BIOETH, V40, P483, DOI 10.1007/s11017-019-09511-x; Evans JH, 2000, HASTINGS CENT REP, V30, P31, DOI 10.2307/3527886; Fahlquist JN, 2018, SCAND J PUBLIC HEALT, V46, P182, DOI 10.1177/1403494817727162; Fernbach A, 2011, J AM ACAD NURSE PRAC, V23, P336, DOI 10.1111/j.1745-7599.2011.00627.x; Field RI, 2008, KENNEDY INST ETHIC J, V18, P111; Fisman DN, 2009, CAN J INFECT DIS MED, V20, P39, DOI 10.1155/2009/946012; Flanigan J, 2014, HEC FORUM, V26, P5, DOI 10.1007/s10730-013-9221-5; Folayan MO, 2016, BMC MED ETHICS, V17, DOI 10.1186/s12910-016-0094-4; Forster M, 2019, J MED ETHICS, V45, P552, DOI 10.1136/medethics-2019-105379; Freedman DO, 2019, MAYO CLIN PROC, V94, P2314, DOI 10.1016/j.mayocp.2019.02.025; Gagneur Arnaud, 2020, Can Commun Dis Rep, V46, P93, DOI 10.14745/ccdr.v46i04a06; Gagneur A, 2019, EUROSURVEILLANCE, V24, P15, DOI 10.2807/1560-7917.ES.2019.24.36.1800641; GILLON R, 1985, BRIT MED J, V291, P130, DOI 10.1136/bmj.291.6488.130; Gillon R, 2003, J MED ETHICS, V29, P307, DOI 10.1136/jme.29.5.307; Giubilini A, 2019, PALGRAVE ST ETHICS P, P1, DOI 10.1007/978-3-030-02068-2; Giubilini A, 2021, BRIT MED BULL, V137, P4, DOI 10.1093/bmb/ldaa036; Giubilini A, 2019, PUBLIC HEALTH ETH-UK, V12, P237, DOI 10.1093/phe/phz014; Giubilini A, 2018, MED HEALTH CARE PHIL, V21, P547, DOI 10.1007/s11019-018-9829-y; Gostin LO, 2020, LANCET INFECT DIS, V20, pE11, DOI 10.1016/S1473-3099(19)30558-4; Gostin LO., 2008, PUBLIC HLTH LAW POWE, V2th ed; Greenberg Joshua, 2017, PLoS Curr, V9, DOI 10.1371/currents.outbreaks.0561a011117a1d1f9596e24949e8690b; Grignolio A., 2018, KDO SE BOJI CEPIV; Groselj U, 2014, WORLD J PEDIATR, V10, P89, DOI 10.1007/s12519-014-0460-6; Grzybowski A, 2017, PATHOG GLOB HEALTH, V111, P200, DOI 10.1080/20477724.2017.1322261; Haire B, 2018, J BIOETHIC INQ, V15, P199, DOI 10.1007/s11673-018-9841-1; Hanna Jeffrey N, 2002, Commun Dis Intell Q Rep, V26, P589; Harris J, 2003, J MED ETHICS, V29, P303, DOI 10.1136/jme.29.5.303; Haviari S, 2015, HUM VACC IMMUNOTHER, V11, P2522, DOI 10.1080/21645515.2015.1082014; Hendrix KS, 2016, AM J PUBLIC HEALTH, V106, P273, DOI 10.2105/AJPH.2015.302952; Herissone-Kelly P, 2011, J MED ETHICS, V37, P584, DOI 10.1136/jme.2009.030114; Hine K, 2011, THEOR MED BIOETH, V32, P375, DOI 10.1007/s11017-011-9185-x; Hviid A, 2019, ANN INTERN MED, V170, P513, DOI 10.7326/M18-2101; Iserson KV, 2021, CAMB Q HEALTHC ETHIC, V30, P59, DOI 10.1017/S096318012000047X; Jacobson RM, 2009, VACCINE, V27, P3291, DOI 10.1016/j.vaccine.2009.02.031; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jennings B., 2016, EMERGENCY ETHICS, DOI [10.1093/med/9780190270742.001.0001, DOI 10.1093/MED/9780190270742.001.0001]; Jones Abbey M, 2012, Adv Prev Med, V2012, P932741, DOI 10.1155/2012/932741; Katz AL, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1485; Krantz I, 2004, SCAND J PUBLIC HEALT, V32, P172, DOI 10.1080/14034940310018192; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Luyten J, 2019, VACCINE, V37, P2494, DOI 10.1016/j.vaccine.2019.03.041; Marceta JA, 2019, MED HEALTH CARE PHIL, V22, P387, DOI 10.1007/s11019-018-9879-1; McAndrew S, 2019, J MED ETHICS, V45, P198, DOI 10.1136/medethics-2018-105069; McIntosh EDG, 2016, J PEDIATR-US, V175, P248, DOI 10.1016/j.jpeds.2016.06.006; McKee Chephra, 2016, J Pediatr Pharmacol Ther, V21, P104, DOI 10.5863/1551-6776-21.2.104; Mintz K, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-040717; National Conference of State Legislatures, STAT REL PHIL EX SCH; Navin MC, 2019, BIOETHICS, V33, P1042, DOI 10.1111/bioe.12645; Odone A, 2015, HUM VACC IMMUNOTHER, V11, P1268, DOI 10.1080/21645515.2015.1019980; Olson O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040590; Opel DJ, 2017, JAMA PEDIATR, V171, P893, DOI 10.1001/jamapediatrics.2017.1868; Opri R, 2018, ALLERGOL IMMUNOPATH, V46, P99, DOI 10.1016/j.aller.2017.02.003; Peretti-Watel Patrick, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Rakar I., 2020, WATER GOVERNANCE CRI, P129, DOI [10.1007/978-3-030-44798-4_9, DOI 10.1007/978-3-030-44798-4_9]; Rhodes R, 2019, THEOR MED BIOETH, V40, P487, DOI 10.1007/s11017-019-09513-9; Saad TC, 2018, MED HEALTH CARE PHIL, V21, P125, DOI 10.1007/s11019-017-9781-2; Salmon DA, 2001, PUBLIC HEALTH REP, V116, P289, DOI 10.1016/S0033-3549(04)50050-X; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Schaefer GO, 2020, VACCINE, V38, P5085, DOI 10.1016/j.vaccine.2020.06.007; Schwartz JL, 2011, PRIMARY CARE, V38, P717, DOI 10.1016/j.pop.2011.07.009; Shanawani H, 2016, J RELIG HEALTH, V55, P384, DOI 10.1007/s10943-016-0200-4; Shea M, 2020, J MED PHILOS, V45, P441, DOI 10.1093/jmp/jhaa014; Smith M, 2015, PEDIATR REV, V36, P227, DOI 10.1542/pir.36-6-227; Spencer JP, 2017, AM FAM PHYSICIAN, V95, P786; Spielthenner G, 2017, HEALTH CARE ANAL, V25, P275, DOI 10.1007/s10728-015-0295-x; Stammers T, 2015, NEW BIOETH, V21, P155, DOI 10.1179/2050287715Z.00000000070; Stirrat GM, 2005, J MED ETHICS, V31, P127, DOI 10.1136/jme.2004.008292; Storr C, 2018, DTSCH ARZTEBL INT, V115, P723, DOI 10.3238/arztebl.2018.0723; Stratton K., 2012, Adverse effects of vaccines: evidence and causality; Sugarman J., 2000, ETHICS PRIMARY CARE; Swaney SE, 2019, HEALTH PROMOT J AUST, V30, P143, DOI 10.1002/hpja.190; Taylor Robert M, 2013, Handb Clin Neurol, V118, P1, DOI 10.1016/B978-0-444-53501-6.00001-9; ter Meulen R, 2016, THEOR MED BIOETH, V37, P517, DOI 10.1007/s11017-016-9387-3; Vaz OM, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0620; Venkatramanan S, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007111; Verweij MF, 2014, VACCINE, V32, P7163, DOI 10.1016/j.vaccine.2014.10.008; Wagner AL, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040155; Williamson L, 2018, BMC MED ETHICS, V19, DOI 10.1186/s12910-018-0322-1; World Health Organisation, 10 THREATS GLOB HLTH	108	3	3	1	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							113	10.3390/vaccines9020113			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO7MK	33540732	gold, Green Published			2022-04-29	WOS:000623324000001
J	Sommerer, C; Schmitt, A; Huckelhoven-Krauss, A; Giese, T; Bruckner, T; Wang, L; Schnitzler, P; Meuer, S; Zeier, M; Schmitt, M				Sommerer, Claudia; Schmitt, Anita; Huckelhoven-Krauss, Angela; Giese, Thomas; Bruckner, Thomas; Wang, Lei; Schnitzler, Paul; Meuer, Stefan; Zeier, Martin; Schmitt, Michael			Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients	VACCINES			English	Article						cytomegalovirus (CMV); CMV reactivation; phosphoprotein 65 (pp65) peptide vaccination; specific T cells; renal transplantation		Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (MontanideT) plus imiquimod (AldaraT) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-gamma ELISpot assays and flow cytometry for CMV-specific CD8(+) T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I-II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8(+) T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned.	[Sommerer, Claudia; Zeier, Martin] Heidelberg Univ, Univ Hosp Heidelberg, Dept Nephrol, D-69117 Heidelberg, Germany; [Sommerer, Claudia; Giese, Thomas; Meuer, Stefan] German Ctr Infect Res DZIF, D-69117 Heidelberg, Germany; [Schmitt, Anita; Huckelhoven-Krauss, Angela; Wang, Lei; Schmitt, Michael] Heidelberg Univ, Dept Internal Med 5, D-69117 Heidelberg, Germany; [Giese, Thomas; Meuer, Stefan] Heidelberg Univ, Inst Immunol, D-69117 Heidelberg, Germany; [Bruckner, Thomas] Heidelberg Univ, Inst Med Biometry & Informat, D-69117 Heidelberg, Germany; [Schnitzler, Paul] Heidelberg Univ, Univ Hosp Heidelberg, Dept Virol, D-69117 Heidelberg, Germany		Sommerer, C (通讯作者)，Heidelberg Univ, Univ Hosp Heidelberg, Dept Nephrol, D-69117 Heidelberg, Germany.; Sommerer, C (通讯作者)，German Ctr Infect Res DZIF, D-69117 Heidelberg, Germany.	claudia.sommerer@med.uni-heidelberg.de; anita.schmitt@med.uni-heidelberg.de; angela.hueckelhoven-krauss@med.uni-heidelberg.de; giese@uni-hd.de; bruckner@imbi.uni-heidelberg.de; Lei.wang@med.uni-heidelberg.de; paul.schnitzler@med.uni-heidelberg.de; stefan.meuer@med.uni-heidelberg.de; martin.zeier@med.uni-heidelberg.de; michael.schmitt@med.uni-heidelberg.de		Giese, Thomas/0000-0002-9649-0424	Else Kroner-Fresenius Foundation, Germany; Division of Nephrology and Renal Clinic Heidelberg; Department of Internal Medicine V, University Hospital Heidelberg	The study was partly funded by the Else Kroner-Fresenius Foundation, Germany, the Division of Nephrology and Renal Clinic Heidelberg, and the Department of Internal Medicine V, University Hospital Heidelberg.	Ayub MA, 2014, INT J GEN MED, V7, P109, DOI 10.2147/IJGM.S57254; Barabas S, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0195-y; Bernstein DI, 2016, VACCINE, V34, P313, DOI 10.1016/j.vaccine.2015.11.056; Bestard O, 2013, AM J TRANSPLANT, V13, P1793, DOI 10.1111/ajt.12256; Chaves SS, 2011, VACCINE, V29, P9618, DOI 10.1016/j.vaccine.2011.10.057; De Keyzer K, 2011, AM J KIDNEY DIS, V58, P118, DOI 10.1053/j.ajkd.2011.04.010; Dikow R, 2011, AM J KIDNEY DIS, V57, P716, DOI 10.1053/j.ajkd.2010.11.031; Ducloux D, 2017, CELL TRANSPLANT, V26, P1601, DOI 10.1177/0963689717735404; Fateh-Moghadam S, 2003, TRANSPLANTATION, V76, P1470, DOI 10.1097/01.TP.0000090163.48433.48; Helantera I, 2010, AM J TRANSPLANT, V10, P2026, DOI 10.1111/j.1600-6143.2010.03225.x; Hill AB, 2018, CURR OPIN VIROL, V28, P161, DOI 10.1016/j.coviro.2018.01.006; Hjelmesaeth J, 2004, DIABETOLOGIA, V47, P1550, DOI 10.1007/s00125-004-1499-z; Hodson EM, 2005, LANCET, V365, P2105, DOI 10.1016/S0140-6736(05)66553-1; Humar A, 2005, AM J TRANSPLANT, V5, P1065, DOI 10.1111/j.1600-6143.2005.00797.x; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Kharfan-Dabaja MA, 2012, LANCET INFECT DIS, V12, P290, DOI 10.1016/S1473-3099(11)70344-9; Kliem V, 2008, AM J TRANSPLANT, V8, P975, DOI 10.1111/j.1600-6143.2007.02133.x; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Ljungman P, 2017, CLIN INFECT DIS, V64, P87, DOI 10.1093/cid/ciw668; Lucia M, 2014, TRANSPL INT, V27, P643, DOI 10.1111/tri.12318; Malonis RJ, 2020, CHEM REV, V120, P3210, DOI 10.1021/acs.chemrev.9b00472; Mastalerz-Migas A, 2013, MED SCI MONITOR, V19, P1013, DOI 10.12659/MSM.889671; Nakamura R, 2016, LANCET HAEMATOL, V3, pE87, DOI 10.1016/S2352-3026(15)00246-X; Nickel P, 2009, TRANSPL IMMUNOL, V20, P238, DOI 10.1016/j.trim.2008.11.002; Pass RF, 2009, NEW ENGL J MED, V360, P1191, DOI 10.1056/NEJMoa0804749; REUSSER P, 1991, BLOOD, V78, P1373; Rozen-Zvi B, 2016, CLIN TRANSPLANT, V30, P980, DOI 10.1111/ctr.12775; Sagedal S, 2004, KIDNEY INT, V66, P329, DOI 10.1111/j.1523-1755.2004.00735.x; Schmitt A, 2009, J IMMUNOL METHODS, V343, P140, DOI 10.1016/j.jim.2009.02.003; Schmitt M, 2017, THERANOSTICS, V7, P1705, DOI 10.7150/thno.18301; Sharples LD, 2003, TRANSPLANTATION, V76, P679, DOI 10.1097/01.TP.0000071200.37399.1D; Witzke O, 2012, TRANSPLANTATION, V93, P61, DOI 10.1097/TP.0b013e318238dab3; Wloch MK, 2008, J INFECT DIS, V197, P1634, DOI 10.1086/588385	33	3	3	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							133	10.3390/vaccines9020133			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7BR	33562163	Green Published, gold			2022-04-29	WOS:000623295800001
J	Yang, XK; Zhao, HT; Li, ZL; Zhu, AQ; Ren, MR; Geng, MJ; Li, Y; Qin, Y; Feng, LZ; Peng, ZB; An, ZJ; Zheng, JD; Li, ZJ; Feng, ZJ				Yang, Xiaokun; Zhao, Hongting; Li, Zhili; Zhu, Aiqin; Ren, Minrui; Geng, Mengjie; Li, Yu; Qin, Ying; Feng, Luzhao; Peng, Zhibin; An, Zhijie; Zheng, Jiandong; Li, Zhongjie; Feng, Zijian			Influenza Vaccine Effectiveness in Mainland China: A Systematic Review and Meta-Analysis	VACCINES			English	Review						influenza; vaccine effectiveness; China; systematic review; meta-analysis		Influenza endangers human health but can be prevented in part by vaccination. Assessing influenza vaccine effectiveness (VE) provides scientific evidence for developing influenza vaccination policy. We conducted a systematic review and meta-analysis of studies that evaluated influenza VE in mainland China. We searched six relevant databases as of 30 August 2019 to identify studies and used Review Manager 5.3 software to analyze the included studies. The Newcastle-Ottawa scale was used to assess the risk of publication bias. We identified 1408 publications, and after removing duplicates and screening full texts, we included 21 studies in the analyses. Studies were conducted in Beijing, Guangzhou, Suzhou, and Zhejiang province from the 2010/11 influenza season through the 2017/18 influenza season. Overall influenza VE for laboratory confirmed influenza was 36% (95% CI: 25-46%). In the subgroup analysis, VE was 45% (95% CI: 18-64%) for children 6-35 months who received one dose of influenza vaccine, and 57% (95% CI: 50-64%) who received two doses. VE was 47% (95% CI: 39-54%) for children 6 months to 8 years, and 18% (95% CI: 0-33%) for adults >= 60 years. For inpatients, VE was 21% (95% CI: -11-44%). We conclude that influenza vaccines that were used in mainland China had a moderate effectiveness, with VE being higher among children than the elderly. Influenza VE should be continuously monitored in mainland China to provide evidence for policy making and improving uptake of the influenza vaccine.	[Yang, Xiaokun; Zhao, Hongting; Li, Zhili; Ren, Minrui; Geng, Mengjie; Li, Yu; Qin, Ying; Peng, Zhibin; Zheng, Jiandong; Li, Zhongjie] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing 102206, Peoples R China; [Zhu, Aiqin] Shanghai Pudong New Area Ctr Dis Control & Preven, Div Infect Dis Prevent & Disinfect Management, Shanghai 200136, Peoples R China; [Feng, Luzhao] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Beijing 100730, Peoples R China; [An, Zhijie] Chinese Ctr Dis Control & Prevent, Natl Immunizat Program, Beijing 102206, Peoples R China; [Feng, Zijian] Chinese Ctr Dis Control & Prevent, Beijing 102206, Peoples R China		Zheng, JD; Li, ZJ (通讯作者)，Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing 102206, Peoples R China.; Feng, ZJ (通讯作者)，Chinese Ctr Dis Control & Prevent, Beijing 102206, Peoples R China.	yangxk@chinacdc.cn; zhaoht@chinacdc.cn; lizl@chinacdc.cn; zhuaiqin28@163.com; renmr@chinacdc.cn; gengmj@chinacdc.cn; liyu1@chinacdc.cn; Qinying@chinacdc.cn; fengluzhao@cams.cn; pengzb@chinacdc.cn; anzjl@chinacdc.cn; zhengjd@chinacdc.cn; lizj@chinacdc.cn; fengzj@chinacdc.cn		Yang, Xiaokun/0000-0001-9571-1144; Zhu, Aiqin/0000-0001-5034-0175	National Science and Technology Major Project [2018ZX10713001-005]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [91846302]; China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases; Emergency Response Mechanism Operation Program, Chinese Center for Disease for Disease Control and Prevention [131031001000015001]	This study was supported by the National Science and Technology Major Project (No. 2018ZX10713001-005), the National Natural Science Foundation of China (91846302), the China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases, and Emergency Response Mechanism Operation Program, Chinese Center for Disease for Disease Control and Prevention (No.131031001000015001). The founders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainslie KEC, 2019, EXPERT REV VACCINES, V18, P615, DOI 10.1080/14760584.2019.1622419; [Anonymous], 2010, MMWR MORB MORTAL WLK, V59, P477; Bian G.L., 2010, ADV MATER, V22, P19; Castilla J, 2018, EUROSURVEILLANCE, V23, P12, DOI 10.2807/1560-7917.ES.2018.23.2.16-00780; [陈晨 Chen Chen], 2017, [中国感染与化疗杂志, Chinese Journal of Infection and Chemotherapy], V17, P29; Chit A, 2015, LANCET INFECT DIS, V15, P1459, DOI 10.1016/S1473-3099(15)00249-2; Colucci Maria Eugenia, 2020, Acta Biomed, V91, P63, DOI 10.23750/abm.v91i3-S.9424; Couch RB, 2007, VACCINE, V25, P7656, DOI 10.1016/j.vaccine.2007.08.042; Derhovanessian E, 2012, MICROB BIOTECHNOL, V5, P226, DOI 10.1111/j.1751-7915.2011.00283.x; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Duan W., 2014, GUO JI BING XUE ZHI, V21, P241; Eisenberg KW, 2008, PEDIATRICS, V122, P911, DOI 10.1542/peds.2007-3304; Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790; Feng S, 2016, VACCINE, V34, P1672, DOI 10.1016/j.vaccine.2016.02.039; Fu CX, 2020, HUM VACC IMMUNOTHER, V16, P595, DOI 10.1080/21645515.2019.1662267; Fu CX, 2015, VACCINE, V33, P2917, DOI 10.1016/j.vaccine.2015.04.063; Fu CX, 2013, INFLUENZA OTHER RESP, V7, P1168, DOI 10.1111/irv.12157; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; He Q., 2014, PHYS LETT B, V14, P599; [贺晴 He Qing], 2016, [中华疾病控制杂志, Chinese Journal of Disease Control & Prevention], V20, P1018; Huang H., 2012, INT J LAB MED, V33, P1932; Izurieta HS, 2015, LANCET INFECT DIS, V15, P293, DOI 10.1016/S1473-3099(14)71087-4; Li L, 2019, LANCET PUBLIC HEALTH, V4, pE473, DOI 10.1016/S2468-2667(19)30163-X; Liu Min, 2005, Zhonghua Liu Xing Bing Xue Za Zhi, V26, P412; Luo Shuying, 2019, Zhonghua Yufang Yixue Zazhi, V53, P576, DOI [10.3760/cma.j.issn.0253.9624.2019.06.007, 10.3760/cma.j.issn.0253-9624.2019.06.007]; Ma CN, 2017, HUM VACC IMMUNOTHER, V13, P2379, DOI [10.1080/21645515.2017.1359364, 10.1080/21645515.2017.1353845]; McKenzie JE, 2016, RESPIROLOGY, V21, P626, DOI 10.1111/resp.12783; Merckx J, 2017, ANN INTERN MED, V167, P394, DOI 10.7326/M17-0848; Parodi V., 2011, DRUG AGING, V28, P93, DOI [10.2165/11586770-000000000-00000, DOI 10.2165/11586770-000000000-00000]; Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0; Qin Y, 2016, VACCINE, V34, P2329, DOI 10.1016/j.vaccine.2016.03.068; Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641; Smetana J, 2018, HUM VACC IMMUNOTHER, V14, P540, DOI 10.1080/21645515.2017.1343226; Staat MA, 2011, VACCINE, V29, P9005, DOI 10.1016/j.vaccine.2011.09.037; SYMPHONY, 2022, JAMA-J AM MED ASSOC; Tenforde MW, 2021, CLIN INFECT DIS, V73, P386, DOI 10.1093/cid/ciaa407; Wang J.Z., 2016, J ALLOY COMPD, V1, P98; Wang Ping, 2011, Zhonghua Liu Xing Bing Xue Za Zhi, V32, P120; Wang R.Q., 2008, CARDIOL YOUNG, V18, P340; Wang Y M, 2018, Zhonghua Liu Xing Bing Xue Za Zhi, V39, P1051, DOI 10.3760/cma.j.issn.0254-6450.2018.08.008; Wang Y, 2018, VACCINE, V36, P2456, DOI 10.1016/j.vaccine.2018.03.039; Wang Y, 2018, HUM VACC IMMUNOTHER, V14, P630, DOI 10.1080/21645515.2017.1397868; Wang Y, 2016, VACCINE, V34, P2460, DOI 10.1016/j.vaccine.2016.03.056; Wells G.A., NEWCASTLE OTTAWA SCA; WHO, INFL SEAS; Wilkinson K, 2017, VACCINE, V35, P2775, DOI 10.1016/j.vaccine.2017.03.092; Wu SS, 2018, VACCINE, V36, P5774, DOI 10.1016/j.vaccine.2018.07.077; Yang J, 2016, VACCINE, V34, P5724, DOI 10.1016/j.vaccine.2016.10.013; Yang P, 2014, VACCINE, V32, P5285, DOI 10.1016/j.vaccine.2014.07.083; Zhang D.T., 2019, RES ASTRON ASTROPHYS, V26, P77; Zhang DT, 2019, VACCINE, V37, P1853, DOI 10.1016/j.vaccine.2019.02.013; Zhang L, 2020, HUM VACC IMMUNOTHER, V16, P816, DOI 10.1080/21645515.2019.1677438; Zhang L, 2018, HUM VACC IMMUNOTHER, V14, P1323, DOI 10.1080/21645515.2018.1441655; Zhang L, 2018, VACCINE, V36, P4993, DOI 10.1016/j.vaccine.2018.07.017; Zhang L, 2017, PEDIATR INFECT DIS J, V36, pE69, DOI 10.1097/INF.0000000000001434; Zhang Pei-ru, 2009, Zhonghua Yufang Yixue Zazhi, V43, P615, DOI 10.3760/cma.j.issn.0253-9624.2009.07.019; [张欣 ZHANG Xin], 2011, [中华传染病杂志, Chinese Journal of Infections Diseases], V29, P154; Zhang Y, 2017, VACCINE, V35, P3129, DOI 10.1016/j.vaccine.2017.03.084	58	2	3	2	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							79	10.3390/vaccines9020079			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6TJ	33498688	gold, Green Published			2022-04-29	WOS:000623273700001
J	Zhao, Y; Baldin, AV; Isayev, O; Werner, J; Zamyatnin, AA; Bazhin, AV				Zhao, Yue; Baldin, Alexey, V; Isayev, Orkhan; Werner, Jens; Zamyatnin, Andrey A., Jr.; Bazhin, Alexandr, V			Cancer Vaccines: Antigen Selection Strategy	VACCINES			English	Review						cancer vaccines; cancer antigens; tumor-specific antigens; tumor-associated antigens; neoantigens; cancer-germline antigens		Unlike traditional cancer therapies, cancer vaccines (CVs) harness a high specificity of the host's immunity to kill tumor cells. CVs can train and bolster the patient's immune system to recognize and eliminate malignant cells by enhancing immune cells' identification of antigens expressed on cancer cells. Various features of antigens like immunogenicity and avidity influence the efficacy of CVs. Therefore, the choice and application of antigens play a critical role in establishing and developing CVs. Tumor-associated antigens (TAAs), a group of proteins expressed at elevated levels in tumor cells but lower levels in healthy normal cells, have been well-studied and developed in CVs. However, immunological tolerance, HLA restriction, and adverse events are major obstacles that threaten TAA-based CVs' efficacy due to the "self-protein" characteristic of TAAs. As "abnormal proteins" that are completely absent from normal cells, tumor-specific antigens (TSAs) can trigger a robust immune response against tumor cells with high specificity and without going through central tolerance, contributing to cancer vaccine development feasibility. In this review, we focus on the unique features of TAAs and TSAs and their application in vaccines, summarizing their performance in preclinical and clinical trials.	[Zhao, Yue; Baldin, Alexey, V; Werner, Jens; Bazhin, Alexandr, V] Ludwig Maximilians Univ Munchen, Dept Gen Visceral & Transplant Surg, D-81377 Munich, Germany; [Baldin, Alexey, V; Zamyatnin, Andrey A., Jr.] Lomonosov Moscow State Univ, Belozersky Inst Phys Chem Biol, Moscow 119992, Russia; [Isayev, Orkhan] Azerbaijan Med Univ, Dept Histol Embryol & Cytol, Baku 370022, Azerbaijan; [Werner, Jens; Bazhin, Alexandr, V] German Canc Consortium DKTK, Partner Site Munich, D-80336 Munich, Germany; [Zamyatnin, Andrey A., Jr.] Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow 119991, Russia; [Zamyatnin, Andrey A., Jr.] Sirius Univ Sci & Technol, Dept Biotechnol, 1 Olymp Ave, Soci 354340, Russia		Bazhin, AV (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Gen Visceral & Transplant Surg, D-81377 Munich, Germany.; Bazhin, AV (通讯作者)，German Canc Consortium DKTK, Partner Site Munich, D-80336 Munich, Germany.	yue.zhao@med.uni-muenchen.de; alexey-baldin@belozersky.msu.ru; isayev.orkhan@yahoo.com; jens.werner@med.uni-muenchen.de; zamyat@belozersky.msu.ru; alexandr.bazhin@med.uni-muenchen.de	Baldin, Alexey/ABC-7462-2021; Zamyatnin, Andrey A./D-6443-2012	Baldin, Alexey/0000-0001-6220-5341; Zamyatnin, Andrey A./0000-0002-3046-4565	Chinese Scholarship CouncilChina Scholarship Council [201906310088]; Ministry of Education and Science of the Russian FederationMinistry of Education and Science, Russian Federation	This research was funded by the Chinese Scholarship Council to Y.Z. (201906310088) and by the Ministry of Education and Science of the Russian Federation to A.V.B. (Alexey V. Baldin).	Aggarwal C, 2019, CLIN CANCER RES, V25, P110, DOI 10.1158/1078-0432.CCR-18-1763; Al-Khadairi G, 2019, CANCERS, V11, DOI 10.3390/cancers11070984; Aleksic M, 2012, EUR J IMMUNOL, V42, P3174, DOI 10.1002/eji.201242606; Almeida LG, 2009, NUCLEIC ACIDS RES, V37, pD816, DOI 10.1093/nar/gkn673; Aung PP, 2014, HUM PATHOL, V45, P259, DOI 10.1016/j.humpath.2013.05.029; Aurisicchio L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1084-4; Bais P, 2017, BIOINFORMATICS, V33, P3110, DOI 10.1093/bioinformatics/btx375; Baldin AV, 2020, CANCERS, V12, DOI 10.3390/cancers12030590; Baldin AV, 2019, BIOCHIMIE, V157, P26, DOI 10.1016/j.biochi.2018.10.019; Baldin AV, 2019, CURR MED CHEM, V26, P427, DOI 10.2174/0929867325666180129100015; Bao L, 2011, CANCER IMMUNOL IMMUN, V60, P1299, DOI 10.1007/s00262-011-1037-z; Bart J, 2002, LANCET ONCOL, V3, P357, DOI 10.1016/S1470-2045(02)00776-3; Batchu RB, 2014, JAMA SURG, V149, P451, DOI 10.1001/jamasurg.2013.4113; Bazhin AV, 2007, INT J CANCER, V120, P1268, DOI 10.1002/ijc.22458; Besser H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0595-z; Bjerregaard AM, 2017, CANCER IMMUNOL IMMUN, V66, P1123, DOI 10.1007/s00262-017-2001-3; Boccardo E, 2007, CURR MED CHEM, V14, P2526, DOI 10.2174/092986707782023316; Bonehill A, 2004, J IMMUNOL, V172, P6649, DOI 10.4049/jimmunol.172.11.6649; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Bright RK, 2014, HUM VACC IMMUNOTHER, V10, P3297, DOI 10.4161/hv.29475; Campos-Perez J, 2013, INT J CANCER, V133, P1400, DOI 10.1002/ijc.28156; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen FJ, 2019, J CLIN INVEST, V129, P2056, DOI 10.1172/JCI99538; Chen JL, 2000, J IMMUNOL, V165, P948, DOI 10.4049/jimmunol.165.2.948; Chen ME, 2020, AM J CANCER RES, V10, P275; Chen R, 2021, MASS SPECTROM REV, V40, P110, DOI 10.1002/mas.21616; Chen XT, 2020, THERANOSTICS, V10, P6011, DOI 10.7150/thno.38742; Chen XF, 2018, INT J CANCER, V143, P2561, DOI 10.1002/ijc.31730; Chen Y, 2012, ONCOGENE, V31, P2140, DOI 10.1038/onc.2011.395; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Chen YQ, 2013, INT J MOL MED, V32, P1366, DOI 10.3892/ijmm.2013.1510; Chia WK, 2012, ANN ONCOL, V23, P997, DOI 10.1093/annonc/mdr341; Chomez P, 2001, CANCER RES, V61, P5544; Coffin JM, 1997, RETROVIRUSES; Cook AM, 2016, CURR OPIN IMMUNOL, V39, P23, DOI 10.1016/j.coi.2015.12.003; COULIE PG, 1995, P NATL ACAD SCI USA, V92, P7976, DOI 10.1073/pnas.92.17.7976; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; Dalgleish AG, 2015, IMMUNOTHERAPY-UK, V7, P309, DOI [10.2217/IMT.14.111, 10.2217/imt.14.111]; Delaunay T, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1407897; DEPLAEN E, 1988, P NATL ACAD SCI USA, V85, P2274; Ding FX, 2009, HEPATOLOGY, V49, P1492, DOI 10.1002/hep.22816; dos Santos LI, 2015, CANCER IMMUNOL IMMUN, V64, P311, DOI 10.1007/s00262-014-1634-8; Dreno B, 2018, LANCET ONCOL, V19, P916, DOI 10.1016/S1470-2045(18)30254-7; Drury SEN, 1998, VET REC, V143, P639; Duperret EK, 2019, CANCER IMMUNOL RES, V7, P174, DOI 10.1158/2326-6066.CIR-18-0283; Duperret EK, 2018, CLIN CANCER RES, V24, P6015, DOI 10.1158/1078-0432.CCR-18-1013; Duraiswamy J, 2003, BLOOD, V101, P3150, DOI 10.1182/blood-2002-10-3092; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003; Esfandiary A, 2015, IMMUNOTHERAPY-UK, V7, P683, DOI [10.2217/imt.15.29, 10.2217/IMT.15.29]; Field MG, 2016, CLIN CANCER RES, V22, P1234, DOI 10.1158/1078-0432.CCR-15-2071; Fijak M, 2006, IMMUNOL REV, V213, P66, DOI 10.1111/j.1600-065X.2006.00438.x; Fiszer D, 1998, AM J REPROD IMMUNOL, V40, P172; Forghanifard MM, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0191-5; Fossa A, 2004, PROSTATE, V59, P440, DOI 10.1002/pros.20025; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Fratta E, 2011, MOL ONCOL, V5, P164, DOI 10.1016/j.molonc.2011.02.001; Fukuda K, 2017, MELANOMA RES, V27, P326, DOI 10.1097/CMR.0000000000000342; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gasser O, 2018, CANCER IMMUNOL IMMUN, V67, P285, DOI 10.1007/s00262-017-2085-9; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Geall AJ, 2015, EXPERT REV VACCINES, V14, P151, DOI 10.1586/14760584.2015.1001244; Gerard C, 2015, J IMMUNOTHER, V38, P311, DOI 10.1097/CJI.0000000000000095; Gibney GT, 2015, CLIN CANCER RES, V21, P712, DOI 10.1158/1078-0432.CCR-14-2468; Gjerstorff MF, 2007, HUM REPROD, V22, P953, DOI 10.1093/humrep/del494; Golovastova MO, 2014, BIOCHEMISTRY-MOSCOW+, V79, P733, DOI 10.1134/S000629791408001X; Gopanenko AV, 2020, CANCERS, V12, DOI 10.3390/cancers12102879; Gordeeva O, 2018, SEMIN CANCER BIOL, V53, P75, DOI 10.1016/j.semcancer.2018.08.006; Gotwals P, 2017, NAT REV CANCER, V17, P286, DOI 10.1038/nrc.2017.17; Haen SP, 2013, CURR OPIN IMMUNOL, V25, P277, DOI 10.1016/j.coi.2013.03.007; Hancock G, 2018, BEST PRACT RES CL OB, V47, P59, DOI 10.1016/j.bpobgyn.2017.09.008; Hemminger JA, 2013, MODERN PATHOL, V26, P282, DOI 10.1038/modpathol.2012.133; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Hos BJ, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1673125; Hui EP, 2013, CANCER RES, V73, P1676, DOI 10.1158/0008-5472.CAN-12-2448; Hundal J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0264-5; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; Iqbal Nida, 2014, Mol Biol Int, V2014, P852748, DOI 10.1155/2014/852748; Iura K, 2015, J PATHOL CLIN RES, V1, P144, DOI 10.1002/cjp2.16; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Karpanen T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01718; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Khan S, 2017, INT J CANCER, V141, P393, DOI 10.1002/ijc.30679; Kim KH, 2012, CANCER IMMUNOL IMMUN, V61, P63, DOI 10.1007/s00262-011-1092-5; Kim MK, 2010, BIOCHEM PHARMACOL, V80, P1930, DOI 10.1016/j.bcp.2010.07.013; Kim SH, 2009, LUNG, V187, P401, DOI 10.1007/s00408-009-9181-3; Kim TJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6317; Kinkead HL, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122857; Kobayashi H, 2001, CANCER RES, V61, P4773; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Krishnadas DK, 2015, CANCER IMMUNOL IMMUN, V64, P1251, DOI 10.1007/s00262-015-1731-3; Lee MY, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001111; Li L, 2017, ANN ONCOL, V28, P11, DOI 10.1093/annonc/mdx681; Li M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-179; Liang RR, 2014, CURR PHARM DESIGN, V20, P1715, DOI 10.2174/13816128113199990533; Liao SJ, 2013, J HUAZHONG U SCI-MED, V33, P735, DOI 10.1007/s11596-013-1189-5; Lin CL, 2002, CANCER RES, V62, P6952; Liu CC, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12446; Liu XL, 2015, CELL IMMUNOL, V295, P77, DOI 10.1016/j.cellimm.2015.03.011; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Lutzky VP, 2010, J VIROL, V84, P407, DOI 10.1128/JVI.01303-09; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Maciag PC, 2009, VACCINE, V27, P3975, DOI 10.1016/j.vaccine.2009.04.041; Matsuzaki J, 2010, P NATL ACAD SCI USA, V107, P7875, DOI 10.1073/pnas.1003345107; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; MILAM AH, 1993, INVEST OPHTH VIS SCI, V34, P91; Mohsen MO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01015; MONACH PA, 1995, IMMUNITY, V2, P45, DOI 10.1016/1074-7613(95)90078-0; Monnier-Benoit S, 2006, GYNECOL ONCOL, V102, P22, DOI 10.1016/j.ygyno.2005.11.039; Morisaki T, 2021, IMMUNOL INVEST, V50, P562, DOI 10.1080/08820139.2020.1778721; Morrow MP, 2013, EXPERT REV VACCINES, V12, P271, DOI [10.1586/erv.13.23, 10.1586/ERV.13.23]; Muhr LSA, 2018, VIROLOGY, V519, P74, DOI 10.1016/j.virol.2018.04.003; Nakagawa H, 2018, CANCER SCI, V109, P513, DOI 10.1111/cas.13505; Navas MC, 2019, AM J PATHOL, V189, P1122, DOI 10.1016/j.ajpath.2019.01.018; Nielsen JS, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1321184; Nowalk A, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.DMIH2-0011-2015; Odunsi K, 2014, CANCER IMMUNOL RES, V2, P37, DOI 10.1158/2326-6066.CIR-13-0126; Oiso M, 1999, INT J CANCER, V81, P387, DOI 10.1002/(SICI)1097-0215(19990505)81:3<387::AID-IJC12>3.0.CO;2-Z; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pan JQ, 2009, MOL CANCER THER, V8, P2754, DOI 10.1158/1535-7163.MCT-08-1176; Pinzani P, 2008, HUM PATHOL, V39, P1474, DOI 10.1016/j.humpath.2008.02.012; Pujol JL, 2016, J THORAC ONCOL, V11, P2208, DOI 10.1016/j.jtho.2016.08.120; Rahma OE, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0353-4; Reuven EM, 2019, ACS NANO, V13, P2936, DOI 10.1021/acsnano.8b07241; Rezvani K, 2009, BLOOD, V113, P2245, DOI 10.1182/blood-2008-03-144071; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Salomon N, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1771925; Sang MX, 2011, VACCINE, V29, P8496, DOI 10.1016/j.vaccine.2011.09.014; Sartorius R, 2008, J IMMUNOL, V180, P3719, DOI 10.4049/jimmunol.180.6.3719; Scheetz L, 2020, CLIN CANCER RES, V26, P4369, DOI 10.1158/1078-0432.CCR-20-0341; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schenck RO, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2876-4; Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108; Schultz ES, 2000, CANCER RES, V60, P6272; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Segal NH, 2008, CANCER RES, V68, P889, DOI 10.1158/0008-5472.CAN-07-3095; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; Sigalotti L, 2005, SEMIN ONCOL, V32, P473, DOI 10.1053/j.seminoncol.2005.07.005; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Smith CC, 2019, NAT REV CANCER, V19, P465, DOI 10.1038/s41568-019-0162-4; Sneddon S, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1684713; Stone JD, 2015, CURR OPIN IMMUNOL, V33, P16, DOI 10.1016/j.coi.2015.01.003; Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548; Tagliamonte M, 2015, CANCER IMMUNOL IMMUN, V64, P1305, DOI 10.1007/s00262-015-1698-0; Tan PX, 2012, BIOCHEM BIOPH RES CO, V419, P801, DOI 10.1016/j.bbrc.2012.02.110; Tanzarella S, 1999, CANCER RES, V59, P2668; Taylor GS, 2014, CLIN CANCER RES, V20, P5009, DOI 10.1158/1078-0432.CCR-14-1122-T; Taylor GS, 2004, J VIROL, V78, P768, DOI 10.1128/JVI.78.2.768-778.2004; Teow SY, 2017, J PATHOG, V2017, DOI 10.1155/2017/7349268; Thomas R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00947; Tian YM, 2017, ONCOTARGET, V8, P45951, DOI 10.18632/oncotarget.17504; Tu W, 2019, DIGEST DIS SCI, V64, P3203, DOI 10.1007/s10620-019-05681-9; Valdespino V, 2005, GYNECOL ONCOL, V96, P92, DOI 10.1016/j.ygyno.2004.08.052; van Buuren MM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28836; van der Burg SH, 2011, CURR OPIN IMMUNOL, V23, P252, DOI 10.1016/j.coi.2010.12.010; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P3038, DOI 10.1002/eji.1830241218; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vansteenkiste JF, 2016, LANCET ONCOL, V17, P822, DOI 10.1016/S1470-2045(16)00099-1; Preciado MV, 2014, WORLD J GASTROENTERO, V20, P15992, DOI 10.3748/wjg.v20.i43.15992; Wallecha A, 2012, J ONCOL, V2012, DOI 10.1155/2012/542851; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang RJ, 2020, CANCER LETT, V471, P88, DOI 10.1016/j.canlet.2019.11.039; Weber JS, 2011, J IMMUNOTHER, V34, P556, DOI 10.1097/CJI.0b013e3182280db1; Welters MJP, 2008, CLIN CANCER RES, V14, P178, DOI 10.1158/1078-0432.CCR-07-1880; Westdorp H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0787-6; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu JJ, 2018, CANCER LETT, V419, P210, DOI 10.1016/j.canlet.2018.01.050; Xu HZ, 2014, GASTROINTEST TUMORS, V1, P135, DOI 10.1159/000365307; Xu PJ, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110640; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001; Yao J, 2014, CANCER IMMUNOL RES, V2, P371, DOI 10.1158/2326-6066.CIR-13-0088; Yarchoan M, 2017, NAT REV CANCER, V17, P209, DOI 10.1038/nrc.2016.154; Yuan JD, 2008, P NATL ACAD SCI USA, V105, P20410, DOI 10.1073/pnas.0810114105; Yuen MF, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/nrdp.2018.35, 10.1038/nrdp.2018.36]; Yutani S, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/473909; Zarour HM, 2000, CANCER RES, V60, P4946; Zhang R, 2020, CANCER IMMUNOL IMMUN, V69, P135, DOI 10.1007/s00262-019-02448-z; Zhang X, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109542; Zhang Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02472; Zhou D, 2019, CANCER BIOL MED, V16, P288, DOI 10.20892/j.issn.2095-3941.2018.0309; Zhu GZ, 2017, ACS NANO, V11, P2387, DOI 10.1021/acsnano.7b00978	186	4	5	6	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							85	10.3390/vaccines9020085			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7AV	33503926	gold, Green Published			2022-04-29	WOS:000623293500001
J	Grabowska, J; Stolk, DA; Twilhaar, MNK; Ambrosini, M; Storm, G; van der Vliet, HJ; de Gruijl, TD; van Kooyk, Y; den Haan, JMM				Grabowska, Joanna; Stolk, Dorian A.; Nijen Twilhaar, Maarten K.; Ambrosini, Martino; Storm, Gert; van der Vliet, Hans J.; de Gruijl, Tanja D.; van Kooyk, Yvette; den Haan, Joke M. M.			Liposomal Nanovaccine Containing alpha-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8(+) T Cell Responses via CD169(+) Macrophages and cDC1	VACCINES			English	Article						vaccination; liposomes; anti-tumor; CD169 macrophage; cDC1; invariant natural killer T cell; alpha galactosylceramide; ganglioside GM3		Successful anti-cancer vaccines aim to prime and reinvigorate cytotoxic T cells and should therefore comprise a potent antigen and adjuvant. Antigen targeting to splenic CD169(+) macrophages was shown to induce robust CD8(+) T cell responses via antigen transfer to cDC1. Interestingly, CD169(+) macrophages can also activate type I natural killer T-cells (NKT). NKT activation via ligands such as alpha-galactosylceramide (alpha GC) serve as natural adjuvants through dendritic cell activation. Here, we incorporated ganglioside GM3 and alpha GC in ovalbumin (OVA) protein-containing liposomes to achieve both CD169(+) targeting and superior DC activation. The systemic delivery of GM3-alpha GC-OVA liposomes resulted in specific uptake by splenic CD169(+) macrophages, stimulated strong IFN gamma production by NKT and NK cells and coincided with the maturation of cDC1 and significant IL-12 production. Strikingly, superior induction of OVA-specific CD8(+) T cells was detected after immunization with GM3-alpha GC-OVA liposomes. CD8(+) T cell activation, but not B cell activation, was dependent on CD169(+) macrophages and cDC1, while activation of NKT and NK cells were partially mediated by cDC1. In summary, GM3-alpha GC antigen-containing liposomes are a potent vaccination platform that promotes the interaction between different immune cell populations, resulting in strong adaptive immunity and therefore emerge as a promising anti-cancer vaccination strategy.	[Grabowska, Joanna; Stolk, Dorian A.; Nijen Twilhaar, Maarten K.; Ambrosini, Martino; van Kooyk, Yvette; den Haan, Joke M. M.] Vrije Univ Amsterdam, Amsterdam Infect & Immun Inst, Dept Mol Cell Biol & Immunol, Amsterdam UMC,Canc Ctr Amsterdam, NL-1081 HZ Amsterdam, Netherlands; [Storm, Gert] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, NL-3584 CG Utrecht, Netherlands; [Storm, Gert] Univ Twente, Dept Biomat Sci & Technol, NL-7500 AE Enschede, Netherlands; [Storm, Gert] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 119228, Singapore; [van der Vliet, Hans J.; de Gruijl, Tanja D.] Vrije Univ Amsterdam, Amsterdam Infect & Immun Inst, Dept Med Oncol, Amsterdam UMC,Canc Ctr Amsterdam, NL-1081 HV Amsterdam, Netherlands; [van der Vliet, Hans J.] Lava Therapeut, NL-3584 CM Utrecht, Netherlands		den Haan, JMM (通讯作者)，Vrije Univ Amsterdam, Amsterdam Infect & Immun Inst, Dept Mol Cell Biol & Immunol, Amsterdam UMC,Canc Ctr Amsterdam, NL-1081 HZ Amsterdam, Netherlands.	j.grabowska@amsterdamumc.nl; d.stolk@amsterdamumc.nl; m.nijentwilhaar@amsterdamumc.nl; ambrosinimartino78@gmail.com; G.Storm@uu.nl; jj.vandervliet@amsterdamumc.nl; td.degruijl@amsterdamumc.nl; y.vankooyk@amsterdamumc.nl; j.denhaan@amsterdamumc.nl	Haan, Joke MM den/A-4281-2010	Haan, Joke MM den/0000-0002-4421-6917; Stolk, Dorian/0000-0002-7365-2275	Dutch Cancer Society (KWF)KWF Kankerbestrijding [VU2014-7200]; NWO ZonMWNetherlands Organization for Scientific Research (NWO)Netherlands Organization for Health Research and Development [TOP 91218024]; Phospholipid Research Center; KWF [VU2016-10449]	This work was supported by the Dutch Cancer Society (KWF) VU2014-7200 (Y.v.K., T.D.d.G., H.J.v.d.V.) and by grants from NWO ZonMW (TOP 91218024) to J.M.M.d.H. and G.S., from the Phospholipid Research Center to J.M.M.d.H. and Y.v.K., and KWF (VU2016-10449) to J.M.M.d.H., T.D.d.G. and Y.v.K.	Affandi AJ, 2020, P NATL ACAD SCI USA, V117, P27528, DOI 10.1073/pnas.2006186117; Ali OA, 2016, CANCER IMMUNOL RES, V4, P95, DOI 10.1158/2326-6066.CIR-14-0126; Allan LL, 2011, J IMMUNOL, V186, P5261, DOI 10.4049/jimmunol.1003615; Asano K, 2011, IMMUNITY, V34, P85, DOI 10.1016/j.immuni.2010.12.011; Ashour D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135143; Backer R, 2010, P NATL ACAD SCI USA, V107, P216, DOI 10.1073/pnas.0909541107; Backer RA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00741; Bai L, 2012, J IMMUNOL, V188, P3053, DOI 10.4049/jimmunol.1102414; Barral P, 2012, EMBO J, V31, P2378, DOI 10.1038/emboj.2012.87; Barral P, 2010, NAT IMMUNOL, V11, P303, DOI 10.1038/ni.1853; Bulbake U, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9020012; Carnaud C, 1999, J IMMUNOL, V163, P4647; Chen WHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039039; Chung Y, 2007, BLOOD, V110, P2013, DOI 10.1182/blood-2006-12-061309; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Doherty DG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01360; Dolen Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1068493; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Eberl G, 2000, EUR J IMMUNOL, V30, P985, DOI 10.1002/(SICI)1521-4141(200004)30:4<985::AID-IMMU985>3.0.CO;2-E; Farrand KJ, 2009, J IMMUNOL, V183, P7732, DOI 10.4049/jimmunol.0902707; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; Ghinnagow R, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1339855; Giaccone G, 2002, CLIN CANCER RES, V8, P3702; Gottschalk C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00379; Grabbe S, 2016, NANOMEDICINE-UK, V11, P2723, DOI 10.2217/nnm-2016-0275; Grabowska J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02472; Hermans IF, 2003, J IMMUNOL, V171, P5140, DOI 10.4049/jimmunol.171.10.5140; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Ishikawa A, 2005, CLIN CANCER RES, V11, P1910, DOI 10.1158/1078-0432.CCR-04-1453; Kawasaki N, 2013, P NATL ACAD SCI USA, V110, P7826, DOI 10.1073/pnas.1219888110; Klaas M, 2012, J IMMUNOL, V189, P2414, DOI 10.4049/jimmunol.1200776; Komohara Y, 2017, CANCER SCI, V108, P290, DOI 10.1111/cas.13137; Kunii N, 2009, CANCER SCI, V100, P1092, DOI 10.1111/j.1349-7006.2009.01135.x; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Loquai C, 2020, J CLIN ONCOL, V38; Macho-Fernandez E, 2014, J IMMUNOL, V193, P961, DOI 10.4049/jimmunol.1303029; Massarelli E, 2019, JAMA ONCOL, V5, P67, DOI 10.1001/jamaoncol.2018.4051; Matsuda JL, 2008, CURR OPIN IMMUNOL, V20, P358, DOI 10.1016/j.coi.2008.03.018; Miyake Y, 2007, J CLIN INVEST, V117, P2268, DOI 10.1172/JCI31990; Nagato K, 2012, J CLIN IMMUNOL, V32, P1071, DOI 10.1007/s10875-012-9697-9; Nakagawa R, 2000, ONCOL RES, V12, P51, DOI 10.3727/096504001108747521; Paget C, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000169; Park JE, 2008, IMMUNOLOGY, V123, P145, DOI 10.1111/j.1365-2567.2007.02760.x; Puryear WB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003291; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Saito M, 2001, NAT BIOTECHNOL, V19, P746, DOI 10.1038/90795; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Sanchez-Paulete AR, 2016, CANCER DISCOV, V6, P71, DOI 10.1158/2159-8290.CD-15-0510; Schnorrer P, 2006, P NATL ACAD SCI USA, V103, P10729, DOI 10.1073/pnas.0601956103; Semmling V, 2010, NAT IMMUNOL, V11, P313, DOI 10.1038/ni.1848; Shibolet O, 2003, INT J CANCER, V106, P236, DOI 10.1002/ijc.11201; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; Starbeck-Miller GR, 2015, ADV EXP MED BIOL, V850, P31, DOI 10.1007/978-3-319-15774-0_3; Stolk D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01990; Stolk DA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00990; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tugues S, 2015, CELL DEATH DIFFER, V22, P237, DOI 10.1038/cdd.2014.134; Twilhaar MKN, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121138; Valente M, 2019, P NATL ACAD SCI USA, V116, P25816, DOI 10.1073/pnas.1913491116; van Dinther D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01997; van Dinther D, 2018, CELL REP, V22, P1484, DOI 10.1016/j.celrep.2018.01.021; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z; Wolf BJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00384; Yu XW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5136	67	5	5	4	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							56	10.3390/vaccines9010056			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6ZT	33467048	Green Published, gold			2022-04-29	WOS:000610821100001
J	Laliberte-Gagne, ME; Bolduc, M; Garneau, C; Olivera-Ugarte, S; Savard, P; Leclerc, D				Laliberte-Gagne, Marie-Eve; Bolduc, Marilene; Garneau, Caroline; Olivera-Ugarte, Santa-Mariela; Savard, Pierre; Leclerc, Denis			Modulation of Antigen Display on PapMV Nanoparticles Influences Its Immunogenicity	VACCINES			English	Article						vaccine platform; papaya mosaic virus (PapMV); rod-shaped nanoparticle; influenza M2e; influenza nucleocapsid; sortase (SrtA)		Background: The papaya mosaic virus (PapMV) vaccine platform is a rod-shaped nanoparticle made of the recombinant PapMV coat protein (CP) self-assembled around a noncoding single-stranded RNA (ssRNA) template. The PapMV nanoparticle induces innate immunity through stimulation of the Toll-like receptors (TLR) 7 and 8. The display of the vaccine antigen at the surface of the nanoparticle, associated with the co-stimulation signal via TLR7/8, ensures a strong stimulation of the immune response, which is ideal for the development of candidate vaccines. In this study, we assess the impact of where the peptide antigen is fused, whether at the surface or at the extremities of the nanoparticles, on the immune response directed to that antigen. Methods: Two different peptides from influenza A virus were used as model antigens. The conserved M2e peptide, derived from the matrix protein 2 was chosen as the B-cell epitope, and a peptide derived from the nucleocapsid was chosen as the cytotoxic T lymphocytes (CTL) epitope. These peptides were coupled at two different positions on the PapMV CP, the N- (PapMV-N) or the C-terminus (PapMV-C), using the transpeptidase activity of Sortase A (SrtA). The immune responses, both humoral and CD8+ T-cell-mediated, directed to the peptide antigens in the two different fusion contexts were analyzed and compared. The impact of coupling density at the surface of the nanoparticle was also investigated. Conclusions: The results demonstrate that coupling of the peptide antigens at the N-terminus (PapMV-N) of the PapMV CP led to an enhanced immune response to the coupled peptide antigens as compared to coupling to the C-terminus. The difference between the two vaccine platforms is linked to the enhanced capacity of the PapMV-N vaccine platform to stimulate TLR7/8. We also demonstrated that the strength of the immune response increases with the density of coupling at the surface of the nanoparticles.	[Laliberte-Gagne, Marie-Eve; Bolduc, Marilene; Garneau, Caroline; Olivera-Ugarte, Santa-Mariela; Leclerc, Denis] Laval Univ, Dept Microbiol Infectiol & Immunol, Fac Med, Quebec City, PQ G1V 4G2, Canada; [Savard, Pierre] Laval Univ, Dept Mol Biol Med Biochem & Pathol, Fac Med, Quebec City, PQ G1V 4G2, Canada		Leclerc, D (通讯作者)，Laval Univ, Dept Microbiol Infectiol & Immunol, Fac Med, Quebec City, PQ G1V 4G2, Canada.	Marie-Eve.L-Gagne@crchudequebec.ulaval.ca; Marilene.Bolduc@crchudequebec.ulaval.ca; Caroline.Garneau@crchudequebec.ulaval.ca; Santa-Mariela-Olivera.Ugarte@crchudequebec.ulaval.ca; Pierre.Savard@crchudequebec.ulaval.ca; Denis.Leclerc@crchudequebec.ulaval.ca		Leclerc, Denis/0000-0002-9323-1638; Olivera, Santa/0000-0002-1229-8399; savard, pierre/0000-0003-4134-0709	Canadian Institute of Health Research (CIHR) of CanadaCanadian Institutes of Health Research (CIHR) [185160]; Natural Sciences and Engineering Research Council (NSERC) of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC) [2016-05852]	This research was funded by the Canadian Institute of Health Research (CIHR-grant #185160) and the Natural Sciences and Engineering Research Council (NSERC-grant#2016-05852) of Canada.	Babin C, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-10; Balke I, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030270; Balke I, 2019, ADV DRUG DELIVER REV, V145, P119, DOI 10.1016/j.addr.2018.08.007; Bolduc M, 2018, NANOMED-NANOTECHNOL, V14, P2563, DOI 10.1016/j.nano.2018.08.010; Brisse M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583077; Carignan D, 2018, NANOMED-NANOTECHNOL, V14, P2317, DOI 10.1016/j.nano.2017.10.015; Carignan D, 2015, VACCINE, V33, P7245, DOI 10.1016/j.vaccine.2015.10.123; Gaspar AH, 2005, J BACTERIOL, V187, P4646, DOI 10.1128/JB.187.13.4646-4655.2005; Hefferon K, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/785382; Hefferon KL, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010011; Ibrahim A, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00803; Jacobitz AW, 2017, ADV PROTEIN CHEM STR, V109, P223, DOI 10.1016/bs.apcsb.2017.04.008; Jazayeri SD, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040169; Laliberte-Gagne ME, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020049; Lebel ME, 2014, J IMMUNOL, V192, P1071, DOI 10.4049/jimmunol.1302030; Leclerc D, 2007, J VIROL, V81, P1319, DOI 10.1128/JVI.01720-06; Mathieu C, 2013, NANOMED-NANOTECHNOL, V9, P839, DOI 10.1016/j.nano.2013.02.009; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Ni R, 2019, LIFE-BASEL, V9, DOI 10.3390/life9030059; Pagliusi S, 2017, VACCINE, V35, P1579, DOI 10.1016/j.vaccine.2017.02.017; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pasin F, 2019, PLANT BIOTECHNOL J, V17, P1010, DOI 10.1111/pbi.13084; Piyush R, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05007; Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111; Plotkin SA, 2011, NAT REV MICROBIOL, V9, P889, DOI 10.1038/nrmicro2668; Poland GA, 2020, MAYO CLIN PROC, V95, P2172, DOI 10.1016/j.mayocp.2020.07.021; Polli AD, 2021, NAT PROD RES, V35, P4148, DOI 10.1080/14786419.2020.1739681; Rajao DS, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00123; Rappuoli R, 2014, P NATL ACAD SCI USA, V111, P12288, DOI 10.1073/pnas.1402981111; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Schneewind O., 2019, MICROBIOL SPECTR, V7; Sharma M, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030089; Steele JFC, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1447; Therien A, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0289-y; Tognotti E, 2010, J INFECT DEV COUNTR, V4, P264, DOI 10.3855/jidc.1204; van Panhuis WG, 2013, NEW ENGL J MED, V369, P2152, DOI 10.1056/NEJMms1215400; Wang M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111338	37	3	3	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							33	10.3390/vaccines9010033			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VM	33435570	gold, Green Submitted, Green Published			2022-04-29	WOS:000610809800001
J	Im, H; Ser, J; Sim, U; Cho, H				Im, Hyobin; Ser, Jinhui; Sim, Uk; Cho, Hoonsung			Promising Expectations for Pneumococcal Vaccination during COVID-19	VACCINES			English	Article						COVID-19; SARS-CoV-2; Streptococcus pneumoniae; co; secondary infections; superinfections; pneumococcal vaccination	COMMUNITY-ACQUIRED PNEUMONIA; RISK-FACTORS; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; IMMUNE DYSFUNCTION; COMMON INFECTIONS; DIABETES-MELLITUS; UNITED-STATES; ADULTS; BACTERIAL	The emergence of new viral infections has increased over the decades. The novel virus is one such pathogen liable for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, popularly known as coronavirus disease 2019 (COVID-19). Most fatalities during the past century's influenza pandemics have cooperated with bacterial co/secondary infections. Unfortunately, many reports have claimed that bacterial co-infection is also predominant in COVID-19 patients (COVID-19 associated co/secondary infection prevalence is up to 45.0%). In the COVID-19 pandemic, Streptococcus pneumoniae is the most common coinfecting pathogen. Half of the COVID-19 mortality cases showed co-infection, and pneumonia-related COVID-19 mortality in patients >65 years was 23%. The weakening of immune function caused by COVID-19 remains a high-risk factor for pneumococcal disease. Pneumococcal disease and COVID-19 also have similar risk factors. For example, underlying medical conditions on COVID-19 and pneumococcal diseases increase the risk for severe illness at any age; COVID-19 is now considered a primary risk factor for pneumococcal pneumonia and invasive pneumococcal disease. Thus, pneumococcal vaccination during the COVID-19 pandemic has become more critical than ever. This review presents positive studies of pneumococcal vaccination in patients with COVID-19 and other medical conditions and the correlational effects of pneumococcal disease with COVID-19 to prevent morbidity and mortality from co/secondary infections and superinfections. It also reports the importance and role of pneumococcal vaccination during the current COVID-19 pandemic era to strengthen the global health system.	[Im, Hyobin] Dept Mkt, Pfizer Pharmaceut Korea, Pfizer Tower 110, Seoul 04631, South Korea; [Ser, Jinhui; Sim, Uk; Cho, Hoonsung] Chonnam Natl Univ, Dept Sch Mat Sci & Engn, Yongbong ro 77, Gwangju 61186, South Korea; [Sim, Uk] Res Inst, NEEL Sci Incorporat, Yongbong ro 77, Gwangju 61186, South Korea		Sim, U; Cho, H (通讯作者)，Chonnam Natl Univ, Dept Sch Mat Sci & Engn, Yongbong ro 77, Gwangju 61186, South Korea.; Sim, U (通讯作者)，Res Inst, NEEL Sci Incorporat, Yongbong ro 77, Gwangju 61186, South Korea.	hyo-bin.im@pfizer.com; jh_ser@jnu.ac.kr; usim@jnu.ac.kr; cho.hoonsung@jnu.ac.kr		Sim, Uk/0000-0001-7767-495X; Ser, Jinhui/0000-0002-8673-7374			Al-Ani AH, 2020, ALIMENT PHARM THER, V52, P54, DOI 10.1111/apt.15779; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; Atkins JL, 2020, J GERONTOL A-BIOL, V75, P2224, DOI 10.1093/gerona/glaa183; Australian Government Department of Health, PEOPL HIGH RISK COR; Avci FY, 2010, ANNU REV IMMUNOL, V28, P107, DOI 10.1146/annurev-immunol-030409-101159; Aykac K, 2021, HUM VACC IMMUNOTHER, V17, P1628, DOI 10.1080/21645515.2020.1849516; Bengoechea JA, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012560; Bennett J.E., 2014, MANDELL DOUGLAS BENN, VVolume 2; Bonnave C, 2019, EUR J CLIN MICROBIOL, V38, P785, DOI 10.1007/s10096-019-03485-3; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Bova IY, 1996, STROKE, V27, P2204, DOI 10.1161/01.STR.27.12.2204; Casqueiro Juliana, 2012, Indian J Endocrinol Metab, V16 Suppl 1, pS27, DOI 10.4103/2230-8210.94253; CDC, PNEUM DIS RISK FACT; CDC, 2021, EV US UPD LIST UND M; Control CFD, 2004, MMWR MORB MORTAL WKL, V53, P1007; Corrales-Medina VF, 2015, JAMA-J AM MED ASSOC, V313, P264, DOI 10.1001/jama.2014.18229; COSMO Healthcare Immunization, IMM PNEUM POL VACC; Cox MJ, 2020, LANCET MICROBE, V1, pE11, DOI 10.1016/S2666-5247(20)30009-4; Defrance T, 2011, CURR OPIN IMMUNOL, V23, P330, DOI 10.1016/j.coi.2011.03.004; Docherty A., 2020, BMJ-BRIT MED J, V1, P20076042, DOI [10.1101/2020.04.23.20076042, DOI 10.1136/BMJ.M1985, 10.1136/bmj.m1985]; EACS BHIVA, 2020, STAT RISK COVID 19 P; Elston JWT, 2017, PUBLIC HEALTH, V143, P60, DOI 10.1016/j.puhe.2016.10.020; Fang XY, 2020, AGING-US, V12, P12493, DOI 10.18632/aging.103579; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Fink G, 2021, BMJ EVID-BASED MED, V26, DOI 10.1136/bmjebm-2020-111549; Friedberg C.K, 1950, ACAD MED, V25, P159; Froes F, 2017, INT J CHRONIC OBSTR, V12, P3457, DOI 10.2147/COPD.S140378; Gansevoort RT, 2020, NAT REV NEPHROL, V16, P705, DOI 10.1038/s41581-020-00349-4; Garcia-Vidal C, 2021, CLIN MICROBIOL INFEC, V27, P83, DOI 10.1016/j.cmi.2020.07.041; Geerlings SE, 1999, FEMS IMMUNOL MED MIC, V26, P259, DOI 10.1016/S0928-8244(99)00142-X; Gillissen A, 2015, CLIN RESPIR J, V9, P257, DOI 10.1111/crj.12135; Gonzalez-Romo F, 2017, REV ESP QUIM, V30, P142; Gostin LO, 2020, JAMA-J AM MED ASSOC, V324, P335, DOI 10.1001/jama.2020.10802; Government of Canada, COR DIS COVID 19 PRE; Grau I, 2014, INT J INFECT DIS, V25, P59, DOI 10.1016/j.ijid.2013.12.013; Grech V, 2020, EARLY HUM DEV, V148, DOI 10.1016/j.earlhumdev.2020.105116; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752; Hamer M, 2020, BRAIN BEHAV IMMUN, V87, P184, DOI 10.1016/j.bbi.2020.05.059; Harvard Medical School, PREV SPREAD COR; Haut Conseil de la Sante Publique, 2013, INF INV PNEUM REC VA; Huijts SM, 2018, CLIN MICROBIOL INFEC, V24, P764, DOI 10.1016/j.cmi.2017.10.006; Imai K, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018553; Izquierdo JL, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.03142-2020; Jacups SP, 2011, VACCINE, V29, P5386, DOI 10.1016/j.vaccine.2011.05.082; Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198; Joseph C, 2013, INFLUENZA OTHER RESP, V7, P105, DOI 10.1111/irv.12089; Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Kiani FZ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79707-y; Kunutsor SK, 2020, EUR J EPIDEMIOL, V35, P431, DOI 10.1007/s10654-019-00579-2; Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P505, DOI 10.1016/j.jmii.2020.05.013; Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046; Lee MS, 2018, INFECT CHEMOTHER, V50, P160, DOI 10.3947/ic.2018.50.2.160; Lim S, 2021, NAT REV ENDOCRINOL, V17, P11, DOI 10.1038/s41574-020-00435-4; LIPSKY BA, 1986, ARCH INTERN MED, V146, P2179, DOI 10.1001/archinte.146.11.2179; Lozano R, 2013, LANCET, V381, P991, DOI 10.1016/S0140-6736(13)60704-7; Maddaloni E, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3321; Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077; Maggi S, 2010, EXPERT REV VACCINES, V9, P3, DOI [10.1586/erv.10.26, 10.1586/ERV.10.26]; Mao R, 2020, LANCET GASTROENTEROL, V5, P667, DOI 10.1016/S2468-1253(20)30126-6; Marin-Hernandez D, 2021, J MED VIROL, V93, P64, DOI 10.1002/jmv.26120; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; Mathers C, 2008, GLOBAL BURDEN OF DISEASE: 2004 UPDATE, P1; McLaughlin JM, 2015, J PRIM PREV, V36, P259, DOI 10.1007/s10935-015-0394-3; Mor A, 2013, EUR J INTERN MED, V24, P349, DOI 10.1016/j.ejim.2013.02.013; Morris DE, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01041; Muller LMAJ, 2005, CLIN INFECT DIS, V41, P281, DOI 10.1086/431587; Nag VL, 2021, DUBAI MED J, V4, P117, DOI 10.1159/000515067; Nunes MC, 2021, MBIO, V12, DOI 10.1128/mBio.02347-20; O'Brien D.G.K.L, 2018, HARRISONS PRINCIPLES; Ortqvist A, 2005, SEMIN RESP CRIT CARE, V26, P563, DOI 10.1055/s-2005-925523; Pai S, VACCINATIONS CANC PA; Palmu AA, 2013, LANCET, V381, P214, DOI 10.1016/S0140-6736(12)61854-6; Papadatou I, 2016, CLIN VACCINE IMMUNOL, V23, P388, DOI 10.1128/CVI.00721-15; Pawlowski C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83641-y; Peleg AY, 2007, DIABETES-METAB RES, V23, P3, DOI 10.1002/dmrr.682; Pittet LF, 2012, CLIN MICROBIOL INFEC, V18, P25, DOI 10.1111/j.1469-0691.2012.03938.x; Portoles-Perez J, 2014, NEFROLOGIA, V34, P545, DOI 10.3265/Nefrologia.pre2014.May.12534; Public Health England, 2020, PNEUM GREEN BOOK; Public Health England, 2020, DISPARITIES RISK OUT; Qureshi H, 2014, THER ADV CHRONIC DIS, V5, P212, DOI 10.1177/2040622314532862; RAMAN AS, 1983, CHEST, V83, P23, DOI 10.1378/chest.83.1.23; Ramirez JA, 2017, CLIN INFECT DIS, V65, P1806, DOI 10.1093/cid/cix647; Rawson TM, 2021, CLIN MICROBIOL INFEC, V27, P9, DOI 10.1016/j.cmi.2020.09.025; Rivero-Calle I, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2018-000359; Rodriguez-Nava G, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.928754; Root-Bernstein R, CORONAVIRUS VACCINE; Root-Bernstein R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050474; Sakamoto A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6080-7; Semenov YR, 2012, LARYNGOSCOPE, V122, P1994, DOI 10.1002/lary.23446; Shea KM, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu024; Singh D, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00164-2019; Smith AM, 2014, CURR TOP MICROBIOL, V385, P327, DOI 10.1007/82_2014_394; Story A.N., ACC CLIN B FOC CARD; Sultana J, 2020, EXPERT REV VACCINES, V19, P919, DOI 10.1080/14760584.2020.1825951; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; The National Advisory Committee on Immunization, 2016, PNEUM VACC CAN IMM G; The National Heart Lung and Blood Institute., 2012, MORBIDITY MORTALITY; The National Institute for Communicable Diseases, PNEUMOCOCCAL CONJUGA; Thindwa D, 2020, VACCINE, V38, P5398, DOI 10.1016/j.vaccine.2020.06.047; Vardakas KZ, 2007, DIABETIC MED, V24, P1168, DOI 10.1111/j.1464-5491.2007.02234.x; Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324; Vaziri ND, 2012, J RENAL NUTR, V22, P149, DOI 10.1053/j.jrn.2011.10.020; Vinogradova Y, 2009, BRIT J GEN PRACT, V59, P742, DOI 10.3399/bjgp09X472629; Vos Q, 2000, IMMUNOL REV, V176, P154; Wang L, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2816-8; Warren-Gash C, 2009, LANCET INFECT DIS, V9, P601, DOI 10.1016/S1473-3099(09)70233-6; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wong ND, 2014, NAT REV CARDIOL, V11, P276, DOI 10.1038/nrcardio.2014.26; World Health Organization, 2020, GUID ROUT IMM SERV C; World Health Organization, 2021, COVID 19 CLIN MAN LI; World Health Organization, 2020, INF PREV CONTR GUID; Wyrwich KW, 2013, PATIENT, V6, P125, DOI 10.1007/s40271-013-0013-4; Xu LZ, 2020, AGING-US, V12, P12410, DOI 10.18632/aging.103383; Yende S, 2008, AM J RESP CRIT CARE, V177, P1242, DOI 10.1164/rccm.200712-1777OC; Yoon HK, 2017, TUBERC RESPIR DIS, V80, P230, DOI 10.4046/trd.2017.80.3.230; Zaidi SR, 2019, RESPIROLOGY, V24, P423, DOI 10.1111/resp.13528; Zanettini C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050427; Zhang DM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3326-z; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	123	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1507	10.3390/vaccines9121507			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1QE	34960253	Green Published, gold			2022-04-29	WOS:000737434100001
J	Russo, L; Croci, I; Campagna, I; Pandolfi, E; Villani, A; Reale, A; Barbieri, MA; Raponi, M; Gesualdo, F; Tozzi, AE				Russo, Luisa; Croci, Ileana; Campagna, Ilaria; Pandolfi, Elisabetta; Villani, Alberto; Reale, Antonino; Barbieri, Maria Antonietta; Raponi, Massimiliano; Gesualdo, Francesco; Tozzi, Alberto Eugenio			Intention of Parents to Immunize Children against SARS-CoV-2 in Italy	VACCINES			English	Article						COVID-19; vaccines; children; vaccine hesitancy	MIXED METHODS; COVID-19	Several countries have targeted adolescents for immunization against SARS-CoV-2 to mitigate COVID-19 spread. In Italy, immunization for children >= 12 years has been available starting from June 2021. We conducted a cross-sectional study to investigate the knowledge, attitude and intention to vaccinate children < 18 years in Italian families. We used a multinomial logistic regression model to investigate factors associated with intention to vaccinate. We collected a total of 1696 responses. Among the 491 families of children >= 12 years, 41.2% would not vaccinate their children and 21.2% were uncertain, while among the 1205 families of children < 12 years, 36.1% would not vaccinate and 33.8% were uncertain. Determinants of intention to vaccinate both age groups were perceived safety and efficacy of vaccines and perceived risk of transmitting infection to adults. For children < 12 years, additional determinants were perceived risk of being infected and being hospitalized because of COVID-19. In view of the expanding strategy to vaccinate adolescents and the availability of immunization for children < 12 years, our results call for a communication strategy targeted at families of children focused on the safety and efficacy of COVID-19 vaccine in children and on the dynamics of infection spread across different age groups. As perceptions in families are volatile and may change rapidly over time, repeated surveys for measuring attitudes to vaccinate would be advisable.	[Russo, Luisa; Croci, Ileana; Campagna, Ilaria; Pandolfi, Elisabetta; Gesualdo, Francesco; Tozzi, Alberto Eugenio] IRCCS, Bambino Gesu Childrens Hosp, Multifactorial & Complex Dis Res Area, I-00165 Rome, Italy; [Villani, Alberto; Reale, Antonino; Barbieri, Maria Antonietta] IRCCS, Bambino Gesu Childrens Hosp, Pediat Emergency Dept, I-00165 Rome, Italy; [Raponi, Massimiliano] IRCCS, Bambino Gesu Childrens Hosp, Hlth Direct, I-00165 Rome, Italy		Gesualdo, F (通讯作者)，IRCCS, Bambino Gesu Childrens Hosp, Multifactorial & Complex Dis Res Area, I-00165 Rome, Italy.	luisa.russo@opbg.net; ileana.croci@opbg.net; ilaria.campagna@opbg.net; elisabetta.pandolfi@opbg.net; alberto.villani@opbg.net; antonino.reale@opbg.net; mantonietta.barbieri@opbg.net; massimiliano.raponi@opbg.net; francesco.gesualdo@opbg.net; albertoeugenio.tozzi@opbg.net	Tozzi, Alberto Eugenio/F-9494-2012	Tozzi, Alberto Eugenio/0000-0002-6884-984X			Alfieri NL, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11725-5; [Anonymous], Governo Italiano-Report Vaccini Anti COVID-19; [Anonymous], COVID Behaviors Dashboard-Johns Hopkins Center for Communication Programs; [Anonymous], PFIZER BIONTECH ANNO; [Anonymous], WHO CORONAVIRUS COVI; [Anonymous], SAMPLE SIZE CALCULAT; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Berardi C, 2020, HEALTH POLICY TECHN, V9, P454, DOI 10.1016/j.hlpt.2020.08.019; Bhuiyan MU, 2021, VACCINE, V39, P667, DOI 10.1016/j.vaccine.2020.11.078; Brandstetter S, 2021, EUR J PEDIATR, V180, P3405, DOI 10.1007/s00431-021-04094-z; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467; Dattner I, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008559; Evans S, 2021, J PSYCHOSOM RES, V150, DOI 10.1016/j.jpsychores.2021.110626; Fedele F, 2021, HUM VACC IMMUNOTHER, V17, P3348, DOI 10.1080/21645515.2021.1928460; Gurdasani D, 2021, J ROY SOC MED, V114, P513, DOI 10.1177/01410768211052589; Italian National Health Institute, EP COVID 19 AGG NAZ; Li X, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.021101; McAteer J, 2020, CLIN INFECT DIS, V71, P703, DOI 10.1093/cid/ciaa433; Moons KGM, 2006, J CLIN EPIDEMIOL, V59, P1092, DOI 10.1016/j.jclinepi.2006.01.009; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Osorio MF, 2021, INFECT DIS CLIN PRAC, V29, pE78, DOI 10.1097/IPC.0000000000000973; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Rhodes ME, 2020, J HEALTH COMMUN, V25, P831, DOI 10.1080/10810730.2021.1871986; Salute M., DELLA COVID 19 WEEKL; Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948; Spiteri G, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.9.2000178; Twohig KA, 2022, LANCET INFECT DIS, V22, P35, DOI 10.1016/S1473-3099(21)00475-8; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Zhang MX, 2021, EXPERT REV VACCINES, V20, P1339, DOI 10.1080/14760584.2021.1967147; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	31	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1469	10.3390/vaccines9121469			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9KO	34960215	Green Published, gold			2022-04-29	WOS:000737283500001
J	Al-Hanawi, MK; Alshareef, N; El-Sokkary, RH				Al-Hanawi, Mohammed Khaled; Alshareef, Noor; El-Sokkary, Rehab H.			Willingness to Receive COVID-19 Vaccination among Older Adults in Saudi Arabia: A Community-Based Survey	VACCINES			English	Article						COVID-19; older adults; hesitancy; Saudi Arabia; vaccine	INFLUENZA VACCINATION; INTENTION	Identifying the factors driving vaccine hesitancy can improve vaccine attitudes and motivate individuals to have the recommended vaccinations. However, failure to address the issue directly, or worse, ignoring it, could deepen such concerns, resulting in lower vaccination rates, leading to elevated rates of illness and vaccine-preventable deaths among older adults. The aim of this study was to explore the rate of acceptance of the COVID-19 vaccine among older adults in Saudi Arabia, along with the associated predicting factors and reasons for hesitancy. This study extracted data from a cross-sectional online survey on the acceptability of COVID-19 vaccination in Saudi Arabia, which was conducted from 8 to 14 December 2020. The sample of the study included 488 older adults aged 50 and older. The major data analytic tools employed in the study were bivariate and multivariable regression analyses. Among the 488 participants, 214 (43.85%) reported willingness to accept the COVID-19 vaccine when available. Older men were more likely to be willing to be vaccinated (adjusted odds ratio (aOR): 2.277; 95% confidence interval (CI): 1.092-4.745) than older women. High levels of education were significantly associated with willingness to be vaccinated. Older adults who had previously refused any vaccine were less likely to take the COVID-19 vaccine (aOR: 0.358; 95% CI: 0.154-0.830). Those who expressed a high or very high level of concern related to becoming infected were more likely to accept the vaccine against COVID-19 (aOR: 4.437; 95% CI: 2.148-9.168). Adverse side effects (27.01%), and safety and efficacy concerns (22.63%) were the most commonly cited reasons for vaccine hesitancy. The vaccination acceptance rate among older adults in Saudi Arabia is low. Interventions designed specifically for older adults addressing worries and concerns related to the vaccine are of paramount importance. In particular, these interventions should be tailored to address gender-based and health literacy level differences.	[Al-Hanawi, Mohammed Khaled; Alshareef, Noor] King Abdulaziz Univ, Fac Econ & Adm, Dept Hlth Serv & Hosp Adm, Jeddah 80200, Saudi Arabia; [Al-Hanawi, Mohammed Khaled; Alshareef, Noor] King Abdulaziz Univ, Hlth Econ Res Grp, Jeddah 80200, Saudi Arabia; [El-Sokkary, Rehab H.] Zagazig Univ, Med Microbiol & Immunol Dept, Fac Med, Zagazig 44519, Egypt		Al-Hanawi, MK (通讯作者)，King Abdulaziz Univ, Fac Econ & Adm, Dept Hlth Serv & Hosp Adm, Jeddah 80200, Saudi Arabia.; Al-Hanawi, MK (通讯作者)，King Abdulaziz Univ, Hlth Econ Res Grp, Jeddah 80200, Saudi Arabia.	mkalhanawi@kau.edu.sa; naalshareef@kau.edu.sa; rehab_elsokkary@zu.edu.eg	El-Sokkary, Rehab/B-9599-2018; Al-Hanawi, Mohammed Khaled/AAB-2455-2020	El-Sokkary, Rehab/0000-0002-8135-7671; Al-Hanawi, Mohammed Khaled/0000-0002-8419-2219	Institutional Fund Projects [IFPRC-207-121-2020]	This research was funded by the Institutional Fund Projects under grant number IFPRC-207-121-2020. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Hanawi MK, 2021, J INFECT PUBLIC HEAL, V14, P1489, DOI 10.1016/j.jiph.2021.08.002; Al-Hanawi MK, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00217; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Al-Qerem WA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.632914; Alfageeh EI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030226; Almaghaslah D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040330; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Betsch C., 2015, SCOTTISH INDEX MULTI, V2, P61, DOI 10.1177/2372732215600716; Betsch C, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5787-9; Betsch C, 2013, HEALTH PSYCHOL, V32, P978, DOI 10.1037/a0031590; Bloom BR, 2020, NEW ENGL J MED, V383, P2202, DOI 10.1056/NEJMp2025331; Callaway E, 2020, NATURE, V584, P334, DOI 10.1038/d41586-020-02386-2; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Chor JSY, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3391; Clouston SAP, 2017, AGE AGEING, V46, P493, DOI 10.1093/ageing/afw229; Cox LS, 2020, LANCET HEALTH LONGEV, V1, pE55, DOI 10.1016/S2666-7568(20)30011-8; Daly M, 2021, JAMA-J AM MED ASSOC, V325, P2397, DOI 10.1001/jama.2021.8246; FDA, US FOOD DRUG ADM COV; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Galbadage T, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00348; Goldstein S, 2015, VACCINE, V33, P4212, DOI 10.1016/j.vaccine.2015.04.042; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Hu XW, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138812; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Kang SJ, 2020, INFECT CHEMOTHER, V52, P154, DOI 10.3947/ic.2020.52.2.154; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Krueger P, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-44; Leung C, 2020, MECH AGEING DEV, V188, DOI 10.1016/j.mad.2020.111255; Leung C, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2103; Liao QY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017713; Lin CJ, 2010, VACCINE, V28, P7706, DOI 10.1016/j.vaccine.2010.07.009; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malani P.N., 2020, JAMA HLTH FORUM; McElhaney JE, 2019, J GERONTOL A-BIOL, V74, P1239, DOI 10.1093/gerona/glz085; MOH, COVID 19 VACC; Nikolovski J., 2021, PLOS ONE, V16, DOI [10.1371/journal.pone.0251963, DOI 10.1371/journal.pone.0251963]; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Poland GA, 2009, PEDIATR INFECT DIS J, V28, P431, DOI 10.1097/INF.0b013e3181a6a511; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Savulescu J, 2021, J MED ETHICS, V47, P78, DOI 10.1136/medethics-2020-106821; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; World Health Organization, 10 HLTH ISS WHO WILL; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	52	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1257	10.3390/vaccines9111257			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI1WM	34835188	gold, Green Published			2022-04-29	WOS:000725911000001
J	Grund, ME; Kramarska, E; Choi, SJ; McNitt, DH; Klimko, CP; Rill, NO; Dankmeyer, JL; Shoe, JL; Hunter, M; Fetterer, DP; Hedrick, ZM; Velez, I; Biryukov, SS; Cote, CK; Berisio, R; Lukomski, S				Grund, Megan E.; Kramarska, Eliza; Choi, Soo Jeon; McNitt, Dudley H.; Klimko, Christopher P.; Rill, Nathaniel O.; Dankmeyer, Jennifer L.; Shoe, Jennifer L.; Hunter, Melissa; Fetterer, David P.; Hedrick, Zander M.; Velez, Ivan; Biryukov, Sergei S.; Cote, Christopher K.; Berisio, Rita; Lukomski, Slawomir			Predictive and Experimental Immunogenicity of Burkholderia Collagen-like Protein 8-Derived Antigens	VACCINES			English	Article						vaccine; Bucl8; subunit vaccine; antigenicity; immunogenicity	PSEUDOMALLEI; PROTECTION; IDENTIFICATION; IMMUNIZATION; MELIOIDOSIS; HOMOLOG; MUTANT; OMPW	Burkholderia pseudomallei is an infectious bacterium of clinical and biodefense concern, and is the causative agent of melioidosis. The mortality rate can reach up to 50% and affects 165,000 people per year; however, there is currently no vaccine available. In this study, we examine the antigen-specific immune response to a vaccine formulated with antigens derived from an outer membrane protein in B. pseudomallei, Bucl8. Here, we employed a number of bioinformatic tools to predict Bucl8-derived epitopes that are non-allergenic and non-toxic, but would elicit an immune response. From these data, we formulated a vaccine based on two extracellular components of Bucl8, the beta-barrel loops and extended collagen and non-collagen domains. Outbred CD-1 mice were immunized with vaccine formulations-composed of recombinant proteins or conjugated synthetic peptides with adjuvant-to assess the antigen-specific immune responses in mouse sera and lymphoid organs. We found that mice vaccinated with either Bucl8-derived components generated a robust TH2-skewed antibody response when antigen was combined with the adjuvant AddaVax, while the TH1 response was limited. Mice immunized with synthetic loop peptides had a stronger, more consistent antibody response than recombinant protein antigens, based on higher IgG titers and recognition of bacteria. We then compared peptide-based vaccines in an established C57BL/6 inbred mouse model and observed a similar TH2-skewed response. The resulting formulations will be applied in future studies examining the protection of Bucl8-derived vaccines.	[Grund, Megan E.; Choi, Soo Jeon; McNitt, Dudley H.; Lukomski, Slawomir] West Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; [Kramarska, Eliza; Berisio, Rita] Natl Res Council CNR IBB, Inst Biostruct & Bioimaging, I-80134 Naples, Italy; [Klimko, Christopher P.; Rill, Nathaniel O.; Dankmeyer, Jennifer L.; Shoe, Jennifer L.; Hunter, Melissa; Hedrick, Zander M.; Velez, Ivan; Biryukov, Sergei S.; Cote, Christopher K.] US Army, Bacteriol Div, Med Res Inst Infect Dis USAMRIID, Frederick, MD 21702 USA; [Fetterer, David P.] US Army, Biostat Div, Med Res Inst Infect Dis USAMRIID, Frederick, MD 21702 USA; [McNitt, Dudley H.] Vanderbilt Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA		Lukomski, S (通讯作者)，West Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.	meg0053@mix.wvu.edu; eliza.kramarska@unicampania.it; sochoi@hsc.wvu.edu; dudley.mcnitt@vumc.org; christopher.p.klimko2.civ@mail.mil; nathaniel.o.rill.ctr@mail.mil; jennifer.l.dankmeyer.civ@mail.mil; jennifer.l.shoe.ctr@mail.mil; melissa.hunter.ctr@mail.mil; david.p.fetterer.ctr@mail.mil; zander.m.hedrick.mil@mail.mil; ivan.velez15.mil@mail.mil; sergei.s.biryukov.civ@mail.mil; christopher.k.cote.civ@mail.mil; rita.berisio@cnr.it; slukomski@hsc.wvu.edu			Vaccine Development Center at WVU-HSC; Research Challenge Grant from the Division of Science and Research, WV Higher Education Policy Commission [HEPC.dsr.18.6]; Broad Agency Announcement (BAA) Research and Development Enterprise, Basic and Applied Sciences Directorate, Basic Research for Combating Weapons of Mass Destruction. (C-WMD) [HDTRA1-14-24-FRCWMD, HDTRA1035955001]; U.S. Defense Threat Reduction Agency (DTRA)United States Department of DefenseDefense Threat Reduction Agency; US Defense Threat Reduction Agency (DTRA) project award [CB10207]; Marie Sklodowska-Curie Action BactiVaxAnti-Bacterial Innovative Vaccines [GA 860325]; COST Action ENOVA-European Network of Vaccine Adjuvants; National Institutes of Health equipmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD016165]; Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P30GM121322, P20GM103434]	S.L. was supported by the Vaccine Development Center at WVU-HSC, Research Challenge Grant no.HEPC.dsr.18.6 from the Division of Science and Research, WV Higher Education Policy Commission. S.L. and M.E.G. acknowledge funding from a grant awarded as a result of Broad Agency Announcement (BAA) HDTRA1-14-24-FRCWMD-Research and Development Enterprise, Basic and Applied Sciences Directorate, Basic Research for Combating Weapons of Mass Destruction. (C-WMD), under contract #HDTRA1035955001. C.K.C. funding was supplied by the U.S. Defense Threat Reduction Agency (DTRA). The US Defense Threat Reduction Agency (DTRA) project award CB10207. E.K. and R.B. acknowledge funding by the Marie Sklodowska-Curie Action BactiVaxAnti-Bacterial Innovative Vaccines, GA 860325 and the COST Action ENOVA-European Network of Vaccine Adjuvants.Flow Cytometry experiments were performed in the West Virginia University Flow Cytometry & Single Cell Core Facility, which is supported by the National Institutes of Health equipment grant number S10OD016165 and the Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant numbers P30GM121322 (TME CoBRE) and P20GM103434 (INBRE).	Amemiya K, 2006, VACCINE, V24, P1413, DOI 10.1016/j.vaccine.2005.09.021; Amemiya K, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040196; [Anonymous], 400 1 IGS MOUSE MODE; [Anonymous], 2021, CDC MULTISTATE INVES; Atkins T, 2002, INFECT IMMUN, V70, P5290, DOI 10.1128/IAI.70.9.5290-5294.2002; Bachert BA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137578; Baker SM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00281-z; Bearss JJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172627; Birnie E, 2019, LANCET INFECT DIS, V19, P892, DOI 10.1016/S1473-3099(19)30157-4; Burtnick MN, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00724-17; Calabro S, 2013, VACCINE, V31, P3363, DOI 10.1016/j.vaccine.2013.05.007; Casey WT, 2016, VACCINE, V34, P2616, DOI 10.1016/j.vaccine.2016.03.088; CDC Lab Alert, 2020, BURKH PSEUD SW US; Cibulski SP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31995-1; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Federici L, 2005, J BIOL CHEM, V280, P15307, DOI 10.1074/jbc.M500401200; Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278; Grund ME, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030495; Grund ME, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242593; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Hara Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006496; Harland DN, 2007, INFECT IMMUN, V75, P4173, DOI 10.1128/IAI.00404-07; Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346; Kessler B, 2017, SCI REP-UK, V7, DOI 10.1038/srep42791; Khakhum N, 2019, MSPHERE, V4, DOI [10.1128/mSphere.00570-18, 10.1128/msphere.00570-18]; Koosakulnirand S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198906; Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829; Limmathurotsakul D, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2015.8, 10.1038/nmicrobiol.2015.8]; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; McClean S, 2016, INFECT IMMUN, V84, P1424, DOI 10.1128/IAI.01248-15; Morici L, 2019, CLIN EXP IMMUNOL, V196, P178, DOI 10.1111/cei.13286; Ngauy V, 2005, J CLIN MICROBIOL, V43, P970, DOI 10.1128/JCM.43.2.970-972.2005; Nieves W, 2014, CLIN VACCINE IMMUNOL, V21, P747, DOI 10.1128/CVI.00119-14; Norris MH, 2011, INFECT IMMUN, V79, P4010, DOI 10.1128/IAI.05044-11; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P226, DOI 10.1073/pnas.83.2.226; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Rhodes KA, 2016, DRUG RESIST UPDATE, V28, P82, DOI 10.1016/j.drup.2016.07.003; Silva EB, 2013, INFECT IMMUN, V81, P4626, DOI 10.1128/IAI.00915-13; Sousa SA, 2016, AMB EXPRESS, V6, DOI 10.1186/s13568-016-0212-1; Southwood S, 1998, J IMMUNOL, V160, P3363; Su YC, 2010, VACCINE, V28, P5005, DOI 10.1016/j.vaccine.2010.05.022; Tapia D, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00229-9; Tapia D, 2021, MBIO, V12, DOI 10.1128/mBio.01227-21; Whitlock GC, 2010, PROCEDIA VACCINOL, V2, P73, DOI 10.1016/j.provac.2010.03.013; Wiersinga WJ, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.107	48	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1219	10.3390/vaccines9111219			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ6QM	34835150	Green Published, gold			2022-04-29	WOS:000726909900001
J	Tobaiqy, M; MacLure, K; Elkout, H; Stewart, D				Tobaiqy, Mansour; MacLure, Katie; Elkout, Hajer; Stewart, Derek			Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database	VACCINES			English	Article						adverse events; adverse drug reaction; thrombotic; COVID-19 vaccine; Pfizer; Moderna; AstraZenaca	SEX	Vaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the Oxford-AstraZeneca vaccine has received much of the attention, the other vaccines should not go unchallenged. This study aimed to determine the frequency of reported thrombotic adverse events and clinical outcomes for these three COVID-19 vaccines, namely, Moderna, Pfizer and Oxford-AstraZeneca. A retrospective descriptive analysis was conducted of spontaneous reports for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines submitted to the EudraVigilance database in the period from 17 February to 14 June 2021. There were 729,496 adverse events for the three vaccines, of which 3420 were thrombotic, mainly Oxford-AstraZeneca (n = 1988; 58.1%) followed by Pfizer (n = 1096; 32.0%) and Moderna (n = 336; 9.8%). As serious adverse events, there were 705 reports of pulmonary embolism for the three vaccines, of which 130 reports (18.4%) were for Moderna, 226 reports (32.1%) for Pfizer and 349 (49.5%) for Oxford-AstraZeneca vaccines. The occurrence of pulmonary embolism is significantly associated with a fatal outcome (p & LE; 0.001). Sixty-three fatalities were recorded (n = 63/3420; 1.8%), of which Moderna (n = 6), Pfizer (n = 25) and Oxford-AstraZeneca (n = 32).	[Tobaiqy, Mansour] Univ Jeddah, Dept Pharmacol, Coll Med, POB 45311, Jeddah 45311, Saudi Arabia; [Elkout, Hajer] Univ Tripoli, Fac Med, Dept Family & Commun Med, POB 13662, Tripoli 13662, Libya; [Stewart, Derek] Qatar Univ, Coll Pharm, QU Hlth, POB 2713, Doha 2713, Qatar		Tobaiqy, M (通讯作者)，Univ Jeddah, Dept Pharmacol, Coll Med, POB 45311, Jeddah 45311, Saudi Arabia.	mtobaiqy@uj.edu.sa; katiemaclure@outlook.com; h.elkout@uot.edu.ly; d.stewart@qu.edu.qa		MacLure, Katie/0000-0003-0686-948X; Stewart, Derek/0000-0001-7360-8592; Tobaiqy, Mansour/0000-0002-4292-0900			Abbattista M, 2021, J THROMB HAEMOST, V19, P2554, DOI 10.1111/jth.15493; Ahmed I, 2007, POSTGRAD MED J, V83, DOI 10.1136/pgmj.2007.059188; [Anonymous], More than 4.89 Billion Shots Given: COVID-19 Tracker in the U.S., 361 Million Doses Have Been Administered; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Breithaupt-Faloppa AC, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1980; Cambron Julia C, 2020, Mayo Clin Proc Innov Qual Outcomes, V4, P249, DOI 10.1016/j.mayocpiqo.2020.02.002; Centers for Disease Control and Prevention (CDC), REC US JOHNS JOHNS J; Ciarambino Tiziana, 2021, Womens Health (Lond), V17, p17455065211022262, DOI 10.1177/17455065211022262; Cines DB, 2021, NEW ENGL J MED, V384, P2254, DOI 10.1056/NEJMe2106315; De Michele M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25010-x; Ebrahimi OV, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.700213; European Medicines Agency, EM M PHARM RISK ASS; European Medicines Agency, EUR MED AG POL ACC E; Evagora-Campbell M, 2021, LANCET, V397, P2447, DOI 10.1016/S0140-6736(21)01326-X; Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Heidari S, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-006854; Hippisley-Cox J, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1931; Joint Council on Vaccination and Immunisation, STAT IMM PRIOR; Klok FA, 2010, AM J RESP CRIT CARE, V181, P501, DOI 10.1164/rccm.200907-1141OC; McCartney PR, 2020, JOGNN-J OBST GYN NEO, V49, P405, DOI 10.1016/j.jogn.2020.08.001; Oldenburg J, 2021, HAMOSTASEOLOGIE, V41, P184, DOI 10.1055/a-1469-7481; Rotondo JC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13091687; Sardella M, 2019, THER ADV DRUG SAF, V10, DOI 10.1177/2042098619882819; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Smadja DM, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.00956-2021; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Tobaiqy M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040393; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; World Health Organization, DRAFT LANDSC COVID 1	34	2	2	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1326	10.3390/vaccines9111326			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF2TV	34835256	Green Published, gold, Green Submitted			2022-04-29	WOS:000723929500001
J	Ul Haq, A; Khan, A; Khan, J; Irum, S; Waheed, Y; Ahmad, S; Nizam-Uddin, N; Albutti, A; Zaman, N; Hussain, Z; Ali, SS; Waseem, M; Kanwal, F; Wei, DQ; Wang, Q				Ul Haq, Azaz; Khan, Abbas; Khan, Jafar; Irum, Shamaila; Waheed, Yasir; Ahmad, Sajjad; Nizam-Uddin, N.; Albutti, Aqel; Zaman, Nasib; Hussain, Zahid; Ali, Syed Shujait; Waseem, Muhammad; Kanwal, Fariha; Wei, Dong-Qing; Wang, Qian			Annotation of Potential Vaccine Targets and Design of a Multi-Epitope Subunit Vaccine against Yersinia pestis through Reverse Vaccinology and Validation through an Agent-Based Modeling Approach	VACCINES			English	Article						Yersinia pestis; vaccine targets; epitope mining; in silico cloning; immune simulation	PROTEIN-STRUCTURE PREDICTION; RECOGNITION; DATABASE	Yersinia pestis is responsible for plague and major pandemics in Asia and Europe. This bacterium has shown resistance to an array of drugs commonly used for the treatment of plague. Therefore, effective therapeutics measurements, such as designing a vaccine that can effectively and safely prevent Y. pestis infection, are of high interest. To fast-track vaccine development against Yersinia pestis, herein, proteome-wide vaccine target annotation was performed, and structural vaccinology-assisted epitopes were predicted. Among the total 3909 proteins, only 5 (rstB, YPO2385, hmuR, flaA1a, and psaB) were shortlisted as essential vaccine targets. These targets were then subjected to multi-epitope vaccine design using different linkers. EAAK, AAY, and GPGPG as linkers were used to link CTL, HTL, and B-cell epitopes, and an adjuvant (beta defensin) was also added at the N-terminal of the MEVC. Physiochemical characterization, such as determination of the instability index, theoretical pI, half-life, aliphatic index, stability profiling, antigenicity, allergenicity, and hydropathy of the ensemble, showed that the vaccine is highly stable, antigenic, and non-allergenic and produces multiple interactions with immune receptors upon docking. In addition, molecular dynamics simulation confirmed the stable binding and good dynamic properties of the vaccine-TLR complex. Furthermore, in silico and immune simulation of the developed MEVC for Y. pestis showed that the vaccine triggered strong immune response after several doses at different intervals. Neutralization of the antigen was observed at the third day of injection. Conclusively, the vaccine designed here for Y. pestis produces an immune response; however, further immunological testing is needed to unveil its real efficacy.	[Ul Haq, Azaz; Khan, Jafar; Zaman, Nasib; Hussain, Zahid; Ali, Syed Shujait] Univ Swat, Ctr Biotechnol & Microbiol, Kanju Campus, Swat 19200, Pakistan; [Khan, Abbas; Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biol Stat, Shanghai 200240, Peoples R China; [Irum, Shamaila] Univ Gujrat, Dept Zool, Gujrat 50700, Punjab, Pakistan; [Waheed, Yasir] Fdn Univ Islamabad, Fdn Univ Med Coll, Multidisciplinary Dept, Islamabad 44000, Pakistan; [Ahmad, Sajjad] Abasyn Univ, Dept Hlth & Biol Sci, Peshawar 25000, Pakistan; [Nizam-Uddin, N.] HITEC Univ, Biomed Engn Dept, Taxila 47080, Pakistan; [Albutti, Aqel] Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, Buraydah 51452, Saudi Arabia; [Waseem, Muhammad] Riphah Int Univ, Fac Rehabil & Allied Hlth Sci, Islamabad 46000, Pakistan; [Kanwal, Fariha] Shanghai Jiao Tong Univ, Sch Biomed Engn, Med X Res Inst, Shanghai 200240, Peoples R China; [Wei, Dong-Qing] Peng Cheng Lab, Vanke Cloud City Phase 1 Bldg 8,Xili St, Shenzhen 518055, Peoples R China; [Wei, Dong-Qing] Shanghai Jiao Tong Univ, Shanghai Islamabad Belgrade Joint Innovat Ctr Ant, State Key Lab Microbial Metab, Joint Lab Int Cooperat Metab & Dev Sci,Minist Edu, Shanghai 200030, Peoples R China; [Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China; [Wang, Qian] Nanjing Med Univ, Dept Med, 140 Hanzhong Rd, Nanjing 210029, Peoples R China		Wei, DQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biol Stat, Shanghai 200240, Peoples R China.; Wei, DQ (通讯作者)，Peng Cheng Lab, Vanke Cloud City Phase 1 Bldg 8,Xili St, Shenzhen 518055, Peoples R China.; Wei, DQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Islamabad Belgrade Joint Innovat Ctr Ant, State Key Lab Microbial Metab, Joint Lab Int Cooperat Metab & Dev Sci,Minist Edu, Shanghai 200030, Peoples R China.; Wei, DQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China.; Wang, Q (通讯作者)，Nanjing Med Univ, Dept Med, 140 Hanzhong Rd, Nanjing 210029, Peoples R China.	azazulhaq612@gmail.com; abbaskhan@sjtu.edu.cn; jafar@uswat.edu.pk; shamaila.irum@uog.edu.pk; yasir.waheed@fui.edu.pk; sahmad@bs.qau.edu.pk; nizam.uddin@hitecuni.edu.pk; as.albutti@qu.edu.sa; nasibzaman@uswat.edu.pk; zahid@uswat.edu.pk; shujaitswati@uswat.edu.pk; m.waseem@riphah.edu.pk; farihakaanwal@gmail.com; dqwei@sjtu.edu.cn; qianwang83@yeah.net	Khan, Abbas/AAF-2409-2020; Kanwal, Fariha/AAA-6503-2019; Waheed, Yasir/AAC-3896-2019	Kanwal, Fariha/0000-0002-8005-4206; Waheed, Yasir/0000-0002-5789-4215; Albutti, Aqel/0000-0001-8697-5340	Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2016YFA0501703]; National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32070662, 61832019, 32030063]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [19430750600]; SJTU JiRLMDS Joint Research Fund; Joint Research Funds for Medical and Engineering and Scientific Research at Shanghai Jiao Tong University [YG2021ZD02]; Center for High-Performance Computing, Shanghai Jiao Tong University	Funding: Dong-Qing Wei is supported by grants from the Key Research Area Grant 2016YFA0501703 of the Ministry of Science and Technology of China, the National Science Foundation of China (Grant No. 32070662, 61832019, 32030063), the Science and Technology Commission of Shanghai Municipality (Grant No.: 19430750600), and the SJTU JiRLMDS Joint Research Fund and Joint Research Funds for Medical and Engineering and Scientific Research at Shanghai Jiao Tong University (YG2021ZD02). The computations were partially performed at the Pengcheng Lab. and the Center for High-Performance Computing, Shanghai Jiao Tong University.	Ahmad I., 2020, COMPUTATIONAL VACCIN, DOI [10.1080/07391102.2020.1845799, DOI 10.1080/07391102.2020.1845799]; Albert NL, 2017, EUR J NUCL MED MOL I, V44, P2230, DOI 10.1007/s00259-017-3799-9; Ali A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37070-z; Barbieri R, 2019, P NATL ACAD SCI USA, V116, P7620, DOI 10.1073/pnas.1901145116; Bazhan SI, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020034; Bueno LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021289; Castiglione F., 2012, INNOVATION VACCINOLO, P17; Chen LH, 2005, NUCLEIC ACIDS RES, V33, pD325, DOI 10.1093/nar/gki008; Chen ZW, 2021, J CELL MOL MED, V25, P1274, DOI 10.1111/jcmm.16200; Chivian D, 2005, PROTEINS, V61, P157, DOI 10.1002/prot.20733; Demeure CE, 2019, GENES IMMUN, V20, P357, DOI 10.1038/s41435-019-0065-0; Deng W, 2002, J BACTERIOL, V184, P4601, DOI 10.1128/JB.184.16.4601-4611.2002; Eichelberger KR, 2019, METHODS MOL BIOL, V2010, P197, DOI 10.1007/978-1-4939-9541-7_14; El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893; Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Han CX, 2019, INT J INFECT DIS, V86, P57, DOI 10.1016/j.ijid.2019.06.025; Hasan M, 2019, INFECT GENET EVOL, V70, P140, DOI 10.1016/j.meegid.2019.03.003; Kelly DF, 2005, ADV EXP MED BIOL, V568, P217; Khan Abd Ullah, 2020, Journal of Network and Computer Applications, V164, P37, DOI 10.1016/j.jnca.2020.102686; Khan A, 2021, COMPUT BIOL MED, V133, DOI 10.1016/j.compbiomed.2021.104420; Khan A, 2020, COMPUT STRUCT BIOTEC, V18, P2174, DOI 10.1016/j.csbj.2020.08.006; Khan A, 2020, INTERDISCIP SCI, V12, P335, DOI 10.1007/s12539-020-00381-9; Khan A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196484; Khan M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49354-z; Khan MT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44013-9; Khan SZ, 2019, INFECT GENET EVOL, V73, P390, DOI 10.1016/j.meegid.2019.06.006; Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493; Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424; Lengths MC, 2018, QUICK GUIDELINE COMP, V16, P75; Li B, 2008, INFECT IMMUN, V76, P1804, DOI 10.1128/IAI.01517-07; Magrane M, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar009; Mahram Atabak, 2010, 24th ACM International Conference on Supercomputing 2010, P73; MAYER H, 1995, CHAOS, V5, P155, DOI 10.1063/1.166098; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mohammed A., 2017, IMMUNOME RES, V13, P2; Guedes RLM, 2019, GENOMICS, V111, P407, DOI 10.1016/j.ygeno.2018.02.017; Nosrati M, 2019, J BIOMED INFORM, V93, DOI 10.1016/j.jbi.2019.103160; Pechous RD, 2016, TRENDS MICROBIOL, V24, P190, DOI 10.1016/j.tim.2015.11.008; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Qu Z., 2001, U.S. Patent, Patent No. [6,254,868, 6254868]; Rapin N, 2011, BIOINFORMATICS, V27, P2013, DOI 10.1093/bioinformatics/btr335; Roy S, 2011, BIOINFORMATION, V6, P315, DOI 10.6026/97320630006315; Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343; Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Shan R, 2019, SWISS MED WKLY, V149, DOI 10.4414/smw.2019.20052; Smiley ST, 2019, INFECT IMMUN, V87, DOI [10.1128/IAI.00126-19, 10.1128/iai.00126-19]; Teijaro JR, 2017, SEMIN IMMUNOPATHOL, V39, P501, DOI 10.1007/s00281-017-0640-2; Wang W, 2016, DATA BRIEF, V9, P345, DOI 10.1016/j.dib.2016.05.025; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Yang HY, 2011, INFECT IMMUN, V79, P4413, DOI 10.1128/IAI.05622-11; Yang RF, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01519-17; Yu CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099368; Zaharieva N, 2019, CURR COMPUT-AID DRUG, V15, P398, DOI 10.2174/1573409915666190318121838; Zauberman A, 2006, INFECT IMMUN, V74, P3239, DOI 10.1128/IAI.00097-06; Zhang R, 2004, NUCLEIC ACIDS RES, V32, pD271, DOI 10.1093/nar/gkh024	57	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1327	10.3390/vaccines9111327			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH0RF	34835260	gold, Green Published			2022-04-29	WOS:000725150000001
J	Hu, W; He, MF; Wang, XN; Sun, Q; Kuang, M				Hu, Wei; He, Meifang; Wang, Xiaoning; Sun, Qiang; Kuang, Ming			Specific CD8(+) TCR Repertoire Recognizing Conserved Antigens of SARS-CoV-2 in Unexposed Population: A Prerequisite for Broad-Spectrum CD8(+) T Cell Immunity	VACCINES			English	Article						SARS-CoV-2; broad-spectrum adaptive immunity; CD8(+) T cell; TCR repertoire; vaccine		Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed variants escaping neutralization antibody immunity established against the original virus. An understanding of broad-spectrum adaptive immunity, including CD8(+) T cell immunity to wide range of epitopes, could help translational efforts to improve coronavirus disease 2019 (COVID-19) prevention and therapy. However, there have been few direct studies in which such immunity exists in a population. Methods: We selected SARS-CoV-2-conserved structural peptides that are not prone to mutation as antigens for broad-spectrum CD8(+) T cell immunity. Peripheral blood mononuclear cells (PBMCs) from unexposed healthy donors were stimulated with these peptides in vitro and CD8(+) T cell-specific response was monitored. The conserved peptide-specific CD8(+) T cells were sorted for T cell receptor (TCR) repertoire sequencing. The presence of specific complementary determining region 3 (CDR3) clones was analyzed in a healthy cohort. Results: For each structural protein, including S, E, M, N, the conserved peptides could potentially provide the largest number of major histocompatibility complex-I (MHC-I) epitopes in the Oriental and Caucasian populations. For conserved peptides from spike (S), envelope (E), membrane (M), nucleocapsid (N) proteins, we found that there were no cross-reactive memory T cells in the unexposed individuals. Instead, their T cells contain naive TCR repertoire recognizing these conserved peptides. Using TCR sequencing and CDR3 clustering for the conserved peptides specific T cells, we found that the recovered patients had a higher proportion of TCR repertoire similar with that of specific CD8(+) T cells in unexposed individuals. Meanwhile, CDR3 clones of the above T cells were widely present in the healthy population. Conclusions: This study provides evidence of broad-spectrum SARS-CoV-2 specific CD8(+) TCR repertoire in unexposed healthy population, which is implicated in the development and implementation of broad-spectrum vaccines against COVID-19.	[Hu, Wei] Sun Yat sen Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou 510080, Peoples R China; [He, Meifang] Sun Yat sen Univ, Lab Gen Surg, Affiliated Hosp 1, Guangzhou 510080, Peoples R China; [Wang, Xiaoning] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing 100853, Peoples R China; [Wang, Xiaoning] Southern Med Univ, Sch Lab Med & Biotechnol, Guangzhou 510515, Peoples R China; [Sun, Qiang] Inst Biotechnol, Lab Cell Engn, Beijing 100071, Peoples R China; [Sun, Qiang] Chinese Acad Med Sci, Res Unit Cell Death Mech, 2020RU009, Beijing 100071, Peoples R China; [Kuang, Ming] Sun Yat Sen Univ, Div Intervent Ultrasound, Affiliated Hosp 1, Guangzhou 510080, Peoples R China; [Kuang, Ming] Sun Yat Sen Univ, Dept Liver Surg, Affiliated Hosp 1, Guangzhou 510080, Peoples R China; [Kuang, Ming] Sun Yat Sen Univ, Ctr Canc, Affiliated Hosp 1, Guangzhou 510080, Peoples R China		Kuang, M (通讯作者)，Sun Yat Sen Univ, Div Intervent Ultrasound, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.; Kuang, M (通讯作者)，Sun Yat Sen Univ, Dept Liver Surg, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.; Kuang, M (通讯作者)，Sun Yat Sen Univ, Ctr Canc, Affiliated Hosp 1, Guangzhou 510080, Peoples R China.	huwei57@mail.sysu.edu.cn; hemeifang@mail.sysu.edu.cn; xiaoningwang@cuc.edu.cn; sunq@bmi.ac.cn; kuangm@mail.sysu.edu.cn		Sun, Qiang/0000-0002-5342-0637	China Postdoctoral Science Foundation Special Fund for COVID-19 Prevention and Control [2020T130146ZX]; Basic and Applied Basic Research Foundation of Guangdong Province [2020A1515111089]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81972483]; Young Teacher Training Program of Sun Yat-sen University [19ykpy60]	This work was supported by the China Postdoctoral Science Foundation Special Fund for COVID-19 Prevention and Control (2020T130146ZX to W.H.), Basic and Applied Basic Research Foundation of Guangdong Province (2020A1515111089 to W.H.), the National Natural Science Foundation of China (81972483 to M.H), the Young Teacher Training Program of Sun Yat-sen University (19ykpy60 to M.H.).	Arunachalam PS, 2020, NAT MED, V26, P932, DOI 10.1038/s41591-020-0858-8; Bakhshandeh B, 2021, MICROB PATHOGENESIS, V154, DOI 10.1016/j.micpath.2021.104831; Bar KJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002721; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Chaillon A, 2013, J VIROL, V87, P12737, DOI 10.1128/JVI.02260-13; Chang YM, 2020, J VIROL, V94, DOI 10.1128/JVI.00935-20; Choi BK, 2014, J IMMUNOTHER, V37, P225, DOI 10.1097/CJI.0000000000000027; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grifoni A, 2020, J VIROL, V94, DOI 10.1128/JVI.00089-20; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Hu W, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229327; Iijima N, 2014, SCIENCE, V346, P93, DOI 10.1126/science.1257530; Jiang XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00392-4; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Luan Binquan, 2022, J Med Chem, V65, P2820, DOI 10.1021/acs.jmedchem.1c00311; Lythgoe KA, 2021, SCIENCE, V372, P256, DOI 10.1126/science.abg0821; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Meckiff Benjamin J, 2020, SSRN, P3641939, DOI [10.1101/2020.06.12.148916, 10.2139/ssrn.3641939]; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Niu ZB, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00704-2; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3; Shomuradova AS, 2020, IMMUNITY, V53, P1245, DOI 10.1016/j.immuni.2020.11.004; Sui ZW, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00596-2; Supasa P, 2021, CELL, V184, P2201, DOI 10.1016/j.cell.2021.02.033; Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243; Verghese M, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.00741-21; Wang Chenxi, 2021, [Journal of Molecular Cell Biology, 分子细胞生物学报], V13, P712; Wang ZY, 2020, BIOCHEM SOC T, V48, P2307, DOI 10.1042/BST20200693; Weber S, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202114062; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Zhang ZR, 2021, CELL DEATH DIFFER, V28, P2765, DOI 10.1038/s41418-021-00782-3; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037; Zhou LL, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101744; Zuo JM, 2021, NAT IMMUNOL, V22, P620, DOI 10.1038/s41590-021-00902-8	39	1	1	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1093	10.3390/vaccines9101093			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN3OE	34696201	Green Published, gold			2022-04-29	WOS:000711680600001
J	Porier, DL; Wilson, SN; Auguste, DI; Leber, A; Coutermarsh-Ott, S; Allen, IC; Caswell, CC; Budnick, JA; Bassaganya-Riera, J; Hontecillas, R; Weger-Lucarelli, J; Weaver, SC; Auguste, AJ				Porier, Danielle L.; Wilson, Sarah N.; Auguste, Dawn I.; Leber, Andrew; Coutermarsh-Ott, Sheryl; Allen, Irving C.; Caswell, Clayton C.; Budnick, James A.; Bassaganya-Riera, Josep; Hontecillas, Raquel; Weger-Lucarelli, James; Weaver, Scott C.; Auguste, Albert J.			Enemy of My Enemy: A Novel Insect-Specific Flavivirus Offers a Promising Platform for a Zika Virus Vaccine	VACCINES			English	Article						flavivirus; insect-specific virus; vaccine; Zika virus; correlates of protection	MOUSE MODEL; DNA VACCINE; INFECTION; IMMUNOGENICITY; TRANSMISSION; COINFECTION; PROTECTS; PHASE-1; SAFETY	Vaccination remains critical for viral disease outbreak prevention and control, but conventional vaccine development typically involves trade-offs between safety and immunogenicity. We used a recently discovered insect-specific flavivirus as a vector in order to develop an exceptionally safe, flavivirus vaccine candidate with single-dose efficacy. To evaluate the safety and efficacy of this platform, we created a chimeric Zika virus (ZIKV) vaccine candidate, designated Aripo/Zika virus (ARPV/ZIKV). ZIKV has caused immense economic and public health impacts throughout the Americas and remains a significant public health threat. ARPV/ZIKV vaccination showed exceptional safety due to ARPV/ZIKV's inherent vertebrate host-restriction. ARPV/ZIKV showed no evidence of replication or translation in vitro and showed no hematological, histological or pathogenic effects in vivo. A single-dose immunization with ARPV/ZIKV induced rapid and robust neutralizing antibody and cellular responses, which offered complete protection against ZIKV-induced morbidity, mortality and in utero transmission in immune-competent and -compromised murine models. Splenocytes derived from vaccinated mice demonstrated significant CD4(+) and CD8(+) responses and significant cytokine production post-antigen exposure. Altogether, our results further support that chimeric insect-specific flaviviruses are a promising strategy to restrict flavivirus emergence via vaccine development.</p>	[Porier, Danielle L.; Wilson, Sarah N.; Auguste, Dawn I.; Auguste, Albert J.] Virginia Tech, Fralin Life Sci Inst, Dept Entomol, Blacksburg, VA 24061 USA; [Leber, Andrew; Hontecillas, Raquel] Nutr Immunol & Mol Med Lab Inst, Blacksburg, VA 24060 USA; [Coutermarsh-Ott, Sheryl; Allen, Irving C.; Caswell, Clayton C.; Budnick, James A.; Weger-Lucarelli, James] Virginia Maryland Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24060 USA; [Allen, Irving C.; Budnick, James A.; Auguste, Albert J.] Virginia Tech, Ctr Emerging Zoonot & Arthropod Borne Pathogens, Blacksburg, VA 24061 USA; [Caswell, Clayton C.; Budnick, James A.] Virginia Maryland Coll Vet Med, Ctr Hlth Res 1, Blacksburg, VA 24060 USA; [Weaver, Scott C.] Univ Texas Med Branch, World Reference Ctr Emerging Viruses & Arboviruse, Galveston, TX 77555 USA; [Weaver, Scott C.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA; [Weaver, Scott C.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA		Auguste, AJ (通讯作者)，Virginia Tech, Fralin Life Sci Inst, Dept Entomol, Blacksburg, VA 24061 USA.; Auguste, AJ (通讯作者)，Virginia Tech, Ctr Emerging Zoonot & Arthropod Borne Pathogens, Blacksburg, VA 24061 USA.	sweaver@utmb.edu	Weaver, Scott/D-6490-2011	Weaver, Scott/0000-0001-8016-8556; Auguste, Albert/0000-0001-9048-0041; Weger-Lucarelli, James/0000-0002-9483-1694; Wilson, Sarah/0000-0003-1293-6255; Porier, Danielle/0000-0001-8837-9673	National Institute of Allergy and Infectious Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [K22AI125474, R01AI153433, R03AI151494, R24AI120942]; Institute for Critical Technology and Applied Science at Virginia Tech; DARPA grantUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [BAA HR001118S0017]; independent 4-VA Collaborative Research Grants; Graduate Student Assembly GRDP award	This work was supported by grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Numbers K22AI125474 and R01AI153433 to A.J.A., R03AI151494 to C.C.C. and I.C.A., and R24AI120942 to SCW. A.J.A. was also supported by a Junior Faculty Award from the Institute for Critical Technology and Applied Science at Virginia Tech. This work was partially supported by a DARPA grant (BAA HR001118S0017) awarded to J.W.-L., A.J.A. and I.C.A. would like to further acknowledge independent 4-VA Collaborative Research Grants. D.L.P. is supported by a Graduate Student Assembly GRDP award.	Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157; Auguste AJ, 2021, VIROLOGY, V562, P50, DOI 10.1016/j.virol.2021.07.004; Bolling BG, 2012, VIROLOGY, V427, P90, DOI 10.1016/j.virol.2012.02.016; Brasil P, 2016, LANCET INFECT DIS, V16, P1307, DOI 10.1016/S1473-3099(16)30372-3; Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636; Bullard BL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35755-z; Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137; Duggal NK, 2019, VIROLOGY, V530, P19, DOI 10.1016/j.virol.2019.02.004; Erasmus JH, 2018, J VIROL, V92, DOI 10.1128/JVI.01274-17; Erasmus JH, 2017, NAT MED, V23, P192, DOI 10.1038/nm.4253; Erasmus JH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004119; Espinosa D, 2018, EBIOMEDICINE, V27, P61, DOI 10.1016/j.ebiom.2017.12.010; Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7; Goenaga S, 2015, VIRUSES-BASEL, V7, P5801, DOI 10.3390/v7112911; Gorman MJ, 2018, CELL HOST MICROBE, V23, P672, DOI 10.1016/j.chom.2018.04.003; Gorshkov K, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03252; Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009; Hazlewood JE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030496; Hobson-Peters J, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax7888; Holbrook MR, 2012, ANTIVIR RES, V96, P353, DOI 10.1016/j.antiviral.2012.10.005; Ishikawa T, 2014, VACCINE, V32, P1326, DOI 10.1016/j.vaccine.2014.01.040; Karimi O, 2016, LANCET, V387, P939, DOI [10.1016/s0140-6736(16)00502-X, 10.1016/S0140-6736(16)00502-X]; Krow-Lucal ER, 2018, LANCET CHILD ADOLESC, V2, P204, DOI 10.1016/S2352-4642(18)30020-8; Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287; Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952; Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010; Leber A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00178; Li XF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02975-w; Modjarrad K, 2018, LANCET, V391, P563, DOI 10.1016/S0140-6736(17)33106-9; Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982; Nasar F, 2012, P NATL ACAD SCI USA, V109, P14622, DOI 10.1073/pnas.1204787109; Oehler E, 2014, EUROSURVEILLANCE, V19, P4; Puntasecca CJ, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009055; Richner JM, 2017, CELL, V169, P176, DOI 10.1016/j.cell.2017.03.016; Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111; Shan C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00737-8; Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322; Sharp TM, 2016, CLIN INFECT DIS, V63, P1198, DOI 10.1093/cid/ciw476; Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503; Vet LJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020258; Weger-Lucarelli J, 2018, VIROLOGY, V521, P138, DOI 10.1016/j.virol.2018.06.004; Weger-Lucarelli J, 2017, J VIROL, V91, DOI 10.1128/JVI.01765-16; Xie XP, 2018, CELL HOST MICROBE, V24, P487, DOI 10.1016/j.chom.2018.09.008; Yan KX, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030368; Yang YJ, 2017, EBIOMEDICINE, V17, P145, DOI 10.1016/j.ebiom.2017.02.003; Zou J, 2018, EBIOMEDICINE, V36, P92, DOI 10.1016/j.ebiom.2018.08.056	46	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1142	10.3390/vaccines9101142			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP4QK	34696250	Green Published			2022-04-29	WOS:000713118200001
J	Coppeta, L; Somma, G; Ferrari, C; Mazza, A; Rizza, S; Aurilio, MT; Perrone, S; Magrini, A; Pietroiusti, A				Coppeta, Luca; Somma, Giuseppina; Ferrari, Cristiana; Mazza, Andrea; Rizza, Stefano; Aurilio, Marco Trabucco; Perrone, Stefano; Magrini, Andrea; Pietroiusti, Antonio			Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19	VACCINES			English	Article						SARS-CoV-2; healthcare workers; COVID-19; vaccine; mRNA vaccine; anti-S-RBD antibodies		The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIFA) was the BNT162b2 mRNA vaccine, developed by BioNTech and Pfizer (Comirnaty). Comirnaty contains a molecule called messenger RNA (mRNA), which is a nucleoside-modified RNA that encodes the SARS-CoV-2 spike glycoprotein. Even if data from phase I suggest that vaccine induced antibodies can persist for up to six months following the second shot of BNT vaccine, data regarding the real duration of immunological protection are lacking. In this study, we aimed to evaluate the duration of serological protection by detecting the presence of anti-S-RBD (receptor-binding domain) antibodies for SARS-CoV-2 among a large group of healthcare workers (HCWs) three months after vaccination. 99% of HCWs had a detectable titre of anti-S SARS-CoV-2 antibodies 90 days after the second vaccine shot. Elderly operators showed significantly lower levels of protective antibodies when compared to the younger ones, thus they could become unprotected earlier than other operators.	[Coppeta, Luca; Somma, Giuseppina; Ferrari, Cristiana; Mazza, Andrea; Perrone, Stefano; Magrini, Andrea; Pietroiusti, Antonio] Univ Roma Tor Vergata, Dept Occupat Med, Viale Oxford 81, I-00133 Rome, Italy; [Rizza, Stefano] Univ Roma Tor Vergata, Dept Traslat Med, Viale Oxford 81, I-00133 Rome, Italy; [Aurilio, Marco Trabucco] Univ Molise, Dept Med & Hlth Sci V Tiberio, I-86100 Campobasso, Italy		Ferrari, C (通讯作者)，Univ Roma Tor Vergata, Dept Occupat Med, Viale Oxford 81, I-00133 Rome, Italy.	luca.coppeta@ptvonline.it; giuseppina.somma@ptvonline.it; cristiana.ferrari@ptvonline.it; andrea.mazza@ptvonline.it; stefano.rizza@ptvonline.it; marco.trabuccoaurilio@unimo1.it; stefano.perrone@ptvonline.it; andrea.magrini@uniroma2.it; pietroiu@uniroma2.it		Trabucco Aurilio, Marco/0000-0003-2327-1455			Coppeta L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060659; Coppeta L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17239082; Crawford KM, 2022, DEV PSYCHOPATHOL, V34, P409, DOI [10.1017/S095457942000139X, 10.1093/infdis/jiaa618]; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; ISS, I VACC ANT COVID 19; Jones NK, 2021, ELIFE, V10, DOI 10.7554/eLife.68808; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Masia M, 2021, J AUTOIMMUN, V123, DOI 10.1016/j.jaut.2021.102703; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rizza S, 2021, J ENDOCRINOL INVEST, V44, P1097, DOI 10.1007/s40618-020-01397-0; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843, 10.21203/rs.3.rs-57112/v1]; Terpos E, 2021, AM J HEMATOL, V96, pE257, DOI 10.1002/ajh.26185; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Aurilio MT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050500; Vassell, 2021, SARS COV 2 ANTIBODIE, DOI [10.1101/2021.04.24.21256207, DOI 10.1101/2021.04.24.21256207]; Vicenti Ilaria, 2021, Open Forum Infect Dis, V8, pofab312, DOI 10.1093/ofid/ofab312; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	25	6	6	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							947	10.3390/vaccines9090947			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2XV	34579184	gold, Green Published			2022-04-29	WOS:000702074200001
J	Donadio, G; Choudhary, M; Lindemer, E; Pawlowski, C; Soundararajan, V				Donadio, Gregory; Choudhary, Mayank; Lindemer, Emily; Pawlowski, Colin; Soundararajan, Venky			Counties with Lower Insurance Coverage and Housing Problems Are Associated with Both Slower Vaccine Rollout and Higher COVID-19 Incidence	VACCINES			English	Article						insurance coverage; vaccination rollout; COVID-19 incidence; socioeconomic factors		Equitable vaccination distribution is a priority for outcompeting the transmission of COVID-19. Here, the impact of demographic, socioeconomic, and environmental factors on county-level vaccination rates and COVID-19 incidence changes is assessed. In particular, using data from 3142 US counties with over 328 million individuals, correlations were computed between cumulative vaccination rate and change in COVID-19 incidence from 1 December 2020 to 6 June 2021, with 44 different demographic, environmental, and socioeconomic factors. This correlation analysis was also performed using multivariate linear regression to adjust for age as a potential confounding variable. These correlation analyses demonstrated that counties with high levels of uninsured individuals have significantly lower COVID-19 vaccination rates (Spearman correlation: -0.460, p-value: <0.001). In addition, severe housing problems and high housing costs were strongly correlated with increased COVID-19 incidence (Spearman correlations: 0.335, 0.314, p-values: <0.001, <0.001). This study shows that socioeconomic factors are strongly correlated to both COVID-19 vaccination rates and incidence rates, underscoring the need to improve COVID-19 vaccination campaigns in marginalized communities.	[Donadio, Gregory; Choudhary, Mayank; Lindemer, Emily; Pawlowski, Colin; Soundararajan, Venky] Nference, One Main St,East Arcade, Cambridge, MA 02142 USA		Soundararajan, V (通讯作者)，Nference, One Main St,East Arcade, Cambridge, MA 02142 USA.	greg@nference.net; mayank@nference.net; elindemer@nference.net; colin@nference.net; venky@nference.net		Pawlowski, Colin/0000-0003-2781-7507	nference, inc.	This work was supported by nference, inc.	[Anonymous], 2021, COVID 19 VACCINATION; Benjamini Y., 1995, CONTROLLING FALSE DI, V57, P289; Brown CC, 2021, VACCINE, V39, P4245, DOI 10.1016/j.vaccine.2021.06.038; Caspi G, SOCIOECONOMIC DISPAR, V2021, DOI [10.1101/ 2021.01.28.21250716, DOI 10.1101/2021.01.28.21250716]; CDC, 2020, COVID DAT TRACK; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; Dalsania AK, 2022, J RACIAL ETHN HEALTH, V9, P288, DOI 10.1007/s40615-020-00952-y; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fernandez M.A.L., DELTA METHOD EPIDEMI; Goldhill O., 2021, VACCINATION RATES FO; Hughes MM, 2021, MMWR-MORBID MORTAL W, V70, P431, DOI 10.15585/mmwr.mm7012e1; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; LaVeist TA, 2005, J URBAN HEALTH, V82, pIII26, DOI 10.1093/jurban/jti061; Magnan S., 2017, NAM PERSPECT, V7, P1; Martins PR, 2021, J INFECT PUBLIC HEAL, V14, P1087, DOI 10.1016/j.jiph.2021.06.018; Negrut N, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.10080; Puranik A., 2021, HIGHER COVID 19 VACC, P1; Ritchie H., 2020, STAT RES; Rosenthal M., FAUCI COVID 19 WORST; Stepanikova I, 2017, AM J PREV MED, V52, pS86, DOI 10.1016/j.amepre.2016.09.024; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592-019-0686-2; WHO, WHO COR COVID 19 DAS; Yeyati E.L., 2021, BROOKINGS 0608	24	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							973	10.3390/vaccines9090973			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2UJ	34579210	Green Published, gold			2022-04-29	WOS:000702065100001
J	Gomes, LR; Durans, AM; Napoleao-Pego, P; Waterman, JA; Freitas, MS; De Sa, NBR; Pereira, LV; Furtado, JS; Aquino, RG; Machado, MCR; Fintelman-Rodrigues, N; Souza, TML; Morel, CM; Provance, DW; De-Simone, SG				Gomes, Larissa R.; Durans, Andressa M.; Napoleao-Pego, Paloma; Waterman, Jessica A.; Freitas, Mariana S.; De Sa, Nathalia B. R.; Pereira, Lilian, V; Furtado, Jessica S.; Aquino, Romario G.; Machado, Mario C. R.; Fintelman-Rodrigues, Natalia; Souza, Thiago M. L.; Morel, Carlos M.; Provance, David W.; De-Simone, Salvatore G.			Multiepitope Proteins for the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD Regions of SARS-CoV-2	VACCINES			English	Article						SARS-CoV-2; COVID-19; linear B cell epitopes; serodiagnostic; IgG; coronavirus; de novo design	GREEN FLUORESCENT PROTEIN; RECEPTOR-BINDING DOMAIN	The COVID-19 pandemic has exposed the extent of global connectivity and collective vulnerability to emerging diseases. From its suspected origins in Wuhan, China, it spread to all corners of the world in a matter of months. The absence of high-performance, rapid diagnostic methods that could identify asymptomatic carriers contributed to its worldwide transmission. Serological tests offer numerous benefits compared to other assay platforms to screen large populations. First-generation assays contain targets that represent proteins from SARS-CoV-2. While they could be quickly produced, each actually has a mixture of specific and non-specific epitopes that vary in their reactivity for antibodies. To generate the next generation of the assay, epitopes were identified in three SARS-Cov-2 proteins (S, N, and Orf3a) by SPOT synthesis analysis. After their similarity to other pathogen sequences was analyzed, 11 epitopes outside of the receptor-binding domain (RBD) of the spike protein that showed high reactivity and uniqueness to the virus. These were incorporated into a ss-barrel protein core to create a highly chimeric protein. Another de novo protein was designed that contained only epitopes in the RBD. In-house ELISAs suggest that both multiepitope proteins can serve as targets for high-performance diagnostic tests. Our approach to bioengineer chimeric proteins is highly amenable to other pathogens and immunological uses.	[Gomes, Larissa R.; Durans, Andressa M.; Napoleao-Pego, Paloma; Waterman, Jessica A.; Freitas, Mariana S.; Fintelman-Rodrigues, Natalia; Souza, Thiago M. L.; Morel, Carlos M.; Provance, David W.; De-Simone, Salvatore G.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Neglected Populat, BR-21040900 Rio De Janeiro, Brazil; [Durans, Andressa M.; Provance, David W.] Fiocruz MS, Interdisciplinary Med Res Lab, Oswaldo Cruz Inst, BR-21040900 Rio De Janeiro, Brazil; [De Sa, Nathalia B. R.] Fiocruz MS, Aids & Mol Immunol Lab, Oswaldo Cruz Inst, BR-21040900 Rio De Janeiro, Brazil; [Pereira, Lilian, V; Furtado, Jessica S.; Aquino, Romario G.] Angra dos Reis Hlth Dept, BR-2390610 Angra Dos Reis, Brazil; [Machado, Mario C. R.] AngraLab Lab, BR-23946010 Angra Dos Reis, Brazil; [Fintelman-Rodrigues, Natalia; Souza, Thiago M. L.] Fiocruz MS, Immunopharmacol Lab, Oswaldo Cruz Inst, BR-21040900 Rio De Janeiro, Brazil; [De-Simone, Salvatore G.] Fed Fluminense Univ, Biol Inst, Dept Cellular & Mol Biol, BR-24020141 Niteroi, RJ, Brazil		De-Simone, SG (通讯作者)，Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Neglected Populat, BR-21040900 Rio De Janeiro, Brazil.; De-Simone, SG (通讯作者)，Fed Fluminense Univ, Biol Inst, Dept Cellular & Mol Biol, BR-24020141 Niteroi, RJ, Brazil.	larissa.gomes@cdts.fiocruz.br; andressa.durans@cdts.fiocruz.br; paloma.pego@cdts.fiocruz.br; jessica.waterman@cdts.fiocruz.br; mariana.freitas@cdts.fiocruz.br; nathalia.ramos@ioc.fiocruz.br; lilian.venuto@estacio.br; epidemioangra@gmail.com; ssa.entomologia@angra.rj.gov.br; marioangralab@hotmail.com; nataliafintelman@gmail.com; tmoreno@cdts.fiocruz.br; carlos.morel@cdts.fiocruz.br; bill.provance@cdts.fiocruz.br; dsimone@cdts.fiocruz.br	De-Simone, Salvatore/I-2989-2013; Gomes, Larissa/AFZ-0438-2022; Provance, David/D-5294-2013	De-Simone, Salvatore/0000-0002-2172-656X; Gomes, Larissa/0000-0001-7194-0858; Freitas, Mariana/0000-0002-3716-467X; de Sa, Nathalia/0000-0002-1084-6435; Fintelman, Natalia/0000-0002-2332-8338; Provance, David/0000-0002-9824-0672	FIOCRUZ-INOVA [VPPCB-007FIO-18-2-27-21, VPPIS -005FIO-20-2-51, VVPCB-005-FIO-20-2-26, INOVA B3-Bovespa]; Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro/FAPERJFundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ) [201.841-2018, 732 E-26 110.198-13]; Brazilian Council for Scientific Research/CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [467.488.2014-2, 301744/2019-0]	This research was funded by FIOCRUZ-INOVA (#VPPCB-007FIO-18-2-27-21 and #VPPIS -005FIO-20-2-51 to S.G.D.-S.; VVPCB-005-FIO-20-2-26 to D.W.P.; INOVA B3-Bovespa to T.M.L.S.), the Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro/FAPERJ (#201.841-2018 to S.G.D.-S. and #732 E-26 110.198-13 to C.M.M.), and the Brazilian Council for Scientific Research/CNPq (#467.488.2014-2 to S.G.D.-S. and #301744/2019-0 to C.M.M.).	Abedi MR, 1998, NUCLEIC ACIDS RES, V26, P623, DOI 10.1093/nar/26.2.623; Close DW, 2015, PROTEINS, V83, P1225, DOI 10.1002/prot.24699; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; da Silva FR, 2014, VACCINE, V32, P6251, DOI 10.1016/j.vaccine.2014.09.019; De-Simone SG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040313; Dowlatshahi S, 2021, ARCH VIROL, V166, P715, DOI 10.1007/s00705-020-04874-2; Du ZW, 2020, EMERG INFECT DIS, V26, P1341, DOI [10.3201/eid2606.200357, 10.1101/2020.02.19.20025452]; Fiorentini S, 2021, LANCET INFECT DIS, V21, pE147, DOI 10.1016/S1473-3099(21)00007-4; Fisher AC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002351; Gao GF, 2018, CELL, V172, P1157, DOI 10.1016/j.cell.2018.02.025; Grayson KJ, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2018.0472; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0; Han HQ, 2020, LANCET INFECT DIS, V20, P655, DOI 10.1016/S1473-3099(20)30174-2; Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266; He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106; Jiang X, 2020, J MED VIROL, V92, P476, DOI 10.1002/jmv.25708; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Jung CY, 2020, INT J INFECT DIS, V99, P266, DOI 10.1016/j.ijid.2020.08.001; Kiss C, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl681; Lechuga GC, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111564; Lee K, 2018, MICROBIOL IMMUNOL, V62, P574, DOI 10.1111/1348-0421.12643; Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685; Liu Haolin, 2021, bioRxiv, DOI 10.1101/2021.02.02.428884; Liu R, 2020, CLIN CHIM ACTA, V505, P172, DOI 10.1016/j.cca.2020.03.009; Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020; Mohammadi A, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102903; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Omori R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73777-8; Ormo M, 1996, SCIENCE, V273, P1392; Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4; Pavoor TV, 2009, P NATL ACAD SCI USA, V106, P11895, DOI 10.1073/pnas.0902828106; Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Shi YL, 2004, J CLIN VIROL, V31, P66, DOI 10.1016/j.jcv.2004.05.006; Tan W., 2020, 20200326 MEDRXIV, DOI [10.1101/2020.03.24.20042382, 10.1101/2020.03.24. 20042382, DOI 10.1101/2020.03.24.20042382]; Teymouri M, 2021, PATHOL RES PRACT, V221, DOI 10.1016/j.prp.2021.153443; Tindale LC, 2020, ELIFE, V9, DOI 10.7554/eLife.57149; To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149; Tosta E, 2020, REV SOC BRAS MED TRO, V53, DOI 10.1590/0037-8682-0669-2020; Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786; Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI [10.1172/JCI138759, 10.1172/JCI138759.]; Wolfel R, 2020, NATURE, V588, pE35, DOI 10.1038/s41586-020-2984-3; Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001; Wu F., 2020, medRxiv, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]; Yan G, 2020, LANCET INFECT DIS, V20, P536, DOI 10.1016/S1473-3099(20)30158-4; Yang C, 2021, NAT CHEM BIOL, V17, P492, DOI 10.1038/s41589-020-00699-x; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zhong JQ, 2004, BIOMOL ENG, V21, P67, DOI 10.1016/j.bioeng.2003.10.004; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu XJ, 2013, J THORAC DIS, V5, pS142, DOI 10.3978/j.issn.2072-1439.2013.06.06; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	54	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							986	10.3390/vaccines9090986			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3EK	34579223	Green Submitted, gold, Green Published			2022-04-29	WOS:000702091300001
J	Maharjan, PM; Cheon, J; Jung, J; Kim, H; Lee, J; Song, M; Jeong, GU; Kwon, Y; Shim, B; Choe, S				Maharjan, Puna Maya; Cheon, Jinyeong; Jung, Jiyun; Kim, Haerim; Lee, Jaewon; Song, Minjeong; Jeong, Gi Uk; Kwon, Youngchan; Shim, Byoungshik; Choe, Sunghwa			Plant-Expressed Receptor Binding Domain of the SARS-CoV-2 Spike Protein Elicits Humoral Immunity in Mice	VACCINES			English	Article						receptor binding domain (RBD); SARS-CoV-2; Nicotiana benthamiana; plant-based vaccine; humoral immunity; glycoengineering; neutralizing antibody; COVID-19; transient expression; plant specific glycosylation	TRANSIENT EXPRESSION; INFLUENZA VACCINE; GLYCOSYLATION; IMMUNOGENICITY; EFFICACY; ANTIBODIES; EFFICIENT; ANTIGEN	The current 15-month coronavirus disease-19 (COVID-19) pandemic caused by SARS-CoV-2 has accounted for 3.77 million deaths and enormous worldwide social and economic losses. A high volume of vaccine production is urgently required to eliminate COVID-19. Inexpensive and robust production platforms will improve the distribution of vaccines to resource-limited countries. Plant species offer such platforms, particularly through the production of recombinant proteins to serve as immunogens. To achieve this goal, here we expressed the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein in the glycoengineered-tobacco plant Nicotiana benthamiana to provide a candidate subunit vaccine. This recombinant RBD elicited humoral immunity in mice via induction of highly neutralizing antibodies. These findings provide a strong foundation to further advance the development of plant-expressed RBD antigens for use as an effective, safe, and inexpensive SARS-CoV-2 vaccine. Moreover, our study further highlights the utility of plant species for vaccine development.	[Maharjan, Puna Maya; Lee, Jaewon; Song, Minjeong] G FLAS Life Sci, 123 Uiryodanji Gil, Osong Eup 28161, Cheongju Si, South Korea; [Maharjan, Puna Maya; Choe, Sunghwa] Seoul Natl Univ, Coll Nat Sci, Sch Biol Sci, Seoul 08826, South Korea; [Cheon, Jinyeong; Jung, Jiyun; Kim, Haerim; Choe, Sunghwa] G FLAS Life Sci, 38 Nakseongdae Ro, Seoul 08790, South Korea; [Jeong, Gi Uk; Kwon, Youngchan] Ctr Convergent Res Emerging Virus Infect, Korea Res Inst Chem Technol, Daejeon 34114, South Korea; [Shim, Byoungshik] Int Vaccine Inst, SNU Res Pk,1 Gwanak Ro, Seoul 08826, South Korea		Choe, S (通讯作者)，Seoul Natl Univ, Coll Nat Sci, Sch Biol Sci, Seoul 08826, South Korea.; Choe, S (通讯作者)，G FLAS Life Sci, 38 Nakseongdae Ro, Seoul 08790, South Korea.	punamaya.maharjan@gflas.com; jinyeong.cheon@gflas.com; jiyun.jung@gflas.com; haerim.kim@gflas.com; 5271248@naver.com; minjeong.song@gflas.com; jay7@krict.re.kr; yckwon@krict.re.kr; ByoungShik.Shim@ivi.int; shchoe@snu.ac.kr	Jeong, Gi Uk/AAD-9899-2022; Choe, Sunghwa/K-5650-2013	Choe, Sunghwa/0000-0001-5541-484X; Jeong, Gi Uk/0000-0002-5509-9330	COVID-19 Vaccine RD program [2016GFRND-GF105]	This work was supported by the COVID-19 Vaccine R&D program (2016GFRND-GF105) in G+FLAS Life Sciences, Inc.	Baisa Gary, 2021, Res Sq, DOI 10.21203/rs.3.rs-137857/v1; Baldassarre A, 2020, EPIGENOMICS-UK, V12, DOI 10.2217/epi-2020-0162; Bhairy, 2017, ASIAN J PHARM CLIN R, V16, P20, DOI [10.22159/ajpcr.2017.v10i2.15825, DOI 10.22159/AJPCR.2017.V10I2.15825]; Bipradut Sil, 2014, American Journal of Plant Sciences, V5, P319; Capell T, 2020, TRENDS PLANT SCI, V25, P635, DOI 10.1016/j.tplants.2020.04.009; Choubini E, 2018, MOL IMMUNOL, V96, P88, DOI 10.1016/j.molimm.2018.03.001; Clinicaltrials, INV THER TREATM PEOP; Clinicaltrials, STUD REC COR LIK PAR; Cole KS, 2004, J VIROL, V78, P1525, DOI 10.1128/JVI.78.3.1525-1539.2004; D'Aoust MA, 2010, PLANT BIOTECHNOL J, V8, P607, DOI 10.1111/j.1467-7652.2009.00496.x; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P2913, DOI 10.1080/21645515.2020.1842034; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Diamos AG, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00200; Donini M, 2019, BIOTECHNOL LETT, V41, P335, DOI 10.1007/s10529-019-02651-z; Dowling W, 2007, J VIROL, V81, P1821, DOI 10.1128/JVI.02098-06; Du YY, 2021, VACCINE, V39, P2287, DOI 10.1016/j.vaccine.2021.03.006; Firacative C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21039-z; Fischer R, 2020, BIOTECHNOL ADV, V40, DOI 10.1016/j.biotechadv.2020.107519; Forno G, 2004, EUR J BIOCHEM, V271, P907, DOI 10.1111/j.1432-1033.2004.03993.x; Grant Oliver C, 2020, bioRxiv, DOI 10.1101/2020.04.07.030445; Hefferon KL, 2014, VACCINES, V2, P642, DOI 10.3390/vaccines2030642; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Hutter J, 2013, J IMMUNOL, V190, P220, DOI 10.4049/jimmunol.1201060; Hughes, 2013, BALBC MOUSE BRENNERS, P290; Justice MJ, 2016, DIS MODEL MECH, V9, P101, DOI 10.1242/dmm.024547; Kang SM, 2005, VIROLOGY, V331, P20, DOI 10.1016/j.virol.2004.10.005; KBP, KBP 201 COVID 19 VAC; Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682; Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02; Kiros TG, 2012, INNOVATION VACCINOLO, V29, P251, DOI DOI 10.1007/978-94-007-4543-8_11; Kumar AU, 2021, CLIN EXP VACCINE RES, V10, P13, DOI 10.7774/cevr.2021.10.1.13; LeBlanc Z, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010005; Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480; Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301; Li T, 2005, GENE THER, V12, P751, DOI 10.1038/sj.gt.3302479; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li XL, 2018, SPRINGERBRIEF MATH, P1, DOI [10.1109/ICDCS.2018.00011, 10.1007/978-3-319-89617-5_1]; Lindbo JA, 2007, PLANT PHYSIOL, V145, P1232, DOI 10.1104/pp.107.106377; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Maharjan PM, 2019, CLIN EXP VACCINE RES, V8, P124, DOI 10.7774/cevr.2019.8.2.124; Makatsa MS, 2021, FRONT PLANT SCI, V12, DOI 10.3389/fpls.2021.589940; Marillonnet S, 2005, NAT BIOTECHNOL, V23, P718, DOI 10.1038/nbt1094; McDonald KA, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00782; Medicago, MED GSK START PHAS 3; Medicago, MED PIP; Montero-Morales L, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00081; Mor TS, 2015, BIOTECHNOL LETT, V37, P2147, DOI 10.1007/s10529-015-1908-z; Mori K, 2005, J VIROL, V79, P10386, DOI 10.1128/JVI.79.16.10386-10396.2005; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878; Ozdilek A, 2020, P NATL ACAD SCI USA, V117, P1280, DOI 10.1073/pnas.1916131117; Paul M, 2011, BIOTECHNOL APPL BIOC, V58, P58, DOI 10.1002/bab.6; Prompetchara E., 2021, BIOMATER TRANSL, V2, P43, DOI [10.3877/cma.j.issn.2096-112X.2021.01.006, DOI 10.3877/CMA.J.ISSN.2096-112X.2021.01.006]; Rattanapisit K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74904-1; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Rosales-Mendoza S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020183; Sabalza M, 2014, BIOTECHNOL LETT, V36, P2367, DOI 10.1007/s10529-014-1621-3; Schillberg S, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00720; Shaaltiel Y, 2007, PLANT BIOTECHNOL J, V5, P579, DOI 10.1111/j.1467-7652.2007.00263.x; Shanmugaraj B, 2021, ASIAN PAC J TROP MED, V14, P49, DOI 10.4103/1995-7645.306736; Shanmugaraj B, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.589995; Shim BS, 2019, CLIN EXP VACCINE RES, V8, P136, DOI 10.7774/cevr.2019.8.2.136; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Strasser R, 2009, J BIOL CHEM, V284, P20479, DOI 10.1074/jbc.M109.014126; Sun SH, 2021, CELL MOL IMMUNOL, V18, P1070, DOI 10.1038/s41423-021-00658-z; Takeyama Natsumi, 2015, Ther Adv Vaccines, V3, P139, DOI 10.1177/2051013615613272; Tee K.L., 2020, PURIFICATION RECOMBI, DOI [10.1101/2020.07.31.231282, DOI 10.1101/2020.07.31.231282, 10.1101/ 2020.07.31.231282]; Thanavala Y, 2005, P NATL ACAD SCI USA, V102, P3378, DOI 10.1073/pnas.0409899102; Versteeg L, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008057; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang CY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16256-y; Wang MY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.587269; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983; WHO, 2003, CONS DOC EP SEV AC R; WHO, MIDDLE E RESP SYNDRO; Wintjens R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00237-9; Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/nchembio.1403, 10.1038/NCHEMBIO.1403]; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8; Yao J, 2015, INT J MOL SCI, V16, P28549, DOI 10.3390/ijms161226122; Zhao FQ, 2020, POULTRY SCI, V99, P3817, DOI 10.1016/j.psj.2020.04.029; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	86	4	4	8	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							978	10.3390/vaccines9090978			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3FM	34579215	Green Published, gold			2022-04-29	WOS:000702094200001
J	Tabor, AE				Tabor, Ala E.			A Review of Australian Tick Vaccine Research	VACCINES			English	Review						Australia; tick vaccines; Rhipicephalus; Ixodes	RHIPICEPHALUS BOOPHILUS MICROPLUS; IXODES-HOLOCYCLUS PARALYSIS; CATTLE TICK; NEUTRALIZING ANTIBODIES; CONCEALED ANTIGEN; PARALYZING TOXIN; BM86 ANTIGEN; GUT CELLS; IMMUNIZATION; EXPRESSION	Tick vaccine research in Australia has demonstrated leadership worldwide through the development of the first anti-tick vaccine in the 1990s. Australia's Commonwealth Scientific and Industrial Research Organisation's (CSIRO) research led to the development of vaccines and/or precursors of vaccines (such as crude extracts) for both the cattle tick and the paralysis tick. CSIRO commercialised the Bm86 vaccine in the early 1990s for Rhipicephalus australis; however, issues with dosing and lack of global conservation led to the market closure of Tick-GARD in Australia. New research programs arose both locally and globally. The Australian paralysis tick Ixodes holocyclus has perplexed research veterinarians since the 1920s; however, not until the 2000s did biotechnology exist to elucidate the neurotoxin-holocyclotoxin family of toxins leading to a proof of concept vaccine cocktail. This review revisits these discoveries and describes tributes to deceased tick vaccine protagonists in Australia, including Sir Clunies Ross, Dr Bernard Stone and Dr David Kemp.	[Tabor, Ala E.] Univ Queensland, Queensland Alliance Agr & Food Innovat, Ctr Anim Sci, 306 Carmody Rd, St Lucia, Qld 4072, Australia; [Tabor, Ala E.] Univ Queensland, Sch Chem & Mol Biosci, 68 Cooper Rd, St Lucia, Qld 4072, Australia		Tabor, AE (通讯作者)，Univ Queensland, Queensland Alliance Agr & Food Innovat, Ctr Anim Sci, 306 Carmody Rd, St Lucia, Qld 4072, Australia.; Tabor, AE (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, 68 Cooper Rd, St Lucia, Qld 4072, Australia.	a.tabor@uq.edu.au	Tabor, Ala/A-5286-2010	Tabor, Ala/0000-0001-7147-1078			Ajmone-Marsan P, 2010, EVOL ANTHROPOL, V19, P148, DOI 10.1002/evan.20267; ALLEN JR, 1979, NATURE, V280, P491, DOI 10.1038/280491a0; ALLEN JR, 1982, PARASITOLOGY, V84, P195, DOI 10.1017/S0031182000044760; ALLEN JR, 1977, CAN J COMP MED, V41, P26; Allingham PG, 1998, J INSECT PHYSIOL, V44, P445, DOI 10.1016/S0022-1910(98)00041-9; Almazan C, 2003, VACCINE, V21, P1492, DOI 10.1016/S0264-410X(02)00683-7; Andreotti R, 2008, REV BRAS PARASITOL V, V17, P93, DOI 10.1590/S1984-29612008000200006; Barker SC, 2004, PARASITOLOGY, V129, pS15, DOI 10.1017/S0031182004005207; Barker SC, 2014, INT J PARASITOL, V44, P941, DOI 10.1016/j.ijpara.2014.08.008; Burger TD, 2014, MOL PHYLOGENET EVOL, V76, P241, DOI 10.1016/j.ympev.2014.03.017; Canales M, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-29; Cobon G.S., 1997, NEW GENERATION VACCI, P1145; Cunha RC, 2012, REV BRAS PARASITOL V, V21, P254, DOI 10.1590/S1984-29612012000300014; de la Fuente J, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030075; DOUBE BM, 1977, AUST VET J, V53, P39, DOI 10.1111/j.1751-0813.1977.tb15819.x; Estrada-Pena A, 2012, J MED ENTOMOL, V49, P794, DOI 10.1603/ME11223; Freeman JM, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-101; Fuller C., 1899, QLD AGR J, V4, P389; Garcia-Garcia JC, 1999, EXP APPL ACAROL, V23, P883, DOI 10.1023/A:1006270615158; Gee G.F., 1959, EC IMPORTANCE CATTLE; Gong HY, 2008, VET PARASITOL, V151, P268, DOI 10.1016/j.vetpar.2007.11.015; GORDON H. McL., 1968, Australian Veterinary Journal, V44, P471, DOI 10.1111/j.1751-0813.1968.tb08973.x; GOTHE R, 1979, J MED ENTOMOL, V16, P357, DOI 10.1093/jmedent/16.5.357; Gough JM, 2005, J INVERTEBR PATHOL, V90, P39, DOI 10.1016/j.jip.2005.05.012; GOUGH JM, 1993, J PARASITOL, V79, P900, DOI 10.2307/3283728; Guerrero FD, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0475-9; Guzman PEE, 2021, VET PARASITOL REG ST, V25, DOI 10.1016/j.vprsr.2021.100591; Hajdusek O, 2010, VACCINE, V28, P2993, DOI 10.1016/j.vaccine.2010.02.008; Hope M, 2010, PARASITE IMMUNOL, V32, P135, DOI 10.1111/j.1365-3024.2009.01168.x; Jackson J, 2007, AUST VET J, V85, P420, DOI 10.1111/j.1751-0813.2007.00183.x; JACKSON LA, 1990, PARASITE IMMUNOL, V12, P141, DOI 10.1111/j.1365-3024.1990.tb00943.x; JARMEY JM, 1995, INSECT BIOCHEM MOLEC, V25, P969, DOI 10.1016/0965-1748(95)00038-W; KAIRE GH, 1966, TOXICON, V4, P91, DOI 10.1016/0041-0101(66)90003-1; Kanduma EG, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04266-0; KEMP DH, 1986, INT J PARASITOL, V16, P115, DOI 10.1016/0020-7519(86)90096-2; KEMP DH, 1989, EXP APPL ACAROL, V7, P43, DOI 10.1007/BF01200452; Lew-Tabor AE, 2016, TICKS TICK-BORNE DIS, V7, P573, DOI 10.1016/j.ttbdis.2015.12.012; Lew-Tabor AE, 2014, TICKS TICK-BORNE DIS, V5, P500, DOI 10.1016/j.ttbdis.2014.03.005; Lew-Tabor AE, 2010, VET PARASITOL, V167, P304, DOI 10.1016/j.vetpar.2009.09.033; Low VL, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0956-5; Mans BJ, 2004, INSECT BIOCHEM MOLEC, V34, P1, DOI 10.1016/j.ibmb.2003.09.002; Mans J, 2004, PARASITOLOGY, V129, pS95, DOI 10.1017/S0031182003004670; Maruyama SR, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2136-2; Masina S, 1999, INT J PARASITOL, V29, P535, DOI 10.1016/S0020-7519(99)00006-5; McKenna RV, 1998, PARASITE IMMUNOL, V20, P325, DOI 10.1046/j.1365-3024.1998.00149.x; Merino O, 2013, VACCINE, V31, P5889, DOI 10.1016/j.vaccine.2013.09.037; Montesino R, 1996, BIOTECHNOL APPL BIOC, V23, P23; Neumann G., 1899, MEMOIRES SOC ZOOLOGI, P107; OPDEBEECK JP, 1988, PARASITE IMMUNOL, V10, P405, DOI 10.1111/j.1365-3024.1988.tb00230.x; Oxer D. T., 1942, Australian Veterinary Journal, V18, P194, DOI 10.1111/j.1751-0813.1942.tb06360.x; PAINE SH, 1983, PARASITOLOGY, V86, P419, DOI 10.1017/S0031182000050617; Patarroyo JH, 2002, VET IMMUNOL IMMUNOP, V88, P163, DOI 10.1016/S0165-2427(02)00154-X; Pienaar R, 2018, VET SCI, V5, DOI 10.3390/vetsci5020053; Piper EK, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12402; RAND KN, 1989, P NATL ACAD SCI USA, V86, P9657, DOI 10.1073/pnas.86.24.9657; RIDING GA, 1994, J IMMUNOL, V153, P5158; RODRIGUEZ M, 1994, J BIOTECHNOL, V33, P135, DOI 10.1016/0168-1656(94)90106-6; Rodriguez-Mallon A, 2015, TICKS TICK-BORNE DIS, V6, P530, DOI 10.1016/j.ttbdis.2015.04.007; Rodriguez-Valle M, 2018, INT J PARASITOL, V48, P71, DOI 10.1016/j.ijpara.2017.07.007; Rodriguez-Valle M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-437; Ross I. C., 1924, Parasitology Cambridge, V16, P365, DOI 10.1017/S0031182000020254; Ross I. C., 1935, Journal of the Council for Scientific and Industrial Research Melbourne, VVol. 8, P8; ROSS I. CLUNIES, 1926, PARASITOL, V18, P410, DOI 10.1017/S0031182000005424; Sackett D., 2006, ASSESSING EC COST EN; Schetters T.P.M., 2014, Vaccine Against Rhipicephalus Ticks, Patent No. [WO2014154847A1, 2014154847]; Schetters T, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1386-8; SCHNITZERLING HJ, 1968, AUST VET J, V44, P7, DOI 10.1111/j.1751-0813.1968.tb04901.x; Song J, 2012, ASIAN PAC J TROP MED, V5, P107, DOI 10.1016/S1995-7645(12)60005-4; Stone B.F., 1979, P347; STONE BF, 1986, AUST VET J, V63, P125, DOI 10.1111/j.1751-0813.1986.tb07681.x; STONE BF, 1989, EXP APPL ACAROL, V7, P59, DOI 10.1007/BF01200453; STONE BF, 1984, AUST J EXP BIOL MED, V62, P189, DOI 10.1038/icb.1984.18; STONE BF, 1982, AUST J EXP BIOL MED, V60, P351, DOI 10.1038/icb.1982.39; STONE BF, 1982, AUST J EXP BIOL MED, V60, P309, DOI 10.1038/icb.1982.34; STONE BF, 1982, AUST J BIOL SCI, V35, P427, DOI 10.1071/BI9820427; STONE BF, 1983, AUST VET J, V60, P65, DOI 10.1111/j.1751-0813.1983.tb05871.x; STONE BF, 1976, AUST J BIOL SCI, V29, P265; STONE BF, 1983, INT J PARASITOL, V13, P447, DOI 10.1016/S0020-7519(83)80007-1; STONE BF, 1963, NATURE, V200, P1233, DOI 10.1038/2001233a0; Stone BF, 1987, PROGR VENOM TOXIN RE, P594; Tabor A., 2017, CATTLE VACCINATION S; Tabor A.E., 2018, TICK TICK BORNE PATH; Tellam RL, 2002, VET PARASITOL, V103, P141, DOI 10.1016/S0304-4017(01)00573-8; Tellam Ross L., 1992, P303; Thurn M.J., 1992, RECENT ADV TOXINOLOG, V30, P557, DOI [10.1016/0041-0101(92)90805-F, DOI 10.1016/0041-0101(92)90805-F]; TRAGER WILLIAM, 1939, JOUR PARASITOL, V25, P57, DOI 10.2307/3272160; Wang MH, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-368; Willadsen P, 1996, PARASITE IMMUNOL, V18, P241, DOI 10.1046/j.1365-3024.1996.d01-90.x; WILLADSEN P, 1995, PARASITOLOGY, V110, pS43, DOI 10.1017/S0031182000001487; WILLADSEN P, 1988, PARASITOL TODAY, V4, P196, DOI 10.1016/0169-4758(88)90084-1; Willadsen P., 2008, DEV NEW IMPROVED VAC; WRIGHT IG, 1983, AUST VET J, V60, P69, DOI 10.1111/j.1751-0813.1983.tb05872.x	92	2	2	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1030	10.3390/vaccines9091030			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2YQ	34579266	Green Published, gold			2022-04-29	WOS:000702076300001
J	Van Duong, T; Lin, CY; Chen, SC; Huang, YK; Okan, O; Dadaczynski, K; Lai, CF				Van Duong, Tuyen; Lin, Cheng-Yu; Chen, Sheng-Chih; Huang, Yung-Kai; Okan, Orkan; Dadaczynski, Kevin; Lai, Chih-Feng			Oxford COVID-19 Vaccine Hesitancy in School Principals: Impacts of Gender, Well-Being, and Coronavirus-Related Health Literacy	VACCINES			English	Article						COVID-19; coronavirus-related health literacy; Oxford COVID-19 vaccine hesitancy; gender; well-being; depression; school principal; employer; Taiwan	PERCEIVED STRESS; CARE WORKERS; ACCEPTANCE; WILLINGNESS; POPULATION; INTENTION; SUPPORT; RECEIVE	Purposes: To explore the associated factors of COVID-19 vaccine hesitancy and examine psychometric properties of the coronavirus-related health literacy questionnaire (HLS-COVID-Q22) and Oxford COVID-19 Vaccine Hesitancy questionnaire. Methods: An online survey was conducted from 23 June to 16 July 2021 on 387 school principals across Taiwan. Data collection included socio-demographic characteristics, information related to work, physical and mental health, COVID-19 related perceptions, sense of coherence, coronavirus-related health literacy, and vaccine hesitancy. Principal component analysis, correlation analysis, linear regression models were used for validating HLS-COVID-Q22, Oxford COVID-19 Vaccine Hesitancy, and examining the associations. Results: HLS-COVID-Q22 and Oxford COVID-19 Vaccine Hesitancy were found with satisfactory construct validity (items loaded on one component with factor loading values range 0.57 to 0.81, and 0.51 to 0.78), satisfactory convergent validity (item-scale correlations range 0.60 to 0.79, and 0.65 to 0.74), high internal consistency (Cronbach's alpha = 0.96 and 0.90), and without floor or ceiling effects (percentages of possibly lowest score and highest score <15%), respectively. Low scores of vaccine hesitancy were found in male principals (regression coefficient, B, -0.69; 95% confidence interval, 95%CI, -1.29, -0.10; p = 0.023), principals with better well-being (B, -0.25; 95%CI, -0.47, -0.03; p = 0.029), and higher HLS-COVID-Q22 (B, -1.22; 95%CI, -1.89, -0.54; p < 0.001). Conclusions: HLS-COVID-Q22 and Oxford COVID-19 Vaccine Hesitancy were valid and reliable tools. Male principals and those with better well-being, and higher health literacy had a lower level of vaccine hesitancy. Improving principals' health literacy and well-being is suggested to be a strategic approach to increase vaccine acceptance for themselves, their staff, and students.	[Van Duong, Tuyen] Taipei Med Univ, Sch Nutr & Hlth Sci, Taipei 11031, Taiwan; [Lin, Cheng-Yu] Shih Hsin Univ, Dept Radio Televis & Film, Taipei 11642, Taiwan; [Chen, Sheng-Chih] Natl Chengchi Univ, Coll Commun, Masters Program Digital Content & Technol, Taipei 11605, Taiwan; [Huang, Yung-Kai] Kaohsiung Med Univ, Coll Dent Med, Dept Oral Hyg, Kaohsiung 80708, Taiwan; [Okan, Orkan] Bielefeld Univ, Fac Educ Sci, Interdisciplinary Ctr Hlth Literacy Res, D-33615 Bielefeld, Germany; [Dadaczynski, Kevin] Fulda Univ Appl Sci, Publ Hlth Ctr Fulda, D-36037 Fulda, Germany; [Dadaczynski, Kevin] Leuphana Univ Lueneburg, Ctr Appl Hlth Sci, D-21335 Luneburg, Germany; [Lai, Chih-Feng] Natl Taichung Univ Educ, Dept Educ, Taichung 40306, Taiwan		Lai, CF (通讯作者)，Natl Taichung Univ Educ, Dept Educ, Taichung 40306, Taiwan.	tvduong@tmu.edu.tw; cyou.lin@msa.hinet.net; scchen@nccu.edu.tw; ykhuang@kmu.edu.tw; orkan.okan@uni-bielefeld.de; kevin.dadaczynski@pg.hs-fulda.de; cflai@mail.ntcu.edu.tw	Van Duong, Tuyen/K-7208-2014; Huang, Yung-Kai/C-7868-2012	Van Duong, Tuyen/0000-0002-2287-0723; Chen, Sheng-Chih/0000-0003-1550-5418; Huang, Yung-Kai/0000-0002-4467-0300; Dadaczynski, Kevin/0000-0002-7367-5362; Lai, Chih-Feng/0000-0003-1007-097X; Okan, Orkan/0000-0003-1714-4783; Lin, Cheng-yu/0000-0001-9315-2190	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST 109-2410-H-142-004]	This research was supported by the Ministry of Science and Technology, Taiwan (grant number: MOST 109-2410-H-142-004).	Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8; Al-Jayyousi GF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060548; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Chan KH, 2020, INT J EPIDEMIOL, V49, P1063, DOI 10.1093/ije/dyaa044; Chang PY, 2021, HEART LUNG, V50, P491, DOI 10.1016/j.hrtlng.2021.03.001; Chew NWS, 2021, INT J INFECT DIS, V106, P52, DOI 10.1016/j.ijid.2021.03.069; Chiu YH, 2016, PEERJ, V4, DOI 10.7717/peerj.2790; Chong YY, 2020, INT J NURS STUD, V108, DOI 10.1016/j.ijnurstu.2020.103644; COVID-HL Consortium COVID-HL Network, COVID HL SCH SURV; Cronbach LJ, 2004, EDUC PSYCHOL MEAS, V64, P391, DOI 10.1177/0013164404266386; Davis CJ, 2022, BRIT J HEALTH PSYCH, V27, P300, DOI 10.1111/bjhp.12546; Doane DP, 2011, J STAT EDUC, V19, DOI 10.1080/10691898.2011.11889611; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Duong Tuyen V, 2019, Health Lit Res Pract, V3, pe91, DOI 10.3928/24748307-20190225-01; Editorial, OV NOV COR 2019NCOV; Elgendy MO, 2021, J MED VIROL, V93, P6535, DOI 10.1002/jmv.27199; Elhadi M, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10987-3; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Field A., 2013, DISCOVERING STAT USI, V4th; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Huynh G, 2021, INFECT DRUG RESIST, V14, P1773, DOI 10.2147/IDR.S308446; Guljas S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18116141; Handebo S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253499; Hashemi-Shahri Seyed Mohammad, 2020, Med J Islam Repub Iran, V34, P63, DOI 10.34171/mjiri.34.63; Jain J, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001205; Kelekar AK, 2021, J AM DENT ASSOC, V152, P596, DOI 10.1016/j.adaj.2021.03.006; Kerr JR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040379; Kessels R, 2021, VACCINE, V39, P4716, DOI 10.1016/j.vaccine.2021.05.069; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kozlov Max, 2021, Nature, DOI 10.1038/d41586-021-02108-2; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kukreti S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030246; Kuo FL, 2020, KAOHSIUNG J MED SCI, V36, P944, DOI 10.1002/kjm2.12294; Lazarus JV, 2020, J HEALTH COMMUN, V25, P799, DOI 10.1080/10810730.2020.1868630; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee EH, 2015, SCAND J CARING SCI, V29, P183, DOI 10.1111/scs.12131; Leung AYM, 2022, AGING MENT HEALTH, V26, P544, DOI 10.1080/13607863.2020.1870206; Lin CY, 2021, NURS OPEN, V8, P1892, DOI 10.1002/nop2.855; Liu TR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060649; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Luk TT, 2021, VACCINE, V39, P3602, DOI 10.1016/j.vaccine.2021.05.036; Makhubela M, 2020, CURR PSYCHOL, DOI 10.1007/s12144-020-00784-3; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Mascarenhas AK, 2021, J DENT EDUC, V85, P1504, DOI 10.1002/jdd.12632; Ministry of Education, REG REG FAC EQ PRIM; Mohamad O, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11361-z; Montagni I, 2021, J PUBLIC HEALTH-UK, V43, P695, DOI 10.1093/pubmed/fdab028; Odone A, 2021, EXPERT REV VACCINES, V20, P559, DOI 10.1080/14760584.2021.1912603; Okan O, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155503; Paakkari L, 2020, LANCET PUBLIC HEALTH, V5, pE249, DOI 10.1016/S2468-2667(20)30086-4; Pakpour AH, 2020, BRAIN BEHAV IMMUN, V89, P524, DOI 10.1016/j.bbi.2020.06.006; Palgi Y, 2021, J AFFECT DISORDERS, V287, P352, DOI 10.1016/j.jad.2021.03.064; Pan W.-C., 2021, 2021 2022 ED TAIWAN, P43; Patel MS, 2021, NATURE, V597, P336, DOI 10.1038/d41586-021-02043-2; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Qiu X, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626717; Racey CS, 2021, VACCINE-X, V8, DOI 10.1016/j.jvacx.2021.100106; Roberti JW, 2006, J COLL COUNS, V9, P135, DOI 10.1002/j.2161-1882.2006.tb00100.x; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Saris WE., 2010, SURV RES METHODS-GER, V4, P61, DOI DOI 10.18148/SRM/2010.V4I1.2682; Schernhammer E, 2022, J PUBLIC HEALTH-UK, V44, pE106, DOI 10.1093/pubmed/fdab122; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE353, DOI 10.1016/S2468-2667(21)00108-0; Sischka P.E., 2020, J AFFECT DISORD REP, V1, P100020, DOI [10.1016/j.jadr.2020.100020, DOI 10.1016/J.JADR.2020.100020]; Stojanovic J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060661; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Taiwan Centers for Disease Control, ATT COVID 19; Tavakol M, 2011, INT J MED EDUC, V2, P1, DOI 10.5116/ijme.4d27.32ff; Tavolacci MP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060654; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Topp CW, 2015, PSYCHOTHER PSYCHOSOM, V84, DOI 10.1159/000376585; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Duong TV, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16183346; Vogt K, 2013, SA J IND PSYCHOL, V39, DOI 10.4102/sajip.v39i1.1111; Wang CP, 2021, PUBLIC HEALTH, V190, P135, DOI 10.1016/j.puhe.2020.02.007; WHO, COVID 19 VACC TRACK; WHO and Cochrane, COVID NMA IN LIV MAP; Wu Shu-Fang Vivienne, 2014, Depress Res Treat, V2014, P239490, DOI 10.1155/2014/239490; Wu YC, 2019, J NURS RES, V27, DOI 10.1097/jnr.0000000000000275; Yilmaz S, 2021, DISASTER MED PUBLIC, DOI 10.1017/dmp.2021.257	86	2	2	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							985	10.3390/vaccines9090985			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ2ZX	34579222	Green Published, gold			2022-04-29	WOS:000702079600001
J	Hamidu, RB; Chalikonda, DM; Hann, HW				Bashir Hamidu, Rukaiya; Chalikonda, Divya M.; Hann, Hie-Won			Gender Disparity in Host Responses to Hepatitis B-Related Hepatocellular Carcinoma: A Case Series	VACCINES			English	Review						hepatitis B virus; chronic hepatitis B; hepatocellular carcinoma; stress; gender disparity; sex difference; survival; prognosis; estrogens; androgens	SERUM TESTOSTERONE; PERSISTENT RISK; LIVER-CANCER; SEX; LAMIVUDINE; THERAPY; IMPACT; VACCINATION; DISEASE	Chronic hepatitis B virus (HBV) infection is one of the most common causes of hepatocellular carcinoma (HCC), a malignant tumor with high mortality worldwide. One remarkable clinical feature of HBV-related HCC is that the risk of development is higher in males and postmenopausal females compared to other females. Increasing evidence also indicates that the prognosis of HBV-associated HCC may involve gender disparity, with females having more favorable outcomes. The proposed mechanism of this gender disparity is thought to be complex and multifactorial. Attributions have been made to gender differences in behavioral risk factors, host stress, immune response, psychology, metabolic risk factors, tumor biology, and hormonal factors. Gender disparities in hormonal factors and stress with consequent incited inflammation and hepatocarcinogenesis in HBV-related HCC is a particularly burgeoning area of investigation. Clarifying these mechanisms could provide insight into HBV-related HCC pathogenesis, and potentially provide a target for prevention and treatment of this disease. Reported herein is a case series involving two families affected by vertically transmitted chronic hepatitis B, longitudinally observed over multiple decades, with family members demonstrating discordant outcomes related to HCC, with worse outcomes among affected males. As a supplement to this case, we review the currently available literature on gender differences in outcomes from HBV-related HCC. In reporting this case series, we aim to add our important observation to the current literature and highlight the need for further research in the mechanisms involved in gender disparity in the prognosis of HBV-related HCC.	[Bashir Hamidu, Rukaiya] Thomas Jefferson Univ Hosp, Dept Med, Philadelphia, PA 19107 USA; [Chalikonda, Divya M.] Thomas Jefferson Univ Hosp, Div Gastroenterol & Hepatol, Dept Med, Philadelphia, PA 19107 USA; [Hann, Hie-Won] Thomas Jefferson Univ Hosp, Liver Dis Prevent Ctr, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA		Hann, HW (通讯作者)，Thomas Jefferson Univ Hosp, Liver Dis Prevent Ctr, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA.	Rukaiya.Bashir-Hamidu@jefferson.edu; divya.chalikonda@jefferson.edu; hie-won.hann@jefferson.edu					Agabio R, 2017, CURR MED CHEM, V24, P2661, DOI 10.2174/0929867323666161202092908; Altekruse SF, 2014, AM J GASTROENTEROL, V109, P542, DOI 10.1038/ajg.2014.11; Ayub A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/810461; Block P, 2020, CURR CANCER THER REV, V16, P253, DOI 10.2174/1573394716666200129121051; Block PD, 2021, HEPAT ONCOL, V8, DOI 10.2217/hep-2020-0028; Chalikonda D.M., 2019, INTEGR CANC SCI THER, V6, DOI [10.15761/ICST.1000300, DOI 10.15761/ICST.1000300]; Chang MH, 2009, RECENT RESULTS CANC, V181, P85; Dargan A, 2017, MINERVA GASTROENTERO, V63, P74, DOI 10.23736/S1121-421X.16.02350-3; Division of Population Health Centers for Disease Control and Prevention, EXC ALC US IS RISK M; Erol A, 2015, DRUG ALCOHOL DEPEN, V156, P1, DOI 10.1016/j.drugalcdep.2015.08.023; Eun JR, 2010, J HEPATOL, V53, P118, DOI 10.1016/j.jhep.2010.02.026; Farinati F, 2009, EUR J GASTROEN HEPAT, V21, P1212, DOI 10.1097/MEG.0b013e32831a86f8; Fattovich G, 2008, J HEPATOL, V48, P335, DOI 10.1016/j.jhep.2007.11.011; Feng H, 2011, J CLIN INVEST, V121, P3159, DOI 10.1172/JCI45967; Hosaka T, 2013, HEPATOLOGY, V58, P98, DOI 10.1002/hep.26180; Iyer JK, 2017, WORLD J GASTROENTERO, V23, P6802, DOI 10.3748/wjg.v23.i37.6802; Kanny D, 2018, AM J PREV MED, V54, P486, DOI 10.1016/j.amepre.2017.12.021; Kennedy B, 2017, J EPIDEMIOL COMMUN H, V71, P947, DOI 10.1136/jech-2016-208706; Kim WR, 2015, CANCER-AM CANCER SOC, V121, P3631, DOI 10.1002/cncr.29537; Klein SL, 2012, BIOESSAYS, V34, P1050, DOI 10.1002/bies.201200099; Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364; Liu WC, 2014, WORLD J GASTROENTERO, V20, P6252, DOI 10.3748/wjg.v20.i20.6252; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Oloruntoba OO, 2015, WORLD J HEPATOL, V7, P460, DOI 10.4254/wjh.v7.i3.460; Pace TWW, 2006, AM J PSYCHIAT, V163, P1630, DOI 10.1176/appi.ajp.163.9.1630; Papatheodoridis GV, 2011, GUT, V60, P1109, DOI 10.1136/gut.2010.221846; Papatheodoridis GV, 2010, J HEPATOL, V53, P348, DOI 10.1016/j.jhep.2010.02.035; Shinn BJ, 2019, WORLD J HEPATOL, V11, P65, DOI 10.4254/wjh.v11.i1.65; Singal AG, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001624; Stroffolini T, 2012, EUR J INTERN MED, V23, pE190, DOI 10.1016/j.ejim.2012.08.009; Vlachogiannakos J, 2013, WORLD J GASTROENTERO, V19, P8822, DOI 10.3748/wjg.v19.i47.8822; White DL, 2012, HEPATOLOGY, V55, P759, DOI 10.1002/hep.24618; Wu Eric M, 2018, Hepatoma Res, V4, DOI 10.20517/2394-5079.2018.87; Yang DY, 2014, CANCER-AM CANCER SOC, V120, P3707, DOI 10.1002/cncr.28912; Yoo Joseph, 2018, Diseases, V6, DOI 10.3390/diseases6020027; YU MW, 1993, CANCER RES, V53, P790	36	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							838	10.3390/vaccines9080838			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6QX	34451963	Green Published, gold			2022-04-29	WOS:000690053900001
J	Korbelik, M				Korbelik, Mladen			Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors	VACCINES			English	Article						cancer immunotherapy; therapeutic vaccine; tumor cell vaccine; photodynamic therapy-generated vaccine; phagocytic receptors; mouse SCCVII tumor	PHOTODYNAMIC THERAPY; CANCER VACCINES; DEATH	The principal event in the function of whole-cell cancer vaccines is the ingestion of vaccine-delivered tumor antigen-containing material, which is performed by the patient's antigen-presenting cells (APCs) through the employment of their phagocytic receptors. The goal of the present study was to identify the phagocytic receptors critical for the therapeutic efficacy of whole-cell cancer vaccines. The model of photodynamic therapy (PDT)-generated vaccines based on mouse SCCVII tumors was utilized, with in vitro expanded SCCVII cells treated by PDT serving as the vaccine material used for treating mice bearing established SCCVII tumors. The therapeutic impact, monitored as delayed progression of vaccinated tumors, was almost completely eliminated when antibodies specifically blocking the activity of LOX-1 scavenger receptor were administered to mice 30 min before vaccination. Similar, but much less pronounced, impacts were found with antibodies neutralizing the activity of CR3/CR4 receptors recognizing complement-opsonized vaccine cells, and with those blocking activating Fc gamma receptors that recognized IgG antibody-based opsonins. A strikingly contrary action, a greatly enhanced tumor control by the vaccine, was found by blocking immune inhibitory receptor, Fc gamma RIIB. The reported findings establish, therefore, an attractive strategy that can be effectively exploited for potent therapeutic enhancement of PDT-generated (and probably other) whole-cell tumor vaccines.	[Korbelik, Mladen] BC Canc, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada		Korbelik, M (通讯作者)，BC Canc, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada.	mkorbelik@bccrc.ca			Canadian Cancer SocietyCanadian Cancer Society (CCS) [701132]	This research was funded by Canadian Cancer Society, grant number 701132.	Keenan BP, 2012, SEMIN ONCOL, V39, P276, DOI 10.1053/j.seminoncol.2012.02.007; Khurana D, 2001, HEAD NECK-J SCI SPEC, V23, P899, DOI 10.1002/hed.1130; Korbelik M, 2007, BRIT J CANCER, V97, P1381, DOI 10.1038/sj.bjc.6604059; Korbelik M, 2011, PHOTOCH PHOTOBIO SCI, V10, P664, DOI 10.1039/c0pp00343c; Korbelik M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030492; Korbelik M, 2020, J PHOTOCH PHOTOBIO B, V204, DOI 10.1016/j.jphotobiol.2020.111780; Korbelik M, 2018, LASER SURG MED, V50, P491, DOI 10.1002/lsm.22810; Korbelik M, 2016, CANCERS, V8, DOI 10.3390/cancers8100094; Korbelik M, 2009, PHOTOCHEM PHOTOBIOL, V85, P1418, DOI 10.1111/j.1751-1097.2009.00610.x; Murphy JE, 2006, BIOCHEM J, V393, P107, DOI 10.1042/BJ20051166; Rosales C, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9042851; Saxena M, 2021, NAT REV CANCER, V21, P360, DOI 10.1038/s41568-021-00346-0; Smith KGC, 2010, NAT REV IMMUNOL, V10, P328, DOI 10.1038/nri2762; Song Q, 2018, IMMUNOL LETT, V196, P11, DOI 10.1016/j.imlet.2018.01.011; Steevels TAM, 2011, EUR J IMMUNOL, V41, P575, DOI 10.1002/eji.201041179	15	0	0	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							904	10.3390/vaccines9080904			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8UO	34452029	Green Published, gold			2022-04-29	WOS:000690198600001
J	Raciborski, F; Jankowski, M; Gujski, M; Pinkas, J; Samel-Kowalik, P				Raciborski, Filip; Jankowski, Mateusz; Gujski, Mariusz; Pinkas, Jaroslaw; Samel-Kowalik, Piotr			Changes in Attitudes towards the COVID-19 Vaccine and the Willingness to Get Vaccinated among Adults in Poland: Analysis of Serial, Cross-Sectional, Representative Surveys, January-April 2021	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccinations; vaccine hesitancy; vaccines; Poland		In December 2020, the first coronavirus disease 2019 (COVID-19) vaccine was authorized in the European Union. This study aimed to assess the changes in attitudes towards the COVID-19 vaccine and the willingness to get vaccinated among adults in Poland between January and April 2021. Secondary data analysis was carried out using data obtained from nationally representative cross-sectional surveys (four consecutive waves: January 2021, n = 1150; February 2021, n = 1179; March 2021, n = 1154; April 2021, n = 1131) carried out by the Public Opinion Research Center. About 31.3% of individuals declared a lack of willingness to vaccinate against COVID-19 regardless of the study wave. Significant changes (p < 0.001) were observed by gender and age. The highest percentage of respondents who declared a lack of willingness to vaccinate against COVID-19 was observed in the youngest age group (18-34 years), 48.5% among males and 45.6% among females. Among individuals over 65 years of age, males significantly more often declared their willingness to be vaccinated than females (p < 0.001). The main argument against the COVID-19 vaccine was concern about the potential side effects. Differences in attitudes towards the COVID-19 vaccine in respect of gender and age indicate the need to implement personalized communications to encourage different social groups to vaccinate against COVID-19.	[Raciborski, Filip; Samel-Kowalik, Piotr] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, PL-02091 Warsaw, Poland; [Jankowski, Mateusz; Pinkas, Jaroslaw] Sch Publ Hlth, Ctr Postgrad Med Educ, PL-01826 Warsaw, Poland; [Gujski, Mariusz] Med Univ Warsaw, Dept Publ Hlth, PL-02097 Warsaw, Poland		Jankowski, M (通讯作者)，Sch Publ Hlth, Ctr Postgrad Med Educ, PL-01826 Warsaw, Poland.; Gujski, M (通讯作者)，Med Univ Warsaw, Dept Publ Hlth, PL-02097 Warsaw, Poland.	filip.raciborski@wum.edu.pl; mjankowski@cmkp.edu.pl; mariusz.gujski@wum.edu.pl; jpinkas@cmkp.edu.pl; piotr.samel@wum.edu.pl	Jankowski, Mateusz/N-7536-2018; Gujski, Mariusz/A-3222-2019	Jankowski, Mateusz/0000-0002-7142-5167; Gujski, Mariusz/0000-0002-2938-4795; Raciborski, Filip/0000-0003-0562-0260	National Centre for Research and Development within the Strategic Programme [GOSPOSTRATEG-II/0007/2020-00]	The project entitled "Building trust in vaccination using the technically advanced communication tools and social impact methods" is financed by the National Centre for Research and Development within the Strategic Programme called Social and Economic Development of Poland in the Globalizing Market-GOSPOSTRATEG II. Grant number GOSPOSTRATEG-II/0007/2020-00".	Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Biasio LR, 2016, HUM VACC IMMUNOTHER, V12, P2984, DOI 10.1080/21645515.2016.1198456; Brodziak A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050411; Chen N, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30183-5]; European Centre for Disease Prevention and Control, COVID 19 VACC TRACK; European Medicines Agency, COVID 19 VACC; Furman FM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124565; Grzeszkiewicz-Radulska, 2012, SOCIOL REV, V1, P83; Hotez P, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100780; Jennings W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060593; Konopinska J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040371; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Krempovych, 2021, ASTRAZENECA VACCINE, P2021, DOI [10.1101/2021.04.08.21255107, DOI 10.1101/2021.04.08.21255107]; Kwok KO, 2020, J INFECTION, V80, pE32, DOI 10.1016/j.jinf.2020.03.027; Leidner AJ, 2019, VACCINE, V37, P226, DOI 10.1016/j.vaccine.2018.11.056; Li J, 2021, J MED VIROL, V93, P1449, DOI 10.1002/jmv.26424; Meyerowitz EA, 2021, ANN INTERN MED, V174, P69, DOI 10.7326/M20-5008; Ministry of Health, 2021, INF REWP COR SARS CO; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Szarowska A, 2021, POL ARCH INTERN MED, V131, P101, DOI 10.20452/pamw.15734; The Public Opinion Research Center, MAT METHODS; Website of the Republic of Poland, NAR PROGR SZCZEP PRZ; Website of the Republic of Poland, VACC COVID 19; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; World Health Organization, WHO DIR GEN OP REM M; Worldometer, 2021, COVID 19 COR PAND	26	7	7	4	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							832	10.3390/vaccines9080832			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8FG	34451957	Green Published, gold			2022-04-29	WOS:000690158800001
J	Santos, KR; Souza, FN; Ramos-Sanchez, EM; Batista, CF; Reis, LC; Fotoran, WF; Heinemann, MB; Goto, H; Gidlund, M; Cunha, AF; Faria, AR; Andrade, HM; Lage, AP; Cerqueira, MNMOP; Della Libera, AMMP				Santos, Kamila R.; Souza, Fernando N.; Ramos-Sanchez, Eduardo M.; Batista, Camila F.; Reis, Luiza C.; Fotoran, Wesley F.; Heinemann, Marcos B.; Goto, Hiro; Gidlund, Magnus; Cunha, Adriano F.; Faria, Angelica Rosa; Andrade, Helida M.; Lage, Andrey P.; Cerqueira, Monica M. O. P.; Della Libera, Alice M. M. P.			Staphylococcus aureus Protection-Related Type 3 Cell-Mediated Immune Response Elicited by Recombinant Proteins and GM-CSF DNA Vaccine	VACCINES			English	Article						vaccine; Staphylococcus aureus; T cell response; mastitis; bovine	COLONY-STIMULATING FACTOR; DELTA-T-CELLS; INFECTION; MEMORY; MASTITIS; ADJUVANT; DEFENSE; MICE	Staphylococcus aureus mastitis remains a major challenge for dairy farming. Here, 24 mice were immunized and divided into four groups: G1: control; G2: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) DNA vaccine; G3: F0F1 ATP synthase subunit alpha (SAS), succinyldiaminopimelate (SDD), and cysteinyl-tRNA synthetase (CTS) recombinant proteins; and G4: SAS+SDD+CTS plus GM-CSF DNA vaccine. The lymphocyte subpopulations, and the intracellular interleukin-17A (IL-17A) and interferon-gamma production in the draining lymph node cells were immunophenotyped by flow cytometry. The immunophenotyping and lymphocyte proliferation was determined in spleen cells cultured with and without S. aureus stimulus. Immunization with S. aureus recombinant proteins generated memory cells in draining lymph nodes. Immunization with the three recombinant proteins plus GM-CSF DNA led to an increase in the percentage of IL-17A(+) cells among overall CD44(+) (memory), T CD4(+), CD4(+) T CD44(+) CD27(-), gamma delta TCR, gamma delta TCR+ CD44(+) CD27(+), and TCRV gamma 4(+) cells. Vaccination with S. aureus recombinant proteins associated with GM-CSF DNA vaccine downregulated T(H)2 immunity. Immunization with the three recombinant proteins plus the GM-CSF DNA led to a proliferation of overall memory T, CD4(+), and CD4(+) TEM cells upon S. aureus stimulus. This approach fostered type 3 immunity, suggesting the development of a protective immune response against S. aureus.	[Santos, Kamila R.; Souza, Fernando N.; Batista, Camila F.; Della Libera, Alice M. M. P.] Univ Sao Paulo, Dept Clin Med, Vet Clin Immunol Res Grp, Fac Med Vet & Zootecnia, BR-05508270 Sao Paulo, Brazil; [Souza, Fernando N.] Univ Fed Paraiba, Programa Posgrad Ciencia Anim, BR-58397000 Areia, Brazil; [Ramos-Sanchez, Eduardo M.; Reis, Luiza C.; Goto, Hiro] Univ Sao Paulo, Lab Soroepidemiol & Imunobiol, Inst Med Trop, Fac Med, BR-05403000 Sao Paulo, Brazil; [Ramos-Sanchez, Eduardo M.] Univ Nacl Toribio Rodriguez Mendoza Amazonas, Dept Salud Publ, Fac Ciencias Salud, Chachapoyas 01000, Peru; [Fotoran, Wesley F.] Inst Butantan, Lab Genet, Div Biol, BR-05503900 Sao Paulo, Brazil; [Heinemann, Marcos B.] Univ Sao Paulo, Dept Med Vet Prevent & Saude Anim, Fac Med Vet & Zootecnia, BR-05508270 Sao Paulo, Brazil; [Goto, Hiro] Univ Sao Paulo, Dept Med Prevent, Fac Med, BR-01246903 Sao Paulo, Brazil; [Gidlund, Magnus] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508900 Sao Paulo, Brazil; [Cunha, Adriano F.; Cerqueira, Monica M. O. P.] Univ Fed Minas Gerais, Dept Tecnol & Inspecao Prod Origem Anim, Escola Vet, BR-31270010 Belo Horizonte, MG, Brazil; [Faria, Angelica Rosa; Andrade, Helida M.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Parasitol, BR-31270901 Belo Horizonte, MG, Brazil; [Faria, Angelica Rosa] Univ Fed Alfenas, Lab Parasitol Clin, Fac Ciencias Farmaceut, BR-37130000 Alfenas, MG, Brazil; [Lage, Andrey P.] Univ Fed Minas Gerais, Dept Med Vet Prevent, Escola Vet, BR-31270010 Belo Horizonte, MG, Brazil		Santos, KR (通讯作者)，Univ Sao Paulo, Dept Clin Med, Vet Clin Immunol Res Grp, Fac Med Vet & Zootecnia, BR-05508270 Sao Paulo, Brazil.	kamilareiss22@gmail.com; nogueirasouza@yahoo.com.br; eduardors22@hotmail.com; camilafre@gmail.com; luizacreis@gmail.com; wesleylfw@hotmail.com; marcosbryan@usp.br; hgoto@usp.br; gidlundm@usp.br; adrianofcunha@hotmail.com.br; angelicarosafaria@gmail.com; helidandrade@gmail.com; aplage@vet.ufmg.br; monicapinhocerqueira@gmail.com; dellalibera@usp.br	Heinemann, Marcos Bryan/AAI-9390-2020; Gidlund, Magnus/ABH-1365-2021; Goto, Hiro/B-5745-2009	Heinemann, Marcos Bryan/0000-0001-6444-9788; Gidlund, Magnus/0000-0003-2047-1136; Goto, Hiro/0000-0001-7048-562X; Ramos-Sanchez, Eduardo Milton/0000-0001-8700-5469	Fundacao de Amparo a Pesquisa do Estado de SAo Paulo-FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2018/23572-3, 2014/23189-4]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]; National Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This work was supported by the FundacAo de Amparo a Pesquisa do Estado de SAo Paulo-FAPESP (grant no 2018/23572-3), and by the CoordenacAo de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) (Finance Code 001). AMMPDL and MBH thank the National Council for Scientific and Technological Development (CNPq) for their fellowships. KRS thanks CAPES for her fellowship. FNS (Process FAPESP n. 2014/23189-4) thanks FAPESP for his fellowship.	Abdeladhim M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001345; Ahlers JD, 2010, BLOOD, V115, P1678, DOI 10.1182/blood-2009-06-227546; Armentrout EI, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8121936; Baldwin CL, 2020, TRANSBOUND EMERG DIS, V67, P119, DOI 10.1111/tbed.13328; Bekeredjian-Ding I, 2017, FUTURE MICROBIOL, V12, P1023, DOI 10.2217/fmb-2017-0138; Bharathan M, 2011, J MAMMARY GLAND BIOL, V16, P409, DOI 10.1007/s10911-011-9233-1; Bosch ME, 2020, MBIO, V11, DOI 10.1128/mBio.01581-20; Bougarn S, 2011, CYTOKINE, V56, P749, DOI 10.1016/j.cyto.2011.09.020; Broker BM, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010031; Buza J, 2009, VET IMMUNOL IMMUNOP, V130, P251, DOI 10.1016/j.vetimm.2008.12.021; Carneiro FRG, 2006, BIOCHEM BIOPH RES CO, V343, P260, DOI 10.1016/j.bbrc.2006.02.140; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Cooper AJR, 2020, J IMMUNOL, V205, P1039, DOI 10.4049/jimmunol.2000143; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Cunha AF, 2020, J DAIRY SCI, V103, P4588, DOI 10.3168/jds.2019-17084; Dillen CA, 2018, J CLIN INVEST, V128, P1026, DOI 10.1172/JCI96481; Duz ALC, 2014, MEM I OSWALDO CRUZ, V109, P1005, DOI 10.1590/0074-02760140208; Fotoran WL, 2017, MOL THER-METH CLIN D, V7, P1, DOI 10.1016/j.omtm.2017.08.004; Giunchetti RC, 2007, VACCINE, V25, P7674, DOI 10.1016/j.vaccine.2007.08.009; Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010; Jing XQ, 2012, ASIAN J ANIM VET ADV, V7, P1266, DOI 10.3923/ajava.2012.1266.1278; Kabelitz D, 2011, CELL MOL LIFE SCI, V68, P2331, DOI 10.1007/s00018-011-0696-4; Kedzierska K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033161; KEHRLI ME, 1991, J DAIRY SCI, V74, P4399, DOI 10.3168/jds.S0022-0302(91)78636-0; Kimura K, 2014, J DAIRY SCI, V97, P4842, DOI 10.3168/jds.2013-7242; Korn T, 2012, ANN NY ACAD SCI, V1247, P34, DOI 10.1111/j.1749-6632.2011.06355.x; Krishnan L, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/578432; Liu LP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68146-4; Mackroth MS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005909; Mahdavi M, 2017, APMIS, V125, P596, DOI 10.1111/apm.12660; Maher BM, 2013, INFECT IMMUN, V81, P4478, DOI 10.1128/IAI.01026-13; Mann SE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00633; Marchitto MC, 2019, P NATL ACAD SCI USA, V116, P10917, DOI 10.1073/pnas.1818256116; Miller LS, 2020, FEMS MICROBIOL REV, V44, P123, DOI 10.1093/femsre/fuz030; Montgomery CP, 2014, INFECT IMMUN, V82, P2125, DOI 10.1128/IAI.01491-14; Murphy AG, 2014, J IMMUNOL, V192, P3697, DOI 10.4049/jimmunol.1303420; Nagaev I, 2001, MOL MICROBIOL, V40, P433, DOI 10.1046/j.1365-2958.2001.02389.x; NICKERSON SC, 1989, J DAIRY SCI, V72, P3286, DOI 10.3168/jds.S0022-0302(89)79490-X; Paape MJ, 2000, ADV EXP MED BIOL, V480, P259; Proctor RA, 2012, VACCINE, V30, P2921, DOI 10.1016/j.vaccine.2011.11.006; Proctor RA, 2012, CLIN INFECT DIS, V54, P1179, DOI 10.1093/cid/cis033; Rainard P, 2018, TRANSBOUND EMERG DIS, V65, P149, DOI 10.1111/tbed.12698; Rainard P, 2020, VET RES, V51, DOI 10.1186/s13567-020-00852-3; Rainard P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063471; Richardson EJ, 2018, NAT ECOL EVOL, V2, P1468, DOI 10.1038/s41559-018-0617-0; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Santos RP, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10112143; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Schumann J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132479; Soares A, 2010, J IMMUNOL METHODS, V362, P43, DOI 10.1016/j.jim.2010.08.007; Souza FN, 2020, ARQ BRAS MED VET ZOO, V72, P2397, DOI 10.1590/1678-4162-11191; Souza FN, 2016, J DAIRY SCI, V99, P2867, DOI 10.3168/jds.2015-10230; Spellberg B, 2010, HUM VACCINES, V6, P857, DOI 10.4161/hv.6.10.12469; STABEL JR, 1991, J DAIRY SCI, V74, P3755, DOI 10.3168/jds.S0022-0302(91)78567-6; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; van Faassen H, 2005, J IMMUNOL, V174, P5341, DOI 10.4049/jimmunol.174.9.5341; Warren TL, 2000, CURR OPIN HEMATOL, V7, P168, DOI 10.1097/00062752-200005000-00007; Woodland DL, 2009, NAT REV IMMUNOL, V9, P153, DOI 10.1038/nri2496; Zeng H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010134; Zhang F, 2018, MBIO, V9, DOI 10.1128/mBio.01949-18	60	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							899	10.3390/vaccines9080899			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2QC	34452024	Green Submitted, Green Published, gold			2022-04-29	WOS:000689781400001
J	Yu, YQ; Lau, MMC; Jiang, H; Lau, JTF				Yu, Yanqiu; Lau, Mason M. C.; Jiang, Hui; Lau, Joseph T. F.			Prevalence and Factors of the Performed or Scheduled COVID-19 Vaccination in a Chinese Adult General Population in Hong Kong	VACCINES			English	Article						COVID-19 vaccination; general population; China; perceptions; personal situation; trust toward the government	INFLUENZA VACCINATION; GENDER-DIFFERENCES; HEALTH; INTENTION; STUDENTS; NURSES; AGE	Background: Globally, COVID-19 vaccination programs have been rolled out. To inform health promotion, this study investigated the prevalence and associated factors of performance or being scheduled to perform at least one dose of COVID-19 vaccination (PSCV) in a Chinese adult general population. Methods: An anonymous, random telephone survey interviewed 500 adults aged 18-75 in Hong Kong, China from 14-27 May 2021. Results: The prevalence of PSCV was 21.0%, which was significantly lower among females and those aged <= 30. Positively associated factors of PSCV included perceived protection effect of vaccination, self-perceived physical fitness for vaccination, compulsory COVID-19 testing experience, perceived need to travel, general trust toward the government, and trust toward the governmental vaccination program, while negatively associated factors included perceived low efficacy of vaccination, concerns about side effects, and chronic disease status. Furthermore, the association between sex and PSCV was fully mediated by stronger concern about side effects and lower levels of self-perceived physical fitness for COVID-19 vaccination among females than males. Conclusion: Moderately low prevalence of COVID-19 vaccination was observed in Hong Kong, where there was no shortage of vaccine supply. To achieve herd immunity, health promotion is greatly warranted and may incorporate messages based on the findings of this study.	[Yu, Yanqiu; Lau, Mason M. C.; Jiang, Hui; Lau, Joseph T. F.] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Ctr Hlth Behav Res, Hong Kong, Peoples R China		Lau, JTF (通讯作者)，Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Ctr Hlth Behav Res, Hong Kong, Peoples R China.	yuyanqiu@link.cuhk.edu.hk; mason-lau@cuhk.edu.hk; 1155102419@link.cuhk.edu.hk; jlau@cuhk.edu.hk		Lau, Joseph/0000-0003-2344-7107	Centre for Health Behaviours Research of the Chinese University of Hong Kong	The study was supported by internal research funding of the Centre for Health Behaviours Research of the Chinese University of Hong Kong. The funding source has no role in this study.	Abalkhail MS, 2017, J INFECT PUBLIC HEAL, V10, P644, DOI 10.1016/j.jiph.2017.05.001; Abbas AH, 2020, INT J SEMIOTIC LAW, DOI 10.1007/s11196-020-09745-2; Adler PS, 2002, ACAD MANAGE REV, V27, P17, DOI 10.2307/4134367; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Applewhite A, 2020, J PRIM CARE COMMUNIT, V11, DOI 10.1177/2150132720958532; BANDURA A, 1991, ORGAN BEHAV HUM DEC, V50, P248, DOI 10.1016/0749-5978(91)90022-L; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bloomberg, 2021, VACC TRACK; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Broche-Perez Yunier, 2021, Front Glob Womens Health, V2, P634088, DOI 10.3389/fgwh.2021.634088; Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; Fedele F, 2021, HUM VACC IMMUNOTHER, V17, P3348, DOI 10.1080/21645515.2021.1928460; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gozgor G, 2022, APPL RES QUAL LIFE, V17, P559, DOI 10.1007/s11482-020-09902-6; Guardian T., 2021, AUSTR VACCINE ROLLOU; Hong Kong S.A.R. Goverment, 2021, HONG KONG VACC DASHB; Hong Kong S.A.R. Goverment, 2020, TOG WE FIGHT VIR; Jung M, 2013, VACCINE, V31, P4860, DOI 10.1016/j.vaccine.2013.07.068; Kabir R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050416; Kaminski J, 2011, CANADIAN J NURSING I, V6, DOI DOI 10.1097/CIN.0000000000000072; Keene J, 2005, J PUBLIC HEALTH-UK, V27, P74, DOI 10.1093/pubmed/fdh208; Khan N, 2021, GASTROENTEROLOGY, V161, P827, DOI 10.1053/j.gastro.2021.05.044; Khubchandani Jagdish, 2021, Brain Behav Immun Health, V15, P100277, DOI 10.1016/j.bbih.2021.100277; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Lau JTF, 2017, SOC PSYCH PSYCH EPID, V52, P525, DOI 10.1007/s00127-017-1340-x; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Magadmi R.M., 2020, BMC PUBLIC HEALTH, V21, P1; Maguen S, 2012, J WOMENS HEALTH, V21, P666, DOI 10.1089/jwh.2011.3113; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; O'Donoghue G, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2841-3; Our World in Data, 2021, CORONAVIRUS COVID 19; Pacella-LaBarbara ML, 2021, J OCCUP ENVIRON MED, V63, P852, DOI 10.1097/JOM.0000000000002298; Patelarou E, 2021, NURS EDUC TODAY, V104, DOI 10.1016/j.nedt.2021.105010; Qunaibi EA, 2021, ELIFE, V10, DOI 10.7554/eLife.68038; Rosenfeld DL, 2020, POLITICIZING COVID 1, DOI [10.31234/osf.io/k23cv, DOI 10.31234/OSF.IO/K23CV]; Sciencenorway.no, 2021, HERES WHY WOMEN ARE; Smith KLW., 2013, HEALTH-LONDON, V5, P1561, DOI [DOI 10.4236/HEALTH.2013.510212, 10.4236/health.2013.510212]; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Soiza RL, 2021, AGE AGEING, V50, P279, DOI 10.1093/ageing/afaa274; South China Morning Post, 2021, S CHINA MORNING POST; United Nations, 2021, LOW INC COUNTR HAV R; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wang ZX, 2021, HUM VACC IMMUNOTHER, V17, P3322, DOI 10.1080/21645515.2021.1917232; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization, COVID 19 ADV PUBL GE; World Health Organization, 2021, WHO COR COVID 19 DAS; Yu YQ, 2021, HUM VACC IMMUNOTHER, V17, P2894, DOI 10.1080/21645515.2021.1909327; Yu YQ, 2022, INT J HEALTH POLICY, V11, P498, DOI 10.34172/ijhpm.2020.195; Yu YW, 2022, IEEE-ASME T MECH, V27, P928, DOI [10.34172/ijhpm.2021.02, 10.1109/TMECH.2021.3075057]	54	2	2	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							847	10.3390/vaccines9080847			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7DU	34451972	Green Published, gold			2022-04-29	WOS:000690087400001
J	Gotz, G; Herold, D; Klotz, PA; Schafer, JT				Goetz, Georg; Herold, Daniel; Klotz, Phil-Adrian; Schaefer, Jan Thomas			Efficiency in COVID-19 Vaccination Campaigns-A Comparison across Germany's Federal States	VACCINES			English	Article						COVID-19; vaccination campaign; efficiency	DEA; STRATEGIES; HOSPITALS; US	Vaccination programs are considered a central pillar of the efforts to stop COVID-19. However, vaccine doses are scarce and several organizational and logistical obstacles, such as the timing of and reserves for second shots and delivery failures, apparently slow down vaccination roll-outs in several countries. Moreover, it is an open question as to where vaccines are administered as efficiently as possible (vaccination centers, hospitals, doctor's offices, pharmacists, etc.). The first aim of our study was to systematically evaluate the efficiency of a country's vaccination campaign. The second aim was to analyze how the integration of doctors' offices into a campaign that formerly relied only on vaccination centers affected the speed of that campaign. Using data on vaccine deliveries and vaccinations given in Germany, we find considerable differences across federal states in terms of efficiency, defined as the ability to administer the most vaccinations out of a given number of available doses. Back-of-the-envelope calculations for January to May 2021 show that vaccinations would have been 3.4-6.9% higher if all federal states had adopted a similar ratio between vaccinations given and vaccines stored, as the most efficient states did. This corresponds to 1.7-3.3% of Germany's total population. In terms of our second research goal, we find evidence that the integration of doctors' offices into the vaccination campaign significantly increased the ratio of vaccinations administered out of a given stock of vaccine doses. On average, there appears to be a structural break in this ratio after doctors' offices were integrated into the vaccination campaign on 5 April 2021. On average, an additional 11.6 out of 100 available doses were administered each week compared to the period prior to that date. We conclude that there are considerable regional differences in the efficiency of the vaccination roll-out. Systematic efficiency analyses are one step to detecting inefficiencies and to identify best practices that can be adopted to eventually speed up the vaccination roll-out in a country.	[Goetz, Georg; Herold, Daniel; Klotz, Phil-Adrian; Schaefer, Jan Thomas] Justus Liebig Univ Giessen, Dept Econ, Licher Str 62, D-35394 Giessen, Germany		Herold, D (通讯作者)，Justus Liebig Univ Giessen, Dept Econ, Licher Str 62, D-35394 Giessen, Germany.	georg.goetz@wirtschaft.uni-giessen.de; daniel.herold@wirtschaft.uni-giessen.de; phil.a.klotz@wirtschaft.uni-giessen.de; jan.t.schaefer@wirtschaft.uni-giessen.de		Herold, Daniel/0000-0002-4500-4385; Goetz, Georg/0000-0001-7878-6726; Klotz, Phil-Adrian/0000-0002-8525-0775			Agrell PJ, 2005, J PROD ANAL, V23, P173, DOI 10.1007/s11123-005-1327-6; Aldamak A, 2017, MEASUREMENT, V106, P161, DOI 10.1016/j.measurement.2017.04.028; BANKER RD, 1984, MANAGE SCI, V30, P1078, DOI 10.1287/mnsc.30.9.1078; BIRCH S, 1992, J HEALTH ECON, V11, P279, DOI 10.1016/0167-6296(92)90004-K; Bubar KM, 2021, SCIENCE, V371, P916, DOI 10.1126/science.abe6959; Caplin A, 2010, J ECON PERSPECT, V24, P183, DOI 10.1257/jep.24.1.183; CHARNES A, 1978, EUR J OPER RES, V2, P429, DOI 10.1016/0377-2217(78)90138-8; Cooper W.W., 2011, HDB DATA ENVELOPMENT; Cylus J, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00453-1; ECDC, 2021, ROLL COVID 19 VACC E; El Zowalaty ME, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100124; Geoffroy F., 2021, VACCINATION STRATEGI, DOI [10.1101/2021.05.04.21256623, DOI 10.1101/2021.05.04.21256623]; Goel R.K., 2021, J EC FINANC, V45, P716, DOI [10.1007/s12197-021-09551-x, DOI 10.1007/S12197-021-09551-X]; Goel RK, 2021, NETNOMICS, V22, P53, DOI 10.1007/s11066-021-09148-w; Hua JL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072309; Jahn B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050434; Jentzsch Anne, 2021, MMW Fortschr Med, V163, P12, DOI 10.1007/s15006-021-9825-7; Kounetas K, 2013, EUR J HEALTH ECON, V14, P979, DOI 10.1007/s10198-012-0446-z; Mallapaty Smriti, 2021, Nature, DOI 10.1038/d41586-021-00450-z; McKee M, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00441-5; Mills MC, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100674; Nas T.F., 2016, COST BENEFIT ANAL TH; Pageaud S., 2021, MEDRXIV, DOI [10.1101/2021.03.17.21253739, DOI 10.1101/2021.03.17.21253739]; Ratzan S, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMp2106137; Rosen B, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00440-6; Rossman H, 2021, NAT MED, V27, P1055, DOI 10.1038/s41591-021-01337-2; Shi FX, 2011, INT J PRODUCT PERFOR, V60, P372, DOI 10.1108/17410401111123544; Shilo S, 2021, NAT REV IMMUNOL, V21, P198, DOI 10.1038/s41577-021-00531-0; Sim F, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00451-3; Staat M, 2006, APPL ECON, V38, P2255, DOI 10.1080/00036840500427502; Tewarson H, 2021, AM J PUBLIC HEALTH, V111, P1073, DOI 10.2105/AJPH.2021.306241; Thanassoulis E, 2000, EUR J OPER RES, V127, P1, DOI 10.1016/S0377-2217(99)00436-1; Torres I, 2021, LANCET, V397, P1804, DOI 10.1016/S0140-6736(21)00893-X; Valdmanis V, 2003, INT J TECHNOL ASSESS, V19, P692, DOI 10.1017/S0266462303000655; Vilches TN, 2021, VACCINE, V39, P2360, DOI 10.1016/j.vaccine.2021.03.058; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; WHO, 2020, NOV COR 2019 N COV S; Zivot E, 2002, J BUS ECON STAT, V20, P25, DOI 10.1198/073500102753410372	38	2	2	6	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							788	10.3390/vaccines9070788			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5FI	34358204	Green Published, gold, Green Submitted			2022-04-29	WOS:000676936900001
J	Uthman, OA; Ndwandwe, D; Uthman, MMB; Yaya, S; Wiysonge, CS				Uthman, Olalekan A.; Ndwandwe, Duduzile; Uthman, Muhammed M. B.; Yaya, Sanni; Wiysonge, Charles S.			Multilevel Analysis of Individual and Contextual Factors Associated with Polio Non-Vaccination in Africa: Further Analyses to Enhance Policy and Opportunity to Save More Lives	VACCINES			English	Article						polio; vaccination; neighbourhood; multilevel analysis; Africa	VACCINES; CHILDREN	Background: Africa was certified polio-free in 2020 and to maintain the polio-free status, African countries need to attain and maintain optimal routine polio vaccination coverage. One indicator for optimal polio vaccination coverage is the prevalence of children who have received no polio vaccination through routine services. The objective of the study was to examine the individual-, neighbourhood-, and country-level factors associated with non-vaccination against polio in Africa. Methods: We applied multivariable multilevel logistic regression analyses on recent demographic and health survey data collected from 2010 onwards in Africa. We identified 64,867 children aged 12-23 months (Level 1) nested within 16,283 neighbourhoods (Level 2) from 32 countries (Level 3). Results: The prevalence of non-vaccination for polio ranged from 2.19% in Egypt to 32.74% in Guinea. We found the following factors to be independent predictors of the increased odds of non-vaccination for polio: being a male child, born to mother with no formal education, living in poorer households; being from a polygamous family, living in neighbourhoods with high maternal illiteracy, high unemployment rate, and low access to media. Conclusions: We found that both individual and contextual factors are associated with non-vaccination for Polio.	[Uthman, Olalekan A.] Univ Warwick, Warwick Ctr Global Hlth, Div Hlth Sci, Med Sch, Coventry CV4 7AL, W Midlands, England; [Uthman, Olalekan A.; Wiysonge, Charles S.] Stellenbosch Univ, Fac Hlth Sci, Dept Global Hlth, Div Epidemiol & Biostat, Francie van Zijl Dr, ZA-7505 Cape Town, South Africa; [Ndwandwe, Duduzile; Wiysonge, Charles S.] South African Med Res Council, Cochrane South Africa, Francie van Zijl Dr, ZA-7501 Cape Town, South Africa; [Uthman, Muhammed M. B.] Univ Ilorin, Coll Hlth Sci, Dept Epidemiol & Community Hlth, Ilorin 240211, Nigeria; [Yaya, Sanni] Univ Ottawa, Sch Int Dev & Global Studies, Ottawa, ON K1N 6N5, Canada; [Yaya, Sanni] Imperial Coll London, George Inst Global Hlth, London SW7 2AZ, England; [Wiysonge, Charles S.] Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Anzio Rd, ZA-7925 Cape Town, South Africa		Uthman, OA (通讯作者)，Univ Warwick, Warwick Ctr Global Hlth, Div Hlth Sci, Med Sch, Coventry CV4 7AL, W Midlands, England.; Uthman, OA (通讯作者)，Stellenbosch Univ, Fac Hlth Sci, Dept Global Hlth, Div Epidemiol & Biostat, Francie van Zijl Dr, ZA-7505 Cape Town, South Africa.	olalekan.uthman@warwick.ac.uk; duduzile.ndwandwe@mrc.ac.za; uthmanmb@yahoo.com; hsanniya@uottawa.ca; Charles.Wiysonge@mrc.ac.za	Ndwandwe, Duduzile/L-2296-2013; Uthman, Olalekan/P-7916-2014; /C-1079-2019	Ndwandwe, Duduzile/0000-0001-7129-3865; Uthman, Muhammed Mubashir B./0000-0002-3012-195X; Wiysonge, Charles/0000-0002-1273-4779; Uthman, Olalekan/0000-0002-8567-3081; /0000-0002-4876-6043	South African Medical Research CouncilSouth African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [43500]	The authors are grateful to DHS Program for providing them with the DHS data. The publication cost for this article was supported by the South African Medical Research Council (project code: 43500).	Bloom DE, 2011, ADV EXP MED BIOL, V697, P1, DOI 10.1007/978-1-4419-7185-2_1; Bosker R.J., 1999, MULTILEVEL ANAL INTR; Browne, 2014, MCMC ESTIMATION MLWI; Browne WJ, 2006, BAYESIAN ANAL, V1, P473, DOI 10.1214/06-BA117; Bryan ML, 2016, EUR SOCIOL REV, V32, P3, DOI 10.1093/esr/jcv059; Charlton C., 2014, MLWIN VERSION 2 31; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.1353/dem.2001.0003; Griffiths P, 2004, HEALTH PLACE, V10, P183, DOI 10.1016/j.healthplace.2003.07.001; Khowaja AR, 2012, B WORLD HEALTH ORGAN, V90, P822, DOI 10.2471/BLT.12.106260; Kravdal O, 2006, DEMOGR RES, V15, P1, DOI 10.4054/DemRes.2006.15.1; Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P443, DOI 10.1136/jech.2004.023473; Montgomery MR, 2000, DEMOGRAPHY, V37, P155, DOI 10.2307/2648118; Ntenda PAM, 2019, PEDIATR NEONATOL, V60, P623, DOI 10.1016/j.pedneo.2019.03.005; Ntenda PAM, 2019, T ROY SOC TROP MED H, V113, P534, DOI 10.1093/trstmh/trz029; Osgood DW., 2003, COMMUNITY CORRELATES; Polio Global Eradication Initiative, 2 OUT 3 WILD POL STR 2 OUT 3 WILD POL STR; Rutstein SO, 2006, GUIDE DHS STAT DEMOG; Sampson RJ, 2003, PERSPECT BIOL MED, V46, pS53, DOI 10.1353/pbm.2003.0059; SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0; Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; Stegmueller D, 2013, AM J POLIT SCI, V57, P748, DOI 10.1111/ajps.12001; UNICEF, 2020, POL VACC CAMP RES AF POL VACC CAMP RES AF; United Nations Development Programme (UNDP), 2014, HUMAN DEV REPORT; Uthman OA, 2017, HUM VACC IMMUNOTHER, V13, P2111, DOI 10.1080/21645515.2017.1336590; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; WARNER BD, 1993, CRIMINOLOGY, V31, P493, DOI 10.1111/j.1745-9125.1993.tb01139.x; Wiysonge C.S., 2020, CONVERSATION; Wiysonge CS, 2006, LANCET, V367, P394, DOI 10.1016/S0140-6736(06)68133-6	30	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							683	10.3390/vaccines9070683			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6KK	34206156	Green Published			2022-04-29	WOS:000677017700001
J	Khan, M; Maker, AV; Jain, S				Khan, Meshaal; Maker, Ajay, V; Jain, Shikha			The Evolution of Cancer Immunotherapy	VACCINES			English	Review						vaccines; immunotherapy; cancer; CAR-T; monoclonal antibodies; checkpoint inhibitor	HIGH-DOSE INTERLEUKIN-2; TALIMOGENE LAHERPAREPVEC; IMMUNE CHECKPOINTS; T-CELLS; THERAPY; VACCINES; BREAST; FUTURE; ANTIBODY; PD-1	Immunotherapy has changed the environment of cancer treatment by providing new and efficacious therapy options for many solid and hematologic malignancies. Although not a new field of oncology, immunotherapy has quickly developed into one of the most flourishing fields in medicine. In this review article, we explore key discoveries which helped to shape our current understanding of the immune system's role in neoplasms. Many landmark developments include the advancements in checkpoint inhibitors, monoclonal antibodies, CAR-T cells and anti-cancer vaccines. We also explore the drawbacks and efficacy of various categories of immunotherapy. Ongoing investigations within immunotherapy, such as the gut microbiome, combining checkpoint inhibitors and gene sequencing, continue to personalize treatments for cancer patients, providing exciting and endless possibilities for the future.	[Khan, Meshaal; Maker, Ajay, V; Jain, Shikha] Univ Illinois, Oncol Dept, Chicago, IL 60607 USA		Khan, M (通讯作者)，Univ Illinois, Oncol Dept, Chicago, IL 60607 USA.	mkhan320@uic.edu; amaker@uic.edu; sjain03@gmail.com		Jain, Shikha/0000-0002-5684-7898			Abbas AK, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat1482; Alhunaidi O, 2019, ECANCERMEDICALSCIENC, V13, DOI 10.3332/ecancer.2019.905; Amgen Inc, 2015, IML TAL LAH SUSP INT; [Anonymous], MICROBIOME IMMUNOTHE; [Anonymous], PD-1/PD-L1 Landscape.; Bota D, 2019, NEURO-ONCOLOGY, V21, P7; Brudno JN, 2019, BLOOD REV, V34, P45, DOI 10.1016/j.blre.2018.11.002; Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239; BURNET M, 1957, BMJ-BRIT MED J, V1, P841, DOI 10.1136/bmj.1.5023.841; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Chang JC, 2007, CLIN CANCER RES, V13, P1, DOI 10.1158/1078-0432.CCR-06-2405; Chen XT, 2020, THERANOSTICS, V10, P6011, DOI 10.7150/thno.38742; Chong EA, 2017, BLOOD, V129, P1039, DOI 10.1182/blood-2016-09-738245; Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015; Conry RM, 2018, HUM VACC IMMUNOTHER, V14, P839, DOI 10.1080/21645515.2017.1412896; Cruz E, 2019, BIOL-TARGETS THER, V13, P33, DOI 10.2147/BTT.S166310; Dermime S, 2002, BRIT MED BULL, V62, P149, DOI 10.1093/bmb/62.1.149; Dutcher JP, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425-014-0026-0; Eshhar Z, 2014, HUM GENE THER, V25, P773, DOI 10.1089/hum.2014.2532; George AP, 2019, COMPUT STRUCT BIOTEC, V17, P484, DOI 10.1016/j.csbj.2019.03.015; Guallar-Garrido S, 2020, IMMUNOTARGETS THER, V9, P1, DOI 10.2147/ITT.S202006; Hemminki O, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00922-1; Houghton AN, 2004, J CLIN INVEST, V114, P468, DOI 10.1172/JCI200422685; Ichim CV, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-8; Iqbal Nida, 2014, Mol Biol Int, V2014, P852748, DOI 10.1155/2014/852748; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Jiang T, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1163462; Keegan P., 2014, CTR DRUG EVALUATION; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Klapper JA, 2008, CANCER-AM CANCER SOC, V113, P293, DOI 10.1002/cncr.23552; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lopes A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1154-7; Lv SZ, 2018, ONCOL RES TREAT, V41, P450, DOI 10.1159/000488202; Ma WD, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01050; Marofi F, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-020-02128-1; McCarthy Edward F, 2006, Iowa Orthop J, V26, P154; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Mougel A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00467; Munisvaradass R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091797; Oostra DR, 2014, BREAST CANCER-TARGET, V6, P103, DOI 10.2147/BCTT.S67297; Osipov A, 2019, ADV CANCER RES, V143, P63, DOI 10.1016/bs.acr.2019.03.002; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pierpont TM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00163; Puri Sonam, 2020, Drugs Context, V9, DOI 10.7573/dic.2019-9-2; Puzanov I, 2016, J CLIN ONCOL, V34, P2619, DOI 10.1200/JCO.2016.67.1529; Ribas, 2015, J IMMUNOTHER CANCER, V3, pP181, DOI [10.1186/2051-1426-3-S2-P181, DOI 10.1186/2051-1426-3-S2-P181]; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; Russell L, 2018, CHIN CLIN ONCOL, V7, DOI 10.21037/cco.2018.04.04; Sedykh SE, 2018, DRUG DES DEV THER, V12, P195, DOI 10.2147/DDDT.S151282; Seimetz D, 2019, CELL MED, V11, DOI 10.1177/2155179018822781; Sermer D, 2019, HEMATOL ONCOL, V37, P95, DOI 10.1002/hon.2591; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stanley M, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0268; Stern Lawrence A, 2020, Cancer Treat Res, V180, P297, DOI 10.1007/978-3-030-38862-1_11; Tan SZ, 2020, BIOMED PHARMACOTHER, V124, DOI 10.1016/j.biopha.2020.109821; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; Tarhini A, 2010, CANCER BIOTHER RADIO, V25, P601, DOI 10.1089/cbr.2010.0865; Teng MWL, 2013, CANC IMMUNOTHERAPY I, V3, P85, DOI [10.1016/B978-0-12-394296-8.00007-5, DOI 10.1016/B978-0-12-394296-8.00007-5]; Thomas L., 1959, CELLULAR HUMORAL ASP; Vu T, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00062; U.S. Food and Drug Administration, FDA APPR NEW TREATM; Shao WM, 2020, CANCER BIOL THER, V21, P570, DOI 10.1080/15384047.2020.1739952; Zhao J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01184	64	2	2	12	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							614	10.3390/vaccines9060614			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ1EC	34200997	Green Published, gold			2022-04-29	WOS:000666316600001
J	Mesonero-Escuredo, S; Morales, J; Mainar-Jaime, RC; Diaz, G; Arnal, JL; Casanovas, C; Barrabes, S; Segales, J				Mesonero-Escuredo, Susana; Morales, Joaquin; Carlos Mainar-Jaime, Raul; Diaz, Gonzalo; Luis Arnal, Jose; Casanovas, Carlos; Barrabes, Sergio; Segales, Joaquim			Effect of Edema Disease Vaccination on Mortality and Growth Parameters in Nursery Pigs in a Shiga Toxin 2e Positive Commercial Farm	VACCINES			English	Article						edema disease; vaccination; antibiotic reduction; productive parameters	ENTEROTOXIGENIC ESCHERICHIA-COLI; ANTIBIOTICS; PREVALENCE; DIARRHEA	Diseases caused by Escherichia coli are recognized as major problems in the swine industry, one of them being edema disease (ED). Importantly, the current decrease in antibiotic use may cause difficulties in controlling the disorders caused by E. coli. Therefore, this study assessed the efficacy of a commercial vaccine against ED in nursery pigs from a farm with previous history of ED. A total of 1344 pigs were monitored; half of them were randomly assigned to a vaccinated group (VG) and the other half to a non-vaccinated group (NVG). The vaccine was administered at 7 days of age. Animals received a pre-starter feed with 2500 ppm of zinc oxide (ZnO) for 2 weeks and a starter feed without ZnO for another 3 weeks. Pen-group weights were recorded at 28 (weaning), 42 (end of pre-starter phase), and 63 days of life (end of nursery phase). Death/culling rates, average daily gain (ADG), and average daily feed intake (ADFI) were calculated for each group at each phase. The overall relative risk of dying/being culled for a pig in the NVG was 5 times higher than that of the VG group but increased to 12 times higher during the starter period. ADG and ADFI were also significantly higher in the VG group for that period. Vaccination against ED significantly reduced pig losses and improved ADG and ADFI, particularly when ZnO was not used.	[Mesonero-Escuredo, Susana; Casanovas, Carlos; Barrabes, Sergio] CEVA Salud Anim, Barcelona 08028, Spain; [Morales, Joaquin; Diaz, Gonzalo] PigCHAMP Pro Europa SL, Segovia 40006, Spain; [Carlos Mainar-Jaime, Raul] Univ Zaragoza, CITA, Dept Patol Anim, Fac Vet,Inst Agroalimentario Aragon IA2, E-50013 Zaragoza, Spain; [Luis Arnal, Jose] Exopol, Zaragoza 50840, Spain; [Segales, Joaquim] Univ Autonoma Barcelona UAB, Dept Sanitat & Anat Anim, Barcelona 08193, Spain; [Segales, Joaquim] Ctr Recerca Sanitat Anim CReSA, IRTA UAB, Campus Univ Autonoma Barcelona, Barcelona 08193, Spain; [Segales, Joaquim] OIE Collaborating Ctr Res & Control Emerging & Re, Barcelona 08193, Spain		Segales, J (通讯作者)，Univ Autonoma Barcelona UAB, Dept Sanitat & Anat Anim, Barcelona 08193, Spain.; Segales, J (通讯作者)，Ctr Recerca Sanitat Anim CReSA, IRTA UAB, Campus Univ Autonoma Barcelona, Barcelona 08193, Spain.; Segales, J (通讯作者)，OIE Collaborating Ctr Res & Control Emerging & Re, Barcelona 08193, Spain.	susana.mesonero-escuredo@ceva.com; joaquin.morales@pigchamp-pro.com; rcmainar@unizar.es; gonzalo.diaz@pigchamp-pro.com; jlarnal@exopol.com; carlos.casanovas@ceva.com; sergiosopeira@gmail.com; joaquim.segales@irta.cat	; Segales, Joaquim/A-4933-2011	Morales, Joaquin/0000-0003-0728-4862; Mainar Jaime, Raul Carlos/0000-0001-5442-7702; Arnal Bernal, Jose Luis/0000-0003-3026-2653; Diaz, Gonzalo/0000-0002-2838-5729; Segales, Joaquim/0000-0002-1539-7261			Amezcua R, 2002, CAN J VET RES, V66, P73; [Anonymous], PRINCIPLES EPIDEMIOL, V3rd; Bednorz C, 2013, INT J MED MICROBIOL, V303, P396, DOI 10.1016/j.ijmm.2013.06.004; BERTSCHINGER HU, 1979, VET MICROBIOL, V3, P281, DOI 10.1016/0378-1135(79)90004-X; Casewell M, 2003, J ANTIMICROB CHEMOTH, V52, P159, DOI 10.1093/jac/dkg313; Cox E., 2019, P ZER ZINC C COP DEN; Fairbrother J, 2019, DIS SWINE, V11th, P807; Fricke R, 2015, PORCINE HEALTH MANAG, V1, DOI 10.1186/2055-5660-1-6; He P, 2015, HUM VACC IMMUNOTHER, V11, P477, DOI 10.1080/21645515.2014.1004026; Jones C., 2012, ANIMAL IND REPORT AS, DOI [10.31274/ans_air-180814-132, DOI 10.31274/ANS_AIR-180814-132]; Lillie-Jaschniski K, 2013, TIERAERZTL UMSCHAU, V68, P377; Liu YY, 2016, LANCET INFECT DIS, V16, P161, DOI 10.1016/S1473-3099(15)00424-7; Luppi A, 2016, PORCINE HEALTH MANAG, V2, DOI 10.1186/s40813-016-0039-9; Martineau GP, 2013, SUIS, V97, P22; Melin L., 2001, P294, DOI 10.1079/9780851995175.0294; Muirhead M.R., 2013, MANAGING PIG HLTH RE, V2nd ed., P229; Nagy B, 2005, INT J MED MICROBIOL, V295, P443, DOI 10.1016/j.ijmm.2005.07.003; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Phillips I, 2004, J ANTIMICROB CHEMOTH, V53, P28, DOI 10.1093/jac/dkg483; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P129, DOI 10.1038/s41577-020-00497-5; Rensing C, 2018, ANTIMICROBIAL RESISTANCE IN BACTERIA FROM LIVESTOCK AND COMPANION ANIMALS, P83, DOI 10.1128/microbiolspec.ARBA-0025-2017; Sachs L., 2006, ANGEW STAT METHODENS, V12th ed., P367; Taylor D.J., 2013, PIG DIS, V9th ed., P154	23	1	1	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							567	10.3390/vaccines9060567			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA0PH	34072889	Green Published, gold			2022-04-29	WOS:000666956900001
J	Stojanovic, J; Boucher, VG; Gagne, M; Gupta, S; Joyal-Desmarais, K; Paduano, S; Aburub, AS; Gorin, SSN; Kassianos, AP; Ribeiro, PAB; Bacon, SL; Lavoie, KL				Stojanovic, Jovana; Boucher, Vincent G.; Gagne, Myriam; Gupta, Samir; Joyal-Desmarais, Keven; Paduano, Stefania; Aburub, Ala' S.; Sheinfeld Gorin, Sherri N.; Kassianos, Angelos P.; Ribeiro, Paula A. B.; Bacon, Simon L.; Lavoie, Kim L.			Global Trends and Correlates of COVID-19 Vaccination Hesitancy: Findings from the iCARE Study	VACCINES			English	Article						COVID-19; vaccine hesitancy; international analysis; cross-sectional survey	GENDER-DIFFERENCES; RISK PERCEPTION; BEHAVIOR; METAANALYSIS; ATTITUDES; VACCINES	The success of large-scale COVID-19 vaccination campaigns is contingent upon people being willing to receive the vaccine. Our study explored COVID-19 vaccine hesitancy and its correlates in eight different countries around the globe. We analyzed convenience sample data collected between March 2020 and January 2021 as part of the iCARE cross-sectional study. Univariate and multivariate statistical analyses were conducted to explore the correlates of vaccine hesitancy. We included 32,028 participants from eight countries, and observed that 27% of the participants exhibited vaccine hesitancy, with increases over time. France reported the highest level of hesitancy (47.3%) and Brazil reported the lowest (9.6%). Women, younger individuals (<= 29 years), people living in rural areas, and those with a lower perceived income were more likely to be hesitant. People who previously received an influenza vaccine were 70% less likely to report COVID-19 vaccine hesitancy. We observed that people reporting greater COVID-19 health concerns were less likely to be hesitant, whereas people with higher personal financial concerns were more likely to be hesitant. Our findings indicate that there is substantial vaccine hesitancy in several countries, with cross-national differences in the magnitude and direction of the trend. Vaccination communication initiatives should target hesitant individuals (women, younger adults, people with lower incomes and those living in rural areas), and should highlight the immediate health, social and economic benefits of vaccination across these settings. Country-level analyses are warranted to understand the complex psychological, socio-environmental, and cultural factors associated with vaccine hesitancy.	[Stojanovic, Jovana; Joyal-Desmarais, Keven; Bacon, Simon L.] Concordia Univ, Dept Hlth Kinesiol & Appl Physiol, Montreal, PQ H4B 1R6, Canada; [Stojanovic, Jovana; Boucher, Vincent G.; Joyal-Desmarais, Keven; Ribeiro, Paula A. B.; Bacon, Simon L.; Lavoie, Kim L.] Ctr Integre Univ Sante & Serv Sociaux Nord Ile Mo, Montreal Behav Med Ctr, Res Ctr, Montreal, PQ H4J 1C5, Canada; [Boucher, Vincent G.; Lavoie, Kim L.] Univ Quebec Montreal UQAM, Dept Psychol, Montreal, PQ C3H 3P8, Canada; [Gagne, Myriam; Gupta, Samir] St Michaels Hosp, Div Respirol, Dept Med, Unity Hlth Toronto, Toronto, ON M5B 1W8, Canada; [Gupta, Samir] Univ Toronto, Keenan Res Ctr, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON M52 3M2, Canada; [Paduano, Stefania] Univ Modena & Reggio Emilia, Sect Publ Hlth, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy; [Aburub, Ala' S.] Isra Univ, Queen Alia Int Airport South Capital Amman, Phys Therapy Dept, Fac Allied Med Sci, Amman 11622, Jordan; [Sheinfeld Gorin, Sherri N.] Univ Michigan, Sch Med, Dept Family Med, Ann Arbor, MI 48109 USA; [Kassianos, Angelos P.] Univ Cyprus, Dept Psychol, CY-2109 Nicosia, Cyprus; [Kassianos, Angelos P.] UCL, Dept Appl Hlth Res, London WC1E 7HB, England		Lavoie, KL (通讯作者)，Ctr Integre Univ Sante & Serv Sociaux Nord Ile Mo, Montreal Behav Med Ctr, Res Ctr, Montreal, PQ H4J 1C5, Canada.; Lavoie, KL (通讯作者)，Univ Quebec Montreal UQAM, Dept Psychol, Montreal, PQ C3H 3P8, Canada.	jovana.stojanovic@mail.concordia.ca; vincent.gosselin.boucher@gmail.com; myriam.gagne@unityhealth.to; samir.gupta@unityhealth.to; joyal008@umn.edu; stefania.paduano@unimore.it; ala.aburub@mail.mcgill.ca; sherri.gorin@gmail.com; kassianos.angelos@ucy.ac.cy; paulaabribeiro@gmail.com; simon.bacon@concordia.ca; Lavoie.kim@uqam.ca	Paduano, Stefania/AAB-8183-2020; Gosselin Boucher, Vincent/AAZ-7569-2021	Paduano, Stefania/0000-0003-3640-9177; Gosselin Boucher, Vincent/0000-0002-3030-6022; Joyal-Desmarais, Keven/0000-0003-0657-8367; Aburub, Ala' S./0000-0003-3573-7304; Ribeiro, Paula/0000-0003-0513-5812; Kassianos, Angelos/0000-0001-6428-2623; Gagne, Myriam/0000-0002-0559-5731	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MM1-174903, MS3-173099, SMC-151518]; Canada Research Chairs ProgramCanada Research Chairs [950-232522]; Fonds de recherche du Quebec-sante (FRQ-S) [251618, 34757]; Fonds de recherche du Quebec-Societe et culture (FRQSC) [2019-SE1-252541]; Ministere de l'Economie et de l'Innovation du Quebec [2020-2022-COVID-19-PSOv2a-51754]	iCARE is supported by the Canadian Institutes of Health Research (CIHR: MM1-174903; MS3-173099; SMC-151518), the Canada Research Chairs Program (950-232522, chair holder: Dr. Kim L. Lavoie), the Fonds de recherche du Quebec-sante (FRQ-S: 251618 and 34757), the Fonds de recherche du Quebec-Societe et culture (FRQSC: 2019-SE1-252541), and the Ministere de l'Economie et de l'Innovation du Quebec (2020-2022-COVID-19-PSOv2a-51754). The study sponsors had no role in the design of the database or the data collection.	Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Adam D, 2021, NATURE, V594, P19, DOI 10.1038/d41586-021-01390-4; [Anonymous], 2021, COVID 19 VACCINE JAN; [Anonymous], COVID WORLD VACCINAT; [Anonymous], COVID 19 VACCINE TRA; [Anonymous], 10 THREATS GLOBAL HL; [Anonymous], 2021, ASTRAZENECAS COVID 1; Bacon SL, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-046127; Betsch C, 2013, HEALTH PSYCHOL, V32, P978, DOI 10.1037/a0031590; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Booth A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247461; Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136; Brien S, 2012, VACCINE, V30, P1255, DOI 10.1016/j.vaccine.2011.12.089; Byrne T., 2021, TRENDS PATTERNS PSYC, DOI [10.1101/2021.03.22.21254130, DOI 10.1101/2021.03.22.21254130]; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dryhurst S, 2020, J RISK RES, V23, P994, DOI 10.1080/13669877.2020.1758193; Faasse K, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.551004; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Galasso V, 2020, P NATL ACAD SCI USA, V117, P27285, DOI 10.1073/pnas.2012520117; Global.Health, DAT SCI IN; Green MS, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00458-w; Gustafson PE, 1998, RISK ANAL, V18, P805, DOI 10.1023/B:RIAN.0000005926.03250.c0; iCARE Study, INF MBMC; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Lavoie K.L., 2021, DETERMINANTS ADHEREN, DOI [10.1101/2021.06.09.21258634, DOI 10.1101/2021.06.09.21258634]; Lazarus JV, 2020, J HEALTH COMMUN, V25, P799, DOI 10.1080/10810730.2020.1868630; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Limaye RJ, 2021, HUM VACC IMMUNOTHER, V17, P1662, DOI 10.1080/21645515.2020.1846400; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; McEachan R, 2016, ANN BEHAV MED, V50, P592, DOI 10.1007/s12160-016-9798-4; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rodrigues CMC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01526; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shrotri M, 2021, LANCET GLOB HEALTH, V9, pE590, DOI 10.1016/S2214-109X(21)00043-7; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/S0140-6736(07)61602-X; Wang Wei, 2020, medRxiv, DOI 10.1101/2020.09.29.20200469; Whitehead M, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n376; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	55	12	12	6	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							661	10.3390/vaccines9060661			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SY8HP	34204379	Green Published, gold			2022-04-29	WOS:000666122400001
J	Clemen, R; Bekeschus, S				Clemen, Ramona; Bekeschus, Sander			ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?	VACCINES			English	Article						antigen; cold physical plasma; gas plasma technology; immunogenicity; oxidative post-translational modifications; oxPTM; reactive nitrogen species; reactive oxygen species	MHC CLASS-I; HYPOCHLOROUS ACID; CANCER-IMMUNITY; OVARIAN-CANCER; PLASMA; THERAPY; CELLS; IMMUNOTHERAPY; MEMORY; LYSATE	Cancer is the second leading cause of death worldwide. Today, the critical role of the immune system in tumor control is undisputed. Checkpoint antibody immunotherapy augments existing antitumor T cell activity with durable clinical responses in many tumor entities. Despite the presence of tumor-associated antigens and neoantigens, many patients have an insufficient repertoires of antitumor T cells. Autologous tumor vaccinations aim at alleviating this defect, but clinical success is modest. Loading tumor material into autologous dendritic cells followed by their laboratory expansion and therapeutic vaccination is promising, both conceptually and clinically. However, this process is laborious, time-consuming, costly, and hence less likely to solve the global cancer crisis. Therefore, it is proposed to re-focus on personalized anticancer vaccinations to enhance the immunogenicity of autologous therapeutic tumor vaccines. Recent work re-established the idea of using the alarming agents of the immune system, oxidative modifications, as an intrinsic adjuvant to broaden the antitumor T cell receptor repertoire in cancer patients. The key novelty is the use of gas plasma, a multi-reactive oxygen and nitrogen species-generating technology, for diversifying oxidative protein modifications in a, so far, unparalleled manner. This significant innovation has been successfully used in proof-of-concept studies and awaits broader recognition and implementation to explore its chances and limitations of providing affordable personalized anticancer vaccines in the future. Such multidisciplinary advance is timely, as the current COVID-19 crisis is inexorably reflecting the utmost importance of innovative and effective vaccinations in modern times.	[Clemen, Ramona; Bekeschus, Sander] Leibniz Inst Plasma Sci & Technol INP, ZIK, Felix Hausdorff Str 2, D-17489 Greifswald, Germany		Bekeschus, S (通讯作者)，Leibniz Inst Plasma Sci & Technol INP, ZIK, Felix Hausdorff Str 2, D-17489 Greifswald, Germany.	ramona.clemen@inp-greifswald.de; Bekeschus@inp-greifswald.de			German Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF) [03Z22DN11, 03Z22Di1, 03Z22D511, 03COV06A, 16GW0344K]; European Social Fund (ESF)European Social Fund (ESF); German Research Foundation (DFG)German Research Foundation (DFG) [AOBJ 669606]; Stiftung Tumorforschung Kopf-Hals; Gerhard-Domagk Foundation Greifswald; Comprehensive Cancer Center Mecklenburg-Vorpommern (CCC-MV) seed funding initiative at the Greifswald University Medical Center in Greifswald, Germany; Ministry of Education, Science, and Culture of Mecklenburg-Vorpommern, Germany [ESF/14-BM-A55-0006-18]; Ferdinand-Eisenberger Stiftung [GeN1/FE-20]	The work within the research group ZIK plasmatis "Plasma-Redox-Effects" is funded by the German Federal Ministry of Education and Research (BMBF, grant numbers 03Z22DN11, 03Z22Di1, 03Z22D511, 03COV06A, and 16GW0344K), the European Social Fund (ESF) conjoint with the Ministry of Education, Science, and Culture of Mecklenburg-Vorpommern, Germany (grant number ESF/14-BM-A55-0006-18), the German Research Foundation (DFG, grant number AOBJ 669606), the Stiftung Tumorforschung Kopf-Hals, the Ferdinand-Eisenberger Stiftung (grant number GeN1/FE-20), the Gerhard-Domagk Foundation Greifswald, and the Comprehensive Cancer Center Mecklenburg-Vorpommern (CCC-MV) seed funding initiative at the Greifswald University Medical Center in Greifswald, Germany. The funding sources had no role in the design of this study or its execution, analyses, interpretation of the data, or decision to publish the results.	Arif Z, 2018, INT J BIOL MACROMOL, V106, P1240, DOI 10.1016/j.ijbiomac.2017.08.122; Azoury SC, 2015, CURR CANCER DRUG TAR, V15, P452, DOI 10.2174/156800961506150805145120; Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Baumgartner CK, 2012, J IMMUNOL, V189, P2309, DOI 10.4049/jimmunol.1200453; Bekeschus S, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040323; Bekeschus S, 2020, ADV SCI, V7, DOI 10.1002/advs.201903438; Carta S, 2009, J LEUKOCYTE BIOL, V86, P549, DOI 10.1189/jlb.1008598; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chiang CLL, 2015, VACCINES-BASEL, V3, P344, DOI 10.3390/vaccines3020344; Chiang CLL, 2013, CLIN CANCER RES, V19, P4801, DOI 10.1158/1078-0432.CCR-13-1185; Chiang CLL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028732; Clemen R, 2021, ADV SCI, V8, DOI 10.1002/advs.202003395; Conlon KC, 2019, J INTERF CYTOK RES, V39, P6, DOI 10.1089/jir.2018.0019; CUNNINGHAM TJ, 1969, CANCER-AM CANCER SOC, V24, P932, DOI 10.1002/1097-0142(196911)24:5<932::AID-CNCR2820240510>3.0.CO;2-5; Dalet A, 2011, EUR J IMMUNOL, V41, P39, DOI 10.1002/eji.201040750; De Backer J, 2018, REDOX BIOL, V19, P1, DOI 10.1016/j.redox.2018.07.019; Di Dalmazi G, 2016, AUTOIMMUN HIGHLIGHTS, V7, DOI 10.1007/s13317-016-0083-0; Eming SA, 2017, SCIENCE, V356, P1026, DOI 10.1126/science.aam7928; Enomoto K, 2012, CLIN EXP IMMUNOL, V168, P186, DOI 10.1111/j.1365-2249.2012.04565.x; FINNEY JW, 1960, CANCER RES, V20, P351; Franchina DG, 2018, TRENDS IMMUNOL, V39, P489, DOI 10.1016/j.it.2018.01.005; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Garg AD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aae0105; Ghetie M.-A., 2008, EXPERT OPIN INV DRUG, V5, P309, DOI [10.1517/13543784.5.3.309, DOI 10.1517/13543784.5.3.309]; Gnanaprakasam JNR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01075; Goldinger SM, 2012, EUR J IMMUNOL, V42, P3049, DOI 10.1002/eji.201142361; Graves DB, 2017, IEEE T RADIAT PLASMA, V1, P281, DOI 10.1109/TRPMS.2017.2710880; Griffiths HR, 2008, AUTOIMMUN REV, V7, P544, DOI 10.1016/j.autrev.2008.04.013; Gu YZ, 2020, ACTA PHARMACOL SIN, V41, P959, DOI 10.1038/s41401-020-0415-5; Hanschmann EM, 2013, ANTIOXID REDOX SIGN, V19, P1539, DOI 10.1089/ars.2012.4599; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Hultqvist M, 2007, J IMMUNOL, V179, P1431, DOI 10.4049/jimmunol.179.3.1431; Hultqvist M, 2006, PLOS MED, V3, P1625, DOI 10.1371/journal.pmed.0030348; Jablonowski H, 2018, PHYS CHEM CHEM PHYS, V20, P25387, DOI 10.1039/c8cp02412j; Jablonowski H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30483-w; Kandalaft LE, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-149; Kandalaft LE, 2011, J CLIN ONCOL, V29, P925, DOI 10.1200/JCO.2009.27.2369; Kandalaft LE, 2010, GYNECOL ONCOL, V116, P222, DOI 10.1016/j.ygyno.2009.11.001; Khalili M, 2019, J PHYS D APPL PHYS, V52, DOI 10.1088/1361-6463/ab31c1; Kloetzel PM, 2004, BBA-MOL CELL RES, V1695, P225, DOI 10.1016/j.bbamcr.2004.10.004; Koelzer VH, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-81; Kotsakis A, 2012, ANN ONCOL, V23, P442, DOI 10.1093/annonc/mdr396; Krewing M, 2020, PLASMA PROCESS POLYM, V17, DOI 10.1002/ppap.202000019; Krewing M, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2018.0966; Kurien BT, 2008, AUTOIMMUN REV, V7, P567, DOI 10.1016/j.autrev.2008.04.019; Lackmann JW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25937-0; Lamberti MJ, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030256; Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034; Li LY, 2021, MOLECULES, V26, DOI 10.3390/molecules26010132; Liang BB, 2019, RHEUMATOLOGY, V58, P1623, DOI 10.1093/rheumatology/kez073; Lin A, 2019, ADV SCI, V6, DOI 10.1002/advs.201802062; Lin AG, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1484978; Lluesma SM, 2016, BIOMEDICINES, V4, DOI 10.3390/biomedicines4020010; Mak TW, 2017, IMMUNITY, V46, P675, DOI 10.1016/j.immuni.2017.03.019; Mannering SI, 2019, DIABETOLOGIA, V62, P351, DOI 10.1007/s00125-018-4760-6; Mookerjee A, 2018, BIOIMPACTS, V8, P211, DOI 10.15171/bi.2018.24; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Nemunaitis J, 2006, CANCER GENE THER, V13, P555, DOI 10.1038/sj.cgt.7700922; Nestle FO, 2005, CURR OPIN IMMUNOL, V17, P163, DOI 10.1016/j.coi.2005.02.003; Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119; Nybo T, 2019, REDOX BIOL, V20, P496, DOI 10.1016/j.redox.2018.10.022; Olin MR, 2014, CRIT REV IMMUNOL, V34, P399, DOI 10.1615/CritRevImmunol.2014011577; Ophir E, 2016, BBA-REV CANCER, V1865, P72, DOI 10.1016/j.bbcan.2015.07.004; PIESSENS WF, 1970, CANCER-AM CANCER SOC, V26, P1212, DOI 10.1002/1097-0142(197012)26:6<1212::AID-CNCR2820260606>3.0.CO;2-J; Poschke I, 2011, CANCER IMMUNOL IMMUN, V60, P1161, DOI 10.1007/s00262-011-1012-8; Poulsen TBG, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8060141; Privat-Maldonado A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9062098; Saini R, 2016, CANCERS, V8, DOI 10.3390/cancers8090083; Saleh R, 2020, SEMIN CANCER BIOL, V65, P13, DOI 10.1016/j.semcancer.2019.07.017; Schmidt-Bleker A, 2014, J PHYS D APPL PHYS, V47, DOI 10.1088/0022-3727/47/14/145201; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Schwaab T, 2004, J UROLOGY, V171, P1036, DOI 10.1097/01.ju.0000113275.91953.5d; Sidney J, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0250-3; Stanley CP, 2019, NATURE, V566, P548, DOI 10.1038/s41586-019-0947-3; Stone JD, 2009, IMMUNOLOGY, V126, P165, DOI 10.1111/j.1365-2567.2008.03015.x; Strollo R, 2015, DIABETOLOGIA, V58, P2851, DOI 10.1007/s00125-015-3746-x; Tanyi JL, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5931; Topfer K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/918471; Van den Bossche J, 2016, CELL REP, V17, P684, DOI 10.1016/j.celrep.2016.09.008; Van den Eynde BJ, 2001, CURR OPIN IMMUNOL, V13, P147, DOI 10.1016/S0952-7915(00)00197-7; Vassilaros S, 2013, IMMUNOTHERAPY-UK, V5, P1177, DOI [10.2217/IMT.13.126, 10.2217/imt.13.126]; von Woedtke T, 2019, IN VIVO, V33, P1011, DOI 10.21873/invivo.11570; Wan XX, 2020, NAT IMMUNOL, V21, P455, DOI 10.1038/s41590-020-0623-7; Wang TT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03915-4; Wende K, 2019, BIOL CHEM, V400, P19, DOI 10.1515/hsz-2018-0242; Wenske S, 2020, BIOINTERPHASES, V15, DOI 10.1116/6.0000529; Winter J, 2015, PLASMA SOURCES SCI T, V24, DOI 10.1088/0963-0252/24/6/064001; Winterbourn CC, 1995, TOXICOL LETT, V82-3, P969, DOI 10.1016/0378-4274(95)03532-X; Winterbourn CC, 2013, ANTIOXID REDOX SIGN, V18, P642, DOI 10.1089/ars.2012.4827; Yang ML, 2018, ANTIOXID REDOX SIGN, V29, P1415, DOI 10.1089/ars.2017.7382; Yusupov M, 2018, PLASMA PROCESS POLYM, V15, DOI 10.1002/ppap.201800022; Zhai LJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01185; Zhang H, 2018, IEEE T PLASMA SCI, V46, P2742, DOI 10.1109/TPS.2018.2834624; Zhang LX, 2020, NANO TODAY, V35, DOI 10.1016/j.nantod.2020.100923; Zheng HC, 2017, ONCOTARGET, V8, P59950, DOI 10.18632/oncotarget.19048; Zhou JY, 2019, J CELL MOL MED, V23, P4854, DOI 10.1111/jcmm.14356	97	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							527	10.3390/vaccines9050527			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI2AL	34069708	gold, Green Published			2022-04-29	WOS:000654626600001
J	Forner, M; Canas-Arranz, R; Defaus, S; de Leon, P; Rodriguez-Pulido, M; Ganges, L; Blanco, E; Sobrino, F; Andreu, D				Forner, Mar; Canas-Arranz, Rodrigo; Defaus, Sira; de Leon, Patricia; Rodriguez-Pulido, Miguel; Ganges, Llilianne; Blanco, Esther; Sobrino, Francisco; Andreu, David			Peptide-Based Vaccines: Foot-and-Mouth Disease Virus, a Paradigm in Animal Health	VACCINES			English	Review						epitope-based vaccines; peptide; vaccines; FMDV; veterinary medicine	CLASSICAL SWINE-FEVER; T-CELL EPITOPE; PROTECTIVE IMMUNE-RESPONSE; VIRAL ANTIGENIC SITE; CLASS-I; NONSTRUCTURAL PROTEINS; TRANSLATION INITIATION; STRUCTURAL PROTEINS; WORLD ORGANIZATION; SURFACE-STRUCTURE	Vaccines are considered one of the greatest global health achievements, improving the welfare of society by saving lives and substantially reducing the burden of infectious diseases. However, few vaccines are fully effective, for reasons ranging from intrinsic limitations to more contingent shortcomings related, e.g., to cold chain transport, handling and storage. In this context, subunit vaccines where the essential antigenic traits (but not the entire pathogen) are presented in rationally designed fashion have emerged as an attractive alternative to conventional ones. In particular, this includes the option of fully synthetic peptide vaccines able to mimic well-defined B- and T-cell epitopes from the infectious agent and to induce protection against it. Although, in general, linear peptides have been associated to low immunogenicity and partial protection, there are several strategies to address such issues. In this review, we report the progress towards the development of peptide-based vaccines against foot-and-mouth disease (FMD) a highly transmissible, economically devastating animal disease. Starting from preliminary experiments using single linear B-cell epitopes, recent research has led to more complex and successful second-generation vaccines featuring peptide dendrimers containing multiple copies of B- and T-cell epitopes against FMD virus or classical swine fever virus (CSFV). The usefulness of this strategy to prevent other animal and human diseases is discussed.	[Forner, Mar; Defaus, Sira; Andreu, David] UPF, Dept Ciencies Expt & Salut DCEXS, Barcelona 08003, Spain; [Canas-Arranz, Rodrigo; de Leon, Patricia; Rodriguez-Pulido, Miguel; Sobrino, Francisco] UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain; [Ganges, Llilianne] Inst Agrifood Res & Technol, OIE Reference Lab Class Swine Fever, Ctr Recerca Sanitat Anim CReSA, Barcelona 08193, Spain; [Blanco, Esther] INIA, Ctr Invest Sanidad Anim, Valdeolmos 28130, Spain		Andreu, D (通讯作者)，UPF, Dept Ciencies Expt & Salut DCEXS, Barcelona 08003, Spain.; Sobrino, F (通讯作者)，UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.	fornermar@gmail.com; rcannas@cbm.csic.es; sira.defaus@upf.edu; pdeleon@cbm.csic.es; mrrodriguez@cbm.csic.es; Llilianne.ganges@irta.cat; blanco@inia.es; fsobrino@cbm.csic.es; david.andreu@upf.edu	; Rodriguez Pulido, Miguel/L-7644-2014; Ganges, Llilianne/O-7342-2017; Blanco, Esther/C-1245-2013	Forner, Mar/0000-0002-8547-2394; de Leon, Patricia/0000-0003-2518-2245; Sobrino, Francisco/0000-0003-4968-8291; Defaus, Sira/0000-0002-3106-458X; Rodriguez Pulido, Miguel/0000-0003-2101-8974; Canas-Arranz, Rodrigo/0000-0002-3063-2477; Ganges, Llilianne/0000-0002-8644-3560; Blanco, Esther/0000-0001-8413-4222	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [828774]; Spanish Ministry of Science, Innovation and UniversitiesSpanish Government [AGL2014-48923-C2, AGL2017-84097-C2-2-R, AGL2016-349 76445-R]; Comunidad de Madrid - ECFEDER fundsComunidad de Madrid [S2013/ABI-350 2906-PLATESA, P2018/BAA-4370]; Generalitat de CatalunyaGeneralitat de CatalunyaGeneral Electric [2009SGR492]; Fundacion Ramon Areces; Maria de Maeztu Program of the Spanish Ministry of Science, Innovation and Universities; Spanish Ministry of Science, Innovation and UniversitiesSpanish Government	This research was funded by the European Commission (project H2020-FETOPEN-2018-2019-2020-01 nffi 828774), by the Spanish Ministry of Science, Innovation and Universities, grants AGL2014-48923-C2 and AGL2017-84097-C2-2-R (to D.A. and F.S.), and AGL2016-349 76445-R (to E.B.), as well as by Comunidad de Madrid co-financed ECFEDER funds (S2013/ABI-350 2906-PLATESA and P2018/BAA-4370 to F.S. and E.B.), and by Generalitat de Catalunya (2009SGR492 to D.A.). Work at Centro de Biologia Molecular "Severo Ochoa" and at UPF was supported by Fundacion Ramon Areces and by the Maria de Maeztu Program of the Spanish Ministry of Science, Innovation and Universities, respectively. M.F. and R.C.-A. were holders of a PhD fellowship from the Spanish Ministry of Science, Innovation and Universities.	ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; Bohorquez JA, 2017, VIRUS RES, V238, P8, DOI 10.1016/j.virusres.2017.05.020; Alexandersen S, 2002, MICROBES INFECT, V4, P1099, DOI 10.1016/S1286-4579(02)01634-9; Asfor AS, 2014, J GEN VIROL, V95, P1104, DOI 10.1099/vir.0.060939-0; BAHNEMANN HG, 1973, ZBL VET MED B, V20, P356; Barfoed AM, 2006, ANTIVIR RES, V72, P178, DOI 10.1016/j.antiviral.2006.07.002; Barteling S J, 1988, Adv Biotechnol Processes, V10, P25; BAXT B, 1995, VIROLOGY, V207, P503, DOI 10.1006/viro.1995.1110; BECK E, 1983, NUCLEIC ACIDS RES, V11, P7873, DOI 10.1093/nar/11.22.7873; Benjamin D C, 1991, Int Rev Immunol, V7, P149, DOI 10.3109/08830189109061772; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; Blanco E, 2001, J VIROL, V75, P3164, DOI 10.1128/JVI.75.7.3164-3174.2001; Blanco E, 2000, J VIROL, V74, P4902, DOI 10.1128/JVI.74.10.4902-4907.2000; Blanco E, 2017, FOOT-AND-MOUTH DISEASE VIRUS: CURRENT RESEARCH AND EMERGING TRENDS, P317; Blanco E, 2016, ANTIVIR RES, V129, P74, DOI 10.1016/j.antiviral.2016.03.005; Blanco E, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/475960; Bonbon E, 2020, REV SCI TECH OIE, V39, P193, DOI 10.20506/rst.39.1.3072; Borras E, 1999, J AM CHEM SOC, V121, P11932, DOI 10.1021/ja9917722; Briand JP, 1997, P NATL ACAD SCI USA, V94, P12545, DOI 10.1073/pnas.94.23.12545; Caceres P, 2020, REV SCI TECH OIE, V39, P289, DOI 10.20506/rst.39.1.3082; Canas-Arranz R, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00498; Canas-Arranz R, 2020, TRANSBOUND EMERG DIS, V67, P1614, DOI 10.1111/tbed.13497; Canas-Arranz R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010019; Cao YM, 2016, EXPERT REV VACCINES, V15, P783, DOI 10.1586/14760584.2016.1140042; CAPSTICK PB, 1962, NATURE, V195, P1163, DOI 10.1038/1951163a0; CAPSTICK PB, 1966, EXP CELL RES, V44, P119, DOI 10.1016/0014-4827(66)90418-6; Carrillo C, 2005, J VIROL, V79, P6487, DOI 10.1128/JVI.79.10.6487-6504.2005; CASON J, 1994, J VIROL METHODS, V49, P209, DOI 10.1016/0166-0934(94)90045-0; Chang CY, 2012, VIRUS RES, V163, P190, DOI 10.1016/j.virusres.2011.09.019; Chen YS, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/19/195101; CLARKE BE, 1987, NUCLEIC ACIDS RES, V15, P7067, DOI 10.1093/nar/15.17.7067; Collen T, 1998, VIRUS RES, V56, P125, DOI 10.1016/S0168-1702(98)00035-5; COLLEN T, 1991, J IMMUNOL, V146, P749; Collen T., 1994, Cell-mediated immunity in ruminants., P173; Combadiere B, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030105; Cox SJ, 2003, VACCINE, V21, P1336, DOI 10.1016/S0264-410X(02)00691-6; Cubillos C, 2008, J VIROL, V82, P7223, DOI 10.1128/JVI.00401-08; Cubillos C, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-66; Curry S, 1996, STRUCTURE, V4, P135, DOI 10.1016/S0969-2126(96)00017-2; de Leon P, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.621537; de Leon P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030513; de los Santos T, 2018, CURR OPIN VIROL, V29, P16, DOI 10.1016/j.coviro.2018.02.005; de Oliveira E, 2005, VACCINE, V23, P2647, DOI 10.1016/j.vaccine.2004.10.041; Defaus S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030406; Di Marco M, 2017, CANCER J, V23, P102, DOI 10.1097/PPO.0000000000000252; Diaz-San Segundo F, 2017, VET MICROBIOL, V206, P102, DOI 10.1016/j.vetmic.2016.12.018; DIMARCHI R, 1986, SCIENCE, V232, P639, DOI 10.1126/science.3008333; DOEL TR, 1988, J GEN VIROL, V69, P2403, DOI 10.1099/0022-1317-69-9-2403; DOEL TR, 1992, J VIROL, V66, P2187, DOI 10.1128/JVI.66.4.2187-2194.1992; Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7; Domingo E, 1992, CURR OPIN GENET DEV, V2, P61, DOI 10.1016/S0959-437X(05)80323-5; Dong XN, 2006, VACCINE, V24, P4029, DOI 10.1016/j.vaccine.2006.01.003; Dong XN, 2006, VACCINE, V24, P1906, DOI 10.1016/j.vaccine.2005.10.039; Dong XN, 2002, VACCINE, V21, P167, DOI 10.1016/S0264-410X(02)00466-8; Dong XN, 2006, VACCINE, V24, P426, DOI 10.1016/j.vaccine.2005.08.002; DOPAZO J, 1988, P NATL ACAD SCI USA, V85, P6811, DOI 10.1073/pnas.85.18.6811; Forner M, 2020, J ORG CHEM, V85, P1626, DOI 10.1021/acs.joc.9b02798; Foster M, 1998, VET QUART, V20, pS28; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; Fry EE, 2005, CURR TOP MICROBIOL, V288, P71; Ganges L, 2011, VIRUS RES, V157, P121, DOI 10.1016/j.virusres.2011.02.003; Gao FS, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1742-3; Gao FS, 2018, GENE, V653, P91, DOI 10.1016/j.gene.2018.02.025; Gao FS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068658; Garcia-Briones MM, 2000, VACCINE, V19, P1167, DOI 10.1016/S0264-410X(00)00313-3; Geale DW, 2015, TRANSBOUND EMERG DIS, V62, P388, DOI 10.1111/tbed.12165; Gerner W, 2006, VIRUS RES, V121, P223, DOI 10.1016/j.virusres.2006.05.006; Gershoni JM, 2007, BIODRUGS, V21, P145, DOI 10.2165/00063030-200721030-00002; GLASS EJ, 1995, VACCINE, V13, P225, DOI 10.1016/0264-410X(95)93141-U; GRASMASSE H, 1992, PEPTIDE RES, V5, P211; Guzman E, 2010, J VIROL, V84, P12375, DOI 10.1128/JVI.01545-10; HALABI G, 1995, J IMMUNOL METHODS, V186, P205, DOI 10.1016/0022-1759(95)00144-Y; Heegaard PMH, 2010, BIOCONJUGATE CHEM, V21, P405, DOI 10.1021/bc900290d; Hill TA, 2014, ANGEW CHEM INT EDIT, V53, P13020, DOI 10.1002/anie.201401058; Ji W, 2015, VIRUS RES, V197, P35, DOI 10.1016/j.virusres.2014.12.006; Kitching P, 2007, VACCINE, V25, P5660, DOI 10.1016/j.vaccine.2006.10.052; KITSON JDA, 1990, VIROLOGY, V179, P26, DOI 10.1016/0042-6822(90)90269-W; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; Knowles NJ, 2003, VIRUS RES, V91, P65, DOI 10.1016/S0168-1702(02)00260-5; Kowalczyk W, 2011, J PEPT SCI, V17, P247, DOI 10.1002/psc.1310; Kowalczyk W, 2010, BIOCONJUGATE CHEM, V21, P102, DOI 10.1021/bc9003316; Kunwar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064405; Kwong PD, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101428; Kyte JA, 2011, CLIN CANCER RES, V17, P4568, DOI 10.1158/1078-0432.CCR-11-0184; Lamonaca V, 1999, HEPATOLOGY, V30, P1088, DOI 10.1002/hep.510300435; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LEA S, 1994, STRUCTURE, V2, P123, DOI 10.1016/S0969-2126(00)00014-9; Lee HB, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0648-2; Lennerz V, 2014, CANCER IMMUNOL IMMUN, V63, P381, DOI 10.1007/s00262-013-1516-5; Li GX, 2012, VET MICROBIOL, V156, P200, DOI 10.1016/j.vetmic.2011.10.012; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Lin M, 2000, J VIROL, V74, P11619, DOI 10.1128/JVI.74.24.11619-11625.2000; Liu SG, 2006, J VIROL METHODS, V134, P125, DOI 10.1016/j.jviromet.2005.12.008; Liu TY, 2013, BIOMACROMOLECULES, V14, P2798, DOI 10.1021/bm400626w; Liu W, 2019, APPL MICROBIOL BIOT, V103, P8075, DOI 10.1007/s00253-019-10081-0; Lombard M, 2007, REV SCI TECH OIE, V26, P117, DOI 10.20506/rst.26.1.1733; Mackenzie JS, 2019, TROP MED INFECT DIS, V4, DOI 10.3390/tropicalmed4020088; Mahajan B, 2010, INFECT IMMUN, V78, P4613, DOI 10.1128/IAI.00533-10; Mason PW, 1997, VIROLOGY, V227, P96, DOI 10.1006/viro.1996.8309; Mateu MG, 1998, VIRUS RES, V53, P27, DOI 10.1016/S0168-1702(97)00127-5; Matthias DM, 2007, VACCINE, V25, P3980, DOI 10.1016/j.vaccine.2007.02.052; McCullough KC, 2005, ILAR J, V46, P230, DOI 10.1093/ilar.46.3.230; MCCULLOUGH KC, 1992, J VIROL, V66, P1835, DOI 10.1128/JVI.66.4.1835-1840.1992; MCCULLOUGH KC, 1992, IMMUNOL LETT, V31, P41, DOI 10.1016/0165-2478(92)90008-C; MCCULLOUGH KC, 1988, IMMUNOLOGY, V65, P187; MCCULLOUGH KC, 1986, IMMUNOLOGY, V58, P421; McCullough KC, 2009, VET IMMUNOL IMMUNOP, V128, P7, DOI 10.1016/j.vetimm.2008.10.290; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; Monso M, 2013, BIOCONJUGATE CHEM, V24, P578, DOI 10.1021/bc300515t; Monso M, 2012, ORG BIOMOL CHEM, V10, P3116, DOI 10.1039/c2ob06819b; Monso M, 2011, J PEPT SCI, V17, P24, DOI 10.1002/psc.1292; MORGAN DO, 1990, AM J VET RES, V51, P40; MOWAT GN, 1962, NATURE, V196, P655, DOI 10.1038/196655a0; Niepmann M, 1996, FEBS LETT, V388, P39, DOI 10.1016/0014-5793(96)00509-1; Ning S, 2020, RES VET SCI, V128, P90, DOI 10.1016/j.rvsc.2019.11.002; Jaworski JP, 2011, J VIROL METHODS, V178, P191, DOI 10.1016/j.jviromet.2011.09.011; Pandya M, 2015, IMMUNOGENETICS, V67, P691, DOI 10.1007/s00251-015-0877-7; Parida S, 2009, EXPERT REV VACCINES, V8, P347, DOI 10.1586/14760584.8.3.347; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; Patarroyo ME, 2008, ACCOUNTS CHEM RES, V41, P377, DOI 10.1021/ar700120t; Patch JR, 2011, CLIN VACCINE IMMUNOL, V18, P280, DOI 10.1128/CVI.00417-10; Paul WE, 2013, FUNDAMENTAL IMMUNOLO; Pedersen LE, 2013, ANIM GENET, V44, P251, DOI 10.1111/j.1365-2052.2012.02400.x; Pedersen LE, 2016, VET IMMUNOL IMMUNOP, V181, P62, DOI 10.1016/j.vetimm.2016.07.012; PESSI A, 1991, Parassitologia (Rome), V33, P79; PFAFF E, 1982, EMBO J, V1, P869, DOI 10.1002/j.1460-2075.1982.tb01262.x; Pinilla Clemencia, 2012, Curr Protoc Immunol, VChapter 9, DOI 10.1002/0471142735.im0905s99; Potocnakova L, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6760830; Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224; Ritmahan W, 2020, IMMUNOGENETICS, V72, P109, DOI 10.1007/s00251-019-01134-9; RODRIGUEZ A, 1994, VIROLOGY, V205, P24, DOI 10.1006/viro.1994.1616; Rodriguez LL, 2011, EXPERT REV VACCINES, V10, P377, DOI [10.1586/ERV.11.4, 10.1586/erv.11.4]; Rosa DS, 2010, ARCH IMMUNOL THER EX, V58, P121, DOI 10.1007/s00005-010-0067-0; ROWLANDS DJ, 1983, NATURE, V306, P694, DOI 10.1038/306694a0; Sabatino D, 2020, J MED CHEM, V63, P14184, DOI 10.1021/acs.jmedchem.0c00848; Sadler Kristen, 2002, J Biotechnol, V90, P195; SAIZ JC, 1992, J GEN VIROL, V73, P2601, DOI 10.1099/0022-1317-73-10-2601; Saker L., 2004, GLOBALIZATION INFECT; Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160; Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9; Sidney J, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101418; Sobrino F, 2001, EMBO REP, V2, P459, DOI 10.1093/embo-reports/kve122; Sobrino F, 2001, VET RES, V32, P1, DOI 10.1051/vetres:2001106; Soria I, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3497401; Soria I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185184; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STROHMAIER K, 1982, J GEN VIROL, V59, P295, DOI 10.1099/0022-1317-59-2-295; Summerfield A, 2009, DEV COMP IMMUNOL, V33, P299, DOI 10.1016/j.dci.2008.05.005; Summerfield A, 2009, VET IMMUNOL IMMUNOP, V128, P205, DOI 10.1016/j.vetimm.2008.10.296; Svitek N, 2015, VET IMMUNOL IMMUNOP, V167, P80, DOI 10.1016/j.vetimm.2015.06.007; Taboga O, 1997, J VIROL, V71, P2606, DOI 10.1128/JVI.71.4.2606-2614.1997; Tam J P, 1995, Biomed Pept Proteins Nucleic Acids, V1, P123; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tami C, 2003, J VIROL, V77, P1219, DOI 10.1128/JVI.77.2.1219-1226.2003; Tarradas J, 2011, VACCINE, V29, P4422, DOI 10.1016/j.vaccine.2011.03.095; THOMAS AAM, 1988, J VIROL, V62, P2782, DOI 10.1128/JVI.62.8.2782-2789.1988; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Tsuji M, 2001, MOL IMMUNOL, V38, P433, DOI 10.1016/S0161-5890(01)00079-7; TUCHSCHERER G, 1995, J BIOTECHNOL, V41, P197, DOI 10.1016/0168-1656(95)00010-N; Uttenthal A, 2010, EXPERT REV VACCINES, V9, P73, DOI 10.1586/ERV.09.130; Valero ML, 2000, J MOL RECOGNIT, V13, P5; Van Regenmortel MHV, 2009, METHODS MOL BIOL, V524, P3, DOI 10.1007/978-1-59745-450-6_1; VANLIEROP MJC, 1994, J GEN VIROL, V75, P2937, DOI 10.1099/0022-1317-75-11-2937; Vanniasinkam T, 2018, METHODS MOL BIOL, V1785, P121, DOI 10.1007/978-1-4939-7841-0_8; Villen J, 2004, VACCINE, V22, P3523, DOI 10.1016/j.vaccine.2004.05.006; Villen J, 2002, CHEMBIOCHEM, V3, P175, DOI 10.1002/1439-7633(20020301)3:2/3<175::AID-CBIC175>3.0.CO;2-W; Villen J, 2006, CHEM BIOL, V13, P815, DOI 10.1016/j.chembiol.2006.06.001; Weber CA, 2009, ADV DRUG DELIVER REV, V61, P965, DOI 10.1016/j.addr.2009.07.001; WILD TF, 1969, J GEN VIROL, V4, P313, DOI 10.1099/0022-1317-4-3-313; Zhang LF, 2018, CELL MOL IMMUNOL, V15, P182, DOI 10.1038/cmi.2017.92; Zhang Q, 2002, ACTA VIROL, V46, P1	173	3	3	9	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							477	10.3390/vaccines9050477			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1LD	34066901	Green Published, gold			2022-04-29	WOS:000654586700001
J	Kim, CJ; Bae, JY; Jun, KI; Chung, HS; Kim, A; Kim, J; Son, HJ; Lee, M; Choi, HJ				Kim, Chung-Jong; Bae, Ji-Yun; Jun, Kang-Il; Chung, Hae-Sun; Kim, Aeyeon; Kim, Jihee; Son, Hee-Jung; Lee, Miae; Choi, Hee-Jung			Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination	VACCINES			English	Article						measles; health personnel; vaccination	REPUBLIC-OF-KOREA; IMMUNOGLOBULIN-G; SEROLOGICAL SURVEY; YOUNG-ADULTS; MMR VACCINE; SEROPREVALENCE; MUMPS; OUTBREAK; RUBELLA; SUSCEPTIBILITY	We aimed to identify the presence of the measles IgG antibody (mIgG-Ab) in healthcare personnel and finding out who needs the measles vaccination. The history of measles vaccination was obtained from the national vaccine registry. A baseline mIgG-Ab test was performed, and the measles vaccine was administered to participants who tested negative or equivocal for mIgG-Abs. During the study, 2885 (87.3%) of the 3303 employees were tested for measles serostatus. The baseline seropositivity rate for mIgG-Abs was 91.9%. Among the 234 seronegative cases, 82.9% were born after 1985. The seroprevalence rate was lower in those who received the measles-mumps-rubella (MMR) vaccine >10 years before the testing time, especially if they were born after 1985 and if there was only one previous record of vaccination. Among the 234 seronegative cases, MMR vaccination was administered in 174 cases, of which serostatus was evaluated in 146 cases. After the first dose, positive seroconversion was achieved in 126 participants (86.3%). After a second dose, 15 achieved (75.0%) positive seroconversion. In healthcare personnel born after the period when measles incidence significantly decreased, it may be necessary to reassess their immune status for measles if more than 10 years have elapsed since the last vaccination.	[Kim, Chung-Jong; Jun, Kang-Il] Ewha Womans Univ, Dept Internal Med, Seoul Hosp, Seoul 07804, South Korea; [Kim, Chung-Jong; Bae, Ji-Yun; Jun, Kang-Il; Chung, Hae-Sun; Lee, Miae; Choi, Hee-Jung] Ewha Educ & Res Ctr Infect, Seoul 07985, South Korea; [Bae, Ji-Yun; Choi, Hee-Jung] Ewha Womans Univ, Dept Internal Med, Mokdong Hosp, Seoul 07985, South Korea; [Chung, Hae-Sun] Ewha Womans Univ, Dept Lab Med, Seoul Hosp, Seoul 07804, South Korea; [Kim, Aeyeon; Kim, Jihee] Ewha Womans Univ, Off Infect Control, Seoul Hosp, Seoul 07804, South Korea; [Son, Hee-Jung] Ewha Womans Univ, Off Infect Control, Mokdong Hosp, Seoul 07985, South Korea; [Lee, Miae] Ewha Womans Univ, Dept Lab Med, Mokdong Hosp, Seoul 07985, South Korea		Kim, CJ (通讯作者)，Ewha Womans Univ, Dept Internal Med, Seoul Hosp, Seoul 07804, South Korea.; Kim, CJ (通讯作者)，Ewha Educ & Res Ctr Infect, Seoul 07985, South Korea.	cj.kim.id@gmail.com; jiyunbae@gmail.com; jki342@gmail.com; sunny0521.chung@ewha.ac.kr; 41808s@eumc.ac.kr; 41121s@eumc.ac.kr; 40757@eumc.ac.kr; miae@ewha.ac.kr; heechoi@ewha.ac.kr		Jun, Kang Il/0000-0002-6019-1238; Bae, Ji Yun/0000-0002-7475-4564; Chung, Hae-Sun/0000-0001-6382-4099	Ewha Education and Research Center for Infection Research Fund [20190052]	This work was supported by grant no. 20190052 from Ewha Education and Research Center for Infection Research Fund.	Antona D, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/s0950268819000050, 10.1017/S0950268819000050]; Bester JC, 2016, JAMA PEDIATR, V170, P1209, DOI 10.1001/jamapediatrics.2016.1787; Boulton ML, 2016, VACCINE, V34, P3037, DOI 10.1016/j.vaccine.2016.04.094; Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309; Chang HH, 2019, INFECT CHEMOTHER, V51, P54, DOI 10.3947/ic.2019.51.1.54; Choe YJ, 2017, J KOREAN MED SCI, V32, P1876, DOI 10.3346/jkms.2017.32.11.1876; Choe YJ, 2017, J MED VIROL, V89, P1528, DOI 10.1002/jmv.24808; Emek M, 2017, PUBLIC HEALTH, V147, P51, DOI 10.1016/j.puhe.2017.01.026; Estofolete CF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62151-3; Fiebelkorn AP, 2016, J INFECT DIS, V213, P1115, DOI 10.1093/infdis/jiv555; Fraser B, 2018, LANCET, V392, P373, DOI 10.1016/S0140-6736(18)31727-6; Fu CX, 2010, VACCINE, V28, P8219, DOI 10.1016/j.vaccine.2010.07.071; Guerra FM, 2017, LANCET INFECT DIS, V17, pE420, DOI 10.1016/S1473-3099(17)30307-9; Hens N, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.1.20998; 차혜경, 2013, Child Health Nursing Research, V19, P216, DOI 10.4094/chnr.2013.19.3.216; Jung J, 2019, INFECT CHEMOTHER, V51, P58, DOI 10.3947/ic.2019.51.1.58; Kang HJ, 2017, VACCINE, V35, P4126, DOI 10.1016/j.vaccine.2017.06.058; Kang JH, 2020, INFECT CHEMOTHER, V52, P113, DOI 10.3947/ic.2020.52.1.113; Khetsuriani N, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819002048; Kontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568; Kwak YG, 2020, INFECT CHEMOTHER, V52, P93, DOI 10.3947/ic.2020.52.1.93; Le NK, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5020015; Lebo EJ, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv006; Levine H, 2015, HUM VACC IMMUNOTHER, V11, P1400, DOI 10.1080/21645515.2015.1032489; Diaz-Ortega JL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73618-8; Mercader S, 2012, CLIN VACCINE IMMUNOL, V19, P1810, DOI 10.1128/CVI.00406-12; Moss WJ, 2017, LANCET, V390, P2490, DOI 10.1016/S0140-6736(17)31463-0; Odemis I, 2019, REV ESP QUIM, V32, P525; Park JW, 2019, INFECT CHEMOTHER, V51, P305, DOI 10.3947/ic.2019.51.3.305; Park SH, 2017, ASIAN PAC J TROP MED, V10, P67, DOI 10.1016/j.apjtm.2016.12.003; Pei L, 2017, VACCINE, V35, P7250, DOI 10.1016/j.vaccine.2017.11.012; Shefer Abigail, 2011, Morbidity and Mortality Weekly Report, V60, P1; Smetana J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170257; Vandermeulen C, 2007, VACCINE, V25, P6672, DOI 10.1016/j.vaccine.2007.07.008; Yang LJ, 2020, CURR OPIN VIROL, V40, P48, DOI 10.1016/j.coviro.2020.05.009; Zhang ZY, 2016, CAN J INFECT DIS MED, V2016, DOI 10.1155/2016/1742530	36	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							501	10.3390/vaccines9050501			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1XQ	34066145	gold, Green Published			2022-04-29	WOS:000654619300001
J	Park, JH; Lee, HK				Park, Jang Hyun; Lee, Heung Kyu			Delivery Routes for COVID-19 Vaccines	VACCINES			English	Review						COVID-19; SARS-CoV-2; vaccine; mucosal vaccine	MEMORY T-CELLS; SARS-COV-2 INFECTION; PROTECTIVE EFFICACY; INFLUENZA VACCINE; IMMUNE-RESPONSE; IMMUNOGENICITY; SAFETY; TRAFFICKING; ACTIVATION; ANTIBODIES	The novel coronavirus, SARS-CoV-2, which causes COVID-19, has resulted in a pandemic with millions of deaths. To eradicate SARS-CoV-2 and prevent further infections, many vaccine candidates have been developed. These vaccines include not only traditional subunit vaccines and attenuated or inactivated viral vaccines but also nucleic acid and viral vector vaccines. In contrast to the diversity in the platform technology, the delivery of vaccines is limited to intramuscular vaccination. Although intramuscular vaccination is safe and effective, mucosal vaccination could improve the local immune responses that block the spread of pathogens. However, a lack of understanding of mucosal immunity combined with the urgent need for a COVID-19 vaccine has resulted in only intramuscular vaccinations. In this review, we summarize the history of vaccines, current progress in COVID-19 vaccine technology, and the status of intranasal COVID-19 vaccines. Future research should determine the most effective route for vaccine delivery based on the platform and determine the mechanisms that underlie the efficacy of different delivery routes.	[Park, Jang Hyun; Lee, Heung Kyu] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon 34141, South Korea		Lee, HK (通讯作者)，Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon 34141, South Korea.	janghyun.park@kaist.ac.kr; heungkyu.lee@kaist.ac.kr		Lee, Heung Kyu/0000-0002-3977-1510	Mobile Clinic Module Project - KAIST; 2020 Joint Research Project of Institutes of Science and Technology; National Research Foundation of KoreaNational Research Foundation of Korea [NRF-2021M3A9D3026428]	This work was supported by Mobile Clinic Module Project funded by KAIST and the 2020 Joint Research Project of Institutes of Science and Technology. This work was also supported by National Research Foundation of Korea (NRF-2021M3A9D3026428).	Ackerman ME, 2018, NAT MED, V24, P1590, DOI 10.1038/s41591-018-0161-0; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Banerjee AK, 2020, CELL, V183, P1325, DOI 10.1016/j.cell.2020.10.004; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Bost P, 2020, CELL, V181, P1475, DOI 10.1016/j.cell.2020.05.006; Bowie AG, 2008, NAT REV IMMUNOL, V8, P911, DOI 10.1038/nri2436; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6; Chu LRC, 2021, VACCINE, V39, P2791, DOI 10.1016/j.vaccine.2021.02.007; Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4; Cook IF, 2008, HUM VACCINES, V4, P67, DOI 10.4161/hv.4.1.4747; Cook IF, 2006, VACCINE, V24, P2395, DOI 10.1016/j.vaccine.2005.11.057; Davies B, 2017, J IMMUNOL, V198, P2233, DOI 10.4049/jimmunol.1601367; de Assis RR, 2021, NAT COMMUN, V12, DOI [10.1038/s41467-020-20095-2, 10.1101/2020.04.15.043364]; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Du YY, 2021, VACCINE, V39, P2287, DOI 10.1016/j.vaccine.2021.03.006; Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Feng LQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18077-5; Flament H, 2021, EUR J IMMUNOL, V51, P298, DOI 10.1038/s41590-021-00870-z; Furuyama Wakako, 2021, bioRxiv, DOI 10.1101/2021.01.19.426885; Gallo O, 2021, MUCOSAL IMMUNOL, V14, P305, DOI 10.1038/s41385-020-00359-2; Ganneru B, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102298; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Hikmet F, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209610; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Iwasaki A, 2020, NAT REV IMMUNOL, V20, P339, DOI 10.1038/s41577-020-0321-6; Joag V, 2021, J IMMUNOL, V206, P931, DOI 10.4049/jimmunol.2001400; Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kim CW, 2021, IMMUNE NETW, V21, DOI 10.4110/in.2021.21.e10; Kim E, 2021, EUR J IMMUNOL, V51, P1774, DOI 10.1002/eji.202149167; Ku MW, 2021, CELL HOST MICROBE, V29, P236, DOI 10.1016/j.chom.2020.12.010; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lei L, 2020, J CELL MOL MED, V24, P11603, DOI 10.1111/jcmm.15620; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251; Mark A, 1999, VACCINE, V17, P2067, DOI 10.1016/S0264-410X(98)00410-1; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Mathew Divij, 2020, bioRxiv, DOI 10.1101/2020.05.20.106401; Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]; McClain MT, 2013, J CLIN VIROL, V58, P689, DOI 10.1016/j.jcv.2013.09.015; Mestecky J, 2007, J IMMUNOL, V179, P5633, DOI 10.4049/jimmunol.179.9.5633; Mohandas S, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102054; Mulchandani R, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13429; Oh JE, 2019, NATURE, V571, P122, DOI 10.1038/s41586-019-1285-1; Okamura S., 2021, LIVE ATTENUATED SARS, DOI [10.1101/2021.02.15.430863, DOI 10.1101/2021.02.15.430863]; Ols S, 2020, CELL REP, V30, P3964, DOI 10.1016/j.celrep.2020.02.111; Palacios R, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04775-4; Park JH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02145; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Qu D, 2005, VACCINE, V23, P924, DOI 10.1016/j.vaccine.2004.07.031; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Ravichandran S, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf2467; Renegar KB, 2004, J IMMUNOL, V173, P1978, DOI 10.4049/jimmunol.173.3.1978; Rha MS, 2021, IMMUNITY, V54, P44, DOI 10.1016/j.immuni.2020.12.002; Rota PA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.49; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Salamanna F, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.594495; Schnyder JL, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101868; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Schultze JL, 2021, CELL, V184, P1671, DOI 10.1016/j.cell.2021.02.029; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Tebas P, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100689; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; van Doremalen Neeltje, 2021, bioRxiv, DOI 10.1101/2021.01.09.426058; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Wakim LM, 2008, SCIENCE, V319, P198, DOI 10.1126/science.1151869; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yadav PD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21639-w; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Yu HQ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01526-2020; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006; Zhou DY, 2021, CELL HOST MICROBE, V29, P551, DOI 10.1016/j.chom.2021.02.019; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	98	7	7	49	103	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							524	10.3390/vaccines9050524			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1ST	34069359	gold, Green Published			2022-04-29	WOS:000654606600001
J	Starostina, EV; Sharabrin, SV; Antropov, DN; Stepanov, GA; Shevelev, GY; Lemza, AE; Rudometov, AP; Borgoyakova, MB; Rudometova, NB; Marchenko, VY; Danilchenko, NV; Chikaev, AN; Bazhan, SI; Ilyichev, AA; Karpenko, LI				Starostina, Ekaterina V.; Sharabrin, Sergei V.; Antropov, Denis N.; Stepanov, Grigory A.; Shevelev, Georgiy Yu.; Lemza, Anna E.; Rudometov, Andrey P.; Borgoyakova, Mariya B.; Rudometova, Nadezhda B.; Marchenko, Vasiliy Yu.; Danilchenko, Natalia V.; Chikaev, Anton N.; Bazhan, Sergei I.; Ilyichev, Alexander A.; Karpenko, Larisa I.			Construction and Immunogenicity of Modified mRNA-Vaccine Variants Encoding Influenza Virus Antigens	VACCINES			English	Article						mRNA-vaccine; influenza virus; mRNA modification; Anti-Reverse Cap Analog; pseudouridine; N6-methyladenosine; 5-methylcytosine	DNA; TRANSLATION	Nucleic acid-based influenza vaccines are a promising platform that have recently and rapidly developed. We previously demonstrated the immunogenicity of DNA vaccines encoding artificial immunogens AgH1, AgH3, and AgM2, which contained conserved fragments of the hemagglutinin stem of two subtypes of influenza A-H1N1 and H3N2-and conserved protein M2. Thus, the aim of this study was to design and characterize modified mRNA obtained using the above plasmid DNA vaccines as a template. To select the most promising protocol for creating highly immunogenic mRNA vaccines, we performed a comparative analysis of mRNA modifications aimed at increasing its translational activity and decreasing toxicity. We used mRNA encoding a green fluorescent protein (GFP) as a model. Eight mRNA-GFP variants with different modifications (M0-M7) were obtained using the classic cap(1), its chemical analog ARCA (anti-reverse cap analog), pseudouridine (psi), N6-methyladenosine (m6A), and 5-methylcytosine (m5C) in different ratios. Modifications M2, M6, and M7, which provided the most intensive fluorescence of transfected HEK293FT cells were used for template synthesis when mRNA encoded influenza immunogens AgH1, AgH3, and AgM2. Virus specific antibodies were registered in groups of animals immunized with a mix of mRNAs encoding AgH1, AgH3, and AgM2, which contained either ARCA (with inclusions of 100% psi and 20% m6A (M6)) or a classic cap(1) (with 100% substitution of U with psi (M7)). M6 modification was the least toxic when compared with other mRNA variants. M6 and M7 RNA modifications can therefore be considered as promising protocols for designing mRNA vaccines.	[Starostina, Ekaterina V.; Sharabrin, Sergei V.; Rudometov, Andrey P.; Borgoyakova, Mariya B.; Rudometova, Nadezhda B.; Marchenko, Vasiliy Yu.; Danilchenko, Natalia V.; Bazhan, Sergei I.; Ilyichev, Alexander A.; Karpenko, Larisa I.] State Res Ctr Virol & Biotechnol Vector, Novosibirsk 630559, Russia; [Antropov, Denis N.; Stepanov, Grigory A.; Shevelev, Georgiy Yu.; Lemza, Anna E.] Russian Acad Sci, Siberian Branch, Inst Chem Biol & Fundamental Med, Novosibirsk 630090, Russia; [Chikaev, Anton N.] Russian Acad Sci, Siberian Branch, Inst Mol & Cellular Biol, Novosibirsk 630090, Russia		Starostina, EV (通讯作者)，State Res Ctr Virol & Biotechnol Vector, Novosibirsk 630559, Russia.	star_ekaterina@rambler.ru; sharabrin.sv@gmail.com; antr0povdn@yandex.ru; stepanovga@niboch.nsc.ru; metatezis@gmail.com; lemza.ae@yandex.ru; rudometov_ap@vector.nsc.ru; borgoyakova_mb@vector.nsc.ru; andreeva_nb@vector.nsc.ru; marchenko_vyu@vector.nsc.ru; danilchenko_nv@vector.nsc.ru; chikaev@mcb.nsc.ru; bazhan@vector.nsc.ru; ilyichev@vector.nsc.ru; lkarpenko@ngs.ru	Antropov, Denis/ABE-1675-2021; Shevelev, Georgiy/P-2774-2019; Stepanov, Grigory A/V-2016-2019; Chikaev, Anton/A-8117-2014	Stepanov, Grigory A/0000-0003-3393-3192; Chikaev, Anton/0000-0001-5423-3457; Sharabrin, Sergei/0000-0003-0664-3587; Karpenko, Larisa/0000-0003-4365-8809; Borgoyakova, Mariya/0000-0002-0768-1561; Starostina, Ekaterina/0000-0002-1733-9524	State Budget Program of ICBFM SB RAS [0245-2019-0001]	The study was conducted under the state assignment of FBRI SRC VB "Vector", Rospotrebnadzor. The work (strategy development and synthesis of mRNA with various modifications) was partially supported by the State Budget Program of ICBFM SB RAS (0245-2019-0001).	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Bazhan S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030448; Bazhan SI, 2022, J BIOMOL STRUCT DYN, V40, P3196, DOI 10.1080/07391102.2020.1845978; Bohnsack KE, 2019, GENES-BASEL, V10, DOI 10.3390/genes10020102; Corder BN, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101186; Dalpke AH, 2012, RNA BIOL, V9, P828, DOI 10.4161/rna.20206; Du RK, 2021, VIROL SIN, V36, P13, DOI 10.1007/s12250-020-00283-6; Durbin AF, 2016, MBIO, V7, DOI 10.1128/mBio.00833-16; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Ilyichev AA, 2020, VAVILOVSKII ZH GENET, V24, P802, DOI 10.18699/VJ20.676; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Karpenko LI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020076; Kumar A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00600; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Mallajosyula VVA, 2014, P NATL ACAD SCI USA, V111, pE2514, DOI 10.1073/pnas.1402766111; Mao YH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13317-9; ModernaTX Inc., SAF TOL IMM VAL 5064; Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Ru WX, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200091; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269; Slobodin B, 2017, CELL, V169, P326, DOI 10.1016/j.cell.2017.03.031; Squires RB, 2012, INFLUENZA OTHER RESP, V6, P404, DOI 10.1111/j.1750-2659.2011.00331.x; Stepanov G, 2018, GENES-BASEL, V9, DOI 10.3390/genes9110531; Svitkin YV, 2017, NUCLEIC ACIDS RES, V45, P6023, DOI 10.1093/nar/gkx135; Tsilibary EP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010047; van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Wang WL, 2015, CLIN VACCINE IMMUNOL, V22, P618, DOI 10.1128/CVI.00091-15; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Wei CJ, 2020, NAT REV DRUG DISCOV, V19, P239, DOI 10.1038/s41573-019-0056-x; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594	35	4	4	11	23	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							452	10.3390/vaccines9050452			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1LQ	34063689	Green Published			2022-04-29	WOS:000654588000001
J	Adam, L; Rosenbaum, P; Bonduelle, O; Combadiere, B				Adam, Lucille; Rosenbaum, Pierre; Bonduelle, Olivia; Combadiere, Behazine			Strategies for Immunomonitoring after Vaccination and during Infection	VACCINES			English	Review						immune responses; vaccination; systems biology; immunomonitoring; COVID-19	YELLOW-FEVER VACCINE; FOLLICULAR HELPER-CELLS; ANTIBODY-RESPONSES; SYSTEMS BIOLOGY; IMMUNE-RESPONSE; PLASMODIUM-FALCIPARUM; SEASONAL INFLUENZA; RNA-SEQ; PROTECTION; IMMUNOLOGY	Immunomonitoring is the study of an individual's immune responses over the course of vaccination or infection. In the infectious context, exploring the innate and adaptive immune responses will help to investigate their contribution to viral control or toxicity. After vaccination, immunomonitoring of the correlate(s) and surrogate(s) of protection is a major asset for measuring vaccine immune efficacy. Conventional immunomonitoring methods include antibody-based technologies that are easy to use. However, promising sensitive high-throughput technologies allowed the emergence of holistic approaches. This raises the question of data integration methods and tools. These approaches allow us to increase our knowledge on immune mechanisms as well as the identification of key effectors of the immune response. However, the depiction of relevant findings requires a well-rounded consideration beforehand about the hypotheses, conception, organization and objectives of the immunomonitoring. Therefore, well-standardized and comprehensive studies fuel insight to design more efficient, rationale-based vaccines and therapeutics to fight against infectious diseases. Hence, we will illustrate this review with examples of the immunomonitoring approaches used during vaccination and the COVID-19 pandemic.	[Adam, Lucille; Rosenbaum, Pierre; Bonduelle, Olivia; Combadiere, Behazine] Sorbonne Univ, INSERM, Ctr Immunol & Malad Infect, F-75013 Paris, France		Combadiere, B (通讯作者)，Sorbonne Univ, INSERM, Ctr Immunol & Malad Infect, F-75013 Paris, France.	lucille.adam@inserm.fr; pierosenbaum@gmail.com; olivia.bonduelle@sorbonne-universite.fr; behazine.combadiere@inserm.fr	Combadiere, Behazine/S-8054-2019	Combadiere, Behazine/0000-0002-2353-4406	European UnionEuropean Commission [681137]	Authors have received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 681137.	Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15; Addetia A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02107-20; Amu S, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0076-x; [Anonymous], 2013, CORR VACC IND PROT M; Barouch DH, 2010, ANNU REV MED, V61, P153, DOI 10.1146/annurev.med.042508.093728; Bender S, 2020, BLOOD, V135, P1750, DOI 10.1182/blood.2019004197; Benichou J, 2012, IMMUNOLOGY, V135, P183, DOI 10.1111/j.1365-2567.2011.03527.x; Bhatt K, 2015, CLIN VACCINE IMMUNOL, V22, P258, DOI 10.1128/CVI.00721-14; Blazevic V, 2006, AIDS RES HUM RETROV, V22, P667, DOI 10.1089/aid.2006.22.667; Bloom DE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00549; Bonduelle O., 2020, LOX 1 IMMATURE NEUTR, p2020.09.15.293100, DOI [10.1101/2020.09.15.293100, DOI 10.1101/2020.09.15.293100]; Boyle MJ, 2015, IMMUNITY, V42, P580, DOI 10.1016/j.immuni.2015.02.012; Bruel T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10844; Cherry JD, 1998, VACCINE, V16, P1901, DOI 10.1016/S0264-410X(98)00226-6; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dalloul I, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007721; Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318; Danilova E, 2006, CLIN VACCINE IMMUNOL, V13, P627, DOI 10.1128/CVI.00026-06; Davis MM, 2017, NAT IMMUNOL, V18, P725, DOI 10.1038/ni.3768; De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4; De Groot AS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00442; Demberg T, 2012, J VIROL, V86, P12591, DOI 10.1128/JVI.00298-12; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Duffy D, 2018, TRENDS BIOTECHNOL, V36, P1107, DOI 10.1016/j.tibtech.2018.06.002; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Furman D, 2015, VACCINE, V33, P5271, DOI 10.1016/j.vaccine.2015.06.117; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292; Germain RN, 2011, ANNU REV IMMUNOL, V29, P527, DOI 10.1146/annurev-immunol-030409-101317; Glennie MJ, 2007, MOL IMMUNOL, V44, P3823, DOI 10.1016/j.molimm.2007.06.151; Goncalves E, 2019, J CLIN INVEST, V129, P1960, DOI 10.1172/JCI125372; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Hannoun C, 2004, VIRUS RES, V103, P133, DOI 10.1016/j.virusres.2004.02.025; Havenar-Daughton C, 2016, J IMMUNOL, V197, P994, DOI 10.4049/jimmunol.1600320; Herati RS, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag2152; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Huang DB, 2004, J INFECTION, V49, P179, DOI 10.1016/j.jinf.2004.05.018; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; KAYHTY H, 1994, BIOLOGICALS, V22, P397, DOI 10.1006/biol.1994.1062; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kreer C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010013; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Le Lann L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68468-3; Lee LH, 2003, VACCINE, V21, P2190, DOI 10.1016/S0264-410X(03)00025-2; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lynn DJ, 2018, J LEUKOCYTE BIOL, V103, P225, DOI 10.1189/jlb.5MR0617-216R; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Mair F, 2016, EUR J IMMUNOL, V46, P34, DOI 10.1002/eji.201545774; Martinon F, 2009, HUM GENE THER, V20, P1291, DOI 10.1089/hum.2009.044; Maslanka SE, 1998, INFECT IMMUN, V66, P2453, DOI 10.1128/IAI.66.6.2453-2459.1998; Mathian A, 2019, ARTHRITIS RHEUMATOL, V71, P756, DOI 10.1002/art.40792; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; Morou A, 2019, NAT IMMUNOL, V20, P1059, DOI 10.1038/s41590-019-0418-x; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0; Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067; Neubauer JC, 2017, CYTOTECHNOLOGY, V69, P57, DOI 10.1007/s10616-016-0037-4; Neumann B, 2015, J LEUKOCYTE BIOL, V97, P19, DOI 10.1189/jlb.1HI0514-243R; Niewold P, 2020, CYTOM PART A, V97, P1165, DOI 10.1002/cyto.a.24211; Noe A, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8624963; Nolan John P, 2013, Curr Protoc Cytom, VChapter 1, DOI 10.1002/0471142956.cy0127s63; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Palgen JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21222-2; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Peeples L, 2020, P NATL ACAD SCI USA, V117, P8218, DOI 10.1073/pnas.2005456117; Pejoski D, 2016, J IMMUNOL, V196, P4814, DOI 10.4049/jimmunol.1502005; Plotkin SA, 2013, CLIN INFECT DIS, V56, P1458, DOI 10.1093/cid/cit048; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Poland GA, 2008, EXPERT OPIN BIOL TH, V8, P1659, DOI 10.1517/14712598.8.11.1659 ; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Querec T, 2006, J EXP MED, V203, P413, DOI 10.1084/jem.20051720; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Rajasekaran N, 2015, IMMUNOTARGETS THER, V4, P91, DOI 10.2147/ITT.S61292; Rappuoli R, 2002, SCIENCE, V297, P937, DOI 10.1126/science.1075173; Rappuoli R, 2019, J EXP MED, V216, P7, DOI 10.1084/jem.20182160; Rappuoli R, 2011, NATURE, V473, P463, DOI 10.1038/nature10124; Ravindran R, 2014, SCIENCE, V343, P313, DOI 10.1126/science.1246829; Reeves PM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69327-x; Sable SB, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00100-19; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119; Silvin A, 2020, CELL, V182, P1401, DOI 10.1016/j.cell.2020.08.002; Smith KA, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00021; Smith SG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184391; Sonobe MH, 2007, BRAZ J MED BIOL RES, V40, P69, DOI 10.1590/S0100-879X2007000100009; Stuart T, 2019, NAT REV GENET, V20, P257, DOI 10.1038/s41576-019-0093-7; Svensson V, 2018, NAT PROTOC, V13, P599, DOI 10.1038/nprot.2017.149; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tang FC, 2009, NAT METHODS, V6, P377, DOI [10.1038/NMETH.1315, 10.1038/nmeth.1315]; Tomaras GD, 2017, IMMUNOL REV, V275, P245, DOI 10.1111/imr.12514; Valmaseda A, 2018, CLIN INFECT DIS, V66, P586, DOI 10.1093/cid/cix837; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Ward AB, 2020, CURR OPIN IMMUNOL, V65, P50, DOI 10.1016/j.coi.2020.03.013; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; ZHAORI G, 1988, J INFECT DIS, V158, P160, DOI 10.1093/infdis/158.1.160; Zhong Z, 2019, CLIN EXP IMMUNOL, V195, P139, DOI 10.1111/cei.13234; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	109	3	3	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							365	10.3390/vaccines9040365			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4MT	33918841	Green Published, gold			2022-04-29	WOS:000643755800001
J	Benis, A; Seidmann, A; Ashkenazi, S				Benis, Arriel; Seidmann, Abraham; Ashkenazi, Shai			Reasons for Taking the COVID-19 Vaccine by US Social Media Users	VACCINES			English	Article						coronavirus; Sars-Cov-2; social media; online social networking; social factors; immunization programs; vaccination; vaccination refusal; vaccination coverage; vaccination hesitancy; health communication; health policy	HESITANCY	Political and public health leaders promoting COVID-19 vaccination should identify the most relevant criteria driving the vaccination decision. Social media is increasingly used as a source of vaccination data and as a powerful communication tool to increase vaccination. In December 2020, we performed a cross-sectional social media-based survey addressing personal sentiments toward COVID-19 vaccination in the USA. Our primary research objective is to identify socio-demographic characteristics and the reasons for the 1644 survey participants' attitudes regarding vaccination. We present clear evidence that, contrary to the prevailing public perceptions, young audiences using social media have mostly a positive attitude towards COVID-19 vaccination (81.5%). These younger individuals want to protect their families and their relatives (96.7%); they see vaccination as an act of civic responsibility (91.9%) and express strong confidence in their healthcare providers (87.7%). Another critical factor is the younger population's fear of personal COVID-19 infection (88.2%); moreover, the greater the number of children the participants have, the greater is their intent to get the COVID-19 vaccine. These results enable a practical public-messaging pathway to reinforce vaccination campaigns addressing the younger population.	[Benis, Arriel] Holon Inst Technol, Fac Ind Engn & Technol Management, IL-5810201 Holon, Israel; [Benis, Arriel] Holon Inst Technol, Fac Digital Technol Med, IL-5810201 Holon, Israel; [Seidmann, Abraham] Boston Univ, Questrom Business Sch, Dept Informat Syst, Boston, MA 02215 USA; [Seidmann, Abraham] Boston Univ, Digital Business Inst, Hlth Analyt & Digital Hlth, Boston, MA 02215 USA; [Ashkenazi, Shai] Ariel Univ, Sch Med, IL-40700 Ariel, Israel		Benis, A (通讯作者)，Holon Inst Technol, Fac Ind Engn & Technol Management, IL-5810201 Holon, Israel.; Benis, A (通讯作者)，Holon Inst Technol, Fac Digital Technol Med, IL-5810201 Holon, Israel.	arrielb@hit.ac.il; avis@bu.edu; shaias@ariel.ac.il	Benis, Arriel/M-6262-2016	Benis, Arriel/0000-0002-9125-8300			Abbasi J, 2021, JAMA-J AM MED ASSOC, V325, P208, DOI 10.1001/jama.2020.22018; Ahmed N, 2018, VACCINE, V36, P7556, DOI 10.1016/j.vaccine.2018.10.049; Ashkenazi S, 2020, VACCINE, V38, P7292, DOI 10.1016/j.vaccine.2020.09.044; Atehortua NA, 2021, HEALTH PROMOT INT, V36, P524, DOI 10.1093/heapro/daaa140; Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4; Bautista JR, 2021, INT J MED INFORM, V148, DOI 10.1016/j.ijmedinf.2021.104375; Benis A, 2021, J MED INTERNET RES, V23, DOI 10.2196/25977; Benis A, 2021, J MED INTERNET RES, V23, DOI 10.2196/22189; Bloom DE, 2021, HEALTH AFFAIR, V40, P410, DOI 10.1377/hlthaff.2020.02012; Campos-Mercade P, 2021, J PUBLIC ECON, V195, DOI 10.1016/j.jpubeco.2021.104367; CDC, COVID DAT TRACK; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Collins GS, 2015, CIRCULATION, V131, P211, DOI [10.1016/j.jclinepi.2014.11.010, 10.1161/CIRCULATIONAHA.114.014508, 10.7326/M14-0697, 10.1186/s12916-014-0241-z, 10.1136/bmj.g7594, 10.1002/bjs.9736]; Comte Blandine, 2020, Netw Syst Med, V3, P67, DOI 10.1089/nsm.2020.0004; Dube E, 2020, EXPERT REV VACCINES, V19, P899, DOI 10.1080/14760584.2020.1825944; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Eysenbach G, 2002, AM J MED, V113, P763, DOI 10.1016/S0002-9343(02)01473-0; Eysenbach G, 2020, J MED INTERNET RES, V22, DOI 10.2196/21820; Facciola A, 2019, J PUBLIC HEALTH RES, V8, P13, DOI 10.4081/jphr.2019.1436; Feemster KA, 2020, HUM VACC IMMUNOTHER, V16, P1004, DOI 10.1080/21645515.2020.1746603; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Gramlich J., 2020, 10 FACTS AM FACEBOOK; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Lin Y., 2021, 10 REDDIT STAT YOU S; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Maimon O, 2010, DATA MINING AND KNOWLEDGE DISCOVERY HANDBOOK, SECOND EDITION, P1, DOI 10.1007/978-0-387-09823-4_1; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Malina D, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMms2033790; Mavragani A, 2020, J MED INTERNET RES, V22, DOI 10.2196/16206; Morley J, 2020, J MED INTERNET RES, V22, DOI 10.2196/19311; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Sanz H., COMPAREGROUPS 4 0 DE; Shen SX, 2019, CAN FAM PHYSICIAN, V65, P175; Shmueli G, 2017, BIG DATA-US, V5, P98, DOI 10.1089/big.2016.0043; Sprout Social, 2021, FAC STRAT; Thomson A, 2018, VACCINE, V36, P6457, DOI 10.1016/j.vaccine.2018.08.031; Ventola C Lee, 2016, P T, V41, P492; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120, 10.1371/journal.pmed.0040296]; Weintraub RL, 2021, HEALTH AFFAIR, V40, P33, DOI 10.1377/hlthaff.2020.01523; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018; Young R., ANTICORONAVIRUS VACC	41	13	13	6	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							315	10.3390/vaccines9040315			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS5BB	33805283	Green Published, gold			2022-04-29	WOS:000643793300001
J	Ma, J; Ma, LL; Yang, MT; Wu, W; Feng, WA; Chen, ZZ				Ma, Jun; Ma, Lulu; Yang, Meiting; Wu, Wei; Feng, Wenhai; Chen, Zhongzhou			The Function of the PRRSV-Host Interactions and Their Effects on Viral Replication and Propagation in Antiviral Strategies	VACCINES			English	Review						PRRSV; host; interaction; immune responses; vaccines	RESPIRATORY SYNDROME VIRUS; PORCINE ALVEOLAR MACROPHAGES; CYSTEINE PROTEASE DOMAIN; INNATE IMMUNE-RESPONSE; NUCLEOCAPSID PROTEIN; CRYSTAL-STRUCTURE; INHIBITS REPLICATION; INTERFERON INDUCTION; PEPTIDE VACCINE; CELL EPITOPE	Porcine reproductive and respiratory syndrome virus (PRRSV) affects the global swine industry and causes disastrous economic losses each year. The genome of PRRSV is an enveloped single-stranded positive-sense RNA of approximately 15 kb. The PRRSV replicates primarily in alveolar macrophages of pig lungs and lymphatic organs and causes reproductive problems in sows and respiratory symptoms in piglets. To date, studies on how PRRSV survives in the host, the host immune response against viral infections, and pathogenesis, have been reported. PRRSV vaccines have been developed, including inactive virus, modified live virus, attenuated live vaccine, DNA vaccine, and immune adjuvant vaccines. However, there are certain problems with the durability and effectiveness of the licensed vaccines. Moreover, the high variability and fast-evolving populations of this RNA virus challenge the design of PRRSV vaccines, and thus effective vaccines against PRRSV have not been developed successfully. As is well known, viruses interact with the host to escape the host's immune response and then replicate and propagate in the host, which is the key to virus survival. Here, we review the complex network and the mechanism of PRRSV-host interactions in the processes of virus infection. It is critical to develop novel antiviral strategies against PRRSV by studying these host-virus interactions and structures to better understand the molecular mechanisms of PRRSV immune escape.	[Ma, Jun; Ma, Lulu; Yang, Meiting; Wu, Wei; Feng, Wenhai; Chen, Zhongzhou] China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China; [Ma, Jun; Ma, Lulu; Yang, Meiting; Wu, Wei; Feng, Wenhai; Chen, Zhongzhou] China Agr Univ, Coll Biol Sci, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing 100193, Peoples R China		Chen, ZZ (通讯作者)，China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China.	majunjun@cau.edu.cn; mll0703@camedu.cn; meitingyang@cau.edu.cn; wuweiyou@cau.edu.cn; whfeng@cau.edu.cn; chenzhongzhou@cau.edu.cn	chen, zhongzhou/E-3900-2015	chen, zhongzhou/0000-0003-1319-9664	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32071210]; National Key Research and Development Program of China [2018YFE0113100]	This work was supported financially by National Natural Science Foundation of China [32071210], National Key Research and Development Program of China [2018YFE0113100].	An TQ, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.197980; An TQ, 2011, VET MICROBIOL, V149, P104, DOI 10.1016/j.vetmic.2010.11.001; Balka G, 2015, VIRUS RES, V200, P1, DOI 10.1016/j.virusres.2015.01.014; Beura LK, 2010, J VIROL, V84, P1574, DOI 10.1128/JVI.01326-09; Binjawadagi B, 2014, INT J NANOMED, V9, P679, DOI 10.2147/IJN.S56127; Blanco E, 2016, ANTIVIR RES, V129, P74, DOI 10.1016/j.antiviral.2016.03.005; BLOEMRAAD M, 1994, VET MICROBIOL, V42, P361, DOI 10.1016/0378-1135(94)90067-1; Chen NH, 2021, RES VET SCI, V134, P102, DOI 10.1016/j.rvsc.2020.12.007; Chen Z, 2014, VIRUS RES, V189, P226, DOI 10.1016/j.virusres.2014.05.027; de Lima M, 2008, VACCINE, V26, P3594, DOI 10.1016/j.vaccine.2008.04.078; Delputte PL, 2005, J GEN VIROL, V86, P1441, DOI 10.1099/vir.0.80675-0; Delputte PL, 2002, J VIROL, V76, P4312, DOI 10.1128/JVI.76.9.4312-4320.2002; Deng ZQ, 2014, NUCLEIC ACIDS RES, V42, P3464, DOI 10.1093/nar/gkt1310; Dhakal S, 2019, VET RES, V50, DOI 10.1186/s13567-019-0712-5; Dhorne-Pollet S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39220-3; Dong JG, 2014, VIROLOGY, V464, P432, DOI 10.1016/j.virol.2014.07.036; Du J, 2016, J VIROL, V90, P682, DOI 10.1128/JVI.02307-15; Du TF, 2017, TRENDS MICROBIOL, V25, P968, DOI 10.1016/j.tim.2017.06.001; Duan X, 1997, ARCH VIROL, V142, P2483, DOI 10.1007/s007050050256; Fan SH, 2016, J VIROL, V90, P6625, DOI 10.1128/JVI.00119-16; Gao JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep25120; Gao L, 2013, J VIROL, V87, P8808, DOI 10.1128/JVI.00718-13; Gao P, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008169; Guo XK, 2013, J VIROL, V87, P1159, DOI 10.1128/JVI.02386-12; Han J, 2009, J VIROL, V83, P9449, DOI 10.1128/JVI.00834-09; Han MY, 2013, VIRUS RES, V172, P54, DOI 10.1016/j.virusres.2012.12.012; Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; Hou J, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-165; Huang YW, 2009, DEV COMP IMMUNOL, V33, P464, DOI 10.1016/j.dci.2008.09.010; Jing HY, 2019, RES VET SCI, V127, P105, DOI 10.1016/j.rvsc.2019.10.004; Jing HY, 2019, VIRUS GENES, V55, P660, DOI 10.1007/s11262-019-01691-x; Jing HY, 2019, VIRUS RES, V268, P18, DOI 10.1016/j.virusres.2019.05.011; Johnson CR, 2011, J GEN VIROL, V92, P1107, DOI 10.1099/vir.0.030213-0; Ke HZ, 2019, J VIROL, V93, DOI 10.1128/JVI.00469-19; Kim JK, 2006, J VIROL, V80, P689, DOI 10.1128/JVI.80.2.689-696.2006; Kim O, 2010, VIROLOGY, V402, P315, DOI 10.1016/j.virol.2010.03.039; Koepke L, 2021, CURR OPIN MICROBIOL, V59, P50, DOI 10.1016/j.mib.2020.07.005; Kreutz LC, 1998, VIRUS RES, V53, P121, DOI 10.1016/S0168-1702(97)00134-2; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Lalonde C, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00097-20; Li HX, 2010, J GEN VIROL, V91, P2947, DOI 10.1099/vir.0.025205-0; Li JN, 2017, VET MICROBIOL, V204, P35, DOI 10.1016/j.vetmic.2017.03.035; Li LL, 2018, ANTIVIR RES, V156, P10, DOI 10.1016/j.antiviral.2018.06.001; Li LW, 2015, SCI REP-UK, V5, DOI 10.1038/srep17010; Li SF, 2011, VACCINE, V29, P3695, DOI 10.1016/j.vaccine.2011.03.002; Li YH, 2012, J GEN VIROL, V93, P829, DOI 10.1099/vir.0.039289-0; Liu F, 2017, VET MICROBIOL, V209, P48, DOI 10.1016/j.vetmic.2017.01.004; Liu HL, 2016, BIOTECHNOL LETT, V38, P1081, DOI 10.1007/s10529-016-2086-3; Liu HL, 2015, VET MICROBIOL, V181, P252, DOI 10.1016/j.vetmic.2015.10.021; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Ma ZX, 2016, SCI REP-UK, V6, DOI 10.1038/srep36312; Martinez-Lobo FJ, 2011, VET MICROBIOL, V154, P58, DOI 10.1016/j.vetmic.2011.06.025; Misinzo GM, 2008, VET RES, V39, DOI 10.1051/vetres:2008031; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Muderspach L, 2000, CLIN CANCER RES, V6, P3406; Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635; Nauwynck HJ, 1999, J GEN VIROL, V80, P297, DOI 10.1099/0022-1317-80-2-297; Oh T, 2019, CAN J VET RES, V83, P57; Ouyang K, 2016, VET RES, V47, DOI 10.1186/s13567-016-0331-3; Pan XC, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02995; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Renken C, 2021, PORCINE HEALTH MANAG, V7, DOI 10.1186/s40813-020-00183-x; Renukaradhya GJ, 2015, VACCINE, V33, P3065, DOI 10.1016/j.vaccine.2015.04.102; Sagong M, 2011, ARCH VIROL, V156, P2187, DOI 10.1007/s00705-011-1116-7; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Shanmukhappa K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-62; Shi XB, 2011, MOL IMMUNOL, V48, P1568, DOI 10.1016/j.molimm.2011.03.004; Snijder EJ, 2013, J GEN VIROL, V94, P2141, DOI 10.1099/vir.0.056341-0; Song ZB, 2019, VET MICROBIOL, V239, DOI 10.1016/j.vetmic.2019.108498; Spearman P, 2009, VACCINE, V27, P243, DOI 10.1016/j.vaccine.2008.10.051; Su F, 2019, J VET MED SCI, V81, P1475, DOI 10.1292/jvms.19-0057; Sun Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168314; Sun Y, 2012, VIRUSES-BASEL, V4, P424, DOI 10.3390/v4040424; Sun YN, 2009, J VIROL, V83, P10931, DOI 10.1128/JVI.02579-08; Tang CJ, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020215; Thanawongnuwech R, 2004, CLIN DIAGN LAB IMMUN, V11, P901, DOI 10.1128/CDLI.11.5.901-908.2004; Van Breedam W, 2010, J GEN VIROL, V91, P1659, DOI 10.1099/vir.0.020503-0; Van Breedam W, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000730; Van Gorp H, 2008, J GEN VIROL, V89, P2943, DOI 10.1099/vir.0.2008/005009-0; van Kasteren PB, 2013, P NATL ACAD SCI USA, V110, pE838, DOI 10.1073/pnas.1218464110; van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056; Veit M, 2014, VIRUS RES, V194, P16, DOI 10.1016/j.virusres.2014.09.010; Vu HLX, 2013, VACCINE, V31, P4330, DOI 10.1016/j.vaccine.2013.07.020; Wang C, 2015, DNA CELL BIOL, V34, P728, DOI 10.1089/dna.2015.2929; Wang D, 2019, J VIROL, V93, DOI 10.1128/JVI.00623-19; Wang G, 2016, DEV COMP IMMUNOL, V62, P1, DOI 10.1016/j.dci.2016.04.019; Wang HL, 2019, J VIROL, V93, DOI 10.1128/JVI.01100-19; Wang J, 2019, J VIROL, V93, DOI 10.1128/JVI.00526-19; Wei ZY, 2020, VIROLOGY, V546, P79, DOI 10.1016/j.virol.2020.04.007; Whitworth KM, 2016, NAT BIOTECHNOL, V34, P20, DOI 10.1038/nbt.3434; Wissink EHJ, 2005, J VIROL, V79, P12495, DOI 10.1128/JVI.79.19.12495-12506.2005; Wissink EHJ, 2004, J GEN VIROL, V85, P3715, DOI 10.1099/vir.0.80402-0; Wongyanin P, 2012, J GEN VIROL, V93, P1236, DOI 10.1099/vir.0.040287-0; Xue F, 2010, J VIROL, V84, P6461, DOI 10.1128/JVI.00301-10; Yang LP, 2017, J VIROL, V91, DOI [10.1128/JVI.02087-16, 10.1128/jvi.02087-16]; Yang S, 2020, COMP IMMUNOL MICROB, V69, DOI 10.1016/j.cimid.2020.101423; Yoo D, 2003, J VIROL, V77, P12173, DOI 10.1128/JVI.77.22.12173-12183.2003; Yu J, 2017, MICROB PATHOGENESIS, V109, P319, DOI 10.1016/j.micpath.2017.04.036; Yu P, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03115; Zhang K, 2013, VIROLOGY, V442, P156, DOI 10.1016/j.virol.2013.04.007; Zhang MF, 2017, J VIROL, V91, DOI [10.1128/jvi.01309-16, 10.1128/JVI.01309-16]; Zhang NZ, 2011, J VIROL, V85, P11709, DOI 10.1128/JVI.05040-11; Zhang Q, 2016, J IMMUNOL, V196, P2272, DOI 10.4049/jimmunol.1502006; Zhang Q, 2014, VIROLOGY, V450, P182, DOI 10.1016/j.virol.2013.12.020; Zhang XB, 2019, J GEN VIROL, V100, P1407, DOI 10.1099/jgv.0.001320; Zhang ZD, 2018, INFECT GENET EVOL, V66, P111, DOI 10.1016/j.meegid.2018.09.024; Zhao GW, 2017, J GEN VIROL, V98, P624, DOI 10.1099/jgv.0.000708; Zhao K, 2019, VET MICROBIOL, V233, P140, DOI 10.1016/j.vetmic.2019.05.003; Zhao YX, 2019, J VIROL, V93, DOI [10.1128/JVI.00001-19, 10.1128/jvi.00001-19]; Zhou YF, 2012, CAN J VET RES, V76, P255	111	2	2	18	26	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							364	10.3390/vaccines9040364			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4YC	33918746	Green Published, gold			2022-04-29	WOS:000643785600001
J	Wang, PW; Ahorsu, DK; Lin, CY; Chen, IH; Yen, CF; Kuo, YJ; Griffiths, MD; Pakpour, AH				Wang, Peng-Wei; Ahorsu, Daniel Kwasi; Lin, Chung-Ying; Chen, I-Hua; Yen, Cheng-Fang; Kuo, Yi-Jie; Griffiths, Mark D.; Pakpour, Amir H.			Motivation to Have COVID-19 Vaccination Explained Using an Extended Protection Motivation Theory among University Students in China: The Role of Information Sources	VACCINES			English	Article						COVID-19; vaccination; protection motivation theory; motivation; information sources	FEAR APPEALS; DETERMINANTS; METAANALYSIS; DECISION; CHILDREN; PARENTS; RUBELLA; MEASLES; MUMPS	Background: The aims of the present study were to examine the prediction of the threat and coping appraisal utilizing an extended protection motivation theory (PMT) for the motivation to have COVID-19 vaccination and the influence of various information sources on coping appraisal among university students in China. Methods: The sample comprised 3145 students from 43 universities in China who completed an online survey including PMT constructs as well as constructs added to PMT. The PMT constructs comprised motivation to have COVID-19 vaccination, threat appraisal, and coping appraisal. The extended PMT constructs comprised knowledge about mechanisms and information sources of COVID-19 vaccination. Results: Perceived severity of COVID-19 was positively associated with motivation to have COVID-19 vaccination. Receiving information concerning COVID-19 vaccination from medical personnel was associated with greater self-efficacy, response efficacy, and knowledge, whereas receiving information concerning COVID-19 vaccination from coworkers/colleagues was associated with less response efficacy and knowledge. Receiving online information concerning COVID-19 vaccination was associated with greater response cost of vaccination efficacy and less knowledge. Conclusions: This study supported the prediction of perceived severity in the PMT for motivation to have COVID-19 vaccination among university students in China. Vaccination information sources have different effects on students' coping appraisal of COVID-19 vaccination.	[Wang, Peng-Wei; Yen, Cheng-Fang] Kaohsiung Med Univ, Sch Med, Dept Psychiat, Coll Med, Kaohsiung 807, Taiwan; [Wang, Peng-Wei; Yen, Cheng-Fang] Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 807, Taiwan; [Ahorsu, Daniel Kwasi] Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Rehabil Sci, Hung Hom, Hong Kong, Peoples R China; [Lin, Chung-Ying] Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan 701, Taiwan; [Lin, Chung-Ying] Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan 701, Taiwan; [Lin, Chung-Ying] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Publ Hlth, Tainan 701, Taiwan; [Chen, I-Hua] Minnan Normal Univ, Sch Educ Sci, Zhangzhou 363000, Peoples R China; [Chen, I-Hua] Fujian Prov Univ, Key Lab Appl Cognit & Personal, Zhangzhou 363000, Peoples R China; [Chen, I-Hua] Krirk Univ, Int Coll, Bangkok 10220, Thailand; [Kuo, Yi-Jie] Taipei Med Univ, Wan Fang Hosp, Dept Orthoped Surg, Taipei 110, Taiwan; [Kuo, Yi-Jie] Taipei Med Univ, Coll Med, Sch Med, Dept Orthoped Surg, Taipei 110, Taiwan; [Griffiths, Mark D.] Nottingham Trent Univ, Psychol Dept, Int Gaming Res Unit, Nottingham NG1 4FQ, England; [Pakpour, Amir H.] Jonkoping Univ, Sch Hlth & Welf, Dept Nursing, S-55318 Jonkoping, Sweden		Yen, CF (通讯作者)，Kaohsiung Med Univ, Sch Med, Dept Psychiat, Coll Med, Kaohsiung 807, Taiwan.; Yen, CF (通讯作者)，Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 807, Taiwan.; Chen, IH (通讯作者)，Minnan Normal Univ, Sch Educ Sci, Zhangzhou 363000, Peoples R China.; Chen, IH (通讯作者)，Fujian Prov Univ, Key Lab Appl Cognit & Personal, Zhangzhou 363000, Peoples R China.; Chen, IH (通讯作者)，Krirk Univ, Int Coll, Bangkok 10220, Thailand.	990107@gap.kmu.edu.tw; daniel.ahorsu@connect.polyu.hk; cylin36933@gs.ncku.edu.tw; ahole.chen@gmail.com; chfaye@kmu.edu.tw; benkuo5@tmu.edu.tw; mark.griffiths@ntu.ac.uk; apakpour@qums.ac.ir	Lin, Chung-Ying/I-5434-2016; Griffiths, Mark D./AAY-3546-2021; Pakpour, Amir H./C-6160-2014	Lin, Chung-Ying/0000-0002-2129-4242; Griffiths, Mark D./0000-0001-8880-6524; Pakpour, Amir H./0000-0002-8798-5345; chen, i hua/0000-0001-6999-6406	Taipei Municipal Wan Fang Hospital Cross-Institutions Fund [110-swf-01]	This study was supported in part by a research grant from the Taipei Municipal Wan Fang Hospital Cross-Institutions Fund (110-swf-01).	[Anonymous], 2020, DRAFT LANDSC COVID 1; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Camerini AL, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.11.005; Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934; Crayne MP, 2020, PSYCHOL TRAUMA-US, V12, pS180, DOI 10.1037/tra0000852; Ding YB, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165728; Fadda M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2200-9; Fan KS, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040487; Farooq A, 2020, J MED INTERNET RES, V22, DOI 10.2196/19128; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Floyd DL, 2000, J APPL SOC PSYCHOL, V30, P407, DOI 10.1111/j.1559-1816.2000.tb02323.x; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jones Abbey M, 2012, Adv Prev Med, V2012, P932741, DOI 10.1155/2012/932741; Kennedy A, 2011, PEDIATRICS, V127, pS92, DOI 10.1542/peds.2010-1722N; Ling M, 2019, SOC SCI MED, V233, P87, DOI 10.1016/j.socscimed.2019.06.002; MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; McIntyre RS, 2020, WORLD PSYCHIATRY, V19, P250, DOI 10.1002/wps.20767; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Odriozola-Gonzalez P, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113108; Oksanen Atte, 2020, JMIR Public Health Surveill, V6, pe19218, DOI 10.2196/19218; Okuhara T, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040475; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; RIPPETOE PA, 1987, J PERS SOC PSYCHOL, V52, P596, DOI 10.1037/0022-3514.52.3.596; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; Rundle AG, 2020, OBESITY, V28, P1008, DOI 10.1002/oby.22813; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schulz PJ, 2021, HEALTH COMMUN, V36, P1505, DOI 10.1080/10410236.2020.1771119; Tabacchi G, 2016, HUM VACC IMMUNOTHER, V12, P1909, DOI 10.1080/21645515.2016.1151990; Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212; Vetter V, 2018, ANN MED, V50, P110, DOI 10.1080/07853890.2017.1407035; Wang XM, 2020, J MED INTERNET RES, V22, DOI 10.2196/22817; Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279	40	31	31	20	37	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							380	10.3390/vaccines9040380			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS4TP	33924604	Green Accepted, gold, Green Published			2022-04-29	WOS:000643773800001
J	Kounis, NG; Koniari, I; de Gregorio, C; Velissaris, D; Petalas, K; Brinia, A; Assimakopoulos, SF; Gogos, C; Kouni, SN; Kounis, GN; Calogiuri, G; Hung, MY				Kounis, Nicholas G.; Koniari, Ioanna; de Gregorio, Cesare; Velissaris, Dimitris; Petalas, Konstantinos; Brinia, Aikaterini; Assimakopoulos, Stelios F.; Gogos, Christos; Kouni, Sophia N.; Kounis, George N.; Calogiuri, GianFranco; Hung, Ming-Yow			Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations	VACCINES			English	Review						allergy; anaphylaxis; COVID-19; Kounis syndrome; vaccines	ADVISORY-COMMITTEE; UNITED-STATES; VACCINE; HYPERSENSITIVITY; MASTOCYTOSIS; ANAPHYLAXIS; COMPLEMENT; ACTIVATION; CHILDREN; MRGPRX2	Vaccines constitute the most effective medications in public health as they control and prevent the spread of infectious diseases and reduce mortality. Similar to other medications, allergic reactions can occur during vaccination. While most reactions are neither frequent nor serious, anaphylactic reactions are potentially life-threatening allergic reactions that are encountered rarely, but can cause serious complications. The allergic responses caused by vaccines can stem from activation of mast cells via Fc epsilon receptor-1 type I reaction, mediated by the interaction between immunoglobulin E (IgE) antibodies against a particular vaccine, and occur within minutes or up to four hours. The type IV allergic reactions initiate 48 h after vaccination and demonstrate their peak between 72 and 96 h. Non-IgE-mediated mast cell degranulation via activation of the complement system and via activation of the Mas-related G protein-coupled receptor X2 can also induce allergic reactions. Reactions are more often caused by inert substances, called excipients, which are added to vaccines to improve stability and absorption, increase solubility, influence palatability, or create a distinctive appearance, and not by the active vaccine itself. Polyethylene glycol, also known as macrogol, in the currently available Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines, and polysorbate 80, also known as Tween 80, in AstraZeneca and Johnson & Johnson COVID-19 vaccines, are excipients mostly incriminated for allergic reactions. This review will summarize the current state of knowledge of immediate and delayed allergic reactions in the currently available vaccines against COVID-19, together with the general and specific therapeutic considerations. These considerations include: The incidence of allergic reactions and deaths under investigation with the available vaccines, application of vaccination in patients with mast cell disease, patients who developed an allergy during the first dose, vasovagal symptoms masquerading as allergic reactions, the COVID-19 vaccination in pregnancy, deaths associated with COVID-19 vaccination, and questions arising in managing of this current ordeal. Careful vaccine-safety surveillance over time, in conjunction with the elucidation of mechanisms of adverse events across different COVID-19 vaccine platforms, will contribute to the development of a safe vaccine strategy. Allergists' expertise in proper diagnosis and treatment of allergic reactions is vital for the screening of high-risk individuals.	[Kounis, Nicholas G.] Univ Patras, Sch Med, Div Cardiol, Dept Internal Med, Patras 26221, Greece; [Koniari, Ioanna] Univ Hosp South Manchester NHS Fdn Trust, Dept Internal Med, Div Cardiol, Manchester M23 9LT, Lancs, England; [de Gregorio, Cesare] Univ Messina, Sch Med, Dept Clin & Expt Med, I-98122 Messina, Italy; [Velissaris, Dimitris] Univ Patras, Dept Internal Med, Patras 26500, Greece; [Petalas, Konstantinos] 251 Gen Air Force Hosp, Dept Allergol, Athens 11525, Greece; [Brinia, Aikaterini] Allergy Practice, Patras 26221, Greece; [Assimakopoulos, Stelios F.] Univ Patras, Sch Med, Dept Internal Med, Div Infect Dis, Patras 26500, Greece; [Gogos, Christos] Papageorgiou Gen Hosp, Covid 19 Unit, Thessaloniki 56403, Greece; [Kouni, Sophia N.] Speech Therapy Practice, Patras 26221, Greece; [Kounis, George N.] St Andrews State Gen Hosp, Dept Ophthalmol, Patras 26335, Greece; [Calogiuri, GianFranco] Civil Hosp NinettoMelli, Pneumonol Dept, I-72027 Pietro Vernoti, Brindisi, Italy; [Calogiuri, GianFranco] Univ Bari, Dept Internal Med Immunol & Infect Dis, Sect Allergol & Clin Immunol, Sch Med, I-70121 Bari, Italy; [Hung, Ming-Yow] Taipei Med Univ, Shuang Ho Hosp, Div Cardiol, Dept Internal Med, New Taipei 23561, Taiwan; [Hung, Ming-Yow] Taipei Med Univ, Sch Med, Div Cardiol, Dept Internal Med,Coll Med, Taipei 110, Taiwan; [Hung, Ming-Yow] Taipei Med Univ, Taipei Heart Inst, Taipei 110, Taiwan		Kounis, NG (通讯作者)，Univ Patras, Sch Med, Div Cardiol, Dept Internal Med, Patras 26221, Greece.	ngkounis@otenet.gr; iokoniari@yahoo.gr; cesare.degregorio@unime.it; dimitrisvelissaris@yahoo.com; kpetalas@hotmail.com; kbrinia@yahoo.gr; sassim@upatras.gr; gogos-grivas@hotmail.com; snkouni@yahoo.gr; gnkounis@gmail.com; gf.calogiuri@libero.it; myhung6@ms77.hinet.net		Gogos, Christos/0000-0002-9598-6954; Hung, Ming-Yow/0000-0002-6912-7523; Petalas, Konstantinos/0000-0003-1680-3062; de Gregorio, Cesare/0000-0003-3022-266X			Ambrosch A, 2001, INT ARCH ALLERGY IMM, V124, P362, DOI 10.1159/000053758; [Anonymous], NTV; Aydin S., 2020, ASNH, V4, P172; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Caballero ML, 2020, J INVEST ALLERG CLIN, V30, P400, DOI 10.18176/jiaci.0562; Calogiuri G., 2018, CLIN IMMUNOL ENDOCR, V4, P9, DOI [10.2174/2212707004666161209161535, DOI 10.2174/2212707004666161209161535]; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Caubet JC, 2014, IMMUNOL ALLERGY CLIN, V34, P597, DOI 10.1016/j.iac.2014.04.004; Center for Disease Control and Prevention, 2020, ALLERGIC REACTIONS I; Centers for Disease Control and Prevention (CDC), 2020, INTERIM CONSIDERATIO; Cheng H, 2017, ANTIVIR RES, V145, P24, DOI 10.1016/j.antiviral.2017.06.015; Chung EH, 2014, CLIN EXP VACCINE RES, V3, P50, DOI 10.7774/cevr.2014.3.1.50; Coors EA, 2005, ANN ALLERG ASTHMA IM, V95, P593, DOI 10.1016/S1081-1206(10)61024-1; Dayneka Natalie, 2020, Can Commun Dis Rep, V46, P384, DOI 10.14745/ccdr.v46i1112a04; Demir S, 2019, INT ARCH ALLERGY IMM, V178, P167, DOI 10.1159/000494130; Dooling K, 2021, MMWR-MORBID MORTAL W, V69, P1657, DOI 10.15585/mmwr.mm695152e2; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Freedberg DE, 2020, GASTROENTEROLOGY, V159, P1129, DOI 10.1053/j.gastro.2020.05.053; Fritsche PJ, 2010, SWISS MED WKLY, V140, P238, DOI smw-12980; Gonzalez-de-Olano D, 2014, INT J CARDIOL, V174, P856, DOI 10.1016/j.ijcard.2014.04.191; Guo XX, 2016, ATHEROSCLEROSIS, V251, P355, DOI 10.1016/j.atherosclerosis.2016.05.020; Halsey NA, 2013, VACCINE, V31, P6107, DOI 10.1016/j.vaccine.2013.09.066; Hawe A, 2010, PHARM RES-DORD, V27, P314, DOI 10.1007/s11095-009-0020-2; He SS, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010286; Hellman L, 1996, ADV EXP MED BIOL, V409, P337; Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8; Jaffe E, 2021, AM J PUBLIC HEALTH, V111, P498, DOI 10.2105/AJPH.2020.306045; Khan S, 2020, EUR HEART J, V41, P3018, DOI 10.1093/eurheartj/ehaa548; Kleine-Tebbe Jorg, 2021, Allergol Select, V5, P26, DOI 10.5414/ALX02215E; Kounis N G, 2014, J Nat Sci Biol Med, V5, P240, DOI 10.4103/0976-9668.136145; Kounis NG, 2018, FORENSIC SCI INT, V282, P79, DOI 10.1016/j.forsciint.2017.11.001; Kounis NG, 2016, ATHEROSCLEROSIS, V251, P498, DOI 10.1016/j.atherosclerosis.2016.05.045; Kounis NG, 2011, FUTUR CARDIOL, V7, P805, DOI [10.2217/FCA.11.63, 10.2217/fca.11.63]; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Laris-Gonzalez A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010124; Leisman DE, 2020, INTENS CARE MED, V46, P1105, DOI 10.1007/s00134-020-06059-6; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; McMurtry C Meghan, 2020, Can Commun Dis Rep, V46, P210, DOI 10.4745/ccdr.v46i06a10; McNeil MM, 2018, J ALLERGY CLIN IMMUN, V141, P463, DOI 10.1016/j.jaci.2017.12.971; McNeil MM, 2016, J ALLERGY CLIN IMMUN, V137, P868, DOI 10.1016/j.jaci.2015.07.048; Min KB, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16224350; Moghimi SM, 2021, MOL THER, V29, P898, DOI 10.1016/j.ymthe.2021.01.030; Moran B.J.I., 2021, PULM PHARMACOL THER, V67, DOI [10.1016/j.pupt.2021.101989, DOI 10.1016/J.PUPT.2021.101989]; Neun BW, 2018, MOLECULES, V23, DOI 10.3390/molecules23071700; Nilsson L, 2017, PEDIAT ALLERG IMM-UK, V28, P628, DOI 10.1111/pai.12762; Nopp A, 2006, ALLERGY, V61, P1366, DOI 10.1111/j.1398-9995.2006.01211.x; Olivera A, 2018, J ALLERGY CLIN IMMUN, V142, P381, DOI 10.1016/j.jaci.2018.01.034; Palma G., 2020, IMMUNOL, V11, DOI [10.3389/fimmu.2020.02094, DOI 10.3389/FIMMU.2020.02094]; Palmiere C, 2017, CROAT MED J, V58, P14, DOI 10.3325/cmj.2017.58.14; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Park KS, 2021, ADV DRUG DELIVER REV, V169, P137, DOI 10.1016/j.addr.2020.12.008; Petrikova M, 2006, INFLAMM RES, V55, pS51, DOI 10.1007/s00011-005-0038-9; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Porebski G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03027; Robinson CL, 2017, MMWR-MORBID MORTAL W, V66, P134, DOI 10.15585/mmwr.mm6605e1; Sanchez-Borges M, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-017-0148-1; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P125, DOI [10.15585/mmwr.mm7004e1, 10.1111/ajt.16517, 10.15585/mmwr.mm7004e1externalicon]; Shimabukuro T, 2021, JAMA-J AM MED ASSOC, V325, P780, DOI 10.1001/jama.2021.0600; Sokolowska M, 2021, ALLERGY, V76, P1629, DOI 10.1111/all.14739; Stone CA, 2019, BRIT J CLIN PHARMACO, V85, P2694, DOI 10.1111/bcp.14112; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003; Szebeni J, 1999, CIRCULATION, V99, P2302, DOI 10.1161/01.CIR.99.17.2302; Teraldsen L.E., 2021, BLOOMBERG; Theoharides TC, 2021, ANN ALLERG ASTHMA IM, V126, P217, DOI 10.1016/j.anai.2020.11.003; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n149; Valent P, 2020, J ALLERGY CLIN IMMUN, V146, P300, DOI 10.1016/j.jaci.2020.06.009; Vrieze J., 2020, SCIENCE, V21, P1126, DOI [10.1126/science.abg2359, DOI 10.1126/SCIENCE.ABG2359]; Weiler CR, 2019, J ALLER CL IMM-PRACT, V7, P2091, DOI 10.1016/j.jaip.2019.02.015; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8	70	46	46	13	33	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							221	10.3390/vaccines9030221			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5DK	33807579	Green Published, gold	Y	N	2022-04-29	WOS:000634174400001
J	Matysiak, J; Matuszewska, E; Kowalski, ML; Kosinski, SW; Smorawska-Sabanty, E; Matysiak, J				Matysiak, Joanna; Matuszewska, Eliza; Kowalski, Marek L.; Kosinski, Slawomir W.; Smorawska-Sabanty, Ewa; Matysiak, Jan			Association between Venom Immunotherapy and Changes in Serum Protein-Peptide Patterns	VACCINES			English	Article						Hymenoptera venom allergy; MALDI-TOF MS; protein-peptide profiling; proteomics; venom immunotherapy	MALDI-TOF-MS; FILAMIN B; ALLERGY; IDENTIFICATION; ACTIVATION; MECHANISMS; WASP; COMPLEMENT; TOLERANCE; DIAGNOSIS	Venom immunotherapy (VIT) is administered to allergic patients to reduce the risk of dangerous systemic reactions following an insect sting. To better understand the mechanism of this treatment and its impact on the human organism, we analysed serum proteomic patterns obtained at five time-points from Hymenoptera-venom-allergic patients undergoing VIT. For statistical analyses, patients were additionally divided into two groups (high responders and low responders) according to serum sIgG4 levels. VIT was found to be associated with changes in seven proteins: the fibrinogen alpha chain, complement C4-A, complement C3, filamin-B, kininogen-1, myosin-9 and inter-alpha-trypsin inhibitor heavy chain H1. The number of discriminative m/z (mass-to-charge ratio) features increased up to the 90th day of VIT, which may be associated with the development of immunity after the administration of increased venom doses. It may also suggest that during VIT, there may occur processes involved not only in protein synthesis but also in protein degradation (caused by proteolytic venom components). The results are consistent with measured serum sIgG4 levels, which increased from 2.04 mgA/I at baseline to 7.25 mgA/I at 90 days. Moreover, the major proteomic changes were detected separately in the high responder group. This may suggest that changes in protein-peptide profiles reflect the actual response to VIT.	[Matysiak, Joanna] President Stanislaw Wojciechowski State Univ Appl, Fac Hlth Sci, PL-62800 Kalisz, Poland; [Matuszewska, Eliza; Matysiak, Jan] Poznan Univ Med Sci, Dept Inorgan & Analyt Chem, PL-60780 Poznan, Poland; [Kowalski, Marek L.; Kosinski, Slawomir W.; Smorawska-Sabanty, Ewa] Med Univ Lodz, Dept Immunol & Allergy, PL-92213 Lodz, Poland		Matysiak, J (通讯作者)，Poznan Univ Med Sci, Dept Inorgan & Analyt Chem, PL-60780 Poznan, Poland.	jkamatysiak@gmail.com; eliza.matuszewska@ump.edu.pl; marek.kowalski@csk.umed.lodz.pl; slawomir.kosinski@csk.umed.lodz.pl; ewasm@csk.umed.lodz.pl; jmatysiak@ump.edu.pl	Matuszewska, Eliza/AAU-2177-2021; Matysiak, Jan/R-6498-2016	Matysiak, Joanna/0000-0002-2475-1066; Matuszewska, Eliza/0000-0002-5765-2603; Matysiak, Jan/0000-0002-9993-1504	Polish National Science Centre [2016/23/D/NZ7/03949]	This project received financial support from the Polish National Science Centre (grant number 2016/23/D/NZ7/03949).	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Albanesi Marcello, 2018, Clin Mol Allergy, V16, P2, DOI 10.1186/s12948-017-0079-y; Arzt L, 2018, ALLERGY, V73, P1223, DOI 10.1111/all.13368; Baldassarre M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007830; Baltz AG, 2012, MOL CELL, V46, P674, DOI 10.1016/j.molcel.2012.05.021; Bidad K, 2014, CYTOM PART B-CLIN CY, V86, P183, DOI 10.1002/cyto.b.21148; Bilo BM, 2008, CURR OPIN ALLERGY CL, V8, P330, DOI 10.1097/ACI.0b013e32830638c5; Bilo MB, 2009, CLIN EXP ALLERGY, V39, P1467, DOI 10.1111/j.1365-2222.2009.03324.x; Bilo MB, 2020, ALLERGO J, V29, P16, DOI 10.1007/s40629-020-00116-8; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Boyle RJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008838.pub2; Calkosinski I, 2009, POSTEP HIG MED DOSW, V63, P395; Choo YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032269; Choo YM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010393; Cortelazzo A, 2010, BLOOD TRANSFUS-ITALY, V8, pS120, DOI 10.2450/2010.019S; Couture R, 2001, EUR J PHARMACOL, V429, P161, DOI 10.1016/S0014-2999(01)01318-8; Davalos D, 2012, SEMIN IMMUNOPATHOL, V34, P43, DOI 10.1007/s00281-011-0290-8; Dhami S, 2017, ALLERGY, V72, P342, DOI 10.1111/all.13077; Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139; Ebo DG, 2007, CYTOM PART B-CLIN CY, V72B, P196, DOI 10.1002/cyto.b.20142; Erzen R, 2012, ALLERGY, V67, P822, DOI 10.1111/j.1398-9995.2012.02817.x; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Galera C, 2009, J INVEST ALLERG CLIN, V19, P225; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Garantziotis S, 2007, J IMMUNOL, V179, P4187, DOI 10.4049/jimmunol.179.6.4187; Goldberg A, 2010, ALLERGY, V65, P391, DOI 10.1111/j.1398-9995.2009.02198.x; Golias Ch, 2007, Hippokratia, V11, P124; Gonzales-van Horn SR, 2015, J LEUKOCYTE BIOL, V98, P185, DOI 10.1189/jlb.3RU0315-099R; Graham F, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0134-0; Guo N, 2014, INT J MOL SCI, V15, P1162, DOI 10.3390/ijms15011162; Heissler SM, 2013, CELL MOL LIFE SCI, V70, P1, DOI 10.1007/s00018-012-1002-9; Heneberg P, 2019, CLIN EXP ALLERGY, V49, P54, DOI 10.1111/cea.13288; Heneberg P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142953; Hogger P, 2001, BIOCHEM BIOPH RES CO, V288, P841, DOI 10.1006/bbrc.2001.5845; Hou GP, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01815; Hsieh JY, 2017, ACTA BIOMATER, V47, P14, DOI 10.1016/j.actbio.2016.09.024; Incorvaia C, 2018, EXPERT REV CLIN IMMU, V14, P53, DOI 10.1080/1744666X.2018.1413350; Jarkvist J, 2020, ALLERGY, V75, P169, DOI 10.1111/all.13980; Jeon YJ, 2009, EMBO REP, V10, P374, DOI 10.1038/embor.2009.23; Jeon YJ, 2008, MOL BIOL CELL, V19, P5116, DOI 10.1091/mbc.E08-06-0576; Klupczynska A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040410; Kosnik M, 2015, EXPERT REV CLIN IMMU, V11, P877, DOI 10.1586/1744666X.2015.1052409; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; Liu YQ, 2019, MBIO, V10, DOI 10.1128/mBio.00574-19; Lopes-Ferreira M, 2004, BIOCHEM PHARMACOL, V68, P2151, DOI 10.1016/j.bcp.2004.07.037; Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166; Mattson L, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5153184; Matuszewska E, 2019, ALLERGY ASTHMA CL IM, V15, DOI 10.1186/s13223-019-0387-5; Matysiak J, 2016, J PHARMACEUT BIOMED, V121, P69, DOI 10.1016/j.jpba.2016.01.009; Matysiak J, 2014, TOXICON, V90, P255, DOI 10.1016/j.toxicon.2014.08.069; Naik SR, 2013, RECENT PATENTS INFLA, V7, P62, DOI 10.2174/1872213X11307010062; Narain NR, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa-2016-0065; Oikonomopoulou K, 2012, SEMIN IMMUNOPATHOL, V34, P151, DOI 10.1007/s00281-011-0280-x; Ozdemir C, 2011, CLIN EXP ALLERGY, V41, P1226, DOI 10.1111/j.1365-2222.2011.03812.x; PANDYA BV, 1983, TOXICON, V21, P515, DOI 10.1016/0041-0101(83)90129-0; Patra A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17227-y; Pecci A, 2018, GENE, V664, P152, DOI 10.1016/j.gene.2018.04.048; Pidde-Queiroz G, 2010, MOL IMMUNOL, V47, P2537, DOI 10.1016/j.molimm.2010.07.003; Pulanic D, 2005, COLLEGIUM ANTROPOL, V29, P341; Rhim T, 2009, ALLERGY, V64, P47, DOI 10.1111/j.1398-9995.2008.01817.x; Trabado AR, 2016, ALLERGY ASTHMA IMMUN, V8, P412, DOI 10.4168/aair.2016.8.5.412; Rueff F, 2014, CLIN EXP ALLERGY, V44, P736, DOI 10.1111/cea.12275; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Sturm GJ, 2018, ALLERGY, V73, P744, DOI 10.1111/all.13262; Subbannayya Y, 2015, J PROTEOMICS, V127, P80, DOI 10.1016/j.jprot.2015.04.021; Swiatly A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3467-2; Tracy JM, 2018, J ALLER CL IMM-PRACT, V6, P1856, DOI 10.1016/j.jaip.2018.08.015; Vaiyapuri S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009687; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Wang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023563; Wang JF, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0070519, 10.1371/journal.pone.0053400]; Whitmarsh AJ, 2009, EMBO REP, V10, P349, DOI 10.1038/embor.2009.44; Xu QM, 2017, J GENET GENOMICS, V44, P335, DOI 10.1016/j.jgg.2017.04.007; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184; Zitnik SEK, 2012, PEDIAT ALLERG IMM-UK, V23, P167, DOI 10.1111/j.1399-3038.2011.01233.x	75	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							249	10.3390/vaccines9030249			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE4ZI	33809001	Green Published, gold			2022-04-29	WOS:000634163800001
J	Ochoa-Reparaz, J; Sebastia, E; Sitja, M; Tamayo, I; Irache, JM; Gamazo, C				Ochoa-Reparaz, Javier; Sebastia, Eduard; Sitja, Marta; Tamayo, Ibai; Manuel Irache, Juan; Gamazo, Carlos			Protection Conferred by Drinking Water Administration of a Nanoparticle-Based Vaccine against Salmonella Enteritidis in Hens	VACCINES			English	Article						Salmonella enteritidis; vaccine; nanoparticles; hens	IMMUNE-RESPONSE; LIVE; ADJUVANTS; PROTEINS; EXTRACTS; EFFICACY; ENTERICA	Salmonellosis remains a major medical and an unmet socioeconomic challenge. Worldwide, more than three million deaths per year are associated with Salmonella enterica serovar Enteritidis infections. Although commercially available vaccines for use in poultry exist, their efficacy is limited. We previously described a method for isolating a heat extract (HE) fraction of the cell surface of S. Enteritidis that contained major antigenic complexes immunogenic in hens naturally infected with the bacterium. One single dose of S. Enteritidis' HE induced protection against lethal salmonellosis in mice. Furthermore, HE encapsulation in nanoparticles of the copolymer of methyl vinyl ether and maleic anhydride (PVM/MA), Gantrez AN, improved and prolonged the protection against the disease in mice. We formulated new preparations of Gantrez AN nanoparticles with HE S. Enteritidis and assessed their stability in drinking water and their efficacy in hens after experimental infection. The oral treatment of six-week-old hens with two doses of HE nanoparticles significantly reduced the Salmonella excretion in hens. Due to the effectiveness of the treatment in reducing bacterial excretion, we conclude that HE nanoencapsulation obtained from S. Enteritidis is a viable novel vaccination approach against salmonellosis in farms.	[Ochoa-Reparaz, Javier; Tamayo, Ibai; Gamazo, Carlos] Univ Navarra, Dept Microbiol & Parasitol, Pamplona 31008, Spain; [Ochoa-Reparaz, Javier] Eastern Washington Univ, Dept Biol, Cheney, WA 99004 USA; [Sebastia, Eduard; Sitja, Marta] Hipra Sci SL, Amer 17170, Spain; [Manuel Irache, Juan] Univ Navarra, Dept Chem & Pharmaceut Technol, Pamplona 31008, Spain		Gamazo, C (通讯作者)，Univ Navarra, Dept Microbiol & Parasitol, Pamplona 31008, Spain.	jochrep@gmail.com; eduard.sebastia@hipra.com; marta.sitja@hipra.com; ibai.tamayo.rodriguez@navarra.es; jmirache@unav.es; cgamazo@unav.es	Irache, Juan Manuel/T-3516-2017; GAMAZO, CARLOS/J-8478-2017	Irache, Juan Manuel/0000-0001-9687-3436; GAMAZO, CARLOS/0000-0002-6586-4657; Sitja, Marta/0000-0001-5963-1163; Ochoa-Reparaz, Javier/0000-0001-9610-3175; Tamayo, Ibai/0000-0003-2860-3359			Arbos P, 2003, J CONTROL RELEASE, V89, P19, DOI 10.1016/S0168-3659(03)00066-X; Arbos P, 2002, J CONTROL RELEASE, V83, P321, DOI 10.1016/S0168-3659(02)00015-9; Bose RJC, 2019, J IND ENG CHEM, V77, P12, DOI 10.1016/j.jiec.2019.04.044; Estevan M, 2006, VET MICROBIOL, V118, P124, DOI 10.1016/j.vetmic.2006.07.004; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Ferreira RBR, 2015, MBIO, V6, DOI 10.1128/mBio.01421-15; Gamazo C, 2017, HUM VACC IMMUNOTHER, V13, P2416, DOI 10.1080/21645515.2017.1348447; Gamazo C, 2015, METHODS MOL BIOL, V1225, P139, DOI 10.1007/978-1-4939-1625-2_10; Gayet R, 2017, MICROBIOL MOL BIOL R, V81, DOI 10.1128/MMBR.00007-17; Gomez S, 2006, J NANOSCI NANOTECHNO, V6, P3283, DOI 10.1166/jnn.2006.471; Han Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00935; Harrison JA, 1997, IMMUNOLOGY, V90, P618, DOI 10.1046/j.1365-2567.1997.00158.x; Huberman YD, 2019, POULTRY SCI, V98, P2422, DOI 10.3382/ps/pez003; Jajere SM, 2019, VET WORLD, V12, P504, DOI 10.14202/vetworld.2019.504-521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Majowicz SE, 2010, CLIN INFECT DIS, V50, P882, DOI 10.1086/650733; Martinez-Becerra FJ, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00473-17; McWhorter AR, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01380; Murillo M, 2002, J CONTROL RELEASE, V85, P237, DOI 10.1016/S0168-3659(02)00276-6; Nandre RM, 2015, CAN J VET RES, V79, P235; Newell DG, 2010, INT J FOOD MICROBIOL, V139, pS3, DOI 10.1016/j.ijfoodmicro.2010.01.021; Ochoa J, 2007, VACCINE, V25, P4410, DOI 10.1016/j.vaccine.2007.03.025; Ochoa-Reparaz J, 2005, VACCINE, V23, P1491, DOI 10.1016/j.vaccine.2004.09.016; Ochoa-Reparaz J, 2004, VET RES, V35, P291, DOI 10.1051/vetres:2004011; Renu S, 2018, INT J NANOMED, V13, P8195, DOI 10.2147/IJN.S185588; Ricke S.C., 2014, ADV BIOL, V2014, P1, DOI [10.1155/2014/813275, DOI 10.1155/2014/813275]; Ruiz-Gaton L, 2018, EUR J PHARM SCI, V118, P165, DOI 10.1016/j.ejps.2018.03.028; Salman HH, 2005, J CONTROL RELEASE, V106, P1, DOI 10.1016/j.jconrel.2005.03.033; Scallan E, 2011, EMERG INFECT DIS, V17, P16, DOI [10.3201/eid1701.P21101, 10.3201/eid1701.091101p2]; Singh M, 2003, INT J PARASITOL, V33, P469, DOI 10.1016/S0020-7519(03)00053-5; SZTEIN MB, 1994, J INFECT DIS, V170, P1508, DOI 10.1093/infdis/170.6.1508; Tamayo I, 2010, CLIN VACCINE IMMUNOL, V17, P1356, DOI 10.1128/CVI.00164-10; Tennant SM, 2016, VACCINE, V34, P2907, DOI 10.1016/j.vaccine.2016.03.072; van de Reep L, 2018, POULTRY SCI, V97, P2733, DOI 10.3382/ps/pey134	34	2	2	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							216	10.3390/vaccines9030216			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5RS	33802556	gold, Green Published			2022-04-29	WOS:000634211600001
J	Temchura, V				Temchura, Vladimir			Decorated and Encapsulated: Virus-Like Particles Against Viral Infections	VACCINES			English	Editorial Material							VACCINE		[Temchura, Vladimir] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Clin & Mol Virol, D-91054 Erlangen, Germany		Temchura, V (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Clin & Mol Virol, D-91054 Erlangen, Germany.	vladimir.temchura@fau.de		Temchura, Vladimir/0000-0002-8600-252X			El-Sayed A, 2020, ENVIRON SCI POLLUT R, V27, P19073, DOI 10.1007/s11356-018-3913-y; Frietze KM, 2016, CURR OPIN VIROL, V18, P44, DOI 10.1016/j.coviro.2016.03.001; Gonelli CA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030239; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Hazlewood JE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030496; Hobson-Peters J, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax7888; Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263; Keikha R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020074; Kim H, 2018, VIRAL IMMUNOL, V31, P174, DOI 10.1089/vim.2017.0141; Kim WS, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040633; Ledford H, 2020, NATURE, V585, P20, DOI 10.1038/d41586-020-02400-7; Lukacs NW, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040783; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Shah VK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01949; Thomas SJ, 2020, HUM VACC IMMUNOTHER, V16, P2524, DOI 10.1080/21645515.2020.1730657; Thrane S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030389; Tong T, 2014, VIROLOGY, V456, P55, DOI 10.1016/j.virol.2014.03.015; Xiao Y, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896-016-0285-6; Zhang NR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030481; Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069	20	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							273	10.3390/vaccines9030273			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5KQ	33803636	Green Published, gold			2022-04-29	WOS:000634193200001
J	Cote, CK; Biryukov, SS; Klimko, CP; Shoe, JL; Hunter, M; Rosario-Acevedo, R; Fetterer, DP; Moody, KL; Meyer, JR; Rill, NO; Dankmeyer, JL; Worsham, PL; Bozue, JA; Welkos, SL				Cote, Christopher K.; Biryukov, Sergei S.; Klimko, Christopher P.; Shoe, Jennifer L.; Hunter, Melissa; Rosario-Acevedo, Raysa; Fetterer, David P.; Moody, Krishna L.; Meyer, Joshua R.; Rill, Nathaniel O.; Dankmeyer, Jennifer L.; Worsham, Patricia L.; Bozue, Joel A.; Welkos, Susan L.			Protection Elicited by Attenuated Live Yersinia pestis Vaccine Strains against Lethal Infection with Virulent Y. pestis	VACCINES			English	Article						plague; Yersinia pestis; vaccine; mice; bubonic; pneumonic; live attenuated vaccine; phage shock protein (PSP)		The etiologic agent of plague, Yersinia pestis, is a globally distributed pathogen which poses both a natural and adversarial threat. Due largely to the rapid course and high mortality of pneumonic plague, vaccines are greatly needed. Two-component protein vaccines have been unreliable and potentially vulnerable to vaccine resistance. We evaluated the safety and efficacy of eight live Y. pestis strains derived from virulent strains CO92 or KIM6+ and mutated in one or more virulence-associated gene(s) or cured of plasmid pPst. Stringent, single-dose vaccination allowed down-selection of the two safest and most protective vaccine candidates, CO92 mutants pgm- pPst- and Delta yscN. Both completely protected BALB/c mice against subcutaneous and aerosol challenge with Y. pestis. Strain CD-1 outbred mice were more resistant to bubonic (but not pneumonic) plague than BALB/c mice, but the vaccines elicited partial protection of CD-1 mice against aerosol challenge, while providing full protection against subcutaneous challenge. A Delta yscN mutant of the nonencapsulated C12 strain was expected to display antigens previously concealed by the capsule. C12 Delta yscN elicited negligible titers to F1 but comparable antibody levels to whole killed bacteria, as did CO92 Delta yscN. Although one dose of C12 Delta yscN was not protective, vaccination with two doses of either CO92 Delta yscN, or a combination of the Delta yscN mutants of C12 and CO92, protected optimally against lethal bubonic or pneumonic plague. Protection against encapsulated Y. pestis required inclusion of F1 in the vaccine and was associated with high anti-F1 titers.	[Cote, Christopher K.; Biryukov, Sergei S.; Klimko, Christopher P.; Shoe, Jennifer L.; Hunter, Melissa; Rosario-Acevedo, Raysa; Fetterer, David P.; Moody, Krishna L.; Meyer, Joshua R.; Rill, Nathaniel O.; Dankmeyer, Jennifer L.; Worsham, Patricia L.; Bozue, Joel A.; Welkos, Susan L.] US Army Med Res Inst Infect Dis USAMRIID, Bacteriol Div, Ft Detrick, MD 21702 USA		Cote, CK (通讯作者)，US Army Med Res Inst Infect Dis USAMRIID, Bacteriol Div, Ft Detrick, MD 21702 USA.	chrstopher.k.cote@gmail.com; sergei.s.biryukov.mil@mail.mil; christopher.p.klimko2.ctr@mail.mil; jennifer.l.shoe.ctr@mail.mil; melissa.hunter.ctr@mail.mil; raysa.rosarioacevedo.mil@mail.mil; david.p.fetterer.ctr@mail.mil; moody_krishna_laroche@lilly.com; joshua.r.meyer15.mil@mail.mil; nathaniel.r.rill.ctr@mail.mil; Jennifer.l.dankmeyer.ctr@mail.mil; patricia.l.worsham.civ@mail.mil; joel.a.bozue.civ@mail.mil; susan.l.welkos.vol@mail.mil	Bozue, Joel/AAE-4363-2022; Bozue, Joel/AAE-4357-2022	Bozue, Joel/0000-0001-6959-8176; Bozue, Joel/0000-0001-6959-8176	U.S. Defense Threat Reduction Agency, project JSTO-CBD [CB10392, CB10645]	This work was funded by the U.S. Defense Threat Reduction Agency, project JSTO-CBD CB10392 and CB10645.	Achtman M, 2004, P NATL ACAD SCI USA, V101, P17837, DOI 10.1073/pnas.0408026101; Adamovicz J.J., 2012, LAB ANIMAL MODELS PL, P113; Allard JB, 2009, EUR J IMMUNOL, V39, P776, DOI 10.1002/eji.200838932; Anderson GW, 1996, INFECT IMMUN, V64, P4580, DOI 10.1128/IAI.64.11.4580-4585.1996; Andrews GP, 1996, INFECT IMMUN, V64, P2180, DOI 10.1128/IAI.64.6.2180-2187.1996; Andrews GP, 1999, INFECT IMMUN, V67, P1533, DOI 10.1128/IAI.67.3.1533-1537.1999; Anisimov AP, 2010, INFECT GENET EVOL, V10, P137, DOI 10.1016/j.meegid.2009.10.003; Auja SJ, 2007, SEMIN IMMUNOL, V19, P377, DOI 10.1016/j.smim.2007.10.009; Aust V, 2018, CYTOKINE, V111, P246, DOI 10.1016/j.cyto.2018.09.001; Bliska JB, 2006, BACTERIAL GENOMES AND INFECTIOUS DISEASES, P213, DOI 10.1007/978-1-59745-152-9_12; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bozue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104524; Bozue J, 2012, FEMS MICROBIOL LETT, V332, P113, DOI 10.1111/j.1574-6968.2012.02583.x; Bozue J, 2011, MICROB PATHOGENESIS, V50, P314, DOI 10.1016/j.micpath.2011.02.005; Brasiale V., 2009, FRONTIERS RES, V1, P473; Buchrieser C, 1999, INFECT IMMUN, V67, P4851, DOI 10.1128/IAI.67.9.4851-4861.1999; Busch RA, 2016, JPEN-PARENTER ENTER, V40, P256, DOI 10.1177/0148607114558489; Cirelli KM, 2017, CURR OPIN IMMUNOL, V47, P64, DOI 10.1016/j.coi.2017.06.008; Cornelius CA, 2008, INFECT IMMUN, V76, P5588, DOI 10.1128/IAI.00699-08; Cowan C, 2005, INFECT IMMUN, V73, P6127, DOI 10.1128/IAI.73.9.6127-6137.2005; Crawford MA, 2009, INFECT IMMUN, V77, P1664, DOI 10.1128/IAI.01208-08; Culbreth MJ, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040205; Daniel C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01830; Darwin AJ, 2001, MOL MICROBIOL, V39, P429, DOI 10.1046/j.1365-2958.2001.02235.x; Demeure CE, 2019, VACCINE, V37, P123, DOI 10.1016/j.vaccine.2018.11.022; Derbise A, 2020, VACCINE, V38, P1888, DOI 10.1016/j.vaccine.2020.01.014; Derbise A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004162; Derbise A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001528; DOLL JM, 1994, AM J TROP MED HYG, V51, P109, DOI 10.4269/ajtmh.1994.51.109; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Dworkin J, 2000, J BACTERIOL, V182, P311, DOI 10.1128/JB.182.2.311-319.2000; Ebner S, 2002, J IMMUNOL, V168, P6199, DOI 10.4049/jimmunol.168.12.6199; Eichelberger KR, 2019, MBIO, V10, DOI 10.1128/mBio.02759-19; Eichelberger KR, 2019, METHODS MOL BIOL, V2010, P197, DOI 10.1007/978-1-4939-9541-7_14; Eisele NA, 2011, AM J PATHOL, V178, P1190, DOI 10.1016/j.ajpath.2010.11.067; Elvin SJ, 2004, MICROB PATHOGENESIS, V37, P177, DOI 10.1016/j.micpath.2004.06.009; Erova TE, 2013, CLIN VACCINE IMMUNOL, V20, P227, DOI 10.1128/CVI.00597-12; Eyerich K, 2017, EUR J IMMUNOL, V47, P607, DOI 10.1002/eji.201646723; Feodorova VA, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040698; Feodorova VA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006511; Feodorova VA, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.34; FETHERSTON JD, 1992, MOL MICROBIOL, V6, P2693, DOI 10.1111/j.1365-2958.1992.tb01446.x; FETHERSTON JD, 1994, MOL MICROBIOL, V13, P697, DOI 10.1111/j.1365-2958.1994.tb00463.x; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Gupta G, 2010, SCAND J IMMUNOL, V71, P186, DOI 10.1111/j.1365-3083.2009.02365.x; Halstead ES, 2018, RESP RES, V19, DOI 10.1186/s12931-017-0708-5; Hartl D, 2006, J ALLERGY CLIN IMMUN, V117, P204, DOI 10.1016/j.jaci.2005.09.023; Heath DG, 1998, VACCINE, V16, P1131, DOI 10.1016/S0264-410X(98)80110-2; Heine HS, 2007, J INFECT DIS, V196, P782, DOI 10.1086/520547; Herbert DR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092276; Hill J, 1997, INFECT IMMUN, V65, P4476, DOI 10.1128/IAI.65.11.4476-4482.1997; Hinnebusch BJ, 2016, INFECT IMMUN, V84, P1932, DOI 10.1128/IAI.00188-16; Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943; JACKSON S, 1956, BRIT J EXP PATHOL, V37, P570; JACKSON S, 1956, BRIT J EXP PATHOL, V37, P577; Jenkins AL, 2009, J MICROBIOL METH, V77, P316, DOI 10.1016/j.mimet.2009.02.013; Jia QM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24581-y; JILG W, 1989, J INFECT DIS, V160, P766, DOI 10.1093/infdis/160.5.766; Kolls JK, 2010, CYTOKINE GROWTH F R, V21, P443, DOI 10.1016/j.cytogfr.2010.11.002; Kolls J, 2010, SEMIN IMMUNOPATHOL, V32, P1, DOI 10.1007/s00281-010-0198-8; Kummer LW, 2008, VACCINE, V26, P6901, DOI 10.1016/j.vaccine.2008.09.063; Lathem WW, 2007, SCIENCE, V315, P509, DOI 10.1126/science.1137195; LEARY SEC, 1995, INFECT IMMUN, V63, P2854, DOI 10.1128/IAI.63.8.2854-2858.1995; Leary SEC, 1995, CONTRIB TO MICROBIOL, V13, P216; Lee-Lewis H, 2010, INFECT IMMUN, V78, P220, DOI 10.1128/IAI.00559-09; Levy Y, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0087-z; Li B, 2012, CLIN VACCINE IMMUNOL, V19, P228, DOI 10.1128/CVI.05559-11; Li B, 2009, INFECT IMMUN, V77, P4356, DOI 10.1128/IAI.00242-09; Liang SC, 2007, J IMMUNOL, V179, P7791, DOI 10.4049/jimmunol.179.11.7791; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lin JS, 2011, J IMMUNOL, V186, P1675, DOI 10.4049/jimmunol.1003303; Lin JS, 2010, VACCINE, V29, P357, DOI 10.1016/j.vaccine.2010.08.099; Margulieux KR, 2016, MBIO, V7, DOI 10.1128/mBio.00334-16; Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5; MEYER KF, 1974, J INFECT DIS, V129, pS85, DOI 10.1093/infdis/129.Supplement_1.S85; MEYER KF, 1970, B WORLD HEALTH ORGAN, V42, P653; Miller NC, 2012, INFECT IMMUN, V80, P1572, DOI 10.1128/IAI.05637-11; Mizel SB, 2009, CLIN VACCINE IMMUNOL, V16, P21, DOI 10.1128/CVI.00333-08; Mostbock S, 2008, J IMMUNOL, V180, P5118, DOI 10.4049/jimmunol.180.7.5118; MOTIN VL, 1994, INFECT IMMUN, V62, P4192, DOI 10.1128/IAI.62.10.4192-4201.1994; Mueller CA, 2005, SCIENCE, V310, P674, DOI 10.1126/science.1118476; Muller K, 2003, INFECT IMMUN, V71, P6178, DOI 10.1128/IAI.71.11.6178-6183.2003; Nair VR, 2016, CELL REP, V16, P1253, DOI 10.1016/j.celrep.2016.06.080; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; Pettersson J, 1999, MOL MICROBIOL, V32, P961, DOI 10.1046/j.1365-2958.1999.01408.x; Philipovskiy AV, 2005, INFECT IMMUN, V73, P1532, DOI 10.1128/IAI.73.3.1532-1542.2005; Pitt L.M., 2004, P PLAG VACC WORKSH G; Plano GV, 2013, IMMUNOL RES, V57, P237, DOI 10.1007/s12026-013-8454-3; Powell BS, 2005, BIOTECHNOL PROGR, V21, P1490, DOI 10.1021/bp050098r; Qiu Y, 2010, SCAND J IMMUNOL, V72, P425, DOI 10.1111/j.1365-3083.2010.02456.x; Quenee LE, 2008, INFECT IMMUN, V76, P2025, DOI 10.1128/IAI.00105-08; Quenee LE, 2012, J INFECT DIS, V206, P1050, DOI 10.1093/infdis/jis433; Quenee LE, 2011, VACCINE, V29, P6572, DOI 10.1016/j.vaccine.2011.06.119; Ritger K., 2011, Morbidity and Mortality Weekly Report, V60, P201; Robinson VL, 2005, FEMS MICROBIOL LETT, V252, P251, DOI 10.1016/j.femsle.2005.09.001; Roggenkamp A, 1997, INFECT IMMUN, V65, P446, DOI 10.1128/IAI.65.2.446-451.1997; Sebbane F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111554; Sellers RS, 2012, VET PATHOL, V49, P32, DOI 10.1177/0300985811429314; Shang XZ, 2002, AM J PATHOL, V161, P257, DOI 10.1016/S0002-9440(10)64177-6; SIKKEMA DJ, 1987, INFECT IMMUN, V55, P572, DOI 10.1128/IAI.55.3.572-578.1987; Slifka MK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00956; Smiley ST, 2008, EXPERT REV VACCINES, V7, P209, DOI 10.1586/14760584.7.2.209; SODEINDE OA, 1992, SCIENCE, V258, P1004, DOI 10.1126/science.1439793; Steenwinckel V, 2009, J IMMUNOL, V182, P4737, DOI 10.4049/jimmunol.0801941; Stepanov A. V., 1999, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, P47; Sun W, 2016, ADV EXP MED BIOL, V918, P313, DOI 10.1007/978-94-024-0890-4_12; Sun W, 2014, INFECT IMMUN, V82, P4390, DOI 10.1128/IAI.02173-14; Sun W, 2013, CURR PHARM BIOTECHNO, V14, P878; Sun W, 2013, INFECT IMMUN, V81, P1172, DOI 10.1128/IAI.01403-12; Sun W, 2011, J INFECT DEV COUNTR, V5, P614, DOI 10.3855/jidc.2030; Sun W, 2011, VACCINE, V29, P2986, DOI 10.1016/j.vaccine.2011.01.099; Swietnicki W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019716; Szaba FM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004142; Taylor VL, 2005, MICROBIOL-SGM, V151, P1919, DOI 10.1099/mic.0.27959-0; Teitelbaum R, 1999, IMMUNITY, V10, P641, DOI 10.1016/S1074-7613(00)80063-1; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; Trevino SR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208277; Verma SK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00602; Wang XY, 2013, EXPERT REV VACCINES, V12, P677, DOI [10.1586/ERV.13.42, 10.1586/erv.13.42]; Wang XR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010095; Wang Z, 2016, BLOOD COAGUL FIBRIN, V27, P667, DOI 10.1097/MBC.0000000000000455; Welkos S, 2002, VACCINE, V20, P2206, DOI 10.1016/S0264-410X(02)00119-6; Welkos SL, 1997, MICROB PATHOGENESIS, V23, P211, DOI 10.1006/mpat.1997.0154; Welkos SL, 1995, CONTRIB TO MICROBIOL, V13, P299; WILLIAMS JE, 1979, B WORLD HEALTH ORGAN, V57, P309; Williamson ED, 2013, CLIN EXP IMMUNOL, V172, P1, DOI 10.1111/cei.12044; Williamson ED, 2012, J MED MICROBIOL, V61, P911, DOI 10.1099/jmm.0.037960-0; WILLIAMSON ED, 1995, FEMS IMMUNOL MED MIC, V12, P223, DOI 10.1111/j.1574-695X.1995.tb00196.x; Worsham PL, 1995, CONTRIB TO MICROBIOL, V13, P325; Zeng XY, 2003, INFECT IMMUN, V71, P1306, DOI 10.1128/IAI.71.3.1306-1315.2003; Zvi A, 2017, VACCINE, V35, P5995, DOI 10.1016/j.vaccine.2017.05.092	132	4	4	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							161	10.3390/vaccines9020161			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UB	33669472	Green Published, gold			2022-04-29	WOS:000623275500001
J	D'Errico, S; Turillazzi, E; Zanon, M; Viola, RV; Frati, P; Fineschi, V				D'Errico, Stefano; Turillazzi, Emanuela; Zanon, Martina; Viola, Rocco Valerio; Frati, Paola; Fineschi, Vittorio			The Model of "Informed Refusal" for Vaccination: How to Fight against Anti-Vaccinationist Misinformation without Disregarding the Principle of Self-Determination	VACCINES			English	Article						vaccination; refusal; misinformation; anti-vaccination movement; vaccine injury compensation	PUBLIC-HEALTH; MANDATORY REQUIREMENT; CHILDHOOD VACCINATION; HPV VACCINATION; MEASLES; COMMUNICATION; IMMUNIZATION; PARENTS; HESITANCY; CHILDREN	Vaccines are arguably a public health success story as well as an incredibly cost-effective medical resource. Despite this, worldwide concerns about their safety are growing, with the risk of increased morbidity and mortality in vaccine-preventable diseases because of vaccine refusal. The global political trend in developed countries is to increasingly reduce mandates and the compulsory nature of vaccination programs. This is due to strong opposition from anti-vaccination movements and groups. While these have existed since the beginnings of vaccinology, they have recently gained a strong foothold through massive exploitation of the media and especially the internet. This has led to widespread misinformation and greater difficulty for governments and health institutions in dealing with parents' concerns and misconceptions. Common strategies in order to maintain a high degree of public acceptance of vaccines include the enhancement of adverse effect reporting systems, the enrichment of scientific literature, and the dissemination of targeted information to parents and health care providers. Vaccine risk perception, in fact, largely exceeds the evidence and is linked to well-known general population cognitive bias, which must be recognized and corrected. Although there is no doubt about the convenience of universal vaccination, a lively international debate is underway with regard to the legitimacy of mandatory vaccination programs. Most scientists agree that the individual's right to self-determination should be preserved. The only way to simultaneously protect the right to health is to introduce an informed refusal model, which aims to guarantee the highest coverage rates for vaccination.	[D'Errico, Stefano; Zanon, Martina] Univ Trieste, Dept Surg Med & Hlth, I-34149 Trieste, Italy; [Turillazzi, Emanuela] Univ Pisa, Inst Legal Med, Dept Surg Pathol, Med Mol & Crit Area, I-56126 Pisa, Italy; [Viola, Rocco Valerio; Frati, Paola; Fineschi, Vittorio] Sapienza Univ Rome, Dept Anat Histol Forens & Orthopaed Sci, Viale Regina Elena 336, I-00161 Rome, Italy; [Frati, Paola; Fineschi, Vittorio] IRCCS Ist Ric & Cura Carattere Sci, Neuromed Mediterranean Neurol Inst, Via Atinense 18, I-86077 Pozzilli, Italy		Fineschi, V (通讯作者)，Sapienza Univ Rome, Dept Anat Histol Forens & Orthopaed Sci, Viale Regina Elena 336, I-00161 Rome, Italy.; Fineschi, V (通讯作者)，IRCCS Ist Ric & Cura Carattere Sci, Neuromed Mediterranean Neurol Inst, Via Atinense 18, I-86077 Pozzilli, Italy.	sderrico@units.it; emanuela.turillazzi@unipi.it; martina.zanon@virgilio.it; roccovalerio.viola@uniroma1.it; paola.frati@uniroma1.it; vittorio.fineschi@uniroma1.it	D'Errico, Stefano/AAO-8500-2020	D'Errico, Stefano/0000-0003-3689-0001; Fineschi, Vittorio/0000-0002-1686-3236; Frati, Paola/0000-0002-0358-7965; Viola, Rocco Valerio/0000-0002-9571-2013			Alavian SM, 2010, CLIN THER, V32, P1, DOI 10.1016/j.clinthera.2010.01.005; Alvarez-Pasquin MJ, 2009, EUROSURVEILLANCE, V14, P18; [Anonymous], 1999, MMWR MORB MORTAL WKL, V48, P241, DOI DOI 10.1001/JAMA.281.16.1481; Asturias EJ, 2016, VACCINE, V34, P3342, DOI 10.1016/j.vaccine.2016.05.018; Balicer RD, 2007, PEDIATRICS, V120, pE1269, DOI 10.1542/peds.2006-3569; Ball R, 2011, PEDIATRICS, V127, pS31, DOI 10.1542/peds.2010-1722F; Blume S, 2006, SOC SCI MED, V62, P628, DOI 10.1016/j.socscimed.2005.06.020; Calvert N, 2013, LANCET, V381, P1625, DOI 10.1016/S0140-6736(13)60953-8; Chan MH, 2012, J PEDIAT INF DIS SOC, V1, P47, DOI [10.1093/jpids/pis007, 10.1093/JPIDS/PIS007]; Clayton E.W, 2012, ADVERSE EFFECTS VACC, P57; Committee on the Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule Board on Population Health and Public Health Practice Institute of Medicine, 2013, CHILDH IMM SCHED SA, P99; Constable C, 2014, VACCINE, V32, P1793, DOI 10.1016/j.vaccine.2014.01.085; Danchin MH, 2018, VACCINE, V36, P6473, DOI 10.1016/j.vaccine.2017.08.003; Dannetun E, 2005, SCAND J PRIM HEALTH, V23, P149, DOI 10.1080/02813430510031306; Davies P, 2002, ARCH DIS CHILD, V87, P22, DOI 10.1136/adc.87.1.22; Diekema DS, 2005, PEDIATRICS, V115, P1428, DOI 10.1542/peds.2005-0316; Eggertson L, 2010, CAN MED ASSOC J, V182, pE199, DOI 10.1503/cmaj.109-3179; European Centre for Disease Prevention and Control, 2014, MEASL RUB MON; Evans G, 2006, CLIN INFECT DIS, V42, pS130, DOI 10.1086/499592; Goldstein S, 2015, VACCINE, V33, P4212, DOI 10.1016/j.vaccine.2015.04.042; Gostin LO, 2015, JAMA-J AM MED ASSOC, V313, P1099, DOI 10.1001/jama.2015.1518; Gottvall M, 2015, HEALTH CARE ANAL, V23, P50, DOI 10.1007/s10728-012-0237-9; Guess AM, 2020, VACCINE, V38, P7799, DOI 10.1016/j.vaccine.2020.10.018; Gust DA, 2004, PEDIATRICS, V114, pE16, DOI 10.1542/peds.114.1.e16; Haverkate M, 2012, EUROSURVEILLANCE, V17, P12; Hendrix KS, 2014, PEDIATRICS, V134, pE675, DOI 10.1542/peds.2013-4077; Hennock EP, 1998, SOC HIST MED, V11, P49, DOI 10.1093/shm/11.1.49; Horne Z, 2015, P NATL ACAD SCI USA, V112, P10321, DOI 10.1073/pnas.1504019112; Institute of Medicine, 2004, IMM SAF REV VACC AUT, DOI [10.17226/10997, DOI 10.17226/10997]; Isaacs D, 2004, J PAEDIATR CHILD H, V40, P392, DOI 10.1111/j.1440-1754.2004.00399.x; Isaacs D, 2004, J PAEDIATR CHILD H, V40, P247, DOI 10.1111/j.1440-1754.2004.00357.x; Isaacs D, 2009, VACCINE, V27, P615, DOI 10.1016/j.vaccine.2008.11.002; Jacobson RA, 2007, VACCINE, V25, P3146, DOI 10.1016/j.vaccine.2007.01.046; Jama A, 2019, PEDIATR HEALTH MED T, V10, P177, DOI 10.2147/PHMT.S212921; Kahan DM, 2013, SCIENCE, V342, P53, DOI 10.1126/science.1245724; Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Keelan J., 2011, DESIGNING NO FAULT V; Kennedy AM, 2005, PUBLIC HEALTH REP, V120, P252, DOI 10.1177/003335490512000306; Ladner J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-670; Leask J., 2002, THE J, V38, P124, DOI [10.1046/j.1440-1754.2002.00791.x, DOI 10.1046/J.1440-1754.2002.00791.X]; Looker C, 2011, B WORLD HEALTH ORGAN, V89, P371, DOI 10.2471/BLT.10.081901; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; Mason BW, 2000, J EPIDEMIOL COMMUN H, V54, P473, DOI 10.1136/jech.54.6.473; McLean Huang, 2011, Morbidity and Mortality Weekly Report, V60, P666; Mello MM, 2008, BIOETHICS, V22, P32, DOI 10.1111/j.1467-8519.2007.00590.x; Mereu N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040701; Meszaros JR, 1996, J CLIN EPIDEMIOL, V49, P697, DOI 10.1016/0895-4356(96)00007-8; Nickerson RS., 1998, REV GEN PSYCHOL, V2, P175, DOI [DOI 10.1037/1089-2680.2.2.175, 10.1037/1089-2680.2.2.175, DOI 10.1037/1089-2680.2.2.175.1998]; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Offit PA, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2434; Olpinski M., 2012, PEDIAT POL, V87, P381, DOI [10.1016/j.pepo.2012.05.003, DOI 10.1016/J.PEPO.2012.05.003]; Panatto D, 2018, HUM VACC IMMUNOTHER, V14, P969, DOI 10.1080/21645515.2017.1407483; Parrish-Sprowl J, 2018, VACCINE, V36, P6529, DOI 10.1016/j.vaccine.2017.09.064; Pelullo CP, 2014, EUROSURVEILLANCE, V19, P27, DOI 10.2807/1560-7917.ES2014.19.35.20889; Poland GA, 2001, VACCINE, V19, P2440, DOI 10.1016/S0264-410X(00)00469-2; Poland GA, 2011, NEW ENGL J MED, V364, P97, DOI 10.1056/NEJMp1010594; Prislin R, 1998, AM J PUBLIC HEALTH, V88, P1821, DOI 10.2105/AJPH.88.12.1821; Raithatha N, 2003, J PUBLIC HEALTH MED, V25, P161, DOI 10.1093/pubmed/fdg034; Salisbury DM, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2435; Salmon DA, 2006, LANCET, V367, P436, DOI 10.1016/S0140-6736(06)68144-0; Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470; Samad L, 2006, VACCINE, V24, P6823, DOI 10.1016/j.vaccine.2006.06.039; Schroder-Back P, 2015, CHEST, V148, P854, DOI 10.1378/chest.15-1162; Schroder-Back Peter, 2009, Central European Journal of Public Health, V17, P183; Schuster M, 2015, VACCINE, V33, P4157, DOI 10.1016/j.vaccine.2015.04.035; Seeman Neil, 2010, Healthc Q, V13 Spec No, P8; Silverman RD, 2015, CHEST, V148, P852, DOI 10.1378/chest.15-1163; Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215; SWALES JD, 1992, LANCET, V340, P1019, DOI 10.1016/0140-6736(92)93021-E; Taylor B, 1999, LANCET, V353, P2026, DOI 10.1016/S0140-6736(99)01239-8; Turillazzi E, 2014, AESTHET PLAST SURG, V38, P759, DOI 10.1007/s00266-014-0337-z; Vrdelja M, 2018, EUR J PUBLIC HEALTH, V28, P934, DOI 10.1093/eurpub/cky114; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Walkinshaw E, 2011, CAN MED ASSOC J, V183, pE1167, DOI 10.1503/cmaj.109-3993; WHO, 2015, WKLY EPIDEMIOL REC, V90, P365; WILLIAMSON S, 1984, ARCH DIS CHILD, V59, P1195, DOI 10.1136/adc.59.12.1195; Wilson CB, 2001, NAT REV IMMUNOL, V1, P160, DOI 10.1038/35100585; Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430; Wynia MK, 2007, AM J BIOETHICS, V7, P2, DOI 10.1080/15265160701795809; Yang YT, 2015, JAMA-J AM MED ASSOC, V313, P247, DOI 10.1001/jama.2014.16286	81	8	9	0	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							110	10.3390/vaccines9020110			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO7KJ	33535717	Green Published, gold, Green Submitted			2022-04-29	WOS:000623318500001
J	Isaacs, A; Li, ZY; Cheung, STM; Wijesundara, DK; McMillan, CLD; Modhiran, N; Young, PR; Ranasinghe, C; Watterson, D; Chappell, KJ				Isaacs, Ariel; Li, Zheyi; Cheung, Stacey T. M.; Wijesundara, Danushka K.; McMillan, Christopher L. D.; Modhiran, Naphak; Young, Paul R.; Ranasinghe, Charani; Watterson, Daniel; Chappell, Keith J.			Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines	VACCINES			English	Article						adjuvant; vaccine; influenza; RSV; microbiology; virology		Subunit vaccines exhibit favorable safety and immunogenicity profiles and can be designed to mimic native antigen structures. However, pairing with an appropriate adjuvant is imperative in order to elicit effective humoral and cellular immune responses. In this study, we aimed to determine an optimal adjuvant pairing with the prefusion form of influenza haemagglutinin (HA) or respiratory syncytial virus (RSV) fusion (F) subunit vaccines in BALB/c mice in order to inform future subunit vaccine adjuvant selection. We tested a panel of adjuvants, including aluminum hydroxide (alhydrogel), QS21, Addavax, Addavax with QS21 (AdQS21), and Army Liposome Formulation 55 with monophosphoryl lipid A and QS21 (ALF55). We found that all adjuvants elicited robust humoral responses in comparison to placebo, with the induction of potent neutralizing antibodies observed in all adjuvanted groups against influenza and in AdQS21, alhydrogel, and ALF55 against RSV. Upon HA vaccination, we observed that none of the adjuvants were able to significantly increase the frequency of CD4(+) and CD8(+) IFN-gamma(+) cells when compared to unadjuvanted antigen. The varying responses to antigens with each adjuvant highlights that those adjuvants most suited for pairing purposes can vary depending on the antigen used and/or the desired immune response. We therefore suggest that an adjuvant trial for different subunit vaccines in development would likely be necessary in preclinical studies.	[Isaacs, Ariel; Cheung, Stacey T. M.; McMillan, Christopher L. D.; Modhiran, Naphak; Young, Paul R.; Watterson, Daniel; Chappell, Keith J.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Li, Zheyi; Ranasinghe, Charani] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, ACT 2601, Australia; [Wijesundara, Danushka K.; Young, Paul R.; Chappell, Keith J.] Univ Queensland, Australian Inst Biotechnol & Nanotechnol, St Lucia, Qld 4072, Australia; [Young, Paul R.; Watterson, Daniel; Chappell, Keith J.] Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld 4072, Australia		Chappell, KJ (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.; Chappell, KJ (通讯作者)，Univ Queensland, Australian Inst Biotechnol & Nanotechnol, St Lucia, Qld 4072, Australia.; Chappell, KJ (通讯作者)，Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld 4072, Australia.	a.isaacs@uq.edu.au; zheyi.li@anu.edu.au; s.cheung@uq.edu.au; d.wijesundara@uq.edu.au; c.mcmillanl@uq.edu.au; n.modhiran@uq.edu.au; p.young@uq.edu.au; charani.ranasinghe@anmedu.au; d.watterson@uq.edu.au; k.chappell@uq.edu.au	Young, Paul R/A-6176-2010	Young, Paul R/0000-0002-2040-5190; McMillan, Christopher/0000-0002-5316-0986; Modhiran, Naphak/0000-0003-3205-4970; Isaacs, Ariel/0000-0002-8499-3083; Li, Zheyi/0000-0002-1128-8631; Cheung, Stacey/0000-0002-2371-1679	NHMRCNational Health and Medical Research Council (NHMRC) of Australia [APP1144025, APP1125107]; Coalition for Epidemic Preparedness and Innovations	This research was funded by NHMRC Project grant APP1144025, NHMRC Development grant APP1125107 and the Coalition for Epidemic Preparedness and Innovations.	Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15; ALSHAKHSHIR RH, 1995, VACCINE, V13, P41, DOI 10.1016/0264-410X(95)80009-3; Baldridge JR, 2004, EXPERT OPIN BIOL TH, V4, P1129, DOI 10.1517/14712598.4.7.1129; Bieback K, 2002, J VIROL, V76, P8729, DOI 10.1128/JVI.76.17.8729-8736.2002; Brewer JM, 2006, IMMUNOL LETT, V102, P10, DOI 10.1016/j.imlet.2005.08.002; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Chang CB, 2008, ACS NANO, V2, P281, DOI 10.1021/nn700385z; Chappell K.J., 2018, CHIMERIC MOL USES TH; Chesko J, 2005, J PHARM SCI-US, V94, P2510, DOI 10.1002/jps.20472; Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3; Collins AM, 2016, IMMUNOL CELL BIOL, V94, P949, DOI 10.1038/icb.2016.65; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; De Gregorio E, 2008, EUR J IMMUNOL, V38, P2068, DOI 10.1002/eji.200838648; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474; DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Fox Christopher B, 2013, Ther Adv Vaccines, V1, P7, DOI 10.1177/2051013613480144; Funchal GA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124082; Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]; George PJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020251; GREENBERG SB, 1979, P NATL ACAD SCI USA, V76, P4622, DOI 10.1073/pnas.76.9.4622; GREENBERG SB, 1978, INFECT IMMUN, V20, P640, DOI 10.1128/IAI.20.3.640-645.1978; GROSS PA, 1977, J INFECT DIS, V136, P623, DOI 10.1093/infdis/136.5.623; Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8; Hansen B, 2011, J PHARM SCI-US, V100, P3245, DOI 10.1002/jps.22555; Hawken J, 2012, VACCINE, V30, P6971, DOI 10.1016/j.vaccine.2012.09.059; Hem S.L., 2007, VACCINE ADJUVANTS DE, P81; Hemann EA, 2013, J IMMUNOL, V191, P2486, DOI 10.4049/jimmunol.1300954; Hiatt A, 2014, P NATL ACAD SCI USA, V111, P5992, DOI 10.1073/pnas.1402458111; Jegaskanda S, 2016, J INFECT DIS, V214, P945, DOI 10.1093/infdis/jiw262; Jegerlehner A, 2004, J IMMUNOL, V172, P5598, DOI 10.4049/jimmunol.172.9.5598; Jully V, 2016, J PHARM SCI-US, V105, P1829, DOI 10.1016/j.xphs.2016.03.032; Khanna M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41506-5; Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kumar A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00600; Li Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79172-7; Lichterfeld M, 2004, BLOOD, V104, P487, DOI 10.1182/blood-2003-12-4341; Liu WC, 2010, J VIROL, V84, P12011, DOI 10.1128/JVI.01316-10; Lu Y, 2014, P NATL ACAD SCI USA, V111, P125, DOI 10.1073/pnas.1308701110; Magro M, 2012, P NATL ACAD SCI USA, V109, P3089, DOI 10.1073/pnas.1115941109; Mameli C, 2018, EXPERT OPIN BIOL TH, V18, P1, DOI 10.1080/14712598.2018.1391786; MEGURO H, 1979, J IMMUNOL, V122, P2521; Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863; Mori A, 2012, EUR J IMMUNOL, V42, P2709, DOI 10.1002/eji.201242372; Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487; MURPHY BR, 1988, J CLIN MICROBIOL, V26, P1595, DOI 10.1128/JCM.26.8.1595-1597.1988; O'Hagan DT, 2007, EXPERT REV VACCINES, V6, P699, DOI 10.1586/14760584.6.5.699; O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/ERV.12.140, 10.1586/erv.12.140]; Oleszycka E, 2014, CURR OPIN IMMUNOL, V28, P1, DOI 10.1016/j.coi.2013.12.007; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Ozorowski G, 2018, J VIROL, V92, DOI 10.1128/JVI.00381-18; Panagioti E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00276; Park SA, 2007, MICROBIOL IMMUNOL, V51, P1099, DOI 10.1111/j.1348-0421.2007.tb04005.x; Quinones-Parra S, 2014, P NATL ACAD SCI USA, V111, P1049, DOI 10.1073/pnas.1322229111; Rallabhandi P, 2012, MBIO, V3, DOI 10.1128/mBio.00218-12; Ranasinghe C, 2007, J IMMUNOL, V178, P2370, DOI 10.4049/jimmunol.178.4.2370; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Schultze V, 2008, VACCINE, V26, P3209, DOI 10.1016/j.vaccine.2008.03.093; SCOTT R, 1977, CLIN EXP IMMUNOL, V28, P19; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Sedova ES, 2019, ACTA NATURAE, V11, P22, DOI 10.32607/20758251-2019-11-4-22-32; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strutt TM, 2018, MUCOSAL IMMUNOL, V11, P668, DOI 10.1038/mi.2017.101; Strutt TM, 2012, P NATL ACAD SCI USA, V109, pE2551, DOI 10.1073/pnas.1205894109; Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243; Valkenburg SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep22666; van de Sandt CE, 2014, J VIROL, V88, P1684, DOI 10.1128/JVI.02843-13; van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548; VELLA S, 1980, J MED VIROL, V6, P203, DOI 10.1002/jmv.1890060303; Von Holle TA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01457; WAGNER DK, 1989, J CLIN MICROBIOL, V27, P589, DOI 10.1128/JCM.27.3.589-592.1989; Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833; Watanabe A, 2019, CELL, V177, P1124, DOI 10.1016/j.cell.2019.03.048; Watson DS, 2012, VACCINE, V30, P2256, DOI 10.1016/j.vaccine.2012.01.070; Watson DS, 2011, CLIN VACCINE IMMUNOL, V18, P289, DOI 10.1128/CVI.00425-10; Watterson D., 2020, RES SQ PREPR, Vv1, DOI [10.21203/rs.3.rs-68892/v1, DOI 10.21203/RS.3.RS-68892/V1]; Wijesundara DK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.592370; Williams MA, 2006, IMMUNOL REV, V211, P146, DOI 10.1111/j.0105-2896.2006.00389.x; Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12; Younis SY, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0245-0; Zhang NR, 2016, CELL MOL IMMUNOL, V13, P180, DOI 10.1038/cmi.2015.03; Zhou X, 2016, ONCOTARGET, V7, P39171, DOI 10.18632/oncotarget.10047; Zimmerli SC, 2005, P NATL ACAD SCI USA, V102, P7239, DOI 10.1073/pnas.0502393102	88	5	5	3	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							71	10.3390/vaccines9020071			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6QH	33498370	Green Published, gold			2022-04-29	WOS:000623265700001
J	Shringi, S; O'Toole, D; Cole, E; Baker, KN; White, SN; Donofrio, G; Li, H; Cunha, CW				Shringi, Smriti; O'Toole, Donal; Cole, Emily; Baker, Katherine N.; White, Stephen N.; Donofrio, Gaetano; Li, Hong; Cunha, Cristina W.			OvHV-2 Glycoprotein B Delivered by a Recombinant BoHV-4 Is Immunogenic and Induces Partial Protection against Sheep-Associated Malignant Catarrhal Fever in a Rabbit Model	VACCINES			English	Article						viral-vectored vaccine; bovine herpesvirus-4; ovine herpesvirus-2; gammaherpesvirus; malignant catarrhal fever; rabbit model; glycoprotein B		An efficacious vaccine for sheep-associated malignant catarrhal fever (SA-MCF) is important for the livestock industry. Research towards SA-MCF vaccine development is hindered by the absence of culture systems to propagate the causative agent, ovine herpesvirus-2 (OvHV-2), which means its genome cannot be experimentally modified to generate an attenuated vaccine strain. Alternative approaches for vaccine development are needed to deliver OvHV-2 antigens. Bovine herpesvirus 4 (BoHV-4) has been evaluated as a vaccine vector for several viral antigens with promising results. In this study, we genetically engineered BoHV-4 to express OvHV-2 glycoprotein B (gB) and evaluated its efficacy as an SA-MCF vaccine using a rabbit model. The construction of a viable recombinant virus (BoHV-4-A Delta TK-OvHV-2-gB) and confirmation of OvHV-2 gB expression were performed in vitro. The immunization of rabbits with BoHV-4-A Delta TK-OvHV-2-gB elicited strong humoral responses to OvHV-2 gB, including neutralizing antibodies. Following intra-nasal challenge with a lethal dose of OvHV-2, 42.9% of the OvHV-2 gB vaccinated rabbits were protected against SA-MCF, while all rabbits in the mock-vaccinated group succumbed to SA-MCF. Overall, OvHV-2 gB delivered by the recombinant BoHV-4 was immunogenic and partly protective against SA-MCF in rabbits. These are promising results towards an SA-MCF vaccine; however, improvements are needed to increase protection rates.	[Shringi, Smriti; Cole, Emily; Baker, Katherine N.; White, Stephen N.; Cunha, Cristina W.] Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA; [O'Toole, Donal] Univ Wyoming, Dept Vet Sci, Laramie, WY 82070 USA; [White, Stephen N.; Li, Hong; Cunha, Cristina W.] ARS, Anim Dis Res Unit, USDA, Pullman, WA 99164 USA; [White, Stephen N.] Washington State Univ, Ctr Reprod Biol, Pullman, WA 99164 USA; [Donofrio, Gaetano] Univ Parma, Dept Med Vet Sci, I-43126 Parma, Italy; [Donofrio, Gaetano; Cunha, Cristina W.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA		Cunha, CW (通讯作者)，Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA.; Cunha, CW (通讯作者)，ARS, Anim Dis Res Unit, USDA, Pullman, WA 99164 USA.; Cunha, CW (通讯作者)，Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.	smriti_shringi@wsu.edu; DOT@uwyo.edu; emily.cole@wsu.edu; kayak@wsu.edu; stephen.white@usda.gov; gaetano.donofrio@unipt.it; hlidyz@gmail.com; cristina.cunha@usda.gov		White, Stephen N./0000-0001-9255-6054	USDA-ARSUnited States Department of Agriculture (USDA)USDA Agricultural Research Service [CWU 2090-32000-037-00D]	The project was funded by USDA-ARS CWU 2090-32000-037-00D.	AlHajri SM, 2017, J VIROL, V91, DOI 10.1128/JVI.02454-16; Areda D, 2018, EPIDEMIOL INFECT, V146, P904, DOI [10.1017/S0950268818000791, 10.1017/s0950268818000791]; Chastant-Maillard S, 2015, TRANSBOUND EMERG DIS, V62, P245, DOI 10.1111/tbed.12155; Cook E, 2019, VACCINE, V37, P5946, DOI 10.1016/j.vaccine.2019.08.040; Cunha CW, 2019, CURR CLIN MICROBIOL, V6, P148, DOI 10.1007/s40588-019-00126-3; Cunha CW, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00108-16; Cunha CW, 2015, VET MICROBIOL, V175, P349, DOI 10.1016/j.vetmic.2014.11.026; Donofrio G, 2008, VACCINE, V26, P6031, DOI 10.1016/j.vaccine.2008.09.023; Donofrio G, 2009, CLIN VACCINE IMMUNOL, V16, P1675, DOI 10.1128/CVI.00224-09; Egyed L, 1996, J CLIN MICROBIOL, V34, P1091, DOI 10.1128/JCM.34.5.1091-1095.1996; Egyed L, 2011, MICROB PATHOGENESIS, V50, P322, DOI 10.1016/j.micpath.2010.10.006; Franceschi V, 2011, VACCINE, V29, P3074, DOI 10.1016/j.vaccine.2011.01.075; Gagnon CA, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00092; Haig DM, 2008, VACCINE, V26, P4461, DOI 10.1016/j.vaccine.2008.06.056; Hussy D, 2001, CLIN DIAGN LAB IMMUN, V8, P123, DOI 10.1128/CDLI.8.1.123-128.2001; Jorge S, 2017, BIOTECH RES INNOV, V1, P6, DOI [10.1016/j.biori.2017.10.001, DOI 10.1016/J.BIORI.2017.10.001]; Lankester F, 2016, VET MICROBIOL, V195, P144, DOI 10.1016/j.vetmic.2016.09.019; Li H, 2006, J VET DIAGN INVEST, V18, P119, DOI 10.1177/104063870601800120; Moore DA, 2010, JAVMA-J AM VET MED A, V237, P87, DOI 10.2460/javma.237.1.87; NAEEM K, 1991, ARCH VIROL, V119, P239, DOI 10.1007/BF01310673; O'Toole D, 2014, VET PATHOL, V51, P437, DOI 10.1177/0300985813520435; OSORIO FA, 1982, VET MICROBIOL, V7, P503, DOI 10.1016/0378-1135(82)90045-1; OSORIO FA, 1983, AM J VET RES, V44, P975; Parameswaran N, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-59; Pedrera M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010115; Russell GC, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-51; Russell GC, 2009, VET J, V179, P324, DOI 10.1016/j.tvjl.2007.11.007; Traul DL, 2007, J VET DIAGN INVEST, V19, P405, DOI 10.1177/104063870701900412; Warming S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni035; Williams LBA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215605; Yang B, 2019, VET MICROBIOL, V229, P130, DOI 10.1016/j.vetmic.2018.12.025	31	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							90	10.3390/vaccines9020090			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7EI	33530566	gold, Green Published			2022-04-29	WOS:000623302700001
J	Booth, JS; Toapanta, FR				Booth, Jayaum S.; Toapanta, Franklin R.			B and T Cell Immunity in Tissues and Across the Ages	VACCINES			English	Review						B cells; T cells; tissue-resident memory cells; intestine; respiratory track; vaccines; mucosal immunity		B and T cells are key components of the adaptive immune system and coordinate multiple facets of immunity including responses to infection, vaccines, allergens, and the environment. In humans, B- and T-cell immunity has been determined using primarily peripheral blood specimens. Conversely, human tissues have scarcely been studied but they host multiple adaptive immune cells capable of mounting immune responses to pathogens and participate in tissue homeostasis. Mucosal tissues, such as the intestines and respiratory track, are constantly bombarded by foreign antigens and contain tissue-resident memory T (T-RM) cells that exhibit superior protective capacity to pathogens. Also, tissue-resident memory B (B-RM) cells have been identified in mice but whether humans have a similar population remains to be confirmed. Moreover, the immune system evolves throughout the lifespan of humans and undergoes multiple changes in its immunobiology. Recent studies have shown that age-related changes in tissues are not necessarily reflected in peripheral blood specimens, highlighting the importance of tissue localization and subset delineation as essential determinants of functional B and T cells at different life stages. This review describes our current knowledge of the main B- and T-cell subsets in peripheral blood and tissues across age groups.	[Booth, Jayaum S.; Toapanta, Franklin R.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21075 USA; [Booth, Jayaum S.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Toapanta, Franklin R.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA		Toapanta, FR (通讯作者)，Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21075 USA.; Toapanta, FR (通讯作者)，Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.	jbooth@som.umaryland.edu; ftoapanta@som.umaryland.edu	Booth, Jayaum/AAU-2839-2021	Toapanta, Franklin/0000-0001-9439-0828	University of Maryland Claude D. Pepper Older Americans Independence Center (UM-AOCIC); National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center [P30-AG028747]	F.R.T. is supported by a Pilot Project funded by the University of Maryland Claude D. Pepper Older Americans Independence Center (UM-AOCIC). The National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center P30-AG028747.	Abdelsamed HA, 2017, J EXP MED, V214, P1593, DOI 10.1084/jem.20161760; Adlowitz DG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128269; Agematsu K, 2000, IMMUNOL TODAY, V21, P204, DOI 10.1016/S0167-5699(00)01605-4; Allen JC, 2020, VACCINE, V38, P8264, DOI 10.1016/j.vaccine.2020.11.002; Allie SR, 2019, NAT IMMUNOL, V20, P97, DOI 10.1038/s41590-018-0260-6; Babu TM, 2014, VACCINE, V32, P6798, DOI 10.1016/j.vaccine.2014.09.070; Bakema JE, 2011, MUCOSAL IMMUNOL, V4, P612, DOI 10.1038/mi.2011.36; BANK I, 1994, CELL IMMUNOL, V156, P424, DOI 10.1006/cimm.1994.1187; Barker KA, 2020, J IMMUNOL, V204; Barone F, 2009, MUCOSAL IMMUNOL, V2, P495, DOI 10.1038/mi.2009.106; Ben-Horin S, 2004, CLIN IMMUNOL, V113, P119, DOI 10.1016/j.clim.2004.06.007; Bergsbaken T, 2017, CELL REP, V19, P114, DOI 10.1016/j.celrep.2017.03.031; Bergsbaken T, 2015, NAT IMMUNOL, V16, P406, DOI 10.1038/ni.3108; Bienenstock J, 2005, IMMUNOL REV, V206, P22, DOI 10.1111/j.0105-2896.2005.00299.x; Bonnaure G, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/7801781; Booth JS, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02263-6; Booth JS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00424; Borsutzky S, 2004, J IMMUNOL, V173, P3305, DOI 10.4049/jimmunol.173.5.3305; Brandtzaeg P, 1999, IMMUNOL REV, V171, P45, DOI 10.1111/j.1600-065X.1999.tb01342.x; Brandtzaeg P, 2010, CURR OPIN GASTROEN, V26, P554, DOI 10.1097/MOG.0b013e32833dccf8; Brandtzaeg P, 2010, IMMUNOL INVEST, V39, P303, DOI 10.3109/08820131003680369; BUDD RC, 1987, J IMMUNOL, V138, P1009; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Cannons JL, 2013, TRENDS IMMUNOL, V34, P200, DOI 10.1016/j.it.2013.01.001; Cazac BB, 2000, IMMUNITY, V13, P443, DOI 10.1016/S1074-7613(00)00044-3; Cerutti A, 2011, ANNU REV IMMUNOL, V29, P273, DOI 10.1146/annurev-immunol-031210-101317; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009; Chu VT, 2013, IMMUNOL REV, V251, P177, DOI 10.1111/imr.12011; Churov AV, 2020, IMMUNOL LETT, V226, P83, DOI 10.1016/j.imlet.2020.07.004; Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247; Cohen IR, 2014, J AUTOIMMUN, V54, P112, DOI 10.1016/j.jaut.2014.05.002; Collins N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11514; Cook DN, 2000, IMMUNITY, V12, P495, DOI 10.1016/S1074-7613(00)80201-0; Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015; de Bree GJ, 2007, J INFECT DIS, V195, P1718, DOI 10.1086/517612; Del Giudice G, 2017, NPJ AGING MECH DIS, V4, DOI 10.1038/s41514-017-0020-0; DELVENTHAL S, 1992, VIRCHOWS ARCH B, V62, P271, DOI 10.1007/BF02899692; Dhume K, 2018, IMMUNOLOGY, V155, P53, DOI 10.1111/imm.12942; Di Niro R, 2015, IMMUNITY, V43, P120, DOI 10.1016/j.immuni.2015.06.013; Dock J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182498; Dogan I, 2009, NAT IMMUNOL, V10, P1292, DOI 10.1038/ni.1814; Dotan I, 2010, INFLAMM BOWEL DIS, V16, P583, DOI 10.1002/ibd.21106; Durek P, 2016, IMMUNITY, V45, P1148, DOI 10.1016/j.immuni.2016.10.022; Ebisawa M, 2011, INT IMMUNOL, V23, P261, DOI 10.1093/intimm/dxq478; Ehrhardt GRA, 2005, J EXP MED, V202, P783, DOI 10.1084/jem.20050879; Ehrhardt GRA, 2003, P NATL ACAD SCI USA, V100, P13489, DOI 10.1073/pnas.1935944100; Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533; Ellyard JI, 2005, EUR J IMMUNOL, V35, P699, DOI 10.1002/eji.200425442; Fagarasan S, 2010, ANNU REV IMMUNOL, V28, P243, DOI 10.1146/annurev-immunol-030409-101314; Falini B, 2003, BLOOD, V102, P3684, DOI 10.1182/blood-2003-03-0750; Farstad IN, 2000, IMMUNOLOGY, V101, P354, DOI 10.1046/j.1365-2567.2000.00118.x; Fink K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00078; Forbes SJ, 2008, INFECT IMMUN, V76, P4137, DOI 10.1128/IAI.00416-08; Forbes SJ, 2011, MBIO, V2, DOI 10.1128/mBio.00042-11; Frasca D, 2004, J IMMUNOL, V172, P2155, DOI 10.4049/jimmunol.172.4.2155; Frasca D, 2016, VACCINE, V34, P2834, DOI 10.1016/j.vaccine.2016.04.023; Fresnay S, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0819-7; Ganusov VV, 2007, TRENDS IMMUNOL, V28, P514, DOI 10.1016/j.it.2007.08.009; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Gebert A, 2004, AM J PATHOL, V164, P65, DOI 10.1016/S0002-9440(10)63097-0; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Giesecke C, 2014, J IMMUNOL, V192, P3091, DOI 10.4049/jimmunol.1302783; Glauzy S, 2018, ARTHRITIS RHEUMATOL, V70, P298, DOI 10.1002/art.40352; Gonzalez-Garcia I, 2006, J IMMUNOL, V176, P4042, DOI 10.4049/jimmunol.176.7.4042; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Gordon A, 2018, CURR EPIDEMIOL REP, V5, P1, DOI 10.1007/s40471-018-0136-1; Goronzy JJ, 2005, CURR OPIN IMMUNOL, V17, P468, DOI 10.1016/j.coi.2005.07.020; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Gourley TS, 2004, SEMIN IMMUNOL, V16, P323, DOI 10.1016/j.smim.2004.08.013; Hao Y, 2011, BLOOD, V118, P1294, DOI 10.1182/blood-2011-01-330530; Heel KA, 1997, J GASTROEN HEPATOL, V12, P122, DOI 10.1111/j.1440-1746.1997.tb00395.x; Henry C, 2019, CELL HOST MICROBE, V25, P357, DOI 10.1016/j.chom.2019.01.002; Hiller AS, 1998, SCAND J IMMUNOL, V47, P159; Hombrink P, 2016, NAT IMMUNOL, V17, P1467, DOI 10.1038/ni.3589; Huang HY, 2018, P NATL ACAD SCI USA, V115, pE6826, DOI 10.1073/pnas.1712628115; Iijima N, 2014, SCIENCE, V346, P93, DOI 10.1126/science.1257530; Islam S, 2017, VACCINE, V35, P5666, DOI 10.1016/j.vaccine.2017.08.044; JACOBSON EB, 1974, CELL IMMUNOL, V13, P416, DOI 10.1016/0008-8749(74)90261-5; Jefferson T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4; Jegaskanda S, 2018, J VIROL, V92, DOI 10.1128/JVI.01970-17; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Johnson RW, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-37; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Joseph F., 2003, AGING IMMUNITY INFEC; Jung J, 2000, EUR J IMMUNOL, V30, P2437, DOI 10.1002/1521-4141(2000)30:8<2437::AID-IMMU2437>3.0.CO;2-M; Kadaoui KA, 2007, J IMMUNOL, V179, P7751, DOI 10.4049/jimmunol.179.11.7751; Kaech SM, 2007, IMMUNITY, V27, P393, DOI 10.1016/j.immuni.2007.08.007; Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307; Kalia V, 2010, IMMUNITY, V32, P91, DOI 10.1016/j.immuni.2009.11.010; Kaml M, 2006, VACCINE, V24, P6808, DOI 10.1016/j.vaccine.2006.06.037; Kang MC, 2016, J VIROL, V90, P2273, DOI 10.1128/JVI.02768-15; Kardava L, 2014, J CLIN INVEST, V124, P3252, DOI 10.1172/JCI74351; Khurana S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002920; Kim DY, 2011, J IMMUNOL, V186, P4253, DOI 10.4049/jimmunol.0903794; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Kositanont U, 2012, VIRAL IMMUNOL, V25, P471, DOI 10.1089/vim.2012.0024; Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Kyu SY, 2009, J IMMUNOL METHODS, V340, P42, DOI 10.1016/j.jim.2008.09.025; Lau D, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai8153; Lino AC, 2016, IMMUNOL REV, V269, P130, DOI 10.1111/imr.12374; Lui PP, 2020, IMMUNOLOGY, V161, P4, DOI 10.1111/imm.13208; Lund FE, 2008, CURR OPIN IMMUNOL, V20, P332, DOI 10.1016/j.coi.2008.03.003; Lund Frances E., 2005, V8, P25; Lycke N, 1999, J IMMUNOL, V163, P913; Martinet KZ, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-8; McHeyzer-Williams LJ, 2015, NAT IMMUNOL, V16, P296, DOI 10.1038/ni.3095; McKinstry KK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6377; McKinstry KK, 2012, J CLIN INVEST, V122, P2847, DOI 10.1172/JCI63689; Medina F, 2002, BLOOD, V99, P2154, DOI 10.1182/blood.V99.6.2154; Menard LC, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87310; Mesin L, 2011, J IMMUNOL, V187, P2867, DOI 10.4049/jimmunol.1003181; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Milner JJ, 2018, CURR OPIN IMMUNOL, V51, P162, DOI 10.1016/j.coi.2018.03.017; Mitchison NA, 2004, NAT REV IMMUNOL, V4, P308, DOI 10.1038/nri1334; Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683; Moskowitz DM, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag0192; Moylan David C, 2016, Pathog Immun, V1, P371, DOI 10.20411/pai.v1i2.166; Mueller SN, 2016, NAT REV IMMUNOL, V16, P79, DOI 10.1038/nri.2015.3; Nair N, 2016, MUCOSAL IMMUNOL, V9, P68, DOI 10.1038/mi.2015.36; Nakayama T, 2003, J IMMUNOL, V170, P1136, DOI 10.4049/jimmunol.170.3.1136; Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; Ng EK, 2003, MEDIAT INFLAMM, V12, P3, DOI 10.1080/0962935031000096917; Odendahl M, 2005, BLOOD, V105, P1614, DOI 10.1182/blood-2004-07-2507; Ogasawara N, 2011, ACTA OTO-LARYNGOL, V131, P116, DOI 10.3109/00016489.2010.520022; Oja AE, 2018, MUCOSAL IMMUNOL, V11, P654, DOI 10.1038/mi.2017.94; Oja AE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02654; Onodera T, 2012, P NATL ACAD SCI USA, V109, P2485, DOI 10.1073/pnas.1115369109; Owen RL, 1999, SEMIN IMMUNOL, V11, P157, DOI 10.1006/smim.1999.0171; Pallett LJ, 2017, J EXP MED, V214, P1567, DOI 10.1084/jem.20162115; Palm NW, 2014, CELL, V158, P1000, DOI 10.1016/j.cell.2014.08.006; Panduro M, 2016, ANNU REV IMMUNOL, V34, P609, DOI 10.1146/annurev-immunol-032712-095948; Pape KA, 2011, SCIENCE, V331, P1203, DOI 10.1126/science.1201730; Park CO, 2018, J ALLERGY CLIN IMMUN, V142, P647, DOI 10.1016/j.jaci.2017.09.042; Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Przekopowitz M, 2015, IMMUNOL CELL BIOL, V93, P429, DOI 10.1038/icb.2015.6; Purwar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016245; Quinn KM, 2018, CELL REP, V23, P3512, DOI 10.1016/j.celrep.2018.05.057; Raeber ME, 2018, IMMUNOL REV, V283, P176, DOI 10.1111/imr.12644; Reboldi A, 2016, SCIENCE, V352, DOI 10.1126/science.aaf4822; Reboldi A, 2016, IMMUNOL REV, V271, P230, DOI 10.1111/imr.12400; RICHMOND I, 1993, THORAX, V48, P1130, DOI 10.1136/thx.48.11.1130; Richter M, 2007, J IMMUNOL, V178, P4506, DOI 10.4049/jimmunol.178.7.4506; Roberts AI, 1999, IMMUNOLOGY, V97, P679; Robinson JK, 2001, J IMMUNOL, V166, P3688, DOI 10.4049/jimmunol.166.6.3688; Rochereau N, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001658; Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580; ROLDAN E, 1992, J EXP MED, V175, P1739, DOI 10.1084/jem.175.6.1739; Rubtsov AV, 2011, BLOOD, V118, P1305, DOI 10.1182/blood-2011-01-331462; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Sakai S, 2014, J IMMUNOL, V192, P2965, DOI 10.4049/jimmunol.1400019; Salerno-Goncalves R, 2002, J IMMUNOL, V169, P2196, DOI 10.4049/jimmunol.169.4.2196; Salerno-Goncalves R, 2005, INFECT IMMUN, V73, P3521, DOI 10.1128/IAI.73.6.3521-3530.2005; Salerno-Goncalves R, 2010, CLIN VACCINE IMMUNOL, V17, P1305, DOI 10.1128/CVI.00234-10; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sanz I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02458; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Scallan E, 2015, FOODBORNE PATHOG DIS, V12, P492, DOI 10.1089/fpd.2014.1915; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Seifert M, 2015, P NATL ACAD SCI USA, V112, pE546, DOI 10.1073/pnas.1416276112; Shen P, 2015, NAT REV IMMUNOL, V15, P441, DOI 10.1038/nri3857; Skon CN, 2013, NAT IMMUNOL, V14, P1285, DOI 10.1038/ni.2745; Soares LRB, 1998, J IMMUNOL, V161, P209; Sobhanie M, 2016, J INFECT DIS, V213, P922, DOI 10.1093/infdis/jiv526; Sohn HW, 2011, BLOOD, V118, P6332, DOI 10.1182/blood-2011-05-353102; Strutt TM, 2018, MUCOSAL IMMUNOL, V11, P668, DOI 10.1038/mi.2017.101; Sztein MB, 2007, CLIN INFECT DIS, V45, pS15, DOI 10.1086/518140; Sztein MB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00516; SZTEIN MB, 1995, J IMMUNOL, V155, P3987; Tabera S, 2008, HAEMATOL-HEMATOL J, V93, P1301, DOI 10.3324/haematol.12857; Talaat KR, 2014, J INFECT DIS, V209, P1860, DOI 10.1093/infdis/jiu123; Tangye SG, 2003, J IMMUNOL, V170, P686, DOI 10.4049/jimmunol.170.2.686; Tangye SG, 2009, EUR J IMMUNOL, V39, P2065, DOI 10.1002/eji.200939531; Teijaro JR, 2010, J VIROL, V84, P9217, DOI 10.1128/JVI.01069-10; Tezuka H, 2007, NATURE, V448, P929, DOI 10.1038/nature06033; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Thome JJC, 2015, TRENDS IMMUNOL, V36, P428, DOI 10.1016/j.it.2015.05.003; Thome JJC, 2014, CELL, V159, P814, DOI 10.1016/j.cell.2014.10.026; Toapanta FR, 2020, MUCOSAL VACCINES: INNOVATION FOR PREVENTING INFECTIOUS DISEASES, 2ND EDITION, P501, DOI 10.1016/B978-0-12-811924-2.00029-8; Toapanta FR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00374; Travis MA, 2007, NATURE, V449, P361, DOI 10.1038/nature06110; Turner DL, 2014, MUCOSAL IMMUNOL, V7, P501, DOI 10.1038/mi.2013.67; Turner JS, 2020, NATURE, V586, P127, DOI 10.1038/s41586-020-2711-0; United Nations, 2019, WORLD POP PROSP; Varona R, 2001, J CLIN INVEST, V107, pR37, DOI 10.1172/JCI11297; Verbrugghe P, 2008, HISTOCHEM CELL BIOL, V129, P311, DOI 10.1007/s00418-007-0369-4; Wahid R, 2008, MUCOSAL IMMUNOL, V1, P389, DOI 10.1038/mi.2008.30; Wahid R, 2015, MUCOSAL IMMUNOL, V8, P1349, DOI 10.1038/mi.2015.24; Wahid R, 2016, CLIN IMMUNOL, V173, P87, DOI 10.1016/j.clim.2016.09.006; Walrath JR, 2011, AM J RESP CELL MOL, V45, P24, DOI 10.1165/rcmb.2010-0241OC; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302; Wei C, 2007, J IMMUNOL, V178, P6624, DOI 10.4049/jimmunol.178.10.6624; Weinberger B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082967; Weiss GE, 2009, J IMMUNOL, V183, P2176, DOI 10.4049/jimmunol.0901297; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Whibley N, 2019, NAT IMMUNOL, V20, P386, DOI 10.1038/s41590-019-0351-z; Willinger T, 2005, J IMMUNOL, V175, P5895, DOI 10.4049/jimmunol.175.9.5895; Wols HAM, 2007, INT IMMUNOL, V19, P837, DOI 10.1093/intimm/dxm051; Wong MT, 2015, CELL REP, V11, P1822, DOI 10.1016/j.celrep.2015.05.022; Woon HG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005799; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11; Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352; Wroe PC, 2012, J INFECT DIS, V205, P1589, DOI 10.1093/infdis/jis240; Yeon SM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11492-7; Zens KD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85832; Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006; Zheng NY, 2004, J CLIN INVEST, V113, P1188, DOI 10.1172/JCI200420255; Zhu J, 2007, J EXP MED, V204, P595, DOI 10.1084/jem.20061792; Zhu J, 2013, NATURE, V497, P494, DOI 10.1038/nature12110; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	218	4	4	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							24	10.3390/vaccines9010024			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6YJ	33419014	Green Published			2022-04-29	WOS:000610817400001
J	Bosch-Camos, L; Lopez, E; Navas, MJ; Pina-Pedrero, S; Accensi, F; Correa-Fiz, F; Park, C; Carrascal, M; Dominguez, J; Salas, ML; Nikolin, V; Collado, J; Rodriguez, F				Bosch-Camos, Laia; Lopez, Elisabet; Navas, Maria Jesus; Pina-Pedrero, Sonia; Accensi, Francesc; Correa-Fiz, Florencia; Park, Chankyu; Carrascal, Montserrat; Dominguez, Javier; Salas, Maria Luisa; Nikolin, Veljko; Collado, Javier; Rodriguez, Fernando			Identification of Promiscuous African Swine Fever Virus T-Cell Determinants Using a Multiple Technical Approach	VACCINES			English	Article						ASFV; CD8(+) T-cells; antigen presentation; IFN&#947; ELISpot; epitope predictions; immunopeptidomics; promiscuous epitope	COMPLEX CLASS-I; CRYO-EM STRUCTURE; DENDRITIC CELLS; READING FRAME; DNA IMMUNIZATION; DOMESTIC PIGS; GENE; EXPRESSION; INFECTION; PEPTIDES	The development of subunit vaccines against African swine fever (ASF) is mainly hindered by the lack of knowledge regarding the specific ASF virus (ASFV) antigens involved in protection. As a good example, the identity of ASFV-specific CD8(+) T-cell determinants remains largely unknown, despite their protective role being established a long time ago. Aiming to identify them, we implemented the IFN gamma ELISpot as readout assay, using as effector cells peripheral blood mononuclear cells (PBMCs) from pigs surviving experimental challenge with Georgia2007/1. As stimuli for the ELISpot, ASFV-specific peptides or full-length proteins identified by three complementary strategies were used. In silico prediction of specific CD8(+) T-cell epitopes allowed identifying a 19-mer peptide from MGF100-1L, as frequently recognized by surviving pigs. Complementarily, the repertoire of SLA I-bound peptides identified in ASFV-infected porcine alveolar macrophages (PAMs), allowed the characterization of five additional SLA I-restricted ASFV-specific epitopes. Finally, in vitro stimulation studies using fibroblasts transfected with plasmids encoding full-length ASFV proteins, led to the identification of MGF505-7R, A238L and MGF100-1L as promiscuously recognized antigens. Interestingly, each one of these proteins contain individual peptides recognized by surviving pigs. Identification of the same ASFV determinants by means of such different approaches reinforce the results presented here.	[Bosch-Camos, Laia; Lopez, Elisabet; Navas, Maria Jesus; Pina-Pedrero, Sonia; Correa-Fiz, Florencia; Rodriguez, Fernando] IRTA, Ctr Recerca Sanitat Anim CReSA, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain; [Bosch-Camos, Laia; Lopez, Elisabet; Navas, Maria Jesus; Pina-Pedrero, Sonia; Accensi, Francesc; Correa-Fiz, Florencia; Rodriguez, Fernando] IRTA, OIE Collaborating Ctr Res & Control Emerging & Re, CReSA, Bellaterra 08193, Spain; [Accensi, Francesc] UAB, IRTA, Ctr Recerca Sanitat Anim CReSA, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain; [Accensi, Francesc] UAB, Fac Vet, Dept Sanitat & Anat Anim, Bellaterra 08193, Spain; [Park, Chankyu] Konkuk Univ, Dept Stem Cells & Regenerat Biol, Seoul 05029, South Korea; [Carrascal, Montserrat] CSIC, Inst Invest Biomed Barcelona, Unidad Espectrometria Masas Biol & Proteom, Bellaterra 08193, Spain; [Dominguez, Javier] Inst Nacl Invest & Tecnol Agr & Alimentaria INIA, Dept Biotecnol, Madrid 28049, Spain; [Salas, Maria Luisa] CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain; [Salas, Maria Luisa] Univ Autonoma Madrid, Madrid 28049, Spain; [Nikolin, Veljko] Boehringer Ingelheim Vet Res Ctr BIVRC GmbH & Co, D-30559 Hannover, Germany; [Collado, Javier] Dept Biol Cellular Fisiol & Immunol, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain		Rodriguez, F (通讯作者)，IRTA, Ctr Recerca Sanitat Anim CReSA, Campus Univ Autonoma Barcelona, Bellaterra 08193, Spain.; Rodriguez, F (通讯作者)，IRTA, OIE Collaborating Ctr Res & Control Emerging & Re, CReSA, Bellaterra 08193, Spain.	laia.bosch@irta.cat; elisabeth.lopezf@gmail.com; mariajesus.navas@irta.cat; sonia.pina@irta.cat; francesc.accensi@irta.cat; flor.correa@irta.cat; chankyu@konkuk.ac.kr; montserrat.carrascal.csic@uab.cat; juncal@inia.es; mlsalas@cbm.csic.es; veljko.nikolin@boehringer-ingelheim.com; javiercolladomiguens@gmail.com; fernando.rodriguez@irta.cat	Dominguez, Javier/I-1210-2015; Park, Chankyu/D-8775-2011; Bosch-Camós, Laia/AAD-6373-2022; Lopez Fernandez, elisabet/AGX-1992-2022; Correa-Fiz, Florencia/L-1529-2015; Pina-Pedrero, Sonia/U-2217-2017; Carrascal, Montserrat/M-1913-2014	Dominguez, Javier/0000-0001-7256-388X; Correa-Fiz, Florencia/0000-0002-9459-5871; Park, Chankyu/0000-0003-4855-2210; Rodriguez, Fernando/0000-0001-7361-8408; Pina-Pedrero, Sonia/0000-0001-5475-4770; Lopez Fernandez, Elisabet/0000-0003-4253-330X; Carrascal, Montserrat/0000-0002-0205-2176	Departament d'Economia i Coneixement de la Generalitat de Catalunya (Spain)Generalitat de Catalunya [2015 DI 037]; Boehringer Ingelheim Veterinary Research Center (BIVRC) GmbH Co. KGBoehringer Ingelheim; Ministerio de Ciencia e Innovacion of SpainSpanish Government [AGL2016-78169-C2-1-R, PID2019-107616RB-I00]; Red de Investigacion en Sanidad Animal (RISA)	This research was funded by Departament d'Economia i Coneixement de la Generalitat de Catalunya (Spain), grant number 2015 DI 037. Studies were co-financed by Boehringer Ingelheim Veterinary Research Center (BIVRC) GmbH & Co. KG, the Ministerio de Ciencia e Innovacion of Spain (grant numbers AGL2016-78169-C2-1-R and PID2019-107616RB-I00) and Red de Investigacion en Sanidad Animal (RISA).	Alejo A, 2018, J VIROL, V92, DOI 10.1128/JVI.01293-18; Alonso C, 2018, J GEN VIROL, V99, P613, DOI 10.1099/jgv.0.001049; Andres G, 2020, J BIOL CHEM, V295, P1, DOI 10.1074/jbc.AC119.011196; Argilaguet JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040942; Arias M, 2002, TRENDS IN EMERGING VIRAL INFECTIONS OF SWINE, P133; Arias M, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040035; Balmelli C, 2005, J LEUKOCYTE BIOL, V77, P923, DOI 10.1189/jlb.1204701; Barderas MG, 2001, ARCH VIROL, V146, P1681, DOI 10.1007/s007050170056; Beltran-Alcrudo D., 2008, AFRICAN SWINE FEVER, P1; Borca MV, 2020, J VIROL, V94, DOI 10.1128/JVI.02017-19; Borca MV, 1998, J VIROL, V72, P2881, DOI 10.1128/JVI.72.4.2881-2889.1998; Bosch-Camos L., 2019, UNMASKING AFRICAN SW; Bosch-Camos L, 2020, PORCINE HEALTH MANAG, V6, DOI 10.1186/s40813-020-00154-2; Bullido R., 1996, Investigacion Agraria Produccion y Sanidad Animales, V11, P29; Cackett G, 2020, J VIROL, V94, DOI 10.1128/JVI.00119-20; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Cardinaud S, 2004, J EXP MED, V199, P1053, DOI 10.1084/jem.20031869; Chalick M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165031; Chapman DAG, 2011, EMERG INFECT DIS, V17, P599, DOI 10.3201/eid1704.101283; Chen WY, 2020, SCI CHINA LIFE SCI, V63, P623, DOI 10.1007/s11427-020-1657-9; Choi H, 2015, TISSUE ANTIGENS, V86, P255, DOI 10.1111/tan.12648; Correa-Fiz F., 2014, IDENTIFICATION POTEN; Costard S, 2013, VIRUS RES, V173, P191, DOI 10.1016/j.virusres.2012.10.030; Diez-Rivero CM, 2010, PROTEINS, V78, P63, DOI 10.1002/prot.22535; Dinter J, 2014, J IMMUNOL, V193, P4322, DOI 10.4049/jimmunol.1400491; Fan SH, 2016, J VIROL, V90, P6625, DOI 10.1128/JVI.00119-16; Franzoni G, 2018, VIRUS RES, V258, P73, DOI 10.1016/j.virusres.2018.10.007; Franzoni G, 2018, VET MICROBIOL, V216, P190, DOI 10.1016/j.vetmic.2018.02.021; Franzoni G, 2017, VET MICROBIOL, V198, P88, DOI 10.1016/j.vetmic.2016.12.010; Gao CX, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02524; Ge SQ, 2018, EMERG INFECT DIS, V24, P2131, DOI 10.3201/eid2411.181274; Gil S, 2008, ARCH VIROL, V153, P1845, DOI 10.1007/s00705-008-0196-5; Goatley LC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020234; Goh S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162571; Golding JP, 2016, VIROLOGY, V493, P154, DOI 10.1016/j.virol.2016.03.019; GOMEZVILLAMANDOS JC, 1995, J GEN VIROL, V76, P2399, DOI 10.1099/0022-1317-76-9-2399; GONZALVO FR, 1986, AM J VET RES, V47, P1249; Graham SP, 2006, P NATL ACAD SCI USA, V103, P3286, DOI 10.1073/pnas.0511273103; GREGG DA, 1995, J VET DIAGN INVEST, V7, P44, DOI 10.1177/104063879500700106; GREGG DA, 1995, J VET DIAGN INVEST, V7, P23, DOI 10.1177/104063879500700104; Han J, 2005, MOL CELL BIOL, V25, P6869, DOI 10.1128/MCB.25.16.6869-6878.2005; Ivanov V, 2011, MOL MED REP, V4, P395, DOI 10.3892/mmr.2011.454; Jancovich JK, 2018, J VIROL, V92, DOI [10.1128/JVI.02219-17, 10.1128/jvi.02219-17]; Jenson JS, 2000, J IMMUNOL METHODS, V242, P33, DOI 10.1016/S0022-1759(00)00222-2; Kim SH, 2020, EMERG MICROBES INFEC, V9, P628, DOI 10.1080/22221751.2020.1738904; Kulpa DA, 2013, J VIROL, V87, P8085, DOI 10.1128/JVI.00701-13; Lacasta A, 2014, J VIROL, V88, P13322, DOI 10.1128/JVI.01893-14; Lee J, 2019, ANIM GENET, V50, P315, DOI 10.1111/age.12785; Li XD, 2018, VET REC, V183, P300, DOI 10.1136/vr.k3774; Liu S, 2019, CELL HOST MICROBE, V26, P836, DOI 10.1016/j.chom.2019.11.004; Lokhandwala S, 2019, VET MICROBIOL, V235, P10, DOI 10.1016/j.vetmic.2019.06.006; Maccari G, 2017, NUCLEIC ACIDS RES, V45, pD860, DOI 10.1093/nar/gkw1050; Mayrand SM, 1998, J IMMUNOL, V160, P39; Le MT, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57712-5; Moise L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.563362; Monteagudo PL, 2017, J VIROL, V91, DOI [10.1128/JVI.01058-17, 10.1128/jvi.01058-17]; MONTGOMERY R. Eustace, 1921, Journal of Comparative Pathology and Therapeutics, V34, P159; Mulumba-Mfumu LK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9020031; Neilan JG, 2004, VIROLOGY, V319, P337, DOI 10.1016/j.virol.2003.11.011; Netherton CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01318; Nielsen M, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0288-x; O'Donnell V, 2017, J VIROL, V91, DOI 10.1128/JVI.01760-16; O'Donnell V, 2015, J VIROL, V89, P6048, DOI 10.1128/JVI.00554-15; ONISK DV, 1994, VIROLOGY, V198, P350, DOI 10.1006/viro.1994.1040; Oura CAL, 1998, J VIROL METHODS, V72, P205, DOI 10.1016/S0166-0934(98)00029-9; Oura CAL, 2005, J GEN VIROL, V86, P2445, DOI 10.1099/vir.0.81038-0; Pan I. C., 1987, African swine fever, P81; Perez-Nunez D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123714; Piriou-Guzylack L, 2008, VET RES, V39, DOI 10.1051/vetres:2008030; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Probst-Kepper M, 2001, J EXP MED, V193, P1189, DOI 10.1084/jem.193.10.1189; Probst-Kepper M, 2004, J IMMUNOL, V173, P5610, DOI 10.4049/jimmunol.173.9.5610; Pymm P, 2017, NAT STRUCT MOL BIOL, V24, P387, DOI 10.1038/nsmb.3381; Ramarathinam SH, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700253; Robbins PF, 1997, J IMMUNOL, V159, P303; Rodriguez F, 2000, VIROLOGY, V268, P233, DOI 10.1006/viro.2000.0209; Rodriguez F, 1998, J VIROL, V72, P5174, DOI 10.1128/JVI.72.6.5174-5181.1998; Rodriguez F, 2001, J VIROL, V75, P7399, DOI 10.1128/JVI.75.16.7399-7409.2001; Ros-Lucas A, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9121078; RuizGonzalvo F, 1996, VIROLOGY, V218, P285, DOI 10.1006/viro.1996.0193; Sang H, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00084; Schellens IMM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136417; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.iy.11.040193.003501; SIMONMATEO C, 1993, EMBO J, V12, P2977, DOI 10.1002/j.1460-2075.1993.tb05960.x; Simulundu E, 2018, TRANSBOUND EMERG DIS, V65, P114, DOI 10.1111/tbed.12635; Sunwoo SY, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010012; Takamatsu HH, 2013, VIRUS RES, V173, P110, DOI 10.1016/j.virusres.2012.11.009; Takashima A, 2001, Curr Protoc Cell Biol, VChapter 2, DOI 10.1002/0471143030.cb0201s00; Trujillo JA, 2014, J BIOL CHEM, V289, P27979, DOI 10.1074/jbc.M114.573402; Tynan FE, 2005, J BIOL CHEM, V280, P23900, DOI 10.1074/jbc.M503060200; Wonderlich ER, 2008, J BIOL CHEM, V283, P3011, DOI 10.1074/jbc.M707760200; YANEZ RJ, 1993, GENE, V134, P161, DOI 10.1016/0378-1119(93)90090-P; Zhang NZ, 2011, J VIROL, V85, P11709, DOI 10.1128/JVI.05040-11; Zhu DY, 2015, INFLAMMATION, V38, P1823, DOI 10.1007/s10753-015-0160-y; ZSAK L, 1993, VIROLOGY, V196, P596, DOI 10.1006/viro.1993.1515	95	7	7	1	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							29	10.3390/vaccines9010029			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6UL	33430316	Green Published, gold			2022-04-29	WOS:000610807000001
J	Cagigi, A; Lore, K				Cagigi, Alberto; Lore, Karin			Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans	VACCINES			English	Review						mRNA vaccine; dendritic cell; protein translation; type I interferon; Th1 polarization; antibody response; SARS-CoV-2	ANTIGEN-PRESENTING CELLS; T-CELL; IN-VIVO; LIPID NANOPARTICLES; H7N9 INFLUENZA; VACCINES; DELIVERY; PROTECTION; INDUCTION; POTENT	In this concise review, we summarize the concepts behind mRNA vaccination. We discuss the innate and adaptive immune response generated by mRNA vaccines in different animal models and in humans. We give examples of viral infections where mRNA vaccines have shown to induce potent responses and we discuss in more detail the recent SARS-CoV-2 mRNA vaccine trials in humans.	[Cagigi, Alberto; Lore, Karin] Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Immunol & Allergy, S-16164 Solna, Sweden		Lore, K (通讯作者)，Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Immunol & Allergy, S-16164 Solna, Sweden.	alberto.cagigi@ki.se; Karin.Lore@ki.se		Lore, Karin/0000-0001-7679-9494	Swedish Research Council (Vetenskapsradet)Swedish Research Council [2019-01036, 2020-05829]; Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation [KAW 2020.0182]	This research was funded by the Swedish Research Council (Vetenskapsradet), grant numbers 2019-01036 and 2020-05829 to K.L. and SciLifeLab/Knut, and the Alice Wallenberg Foundation, grant number KAW 2020.0182 to K.L.	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Akinc A, 2010, MOL THER, V18, P1357, DOI 10.1038/mt.2010.85; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Allard SD, 2012, CLIN IMMUNOL, V142, P252, DOI 10.1016/j.clim.2011.10.010; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Asselin-Paturel C, 2005, J EXP MED, V201, P1157, DOI 10.1084/jem.20041930; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Bourquin C, 2007, BLOOD, V109, P2953, DOI 10.1182/blood-2006-07-033258; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Chen S, 2016, J CONTROL RELEASE, V235, P236, DOI 10.1016/j.jconrel.2016.05.059; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; De Beuckelaer A, 2017, TRENDS MOL MED, V23, P216, DOI 10.1016/j.molmed.2017.01.006; De Beuckelaer A, 2016, MOL THER, V24, P2012, DOI 10.1038/mt.2016.161; Erasmus JH, 2018, MOL THER, V26, P2507, DOI 10.1016/j.ymthe.2018.07.010; Espeseth AS, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0163-z; Eygeris Y, 2020, NANO LETT, V20, P4543, DOI 10.1021/acs.nanolett.0c01386; Francica JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7565; Gabor, 2020, PHASE 1 ASSESSMENT S, DOI [10.1101/2020.11.09.20228551, DOI 10.1101/2020.11.09.20228551]; Gandhi RT, 2016, JAIDS-J ACQ IMM DEF, V71, P246, DOI 10.1097/QAI.0000000000000852; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Graham BS, 2018, JAMA-J AM MED ASSOC, V319, P1431, DOI 10.1001/jama.2018.0345; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Heesters BA, 2016, TRENDS IMMUNOL, V37, P844, DOI 10.1016/j.it.2016.10.003; Hekele A, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.54; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; John S, 2018, VACCINE, V36, P1689, DOI 10.1016/j.vaccine.2018.01.029; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Kowalczyk A, 2016, VACCINE, V34, P3882, DOI 10.1016/j.vaccine.2016.05.046; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kulkarni JA, 2018, NUCLEIC ACID THER, V28, P146, DOI 10.1089/nat.2018.0721; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Lazzaro S, 2015, IMMUNOLOGY, V146, P312, DOI 10.1111/imm.12505; Lee SM, 2021, ANGEW CHEM INT EDIT, V60, P5848, DOI 10.1002/anie.202013927; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Liang F, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2094; Lindgren G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01539; Lindsay KE, 2019, NAT BIOMED ENG, V3, P371, DOI 10.1038/s41551-019-0378-3; Lipsitch M, 2020, NAT REV IMMUNOL, V20, P709, DOI 10.1038/s41577-020-00460-4; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Maugeri M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12275-6; McNamara MA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/794528; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Meyer M, 2018, J INFECT DIS, V217, P451, DOI 10.1093/infdis/jix592; Monath TP, 2012, VACCINES, DOI 10.1016/B978-1-4557-0090-5.00043-4; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Oberli MA, 2017, NANO LETT, V17, P1326, DOI 10.1021/acs.nanolett.6b03329; Ols S, 2019, NAT BIOMED ENG, V3, P331, DOI 10.1038/s41551-019-0399-y; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Persano S, 2017, BIOMATERIALS, V125, P81, DOI 10.1016/j.biomaterials.2017.02.019; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Pollard C, 2013, MOL THER, V21, P251, DOI 10.1038/mt.2012.202; Rauch S, 2020, MRNA BASED SARS COV2, V2020, DOI [10.23.351775, 10.1101/2020.10.23.351775., DOI 10.1101/2020.10.23.351775, 10.1101/2020.10.23.351775]; Rauch S., 2020, MRNA VACCINE CVNCOV, DOI [10.1101/2020.12.23.424138, DOI 10.1101/2020.12.23.424138]; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Richner JM, 2017, CELL, V169, P176, DOI 10.1016/j.cell.2017.03.016; Routy JP, 2010, CLIN IMMUNOL, V134, P140, DOI 10.1016/j.clim.2009.09.009; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; SANDS H, 1994, MOL PHARMACOL, V45, P932; Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269; Schnee M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004746; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P961, DOI 10.1016/j.jaci.2013.11.043; Simmons DP, 2012, J IMMUNOL, V188, P3116, DOI 10.4049/jimmunol.1101313; Stitz L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006108; Tam HH, 2016, P NATL ACAD SCI USA, V113, pE6639, DOI 10.1073/pnas.1606050113; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Van Craenenbroeck AH, 2015, TRANSPLANTATION, V99, P120, DOI 10.1097/TP.0000000000000272; van den Elzen P, 2005, NATURE, V437, P906, DOI 10.1038/nature04001; Van Gulck E, 2012, AIDS, V26, pF1, DOI 10.1097/QAD.0b013e32834f33e8; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Weissman D., 2021, CELL HOST MICROBE, V29, P23, DOI [10.1016/j.chom.2020.11.012, DOI 10.1016/j.chom.2020.11.012]; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xie Xuping, 2021, bioRxiv, DOI 10.1101/2021.01.07.425740; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; ZHOU X, 1994, VACCINE, V12, P1510, DOI 10.1016/0264-410X(94)90074-4	84	31	31	3	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							61	10.3390/vaccines9010061			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6TZ	33477534	gold, Green Published			2022-04-29	WOS:000610805800001
J	Costantino, C; Mazzucco, W; Bonaccorso, N; Cimino, L; Conforto, A; Sciortino, M; Catalano, G; D'Anna, MR; Maiorana, A; Venezia, R; Corsello, G; Vitale, F				Costantino, Claudio; Mazzucco, Walter; Bonaccorso, Nicole; Cimino, Livia; Conforto, Arianna; Sciortino, Martina; Catalano, Gabriele; D'Anna, Maria Rosa; Maiorana, Antonio; Venezia, Renato; Corsello, Giovanni; Vitale, Francesco			Educational Interventions on Pregnancy Vaccinations during Childbirth Classes Improves Vaccine Coverages among Pregnant Women in Palermo's Province	VACCINES			English	Article						maternal immunization; influenza vaccination; diphtheria-tetanus-pertussis vaccination; childbirth courses; vaccination counseling	INFLUENZA VACCINATION; PERTUSSIS; IMMUNIZATION; PNEUMONIA; DISEASE	Maternal immunization is considered the best intervention in order to prevent influenza infection of pregnant women and influenza and pertussis infection of newborns. Despite the existing recommendations, vaccination coverage rates in Italy remain very low. Starting from August 2018, maternal immunization against influenza and diphtheria-tetanus-pertussis were strongly recommended by the Italian Ministry of Health. We conducted a cross sectional study to estimate the effectiveness of an educational intervention, conducted during childbirth classes in three general hospitals in the Palermo metropolitan area, Italy, on vaccination adherence during pregnancy. To this end, a questionnaire on knowledge, attitudes, and immunization practices was structured and self-administered to a sample of pregnant women attending childbirth classes. Then, an educational intervention on maternal immunization, followed by a counseling, was conducted by a Public Health medical doctor. After 30 days following the interventions, the adherence to the recommended vaccinations (influenza and pertussis) was evaluated. At the end of the study 326 women were enrolled and 201 responded to the follow-up survey. After the intervention, among the responding pregnant women 47.8% received influenza vaccination (+44.8%), 57.7% diphtheria-tetanus-pertussis vaccination (+50.7%) and 64.2% both the recommended vaccinations (+54.8%). A significant association was found between pregnant women that received at least one vaccination during pregnancy and higher educational level (graduation degree/master's degree), employment status (employed part/full-time) and influenza vaccination adherence during past seasons (at least one during last five years). The implementation of vaccination educational interventions, including counseling by healthcare professionals (HCPs), on maternal immunization during childbirth courses improved considerably the vaccination adherence during pregnancy.	[Costantino, Claudio; Mazzucco, Walter; Bonaccorso, Nicole; Cimino, Livia; Conforto, Arianna; Sciortino, Martina; Catalano, Gabriele; Venezia, Renato; Corsello, Giovanni; Vitale, Francesco] Univ Palermo, Internal Med & Med Specialties PROMISE G DAlessan, Dept Hlth Promot Sci Maternal & Infant Care, I-90127 Palermo, Italy; [D'Anna, Maria Rosa] Buccheri La Ferla Fatebenefratelli Hosp, HCU Obstet & Gynecol, I-90100 Palermo, Italy; [Maiorana, Antonio] ARNAS Osped Civ Di Cristina Benfratelli Hosp, HCU Obstet & Gynecol, I-90127 Palermo, Italy		Costantino, C (通讯作者)，Univ Palermo, Internal Med & Med Specialties PROMISE G DAlessan, Dept Hlth Promot Sci Maternal & Infant Care, I-90127 Palermo, Italy.	claudio.costantino01@unipa.it; walter.mazzucco@unipa.it; nicole.bonaccorso@unipa.it; livia.cimino@unipa.it; arianna.conforto@unipa.it; martina.sciortino@unipa.it; gabriele.catalano19@gmail.com; danna.mr@gmail.com; maioran@alice.it; renato.venezia@unipa.it; giovanni.corsello@unipa.it; francesco.vitale@unipa.it	Costantino, Claudio/F-4742-2018	Costantino, Claudio/0000-0002-3397-7331; CORSELLO, Giovanni/0000-0002-0218-8110; MAZZUCCO, WALTER/0000-0001-5090-1366; Vitale, Francesco/0000-0002-6354-8060			Acs N, 2005, BIRTH DEFECTS RES A, V73, P989, DOI 10.1002/bdra.20195; Arghittu A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115642; Carlisle N, 2019, MIDWIFERY, V72, P67, DOI 10.1016/j.midw.2019.02.008; Centers for Disease Control and Prevention, INFL FLU VACC PREGN; Chu HY, 2014, CLIN INFECT DIS, V59, P560, DOI 10.1093/cid/ciu327; Costantino C, 2019, ANN IG MED PREV COMU, V31, P35, DOI 10.7416/ai.2019.2256; Costantino C, 2020, HUM VACC IMMUNOTHER, V16, P2415, DOI 10.1080/21645515.2020.1728157; FREEMAN DW, 1959, AM J OBSTET GYNECOL, V78, P1172, DOI 10.1016/0002-9378(59)90570-8; Harris JW, 1919, J AMER MED ASSOC, V72, P978, DOI 10.1001/jama.1919.02610140008002; Italian Ministry of Health, REC VACC PREGN CHILD; Italian Ministry of Health,, NAT VACC PLAN 2017 2; Kilich E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234827; KIRSHON B, 1988, J REPROD MED, V33, P399; KORT BA, 1986, AM J PERINAT, V3, P179, DOI 10.1055/s-2007-999862; Kourtis AP, 2014, NEW ENGL J MED, V370, P2211, DOI 10.1056/NEJMra1213566; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Liang JL, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6702a1; Lorini C, 2018, HUM VACC IMMUNOTHER, V14, P478, DOI 10.1080/21645515.2017.1392423; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; Mak TK, 2008, LANCET INFECT DIS, V8, P44, DOI 10.1016/S1473-3099(07)70311-0; Marotta C, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5646-8; Mclntyre P, 2009, CURR OPIN INFECT DIS, V22, P215, DOI 10.1097/QCO.0b013e32832b3540; Noble G.R., 1982, BASIC APPL INFLUENZA, P41; O'Leary ST, 2019, OBSTET GYNECOL, V133, P40, DOI 10.1097/AOG.0000000000003005; Pathirana J, 2015, VACCINE, V33, P2971, DOI 10.1016/j.vaccine.2015.04.070; Poland GA, 2011, CLIN INFECT DIS, V52, pS253, DOI 10.1093/cid/ciq116; Rodriguez-Blanco N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020291; SCHOENBAUM S C, 1979, Clinical Obstetrics and Gynecology, V22, P293, DOI 10.1097/00003081-197906000-00006; Sebghati M, 2021, BEST PRACT RES CL OB, V76, P53, DOI 10.1016/j.bpobgyn.2021.03.007; Shahab S, 1994, VIRAL DIS PREGNANCY, P215; Vilca LM, 2020, EUR J OBSTET GYN R B, V247, P10, DOI 10.1016/j.ejogrb.2020.02.007; WIDELOCK D, 1963, PUBLIC HEALTH REP, V78, P1, DOI 10.2307/4591714; Wiley KE, 2013, VACCINE, V31, P3972, DOI 10.1016/j.vaccine.2013.06.015; Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046	34	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1455	10.3390/vaccines9121455			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YK5ZA	34960202	Green Published, gold			2022-04-29	WOS:000745289300001
J	Intapiboon, P; Seepathomnarong, P; Ongarj, J; Surasombatpattana, S; Uppanisakorn, S; Mahasirimongkol, S; Sawaengdee, W; Phumiamorn, S; Sapsutthipas, S; Sangsupawanich, P; Chusri, S; Pinpathomrat, N				Intapiboon, Porntip; Seepathomnarong, Purilap; Ongarj, Jomkwan; Surasombatpattana, Smonrapat; Uppanisakorn, Supattra; Mahasirimongkol, Surakameth; Sawaengdee, Waritta; Phumiamorn, Supaporn; Sapsutthipas, Sompong; Sangsupawanich, Pasuree; Chusri, Sarunyou; Pinpathomrat, Nawamin			Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population	VACCINES			English	Article						intradermal; mRNA vaccine; inactivated SARS-CoV-2; COVID-19; immunogenicity	ADENOVIRUS; ETHICS	Effective vaccine coverage is urgently needed to tackle the COVID-19 pandemic. Inactivated vaccines have been introduced in many countries for emergency usage, but have only provided limited protection. Heterologous vaccination is a promising strategy to maximise vaccine immunogenicity. Here, we conducted a phase I, randomised control trial to observe the safety and immunogenicity after an intradermal boost, using a fractional dosage (1:5) of BNT162b2 mRNA vaccine in healthy participants in Songkhla, Thailand. In total, 91 volunteers who had been administered with two doses of inactivated SARS-CoV-2 (CoronaVac) were recruited into the study, and then randomised (1:1:1) to received different regimens of the third dose. An intramuscular booster with a full dose of BNT162b2 was included as a conventional control, and a half dose group was included as reciprocal comparator. Both, immediate and delayed adverse events following immunisation (AEFI) were monitored. Humoral and cellular immune responses were examined to observe the booster effects. The intradermal booster provided significantly fewer systemic side effects, from 70% down to 19.4% (p < 0.001); however, they were comparable to local reactions with the conventional intramuscular booster. In the intradermal group after receiving only one fifth of the conventional dosage, serum Anti-RBD IgG was halved compared to the full dose of an intramuscular injection. However, the neutralising function against the Delta strain remained intact. T cell responses were also less effective in the intradermal group compared to the intramuscular booster. Together, the intradermal booster, using a fractional dose of BNT162b2, can reduce systemic reactions and provides a good level and function of antibody responses compared to the conventional booster. This favourable intradermal boosting strategy provides a suitable alternative for vaccines and effective vaccine management to increase the coverage during the vaccine shortage.	[Intapiboon, Porntip; Chusri, Sarunyou] Prince Songkla Univ, Dept Internal Med, Fac Med, Hat Yai 90110, Thailand; [Seepathomnarong, Purilap; Ongarj, Jomkwan; Pinpathomrat, Nawamin] Prince Songkla Univ, Dept Biomed Sci & Biomed Engn, Fac Med, Hat Yai 90110, Thailand; [Surasombatpattana, Smonrapat] Prince Songkla Univ, Dept Pathol, Fac Med, Hat Yai 90110, Thailand; [Uppanisakorn, Supattra; Sangsupawanich, Pasuree] Prince Songkla Univ, Clin Res Ctr, Fac Med, Hat Yai 90110, Thailand; [Mahasirimongkol, Surakameth; Sawaengdee, Waritta] Minist Publ Hlth, Dept Med Sci, Nonthaburi 11000, Thailand; [Phumiamorn, Supaporn; Sapsutthipas, Sompong] Minist Publ Hlth, Inst Biol Prod, Dept Med Sci, Nonthaburi 11000, Thailand		Pinpathomrat, N (通讯作者)，Prince Songkla Univ, Dept Biomed Sci & Biomed Engn, Fac Med, Hat Yai 90110, Thailand.	iporntip@medicine.psu.ac.th; 6310320007@psu.ac.th; 5910210489@psu.ac.th; pornapat.s@psu.ac.th; ssupattr@medicine.psu.ac.th; surakameth.m@dmsc.mail.go.th; waritta.s@dmsc.mail.go.th; supaporn.p@dmsc.mail.go.th; sompong.s@dmsc.mail.go.th; pasuree.s@psu.ac.th; sarunyouchusri@hotmail.com; nawamin.p@psu.ac.th	Pinpathomrat, Nawamin/ABE-4538-2021	Pinpathomrat, Nawamin/0000-0002-0776-595X; Chusri, Sarunyou/0000-0002-3116-2518			Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Briggs DJ, 2000, B WORLD HEALTH ORGAN, V78, P693; Burgos Rodrigo M, 2021, Drugs Context, V10, DOI 10.7573/dic.2020-12-2; European Centre for Disease Prevention and Control, 2021, THREAT ASS BRIEF EM; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Feng S, 2021, NAT MED, V27, P2032, DOI 10.1038/s41591-021-01540-1; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Henn W, 2020, VACCINE, V38, P5396, DOI 10.1016/j.vaccine.2020.06.058; Hitchings MDT., 2021, LANCET REG HLTH AM, P100025, DOI [10.1016/j.lana.2021.100025, DOI 10.1016/J.LANA.2021.100025]; Johnson Bryan A, 2020, bioRxiv, DOI 10.1101/2020.08.26.268854; Jordan SC, 2021, CELL MOL IMMUNOL, V18, P2554, DOI 10.1038/s41423-021-00767-9; Kandeil A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030214; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lee EK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050506; Levin Y, 2021, VACCINE, V39, P2821, DOI 10.1016/j.vaccine.2021.04.017; Liu ZM, 2021, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2021.1940652; Lo Sasso B, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11071135; Lustig Y, 2021, LANCET RESP MED, V9, P999, DOI 10.1016/S2213-2600(21)00220-4; Migliore A, 2021, RISK MANAG HEALTHC P, V14, P2079, DOI 10.2147/RMHP.S309707; Ministry of Public Health T, COR DIS 2019 SIT; Momin T, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101020; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; O'Hara GA, 2012, J INFECT DIS, V205, P772, DOI 10.1093/infdis/jir850; Pinpathomrat N, 2021, VACCINE, V39, P1452, DOI 10.1016/j.vaccine.2021.01.034; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rahman F, 2000, HEPATOLOGY, V31, P521, DOI 10.1002/hep.510310237; Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118; Roozen G.V.T., 2021, TOLERABILITY SAFETY, DOI [10.2139/ssrn.3892129, DOI 10.2139/SSRN.3892129]; Schnyder JL, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101868; Shrotri M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245532; Singh JA, 2021, LANCET INFECT DIS, V21, pE103, DOI 10.1016/S1473-3099(20)30923-3; Stylianou E, 2015, VACCINE, V33, P6800, DOI 10.1016/j.vaccine.2015.10.017; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Tea F, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003656; Tebas P, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100689; Vacharathit V, 2021, LANCET INFECT DIS, V21, P1352, DOI 10.1016/S1473-3099(21)00568-5; van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y; Wall EC, 2021, LANCET, V397, P2331, DOI 10.1016/S0140-6736(21)01290-3; Wendler D, 2020, SCIENCE, V370, P1277, DOI 10.1126/science.abf5084; Xiang TD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.708523	44	3	3	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1375	10.3390/vaccines9121375			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YJ6UK	34960122	Green Published, gold			2022-04-29	WOS:000744666900001
J	Khandker, SS; Godman, B; Jawad, MI; Meghla, BA; Tisha, TA; Khondoker, MU; Haq, MA; Charan, J; Talukder, AA; Azmuda, N; Sharmin, S; Jamiruddin, MR; Haque, M; Adnan, N				Khandker, Shahad Saif; Godman, Brian; Jawad, Md. Irfan; Meghla, Bushra Ayat; Tisha, Taslima Akter; Khondoker, Mohib Ullah; Haq, Md. Ahsanul; Charan, Jaykaran; Talukder, Ali Azam; Azmuda, Nafisa; Sharmin, Shahana; Jamiruddin, Mohd. Raeed; Haque, Mainul; Adnan, Nihad			A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues	VACCINES			English	Review						clinical trials; COVID-19 vaccines; systematic review; inactivated vaccines; mRNA vaccines; nanoparticle-based vaccines; recombinant vaccines; prime-booster strategy	RESPIRATORY SYNDROME CORONAVIRUS; MESSENGER-RNA VACCINES; SARS CORONAVIRUS; IN-VIVO; ANTIGENIC RELATIONSHIPS; PROTECTIVE EFFICACY; BAT CORONAVIRUSES; IMMUNE-RESPONSES; VIRAL LOAD; SARS-COV-2	COVID-19 vaccines are indispensable, with the number of cases and mortality still rising, and currently no medicines are routinely available for reducing morbidity and mortality, apart from dexamethasone, although others are being trialed and launched. To date, only a limited number of vaccines have been given emergency use authorization by the US Food and Drug Administration and the European Medicines Agency. There is a need to systematically review the existing vaccine candidates and investigate their safety, efficacy, immunogenicity, unwanted events, and limitations. The review was undertaken by searching online databases, i.e., Google Scholar, PubMed, and ScienceDirect, with finally 59 studies selected. Our findings showed several types of vaccine candidates with different strategies against SARS-CoV-2, including inactivated, mRNA-based, recombinant, and nanoparticle-based vaccines, are being developed and launched. We have compared these vaccines in terms of their efficacy, side effects, and seroconversion based on data reported in the literature. We found mRNA vaccines appeared to have better efficacy, and inactivated ones had fewer side effects and similar seroconversion in all types of vaccines. Overall, global variant surveillance and systematic tweaking of vaccines, coupled with the evaluation and administering vaccines with the same or different technology in successive doses along with homologous and heterologous prime-booster strategy, have become essential to impede the pandemic. Their effectiveness appreciably outweighs any concerns with any adverse events.	[Khandker, Shahad Saif; Khondoker, Mohib Ullah; Haq, Md. Ahsanul; Jamiruddin, Mohd. Raeed; Adnan, Nihad] Gonoshasthaya RNA Mol Diagnost & Res Ctr, Dhaka 1205, Bangladesh; [Godman, Brian] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G1 1XQ, Lanark, Scotland; [Godman, Brian] Sefako Makgatho Hlth Sci Univ, Sch Pharm, Div Publ Hlth Pharm & Management, ZA-0204 Pretoria, South Africa; [Godman, Brian] Ajman Univ, Ctr Med & Bioallied Hlth Sci Res, POB 346, Ajman, U Arab Emirates; [Jawad, Md. Irfan; Meghla, Bushra Ayat; Tisha, Taslima Akter; Talukder, Ali Azam; Azmuda, Nafisa; Adnan, Nihad] Jahangirnagar Univ, Dept Microbiol, Savar 1342, Bangladesh; [Khondoker, Mohib Ullah] Gonoshasthaya Samaj Vittik Med Coll, Dept Community Med, Savar 1344, Bangladesh; [Charan, Jaykaran] All India Inst Med Sci, Dept Pharmacol, Jodhpur 342005, Rajasthan, India; [Sharmin, Shahana; Jamiruddin, Mohd. Raeed] BRAC Univ, Dept Pharm, Dhaka 1212, Bangladesh; [Haque, Mainul] Natl Def Univ Malaysia, Univ Pertahanan Nasl Malaysia, Fac Med & Def Hlth, Unit Pharmacol, Kuala Lumpur 57000, Malaysia		Adnan, N (通讯作者)，Gonoshasthaya RNA Mol Diagnost & Res Ctr, Dhaka 1205, Bangladesh.; Adnan, N (通讯作者)，Jahangirnagar Univ, Dept Microbiol, Savar 1342, Bangladesh.; Haque, M (通讯作者)，Natl Def Univ Malaysia, Univ Pertahanan Nasl Malaysia, Fac Med & Def Hlth, Unit Pharmacol, Kuala Lumpur 57000, Malaysia.	shahad@rnabiotech.com.bd; Brian.Godman@strath.ac.uk; rishadirfan97@gmail.com; meghla.ju@gmail.com; taslima.tisha.bd@gmail.com; mohib@gonoshasthayakendra.org; ahsan@rnabiotech.com.bd; charanj@aiimsjodhpur.edu.in; aat@juniv.edu; azmuda@juniv.edu; sharmin@bracu.ac.bd; mohd.raeed@bracu.ac.bd; mainul@upnm.edu.my; nihad@juniv.edu	Jamiruddin, Mohd. Raeed/ABA-3747-2020	Jamiruddin, Mohd. Raeed/0000-0003-0495-4808; Charan, Dr. Jaykaran/0000-0002-4857-6725; Adnan, Nihad/0000-0002-4999-4793; Godman, Brian/0000-0001-6539-6972			Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Abbas K, 2020, LANCET GLOB HEALTH, V8, pE1264, DOI [10.1016/S2214-109X(20)30308-9, 10.1016/52214-109X(20)30308-9]; Abena PM, 2020, AM J TROP MED HYG, V102, P1184, DOI 10.4269/ajtmh.20-0290; Abubakar AR, 2020, INFECT DRUG RESIST, V13, P4673, DOI 10.2147/IDR.S289037; Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Adnan N, 2022, EXPERT REV ANTI-INFE, V20, P473, DOI 10.1080/14787210.2021.1976144; Adnan N, 2021, MICROBIOL RESOUR ANN, V10, DOI 10.1128/MRA.00124-21; Afkhami S, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.30; Alam ABMM, 2021, EXPERT REV VACCINES, V20, P1167, DOI 10.1080/14760584.2021.1951248; Allawadhi P, 2020, NANO TODAY, V35, DOI 10.1016/j.nantod.2020.100982; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; Anderson EL, 2020, RISK ANAL, V40, P902, DOI 10.1111/risa.13500; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], NHI PM NOVAVAX VACCI; Apostolopoulos V, 2013, J DRUG DELIV, V2013, DOI 10.1155/2013/869718; Ayouni I, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11111-1; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565; Balakrishnan VS, 2020, LANCET INFECT DIS, V20, P1128, DOI 10.1016/S1473-3099(20)30709-X; Barouch DH, 2013, J INFECT DIS, V207, P248, DOI 10.1093/infdis/jis671; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Barros-Martins J, 2021, NAT MED, V27, P1525, DOI 10.1038/s41591-021-01449-9; Begum J, 2021, TRANSBOUND EMERG DIS, V68, P1111, DOI 10.1111/tbed.13804; Bleibtreu A, 2020, MED MALADIES INFECT, V50, P243, DOI 10.1016/j.medmal.2019.10.004; Bonam SR, 2021, NANO TODAY, V36, DOI 10.1016/j.nantod.2020.101051; Borges O, 2005, INT J PHARMACEUT, V299, P155, DOI 10.1016/j.ijpharm.2005.04.037; Bosis S, 2007, J CLIN VIROL, V38, P251, DOI 10.1016/j.jcv.2006.11.014; Bouazzaoui A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020140; BRADBURNE AF, 1970, ARCH GES VIRUSFORSCH, V31, P352, DOI 10.1007/BF01253769; Bradley T, 2021, NEW ENGL J MED, V384, P1959, DOI 10.1056/NEJMc2102051; Castelli GP, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03572-y; CDC, HUM COR TYP CDC2020; CDC Immunization Services Division (ISD), 2021, NAT CTR IMM RESP DIS; Cenat JM, 2021, PSYCHIAT RES, V295, DOI 10.1016/j.psychres.2020.113599; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P226; Chalannavar R.K., 2021, IJRSI, V8, P191, DOI DOI 10.51244/IJRSI.2021.8312; Chandler M, 2020, CURR OPIN BIOTECH, V63, P8, DOI 10.1016/j.copbio.2019.10.011; Chang-Monteagudo A., 2021, SINGLE DOSE SARS COV, DOI [DOI 10.1101/2021.02.22.21252091, 10.1101/2021.02.22.21252091]; Charan J, 2021, EXPERT REV CLIN PHAR, V14, P95, DOI 10.1080/17512433.2021.1856655; Chemaitelly H, 2021, NAT MED, V27, P1614, DOI 10.1038/s41591-021-01446-y; Christensen D, 2012, J CONTROL RELEASE, V160, P468, DOI 10.1016/j.jconrel.2012.03.016; Chu DKW, 2008, J GEN VIROL, V89, P1282, DOI 10.1099/vir.0.83605-0; Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410; Chu LRC, 2021, VACCINE, V39, P2791, DOI 10.1016/j.vaccine.2021.02.007; Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299; Cosma S, 2021, AM J OBSTET GYNECOL, V224, DOI [10.1016/j.ajog.2020.10.OO5, 10.1016/j.ajog.2020.10.005]; Crasto A., NEW DRUG APPROVALS; Creech CB, 2013, HUM VACC IMMUNOTHER, V9, P2548, DOI 10.4161/hv.26038; Custers J, 2021, VACCINE, V39, P3081, DOI 10.1016/j.vaccine.2020.09.018; Deng Y, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0056-7; Dorlass EG, 2020, BRAZ J MICROBIOL, V51, P1117, DOI 10.1007/s42770-020-00347-5; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Dzieciatkowski T, 2020, CARDIOL J, V27, P175, DOI 10.5603/CJ.a2020.0055; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Edwards DK, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-016-1111-6; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Esper F, 2006, EMERG INFECT DIS, V12, P775, DOI 10.3201/eid1205.051316; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; FDA FDA, 2020, FDA BRIEF DOC MOD CO; Feikin DR, 2017, CLIN INFECT DIS, V64, pS337, DOI 10.1093/cid/cix148; Fernandez J, 2022, J MED VIROL, V94, P399, DOI 10.1002/jmv.27310; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Fung M, 2021, TRANSPL INFECT DIS, V23, DOI 10.1111/tid.13477; Ganneru B, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102298; Gastanaduy PA, 2013, MMWR-MORBID MORTAL W, V62, P480; Ghebremedhin B, 2014, EUR J MICROBIOL IMMU, V4, P26, DOI 10.1556/EuJMI.4.2014.1.2; Godman B, 2020, BANG J MED SCI, pS103, DOI [10.3329/bjms.v19i0.48413, DOI 10.3329/BJMS.V19I0.48413]; Godman B, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.585832; Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913; Green MD, 2017, COMPREHENSIVE GUIDE TO TOXICOLOGY IN NONCLINICAL DRUG DEVELOPMENT, 2ND EDITION, P709, DOI 10.1016/B978-0-12-803620-4.00027-X; Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013; Guan S, 2017, GENE THER, V24, P133, DOI 10.1038/gt.2017.5; Gupta PN, 2011, COLLOID SURFACE B, V82, P118, DOI 10.1016/j.colsurfb.2010.08.027; Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Halloran ME, 1996, AM J EPIDEMIOL, V144, P83, DOI 10.1093/oxfordjournals.aje.a008858; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734; Haq A, 2021, BANGLADESH J MED SCI, V20, pS131, DOI 10.3329/bjms.v20i5.55407; Hatmi Zinat Nadia, 2021, SN Compr Clin Med, V3, P419, DOI 10.1007/s42399-021-00749-y; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Henry Brandon, 2020, Acta Biomed, V91, pe2020008, DOI 10.23750/abm.v91i3.10217; Hirotsu Y, 2021, J INFECTION, V82, P307, DOI 10.1016/j.jinf.2021.03.013; Horby P, 2020, NEW ENGL J MED, V383, P2030, DOI 10.1056/NEJMoa2022926; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Huang C, 2020, Lancet, V395, P497; Hwang SE, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1983389; Islam MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01477; Islam MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227836; Islam MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251605; Islam MA, 2018, NAT BIOMED ENG, V2, P850, DOI 10.1038/s41551-018-0284-0; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jacot D, 2020, MICROBES INFECT, V22, P617, DOI 10.1016/j.micinf.2020.08.004; Jahromi M, 2021, MICROB PATHOGENESIS, V158, DOI 10.1016/j.micpath.2021.105086; Jalkanen P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24285-4; Jamiruddin MR, 2021, EXPERT REV VACCINES, V20, P1651, DOI 10.1080/14760584.2021.1977630; Jamiruddin MR, 2021, J INFLAMM RES, V14, P2497, DOI 10.2147/JIR.S313188; Jeewandara C., 2021, ANTIBODY T CELL RESP, DOI [10.1101/2021.07.15.21260621, DOI 10.1101/2021.07.15.21260621]; Josefsberg JO, 2012, BIOTECHNOL BIOENG, V109, P1443, DOI 10.1002/bit.24493; Kames J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72533-2; Kapila K, 2004, MED J ARMED FORCES I, V60, P91, DOI [10.1016/S0377-1237(04)80176-X, DOI 10.1016/S0377-1237(04)80176-X]; Karacin C, 2021, FUTURE ONCOL, V17, P4447, DOI 10.2217/fon-2021-0597; Karamese M, 2022, J MED VIROL, V94, P173, DOI 10.1002/jmv.27289; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kauffman KJ, 2016, J CONTROL RELEASE, V240, P227, DOI 10.1016/j.jconrel.2015.12.032; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682; Khandker SS, 2021, J CLIN MED, V10, DOI 10.3390/jcm10163493; Khandker SS, 2020, CURR DRUG METAB, V21, P579, DOI 10.2174/1389200221666200610173724; Kheirollahpour Mehdi, 2020, Pharmaceutical Nanotechnology, V8, P6, DOI 10.2174/2211738507666191024162042; Khurana A, 2021, NANO TODAY, V38, DOI 10.1016/j.nantod.2021.101142; Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011; Kim E, 2014, VACCINE, V32, P5975, DOI 10.1016/j.vaccine.2014.08.058; Kim MG, 2014, ASIAN J PHARM SCI, V9, P227, DOI 10.1016/j.ajps.2014.06.002; Klompas M, 2020, JAMA-J AM MED ASSOC, V324, P441, DOI 10.1001/jama.2020.12458; Klucker MF, 2012, J PHARM SCI-US, V101, P4490, DOI 10.1002/jps.23311; Kluge HHP, 2020, LANCET, V395, P1678, DOI 10.1016/S0140-6736(20)31067-9; Kobinger GP, 2007, VACCINE, V25, P5220, DOI 10.1016/j.vaccine.2007.04.065; Koetz A, 2006, CLIN MICROBIOL INFEC, V12, P1089, DOI 10.1111/j.1469-0691.2006.01506.x; Kong N, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw1565; Kovyrshina A. V., 2020, Immunologiya, V41, P135, DOI 10.33029/0206-4952-2020-41-2-135-143; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kupfer B, 2007, EUR J MED RES, V12, P134; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102; Lau SKP, 2007, VIROLOGY, V367, P428, DOI 10.1016/j.virol.2007.06.009; Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05; Lepenies B, 2013, ADV DRUG DELIVER REV, V65, P1271, DOI 10.1016/j.addr.2013.05.007; Li JX, 2021, NAT MED, V27, P1062, DOI 10.1038/s41591-021-01330-9; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Lin A., 2021, HETEROLOGOUS VACCINA, DOI [10.1101/2021.05.17.21257134, DOI 10.1101/2021.05.17.21257134]; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Liu XX, 2021, LANCET, V398, P856, DOI 10.1016/S0140-6736(21)01694-9; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lu-Culligan A., 2021, NEW YORK TIMES; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Malande O.O., 2021, EC PAEDIAT, V10, P22; Male V, 2021, NAT REV IMMUNOL, V21, P200, DOI 10.1038/s41577-021-00525-y; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Mark C, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.29295; Martin J.E., 2009, CLIN VIROLOGY, V3rd; Maruggi G, 2017, VACCINE, V35, P361, DOI 10.1016/j.vaccine.2016.11.040; Matin MA, 2021, MICROBIOL RESOUR ANN, V10, DOI 10.1128/MRA.00511-21; MCINTOSH K, 1969, J IMMUNOL, V102, P1109; Medeiros-Ribeiro AC, 2021, NAT MED, V27, P1744, DOI 10.1038/s41591-021-01469-5; Medicines & Healthcare Products Regulatory Agency, COVID 19 VACC ASTRAZ; Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172; Mendez-Brito A, 2021, J INFECTION, V83, P281, DOI 10.1016/j.jinf.2021.06.018; Mihindukulasuriya KA, 2008, J VIROL, V82, P5084, DOI 10.1128/JVI.02722-07; Milligan ID, 2016, JAMA-J AM MED ASSOC, V315, P1610, DOI 10.1001/jama.2016.4218; Misumi S, 2009, J IMMUNOL, V182, P6061, DOI 10.4049/jimmunol.0802928; Mohandas S, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102054; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Naveca F., 2021, SARS COV 2 REINFECTI; Nel AE, 2021, ACS NANO, V15, P5793, DOI 10.1021/acsnano.1c01845; NIH, USDOHHS STUD QUAL AS; Ogunleye OO, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01205; Oishee MJ, 2021, INFECT DRUG RESIST, V14, P1049, DOI 10.2147/IDR.S289629; Oldenburg J, 2021, HAMOSTASEOLOGIE, V41, P184, DOI 10.1055/a-1469-7481; Ostadgavahi AT, 2021, J INFECT DEV COUNTR, V15, P653, DOI 10.3855/jidc.15368; Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI [10.1586/erv.10.89, 10.1586/ERV.10.89]; Oyston P, 2012, J MED MICROBIOL, V61, P889, DOI 10.1099/jmm.0.039180-0; Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Pawar D, 2013, EUR J PHARM BIOPHARM, V85, P550, DOI 10.1016/j.ejpb.2013.06.017; PENSAERT MB, 1981, ARCH VIROL, V68, P45, DOI 10.1007/BF01315166; Pepini T, 2017, J IMMUNOL, V198, P4012, DOI 10.4049/jimmunol.1601877; Perkmann T, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13632; Plotkin SA, 2011, HISTORY OF VACCINE DEVELOPMENT, P1, DOI 10.1007/978-1-4419-1339-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard AJ, 2021, LANCET INFECT DIS, V21, P493, DOI 10.1016/S1473-3099(20)30476-X; Prather KA, 2020, SCIENCE, V368, P1422, DOI 10.1126/science.abc6197; Qi F, 2019, FRONT CHEM SCI ENG, V13, P14, DOI 10.1007/s11705-018-1729-4; Raghuwanshi D, 2012, VACCINE, V30, P7292, DOI 10.1016/j.vaccine.2012.09.036; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Ranzani O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2015; Robba C, 2020, EXPERT REV RESP MED, V14, P865, DOI 10.1080/17476348.2020.1778470; Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sahoo JP., 2021, BIOL RES TOD, V3, P261; Sainz V, 2015, BIOCHEM BIOPH RES CO, V468, P504, DOI 10.1016/j.bbrc.2015.08.023; Sapkal GN, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab051; Scheinberg DA, 2013, ADV DRUG DELIVER REV, V65, P2016, DOI 10.1016/j.addr.2013.07.013; Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269; See RH, 2008, J GEN VIROL, V89, P2136, DOI 10.1099/vir.0.2008/001891-0; Seyahi E, 2021, RHEUMATOL INT, V41, P1429, DOI 10.1007/s00296-021-04910-7; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Shapiro RS, 2021, INT J DERMATOL, V60, P1047, DOI 10.1111/ijd.15673; Sharma Aadya, 2021, Int Soc Sci J, DOI 10.1111/issj.12266; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Shen YB, 2018, MEDCHEMCOMM, V9, P226, DOI 10.1039/c7md00158d; Siddhartha Dutta, 2021, Journal of Applied Pharmaceutical Science, V11, P1, DOI 10.7324/JAPS.2021.110801; Sil BK, 2021, INT J NANOMED, V16, P4739, DOI 10.2147/IJN.S313140; Sil BK, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246346; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; Solforosi L, 2021, J EXP MED, V218, DOI 10.1084/jem.20202756; Soysal A, 2021, HUM VACC IMMUNOTHER, V17, P3876, DOI 10.1080/21645515.2021.1953344; Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775; Stauffer Fausto, 2006, Recent Pat Antiinfect Drug Discov, V1, P291, DOI 10.2174/157489106778777673; Tang JLW, 2021, J INFECTION, V82, pE8, DOI 10.1016/j.jinf.2021.01.007; Tang L, 2004, DNA CELL BIOL, V23, P391, DOI 10.1089/104454904323145272; Tang P, 2021, NAT MED, V27, P2136, DOI 10.1038/s41591-021-01583-4; Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06; Tang ZM, 2021, NANO TODAY, V36, DOI 10.1016/j.nantod.2020.101019; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tleyjeh IM, 2021, CLIN MICROBIOL INFEC, V27, P215, DOI 10.1016/j.cmi.2020.10.036; Torres I., 2021, B T CELL IMMUNE RESP, DOI [10.1101/2021.04.19.21255723, DOI 10.1101/2021.04.19.21255723]; Tucker S.N, 2020, PRECLINICAL STUDIES, DOI [10.1101/2020.09.04.283853, DOI 10.1101/2020.09.04.283853]; TYRRELL DA, 1966, LANCET, V1, P76; Ulery BD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017642; Ulmer JB, 2006, NAT BIOTECHNOL, V24, P1377, DOI 10.1038/nbt1261; Vallee A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10173817; van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024; van der Hoek L, 2007, ANTIVIR THER, V12, P651; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1056/NEJMc2004973, 10.1101/2020.03.09.20033217]; Nonaka CKV, 2021, EMERG INFECT DIS, V27, P1522, DOI 10.3201/eid2705.210191; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Wall EC, 2021, LANCET, V397, P2331, DOI 10.1016/S0140-6736(21)01290-3; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Walsh G., 2013, PHARM BIOTECHNOLOGY; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wanlapakorn W., 2021, RES SQ, DOI [10.21203/rs.3.rs-785693/v2, DOI 10.21203/RS.3.RS-785693/V2]; Wee S.L., 2020, NEW YORK TIMES; WHO WHO, 2020, WHO DISC HYDR LOP RI; Wold WSM, 2013, CURR GENE THER, V13, P421; Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06; Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041; Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11; Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803; Wu SP, 2021, LANCET INFECT DIS, V21, P1654, DOI 10.1016/S1473-3099(21)00396-0; Wu TC, 2021, J AFFECT DISORDERS, V281, P91, DOI 10.1016/j.jad.2020.11.117; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Xiong XM, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.700014; Xu SQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186582; Yadav PD, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab104; Yang D, 2021, INT J NANOMED, V16, P623, DOI 10.2147/IJN.S296383; Yang L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00243-2; Yau K, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.23622; Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zhang JQ, 2007, VIROLOGY, V369, P92, DOI 10.1016/j.virol.2007.06.035; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069; Zheng BJ, 2004, EMERG INFECT DIS, V10, P176, DOI 10.3201/eid1002.030533; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	268	2	2	14	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1387	10.3390/vaccines9121387			37	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XZ0CR	34960133	gold, Green Published, Green Accepted			2022-04-29	WOS:000737331300001
J	Li, Q; Liu, ZH; Liu, Y; Liang, C; Shu, JY; Jin, X; Li, CY; Kou, ZH				Li, Qiao; Liu, Zhihua; Liu, Yi; Liang, Chen; Shu, Jiayi; Jin, Xia; Li, Chuanyou; Kou, Zhihua			A Combined Adjuvant TF-Al Consisting of TFPR1 and Aluminum Hydroxide Augments Strong Humoral and Cellular Immune Responses in Both C57BL/6 and BALB/c Mice	VACCINES			English	Article						adjuvant; TFPR1; combined adjuvant; inbred mouse strains; TLR2	DOUBLE-BLIND; VACCINE; SYSTEM; IMMUNOGENICITY; STRATEGIES; CELLS	TFPR1 is a novel adjuvant for protein and peptide antigens, which has been demonstrated in BALB/c mice in our previous studies; however, its adjuvanticity in mice with different genetic backgrounds remains unknown, and its adjuvanticity needs to be improved to fit the requirements for various vaccines. In this study, we first compared the adjuvanticity of TFPR1 in two commonly used inbred mouse strains, BALB/c and C57BL/6 mice, in vitro and in vivo, and demonstrated that TFPR1 activated TLR2 to exert its immune activity in vivo. Next, to prove the feasibility of TFPR1 acting as a major component of combined adjuvants, we prepared a combined adjuvant, TF-Al, by formulating TFPR1 and alum at a certain ratio and compared its adjuvanticity with that of TFPR1 and alum alone using OVA and recombinant HBsAg as model antigens in both BALB/c and C57BL/6 mice. Results showed that TFPR1 acts as an effective vaccine adjuvant in both BALB/c mice and C57BL/6 mice, and further demonstrated the role of TLR2 in the adjuvanticity of TFPR1 in vivo. In addition, we obtained a novel combined adjuvant, TF-Al, based on TFPR1, which can augment antibody and cellular immune responses in mice with different genetic backgrounds, suggesting its promise for vaccine development in the future.	[Li, Qiao; Liu, Yi; Liang, Chen; Li, Chuanyou] Capital Med Univ, Beijing TB & Thorac Tumor Res Inst, Beijing Chest Hosp, Dept Bacteriol & Immunol, Beijing 101149, Peoples R China; [Liu, Zhihua; Shu, Jiayi; Jin, Xia; Kou, Zhihua] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China		Li, CY (通讯作者)，Capital Med Univ, Beijing TB & Thorac Tumor Res Inst, Beijing Chest Hosp, Dept Bacteriol & Immunol, Beijing 101149, Peoples R China.; Jin, X; Kou, ZH (通讯作者)，Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.	liqiao@mail.ccmu.edu.cn; Liuzhihua@shphc.org.cn; capitalliuyi@mail.ccmu.edu.cn; liangchen@mail.ccmu.edu.cn; shujiayi@shphc.org.cn; jinxia@serum-china.com.cn; lichuanyou@ccmu.edu.cn; kouzhihua@shphc.org.cn		, Yi/0000-0003-4364-7712; Li, Qiao/0000-0001-9299-445X	Mega-Projects of Science and Technology Research [2018ZX10301407-006]; Beijing Key Clinical Specialty Project [20201214]	FundingThis research was funded by Mega-Projects of Science and Technology Research (grant number: 2018ZX10301407-006) and Beijing Key Clinical Specialty Project (grant number: 20201214).	Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Burakova Y, 2018, VIRAL IMMUNOL, V31, P11, DOI 10.1089/vim.2017.0049; Carter D, 2020, CURR TOP MICROBIOL, V428, P103, DOI 10.1007/82_2018_112; Cerofolini L, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0115-7; Danielsson R, 2021, SEMIN CELL DEV BIOL, V115, P3, DOI 10.1016/j.semcdb.2020.12.008; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011; Dunne A, 2011, CURR OPIN PHARMACOL, V11, P404, DOI 10.1016/j.coph.2011.03.004; Garcia A, 2014, APMIS, V122, P257, DOI 10.1111/apm.12143; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681; Hardt K, 2016, VACCINE, V34, P6691, DOI 10.1016/j.vaccine.2016.10.078; Huang LM, 2017, J INFECT DIS, V215, P1711, DOI 10.1093/infdis/jix154; Jarnagin K, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114543; Karandikar SH, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127882; Kayraklioglu N, 2021, METHODS MOL BIOL, V2197, P51, DOI 10.1007/978-1-0716-0872-2_4; Lecrenier N, 2018, EXPERT REV VACCINES, V17, P619, DOI 10.1080/14760584.2018.1495565; Leroux-Roels G, 2014, HUM VACC IMMUNOTHER, V10, P2211, DOI 10.4161/hv.29375; Li Q, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120869; [李悄 Li Qiao], 2018, [军事医学, Military Medical Sciences], V42, P101; Lindemann M, 2017, SCAND J IMMUNOL, V85, P51, DOI 10.1111/sji.12497; Liu T, 2002, INFECT IMMUN, V70, P6638, DOI 10.1128/IAI.70.12.6638-6645.2002; Locarnini S, 2015, J HEPATOL, V62, pS76, DOI 10.1016/j.jhep.2015.01.018; Luchner M, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020142; Martinon S, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/3974127; Mascola JR, 2020, NAT REV IMMUNOL, V20, P87, DOI 10.1038/s41577-019-0243-3; McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005; Montomoli E, 2011, EXPERT REV VACCINES, V10, P1053, DOI [10.1586/ERV.11.48, 10.1586/erv.11.48]; Mosley YYC, 2017, IMMUNOL RES, V65, P1139, DOI 10.1007/s12026-017-8957-4; Mount A, 2013, EXPERT REV VACCINES, V12, P733, DOI 10.1586/14760584.2013.811185; O'Hagan DT, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101426; Pahlavanneshan S, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/9912188; Paudel YN, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105172; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; Pulendran B, 2020, SCIENCE, V369, P1582, DOI 10.1126/science.aay4014; Rappuoli R, 2018, CURR OPIN IMMUNOL, V53, P111, DOI 10.1016/j.coi.2018.04.019; Reed SG, 2020, CURR OPIN IMMUNOL, V65, P97, DOI 10.1016/j.coi.2020.08.008; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Richmond P, 2021, LANCET, V397, P682, DOI 10.1016/S0140-6736(21)00241-5; Rivera L, 2018, VACCINE, V36, P3967, DOI 10.1016/j.vaccine.2018.05.051; Schijns VEJC, 2011, EXPERT REV VACCINES, V10, P539, DOI [10.1586/erv.11.21, 10.1586/ERV.11.21]; Shan WJ, 2019, NANO LETT, V19, P1719, DOI 10.1021/acs.nanolett.8b04722; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Sjaastad FV, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01786; Stevens JC, 2007, TRENDS MOL MED, V13, P512, DOI 10.1016/j.molmed.2007.10.001; Sun WL, 2020, VACCINE, V38, P288, DOI 10.1016/j.vaccine.2019.10.017; Tam WY, 2020, J MOL MED, V98, P1215, DOI 10.1007/s00109-020-01953-4; Vetter V, 2018, ANN MED, V50, P110, DOI 10.1080/07853890.2017.1407035; Wang N, 2019, J CONTROL RELEASE, V303, P130, DOI 10.1016/j.jconrel.2019.04.025; Wang YB, 2020, ACCOUNTS CHEM RES, V53, P1046, DOI 10.1021/acs.accounts.9b00631; Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9	54	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1408	10.3390/vaccines9121408			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YA1GI	34960154	gold, Green Published			2022-04-29	WOS:000738090100001
J	San Segundo, D; Comins-Boo, A; Lamadrid-Perojo, P; Irure-Ventura, J; Castillo-Oti, JM; Wallman, R; Calvo-Montes, J; Mendez-Legaza, JM; Baamonde-Calzada, C; Sanchez-Molina, I; Lecue-Martinez, M; Ventisca-Perez, S; Batlle-Lopez, A; Hoyos, ML				San Segundo, David; Comins-Boo, Alejandra; Lamadrid-Perojo, Patricia; Irure-Ventura, Juan; Castillo-Oti, Jose Maria; Wallman, Reinhard; Calvo-Montes, Jorge; Mendez-Legaza, Jose Manuel; Baamonde-Calzada, Carmela; Sanchez-Molina, Isabel; Lecue-Martinez, Marina; Ventisca-Perez, Silvia; Batlle-Lopez, Ana; Hoyos, Marcos Lopez			COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision	VACCINES			English	Article						mRNA vaccine; SARS-CoV-2; cellular-immune response; nursing home residents; public health	CHADOX1 NCOV-19; UNITED-STATES; STAFF; BNT162B2	Nursing home residents (NHR) have been targeted as a vaccination priority due to their higher risk of worse outcome after COVID-19 infection. The mRNA-based vaccine BTN2b2 was first approved in Europe for NHRs. The assessment of the specific vaccine immune response (both humoral and cellular) at long term in NHRs has not been addressed yet. A representative sample of 624 NHR subjects in Northern region of Spain was studied to assess immune response against full vaccination with BTN2b2. The anti-S1 antibody levels and specific T cells were measured at two and six months after vaccination. 24.4% of NHR had a previous infection prior to vaccination. The remaining NHR were included in the full vaccination assessment group (FVA). After two months, a 94.9% of the FVA presented anti-S1 antibodies, whereas those seronegative without specific cellular response were 2.54%. At long-term, the frequency of NHR within the FVA group with anti-S1 antibodies at six months were 88.12% and the seronegative subjects without specific cellular response was 8.07%. The cellular immune assays complement the humoral test in the immune vaccine response assessment. Therefore, the cellular immune assessment in NHRs allows for the fine tuning of those seronegative subjects with potential competent immune responses against the vaccine.	[San Segundo, David; Comins-Boo, Alejandra; Irure-Ventura, Juan; Hoyos, Marcos Lopez] Univ Hosp Marques Valdecilla, Immunol Dept, Santander 39008, Spain; [San Segundo, David; Lamadrid-Perojo, Patricia; Hoyos, Marcos Lopez] Res Inst Marques Valdecilla IDIVAL, Transplantat & Autoimmun Lab, Santander 39008, Spain; [Castillo-Oti, Jose Maria; Lecue-Martinez, Marina; Ventisca-Perez, Silvia] Liencres Hosp, Epidemiol Monitoring & Intervent Unit, Pielagos 39120, Spain; [Castillo-Oti, Jose Maria] Res Inst Marques de Valdecilla IDIVAL, Comunitary Hlth Grp, Santander 39008, Spain; [Castillo-Oti, Jose Maria] Univ Cantabria, Sch Nursing, Nursing Dept, Santander 39008, Spain; [Wallman, Reinhard] Cantabrian Govt, Dept Publ Hlth, Cantabria 39008, Spain; [Calvo-Montes, Jorge; Mendez-Legaza, Jose Manuel] Univ Hosp Marques de Valdecilla, Microbiol Dept, Santander 39008, Spain; [Calvo-Montes, Jorge; Mendez-Legaza, Jose Manuel] Res Inst Marques de Valdecilla IDIVAL, Epidemiol & Mol & Pathogen Mech Infect Dis & Clin, Santander 39008, Spain; [Baamonde-Calzada, Carmela] Sierrallana Hosp, Clin Anal Dept, Torrelavega 39300, Spain; [Sanchez-Molina, Isabel] Laredo Hosp, Clin Anal Dept, Laredo 39770, Spain; [Batlle-Lopez, Ana] Univ Hosp Marques de Valdecilla, Haematol Dept, Santander 39008, Spain; [Batlle-Lopez, Ana] IDIVAL, Haematol Neoplasms & Haematopoiet Stem Cells Tran, Santander 39008, Spain; [Batlle-Lopez, Ana] Serv Cantabro Salud SCS, Lab Informat Management Syst Coordinator LISCAN, Consejeria Sanidad, Cantabria 39008, Spain; [Hoyos, Marcos Lopez] Univ Cantabria, Mol Biol Dept, Santander 39011, Spain		Hoyos, ML (通讯作者)，Univ Hosp Marques Valdecilla, Immunol Dept, Santander 39008, Spain.; Hoyos, ML (通讯作者)，Res Inst Marques Valdecilla IDIVAL, Transplantat & Autoimmun Lab, Santander 39008, Spain.; Hoyos, ML (通讯作者)，Univ Cantabria, Mol Biol Dept, Santander 39011, Spain.	david.sansegundo@scsalud.es; alejandra.comins@scsalud.es; juan.irure@scsalud.es; juan.irure@scsalud.es; josemaria.castillo@scsalud.es; reinhard.wallmann@scsalud.es; jorge.calvo@scsalud.es; josemanuel.mendez@scsalud.es; carmela.baamonde@scsalud.es; isabel.sanchez-molina@scsalud.es; marina.lecue@scsalud.es; silvia.ventisca@scsalud.es; mana.batlle@scsalud.es; marcos.lopez@scsalud.es	López-Hoyos, Marcos/ABC-1024-2020; San Segundo, David/O-9499-2016	López-Hoyos, Marcos/0000-0003-0562-427X; Lamadrid, Patricia/0000-0002-8363-3182; Castillo Oti, Jose Maria/0000-0002-1745-6333; Mendez-Legaza, Jose Manuel/0000-0002-3908-7057; San Segundo, David/0000-0001-5745-9072	Cantabrian Government [2020 UIC22-PUB-0019]	FundingThis research was partially supported by grant from Cantabrian Government #2020 UIC22-PUB-0019 (to M.L.H.).	Bagchi S, 2021, MMWR-MORBID MORTAL W, V70, P52, DOI 10.15585/mmwr.mm7002e2; Blain H, 2022, ALLERGY, V77, P271, DOI 10.1111/all.15007; Blain H, 2020, EUR GERIATR MED, V11, P899, DOI 10.1007/s41999-020-00405-z; Collier DA, 2021, NATURE, V596, P417, DOI 10.1038/s41586-021-03739-1; Crotty S, 2021, SCIENCE, V372, P1392, DOI 10.1126/science.abj2258; Cucchiari D, 2021, AM J TRANSPLANT, V21, P2727, DOI 10.1111/ajt.16701; Dooling K, 2020, MMWR-MORBID MORTAL W, V69, P1857, DOI 10.15585/mmwr.mm6949e1; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Feifer RA, 2021, J AM MED DIR ASSOC, V22, P1853, DOI 10.1016/j.jamda.2021.07.006; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Herrera S, 2021, AM J TRANSPLANT, V21, P3971, DOI 10.1111/ajt.16768; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Malard F, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00534-z; Malipiero G, 2021, IMMUNOL RES, V69, P576, DOI 10.1007/s12026-021-09226-z; Mazagatos C, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100452; Muller L, 2021, CLIN INFECT DIS, V73, P2065, DOI 10.1093/cid/ciab381; Parry H, 2021, LANCET HEALTH LONGEV, V2, pE554, DOI 10.1016/S2666-7568(21)00169-0; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Salazar E, 2020, J CLIN INVEST, V130, P6728, DOI 10.1172/JCI141206; San Segundo D, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9080868; Tut G, 2021, LANCET HEALTH LONGEV, V2, pE544, DOI 10.1016/S2666-7568(21)00168-9; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]	22	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1429	10.3390/vaccines9121429			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0IT	34960173	Green Published, gold			2022-04-29	WOS:000737347100001
J	Adeyanju, GC; Sprengholz, P; Betsch, C; Essoh, TA				Adeyanju, Gbadebo Collins; Sprengholz, Philipp; Betsch, Cornelia; Essoh, Tene-Alima			Caregivers' Willingness to Vaccinate Their Children against Childhood Diseases and Human Papillomavirus: A Cross-Sectional Study on Vaccine Hesitancy in Malawi	VACCINES			English	Article						immunization; vaccine hesitancy; vaccine demand; vaccination; Malawi; drivers; caregivers; childhood diseases; human papillomavirus (HPV); adolescent	IMMUNIZATION COVERAGE; CERVICAL-CANCER; AGE; AFRICA	Background: Vaccines are among the most effective and cost-efficient public health interventions for promoting child health. However, uptake is considerably affected by vaccine hesitancy. An example is Malawi, with a decline in second vaccine doses and the highest cervical cancer incidence and mortality rate in Sub-Saharan Africa. Understanding vaccine hesitancy is especially important when new vaccines are introduced. This study explores factors contributing to vaccine hesitancy for routine childhood immunization and the human papillomavirus vaccine in Malawi. Methods: The study used a cross-sectional survey design targeting caregivers of children under five years old and adolescent girls. The sample population was derived using three inclusion criteria: one district with low vaccine uptake (Dowa), one district with high vaccine uptake (Salima), and one district where human papillomavirus vaccine was piloted earlier (Zomba). A convenience sample of one primary and one secondary health facility was selected within each district, and participants were systematically included (n = 600). The measures were based on 5C scale for measuring vaccine hesitancy. Multiple regression analyses were performed to explore vaccination intention predictors. Results: Confidence in vaccine safety was the strongest predictor of routine childhood immunization, followed by constraints due to everyday stress. Caregivers had lower confidence in vaccine safety and efficacy when they believed rumors and misinformation and were unemployed. Confidence was higher for those who had more trust in healthcare workers. Age, gender, religion, education, employment, belief in rumors, and trust in healthcare workers were considered predictors of vaccination intention. A husband's positive attitude (approval) increased childhood vaccination intention. For human papillomavirus, vaccination intentions were higher for those with lower education, more trust in healthcare workers, lower complacency, and a lower tendency toward calculating the benefits and risks of vaccination. Knowledge of human papillomavirus did not increase vaccination intention, but the need to attain a husband's approval did. Being a young adult and unemployed increased belief in rumors, while trust in healthcare workers reduced the belief. Conclusions: This study provides good insights into the drivers of vaccine hesitancy across different contexts in Malawi. However, further studies are necessary to understand low risk perception among elderly people and the declining trend in second vaccine doses.	[Adeyanju, Gbadebo Collins; Sprengholz, Philipp; Betsch, Cornelia] Univ Erfurt, Psychol & Infect Dis Lab PIDI, Media & Commun Sci, Nordhauser Str 63, D-99089 Erfurt, Germany; [Adeyanju, Gbadebo Collins; Sprengholz, Philipp; Betsch, Cornelia] Univ Erfurt, Ctr Empir Res Econ & Behav Sci CEREB, Nordhauser Str 63, D-99089 Erfurt, Germany; [Essoh, Tene-Alima] Agence Med Prevent, Reg Directorate Africa, 08 BP 660, Abidjan, Cote Ivoire		Adeyanju, GC (通讯作者)，Univ Erfurt, Psychol & Infect Dis Lab PIDI, Media & Commun Sci, Nordhauser Str 63, D-99089 Erfurt, Germany.; Adeyanju, GC (通讯作者)，Univ Erfurt, Ctr Empir Res Econ & Behav Sci CEREB, Nordhauser Str 63, D-99089 Erfurt, Germany.	gbadebo.adeyanju@uni-erfurt.de; philipp.sprengholz@uni-erfurt.de; cornelia.betsch@uni-erfurt.de; tae@aamp.org		Adeyanju, Gbadebo Collins/0000-0002-5398-0183; Betsch, Cornelia/0000-0002-2856-7303	Merck Sharp & Dohme (MSD) through the Agence de Medecine Preventive Afrique [8102758105]	This work was supported by an unconditional educational grant from Merck Sharp & Dohme (MSD) through the Agence de Medecine Preventive Afrique (Ref. No. 8102758105). However, they had no influence on the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, GLOBAL VACCINE ACTIO; [Anonymous], 2017, WHO SAGE NATL IMMUNI; [Anonymous], 2019, UNICEF REPORT IMMUNI; [Anonymous], 2014, STRATEGIC ADVISORY G; ARNETT J, 1992, DEV REV, V12, P339, DOI 10.1016/0273-2297(92)90013-R; Ashrafi GH, 2016, HUMAN PAPILLOMAVIRUS - RESEARCH IN A GLOBAL PERSPECTIVE, P243, DOI 10.5772/63965; Ault K. A., 2006, Infectious Diseases in Obstetrics and Gynecology, V13, P1, DOI 10.1155/IDOG/2006/40470; Bangura JB, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09169-4; Baseman JG, 2005, J CLIN VIROL, V32, pS16, DOI 10.1016/j.jcv.2004.12.008; Bellhouse D.R., 2005, ENCY BIOSTATISTICS, V8, P1, DOI [10.1002/0470011815.b2a16077, DOI 10.1002/0470011815.B2A16077, 10.1002/0470011815.b2a16077/abstract, DOI 10.1002/0470011815.B2A16077/ABSTRACT]; Betsch C., 2015, SCOTTISH INDEX MULTI, V2, P61, DOI 10.1177/2372732215600716; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Bonem EM, 2015, J BEHAV DECIS MAKING, V28, P317, DOI 10.1002/bdm.1848; Bouassa RSM, 2017, MED SANTE TROP, V27, P16, DOI [10.1684/mst.2017.0648, 10.1684/mst.2016.0648]; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruni L., 2019, SUMMARY REPORT, piv; Burki T, 2019, LANCET DIGIT HEALTH, V1, pE258, DOI 10.1016/S2589-7500(19)30136-0; Chadza E., 2012, Health, V4, P1015, DOI 10.4236/health.2012.411155; Choueiry G., QUANTIFYING HLTH; Clair K., 2019, THESIS U CALIFORNIA; Cooper S, 2018, HUM VACC IMMUNOTHER, V14, P2355, DOI 10.1080/21645515.2018.1460987; Costa JC, 2020, VACCINE, V38, P1160, DOI 10.1016/j.vaccine.2019.11.024; Dube E, 2018, EXPERT REV VACCINES, V17, P989, DOI 10.1080/14760584.2018.1541406; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; European Centre for Disease Prevention and Control (ECDC), 2020, SYST SCOP REV SOC ME; European Centre for Disease Prevention and Control (ECDC), 2017, CAT INT ADDR VACC HE; Feletto M, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001711; Ferlay J, 2018, GLOBAL CANC OBSERVAT; Fort VK, 2011, PATIENT PREFER ADHER, V5, P125, DOI 10.2147/PPA.S17317; Fournet N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5103-8; Global Alliance for Vaccine and Immunization (GAVI), 2019, ANN PROGR REPORT; Global Alliance for Vaccine and Immunization (GAVI), 2021, FACTS FIG STAT MEAS; Gulland A., 2019, TELEGRAPH 0520; Hanifi SMA, 2018, VACCINE, V36, P3323, DOI 10.1016/j.vaccine.2018.04.059; Jegede AS, 2007, PLOS MED, V4, P417, DOI 10.1371/journal.pmed.0040073; Kamara L, 2013, HEALTH POLICY PLANN, V28, P11, DOI 10.1093/heapol/czs020; Karafillakis E, 2019, HUM VACC IMMUNOTHER, V15, P1615, DOI 10.1080/21645515.2018.1564436; Keneally M., 2019, ABC NEWS; LaFond A, 2015, HEALTH POLICY PLANN, V30, P298, DOI 10.1093/heapol/czu011; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Lapsley DK, 2010, J YOUTH ADOLESCENCE, V39, P847, DOI 10.1007/s10964-009-9409-9; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Liu XX, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0708-8; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Madhi SA, 2018, HUM VACC IMMUNOTHER, V14, P2335, DOI 10.1080/21645515.2018.1522921; Magombo-Mana K., 2019, MALAWI LAUNCHES HPV; Malawi Ministry of Health (MOH), MAL NAT ROUT IMM DAT; Malawi Ministry of Health (MOH), HPV VACC DEM PROJ EV; Martin R., 2013, DECADE VACCINE ACTIO; Maseko FC, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-420; Maseko Fresier Chidyaonga, 2015, Pan Afr Med J, V22, P247, DOI 10.11604/pamj.2015.22.247.6439; Masters NB, 2018, HUM VACC IMMUNOTHER, V14, P2340, DOI 10.1080/21645515.2018.1480242; Matta P, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09526-3; Merten S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135222; Mihigo Richard, 2017, Pan Afr Med J, V27, P12, DOI 10.11604/pamj.supp.2017.27.3.12127; Mora T, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5810-1; Msyamboza KP, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4526-y; Msyamboza Kelias Phiri, 2012, BMC Res Notes, V5, P149, DOI 10.1186/1756-0500-5-149; National Statistical Office (NSO) [Malawi] ICF, 2017, MAL DEM HLTH SURV, P143; Ogbuanu IU, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210648; Okeibunor Joseph C, 2018, J Immunol Sci, VSuppl, P46; Oku A, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4020-6; Okwo-Bele J.-M., 2015, TOGETHER WE CAN CLOS; Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3; Regional Office for Africa, 2019, WHO EXP CAUT STAGN I; Remes P, 2012, VACCINE, V30, P5363, DOI 10.1016/j.vaccine.2012.06.025; Renner B, 2000, INT J BEHAV MED, V7, P143, DOI 10.1207/S15327558IJBM0702_4; Rolison JJ, 2014, J GERONTOL B-PSYCHOL, V69, P870, DOI 10.1093/geronb/gbt081; Roser M., 2019, VACCINATION; Ruijs WLM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-511; Sambala EZ, 2018, HUM VACC IMMUNOTHER, V14, P2365, DOI 10.1080/21645515.2018.1460985; Steffens MS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7659-3; Tarantola D., 2014, ANN VACCINES IMMUN, V1, P1007; Tsega A., 2016, Vaccine Reports, V6, P8, DOI 10.1016/j.vacrep.2016.06.001; Vermandere H., 2016, AFR FOCUS, V29, P117, DOI [10.1163/2031356X-02902010, DOI 10.1163/2031356X-02902010, 10.21825/af.v29i2.4851, DOI 10.21825/AF.V29I2.4851]; Vermandere H, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2219-y; WHO-UNICEF Joint Reporting Form (JRF), 2018, MAL DAT; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Wiyeh AB, 2018, EXPERT REV VACCINES, V17, P1063, DOI 10.1080/14760584.2018.1549994; Wiysonge C.S., 2019, THINK GLOBAL HLTH; World Health Organization, 2018, IMMUNIZATION VACCINE; World Health Organization, 2020, IMM COV KEY CHALL 15; World Health Organization, 2019, IMM IMPR VACC DEM AD; World Health Organization Immunization, 2015, VACC HES GROW CHALL; World Health Organization UNICEF, PROGR CHALL ACH UN I; World Health Organization (WHO), 2005, GLOB IMM VIS STRAT G; Zhao LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124978	88	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1231	10.3390/vaccines9111231			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XK6UI	34835162	Green Submitted, Green Published, gold			2022-04-29	WOS:000727597700001
J	Crutcher, M; Seidler, PM				Crutcher, Madison; Seidler, Paul M.			Maximizing Completion of the Two-Dose COVID-19 Vaccine Series with Aid from Infographics	VACCINES			English	Article						COVID-19; public health; vaccine hesitancy; vaccine confidence; vaccination; therapeutic adherence	SAFETY	Two of the three COVID-19 vaccines approved in the United States require two doses to reach full efficacy, as do others available elsewhere in the world. The complete series of multidose COVID-19 vaccines offers stronger protection against infection by SARS-CoV-2 compared to single-dose injections with the same vaccines. Achieving perfect community-level adherence is a challenge in any public health campaign, even in non-pandemic times. Vaccines requiring multiple doses combined with a surge of vaccine hesitancy and misinformation that has been witnessed by the public during the COVID-19 pandemic are exacerbating the challenge of ensuring the world's population achieves a sufficient level of immunity against COVID-19. Here, we describe the results of our study in which we sought to determine whether completion of a two-dose COVID-19 vaccine regimen could be improved by disseminating infographics that explain what the vaccine is and why returning for the second dose is beneficial. Our results show that the proportion of COVID-19 vaccine recipients returning for a second inoculation grew after COVID-19 vaccine infographics were distributed to first-time vaccine recipients. We suggest that extending communication and outreach initiatives into the clinic positively influences the rate of follow-up visits, and that infographics are useful tools to aid and bolster the deployment of COVID-19 vaccines.	[Crutcher, Madison; Seidler, Paul M.] Univ Southern Calif, Dept Pharmacol & Pharmaceut Sci, Sch Pharm, 1985 Zonal Ave, Los Angeles, CA 90089 USA		Seidler, PM (通讯作者)，Univ Southern Calif, Dept Pharmacol & Pharmaceut Sci, Sch Pharm, 1985 Zonal Ave, Los Angeles, CA 90089 USA.	mcrutche@usc.edu; pseidler@usc.edu			University of Southern California School of Pharmacy	This project was supported by startup funds awarded to P.S. from the University of Southern California School of Pharmacy.	Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; Aw J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080900; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bandi C., 2021, SOC SCI RES NETW, DOI [10.2139/ssrn.3909792, DOI 10.2139/SSRN.3909792]; Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575; Cutler RL, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-016982; Ella R, 2021, LANCET INFECT DIS, V21, P950, DOI 10.1016/S1473-3099(21)00070-0; Han BH, 2021, LANCET INFECT DIS, V21, P1645, DOI 10.1016/S1473-3099(21)00319-4; Jalkanen P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24285-4; Jean-Jacques M, 2021, JAMA-J AM MED ASSOC, V325, P829, DOI 10.1001/jama.2021.1205; Kreps SE, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080901; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Livingston Edward H, 2021, JAMA, V325, P898, DOI 10.1001/jama.2021.1375; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Mendel-Van Alstyne JA, 2018, VACCINE, V36, P6464, DOI 10.1016/j.vaccine.2017.09.007; Nelson JC, 2009, AM J PUBLIC HEALTH, V99, pS389, DOI 10.2105/AJPH.2008.151332; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3; Widdice LE, 2011, PEDIATRICS, V127, P77, DOI 10.1542/peds.2010-0812; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	26	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1229	10.3390/vaccines9111229			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG5LX	34835158	Green Published, gold			2022-04-29	WOS:000724795500001
J	Haile, AF; Woodfint, RM; Kim, E; Joldrichsen, MR; Berhe, N; Gebreyes, WA; Boyaka, PN				Haile, Aklilu F.; Woodfint, Rachel M.; Kim, Eunsoo; Joldrichsen, Marisa R.; Berhe, Nega; Gebreyes, Wondwoossen A.; Boyaka, Prosper N.			Broad-Spectrum and Gram-Negative-Targeting Antibiotics Differentially Regulate Antibody Isotype Responses to Injected Vaccines	VACCINES			English	Article						antibiotics; IgA responses; vaccines	GUT MICROBIOME; ROTAVIRUS VACCINE; IGA RESPONSES; MUCOSAL IGA; CELLS; INDUCTION; BACTERIA; IMMUNITY; PROTECT; TOXIN	Antibiotics are extensively used worldwide for the treatment of common infections by agents such as E. coli and Salmonella. They also represent the most common cause of alteration of the microbiota in people. We addressed whether broad-spectrum and Gram-negative-targeting antibiotics differentially regulate systemic and mucosal immune responses to vaccines. Antibiotics treatment enhances serum IgG1 responses in mice immunized systemically with a model polyvalent vaccine. This increase was not seen for other IgG subclasses and was dependent on the immunogenicity of vaccine antigens. The broad-spectrum antibiotic cocktail also enhanced serum IgA responses. Interestingly, both the broad spectrum and the antibiotic targeting Gram-negative bacteria enhanced the number of IgA antibody secreting cells in the intestinal lamina propria. This effect was unlikely to be due to an increase in cells expressing gut-homing receptors (i.e., CCR9 and alpha(4)beta(7)) in peripheral tissues. On the other hand, the microbiome in mice treated with antibiotics was characterized by an overall reduction of the number of firmicutes. Furthermore, Bacteroidetes were increased by either treatment, and Proteobacteria were increased by the broad-spectrum antibiotics cocktail. Thus, immunoglobulin isotype and subclass responses are differentially regulated by oral antibiotics treatment and the gut microbiota shapes mucosal antibody responses after systemic immunization.	[Haile, Aklilu F.; Woodfint, Rachel M.; Kim, Eunsoo; Joldrichsen, Marisa R.; Boyaka, Prosper N.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Haile, Aklilu F.; Berhe, Nega] Addis Ababa Univ, Aklilu Lemma Inst Pathobiol, Addis Ababa 1000, Ethiopia; [Gebreyes, Wondwoossen A.] Ohio State Univ, Dept Prevent Med, Columbus, OH 43210 USA; [Gebreyes, Wondwoossen A.; Boyaka, Prosper N.] Ohio State Univ, Global One Hlth Initiat, Columbus, OH 43210 USA; [Gebreyes, Wondwoossen A.; Boyaka, Prosper N.] Ohio State Univ, Infect Dis Inst, Columbus, OH 43210 USA; [Boyaka, Prosper N.] Ohio State Univ, Dept Microbial Immun & Infect, Columbus, OH 43210 USA		Boyaka, PN (通讯作者)，Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA.; Boyaka, PN (通讯作者)，Ohio State Univ, Global One Hlth Initiat, Columbus, OH 43210 USA.; Boyaka, PN (通讯作者)，Ohio State Univ, Infect Dis Inst, Columbus, OH 43210 USA.; Boyaka, PN (通讯作者)，Ohio State Univ, Dept Microbial Immun & Infect, Columbus, OH 43210 USA.	aklilu.feleke@aau.edu.et; woodfint.1@buckeyemail.osu.edu; Kim.3772@osu.edu; joldrichsen.1@buckeyemail.osu.edu; nega.berhe@aau.edu.et; gebreyes.1@osu.edu; boyaka.1@osu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AI18958, R01 DK101323, R01AI145144]; NIH FogartyUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW008650]	FundingThis work was supported by NIH grants R01 AI18958, R01 DK101323, and R01AI145144. A.H. was supported by a NIH Fogarty D43TW008650 fellowship.	Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Backhed F, 2015, CELL HOST MICROBE, V17, P690, DOI [10.1016/j.chom.2015.04.004, 10.1016/j.chom.2015.05.012]; Blazquez AB, 2017, TRANSL RES, V179, P199, DOI 10.1016/j.trsl.2016.09.003; Bonnegarde-Bernard A, 2014, MUCOSAL IMMUNOL, V7, P257, DOI 10.1038/mi.2013.43; Boyaka P., 2019, CLIN IMMUNOL, DOI [10.1016/B978-0-7020-6896-6.00020-X, DOI 10.1016/B978-0-7020-6896-6.00020-X]; Boyaka PN, 2003, J IMMUNOL, V170, P454, DOI 10.4049/jimmunol.170.1.454; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; Broad J, 2020, CURR OPIN INFECT DIS, V33, P517, DOI 10.1097/QCO.0000000000000687; Cassani B, 2011, GASTROENTEROLOGY, V141, P2109, DOI 10.1053/j.gastro.2011.09.015; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Crotty S, 2015, NAT REV IMMUNOL, V15, P185, DOI 10.1038/nri3803; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Di Luccia B, 2020, CELL HOST MICROBE, V27, P899, DOI 10.1016/j.chom.2020.04.008; Ding RX, 2019, J FOOD DRUG ANAL, V27, P623, DOI 10.1016/j.jfda.2018.12.012; Duverger A, 2010, J IMMUNOL, V185, P5943, DOI 10.4049/jimmunol.0902795; Elias SD, 2019, FOOD MICROBIOL, V84, DOI 10.1016/j.fm.2019.05.001; Gilbert JA, 2018, NAT MED, V24, P392, DOI 10.1038/nm.4517; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Harris VC, 2017, J INFECT DIS, V215, P34, DOI 10.1093/infdis/jiw518; Huda MN, 2014, PEDIATRICS, V134, pE362, DOI 10.1542/peds.2013-3937; Jee J, 2015, MUCOSAL IMMUNOL, V8, P735, DOI 10.1038/mi.2014.105; Kho ZY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01835; Kim D, 2016, NAT MED, V22, P524, DOI 10.1038/nm.4075; Kim E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01692; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Lamouse-Smith ES, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027662; Lecuyer E, 2014, IMMUNITY, V40, P608, DOI 10.1016/j.immuni.2014.03.009; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Libertucci J, 2019, NAT MICROBIOL, V4, P35, DOI 10.1038/s41564-018-0278-4; Lynn DJ, 2018, J LEUKOCYTE BIOL, V103, P225, DOI 10.1189/jlb.5MR0617-216R; Maeda K, 2010, BLOOD, V115, P4699, DOI 10.1182/blood-2009-07-230631; Maidens C, 2013, BRIT J CLIN PHARMACO, V75, P663, DOI 10.1111/j.1365-2125.2012.04404.x; Nash AK, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0373-4; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Qadri F, 2005, CLIN MICROBIOL REV, V18, P465, DOI 10.1128/CMR.18.3.465-483.2005; Rowe JC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36370-8; Salk HM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162803; Scarpellini E, 2015, DIGEST LIVER DIS, V47, P1007, DOI 10.1016/j.dld.2015.07.008; Stanaway JD, 2019, LANCET INFECT DIS, V19, P1312, DOI 10.1016/S1473-3099(19)30418-9; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Uchiyama R, 2014, J INFECT DIS, V210, P171, DOI 10.1093/infdis/jiu037; Vazquez MI, 2015, CYTOKINE, V74, P318, DOI 10.1016/j.cyto.2015.02.007; Wang CW, 2013, J EXP MED, V210, P475, DOI 10.1084/jem.20121088; Wen K, 2012, VACCINE, V30, P1198, DOI 10.1016/j.vaccine.2011.11.107; Wilmore JR, 2018, CELL HOST MICROBE, V23, P302, DOI 10.1016/j.chom.2018.01.005; Zhao T, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0194-5; Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422-020-0332-7; Zimmermann P, 2019, J ALLERGY CLIN IMMUN, V143, P467, DOI 10.1016/j.jaci.2018.09.025; Zimmermann P, 2018, VACCINE, V36, P207, DOI 10.1016/j.vaccine.2017.08.069	51	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1240	10.3390/vaccines9111240			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK6AF	34835171	Green Published, gold			2022-04-29	WOS:000727545200001
J	Khatri, I; Diks, AM; van den Akker, EB; Oosten, LEM; Zwaginga, JJ; Reinders, MJT; van Dongen, JJM; Berkowska, MA				Khatri, Indu; Diks, Annieck M.; van den Akker, Erik B.; Oosten, Liesbeth E. M.; Zwaginga, Jaap Jan; Reinders, Marcel J. T.; van Dongen, Jacques J. M.; Berkowska, Magdalena A.			Longitudinal Dynamics of Human B-Cell Response at the Single-Cell Level in Response to Tdap Vaccination	VACCINES			English	Article						B-cell receptor repertoire; Tdap vaccine; pertussis; single cell; vaccination	GENE REARRANGEMENTS; ANTIBODIES; ANTIGEN; RECOMBINATION; IDENTIFICATION; DIVERSITY; INFECTION; SEGMENTS; SURVIVAL; BLOOD	To mount an adequate immune response against pathogens, stepwise mutation and selection processes are crucial functions of the adaptive immune system. To better characterize a successful vaccination response, we performed longitudinal (days 0, 5, 7, 10, and 14 after Boostrix vaccination) analysis of the single-cell transcriptome as well as the B-cell receptor (BCR) repertoire (scBCR-rep) in plasma cells of an immunized donor and compared it with baseline B-cell characteristics as well as flow cytometry findings. Based on the flow cytometry knowledge and literature findings, we discriminated individual B-cell subsets in the transcriptomics data and traced over-time maturation of plasmablasts/plasma cells (PB/PCs) and identified the pathways associated with the plasma cell maturation. We observed that the repertoire in PB/PCs differed from the baseline B-cell repertoire e.g., regarding expansion of unique clones in post-vaccination visits, high usage of IGHG1 in expanded clones, increased class-switching events post-vaccination represented by clonotypes spanning multiple IGHC classes and positive selection of CDR3 sequences over time. Importantly, the Variable gene family-based clustering of BCRs represented a similar measure as the gene-based clustering, but certainly improved the clustering of BCRs, as BCRs from duplicated Variable gene families could be clustered together. Finally, we developed a query tool to dissect the immune response to the components of the Boostrix vaccine. Using this tool, we could identify the BCRs related to anti-tetanus and anti-pertussis toxoid BCRs. Collectively, we developed a bioinformatic workflow which allows description of the key features of an ongoing (longitudinal) immune response, such as activation of PB/PCs, Ig class switching, somatic hypermutation, and clonal expansion, all of which are hallmarks of antigen exposure, followed by mutation & selection processes.	[Khatri, Indu; Diks, Annieck M.; van Dongen, Jacques J. M.; Berkowska, Magdalena A.] Leiden Univ, Med Ctr, Dept Immunol, Leiden, Netherlands; [Khatri, Indu; van den Akker, Erik B.; Reinders, Marcel J. T.] Leiden Univ, Med Ctr, Leiden Computat Biol Ctr, NL-2333 ZC Leiden, Netherlands; [van den Akker, Erik B.] Leiden Univ, Med Ctr, Dept Mol Epidemiol, NL-2333 ZC Leiden, Netherlands; [Oosten, Liesbeth E. M.; Zwaginga, Jaap Jan] Leiden Univ, Med Ctr, Dept Hematol, NL-2333 ZA Leiden, Netherlands; [Reinders, Marcel J. T.] Delft Univ Technol, Delft Bioinformat Lab, NL-2628 CD Delft, Netherlands		van Dongen, JJM (通讯作者)，Leiden Univ, Med Ctr, Dept Immunol, Leiden, Netherlands.	i.khatri@lumc.nl; A.M.Diks@lumc.nl; e.b.van_den_akker@lumc.nl; L.E.M.Oosten@lumc.nl; j.j.zwaginga@lumc.nl; M.J.T.Reinders@tudelft.nl; J.J.M.van_Dongen@lumc.nl; M.A.Berkowska@lumc.nl	Khatri, Indu/Y-2429-2018	Khatri, Indu/0000-0002-7993-1953; DIKS, ANNIECK/0000-0001-9941-805X; Zwaginga, Jaap Jan/0000-0003-1228-7769; van Dongen, Jacques J.M./0000-0002-3650-7087; van den Akker, Erik/0000-0002-7693-0728	PERISCOPE program; Innovative Medicines Initiative 2 Joint Undertaking [115910]; European Union's Horizon 2020 research and innovation program; European Federation of Pharmaceutical Industries and Associations (EFPIA); Bill and Melinda Gates Foundation (BMGF)Bill & Melinda Gates Foundation; European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant [707404]	This project has received funding from the PERISCOPE program. PERISCOPE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115910. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations (EFPIA) and Bill and Melinda Gates Foundation (BMGF). IK received personal funding for this work from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 707404.	Acquaye-Seedah E, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00004-18; Andreani V, 2018, P NATL ACAD SCI USA, V115, pE9630, DOI 10.1073/pnas.1809739115; Belessi C, 2005, MOL MED, V11, P52, DOI 10.2119/2005-00044.Belessi; Bergmann H, 2013, J EXP MED, V210, P31, DOI 10.1084/jem.20121076; Berkowska MA, 2015, J IMMUNOL, V195, P1417, DOI 10.4049/jimmunol.1402708; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bischof J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161569; Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017; Brauninger A, 2001, EUR J IMMUNOL, V31, P3631; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Cohen S, 2012, CYTOKINE, V60, P13, DOI 10.1016/j.cyto.2012.06.019; Collins AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02249; Diks AM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.666953; Eisen HN, 2014, CANCER IMMUNOL RES, V2, P381, DOI 10.1158/2326-6066.CIR-14-0029; Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533; Fang LJ, 2013, NEURO-ONCOLOGY, V15, P1479, DOI 10.1093/neuonc/not110; Galson JD, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0322-z; Galson JD, 2015, EBIOMEDICINE, V2, P2070, DOI 10.1016/j.ebiom.2015.11.034; Gil-Yarom N, 2017, P NATL ACAD SCI USA, V114, P562, DOI 10.1073/pnas.1612195114; GlaxoSmithKline, 2020, BOOSTRIX TET TOX RED; Hammarlund E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01901-w; Hao Y, 2011, BLOOD, V118, P1294, DOI 10.1182/blood-2011-01-330530; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Hovelmeyer N, 2014, EUR J IMMUNOL, V44, P545, DOI 10.1002/eji.201343655; Hong BB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00128; Horns F, 2019, P NATL ACAD SCI USA, V116, P1261, DOI 10.1073/pnas.1814213116; Horns F, 2016, ELIFE, V5, DOI [10.7554/eLife.23066, 10.7554/eLife.16578]; Imani F, 2001, CLIN IMMUNOL, V100, P355, DOI 10.1006/clim.2001.5073; Jash A, 2016, J IMMUNOL, V197, P1159, DOI 10.4049/jimmunol.1600882; Jasper GA, 2011, CYTOM PART B-CLIN CY, V80B, P83, DOI 10.1002/cyto.b.20567; Kernfeld EM, 2018, IMMUNITY, V48, P1258, DOI 10.1016/j.immuni.2018.04.015; Khatri I, 2021, GENES IMMUN, V22, P172, DOI 10.1038/s41435-021-00143-7; KORSMEYER SJ, 1981, P NATL ACAD SCI-BIOL, V78, P7096, DOI 10.1073/pnas.78.11.7096; Lavinder JJ, 2014, P NATL ACAD SCI USA, V111, P2259, DOI 10.1073/pnas.1317793111; Li AH, 2004, BLOOD, V103, P4602, DOI 10.1182/blood-2003-11-3857; Lin W, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1231-2; Lingwood D, 2012, NATURE, V489, P566, DOI 10.1038/nature11371; Masclarelli S, 2008, BBA-MOL CELL RES, V1783, P578, DOI 10.1016/j.bbamcr.2008.01.003; Montague Z, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109173; MOTICKA EJ, 1978, CELL IMMUNOL, V41, P406, DOI 10.1016/0008-8749(78)90237-X; Mylka V., 2020, COMP ANAL ANTIBODY A, DOI [10.1101/2020.11.16.384222, DOI 10.1101/2020.11.16.384222]; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; Nourmohammad A, 2019, MOL BIOL EVOL, V36, P2184, DOI 10.1093/molbev/msz143; Odendahl M, 2005, BLOOD, V105, P1614, DOI 10.1182/blood-2004-07-2507; Pan-Hammarstrom Q, 2007, ADV IMMUNOL, V93, P1, DOI 10.1016/S0065-2776(06)93001-6; Pappas L, 2014, NATURE, V516, P418, DOI 10.1038/nature13764; Peng YZ, 2017, J BIOL CHEM, V292, P12285, DOI 10.1074/jbc.M117.794834; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Sevigny LM, 2013, INFECT IMMUN, V81, P3992, DOI 10.1128/IAI.00462-13; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shi Z, 2019, CELL DISCOV, V5, DOI 10.1038/s41421-019-0137-3; Stern JNH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008879; Storb U, 1996, Semin Immunol, V8, P131, DOI 10.1006/smim.1996.0017; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Todd DJ, 2009, J EXP MED, V206, P2151, DOI 10.1084/jem.20090738; Toellner KM, 2015, BLOOD, V126, P2076, DOI 10.1182/blood-2015-09-666529; Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Yaari G, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks457; YAMADA M, 1991, J EXP MED, V173, P395, DOI 10.1084/jem.173.2.395; Zuckerman NS, 2010, J AUTOIMMUN, V35, P325, DOI 10.1016/j.jaut.2010.07.004	62	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1352	10.3390/vaccines9111352			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XN1UR	34835283	Green Published, Green Submitted, gold			2022-04-29	WOS:000729298300001
J	Lau, CS; Phua, SK; Liang, YL; Oh, HML; Aw, TC				Lau, Chin-Shern; Phua, Soon Kieng; Liang, Ya-Li; Oh, Helen May-Lin; Aw, Tar-Choon			Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naive Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine	VACCINES			English	Article						SARS-CoV-2; mRNA vaccines; spike antibodies; neutralizing antibodies	POSTVACCINATION	Background: Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naive subjects from Southeast Asia is not well known. Methods: 77 COVID-naive vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and neutralizing antibodies (N-Ab)] pre-vaccination, 10 days after dose 1, and 20/40/60/90/120/150/180 days after dose 2. Results: 10 days after dose 1, 67.6% (48/71)/69.0% (49/71) were T-Ab/IgG positive; only 15.5% (11/71)/14.1% (10/71) were N-Ab/IgM positive. While all (100%) subjects had brisk T-Ab, IgG and N-Ab antibody responses 20 days after complete vaccination, only 79.1% (53/67) were IgM positive. At 180 days (n = 8), T-Ab/IgG/N-Ab were still reactive (lowest T-Ab 186 U/mL, IgG 617 AU/mL, N-Ab 0.39 mu g/mL), but IgM was negative in all samples. Spike antibody thresholds of T-Ab 74.1 U/mL (r = 0.95) and IgG 916 AU/mL (r = 0.95) corresponded to N-Ab reactivity (> 0.3 mu g/mL). Non-linear regression analysis showed that N-Ab would decrease to 0.3 mu g/mL by 241 days, whereas T-Ab/IgG would need 470/163 days to reach titers of T-Ab/IgG associated with a N-Ab 0.3 mu g/mL (76.4 U/mL and 916 AU/mL respectively). Conclusions: The antibody responses of T-Ab, IgG and N-Ab remain high and durable even at 180 days. N-Ab titers are expected to remain reactive up to 241 days post-vaccination.	[Lau, Chin-Shern; Phua, Soon Kieng; Liang, Ya-Li; Aw, Tar-Choon] Changi Gen Hosp, Dept Lab Med, Singapore 529889, Singapore; [Oh, Helen May-Lin] Changi Gen Hosp, Dept Infect Dis, Singapore 529889, Singapore; [Aw, Tar-Choon] Natl Univ Singapore, Dept Med, Singapore 119077, Singapore; [Aw, Tar-Choon] Duke NUS Med Sch, Acad Pathol Program, Singapore 169857, Singapore		Aw, TC (通讯作者)，Changi Gen Hosp, Dept Lab Med, Singapore 529889, Singapore.; Aw, TC (通讯作者)，Natl Univ Singapore, Dept Med, Singapore 119077, Singapore.; Aw, TC (通讯作者)，Duke NUS Med Sch, Acad Pathol Program, Singapore 169857, Singapore.	michael.lau@mohh.com.sg; soon_kieng_phua@cgh.com.sg; yali_liang@cgh.com.sg; helen.oh.m.1@singhealth.com.sg; tarchoon@gmail.com		Aw, TarChoon/0000-0002-7814-8836			Bayart JL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101092; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Demonbreun AR, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101018; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Favresse J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071364; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Favresse J, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9030556; Favresse J, 2021, CLIN CHEM LAB MED, V59, pE179, DOI 10.1515/cclm-2020-1736; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Grenache DG, 2021, J APPL LAB MED, V6, P491, DOI 10.1093/jalm/jfaa195; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Jalkanen P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24285-4; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lau CS, 2021, PRACT LAB MED, V25, DOI 10.1016/j.plabm.2021.e00230; Lau CS, 2020, CLIN CHIM ACTA, V510, P760, DOI 10.1016/j.cca.2020.09.005; Lau CS, 2020, J APPL LAB MED, V5, P1313, DOI 10.1093/jalm/jfaa134; Lau C.S, 2021, J EXP PATHOL, V2, P117; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Roltgen Katharina, 2021, medRxiv, DOI 10.1101/2021.04.05.21254952; Steensels D, 2021, JAMA-J AM MED ASSOC, V326, P1533, DOI 10.1001/jama.2021.15125; Suhandynata RT, 2021, CLIN CHEM, V67, P404, DOI 10.1093/clinchem/hvaa262; Thompson MG, 2021, NEW ENGL J MED, V385, P1355, DOI 10.1056/NEJMoa2110362; Tretyn A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081952; Van Elslande J, 2021, CLIN INFECT DIS, V73, P2366, DOI 10.1093/cid/ciab219; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3; Wheatley AK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21444-5; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	30	2	2	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1241	10.3390/vaccines9111241			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XE9VU	34835172	Green Published, gold			2022-04-29	WOS:000723730100001
J	Li, Y; Wang, HQ; Furnback, W; Wang, BCM; Zhu, SQ; Dong, P				Li, Yan; Wang, Huaqing; Furnback, Wesley; Wang, Bruce C. M.; Zhu, Shuiqing; Dong, Peng			The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities	VACCINES			English	Article						cost-effectiveness; pneumococcal conjugate vaccine; PCV 13; China	ACUTE OTITIS-MEDIA; STREPTOCOCCUS-PNEUMONIAE; CHILDREN YOUNGER; UNITED-STATES; DISEASE; IMPACT; USA; IMMUNIZATION; INFANTS; BURDEN	Objective: This study estimates the cost-effectiveness of vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) among infants in Beijing, Shanghai, Shenzhen, Chengdu, Karamay, Qingdao, and Suzhou. Methods: A previously published cost-effectiveness model comparing vaccination with PCV13 to no vaccination was localized to the included Chinese cities. A systematic literature review was undertaken to identify age-specific incidence rates for pneumococcal bacteremia, pneumococcal meningitis, pneumonia, and otitis media (AOM). Age-specific direct medical costs of treating the included pneumococcal diseases were taken from the Chinese Health Insurance Association database. The base case analysis evaluated vaccine efficacy using direct effect and indirect effects (DE+ IDE). A subsequent scenario analysis evaluated the model outcomes if only DE was considered. A vaccination rate of 70% was used. The model reported outcomes over a one-year period after it was assumed the vaccine effects had reached a steady state (5-7 years after vaccine introduction) to include the direct and indirect effects of vaccination. Health outcomes were discounted at 5% during the steady-state period. Results: Vaccination with PCV13 was cost-effective in the base case analysis for all included cities with the incremental cost-effectiveness ratio (ICER) ranging from 1145 CNY(Shenzhen) to 15,422 CNY (Qingdao) per quality-adjusted life-year (QALY) gained. PCV13 was the dominant strategy in Shanghai with lower incremental costs and higher incremental QALYs. PCV13 remained cost-effective in the DE-only analysis with all ICERs falling below a cost-effectiveness threshold of three times GDP per capita in each city. Conclusions: Vaccination with PCV13 was a cost-effective strategy in the analyzed cities for both the DE-only and DE + IDE analyses. PCV13 became very cost-effective when a vaccination rate was reached where IDE is observed.	[Li, Yan; Wang, Huaqing] Chinese Ctr Dis Control & Prevent, Beijing 100050, Peoples R China; [Furnback, Wesley; Wang, Bruce C. M.] Elysia Grp LLC, 199 Water St 14th Floor, New York, NY 10038 USA; [Zhu, Shuiqing; Dong, Peng] Pfizer Investment Co Ltd, Shanghai 200041, Peoples R China		Zhu, SQ (通讯作者)，Pfizer Investment Co Ltd, Shanghai 200041, Peoples R China.	liyan2@chinacdc.cn; wanghq@chinacdc.cn; wes.furnback@elysiagroup.com; bruce.wang@elysiagroup.com; shuiqing.zhu@pfizer.com; peng.dong@pfizer.com					[Anonymous], 2019, Weekly Epidemiological Record, V94, P85; [Anonymous], 2018, SICH PROV DEV REF 20; Beijing Price Monitoring Center, 2018, BEIJ MUN DEV REF 201; Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/00006454-200209000-00005; Brinkhoff T, 2019, CITY POPULATION POPU; Caldwell R, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1021-x; Ceyhan M, 2018, HUM VACC IMMUNOTHER, V14, P106, DOI 10.1080/21645515.2017.1371378; Che DT, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-56; Chen Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027333; China Guidelines for Pharmacoeconomic Evaluations Working Group, 2020, CHIN GUID PHARM EV; Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005; Development and Reform Commission of Shenzhen Municipality, 2021, NOT GUANGD PROV DEV; Dinleyici EC, 2008, EXPERT REV VACCINES, V7, P1367, DOI 10.1586/14760584.7.9.1367; Earnshaw SR, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-101; European Medicines Agency (EMA), 2020, PREV 13 EPAR PROD IN; Fireman B, 2003, PEDIATR INFECT DIS J, V22, P10, DOI 10.1097/00006454-200301000-00006; Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9; Hausdorff WP, 2002, PEDIATR INFECT DIS J, V21, P1008, DOI 10.1097/00006454-200211000-00007; Hu Shanlian, 2014, Value Health Reg Issues, V3, P197, DOI 10.1016/j.vhri.2014.04.007; Hu SL, 2014, INT J INFECT DIS, V26, P116, DOI 10.1016/j.ijid.2014.04.012; Jiangsu Development and Reform Commission, 2020, NOT PROV DEV REF COM; Klok RM, 2013, CLIN THER, V35, P119, DOI 10.1016/j.clinthera.2012.12.006; Liu YD, 2008, DIAGN MICR INFEC DIS, V61, P256, DOI 10.1016/j.diagmicrobio.2008.02.004; Maurer KA, 2016, VACCINE, V34, P6343, DOI 10.1016/j.vaccine.2016.10.051; Melegaro A, 2004, VACCINE, V22, P4203, DOI 10.1016/j.vaccine.2004.05.003; Metcalf BJ, 2016, CLIN MICROBIOL INFEC, V22, DOI [10.1016/j.cmi.2016.08.001, 10.1016/j.cmi.2015.08.027]; Mo XT, 2016, PEDIATR INFECT DIS J, V35, pE353, DOI 10.1097/INF.0000000000001288; Moore MR, 2016, LANCET RESP MED, V4, P399, DOI 10.1016/S2213-2600(16)00052-7; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Morrow A, 2007, CAN J INFECT DIS MED, V18, P121, DOI 10.1155/2007/713576; Mucino-Ortega E, 2011, VALUE HEALTH, V14, pS65, DOI 10.1016/j.jval.2011.05.025; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Qingdao Municipal Health Commission Notice on Forwarding the, 2021, NOT SHAND PROV DEV R; Qingdao Municipal Price Bureau Notice of Qingdao Municipal Price Bureau and Qingdao Municipal Health and Family Planning Commission on Forwarding the, 2018, NOT SHAND PROV PRIC; Ray GT, 2006, PEDIATR INFECT DIS J, V25, P494, DOI 10.1097/01.inf.0000222403.42974.8b; Rose M, 2009, EXPERT REV VACCINES, V8, P1351, DOI [10.1586/erv.09.78, 10.1586/ERV.09.78]; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Shen KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201245; Simonsen L, 2014, LANCET RESP MED, V2, P387, DOI 10.1016/S2213-2600(14)70032-3; Stoecker C, 2013, PEDIATRICS, V132, pE324, DOI 10.1542/peds.2012-3350; Strutton DR, 2012, J INFECTION, V64, P54, DOI 10.1016/j.jinf.2011.10.015; Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7; Wasserman M., 2016, OPEN FORUM INFECT DI; World Health Organization, 2008, EST HIB PNEUM DEATHS; Wu DBC, 2015, VACCINE, V33, P1633, DOI 10.1016/j.vaccine.2015.01.081; Yao KH, 2008, VACCINE, V26, P4425, DOI 10.1016/j.vaccine.2008.06.052; Yao KH, 2011, VACCINE, V29, P2296, DOI 10.1016/j.vaccine.2011.01.027; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhou FJ, 2008, PEDIATRICS, V121, P253, DOI 10.1542/peds.2007-0619; Zhou H, 2018, HUM VACC IMMUNOTHER, V14, P1444, DOI 10.1080/21645515.2018.1438794; Zhu FC, 2016, PEDIATR INFECT DIS J, V35, P999, DOI 10.1097/INF.0000000000001248	52	0	0	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1368	10.3390/vaccines9111368			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ7YZ	34835299	Green Published, gold			2022-04-29	WOS:000726999600001
J	Maiorova, V; Mollaev, MD; Vikhreva, P; Kulakovskaya, E; Pershin, D; Chudakov, DM; Kibardin, A; Maschan, MA; Larin, S				Maiorova, Varvara; Mollaev, Murad D.; Vikhreva, Polina; Kulakovskaya, Elena; Pershin, Dmitry; Chudakov, Dmitriy M.; Kibardin, Alexey; Maschan, Michael A.; Larin, Sergey			Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines	VACCINES			English	Article						ligand-based targeting; CAR T cell therapy; acute myeloid leukemia	ACUTE MYELOID-LEUKEMIA; AFFINITY; LIGAND	Relapsed/refractory acute myeloid leukemia (AML) cannot be cured with chemotherapy alone, as the blasts survive the treatment. Chimeric antigen receptor (CAR) approaches for AML are being actively developed. CARs promote immune reactions through recognition of the target molecular epitopes at the surface of cancer cells. The recognition involves the extracellular portion of the CAR protein, which corresponds to either the antibody or the physiological binding partner of the targeted antigen. Here, we design a chimeric receptor with a full-length natural Flt3-ligand recognition module that targets Flt3 tyrosine kinase, known as an adverse marker in AML. We demonstrate specific killing of Flt3-positive THP-1 cells by Flt3-CAR T cells and the lack of cytotoxicity towards Flt3-negative U937 cells. We prove that the inherent cytolytic capacity of T cells is essential for the killing. Finally, we confirm the authenticity of targeting by its competitive dose-dependent inhibition with a soluble Flt3-ligand. The developed system can be viewed as a non-immunogenic functional equivalent of scFv-mediated targeting. The robust in vitro antitumor effects of Flt3-CAR T cells, combined with their low off-target cytotoxicity, hold promise for AML treatment.	[Maiorova, Varvara; Mollaev, Murad D.; Vikhreva, Polina; Kulakovskaya, Elena; Pershin, Dmitry; Kibardin, Alexey; Maschan, Michael A.; Larin, Sergey] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, Moscow 117997, Russia; [Maiorova, Varvara; Chudakov, Dmitriy M.] Skolkovo Inst Sci & Technol, Ctr Life Sci, Moscow 121205, Russia; [Chudakov, Dmitriy M.] Pirogov Russian Natl Res Med Univ, Inst Translat Med, Moscow 117997, Russia; [Chudakov, Dmitriy M.] Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia		Maiorova, V (通讯作者)，Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, Moscow 117997, Russia.; Maiorova, V (通讯作者)，Skolkovo Inst Sci & Technol, Ctr Life Sci, Moscow 121205, Russia.	Chudakovdm@gmail.com; murad.mollaev@fccho-moscow.ru; polina266@gmail.com; elena.kulakovskaya@fccho-moscow.ru; dmitry.pershin@fccho-moscow.ru; Chudakovdm@gmail.com; alexey.kibardin@fccho-moscow.ru; Michael.Maschan@fccho-moscow.ru; sergey.larin@fccho-moscow.ru	Mollaev, Murad/AAY-6788-2021	Mollaev, Murad/0000-0003-0539-6393; Maiorova, Varvara/0000-0001-7066-4919	Dmitry Rogachev National Medical Research Center of Hematology, Oncology and Immunology Foundation "Science-for Children's Benefit"; Ministry of Science and Higher Education of the Russian Federation [075-15-2020-807]	The research was funded by Dmitry Rogachev National Medical Research Center of Hematology, Oncology and Immunology Foundation "Science-for Children's Benefit" and by grant of the Ministry of Science and Higher Education of the Russian Federation No. 075-15-2020-807.	[Anonymous], 2020, AMGEN PHASE 1 STUDY; Arcangeli S, 2017, MOL THER, V25, P1933, DOI 10.1016/j.ymthe.2017.04.017; Bai Y, 2015, J HUAZHONG U SCI-MED, V35, P689, DOI 10.1007/s11596-015-1491-5; Casucci M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00507; Casucci M, 2013, BLOOD, V122, P3461, DOI 10.1182/blood-2013-04-493361; de Bruijn S, 2019, CANCERS, V11, DOI 10.3390/cancers11091396; DeMaria PJ, 2019, HEMATOL ONCOL CLIN N, V33, P199, DOI 10.1016/j.hoc.2018.12.001; Drexler HG, 1996, LEUKEMIA, V10, P588; Fernandez S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143429; Gill S, 2014, BLOOD, V123, P2343, DOI 10.1182/blood-2013-09-529537; Graddis TJ, 1998, J BIOL CHEM, V273, P17626, DOI 10.1074/jbc.273.28.17626; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jetani H, 2018, LEUKEMIA, V32, P1168, DOI 10.1038/s41375-018-0009-0; Kazi JU, 2019, PHYSIOL REV, V99, P1433, DOI 10.1152/physrev.00029.2018; Kenderian SS, 2015, LEUKEMIA, V29, P1637, DOI 10.1038/leu.2015.52; Lee JB, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094590; Li LL, 2020, J CANCER, V11, P5424, DOI 10.7150/jca.46308; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; Lynn RC, 2016, LEUKEMIA, V30, P1355, DOI 10.1038/leu.2016.35; Mardiana S, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00697; Maschan M, 2020, BONE MARROW TRANSPL, V55, DOI 10.1038/s41409-019-0531-3; Peterlin P, 2019, HAEMATOLOGICA, V104, pE240, DOI 10.3324/haematol.2018.209460; Petrov I, 2016, AGING-US, V8, P2936, DOI 10.18632/aging.101102; Rousseau RF, 2006, BLOOD, V107, P1332, DOI 10.1182/blood-2005-03-1259; Shcherbo D, 2009, BIOCHEM J, V418, P567, DOI 10.1042/BJ20081949; Shrestha E, 2020, BLOOD, V136, DOI 10.1182/blood-2020-142745; Sommer C, 2020, MOL THER, V28, P2237, DOI 10.1016/j.ymthe.2020.06.022; Thokala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159477; Wang Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0603-7	29	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1238	10.3390/vaccines9111238			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH3SN	34835169	Green Published, gold			2022-04-29	WOS:000725358500001
J	Rahmani, A; Dini, G; Orsi, A; Sticchi, L; Bruzzone, B; Montecucco, A; Pellegrini, L; Manca, A; Domnich, A; Battistini, A; Vitturi, BK; Zacconi, S; Debarbieri, N; Icardi, G; Durando, P				Rahmani, Alborz; Dini, Guglielmo; Orsi, Andrea; Sticchi, Laura; Bruzzone, Bianca; Montecucco, Alfredo; Pellegrini, Luca; Manca, Alessia; Domnich, Alexander; Battistini, Angela; Kusznir Vitturi, Bruno; Zacconi, Sonia; Debarbieri, Nicoletta; Icardi, Giancarlo; Durando, Paolo			Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy	VACCINES			English	Article						COVID-19; mRNA vaccine; mass vaccination campaign; occupational health; healthcare workers; reactogenicity; adverse reactions	SEX-BASED DIFFERENCES; IMMUNITY	Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few studies have assessed its reactogenicity among the young working age population. An online survey was conducted to investigate the adverse reactions occurring in the 7 days following the first and second vaccination doses amongst resident doctors of the University of Genoa, employed at the IRCCS Ospedale Policlinico San Martino of Genoa, between 11 January and 16 March 2021. A total of 512 resident physicians were invited to participate in the study (female = 53.2%; mean age = 28.9 years), of whom 296 (female = 53.4%, mean age = 28.9 years) and 275 (female = 55.3%, mean age = 29.1 years) completed the survey after their first and second vaccination doses, respectively. In the 7 days following the first dose, most common adverse reactions were local pain (96.3%), fatigue (42.6%), headache (33.8%), arthromyalgia (28.0%), and 5.1% reported fever, while following the second dose, participants reported local pain (93.5%), fatigue (74.9%), headache (57.5%), arthromyalgia (58.2%), and fever (30.9%), with a higher prevalence among females. Systemic (but not local) reactions increased following the second vaccination, reaching severe intensity in 9.8% of participants and causing three or more events of moderate intensity in 23.7% of participants. Adverse reactions preventing regular daily activities could cause absenteeism among workers. These results can be useful to inform populations of young individuals, set expectations, and improve adherence to vaccination campaigns.	[Rahmani, Alborz; Dini, Guglielmo; Orsi, Andrea; Sticchi, Laura; Montecucco, Alfredo; Pellegrini, Luca; Kusznir Vitturi, Bruno; Zacconi, Sonia; Icardi, Giancarlo; Durando, Paolo] Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; [Rahmani, Alborz; Dini, Guglielmo; Pellegrini, Luca; Manca, Alessia; Debarbieri, Nicoletta; Durando, Paolo] IRCCS Osped Policlin San Martino, Occupat Med Unit, I-16132 Genoa, Italy; [Orsi, Andrea; Sticchi, Laura; Bruzzone, Bianca; Domnich, Alexander; Battistini, Angela; Icardi, Giancarlo] IRCCS Osped Policlin San Martino, Hyg Unit, I-16132 Genoa, Italy		Durando, P (通讯作者)，Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy.; Durando, P (通讯作者)，IRCCS Osped Policlin San Martino, Occupat Med Unit, I-16132 Genoa, Italy.	alborz.rahmani@edu.unige.it; guglielmo.dini@unige.it; andrea.orsi@unige.it; laura.sticchi@unige.it; bianca.bruzzone@hsanmartino.it; alfredo.montecucco@edu.unige.it; luca.pellegrini@edu.unige.it; alessia.manca@hsanmartino.it; alexander.domnich@hsanmartino.it; angela.battistini@hsanmartino.it; bruno.kusznir.vitturi@edu.unige.it; sonia.zacconi@edu.unige.it; nicoletta.debarbieri@hsanmartino.it; icardi@unige.it; durando@unige.it	Orsi, Andrea/AAC-7431-2022	Orsi, Andrea/0000-0002-2433-9610			Bandyopadhyay S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003097; Barac A, 2021, WORK, V69, P751, DOI 10.3233/WOR-205253; Boffetta P, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85215-4; Chapin-Bardales J, 2021, JAMA-J AM MED ASSOC, V325, P2201, DOI 10.1001/jama.2021.5374; Chodick G, 2022, CLIN INFECT DIS, V74, P472, DOI 10.1093/cid/ciab438; Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054; Dini G, 2021, INT J OCCUP MED ENV, V34, P189, DOI 10.13075/ijomeh.1896.01759; FDA Briefing Document, 2020, VACC REL BIOL PROD A; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Gomez-Ochoa SA, 2021, AM J EPIDEMIOL, V190, P161, DOI 10.1093/aje/kwaa191; Harris T, 2017, VACCINE, V35, P2600, DOI 10.1016/j.vaccine.2017.03.035; Kim DD, 2021, JAMA NEUROL, V78, P789, DOI 10.1001/jamaneurol.2021.1042; Lee YW, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e153; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Ministero della Salute, 2020, COMM STRAORD EM I SU; Paller CJ, 2009, PAIN MED, V10, P289, DOI 10.1111/j.1526-4637.2008.00558.x; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rief W., 2021, JAMA HLTH FORUM, V2, pe210804, DOI [10.1001/jamahealthforum.2021.0804, DOI 10.1001/JAMAHEALTHFORUM.2021.0804]; Tadount F, 2020, VACCINE, V38, P444, DOI 10.1016/j.vaccine.2019.10.091; Tre-Hardy M, 2021, J INFECTION, V83, P277, DOI 10.1016/j.jinf.2021.03.025; Van Lint S, 2013, HUM VACC IMMUNOTHER, V9, P265, DOI 10.4161/hv.22661; Wen F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31999-x	23	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1269	10.3390/vaccines9111269			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK2MW	34835199	gold, Green Published			2022-04-29	WOS:000727306800001
J	Yagi, A; Ueda, Y; Kakuda, M; Nakagawa, S; Hiramatsu, K; Miyoshi, A; Kobayashi, E; Kimura, T; Kurosawa, M; Yamaguchi, M; Adachi, S; Kudo, R; Sekine, M; Suzuki, Y; Sukegawa, A; Ikeda, S; Miyagi, E; Enomoto, T; Kimura, T				Yagi, Asami; Ueda, Yutaka; Kakuda, Mamoru; Nakagawa, Satoshi; Hiramatsu, Kosuke; Miyoshi, Ai; Kobayashi, Eiji; Kimura, Toshihiro; Kurosawa, Megumi; Yamaguchi, Manako; Adachi, Sosuke; Kudo, Risa; Sekine, Masayuki; Suzuki, Yukio; Sukegawa, Akiko; Ikeda, Sayaka; Miyagi, Etsuko; Enomoto, Takayuki; Kimura, Tadashi			Cervical Cancer Protection in Japan: Where Are We?	VACCINES			English	Review						HPV vaccine; cervical cancer; government suspension of recommendation; adverse events; vaccine hesitancy	HUMAN-PAPILLOMAVIRUS; HPV VACCINE; WOMEN; RISK; HESITANCY	In Japan, government subsidies for human papillomavirus (HPV) vaccination of girls aged 13-16 commenced in 2010. By early 2013, vaccination had become a widely accepted national immunization program. However, in June of 2013, the Ministry of Health, Labor, and Welfare (MHLW), the government's lead agency, suspended its recommendation for vaccination in response to reports of adverse vaccine events. The rate of HPV vaccination quickly dropped from 70% to almost zero, where it has lingered for eight years. In 2020, a new 9-valent HPV vaccine was licensed in Japan. The momentum seemed to be building for the resumption of HPV vaccinations, yet Japanese mothers remain widely hesitant about vaccinating their daughters, despite the well-proven safety and efficacy of the HPV vaccines. The Japanese government and our educational and medical institutions must work harder as a team to inform our parents and their children about the life-saving benefits of the HPV vaccine, and at the same time, we must respond to all their concerns and questions. The vaccine hesitancy of unvaccinated women born in 2000 and thereafter is a natural consequence of the suspension of the government's recommendation. We must also take every possible measure to reduce the significant risk for cervical cancer these women have.	[Yagi, Asami; Ueda, Yutaka; Kakuda, Mamoru; Nakagawa, Satoshi; Hiramatsu, Kosuke; Miyoshi, Ai; Kobayashi, Eiji; Kimura, Tadashi] Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Osaka 5650871, Japan; [Kurosawa, Megumi; Yamaguchi, Manako; Adachi, Sosuke; Kudo, Risa; Sekine, Masayuki; Enomoto, Takayuki] Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Suzuki, Yukio; Sukegawa, Akiko; Miyagi, Etsuko] Yokohama City Univ, Dept Obstet & Gynecol, Sch Med, Yokohama, Kanagawa 2360004, Japan; [Ikeda, Sayaka] Natl Canc Ctr, Ctr Canc Control & Informat Serv, Div Canc Stat Integrat, Tokyo 1040045, Japan		Ueda, Y (通讯作者)，Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Osaka 5650871, Japan.	a.yagi@gyne.med.osaka-u.ac.jp; y.ueda@gyne.med.osaka-u.ac.jp; mamorukakuda@gyne.med.osaka-u.ac.jp; s.nakagawa@gyne.med.osaka-u.ac.jp; hiramatsu@gyne.med.osaka-u.ac.jp; aimiyoshi20090808@gyne.med.osaka-u.ac.jp; ekobayashi@gyne.med.osaka-u.ac.jp; binbin@gyne.med.osaka-u.ac.jp; m-kurosawa@med.niigata-u.ac.jp; manako0131@gmail.com; sadachi@med.niigata-u.ac.jp; pearpear@med.niigata-u.ac.jp; masa@med.niigata-u.ac.jp; yetii@yokohama-cu.ac.jp; aki69kin@yokohama-cu.ac.jp; sayakaikeda0201@gmail.com; emiyagi@yokohama-cu.ac.jp; enomoto@med.niigata-u.ac.jp; tadashi@gyne.med.osaka-u.ac.jp	Sekine, Masayuki/AAB-8321-2022	Kakuda, Mamoru/0000-0003-2768-8848; Miyagi, Etsuko/0000-0002-5492-0844; Ueda, Yutaka/0000-0001-8760-6379; Sekine, Masayuki/0000-0003-0751-6395	Health and Labor Science Research Grant [20EA1025]; Japan Agency for Medical Research and DevelopmentJapan Agency for Medical Research and Development (AMED) [21ck0106562h0002]	This work was supported by Health and Labor Science Research Grant (#20EA1025) and the Japan Agency for Medical Research and Development (#21ck0106562h0002). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.	Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3; Baseman JG, 2005, J CLIN VIROL, V32, pS16, DOI 10.1016/j.jcv.2004.12.008; Center for Disease Control and Prevention, 2015, ADV COMM IMM PRACT A; Corcoran B, 2018, LANCET, V391, P2103, DOI 10.1016/S0140-6736(18)30854-7; European Medicines Agency, 2015, HPV VACC EMA CONF EV; French National Agency for Medicines and Health Products Safety, 2015, VACC INF HPV RISQ MA; Global Advisory Committee on Vaccine Safety (World Health Organization), SAF HPV VACC; Hansen PR, 2020, VACCINE, V38, P1842, DOI 10.1016/j.vaccine.2019.12.019; Ikeda S, 2021, CANCER SCI, V112, P839, DOI 10.1111/cas.14682; Japan Family Planning Association, 2014, 7 SURV LIV ATT MEN W; Larson HJ, 2014, HUM VACC IMMUNOTHER, V10, P2543, DOI 10.4161/21645515.2014.969618; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Luostarinen T, 2018, INT J CANCER, V142, P2186, DOI 10.1002/ijc.31231; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Merck Co. Inc., SYLG 9 INT FORM REV, V3; Merck Co. Inc., GARD INT FORM REV DE, V9; Miura S, 2006, INT J CANCER, V119, P2713, DOI 10.1002/ijc.22195; Miyoshi A, 2021, HUM VACC IMMUNOTHER, V17, P1068, DOI 10.1080/21645515.2020.1830684; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244; Nakagawa S, 2020, CANCER SCI, V111, P2156, DOI 10.1111/cas.14406; Okubo R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060662; Onuki M, 2020, CANCER SCI, V111, P2546, DOI 10.1111/cas.14445; Onuki M, 2009, CANCER SCI, V100, P1312, DOI 10.1111/j.1349-7006.2009.01161.x; Organisation for Economic Co-Operation and Development (OECD), 2019, OECD REV PUBL HLTH J, DOI [10.1787/9789264311602-en, DOI 10.1787/9789264311602-EN]; Rajkumar T, 2006, INT J CANCER, V118, P1481; Simms KT, 2020, LANCET PUBLIC HEALTH, V5, pE223, DOI 10.1016/S2468-2667(20)30010-4; Suzuki S, 2018, PAPILLOMAVIRUS RES, V5, P96, DOI 10.1016/j.pvr.2018.02.002; Tanaka Y, 2016, LANCET ONCOL, V17, P868, DOI 10.1016/S1470-2045(16)00147-9; The Japan Expert Council on Promotion of Vaccine, VIEWS REL AC GROUPS; Tsuda K, 2016, CLIN INFECT DIS, V63, P1634, DOI 10.1093/cid/ciw647; Ueda Y, 2021, CANCER PREV RES, V14, P683, DOI 10.1158/1940-6207.CAPR-21-0091; Ueda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73120-1; Ueda Y, 2018, LANCET ONCOL, V19, P1563, DOI 10.1016/S1470-2045(18)30573-4; Ueda Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31652-7; Ugumori N, 2021, HUM VACC IMMUNOTHER, V17, P3096, DOI 10.1080/21645515.2021.1910001; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Yagi A, 2021, CANCER SCI, V112, P3691, DOI 10.1111/cas.15060; Yagi A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73106-z; Yagi A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030502; Yagi A, 2019, VACCINE, V37, P2889, DOI 10.1016/j.vaccine.2019.04.044; Yagi A, 2019, CANCER RES, V79, P1252, DOI 10.1158/0008-5472.CAN-18-3109	43	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1263	10.3390/vaccines9111263			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF3IK	34835194	Green Published, gold			2022-04-29	WOS:000723967700001
J	Bayart, JL; Douxfils, J; Gillot, C; David, C; Mullier, F; Elsen, M; Eucher, C; Van Eeckhoudt, S; Roy, T; Gerin, V; Wieers, G; Laurent, C; Closset, M; Dogne, JM; Favresse, J				Bayart, Jean-Louis; Douxfils, Jonathan; Gillot, Constant; David, Clara; Mullier, Francois; Elsen, Marc; Eucher, Christine; Van Eeckhoudt, Sandrine; Roy, Tatiana; Gerin, Vincent; Wieers, Gregoire; Laurent, Christine; Closset, Melanie; Dogne, Jean-Michel; Favresse, Julien			Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers	VACCINES			English	Article						COVID-19; SARS-CoV-2; mRNA vaccine; BNT162b2; antibody response; neutralizing antibodies	COVID-19; VACCINE; INFECTION	Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still scarce and are important to design vaccination strategies. In this study, 231 healthcare professionals received the two-dose regimen of BNT162b2. Of these, 158 were seronegative and 73 were seropositive at baseline. Samples were collected at several time points. The neutralizing antibodies (NAbs) and antibodies against the nucleocapsid and the spike protein of SARS-CoV-2 were measured. At day 180, a significant antibody decline was observed in seronegative (-55.4% with total antibody assay; -89.6% with IgG assay) and seropositive individuals (-74.8% with total antibody assay; -79.4% with IgG assay). The estimated half-life of IgG from the peak humoral response was 21 days (95% CI: 13-65) in seronegative and 53 days (95% CI: 40-79) in seropositive individuals. The estimated half-life of total antibodies was longer and ranged from 68 days (95% CI: 54-90) to 114 days (95% CI: 87-167) in seropositive and seronegative individuals, respectively. The decline of NAbs was more pronounced (-98.6%) and around 45% of the subjects tested were negative at day 180. Whether this decrease correlates with an equivalent drop in the clinical effectiveness against the virus would require appropriate clinical studies.</p>	[Bayart, Jean-Louis; Roy, Tatiana; Gerin, Vincent] Clin St Pierre, Dept Lab Med, B-1340 Ottignies, Belgium; [Douxfils, Jonathan; Gillot, Constant; Dogne, Jean-Michel; Favresse, Julien] Univ Namur, Namur Res Inst LIfe Sci, Dept Pharm, B-5000 Namur, Belgium; [Douxfils, Jonathan; David, Clara] Qualiblood Sa, B-5000 Namur, Belgium; [Mullier, Francois; Closset, Melanie] Catholic Univ Louvain, Dept Lab Med, B-5530 Yvoir, Belgium; [Elsen, Marc; Eucher, Christine; Favresse, Julien] Clin St Luc Bouge, Dept Lab Med, B-5004 Bouge, Belgium; [Van Eeckhoudt, Sandrine] Clin St Luc Bouge, Dept Internal Med, B-5004 Bouge, Belgium; [Wieers, Gregoire] Clin St Pierre, Dept Internal Med, B-1340 Ottignies, Belgium; [Laurent, Christine] Catholic Univ Louvain, Dept Internal Med, CHU UCL Namur, B-5530 Yvoir, Belgium		Douxfils, J (通讯作者)，Univ Namur, Namur Res Inst LIfe Sci, Dept Pharm, B-5000 Namur, Belgium.; Douxfils, J (通讯作者)，Qualiblood Sa, B-5000 Namur, Belgium.	jean-louis.bayart@cspo.be; jonathan.douxfils@unamur.be; constant.gillot@unamur.be; clara.david@qualiblood.eu; francois.mullier@uclouvain.be; marc.elsen@slbo.be; c.eucher@labstluc.be; sandrine.vaneeckhoudt@slbo.be; tatiana.roy@cspo.be; vincent.gerin@cspo.be; gregoire.wieers@cspo.be; christine.laurent@uclouvain.be; melanie.closset@uclouvain.be; jean-michel.dogne@unamur.be; julien.favresse@slbo.be	Mullier, Francois/AAZ-9736-2021; Douxfils, Jonathan/C-8483-2014	Mullier, Francois/0000-0001-6947-6099; Douxfils, Jonathan/0000-0002-7644-5298; Gillot, Constant/0000-0002-4151-9760			Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; [Anonymous], 2021, NATURE, V596, P317, DOI 10.1038/d41586-021-02219-w; Bayart JL, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9061340; Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Bonifacius A, 2021, IMMUNITY, V54, P340, DOI 10.1016/j.immuni.2021.01.008; Braeye T, 2021, VACCINE, V39, P5456, DOI 10.1016/j.vaccine.2021.08.060; Cocomazzi G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080913; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dolscheid-Pommerich R, 2022, J MED VIROL, V94, P388, DOI 10.1002/jmv.27287; Douxfils J, 2021, J INFECTION, V83, pE4, DOI 10.1016/j.jinf.2021.08.023; Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Egbert ER, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.23256; ERDMAN DD, 1993, J MED VIROL, V41, P44, DOI 10.1002/jmv.1890410110; Favresse J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071364; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Favresse J, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.05.004; Favresse J, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9030556; Favresse J, 2021, CLIN CHEM LAB MED, V59, pE179, DOI 10.1515/cclm-2020-1736; Favresse J, 2020, CLIN CHEM, V66, P1104, DOI 10.1093/clinchem/hvaa131; Ferrari D, 2021, CLIN CHIM ACTA, V522, P144, DOI [10.17632/576CHJW8TP, 10.1016/j.cca.2021.08.024, 10.17632/576CHJW8TP.1]; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Haute Autorite de Sante, POP EL DOS RAPP VACC; Hirotsu Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.722766; Israel A, 2022, VACCINES-BASEL, V10, DOI [10.3390/vaccines10010064, 10.1101/2021.08.19.21262111]; Jung K, 2021, J CLIN LAB ANAL, V35, DOI 10.1002/jcla.23921; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Knies A, 2022, REV MED VIROL, V32, DOI 10.1002/rmv.2272; L'Huillier AG, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.01.005; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Lustig Y, 2021, LANCET RESP MED, V9, P999, DOI 10.1016/S2213-2600(21)00220-4; MCTA Shamier, VIROLOGICAL CHARACTE, DOI [10.1101/2021.08.20.21262158, DOI 10.1101/2021.08.20.21262158]; Nie JH, 2020, NAT PROTOC, V15, DOI 10.1038/s41596-020-0394-5; Padoan A, 2021, CLIN CHIM ACTA, V519, P60, DOI 10.1016/j.cca.2021.04.006; Perkmann T, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.00218-21; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Roche Diagnostics, 2021, EL ANTISARS COV 2 S; Rubin R, 2021, JAMA-J AM MED ASSOC, V325, P1241, DOI 10.1001/jama.2021.3370; Rus KR, 2021, J CLIN VIROL, V139, DOI 10.1016/j.jcv.2021.104820; Salvagno GL, 2021, J INFECTION, V83, pE4, DOI 10.1016/j.jinf.2021.06.024; Salvagno GL, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11050832; Sattler A, 2020, J CLIN INVEST, V130, DOI 10.1172/JCI140965; Shrotri M, 2021, LANCET, V398, P385, DOI 10.1016/S0140-6736(21)01642-1; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Stephenson J., 2021, JAMA HLTH FORUM, V2, pe211195, DOI [10.1001/jamahealthforum.2021.1195, DOI 10.1001/JAMAHEALTHFORUM.2021.1195]; Tan AT, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108728; To KKW, 2021, CLIN INFECT DIS, V72, pE659, DOI 10.1093/cid/ciaa1368; Tober-Lau P., 2021, LONG TERM IMMUNOGENI, DOI [10.1101/2021.08.26.21262468, DOI 10.1101/2021.08.26.21262468]; Tre-Hardy M, 2021, J INFECTION, V83, P277, DOI 10.1016/j.jinf.2021.03.025	49	22	22	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1092	10.3390/vaccines9101092			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP3AV	34696200	gold, Green Published, Green Submitted			2022-04-29	WOS:000713009600001
J	Lu, XR; Fu, CC; Wang, QY; He, QW; Hee, J; Takesue, R; Tang, K				Lu, Xinran; Fu, Chuchu; Wang, Qianyun; He, Qiwei; Hee, Jiayi; Takesue, Rie; Tang, Kun			Women's Empowerment and Children's Complete Vaccination in the Democratic Republic of the Congo: A Cross-Sectional Analysis	VACCINES			English	Article						women's empowerment; complete vaccination; the Democratic Republic of the Congo; intrinsic agency; enabling resources	CHILDHOOD IMMUNIZATION; MATERNAL EDUCATION; AFRICA DEVELOPMENT; SEXUAL VIOLENCE; HEALTH; INDIA; DETERMINANTS; ASSOCIATION; COVERAGE; CARE	(1) Background: The empowerment of women contributes to better child health and wellness. This study aimed to examine the association between women's empowerment and complete vaccination of children, as recommended in the National Expanded Program on Immunization (EPI) in the Democratic Republic of the Congo (DRC). (2) Methods: In this cross-sectional study, a principal component analysis (PCA) was conducted on data from the Multiple-Indicator Cluster Survey 6 (MICS-6) to determine the dimensions of women's empowerment. Logistic regression analysis was used to assess the association between women's empowerment and complete vaccination of children stratified by household wealth. In total, 3524 women with children aged 12-23 months were included in the study. (3) Results: Women's empowerment was defined by three dimensions, namely intrinsic agency, enabling resources, and social independence. Children of women with high levels of empowerment had higher odds of complete vaccination, with values of 1.63 (p = 0.002) and 1.59 (p = 0.012) for intrinsic agency and enabling resources of the empowerment, respectively, compared to the children of women with low levels of empowerment; however, social independence failed to be associated with the vaccination status of children. After stratification by household wealth, the OR of complete vaccination was higher in women from middle-income households with high levels of intrinsic agency (OR: 2.35, p = 0.021) compared to women from poor households with high levels of intrinsic agency (OR: 1.92, p = 0.004). (4) Conclusions: Higher levels of women's empowerment, especially intrinsic agency and enabling resources, were associated with complete vaccination in children in the DRC. Household wealth status influenced the associations. The empowerment of women is crucial in promoting the complete vaccination of children and providing equal access to vaccines.</p>	[Lu, Xinran; He, Qiwei; Tang, Kun] Tsinghua Univ, Vanke Sch Publ Hlth, Beijing 100084, Peoples R China; [Lu, Xinran] Peking Univ, Sch Publ Hlth, Beijing 100083, Peoples R China; [Fu, Chuchu] China Agr Univ, Coll Humanities & Dev Studies, Beijing 100193, Peoples R China; [Wang, Qianyun] Peking Univ, Inst Populat Res, Beijing 100871, Peoples R China; [Hee, Jiayi] Univ Queensland, Sch Publ Hlth, Herston, Qld 4006, Australia; [Takesue, Rie] UNICEF Headquarters, New York, NY 10017 USA		Tang, K (通讯作者)，Tsinghua Univ, Vanke Sch Publ Hlth, Beijing 100084, Peoples R China.	luxr@pku.edu.cn; fuchuchu@cau.edu.cn; wangqianyun@stu.pku.edu.cn; heqiwei@mail.tsinghua.edu.cn; j.hee@uqconnect.edu.au; rtakesue@unicef.org; tangk@mail.tsinghua.edu.cn	Lu, Xinran/AGX-4952-2022	Lu, Xinran/0000-0002-9989-1573; Hee, Jia Yi/0000-0002-5863-4458	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [72074130]; Spring Breeze Foundation of Tsinghua University [20203080035]	This research was funded by National Natural Science Foundation of China (No. 72074130) and Spring Breeze Foundation of Tsinghua University (No. 20203080035).	Abreha SK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235825; Acharya P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202742; Alfonso VH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217426; Antai D, 2012, INT J INFECT DIS, V16, pE136, DOI 10.1016/j.ijid.2011.11.004; Ashbaugh HR, 2018, VACCINE, V36, P587, DOI 10.1016/j.vaccine.2017.11.049; Asuman D, 2018, HEALTH ECON REV, V8, DOI 10.1186/s13561-018-0193-7; Bago BJ., 2018, CURR PEDIAT RES, V22, P95; Bartlett MS, 1950, B J PSYCHOL-STAT SEC, V3, P77, DOI 10.1111/j.2044-8317.1950.tb00285.x; Bazira L, 2015, Bull Soc Pathol Exot, V108, P235, DOI 10.1007/s13149-015-0447-4; Berhe M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175902; Borooah VK, 2004, SOC SCI MED, V58, P1719, DOI 10.1016/S0277-9536(03)00342-3; Burroway R, 2018, SOC SCI MED, V213, P63, DOI 10.1016/j.socscimed.2018.07.036; Cohen DK, 2014, J PEACE RES, V51, P418, DOI 10.1177/0022343314523028; Collins ND, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0566-9; Debie A, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01166-8; Debnath A, 2016, ECOL FOOD NUTR, V55, P508, DOI 10.1080/03670244.2016.1223652; Delprato M, 2017, ANN GLOB HEALTH, V83, P557, DOI 10.1016/j.aogh.2017.10.005; Delrieu I, 2015, VACCINE, V33, P7290, DOI 10.1016/j.vaccine.2015.10.107; Doshi RH, 2015, VACCINE, V33, P6786, DOI 10.1016/j.vaccine.2015.10.020; Doshi RH, 2015, VACCINE, V33, P3407, DOI 10.1016/j.vaccine.2015.04.067; Essilfie G, 2020, AFR DEV REV, V32, P200, DOI 10.1111/1467-8268.12428; Ewerling F, 2017, LANCET GLOB HEALTH, V5, pE916, DOI 10.1016/S2214-109X(17)30292-9; Fatiregun AA, 2012, VACCINE, V30, P730, DOI 10.1016/j.vaccine.2011.11.082; Gumede N, 2013, EMERG INFECT DIS, V19, P1583, DOI 10.3201/eid1910.130028; INS, 2019, ENQ GRAPP IND MULT 2; Janssens W, 2011, J EUR ECON ASSOC, V9, P1082, DOI 10.1111/j.1542-4774.2011.01041.x; Johnson K, 2010, JAMA-J AM MED ASSOC, V304, P553, DOI 10.1001/jama.2010.1086; Jones RE, 2020, SOC SCI MED, V247, DOI 10.1016/j.socscimed.2020.112803; Jorba J, 2017, MMWR-MORBID MORTAL W, V66, P1185, DOI 10.15585/mmwr.mm6643a6; Kabeer N, 1999, DEV CHANGE, V30, P435, DOI 10.1111/1467-7660.00125; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; Kamau N, 2001, East Afr Med J, V78, P590; Kawaguchi L, 2014, NAGOYA J MED SCI, V76, P161; Khan MT, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013853; Le Gargasson JB, 2013, VACCINE, V31, P1886, DOI 10.1016/j.vaccine.2013.02.024; Malhotra A., MEASURING WOMENS EMP; Mathew JL, 2012, INDIAN PEDIATR, V49, P203, DOI 10.1007/s13312-012-0063-z; Mbaeyi C, 2019, MMWR-MORBID MORTAL W, V68, P225, DOI 10.15585/mmwr.mm6809a2; Mekonnen AG, 2021, BMC WOMENS HEALTH, V21, DOI 10.1186/s12905-021-01183-x; Miedema SS, 2018, WORLD DEV, V110, P453, DOI 10.1016/j.worlddev.2018.05.031; Minetti A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001544; Ntambue AM, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7260-9; Onah MN, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250014; Onah MN, 2021, SSM-POPUL HLTH, V13, DOI 10.1016/j.ssmph.2020.100718; Otshudiema JO, 2017, MMWR-MORBID MORTAL W, V66, P335, DOI 10.15585/mmwr.mm6612a5; Pandey S, 2012, HEALTH EDUC J, V71, P642, DOI 10.1177/0017896911419343; Porth JM, 2021, AM J PREV MED, V60, pS87, DOI 10.1016/j.amepre.2020.08.015; Pratley P, 2016, SOC SCI MED, V169, P119, DOI 10.1016/j.socscimed.2016.08.001; Rettig EM, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03829; Sado L, 2014, SOC SCI MED, V114, P169, DOI 10.1016/j.socscimed.2014.05.047; Sarker AR, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55080480; Tamirat KS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7356-2; Tesema GA, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09965-y; Thorpe S, 2016, MATERN CHILD HLTH J, V20, P172, DOI 10.1007/s10995-015-1817-8; Topuzoglu A, 2007, EUR J PUBLIC HEALTH, V17, P348, DOI 10.1093/eurpub/ckl250; UN, 1995, REP 4 WORLD C WOM; UNDP, SDGS ACT; UNICEF, MULT IND CLUST SURV; Varkey P, 2010, J WOMENS HEALTH, V19, P71, DOI 10.1089/jwh.2009.1444; Vikram K, 2012, SOC SCI MED, V75, P331, DOI 10.1016/j.socscimed.2012.02.043; Voronca D, 2018, INT J PUBLIC HEALTH, V63, P641, DOI 10.1007/s00038-017-1059-1; Wado Yohannes Dibaba, 2014, Pan Afr Med J, V17 Suppl 1, P9, DOI 10.11694/pamj.supp.2014.17.1.3135; WHO, WHO SECR ANN REP 202; Williams J., 2005, MEASURING GENDER WOM; Yaya S, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-019-0129-8	65	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1117	10.3390/vaccines9101117			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP9DC	34696225	Green Published, gold			2022-04-29	WOS:000713423700001
J	Shamsrizi, P; Kramer, FJ; Addo, MM; Fathi, A				Shamsrizi, Parichehr; Kramer, Frederik Johannes; Addo, Marylyn Martina; Fathi, Anahita			Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccine; clinical trial; recruitment; motivation; demographic; MVA-SARS-2-S; phase 1	RECRUITMENT; MOTIVATIONS; VOLUNTEERS; BARRIERS	The development of an effective vaccine against SARS-CoV-2 marks one of the highest priorities during the ongoing pandemic. However, recruitment of participants for clinical trials can be challenging, and recruitment failure is among the most common reasons for discontinuation in clinical trials. From 20 May 2020, public announcements about a planned phase I trial of the vaccine candidate MVA-SARS-2-S against SARS-CoV-2 began, and interested individuals started contacting the study team via designated e-mail. All emails received from these individuals between 20 May 2020-30 September 2020 were assessed. Of the 2541 interested volunteers, 62% contacted the study team within three days after the first media announcement. The average age was 61 years (range 16-100), 48% of volunteers were female and 52% male. A total of 274, 186, and 53 individuals, respectively, reported medical pre-conditions, were health-care workers, or had frequent inter-person contacts. In conclusion, we report a high number of volunteers, with a considerable percentage stating factors for an elevated risk to acquire COVID-19 or develop severe disease. Factors such as media coverage and the perception of a disease as an acute threat may influence the individual's choice to volunteer for a vaccine trial. Our data provide first important insights to better understand reasons to participate in such trials to facilitate trial implementation and recruitment.</p>	[Shamsrizi, Parichehr; Kramer, Frederik Johannes; Addo, Marylyn Martina; Fathi, Anahita] Univ Med Ctr Hamburg Eppendorf, Dept Med, Div Infect Dis, D-20246 Hamburg, Germany; [Shamsrizi, Parichehr; Kramer, Frederik Johannes; Addo, Marylyn Martina; Fathi, Anahita] Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, D-20359 Hamburg, Germany; [Shamsrizi, Parichehr; Addo, Marylyn Martina; Fathi, Anahita] Hamburg Lubeck Borstel Riems, German Ctr Infect Res, D-38124 Hamburg, Germany; [Kramer, Frederik Johannes] Karl Landsteiner Univ Hlth Sci, Med Sch, A-3500 Krems An Der Donau, Austria		Fathi, A (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Med, Div Infect Dis, D-20246 Hamburg, Germany.; Fathi, A (通讯作者)，Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, D-20359 Hamburg, Germany.; Fathi, A (通讯作者)，Hamburg Lubeck Borstel Riems, German Ctr Infect Res, D-38124 Hamburg, Germany.	p.shamsrizi@uke.de; 61807207@edu.kl.ac.at; m.addo@uke.de; a.fathi@uke.de		Fathi, Anahita/0000-0002-9351-9471; Shamsrizi, Dr. Parichehr/0000-0002-0376-0967; Addo, Marylyn/0000-0003-2836-9224	German Center for Infection Research [DZIF 01.921]	FundingThis research was funded by the German Center for Infection Research (DZIF 01.921).	Bogdan C., 2021, EPIDEMIOL B, DOI [10.25646/775521, DOI 10.25646/775521]; Detoc M, 2019, VACCINE, V37, P6633, DOI 10.1016/j.vaccine.2019.09.048; Detoc M, 2017, EXPERT REV VACCINES, V16, P467, DOI 10.1080/14760584.2017.1297706; Kadam Rashmi Ashish, 2016, Perspect Clin Res, V7, P137, DOI 10.4103/2229-3485.184820; Laires PA, 2021, JMIR PUBLIC HLTH SUR, V7, P161, DOI 10.2196/22794; Mody L, 2008, J AM GERIATR SOC, V56, P2340, DOI 10.1111/j.1532-5415.2008.02015.x; Tishler CL, 2002, J CLIN PHARMACOL, V42, P365, DOI 10.1177/0091270002424001; van den Bogert CA, 2017, J CLIN EPIDEMIOL, V88, P140, DOI 10.1016/j.jclinepi.2017.05.001; Zhang ADD, 2022, J GEN INTERN MED, V37, P700, DOI 10.1007/s11606-021-06670-3	9	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1208	10.3390/vaccines9101208			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR6HX	34696316	Green Published, gold			2022-04-29	WOS:000714599800001
J	Sirufo, MM; Raggiunti, M; Magnanimi, LM; Ginaldi, L; De Martinis, M				Sirufo, Maria Maddalena; Raggiunti, Martina; Magnanimi, Lina Maria; Ginaldi, Lia; De Martinis, Massimo			Henoch-Schonlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report	VACCINES			English	Article						Henoch-Schonlein purpura (HSP); IgA-mediated vasculitis; small vessels; palpable purpura; haematuria; COVID-19; ChAdOx1 nCoV-19 vaccine (AZD1222); Vaxzevria; arthralgia; COVID-19 vaccine	IMMUNOGLOBULIN-A VASCULITIS; INFLUENZA VACCINATION; IGA VASCULITIS; PATIENT	A 76 year-old female came to our observation one week after the vaccination with ChAdOx1 nCoV-19 AZD1222 for the onset of purpuric rash on her gluteal and legs regions associated with coxalgia and episodes of macrohaematuria. Henoch-Schonlein purpura (HSP) was diagnosed on the basis of the revised criteria developed by the European League Against Rheumatism, the Paediatric Rheumatology International Trials Organization, and the Paediatric Rheumatology European Society (EULAR/PRINTO/PRES). HSP is a common IgA-mediated small vessel vasculitis, typical of childhood, that affects several systems and is characterized by a tetrad of dermatological, abdominal, joint, and renal manifestations. The Etiology of HSP is not completely understood, but it was observed following upper respiratory tract infections, medications, vaccinations, and malignancies. HSP has previously been reported following immunization with various vaccines, mostly within 12 weeks post, suggesting a possible correlation. To our knowledge, this is the first report of the possible association between COVID-19 ChAdOx1 nCoV-19 AZD1222 and the onset of HSP in a previously healthy woman. No similar cases were reported amongst 23.848 participants in the ChAdOx1 nCoV-19 AZD1222 trial.	[Sirufo, Maria Maddalena; Raggiunti, Martina; Magnanimi, Lina Maria; Ginaldi, Lia; De Martinis, Massimo] Univ Aquila, Dept Life Hlth & Environm Sci, I-67100 Laquila, Italy; [Sirufo, Maria Maddalena; Raggiunti, Martina; Ginaldi, Lia; De Martinis, Massimo] AUSL 04 Teramo, Allergy & Clin Immunol Unit, I-64100 Teramo, Italy		De Martinis, M (通讯作者)，Univ Aquila, Dept Life Hlth & Environm Sci, I-67100 Laquila, Italy.; De Martinis, M (通讯作者)，AUSL 04 Teramo, Allergy & Clin Immunol Unit, I-64100 Teramo, Italy.	maddalena.sirufo@gmail.com; martinaraggiunti@libero.it; linamaria.magnanimi01@icatt.it; lia.ginaldi@cc.univaq.it; demartinis@cc.univaq.it	DE MARTINIS, MASSIMO/N-8725-2015	DE MARTINIS, MASSIMO/0000-0003-4253-1312; Martina, Raggiunti/0000-0003-1825-9355			AlGhoozi DA, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2020-239910; Allez M, 2020, ARTHRITIS RHEUMATOL, V72, P1952, DOI 10.1002/art.41428; Barbetta Laura, 2021, Clin Exp Rheumatol, V39 Suppl 129, P191, DOI 10.55563/clinexprheumatol/5epvob; Bellanti JA, 2021, ALLERGY ASTHMA PROC, V42, P386, DOI 10.2500/aap.2021.42.210063; BLUMBERG S, 1980, ARCH INTERN MED, V140, P847, DOI 10.1001/archinte.140.6.847; Borocco C, 2021, ARCH PEDIATRIE, V28, P573, DOI 10.1016/j.arcped.2021.06.004; El Hasbani G, 2021, PEDIATR DERMATOL, V38, P1359, DOI 10.1111/pde.14699; Felicetti P, 2016, VACCINE, V34, P6634, DOI 10.1016/j.vaccine.2015.09.027; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Hetland LE, 2017, ACTA DERM-VENEREOL, V97, P1160, DOI 10.2340/00015555-2733; Hines AM, 2021, VACCINE, V39, P4571, DOI 10.1016/j.vaccine.2021.06.079; Hoskins B, 2021, PEDIATR ANN, V50, pE44, DOI 10.3928/19382359-20201211-01; Huang Y, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-02163-3; Jacobi M, 2021, PEDIATR INFECT DIS J, V40, pE93, DOI 10.1097/INF.0000000000003001; Jariwala S, 2011, ANN ALLERG ASTHMA IM, V107, P180, DOI 10.1016/j.anai.2011.05.006; Kantor R, 2020, ISR MED ASSOC J, V22, P654; Kumar G, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-242192; Ledford DK, 2017, J ALLER CL IMM-PRACT, V5, P210, DOI 10.1016/j.jaip.2016.05.022; Li NL, 2021, CAN J KIDNEY HEALTH, V8, DOI 10.1177/2054358121991684; Obeid M, 2021, LANCET RHEUMATOL, V3, pE617, DOI 10.1016/S2665-9913(21)00211-3; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; Onate Irene, 2021, Nefrologia (Engl Ed), DOI 10.1016/j.nefro.2021.07.009; Piram M, 2013, CURR OPIN RHEUMATOL, V25, P171, DOI 10.1097/BOR.0b013e32835d8e2a; Rosenblum HG, 2021, MMWR-MORBID MORTAL W, V70, P1094, DOI 10.15585/mmwr.mm7032e4; Ruperto N, 2010, ANN RHEUM DIS, V69, P790, DOI 10.1136/ard.2009.116624; Sandhu S, 2021, DERMATOL THER, V34, DOI 10.1111/dth.14551; Serafinelli J, 2021, PEDIATR NEPHROL, V36, P3789, DOI 10.1007/s00467-021-05212-7; Sharif K, 2020, ISR MED ASSOC J, V22, P648; Shrestha S, 2021, DRUGS THER PERSPECT, V37, P376, DOI 10.1007/s40267-021-00852-z; Sugino H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147538; Suso AS, 2020, KIDNEY INT REP, V5, P2074, DOI 10.1016/j.ekir.2020.08.016; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Van de Perre E, 2021, CLIN KIDNEY J, V14, P1953, DOI 10.1093/ckj/sfaa251; Watanabe T, 2001, PEDIATR NEPHROL, V16, P458, DOI 10.1007/s004670100569; Zhu ZG, 2018, HUM VACC IMMUNOTHER, V14, P2666, DOI 10.1080/21645515.2018.1486354	35	7	7	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1078	10.3390/vaccines9101078			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP5MC	34696186	gold, Green Published			2022-04-29	WOS:000713174600001
J	Blanchard-Rohner, G; Didierlaurent, A; Tilmanne, A; Smeesters, P; Marchant, A				Blanchard-Rohner, Geraldine; Didierlaurent, Arnaud; Tilmanne, Anne; Smeesters, Pierre; Marchant, Arnaud			Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention	VACCINES			English	Review						COVID-19; SARS-CoV-2; pediatric; multisystem inflammatory syndrome in children (MIS-C); immunopathogenesis	SARS-COV-2; CHILDREN; RESPONSES; ANTIBODY; DISEASE; AGE; INFECTION; IMMUNITY; INFANTS	Children are unique in the context of the COVID-19 pandemic. Overall, SARS-CoV-2 has a lower medical impact in children as compared to adults. A higher proportion of children than adults remain asymptomatic following SARS-CoV-2 infection and severe disease and death are also less common. This relative resistance contrasts with the high susceptibility of children to other respiratory tract infections. The mechanisms involved remain incompletely understood but could include the rapid development of a robust innate immune response. On the other hand, children develop a unique and severe complication, named multisystem inflammatory syndrome in children, several weeks after the onset of symptoms. Although children play an important role in the transmission of many pathogens, their contribution to the transmission of SARS-CoV-2 appears lower than that of adults. These unique aspects of COVID-19 in children must be considered in the benefit-risk analysis of vaccination. Several COVID-19 vaccines have been authorized for emergency use in adolescents and clinical studies are ongoing in children. As the vaccination of adolescents is rolled out in several countries, we shall learn about the impact of this strategy on the health of children and on transmission within communities.	[Blanchard-Rohner, Geraldine] Univ Geneva, Fac Med, Ctr Vaccinol, Dept Pathol & Immunol, CH-1205 Geneva, Switzerland; [Blanchard-Rohner, Geraldine; Didierlaurent, Arnaud] Univ Geneva, Geneva Univ Hosp, Pediat Immunol & Vaccinol Unit, Div Gen Pediat,Dept Pediat Gynecol & Obstet, CH-1205 Geneva, Switzerland; [Blanchard-Rohner, Geraldine] Childrens Hosp Geneva, 6 Rue Willy Donze, CH-1211 Geneva, Switzerland; [Tilmanne, Anne; Smeesters, Pierre] Univ Libre Bruxelles, Childrens Hosp Queen Fabiola, B-1020 Brussels, Belgium; [Marchant, Arnaud] Univ Libre Bruxelles, Inst Med Immunol, B-1050 Charleroi, Belgium		Blanchard-Rohner, G (通讯作者)，Univ Geneva, Fac Med, Ctr Vaccinol, Dept Pathol & Immunol, CH-1205 Geneva, Switzerland.; Blanchard-Rohner, G (通讯作者)，Univ Geneva, Geneva Univ Hosp, Pediat Immunol & Vaccinol Unit, Div Gen Pediat,Dept Pediat Gynecol & Obstet, CH-1205 Geneva, Switzerland.; Blanchard-Rohner, G (通讯作者)，Childrens Hosp Geneva, 6 Rue Willy Donze, CH-1211 Geneva, Switzerland.	Geraldine.blanchardrohner@hcuge.ch; arnaud.didierlaurent@unige.ch; anne.tilmanne@huderf.be; pierre.smeesters@huderf.be; Arnaud.Marchant@ulb.be					Abrams JY, 2020, J PEDIATR-US, V226, P45, DOI 10.1016/j.jpeds.2020.08.003; Ahmed M, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100527; Anderson EM, 2021, CELL, V184, P1858, DOI 10.1016/j.cell.2021.02.010; Anderson EM, 2021, J PEDIAT INF DIS SOC, V10, P669, DOI 10.1093/jpids/piaa161; Archard D, 2021, MED LAW REV, V29, P716, DOI 10.1093/medlaw/fwab024; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Aykac K, 2021, J MED VIROL, V93, P3077, DOI 10.1002/jmv.26853; Bartsch YC, 2021, NAT MED, V27, P454, DOI 10.1038/s41591-021-01263-3; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360; Bellino S, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-009399; Bi QF, 2020, LANCET INFECT DIS, V20, P148, DOI 10.1016/S1473-3099(20)30369-8; Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4; Bixler D, 2020, MMWR-MORBID MORTAL W, V69, P1324, DOI 10.15585/mmwr.mm6937e4; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Bloise S, 2021, EUR J PEDIATR, V180, P3335, DOI 10.1007/s00431-021-04124-w; Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707; Caldarale F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654587; Callaway E, 2021, NATURE, V592, P670, DOI 10.1038/d41586-021-01061-4; Canna SW, 2020, BLOOD, V135, P1332, DOI 10.1182/blood.2019000936; Carter MJ, 2020, NAT MED, V26, P1701, DOI 10.1038/s41591-020-1054-6; Casanova JL, 2020, HUM GENET, V139, P681, DOI 10.1007/s00439-020-02184-w; Cattalini M, 2021, PEDIATR RHEUMATOL, V19, DOI 10.1186/s12969-021-00511-7; Chakraborty S, 2021, NAT IMMUNOL, V22, P67, DOI [10.1038/s41590-020-00828-7, 10.1101/2020.05.15.20103341]; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Chen YZ, 2020, CELL, V183, P1496, DOI 10.1016/j.cell.2020.10.051; Cheng MH, 2020, P NATL ACAD SCI USA, V117, P25254, DOI 10.1073/pnas.2010722117; Cheng Mary Hongying, 2020, bioRxiv, DOI 10.1101/2020.05.21.109272; Cohen CA, 2021, NAT COMMUN, V12, DOI [10.1038/s41467-021-24938-4, 10.1101/2021.02.02.21250988]; Consiglio CR, 2020, CELL, V183, P968, DOI 10.1016/j.cell.2020.09.016; Cotugno N, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108852; Dattner I, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008559; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; Decker ML, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17865-2; Diorio C, 2020, J CLIN INVEST, V130, P5967, DOI 10.1172/JCI140970; Dolhnikoff M, 2020, LANCET CHILD ADOLESC, V4, P790, DOI 10.1016/S2352-4642(20)30257-1; Duarte-Neto AN, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100850; Duarte-Salles Talita, 2020, medRxiv, DOI 10.1101/2020.10.29.20222083; Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Felsenstein S, 2020, CLIN IMMUNOL, V220, DOI 10.1016/j.clim.2020.108588; Forbes H, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n628; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; FRENCK RW, 2021, LANCET, V385, P239, DOI DOI 10.1016/S0140-6736(21)01453-7; Gargano JW, 2021, MMWR-MORBID MORTAL W, V70, P977, DOI 10.15585/mmwr.mm7027e2; Garrido C, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj3684; Garrido C, 2021, JCI INSIGHT, V6, DOI [10.1172/jci.insight.150909, 10.1101/2021.04.17.21255663]; Goenka A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100327; Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2; Gorse GJ, 2020, J MED VIROL, V92, P512, DOI 10.1002/jmv.25715; Gostin LO, 2021, JAMA-J AM MED ASSOC, V326, P25, DOI 10.1001/jama.2021.9342; Grazioli S, 2021, J PEDIAT INF DIS SOC, V10, P706, DOI 10.1093/jpids/piaa142; Gruber Conor, 2020, medRxiv, DOI 10.1101/2020.07.04.20142752; Hachim Asmaa, 2021, medRxiv, DOI 10.1101/2021.01.03.21249180; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Han BH, 2021, LANCET INFECT DIS, V21, P1645, DOI 10.1016/S1473-3099(21)00319-4; Harwood R, 2021, LANCET CHILD ADOLESC, V5, P133, DOI 10.1016/S2352-4642(20)30304-7; Heald-Sargent T, 2020, JAMA PEDIATR, V174, P902, DOI 10.1001/jamapediatrics.2020.3651; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285; Henry BM, 2020, CLIN BIOCHEM, V81, P1, DOI 10.1016/j.clinbiochem.2020.05.012; Janka GE, 2007, EUR J PEDIATR, V166, P95, DOI 10.1007/s00431-006-0258-1; Jhaveri R, 2021, J PEDIAT INF DIS SOC, V10, P937, DOI 10.1093/jpids/piab061; Jing QL, 2020, LANCET INFECT DIS, V20, P1141, DOI 10.1016/S1473-3099(20)30471-0; Kim J, 2021, ARCH DIS CHILD, V106, P709, DOI 10.1136/archdischild-2020-319910; Koh WC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240205; Ladhani SN, 2021, J INFECTION, V83, P294, DOI 10.1016/j.jinf.2021.07.015; Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669; Laxminarayan R, 2020, SCIENCE, V370, P691, DOI 10.1126/science.abd7672; Li G, 2021, ETHICS BEHAV, DOI 10.1080/10508422.2021.1932502; Li W, 2020, CLIN INFECT DIS, V71, P1943, DOI 10.1093/cid/ciaa450; Liu PC, 2020, EMERG MICROBES INFEC, V9, P1254, DOI 10.1080/22221751.2020.1772677; Liu ZR, 2020, INT J INFECT DIS, V99, P325, DOI 10.1016/j.ijid.2020.06.036; Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344; Lu WJ, 2021, BMC PEDIATR, V21, DOI 10.1186/s12887-021-02561-y; Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725; Madewell Zachary J, 2020, medRxiv, DOI 10.1101/2020.07.29.20164590; Mantovani A, 2021, PEDIATR RES, V89, P733, DOI 10.1038/s41390-020-1015-2; Martin Blake, 2021, medRxiv, DOI 10.1101/2021.07.19.21260767; Moratto D, 2020, EUR J IMMUNOL, V50, P1412, DOI 10.1002/eji.202048724; Moreews M, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abh1516; Munro APS, 2020, CURR OPIN INFECT DIS, V33, P540, DOI 10.1097/QCO.0000000000000690; Muus C, 2021, NAT MED, V27, P546, DOI 10.1038/s41591-020-01227-z; Neeland MR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21414-x; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; Nishiura H., 2020, AGE SPECIFICITY CASE, DOI [10.1101/2020.03.09.20033142, DOI 10.1101/2020.03.09.20033142]; Ouldali N, 2021, JAMA-J AM MED ASSOC, V325, P855, DOI 10.1001/jama.2021.0694; Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008; Park YJ, 2020, EMERG INFECT DIS, V26, P2465, DOI 10.3201/eid2610.201315; Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732; Pierce Carl A, 2021, medRxiv, DOI 10.1101/2021.02.12.21251310; Plotkin SA, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2021-050531; Poline J, 2021, CLIN INFECT DIS, V72, P2215, DOI 10.1093/cid/ciaa1044; Posfay-Barbe KM, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1576; Reukers DFM, 2022, CLIN INFECT DIS, V74, P52, DOI 10.1093/cid/ciab237; Ricke DO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640093; Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/50140-6736(20)31094-1, 10.1016/S0140-6736(20)31094-1]; Rostad CA, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-018242; Schauer J, 2021, J PEDIATR-US, V238, P317, DOI 10.1016/j.jpeds.2021.06.083; Schouten LR, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0529-4; Schultze JL, 2021, CELL, V184, P1671, DOI 10.1016/j.cell.2021.02.029; Seery V, 2021, EBIOMEDICINE, V67, DOI 10.1016/j.ebiom.2021.103357; Selva KJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22236-7; Sermet-Gaudelus I, 2021, EUROSURVEILLANCE, V26, P9, DOI 10.2807/1560-7917.ES.2021.26.13.2001782; Steinmana JB, 2020, P NATL ACAD SCI USA, V117, P24620, DOI 10.1073/pnas.2012358117; Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0; Tosif S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19545-8; Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094; Ulyte A, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n616; Vakkila J, 2004, CLIN EXP IMMUNOL, V135, P455, DOI 10.1111/j.1365-2249.2003.02388.x; Valiathan R, 2016, SCAND J IMMUNOL, V83, P255, DOI 10.1111/sji.12413; Vella LA, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf7570; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Vono M, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109773; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang ZL, 2020, J INFECTION, V81, P179, DOI 10.1016/j.jinf.2020.03.040; Weisberg SP, 2021, NAT IMMUNOL, V22, P25, DOI 10.1038/s41590-020-00826-9; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369; Wu H, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10895; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang F, 2021, SCIENCE, V372, P738, DOI 10.1126/science.abf6648; Yonker LM, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149633; Yonker LM, 2020, J PEDIATR-US, V227, P45, DOI 10.1016/j.jpeds.2020.08.037; Zhang JJ, 2020, LANCET INFECT DIS, V20, P793, DOI 10.1016/S1473-3099(20)30230-9; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zhang YG, 2020, CELL MOL IMMUNOL, V17, P768, DOI 10.1038/s41423-020-0438-3; Zhu YS, 2021, CLIN INFECT DIS, V72, pE1146, DOI 10.1093/cid/ciaa1825; Zimmerman KO, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-048090	130	7	8	8	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1002	10.3390/vaccines9091002			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW4PY	34579240	gold, Green Published			2022-04-29	WOS:000700141100001
J	Jeong, SK; Heo, YK; Jeong, JH; Ham, SJ; Yum, JS; Ahn, BC; Song, CS; Chun, EY				Jeong, Soo-Kyung; Heo, Yoon-Ki; Jeong, Jei-Hyun; Ham, Su-Jin; Yum, Jung-Sun; Ahn, Byung-Cheol; Song, Chang-Seon; Chun, Eun-Young			COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity	VACCINES			English	Article						SARS-CoV-2; subunit vaccine; adjuvant; TLR agonist; neutralizing antibody; IFN-gamma-producing T cell; cell-mediated immunity; ferret model; mucosal immunity	ADJUVANT; RESPONSES; COMPONENTS; CELLS; MF59	The development of COVID-19 vaccines is critical in controlling global health issues under the COVID-19 pandemic. The subunit vaccines are the safest and most widely used vaccine platform and highly effective against a multitude of infectious diseases. An adjuvant is essential for subunit vaccines to enhance the magnitude and durability of immune responses. In this study, we determined whether a combination of toll-like receptor (TLR)1/2 and TLR3 agonists (L-pampo) can be a potent adjuvant for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subunit vaccine. We measured a neutralizing antibody (nAb) and an angiotensin-converting enzyme 2 (ACE2) receptor-blocking antibody against SARS-CoV-2 receptor-binding domain (RBD). We also detected interferon-gamma (IFN-gamma) production by using ELISPOT and ELISA assays. By employing a ferret model, we detected nAbs and IFN-gamma producing cells and measured viral load in nasal wash after the challenge of SARS-CoV-2. We found that SARS-CoV-2 antigens with L-pampo stimulated robust humoral and cellular immune responses. The efficacy of L-pampo was higher than the other adjuvants. Furthermore, in the ferret model, SARS-CoV-2 antigens with L-pampo elicited nAb response and antigen-specific cellular immune response against SARS-CoV-2, resulting in substantially decreased viral load in their nasal wash. Our study suggests that SARS-CoV-2 antigens formulated with TLR agonists, L-pampo, can be a potent subunit vaccine to promote sufficient protective immunity against SARS-CoV-2.	[Jeong, Soo-Kyung; Heo, Yoon-Ki; Ham, Su-Jin; Yum, Jung-Sun; Ahn, Byung-Cheol; Chun, Eun-Young] CHA Vaccine Inst, R&D Ctr, Seongnam Si 13493, South Korea; [Jeong, Jei-Hyun; Song, Chang-Seon] Konkuk Univ, Coll Vet Med, Seoul 05029, South Korea		Chun, EY (通讯作者)，CHA Vaccine Inst, R&D Ctr, Seongnam Si 13493, South Korea.; Song, CS (通讯作者)，Konkuk Univ, Coll Vet Med, Seoul 05029, South Korea.	soodding@chamc.co.kr; hyk0345@chamc.co.kr; nar2lss@hanmail.net; gkatn0217@chamc.co.kr; jsyum@chamc.co.kr; bcahn@chamc.co.kr; songcs@konkuk.ac.kr; echun@chamc.co.kr		Song, Chang-Seon/0000-0002-4158-6402	Korea Ministry of Health and WelfareMinistry of Health & Welfare, Republic of Korea [HV20C0108]; Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIT) [2020M3A9I2108400]	This work was funded by Korea Ministry of Health and Welfare (HV20C0108) and Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2020M3A9I2108400).	Arunachalam PS, 2021, NATURE, V594, P253, DOI 10.1038/s41586-021-03530-2; Bonifacius A, 2021, IMMUNITY, V54, P340, DOI 10.1016/j.immuni.2021.01.008; Calabro S, 2013, VACCINE, V31, P3363, DOI 10.1016/j.vaccine.2013.05.007; Dillon S, 2004, J IMMUNOL, V172, P4733, DOI 10.4049/jimmunol.172.8.4733; Doherty M, 2016, VACCINE, V34, P6681, DOI 10.1016/j.vaccine.2016.11.015; Enkirch T, 2015, VIROLOGY, V479, P259, DOI 10.1016/j.virol.2015.03.017; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Francica Joseph R, 2021, bioRxiv, DOI 10.1101/2021.03.02.433390; Gai WW, 2008, VIRAL IMMUNOL, V21, P27, DOI 10.1089/vim.2007.0079; Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang HB, 2009, INFECT IMMUN, V77, P1774, DOI 10.1128/IAI.00086-09; Hur KH, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00521; Korsholm KS, 2010, IMMUNOLOGY, V129, P75, DOI 10.1111/j.1365-2567.2009.03164.x; Kuo TY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77077-z; Lee BR, 2016, SCI REP-UK, V6, DOI 10.1038/srep32526; Lee JH, 2014, J VET SCI, V15, P563, DOI 10.4142/jvs.2014.15.4.563; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI 10.1038/s41564-020-0688-y; Liang JG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21634-1; Lien CE, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88283-8; Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061; REED L. J., 1938, AMER JOUR HYG, V27, P493; Ryan KA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20439-y; S Arunachalam Prabhu, 2021, bioRxiv, DOI 10.1101/2021.02.10.430696; Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; Volz E, 2021, CELL, V184, P64, DOI 10.1016/j.cell.2020.11.020; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Ward B.J., 2020, PHASE 1 TRIAL CANDID, DOI [DOI 10.1101/2020.11.04.20226282, 10.1101/2020.11.04.20226282]; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Yum JS, 2012, CLIN VACCINE IMMUNOL, V19, P120, DOI 10.1128/CVI.05355-11; Zhao K, 2011, VACCINE, V29, P6670, DOI 10.1016/j.vaccine.2011.06.100; Zuo JM, 2021, NAT IMMUNOL, V22, P620, DOI 10.1038/s41590-021-00902-8	36	2	2	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							957	10.3390/vaccines9090957			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3FW	34579194	Green Published, gold			2022-04-29	WOS:000702095200001
J	Peng, LH; Guo, Y; Hu, DH				Peng, Lihong; Guo, Yi; Hu, Dehua			Information Framing Effect on Public's Intention to Receive the COVID-19 Vaccination in China	VACCINES			English	Article						COVID-19 vaccine; information framing; framing effect; risk disclosure; perceived vaccine efficacy	HPV VACCINATION; UNITED-STATES; YOUNG-ADULTS; OLDER-ADULTS; MESSAGE; ACCEPTABILITY; PERCEPTIONS; ACCEPTANCE; MOTIVATION; DECISIONS	The aims of the study were (1) to explore information framing effect on the public's intention to receive the COVID-19 vaccination and (2) to understand the key factors influencing the intention of COVID-19 vaccinations in China. An online questionnaire survey was conducted to explore the influence of demographic characteristics, individual awareness, social relationship, risk disclosure, perceived vaccine efficacy, and protection duration under the assumptions of information framing. The results showed that (1) the persuasion effect under loss frame was higher than that under gain frame (B = 0.616 vs. 0.552); (2) there was no significant difference between sex, age, income, occupation, educational background and residence for the participants' intention to be vaccinated; whether family members/friends were vaccinated had a strong correlation with their vaccination intention under the gain frame; (3) the higher the understanding of COVID-19 and the compliance with government COVID-19 prevention and control measures were, the higher the vaccination intention was; (4) risk disclosure had the greatest impact on people's COVID-19 vaccination intention; (5) perceived vaccine effectiveness and duration of protection had little effect on people's intention to receive vaccination. The influence of information framing on the intention of COVID-19 vaccination is different. The publicity of relevant health information should pay attention to the influence of information framing and contents on the behavior of public vaccination, so as to enhance public health awareness and promote the vaccination of the whole population.	[Peng, Lihong; Guo, Yi; Hu, Dehua] Cent South Univ, Sch Life Sci, Dept Biomed Informat, Changsha 410013, Peoples R China		Hu, DH (通讯作者)，Cent South Univ, Sch Life Sci, Dept Biomed Informat, Changsha 410013, Peoples R China.	penglh@csu.edu.cn; yiguo@csu.edu.cn; hudehua@csu.edu.cn		Guo, Yi/0000-0003-2727-9809	National Social Science Fund of China [20BTQ081]	This research was funded by The National Social Science Fund of China (Grant Number 20BTQ081).	Abhyankar Purva, 2008, Psychol Health Med, V13, P1, DOI 10.1080/13548500701235732; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Ansari-Moghaddam A, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11134-8; Arendt F, 2018, J HEALTH COMMUN, V23, P800, DOI 10.1080/10810730.2018.1527878; Biasio LR, 2021, HUM VACC IMMUNOTHER, V17, P1304, DOI 10.1080/21645515.2020.1829315; Chen AC, 2020, J CELL PHYSIOL, V235, P7970, DOI 10.1002/jcp.29451; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; Chen TE, 2021, HEALTH COMMUN, DOI 10.1080/10410236.2021.1876814; Cho DN, 2020, J NATL MED ASSOC, V112, P639, DOI 10.1016/j.jnma.2020.06.005; Chu HR, 2021, PATIENT EDUC COUNS, V104, P1878, DOI 10.1016/j.pec.2021.02.031; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Cox AD, 2006, J MARKETING, V70, P79, DOI 10.1509/jmkg.2006.70.1.79; Danchin M, 2020, AUST J GEN PRACT, V49, P625, DOI 10.31128/AJGP-08-20-5559; Deary IJ, 2007, J EPIDEMIOL COMMUN H, V61, P378, DOI 10.1136/jech.2005.039206; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Elliot AJ, 2002, J PERS SOC PSYCHOL, V82, P804, DOI 10.1037/0022-3514.82.5.804; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Ferguson E, 2007, BRIT J PSYCHOL, V98, P667, DOI 10.1348/000712607X190692; Fishbein M, 2011, PREDICTING AND CHANGING BEHAVIOR: THE REASONED ACTION APPROACH, P1; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Galbadage T, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00348; Gaygisiz U, 2010, VACCINE, V29, P329, DOI 10.1016/j.vaccine.2010.10.030; Gerend MA, 2008, ANN BEHAV MED, V35, P221, DOI 10.1007/s12160-008-9024-0; Gerend MA, 2007, HEALTH PSYCHOL, V26, P745, DOI 10.1037/0278-6133.26.6.745; Giannouchos TV, 2021, J EVAL CLIN PRACT, V27, P996, DOI 10.1111/jep.13588; Gillis JL, 2020, JAIDS-J ACQ IMM DEF, V84, P295, DOI 10.1097/QAI.0000000000002335; Gottfredson LS, 2004, J PERS SOC PSYCHOL, V86, P174, DOI 10.1037/0022-3514.86.1.174; Gruner S, 2021, APPL ECON LETT, V28, P1847, DOI 10.1080/13504851.2020.1854445; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Hoffner C, 2009, HEALTH COMMUN, V24, P189, DOI 10.1080/10410230902804067; Hsu HT, 2021, J SOC DISTRESS HOMEL, DOI 10.1080/10530789.2021.1925046; Kester LM, 2014, GYNECOL ONCOL, V132, pS9, DOI 10.1016/j.ygyno.2013.12.033; Kim S, 2019, HEALTH COMMUN, V34, P21, DOI 10.1080/10410236.2017.1384353; Ko HS, 2015, YONSEI MED J, V56, P1071, DOI 10.3349/ymj.2015.56.4.1071; Kwok KO, 2020, EMERG INFECT DIS, V26, P1575, DOI 10.3201/eid2607.200500; Lazarus JV, 2021, NAT MED, V27, P354, DOI 10.1038/s41591-020-01226-0; Lee AY, 2004, J PERS SOC PSYCHOL, V86, P205, DOI 10.1037/0022-3514.86.2.205; Mazur DJ, 1997, J GEN INTERN MED, V12, P114, DOI 10.1007/s11606-006-5006-8; McCaul KD, 2002, HEALTH PSYCHOL, V21, P624, DOI 10.1037//0278-6133.21.6.624; Mir HH, 2021, DIABETES METAB SYND, V15, P1017, DOI 10.1016/j.dsx.2021.05.006; Mo PKH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020129; Nan XL, 2012, HEALTH COMMUN, V27, P559, DOI 10.1080/10410236.2011.617243; Nan XL, 2012, HEALTH COMMUN, V27, P10, DOI 10.1080/10410236.2011.567447; Nandakumar N, 2017, MARK INTELL PLAN, V35, P442, DOI 10.1108/MIP-07-2016-0117; Parletta N, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00145; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rothman AJ, 1997, PSYCHOL BULL, V121, P3, DOI 10.1037/0033-2909.121.1.3; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Seale H, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05833-1; Seboka BT, 2021, RISK MANAG HEALTHC P, V14, P2743, DOI 10.2147/RMHP.S315043; Aci OS, 2022, INT J NURS KNOWL, V33, P136, DOI 10.1111/2047-3095.12342; Shacham M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073804; Singh T, 2005, J CONSUM MARK, V22, P369, DOI 10.1108/07363760510631101; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; Updegraff JA, 2015, HEALTH PSYCHOL, V34, P20, DOI 10.1037/hea0000101; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wang ZX, 2021, HUM VACC IMMUNOTHER, V17, P3322, DOI 10.1080/21645515.2021.1917232; Wong LP, 2010, VACCINE, V28, P4499, DOI 10.1016/j.vaccine.2010.04.043; Yu YW, 2022, IEEE-ASME T MECH, V27, P928, DOI [10.34172/ijhpm.2021.02, 10.1109/TMECH.2021.3075057]	64	2	2	19	30	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							995	10.3390/vaccines9090995			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ2WS	34579232	Green Published, gold			2022-04-29	WOS:000702071200001
J	Su, ZH; McDonnell, D; Li, XS; Bennett, B; Segalo, S; Abbas, J; Cheshmehzangi, A; Xiang, YT				Su, Zhaohui; McDonnell, Dean; Li, Xiaoshan; Bennett, Bindi; Segalo, Sabina; Abbas, Jaffar; Cheshmehzangi, Ali; Xiang, Yu-Tao			COVID-19 Vaccine Donations-Vaccine Empathy or Vaccine Diplomacy? A Narrative Literature Review	VACCINES			English	Review						COVID-19; vaccination; inequality; vaccine diplomacy; vaccine empathy	HEALTH	Introduction: Vaccine inequality inflames the COVID-19 pandemic. Ensuring equitable immunization, vaccine empathy is needed to boost vaccine donations among capable countries. However, damaging narratives built around vaccine donations such as "vaccine diplomacy" could undermine nations' willingness to donate their vaccines, which, in turn, further exacerbate global vaccine inequality. However, while discussions on vaccine diplomacy are on the rise, there is limited research related to vaccine diplomacy, especially in terms of its characteristics and effects on vaccine distribution vis-a-vis vaccine empathy. Thus, to bridge the research gap, this study aims to examine the defining attributes of vaccine diplomacy and its potential effects on COVID-19 immunization, particularly in light of vaccine empathy. Methods: A narrative review was conducted to shed light on vaccine diplomacy's defining attributes and effects in the context of COVID-19 vaccine distribution and dissemination. Databases such as PubMed and Medline were utilized for literature search. Additionally, to ensure up-to-date insights are included in the review, validated reports and reverse tracing of eligible articles' reference lists in Google Scholar have also been conducted to locate relevant records. Results: Vaccine empathy is an individual or a nation's capability to sympathize with other individuals or nations' vaccine wants and needs, whereas vaccine diplomacy is a nation's vaccine efforts that aim to build mutually beneficial relationships with other nations ultimately. Our findings show that while both vaccine empathy and vaccine diplomacy have their strengths and weaknesses, they all have great potential to improve vaccine equality, particularly amid fast-developing and ever-evolving global health crises such as COVID-19. Furthermore, analyses show that, compared to vaccine empathy, vaccine diplomacy might be a more sustainable solution to improve vaccine donations mainly because of its deeper and stronger roots in multilateral collaboration and cooperation. Conclusion: Similar to penicillin, automated external defibrillators, or safety belts amid a roaring global health disaster, COVID-19 vaccines are, essentially, life-saving consumer health products that should be available to those who need them. Though man-made and complicated, vaccine inequality is nonetheless a solvable issue-gaps in vaccine distribution and dissemination can be effectively addressed by timely vaccine donations. Overall, our study underscores the instrumental and indispensable role of vaccine diplomacy in addressing the vaccine inequality issue amid the COVID-19 pandemic and its potentials for making even greater contributions in forging global solidarity amid international health emergencies. Future research could investigate approaches that could further inspire and improve vaccine donations among capable nations at a global scale to advance vaccine equity further.	[Su, Zhaohui] UT Hlth San Antonio, Mays Canc Ctr, Sch Nursing, Ctr Smart & Connected Hlth Technol, San Antonio, TX 78229 USA; [McDonnell, Dean] Inst Technol, Dept Humanities, Carlow R93 V960, Ireland; [Li, Xiaoshan] Beijing Normal Univ Hong Kong Baptist Univ United, Program Publ Relat & Advertising, Hong Kong 519087, Peoples R China; [Bennett, Bindi] Univ Sunshine Coast, Maroochydore, Qld 4558, Australia; [Segalo, Sabina] Univ Sarajevo, Dept Microbiol, Fac Med, Sarajevo 71000, Bosnia & Herceg; [Abbas, Jaffar] Shanghai Jiao Tong Univ, Antai Coll Econ & Management, Sch Media & Commun, Shanghai 200240, Peoples R China; [Cheshmehzangi, Ali] Univ Nottingham Ningbo China, Fac Sci & Engn, Dept Architecture & Built Environm, Ningbo 315100, Peoples R China; [Cheshmehzangi, Ali] Hiroshima Univ, Network Educ & Res Peace & Sustainabil NERPS, Hiroshima 7398527, Japan; [Xiang, Yu-Tao] Univ Macau, Inst Adv Studies Humanities & Social Sci, Inst Translat Med, Fac Hlth Sci,Dept Publ Hlth & Med Adm,Ctr Cognit, Taipa 999078, Macao, Peoples R China		Xiang, YT (通讯作者)，Univ Macau, Inst Adv Studies Humanities & Social Sci, Inst Translat Med, Fac Hlth Sci,Dept Publ Hlth & Med Adm,Ctr Cognit, Taipa 999078, Macao, Peoples R China.	szh@utexas.edu; dean.mcdonnell@itcarlow.ie; xiaoshan.li@utexas.edu; bbennet1@usc.edu.au; sabina.segalo11@gmail.com; dr.abbas.jaffar@outlook.com; Ali.Cheshmehzangi@nottingham.edu.cn; ytxiang@um.edu.mo	Šegalo, Sabina/AAD-2196-2021; McDonnell, Dean/ABE-7199-2021; Abbas, Jaffar/Z-3914-2019	Šegalo, Sabina/0000-0002-9280-3278; McDonnell, Dean/0000-0001-6043-8272; Abbas, Jaffar/0000-0002-8830-1435; Su, Zhaohui/0000-0003-2005-9504; Li, Xiaoshan/0000-0002-1765-4815; Bennett, Bindi/0000-0002-0111-4670; Cheshmehzangi, Ali/0000-0003-2657-4865			Agren D., US SEND 4M ASTRAZENE; Aisha Ibrahim Mohammed D.S.C.C, 2021, EUR J MOL CLIN MED, V7, P3882; AlKhaldi M, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00195-2; Amiruddin A, 2017, PSYCHOPHYSIOLOGY, V54, P864, DOI 10.1111/psyp.12846; [Anonymous], 2020, LANCET, V396, P867, DOI 10.1016/S0140-6736(20)32001-8; [Anonymous], ECONOMIST; [Anonymous], TIMES INDIA; Baraniuk C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n743; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bhuyan A, 2021, LANCET, V397, P1611, DOI 10.1016/S0140-6736(21)00993-4; Bollyky T.J, 2021, YEAR OUT ADDRESSING; Chattu VK, 2021, HEALTH PROMOT PERSPE, V11, P1, DOI 10.34172/hpp.2021.01; Corum J., CORONAVIRUS VARIANTS; Duke Global Health Innovation Center, INT COVAX MAP; Eaton L, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n292; Grant MJ, 2009, HEALTH INFO LIBR J, V26, P91, DOI 10.1111/j.1471-1842.2009.00848.x; Guidry JPD, 2021, VACCINE, V39, P2452, DOI 10.1016/j.vaccine.2021.03.027; Hotez PJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005320; Hotez PJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002808; Hotez PJ, 2010, SCIENCE, V327, P1301, DOI 10.1126/science.1189028; Hui M., CHINAS VACCINE DIPLO; Javed S, 2020, HEALTH PROMOT PERSPE, V10, P300, DOI 10.34172/hpp.2020.48; Jennings M., VACCINE DIPLOMACY SO; Johns Hopkins University, COVID 19 GLOB MAP; Kim JH, 2021, LANCET GLOB HEALTH, V9, pE1017, DOI 10.1016/S2214-109X(21)00140-6; Kobierecka A, 2021, INT POLITICS, V58, P937, DOI 10.1057/s41311-020-00273-1; Lagman JDN, 2021, J PUBLIC HEALTH-UK, V43, pE375, DOI 10.1093/pubmed/fdab088; Mehrotra N, VACCINE INEQUALITY I; Mueller B., VAST GLOBAL VACCINAT; Muthanna K. A., 2011, J DEFENCE STUDIES, V5, p[1, 1]; Nhamo G, 2021, GLOB PUBLIC HEALTH, V16, P319, DOI 10.1080/17441692.2020.1860249; Oli S., WE NEED HELP; Our world in data, COR COVID 19 VACC; Palmer J., CHINAS VACCINE DIPLO; Pannu J, 2021, LANCET GLOB HEALTH, V9, pE744, DOI 10.1016/S2214-109X(21)00091-7; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ramirez J, 2018, GLOBALIZATION HEALTH, V14, DOI 10.1186/s12992-018-0428-8; Sharun K, 2021, ARCH MED RES, V52, P761, DOI 10.1016/j.arcmed.2021.04.006; Sharun K, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab064; Su ZH, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/26111; Su Zhaohui, 2021, Brain Behav Immun Health, V12, P100204, DOI 10.1016/j.bbih.2021.100204; Su Zhaohui, 2020, Brain Behav Immun Health, V9, P100159, DOI 10.1016/j.bbih.2020.100159; Su ZhaoHui, 2019, Journal of Communication in Healthcare, V12, P170, DOI 10.1080/17538068.2019.1680038; Usher AD, 2021, LANCET, V397, P1171, DOI 10.1016/S0140-6736(21)00721-2; Vanderslott S, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa112; World Health Organization, COVAX WORK GLOB EQ A	46	8	8	29	30	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1024	10.3390/vaccines9091024			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3MK	34579261	Green Published, gold			2022-04-29	WOS:000702112300001
J	Ricco, M; Ferraro, P; Peruzzi, S; Balzarini, F; Ranzieri, S				Ricco, Matteo; Ferraro, Pietro; Peruzzi, Simona; Balzarini, Federica; Ranzieri, Silvia			Mandate or Not Mandate: Knowledge, Attitudes, and Practices of Italian Occupational Physicians towards SARS-CoV-2 Immunization at the Beginning of Vaccination Campaign	VACCINES			English	Article						knowledge; occupational physicians; risk perception; SARS-CoV-2; COVID-19	HEALTH-CARE WORKERS; COVID-19 VACCINE; UNITED-STATES; INFLUENZA; COVERAGE; BELIEFS; ADULTS	Vaccinations used to prevent coronavirus disease (COVID-19)-the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-are critical in order to contain the ongoing pandemic. However, SARS-CoV-2/COVID-19 vaccination rates have only slowly increased since the beginning of the vaccination campaign, even with at-risk workers (e.g., HCWs), presumptively because of vaccine hesitancy. Vaccination mandates are considered instrumental in order to rapidly improve immunization rates (but they minimize the impact of vaccination campaigns). In this study, we investigated the acceptance (i.e., knowledge, attitudes, and practices) from occupational physicians (OPs)) in regard to SARS-CoV-2/COVID-19 vaccination mandates. A total of 166 OPs participated in an internet-based survey by completing structured questionnaires. Adequate, general knowledge of SARS-CoV-2/COVID-19 was found in the majority of OPs. High perception of SARS-CoV-2 risk was found in around 80% of participants (79.5% regarding its occurrence, 81.9% regarding its potential severity). SARS-CoV-2/COVID-19 vaccination was endorsed by 90.4% of respondents, acceptance for SARS-CoV-2 vaccine was quite larger for mRNA formulates (89.8%) over adenoviral ones (59.8%). Endorsement of vaccination mandates was reported by 60.2% of respondents, and was more likely endorsed by OPs who exhibited higher concern for SARS-CoV-2 infection occurrence (odds ratio 3.462, 95% confidence intervals 1.060-11.310), who were likely to accept some sort of payment/copayment for SARS-CoV-2/COVID-19 vaccination (3.896; 1.607; 9.449), or who were more likely to believe HCWs not vaccinates against SARS-CoV-2 as unfit for work (4.562; 1.935; 10.753). In conclusion, OPs exhibited wide acceptance of SARS-CoV-2/COVID-19 vaccinations, and the majority endorsed vaccination mandates for HCWs, which may help improve vaccination rates in occupational settings.	[Ricco, Matteo] AUSL IRCCS Reggio Emilia, Serv Prevenzione Sicurezza Negli Ambienti Lavora, I-42122 Reggio Emilia, Italy; [Ferraro, Pietro] Hosp S Camillo Lellis, ASL Foggia, Occupat Hlth & Safety Serv, I-41121 Foggia, Italy; [Peruzzi, Simona] Osped Civile Guastalla, Lab Analisi Chim Cliniche Microbiologi, AUSL IRCCS Reggio Emilia, I-42016 Guastalla, Italy; [Balzarini, Federica] Agenzia Tutela Salute ATS Bergamo, Dipt P A A P S S, Serv Autorizzazione Accreditamento, I-24121 Bergamo, Italy; [Ranzieri, Silvia] Univ Parma, Dept Med & Surg, I-43126 Parma, PR, Italy		Ricco, M (通讯作者)，AUSL IRCCS Reggio Emilia, Serv Prevenzione Sicurezza Negli Ambienti Lavora, I-42122 Reggio Emilia, Italy.	matteo.ricco@ausl.re.it; dott.pietro.ferraro@gmail.com; simona.peruzzi@ausl.re.it; federica.balzarini@ats-bg.it; silvia.ranzieri@unipr.it	Riccò, Matteo/T-8078-2019	Riccò, Matteo/0000-0002-6525-2159; Ranzieri, Silvia/0000-0002-9607-8624; Ferraro, Pietro/0000-0002-9149-1647			Abdulla ZA, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10070788; [Anonymous], 2008, OFFICIAL GAZETTE ITA; [Anonymous], 2021, VACCINO 300 OPERATOR; ANSA, 2021, COVID IT VACC CAMP S; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Betsch C, 2014, VACCINE, V32, P4478, DOI 10.1016/j.vaccine.2014.06.046; Canova V., 2020, SWISS MED WKLY, V150, DOI [10.4414/smw.2020.20257, DOI 10.4414/SMW.2020.20257]; Cheng HY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060582; Craxi L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030189; Di Gennaro F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030371; Di Giuseppe G, 2021, EXPERT REV VACCINES, V20, P881, DOI 10.1080/14760584.2021.1922081; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Di Valerio Z., ANN IG; Dini G, 2021, INT J OCCUP MED ENV, V34, P189, DOI 10.13075/ijomeh.1896.01759; Durando P, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040141; Dzieciolowska S, 2021, AM J INFECT CONTROL, V49, P1152, DOI 10.1016/j.ajic.2021.04.079; ECDC, 2020, EUR CTR DIS PREV CON; European Center for Disease Prevention and Control (ECDC), 2021, ROLL COVID 19 VACC E; European Center for Disease Prevention and Control (ECDC), 2020, OV EU EEA COUNTR REC; European Commission, 2020, COR COMM VACC STRAT; European Medicines Agency (EMA), 2021, COVID 19 VACC SAF UP; Eyre DW, 2020, ELIFE, V9, DOI 10.7554/eLife.60675; Falato R, 2011, MED LAV, V102, P208; Fall E, 2018, PSYCHOL HEALTH, V33, P746, DOI 10.1080/08870446.2017.1401623; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Garcia LY, 2020, VACCINE, V38, P7587, DOI 10.1016/j.vaccine.2020.10.026; Gharpure R, 2021, MMWR-MORBID MORTAL W, V70, P178, DOI 10.15585/mmwr.mm7005e2; Giannouchos TV, 2021, J EVAL CLIN PRACT, V27, P996, DOI 10.1111/jep.13588; Gostin LO, 2021, JAMA-J AM MED ASSOC, V325, P532, DOI 10.1001/jama.2020.26553; Graeber D, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248372; Guljas S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18116141; Harapan H, 2020, HUM VACC IMMUNOTHER, V16, P3074, DOI 10.1080/21645515.2020.1819741; Heiervang E, 2011, SOC PSYCH PSYCH EPID, V46, P69, DOI 10.1007/s00127-009-0171-9; Huang Yu, 2017, JMIR Public Health Surveill, V3, pe81, DOI 10.2196/publichealth.7663; Italian National Institute of Statistics (ISTAT), STAT HLTH I IT; Janssen C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060547; Jennings W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060593; Kaushal S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242132; Kwok K.O., J INFECT; La Torre G, 2017, HEALTHCARE-BASEL, V5, DOI 10.3390/healthcare5010013; Largent EA, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.33324; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Ledda C, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052703; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loulergue P, 2009, VACCINE, V27, P4240, DOI 10.1016/j.vaccine.2009.03.039; Lucia V.C., J PUBLIC HEALTH-UK; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141; Manzoli L, 2015, EPIDEMIOL PREV, V39, P81; Mitchell KC, 2018, VECTOR-BORNE ZOONOT, V18, P173, DOI 10.1089/vbz.2017.2188; Olalla J, 2020, QJM-INT J MED, V113, P794, DOI 10.1093/qjmed/hcaa238; Paterlini M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1065; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pottegard A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1114; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; RICCo M, 2020, J Prev Med Hyg, V61, pE66, DOI 10.15167/2421-4248/jpmh2020.61.1.1155; Ricco M, 2017, J Prev Med Hyg, V58, pE141; Ricco M, 2021, TROP MED INFECT DIS, V6, DOI 10.3390/tropicalmed6030116; Ricco Matteo, 2020, Acta Biomed, V91, DOI 10.23750/abm.v91i3.9727; Ricco M, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5030117; Ricco M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051515; Ricco M, 2017, INT J OCCUP MED ENV, V30, P775, DOI 10.13075/ijomeh.1896.00895; Ricco M, 2016, IND HEALTH, V54, P554, DOI 10.2486/indhealth.2015-0249; Rivett L, 2020, ELIFE, V9, DOI 10.7554/eLife.58728; Rothstein MA, 2021, AM J PUBLIC HEALTH, V111, P1061, DOI 10.2105/AJPH.2020.306166; Sabbatucci M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122540; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Signorelli C, 2017, VACCINE, V35, P4057, DOI 10.1016/j.vaccine.2017.06.011; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Spagnolo L, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57050479; Spinewine A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050469; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Verger P, 2021, HUM VACC IMMUNOTHER, V17, P2934, DOI 10.1080/21645515.2021.1921523; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Verger P, 2020, EXPERT REV VACCINES, V19, P991, DOI 10.1080/14760584.2020.1825945; Wendt R, 2020, INFECT CONT HOSP EP, V41, P1209, DOI 10.1017/ice.2020.268; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018; Yates F.J., 1992, WILEY SERIES HUMAN P, P1	79	4	4	2	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							889	10.3390/vaccines9080889			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UH9XU	34452014	gold, Green Published			2022-04-29	WOS:000690274600001
J	Rocconi, RP; Stanbery, L; da Silva, LM; Barrington, RA; Aaron, P; Manning, L; Horvath, S; Wallraven, G; Bognar, E; Walter, A; Nemunaitis, J				Rocconi, Rodney P.; Stanbery, Laura; Madeira da Silva, Luciana; Barrington, Robert A.; Aaron, Phylicia; Manning, Luisa; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Walter, Adam; Nemunaitis, John			Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer	VACCINES			English	Article						Vigil; immune response; NanoString; TIS; gene expression profile; immunotherapy; ovarian cancer	DOUBLE-BLIND; MAINTENANCE THERAPY; CELL RESPONSES; PD-1 BLOCKADE; PHASE-II; PLATINUM; IMMUNOTHERAPY; PEMBROLIZUMAB; CHEMOTHERAPY; CARCINOMA	Aim: To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. Patients and Methods: Recurrent ovarian cancer patients (n = 21) enrolled in prior clinical trials. Results: GEP stratified by TISHIGH vs. TISLOW demonstrated OS benefit (NR vs. 5.8 months HR 0.23; p = 0.0379), and in particular, MHC-II elevated baseline expression was correlated with OS advantage (p = 0.038). Moreover, 1-year OS was 75% in TISHIGH patients vs. 25% in TISLOW (p = 0.03795). OS was also correlated with positive gamma-IFN ELISPOT response, 36.8 vs. 23.0 months (HR 0.19, p = 0.0098). Conclusion: Vigil demonstrates OS benefit in correlation with TISHIGH score, elevated MHC-II expression and positive gamma-IFN ELISPOT in recurrent ovarian cancer patients.	[Rocconi, Rodney P.] Univ S Alabama, Div Gynecol Oncol, Mitchell Canc Inst, Mobile, AL 36604 USA; [Stanbery, Laura; Aaron, Phylicia; Manning, Luisa; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Nemunaitis, John] Gradalis Inc, 2545 Golden Bear Dr,Suite 110, Carrollton, TX 75006 USA; [Madeira da Silva, Luciana; Barrington, Robert A.] Univ S Alabama, Dept Microbiol & Immunol, Mobile, AL 36688 USA; [Walter, Adam] Promedica, Sylvania, OH 43560 USA		Nemunaitis, J (通讯作者)，Gradalis Inc, 2545 Golden Bear Dr,Suite 110, Carrollton, TX 75006 USA.	rocconi@health.southalabama.edu; lnejedlik@gradalisinc.com; lsilva@health.southalabama.edu; rbarrington@health.southalabama.edu; paaron@gradalisinc.com; lmanning@gradalisinc.com; shorvath@gradalisinc.com; gwallraven@gradalisinc.com; ebognar@gradalisinc.com; adam.walterMD@promedica.org; jnemunaitis@gradalisinc.com					American Cancer Society, CANC FACTS FIGURES 2; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Bognar, 2020, CANC SCI RES, V3, P1, DOI [10.33425/2639-8478.1055, DOI 10.33425/2639-8478.1055]; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Coleman RL, 2017, LANCET, V390, P1949, DOI 10.1016/S0140-6736(17)32440-6; Cosma Gabriela, 2018, F1000Res, V7, DOI 10.12688/f1000research.14115.1; Craig DJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040562; Danaher P, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0367-1; Dieu-Nosjean MC, 2008, J CLIN ONCOL, V26, P4410, DOI 10.1200/JCO.2007.15.0284; Disis ML, 2019, JAMA ONCOL, V5, P393, DOI 10.1001/jamaoncol.2018.6258; Feins S, 2019, AM J HEMATOL, V94, pS3, DOI 10.1002/ajh.25418; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Frey AB, 2015, VACCINE, V33, P7393, DOI 10.1016/j.vaccine.2015.08.096; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gonzalez-Martin A, 2019, NEW ENGL J MED, V381, P2391, DOI 10.1056/NEJMoa1910962; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Hanker LC, 2012, ANN ONCOL, V23, P2605, DOI 10.1093/annonc/mds203; James FR, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3585-x; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kehoe S, 2015, LANCET, V386, P249, DOI 10.1016/S0140-6736(14)62223-6; Leone P, 2013, JNCI-J NATL CANCER I, V105, P1172, DOI 10.1093/jnci/djt184; Li X, 2007, CANCER LETT, V253, P144, DOI 10.1016/j.canlet.2007.01.024; Manzoni M, 2010, ONCOLOGY-BASEL, V79, P187, DOI 10.1159/000320609; Maples P., 2010, BIOPROCESS J, V8, P4; Markman M, 2003, J CLIN ONCOL, V21, P2460, DOI 10.1200/JCO.2003.07.013; Matulonis UA, 2019, ANN ONCOL, V30, P1080, DOI 10.1093/annonc/mdz135; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Messori A., 2013, J CANC THER, V4, P1242, DOI [10.4236/jct.2013.47145, DOI 10.4236/JCT.2013.47145]; Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468; Metzinger MN, 2019, ONCOLOGY-BASEL, V97, P59, DOI 10.1159/000500488; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Morand S, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa077; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Napoletano C, 2010, J CELL MOL MED, V14, P2748, DOI 10.1111/j.1582-4934.2009.00911.x; Nemunaitis J, 2020, CLIN ONCOL RES, V2020, P1, DOI [10.31487/j.cor.2020.04.02, DOI 10.31487/J.COR.2020.04.02]; Oh J, 2020, GYNECOL ONCOL REP, V34, DOI 10.1016/j.gore.2020.100648; Oh J, 2016, GYNECOL ONCOL, V143, P504, DOI 10.1016/j.ygyno.2016.09.018; Pages F, 2009, J CLIN ONCOL, V27, P5944, DOI 10.1200/JCO.2008.19.6147; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Poveda A, 2020, J CLIN ONCOL, V38; Pujade-Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470-2045(17)30469-2; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rocconi RP, 2020, LANCET ONCOL, V21, P1661, DOI 10.1016/S1470-2045(20)30533-7; Senzer N., 2013, J VACCINES VACCIN, V4, P209, DOI DOI 10.4172/2157-7560.1000209; Senzer N, 2012, MOL THER, V20, P679, DOI 10.1038/mt.2011.269; Shi YF, 2006, CELL RES, V16, P126, DOI 10.1038/sj.cr.7310017; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Varga A, 2019, GYNECOL ONCOL, V152, P243, DOI 10.1016/j.ygyno.2018.11.017	52	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							894	10.3390/vaccines9080894			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9AL	34452019	Green Published, gold			2022-04-29	WOS:000690213900001
J	Salerno, L; Craxi, L; Amodio, E; Coco, GL				Salerno, Laura; Craxi, Lucia; Amodio, Emanuele; Lo Coco, Gianluca			Factors Affecting Hesitancy to mRNA and Viral Vector COVID-19 Vaccines among College Students in Italy	VACCINES			English	Article						vaccine hesitancy; COVID-19; mRNA vaccines; viral vector vaccines; college students; Italy	VACCINATION INTENTIONS; WILLINGNESS; INVENTORY; VERSION	Vaccine hesitancy (VH) may be significant in jeopardizing efforts to mass containment of COVID-19. A cross-sectional survey was carried out on a sample of 2667 Italian college students, before the COVID-19 vaccines became available for this age group (from 7 May to 31 May 2021). An online survey was created to obtain information about socio-demographic, health-related, and psychological factors linked to mRNA and viral vector COVID-19 vaccines. Statistically significant higher VH (30.4%) and vaccine resistance (12.2%) rates were found for viral vector than mRNA COVID-19 vaccines (7.2% and 1.0%, respectively; p < 0.001). Factors related to viral vector VH were partially different from those related to mRNA VH. Students with greater endorsement on conspiracy statements and negative attitudes toward the vaccine had higher odds of being vaccine-hesitant or -resistant. Students who had received a previous COVID-19 test and who scored higher on the agreeableness personality dimension had lower odds to be vaccine-hesitant or -resistant. The willingness to choose the vaccine was related to the viral vector but not to the mRNA VH. Taking into consideration the factors involved in vaccine hesitancy/resistance in college students could represent a key public health strategy to increase vaccine coverage and reduce viral spreading.	[Salerno, Laura; Lo Coco, Gianluca] Univ Palermo, Dept Psychol Educ Sci & Human Movement, I-90128 Palermo, Italy; [Craxi, Lucia] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, I-90127 Palermo, Italy; [Amodio, Emanuele] Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties, I-90127 Palermo, Italy		Craxi, L (通讯作者)，Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, I-90127 Palermo, Italy.	laura.salerno@unipa.it; lucia.craxi@unipa.it; emanuele.amodio@unipa.it; gianluca.lococo@unipa.it	Lo Coco, Gianluca/AAG-9189-2021; Craxi, Lucia/F-2269-2018	Salerno, Laura/0000-0002-3801-7006; Amodio, Emanuele/0000-0001-5482-5268; Craxi, Lucia/0000-0002-3997-1504; Lo Coco, Gianluca/0000-0001-9027-1899			Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barello S, 2021, PSYCHOL MED, DOI 10.1017/S003329172100101X; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Boytchev H, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n414; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; de Bekker-Grob EW, 2018, VACCINE, V36, P1467, DOI 10.1016/j.vaccine.2018.01.054; Ding YN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237626; European Medicines Agency, 2021, COVID 19 VACC ASTRAZ; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Graupensperger S, 2021, VACCINE, V39, P2060, DOI 10.1016/j.vaccine.2021.03.018; Guido G, 2015, PERS INDIV DIFFER, V76, P135, DOI 10.1016/j.paid.2014.11.053; Hertie School, 2021, WILL TAK COVID 19 VA; Hotez PJ, 2021, LANCET, V397, P1165, DOI 10.1016/S0140-6736(21)00372-X; Islam MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251605; Koehler P, 2020, LANCET INFECT DIS, V21, pE149, DOI 10.1016/S1473-3099(20)30847-1; Kreps SE, 2021, VACCINE, V39, P3250, DOI 10.1016/j.vaccine.2021.04.044; Lackner CL, 2021, VACCINE-X, V8, DOI 10.1016/j.jvacx.2021.100091; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Oltermann P., SCEPTICISM OXFORD VA; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rammstedt B, 2007, J RES PERS, V41, P203, DOI 10.1016/j.jrp.2006.02.001; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Rodriguez-Blanco N, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105272; Shapiro GK, 2016, PAPILLOMAVIRUS RES, V2, P167, DOI 10.1016/j.pvr.2016.09.001; Sharma M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094617; Sprengholz P, 2021, EUR J INTERN MED, V87, P106, DOI 10.1016/j.ejim.2021.03.015; Tavolacci MP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060654; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Viswanath K, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10862-1; Vogel G, 2021, SCIENCE, V372, P14, DOI 10.1126/science.372.6537.14; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang C, 2021, VACCINE, V39, P2833, DOI 10.1016/j.vaccine.2021.04.020; WHO, 2021, WHO STAT ASTRAZENEC; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206	45	11	11	13	24	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							927	10.3390/vaccines9080927			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UH2MQ	34452052	gold, Green Published			2022-04-29	WOS:000689772400001
J	Yu, EM; Linville, L; Rosenthal, M; Aragon-Ching, JB				Yu, Eun-mi; Linville, Laura; Rosenthal, Matthew; Aragon-Ching, Jeanny B.			A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma	VACCINES			English	Review						renal cell cancer; checkpoint inhibitors; immunotherapy; vascular endothelial growth factors	PHASE-III TRIAL; ADJUVANT SUNITINIB; INTERFERON-ALPHA; OPEN-LABEL; EVEROLIMUS; NIVOLUMAB; CABOZANTINIB; NEPHRECTOMY; COMBINATION; PLACEBO	The use of checkpoint inhibitors in advanced and metastatic renal cell carcinomas (RCCs) has rapidly evolved over the past several years. While immune-oncology (IO) drug therapy has been successful at resulting in improved responses and survival, combination therapies with immune checkpoint inhibitors and vascular endothelial growth factor (VEGF) inhibitors have further improved outcomes. This article reviews the landmark trials that have led to the approval of IO therapies, including the Checkmate 214 trial and combination IO/VEGF TKI therapies with Checkmate 9ER, CLEAR, and Keynote-426, and it includes a discussion on promising therapies moving in the future.	[Yu, Eun-mi; Aragon-Ching, Jeanny B.] Inova Schar Canc Inst, GU Med Oncol, Fairfax, VA 22031 USA; [Linville, Laura; Rosenthal, Matthew] George Washington Univ, Med Ctr, Dept Internal Med, Washington, DC 20037 USA		Aragon-Ching, JB (通讯作者)，Inova Schar Canc Inst, GU Med Oncol, Fairfax, VA 22031 USA.	eunmi.yu@inova.org; llinville@mfa.gwu.edu; mrosenthal@mfa.gwu.edu; jeanny.aragon-ching@inova.org	Aragon-Ching, Jeanny/AAJ-4969-2020	Aragon-Ching, Jeanny/0000-0002-6714-141X			Beuselinck B, 2015, CLIN CANCER RES, V21, P1329, DOI 10.1158/1078-0432.CCR-14-1128; Choueiri TK, 2021, NEW ENGL J MED, V384, P829, DOI 10.1056/NEJMoa2026982; Choueiri TK, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.LBA5; Choueiri TK, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.TPS4599; Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Figlin RA, 2020, CLIN CANCER RES, V26, P2327, DOI 10.1158/1078-0432.CCR-19-2427; Ghini V, 2020, CANCERS, V12, DOI 10.3390/cancers12123574; Grimm MO, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.446; Gul A, 2020, J CLIN ONCOL, V38, P3088, DOI 10.1200/JCO.19.03315; Haas NB, 2017, JAMA ONCOL, V3, P1249, DOI 10.1001/jamaoncol.2017.0076; Heng DYC, 2013, LANCET ONCOL, V14, P141, DOI 10.1016/S1470-2045(12)70559-4; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; Jonasch E, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4797; Knox JJ, 2017, ANN ONCOL, V28, P1339, DOI 10.1093/annonc/mdx075; McDermott DF, 2005, J CLIN ONCOL, V23, P133, DOI 10.1200/JCO.2005.03.206; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.20.1.289; Motzer R, 2021, NEW ENGL J MED, V384, P1289, DOI 10.1056/NEJMoa2035716; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Motzer RJ, 2018, EUR UROL, V73, P62, DOI 10.1016/j.eururo.2017.09.008; Motzer RJ, 2017, J CLIN ONCOL, V35, P3916, DOI 10.1200/JCO.2017.73.5324; Motzer RJ, 2015, LANCET ONCOL, V16, P1473, DOI 10.1016/S1470-2045(15)00290-9; Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219; Pal SK, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.TPS370; Ravaud A, 2016, NEW ENGL J MED, V375, P2246, DOI 10.1056/NEJMoa1611406; Ravi P, 2020, JAMA ONCOL, V6, P1606, DOI 10.1001/jamaoncol.2020.2169; Riley RS, 2019, NAT REV DRUG DISCOV, V18, P175, DOI 10.1038/s41573-018-0006-z; Rini B.I., 2018, ANN ONCOL, V29, pviii724, DOI [10.1093/annonc/mdy424.037, DOI 10.1093/ANNONC/MDY424.037]; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Siegel R.L., CANC STAT 2021 CA CA, V71, P33, DOI [10.3322/caac.21654, DOI 10.3322/CAAC.21654]; Stephenson AJ, 2004, J UROLOGY, V172, P58, DOI 10.1097/01.ju.0000132126.85812.7d; Tamma R, 2019, UROL ONCOL-SEMIN ORI, V37, DOI 10.1016/j.urolonc.2019.01.025; Vuong L, 2019, CANCER DISCOV, V9, P1349, DOI 10.1158/2159-8290.CD-19-0499; Yekeduz E, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.321; Zhang T, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.TPS366	41	2	2	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							919	10.3390/vaccines9080919			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6QZ	34452045	gold, Green Published			2022-04-29	WOS:000690054100001
J	Al-Sanafi, M; Sallam, M				Al-Sanafi, Mariam; Sallam, Malik			Psychological Determinants of COVID-19 Vaccine Acceptance among Healthcare Workers in Kuwait: A Cross-Sectional Study Using the 5C and Vaccine Conspiracy Beliefs Scales	VACCINES			English	Article						vaccine hesitancy; anti-vaccine; intention to vaccinate; vaccine rejection; SARS-CoV-2 prevention	IMMUNIZATION; HESITANCY; INTENTION	Acceptance of coronavirus disease 2019 (COVID-19) vaccination appears as a decisive factor necessary to control the ongoing pandemic. Healthcare workers (HCWs) are among the highest risk groups for infection. The current study aimed to evaluate COVID-19 vaccine acceptance among HCWs in Kuwait, with identification of the psychological determinants of COVID-19 vaccine hesitancy. The study was conducted using an online anonymous survey distributed between 18 March 2021 and 29 March 2021. The sampling strategy was convenience-based depending on chain-referral sampling. Psychological determinants of COVID-19 vaccine acceptance were assessed using the 5C subscales and the Vaccine Conspiracy Beliefs Scale (VCBS). The total number of study participants was 1019, with the largest group being physicians (28.7%), pharmacists (20.2%), dentists (16.7%), and nurses (12.5%). The overall rate for COVID-19 vaccine acceptance was 83.3%, with 9.0% who were not willing to accept vaccination and 7.7% who were unsure. The highest rate for COVID-19 vaccine acceptance was seen among dentists (91.2%) and physicians (90.4%), while the lowest rate was seen among nurses (70.1%; p < 0.001). A higher level of COVID-19 vaccine hesitancy was found among females, participants with a lower educational level, and HCWs in the private sector. A preference for mRNA vaccine technology and Pfizer-BioNTech COVID-19 vaccine was found among the majority of participants (62.6% and 69.7%, respectively). COVID-19 vaccine hesitancy was significantly linked to the embrace of vaccine conspiracy beliefs. The highest 5C psychological predictors of COVID-19 vaccine acceptance were high levels of collective responsibility and confidence, and lower levels of constraints and calculation. The VCBS and 5C subscales (except the calculation subscale) showed acceptable levels of predicting COVID-19 vaccine acceptance based on receiver operating characteristic analyses. The participants who depended on social media platforms, TV programs, and news releases as their main sources of knowledge about COVID-19 vaccines showed higher rates of COVID-19 vaccine hesitancy. An overall satisfactory level of COVID-19 vaccine acceptance was seen among HCWs in Kuwait, which was among the highest rates reported globally. However; higher levels of vaccine hesitancy were observed among certain groups (females, nurses and laboratory workers, HCWs in the private sector), which should be targeted with more focused awareness programs. HCWs in Kuwait can play a central role in educating their patients and the general public about the benefits of COVID-19 vaccination to halt the spread of SARS-CoV-2, considering the high rates of vaccine hesitancy observed among the general public in Kuwait and the Middle East.	[Al-Sanafi, Mariam] Farwaniya Hosp, Dept Clin Pharm, Kuwait 25210, Kuwait; [Al-Sanafi, Mariam] Publ Author Appl Educ & Training, Coll Hlth Sci, Dept Pharmaceut Sci, Safat 13092, Kuwait; [Sallam, Malik] Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan; [Sallam, Malik] Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan; [Sallam, Malik] Lund Univ, Fac Med, Dept Translat Med, S-22184 Malmo, Sweden		Sallam, M (通讯作者)，Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan.; Sallam, M (通讯作者)，Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan.; Sallam, M (通讯作者)，Lund Univ, Fac Med, Dept Translat Med, S-22184 Malmo, Sweden.	mb.alsanafi@paaet.edu.kw; malik.sallam@ju.edu.jo	Sallam, Malik/O-5021-2014; Alsanafi, Mariam/ABC-1710-2021	Sallam, Malik/0000-0002-0165-9670; Alsanafi, Mariam/0000-0002-1366-3693			Abolfotouh MA, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05443-3; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; Anand P, 2021, PATIENT SAF SURG, V15, DOI 10.1186/s13037-021-00291-9; Awadhi EA, 2021, RISK MANAG HEALTHC P, V14, P1413, DOI 10.2147/RMHP.S300602; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Ball P, 2020, NATURE, V581, P371, DOI 10.1038/d41586-020-01452-z; Baraniuk C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n743; Baraniuk C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n421; Barello S, 2021, PSYCHOL MED, DOI 10.1017/S003329172100101X; Betsch C., 2015, SCOTTISH INDEX MULTI, V2, P61, DOI 10.1177/2372732215600716; Betsch C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034869; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Carvalho T, 2021, NAT REV IMMUNOL, V21, P245, DOI 10.1038/s41577-021-00522-1; Checkmarket, SAMPL SIZ CALC; Chirumbolo S, 2021, J MED VIROL, V93, P4049, DOI 10.1002/jmv.26922; COVID19 Vaccine Tracker, KUW 2 VACC APPR US K KUW 2 VACC APPR US K; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Dzieciolowska S, 2021, AM J INFECT CONTROL, V49, P1152, DOI 10.1016/j.ajic.2021.04.079; Fares Samar, 2021, J Prim Care Community Health, V12, p21501327211013303, DOI 10.1177/21501327211013303; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Ghazy Ramy Mohamed, 2021, J Prim Care Community Health, V12, p21501327211018568, DOI 10.1177/21501327211018568; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Iacobucci G, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n612; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Ledford H., J JS 1 SHOT COVID VA J JS 1 SHOT COVID VA; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mohanty A, 2019, J FAM MED PRIM CARE, V8, P2568, DOI 10.4103/jfmpc.jfmpc_431_19; Mukaetova-Ladinska EB, 2021, EUR ARCH PSY CLIN N, V271, P235, DOI 10.1007/s00406-020-01210-2; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nguyen LH, 2020, LANCET PUBLIC HEALTH, V5, pE475, DOI 10.1016/S2468-2667(20)30164-X; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Nohl A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050424; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; Our World in Data, KUW COR PAND COUNTR KUW COR PAND COUNTR; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Paris C, 2021, INFECT DIS NOW, V51, P484, DOI 10.1016/j.idnow.2021.04.001; Peretti-Watel Patrick, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pottegard A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1114; Puci MV, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040535; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sallam M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052407; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sallam M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243264; Sallam M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144915; Salman A, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8030264; Shapiro GK, 2016, PAPILLOMAVIRUS RES, V2, P167, DOI 10.1016/j.pvr.2016.09.001; Spinewine A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050469; Statista, EST POP KUW 2012 201 EST POP KUW 2012 201; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Trafimow D, 2019, ECONOMETRICS, V7, DOI 10.3390/econometrics7020026; Trafimow D, 2017, NEW IDEAS PSYCHOL, V45, P19, DOI 10.1016/j.newideapsych.2017.01.002; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wheeler M, 2013, HUM VACC IMMUNOTHER, V9, P1782, DOI 10.4161/hv.25959; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Wiysonge CS, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1893062; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	75	16	16	16	25	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							701	10.3390/vaccines9070701			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TO7PC	34202298	Green Published, gold			2022-04-29	WOS:000677097500001
J	Chan, WL; Ho, YHT; Wong, CKH; Choi, HCW; Lam, KO; Yuen, KK; Kwong, D; Hung, I				Chan, Wing-Lok; Ho, Yuen-Hung Tricia; Wong, Carlos King-Ho; Choi, Horace Cheuk-Wai; Lam, Ka-On; Yuen, Kwok-Keung; Kwong, Dora; Hung, Ivan			Acceptance of COVID-19 Vaccination in Cancer Patients in Hong Kong: Approaches to Improve the Vaccination Rate	VACCINES			English	Article						cancer; vaccination; acceptance; anxiety; COVID-19		Emerging efficacy and safety data have led to the authorization of COVID-19 vaccines worldwide, but most trials excluded patients with active malignancies. This study evaluates the intended acceptance of COVID-19 vaccination in cancer patients in Hong Kong. Methods: 660 adult cancer patients received a survey, in paper or electronic format, between 31 January 2021 and 15 February 2021. The survey included patient's clinical characteristics, perceptions of COVID-19 and vaccination, vaccine knowledge, cancer health literacy, and Hospital Anxiety and Depression scale (HADS). The primary outcome was the intended acceptance of COVID-19 vaccine in cancer patients. Multivariable analysis was performed to identify factors associated with intended acceptance. Results: The intended acceptance of COVID-19 vaccination was 17.9%. A total of 487 (73.8%) believed that vaccination could prevent them from infection. Over 70% worried about vaccine negative effects on cancer and its side effects. Factors associated with intended acceptance included higher level of "belief in vaccine on preventing them from getting COVID-19", less worry about long-term side effects of vaccine, lower level of cancer health literacy, and normal HADS (Depression scale). Conclusions: To improve vaccine acceptance rate, public education campaigns specific to cancer patients to gain their trust in efficacy and relieve their worries are needed.	[Chan, Wing-Lok; Ho, Yuen-Hung Tricia; Lam, Ka-On; Kwong, Dora] Univ Hong Kong, LKS Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China; [Wong, Carlos King-Ho] Univ Hong Kong, LKS Fac Med, Dept Pharmacol & Pharm, Hong Kong, Peoples R China; [Wong, Carlos King-Ho] Univ Hong Kong, LKS Fac Med, Dept Family Med & Primary Care, Hong Kong, Peoples R China; [Choi, Horace Cheuk-Wai; Yuen, Kwok-Keung] Queen Mary Hosp, Dept Clin Oncol, Hong Kong, Peoples R China; [Hung, Ivan] Univ Hong Kong, LKS Fac Med, Dept Med, Hong Kong, Peoples R China		Chan, WL (通讯作者)，Univ Hong Kong, LKS Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China.	winglok@hku.hk; triciaho@hku.hk; carlosho@hku.hk; hcchoi@hku.hk; lamkaon@hku.hk; yuenkk1@hku.hk; dlwkwong@hku.hk; ivanhung@hku.hk	Hung, Ivan FN/ABD-5916-2021; Wong, Carlos King-ho/B-4322-2011	Hung, Ivan FN/0000-0002-1556-2538; Wong, Carlos King-ho/0000-0002-6895-6071; Chan, Wing Lok/0000-0001-9793-9273			Annunziata MA, 2020, SUPPORT CARE CANCER, V28, P3921, DOI 10.1007/s00520-019-05244-8; [Anonymous], MSK COVID 19 VACCINE; [Anonymous], Consensus Interim Recommendations on the Use of COVID-19 Vaccines in Hong Kong (As of Jan 7, 2021); [Anonymous], **NON-TRADITIONAL**; [Anonymous], COVID 19 CORONAVIRUS; Cancer Research UK, STUDY LOOK COVID 19 STUDY LOOK COVID 19; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Dumenci L, 2014, J HEALTH COMMUN, V19, P205, DOI 10.1080/10810730.2014.943377; Giannakoulis VG, 2020, JCO GLOB ONCOL, V6, P799, DOI 10.1200/GO.20.00225; Grist JT, 2021, RADIOLOGY, V301, P1353, DOI 10.1148/radiol.2021210033; Halpin SJ, 2021, J MED VIROL, V93, P1013, DOI 10.1002/jmv.26368; Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9; Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; National Comprehensive Cancer Network, PREL REC NCCN COVID; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Rogado J, 2020, CLIN TRANSL ONCOL, V22, P2364, DOI 10.1007/s12094-020-02381-z; SEOM, UPD POS REC SEOM REL UPD POS REC SEOM REL; The Government of Hong Kong Special Administrative Region, COVID VACC COVID VACC; Wang QQ, 2021, JAMA ONCOL, V7, P220, DOI 10.1001/jamaoncol.2020.6178; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980	23	5	5	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							792	10.3390/vaccines9070792			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8HU	34358208	Green Published, gold			2022-04-29	WOS:000677146100001
J	Hauser, A; Carnell, G; Held, K; Sulbaran, G; Tischbierek, N; Rogers, L; Pollakis, G; Tonks, P; Hoelscher, M; Ding, S; Sanders, RW; Geldmacher, C; Sattentau, Q; Weissenhorn, W; Heeney, JL; Peterhoff, D; Wagner, R				Hauser, Alexandra; Carnell, George; Held, Kathrin; Sulbaran, Guidenn; Tischbierek, Nadine; Rogers, Lisa; Pollakis, Georgios; Tonks, Paul; Hoelscher, Michael; Ding, Song; Sanders, Rogier W.; Geldmacher, Christof; Sattentau, Quentin; Weissenhorn, Winfried; Heeney, Jonathan L.; Peterhoff, David; Wagner, Ralf			Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses	VACCINES			English	Article						HIV vaccine; envelope; stabilized trimer; clade C; consensus; centralized sequence; immunization; immunogen design; antibody response; peptide microarray	GLYCOPROTEIN COMPLEX; ENV; DIVERSITY; PROTEIN; EPITOPE; DESIGN; BROAD; 2G12	Stabilization of the HIV-1 Envelope glycoprotein trimer (Env) in its native pre-fusion closed conformation is regarded as one of several requirements for the induction of neutralizing antibody (nAb) responses, which, in turn, will most likely be a prerequisite for the development of an efficacious preventive vaccine. Here, we systematically analyzed how the stepwise stabilization of a clade C consensus (ConC) Env immunogen impacts biochemical and biophysical protein traits such as antigenicity, thermal stability, structural integrity, and particle size distribution. The increasing degree of conformational rigidification positively correlates with favorable protein characteristics, leading to optimized homogeneity of the protein preparations, increased thermal stability, and an overall favorable binding profile of structure-dependent broadly neutralizing antibodies (bnAbs) and non-neutralizing antibodies (non-nAbs). We confirmed that increasing the structural integrity and stability of the Env trimers positively correlates with the quality of induced antibody responses by the immunogens. These and other data contribute to the selection of ConCv5 KIKO as novel Env immunogens for use within the European Union's H2020 Research Consortium EHVA (European HIV Alliance) for further preclinical analysis and phase 1 clinical development.	[Hauser, Alexandra; Tischbierek, Nadine; Peterhoff, David; Wagner, Ralf] Univ Regensburg, Inst Med Microbiol & Hyg, Mol Microbiol Virol, D-93053 Regensburg, Germany; [Carnell, George; Tonks, Paul; Heeney, Jonathan L.] Univ Cambridge, Dept Vet Med, Lab Viral Zoonot, Madingley Rd, Cambridge CB3 0ES, England; [Held, Kathrin; Rogers, Lisa; Hoelscher, Michael; Geldmacher, Christof] Ludwig Maximilians Univ Munchen, Div Infect Dis & Trop Med, Univ Hosp, D-80802 Munich, Germany; [Held, Kathrin; Rogers, Lisa; Hoelscher, Michael; Geldmacher, Christof] German Ctr Infect Res DZIF, Partner Site Munich, D-80802 Munich, Germany; [Sulbaran, Guidenn; Weissenhorn, Winfried] Univ Grenoble Alpes, Inst Biol Struct IBS, CNRS, CEA, F-38000 Grenoble, France; [Pollakis, Georgios] Univ Liverpool, Dept Clin Infect Microbiol & Immunol CIMI, Liverpool L69 7BE, Merseyside, England; [Pollakis, Georgios] NIHR Hlth Protect Res Unit Emerging & Zoonot Infe, Liverpool L69 7BE, Merseyside, England; [Ding, Song] EuroVacc Fdn, NL-1105 BP Amsterdam, Netherlands; [Sanders, Rogier W.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands; [Sanders, Rogier W.] Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA; [Sattentau, Quentin] Univ Oxford, Sir Willian Dunn Sch Pathol, Oxford OX1 3RE, England; [Peterhoff, David; Wagner, Ralf] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, D-93053 Regensburg, Germany		Wagner, R (通讯作者)，Univ Regensburg, Inst Med Microbiol & Hyg, Mol Microbiol Virol, D-93053 Regensburg, Germany.; Wagner, R (通讯作者)，Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, D-93053 Regensburg, Germany.	Alexandra.Hauser@ukr.de; gwc26@cam.ac.uk; kathrin.held@med.uni-muenchen.de; Guidenn.sulbaran-Machado@ibs.fr; Nadine1.Tischbierek@stud.uni-regensburg.de; rogers@lrz.uni-muenchen.de; G.Pollakis@liverpool.ac.uk; pt10001@cam.ac.uk; hoelscher@lrz.uni-muenchen.de; song.ding@eurovacc.org; r.w.sanders@amc.uva.nl; geldmacher@lrz.uni-muenchen.de; quentin.sattentau@path.ox.ac.uk; Winfried.Weissenhorn@ibs.fr; jlh66@cam.ac.uk; David.Peterhoff@ukr.de; ralf.wagner@ukr.de	Sulbaran, Guidenn/AAW-9751-2021; Peterhoff, David/ABD-6746-2020; Carnell, George/AAB-4421-2022	Carnell, George/0000-0001-8875-0989; Weissenhorn, Winfried/0000-0001-5532-4959; Peterhoff, David/0000-0001-5911-6233; Hauser, Alexandra/0000-0002-9738-392X; Held, Kathrin/0000-0001-7057-6935; Heeney, Jonathan/0000-0003-2702-1621	European UnionEuropean Commission [681032]; Grenoble Instruct-ERIC center [UAR 3518]; FRISBI [ANR-10-INBS-05-02]; GRAL, a project of the University Grenoble Alpes graduate school (Ecoles Universitaires de Recherche) CBH-EUR-GS [ANR-17-EURE-0003]; Auvergne-Rhone-Alpes RegionRegion Auvergne-Rhone-AlpesRegion Bourgogne-Franche-ComteRegion Hauts-de-FranceRegion Nouvelle-Aquitaine; Fondation Recherche Medicale (FRM)Fondation pour la Recherche Medicale; fonds FEDER; eGIS-Infrastructures en Biologie Sante et Agronomie (IBiSA)	This research was funded by the European Union's horizon 2020 research and innovation programme under grant agreement No 681032. WW acknowledges access to the platforms of the Grenoble Instruct-ERIC center (IBS and ISBG; UAR 3518 CNRS-CEA-UGA-EMBL) within the Grenoble Partnership for Structural Biology (PSB), with support from FRISBI (ANR-10-INBS-05-02) and GRAL, a project of the University Grenoble Alpes graduate school (Ecoles Universitaires de Recherche) CBH-EUR-GS (ANR-17-EURE-0003). The IBS electron microscope facility is supported by the Auvergne-Rhone-Alpes Region, the Fondation Recherche Medicale (FRM), the fonds FEDER and th eGIS-Infrastructures en Biologie Sante et Agronomie (IBiSA).	Aldon Y, 2018, CELL REP, V24, P3324, DOI 10.1016/j.celrep.2018.08.051; [Anonymous], 2020, UNAIDS PEOPLE LIVING, V2021, P2019; Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Cheng C, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107981; ClinicalTrials.gov, MOD INT RAT DES SYNT MOD INT RAT DES SYNT; de la Pena AT, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0445-y; de la Pena AT, 2018, J VIROL, V92, DOI 10.1128/JVI.01957-17; de la Pena AT, 2017, CELL REP, V20, P1805, DOI 10.1016/j.celrep.2017.07.077; de Taeye SW, 2015, CELL, V163, P1702, DOI 10.1016/j.cell.2015.11.056; del Moral-Sanchez I, 2019, EXPERT REV VACCINES, V18, P1127, DOI 10.1080/14760584.2019.1690458; Dubrovskaya V, 2019, IMMUNITY, V51, P915, DOI 10.1016/j.immuni.2019.10.008; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Gottardo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075665; Guenaga J, 2017, IMMUNITY, V46, P792, DOI 10.1016/j.immuni.2017.04.014; Guenaga J, 2016, J VIROL, V90, P2806, DOI 10.1128/JVI.02652-15; Guenaga J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004570; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hemelaar J, 2019, LANCET INFECT DIS, V19, P143, DOI 10.1016/S1473-3099(18)30647-9; Joachim A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00719; Joseph S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00149; Julien JP, 2015, P NATL ACAD SCI USA, V112, P11947, DOI 10.1073/pnas.1507793112; Koch K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08273-7; Kratochvil S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00595; McGuire AT, 2013, J EXP MED, V210, P655, DOI 10.1084/jem.20122824; Medina-Ramirez M, 2017, CURR OPIN HIV AIDS, V12, P241, DOI 10.1097/COH.0000000000000363; Msafiri F, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111722; Nadai Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00717; Nickle DC, 2003, SCIENCE, V299, P1515; Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808; Peterhoff D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060642; Porebski BT, 2016, PROTEIN ENG DES SEL, V29, P245, DOI 10.1093/protein/gzw015; Pugach P, 2015, J VIROL, V89, P3380, DOI 10.1128/JVI.03473-14; Rawi R, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108432; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Ringe RP, 2013, P NATL ACAD SCI USA, V110, P18256, DOI 10.1073/pnas.1314351110; Rutten L, 2018, CELL REP, V23, P584, DOI 10.1016/j.celrep.2018.03.061; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Sharma SK, 2015, CELL REP, V11, P539, DOI 10.1016/j.celrep.2015.03.047; Silva M, 2017, CELL REP, V21, P3672, DOI 10.1016/j.celrep.2017.12.014; Sliepen K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10262-5; Sliepen K, 2016, EXPERT REV VACCINES, V15, P349, DOI 10.1586/14760584.2016.1129905; Stephenson KE, 2015, J IMMUNOL METHODS, V416, P105, DOI 10.1016/j.jim.2014.11.006; van Gils MJ, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.199; Venkatesan P, 2021, LANCET MICROBE, V2, pE95; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	52	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							750	10.3390/vaccines9070750			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6WH	34358165	gold, Green Published, Green Submitted			2022-04-29	WOS:000677048600001
J	Holzmann-Littig, C; Braunisch, MC; Kranke, P; Popp, M; Seeber, C; Fichtner, F; Littig, B; Carbajo-Lozoya, J; Allwang, C; Frank, T; Meerpohl, JJ; Haller, B; Schmaderer, C				Holzmann-Littig, Christopher; Braunisch, Matthias Christoph; Kranke, Peter; Popp, Maria; Seeber, Christian; Fichtner, Falk; Littig, Bianca; Carbajo-Lozoya, Javier; Allwang, Christine; Frank, Tamara; Meerpohl, Joerg Johannes; Haller, Bernhard; Schmaderer, Christoph			COVID-19 Vaccination Acceptance and Hesitancy among Healthcare Workers in Germany	VACCINES			English	Article						COVID-19; vaccine; vaccination; vaccination hesitancy; vaccine refusal; vaccination campaign	INFLUENZA VACCINATION; EUROPE	Vaccination hesitancy is a threat to herd immunity. Healthcare workers (HCWs) play a key role in promoting Coronavirus disease 2019 (COVID-19) vaccination in the general population. We therefore aimed to provide data on COVID-19 vaccination acceptance/hesitancy among German HCWs. For this exploratory, cross-sectional study, an online survey was conducted in February 2021. The survey included 54 items on demographics; previous vaccination behavior; trust in vaccines, physicians, the pharmaceutical industry and health politics; fear of adverse effects; assumptions regarding the consequences of COVID-19; knowledge about vaccines; and information seeking behavior. Odds ratios with 95% confidence intervals were calculated and chi-square tests were performed. Four thousand five hundred surveys were analyzed. The overall vaccination acceptance was 91.7%. The age group <= 20 years showed the lowest vaccination acceptance. Factors associated with vaccination hesitancy were lack of trust in authorities and pharmaceutical companies. Attitudes among acquaintances were associated with vaccination hesitancy too. Participants with vaccination hesitancy more often obtained information about COVID-19 vaccines via messenger services or online video platforms and underperformed in the knowledge test. We found high acceptance amongst German HCWs. Several factors associated with vaccination hesitancy were identified which could be targeted in HCW vaccination campaigns.	[Holzmann-Littig, Christopher; Braunisch, Matthias Christoph; Littig, Bianca; Carbajo-Lozoya, Javier; Schmaderer, Christoph] Tech Univ Munich, Sch Med, Dept Nephrol, Klinikum Rechts Isar, D-81675 Munich, Germany; [Holzmann-Littig, Christopher] Tech Univ Munich, TUM Med Educ Ctr, Sch Med, D-81675 Munich, Germany; [Kranke, Peter; Popp, Maria] Univ Hosp Wuerzburg, Dept Anesthesiol Intens Care Emergency Med & Pain, D-97080 Wurzburg, Germany; [Seeber, Christian; Fichtner, Falk] Univ Hosp Leipzig, Dept Anesthesiol & Intens Care, D-04103 Leipzig, Germany; [Allwang, Christine; Frank, Tamara] Tech Univ Munich, Sch Med, Clin & Polyclin Psychosomat Med & Psychotherapy, Klinikum Rechts Isar, D-81675 Munich, Germany; [Meerpohl, Joerg Johannes] Univ Freiburg, Med Ctr, D-79110 Freiburg, Germany; [Meerpohl, Joerg Johannes] Univ Freiburg, Inst Evidence Med, Fac Med, D-79110 Freiburg, Germany; [Meerpohl, Joerg Johannes] Cochrane Germany Fdn, Cochrane Germany, D-79110 Freiburg, Germany; [Haller, Bernhard] Tech Univ Munich, Sch Med, Inst Med Informat, Stat & Epidemiol, D-81675 Munich, Germany		Holzmann-Littig, C (通讯作者)，Tech Univ Munich, Sch Med, Dept Nephrol, Klinikum Rechts Isar, D-81675 Munich, Germany.; Holzmann-Littig, C (通讯作者)，Tech Univ Munich, TUM Med Educ Ctr, Sch Med, D-81675 Munich, Germany.	christopher.holzmann-littig@mri.tum.de; matthias.braunisch@tum.de; Kranke_P@ukw.de; popp_m4@ukw.de; christian.seeber@medizin.uni-leipzig.de; falk.fichtner@medizin.uni-leipzig.de; bianca.littig@web.de; javier.carbajolozoya@mri.tum.de; christine.allwang@mri.tum.de; tamara.frank@mri.tum.de; meerpohl@ifem.uni-freiburg.de; bernhard.haller@mri.tum.de; Christoph.Schmaderer@mri.tum.de	Haller, Bernhard/I-1943-2019; Carbajo-Lozoya, Javier/AAC-2007-2022	Haller, Bernhard/0000-0002-9723-393X; Carbajo-Lozoya, Javier/0000-0003-2843-2000; Allwang, Christine/0000-0002-2874-6168; Holzmann-Littig, Christopher/0000-0002-9849-148X; Popp, Maria/0000-0002-1155-3060	BMBFFederal Ministry of Education & Research (BMBF); CEOsys as part of the national COVID-19 network NUM	The project was funded by the BMBF. The funder of the CEOsys as part of the national COVID-19 network NUM (BMBF) did not participate in study design, data collection, data analysis or writing of the manuscript.	Aloweidi A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105111; American Nurses Foundation, 2020, DEC PULS NAT NURS CO; [Anonymous], 2021, LANCET HAEMATOL, V8, pE305, DOI 10.1016/S2352-3026(21)00107-1; Bethlehem J, 2010, INT STAT REV, V78, P161, DOI 10.1111/j.1751-5823.2010.00112.x; Betsch. C., 2021, COSMO COVID 19 SNAPS; Betsch C, 2020, LANCET, V395, P1255, DOI 10.1016/S0140-6736(20)30729-7; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Bouder F, 2015, RISK ANAL, V35, P1210, DOI 10.1111/risa.12386; Bundesamt S., 2019, BEV ANZ EINW BUND DE; Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038; COSMO COVID-19 Snapshot Monitoring, 2021, FOK COVID 19 IMPF EI; Di Gennaro F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030371; DIVI-Deutsche Interdisziplinare Verienigung fur Intensiv- und Notfallmedizin, 2021, MEHR ALS 75 PROZ WOL; Doring N., 2016, FORSCHUNGSMETHODEN E; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dzieciolowska S, 2021, AM J INFECT CONTROL, V49, P1152, DOI 10.1016/j.ajic.2021.04.079; Edwards KM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2146; Erber J., 2020, STRATEGIES INFECT CO, DOI [10.2139/ssrn.3678599, DOI 10.2139/SSRN.3678599]; European Commission, EUR KOMM ERT DRITT Z; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Friedrich MJ, 2019, JAMA-J AM MED ASSOC, V321, P1041, DOI 10.1001/jama.2019.1934; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Hlatshwako TG, 2021, LANCET DIGIT HEALTH, V3, pe76, DOI 10.1016/S2589-7500(21)00002-9; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Karagiannidis C, 2021, MED KLIN-INTENSIVMED, V116, P216, DOI 10.1007/s00063-021-00797-1; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Leiner D.J., 2019, SOSCI SURVEY 3 1 06; Lenzner T., 2016, QUESTION WORDING VER; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Meerpohl J.J., 2020, COLLABORATING RESPON, V12, P9, DOI [10.1002/14651858.CD2020029, DOI 10.1002/14651858.CD2020029]; Meyer M.N., 2020, HEALTHCARE WORKER IN, DOI [10.1001/jamanetworkopen.2021.5344, DOI 10.1001/JAMANETWORKOPEN.2021.5344]; Neufeind J, 2021, HUM VACC IMMUNOTHER, V17, P664, DOI 10.1080/21645515.2020.1801072; Nohl A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050424; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Polyakova M, 2020, P NATL ACAD SCI USA, V117, P27934, DOI 10.1073/pnas.2014279117; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Revive Health, 2020, SURV FIND REP PHYS N; Robert-Koch-Institut, 2021, COVID 19 IMPF MON DE; Robert-Koch-Institute, 2021, EPIDEMIOLOGISCHES B; Robert-Koch-Institute, TAGL LAG RKIZUR COR; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sanci L, 2018, AUST J GEN PRACT, V47, P829, DOI 10.31128/AJGP-07-18-4626; Schrading WA, 2021, ACAD EMERG MED, V28, P455, DOI 10.1111/acem.14236; Sivan M, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4938; Squeri Raffaele, 2019, Acta Biomed, V90, P45, DOI 10.23750/abm.v90i9-S.8703; Stebbins R, 2001, EXPLORATORY RES SOCI, V48; To KW, 2016, J HOSP INFECT, V94, P133, DOI 10.1016/j.jhin.2016.07.003; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Wiysonge CS, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1893062	57	23	23	35	57	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							777	10.3390/vaccines9070777			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5UG	34358193	gold, Green Published			2022-04-29	WOS:000676975700001
J	Siriwattananon, K; Manopwisedjaroen, S; Shanmugaraj, B; Prompetchara, E; Ketloy, C; Buranapraditkun, S; Tharakhet, K; Kaewpang, P; Ruxrungtham, K; Thitithanyanont, A; Phoolcharoen, W				Siriwattananon, Konlavat; Manopwisedjaroen, Suwimon; Shanmugaraj, Balamurugan; Prompetchara, Eakachai; Ketloy, Chutitorn; Buranapraditkun, Supranee; Tharakhet, Kittipan; Kaewpang, Papatsara; Ruxrungtham, Kiat; Thitithanyanont, Arunee; Phoolcharoen, Waranyoo			Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations	VACCINES			English	Article						adjuvant; COVID-19; SARS-CoV-2; receptor-binding domain; plant-based vaccine; subunit vaccine	MONOPHOSPHORYL-LIPID-A; INFLUENZA-VIRUS VACCINE; HEPATITIS-B-VACCINE; IFN-GAMMA; IMMUNE-RESPONSES; ANTIBODY; CELLS; MICE; IMMUNIZATION; STIMULATION	Due to the rapid transmission of the coronavirus disease 2019 (COVID-19) causing serious public health problems and economic burden, the development of effective vaccines is a high priority for controlling the virus spread. Our group has previously demonstrated that the plant-produced receptor-binding domain (RBD) of SARS-CoV-2 fused with Fc of human IgG was capable of eliciting potent neutralizing antibody and cellular immune responses in animal studies, and the immunogenicity could be improved by the addition of an alum adjuvant. Here, we performed a head-to-head comparison of different commercially available adjuvants, including aluminum hydroxide gel (alum), AddaVax (MF59), monophosphoryl lipid A from Salmonella minnesota R595 (mPLA-SM), and polyinosinic-polycytidylic acid (poly(I:C)), in mice by combining them with plant-produced RBD-Fc, and the differences in the immunogenicity of RBD-Fc with different adjuvants were evaluated. The specific antibody responses in terms of total IgG, IgG1, and IgG2a subtypes and neutralizing antibodies, as well as vaccine-specific T-lymphocyte responses, induced by the different tested adjuvants were compared. We observed that all adjuvants tested here induced a high level of total IgG and neutralizing antibodies, but mPLA-SM and poly (I:C) showed the induction of a balanced IgG1 and IgG2a (Th2/Th1) immune response. Further, poly (I:C) significantly increased the frequency of IFN-gamma-expressing cells compared with control, whereas no significant difference was observed between the adjuvanted groups. This data revealed the adjuvants' role in enhancing the immune response of RBD-Fc vaccination and the immune profiles elicited by different adjuvants, which could prove helpful for the rational development of next-generation SARS-CoV-2 RBD-Fc subunit vaccines. However, additional research is essential to further investigate the efficacy and safety of this vaccine formulation before clinical trials.	[Siriwattananon, Konlavat; Phoolcharoen, Waranyoo] Chulalongkorn Univ, Res Unit Plant Produced Pharmaceut, Bangkok 10330, Thailand; [Siriwattananon, Konlavat; Phoolcharoen, Waranyoo] Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Bangkok 10330, Thailand; [Manopwisedjaroen, Suwimon; Thitithanyanont, Arunee] Mahidol Univ, Fac Sci, Dept Microbiol, Bangkok 10400, Thailand; [Shanmugaraj, Balamurugan] Baiya Phytopharm Co Ltd, Bangkok 10330, Thailand; [Prompetchara, Eakachai; Ketloy, Chutitorn; Buranapraditkun, Supranee; Tharakhet, Kittipan; Kaewpang, Papatsara; Ruxrungtham, Kiat] Chulalongkorn Univ, Fac Med, Ctr Excellence Vaccine Res & Dev, Chula Vaccine Res Ctr Chula VRC, Bangkok 10330, Thailand; [Prompetchara, Eakachai; Ketloy, Chutitorn] Chulalongkorn Univ, Fac Med, Dept Lab Med, Bangkok 10330, Thailand; [Buranapraditkun, Supranee; Ruxrungtham, Kiat] Chulalongkorn Univ, Fac Med, Dept Med, Bangkok 10330, Thailand		Phoolcharoen, W (通讯作者)，Chulalongkorn Univ, Res Unit Plant Produced Pharmaceut, Bangkok 10330, Thailand.; Phoolcharoen, W (通讯作者)，Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Bangkok 10330, Thailand.	6176452333@student.chula.ac.th; swiboonut@gmail.com; balamurugan.s@baiyaphytopharm.com; Eakachai.p@chula.ac.th; Chutitorn.k@chula.ac.th; bsuprane2001@yahoo.com; kankittipan12@hotmail.com; Kaewpangpapatsara@gmail.com; kiat.r@chula.ac.th; arunee.thi@mahidol.edu; Waranyoo.P@chula.ac.th	Thitithanyanont, Arunee/AAN-4383-2021	Thitithanyanont, Arunee/0000-0002-9756-4763; Manopwisedjaroen, Suwimon/0000-0002-7571-8733; Phoolcharoen, Waranyoo/0000-0001-5958-7406	Baiya Phytopharm Co., Ltd. (Bangkok, Thailand)	This research was funded by Baiya Phytopharm Co., Ltd. (Bangkok, Thailand).	Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; Aoshi T, 2017, VIRAL IMMUNOL, V30, P463, DOI 10.1089/vim.2017.0026; Bahrami A, 2020, FUTURE VIROL, V15, P533, DOI 10.2217/fvl-2020-0129; Bill RM, 2015, J PHARM PHARMACOL, V67, P319, DOI 10.1111/jphp.12353; Bill RM, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00085; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Bodewes R, 2010, J VIROL, V84, P7943, DOI 10.1128/JVI.00549-10; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bradley LM, 1996, J IMMUNOL, V157, P1350; Burakova Y, 2018, VIRAL IMMUNOL, V31, P11, DOI 10.1089/vim.2017.0049; Capell T, 2020, TRENDS PLANT SCI, V25, P635, DOI 10.1016/j.tplants.2020.04.009; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Cekic C, 2009, J BIOL CHEM, V284, P31982, DOI 10.1074/jbc.M109.046383; Chan HT, 2015, PLANT BIOTECHNOL J, V13, P1056, DOI 10.1111/pbi.12471; Chin KL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/5212910; Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333; COUTELIER JP, 1988, J EXP MED, V168, P2373, DOI 10.1084/jem.168.6.2373; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474; Diego-Martin B, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.612781; Exley C, 2010, TRENDS IMMUNOL, V31, P103, DOI 10.1016/j.it.2009.12.009; Frank-Bertoncelj M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00028; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; Gupta T, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106717; Ho NI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02874; Hofmeister Y, 2011, J VIROL, V85, P1896, DOI 10.1128/JVI.02155-10; HogenEsch H, 2002, VACCINE, V20, pS34, DOI 10.1016/S0264-410X(02)00169-X; Hovden AO, 2005, SCAND J IMMUNOL, V62, P36, DOI 10.1111/j.1365-3083.2005.01633.x; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06; IBio, IBIO 201 DEM AB EL A; Ichinohe T, 2007, MICROBES INFECT, V9, P1333, DOI 10.1016/j.micinf.2007.06.007; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Ko EJ, 2018, HUM VACC IMMUNOTHER, V14, P3041, DOI 10.1080/21645515.2018.1495301; Kurella S, 2000, Indian J Clin Biochem, V15, P83, DOI 10.1007/BF02867548; Lakhan N, 2016, J IMMUNOL METHODS, V439, P37, DOI 10.1016/j.jim.2016.09.008; Le Bon A, 2006, J IMMUNOL, V176, P2074, DOI 10.4049/jimmunol.176.4.2074; Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1; Levie K, 2002, SCAND J INFECT DIS, V34, P610, DOI 10.1080/00365540110080881; Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Li YG, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-114; Liu ZZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00402-5; Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Martins KA, 2015, EXPERT REV VACCINES, V14, P447, DOI 10.1586/14760584.2015.966085; Mastelic Beatris, 2010, Biologicals, V38, P594, DOI 10.1016/j.biologicals.2010.06.002; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004; McCluskie MJ, 2013, INT IMMUNOPHARMACOL, V16, P50, DOI 10.1016/j.intimp.2013.03.021; Moran TM, 1999, J INFECT DIS, V180, P579, DOI 10.1086/314952; Neerukonda SN, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060426; Ng Wern Hann, 2020, F1000Res, V9, DOI 10.12688/f1000research.25998.1; O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061; Patil HP, 2014, J CONTROL RELEASE, V174, P51, DOI 10.1016/j.jconrel.2013.11.013; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x; Rattanapisit K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74904-1; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Rosales-Mendoza S., 2014, GENETICALLY ENG PLAN, P265, DOI [10.1007/978-1-4939-0850-9_13, DOI 10.1007/978-1-4939-0850-9_13]; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Rybicki EP, 2014, VIROL J, V11, DOI 10.1186/s12985-014-0205-0; Sarkar I, 2019, EXPERT REV VACCINES, V18, P505, DOI 10.1080/14760584.2019.1604231; Sarkar I, 2016, VACCINE, V34, P5114, DOI 10.1016/j.vaccine.2016.08.053; Schillberg S, 2021, J PLANT PHYSIOL, V258, DOI 10.1016/j.jplph.2020.153359; Shanmugaraj B, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020148; Shanmugaraj B, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.589995; Shanmugaraj B, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9070842; Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773; Sharma S, 2013, EXPERT OPIN THER TAR, V17, P481, DOI 10.1517/14728222.2013.781585; Siriwattananon K, 2021, FRONT PLANT SCI, V12, DOI 10.3389/fpls.2021.682953; Siriwattananon K, 2021, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.604663; Sivakumar SM, 2011, SAUDI PHARM J, V19, P197, DOI 10.1016/j.jsps.2011.06.003; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Stoger E, 2014, ANNU REV PLANT BIOL, V65, P743, DOI 10.1146/annurev-arplant-050213-035850; Takeyama Natsumi, 2015, Ther Adv Vaccines, V3, P139, DOI 10.1177/2051013615613272; Tau G, 1999, ALLERGY, V54, P1233, DOI 10.1034/j.1398-9995.1999.00099.x; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tong NKC, 2005, KIDNEY INT, V68, P2298, DOI 10.1111/j.1523-1755.2005.00689.x; Toussi DN, 2014, VACCINES, V2, P323, DOI 10.3390/vaccines2020323; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Vartak A, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020012; Vogel FR, 2000, CLIN INFECT DIS, V30, pS266, DOI 10.1086/313883; Wang M, 2016, BIOENGINEERED, V7, P155, DOI 10.1080/21655979.2016.1191707; Wang MY, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.587269; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; World Health Organization, COR DIS COVID 19 OUT; World Health Organization, WEEKL OP UPD COVID 1; World Health Organization, NOV COR CHIN; Xu Y, 2007, FEMS IMMUNOL MED MIC, V51, P480, DOI 10.1111/j.1574-695X.2007.00322.x; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8; Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427; Zhang NR, 2016, CELL MOL IMMUNOL, V13, P180, DOI 10.1038/cmi.2015.03; Zhang NR, 2014, EXPERT REV VACCINES, V13, P761, DOI 10.1586/14760584.2014.912134; Zhao J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.602256	100	2	2	8	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							744	10.3390/vaccines9070744			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5SN	34358160	Green Published, gold			2022-04-29	WOS:000676971200001
J	Terpos, E; Politou, M; Ntanasis-Stathopoulos, I; Karalis, V; Merkouri, E; Fotiou, D; Gavriatopoulou, M; Malandrakis, P; Kastritis, E; Trougakos, IP; Dimopoulos, MA				Terpos, Evangelos; Politou, Marianna; Ntanasis-Stathopoulos, Ioannis; Karalis, Vangelis; Merkouri, Efrosyni; Fotiou, Despina; Gavriatopoulou, Maria; Malandrakis, Panagiotis; Kastritis, Efstathios; Trougakos, Ioannis P.; Dimopoulos, Meletios A.			High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events	VACCINES			English	Article						SARS-CoV-2; COVID-19; ChAdOx1 nCov-19; anti-PF4; antibodies; vaccine; thrombosis	HEPARIN-INDUCED THROMBOCYTOPENIA; WARFARIN THROMBOPROPHYLAXIS; CLINICAL-SIGNIFICANCE; SURGERY; EXAMPLE; HIT; IGG	It is unclear whether the ChAdOx1 nCov-19 vaccine can induce the development of anti-PF4 antibodies in vaccinated individuals who have not developed thrombosis. The aim of this prospective study was to evaluate the presence of antibodies against heparin/PF4 in adults who received a first dose of the ChAdOx1 nCov-19 vaccine, and correlate them with clinical data and antibody responses to the vaccine. We detected non-platelet activating anti-PF4 antibodies in 67% (29/43) of the vaccinated individuals on day 22 following the first dose of the ChAdOx1 nCov-19 vaccine, though these were detected in low titers. Furthermore, there was no correlation between the presence of anti-PF4 IgG antibodies and the baseline clinical characteristics of the patients. Our findings suggest that the ChAdOx1 nCov-19 vaccine can elicit anti-PF4 antibody production even in recipients without a clinical manifestation of thrombosis. The presence of anti-PF4 antibodies was not sufficient to provoke clinically evident thrombosis. Our results offer an important insight into the ongoing investigations regarding the underlying multifactorial pathophysiology of thrombotic events induced by the ChAdOx1 nCov-19 vaccine.	[Terpos, Evangelos; Ntanasis-Stathopoulos, Ioannis; Fotiou, Despina; Gavriatopoulou, Maria; Malandrakis, Panagiotis; Kastritis, Efstathios; Dimopoulos, Meletios A.] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, PS-11528 Athens, Greece; [Politou, Marianna; Merkouri, Efrosyni] Natl & Kapodistrian Univ Athens, Aretaieio Hosp, Sch Med, Hematol Lab Blood Bank, PS-11528 Athens, Greece; [Karalis, Vangelis] Natl & Kapodistrian Univ Athens, Sch Hlth Sci, Dept Pharm, PS-15784 Athens, Greece; [Trougakos, Ioannis P.] Natl & Kapodistrian Univ Athens, Fac Biol, Dept Cell Biol & Biophys, PS-15784 Athens, Greece		Terpos, E (通讯作者)，Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, PS-11528 Athens, Greece.	eterpos@med.uoa.gr; mpolitou@med.uoa.gr; johnntanasis@med.uoa.gr; vkaralis@pharm.uoa.gr; fmerk62@yahoo.gr; desfotiou@med.uoa.gr; mariagabria@gmail.com; panosmalandrakis@gmail.com; ekastritis@gmail.com; itrougakos@biol.uoa.gr; mdimop@med.uoa.gr	; /L-9642-2019; Trougakos, Ioannis/R-6149-2018	Ntanasis-Stathopoulos, Ioannis/0000-0002-6328-9783; /0000-0003-0492-0712; Dimopoulos, Meletios/0000-0001-8990-3254; Kastritis, Efstathios/0000-0001-8191-5832; Terpos, Evangelos/0000-0001-5133-1422; Trougakos, Ioannis/0000-0002-6179-2772			Brodard J, 2021, J THROMB HAEMOST, V19, P1294, DOI 10.1111/jth.15262; Elalamy I, 2021, THROMB HAEMOSTASIS, V121, P982, DOI 10.1055/a-1499-0119; Franchini M, 2021, EUR J HAEMATOL, V107, P173, DOI 10.1111/ejh.13665; Gavriatopoulou M, 2021, CLIN EXP MED, V21, P167, DOI 10.1007/s10238-020-00671-y; Gavriatopoulou M, 2020, CLIN EXP MED, V20, P493, DOI 10.1007/s10238-020-00648-x; Greinacher A, 2007, J THROMB HAEMOST, V5, P1666, DOI 10.1111/j.1538-7836.2007.02617.x; Greinacher A, 2017, J THROMB HAEMOST, V15, P2099, DOI 10.1111/jth.13813; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Grigoryan L, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101422; Hursting MJ, 2010, AM J CLIN PATHOL, V134, P774, DOI 10.1309/AJCPG0MNR5NGKNFX; Jay RM, 2008, J THROMB HAEMOST, V6, P1598, DOI 10.1111/j.1538-7836.2008.03040.x; Juhl D, 2006, EUR J HAEMATOL, V76, P420, DOI 10.1111/j.1600-0609.2005.00621.x; Kadkhoda K, 2021, J THROMB HAEMOST, V19, P1831, DOI 10.1111/jth.15348; Korompoki E, 2021, J INFECTION, V83, P1, DOI 10.1016/j.jinf.2021.05.004; Krauel K, 2011, BLOOD, V117, P1370, DOI 10.1182/blood-2010-08-301424; McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Morel-Kopp MC, 2016, J THROMB HAEMOST, V14, P2548, DOI 10.1111/jth.13516; Nazy I, 2021, J THROMB HAEMOST, V19, P1342, DOI 10.1111/jth.15283; Padmanabhan A, 2017, CHEST, V152, P478, DOI 10.1016/j.chest.2017.03.050; Platton S, 2021, J THROMB HAEMOST, V19, P2007, DOI 10.1111/jth.15362; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Post N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244126; Pruthi RK, 2009, J THROMB HAEMOST, V7, P499, DOI 10.1111/j.1538-7836.2008.03263.x; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Reynolds CJ, 2021, SCIENCE, V372, P1418, DOI 10.1126/science.abh1282; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Sorvoll IH, 2021, J THROMB HAEMOST, V19, P1813, DOI 10.1111/jth.15352; Tentolouris A, 2021, CLIN EXP MED, V21, P161, DOI 10.1007/s10238-020-00680-x; Terpos E, 2021, BLOOD, V137, P3674, DOI 10.1182/blood.2021011904; Terpos E, 2021, AM J HEMATOL, V96, pE257, DOI 10.1002/ajh.26185; Thiele T, 2021, BLOOD, V138, P299, DOI 10.1182/blood.2021012217; Trougakos IP, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929-020-00703-5; von Hundelshausen P, 2021, THROMB HAEMOSTASIS, V121, P1395, DOI 10.1055/a-1481-3039; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Warkentin TE, 2008, AM J MED, V121, P632, DOI 10.1016/j.amjmed.2008.03.012; Warkentin TE, 2019, EXPERT REV HEMATOL, V12, P685, DOI 10.1080/17474086.2019.1636645; Warkentin TE, 2019, INT J LAB HEMATOL, V41, P15, DOI 10.1111/ijlh.12993; Yu J, 2020, BLOOD, V136, P2080, DOI 10.1182/blood.2020008248	40	10	10	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							712	10.3390/vaccines9070712			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8US	34358129	gold, Green Published			2022-04-29	WOS:000677179700001
J	Wang, ZN; Zhao, XH; Wang, Y; Sun, C; Sun, M; Gao, XY; Jia, FT; Shan, CX; Yang, GL; Wang, JZ; Huang, HB; Shi, CW; Yang, WT; Qian, AD; Wang, CF; Jiang, YL				Wang, Zhannan; Zhao, Xiaohan; Wang, Ying; Sun, Chao; Sun, Ming; Gao, Xingyun; Jia, Futing; Shan, Chenxin; Yang, Guilian; Wang, Jianzhong; Huang, Haibin; Shi, Chunwei; Yang, Wentao; Qian, Aidong; Wang, Chunfeng; Jiang, Yanlong			In Vivo Production of HN Protein Increases the Protection Rates of a Minicircle DNA Vaccine against Genotype VII Newcastle Disease Virus	VACCINES			English	Article						minicircle DNA; CRIM; dual promoter; NDV vaccine	RECOMBINANT SALMONELLA; TYPHIMURIUM; ELICITS	The Cre-recombinase mediated in vivo minicircle DNA vaccine platform (CRIM) provided a novel option to replace a traditional DNA vaccine. To further improve the immune response of our CRIM vaccine, we designed a dual promoter expression plasmid named pYL87 which could synthesize short HN protein under a prokaryotic in vivo promoter P-pagC and full length HN protein of genotype VII Newcastle disease virus (NDV) under the previous eukaryotic CMV promoter at the same time. Making use of the self-lysed Salmonella strain as a delivery vesicle, chickens immunized with the pYL87 construction showed an increased serum haemagglutination inhibition antibody response, as well as an increased cell proliferation level and cellular IL-4 and IL-18 cytokines, compared with the previous CRIM vector pYL47. After the virus challenge, the pYL87 vector could provide 80% protection compared to 50% protection against genotype VII NDV in pYL47 immunized chickens, indicating a promising dual promoter strategy used in vaccine design.	[Wang, Zhannan; Zhao, Xiaohan; Wang, Ying; Sun, Chao; Sun, Ming; Gao, Xingyun; Jia, Futing; Shan, Chenxin; Yang, Guilian; Wang, Jianzhong; Huang, Haibin; Shi, Chunwei; Yang, Wentao; Qian, Aidong; Wang, Chunfeng; Jiang, Yanlong] Jilin Agr Univ, Jilin Prov Key Lab Anim Microecol & Hlth Breeding, Coll Anim Med,Jilin Prov Engn Res Ctr Anim Probio, Key Lab Anim Prod Prod Qual & Secur,Minist Educ, Changchun 130118, Peoples R China		Wang, CF; Jiang, YL (通讯作者)，Jilin Agr Univ, Jilin Prov Key Lab Anim Microecol & Hlth Breeding, Coll Anim Med,Jilin Prov Engn Res Ctr Anim Probio, Key Lab Anim Prod Prod Qual & Secur,Minist Educ, Changchun 130118, Peoples R China.	wangzhannan2021@163.com; zzzxxxhhh2021@163.com; wangying202106@163.com; sunchao0602@163.com; sunming202106@163.com; gaoxingyun2021@163.com; puffting@163.com; scx1394706137@163.com; yangguilian@jlau.edu.cn; jianzhongw@jlau.edu.cn; nmdhuanghaihin@163.com; shichunwei09@163.com; yangwentao@jlau.edu.cn; qianaidong0115@163.com; wangchunfeng@jlau.edu.cn; yanlong.jiang@jlau.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32072897,31602092, 31802223]; Science and technology research project of Jilin Provincial Education Department [JJKH20200358KJ, 32072897]	This research was funded by the National Natural Science Foundation of China, grant numbers 32072897,31602092 and 31802223, Science and technology research project of Jilin Provincial Education Department, grant number JJKH20200358KJ. The APC was funded by 32072897.	Bumann D, 2001, INFECT IMMUN, V69, P7493, DOI 10.1128/IAI.69.12.7493-7500.2001; Cohen RN, 2009, J CONTROL RELEASE, V135, P166, DOI 10.1016/j.jconrel.2008.12.016; Felber BK, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107624; Gao X, 2019, J APPL MICROBIOL, V126, P1362, DOI 10.1111/jam.14228; Gehring S, 2005, J MED VIROL, V75, P249, DOI 10.1002/jmv.20264; Heithoff DM, 1997, P NATL ACAD SCI USA, V94, P934, DOI 10.1073/pnas.94.3.934; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; Hu ZL, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-208; Jiang YL, 2019, APPL ENVIRON MICROB, V85, DOI 10.1128/AEM.00407-19; Jiang YL, 2014, INT J MED MICROBIOL, V304, P431, DOI 10.1016/j.ijmm.2014.02.006; Kong W, 2008, P NATL ACAD SCI USA, V105, P9361, DOI 10.1073/pnas.0803801105; Kong W, 2012, P NATL ACAD SCI USA, V109, P19414, DOI 10.1073/pnas.1217554109; Li JY, 2013, VACCINE, V31, P3747, DOI 10.1016/j.vaccine.2013.04.037; Li YZ, 2021, EMERG MICROBES INFEC, V10, P342, DOI 10.1080/22221751.2021.1887767; Liu F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60783-z; Meunier M, 2018, VACCINE, V36, P2119, DOI 10.1016/j.vaccine.2018.03.004; MILLER VL, 1992, INFECT IMMUN, V60, P3763, DOI 10.1128/IAI.60.9.3763-3770.1992; Stachyra A, 2017, VIRUS RES, V232, P41, DOI 10.1016/j.virusres.2017.01.025; Sun JF, 2020, VACCINE, V38, P7337, DOI 10.1016/j.vaccine.2020.09.039; Wang SF, 2011, INFECT IMMUN, V79, P937, DOI 10.1128/IAI.00445-10; Zhang R, 2010, VET MICROBIOL, V141, P246, DOI 10.1016/j.vetmic.2009.09.020; Zhang Z, 2020, PARASITOL RES, V119, P2885, DOI 10.1007/s00436-020-06745-w	22	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							723	10.3390/vaccines9070723			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6ZP	34358140	Green Published, gold			2022-04-29	WOS:000677057200001
J	Albutti, A; Longet, S; McEntee, CP; Quinn, S; Liddicoat, A; Rimniceanu, C; Lycke, N; Lynch, L; Cardell, S; Lavelle, EC				Albutti, Aqel; Longet, Stephanie; McEntee, Craig P.; Quinn, Shauna; Liddicoat, Alex; Rimniceanu, Cristiana; Lycke, Nils; Lynch, Lydia; Cardell, Susanna; Lavelle, Ed C.			Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines	VACCINES			English	Article						adjuvant; oral vaccine; NKT cells	T-CELLS; HELICOBACTER-PYLORI; O1 INFECTION; TH17 CELLS; RESPONSES; RECEPTOR; IGA; COLONIZATION; RECOGNITION; VACCINATION	Oral vaccination has the potential to offer a safer and more efficacious approach for protection against enteric pathogens than injection-based approaches, especially in developing countries. One key advantage is the potential to induce intestinal immune responses in addition to systemic immunity. In general, antigen delivery via the oral route triggers weak immune responses or immunological tolerance. The effectiveness of oral vaccination can be improved by co-administering adjuvants. However, a major challenge is the absence of potent and safe oral adjuvants for clinical application. Here, the Type II NKT cell activator sulfatide is shown for the first time to be an effective oral adjuvant for Vibrio cholerae vaccine antigens in a mouse model. Specifically, administration of sulfatide with the oral cholera vaccine Dukoral(R) resulted in enhancement of intestinal antigen-specific IgA in addition to Th1 and Th17 immune responses. In summary, sulfatide is a promising adjuvant for inclusion in an oral cholera vaccine and our data further support the potential of adjuvants targeting NKT cells in new vaccine strategies.	[Albutti, Aqel; Longet, Stephanie; McEntee, Craig P.; Quinn, Shauna; Liddicoat, Alex; Lynch, Lydia; Lavelle, Ed C.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Adjuvant Res Grp, Sch Biochem & Immunol, Dublin D02 R590, Ireland; [Albutti, Aqel] Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, Buraydah 52571, Saudi Arabia; [Rimniceanu, Cristiana; Lycke, Nils; Cardell, Susanna] Univ Gothenburg, Dept Microbiol & Immunol, Inst Biomed, Box 435, S-40530 Gothenburg, Sweden; [Lavelle, Ed C.] Trinity Coll Dublin, Ctr Res Adaptat Nanostruct & Nanodevices, Dublin D02 PN40, Ireland; [Lavelle, Ed C.] Trinity Coll Dublin, Adv Mat Bioengn Res Ctr, Dublin D02 PN40, Ireland		Lavelle, EC (通讯作者)，Trinity Coll Dublin, Trinity Biomed Sci Inst, Adjuvant Res Grp, Sch Biochem & Immunol, Dublin D02 R590, Ireland.; Lavelle, EC (通讯作者)，Trinity Coll Dublin, Ctr Res Adaptat Nanostruct & Nanodevices, Dublin D02 PN40, Ireland.; Lavelle, EC (通讯作者)，Trinity Coll Dublin, Adv Mat Bioengn Res Ctr, Dublin D02 PN40, Ireland.	as.albutti@qu.edu.sa; stephanie.longet@well.ox.ac.uk; mcentec@tcd.ie; squinn2@tcd.ie; LIDDICOA@tcd.ie; cristiana.rimniceanu@gu.se; nils.lycke@microbio.gu.se; lynchl3@tcd.ie; susanna.cardell@microbio.gu.se; lavellee@tcd.ie	Cardell, Susanna/ABC-4944-2021; Lynch, Lydia/ABD-5598-2021; Lavelle, Ed/A-1716-2008	Lavelle, Ed/0000-0002-3167-1080; Albutti, Aqel/0000-0001-8697-5340; Longet, Stephanie/0000-0001-5026-431X	Science Foundation Ireland (SFI)Science Foundation Ireland [12/IA/1421, 19/FFP/6484]; SFI Research Centre, Advanced Materials and BioEngineering Research (AMBER)Science Foundation Ireland [SFI/12/RC/2278]; Qassim University, Ministry of Education, Saudi Arabia; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [P300PB-164740]	This research was funded by Science Foundation Ireland (SFI) under grant numbers 12/IA/1421 and 19/FFP/6484 and the SFI Research Centre, Advanced Materials and BioEngineering Research (AMBER) under grant number SFI/12/RC/2278. A.A. was supported by Qassim University, Ministry of Education, Saudi Arabia. S.L. was supported by the Swiss National Science Foundation (grant number P300PB-164740).	Abautret-Daly AE, 2014, BIOCHEM PHARMACOL, V92, P173, DOI 10.1016/j.bcp.2014.08.017; Ambrosino E, 2007, J IMMUNOL, V179, P5126, DOI 10.4049/jimmunol.179.8.5126; Arrenberg P, 2011, GASTROENTEROLOGY, V140, P646, DOI 10.1053/j.gastro.2010.10.003; Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531; Bhuiyan TR, 2009, INFECT IMMUN, V77, P1888, DOI 10.1128/IAI.01101-08; Cao AT, 2012, J IMMUNOL, V189, P4666, DOI 10.4049/jimmunol.1200955; Choi BK, 1999, INFECT IMMUN, V67, P5755, DOI 10.1128/IAI.67.11.5755-5761.1999; Datta SK, 2010, P NATL ACAD SCI USA, V107, P10638, DOI 10.1073/pnas.1002348107; Davitt CJH, 2019, MUCOSAL IMMUNOL, V12, P1055, DOI 10.1038/s41385-019-0159-z; Davitt CJH, 2016, J CONTROL RELEASE, V233, P162, DOI 10.1016/j.jconrel.2016.05.001; Dhodapkar MV, 2017, J IMMUNOL, V198, P1015, DOI 10.4049/jimmunol.1601399; Dieude M, 2011, J IMMUNOL, V186, P4771, DOI 10.4049/jimmunol.1000921; Dowds CM, 2015, CLIN IMMUNOL, V159, P128, DOI 10.1016/j.clim.2015.05.008; Exley MA, 2001, J IMMUNOL, V167, P5531, DOI 10.4049/jimmunol.167.10.5531; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; Fuss IJ, 2014, GUT, V63, P1728, DOI 10.1136/gutjnl-2013-305671; Halder RC, 2007, J CLIN INVEST, V117, P2302, DOI 10.1172/JCI31602; Harris AM, 2009, INFECT IMMUN, V77, P3850, DOI 10.1128/IAI.00369-09; Harris JB, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000221; Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552; Honke K, 2013, P JPN ACAD B-PHYS, V89, P129, DOI 10.2183/pjab.89.129; HORNQUIST CE, 1995, J IMMUNOL, V155, P2877; Huang WY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02424; Iinuma C, 2015, INT IMMUNOL, V27, P105, DOI 10.1093/intimm/dxu088; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; Jansson L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004487; Kamisago S, 1996, INFECT IMMUN, V64, P624, DOI 10.1128/IAI.64.2.624-628.1996; Kjerrulf M, 1997, IMMUNOLOGY, V92, P60, DOI 10.1046/j.1365-2567.1997.00312.x; Kuchta A, 2011, CLIN VACCINE IMMUNOL, V18, P1371, DOI 10.1128/CVI.05088-11; Kwiecinski J, 2013, INFECT IMMUN, V81, P1114, DOI 10.1128/IAI.01334-12; Lemoine C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020304; Longet S, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0139-z; Luoma AM, 2013, IMMUNITY, V39, P1032, DOI 10.1016/j.immuni.2013.11.001; Nieuwenhuis EES, 2009, J CLIN INVEST, V119, P1241, DOI 10.1172/JCI36509; Nishioka Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00548; Ramirez JEV, 2017, ADV DRUG DELIVER REV, V114, P116, DOI 10.1016/j.addr.2017.04.008; Sagami S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169681; Shah HB, 2012, J LEUKOCYTE BIOL, V92, P883, DOI 10.1189/jlb.0412177; Shamshiev A, 2002, J EXP MED, V195, P1013, DOI 10.1084/jem.20011963; Singh AK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01969; Sundell I Birgitta, 2010, J Stem Cells, V5, P33, DOI jsc.2010.5.1.33; Villavedra M, 1997, RES IMMUNOL, V148, P257, DOI 10.1016/S0923-2494(97)80867-X; Weil AA, 2009, INFECT IMMUN, V77, P5090, DOI 10.1128/IAI.00793-09	43	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							619	10.3390/vaccines9060619			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5QQ	34201310	Green Published, gold			2022-04-29	WOS:000665942700001
J	Fredsgaard, L; Goksoyr, L; Thrane, S; Aves, KL; Theander, TG; Sander, AF				Fredsgaard, Laurits; Goksoyr, Louise; Thrane, Susan; Aves, Kara-Lee; Theander, Thor G.; Sander, Adam F.			Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems	VACCINES			English	Article						vaccine; virus-like particle; conjugation system; vaccine design; modular vaccine platform	PROTEIN; IMMUNOGENICITY; CAPSOMERES; PROTECTION; RESPONSES; EFFICACY; IMMUNITY; REVEALS	Capsid virus-like particles (cVLPs) are used as molecular scaffolds to increase the immunogenicity of displayed antigens. Modular platforms have been developed whereby antigens are attached to the surface of pre-assembled cVLPs. However, it remains unknown to what extent the employed cVLP backbone and conjugation system may influence the immune response elicited against the displayed antigen. Here, we performed a head-to-head comparison of antigen-specific IgG responses elicited by modular cVLP-vaccines differing by their employed cVLP backbone or conjugation system, respectively. Covalent antigen conjugation (i.e., employing the SpyTag/SpyCatcher system) resulted in significantly higher antigen-specific IgG titers compared to when using affinity-based conjugation (i.e., using biotin/streptavidin). The cVLP backbone also influenced the antigen-specific IgG response. Specifically, vaccines based on the bacteriophage AP205 cVLP elicited significantly higher antigen-specific IgG compared to corresponding vaccines using the human papillomavirus major capsid protein (HPV L1) cVLP. In addition, the AP205 cVLP platform mediated induction of antigen-specific IgG with a different subclass profile (i.e., higher IgG2a and IgG2b) compared to HPV L1 cVLP. These results demonstrate that the cVLP backbone and conjugation system can individually affect the IgG response elicited against a displayed antigen. These data will aid the understanding and process of tailoring modular cVLP vaccines to achieve improved immune responses.	[Fredsgaard, Laurits; Goksoyr, Louise; Aves, Kara-Lee; Theander, Thor G.; Sander, Adam F.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Ctr Med Parasitol, DK-2200 Copenhagen, Denmark; [Goksoyr, Louise; Thrane, Susan; Sander, Adam F.] AdaptVac Aps, DK-2970 Horsholm, Denmark		Sander, AF (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Ctr Med Parasitol, DK-2200 Copenhagen, Denmark.; Sander, AF (通讯作者)，AdaptVac Aps, DK-2970 Horsholm, Denmark.	laurits@fredsgaardlarsen.com; louiseg@sund.ku.dk; susanthrane@gmail.com; kara-lee@sund.ku.dk; thor@sund.ku.dk; asander@sund.ku.dk	; Theander, Thor G./F-6714-2015	Aves, Kara-Lee/0000-0002-0068-7733; Goksoyr, Louise/0000-0003-4508-9857; Thrane, Susan/0000-0001-6596-3527; Bertelsen, Adam Frederik Sander/0000-0002-8782-7830; Theander, Thor G./0000-0002-3509-7514; Larsen, Laurits Fredsgaard/0000-0003-3891-3414	Independent Research Fund Denmark [611000177B]	This research was funded by Independent Research Fund Denmark, grant number 611000177B.	Abdoli A, 2013, IRAN J BASIC MED SCI, V16, P891; Akhras S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08787-0; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Anuar INAK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09678-w; Aves KL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020185; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bachmann MF, 1996, IMMUNOL TODAY, V17, P553, DOI 10.1016/S0167-5699(96)10066-9; Biemelt S, 2003, J VIROL, V77, P9211, DOI 10.1128/JVI.77.17.9211-9220.2003; Bonnet J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43564; Brune KD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01432; Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234; Buck CB, 2005, J VIROL, V79, P2839, DOI 10.1128/JVI.79.5.2839-2846.2005; Buldun CM, 2018, J AM CHEM SOC, V140, P3008, DOI 10.1021/jacs.7b13237; CARTER JJ, 1991, VIROLOGY, V182, P513, DOI 10.1016/0042-6822(91)90592-Y; Chackerian B, 2001, J CLIN INVEST, V108, P415, DOI 10.1172/JCI200111849; Chen XJS, 2000, MOL CELL, V5, P557, DOI 10.1016/S1097-2765(00)80449-9; De Vincenzo R, 2014, INT J WOMENS HEALTH, V6, P999, DOI 10.2147/IJWH.S50365; DeMonte D, 2013, PROTEINS, V81, P1621, DOI 10.1002/prot.24320; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; Escolano A, 2019, NATURE, V570, P468, DOI 10.1038/s41586-019-1250-z; Fierer JO, 2014, P NATL ACAD SCI USA, V111, pE1176, DOI 10.1073/pnas.1315776111; Geeraedts F, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000138; Gomes AC, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020047; Janitzek CM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41522-5; Kasaraneni N, 2017, MBIO, V8, DOI 10.1128/mBio.01860-17; Keeble AH, 2020, CHEM SCI, V11, P7281, DOI 10.1039/d0sc01878c; Keeble AH, 2019, P NATL ACAD SCI USA, V116, P26523, DOI 10.1073/pnas.1909653116; Keller SA, 2010, J IMMUNOL, V184, P26, DOI 10.4049/jimmunol.0901540; Kreimer AR, 2018, VACCINE, V36, P4774, DOI 10.1016/j.vaccine.2017.12.078; Kreimer AR, 2015, LANCET ONCOL, V16, P775, DOI 10.1016/S1470-2045(15)00047-9; Lange UG, 2004, INFECT IMMUN, V72, P4924, DOI 10.1128/IAI.72.8.4924-4928.2004; Li L, 2014, J MOL BIOL, V426, P309, DOI 10.1016/j.jmb.2013.10.021; Link A, 2012, J IMMUNOL, V188, P3724, DOI 10.4049/jimmunol.1103312; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Mohsen MO, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030037; Mohsen MO, 2017, J CONTROL RELEASE, V251, P92, DOI 10.1016/j.jconrel.2017.02.031; Palladini A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1408749; Proschel M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179740; Roder J, 2017, SMALL, V13, DOI 10.1002/smll.201702151; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Schadlich L, 2009, J VIROL, V83, P7690, DOI 10.1128/JVI.02588-08; Schiller J, 2018, VACCINE, V36, P4768, DOI 10.1016/j.vaccine.2017.12.079; Schmitz N, 2012, EUR J IMMUNOL, V42, P863, DOI 10.1002/eji.201041225; Schwenk R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111020; Shishovs M, 2016, J MOL BIOL, V428, P4267, DOI 10.1016/j.jmb.2016.08.025; Slifka MK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00956; Smith EC, 2003, PARASITOL RES, V89, P26, DOI 10.1007/s00436-002-0687-3; Smith ML, 2006, VIROLOGY, V348, P475, DOI 10.1016/j.virol.2005.12.039; Tan LL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165074; Thones N, 2008, J VIROL, V82, P5472, DOI 10.1128/JVI.02482-07; Thrane S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030389; Thrane S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0181-1; Thrane S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143071; Tota JE, 2020, JNCI-J NATL CANCER I, V112, P818, DOI 10.1093/jnci/djz222; Tumban E, 2013, VACCINE, V31, P4647, DOI 10.1016/j.vaccine.2013.07.052; Veggiani G, 2016, P NATL ACAD SCI USA, V113, P1202, DOI 10.1073/pnas.1519214113; Wu XL, 2018, J AM CHEM SOC, V140, P17474, DOI 10.1021/jacs.8b08250; Zakeri B, 2012, P NATL ACAD SCI USA, V109, pE690, DOI 10.1073/pnas.1115485109	59	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							539	10.3390/vaccines9060539			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY9BV	34063871	Green Published, gold			2022-04-29	WOS:000666175300001
J	Lo Presti, E; Dieli, F; Meraviglia, S				Lo Presti, Elena; Dieli, Francesco; Meraviglia, Serena			Lymphopenia in COVID-19: gamma delta T Cells-Based Therapeutic Opportunities	VACCINES			English	Article						SARS-CoV-2; gamma delta T cells; COVID-19	DENDRITIC CELLS; LYMPHOCYTES; RESPONSES; CANCER; IMMUNOTHERAPY; RECIPIENTS; INNATE; BLOOD	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dysregulates the immune system by lymphopenia of B cells, monocytes, eosinophils, basophils, and cytotoxic cells such as CD8, gamma delta T cells, and natural killer (NK) cells. Despite many studies being conducted to better understand the effects of SARS-CoV-2 on the immune system, many mechanisms still remain unclear, hindering the development of novel therapeutic approaches and strategies to improve the host's immune defense. This mini-review summarizes the findings on the role of gamma delta T cells in coronavirus disease 2019 (COVID-19), providing an overview of the excellent anti-viral therapeutic potential of gamma delta T cells, that had not yet been exploited in depth.	[Lo Presti, Elena] Natl Res Council CNR, Inst Biomed Res & Innovat IRIB, I-90146 Palermo, Italy; [Dieli, Francesco; Meraviglia, Serena] Univ Palermo, Cent Lab Adv Diag & Biomed Res CLADIBIOR, I-90127 Palermo, Italy; [Dieli, Francesco; Meraviglia, Serena] Univ Palermo, Dept Biomed Neurosci & Adv Diag, I-90133 Palermo, Italy		Lo Presti, E (通讯作者)，Natl Res Council CNR, Inst Biomed Res & Innovat IRIB, I-90146 Palermo, Italy.	elena.lopresti@cnr.it; francesco.dieli@unipa.it; serena.meraviglia@unipa.it		Lo Presti, Elena/0000-0001-5401-4545	Ministry of Education and Research, PRIN 2017	This research was supported by funds from the Ministry of Education and Research, PRIN 2017 to S.M.	Abate G, 2016, INFECT IMMUN, V84, P580, DOI 10.1128/IAI.01262-15; Angelini DF, 2011, J LEUKOCYTE BIOL, V89, P75, DOI 10.1189/jlb.0710413; Antonioli L, 2020, CELL MOL IMMUNOL, V17, P672, DOI 10.1038/s41423-020-0450-7; Bai YP, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20204305; Bhagat G, 2008, J CLIN INVEST, V118, P281, DOI 10.1172/JCI30989; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Bortolotti D, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9091975; Brandes M, 2005, SCIENCE, V309, P264, DOI 10.1126/science.1110267; Brufsky A, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02433-6; Caccamo N, 2006, J IMMUNOL, V177, P5290, DOI 10.4049/jimmunol.177.8.5290; Caccamo N, 2006, EUR J IMMUNOL, V36, P2681, DOI 10.1002/eji.200636220; Caccamo N, 2020, BRIT J HAEMATOL, V190, pE185, DOI 10.1111/bjh.16895; Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3; Carissimo G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19080-6; Dandekar AA, 2005, J VIROL, V79, P9388, DOI 10.1128/JVI.79.15.9388-9396.2005; Das H, 2001, IMMUNITY, V15, P83, DOI 10.1016/S1074-7613(01)00168-6; Davey MS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04076-0; De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4; de Sousa TR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030436; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Fathi N, 2020, CELL BIOL INT, V44, P1792, DOI 10.1002/cbin.11403; Fournie JJ, 2013, CELL MOL IMMUNOL, V10, P35, DOI 10.1038/cmi.2012.39; Garber K., 2020, NAT BIOTECHNOL, V38, P389, DOI [10.1038/s41587-020-0487-2, DOI 10.1038/S41587-020-0487-2]; Gattinoni L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842; Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500; Haljasmagi L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77525-w; Hudspeth K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00069; Jouan Y, 2020, J EXP MED, V217, DOI 10.1084/jem.20200872; Kabelitz D, 2001, EUR J MED RES, V6, P169; Kenna T, 2004, CLIN IMMUNOL, V113, P56, DOI 10.1016/j.clim.2004.05.003; Knight A, 2010, BLOOD, V116, P2164, DOI 10.1182/blood-2010-01-255166; Lafarge X, 2001, J INFECT DIS, V184, P533, DOI 10.1086/322843; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Lei L, 2020, J CELL MOL MED, V24, P11603, DOI 10.1111/jcmm.15620; Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763; Lo MW, 2020, J IMMUNOL, V205, P1488, DOI 10.4049/jimmunol.2000644; Lo Presti E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01401; Lopes N, 2021, NAT IMMUNOL, V22, P179, DOI 10.1038/s41590-020-00848-3; Mangan BA, 2013, J IMMUNOL, V191, P30, DOI 10.4049/jimmunol.1300121; Martino A, 2005, J CLIN IMMUNOL, V25, P230, DOI 10.1007/s10875-005-4080-8; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Mehta Puja, 2020, Lancet, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Meoni G, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009243; Poccia F, 2006, J INFECT DIS, V193, P1244, DOI 10.1086/502975; Polito VA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02717; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Rampoldi F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030743; Rijkers G, 2020, CELL MOL IMMUNOL, V17, P771, DOI 10.1038/s41423-020-0473-0; Rodrigues NV, 2018, CANCER IMMUNOL RES, V6, P448, DOI 10.1158/2326-6066.CIR-17-0327; Saghazadeh A, 2020, EXPERT REV CLIN IMMU, V16, P465, DOI 10.1080/1744666X.2020.1750954; Sant S, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1079; Silva-Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904; Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678; Wilk AJ, 2020, NAT MED, V26, P1070, DOI [10.1038/s41591-020-0944-y, 10.1101/2020.04.17.20069930]; Xu Y, 2020, NAT MED, V26, P502, DOI 10.1038/s41591-020-0817-4; Yazdanifar M, 2020, CRIT REV MICROBIOL, V46, P689, DOI 10.1080/1040841X.2020.1822279; Youm YH, 2012, CELL REP, V1, P56, DOI 10.1016/j.celrep.2011.11.005; Zhang BC, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00157; Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2	63	1	1	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							562	10.3390/vaccines9060562			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ7CM	34071430	Green Published, gold			2022-04-29	WOS:000666718500001
J	Maiorano, BA; Schinzari, G; Ciardiello, D; Rodriquenz, MG; Cisternino, A; Tortora, G; Maiello, E				Maiorano, Brigida Anna; Schinzari, Giovanni; Ciardiello, Davide; Rodriquenz, Maria Grazia; Cisternino, Antonio; Tortora, Giampaolo; Maiello, Evaristo			Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities	VACCINES			English	Review						prostate cancer; renal cancer; urothelial cancer; vaccines; immunotherapy	RESISTANT PROSTATE-CANCER; PERSONALIZED PEPTIDE VACCINATION; I CLINICAL-TRIAL; METASTATIC UROTHELIAL CARCINOMA; CYTOTOXIC T-LYMPHOCYTES; PHASE-I; SIPULEUCEL-T; OPEN-LABEL; CELLULAR IMMUNOTHERAPY; DOSE CYCLOPHOSPHAMIDE	Background: In the last years, many new treatment options have widened the therapeutic scenario of genitourinary malignancies. Immunotherapy has shown efficacy, especially in the urothelial and renal cell carcinomas, with no particular relevance in prostate cancer. However, despite the use of immune checkpoint inhibitors, there is still high morbidity and mortality among these neoplasms. Cancer vaccines represent another way to activate the immune system. We sought to summarize the most recent advances in vaccine therapy for genitourinary malignancies with this review. Methods: We searched PubMed, Embase and Cochrane Database for clinical trials conducted in the last ten years, focusing on cancer vaccines in the prostate, urothelial and renal cancer. Results: Various therapeutic vaccines, including DNA-based, RNA-based, peptide-based, dendritic cells, viral vectors and modified tumor cells, have been demonstrated to induce specific immune responses in a variable percentage of patients. However, these responses rarely corresponded to significant survival improvements. Conclusions: Further preclinical and clinical studies will improve the knowledge about cancer vaccines in genitourinary malignancies to optimize dosage, select targets with a driver role for tumor development and growth, and finally overcome resistance mechanisms. Combination strategies represent possibly more effective and long-lasting treatments.	[Maiorano, Brigida Anna; Ciardiello, Davide; Rodriquenz, Maria Grazia; Maiello, Evaristo] Fdn Casa Sollievo della Sofferenza IRCCS, Oncol Unit, I-73013 San Giovanni Rotondo, Italy; [Maiorano, Brigida Anna; Schinzari, Giovanni; Tortora, Giampaolo] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, I-00168 Rome, Italy; [Schinzari, Giovanni; Tortora, Giampaolo] Fdn A Gemelli Polidin IRCCS, Comprehens Canc Ctr, Med Oncol Unit, I-00168 Rome, Italy; [Ciardiello, Davide] Luigi Vanvitelli Univ Campania, Dept Precis Med, Med Oncol, I-80131 Naples, Italy; [Cisternino, Antonio] Fdn Casa Sollievo della Sofferenza IRCCS, Urol Unit, I-73013 San Giovanni Rotondo, Italy		Maiorano, BA (通讯作者)，Fdn Casa Sollievo della Sofferenza IRCCS, Oncol Unit, I-73013 San Giovanni Rotondo, Italy.; Maiorano, BA (通讯作者)，Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, I-00168 Rome, Italy.	brigidamaiorano@gmail.com; giovanni.schinzari@policlinicogemelli.it; davideciardiello@yahoo.it; grazia.rodriquenz@gmail.com; antonio.cisternino@operapadrepio.it; giampaolo.tortora@polidinicogemelli.it; e.maiello@operapadrepio.it	Ciardiello, Davide/AAC-4613-2022; rodriquenz, maria grazia/AAC-1142-2022; Maiorano, Brigida/AHB-1496-2022	Ciardiello, Davide/0000-0003-1826-0305; Maiorano, Brigida Anna/0000-0001-5423-3158			Amato RJ, 2008, J IMMUNOTHER, V31, P577, DOI 10.1097/CJI.0b013e31817deafd; Amato RJ, 2014, J IMMUNOTHER, V37, P237, DOI 10.1097/CJI.0000000000000029; Amato RJ, 2010, CLIN CANCER RES, V16, P5539, DOI 10.1158/1078-0432.CCR-10-2082; Anastasopoulou EA, 2015, CANCER IMMUNOL IMMUN, V64, P1123, DOI 10.1007/s00262-015-1717-1; Antonarakis ES, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.216; Antonarakis ES, 2017, CLIN CANCER RES, V23, P2451, DOI 10.1158/1078-0432.CCR-16-1780; Araki H, 2015, CANCER IMMUNOL IMMUN, V64, P1565, DOI 10.1007/s00262-015-1756-7; Balar AV, 2017, LANCET ONCOL, V18, P1483, DOI 10.1016/S1470-2045(17)30616-2; Bansal D, 2021, CANCERS, V13, DOI 10.3390/cancers13020334; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bilusic M, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002374; Cappuccini F, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000928; Castiello L, 2017, CLIN CANCER RES, V23, P3352, DOI 10.1158/1078-0432.CCR-16-2199; Cha HR, 2020, CANCER RES, V80, P1615, DOI 10.1158/0008-5472.CAN-19-2948; Choueiri TK, 2021, NEW ENGL J MED, V384, P829, DOI 10.1056/NEJMoa2026982; Chudley L, 2012, CANCER IMMUNOL IMMUN, V61, P2161, DOI 10.1007/s00262-012-1270-0; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; Derre L, 2017, CLIN CANCER RES, V23, P717, DOI 10.1158/1078-0432.CCR-16-1189; Diaz-Montero CM, 2020, NAT REV NEPHROL, V16, P721, DOI 10.1038/s41581-020-0316-3; Drake CG, 2006, ADV IMMUNOL, V90, P51, DOI 10.1016/S0065-2776(06)90002-9; Fakhrejahani F, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.6_suppl.159; Farsaci B., 2013, J IMMUNOTHER CANCER, V1, P97, DOI [10.1186/2051-1426-1-S1-P97, DOI 10.1186/2051-1426-1-S1-P97]; Fenoglio D, 2013, CANCER IMMUNOL IMMUN, V62, P1041, DOI 10.1007/s00262-013-1415-9; Figlin RA, 2020, CLIN CANCER RES, V26, P2327, DOI 10.1158/1078-0432.CCR-19-2427; Fong L, 2012, ANN ONCOL, V23, P310; Fossa A, 2004, PROSTATE, V59, P440, DOI 10.1002/pros.20025; Fujio K, 2015, ONCOL REP, V33, P1585, DOI 10.3892/or.2015.3770; Funt S, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3005; Galsky MD, 2020, LANCET, V395, P1547, DOI 10.1016/S0140-6736(20)30230-0; Gilboa E, 2007, J CLIN INVEST, V117, P1195, DOI 10.1172/JCI31205; Grivas P, 2017, ANN ONCOL, V28, P680, DOI 10.1093/annonc/mdx063; Gulley JL, 2019, J CLIN ONCOL, V37, P1051, DOI 10.1200/JCO.18.02031; Gulley JL, 2013, CANCER IMMUNOL IMMUN, V62, P1521, DOI 10.1007/s00262-013-1448-0; Harrop R, 2013, CANCER IMMUNOL IMMUN, V62, P1511, DOI 10.1007/s00262-013-1457-z; Harrop R, 2012, CANCER IMMUNOL IMMUN, V61, P2283, DOI 10.1007/s00262-012-1302-9; Jaini R, 2014, INT J CANCER, V134, P1695, DOI 10.1002/ijc.28488; Jochems C, 2014, CANCER IMMUNOL IMMUN, V63, P407, DOI 10.1007/s00262-014-1524-0; Kamrava M, 2012, PROSTATE CANCER P D, V15, P289, DOI 10.1038/pcan.2012.7; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Karbach J, 2011, CLIN CANCER RES, V17, P861, DOI 10.1158/1078-0432.CCR-10-1811; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kongsted P, 2017, CYTOTHERAPY, V19, P500, DOI 10.1016/j.jcyt.2017.01.007; Kreiter S, 2011, CURR OPIN IMMUNOL, V23, P399, DOI 10.1016/j.coi.2011.03.007; Ku J, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.368; Kubler H, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0068-y; Kumari S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218151; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Kyriakopoulos CE, 2020, CLIN CANCER RES, V26, P5162, DOI 10.1158/1078-0432.CCR-20-0945; LAMM DL, 1980, J UROLOGY, V124, P38, DOI 10.1016/S0022-5347(17)55282-9; Lilleby W, 2017, CANCER IMMUNOL IMMUN, V66, P891, DOI 10.1007/s00262-017-1994-y; Liverani C, 2017, CELL MOL BIOENG, V10, P223, DOI 10.1007/s12195-017-0483-x; Madan RA, 2019, JNCI-J NATL CANCER I, V111, P219, DOI 10.1093/jnci/djy145; Madan RA, 2012, LANCET ONCOL, V13, P501, DOI 10.1016/S1470-2045(12)70006-2; Matsumoto K, 2011, BJU INT, V108, P831, DOI 10.1111/j.1464-410X.2010.09933.x; McNeel DG, 2019, J CLIN ONCOL, V37, P3507, DOI 10.1200/JCO.19.01701; McNeel Douglas G, 2018, Oncotarget, V9, P25586, DOI 10.18632/oncotarget.25387; McNeel DG, 2015, HUM VACC IMMUNOTHER, V11, P2469, DOI 10.1080/21645515.2015.1062190; Mercatali L, 2018, JOVE-J VIS EXP, DOI 10.3791/57113; Minami T, 2017, INT IMMUNOPHARMACOL, V44, P197, DOI 10.1016/j.intimp.2017.01.014; Minami T, 2015, J IMMUNOTHER, V38, P285, DOI 10.1097/CJI.0000000000000090; Miserocchi G, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1328-z; Morse MA, 2011, EXPERT REV VACCINES, V10, P733, DOI [10.1586/erv.11.20, 10.1586/ERV.11.20]; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer R, 2021, NEW ENGL J MED, V384, P1289, DOI 10.1056/NEJMoa2035716; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Noguchi M, 2021, ONCOL REP, V45, P159, DOI 10.3892/or.2020.7847; Noguchi M, 2020, CANCER IMMUNOL IMMUN, V69, P847, DOI 10.1007/s00262-020-02498-8; Noguchi M, 2018, CANCER SCI, V109, P2660, DOI 10.1111/cas.13709; Noguchi M, 2016, CANCER IMMUNOL IMMUN, V65, P151, DOI 10.1007/s00262-015-1781-6; Noguchi M, 2016, CLIN CANCER RES, V22, P54, DOI 10.1158/1078-0432.CCR-15-1265; Noguchi M, 2015, CANCER IMMUNOL IMMUN, V64, P493, DOI 10.1007/s00262-015-1660-1; Noguchi M, 2012, PROSTATE, V72, P834, DOI 10.1002/pros.21485; Obara W, 2017, ANN ONCOL, V28, P798, DOI 10.1093/annonc/mdw675; Obara W, 2018, CANCER SCI, V109, P550, DOI 10.1111/cas.13506; Obara W, 2017, CANCER SCI, V108, P1452, DOI 10.1111/cas.13278; Obara W, 2017, CANCER IMMUNOL IMMUN, V66, P17, DOI 10.1007/s00262-016-1915-5; Obradovic AZ, 2020, CLIN CANCER RES, V26, P3182, DOI 10.1158/1078-0432.CCR-19-3372; Ogasawara M, 2018, THER APHER DIAL, V22, P266, DOI 10.1111/1744-9987.12694; Ott PA, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-CT125; Oudard S, 2011, CANCER IMMUNOL IMMUN, V60, P261, DOI 10.1007/s00262-010-0935-9; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Pang X, 2013, BIOSCI BIOTECH BIOCH, V77, P766, DOI 10.1271/bbb.120893; Perez SA, 2014, CANCER IMMUNOL IMMUN, V63, P1141, DOI 10.1007/s00262-014-1582-3; Perez SA, 2013, CANCER IMMUNOL IMMUN, V62, P1599, DOI 10.1007/s00262-013-1461-3; Powers E, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00978-z; Powles T, 2020, LANCET ONCOL, V21, P1563, DOI 10.1016/S1470-2045(20)30436-8; Powles T, 2020, NEW ENGL J MED, V383, P1218, DOI 10.1056/NEJMoa2002788; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Redman JM, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0409-8; Rini BI, 2019, LANCET, V393, P2404, DOI 10.1016/S0140-6736(19)30723-8; Rini BI, 2016, LANCET ONCOL, V17, P1599, DOI 10.1016/S1470-2045(16)30408-9; Saade F, 2012, EXPERT REV VACCINES, V11, P189, DOI [10.1586/ERV.11.188, 10.1586/erv.11.188]; Sanchez-Paulete AR, 2017, ANN ONCOL, V28, P44, DOI 10.1093/annonc/mdx237; Sasada T, 2012, HUM VACC IMMUNOTHER, V8, P1309, DOI 10.4161/hv.20988; Scheid E, 2016, CANCER IMMUNOL RES, V4, P881, DOI 10.1158/2326-6066.CIR-15-0189; Schellhammer PF, 2013, UROLOGY, V81, P1297, DOI 10.1016/j.urology.2013.01.061; Scholz M, 2017, IMMUNOTARGETS THER, V6, P11, DOI 10.2147/ITT.S122497; Schuhmacher J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001157; Sharma P, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.142; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; Shore ND, 2020, MOL THER, V28, P1238, DOI 10.1016/j.ymthe.2020.02.018; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590; Simons JW, 2006, UROL ONCOL-SEMIN ORI, V24, P419, DOI 10.1016/j.urolonc.2005.08.021; Slovin SF, 2013, VACCINE, V31, P943, DOI 10.1016/j.vaccine.2012.11.096; Small EJ, 2015, CLIN CANCER RES, V21, P3862, DOI 10.1158/1078-0432.CCR-15-0079; Suekane S, 2017, CANCER SCI, V108, P2430, DOI 10.1111/cas.13404; Surolia I, 2014, EXPERT OPIN BIOL TH, V14, P1769, DOI 10.1517/14712598.2014.955010; Sylvester RJ, 2011, INT J UROL, V18, P113, DOI 10.1111/j.1442-2042.2010.02678.x; Tagliamonte M, 2014, HUM VACC IMMUNOTHER, V10, P3332, DOI 10.4161/21645515.2014.973317; Tanaka T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/262967; Voutsas IF, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0183-4; Vuky J, 2013, ONCOLOGIST, V18, P687, DOI 10.1634/theoncologist.2011-0234; Walter S, 2012, NAT MED, V18, P1254, DOI 10.1038/nm.2883; Ward JE, 2007, EXPERT OPIN BIOL TH, V7, P1893, DOI 10.1517/14712598.7.12.1893; Westdorp H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0787-6; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Xi HB, 2015, BIOL PHARM BULL, V38, P827, DOI 10.1248/bpb.b14-00518; Yoshimura K, 2013, BRIT J CANCER, V108, P1260, DOI 10.1038/bjc.2013.90; Yoshimura K, 2016, EUR UROL, V70, P35, DOI 10.1016/j.eururo.2015.12.050; Zheng K, 2015, J BUON, V20, P505	121	4	4	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							623	10.3390/vaccines9060623			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ5VN	34207536	gold, Green Published, Green Submitted			2022-04-29	WOS:000666632800001
J	Walkowski, W; Bassett, J; Bhalla, M; Pfeifer, BA; Ghanem, ENB				Walkowski, William; Bassett, Justin; Bhalla, Manmeet; Pfeifer, Blaine A.; Ghanem, Elsa N. Bou			Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease	VACCINES			English	Review						intranasal; pulmonary; respiratory tract; vaccine; pneumococcal disease; aging	STREPTOCOCCUS-PNEUMONIAE COLONIZATION; SEROTYPE-INDEPENDENT PROTECTION; CALCIUM-PHOSPHATE NANOPARTICLES; RESISTANT BORDETELLA-PERTUSSIS; COMMUNITY-ACQUIRED PNEUMONIA; CONJUGATE VACCINE; INFLUENZA-VIRUS; DRUG-RESISTANCE; BACTERIAL COINFECTIONS; NASAL IMMUNIZATION	This mini-review will cover recent trends in intranasal (IN) vaccine delivery as it relates to applications for respiratory tract diseases. The logic and rationale for IN vaccine delivery will be compared to methods and applications accompanying this particular administration route. In addition, we will focus extended discussion on the potential role of IN vaccination in the context of respiratory tract diseases, with a special emphasis on pneumococcal disease. Here, elements of this disease, including its prevalence and impact upon the elderly population, will be viewed from the standpoint of improving health outcomes through vaccine design and delivery technology and how IN administration can play a role in such efforts.	[Walkowski, William; Bassett, Justin; Pfeifer, Blaine A.] SUNY Buffalo, Dept Chem & Biol Engn, Buffalo, NY 14260 USA; [Bhalla, Manmeet; Ghanem, Elsa N. Bou] SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14203 USA		Ghanem, ENB (通讯作者)，SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14203 USA.	wewalkow@buffalo.edu; jdbasset@buffalo.edu; manmeetp@buffalo.edu; blainepf@buffalo.edu; elsaboug@buffalo.edu	Bassett, Justin/AAZ-4883-2021		National Institutes of Health (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG064215]	This research was funded by the National Institutes of Health (NIA), grant number AG064215.	Abed Y, 2006, ANTIVIR RES, V70, P1, DOI 10.1016/j.antiviral.2006.01.006; Abelenda-Alonso G, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa066; Adderson EE, 2001, SPRINGER SEMIN IMMUN, V23, P387, DOI 10.1007/s281-001-8166-x; Avendano Carvajal L., 2020, PEDIAT RESPIR DIS, P263, DOI [DOI 10.1007/978-3-030-26961-6_28, 10.1007/978-3-030-26961-6_28]; Babb R, 2016, CLIN SCI, V130, P697, DOI 10.1042/CS20150699; Bakaletz LO, 2017, CURR OPIN MICROBIOL, V35, P30, DOI 10.1016/j.mib.2016.11.003; Ballinger MN, 2010, J INTERF CYTOK RES, V30, P643, DOI 10.1089/jir.2010.0049; Barkai G, 2005, EMERG INFECT DIS, V11, P829; Bellerose MM, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00396-20; Berical AC, 2016, ANN AM THORAC SOC, V13, P933, DOI 10.1513/AnnalsATS.201511-778FR; Beule, 2010, GMS Curr. Top. Otorhinolaryngol. Head Neck Surg, V9, pDOC07, DOI 10.3205/cto000071; Bhalla M, 2020, AGING CELL, V19, DOI 10.1111/acel.13218; Blanchette-Cain K, 2013, MBIO, V4, DOI 10.1128/mBio.00745-13; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Boe DM, 2017, CLIN EXP IMMUNOL, V187, P16, DOI 10.1111/cei.12881; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Buffa S, 2011, BIOGERONTOLOGY, V12, P473, DOI 10.1007/s10522-011-9353-4; Butler JC, 1999, CLIN INFECT DIS, V28, P730, DOI 10.1086/515220; Centers for Disease Control and Prevention, 2019, ACT BACT COR SURV RE; Centers for Disease Control and Prevention, 2017, ACT BACT COR SURV RE; Centers for Disease Control and Prevention, 2015, ACT BACT COR SURV RE; Centers for Disease Control and Prevention, 2016, ACT BACT COR SURV RE; Cerutti A, 2013, J LEUKOCYTE BIOL, V94, P677, DOI 10.1189/jlb.1112596; Chao YS, 2015, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00194; Chen HH, 2019, AM J TROP MED HYG, V101, P1042, DOI 10.4269/ajtmh.18-0930; Chen WH, 2009, TRENDS IMMUNOL, V30, P351, DOI 10.1016/j.it.2009.05.002; Chong C.P., 2008, SOUTH MED J, V101, P1141, DOI [10.1097/SMJ.0b013e318181d5b5, DOI 10.1097/SMJ.0b013e318181d5b5]; Chow EJ, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2491-9; Nguyen CT, 2011, VACCINE, V29, P5731, DOI 10.1016/j.vaccine.2011.05.095; D'Mello A, 2020, P NATL ACAD SCI USA, V117, P33507, DOI 10.1073/pnas.2010428117; Dagan R, 1998, PEDIATR INFECT DIS J, V17, P880, DOI 10.1097/00006454-199810000-00006; Davis BM, 2012, AM J EPIDEMIOL, V175, P363, DOI 10.1093/aje/kwr402; de Sevilla MF, 2012, PEDIATR INFECT DIS J, V31, P124, DOI 10.1097/INF.0b013e318241d09e; Dehghan S, 2014, INT J PHARMACEUT, V475, P1, DOI 10.1016/j.ijpharm.2014.08.032; Diavatopoulos DA, 2010, FASEB J, V24, P1789, DOI 10.1096/fj.09-146779; Dockrell DH, 2012, CHEST, V142, P482, DOI 10.1378/chest.12-0210; Drijkoningen JJC, 2014, CLIN MICROBIOL INFEC, V20, P45, DOI 10.1111/1469-0691.12461; Ferreira DM, 2013, AM J RESP CRIT CARE, V187, P855, DOI 10.1164/rccm.201212-2277OC; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; Ghanem ENB, 2018, J IMMUNOL, V200, P3739, DOI 10.4049/jimmunol.1701065; Ghanem ENB, 2015, J IMMUNOL, V194, P1090, DOI 10.4049/jimmunol.1402401; Gideon HP, 2011, IMMUNOL RES, V50, P202, DOI 10.1007/s12026-011-8229-7; Goncalves VM, 2019, EXPERT REV VACCINES, V18, P781, DOI 10.1080/14760584.2019.1643719; Greenberg Harry B, 2004, Pediatr Infect Dis J, V23, pS254, DOI 10.1097/01.inf.0000144756.69887.f8; Gustafson CE, 2018, CLIN SCI, V132, P1925, DOI 10.1042/CS20171157; Hanage WP, 2008, FUTURE MICROBIOL, V3, P23, DOI 10.2217/17460913.3.1.23; He Q, 2000, CLIN DIAGN LAB IMMUN, V7, P899, DOI 10.1128/CDLI.7.6.899-903.2000; Heikkinen T, 2003, CLIN MICROBIOL REV, V16, P230, DOI 10.1128/CMR.16.2.230-241.2003; Henig O, 2017, INFECT DIS CLIN N AM, V31, P689, DOI 10.1016/j.idc.2017.07.015; Hill AB, 2018, ACS INFECT DIS, V4, P1553, DOI 10.1021/acsinfecdis.8b00100; ICKOVIC MR, 1983, ANN INST PASTEUR IMM, VD134, P385, DOI 10.1016/S0769-2625(83)80029-4; Jochems SP, 2019, J CLIN INVEST, V129, P4523, DOI 10.1172/JCI128865; Jones CH, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701797; Jwa MY, 2018, J MICROBIOL, V56, P579, DOI 10.1007/s12275-018-8347-1; Kadioglu A, 2008, NAT REV MICROBIOL, V6, P288, DOI 10.1038/nrmicro1871; Kamachi K, 2020, EMERG INFECT DIS, V26, P2511, DOI 10.3201/eid2610.201035; Keller LE, 2016, MBIO, V7, DOI 10.1128/mBio.01792-15; Khademi F, 2018, MICROB PATHOGENESIS, V125, P507, DOI 10.1016/j.micpath.2018.10.023; Kim L, 2016, CLIN MICROBIOL REV, V29, P525, DOI 10.1128/CMR.00058-15; Kodama S, 2006, LARYNGOSCOPE, V116, P331, DOI 10.1097/01.mlg.0000194222.93067.f7; Kong IG, 2013, INFECT IMMUN, V81, P1625, DOI 10.1128/IAI.00240-13; Krone CL, 2014, LANCET RESP MED, V2, P141, DOI 10.1016/S2213-2600(13)70165-6; Kulka K, 2012, JOVE-J VIS EXP, DOI 10.3791/3820; Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999; Li HS, 2016, J CONTROL RELEASE, V233, P114, DOI 10.1016/j.jconrel.2016.05.032; Liberati A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000022.pub3; Lin YH, 2017, EXPERT REV VACCINES, V16, P895, DOI 10.1080/14760584.2017.1355733; Liu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069649; Liu J, 2020, INT J SURG, V81, P1, DOI 10.1016/j.ijsu.2020.07.032; Liu P.V., 1996, MED MICROBIOLOGY, V4th; Loughran AJ, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0004-2018; Luck JN, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.613287; Mabhula A, 2019, MEDCHEMCOMM, V10, P1342, DOI 10.1039/c9md00057g; Machado MB, 2019, REV PAUL PEDIATR, V37, P351, DOI 10.1590/1984-0462/;2019;37;3;00006; Malley R, 2005, P NATL ACAD SCI USA, V102, P4848, DOI 10.1073/pnas.0501254102; Malley R, 2001, INFECT IMMUN, V69, P4870, DOI 10.1128/IAI.69.8.4870-4873.2001; Manjelievskaia J, 2016, T ROY SOC TROP MED H, V110, P186, DOI 10.1093/trstmh/trw006; Marks LR, 2013, MBIO, V4, DOI 10.1128/mBio.00438-13; Marks LR, 2012, INFECT IMMUN, V80, P2744, DOI 10.1128/IAI.00488-12; Marttin E, 1998, ADV DRUG DELIVER REV, V29, P13, DOI 10.1016/S0169-409X(97)00059-8; Masson JD, 2017, EXPERT REV VACCINES, V16, P289, DOI 10.1080/14760584.2017.1244484; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05; McCullers JA, 2014, NAT REV MICROBIOL, V12, P252, DOI 10.1038/nrmicro3231; Metzger DW, 2013, J IMMUNOL, V191, P2047, DOI 10.4049/jimmunol.1301152; Meyer KC, 2004, AGEING RES REV, V3, P55, DOI 10.1016/j.arr.2003.07.002; Meyer KC, 2001, RESP PHYSIOL, V128, P23, DOI 10.1016/S0034-5687(01)00261-4; Mitsi E, 2020, AM J RESP CRIT CARE, V201, P335, DOI 10.1164/rccm.201903-0607OC; Mizgerd JP, 2012, AM J RESP CRIT CARE, V186, P824, DOI 10.1164/rccm.201206-1063PP; Morris PS, 2009, PEDIATR CLIN N AM, V56, P101, DOI 10.1016/j.pcl.2008.10.009; Mudgal R, 2020, HUM VACC IMMUNOTHER, V16, P2921, DOI 10.1080/21645515.2020.1805992; Musher D., 2017, PNEUMOCOCCAL VACCINA; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Nguyen DT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127098; Obaro S, 2002, J MED MICROBIOL, V51, P98, DOI 10.1099/0022-1317-51-2-98; Ogra PL, 2001, CLIN MICROBIOL REV, V14, P430, DOI 10.1128/CMR.14.2.430-445.2001; Ortman JM., 2014, AGING NATION OLDER P; Park S, 2011, INFECT IMMUN, V79, P314, DOI 10.1128/IAI.00768-10; Pettigrew MM, 2014, INFECT IMMUN, V82, P4607, DOI 10.1128/IAI.02225-14; Pichichero ME, 2007, JAMA-J AM MED ASSOC, V298, P1772, DOI 10.1001/jama.298.15.1772; Pinti M, 2016, EUR J IMMUNOL, V46, P2286, DOI 10.1002/eji.201546178; Reljic R, 2013, INFECT IMMUN, V81, P4071, DOI 10.1128/IAI.00786-13; RELYVELD EH, 1985, ANN ALLERGY, V54, P521; Ridda I, 2009, VACCINE, V27, P1628, DOI 10.1016/j.vaccine.2008.11.098; Rodrigues TC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191692; Roy CJ, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-153; Salha D, 2012, INFECT IMMUN, V80, P2212, DOI 10.1128/IAI.06348-11; Sen G, 2006, INFECT IMMUN, V74, P2177, DOI 10.1128/IAI.74.4.2177-2186.2006; Shainheit MG, 2014, INFECT IMMUN, V82, P694, DOI 10.1128/IAI.01289-13; Shekhar S, 2019, APPL ENVIRON MICROB, V85, DOI 10.1128/AEM.02235-18; Shenoy AT, 2020, MUCOSAL IMMUNOL, V13, P334, DOI 10.1038/s41385-019-0229-2; Shim BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027953; Shiri T, 2019, VALUE HEALTH, V22, P1329, DOI 10.1016/j.jval.2019.06.011; Short KR, 2012, FUTURE MICROBIOL, V7, P609, DOI [10.2217/fmb.12.29, 10.2217/FMB.12.29]; Shrestha S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005982; Siegel SJ, 2014, CELL HOST MICROBE, V16, P55, DOI 10.1016/j.chom.2014.06.005; Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/ERV.12.53, 10.1586/erv.12.53]; Simell B, 2011, VACCINE, V29, P1929, DOI 10.1016/j.vaccine.2010.12.121; Simmons SR, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00653-20; Smith AM, 2014, CURR TOP MICROBIOL, V385, P327, DOI 10.1007/82_2014_394; Smith NMS, 2018, MUCOSAL IMMUNOL, V11, P220, DOI 10.1038/mi.2017.43; Smith T, 2014, CURR TOP MICROBIOL, V374, P53, DOI 10.1007/82_2012_279; Sokolova V, 2010, BIOMATERIALS, V31, P5627, DOI 10.1016/j.biomaterials.2010.03.067; Stasi C, 2020, EUR J PHARMACOL, V889, DOI 10.1016/j.ejphar.2020.173644; Stupka John E, 2009, Aging health, V5, P763, DOI 10.2217/ahe.09.74; Suarez I, 2019, DTSCH ARZTEBL INT, V116, P729, DOI 10.3238/arztebl.2019.0729; Suzuki H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126352; Suzuki M, 2017, LANCET INFECT DIS, V17, P313, DOI [10.1016/S1473-3099(17)30049-X, 10.1016/s1473-3099(17)30049-x]; Tada R, 2018, INT IMMUNOPHARMACOL, V61, P385, DOI 10.1016/j.intimp.2018.06.027; Thompson MG, 2010, JAMA-J AM MED ASSOC, V304, P1778; Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057; Tomar J, 2018, J CONTROL RELEASE, V288, P199, DOI 10.1016/j.jconrel.2018.09.006; Torres A, 2018, RESP MED, V137, P6, DOI 10.1016/j.rmed.2018.02.007; Treanor J, 1999, ANTIVIR RES, V44, P79, DOI 10.1016/S0166-3542(99)00062-5; van Werkhoven CH, 2015, CLIN INFECT DIS, V61, P1835, DOI 10.1093/cid/civ686; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Wang DD, 2018, IMMUNOL INVEST, V47, P403, DOI 10.1080/08820139.2018.1439505; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Wang Xuan-Yi, 2011, Interdiscip Perspect Infect Dis, V2011, P146376, DOI 10.1155/2011/146376; Weiser JN, 2018, NAT REV MICROBIOL, V16, P354, DOI 10.1038/s41579-018-0001-8; Whitney CG, 2004, INFECT DIS CLIN N AM, V18, P899, DOI 10.1016/j.idc.2004.07.008; Wright AKA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003274; Wright AKA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002622; Wroe PC, 2012, J INFECT DIS, V205, P1589, DOI 10.1093/infdis/jis240; Wu KF, 2014, VACCINE, V32, P4179, DOI 10.1016/j.vaccine.2014.05.019; Wu ML, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00445; Wunderink RG, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2471; Xu JH, 2015, SCAND J IMMUNOL, V81, P177, DOI 10.1111/sji.12267; Xu Z, 2019, EMERG MICROBES INFEC, V8, P461, DOI [10.1080/22221751.2019.1587315, 10.6084/m9.figshare.7937375.v2]; Yang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138941; Yuan ZQ, 2011, IMMUNOL RES, V51, P108, DOI 10.1007/s12026-011-8234-x; Yusuf H, 2017, HUM VACC IMMUNOTHER, V13, P34, DOI 10.1080/21645515.2016.1239668; Zaman M, 2016, SCI REP-UK, V6, DOI 10.1038/srep39274; Zhou H, 2012, EMERG INFECT DIS, V18, P294, DOI 10.3201/eid1802.102025; Zoorob R, 2012, AM FAM PHYSICIAN, V86, P817	156	3	3	6	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							589	10.3390/vaccines9060589			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY7AA	34199398	gold, Green Published			2022-04-29	WOS:000666035000001
J	Anichini, G; Terrosi, C; Savellini, GG; Gandolfo, C; Franchi, F; Cusi, MG				Anichini, Gabriele; Terrosi, Chiara; Savellini, Gianni Gori; Gandolfo, Claudia; Franchi, Federico; Cusi, Maria Grazia			Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants	VACCINES			English	Article						SARS-CoV-2; vaccine; variants; neutralizing antibody	MUTATIONS	Due to their increased transmissibility, three variants of high concern have emerged in the United Kingdom (also known as B.1.1.7 lineage or VOC-202012/01), South Africa (B.1.351 lineage), and Brazil (P1 lineage) with multiple substitutions in the spike protein. Since neutralizing antibodies elicited by vaccination are likely considered as correlates of protection for SARS-CoV-2 infection, it is important to analyze whether vaccinees with mRNA BNT162b2 are equally protected against these emerging SARS-CoV-2 variants. To this aim, we enrolled healthy subjects one month after complete vaccination with Comirnaty and evaluated the neutralizing response against the native Wuhan strain and the emerging B.1.1.7, B.1.351 and P1 lineages, by using the microneutralization assay, currently considered the gold standard test for the evaluation and detection of functional neutralizing antibodies. The most remarkable finding of this study was the significantly lower neutralizing antibody titer against B.1.351 lineage, compared to the wild-type virus. No significant differences were observed with the other two lineages. These findings provide evidence that vaccinated subjects may not be equally protected against all SARS-CoV-2 lineages.	[Anichini, Gabriele; Terrosi, Chiara; Savellini, Gianni Gori; Gandolfo, Claudia; Cusi, Maria Grazia] Siena Univ Hosp, Dept Med Biotechnol, Virol Unit, I-53100 Siena, Italy; [Franchi, Federico] Siena Univ Hosp, Dept Med Surg & Neurosci, Emergency Anesthesia & Intens Care Unit, I-53100 Siena, Italy		Cusi, MG (通讯作者)，Siena Univ Hosp, Dept Med Biotechnol, Virol Unit, I-53100 Siena, Italy.	gabriele.anichini@studentunisi.it; chiara.terrosi@unisi.it; gianni.gori@unisi.it; daudia.gandolfo@unisi.it; federico.franchi@unisi.it; mariagrazia.cusi@unisi.it	CUSI, MARIA GRAZIA/K-2377-2018; Savellini, Gianni Gori/D-1904-2019; Gandolfo, Claudia/U-4982-2019	CUSI, MARIA GRAZIA/0000-0001-8869-8164; Savellini, Gianni Gori/0000-0003-2287-9258; Gandolfo, Claudia/0000-0003-2174-0713; Anichini, Gabriele/0000-0001-9895-2488; MARITTI, MICAELA/0000-0003-0606-6353			Anichini G, 2021, NEW ENGL J MED, V385, P90, DOI 10.1056/NEJMc2103825; [Anonymous], MRNA 1273 VACCINE IN, DOI [10.1101/2021.01.25.427948v1.abstract, DOI 10.1101/2021.01.25.427948V1.ABSTRACT]; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Greaney AJ, 2021, CELL HOST MICROBE, V29, P44, DOI 10.1016/j.chom.2020.11.007; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Liu LH, 2020, NATURE, V584, P450, DOI 10.1038/s41586-020-2571-7; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Shen XY, 2021, NEW ENGL J MED, V384, P2352, DOI 10.1056/NEJMc2103740; Stamatatos L, 2021, SCIENCE, V372, P1413, DOI 10.1126/science.abg9175; Starr TN, 2021, SCIENCE, V371, P850, DOI 10.1126/science.abf9302; Zhang LZ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19808-4	20	6	6	5	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							517	10.3390/vaccines9050517			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI9VA	34069852	Green Published, gold			2022-04-29	WOS:000655175200001
J	Brodziak, A; Sigorski, D; Osmola, M; Wilk, M; Gawlik-Urban, A; Kiszka, J; Machulska-Ciuraj, K; Sobczuk, P				Brodziak, Anna; Sigorski, Dawid; Osmola, Malgorzata; Wilk, Michal; Gawlik-Urban, Angelika; Kiszka, Joanna; Machulska-Ciuraj, Katarzyna; Sobczuk, Pawel			Attitudes of Patients with Cancer towards Vaccinations-Results of Online Survey with Special Focus on the Vaccination against COVID-19	VACCINES			English	Article						vaccination; vaccine; cancer; COVID-19; influenza	HEALTH-CARE WORKERS; INFLUENZA VACCINATION; SOLID TUMORS; PERCEPTION; COVERAGE	Recently developed COVID-19 vaccines significantly reduce the risk of severe coronavirus disease, which is essential in the particularly vulnerable cancer patient population. There is a growing anti-vaccine concern that may affect the success of the fight against the SARS-CoV2 pandemic. To evaluate opinions and attitudes toward vaccination, we conducted an anonymous online survey among Polish patients diagnosed with cancer. We analyzed how socio-demographic factors, type of cancer, comorbidities, previous influenza vaccinations, and information sources affect the general willingness and opinions about vaccinations, emphasizing vaccination against COVID-19. Six hundred thirty-five patients (80.2% female) participated in the study. A positive attitude towards vaccination was presented by 73.7%, neutral by 17.8%, while negative by 8.5%. Willingness to get vaccinated was declared by 60.3%, 23.5% were unwilling, and 16.2% were undecided. Significant predictors of willingness were education, marital status, active anti-cancer treatment, previous influenza vaccination, and positive attitude towards vaccinations. Patients with cancer have concerns regarding safety, effectiveness, and the process of development of the COVID-19 vaccine. Overall, patients with cancer present positive attitudes towards COVID-19 vaccination but required sufficient information on its efficacy and side effects.	[Brodziak, Anna; Sobczuk, Pawel] Med Univ Warsaw, Lab Ctr Preclin Res, Dept Expt & Clin Physiol, PL-02097 Warsaw, Poland; [Brodziak, Anna] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, PL-02781 Warsaw, Poland; [Sigorski, Dawid] Univ Warmia & Mazury, Dept Oncol, PL-11228 Olsztyn, Poland; [Sigorski, Dawid] Minist Interior & Adm Hosp, Warmian Masurian Canc Ctr, Dept Oncol & Immunooncol, PL-11228 Olsztyn, Poland; [Osmola, Malgorzata] Med Univ Warsaw, Univ Clin Ctr, Dept Hematol Transplantat & Internal Med, PL-02097 Warsaw, Poland; [Wilk, Michal] European Hlth Ctr, Dept Oncol, Ctr Postgrad Med Educ, PL-05400 Otwock, Poland; [Gawlik-Urban, Angelika] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Clin Oncol, PL-31115 Krakow, Poland; [Kiszka, Joanna] Subcarpathian Canc Ctr, PL-35055 Rzeszow, Poland; [Machulska-Ciuraj, Katarzyna] St John Dukla Oncol Ctr Lublin Reg, Dept Clin Oncol, PL-20090 Lublin, Poland; [Sobczuk, Pawel] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, PL-02781 Warsaw, Poland		Sobczuk, P (通讯作者)，Med Univ Warsaw, Lab Ctr Preclin Res, Dept Expt & Clin Physiol, PL-02097 Warsaw, Poland.; Sobczuk, P (通讯作者)，Maria Sklodowska Curie Natl Res Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, PL-02781 Warsaw, Poland.	anna.brodziak@wum.edu.pl; dawidsigorski@wp.pl; malgorzata.osmola@wum.edu.pl; wilk.m@onet.eu; a_gawlik_urban@pwsztar.edu.pl; kiszka_joanna@wp.pl; k.machulska@interia.pl; pawel.sobczuk@pib-nio.pl	Sigorski, Dawid/AAP-1157-2020; Sobczuk, Pawel/M-5876-2018; Osmola, Małgorzata/ABB-3318-2021; Wilk, Michal/V-6527-2017	Sigorski, Dawid/0000-0002-4799-9611; Sobczuk, Pawel/0000-0002-4103-1626; Wilk, Michal/0000-0002-0261-8133; Brodziak, Anna/0000-0002-0017-1040; MC, Katarzyna/0000-0002-5320-9321			Akin S, 2016, ANN ONCOL, V27; Alzaid EH, 2020, J FAM MED PRIM CARE, V9, P4904, DOI 10.4103/jfmpc.jfmpc_674_20; Ariza-Heredia EJ, 2015, INFECT CONT HOSP EP, V36, P1239, DOI 10.1017/ice.2015.150; Bandyopadhyay S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003097; Barriere J, 2021, ANN ONCOL, V32, P673, DOI 10.1016/j.annonc.2021.01.066; Desai A, 2021, NAT REV CLIN ONCOL, V18, P313, DOI 10.1038/s41571-021-00487-z; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Garassino MC, 2021, ANN ONCOL, V32, P579, DOI 10.1016/j.annonc.2021.01.068; Glatter KA, 2021, AM J MED, V134, P176, DOI 10.1016/j.amjmed.2020.08.019; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Grivas P, 2021, ANN ONCOL, V32, P787, DOI 10.1016/j.annonc.2021.02.024; Jacobson RM, 2015, MAYO CLIN PROC, V90, P1562, DOI 10.1016/j.mayocp.2015.09.006; Kelkar AH, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9030351; Kowalski J, 2020, PSYCHIAT RES, V294, DOI 10.1016/j.psychres.2020.113540; Loulergue P, 2008, Ann Oncol, V19, P1658, DOI 10.1093/annonc/mdn531; Marra A, 2021, ANN ONCOL, V32, P113, DOI 10.1016/j.annonc.2020.10.473; McAteer J, 2020, CLIN INFECT DIS, V71, P703, DOI 10.1093/cid/ciaa433; National Comprehensive Cancer Network, PREL REC NCCN COVID; Patt D, 2020, JCO CLIN CANCER INFO, V4, P1059, DOI 10.1200/CCI.20.00134; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Poeppl W, 2015, VACCINE, V33, P1682, DOI 10.1016/j.vaccine.2015.02.029; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ribas A, 2021, CANCER DISCOV, V11, P233, DOI 10.1158/2159-8290.CD-20-1817; Riedel Stefan, 2005, Proc (Bayl Univ Med Cent), V18, P21; Saini KS, 2020, EUR J CANCER, V139, P43, DOI 10.1016/j.ejca.2020.08.011; Sigorski D, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000970; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Urun Y, 2013, J BUON, V18, P511; Vinograd I, 2014, CLIN MICROBIOL INFEC, V20, P899, DOI 10.1111/1469-0691.12625; Vollaard A, 2017, EUR J CANCER, V76, P134, DOI 10.1016/j.ejca.2017.02.012; Wysocki PJ, 2020, ONCOL CLIN PRACT, V16, P41, DOI 10.5603/OCP.2020.0012; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018; Zaorsky NG, 2017, ANN ONCOL, V28, P400, DOI 10.1093/annonc/mdw604	35	16	17	1	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							411	10.3390/vaccines9050411			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1ZX	33919048	Green Published, gold			2022-04-29	WOS:000654625200001
J	Ciardi, F; Menon, V; Jensen, JL; Shariff, MA; Pillai, A; Venugopal, U; Kasubhai, M; Dimitrov, V; Kanna, B; Poole, BD				Ciardi, Federico; Menon, Vidya; Jensen, Jamie L.; Shariff, Masood A.; Pillai, Anjana; Venugopal, Usha; Kasubhai, Moiz; Dimitrov, Vihren; Kanna, Balavenkatesh; Poole, Brian D.			Knowledge, Attitudes and Perceptions of COVID-19 Vaccination among Healthcare Workers of an Inner-City Hospital in New York	VACCINES			English	Article						COVID-19; vaccine hesitancy; healthcare workers; vaccine attitudes	INTENTION	Introduction: New York City is one of the areas most affected by the COVID-19 pandemic in the United States. Healthcare workers are among those at high risk of contracting the virus, and a vital source of information and trust in vaccines to the community. Methods: This study was conducted about attitudes towards COVID-19 vaccination among healthcare workers at a public hospital in New York City during the beginning of COVID-19 vaccination. 428 hospital employees responded. Results: Several factors were significantly associated with vaccine attitudes, including demographics such as gender (p = 0.002), age (p = 0.005), race (p < 0.001) and home location (p < 0.001), role within the hospital (p < 0.001), knowledge about the virus (p < 0.001) and confidence in and expectations about personal protective equipment and behaviors (p < 0.001). Structural equation modeling revealed that the most predictive factors were prior vaccine attitudes and concern with the speed of testing and approval of the vaccines (p < 0.001). Multivariate analysis reinforced these, while also identifying perceived personal risk as significant (p = 0.033). Conclusions: Several modifiable factors that reflect confidence in science, scientific knowledge, personal risk perception, experience and medical authority are correlated with vaccine attitudes, indicating that a holistic educational approach to improve trust in science is likely to be effective in long-term reduction in vaccine hesitancy.	[Ciardi, Federico; Menon, Vidya; Shariff, Masood A.; Pillai, Anjana; Venugopal, Usha; Kasubhai, Moiz; Dimitrov, Vihren; Kanna, Balavenkatesh] NYC Hlth & Hosp Lincoln, Dept Med, The Bronx, NY 10451 USA; [Jensen, Jamie L.] Brigham Young Univ, Dept Biol, Provo, UT 84602 USA; [Poole, Brian D.] Brigham Young Univ, Dept Microbiol & Mol Biol, Provo, UT 84602 USA		Menon, V (通讯作者)，NYC Hlth & Hosp Lincoln, Dept Med, The Bronx, NY 10451 USA.	ciardif@nychhc.org; menonv@nychhc.org; jamie.jensen@byu.edu; shariffm@nychhc.org; anjana.pillai@nychhc.org; usha.venugopal@nychhc.org; Moiz.Kasubhai@nychhc.org; vihren.dimitrov@nychhc.org; balavenkatesh.kanna@nychhc.org; brian_poole@byu.edu		Poole, Brian/0000-0002-3205-640X; Ciardi, Federico/0000-0002-1604-1267; Jensen, Jamie/0000-0002-2249-0405; Shariff, Masood/0000-0003-4082-4066			Adhikari EH, 2021, JAMA-J AM MED ASSOC, V325, P1039, DOI 10.1001/jama.2021.1658; [Anonymous], **NON-TRADITIONAL**; [Anonymous], EMPLOYED PERSONS DET; [Anonymous], COVID 19 VACCINE HOS; Brenan, 2020, WILLINGNESS GET COVI; Closson T., 2021, NEW YORK TIMES; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Funk C., 2020, INTENT GET COVID 19; Hogan C, 2020, INT J EMERG MED, V13, DOI 10.1186/s12245-020-00309-6; Johnson DK, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020039; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; McClendon S., NEW SURVEY 13K US NU; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; NYC Health, COVID 19 LAT DAT; Omer SB, 2020, JAMA-J AM MED ASSOC, V324, P2095, DOI 10.1001/jama.2020.20892; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; World Health Organization, DRAFT LANDSC TRACK C	27	22	22	2	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							516	10.3390/vaccines9050516			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1XL	34067743	gold, Green Published			2022-04-29	WOS:000654618800001
J	Gholizadeh, Z; Iqbal, MS; Li, R; Romerio, F				Gholizadeh, Zahra; Iqbal, Mohd. Shameel; Li, Rui; Romerio, Fabio			The HIV-1 Antisense Gene ASP: The New Kid on the Block	VACCINES			English	Review						HIV-1; natural antisense transcription; antisense protein (ASP); overprinting; replication; pathogenesis; spread	LEUKEMIA-VIRUS TYPE-1; HUMAN-IMMUNODEFICIENCY-VIRUS; HTLV-1 BZIP FACTOR; OVERLAPPING GENES; STRUCTURAL DISORDER; DOWN-REGULATION; PROTEIN ASP; FACTOR HBZ; DE-NOVO; RNA	Viruses have developed incredibly creative ways of making a virtue out of necessity, including taking full advantage of their small genomes. Indeed, viruses often encode multiple proteins within the same genomic region by using two or more reading frames in both orientations through a process called overprinting. Complex retroviruses provide compelling examples of that. The human immunodeficiency virus type 1 (HIV-1) genome expresses sixteen proteins from nine genes that are encoded in the three positive-sense reading frames. In addition, the genome of some HIV-1 strains contains a tenth gene in one of the negative-sense reading frames. The so-called Antisense Protein (ASP) gene overlaps the HIV-1 Rev Response Element (RRE) and the envelope glycoprotein gene, and encodes a highly hydrophobic protein of similar to 190 amino acids. Despite being identified over thirty years ago, relatively few studies have investigated the role that ASP may play in the virus lifecycle, and its expression in vivo is still questioned. Here we review the current knowledge about ASP, and we discuss some of the many unanswered questions.	[Gholizadeh, Zahra; Iqbal, Mohd. Shameel; Li, Rui; Romerio, Fabio] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA		Romerio, F (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA.	zgholiz1@jhu.edu; miqbal9@jhmi.edu; rli74@jhmi.edu; fromeri2@jhmi.edu	Iqbal, Mohd Shameel/AAD-9641-2021	Romerio, Fabio/0000-0002-2070-297X	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [5R01AI120008, 7R01AI144983]	This work was supported in part by research grants from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) to F.R. (5R01AI120008; 7R01AI144983).	Affram Y, 2019, J VIROL, V93, DOI 10.1128/JVI.00574-19; Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182/blood-2008-04-154286; BARRELL BG, 1976, NATURE, V264, P34, DOI 10.1038/264034a0; Belshaw R, 2007, GENOME RES, V17, P1496, DOI 10.1101/gr.6305707; Bentley K, 2004, ARCH VIROL, V149, P2277, DOI 10.1007/s00705-004-0386-8; Berger CT, 2015, J VIROL, V89, P4015, DOI 10.1128/JVI.03435-14; Bergeron D, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M113.472654; Bet A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0135-y; Boehme KW, 2013, J VIROL, V87, P12967, DOI 10.1128/JVI.02080-13; Bowder D, 2018, VIROLOGY, V521, P158, DOI 10.1016/j.virol.2018.06.005; Briquet S, 2002, VIROLOGY, V292, P177, DOI 10.1006/viro.2001.1224; Briquet S, 2001, GENE, V267, P157, DOI 10.1016/S0378-1119(01)00404-8; Carter CW, 2021, CURR OPIN STRUC BIOL, V68, P142, DOI 10.1016/j.sbi.2021.01.004; CASINO A, 1981, NUCLEIC ACIDS RES, V9, P1499, DOI 10.1093/nar/9.6.1499; Cassan E, 2016, P NATL ACAD SCI USA, V113, P11537, DOI 10.1073/pnas.1605739113; Champiat S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039311; Chellappan P, 2005, P NATL ACAD SCI USA, V102, P10381, DOI 10.1073/pnas.0504439102; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Chirico N, 2010, P ROY SOC B-BIOL SCI, V277, P3809, DOI 10.1098/rspb.2010.1052; Chung WY, 2007, PLOS COMPUT BIOL, V3, P855, DOI 10.1371/journal.pcbi.0030091; Clerc I, 2008, J BIOL CHEM, V283, P23903, DOI 10.1074/jbc.M803116200; Clerc I, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-74; Delaye L, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-31; Dimonte S, 2017, J MED VIROL, V89, P112, DOI 10.1002/jmv.24611; Dreux M, 2010, CELL CYCLE, V9, P1295, DOI 10.4161/cc.9.7.11109; Ekman D, 2010, J MOL BIOL, V396, P396, DOI 10.1016/j.jmb.2009.11.053; Fan J, 2010, J VIROL, V84, P7278, DOI 10.1128/JVI.02239-09; Fellner L, 2015, BMC EVOL BIOL, V15, DOI 10.1186/s12862-015-0558-z; Fischer D, 1999, BIOINFORMATICS, V15, P759, DOI 10.1093/bioinformatics/15.9.759; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Karlin D, 2003, J GEN VIROL, V84, P3239, DOI 10.1099/vir.0.19451-0; Kobayashi-Ishihara M, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-38; Kyei GB, 2009, J CELL BIOL, V186, P255, DOI 10.1083/jcb.200903070; Laverdure S, 2016, J VIROL, V90, P3600, DOI 10.1128/JVI.02634-15; Laverdure S, 2012, J VIROL, V86, P13785, DOI 10.1128/JVI.01723-12; Li CY, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000734; Li F, 2006, ANNU REV MICROBIOL, V60, P503, DOI 10.1146/annurev.micro.60.080805.142205; Liu ZL, 2019, J VIROL, V93, DOI 10.1128/JVI.01757-18; Long M, 2003, NAT REV GENET, V4, P865, DOI 10.1038/nrg1204; Mancarella A, 2019, J GEN VIROL, V100, P863, DOI 10.1099/jgv.0.001244; Matsuoka M, 2020, RETROVIROLOGY, V17, DOI 10.1186/s12977-020-0511-0; McVeigh A, 2000, INFECT IMMUN, V68, P5710, DOI 10.1128/IAI.68.10.5710-5715.2000; MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994; Michel AM, 2012, GENOME RES, V22, P2219, DOI 10.1101/gr.133249.111; MILLER RH, 1988, SCIENCE, V239, P1420, DOI 10.1126/science.3347840; Miura M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-118; Miyazaki M, 2007, J VIROL, V81, P5714, DOI 10.1128/JVI.02511-06; Nelson CW, 2020, MOL BIOL EVOL, V37, P2440, DOI 10.1093/molbev/msaa087; Pavesi A, 1997, J MOL EVOL, V44, P625, DOI 10.1007/PL00006185; Pavesi A, 2020, VIROLOGY, V546, P51, DOI 10.1016/j.virol.2020.03.007; Pavesi A, 2019, VIROLOGY, V532, P39, DOI 10.1016/j.virol.2019.03.017; Pavesi A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202513; Pavesi A, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003162; Pluta A, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101079; Pushker R, 2010, J VIROL, V84, P3644, DOI 10.1128/JVI.01959-09; Rancurel C, 2009, J VIROL, V83, P10719, DOI 10.1128/JVI.00595-09; Ribrioux S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-122; Sabath N, 2012, MOL BIOL EVOL, V29, P3767, DOI 10.1093/molbev/mss179; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001274; Savoret J, 2021, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.625941; Savoret J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00020; Singh M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-60; Sorek R, 2007, RNA, V13, P1603, DOI 10.1261/rna.682507; Taliansky M, 2003, J VIROL, V77, P3031, DOI 10.1128/JVI.77.5.3031-3040.2003; Taniguchi Y, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-64; Toll-Riera M, 2009, MOL BIOL EVOL, V26, P603, DOI 10.1093/molbev/msn281; Torresilla C, 2013, J VIROL, V87, P5089, DOI 10.1128/JVI.00225-13; van Knippenberg I, 2010, J GEN VIROL, V91, P2002, DOI 10.1099/vir.0.021774-0; Vanderperre B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070698; VANHEEBROSSOLLET C, 1995, VIROLOGY, V206, P196, DOI 10.1016/S0042-6822(95)80034-4; Wensman JJ, 2013, J GEN VIROL, V94, P263, DOI 10.1099/vir.0.047175-0; Willis S, 2018, GENETICS, V210, P303, DOI 10.1534/genetics.118.301249; Wilson GA, 2005, MICROBIOL-SGM, V151, P2499, DOI 10.1099/mic.0.28146-0; Yooseph S, 2007, PLOS BIOL, V5, P432, DOI 10.1371/journal.pbio.0050016; Yoshida M, 2008, J VIROL, V82, P9359, DOI 10.1128/JVI.00242-08; Zapata JC, 2017, VIROLOGY, V506, P34, DOI 10.1016/j.virol.2017.03.002; Zhao TJ, 2014, ARCH VIROL, V159, P1849, DOI 10.1007/s00705-014-2099-y; Zhou Q, 2008, GENOME RES, V18, P1446, DOI 10.1101/gr.076588.108	80	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							513	10.3390/vaccines9050513			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1WU	34067514	Green Published, gold			2022-04-29	WOS:000654617100001
J	Kang, HJ; Kim, MJ; Chu, KB; Lee, SH; Moon, EK; Quan, FS				Kang, Hae-Ji; Kim, Min-Ju; Chu, Ki-Back; Lee, Su-Hwa; Moon, Eun-Kyung; Quan, Fu-Shi			Passive Immunity and Antibody Response Induced by Toxoplasma gondii VLP Immunization	VACCINES			English	Article						Toxoplasma gondii; virus-like particle; CpG-ODN; antibody response; cytokine	CPG-OLIGODEOXYNUCLEOTIDES; PROTECTIVE IMMUNITY; PARTICLE VACCINE; INFECTION; SUPPRESSION; PREVENTION; STRATEGIES; INDUCTION; SERUM; MICE	Passive immunity can provide immediate protection against infectious pathogens. To date, only a few studies have investigated the effect of passive immunization against Toxoplasma gondii, and the use of immune sera acquired from VLP-vaccinated mice for passive immunity assessment remains unreported. In this study, immune sera were produced by a single immunization with virus-like particles (VLPs) expressing the inner membrane complex (IMC), rhoptry protein 18 (ROP18), and microneme protein 8 (MIC8) of Toxoplasma gondii, with or without a CpG-ODN adjuvant. The passive immunization of immune sera conferred protection in mice, as indicated by their potent parasite-specific antibody response, lessened brain cyst counts, lower bodyweight loss, and enhanced survival. In order to confirm that the immune sera of the VLP-immunized mice were truly protective, the antibody responses and other immunological parameters were measured in the VLP-immunized mice. We found that VLP immunization induced higher levels of parasite-specific IgG, IgG subclass, and IgM antibody responses in the sera and intestines than in the controls. Enhanced Th1 and Th2-associated cytokines in the spleen, diminished brain cyst counts, and lessened body weight loss were found following T. gondii ME49 challenge infection. These results suggest that passive immunization with the immune sera acquired from VLP-vaccinated mice can confer adequate protection against T. gondii infection.	[Kang, Hae-Ji; Kim, Min-Ju; Chu, Ki-Back] Kyung Hee Univ, Grad Sch, Dept Biomed Sci, Seoul 02447, South Korea; [Lee, Su-Hwa; Moon, Eun-Kyung; Quan, Fu-Shi] Kyung Hee Univ, Sch Med, Dept Med Zool, Seoul 02447, South Korea; [Quan, Fu-Shi] Kyung Hee Univ, Dept Med Res Ctr Bioreact React Oxygen Species, Grad Sch, Sch Med, Seoul 02447, South Korea; [Quan, Fu-Shi] Kyung Hee Univ, Grad Sch, Sch Med, Biomed Sci Inst, Seoul 02447, South Korea		Quan, FS (通讯作者)，Kyung Hee Univ, Sch Med, Dept Med Zool, Seoul 02447, South Korea.; Quan, FS (通讯作者)，Kyung Hee Univ, Dept Med Res Ctr Bioreact React Oxygen Species, Grad Sch, Sch Med, Seoul 02447, South Korea.; Quan, FS (通讯作者)，Kyung Hee Univ, Grad Sch, Sch Med, Biomed Sci Inst, Seoul 02447, South Korea.	haedi1202@naver.com; mj16441@naver.com; ckb421@gmail.com; dltnghk228@nate.com; ekmoon@khu.ac.kr; fsquan@khu.ac.kr			National Research Foundation of Korea (NRF)National Research Foundation of Korea [2018R1A6A1A03025124]; Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [HV20C0085, HV20C0142]	This research was funded by the National Research Foundation of Korea (NRF), grant number 2018R1A6A1A03025124, and the Ministry of Health & Welfare, Republic of Korea [HV20C0085, HV20C0142].	ARAUJO FG, 1974, J IMMUNOL, V113, P1424; Arenas-Gamboa AM, 2008, INFECT IMMUN, V76, P2448, DOI 10.1128/IAI.00767-07; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Chuang SC, 2017, PARASITE, V24, DOI 10.1051/parasite/2017004; Dubey JP, 2009, VET PARASITOL, V163, P1, DOI 10.1016/j.vetpar.2009.02.026; EL-Malky MA, 2014, PARASITOL RES, V113, P2277, DOI 10.1007/s00436-014-3882-0; FOSTER BG, 1968, CAN J MICROBIOL, V14, P103, DOI 10.1139/m68-018; FRENKEL JK, 1982, INFECT IMMUN, V38, P360, DOI 10.1128/IAI.38.1.360-367.1982; Hanagata N, 2017, INT J NANOMED, V12, P515, DOI 10.2147/IJN.S114477; HOWE DK, 1995, J INFECT DIS, V172, P1561, DOI 10.1093/infdis/172.6.1561; Justiz Vaillant A.A., 2021, IMMUNOGLOBULIN; Kang HJ, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12100989; Kang HJ, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12799; Kang HJ, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070342; Kim MC, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11040188; Klinman DM, 2004, IMMUNOL REV, V199, P201, DOI 10.1111/j.0105-2896.2004.00148.x; Kringel H, 2004, VET PARASITOL, V123, P55, DOI 10.1016/j.vetpar.2004.01.021; Kum DB, 2020, EMERG MICROBES INFEC, V9, P520, DOI 10.1080/22221751.2020.1730709; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Lau YL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157901; Lee DH, 2016, ACTA TROP, V164, P77, DOI 10.1016/j.actatropica.2016.08.025; Lee SH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220865; Lee SH, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03073; Lee SH, 2018, VACCINE, V36, P5692, DOI 10.1016/j.vaccine.2018.08.016; Lee SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175644; Lipford GB, 1997, EUR J IMMUNOL, V27, P2340, DOI 10.1002/eji.1830270931; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MASIHI KN, 1977, ZBL BAKT-INT J MED M, V237, P405; MASIHI KN, 1977, EXPERIENTIA, V33, P1586, DOI 10.1007/BF01934012; MASIHI KN, 1978, ZBL BAKT-INT J MED M, V240, P135; Milicic A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07246-0; Mine Yoshinori, 2002, Journal of Medicinal Food, V5, P159, DOI 10.1089/10966200260398198; Mohamed RM, 2003, VACCINE, V21, P2852, DOI [10.1016/S0264-410X(03)00157-9, 10.1016/s0264-410X(03)00157-9]; Pappas G, 2009, INT J PARASITOL, V39, P1385, DOI 10.1016/j.ijpara.2009.04.003; PAVIA CS, 1986, J IMMUNOL, V137, P2985; Pittman KJ, 2015, MICROBIOL MOL BIOL R, V79, P387, DOI 10.1128/MMBR.00027-15; Quan FS, 2007, J VIROL, V81, P3514, DOI 10.1128/JVI.02052-06; Quan FS, 2013, VIRAL IMMUNOL, V26, P385, DOI 10.1089/vim.2013.0013; Quan FS, 2012, VACCINE, V30, P180, DOI 10.1016/j.vaccine.2011.11.028; Lopes FMR, 2007, BRAZ J INFECT DIS, V11, P496, DOI 10.1590/S1413-86702007000500011; Saadatnia G, 2012, SCAND J INFECT DIS, V44, P805, DOI 10.3109/00365548.2012.693197; Santamaria MH, 2016, PARASITOLOGY, V143, P60, DOI 10.1017/S0031182015001456; Simell B, 2012, CLIN VACCINE IMMUNOL, V19, P1618, DOI 10.1128/CVI.00248-12; Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P600; Villafana T, 2017, EXPERT REV VACCINES, V16, P737, DOI 10.1080/14760584.2017.1333425; Yang Y, 2019, INT IMMUNOPHARMACOL, V69, P279, DOI 10.1016/j.intimp.2019.01.024; Ye JQ, 2012, IMMUNOTHERAPY-UK, V4, P175, DOI [10.2217/imt.11.167, 10.2217/IMT.11.167]	48	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							425	10.3390/vaccines9050425			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3EX	33922808	gold, Green Published			2022-04-29	WOS:000654709500001
J	Kim, Y; Hwang, JY; Lee, KM; Lee, E; Park, H				Kim, Yunhwa; Hwang, Ji-Young; Lee, Kyung-Min; Lee, Eunsil; Park, Hosun			Cross-Sectional Study of Varicella Zoster Virus Immunity in Healthy Korean Children Assessed by Glycoprotein Enzyme-Linked Immunosorbent Assay and Fluorescent Antibody to Membrane Antigen Test	VACCINES			English	Article						varicella; vaccine; immunity; glycoprotein; ELISA; FAMA	VACCINE EFFECTIVENESS; UNITED-STATES; OUTBREAK; EPIDEMIOLOGY; COVERAGE; PROGRAM; IMPACT	The prevalence of varicella is especially high among children in the age group of 4-6 years in South Korea, regardless of vaccination. We investigated the immune status of healthy children enrolled in day-care centers and compared pre- and post-vaccination immunity. Antibody titers were measured using a glycoprotein enzyme-linked immunosorbent assay (gpEIA) kit, and the seroconversion rate was assessed using a fluorescent antibody to membrane antigen (FAMA) test. Among 541 vaccinated children, 109 (20.1%) had breakthrough varicella. However, 13 (72.2%) of the 18 unvaccinated children had a history of varicella. The gpEIA geometric mean titers (GMTs) of pre- and 5 weeks post-vaccination in 1-year-old children were 14.7 and 72 mIU/mL, respectively, and the FAMA seroconversion rate was 91.1%. The gpEIA GMTs of 2-, 3-, 4-, 5-, and 6-year-old children were 104.1, 133.8, 223.5, 364.1, and 353.0 mIU/mL, respectively. Even though the gpEIA GMT increased with age, the pattern of gpEIA titer distribution in 4- to 6-year-old vaccinees without varicella history represented both waning immunity and natural boosting immunity. These results suggest that some vaccinees are vulnerable to varicella infection. Therefore, it is necessary to consider a two-dose varicella vaccine regimen in South Korea.	[Kim, Yunhwa; Hwang, Ji-Young; Lee, Kyung-Min; Park, Hosun] Yeungnam Univ, Dept Microbiol, Coll Med, Daegu 42415, South Korea; [Lee, Eunsil] Yeungnam Univ, Dept Pediat, Coll Med, Daegu 42415, South Korea; [Park, Hosun] Yeungnam Univ, Clin Trial Ctr, Immunogen Evaluat Lab, Med Ctr, Daegu 42415, South Korea		Park, H (通讯作者)，Yeungnam Univ, Dept Microbiol, Coll Med, Daegu 42415, South Korea.; Park, H (通讯作者)，Yeungnam Univ, Clin Trial Ctr, Immunogen Evaluat Lab, Med Ctr, Daegu 42415, South Korea.	linbi@ynu.ac.kr; generous81@naver.com; blackxg@naver.com; les2055@ynu.ac.kr; hspark@ynu.ac.kr			Ministry of Food and Drug SafetyMinistry of Food & Drug Safety (MFDS) [09122KFDA423, 13172KFDA315]	This research was funded by the Ministry of Food and Drug Safety in 2009 and 2013, grant numbers 09122KFDA423 and 13172KFDA315.	[Anonymous], Statistics for Inoculation Rate in Varicella Vaccine; [Anonymous], INFECT DIS SURVEILLA; [Anonymous], 2015, NCIRS FACT SHEET VAR; Arnedo-Pena A, 2006, PEDIATR INFECT DIS J, V25, P774, DOI 10.1097/01.inf.0000232631.06763.8b; Chan YWD, 2020, HUM VACC IMMUNOTHER, V16, P499, DOI 10.1080/21645515.2019.1663121; Choi UY, 2016, HUM VACC IMMUNOTHER, V12, P2560, DOI 10.1080/21645515.2016.1190056; Galil K, 2002, PEDIATR INFECT DIS J, V21, P931, DOI 10.1097/00006454-200210000-00009; Cenoz MG, 2013, EUROSURVEILLANCE, V18, P2; GERSHON AA, 1975, PEDIATRICS, V56, P1005; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; Jeon JS, 2016, VIROLOGY, V496, P277, DOI 10.1016/j.virol.2016.06.017; Jung J, 2019, J KOREAN MED SCI, V34, DOI 10.3346/jkms.2019.34.e53; Kang Jin Han, 2000, Pediatric Infection and Vaccine, V7, P129; Kim Keon Yeop, 2012, J Prev Med Public Health, V45, P267, DOI 10.3961/jpmph.2012.45.4.267; Kim YH, 2014, YONSEI MED J, V55, P459, DOI 10.3349/ymj.2014.55.2.459; Kurugol Z, 2011, INT J INFECT DIS, V15, pE475, DOI 10.1016/j.ijid.2011.03.016; Lee H., 2005, SURVEY EFFICACY SAFE, V139; Lee H.K., 2007, P 57 ANN FALL M KOR, P90; Lee H, 2013, J KOREAN MED SCI, V28, P195, DOI 10.3346/jkms.2013.28.2.195; Lee YH, 2016, J KOREAN MED SCI, V31, P1897, DOI 10.3346/jkms.2016.31.12.1897; Meyer PA, 2000, J INFECT DIS, V182, P383, DOI 10.1086/315714; Michalik DE, 2008, J INFECT DIS, V197, P944, DOI 10.1086/529043; NDUMBE PM, 1988, J MED VIROL, V25, P171, DOI 10.1002/jmv.1890250207; Offit P. A., 2013, VACCINES-BASEL, V6th; Oh SH, 2014, CLIN VACCINE IMMUNOL, V21, P762, DOI 10.1128/CVI.00645-13; Ozaki T, 2013, J INFECT CHEMOTHER, V19, P188, DOI 10.1007/s10156-013-0577-x; Park B, 2011, J KOREAN MED SCI, V26, P711, DOI 10.3346/jkms.2011.26.6.711; Pozza F, 2011, VACCINE, V29, P9480, DOI 10.1016/j.vaccine.2011.10.022; Shapiro ED, 2011, J INFECT DIS, V203, P312, DOI 10.1093/infdis/jiq052; Siedler A, 2010, EUROSURVEILLANCE, V15, P14; Spackova M, 2010, VACCINE, V28, P686, DOI 10.1016/j.vaccine.2009.10.086; Tafuri S, 2013, HUM VACC IMMUNOTHER, V9, P184, DOI 10.4161/hv.22373; Tafuri S, 2010, VACCINE, V28, P1594, DOI 10.1016/j.vaccine.2009.11.047; Vazquez M, 2001, NEW ENGL J MED, V344, P955, DOI 10.1056/NEJM200103293441302; WILLIAMS V, 1974, J INFECT DIS, V130, P669, DOI 10.1093/infdis/130.6.669; Workowski Kimberly A, 2010, MMWR Recomm Rep, V59, P1	36	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							492	10.3390/vaccines9050492			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1FS	34065863	Green Published, gold			2022-04-29	WOS:000654572600001
J	Saillard, M; Cenerenti, M; Romero, P; Jandus, C				Saillard, Margaux; Cenerenti, Mara; Romero, Pedro; Jandus, Camilla			Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer	VACCINES			English	Review						CD4 T cells; immunotherapy; antigen-specific; cancer; immune monitoring	ANTITUMOR IMMUNE-RESPONSES; MESSENGER-RNA VACCINE; TUMOR-REACTIVE CD4(+); METASTATIC MELANOMA; DENDRITIC CELLS; CHECKPOINT BLOCKADE; MAGE-3 PROTEIN; LUNG-CANCER; TH9 CELLS; ANTIGEN	Immunotherapy has become a standard treatment in many cancers and it is based on three main therapeutic axes: immune checkpoint blockade (ICB), vaccination and adoptive cell transfer (ACT). If originally these therapies mainly focused on exploiting CD8 T cells given their role in the direct elimination of tumor cells, increasing evidence highlights the crucial role CD4 T cells play in the antitumor immune response. Indeed, these cells can profoundly modulate the tumor microenvironment (TME) by secreting different types of cytokine or by directly eliminating cancer cells. In this review, we describe how different CD4 T cell subsets can contribute to tumor immune responses during immunotherapy and the novel high-throughput immune monitoring tools that are expected to facilitate the study of CD4 T cells, at antigen-specific and single cell level, thus accelerating bench-to-bed translational research in cancer.	[Saillard, Margaux; Romero, Pedro] Univ Lausanne, Dept Oncol, CH-1006 Epalinges, Switzerland; [Cenerenti, Mara; Jandus, Camilla] Univ Geneva, Dept Pathol & Immunol, Fac Med, CH-1211 Geneva, Switzerland; [Cenerenti, Mara; Jandus, Camilla] Ludwig Inst Canc Res, Lausanne Branch, CH-1006 Epalinges, Switzerland		Jandus, C (通讯作者)，Univ Geneva, Dept Pathol & Immunol, Fac Med, CH-1211 Geneva, Switzerland.; Jandus, C (通讯作者)，Ludwig Inst Canc Res, Lausanne Branch, CH-1006 Epalinges, Switzerland.	margaux.saillard@unil.ch; mara.cenerenti@unige.ch; pedro.romero@hospvd.ch; Camilla.Jandus@unige.ch		Saillard, Margaux/0000-0001-9467-1830; Jandus, Camilla/0000-0002-7405-5747; Cenerenti, Mara/0000-0001-6630-0557	San Salvatore Foundation	This work was supported by a grant from the San Salvatore Foundation.	Aarntzen EHJG, 2013, CANCER RES, V73, P19, DOI 10.1158/0008-5472.CAN-12-1127; Abdul-Wahid A, 2016, INT J CANCER, V139, P841, DOI 10.1002/ijc.30121; Abdulrahman Z, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000563; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Altomonte M, 2003, ONCOGENE, V22, P6564, DOI 10.1038/sj.onc.1206960; Amicarella F, 2017, GUT, V66, P692, DOI 10.1136/gutjnl-2015-310016; Asadzadeh Z, 2017, CELL IMMUNOL, V322, P15, DOI 10.1016/j.cellimm.2017.10.015; Atanackovic D, 2004, J IMMUNOL, V172, P3289, DOI 10.4049/jimmunol.172.5.3289; Atkinson V, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001681; Ayyoub M, 2010, CLIN CANCER RES, V16, P4607, DOI 10.1158/1078-0432.CCR-10-1485; Balanca CC, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142513; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Basu P, 2018, INT J GYNECOL CANCER, V28, P764, DOI 10.1097/IGC.0000000000001235; Baumgaertner P, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1216290; Bol KF, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0580-6; Bowyer S, 2016, BRIT J CANCER, V114, P1084, DOI 10.1038/bjc.2016.107; Bradshaw EM, 2008, CLIN IMMUNOL, V129, P10, DOI 10.1016/j.clim.2008.06.009; Brossart P, 2020, CLIN CANCER RES, V26, P4442, DOI 10.1158/1078-0432.CCR-20-0305; Cachot A, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe3348; Cafri G, 2020, J CLIN INVEST, V130, P5976, DOI 10.1172/JCI134915; Cappuccini F, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000928; Chandra J, 2021, CANCER IMMUNOL IMMUN, V70, P743, DOI 10.1007/s00262-020-02720-7; Chattopadhyay PK, 2014, NAT IMMUNOL, V15, P128, DOI 10.1038/ni.2796; Chen XH, 2018, ONCOL LETT, V16, P253, DOI 10.3892/ol.2018.8612; Choi JR, 2020, BIOTECHNIQUES, V69, P227, DOI 10.2144/btn-2020-0047; Choi YJ, 2020, CLIN CANCER RES, V26, P1616, DOI 10.1158/1078-0432.CCR-19-1513; Contreras A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0358-2; Costa-Nunes C, 2019, CLIN CANCER RES, V25, P4320, DOI 10.1158/1078-0432.CCR-18-1356; CZERKINSKY C, 1988, J IMMUNOL METHODS, V110, P29, DOI 10.1016/0022-1759(88)90079-8; De Keersmaecker B, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000329; Deng J, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0190-5; Dillard P, 2021, MOL THER, V29, P1199, DOI 10.1016/j.ymthe.2020.11.019; Dreno B, 2018, LANCET ONCOL, V19, P916, DOI 10.1016/S1470-2045(18)30254-7; Duftner C, 2003, ARTHRITIS RES THER, V5, pR292, DOI 10.1186/ar793; Duhen R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21383-1; Dura B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6940; Feng QH, 2012, GYNECOL ONCOL, V127, P412, DOI 10.1016/j.ygyno.2012.07.098; Fernandez-Poma SM, 2017, CANCER RES, V77, P3672, DOI 10.1158/0008-5472.CAN-17-0236; Ferris ST, 2020, NATURE, V584, P624, DOI 10.1038/s41586-020-2611-3; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101; Gacerez AT, 2018, CANCER GENE THER, V25, P117, DOI 10.1038/s41417-018-0012-7; Galluzzi L, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.967147; Garrido F, 2016, CURR OPIN IMMUNOL, V39, P44, DOI 10.1016/j.coi.2015.12.007; Geiger R, 2009, J EXP MED, V206, P1525, DOI 10.1084/jem.20090504; Gu-Trantien C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91487; Guan S, 2017, GENE THER, V24, P133, DOI 10.1038/gt.2017.5; Gunn GR, 2001, J IMMUNOL, V167, P6471, DOI 10.4049/jimmunol.167.11.6471; Haabeth OAW, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1039763; Hadrup SR, 2009, NAT METHODS, V6, P520, DOI 10.1038/nmeth.1345; Houot R, 2015, CANCER IMMUNOL RES, V3, P1115, DOI 10.1158/2326-6066.CIR-15-0190; Hu ZT, 2021, NAT MED, V27, P515, DOI 10.1038/s41591-020-01206-4; Huang YJ, 2007, ARCH IMMUNOL THER EX, V55, P205, DOI 10.1007/s00005-007-0029-3; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Jandus C, 2009, CANCER RES, V69, P8085, DOI 10.1158/0008-5472.CAN-09-2226; Kamada T, 2019, P NATL ACAD SCI USA, V116, P9999, DOI 10.1073/pnas.1822001116; Kandalaft LE, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22664; Karlsson AC, 2003, J IMMUNOL METHODS, V283, P141, DOI 10.1016/j.jim.2003.09.001; Kayser S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.1002723; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kim IK, 2015, NAT MED, V21, P1010, DOI 10.1038/nm.3922; Kitano S, 2013, CANCER IMMUNOL RES, V1, P235, DOI 10.1158/2326-6066.CIR-13-0068; Koski GK, 2012, J IMMUNOTHER, V35, P54, DOI 10.1097/CJI.0b013e318235f512; Kuball J, 2005, IMMUNITY, V22, P117, DOI 10.1016/j.immuni.2004.12.005; Kwok WW, 2003, CLIN IMMUNOL, V106, P23, DOI 10.1016/S1521-6616(02)00018-9; Laheurte C, 2019, BRIT J CANCER, V121, P405, DOI 10.1038/s41416-019-0531-5; Lee ST, 2007, YONSEI MED J, V48, P1, DOI 10.3349/ymj.2007.48.1.1; Li XK, 2018, SMALL, V14, DOI 10.1002/smll.201800698; Li XK, 2017, LAB CHIP, V17, P2208, DOI 10.1039/c7lc00277g; Lines JL, 2014, CANCER RES, V74, P1924, DOI 10.1158/0008-5472.CAN-13-1504; Ling A, 2016, J PATHOL CLIN RES, V2, P21, DOI 10.1002/cjp2.31; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Lu Y, 2012, J CLIN INVEST, V122, P4160, DOI 10.1172/JCI65459; Lu YC, 2017, J CLIN ONCOL, V35, P3322, DOI 10.1200/JCO.2017.74.5463; Marchand M, 2003, EUR J CANCER, V39, P70, DOI 10.1016/S0959-8049(02)00479-3; Maruhashi T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001014; McCann KJ, 2016, CLIN CANCER RES, V22, P4827, DOI 10.1158/1078-0432.CCR-15-2507; McNeel DG, 2019, J CLIN ONCOL, V37, P3507, DOI 10.1200/JCO.19.01701; Melief CJM, 2015, J CLIN INVEST, V125, P3401, DOI 10.1172/JCI80009; Meng XY, 2018, ONCOL LETT, V16, P3917, DOI 10.3892/ol.2018.9112; Merouane A, 2015, BIOINFORMATICS, V31, P3189, DOI 10.1093/bioinformatics/btv355; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Nagasaki J, 2020, BLOOD ADV, V4, P4069, DOI 10.1182/bloodadvances.2020002098; Newell EW, 2009, NAT METHODS, V6, P497, DOI 10.1038/nmeth.1344; Oh DY, 2020, CELL, V181, P1612, DOI 10.1016/j.cell.2020.05.017; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Ott PA, 2020, CELL, V183, P347, DOI 10.1016/j.cell.2020.08.053; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Papachristofilou A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0520-5; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Patrinely JR, 2020, EUR J CANCER, V135, P211, DOI 10.1016/j.ejca.2020.05.005; Peeters LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01160; Perez CR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13368-y; Perez-Diez A, 2007, BLOOD, V109, P5346, DOI 10.1182/blood-2006-10-051318; Perret R, 2013, CANCER RES, V73, P6597, DOI 10.1158/0008-5472.CAN-13-0875; Phan-Lai V, 2016, CLIN CANCER RES, V22, P2207, DOI 10.1158/1078-0432.CCR-15-2273; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]; Preglej T, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133393; Purwar R, 2012, NAT MED, V18, P1248, DOI 10.1038/nm.2856; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Rockinger GA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000435; Romano E, 2015, P NATL ACAD SCI USA, V112, P6140, DOI 10.1073/pnas.1417320112; Romero P, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf0685; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Sabbatini P, 2012, CLIN CANCER RES, V18, P6497, DOI 10.1158/1078-0432.CCR-12-2189; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Salomon N, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1771925; Scurr M, 2012, CELL IMMUNOL, V279, P21, DOI 10.1016/j.cellimm.2012.08.004; Shah NN, 2020, J CLIN ONCOL, V38, P1938, DOI 10.1200/JCO.19.03279; Sharma A, 2019, CLIN CANCER RES, V25, P1233, DOI 10.1158/1078-0432.CCR-18-0762; Sharma A, 2012, CANCER-AM CANCER SOC, V118, P4354, DOI 10.1002/cncr.26734; Shen YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10889-4; Shi WW, 2014, DNA CELL BIOL, V33, P355, DOI 10.1089/dna.2013.2332; Shitara K, 2018, ANN NY ACAD SCI, V1417, P104, DOI 10.1111/nyas.13625; Sledzinska A, 2020, IMMUNITY, V52, P151, DOI 10.1016/j.immuni.2019.12.007; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Stoll G, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27884; Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110; Tanyi JL, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00297-5; Tay RE, 2021, CANCER GENE THER, V28, P5, DOI 10.1038/s41417-020-0183-x; Tel J, 2013, CANCER RES, V73, P1063, DOI 10.1158/0008-5472.CAN-12-2583; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Torres AJ, 2014, ANAL CHEM, V86, P11562, DOI 10.1021/ac4030297; Torres AJ, 2013, LAB CHIP, V13, P90, DOI 10.1039/c2lc40869d; Tosch C, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0274-x; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Trimble CL, 2015, LANCET, V386, P2078, DOI 10.1016/S0140-6736(15)00239-1; Tsui NBY, 2002, CLIN CHEM, V48, P1647; van Poelgeest MIE, 2016, CLIN CANCER RES, V22, P2342, DOI 10.1158/1078-0432.CCR-15-2594; Vansteenkiste JF, 2016, LANCET ONCOL, V17, P822, DOI 10.1016/S1470-2045(16)00099-1; Vargas FA, 2018, CANCER CELL, V33, P649, DOI 10.1016/j.ccell.2018.02.010; Vegran F, 2015, CANCER RES, V75, P475, DOI 10.1158/0008-5472.CAN-14-2748; Verma S, 2016, J VIROL, V90, P650, DOI 10.1128/JVI.02123-15; Wang DR, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99048; Wang Y, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01311-z; Wargowski E, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0333-y; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Xie XX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.563044; Xie Y, 2010, J EXP MED, V207, P651, DOI 10.1084/jem.20091921; Yang YM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1209; Zaidi N, 2019, ANN NY ACAD SCI, V1445, P62, DOI 10.1111/nyas.14049; Zappasodi R, 2019, NAT MED, V25, P759, DOI 10.1038/s41591-019-0420-8; Zaretsky I, 2012, LAB CHIP, V12, P5007, DOI 10.1039/c2lc40808b; Zhang Y, 2005, EUR J IMMUNOL, V35, P1066, DOI 10.1002/eji.200425847; Zhang Y, 2005, J IMMUNOL, V174, P2404, DOI 10.4049/jimmunol.174.4.2404; Zhuang Y, 2012, CANCER IMMUNOL IMMUN, V61, P1965, DOI 10.1007/s00262-012-1241-5; Zuazo M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910293; Zwaveling S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/jimmunol.169.1.350	155	3	3	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							454	10.3390/vaccines9050454			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1FK	34064410	gold, Green Published			2022-04-29	WOS:000654571700001
J	Stefanizzi, P; De Nitto, S; Spinelli, G; Lattanzio, S; Stella, P; Ancona, D; Dell'Aera, M; Padovano, M; Soldano, S; Tafuri, S; Bianchi, FP				Stefanizzi, Pasquale; De Nitto, Sara; Spinelli, Giuseppe; Lattanzio, Sabrina; Stella, Paolo; Ancona, Domenica; Dell'Aera, Maria; Padovano, Margherita; Soldano, Savino; Tafuri, Silvio; Bianchi, Francesco Paolo			Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study	VACCINES			English	Article						post-marketing active surveillance; vaccination; influenza; causality assessment; adverse reactions	EVENTS; CHILDREN	Since the influenza season 2018/19, the Italian Ministry of Health recommended a dose of cell-based quadrivalent vaccine (Flucelvax Tetra) for HCWs (healthcare workers), because this vaccine seemed more efficacious in the prevention of AH3N2 virus. Due to the lack of pre-registration data, the safety profile of this new vaccine must be investigated in post-marketing surveillance. The aim of our study is to evaluate, through a post-marketing active surveillance program developed during the 2019/20 influenza season, any Adverse Events Following Immunization (AEFIs) that happened in the 7 days after immunization with Flucelvax Tetra. The study was carried out in a sample of HCWs of Policlinico General University-Hospital (Apulia, South Italy). AEFIs were classified as 'serious' or 'not serious' according to the WHO (World Health Organization) guidelines; the WHO causality assessment algorithm was applied to classify serious AEFIs. A total of 741 HCWs were enrolled, and 430 AEFIs (reporting rate: 58.0 (95%CI: 54.4-61.6) x 100 enrolled) were recorded. Of these, 429 of 430 (99.8%; reporting rate: 57.8 (95%CI: 54.2-61.5) x 100 enrolled) were classified as not serious and one (0.2%; reporting rate: 0.13 (0.03-0.75) x 100 enrolled) was classified as serious. Local reactions were the adverse reaction reported most frequently (88%); regarding the serious AEFI, causality assessment excluded the causal link with the administration of the vaccine. All the AEFIs resolved without sequelae. Flucelvax Tetra showed a profile of high safety. Due to their characteristics of greater sensitivity than passive surveillance, active surveillance programs can be useful in defining the safety profiles of a given vaccine/drug in certain population subgroups.	[Stefanizzi, Pasquale; De Nitto, Sara; Spinelli, Giuseppe; Lattanzio, Sabrina; Tafuri, Silvio; Bianchi, Francesco Paolo] Aldo Moro Univ Bari, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy; [Stella, Paolo; Ancona, Domenica] Reg Ctr Pharmacovigilance, I-52100 Puglia, Italy; [Dell'Aera, Maria; Padovano, Margherita] Bari Policlin Gen Hosp, Dept Pharm, I-70124 Bari, Italy; [Soldano, Savino] Bari Policlin Gen Hosp, Hlth Hosp Management, I-70124 Bari, Italy		Tafuri, S (通讯作者)，Aldo Moro Univ Bari, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy.	pasquale.stefanizzi@uniba.it; sara.denitto@asl.bari.it; giuseppe.spinelli@uniba.it; sabrina.lattanzio@uniba.it; p.stella@regione.puglia.it; domenica.ancona@aslbat.it; Maria.dellaera@policlinico.ba.it; margherita.padovano@policlinico.ba.it; savino.soldano@policlinico.ba.it; silvio.tafuri@uniba.it; dr.francesco.bianchi@gmail.com	Bianchi, Francesco Paolo/AAU-2597-2020	Bianchi, Francesco Paolo/0000-0002-9659-0193; tafuri, silvio/0000-0003-4194-0210	Puglia Region, Center for Phamacovigilance	Study was supported by Puglia Region, Center for Phamacovigilance.	AIFA, GUID VAL REAZ AVV OS; Alegiani SS, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6260-5; Bianchi FP, 2020, AM J INFECT CONTROL, V48, P368, DOI 10.1016/j.ajic.2019.09.024; Black CL, 2018, MMWR-MORBID MORTAL W, V67, P1050, DOI 10.15585/mmwr.mm6738a2; CDC, REC VACC HEALTHC WOR; Centers for Disease Control and Prevention (CDC), CELL BAS FLU VACC; Danova J, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4083-4; European Commission, SUMM DEC EUR UN REL; European Medicines Agency, FLUC TETR INFL VACC; European Medicines Agency, 2014, ADD GUID ENH SAF SUR; Griffin MR, 2009, AM J PUBLIC HEALTH, V99, pS345, DOI 10.2105/AJPH.2008.143081; Hazell L, 2006, DRUG SAFETY, V29, P385, DOI 10.2165/00002018-200629050-00003; Italian Government, LEGISLATIVE DECREE N; Italian Ministry of Health, PREV CONTR INFL REC; Marquez EJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14396-9; Maurici M, 2019, HUM VACC IMMUNOTHER, V15, P631, DOI 10.1080/21645515.2018.1536587; Newes-Adeyi G, 2012, VACCINE, V30, P1050, DOI 10.1016/j.vaccine.2011.12.041; Pillsbury A, 2015, EUROSURVEILLANCE, V20, P6, DOI 10.2807/1560-7917.ES.2015.20.43.30050; Prato R, 2010, EXPERT REV VACCINES, V9, P277, DOI 10.1586/ERV.10.11; Regan AK, 2015, VACCINE, V33, P3689, DOI [10.1016/j.vaccine.2015.06.022, 10]; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; Signorelli C, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h116; Stefanizzi P, 2020, HUM VACC IMMUNOTHER, V16, P1875, DOI 10.1080/21645515.2019.1704124; Stefanizzi P, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040140; U.S. National Library. Clinical Trial.gov, 2015, SAF IMM 3 INFL VACC; Vimercati L, 2019, HUM VACC IMMUNOTHER, V15, P2927, DOI 10.1080/21645515.2019.1625645; World Health Organization, 2018, US MAN REV WHO CLASS	27	4	4	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							456	10.3390/vaccines9050456			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1YP	34064483	gold, Green Published			2022-04-29	WOS:000654621800001
J	Sulman, S; Savidge, BO; Alqaseer, K; Das, MK; Abadi, NN; Pearl, JE; Turapov, O; Mukamolova, GV; Akhtar, MW; Cooper, AM				Sulman, Sadaf; Savidge, Benjamin O.; Alqaseer, Kawther; Das, Mrinal K.; Abadi, Neda Nezam; Pearl, John E.; Turapov, Obolbek; Mukamolova, Galina V.; Akhtar, M. Waheed; Cooper, Andrea May			Balance between Protection and Pathogenic Response to Aerosol Challenge with Mycobacterium tuberculosis (Mtb) in Mice Vaccinated with TriFu64, a Fusion Consisting of Three Mtb Antigens	VACCINES			English	Article						tuberculosis; vaccine; antigen; weight loss	BCG VACCINATION; INFECTION; IMMUNITY	Tuberculosis vaccines capable of reducing disease worldwide have proven difficult to develop. BCG is effective in limiting childhood disease, but adult TB is still a major public health issue. Development of new vaccines requires identification of antigens that are both spatially and temporally available throughout infection, and immune responses to which reduce bacterial burden without increasing pathologic outcomes. Subunit vaccines containing antigen require adjuvants to drive appropriate long-lived responses. We generated a triple-antigen fusion containing the virulence-associated EsxN (Rv1793), the PPE42 (Rv2608), and the latency associated Rv2628 to investigate the balance between bacterial reduction and weight loss in an animal model of aerosol infection. We found that in both a low pattern recognition receptor (PRR) engaging adjuvant and a high PRR-engaging adjuvant (MPL/TDM/DDA) the triple-antigen fusion could reduce the bacterial burden, but also induced weight loss in the mice upon aerosol infection. The weight loss was associated with an imbalance between TNF alpha and IL-17 transcription in the lung upon challenge. These data indicate the need to assess both protective and pathogenic responses when investigating subunit vaccine activity.	[Sulman, Sadaf; Savidge, Benjamin O.; Alqaseer, Kawther; Das, Mrinal K.; Abadi, Neda Nezam; Pearl, John E.; Turapov, Obolbek; Mukamolova, Galina V.; Cooper, Andrea May] Univ Leicester, Dept Resp Sci, Leicester LE1 7RH, Leics, England; [Sulman, Sadaf; Akhtar, M. Waheed] Univ Punjab, Sch Biol Sci, Lahore 54590, Pakistan; [Savidge, Benjamin O.; Alqaseer, Kawther; Das, Mrinal K.; Pearl, John E.; Turapov, Obolbek; Mukamolova, Galina V.; Cooper, Andrea May] Univ Leicester, Leicester TB Res Grp LTBRG, Leicester LE1 7RH, Leics, England; [Alqaseer, Kawther] Univ Kufa, Fac Nursing, Dept Basic Sci, POB 21, Najaf Governorate 540011, Najaf, Iraq; [Abadi, Neda Nezam] Univ Coll Cork, APC Microbiome Ireland, Cork T12 YT20, Ireland		Cooper, AM (通讯作者)，Univ Leicester, Dept Resp Sci, Leicester LE1 7RH, Leics, England.; Cooper, AM (通讯作者)，Univ Leicester, Leicester TB Res Grp LTBRG, Leicester LE1 7RH, Leics, England.	sadafsulman.sbs@pu.edu.pk; bos8@le.ac.uk; kawthera.hasan@uokufa.edu.iq; mkd12@le.ac.uk; nnezamabadi@ucc.ie; jep38@le.ac.uk; ot16@le.ac.uk; gvm4@le.ac.uk; mwa.sbs@pu.edu.pk; amc72@le.ac.uk		Nezamabadi, Neda/0000-0001-6853-084X; SAVIDGE, Benjamin/0000-0002-3779-8787; Cooper, Andrea/0000-0001-6050-3863	MRC-UKRIUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/P011136/1]; Royal SocietyRoyal Society of LondonEuropean Commission [WM150032]; Pakistan Academy of Sciences; Commonwealth Split-site Scholarship [PKCN-2017-158]; Higher Education and Scientific Research Iraq; Newton International Fellowship [NF160754]; UK Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/P001513/1]	This work was supported by MRC-UKRI, grant number MR/P011136/1 and the Royal Society, grant number WM150032 to AMC; a Pakistan Academy of Sciences grant to MWA; a Commonwealth Split-site Scholarship (PKCN-2017-158) to SS; Support from Higher Education and Scientific Research Iraq to KA; a Newton International Fellowship grant number NF160754 to MKD; a UK Biotechnology and Biological Sciences Research Council grant BB/P001513/1 to GVM.	Akhter M, 2020, TUBERCULOSIS, V124, DOI 10.1016/j.tube.2020.101981; Andersen P, 2019, NAT REV IMMUNOL, V19, P550, DOI 10.1038/s41577-019-0174-z; Arlehamn CSL, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018465; Bertholet S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001094; Brazier B, 2020, SEMIN IMMUNOPATHOL, V42, P315, DOI 10.1007/s00281-020-00794-0; Cooper AM, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a018556; Cooper AM, 2012, CURR OPIN IMMUNOL, V24, P431, DOI 10.1016/j.coi.2012.04.008; Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703; Cruz A, 2010, J EXP MED, V207, P1609, DOI 10.1084/jem.20100265; Day TA, 2021, LANCET RESP MED, V9, P373, DOI 10.1016/S2213-2600(20)30319-2; Ewann F, 2002, INFECT IMMUN, V70, P2256, DOI 10.1128/IAI.70.5.2256-2263.2002; Horton KC, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002119, 10.1371/journal.pmed.1002152]; Junqueira-Kipnis AP, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00188; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Khurshid S, 2013, TUBERCULOSIS, V93, P654, DOI 10.1016/j.tube.2013.07.005; Kozak R, 2011, VACCINE, V29, P1519, DOI 10.1016/j.vaccine.2010.12.012; Li JY, 2015, CELL METAB, V22, P799, DOI 10.1016/j.cmet.2015.09.012; Lin PL, 2007, J INVEST DERM SYMP P, V12, P22, DOI 10.1038/sj.jidsymp.5650027; Lu Y, 2012, SCAND J IMMUNOL, V76, P271, DOI 10.1111/j.1365-3083.2012.02726.x; Moguche AO, 2017, CELL HOST MICROBE, V21, P695, DOI 10.1016/j.chom.2017.05.012; Moguche AO, 2015, J EXP MED, V212, P715, DOI 10.1084/jem.20141518; Orme IM, 2015, NAT IMMUNOL, V16, P57, DOI 10.1038/ni.3048; Pearl JE, 2004, J IMMUNOL, V173, P7490, DOI 10.4049/jimmunol.173.12.7490; Pearl JE, 2018, CELL MOL IMMUNOL, V15, P226, DOI 10.1038/cmi.2017.145; Prada-Medina CA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01767-4; Rhoades ER, 1997, TUBERCLE LUNG DIS, V78, P57, DOI 10.1016/S0962-8479(97)90016-2; Roberts AD, 2002, METHOD MICROBIOL, V32, P433; Robinson RT, 2015, IMMUNOL REV, V264, P46, DOI 10.1111/imr.12259; Roupie V, 2007, INFECT IMMUN, V75, P941, DOI 10.1128/IAI.01137-06; Shemer A, 2020, IMMUNITY, V53, P1033, DOI 10.1016/j.immuni.2020.09.018; Sulman S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050519; Torrado E, 2015, J EXP MED, V212, P1449, DOI 10.1084/jem.20141520; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Woodworth JS, 2014, J IMMUNOL, V192, P3247, DOI 10.4049/jimmunol.1300283	34	1	1	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							519	10.3390/vaccines9050519			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1HW	34070048	Green Published, gold			2022-04-29	WOS:000654578200001
J	Su, CM; Rowland, RRR; Yoo, D				Su, Chia-Ming; Rowland, Raymond Robert Richard; Yoo, Dongwan			Recent Advances in PRRS Virus Receptors and the Targeting of Receptor-Ligand for Control	VACCINES			English	Review						porcine reproductive and respiratory syndrome; receptor; PRRSV; CD163	RESPIRATORY SYNDROME VIRUS; EQUINE ARTERITIS VIRUS; TRANSMEMBRANE 4 SUPERFAMILY; CELL-LINES; ALVEOLAR MACROPHAGES; HEPARAN-SULFATE; CONFERS RESISTANCE; MOLECULAR-CLONING; CD163 EXPRESSION; FULLY RESISTANT	Cellular receptors play a critical role in viral infection. At least seven cellular molecules have been identified as putative viral entry mediators for porcine reproductive and respiratory syndrome virus (PRRSV). Accumulating data indicate that among these candidates, CD163, a cysteine-rich scavenger receptor on macrophages, is the major receptor for PRRSV. This review discusses the recent advances and understanding of the entry of PRRSV into cells, viral pathogenesis in CD163 gene-edited swine, and CD163 as a potential target of receptor-ligand for the control of PRRS.	[Su, Chia-Ming; Rowland, Raymond Robert Richard; Yoo, Dongwan] Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA		Yoo, D (通讯作者)，Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA.	cmsu2@illinois.edu; rowland7@illinois.edu; dyoo@illinois.edu	Yoo, Dongwan/AAG-8884-2021	Yoo, Dongwan/0000-0002-6730-9729; Su, Chia-Ming/0000-0001-9317-5886	Agriculture and Food Research Initiative (AFRI) Competitive Grants from the US Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) [2018-67015-28287, 2016-09462]	This project was supported by the Agriculture and Food Research Initiative (AFRI) Competitive Grants no. 2018-67015-28287 and 2016-09462, 2017-2021, from the US Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA).	Areschoug T, 2009, CELL MICROBIOL, V11, P1160, DOI 10.1111/j.1462-5822.2009.01326.x; BAUTISTA EM, 1993, J VET DIAGN INVEST, V5, P163, DOI 10.1177/104063879300500204; BENFIELD DA, 1992, J VET DIAGN INVEST, V4, P127, DOI 10.1177/104063879200400202; Burkard C, 2018, J VIROL, V92, DOI [10.1128/JVI.00415-18, 10.1128/jvi.00415-18]; Burkard C, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006206; Cai YY, 2015, J VIROL, V89, P844, DOI 10.1128/JVI.02697-14; Calvert JG, 2007, J VIROL, V81, P7371, DOI 10.1128/JVI.00513-07; Chen JY, 2019, INT J BIOL SCI, V15, P481, DOI 10.7150/ijbs.25862; Chen NH, 2011, J GEN VIROL, V92, P880, DOI 10.1099/vir.0.027995-0; Chen Y, 2014, VIRUS RES, V179, P85, DOI 10.1016/j.virusres.2013.11.008; Das PB, 2011, VIROLOGY, V410, P385, DOI 10.1016/j.virol.2010.12.002; Das PB, 2010, J VIROL, V84, P1731, DOI 10.1128/JVI.01774-09; Davis DAS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00470; Delputte PL, 2007, J VIROL, V81, P9546, DOI 10.1128/JVI.00569-07; Delputte PL, 2004, J VIROL, V78, P8094, DOI 10.1128/JVI.78.15.8094-8101.2004; Delputte PL, 2002, J VIROL, V76, P4312, DOI 10.1128/JVI.76.9.4312-4320.2002; DIJKSTRA CD, 1985, ADV EXP MED BIOL, V186, P409; Dobbe JC, 2001, VIROLOGY, V288, P283, DOI 10.1006/viro.2001.1074; Dokland T, 2010, VIRUS RES, V154, P86, DOI 10.1016/j.virusres.2010.07.029; Du TF, 2017, TRENDS MICROBIOL, V25, P968, DOI 10.1016/j.tim.2017.06.001; Duan X, 1997, ARCH VIROL, V142, P2483, DOI 10.1007/s007050050256; Duan XB, 1998, J VIROL, V72, P4520, DOI 10.1128/JVI.72.5.4520-4523.1998; Fitter S, 1999, BIOCHEM J, V338, P61, DOI 10.1042/0264-6021:3380061; Gao JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep25120; Giroglou T, 2001, J VIROL, V75, P1565, DOI 10.1128/JVI.75.3.1565-1570.2001; Guo CH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01846; Guo LJ, 2014, J VIROL, V88, P10448, DOI 10.1128/JVI.01117-14; Guo ZH, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0910-6; Hedges JF, 2001, IMMUNOLOGY, V103, P498, DOI 10.1046/j.1365-2567.2001.01262.x; Heikema AP, 2010, INFECT IMMUN, V78, P3237, DOI 10.1128/IAI.01273-09; Hintz KA, 2002, J LEUKOCYTE BIOL, V72, P711; Hou GP, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01815; Huang C, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01361-7; Huang YW, 2009, DEV COMP IMMUNOL, V33, P464, DOI 10.1016/j.dci.2008.09.010; Jackson T, 1996, J VIROL, V70, P5282, DOI 10.1128/JVI.70.8.5282-5287.1996; Jiang CL, 2013, DEV COMP IMMUNOL, V39, P127, DOI 10.1016/j.dci.2012.01.003; Johnson CR, 2011, J GEN VIROL, V92, P1107, DOI 10.1099/vir.0.030213-0; Jones C, 2003, MOL MICROBIOL, V49, P1213, DOI 10.1046/j.1365-2958.2003.03634.x; Joo EE, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4510; Jusa ER, 1997, AM J VET RES, V58, P488; Kappes MA, 2015, VIROLOGY, V479, P475, DOI 10.1016/j.virol.2015.02.012; Karniychuk UU, 2013, VIRUS RES, V176, P285, DOI 10.1016/j.virusres.2013.05.005; Karniychuk UU, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-30; KIM HS, 1993, ARCH VIROL, V133, P477, DOI 10.1007/BF01313785; Kim JK, 2006, J VIROL, V80, P689, DOI 10.1128/JVI.80.2.689-696.2006; KONISHI S, 1975, JPN J VET SCI, V37, P259; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Kuhn JH, 2016, ARCH VIROL, V161, P755, DOI 10.1007/s00705-015-2672-z; Lee YJ, 2010, ARCH VIROL, V155, P1319, DOI 10.1007/s00705-010-0699-8; Lee YJ, 2010, J VIROL METHODS, V163, P410, DOI 10.1016/j.jviromet.2009.11.003; Li LL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010040; Li LL, 2018, ANTIVIR RES, V156, P10, DOI 10.1016/j.antiviral.2018.06.001; Li LL, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0399-5; Li Y, 2018, VIROLOGY, V517, P164, DOI 10.1016/j.virol.2017.12.017; Li YH, 2015, VIRUS RES, V202, P48, DOI 10.1016/j.virusres.2014.12.027; Lozach Pierre-Yves, 2007, Methods Mol Biol, V379, P51; Lu ZC, 2012, VIROLOGY, V432, P99, DOI 10.1016/j.virol.2012.05.022; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Ma HF, 2017, J VIROL, V91, DOI 10.1128/JVI.01897-16; MAESS J, 1970, ARCH GES VIRUSFORSCH, V30, P47, DOI 10.1007/BF01262582; Magar R., 1995, Corona- and related viruses: current concepts in molecular biology and pathogenesis Laval, Quebec, Canada 27 August-1 September 1994., P139; MARDASSI H, 1994, CAN J VET RES, V58, P55; Mengeling WL, 1998, AM J VET RES, V59, P1540; Misinzo G, 2006, J VIROL, V80, P3487, DOI 10.1128/JVI.80.7.3487-3494.2006; Monteiro VG, 2005, PARASITOL RES, V97, P380, DOI 10.1007/s00436-005-1460-1; Morgan SB, 2013, VET MICROBIOL, V163, P13, DOI 10.1016/j.vetmic.2012.11.024; Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635; Nelsen CJ, 1999, J VIROL, V73, P270, DOI 10.1128/JVI.73.1.270-280.1999; Neumann EJ, 2005, JAVMA-J AM VET MED A, V227, P385, DOI 10.2460/javma.2005.227.385; Nielsen MJ, 2010, ANTIOXID REDOX SIGN, V12, P261, DOI 10.1089/ars.2009.2792; Onofre Gabriela, 2009, Acta Medica (Hradec Kralove), V52, P57; Patton JB, 2009, VIRUS RES, V140, P161, DOI 10.1016/j.virusres.2008.12.002; PLAGEMANN PGW, 1992, ADV VIRUS RES, V41, P99, DOI 10.1016/S0065-3527(08)60036-6; Prather RS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13794-2; Prather RS, 2013, J VIROL, V87, P9538, DOI 10.1128/JVI.00177-13; Provost C, 2017, VET MICROBIOL, V207, P143, DOI 10.1016/j.vetmic.2017.06.012; RADWAN AI, 1973, VIROLOGY, V51, P71, DOI 10.1016/0042-6822(73)90366-8; Rempel H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001967; ROBERTS JJ, 1995, BRIT J HAEMATOL, V89, P853; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Sagong M, 2012, J VIROL METHODS, V179, P26, DOI 10.1016/j.jviromet.2011.08.016; Sanchez C, 1999, J IMMUNOL, V162, P5230; Sanchez-Carvajal JM, 2019, VET RES COMMUN, V43, P187, DOI 10.1007/s11259-019-09755-x; Schaer CA, 2006, CIRC RES, V99, P943, DOI 10.1161/01.RES.0000247067.34173.1b; Shanmukhappa K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-62; Sincock PM, 1999, J CELL SCI, V112, P833; Snijder EJ, 1998, ADV EXP MED BIOL, V440, P97; Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; STUECKEMANN JA, 1982, J GEN VIROL, V59, P263, DOI 10.1099/0022-1317-59-2-263; Tian DB, 2012, J VIROL, V86, P3701, DOI 10.1128/JVI.06836-11; Tian KG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000526; Trible BR, 2015, J VIROL, V89, P6515, DOI 10.1128/JVI.03287-14; Van den Heuvel MM, 1999, J LEUKOCYTE BIOL, V66, P858, DOI 10.1002/jlb.66.5.858; Van Gorp H, 2008, J GEN VIROL, V89, P2943, DOI 10.1099/vir.0.2008/005009-0; Van Gorp H, 2010, MOL IMMUNOL, V47, P1650, DOI 10.1016/j.molimm.2010.02.008; Van Gorp H, 2010, J VIROL, V84, P3101, DOI 10.1128/JVI.02093-09; Van Gorp H, 2009, ARCH VIROL, V154, P1939, DOI 10.1007/s00705-009-0527-1; Vanderheijden N, 2003, J VIROL, V77, P8207, DOI 10.1128/JVI.77.15.8207-8215.2003; Vanderheijden N, 2001, ADV EXP MED BIOL, V494, P683; Verheije MH, 2002, VIROLOGY, V303, P364, DOI 10.1006/viro.2002.1711; Wang HT, 2019, INT J BIOL SCI, V15, P1993, DOI 10.7150/ijbs.34269; Wang J, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090876; Wang XP, 2019, J VIROL METHODS, V274, DOI 10.1016/j.jviromet.2019.113727; Wang XP, 2013, J VIROL METHODS, V193, P383, DOI 10.1016/j.jviromet.2013.06.035; Weesendorp E, 2013, VET MICROBIOL, V163, P1, DOI 10.1016/j.vetmic.2012.09.013; Weingartl HM, 2002, J VIROL METHODS, V104, P203, DOI 10.1016/S0166-0934(02)00085-X; Welch SKW, 2010, VIRUS RES, V154, P98, DOI 10.1016/j.virusres.2010.07.018; Wells KD, 2017, J VIROL, V91, DOI [10.1128/JVI.01521-16, 10.1128/jvi.01521-16]; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Whitworth KM, 2016, NAT BIOTECHNOL, V34, P20, DOI 10.1038/nbt.3434; Whitworth KM, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.121723; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wu JJ, 2014, MOL CELL BIOCHEM, V394, P275, DOI 10.1007/s11010-014-2103-6; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Xia WL, 2018, VET MICROBIOL, V219, P1, DOI 10.1016/j.vetmic.2018.04.006; Xie JX, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010036; Xie JX, 2018, VET RES, V49, DOI 10.1186/s13567-018-0569-z; Xie JX, 2017, J GEN VIROL, V98, P2030, DOI 10.1099/jgv.0.000859; Xu HL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040592; Xu K, 2020, ELIFE, V9, DOI 10.7554/eLife.57132; Xue BY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02313; Yang HQ, 2018, ANTIVIR RES, V151, P63, DOI 10.1016/j.antiviral.2018.01.004; Yu P, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03115; Yuste M, 2017, VET MICROBIOL, V198, P72, DOI 10.1016/j.vetmic.2016.12.004; Zhang C, 2018, ONCOTARGET, V9, P2175, DOI [10.18632/oncotarget.23299, 10.18632/oncotarget.25667]; Zhang K, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2051-1; Zhou EM, 2008, J VIROL METHODS, V149, P300, DOI 10.1016/j.jviromet.2008.01.010; Zhu L, 2014, VIROL J, V11, DOI 10.1186/s12985-014-0225-9; Zhu ZB, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00501; Zou ZC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024559	131	2	2	1	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							354	10.3390/vaccines9040354			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4YK	33916997	gold, Green Published			2022-04-29	WOS:000643786400001
J	Zhang, TT; Gu, YC; Liu, XH; Yuan, R; Zhou, Y; Dai, YP; Fang, P; Feng, YJ; Cao, GL; Chen, H; Xue, RY; Hu, XL; Gong, CL				Zhang, Tingting; Gu, Yuchao; Liu, Xiaohan; Yuan, Rui; Zhou, Yang; Dai, Yaping; Fang, Ping; Feng, Yongjie; Cao, Guangli; Chen, Hui; Xue, Renyu; Hu, Xiaolong; Gong, Chengliang			Incidence of Carassius auratus Gibelio Gill Hemorrhagic Disease Caused by CyHV-2 Infection Can Be Reduced by Vaccination with Polyhedra Incorporating Antigens	VACCINES			English	Article						CyHV-2; vaccine; polyhedral microcrystals; cypoviruspolyhedra	SALMO-SALAR L.; PROTECTIVE IMMUNITY; CYPOVIRUS POLYHEDRA; PROTEIN; CARP; MICROCRYSTALS; FISH; BETA; IMMOBILIZATION; IMMUNIZATION	Encapsulation of antigens within protein microcrystals (polyhedra) is a promising approach for the stable delivery of vaccines. In this study, a vaccine was encapsulated into polyhedra against cyprinid herpesvirus II (CyHV-2). CyHV-2 typically infects gibel carp, Carassius auratus gibelio, causing gill hemorrhagic disease. The vaccine was constructed using a codon-optimized sequence, D4ORF, comprising the ORF72 (region 1-186 nt), ORF66 (region 993-1197 nt), ORF81 (region 603-783 nt), and ORF82 (region 85-186 nt) genes of CyHV-2. The H1-D4ORF and D4ORF-VP3 sequences were, respectively, obtained by fusing the H1-helix sequence (region 1-90 nt) ofBombyx mori cypovirus(BmCPV) polyhedrin to the 5 ' terminal end of D4ORF and by fusing a partial sequence (1-279 nt) of the BmCPV VP3 gene to the 3 ' terminal end of D4ORF. Furthermore, BmNPV-H1-D4ORF-polh and BmNPV-D4ORF-VP3-polh recombinant B. mori nucleopolyhedroviruses (BmNPVs), belonging to the family Baculoviridae, and co-expressing BmCPV polyhedrin and H1-D4ORF or D4ORF-VP3, were constructed. H1-D4ORF and D4ORF-VP3 fusion proteins were confirmed to be encapsulated into recombinant cytoplasmic polyhedra by Western blotting. Degradation of vaccine proteins was assessed by SDS-PAGE, and the results showed that the encapsulated vaccine proteins in polyhedra could be protected from degradation. Furthermore, when gibel carp were vaccinated with the purified polyhedra from BmNPV-H1-D4ORF-polh and BmNPV-D4ORF-VP3-polh via injection, the antibody titers in the serum of the vaccinated fish reached 1:6400-1:12,800 at 3 weeks post-vaccination. Therelative percentage of survival of immunized gibel carp reached 64.71% and 58.82%, respectively, following challenge with CyHV-2. These results suggest that incorporating vaccine protein into BmCPV polyhedra may be a novel approach for developing aquaculture microencapsulated vaccines.	[Zhang, Tingting; Gu, Yuchao; Dai, Yaping; Feng, Yongjie; Cao, Guangli; Xue, Renyu; Hu, Xiaolong; Gong, Chengliang] Soochow Univ, Sch Biol & Basic Med Sci, Suzhou 215123, Peoples R China; [Liu, Xiaohan; Yuan, Rui; Fang, Ping; Chen, Hui] Jiangsu Ctr Control & Prevent Aquat Anim Infect D, Nanjing 210036, Peoples R China; [Zhou, Yang] Dafeng Dist Aquaculture Tech Extens Stn Yancheng, Yancheng 224100, Peoples R China; [Feng, Yongjie; Cao, Guangli; Xue, Renyu; Hu, Xiaolong; Gong, Chengliang] Soochow Univ, Agr Biotechnol Res Inst, Agr Biotechnol & Ecol Res Inst, Suzhou 215123, Peoples R China		Hu, XL; Gong, CL (通讯作者)，Soochow Univ, Sch Biol & Basic Med Sci, Suzhou 215123, Peoples R China.; Hu, XL; Gong, CL (通讯作者)，Soochow Univ, Agr Biotechnol Res Inst, Agr Biotechnol & Ecol Res Inst, Suzhou 215123, Peoples R China.	zhangtt199403@163.com; 20185221003@stu.suda.edu.cn; xiaohanliu1975@163.com; yr8624@163.com; 99142028@163.com; 20174221043@stu.suda.edu.cn; jsscykzx@163.com; yjfeng@suda.edu.cn; caoguangli@suda.edu.cn; chenhulisbf@163.com; xuery@suda.edu.cn; xlhu2013@suda.edu.cn; gongcl@suda.edu.cn			Key Research and Development Program of Jiangsu Province (Modern Agriculture) [BE2016322]; Agricultural Science and Technology Independent Innovation Fund of Jiangsu Province of China [CX(17)2027]; Triple-New Project of Aquaculture of Jiangsu Province of China [D2017-3]; Priority Academic Program of Development of Jiangsu Higher Education - Ministry of Agriculture and Rural Affairs of China	This research was funded by the Key Research and Development Program of Jiangsu Province (Modern Agriculture) (BE2016322), the Agricultural Science and Technology Independent Innovation Fund of Jiangsu Province of China (CX(17)2027), the Triple-New Project of Aquaculture of Jiangsu Province of China (D2017-3), a project funded by the Priority Academic Program of Development of Jiangsu Higher Education, and a project entitled `Animal Epidemic Situation and Control' funded by the Ministry of Agriculture and Rural Affairs of China.	Abe S, 2015, ADV MATER, V27, P7951, DOI 10.1002/adma.201503827; Abe T, 2003, J IMMUNOL, V171, P1133, DOI 10.4049/jimmunol.171.3.1133; Adams A, 2019, FISH SHELLFISH IMMUN, V90, P210, DOI 10.1016/j.fsi.2019.04.066; Beck NB, 2000, GENE THER, V7, P1274, DOI 10.1038/sj.gt.3301246; Cao GL, 2012, CAN J MICROBIOL, V58, P872, DOI [10.1139/w2012-064, 10.1139/W2012-064]; Cao ZW, 2019, FISH SHELLFISH IMMUN, V93, P879, DOI 10.1016/j.fsi.2019.08.036; Collins C, 2019, FISH SHELLFISH IMMUN, V85, P106, DOI 10.1016/j.fsi.2018.07.012; Coulibaly F, 2007, NATURE, V446, P97, DOI 10.1038/nature05628; Cui LC, 2015, VACCINE, V33, P3092, DOI 10.1016/j.vaccine.2015.05.002; Embregts CWE, 2019, FISH SHELLFISH IMMUN, V85, P66, DOI 10.1016/j.fsi.2018.03.028; Fredriksen BN, 2011, VACCINE, V29, P8338, DOI 10.1016/j.vaccine.2011.08.087; Fredriksen BN, 2012, VACCINE, V30, P656, DOI 10.1016/j.vaccine.2011.10.105; Huo XC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040567; Ijiri H, 2009, BIOMATERIALS, V30, P4297, DOI 10.1016/j.biomaterials.2009.04.046; Ikeda K, 2006, PROTEOMICS, V6, P54, DOI 10.1002/pmic.200500022; Ito T, 2015, VET MICROBIOL, V175, P139, DOI 10.1016/j.vetmic.2014.11.005; Ji Jie, 2015, Biology-Basel, V4, P664, DOI 10.3390/biology4040664; Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001; Li K, 2019, FISH SHELLFISH IMMUN, V92, P101, DOI 10.1016/j.fsi.2019.05.065; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ma J, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7110569; Matsumoto G, 2014, BIOMATERIALS, V35, P1326, DOI 10.1016/j.biomaterials.2013.10.051; Matsumoto G, 2012, SCI REP-UK, V2, DOI 10.1038/srep00935; Mori H, 2007, J BIOL CHEM, V282, P17289, DOI 10.1074/jbc.M608106200; Mori H, 2018, SPECTROCHIM ACTA A, V203, P19, DOI 10.1016/j.saa.2018.05.066; Munang'andu HM, 2012, VACCINE, V30, P4007, DOI 10.1016/j.vaccine.2012.04.039; Nishishita N, 2011, BIOMATERIALS, V32, P3555, DOI 10.1016/j.biomaterials.2010.12.063; Remminghorst U, 2006, BIOTECHNOL LETT, V28, P1701, DOI 10.1007/s10529-006-9156-x; Ren PengLi, 2016, Journal of Tropical Medicine (Guangzhou), V16, P140; ROHRMANN GF, 1986, J GEN VIROL, V67, P1499, DOI 10.1099/0022-1317-67-8-1499; Shimabukuro J, 2014, MAT SCI ENG C-MATER, V42, P64, DOI 10.1016/j.msec.2014.05.013; Su H, 2018, FISH SHELLFISH IMMUN, V83, P84, DOI 10.1016/j.fsi.2018.09.003; Tafalla C, 2013, FISH SHELLFISH IMMUN, V35, P1740, DOI 10.1016/j.fsi.2013.02.029; Wang EL, 2018, FISH SHELLFISH IMMUN, V73, P262, DOI 10.1016/j.fsi.2017.12.034; Wang L, 2012, B EUR ASSOC FISH PAT, V32, P164; Wu T, 2013, AQUACULTURE, V412, P8, DOI 10.1016/j.aquaculture.2013.07.004; Xue RY, 2013, FISH SHELLFISH IMMUN, V34, P348, DOI 10.1016/j.fsi.2012.11.024; Zhang LL, 2016, FISH SHELLFISH IMMUN, V49, P344, DOI 10.1016/j.fsi.2016.01.003; Zhang YL, 2014, MOL BIOL REP, V41, P2657, DOI 10.1007/s11033-014-3124-7; Zhang YL, 2017, APPL MICROBIOL BIOT, V101, P3703, DOI 10.1007/s00253-017-8158-z; Zhou Y, 2015, FISH SHELLFISH IMMUN, V47, P1024, DOI 10.1016/j.fsi.2015.11.012; Zhu M, 2015, J VIROL METHODS, V219, P67, DOI 10.1016/j.jviromet.2015.03.019	42	0	0	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							397	10.3390/vaccines9040397			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4TZ	33923836	gold, Green Published			2022-04-29	WOS:000643774800001
J	Merlano, MC; Abbona, A; Paccagnella, M; Falletta, A; Granetto, C; Ricci, V; Fea, E; Denaro, N; Ruatta, F; Merlotti, A; Bertetto, O; Crosetto, N; Galizia, D; Basirico, M; Gammaitoni, L; Sangiolo, D; Aglietta, M; Garrone, O				Merlano, Marco Carlo; Abbona, Andrea; Paccagnella, Matteo; Falletta, Antonella; Granetto, Cristina; Ricci, Vincenzo; Fea, Elena; Denaro, Nerina; Ruatta, Fiorella; Merlotti, Anna; Bertetto, Oscar; Crosetto, Nicola; Galizia, Danilo; Basirico, Marco; Gammaitoni, Loretta; Sangiolo, Dario; Aglietta, Massimo; Garrone, Ornella			Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy	VACCINES			English	Article						end-stage cancer patients; immunotherapy; cytokinome		Published data suggest that immunotherapy plays a role even in patients with very advanced tumours. We investigated the immune profile of end-stage cancer patients treated with immunotherapy to identify changes induced by treatment. Breast, colon, renal and prostate cancer patients were eligible. Treatment consisted of metronomic cyclophosphamide, low-dose interleukin-2 (IL-2) and a single radiation shot. A panel of 16 cytokines was assessed using automated ELISA before treatment (T0), after radiation (RT; T1), at cycle 2 (T2) and at disease progression (TPD). Receiving operating characteristic (ROC) analysis was used to identify cytokine cut-off related to overall survival (OS). Principal component analysis (PCA) was used to identify the immune profile correlating better with OS and progression-free survival. Twenty-three patients were enrolled. High IL-2, low IL-8 and CCL-2 correlated with OS. The PCA identified a cluster of patients, with high IL-2, IL-12 and IFN-gamma levels at T0 having longer PFS and OS. In all cohorts, IL-2 and IL-5 increased from T0 to T2; a higher CCL-4 level compared to T2 and a higher IL-8 level compared to T0 were found at TPD. The progressive increase of the IL-10 level during treatment negatively correlated with OS. Our data suggested that baseline cytokine levels may predict patients' outcome and that the treatment may affect their kinetic even in end-stage patients. Cytokine profiling of end-stage patients might offer a tool for medical decisions (EUDRACT: 2016-000578-39).	[Merlano, Marco Carlo; Gammaitoni, Loretta; Sangiolo, Dario; Aglietta, Massimo] FPO IRCCS, Candiolo Canc Inst, Dept Med Oncol, Expt Cell Therapy Lab, I-10060 Turin, Italy; [Abbona, Andrea; Paccagnella, Matteo; Falletta, Antonella; Garrone, Ornella] ARCO Fdn, Translat Oncol, I-12100 Cuneo, Italy; [Granetto, Cristina; Ricci, Vincenzo; Fea, Elena; Denaro, Nerina; Ruatta, Fiorella] S Croce & Carle Teaching Hosp, Dept Med Oncol, I-12100 Cuneo, Italy; [Merlotti, Anna] S Croce & Carle Teaching Hosp, Dept Radiotherapy, I-12100 Cuneo, Italy; [Bertetto, Oscar] Rete Oncol Piemonte & Valle Aosta, I-10125 Turin, Italy; [Crosetto, Nicola] Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; [Galizia, Danilo] FPO IRCCS, Candiolo Canc Inst, Multidisciplinary Oncol Outpatient Clin, I-10060 Turin, Italy; [Basirico, Marco; Sangiolo, Dario; Aglietta, Massimo] Univ Turin, Dept Oncol, I-10043 Turin, Italy; [Garrone, Ornella] S Croce & Carle Teaching Hosp, Breast Unit, I-12100 Cuneo, Italy		Merlano, MC (通讯作者)，FPO IRCCS, Candiolo Canc Inst, Dept Med Oncol, Expt Cell Therapy Lab, I-10060 Turin, Italy.	marcocarlo.merlano@ircc.it; abbona.andrea@gmail.com; matteo.babeuf@gmail.com; antonella.falletta.92@gmail.com; granetto.c@ospedale.cuneo.it; vincenzoricci22@libero.it; fea.e@ospedale.cuneo.it; nerinadenaro@gmail.com; fiorella.ruatta@gmail.com; merlotti.a@ospedale.cuneo.it; obertetto@cittadellasalute.to.it; nicola.crosetto@scilifelab.se; danilo.galizia@ircc.it; marco.basirico@ircc.it; loretta.gammaitoni@ircc.it; dario.sangiolo@ircc.it; massimo.aglietta@unito.it; ornella.garrone@gmail.com	sangiolo, dario/AAC-4647-2022; Garrone, Ornella/AAC-5978-2022; Sangiolo, Dario/ADQ-1991-2022	sangiolo, dario/0000-0002-7163-7071; Garrone, Ornella/0000-0001-7359-5410; Galizia, Danilo/0000-0003-4851-5938; denaro, nerina/0000-0002-8605-4290	Rete Oncologica del Piemonte e della Valle d'Aosta (Piedmont and Aosta Valley Cancer Network) [1265/2016-342/2018]	This study was funded by the Rete Oncologica del Piemonte e della Valle d'Aosta (Piedmont and Aosta Valley Cancer Network), grant number: 1265/2016-342/2018.	Amin A, 2014, J KIDNEY CANCER VHL, V1, P74, DOI 10.15586/jkcvhl.2014.18; Ascierto PA, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-116; Associazione Italiana Oncologia Medica (AIOM), 2016 GUID; Bakouny Z, 2020, NAT MED, V26, P650, DOI 10.1038/s41591-020-0873-9; Barbari C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145009; Dubitzky W., 2013, ENCY SYSTEMBIOL, P154; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Garrone O, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000876; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Glisch C, 2020, AM J HOSP PALLIAT ME, V37, P179, DOI 10.1177/1049909119862785; Gollob JA, 1999, J IMMUNOL, V162, P4472; Heinhuis KM, 2019, ANN ONCOL, V30, P219, DOI 10.1093/annonc/mdy551; Hirsch L, 2019, BRIT J CANCER, V120, P3, DOI 10.1038/s41416-018-0294-4; Hong CC, 2013, BREAST CANCER RES TR, V139, P477, DOI 10.1007/s10549-013-2549-3; Kawaguchi K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39476-9; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; KONRAD MW, 1990, CANCER RES, V50, P2009; Korbecki J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218412; Mahmoudpour SH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43530-x; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; Merlano MC, 2020, CURR OPIN ONCOL, V32, P203, DOI 10.1097/CCO.0000000000000623; Merlano MC, 2018, CLIN TRANSL RAD ONCO, V12, P47, DOI 10.1016/j.ctro.2018.08.001; NAKAMURA Y, 1990, AM J RESP CELL MOL, V3, P291, DOI 10.1165/ajrcmb/3.4.291; Pluvy J, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00310-2017; Qin S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1091-2; Roviello G, 2017, IMMUNOTHERAPY-UK, V9, P25, DOI 10.2217/imt-2016-0107; SCHAAFSMA MR, 1991, BLOOD, V78, P1981; Spoormakers TJP, 2003, CANCER IMMUNOL IMMUN, V52, P179, DOI 10.1007/s00262-002-0369-0; Tomaki M, 2000, J IMMUNOL, V165, P4040, DOI 10.4049/jimmunol.165.7.4040; Tomova R, 2006, ANTICANCER RES, V26, P2037; Varricchi G, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1393134; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wigginton JM, 1996, JNCI-J NATL CANCER I, V88, P38, DOI 10.1093/jnci/88.1.38; Wigginton JM, 2001, J IMMUNOL, V166, P1156, DOI 10.4049/jimmunol.166.2.1156; Zhao S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139598	36	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							235	10.3390/vaccines9030235			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6CK	33800511	Green Published, gold			2022-04-29	WOS:000634239400001
J	Queiroz, AMV; Oliveira, JWD; Moreno, CJ; Guerin, DMA; Silva, MS				Vasconcelos Queiroz, Aline Maria; de Freitas Oliveira, Johny Wysllas; Moreno, Claudia Jassica; Guerin, Diego M. A.; Silva, Marcelo Sousa			VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases	VACCINES			English	Review						virus-like particles; vaccine; trypanosomatids; Chagas disease; leishmaniasis; African trypanosomiasis	VIRUS-LIKE PARTICLES; DOUBLE-BLIND; VACCINATION; IMMUNOGENICITY; PARASITES; EFFICACY; DESIGN; SAFETY; CELLS; GENE	Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei. In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite-host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids.	[Vasconcelos Queiroz, Aline Maria; de Freitas Oliveira, Johny Wysllas; Moreno, Claudia Jassica; Silva, Marcelo Sousa] Univ Fed Rio Grande do Norte, Dept Clin & Toxicol Anal, Immunoparasitol Lab, BR-59078970 Natal, RN, Brazil; [Vasconcelos Queiroz, Aline Maria; Silva, Marcelo Sousa] Univ Fed Rio Grande do Norte, Postgrad Program Pharmaceut Sci, BR-59078970 Natal, RN, Brazil; [de Freitas Oliveira, Johny Wysllas; Moreno, Claudia Jassica; Silva, Marcelo Sousa] Univ Fed Rio Grande do Norte, Postgrad Program Biochem, BR-59078970 Natal, RN, Brazil; [Guerin, Diego M. A.] Univ Basque Country, Inst Biofis, Dept Biochem & Mol Biol, CSIC,UPV EHU, Bizkaia 48940, Spain; [Silva, Marcelo Sousa] Univ Nova Lisboa, Inst Hyg & Trop Med, Global Hlth & Trop Med, P-1349008 Lisbon, Portugal		Silva, MS (通讯作者)，Univ Fed Rio Grande do Norte, Dept Clin & Toxicol Anal, Immunoparasitol Lab, BR-59078970 Natal, RN, Brazil.; Silva, MS (通讯作者)，Univ Fed Rio Grande do Norte, Postgrad Program Pharmaceut Sci, BR-59078970 Natal, RN, Brazil.; Silva, MS (通讯作者)，Univ Fed Rio Grande do Norte, Postgrad Program Biochem, BR-59078970 Natal, RN, Brazil.; Guerin, DMA (通讯作者)，Univ Basque Country, Inst Biofis, Dept Biochem & Mol Biol, CSIC,UPV EHU, Bizkaia 48940, Spain.; Silva, MS (通讯作者)，Univ Nova Lisboa, Inst Hyg & Trop Med, Global Hlth & Trop Med, P-1349008 Lisbon, Portugal.	alinemariavq@gmail.com; johny3355@hotmail.com; claudia.mrn1@gmail.com; diego.guerin@ehu.es; mssilva@ihmt.unl.pt		Queiroz, Aline/0000-0002-1811-7376; De Freitas Oliveira, Johny Wysllas/0000-0002-3100-0420; Silva, Marcelo/0000-0002-1000-0149; Moreno, Claudia/0000-0002-6948-9823	Global Health and Tropical Medicine, Fundacao para Ciencia e Tecnologia (FCT), Portugal [IHMT UID/multi/04413/2013, PTDC/CVT-CVT/28908/2017]; Grupos de Investigacion de la UPV/EHU [GIU18/172]; CSIC Programa I-COOP+2020, Spain [ICOOPB20503]	This research was funded by Global Health and Tropical Medicine (Grant number IHMT UID/multi/04413/2013 and Grant number PTDC/CVT-CVT/28908/2017), Fundacao para Ciencia e Tecnologia (FCT), Portugal; Grant GIU18/172 Grupos de Investigacion de la UPV/EHU, and Grant from CSIC Programa I-COOP+2020 (ICOOPB20503), Spain.	Abaza SM, 2019, PARASITOL UNITED J, V12, P163, DOI 10.21608/puj.2019.20020.1055; [Anonymous], 2019, DNDI DRUGS NEGLECTED; Balke I, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030270; Beaumier CM, 2016, VACCINE, V34, P2996, DOI 10.1016/j.vaccine.2016.03.074; Bivona AE, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165658; Black SJ, 2016, PARASITE IMMUNOL, V38, P735, DOI 10.1111/pim.12387; Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608; Brito LA, 2011, J PHARM SCI-US, V100, P34, DOI 10.1002/jps.22267; Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2; Cecilio P, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005951; Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381; Chichester JA, 2018, VACCINE, V36, P5865, DOI 10.1016/j.vaccine.2018.08.033; Choi WH, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8040091; Chroboczek J, 2014, ACTA BIOCHIM POL, V61, P531; Crisci E, 2012, VET IMMUNOL IMMUNOP, V148, P211, DOI 10.1016/j.vetimm.2012.04.026; Jimenez-Chavez AD, 2019, VACCINE, V37, P7256, DOI 10.1016/j.vaccine.2019.09.068; Deml L, 2005, MOL IMMUNOL, V42, P259, DOI 10.1016/j.molimm.2004.06.028; Dumonteil E, 2020, VACCINE, V38, P4584, DOI 10.1016/j.vaccine.2020.05.010; Silva RFE, 2017, TROPICAL DISEASES: AN OVERVIEW OF MAJOR DISEASES OCCURRING IN THE AMERICAS, P88; Frietze KM, 2016, CURR OPIN VIROL, V18, P44, DOI 10.1016/j.coviro.2016.03.001; Ghorbani M, 2018, DRUG DES DEV THER, V12, P25, DOI 10.2147/DDDT.S146521; Gomes AC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00226; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; Herrero R, 2008, VACCINE, V26, P4795, DOI 10.1016/j.vaccine.2008.07.002; Hervas-Stubbs S, 2007, J IMMUNOL, V178, P2361, DOI 10.4049/jimmunol.178.4.2361; Hieu NT, 2002, VACCINE, V20, P1803, DOI 10.1016/S0264-410X(01)00518-7; Huertas-Diaz MC, 2019, VACCINE, V37, P2925, DOI 10.1016/j.vaccine.2019.04.042; Jackson AP, 2016, MOL BIOCHEM PARASIT, V209, P64, DOI 10.1016/j.molbiopara.2016.03.007; Jackson AP, 2010, MOL BIOL EVOL, V27, P33, DOI 10.1093/molbev/msp214; Jain NK, 2015, ADV DRUG DELIVER REV, V93, P42, DOI 10.1016/j.addr.2014.10.023; Janitzek CM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41522-5; Jeong H, 2017, J MICROBIOL, V55, P220, DOI 10.1007/s12275-017-7058-3; Kennedy PGE, 2019, J NEUROL, V266, P2334, DOI 10.1007/s00415-019-09425-7; Lee SH, 2018, VACCINE, V36, P5692, DOI 10.1016/j.vaccine.2018.08.016; Fernandez-Presas AM, 2017, REV INST MED TROP SP, V59, DOI [10.1590/s1678-9946201759046, 10.1590/S1678-9946201759046]; McLemore Monica R, 2006, Clin J Oncol Nurs, V10, P559; Metz SW, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0970-2; Metz SW, 2016, METHODS MOL BIOL, V1426, P297, DOI 10.1007/978-1-4939-3618-2_27; Michel-Todo L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010130; Moreno CJG, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040178; Moura APV, 2017, ACS CENTRAL SCI, V3, P1026, DOI 10.1021/acscentsci.7b00311; Naskalska A, 2015, POL J MICROBIOL, V64, P3; Oli AN, 2020, IMMUNOTARGETS THER, V9, P13, DOI 10.2147/ITT.S241064; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Parthasarathy A, 2020, RSC MED CHEM, V11, P625, DOI 10.1039/d0md00122h; Pavanelli W.R, 2016, BIOSA DE, V10, P147; PECHCANUL ADL, 2017, THE J, V2017, P1, DOI DOI 10.1155/2017/3751403; Perez-Molina JA, 2018, LANCET, V391, P82, DOI 10.1016/S0140-6736(17)31612-4; Perotti M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010035; Pijlman GP, 2015, BIOTECHNOL J, V10, P659, DOI 10.1002/biot.201400427; Pillet S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216533; Qian CY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010139; Rafati S., 2003, Current Genomics, V4, P253, DOI 10.2174/1389202033490439; Rios LE, 2019, ACTA TROP, V200, DOI 10.1016/j.actatropica.2019.105168; Rodriguez-Morales O, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/489758; Roy P, 2009, ADV EXP MED BIOL, V655, P145, DOI 10.1007/978-1-4419-1132-2_11; Sarkar Bishajit, 2019, [Korean Journal of Microbiology, 미생물학회지], V55, P327, DOI 10.7845/kjm.2019.9089; Serradell MC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08265-9; Silva-Barrios S, 2019, EUR J IMMUNOL, V49, P1082, DOI 10.1002/eji.201847917; Silva-Barrios S, 2018, TRENDS PARASITOL, V34, P155, DOI 10.1016/j.pt.2017.10.001; Singh K, 2020, J VIROL, V94, DOI 10.1128/JVI.01884-19; Soaresa RP, 2017, PROTIST, V168, P326, DOI 10.1016/j.protis.2017.03.004; Thomaz-Soccol Vanete, 2018, Recent Pat Biotechnol, V12, P21, DOI 10.2174/1872208311666170510121126; Venters Charmaine, 2004, Expert Rev Vaccines, V3, P119, DOI 10.1586/14760584.3.2.119; Visciano ML, 2011, VACCINE, V29, P4903, DOI 10.1016/j.vaccine.2011.05.005; World Health Organization, 2005, WHO TECHN REP SER, V927, P55; World Health Organization, 2021, DRAFT LANDSCAPE COVI; Yan D, 2015, APPL MICROBIOL BIOT, V99, P10415, DOI 10.1007/s00253-015-7000-8; Yenkoidiok-Douti L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53208-z; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zlotnick A, 2011, TRENDS MICROBIOL, V19, P14, DOI 10.1016/j.tim.2010.11.003	71	0	0	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							220	10.3390/vaccines9030220			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6EF	33807516	gold, Green Published			2022-04-29	WOS:000634244100001
J	You, SH; Jang, EJ; Kim, MS; Lee, MT; Kang, YJ; Lee, JE; Eom, JH; Jung, SY				You, Seung-Hun; Jang, Eun Jin; Kim, Myo-Song; Lee, Min-Taek; Kang, Ye-Jin; Lee, Jae-Eun; Eom, Joo-Hyeon; Jung, Sun-Young			Change Point Analysis for Detecting Vaccine Safety Signals	VACCINES			English	Article						change point analysis; vaccines; data mining; pharmacovigilance; adverse events; signal detection; human papilloma virus vaccines	BAYESIAN-ANALYSIS; R-PACKAGE; MODELS; TRENDS; RISK	It is important to detect signals of abrupt changes in adverse event reporting in order to notice public safety concerns and take prompt action, especially for vaccines under national immunization programs. In this study, we assessed the applicability of change point analysis (CPA) for signal detection in vaccine safety surveillance. The performances of three CPA methods, namely Bayesian change point analysis, Taylor's change point analysis (Taylor-CPA), and environmental time series change point detection (EnvCpt), were assessed via simulated data with assumptions for the baseline number of events and degrees of change. The analysis was validated using the Korea Adverse Event Reporting System (KAERS) database. In the simulation study, the Taylor-CPA method exhibited better results for the detection of a change point (accuracy of 96% to 100%, sensitivity of 7% to 100%, specificity of 98% to 100%, positive predictive value of 25% to 85%, negative predictive value of 96% to 100%, and balanced accuracy of 53% to 100%) than the other two CPA methods. When the CPA methods were applied to reports of syncope or dizziness following human papillomavirus (HPV) immunization in the KAERS database, Taylor-CPA and EnvCpt detected a change point (Q2/2013), which was consistent with actual public safety concerns. CPA can be applied as an efficient tool for the early detection of vaccine safety signals.	[You, Seung-Hun; Kim, Myo-Song; Lee, Min-Taek; Kang, Ye-Jin; Lee, Jae-Eun; Eom, Joo-Hyeon; Jung, Sun-Young] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea; [You, Seung-Hun; Kim, Myo-Song; Lee, Min-Taek; Kang, Ye-Jin; Lee, Jae-Eun; Eom, Joo-Hyeon; Jung, Sun-Young] Chung Ang Univ, Dept Global Innovat Drugs, Grad Sch, Seoul 06974, South Korea; [Jang, Eun Jin] Andong Natl Univ, Dept Informat Stat, Andong 36729, South Korea		Jung, SY (通讯作者)，Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea.; Jung, SY (通讯作者)，Chung Ang Univ, Dept Global Innovat Drugs, Grad Sch, Seoul 06974, South Korea.	dbtmdgnssla@cau.ac.kr; ejjang@anu.ac.kr; myosong@cau.ac.kr; come410@cau.ac.kr; asnmoty11000@cau.ac.kr; lje427@cau.ac.kr; eomjoohyeon@cau.ac.kr; jsyoung@cau.ac.kr		Jung, Sun-Young/0000-0003-2032-112X; Lee, Min-Taek/0000-0002-3178-9660; eom, joohyeon/0000-0003-4890-7499; Jang, Eun Jin/0000-0002-9137-9815; Kim, Myo-song/0000-0002-9094-8780; You, Seung-Hun/0000-0002-2430-6907	government-wide R&D fund project for infectious disease research (GFID), Republic of Korea [HG18C0066]	This research was supported by a government-wide R&D fund project for infectious disease research (GFID), Republic of Korea (grant number: HG18C0066).	BARRY D, 1993, J AM STAT ASSOC, V88, P309, DOI 10.1080/01621459.1993.10594323; Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466; Beaulieu C, 2018, J CLIMATE, V31, P9519, DOI 10.1175/JCLI-D-17-0863.1; Begueria S, 2006, NAT HAZARDS, V37, P315, DOI 10.1007/s11069-005-5182-6; Bonaldo G, 2019, BRIT J CLIN PHARMACO, V85, P634, DOI 10.1111/bcp.13841; Centers for Disease Control and Prevention, SAFETY INFORM VACCIN; Choi Nam-Kyong, 2007, J Prev Med Public Health, V40, P278; Dunn AG, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4343; Erdman C, 2007, J STAT SOFTW, V23, P1; European Medicines Agency. Human medicines, HPV VACCINES EMA CON; Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Jacoby P, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-031851; Kass-Hout TA, 2012, J AM MED INFORM ASSN, V19, P1075, DOI 10.1136/amiajnl-2011-000793; Killick R, 2012, J AM STAT ASSOC, V107, P1590, DOI 10.1080/01621459.2012.737745; Killick R, 2014, J STAT SOFTW, V58, P1; Korea Institute of Drug Safety and Risk Management, 2014, ADVERSE EVENT REPORT; Korea Institute of Drug Safety and Risk Management, USER GUIDE KOREA I D; Lei JY, 2018, VACCINE, V36, P1577, DOI 10.1016/j.vaccine.2018.02.012; Markowitz LE, 2014, MMWR RECOMM REP, V63, P1; Moran JL, 2010, CRIT CARE, V14, DOI 10.1186/cc9182; Morimoto A, 2015, INT J CLIN ONCOL, V20, P549, DOI 10.1007/s10147-014-0723-1; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ohlssen D, 2014, PHARM STAT, V13, P55, DOI 10.1002/pst.1592; Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001; Ruklisa D, 2015, GENOME MED, V7, DOI 10.1186/s13073-014-0120-4; Taylor W, CHANGE POINT ANAL PO; Tribouilloy C, 2012, CIRCULATION, V126, P2852, DOI 10.1161/CIRCULATIONAHA.112.111260; Trinh NTH, 2019, PHARMACOEPIDEM DR S, V28, P370, DOI 10.1002/pds.4613; Tsuda K, 2016, CLIN INFECT DIS, V63, P1634, DOI 10.1093/cid/ciw647; Velez DR, 2007, GENET EPIDEMIOL, V31, P306, DOI 10.1002/gepi.20211; Wolfe S., 2015, EPIDEMIOLOGY PREVENT, V13th ed; Wong CK, 2017, J CLIN SLEEP MED, V13, P223, DOI 10.5664/jcsm.6452; World Health Organization, 2013, VACCINE SAFETY BASIC; World Health Organization, SAFETY UPDATE HUMAN; World Health Organization (WHO), 2012, INFORM SHEET OBSERVE	36	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							206	10.3390/vaccines9030206			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5GN	33801188	Green Published, gold			2022-04-29	WOS:000634182500001
J	Garzon-Chavez, D; Rivas-Condo, J; Echeverria, A; Mozo, J; Quentin, E; Reyes, J; Teran, E				Garzon-Chavez, Daniel; Rivas-Condo, Jackson; Echeverria, Adriana; Mozo, Jhoanna; Quentin, Emmanuelle; Reyes, Jorge; Teran, Enrique			COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population	VACCINES			English	Article						COVID-19; BCG vaccine; BCG vaccine coverage; Ecuador	MORTALITY	The Bacillus Calmette-Guerin (BCG) is a well-known vaccine with almost a century of use, with the apparent capability to improve cytokine production and epigenetics changes that could develop a better response to pathogens. It has been postulated that BCG protection against SARS-CoV-2 has a potential role in the pandemic, through the presence of homologous amino acid sequences. To identify a possible link between BCG vaccination coverage and COVID-19 cases, we used official epidemic data and Ecuadorian Ministry of Health and Pan American Health Organization vaccination information. BCG information before 1979 was available only at a national level. Therefore, projections based on the last 20 years were performed, to compare by specific geographic units. We used a Mann-Kendall test to identify BCG coverage variations, and mapping was conducted with a free geographic information system (QGIS). Nine provinces where BCG vaccine coverage was lower than 74.25% show a significant statistical association (chi(2) Pearson's = 4.800, df = 1, p = 0.028), with a higher prevalence of cases for people aged 50 to 64 years than in younger people aged 20 to 49 years. Despite the availability of BCG vaccination data and the mathematical models needed to compare these data with COVID-19 cases, our results show that, in geographic areas where BCG coverage was low, 50% presented a high prevalence of COVID-19 cases that were young; thus, low-coverage years were more affected.	[Garzon-Chavez, Daniel; Teran, Enrique] Univ San Francisco Quito, Colegio Ciencias Salud, Quito 170901, Ecuador; [Rivas-Condo, Jackson; Echeverria, Adriana; Mozo, Jhoanna] Minist Salud Publ Ecuador, Quito 170146, Ecuador; [Quentin, Emmanuelle] Univ Tecnol Equinoccial, Ctr Invest Salud Publ & Epidemiol Clin, Quito 170527, Ecuador; [Reyes, Jorge] Hosp IESS Quito Sur, Serv Lab, Quito 170111, Ecuador; [Reyes, Jorge] Univ Cent Ecuador, Fac Ciencias Quim, Quito 170403, Ecuador		Teran, E (通讯作者)，Univ San Francisco Quito, Colegio Ciencias Salud, Quito 170901, Ecuador.	dgarzonc@usfq.edu.ec; jackson.rivas@msp.gob.ec; pauliem72@gmail.com; johana.mozo@msp.gob.ec; emmanuelle.quentin@gmail.com; jorgereyes83@gmail.com; eteran@usfq.edu.ec	Quentin, Emmanuelle/C-3684-2019; Terán, Enrique/L-6000-2016	Quentin, Emmanuelle/0000-0001-5600-2361; Terán, Enrique/0000-0001-6979-5655; Reyes, Jorge A/0000-0002-5215-164X			[Anonymous], Registro Civil Ecuador Cifras Mortalidad 2020 (Mortality 2020); [Anonymous], 2020, MOD TRANSM VIR CAUS; Arias-Reyes C, 2020, RESP PHYSIOL NEUROBI, V277, DOI 10.1016/j.resp.2020.103443; Aris T., 2017, SCI REP-UK, DOI [10.4172/scientificreports.656, DOI 10.4172/SCIENTIFICREPORTS.656]; Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020; Bandari J, 2018, EUR UROL FOCUS, V4, P481, DOI 10.1016/j.euf.2018.06.018; BREWER TF, 1995, CLIN INFECT DIS, V20, P126, DOI 10.1093/clinids/20.1.126; Charoenlap S, 2020, ASIAN PAC J ALLERGY, V38, P150, DOI 10.12932/AP-310520-0863; de Laval B, 2020, CELL STEM CELL, V26, P657, DOI 10.1016/j.stem.2020.01.017; Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117; Ebrahim SH., 2020, BMJ, V368, pM1066, DOI [10.1136/bmj.m1066, DOI 10.1136/BMJ.M1066]; Escobar Luis E, 2020, medRxiv, DOI [10.1073/pnas.2008410117, 10.1101/2020.05.05.20091975]; Glaziou Philippe, 2014, Cold Spring Harb Perspect Med, V5, pa017798, DOI 10.1101/cshperspect.a017798; Glisic S, 2020, J PROTEOME RES, V19, P4649, DOI 10.1021/acs.jproteome.0c00410; Gupta A, 2020, MODEL EARTH SYST ENV, V6, P2645, DOI 10.1007/s40808-020-00838-2; Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189; Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019; Hu L, 2020, CLIN INFECT DIS, V71, P2089, DOI 10.1093/cid/ciaa539; Johns Hopkins University & Medicine, COR COVID 19 GLOB CA; Klinger D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030378; Lerner SP, 2016, BLADDER CANCER, V2, P165, DOI 10.3233/BLC-160053; Lopez E., 2018, VENEZUELAN REFUGEES; Mantovani A, 2020, NEW ENGL J MED, V383, P1078, DOI 10.1056/NEJMcibr2011679; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Nuovo G, 2020, ANN DIAGN PATHOL, V48, DOI 10.1016/j.anndiagpath.2020.151600; Peschken CA, 2020, J RHEUMATOL, V47, P787, DOI 10.3899/jrheum.200395; Pettenati C, 2018, NAT REV UROL, V15, P615, DOI 10.1038/s41585-018-0055-4; Rakshit S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130540; Ricco Matteo, 2020, Acta Biomed, V91, P207, DOI 10.23750/abm.v91i2.9700; Romero-Sandoval N, 2009, INT J TUBERC LUNG D, V13, P1569; Sharma AR, 2020, ALLERGOL IMMUNOPATH, V48, P507, DOI 10.1016/j.aller.2020.05.002; Shingadia D., 2017, ADV EXP MED BIOL, V568, P117; Suliman S, 2016, J IMMUNOL, V197, P1100, DOI 10.4049/jimmunol.1501996; TeruYn, 2020, CLIN SCI MED TECHNOL, P59, DOI [10.34141/LJCS2640133, DOI 10.34141/LJCS2640133]; Toraih EA, 2021, J MED VIROL, V93, P1950, DOI 10.1002/jmv.26707; Urashima M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155589; Venkataraman A, 2015, VACCINE, V33, P5470, DOI 10.1016/j.vaccine.2015.07.103; Wassenaar TM, 2020, LETT APPL MICROBIOL, V71, P498, DOI 10.1111/lam.13365; Weng CH, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001569; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	42	3	3	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							91	10.3390/vaccines9020091			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7JF	33513693	Green Published, gold			2022-04-29	WOS:000623315400001
J	Gori, D; Reno, C; Remondini, D; Durazzi, F; Fantini, MP				Gori, Davide; Reno, Chiara; Remondini, Daniel; Durazzi, Francesco; Fantini, Maria Pia			Are We Ready for the Arrival of the New COVID-19 Vaccinations? Great Promises and Unknown Challenges Still to Come	VACCINES			English	Review						SARS-CoV-2; COVID-19; vaccination; vaccine hesitancy; social media; Twitter		While the SARS-CoV-2 pandemic continues to strike and collect its death toll throughout the globe, as of 31 January 2021, the vaccine candidates worldwide were 292, of which 70 were in clinical testing. Several vaccines have been approved worldwide, and in particular, three have been so far authorized for use in the EU. Vaccination can be, in fact, an efficient way to mitigate the devastating effect of the pandemic and offer protection to some vulnerable strata of the population (i.e., the elderly) and reduce the social and economic burden of the current crisis. Regardless, a question is still open: after vaccination availability for the public, will vaccination campaigns be effective in reaching all the strata and a sufficient number of people in order to guarantee herd immunity? In other words: after we have it, will we be able to use it? Following the trends in vaccine hesitancy in recent years, there is a growing distrust of COVID-19 vaccinations. In addition, the online context and competition between pro- and anti-vaxxers show a trend in which anti-vaccination movements tend to capture the attention of those who are hesitant. Describing this context and analyzing its possible causes, what interventions or strategies could be effective to reduce COVID-19 vaccine hesitancy? Will social media trend analysis be helpful in trying to solve this complex issue? Are there perspectives for an efficient implementation of COVID-19 vaccination coverage as well as for all the other vaccinations?	[Gori, Davide; Reno, Chiara; Fantini, Maria Pia] Univ Bologna, Dept Biomed & Neuromotor Sci, I-40138 Bologna, Italy; [Remondini, Daniel; Durazzi, Francesco] Univ Bologna, Dept Phys & Astron, I-40138 Bologna, Italy		Reno, C (通讯作者)，Univ Bologna, Dept Biomed & Neuromotor Sci, I-40138 Bologna, Italy.	davide.gori4@unibo.it; chiara.reno@studio.unibo.it; daniel.remondini@unibo.it; francesco.durazzi2@unibo.it; mariapia.fantini@unibo.it	Gori, Davide/AAC-3486-2022; Reno, Chiara/ABA-5613-2020	Gori, Davide/0000-0003-4954-9419; Reno, Chiara/0000-0002-7933-2141; Remondini, Daniel/0000-0003-3185-7456; Durazzi, Francesco/0000-0001-8729-6438; Fantini, Maria Pia/0000-0002-3257-6552			Abbasi J, 2020, JAMA-J AM MED ASSOC, V324, P1125, DOI 10.1001/jama.2020.16866; [Anonymous], COVID 19 VACCINES KE; [Anonymous], The COVID-19 Pandemic Has Changed Education Forever. This Is How (Blog); [Anonymous], COVID 19 VACCINATION; [Anonymous], Coronavirus: Vaccines and the Origin; [Anonymous], STORY MRNA ONCE DISM; [Anonymous], The Oxford/AstraZeneca COVID-19 vaccine: what you need to know; [Anonymous], INCREASED RISK HOSPI; [Anonymous], AIFA AUTORIZZATO VAC; [Anonymous], AP NORC POLL ONLY HA; [Anonymous], RISK ASSESSMENT RISK; [Anonymous], Pneumonia of unknown cause-China; [Anonymous], SUSPICIONS GROW NANO; [Anonymous], EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baldo V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010021; Buller DB, 2019, HUM VACC IMMUNOTHER, V15, P1479, DOI 10.1080/21645515.2019.1581555; Callaway E, 2021, NATURE, V590, P15, DOI 10.1038/d41586-021-00241-6; Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y; Cambria E, 2016, IEEE INTELL SYST, V31, P102, DOI 10.1109/MIS.2016.31; Deiner MS, 2019, HEALTH INFORM J, V25, P1116, DOI 10.1177/1460458217740723; Durazzi F, INT EXPERT COMMUNITI; European Centre for Disease Prevention and Control, 2020, SYST SCOP REV SOC ME; Fantini MP, 2020, ITAL J PEDIATR, V46, DOI 10.1186/s13052-020-00844-1; Fitzpatrick MC, 2021, SCIENCE, V371, P890, DOI 10.1126/science.abg2334; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Greenhalgh T, 2005, BRIT MED J, V331, P1064, DOI 10.1136/bmj.38636.593461.68; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Moore JP, 2021, JAMA-J AM MED ASSOC, V325, P821, DOI 10.1001/jama.2021.1114; Nan XL, 2012, HEALTH COMMUN, V27, P829, DOI 10.1080/10410236.2012.661348; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Piedrahita-Valdes H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010028; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; World Health Organization, 2019, 10 THREATS GLOB HLTH; Yadollahi A, 2017, ACM COMPUT SURV, V50, DOI 10.1145/3057270	38	5	5	4	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							173	10.3390/vaccines9020173			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6WU	33670697	Green Published, gold			2022-04-29	WOS:000623282800001
J	Seliner, J; Rommer, PS				Seliner, Johann; Rommer, Paulus S.			Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies	VACCINES			English	Review						vaccination; COVID-19; SARS-CoV-2; multiple sclerosis; disease-modifying drugs; immune-depleting therapies; CD20 depletion; cladribine; alemtuzumab	ALEMTUZUMAB; RECONSTITUTION; OCRELIZUMAB; RITUXIMAB; COVID-19; FEATURES; PLACEBO; TRIALS; CELLS; CD52	Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the pandemic is not yet in sight, vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) may be an elegant strategy to overcome the potential hazards associated with initiating and continuing treatment with immune-depleting agents. In this review, we summarize the immunological effects of immune-depleting therapy and underlying considerations for the hitherto existing recommendations that suggest a restricted use of immune-deleting therapies during the pandemic. Moreover, we critically discuss open questions regarding vaccination in general and against SARS-CoV-2 in pwMS.	[Seliner, Johann] Landesklinikum Mistelbach Ganserndorf, Dept Neurol, A-2130 Mistelbach, Austria; [Seliner, Johann] Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, D-81675 Munich, Germany; [Seliner, Johann] Paracelsus Med Univ, Christian Doppler Med Ctr, Dept Neurol, A-5020 Salzburg, Austria; [Rommer, Paulus S.] Med Univ Vienna, Dept Neurol, A-1090 Vienna, Austria		Seliner, J (通讯作者)，Landesklinikum Mistelbach Ganserndorf, Dept Neurol, A-2130 Mistelbach, Austria.; Seliner, J (通讯作者)，Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, D-81675 Munich, Germany.; Seliner, J (通讯作者)，Paracelsus Med Univ, Christian Doppler Med Ctr, Dept Neurol, A-5020 Salzburg, Austria.	johann.sellner@mistelbach.lknoe.at; paulus.rommer@meduniwien.ac.at					Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; BAKER D, 2017, NEUROL-NEUROIMMUNOL, V4, DOI [10.1212/NXI.0000000000000360, DOI 10.1212/NXI.0000000000000360]; Baker D, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102174; Baker D, 2017, JAMA NEUROL, V74, P961, DOI 10.1001/jamaneurol.2017.0676; Bar-Or A, 2008, ANN NEUROL, V63, P395, DOI 10.1002/ana.21363; BAROR A, 2020, MULT SCLER RELAT DIS, V95, DOI DOI 10.1212/WNL.0000000000010380; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BSTEH G, 2020, EUR, DOI DOI 10.1111/ENE.14555; Ceronie B, 2018, J NEUROL, V265, P1199, DOI 10.1007/s00415-018-8830-y; Chaudhry F, 2020, J NEUROL SCI, V418, DOI 10.1016/j.jns.2020.117147; CIOTTI JR, 2020, NEUROLOGY, V45, P2439, DOI DOI 10.1016/J.MSARD.2020.102439; Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; Coles AJ, 2006, J NEUROL, V253, P98, DOI 10.1007/s00415-005-0934-5; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Coles AJ, 2012, LANCET, V380, P1829, DOI 10.1016/S0140-6736(12)61768-1; Comi G, 2019, MULT SCLER RELAT DIS, V29, P168, DOI 10.1016/j.msard.2019.01.038; EDRIDGE AWD, 2020, MULT SCLER RELAT DIS, V26, P1691, DOI DOI 10.1038/S41591-020-1083-1; Epstein DJ, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy174; Finding O, 2021, DRUG DISCOV TODAY, V26, P416, DOI 10.1016/j.drudis.2020.11.022; Ginaldi L, 1998, LEUKEMIA RES, V22, P185, DOI 10.1016/S0145-2126(97)00158-6; Gingele S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010012; GIOVANNONI G, 2020, CELL, V39, P2073, DOI DOI 10.1016/J.MSARD.2020.102073; Giovannoni G, 2018, MULT SCLER J, V24, P1594, DOI 10.1177/1352458517727603; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gross CC, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00606; Gross CC, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000289; Hale G, 2001, CYTOTHERAPY, V3, P137, DOI 10.1080/146532401753174098; HAUER L, 2020, THE J, P1, DOI DOI 10.1007/S00415-020-10107-Y; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hauser Stephen L, 2008, N Engl J Med, V358, P676, DOI 10.1056/NEJMoa0706383; Heming M, 2021, IMMUNITY, V54, P164, DOI 10.1016/j.immuni.2020.12.011; Jones JA, 2013, LEUKEMIA LYMPHOMA, V54, P2654, DOI 10.3109/10428194.2013.788179; Kappos L, 2011, LANCET, V378, P1779, DOI 10.1016/S0140-6736(11)61649-8; Karamyan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155795; Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Leist TP, 2011, CLIN NEUROPHARMACOL, V34, P28, DOI 10.1097/WNF.0b013e318204cd90; Li KN, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19943-y; Lin CJ, 2020, JACC-BASIC TRANSL SC, V5, P1240, DOI 10.1016/j.jacbts.2020.11.006; LIU MA, 2010, FRONT IMMUNOL, V33, P504, DOI DOI 10.1016/J.IMMUNI.2010.10.004; Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581; Mazzitelli Maria, 2020, Infez Med, V28, P258; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468; Moser T, 2020, ANN CLIN TRANSL NEUR, V7, P2199, DOI 10.1002/acn3.51206; Moser T, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102647; Munro N, 2020, AACN ADV CRIT CARE, V31, P268, DOI 10.4037/aacnacc2020802; Ng HS, 2020, EXPERT OPIN DRUG SAF, V19, P1069, DOI 10.1080/14740338.2020.1807002; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rao SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039416; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843, 10.21203/rs.3.rs-57112/v1]; Ruck T, 2015, INT J MOL SCI, V16, P16414, DOI 10.3390/ijms160716414; Saksena S, 2021, CYTOM PART B-CLIN CY, V100, P33, DOI 10.1002/cyto.b.21988; Schuh E, 2016, J IMMUNOL, V197, P1111, DOI 10.4049/jimmunol.1600089; SCHWEITZER F, 2020, THE J, P1, DOI DOI 10.1007/S00415-019-09690-6; Sellner J, 2020, EUR J NEUROL, V27, P1762, DOI 10.1111/ene.14278; SELLNER J, 2021, EUR, DOI DOI 10.1111/ENE.14713; Sellner J, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102492; Seyran M, 2021, FEBS J, V288, P5010, DOI 10.1111/febs.15651; Sorensen PS, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419836913; Stuve O, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419854986; Thakolwiboon Smathorn, 2020, Int J MS Care, V22, P151, DOI 10.7224/1537-2073.2020-037; Thevarajan I, 2020, NAT MED, V26, P453, DOI 10.1038/s41591-020-0819-2; Thompson SAJ, 2010, J CLIN IMMUNOL, V30, P99, DOI 10.1007/s10875-009-9327-3; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; von Oertzen TJ, 2021, EUR J NEUROL, V28, P7, DOI 10.1111/ene.14521; Warnke C, 2010, DRUG DES DEV THER, V4, P117; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Woodruff M, 2020, CRITICALLY ILL SARS, DOI [10.1101/2020.04.29.20083717, DOI 10.1101/2020.04.29.20083717]; Zabalza A, 2021, EUR J NEUROL, V28, P3384, DOI 10.1111/ene.14690; Zappulo E, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz445; Zheng C, 2020, CNS DRUGS, V34, P879, DOI 10.1007/s40263-020-00756-y; ZRZAVY T, 2020, EUR, DOI DOI 10.1111/ENE.14578; ZRZAVY T, 2019, NAT MED, V10, P1883, DOI DOI 10.3389/FIMMU.2019.01883	74	11	12	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							99	10.3390/vaccines9020099			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7FI	33525459	Green Published, gold			2022-04-29	WOS:000623305300001
J	Zhao, ZK; Chen, XH; Chen, YB; Li, H; Fang, K; Chen, HC; Li, XM; Qian, P				Zhao, Zekai; Chen, Xinghua; Chen, Yibao; Li, Hui; Fang, Kui; Chen, Huanchun; Li, Xiangmin; Qian, Ping			A Self-Assembling Ferritin Nanoplatform for Designing Classical Swine Fever Vaccine: Elicitation of Potent Neutralizing Antibody	VACCINES			English	Article						ferritin nanoplatform; classical swine fever virus; E2; neutralizing antibody		Protein-based self-assembling nanoplatforms exhibit superior immunogenicity compared with soluble antigens. Here, we present a comprehensive vaccine strategy for displaying classical swine fever virus (CSFV) E2 glycoprotein on the surface of ferritin (fe) nanocages. An E2-specific blocking antibody assay showed that the blocking rates in pE2-fe/Gel02 (84.3%) and a half-dose cohort of E2-fe/Gel02 (81.9%) were significantly higher (p < 0.05) than that in a ferritin-free cohort of pE2/Gel02 (62.7%) at 21 days post immunization (dpi) in vivo. Furthermore, quantitation of neutralizing potency revealed that a highly significant difference (p < 0.001) was observed between the pE2-fe/Gel02 cohort (1:32, equivalent to live-attenuated strain C at 1:32) and the pE2/Gel02 cohort (1:4) at 21 dpi. Moreover, the innate immune cytokines of IL-4 and IFN-gamma activated by the half-dose (20 mu g) cohort of E2-fe/Gel02 were equivalent to those elicited by the full dose (40 mu g) of purified E2 in the pE2/Gel02 cohort at most time points. In conclusion, we successfully obtained an antigen-displaying E2-ferritin nanoplatform and confirmed high ferritin-assisted humoral and cellular immunities. Our results provided a novel paradigm of self-assembling nanovaccine development for the defense and elimination of potentially pandemic infectious viral pathogens.	[Zhao, Zekai; Chen, Xinghua; Chen, Yibao; Li, Hui; Fang, Kui; Chen, Huanchun; Li, Xiangmin; Qian, Ping] Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan 430070, Peoples R China; [Zhao, Zekai; Chen, Xinghua; Chen, Yibao; Li, Hui; Fang, Kui; Chen, Huanchun; Li, Xiangmin; Qian, Ping] Huazhong Agr Univ, Coll Vet Med, Wuhan 430070, Peoples R China		Qian, P (通讯作者)，Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan 430070, Peoples R China.; Qian, P (通讯作者)，Huazhong Agr Univ, Coll Vet Med, Wuhan 430070, Peoples R China.	zekaizhao@yeah.net; cxhdeyx129@163.com; yibaochen@webmail.hzau.edu.cn; huilihzau@yeah.net; fangkui1987@126.com; liuchenxinxin@163.com; lixiangmin@mail.hzau.edu.cn; qianp@mail.hzau.edu.cn		Zhao, Zekai/0000-0002-3816-5471	National Program on Key Research Project of China [2018YFD0500801, 2018YFD0500204]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [2662016PY003]; Natural Science Foundation of Hubei ProvinceNatural Science Foundation of Hubei Province [2019CFA010]	This research was supported by the National Program on Key Research Project of China (2018YFD0500801, 2018YFD0500204), the Fundamental Research Funds for the Central Universities (2662016PY003), and Natural Science Foundation of Hubei Province (2019CFA010).	Abid M, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040279; Bellini M, 2020, SMALL, V16, DOI 10.1002/smll.202001450; Cao T, 2019, VIRUS GENES, V55, P238, DOI 10.1007/s11262-018-01631-1; Carty M, 2021, BIOCHEM PHARMACOL, V183, DOI 10.1016/j.bcp.2020.114316; Chen JY, 2019, VACCINE, V37, P6535, DOI 10.1016/j.vaccine.2019.08.039; Chen YB, 2020, VACCINE, V38, P5647, DOI 10.1016/j.vaccine.2020.06.063; Choe S, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040251; Englezou PC, 2018, MOL THER-NUCL ACIDS, V12, P118, DOI 10.1016/j.omtn.2018.04.019; Fan HY, 2008, MOL IMMUNOL, V45, P653, DOI 10.1016/j.molimm.2007.07.009; Feng L, 2020, ENG LIFE SCI, V20, P320, DOI 10.1002/elsc.201900147; Ganges L, 2020, VIRUS RES, V289, DOI 10.1016/j.virusres.2020.198151; Graham SP, 2012, VACCINE, V30, P2742, DOI 10.1016/j.vaccine.2012.02.029; Han JA, 2014, NANOMED-NANOTECHNOL, V10, P561, DOI 10.1016/j.nano.2013.11.003; Ismail Nermeen M., 2018, VirusDisease, V29, P324, DOI 10.1007/s13337-018-0463-3; Ji SW, 2018, ARCH VIROL, V163, P1831, DOI 10.1007/s00705-018-3809-7; Jiang ZY, 2020, VET MICROBIOL, V251, DOI 10.1016/j.vetmic.2020.108886; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Kelly HG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136653; Kesik M, 2004, IMMUNOL LETT, V91, P197, DOI 10.1016/j.imlet.2003.12.001; Li YF, 2020, BIOTECHNOL LETT, V42, P1169, DOI 10.1007/s10529-020-02853-w; Li YF, 2018, VIROLOGY, V519, P197, DOI 10.1016/j.virol.2018.04.016; Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001; Luo L, 2013, TRANSBOUND EMERG DIS, V60, P143, DOI 10.1111/j.1865-1682.2012.01327.x; Powell Abigail E, 2020, bioRxiv, DOI 10.1101/2020.08.28.272518; Shan H, 2020, NANOSCALE, V12, P22268, DOI 10.1039/d0nr04520a; Sliepen K, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0210-4; Tao LN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030510; Tong C, 2017, J MICROBIOL BIOTECHN, V27, P1701, DOI 10.4014/jmb.1704.04065; Wang MM, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070775; Wu QF, 2013, J VIROL METHODS, V187, P251, DOI 10.1016/j.jviromet.2012.11.018; Xia SL, 2016, VET MICROBIOL, V196, P50, DOI 10.1016/j.vetmic.2016.10.001; Xu HL, 2020, BMC MICROBIOL, V20, DOI 10.1186/s12866-020-1713-2; Zhang HW, 2018, VACCINE, V36, P7353, DOI 10.1016/j.vaccine.2018.10.030; Zhang HW, 2014, VACCINE, V32, P6607, DOI 10.1016/j.vaccine.2014.10.003; Zhao FJ, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01433-8	35	2	2	4	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							45	10.3390/vaccines9010045			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6YX	33451123	gold, Green Published			2022-04-29	WOS:000610818900001
J	Gonzaga, ZJC; Chen, SX; Lehoux, M; Segura, M; Rehm, BHA				Gonzaga, Zennia Jean C.; Chen, Shuxiong; Lehoux, Melanie; Segura, Mariela; Rehm, Bernd H. A.			Engineering Antigens to Assemble into Polymer Particle Vaccines for Prevention of Streptococcus suis Infection	VACCINES			English	Article						Streptococcus suis; particulate vaccine; biopolymer; subunit vaccine	PROTECTIVE ANTIGEN; ALPHA-ENOLASE; DELIVERY; PROTEIN; CELL; IDENTIFICATION; BEADS	Streptococcus suis is a zoonotic pathogen affecting pigs and humans. This bacterium causes severe economic losses in the swine industry and poses a serious threat to public health and food safety. There is no effective commercial vaccine available for pigs or humans. In this study, we applied the biopolymer particle (BP) vaccine technology to incorporate seven conserved S. suis antigens (38 kDa protein (38), enolase (Enol), SSU1915, SSU1355, SSU0185, SSU1215, and SSU1773 (SSU1 and SSU2)). Two combinations of these antigens (38 and Enol; all SSU antigens designated as SSU1 and SSU2) were engineered to mediate production of BPs coated with either antigens 38 and Enol or SSU1 and SSU2 inside recombinant Escherichia coli. The isolated and purified empty BPs, 38-BP-Enol and SSU1-BP-SSU2, showed size ranges of 312-428 nm and 292-344 nm with and without the QuilA(R) adjuvant, respectively, and all showed a negative surface charge. Further characterization of purified BPs confirmed the presence of the expected antigen-comprising fusion proteins as assessed by tryptic peptide fingerprinting analysis using quadrupole time-of-flight mass spectrometry and immunoblotting. Vaccination with 38-BP-Enol and SSU1-BP-SSU2 formulated with and without QuilA(R) adjuvant induced significant antigen-specific humoral immune responses in mice. Antigen-coated BPs induced significant and specific Ig (IgM + IgG) and IgG immune responses (1.0 x 10(6)-1.0 x 10(7)) when compared with mice vaccinated with empty BPs. Functionality of the immune response was confirmed in challenge experiments using an acute murine S. suis infection model, which showed 100% survival of the 38-BP-Enol and SSU1-BP-SSU2 vaccinated mice compared to 70% survival when vaccinated with empty BPs. Overall, our data suggest that S. suis antigen-coated BPs could be developed into particulate vaccines that induce protective immunity against S. suis infections.	[Gonzaga, Zennia Jean C.; Chen, Shuxiong; Rehm, Bernd H. A.] Griffith Univ, Griffith Inst Drug Discovery, Ctr Cell Factories & Biopolymers CCFB, Don Young Rd, Natha, Qld 4111, Australia; [Lehoux, Melanie; Segura, Mariela] Univ Montreal, Fac Vet Med, Res Grp Infect Dis Prod Anim, 3200 Rue Sicotte,CP5000, St Hyacinthe, PQ J2S 7C6, Canada; [Lehoux, Melanie; Segura, Mariela] Univ Montreal, Fac Vet Med, Swine & Poultry Infect Dis Res Ctr, 3200 Rue Sicotte,CP5000, St Hyacinthe, PQ J2S 7C6, Canada; [Rehm, Bernd H. A.] Griffith Univ, Menzies Hlth Inst Queensland MHIQ, Gold Coast, Qld 4222, Australia		Rehm, BHA (通讯作者)，Griffith Univ, Griffith Inst Drug Discovery, Ctr Cell Factories & Biopolymers CCFB, Don Young Rd, Natha, Qld 4111, Australia.; Rehm, BHA (通讯作者)，Griffith Univ, Menzies Hlth Inst Queensland MHIQ, Gold Coast, Qld 4222, Australia.	jean.gonzaga@griffithuni.edu.au; shuxiong.chen@griffith.edu.au; melanie.lehoux@umontreal.ca; mariela.segura@umontreal.ca; b.rehm@griffith.edu.au		Segura, Mariela/0000-0002-7489-4882	Australian Research Council (ARC)Australian Research Council [DP200100874]; ARC Linkage Infrastructure, Equipment and FacilitiesAustralian Research Council [LE20010014]	B.H.A.R. acknowledges the support from the Australian Research Council (ARC) Discovery Project (DP200100874) and the ARC Linkage Infrastructure, Equipment and Facilities (LE20010014).	Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Bergmann S, 2001, MOL MICROBIOL, V40, P1273, DOI 10.1046/j.1365-2958.2001.02448.x; Brockmeier SL, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00559-17; Calzas C, 2015, INFECT IMMUN, V83, P441, DOI 10.1128/IAI.02427-14; Chen SX, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202102089; De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006; Draper JL, 2012, BIOENGINEERED, V3, P203, DOI 10.4161/bioe.19567; Dutkiewicz J, 2017, ANN AGR ENV MED, V24, P683, DOI 10.26444/aaem/79813; DUVERNOY O, 1995, THORAC CARDIOV SURG, V43, P271, DOI 10.1055/s-2007-1013226; El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893; Estrada AA, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00377-19; Evert B, 2020, ACS APPL BIO MATER, V3, P8911, DOI 10.1021/acsabm.0c01195; Gonzalez-Miro M, 2019, BIOMACROMOLECULES, V20, P3213, DOI 10.1021/acs.biomac.9b00509; Gonzalez-Miro M, 2018, ACS BIOMATER SCI ENG, V4, P3413, DOI 10.1021/acsbiomaterials.8b00579; Gonzalez-Miro M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20205-7; Gottschalk Marcelo, 2007, Animal Health Research Reviews, V8, P29, DOI 10.1017/S1466252307001247; Gottschalk M, 2010, FUTURE MICROBIOL, V5, P371, DOI 10.2217/FMB.10.2; Goyette-Desjardins G, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.45; Grage K, 2009, BIOMACROMOLECULES, V10, P660, DOI 10.1021/bm801394s; Hay I.D., 2014, HYDROCARBON LIPID MI, P71; Hocking PJ, 1994, CHEM TECHNOLOGY BIOD; Honary S, 2013, TROP J PHARM RES, V12, P255, DOI 10.4314/tjpr.v12i2.19; Hsueh KJ, 2014, TRANSBOUND EMERG DIS, V61, pE35, DOI 10.1111/tbed.12067; Huang JH, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00118; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2; Mamat U., 2013, NATURE METHODS, V10, P916, DOI [10.1038/nmeth.f.367, DOI 10.1038/NMETH.F.367]; Martinez-Donato G, 2016, CLIN VACCINE IMMUNOL, V23, P370, DOI 10.1128/CVI.00687-15; Misener S, 2000, BIOINFORMATICS METHO; Moradali MF, 2020, NAT REV MICROBIOL, V18, P195, DOI 10.1038/s41579-019-0313-3; Okura M, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5030045; Okwumabua O, 2005, CLIN DIAGN LAB IMMUN, V12, P484, DOI 10.1128/CDLI.12.4.484-490.2005; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; Parlane NA, 2012, CLIN VACCINE IMMUNOL, V19, P37, DOI 10.1128/CVI.05505-11; Peters V, 2006, APPL ENVIRON MICROB, V72, P1777, DOI 10.1128/AEM.72.3.1777-1783.2006; Potocnakova L, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6760830; Rehm BHA, 2017, CURR OPIN BIOTECH, V48, P42, DOI 10.1016/j.copbio.2017.03.018; Rieckmann K, 2020, PORCINE HEALTH MANAG, V6, DOI 10.1186/s40813-020-00150-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd ed.; Segura M, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090707; Segura M, 2017, TRENDS MICROBIOL, V25, P586, DOI 10.1016/j.tim.2017.02.005; Segura M, 2015, EXPERT REV VACCINES, V14, P1587, DOI 10.1586/14760584.2015.1101349; Slater JD, 2003, VET MICROBIOL, V93, P197, DOI 10.1016/S0378-1135(03)00030-0; Soda N, 2021, ACS APPL MATER INTER, V13, P31418, DOI 10.1021/acsami.1c05355; Takeuchi D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031265; Thompson T., 2013, Compositions for Separation Methods, Patent No. [WO2013190453A2, 2013190453]; Wibowo D, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120597; Zhang AD, 2009, VACCINE, V27, P1348, DOI 10.1016/j.vaccine.2008.12.047	49	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1386	10.3390/vaccines9121386			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2HP	34960132	Green Published, gold			2022-04-29	WOS:000737479400001
J	Patwary, MM; Bardhan, M; Disha, AS; Hasan, M; Haque, MZ; Sultana, R; Hossain, MR; Browning, MHEM; Alam, MA; Sallam, M				Patwary, Muhammad Mainuddin; Bardhan, Mondira; Disha, Asma Safia; Hasan, Mehedi; Haque, Md. Zahidul; Sultana, Rabeya; Hossain, Md. Riad; Browning, Matthew H. E. M.; Alam, Md. Ashraful; Sallam, Malik			Determinants of COVID-19 Vaccine Acceptance among the Adult Population of Bangladesh Using the Health Belief Model and the Theory of Planned Behavior Model	VACCINES			English	Article						coronavirus; vaccine acceptance; Health Belief Model; Theory of Planned Behavior; Bangladesh	HESITANCY; INTENTION	Vaccination is undoubtedly one of the most effective strategies to halt the COVID-19 pandemic. The current study aimed to investigate the acceptance of COVID-19 vaccination and its associated factors using two health behavior change frameworks: the Health Belief Model (HBM) and the Theory of Planned Behavior (TPB). A total of 639 Bangladeshi adults (mean age: 24 years) participated in a cross-sectional online study between July and August 2021. The questionnaire covered questions regarding vaccine intentions, sociodemographic features, health status, perceived trust in/satisfaction with health authorities, reasons for vaccine hesitancy, and factors related to the health behavior change frameworks. Hierarchical logistic regression was employed to determine associations between these predictors and vaccine acceptance. The intention to get a COVID-19 vaccination was expressed among 85% of the participants. In fully adjusted models, students and respondents with more normal body weights reported higher intentions to get vaccinated. Respondents were also more likely to seek vaccination if they reported greater levels of perceived susceptibility, benefits, and cues to action, as well as lower levels of barriers and self-efficacy. Fear of future vaccine side effects was the most common reason for COVID-19 vaccine hesitancy and was expressed by 94% of the vaccine-hesitant respondents. These factors should be considered by health authorities in Bangladesh and perhaps other countries when addressing the plateauing COVID-19 vaccination rates in many populations.	[Patwary, Muhammad Mainuddin; Bardhan, Mondira; Disha, Asma Safia; Haque, Md. Zahidul] Environm & Sustainabil Res Initiat, Khulna 9208, Bangladesh; [Patwary, Muhammad Mainuddin; Bardhan, Mondira; Haque, Md. Zahidul; Sultana, Rabeya] Khulna Univ, Life Sci Sch, Environm Sci Discipline, Khulna 9208, Bangladesh; [Disha, Asma Safia] Univ Chem & Technol, Environm Technol & Engn, Prague 16628, Czech Republic; [Hasan, Mehedi] Bangabandhu Sheikh Mujibur Rahman Sci & Technol U, Dept Environm Sci & Disaster Management, Gopalganj 8100, Bangladesh; [Hossain, Md. Riad] Khulna Univ Engn & Technol, Inst Disaster Management, Khulna 9203, Bangladesh; [Browning, Matthew H. E. M.] Clemson Univ, Dept Pk Recreat & Tourism Management, Clemson, SC 29634 USA; [Alam, Md. Ashraful] Univ Tokyo, Grad Sch Med, Dept Global Hlth Policy, Tokyo 1130033, Japan; [Sallam, Malik] Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan; [Sallam, Malik] Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan		Sallam, M (通讯作者)，Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan.; Sallam, M (通讯作者)，Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan.	raju.es111012@gmail.com; mondirabardhan.22@gmail.com; dishaa@vscht.cz; mehedi.esd16@bsmrstu.edu.bd; rtr.zahid@gmail.com; rabeya.sultana@ku.ac.bd; riad.hossain@idm.kuet.ac.bd; mhb2@clemson.edu; aalam@m.u-tokyo.ac.jp; malik.sallam@ju.edu.jo	Alam, Ashraful/D-4637-2019; Patwary, Muhammad Mainuddin/AAK-8748-2020; Sallam, Malik/O-5021-2014; Browning, Matthew/D-2111-2014	Alam, Ashraful/0000-0002-7562-477X; Patwary, Muhammad Mainuddin/0000-0001-8895-9723; Sallam, Malik/0000-0002-0165-9670; Hasan, Mehedi/0000-0002-8516-7197; Haque, Md. Zahidul/0000-0002-8658-8962; Browning, Matthew/0000-0003-2296-7602; Sultana, Rabeya/0000-0002-1712-9842; Bardhan, Mondira/0000-0003-4642-1815; Hossain, Md. Riad/0000-0003-0676-3458			Abedin M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250495; Abul Kalam M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256496; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Al-Sanafi M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070701; Alam ABMM, 2021, EXPERT REV VACCINES, V20, P1167, DOI 10.1080/14760584.2021.1951248; Alhalaseh L, 2020, VACCINE, V38, P7372, DOI 10.1016/j.vaccine.2020.09.002; Ali M, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-050303; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; [Anonymous], DAILY STAR; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Banik R, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06406-y; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Cerda AA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.626852; Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.3.CO;2-D; Coe AB, 2022, RES SOC ADMIN PHARM, V18, P2593, DOI 10.1016/j.sapharm.2021.04.023; Dasgupta P, 2018, INDIAN J PUBLIC HLTH, V62, P253, DOI 10.4103/ijph.IJPH_397_17; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Fan CW, 2021, HUM VACC IMMUNOTHER, V17, P3413, DOI 10.1080/21645515.2021.1933687; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gabriel EH, 2019, J SCI MED SPORT, V22, P544, DOI 10.1016/j.jsams.2018.11.004; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111222; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Godin G, 1996, AM J HEALTH PROMOT, V11, P87, DOI 10.4278/0890-1171-11.2.87; Goruntla N, 2021, ASIAN PAC J TROP MED, V14, P165, DOI 10.4103/1995-7645.312512; Han E, 2020, LANCET, V396, P1525, DOI 10.1016/S0140-6736(20)32007-9; Haque MMA, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e07376; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Haug N, 2020, NAT HUM BEHAV, V4, DOI 10.1038/s41562-020-01009-0; Herbec A., 2020, PERCEIVED RISK FACTO, DOI [10.31234/osf.io/xj5z7, DOI 10.31234/OSF.IO/XJ5Z7]; Hossain M.S., 2020, J BIOMED ANAL, V3, P1, DOI [10.30577/jba.v3i2.40, DOI 10.30577/JBA.V3I2.40]; Hossain MB, 2021, COVID 19 VACCINE HES, DOI [DOI 10.1101/2021.04.23.21255844, 10.1101/2021.04.23.21255844]; Islam MS, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11880-9; Jackson SE, 2021, NICOTINE TOB RES, V23, P1623, DOI 10.1093/ntr/ntab039; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Jennings W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060593; Kabir R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050416; Kanozia R., 2021, MEDIA ASIA, DOI 10.1080/01296612.2021.1921963; Kazi Asequl A., 2021, RES SQ, DOI [10.21203/rs.3.rs-506924/v1, DOI 10.21203/RS.3.RS-506924/V1]; Kerr JR, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-048025; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Ledford H, 2020, NATURE, V586, P488, DOI 10.1038/d41586-020-02946-6; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Mahmud S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257096; Mangtani P, 2005, PREV MED, V41, P545, DOI 10.1016/j.ypmed.2005.02.001; Mo PKH, 2015, HEALTH EDUC RES, V30, P706, DOI 10.1093/her/cyv038; Moona A A, 2021, Infect Prev Pract, V3, P100159, DOI 10.1016/j.infpip.2021.100159; Parvej MI, 2021, ASIAN PAC J TROP MED, V14, P341, DOI 10.4103/1995-7645.321610; Paul A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256493; Regmi K, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18084274; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Ruma P, WAIT IS OVER BANGLAD; Sallam M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052407; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Seale H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235112; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Statulator, STAT FREE ON LIN STA; Tao LY, 2021, HUM VACC IMMUNOTHER, V17, P2378, DOI 10.1080/21645515.2021.1892432; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Thaker J, 2021, J HEALTH COMMUN, V26, P104, DOI 10.1080/10810730.2021.1899346; Townsend MJ, 2021, OBESITY, V29, P634, DOI 10.1002/oby.23131; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Tumban E, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010054; Vallis M, 2021, OBESITY, V29, P1128, DOI 10.1002/oby.23182; Viana J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23938-8; Wada K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059272; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wells A., 1995, BEHAV COGN PSYCHOTH, V23, P301, DOI [DOI 10.1017/S1352465800015897, 10.1017/S1352465800015897]; WHO, COVID 19 PUBL HLTH E; Wolff K, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.648289; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization (WHO), BANGL MORB MORT WEEK; Worldometer S., 2020, COVID 19 COR PAND WO; Yahaghi R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070684; Yan E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070696; Zampetakis LA, 2021, APPL PSYCHOL-HLTH WE, V13, P469, DOI 10.1111/aphw.12262	83	3	3	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1393	10.3390/vaccines9121393			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY8WD	34960138	Green Published, gold			2022-04-29	WOS:000737244800001
J	Ramatillah, DL; Gan, SH; Sulaiman, SAS; Puja, D; Abubakar, U; Jaber, AAS; Lukas, S; Jusnita, N				Ramatillah, Diana Laila; Gan, Siew Hua; Sulaiman, Syed Azhar Syed; Puja, Dama; Abubakar, Usman; Jaber, Ammar Ali Saleh; Lukas, Stefanus; Jusnita, Nina			Evaluation of Treatment Outcome for Pneumonia among Pre-Vaccinated COVID-19 Patients with/without Comorbidity in a Public Hospital in Bengkulu, Indonesia	VACCINES			English	Article						COVID-19; Pneumonia; green zone; pre-vaccination		Pneumonia is one of the common complications of SARS-CoV-2 infection where most patients have moderate to severe symptoms that pose a higher risk for death. This study aims to evaluate the treatment outcome of COVID-19-associated Pneumonia among patients with/without comorbidity in a public hospital in Indonesia. This is a retrospective cohort study involving unvaccinated confirmed COVID-19 patients admitted to the hospital between March and December 2020. All confirmed COVID-19 patients with Pneumonia (n = 1522) treated at the hospital were included. The majority of patients (99%) had mild COVID-19 symptoms while the remaining had moderate symptoms. The median age was about 32 years old and the average treatment duration was 6.25 +/- 1.83 days. Most patients (88.8%) received a combination of azithromycin and oseltamivir. There was a very significant relationship (p < 0.001) between comorbidities with treatment and duration of treatment of Pneumonia in COVID-19 patients. Although most patients had Pneumonia and comorbidities, they were successfully treated with azithromycin and oseltamivir combination following approximately five days of treatment.	[Ramatillah, Diana Laila; Puja, Dama; Lukas, Stefanus; Jusnita, Nina] Univ 17 Agustus 1945 Jakarta, Fac Pharm, Jakarta 14350, Indonesia; [Gan, Siew Hua] Monash Univ Malaysia, Sch Pharm, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia; [Sulaiman, Syed Azhar Syed; Abubakar, Usman] Univ Sains Malaysia, Sch Pharmaceut Sci, Discipline Clin Pharm, Gelugor 11800, Penang, Malaysia; [Jaber, Ammar Ali Saleh] Dubai Pharm Coll Girls, Dept Clin Pharm & Pharmacotherapeut, Dubai 19099, U Arab Emirates		Ramatillah, DL (通讯作者)，Univ 17 Agustus 1945 Jakarta, Fac Pharm, Jakarta 14350, Indonesia.	gan.siewhua@monash.edu; Dr.ammar@dpc.edu; stefanus.lukas@uta45jakarta.ac.id; nina.jusnita@uta45jakarta.ac.id	; gan, siew hua/A-6266-2011	Abubakar, Usman/0000-0002-7549-2877; gan, siew hua/0000-0001-6470-3651; Ramatillah, Diana Laila/0000-0002-3921-3455; Jaber, Ammar/0000-0003-0411-1923			Adams ML, 2020, EMERG INFECT DIS, V26, P1831, DOI 10.3201/eid2608.200679; [Anonymous], 2016, STATISTA PREVALENCE; Atkins JL, 2020, J GERONTOL A-BIOL, V75, P2224, DOI 10.1093/gerona/glaa183; Beurnier A, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01875-2020; Boddington N. L., 2020, COVID 19 GREAT BRITA, DOI [10.1101/2020.05.18.20086157, DOI 10.1101/2020.05.18.20086157]; Burhan E., 2020, TREATMENT PROTOKOL C, V1st; Chen C., 2021, CHARACTERISTICS DEAT, DOI [10.1101/2020.05.07.20092882, DOI 10.1101/2020.05.07.20092882]; Daniels LB, 2020, AM J CARDIOL, V136, P149, DOI 10.1016/j.amjcard.2020.09.012; de Souza FSH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248580; Feng ZC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18786-x; Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198; Government Bengkulu, 2021, IND MIN HLTH GARM BE; Government Bengkulu, 2020, IND MIN HLTH GARM BE; Hernandez-Vasquez Akram, 2020, J Prev Med Public Health, V53, P211, DOI 10.3961/jpmph.20.186; Iwasawa T, 2020, JPN J RADIOL, V38, P394, DOI 10.1007/s11604-020-00956-y; Kemkes R.I, 2020, PROJECT YOURSELF YOU; Kumar Y, 2020, J INFECT PUBLIC HEAL, V13, P1210, DOI 10.1016/j.jiph.2020.06.016; Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672; Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79; Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020; Mahil SK, 2021, J ALLERGY CLIN IMMUN, V147, P60, DOI 10.1016/j.jaci.2020.10.007; Merzon E, 2022, J ATTEN DISORD, V26, P491, DOI 10.1177/10870547211003659; Ministry of Home Affairs Working Team of Indonesia, 2020, GEN GUID FAC COVID 1; Moreno-Perez O, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102523; Ouassou H, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/1357983; PDPI PERKI PAPDI PERDATIN IDAI COVID-19 Treatment Guideline Edition 3, PED TAT COVID 19 202, P37; Permana R.C.E., 2020, PARADIG J KAJI BUDAY, V4, P27, DOI [10.17510/paradigma.v4i1.157, DOI 10.17510/PARADIGMA.V4I1.157]; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Qiu FF, 2017, ONCOTARGET, V8, P268, DOI 10.18632/oncotarget.13613; Ramatillah DL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250147; Richardson S., 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI [DOI 10.1001/JAMA.2020.6775, 10.1001/jama.2020.7681]; Sebayang R, 2020, AWAS WHO AKHIRNYA TE; Suhartati S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1]; The Indonesian Food and Drug Authority, 2020, INF COVID 19 DRUGS I; Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40; Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4; WHO, 2020, 76 WHO; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization (WHO), TABL THER WHO COORD; Yang Y, 2020, MEDRXIV, DOI [10.1101/2020.02.11.20021493, 10.1101/2020.02.11.20021493v2, DOI 10.1101/2020.02.11.20021493]; Yin TX, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05915-0; Zeng FR, 2020, AGING-US, V12, P20982, DOI 10.18632/aging.103980; Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012	43	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1411	10.3390/vaccines9121411			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0AY	34960157	Green Published, gold			2022-04-29	WOS:000737326800001
J	Shi, XK; Zhou, X; Yue, C; Gao, SL; Sun, ZQ; Lu, C; Zuo, L				Shi, Xiaokai; Zhou, Xiao; Yue, Chuang; Gao, Shenglin; Sun, Zhiqin; Lu, Chao; Zuo, Li			A Five Collagen-Related Gene Signature to Estimate the Prognosis and Immune Microenvironment in Clear Cell Renal Cell Cancer	VACCINES			English	Article						collagen; epithelial-mesenchymal transition (EMT); GSEA; immune microenvironment; prognosis	CARCINOMA; MACROPHAGES; ASSOCIATION; PROGRESSION; STATISTICS; EXPRESSION; MIGRATION; INVASION; GROWTH	Collagen is the main component of the extracellular matrix (ECM) and might play an important role in tumor microenvironments. However, the relationship between collagen and clear cell renal cell cancer (ccRCC) is still not fully clarified. Hence, we aimed to establish a collagen-related signature to predict the prognosis and estimate the tumor immune microenvironment in ccRCC patients. Patients with a high risk score were often correlated with unfavorable overall survival (OS) and an immunosuppressive microenvironment. In addition, the collagen-related genetic signature was highly correlated with clinical pathological features and can be considered as an independent prognostic factor in ccRCC patients. Moreover, GSEA results show that patients with a high risk grade tend to be associated with epithelial-mesenchymal junctions (EMT) and immune responses. In this study, we developed a collagen-related gene signature, which might possess the potential to predict the prognosis and immune microenvironment of ccRCC patients and function as an independent prognostic factor in ccRCC.	[Shi, Xiaokai; Yue, Chuang; Gao, Shenglin; Lu, Chao; Zuo, Li] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Urol, Changzhou 213000, Jiangsu, Peoples R China; [Zhou, Xiao] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Oncol, Changzhou 213000, Jiangsu, Peoples R China; [Sun, Zhiqin] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Sch Clin Med, Changzhou 213000, Jiangsu, Peoples R China		Zuo, L (通讯作者)，Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Urol, Changzhou 213000, Jiangsu, Peoples R China.	shixiaokai@njmu.edu.cn; zhouxiao@stu.njmu.edu.cn; yuechuang9897@163.com; gsl_cmu@163.com; szq719819@163.com; deerchao@163.com; zuoli@njmu.edu.cn					Afik R, 2016, J EXP MED, V213, P2315, DOI 10.1084/jem.20151193; Banyard J, 2007, CLIN CANCER RES, V13, P2634, DOI 10.1158/1078-0432.CCR-06-2163; Barbi J, 2014, IMMUNOL REV, V259, P115, DOI 10.1111/imr.12172; Cai X, 2018, J CELL BIOCHEM, V119, P4717, DOI 10.1002/jcb.26651; Casimiro S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091415; Cavaco ACM, 2020, CANCER METAST REV, V39, P603, DOI 10.1007/s10555-020-09888-5; Chattopadhyay I, 2009, ONCOL REP, V21, P1135, DOI 10.3892/or_00000333; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1; Dennis KL, 2013, CURR OPIN ONCOL, V25, P637, DOI 10.1097/CCO.0000000000000006; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Fang S, 2019, THORAC CANCER, V10, P277, DOI 10.1111/1759-7714.12947; Garcia-Mendoza MG, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0703-7; Gloushankova NA, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1469, DOI 10.1134/S0006297918120052; Haque S, 2017, HUM VACC IMMUNOTHER, V13, P1741, DOI 10.1080/21645515.2017.1327107; Heichler C, 2020, GUT, V69, P1269, DOI 10.1136/gutjnl-2019-319200; Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006; Ingman WV, 2006, DEV DYNAM, V235, P3222, DOI 10.1002/dvdy.20972; Jing YY, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-29; Kato T, 2018, CLIN CANCER RES, V24, P4820, DOI 10.1158/1078-0432.CCR-18-0205; Kita Y, 2009, EJSO-EUR J SURG ONC, V35, P52, DOI 10.1016/j.ejso.2008.01.025; Kumari N, 2016, TUMOR BIOL, V37, P11553, DOI 10.1007/s13277-016-5098-7; Lai SL, 2019, CANCERS, V11, DOI 10.3390/cancers11111766; Larsen AMH, 2020, J IMMUNOL, V205, P1461, DOI 10.4049/jimmunol.1900789; Legendre F, 2003, J BIOL CHEM, V278, P2903, DOI 10.1074/jbc.M110773200; Li B, 2019, CURR MED CHEM, V26, P3009, DOI 10.2174/0929867324666170804143706; Li F, 2021, COMPUT BIOL CHEM, V92, DOI 10.1016/j.compbiolchem.2021.107453; Li JL, 2019, PEERJ, V7, DOI 10.7717/peerj.7705; Lin WZ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00796; Liverani C, 2017, CELL MOL BIOENG, V10, P223, DOI 10.1007/s12195-017-0483-x; Miyake M, 2017, ONCOTARGET, V8, P36099, DOI 10.18632/oncotarget.16432; Molina AM, 2014, EUR J CANCER, V50, P351, DOI 10.1016/j.ejca.2013.08.021; Owusu-Ansah KG, 2019, INT J ONCOL, V55, P391, DOI 10.3892/ijo.2019.4825; Pankova D, 2019, EMBO J, V38, DOI 10.15252/embj.2018100532; Peng DH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18298-8; Pourreyron C, 2014, BRIT J DERMATOL, V170, P1256, DOI 10.1111/bjd.12715; Qiu S, 2019, CANCER SCI, V110, P2110, DOI 10.1111/cas.14078; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ritzenthaler JD, 2008, MOL BIOSYST, V4, P1160, DOI 10.1039/b800533h; Shen LH, 2016, ONCOL REP, V36, P877, DOI 10.3892/or.2016.4869; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Varol C, 2019, METHODS MOL BIOL, V1944, P203, DOI 10.1007/978-1-4939-9095-5_15; Wan FN, 2015, ONCOTARGET, V6, P27378, DOI 10.18632/oncotarget.4860; Win Aung Zaw, 2015, World J Nucl Med, V14, P36, DOI 10.4103/1450-1147.150535; Wu Y, 2016, J CELL MOL MED, V20, P2328, DOI 10.1111/jcmm.12924; Zeng XT, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010091; Zhang H, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1030-y; Zhou ZH, 2017, J CANCER, V8, P1466, DOI 10.7150/jca.18466	50	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1510	10.3390/vaccines9121510			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY8ZR	34960256	Green Submitted, gold, Green Published			2022-04-29	WOS:000737254100001
J	Buchhorn, R; Meyer, C; Schulze-Forster, K; Junker, J; Heidecke, H				Buchhorn, Reiner; Meyer, Carlotta; Schulze-Forster, Kai; Junker, Juliane; Heidecke, Harald			Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome?	VACCINES			English	Article						COVID-19; autoantibodies; children; multisystem inflammatory syndrome; SARS-CoV-2 vaccination; Hashimoto thyroiditis		Multisystem inflammatory syndrome (MIS) is a new systemic inflammatory acute onset disease that mainly affects children (MIS-C) and, at a lesser frequency, adults (MIS-A); it typically occurs 3-6 weeks after acute SARS-CoV infection. It has been postulated and shown in adults that MIS may occur after SARS-CoV-2 vaccination (MIS-V). Our current case is one of the first published cases with a multisystem inflammatory syndrome in an 18-year-old adolescent after the SARS-CoV-2 vaccine from Pfizer/BionTech (BNT162b2), who fulfills the published level 1 criteria for a definitive disease: age < 21 years, fever > 3 consecutive days, pericardial effusion, elevated CRP/NT-BNP/Troponin T/D-dimeres, cardiac involvement, and positive SARS-CoV-2 antibodies. The disease starts 10 weeks after the second vaccination, with a fever (up to 40 & DEG;C) and was treated with amoxicillin for suspected pneumonia. The SARS CoV-2-PCR and several antigen tests were negative. With an ongoing fever, he was hospitalized 14 days later. A pericardial effusion (10 mm) was diagnosed by echocardiography. The C-reactive protein (174 mg/L), NT-BNP (280 pg/mL), and Troponin T (28 pg/mL) values were elevated. Due to highly elevated D-dimeres (> 35,000 mu g/L), a pulmonary embolism was excluded by thoracal computer tomography. If the boy did not improve with intravenous antibiotics, he was treated with intravenous immunoglobulins; however, the therapy was discontinued after 230 mg/kg if he developed high fever and hypotension. A further specialized clinic treated him with colchicine and ibuprofen. The MIS-V was discovered late, 4 months after the onset of the disease. As recently shown in four children with MIS-C after SARS-CoV-2 infection and a girl with Hashimoto thyroiditis after BNT162b2 vaccination, we found elevated functional autoantibodies against G-protein-coupled receptors that may be important for pathophysiology but are not conclusive for the diagnosis of MIS-C. Conclusion: We are aware that a misattribution of MIS-V as a severe complication of coronavirus vaccination can lead to increased vaccine hesitancy and blunt the global COVID-19 vaccination drive. However, the pediatric population is at a higher risk for MIS-C and a very low risk for COVID-19 mortality. The publication of such cases is very important to make doctors aware of this complication of the vaccination, so that therapy with intravenous immunoglobulins can be initiated at an early stage.	[Buchhorn, Reiner] Caritas Krankenhaus Bad Mergentheim, Dept Pediat, Uhlandstr 7, D-97980 Bad Mergentheim, Germany; [Buchhorn, Reiner] Kinderkardiol & Erwachsene Angeborenen Herzfehler, Praxis Kinder & Jugendmed, Bahnhof 1, D-74670 Forchtenberg, Germany; [Meyer, Carlotta; Schulze-Forster, Kai; Junker, Juliane; Heidecke, Harald] CellTrend GmbH, D-14943 Luckenwalde, Germany		Buchhorn, R (通讯作者)，Caritas Krankenhaus Bad Mergentheim, Dept Pediat, Uhlandstr 7, D-97980 Bad Mergentheim, Germany.; Buchhorn, R (通讯作者)，Kinderkardiol & Erwachsene Angeborenen Herzfehler, Praxis Kinder & Jugendmed, Bahnhof 1, D-74670 Forchtenberg, Germany.	ProKidsCare@praxisgemeinschaft-forchtenberg.de					Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475; Brisinda D, 2012, CIRC J, V76, P1345, DOI 10.1253/circj.CJ-11-1374; Buchhorn R, 2021, MONATSSCHR KINDERH, V169, P645, DOI 10.1007/s00112-021-01197-7; Buchhorn R., 2020, INT CARDIOVASC FORUM, DOI [10.17987/icfj.v20i0.685, DOI 10.17987/ICFJ.V20I0.685]; Buchhorn R, 2021, ISR MED ASSOC J; Buchhorn R, 2020, J BIOMED ENG MED IMA, V7, P1, DOI [10.14738/jbemi.74.8589, DOI 10.14738/JBEMI.74.8589]; Camino Manuela, 2019, Front Biosci (Elite Ed), V11, P102; Dotan A, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102792; Dungen HD, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.119.006155; Feghali Karen, 2021, J Clin Transl Endocrinol Case Rep, V22, P100094, DOI 10.1016/j.jecr.2021.100094; Huston JM, 2011, J INTERN MED, V269, P45, DOI 10.1111/j.1365-2796.2010.02321.x; Lagoumintzis G, 2021, FOOD CHEM TOXICOL, V149, DOI 10.1016/j.fct.2021.112009; Liu WK, 2021, HELL J CARDIOL, V62, P265, DOI 10.1016/j.hjc.2020.12.004; Salzman MB, 2021, EMERG INFECT DIS, V27, P1944, DOI 10.3201/eid2707.210594; Tschope C, 2021, NAT REV CARDIOL, V18, P169, DOI 10.1038/s41569-020-00435-x; Vogel TP, 2021, VACCINE, V39, P3037, DOI 10.1016/j.vaccine.2021.01.054; Wallukat G, 2021, J TRANSL AUTOIMMUN, V4, DOI 10.1016/j.jtauto.2021.100100; Wu YJ, 2021, INFLAMMATION, V44, P821, DOI 10.1007/s10753-020-01396-6	18	5	5	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1353	10.3390/vaccines9111353			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF5MT	34835284	Green Published, gold			2022-04-29	WOS:000724114900001
J	Ghasemi, S; Saffar, KN; Ebrahimi, F; Khatami, P; Monazah, A; Alizadeh, GA; Ettehadi, HA; Rad, I; Nojehdehi, S; Kehtari, M; Kouhkan, F; Barjasteh, H; Moradi, S; Ghorbani, MH; Khodaie, A; Papizadeh, M; Najafi, R; Naghneh, E; Sadeghi, D; Rahjerdi, AK				Ghasemi, Soheil; Saffar, Kosar Naderi; Ebrahimi, Firooz; Khatami, Pezhman; Monazah, Arina; Alizadeh, Ghorban-Ali; Ettehadi, Hossein-Ali; Rad, Iman; Nojehdehi, Shahrzad; Kehtari, Mousa; Kouhkan, Fatemeh; Barjasteh, Hesam; Moradi, Sohrab; Ghorbani, Mohammad-Hosein; Khodaie, Ali; Papizadeh, Moslem; Najafi, Roghayeh; Naghneh, Ehsan; Sadeghi, Davood; Rahjerdi, Ahmad Karimi			Development of Inactivated FAKHRAVAC(R) Vaccine against SARS-CoV-2 Virus: Preclinical Study in Animal Models	VACCINES			English	Article						SARS-CoV-2; vaccine candidate; FAKHRAVAC; COVID-19		The recent viral infection disease pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global public health crisis. Iran, as one of the countries that reported over five million infected cases by September 2021, has been concerned with the urgent development of effective vaccines against SARS-CoV-2. In this paper, we report the results of a study on potency and safety of an inactivated SARS-CoV-2 vaccine candidate (FAKHRAVAC) in a preclinical study so as to confirm its potential for further clinical evaluation. Here, we developed a pilot-scale production of FAKHRAVAC, a purified inactivated SARS-CoV-2 virus vaccine candidate that induces neutralizing antibodies in Balb/c mice, guinea pigs, rabbits, and non-human primates (Rhesus macaques-RM). After obtaining ethical code of IR.IUMS.REC.1399.566, immunizations of animals were conducted by using either of three different vaccine dilutions; High (H): 10 mu g/dose, Medium (M): 5 mu g/dose, and Low (L): 1 mu g/dose, respectively. In the process of screening for viral seeds, viral strains that resulted in the most severe clinical manifestation in patients have been isolated for vaccine development. The viral seed produced the optimal immunity against SARS-CoV-2 virus, which suggests a possible broader neutralizing ability against SARS-CoV-2 strains. The seroconversion rate at the H-, M-, and L-dose groups of all tested animals reached 100% by 28 days after immunization. These data support the eligibility of FAKHRAVAC vaccine candidate for further evaluation in a clinical trial.	[Ghasemi, Soheil; Saffar, Kosar Naderi; Khatami, Pezhman; Monazah, Arina; Alizadeh, Ghorban-Ali; Ettehadi, Hossein-Ali; Barjasteh, Hesam; Moradi, Sohrab; Ghorbani, Mohammad-Hosein; Khodaie, Ali; Papizadeh, Moslem; Najafi, Roghayeh; Naghneh, Ehsan; Rahjerdi, Ahmad Karimi] Milad Daro Noor Pharmaceut MDNP Co, Unit 3,Mirsharifi Alley,Valiasr St, Tehran 1986936914, Iran; [Saffar, Kosar Naderi; Rad, Iman; Nojehdehi, Shahrzad; Kehtari, Mousa; Kouhkan, Fatemeh; Rahjerdi, Ahmad Karimi] Stem Cell Technol Res Ctr STRC, Bldg 9,2nd East Alley,Mohammad Ali Keshavarz Blvd, Tehran 1997775555, Iran; [Ebrahimi, Firooz; Sadeghi, Davood] Imam Hussein Univ, Fac Basic Sci, Dept Biol, Tehran 1698715461, Iran		Rahjerdi, AK (通讯作者)，Milad Daro Noor Pharmaceut MDNP Co, Unit 3,Mirsharifi Alley,Valiasr St, Tehran 1986936914, Iran.; Rahjerdi, AK (通讯作者)，Stem Cell Technol Res Ctr STRC, Bldg 9,2nd East Alley,Mohammad Ali Keshavarz Blvd, Tehran 1997775555, Iran.	S-Ghasemi@mdnp.ir; K-Naderi@mdnp.ir; ebrahimi@ihu.ac.ir; P-Khatami@mndp.ir; A-Monazah@mndp.ir; GA-Alizadeh@mndp.ir; HA-Ettehadi@mndp.ir; rad@strc.ac.ir; sh.nojehdehi@strc.ac.ir; kehtari@strc.ac.ir; f.kouhkan@yahoo.com; H-Barjasteh@mdnp.ir; S-Moradi@mdnp.ir; MH-Ghorbani@mdnp.ir; A-Khodaie@mdnp.ir; M-Papizadeh@mdnp.ir; R-Najafi@mdnp.ir; E-Naghneh@mdnp.ir; sadeghi@ihu.ac.ir; A-Karimi@mdnp.ir			Milad Daro Noor Pharmaceutical (MDNP) Company; MNDP	This research was funded by Milad Daro Noor Pharmaceutical (MDNP) Company, and the APC was funded by MNDP.	Barati B, 2018, IRAN J IMMUNOL, V15, P47, DOI IJIv15i1A5; Bitencourt-Ferreira G, 2019, METHODS MOL BIOL, V2053, P149, DOI 10.1007/978-1-4939-9752-7_10; Blair RV, 2021, AM J PATHOL, V191, P274, DOI 10.1016/j.ajpath.2020.10.016; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gibson-Corley KN, 2013, VET PATHOL, V50, P1007, DOI 10.1177/0300985813485099; HAMILTON MA, 1978, ENVIRON SCI TECHNOL, V12, P417, DOI 10.1021/es60140a017; Hatcher EL, 2017, NUCLEIC ACIDS RES, V45, pD482, DOI 10.1093/nar/gkw1065; Jeshvaghani FS, 2016, PROTEIN PEPTIDE LETT, V23, P33, DOI 10.2174/0929866522666151026122116; Khodayari K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1852962; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Planas D., 2021, NAT MED, V27, P917, DOI [DOI 10.1038/s41591-021-01318-5, 10.1038/s41591-021-01318-5]; Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772; Public Health Ontario, 2021, TRENDS COVID 19 INC, P1; Ramakrishnan Muthannan Andavar, 2016, World J Virol, V5, P85, DOI 10.5501/wjv.v5.i2.85; REED L. J., 1938, AMER JOUR HYG, V27, P493; Safari I, 2021, J MED VIROL, V93, P2010, DOI 10.1002/jmv.26553; Starr TN, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100255; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Trougakos IP, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929-020-00703-5; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; WHO, 2021, COVID 19 WEEKL EP UP; Yadav PD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21639-w; Zellweger RM, 2020, EXPERT REV VACCINES, V19, P691, DOI 10.1080/14760584.2020.1800463	24	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1271	10.3390/vaccines9111271			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI0ET	34835202	Green Published, gold			2022-04-29	WOS:000725797200001
J	Bagateli, LE; Saeki, EY; Fadda, M; Agostoni, C; Marchisio, P; Milani, GP				Bagateli, Leonardo Evangelista; Saeki, Edna Yayoi; Fadda, Marta; Agostoni, Carlo; Marchisio, Paola; Milani, Gregorio Paolo			COVID-19 Vaccine Hesitancy among Parents of Children and Adolescents Living in Brazil	VACCINES			English	Article						SARS-CoV-2; low-income country; vaccination; children; adolescents; variants; barriers; Parent Attitudes about Childhood Vaccines	CORONAVIRUS DISEASE 2019; WILLINGNESS; ACCEPTANCE; INFLUENZA	Background: The immunization of large portions of populations in low/middle-income countries is considered one of the key measures to limit the development of new SARS-CoV-2 variants. However, parental vaccine hesitancy might be an important obstacle to pediatric vaccination. The aim of this survey was to study the prevalence and extent of COVID-19 vaccine hesitancy among parents of children and adolescents living in Brazil. Methods: Caregivers of children and adolescents referred to the emergency department of Hospital Estadual de Bauru, Sao Paulo (Brazil) were invited to fill in a validated questionnaire on vaccine hesitancy and to report their willingness for themselves and their offspring to receive a COVID-19 vaccine. Results: A total of 501 consecutive caregivers filled in the survey. Response rate was 100%. A minority (N = 14, 2.8%) of caregivers were hesitant about vaccines. Despite this, half of them declared they were willing to vaccinate their offspring against COVID-19. Conclusions: This survey identifies that vaccine hesitancy is very low among caregivers living in Brazil and that even many of the hesitant caregivers are willing to vaccinate their offspring against COVID-19. This study highlights the importance of offering the COVID-19 vaccination to the whole population, including subjects that present uncertainty about other vaccines.</p>	[Bagateli, Leonardo Evangelista; Agostoni, Carlo; Marchisio, Paola; Milani, Gregorio Paolo] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy; [Saeki, Edna Yayoi] Hosp Estadual Bauru, Pediat, BR-17033360 Bauru, SP, Brazil; [Fadda, Marta] Univ Svizzera Italiana, Fac Sci Biomed, CH-6900 Lugano, Switzerland; [Agostoni, Carlo; Marchisio, Paola; Milani, Gregorio Paolo] Fdn IRCCS Ca Granda Osped Maggiore Polcilin, Pediat Unit, I-20122 Milan, Italy		Agostoni, C (通讯作者)，Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy.; Agostoni, C (通讯作者)，Fdn IRCCS Ca Granda Osped Maggiore Polcilin, Pediat Unit, I-20122 Milan, Italy.	leonardo.evangelistabagateli@studenti.unimi.it; eysaeki@yahoo.com.br; marta.fadda@usi.ch; carlo.agostoni@unimi.it; paola.marchisio@unimi.it; milani.gregoriop@gmail.com	Agostoni, Carlo/B-3470-2015; Milani, Gregorio Paolo/I-7777-2015	Agostoni, Carlo/0000-0002-5006-0832; Milani, Gregorio Paolo/0000-0003-3829-4254; Fadda, Marta/0000-0003-3537-0346	Italian Ministry of Health, Ricerca corrente 2020	The research was partially funded by a grant of the Italian Ministry of Health, Ricerca corrente 2020.	Alauzet P, 2021, EUR J PEDIATR, V180, P303, DOI 10.1007/s00431-020-03751-z; Lopes ADA, 2021, TROP MED INT HEALTH, V26, P115, DOI 10.1111/tmi.13529; Alzahrani SH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070798; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Azizi FSM, 2017, VACCINE, V35, P2955, DOI 10.1016/j.vaccine.2017.04.010; de Araujo LA, 2021, J PEDIAT-BRAZIL, V97, P369, DOI 10.1016/j.jped.2020.08.008; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; de Winter JP, 2020, EUR J PEDIATR, V179, P1175, DOI 10.1007/s00431-020-03668-7; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Engzell P, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022376118; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1126/science.abh2644Article, 10.1101/2021.02.26.21252554]; Garcia-Salido A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03332-4; Garcia-Vera C, 2022, EUR J PEDIATR, V181, P1235, DOI 10.1007/s00431-021-04235-4; Goldman RD, 2021, J PEDIATR-US, V228, P87, DOI 10.1016/j.jpeds.2020.08.005; Goldman RD, 2020, CLIN THER, V42, P2124, DOI 10.1016/j.clinthera.2020.09.012; Han BH, 2021, LANCET INFECT DIS, V21, P1645, DOI 10.1016/S1473-3099(21)00319-4; Joshi A, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.698111; Kamidani S, 2021, CURR OPIN PEDIATR, V33, P144, DOI 10.1097/MOP.0000000000000978; Klass P, 2021, NEW ENGL J MED, V384, P589, DOI 10.1056/NEJMp2034765; Koenig J, 2021, EUR CHILD ADOLES PSY, DOI 10.1007/s00787-021-01843-1; Kompaniyets L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.11182; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lin SY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080884; Lopez-Bueno R, 2021, PREV MED, V143, DOI 10.1016/j.ypmed.2020.106349; Milani G.P., 2021, ARCH DIS CHILD, V106, P999, DOI [10.1136/archdischild-2020-321108, DOI 10.1136/archdischild-2020-321108]; Milani GP, 2021, JAMA PEDIATR, V175, P193, DOI 10.1001/jamapediatrics.2020.3595; Montalti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040366; Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483; Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Principi N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020127; Qamar Mohammad Aadil, 2020, J Ayub Med Coll Abbottabad, V32(Suppl 1), pS695; Rajmil L, 2021, BMJ PAEDIATR OPEN, V5, DOI 10.1136/bmjpo-2021-001043; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Rhodes ME, 2020, J HEALTH COMMUN, V25, P831, DOI 10.1080/10810730.2021.1871986; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; Song XY, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.20495; Sperotto F, 2021, EUR J PEDIATR, V180, P307, DOI 10.1007/s00431-020-03766-6; Strelitz B, 2015, VACCINE, V33, P1802, DOI 10.1016/j.vaccine.2015.02.034; Szilagyi PG, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-052335; Teasdale CA, 2021, J PEDIATR-US, V237, P292, DOI 10.1016/j.jpeds.2021.07.021; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Vasudevan L, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09598-1; Vignier N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060682; Viner RM, 2020, LANCET CHILD ADOLESC, V4, P397, DOI 10.1016/S2352-4642(20)30095-X; Whelan SO, 2021, EUR J PEDIATR, V180, P2839, DOI 10.1007/s00431-021-04039-6; Yang XY, 2020, CHILDREN-BASEL, V7, DOI 10.3390/children7120311	47	9	9	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1115	10.3390/vaccines9101115			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP4UC	34696223	Green Published, gold			2022-04-29	WOS:000713127800001
J	Isa, NF; Bensaude, O; Aziz, NC; Murphy, S				Isa, Nur Firdaus; Bensaude, Olivier; Aziz, Nadiah C.; Murphy, Shona			HSV-1 ICP22 Is a Selective Viral Repressor of Cellular RNA Polymerase II-Mediated Transcription Elongation	VACCINES			English	Article						cyclin-dependent kinase; transcription elongation checkpoint; tegument protein VP16; immediate-early protein; amber codon suppression technology	SIMPLEX-VIRUS TYPE-1; CARBOXYL-TERMINAL DOMAIN; EARLY PROTEIN ICP22; P-TEFB; DNA-REPLICATION; CDK9; EXPRESSION; BINDING; COMPLEX; CTD	The Herpes Simplex Virus (HSV-1) immediate-early protein ICP22 interacts with cellular proteins to inhibit host cell gene expression and promote viral gene expression. ICP22 inhibits phosphorylation of Ser2 of the RNA polymerase II (pol II) carboxyl-terminal domain (CTD) and productive elongation of pol II. Here we show that ICP22 affects elongation of pol II through both the early-elongation checkpoint and the poly(A)-associated elongation checkpoint of a protein-coding gene model. Coimmunoprecipitation assays using tagged ICP22 expressed in human cells and pulldown assays with recombinant ICP22 in vitro coupled with mass spectrometry identify transcription elongation factors, including P-TEFb, additional CTD kinases and the FACT complex as interacting cellular factors. Using a photoreactive amino acid incorporated into ICP22, we found that L191, Y230 and C225 crosslink to both subunits of the FACT complex in cells. Our findings indicate that ICP22 interacts with critical elongation regulators to inhibit transcription elongation of cellular genes, which may be vital for HSV-1 pathogenesis. We also show that the HSV viral activator, VP16, has a region of structural similarity to the ICP22 region that interacts with elongation factors, suggesting a model where VP16 competes with ICP22 to deliver elongation factors to viral genes.	[Isa, Nur Firdaus; Murphy, Shona] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Isa, Nur Firdaus; Aziz, Nadiah C.] Int Islamic Univ Malaysia, Dept Biotechnol, Res Unit Bioinformat & Computat Biol, Kulliyyah Sci, Kuantan 25200, Pahang, Malaysia; [Bensaude, Olivier] PSL Res Univ, Ecole Normale Super, CNRS, Inst Biol,UMR 8197,INSERM,U1024, F-75005 Paris, France		Isa, NF; Murphy, S (通讯作者)，Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.; Isa, NF (通讯作者)，Int Islamic Univ Malaysia, Dept Biotechnol, Res Unit Bioinformat & Computat Biol, Kulliyyah Sci, Kuantan 25200, Pahang, Malaysia.	firdaus.isa@path.ox.ac.uk; bensaude@biologie.ens.fr; nadiah.aziz@live.iium.edu.my; shona.murphy@path.ox.ac.uk		Isa, Nur Firdaus/0000-0003-3476-6306; Murphy, Shona/0000-0001-5276-9645	Wellcome Trust Investigator AwardWellcome Trust; Centre National de Recherche Scientifique; Ecole Normale Superieure; Institut National de la Sante et de la Recherche Medicale, FranceInstitut National de la Sante et de la Recherche Medicale (Inserm); Malaysia Ministry of Higher Education and IIUM Malaysia	Wellcome Trust Investigator Award WT210641/Z/18/Z to S.M.; O.B. acknowledges support from the Centre National de Recherche Scientifique, the Ecole Normale Superieure and the Institut National de la Sante et de la Recherche Medicale, France; N.F.I. acknowledges support from The Malaysia Ministry of Higher Education and IIUM Malaysia.	Adam PR, 2012, BIOCHEMISTRY-US, V51, P4062, DOI 10.1021/bi300243z; Adlakha M, 2020, J VIROL, V94, DOI 10.1128/JVI.01564-19; Advani SJ, 2003, P NATL ACAD SCI USA, V100, P4825, DOI 10.1073/pnas.0730735100; Babb R, 2001, MOL CELL BIOL, V21, P4700, DOI 10.1128/MCB.21.14.4700-4712.2001; Bartkowiak B, 2010, GENE DEV, V24, P2303, DOI 10.1101/gad.1968210; Baumli S, 2008, EMBO J, V27, P1907, DOI 10.1038/emboj.2008.121; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Blau J, 1996, MOL CELL BIOL, V16, P2044; Bosken CA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4505; Bowman JJ, 2009, J VIROL, V83, P8733, DOI 10.1128/JVI.00810-09; Chen FX, 2015, CELL, V162, P1003, DOI 10.1016/j.cell.2015.07.042; Corden JL, 2013, CHEM REV, V113, P8423, DOI 10.1021/cr400158h; Cun W, 2009, SCI CHINA SER C, V52, P344, DOI 10.1007/s11427-009-0051-2; Dembowski JA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006166; Diner BA, 2015, MOL CELL PROTEOMICS, V14, P2341, DOI 10.1074/mcp.M114.047068; Durand LO, 2008, J VIROL, V82, P10591, DOI 10.1128/JVI.01242-08; Durand LO, 2005, J VIROL, V79, P6757, DOI 10.1128/JVI.79.11.6757-6762.2005; Fox HL, 2017, MBIO, V8, DOI 10.1128/mBio.00745-17; Fraser KA, 2005, J VIROL, V79, P11323, DOI 10.1128/JVI.79.17.11323-11334.2005; Guo L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045749; Hsin JP, 2012, GENE DEV, V26, P2119, DOI 10.1101/gad.200303.112; Jeronimo C, 2007, MOL CELL, V27, P262, DOI 10.1016/j.molcel.2007.06.027; Jiang H, 2019, BIOCHEM BIOPH RES CO, V508, P864, DOI 10.1016/j.bbrc.2018.11.150; Kalamvoki M, 2011, J VIROL, V85, P9472, DOI 10.1128/JVI.00876-11; Kemble DJ, 2015, MOL CELL, V60, P294, DOI 10.1016/j.molcel.2015.09.008; Kent JR, 2004, J VIROL, V78, P10178, DOI 10.1128/JVI.78.18.10178-10186.2004; Knipe DM, 2008, NAT REV MICROBIOL, V6, P211, DOI 10.1038/nrmicro1794; Kobbi L, 2016, P NATL ACAD SCI USA, V113, P12721, DOI 10.1073/pnas.1612331113; Kurosu T, 2004, CURR BIOL, V14, P1112, DOI 10.1016/j.cub.2004.06.020; La Boissiere S, 1999, EMBO J, V18, P480; Laitem C, 2015, NAT STRUCT MOL BIOL, V22, P396, DOI 10.1038/nsmb.3000; Li QT, 2005, J BIOL CHEM, V280, P28819, DOI 10.1074/jbc.M502712200; Liu Y, 2020, NATURE, V577, P426, DOI 10.1038/s41586-019-1820-0; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Manavalan APC, 2019, EMBO REP, V20, DOI 10.15252/embr.201847592; Maruzuru Y, 2013, J VIROL, V87, P9323, DOI 10.1128/JVI.01581-13; Matundan H, 2019, J VIROL, V93, DOI 10.1128/JVI.01803-18; Matundan HH, 2019, INVEST OPHTH VIS SCI, V60, P3398, DOI 10.1167/iovs.19-27701; Michalski A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.011015; Mostafa HH, 2013, J VIROL, V87, P13510, DOI 10.1128/JVI.02424-13; OAKES JE, 1976, VIROLOGY, V75, P145, DOI 10.1016/0042-6822(76)90013-1; Ogle WO, 1999, J VIROL, V73, P4305, DOI 10.1128/JVI.73.5.4305-4315.1999; Orlando JS, 2006, J VIROL, V80, P4005, DOI 10.1128/JVI.80.8.4005-4016.2006; Ou M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079007; Pham ND, 2013, CURR OPIN CHEM BIOL, V17, P90, DOI 10.1016/j.cbpa.2012.10.034; POFFENBERGER KL, 1994, ARCH VIROL, V139, P111, DOI 10.1007/BF01309458; ProdHon C, 1996, VIROLOGY, V226, P393, DOI 10.1006/viro.1996.0667; Ransom M, 2010, CELL, V140, P183, DOI 10.1016/j.cell.2010.01.004; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; RICE SA, 1995, J VIROL, V69, P5550, DOI 10.1128/JVI.69.9.5550-5559.1995; Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4; SCHWYZER M, 1994, J GEN VIROL, V75, P1703, DOI 10.1099/0022-1317-75-7-1703; SEARS AE, 1985, J VIROL, V55, P338, DOI 10.1128/JVI.55.2.338-346.1985; Tellier M, 2020, NUCLEIC ACIDS RES, V48, P7712, DOI 10.1093/nar/gkaa514; Vos SM, 2018, NATURE, V560, P607, DOI 10.1038/s41586-018-0440-4; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Winkler DD, 2011, J BIOL CHEM, V286, P18369, DOI 10.1074/jbc.R110.180778; Wu Y, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.668461; Yang JY, 2016, CELL REP, V14, P1128, DOI 10.1016/j.celrep.2015.12.096; Zaborowska J, 2016, NAT STRUCT MOL BIOL, V23, P771, DOI 10.1038/nsmb.3285; Zaborowska J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107654	61	3	3	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1054	10.3390/vaccines9101054			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI8WI	34696162	Green Published, Green Submitted, gold			2022-04-29	WOS:000726384000001
J	Ren, J; Maimaiti, H; Sun, XD; Huang, ZY; Liu, JC; Yang, JP; Li, Z; Bai, QR; Lu, YH				Ren, Jia; Maimaiti, Hairenguli; Sun, Xiaodong; Huang, Zhuoying; Liu, Jiechen; Yang, Jianping; Li, Zhi; Bai, Qingrui; Lu, Yihan			Cost-Effectiveness of Three Poliovirus Immunization Schedules in Shanghai, China	VACCINES			English	Article						poliomyelitis; poliovirus; live attenuated oral polio vaccine; inactivated polio vaccine; cost-effectiveness analysis; cost-benefit analysis	PARALYTIC POLIOMYELITIS; VACCINE; ERADICATION; IMPACT; EPIDEMIOLOGY; POLICIES	In Shanghai, China, a polio immunization schedule of four inactivated polio vaccines (IPV) has been implemented since 2020, replacing the schedules of a combination of two IPVs and two bivalent live attenuated oral polio vaccines (bOPV), and four trivalent live attenuated oral polio vaccines (tOPV). This study aimed to assess the cost-effectiveness of these three schedules in infants born in 2016, in preventing vaccine-associated paralytic poliomyelitis (VAPP). We performed a decision tree model and estimated incremental cost-effectiveness ratio (ICER). Compared to the four-tOPV schedule, the two-IPV-two-bOPV schedule averted 1.2 VAPP cases and 16.83 disability-adjusted life years (DALY) annually; while the four-IPV schedule averted 1.35 VAPP cases and 18.96 DALY annually. Consequently, ICERVAPP and ICERDALY were substantially high for two-IPV-two-bOPV (CNY 12.96 million and 0.93 million), and four-IPV (CNY 21.24 million and 1.52 million). Moreover, net monetary benefit of the two-IPV-two-bOPV and four-IPV schedules was highest when the cost of IPV was hypothesized to be less than CNY 23.75 or CNY 9.11, respectively, and willingness-to-pay was hypothesized as CNY 0.6 million in averting one VAPP-induced DALY. IPV-containing schedules are currently cost-ineffective in Shanghai. They may be cost-effective by reducing the prices of IPV, which may accelerate polio eradication in Chinese settings.	[Ren, Jia; Sun, Xiaodong; Huang, Zhuoying; Liu, Jiechen; Yang, Jianping; Li, Zhi; Bai, Qingrui] Shanghai Municipal Ctr Dis Control & Prevent, Inst Immunizat, Shanghai 200336, Peoples R China; [Maimaiti, Hairenguli; Lu, Yihan] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Minist Educ Key Lab Publ Hlth Safety, Shanghai 200032, Peoples R China		Lu, YH (通讯作者)，Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Minist Educ Key Lab Publ Hlth Safety, Shanghai 200032, Peoples R China.	renjia@scdc.sh.cn; rglmmthai20@fudan.edu.cn; sunxiaodong@scdc.sh.cn; huangzhuoying@scdc.sh.cn; liu-jiechen@scdc.sh.cn; yangjianping@scdc.sh.cn; lizhi@scdc.sh.cn; baiqingrui@scdc.sh.cn; luyihan@fudan.edu.cn		Lu, Yihan/0000-0003-4651-9433	Shanghai Three-year Action Plan [2020-2022, GWV-10.1-XK16, GWV-1.1]	This work was supported by the Shanghai Three-year Action Plan (2020-2022) for Public Health (grant no. GWV-10.1-XK16 and GWV-1.1). The funding organization had no role in study design, data analysis, statistical input, review of drafts, writing of the article, identification of papers for inclusion, or any other form of input.	Alexander LN, 2004, JAMA-J AM MED ASSOC, V292, P1696, DOI 10.1001/jama.292.14.1696; Alvis N, 2010, REV PANAM SALUD PUBL, V27, P352, DOI 10.1590/S1020-49892010000500005; [Anonymous], 2016, Wkly Epidemiol Rec, V91, P145; [Anonymous], 2016, 2942016 WS; [Anonymous], 2017, SHANGHAI COMPENSATIO; [Anonymous], Circulating Vaccine-Derived Poliovirus-GPEI; [Anonymous], 2017, PRACTICAL REGULATION, V2017; Arakawa I, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0097-8; Sartori AMC, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049005492; Diop OM, 2014, MMWR-MORBID MORTAL W, V63, P242; Domingues CMAS, 2014, J INFECT DIS, V210, pS143, DOI 10.1093/infdis/jit588; Duan M.J., 2017, CHIN J VACCINES IMMU, V23, P134; Griffiths UK, 2006, VACCINE, V24, P5670, DOI 10.1016/j.vaccine.2006.05.032; Hsu CH, 2019, MMWR-MORBID MORTAL W, V68, P1029, DOI 10.15585/mmwr.mm6845a5; Huang Z., 2020, J MICROBES INFECT, V15, P337; Huang Zhuoying, 2019, Zhonghua Yufang Yixue Zazhi, V53, P513, DOI 10.3760/cma.j.issn.0253-9624.2019.05.015; Ivanova OE, 2018, INT J INFECT DIS, V76, P64, DOI 10.1016/j.ijid.2018.08.017; Khan MM, 2017, PUBLIC HEALTH, V142, P31, DOI 10.1016/j.puhe.2016.10.016; Khan MM, 2008, VACCINE, V26, P2034, DOI 10.1016/j.vaccine.2008.02.008; Le V, 2021, J MANAG CARE SPEC PH, V27, P327, DOI 10.18553/jmcp.2021.27.3.327; Li R.P., 2007, STRATEGIC ANAL COST; Liu M.Y., 2020, SHANGHAI J PREV MED, V32, P627; Lopalco PL, 2017, EPIDEMIOL INFECT, V145, P413, DOI [10.1017/S0950268816002569, 10.1017/s0950268816002569]; Mao Z.H., 2004, MED EC 2004; Miller MA, 1996, JAMA-J AM MED ASSOC, V276, P967, DOI 10.1001/jama.276.12.967; Nanteza MB, 2015, J MED VIROL, V87, P2163, DOI 10.1002/jmv.24285; Nasir UN, 2016, HUM VACC IMMUNOTHER, V12, P658, DOI 10.1080/21645515.2015.1088617; Offit PA., 2008, VACCINES-BASEL, V5th, P631, DOI [10.1016/b978-1-4160-3611-1.50030-1, DOI 10.1016/B978-1-4160-3611-1.50030-1]; Pan JH, 2021, INNOVATION-AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100113; Platt LR, 2014, J INFECT DIS, V210, pS380, DOI 10.1093/infdis/jiu184; Shanghai Bureau of Statistics, 2016, SHANGH STAT B NAT EC, VVolume 3, P19; Shanghai Bureau of Statistics, 2013, SHANGH STAT B NAT EC, VVolume 3, P7; Shanghai Bureau of Statistics, 2015, SHANGH STAT B NAT EC, VVolume 3, P20; Shanghai Bureau of Statistics, 2014, SHANGH STAT B NAT EC, VVolume 3, P14; Shanghai Bureau of Statistics National Investigation Corps Shanghai Bureau of Statistics, 2017, 2017 SHANGH STAT YB; Shanghai Municipal Health Commission, 2020, NOT ADJ IMM PROGR PO; Tebbens RJD, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1112-8; Tebbens RJD, 2010, VACCINE, V29, P334, DOI 10.1016/j.vaccine.2010.10.026; Thompson KM, 2008, AM J PUBLIC HEALTH, V98, P1322, DOI 10.2105/AJPH.2007.122192; Thompson KM, 2006, RISK ANAL, V26, P1423, DOI 10.1111/j.1539-6924.2006.00831.x; TreeAge, 2017, TREEAGE PRO 2017 US, P256; Tucker AW, 2001, AUST NZ J PUBL HEAL, V25, P411, DOI 10.1111/j.1467-842X.2001.tb00648.x; Wattigney WA, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.5.e83; World Bank, COUNTR INC GROUPS; World Health Organization, 2019, POL WHO RESP; World Health Organization Department Immunization, 2014, PRINC CONS ADD VACC; World Hlth Org, 2017, VACCINE, V35, P1197, DOI 10.1016/j.vaccine.2016.11.017; Wu WD, 2018, VACCINE, V36, P1209, DOI 10.1016/j.vaccine.2018.01.019; Wu Z.M., 1999, CHIN J VACCINES IMMU, V6, P6; Yang L.X., 2015, INCREMENTAL COST STU; Yu WZ, 2014, J INFECT DIS, V210, pS268, DOI 10.1093/infdis/jit332	51	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1062	10.3390/vaccines9101062			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WV4BI	34696170	Green Published			2022-04-29	WOS:000717183100001
J	Marques, JS; Bodro, M; Torres, B; Garcia, F; Martinez, JA; Leal, L				Silva Marques, Joana; Bodro, Marta; Torres, Berta; Garcia, Felipe; Antonio Martinez, Jose; Leal, Lorna			Pulmonary Infection Caused by Mycobacterium malmoense in a Chronic HIV-Infected Individual Participating in a Therapeutic Vaccine Trial	VACCINES			English	Article						Mycobacterium malmoense; HIV; therapeutic vaccine	AEROSOLIZED INTERFERON-ALPHA; INTERRUPTION; ETHAMBUTOL; RIFAMPICIN	We report a case of Mycobacterium malmoense pulmonary infection and HIV-1 chronic co-infection in a 60-year-old man while participating in an HIV-1 therapeutic vaccine clinical trial and during the analytical treatment interruption. We present clinical and therapeutic features of a complicated M. malmoense pulmonary infection along with discussion of the possible relation to the HIV-1 cure-related interventions.	[Silva Marques, Joana; Bodro, Marta; Torres, Berta; Garcia, Felipe; Antonio Martinez, Jose; Leal, Lorna] Univ Barcelona, Hosp Clin Barcelona, Infect Dis Dept, Barcelona 08036, Spain; [Silva Marques, Joana] Ctr Hosp Tondela Viseu, Internal Med Dept, P-3504509 Viseu, Portugal		Leal, L (通讯作者)，Univ Barcelona, Hosp Clin Barcelona, Infect Dis Dept, Barcelona 08036, Spain.	6814@hstviseu.min-saude.pt; mbodro@clinic.cat; btorres@clinic.cat; felipegarcia@ub.edu; jamarti@clinic.cat; laleal@clinic.cat	, Felipe/F-4242-2014; Leal, Lorna/L-2773-2015	, Felipe/0000-0001-7658-5832; 	Spanish Ministry of Economy (MINECO)Spanish Government [SAF-2015-66193, SAF-2017-88089-R, RTI2018-096309-B-I00]; Fondo Europeo para el Desarrollo Regional (FEDER)European Commission; Spanish AIDS Research Network [RD/16/0025/0002, RD16/0025/0014-ISCIII-FEDER]	This study was partially supported by grants from the Spanish Ministry of Economy (MINECO) (grants: SAF-2015-66193, SAF-2017-88089-R, RTI2018-096309-B-I00); Fondo Europeo para el Desarrollo Regional (FEDER); the Spanish AIDS Research Network RD/16/0025/0002 and RD16/0025/0014-ISCIII-FEDER (RIS).	Ananworanich J, 2006, LANCET, V368, P459, DOI 10.1016/S0140-6736(06)69153-8; Bogdan C, 2004, IMMUNOL REV, V202, P33, DOI 10.1111/j.0105-2896.2004.00207.x; Cintolo JA, 2012, FUTURE ONCOL, V8, P1273, DOI [10.2217/FON.12.125, 10.2217/fon.12.125]; Daou S, 2013, AIDS, V27, P668, DOI 10.1097/QAD.0b013e32835db0af; Garcia F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004682; Garlin AB, 2005, CLIN INFECT DIS, V41, pE83, DOI 10.1086/497074; Giosue S, 1998, AM J RESP CRIT CARE, V158, P1156, DOI 10.1164/ajrccm.158.4.9803065; Giosue S, 2000, EUR CYTOKINE NETW, V11, P99; Haworth CS, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2017-210927; Hoefsloot W, 2008, INT J TUBERC LUNG D, V12, P987; Jenkins PA, 2008, THORAX, V63, P627, DOI 10.1136/thx.2007.087999; JENKINS PA, 1979, TUBERCLE, V60, P71, DOI 10.1016/0041-3879(79)90038-2; Jenkins PA, 2001, THORAX, V56, P167; Leal L, 2017, EXPERT REV VACCINES, V16, P587, DOI 10.1080/14760584.2017.1322513; O'Shea JJ, 2000, NAT IMMUNOL, V1, P17, DOI 10.1038/76872; Pigem R, 2013, J AM ACAD DERMATOL, V69, pE192, DOI 10.1016/j.jaad.2013.04.048; Podzamczer D., 2019, GU A PRACTICA SIDA, P283; Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013; Sabbatani S, 2006, SCAND J INFECT DIS, V38, P205, DOI 10.1080/00365540500263268; SCHRODER KH, 1982, ZBL BAKT-INT J MED M, V253, P279, DOI 10.1016/S0174-3031(82)80062-0; Telesca Claudia, 2007, J Infect, V54, pe223, DOI 10.1016/j.jinf.2006.12.009; Thomsen VO, 2002, SCAND J INFECT DIS, V34, P648, DOI 10.1080/00365540210147813	22	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1103	10.3390/vaccines9101103			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WV1DW	34696211	gold, Green Published			2022-04-29	WOS:000716978300001
J	Thaker, J; Ganchoudhuri, S				Thaker, Jagadish; Ganchoudhuri, Somrita			The Role of Attitudes, Norms, and Efficacy on Shifting COVID-19 Vaccine Intentions: A Longitudinal Study of COVID-19 Vaccination Intentions in New Zealand	VACCINES			English	Article						COVID-19 vaccine intention; vaccine hesitancy; theory of planned behaviour; vaccine attitudes; social norms; efficacy; longitudinal data; behavior change; vaccination campaigns; New Zealand	PERCEIVED BEHAVIORAL-CONTROL; HPV-VACCINATION; WILLINGNESS; HESITANCY	While public intentions to get a COVID-19 vaccine have been shifting around the world, few studies track factors that help us understand and improve COVID-19 vaccine uptake. This study focuses on identifying changing public intentions to get a COVID-19 vaccine in New Zealand, a country that has been largely successful in containing the pandemic but risks new outbreaks as less than 20% of the population is fully vaccinated by August 2021. Data on COVID-19 intentions were collected just after the vaccine approval and rollout targeting old-age groups in February 2021 and then before the general public rollout in May 2021 (n = 650, 60% reinterview response rate). Results show that intention to get a COVID-19 vaccine increased in three months and was the highest in the last one year. Consistent with the Theory of Planned Behaviour, attitudes and efficacy beliefs were significantly associated with COVID-19 vaccine intentions, in the cross-sectional as well as longitudinal analyses. Findings highlight the persisting influence of attitudes, efficacy beliefs, and past intentions on future decision-making process to get a COVID-19 vaccine. Future research opportunities to understand vaccine intentions and improve public vaccine uptake are highlighted.</p>	[Thaker, Jagadish] Massey Univ, Sch Commun Journalism & Mkt, Wellington 6011, New Zealand; [Ganchoudhuri, Somrita] Natl Univ Singapore, Dept Commun & New Media, Singapore 119077, Singapore		Thaker, J (通讯作者)，Massey Univ, Sch Commun Journalism & Mkt, Wellington 6011, New Zealand.	j.thaker@massey.ac.nz; somrita987@gmail.com			Massey University	This research was funded by Massey University.	Ajzen I, 2002, J APPL SOC PSYCHOL, V32, P665, DOI 10.1111/j.1559-1816.2002.tb00236.x; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Alberts CJ, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4091-4; Babicki M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050503; Bandura A., 1997, SELF EFFICACY EXERCI; Daalder M., 2021, WHATS NZS SLOW VACCI; Dai HC, 2021, NATURE, V597, P404, DOI 10.1038/s41586-021-03843-2; Daly M, 2021, AM J PREV MED, V60, P766, DOI 10.1016/j.amepre.2021.01.008; Farmer M, 2021, NPR; Field A., 2013, DISCOVERING STAT USI, V4th ed; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Gibson LP, 2021, ANN BEHAV MED, V55, P805, DOI 10.1093/abm/kaab041; Hagger MS, 2021, PSYCHOL HEALTH, V36, P307, DOI 10.1080/08870446.2020.1784420; Hamilton K, 2020, HEALTH PSYCHOL, V39, P863, DOI 10.1037/hea0000940; Hofman R, 2014, HEALTH EDUC RES, V29, P83, DOI 10.1093/her/cyt092; Kerr JR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040379; Latkin CA, 2021, BEHAV SCI-BASEL, V11, DOI 10.3390/bs11040056; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; McIntyre N, 2021, GUARDIAN 0708; Parkinson J, 2017, J CONSUM BEHAV, V16, P413, DOI 10.1002/cb.1641; Plank, PHASED BORDER REOPEN; Pot M, 2017, PREV MED, V100, P41, DOI 10.1016/j.ypmed.2017.04.005; Prickett KC, 2021, LANCET REG HEALTH-W, V14, DOI 10.1016/j.lanwpc.2021.100241; Riebl SK, 2015, EAT BEHAV, V18, P160, DOI 10.1016/j.eatbeh.2015.05.016; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Sinclair S, 2021, HEALTH COMMUN, DOI 10.1080/10410236.2021.1937832; Sniehotta FF, 2014, HEALTH PSYCHOL REV, V8, P1, DOI 10.1080/17437199.2013.869710; Stokes M, 2021, KFF COVID 19 VACCINE; Stout ME, 2020, J COMMUN HEALTH, V45, P1187, DOI 10.1007/s10900-020-00837-5; Thaker J, 2021, J HEALTH COMMUN, V26, P104, DOI 10.1080/10810730.2021.1899346; To QG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050479; Turner N, 2019, NEW ZEAL MED J, V132, P8; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; Varley K., 2021, THESE ARE BEST PLACE; Wee S-L., 2021, NEW YORK TIMES; Whiting, MORE PEOPLE NOW PLAN; World Health Organization, NZ TAK EARL HARD ACT; Wu AMS, 2020, J INFECT PUBLIC HEAL, V13, P970, DOI 10.1016/j.jiph.2020.04.009; Xiao XZ, 2021, ATL J COMMUN, V29, P93, DOI 10.1080/15456870.2019.1708743; Xiao XZ, 2020, VACCINE, V38, P5131, DOI 10.1016/j.vaccine.2020.04.076; Xiao XZ, 2020, HUM BRAIN MAPP, V41, P2883, DOI 10.1002/hbm.24984; Yahaghi R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070684; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2	47	1	1	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1132	10.3390/vaccines9101132			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WO0YZ	34696240	gold, Green Published			2022-04-29	WOS:000712190200001
J	Trombetta, CM; Montomoli, E				Trombetta, Claudia Maria; Montomoli, Emanuele			Progress on Seasonal and Pandemic Influenza Vaccines	VACCINES			English	Editorial Material									[Trombetta, Claudia Maria; Montomoli, Emanuele] Univ Siena, Dept Mol & Dev Med, I-53100 Siena, Italy		Trombetta, CM (通讯作者)，Univ Siena, Dept Mol & Dev Med, I-53100 Siena, Italy.	trombetta@unisi.it; emanuele.montomoli@unisi.it	MONTOMOLI, EMANUELE/Q-2122-2015	MONTOMOLI, EMANUELE/0000-0001-7595-4974; Trombetta, Claudia Maria/0000-0001-7229-9919			Caceres CJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070703; Carter NJ, 2011, DRUGS, V71, P1591, DOI 10.2165/11206860-000000000-00000; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020325; Hayashi H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040768; Manenti A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010043; Mo J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070800; Owusu D, 2020, MMWR-MORBID MORTAL W, V69, P40, DOI 10.15585/mmwr.mm6902e1; Tan S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050468; Tasker S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030224; Trombetta CM, 2019, EXPERT REV VACCINES, V18, P737, DOI 10.1080/14760584.2019.1639503; Trombetta CM, 2016, EXPERT REV VACCINES, V15, P967, DOI 10.1586/14760584.2016.1164046	11	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1068	10.3390/vaccines9101068			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN9AR	34696176	Green Published			2022-04-29	WOS:000712058700001
J	Chatterjee, R; Sahoo, P; Mahapatra, SR; Dey, J; Ghosh, M; Kushwaha, GS; Misra, N; Suar, M; Raina, V; Son, YO				Chatterjee, Rahul; Sahoo, Panchanan; Mahapatra, Soumya Ranjan; Dey, Jyotirmayee; Ghosh, Mrinmoy; Kushwaha, Gajraj Singh; Misra, Namrata; Suar, Mrutyunjay; Raina, Vishakha; Son, Young-Ok			Development of a Conserved Chimeric Vaccine for Induction of Strong Immune Response against Staphylococcus aureus Using Immunoinformatics Approaches	VACCINES			English	Article						Staphylococcus aureus; SdrD; SdrE; immunoinformatics; multi-epitope vaccine	PROTEIN-STRUCTURE PREDICTION; EPITOPE PEPTIDE VACCINE; MICE; INFECTIONS; PROTECTION; WEB	Staphylococcus aureus is one of the most notorious Gram-positive bacteria with a very high mortality rate. The WHO has listed S. aureus as one of the ESKAPE pathogens requiring urgent research and development efforts to fight against it. Yet there is a major layback in the advancement of effective vaccines against this multidrug-resistant pathogen. SdrD and SdrE proteins are attractive immunogen candidates as they are conserved among all the strains and contribute specifically to bacterial adherence to the host cells. Furthermore, these proteins are predicted to be highly antigenic and essential for pathogen survival. Therefore, in this study, using the immunoinformatics approach, a novel vaccine candidate was constructed using highly immunogenic conserved T-cell and B-cell epitopes along with specific linkers, adjuvants, and consequently modeled for docking with human Toll-like receptor 2. Additionally, physicochemical properties, secondary structure, disulphide engineering, and population coverage analysis were also analyzed for the vaccine. The constructed vaccine showed good results of worldwide population coverage and a promising immune response. For evaluation of the stability of the vaccine-TLR-2 docked complex, a molecular dynamics simulation was performed. The constructed vaccine was subjected to in silico immune simulations by C-ImmSim and Immune simulation significantly provided high levels of immunoglobulins, T-helper cells, T-cytotoxic cells, and INF-gamma. Lastly, upon cloning, the vaccine protein was reverse transcribed into a DNA sequence and cloned into a pET28a (+) vector to ensure translational potency and microbial expression. The overall results of the study showed that the designed novel chimeric vaccine can simultaneously elicit humoral and cell-mediated immune responses and is a reliable construct for subsequent in vivo and in vitro studies against the pathogen.	[Chatterjee, Rahul; Mahapatra, Soumya Ranjan; Dey, Jyotirmayee; Misra, Namrata; Suar, Mrutyunjay; Raina, Vishakha] Deemed Univ, Sch Biotechnol, Kalinga Inst Ind Technol KIIT, Bhubaneswar 751024, India; [Sahoo, Panchanan] Kalinga Inst Ind Technol KIIT Deemed Univ, Kalinga Inst Med Sci, Bhubaneswar 751024, India; [Ghosh, Mrinmoy; Kushwaha, Gajraj Singh; Misra, Namrata; Suar, Mrutyunjay] Kalinga Inst Ind Technol KIIT Deemed Univ, KIIT Technol Business Incubator KIIT TBI, Bhubaneswar 751024, India; [Kushwaha, Gajraj Singh] Int Ctr Genet Engn & Biotechnol ICGEB, Transcript Regulat Grp, New Delhi 110067, India; [Son, Young-Ok] Jeju Natl Univ, Fac Biotechnol, Dept Anim Biotechnol, Jeju 63243, South Korea; [Son, Young-Ok] Jeju Natl Univ, Biohlth Mat Core Facil Ctr, Jeju 63243, South Korea; [Son, Young-Ok] Jeju Natl Univ, Pract Translat Res Ctr, Jeju 63243, South Korea; [Son, Young-Ok] Jeju Natl Univ, Interdisciplinary Grad Program Adv Convergence Te, Jeju 63243, South Korea		Raina, V (通讯作者)，Deemed Univ, Sch Biotechnol, Kalinga Inst Ind Technol KIIT, Bhubaneswar 751024, India.; Son, YO (通讯作者)，Jeju Natl Univ, Fac Biotechnol, Dept Anim Biotechnol, Jeju 63243, South Korea.; Son, YO (通讯作者)，Jeju Natl Univ, Biohlth Mat Core Facil Ctr, Jeju 63243, South Korea.; Son, YO (通讯作者)，Jeju Natl Univ, Pract Translat Res Ctr, Jeju 63243, South Korea.; Son, YO (通讯作者)，Jeju Natl Univ, Interdisciplinary Grad Program Adv Convergence Te, Jeju 63243, South Korea.	rahulksbt@gmail.com; panchanan.sahoo@kims.ac.in; soumyaranjanmahapatra685@gmail.com; jmdey1997@gmail.com; mringhs2010@gmail.com; gajraj@kiitincubator.in; namrata@kiitincubator.in; mrutyunjay@kiitincubator.in; vraina@kiitbiotech.ac.in; sounagi@jejunu.ac.kr	Ghosh, Mrinmoy/ABB-4479-2021; Dey, Jyotirmayee/ABC-2152-2021; Kushwaha, Gajraj Singh/AAS-7905-2021	Dey, Jyotirmayee/0000-0002-5543-7109; Kushwaha, Gajraj Singh/0000-0002-1663-2497; Mahapatra, Soumya Ranjan/0000-0002-8927-458X; Ghosh, Mrinmoy/0000-0001-6817-622X; Son, Youngok/0000-0003-0154-4061	DBT-BUILDER program at KIIT Deemed to Be University, Bhubaneswar [BT/INF/22/SP42155/2021]; National Research Foundation of Korea (NRF) - Korean government (MSIT) [2020R1A2C2004128]; Korea Basic Science Institute (National Research Facilities and Equipment Center) - Ministry of Education [2020R1A6C101A188]	We acknowledge infrastructure support available through the DBT-BUILDER program (BT/INF/22/SP42155/2021) at KIIT Deemed to Be University, Bhubaneswar. The technical support from National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2020R1A2C2004128) and the Korea Basic Science Institute (National Research Facilities and Equipment Center) grant funded by the Ministry of Education (2020R1A6C101A188).	Adhikari RC, 2018, ENERGY SUSTAIN DEV, V45, P38, DOI 10.1016/j.esd.2018.04.003; Brown EL, 2009, CLIN MICROBIOL INFEC, V15, P156, DOI 10.1111/j.1469-0691.2008.02648.x; Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153; Chen R, 2012, BIOTECHNOL ADV, V30, P1102, DOI 10.1016/j.biotechadv.2011.09.013; Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039; Choi SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136021; Coates R, 2014, FUTURE MICROBIOL, V9, P75, DOI 10.2217/fmb.13.145; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Cong YG, 2020, J ADV RES, V21, P169, DOI 10.1016/j.jare.2019.10.005; Cooper MD, 2015, NAT REV IMMUNOL, V15, P191, DOI 10.1038/nri3801; Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346; Daum RS, 2012, CLIN INFECT DIS, V54, P560, DOI 10.1093/cid/cir828; Delfani S, 2016, MED MICROBIOL IMMUN, V205, P47, DOI 10.1007/s00430-015-0425-y; Dey J, 2021, MICROB PATHOGENESIS, V160, DOI 10.1016/j.micpath.2021.105171; Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278; Fluit AC, 2012, CLIN MICROBIOL INFEC, V18, P735, DOI 10.1111/j.1469-0691.2012.03846.x; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Gaafar BBM, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6124030; Gasteiger E., 2005, PROTEOM PROTOC HDB, P571, DOI [10.1385/1-59259-890-0:571, 10.1385/1-59259-890, DOI 10.1385/1592598900]; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; GURUPRASAD K, 1990, PROTEIN ENG, V4, P155, DOI 10.1093/protein/4.2.155; Hajighahramani N, 2017, INFECT GENET EVOL, V48, P83, DOI 10.1016/j.meegid.2016.12.010; Ikawaty R., 2010, International Journal of Dairy Science, V5, P60; Jensen SO, 2009, FUTURE MICROBIOL, V4, P565, DOI 10.2217/FMB.09.30; Karauzum H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.624310; Kaufman D, 2006, CURR OPIN INVEST DR, V7, P172; Khatoon N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08842-w; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kim NH, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05641-z; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Kuhns JJ, 1999, J BIOL CHEM, V274, P36422, DOI 10.1074/jbc.274.51.36422; Kuklin NA, 2006, INFECT IMMUN, V74, P2215, DOI 10.1128/IAI.74.4.2215-2223.2006; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee B, 2020, J CLIN INVEST, V130, P1122, DOI 10.1172/JCI130728; Lehman SM, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010088; Levy J, 2015, HUM VACC IMMUNOTHER, V11, P620, DOI 10.1080/21645515.2015.1011021; Luna BM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217439; Mahapatra SR, 2021, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2021.1964600; Mahapatra SR, 2020, EXPERT REV VACCINES, V19, P871, DOI 10.1080/14760584.2020.1811091; Mahendran A, 2016, INT J COMPUT VISION, V120, P233, DOI 10.1007/s11263-016-0911-8; Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Miller LS, 2020, FEMS MICROBIOL REV, V44, P123, DOI 10.1093/femsre/fuz030; Pandey RK, 2018, VACCINE, V36, P2262, DOI 10.1016/j.vaccine.2018.03.042; Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1; Parker D, 2018, VIRULENCE, V9, P700, DOI 10.1080/21505594.2018.1426965; Parlet CP, 2019, TRENDS MICROBIOL, V27, P497, DOI 10.1016/j.tim.2019.01.008; Pian Y., 2016, SCI REP-UK, V6, P1; Pier GB, 2013, HUM VACC IMMUNOTHER, V9, P1865, DOI 10.4161/hv.25182; Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Roos K, 2019, J CHEM THEORY COMPUT, V15, P1863, DOI 10.1021/acs.jctc.8b01026; Saadi M, 2017, INFECT GENET EVOL, V51, P227, DOI 10.1016/j.meegid.2017.04.009; Sakib M. Sadman, 2014, Advances in Bioinformatics, V2014, P402492, DOI 10.1155/2014/402492; Sarkar B, 2021, EXPERT REV VACCINES, DOI 10.1080/14760584.2021.1874925; Spellberg B, 2008, INFECT IMMUN, V76, P4574, DOI 10.1128/IAI.00700-08; Stranger-Jones YK, 2006, P NATL ACAD SCI USA, V103, P16942, DOI 10.1073/pnas.0606863103; Wardenburg JB, 2008, J EXP MED, V205, P287, DOI 10.1084/jem.20072208; Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Xiao Y, 2001, IMMUNOL LETT, V77, P3, DOI 10.1016/S0165-2478(01)00187-0; Yimin, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074287; Zorzet A, 2014, UPSALA J MED SCI, V119, P170, DOI 10.3109/03009734.2014.897277	67	5	5	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1038	10.3390/vaccines9091038			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3GL	34579274	Green Published, gold			2022-04-29	WOS:000702096700001
J	Luo, X; Niu, YJ; Fu, XZ; Lin, Q; Liang, HR; Liu, LH; Li, NQ				Luo, Xia; Niu, Yinjie; Fu, Xiaozhe; Lin, Qiang; Liang, Hongru; Liu, Lihui; Li, Ningqiu			Large-Scale Microcarrier Culture of Chinese Perch Brain Cell for Viral Vaccine Production in a Stirred Bioreactor	VACCINES			English	Article						CPB cell line; microcarrier; Cytodex 1; suspension culture; bioreactor	SUSPENSION-CULTURE; VERO CELLS; MDCK CELLS; VIRUS; GROWTH; EXPANSION; LINES	Mandarin fish (Siniperca chuatsi) is one of the important cultured fish species in China. Infectious spleen and kidney necrosis virus (ISKNV) and Siniperca Chuatsi rhabdovirus (SCRV) have hindered the development of mandarin fish farming industry. Vaccination is the most effective method for control of viral diseases, however viral vaccine production requires the large-scale culture of cells. Herein, a suspension culture system of Chinese perch brain cell (CPB) was developed on Cytodex 1 microcarrier in a stirred bioreactor. Firstly, CPB cells were cultured using Cytodex 1 microcarrier in 125 mL stirring flasks. With the optimum operational parameters, CPB cells grew well, distributed uniformly, and could fully cover the microcarriers. Then, CPB cells were digested with trypsin and expanded step-by-step with different expansion ratios from the 125 mL stirring bottle to a 500 mL stirring bottle, and finally to a 3-L bioreactor. Results showed that with an expansion ratio of 1:3, we achieved a high cell density level (2.25 x 10(6) cells/mL) with an efficient use of the microcarriers, which also confirmed the data obtained from the 125 mL stirring flask. Moreover, obvious cytopathic effects (CPE) were observed in the suspended CPB cells post-infection with ISKNV and SCRV. This study provided a large-scale culture system of CPB cells for virus vaccine production.	[Luo, Xia; Niu, Yinjie; Fu, Xiaozhe; Lin, Qiang; Liang, Hongru; Liu, Lihui; Li, Ningqiu] Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Guangdong Prov Key Lab Aquat Anim Immune Technol, Key Lab Fishery Drug Dev,Minist Agr & Rural Affai, Guangzhou 510380, Peoples R China		Li, NQ (通讯作者)，Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Guangdong Prov Key Lab Aquat Anim Immune Technol, Key Lab Fishery Drug Dev,Minist Agr & Rural Affai, Guangzhou 510380, Peoples R China.	luoxia@prfri.ac.cn; nyj@prfri.ac.cn; fuxiaozhe@prfri.ac.cn; linq@prfri.ac.cn; hrliang@prfri.ac.cn; liulh@prfri.ac.cn; nqli@prfri.ac.cn			National Key Research and Development Program of China [2019YFD0900103]; Special Funds for Economic Development of Marine Economy of Guangdong Province [2019A1]; Guangdong Provincial Special Fund for Modern Agriculture Industry Technology Innovation Teams [2019KJ140, 2019KJ141]; Science and Technology Program of Guangzhou, China [202102080275]	This work was funded by the National Key Research and Development Program of China (2019YFD0900103), Special Funds for Economic Development of Marine Economy of Guangdong Province (2019A1) and Guangdong Provincial Special Fund for Modern Agriculture Industry Technology Innovation Teams (2019KJ140, 2019KJ141), Science and Technology Program of Guangzhou, China (202102080275).	Alfred R, 2011, BIOTECHNOL PROGR, V27, P811, DOI 10.1002/btpr.591; Aunins JG, 2003, BIOTECHNOL PROGR, V19, P2, DOI 10.1021/bp0256521; Bock A, 2009, BIOTECHNOL PROGR, V25, P1717, DOI 10.1002/btpr.262; Brindley David, 2011, J Tissue Eng, V2011, P620247, DOI 10.4061/2011/620247; BUCK CD, 1985, J VIROL METHODS, V10, P171, DOI 10.1016/0166-0934(85)90103-X; Clark J, 1980, Dev Biol Stand, V46, P117; Dong CF, 2008, VIRUS RES, V135, P273, DOI 10.1016/j.virusres.2008.04.004; FORESTELL SP, 1992, BIOTECHNOL BIOENG, V39, P305, DOI 10.1002/bit.260390308; Fu X, 2015, J FISH BIOL, V86, P32, DOI 10.1111/jfb.12540; Fu XZ, 2017, ARCH VIROL, V162, P2829, DOI 10.1007/s00705-017-3416-z; Fujii G, 2021, ULTRASON SONOCHEM, V73, DOI 10.1016/j.ultsonch.2021.105488; Goh TKP, 2013, BIORESEARCH OPEN ACC, V2, P84, DOI 10.1089/biores.2013.0001; He JG, 2000, J FISH DIS, V23, P219, DOI 10.1046/j.1365-2761.2000.00213.x; Hu AYC, 2008, VACCINE, V26, P5736, DOI 10.1016/j.vaccine.2008.08.015; [贾路路 Jia Lulu], 2018, [中国水产科学, Journal of Fishery Sciences of China], V25, P211; Kiesslich S, 2021, BIOTECHNOL BIOENG, V118, P2649, DOI 10.1002/bit.27785; Luo Xia, 2022, Journal of Northwest A & F University - Natural Science Edition, V50, P1; Ma T, 2016, BIOCHEM ENG J, V108, P44, DOI 10.1016/j.bej.2015.07.014; Maartens JH, 2017, EXPERT OPIN BIOL TH, V17, P1221, DOI 10.1080/14712598.2017.1360273; NICHOLSON BL, 1980, APPL ENVIRON MICROB, V39, P394, DOI 10.1128/AEM.39.2.394-397.1980; Nilsson K, 1988, Biotechnol Genet Eng Rev, V6, P403; Ren ZH, 2015, APPL MICROBIOL BIOT, V99, P2999, DOI 10.1007/s00253-015-6406-7; Roberts EL, 2019, J BIOL ENG, V13, DOI 10.1186/s13036-019-0153-8; Rourou S, 2007, VACCINE, V25, P3879, DOI 10.1016/j.vaccine.2007.01.086; Shen CF, 2019, VACCINE, V37, P6996, DOI 10.1016/j.vaccine.2019.07.003; Sousa M, 2019, VACCINE, V37, P7041, DOI 10.1016/j.vaccine.2019.07.009; Souza MCO, 2009, VACCINE, V27, P6420, DOI 10.1016/j.vaccine.2009.06.023; Sun XM, 2000, J BIOSCI BIOENG, V90, P32, DOI 10.1016/S1389-1723(00)80030-4; Takahashi I, 2017, CYTOTECHNOLOGY, V69, P503, DOI 10.1007/s10616-016-9999-5; Trabelsi K, 2012, APPL MICROBIOL BIOT, V93, P1031, DOI 10.1007/s00253-011-3574-y; Tree JA, 2001, VACCINE, V19, P3444, DOI 10.1016/S0264-410X(01)00053-6; VANWEZEL AL, 1967, NATURE, V216, P64, DOI 10.1038/216064a0; Wang WeiLing, 2017, Journal of Shanghai Ocean University, V26, P784; Weber Christian, 2007, Open Biomed Eng J, V1, P38, DOI 10.2174/1874120700701010038; Wen LH, 2019, AVIAN PATHOL, V48, P183, DOI 10.1080/03079457.2018.1556385; Yang JJ, 2019, AMB EXPRESS, V9, DOI 10.1186/s13568-019-0794-5; Yin M., 2019, HEILONGJIANG ANIM SC, V13, P16; Zhang JC, 2019, FISH SHELLFISH IMMUN, V89, P52, DOI 10.1016/j.fsi.2019.03.040; Zhang LJ, 2018, FISH SHELLFISH IMMUN, V77, P474, DOI 10.1016/j.fsi.2018.03.047; Zhang Q., 1999, CHINESE SCI BULL, V5, P55	40	0	0	16	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1003	10.3390/vaccines9091003			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3BK	34579239	Green Published, gold			2022-04-29	WOS:000702083500001
J	Triantafyllidis, KK; Giannos, P; Mian, IT; Kyrtsonis, G; Kechagias, KS				Triantafyllidis, Konstantinos Katsikas; Giannos, Panagiotis; Mian, Imran Tariq; Kyrtsonis, George; Kechagias, Konstantinos S.			Varicella Zoster Virus Reactivation Following COVID-19 Vaccination: A Systematic Review of Case Reports	VACCINES			English	Review						coronavirus; SARS-CoV-2; COVID-19 vaccine; Varicella zoster virus; herpes zoster; systematic review; case reports; case series		The newly developed COVID-19 vaccines have established a safe profile, yet some individuals experience a wide range of adverse events. Recently, reactivation of varicella zoster virus (VZV) has been observed after administration of different COVID-19 vaccines, although causality remains a matter of debate. The aim of this systematic review was to examine the available literature and provide an overview of reported cases of VZV reactivation following COVID-19 vaccination. We identified 12 eligible articles which included 91 patients with herpes zoster (HZ) following COVID-19 vaccination. Hypertension was the main comorbidity present in 18% of patients (16/91). Additionally, 13% of patients (12/91) had an autoimmune condition with rheumatoid arthritis being the most common (4/12). Moreover, 10% of patients (9/91) were receiving immunosuppressants. The dermatomal distribution of skin lesions varied among patients, with the mammary region being most affected. On average, symptoms developed 5.8 days post-vaccination irrespective of dose and treatment with oral valacyclovir as a monotherapy was employed in most patients (23/91). HZ is possibly a condition clinicians may expect to encounter in patients receiving COVID-19 vaccines. While causality has not yet been established increased awareness and early recognition of the disorder would be crucial for the optimal management of these patients.	[Triantafyllidis, Konstantinos Katsikas] Taunton & Somerset NHS Fdn Trust, Musgrove Pk Hosp, Dept Nutr & Dietet, Taunton TA1 5DA, Somerset, England; [Triantafyllidis, Konstantinos Katsikas; Giannos, Panagiotis; Kechagias, Konstantinos S.] Soc Meta Res & Biomed Innovat, London W12 0BZ, England; [Giannos, Panagiotis] Imperial Coll London, Fac Nat Sci, Dept Life Sci, London SW7 2AZ, England; [Mian, Imran Tariq] Brighton & Sussex Med Sch, Falmer BN1 9PX, England; [Kyrtsonis, George] Croydon Univ Hosp, Dept Gen Surg, London CR7 7YE, England; [Kechagias, Konstantinos S.] Imperial Coll London, Fac Med, Dept Metab Digest & Reprod, London W12 0NN, England		Kechagias, KS (通讯作者)，Soc Meta Res & Biomed Innovat, London W12 0BZ, England.; Kechagias, KS (通讯作者)，Imperial Coll London, Fac Med, Dept Metab Digest & Reprod, London W12 0NN, England.	k.katsikas-triantafyllidis18@alumni.imperial.ac.uk; panagiotis.giannos19@imperial.ac.uk; i.mian1@uni.bsms.ac.uk; georgios.kyrtsonis@nhs.net; konstantinos.kechagias18@imperial.ac.uk		Giannos, Panagiotis/0000-0003-1037-1983; Katsikas Triantafyllidis, Konstantinos/0000-0002-3858-4473			Aksu SB, 2021, CLIN EXP VACCINE RES, V10, P198, DOI 10.7774/cevr.2021.10.2.198; Alpalhao M, 2021, J EUR ACAD DERMATOL, V35, pE750, DOI 10.1111/jdv.17555; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Arora P, 2021, J COSMET DERMATOL-US, V20, P3389, DOI 10.1111/jocd.14268; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Bostan E, 2021, J COSMET DERMATOL-US, V20, P1566, DOI 10.1111/jocd.14035; Catala A, 2022, BRIT J DERMATOL, V186, P142, DOI 10.1111/bjd.20639; Chiu HH., 2021, QJM-INT J MED, DOI 10.1093/qjmed/hcab208; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Depledge DP, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070349; Diez-Domingo J, 2021, DERMATOLOGY THER, V11, P1119, DOI 10.1007/s13555-021-00549-1; Eid E, 2021, J MED VIROL, V93, P5231, DOI 10.1002/jmv.27036; Eshleman E, 2011, FUTURE VIROL, V6, P341, DOI 10.2217/FVL.10.90; Furer V, 2021, RHEUMATOLOGY, V60, pSI90, DOI 10.1093/rheumatology/keab345; Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674; Johnson J., 2021, JOHNSON JOHNSON COVI; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Kelly WN, 2007, PHARMACOEPIDEM DR S, V16, P581, DOI 10.1002/pds.1399; Lee C, 2021, J COSMET DERMATOL-US, V20, P1960, DOI 10.1111/jocd.14210; Loubet P, 2021, NAT MED, V27, P1319, DOI 10.1038/s41591-021-01435-1; Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]; Marra F, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa005; Medicines Healthcare Products Regulatory Agency, 2021, COR VACC WEEKL SUMM; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Psichogiou M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060572; Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387; Rodriguez-Jimenez Pedro, 2021, JAAD Case Rep, V12, P58, DOI 10.1016/j.jdcr.2021.04.014; Tessas I, 2021, J EUR ACAD DERMATOL, V35, pE620, DOI 10.1111/jdv.17422; Walter R, 1999, LANCET, V353, P810, DOI 10.1016/S0140-6736(99)00623-6; West JA, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00122; XU B, 2020, J INFECTION, V81, pE51, DOI 10.1016/j.jinf.2020.04.012; Yang X, 2020, LANCET RESP MED, V8, pE26; Zak-Prelich M, 2002, EPIDEMIOL INFECT, V129, P593, DOI 10.1017/S0950268802007793; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594	40	10	10	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1013	10.3390/vaccines9091013			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3RD	34579250	Green Published, gold			2022-04-29	WOS:000702124800001
J	Xiao, QY; Liu, X; Wang, RR; Mao, YM; Chen, H; Li, XM; Liu, XX; Dai, JM; Gao, JL; Fu, H; Zheng, PP				Xiao, Qianyi; Liu, Xin; Wang, Ruru; Mao, Yimeng; Chen, Hao; Li, Xiaomei; Liu, Xiaoxi; Dai, Junming; Gao, Junling; Fu, Hua; Zheng, Pinpin			Predictors of Willingness to Receive the COVID-19 Vaccine after Emergency Use Authorization: The Role of Coping Appraisal	VACCINES			English	Article						COVID-19 vaccine; willingness; emergency use authorization; protection motivation theory; China	RISK PERCEPTIONS; PARENTS; INTENTION; ONLINE; DECISIONS; HESITANCY; BEHAVIOR	The current study aims to identify psychosocial factors based on protection motivation theory (PMT) influencing Chinese adults' willingness to receive the COVID-19 vaccine after the emergency use authorization of the New Coronavirus Inactivated Vaccine in China. A cross-sectional online survey was conducted among Chinese residents aged 18-59 years, and 2528 respondents from 31 provinces and autonomous regions were included in the current study. Based on PMT, threat appraisals and coping appraisals were measured. Hierarchical multiple regressions and multivariate logistic regressions were used to identify the relationships between the PMT constructs and vaccination willingness after other covariates were controlled for. A total of 1411 (55.8%) respondents reported being willing to receive the COVID-19 vaccine. The PMT model explained 26.6% (p < 0.001) of the variance in the vaccine willingness. The coping appraisals, including response efficacy, self-efficacy, and response costs, were significantly correlated with the willingness to receive the COVID-19 vaccine, and response efficacy was the strongest influencing factor (adjusted OR = 2.93, 95% CI: 2.42-3.54). In conclusion, the coping appraisals for vaccination, instead of threat appraisals regarding the pandemic itself, mainly influenced people's willingness to get vaccinated after the emergency use authorization of the COVID-19 vaccine in China. These findings are helpful for developing education and interventions to promote vaccination willingness and enhance public health outcomes during a pandemic.	[Xiao, Qianyi; Liu, Xin; Wang, Ruru; Mao, Yimeng; Chen, Hao; Li, Xiaomei; Liu, Xiaoxi; Dai, Junming; Gao, Junling; Fu, Hua; Zheng, Pinpin] Fudan Univ, Sch Publ Hlth, Dept Prevent Med & Hlth Educ, Shanghai 200032, Peoples R China		Zheng, PP (通讯作者)，Fudan Univ, Sch Publ Hlth, Dept Prevent Med & Hlth Educ, Shanghai 200032, Peoples R China.	xiaoqianyi@fudan.edu.cn; 19211020043@fudan.edu.cn; 18211020093@fudan.edu.cn; 18211020031@fudan.edu.cn; 18111020014@fudan.edu.cn; 18211020030@fudan.edu.cn; 19211020041@fudan.edu.cn; jmdai@fudan.edu.cn; jlgao@fudan.edu.cn; hfu@fudan.edu.cn; zpinpin@shmu.edu.cn		Xiao, Qianyi/0000-0002-6584-9684; Gao, Junling/0000-0002-0694-2010; Chen, Hao/0000-0002-7886-7822	Shanghai Municipal Committee for Health and Family Planning [GWV-10.1-XK14]	This research was funded by the grant from the Shanghai Municipal Committee for Health and Family Planning, grant number GWV-10.1-XK14.	Agarwal V, 2014, J AM COLL HEALTH, V62, P416, DOI 10.1080/07448481.2014.917650; [Anonymous], APPR NEW COR IN VACC; BENNETT P, 1992, HEALTH EDUC RES, V7, P341, DOI 10.1093/her/7.3.341; Betsch C, 2012, VACCINE, V30, P3723, DOI 10.1016/j.vaccine.2012.03.078; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Britt RK, 2014, HEALTH PSYCHOL BEHAV, V2, P52, DOI 10.1080/21642850.2013.869175; Camerini AL, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.11.005; Chen NTN, 2015, RISK ANAL, V35, P1268, DOI 10.1111/risa.12348; de Vreese CH, 2016, COMMUN METHODS MEAS, V10, P69, DOI 10.1080/19312458.2016.1150441; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Fall E, 2018, PSYCHOL HEALTH, V33, P746, DOI 10.1080/08870446.2017.1401623; Floyd DL, 2000, J APPL SOC PSYCHOL, V30, P407, DOI 10.1111/j.1559-1816.2000.tb02323.x; Fogel Joshua, 2016, Ther Adv Vaccines, V4, P3, DOI 10.1177/2051013616629881; Gainforth HL, 2012, J CANCER EDUC, V27, P717, DOI 10.1007/s13187-012-0389-1; Glanz K, 1997, HLTH BEHAV HLTH ED T; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Gust DA, 2008, PEDIATRICS, V122, P718, DOI 10.1542/peds.2007-0538; Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112; Kim Y, 2015, DISASTER MED PUBLIC, V9, P145, DOI 10.1017/dmp.2014.87; Kondo N, 2012, J EPIDEMIOL COMMUN H, V66, DOI 10.1136/jech-2011-200321; Lee HO, 2015, J HEALTH COMMUN, V20, P285, DOI 10.1080/10810730.2014.927035; Liao QY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017713; Liu RG, 2016, HUM VACC IMMUNOTHER, V12, P1155, DOI 10.1080/21645515.2015.1123358; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Meszaros JR, 1996, J CLIN EPIDEMIOL, V49, P697, DOI 10.1016/0895-4356(96)00007-8; Milne S, 2000, J APPL SOC PSYCHOL, V30, P106, DOI 10.1111/j.1559-1816.2000.tb02308.x; Monat A., 2001, STRESS COPING ANTHOL; Nunally J., 1978, PSYCHOMETRIC THEORY; Poland GA, 2011, NEW ENGL J MED, V364, P97, DOI 10.1056/NEJMp1010594; Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085; Rogers R.W., 1983, SOCIAL PSYCHOPHYSIOL, P153; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; Ropeik D, 2013, HUM VACC IMMUNOTHER, V9, P1815, DOI 10.4161/hv.25250; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Tang MY, 2016, J HEALTH PSYCHOL, V21, P781, DOI 10.1177/1359105314539527; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, 2020, COR COVID 19 CAS COU	37	3	3	7	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							967	10.3390/vaccines9090967			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ2YL	34579204	Green Published, gold			2022-04-29	WOS:000702075800001
J	Zaderer, V; Posch, W; Gstir, R; Filipek, PA; Bonn, GK; Aramwit, P; Huber, LA; Wilflingseder, D				Zaderer, Viktoria; Posch, Wilfried; Gstir, Ronald; Filipek, Przemyslaw A.; Bonn, Guenther K.; Aramwit, Pornanong; Huber, Lukas A.; Wilflingseder, Doris			P80 Natural Essence Exerts Efficient Anti-HIV-1- as Well as Adjuvant Effects in DCs	VACCINES			English	Article						HIV-1; complement; dendritic cells; P80 natural essence	DENDRITIC CELLS; HIV; LONGAN; MATURATION; POLYSACCHARIDE; COMPLEMENT; SURVIVAL; KINASE	Dendritic cells (DCs), as well as complement, play a major role during human immunodeficiency virus 1 (HIV-1) entry and infection at mucosal sites. Together, DCs and complement are key points for understanding host defence against HIV-1 infection and for studying the impact of new drugs on the regulation of innate host-pathogen interactions and adaptive immunity. For this, we evaluated the antiviral effect of the P80 natural essence (Longan extract) on interactions of non- and complement-opsonized HIV-1 with DCs. In viability assays, we first illustrated the effects of P80 natural essence on DC function. We found that P80 concentrations above 1.5% caused increased cell death, while at concentrations between 0.5% and 1% the compound exerted efficient antiviral effects in DCs and illustrated an adjuvant effect regarding DC activation. DC maturation, as well as co-stimulatory capacity, were significantly improved by P80 natural essence via p38 MAPK phosphorylation in presence of the viral challenge independent of the opsonization pattern. These findings might be exploited for future therapeutic options to target DC subsets directly at mucosal sites by P80 natural essence and to block entry of both, non- and complement-opsonized HIV-1.	[Zaderer, Viktoria; Posch, Wilfried; Wilflingseder, Doris] Med Univ Innsbruck, Inst Hyg & Med Microbiol, A-6020 Innsbruck, Austria; [Gstir, Ronald; Filipek, Przemyslaw A.; Bonn, Guenther K.; Huber, Lukas A.] ADSI Austrian Drug Screening Inst GmbH, A-6020 Innsbruck, Austria; [Aramwit, Pornanong] Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharm Practice, Bangkok 10330, Thailand; [Aramwit, Pornanong] Chulalongkorn Univ, Ctr Excellence Bioact Resources Innovat Clin Appl, Bangkok 10330, Thailand; [Huber, Lukas A.] Med Univ Innsbruck, Bioctr Innsbruck, Inst Cell Biol, A-6020 Innsbruck, Austria		Wilflingseder, D (通讯作者)，Med Univ Innsbruck, Inst Hyg & Med Microbiol, A-6020 Innsbruck, Austria.	viktoria.zaderer@i-med.ac.at; wilfried.posch@i-med.ac.at; ronald.gstir@adsi.ac.at; przemyslaw.filipek@adsi.ac.at; Guenther.Bonn@adsi.ac.at; aramwit@gmail.com; lukas.a.huber@i-med.ac.at; doris.wilflingseder@i-med.ac.at	Posch, Wilfried/AAH-6845-2019	Posch, Wilfried/0000-0001-8955-7654; Wilflingseder, Doris/0000-0002-5888-5118; Huber, Lukas Alfons/0000-0003-1116-2120	Austrian Science Fund (FWF)Austrian Science Fund (FWF) [P33510B13]; CBD (Cellular Basis of Diseases) [FWF DOC 82]	This study was supported by the Austrian Science Fund (FWF)-Project Number P33510B13 (DW) and CBD (Cellular Basis of Diseases), FWF DOC 82 (D.W.). The funding body did not have any role in designing the study and data handling, analysis or collection.	Aiba S, 2003, J INVEST DERMATOL, V120, P390, DOI 10.1046/j.1523-1747.2003.12065.x; Apriyanto DR, 2016, JPN J INFECT DIS, V69, P213, DOI 10.7883/yoken.JJID.2015.107; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Bai YJ, 2020, CARBOHYD POLYM, V229, DOI 10.1016/j.carbpol.2019.115475; Banki Z, 2005, IMMUNOL LETT, V97, P209, DOI 10.1016/j.imlet.2004.11.007; Banki Z, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000891; Chinsembu KC, 2019, REV BRAS FARMACOGN, V29, P504, DOI 10.1016/j.bjp.2018.10.006; Fackler OT, 2007, NAT REV IMMUNOL, V7, P310, DOI 10.1038/nri2041; Harman AN, 2006, J IMMUNOL, V177, P7103, DOI 10.4049/jimmunol.177.10.7103; Kessans SA, 2013, PLANT BIOTECHNOL J, V11, P681, DOI 10.1111/pbi.12058; Liszewski MK, 2019, J IMMUNOL, V203, P3, DOI 10.4049/jimmunol.1900527; Liu GM, 2018, FOOD CHEM, V256, P268, DOI 10.1016/j.foodchem.2018.02.064; Manel N, 2010, NATURE, V467, P214, DOI 10.1038/nature09337; Mason H.S., 2015, MUCOSAL IMMUNOL, V2, P1271, DOI [10.1016/B978-0-12-415847-4.00065-3, DOI 10.1016/B978-0-12-415847-4.00065-3]; Nijmeijer BM, 2021, MUCOSAL IMMUNOL, V14, P743, DOI 10.1038/s41385-021-00376-9; Posch W, 2021, MBIO, V12, DOI 10.1128/mBio.00904-21; Posch W, 2021, J ALLERGY CLIN IMMUN, V148, P909, DOI 10.1016/j.jaci.2021.05.047; Posch W, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005005; Posch W, 2012, J ALLERGY CLIN IMMUN, V130, P1368, DOI 10.1016/j.jaci.2012.08.025; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Rong Y, 2019, CARBOHYD POLYM, V213, P247, DOI 10.1016/j.carbpol.2019.03.007; Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839; Tam JCH, 2014, SCIENCE, V345, P1134, DOI 10.1126/science.1256070; Wang Z, 2020, FOOD SCI BIOTECHNOL, V29, P683, DOI 10.1007/s10068-019-00708-3; White TE, 2013, CELL HOST MICROBE, V13, P441, DOI 10.1016/j.chom.2013.03.005; White TE, 2013, VIROLOGY, V436, P81, DOI 10.1016/j.virol.2012.10.029; Wilflingseder D, 2007, J IMMUNOL, V178, P7840, DOI 10.4049/jimmunol.178.12.7840; Wilflingseder D, 2015, J INFECT DIS, V212, P44, DOI 10.1093/infdis/jiv014; Yi Y, 2011, MOLECULES, V16, P6148, DOI 10.3390/molecules16076148	29	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							976	10.3390/vaccines9090976			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2YN	34579213	Green Published, gold			2022-04-29	WOS:000702076000001
J	Fabricius, D; Ludwig, C; Scholz, J; Rode, I; Tsamadou, C; Jacobsen, EM; Winkelmann, M; Grempels, A; Lotfi, R; Janda, A; Korper, S; Adler, G; Debatin, KM; Schrezenmeier, H; Jahrsdorfer, B				Fabricius, Dorit; Ludwig, Carolin; Scholz, Judith; Rode, Immanuel; Tsamadou, Chrysanthi; Jacobsen, Eva-Maria; Winkelmann, Martina; Grempels, Aline; Lotfi, Ramin; Janda, Ales; Koerper, Sixten; Adler, Guido; Debatin, Klaus-Michael; Schrezenmeier, Hubert; Jahrsdoerfer, Bernd			mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects	VACCINES			English	Article						heterologous vaccination regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2; including current VOCs; RNA vaccines may facilitate rapid (re-) qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies		To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)-B.1.1.7, B.1.351 and P.1-a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study, we compared immunological responses in 144 individuals vaccinated with the mRNA vaccines BNT162b2 or mRNA-1273 and the vector vaccine ChAdOx1-nCoV-19, either alone, in combination, or in the context of COVID-19-convalescence. Unvaccinated COVID-19-convalescent subjects served as a reference. We found that cellular and serological immune responses, including neutralizing capacity against VOCs, were significantly stronger with mRNA vaccines as compared with COVID-19-convalescent individuals or vaccinated individuals receiving the vector vaccine ChAdOx1-nCoV-19. Booster immunizations with mRNA vaccines triggered strong and broadly neutralizing antibody and IFN-gamma responses in 100% of vaccinated individuals investigated. This effect was particularly strong in COVID-19-convalescent and ChAdOx1-nCoV-19-primed individuals, who were characterized by comparably moderate cellular and neutralizing antibody responses before mRNA vaccine booster. Heterologous vaccination regimes and convalescent booster regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs. Furthermore, such regimes may facilitate rapid (re-)qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies.	[Fabricius, Dorit; Ludwig, Carolin; Scholz, Judith; Rode, Immanuel; Tsamadou, Chrysanthi; Jacobsen, Eva-Maria; Winkelmann, Martina; Grempels, Aline; Lotfi, Ramin; Janda, Ales; Koerper, Sixten; Adler, Guido; Debatin, Klaus-Michael; Schrezenmeier, Hubert; Jahrsdoerfer, Bernd] Inst Clin Transfus Med & Immunogenet, Div Immune Cell Therapeut, Helmholtzstr 10, D-89081 Ulm, Germany		Jahrsdorfer, B (通讯作者)，Inst Clin Transfus Med & Immunogenet, Div Immune Cell Therapeut, Helmholtzstr 10, D-89081 Ulm, Germany.	dorit.fabricius@uni-ulm.de; c.ludwig@blutspende.de; judith.scholz@uni-ulm.de; i.rode@blutspende.de; c.tsamadou@blutspende.de; eva-maria.jacobsen@uni-ulm.de; m.winkelmann@blutspend.de; a.grempels@blutspende.de; r.lotfi@blutspende.de; ales.janda@uniklinik-ulm.de; s.koerper@blutspende.de; guidoadler46@gmail.com; klaus-Michael.Debatin@uniklinik-ulm.de; h.schrezenmeier@blutspende.de; bernd.jahrsdoerfer@uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Janda, Ales/0000-0001-5604-8378; Jahrsdorfer, Bernd/0000-0002-8334-5244; Ludwig, Carolin/0000-0001-8820-8479	Ministry for Science, Research, and Arts of Baden-Wurttemberg, Germany; German Federal Ministry of Health; German Red Cross Blood Transfusion Service Baden-Wurttemberg-Hessen	This work received grant support from the Ministry for Science, Research, and Arts of Baden-Wurttemberg, Germany, from the German Federal Ministry of Health to H.S., and from the German Red Cross Blood Transfusion Service Baden-Wurttemberg-Hessen to B.J.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Casciola-Rosen Livia, 2020, medRxiv, DOI 10.1101/2020.10.13.20211664; Cohen KW, 2021, CELL REP MED, V2, DOI [10.1016/j.xcrm.2021.100354, 10.1101/2021.04.19.21255739]; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; He Qian, 2021, Emerging Microbes & Infections, V10, P629, DOI 10.1080/22221751.2021.1902245; Hillus D., 2021, MEDRXIV, DOI [10.1101/2021.05.19.21257334, DOI 10.1101/2021.05.19.21257334]; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hurlburt NK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19231-9; Jahrsdorfer B, 2021, J IMMUNOL, V206, P2614, DOI 10.4049/jimmunol.2100036; Jahrsdorfer B, 2021, J INFECT DIS, V223, P796, DOI 10.1093/infdis/jiaa656; Janiaud P, 2021, JAMA-J AM MED ASSOC, V325, P1185, DOI 10.1001/jama.2021.2747; Korper S, 2021, TRANSFUS MED HEMOTH, V48, P137, DOI 10.1159/000515610; Libster R, 2021, NEW ENGL J MED, V384, P610, DOI 10.1056/NEJMoa2033700; Lopez Bernal J, 2021, EARLY EFFECTIVENESS, V2021, DOI 10.1101/2021.03.01.21252652; Mazzoni A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149150; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Shaw RH, 2021, LANCET, V397, P2043, DOI [10.1016/S0140-6736(21)01115-6, 10.1016/S0140-6736(21)01158-2]; Simonovich VA, 2021, NEW ENGL J MED, V384, P619, DOI 10.1056/NEJMoa2031304; Stamatatos L, 2021, SCIENCE, V372, P1413, DOI 10.1126/science.abg9175; Vanshylla K, 2021, CELL HOST MICROBE, V29, P917, DOI 10.1016/j.chom.2021.04.015; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651	24	9	9	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							918	10.3390/vaccines9080918			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2WP	34452043	Green Published, gold			2022-04-29	WOS:000689798300001
J	Toh, ZQ; Quang, C; Tooma, JA; Garland, SM; Mulholland, K; Licciardi, PV				Toh, Zheng Quan; Quang, Chau; Tooma, Joseph A.; Garland, Suzanne M.; Mulholland, Kim; Licciardi, Paul V.			Australia's Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific	VACCINES			English	Review						alternative vaccine schedules; pneumococcal vaccines; human papillomavirus vaccine; vaccine evaluation and Australia	RANDOMIZED CONTROLLED-TRIAL; PAPUA-NEW-GUINEA; CONJUGATE VACCINE; POLYSACCHARIDE VACCINE; STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY MORTALITY; MATERNAL IMMUNIZATION; NORTHERN-TERRITORY; INDIGENOUS INFANTS; PARTICLE VACCINE	Australian researchers have made substantial contributions to the field of vaccinology over many decades. Two examples of this contribution relate to pneumococcal vaccines and the human papillomavirus (HPV) vaccine, with a focus on improving access to these vaccines in lowand lower-middle-income countries (LLMICs). Many LLMICs considering introducing one or both of these vaccines into their National Immunisation Programs face significant barriers such as cost, logistics associated with vaccine delivery. These countries also often lack the resources and expertise to undertake the necessary studies to evaluate vaccine performance. This review summarizes the role of Australia in the development and/or evaluation of pneumococcal vaccines and the HPV vaccine, including the use of alternative vaccine strategies among countries situated in the Asia-Pacific region. The outcomes of these research programs have had significant global health impacts, highlighting the importance of these vaccines in preventing pneumococcal disease as well as HPV-associated diseases.	[Toh, Zheng Quan; Quang, Chau; Garland, Suzanne M.; Mulholland, Kim; Licciardi, Paul V.] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Toh, Zheng Quan; Quang, Chau; Mulholland, Kim; Licciardi, Paul V.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Tooma, Joseph A.] Australia Cerv Canc Fdn, Fortitude Valley, Qld 4006, Australia; [Garland, Suzanne M.] Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia; [Garland, Suzanne M.] Royal Womens Hosp, Ctr Womens Infect Dis Res, Reg WHO HPV Reference Lab, Parkville, Vic 3052, Australia; [Mulholland, Kim] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England		Licciardi, PV (通讯作者)，Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.; Licciardi, PV (通讯作者)，Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.	zhenq.quantoh@mcri.edu.au; chau.quang@mcri.edu.au; joe.tooma@accf.org.au; Suzanne.garland@thewomens.org.au; kim.mulholland@mcri.edu.au; paul.licciardi@mcri.edu.au		Licciardi, Paul/0000-0001-6086-6285; Quang, Chau/0000-0003-1423-7167			Aho Celestine, 2016, Vaccine Rep, V6, P36, DOI 10.1016/j.vacrep.2016.08.002; Ali H, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2032; [Anonymous], 2014, Wkly Epidemiol Rec, V89, P465; Arbyn M, 2014, J PATHOL, V234, P431, DOI 10.1002/path.4424; Australian Cervical Cancer Foundation, ACCFS ACH FUT PLANS; Australian Institute of Health and Welfare, 2019, AN CERV CANC ABN OUT; Batmunkh T, 2020, VACCINE, V38, P4316, DOI 10.1016/j.vaccine.2020.04.041; Berical AC, 2016, ANN AM THORAC SOC, V13, P933, DOI 10.1513/AnnalsATS.201511-778FR; Binks MJ, 2020, LANCET CHILD ADOLESC, V4, P425, DOI 10.1016/S2352-4642(20)30090-0; Binks MJ, 2018, PNEUMONIA, V10, DOI 10.1186/s41479-018-0057-2; Binks MJ, 2015, VACCINE, V33, P6579, DOI 10.1016/j.vaccine.2015.10.101; Borrow R, 2012, CURR OPIN INFECT DIS, V25, P292, DOI 10.1097/QCO.0b013e3283531b0f; Brotherton JML, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100177; Brotherton JML, 2011, LANCET, V377, P2085, DOI 10.1016/S0140-6736(11)60551-5; Centers for Disease Control and Prevention, GLON PNEUM DIS VACC; Chan J, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021512; Chelimo C, 2013, J INFECTION, V66, P207, DOI 10.1016/j.jinf.2012.10.024; Chesson HW, 2014, SEX TRANSM DIS, V41, P660, DOI 10.1097/OLQ.0000000000000193; Chow E.P.F., PREVALENCE HUMAN PAP; Chow EPF, 2015, LANCET INFECT DIS, V15, P1314, DOI 10.1016/S1473-3099(15)00055-9; Chow EPF, 2015, SEX TRANSM INFECT, V91, P214, DOI 10.1136/sextrans-2014-051813; ClinicalTrials.gov, DOS RED IMM SAF STUD; ClinicalTrials.gov, HPV VACC IMM HIGH RI; ClinicalTrials.gov, EV PCV SCHED NAIV PO; Cornall AM, 2020, VACCINE, V38, P6304, DOI 10.1016/j.vaccine.2020.07.037; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; Dehlendorff C, 2021, JNCI-J NATL CANCER I, V113, P869, DOI 10.1093/jnci/djaa209; DOUGLAS RM, 1986, AM J DIS CHILD, V140, P1183, DOI 10.1001/archpedi.1986.02140250109044; DOUGLAS RM, 1984, J INFECT DIS, V149, P861, DOI 10.1093/infdis/149.6.861; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; DOUGLAS RM, 1986, COMMUNITY HEALTH ST, V10, P189; Douglas Robert M., 2010, Papua New Guinea Medical Journal, V53, P99; Dunne EM, 2018, LANCET GLOB HEALTH, V6, pE1375, DOI 10.1016/S2214-109X(18)30383-8; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; Ed C., HPV VACCINATION AFRI; Fathima P, 2019, LANCET CHILD ADOLESC, V3, P713, DOI 10.1016/S2352-4642(19)30249-4; Fathima P, 2018, CLIN INFECT DIS, V66, P1075, DOI 10.1093/cid/cix923; Flasche S, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001839; Francis JP, 2009, CLIN VACCINE IMMUNOL, V16, P1633, DOI 10.1128/CVI.00247-09; Garland SM, 2018, VACCINE, V36, P3221, DOI 10.1016/j.vaccine.2018.04.080; Gidding HF, 2018, VACCINE, V36, P2650, DOI 10.1016/j.vaccine.2018.03.058; Guignard A, 2019, EXPERT REV VACCINES, V18, P119, DOI 10.1080/14760584.2019.1574224; Haasis MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131156; Hall MT, 2019, LANCET PUBLIC HEALTH, V4, pE19, DOI 10.1016/S2468-2667(18)30183-X; Henschke H., EFFECTIVENESS IMMUNO; Hildesheim A, 2007, JAMA-J AM MED ASSOC, V298, P743, DOI 10.1001/jama.298.7.743; International Vaccine Access Center and Johns Hopkins Bloomberg School of Public Health, VIEW HUB REP GLOB VA; Kjaer SK, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100401; Kreimer AR, 2020, JNCI-J NATL CANCER I, V112, DOI 10.1093/jnci/djaa011; Kreimer AR, 2018, VACCINE, V36, P4774, DOI 10.1016/j.vaccine.2017.12.078; La Vincente S.F., 2019, BMC PUBLIC HEALTH, V19, P333, DOI [10.1186/s12889-019-6639-y, DOI 10.1186/s12889-019-6639-y]; LEACH AJ, 1994, PEDIATR INFECT DIS J, V13, P983, DOI 10.1097/00006454-199411000-00009; Leach AJ, 2021, BMC PEDIATR, V21, DOI 10.1186/s12887-021-02552-z; Leach AJ, 2021, VACCINE-X, V7, DOI 10.1016/j.jvacx.2021.100086; Leach AJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007247; Lehmann D, 2002, VACCINE, V20, P1837, DOI 10.1016/S0264-410X(02)00040-3; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Licciardi PV, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.46; Licciardi PV, 2016, J ALLERGY CLIN IMMUN, V137, P1772, DOI 10.1016/j.jaci.2015.12.1303; Licciardi PV, 2014, VACCINE, V32, P2321, DOI 10.1016/j.vaccine.2014.02.064; Machalek DA, 2018, J INFECT DIS, V217, P1590, DOI 10.1093/infdis/jiy075; Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3; Mackenzie GA, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-14; Moberley S, 2017, VACCINE, V35, P2908, DOI 10.1016/j.vaccine.2017.04.040; Murdoch DR, 2018, LANCET INFECT DIS, V18, P1162, DOI 10.1016/S1473-3099(18)30407-9; National Centre for Immunisation Research and Surveillance, SIGN EV PNEUM VACC P; O'Grady KF, 2010, B WORLD HEALTH ORGAN, V88, P139, DOI 10.2471/BLT.09.068239; O'Grady KAF, 2018, HUM VACC IMMUNOTHER, V14, P2768, DOI 10.1080/21645515.2018.1488562; O'Grady KAF, 2010, CLIN INFECT DIS, V50, P970, DOI 10.1086/651079; ODempsey TJD, 1996, VACCINE, V14, P963, DOI 10.1016/0264-410X(96)00009-6; Osborne SL, 2015, VACCINE, V33, P201, DOI 10.1016/j.vaccine.2014.10.045; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Pomat WS, 2019, CLIN INFECT DIS, V68, P1472, DOI 10.1093/cid/ciy743; Pomat WS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056698; Reyburn R, 2021, LANCET GLOB HEALTH, V9, pE91, DOI 10.1016/S2214-109X(20)30421-6; RILEY ID, 1981, ARCH DIS CHILD, V56, P354, DOI 10.1136/adc.56.5.354; RILEY ID, 1991, REV INFECT DIS, V13, pS535; RILEY ID, 1986, LANCET, V2, P877; RILEY ID, 1977, LANCET, V1, P1338; Russell FM, 2010, CLIN VACCINE IMMUNOL, V17, P1970, DOI 10.1128/CVI.00117-10; Russell FM, 2010, VACCINE, V28, P3341, DOI 10.1016/j.vaccine.2010.02.087; Russell FM, 2010, VACCINE, V28, P3086, DOI 10.1016/j.vaccine.2010.02.065; Russell FM, 2009, VACCINE, V27, P5685, DOI 10.1016/j.vaccine.2009.06.098; Safaeian M, 2013, CANCER PREV RES, V6, P1242, DOI 10.1158/1940-6207.CAPR-13-0203; Sankaranarayanan R, 2016, LANCET ONCOL, V17, P67, DOI 10.1016/S1470-2045(15)00414-3; Satzke C, 2019, VACCINE, V37, P296, DOI 10.1016/j.vaccine.2018.10.077; Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86; Scott JAG, 2011, CLIN INFECT DIS, V53, P663, DOI 10.1093/cid/cir444; SHAHID NS, 1995, LANCET, V346, P1252, DOI 10.1016/S0140-6736(95)91861-2; Single-Dose HPV Vaccine Evaluation Consortium, REV CURR PUBL EV SIN; Soohoo Melissa, 2013, Open AIDS J, V7, P58, DOI 10.2174/1874613601307010058; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Tabrizi SN, 2014, LANCET INFECT DIS, V14, P958, DOI 10.1016/S1473-3099(14)70841-2; Tabrizi SN, 2012, J INFECT DIS, V206, P1645, DOI 10.1093/infdis/jis590; Temple B, 2021, VACCINE, V39, P2303, DOI 10.1016/j.vaccine.2021.02.043; Temple B, 2019, LANCET INFECT DIS, V19, P497, DOI 10.1016/S1473-3099(18)30734-5; Temple B, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019795; Toh ZQ, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040200; Toh ZQ, 2019, INFECT DRUG RESIST, V12, P1951, DOI 10.2147/IDR.S178381; Toh ZQ, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy147; Toh ZQ, 2017, CLIN INFECT DIS, V64, P852, DOI 10.1093/cid/ciw865; Toh ZQ, 2015, VACCINE, V33, P5042, DOI 10.1016/j.vaccine.2015.07.102; Turner HC, 2018, LANCET INFECT DIS, V18, P937, DOI 10.1016/S1473-3099(18)30478-X; van den Biggelaar AHJ, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010017; Van der Sande M.A.B., HUMAN PAPILLOMAVIRUS; von Mollendorf C, 2019, VACCINE, V37, P4068, DOI 10.1016/j.vaccine.2019.05.078; Vorsters A, 2019, INT J INFECT DIS, V88, P110, DOI 10.1016/j.ijid.2019.09.006; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Weaver R, 2020, LANCET REG HEALTH-W, V2, DOI 10.1016/j.lanwpc.2020.100014; ZHOU J, 1991, VIROLOGY, V185, P251, DOI 10.1016/0042-6822(91)90772-4	110	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							921	10.3390/vaccines9080921			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4GR	34452046	Green Published, gold			2022-04-29	WOS:000689892100001
J	Akbay, B; Abidi, SH; Ibrahim, MAA; Mukhatayev, Z; Ali, S				Akbay, Burkitkan; Abidi, Syed Hani; Ibrahim, Mahmoud A. A.; Mukhatayev, Zhussipbek; Ali, Syed			Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes	VACCINES			English	Article						human coronaviruses; MERS; SARS-CoV-2; SARS-CoV; epitope; vaccine	FAST INTERACTION REFINEMENT; CROSS-REACTIVITY; COVID-19 VACCINE; CORONAVIRUS; PREDICTION; EFFICACY; WEB; SEQUENCE; DISEASE; TRIAL	The SARS-CoV-2 pandemic has created a public health crisis worldwide. Although vaccines against the virus are efficiently being rolled out, they are proving to be ineffective against certain emerging SARS-CoV-2 variants. The high degree of sequence similarity between SARS-CoV-2 and other human coronaviruses (HCoV) presents the opportunity for designing vaccines that may offer protection against SARS-CoV-2 and its emerging variants, with cross-protection against other HCoVs. In this study, we performed bioinformatics analyses to identify T and B cell epitopes originating from spike, membrane, nucleocapsid, and envelope protein sequences found to be evolutionarily conserved among seven major HCoVs. Evolutionary conservation of these epitopes indicates that they may have critical roles in viral fitness and are, therefore, unlikely to mutate during viral replication thus making such epitopes attractive candidates for a vaccine. Our designed vaccine construct comprises of twelve T and six B cell epitopes that are conserved among HCoVs. The vaccine is predicted to be soluble in water, stable, have a relatively long half-life, and exhibit low allergenicity and toxicity. Our docking results showed that the vaccine forms stable complex with toll-like receptor 4, while the immune simulations predicted that the vaccine may elicit strong IgG, IgM, and cytotoxic T cell responses. Therefore, from multiple perspectives, our multi-subunit vaccine design shows the potential to elicit a strong immune-protective response against SARS-CoV-2 and its emerging variants while carrying minimal risk for causing adverse effects.	[Akbay, Burkitkan; Mukhatayev, Zhussipbek; Ali, Syed] Nazarbayev Univ, Nazarbayev Sch Med, Dept Biomed Sci, Nur Sultan 010000, Kazakhstan; [Abidi, Syed Hani] Aga Khan Univ, Dept Biol & Biomed Sci, Karachi 74800, Pakistan; [Ibrahim, Mahmoud A. A.] Minia Univ, Fac Sci, Chem Dept, Computat Chem Lab, Al Minya 61519, Egypt		Ali, S (通讯作者)，Nazarbayev Univ, Nazarbayev Sch Med, Dept Biomed Sci, Nur Sultan 010000, Kazakhstan.; Abidi, SH (通讯作者)，Aga Khan Univ, Dept Biol & Biomed Sci, Karachi 74800, Pakistan.	burkitkan.akbay@nu.edu.kz; m.haniabidi@gmail.com; m.ibrahim@compchem.net; zhussipbek.mukhatayev@nu.edu.kz; syed.ali@nu.edu.kz	Ibrahim, Mahmoud A. A./J-2936-2014; Mukhatayev, Zhussipbek/AAD-9827-2021	Ibrahim, Mahmoud A. A./0000-0003-4819-2040; Mukhatayev, Zhussipbek/0000-0002-5592-5727; Akbay, Burkitkan/0000-0001-6389-170X			Peele KA, 2021, J BIOMOL STRUCT DYN, V39, P3793, DOI 10.1080/07391102.2020.1770127; Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495; Bhasin M, 2004, VACCINE, V22, P3195, DOI 10.1016/j.vaccine.2004.02.005; Bhasin M, 2007, J BIOSCIENCES, V32, P31, DOI 10.1007/s12038-007-0004-5; Bilich T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf7517; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Botelho S., 2021, BIOCH TERTIARY PROTE; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Cao YM, 2017, ANTIVIR RES, V140, P133, DOI 10.1016/j.antiviral.2017.01.023; Che XY, 2005, J INFECT DIS, V191, P2033, DOI 10.1086/430355; Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Crooke SN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70864-8; de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Dong R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01784; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Duan LW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576622; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Enany S, 2014, J INFECT PUBLIC HEAL, V7, P296, DOI 10.1016/j.jiph.2014.02.002; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Ferretti AP, 2020, IMMUNITY, V53, P1095, DOI 10.1016/j.immuni.2020.10.006; Foroutan M, 2020, COMP IMMUNOL MICROB, V69, DOI 10.1016/j.cimid.2020.101413; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101; Gallagher Kathleen M E, 2021, bioRxiv, DOI 10.1101/2021.05.03.442455; Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464; Guo L, 2014, APPL MICROBIOL BIOT, V98, P3495, DOI 10.1007/s00253-013-5408-6; Gupta S., 2013, PLOS ONE, V8, pE73597, DOI 10.1371/journal.pone.0073957; Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95; Hebditch M, 2017, BIOINFORMATICS, V33, P3098, DOI [10.1093/bioinformatics/btx345, 10.1093/BIOINFORMATICS/BTX345]; Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Ikram A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34254-5; Ilinskaya AN, 2016, TOXICOL APPL PHARM, V299, P70, DOI 10.1016/j.taap.2016.01.005; Jones I, 2021, LANCET, V397, P642, DOI 10.1016/S0140-6736(21)00191-4; Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236; Kar T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67749-1; Kared H, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145476; Karim SSA, 2021, LANCET, V397, P1263, DOI 10.1016/S0140-6736(21)00468-2; Katoh Kazutaka, 2013, Mol Biol Evol, V30, P772, DOI 10.1093/molbev/mst010; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Kesmir C, 2002, PROTEIN ENG, V15, P287, DOI 10.1093/protein/15.4.287; Khan Saahir, 2020, bioRxiv, DOI 10.1101/2020.03.24.006544; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Kiyotani K, 2020, J HUM GENET, V65, P569, DOI 10.1038/s10038-020-0771-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Ladner Jason T, 2020, bioRxiv, DOI 10.1101/2020.07.27.222943; Lam LKM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0039-z; Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424; Larsson A, 2014, BIOINFORMATICS, V30, P3276, DOI 10.1093/bioinformatics/btu531; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Lennerz V, 2014, CANCER IMMUNOL IMMUN, V63, P381, DOI 10.1007/s00262-013-1516-5; Letko Michael, 2020, bioRxiv, DOI 10.1101/2020.01.22.915660; Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Li Y, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108915; Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lu S, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108666; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Martin WR, 2021, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2021.1894986; Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mukherjee S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020290; Naz A, 2015, INFECT GENET EVOL, V32, P280, DOI 10.1016/j.meegid.2015.03.027; Nielsen M, 2005, IMMUNOGENETICS, V57, P33, DOI 10.1007/s00251-005-0781-7; Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26; Ohto U, 2012, J BIOL CHEM, V287, P40611, DOI 10.1074/jbc.M112.404608; Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147; Pinotti F, 2021, BMC MED, V19, DOI 10.1186/s12916-020-01887-1; Rapin N, 2011, BIOINFORMATICS, V27, P2013, DOI 10.1093/bioinformatics/btr335; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Saletti G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78506-9; Sanami S, 2020, INT J BIOL MACROMOL, V164, P871, DOI 10.1016/j.ijbiomac.2020.07.117; Sarkar B, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151955; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Schwarz T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.629185; Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0; Slingluff CL, 2013, CLIN CANCER RES, V19, P4228, DOI 10.1158/1078-0432.CCR-13-0002; Snyder Thomas M, 2020, medRxiv, DOI 10.1101/2020.07.31.20165647; ul Qamar MT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244176; TARKE A, 2021, CELL REP MED, V2, DOI DOI 10.1016/J.XCRM.2021.100204; Toledo H, 2001, VACCINE, V19, P4328, DOI 10.1016/S0264-410X(01)00111-6; Trifinopoulos J, 2016, NUCLEIC ACIDS RES, V44, pW232, DOI 10.1093/nar/gkw256; Tso FY, 2021, INT J INFECT DIS, V102, P577, DOI 10.1016/j.ijid.2020.10.104; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wang DL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030355; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Wlodawer A, 2017, METHODS MOL BIOL, V1606, P595, DOI 10.1007/978-1-4939-7000-1_24; Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Yazdani Z, 2020, INFECT DRUG RESIST, V13, P3007, DOI 10.2147/IDR.S264573; Zhang HH, 2010, VET IMMUNOL IMMUNOP, V136, P92, DOI 10.1016/j.vetimm.2010.02.018; Zhao YC, 2021, CELL RES, V31, P818, DOI 10.1038/s41422-021-00495-9; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	102	2	2	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							702	10.3390/vaccines9070702			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6QR	34206865	gold, Green Published			2022-04-29	WOS:000677034000001
J	Della Polla, G; Licata, F; Angelillo, S; Pelullo, CP; Bianco, A; Angelillo, IF				Della Polla, Giorgia; Licata, Francesca; Angelillo, Silvia; Pelullo, Concetta Paola; Bianco, Aida; Angelillo, Italo Francesco			Characteristics of Healthcare Workers Vaccinated against Influenza in the Era of COVID-19	VACCINES			English	Article						COVID-19 pandemic; healthcare workers; influenza vaccination; Italy; survey; vaccination coverage	SEASONAL INFLUENZA; AT-RISK; ATTITUDES; COVERAGE; DISEASE; KNOWLEDGE; INTENTION	Understanding the potential impact of COVID-19 on receiving influenza vaccination among healthcare workers (HCWs) is of utmost importance. The purposes of the present cross-sectional study were to describe the characteristics and to explore the predictors of receiving influenza vaccination among a large cohort of Italian HCWs in hospital settings. Information was collected through an anonymous questionnaire from December 2020 through January 2021. General and practice characteristics, perceived risk of seasonal influenza, attitudes towards efficacy and safety of influenza vaccination, and reasons behind the decision to be vaccinated against influenza were explored. Fewer than half (46.2%) of HCWs agreed that influenza is a serious illness and perceived the risk of getting infected with influenza, and concerns about the safety of the vaccination were significant positive predictors. Fewer than half of the respondents were not concerned at all about the efficacy (48.6%) and safety (49.8%) of influenza vaccination, and 51.9% reported that they have not received a seasonal influenza vaccine during the previous season. The most mentioned reason for receiving the influenza vaccine in the current season was that influenza and COVID-19 share some similar symptoms. Study results will aid policymakers in developing vaccination education programs, promotion of trust to address negative misconceptions, and to achieve future high coverage among this high-risk group.	[Della Polla, Giorgia] Univ Campania Luigi Vanvitelli, Teaching Hosp, Hlth Direct, Via Santa Maria di Costantinopoli 104, I-80138 Naples, Italy; [Licata, Francesca; Angelillo, Silvia; Bianco, Aida] Univ Catanzaro Magna Graecia, Dept Hlth Sci, Viale Europa, I-88100 Catanzaro, Italy; [Pelullo, Concetta Paola; Angelillo, Italo Francesco] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via L Armanni 5, I-80138 Naples, Italy		Angelillo, IF (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Expt Med, Via L Armanni 5, I-80138 Naples, Italy.	giorgia.dellapolla@unicampania.it; francesca.licata@studenti.unicz.it; silvia.angelillo@studenti.unicz.it; concettapaola.pelullo@unicampania.it; a.bianco@unicz.it; italof.angelillo@unicampania.it		Licata, Francesca/0000-0003-3704-6822; angelillo, silvia/0000-0001-8103-5368; Angelillo, Italo F/0000-0003-1213-6602; BIANCO, Aida/0000-0003-4674-0306; Pelullo, Concetta Paola/0000-0003-4228-8703			Ashkenazi S, 2020, VACCINE, V38, P7292, DOI 10.1016/j.vaccine.2020.09.044; Bertoldo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215978; Bianco A, 2019, VACCINE, V37, P984, DOI 10.1016/j.vaccine.2018.12.062; Boey L, 2018, VACCINE, V36, P3351, DOI 10.1016/j.vaccine.2018.04.044; Bonet-Esteve A, 2021, BMC FAM PRACT, V22, DOI 10.1186/s12875-021-01434-8; Costantino C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040686; Della Polla G, 2020, HUM VACC IMMUNOTHER, V16, P2744, DOI 10.1080/21645515.2020.1744367; Della Polla G, 2020, HUM VACC IMMUNOTHER, V16, P2422, DOI 10.1080/21645515.2020.1720441; Di Giuseppe G, 2021, EXPERT REV VACCINES, V20, P881, DOI 10.1080/14760584.2021.1922081; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Durando P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010779; Filia A, 2019, EUROSURVEILLANCE, V24, P8, DOI 10.2807/1560-7917.ES.2019.24.6.1800275; Giese C, 2016, VACCINE, V34, P3657, DOI 10.1016/j.vaccine.2016.05.028; Hagemeister MH, 2018, PUBLIC HEALTH, V154, P102, DOI 10.1016/j.puhe.2017.10.027; Hofmann F, 2006, INFECTION, V34, P142, DOI 10.1007/s15010-006-5109-5; Hulo S, 2017, VACCINE, V35, P205, DOI 10.1016/j.vaccine.2016.11.086; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jimenez-Garcia R, 2017, VACCINE, V35, P101, DOI 10.1016/j.vaccine.2016.11.039; Kelly BJ, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06085-9; Kopsidas I, 2020, VACCINE, V38, P4609, DOI 10.1016/j.vaccine.2020.05.021; Lee RU, 2019, CLIN INFECT DIS, V68, P1839, DOI 10.1093/cid/ciy812; Lim DW, 2020, HUM VACC IMMUNOTHER, V16, P1118, DOI 10.1080/21645515.2019.1688037; Marano G, 2021, EXPERT REV VACCINES, V20, P73, DOI 10.1080/14760584.2021.1874927; Ministero della Salute, PIAN NAZ PREV VACC 1 PIAN NAZ PREV VACC 1; Napolitano F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010063; Napolitano F, 2019, VACCINE, V37, P6900, DOI 10.1016/j.vaccine.2019.09.053; Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943; Napolitano F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194920; Nowak GJ, 2015, VACCINE, V33, P2741, DOI 10.1016/j.vaccine.2015.04.064; Pelullo CP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020148; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rabensteiner A, 2018, VACCINE, V36, P535, DOI 10.1016/j.vaccine.2017.12.007; Stata Corporation, 2017, STATA REFERENCE MANU; Sturm L, 2021, VACCINE, V39, P1921, DOI 10.1016/j.vaccine.2021.03.003; von Linstow ML, 2020, VACCINE, V38, P6570, DOI 10.1016/j.vaccine.2020.08.010; Vrachnaki O, 2020, HUM VACC IMMUNOTHER, V16, P2663, DOI 10.1080/21645515.2020.1741311; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; WHO, INFL SEAS; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Wu MJ, 2021, VACCINE, V39, P1788, DOI 10.1016/j.vaccine.2021.01.065	40	5	5	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							695	10.3390/vaccines9070695			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6XJ	34202867	Green Published, gold			2022-04-29	WOS:000677051400001
J	Indini, A; Tourlaki, A; Grossi, F; Gambini, D; Brambilla, L				Indini, Alice; Tourlaki, Athanasia; Grossi, Francesco; Gambini, Donatella; Brambilla, Lucia			COVID-19 Vaccination in Patients with Classic Kaposi's Sarcoma	VACCINES			English	Article						COVID-19; vaccination; Kaposi's sarcoma; SARS-CoV-2; cancer; HHV-8 DNA	CLINICAL CHARACTERISTICS; RISK-FACTORS; CANCER; MULTICENTER; INFECTION; MORTALITY; INFLUENZA; CHINA	The novel coronavirus disease 2019 (COVID-19) has represented an overwhelming challenge for worldwide health systems. Patients with cancer are considered at higher risk for severe COVID-19 and increased mortality in case of infection. Although data on the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with cancer are limited, there is enough evidence supporting anti-infective vaccination in general in patients with active cancer, or with history of previous malignancy. Subjects with classic Kaposi's sarcoma (KS) represent a small subset of cancer patients, which should be considered at heightened risk for infections due to several factors including age, and impaired immune function status. Several cases of human herpesviruses reactivation among critically ill COVID-19 patients have been described. Moreover, in case of severe infection and treatment with immunomodulating agents, patients with CKS are exposed at significant risk of viral reactivation and disease progression. Considering the baseline clinical risk factors of patients with CKS, and the complex interplay of the two viral agents, SARS-CoV-2 vaccination should be strongly recommended among patients with KS. KS represents an interesting field to study the interactions among chronic viral infections, SARS-CoV-2 and the host's immune system. Prospective observational studies are needed to provide more insights on vaccine activity and safety among patients with cancer, optimal vaccine schedules, potential interactions with antineoplastic therapies, and other comorbidities including chronic viral infections.	[Indini, Alice; Gambini, Donatella] Osped Maggiore Policlin, Med Oncol Unit, Fdn IRCCS Ca Granda, I-20122 Milan, Italy; [Tourlaki, Athanasia; Brambilla, Lucia] Osped Maggiore Policlin, Dermatol Unit, Fdn IRCCS Ca Granda, I-20122 Milan, Italy; [Grossi, Francesco] Univ Insubria, Dept Med & Surg, Med Oncol Unit, ASST Sette Laghi, I-21100 Varese, Italy		Indini, A (通讯作者)，Osped Maggiore Policlin, Med Oncol Unit, Fdn IRCCS Ca Granda, I-20122 Milan, Italy.	alice.indini@policlinico.mi.it; athanasia.tourlaki@policlinico.mi.it; francesco.grossi@asst-settelaghi.it; donatella.gambini@policlinico.mi.it; lucia.brambilla@policlinico.mi.it	gambini, donatella/ABA-9996-2021; Indini, Alice/AAC-2396-2022	gambini, donatella/0000-0002-0709-536X; Indini, Alice/0000-0001-8686-4106; Grossi, Francesco/0000-0001-8412-3136	 [RC-2021-185/01]	This research was partially funded by the current research project RC-2021-185/01.	Alomari N, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101097; Aneja KK, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00613; Ariza-Heredia EJ, 2015, HUM VACC IMMUNOTHER, V11, P2606, DOI 10.1080/21645515.2015.1062189; Brambilla L, 2020, EUR J DERMATOL, V30, P754, DOI 10.1684/ejd.2020.3924; Brydak LB, 2001, SUPPORT CARE CANCER, V9, P65, DOI 10.1007/s005200000186; Cappelletti M, 2012, J INVEST DERMATOL, V132, P2414, DOI 10.1038/jid.2012.151; Cesarman E, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0060-9; Chamilos G, 2021, CLIN INFECT DIS, V72, P351, DOI 10.1093/cid/ciaa1079; Chen Jungang, 2020, bioRxiv, DOI 10.1101/2020.10.02.324228; Corti C, 2021, EUR J CANCER, V148, P316, DOI 10.1016/j.ejca.2021.01.046; Delyon J, 2020, ANN ONCOL, V31, pS732, DOI 10.1016/j.annonc.2020.08.1201; Desai A, 2021, NAT REV CLIN ONCOL, V18, P313, DOI 10.1038/s41571-021-00487-z; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Elkrief A, 2020, EUR J CANCER, V139, P181, DOI 10.1016/j.ejca.2020.08.017; Maia CMF, 2021, INT J INFECT DIS, V104, P732, DOI 10.1016/j.ijid.2021.02.033; Genovese G, 2019, J EUR ACAD DERMATOL, V33, pE269, DOI 10.1111/jdv.15543; Giesen N, 2021, EUR J CANCER, V147, P154, DOI 10.1016/j.ejca.2021.01.033; Grivas P, 2021, ANN ONCOL, V32, P787, DOI 10.1016/j.annonc.2021.02.024; Indini A, 2020, CRIT REV ONCOL HEMAT, V153, DOI 10.1016/j.critrevonc.2020.103059; Indini A, 2020, EUR J CANCER, V132, P17, DOI 10.1016/j.ejca.2020.03.024; King C, 2021, TRENDS IMMUNOL, V42, P312, DOI 10.1016/j.it.2021.02.003; Le Balc'h P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03252-3; Ljungman P, 2012, CLIN MICROBIOL INFEC, V18, P93, DOI 10.1111/j.1469-0691.2012.03971.x; Mariggio G, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0275; National Institute of Health, COVID 19 TREATM GUID; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Simonnet A, 2021, INFECT DIS NOW, V51, P296, DOI 10.1016/j.idnow.2021.01.005; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Thibaudin M, 2020, EUR J CANCER, V139, P70, DOI 10.1016/j.ejca.2020.08.013; Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7; Yekeduz E, 2020, EUR J CANCER, V141, P92, DOI 10.1016/j.ejca.2020.09.028	34	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							632	10.3390/vaccines9060632			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ1HP	34200648	Green Published, gold			2022-04-29	WOS:000666325700001
J	Lanfermann, C; Wintgens, S; Ebensen, T; Kohn, M; Laudeley, R; Schulze, K; Rheinheimer, C; Hegemann, JH; Guzman, CA; Klos, A				Lanfermann, Christian; Wintgens, Sebastian; Ebensen, Thomas; Kohn, Martin; Laudeley, Robert; Schulze, Kai; Rheinheimer, Claudia; Hegemann, Johannes H.; Guzman, Carlos Alberto; Klos, Andreas			Prophylactic Multi-Subunit Vaccine against Chlamydia trachomatis: In Vivo Evaluation in Mice	VACCINES			English	Article						Chlamydia trachomatis; vaccine; mouse model; lung infection; immune response; polymorphic membrane proteins; Pmp; Ctad1; c-di-AMP; sexually-transmitted disease	POLYMORPHIC-MEMBRANE-PROTEIN; PROTECTIVE IMMUNE-RESPONSES; GENITAL-TRACT; IMMUNIZATION; PNEUMONIAE; ADJUVANTS; IMMUNOGENICITY; RECOMBINATION; IMMUNOLOGY; EXPRESSION	Chlamydia trachomatis is the most frequent sexually-transmitted disease-causing bacterium. Urogenital serovars of this intracellular pathogen lead to urethritis and cervicitis. Ascending infections result in pelvic inflammatory disease, salpingitis, and oophoritis. One of 200 urogenital infections leads to tubal infertility. Serovars A-C cause trachoma with visual impairment. There is an urgent need for a vaccine. We characterized a new five-component subunit vaccine in a mouse vaccination-lung challenge infection model. Four recombinant Pmp family-members and Ctad1 from C. trachomatis serovar E, all of which participate in adhesion and binding of chlamydial elementary bodies to host cells, were combined with the mucosal adjuvant cyclic-di-adenosine monophosphate. Intranasal application led to a high degree of cross-serovar protection against urogenital and ocular strains of C. trachomatis, which lasted at least five months. Critical evaluated parameters were body weight, clinical score, chlamydial load, a granulocyte marker and the cytokines IFN-gamma/TNF-alpha in lung homogenate. Vaccine antigen-specific antibodies and a mixed Th1/Th2/Th17 T cell response with multi-functional CD4(+) and CD8(+) T cells correlate with protection. However, serum-transfer did not protect the recipients suggesting that circulating antibodies play only a minor role. In the long run, our new vaccine might help to prevent the feared consequences of human C. trachomatis infections.	[Lanfermann, Christian; Kohn, Martin; Laudeley, Robert; Rheinheimer, Claudia; Klos, Andreas] Med Sch Hannover, Inst Med Microbiol & Hosp Epidemiol, D-30625 Hannover, Germany; [Wintgens, Sebastian; Hegemann, Johannes H.] Heinrich Heine Univ Dusseldorf, Inst Funct Microbial Genom, D-40225 Dusseldorf, Germany; [Ebensen, Thomas; Schulze, Kai; Guzman, Carlos Alberto] Helmholtz Ctr Infect Res, Dept Vaccinol & Appl Microbiol, D-38124 Braunschweig, Germany		Klos, A (通讯作者)，Med Sch Hannover, Inst Med Microbiol & Hosp Epidemiol, D-30625 Hannover, Germany.	Lanfermann.Christian@mh-hannover.de; Sebastian.Wintgens@uni-duesseldorf.de; Thomas.Ebensen@helmholtz-hzi.de; Kohn.Martin@mh-hannover.de; Laudeley.Robert@mh-hannover.de; Kai.Schulze@helmholtz-hzi.de; Rheinheimer.Claudia@mh-hannover.de; Johannes.Hegemann@hhu.de; CarlosAlberto.Guzman@helmholtz-hzi.de; Klos.Andreas@mh-hannover.de		Hegemann, Johannes H./0000-0003-4733-2435; Guzman, Carlos Alberto/0000-0002-2913-5254	MHH-LOM of the research group Klos; ZIB PhD program from the Hannover Medical School; European Community's Horizon 2020 grant [730964]; Helmholtz Association (HAI-IDR); Graduate School 'Molecules of Infection (MOI III)' - Jurgen Manchot Foundation	The experiments performed in the mouse model and the analysis of the obtained tissue and blood samples were mainly funded by MHH-LOM of the research group Klos. Christian Lanfermann and Martin Kohn were partially funded by the ZIB PhD program from the Hannover Medical School. The HZI research was partially funded by grants from the European Community's Horizon 2020 grant agreement no. 730964 (TRANSVAC2), and the Helmholtz Association (HAI-IDR). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. S.W. was a scholarship holder of the Graduate School `Molecules of Infection (MOI III)' funded by the Jurgen Manchot Foundation.	Abraham S, 2019, LANCET INFECT DIS, V19, P1091, DOI 10.1016/S1473-3099(19)30279-8; Bastidas RJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a010256; Becker E, 2014, MICROBIOLOGYOPEN, V3, P544, DOI 10.1002/mbo3.186; Bode J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050327; Borges V, 2019, MICROB GENOMICS, V5, DOI 10.1099/mgen.0.000313; Brunham RC, 2005, NAT REV IMMUNOL, V5, P149, DOI 10.1038/nri1551; Brunham RC, 2013, VACCINE, V31, P1892, DOI 10.1016/j.vaccine.2013.01.024; Crane DD, 2006, P NATL ACAD SCI USA, V103, P1894, DOI 10.1073/pnas.0508983103; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Darville Toni, 2005, Semin Pediatr Infect Dis, V16, P235, DOI 10.1053/j.spid.2005.06.004; De La Maza L.M., 2020, CHLAMYDIA BIOL GENOM; de la Maza LM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00543-16, 10.1128/cvi.00543-16]; Durando P, 2011, HUM VACCINES, V7, P29, DOI 10.4161/hv.7.0.14560; Dutow P, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftv120; Ebensen T, 2007, VACCINE, V25, P1464, DOI 10.1016/j.vaccine.2006.10.033; Ebensen T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01223; Ebensen T, 2011, VACCINE, V29, P5210, DOI 10.1016/j.vaccine.2011.05.026; Faris R, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00399; Gaston JSH, 2000, SEX TRANSM INFECT, V76, P156, DOI 10.1136/sti.76.3.156; Gherardi MM, 2004, J IMMUNOL, V172, P6209, DOI 10.4049/jimmunol.172.10.6209; Gill N, 2010, NAT IMMUNOL, V11, P558, DOI 10.1038/ni0710-558; Gottlieb SL, 2017, CURR OPIN INFECT DIS, V30, P77, DOI 10.1097/QCO.0000000000000343; Grimwood J, 1999, Microb Comp Genomics, V4, P187, DOI 10.1089/omi.1.1999.4.187; Hoenderboom BM, 2019, SEX TRANSM INFECT, V95, P300, DOI 10.1136/sextrans-2018-053778; Inic-Kanada A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144380; Joseph SJ, 2012, MOL BIOL EVOL, V29, P3933, DOI 10.1093/molbev/mss198; Kari L, 2014, INFECT IMMUN, V82, P2756, DOI 10.1128/IAI.01686-14; Karunakaran KP, 2015, VACCINE, V33, P2159, DOI 10.1016/j.vaccine.2015.02.055; Kaser T, 2017, VACCINE, V35, P91, DOI 10.1016/j.vaccine.2016.11.050; Kohn M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626627; Landi A, 2017, VACCINE, V35, P6949, DOI 10.1016/j.vaccine.2017.10.072; Lesiak-Markowicz I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54886-5; Lirussi D, 2017, EBIOMEDICINE, V22, P100, DOI 10.1016/j.ebiom.2017.07.016; Luczak SET, 2016, J BIOL CHEM, V291, P22806, DOI 10.1074/jbc.M116.728915; Molleken K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003325; Molleken K, 2010, MOL MICROBIOL, V78, P1004, DOI 10.1111/j.1365-2958.2010.07386.x; Muller T, 2017, VACCINE, V35, P2801, DOI 10.1016/j.vaccine.2017.04.017; Pal S, 2005, INFECT IMMUN, V73, P8153, DOI 10.1128/IAI.73.12.8153-8160.2005; Pal S, 2001, INFECT IMMUN, V69, P6240, DOI 10.1128/IAI.69.10.6240-6247.2001; Pal S, 2017, VACCINE, V35, P2543, DOI 10.1016/j.vaccine.2017.03.070; Pal S, 2015, IMMUNOLOGY, V146, P432, DOI 10.1111/imm.12520; Phillips S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00070; Plante M, 2000, J INFECT DIS, V182, P848, DOI 10.1086/315801; Poston TB, 2019, VACCINE, V37, P7289, DOI 10.1016/j.vaccine.2017.01.023; Qu YY, 2015, INFECT IMMUN, V83, P4056, DOI 10.1128/IAI.00841-15; Rother M, 2018, CELL HOST MICROBE, V23, P661, DOI 10.1016/j.chom.2018.04.002; Rowley J, 2019, B WORLD HEALTH ORGAN, V97, P548, DOI 10.2471/BLT.18.228486; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Alberti AS, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0010-z; Schlott T, 2005, GYNECOL ONCOL, V98, P409, DOI 10.1016/j.ygyno.2005.04.034; Schulze K, 2017, NANOMED-NANOTECHNOL, V13, P2463, DOI 10.1016/j.nano.2017.08.015; Seedat J., 2013, EPIDEMIOLOGISCHES B, V46; Sethi S, 2017, INDIAN J MED RES, V146, P59, DOI [10.4103/ijmr.IJMR_981_15, 10.4103/ijmr.ijmr_981_15]; Smelov V, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02195; Sommer K, 2009, FEMS IMMUNOL MED MIC, V55, P206, DOI 10.1111/j.1574-695X.2008.00503.x; Stallmann S, 2016, CELL MICROBIOL, V18, P761, DOI 10.1111/cmi.12549; Stary G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa8205; Tan C, 2010, CELL MICROBIOL, V12, P174, DOI 10.1111/j.1462-5822.2009.01389.x; Uddowla S, 2007, VACCINE, V25, P7984, DOI 10.1016/j.vaccine.2007.09.030; Wern JE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00569; Yu H, 2012, INFECT IMMUN, V80, P1510, DOI 10.1128/IAI.06338-11	61	1	1	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							609	10.3390/vaccines9060609			34	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ7KD	34204170	Green Published, gold			2022-04-29	WOS:000666738400001
J	Palladino, R; Ceriotti, D; De Ambrosi, D; De Vito, M; Farsoni, M; Seminara, G; Barone-Adesi, F				Palladino, Raffaele; Ceriotti, Daniele; De Ambrosi, Damiano; De Vito, Marta; Farsoni, Marco; Seminara, Giuseppina; Barone-Adesi, Francesco			A Quantitative Benefit-Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy	VACCINES			English	Article						COVID-19; vaccine; ChAdOx1 nCoV-19; benefit-risk analysis; thrombo-embolic events		The Oxford-AstraZeneca ChAdOx1 nCoV-19 is a vaccine against the COVID-19 infection that was granted a conditional marketing authorization by the European Commission in January 2021. However, following a report from the Pharmacovigilance Risk Assessment Committee (PRAC) of European Medicines Agency, which reported an association with thrombo-embolic events (TEE), in particular disseminated intravascular coagulation (DIC) and cerebral venous sinus thrombosis (CVST), many European countries either limited it to individuals older than 55-60 years or suspended its use. We used publicly available data to carry out a quantitative benefit-risk analysis of the vaccine among people under 60 in Italy. Specifically, we used data from PRAC, Eudravigilance and ECDC to estimate the excess number of deaths for TEE, DIC and CVST expected in vaccine users, stratified by age groups. We then used data from the National Institute of Health to calculate age-specific COVID-19 mortality rates in Italy. Preventable deaths were calculated assuming a 72% vaccine efficacy over an eight-month period. Finally, the benefit-risk ratio of ChAdOx1 nCoV-19 vaccination was calculated as the ratio of preventable COVID-19 deaths to vaccine-related deaths, using Monte-Carlo simulations. We found that among subjects aged 20-29 years the benefit-risk (B-R) ratio was not clearly favorable (0.70; 95% Uncertainty Interval (UI): 0.27-2.11). However, in the other age groups the benefits of vaccination largely exceeded the risks (for age 30-49, B-R ratio: 22.9: 95%UI: 10.1-186.4). For age 50-59, B-R ratio: 1577.1: 95%UI: 1176.9-2121.5). Although many countries have limited the use of the ChAdOx1 nCoV-19 vaccine, the benefits of using this vaccine clearly outweigh the risks in people older than 30 years. Study limitations included risk of underreporting and that we did not provide age-specific estimates. The use of this vaccine should be a strategic and fundamental part of the immunization campaign considering its safety and efficacy in preventing COVID-19 and its complications.	[Palladino, Raffaele] Univ Federico II Naples, Dept Publ Hlth, I-80131 Naples, Italy; [Palladino, Raffaele] Imperial Coll, Dept Primary Care & Publ Hlth, London W6 8RP, England; [Palladino, Raffaele] Univ Federico II Naples, CIRMIS Interdept Ctr Res Healthcare Management &, I-80131 Naples, Italy; [Ceriotti, Daniele; De Ambrosi, Damiano; De Vito, Marta; Farsoni, Marco; Seminara, Giuseppina; Barone-Adesi, Francesco] Univ Piemonte Orientale, Dept Translat Med, I-28100 Novara, Italy; [Barone-Adesi, Francesco] Univ Piemonte Orientale, CRIMEDIM Res Ctr Emergency & Disaster Med, I-28100 Novara, Italy		Palladino, R (通讯作者)，Univ Federico II Naples, Dept Publ Hlth, I-80131 Naples, Italy.; Palladino, R (通讯作者)，Imperial Coll, Dept Primary Care & Publ Hlth, London W6 8RP, England.; Palladino, R (通讯作者)，Univ Federico II Naples, CIRMIS Interdept Ctr Res Healthcare Management &, I-80131 Naples, Italy.	raffaele.palladino@unina.it; 10036607@studenti.uniupo.it; 10025954@studenti.uniupo.it; 10030824@studenti.uniupo.it; 20002321@studenti.uniupo.it; 20001534@studenti.uniupo.it; francesco.baroneadesi@uniupo.it	Palladino, Raffaele/AAG-6823-2020	Palladino, Raffaele/0000-0002-3437-812X; Barone-Adesi, Francesco/0000-0003-1550-436X; Ceriotti, Daniele/0000-0002-0270-4058			[Anonymous], FIGLIUOLO PRESSING P; [Anonymous], DATA COVID 19 VACCIN; [Anonymous], EUROPEAN DATABASE SU; [Anonymous], 2021, PHARMACOVIGILANCE RI; [Anonymous], ACCESS BACKGROUND IN; [Anonymous], COVID 19 INTEGRATED; [Anonymous], RECOMMENDATION EMERG; [Anonymous], CORONAVIRUS COVID 19; [Anonymous], WHO LISTS 2 ADDITION; Arlegui H, 2020, DRUG SAFETY, V43, P1089, DOI 10.1007/s40264-020-00984-7; Caristia S, 2020, EPIDEMIOL PREV, V44, P60, DOI 10.19191/EP20.5-6.S2.104; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; European Medicine Agency, 2021, EMA2398222021; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Mishra H, 2021, ENVIRON SCI POLLUT R, V28, P56053, DOI 10.1007/s11356-021-14531-z; Palladino R, 2021, DISASTER MED PUBLIC, V15, pE40, DOI 10.1017/dmp.2020.433; Palladino R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165644; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699	22	3	3	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							618	10.3390/vaccines9060618			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6UG	34201330	Green Published, gold			2022-04-29	WOS:000666697100001
J	Dumoulin, DW; Cornelissen, R; Bezemer, K; Baart, SJ; Aerts, JGJV				Dumoulin, Daphne W.; Cornelissen, Robin; Bezemer, Koen; Baart, Sara J.; Aerts, Joachim G. J. V.			Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials	VACCINES			English	Article						malignant pleural mesothelioma; dendritic cells; vaccination; tumor lysate; immunotherapy	MALIGNANT-PLEURAL-MESOTHELIOMA; RANDOMIZED PHASE-III; IMMUNOTHERAPY; MULTICENTER; LYSATE; CHEMOTHERAPY; CISPLATIN; NIVOLUMAB	Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated, poor survival of approximately nine months from diagnosis. Until recently, phase II-III immunotherapy trials did not show any significant benefit. The lack of immunotherapy efficacy can be explained by the fact that mesothelioma is a tumor with an "immune desert" phenotype, meaning a non-inflamed tumor characterized by low T-cell infiltration. By administration of DCs, which were ex-vivo cultured, exposed to (tumor-associated) antigens, and subsequently activated, this "immune desert" phenotype might be turned into an "inflamed" phenotype. Three phase I/II studies have been performed and published using activated DCs, which support this concept. We here report on the long-term survival of patients treated with DCs in three phase I/II studies. Methods: Survival data of the phase I/II trials using DC therapy in MPM patients were obtained and subsequently analyzed. In the first two trials, DCs were loaded with autologous tumor lysate. In the third trial, DCs were loaded with allogeneic mesothelioma tumor cell line lysate. Results: In the three studies combined, 29 patients with MPM were treated with DC vaccination between 2006 and 2015. At data cut-off, the median OS was 27 months (95% CI: 21-47 months). OS at 2 years was 55.2% (95% CI: 39.7-76.6%), and OS at 5 years was 20.7% (95% CI: 10.1-42.2%). Conclusions: The long-term survival of DC therapy in MPM in these three trials is promising, which is the basis for the randomized phase II/III DENIM study. This DENIM study is currently enrolling, and the results of which have to be awaited for definite conclusions.	[Dumoulin, Daphne W.; Cornelissen, Robin; Bezemer, Koen; Aerts, Joachim G. J. V.] Erasmus MC Canc Inst, Dept Pulm Med, NL-3015 GD Rotterdam, Netherlands; [Baart, Sara J.] Erasmus MC, Dept Biostat, NL-3015 GD Rotterdam, Netherlands		Dumoulin, DW (通讯作者)，Erasmus MC Canc Inst, Dept Pulm Med, NL-3015 GD Rotterdam, Netherlands.	d.dumoulin@erasmusmc.nl; r.cornelissen@erasmusmc.nl; k.bezemer@erasmusmc.nl; s.baart@erasmusmc.nl; j.aerts@erasmusmc.nl		Dumoulin, Daphne/0000-0001-5578-7902; Cornelissen, Robin/0000-0002-4289-3092			Aerts J, 2017, J THORAC ONCOL, V12, pS295, DOI 10.1016/j.jtho.2016.11.304; Aerts JG, 2013, CANCER RES, V73, P2381, DOI 10.1158/0008-5472.CAN-12-3932; Aerts JGJV, 2018, CLIN CANCER RES, V24, P766, DOI 10.1158/1078-0432.CCR-17-2522; Baas P, 2021, LANCET, V397, P375, DOI 10.1016/S0140-6736(20)32714-8; Belderbos RA, 2019, TRANSL LUNG CANCER R, V8, P280, DOI 10.21037/tlcr.2019.05.05; Chardin D, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000645; Cornelissen R, 2016, AM J RESP CRIT CARE, V193, P1023, DOI 10.1164/rccm.201508-1573OC; Dammeijer F, 2020, CANCER CELL, V38, P685, DOI 10.1016/j.ccell.2020.09.001; de Gooijer CJ, 2021, LANCET RESP MED, V9, P585, DOI 10.1016/S2213-2600(20)30362-3; Dumoulin DW, 2017, FUTURE ONCOL, V13, P1747, DOI 10.2217/fon-2017-0234; Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136; Galluzzi L, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7807; Gettinger S, 2019, J THORAC ONCOL, V14, pS244, DOI 10.1016/j.jtho.2019.08.486; Hegmans JP, 2010, AM J RESP CRIT CARE, V181, P1383, DOI 10.1164/rccm.200909-1465OC; Joseph RW, 2018, CLIN CANCER RES, V24, P4960, DOI 10.1158/1078-0432.CCR-17-2386; Katsurada M, 2019, ANTICANCER RES, V39, P815, DOI 10.21873/anticanres.13180; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Noordam L, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1474318; Popat S, 2020, ANN ONCOL, V31, P1734, DOI 10.1016/j.annonc.2020.09.009; Reck M, 2019, J CLIN ONCOL, V37, P537, DOI 10.1200/JCO.18.00149; van Meerbeeck JP, 2005, J CLIN ONCOL, V23, P6881, DOI 10.1200/JCO.20005.14.589; Veltman JD, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/798467; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Vroman H, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000251	25	4	4	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							525	10.3390/vaccines9050525			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1YT	34069348	Green Published, gold			2022-04-29	WOS:000654622200001
J	Fuady, A; Nuraini, N; Sukandar, KK; Lestari, BW				Fuady, Ahmad; Nuraini, Nuning; Sukandar, Kamal K.; Lestari, Bony W.			Targeted Vaccine Allocation Could Increase the COVID-19 Vaccine Benefits Amidst Its Lack of Availability: A Mathematical Modeling Study in Indonesia	VACCINES			English	Article						COVID-19; vaccine; strategy; modeling; low- and middle-income countries	STRATEGIES	With a limited number of vaccines and healthcare capacity shortages, particularly in low- and middle-income countries, vaccination programs should seek the most efficient strategy to reduce the negative impact of the COVID-19 pandemics. This study aims at assessing several scenarios of delivering the vaccine to people in Indonesia. We develop a model for several scenarios of delivering vaccines: without vaccination, fair distribution, and targeted distribution to five and eight districts with the highest COVID-19 incidence in West Java, one of the most COVID-19-affected regions in Indonesia. We calculate the needs of vaccines and healthcare staff for the program, then simulate the model for the initial 4-month and one-year scenarios. A one-year vaccination program would require 232,000 inoculations per day by 4833 vaccinators. Targeted vaccine allocation based on the burden of COVID-19 cases could benefit the COVID-19 vaccination program by lowering at least 5000 active cases. The benefits would increase by improving the number of vaccines and healthcare staff. Amidst lacking available vaccines, targeted vaccine allocation based on the burden of COVID-19 cases could increase the benefit of the COVID-19 vaccination program but still requires progressive efforts to improve healthcare capacity and vaccine availability for optimal protection for people.	[Fuady, Ahmad] Univ Indonesia, Fac Med, Dept Community Med, Jakarta 10310, Indonesia; [Fuady, Ahmad] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, NL-3015 GD Rotterdam, Netherlands; [Nuraini, Nuning; Sukandar, Kamal K.] Inst Teknol Bandung, Dept Math, Bandung 40132, Indonesia; [Nuraini, Nuning; Lestari, Bony W.] Epidemiol Grp COVID 19 Task Force West Java, Bandung 40171, Indonesia; [Lestari, Bony W.] Univ Padjadjaran, Fac Med, Dept Publ Hlth, Bandung 40161, Indonesia; [Lestari, Bony W.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 GA Nijmegen, Netherlands		Fuady, A (通讯作者)，Univ Indonesia, Fac Med, Dept Community Med, Jakarta 10310, Indonesia.; Fuady, A (通讯作者)，Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, NL-3015 GD Rotterdam, Netherlands.	ahmad.fuady01@ui.ac.id; nuning@math.itb.ac.id; kamalkhairudin@students.itb.ac.id; bony.wiem@unpad.ac.id	; Lestari, Bony Wiem/D-5676-2017	Sukandar, Kamal Khairudin/0000-0002-7175-4403; Lestari, Bony Wiem/0000-0002-6476-2034	Provincial Government of West Java, Indonesia; Institute of Technology Bandung	This research was partially funded by the Provincial Government of West Java, Indonesia and Institute of Technology Bandung Research Grant 2021.	Bielicki JA, 2020, LANCET INFECT DIS, V20, pE261, DOI 10.1016/S1473-3099(20)30458-8; Bubar KM, 2021, SCIENCE, V371, P916, DOI 10.1126/science.abe6959; Burgos Rodrigo M, 2021, Drugs Context, V10, DOI 10.7573/dic.2020-12-2; Coalition for Epidemic Preparedness Innovations, 2020, CEPI SURV ASS POT CO; Figueroa JP, 2021, LANCET, V397, P562, DOI 10.1016/S0140-6736(21)00242-7; Foy BH, 2021, INT J INFECT DIS, V103, P431, DOI 10.1016/j.ijid.2020.12.075; Fuady A., 2019, ARSITEKTUR JAMINAN K; Gayle H., 2020, FRAMEWORK EQUITABLE, V10; Goldstein JR, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026322118; Hattaf K, 2013, ELECTRON J QUAL THEO, P1; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Li Q, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108378; Liu YZ, 2020, J MED ETHICS, V46, P499, DOI 10.1136/medethics-2020-106516; Lloyd-Sherlock P, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n299; McAllister S, 2017, PUBLIC HEALTH ACTION, V7, P206, DOI 10.5588/pha.17.0026; Motta M., 2021, FRONTIERS POLITICAL, V3, P1, DOI [DOI 10.3389/FPOS.2021.630133, 10.3389/fpos.2021.630133]; Nuraini N., 2020, MATH MODELS ASSESSIN, DOI [10.1101/2020.12.21.20248241, DOI 10.1101/2020.12.21.20248241]; Olivares A, 2021, CHAOS SOLITON FRACT, V146, DOI 10.1016/j.chaos.2021.110895; Piot P, 2019, NATURE, V575, P119, DOI 10.1038/s41586-019-1656-7; Rappuoli R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2888; Schwartz JL, 2020, NEW ENGL J MED, V383, P1703, DOI 10.1056/NEJMp2026393; Smith J, 2011, LANCET, V378, P428, DOI 10.1016/S0140-6736(11)60478-9; Tomlin J, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01960; World Health Organization, 2020, COVAX WORK GLOB EQ A; World Health Organization, 2020, COVID 19 VACC ACC SU; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	26	8	7	5	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							462	10.3390/vaccines9050462			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1UA	34066317	gold, Green Published			2022-04-29	WOS:000654609900001
J	Hensley, C; Zhou, P; Schnur, S; Mahsoub, HM; Liang, Y; Wang, MX; Page, C; Yuan, LJ; Bronshtein, V				Hensley, Casey; Zhou, Peng; Schnur, Sofia; Mahsoub, Hassan M.; Liang, Yu; Wang, Min-Xuan; Page, Caroline; Yuan, Lijuan; Bronshtein, Victor			Thermostable, Dissolvable Buccal Film Rotavirus Vaccine Is Highly Effective in Neonatal Gnotobiotic Pig Challenge Model	VACCINES			English	Article						thermostable; oral film vaccine; rotavirus; diarrhea; gnotobiotic pigs	CELL RESPONSES; PROTECTION; EFFICACY; DIARRHEA; INFANTS; IMMUNOGENICITY; SERUM; GHANA; LIVE	Difficulties related to storage and transport of currently available live oral rotavirus vaccines can have detrimental consequences on the efficacy of the vaccines. Thus, there is a great need for thermostable vaccines that can eliminate the necessity for cold chain storage or reconstitution before administration. In this study, we developed a dissolvable oral polymeric film comprised of a live attenuated thermostable tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) powder and antacid (CaCO3). Immunogenicity and protective efficacy of the vaccine after buccal delivery was evaluated in the gnotobiotic pig model of human rotavirus (HRV) infection and diarrhea. Two doses of the vaccine were highly immunogenic and conferred strong protection against virus shedding and diarrhea upon challenge with a high dose of a virulent G1 HRV in gnotobiotic pigs. Those pigs vaccinated with the preserved film vaccine had significantly delayed onset of diarrhea; reduced duration and area under the curve of diarrhea; delayed onset of fecal virus shedding; and reduced duration and peak of fecal virus shedding titers compared to pigs in both the placebo and the reconstituted liquid oral RRV-TV vaccine groups. Associated with the strong protection, high titers of serum virus neutralization antibodies against each of the four RRV-TV mono-reassortants and G1 HRV-specific serum IgA and IgG antibodies, as well as intestinal IgA antibodies, were induced by the preserved film vaccine. These results demonstrated the effectiveness of our thermostable buccal film rotavirus vaccine and warrant further investigation into the promise of the novel technology in addressing drawbacks of the current live oral HRV vaccines.	[Hensley, Casey; Zhou, Peng; Schnur, Sofia; Mahsoub, Hassan M.; Liang, Yu; Yuan, Lijuan] Virginia Tech, Dept Biomed Sci & Pathobiol, Virginia Maryland Coll Vet Med, Blacksburg, VA 24061 USA; [Wang, Min-Xuan; Page, Caroline; Bronshtein, Victor] Universal Stabilizat Technol Inc, San Diego, CA 92121 USA		Yuan, LJ (通讯作者)，Virginia Tech, Dept Biomed Sci & Pathobiol, Virginia Maryland Coll Vet Med, Blacksburg, VA 24061 USA.; Bronshtein, V (通讯作者)，Universal Stabilizat Technol Inc, San Diego, CA 92121 USA.	lhcasey@vt.edu; pengz81@vt.edu; sschnur@vt.edu; hmahsoub@vt.edu; yul20@vt.edu; minw@vitrilife.com; pengz81@vt.edu; lyuan@vt.edu; victorb@vitrilife.com	Mahsoub, Hassan/AAP-4007-2020; Yuan, Lijuan/A-2468-2008	Mahsoub, Hassan/0000-0002-1350-7172; Yuan, Lijuan/0000-0003-0709-5228; Wang, Min-Xuan/0000-0003-1580-678X	NIAID, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [2R44AI118009-02]	This research was funded by a grant 2R44AI118009-02 from NIAID, NIH to V.B. (PI) and L.Y. (subcontract PI).	AIYAR J, 1990, J INFECT DIS, V162, P1383, DOI 10.1093/infdis/162.6.1383; Armah GE, 2013, J INFECT DIS, V208, P423, DOI 10.1093/infdis/jit174; Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6; Bajrovic I, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aau4819; Bines JE, 2005, CURR OPIN GASTROEN, V21, P20; Bines JE, 2015, J PAEDIATR CHILD H, V51, P34, DOI 10.1111/jpc.12815; Boom JA, 2010, PEDIATRICS, V125, pE199, DOI 10.1542/peds.2009-1021; Brandtzaeg P, 2013, J ORAL MICROBIOL, V5, DOI 10.3402/jom.v5i0.20401; Bronshtein V., 2019, U.S. Patent, Patent No. [10,272,033, 10272033]; Bronshtein V., 2016, U.S. Patent, Patent No. [9,469,835 B2, 9469835]; Bronshtein V., 2005, U.S. Patent, Patent No. [2,005,117,962 A1, 2005117962]; Centers for Disease Control and Prevention, ROT; FRIEDMAN MG, 1993, CLIN EXP IMMUNOL, V92, P194, DOI 10.1111/j.1365-2249.1993.tb03379.x; Gilmartin AA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0143; Glaxo S.K., ROTARIX ROTAVIRUS VA; Hibbs BF, 2014, MMWR-MORBID MORTAL W, V63, P81; Holmgren J, 2017, VACCINE, V35, P3355, DOI 10.1016/j.vaccine.2017.05.005; Kapikian AZ, 1996, J INFECT DIS, V174, pS65, DOI 10.1093/infdis/174.Supplement_1.S65; Kerdpanich A, 2010, HUM VACCINES, V6, P254, DOI 10.4161/hv.6.3.10428; Knipe D.M., 2013, FIELDS VIROLOGY, V6, P2; Kraan H, 2014, J CONTROL RELEASE, V190, P580, DOI 10.1016/j.jconrel.2014.05.060; Kumar P, 2021, J PHARM SCI-US, V110, P760, DOI 10.1016/j.xphs.2020.09.047; Lamberti LM, 2016, PEDIATR INFECT DIS J, V35, P992, DOI 10.1097/INF.0000000000001232; Luczo JM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00320-9; Mackay CR, 2001, SCIENCE, V291, P2323, DOI 10.1126/science.1059984; Murphy BR, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P799, DOI 10.1016/B978-012491543-5/50047-4; Oprins H., 2011, U.S. Patent, Patent No. [20110304987 A1, 20110304987]; Parreno V, 1999, J GEN VIROL, V80, P1417, DOI 10.1099/0022-1317-80-6-1417; Patel MM, 2012, LANCET INFECT DIS, V12, P561, DOI 10.1016/S1473-3099(12)70029-4; Pecenka C, 2018, VACCINE, V36, P7472, DOI 10.1016/j.vaccine.2018.10.068; Ramesh A, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040177; Saif LJ, 1996, ARCH VIROL, P153; Smith TG, 2015, VACCINE, V33, P2203, DOI 10.1016/j.vaccine.2015.03.025; Thomas J., CRACKING COLD CHAIN; Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1; Twitchell EL, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0136-y; Uddin M, 2019, J PHARM PHARM SCI, V22, P388, DOI 10.18433/jpps30528; Universal Stabilization Technologies Inc., VITRILIFE TECHN OV; Vesikari T, 2007, LANCET, V370, P1757, DOI 10.1016/S0140-6736(07)61744-9; Ward LA, 1996, J GEN VIROL, V77, P1431, DOI 10.1099/0022-1317-77-7-1431; WARD RL, 1995, VACCINE, V13, P1226, DOI 10.1016/0264-410X(95)00060-E; World Health Organization, ROT; World Health Organization, GLOB US VACC REC; Yang X., 2014, BR J VIROL, V1, P87; Yuan L, 2017, LAB MODELS FOODBORNE, P95; Yuan LJ, 2008, VACCINE, V26, P3322, DOI 10.1016/j.vaccine.2008.03.085; Yuan LJ, 2017, GNOTOBIOTICS, P349, DOI 10.1016/B978-0-12-804561-9.00005-0; Yuan LJ, 1996, J VIROL, V70, P3075, DOI 10.1128/JVI.70.5.3075-3083.1996	48	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							437	10.3390/vaccines9050437			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1XN	33946555	Green Published			2022-04-29	WOS:000654619000001
J	Klinger, D; Hill, BL; Barda, N; Halperin, E; Gofrit, ON; Greenblatt, CL; Rappoport, N; Linial, M; Bercovier, H				Klinger, Danielle; Hill, Brian L.; Barda, Noam; Halperin, Eran; Gofrit, Ofer N.; Greenblatt, Charles L.; Rappoport, Nadav; Linial, Michal; Bercovier, Herve			Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer's Disease and Parkinson's Disease	VACCINES			English	Article						Bacillus Calmette-Guerin; tuberculosis; immunotherapy; non-muscle-invasive bladder cancer (NMIBC); neurodegenerative disease	CALMETTE-GUERIN TREATMENT; REGULATORY T-CELLS; IMMUNE-RESPONSES; VACCINATION; TUBERCULOSIS; PROTECTION; MODEL; PREVALENCE; EFFICACY	Bacillus Calmette-Guerin (BCG) is a live attenuated form of Mycobacterium bovis that was developed 100 years ago as a vaccine against tuberculosis (TB) and has been used ever since to vaccinate children globally. It has also been used as the first-line treatment in patients with nonmuscle invasive bladder cancer (NMIBC), through repeated intravesical applications. Numerous studies have shown that BCG induces off-target immune effects in various pathologies. Accumulating data argue for the critical role of the immune system in the course of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). In this study, we tested whether repeated exposure to BCG during the treatment of NMIBC is associated with the risk of developing AD and PD. We presented a multi-center retrospective cohort study with patient data collected between 2000 and 2019 that included 12,185 bladder cancer (BC) patients, of which 2301 BCG-treated patients met all inclusion criteria, with a follow-up of 3.5 to 7 years. We considered the diagnosis date of AD and nonvascular dementia cases for BC patients. The BC patients were partitioned into those who underwent a transurethral resection of the bladder tumor followed by BCG therapy, and a disjoint group that had not received such treatment. By applying Cox proportional hazards (PH) regression and competing for risk analyses, we found that BCG treatment was associated with a significantly reduced risk of developing AD, especially in the population aged 75 years or older. The older population (>= 75 years, 1578 BCG treated, and 5147 controls) showed a hazard ratio (HR) of 0.726 (95% CI: 0.529-0.996; p-value = 0.0473). While in a hospital-based cohort, BCG treatment resulted in an HR of 0.416 (95% CI: 0.203-0.853; p-value = 0.017), indicating a 58% lower risk of developing AD. The risk of developing PD showed the same trend with a 28% reduction in BCG-treated patients, while no BCG beneficial effect was observed for other age-related events such as Type 2 diabetes (T2D) and stroke. We attributed BCG's beneficial effect on neurodegenerative diseases to a possible activation of long-term nonspecific immune effects. We proposed a prospective study in elderly people for testing intradermic BCG inoculation as a potential protective agent against AD and PD.	[Klinger, Danielle; Linial, Michal] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; [Hill, Brian L.; Halperin, Eran] Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA 90095 USA; [Barda, Noam] Clalit Hlth Serv, Clalit Res Inst, Innovat Div, IL-6578898 Ramat Gan, Israel; [Barda, Noam] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Gofrit, Ofer N.] Hadassah Univ Hosp, Dept Urol, IL-91904 Jerusalem, Israel; [Greenblatt, Charles L.; Bercovier, Herve] Hebrew Univ Jerusalem, Dept Microbiol & Mol Genet, Fac Med, IL-91904 Jerusalem, Israel; [Rappoport, Nadav] Ben Gurion Univ Negev, Dept Software & Informat Syst Engn, Fac Engn Sci, IL-84105 Beer Sheva, Israel		Linial, M (通讯作者)，Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	danielle.klinger@mail.huji.ac.il; blhill@g.ucla.edu; noambard@gmail.com; eranhalperin@gmail.com; ogofrit@gmail.com; charlesg@ekmd.huji.ac.il; nadavrap@bgu.ac.il; michall@cc.huji.ac.il; hb@cc.huji.ac.il	Greenblatt, Chuck/ABC-8220-2021; Rappoport, Nadav/AAA-3769-2019; Barda, Noam/AAC-9434-2020	Rappoport, Nadav/0000-0002-7218-2558; Barda, Noam/0000-0002-3400-235X; Bercovier, Herve (hillel)/0000-0001-7297-3029; Linial, Michal/0000-0002-9357-4526; Hill, Brian/0000-0002-6881-5770; Gofrit, Ofer/0000-0001-8815-6488	ISFIsrael Science Foundation [2753/20]	This research was funded by ISF grant number 2753/20 to M.L.	Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240; Abdallah AM, 2015, SCI REP-UK, V5, DOI 10.1038/srep15443; Anderson EJ, 2012, VACCINE, V30, P2083, DOI 10.1016/j.vaccine.2012.01.053; Andrew MK, 2018, WOMENS HEALTH, V14, DOI 10.1177/1745506518817995; Aronson NE, 2004, JAMA-J AM MED ASSOC, V291, P2086, DOI 10.1001/jama.291.17.2086; Arts RJW, 2016, CELL REP, V17, P2562, DOI 10.1016/j.celrep.2016.11.011; Baek H, 2016, ONCOTARGET, V7, P69347, DOI 10.18632/oncotarget.12469; Bird TD, 2008, GENET MED, V10, P231, DOI 10.1097/GIM.0b013e31816b64dc; Blok BA, 2015, J LEUKOCYTE BIOL, V98, P347, DOI 10.1189/jlb.5RI0315-096R; Bouffioux C R, 1984, Prog Clin Biol Res, V162A, P11; Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033; Burns A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b158; Cirovic B, 2020, CELL HOST MICROBE, V28, P322, DOI 10.1016/j.chom.2020.05.014; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Dockrell HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01134; Dugger BN, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028035; Ehdaie B, 2013, EUR UROL, V64, P579, DOI 10.1016/j.eururo.2013.05.027; Ferretti MT, 2018, NAT REV NEUROL, V14, P457, DOI 10.1038/s41582-018-0032-9; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Freedman DM, 2016, CANCER MED-US, V5, P2965, DOI 10.1002/cam4.850; Fuge O, 2015, RES REP UROL, V7, P65, DOI 10.2147/RRU.S63447; Gate D, 2020, NATURE, V577, P399, DOI 10.1038/s41586-019-1895-7; Gaugler J, 2019, ALZHEIMERS DEMENT, V15, P321, DOI 10.1016/j.jalz.2019.01.010; Gengenbacher M, 2017, CURR OPIN IMMUNOL, V47, P8, DOI 10.1016/j.coi.2017.06.007; Giamarellos-Bourboulis EJ, 2020, CELL, V183, P315, DOI 10.1016/j.cell.2020.08.051; Gofrit ON, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224433; Hadley W., DPLYR GRAMMAR DATA M; Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189; Han JS, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110393; Hanson HA, 2017, J GERONTOL B-PSYCHOL, V72, P1032, DOI 10.1093/geronb/gbw040; Hemmer B, 2015, LANCET NEUROL, V14, P406, DOI 10.1016/S1474-4422(14)70305-9; Irvine K, 2012, J CLIN EXP NEUROPSYC, V34, P989, DOI 10.1080/13803395.2012.712676; Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014; Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005; Klinger D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030378; Kodesh A, 2019, INT PSYCHOGERIATR, V31, P1059, DOI 10.1017/S1041610218001461; Kuhtreiber WM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0062-8; Lacan G, 2013, J NEUROSCI RES, V91, P1292, DOI 10.1002/jnr.23253; Lenis Andrew T, 2017, Clin Genitourin Cancer, V15, pe25, DOI 10.1016/j.clgc.2016.06.014; Li YY, 2018, RENAL FAILURE, V40, P280, DOI 10.1080/0886022X.2018.1456462; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Masters CL, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.56; Minassian AM, 2012, J INFECT DIS, V205, P1035, DOI 10.1093/infdis/jis012; Minhas PS, 2021, NATURE, V590, P122, DOI 10.1038/s41586-020-03160-0; Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020; Moorlag SJCFM, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100073; Mukherjee N, 2019, CURR OPIN UROL, V29, P181, DOI 10.1097/MOU.0000000000000595; Munafo A, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.614643; Nebel RA, 2018, ALZHEIMERS DEMENT, V14, P1171, DOI 10.1016/j.jalz.2018.04.008; Nguipdop-Djomo P, 2016, LANCET INFECT DIS, V16, P219, DOI 10.1016/S1473-3099(15)00400-4; Niu H, 2017, NEUROLOGIA, V32, P523, DOI 10.1016/j.nrl.2016.02.016; Pardridge WM, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110394; Pettenati C, 2018, NAT REV UROL, V15, P615, DOI 10.1038/s41585-018-0055-4; Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424; Qi FF, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0808-7; Ravn P, 1997, J IMMUNOL, V158, P1949; Ristori G, 2014, NEUROLOGY, V82, P41, DOI 10.1212/01.wnl.0000438216.93319.ab; Rogers J, 2007, INT REV NEUROBIOL, V82, P235, DOI 10.1016/S0074-7742(07)82012-5; Rosen B, 2015, HEALT SYST TRANSIT, V17, P1; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.2307/2335876; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Snyder HM, 2017, ALZHEIMERS DEMENT, V13, P267, DOI 10.1016/j.jalz.2016.11.002; Sylvester RJ, 2011, INT J UROL, V18, P113, DOI 10.1111/j.1442-2042.2010.02678.x; Tan EK, 2020, NAT REV NEUROL, V16, P303, DOI 10.1038/s41582-020-0344-4; Therneau T., 2020, CRAN R; Therneau T., 2020, Package for Survival Analysis in R [; Uddin MS, 2019, MOL NEUROBIOL, V56, P2450, DOI 10.1007/s12035-018-1237-z; van der Willik KD, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.13019; Vogel JW, 2021, NAT MED, V27, P871, DOI 10.1038/s41591-021-01309-6; Wang J, 2017, NAT REV NEUROL, V13, P612, DOI 10.1038/nrneurol.2017.111; Yamazaki-Nakashimada MA, 2020, HUM VACC IMMUNOTHER, V16, P1841, DOI 10.1080/21645515.2019.1706930; Yiannopoulou KG, 2013, THER ADV NEUROL DISO, V6, P19, DOI 10.1177/1756285612461679	73	8	8	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							491	10.3390/vaccines9050491			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3EJ	34064775	gold, Green Published			2022-04-29	WOS:000654708100001
J	Kowalska, M; Niewiadomska, E; Baranski, K; Kaleta-Pilarska, A; Brozek, G; Zejda, JE				Kowalska, Malgorzata; Niewiadomska, Ewa; Baranski, Kamil; Kaleta-Pilarska, Angelina; Brozek, Grzegorz; Zejda, Jan Eugeniusz			Association between Influenza Vaccination and Positive SARS-CoV-2 IgG and IgM Tests in the General Population of Katowice Region, Poland	VACCINES			English	Article						influenza vaccination; seropositivity of COVID-19; cross-sectional study		The explanation of the potential interaction between the influenza vaccine and SARS-CoV-2 infection is urgently needed in the public health. The objective of the study is to compare the occurrence of positive SARS-CoV-2 IgG and IgM tests in subjects with and without recent (last year) seasonal influenza vaccinations. In a cross-sectional study located in three large towns of Silesian Voivodeship (Poland), we studied 5479 subjects in which 1253 (22.9%) had a positive anti-SARS-CoV-2 IgG test and 400 (7.3%) had a positive anti-SARS-CoV-2 IgM test. Seasonal influenza vaccination remains an independent factor protecting against positive IgG tests (OR = 0.68; 0.55-0.83). The effect is not apparent with IgM antibodies. The obtained results confirmed that the serological status of SARS-CoV-2 infection depends on vaccination against seasonal influenza.	[Kowalska, Malgorzata; Baranski, Kamil; Kaleta-Pilarska, Angelina; Brozek, Grzegorz; Zejda, Jan Eugeniusz] Med Univ Silesia, Dept Epidemiol, Sch Med Sci Katowice, PL-40752 Katowice, Poland; [Niewiadomska, Ewa] Med Univ Silesia, Sch Publ Hlth Bytom, Dept Epidemiol & Biostat, PL-41902 Katowice, Poland		Baranski, K (通讯作者)，Med Univ Silesia, Dept Epidemiol, Sch Med Sci Katowice, PL-40752 Katowice, Poland.	mkowalska@sum.edu.pl; eniewiadomska@sum.edu.pl; kbaranski@sum.edu.pl; akaleta@sum.edu.pl; gbrozek@sum.edu.pl; jzejda@sum.edu.pl		Baranski, Kamil/0000-0002-0106-9662; Ewa, Niewiadomska/0000-0003-0612-1949; Brozek, Grzegorz/0000-0002-0716-6471; Kaleta-Pilarska, Angelina/0000-0003-4525-9553; Kowalska, Malgorzata/0000-0002-9386-0346	Medical Research Agency in Poland [2020/ABM/COVID19/0044]	The results of this study were a consequence of a project titled: Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration (EpiSARS2), supported by the Medical Research Agency in Poland (2020/ABM/COVID19/0044).	Altenburg AF, 2014, VIRUSES-BASEL, V6, P2735, DOI 10.3390/v6072735; Amato M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030535; [Anonymous], ClinicalTrials.gov Identifier: NCT04627623; Bai L, 2021, CELL RES, V31, P395, DOI 10.1038/s41422-021-00473-1; Bajgain KT, 2021, AM J INFECT CONTROL, V49, P238, DOI 10.1016/j.ajic.2020.06.213; Belongia EA, 2020, SCIENCE, V368, P1163, DOI 10.1126/science.abd2220; Conlon A, 2021, AM J INFECT CONTROL, V49, P694, DOI 10.1016/j.ajic.2021.02.012; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; Debisarun PA., 2020, EFFECT INFLUENZA VAC, DOI [10.1101/2020.10.14.20212498, https://doi.org/10.1101/2020.10.14.20212498, DOI 10.1101/2020.10.14.20212498]; Del Riccio M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217870; Fink G, 2021, BMJ EVID-BASED MED, V26, DOI 10.1136/bmjebm-2020-111549; Grech V, 2020, EARLY HUM DEV, V148, DOI 10.1016/j.earlhumdev.2020.105116; Iacobucci G, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3720; Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266; Maltezou HC, 2020, VACCINE, V38, P6078, DOI 10.1016/j.vaccine.2020.07.058; Manzanares-Meza LD, 2020, BOL MED HOSP INFANT, V77, P262, DOI [10.24875/BMHIM.20000183, 10.24875/bmhim.20000183]; Marin-Hernandez D, 2021, J MED VIROL, V93, P64, DOI 10.1002/jmv.26120; Martinez-Baz I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040611; Noale M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030471; Patwardhan A, 2021, CUREUS, V13, DOI 10.7759/cureus.12533; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Reina J, 2021, MED CLIN-BARCELONA, V156, P17, DOI 10.1016/j.medcli.2020.10.012; Richardson S., 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI [DOI 10.1001/JAMA.2020.6775, 10.1001/jama.2020.7681]; Salem ML, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109752; Sultana J, 2020, EXPERT REV VACCINES, V19, P919, DOI 10.1080/14760584.2020.1825951; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; World Health Organization, 2020, POP BAS AG STRAT SER; Yue HH, 2020, J MED VIROL, V92, P2870, DOI 10.1002/jmv.26163; Zanettini Claudio, 2020, medRxiv, DOI 10.1101/2020.06.24.20129817; Zejda JE, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18063188	31	3	3	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							415	10.3390/vaccines9050415			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1OI	33919206	Green Published, gold			2022-04-29	WOS:000654595100001
J	Kuliese, M; Mickiene, A; Jancoriene, L; Zablockiene, B; Gefenaite, G				Kuliese, Monika; Mickiene, Aukse; Jancoriene, Ligita; Zablockiene, Birute; Gefenaite, Giedre		Study Grp	Age-Specific Seasonal Influenza Vaccine Effectiveness against Different Influenza Subtypes in the Hospitalized Population in Lithuania during the 2015-2019 Influenza Seasons	VACCINES			English	Article						hospital surveillance; risk groups; older people; underlying conditions; influenza; severe outcomes; laboratory-confirmed	TEST-NEGATIVE DESIGN; EUROPEAN REGION; OLDER; A(H3N2); IMMUNOSENESCENCE; PREDOMINANCE; A(H1N1)PDM09; EFFICACY; ADULTS; IMPACT	Background: Continuous monitoring of seasonal influenza vaccine effectiveness (SIVE) is needed due to the changing nature of influenza viruses and it supports the decision on the annual update of vaccine composition. Age-specific SIVE was evaluated against different influenza subtypes in the hospitalized population in Lithuania during four influenza seasons. Methods: A test-negative case-control study design was used. SIVE and its 95% confidence intervals (95% CI) were calculated as (1 - odds ratio (OR)) x 100%. Results: Adjusted SIVE in 18-64-year-old individuals against influenza A, A(H1N1)pdm09 and B/Yamagata were 78.0% (95% CI: 1.7; 95.1%), 88.6% (95% CI: -47.4; 99.1%), and 76.8% (95% CI: -109.9; 97.4%), respectively. Adjusted SIVE in individuals aged 65 years and older against influenza A, influenza B, and B/Yamagata were 22.6% (95% CI: -36.5; 56.1%), 75.3% (95% CI: 12.2; 93.1%) and 73.1% (95% CI: 3.2; 92.5%), respectively. Unadjusted SIVE against influenza A(H3N2) among 18-64-year-old patients was 44.8% (95% CI: -171.0; 88.8%) and among those aged 65 years and older was 5.0% (95% CI: -74.5; 48.3%). Conclusions: Point estimates suggest high SIVE against influenza A in 18-64-year-old participants, and against influenza B and B/Yamagata in those 65 years old and older.	[Kuliese, Monika; Mickiene, Aukse; Gefenaite, Giedre] Lithuanian Univ Hlth Sci, Dept Infect Dis, Baltijos St 120, LT-47116 Kaunas, Lithuania; [Jancoriene, Ligita; Zablockiene, Birute] Vilnius Univ, Inst Clin Med, Clin Infect Dis & Dermatovenerol, Fac Med, Santariskiu St 14, LT-08406 Vilnius, Lithuania; [Jancoriene, Ligita; Zablockiene, Birute] Vilnius Univ Hosp Santaros Klin, Ctr Infect Dis, Santariskiu St 14, LT-08406 Vilnius, Lithuania; [Gefenaite, Giedre] Lund Univ, Dept Hlth Sci, Fac Med, Box 157, S-22100 Lund, Sweden		Kuliese, M (通讯作者)，Lithuanian Univ Hlth Sci, Dept Infect Dis, Baltijos St 120, LT-47116 Kaunas, Lithuania.	monika.kuliese@lsmuni.lt; aukse.mickiene@lsmuni.lt; ligita.jancoriene@santa.lt; birute.zablockiene@santa.lt; giedre.gefenaite@med.lu.se		Kuliese, Monika/0000-0002-4601-4585	Research Council of LithuaniaResearch Council of Lithuania (LMTLT) [SEN03/2015]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [634446]; I-MOVE+ (Influenza Monitoring Vaccines Effectiveness in Europe in Elderly) Network	This study was supported by the Research Council of Lithuania (agreement No. SEN03/2015), the European Commission Horizon 2020 program (agreement 634446) and by the I-MOVE+ (Influenza Monitoring Vaccines Effectiveness in Europe in Elderly) Network.	Adlhoch C, 2018, EUROSURVEILLANCE, V23, P7, DOI 10.2807/1560-7917.ES.2018.23.13.18-00146; Broberg E, 2016, EUROSURVEILLANCE, V21, P8, DOI 10.2807/1560-7917.ES.2016.21.13.30184; Castilla J, 2020, VACCINE, V38, P1925, DOI 10.1016/j.vaccine.2020.01.028; Castilla J, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.7.18-00057; Castilla J, 2018, EUROSURVEILLANCE, V23, P12, DOI 10.2807/1560-7917.ES.2018.23.2.16-00780; Cech D.J., 2012, FUNCTIONAL MOVEMENT, P88, DOI [10.1016/B978-1-4160-4978-4.00005-3, 10.1016/b978-1-4160-4978-4.00005-3, DOI 10.1016/B978-1-4160-4978-4.00005-3]; Chan YWD, 2019, HUM VACC IMMUNOTHER, V15, P97, DOI 10.1080/21645515.2018.1514222; Darvishian M, 2017, LANCET RESP MED, V5, P200, DOI 10.1016/S2213-2600(17)30043-7; DAVIES JR, 1989, EPIDEMIOL INFECT, V102, P325, DOI 10.1017/S0950268800030004; De Serres G, 2013, Euro Surveill, V18; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Esposito S, 2016, HUM VACC IMMUNOTHER, V12, P1777, DOI 10.1080/21645515.2016.1150396; European Centre for Disease Prevention and Control (ECDC), 2018, SEASONAL INFLUENZA V; European Centre for Disease Prevention and Control European Centre for Disease Prevention and Control, 2017, INFL VIR CHAR SUMM E; Foppa IM, 2013, VACCINE, V31, P3104, DOI 10.1016/j.vaccine.2013.04.026; Gherasim A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179160; Khoury J, 2018, EUR J CLIN MICROBIOL, V37, P319, DOI 10.1007/s10096-017-3135-0; Kuliese M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017835; Martirosyan L, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-36; McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647; McLean HQ, 2014, CLIN INFECT DIS, V59, P1375, DOI 10.1093/cid/ciu680; Melidou A, 2020, VACCINE, V38, P5707, DOI 10.1016/j.vaccine.2020.06.031; Melidou A, 2017, VACCINE, V35, P4828, DOI 10.1016/j.vaccine.2017.07.057; Mira-Iglesias A., 2018, Eurosurveillance, V23, P00318; Pebody R, 2019, EUROSURVEILLANCE, V24, P23, DOI 10.2807/1560-7917.ES.2019.24.31.1800488; Puig-Barbera J, 2017, VACCINE, V35, P7331, DOI 10.1016/j.vaccine.2017.10.100; Reber AJ, 2012, AGING DIS, V3, P68; Rizzo C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030427; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Russell K, 2018, VACCINE, V36, P1272, DOI 10.1016/j.vaccine.2018.01.045; Sambhara S, 2009, CURR TOP MICROBIOL, V333, P413, DOI 10.1007/978-3-540-92165-3_20; Skowronski DM, 2019, CLIN INFECT DIS, V68, P1754, DOI 10.1093/cid/ciy876; Stuurman AL, 2020, VACCINE, V38, P6455, DOI 10.1016/j.vaccine.2020.07.063; Suess T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051653; Sullivan SG, 2014, EXPERT REV VACCINES, V13, P1571, DOI 10.1586/14760584.2014.966695; Tenforde MW, 2021, CLIN INFECT DIS, V73, P386, DOI 10.1093/cid/ciaa407; Trebbien R, 2017, J CLIN VIROL, V94, P1, DOI 10.1016/j.jcv.2017.06.007; Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153; WHO, 2012, WORLD MALARIA REPORT 2012, P1; Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682	40	0	0	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							455	10.3390/vaccines9050455			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3JP	34064455	Green Published, gold			2022-04-29	WOS:000654721800001
J	Zanettini, C; Omar, M; Dinalankara, W; Imada, EL; Colantuoni, E; Parmigiani, G; Marchionni, L				Zanettini, Claudio; Omar, Mohamed; Dinalankara, Wikum; Imada, Eddie Luidy; Colantuoni, Elizabeth; Parmigiani, Giovanni; Marchionni, Luigi			Influenza Vaccination and COVID-19 Mortality in the USA: An Ecological Study	VACCINES			English	Article						COVID-19; mortality; influenza; influenza vaccine; vaccination coverage	PROPENSITY SCORE; T-CELLS; ASSOCIATION; ILLNESS; ADULTS; VIRUS	The COVID-19 mortality rate is higher in the elderly and in those with pre-existing chronic medical conditions. The elderly also suffer from increased morbidity and mortality from seasonal influenza infections; thus, an annual influenza vaccination is recommended for them. In this study, we explore a possible county-level association between influenza vaccination coverage in people aged 65 years and older and the number of deaths from COVID-19. To this end, we used COVID-19 data up to 14 December 2020 and US population health data at the county level. We fit quasi-Poisson regression models using influenza vaccination coverage in the elderly population as the independent variable and the COVID-19 mortality rate as the outcome variable. We adjusted for an array of potential confounders using different propensity score regression methods. Results show that, on the county level, influenza vaccination coverage in the elderly population is negatively associated with mortality from COVID-19, using different methodologies for confounding adjustment. These findings point to the need for studying the relationship between influenza vaccination and COVID-19 mortality at the individual level to investigate any underlying biological mechanisms.	[Zanettini, Claudio; Omar, Mohamed; Dinalankara, Wikum; Imada, Eddie Luidy; Marchionni, Luigi] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA; [Colantuoni, Elizabeth] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA; [Parmigiani, Giovanni] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02215 USA; [Parmigiani, Giovanni] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA		Marchionni, L (通讯作者)，Weill Cornell Med, Dept Pathol & Lab Med, New York, NY 10065 USA.	clz4002@med.cornell.edu; mao4005@med.cornell.edu; wdd4001@med.cornell.edu; eli4001@med.cornell.edu; ejohnso2@jhmi.edu; gp@jimmy.harvard.edu; lum4003@med.cornell.edu	Marchionni, Luigi/S-6774-2017; Omar, Mohamed N./AAH-5967-2020; Imada, Eddie/U-1774-2019	Marchionni, Luigi/0000-0002-7336-8071; Omar, Mohamed N./0000-0002-8068-1920; Imada, Eddie/0000-0001-9527-3703; Zanettini, Claudio/0000-0001-5043-8033	NIH-NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA006973, 5P30CA006516-56]	This research was funded by NIH-NCI grants P30CA006973 (L.M.) and 5P30CA006516-56 (G.P.).	Amato M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030535; [Anonymous], 2020, LANCET, DOI [DOI 10.1016/S0140-6736(20)31094-1, 10.1016/S0140-6736(20)31094-1]; Austin PC, 2019, STAT METHODS MED RES, V28, P1365, DOI 10.1177/0962280218756159; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Chen N, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30183-5]; Chow EJ, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2491-9; Conlon A, 2021, AM J INFECT CONTROL, V49, P694, DOI 10.1016/j.ajic.2021.02.012; Connors TJ, 2016, AM J RESP CELL MOL, V54, P822, DOI 10.1165/rcmb.2015-0297OC; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Fink G., 2020, INACTIVATED TRIVALEN, DOI 10.1136/bmjebm-2020-111549; Fry AM, 2014, CLIN INFECT DIS, V59, P406, DOI 10.1093/cid/ciu328; Garrido MM, 2014, HEALTH SERV RES, V49, P1701, DOI 10.1111/1475-6773.12182; Gold JAW, 2020, MMWR-MORBID MORTAL W, V69, P1517, DOI 10.15585/mmwr.mm6942e1; Goldstein JR, 2020, P NATL ACAD SCI USA, V117, P22035, DOI 10.1073/pnas.2006392117; Green I, 2021, HUM VACC IMMUNOTHER, V17, P2169, DOI 10.1080/21645515.2020.1852010; Hak E, 2002, CLIN INFECT DIS, V35, P370, DOI 10.1086/341403; Harrison SL, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003321; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285; Konala Venu Madhav, 2020, Eur J Case Rep Intern Med, V7, P001656, DOI 10.12890/2020_001656; Lambert ND, 2012, EXPERT REV VACCINES, V11, P985, DOI [10.1586/ERV.12.61, 10.1586/erv.12.61]; Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1; Madjid M, 2007, EUR HEART J, V28, P1205, DOI 10.1093/eurheartj/ehm035; Mao HW, 2010, J VIROL, V84, P4148, DOI 10.1128/JVI.02340-09; Marin-Hernandez D, 2021, J MED VIROL, V93, P64, DOI 10.1002/jmv.26120; McElhaney JE, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00181-1; Noale M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030471; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Pizzolla A, 2018, J CLIN INVEST, V128, P721, DOI 10.1172/JCI96957; Prats-Uribe A., 2020, ETHNICITY COMORBIDIT, DOI [10.1101/2020.05.06.20092676, DOI 10.1101/2020.05.06.20092676]; Ragni P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040675; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Roser M., 2020, CORONAVIRUS PANDEMIC; Singu S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00406; Taksler GB, 2015, CLIN INFECT DIS, V61, P1495, DOI 10.1093/cid/civ630; Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006; Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206; Vella LA, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf7570; Warren-Gash C, 2011, J INFECT DIS, V203, P1710, DOI 10.1093/infdis/jir171; WEDDERBURN RWM, 1974, BIOMETRIKA, V61, P439, DOI 10.2307/2334725; Wilcox CR, 2021, BMJ OPEN RESPIR RES, V8, DOI 10.1136/bmjresp-2020-000857; Wolff GG, 2020, VACCINE, V38, P350, DOI 10.1016/j.vaccine.2019.10.005; Wu X, 2020, MANAGEMENT TRANSFORMATION OF HUAWEI, P1, DOI 10.1017/9781108550987; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhang ZW, 2016, STAT METHODS MED RES, V25, P314, DOI 10.1177/0962280212452333; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	47	6	6	6	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							427	10.3390/vaccines9050427			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1EO	33923159	gold, Green Submitted, Green Published			2022-04-29	WOS:000654569500001
J	Akbar, SMF; Al Mahtab, M; Begum, F; Hossain, SAS; Sarker, S; Shrestha, A; Khan, MSI; Yoshida, O; Hiasa, Y				Akbar, Sheikh Mohammad Fazle; Al Mahtab, Mamun; Begum, Ferdousi; Hossain, Shaikh A. Shahed; Sarker, Sukumar; Shrestha, Ananta; Khan, Md Sakirul Islam; Yoshida, Osamu; Hiasa, Yoichi			Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia	VACCINES			English	Review						hepatitis B vaccine; EPI; birth-dose vaccine; SEARO	REGION; HBV; IMMUNIZATION; SURFACE; DETERMINANT; MANAGEMENT; CHILDREN; THERAPY; VARIANT; GENE	The World Health Organization (WHO) South-East Asia Regional Office (SEARO) covers 11 countries with a combined population of about 2 billion people, making it the most populous of the six WHO regions. In 1992, the WHO advocated including the hepatitis B vaccine in the Expanded Program of Immunization (EPI) and vaccinating all infants and children three times within 1 year of birth (HepB3). Recently, the WHO advocate birth-dose hepatitis B vaccination (HepB-BD) as soon as possible after birth, preferably within 24 hours. In 2016, the SEARO endorsed a regional hepatitis B control goal with a target of hepatitis B surface antigen (HBsAg) seroprevalence of <= 1% among children aged >= 5 years by 2020. Of the 11 SEARO countries, four achieved this target on schedule. Out of these four countries, two countries (Bangladesh and Nepal) have not adopted HepB-BD in EPI program. On the other hand, the coverage of HepB3 is not satisfactory in some SEARO countries, including India which adopted HepB-BD but could not achieve the overall target of SEARO. Thus, it is a point of debate whether emphasis should be placed on proper implementation of HepB3 or whether a new agenda of HepB-BD should be incorporated in developing countries of SEARO. The article discusses strengthening and expanding the Hepatitis B vaccination program in SEARO countries with an emphasis on HepB and HepB-BD programs.	[Akbar, Sheikh Mohammad Fazle; Yoshida, Osamu; Hiasa, Yoichi] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Toon City, Ehime 7910295, Japan; [Al Mahtab, Mamun] Bangabandhu Sheikh Mujib Med Univ, Dept Hepatol, Dhaka 1000, Bangladesh; [Begum, Ferdousi] Holy Family Red Crescent Med Coll, Dhaka 1000, Bangladesh; [Hossain, Shaikh A. Shahed] BRAC Univ, BRAC James P Grant Sch Publ Hlth, Dhaka 1212, Bangladesh; [Sarker, Sukumar] Save Children Fund, Dhaka 1212, Bangladesh; [Shrestha, Ananta] Liver Fdn Nepal, Kathmandu 44600, Nepal; [Khan, Md Sakirul Islam] Ehime Univ, Grad Sch Med, Dept Anat & Embryol, Toon City, Ehime 7910295, Japan		Akbar, SMF (通讯作者)，Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Toon City, Ehime 7910295, Japan.	sheikhmohammadfazle@gmail.com; shwapnil@agni.com; smbakhtiar2017@gmail.com; shahed.hossain@bracu.ac.bd; ssarker56@gmail.com; anant_02@hotmail.com; sakirul@m.ehime-u.ac.jp; yoshidao@m.ehime-u.ac.jp; hiasa@m.ehime-u.ac.jp	Hiasa, Yoichi/ABD-2759-2021	Hiasa, Yoichi/0000-0003-4117-339X; Khan, Sakirul/0000-0001-5734-0899	Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED) [20fk0310103h1904]	The study was supported in part by a grant-in-aid from Japan Agency for Medical Research and Development (AMED) to Sheikh Mohammad Fazle Akbar (Grant number 20fk0310103h1904).	Al Mahtab M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201236; Al-Mahtab M, 2013, HEPATOL INT, V7, P981, DOI 10.1007/s12072-013-9486-4; Allain JP, 2016, NAT REV GASTRO HEPAT, V13, P643, DOI 10.1038/nrgastro.2016.138; Allison RD, 2016, VACCINE, V34, P2403, DOI 10.1016/j.vaccine.2016.03.063; Banerjee A, 2007, J CLIN VIROL, V40, P312, DOI 10.1016/j.jcv.2007.08.009; Chang MH, 2016, GASTROENTEROLOGY, V151, P472, DOI 10.1053/j.gastro.2016.05.048; Creati M, 2007, VACCINE, V25, P5985, DOI 10.1016/j.vaccine.2007.05.055; Dalvi S, 2015, HUM VACC IMMUNOTHER, V11, P901, DOI 10.1080/21645515.2015.1010953; Dienstag JL, 2009, HEPATOLOGY, V49, pS112, DOI 10.1002/hep.22920; Dinesha TR, 2018, J VIRAL HEPATITIS, V25, P718, DOI 10.1111/jvh.12858; Horiike N, 2005, J CLIN VIROL, V32, P156, DOI 10.1016/j.jcv.2004.07.004; Hossain MG, 2019, INFECT AGENTS CANCER, V14, DOI 10.1186/s13027-019-0253-6; Lada O, 2006, J VIROL, V80, P2968, DOI 10.1128/JVI.80.6.2968-2975.2006; Levrero M, 2018, CURR OPIN VIROL, V30, P80, DOI 10.1016/j.coviro.2018.04.006; Liem KS, 2019, GUT, V68, P2206, DOI 10.1136/gutjnl-2019-318981; Ma L, 2014, REV MED VIROL, V24, P396, DOI 10.1002/rmv.1801; Memirie ST, 2020, COST EFFECT RESOUR A, V18, DOI 10.1186/s12962-020-00219-7; Moturi Edna, 2018, J Immunol Sci, VSuppl, P31; Narayanswamy K, 2011, J Indian Med Assoc, V109, P766; Nwokediuko SC, 2011, HEPAT MON, V11, P786, DOI 10.5812/kowsar.1735143X.757; Parija PP, 2020, HUM VACC IMMUNOTHER, V16, P158, DOI 10.1080/21645515.2019.1640557; Posuwan N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150499; Reardon JM, 2019, CONFL HEALTH, V13, DOI 10.1186/s13031-019-0188-y; Sandhu HS, 2020, MMWR-MORBID MORTAL W, V69, P988, DOI 10.15585/mmwr.mm6930a2; Sarin SK, 2020, LANCET GASTROENTEROL, V5, P167, DOI 10.1016/S2468-1253(19)30342-5; Seaman CP, 2020, LANCET GLOB HEALTH, V8, pE931, DOI 10.1016/S2214-109X(20)30231-X; Si JH, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027696; Theamboonlers A, 2001, TOHOKU J EXP MED, V193, P197, DOI 10.1620/tjem.193.197; WHO, 2020, PREV MOTH CHILD TRAN; Wong GLH, 2016, LANCET INFECT DIS, V16, P1313, DOI 10.1016/S1473-3099(16)30214-6; ZANETTI AR, 1988, LANCET, V2, P1132; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	32	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							374	10.3390/vaccines9040374			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4MV	33921259	gold, Green Published			2022-04-29	WOS:000643756000001
J	Alcaide, EG; Krishnarajah, S; Junker, F				Alcaide, Enrique Gomez; Krishnarajah, Sinduya; Junker, Fabian			Dendritic Cell Tumor Vaccination via Fc Gamma Receptor Targeting: Lessons Learned from Pre-Clinical and Translational Studies	VACCINES			English	Review						Fc gamma receptors; dendritic cells; vaccination; immune oncology; recombinant immune complexes	MHC CLASS-I; ANTIGEN PRESENTATION; T-CELLS; ANTITUMOR-ACTIVITY; SIGNALING MODULES; IMMUNE-COMPLEXES; CANCER VACCINES; DENGUE VACCINE; DC SUBSETS; EXPRESSION	Despite significant recent improvements in the field of immunotherapy, cancer remains a heavy burden on patients and healthcare systems. In recent years, immunotherapies have led to remarkable strides in treating certain cancers. However, despite the success of checkpoint inhibitors and the advent of cellular therapies, novel strategies need to be explored to (1) improve treatment in patients where these approaches fail and (2) make such treatments widely and financially accessible. Vaccines based on tumor antigens (Ag) have emerged as an innovative strategy with the potential to address these areas. Here, we review the fundamental aspects relevant for the development of cancer vaccines and the critical role of dendritic cells (DCs) in this process. We first offer a general overview of DC biology and routes of Ag presentation eliciting effective T cell-mediated immune responses. We then present new therapeutic avenues specifically targeting Fc gamma receptors (Fc gamma R) as a means to deliver antigen selectively to DCs and its effects on T-cell activation. We present an overview of the mechanistic aspects of Fc gamma R-mediated DC targeting, as well as potential tumor vaccination strategies based on preclinical and translational studies. In particular, we highlight recent developments in the field of recombinant immune complex-like large molecules and their potential for DC-mediated tumor vaccination in the clinic. These findings go beyond cancer research and may be of relevance for other disease areas that could benefit from Fc gamma R-targeted antigen delivery, such as autoimmunity and infectious diseases.	[Alcaide, Enrique Gomez; Junker, Fabian] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Pharmaceut Sci, Roche Pharma Res & Early Dev, Grenzacherstr 124, CH-4070 Basel, Switzerland; [Krishnarajah, Sinduya] Univ Zurich, Inst Expt Immunol, CH-8057 Zurich, Switzerland		Junker, F (通讯作者)，F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Pharmaceut Sci, Roche Pharma Res & Early Dev, Grenzacherstr 124, CH-4070 Basel, Switzerland.	enrique.gomez_alcaide@roche.com; krishnarajah@immunology.uzh.ch; fabian.junker@roche.com	Junker, Fabian/ABE-5870-2020	Junker, Fabian/0000-0003-4548-9842; Krishnarajah, Sinduya/0000-0003-2348-1751; Gomez Alcaide, Enrique/0000-0003-0542-303X			Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Balan S, 2019, INT REV CEL MOL BIO, V348, P1, DOI 10.1016/bs.ircmb.2019.07.004; Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; Ben Mkaddem S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00811; Bishop MR, 2004, J CLIN ONCOL, V22, P3886, DOI 10.1200/JCO.2004.01.127; Blanco P, 2008, CYTOKINE GROWTH F R, V19, P41, DOI 10.1016/j.cytogfr.2007.10.004; Blankenstein T, 2012, NAT REV CANCER, V12, P307, DOI 10.1038/nrc3246; Bol KF, 2016, CLIN CANCER RES, V22, P1897, DOI 10.1158/1078-0432.CCR-15-1399; Boruchov AM, 2005, J CLIN INVEST, V115, P2914, DOI 10.1172/JCI24772; Bournazos S, 2017, IMMUNITY, V47, P224, DOI 10.1016/j.immuni.2017.07.009; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Bruhns P, 2009, BLOOD, V113, P3716, DOI 10.1182/blood-2008-09-179754; Bulliard Y, 2013, J EXP MED, V210, P1685, DOI 10.1084/jem.20130573; Capuano C, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1290037; Carmi Y, 2015, NATURE, V521, P99, DOI 10.1038/nature14424; Carter D, 2020, CURR TOP MICROBIOL, V428, P103, DOI 10.1007/82_2018_112; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chaplin DD, 2010, J ALLERGY CLIN IMMUN, V125, pS3, DOI 10.1016/j.jaci.2009.12.980; Chen KQ, 2016, INT IMMUNOPHARMACOL, V34, P1, DOI 10.1016/j.intimp.2016.02.007; Chung EH, 2014, CLIN EXP VACCINE RES, V3, P50, DOI 10.7774/cevr.2014.3.1.50; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Cuzzubbo S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615240; Dalod M, 2014, EMBO J, V33, P1104, DOI 10.1002/embj.201488027; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; Dixon KJ, 2021, CANCERS, V13, DOI 10.3390/cancers13020312; Dong MB, 2016, J IMMUNOL METHODS, V432, P4, DOI 10.1016/j.jim.2015.08.015; Dutertre CA, 2019, IMMUNITY, V51, P573, DOI 10.1016/j.immuni.2019.08.008; Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797; Finn OJ, 2003, NAT REV IMMUNOL, V3, P630, DOI 10.1038/nri1150; Fischetti L, 2017, CYTOKINE, V99, P287, DOI 10.1016/j.cyto.2017.08.009; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; Fletcher EAK, 2018, J IMMUNOL, V201, P87, DOI 10.4049/jimmunol.1700911; Floreani AA, 2007, CELL CYCLE, V6, P2835, DOI 10.4161/cc.6.22.4899; Flores M, 2009, J IMMUNOL, V183, P7129, DOI 10.4049/jimmunol.0901169; Gholizadeh Z, 2018, J CELL MOL MED, V22, P558, DOI 10.1111/jcmm.13343; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Guery L, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.988476; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARPER M, 1987, MOL IMMUNOL, V24, P97, DOI 10.1016/0161-5890(87)90081-2; Hegde GV, 2008, INT IMMUNOPHARMACOL, V8, P819, DOI 10.1016/j.intimp.2008.01.031; Hilchey SP, 2009, BLOOD, V113, P3809, DOI 10.1182/blood-2008-10-185280; Ho NI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02874; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Hussain K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00390; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; Ito T, 2004, J IMMUNOL, V172, P4253, DOI 10.4049/jimmunol.172.7.4253; Jain A, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4024; Junker F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01393; Junker F, 2018, J IMMUNOL METHODS, V454, P32, DOI 10.1016/j.jim.2017.12.002; Kayaga J, 1999, GENE THER, V6, P1475, DOI 10.1038/sj.gt.3300961; Kenkre VP, 2016, CLIN CANCER RES, V22, P821, DOI 10.1158/1078-0432.CCR-15-1848; Kerntke C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00118; Khong H, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0160-y; Kim DS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165603; Kim MY, 2018, PLANT BIOTECHNOL J, V16, P1283, DOI 10.1111/pbi.12869; Kim MY, 2017, PLANT BIOTECHNOL J, V15, P1590, DOI 10.1111/pbi.12741; Kolev M, 2018, SEMIN IMMUNOL, V37, P85, DOI 10.1016/j.smim.2018.02.003; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246; Lahiri A, 2008, VACCINE, V26, P6777, DOI 10.1016/j.vaccine.2008.09.045; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; Landsverk OJB, 2012, J LEUKOCYTE BIOL, V91, P729, DOI 10.1189/jlb.0311150; Langford C., 2015, NEPHRON S2, V129, P96; Lehmann CHK, 2017, J EXP MED, V214, P1509, DOI 10.1084/jem.20160951; Li J, 2010, CLIN EXP IMMUNOL, V162, P251, DOI 10.1111/j.1365-2249.2010.04244.x; Li JK, 2017, ADV EXP MED BIOL, V1024, P195, DOI 10.1007/978-981-10-5987-2_9; Li SS, 2019, J VIROL, V93, DOI 10.1128/JVI.02041-18; Liu Y, 2006, J IMMUNOL, V177, P8440, DOI 10.4049/jimmunol.177.12.8440; Lopez S, 2015, TOXICOL APPL PHARM, V288, P289, DOI 10.1016/j.taap.2015.08.001; Lu BL, 2020, J MED CHEM, V63, P2282, DOI 10.1021/acs.jmedchem.9b01044; Lu Y, 2007, MOL PHARMACEUT, V4, P695, DOI 10.1021/mp070050b; Luckashenak N, 2008, IMMUNITY, V28, P521, DOI 10.1016/j.immuni.2008.02.018; Lux A, 2013, J IMMUNOL, V190, P4315, DOI 10.4049/jimmunol.1200501; McGovern N, 2015, INT IMMUNOL, V27, P65, DOI 10.1093/intimm/dxu091; Means TK, 2005, J CLIN INVEST, V115, P407, DOI 10.1172/JCI200523025; Mekhaiel DNA, 2011, SCI REP-UK, V1, DOI 10.1038/srep00124; Melief CJM, 2015, J CLIN INVEST, V125, P3401, DOI 10.1172/JCI80009; MELLMAN I, 1984, J CELL BIOL, V98, P1163, DOI 10.1083/jcb.98.4.1163; Mogilenko DA, 2021, IMMUNITY, V54, P99, DOI 10.1016/j.immuni.2020.11.005; Mouries J, 2008, BLOOD, V112, P3713, DOI 10.1182/blood-2008-03-146290; Moyer TJ, 2016, J CLIN INVEST, V126, P799, DOI 10.1172/JCI81083; Musumeci A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01222; Nagelkerke SQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02237; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nimmerjahn F, 2016, J CLIN IMMUNOL, V36, pS83, DOI 10.1007/s10875-016-0249-6; Obeid J, 2015, SEMIN ONCOL, V42, P549, DOI 10.1053/j.seminoncol.2015.05.006; Oberkampf M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04686-8; Ortiz DF, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9418; Palucka K, 2013, IMMUNITY, V39, P38, DOI 10.1016/j.immuni.2013.07.004; Patel PM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1433516; Pegu A, 2008, J IMMUNOL, V180, P3399, DOI 10.4049/jimmunol.180.5.3399; Pham GH, 2014, VACCINE, V32, P5212, DOI 10.1016/j.vaccine.2014.07.050; Poulart V, 2016, HAEMATOLOGICA, V101, P529; Prince LR, 2011, CURR OPIN PHARMACOL, V11, P397, DOI 10.1016/j.coph.2011.06.007; Prue RL, 2015, J IMMUNOTHER, V38, P71, DOI 10.1097/CJI.0000000000000063; Qiao JL, 2015, IMMUNOL REV, V268, P241, DOI 10.1111/imr.12370; Qureshi OS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17255-8; Rafiq K, 2002, J CLIN INVEST, V110, P71, DOI 10.1172/JCI200215640; Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Reis ES, 2018, NAT REV IMMUNOL, V18, P5, DOI 10.1038/nri.2017.97; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Riol-Blanco L, 2005, J IMMUNOL, V174, P4070, DOI 10.4049/jimmunol.174.7.4070; Robinett RA, 2018, CELL SYST, V7, P41, DOI 10.1016/j.cels.2018.05.018; Rodriguez-Fernandez JL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00528; Rowley TF, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0149-9; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Santana-Magal N, 2018, JOVE-J VIS EXP, DOI 10.3791/57188; Schnurr M, 2005, BLOOD, V105, P2465, DOI 10.1182/blood-2004-08-3105; Schrand B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05566-x; Schreibelt G, 2010, CANCER IMMUNOL IMMUN, V59, P1573, DOI 10.1007/s00262-010-0833-1; Schuurhuis DH, 2006, J IMMUNOL, V176, P4573, DOI 10.4049/jimmunol.176.8.4573; Schuurhuis DH, 2002, J IMMUNOL, V168, P2240, DOI 10.4049/jimmunol.168.5.2240; See P, 2017, SCIENCE, V356, DOI 10.1126/science.aag3009; Sepulveda-Toepfer JA, 2019, HUM VACC IMMUNOTHER, V15, P179, DOI 10.1080/21645515.2018.1514223; Shen ZH, 1997, J IMMUNOL, V158, P2723; Shepshelovich D, 2018, CANCER MED-US, V7, P5478, DOI 10.1002/cam4.1819; Sousa CRE, 2004, CURR OPIN IMMUNOL, V16, P21, DOI 10.1016/j.coi.2003.11.007; Spirig R, 2018, J IMMUNOL, V200, P2542, DOI 10.4049/jimmunol.1701171; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162; Stapleton NM, 2015, IMMUNOL REV, V268, P253, DOI 10.1111/imr.12331; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Strefford JC, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-116750; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Swann JB, 2007, J CLIN INVEST, V117, P1137, DOI 10.1172/JCI31405; Tagliamonte M, 2014, HUM VACC IMMUNOTHER, V10, P3332, DOI 10.4161/21645515.2014.973317; Tel J, 2012, IMMUNOBIOLOGY, V217, P1017, DOI 10.1016/j.imbio.2012.01.016; Tout M, 2017, CLIN PHARMACOKINET, V56, P635, DOI 10.1007/s40262-016-0470-8; Usman N., 2021, TYPE 3 HYPERSENSITIV; van Duin D, 2006, TRENDS IMMUNOL, V27, P49, DOI 10.1016/j.it.2005.11.005; van Montfoort N, 2012, EUR J IMMUNOL, V42, P598, DOI 10.1002/eji.201141613; van Vliet SJ, 2008, IMMUNOL CELL BIOL, V86, P580, DOI 10.1038/icb.2008.55; Vankemmelbeke M, 2020, CANCER RES, V80, P3399, DOI 10.1158/0008-5472.CAN-19-3599; vanVugt MJ, 1996, BLOOD, V87, P3593, DOI 10.1182/blood.V87.9.3593.bloodjournal8793593; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Wang XY, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-018-0095-z; Westdorp H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0787-6; Whiteside TL, 2004, CANCER IMMUNOL IMMUN, V53, P240, DOI 10.1007/s00262-003-0468-6; Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292; Wimmers F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00165; Yang L, 2004, ADV CANCER RES, V92, P13, DOI 10.1016/S0065-230X(04)92002-7	148	3	3	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							409	10.3390/vaccines9040409			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5AE	33924183	Green Published, gold			2022-04-29	WOS:000643791000001
J	Costa-Lourenco, APR; Su, XH; Le, WJ; Yang, ZY; Patts, GJ; Massari, P; Genco, CA				Costa-Lourenco, Ana Paula R.; Su, Xiaohong; Le, Wenjing; Yang, Zhaoyan; Patts, Gregory J.; Massari, Paola; Genco, Caroline A.			Epidemiological and Clinical Observations of Gonococcal Infections in Women and Prevention Strategies	VACCINES			English	Article						Neisseria gonorrhoeae; sexually transmitted diseases; vaccines; clinical manifestations	NEISSERIA-GONORRHOEAE; CHLAMYDIA-TRACHOMATIS; RISK; VACCINE; TRANSMISSION; PREVALENCE; RESISTANCE; DISEASE	Neisseria gonorrhoeae is rapidly developing antimicrobial resistance. There is an urgent need for an effective gonococcal vaccine. In this study we examined epidemiological and clinical factors associated with gonorrhea in a cohort of women exposed to men with gonococcal urethritis attending the National Center for STD Control clinic in Nanjing, China, to understand the natural history and the risk factors for gonorrhea in this vulnerable population. This analysis will help identify the best target populations for vaccination, which is essential information for the development of vaccine strategies. We observed that 75% of the women in our cohort yielded a N. gonorrhoeae positive culture (infected women) and reported multiple sexual exposures to their infected partner. Infected women were younger than exposed but uninfected women. Contrary to the general belief that gonorrhea is asymptomatic in most women, 68% of the infected women acknowledged symptoms during their STD clinic visit, and overt inflammatory responses were detected upon medical examination in 88% of subjects. Other sexually transmitted infections were detected in 85% of subjects. This study confirmed that N. gonorrhoeae infections are underdiagnosed in women and, consequentially, untreated. Thus, our analysis reinforces the need to establish strategies for gonococcal prevention through the determination of the target population for a gonococcal vaccine.	[Costa-Lourenco, Ana Paula R.; Massari, Paola; Genco, Caroline A.] Tufts Univ, Sch Med, Dept Immunol, 136 Harrison Ave, Boston, MA 02111 USA; [Su, Xiaohong; Le, Wenjing] Chinese Acad Med Sci & Peking Union Med Coll, Inst Dermatol, 12 Jiangwangmiao St, Nanjing 210042, Peoples R China; [Yang, Zhaoyan; Patts, Gregory J.] Boston Univ, Sch Publ Hlth, Biostat & Epidemiol Data Analyt Ctr, 85 East Newton St, Boston, MA 02118 USA		Genco, CA (通讯作者)，Tufts Univ, Sch Med, Dept Immunol, 136 Harrison Ave, Boston, MA 02111 USA.	ana.lourenco@tufts.edu; suxh@ncstdlc.org; lewj@ncstdlc.org; zy@bu.edu; gpatts@bu.edu; paola.massari@tufts.edu; caroline.genco@tufts.edu		Massari, Paola/0000-0003-3106-0711	NIH/NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI116969]	This work was funded by NIH/NIAID, grant number R01 AI116969 (C. A. Genco).	Ayinde O, 2020, SEX TRANSM INFECT, V96, P251, DOI 10.1136/sextrans-2019-054253; Bautista CT, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0074-5; BERGER GS, 1975, BRIT J VENER DIS, V51, P307; BOSLEGO JW, 1991, VACCINE, V9, P154, DOI 10.1016/0264-410X(91)90147-X; Brabin L, 2001, BRIT MED J, V323, P394, DOI 10.1136/bmj.323.7309.394; Cattley C., 2015, ADV INFECT DIS, V5, DOI [10.4236/aid.2015.54020, DOI 10.4236/AID.2015.54020]; CDC, 2019, SEXUALLY TRANSMITTED; Centers for Disease Control and Prevention, 2019, EP INF 7 2; Chang SX, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234261; Coleman JS, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00342-18; De Francesco MA, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9040193; Detels R, 2011, SEX TRANSM DIS, V38, P503, DOI 10.1097/OLQ.0b013e318206c288; ECDC, 2020, ANN EPIDEMIOLOGICAL; Edwards JL, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00102; GREENBERG L, 1974, CAN J PUBLIC HEALTH, V65, P29; Gursahaney PR, 2010, SEX TRANSM DIS, V37, P356, DOI 10.1097/OLQ.0b013e3181d40ff1; Hobbs MM, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00123; Hook EW, 2012, AM J MED SCI, V343, P10, DOI 10.1097/MAJ.0b013e31823ea276; Horner P, 2018, J EUR ACAD DERMATOL, V32, P1845, DOI 10.1111/jdv.15146; Johnson MB, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00077; Kirkcaldy RD, 2019, SEX HEALTH, V16, P401, DOI 10.1071/SH19061; Li Y, 2020, CLIN INFECT DIS, V70, P805, DOI 10.1093/cid/ciz294; Lin JSL, 1998, J INFECT DIS, V178, P1707, DOI 10.1086/314485; Lovett A, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03187; LYCKE E, 1980, SEX TRANSM DIS, V7, P6, DOI 10.1097/00007435-198001000-00002; McLaughlin SE, 2019, METHODS MOL BIOL, V1997, P29, DOI 10.1007/978-1-4939-9496-0_2; McLaughlin SE, 2019, SEX TRANSM DIS, V46, P86, DOI 10.1097/OLQ.0000000000000926; PLATT R, 1983, JAMA-J AM MED ASSOC, V250, P3205, DOI 10.1001/jama.250.23.3205; Plummer EL, 2021, CLIN INFECT DIS, V73, P659, DOI 10.1093/cid/ciab061; Prevention CfDCa Services UDoHaH, 2013, ANT RES THREATS US; Ravel J, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-29; Reekie J, 2018, CLIN INFECT DIS, V66, P437, DOI 10.1093/cid/cix769; Rice P.A., 1996, P 10 INT PATH NEISS P 10 INT PATH NEISS; Rice PA, 2017, ANNU REV MICROBIOL, V71, P665, DOI 10.1146/annurev-micro-090816-093530; Russell MW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02417; Shaughnessy J, 2019, METHODS MOL BIOL, V1997, P1, DOI 10.1007/978-1-4939-9496-0_1; Unemo M, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0136-6, 10.1038/s41572-019-0128-6]; VILLE Y, 1991, BRIT J OBSTET GYNAEC, V98, P1260, DOI 10.1111/j.1471-0528.1991.tb15399.x; Viscardi RM, 2014, ARCH DIS CHILD-FETAL, V99, pF87, DOI 10.1136/archdischild-2012-303351; Wetzler LM, 2016, CLIN VACCINE IMMUNOL, V23, P656, DOI 10.1128/CVI.00230-16; Workowski KA, 2015, MMWR RECOMM REP, V64, P1	41	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							327	10.3390/vaccines9040327			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4UW	33915835	Green Published, gold			2022-04-29	WOS:000643777100001
J	Bullard, BL; Weaver, EA				Bullard, Brianna L.; Weaver, Eric A.			Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine	VACCINES			English	Review						universal vaccine; stalk; headless; chimeric; mosaic; consensus; centralized; epigraph; COBRA; ancestral	COMPUTATIONALLY OPTIMIZED HEMAGGLUTININ; BROADLY NEUTRALIZING ANTIBODIES; VIRUS HEMAGGLUTININ; PROTECTS MICE; ESCHERICHIA-COLI; STALK DOMAIN; DESIGN; STEM; IMMUNITY; HA	Influenza virus has significant viral diversity, both through antigenic drift and shift, which makes development of a vaccine challenging. Current influenza vaccines are updated yearly to include strains predicted to circulate in the upcoming influenza season, however this can lead to a mismatch which reduces vaccine efficacy. Several strategies targeting the most abundant and immunogenic surface protein of influenza, the hemagglutinin (HA) protein, have been explored. These strategies include stalk-directed, consensus-based, and computationally derived HA immunogens. In this review, we explore vaccine strategies which utilize novel antigen design of the HA protein to improve cross-reactive immunity for development of a universal influenza vaccine.	[Bullard, Brianna L.; Weaver, Eric A.] Univ Nebraska Lincoln, Sch Biol Sci, Nebraska Ctr Virol, Lincoln, NE 68504 USA		Weaver, EA (通讯作者)，Univ Nebraska Lincoln, Sch Biol Sci, Nebraska Ctr Virol, Lincoln, NE 68504 USA.	bbullard@huskers.unl.edu; eweaver2@unl.edu		Bullard, Brianna/0000-0002-6702-0079	National Institute of Health under Ruth L. Kirschstein National Research Service Award 1 T32 [AI125207]; National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI147109]	This research was funded by the National Institute of Health under Ruth L. Kirschstein National Research Service Award 1 T32 (AI125207) and National Institute of Allergy and Infectious Diseases (R01AI147109).	Allen JD, 2019, J VIROL, V93, DOI 10.1128/JVI.00946-18; Allen JD, 2017, VACCINE, V35, P5209, DOI 10.1016/j.vaccine.2017.07.107; Bar-Peled Y, 2019, VACCINE, V37, P6022, DOI 10.1016/j.vaccine.2019.08.062; Bernstein DI, 2020, LANCET INFECT DIS, V20, P80, DOI 10.1016/S1473-3099(19)30393-7; Bhatt S, 2011, MOL BIOL EVOL, V28, P2443, DOI 10.1093/molbev/msr044; Black S, 2011, PEDIATR INFECT DIS J, V30, P1081, DOI 10.1097/INF.0b013e3182367662; Bommakanti G, 2012, J VIROL, V86, P13434, DOI 10.1128/JVI.01429-12; Bommakanti G, 2010, P NATL ACAD SCI USA, V107, P13701, DOI 10.1073/pnas.1007465107; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Broecker F, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0126-4; Bullard BL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21508-6; Cai W, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-33; Carter DM, 2017, J VIROL, V91, DOI [10.1128/JVI.01283-17, 10.1128/jvi.01283-17]; Carter DM, 2016, J VIROL, V90, P4720, DOI 10.1128/JVI.03152-15; CDC, CDC SEAS FLU VACC EF; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; Chen MW, 2008, P NATL ACAD SCI USA, V105, P13538, DOI 10.1073/pnas.0806901105; Chen SH, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/901817; Christensen SR, 2019, J VIROL, V93, DOI [10.1128/JVI.02134-18, 10.1128/jvi.02134-18]; Corbett KS, 2019, MBIO, V10, DOI 10.1128/mBio.02810-18; Corder BN, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040195; Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18; Crevar CJ, 2015, HUM VACC IMMUNOTHER, V11, P572, DOI 10.1080/21645515.2015.1012013; Darricarrere N, 2018, J VIROL, V92, DOI 10.1128/JVI.01349-18; Deng L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02725-4; DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Ducatez MF, 2016, VET MICROBIOL, V189, P59, DOI 10.1016/j.vetmic.2016.04.025; Ducatez MF, 2011, P NATL ACAD SCI USA, V108, P349, DOI 10.1073/pnas.1012457108; Eggink D, 2014, J VIROL, V88, P699, DOI 10.1128/JVI.02608-13; Ellebedy AH, 2009, VACCINE, V27, pD65, DOI 10.1016/j.vaccine.2009.08.038; Elliott STC, 2018, HUM GENE THER, V29, P1044, DOI 10.1089/hum.2018.102; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Ermler ME, 2017, J VIROL, V91, DOI 10.1128/JVI.00286-17; Fiore AE, 2009, CURR TOP MICROBIOL, V333, P43, DOI 10.1007/978-3-540-92165-3_3; Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461; Florek NW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181738; Foppa IM, 2015, VACCINE, V33, P3003, DOI 10.1016/j.vaccine.2015.02.042; Giles BM, 2012, J INFECT DIS, V205, P1562, DOI 10.1093/infdis/jis232; Giles BM, 2012, CLIN VACCINE IMMUNOL, V19, P128, DOI 10.1128/CVI.05533-11; Giles BM, 2011, VACCINE, V29, P3043, DOI 10.1016/j.vaccine.2011.01.100; GRAVES PN, 1983, VIROLOGY, V126, P106, DOI 10.1016/0042-6822(83)90465-8; Heaton NS, 2013, P NATL ACAD SCI USA, V110, P20248, DOI 10.1073/pnas.1320524110; Howley PM, 2013, FIELDS VIROLOGY; Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263; Isakova-Sivak I, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030061; Isakova-Sivak I, 2018, VIROLOGY, V518, P313, DOI 10.1016/j.virol.2018.03.013; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jang YH, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00344; Jones JC, 2014, J VIROL, V88, P1175, DOI 10.1128/JVI.02526-13; Kamlangdee A, 2016, J VIROL, V90, P6771, DOI 10.1128/JVI.00730-16; Kamlangdee A, 2014, J VIROL, V88, P13300, DOI 10.1128/JVI.01532-14; Kingstad-Bakke BA, 2019, VACCINE, V37, P5051, DOI 10.1016/j.vaccine.2019.06.077; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Knossow M, 2006, IMMUNOLOGY, V119, P1, DOI 10.1111/j.1365-2567.2006.02421.x; Krammer F, 2014, J VIROL, V88, P3432, DOI 10.1128/JVI.03004-13; Krammer F, 2013, CURR OPIN VIROL, V3, P521, DOI 10.1016/j.coviro.2013.07.007; Krammer F, 2013, J VIROL, V87, P6542, DOI [10.1128/JVI.00641-13, 10.1128/JVI.03183-13]; Laddy DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002517; Laddy DJ, 2007, VACCINE, V25, P2984, DOI 10.1016/j.vaccine.2007.01.063; Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977; Lai SJ, 2016, LANCET INFECT DIS, V16, pE108, DOI 10.1016/S1473-3099(16)00153-5; Lee Jong-Soo, 2013, J Virol Methods, V194, P280, DOI 10.1016/j.jviromet.2013.08.022; Lin SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092822; Lin SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039075; Lingel A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14891-y; Liu WC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010040; Liu WC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00756; Lu Y, 2014, P NATL ACAD SCI USA, V111, P125, DOI 10.1073/pnas.1308701110; Mallajosyula VVA, 2014, P NATL ACAD SCI USA, V111, pE2514, DOI 10.1073/pnas.1402766111; Margine I, 2013, J VIROL, V87, P10435, DOI 10.1128/JVI.01715-13; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nachbagauer R, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030047; Neerukonda SN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030382; Ng S, 2019, NAT MED, V25, P962, DOI 10.1038/s41591-019-0463-x; NOBUSAWA E, 1991, VIROLOGY, V182, P475, DOI 10.1016/0042-6822(91)90588-3; Nunez IA, 2020, VACCINE, V38, P830, DOI 10.1016/j.vaccine.2019.10.097; Park JK, 2018, MBIO, V9, DOI [10.1128/mbio.02284-17, 10.1128/mBio.02284-17]; Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0; Peiris JSM, 2009, REV SCI TECH OIE, V28, P161, DOI 10.20506/rst.28.1.1871; Pleguezuelos O, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0174-9; Qiu XT, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020045; Reneer ZB, 2021, J VIROL, V95, DOI 10.1128/JVI.01526-20; Reneer ZB, 2019, BIOCHEM SOC T, V47, P251, DOI 10.1042/BST20180602; Ross TM, 2019, VACCINE, V37, P2369, DOI 10.1016/j.vaccine.2019.03.018; Ryder AB, 2016, J VIROL, V90, P2544, DOI 10.1128/JVI.02598-15; Sautto GA, 2020, J IMMUNOL, V204, P375, DOI 10.4049/jimmunol.1900379; Sautto Giuseppe A, 2018, Immunohorizons, V2, P226, DOI 10.4049/immunohorizons.1800044; Skarlupka AL, 2019, HUM VACC IMMUNOTHER, V15, P2013, DOI 10.1080/21645515.2019.1653743; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Steinhauer DA, 1999, VIROLOGY, V258, P1, DOI 10.1006/viro.1999.9716; Sun WN, 2019, J VIROL, V93, DOI 10.1128/JVI.00333-19; Swalley SE, 2004, BIOCHEMISTRY-US, V43, P5902, DOI 10.1021/bi049807k; Theiler J, 2018, STAT MED, V37, P181, DOI 10.1002/sim.7203; Theiler J, 2016, SCI REP-UK, V6, DOI 10.1038/srep33987; Thrane S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030389; Thurmond J, 2008, BIOINFORMATICS, V24, P1639, DOI 10.1093/bioinformatics/btn251; Valkenburg SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep22666; van der Lubbe JEM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02350; Kerkhove MD, 2013, INFLUENZA OTHER RESP, V7, P872, DOI 10.1111/irv.12074; Wang TT, 2010, P NATL ACAD SCI USA, V107, P18979, DOI 10.1073/pnas.1013387107; Weaver EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018314; Webby RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140702; WHO, INFL SEAS; Wohlbold TJ, 2015, VACCINE, V33, P3314, DOI 10.1016/j.vaccine.2015.05.038; Wong TM, 2017, J VIROL, V91, DOI 10.1128/JVI.01581-17; Worch R, 2014, ACTA BIOCHIM POL, V61, P421; Wu PP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01649; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Yoon SW, 2014, CURR TOP MICROBIOL, V385, P359, DOI 10.1007/82_2014_396	110	8	8	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							257	10.3390/vaccines9030257			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6RR	33805749	gold, Green Published			2022-04-29	WOS:000634279200001
J	Li, ML; Shih, SR; Tolbert, BS; Brewer, G				Li, Mei-Ling; Shih, Shin-Ru; Tolbert, Blanton S.; Brewer, Gary			Enterovirus A71 Vaccines	VACCINES			English	Review						Enterovirus A71; hand; foot and mouth disease (HFMD); vaccine; Sinovac		Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.	[Li, Mei-Ling; Brewer, Gary] Rutgers Robert Wood Johnson Med Sch, Dept Biochem & Mol Biol, Piscataway, NJ 08854 USA; [Shih, Shin-Ru] Chang Gung Univ, Coll Med, Res Ctr Emerging Viral Infect, Taoyuan 333, Taiwan; [Shih, Shin-Ru] Linkou Chang Gung Mem Hosp, Dept Lab Med, Taoyuan 333, Taiwan; [Shih, Shin-Ru] Chang Gung Univ, Coll Med, Dept Med Biotechnol & Lab Sci, Taoyuan 333, Taiwan; [Shih, Shin-Ru] Chang Gung Univ Sci & Technol, Res Ctr Food & Cosmet Safety, Res Ctr Chinese Herbal Med, Taoyuan 333, Taiwan; [Shih, Shin-Ru] Chang Gung Univ Sci & Technol, Coll Human Ecol, Grad Inst Hlth Ind Technol, Taoyuan 333, Taiwan; [Tolbert, Blanton S.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA		Li, ML (通讯作者)，Rutgers Robert Wood Johnson Med Sch, Dept Biochem & Mol Biol, Piscataway, NJ 08854 USA.	lime@rwjms.rutgers.edu; srshih@mail.cgu.edu.tw; bst18@case.edu; brewerga@rwjms.rutgers.edu		Brewer, Gary/0000-0002-4180-3964; Li, Mei-Ling/0000-0001-6172-5521	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 GM126833]; Research Center for Emerging Viral Infections from The Featured Areas Research Center Program; Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST 108-3017-F 182-001]	This work was funded by National Institutes of Health R01 GM126833 to B.S.T. and G.B., and by the Research Center for Emerging Viral Infections from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education in Taiwan and the Ministry of Science and Technology, Taiwan (MOST 108-3017-F 182-001) to S.R.S.	ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Arita M, 2007, J VIROL, V81, P9386, DOI 10.1128/JVI.02856-06; Aw-Yong KL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165659; Bek EJ, 2011, VACCINE, V29, P4829, DOI 10.1016/j.vaccine.2011.04.070; Chakrabarti BK, 2002, J VIROL, V76, P5357, DOI 10.1128/JVI.76.11.5357-5368.2002; Chang CK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25091-7; Chang JY, 2012, VACCINE, V30, P703, DOI 10.1016/j.vaccine.2011.11.087; Chang LY, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0552-7; Chang YK, 2018, REV INST MED TROP SP, V60, DOI [10.1590/S1678-9946201860070, 10.1590/s1678-9946201860070]; Chen BS, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00261; Cheng A, 2013, VACCINE, V31, P2471, DOI 10.1016/j.vaccine.2013.03.015; Chong P, 2015, CLIN INFECT DIS, V60, P797, DOI 10.1093/cid/ciu852; Chong P, 2012, HUM VACC IMMUNOTHER, V8, P1775, DOI 10.4161/hv.21739; Chou AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079783; Chou AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034834; Chung YC, 2006, WORLD J GASTROENTERO, V12, P921, DOI 10.3748/wjg.v12.i6.921; Dong CH, 2011, VACCINE, V29, P6269, DOI 10.1016/j.vaccine.2011.06.044; Foo DGW, 2007, MICROBES INFECT, V9, P1299, DOI 10.1016/j.micinf.2007.06.002; Fournillier A, 2001, J VIROL, V75, P12088, DOI 10.1128/JVI.75.24.12088-12097.2001; Fujii K, 2018, J VIROL, V92, DOI 10.1128/JVI.00682-18; Guang D, 2007, VIRUS RES, V125, P61, DOI 10.1016/j.virusres.2006.12.005; Han JF, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-106; Han X, 2014, HUM VACC IMMUNOTHER, V10, P2220, DOI 10.4161/hv.29123; Hu YC, 2003, BIOTECHNOL LETT, V25, P919, DOI 10.1023/A:1024071514438; Hu YM, 2018, HUM VACC IMMUNOTHER, V14, P1517, DOI 10.1080/21645515.2018.1442997; Huang LM, 2019, VACCINE, V37, P1827, DOI 10.1016/j.vaccine.2019.02.023; Huang SW, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0574-1; Huo CL, 2017, VACCINE, V35, P7322, DOI 10.1016/j.vaccine.2017.10.101; Hyakumura M, 2015, J VIROL, V89, P11312, DOI 10.1128/JVI.01123-15; In HJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178259; Jiang LP, 2015, VACCINE, V33, P6596, DOI 10.1016/j.vaccine.2015.10.104; Kung YA, 2014, EXPERT OPIN BIOL TH, V14, P1455, DOI 10.1517/14712598.2014.935330; Lee Kyung Yeon, 2016, Korean J Pediatr, V59, P395; Lei DL, 2020, VACCINE, V38, P4917, DOI 10.1016/j.vaccine.2020.05.001; Li HY, 2013, VACCINE, V31, P3281, DOI 10.1016/j.vaccine.2013.05.019; Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224; Liang ZL, 2011, VACCINE, V29, P9668, DOI 10.1016/j.vaccine.2011.10.018; Lin JY, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0560-7; Lin YL, 2012, VACCINE, V30, P1305, DOI 10.1016/j.vaccine.2011.12.081; Liu JN, 2010, VACCINE, V28, P7444, DOI 10.1016/j.vaccine.2010.08.080; Mao QY, 2016, EXPERT REV VACCINES, V15, P599, DOI 10.1586/14760584.2016.1138862; Meng T, 2014, J VIROL, V88, P5803, DOI 10.1128/JVI.00289-14; Meng T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021757; Minor PD, 2004, NAT REV MICROBIOL, V2, P473, DOI 10.1038/nrmicro906; Mustafa S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040742; Nikonov OS, 2017, BIOCHEMISTRY-MOSCOW+, V82, P1615, DOI 10.1134/S0006297917130041; Nishimura Y, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003511; Ooi MH, 2010, LANCET NEUROL, V9, P1097, DOI 10.1016/S1474-4422(10)70209-X; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Puenpa J, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0573-2; Qian CY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010139; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Sadeghipour S, 2013, J VIROL, V87, P1759, DOI 10.1128/JVI.02139-12; Shih SR, 2011, J VIROL, V85, P9658, DOI 10.1128/JVI.05063-11; Tsai YH, 2019, J VIROL, V93, DOI 10.1128/JVI.02308-18; Tsou YL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003692; Ventarola D, 2015, CLIN DERMATOL, V33, P340, DOI 10.1016/j.clindermatol.2014.12.011; Wang X, 2018, ARCH VIROL, V163, P1851, DOI 10.1007/s00705-018-3797-7; Wang XX, 2012, NAT STRUCT MOL BIOL, V19, P424, DOI 10.1038/nsmb.2255; Wang XL, 2019, HUM VACC IMMUNOTHER, V15, P1183, DOI 10.1080/21645515.2019.1581539; Wei MW, 2017, J INFECT DIS, V215, P56, DOI 10.1093/infdis/jiw502; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wu CN, 2001, VACCINE, V20, P895, DOI 10.1016/S0264-410X(01)00385-1; Xu LF, 2014, THERANOSTICS, V4, P498, DOI 10.7150/thno.7457; Yan Q, 2016, VACCINE, V34, P4196, DOI 10.1016/j.vaccine.2016.06.058; Yee PTI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41285-z; Yeh MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027082; Zhang C, 2015, VACCINE, V33, P2335, DOI 10.1016/j.vaccine.2015.03.034; Zhang W, 2018, EMERG MICROBES INFEC, V7, DOI [10.1038/S41426-018-0094-1, 10.1038/s41426-018-0094-1]; Zhao DD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181182; Zhou SL, 2015, J MED VIROL, V87, P256, DOI 10.1002/jmv.24018; Zhou Y, 2016, EXPERT REV VACCINES, V15, P803, DOI 10.1080/14760584.2016.1191357; Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1; Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923	75	2	3	6	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							199	10.3390/vaccines9030199			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE4ZA	33673595	Green Published, gold			2022-04-29	WOS:000634163000001
J	Makhoul, M; Chemaitelly, H; Ayoub, HH; Seedat, S; Abu-Raddad, LJ				Makhoul, Monia; Chemaitelly, Hiam; Ayoub, Houssein H.; Seedat, Shaheen; Abu-Raddad, Laith J.			Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China	VACCINES			English	Article						severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); COVID-19; coronavirus; epidemiology; vaccine; mathematical model	SARS-COV-2	This study forecasts Coronavirus Disease 2019 (COVID-19) vaccination impact in two countries at different epidemic phases, the United States (US) and China. We assessed the impact of both a vaccine that prevents infection (VES of 95%) and a vaccine that prevents only disease (VEP of 95%) through mathematical modeling. For VES of 95% and gradual easing of restrictions, vaccination in the US reduced the peak incidence of infection, disease, and death by >55% and cumulative incidence by >32% and in China by >77% and >65%, respectively. Nearly three vaccinations were needed to avert one infection in the US, but only one was needed in China. For VEP of 95%, vaccination benefits were half those for VES of 95%. In both countries, impact of vaccination was substantially enhanced with rapid scale-up, vaccine coverage >50%, and slower or no easing of restrictions, particularly in the US. COVID-19 vaccination can flatten, delay, and/or prevent future epidemic waves. However, vaccine impact is destined to be heterogeneous across countries because of an underlying "epidemiologic inequity" that reduces benefits for countries already at high incidence, such as the US. Despite 95% efficacy, actual vaccine impact could be meager in such countries if vaccine scale-up is slow, acceptance is poor, or restrictions are eased prematurely.	[Makhoul, Monia; Chemaitelly, Hiam; Seedat, Shaheen; Abu-Raddad, Laith J.] Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Qatar, Infect Dis Epidemiol Grp, Doha 24144, Qatar; [Makhoul, Monia; Chemaitelly, Hiam; Seedat, Shaheen; Abu-Raddad, Laith J.] Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Qatar, World Hlth Org Collaborating Ctr Dis Epidemiol An, Doha 24144, Qatar; [Makhoul, Monia; Seedat, Shaheen; Abu-Raddad, Laith J.] Cornell Univ, Dept Populat Hlth Sci, Weill Cornell Med, New York, NY 10022 USA; [Ayoub, Houssein H.] Qatar Univ, Dept Math Stat & Phys, Doha 2713, Qatar		Abu-Raddad, LJ (通讯作者)，Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Qatar, Infect Dis Epidemiol Grp, Doha 24144, Qatar.; Abu-Raddad, LJ (通讯作者)，Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Qatar, World Hlth Org Collaborating Ctr Dis Epidemiol An, Doha 24144, Qatar.; Abu-Raddad, LJ (通讯作者)，Cornell Univ, Dept Populat Hlth Sci, Weill Cornell Med, New York, NY 10022 USA.	mom2039@qatar-med.cornell.edu; hsc2001@qatar-med.cornell.edu; hayoub@qu.edu.qa; shs4004@qatar-med.cornell.edu; lja2002@qatar-med.cornell.edu		AYOUB, Houssein/0000-0003-2512-6657; Chemaitelly, Hiam/0000-0002-8756-6968; Abu-Raddad, Laith/0000-0003-0790-0506	NPRP grant from the Qatar National Research Fund (Qatar Foundation) [9-040-3-008, 12S-0216-190094]	The developed mathematical models were made possible by NPRP grant number 9-040-3-008 (Principal investigator: LJA) and NPRP grant number 12S-0216-190094 (Principal investigator: LJA) from the Qatar National Research Fund (a member of Qatar Foundation; https://www.qnrf.org, accessed on 4 March 2021). The statements made herein are solely the responsibility of the authors.	Abu-Raddad L.J., 2021, SARS COV 2 REINFECTI, DOI [10.1101/2021.01.15.21249731, DOI 10.1101/2021.01.15.21249731]; Ayoub, 2020, CHARACTERIZING KEY A, DOI DOI 10.1101/2020.04.08.20058214; Bajema KL, 2021, JAMA INTERN MED, V181, P450, DOI 10.1001/jamainternmed.2020.7976; Bubar Kate M, 2021, medRxiv, DOI [10.1101/2020.09.08.20190629, 10.1126/science.abe6959]; Colson P, 2020, EUR J CLIN MICROBIOL, V39, P1983, DOI 10.1007/s10096-020-03900-0; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; Gilardino RE, 2020, INT J HEALTH POLICY, V9, P503, DOI 10.34172/ijhpm.2020.117; Goldstein E, 2021, J INFECT DIS, V223, P362, DOI [10.1093/infdis/jiaa691, 10.1101/2020.07.19.20157362]; Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; He WQ, 2020, J MED VIROL, V92, P2543, DOI 10.1002/jmv.26041; HE X, 2020, NAT MED, V26, P672, DOI [10.1038/s41591-020-0869-5, DOI 10.1038/S41591-020-0869-5]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kaplan J., 3 GLOBAL POPULATION; Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Lauring AS, 2021, JAMA-J AM MED ASSOC, V325, P529, DOI 10.1001/jama.2020.27124; Li RY, 2020, SCIENCE, V368, P489, DOI [10.1126/science.abb3221, 10.1101/2020.02.14.20023127]; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Macartney K, 2020, LANCET CHILD ADOLESC, V4, P807, DOI 10.1016/S2352-4642(20)30251-0; Makhoul M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040668; MATLAB &REG;, 2019, LANG TECHN COMP; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; Merckx J, 2020, DTSCH ARZTEBL INT, V117, P553, DOI 10.3238/arztebl.2020.0553; Nishiura H., 2020, AGE SPECIFICITY CASE, DOI [10.1101/2020.03.09.20033142, DOI 10.1101/2020.03.09.20033142]; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prado-Vivar B, 2020, COVID 19 REINFECTION; Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468; Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517; Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127; Seedat S., 2020, SARS COV 2 INFECT HO, DOI [10.1101/2020.11.29.20240416, DOI 10.1101/2020.11.29.20240416]; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; To Kelvin Kai-Wang, 2021, Clin Infect Dis, V73, pe2946, DOI 10.1093/cid/ciaa1275; United Nations, SHARED RESPONSIBILIT; United Nations Department of Economic and Social Affairs Population Dynamics, 2019 REV WORLD POP P; Van Elslande J, 2021, CLIN INFECT DIS, V73, P354, DOI 10.1093/cid/ciaa1330; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; World Health Organization, REP WHO CHIN JOINT M; World Health Organization, INT GUID CERT CLASS; World Health Organization (WHO), CLIN MAN COVID 19; Younuskunju, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1846, DOI 10.1093/CID/CIAA1846]; Zhu Y., 2020, CHILDREN UNLIKELY HA, V2020, DOI [10.2139/ssrn.3564428, DOI 10.1101/2020.03.26.20044826]; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	47	5	5	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							223	10.3390/vaccines9030223			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5DU	33807647	Green Published, gold, Green Submitted			2022-04-29	WOS:000634175400001
J	Parthasarathi, BC; Kumar, B; Nagar, G; Manjunathachar, HV; de la Fuente, J; Ghosh, S				Parthasarathi, Balasamudram Chandrasekhar; Kumar, Binod; Nagar, Gaurav; Manjunathachar, Haranahally Vasanthachar; de la Fuente, Jose; Ghosh, Srikant			Analysis of Genetic Diversity in Indian Isolates of Rhipicephalus microplus Based on Bm86 Gene Sequence	VACCINES			English	Article						tick; Rhipicephalus microplus; Bm86 gene; diversity; in silico analysis; tick control; cattle	TICK INFESTATIONS; CATTLE; VACCINE; EFFICACY; ANTIGEN; ACARI	The control of cattle tick, Rhipicephalus microplus, is focused on repeated use of acaricides. However, due to growing acaricide resistance and residues problem, immunization of animals along with limited use of effective acaricides is considered a suitable option for the control of tick infestations. To date, more than fifty vaccine candidates have been identified and tested worldwide, but two vaccines were developed using the extensively studied candidate, Bm86. The main reason for limited vaccine commercialization in other countries is genetic diversity in the Bm86 gene leading to considerable variation in vaccine efficacy. India, with 193.46 million cattle population distributed in 28 states and 9 union territories, is suffering from multiple tick infestation dominated by R. microplus. As R. microplus has developed multi-acaricide resistance, an efficacious vaccine may provide a sustainable intervention for tick control. Preliminary experiments revealed that the presently available commercial vaccine based on the BM86 gene is not efficacious against Indian strain. In concert with the principle of reverse vaccinology, genetic polymorphism of the Bm86 gene within Indian isolates of R. microplus was studied. A 578 bp conserved nucleotide sequences of Bm86 from 65 R. microplus isolates collected from 9 Indian states was sequenced and revealed 95.6-99.8% and 93.2-99.5% identity in nucleotides and amino acids sequences, respectively. The identities of nucleotides and deduced amino acids were 94.7-99.8% and 91.8-99.5%, respectively, between full-length sequence (orf) of the Bm86 gene of IVRI-I strain and published sequences of vaccine strains. Six nucleotides deletion were observed in Indian Bm86 sequences. Four B-cell epitopes (D519-K554, H563-Q587, C598-T606, T609-K623), which are present in the conserved region of the IVRI-I Bm86 sequence, were selected. The results confirm that the use of available commercial Bm86 vaccines is not a suitable option against Indian isolates of R. microplus. A country-specific multi-epitope Bm86 vaccine consisting of four specific B-cell epitopes along with candidate molecules, subolesin and tropomyosin in chimeric/co-immunization format may provide a sustainable option for implementation in an integrated tick management system.	[Parthasarathi, Balasamudram Chandrasekhar; Nagar, Gaurav; Ghosh, Srikant] ICAR Indian Vet Res Inst, Div Parasitol, Entomol Lab, Izatnagar 243122, Uttar Pradesh, India; [Kumar, Binod] Junagadh Agr Univ, Dept Vet Parasitol, Coll Vet Sci & AH, Junagadh 362001, Gujarat, India; [Manjunathachar, Haranahally Vasanthachar] ICMR Natl Inst Res Tribal Hlth, Nagpur Rd,PO Garha, Jabalpur, India; [de la Fuente, Jose] IREC CSIC UCLM JCCM, Inst Invest Recursos Cineget, SaBio, Ronda de Toledo S-N, Ciudad Real 13005, Spain; [de la Fuente, Jose] Oklahoma State Univ, Dept Vet Pathobiol, Ctr Vet Hlth Sci, Stillwater, OK 74078 USA		Ghosh, S (通讯作者)，ICAR Indian Vet Res Inst, Div Parasitol, Entomol Lab, Izatnagar 243122, Uttar Pradesh, India.	parthb763@gmail.com; drkumarbinod@gmail.com; gauravn19@gmail.com; manjunathachar632@gmail.com; jose_delafuente@yahoo.com; sghoshtick@gmail.com		de la Fuente, Jose/0000-0001-7383-9649; BC, Parthasarathi/0000-0002-1241-4599	Indian Council of Agricultural Research, New Delhi through the National Agricultural Science Fund [NASF/ABA-6015/201617/357, NFBSFARA/BSA-4004/2013-14]; University Grant Commission (UGC)University Grants Commission, India; Indian Veterinary Research InstituteIndian Council of Agricultural Research (ICAR)	The authors are grateful to the Indian Council of Agricultural Research, New Delhi, for funding through the National Agricultural Science Fund (Grant number NASF/ABA-6015/201617/357 and NFBSFARA/BSA-4004/2013-14 and also wish to thank The University Grant Commission (UGC) for providing Junior Research Fellowship (JRF). The APC is funded by the Indian Veterinary Research Institute.	Adehan S. B., 2016, African Journal of Agricultural Research, V11, P1199; Agrawal Anju, 2010, Journal of Water Resource and Protection, V2, P432, DOI 10.4236/jwarp.2010.25050; ANBARASI P, 2014, THE J, V38, P260, DOI DOI 10.1007/S12639-012-0228-7; [Anonymous], FACT SHEET RTS S MAL; Barre N, 2010, REV SCI TECH OIE, V29, P149; Blake DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001279; Bulut S, 2011, ENVIRON MONIT ASSESS, V181, P555, DOI 10.1007/s10661-010-1849-x; Bulut S, 2010, J ANIM VET ADV, V9, P2797, DOI 10.3923/javaa.2010.2797.2801; Clark EL, 2017, TRENDS PARASITOL, V33, P231, DOI 10.1016/j.pt.2016.08.007; de la Fuente Jose, 2007, Animal Health Research Reviews, V8, P23, DOI 10.1017/S1466252307001193; Department of Animal Husbandry & Dairying (DAHD),, 2019, IND 20 LIV CENS; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Drew DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051023; Eisen DP, 2002, AM J TROP MED HYG, V67, P8, DOI 10.4269/ajtmh.2002.67.8; El-Ashram S, 2019, INSECTS, V10, DOI 10.3390/insects10110404; Flower Darren R, 2010, Immunome Res, V6 Suppl 2, pS1, DOI 10.1186/1745-7580-6-S2-S1; Food and Agriculture Organization of The United Nations (FAO), 2019, STATISTICS-ABINGDON; Freeman JM, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-101; Garcia-Garcia JC, 1999, EXP APPL ACAROL, V23, P883, DOI 10.1023/A:1006270615158; Ghosh S, 2007, PARASITOL RES, V101, pS207, DOI 10.1007/s00436-007-0684-7; Ghosh S, 2014, J VECTOR DIS, V51, P259; Ghoshal S, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2592-y; Godara R, 2019, TROP ANIM HEALTH PRO, V51, P1203, DOI 10.1007/s11250-019-01810-8; Graf JF, 2004, PARASITOLOGY, V129, pS427, DOI 10.1017/S0031182004006079; Healer J, 2004, MOL MICROBIOL, V52, P159, DOI 10.1111/j.1365-2958.2003.03974.x; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; Hue T, 2017, EXP APPL ACAROL, V73, P245, DOI 10.1007/s10493-017-0184-0; Jayaraj Ravindran, 2016, Interdiscip Toxicol, V9, P90, DOI 10.1515/intox-2016-0012; Jiang LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041115; Kaewmongkol S, 2015, EXP APPL ACAROL, V66, P247, DOI 10.1007/s10493-015-9897-0; Kumar A, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-3022-5; Kumar B, 2017, VACCINE, V35, P5682, DOI 10.1016/j.vaccine.2017.08.049; Kumar B, 2012, PARASITOL RES, V111, P629, DOI 10.1007/s00436-012-2879-9; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Mahan A.A, 2018, PESTS VECTOR BORNE D, P783, DOI 10.3920/978-90-8686-863-6; Manjunathachar HV, 2019, TRANSBOUND EMERG DIS, V66, P422, DOI 10.1111/tbed.13038; Minjauw B, 2003, TICK BORNE DIS POVER; Olwoch JM, 2007, ONDERSTEPOORT J VET, V74, P45, DOI 10.4102/ojvr.v74i1.139; Perez-Perez D, 2010, VET PARASITOL, V167, P321, DOI 10.1016/j.vetpar.2009.09.034; Rodriguez-Hidalgo R, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0174652, 10.1371]; Rodriguez-Valle M, 2012, VACCINE, V30, P3453, DOI 10.1016/j.vaccine.2012.03.020; Roy S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00673; Shakya M, 2020, EXP APPL ACAROL, V80, P591, DOI 10.1007/s10493-020-00481-7; Shakya M, 2014, VACCINE, V32, P3488, DOI 10.1016/j.vaccine.2014.04.053; Sossai S, 2005, EXP APPL ACAROL, V37, P199, DOI 10.1007/s10493-005-3262-7; Higa LDS, 2020, PREV VET MED, V174, DOI 10.1016/j.prevetmed.2019.104837; Suarez M, 2016, LIVEST SCI, V187, P48, DOI 10.1016/j.livsci.2016.02.005; Terheggen U, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0183-5; Ticks FAO Acaricide Resistance Diagnosis Management and Prevention, 2004, AC RES DIAGN MAN PRE; Valle MR, 2004, EXP APPL ACAROL, V34, P375, DOI 10.1023/B:APPA.0000049223.92326.02; Walker AR., 2003, BIOSCIENCE REP	51	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							194	10.3390/vaccines9030194			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5XU	33652549	gold, Green Published			2022-04-29	WOS:000634227400001
J	Taniguchi, M; Ueda, Y; Yagi, A; Miyoshi, A; Tanaka, Y; Minekawa, R; Endo, M; Tomimatsu, T; Hirai, K; Nakayama, T; Kimura, T				Taniguchi, Mariko; Ueda, Yutaka; Yagi, Asami; Miyoshi, Ai; Tanaka, Yusuke; Minekawa, Ryoko; Endo, Masayuki; Tomimatsu, Takuji; Hirai, Kei; Nakayama, Tomio; Kimura, Tadashi			Disparity of Cervical Cancer Risk in Young Japanese Women: Bipolarized Status of HPV Vaccination and Cancer Screening	VACCINES			English	Article						cervical cancer; screening rate; HPV vaccine; vaccination status; health consciousness		Women born between 1994 and 1999 achieved high vaccination rates for human papillomavirus (HPV); they are now reaching the age of cervical cancer screening programs in Japan. In this study, we aimed to investigate the health awareness of HPV-vaccinated and unvaccinated women and to create tailored leaflets recommending cervical cancer screening for each. Surveys on the cancer screening rates for HPV-vaccinated and unvaccinated women aged 20 and 21 have demonstrated that the rate was significantly higher (p < 0.01) in vaccinated (6.2%) than in unvaccinated women (3.1%). Next, interviews and Internet questionnaires clarified that there was a trend that vaccinated women have a better health consciousness than the unvaccinated ones, and that in unvaccinated women, their willingness to receive cervical cancer screening was significantly enhanced by the fear of developing cancer. Finally, in a prospective study, the increase in the screening rate for both vaccinated and unvaccinated groups after they read tailored leaflets, from 6.4% to 7.4% and from 3.9% to 5.1%, respectively, was not statistically significant compared to the groups provided with a standard reminder letter. Cervical cancer control measures might be enhanced by recommending cervical cancer screening in ways better tailored to HPV vaccination status.	[Taniguchi, Mariko; Ueda, Yutaka; Yagi, Asami; Miyoshi, Ai; Tomimatsu, Takuji; Kimura, Tadashi] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan; [Tanaka, Yusuke] Osaka Rosai Hosp, Dept Obstet & Gynecol, 1179-3 Nagasone Cho, Sakai, Osaka 5918025, Japan; [Minekawa, Ryoko] Ogata Family Clin, 2-3 Matsunouchi Cho, Ashiya, Hyogo 6590094, Japan; [Endo, Masayuki] Osaka Univ, Grad Sch Med, Div Hlth Sci, Dept Childrens & Womens Hlth, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan; [Hirai, Kei] Osaka Univ, Grad Sch Human Sci, Dept Clin Psychol, 1-2 Yamadaoka, Suita, Osaka 5650871, Japan; [Nakayama, Tomio] Natl Canc Ctr, Ctr Publ Hlth Sci, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan		Ueda, Y (通讯作者)，Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mariko27qoo@gyne.med.osaka-u.ac.jp; ZVF03563@nifty.ne.jp; a.yagi@gyne.med.osaka-u.ac.jp; aimiyoshi20090808@yahoo.co.jp; ytanaka@gyne.med.osaka-u.ac.jp; minekawa@ogatafamilyclinic.com; endo@gyne.med.osaka-u.ac.jp; tomimatsu@gyne.med.osaka-u.ac.jp; khirai@grappo.jp; tomnakay@ncc.go.jp; tadashi@gyne.med.osaka-u.ac.jp		MINEKAWA, RYOKO/0000-0001-7429-3203; Ueda, Yutaka/0000-0001-8760-6379; Nakayama, Tomio/0000-0002-3354-5096	Health and Labor Sciences Research GrantMinistry of Health, Labour and Welfare, Japan [H29-024]	This study was supported by a Health and Labor Sciences Research Grant (H29-024).	Abe K, 2016, ASTROPART PHYS, V81, P39, DOI 10.1016/j.astropartphys.2016.04.003; [Anonymous], OECD HLTH CARE QUALI; Garland SM, 2014, EXPERT OPIN BIOL TH, V14, P527, DOI 10.1517/14712598.2014.880418; Guo FJ, 2017, J WOMENS HEALTH, V26, P1114, DOI 10.1089/jwh.2017.6424; Hall MT, 2019, LANCET PUBLIC HEALTH, V4, pE19, DOI 10.1016/S2468-2667(18)30183-X; Hanley SJB, 2015, LANCET, V385, P2571, DOI 10.1016/S0140-6736(15)61152-7; Ikeda S, 2019, EXPERT REV VACCINES, V18, P323, DOI 10.1080/14760584.2019.1584040; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Luostarinen T, 2018, INT J CANCER, V142, P2186, DOI 10.1002/ijc.31231; Ministry of Health Labour and Welfare, COMPREHENSIVE SURVEY; Nakagawa S, 2020, CANCER SCI, V111, P2156, DOI 10.1111/cas.14406; Sakamoto J, 2018, PAPILLOMAVIRUS RES, V6, P46, DOI 10.1016/j.pvr.2018.10.001; Tanaka Y, 2016, LANCET ONCOL, V17, P868, DOI 10.1016/S1470-2045(16)00147-9; Taniguchi M, 2019, VACCINE, V37, P4424, DOI 10.1016/j.vaccine.2019.06.064; U.S. Cancer Statistics Working Group United States, CANC STAT 1999 2014; Ueda Y, 2015, AM J OBSTET GYNECOL, V212, P405, DOI 10.1016/j.ajog.2014.11.037; Yagi A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73106-z; Yagi A, 2019, CANCER RES, V79, P1252, DOI 10.1158/0008-5472.CAN-18-3109; Yamaguchi M, 2018, PAPILLOMAVIRUS RES, V6, P6, DOI 10.1016/j.pvr.2018.05.002	19	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							280	10.3390/vaccines9030280			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6AH	33808630	Green Published, gold			2022-04-29	WOS:000634233900001
J	Akatsu, H				Akatsu, Hiroyasu			Exploring the Effect of Probiotics, Prebiotics, and Postbiotics in Strengthening Immune Activity in the Elderly	VACCINES			English	Review						probiotic; prebiotic; postbiotic; elderly; gut microbiota (GM); influenza; vaccination; immunity		Vaccination is the easiest way to stimulate the immune system to confer protection from disease. However, the inefficacy of vaccination in the elderly, especially those under nutritional control such as individuals receiving artificial nutrition after cerebral infarction or during dementia, has led to the search for an adjuvant to augment the acquired immune response in this population. The cross-talk between the gut microbiota and the host immune system is gaining attention as a potential adjuvant for vaccines. Probiotics, prebiotics, and postbiotics, which are commonly used to modulate gut health, may enhance the immune response and the effectiveness of vaccination in the elderly. This review summarizes the use of these gut modulators as adjuvants to boost both the innate and acquired immune responses in the elderly under nutritional control. Although the clinical evidence on this topic is limited and the initial findings await clarification through future studies with large sample sizes and proper study designs, they highlight the necessity for additional research in this field, especially in light of the ongoing COVID-19 pandemic, which is disproportionately affecting the elderly.	[Akatsu, Hiroyasu] Nagoya City Univ, Grad Sch Med Sci, Dept Community Based Med Educ, Nagoya, Aichi 4678601, Japan		Akatsu, H (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Community Based Med Educ, Nagoya, Aichi 4678601, Japan.	akatu@med.nagoya-cu.ac.jp		Akatsu, Hiroyasu/0000-0002-0089-6033	Research Funding for Longevity Sciences from the National Center for Geriatrics and Gerontology (NCGG), Japan [20-5]	This work was partially supported by the Research Funding for Longevity Sciences from the National Center for Geriatrics and Gerontology (NCGG) (grant #20-5 to H.A.), Japan.	Agarwal S, 2010, ANN ALLERG ASTHMA IM, V104, P183, DOI 10.1016/j.anai.2009.11.009; Akatsu H., 2011, JPN J GERIATR, V48, P67; Akatsu H, 2016, GERIATR GERONTOL INT, V16, P205, DOI 10.1111/ggi.12454; Akatsu H, 2013, J AM GERIATR SOC, V61, P1828, DOI 10.1111/jgs.12474; Akatsu H, 2013, JPEN-PARENTER ENTER, V37, P631, DOI 10.1177/0148607112467819; Bartosch S, 2004, APPL ENVIRON MICROB, V70, P3575, DOI 10.1128/AEM.70.6.3575-3581.2004; Boge T, 2009, VACCINE, V27, P5677, DOI 10.1016/j.vaccine.2009.06.094; Bosch M, 2012, NUTR HOSP, V27, P504, DOI [10.3305/nh.2012.27.2.5519, 10.1590/S0212-16112012000200023]; Bunout D, 2002, JPEN-PARENTER ENTER, V26, P372, DOI 10.1177/0148607102026006372; Calder AE, 2011, NEUROIMMUNOMODULAT, V18, P281, DOI 10.1159/000329496; Chidgey A, 2007, SEMIN IMMUNOL, V19, P331, DOI 10.1016/j.smim.2007.10.006; Chinen T, 2012, IMMUNOL REV, V245, P45, DOI 10.1111/j.1600-065X.2011.01083.x; Chuang L, 2007, J AGR FOOD CHEM, V55, P11080, DOI 10.1021/jf071786o; Ciabattini A, 2020, SEMIN IMMUNOPATHOL, V42, P619, DOI 10.1007/s00281-020-00821-0; Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010; Cianci R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040636; CONGE GA, 1980, REPROD NUTR DEV, V20, P929, DOI 10.1051/rnd:19800603; Franza L, 2019, J BIOL REG HOMEOS AG, V33, P1321, DOI 10.23812/Editorial; FULLER R, 1989, J APPL BACTERIOL, V66, P365; GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401; Gill HS, 2001, AM J CLIN NUTR, V74, P833; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Goronzy JJ, 2017, IMMUNITY, V46, P364, DOI 10.1016/j.immuni.2017.03.010; Goto Y, 2012, IMMUNOL REV, V245, P147, DOI 10.1111/j.1600-065X.2011.01078.x; Guillemard E, 2010, BRIT J NUTR, V103, P58, DOI 10.1017/S0007114509991395; Hapfelmeier S, 2010, SCIENCE, V328, P1705, DOI 10.1126/science.1188454; Hartemink R, 1997, J APPL MICROBIOL, V83, P367, DOI 10.1046/j.1365-2672.1997.00239.x; HEREMANS H, 1994, EUR J IMMUNOL, V24, P1155, DOI 10.1002/eji.1830240522; Jorjao Adeline Lacerda, 2015, ScientificWorldJournal, V2015, P716749, DOI 10.1155/2015/716749; Keener A, 2019, NATURE, V575, pS48, DOI 10.1038/d41586-019-03638-6; Kim D, 2016, NAT MED, V22, P524, DOI 10.1038/nm.4075; Kotani Yoshifumi, 2010, Immun Ageing, V7, P11, DOI 10.1186/1742-4933-7-11; Langkamp-Henken B, 2004, J AM GERIATR SOC, V52, P3, DOI 10.1111/j.1532-5415.2004.52003.x; Langkamp-Henken B, 2006, J AM GERIATR SOC, V54, P1861, DOI 10.1111/j.1532-5415.2006.00982.x; Lei WT, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111175; Lesourd B, 1999, P NUTR SOC, V58, P685, DOI 10.1017/S0029665199000907; Li L, 2019, LANCET PUBLIC HEALTH, V4, pE473, DOI 10.1016/S2468-2667(19)30163-X; Li N, 2009, PEDIATR RES, V66, P203, DOI 10.1203/PDR.0b013e3181aabd4f; Lynn DJ, 2018, J LEUKOCYTE BIOL, V103, P225, DOI 10.1189/jlb.5MR0617-216R; Macpherson AJ, 2012, IMMUNOL REV, V245, P132, DOI 10.1111/j.1600-065X.2011.01072.x; Malagon-Rojas JN, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020389; Jose HGM, 2020, FOOD RES INT, V137, DOI 10.1016/j.foodres.2020.109660; Maruyama M, 2016, INT J FOOD SCI NUTR, V67, P67, DOI 10.3109/09637486.2015.1126564; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Metchnikoff E., 1908, PROLONGATION LIFE; Nagafuchi S, 2015, PHARMACEUTICALS, V8, P351, DOI 10.3390/ph8020351; Namba K, 2010, BIOSCI BIOTECH BIOCH, V74, P939, DOI 10.1271/bbb.90749; Odamaki T, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0708-5; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Praharaj I, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0144; Ryan FJ, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00484-19; Sapey E, 2014, BLOOD, V123, P239, DOI 10.1182/blood-2013-08-519520; Schmitt V, 2013, EXP GERONTOL, V48, P1379, DOI 10.1016/j.exger.2013.09.003; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Sheih YH, 2001, J AM COLL NUTR, V20, P149, DOI 10.1080/07315724.2001.10719027; Smetana J, 2018, HUM VACC IMMUNOTHER, V14, P540, DOI 10.1080/21645515.2017.1343226; Thomas R, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-0173-8; Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; United Nations, 2020, STESASERA451; United Nations, 2019, STESASERA430; van Puyenbroeck K, 2012, AM J CLIN NUTR, V95, P1165, DOI 10.3945/ajcn.111.026831; Vos AP, 2007, PEDIAT ALLERG IMM-UK, V18, P304, DOI 10.1111/j.1399-3038.2007.00515.x; Wack A, 1998, INT IMMUNOL, V10, P1281, DOI 10.1093/intimm/10.9.1281; WHO-World Health Organization, 2020, COVID WHO STRATEGY U; Yeh TL, 2018, DRUG DES DEV THER, V12, P217, DOI 10.2147/DDDT.S155110; Zimmermann P, 2018, VACCINE, V36, P207, DOI 10.1016/j.vaccine.2017.08.069	68	8	8	6	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							136	10.3390/vaccines9020136			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6TD	33567790	Green Published, gold			2022-04-29	WOS:000623273100001
J	Corsini, B; Aguinagalde, L; Ruiz, S; Domenech, M; Yuste, J				Corsini, Bruno; Aguinagalde, Leire; Ruiz, Susana; Domenech, Mirian; Yuste, Jose			Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System	VACCINES			English	Article						S. pneumoniae; vaccine protein; LytA; LytC; Pce; cell wall hydrolases; complement; phagocytosis	INVASIVE PNEUMOCOCCAL DISEASE; CONJUGATE VACCINES; PENICILLIN SUSCEPTIBILITY; IMMUNIZATION; ANTIBODIES; POLYSACCHARIDE; MICE; PNEUMOLYSIN; INFECTION; VIRULENCE	The emergence of non-vaccine serotypes of Streptococcus pneumoniae after the use of vaccines based in capsular polysaccharides demonstrates the need of a broader protection vaccine based in protein antigens and widely conserved. In this study, we characterized three important virulence factors of S. pneumoniae namely LytA, LytC, and Pce as vaccine candidates. These proteins are choline-binding proteins that belong to the cell wall hydrolases' family. Immunization of mice with LytA, LytC, or Pce induced high titers of immunoglobulins G (IgGs) of different subclasses, with IgG1, IgG2a, and IgG2b as the predominant immunoglobulins raised. These antibodies activated the classical pathway of the complement system by increasing the recognition of C1q on the surface of pneumococcal strains of different serotypes. Consequently, the key complement component C3 recognized more efficiently these strains in the presence of specific antibodies elicited by these proteins, activating, therefore, the phagocytosis. Finally, a mouse sepsis model of infection was established, confirming that vaccination with these proteins controlled bacterial replication in the bloodstream, increasing the survival rate. Overall, these results demonstrate that LytA, LytC, and Pce can be protein antigens to be contained in a future universal vaccine against S. pneumoniae.	[Corsini, Bruno; Aguinagalde, Leire; Domenech, Mirian; Yuste, Jose] Inst Salud Carlos III, Natl Ctr Microbiol, Spanish Pneumococcal Reference Lab, Madrid 28220, Spain; [Ruiz, Susana; Yuste, Jose] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid 28029, Spain; [Ruiz, Susana] CSIC, Ctr Invest Biol, Madrid 28040, Spain		Domenech, M; Yuste, J (通讯作者)，Inst Salud Carlos III, Natl Ctr Microbiol, Spanish Pneumococcal Reference Lab, Madrid 28220, Spain.; Yuste, J (通讯作者)，Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid 28029, Spain.	brunoccorsini@gmail.com; leire_agui@hotmail.com; sruiz@ciberes.org; mdomenech@isciii.es; jyuste@isciii.es	Domenech, Mirian/G-2561-2018	Domenech, Mirian/0000-0002-0942-8180; YUSTE, JOSE/0000-0001-7996-0837	Ministerio de Economia, Industria y CompetitividadSpanish Government [SAF2017-83388]; Brazilian Program Ciencia Sem Fronteiras (CsF) from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF); FPI fellowship from MINECOSpanish Government	This research was funded by Ministerio de Economia, Industria y Competitividad (grant number SAF2017-83388). B.C. and L.A. were supported, respectively, by a fellowship from the Brazilian Program Ciencia Sem Fronteiras (CsF) from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and by an FPI fellowship from MINECO.	Ahn JG, 2015, VACCINE, V33, P4770, DOI 10.1016/j.vaccine.2015.08.002; AMIR J, 1990, J INFECT DIS, V162, P163, DOI 10.1093/infdis/162.1.163; Azoulay-Dupuis E, 2000, ANTIMICROB AGENTS CH, V44, P1575, DOI 10.1128/AAC.44.6.1575-1577.2000; Bologa M, 2012, VACCINE, V30, P7461, DOI 10.1016/j.vaccine.2012.10.076; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; BREDIUS RGM, 1992, INFECT IMMUN, V60, P4838, DOI 10.1128/IAI.60.11.4838-4847.1992; BRILES DE, 1981, NATURE, V294, P88, DOI 10.1038/294088a0; Brown JS, 2002, P NATL ACAD SCI USA, V99, P16969, DOI 10.1073/pnas.012669199; Brown JS, 2001, INFECT IMMUN, V69, P6702, DOI 10.1128/IAI.69.11.6702-6706.2001; Cafini F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012041; CANVIN JR, 1995, J INFECT DIS, V172, P119, DOI 10.1093/infdis/172.1.119; Cassiolato AP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208211; Chan WY, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00846-18; Converso TR, 2017, VACCINE, V35, P5140, DOI 10.1016/j.vaccine.2017.08.010; Corsini B, 2016, VACCINE, V34, P6148, DOI 10.1016/j.vaccine.2016.11.001; de Miguel S, 2021, CLIN INFECT DIS, V73, pE3778, DOI 10.1093/cid/ciaa1483; Desa MN, 2008, EPIDEMIOL INFECT, V136, P940, DOI 10.1017/S0950268807009363; Domenech M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02700; Eldholm V, 2009, MICROBIOL-SGM, V155, P2223, DOI 10.1099/mic.0.026328-0; Exley RM, 2005, J EXP MED, V201, P1637, DOI 10.1084/jem.20041548; Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368; Feldman C, 2014, J INFECTION, V69, P309, DOI 10.1016/j.jinf.2014.06.006; Fenoll A, 2015, VACCINE, V33, P5691, DOI 10.1016/j.vaccine.2015.08.009; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; Garcia P, 1999, MOL MICROBIOL, V33, P128, DOI 10.1046/j.1365-2958.1999.01455.x; Giefing C, 2008, J EXP MED, V205, P117, DOI 10.1084/jem.20071168; Gosink KK, 2000, INFECT IMMUN, V68, P5690, DOI 10.1128/IAI.68.10.5690-5695.2000; Hermoso JA, 2005, NAT STRUCT MOL BIOL, V12, P533, DOI 10.1038/nsmb940; Jayasinghe S, 2017, CLIN INFECT DIS, V64, P175, DOI 10.1093/cid/ciw720; JOHANSSON PJH, 1992, SCAND J INFECT DIS, V24, P357; Jomaa M, 2005, INFECT IMMUN, V73, P6852, DOI 10.1128/IAI.73.10.6852-6859.2005; Kamtchoua T, 2013, VACCINE, V31, P327, DOI 10.1016/j.vaccine.2012.11.005; Kaur R, 2020, VACCINE, V38, P4423, DOI 10.1016/j.vaccine.2020.04.063; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Lagartera L, 2005, ACTA CRYSTALLOGR F, V61, P221, DOI 10.1107/S1744309105001636; Lawrence H, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003326; Lipsitch M, 2016, MBIO, V7, DOI 10.1128/mBio.00428-16; LOCK RA, 1992, MICROB PATHOGENESIS, V12, P137, DOI 10.1016/0882-4010(92)90116-6; Lopez R, 2004, FEMS MICROBIOL REV, V28, P553, DOI 10.1016/j.femsre.2004.05.002; Lottenbach KR, 1999, INFECT IMMUN, V67, P4935, DOI 10.1128/IAI.67.9.4935-4938.1999; Marshall HS, 2020, NEW ENGL J MED, V382, P318, DOI 10.1056/NEJMoa1900236; Masomian M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010132; McLaughlin JM, 2019, VACCINE, V37, P6310, DOI 10.1016/j.vaccine.2019.08.059; McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312; Morales M, 2010, J BACTERIOL, V192, P2624, DOI 10.1128/JB.01501-09; Moscoso M, 2006, J BACTERIOL, V188, P7785, DOI 10.1128/JB.00673-06; Ogunniyi AD, 2000, INFECT IMMUN, V68, P3028, DOI 10.1128/IAI.68.5.3028-3033.2000; Ogunniyi AD, 2001, INFECT IMMUN, V69, P5997, DOI 10.1128/IAI.69.10.5997-6003.2001; Ouldali N, 2021, LANCET INFECT DIS, V21, P137, DOI 10.1016/S1473-3099(20)30165-1; Ramos-Sevillano E, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005500; Ramos-Sevillano E, 2015, INFECT IMMUN, V83, P591, DOI 10.1128/IAI.02811-14; Ramos-Sevillano E, 2012, ANTIMICROB AGENTS CH, V56, P5534, DOI 10.1128/AAC.01470-12; Ramos-Sevillano E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044135; Ramos-Sevillano E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023626; Read RC, 2017, VACCINE, V35, P427, DOI 10.1016/j.vaccine.2016.11.071; Regev-Yochay G, 2017, VACCINE, V35, P2449, DOI 10.1016/j.vaccine.2017.03.031; Rieux V, 2001, J INFECT DIS, V184, P66, DOI 10.1086/320992; RomeroSteiner S, 1997, CLIN DIAGN LAB IMMUN, V4, P415, DOI 10.1128/CDLI.4.4.415-422.1997; Rosini R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01048; Sakai F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067147; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; Savulescu C, 2017, LANCET RESP MED, V5, P648, DOI [10.1016/S2213-2600(17)30110-8, 10.1016/s2213-2600(17)30110-8]; Sempere J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00309; Shelly MA, 1997, INFECT IMMUN, V65, P242, DOI 10.1128/IAI.65.1.242-247.1997; Soininen A, 1999, VACCINE, V17, P1889, DOI 10.1016/S0264-410X(98)00475-7; Standish AJ, 2009, J IMMUNOL, V183, P2602, DOI 10.4049/jimmunol.0900688; Uddin S, 2006, VACCINE, V24, P5637, DOI 10.1016/j.vaccine.2006.03.088; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Wizemann TM, 2001, INFECT IMMUN, V69, P1593, DOI 10.1128/IAI.69.3.1593-1598.2001; Wuorimaa T, 2001, VACCINE, V19, P1863, DOI 10.1016/S0264-410X(00)00441-2; Yuan ZQ, 2011, IMMUNOL RES, V51, P108, DOI 10.1007/s12026-011-8234-x; Yuste J, 2008, INFECT IMMUN, V76, P3761, DOI 10.1128/IAI.00291-08	74	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							186	10.3390/vaccines9020186			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7AE	33672306	gold, Green Published			2022-04-29	WOS:000623291800001
J	Xu, YQ; He, Y; Momben-Abolfath, S; Eller, N; Norton, M; Zhang, P; Scott, D; Struble, EB				Xu, Yanqun; He, Yong; Momben-Abolfath, Sanaz; Eller, Nancy; Norton, Malgorzata; Zhang, Pei; Scott, Dorothy; Struble, Evi Budo			Entry and Disposition of Zika Virus Immune Complexes in a Tissue Culture Model of the Maternal-Fetal Interface	VACCINES			English	Article						anti-Zika antibodies; anti-Zika IgG; antibody dependent enhancement	FC-RECEPTOR FCRN; INFECTION; TRANSPORT	Zika virus (ZIKV) infections have been associated with an increased incidence of severe microcephaly and other neurodevelopmental disorders in newborn babies. Passive immunization with anti-ZIKV neutralizing antibodies has the potential to become a feasible treatment or prophylaxis option during pregnancy. Prior to clinical use, such antibodies should be assessed for their ability to block ZIKV passage to the fetus. We used human placental and mammalian cell monolayers that express FcRn and laboratory preparations of anti-ZIKV antibodies as a model system to investigate the disposition of ZIKV/antibody immune complexes (ICs) at the maternal-fetal interface. We further characterized solution properties of the ICs to evaluate whether these are related to in vitro effects. We found that both ZIKV and ZIKV envelope glycoprotein can enter and passage through epithelial cells, especially those that overexpress FcRn. In the presence of ZIKV antibodies, Zika virus entry was bimodal, with reduced entry at the lowest (0.3-3 ng/mL) and highest (mu g/mL) antibody concentrations. Intermediate concentrations attenuated inhibition or enhanced viral entry. With respect to anti-ZIKV antibodies, we found that their degradation was accelerated when presented as ICs containing increased amounts of ZIKV immunogen. Of the two monoclonal antibodies tested, the preparation with higher aggregation also exhibited higher degradation. Our studies confirm that intact Zika virus and its envelope immunogen have the potential to enter and be transferred across placental and other epithelial cells that express FcRn. Presence of anti-ZIKV IgG antibodies can either block or enhance cellular entry, with the antibody concentration playing a complex role in this process. Physicochemical properties of IgG antibodies can influence their degradation in vitro.	[Xu, Yanqun; He, Yong; Momben-Abolfath, Sanaz; Eller, Nancy; Norton, Malgorzata; Zhang, Pei; Scott, Dorothy; Struble, Evi Budo] US FDA, Lab Plasma Derivat, Div Plasma Prot Therapeut, Off Tissues & Adv Therapies,Ctr Biol Evaluat & Re, Silver Spring, MD 20993 USA		Struble, EB (通讯作者)，US FDA, Lab Plasma Derivat, Div Plasma Prot Therapeut, Off Tissues & Adv Therapies,Ctr Biol Evaluat & Re, Silver Spring, MD 20993 USA.	Yanqun.Xu@fda.hhs.gov; Yong.He@fda.hhs.gov; Sanaz.MombenAbolfath@fda.hhs.gov; nancy.eller@fda.hhs.gov; Malgorzata.Norton@fda.hhs.gov; Pei.Zhang@fda.hhs.gov; Dorothy.Scott@fda.hhs.gov; evi.struble@fda.hhs.gov		struble, evi/0000-0003-2068-4174	Oak Ridge Institute for Science and Education Fellowship	The authors thank Jennifer Reed, PhD, CBER, FDA for helpful discussions and critical input with this project; Maria Rios, PhD, CBER, FDA for helpful discussions and for providing ZIKV PCR standards; Richard Blumberg, MD Brigham and Women's Hospital, Harvard University for providing MDCK/FcRn cell line; Erik Rytting, PhD, University of Texas Medical Branch, for providing BeWo b30 clone line; and Micheal B. Murphy, PhD, from CTytiva for his assistance with Biacore analysis. S.M-A. is recipient of the Oak Ridge Institute for Science and Education Fellowship, administered through an interagency agreement between the U.S. Department of Energy and the FDA.	Abdiche YN, 2015, MABS-AUSTIN, V7, P331, DOI 10.1080/19420862.2015.1008353; Agrelli A, 2019, INFECT GENET EVOL, V69, P22, DOI 10.1016/j.meegid.2019.01.018; Barr KL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004931; Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008; Blumberg LJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax9586; Bode CJ, 2006, METH MOLEC MED, V122, P225; Chung S, 2019, MABS-AUSTIN, V11, P942, DOI 10.1080/19420862.2019.1605270; Claypool SM, 2004, MOL BIOL CELL, V15, P1746, DOI 10.1091/mbc.E03-11-0832; Foss S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02049; Garcia M, 2019, J MOL DIAGN, V21, P1025, DOI 10.1016/j.jmoldx.2019.06.004; Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3; Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006; Hosier H, 2020, J CLIN INVEST, V130, P4947, DOI 10.1172/JCI139569; Kostyuchenko VA, 2016, NATURE, V533, P425, DOI 10.1038/nature17994; Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Neufeldt CJ, 2018, NAT REV MICROBIOL, V16, P125, DOI 10.1038/nrmicro.2017.170; Ovacik M, 2018, CTS-CLIN TRANSL SCI, V11, P540, DOI 10.1111/cts.12567; Pattnaik A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020266; Paul LM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.72; Pyzik M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01540; Rathore APS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3208; Ryman JT, 2017, CPT-PHARMACOMET SYST, V6, P576, DOI 10.1002/psp4.12224; Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517; Screaton G, 2015, NAT REV IMMUNOL, V15, P745, DOI 10.1038/nri3916; Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7; Sridhar S., 2016, EMERG MICROBES INFEC, V5, P1, DOI [10.1038/emi.2016.99, DOI 10.1038/EMI.2016.99]; Tamhankar M, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1200-2; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Zhao X, 2019, CELL, V177, P1553, DOI 10.1016/j.cell.2019.04.035; Zimmerman MG, 2018, CELL HOST MICROBE, V24, P731, DOI 10.1016/j.chom.2018.10.008	31	1	1	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							145	10.3390/vaccines9020145			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7IZ	33670199	Green Published, Green Submitted, gold			2022-04-29	WOS:000623314800001
J	Conty, MLD; Pardilla, MBE; Sanchez, MG; Rodriguez, LG; Muner-Hernando, ML; Vicente, AR; Recarte, PP; Varea, AM; Diago, CM; Melguizo, SC; Martinez-Perez, O				de la Cruz Conty, Maria Luisa; Encinas Pardilla, Maria Begona; Garcia Sanchez, Marta; Gonzalez Rodriguez, Laura; Muner-Hernando, Marta Luisa; Royuela Vicente, Ana; Pintado Recarte, Pilar; Martinez Varea, Alicia; Martinez Diago, Clara; Cruz Melguizo, Sara; Martinez-Perez, Oscar		Spanish Obstet Emergency Grp	Impact of Recommended Maternal Vaccination Programs on the Clinical Presentation of SARS-CoV-2 Infection: A Prospective Observational Study	VACCINES			English	Article						SARS-CoV-2; covid 19; pregnancy; passive immunization; maternal immunization; influenza vaccines; diphtheria tetanus pertussis vaccine		The COVID-19 pandemic has raised questions about the possible cross immunity resulting from common vaccination programs and SARS-CoV-2 infection. Therefore, the Spanish Obstetric Emergency group performed a multicenter prospective study on the vaccination status of Influenza and Tdap (diphtheria, tetanus and pertussis vaccine boost administered in adulthood) in consecutive cases of SARS-CoV-2 infection in a pregnancy cohort, in order to assess its possible association with the clinical presentation and severity of symptoms of SARS-CoV-2 infection, as well as to determine the factors that may affect vaccination adherence. A total of 1150 SARS-CoV-2 positive pregnant women from 78 Spanish hospitals were analyzed: 183 had not received either vaccine, 23 had been vaccinated for Influenza only, 529 for Tdap only and 415 received both vaccines. No association was observed between the vaccination status and the clinical presentation of SARS-CoV-2 infection and/or the severity of symptoms. However, a lower adherence to the administration of both vaccines was observed in the Latin-American subgroup. Based on the results above, we reinforce the importance of maternal vaccination programs in the actual pandemic. Health education campaigns should be specially targeted to groups less likely to participate in these programs, as well as for a future SARS-CoV-2 vaccination campaign.	[de la Cruz Conty, Maria Luisa] Puerta Hierro Univ Hosp Majadahonda, Fdn Invest Biomed, Madrid 28222, Spain; [Encinas Pardilla, Maria Begona; Cruz Melguizo, Sara; Martinez-Perez, Oscar] Puerta Hierro Univ Hosp Majadahonda, Dept Gynecol & Obstet, Madrid 28222, Spain; [Garcia Sanchez, Marta] Quironsalud Malaga Univ Hosp, Dept Gynecol & Obstet, Malaga 29004, Spain; [Gonzalez Rodriguez, Laura] Alvaro Cunqueiro Hosp Vigo, Dept Gynecol & Obstet, Pontevedra 36213, Spain; [Muner-Hernando, Marta Luisa] La Paz Univ Hosp, Dept Gynecol & Obstet, Madrid 28046, Spain; [Royuela Vicente, Ana] Puerta Hierro Biomed Res Inst IDIPHISA CIBERESP, Biostat Unit, Madrid 28222, Spain; [Pintado Recarte, Pilar] Gregorio Maranon Univ Hosp, Dept Gynecol & Obstet, Madrid 28007, Spain; [Martinez Varea, Alicia] La Fe Univ, Dept Gynecol & Obstet, Valencia 46026, Spain; [Martinez Varea, Alicia] Polytech Hosp, Valencia 46026, Spain; [Martinez Diago, Clara] Doctor Josep Trueta Univ Hosp Girona, Dept Gynecol & Obstet, Girona 17007, Spain; [Martinez-Perez, Oscar] Univ Autonoma Madrid, Dept Obstet & Ginecol, Madrid 28029, Spain		Sanchez, MG (通讯作者)，Quironsalud Malaga Univ Hosp, Dept Gynecol & Obstet, Malaga 29004, Spain.	farmcruz@gmail.com; mariabegona.encinas@salud.madrid.org; mgsanchez.mlg@quironsalud.es; Laura.Gonzalez.Rodriguez@sergas.es; martal.muner@salud.madrid.org; aroyuela@idiphim.org; ppintado@salud.madrid.org; martinez_alivar@gva.es; clmartinez.girona.ics@gencat.cat; scruzm@salud.madrid.org; omartinez@ucam.edu	PEREZ, OSCAR MARTINEZ/AAI-5893-2021; MARTINEZ-PEREZ, OSCAR/ABI-6882-2020; García, José Manuel Adánez/AAN-6889-2021; de la Cruz, María Luisa/AAH-6542-2020	PEREZ, OSCAR MARTINEZ/0000-0002-1457-3446; García, José Manuel Adánez/0000-0001-9532-5788; de la Cruz, María Luisa/0000-0002-0206-1750; Prats Rodriguez, Pilar/0000-0001-9216-9118; Martinez Diago, Clara/0000-0003-4268-2524; Puerto Tamayo, Linda Grace/0000-0001-5539-6397; GARCIA SANCHEZ, MARTA/0000-0001-7292-178X; BROULLON MOLANES, JOSE ROMAN/0000-0002-4214-0293	Instituto de Salud Carlos III-Spanish Ministry of Health - Fondo Europeo de Desarrollo Regional (FEDER) funds [COV20/00021]	This research was supported by public funds obtained in competitive calls: Grant COV20/00021 from the Instituto de Salud Carlos III-Spanish Ministry of Health, and co-financed with Fondo Europeo de Desarrollo Regional (FEDER) funds.	[Anonymous], How to protect yourself and others; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Berg MK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1463; COVID-19 Real-Time Learning Network, VACCINES DEV; Doherty M, 2016, VACCINE, V34, P6681, DOI 10.1016/j.vaccine.2016.11.015; Ellington S, 2020, MMWR-MORBID MORTAL W, V69, P769, DOI [10.15585/mmwr.mm6925a1, 10.15585/mmwr.mm6925a1externalicon]; Pardilla MBE, 2020, REV ESP SALUD PUBLIC, V94; Forster AS, 2017, J EPIDEMIOL COMMUN H, V71, P544, DOI 10.1136/jech-2016-207366; Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1; Hoogink J, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08844-w; Huang JS, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.184; Jehi L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237419; Lu PJ, 2014, AM J INFECT CONTROL, V42, P763, DOI 10.1016/j.ajic.2014.03.021; Martinez-Baz I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040611; Miller A., 2020, CORRELATION UNIVERSA, DOI [10.1101 /2020.03.24.20042937, 10.1101/2020.03.24.20042937]; Ministerio de Sanidad Consumo y Bienestar Social, PREG RESP VAC FRENT; Ministerio de Sanidad Consumo y Bienestar Social Gobierno de Espana, COB VAC DAT EST ACT; Ministerio de Sanidad Servicios Sociales e Igualdad Gobierno de Espana, PREG RESP VAC TOSF E; Murillo-Zamora E, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05408-6; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Ortiz-Prado E., 2020, EPIDEMIOLOGICAL SOCI, DOI [10.1101/2020.05.08.20095943v2, DOI 10.1101/2020.05.08.20095943V2]; Poblador-Plou B, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17145171; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Reche PA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586984; Schindler T, 2020, INACTIVATED TRIVALEN, DOI [10.1101/2020.06.29.20142505v1, DOI 10.1101/2020.06.29.20142505V1]; Thomson A, 2018, VACCINE, V36, P6457, DOI 10.1016/j.vaccine.2018.08.031; Verelst F, 2019, VACCINE, V37, P2079, DOI 10.1016/j.vaccine.2019.02.056; WHO, 2013, GLOB VACC ACT PLAN 2; World Health Organization, WHO2019NCOVCLIN20205	30	3	4	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							31	10.3390/vaccines9010031			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6WQ	33429912	Green Published, gold			2022-04-29	WOS:000610812900001
J	McMillan, CLD; Young, PR; Watterson, D; Chappell, KJ				McMillan, Christopher L. D.; Young, Paul R.; Watterson, Daniel; Chappell, Keith J.			The Next Generation of Influenza Vaccines: Towards a Universal Solution	VACCINES			English	Review						influenza; vaccine; universal influenza vaccine; hemagglutinin; pandemic		Influenza viruses remain a constant burden in humans, causing millions of infections and hundreds of thousands of deaths each year. Current influenza virus vaccine modalities primarily induce antibodies directed towards the highly variable head domain of the hemagglutinin protein on the virus surface. Such antibodies are often strain-specific, meaning limited cross-protection against divergent influenza viruses is induced, resulting in poor vaccine efficacy. To attempt to counteract this, yearly influenza vaccination with updated formulations containing antigens from more recently circulating viruses is required. This is an expensive and time-consuming exercise, and the constant arms race between host immunity and virus evolution presents an ongoing challenge for effective vaccine development. Furthermore, there exists the constant pandemic threat of highly pathogenic avian influenza viruses with high fatality rates (similar to 30-50%) or the emergence of new, pathogenic reassortants. Current vaccines would likely offer little to no protection from such viruses in the event of an epidemic or pandemic. This highlights the urgent need for improved influenza virus vaccines capable of providing long-lasting, robust protection from both seasonal influenza virus infections as well as potential pandemic threats. In this narrative review, we examine the next generation of influenza virus vaccines for human use and the steps being taken to achieve universal protection.	[McMillan, Christopher L. D.; Young, Paul R.; Watterson, Daniel; Chappell, Keith J.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Young, Paul R.; Chappell, Keith J.] Univ Queensland, Australian Inst Biotechnol & Nanotechnol, St Lucia, Qld 4072, Australia; [Young, Paul R.; Watterson, Daniel; Chappell, Keith J.] Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld 4072, Australia		McMillan, CLD; Chappell, KJ (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.; Chappell, KJ (通讯作者)，Univ Queensland, Australian Inst Biotechnol & Nanotechnol, St Lucia, Qld 4072, Australia.; Chappell, KJ (通讯作者)，Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld 4072, Australia.	c.mcmillan1@uq.edu.au; p.young@uq.edu.au; d.watterson@uq.edu.au; k.chappell@uq.edu.au	Young, Paul R/A-6176-2010	Young, Paul R/0000-0002-2040-5190; McMillan, Christopher/0000-0002-5316-0986			Alcock R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000490; Allen JD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204284; Ana-Sosa-Batiz F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154461; Andersson AMC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046395; Asha K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020192; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Bianchi E, 2005, J VIROL, V79, P7380, DOI 10.1128/JVI.79.12.7380-7388.2005; Bolduc M, 2018, NANOMED-NANOTECHNOL, V14, P2563, DOI 10.1016/j.nano.2018.08.010; Bommakanti G, 2012, J VIROL, V86, P13434, DOI 10.1128/JVI.01429-12; Bosch BJ, 2010, J VIROL, V84, P10366, DOI 10.1128/JVI.01035-10; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Bragstad K, 2013, VACCINE, V31, P2281, DOI 10.1016/j.vaccine.2013.02.061; Braucher DR, 2012, CLIN VACCINE IMMUNOL, V19, P1722, DOI 10.1128/CVI.00315-12; Broecker F, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0126-4; Cardoso FM, 2014, J VIROL, V88, P8278, DOI 10.1128/JVI.03178-13; Carignan D, 2015, VACCINE, V33, P7245, DOI 10.1016/j.vaccine.2015.10.123; Carter DM, 2016, J VIROL, V90, P4720, DOI 10.1128/JVI.03152-15; Chen MW, 2008, P NATL ACAD SCI USA, V105, P13538, DOI 10.1073/pnas.0806901105; Choi EJ, 2017, INFECT CHEMOTHER, V49, P117, DOI 10.3947/ic.2017.49.2.117; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Corti D, 2010, J CLIN INVEST, V120, P1663, DOI 10.1172/JCI41902; De Filette M, 2008, J BIOL CHEM, V283, P11382, DOI 10.1074/jbc.M800650200; Deng L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02725-4; Deroo T, 1996, VACCINE, V14, P561, DOI 10.1016/0264-410X(95)00157-V; DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Doyle TM, 2013, ANTIVIR RES, V100, P567, DOI 10.1016/j.antiviral.2013.09.018; Dreyfus C, 2012, SCIENCE, V337, P1343, DOI 10.1126/science.1222908; Dunand CJH, 2016, CELL HOST MICROBE, V19, P800, DOI 10.1016/j.chom.2016.05.014; Ellebedy AH, 2014, P NATL ACAD SCI USA, V111, P13133, DOI 10.1073/pnas.1414070111; Epstein SL, 2005, VACCINE, V23, P5404, DOI 10.1016/j.vaccine.2005.04.047; Ermler ME, 2017, J VIROL, V91, DOI 10.1128/JVI.00286-17; Fan JA, 2004, VACCINE, V22, P2993, DOI 10.1016/j.vaccine.2004.02.021; Feng JQ, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-102; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Fleeton MN, 2001, J INFECT DIS, V183, P1395, DOI 10.1086/319857; Florek NW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181738; Giles BM, 2012, J INFECT DIS, V205, P1562, DOI 10.1093/infdis/jis232; Giles BM, 2011, VACCINE, V29, P3043, DOI 10.1016/j.vaccine.2011.01.100; Grant E, 2013, IMMUNOL CELL BIOL, V91, P184, DOI 10.1038/icb.2012.78; Hai R, 2012, J VIROL, V86, P5774, DOI 10.1128/JVI.00137-12; Hashemi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045765; Hause BM, 2014, MBIO, V5, DOI 10.1128/mBio.00031-14; He F, 2016, EXPERT REV VACCINES, V15, P215, DOI 10.1586/14760584.2016.1115352; Hekele A, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.54; Herrera-Rodriguez J, 2018, VIROLOGY, V515, P21, DOI 10.1016/j.virol.2017.11.018; Hessel A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088340; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Hoelscher MA, 2006, LANCET, V367, P475, DOI 10.1016/S0140-6736(06)68076-8; Hohenadl C., 2011, J. Infect. Dis, V205, P28, DOI 10.1093/infdis/jir711; Holman DH, 2008, VACCINE, V26, P2627, DOI 10.1016/j.vaccine.2008.02.053; Howley P.M., 2013, FIELDS VIROLOGY, V6th; Huber VC, 2009, VACCINE, V27, P1192, DOI 10.1016/j.vaccine.2008.12.023; Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062; Ichihashi T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024626; Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263; Ibanez LI, 2018, VACCINE, V36, P1592, DOI 10.1016/j.vaccine.2018.02.019; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Johansson BE, 1998, VACCINE, V16, P1009, DOI 10.1016/S0264-410X(97)00279-X; JOHANSSON BE, 1989, J VIROL, V63, P1239, DOI 10.1128/JVI.63.3.1239-1246.1989; Kallewaard NL, 2016, CELL, V166, P596, DOI 10.1016/j.cell.2016.05.073; Kamlangdee A, 2014, J VIROL, V88, P13300, DOI 10.1128/JVI.01532-14; Kim Joo Young, 2013, Immune Netw, V13, P275, DOI 10.4110/in.2013.13.6.275; Kim MC, 2013, ANTIVIR RES, V99, P328, DOI 10.1016/j.antiviral.2013.06.010; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Koday MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189780; Kovesdi I, 2010, VIRUSES-BASEL, V2, P1681, DOI 10.3390/v2081681; Krammer F, 2018, MBIO, V9, DOI 10.1128/mBio.02332-17; Krammer F, 2014, J VIROL, V88, P2340, DOI 10.1128/JVI.03183-13; Krammer F, 2013, J VIROL, V87, P6542, DOI [10.1128/JVI.00641-13, 10.1128/JVI.03183-13]; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; Lu Y, 2014, P NATL ACAD SCI USA, V111, P125, DOI 10.1073/pnas.1308701110; Mallajosyula VVA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00329; Mallajosyula VVA, 2014, P NATL ACAD SCI USA, V111, pE2514, DOI 10.1073/pnas.1402766111; Manz B, 2016, J VIROL, V90, P5928, DOI 10.1128/JVI.00130-16; Margine I, 2013, J VIROL, V87, P4728, DOI 10.1128/JVI.03509-12; Martinet W, 1997, EUR J BIOCHEM, V247, P332, DOI 10.1111/j.1432-1033.1997.00332.x; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195; Mullarkey CE, 2016, MBIO, V7, DOI 10.1128/mBio.01624-16; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nachbagauer R, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.15; Nachbagauer R, 2014, J VIROL, V88, P13260, DOI 10.1128/JVI.02133-14; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Noh JY, 2013, INFECT CHEMOTHER, V45, P375, DOI 10.3947/ic.2013.45.4.375; Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0; Park KS, 2011, VACCINE, V29, P5481, DOI 10.1016/j.vaccine.2011.05.062; Park Min-Hee, 2012, Immune Netw, V12, P261, DOI 10.4110/in.2012.12.6.261; Partridge J, 2013, VACCINE, V31, P728, DOI 10.1016/j.vaccine.2012.10.111; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Pica N, 2013, ANNU REV MED, V64, P189, DOI [10.1146/annurev-med-120611-145115, 10.1146/annure]; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Price GE, 2009, VACCINE, V27, P6512, DOI 10.1016/j.vaccine.2009.08.053; Ramos EL, 2015, J INFECT DIS, V211, P1038, DOI 10.1093/infdis/jiu539; Rao SS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009812; Robinson Harriet L., 1997, Journal of Infectious Diseases, V176, pS50, DOI 10.1086/514176; ROBINSON HL, 1993, VACCINE, V11, P957, DOI 10.1016/0264-410X(93)90385-B; Rockman S, 2013, J VIROL, V87, P3053, DOI 10.1128/JVI.02434-12; Roy CJ, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-153; Shoji Y, 2011, HUM VACCINES, V7, P199, DOI 10.4161/hv.7.0.14595; Smith LR, 2010, VACCINE, V28, P2565, DOI 10.1016/j.vaccine.2010.01.029; Srivastava V, 2013, J VIROL, V87, P5831, DOI 10.1128/JVI.00273-13; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Sui ZW, 2010, VACCINE, V28, P7690, DOI 10.1016/j.vaccine.2010.09.019; Sun WN, 2019, J VIROL, V93, DOI 10.1128/JVI.00333-19; Tang M, 2002, ARCH VIROL, V147, P2125, DOI 10.1007/s00705-002-0870-y; Tao WQ, 2017, ANTIVIR RES, V141, P62, DOI 10.1016/j.antiviral.2017.01.021; Thomson CA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00087; Tidona C., 2012, SPRINGER INDEX VIRUS; Tompkins SM, 2007, EMERG INFECT DIS, V13, P426, DOI 10.3201/eid1303.061125; U.S. Food and Drug Administration, INFL VIR VACC 2014 2; Uddback IEM, 2016, SCI REP-UK, V6, DOI 10.1038/srep35033; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Valkenburg SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep22666; Vemula SV, 2010, EXPERT OPIN BIOL TH, V10, P1469, DOI 10.1517/14712598.2010.519332; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Wan HQ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7114; Wang SC, 2019, VIROLOGY, V526, P125, DOI 10.1016/j.virol.2018.10.005; Wang TT, 2010, P NATL ACAD SCI USA, V107, P18979, DOI 10.1073/pnas.1013387107; Wang TT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000796; Wang WL, 2015, CLIN VACCINE IMMUNOL, V22, P618, DOI 10.1128/CVI.00091-15; Weaver EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073313; Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wohlbold TJ, 2015, VACCINE, V33, P3314, DOI 10.1016/j.vaccine.2015.05.038; Wold WSM, 2013, CURR GENE THER, V13, P421; Wong FYK, 2015, EMERG INFECT DIS, V21, P511, DOI 10.3201/eid2103.141488; World Health Organisation, CUM NUMB CONF HUM CA; World Health Organisation, INFL SEAS; World Health Organisation, INFL SEAS FACT SHEET; Xiong FF, 2020, EMERG MICROBES INFEC, V9, P78, DOI 10.1080/22221751.2019.1708214; Yamaji R, 2015, J VIROL, V89, P3947, DOI 10.1128/JVI.03328-14; Yan J, 2018, VACCINE, V36, P3079, DOI 10.1016/j.vaccine.2017.09.086; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Zhou DM, 2010, MOL THER, V18, P2182, DOI 10.1038/mt.2010.202	135	9	9	3	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							26	10.3390/vaccines9010026			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6XM	33430278	Green Published, gold			2022-04-29	WOS:000610815100001
J	Cao, H; Wang, YF; Luan, N; Lin, KY; Liu, CB				Cao, Han; Wang, Yunfei; Luan, Ning; Lin, Kangyang; Liu, Cunbao			Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy	VACCINES			English	Article						varicella zoster virus; glycoprotein E; carboxyl-terminal mutation; mRNA vaccine; cell-mediated immunity	TRANS-GOLGI NETWORK; T-CELL RESPONSES; HERPES-ZOSTER; VIRAL REPLICATION; SUBUNIT VACCINE; VZV; IMMUNOGENICITY; GE; PROTECTION; DOMAIN	Glycoprotein E (gE) is one of the most abundant glycoproteins in varicella-zoster virus and plays pivotal roles in virus replication and transmission between ganglia cells. Its extracellular domain has been successfully used as an antigen in subunit zoster vaccines. The intracellular C-terminal domain was reported to be decisive for gE trafficking between the endoplasmic reticulum, trans-Golgi network and endosomes and could influence virus spread and virus titers. Considering that the trafficking and distribution of mRNA vaccine-translated gE may be different from those of gE translated against the background of the viral genome (e.g., most gE in virus-infected cells exists as heterodimers with another glycoprotein, gI,), which may influence the immunogenicity of gE-based mRNA vaccines, we compared the humoral and cellular immunity induced by LNP-encapsulated mRNA sequences encoding the whole length of gE, the extracellular domain of gE and a C-terminal double mutant of gE (mutant Y569A with original motif AYRV, which targets gE to TGN, and mutants S593A, S595A, T596A and T598A with the original motif SSTT) that were reported to enhance virus spread and elevate virus titers. The results showed that while the humoral and cellular immunity induced by all of the mRNA vaccines was comparable to or better than that induced by the AS01B-adjuvanted subunit vaccines, the C-terminal double mutant of gE showed stable advantages in all of the indicators tested, including gE-specific IgG titers and T cell responses, and could be adopted as a candidate for both safer varicella vaccines and effective zoster vaccines.	[Cao, Han; Wang, Yunfei; Luan, Ning; Lin, Kangyang; Liu, Cunbao] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China		Liu, CB (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.	caohan@imbcams.com.cn; wangyf@imbcams.com; luanning@imbcams.com.cn; linky6679@163.com; cunbao_liu@163.com		Liu, Cunbao/0000-0002-2101-2612	CAMS Initiative for Innovative Medicine [2021-I2M-1-043]; Major Science and Technology Special Projects of Yunnan Province, China [202002AA100009]; China Health and Longevity Innovation Competition [2021-JKCS-012]; Special Biomedicine Projects of Yunnan Province [202102AA310035]; Basic Research Projects of Yunnan Province [202101AT070286]; Funds for the Training of High-Level Health Technical Personnel in Yunnan Province [H-2019063]; Funds for High-Level Scientific and Technological Talents Selection Special Project of Yunnan Province	This work was supported by the CAMS Initiative for Innovative Medicine (grant number 2021-I2M-1-043), the Major Science and Technology Special Projects of Yunnan Province, China (grant number 202002AA100009), the China Health and Longevity Innovation Competition (2021-JKCS-012), the Special Biomedicine Projects of Yunnan Province (202102AA310035), the Basic Research Projects of Yunnan Province (202101AT070286), the Funds for the Training of High-Level Health Technical Personnel in Yunnan Province (grant number H-2019063) and the Funds for High-Level Scientific and Technological Talents Selection Special Project of Yunnan Province.	Arruti M, 2017, J NEUROVIROL, V23, P451, DOI 10.1007/s13365-017-0519-y; Asada H, 2019, VACCINE, V37, P6776, DOI 10.1016/j.vaccine.2019.09.031; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Berarducci B, 2006, J VIROL, V80, P9481, DOI 10.1128/JVI.00533-06; Breuer J, 2018, J INFECT DIS, V218, pS75, DOI 10.1093/infdis/jiy279; Cao H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040310; Chlibek R, 2013, J INFECT DIS, V208, P1953, DOI 10.1093/infdis/jit365; Cohen JI, 2015, NEW ENGL J MED, V372, P2149, DOI 10.1056/NEJMe1505050; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095; Dendouga N, 2012, VACCINE, V30, P3126, DOI 10.1016/j.vaccine.2012.01.088; GarciaValcarcel M, 1997, VACCINE, V15, P709, DOI 10.1016/S0264-410X(96)00228-9; GERSHON AA, 1994, J VIROL, V68, P6372, DOI 10.1128/JVI.68.10.6372-6390.1994; Gilbert PB, 2014, J INFECT DIS, V210, P1573, DOI 10.1093/infdis/jiu279; Gilderman LI, 2008, CLIN VACCINE IMMUNOL, V15, P314, DOI 10.1128/CVI.00310-07; Haberthur K, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002367; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Krause PR, 2000, NAT MED, V6, P451, DOI 10.1038/74715; Levin MJ, 2017, EXPERT REV VACCINES, V16, P1217, DOI 10.1080/14760584.2017.1395703; Liu CB, 2021, VACCINE, V39, P263, DOI 10.1016/j.vaccine.2020.12.005; Liu CB, 2018, INT J PHARMACEUT, V553, P327, DOI 10.1016/j.ijpharm.2018.10.054; Malavige GN, 2008, CLIN EXP IMMUNOL, V152, P522, DOI 10.1111/j.1365-2249.2008.03633.x; Mo CJ, 2002, VIROLOGY, V304, P176, DOI 10.1006/viro.2002.1556; Mo CJ, 2000, J VIROL, V74, P11377, DOI 10.1128/JVI.74.23.11377-11387.2000; Moffat J, 2004, J VIROL, V78, P12406, DOI 10.1128/JVI.78.22.12406-12415.2004; Monslow MA, 2020, VACCINE, V38, P5793, DOI 10.1016/j.vaccine.2020.06.062; Olson JK, 1997, J VIROL, V71, P4042, DOI 10.1128/JVI.71.5.4042-4054.1997; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Richner JM, 2017, CELL, V169, P176, DOI 10.1016/j.cell.2017.03.016; Roberts AD, 2005, J EXP MED, V202, P123, DOI 10.1084/jem.20050137; Sckisel GD, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0235-4; Steain M, 2014, J VIROL, V88, P2704, DOI 10.1128/JVI.03445-13; Upadhyay S, 2018, PLANTA, V248, P519, DOI 10.1007/s00425-018-2911-0; Wang PF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030222; Wang YF, 2021, VIROL SIN, V36, P122, DOI 10.1007/s12250-020-00261-y; Wang ZH, 2000, J VIROL, V74, P6600, DOI 10.1128/JVI.74.14.6600-6613.2000; Wang ZH, 2001, J VIROL, V75, P323, DOI 10.1128/JVI.75.1.323-340.2001; Weinberg A, 2010, CURR TOP MICROBIOL, V342, P341, DOI 10.1007/82_2010_31; Wui SR, 2019, VACCINE, V37, P2131, DOI 10.1016/j.vaccine.2019.02.048; Xu SQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186582; Zerboni L, 2014, NAT REV MICROBIOL, V12, P197, DOI 10.1038/nrmicro3215; Zhu ZL, 1996, J VIROL, V70, P6563, DOI 10.1128/JVI.70.10.6563-6575.1996	45	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1440	10.3390/vaccines9121440			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1MN	34960186	Green Published, gold			2022-04-29	WOS:000737424600001
J	Lim, SH; Choi, SH; Kim, B; Kim, JY; Ji, YS; Kim, SH; Kim, CK; Kim, T; Choo, EJ; Moon, JE; Yun, J; Park, SK				Lim, Sung-Hee; Choi, Seong-Hyeok; Kim, Bora; Kim, Ji-Youn; Ji, Young-Sok; Kim, Se-Hyung; Kim, Chan-Kyu; Kim, Tark; Choo, Eun-Ju; Moon, Ji-Eun; Yun, Jina; Park, Seong-Kyu			Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine	VACCINES			English	Article						ChAdOx1; BNT162b2; SARS-CoV-2 vaccines; neutralizing antibodies immunogenicity		The COVID-19 pandemic is changing rapidly and requires different strategies to maintain immunization. In Korea, different COVID-19 vaccines are recommended and available for various populations, including healthcare workers (HCWs) at high risk of SARS-CoV-2 infection. We plan to evaluate the adverse events (AEs) and immunogenicity of the BNT162b2 and ChAdOx1 vaccines in HCWs at a single center. This cohort study included HCWs fully vaccinated with either BNT162b2 or ChAdOx1. Blood samples were taken eight weeks after the second vaccination with both COVID-19 vaccines and six months after the second vaccination from participants with the BNT162b2 vaccine. The primary endpoint for immunogenicity was the serum neutralizing antibody responses eight weeks after vaccination. The secondary endpoint was the incidence of various AEs within 28 days of each vaccination. Between 16 March and 23 June 2021, 115 participants were enrolled (65 in the ChAdOx1 group and 50 in the BNT162b2 group). Significantly higher surrogate virus neutralization test (sVNT) inhibition was observed in participants vaccinated with two doses of BNT162b2 (mean (SD) 91.4 (9.68)%) than in those vaccinated with ChAdOx1 (mean (SD) 73.3 (22.57)%). The effectiveness of the BNT162b2 vaccine was maintained across all age and gender categories. At six months after the second dose, serum antibody levels declined significantly in the BNT162b2 group. The main adverse events, including fever, myalgia, fatigue, and headache, were significantly higher in the ChAdOx1 group after the first dose, whereas, after the second dose, those AEs were significantly higher in the BNT162b2 group (p < 0.05). Two doses of either the ChAdOx1 or the BNT162b2 COVID-19 vaccine resulted in very high seropositivity among the HCWs at our center. The quality of the antibody response, measured by sVNT inhibition, was significantly better with the BNT162b2 vaccine than with the ChAdOx1 vaccine. There was no significant association between neutralizing antibody response and AE after each vaccination in our cohort.	[Lim, Sung-Hee; Choi, Seong-Hyeok; Kim, Bora; Kim, Ji-Youn; Ji, Young-Sok; Kim, Se-Hyung; Kim, Chan-Kyu; Yun, Jina; Park, Seong-Kyu] Soonchunhyang Univ, Bucheon Hosp, Dept Med, Div Hematol Oncol, Bucheon 14584, South Korea; [Kim, Tark; Choo, Eun-Ju] Soonchunhyang Univ, Bucheon Hosp, Dept Med, Div Infect Dis, Bucheon 14584, South Korea; [Moon, Ji-Eun] Soonchunhyang Univ, Bucheon Hosp, Dept Biostat, Bucheon 14584, South Korea		Yun, J; Park, SK (通讯作者)，Soonchunhyang Univ, Bucheon Hosp, Dept Med, Div Hematol Oncol, Bucheon 14584, South Korea.	polluxis82@gmail.com; 20210225@schmc.ac.kr; 20161294@schmc.ac.kr; banji79@schmc.ac.kr; 106258@schmc.ac.kr; shkim@schmc.ac.kr; md53097@schmc.ac.kr; ktocc@schmc.ac.kr; mdchoo@schmc.ac.kr; moon6188@schmc.ac.kr; 19983233@schmc.ac.kr; skpark@schmc.ac.kr		Moon, jieun/0000-0002-7293-7463; Yun, Jina/0000-0001-5897-8309; Choo, Eun Ju/0000-0003-2842-7041; Kim, Chankyu/0000-0002-1517-9950	Soonchunhyang University Bucheon Hospital Research Fund [20190627]; Soonchunhyang University Research Fund [2021]	This work was supported by the Soonchunhyang University Bucheon Hospital Research Fund (No. 20190627) and Soonchunhyang University Research Fund (2021).	Addetia A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02107-20; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bosnjak B, 2021, CELL MOL IMMUNOL, V18, P936, DOI 10.1038/s41423-020-00573-9; CDC (Central Disease Control), 2021, COR COVID 19 DASHB; Chen N., 2020, The Lancet, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chia WN, 2021, LANCET MICROBE, V2, pE240, DOI 10.1016/S2666-5247(21)00025-2; Cox RJ, 2020, NAT REV IMMUNOL, V20, P581, DOI 10.1038/s41577-020-00436-4; Hinton R.D.M., 2021, CONVALESCENT PLASMA; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kim T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060648; Naaber P, 2021, LANCET REG HEALTH-EU, V10, DOI 10.1016/j.lanepe.2021.100208; Padoan A, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103101; Park JY, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132844; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Taylor SC, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02438-20; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1	18	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1379	10.3390/vaccines9121379			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2LB	34960125	gold, Green Published			2022-04-29	WOS:000737488400001
J	Wieteska-Milek, M; Szmit, S; Florczyk, M; Kusmierczyk-Droszcz, B; Ryczek, R; Kurzyna, M				Wieteska-Milek, Maria; Szmit, Sebastian; Florczyk, Michal; Kusmierczyk-Droszcz, Beata; Ryczek, Robert; Kurzyna, Marcin			COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination	VACCINES			English	Article						pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension; COVID-19 vaccine; vaccination; post-vaccination symptoms; safety	HOSPITAL ANXIETY; IMPACT	The incidence of COVID-19 infection in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is similar to that in the general population, but the mortality rate is much higher. COVID-19 vaccination is strongly recommended for PAH/CTEPH patients. The aim of our cross-sectional study was to identify reasons why PAH/CTEPH patients refused vaccination against COVID-19. Moreover, we assessed the safety profile of approved COVID-19 vaccines in PAH/CTEPH patients. We examined 261 patients (164 PAH patients and 97CTEPH patients) with a median age of 60 (18-92) years, 62% of which were female. Sixty-one patients (23%) refused to be vaccinated. The main reason for unwillingness to be vaccinated was anxiety about adverse events (AEs, 61%). Age and fear of COVID-19 in the univariate analysis and age >= 60 years in the multivariate regression analysis were factors that impacted willingness to be vaccinated (OR = 2.5; p = 0.005). AEs were reported in 61% of vaccinated patients after the first dose and in 40.5% after the second dose (p = 0.01). The most common reported AEs were pain at the injection site (54.5%), fever (22%), fatigue (21%), myalgia (10.5%), and headache (10%). A lower percentage of AEs was reported in older patients (OR = 0.3; p = 0.001). The COVID-19 vaccines are safe for PAH/CTEPH patients. The results obtained in this study may encourage patients of these rare but severe cardio-pulmonary diseases to get vaccinated against COVID-19.	[Wieteska-Milek, Maria; Szmit, Sebastian; Florczyk, Michal; Kurzyna, Marcin] European Hlth Ctr, Ctr Postgrad Med Educ, Dept Pulm Circulat Thromboembol Dis & Cardiol, PL-05400 Otwock, Poland; [Kusmierczyk-Droszcz, Beata] Natl Inst Cardiol, Dept Congenital Heart Dis, PL-04628 Warsaw, Poland; [Ryczek, Robert] Mil Inst Med, Dept Cardiol & Internal Dis, PL-04349 Warsaw, Poland		Wieteska-Milek, M (通讯作者)，European Hlth Ctr, Ctr Postgrad Med Educ, Dept Pulm Circulat Thromboembol Dis & Cardiol, PL-05400 Otwock, Poland.	mwiet@mp.pl; sszmit@cmkp.edu.pl; michal_florczyk@wp.pl; bkusmier@gmail.com; raryczek@gmail.com; mkurzyna@cmkp.edu.pl	; Kurzyna, Marcin/AAA-1244-2020	Wieteska, Maria/0000-0001-6848-5698; Kurzyna, Marcin/0000-0002-6746-469X; Florczyk, Michal/0000-0003-4995-9645	Centre of Postgraduate Medical Education in Poland [501-1-054-25-21]	This research was funded by the Centre of Postgraduate Medical Education in Poland, grant number 501-1-054-25-21.	Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8; Babicki M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050503; Belge C, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00520-2020; Bhatia RT, 2021, EUR HEART J, V42, P215, DOI 10.1093/eurheartj/ehaa742; Breathnach AS, 2021, J INFECTION, V82, pE11, DOI 10.1016/j.jinf.2021.01.005; Brodziak A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050411; Chudasama YV, 2020, DIABETES METAB SYND, V14, P965, DOI 10.1016/j.dsx.2020.06.042; Driggin E, 2021, J AM COLL CARDIOL, V77, P1938, DOI 10.1016/j.jacc.2021.02.017; Ford GA, 2021, EUR HEART J-QUAL CAR, V7, P526, DOI 10.1093/ehjqcco/qcab061; Galie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317; Girerd N, 2021, J CLIN MED, V10, DOI 10.3390/jcm10194311; Godinas L, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-01752-1; Hanrath AT, 2021, J INFECTION, V82, pE29, DOI 10.1016/j.jinf.2020.12.023; Hatmal MM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060556; Kaur RJ, 2021, INDIAN J CLIN BIOCHE, V36, P427, DOI 10.1007/s12291-021-00968-z; Kopec G, 2021, THER ADV CHRONIC DIS, V12, DOI 10.1177/20406223211002961; Kopec G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010173; Lee JD, 2020, ANN AM THORAC SOC, V17, P1576, DOI 10.1513/AnnalsATS.202005-521OC; Oehler D, 2021, TRANSPL INFECT DIS, DOI 10.1111/tid.13681; Pilch I, 2021, PEERJ, V9, DOI 10.7717/peerj.11263; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Raciborski F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091000; Roncalli J, 2021, ARCH CARDIOVASC DIS, V114, P434, DOI 10.1016/j.acvd.2021.04.004; Sigorski D, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000970; Statistics and Research, COR COVID 19 VACC; Szarowska A, 2021, POL ARCH INTERN MED, V131, P101, DOI 10.20452/pamw.15734; Wall Caroline, 2016, J Intensive Care Soc, V17, P160, DOI 10.1177/1751143715618683; Website of the Republic of Poland, NARODOWY PROGRAM SZC; Wichowicz HM, 2011, PSYCHIATR POL, V45, P505; Wieteska M, 2016, CLIN APPL THROMB-HEM, V22, P92, DOI 10.1177/1076029614536604; Wieteska-Milek M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10184195; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Yuan Ping, 2020, medRxiv, DOI 10.1101/2020.11.03.20224998; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	34	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1395	10.3390/vaccines9121395			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	0G9VI	34960141	Green Published, gold			2022-04-29	WOS:000778388900001
J	Forgeschi, G; Cavallo, G; Lorini, C; Balboni, F; Sequi, F; Bonaccorsi, G				Forgeschi, Guglielmo; Cavallo, Giuseppe; Lorini, Chiara; Balboni, Fiamma; Sequi, Francesca; Bonaccorsi, Guglielmo			Investigating Adherence to COVID-19 Vaccination and Serum Antibody Concentration among Hospital Workers-The Experience of an Italian Private Hospital	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccine hesitancy; vaccine adherence; anti-S antibodies	HESITANCY; INTENTION	SARS-CoV-2 transmission has been high, especially among healthcare workers worldwide during the first wave. Vaccination is recognized as the most effective approach to combat the pandemic, but hesitation to get vaccinated represents an obstacle. Another important issue is the duration of protection after administration of the full vaccination cycle. Based on these premises, we conducted a study to evaluate vaccination adherence and the anti-S antibodies levels among hospital workers, from January to March, 2021. To assess adherence, an anonymous questionnaire was used. Anti-S antibody levels were obtained from the monitoring serological sample database. In total, 56.2% of the unvaccinated people did not report a previous infection from COVID-19. Among those who have not been vaccinated, 12.5% showed distrust against the vaccine, 8.3% stated to have received contraindications to the vaccination, and 6.3% did not report any choice. Analyzing anti-S antibody levels, only one person was found to have a value below the lower cut-off, two weeks, and three months after receiving their second dose. One was below the cut-off after two weeks, and then above the same cut-off after three months. The results of our survey should be seen as a stimulus to further sensitize hospital staff to the importance of vaccination and pay attention to anti-S antibody levels monitoring.	[Forgeschi, Guglielmo; Balboni, Fiamma; Sequi, Francesca] Ist Fiorentino Cura & Assistenza SpA IFCA, Via Pergolino 4, I-50139 Florence, Italy; [Cavallo, Giuseppe; Lorini, Chiara; Bonaccorsi, Guglielmo] Univ Florence, Dept Hlth Sci, Viale GB Morgagni 48, I-50134 Florence, Italy		Cavallo, G (通讯作者)，Univ Florence, Dept Hlth Sci, Viale GB Morgagni 48, I-50134 Florence, Italy.	giuseppe.cavallo@unifi.it; chiara.lorini@unifi.it; fiamma.balboni@hotmail.it; guglielmo.bonaccorsi@unifi.it		Lorini, Chiara/0000-0003-3170-1857; CAVALLO, GIUSEPPE/0000-0002-6171-5101; bonaccorsi, guglielmo/0000-0002-5171-4308			Al-Kuwari MG, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.679254; Habas K, 2020, EXPERT REV ANTI-INFE, V18, P1201, DOI 10.1080/14787210.2020.1797487; Higgins V, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.03149-20; Islam MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251605; Joshi A, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.698111; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Perkmann T, 2020, CLIN CHEM, V66, P1405, DOI 10.1093/clinchem/hvaa198; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Porto MH, 2021, INT J INFECT DIS, DOI DOI 10.1016/J.IJID.2021.06.010; Ran L, 2020, CLIN INFECT DIS, V71, P2218, DOI 10.1093/cid/ciaa287; Shahcheraghi SH, 2021, THER DELIV, V12, P235, DOI 10.4155/tde-2020-0129; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Aurilio MT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050500; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021	15	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1332	10.3390/vaccines9111332			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH1TQ	34835263	Green Published, gold			2022-04-29	WOS:000725224900001
J	Hayawi, K; Shahriar, S; Serhani, MA; Alashwal, H; Masud, MM				Hayawi, Kadhim; Shahriar, Sakib; Serhani, Mohamed Adel; Alashwal, Hany; Masud, Mohammad M.			Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review	VACCINES			English	Review						SARS-CoV-2; variants of concern; vaccine effectiveness; COVID-19; vaccine efficacy	NCOV-19 AZD1222 VACCINE; INFECTION; EFFICACY; IMPACT; EPIDEMIC; WORKERS	Background: With the emergence and spread of new SARS-CoV-2 variants, concerns are raised about the effectiveness of the existing vaccines to protect against these new variants. Although many vaccines were found to be highly effective against the reference COVID-19 strain, the same level of protection may not be found against mutation strains. The objective of this study is to systematically review relevant studies in the literature and compare the efficacy of COVID-19 vaccines against new variants. Methods: We conducted a systematic review of research published in Scopus, PubMed, and Google Scholar until 30 August 2021. Studies including clinical trials, prospective cohorts, retrospective cohorts, and test negative case-controls that reported vaccine effectiveness against any COVID-19 variants were considered. PRISMA recommendations were adopted for screening, eligibility, and inclusion. Results: 129 unique studies were reviewed by the search criteria, of which 35 met the inclusion criteria. These comprised of 13 test negative case-control studies, 6 Phase 1-3 clinical trials, and 16 observational studies. The study location, type, vaccines used, variants considered, and reported efficacies were highlighted. Conclusion: Full vaccination (two doses) offers strong protection against Alpha (B.1.1.7) with 13 out of 15 studies reporting more than 84% efficacy. The results are not conclusive against the Beta (B.1.351) variant for fully vaccinated individuals with 4 out of 7 studies reporting efficacies between 22 and 60% and 3 out of 7 studies reporting efficacies between 75 and 100%. Protection against Gamma (P.1) variant was lower than 50% according to two studies in fully vaccinated individuals. The data on Delta (B.1.617.2) variant is limited but indicates lower protection compared to other variants.	[Hayawi, Kadhim; Shahriar, Sakib] Zayed Univ, Coll Technol Innovat, Abu Dhabi 51133, U Arab Emirates; [Serhani, Mohamed Adel; Alashwal, Hany; Masud, Mohammad M.] UAE Univ, Coll Informat Technol, Abu Dhabi 15551, U Arab Emirates		Serhani, MA (通讯作者)，UAE Univ, Coll Informat Technol, Abu Dhabi 15551, U Arab Emirates.	sakib.shahriar@zu.ac.ae		Hayawi, Abdul Kadhim/0000-0002-8092-4590; Serhani, Mohamed Adel/0000-0001-7001-3710	Zayed University [RIF R20132]; Zayed Center for Health Science, UAE University [12R005]	FundingThis work was supported by both Zayed University under the research grant RIF R20132 and Zayed Center for Health Science, UAE University under grant # 12R005.	Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Betti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060592; Bordon Y, 2021, NAT REV IMMUNOL, V21, P274, DOI 10.1038/s41577-021-00548-5; CDC, 2020, COR DIS 2019 COVID 1; Chandir S, 2020, VACCINE, V38, P7146, DOI 10.1016/j.vaccine.2020.08.019; Charmet T, 2021, LANCET REG HEALTH-EU, V8, DOI 10.1016/j.lanepe.2021.100171; Chemaitelly H, 2021, NAT MED, V27, P1614, DOI 10.1038/s41591-021-01446-y; Chung H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1943; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Duerr R, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI152702; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Flacco ME, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060628; Fontanet A, 2021, LANCET, V397, P952, DOI 10.1016/S0140-6736(21)00370-6; Fowlkes A, 2021, MMWR-MORBID MORTAL W, V70, P1167, DOI 10.15585/mmwr.mm7034e4; Gustafson CE, 2020, J ALLERGY CLIN IMMUN, V145, P1309, DOI 10.1016/j.jaci.2020.03.017; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Hall VJ., 2021, SSRN ELECT J, DOI [10.2139/ssrn.3790399, DOI 10.2139/SSRN.3790399]; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Herlihy R, 2021, MMWR-MORBID MORTAL W, V70, P1084, DOI 10.15585/mmwr.mm7032e2; Hitchings MDT., 2021, LANCET REG HLTH AM, P100025, DOI [10.1016/j.lana.2021.100025, DOI 10.1016/J.LANA.2021.100025]; Hoy D, 2012, J CLIN EPIDEMIOL, V65, P934, DOI 10.1016/j.jclinepi.2011.11.014; Keegan L.T., 2021, PROGR DELTA VARIANT, DOI [10.1101/2021.08.09.21261554, DOI 10.1101/2021.08.09.21261554]; Kissling E, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.29.2100670; Krause P, 2020, LANCET, V396, P741, DOI 10.1016/S0140-6736(20)31821-3; Lefevre B., 2021, IMPACT B 1 351 BETA, DOI [10.1101/2021.07.28.21261285, DOI 10.1101/2021.07.28.21261285]; Li XN, 2021, EMERG MICROBES INFEC, V10, P1751, DOI 10.1080/22221751.2021.1969291; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Lockhart, 2021, 6 MONTH SAFETY EFFIC, DOI [10.1101/2021.07.28.21261159, DOI 10.1101/2021.07.28.21261159]; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n296; Majumder MS, 2020, LANCET GLOB HEALTH, V8, pE627, DOI 10.1016/S2214-109X(20)30113-3; McKibbin W, 2021, ASIAN ECON PAP, V20, P1, DOI 10.1162/asep_a_00796; Nasreen S., 2021, MEDRXIV, DOI [DOI 10.1101/2021.06.28.21259420, 10.1101/2021.06.28.21259420]; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Public Health England, 2021, SARS COV 2 VARIANTS; Puranik Arjun, 2021, medRxiv, DOI 10.1101/2021.08.06.21261707; Ranzani O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2015; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Schaefer GO, 2021, JAMA-J AM MED ASSOC, V326, P903, DOI 10.1001/jama.2021.13226; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; Shrotri M, 2021, LANCET INFECT DIS, V21, P1529, DOI 10.1016/S1473-3099(21)00289-9; Skegg D, 2021, LANCET, V397, P777, DOI 10.1016/S0140-6736(21)00424-4; Skowronski DM, 2022, CLIN INFECT DIS, V74, P1158, DOI 10.1093/cid/ciab616; Skowronski DM, 2012, CLIN INFECT DIS, V55, P332, DOI 10.1093/cid/cis431; Soiza RL, 2021, AGE AGEING, V50, P279, DOI 10.1093/ageing/afaa274; Sprague S., 2021, MEDRXIV, DOI [10.1101/2021.05.21.21257600, DOI 10.1101/2021.05.21.21257600]; Sridhar D, 2021, SCIENCE, V371, P230, DOI 10.1126/science.abf7921; Tang P, 2021, NAT MED, V27, P2136, DOI 10.1038/s41591-021-01583-4; Tartof S.Y., 2021, SSRN SCHOLARLY PAPER, DOI [10.2139/ssrn.3909743, DOI 10.2139/SSRN.3909743]; Tenforde MW, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab687, 10.1101/2021.07.08.21259776]; Thiruvengadam R., 2021, LANCET, DOI [10.2139/ssrn.3884946, DOI 10.2139/SSRN.3884946]; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3	56	1	1	17	17	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1305	10.3390/vaccines9111305			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG2IW	34835238	Green Published, gold			2022-04-29	WOS:000724582800001
J	Tomasi, M; Dalsass, M; Beghini, F; Zanella, I; Caproni, E; Fantappie, L; Gagliardi, A; Irene, C; Koenig, E; Frattini, L; Masetti, G; Isaac, SJ; Armanini, F; Cumbo, F; Blanco-Miguez, A; Grandi, A; Segata, N; Grandi, G				Tomasi, Michele; Dalsass, Mattia; Beghini, Francesco; Zanella, Ilaria; Caproni, Elena; Fantappie, Laura; Gagliardi, Assunta; Irene, Carmela; Koenig, Enrico; Frattini, Luca; Masetti, Giulia; Isaac, Samine Jessica; Armanini, Federica; Cumbo, Fabio; Blanco-Miguez, Aitor; Grandi, Alberto; Segata, Nicola; Grandi, Guido			Commensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines	VACCINES			English	Article						cancer vaccines; microbiome; immunotherapy; OMVs; personalized medicine	IMMUNOTHERAPY; MICROBIOME; RESISTANCE; ALIGNMENT; IMMUNITY; QUALITY	A large body of data both in animals and humans demonstrates that the gut microbiome plays a fundamental role in cancer immunity and in determining the efficacy of cancer immunotherapy. In this work, we have investigated whether and to what extent the gut microbiome can influence the antitumor activity of neo-epitope-based cancer vaccines in a BALB/c-CT26 cancer mouse model. Similarly to that observed in the C57BL/6-B16 model, Bifidobacterium administration per se has a beneficial effect on CT26 tumor inhibition. Furthermore, the combination of Bifidobacterium administration and vaccination resulted in a protection which was superior to vaccination alone and to Bifidobacterium administration alone, and correlated with an increase in the frequency of vaccine-specific T cells. The gut microbiome analysis by 16S rRNA gene sequencing and shotgun metagenomics showed that tumor challenge rapidly altered the microbiome population, with Muribaculaceae being enriched and Lachnospiraceae being reduced. Over time, the population of Muribaculaceae progressively reduced while the Lachnospiraceae population increased-a trend that appeared to be retarded by the oral administration of Bifidobacterium. Interestingly, in some Bacteroidales, Prevotella and Muribaculacee species we identified sequences highly homologous to immunogenic neo-epitopes of CT26 cells, supporting the possible role of "molecular mimicry " in anticancer immunity. Our data strengthen the importance of the microbiome in cancer immunity and suggests a microbiome-based strategy to potentiate neo-epitope-based cancer vaccines.	[Tomasi, Michele; Dalsass, Mattia; Beghini, Francesco; Zanella, Ilaria; Caproni, Elena; Irene, Carmela; Koenig, Enrico; Frattini, Luca; Masetti, Giulia; Isaac, Samine Jessica; Armanini, Federica; Cumbo, Fabio; Blanco-Miguez, Aitor; Segata, Nicola; Grandi, Guido] Univ Trento, Dept Cellular Computat & Integrat Biol, I-38123 Trento, Italy; [Fantappie, Laura; Gagliardi, Assunta; Grandi, Alberto] Toscana Life Sci, I-53100 Siena, Italy; [Grandi, Alberto] BiOMViS Srl, Via Fiorentina 1, I-53100 Siena, Italy		Grandi, G (通讯作者)，Univ Trento, Dept Cellular Computat & Integrat Biol, I-38123 Trento, Italy.	michele.tomasi.2@unitn.it; mattia.dalsass@unitn.it; francesco.beghini@unitn.it; ilaria.zanella@unitn.it; elena.caproni@unitn.it; l.fantappie@toscanalifesciences.org; a.gagliardi@toscanalifesciences.org; carmela.irene@unitn.it; enrico.koenig@unitn.it; luca83@gmail.com; giulia.masetti@unitn.it; samine.isaac@gmail.com; federica.armanini@unitn.it; fabio.cumbo@unitn.it; aitor.blancomiguez@unitn.it; a.grandi@toscanalifesciences.org; nicola.segata@unitn.it; guido.grandi@unitn.it	Beghini, Francesco/ABE-9981-2021; Blanco-Miguez, Aitor/H-3628-2017	Beghini, Francesco/0000-0002-8105-9607; Konig, Enrico/0000-0002-1560-5948; Tomasi, Michele/0000-0002-9613-1720; MASETTI, GIULIA/0000-0002-8513-2509; Blanco-Miguez, Aitor/0000-0001-7386-5572	Advanced ERC grant [OMVAC 340915, VACCIBIOME 834634]	This research was founded by the Advanced ERC grant OMVAC 340915 and by the Advanced ERC grant VACCIBIOME 834634, both assigned to Guido Grandi. The APC was founded by Advanced ERC grant OMVAC 340915.	Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1111/j.1442-9993.2001.01070.pp.x; Aziz Nabil, 2016, For Immunopathol Dis Therap, V7, P41, DOI 10.1615/ForumImmunDisTher.2016017095; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Beghini F, 2021, ELIFE, V10, DOI 10.7554/eLife.65088; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boursi B, 2015, EUR J CANCER, V51, P2655, DOI 10.1016/j.ejca.2015.08.015; Bresciani A, 2016, IMMUNOLOGY, V148, P34, DOI 10.1111/imm.12585; Buchfink B, 2015, NAT METHODS, V12, P59, DOI 10.1038/nmeth.3176; Bui VT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00576; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; Douglas A.E, 2019, Q REV BIOL, V94, P236; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Fantappie L, 2017, MOL CELL PROTEOMICS, V16, P1348, DOI 10.1074/mcp.M116.065094; Fluckiger A, 2020, SCIENCE, V369, P936, DOI 10.1126/science.aax0701; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Gil-Cruz C, 2019, SCIENCE, V366, P881, DOI 10.1126/science.aav3487; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Grandi A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00481; Grandi A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00253; Hundal J, 2020, CANCER IMMUNOL RES, V8, P409, DOI 10.1158/2326-6066.CIR-19-0401; Kang DWD, 2019, PEERJ, V7, DOI 10.7717/peerj.7359; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Klebanoff CA, 2011, IMMUNOL REV, V239, P27, DOI 10.1111/j.1600-065X.2010.00979.x; Klock HE, 2008, PROTEINS, V71, P982, DOI 10.1002/prot.21786; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Kroemer G, 2018, NAT REV IMMUNOL, V18, P87, DOI 10.1038/nri.2018.4; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lee SH, 2021, NAT MICROBIOL, V6, P277, DOI 10.1038/s41564-020-00831-6; Li DH, 2015, BIOINFORMATICS, V31, P1674, DOI 10.1093/bioinformatics/btv033; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Masella AP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-31; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Parks DH, 2015, GENOME RES, V25, P1043, DOI 10.1101/gr.186072.114; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; Pro SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196551; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Rizzello V, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/473097; Routy B, 2018, NAT REV CLIN ONCOL, V15, P382, DOI 10.1038/s41571-018-0006-2; Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Thorburn AN, 2014, IMMUNITY, V40, P833, DOI 10.1016/j.immuni.2014.05.014; Tseng HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011590; Uribe-Herranz M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.94952; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918; Zitvogel L, 2016, CELL, V165, P276, DOI 10.1016/j.cell.2016.03.001	53	0	0	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1356	10.3390/vaccines9111356			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI2NJ	34835287	Green Published, gold			2022-04-29	WOS:000725954900001
J	Velardo, F; Watson, V; Arwidson, P; Alla, F; Luchini, S; Schwarzinger, M				Velardo, Fanny; Watson, Verity; Arwidson, Pierre; Alla, Francois; Luchini, Stephane; Schwarzinger, Michael			Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population	VACCINES			English	Article						SARS-CoV-2; COVID-19; mass vaccination; anti-vaccination behavior; vaccine hesitancy; survey experiment; discrete choice experiment; France	SARS-COV-2	It can be assumed that higher SARS-CoV-2 infection risk is associated with higher COVID-19 vaccination intentions, although evidence is scarce. In this large and representative survey of 6007 adults aged 18-64 years and residing in France, 8.1% (95% CI, 7.5-8.8) reported a prior SARS-CoV-2 infection in December 2020, with regional variations according to an East-West gradient (p < 0.0001). In participants without prior SARS-CoV-2 infection, COVID-19 vaccine hesitancy was substantial, including 41.3% (95% CI, 39.8-42.8) outright refusal of COVID-19 vaccination. Taking into account five characteristics of the first approved vaccines (efficacy, duration of immunity, safety, country of the vaccine manufacturer, and place of administration) as well as the initial setting of the mass vaccination campaign in France, COVID-19 vaccine acceptance would reach 43.6% (95% CI, 43.0-44.1) at best among working-age adults without prior SARS-CoV-2 infection. COVID-19 vaccine acceptance was primarily driven by vaccine characteristics, sociodemographic and attitudinal factors. Considering the region of residency as a proxy of the likelihood of getting infected, our study findings do not support the assumption that SARS-CoV-2 infection risk is associated with COVID-19 vaccine acceptance.	[Velardo, Fanny; Alla, Francois; Schwarzinger, Michael] Bordeaux Univ Hosp, Dept Methodol & Innovat Prevent, F-33000 Bordeaux, France; [Velardo, Fanny; Alla, Francois; Schwarzinger, Michael] Univ Bordeaux, Inserm UMR 1219 Bordeaux Populat Hlth, F-33000 Bordeaux, France; [Watson, Verity] Univ Aberdeen, Hlth Econ Res Unit HERU, Aberdeen AB25 2ZD, Scotland; [Arwidson, Pierre] Sante Publ France, F-94410 St Maurice, France; [Luchini, Stephane] Aix Marseille Univ, CNRS, EHESS, Cent Marseille,AMSE, F-13001 Marseille, France		Schwarzinger, M (通讯作者)，Bordeaux Univ Hosp, Dept Methodol & Innovat Prevent, F-33000 Bordeaux, France.; Schwarzinger, M (通讯作者)，Univ Bordeaux, Inserm UMR 1219 Bordeaux Populat Hlth, F-33000 Bordeaux, France.	fanny.velardo@chu-bordeaux.fr; v.watson@abdn.ac.uk; pierre.arwidson@santepubliquefrance.fr; francois.alla@u-bordeaux.fr; stephane.luchini@univ-amu.fr; michael.schwarzinger@chu-bordeaux.fr			Santepublique France; Agence Nationale de la RechercheFrench National Research Agency (ANR)European Commission	Online survey experiments were funded by Santepublique France. This research was funded by Agence Nationale de la Recherche (ANR-21-CO16-0006-01).	Agranov M, 2021, ECON LETT, V206, DOI 10.1016/j.econlet.2021.109979; [Anonymous], 2020, PFIZER BIONTECH PFIZ; [Anonymous], 2020, MODERNA MODERNAS COV; AstraZeneca Oxford University, 2020, AZD1222 VACC MET PRI; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bendavid E, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13484; Betsch C, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0056; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Craig BM, 2021, PATIENT, V14, P309, DOI 10.1007/s40271-021-00508-0; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; European Medicines Agency, COVID 19 VACC AUTH U; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Hauber AB, 2016, VALUE HEALTH, V19, P300, DOI 10.1016/j.jval.2016.04.004; Hoze N, 2021, LANCET PUBLIC HEALTH, V6, pE408, DOI 10.1016/S2468-2667(21)00064-5; Islam N, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1137; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; McPhedran R, 2021, ECON LETT, V200, DOI 10.1016/j.econlet.2021.109747; Moore S, 2021, LANCET INFECT DIS, V21, P793, DOI 10.1016/S1473-3099(21)00143-2; O'Driscoll M, 2020, NATURE, DOI 10.1038/s41586-020-2918-0; Olivera Mesa D., 2021, 43 IMP COLL, DOI [10.25561/87096, DOI 10.25561/87096]; Ostergaard SD, 2021, LANCET, V397, P1441, DOI 10.1016/S0140-6736(21)00762-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Roser M., CORONAVIRUS COVID 19; Saad-Roy CM, 2020, SCIENCE, V370, P811, DOI 10.1126/science.abd7343; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schwarzinger M., 2021, VACCINES-BASEL; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Schwarzinger M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010199; von Haefen RH, 2005, AM J AGR ECON, V87, P1061, DOI 10.1111/j.1467-8276.2005.00794.x; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1	38	0	0	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1364	10.3390/vaccines9111364			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XL4PD	34835295	Green Published, gold			2022-04-29	WOS:000728126200001
J	Yu, YQ; Lau, MMC; Lau, JTF				Yu, Yanqiu; Lau, Mason M. C.; Lau, Joseph Tak-Fai			Positive Association between Individualism and Vaccination Resistance against COVID-19 Vaccination among Chinese Adults: Mediations via Perceived Personal and Societal Benefits	VACCINES			English	Article						vaccination resistance; COVID-19 vaccination; personal benefits; societal benefits; individualism; China	HEALTH BELIEF MODEL; COLLECTIVISM; ACCEPTANCE	Background: Vaccination resistance is the key hurdle against herd immunity as it limits the final vaccination coverage. This study investigated the prevalence and factors of COVID-19 vaccination resistance (i.e., those indicating definitely not taking up COVID-19 vaccination), including individualism, perceived personal benefits (PPB) and perceived societal benefits (PSB) of COVID-19 vaccination, and related mechanisms of the association. Methods: A random telephone survey interviewed 395 unvaccinated adults aged 18-75 not having scheduled for COVID-19 vaccination in May 2021 in Hong Kong, China (response rate = 56.8%). Results: The prevalence of vaccination resistance was 56.5%. Adjusted for background factors, individualism, PPB, and PSB were significantly associated with vaccination resistance. Path analysis showed that individualism exhibited a direct effect on vaccination resistance and a 3-step indirect effect (individualism & RARR; PSB & RARR; PPB & RARR; vaccination resistance) that explained 46.8% of the total effect. The two 2-step indirect paths via PPB only and via PSB only were non-significant. Conclusion: High prevalence of vaccination resistance was observed. Individualism increased vaccination resistance via its direct and indirect effects. Health promotion may emphasize collective good to reduce the impact of individualism and promote PPB/PSB, which may reduce vaccination resistance directly and alleviate the impact of individualism on vaccination resistance indirectly.	[Lau, Joseph Tak-Fai] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Ctr Hlth Behav Res, Hong Kong, Peoples R China		Lau, JTF (通讯作者)，Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Ctr Hlth Behav Res, Hong Kong, Peoples R China.	yuyanqiu@link.cuhk.edu.hk; mason-lau@cuhk.edu.hk; jlau@cuhk.edu.hk		Lau, Joseph/0000-0003-2344-7107	Centre for Health Behaviours Research of the Chinese University of Hong Kong	The study was supported by internal research funding of the Centre for Health Behaviours Research of the Chinese University of Hong Kong. The funding source has no role in this study.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Betsch C, 2018, NAT HUM BEHAV, V2, P881, DOI 10.1038/s41562-018-0478-1; Biddlestone M, 2020, BRIT J SOC PSYCHOL, V59, P663, DOI 10.1111/bjso.12397; Bloomberg, VACC TRACK 2021; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Bronfenbrenner U., 1992, ECOLOGICAL SYSTEMS T; Castle C., 2021, INDIVIDUALISM COLLEC; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; Dietrich T., 2017, SEGMENTATION SOCIAL, V1; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Guillon M, 2021, PUBLIC HEALTH, V198, P200, DOI 10.1016/j.puhe.2021.07.035; Gul F, 2001, ECONOMETRICA, V69, P1403, DOI 10.1111/1468-0262.00252; Hagger MS, 2019, APPL PSYCHOL-HLTH WE, V11, P407, DOI 10.1111/aphw.12153; Hsieh FY, 1998, STAT MED, V17, P1623, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Khan N, 2021, GASTROENTEROLOGY, V161, P827, DOI 10.1053/j.gastro.2021.05.044; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kwok KO, 2020, EMERG INFECT DIS, V26, P1575, DOI 10.3201/eid2607.200500; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Luo ST, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821000947; Mai YJ, 2012, COMPUT HUM BEHAV, V28, P2376, DOI 10.1016/j.chb.2012.07.009; Moore JX, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080879; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Prochaska J.O., 1994, CHANGING GOOD; Qunaibi EA, 2021, ELIFE, V10, DOI 10.7554/eLife.68038; Rieger M., 2020, SOC HLTH BEHAV, V3, P78, DOI [10.4103/SHB.SHB_39_20, DOI 10.4103/SHB.SHB_39_20]; S.A.R Government, HONG KONG HONG KONG; S.A.R Government, 2020, HONG KONG TOG WE FIG; S.A.R Government, HONG KONG EARL VACC; Schneider CR, 2021, J RISK RES, V24, P294, DOI 10.1080/13669877.2021.1890637; She R, 2021, INFECT CONT HOSP EP, DOI 10.1017/ice.2021.201; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Suess C, 2022, TOURISM MANAGE, V88, DOI 10.1016/j.tourman.2021.104405; Triandis HC, 2001, J PERS, V69, P907, DOI 10.1111/1467-6494.696169; Triandis HC, 1998, J PERS SOC PSYCHOL, V74, P118, DOI 10.1037/0022-3514.74.1.118; Vayisoglu SK, 2019, JNP-J NURSE PRACT, V15, P517, DOI 10.1016/j.nurpra.2019.04.004; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; Wu CH, 2021, INFORMATION, V12, DOI 10.3390/info12020066; Xia DQ, 2019, ENERG POLICY, V132, P208, DOI 10.1016/j.enpol.2019.05.014; Yigit M, 2021, PEDIATR INFECT DIS J, V40, pE134, DOI 10.1097/INF.0000000000003042; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Yu YQ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080847; Yu YQ, 2021, INT J HEALTH POLICY, DOI 10.34172/ijhpm.2021.64; Yu YQ, 2021, HUM VACC IMMUNOTHER, V17, P2894, DOI 10.1080/21645515.2021.1909327; Yu YQ, 2022, INT J HEALTH POLICY, V11, P498, DOI 10.34172/ijhpm.2020.195; Yu YW, 2022, IEEE-ASME T MECH, V27, P928, DOI [10.34172/ijhpm.2021.02, 10.1109/TMECH.2021.3075057]	49	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1225	10.3390/vaccines9111225			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XJ9CW	34835156	gold, Green Published			2022-04-29	WOS:000727077500001
J	Gatto, NM; Lee, JRSE; Massai, D; Zamarripa, S; Sasaninia, B; Khurana, D; Michaels, K; Freund, D; Nightingale, J; Firek, A				Gatto, Nicole M.; Lee, Jerusha E.; Massai, Donatella; Zamarripa, Susanna; Sasaninia, Bijan; Khurana, Dhruv; Michaels, Kelsey; Freund, Deborah; Nightingale, Judi; Firek, Anthony			Correlates of COVID-19 Vaccine Acceptance, Hesitancy and Refusal among Employees of a Safety Net California County Health System with an Early and Aggressive Vaccination Program: Results from a Cross-Sectional Survey	VACCINES			English	Article						vaccine hesitancy; COVID-19; pandemic; SARS-CoV-2; healthcare workers; vaccine acceptance; physicians; nurses; determinants	INFLUENZA VACCINATION	Since health professionals provide frontline care to COVID-19 patients, information on vaccine acceptance among healthcare workers is needed. We developed and implemented an anonymous internet-based cross-sectional survey with direct solicitation among employees of a safety net health system. Items queried demographic and health-related characteristics, experience with and knowledge of COVID-19, and determinants of decisions to vaccinate. COVID-19 vaccine acceptance groups (acceptors, hesitant, refusers) were defined; an adapted version of the WHO vaccine hesitancy scale was included. The survey demonstrated good reliability (Cronbach's alpha = 0.92 for vaccine hesitancy scale; 0.93 for determinants). General linear and logistic regression methods examined factors which were univariately associated with vaccine hesitancy and vaccine acceptance, respectively. Multivariable models were constructed with stepwise model-building procedures. Race/ethnicity, marital status, job classification, immunocompromised status, flu vaccination and childhood vaccination opinions independently predicted hesitancy scale scores. Gender, education, job classification and BMI independently predicted acceptance, hesitancy, and refusal groups. Among hesitant employees, uncertainty was reflected in reports of motivating factors influencing their indecision. Despite a strong employee-support environment and job protection, respondents reported physical and mental health effects. The appreciation of varied reasons for refusing vaccination should lead to culturally sensitive interventions to increase vaccination rates amongst healthcare workers.	[Gatto, Nicole M.; Massai, Donatella; Freund, Deborah] Claremont Grad Univ, Sch Community & Global Hlth, 150 E 10th St, Claremont, CA 91711 USA; [Lee, Jerusha E.; Freund, Deborah] Claremont Grad Univ, Dept Econ Sci, 150 E 10th St, Claremont, CA 91711 USA; [Zamarripa, Susanna; Sasaninia, Bijan; Khurana, Dhruv; Michaels, Kelsey; Nightingale, Judi; Firek, Anthony] Riverside Univ Hlth Syst, Comparat Effectiveness & Clin Outcomes Res Ctr, 26520 Cactus Ave, Moreno Valley, CA 92555 USA		Gatto, NM (通讯作者)，Claremont Grad Univ, Sch Community & Global Hlth, 150 E 10th St, Claremont, CA 91711 USA.	donatella.massai@cgu.edu		Gatto, Nicole/0000-0001-7873-8310; Firek, Anthony/0000-0001-6649-2798; Khurana, Dhruv/0000-0002-3108-9517			Achat H, 1999, AUST NZ J PUBL HEAL, V23, P285, DOI 10.1111/j.1467-842X.1999.tb01257.x; Amin DP, 2021, AM J EMERG MED, V48, P372, DOI 10.1016/j.ajem.2021.01.089; [Anonymous], 2014, REP SAGE WORK GROUP; [Anonymous], 2020, BEH CONS ACC UPT COV; [Anonymous], 2020, 22 WHO; Baniak LM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080858; Benecke Olivia, 2019, Glob Pediatr Health, V6, p2333794X19862949, DOI 10.1177/2333794X19862949; Berry SD, 2021, J AM GERIATR SOC, V69, P1140, DOI 10.1111/jgs.17136; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Ciardi F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050516; Cooper M., 2021, NEW YORK TIMES 0315; File T., 2021, AM COUNTS STORIES NU; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Funk C, 2021, GROWING SHARE AM SAY; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Goldstein S, 2015, VACCINE, V33, P4212, DOI 10.1016/j.vaccine.2015.04.042; Gostin LO, 2005, AM J PUBLIC HEALTH, V95, P576, DOI 10.2105/AJPH.2004.055152; Grumbach K, 2021, JAMA INTERN MED, V181, P1008, DOI 10.1001/jamainternmed.2021.1445; Halbrook M, 2022, CLIN INFECT DIS, V74, P1166, DOI 10.1093/cid/ciab614; Higgins ST, 2021, PREV MED, V145, DOI 10.1016/j.ypmed.2021.106421; Huetteman E., COVID VACCINE HESITA; Johns Hopkins University & Medicine, COR RES CTR; Karafillakis E, 2018, CLIN MICROBIOL INFEC, V24, P799, DOI 10.1016/j.cmi.2018.04.001; Katzman JG, 2021, J PRIM CARE COMMUNIT, V12, DOI 10.1177/21501327211007026; KFF, WASH POST, P2021; Kociolek LK, 2021, INFECT CONT HOSP EP, V42, P775, DOI [10.1017/ice.2021.58, 10.1017/ice.2021.415]; Kompaniyets L, 2021, PREV CHRONIC DIS, V18, DOI 10.5888/pcd18.210123; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kuter BJ, 2021, VACCINE, V39, P1693, DOI 10.1016/j.vaccine.2021.02.029; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lin CJ, 2012, JT COMM J QUAL PATIE, V38, P67, DOI 10.1016/S1553-7250(12)38009-4; Meyer MN, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.5344; Morley, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab054, DOI 10.1093/cid/ciab054]; Newitt P., 2021, BECKERS ASC REV; Paterson P, 2018, VACCINE, V36, P5397, DOI 10.1016/j.vaccine.2017.08.016; Pelcic G, 2016, CROAT MED J, V57, P516, DOI 10.3325/cmj.2016.57.516; Piltch-Loeb R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010076; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rosenthal N, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.29058; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Santibanez TA, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-007609; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schrading WA, 2021, ACAD EMERG MED, V28, P455, DOI 10.1111/acem.14236; Schwartz Jason L, 2012, Virtual Mentor, V14, P50, DOI 10.1001/virtualmentor.2012.14.1.mhst1-1201; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Stobbe M., 2021, AP NEWS; Taylor S, 2020, J ANXIETY DISORD, V76, DOI 10.1016/j.janxdis.2020.102327; Townsel C, 2021, J PERINATOL, V41, P2549, DOI 10.1038/s41372-021-01173-9; Unroe KT, 2021, J AM GERIATR SOC, V69, P593, DOI 10.1111/jgs.17022; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wilson FA, 2014, VACCINE, V32, P2441, DOI 10.1016/j.vaccine.2014.02.084; Wilson RJI, 2020, INT J QUAL STUD HEAL, V15, DOI 10.1080/17482631.2020.1757336; Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430; World Health Organization, 10 THREATS GLOB GEAL	57	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1152	10.3390/vaccines9101152			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XK5RW	34696260	Green Published, Green Submitted, gold			2022-04-29	WOS:000727523500001
J	Lukic, A; De Vincenzo, R; Ciavattini, A; Ricci, C; Senatori, R; Ruscito, I; Frega, A				Lukic, Ankica; De Vincenzo, Rosa; Ciavattini, Andrea; Ricci, Caterina; Senatori, Roberto; Ruscito, Ilary; Frega, Antonio			Are We Facing a New Colposcopic Practice in the HPV Vaccination Era? Opportunities, Challenges, and New Perspectives	VACCINES			English	Editorial Material						colposcopy; HPV vaccines; high grade intraepithelial lesions; cervical cancer; cervical adenocarcinoma; risk stratification; HPV genotyping; colposcopic referral criteria	CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS VACCINE; ENDOCERVICAL CURETTAGE; RANDOM BIOPSY; WOMEN; RISK; LESIONS; ADENOCARCINOMA; RECOMMENDATIONS; REDUCTION	The combination of primary and secondary prevention has already influenced the colposcopic practice by reduction in HPV (human papillomavirus) vaccine-type HSIL (HIGH-GRADE SIL), colposcopy referral numbers, colposcopic positive predictive value (PPV) for CIN2+, and by modification of referral pattern, colposcopic performance, and procedures. Different strategies, both isolated and combined, have been proposed in order to maintain the diagnostic accuracy of colposcopy: patient risk stratification based on immediate or future risk of CIN3+ or on HPV genotyping after a positive screening test. Data are needed to support alternative colposcopic strategies based on vaccination status and on the application of artificial intelligence where the patient's risk stratification is implicit in precision medicine which involves the transition from an operator-dependent morphology-based to a less-operator dependent, more biomolecular management. The patient's risk stratification based on any combination of "history " and "test results " to decrease colposcopy workload further reduce colposcopic and histologic morphological approaches, while adding genotyping to the risk stratification paradigm means less cytologic morphologic diagnosis. In Italy, there is a strong colposcopic tradition and there is currently no immediate need to reduce the number of colposcopies. Instead, there is a need for more accredited colposcopists to maintain the diagnostic accuracy of colposcopy in the vaccination era.	[Lukic, Ankica; Ruscito, Ilary; Frega, Antonio] Sapienza Univ Rome, St Andrea Hosp, Dept Surg & Med Sci & Translat Med, Via Grottarossa 1035-1039, I-00189 Rome, Italy; [Lukic, Ankica; De Vincenzo, Rosa; Ciavattini, Andrea; Senatori, Roberto; Frega, Antonio] Italian Soc Colposcopy & Cervicovaginal Pathol SI, I-00186 Rome, Italy; [De Vincenzo, Rosa; Ricci, Caterina] Fdn Policlin Univ A Gemelli, Gynecol Oncol Unit, IRCCS, Dipartimento Sci Salute Donna Bambino & Sanita Pu, I-00168 Rome, Italy; [De Vincenzo, Rosa] Univ Cattolica Sacro Cuore, Dipartimento Sci Vita & Sanita Pubbl, I-00168 Rome, Italy; [Ciavattini, Andrea] Univ Politecn Marche, Dept Odontostomatol & Specialized Clin Sci, Gynecol Sect, I-60121 Ancona, Italy		Ricci, C (通讯作者)，Fdn Policlin Univ A Gemelli, Gynecol Oncol Unit, IRCCS, Dipartimento Sci Salute Donna Bambino & Sanita Pu, I-00168 Rome, Italy.	ankica.lukic@uniroma1.it; rosa.devincenzo@unicatt.it; andrea.ciavattini@ospedaliriuniti.marche.it; caterina.ricci@policlinicogemelli.it; robertosenatori@gmail.com; ilary.ruscito@uniroma1.it; antonio.frega@uniroma1.it	Ricci, Caterina/AAC-6077-2022; Ciavattini, Andrea/AAC-3266-2022	Ricci, Caterina/0000-0002-0808-999X; Ciavattini, Andrea/0000-0002-8037-4947; de vincenzo, rosa/0000-0001-7408-0435			Martellucci CA, 2021, BJOG-INT J OBSTET GY, V128, P532, DOI 10.1111/1471-0528.16429; Adegoke O, 2012, J WOMENS HEALTH, V21, P1031, DOI 10.1089/jwh.2011.3385; Baio G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049699; Bogani G, 2020, INT J GYNECOL OBSTET, V148, P133, DOI 10.1002/ijgo.13021; Bogani G, 2019, INT J GYNECOL OBSTET, V147, P233, DOI 10.1002/ijgo.12934; Bonde JH, 2020, J LOW GENIT TRACT DI, V24, P1, DOI 10.1097/LGT.0000000000000494; Bray F, 2005, CANCER EPIDEM BIOMAR, V14, P2191, DOI 10.1158/1055-9965.EPI-05-0231; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brotherton JML, 2015, PAPILLOMAVIRUS RES, V1, P59, DOI 10.1016/j.pvr.2015.05.005; Brusselaers N, 2019, AM J OBSTET GYNECOL, V221, P9, DOI 10.1016/j.ajog.2018.12.011; Canfell K, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100170; Carozzi FM, 2016, J CLIN VIROL, V84, P74, DOI 10.1016/j.jcv.2016.09.011; Carozzi F, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2945-8; Castanon A, 2016, INT J CANCER, V139, P1040, DOI 10.1002/ijc.30152; Chen Q, 2016, J LOW GENIT TRACT DI, V20, P207, DOI 10.1097/LGT.0000000000000184; Ciavattini A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030354; Cleveland AA, 2020, INT J CANCER, V146, P810, DOI 10.1002/ijc.32340; Cruickshank ME, 2017, BJOG-INT J OBSTET GY, V124, P1386, DOI 10.1111/1471-0528.14562; Demarco M, 2020, ECLINICALMEDICINE, V22, DOI 10.1016/j.eclinm.2020.100293; Demarco M, 2020, J LOW GENIT TRACT DI, V24, P144, DOI 10.1097/LGT.0000000000000530; Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3; Egemen D, 2020, J LOW GENIT TRACT DI, V24, P132, DOI 10.1097/LGT.0000000000000529; Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354; Guo FJ, 2018, AM J PREV MED, V55, P197, DOI 10.1016/j.amepre.2018.03.013; Hariri S, 2015, VACCINE, V33, P1608, DOI 10.1016/j.vaccine.2015.01.084; Hodgson A, 2019, ARCH PATHOL LAB MED, V143, P34, DOI 10.5858/arpa.2018-0259-RA; Huh WK, 2014, OBSTET GYNECOL, V124, P670, DOI 10.1097/AOG.0000000000000458; Jach R, 2020, GINEKOL POL, V91, P362, DOI 10.5603/GP.2020.0075; Jeronimo J, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.02.047; Kjaer SK, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100401; Kumar N, 2019, EUR J OBSTET GYN R B, V240, P68, DOI 10.1016/j.ejogrb.2019.06.006; Landy R, 2018, INT J CANCER, V142, P709, DOI 10.1002/ijc.31094; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Liverani C.A., 2016, TRENDS GYNECOL ONCOL, V1, pe102, DOI [10.4172/CTGO.1000.e102, DOI 10.4172/CTGO.1000.E102]; Liverani CA, 2020, J ONCOL, V2020, DOI 10.1155/2020/8887672; Massad LS, 2009, J LOW GENIT TRACT DI, V13, P137, DOI 10.1097/LGT.0b013e31819308d4; Ministero Della Salute Piano Nazionale Della Prevenzione 2010-2012, 2010, 001068P14012013 DGPR, P1; Mitra A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15856-y; Mix JM, 2021, CANCER EPIDEM BIOMAR, V30, P30, DOI 10.1158/1055-9965.EPI-20-0846; Munro A, 2017, BJOG-INT J OBSTET GY, V124, P1394, DOI 10.1111/1471-0528.14563; Nam K, 2013, J LOW GENIT TRACT DI, V17, P1, DOI 10.1097/LGT.0b013e31825afd5b; Norenhag J, 2020, BJOG-INT J OBSTET GY, V127, P171, DOI 10.1111/1471-0528.15854; Olsson SE, 2020, PAPILLOMAVIRUS RES, V10, DOI 10.1016/j.pvr.2020.100203; Palmer T, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1161; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Pedersen K, 2018, EUR J CANCER, V91, P68, DOI 10.1016/j.ejca.2017.12.018; Perkins RB, 2020, J LOW GENIT TRACT DI, V24, P102, DOI 10.1097/LGT.0000000000000525; Pirog EC, 2014, MODERN PATHOL, V27, P1559, DOI 10.1038/modpathol.2014.55; Pollock KGJ, 2014, BRIT J CANCER, V111, P1824, DOI 10.1038/bjc.2014.479; Pretorius RG, 2004, AM J OBSTET GYNECOL, V191, P430, DOI 10.1016/j.ajog.2004.02.065; Pretorius RG, 2012, J LOW GENIT TRACT DI, V16, P333, DOI 10.1097/LGT.0b013e3182480c18; Pretorius RG, 2011, J LOW GENIT TRACT DI, V15, P180, DOI 10.1097/LGT.0b013e3181fb4547; Ronco G., 2012, EPIDEMIOL PREV, V36, P1; Rossi PG, 2017, PREV MED, V98, P21, DOI 10.1016/j.ypmed.2016.11.020; Sherman ME, 2003, CANCER EPIDEM BIOMAR, V12, P372; Silver MI, 2018, OBSTET GYNECOL, V132, P725, DOI 10.1097/AOG.0000000000002812; Smith LM, 2015, PEDIATRICS, V135, pE1131, DOI 10.1542/peds.2014-2961; Spinillo A, 2016, J LOW GENIT TRACT DI, V20, P22, DOI 10.1097/LGT.0000000000000155; Spinillo A, 2014, GYNECOL ONCOL, V134, P527, DOI 10.1016/j.ygyno.2014.07.006; Stoler MH, 2019, GYNECOL ONCOL, V153, P26, DOI 10.1016/j.ygyno.2018.12.024; Stoler MH, 2011, INT J CANCER, V128, P1354, DOI 10.1002/ijc.25470; van der Marel J, 2014, BJOG-INT J OBSTET GY, V121, P1117, DOI 10.1111/1471-0528.12668; Wentzensen N, 2017, J LOW GENIT TRACT DI, V21, P216, DOI 10.1097/LGT.0000000000000322; Wright TC, 2019, GYNECOL ONCOL, V154, P360, DOI 10.1016/j.ygyno.2019.05.012; Zhou X, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01434	65	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1081	10.3390/vaccines9101081			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI8PU	34696189	Green Published, gold			2022-04-29	WOS:000726367000001
J	Ramirez, GA; Asperti, C; Cucca, V; Yacoub, MR				Ramirez, Giuseppe A.; Asperti, Chiara; Cucca, Valentina; Yacoub, Mona-Rita			Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases	VACCINES			English	Review						COVID-19; vaccine; autoimmune diseases; allergy; rheumatic diseases; primary immunodeficiency; mastocytosis	MESSENGER-RNA VACCINES; COVID-19 VACCINATION; ALLERGIC REACTIONS; SAFETY; MASTOCYTOSIS; INFECTION; SYMPTOMS; HISTORY; RISK	Aberrant deployment of the immune response is a hallmark pathogenic feature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19), possibly accounting for high morbidity and mortality, especially in patients with comorbidities, including immune-mediated disorders. Immunisation with SARS-COV-2 vaccines successfully instructs the immune system to limit viral spread into tissues, mitigate COVID-19 manifestations and prevent its most detrimental inflammatory complications in the general population. Patients with immune-mediated diseases have been excluded from vaccine registration trials, foreclosing the acquisition of specific efficacy and safety data. In this review, we aimed to summarise and critically discuss evidence from real-world studies addressing this issue to provide a comprehensive view of the impact of vaccination practices in patients with allergy, autoimmunity or immunodeficiency. We analysed clinical and laboratory data from 34 studies involving more than 13,000 subjects with various immune disorders who were vaccinated with mRNA- DNA- or inactivated viral particle-based vaccines. These data globally support the safe and effective use of SARS-CoV-2 vaccines in patients with immune-mediated diseases, although patient-tailored strategies to determine vaccination timing, vaccine choice and background therapy management are warranted to optimise vaccination outcomes. More data are needed regarding patients with primary immunodeficiencies.	[Ramirez, Giuseppe A.; Asperti, Chiara; Cucca, Valentina; Yacoub, Mona-Rita] Univ Vita Salute San Raffaele, Div Immunol Transplants & Infect Dis, I-20132 Milan, Italy; [Ramirez, Giuseppe A.; Asperti, Chiara; Cucca, Valentina; Yacoub, Mona-Rita] IRCCS Osped San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis, I-20132 Milan, Italy		Ramirez, GA (通讯作者)，Univ Vita Salute San Raffaele, Div Immunol Transplants & Infect Dis, I-20132 Milan, Italy.; Ramirez, GA (通讯作者)，IRCCS Osped San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis, I-20132 Milan, Italy.	asperti.chiara@hsr.it; yacoub.monarita@hsr.it	Ramirez, Giuseppe Alvise/K-4923-2018; Yacoub, Mona Rita/AAP-6227-2020	Ramirez, Giuseppe Alvise/0000-0002-2889-366X; Yacoub, Mona Rita/0000-0003-2417-0410			Achiron A, 2021, THER ADV NEUROL DISO, V14, DOI 10.1177/17562864211012835; Allen-Philbey K, 2021, MULT SCLER RELAT DIS, V52, DOI 10.1016/j.msard.2021.103028; Avouac J, 2021, LANCET RHEUMATOL, V3, pE419, DOI 10.1016/S2665-9913(21)00059-X; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Barbhaiya M, 2021, ANN RHEUM DIS, V80, P1352, DOI 10.1136/annrheumdis-2021-220732; Bilich T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf7517; Bingham CO, 2009, J RHEUMATOL, V36, P2335, DOI 10.3899/jrheum.090369; Blumenthal KG, 2021, NEW ENGL J MED, V384, P1273, DOI 10.1056/NEJMc2102131; Blumenthal KG, 2021, JAMA-J AM MED ASSOC, V325, P1562, DOI 10.1001/jama.2021.3976; Boekel L, 2021, LANCET RHEUMATOL, V3, pE541, DOI 10.1016/S2665-9913(21)00181-8; Bonelli MM, 2021, ANN RHEUM DIS, V80, P1355, DOI 10.1136/annrheumdis-2021-220408; Braun-Moscovici Y, 2021, ANN RHEUM DIS, V80, P1317, DOI 10.1136/annrheumdis-2021-220503; Brito-Zeron P, 2021, CLIN EXP RHEUMATOL, V39, P676; Buttari F, 2021, MULT SCLER RELAT DIS, V52, DOI 10.1016/j.msard.2021.102983; Caminati M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080853; Campochiaro C, 2021, ANN RHEUM DIS, V80, P816, DOI 10.1136/annrheumdis-2020-219811; Cherian S, 2021, RHEUMATOL INT, V41, P1441, DOI 10.1007/s00296-021-04917-0; Ciceri F, 2020, CRIT CARE RESUSC, V22, P95; Connolly CM, 2021, ANN RHEUM DIS, V80, P1100, DOI 10.1136/annrheumdis-2021-220231; Dages KN, 2021, ANN ALLERG ASTHMA IM, V127, P257, DOI 10.1016/j.anai.2021.04.024; Damiani G, 2021, CLIN EXP DERMATOL, V46, P1106, DOI 10.1111/ced.14631; Danza A, 2013, LUPUS, V22, P1286, DOI 10.1177/0961203313493032; Engler RJM, 2008, ARCH INTERN MED, V168, P2405, DOI 10.1001/archinternmed.2008.513; Furer V, 2021, ANN RHEUM DIS, V80, P1330, DOI 10.1136/annrheumdis-2021-220647; Gao YD, 2021, ALLERGY, V76, P428, DOI 10.1111/all.14657; Geisen UM, 2021, ANN RHEUM DIS, V80, P1306, DOI 10.1136/annrheumdis-2021-220272; Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3; Giollo A, 2021, ANN RHEUM DIS, V80, DOI [10.1136/annrheumdis-2020-217598, 10.1136/annrheumdis-2020-218845, 10.1136/annrheumdis-2020-218830]; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Guerrieri S, 2022, J NEUROL, V269, P39, DOI 10.1007/s00415-021-10663-x; Haberman RH, 2021, ANN RHEUM DIS, V80, P1339, DOI 10.1136/annrheumdis-2021-220597; Hagin D, 2021, J ALLERGY CLIN IMMUN, V148, P739, DOI 10.1016/j.jaci.2021.05.029; Hammam N, 2021, RHEUMATOL INT, V41, P1607, DOI 10.1007/s00296-021-04941-0; Heffler E, 2021, ALLERGY, V76, P887, DOI 10.1111/all.14532; Jahnz-Rozyk K, 2004, MEDIAT INFLAMM, V13, P195, DOI 10.1080/09511920410001713501; Jowett B, 1881, THUCYDIDES HIST PELO; Kaakati R, 2021, J ALLER CL IMM-PRACT, V9, P3198, DOI 10.1016/j.jaip.2021.05.010; Khan N, 2021, GASTROENTEROLOGY, V161, P827, DOI 10.1053/j.gastro.2021.05.044; Klugar M, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10080752; Kronzer VL, 2019, ARTHRITIS RHEUMATOL, V71, P1217, DOI 10.1002/art.40858; Larson KF, 2021, CIRCULATION, V144, P506, DOI 10.1161/CIRCULATIONAHA.121.055913; Lee SC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77791-8; Lupus_Research_Alliance, 2021, 2 3 PEOPL LUP WOULD; Maguire D, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02524-4; Mahil SK, 2021, LANCET RHEUMATOL, V3, pE627, DOI 10.1016/S2665-9913(21)00212-5; Metzler KD, 2011, BLOOD, V117, P953, DOI 10.1182/blood-2010-06-290171; Miyachi T, 2020, LANCET, V395, P31, DOI 10.1016/S0140-6736(19)32686-8; Moghimi SM, 2021, MOL THER, V29, P898, DOI 10.1016/j.ymthe.2021.01.030; Morgan AJ, 2007, CLIN EXP IMMUNOL, V147, P389, DOI 10.1111/j.1365-2249.2006.03304.x; Myles IA, 2021, VACCINE, V39, P4404, DOI 10.1016/j.vaccine.2021.06.061; Nittner-Marszalska M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060553; Pablos JL, 2020, ANN RHEUM DIS, V79, P1170, DOI 10.1136/annrheumdis-2020-217763; Paoletti G, 2021, WORLD ALLERGY ORGAN, V14, DOI 10.1016/j.waojou.2021.100541; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Picard M, 2015, CLIN REV ALLERG IMMU, V49, P177, DOI 10.1007/s12016-014-8416-0; Pineros YSS, 2019, ALLERGY, V74, P1898, DOI 10.1111/all.13802; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Priori R., 2021, ANN RHEUM DIS, V80, P953, DOI [10.1136/annrheumdis-2021-220059, DOI 10.1136/annrheumdis-2021-220059]; Radic M, 2013, SEMIN IMMUNOPATHOL, V35, P465, DOI 10.1007/s00281-013-0376-6; Rama TA, 2021, J ALLERGY CLIN IMMUN, V147, P877, DOI 10.1016/j.jaci.2021.01.004; Ramirez GA, 2021, CLIN IMMUNOL, V231, DOI 10.1016/j.clim.2021.108845; Ramirez GA, 2021, CLIN MICROBIOL INFEC, V27, P1190, DOI 10.1016/j.cmi.2021.05.023; Ramirez Giuseppe A, 2021, Minerva Med, DOI 10.23736/S0026-4806.21.07331-6; Ramirez GA, 2021, ANN RHEUM DIS, V80, DOI 10.1136/annrheumdis-2021-220539; Ramirez GA, 2020, SEMIN ARTHRITIS RHEU, V50, P1150, DOI 10.1016/j.semarthrit.2020.06.012; Rathi M, 2021, LUPUS, V30, P158, DOI 10.1177/0961203320962855; Reynolds CJ, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abf3698; Riggioni C, 2020, ALLERGY, V75, P2503, DOI 10.1111/all.14449; Rojas-Perez-Ezquerra P, 2021, J INVEST ALLERG CLIN, V31, P180, DOI 10.18176/jiaci.0683; Rubio JLC, 2022, MED CLIN-BARCELONA, V158, P91, DOI 10.1016/j.medcli.2021.05.003; Ruddy JA, 2021, ANN RHEUM DIS, V80, P1351, DOI 10.1136/annrheumdis-2021-220656; Salviani C, 2021, ANN RHEUM DIS, V80, DOI 10.1136/annrheumdis-2021-220496; Schioppo T, 2021, RHEUMATOLOGY, DOI 10.1093/rheumatology/keab611; SEQUEIRA JF, 1993, LUPUS, V2, P187, DOI 10.1177/096120339300200311; Shields AM, 2021, J ALLERGY CLIN IMMUN, V147, P870, DOI 10.1016/j.jaci.2020.12.620; Simon D, 2022, ARTHRITIS RHEUMATOL, V74, P33, DOI 10.1002/art.41914; Simon D, 2021, ANN RHEUM DIS, V80, P1312, DOI 10.1136/annrheumdis-2021-220461; Simonetti O, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9040401; Spiera R, 2021, ANN RHEUM DIS, V80, P1357, DOI 10.1136/annrheumdis-2021-220604; Strangfeld A, 2021, ANN RHEUM DIS, V80, P930, DOI 10.1136/annrheumdis-2020-219498; Tan CK, 2021, J HEPATOL, V75, P1250, DOI 10.1016/j.jhep.2021.06.009; Valor-Mendez L, 2021, ANN RHEUM DIS, V80, DOI 10.1136/annrheumdis-2021-220898; Veenstra J, 2021, ANN RHEUM DIS, V80, DOI 10.1136/annrheumdis-2021-220736; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Wack S, 2021, J AM ACAD DERMATOL, V85, P1274, DOI 10.1016/j.jaad.2021.07.054; Watad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050435; Wong SY, 2021, GASTROENTEROLOGY, V161, P715, DOI 10.1053/j.gastro.2021.04.025; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238	91	1	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1147	10.3390/vaccines9101147			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ8KP	34696255	gold, Green Published			2022-04-29	WOS:000714059800001
J	Ananworanich, J; Heaton, PM				Ananworanich, Jintanat; Heaton, Penny M.			Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities	VACCINES			English	Review						RSV; lower respiratory tract infection; monoclonal antibody; LMIC	RESPIRATORY SYNCYTIAL VIRUS; YOUNG-CHILDREN; DISEASE; VACCINE; MOTAVIZUMAB; RISK; HOSPITALIZATIONS; PROPHYLAXIS; PALIVIZUMAB; INFECTIONS	Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTIs) in infants. Most deaths occur in infants under 3 months old, and those living in low and middle-income countries (LMICs). There are no maternal or infant RSV vaccines currently approved. An RSV monoclonal antibody (mAb) could fill the gap until vaccines are available. It could also be used when a vaccine is not given, or when there is insufficient time to vaccinate and generate an antibody response. The only currently approved RSV mAb, palivizumab, is too costly and needs monthly administration, which is not possible in LMICs. It is imperative that a safe, effective, and affordable mAb to prevent severe RSV LRTI be developed for infants in LMICs. Next generation, half-life extended mAbs in clinical development, such as nirsevimab, show promise in protecting infants against RSV LRTI. Given that a single dose could cover an entire 5-month season, there is an opportunity to make RSV mAbs affordable for LMICs by investing in improvements in manufacturing efficiency. The challenges of using RSV mAbs in LMICs are the complexities of integrating them into existing healthcare delivery programs and surveillance systems, both of which are needed to define seasonal patterns, and monitor for escape mutants. Collaboration with key stakeholders such as the World Health Organization and Gavi, the Vaccine Alliance, will be essential for achieving this goal.	[Ananworanich, Jintanat; Heaton, Penny M.] Bill & Melinda Gates Med Res Inst, Cambridge, MA 02139 USA; [Ananworanich, Jintanat] Univ Amsterdam, Amsterdam Med Ctr, Dept Global Hlth, NL-1105 BP Amsterdam, Netherlands		Heaton, PM (通讯作者)，Bill & Melinda Gates Med Res Inst, Cambridge, MA 02139 USA.	jananworanich@outlook.com; Penny.Heaton@GatesMRI.org					Aliprantis AO, 2021, CLIN PHARM DRUG DEV, V10, P556, DOI 10.1002/cpdd.883; American Academy of Pediatrics (AAP), INT GUID US PAL PROP; Andeweg SP, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88524-w; Baral R, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-046563; Blanco JCG, 2017, VACCINE, V35, P3951, DOI 10.1016/j.vaccine.2017.06.009; Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1665, 10.1542/peds.2014-1666]; Buchwald AG, 2021, CLIN INFECT DIS, V73, pE4421, DOI 10.1093/cid/ciaa648; Carbonell-Estrany X, 2017, J MATERN-FETAL NEO M, V30, P134, DOI 10.3109/14767058.2016.1165199; Carbonell-Estrany X, 2010, PEDIATRICS, V125, pE35, DOI 10.1542/peds.2008-1036; Delgado M Florencia, 2004, Expert Rev Vaccines, V3, P693, DOI 10.1586/14760584.3.6.693; Domachowske JB, 2018, PEDIATR INFECT DIS J, V37, P886, DOI [10.1097/INF.0000000000001916, 10.1097/inf.0000000000001916]; Feltes TF, 2011, PEDIATR RES, V70, P186, DOI 10.1203/PDR.0b013e318220a553; Fergie J, 2021, HUM VACC IMMUNOTHER, V17, P1536, DOI 10.1080/21645515.2020.1822134; Griffin MP, 2020, NEW ENGL J MED, V383, P415, DOI 10.1056/NEJMoa1913556; Griffin MP, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01714-16, 10.1128/aac.01714-16]; Higgins D, 2016, VACCINE, V34, P2870, DOI 10.1016/j.vaccine.2016.03.109; KIM HW, 1976, PEDIATR RES, V10, P75, DOI 10.1203/00006450-197601000-00015; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Lee CH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13108-2; Li Y, 2021, LANCET INFECT DIS, V21, P1303, DOI 10.1016/S1473-3099(20)30703-9; Li Y, 2021, LANCET RESP MED, V9, P175, DOI 10.1016/S2213-2600(20)30322-2; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; Mazur NI, 2019, J INFECT DIS, V219, P59, DOI 10.1093/infdis/jiy477; McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914; Modjarrad K, 2016, VACCINE, V34, P190, DOI 10.1016/j.vaccine.2015.05.093; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; O'Brien KL, 2015, LANCET INFECT DIS, V15, P1398, DOI 10.1016/S1473-3099(15)00247-9; Obando-Pacheco P, 2018, J INFECT DIS, V217, P1356, DOI 10.1093/infdis/jiy056; Ohuma EO, 2012, AM J EPIDEMIOL, V176, P794, DOI 10.1093/aje/kws257; Openshaw PJM, 2017, ANNU REV IMMUNOL, V35, P501, DOI 10.1146/annurev-immunol-051116-052206; Papenburg J, 2021, J PEDIAT INF DIS SOC, V10, P237, DOI 10.1093/jpids/piaa046; PATH, RSV VACC MAB SNAPSH; Pierre V., 2020, P AM C PHARM COP11 V; Pollock J, 2017, BIOTECHNOL PROGR, V33, P854, DOI 10.1002/btpr.2492; Rid A, 2014, VACCINE, V32, P4708, DOI 10.1016/j.vaccine.2014.04.022; Ruckwardt TJ, 2019, IMMUNITY, V51, P429, DOI 10.1016/j.immuni.2019.08.007; Scheltema NM, 2017, LANCET GLOB HEALTH, V5, pE984, DOI 10.1016/S2214-109X(17)30344-3; Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Simoes EAF, 2021, CLIN INFECT DIS, V73, pE4400, DOI 10.1093/cid/ciaa951; Srikantiah P., 2021, COMMUNICATION; Stensballe LG, 2009, J PEDIATR-US, V154, P296, DOI 10.1016/j.jpeds.2008.07.053; Tabor DE, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.01828-20; Taleb SA, 2018, EUR J CLIN MICROBIOL, V37, P1817, DOI 10.1007/s10096-018-3289-4; Tang AM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12137-1; WHO, 2012, WORLD MALARIA REPORT 2012, P1; WHO Department of Immunization Vaccines and Biologicals' Technical Advisory Group, PREF PRODUCT CHAR MO; Zhu Q, 2018, J INFECT DIS, V218, P572, DOI 10.1093/infdis/jiy189; Zhu Q, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj1928	49	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							961	10.3390/vaccines9090961			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3CH	34579198	Green Published, gold			2022-04-29	WOS:000702085800001
J	Aleem, MT; Shi, JW; Yu, ZQ; Wen, ZH; Zhang, Y; Liang, M; Lakho, SA; Haseeb, M; Ali, H; Hassan, MW; Song, XK; Li, XR; Xu, LX; Yan, RF				Aleem, Muhammad Tahir; Shi, Jiawen; Yu, Zhengqing; Wen, Zhaohai; Zhang, Yang; Liang, Meng; Lakho, Shakeel Ahmed; Haseeb, Muhammad; Ali, Haider; Hassan, Muhammad Waqas; Song, Xiaokai; Li, Xiangrui; Xu, Lixin; Yan, Ruofeng			Characterization of Membrane-Associated Progesterone Receptor Component-2 (MAPRC2) from Trichinella spiralis and Its Interaction with Progesterone and Mifepristone	VACCINES			English	Article						hormones; MAPRC2; mifepristone; progesterone; progesterone receptor; Trichinella spiralis	TH2-TYPE CYTOKINES; DOMESTIC PIGS; IN-VITRO; EXPRESSION; PREGNANCY; SEQUENCE; IMMUNITY; HORMONES; PROTEIN; HENAN	Trichinellosis is a foodborne zoonotic disease caused by Trichinella spp., including Trichinella spiralis. In the present study, T. spiralis membrane-associated progesterone receptor component-2 (Ts-MAPRC2) gene was cloned and characterized using protein sequencing analysis. Furthermore, the expression, purification, immunoblot assay, binding ability with progesterone antibody, and immunofluorescence assay were performed. A direct effect of progesterone (P4) and mifepristone (RU486) on the Ts-MAPRC2 gene was determined using in vitro cell culture that showed different expression levels at all developmental stages (muscle larvae (ML), female adult worm (F-AL), male adult worm (M-AL), and newborn larvae (NBL)). Subsequently, the in vitro phenotypic effects of P4, RU486, and rTs-MAPRC2-Ab on F-AL and ML stages were measured. Later, the in vivo phenotypic effect and relative mRNA expression of mifepristone on the F-AL stage were studied. Our results revealed that the Ts-MAPRC2 gene is critical to maintaining pregnancy in the female adult worm (F-AL) of T. spiralis. The 300 ng/mL of P4 and 100 ng/mL of RU486 showed downregulation of the Ts-MAPRC2 gene in F-AL (p <= 0.05). This plays an important role in abortion and possibly decreases the worm burden of T. spiralis in the host. Only 30 ng/mL P4 showed significant upregulation in F-AL (p <= 0.05). The current study provides new insights regarding the antihormone (P4 and RU486) drug design and vaccine therapy of recombinant (rTs-MAPRC2) protein as well as their combined effects to control T. spiralis infection.	[Aleem, Muhammad Tahir; Shi, Jiawen; Yu, Zhengqing; Wen, Zhaohai; Zhang, Yang; Liang, Meng; Lakho, Shakeel Ahmed; Haseeb, Muhammad; Ali, Haider; Hassan, Muhammad Waqas; Song, Xiaokai; Li, Xiangrui; Xu, Lixin; Yan, Ruofeng] Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Nanjing 210095, Peoples R China		Yan, RF (通讯作者)，Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Nanjing 210095, Peoples R China.	2018207076@njau.edu.cn; 2019107080@njau.edu.cn; 2018207044@njau.edu.cn; 2019207057@njau.edu.cn; 2018207018@njau.edu.cn; 2018207024@njau.edu.cn; 2017207046@njau.edu.cn; 2016207041@njau.edu.cn; 2018207074@njau.edu.cn; 2015207037@njau.edu.cn; songxiaokai@njau.edu.cn; lixiangrui@njau.edu.cn; xulixin@njau.edu.cn; yanruofeng@njau.edu.cn		ALEEM, MUHAMMAD TAHIR/0000-0001-8899-2777; Haseeb, Muhammad/0000-0002-2587-0171; hasan, Muhammad waqqas/0000-0001-8560-7714	Natural Science Foundation of Jiangsu Province, ChinaNatural Science Foundation of Jiangsu Province [BK20141365]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the Natural Science Foundation of Jiangsu Province, China (BK20141365) and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Aguilar-Diaz H, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2703-1; Aimulajiang K, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10010138; Anderson L.L., 2009, REPROD BIOL PIGS; Anzaldua SR, 2002, ANAT HISTOL EMBRYOL, V31, P308, DOI 10.1046/j.1439-0264.2002.00414.x; Bai X, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01472; Cahill MA, 2007, J STEROID BIOCHEM, V105, P16, DOI 10.1016/j.jsbmb.2007.02.002; Chen JZ, 2014, MED RES REV, V34, P979, DOI 10.1002/med.21311; Cui J, 2011, VET J, V190, P323, DOI 10.1016/j.tvjl.2010.12.025; Cui J, 2013, VET PARASITOL, V194, P133, DOI 10.1016/j.vetpar.2013.01.038; Falkenstein E, 1996, BIOCHEM BIOPH RES CO, V229, P86, DOI 10.1006/bbrc.1996.1761; Feng S, 2013, J PARASITOL, V99, P426, DOI 10.1645/12-46.1; Gagliardo LF, 2002, INFECT IMMUN, V70, P1853, DOI 10.1128/IAI.70.4.1853-1859.2002; Gonzalez CG, 1997, J ENDOCRINOL INVEST, V20, P397, DOI 10.1007/BF03347991; Gu Y, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01475; Hlaka Lerato, 2017, J Parasit Dis, V41, P799, DOI 10.1007/s12639-017-0891-9; Hu W, 2003, NAT GENET, V35, P139, DOI 10.1038/ng1236; Ikoma D., 2018, CLIN OBSTET GYNECOL, V4, P4, DOI [10.15761/COGRM.1000205, DOI 10.15761/COGRM.1000205]; Jiang P, 2016, PARASITOL RES, V115, P4707, DOI 10.1007/s00436-016-5240-x; Kapp N, 2013, CONTRACEPTION, V88, P350, DOI 10.1016/j.contraception.2012.10.027; Liu RD, 2013, PARASITOL RES, V112, P4113, DOI 10.1007/s00436-013-3602-1; LIU TC, 1993, ENDOCRINOLOGY, V132, P1189, DOI 10.1210/en.132.3.1189; Losel RM, 2008, STEROIDS, V73, P929, DOI 10.1016/j.steroids.2007.12.017; Miller L, 1996, LIFE SCI, V59, P1, DOI 10.1016/0024-3205(96)00122-1; Miyaura H, 2002, J IMMUNOL, V168, P1087, DOI 10.4049/jimmunol.168.3.1087; Murrell KD, 2011, EMERG INFECT DIS, V17, P2194, DOI 10.3201/eid1712.110896; Nunez GG, 2005, PARASITOLOGY, V131, P255, DOI 10.1017/S0031182005007468; Oliveira G, 2001, TRENDS PARASITOL, V17, P501, DOI 10.1016/S1471-4922(01)02019-0; Peluso JJ, 2006, BIOL REPROD, V75, P2, DOI 10.1095/biolreprod.105.049924; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Piccinni MP, 2000, J NEUROIMMUNOL, V109, P30, DOI 10.1016/S0165-5728(00)00299-X; Roberts CW, 2001, CLIN MICROBIOL REV, V14, P476, DOI 10.1128/CMR.14.3.476-488.2001; Song YY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01544; VIRGO BB, 1974, ENDOCRINOLOGY, V95, P1486, DOI 10.1210/endo-95-5-1486; Wang L, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-40; WHO, 2016, MULT BAS RANK RISK M; Yang Y, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00122; Yang Y, 2015, PARASITOLOGY, V142, P783, DOI 10.1017/S0031182014001851; Yang ZS, 2018, VACCINE, V36, P248, DOI 10.1016/j.vaccine.2017.11.048; Yu Y.R., 2015, J INFECT DIS THER, V3, P251, DOI [10.4172/2332-0877.1000251, DOI 10.4172/2332-0877.1000251]; Yu ZQ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040357; Zhang NZ, 2018, TRANSBOUND EMERG DIS, V65, P1447, DOI 10.1111/tbed.12917	42	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							934	10.3390/vaccines9080934			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5II	34452060	Green Published, Green Submitted, gold			2022-04-29	WOS:000689964000001
J	Chang, CW; Liu, YC; Jiao, C; Liu, HW; Gong, J; Chen, XC; Chang, LJ				Chang, Cheng-Wei; Liu, Yuchen; Jiao, Cheng; Liu, Hongwei; Gong, Jie; Chen, Xiaochuan; Chang, Lung-Ji			A Glimpse into the Diverse Cellular Immunity against SARS-CoV-2	VACCINES			English	Article						COVID-19; SARS-CoV-2; cellular immunity; vaccine	EPSTEIN-BARR-VIRUS; T-CELLS	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific cellular immune response has been shown to play a critical role in preventing severe illness or death in patients infected with SARS-CoV-2 or its variants. Given the multiple T-cell epitopes shared by wild-type virus and its variants, we hypothesized that vaccines that target multiple T-cell epitopes of SARS-CoV-2 may provide a "universal protection" against the wild-type virus as well as its variants, even the heavily mutated ones. To test this, we assessed SARS-CoV-2-specific T-cell precursors in healthy individuals using overlapping peptide pools of SARS-CoV-2 structural and functional proteins, including spike (S), membrane (M), envelope (E), nucleocapsid (N), and protease (P) proteins as target antigens. Diverse T-cell precursor frequencies specific to these viral antigens were detected in healthy individuals, including high, medium, low, and no responders. This was further confirmed by efficient induction of anti-SARS-CoV-2 T-cell immune responses using ex vivo dendritic cell (DC)/T cell coculture. The results demonstrated T-cell responses consistent with the precursor frequencies of each of the individuals tested. Importantly, the combination of all five viral peptide pools induced the strongest cellular immune response, and further, after a DC-peptides re-stimulation, even the no responders developed an increased anti-viral T-cell response. These analyses recapitulate the presence of a broad anti-SARS-CoV-2 cellular immunity even in an immune naive population, which could be enhanced by antigen presenting cells presenting the overlapping antigenic peptides. Given the critical role of cellular immunity in COVID-19 protection, these results have important implications for vaccine design and immunotherapy in fighting SARS-CoV-2 and its variants.	[Chang, Cheng-Wei; Liu, Yuchen; Jiao, Cheng; Chen, Xiaochuan; Chang, Lung-Ji] Shenzhen Genoimmune Med Inst, Shenzhen 518000, Peoples R China; [Liu, Hongwei; Gong, Jie; Chang, Lung-Ji] Univ Elect Sci & Technol China, Sch Med, Chengdu 610054, Peoples R China; [Chen, Xiaochuan] Wellness Med Ctr, Rochelle Pk, NY 07662 USA		Chang, LJ (通讯作者)，Shenzhen Genoimmune Med Inst, Shenzhen 518000, Peoples R China.; Chang, LJ (通讯作者)，Univ Elect Sci & Technol China, Sch Med, Chengdu 610054, Peoples R China.	agdsogood@163.com; yuchenliu601@yeah.net; verajoe@mail.ru; l200711440714@163.com; 18647442552@163.com; xiaochuan.chen@szgimi.org; c@szgimi.org		Chang, Lung-Ji/0000-0003-2395-5216	Science and Technology Planning Technical Research Project of Shenzhen [KQTD20140630143254906, JCYJ20170817172416991]; Foundation for Introduction and Training of Outstanding Scholarship of the National "985" Project [985: A1098531023601102]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [ZYGX2016Z009]	This work is funded by research funds from the Science and Technology Planning Technical Research Project of Shenzhen (KQTD20140630143254906, JCYJ20170817172416991) and the Foundation for Introduction and Training of Outstanding Scholarship of the National "985" Project (Project 985: A1098531023601102) and the Fundamental Research Funds for the Central Universities (ZYGX2016Z009).	Alshukairi AN, 2016, EMERG INFECT DIS, V22, P1113, DOI 10.3201/eid2206.160010; Altmann DM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6160; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Birra D, 2020, IMMUNOL RES, V68, P161, DOI 10.1007/s12026-020-09137-5; Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen N, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30183-5]; Chen Xiaochuan, 2004, Retrovirology, V1, P37, DOI 10.1186/1742-4690-1-37; Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003; Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312; Dong Lujia, 2010, J Pediatr Hematol Oncol, V32, pe31, DOI 10.1097/MPH.0b013e3181bf5e2d; Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Han SH, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-34; Hanley PJ, 2011, CYTOTHERAPY, V13, P976, DOI 10.3109/14653249.2011.575356; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Iwasaki A, 2020, NAT REV IMMUNOL, V20, P339, DOI 10.1038/s41577-020-0321-6; Kannan K, 1996, CELL IMMUNOL, V171, P10, DOI 10.1006/cimm.1996.0167; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Neumann-Haefelin C, 2013, CURR OPIN RHEUMATOL, V25, P426, DOI 10.1097/BOR.0b013e328362018f; Odak I, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102885; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shin HS, 2019, CLIN INFECT DIS, V68, P984, DOI 10.1093/cid/ciy595; Tan MK, 2020, IMMUNOLOGY, V160, P261, DOI 10.1111/imm.13223; Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang B, 2020, J MED VIROL, V92, P1684, DOI 10.1002/jmv.25946; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Zhou P., 2020, NATURE, V579, P270, DOI [10.1038/s41586-020-2012-7, DOI 10.1038/s41586-020-2012-7]	35	0	0	4	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							827	10.3390/vaccines9080827			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9OD	34451952	Green Published, gold, Green Submitted			2022-04-29	WOS:000690249500001
J	Porat, T; Burnell, R; Calvo, RA; Ford, E; Paudyal, P; Baxter, WL; Parush, A				Porat, Talya; Burnell, Ryan; Calvo, Rafael A.; Ford, Elizabeth; Paudyal, Priya; Baxter, Weston L.; Parush, Avi			"Vaccine Passports" May Backfire: Findings from a Cross-Sectional Study in the UK and Israel on Willingness to Get Vaccinated against COVID-19	VACCINES			English	Article						COVID-19; public health; self-determination theory; vaccine passports; vaccination	SELF-DETERMINATION THEORY; REASONS	Domestic "vaccine passports" are being implemented across the world as a way of increasing vaccinated people's freedom of movement and to encourage vaccination. However, these vaccine passports may affect people's vaccination decisions in unintended and undesirable ways. This cross-sectional study investigated whether people's willingness and motivation to get vaccinated relate to their psychological needs (autonomy, competence and relatedness), and how vaccine passports might affect these needs. Across two countries and 1358 participants, we found that need frustration-particularly autonomy frustration-was associated with lower willingness to get vaccinated and with a shift from self-determined to external motivation. In Israel (a country with vaccine passports), people reported greater autonomy frustration than in the UK (a country without vaccine passports). Our findings suggest that control measures, such as domestic vaccine passports, may have detrimental effects on people's autonomy, motivation, and willingness to get vaccinated. Policies should strive to achieve a highly vaccinated population by supporting individuals' autonomous motivation to get vaccinated and using messages of autonomy and relatedness, rather than applying pressure and external controls.	[Porat, Talya; Burnell, Ryan; Calvo, Rafael A.; Baxter, Weston L.] Imperial Coll London, Dyson Sch Design Engn, London SW7 2DB, England; [Ford, Elizabeth; Paudyal, Priya] Brighton & Sussex Med Sch, Dept Primary Care & Publ Hlth, Brighton BN1 9PH, E Sussex, England; [Parush, Avi] Technion Israel Inst Technol, Fac Ind Engn & Management, IL-3200003 Haifa, Israel		Porat, T (通讯作者)，Imperial Coll London, Dyson Sch Design Engn, London SW7 2DB, England.	t.porat@imperial.ac.uk; r.burnell@imperial.ac.uk; r.calvo@imperial.ac.uk; E.M.Ford@bsms.ac.uk; P.Paudyal@bsms.ac.uk; weston.baxter@imperial.ac.uk; aparush@technion.ac.il		Ford, Elizabeth/0000-0001-5613-8509	Leverhulme Centre for the Future of Intelligence	R.B. and R.A.C. are funded by the Leverhulme Centre for the Future of Intelligence.	Balicer RD, 2021, SCIENCE, V372, P663, DOI 10.1126/science.abj3858; Benita M, 2020, MOTIV EMOTION, V44, P67, DOI 10.1007/s11031-019-09781-x; Brown RCH, 2021, LANCET INFECT DIS, V21, pE58, DOI 10.1016/S1473-3099(20)30766-0; Carmi R., 2021, TELEGRAPH; Chen BW, 2015, MOTIV EMOTION, V39, P216, DOI 10.1007/s11031-014-9450-1; Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01; Del Riccio M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060633; Demasi M., 2021, BMJ-BRIT MED J, V373, pN861, DOI [10.1136/bmj.n861, DOI 10.1136/BMJ.N861]; Douglas KM, 2017, CURR DIR PSYCHOL SCI, V26, P538, DOI 10.1177/0963721417718261; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; GOV.UK GOV.UK, CORONAVIRUS COVID 19; Haerens L, 2015, PSYCHOL SPORT EXERC, V16, P26, DOI 10.1016/j.psychsport.2014.08.013; KFF, VACC PASSP WHAT WE K; Kofler N, 2020, NATURE, V581, P379, DOI 10.1038/d41586-020-01451-0; Levesque CS, 2007, HEALTH EDUC RES, V22, P691, DOI 10.1093/her/cyl148; Markland D, 2010, PSYCHOL SPORT EXERC, V11, P91, DOI 10.1016/j.psychsport.2009.07.001; Martela F, 2021, EUR REV SOC PSYCHOL, V32, P305, DOI 10.1080/10463283.2020.1857082; Ng JYY, 2012, PERSPECT PSYCHOL SCI, V7, P325, DOI 10.1177/1745691612447309; Our World in Data (OWiD), COR COV 19 VACC; Pelletier LG, 2001, MOTIV EMOTION, V25, P279, DOI 10.1023/A:1014805132406; Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017; Porat T, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.573397; Prolific, IT WORKS; Rosen B, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00440-6; RYAN RM, 1989, J PERS SOC PSYCHOL, V57, P749, DOI 10.1037/0022-3514.57.5.749; Ryan RM, 2017, SELF-DETERMINATION THEORY: BASIC PSYCHOLOGICAL NEEDS IN MOTIVATION, DEVELOPMENT, AND WELLNESS, P1, DOI 10.1521/978.14625/28806; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Ryan RM., 2008, EUROPEAN HLTH PSYCHO, V10, P2, DOI DOI 10.1080/17509840701827437; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; The Local Denmark, DENMARK LAUNCHES NEW; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; Vansteenkiste M, 2020, MOTIV EMOTION, V44, P1, DOI 10.1007/s11031-019-09818-1; Vansteenkiste M, 2013, J PSYCHOTHER INTEGR, V23, P263, DOI 10.1037/a0032359; Voo TC, 2021, B WORLD HEALTH ORGAN, V99, P155, DOI 10.2471/BLT.20.280701	34	6	6	6	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							902	10.3390/vaccines9080902			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6MT	34452027	Green Accepted, Green Published, gold			2022-04-29	WOS:000690043100001
J	Sowa, P; Kiszkiel, L; Laskowski, PP; Alimowski, M; Szczerbinski, L; Paniczko, M; Moniuszko-Malinowska, A; Kaminski, K				Sowa, Pawel; Kiszkiel, Lukasz; Laskowski, Piotr Pawel; Alimowski, Maciej; Szczerbinski, Lukasz; Paniczko, Marlena; Moniuszko-Malinowska, Anna; Kaminski, Karol			COVID-19 Vaccine Hesitancy in Poland-Multifactorial Impact Trajectories	VACCINES			English	Article						vaccine hesitancy; COVID-19; vaccine acceptability; SARS-CoV-2	INTENTION; WILLINGNESS	Since the declaration of the SARS-CoV-2 pandemic confirmed by World Health Organization, work on the development of vaccines has been stimulated. When vaccines are commonly available, a major problem is persistent vaccine hesitancy in many European countries. The main goal of our study was to understand the multidimensional factors inducing this phenomenon in Poland. Our study was carried out at the third wave's peak of the pandemic, with record rates of daily cases and deaths associated with COVID-19. The results indicate that vaccine hesitancy/acceptability should always be considered in an interdisciplinary manner and according to identified factors where most negative attitudes could be altered. Our analyses included the assessment of a representative quota sample of adult Poles (N = 1000). The vaccine hesitancy in the studied group reached 49.2%. We performed stepwise logistic regression modeling to analyze variables set into six trajectories (groups) predicting the willingness to vaccinate. Apart from typical, socio-demographic and economic determinants, we identified the fear of vaccines' side effects, beliefs in conspiracy theories and physical fitness. We were also able to establish the order of importance of factors used in a full model of all impact trajectories.	[Sowa, Pawel; Paniczko, Marlena; Kaminski, Karol] Med Univ Bialystok, Dept Populat Med & Lifestyle Dis Prevent, Waszyngtona 13A, PL-15089 Bialystok, Poland; [Kiszkiel, Lukasz; Laskowski, Piotr Pawel] Univ Bialystok, Soc & Cognit Unit, PL-15403 Bialystok, Poland; [Alimowski, Maciej] Univ Bialystok, Doctoral Sch Social Sci, PL-15403 Bialystok, Poland; [Szczerbinski, Lukasz] Med Univ Bialystok, Dept Endocrinol Diabetol & Internal Med, PL-15276 Bialystok, Poland; [Szczerbinski, Lukasz] Med Univ Bialystok, Clin Res Ctr, PL-15276 Bialystok, Poland; [Moniuszko-Malinowska, Anna] Med Univ Bialystok, Dept Infect Dis & Neuroinfect, PL-15089 Bialystok, Poland; [Kaminski, Karol] Univ Hosp Bialystok, Dept Cardiol, PL-15276 Bialystok, Poland		Kaminski, K (通讯作者)，Med Univ Bialystok, Dept Populat Med & Lifestyle Dis Prevent, Waszyngtona 13A, PL-15089 Bialystok, Poland.; Kaminski, K (通讯作者)，Univ Hosp Bialystok, Dept Cardiol, PL-15276 Bialystok, Poland.	sowa@umb.edu.pl; lukaszkiszkiel@gmail.com; pio.laskowski@gmail.com; m.alimowski@uwb.edu.pl; lukasz.szczerbinski@umb.edu.pl; m.paniczko@gmail.com; annamoniuszko@op.pl; fizklin@gmail.com	Dubatówka, Marlena/ABD-5464-2021; Kaminski, Karol/J-4515-2014; Moniuszko, Anna/T-8136-2018	Dubatówka, Marlena/0000-0001-5977-0745; Kaminski, Karol/0000-0002-9465-2581; Alimowski, Maciej/0000-0003-0290-4217; Moniuszko, Anna/0000-0002-3994-8785; Kiszkiel, Lukasz/0000-0002-0712-3260; Szczerbinski, Lukasz/0000-0002-6201-0605; Laskowski, Piotr/0000-0002-8512-607X	National Science CentreNational Science Centre, Poland [2020/37/B/NZ7/03380]	This research was funded by the National Science Centre grant within the program OPUS-19 (grant number 2020/37/B/NZ7/03380).	Ali KF, 2020, J MED INTERNET RES, V22, DOI 10.2196/19913; [Anonymous], DIFFERENT COVID 19 V; [Anonymous], TREATMENTS VACCINES; Bertin P, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.565128; Betsch C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034869; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Brotherton R, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00279; Brown JB, 2018, MOL INFORM, V37, DOI 10.1002/minf.201700127; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gemenis K., COVID 19 CONSPIRACY; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Grabowski J, 2021, EUROSURVEILLANCE, V26, P18, DOI 10.2807/1560-7917.ES.2021.26.7.2100117; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Kachurka R., 2021, WORK PAP U WARS FAC, V7, P335; Konopinska J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040371; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Li X., 2019, ARXIV190610845; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Pisaniak P, 2021, INT J GEN MED, V14, P3235, DOI 10.2147/IJGM.S302699; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sarasty O, 2020, VACCINE, V38, P8090, DOI 10.1016/j.vaccine.2020.11.013; Seale H, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05833-1; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Silva B.C., 2019, MULTILEVEL STRUCTURA, V1; Silva BC, 2017, SWISS POLIT SCI REV, V23, P423, DOI 10.1111/spsr.12270; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; The SAGE Vaccine Hesitancy Working Group, 2013, WHAT INFL VACC ACC M; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Wawrzuta D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050481; Wolf MS, 2020, ANN INTERN MED, V173, P100, DOI 10.7326/M20-1239; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wu J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22034-1; Zuo JM, 2021, NAT IMMUNOL, V22, P620, DOI 10.1038/s41590-021-00902-8	53	14	14	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							876	10.3390/vaccines9080876			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8QK	34452001	Green Published, gold			2022-04-29	WOS:000690187800001
J	Torres-Corral, Y; Girons, A; Gonzalez-Barreiro, O; Seoane, R; Riaza, A; Santos, Y				Torres-Corral, Yolanda; Girons, Albert; Gonzalez-Barreiro, Oscar; Seoane, Rafael; Riaza, Ana; Santos, Ysabel			Effect of Bivalent Vaccines against Vibrio anguillarum and Aeromonas salmonicida Subspecie achromogenes on Health and Survival of Turbot	VACCINES			English	Article						atypical furunculosis; vibriosis; autogenous vaccine; turbot; adjuvants	SALMO-SALAR L.; SCOPHTHALMUS-MAXIMUS L.; ATLANTIC SALMON; RAINBOW-TROUT; FISH; FURUNCULOSIS; VACCINATION; PROTECTION; INJECTION; ANTIGENS	The efficacy of intraperitoneal injection of an oil-based bivalent autogenous vaccine and the commercial vaccine AlphaJect 3000 (Pharmaq AS) to prevent atypical furunculosis and vibriosis in turbot was analyzed. The effect of both vaccines on health parameters and survival of fish after challenge with V. anguillarum and A. salmonicida subsp. achromogenes was tested. The autogenous vaccine conferred high levels of protection and long-lasting immunity against both pathogens with a single dose. However, severe side effects were observed in turbot injected with this autovaccine and minor negative effects with the AlphaJect 3000 vaccine and the adjuvant Montanide or Eolane. All vaccinated fish showed remarkable antibody agglutination titers, higher than those of control fish, which were maintained 160 d after vaccination. In conclusion, the autogenous bivalent vaccine induces long-lasting protection against atypical furunculosis and vibriosis in turbot, after administration of a single dose, at the cost of high side effects in fish. Therefore, the development of new vaccines should focus on autovaccines and the use of liquid paraffin adjuvants that increase protection with reduced or no side effects.	[Torres-Corral, Yolanda; Santos, Ysabel] Univ Santiago de Compostela, Inst Anal Quim & Biol IAQBUS, Dept Microbiol & Parasitol, Santiago De Compostela 15782, Spain; [Girons, Albert] Ictiovet SL, Barcelona 08025, Spain; [Gonzalez-Barreiro, Oscar; Riaza, Ana] Stolt Sea Farm, Edificio Quercus, Santiago De Compostela 15707, Spain; [Seoane, Rafael] Univ Santiago de Compostela, Fac Med & Odontol, Dept Microbiol & Parasitol, Santiago De Compostela 15782, Spain		Torres-Corral, Y; Santos, Y (通讯作者)，Univ Santiago de Compostela, Inst Anal Quim & Biol IAQBUS, Dept Microbiol & Parasitol, Santiago De Compostela 15782, Spain.	yolanda.torres.corral@gmail.com; albert.girons@ictiovet.com; o.gonzalez@stolt.com; rafael.seoane@usc.es; a.riaza@stolt.com; ysabel.santos@usc.es	Santos, Ysabel/L-2466-2014; Seoane, Rafael/AAQ-6594-2021	Santos, Ysabel/0000-0003-4398-4102; Seoane, Rafael/0000-0001-8719-4503; Torres Corral, Yolanda/0000-0002-7959-1645	Proof-of-Concept Program "Acelerador de Transferencia" from the Universidade of Santiago de Compostela (Spain)	This work was partially supported by the Proof-of-Concept Program "Acelerador de Transferencia" from the Universidade of Santiago de Compostela (Spain).	Aucouturier J, 2001, VACCINE, V19, P2666, DOI 10.1016/S0264-410X(00)00498-9; Austin B, 2016, BACTERIAL FISH PATHO; Bao PC, 2019, FISH SHELLFISH IMMUN, V88, P84, DOI 10.1016/j.fsi.2019.02.014; Berg A, 2006, DIS AQUAT ORGAN, V69, P239, DOI 10.3354/dao069239; Berg A, 2007, AQUACULTURE, V265, P9, DOI 10.1016/j.aquaculture.2007.02.014; Bjornsdottir B, 2005, J FISH DIS, V28, P181, DOI 10.1111/j.1365-2761.2005.00617.x; Bondad-Reantaso MG, 2012, 547 FAO; Buller N. B., 2014, Bacteria and fungi from fish and other aquatic animals: A practical identification manual, DOI 10.1079/9781845938055.0000; Cazenave J, 2005, HYDROBIOLOGIA, V537, P25, DOI 10.1007/s10750-004-1638-z; Coscelli G. A., 2015, Aquaculture, V445, P22, DOI 10.1016/j.aquaculture.2015.04.011; Failde LD, 2013, MICROB PATHOGENESIS, V65, P82, DOI 10.1016/j.micpath.2013.09.003; Dekic, 2016, PRAX VET, V53, P191; Durbin AP, 1999, J INFECT DIS, V179, P1345, DOI 10.1086/314769; Ellis AE, 1997, DEV BIOLOGICALS, V90, P107; European Commission, 2010, EUR WORLDS NO 1 TOUR, P2; FAO, 2018, EST MUND PESC AC 201; Fazio F, 2019, AQUACULTURE, V500, P237, DOI 10.1016/j.aquaculture.2018.10.030; Garcia Carballas C.M., 2018, THESIS U SANTIAGO CO; Gudmundsdottir BK, 2007, VACCINE, V25, P5512, DOI 10.1016/j.vaccine.2007.02.009; Hastein T, 2005, DEV BIOLOGICALS, V121, P55; Jaafar RM, 2015, FISH SHELLFISH IMMUN, V47, P797, DOI 10.1016/j.fsi.2015.10.023; Kim JH, 2014, ASIAN AUSTRAL J ANIM, V27, P1360, DOI 10.5713/ajas.2014.14110; Koppang EO, 2005, J FISH DIS, V28, P13, DOI 10.1111/j.1365-2761.2004.00583.x; Li J, 2020, AQUACULTURE, V524, DOI 10.1016/j.aquaculture.2020.735259; Liu XH, 2018, VACCINE, V36, P1460, DOI 10.1016/j.vaccine.2018.01.067; Melingen GO, 2002, AQUACULTURE, V214, P397, DOI 10.1016/S0044-8486(01)00867-5; Menanteau-Ledouble S, 2016, DIS AQUAT ORGAN, V120, P49, DOI 10.3354/dao03006; Midtlyng PJ, 1998, DIS AQUAT ORGAN, V32, P91, DOI 10.3354/dao032091; Midtlyng PJ, 1997, DEV BIOLOGICALS, V90, P371; Mikkelsen H, 2011, FISH SHELLFISH IMMUN, V30, P330, DOI 10.1016/j.fsi.2010.11.007; Montenegro D, 2012, REV BIOL MAR OCEANOG, V47, P99, DOI 10.4067/S0718-19572012000100009; Mutoloki S, 2008, FISH SHELLFISH IMMUN, V24, P386, DOI 10.1016/j.fsi.2007.08.009; Noia M, 2014, FISH SHELLFISH IMMUN, V38, P244, DOI 10.1016/j.fsi.2014.03.020; NORQVIST A, 1989, APPL ENVIRON MICROB, V55, P1400, DOI 10.1128/AEM.55.6.1400-1405.1989; NOVOTNY AJ, 1978, US NMFS MAR FISH REV, V40, P52; Romstad AB, 2013, VACCINE, V31, P791, DOI 10.1016/j.vaccine.2012.11.069; Ronsholdt B, 1999, AQUACULTURE, V174, P213, DOI 10.1016/S0044-8486(99)00016-2; Santos Y, 2005, J FISH DIS, V28, P165, DOI 10.1111/j.1365-2761.2005.00610.x; SANTOS Y, 1995, APPL ENVIRON MICROB, V61, P2493, DOI 10.1128/AEM.61.7.2493-2498.1995; Satheeshkumar P., 2012, Comparative Clinical Pathology, V21, P1187, DOI 10.1007/s00580-011-1259-7; Toranzo AE, 2005, AQUACULTURE, V246, P37, DOI 10.1016/j.aquaculture.2005.01.002; Toranzo AE, 1997, DEV BIOLOGICALS, V90, P93; VIGNEULLE M, 1991, DIS AQUAT ORGAN, V11, P85, DOI 10.3354/dao011085; Villumsen KR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06324-7; Wiklund T, 1998, DIS AQUAT ORGAN, V32, P49, DOI 10.3354/dao032049	46	2	2	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							906	10.3390/vaccines9080906			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7KZ	34452031	gold, Green Published			2022-04-29	WOS:000690106100001
J	Halpin, K; Graham, K; Durr, PA				Halpin, Kim; Graham, Kerryne; Durr, Peter A.			Sero-Monitoring of Horses Demonstrates the Equivac (R) HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres	VACCINES			English	Article						Hendra virus; Hendra virus vaccine; One Health; zoonoses	G-GLYCOPROTEIN; RESPONSES; PROTECTS	Hendra virus (HeV) is a high consequence zoonotic pathogen found in Australia. The HeV vaccine was developed for use in horses and provides a One Health solution to the prevention of human disease. By protecting horses from infection, the vaccine indirectly protects humans as well, as horses are the only known source of infection for humans. The sub-unit-based vaccine, containing recombinant HeV soluble G (sG) glycoprotein, was released by Pfizer Animal Health (now Zoetis) for use in Australia at the end of 2012. The purpose of this study was to collate post-vaccination serum neutralising antibody titres as a way of assessing how the vaccine has been performing in the field. Serum neutralization tests (SNTs) were performed on serum samples from vaccinated horses submitted to the laboratory by veterinarians. The SNT results have been analysed, together with age, dates of vaccinations, date of sampling and location. Results from 332 horses formed the data set. Provided horses received at least three vaccinations (consisting of two doses 3-6 weeks apart, and a third dose six months later), horses had high neutralising titres (median titre for three or more vaccinations was 2048), and none tested negative.	[Halpin, Kim; Graham, Kerryne; Durr, Peter A.] Commonwealth Sci & Ind Res Org CSIRO, Australian Ctr Dis Preparedness ACDP, 5 Portarlington Rd, East Geelong, Vic 3219, Australia		Halpin, K (通讯作者)，Commonwealth Sci & Ind Res Org CSIRO, Australian Ctr Dis Preparedness ACDP, 5 Portarlington Rd, East Geelong, Vic 3219, Australia.	kim.halpin@csiro.au; kerryne.graham@csiro.au; peter.durr@csiro.au	Halpin, Kim/AFN-3101-2022; Durr, Peter/O-2948-2014	Durr, Peter/0000-0003-0851-5300; Halpin, Kim/0000-0002-1279-5010			[Anonymous], PTEROPUS POLIOCEPHAL, DOI DOI 10.2305/IUCN.UK.2008.RLTS.T18751A8554062.EN; Australian Pesticides and Veterinary Medicines Authority, HENDR VIR VACC PROD; Baldock F. C., 1996, Singapore Veterinary Journal, V20, P57; Barrett RS, 2021, AUST VET J, V99, P412, DOI 10.1111/avj.13099; Bossart KN, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004241; Bossart KN, 2005, J VIROL, V79, P6690, DOI 10.1128/JVI.79.11.6690-6702.2005; Broder CC, 2013, ANTIVIR RES, V100, P8, DOI 10.1016/j.antiviral.2013.06.012; Eby P., PTEROPUS SCAPULATUS, DOI [10.2305/IUCN.UK.2016-1.RLTS.T18758A22087637.en, DOI 10.2305/IUCN.UK.2016-1.RLTS.T18758A22087637.EN]; Hafi A., ESTIMATING VALUE AUS, DOI [10.25814/sqnq-k268, DOI 10.25814/SQNQ-K268]; Halpin K, 2000, J GEN VIROL, V81, P1927, DOI 10.1099/0022-1317-81-8-1927; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Horowitz A, 2010, J IMMUNOL, V185, P2808, DOI 10.4049/jimmunol.1000844; Johnson N, 2010, VACCINE, V28, P3896, DOI 10.1016/j.vaccine.2010.03.039; Mansfield KL, 2016, VACCINE, V34, P5959, DOI 10.1016/j.vaccine.2016.09.058; Manyweathers J, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1006-7; McEachern JA, 2008, VACCINE, V26, P3842, DOI 10.1016/j.vaccine.2008.05.016; McNabb L, 2014, J VIROL METHODS, V200, P22, DOI 10.1016/j.jviromet.2014.01.010; Middleton D, 2014, EMERG INFECT DIS, V20, P372, DOI 10.3201/eid2003.131159; MUMFORD JA, 1994, VET REC, V134, P158, DOI 10.1136/vr.134.7.158; MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; OIE, 2019, MANUAL DIAGNOSTIC TE; Paillot R, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5020042; Pallister J, 2011, VACCINE, V29, P5623, DOI 10.1016/j.vaccine.2011.06.015; Playford EG, 2010, EMERG INFECT DIS, V16, P219, DOI 10.3201/eid1602.090552; Roberts B., PTEROPUS CONSPICILLA, DOI [10.2305/IUCN.UK.2020-3.RLTS.T18721A22080456.en, DOI 10.2305/IUCN.UK.2020-3.RLTS.T18721A22080456.EN]; Roberts B., 2017, PTEROPUS ALECTO IUCN, DOI [10.2305/IUCN.UK.2017-2.RLTS.T18715A22080057.en, DOI 10.2305/IUCN.UK.2017-2.RLTS.T18715A22080057.EN]; Soboll G, 2010, VET IMMUNOL IMMUNOP, V135, P100, DOI 10.1016/j.vetimm.2009.11.007; Tan RHH, 2018, AUST VET J, V96, P161, DOI 10.1111/avj.12694; Taylor C, 2012, EMERG INFECT DIS, V18, P2025, DOI 10.3201/eid1812.120722; WHO, 2013, WHO TECH REP SER, V982, P1	30	0	0	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							731	10.3390/vaccines9070731			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5UX	34358146	Green Published			2022-04-29	WOS:000676977400001
J	Khuc, QV; Nguyen, T; Nguyen, T; Pham, L; Le, DT; Ho, HH; Truong, TB; Tran, QK				Quy Van Khuc; Trang Nguyen; Thuy Nguyen; Linh Pham; Dang-Trung Le; Hong-Hai Ho; Tien-Binh Truong; Quoc-Khai Tran			Young Adults' Intentions and Rationales for COVID-19 Vaccination Participation: Evidence from a Student Survey in Ho Chi Minh City, Vietnam	VACCINES			English	Article						COVID-19; vaccination participation; students; Ho Chi Minh city	VACCINES	The COVID-19 pandemic, a source of fear and anxiety worldwide, has caused many adverse impacts. Collaborative efforts to end COVID-19 have included extensive research on vaccines. Many vaccination campaigns have been launched in many countries, including Vietnam, to create community immunization. However, citizens' willingness to participate is a prerequisite for effective vaccination programs and other related policies. Among all demographic groups, participation rates among young adults are of interest because they are an important workforce and are a source of high infection risk in the community. In March 2021, a pool of approximately 6000 participants in Ho Chi Minh City were randomly polled using an email-based online survey. The exploratory results of 398 valid observations show that students' perceptions of the dangers of COVID-19 and the importance of vaccination were both relatively high (4.62/5 and 4.74/5, respectively). Furthermore, 83.41 percent of students polled (n = 332) chose vaccination, while 16.59 percent chose hesitation (n = 64) and not to be vaccinated (n = 2). More importantly, our estimated results of the Bayesian regression model (BRM) show that the perceived importance of the vaccine, concerns about the vaccine's side effects, and a lack of access to information are the top three reasons for their reluctance and/or refusal to get vaccinated. These findings are a valuable resource for politicians, researchers, and those interested in COVID-19 vaccinations to devise and execute campaigns to effectively combat this terrifying pandemic.	[Quy Van Khuc; Thuy Nguyen] Vietkaplab, Hanoi 100000, Vietnam; [Trang Nguyen] Natl Econ Univ, Sch Banking Finance, Hanoi 100000, Vietnam; [Linh Pham] Univ Cent Oklahoma, Dept Econ, Edmond, OK 73034 USA; [Dang-Trung Le] Real Time Analyt, Ho Chi Minh City 700000, Vietnam; [Hong-Hai Ho; Tien-Binh Truong] Phenikaa Univ, Fac Business & Econ, Hanoi 12116, Vietnam; [Quoc-Khai Tran] U Mirth Ha Natl Pk, Ca Mau 970000, Vietnam		Nguyen, T (通讯作者)，Vietkaplab, Hanoi 100000, Vietnam.	quy.khucvan@vietkap.com; 11207216@st.neu.edu.vn; K58.1911140567@ftu.edu.vn; lpham17@uco.edu; trungle@rta.vn; hai.hohong@phenikaa-uni.edu.vn; binh.truongtien@phenikaa-uni.edu.vn; vqguminhha@gmail.com	Khuc, Quy/X-2279-2019	Khuc, Quy/0000-0001-9516-2413; Ho, Hai/0000-0001-8123-157X; Nguyen, Thuy/0000-0002-7549-1399			Al-Qerem WA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.632914; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; Anh L., MINISTRY HLTH ANNOUN; Anh T., REACTION RATE COVID; Barasa, 2021, ASSESSING LEVEL DETE, P1, DOI [10.1101/2021.06.11.21258775, DOI 10.1101/2021.06.11.21258775]; Biasio LR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030268; Bo Y Te, VACC 15 1000 EMPL SA; Bo Y Te, PRIM MIN DIR LSO WHO; Bo Y Te, COVID 19 ACUT RESP I; Bo Y Te, COVID 19 VACC STR WI; Cahapay MB, 2022, J HUM BEHAV SOC ENVI, V32, P325, DOI 10.1080/10911359.2021.1896409; de Moura MC, 2021, EBIOMEDICINE, V66, DOI 10.1016/j.ebiom.2021.103339; Centers for Disease Control and Prevention, SCI BRIEF COVID 19 V; Centers for Disease Control and Prevention (CDC), BEN GETT COVID 19 VA; Centers for Disease Control and Prevention (CDC), 2021, LARG CDC COVID 19 VA; Chan T., JUNE 20 1000 WORKERS; Courtot, 2021, CONFRONTING COVID 19; Dan L., PVFCCO DEPLOYS VACCI; de Figueiredo A., 2021, COVID 19 VACCINE ACC, DOI [10.1101/2021.05.30.21258074, DOI 10.1101/2021.05.30.21258074]; Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505; Dexter F, 2013, ANESTH ANALG, V117, P537, DOI 10.1213/ANE.0b013e31829ed28f; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Green MS, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00458-w; Harapan H, 2020, HUM VACC IMMUNOTHER, V16, P3074, DOI 10.1080/21645515.2020.1819741; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Hou ZY, 2014, VACCINE, V32, P4471, DOI 10.1016/j.vaccine.2014.06.047; Kadoya Y, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094864; Kennethe D., 1994, BAILEY METHODS SOCIA; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Khuc, 2021, OSF PREPR, DOI [10.31219/osf.io/qpa9t, DOI 10.31219/OSF.IO/QPA9T]; Kreps SE, 2021, VACCINE, V39, P3250, DOI 10.1016/j.vaccine.2021.04.044; Larson A., 2021, EXPLORING BEHAV DETE, DOI [10.1101/2021.04.23.21255974, DOI 10.1101/2021.04.23.21255974]; Latkin CA, 2021, SOC SCI MED, V270, DOI 10.1016/j.socscimed.2021.113684; Lazarus JV, 2020, J HEALTH COMMUN, V25, P799, DOI 10.1080/10810730.2020.1868630; Le TAT, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020559; Long H., MORE 69500 EMPLOYEES; Luan T., COVID 19 MAKES VIETN; Mai T., HO CHI MINH CITY POP; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; McPhedran R, 2021, ECON LETT, V200, DOI 10.1016/j.econlet.2021.109747; Muqattash R, 2020, DATA BRIEF, V33, DOI 10.1016/j.dib.2020.106446; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nguyen T., VIETNAM FACES GREAT; Nhan D., 3 WAVE CORONAVIRUS V; Prekker M.E., 2021, CENT DIS CONTROL PRE, DOI [10.15585/mmwr.mm7008a4, DOI 10.15585/MMWR.MM7008A4]; Qin W, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250112; Vuong QH, 2020, METHODSX, V7, DOI 10.1016/j.mex.2020.100924; Khuc QV, 2021, FORESTS, V12, DOI 10.3390/f12050521; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Sun SF, 2021, PREV MED REP, V22, DOI 10.1016/j.pmedr.2021.101350; The SAGE Working Group on Vaccine Hesitancy, WHAT INF VACC ACC MO; Thuan T., 1 INJECTIONS; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Tran T, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12093819; van de Schoot R, 2014, CHILD DEV, V85, P842, DOI 10.1111/cdev.12169; La VP, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12072931; VNS, VIET NAM REC 1 DEATH; Vuong QH, 2021, DATA BRIEF, V36, DOI 10.1016/j.dib.2021.106991; Vuong QH, 2020, NATURE, V582, P149, DOI 10.1038/d41586-020-01694-x; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; World Bank, 2008, GLOBAL ECONOMIC PROSPECTS: TECHNOLOGY DIFFUSION IN THE DEVELOPING WORLD, P1, DOI 10.1596/978-0-8213-7365-1; Wright KB, 2005, J COMPUT-MEDIAT COMM, V10; Yang Y, 2021, J COMMUN HEALTH, V46, P1090, DOI 10.1007/s10900-021-00993-2; Yeo HY, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0163-2; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	72	9	9	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							794	10.3390/vaccines9070794			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TO7EE	34358210	gold, Green Published			2022-04-29	WOS:000677069100001
J	Vernet, R; Charrier, E; Grogg, J; Mach, N				Vernet, Remi; Charrier, Emily; Grogg, Julien; Mach, Nicolas			A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein	VACCINES			English	Review						SARS-CoV-2; COVID-19; ELISA; antibodies	COVID-19	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic with at least 3.8 million deaths to date. For that reason, finding an efficient vaccine for this virus quickly became a global priority. The majority of vaccines now marketed are based on the SARS-CoV-2 spike protein that has been described as the keystone for optimal immunization. In order to monitor SARS-CoV-2 spike-specific humoral responses generated by immunization or infection, we have developed a robust and reproducible enzyme-linked immunosorbent assay (ELISA) protocol. This protocol describes a method for quantitative detection of IgG antibodies against the SARS-CoV-2 spike protein using antigen-coated microtiter plates. Results showed that antibodies could be quantified between the range of 1.953 ng/mL to 500 ng/mL with limited inter- and intra-assay variability.	[Vernet, Remi; Charrier, Emily; Mach, Nicolas] Geneva Univ Hosp & Med Sch, Dept Oncol, CH-1211 Geneva, Switzerland; [Vernet, Remi; Charrier, Emily; Mach, Nicolas] Geneva Univ Hosp, Ctr Translat Res Oncohematol, Div Oncol, CH-1211 Geneva, Switzerland; [Vernet, Remi; Charrier, Emily; Mach, Nicolas] Univ Geneva, CH-1211 Geneva, Switzerland; [Charrier, Emily; Grogg, Julien] MaxiVAX SA, CH-1202 Geneva, Switzerland		Vernet, R (通讯作者)，Geneva Univ Hosp & Med Sch, Dept Oncol, CH-1211 Geneva, Switzerland.; Vernet, R (通讯作者)，Geneva Univ Hosp, Ctr Translat Res Oncohematol, Div Oncol, CH-1211 Geneva, Switzerland.; Vernet, R (通讯作者)，Univ Geneva, CH-1211 Geneva, Switzerland.	remi.vernet@hcuge.ch; emily.charrier@unige.ch; jgrogg@maxivax.ch; nicolas.mach@hcuge.ch	mach, nicolas/AAZ-5302-2021	VERNET, Remi/0000-0003-0213-3539; Charrier, Emily/0000-0001-6143-509X; Grogg, Julien/0000-0002-9479-0933	MaxiVAX	This work was funded by MaxiVAX. This financial support has not played any role in the study design, collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.	[Anonymous], WHO COR DIS COVID 19; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Chowdhury MA, 2020, J INFECT PUBLIC HEAL, V13, P1619, DOI 10.1016/j.jiph.2020.07.001; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Hormati A, 2021, IRAN J ALLERGY ASTHM, V20, P244, DOI 10.18502/ijaai.v20i2.6057; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Laing K., IMMUNE RESPONSES VIR; Liu XM, 2020, EMERG MICROBES INFEC, V9, P1269, DOI 10.1080/22221751.2020.1773324; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Marklund E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241104; Paces J, 2020, PHYSIOL RES, V69, P379, DOI 10.33549/physiolres.934492; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prakash O, 2021, CLIN EPIDEMIOL GLOB, V11, DOI 10.1016/j.cegh.2021.100766; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Simand, 2021, CANCER CELL, V39, P1, DOI [10.21203/rs.3.rs-554993/v1, DOI 10.21203/RS.3.RS-554993/V1]; Sreepadmanabh M, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-00114-6; Toor SM, 2021, IMMUNOLOGY, V162, P30, DOI 10.1111/imm.13262; Vernet R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050484; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang DL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030355; Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI [10.1172/JCI138759, 10.1172/JCI138759.]	21	0	0	8	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							770	10.3390/vaccines9070770			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7YE	34358186	gold, Green Published			2022-04-29	WOS:000677121100001
J	Wilson, WC; Faburay, B; Trujillo, JD; Ragan, I; Sunwoo, SY; Morozov, I; Shivanna, V; Balogh, A; Urbaniak, K; McVey, DS; Bold, D; Gaudreault, NN; Schirtzinger, EE; Ma, WJ; Richt, JA				Wilson, William C.; Faburay, Bonto; Trujillo, Jessie D.; Ragan, Izabela; Sunwoo, Sun-Young; Morozov, Igor; Shivanna, Vinay; Balogh, Aaron; Urbaniak, Kinga; McVey, D. Scott; Bold, Dashzeveg; Gaudreault, Natasha N.; Schirtzinger, Erin E.; Ma, Wenjun; Richt, Juergen A.			Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle	VACCINES			English	Article						Rift Valley fever virus; cattle; subunit vaccine; efficacy	MONOCLONAL-ANTIBODIES; GENETIC-CHARACTERIZATION; NONSTRUCTURAL PROTEINS; IMMUNOGENICITY; EFFICACY; SAFETY; MP-12; IGG	Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen that causes periodic outbreaks of abortion in ruminant species and hemorrhagic disease in humans in sub-Saharan Africa. These outbreaks have a significant impact on veterinary and public health. Its introduction to the Arabian Peninsula in 2003 raised concerns of further spread of this transboundary pathogen to non-endemic areas. These concerns are supported by the presence of competent vectors in many non-endemic countries. There is no licensed RVF vaccine available for humans and only a conditionally licensed veterinary vaccine available in the United States. Currently employed modified live attenuated virus vaccines in endemic countries lack the ability for differentiating infected from vaccinated animals (DIVA). Previously, the efficacy of a recombinant subunit vaccine based on the RVFV Gn and Gc glycoproteins, derived from the 1977 human RVFV isolate ZH548, was demonstrated in sheep. In the current study, cattle were vaccinated subcutaneously with the Gn only, or Gn and Gc combined, with either one or two doses of the vaccine and then subjected to heterologous virus challenge with the virulent Kenya-128B-15 RVFV strain, isolated from Aedes mosquitoes in 2006. The elicited immune responses by some vaccine formulations (one or two vaccinations) conferred complete protection from RVF within 35 days after the first vaccination. Vaccines given 35 days prior to RVFV challenge prevented viremia, fever and RVFV-associated histopathological lesions. This study indicates that a recombinant RVFV glycoprotein-based subunit vaccine platform is able to prevent and control RVFV infections in target animals.	[Wilson, William C.; McVey, D. Scott; Schirtzinger, Erin E.] ARS, USDA, Arthropod Borne Anim Dis Res Unit, Manhattan, KS 66502 USA; [Faburay, Bonto; Trujillo, Jessie D.; Ragan, Izabela; Sunwoo, Sun-Young; Morozov, Igor; Shivanna, Vinay; Balogh, Aaron; Urbaniak, Kinga; Bold, Dashzeveg; Gaudreault, Natasha N.; Ma, Wenjun; Richt, Juergen A.] Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA; [Faburay, Bonto] USDA, APHIS, Natl Vet Serv Labs Plum Isl Anim Dis Ctr, Greenport, NY 11944 USA; [Ragan, Izabela] Colorado State Univ, Ft Collins, CO 80523 USA; [Shivanna, Vinay] Texas Biomed Res Inst, San Antonio, TX 78227 USA; [Urbaniak, Kinga] Natl Vet Res Inst, PL-24100 Pulawy, Poland; [McVey, D. Scott] Univ Nebraska, Sch Vet Med & Biomed Sci, Lincoln, NE 68583 USA; [Ma, Wenjun] Univ Missouri, Dept Vet Pathobiol & Mol Microbiol & Immunol, Columbia, MO 65211 USA		Wilson, WC (通讯作者)，ARS, USDA, Arthropod Borne Anim Dis Res Unit, Manhattan, KS 66502 USA.; Richt, JA (通讯作者)，Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA.	william.wilson2@usda.gov; Bonto.Faburay@usda.gov; jdtrujillo@vet.k-state.edu; Izabela.Ragan@colostate.edu; sunwoosy@gmail.com; imorozov@vet.k-state.edu; vshivanna@txbiomed.org; aaron.balogh@wisc.edu; kinga.urbaniak@piwet.pulawy.pl; dmcvey2@unl.edu; bold@vet.k-state.edu; nng5757@k-state.edu; eesem@vet.k-state.edu; wma@missouri.edu; jricht@vet.k-state.edu	Shivanna, Vinay/AAC-9236-2019	Shivanna, Vinay/0000-0002-4625-954X; Ragan, Izabela/0000-0002-1379-6015; Sunwoo, Sun young/0000-0003-4688-641X; Urbaniak, Kinga/0000-0002-7965-9216; Wilson, William/0000-0002-7877-9224; McVey, David Scott/0000-0001-8321-3287	Department of Homeland SecurityUnited States Department of Homeland Security (DHS); Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD) [HSHQDC 16-A-B0006]; AMP Core of the Center on Emerging and Zoonotic Infectious Diseases (CEZID) of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20GM130448]; Kansas State NBAF Transition Funds; USDA, Agricultural Research ServiceUnited States Department of Agriculture (USDA)USDA Agricultural Research Service	This work was funded by grants of the Department of Homeland Security, the Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Grant No. HSHQDC 16-A-B0006, the AMP Core of the Center on Emerging and Zoonotic Infectious Diseases (CEZID) of the National Institutes of Health under award number P20GM130448, and Kansas State NBAF Transition Funds. This work was also partially supported by the USDA, Agricultural Research Service.	Al-Hazmi M, 2003, CLIN INFECT DIS, V36, P245, DOI 10.1086/345671; BESSELAAR TG, 1992, ARCH VIROL, V125, P239, DOI 10.1007/BF01309641; BESSELAAR TG, 1994, RES VIROLOGY, V145, P13, DOI 10.1016/S0923-2516(07)80002-1; BESSELAAR TG, 1991, RES VIROLOGY, V142, P469, DOI 10.1016/0923-2516(91)90069-F; CAPLEN H, 1985, J GEN VIROL, V66, P2271, DOI 10.1099/0022-1317-66-10-2271; Chengula AA, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-549; Chevalier V, 2013, CLIN MICROBIOL INFEC, V19, P705, DOI 10.1111/1469-0691.12163; Dungu B, 2010, VACCINE, V28, P4581, DOI 10.1016/j.vaccine.2010.04.085; Faburay B, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5030029; Faburay B, 2016, SCI REP-UK, V6, DOI 10.1038/srep27719; Faburay B, 2014, VECTOR-BORNE ZOONOT, V14, P746, DOI 10.1089/vbz.2014.1650; Faburay B, 2013, VECTOR-BORNE ZOONOT, V13, P619, DOI 10.1089/vbz.2012.1285; Fernandez JC, 2012, CLIN VACCINE IMMUNOL, V19, P5, DOI 10.1128/CVI.05420-11; Hossain MM, 2016, VECTOR-BORNE ZOONOT, V16, P550, DOI 10.1089/vbz.2014.1721; Hunter P, 2002, ONDERSTEPOORT J VET, V69, P95; Ikegami T, 2012, ANTIVIR RES, V95, P293, DOI 10.1016/j.antiviral.2012.06.001; Kading RC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006761; Kortekaas J, 2012, VACCINE, V30, P3423, DOI 10.1016/j.vaccine.2012.03.027; Kortekaas J, 2010, VACCINE, V28, P4394, DOI 10.1016/j.vaccine.2010.04.048; Kulkarni MA, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.33; Lagare A, 2019, VET MED SCI, V5, P70, DOI 10.1002/vms3.135; Linthicum KJ, 2016, ANNU REV ENTOMOL, V61, P395, DOI 10.1146/annurev-ento-010715-023819; Makoschey B, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004550; Maluleke MR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006576; Miller BR, 2002, EMERG INFECT DIS, V8, P1492, DOI 10.3201/eid0812.020194; Njenga MK, 2019, CURR CLIN MICROBIOL, V6, P18, DOI 10.1007/s40588-018-0110-1; Paweska JT, 2008, VET MICROBIOL, V127, P21, DOI 10.1016/j.vetmic.2007.07.031; Pittman PR, 2016, VACCINE, V34, P523, DOI 10.1016/j.vaccine.2015.11.078; Pittman PR, 2016, VACCINE, V34, P424, DOI 10.1016/j.vaccine.2015.12.030; Pittman PR, 1999, VACCINE, V18, P181, DOI 10.1016/S0264-410X(99)00218-2; Ragan IK, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/jcm.01626-17, 10.1128/JCM.01626-17]; Shoemaker TR, 2019, AM J TROP MED HYG, V100, P659, DOI 10.4269/ajtmh.18-0732; Spik K, 2006, VACCINE, V24, P4657, DOI 10.1016/j.vaccine.2005.08.034; Turell MJ, 2010, J MED ENTOMOL, V47, P884, DOI 10.1603/ME10007; van Vuren PJ, 2019, EMERG INFECT DIS, V25, P338, DOI 10.3201/eid2502.181289; von Teichman B, 2011, VACCINE, V29, P5771, DOI 10.1016/j.vaccine.2011.05.055; Warimwe GM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20617; WHO, RIFT VALL FEV MAYOTT RIFT VALL FEV MAYOTT; Schreur PJW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030301; Wilson WC, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8050145; Wilson WC, 2013, J VIROL METHODS, V193, P426, DOI 10.1016/j.jviromet.2013.07.006	41	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							748	10.3390/vaccines9070748			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5EQ	34358166	Green Published, gold			2022-04-29	WOS:000676935100001
J	Dudek, K; Szacawa, E; Nicholas, RAJ				Dudek, Katarzyna; Szacawa, Ewelina; Nicholas, Robin A. J.			Recent Developments in Vaccines for Bovine Mycoplasmoses Caused by Mycoplasma bovis and Mycoplasma mycoides subsp. mycoides	VACCINES			English	Review						vaccine; cattle; Mycoplasma bovis; Mycoplasma mycoides subsp; mycoides	CONTAGIOUS BOVINE; IMMUNE-RESPONSES; EXPERIMENTAL CHALLENGE; FIELD TRIAL; BIOFILM FORMATION; FEEDLOT CATTLE; PROTEINS; CALVES; VACCINATION; PROTECTION	Two of the most important diseases of cattle are caused by mycoplasmas. Mycoplasma bovis is a world-wide bovine pathogen that can cause pneumonia, mastitis and arthritis. It has now spread to most, if not all, cattle-rearing countries. Due to its increasing resistance to antimicrobial therapy, vaccination is the principal focus of the control of infection, but effective vaccines are currently lacking. Despite being eradicated from most parts of the world, Mycoplasma mycoides subsp. mycoides, the cause of contagious bovine pleuropneumonia (CBPP), continues to plague sub-Saharan Africa, affecting at least 25 countries. Numerous new experimental vaccines have been developed over the last 20 years to improve on protection afforded by the T1/44, a live vaccine in continuous use in Africa for over 60 years, but none so far have succeeded; indeed, many have exacerbated the disease. Tools for diagnosis and control are adequate for eradication but what is necessary are resources to improve vaccine coverage to levels last seen in the 1970s, when CBPP was restricted to a few countries in Africa. This paper summarizes the results of the main studies in the field of experimental mycoplasma vaccines, reviews data on commercially available bacterin vaccines and addresses issues relating to the search for new candidates for effective vaccines to reduce economic losses in the cattle industry caused by these two mycoplasmas.	[Dudek, Katarzyna; Szacawa, Ewelina] Natl Vet Res Inst, Dept Cattle & Sheep Dis, PL-24100 Pulawy, Poland; [Nicholas, Robin A. J.] The Oaks, Nutshell Lane, Farnham GU9 0HG, Surrey, England		Dudek, K (通讯作者)，Natl Vet Res Inst, Dept Cattle & Sheep Dis, PL-24100 Pulawy, Poland.	katarzyna.dudek@piwet.pulawy.pl; ewelina.szacawa@piwet.pulawy.pl; robin.a.j.nicholas@gmail.com		Szacawa, Ewelina/0000-0003-1815-5724			[Anonymous], DECADE PROTECTING LI; [Anonymous], MYCO B ONE DOSE; Bashiruddin, 1996, VET B, V66, P195; Blancou J, 1996, REV SCI TECH OIE, V15, P1263; BOOTHBY JT, 1986, CORNELL VET, V76, P188; Burki S, 2015, VET MICROBIOL, V179, P15, DOI 10.1016/j.vetmic.2015.02.024; Carozza M, 2015, VACCINE, V33, P141, DOI 10.1016/j.vaccine.2014.10.088; Chen H.-W, 2015, ADV PROTEIN CHEM STR; CHIMA JC, 1980, VET MICROBIOL, V5, P113, DOI 10.1016/0378-1135(80)90015-2; Citti C, 2013, TRENDS MICROBIOL, V21, P196, DOI 10.1016/j.tim.2013.01.003; Cottew, 1987, REV SCI TECH OIE, V6, P625; Devi VR, 2014, ACTA VET SCAND, V56, DOI 10.1186/s13028-014-0045-3; Dudek K, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9080640; Dudek K, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050407; Dudek K, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2122-3; Dudek K, 2018, J VET RES, V62, P269, DOI 10.2478/jvetres-2018-0038; Dudek K, 2018, ACTA VET HUNG, V66, P226, DOI 10.1556/004.2018.021; Dudek K, 2017, J VET RES, V61, P433, DOI 10.1515/jvetres-2017-0060; Dudek K, 2017, MED WETER, V73, P425, DOI 10.21521/mw.5739; Dudek K, 2016, VACCINE, V34, P3051, DOI 10.1016/j.vaccine.2016.04.087; Frey J, 1999, MYCOPLASMAS RUMINANT, VVolume 3, P128; Frey J., 2000, PROTECTIVE EFFICACY, VVolume 4, P75; HOWARD CJ, 1987, VET REC, V121, P372, DOI 10.1136/vr.121.16.372; Huabschle O.J.B, 2005, P FAO OIE AU CONS M, P91; Hubschle OJB, 2003, J VET MED B, V50, P298, DOI 10.1046/j.1439-0450.2003.00659.x; Jores J, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00214-2; Klein U, 2019, VET MICROBIOL, V238, DOI 10.1016/j.vetmic.2019.108432; Lutta HO, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02453-w; March JB, 2004, VACCINE, V22, P4358, DOI 10.1016/j.vaccine.2004.03.066; Mariner JC, 2009, ONDERSTEPOORT J VET, V76, P135; McAuliffe L, 2006, MICROBIOL-SGM, V152, P913, DOI 10.1099/mic.0.28604-0; Mulongo M, 2015, INFECT IMMUN, V83, P1992, DOI 10.1128/IAI.00003-15; Mulongo M, 2013, VACCINE, V31, P1406, DOI 10.1016/j.vaccine.2012.12.055; Mwirigi M, 2016, VET IMMUNOL IMMUNOP, V169, P63, DOI 10.1016/j.vetimm.2015.12.006; Nicholas R, 2008, MYCOPLASMA DISEASES OF RUMINANTS, P1, DOI 10.1079/9780851990125.0000; Nicholas R., 2000, Veterinary Bulletin, V70, P827; Nicholas R.A.J, 2017, VET B, V12, P1; Nicholas RAJ, 2003, RES VET SCI, V74, P105, DOI 10.1016/S0034-5288(02)00155-8; Nicholas RAJ, 2002, VACCINE, V20, P3569, DOI 10.1016/S0264-410X(02)00340-7; Nkando I, 2016, VET IMMUNOL IMMUNOP, V171, P103, DOI 10.1016/j.vetimm.2016.02.010; OIE, 1994, P OIE SCI C FOOT MOU, P55; Park H, 2020, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.01657; POUMARAT F, 1994, VET MICROBIOL, V40, P305, DOI 10.1016/0378-1135(94)90119-8; Prysliak T, 2018, VET IMMUNOL IMMUNOP, V197, P7, DOI 10.1016/j.vetimm.2018.01.004; Prysliak T, 2017, VACCINE, V35, P6604, DOI 10.1016/j.vaccine.2017.10.037; Prysliak T, 2016, CAN J MICROBIOL, V62, P492, DOI 10.1139/cjm-2015-0762; Prysliak T, 2013, MICROB PATHOGENESIS, V55, P1, DOI 10.1016/j.micpath.2012.12.001; Schieck E, 2014, VET MICROBIOL, V172, P285, DOI 10.1016/j.vetmic.2014.04.018; Shirani I, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090770; Soehnlen MK, 2011, VACCINE, V29, P5347, DOI 10.1016/j.vaccine.2011.05.092; STOTT EJ, 1987, VET REC, V121, P342, DOI 10.1136/vr.121.15.342; Wang YF, 2020, VACCINE, V38, P549, DOI 10.1016/j.vaccine.2019.10.061; World Organisation for Animal Health (OIE), ANN REPORT; World Organization for Animal Health (OIE), 2018, MANUAL DIAGNOSTIC TE; Xin JQ, 2012, VET J, V191, P166, DOI 10.1016/j.tvjl.2011.02.011; Zhang R, 2014, VACCINE, V32, P3107, DOI 10.1016/j.vaccine.2013.12.004; Zhang YK, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00740-19; Zubair M, 2020, MICROB PATHOGENESIS, V143, DOI 10.1016/j.micpath.2020.104135	58	2	2	3	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							549	10.3390/vaccines9060549			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3DQ	34073966	Green Published			2022-04-29	WOS:000666450600001
J	Mokaya, J; Kimathi, D; Lambe, T; Warimwe, GM				Mokaya, Jolynne; Kimathi, Derick; Lambe, Teresa; Warimwe, George M.			What Constitutes Protective Immunity Following Yellow Fever Vaccination?	VACCINES			English	Review						yellow fever virus; yellow fever; yellow fever vaccine; humoral immune response; cell-mediated immune response	CELL-MEDIATED-IMMUNITY; VIRUS; IMMUNOGENICITY; SAFETY; 17D; RESPONSES; DYNAMICS	Yellow fever (YF) remains a threat to global health, with an increasing number of major outbreaks in the tropical areas of the world over the recent past. In light of this, the Eliminate Yellow Fever Epidemics Strategy was established with the aim of protecting one billion people at risk of YF through vaccination by the year 2026. The current YF vaccine gives excellent protection, but its use is limited by shortages in supply due to the difficulties in producing the vaccine. There are good grounds for believing that alternative fractional dosing regimens can produce strong protection and overcome the problem of supply shortages as less vaccine is required per person. However, immune responses to these vaccination approaches are yet to be fully understood. In addition, published data on immune responses following YF vaccination have mostly quantified neutralising antibody titers. However, vaccine-induced antibodies can confer immunity through other antibody effector functions beyond neutralisation, and an effective vaccine is also likely to induce strong and persistent memory T cell responses. This review highlights the gaps in knowledge in the characterisation of YF vaccine-induced protective immunity in the absence or presence of neutralising antibodies. The assessment of biophysical antibody characteristics and cell-mediated immunity following YF vaccination could help provide a comprehensive landscape of YF vaccine-induced immunity and a better understanding of correlates of protective immunity.	[Mokaya, Jolynne; Kimathi, Derick; Warimwe, George M.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford OX1 3SU, England; [Mokaya, Jolynne; Kimathi, Derick; Warimwe, George M.] KEMRI Wellcome Trust Res Programme, POB 230-80108, Kilifi 8010, Kenya; [Lambe, Teresa] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England		Mokaya, J (通讯作者)，Univ Oxford, Ctr Trop Med & Global Hlth, Oxford OX1 3SU, England.; Mokaya, J (通讯作者)，KEMRI Wellcome Trust Res Programme, POB 230-80108, Kilifi 8010, Kenya.	jolynne.mokaya@ndm.ox.ac.uk; DKimathi@kemri-wellcome.org; teresa.lambe@ndm.ox.ac.uk; george.warimwe@ndm.ox.ac.uk		Mokaya, Jolynne/0000-0001-8398-0689; Kimathi, Derick/0000-0002-6998-0700	Wellcome TrustWellcome TrustEuropean Commission [220991/Z/20/Z, 203077_Z_16_Z]; Oak Foundation fellowship	J.M., T.L. andG.M.W. are supported by aWellcome Trust grant [grant number 220991/Z/20/Z]. D.K. and G.M.W. are also supported by an Oak Foundation fellowship and aWellcome Trust grant [grant number 203077_Z_16_Z]. TL is a Jenner Investigator.	Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Barrett ADT, 1997, BIOLOGICALS, V25, P17, DOI 10.1006/biol.1997.0056; Beasley DWC, 2015, ANTIVIR RES, V115, P48, DOI 10.1016/j.antiviral.2014.12.010; Bifani AM, 2020, CURR TREAT OPT INFEC, V12, P398, DOI 10.1007/s40506-020-00237-2; Blom K, 2013, J IMMUNOL, V190, P2150, DOI 10.4049/jimmunol.1202234; Bovay A, 2021, HUM VACC IMMUNOTHER, V17, P2471, DOI 10.1080/21645515.2021.1891752; Bovay A, 2020, VACCINE, V38, P2172, DOI 10.1016/j.vaccine.2020.01.045; Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Caldas IR, 2014, VACCINE, V32, P4977, DOI 10.1016/j.vaccine.2014.07.021; Campi-Azevedo AC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02192; Campi-Azevedo AC, 2019, EMERG INFECT DIS, V25, P1511, DOI 10.3201/eid2508.181432; Campos JLS, 2018, NAT IMMUNOL, V19, P1189, DOI 10.1038/s41590-018-0210-3; Casey RM, 2019, NEW ENGL J MED, V381, P444, DOI 10.1056/NEJMoa1710430; Chan KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.164, 10.1038/nmicrobiol.2016.164]; Chen LH, 2020, TROP DIS TRAVEL MED, V6, DOI 10.1186/s40794-020-0101-0; Chowdhury PR, 2015, CLIN INFECT DIS, V61, pS586, DOI 10.1093/cid/civ603; Chung AW, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0380-3; da Costa-Rocha IA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01211; Davis EH, 2020, VIRAL IMMUNOL, V33, P12, DOI 10.1089/vim.2019.0107; de Noronha TG, 2019, VACCINE, V37, P7147, DOI 10.1016/j.vaccine.2019.09.051; Domingo C, 2019, LANCET INFECT DIS, V19, P1363, DOI 10.1016/S1473-3099(19)30323-8; ERDMAN DD, 1993, J MED VIROL, V41, P44, DOI 10.1002/jmv.1890410110; Fernandez-Garcia MD, 2016, MBIO, V7, DOI 10.1128/mBio.01956-15; Fernandez-Garcia MD, 2009, CELL HOST MICROBE, V5, P318, DOI 10.1016/j.chom.2009.04.001; Fischinger S, 2019, J IMMUNOL METHODS, V473, DOI 10.1016/j.jim.2019.07.002; Gardner CL, 2010, CLIN LAB MED, V30, P237, DOI 10.1016/j.cll.2010.01.001; Gibney KB, 2012, AM J TROP MED HYG, V87, P1112, DOI 10.4269/ajtmh.2012.12-0182; Gould EA, 2008, LANCET, V371, P500, DOI 10.1016/S0140-6736(08)60238-X; Idoko OT, 2019, EXPERT REV VACCINES, V18, P867, DOI 10.1080/14760584.2019.1640118; Irvine EB, 2020, GLYCOBIOLOGY, V30, P241, DOI 10.1093/glycob/cwaa018; James EA, 2013, J VIROL, V87, P12794, DOI 10.1128/JVI.01160-13; Jennewein MF, 2017, TRENDS IMMUNOL, V38, P358, DOI 10.1016/j.it.2017.02.004; Juan-Giner A, 2021, LANCET, V397, P119, DOI 10.1016/S0140-6736(20)32520-4; Karsten CB, 2019, J IMMUNOL METHODS, V471, P46, DOI 10.1016/j.jim.2019.05.006; Klitting R, 2018, GENES-BASEL, V9, DOI 10.3390/genes9090425; Lindsey NP, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay108; Lopez P, 2016, PEDIATR INFECT DIS J, V35, P1140, DOI 10.1097/INF.0000000000001250; Marraco SAF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3700; Martins MA, 2007, CLIN EXP IMMUNOL, V148, P90, DOI 10.1111/j.1365-2249.2006.03317.x; Martins RD, 2018, VACCINE, V36, P4112, DOI 10.1016/j.vaccine.2018.05.041; MISHRA N, 2020, MBIO, V11, DOI DOI 10.1128/MBIO.0249-19; Miyaji KT, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759002, 10.1590/s1678-9946201759002]; Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429; Nguyen Lam-Tung, 2015, Mol Biol Evol, V32, P268, DOI 10.1093/molbev/msu300; Nnaji CA, 2020, VACCINE, V38, P1291, DOI [10.1016./j.vaccine.2019.12.018, 10.1016/j.vaccine.2019.12.018]; Nunes MRT, 2012, J VIROL, V86, P13263, DOI 10.1128/JVI.00565-12; PATH, YELL FEV VACC POT DO; Pulendran B, 2009, NAT REV IMMUNOL, V9, P741, DOI 10.1038/nri2629; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; Roman VRG, 2014, ANTIBODY FC: LINKING ADAPTIVE AND INNATE IMMUNITY, P1; Roukens AH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001993; Roukens AHE, 2018, ANN INTERN MED, V169, P761, DOI 10.7326/M18-1529; Salerno-Goncalves R, 2006, TRENDS MICROBIOL, V14, P536, DOI 10.1016/j.tim.2006.10.004; Sall AA, 2010, J VIROL, V84, P765, DOI 10.1128/JVI.01738-09; Selva KJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22236-7; Shearer FM, 2017, LANCET INFECT DIS, V17, P1209, DOI 10.1016/S1473-3099(17)30419-X; Staples JE, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0205-6; Suscovich TJ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb4757; Tay MZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00332; Vanderven HA, 2018, J INFECT DIS, V217, P12, DOI 10.1093/infdis/jix554; Vratskikh O, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003458; Watson AM, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040077; Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117; WHO, 2015, VACCINE, V33, P76, DOI 10.1016/j.vaccine.2014.05.040; Wieten RW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149871; World Health Organisation, 2016, YELL FEV LAB DIAGN T; World Health Organisation, 2017, WKLY EPIDEMIOL REC, V92, P193	69	0	0	7	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							671	10.3390/vaccines9060671			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ2SN	34207358	Green Published, gold			2022-04-29	WOS:000666421700001
J	Ravindranath, MH; Hilali, FE; Filippone, EJ				Ravindranath, Mepur H.; Hilali, Fatiha El; Filippone, Edward J.			Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg	VACCINES			English	Review						intravenous immunoglobulin (IVIg); human leukocyte antigen-I (HLA-1); polyreactive mAbs; monospecific mAbs; shared epitopes; immunosuppression; T-cells; B-memory cells; T-regulatory cells; blastogenesis; proliferation; antibody production	INTRAVENOUS IMMUNE GLOBULIN; MHC CLASS-I; T-CELL PROLIFERATION; LEUKOCYTE ANTIGEN ANTIBODIES; HEAVY-CHAINS; IMMUNOGLOBULINS IVIG; REGULATORY CELLS; PERIPHERAL-BLOOD; PEPTIDE-BINDING; OPERATIONAL TOLERANCE	HLA class-I (HLA-I) polyreactive monoclonal antibodies (mAbs) reacting to all HLA-I alleles were developed by immunizing mice with HLA-E monomeric, alpha-heavy chain (alpha HC) open conformers (OCs). Two mAbs (TFL-006 and TFL-007) were bound to the alpha HC's coated on a solid matrix. The binding was inhibited by the peptide (117)AYDGKDY(123), present in all alleles of the six HLA-I isoforms but masked by beta 2-microglobulin (beta 2-m) in intact HLA-I trimers (closed conformers, CCs). IVIg preparations administered to lower anti-HLA Abs in pre-and post-transplant patients have also shown HLA-I polyreactivity. We hypothesized that the mAbs that mimic IVIg HLA-I polyreactivity might also possess the immunomodulatory capabilities of IVIg. We tested the relative binding affinities of the mAbs and IVIg for both OCs and CCs and compared their effects on (a) the phytohemagglutinin (PHA)-activation T-cells; (b) the production of anti-HLA-II antibody (Ab) by B-memory cells and anti-HLA-I Ab by immortalized B-cells; and (c) the upregulation of CD4+, CD25+, and Fox P-3+ T-regs. The mAbs bound only to OC, whereas IVIg bound to both CC and OC. The mAbs suppressed blastogenesis and proliferation of PHA-activated T-cells and anti-HLA Ab production by B-cells and expanded T-regs better than IVIg. We conclude that a humanized version of the TFL-mAbs could be an ideal, therapeutic IVIg-mimetic.	[Ravindranath, Mepur H.] Childrens Hosp, Dept Hematol & Oncol, Los Angeles, CA 90027 USA; [Ravindranath, Mepur H.] Terasaki Fdn Lab, Santa Monica, CA 90064 USA; [Hilali, Fatiha El] Mohamed V Hosp, Mekines 50060, Morocco; [Filippone, Edward J.] Thomas Jefferson Univ, Div Nephrol, Dept Med, Sidney Kimmel Med Coll, Philadelphia, PA 19145 USA		Ravindranath, MH (通讯作者)，Childrens Hosp, Dept Hematol & Oncol, Los Angeles, CA 90027 USA.; Ravindranath, MH (通讯作者)，Terasaki Fdn Lab, Santa Monica, CA 90064 USA.	thiruranganath04@gmail.com; hfatiha@gmail.com; kidneys@comcast.net		Ravindranath, Mepur/0000-0002-5731-4129; EL HILALI, FATIHA/0000-0002-3292-5353	Terasaki Foundation Laboratory	This research utilizes the funds received from Mark Terasaki, first son of Late Prof. Paul Terasaki and Terasaki Foundation Laboratory.	Aktas O, 2001, J NEUROIMMUNOL, V114, P160, DOI 10.1016/S0165-5728(01)00243-0; Alachkar N, 2012, TRANSPLANTATION, V94, P165, DOI 10.1097/TP.0b013e318253f7b6; Alarabi A, 1995, TRANSPLANT P, V27, P3448; Allen RL, 2004, CURR MOL MED, V4, P59, DOI 10.2174/1566524043479329; Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Allen RL, 1999, J IMMUNOL, V162, P5045; AMRAN D, 1994, CLIN IMMUNOL IMMUNOP, V73, P180, DOI 10.1006/clin.1994.1186; Andersson J, 1996, CLIN EXP IMMUNOL, V104, P10, DOI 10.1111/cei.1996.104.s1.10; Angulo R, 1998, CYTOMETRY, V34, P143, DOI 10.1002/(SICI)1097-0320(19980615)34:3&lt;143::AID-CYTO4&gt;3.0.CO;2-I; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Arosa FA, 2007, TRENDS IMMUNOL, V28, P115, DOI 10.1016/j.it.2007.01.002; Arosa FA, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00665; Aubin E, 2010, BLOOD, V115, P1727, DOI 10.1182/blood-2009-06-225417; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Baroja-Mazo A, 2019, AM J TRANSPLANT, V19, P48, DOI 10.1111/ajt.15023; Baroja-Mazo A, 2016, WORLD J GASTROENTERO, V22, P7676, DOI 10.3748/wjg.v22.i34.7676; BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; CAPPS GG, 1993, J IMMUNOL, V151, P159; CARRENO BM, 1994, EUR J IMMUNOL, V24, P1285, DOI 10.1002/eji.1830240607; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cobbold SP, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015545; Dai HL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01044; Darabi K, 2006, TRANSFUSION, V46, P741, DOI 10.1111/j.1537-2995.2006.00792.x; DEMARIA S, 1994, J BIOL CHEM, V269, P6689; DEMARIA S, 1993, INT J CLIN LAB RES, V23, P61, DOI 10.1007/BF02592285; DEMARIA S, 1992, CELL IMMUNOL, V142, P103, DOI 10.1016/0008-8749(92)90272-Q; EL Hilali F., 2017, INT J IMMUNOL, V5, P53, DOI [10.11648/j.iji.20170504.11, DOI 10.11648/J.IJI.20170504.11]; Ephrem A, 2008, BLOOD, V111, P715, DOI 10.1182/blood-2007-03-079947; Filippone EJ, 2021, AM J TRANSPLANT, V21, P431, DOI 10.1111/ajt.16127; Glotz D, 2002, AM J TRANSPLANT, V2, P758, DOI 10.1034/j.1600-6143.2002.20809.x; GLOTZ D, 1993, TRANSPLANTATION, V56, P335, DOI 10.1097/00007890-199308000-00015; Graca L, 2002, J EXP MED, V195, P1641, DOI 10.1084/jem.20012097; GUILD BC, 1984, J BIOL CHEM, V259, P9235; Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789; Hurez V, 1994, Ther Immunol, V1, P269; Ippoliti F, 2006, PEDIAT ALLERG IMM-UK, V17, P337, DOI 10.1111/j.1399-3038.2006.00417.x; Jhun J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00352; Jones DC, 2011, J IMMUNOL, V186, P2990, DOI 10.4049/jimmunol.1003078; Jordan SC, 2003, TRANSPLANTATION, V76, P631, DOI 10.1097/01.TP.0000080685.31697.FC; Jordan SC, 2004, J AM SOC NEPHROL, V15, P3256, DOI 10.1097/01.ASN.0000145878.92906.9F; Jordan SC, 1998, TRANSPLANTATION, V66, P800, DOI 10.1097/00007890-199809270-00017; Jordan SC, 2009, TRANSPLANTATION, V88, P1, DOI 10.1097/TP.0b013e3181a9e89a; Jucaud V, 2017, TRANSPLANTATION, V101, P764, DOI 10.1097/TP.0000000000001420; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192; Khare SD, 1996, J CLIN INVEST, V98, P2746, DOI 10.1172/JCI119100; Kikuchi J, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0526-4; KLAESSON S, 1993, SCAND J IMMUNOL, V38, P477, DOI 10.1111/j.1365-3083.1993.tb02591.x; Koffman BM, 1997, MUSCLE NERVE, V20, P1102, DOI 10.1002/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.3.CO;2-C; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Li Y, 2004, AM J TRANSPLANT, V4, P2118, DOI 10.1111/j.1600-6143.2004.00611.x; Lin CY, 2002, NAT IMMUNOL, V3, P1208, DOI 10.1038/ni853; Luscher MA, 1998, AIDS RES HUM RETROV, V14, P99, DOI 10.1089/aid.1998.14.99; MacMillan HF, 2009, CLIN IMMUNOL, V132, P222, DOI 10.1016/j.clim.2009.04.002; MADRIGAL JA, 1991, J EXP MED, V174, P1085, DOI 10.1084/jem.174.5.1085; Majdic O., 1989, LEUKOCYTE TYPING 4, V511; Marfo K, 2012, TRANSPLANTATION, V94, P345, DOI 10.1097/TP.0b013e3182590d2e; Marsh SG, 2000, HLA FACTS BOOK; MATKO J, 1994, J IMMUNOL, V152, P3353; McIntyre JA, 1996, TRANSPLANTATION, V62, P691, DOI 10.1097/00007890-199609150-00027; Miyagi F, 1997, J NEUROIMMUNOL, V78, P127, DOI 10.1016/S0165-5728(97)00090-8; Morales-Buenrostro LE, 2008, TRANSPLANTATION, V86, P1111, DOI 10.1097/TP.0b013e318186d87b; Mustelin T, 2005, NAT REV IMMUNOL, V5, P43, DOI 10.1038/nri1530; Nair V, 2012, CLIN TRANSPLANT, V26, pE261, DOI 10.1111/j.1399-0012.2012.01657.x; Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736; NISSEN MH, 1993, DAN MED BULL, V40, P56; NISSEN MH, 1987, J IMMUNOL, V139, P1022; Onrust SV, 1999, DRUGS, V58, P79, DOI 10.2165/00003495-199958010-00009; PARHAM P, 1979, J IMMUNOL, V123, P342; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; Perez EE, 2017, J ALLERGY CLIN IMMUN, V139, pS1, DOI 10.1016/j.jaci.2016.09.023; Perosa F, 2003, J IMMUNOL, V171, P1918, DOI 10.4049/jimmunol.171.4.1918; Pons JA, 2008, TRANSPLANTATION, V86, P1370, DOI 10.1097/TP.0b013e318188d3e6; Prasad NKA, 1998, J IMMUNOL, V161, P3781; Raine T, 2006, RHEUMATOLOGY, V45, P1338, DOI 10.1093/rheumatology/kel305; Ravindranath MH, 2014, CLIN EXP IMMUNOL, V178, P154, DOI 10.1111/cei.12391; Ravindranath M.H., 2021, MONOCLONAL ANTIBODIE; Ravindranath MH, 2017, J IMMUNOL METHODS, V450, P73, DOI 10.1016/j.jim.2017.07.016; Ravindranath MH, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/3475926; Ravindranath Mepur H, 2013, Clin Transpl, P293; Ravindranath MH, 2017, TRANSPLANTATION, V101, pE153, DOI 10.1097/TP.0000000000001629; Ravindranath MH, 2013, BLOOD, V121, P2013, DOI 10.1182/blood-2012-08-447771; Ravindranath MH, 2011, MOL IMMUNOL, V48, P423, DOI 10.1016/j.molimm.2010.09.011; Ravindranath MH, 2010, J IMMUNOL, V185, P1935, DOI 10.4049/jimmunol.1000424; Ravindranath MH, 2010, MOL IMMUNOL, V47, P1121, DOI 10.1016/j.molimm.2009.10.024; RODRIGUEZ MA, 1990, IMMUNOLOGY, V69, P554; ROSS CN, 1993, TRANSPLANTATION, V55, P785, DOI 10.1097/00007890-199304000-00019; Sablik KA, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03106; Sali AD, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2015.18; Santos SG, 2004, J BIOL CHEM, V279, P53062, DOI 10.1074/jbc.M408794200; Santos SG, 2006, J IMMUNOL, V176, P2942, DOI 10.4049/jimmunol.176.5.2942; Sapir T, 2005, CLIN REV ALLERG IMMU, V29, P185, DOI 10.1385/CRIAI:29:3:185; Sasaki T, 2014, INT J CANCER, V134, P1558, DOI 10.1002/ijc.28484; Sbrana S, 1993, Allerg Immunol (Paris), V25, P35; SCHNABL E, 1990, J EXP MED, V171, P1431, DOI 10.1084/jem.171.5.1431; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; Sethi S, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6804678; Smith KD, 1996, J IMMUNOL, V157, P2470; Stegall MD, 2006, AM J TRANSPLANT, V6, P346, DOI 10.1111/j.1600-6143.2005.01178.x; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; Tawfik DS, 2012, PEDIAT ALLERG IMM-UK, V23, P88, DOI 10.1111/j.1399-3038.2010.01129.x; TONGIO MM, 1985, TISSUE ANTIGENS, V26, P271; TYAN DB, 1994, TRANSPLANTATION, V57, P553; van Maurik A, 2002, J IMMUNOL, V169, P5401; VANSCHAIK IN, 1992, J CLIN IMMUNOL, V12, P325, DOI 10.1007/BF00920789; Vigna JL, 1996, J IMMUNOL, V157, P4503; Vo AA, 2008, NEW ENGL J MED, V359, P242, DOI 10.1056/NEJMoa0707894; Vo AA, 2014, TRANSPLANTATION, V98, P312, DOI 10.1097/TP.0000000000000064; Vo AA, 2010, TRANSPLANTATION, V89, P1095, DOI 10.1097/TP.0b013e3181d21e7f; Ward P.A., 1999, MONOCLONAL ANTIBODY, P1; Zachary AA, 2003, TRANSPLANTATION, V76, P1519, DOI 10.1097/01.TP.0000090868.88895.E0; Zhou B, 2008, TISSUE ANTIGENS, V72, P98, DOI 10.1111/j.1399-0039.2008.01074.x; Zhu D, 2014, CLIN EXP IMMUNOL, V177, P464, DOI 10.1111/cei.12307	116	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							680	10.3390/vaccines9060680			33	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8TC	34205517	Green Published, gold			2022-04-29	WOS:000666152500001
J	Rehman, A; Ahmad, S; Shahid, F; Albutti, A; Alwashmi, ASS; Aljasir, MA; Alhumeed, N; Qasim, M; Ashfaq, UA; ul Qamar, MT				Rehman, Abdur; Ahmad, Sajjad; Shahid, Farah; Albutti, Acjel; Alwashmi, Ameen S. S.; Aljasir, Mohammad Abdullah; Alhumeed, Naif; Qasim, Muhammad; Ashfaq, Usman Ali; ul Qamar, Muhammad Tahir			Integrated Core Proteomics, Subtractive Proteomics, and Immunoinformatics Investigation to Unveil a Potential Multi-Epitope Vaccine against Schistosomiasis	VACCINES			English	Article						schistosomiasis; Schistosoma japonicum; Schistosoma mansoni; Schistosoma haematobium; multi-epitope vaccine; MD simulation	HIDDEN MARKOV MODEL; B-CELL EPITOPES; PEPTIDE VACCINE; WEB SERVER; SUBUNIT VACCINE; DRUGGABLE GENOME; RATIONAL DESIGN; ORAL VACCINE; T-CELLS; PREDICTION	Schistosomiasis is a parasitic infection that causes considerable morbidity and mortality in the world. Infections of parasitic blood flukes, known as schistosomes, cause the disease. No vaccine is available yet and thus there is a need to design an effective vaccine against schistosomiasis. Schistosoma japonicum, Schistosoma mansoni, and Schistosoma haematobium are the main pathogenic species that infect humans. In this research, core proteomics was combined with a subtractive proteomics pipeline to identify suitable antigenic proteins for the construction of a multi-epitope vaccine (MEV) against human-infecting Schistosoma species. The pipeline revealed two antigenic proteins-calcium binding and mycosubtilin synthase subunit C-as promising vaccine targets. T and B cell epitopes from the targeted proteins were predicted using multiple bioinformatics and immunoinformatics databases. Seven cytotoxic T cell lymphocytes (CTL), three helper T cell lymphocytes (HTL), and four linear B cell lymphocytes (LBL) epitopes were fused with a suitable adjuvant and linkers to design a 217 amino-acid-long MEV. The vaccine was coupled with a TLR-4 agonist (RS-09; Sequence: APPHALS) adjuvant to enhance the immune responses. The designed MEV was stable, highly antigenic, and non-allergenic to human use. Molecular docking, molecular dynamics (MD) simulations, and molecular mechanics/generalized Born surface area (MMGBSA) analysis were performed to study the binding affinity and molecular interactions of the MEV with human immune receptors (TLR2 and TLR4) and MHC molecules (MHC I and MHC II). The MEV expression capability was tested in an Escherichia coli (strain-K12) plasmid vector pET-28a(+). Findings of these computer assays proved the MEV as highly promising in establishing protective immunity against the pathogens; nevertheless, additional validation by in vivo and in vitro experiments is required to discuss its real immune-protective efficacy.	[Rehman, Abdur; Shahid, Farah; Qasim, Muhammad; Ashfaq, Usman Ali] Govt Coll Univ, Dept Bioinformat & Biotechnol, Faisalabad 38000, Pakistan; [Ahmad, Sajjad] Abasyn Univ, Dept Hlth & Biol Sci, Peshawar 25000, Pakistan; [Albutti, Acjel] Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, Buraydah 51452, Saudi Arabia; [Alwashmi, Ameen S. S.; Aljasir, Mohammad Abdullah] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 51452, Saudi Arabia; [Alhumeed, Naif] Minist Educ, Riyadh 11153, Saudi Arabia; [ul Qamar, Muhammad Tahir] Guangxi Univ, Coll Life Sci & Technol, Nanning 530004, Peoples R China		ul Qamar, MT (通讯作者)，Guangxi Univ, Coll Life Sci & Technol, Nanning 530004, Peoples R China.	abdurrehman93@gcuf.edu.pk; sajjad.ahmad@abasyn.edu.pk; farahshahid24@gcuf.edu.pk; as.albutti@qu.edu.sa; Aswshmy@qu.edu.sa; Mjasr@qu.edu.sa; Naifalhumeed@hotmail.com; qasimawan@gcuf.edu.pk; ashfaqua@gcuf.edu.pk; m.tahirulqamar@gxu.edu.cn	Alhumeed, Naif/AAR-7956-2021; Tahir ul Qamar, Muhammad/E-5803-2015; Ahmad, Sajjad/ABG-7863-2020	Alhumeed, Naif/0000-0001-5221-3073; Tahir ul Qamar, Muhammad/0000-0003-4832-4250; Ahmad, Sajjad/0000-0003-0754-1742; Albutti, Aqel/0000-0001-8697-5340; Qasim, Muhammad/0000-0001-8139-538X	Qassim University, Saudi Arabia	The APC was funded by Qassim University, Saudi Arabia.	Abbas G, 2020, EUR J PHARM SCI, V142, DOI 10.1016/j.ejps.2019.105160; Adhikari UK, 2017, INFECT GENET EVOL, V56, P75, DOI 10.1016/j.meegid.2017.10.022; Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010; Ahmad S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030293; Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529; Azam SS, 2014, GENOMICS, V104, P203, DOI 10.1016/j.ygeno.2014.07.007; Banerjee S., 2020, IMMUNO INFORMATICS A; Baseer S, 2017, BIOLOGICALS, V50, P87, DOI 10.1016/j.biologicals.2017.08.004; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Burley SK, 2017, METHODS MOL BIOL, V1606, P627, DOI 10.1007/978-1-4939-7000-1_26; Campbell SJ, 2018, TRENDS PARASITOL, V34, P53, DOI 10.1016/j.pt.2017.09.004; Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P11409, DOI 10.26355/eurrev_202011_23634; Chang S, 2010, POULTRY SCI, V89, P2083, DOI 10.3382/ps.2010-00740; Chen R, 2012, BIOTECHNOL ADV, V30, P1102, DOI 10.1016/j.biotechadv.2011.09.013; Chew SY, 2016, MYCOSES, V59, P262, DOI 10.1111/myc.12455; Cohen J, 2016, SCIENCE, V351, P16, DOI 10.1126/science.351.6268.16; Coler RN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013677; Cooper MD, 2015, NAT REV IMMUNOL, V15, P191, DOI 10.1038/nri3801; Corradin Giarnpietro, 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P259, DOI 10.2174/187153007782794371; Dar HA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90868-2; Dar HA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030088; De Vries SJ, 2010, NAT PROTOC, V5, P883, DOI 10.1038/nprot.2010.32; DeLano W.L., 2002, CCP4 NEWSLETTER P CR, V40, P82; Deleage G, 2017, BIOINFORMATICS, V33, P3991, DOI 10.1093/bioinformatics/btx521; Deng W, 2007, BIOINFORMATICS, V23, P2334, DOI 10.1093/bioinformatics/btm331; Dhanda SK, 2019, NUCLEIC ACIDS RES, V47, pW502, DOI 10.1093/nar/gkz452; Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30; Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619; Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Durdagi S, 2018, J MOL GRAPH MODEL, V85, P122, DOI 10.1016/j.jmgm.2018.07.010; Frimpong-Boateng K., 2017, GLOB HLTH MOL MED OU; Garg VK, 2016, BIOINFORMATION, V12, P74, DOI 10.6026/97320630012074; Gasteiger E., 2005, PROTEOM PROTOC HDB, P571, DOI [10.1385/1-59259-890-0:571, 10.1385/1-59259-890, DOI 10.1385/1592598900]; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; Gordon CA, 2019, TROP MED INFECT DIS, V4, DOI 10.3390/tropicalmed4010040; Gori A, 2013, AMINO ACIDS, V45, P257, DOI 10.1007/s00726-013-1526-9; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Grote A., SNAPGENE VIEWER; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Hajighahramani N, 2017, INFECT GENET EVOL, V48, P83, DOI 10.1016/j.meegid.2016.12.010; Hassan A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2951-4; Hoffmann KF, 2014, SCIENCE, V346, P168, DOI 10.1126/science.1261139; Homeyer N, 2012, MOL INFORM, V31, P114, DOI 10.1002/minf.201100135; Huang Y, 2010, BIOINFORMATICS, V26, P680, DOI 10.1093/bioinformatics/btq003; Ivory Catherine, 2004, Genet Vaccines Ther, V2, P17, DOI 10.1186/1479-0556-2-17; Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008; Johnson LS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-431; Kar PP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02213; Karkhah A, 2017, COMPUT BIOL CHEM, V67, P244, DOI 10.1016/j.compbiolchem.2017.01.011; Khalid H, 2020, J BIOMED INFORM, V108, DOI 10.1016/j.jbi.2020.103498; Khan MAA, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04064-8; Khan SZ, 2019, INFECT GENET EVOL, V73, P390, DOI 10.1016/j.meegid.2019.06.006; Khatoon N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08842-w; Kirksey TJ, 1999, J BIOL CHEM, V274, P37259, DOI 10.1074/jbc.274.52.37259; Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493; Kringelum JV, 2013, MOL IMMUNOL, V53, P24, DOI 10.1016/j.molimm.2012.06.001; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kurup R, 2010, J VECTOR DIS, V47, P228; Kuzmanic A, 2010, BIOPHYS J, V98, P861, DOI 10.1016/j.bpj.2009.11.011; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289; Lengths MC, 2018, QUICK GUIDELINE COMP, V16, P75; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Madden T., 2013, The NCBI Handbook, V2nd; Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551; Mahmood M, 2021, INFECT GENET EVOL, V91, DOI 10.1016/j.meegid.2021.104795; Mamede LD, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104473; Messaoudi A, 2013, THEOR BIOL MED MODEL, V10, DOI 10.1186/1742-4682-10-22; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; Monath T.P., 1990, FLAVIVIRUSES; Mullen MM, 2002, MOL CELL, V9, P375, DOI 10.1016/S1097-2765(02)00465-3; Nagpal G, 2017, SCI REP-UK, V7, DOI 10.1038/srep42851; Nain Z, 2020, J BIOMOL STRUCT DYN, V38, P4850, DOI 10.1080/07391102.2019.1692072; Naz A, 2015, INFECT GENET EVOL, V32, P280, DOI 10.1016/j.meegid.2015.03.027; Nezafat N, 2017, MOL BIOSYST, V13, P699, DOI 10.1039/c6mb00772d; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; Ohto U, 2012, J BIOL CHEM, V287, P40611, DOI 10.1074/jbc.M112.404608; One E, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104186; Onile OS, 2020, PEERJ, V8, DOI 10.7717/peerj.8795; Pennisi E, 2018, SCIENCE, V361, P832, DOI 10.1126/science.361.6405.832; Pritam M, 2020, INT J BIOL MACROMOL, V158, P159, DOI 10.1016/j.ijbiomac.2020.04.191; Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224; Qamar MTU, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38450-1; Rahman N, 2020, GENOMICS, V112, P3473, DOI 10.1016/j.ygeno.2020.06.026; Rahmani A, 2019, INT J BIOL MACROMOL, V141, P125, DOI 10.1016/j.ijbiomac.2019.08.259; Rapin N, 2011, BIOINFORMATICS, V27, P2013, DOI 10.1093/bioinformatics/btr335; Rosano GL, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00172; Saadi M, 2017, INFECT GENET EVOL, V51, P227, DOI 10.1016/j.meegid.2017.04.009; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121; Samson O.O., 2018, J COMPUT BIOL BIOINF, V8, P1; Sanches RCO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.621706; Sanober G, 2017, GENE REP, V7, P147, DOI 10.1016/j.genrep.2017.04.008; Shahid F, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104199; Shenoy P. J., 1998, Performance Evaluation Review, V26, P44; Shrestha B, 2004, J VIROL, V78, P8312, DOI 10.1128/jvi.78.15.8312-8321.2004; Solanki V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26689-7; Tahir Ul Qamar Muhammad, 2020, PLoS One, V15, pe0244176, DOI 10.1371/journal.pone.0244176; ul Qamar MT, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00752-w; ul Qamar MT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020288; Tarang S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57906-x; Tebeje BM, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1799-4; Thomson SA, 1998, J VIROL, V72, P2246, DOI 10.1128/JVI.72.3.2246-2252.1998; Turner P., 2007, BIOS INSTANT NOTES M; Turner P.J., XMGRACE VERSION 5 1; ul Ain Q, 2018, MICROB PATHOGENESIS, V125, P336, DOI 10.1016/j.micpath.2018.09.042; ul Qamar MT, 2021, COMPUT BIOL MED, V132, DOI 10.1016/j.compbiomed.2021.104389; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Wu W, 2011, PARASITOL RES, V109, P1501, DOI 10.1007/s00436-011-2670-3; Yadav S, 2020, PATHOG GLOB HEALTH, V114, P471, DOI 10.1080/20477724.2020.1842976; Zaharieva N, 2019, CURR COMPUT-AID DRUG, V15, P398, DOI 10.2174/1573409915666190318121838; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154	122	11	11	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							658	10.3390/vaccines9060658			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ1DF	34208663	gold, Green Published			2022-04-29	WOS:000666314300001
J	Soltan, MA; Elbassiouny, N; Gamal, H; Elkaeed, EB; Eid, RA; Eldeen, MA; Al-Karmalawy, AA				Soltan, Mohamed A.; Elbassiouny, Nada; Gamal, Helmy; Elkaeed, Eslam B.; Eid, Refaat A.; Eldeen, Muhammad Alaa; Al-Karmalawy, Ahmed A.			In Silico Prediction of a Multitope Vaccine against Moraxella catarrhalis: Reverse Vaccinology and Immunoinformatics	VACCINES			English	Article						Moraxella catarrhalis; vaccinomics; reverse vaccinology; immunoinformatics; epitope mapping; multitope vaccine	OUTER-MEMBRANE PROTEINS; DESIGN; SERVER; WEB; IDENTIFICATION; CANDIDATES; ANTIGENS; PEPTIDE; TOOL	Moraxella catarrhalis (M. catarrhalis) is a Gram-negative bacterium that can cause serious respiratory tract infections and middle ear infections in children and adults. M. catarrhalis has demonstrated an increasing rate of antibiotic resistance in the last few years, thus development of an effective vaccine is a major health priority. We report here a novel designed multitope vaccine based on the mapped epitopes of the vaccine candidates filtered out of the whole proteome of M. catarrhalis. After analysis of 1615 proteins using a reverse vaccinology approach, only two proteins (outer membrane protein assembly factor BamA and LPS assembly protein LptD) were nominated as potential vaccine candidates. These proteins were found to be essential, outer membrane, virulent and non-human homologs with appropriate molecular weight and high antigenicity score. For each protein, cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL) and B cell lymphocyte (BCL) epitopes were predicted and confirmed to be highly antigenic and cover conserved regions of the proteins. The mapped epitopes constituted the base of the designed multitope vaccine where suitable linkers were added to conjugate them. Additionally, beta defensin adjuvant and pan-HLA DR-binding epitope (PADRE) peptide were also incorporated into the construct to improve the stimulated immune response. The constructed multitope vaccine was analyzed for its physicochemical, structural and immunological characteristics and it was found to be antigenic, soluble, stable, non-allergenic and have a high affinity to its target receptor. Although the in silico analysis of the current study revealed that the designed multitope vaccine has the ability to trigger a specific immune response against M. catarrhalis, additional translational research is required to confirm the effectiveness of the designed vaccine.	[Soltan, Mohamed A.] Sinai Univ, Fac Pharm, Dept Microbiol & Immunol, Ismailia 41611, Egypt; [Elbassiouny, Nada] Sinai Univ, Fac Pharm, Dept Pharmacol, Ismailia 41611, Egypt; [Gamal, Helmy] Mansoura Univ, Fac Sci, Chem Dept, Biochem Div, Mansoura 35516, Egypt; [Elkaeed, Eslam B.] AlMaarefa Univ, Coll Pharm, Dept Pharmaceut Sci, Riyadh 13713, Saudi Arabia; [Elkaeed, Eslam B.] Al Azhar Univ, Fac Pharm Boys, Dept Pharmaceut Organ Chem, Cairo 11884, Egypt; [Eid, Refaat A.] King Khalid Univ, Coll Med, Dept Pathol, Abha 62529, Saudi Arabia; [Eldeen, Muhammad Alaa] Zagazig Univ, Fac Sci, Zool Dept, Cell Biol Histol & Genet Div, Zagazig 44519, Egypt; [Al-Karmalawy, Ahmed A.] Horus Univ Egypt, Fac Pharm, Dept Pharmaceut Med Chem, New Damietta 34518, Egypt		Al-Karmalawy, AA (通讯作者)，Horus Univ Egypt, Fac Pharm, Dept Pharmaceut Med Chem, New Damietta 34518, Egypt.	mohamed.mohamed@su.edu.eg; nada.elbasuny@su.edu.eg; helmy.mohamed@su.edmeg; ikaeed@mcst.edu.sa; refaat_eid@yahoo.com; dr.muhammadalaa@gmail.com; akarmalawy@horus.edu.eg	Al-Karmalawy, Ahmed A./AAE-3311-2021; Mohy Eldeen, Muhammad Alaa Eldeen Abdelaziz/ABH-1762-2021; Elkaeed, Eslam B./R-4249-2019	Al-Karmalawy, Ahmed A./0000-0002-8173-6073; Elkaeed, Eslam B./0000-0002-2546-8035; Gamal, Helmy/0000-0003-2188-8566; Soltan, Mohamed/0000-0003-3030-1659; Alaa Eldeen, Muhammad/0000-0001-5280-7736			Awan FM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010139; Bernhard S, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13694; Bertot GM, 2004, J INFECT DIS, V189, P1304, DOI 10.1086/382508; Capelli R, 2018, ANTIBODIES, V7, DOI 10.3390/antib7030026; Carvalho TF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166582; Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396; Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346; Delfani S, 2015, CLIN EXP VACCINE RES, V4, P99, DOI 10.7774/cevr.2015.4.1.99; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Gasteiger E., 2005, PROTEOM PROTOC HDB, P571, DOI [10.1385/1-59259-890-0:571, 10.1385/1-59259-890, DOI 10.1385/1592598900]; Ghaffari-Nazari H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142563; Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Hajighahramani N, 2017, INFECT GENET EVOL, V48, P83, DOI 10.1016/j.meegid.2016.12.010; Hasan M, 2019, MICROB PATHOGENESIS, V130, P19, DOI 10.1016/j.micpath.2019.02.023; Hegde NR, 2018, EXPERT OPIN DRUG DIS, V13, P117, DOI 10.1080/17460441.2018.1413088; Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458; Jiang PF, 2017, VACCINE, V35, P3096, DOI 10.1016/j.vaccine.2017.04.031; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Leow CY, 2020, CLIN EXP VACCINE RES, V9, P15, DOI 10.7774/cevr.2020.9.1.15; Lin J, 2002, MICROBES INFECT, V4, P325, DOI 10.1016/S1286-4579(02)01545-9; Majid M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55613-w; Okuda S, 2016, NAT REV MICROBIOL, V14, P337, DOI 10.1038/nrmicro.2016.25; Oliveira-Nascimento L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00079; Pandey RK, 2016, BIOMED PHARMACOTHER, V83, P141, DOI 10.1016/j.biopha.2016.06.010; Perez AC, 2014, PATHOG DIS, V70, P280, DOI 10.1111/2049-632X.12129; Poland GA, 2009, PHARMACOGENOMICS, V10, P837, DOI [10.2217/pgs.09.25, 10.2217/PGS.09.25]; Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339; Ren DB, 2016, EXPERT OPIN THER TAR, V20, P19, DOI 10.1517/14728222.2015.1081686; Rizwan M, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1540-0; Saha Sudipto, 2006, Genomics Proteomics & Bioinformatics, V4, P42, DOI 10.1016/S1672-0229(06)60015-6; Singh B, 2016, MBIO, V7, DOI 10.1128/mBio.00066-16; Solanki V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26689-7; Soltan MA, 2020, OMICS, V24, P195, DOI 10.1089/omi.2019.0183; Verhaegh SJC, 2011, VACCINE, V29, P5603, DOI 10.1016/j.vaccine.2011.06.019; Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110; Wen QF, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01236; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Yassin GM, 2016, J INFECT DIS, V213, P1938, DOI 10.1093/infdis/jiw062; Yu NY, 2010, BIOINFORMATICS, V26, P1608, DOI 10.1093/bioinformatics/btq249	41	17	17	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							669	10.3390/vaccines9060669			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6NH	34207238	gold, Green Published			2022-04-29	WOS:000666679000001
J	Buharideen, SM; Hassan, MSH; Najimudeen, SM; Niu, DY; Czub, M; Gomis, S; Abdul-Careem, MF				Buharideen, Sabrina M.; Hassan, Mohamed S. H.; Najimudeen, Shahnas M.; Niu, Dongyan; Czub, Markus; Gomis, Susantha; Abdul-Careem, Mohamed Faizal			Immune Responses in Laying Hens after an Infectious Bronchitis Vaccination of Pullets: A Comparison of Two Vaccination Strategies	VACCINES			English	Article						infectious bronchitis virus; laying hen; infectious bronchitis vaccine; cell-mediated immune response; antibody-mediated immune response	VIRUS; PROTECTION; LIVE; CHICKENS; EFFICACY; PATHOGENESIS; CHALLENGE; CANADA	For decades, vaccinations have been used to limit infectious bronchitis (IB) in both the broiler and layer industries. Depending on the geographical area, live attenuated vaccines are used either alone or in combination with inactivated vaccines to control infectious bronchitis virus (IBV) infections. It has been shown that administering inactivated vaccines preceded by priming with live attenuated vaccines in pullets protects laying hens against IB. However, the immunological basis of this protective response has not been adequately investigated. The objective of the study was to compare two vaccination strategies adapted by the Canadian poultry industry in terms of their ability to systemically induce an adequate immune response in IBV-impacted tissues in laying hens. The first vaccination strategy (only live attenuated IB vaccines) and second vaccination strategy (live attenuated and inactivated IB vaccines) were applied. Serum anti-IBV antibodies were measured at two time points, i.e., 3 weeks and 10 weeks post last vaccination. The recruitment of T cell subsets (i.e., CD4+ and CD8+ T cells), and the interferon (IFN)-gamma mRNA expression were measured at 10 weeks post last vaccination. We observed that vaccination strategy 2 induced significantly higher serum anti-IBV antibody responses that were capable of neutralizing an IBV Mass variant associated with a flock history of shell-less egg production better than a Delmarva (DMV)1639 variant, as well as a significantly higher IFN-gamma mRNA expression in the lungs, kidneys, and oviduct. We also observed that both vaccination strategies recruited CD4+ T cells as well as CD8+ T cells to the examined tissues at various extents. Our findings indicate that vaccination strategy 2 induces better systemic and local host responses in laying hens.	[Buharideen, Sabrina M.; Hassan, Mohamed S. H.; Najimudeen, Shahnas M.; Niu, Dongyan; Czub, Markus; Abdul-Careem, Mohamed Faizal] Univ Calgary, Fac Vet Med, Hlth Res Innovat Ctr 2C53, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada; [Gomis, Susantha] Univ Saskatchewan, Western Coll Vet Med, Dept Vet Pathol, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada		Abdul-Careem, MF (通讯作者)，Univ Calgary, Fac Vet Med, Hlth Res Innovat Ctr 2C53, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	sabrina.buharideen@ucalgary.ca; msh.hassan@ucalgary.ca; fathimashahnas.moham@ucalgary.ca; dongyan.niu@ucalgary.ca; m.czub@ucalgary.ca; smg127@mail.usask.ca; faizal.abdulcareem@ucalgary.ca		Najimudeen, Shahnas/0000-0001-9767-8341; Hassan, Mohamed/0000-0002-7424-5305; Niu, Yan/0000-0002-4483-5734	Alberta Agriculture and Forestry (AAF); Egg Farmers of Canada (EFC)	We acknowledge operational funding from Alberta Agriculture and Forestry (AAF) and Egg Farmers of Canada (EFC).	Abdel-Moneim A.S., 2017, EMERGING RE EMERGING, P133; Amarasinghe A, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1720-9; Amarasinghe A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080437; AMBALI AG, 1990, AVIAN DIS, V34, P809, DOI 10.2307/1591367; Awad F, 2016, AVIAN PATHOL, V45, P169, DOI 10.1080/03079457.2015.1137866; BOX PG, 1985, AVIAN PATHOL, V14, P9, DOI 10.1080/03079458508436204; Cavanagh D, 2003, AVIAN PATHOL, V32, P567, DOI 10.1080/03079450310001621198; Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055; CHONG KT, 1982, J COMP PATHOL, V92, P199, DOI 10.1016/0021-9975(82)90078-0; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Collisson EW, 2000, DEV COMP IMMUNOL, V24, P187, DOI 10.1016/S0145-305X(99)00072-5; Cook JKA, 2012, AVIAN PATHOL, V41, P239, DOI 10.1080/03079457.2012.680432; Cook JKA, 1999, AVIAN PATHOL, V28, P477, DOI 10.1080/03079459994506; Cook JKA, 2001, AVIAN PATHOL, V30, P423, DOI 10.1080/03079450120066421; Cottral G.E., 1978, MANUAL STANDARDIZED, P60; CRINION RAP, 1972, AVIAN DIS, V16, P351, DOI 10.2307/1588800; De Wit JJ, 2010, AVIAN PATHOL, V39, P123, DOI 10.1080/03079451003604639; de Wit JJ, 2020, AVIAN PATHOL, V49, P185, DOI 10.1080/03079457.2019.1710462; de Wit JJ, 2019, AVIAN PATHOL, V48, P135, DOI 10.1080/03079457.2018.1556778; dos Santos RM, 2019, J VET MED SCI, V81, P612, DOI 10.1292/jvms.18-0065; FINNEY PM, 1990, AVIAN PATHOL, V19, P435, DOI 10.1080/03079459008418698; Forlenza M, 2012, METHODS MOL BIOL, V820, P7, DOI 10.1007/978-1-61779-439-1_2; Ghani S, 2009, IMMUNOLOGY, V128, pe870, DOI 10.1111/j.1365-2567.2009.03096.x; Gumming R. B., 1962, Australian Veterinary Journal, V38, P554, DOI 10.1111/j.1751-0813.1962.tb04027.x; Hassan MSH, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111054; Ignjatovic J, 2002, J COMP PATHOL, V126, P115, DOI 10.1053/jcpa.2001.0528; Ismail MI, 2020, J VET SCI, V21, DOI 10.4142/jvs.2020.21.e76; Jackwood MW, 2012, AVIAN DIS, V56, P634, DOI 10.1637/10227-043012-Review.1; Jordan B, 2017, VET MICROBIOL, V206, P137, DOI 10.1016/j.vetmic.2017.01.002; KUSTERS JG, 1990, VACCINE, V8, P605, DOI 10.1016/0264-410X(90)90018-H; Laconi A, 2020, VACCINE, V38, P1486, DOI 10.1016/j.vaccine.2019.11.064; Ladman BS, 2002, AVIAN DIS, V46, P938, DOI 10.1637/0005-2086(2002)046[0938:POCALA]2.0.CO;2; Le Page C, 2000, Rev Immunogenet, V2, P374; Lee HJ, 2010, VACCINE, V28, P2887, DOI 10.1016/j.vaccine.2010.01.062; Lopes PD, 2018, VACCINE, V36, P2630, DOI 10.1016/j.vaccine.2018.03.065; Najimudeen SM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9100779; Martin EAK, 2014, AVIAN PATHOL, V43, P264, DOI 10.1080/03079457.2014.916395; Milek J, 2018, J VET RES, V62, P249, DOI 10.2478/jvetres-2018-0035; Okino CH, 2013, VIRAL IMMUNOL, V26, P259, DOI 10.1089/vim.2013.0015; Petrik M., 2018, P AVMA AM ASS AV PAT; Roh HJ, 2013, AVIAN DIS, V57, P248, DOI 10.1637/10459-112812-Reg.1; Sasipreeyajan J, 2012, THAI J VET MED, V42, P73; SCHALK A. F., 1931, Journal of the American Veterinary Medical Association, V78, P413; Senapathi UD, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110635; Seo SH, 1997, J VIROL, V71, P5173, DOI 10.1128/JVI.71.7.5173-5177.1997; Seo SH, 2000, VIROLOGY, V269, P183, DOI 10.1006/viro.2000.0211; SEVOIAN M., 1957, Avian Diseases, V1, P136, DOI 10.2307/1587727; VANROEKEL H, 1951, AM J VET RES, V12, P140	48	0	0	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							531	10.3390/vaccines9050531			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1LP	34065415	Green Published, gold			2022-04-29	WOS:000654587900001
J	Gong, D; Jiang, QY; Chantler, T; Sun, FY; Zou, JT; Cheng, JJ; Chen, YQ; Li, CY; Sun, M; Howard, N				Gong, Dan; Jiang, Qiyun; Chantler, Tracey; Sun, Fiona Yueqian; Zou, Jiatong; Cheng, Jiejie; Chen, Yuqian; Li, Chengyue; Sun, Mei; Howard, Natasha			Health System Barriers and Facilitators to Delivering Additional Vaccines through the National Immunisation Programme in China: A Qualitative Study of Provider and Service-User Perspectives	VACCINES			English	Article						vaccination; routine immunization; health systems; barriers and facilitators; China	DESCRIPTIVE ANALYSIS; DECISION-MAKING; IMPLEMENTATION; COUNTRIES	In China, there are two categories of vaccines available from the Chinese Center for Disease Control and associated public health agencies. Extended Program of Immunization (EPI) vaccines are government-funded and non-EPI vaccines are voluntary and paid for out-of-pocket. The government plans to transition some non-EPI vaccines to EPI in the coming years, which may burden public health system capacity, particularly in terms of budget, workforce, supply chains, and information systems. Our study explored vaccinator and caregiver perspectives on introducing non-EPI vaccines into routine immunization and perceived facilitators and barriers affecting this transition. We conducted a qualitative study from a realist perspective, analysing semi-structured interviews with 26 vaccination providers and 160 caregivers in three provinces, selected to represent regional socioeconomic disparities across Eastern, Central, and Western China. Data were analysed thematically, using deductive and inductive coding. Most participants were positive about adding vaccines to the national schedule. Candidate EPI vaccines most frequently recommended by participants were varicella, mumps vaccine, and hand-foot-mouth disease. Providers generally considered existing workspaces, cold-chain equipment, and funding sufficient, but described frontline staffing and vaccine information systems as requiring improvement. This is the first qualitative study to explore interest, barriers, and facilitators related to adding vaccines to China's national schedule from provider and caregiver perspectives. Findings can inform government efforts to introduce additional vaccines, by including efforts to retain and recruit vaccine programme staff and implement whole-process data management and health information systems that allow unified nationwide data collection and sharing.	[Gong, Dan; Jiang, Qiyun; Cheng, Jiejie; Chen, Yuqian; Li, Chengyue; Sun, Mei] Fudan Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Gong, Dan; Jiang, Qiyun; Cheng, Jiejie; Chen, Yuqian; Li, Chengyue; Sun, Mei] Fudan Univ, Res Inst Hlth Dev Strategies, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Chantler, Tracey; Howard, Natasha] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, 15-17 Tavistock Pl, London WC1H 9SH, England; [Sun, Fiona Yueqian] Univ London, London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England; [Zou, Jiatong] Shanghai Municipal Ctr Dis Control & Prevent, Dept Org & Personnel, 1380 West Zhongshan Rd, Shanghai 200336, Peoples R China; Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2, Singapore 117549, Singapore		Li, CY; Sun, M (通讯作者)，Fudan Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 130 Dongan Rd, Shanghai 200032, Peoples R China.; Li, CY; Sun, M (通讯作者)，Fudan Univ, Res Inst Hlth Dev Strategies, 130 Dongan Rd, Shanghai 200032, Peoples R China.	18211020057@fudan.edu.cn; qiyun_jiang@163.com; Tracey.Chantler@lshtm.ac.uk; Fiona.Sun@lshtm.ac.uk; zoujiatong@scdc.sh.cn; 18211020050@fudan.edu.cn; chenyuqian96@163.com; lichengyue@fudan.edu.cn; sunmei@fudan.edu.cn; natasha.howard@nus.edu.sg		Chantler, Tracey/0000-0001-7776-7339; sun, mei/0000-0001-5987-5977; Howard, Natasha/0000-0003-4174-7349	National Institute for Health Research from the UK Government [EPIDZL9012]; Public Health England (PHE); National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71974035, 71774031, 72074048]; Ministry of Education of Humanities and Social Science project [19YJCZH143]; Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022) [GWV-10.1-XK23]; Shanghai Foundation for Talents Development [2020128]; National University of Singapore Saw Swee Hock School of Public HealthNational University of Singapore; National Institute for Health Research Health Protection Research Unit in Immunisation at London School of Hygiene and Tropical Medicine	This research was funded by the National Institute for Health Research (reference EPIDZL9012), using UK aid from the UK Government to support global health research and supported by the National Institute for Health Research Health Protection Research Unit in Immunisation at London School of Hygiene and Tropical Medicine, in partnership with Public Health England (PHE). The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. MS is supported by the National Natural Science Foundation of China (71974035), the Ministry of Education of Humanities and Social Science project (19YJCZH143), and the Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022) (GWV-10.1-XK23). CL is supported by the National Natural Science Foundation of China (71774031 and 72074048) and the Shanghai Foundation for Talents Development (grant number 2020128). NH is funded by the National University of Singapore Saw Swee Hock School of Public Health. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, UK Department of Health and Social Care, NHS, PHE, or any other funders. Funders had no input into study design, implementation, analysis or conclusions.	Abebe AM, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5302307; [Anonymous], 2014, B WORLD HEALTH ORGAN, V92, P314, DOI 10.2471/BLT.14.020514; [Anonymous], 2009, CHINA GOV PROCURE, P18; Burns JE, 2009, REV PANAM SALUD PUBL, V26, P398, DOI 10.1590/S1020-49892009001100003; Chen L., 2017, CHIN J VACCINES IMMU, V23; DeRoeck D, 2005, VACCINE, V23, P2762, DOI 10.1016/j.vaccine.2004.11.044; Dong W., 2007, CHIN PREV MED, V8, P304; Edmunds WJ, 2000, HEALTH POLICY PLANN, V15, P408, DOI 10.1093/heapol/15.4.408; Fang Q., 2011, J COMMUNITY MED, V9, P6; Glisczinski D, 2018, J TRANSFORM EDUC, V16, P175, DOI 10.1177/1541344618777367; Guo H., 2020, MOD PREV MED, V47, P16; Jauregui B, 2015, VACCINE, V33, pA28, DOI 10.1016/j.vaccine.2014.10.090; Jiao Y., 2009, CHIN PRIM HLTH CARE, V23, P42; Kang G., 2020, CHIN J VACCINES IMMU, V26, P450; L-s C., 2012, CHIN J VACCIN IMMUN, V18, P162; Ladner J, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1824-5; Levine OS, 1998, PEDIATR INFECT DIS J, V17, pS95, DOI 10.1097/00006454-199809001-00003; Li L., 2008, CHIN J VACCINES IMMU, V14, P277; Liang XF, 2013, VACCINE, V31, pJ8, DOI 10.1016/j.vaccine.2012.12.019; Lin S., 2019, CHIN J VACCINES IMMU, V25, P326; Liu C., 2009, MED INF, V22, P1929; Lou T., 2014, CHIN PRIM HLTH CARE, V28, P34; Martin DW, 2015, J PUBLIC HEALTH MAN, V21, P296, DOI 10.1097/PHH.0000000000000040; Maxwell J.A., 2012, REALIST APPROACH QUA; McMahon E, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7100458; Rossi IA, 2007, VACCINE, V25, P7075, DOI 10.1016/j.vaccine.2007.07.058; The Central People's Government of the People's Republic of China, ORDER DIS CONTROL PR; The Central People's Government of the People's Republic of China, 40 CENTR PEOPL GOV P; Wang H., 2019, CHIN J VACC IMMUN, V25, P359; Wang K., 1999, CHIN J EPIDEMIOL, V20, P7; Wu WD, 2019, VACCINE, V37, P6268, DOI 10.1016/j.vaccine.2019.08.070; Xi J., 2014, CHINA PUBLIC HLTH MA, V30, P372; Xu WB, 2020, VACCINE, V38, P878, DOI 10.1016/j.vaccine.2019.10.086; Zhang J., 2013, CHIN HLTH EC, V32, P62; Zhang Y., 2011, CHIN PRIM HLTH CARE, V25, P15; Zhao JianHai, 2009, Modern Preventive Medicine, V36, P3463; 潘金仁, 2014, [中华预防医学杂志, Chinese Journal of Preventive Medicine], V48, P1107	37	0	0	7	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							476	10.3390/vaccines9050476			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1ZK	34066844	Green Published, Green Accepted, gold			2022-04-29	WOS:000654623900001
J	Aurilio, MT; Mennini, FS; Gazzillo, S; Massini, L; Bolcato, M; Feola, A; Ferrari, C; Coppeta, L				Trabucco Aurilio, Marco; Mennini, Francesco Saverio; Gazzillo, Simone; Massini, Laura; Bolcato, Matteo; Feola, Alessandro; Ferrari, Cristiana; Coppeta, Luca			Intention to Be Vaccinated for COVID-19 among Italian Nurses during the Pandemic	VACCINES			English	Article						COVID-19 vaccine; public health ethics; healthcare workers; nurse	HEALTH-CARE WORKERS; INFLUENZA VACCINATION; SARS-COV-2; STRATEGIES; HESITANCY; BELIEFS; WORKING	Background: While the COVID-19 pandemic has spread globally, health systems are overwhelmed by both direct and indirect mortality from other treatable conditions. COVID-19 vaccination was crucial to preventing and eliminating the disease, so vaccine development for COVID-19 was fast-tracked worldwide. Despite the fact that vaccination is commonly recognized as the most effective approach, according to the World Health Organization (WHO), vaccine hesitancy is a global health issue. Methods: We conducted a cross-sectional online survey of nurses in four different regions in Italy between 20 and 28 December 2020 to obtain data on the acceptance of the upcoming COVID-19 vaccination in order to plan specific interventions to increase the rate of vaccine coverage. Results: A total of 531 out of the 5000 nurses invited completed the online questionnaire. Most of the nurses enrolled in the study (73.4%) were female. Among the nurses, 91.5% intended to accept vaccination, whereas 2.3% were opposed and 6.2% were undecided. Female sex and confidence in vaccine efficacy represent the main predictors of vaccine intention among the study population using a logistic regression model, while other factors including vaccine safety concerns (side effects) were non-significant. Conclusions: Despite the availability of a safe and effective vaccine, intention to be vaccinated was suboptimal among nurses in our sample. We also found a significant number of people undecided as to whether to accept the vaccine. Contrary to expectations, concerns about the safety of the vaccine were not found to affect the acceptance rate; nurses' perception of vaccine efficacy and female sex were the main influencing factors on attitudes toward vaccination in our sample. Since the success of the COVID-19 immunization plan depends on the uptake rate, these findings are of great interest for public health policies. Interventions aimed at increasing employee awareness of vaccination efficacy should be promoted among nurses in order to increase the number of vaccinated people.	[Trabucco Aurilio, Marco; Massini, Laura] Univ Molise, Dept Med & Hlth Sci V Tiberio, I-86100 Campobasso, Italy; [Mennini, Francesco Saverio; Gazzillo, Simone] Univ Roma Tor Vergata, EEHTA CEIS, DEF Dept, Fac Econ, I-00133 Rome, Italy; [Mennini, Francesco Saverio] Univ Kingston, Inst Leadership & Management Hlth, Kingston Upon Thames KT1 2EE, Surrey, England; [Bolcato, Matteo] Univ Padua, Legal Med, Via G Falloppio 50, I-35121 Padua, Italy; [Feola, Alessandro] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy; [Ferrari, Cristiana; Coppeta, Luca] Univ Roma Tor Vergata, Dept Occupat Med, I-00133 Rome, Italy		Bolcato, M (通讯作者)，Univ Padua, Legal Med, Via G Falloppio 50, I-35121 Padua, Italy.	marco.trabuccoaurilio@unimol.it; mennini@uniroma2.it; simone.gazzillo@uniroma2.it; laura.massini@unimol.it; matteo.bolcato@unipd.it; alessandro.feola@unicampania.it; cristiana.ferrari@ptvonline.it; luca.coppeta@ptvonline.it	coppeta, luca/X-6052-2019; Feola, Alessandro/AAI-4601-2020	coppeta, luca/0000-0003-2470-6107; Feola, Alessandro/0000-0002-9666-2636; Massini, Laura/0000-0002-5863-4247; Trabucco Aurilio, Marco/0000-0003-2327-1455			Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bolcato M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052484; Bolcato M, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9010017; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Chor JSY, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3391; Coppeta L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17239082; Coppeta L, 2019, HUM VACC IMMUNOTHER, V15, P2847, DOI 10.1080/21645515.2019.1616505; Corace K, 2013, AM J INFECT CONTROL, V41, P679, DOI 10.1016/j.ajic.2013.01.014; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; EMA, TREATM VACC COVID 19; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Guthmann JP, 2012, VACCINE, V30, P4648, DOI 10.1016/j.vaccine.2012.04.098; Hardt K, 2016, VACCINE, V34, P6691, DOI 10.1016/j.vaccine.2016.10.078; Honein MA, 2020, MMWR-MORBID MORTAL W, V69, P1860, DOI 10.15585/mmwr.mm6949e2; Hughes MM, 2020, CLIN INFECT DIS, V70, P2496, DOI 10.1093/cid/ciz676; INAIL, 2020, TREND ACC WORK OCC D; ISS-COVID-19, INT SURV DAT IT; Istituto Superiore di Sanita PASSI e PASSI d'Argento e la pandemia COVID-19, 2021, 52021 ISS; Italian Ministry of Health, 2020, STRAT PLAN COVID 19; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Liao QY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017713; Lin CJ, 2010, VACCINE, V28, P7706, DOI 10.1016/j.vaccine.2010.07.009; Lytras T, 2016, HUM VACC IMMUNOTHER, V12, P671, DOI 10.1080/21645515.2015.1106656; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Odone Anna, 2020, Acta Biomed, V91, pe2020031, DOI 10.23750/abm.v91i3.10549; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2; Petravic L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030247; Prati G, 2020, HEALTH EDUC RES, V35, P505, DOI 10.1093/her/cyaa043; Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018; Ricco M, 2017, INT J OCCUP MED ENV, V30, P775, DOI 10.13075/ijomeh.1896.00895; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; World Health Organization, SAGE WORK GROUP DEAL; World Health Organization, 2021, WEEKLY EPIDEMIOLOGIC; Zarocostas J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2877	37	17	17	7	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							500	10.3390/vaccines9050500			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1EH	34066068	Green Accepted, Green Published, gold			2022-04-29	WOS:000654568800001
J	Montalti, M; Rallo, F; Guaraldi, F; Bartoli, L; Po, G; Stillo, M; Perrone, P; Squillace, L; Dallolio, L; Pandolfi, P; Resi, D; Fantini, MP; Reno, C; Gori, D				Montalti, Marco; Rallo, Flavia; Guaraldi, Federica; Bartoli, Lapo; Po, Giulia; Stillo, Michela; Perrone, Paola; Squillace, Lorena; Dallolio, Laura; Pandolfi, Paolo; Resi, Davide; Fantini, Maria Pia; Reno, Chiara; Gori, Davide			Would Parents Get Their Children Vaccinated Against SARS-CoV-2? Rate and Predictors of Vaccine Hesitancy According to a Survey over 5000 Families from Bologna, Italy	VACCINES			English	Article						vaccine hesitancy; children; vaccination; COVID-19; SARS-CoV-2; survey	FUTURE COVID-19 VACCINE; SEX	In the near future, COVID-19 vaccine efficacy trials in larger cohorts may offer the possibility to implement child and adolescent vaccination. The opening of the vaccination for these strata may play a key role in order to limit virus circulation, infection spreading towards the most vulnerable subjects, and plan safe school reopening. Vaccine hesitancy (VH) could limit the ability to reach the coverage threshold required to ensure herd immunity. The aim of this study was to investigate the prevalence and determinants of VH among parents/guardians toward a potentially available COVID-19 vaccination for children and adolescents. An online survey was performed in parents/guardians of children aged <18 years old, living in Bologna. Overall, 5054 questionnaires were collected. A vast majority (60.4%) of the parents/guardians were inclined to vaccinate, while 29.6% were still considering the opportunity, and 9.9% were hesitant. Highest vaccine hesitancy rates were detected in female parents/guardians of children aged 6-10 years, <= 29 years old, with low educational level, relying on information found in the web/social media, and disliking mandatory vaccination policies. Although preliminary, these data could help in designing target strategies to implement adherence to a vaccination campaign, with special regard to web-based information.	[Montalti, Marco; Rallo, Flavia; Dallolio, Laura; Fantini, Maria Pia; Reno, Chiara; Gori, Davide] Univ Bologna, Unit Hyg, Dept Biomed & Neuromotor Sci, Publ Hlth & Med Stat, I-40126 Bologna, Italy; [Guaraldi, Federica] IRCCS Ist Sci Neurol Bologna, I-40139 Bologna, Italy; [Bartoli, Lapo] Univ Bologna, Dept Med & Surg Sci, Unit Primary Hlth Care, I-40126 Bologna, Italy; [Po, Giulia] Univ Ferrara, Sch Hyg & Prevent Med, I-44121 Ferrara, Italy; [Stillo, Michela; Perrone, Paola; Squillace, Lorena; Pandolfi, Paolo; Resi, Davide] Bologna Local Hlth Author, Dept Publ Hlth, I-40124 Bologna, Italy		Montalti, M (通讯作者)，Univ Bologna, Unit Hyg, Dept Biomed & Neuromotor Sci, Publ Hlth & Med Stat, I-40126 Bologna, Italy.	marco.montalti7@studio.unibo.it; flavia.rallo@studio.unibo.it; federica.guaraldi@yahoo.it; lapo.bartoli@studio.unibo.it; giulia.po@edu.unife.it; michela.stillo@ausl.bologna.it; paola.perrone@ausl.bologna.it; lorena.squillace@ausl.bologna.it; laura.dallolio@unibo.it; paolo.pandolfi@ausl.bologna.it; davide.resi@ausl.bologna.it; mariapia.fantini@unibo.it; chiara.reno@studio.unibo.it; davide.gori4@unibo.it	Gori, Davide/AAC-3486-2022; Montalti, Marco/AAQ-2494-2021; Reno, Chiara/ABA-5613-2020	Gori, Davide/0000-0003-4954-9419; Montalti, Marco/0000-0001-7276-0277; Reno, Chiara/0000-0002-7933-2141; Dallolio, Laura/0000-0001-7555-9659; Po, Giulia/0000-0002-9427-8868; Fantini, Maria Pia/0000-0002-3257-6552			Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bhopal SS, 2021, LANCET CHILD ADOLESC, V5, pE12, DOI 10.1016/S2352-4642(21)00066-3; Bocquier A, 2018, VACCINE, V36, P7666, DOI 10.1016/j.vaccine.2018.10.085; Brookman S, 2021, LANCET CHILD ADOLESC, V5, pE9, DOI 10.1016/S2352-4642(21)00030-4; Colao A, 2020, LANCET PUBLIC HEALTH, V5, pE170, DOI 10.1016/S2468-2667(20)30124-9; Deiner MS, 2019, HEALTH INFORM J, V25, P1116, DOI 10.1177/1460458217740723; Fantini MP, 2020, ITAL J PEDIATR, V46, DOI 10.1186/s13052-020-00844-1; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Gualano MR, 2018, VACCINE, V36, P3368, DOI 10.1016/j.vaccine.2018.04.029; Guess AM, 2020, VACCINE, V38, P7799, DOI 10.1016/j.vaccine.2020.10.018; Haleemunnissa S, 2021, CHILD YOUTH SERV REV, V120, DOI 10.1016/j.childyouth.2020.105754; Italian Ministry of Health, ANTICOVID 19 NATL VA; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Kang GJ, 2017, VACCINE, V35, P3621, DOI 10.1016/j.vaccine.2017.05.052; Kempe A, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-3852; Klass P, 2021, NEW ENGL J MED, V384, P589, DOI 10.1056/NEJMp2034765; Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loades ME, 2020, J AM ACAD CHILD PSY, V59, P1218, DOI 10.1016/j.jaac.2020.05.009; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n723; Mintz K, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-040717; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Regional School Office for Emilia-Romagna, 2020, UPDATE PROTOCOL MANA; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; UNESCO, ADVERSE CONSEQUENCES; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; World Health Organization, GLOBAL VACCINE ACTIO; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827	35	33	33	3	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							366	10.3390/vaccines9040366			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS6BZ	33920109	Green Published, gold			2022-04-29	WOS:000643863500001
J	Panaiotov, S; Hodzhev, Y; Tolchkov, V; Tsafarova, B; Mihailov, A; Stefanova, T				Panaiotov, Stefan; Hodzhev, Yordan; Tolchkov, Vladimir; Tsafarova, Borislava; Mihailov, Alexander; Stefanova, Tzvetelina			Complete Genome Sequence, Genome Stability and Phylogeny of the Vaccine Strain Mycobacterium bovis BCG SL222 Sofia	VACCINES			English	Article						BCG vaccine; BCG sub-strains; BCG-I; BCG SL222 Sofia; complete genome; phylogeny		Mycobacterium bovis bacillus Calmette-Guerin (BCG) is the only live attenuated vaccine available against tuberculosis. The first BCG vaccination was done exactly 100 years ago, in 1921. The BCG vaccine strains used worldwide represent a family of daughter sub-strains with distinct genotypic characteristics. BCG SL222 Sofia is a seed lot sub-strain descending from the Russian BCG-I (seed lot 374a) strain and has been used for vaccine production in Bulgaria since 1972. Here, we report the assembled circular genome sequence of Mycobacterium bovis BCG SL222 Sofia and phylogeny analysis with the most closely related BCG sub-strains. The full circular genome of BCG SL222 Sofia had a length of 4,370,706 bp with an average GC content of 65.60%. After 49 years of in vitro evolution in a freeze-dried condition, we identified four SNP mutations as compared to the reference BCG-I (Russia-368) sequence. BCG vaccination is of central importance for the TB elimination programs in many countries. Since 1991, almost 40 million vaccine doses of the BCG SL222 Sofia have been distributed annually through the United Nations Children's Fund (UNICEF) and the Pan American Health Organization (PAHO) to approximately 120 countries. The availability of the complete reference genome sequence for M. bovis BCG SL222 Sofia, a WHO reference reagent for the Russian BCG-I sub-strain, will facilitate the identity assurance of the genomic stability, will contribute to more consistent manufacturing, and has an important value in standardization and differentiation of sub-strains used in vaccine production. We propose to rename the sub-strain BCG SL222 Sofia to BCG-Sofia for practical and common use.	[Panaiotov, Stefan; Hodzhev, Yordan; Tolchkov, Vladimir; Tsafarova, Borislava] Natl Ctr Infect & Parasit Dis, Sofia 1504, Bulgaria; [Mihailov, Alexander; Stefanova, Tzvetelina] BB NCIPD Ltd, Sofia 1504, Bulgaria		Panaiotov, S (通讯作者)，Natl Ctr Infect & Parasit Dis, Sofia 1504, Bulgaria.	spanaiotov@ncipd.org; y.hodzhev@ncipd.org; tolchkov@ncipd.org; b.tsafarova@ncipd.org; bcg@bulbio.com; t.stefanova@bulbio.com	Panaiotov, Stefan/AAR-6396-2021; Hodzhev, Yordan/AAH-9913-2021	Panaiotov, Stefan/0000-0001-9997-5198; Tolchkov, Vladimir/0000-0001-8005-6036; Hodzhev, Yordan/0000-0002-7770-3316; Tsafarova, Borislava/0000-0002-8183-3869	BULGARIAN NATIONAL SCIENCE FUND (BNSF)National Science Fund of Bulgaria [DN13/4-15.12.2017]; EUROPEAN FUND FOR REGIONAL DEVELOPMENT THROUGH OPERATIONAL PROGRAM SCIENCE AND EDUCATION FOR SMART GROWTH 2014-2020 [BG05M2OP001-1.002-0001-C04]	This research was funded by the BULGARIAN NATIONAL SCIENCE FUND (BNSF), grant number DN13/4-15.12.2017 and the EUROPEAN FUND FOR REGIONAL DEVELOPMENT THROUGH OPERATIONAL PROGRAM SCIENCE AND EDUCATION FOR SMART GROWTH 2014-2020, grant number BG05M2OP001-1.002-0001-C04.	Abdallah Abdallah M, 2017, Adv Exp Med Biol, V1019, P155, DOI 10.1007/978-3-319-64371-7_8; Abdallah AM, 2015, SCI REP-UK, V5, DOI 10.1038/srep15443; Ausubel M., 1988, CURRENT PROTOCOLS MO; Borgers K, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5909-5; Cernuschi T, 2018, VACCINE, V36, P498, DOI 10.1016/j.vaccine.2017.12.010; Chouchkova M., 1981, THESIS NATL CTR INFE; Engibarov A, 1986, Dev Biol Stand, V58 ( Pt A), P163; Guerin C., 1948, REV AT, V27, P183; Ho MM, 2011, VACCINE, V29, P512, DOI 10.1016/j.vaccine.2010.10.066; Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199; Keller PM, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-120; [Леви Д.Т. Levi D.T.], 2016, [Биопрепараты. Профилактика, диагностика, лечение, BIOpreparations. Prevention, Diagnosis, Treatment, Biopreparaty. Profilaktika, diagnostika, lechenie], V16, P49; Luca Simona, 2013, Maedica (Bucur), V8, P53; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Mangtani P, 2017, HEALTH TECHNOL ASSES, V21, P1, DOI 10.3310/hta21390; Markey K., 2010, WHO EXPERT COMMITTEE; Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020; Mostowy S, 2003, VACCINE, V21, P4270, DOI 10.1016/S0264-410X(03)00484-5; Mustafa A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040736; Narvskaya O, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-06973-5; Otrashevskaya E. V., 2018, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P58; Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026; Sotnikova EA, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00182-16; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; Stefanova T, 2003, J CLIN MICROBIOL, V41, P5349, DOI 10.1128/JCM.41.11.5349.2003; Stefanova T, 2014, BIOTECHNOL BIOTEC EQ, V28, P387, DOI 10.1080/13102818.2014.927200; VAN DEINSE F, 1950, Bull World Health Organ, V2, P347; van Puffelen JH, 2020, NAT REV UROL, V17, P513, DOI 10.1038/s41585-020-0346-4; VANSOOLINGEN D, 1994, METHOD ENZYMOL, V235, P196; Voronina OL, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3355-1; WHO, 2013, 07274 WHO	31	0	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							237	10.3390/vaccines9030237			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5TG	33803448	gold, Green Published			2022-04-29	WOS:000634215600001
J	Dollery, SJ; Zurawski, DV; Gaidamakova, EK; Matrosova, VY; Tobin, JK; Wiggins, TJ; Bushnell, RV; MacLeod, DA; Alamneh, YA; Abu-Taleb, R; Escatte, MG; Meeks, HN; Daly, MJ; Tobin, GJ				Dollery, Stephen J.; Zurawski, Daniel, V; Gaidamakova, Elena K.; Matrosova, Vera Y.; Tobin, John K.; Wiggins, Taralyn J.; Bushnell, Ruth, V; MacLeod, David A.; Alamneh, Yonas A.; Abu-Taleb, Rania; Escatte, Mariel G.; Meeks, Heather N.; Daly, Michael J.; Tobin, Gregory J.			Radiation-Inactivated Acinetobacter baumannii Vaccine Candidates	VACCINES			English	Article						A. baumannii; vaccine; mouse; whole-cell; irradiated; protective; MDP; inactivated; pulmonary; Deinococcus		Acinetobacter baumannii is a bacterial pathogen that is often multidrug-resistant (MDR) and causes a range of life-threatening illnesses, including pneumonia, septicemia, and wound infections. Some antibiotic treatments can reduce mortality if dosed early enough before an infection progresses, but there are few other treatment options when it comes to MDR-infection. Although several prophylactic strategies have been assessed, no vaccine candidates have advanced to clinical trials or have been approved. Herein, we rapidly produced protective whole-cell immunogens from planktonic and biofilm-like cultures of A. baumannii, strain AB5075 grown using a variety of methods. After selecting a panel of five cultures based on distinct protein profiles, replicative activity was extinguished by exposure to 10 kGy gamma radiation in the presence of a Deinococcus antioxidant complex composed of manganous (Mn2+) ions, a decapeptide, and orthophosphate. Mn2+ antioxidants prevent hydroxylation and carbonylation of irradiated proteins, but do not protect nucleic acids, yielding replication-deficient immunogenic A. baumannii vaccine candidates. Mice were immunized and boosted twice with 1.0 x 10(7) irradiated bacterial cells and then challenged intranasally with AB5075 using two mouse models. Planktonic cultures grown for 16 h in rich media and biofilm cultures grown in static cultures underneath minimal (M9) media stimulated immunity that led to 80-100% protection.	[Dollery, Stephen J.; Tobin, John K.; Wiggins, Taralyn J.; Bushnell, Ruth, V; MacLeod, David A.; Tobin, Gregory J.] Biol Mimet Inc, 124 Byte Dr, Frederick, MD 21702 USA; [Zurawski, Daniel, V; Alamneh, Yonas A.; Abu-Taleb, Rania; Escatte, Mariel G.] Walter Reed Army Inst Res, Ctr Infect Dis Res, Wound Infect Dept, Bacterial Dis Branch, Silver Spring, MD 20910 USA; [Gaidamakova, Elena K.; Matrosova, Vera Y.; Daly, Michael J.] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA; [Gaidamakova, Elena K.; Matrosova, Vera Y.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA; [Meeks, Heather N.] Def Threat Reduct Agcy, Ft Belvoir, VA 22060 USA		Dollery, SJ (通讯作者)，Biol Mimet Inc, 124 Byte Dr, Frederick, MD 21702 USA.	Dollery@BMI-MD.com; dvzurawski@gmail.com; elena.gaidamakova.ctr@usuhs.edu; vera.matrosova.ctr@usuhs.edu; john.tobin@bmi-md.com; wiggins@bmi-md.com; bushnell@bmi-md.com; dmacleod8@gmail.com; yoann.s.lebreton.ctr@mail.mil; rania.abu-taleb.ctr@mail.mil; mariel.g.escatte.ctr@mail.mil; heather.n.meeks4.civ@mail.mil; michael.daly@usuhs.edu; tobin@bmi-md.com	Zurawski, Daniel/B-6578-2009	Zurawski, Daniel/0000-0002-7920-5601; Dollery, Steve/0000-0002-1712-3811	STTR Phase II from the Defense Threat Reduction Agency of the US Department of Defense [HDTRA 1-17-C-0030]	This research was funded through STTR Phase II contract HDTRA 1-17-C-0030 from the Defense Threat Reduction Agency of the US Department of Defense.	Alvarez-Fraga L, 2016, VIRULENCE, V7, P443, DOI 10.1080/21505594.2016.1145335; ANDERSON AW, 1956, FOOD TECHNOL-CHICAGO, V10, P575; Anderson SE, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00271-18; Barki KG, 2019, ANN SURG, V269, P756, DOI 10.1097/SLA.0000000000002504; Bruckbauer ST, 2020, MOL CELL PROTEOMICS, V19, P1375, DOI 10.1074/mcp.RA120.002092; Centers for Disease Control and Prevention (CDC), 2019, 2019 AR THREATS REP; Chin CY, 2018, NAT MICROBIOL, V3, P563, DOI 10.1038/s41564-018-0151-5; da Silva KE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209367; Dabral N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107180; Daly MJ, 2012, DNA REPAIR, V11, P12, DOI 10.1016/j.dnarep.2011.10.024; Daly MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012570; Daly MJ, 2009, NAT REV MICROBIOL, V7, P237, DOI 10.1038/nrmicro2073; Daly MJ, 2004, SCIENCE, V306, P1025, DOI 10.1126/science.1103185; Datta SK, 2006, IMMUNITY, V25, P143, DOI 10.1016/j.immuni.2006.05.013; de Breij A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010732; Di Venanzio G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10706-y; Eijkelkamp BA, 2011, FEMS MICROBIOL LETT, V323, P44, DOI 10.1111/j.1574-6968.2011.02362.x; Falagas ME, 2007, CRIT CARE, V11, DOI 10.1186/cc5911; Gaddy JA, 2012, INFECT IMMUN, V80, P1015, DOI 10.1128/IAI.06279-11; Gaidamakova EK, 2012, CELL HOST MICROBE, V12, P117, DOI 10.1016/j.chom.2012.05.011; Gayen M, 2017, VACCINE, V35, P3672, DOI 10.1016/j.vaccine.2017.05.016; Harding CM, 2018, NAT REV MICROBIOL, V16, P91, DOI 10.1038/nrmicro.2017.148; Harro JM, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00586-19; He T, 2019, NAT MICROBIOL, V4, P1450, DOI 10.1038/s41564-019-0445-2; Jacobs AC, 2014, MBIO, V5, DOI 10.1128/mBio.01076-14; Lashinsky JN, 2017, INFECT DIS THER, V6, P199, DOI 10.1007/s40121-017-0153-2; Lee CR, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00055; Lipsitch M, 2016, MBIO, V7, DOI 10.1128/mBio.00428-16; Lob SH, 2016, INT J ANTIMICROB AG, V47, P317, DOI 10.1016/j.ijantimicag.2016.01.015; Martin SS, 2010, VACCINE, V28, P1031, DOI 10.1016/j.vaccine.2009.10.126; Martinez-Guitian M, 2021, J INFECT DIS, V223, P1356, DOI 10.1093/infdis/jiaa522; Mishra RPN, 2012, CURR OPIN MICROBIOL, V15, P596, DOI 10.1016/j.mib.2012.08.002; Moore HN, 1936, J BACTERIOL, V31, P581, DOI 10.1128/JB.31.6.581-584.1936; Nielsen TB, 2017, J INFECT DIS, V216, P489, DOI 10.1093/infdis/jix315; Peana M, 2020, INORG CHEM, V59, P4661, DOI 10.1021/acs.inorgchem.9b03737; Peleg AY, 2008, CLIN MICROBIOL REV, V21, P538, DOI 10.1128/CMR.00058-07; Regeimbal JM, 2016, ANTIMICROB AGENTS CH, V60, P5806, DOI 10.1128/AAC.02877-15; Rumbo-Feal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072968; Sharma A, 2017, P NATL ACAD SCI USA, V114, pE9253, DOI 10.1073/pnas.1713608114; Ramirez MS, 2010, J CLIN MICROBIOL, V48, P1488, DOI 10.1128/JCM.01264-09; Spellberg B, 2013, NAT REV DRUG DISCOV, V12, P963, DOI 10.1038/nrd3957-c1; Thompson MG, 2014, ANTIMICROB AGENTS CH, V58, P1332, DOI 10.1128/AAC.01944-13; Tobin GJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228006; Touchon M, 2014, GENOME BIOL EVOL, V6, P2866, DOI 10.1093/gbe/evu225; Traglia GM, 2014, GENOME BIOL EVOL, V6, P2235, DOI 10.1093/gbe/evu176; WHO, WHY IS VACC IMP ADDR; Williams CL, 2016, APPL ENVIRON MICROB, V82, P6174, DOI 10.1128/AEM.01813-16	47	4	4	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							96	10.3390/vaccines9020096			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6YY	33514059	Green Published, gold			2022-04-29	WOS:000623288500001
J	Huang, HY; Silva, BBI; Tsai, SP; Tsai, CY; Tyan, YC; Lin, TC; Flores, RJD; Chuang, KP				Huang, Huai-Ying; Silva, Benji Brayan, I; Tsai, Shen-Pang; Tsai, Ching-Yi; Tyan, Yu-Chang; Lin, Tzu-Che; Flores, Ronilo Jose D.; Chuang, Kuo-Pin			Immunogenicity and Protective Activity of Pigeon Circovirus Recombinant Capsid Protein Virus-Like Particles (PiCV rCap-VLPs) in Pigeons (Columba livia) Experimentally Infected with PiCV	VACCINES			English	Article						pigeon circovirus (PiCV); young pigeon disease syndrome (YPDS); virus-like particles (VLPs); immunogenicity; mammalian expression system		Pigeon circovirus (PiCV) is the most recurrent virus diagnosed in pigeons and is among the major causative agents of young pigeon disease syndrome (YPDS). Due to the lack of an established laboratory protocol for PiCV cultivation, development of prophylaxis is hampered. Alternatively, virus-like particles (VLPs), which closely resemble native viruses but lack the viral genetic material, can be generated using a wide range of expression systems and are shown to have strong immunogenicity. Therefore, the use of VLPs provides a promising prospect for vaccine development. In this study, transfected human embryonic kidney (HEK-293) cells, a mammalian expression system, were used to express the PiCV capsid protein (Cap), which is a major component of PiCV and believed to contain antibody epitopes, to obtain self-assembled VLPs. The VLPs were observed to have a spherical morphology with diameters ranging from 12 to 26 nm. Subcutaneous immunization of pigeons with 100 mu g PiCV rCap-VLPs supplemented with water-in-oil-in-water (W/O/W) adjuvant induced specific antibodies against PiCV. Observations of the cytokine expression and T-cell proliferation levels in spleen samples showed significantly higher T-cell proliferation and IFN- gamma expression in pigeons immunized with VLPs compared to the controls (p < 0.05). Experimentally infected pigeons that were vaccinated with VLPs also showed no detectable viral titer. The results of the current study demonstrated the potential use of PiCV rCap-VLPs as an effective vaccine candidate against PiCV.	[Huang, Huai-Ying; Tsai, Shen-Pang; Tsai, Ching-Yi; Chuang, Kuo-Pin] Natl Pingtung Univ Sci & Technol, Int Coll, Int Degree Program Anim Vaccine Tehnol, Pingtung 912, Taiwan; [Silva, Benji Brayan, I; Flores, Ronilo Jose D.] Univ Philippines Los Banos, Grad Sch, Laguna 4031, Philippines; [Tyan, Yu-Chang; Chuang, Kuo-Pin] Natl Pingtung Univ Sci & Technol, Coll Vet Med, Grad Inst Anim Vaccine Technol, Pingtung 912, Taiwan; [Tyan, Yu-Chang; Chuang, Kuo-Pin] Kaohsiung Med Univ, Coll Med, Sch Med, Kaohsiung 807, Taiwan; [Tyan, Yu-Chang] Kaohsiung Med Univ, Dept Med Imaging & Radiol Sci, Kaohsiung 807, Taiwan; [Tyan, Yu-Chang] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 804, Taiwan; [Tyan, Yu-Chang] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan; [Tyan, Yu-Chang] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan; [Tyan, Yu-Chang] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 807, Taiwan; [Lin, Tzu-Che] Natl Pingtung Univ Sci & Technol, Coll Agr, Dept Plant Ind, Pingtung 912, Taiwan; [Flores, Ronilo Jose D.] Univ Philippines Los Banos, Coll Arts & Sci, Inst Biol Sci, Laguna 4031, Philippines; [Chuang, Kuo-Pin] Natl Pingtung Univ Sci & Technol, Res Ctr Anim Biol, Pingtung 912, Taiwan; [Chuang, Kuo-Pin] Kaohsiung Med Univ, Sch Dent, Kaohsiung 807, Taiwan		Chuang, KP (通讯作者)，Natl Pingtung Univ Sci & Technol, Int Coll, Int Degree Program Anim Vaccine Tehnol, Pingtung 912, Taiwan.; Chuang, KP (通讯作者)，Natl Pingtung Univ Sci & Technol, Coll Vet Med, Grad Inst Anim Vaccine Technol, Pingtung 912, Taiwan.; Chuang, KP (通讯作者)，Kaohsiung Med Univ, Coll Med, Sch Med, Kaohsiung 807, Taiwan.; Chuang, KP (通讯作者)，Natl Pingtung Univ Sci & Technol, Res Ctr Anim Biol, Pingtung 912, Taiwan.; Chuang, KP (通讯作者)，Kaohsiung Med Univ, Sch Dent, Kaohsiung 807, Taiwan.	vetlaenwe@gmail.com; bisilva@up.edu.ph; ksrobert@ms24.hinet.net; j10785002@g4e.npust.edu.tw; yctyan@kmu.edu.tw; tdin@mail.npust.edu.tw; rdflores3@up.edu.ph; kpchuang@g4e.npust.edu.tw		Chuang, Kuo Pin/0000-0002-3973-8390; Tyan, Yu-Chang/0000-0002-1917-5893; Silva, Benji Brayan/0000-0002-1376-3053	Higher Education Sprout Project by the Ministry of Education; Ministry of Science and Technology [MOST 107-3017-F-020-003]	This research was funded by Higher Education Sprout Project by the Ministry of Education and the Ministry of Science and Technology (MOST 107-3017-F-020-003).	Alvim RGF, 2019, VACCINE, V37, P6970, DOI 10.1016/j.vaccine.2019.05.064; Blanchard P, 2003, VACCINE, V21, P4565, DOI 10.1016/S0264-410X(03)00503-6; Bonne N, 2009, J GEN VIROL, V90, P640, DOI 10.1099/vir.0.006932-0; Borghetti P, 2013, VET MICROBIOL, V163, P42, DOI 10.1016/j.vetmic.2012.12.007; Braun M, 2012, EUR J IMMUNOL, V42, P330, DOI 10.1002/eji.201142064; Crisci E, 2012, VET IMMUNOL IMMUNOP, V148, P211, DOI 10.1016/j.vetimm.2012.04.026; Daum I, 2009, AVIAN PATHOL, V38, P135, DOI 10.1080/03079450902737797; Duchatel JP, 2011, ISR J VET MED, V66, P26; Fort M, 2009, VACCINE, V27, P4031, DOI 10.1016/j.vaccine.2009.04.028; Franciosini MP, 2005, AVIAN DIS, V49, P340, DOI 10.1637/7334-012705R.1; Freick M, 2008, J VIROL METHODS, V148, P226, DOI 10.1016/j.jviromet.2007.11.003; Fu Y, 2016, VIRUS RES, V211, P9, DOI 10.1016/j.virusres.2015.08.022; Gai WW, 2020, MICROB PATHOGENESIS, V139, DOI 10.1016/j.micpath.2019.103905; Gilbert RWD, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4020021; Hashiguchi A, 2017, METHOD ENZYMOL, V586, P97, DOI 10.1016/bs.mie.2016.09.030; Heath L, 2006, J VIROL, V80, P7219, DOI 10.1128/JVI.02559-05; Huang YL, 2017, AVIAN PATHOL, V46, P359, DOI 10.1080/03079457.2017.1284305; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Lai GH, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-115; Li PC, 2016, VACCINE, V34, P696, DOI 10.1016/j.vaccine.2015.09.007; Liu FX, 2012, RES VET SCI, V93, P553, DOI 10.1016/j.rvsc.2011.10.018; Liu XY, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-2253-6; Loiko MR, 2018, ARCH VIROL, V163, P3083, DOI 10.1007/s00705-018-3990-8; Mankertz A, 2000, ARCH VIROL, V145, P2469, DOI 10.1007/s007050070002; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Mutthi P, 2018, ARCH VIROL, V163, P2947, DOI 10.1007/s00705-018-3944-1; Plummer EM, 2011, WIRES NANOMED NANOBI, V3, P174, DOI 10.1002/wnan.119; Raue R, 2005, AVIAN PATHOL, V34, P418, DOI 10.1080/03079450500267825; Roy P, 2003, AVIAN DIS, V47, P218, DOI 10.1637/0005-2086(2003)047[0218:DOPCBP]2.0.CO;2; Santos HM, 2020, VET MICROBIOL, V242, DOI 10.1016/j.vetmic.2020.108591; Shirbaghaee Z, 2016, BIOPOLYMERS, V105, P113, DOI 10.1002/bip.22759; Smyth JA, 2001, J VET DIAGN INVEST, V13, P475, DOI 10.1177/104063870101300604; Stenzel T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219175; Stenzel T, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110596; Todd D, 2002, VET MICROBIOL, V89, P1, DOI 10.1016/S0378-1135(02)00154-2; Todd D, 2001, VIROLOGY, V286, P354, DOI 10.1006/viro.2001.0985; Trible BR, 2011, CLIN VACCINE IMMUNOL, V18, P749, DOI 10.1128/CVI.00418-10; Tsai SS, 2014, ARCH VIROL, V159, P921, DOI 10.1007/s00705-013-1906-1; Urakami A, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00090-17; Wang KC, 2017, VIRUS RES, V233, P1, DOI 10.1016/j.virusres.2017.03.007; Wang Y, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-019-0940-0; Woods LW, 2000, J AVIAN MED SURG, V14, P154, DOI 10.1647/1082-6742(2000)014[0154:CIONB]2.0.CO;2; Yang C, 2017, J VIROL METHODS, V247, P1, DOI 10.1016/j.jviromet.2017.05.003; Yang RC, 2004, J VIROL, V78, P11152, DOI 10.1128/JVI.78.20.11152-11160.2004; Zhu SS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147432; Zhu YW, 2011, IMMUNITY, V34, P466, DOI 10.1016/j.immuni.2011.04.008; Zucchelli E, 2017, MOL THER-METH CLIN D, V4, P102, DOI 10.1016/j.omtm.2017.01.002	47	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							98	10.3390/vaccines9020098			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6VB	33525416	gold, Green Published			2022-04-29	WOS:000623278100001
J	Alabdullah, HA; Overgaard, E; Scarbrough, D; Williams, JE; Mousa, OM; Dunn, G; Bond, L; McGuire, MA; Tinker, JK				Alabdullah, Hussain A.; Overgaard, Elise; Scarbrough, Danielle; Williams, Janet E.; Mohammad Mousa, Omid; Dunn, Gary; Bond, Laura; McGuire, Mark A.; Tinker, Juliette K.			Evaluation of the Efficacy of a Cholera Toxin-Based Staphylococcus aureus Vaccine against Bovine Intramammary Challenge	VACCINES			English	Article						Staphylococcus aureus; vaccine; bovine; mastitis		Staphylococcus aureus (S. aureus) is a primary agent of bovine mastitis and a source of significant economic loss for the dairy industry. We previously reported antigen-specific immune induction in the milk and serum of dairy cows following vaccination with a cholera toxin A(2) and B subunit (CTA(2)/B) based vaccine containing the iron-regulated surface determinant A (IsdA) and clumping factor A (ClfA) antigens of S. aureus (IsdA + ClfA-CTA(2)/B). The goal of the current study was to assess the efficacy of this vaccine to protect against S. aureus infection after intramammary challenge. Six mid-lactation heifers were randomized to vaccinated and control groups. On days 1 and 14 animals were inoculated intranasally with vaccine or vehicle control, and on day 20 animals were challenged with S. aureus. Clinical outcome, milk quality, bacterial shedding, and somatic cell count (SCC) were followed for ten days post-challenge. Vaccinated animals did not show signs of clinical S. aureus mastitis and had lower SCCs compared to control animals during the challenge period. Reductions in bacterial shedding were observed but were not significant between groups. Antibody analysis of milk and serum indicated that, upon challenge, vaccinated animals produced enhanced IsdA- and ClfA-CTA(2)/B specific immunoglobulin G (IgG) responses, while responses to CTA(2)/B alone were not different between groups. Responses after challenge were largely IgG1 against the IsdA antigen and mixed IgG1/IgG2 against the ClfA antigen. In addition, there was a significant increase in interferon gamma (IFN-gamma) expression from blood cells in vaccinated animals on day 20. While preliminary, these findings support evidence of the induction of active immunity by IsdA + ClfA-CTA(2)/B, and further assessment of this vaccine is warranted.	[Alabdullah, Hussain A.; Williams, Janet E.; McGuire, Mark A.] Univ Idaho, Dept Anim & Vet Sci, Moscow, ID 83844 USA; [Overgaard, Elise; Scarbrough, Danielle; Tinker, Juliette K.] Boise State Univ, Biomol Sci Grad Program, Boise, ID 83725 USA; [Mohammad Mousa, Omid; Dunn, Gary; Tinker, Juliette K.] Boise State Univ, Dept Biol Sci, Boise, ID 83725 USA; [Bond, Laura] Boise State Univ, Biomol Res Ctr, Boise, ID 83725 USA		Tinker, JK (通讯作者)，Boise State Univ, Biomol Sci Grad Program, Boise, ID 83725 USA.; Tinker, JK (通讯作者)，Boise State Univ, Dept Biol Sci, Boise, ID 83725 USA.	hussain.alabdullah@wsu.edu; eliseovergaard@u.boisestate.edu; danielleholt@u.boisestate.edu; janetw@uidaho.edu; omidmohammadmousa@u.boisestate.edu; gary.dunn@student.montana.edu; LBOND@boisestate.edu; mmcguire@uidaho.edu; juliettetinker@boisestate.edu	Williams, Janet/AAP-6089-2021	Overgaard, Elise/0000-0001-9904-1635; Mohammad Mousa, Omid/0000-0002-4593-6713; Dunn, Gary/0000-0002-6474-9761; Williams, Janet/0000-0002-9769-1789; Bond, Laura/0000-0003-4975-1019	USDA AFRI standard grant [2013-01189]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM103408, P20GM109095]; Biomolecular Research Center at Boise State; National Science FoundationNational Science Foundation (NSF) [0619793, 0923535]; MJ Murdock Charitable Trust; Idaho State Board of Education	This research was funded by a 2013 USDA AFRI standard grant (#2013-01189, PI-Tinker, Co-PI McGuire), and a faculty seed grant to J.K.T. from an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (#P20GM103408 and P20GM109095). We also acknowledge support from The Biomolecular Research Center at Boise State with funding from the National Science Foundation, Grants #0619793 and #0923535, the MJ Murdock Charitable Trust, and the Idaho State Board of Education.	Abu DI, 2003, J VIROL, V77, P5589, DOI 10.1128/JVI.77.10.5589-5597.2003; Anjuere F, 2003, J IMMUNOL, V170, P1586, DOI 10.4049/jimmunol.170.3.1586; APHIS U., 2014, DAIRY 2014 MILK QUAL, V2016; Arlian BM, 2011, CLIN VACCINE IMMUNOL, V18, P1543, DOI 10.1128/CVI.05146-11; Atalla H, 2009, VET MICROBIOL, V137, P326, DOI 10.1016/j.vetmic.2009.01.027; Baldauf KJ, 2015, TOXINS, V7, P974, DOI 10.3390/toxins7030974; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bouchard D, 2012, J BACTERIOL, V194, P6292, DOI 10.1128/JB.01188-12; Bradley AJ, 2015, J DAIRY SCI, V98, P1706, DOI 10.3168/jds.2014-8332; BROMANDER AK, 1995, ADV EXP MED BIOL, V371, P1501; Burnham KP., 2003, MODEL SELECTION INFE, V67, P655, DOI DOI 10.1016/J.EC0LM0DEL.2003.11.004; Burvenich C, 2003, VET RES, V34, P521, DOI 10.1051/vetres:2003023; Camussone CM, 2013, J DAIRY RES, V80, P72, DOI 10.1017/S0022029912000593; Castagliuolo I, 2006, VACCINE, V24, P4393, DOI 10.1016/j.vaccine.2006.02.055; Cha E, 2011, J DAIRY SCI, V94, P4476, DOI 10.3168/jds.2010-4123; Clarke SR, 2009, INFECT IMMUN, V77, P2408, DOI 10.1128/IAI.01304-08; Clarke SR, 2006, J INFECT DIS, V193, P1098, DOI 10.1086/501471; Cong YZ, 1997, J IMMUNOL, V159, P5301; Coussens PM, 2004, INFECT IMMUN, V72, P1409, DOI 10.1128/IAI.72.3.1409-1422.2004; Creech CB, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz532; Eriksson K, 2003, INFECT IMMUN, V71, P1740, DOI 10.1128/IAI.71.4.1740-1747.2003; Fluit AC, 2010, J CLIN MICROBIOL, V48, P3979, DOI 10.1128/JCM.01191-10; Freick M, 2016, TIERAERZTL PRAX G N, V44, P219, DOI 10.15653/TPG-150912; George-Chandy A, 2001, INFECT IMMUN, V69, P5716, DOI 10.1128/IAI.69.9.5716-5725.2001; Gomez MI, 2002, INFECT IMMUN, V70, P4254, DOI 10.1128/IAI.70.8.4254-4260.2002; Gong R, 2010, CLIN VACCINE IMMUNOL, V17, P1746, DOI 10.1128/CVI.00162-10; Gonzales VK, 2013, TISSUE ENG PART C-ME, V19, P892, DOI 10.1089/ten.tec.2013.0009; Gunther J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05107-4; HAJISHENGALLIS G, 1995, J IMMUNOL, V154, P4322; Hawkins J, 2012, CLIN VACCINE IMMUNOL, V19, P1641, DOI 10.1128/CVI.00354-12; Hebert A, 2000, FEMS MICROBIOL LETT, V193, P57, DOI 10.1016/S0378-1097(00)00455-9; Heikkila AM, 2018, J DAIRY SCI, V101, P9493, DOI 10.3168/jds.2018-14824; Herron-Olson L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001120; Holmgren Jan, 2003, Expert Rev Vaccines, V2, P205, DOI 10.1586/14760584.2.2.205; JOBLING MG, 1992, INFECT IMMUN, V60, P4915, DOI 10.1128/IAI.60.11.4915-4924.1992; Kim HK, 2010, VACCINE, V28, P6382, DOI 10.1016/j.vaccine.2010.02.097; Kim Y, 2011, BMC VET RES, V7, DOI 10.1186/1746-6148-7-51; Landin H, 2015, ACTA VET SCAND, V57, DOI 10.1186/s13028-015-0171-6; Lee JW, 2005, CAN J VET RES, V69, P11; Leitner G, 2003, VET IMMUNOL IMMUNOP, V93, P31, DOI 10.1016/S0165-2427(03)00051-5; Lin L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000703; Liu T, 2016, MOL IMMUNOL, V75, P21, DOI 10.1016/j.molimm.2016.05.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maira-Litran T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043813; Martin M, 2001, INFECT IMMUN, V69, P252, DOI 10.1128/IAI.69.1.252-261.2001; Mattsson J, 2015, MUCOSAL IMMUNOL, V8, P815, DOI 10.1038/mi.2014.111; Middleton JR, 2006, J DAIRY RES, V73, P10, DOI 10.1017/S0022029905001354; Misra N, 2018, VACCINE, V36, P3513, DOI 10.1016/j.vaccine.2018.04.067; Misra N, 2017, FEMS MICROBIOL LETT, V364, DOI 10.1093/femsle/fnx082; Nashar TO, 1997, IMMUNOLOGY, V91, P572, DOI 10.1046/j.1365-2567.1997.00291.x; Piepers S, 2017, J DAIRY SCI, V100, P769, DOI 10.3168/jds.2016-11269; PRASAD LBM, 1968, CANADIAN VET J, V9, P107; Proctor RA, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0037-2018; Riollet C, 2001, J DAIRY SCI, V84, P1077, DOI 10.3168/jds.S0022-0302(01)74568-7; Roberson JR, 1998, J DAIRY SCI, V81, P687, DOI 10.3168/jds.S0022-0302(98)75624-3; Rollin E, 2015, PREV VET MED, V122, P257, DOI 10.1016/j.prevetmed.2015.11.006; Royal JM, 2017, TOXINS, V9, DOI 10.3390/toxins9120379; Russell MW, 1996, INFECT IMMUN, V64, P1272, DOI 10.1128/IAI.64.4.1272-1283.1996; Sacco SC, 2020, MICROB PATHOGENESIS, V142, DOI 10.1016/j.micpath.2020.104017; Schnitzler AC, 2007, INFECT IMMUN, V75, P3150, DOI 10.1128/IAI.00581-06; Schukken YH, 2014, J DAIRY SCI, V97, P5250, DOI 10.3168/jds.2014-8008; SCHUKKEN YH, 1994, J DAIRY SCI, V77, P639, DOI 10.3168/jds.S0022-0302(94)76994-0; Shkreta L, 2004, VACCINE, V23, P114, DOI 10.1016/j.vaccine.2004.05.002; Snider DP, 2017, CRIT REV IMMUNOL, V37, P499, DOI 10.1615/CritRevImmunol.v37.i2-6.150; Sol J, 1997, J DAIRY SCI, V80, P2803, DOI 10.3168/jds.S0022-0302(97)76243-X; Stapleton MR, 2012, J MED MICROBIOL, V61, P766, DOI 10.1099/jmm.0.040915-0; Sultan F, 1998, INFECT IMMUN, V66, P462, DOI 10.1128/IAI.66.2.462-468.1998; Wenz JR, 2006, JAVMA-J AM VET MED A, V229, P259, DOI 10.2460/javma.229.2.259; Wiedinger Kari, 2017, Ther Adv Vaccines, V5, P15, DOI 10.1177/2051013617691041; Wilson GJ, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00505-18, 10.1128/iai.00505-18]; Wolf C, 2011, PROTEOMICS, V11, P2491, DOI 10.1002/pmic.201000698; Xu HY, 2011, CLIN VACCINE IMMUNOL, V18, P893, DOI 10.1128/CVI.00066-11; XUAMANO JC, 1994, VACCINE, V12, P903, DOI 10.1016/0264-410X(94)90033-7; Zaatout N, 2020, J APPL MICROBIOL, V129, P1102, DOI 10.1111/jam.14706; Zhang L, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0610-y	75	5	5	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							6	10.3390/vaccines9010006			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6YF	33374191	Green Published, gold			2022-04-29	WOS:000610817000001
J	Brendle, S; Cladel, N; Balogh, K; Alam, S; Christensen, N; Meyers, C; Hu, JF				Brendle, Sarah; Cladel, Nancy; Balogh, Karla; Alam, Samina; Christensen, Neil; Meyers, Craig; Hu, Jiafen			A Comparative Study on Delivery of Externally Attached DNA by Papillomavirus VLPs and Pseudoviruses	VACCINES			English	Article						virus-like particles (VLPs); L1; L2; pseudovirus (PSV); papillomavirus; DNA delivery; GFP; flow cytometry; HPV16; HPV58; CRPV	VIRUS-LIKE PARTICLES; MINOR CAPSID PROTEIN; CYTOTOXIC T-LYMPHOCYTES; L2; CELLS; HPV; BINDING; TYPE-16; VACCINES; NEUTRALIZATION	Human papillomavirus (HPV) 16 capsids have been chosen as a DNA delivery vehicle in many studies. Our preliminary studies suggest that HPV58 capsids could be better vehicles than HPV16 capsids to deliver encapsidated DNA in vitro and in vivo. In the current study, we compared HPV16, HPV58, and the cottontail rabbit papillomavirus (CRPV) capsids either as L1/L2 VLPs or pseudoviruses (PSVs) to deliver externally attached GFP-expressing DNA. Both rabbit and human cells were used to test whether there was a species-specific effect. DNA delivery efficiency was determined by quantifying either GFP-expressing cell populations or mean fluorescent intensities (MFI) by flow cytometry. Interestingly, CRPV and 58-VLPs and PSVs were significantly more efficient at delivering attached DNA when compared to 16-VLPs and PSVs. A capsid/DNA ratio of 2:1 showed the highest efficiency for delivering external DNA. The PSVs with papillomavirus DNA genomes also showed higher efficiency than those with irrelevant plasmid DNA. HPV16L1/58L2 hybrid VLPs displayed increased efficiency compared to HPV58L1/16L2 VLPs, suggesting that L2 may play a critical role in the delivery of attached DNA. Additionally, we demonstrated that VLPs increased in vivo infectivity of CRPV DNA in rabbits. We conclude that choosing CRPV or 58 capsids to deliver external DNA could improve DNA uptake in in vitro and in vivo models.	[Brendle, Sarah; Cladel, Nancy; Balogh, Karla; Christensen, Neil; Hu, Jiafen] Penn State Univ, Coll Med, Jake Gittlen Labs Canc Res, Hershey, PA 17033 USA; [Brendle, Sarah; Cladel, Nancy; Balogh, Karla; Christensen, Neil; Hu, Jiafen] Penn State Univ, Coll Med, Dept Pathol & Lab Med, Hershey, PA 17033 USA; [Alam, Samina; Christensen, Neil; Meyers, Craig] Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA		Hu, JF (通讯作者)，Penn State Univ, Coll Med, Jake Gittlen Labs Canc Res, Hershey, PA 17033 USA.; Hu, JF (通讯作者)，Penn State Univ, Coll Med, Dept Pathol & Lab Med, Hershey, PA 17033 USA.	ganzelly@gmail.com; ncladel@gmail.com; kkb2@psu.edu; sra116@psu.edu; ndc1@psu.edu; cmeyers@pennstatehealth.psu.edu; fjh4@psu.edu		Hu, Jiafen/0000-0001-8700-9937	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA47622]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Jake Gittlen Memorial Golf Tournament	FundingThis work was supported by the National Cancer Institute grant R01 CA47622 from the National Institutes of Health to NDC and the Jake Gittlen Memorial Golf Tournament.	Broutian TR, 2010, J GEN VIROL, V91, P531, DOI 10.1099/vir.0.012732-0; Buck CB, 2008, J VIROL, V82, P5190, DOI 10.1128/JVI.02726-07; Buck CB, 2013, VIROLOGY, V445, P169, DOI 10.1016/j.virol.2013.05.038; Campos SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004463; Cladel NM, 2008, J VIROL METHODS, V148, P34, DOI 10.1016/j.jviromet.2007.10.005; Cladel NM, 2019, EMERG MICROBES INFEC, V8, P1108, DOI 10.1080/22221751.2019.1637072; Conway MJ, 2009, VIROLOGY, V393, P295, DOI 10.1016/j.virol.2009.08.010; Cuburu N, 2012, J CLIN INVEST, V122, P4606, DOI 10.1172/JCI63287; Culp TD, 2006, J VIROL, V80, P11381, DOI 10.1128/JVI.01328-06; Dochez C, 2014, VACCINE, V32, P1595, DOI 10.1016/j.vaccine.2013.10.081; Fausch SC, 2005, VACCINE, V23, P1720, DOI 10.1016/j.vaccine.2004.09.035; Fausch SC, 2003, CANCER RES, V63, P3478; Garcea RL, 2004, CURR OPIN BIOTECH, V15, P513, DOI 10.1016/j.copbio.2004.10.002; Goetschius DJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83076-5; Greenstone HL, 1998, P NATL ACAD SCI USA, V95, P1800, DOI 10.1073/pnas.95.4.1800; Handisurya A, 2012, VIROLOGY, V433, P385, DOI 10.1016/j.virol.2012.08.035; Holmgren SC, 2005, J VIROL, V79, P3938, DOI 10.1128/JVI.79.7.3938-3948.2005; Hu JF, 2006, J IMMUNOL, V177, P8037, DOI 10.4049/jimmunol.177.11.8037; Kamper N, 2006, J VIROL, V80, P759, DOI 10.1128/JVI.80.2.759-768.2006; Kawana K, 1999, J VIROL, V73, P6188, DOI 10.1128/JVI.73.7.6188-6190.1999; Kines RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120797; Lenz P, 2003, CLIN IMMUNOL, V106, P231, DOI 10.1016/S1521-6616(02)00039-6; Lenz P, 2001, J IMMUNOL, V166, P5346, DOI 10.4049/jimmunol.166.9.5346; Liu WJ, 1997, VIROLOGY, V227, P474, DOI 10.1006/viro.1996.8348; Liu WJ, 2001, VACCINE, V20, P862, DOI 10.1016/S0264-410X(01)00406-6; Lowe J, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-150; Mach H, 2006, J PHARM SCI-US, V95, P2195, DOI 10.1002/jps.20696; Malboeuf CM, 2007, VACCINE, V25, P3270, DOI 10.1016/j.vaccine.2007.01.067; Meyers C, 2002, J VIROL, V76, P4723, DOI 10.1128/JVI.76.10.4723-4733.2002; Mitsunaga M, 2011, CANCER PREV RES, V4, P767, DOI 10.1158/1940-6207.CAPR-10-0334; MULLER M, 1995, J VIROL, V69, P948; Ohlschlager P, 2003, J VIROL, V77, P4635, DOI 10.1128/JVI.77.8.4635-4645.2003; Peng SW, 1998, VIROLOGY, V240, P147, DOI 10.1006/viro.1997.8912; Petry H, 2003, CURR OPIN MOL THER, V5, P524; Roberts JN, 2007, NAT MED, V13, P857, DOI 10.1038/nm1598; RODEN RBS, 1994, J VIROL, V68, P7260, DOI 10.1128/JVI.68.11.7260-7266.1994; Roden RBS, 1996, J VIROL, V70, P5875, DOI 10.1128/JVI.70.9.5875-5883.1996; Rubio I, 2011, VIROLOGY, V409, P348, DOI 10.1016/j.virol.2010.10.017; Schell TD, 2001, CANCER RES, V61, P873; Schiller J T, 2001, J Natl Cancer Inst Monogr, P50; Schwarz K, 2005, EUR J IMMUNOL, V35, P816, DOI 10.1002/eji.200425755; Shi W, 2001, J VIROL, V75, P10139, DOI 10.1128/JVI.75.21.10139-10148.2001; SUN XY, 1995, VIROLOGY, V213, P321, DOI 10.1006/viro.1995.0005; Touze A, 2000, FEMS MICROBIOL LETT, V189, P121, DOI 10.1111/j.1574-6968.2000.tb09217.x; Touze A, 1998, NUCLEIC ACIDS RES, V26, P1317, DOI 10.1093/nar/26.5.1317; Wang JW, 2013, VIROLOGY, V445, P175, DOI 10.1016/j.virol.2013.04.017; Yang RC, 2003, J VIROL, V77, P3531, DOI 10.1128/JVI.77.6.3531-3541.2003; Zhao KN, 1998, VIROLOGY, V243, P482, DOI 10.1006/viro.1998.9091; ZHOU J, 1994, J VIROL, V68, P619, DOI 10.1128/JVI.68.2.619-625.1994	49	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1501	10.3390/vaccines9121501			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY8VC	34960247	Green Published, gold			2022-04-29	WOS:000737242100001
J	Chaudhuri, P; Saminathan, M; Ali, SA; Kaur, G; Singh, SV; Lalsiamthara, J; Goswami, TK; Singh, AK; Singh, SK; Malik, P; Singh, RK				Chaudhuri, Pallab; Saminathan, Mani; Ali, Syed Atif; Kaur, Gurpreet; Singh, Shiv Varan; Lalsiamthara, Jonathan; Goswami, Tapas K.; Singh, Ashwini K.; Singh, Sandeep K.; Malik, Praveen; Singh, Raj K.			Immunization with Brucella abortus S19 Delta per Conferred Protection in Water Buffaloes against Virulent Challenge with B. abortus Strain S544	VACCINES			English	Article						brucellosis; live attenuated vaccine; S19 Delta per; buffalo; DIVA; protective efficacy	THERAPEUTIC REGIMENS; BACTERIAL SURVIVAL; BOVINE BRUCELLOSIS; BUBALUS-BUBALIS; ROUGH VACCINES; RESPONSES; CATTLE; RB51; VACCINATION; MELITENSIS	Vaccination of cattle and buffaloes with Brucella abortus strain 19 has been the mainstay for control of bovine brucellosis. However, vaccination with S19 suffers major drawbacks in terms of its safety and interference with serodiagnosis of clinical infection. Brucella abortus S19 increment per, a perosamine synthetase wbkB gene deletion mutant, overcomes the drawbacks of the S19 vaccine strain. The present study aimed to evaluate the potential of Brucella abortus S19 & UDelta;per vaccine candidate in the natural host, buffaloes. Safety of S19 increment per, for animals use, was assessed in guinea pigs. Protective efficacy of vaccine was assessed in buffaloes by immunizing with normal dose (4 x 10(10) colony forming units (CFU)/animal) and reduced dose (2 x 10(9) CFU/animal) of S19 & UDelta;per and challenged with virulent strain of B. abortus S544 on 300 days post immunization. Bacterial persistency of S19 increment per was assessed in buffalo calves after 42 days of inoculation. Different serological, biochemical and pathological studies were performed to evaluate the S19 increment per vaccine. The S19 & UDelta;per immunized animals showed significantly low levels of anti-lipopolysaccharides (LPS) antibodies. All the immunized animals were protected against challenge infection with B. abortus S544. Sera from the majority of S19 & UDelta;per immunized buffalo calves showed moderate to weak agglutination to RBPT antigen and thereby, could apparently be differentiated from S19 vaccinated and clinically-infected animals. The S19 & UDelta;per was more sensitive to buffalo serum complement mediated lysis than its parent strain, S19. Animals culled at 6-weeks-post vaccination showed no gross lesions in organs and there was comparatively lower burden of infection in the lymph nodes of S19 & UDelta;per immunized animals. With attributes of higher safety, strong protective efficacy and potential of differentiating infected from vaccinated animals (DIVA), S19 & UDelta;per would be a prospective alternate to conventional S19 vaccines for control of bovine brucellosis as proven in buffaloes.	[Chaudhuri, Pallab; Ali, Syed Atif; Kaur, Gurpreet; Singh, Shiv Varan] ICAR Indian Vet Res Inst, Div Bacteriol & Mycol, Bareilly 243122, Uttar Pradesh, India; [Saminathan, Mani] ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India; [Lalsiamthara, Jonathan] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; [Goswami, Tapas K.] ICAR Indian Vet Res Inst Izatnagar, Immunol Sect, Bareilly 243122, Uttar Pradesh, India; [Singh, Ashwini K.; Singh, Sandeep K.; Malik, Praveen] Chaudhary Charan Singh Natl Inst Anim Hlth, Baghpat 250609, Uttar Pradesh, India; [Singh, Raj K.] ICAR Indian Vet Res Inst, Div Biotechnol, Bareilly 243122, Uttar Pradesh, India		Chaudhuri, P (通讯作者)，ICAR Indian Vet Res Inst, Div Bacteriol & Mycol, Bareilly 243122, Uttar Pradesh, India.	pallab.chaudhuri@icar.gov.in; m.saminathan@icar.gov.in; atifali@gate.sinica.edu.tw; 22gurpreet1990@gmail.com; shivvaransingh1@gmail.com; lalsiamt@ohsu.edu; tapas.goswami@icar.gov.in; ashwini.kumar.niah@gov.in; sandeep.niah@gov.in; praveen.malik.niah@gov.in; rks_virology@rediffmail.com	Lalsiamthara, Jonathan/AAE-7395-2022		CCS National Institute of Animal Health; Department of Biotechnology (DBT)-Network Project on Brucellosis/2012, New Delhi [102/IFD/SAN/3141/2012-2013, CAAST/2017-18/01]	We acknowledge the funding supports received from the Department of Biotechnology (DBT)-Network Project on Brucellosis/2012, New Delhi (SAN NO. 102/IFD/SAN/3141/2012-2013, dated 27 September 2012) and ICAR funded CAAST-Advanced Centre for Livestock Health (ACLH) (CAAST/2017-18/01, dated 28 March 2018).	Adesiyun AA, 2010, TROP ANIM HEALTH PRO, V42, P1685, DOI 10.1007/s11250-010-9621-3; Ahmed W, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00030; Allen CA, 1998, INFECT IMMUN, V66, P1008, DOI 10.1128/IAI.66.3.1008-1016.1998; BJORKMAN G, 1962, J AM VET MED ASSOC, V140, P1192; Bundle DR, 2017, ACCOUNTS CHEM RES, V50, P2958, DOI 10.1021/acs.accounts.7b00445; Caporale V, 2010, VET ITAL, V46, P13; Chaudhuri P, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.01336-15; CHEVILLE NF, 1992, AM J VET RES, V53, P1881; DAVIES G, 1980, J BIOL STAND, V8, P165, DOI 10.1016/S0092-1157(80)80033-3; Dhand NK, 2005, REV SCI TECH OIE, V24, P879, DOI 10.20506/rst.24.3.1614; Diptee MD, 2007, REV SCI TECH OIE, V26, P669, DOI 10.20506/rst.26.3.1773; EISENSCHENK FC, 1995, AM J VET RES, V56, P1592; Fosgate GT, 2003, PREV VET MED, V58, P211, DOI 10.1016/S0167-5877(03)00048-5; Ganesh NV, 2014, J AM CHEM SOC, V136, P16260, DOI 10.1021/ja5081184; Gheibi A, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e01079; Godfroid F, 1998, INFECT IMMUN, V66, P5485, DOI 10.1128/IAI.66.11.5485-5493.1998; Godfroid J, 2002, VET MICROBIOL, V90, P135, DOI 10.1016/S0378-1135(02)00217-1; Gonzalez M, 2009, IMMUNOBIOLOGY, V214, P113, DOI 10.1016/j.imbio.2008.07.004; Gopalakrishnan A, 2016, J ANIM PLANT SCI, V26, P1542; Guiard J, 2013, ANGEW CHEM INT EDIT, V52, P7181, DOI 10.1002/anie.201302303; HALL WH, 1990, REV INFECT DIS, V12, P1060; Harms Jerome S, 2009, J Immune Based Ther Vaccines, V7, P1, DOI 10.1186/1476-8518-7-1; Khan MZ, 2018, TROP MED INFECT DIS, V3, DOI 10.3390/tropicalmed3020065; Kurar E, 1997, VACCINE, V15, P1851, DOI 10.1016/S0264-410X(97)00140-0; Lalsiamthara J, 2017, J VET SCI, V18, P281, DOI 10.4142/jvs.2017.18.S1.281; Lalsiamthara J, 2015, VACCINE, V33, P2577, DOI 10.1016/j.vaccine.2015.04.004; Lokamar PN, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02283-w; Mandal SS, 2017, ACS CENTRAL SCI, V3, P224, DOI 10.1021/acscentsci.7b00019; McGiven J, 2015, J CLIN MICROBIOL, V53, P1204, DOI 10.1128/JCM.03185-14; McQuiston JR, 1999, INFECT IMMUN, V67, P3830, DOI 10.1128/IAI.67.8.3830-3835.1999; Meltzer E, 2010, CLIN INFECT DIS, V51, pE12, DOI 10.1086/653608; Meyer M E, 1969, Proc Annu Meet U S Anim Health Assoc, V73, P159; MILWARD FW, 1984, AM J VET RES, V45, P1825; Monreal D, 2003, INFECT IMMUN, V71, P3261, DOI 10.1128/IAI.71.6.3261-3271.2003; Moriyon I, 2004, VET RES, V35, P1, DOI 10.1051/vetres:2003037; Nicoletti P., 1990, Animal brucellosis., P283; NICOLETTI P, 1989, AM J VET RES, V50, P1004; Olsen SC, 1997, J WILDLIFE DIS, V33, P146, DOI 10.7589/0090-3558-33.1.146; Pakzad I, 2009, IRAN J IMMUNOL, V6, P12, DOI IJIv6i1A2; Pasquevich KA, 2009, INFECT IMMUN, V77, P436, DOI 10.1128/IAI.01151-08; PLOMMET M, 1976, Annales de Recherches Veterinaires, V7, P9; Radwan A I, 1993, Rev Sci Tech, V12, P909; Ramnanan A., 2018, J BUFFALO SCI, V7, P29, DOI [10.6000/1927-520X.2018.07.02.1, DOI 10.6000/1927-520X.2018.07.02.1]; Renukaradhya GJ, 2002, VET MICROBIOL, V90, P183, DOI 10.1016/S0378-1135(02)00253-5; Saminathan M, 2016, J EXP BIOL AGRIC SCI, V4, P338, DOI 10.18006/2016.4(3S).338.367; Schurig GG, 2002, VET MICROBIOL, V90, P479, DOI 10.1016/S0378-1135(02)00255-9; SCHURIG GG, 1991, VET MICROBIOL, V28, P171, DOI 10.1016/0378-1135(91)90091-S; Shumilov KV, 2010, VACCINE, V28, pF31, DOI 10.1016/j.vaccine.2010.03.049; Singh BB, 2015, PREV VET MED, V119, P211, DOI 10.1016/j.prevetmed.2015.03.013; Solanki K.S., 2019, J ANIM RES, V9, P79; STEVENS MG, 1995, VET IMMUNOL IMMUNOP, V44, P223, DOI 10.1016/0165-2427(94)05311-F; STEVENS MG, 1994, J CLIN MICROBIOL, V32, P1065, DOI 10.1128/JCM.32.4.1065-1066.1994; THOMAS EL, 1981, VET REC, V108, P90, DOI 10.1136/vr.108.5.90; Ugalde JE, 2003, INFECT IMMUN, V71, P6264, DOI 10.1128/IAI.71.11.6264-6269.2003; van Waveren G M, 1965, Bull Off Int Epizoot, V63, P1015; Velasquez LN, 2012, MICROBES INFECT, V14, P639, DOI 10.1016/j.micinf.2012.02.004; Winter AJ, 1996, AM J VET RES, V57, P677; Wyatt H V, 2010, J R Nav Med Serv, V96, P185; Zhao ZP, 2009, VACCINE, V27, P5214, DOI 10.1016/j.vaccine.2009.06.075; Zriba S, 2019, VACCINE-X, V3, DOI 10.1016/j.jvacx.2019.100041	60	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1423	10.3390/vaccines9121423			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YH4UE	34960169	Green Published, gold			2022-04-29	WOS:000743163600001
J	Medina-Maguees, LG; Gergen, J; Jasny, E; Petsch, B; Lopera-Madrid, J; Medina-Maguees, ES; Salas-Quinchucua, C; Osorio, JE				Medina-Maguees, Lex G.; Gergen, Janina; Jasny, Edith; Petsch, Benjamin; Lopera-Madrid, Jaime; Medina-Maguees, Emily S.; Salas-Quinchucua, Cristhian; Osorio, Jorge E.			mRNA Vaccine Protects against Zika Virus	VACCINES			English	Article						AG129; challenge; flavivirus; lipid nanoparticles; mice; mRNA vaccines; RNActive(R); Zika vaccines; Zika virus; ZIKV		Zika virus (ZIKV), a mosquito-borne flavivirus, has recently triggered global concern due to severe health complications. In 2015, a large ZIKV outbreak occurred in the Americas and established a link between ZIKV and microcephaly in newborn babies, spontaneous abortion, persistent viremia, and Guillain-Barre syndrome. While antivirals are being developed and prevention strategies focus on vector control, a safe and effective Zika vaccine remains unavailable. Messenger RNA (mRNA) vaccine technology has arisen as a flexible, simplified, and fast vaccine production platform. Here, we report on an mRNA vaccine candidate that encodes the pre-membrane and envelope (prM-E) glycoproteins of ZIKV strain Brazil SPH2015 and is encapsulated in lipid nanoparticles (LNPs). Our ZIKV prM-E mRNA-LNP vaccine candidate induced antibody responses that protected in AG129 mice deficient in interferon (IFN) alpha/beta/gamma (IFN-alpha/beta/gamma) receptors. Notably, a single administration of ZIKV prM-E mRNA-LNP protected against a lethal dose of ZIKV, while a two-dose strategy induced strong protective immunity. E-specific double-positive IFN-gamma and TNF-alpha T-cells were induced in BALB/c mice after immunizations with a two-dose strategy. With the success of mRNA vaccine technology in facing the coronavirus (COVID-19) pandemic, our data support the development of prM-E RNActive(R) as a promising mRNA vaccine against Zika to counter future epidemics.	[Medina-Maguees, Lex G.; Lopera-Madrid, Jaime; Medina-Maguees, Emily S.; Salas-Quinchucua, Cristhian; Osorio, Jorge E.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; [Gergen, Janina; Jasny, Edith; Petsch, Benjamin] CureVac AG, Friedrich Miescher Str 15, D-72076 Tubingen, Germany		Medina-Maguees, LG; Osorio, JE (通讯作者)，Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.	medinamagues@wisc.edu; janina.gergen@curevac.com; edith.jasny@curevac.com; benjamin.petsch@curevac.com; jorge.osorio@wisc.edu	Petsch, Benni/AAL-7767-2020	Medina Magues, Lex Guillermo/0000-0002-4242-6945; OSORIO, JORGE/0000-0002-7474-6150	CureVac AG	This research was funded by CureVac AG.	Agbulos Darrell S, 2016, Curr Protoc Microbiol, V43, DOI 10.1002/cpmc.19; Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI [10.1371/journal.pntd.0004750, 10.1371/journal.pntd.0004682]; Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI [10.3201/eid2006.140138, 10.3201/eid2011.141380]; Chahal JS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00193-w; Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296; Dowd KA, 2011, VIROLOGY, V411, P306, DOI 10.1016/j.virol.2010.12.020; Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715; Erasmus JH, 2018, MOL THER, V26, P2507, DOI 10.1016/j.ymthe.2018.07.010; Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287; Li XF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02975-w; Luisi K, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba5068; Osuna CE, 2017, J INFECT DIS, V216, pS928, DOI 10.1093/infdis/jix540; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pattnaik A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020266; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Rauch S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00311-w; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Salvo MA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006210; Sampathkumar P, 2016, MAYO CLIN PROC, V91, P514, DOI 10.1016/j.mayocp.2016.02.017; Schnee M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004746; Smith DR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005296; SMITHBURN KC, 1952, J IMMUNOL, V69, P223; Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192	26	2	2	19	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1464	10.3390/vaccines9121464			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YB3PJ	34960211	Green Published, gold			2022-04-29	WOS:000738928300001
J	Purvis, RS; Hallgren, E; Moore, RA; Willis, DE; Hall, S; Gurel-Headley, M; McElfish, PA				Purvis, Rachel S.; Hallgren, Emily; Moore, Ramey A.; Willis, Don E.; Hall, Spencer; Gurel-Headley, Morgan; McElfish, Pearl A.			Trusted Sources of COVID-19 Vaccine Information among Hesitant Adopters in the United States	VACCINES			English	Article						COVID-19; COVID-19 vaccine; vaccine hesitancy; trusted sources	DEFINITION	The World Health Organization has identified vaccine hesitancy as a top health concern. Emerging research shows that those who are hesitant may still get vaccinated; however, little is known about those who say they are hesitant but still get vaccinated. Most people have high trust in several sources of COVID-19 information, and trust in certain information sources such as the Centers for Disease Control and Prevention and health care providers was associated with being vaccinated. This study explored trusted information sources among hesitant adopters in the United States with a survey respondents completed while waiting after receiving a COVID-19 vaccine dose. The study included (n = 867) respondents. The majority of respondents were female (60.21%); were between the ages of 18 and 44 years old (71.97%); and were diverse, with most identifying as White (44.54%) or Hispanic/Latinx (32.55%). Hesitant adopters reported multiple trusted sources of COVID-19 vaccine information, which can be grouped into four emergent subthemes: (1) Health care/Medical science, (2) Personal relationships, (3) News and social media, and (4) Individual/Myself. Some respondents expressed a distrust of all sources of COVID-19 vaccine information, despite receiving the vaccine, describing a lack of trust in traditional sources of information such as the mainstream media or government. This study contributes to the literature by documenting trusted sources of COVID-19 vaccine information among hesitant adopters in the United States. Findings provide important insights about respondents' trusted sources of COVID-19 vaccine information that can inform future public health messaging campaigns intended to increase vaccine uptake among hesitant adopters.	[Purvis, Rachel S.; Hallgren, Emily; Moore, Ramey A.; Willis, Don E.; McElfish, Pearl A.] Univ Arkansas Med Sci Northwest, Coll Med, 1125 N Coll Ave, Fayetteville, AR 72703 USA; [Hall, Spencer] Univ Arkansas Med Sci Northwest, Off Community Hlth & Res, 1125 N Coll Ave, Fayetteville, AR 72703 USA; [Gurel-Headley, Morgan] Univ Arkansas Med Sci, Coll Med, 4301 W Markham St, Little Rock, AR 72205 USA; [Gurel-Headley, Morgan] Univ Arkansas Med Sci, Fay W Boozman Coll Publ Hlth, 4301 W Markham St, Little Rock, AR 72205 USA		McElfish, PA (通讯作者)，Univ Arkansas Med Sci Northwest, Coll Med, 1125 N Coll Ave, Fayetteville, AR 72703 USA.	rspurvis@uams.edu; ehallgren@uams.edu; rameymoore@uams.edu; dewillis@uams.edu; shall@uams.edu; mpgurel@uams.edu; pamcelfish@uams.edu	Moore, Ramey/AHB-1570-2022; Willis, Don/AAF-5959-2021	Willis, Don/0000-0001-9612-489X; Moore, Ramey/0000-0002-7888-6839; McElfish, Pearl/0000-0002-4033-6241	University of Arkansas for Medical Sciences Translational Research Institute; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences of National Institutes of Health (NIH) [UL1 TR003107]; Rapid Acceleration of Diagnostics (RADx) [NIH 3 R01MD013852-02S3]; Community Engagement Alliance (CEAL) Against COVID-19 Disparities [NIH 10T2HL156812-01]	The community engagement related to this research is supported by the University of Arkansas for Medical Sciences Translational Research Institute funding awarded through the National Center for Research Resources and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) (UL1 TR003107); Rapid Acceleration of Diagnostics (RADx) (NIH 3 R01MD013852-02S3); and Community Engagement Alliance (CEAL) Against COVID-19 Disparities (NIH 10T2HL156812-01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Ali SH, 2020, JMIR PUBLIC HLTH SUR, V6, P154, DOI 10.2196/21071; Bergman M.M., 2008, ADV MIXED METHODS RE; Boyle J., 2020, WHO DO AM TRUST COVI; Boyle J., 2020, CASES INCREASE AM TR; Boyle J., 2020, AM TRUST COVID 19 IN; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Centers for Disease Control and Prevention, COVID 19 VACCINATION; Centers for Disease Control and Prevention, CDC COVID DAT TRACK; Centers for Disease Control and Prevention, 2019, BRFSS QUEST; Creswell J.W, 2013, RES DESIGN QUALITATI; Creswell JW., 2003, HDB MIXED METHODS SO, V209, P240; Creswell JW, 2010, DESIGNING CONDUCTING, P488; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Earnshaw VA, 2020, TRANSL BEHAV MED, V10, P850, DOI 10.1093/tbm/ibaa090; Enkel SL, 2018, VACCINE, V36, P6459, DOI 10.1016/j.vaccine.2017.09.088; Fridman I, 2020, JMIR PUBLIC HLTH SUR, V6, P398, DOI 10.2196/22060; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Henrich N, 2011, HEALTH PROMOT PRACT, V12, P610, DOI 10.1177/1524839910363536; Hughes MM, 2021, MMWR-MORBID MORTAL W, V70, P431, DOI 10.15585/mmwr.mm7012e1; Johnson R., 2004, ED RES, P14, DOI [DOI 10.3102/0013189X033007014, 10.3102/0013189X033007014]; Johnson RB, 2007, J MIX METHOD RES, V1, P112, DOI 10.1177/1558689806298224; Kirzinger A., KFF COVID 19 VACCINE; Kuckartz U., 2019, ANAL QUALITATIVE DAT; Latkin CA, 2021, BEHAV SCI-BASEL, V11, DOI 10.3390/bs11040056; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; McElfish PA, 2021, J CLIN TRANSL SCI, V5, DOI 10.1017/cts.2020.562; McFadden SM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231808; Mitchell A, 2020, AM IMMERSED COVID 19; Neergaard MA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-52; Pew Research Center, 2020, AM VIEWS NEWS MED CO; Piltch-Loeb R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251095; Qiao Shan, 2020, medRxiv, DOI 10.1101/2020.12.02.20242982; Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033; Quinn SC, 2017, VACCINE, V35, P1167, DOI 10.1016/j.vaccine.2016.12.046; Ritchie H., 2020, CORONAVIRUS PANDEMIC; Sale JEM, 2002, QUAL QUANT, V36, P43, DOI 10.1023/A:1014301607592; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; Thangaraju P, 2019, CUKUROVA MED J, V44, P1150, DOI 10.17826/cumj.514157; United States Census Bureau, QUICKFACTS ARK; Weiland, 2021, NEW YORK TIMES; Willis DE, 2021, CTS-CLIN TRANSL SCI, V14, P2200, DOI 10.1111/cts.13077; Wong LP, 2010, J COMMUN HEALTH, V35, P676, DOI 10.1007/s10900-010-9271-4	43	1	1	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1418	10.3390/vaccines9121418			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YH0UR	34960164	Green Published, gold			2022-04-29	WOS:000742892300001
J	Yang, DQ; Zhang, LX; Duan, JK; Huang, Q; Yu, Y; Zhou, JA; Lu, H				Yang, Deqiang; Zhang, Lixia; Duan, Jinkun; Huang, Qiang; Yu, Yao; Zhou, Jungang; Lu, Hong			A Single Vaccination of IBDV Subviral Particles Generated by Kluyveromyces marxianus Efficiently Protects Chickens against Novel Variant and Classical IBDV Strains	VACCINES			English	Article						novel variant IBDV; Kluyveromyces marxianus; subviral particles; vaccine; protection	INFECTIOUS BURSAL DISEASE; VIRUS-LIKE PARTICLES; CAPSID PROTEIN; STRUCTURAL POLYMORPHISM; HIGHLY EFFICIENT; INSECT CELLS; EXPRESSION; DIVERSITY; YEAST; HOST	Infectious bursal disease (IBD), caused by the infectious bursal disease virus (IBDV), is a highly contagious and immunosuppressive disease in chickens worldwide. The novel variant IBDV (nvIBDV) has been emerging in Chinese chicken farms since 2017, but there are no available vaccines that can provide effective protection. Herein, the capsid protein VP2 from nvIBDV strain FJ-18 was expressed in Kluyveromyces marxianus with the aim to produce nvIBDV subviral particles (SVPs). Two recombinant strains constructed for expression of nvIBDV VP2 (nvVP2) and His-tagged VP2 (nvHVP2) formed two types of nvIBDV subviral particles (SVPs), namely nvVP2-SVPs and nvHVP2-SVPs. TEM scans showed that both SVPs were about 25 nm in diameter, but there was a large portion of nvVP2-SVPs showing non-spherical particles. Molecular dynamics simulations indicate that an N-terminal His tag strengthened the interaction of the nvHVP2 monomer and contributed to the assembly of SVPs. Vaccination of chicks with the nvHVP2-SVPs provided 100% protection against novel variant IBDV infection when challenged with the FJ-18 strain, as well as the classical strain BC6/85. By contrast, vaccination with the nvVP2-SVPs only provided 60% protection against their parent FJ-18 strain, suggesting that the stable conformation of subviral particles posed a great impact on their protective efficacy. Our results showed that the nvHVP2-SVPs produced by the recombinant K. marxianus strain is an ideal vaccine candidate for IBDV eradication.	[Yang, Deqiang; Huang, Qiang; Yu, Yao; Zhou, Jungang; Lu, Hong] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, 2005 Songhu Rd, Shanghai 200438, Peoples R China; [Yang, Deqiang; Huang, Qiang; Yu, Yao; Zhou, Jungang; Lu, Hong] Shanghai Engn Res Ctr Ind Microorganisms, 2005 Songhu Rd, Shanghai 200438, Peoples R China; [Zhang, Lixia; Duan, Jinkun] Tianjin Ruipu Biotechnol Co Ltd, Tianjin 300350, Peoples R China; [Lu, Hong] East China Univ Sci & Technol, Shanghai Collaborat Innovat Ctr Biomfg SCICB, 130 Meilong Rd, Shanghai 200237, Peoples R China		Zhou, JA; Lu, H (通讯作者)，Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, 2005 Songhu Rd, Shanghai 200438, Peoples R China.; Zhou, JA; Lu, H (通讯作者)，Shanghai Engn Res Ctr Ind Microorganisms, 2005 Songhu Rd, Shanghai 200438, Peoples R China.; Lu, H (通讯作者)，East China Univ Sci & Technol, Shanghai Collaborat Innovat Ctr Biomfg SCICB, 130 Meilong Rd, Shanghai 200237, Peoples R China.	18110700060@fudan.edu.cn; lixiazhang@ringpu.com; jkduan@ringpu.com; huangqiang@fudan.edu.cn; yaoyu@fudan.edu.cn; zhoujg@fudan.edu.cn; honglv@fudan.edu.cn		Zhou, Jungang/0000-0001-9618-1683	Science and Technology Research Program of Shanghai [19DZ2282100]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31970068]	FundingThis research was funded by the Science and Technology Research Program of Shanghai, grant number 18391901800; National Natural Science Foundation of China, grant number 31970068; and Science and Technology Research Program of Shanghai, grant number 19DZ2282100.	CHETTLE N, 1989, VET REC, V125, P271, DOI 10.1136/vr.125.10.271; COSGROVE AS, 1962, AVIAN DIS, V6, P385, DOI 10.2307/1587909; Cui P, 2013, ARCH VIROL, V158, P1973, DOI 10.1007/s00705-013-1682-y; Dalton AC, 2014, PROTEIN SCI, V23, P517, DOI 10.1002/pro.2439; Duan JK, 2019, APPL MICROBIOL BIOT, V103, P833, DOI 10.1007/s00253-018-9487-2; Fan LJ, 2020, VET MICROBIOL, V251, DOI 10.1016/j.vetmic.2020.108905; Fan LJ, 2020, VET MICROBIOL, V240, DOI 10.1016/j.vetmic.2019.108507; Fan LJ, 2019, VET MICROBIOL, V230, P212, DOI 10.1016/j.vetmic.2019.01.023; Galloux M, 2007, J BIOL CHEM, V282, P20774, DOI 10.1074/jbc.M701048200; Gietz RD, 2007, NAT PROTOC, V2, P38, DOI 10.1038/nprot.2007.15; Gomez E, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-020-01029-z; Groeneveld P, 2009, FEBS J, V276, P254, DOI 10.1111/j.1742-4658.2008.06778.x; He XM, 2019, VET MICROBIOL, V239, DOI 10.1016/j.vetmic.2019.108458; HENSING M, 1994, APPL MICROBIOL BIOT, V42, P516, DOI 10.1007/s002530050287; Huang XF, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0006-8; Irigoyen N, 2012, J BIOL CHEM, V287, P24473, DOI 10.1074/jbc.M112.356113; JACKWOOD DH, 1987, AVIAN DIS, V31, P766, DOI 10.2307/1591028; Kim HJ, 2017, LETT APPL MICROBIOL, V64, P111, DOI 10.1111/lam.12695; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Lauring AS, 2010, NAT BIOTECHNOL, V28, P573, DOI 10.1038/nbt.1635; Li GP, 2020, AVIAN PATHOL, V49, P557, DOI 10.1080/03079457.2020.1791314; Liu FX, 2013, COMP IMMUNOL MICROB, V36, P343, DOI 10.1016/j.cimid.2013.02.002; Liu Y, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-018-0993-9; Lu Z, 2015, VIRUS RES, V203, P92, DOI 10.1016/j.virusres.2015.04.003; Lua LHL, 2014, BIOTECHNOL BIOENG, V111, P425, DOI 10.1002/bit.25159; MAZARIEGOS LA, 1990, AVIAN DIS, V34, P203, DOI 10.2307/1591353; MCFERRAN JB, 1980, AVIAN PATHOL, V9, P395, DOI 10.1080/03079458008418423; Muller H, 2012, AVIAN PATHOL, V41, P133, DOI 10.1080/03079457.2012.661403; Myint O, 2021, AVIAN PATHOL, V50, P6, DOI 10.1080/03079457.2020.1822989; Saugar I, 2005, STRUCTURE, V13, P1007, DOI 10.1016/j.str.2005.04.012; Saugar I, 2010, J BIOL CHEM, V285, P3643, DOI 10.1074/jbc.M109.075994; Taghavian O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083210; Thai TN, 2021, AVIAN PATHOL, V50, P174, DOI 10.1080/03079457.2020.1869698; Wang M, 2016, VACCINE, V34, P3508, DOI 10.1016/j.vaccine.2016.02.072; Wang MY, 2000, BIOTECHNOL BIOENG, V67, P104, DOI 10.1002/(SICI)1097-0290(20000105)67:1&lt;104::AID-BIT12&gt;3.0.CO;2-I; Wang YL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020142; Wei YW, 2008, VIRUS RES, V131, P279, DOI 10.1016/j.virusres.2007.08.013; Wei YW, 2006, BIOCHEM BIOPH RES CO, V350, P277, DOI 10.1016/j.bbrc.2006.09.040; Xu AH, 2020, VIRUS RES, V276, DOI 10.1016/j.virusres.2019.197833; Yamaji H, 2014, APPL MICROBIOL BIOT, V98, P1963, DOI 10.1007/s00253-013-5474-9; Yang DQ, 2021, MICROB CELL FACT, V20, DOI 10.1186/s12934-021-01514-5; Yang H, 2020, CURR OPIN VIROL, V44, P139, DOI 10.1016/j.coviro.2020.08.001	42	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1443	10.3390/vaccines9121443			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ8CH	34960188	gold, Green Published			2022-04-29	WOS:000737874500001
J	Dominguez, A; Varela, C; Soldevila, N; Izquierdo, C; Guerrero, M; Penuelas, M; Martinez, A; Godoy, P; Borras, E; Rius, C; Torner, N; Avellon, AM; Castilla, J				Dominguez, Angela; Varela, Carmen; Soldevila, Nuria; Izquierdo, Conchita; Guerrero, Maria; Penuelas, Marina; Martinez, Ana; Godoy, Pere; Borras, Eva; Rius, Cristina; Torner, Nuria; Avellon, Ana Maria; Castilla, Jesus			Hepatitis A Outbreak Characteristics: A Comparison of Regions with Different Vaccination Strategies, Spain 2010-2018	VACCINES			English	Article						Hepatitis A; outbreak; transmission; vaccination strategy; risk groups	COST-EFFECTIVENESS ANALYSIS; HOSPITALIZATIONS; IMMUNIZATION; EPIDEMIOLOGY; TRENDS; IMPACT	We compared the cumulative incidence and characteristics of hepatitis A outbreaks in two groups of Spanish autonomous regions according to whether a universal or risk group vaccination strategy was followed. Outbreaks between 2010 and 2018 were analyzed. The cumulative incidence rate of outbreaks was estimated and compared by estimating the rate ratio (RR). The characteristics of the outbreaks and those of the first cases were compared. Adjusted OR (aOR) were calculated using a multivariate logistic regression model. Outbreak incidence was 16.04 per million persons in regions with universal vaccination and 20.76 in those with risk-group vaccination (RR 0.77; 95%CI 0.62-0.94). Imported outbreaks accounted for 65% in regions with universal vaccination and 28.7% in regions with risk-group vaccination (aOR 3.88; 95%CI 2.13-7.09). Adolescents and young adults aged 15-44 years and men who have sex with men were less frequently the first case of the outbreak in regions with a universal vaccination strategy (aOR 0.54; 95%CI 0.32-0.92 and 0.23; 95%CI 0.07-0.82, respectively). The cumulative incidence rate of outbreaks was lower in regions with universal vaccination. In all regions, independently of the vaccination strategy, activities to vaccinate persons belonging to high-risk groups for infection should be emphasized.	[Dominguez, Angela; Soldevila, Nuria] Univ Barcelona, Dept Med, Barcelona 08036, Spain; [Dominguez, Angela; Varela, Carmen; Soldevila, Nuria; Martinez, Ana; Godoy, Pere; Borras, Eva; Rius, Cristina; Torner, Nuria; Avellon, Ana Maria; Castilla, Jesus] Inst Salud Carlos III, CIBER Epidemiol & Salud Publ CIBERESP, Madrid 28029, Spain; [Varela, Carmen; Guerrero, Maria; Penuelas, Marina] Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid 28029, Spain; [Izquierdo, Conchita; Martinez, Ana; Godoy, Pere; Borras, Eva] Agencia Salut Publ Catalunya, Barcelona 08005, Spain; [Rius, Cristina] Agencia Salut Publ Barcelona, Barcelona 08023, Spain; [Avellon, Ana Maria] Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28222, Spain; [Castilla, Jesus] Inst Salud Publ Navarra IdiSNA, Pamplona 31003, Spain		Soldevila, N (通讯作者)，Univ Barcelona, Dept Med, Barcelona 08036, Spain.; Soldevila, N (通讯作者)，Inst Salud Carlos III, CIBER Epidemiol & Salud Publ CIBERESP, Madrid 28029, Spain.	angela.dominguez@ub.edu; mvarelam@isciii.es; nsoldevila@ub.edu; conchita.izquierdo@gencat.cat; m.guerrero@isciii.es; marina.penuelas@isciii.es; a.martinez@gencat.cat; pere.godoy@gencat.cat; eva.borras@gencat.cat; crius@aspb.cat; nuriatorner@ub.edu; aavellon@isciii.es; jcastilc@navarra.es	; Castilla, Jesus/B-9048-2008	Guerrero-Vadillo, Maria/0000-0003-0575-789X; Castilla, Jesus/0000-0002-6396-7265; Soldevila, Nuria/0000-0002-1353-5325; Penuelas, Marina/0000-0002-5909-7957; Torner, Nuria/0000-0003-0143-5295	Programme of Prevention, Surveillance, and Control of Transmissible Diseases (PREVICET), CIBER de Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III, Madrid [ESPC07/2021]	This study was funded by the Programme of Prevention, Surveillance, and Control of Transmissible Diseases (PREVICET), CIBER de Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III, Madrid (Grant number ESPC07/2021).	[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2012, Wkly Epidemiol Rec, V87; Arteaga-Rodriguez A, 2010, EUR J GASTROEN HEPAT, V22, P1284, DOI 10.1097/MEG.0b013e32833bce39; Averhoff F., 2020, PRINCIPLES PRACTICE, V9th, P2243; Batdorf SJ, 2021, MMWR-MORBID MORTAL W, V70, P269, DOI [10.15585/mmwr.mm7008a2externalicon, 10.15585/mmwr.mm7008a2]; Bauer D, 2021, EUR J CLIN MICROBIOL, V40, P335, DOI 10.1007/s10096-020-04028-x; Brouwer AF, 2020, EPIDEMIOLOGY, V31, P628, DOI 10.1097/EDE.0000000000001218; Bruguera M, 1999, MED CLIN-BARCELONA, V112, P406; Chi V, 2018, CURR OPIN PEDIATR, V30, P689, DOI 10.1097/MOP.0000000000000672; Fahrni O, 2020, PEDIATR INFECT DIS J, V39, P164, DOI 10.1097/INF.0000000000002526; Fortea JI, 2020, REV CLIN ESP, V220, P400, DOI 10.1016/j.rce.2019.08.005; Gallone MF, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005884; Gassowski M, 2018, EUROSURVEILLANCE, V23, P8, DOI 10.2807/1560-7917.ES.2018.23.27.1800329; Ghildayal N, 2019, INT J HEALTH CARE Q, V32, P1175, DOI 10.1108/IJHCQA-05-2019-0096; Gozlan Y, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.29.30575; Guzzetta G, 2019, EPIDEMICS-NETH, V29, DOI 10.1016/j.epidem.2019.100351; Hankin-Wei A, 2016, VACCINE, V34, P4243, DOI 10.1016/j.vaccine.2016.06.040; Bustabad AH, 2020, REV ESP ENFERM DIG, V112, P448, DOI 10.17235/reed.2020.6687/2019; Hofmeister MG, 2021, J INFECT DIS, V223, P426, DOI 10.1093/infdis/jiaa636; Jacobsen KH, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031716; James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7; Lin KY, 2021, J INFECT DIS, V223, P359, DOI 10.1093/infdis/jiaa638; Ortega RL, 2018, REV ESP SALUD PUBLIC, V92; Mello VM, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030281; Mellou K, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000382; Ministerio de Sanidad Servicios Sociales e Igualdad, 1996, B OF ESTADO, V21, P2153; Navas E, 2005, VACCINE, V23, P2185, DOI 10.1016/j.vaccine.2005.01.065; Ndumbi P, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.33.1700641; Nelson NP, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6905a1; O'Connor L, 2018, EPIDEMIOL INFECT, V146, P705, DOI 10.1017/S0950268818000638; Papaevangelou V, 2016, HUM VACC IMMUNOTHER, V12, P1852, DOI 10.1080/21645515.2016.1151589; Plunkett J, 2019, VACCINE-X, V1, DOI 10.1016/j.jvacx.2019.100014; Ponencia del Programa y Registro de Vacunaciones, 2018, VAC GRUP RIESG TOD E; Ramsay LC, 2019, VACCINE, V37, P1467, DOI 10.1016/j.vaccine.2019.01.070; Rodriguez-Tajes S, 2018, LIVER INT, V38, P588, DOI 10.1111/liv.13606; Sharp A, 2019, VACCINE, V37, P1521, DOI 10.1016/j.vaccine.2019.01.026; Stuurman AL, 2017, HUM VACC IMMUNOTHER, V13, P724, DOI 10.1080/21645515.2016.1242539; Torner N, 2011, J VIRAL HEPATITIS, V18, pe1, DOI 10.1111/j.1365-2893.2010.01395.x; Tortajada C, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-11; Werber D, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.5.30457; Whelan S, 2021, FIELDS VIROLOGY, P30; Wong CKH, 2017, VACCINE, V35, P3153, DOI 10.1016/j.vaccine.2017.04.050; Wooten Darcy A, 2019, Top Antivir Med, V26, P117; World Health Organization, 2021, HEP KEY FACTS; Yin SM, 2020, CLIN INFECT DIS, V71, pE571, DOI 10.1093/cid/ciaa298; Yoon EL, 2017, CLIN MOL HEPATOL, V23, P196, DOI 10.3350/cmh.2017.0034; Zhang L, 2020, HUM VACC IMMUNOTHER, V16, P1565, DOI 10.1080/21645515.2020.1769389	47	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1214	10.3390/vaccines9111214			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI3PX	34835145	Green Published, gold			2022-04-29	WOS:000726029100001
J	Gao, Q; Yang, YL; Quan, WP; Zheng, JC; Luo, YZ; Wang, H; Chen, XN; Huang, Z; Chen, XJ; Xu, RD; Zhang, GH; Gong, L				Gao, Qi; Yang, Yunlong; Quan, Weipeng; Zheng, Jiachen; Luo, Yizhuo; Wang, Heng; Chen, Xiongnan; Huang, Zhao; Chen, Xiaojun; Xu, Runda; Zhang, Guihong; Gong, Lang			The African Swine Fever Virus with MGF360 and MGF505 Deleted Reduces the Apoptosis of Porcine Alveolar Macrophages by Inhibiting the NF-kappa B Signaling Pathway and Interleukin-1 beta	VACCINES			English	Article						African swine fever virus; MGF; CD2v; NF-kappa B; IL-1 beta; apoptosis	MULTIGENE FAMILIES; GENE-EXPRESSION; ISOLATE; CELLS; INTERFERON; INFECTION; VIRULENCE; REPLICATION; FAMILY-360; PROTECTS	African swine fever virus (ASFV) poses serious threats to the swine industry. The mortality rate of African swine fever (ASF) is 100%, and there is no effective vaccine currently available. Complex immune escape strategies of ASFV are crucial factors affecting immune prevention and vaccine development. CD2v and MGF360-505R genes have been implicated in the modulation of the immune response. The molecular mechanisms contributing to innate immunity are poorly understood. In this study, we discover the cytopathic effect and apoptosis of & UDelta;CD2v/& UDelta;MGF360-505R-ASFV after infection in porcine alveolar macrophages (PAMs) was significantly less than wild-type ASFV. We demonstrated that CD2v- and MGF360-505R-deficient ASFV decrease the level of apoptosis by inhibiting the NF-kappa B signaling pathway and IL-1 beta mRNA transcription. Compared with wild-type ASFV infection, the levels of phospho-NF-kappa B p65 and p-I kappa B protein decreased in CD2v- and MGF360-505R-deficient ASFV. Moreover, CD2v- and MGF360-505R-deficient ASFV induced less IL-1 beta production than wild-type ASFV and was attenuated in replication compared with wild-type ASFV. We further found that MGF360-12L, MGF360-13L, and MGF-505-2R suppress the promoter activity of NF-kappa B by reporter assays, and CD2v activates the NF-kappa B signaling pathway. These findings suggested that CD2v- and MGF360-505R-deficient ASFV could reduce the level of ASFV p30 and the apoptosis of PAMs by inhibiting the NF-kappa B signaling pathway and IL-1 beta mRNA transcription, which might reveal a novel strategy for ASFV to maintain the replication of the virus in the host.	[Gao, Qi; Yang, Yunlong; Quan, Weipeng; Zheng, Jiachen; Luo, Yizhuo; Wang, Heng; Chen, Xiongnan; Huang, Zhao; Chen, Xiaojun; Xu, Runda; Zhang, Guihong; Gong, Lang] South China Agr Univ, Key Lab Zoonosis Prevent & Control Guangdong Prov, Coll Vet Med, Guangzhou 510462, Peoples R China; [Gao, Qi; Wang, Heng; Zhang, Guihong; Gong, Lang] Guangdong Lab Lingnan Modern Agr, Maoming Branch, Maoming 525000, Peoples R China; [Yang, Yunlong; Luo, Yizhuo; Wang, Heng] South China Agr Univ, Res Ctr African Swine Fever Prevent & Control, Guangzhou 510642, Peoples R China; [Quan, Weipeng; Zheng, Jiachen; Chen, Xiongnan; Huang, Zhao; Chen, Xiaojun; Xu, Runda; Gong, Lang] African Swine Fever Reg Lab China Guangzhou, Guangzhou 510642, Peoples R China		Zhang, GH; Gong, L (通讯作者)，South China Agr Univ, Key Lab Zoonosis Prevent & Control Guangdong Prov, Coll Vet Med, Guangzhou 510462, Peoples R China.; Zhang, GH; Gong, L (通讯作者)，Guangdong Lab Lingnan Modern Agr, Maoming Branch, Maoming 525000, Peoples R China.; Gong, L (通讯作者)，African Swine Fever Reg Lab China Guangzhou, Guangzhou 510642, Peoples R China.	qigao2021@scau.edu.cn; yunlongyang@stu.scau.edu.cn; weipengquan@stu.scau.edu.cn; zhengjc@stu.scau.edu.cn; lawzz@stu.scau.edu.cn; wangheng2009@scau.edu.cn; cxn201314@stu.scau.edu.cn; yingwenmulu@stu.scau.edu.cn; xiaojunchen@stu.scau.edu.cn; 18819255305@163.com; guihongzh@scau.edu.cn; gonglang@scau.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31941004]; Key-Area Research and Development Program of Guangdong Province [2019B020211003]; Science and Technology Project of Guangdong Pig Industrial Park [GDSCYY2020-024]; China Agriculture Research System of MOF and MARA [cars35]	This research was funded by the National Natural Science Foundation of China [grant number 31941004], the Key-Area Research and Development Program of Guangdong Province [grant number 2019B020211003], Science and Technology Project of Guangdong Pig Industrial Park [grant number GDSCYY2020-024], and China Agriculture Research System of MOF and MARA [grant number cars35].	Afonso CL, 2004, J VIROL, V78, P1858, DOI 10.1128/JVI.78.4.1858-1864.2004; Alejo A, 2018, J VIROL, V92, DOI 10.1128/JVI.01293-18; ALMENDRAL JM, 1990, J VIROL, V64, P2064, DOI 10.1128/JVI.64.5.2064-2072.1990; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Benedict CA, 2002, NAT IMMUNOL, V3, P1013, DOI 10.1038/ni1102-1013; Bergmann S, 2019, VIROLOGY, V534, P54, DOI 10.1016/j.virol.2019.05.020; Borca MV, 1998, J VIROL, V72, P2881, DOI 10.1128/JVI.72.4.2881-2889.1998; BREESE SS, 1966, VIROLOGY, V28, P420, DOI 10.1016/0042-6822(66)90054-7; Burrage TG, 2004, J VIROL, V78, P2445, DOI 10.1128/JVI.78.5.2445-2453.2004; Cisek Agata A., 2016, Annals of Parasitology, V62, P161, DOI 10.17420/ap6203.49; Correia S, 2013, VIRUS RES, V173, P87, DOI 10.1016/j.virusres.2012.10.013; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dixon LK, 2019, VIRUS RES, V266, P25, DOI 10.1016/j.virusres.2019.04.002; Dixon LK, 2019, ANTIVIR RES, V165, P34, DOI 10.1016/j.antiviral.2019.02.018; Galindo I, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050103; Goatley LC, 2011, J VIROL, V85, P3294, DOI 10.1128/JVI.01994-10; Golding JP, 2016, VIROLOGY, V493, P154, DOI 10.1016/j.virol.2016.03.019; GONZALEZ A, 1990, J VIROL, V64, P2073; Haig DM, 2001, RES VET SCI, V70, P205, DOI 10.1053/rvsc.2001.0462; Hernaez B, 2006, VIROLOGY, V350, P1, DOI 10.1016/j.virol.2006.01.021; Hilbi H, 1997, PARASITOLOGY, V115, pS79, DOI 10.1017/S0031182097001790; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kay-Jackson PC, 2004, J GEN VIROL, V85, P119, DOI 10.1099/vir.0.19435-0; King DP, 2003, J VIROL METHODS, V107, P53, DOI 10.1016/S0166-0934(02)00189-1; Krug PW, 2015, J VIROL, V89, P2324, DOI 10.1128/JVI.03250-14; Lau SK, 2004, AM J CLIN PATHOL, V122, P794, DOI 10.1309/QHD6YFN81KQXUUH6; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Monteagudo PL, 2017, J VIROL, V91, DOI [10.1128/JVI.01058-17, 10.1128/jvi.01058-17]; Munday J, 1999, J LEUKOCYTE BIOL, V66, P705, DOI 10.1002/jlb.66.5.705; O'Donnell V, 2015, J VIROL, V89, P6048, DOI 10.1128/JVI.00554-15; Pikalo J, 2019, VIRUS RES, V271, DOI 10.1016/j.virusres.2019.04.001; Piotrowska A, 2008, POSTEP HIG MED DOSW, V62, P64; RamiroIbanez F, 1996, J GEN VIROL, V77, P2209, DOI 10.1099/0022-1317-77-9-2209; Reis AL, 2016, VACCINE, V34, P4698, DOI 10.1016/j.vaccine.2016.08.011; RODRIGUEZ JM, 1993, J VIROL, V67, P5312; Rowlands RJ, 2008, EMERG INFECT DIS, V14, P1870, DOI 10.3201/eid1412.080591; Roy D, 2006, FRONT BIOSCI-LANDMRK, V11, P889, DOI 10.2741/1845; Saade G, 2020, VET RES, V51, DOI 10.1186/s13567-020-00807-8; Sabal C., 2021, VIRUSES-BASEL, V13, P1480; THOMSON GR, 1985, ONDERSTEPOORT J VET, V52, P201; YOZAWA T, 1994, VIROLOGY, V202, P997, DOI 10.1006/viro.1994.1426; Zhang B, 2007, DIABETES, V56, P1316, DOI 10.2337/db06-1273; Zhao DM, 2019, EMERG MICROBES INFEC, V8, P438, DOI 10.1080/22221751.2019.1590128; Zhuo Y., 2021, VET MICROBIOL, V263, P109265; Zhuo YS, 2021, VIROL SIN, V36, P176, DOI 10.1007/s12250-020-00304-4; Zou LT, 2020, AGING-US, V12, P2440, DOI 10.18632/aging.102753; Zsak L, 2001, J VIROL, V75, P3066, DOI 10.1128/JVI.75.7.3066-3076.2001; Zsak Laszlo, 2002, ScientificWorldJournal, V2, P1186	49	0	0	10	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1371	10.3390/vaccines9111371			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF5TJ	34835302	Green Published, gold			2022-04-29	WOS:000724132600001
J	Iguacel, I; Maldonado, AL; Ruiz-Cabello, AL; Casaus, M; Moreno, LA; Martinez-Jarreta, B				Iguacel, Isabel; Maldonado, Aurelio Luna; Ruiz-Cabello, Aurelio Luna; Casaus, Marta; Moreno, Luis Alberto; Martinez-Jarreta, Begona			Association between COVID-19 Vaccine Side Effects and Body Mass Index in Spain	VACCINES			English	Article						SARS CoV-2; vaccination; overweight; obesity; vaccine adverse events	SERUM PROGESTERONE LEVELS; IMMUNOGLOBULIN-G; INJECTION; REACTOGENICITY	COVID-19 vaccines have shown high efficacy, with most side effects being mild-moderate and more frequently reported by females and people at younger ages. Since no studies have assessed the impact that weight status could have on the reported adverse reactions, we aim to study the association between weight status and reported side effects. We included data on 2136 adults from an online survey conducted from 6 May to 9 June 2021. The questionnaire was filled in by participants over Google forms. Generalized Linear Mixed Models were used. A higher risk of presenting fever & GE;38 & DEG;, vomiting, diarrhea and chills was found in those with a non-overweight status compared to those overweight after adjusting for age, sex, education, medication to prevent/relieve post-vaccination effects and vaccine administered. When adjusting, most of the significant effects, in the association between side effects of the COVID-19 vaccine and weight status, did not remain significant. In conclusion, a non-overweight status was associated with a higher risk of presenting fever & GE;38 & DEG;, vomiting, diarrhea and chills compared to those overweight. Nevertheless, most of the reported side effects to COVID-19 vaccine were not associated with a higher risk of presenting more adverse effects, and individual differences were determined by sex and age.	[Iguacel, Isabel; Casaus, Marta; Moreno, Luis Alberto] Univ Zaragoza, Fac Hlth Sci, Zaragoza 50009, Spain; [Iguacel, Isabel; Moreno, Luis Alberto] Inst Agroalimentario Aragon, Zaragoza 50013, Spain; [Iguacel, Isabel; Moreno, Luis Alberto; Martinez-Jarreta, Begona] Inst Invest Sanitaria Aragon, Zaragoza 50009, Spain; [Iguacel, Isabel; Moreno, Luis Alberto] Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Zaragoza 50009, Spain; [Maldonado, Aurelio Luna; Ruiz-Cabello, Aurelio Luna] Univ Murcia, Dept Sociosanit Sci, Murcia 30100, Spain; [Martinez-Jarreta, Begona] Univ Zaragoza, Fac Med, Zaragoza 50009, Spain		Iguacel, I (通讯作者)，Univ Zaragoza, Fac Hlth Sci, Zaragoza 50009, Spain.; Iguacel, I (通讯作者)，Inst Agroalimentario Aragon, Zaragoza 50013, Spain.; Iguacel, I (通讯作者)，Inst Invest Sanitaria Aragon, Zaragoza 50009, Spain.; Iguacel, I (通讯作者)，Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Zaragoza 50009, Spain.	iguacel@unizar.es; aurluna@um.es; aurelio.luna@um.es; mcasausm@gmail.com; lmoreno@unizar.es; mjarreta@unizar.es	Martinez-Jarreta, Begona/AAE-5805-2020	Martinez-Jarreta, Begona/0000-0001-6469-9189; Luna, Aurelio/0000-0001-7760-7415; Moreno Aznar, Luis A./0000-0003-0454-653X; Iguacel, Isabel/0000-0003-4242-5464			Aga QAA, 2021, J MED VIROL, V93, P6588, DOI 10.1002/jmv.27214; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bae S, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e115; Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596; Coggins SA, 2022, OPEN FORUM INFECT DI, V9, DOI [10.1093/ofid/ofab575, 10.1101/2021.06.25.21259544]; Davies A, 2020, NUTRITION, V71, DOI 10.1016/j.nut.2019.110622; Di Resta C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050522; Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928; Esposito S, 2016, VACCINE, V34, P56, DOI 10.1016/j.vaccine.2015.11.019; Finberg R.W., 2021, NO VACCINE SIDE EFFE; Graham Flora, 2021, Nature, DOI 10.1038/d41586-021-00932-0; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Izumo T, 2021, RESPIR INVESTIG, V59, P635, DOI 10.1016/j.resinv.2021.06.003; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; Lee YW, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e153; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Ng WH, 2021, MBIO, V12, DOI 10.1128/mBio.03647-20; Pellini R., 2021, OBESITY MAY HAMPER S, DOI [10.1101/2021.02.24.21251664, DOI 10.1101/2021.02.24.21251664]; Petousis-Harris H, 2008, VACCINE, V26, P6299, DOI 10.1016/j.vaccine.2008.08.052; Petousis-Harris H, 2015, HUM VACC IMMUNOTHER, V11, P1875, DOI 10.1080/21645515.2015.1016670; Pondo T, 2014, VACCINE, V32, P3548, DOI 10.1016/j.vaccine.2014.04.025; Quick V, 2015, J NUTR EDUC BEHAV, V47, P94, DOI 10.1016/j.jneb.2014.08.012; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Sprent J, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj9256; Watanabe M, 2022, DIABETES-METAB RES, V38, DOI 10.1002/dmrr.3465; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Zhang YJ, 2008, PHARMACOEPIDEM DR S, V17, P1060, DOI 10.1002/pds.1657	28	4	4	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1321	10.3390/vaccines9111321			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ5YC	34835252	gold, Green Published			2022-04-29	WOS:000726862000001
J	Oduwole, EO; Esterhuizen, TM; Mahomed, H; Wiysonge, CS				Oduwole, Elizabeth O.; Esterhuizen, Tonya M.; Mahomed, Hassan; Wiysonge, Charles S.			Estimating Vaccine Confidence Levels among Healthcare Staff and Students of a Tertiary Institution in South Africa	VACCINES			English	Article						vaccine confidence; vaccine hesitancy; vaccination intention; immunization; COVID-19; survey; healthcare workers; South Africa	HESITANCY; COVID-19; WORKERS; COVERAGE; 1ST	Healthcare workers were the first group scheduled to receive COVID-19 vaccines when they became available in South Africa. Therefore, estimating vaccine confidence levels and intention to receive COVID-19 vaccines among healthcare workers ahead of the national vaccination roll-out was imperative. We conducted an online survey from 4 February to 7 March 2021, to assess vaccine sentiments and COVID-19 vaccine intentions among healthcare staff and students at a tertiary institution in South Africa. We enrolled 1015 participants (74.7% female). Among the participants, 89.5% (confidence interval (CI) 87.2-91.4) were willing to accept a COVID-19 vaccine, 95.4% (CI 93.9-96.6) agreed that vaccines are important for them, 95.4% (CI 93.8-96.6) that vaccines are safe, 97.4% (CI 96.2-98.3) that vaccines are effective, and 96.1% (CI 94.6-97.2) that vaccines are compatible with religion. Log binomial regression revealed statistically significant positive associations between COVID-19 vaccine acceptance and the belief that vaccines are safe (relative risk (RR) 32.2, CI 4.67-221.89), effective (RR 21.4, CI 3.16-145.82), important for children (RR 3.5, CI 1.78-6.99), important for self (RR 18.5, CI 4.78-71.12), or compatible with religion (RR 2.2, CI 1.46-3.78). The vaccine confidence levels of the study respondents were highly positive. Nevertheless, this could be further enhanced by targeted interventions.	[Oduwole, Elizabeth O.; Mahomed, Hassan] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Hlth Syst & Publ Hlth, ZA-7505 Cape Town, South Africa; [Esterhuizen, Tonya M.; Wiysonge, Charles S.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Epidemiol & Biostat, ZA-7505 Cape Town, South Africa; [Wiysonge, Charles S.] South African Med Res Council, Cochrane South Africa, ZA-7505 Cape Town, South Africa		Oduwole, EO (通讯作者)，Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Hlth Syst & Publ Hlth, ZA-7505 Cape Town, South Africa.	oduwoleelizabeth@gmail.com; tonyae@sun.ac.za; hmahomed@sun.ac.za; Charles.Wiysonge@mrc.ac.za	Oduwole, Elizabeth O./AAU-6962-2020	Oduwole, Elizabeth O./0000-0002-7192-242X; Wiysonge, Charles/0000-0002-1273-4779	South African Medical Research Council (SAMRC) Internship Scholarship programme [57020]; SAMRC through Cochrane South Africa [43500]	This research was funded by the South African Medical Research Council (SAMRC) Internship Scholarship programme (SAMRC Project Code: 57020). The APC was funded by the SAMRC through Cochrane South Africa (SAMRC Project Code: 43500).	Ahmed A, 2018, J INFECT PUBLIC HEAL, V11, P153, DOI 10.1016/j.jiph.2017.09.007; [Anonymous], 2020, ANAL REPORT 1 2 3 WA; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Blankenship Elizabeth B, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-138; Boyon N., 3 4 ADULTS GLOBALLY; Carcelen AC, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1948784; CDC, SAF COVID 19 VACC; CDC COVID Data Tracker, COR DIS 2019 COVID 1; CDC-Africa, MAJ AFR WOULD TAK SA; Challen R, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n579; Costa JC, 2020, VACCINE, V38, P1160, DOI 10.1016/j.vaccine.2019.11.024; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gebremeskel AT, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-006108; Institute for Global Change, COMB VACC MIS AG INT; Johns Hopkins Medicine, NEW STRAIN COR WHAT; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Kelly BJ, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06085-9; Kose S, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13917; Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Li HOY, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002604; Li M, 2021, POSTGRAD MED J, DOI 10.1136/postgradmedj-2021-140195; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Maltezou HC, 2008, VACCINE, V26, P1408, DOI 10.1016/j.vaccine.2008.01.049; Mitra Tanushree, 2016, P 10 INT AAAI C WEB, P269; Morley, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab054, DOI 10.1093/cid/ciab054]; National Institute for Communicable Diseases, LAT CONF CAS COVID 1; NICD, COVID 19 2 WAV S AFR; Njeru I, 2016, PAN AFR MED J, V24, DOI 10.11604/pamj.2016.24.120.8986; Oduwole EO, 2021, VACCINE, V39, P5506, DOI 10.1016/j.vaccine.2021.08.054; Oduwole EO, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-049877; Ofri D., NEW YORKER; Olufowote JO, 2011, HEALTH COMMUN, V26, P743, DOI 10.1080/10410236.2011.566830; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Pew Research Center CARY LYNNE THIGPEN CARY FUNK, MOST AM EXP COVID 19; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Razai MS, 2021, J ROY SOC MED, V114, P295, DOI 10.1177/01410768211018951; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; SA Corona Virus Online Portal, 2021, ALL YOU NEED KNOW CO, P13; Salyer SJ, 2021, LANCET, V397, P1265, DOI 10.1016/S0140-6736(21)00632-2; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Stratford J., 2020, JUDICIAL REV, V25, P105, DOI [10.1080/10854681.2020.1780664, DOI 10.1080/10854681.2020.1780664]; Stuart R., 2021, NEW VARIANTS CORONAV, P1; UChicago Medicine, WER RES ABL DEV COVI; Ungar L., 2021, GENDER VACCINE GAP M; Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; WHO, 2020, COVID 19 PUBL HLTH E; Worldometer, COR DEATH TOLL TREND; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	55	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1246	10.3390/vaccines9111246			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG9UR	34835177	Green Published, Green Submitted, gold			2022-04-29	WOS:000725091300001
J	Abuelizz, HA; AlRasheed, MM; Alhoshani, A; Alhawassi, T				Abuelizz, Hatem A.; AlRasheed, Maha M.; Alhoshani, Ali; Alhawassi, Tariq			Genetic Insights into the Middle East Respiratory Syndrome Coronavirus Infection among Saudi People	VACCINES			English	Article						dipeptidyl peptidase 4; DPP4; MERS-CoV; middle east respiratory syndrome	DIPEPTIDYL PEPTIDASE 4; RECEPTOR; GLYCOSYLATION; CELL	Background: The Middle East respiratory syndrome coronavirus (MERS-CoV) was isolated for the first time in Saudi Arabia from a patient suffering from atypical pneumonia. The Saudi Genome database was built by King Abdulaziz Medical City via the next-generation sequencing of 7000 candidates. Method: A large list of point mutations were reported in the region of the dipeptidyl peptidase 4 (DPP4) gene. The DPP4 amino acid residues correlated to MERS-CoV entry and the site of activity of DPP4 inhibitors was investigated. We retrieved the SNPs (Single-Nucleotide Polymorphism) with a variation frequency of > 0.05. Results: SNP 2:162,890,175 and SNP 2:162,891,848 in the intronic region were located within 50 bp of amino acid residues responsible for MERS-CoV entry, amino acids 259-296 and 205-258, respectively. The variation frequency of SNP 2:162,890,175 was 2321 out of 2379 screened individuals. Moreover, mutation of SNP 2:162,891,848, which is located near amino acid residues E205 and E206 (crucial for the activity of DPP4 inhibitors), occurred in 76 out of 2379 screened individuals. Conclusions: Our study shows high variation frequency in the DPP4 region reported in the Saudi Genome database. The identified SNPs are of high significance for MERS-CoV infection in better understanding disease pathogenesis.	[Abuelizz, Hatem A.] King Saud Univ, Dept Pharmaceut Chem, Coll Pharm, POB 2457, Riyadh 11451, Saudi Arabia; [AlRasheed, Maha M.; Alhawassi, Tariq] King Saud Univ, Dept Clin Pharm, Coll Pharm, POB 2457, Riyadh 11451, Saudi Arabia; [Alhoshani, Ali] King Saud Univ, Coll Pharm, Dept Pharmacol & Toxicol, POB 2457, Riyadh 11451, Saudi Arabia		Abuelizz, HA (通讯作者)，King Saud Univ, Dept Pharmaceut Chem, Coll Pharm, POB 2457, Riyadh 11451, Saudi Arabia.	habuelizz@ksu.edu.sa; ahoshani@ksu.edu.sa	Abuelizz, Hatem/E-5871-2017; Alhoshani, Ali/B-2675-2019	Abuelizz, Hatem/0000-0002-7092-7544; AlRasheed, Maha/0000-0001-6668-2874; Alhoshani, Ali/0000-0002-3450-283X	King Abdulaziz City for Science and Technology (KACST),Target Research Program, Middle East Respiratory Syndrome-Corona Virus (MERS-CoV RGP) [17-1]	By King Abdulaziz City for Science and Technology (KACST), Target Research Program, Middle East Respiratory Syndrome-Corona Virus (MERS-CoV RGP) grant no. 17-1.	Abdulwahab F, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0693-2; Abouelhoda M, 2016, GENET MED, V18, P1244, DOI 10.1038/gim.2016.37; Aertgeerts K, 2004, PROTEIN SCI, V13, P145, DOI 10.1110/ps.03352504; Alburikan KA, 2020, SAUDI PHARM J, V28, P161, DOI 10.1016/j.jsps.2019.11.016; Aleanizy FS, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2137-3; Arulmozhiraja S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166275; Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742; Bardaweel SK, 2021, ACTA PHARMACEUT, V71, P175, DOI 10.2478/acph-2021-0013; Barlan A, 2014, J VIROL, V88, P4953, DOI 10.1128/JVI.00161-14; Bassendine MF, 2020, J DIABETES, V12, P649, DOI 10.1111/1753-0407.13052; Bermingham A, 2012, EUROSURVEILLANCE, V17, P6; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X; Hou Y, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01673-z; Kleine-Weber H, 2020, EMERG MICROBES INFEC, V9, P155, DOI 10.1080/22221751.2020.1713705; Krejner-Bienias A, 2021, ARCH IMMUNOL THER EX, V69, DOI 10.1007/s00005-020-00602-5; Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0; Leist SR, 2020, METHODS MOL BIOL, V2099, P137, DOI 10.1007/978-1-0716-0211-9_12; Peck KM, 2017, J VIROL, V91, DOI 10.1128/JVI.00534-17; Peck KM, 2015, J VIROL, V89, P4696, DOI 10.1128/JVI.03445-14; Pitocco D, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108162; Raj VS, 2014, EMERG INFECT DIS, V20, P1339, DOI 10.3201/eid2008.140663; Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005; Saksena N, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.581726; Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3; Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565; Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92; World Health Organization, MERS SIT UPD JAN 202; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2; Zhu ZX, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01479-w	31	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1193	10.3390/vaccines9101193			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS1LG	34696302	Green Published, gold			2022-04-29	WOS:000714949700001
J	Concha, G; Frickmann, H; Oey, A; Strengert, M; Kreienbrock, L; Kann, S				Concha, Gustavo; Frickmann, Hagen; Oey, Anke; Strengert, Monika; Kreienbrock, Lothar; Kann, Simone			Direct and Indirect Proof of SARS-CoV-2 Infections in Indigenous Wiwa Communities in North-Eastern Colombia-A Cross-Sectional Assessment Providing Preliminary Surveillance Data	VACCINES			English	Article						COVID-19; indigenous; Colombia; surveillance; prevalence; incidence; outbreak	COVID-19; PEOPLE; POPULATIONS	To provide initial data on local SARS-CoV-2 epidemiology and spread in indigenous communities in north-eastern Colombia, respiratory swabs and serum samples from volunteers of indigenous communities were examined in March and April 2021. Samples from non-indigenous Colombians from the same villages were included as well. While previous exposure to SARS-CoV-2 was assessed by analysing serum samples for IgG and IgM with a rapid antibody point-of-care-test (POCT), screening for active infections was carried out with an antigen POCT test and real-time PCR from nasal swabs. In 380 indigenous and 72 non-indigenous volunteers, 61 (13.5%) active infections and an additional 113 (25%) previous infections were identified using diagnostic serology and molecular assays. Previous infections were more frequent in non-indigenous volunteers, and relevant associations of clinical features with active or previous SARS-CoV-2 infections were not observed. Symptoms reported were mild to moderate. SARS-CoV-2 was frequent in the assessed Colombian indigenous communities, as 38.5% of the study participants showed signs of exposure to SARS-CoV-2, which confirms the need to include these indigenous communities in screening and vaccination programs.</p>	[Concha, Gustavo] Org Wiwa Yugumaiun Bunkauanarrua Tayrona OWYBT, Dept Hlth Advocacy, Valledupar 2000001, Colombia; [Frickmann, Hagen] Bundeswehr Hosp Hamburg, Dept Microbiol & Hosp Hyg, D-20359 Hamburg, Germany; [Frickmann, Hagen] Univ Med Rostock, Inst Med Microbiol Virol & Hyg, D-18057 Rostock, Germany; [Oey, Anke; Kreienbrock, Lothar] Univ Vet Med Hannover, Inst Biometry Epidemiol & Informat Proc, D-30559 Hannover, Germany; [Strengert, Monika] Helmholtz Ctr Infect Res, D-38124 Braunschweig, Germany; [Strengert, Monika] TWINCORE Ctr Expt & Clin Infect Res, D-30625 Hannover, Germany; [Kann, Simone] Med Mission Inst, D-97074 Wurzburg, Germany		Kann, S (通讯作者)，Med Mission Inst, D-97074 Wurzburg, Germany.	gustavoconcha16@gmail.com; frickmann@bnitm.de; Anke.Oey@tiho-hannover.de; Monika.Strengert@helmholtz-hzi.de; lothar.kreienbrock@tiho-hannover.de; simone.kann@medmissio.de			Medical Mission Institute	This research was funded by the Medical Mission Institute.	Amigo I, 2020, SCIENCE, V368, P352, DOI 10.1126/science.368.6489.352; Argoty-Pantoja AD, 2021, PUBLIC HEALTH, V193, P69, DOI 10.1016/j.puhe.2021.01.023; Ballesteros N, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009327; Banning J, 2020, CAN MED ASSOC J, V192, pE993, DOI 10.1503/cmaj.1095891; Banning J, 2020, CAN MED ASSOC J, V192, pE787, DOI 10.1503/cmaj.1095879; Baqui P, 2020, LANCET GLOB HEALTH, V8, P1018, DOI 10.1016/S2214-109X(20)30285-0; Charlier P, 2020, LANCET, V396, P1069, DOI 10.1016/S0140-6736(20)32068-7; Cifuentes MP, 2021, J EPIDEMIOL COMMUN H, V75, P610, DOI 10.1136/jech-2020-216275; Cupertino GA, 2020, AM J TROP MED HYG, V103, P609, DOI 10.4269/ajtmh.20-0563; Curtice K, 2020, LANCET, V395, P1753, DOI 10.1016/S0140-6736(20)31242-3; De la Hoz-Restrepo F, 2020, INT J INFECT DIS, V99, P522, DOI 10.1016/j.ijid.2020.08.017; Emmerich P, 2021, TROP MED INT HEALTH, V26, P621, DOI 10.1111/tmi.13569; Ferrante L, 2020, SCIENCE, V368, P251, DOI 10.1126/science.abc0073; Finlay S, 2020, AUST NZ J PUBL HEAL, V44, P251, DOI 10.1111/1753-6405.13010; Frickmann H, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9030627; Goha A, 2021, J EPIDEMIOL COMMUN H, V75, P207, DOI 10.1136/jech-2020-214755; Goncalves J, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113094; Hillier SA, 2020, CAN J PUBLIC HEALTH, V111, P1000, DOI 10.17269/s41997-020-00444-w; Hur KH, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00521; Kann S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092786; Kann S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051517; Kaplan HS, 2020, LANCET, V395, P1727, DOI 10.1016/S0140-6736(20)31104-1; Montag D, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004479; Oh SM, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e101; Power T, 2020, J CLIN NURS, V29, P2737, DOI 10.1111/jocn.15320; Reinders S, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-044197; Santos VS, 2021, J PUBLIC HEALTH-UK, V43, pE250, DOI 10.1093/pubmed/fdaa176; Teixeira SC, 2020, PUBLIC HEALTH, V186, P127, DOI 10.1016/j.puhe.2020.07.021; Vieira CM, 2020, MATURITAS, V136, P38, DOI 10.1016/j.maturitas.2020.04.004; Zavaleta C, 2020, NATURE, V580, P185, DOI 10.1038/d41586-020-01032-1; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	31	0	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1120	10.3390/vaccines9101120			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO8DD	34696227	Green Published, gold			2022-04-29	WOS:000712677200001
J	Debska-Slizien, A; Slizien, Z; Muchlado, M; Kubanek, A; Piotrowska, M; Dabrowska, M; Tarasewicz, A; Chamienia, A; Biedunkiewicz, B; Renke, M; Tylicki, L				Debska-Slizien, Alicja; Slizien, Zuzanna; Muchlado, Marta; Kubanek, Alicja; Piotrowska, Magdalena; Dabrowska, Malgorzata; Tarasewicz, Agnieszka; Chamienia, Andrzej; Biedunkiewicz, Bogdan; Renke, Marcin; Tylicki, Leszek			Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study-The COViNEPH Project	VACCINES			English	Article						COVID-19; kidney transplant recipients; mRNA vaccines; seroconversion	SARS-COV-2	Background: The efficacy of SARS-CoV-2 vaccination among kidney transplant recipients (KTR) is low. The main goal of this study was to analyze factors that may influence the humoral response to vaccination. Methods: We analyzed the titer magnitude of IgG antibodies directed against spike (S)-SARS-CoV-2 antigen after the second dose of the mRNA vaccine in 142 infection naive KTR (83 men, i.e., 58.4%) with a median age (IQR) of 54 (41-63), and 36 respective controls without chronic kidney disease. mRNA-1273 or BNT162b2 were applied in 26% and 74% of KTR, respectively. Results: S-specific immune response (seroconversion) was seen in 73 (51.41%) of KTR, and in all controls 36 (100%). Independent predictors of no response were elder age, shorter transplantation vintage, and a more than two-drug immunosuppressive protocol. In subgroup analyses, the seroconversion rate was highest among KTR without MMF/MPS treatment (70%), treated with no more than two immunosuppressants (69.2%), treated without corticosteroid (66.7%), younger patients aged <54 years (63.2%), and those vaccinated with the mRNA-1273 vaccine (62.16%). The independent predictors of higher S-antibody titer among responders were younger age, treatment with no more than two immunosuppressants, and the mRNA-1273 vaccination. Conclusions: Our study confirmed a low rate of seroconversion after vaccination with the mRNA vaccine in KTR. The major modifiable determinants of humoral response were the composition of the immunosuppressive protocol, as well as the type of vaccine. The latter could be taken into consideration when initial vaccination as well as booster vaccination is considered in KTR.	[Debska-Slizien, Alicja; Slizien, Zuzanna; Muchlado, Marta; Tarasewicz, Agnieszka; Chamienia, Andrzej; Biedunkiewicz, Bogdan; Tylicki, Leszek] Med Univ Gdansk, Fac Med, Dept Nephrol Transplantol & Internal Med, PL-80210 Gdansk, Poland; [Kubanek, Alicja; Renke, Marcin] Med Univ Gdansk, Fac Hlth Sci, Dept Occupat Metab & Internal Dis, PL-81519 Gdynia, Poland; [Piotrowska, Magdalena] Med Univ Gdansk, Fac Med, Dept Med Immunol, PL-80210 Gdansk, Poland; [Dabrowska, Malgorzata] Univ Clin Ctr, Cent Clin Lab, PL-80952 Gdansk, Poland		Tylicki, L (通讯作者)，Med Univ Gdansk, Fac Med, Dept Nephrol Transplantol & Internal Med, PL-80210 Gdansk, Poland.	adeb@gumed.edu.pl; zuzanna.slizien@gumed.edu.pl; marta.muchlado@gumed.edu.pl; alicja.kubanek@gumed.edu.pl; m.piotrowska@gumed.edu.pl; mdabrowska@uck.gda.pl; ataras@gumed.edu.pl; chamien@gumed.edu.pl; bogdan.biedunkiewicz@gumed.edu.pl; mrenke@gumed.edu.pl; leszek.tylicki@gumed.edu.pl	Piotrowska, Magdalena/AAD-4468-2019; Renke, Marcin/AAN-5505-2020; Tylicki, Leszek/T-8466-2018	Piotrowska, Magdalena/0000-0002-1630-3773; Renke, Marcin/0000-0001-5968-2155; Debska-Slizien, Maria Alicja/0000-0001-8210-8063; Tylicki, Leszek/0000-0002-5515-5072; Chamienia, Andrzej/0000-0002-9213-4801	 [01-0521/08/122]	The study was supported by a grant for "Experienced Researcher" No. 01-0521/08/122 via "Excellence Initiative Research University" program implemented at the Medical University of Gda ' nsk.	Aslam S, 2021, J HEART LUNG TRANSPL, V40, P763, DOI 10.1016/j.healun.2021.04.018; Azzi Y, 2021, TRANSPLANTATION, V105, P37, DOI 10.1097/TP.0000000000003523; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Benotmane I, 2021, KIDNEY INT, V99, P1498, DOI 10.1016/j.kint.2021.04.005; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Chadban SJ, 2020, TRANSPLANTATION, V104, pS11, DOI 10.1097/TP.0000000000003136; Cheng LL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00718-w; Deming ME, 2021, NAT MED, V27, P1510, DOI 10.1038/s41591-021-01463-x; Firket L, 2021, AM J TRANSPLANT, V21, P3806, DOI 10.1111/ajt.16726; Grupper A, 2021, AM J TRANSPLANT, V21, P2909, DOI 10.1111/ajt.16710; Heldman MR, 2021, J AM SOC NEPHROL, V32, P1021, DOI 10.1681/ASN.2021010023; Hou YC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080885; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Kumar D, 2016, TRANSPLANTATION, V100, P662, DOI 10.1097/TP.0000000000000861; Lazarus R., 2001, IMMUNOGENICITY SAFET; Narasimhan M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070708; Pan Ke, 2021, bioRxiv, DOI 10.1101/2021.07.20.453160; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Powell AA, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.28.2100634; Rashidi-Alavijeh J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070738; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Shaw RH, 2021, LANCET, V397, P2043, DOI [10.1016/S0140-6736(21)01115-6, 10.1016/S0140-6736(21)01158-2]; Stock PG, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI151178; Stumpf J, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100178; Tregoning JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/s41577-021-00592-1; Tylicki L, 2021, POL ARCH INTERN MED, V131, P797, DOI 10.20452/pamw.16069; Uttamrao PP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.692937; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	29	9	9	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1165	10.3390/vaccines9101165			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YN5DM	34696273	Green Published, gold			2022-04-29	WOS:000747279100001
J	Kezhong, A; Lu, XY; Wang, J; Hu, LJ; Li, BZ; Lu, YH				Kezhong, A.; Lu, Xinyue; Wang, Jing; Hu, Linjie; Li, Bingzhe; Lu, Yihan			Association between Adult Vaccine Hesitancy and Parental Acceptance of Childhood COVID-19 Vaccines: A Web-Based Survey in a Northwestern Region in China	VACCINES			English	Article						vaccine hesitancy; parental acceptance of childhood vaccination; childhood COVID-19 vaccine; resource-limited setting; minority population		China has initiated the COVID-19 vaccination for children aged 15-17 years since late July 2020. This study aimed to determine the association between adult vaccine hesitancy and parental acceptance of childhood COVID-19 vaccines in a multi-ethnicity area of northwestern China. A web-based investigation was performed with a convenience sampling strategy to recruit the parents aged 20-49 years. In a total of 13,451 valid respondents, 66.1% had received the COVID-19 vaccination, 26.6% were intent to receive, while 7.3% were not intent, with an increasing vaccine hesitancy (p < 0.001). Moreover, vaccination uptake of four common vaccines in their children remained low (29.0% for influenza vaccine, 17.9% for pneumonia vaccine, 10.9% for rotavirus vaccine, 8.0% for Enterovirus-71 vaccine), while overall parental acceptance of childhood COVID-19 vaccines was 50.0% (32.7% for those aged 0-5, 46.6% for 6-10, 73.3% for 11-18; p < 0.001). Vaccination uptake of these four vaccines and parental acceptance of childhood COVID-19 vaccine were negatively associated with adult vaccine hesitancy. In addition, respondents mostly preferred childhood COVID-19 vaccines with weak mild common adverse events (beta = 1.993) and no severe adverse events (beta = 1.731), demonstrating a positive association with adult vaccine hesitancy. Thus, it warrants specific countermeasures to reduce adult vaccine hesitancy and improve strategies for childhood vaccination.	[Kezhong, A.] Qinghai Prov Ctr Dis Control & Prevent, Inst Immunizat, Xining 810007, Peoples R China; [Lu, Xinyue; Hu, Linjie; Li, Bingzhe; Lu, Yihan] Fudan Univ, Dept Epidemiol, Key Lab Publ Hlth Safety, Minist Educ,Sch Publ Hlth, Shanghai 200032, Peoples R China; [Wang, Jing] Xian Jiaotong Liverpool Univ, Dept Hlth & Environm Sci, Suzhou 215123, Peoples R China		Lu, YH (通讯作者)，Fudan Univ, Dept Epidemiol, Key Lab Publ Hlth Safety, Minist Educ,Sch Publ Hlth, Shanghai 200032, Peoples R China.	akz1307@126.com; Jing.Wang18@student.xjtlu.edu.cn; Jing.Wang18@student.xjtlu.edu.cn; ljhu20@fudan.edu.cn; bzli19@fudan.edu.cn; luyihan@fudan.edu.cn		Wang, Jing/0000-0002-6263-4039; Lu, Yihan/0000-0003-4651-9433	Shanghai Three-year Action Plan [20202022, GWV-10.1-XK16]	This work was supported by the Shanghai Three-year Action Plan (20202022) for Public Health (Grant No. GWV-10.1-XK16). The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Akel KB, 2021, HUM VACC IMMUNOTHER, V17, P2639, DOI 10.1080/21645515.2021.1884476; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Chen LJ, 2021, INT J AGING HUM DEV, V92, P301, DOI 10.1177/0091415019896224; Chung YM, 2017, MATERN CHILD HLTH J, V21, P2178, DOI 10.1007/s10995-017-2336-6; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2018, EXPERT REV VACCINES, V17, P989, DOI 10.1080/14760584.2018.1541406; Ghinai I, 2013, GLOB PUBLIC HEALTH, V8, P1138, DOI 10.1080/17441692.2013.859720; Gidengil C, 2019, VACCINE, V37, P6793, DOI 10.1016/j.vaccine.2019.08.068; Gust DA, 2008, PEDIATRICS, V122, P718, DOI 10.1542/peds.2007-0538; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hviid A, 2019, ANN INTERN MED, V170, P513, DOI 10.7326/M18-2101; Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Li X, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.021101; Liu Y, 2021, HUM VACC IMMUNOTHER, V17, P157, DOI 10.1080/21645515.2020.1765620; Lu J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050472; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mereckiene J, 2008, Euro Surveill, V13; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033; Simas C, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00279-w; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Wagner AL, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040155; Wang Q, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040342; Yan SJ, 2021, HUM VACC IMMUNOTHER, V17, P1403, DOI 10.1080/21645515.2020.1826250; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	31	3	3	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1088	10.3390/vaccines9101088			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI9CM	34696196	gold, Green Published			2022-04-29	WOS:000726400000001
J	Kuznetsova, L; Cortassa, G; Trilla, A				Kuznetsova, Lidia; Cortassa, Giorgio; Trilla, Antoni			Effectiveness of Mandatory and Incentive-Based Routine Childhood Immunization Programs in Europe: A Systematic Review of the Literature	VACCINES			English	Review						child immunization; mandatory vaccination; vaccine-preventable diseases; vaccination coverage; incidence; COVID-19; Europe	VACCINE COVERAGE; VACCINATIONS	There is a lack of comprehensive and systematic data and evidence regarding the effectiveness of mandatory and incentive-based vaccination schemes. The results of such programs in some countries have not been adequately studied. A number of countries have recently introduced tightening vaccination measures, and it is important to analyze and assess the results of these programs. The unprecedented situation due to the COVID-19 pandemic and mass vaccination made the topic of the effectiveness of vaccination policies and mandates even more relevant. The aim of the study is to assess childhood vaccination programs implemented in selected countries. The study focuses on initiatives implemented in the European Region of the World Health Organization (WHO). A total of 466 full-text articles were assessed for eligibility, and 26 articles on seven countries were included in the synthesis. Additionally, we obtained and performed an analysis of data on the impact of COVID-19 on vaccine coverage and incidence of vaccine-preventable diseases, and the implementation of vaccine mandates in the selected countries. The evidence collected and analyzed in this review allowed us to conclude that the introduction of children routine vaccination mandates increases vaccine coverage and reduces the incidence of vaccine-preventable diseases when compared to the situation before the introduction of the mandates.</p>	[Kuznetsova, Lidia; Trilla, Antoni] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth, E-08036 Barcelona, Spain; [Cortassa, Giorgio] Hosp Santa Corona, Emergency Dept, I-17027 Pietra Ligure, Italy		Kuznetsova, L (通讯作者)，Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth, E-08036 Barcelona, Spain.	lidia.kuznetsova@isglobal.org; cortassa@hotmail.com; ATRILLA@clinic.cat					Adamo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226513; Adams J, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19940; [Anonymous], BBC; [Anonymous], THE CNN; [Anonymous], 2016, SLUZBENI GLASNIK RS; [Anonymous], PAIS; [Anonymous], 2009, LAW REPUBLIC MOLDOVA; [Anonymous], GU SERIE GEN; [Anonymous], 2020, BGBL, VI, P148; Bechini A, 2019, EXPERT REV VACCINES, V18, P693, DOI 10.1080/14760584.2019.1639502; Brujic M, 2020, ETNOANTROPOLOSKI PRO, V15, P979, DOI 10.21301/eap.v15i4.2; [Букова В. Bukova V.], 2017, [Эпидемиология и вакцинопрофилактика, Epidemiologiya i vaktsinoprofilaktika], V16, P96; Causey K, 2021, LANCET, V398, P522, DOI 10.1016/S0140-6736(21)01337-4; Cohen R, 2020, MED MALADIES INFECT, V50, P74, DOI 10.1016/j.medmal.2019.11.007; Costantino Claudio, 2020, Acta Biomed, V91, P35, DOI 10.23750/abm.v91i3-S.9413; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; DW News, DW NEWS; Gallup Inc, 1 BILL WORLDW UNW TA; Gianfredi V, 2019, ANN IG MED PREV COMU, V31, P191, DOI 10.7416/ai.2019.2282; Gori D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010057; Gualano MR, 2019, HUM VACC IMMUNOTHER, V15, P918, DOI 10.1080/21645515.2018.1564437; Heininger U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155949; Kantsone I, 2016, EUROSURVEILLANCE, V21, P11, DOI 10.2807/1560-7917.ES.2016.21.48.30414; Lee C, 2016, J INFECTION, V72, P659, DOI 10.1016/j.jinf.2016.04.002; Legifrance, 2018, OFF J FRENCH REPUBLI; Levy-Bruhl D, 2019, EUROSURVEILLANCE, V24, P6, DOI 10.2807/1560-7917.ES.2019.24.25.1900301; Mankertz A., 2021, EPID B, V15, P3, DOI [10.25646/8109, DOI 10.25646/8109]; [Мельник А.А. Melnik A.A.], 2019, [Эпидемиология и вакцинопрофилактика, Epidemiologiya i vaktsinoprofilaktika], V18, P34, DOI 10.31631/2073-3046-2019-18-4-34-40; Neugebauer M, 2020, Z EVIDENZ FORTBILD Q, V158, P74, DOI 10.1016/j.zefq.2020.10.009; Patic A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227413; Public Health Center of the Ministry of Health of Ukraine, VACCINATION COVERAGE; Public Health Center of the Ministry of Health of Ukraine, INF DIS MORB POP UKR; Ristic M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216219; Robert Koch Institut, 2021, EPIDEMIOL B, V1, P26; Robert Koch Institut, 2021, EPIDEMIOL B, V22, P15; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Signorelli C, 2019, ANN IG MED PREV COMU, V31, P36, DOI 10.7416/ai.2019.2275; Signorelli C, 2018, ANN IG MED PREV COMU, V30, P1, DOI 10.7416/ai.2018.2227; Taine M, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.666848; Trentini F, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1318-5; Vaz OM, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0620; Wagner KS, 2012, EMERG INFECT DIS, V18, P217, DOI 10.3201/eid1802.110987; Will RC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21870-5; World Health Organization, 2020, EPIDATA 7 2020; World Health Organization, 2020, WHO VACC PREV DIS MO; World Health Organization, 2020, GLOBAL TUBERCULOSIS; Zanella B, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030512	48	1	1	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1173	10.3390/vaccines9101173			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO9KN	34696280	Green Published			2022-04-29	WOS:000712764000001
J	Lawal, G; Xiao, Y; Rahnemai-Azar, AA; Tsilimigras, DI; Kuang, M; Bakopoulos, A; Pawlik, TM				Lawal, Gbemisola; Xiao, Yao; Rahnemai-Azar, Amir A.; Tsilimigras, Diamantis I.; Kuang, Ming; Bakopoulos, Anargyros; Pawlik, Timothy M.			The Immunology of Hepatocellular Carcinoma	VACCINES			English	Review						hepatocellular carcinoma; liver cancer; vaccine; immunotherapy; immune checkpoint inhibition; PD-1/PD-L1; combined therapy	CHIMERIC ANTIGEN RECEPTORS; CYTOKINE RELEASE SYNDROME; TUMOR MUTATIONAL BURDEN; INDUCED KILLER-CELLS; T-CELLS; DENDRITIC CELLS; CIK CELLS; CAR-T; IMMUNOTHERAPY; SORAFENIB	Liver cancer is the third leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. Liver resection or transplantation offer the only potentially curative options for HCC; however, many patients are not candidates for surgical resection, either due to presentation at advanced stages or poor liver function and portal hypertension. Liver transplantation is also limited to patients with certain characteristics, such as those that meet the Milan criteria (one tumor & LE; 5 cm, or up to three tumors no larger than 3 cm, along with the absence of gross vascular invasion or extrahepatic spread). Locoregional therapies, such as ablation (radiofrequency, ethanol, cryoablation, microwave), trans-arterial therapies like chemoembolization (TACE) or radioembolization (TARE), and external beam radiation therapy, have been used mainly as palliative measures with poor prognosis. Therefore, emerging novel systemic treatments, such as immunotherapy, have increasingly become popular. HCC is immunogenic, containing infiltrating tumor-specific T-cell lymphocytes and other immune cells. Immunotherapy may provide a more effective and discriminatory targeting of tumor cells through induction of a tumor-specific immune response in cancer cells and can improve post-surgical recurrence-free survival in HCC. We herein review evidence supporting different immunomodulating cell-based technology relative to cancer therapy in vaccines and targeted therapies, such as immune checkpoint inhibitors, in the management of hepatocellular carcinoma among patients with advanced disease.</p>	[Lawal, Gbemisola; Rahnemai-Azar, Amir A.] Calif Univ Sci & Med, Div Surg Oncol, Dept Surg, Arrowhead Reg Canc Ctr, Colton, CA 92324 USA; [Xiao, Yao; Kuang, Ming] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Liver Surg, Guangzhou 510080, Peoples R China; [Tsilimigras, Diamantis I.; Pawlik, Timothy M.] Ohio State Univ, Coll Med, Ohio State Comprehens Canc Ctr, Dept Surg, Columbus, OH 43210 USA; [Bakopoulos, Anargyros] Univ Athens, Attikon Univ Hosp, Dept Surg, Athens 12462, Greece		Tsilimigras, DI (通讯作者)，Ohio State Univ, Coll Med, Ohio State Comprehens Canc Ctr, Dept Surg, Columbus, OH 43210 USA.	msgbemy@yahoo.com; xiaoyao_pumc@126.com; arahnema.azar@gmail.com; diamantis.tsilimigras@osumc.edu; kuangminda@hotmail.com; vincent0@otenet.gr; tim.pawlik@osumc.edu		Xiao, Yao/0000-0003-0062-9813			Abd El Aziz MA, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040616; Agdashian D, 2019, CANCER IMMUNOL IMMUN, V68, P599, DOI 10.1007/s00262-019-02299-8; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Ang Celina, 2019, Oncotarget, V10, P4018, DOI 10.18632/oncotarget.26998; Birgani MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020405; Brunicardi F.C., 2019, SCHWARTZ PRINCIPLES; Byun JS, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/6862439; Cao J, 2019, WORLD J GASTROENTERO, V25, P3649, DOI 10.3748/wjg.v25.i27.3649; Chang BY, 2019, CANCER IMMUNOL IMMUN, V68, P353, DOI 10.1007/s00262-018-2271-4; Chang BY, 2018, LIVER INT, V38, P1449, DOI 10.1111/liv.13697; Chen C, 2017, CANCER IMMUNOL IMMUN, V66, P475, DOI 10.1007/s00262-016-1949-8; Chew V, 2010, J HEPATOL, V52, P370, DOI 10.1016/j.jhep.2009.07.013; Couri T, 2019, HEPATOL INT, V13, P125, DOI 10.1007/s12072-018-9919-1; Dardalhon V, 2010, J IMMUNOL, V185, P1383, DOI 10.4049/jimmunol.0903275; Docta RY, 2019, HEPATOLOGY, V69, P2061, DOI 10.1002/hep.30477; Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678; Duffy AG, 2017, J HEPATOL, V66, P545, DOI 10.1016/j.jhep.2016.10.029; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Feun LG, 2019, CANCER-AM CANCER SOC, V125, P3603, DOI 10.1002/cncr.32339; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Fu YJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1396-4; Gonzalez-Carmona MA, 2006, LIVER INT, V26, P369, DOI 10.1111/j.1478-3231.2005.01235.x; Goodman AM, 2017, MOL CANCER THER, V16, P2598, DOI 10.1158/1535-7163.MCT-17-0386; Goyal L, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-3183; Greten TF, 2019, J HEPATOL, V70, P999, DOI 10.1016/j.jhep.2019.01.027; Gross G, 2016, ANNU REV PHARMACOL, V56, P59, DOI 10.1146/annurev-pharmtox-010814-124844; Guo XL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01118; Harding JJ, 2019, CLIN CANCER RES, V25, P2116, DOI 10.1158/1078-0432.CCR-18-2293; He AR, 2020, J CLIN ONCOL, V38; He GX, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0256-0; Heinrich B, 2018, ONCOL RES TREAT, V41, P292, DOI 10.1159/000488916; Ho WJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000932; Ho WJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000394; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hoseini SS, 2017, CANCER LETT, V399, P44, DOI 10.1016/j.canlet.2017.04.013; Ishiguro T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4291; Jiang RQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15129; Jiang SS, 2015, ONCOTARGET, V6, P41339, DOI 10.18632/oncotarget.5463; Jin HJ, 2017, GASTROENTEROLOGY, V153, P799, DOI 10.1053/j.gastro.2017.05.045; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kawaoka T, 2020, HEPATOL RES, V50, P885, DOI 10.1111/hepr.13496; Keenan BP, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0749-z; Kelley RK, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4073; Kudo M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4072; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li D, 2020, GASTROENTEROLOGY, V158, P2250, DOI 10.1053/j.gastro.2020.02.011; Li KS, 2021, AM J TRANSL RES, V13, P156; Liu H, 2017, CLIN CANCER RES, V23, P478, DOI 10.1158/1078-0432.CCR-16-1203; Liu Q, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001748; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS4152; Lu Z, 2017, J HEPATOL, V67, P739, DOI 10.1016/j.jhep.2017.05.019; Luo XB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00623; Masucci MT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01146; Meng YM, 2017, HUM VACC IMMUNOTHER, V13, P1379, DOI 10.1080/21645515.2017.1285987; Pan Chang-Chuan, 2010, Chin J Cancer, V29, P596; Pan QZ, 2020, CANCER IMMUNOL IMMUN, V69, P825, DOI 10.1007/s00262-020-02486-y; Park R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030447; Patel K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186757; Pinato DJ, 2019, ANN ONCOL, V30, P288; Pinato DJ, 2020, ONCOGENE, V39, P3620, DOI 10.1038/s41388-020-1249-9; Pinato DJ, 2017, J HEPATOL, V66, P338, DOI 10.1016/j.jhep.2016.09.008; Principe N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584423; Qayyum A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0766-y; Rong XX, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1086060; Sepich-Poore GD, 2021, SCIENCE, V371, P1331, DOI 10.1126/science.abc4552; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Shi DH, 2020, CLIN CANCER RES, V26, P3979, DOI 10.1158/1078-0432.CCR-19-3259; Sun B, 2019, CANCER IMMUNOL RES, V7, P1813, DOI 10.1158/2326-6066.CIR-19-0026; Tada F, 2012, INT J ONCOL, V41, P1601, DOI 10.3892/ijo.2012.1626; Tang WW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0187-x; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Tovoli F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040578; Townsend C.M., 2017, SABISTON TXB SURG; Tseng HC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18444-2; Tsuchiya N, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1346764; Vey Norbert, 2018, Oncotarget, V9, P17675, DOI 10.18632/oncotarget.24832; Wan SS, 2014, GASTROENTEROLOGY, V147, P1393, DOI 10.1053/j.gastro.2014.08.039; Wang FS, 2002, WORLD J GASTROENTERO, V8, P464, DOI 10.3748/wjg.v8.i3.464; Wang G, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2509-x; Wang XC, 2019, J HEPATOL, V71, P731, DOI 10.1016/j.jhep.2019.05.015; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Xie YJ, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8740976; Xu F, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0777-4; Xu KY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.581270; Xu XJ, 2014, CANCER LETT, V343, P172, DOI 10.1016/j.canlet.2013.10.004; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yang T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4871-y; Yao RR, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1312-y; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yau T, 2019, ANN ONCOL, V30, P874; Yau T, 2020, JAMA ONCOL, V6, DOI 10.1001/jamaoncol.2020.4564; Yin Z, 2018, J CELL BIOCHEM, V119, P9419, DOI 10.1002/jcb.27259; Zhang PF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01222-5; Zhang RY, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00233; Zhang YS, 2005, WORLD J GASTROENTERO, V11, P3339, DOI 10.3748/wjg.v11.i22.3339; Zhao YH, 2018, CELL PHYSIOL BIOCHEM, V47, P721, DOI 10.1159/000490025; Zheng Y, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0650-9; Zhou GY, 2017, GASTROENTEROLOGY, V153, P1107, DOI 10.1053/j.gastro.2017.06.017; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6; Zhu AX, 2014, JAMA-J AM MED ASSOC, V312, P57, DOI 10.1001/jama.2014.7189; Zhu W, 2018, HEPATOLOGY, V68, P574, DOI 10.1002/hep.29844; Zou F, 2021, MOL THER, V29, P1794, DOI 10.1016/j.ymthe.2021.01.021	103	1	1	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1184	10.3390/vaccines9101184			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS6UR	34696292	Green Published, gold			2022-04-29	WOS:000715314600001
J	Mitsikostas, DD; Aravantinou-Fatorou, K; Deligianni, C; Kravvariti, E; Korompoki, E; Mylona, M; Vryttia, P; Papagiannopoulou, G; Delicha, EM; Dellis, A; Tsivgoulis, G; Dimopoulos, MA; Amanzio, M; Sfikakis, PP				Mitsikostas, Dimos D.; Aravantinou-Fatorou, Konstantina; Deligianni, Christina; Kravvariti, Evrydiki; Korompoki, Eleni; Mylona, Maria; Vryttia, Pinelopi; Papagiannopoulou, Georgia; Delicha, Eumorphia-Maria; Dellis, Athanasios; Tsivgoulis, Georgios; Dimopoulos, Meletios A.; Amanzio, Martina; Sfikakis, Petros P.			Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers	VACCINES			English	Article						SARS-CoV-2; nocebo; vaccine hesitancy; healthcare workers; tolerability; adverse event	PLACEBO; SEX	Among healthcare workers (HCWs), SARS-CoV-2 vaccine hesitancy may be linked to a higher susceptibility to nocebo effects, i.e., adverse events (AEs) experienced after medical treatments due to negative expectations. To investigate this hypothesis a cross-sectional survey was performed with a self-completed questionnaire that included a tool (Q-No) for the identification of nocebo-prone individuals. A total of 1309 HCWs (67.2% women; 43.4% physicians; 28.4% nurses; 11.5% administrative staff; 16.6% other personnel) completed the questionnaires, among whom 237 (18.1%) had declined vaccination. Q-No scores were >= 15 in 325 participants (24.8%) suggesting nocebo-prone behavior. In a multivariate logistic regression model with Q-No score, age, gender, and occupation as independent variables, estimated odds ratios (ORs) of vaccination were 0.43 (i.e., less likely, p < 0.001) in participants with Q-No score >= 15 vs. Q-No score < 15, 0.58 in females vs. males (p = 0.013), and 4.7 (i.e., more likely) in physicians vs. other HCWs (p < 0.001), independent of age, which was not significantly associated with OR of vaccination. At least one adverse effect (AE) was reported by 67.5% of vaccinees, mostly local pain and flu-like symptoms. In a multivariate logistic regression model, with Q-No score, age, gender, and occupation as independent variables, estimated ORs of AE reporting were 2.0 in females vs. males (p < 0.001) and 1.47 in physicians vs. other HCWs (p = 0.017) independently of age and Q-No score, which were not significantly associated with OR of AE. These findings suggest that nocebo-prone behavior in HCWs is associated with SARS-CoV-2 vaccination hesitancy indicating a potential benefit of a campaign focused on nocebo-prone people.	[Mitsikostas, Dimos D.; Aravantinou-Fatorou, Konstantina] Natl & Kapodistrian Univ Athens, Aeginit Hosp, Med Sch, Neurol Dept 1, Athens 11528, Greece; [Deligianni, Christina] Univ Copenhagen, Rigshosp Glostrup, Danish Headache Ctr, DK-2600 Copenhagen, Denmark; [Kravvariti, Evrydiki; Mylona, Maria; Sfikakis, Petros P.] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Joint Rheumatol Program, Dept Propaedeut Internal Med 1,Med Sch, Athens 11527, Greece; [Korompoki, Eleni; Vryttia, Pinelopi; Dimopoulos, Meletios A.] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Med Sch, Dept Clin Therapeut, Athens 11528, Greece; [Papagiannopoulou, Georgia; Tsivgoulis, Georgios] Natl & Kapodistrian Univ Athens, Attikon Hosp, Med Sch, Neurol Dept 2, Athens 12462, Greece; [Delicha, Eumorphia-Maria] ASTAT, Stat Clin Res, Glifadha 16675, Greece; [Dellis, Athanasios] Natl & Kapodistrian Univ Athens, Aretaie Hosp, Med Sch, Surg Dept 2, Athens 11528, Greece; [Amanzio, Martina] Univ Turin, Dept Psychol, Via Verdi 10, I-10124 Turin, Italy		Mitsikostas, DD (通讯作者)，Natl & Kapodistrian Univ Athens, Aeginit Hosp, Med Sch, Neurol Dept 1, Athens 11528, Greece.	dmitsikostas@uoa.gr; k.h.aravantinou@gmail.com; cdchristina@gmail.com; evkrav@med.uoa.gr; e.korompoki@imperial.ac.uk; mamylona@med.uoa.gr; pinelopivrt@gmail.com; georgiapap22@hotmail.com; edelicha@astat.gr; aedellis@gmail.com; tsivgoulisgiorg@yahoo.gr; mdimop@med.uoa.gr; martina.amanzio@unito.it; psfikakis@med.uoa.gr	Amanzio, Martina/A-9085-2010	Amanzio, Martina/0000-0002-2504-032X; Aravantinou-Fatorou, Konstantina/0000-0002-0687-0563; Dimopoulos, Meletios/0000-0001-8990-3254			Amanzio M, 2021, EXPERT REV CLIN PHAR, V14, P439, DOI 10.1080/17512433.2021.1900728; Amanzio M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00100; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Balant LP, 2000, INT J CLIN PHARM TH, V38, P47; Benedetti F, 2019, SEMIN ARTHRITIS RHEU, V49, pS18, DOI 10.1016/j.semarthrit.2019.09.015; Colloca L, 2020, NEW ENGL J MED, V382, P554, DOI 10.1056/NEJMra1907805; Daniali H, 2022, SCAND J PUBLIC HEALT, V50, P61, DOI 10.1177/14034948211018385; Faasse K, 2017, VACCINE, V35, P6872, DOI 10.1016/j.vaccine.2017.10.004; Fragoulis George E, 2020, Mediterr J Rheumatol, V31, P288, DOI 10.31138/mjr.31.3.288; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gao JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231924; Holzmann-Littig C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070777; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Klosterhalfen S, 2009, J PSYCHOSOM RES, V66, P323, DOI 10.1016/j.jpsychores.2008.09.019; Kong J, 2008, J NEUROSCI, V28, P13354, DOI 10.1523/JNEUROSCI.2944-08.2008; Kravvariti Evrydiki, 2019, Mediterr J Rheumatol, V30, P63, DOI 10.31138/mjr.30.1.63; Kravvariti E, 2018, NAT REV RHEUMATOL, V14, P727, DOI 10.1038/s41584-018-0110-9; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mitsikostas DD, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01178-3; Mitsikostas DD, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0813-3; Mitsikostas DD, 2015, NEUROL SCI, V36, P379, DOI 10.1007/s10072-014-1959-2; Okais C, 2011, VACCINE, V29, P6321, DOI 10.1016/j.vaccine.2011.05.045; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Paris C, 2021, INFECT DIS NOW, V51, P484, DOI 10.1016/j.idnow.2021.04.001; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Roberto G, 2014, VACCINE, V32, P3328, DOI 10.1016/j.vaccine.2013.11.051; Scales D, 2021, NEW ENGL J MED, V385, P678, DOI 10.1056/NEJMp2103798; Swider K, 2013, PAIN, V154, P1312, DOI 10.1016/j.pain.2013.04.001; Vambheim SM, 2017, J PAIN RES, V10, P1831, DOI 10.2147/JPR.S134745; Woolf K, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100180; Yiangou A, 2021, HEADACHE, V61, P157, DOI 10.1111/head.14026; Zis P, 2018, INT REV NEUROBIOL, V139, P443, DOI 10.1016/bs.irn.2018.07.025	36	3	3	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1179	10.3390/vaccines9101179			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WU0SQ	34696287	gold, Green Published			2022-04-29	WOS:000716264800001
J	Shukla, M; Chandley, P; Rohatgi, S				Shukla, Manisha; Chandley, Pankaj; Rohatgi, Soma			The Role of B-Cells and Antibodies against Candida Vaccine Antigens in Invasive Candidiasis	VACCINES			English	Review						systemic candidiasis; humoral immunity; B-cells; antibodies; vaccines	SECRETED ASPARTYL PROTEINASES; PROTECTIVE IMMUNE-RESPONSES; HUMAN RECOMBINANT ANTIBODY; HEMATOGENOUSLY DISSEMINATED CANDIDIASIS; GALLERIA-MELLONELLA LARVAE; IGG3 MONOCLONAL-ANTIBODY; ENHANCE MOUSE RESISTANCE; HUMAN DENDRITIC CELLS; N-TERMINAL DOMAIN; BETA-GLUCAN	Systemic candidiasis is an invasive fungal infection caused by members of the genus Candida. The recent emergence of antifungal drug resistance and increased incidences of infections caused by non-albicans Candida species merit the need for developing immune therapies against Candida infections. Although the role of cellular immune responses in anti-Candida immunity is well established, less is known about the role of humoral immunity against systemic candidiasis. This review summarizes currently available information on humoral immune responses induced by several promising Candida vaccine candidates, which have been identified in the past few decades. The protective antibody and B-cell responses generated by polysaccharide antigens such as mannan, beta-glucan, and laminarin, as well as protein antigens like agglutinin-like sequence gene (Als3), secreted aspartyl proteinase (Sap2), heat shock protein (Hsp90), hyphally-regulated protein (Hyr1), hyphal wall protein (Hwp1), enolase (Eno), phospholipase (PLB), pyruvate kinase (Pk), fructose bisphosphate aldolase (Fba1), superoxide dismutase gene (Sod5) and malate dehydrogenase (Mdh1), are outlined. As per studies reviewed, antibodies induced in response to leading Candida vaccine candidates contribute to protection against systemic candidiasis by utilizing a variety of mechanisms such as opsonization, complement fixation, neutralization, biofilm inhibition, direct candidacidal activity, etc. The contributions of B-cells in controlling fungal infections are also discussed. Promising results using anti-Candida monoclonal antibodies for passive antibody therapy reinforces the need for developing antibody-based therapeutics including anti-idiotypic antibodies, single-chain variable fragments, peptide mimotopes, and antibody-derived peptides. Future research involving combinatorial immunotherapies using humanized monoclonal antibodies along with antifungal drugs/cytokines may prove beneficial for treating invasive fungal infections.	[Shukla, Manisha; Chandley, Pankaj; Rohatgi, Soma] Indian Inst Technol Roorkee, Dept Biosci & Bioengn, Roorkee 247667, Utt, India		Rohatgi, S (通讯作者)，Indian Inst Technol Roorkee, Dept Biosci & Bioengn, Roorkee 247667, Utt, India.	mshukla@bt.iitr.ac.in; pankaj_c@bt.iitr.ac.in; soma.rohatgi@bt.iitr.ac.in	Chandley, Pankaj/AGM-2932-2022	CHANDLEY, PANKAJ/0000-0001-7034-7614	Ramalingaswami grant (Dept. of Biotechnology, Govt. of India); Early Career Research Award (Science and Engineering Research Board, Govt. of India); DBT-JRF Fellowship; ICMR-JRF Fellowship	This work was supported by the Ramalingaswami grant (Dept. of Biotechnology, Govt. of India) and Early Career Research Award (Science and Engineering Research Board, Govt. of India) to SR. The authors acknowledge the DBT-JRF Fellowship grant to MS, the ICMR-JRF Fellowship grant to PC, and research and infrastructural facilities at IIT-Roorkee.	Adamo R, 2011, J CARBOHYD CHEM, V30, P249, DOI 10.1080/07328303.2011.604453; Adams AL, 2021, VACCINE, V39, P4099, DOI 10.1016/j.vaccine.2021.06.001; Ahmad S, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9040807; Alqarihi A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42517-y; Antachopoulos C, 2005, BRIT J HAEMATOL, V129, P583, DOI 10.1111/j.1365-2141.2005.05498.x; Aoki W, 2013, PATHOG DIS, V67, P67, DOI 10.1111/2049-632X.12003; Ashman RB, 1999, MICROBIOL-SGM, V145, P1631, DOI 10.1099/13500872-145-7-1631; Bailey DA, 1996, J BACTERIOL, V178, P5353, DOI 10.1128/jb.178.18.5353-5360.1996; Balish E, 1998, J INFECT DIS, V178, P478, DOI 10.1086/515645; Baquir B, 2010, J INFECT DIS, V201, P473, DOI 10.1086/649901; BENO DWA, 1995, J IMMUNOL, V154, P5273; Beucher B, 2009, FEMS IMMUNOL MED MIC, V55, P314, DOI 10.1111/j.1574-695X.2008.00502.x; Bhattacharya S, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9060312; BISTONI F, 1988, J MED VET MYCOL, V26, P285; BOHLER K, 1994, GENITOURIN MED, V70, P182; BORG M, 1988, INFECT IMMUN, V56, P626, DOI 10.1128/IAI.56.3.626-631.1988; Boxx GM, 2009, MOL IMMUNOL, V46, P473, DOI 10.1016/j.molimm.2008.10.008; Brena S, 2007, INFECT IMMUN, V75, P3680, DOI 10.1128/IAI.01840-06; Bromuro C, 2002, INFECT IMMUN, V70, P5462, DOI 10.1128/IAI.70.10.5462-5470.2002; Bromuro C, 2010, VACCINE, V28, P2615, DOI 10.1016/j.vaccine.2010.01.012; Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404; Bugli F, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/403121; Bundle DR, 2018, MOLECULES, V23, DOI 10.3390/molecules23081961; Bundle DR, 2012, ACS CHEM BIOL, V7, P1754, DOI 10.1021/cb300345e; Bystricky S, 2003, IMMUNOL LETT, V85, P251, DOI 10.1016/S0165-2478(02)00241-9; CaesarTonThat TC, 1997, INFECT IMMUN, V65, P5354, DOI 10.1128/IAI.65.12.5354-5357.1997; Calandra T, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1313-6; Capodicasa C, 2011, PLANT BIOTECHNOL J, V9, P776, DOI 10.1111/j.1467-7652.2010.00586.x; Carneiro C, 2016, ACTA BIOMATER, V39, P133, DOI 10.1016/j.actbio.2016.05.001; CARROW EW, 1984, CLIN IMMUNOL IMMUNOP, V33, P371, DOI 10.1016/0090-1229(84)90308-8; Casadevall A, 2002, CURR OPIN MICROBIOL, V5, P386, DOI 10.1016/S1369-5274(02)00337-5; Cassone A, 2005, CURR MOL MED, V5, P377, DOI 10.2174/1566524054022549; CASSONE A, 1995, INFECT IMMUN, V63, P2619, DOI 10.1128/IAI.63.7.2619-2624.1995; Cassone A, 2007, INFECT IMMUN, V75, P4675, DOI 10.1128/IAI.00083-07; Cassone A, 2010, J INFECT DIS, V202, P1930, DOI 10.1086/657417; Chen SM, 2020, EMERG MICROBES INFEC, V9, P2417, DOI 10.1080/22221751.2020.1840927; Chiani P, 2009, VACCINE, V27, P513, DOI 10.1016/j.vaccine.2008.11.030; Chin VK, 2014, BIOMED REP, V2, P869, DOI 10.3892/br.2014.365; Cleary IA, 2011, MICROBIOL-SGM, V157, P1806, DOI 10.1099/mic.0.046326-0; COKER LA, 1992, J LEUKOCYTE BIOL, V51, P305, DOI 10.1002/jlb.51.3.305; Coleman DA, 2009, J MICROBIOL METH, V78, P71, DOI 10.1016/j.mimet.2009.05.002; Conti HR, 2015, J IMMUNOL, V195, P780, DOI 10.4049/jimmunol.1500909; Conti HR, 2010, MICROBES INFECT, V12, P518, DOI 10.1016/j.micinf.2010.03.013; Corouge M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121776; Cutler JE, 2005, CURR MOL MED, V5, P383, DOI 10.2174/1566524054022576; De Bernardis F, 1999, J INFECT DIS, V179, P201, DOI 10.1086/314546; De Bernardis F, 2002, INFECT IMMUN, V70, P2725, DOI 10.1128/IAI.70.5.2725-2729.2002; De Bernardis F, 2000, INFECT IMMUN, V68, P3297, DOI 10.1128/IAI.68.6.3297-3304.2000; De Bernardis F, 2007, J INFECT DIS, V195, P149, DOI 10.1086/509891; De Bernardis F, 2015, PATHOGENS, V4, P697, DOI 10.3390/pathogens4040697; De Bernardis F, 2012, VACCINE, V30, P4490, DOI 10.1016/j.vaccine.2012.04.069; De Bernardis F, 2010, FEMS YEAST RES, V10, P432, DOI 10.1111/j.1567-1364.2010.00620.x; Carvalho Ricardo José Victal de, 2003, Rev. Assoc. Med. Bras., V49, P434; DeBernardis F, 1997, INFECT IMMUN, V65, P3399, DOI 10.1128/IAI.65.8.3399-3405.1997; Delsing CE, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-166; Djordjevic JT, 2010, FRONT MICROBIOL, V1, DOI 10.3389/fmicb.2010.00125; Dong S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32256; Drobacheff C, 2001, CLIN CHEM LAB MED, V39, P519, DOI 10.1515/CCLM.2001.087; Dwivedi P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016218; Edwards JE, 2018, CLIN INFECT DIS, V66, P1928, DOI 10.1093/cid/ciy185; Elhasan LME, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/8280925; Fernandez-Arenas E, 2004, PROTEOMICS, V4, P3007, DOI 10.1002/pmic.200400929; Frohner IE, 2009, MOL MICROBIOL, V71, P240, DOI 10.1111/j.1365-2958.2008.06528.x; Gao Y, 2019, MYCOPATHOLOGIA, V184, P1, DOI 10.1007/s11046-018-0301-6; Gardner Alison, 2007, Clin J Oncol Nurs, V11, P29, DOI 10.1188/07.CJON.29-32; Ghadjari A, 1997, FEMS IMMUNOL MED MIC, V19, P115, DOI 10.1111/j.1574-695X.1997.tb01080.x; Ghannoum MA, 2000, CLIN MICROBIOL REV, V13, P122, DOI 10.1128/CMR.13.1.122-143.2000; Gil-Bona A, 2015, J PROTEOME RES, V14, P142, DOI 10.1021/pr5007944; Gintjee TJ, 2020, J FUNGI, V6, DOI 10.3390/jof6010028; Gozalbo D, 2009, FRONT BIOSCI-LANDMRK, V14, P1970, DOI 10.2741/3356; Hamad M, 2012, MYCOSES, V55, P205, DOI 10.1111/j.1439-0507.2011.02078.x; Han Y, 1997, INFECT IMMUN, V65, P4100, DOI 10.1128/IAI.65.10.4100-4107.1997; Han Y, 1999, J INFECT DIS, V179, P1477, DOI 10.1086/314779; Han Y, 2000, INFECT IMMUN, V68, P1649, DOI 10.1128/IAI.68.3.1649-1654.2000; HAN YM, 1995, INFECT IMMUN, V63, P2714, DOI 10.1128/IAI.63.7.2714-2719.1995; Han YM, 2001, J IMMUNOL, V167, P1550, DOI 10.4049/jimmunol.167.3.1550; Han YM, 1998, INFECT IMMUN, V66, P5771, DOI 10.1128/IAI.66.12.5771-5776.1998; Han Y, 2012, ARCH PHARM RES, V35, P2021, DOI 10.1007/s12272-012-1120-9; Haraguchi N, 2010, INFECT IMMUN, V78, P2302, DOI 10.1128/IAI.01398-09; Harpf V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01471; He ZX, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00920; Heilmann CJ, 2011, MICROBIOL-SGM, V157, P2297, DOI 10.1099/mic.0.049395-0; Hernandez-Santos N, 2012, CELL HOST MICROBE, V11, P425, DOI 10.1016/j.chom.2012.04.008; Hoogeboom R, 2013, J EXP MED, V210, P59, DOI 10.1084/jem.20121801; Hoyer LL, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00280; Huai YY, 2016, ADV HEALTHC MATER, V5, P786, DOI 10.1002/adhm.201500930; Huang HB, 2010, MBIO, V1, DOI 10.1128/mBio.00164-10; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Hube B, 1997, INFECT IMMUN, V65, P3529, DOI 10.1128/IAI.65.9.3529-3538.1997; Huppler AR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3893; Ibrahim AS, 2006, INFECT IMMUN, V74, P3039, DOI 10.1128/IAI.74.5.3039-3041.2006; Ibrahim AS, 2005, INFECT IMMUN, V73, P999, DOI 10.1128/IAI.73.2.999-1005.2005; Ibrahim AS, 2013, VACCINE, V31, P5549, DOI 10.1016/j.vaccine.2013.09.016; Ishibashi K, 2005, FEMS IMMUNOL MED MIC, V44, P99, DOI 10.1016/j.femsim.2004.12.012; Ishibashi K., 2010, Japanese Journal of Medical Mycology, V51, P99, DOI 10.3314/jjmm.51.99; JENSEN J, 1993, J INFECT DIS, V167, P912, DOI 10.1093/infdis/167.4.912; JENSEN J, 1994, J INFECT DIS, V170, P900, DOI 10.1093/infdis/170.4.900; JonesCarson J, 1997, J IMMUNOL, V158, P4328; Jouault T, 1997, CLIN DIAGN LAB IMMUN, V4, P328, DOI 10.1128/CDLI.4.3.328-333.1997; Kabir ME, 2011, APPL MICROBIOL BIOT, V92, P1151, DOI 10.1007/s00253-011-3412-2; Kaposzta R, 1999, ADV CELL MOL BIOL ME, V6, P317, DOI 10.1016/S1874-5172(99)80018-2; Karwa R, 2009, ANN PHARMACOTHER, V43, P1818, DOI 10.1345/aph.1M218; Knotigova PT, 2015, PHARM RES-DORDR, V32, P1186, DOI 10.1007/s11095-014-1516-y; Konig A, 2020, TOXINS, V12, DOI 10.3390/toxins12080469; Kozel TR, 2004, INFECT IMMUN, V72, P209, DOI 10.1128/IAI.72.1.209-218.2004; Kullberg BJ, 2015, NEW ENGL J MED, V373, P1445, DOI 10.1056/NEJMra1315399; Kumar H, 2009, J IMMUNOL, V183, P8061, DOI 10.4049/jimmunol.0902477; Lain A, 2007, CLIN VACCINE IMMUNOL, V14, P318, DOI 10.1128/CVI.00396-06; LeibundGut-Landmann S, 2012, CURR OPIN IMMUNOL, V24, P449, DOI 10.1016/j.coi.2012.04.007; Leidich SD, 1998, J BIOL CHEM, V273, P26078, DOI 10.1074/jbc.273.40.26078; Leu SJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082903; Li FQ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-253; Li MM, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02977-5; Li R, 2017, J IMMUNOL, V198, P3245, DOI 10.4049/jimmunol.1601572; Li W, 2007, CELL MICROBIOL, V9, P306, DOI 10.1111/j.1462-5822.2006.00786.x; Li WJ, 2013, CLIN VACCINE IMMUNOL, V20, P582, DOI 10.1128/CVI.00689-12; Li WQ, 2011, VACCINE, V29, P5526, DOI 10.1016/j.vaccine.2011.05.030; Li XZ, 2021, INT J BIOL MACROMOL, V173, P327, DOI 10.1016/j.ijbiomac.2021.01.105; Liao GC, 2016, ACS INFECT DIS, V2, P123, DOI 10.1021/acsinfecdis.5b00104; Liao GC, 2015, BIOCONJUGATE CHEM, V26, P466, DOI 10.1021/bc500575a; Liao J, 2019, EUR J MED CHEM, V173, P250, DOI 10.1016/j.ejmech.2019.04.001; Lilly EA, 2018, MBIO, V9, DOI 10.1128/mBio.01472-17; Lin L, 2008, CLIN VACCINE IMMUNOL, V15, P582, DOI 10.1128/CVI.00427-07; Lin L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000703; Lin L, 2009, FEMS IMMUNOL MED MIC, V55, P293, DOI 10.1111/j.1574-695X.2008.00531.x; Lionakis MS, 2014, MED MYCOL, V52, P555, DOI 10.1093/mmy/myu029; Lionakis MS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003079; Lipinski T, 2013, J IMMUNOL, V190, P4116, DOI 10.4049/jimmunol.1202937; Lipinski T, 2012, VACCINE, V30, P6263, DOI 10.1016/j.vaccine.2012.08.010; Lipinski T, 2011, BIOCONJUGATE CHEM, V22, P274, DOI 10.1021/bc100397b; Londono LP, 2000, FEMS IMMUNOL MED MIC, V27, P117, DOI 10.1016/S0928-8244(99)00175-3; Lopez-Ribot JL, 2004, FEMS IMMUNOL MED MIC, V41, P187, DOI 10.1016/j.femsim.2004.03.012; Louie A, 2011, ANTIMICROB AGENTS CH, V55, P3295, DOI 10.1128/AAC.01324-10; Medrano-Diaz CL, 2018, MICROB PATHOGENESIS, V124, P21, DOI 10.1016/j.micpath.2018.08.024; Luo GPS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025909; Luo G, 2010, J INFECT DIS, V201, P1718, DOI 10.1086/652407; MACDONALD F, 1980, J MED MICROBIOL, V13, P423, DOI 10.1099/00222615-13-3-423; Machova E, 2015, J MICROBIOL BIOTECHN, V25, P1177, DOI 10.4014/jmb.1410.10050; Machova E, 2008, Z NATURFORSCH C, V63, P909; Magliani W, 2008, FRONT BIOSCI-LANDMRK, V13, P6920, DOI 10.2741/3199; MAITI PK, 1985, MYCOPATHOLOGIA, V91, P79, DOI 10.1007/BF00436540; MANGENEY M, 1989, CELL IMMUNOL, V122, P329, DOI 10.1016/0008-8749(89)90081-6; Martchenko M, 2004, MOL BIOL CELL, V15, P456, DOI 10.1091/mbc.E03-03-0179; Masek J, 2011, J CONTROL RELEASE, V151, P193, DOI 10.1016/j.jconrel.2011.01.016; MATTHEWS R, 1992, IMMUNOL TODAY, V13, P345, DOI 10.1016/0167-5699(92)90169-8; MATTHEWS R, 1991, J IMMUNOL METHODS, V143, P73, DOI 10.1016/0022-1759(91)90274-J; MATTHEWS R, 1995, J INFECT DIS, V171, P1668, DOI 10.1093/infdis/171.6.1668; MATTHEWS RC, 1991, IMMUNOLOGY, V74, P20; Matthews RC, 2003, ANTIMICROB AGENTS CH, V47, P2208, DOI 10.1128/AAC.47.7.2208-2216.2003; Matveev AL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215535; Mayer FL, 2013, VIRULENCE, V4, P119, DOI 10.4161/viru.22913; Medici NP, 2015, MEM I OSWALDO CRUZ, V110, P966, DOI 10.1590/0074-02760150335; Mencacci A, 1998, J EXP MED, V187, P307, DOI 10.1084/jem.187.3.307; Mencacci A., 2000, Current Pharmaceutical Biotechnology, V1, P235, DOI 10.2174/1389201003378924; Mikulska M, 2010, CRIT CARE, V14, DOI 10.1186/cc9365; Millon L, 2001, J ACQ IMMUN DEF SYND, V26, P137, DOI 10.1097/00126334-200102010-00005; Montagnoli C, 2004, MED MYCOL, V42, P319, DOI 10.1080/13693780310001644653; Mowlds P, 2010, MICROBES INFECT, V12, P146, DOI 10.1016/j.micinf.2009.11.004; Mukherjee PK, 2001, MICROBIOL-SGM, V147, P2585, DOI 10.1099/00221287-147-9-2585; Murciano C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033362; Naglik JR, 2003, MICROBIOL MOL BIOL R, V67, P400, DOI 10.1128/MMBR.67.3.400-428.2003; Naglik JR, 2006, J MED MICROBIOL, V55, P1323, DOI 10.1099/jmm.0.46737-0; Nami S, 2019, BIOMED PHARMACOTHER, V110, P857, DOI 10.1016/j.biopha.2018.12.009; Netea MG, 2004, MICROBES INFECT, V6, P985, DOI 10.1016/j.micinf.2004.05.013; Netea MG, 2003, EUR J IMMUNOL, V33, P3409, DOI 10.1002/eji.200323737; Netea MG, 1999, J IMMUNOL, V163, P1498; Netea MG, 2015, NAT REV IMMUNOL, V15, P630, DOI 10.1038/nri3897; Newman SL, 2001, INFECT IMMUN, V69, P6813, DOI 10.1128/IAI.69.11.6813-6822.2001; Ngo LY, 2014, J INFECT DIS, V209, P109, DOI 10.1093/infdis/jit413; Nishiya CT, 2016, INFECT IMMUN, V84, P386, DOI 10.1128/IAI.00890-15; Nobile CJ, 2006, PLOS PATHOG, V2, P636, DOI 10.1371/journal.ppat.0020063; Nur S, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008115; Oykhman P, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/249482; Pachl J, 2006, CLIN INFECT DIS, V42, P1404, DOI 10.1086/503428; Papon N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003550; Pappas PC, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.26; Pathakumari B, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110550; Paulovicova E, 2007, INT IMMUNOPHARMACOL, V7, P1325, DOI 10.1016/j.intimp.2007.05.014; Paulovicova E, 2016, CELL MICROBIOL, V18, P1294, DOI 10.1111/cmi.12631; Paulovicova L, 2013, SCAND J IMMUNOL, V77, P431, DOI 10.1111/sji.12044; Paulovicova L, 2019, FEMS YEAST RES, V19, DOI 10.1093/femsyr/foz009; Paulovicova L, 2015, J MICROBIOL IMMUNOL, V48, P9, DOI 10.1016/j.jmii.2013.08.020; Paulovicova L, 2012, INT IMMUNOPHARMACOL, V14, P179, DOI 10.1016/j.intimp.2012.07.004; Paulovicova L, 2010, FEMS IMMUNOL MED MIC, V58, P307, DOI 10.1111/j.1574-695X.2009.00642.x; Pericolini E, 2015, MBIO, V6, DOI 10.1128/mBio.00724-15; Phan QT, 2007, PLOS BIOL, V5, P543, DOI 10.1371/journal.pbio.0050064; Pietrella D, 2010, VACCINE, V28, P1717, DOI 10.1016/j.vaccine.2009.12.021; Pitarch A, 2001, PROTEOMICS, V1, P550, DOI 10.1002/1615-9861(200104)1:4<550::AID-PROT550>3.0.CO;2-W; Polonelli L, 2003, INFECT IMMUN, V71, P6205, DOI 10.1128/IAI.71.11.6205-6212.2003; Polonelli L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105727; QIAN QF, 1994, J IMMUNOL, V152, P5000; Quintin J, 2014, EUR J IMMUNOL, V44, P2405, DOI 10.1002/eji.201343828; Rachini A, 2007, INFECT IMMUN, V75, P5085, DOI 10.1128/IAI.00278-07; Rahman D, 2007, MICROBES INFECT, V9, P615, DOI 10.1016/j.micinf.2007.01.012; Rapaka RR, 2010, J EXP MED, V207, P2907, DOI 10.1084/jem.20100034; Raska M, 2005, FOLIA MICROBIOL, V50, P77, DOI 10.1007/BF02931297; Raska M, 2008, MED MYCOL, V46, P411, DOI 10.1080/13693780701883508; Richardson JP, 2015, VIRULENCE, V6, P327, DOI 10.1080/21505594.2015.1004977; Richie DL, 2012, ANTIMICROB AGENTS CH, V56, P3963, DOI 10.1128/AAC.00435-12; Robinett NG, 2019, J BIOL CHEM, V294, P2700, DOI 10.1074/jbc.RA118.007095; ROILIDES E, 1995, J LEUKOCYTE BIOL, V57, P651, DOI 10.1002/jlb.57.4.651; Romagnoli G, 2004, J LEUKOCYTE BIOL, V75, P117, DOI 10.1189/jlb.0503226; ROMANI L, 1992, INFECT IMMUN, V60, P4950, DOI 10.1128/IAI.60.11.4950-4952.1992; Romani L, 1999, CURR OPIN MICROBIOL, V2, P363, DOI 10.1016/S1369-5274(99)80064-2; ROMANI L, 1994, EUR J IMMUNOL, V24, P909, DOI 10.1002/eji.1830240419; Romani Luigina, 2007, P1, DOI 10.1007/978-1-4020-6397-8_1; Romani L, 2015, SEMIN IMMUNOPATHOL, V37, P163, DOI 10.1007/s00281-014-0464-2; Rosario-Colon J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22116162; Rudkin FM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07738-1; Sandini S, 2011, FEMS IMMUNOL MED MIC, V62, P215, DOI 10.1111/j.1574-695X.2011.00802.x; Sanglard D, 1997, INFECT IMMUN, V65, P3539, DOI 10.1128/IAI.65.9.3539-3546.1997; Santoni G, 2002, INFECT IMMUN, V70, P4791, DOI 10.1128/IAI.70.9.4791-4797.2002; Satala D, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8071046; Schatzman SS, 2020, J BIOL CHEM, V295, P570, DOI 10.1074/jbc.RA119.011084; Schmidt CS, 2012, VACCINE, V30, P7594, DOI 10.1016/j.vaccine.2012.10.038; Schmidt S, 2013, CLIN VACCINE IMMUNOL, V20, P452, DOI 10.1128/CVI.00606-12; Selvakumar D, 2006, BIOL PHARM BULL, V29, P1848, DOI 10.1248/bpb.29.1848; Sendid B, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90402-4; Seo Beom-Seok, 2013, Immune Netw, V13, P205, DOI 10.4110/in.2013.13.5.205; Sheehan G, 2018, VIRULENCE, V9, P163, DOI 10.1080/21505594.2017.1370174; Shen H, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01648; Shi HX, 2018, VACCINE, V36, P5717, DOI 10.1016/j.vaccine.2018.08.011; Shibasaki S, 2018, PROTEOMES, V6, DOI 10.3390/proteomes6030034; Shibasaki S, 2014, BIOCONTROL SCI, V19, P51, DOI 10.4265/bio.19.51; Shibasaki S, 2013, PATHOG DIS, V69, P262, DOI 10.1111/2049-632X.12068; Shukla M, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00312-20; Silva RC, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00066; Singh S, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007460; SINHA BK, 1987, ZBL BAKT-INT J MED M, V266, P316; Smolenski G, 1997, MICROBIOL-SGM, V143, P349, DOI 10.1099/00221287-143-2-349; SPACCAPELO R, 1995, J IMMUNOL, V155, P1349; Spellberg B, 2005, J INFECT DIS, V192, P336, DOI 10.1086/430952; Spellberg BJ, 2006, J INFECT DIS, V194, P256, DOI 10.1086/504691; Spellberg BJ, 2005, INFECT IMMUN, V73, P6191, DOI 10.1128/IAI.73.9.6191-6193.2005; Spellberg B, 2008, INFECT IMMUN, V76, P4574, DOI 10.1128/IAI.00700-08; Spellberg B, 2008, J INFECT DIS, V197, P967, DOI 10.1086/529204; Staib P, 2008, ANTIMICROB AGENTS CH, V52, P146, DOI 10.1128/AAC.01072-07; Stuyt RJL, 2002, INFECT IMMUN, V70, P3284, DOI 10.1128/IAI.70.6.3284-3286.2002; Suenobu N, 2002, VACCINE, V20, P2972, DOI 10.1016/S0264-410X(02)00218-9; Sui X, 2017, VACCINE, V35, P5786, DOI 10.1016/j.vaccine.2017.08.082; SUNDSTROM P, 1994, J INFECT DIS, V170, P390, DOI 10.1093/infdis/170.2.390; SWOBODA RK, 1993, INFECT IMMUN, V61, P4263, DOI 10.1128/IAI.61.10.4263-4271.1993; Theiss S, 2006, INT J MED MICROBIOL, V296, P405, DOI 10.1016/j.ijmm.2006.03.003; Tian R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060779; Torosantucci A, 2005, J EXP MED, V202, P597, DOI 10.1084/jem.20050749; Torosantucci A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02977-6; Torosantucci A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005392; Tso GHW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00897; Tsoni SV, 2009, INFECT IMMUN, V77, P3679, DOI 10.1128/IAI.00233-09; Tsuchimori N, 2000, INFECT IMMUN, V68, P1997, DOI 10.1128/IAI.68.4.1997-2002.2000; Unsinger J, 2012, J INFECT DIS, V206, P606, DOI 10.1093/infdis/jis383; Uppuluri P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01349; Uppuluri P, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007056; van de Veerdonk FL, 2012, CLIN MICROBIOL INFEC, V18, P112, DOI 10.1111/j.1469-0691.2011.03676.x; de Veerdonk FLV, 2010, CURR FUNGAL INFECT R, V4, P238, DOI 10.1007/s12281-010-0034-6; van de Veerdonk FL, 2011, ARTHRITIS RHEUM-US, V63, P1507, DOI 10.1002/art.30314; van de Veerdonk FL, 2010, SHOCK, V34, P407, DOI 10.1097/SHK.0b013e3181d67041; van Deventer Hanneke J., 1996, Clin Microbiol Infect, V2, P36; Van Enckevort FHJ, 1999, MED MYCOL, V37, P419, DOI 10.1046/j.1365-280X.1999.00247.x; Vilanova M, 2004, IMMUNOLOGY, V111, P334, DOI 10.1111/j.1365-2567.2004.01819.x; Voigt J, 2018, EUR J IMMUNOL, V48, P1456, DOI 10.1002/eji.201747450; Vonk AG, 2006, J INFECT DIS, V193, P1419, DOI 10.1086/503363; Vonk AG, 2006, EXPERT OPIN BIOL TH, V6, P891, DOI 10.1517/14712598.6.9.891; VUDHICHAMNONG K, 1982, ARCH ORAL BIOL, V27, P617, DOI 10.1016/0003-9969(82)90184-4; Wagner RD, 1996, J INFECT DIS, V174, P589, DOI 10.1093/infdis/174.3.589; Wang GY, 2006, VACCINE, V24, P6065, DOI 10.1016/j.vaccine.2006.05.022; Wang XJ, 2015, VIRULENCE, V6, P309, DOI 10.4161/21505594.2014.983015; Wang YC, 2014, HUM VACC IMMUNOTHER, V10, P1057, DOI 10.4161/hv.27714; Warnock David W, 2007, Nihon Ishinkin Gakkai Zasshi, V48, P1, DOI 10.3314/jjmm.48.1; Whibley N, 2015, J IMMUNOL, V195, P3781, DOI 10.4049/jimmunol.1500870; Whibley N, 2015, CYTOKINE, V76, P42, DOI 10.1016/j.cyto.2015.07.025; WHITE TC, 1993, J BACTERIOL, V175, P6126, DOI 10.1128/JB.175.19.6126-6133.1993; WHITE TC, 1995, J BACTERIOL, V177, P5215, DOI 10.1128/jb.177.18.5215-5221.1995; Whitney PG, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004276; Wu XY, 2008, CHEM-EUR J, V14, P6474, DOI 10.1002/chem.200800352; Wu XY, 2007, ORG BIOMOL CHEM, V5, P3477, DOI 10.1039/b709912f; Xin H, 2008, P NATL ACAD SCI USA, V105, P13526, DOI 10.1073/pnas.0803195105; Xin H, 2019, VACCINE, V37, P2430, DOI 10.1016/j.vaccine.2019.03.061; Xin H, 2016, VACCINE, V34, P245, DOI 10.1016/j.vaccine.2015.11.035; Xin H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035106; Xin H, 2011, CLIN VACCINE IMMUNOL, V18, P1656, DOI 10.1128/CVI.05215-11; Xu Meilan, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P1030; Yang F, 2016, CARBOHYD POLYM, V145, P48, DOI 10.1016/j.carbpol.2016.03.024; Yang Q, 2005, VACCINE, V23, P4088, DOI 10.1016/j.vaccine.2004.07.005; Yeaman MR, 2014, P NATL ACAD SCI USA, V111, pE5555, DOI 10.1073/pnas.1415610111; Youssef EG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00076; Zhang MX, 2006, INFECT IMMUN, V74, P362, DOI 10.1128/IAI.74.1.362-369.2006; Zhang MX, 1997, INFECT IMMUN, V65, P3822, DOI 10.1128/IAI.65.9.3822-3827.1997; Zhang MX, 1998, INFECT IMMUN, V66, P6027, DOI 10.1128/IAI.66.12.6027-6029.1998; Zito A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148714	290	2	2	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1159	10.3390/vaccines9101159			38	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WT2KC	34696267	gold, Green Published			2022-04-29	WOS:000715696800001
J	Chiu, LC; Lin, SM; Lo, YL; Kuo, SCH; Yang, CT; Hsu, PC				Chiu, Li-Chung; Lin, Shu-Min; Lo, Yu-Lun; Kuo, Scott Chih-Hsi; Yang, Cheng-Ta; Hsu, Ping-Chih			Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)	VACCINES			English	Review						immunotherapy; programmed death-ligand 1 (PD-L1); cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); immune checkpoint inhibitor; non-small cell lung cancer (NSCLC); cancer vaccination; early stage; surgery	NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; PHASE-III; NEOADJUVANT IMMUNOTHERAPY; 1ST-LINE TREATMENT; ADJUVANT CHEMOTHERAPY; SINGLE-ARM; MULTICENTER; DURVALUMAB; THERAPY	Early-stage NSCLC (stages I and II, and some IIIA diseases) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases, with surgery being its main treatment modality. The risk of disease recurrence and cancer-related death, however, remains high among NSCLC patients after complete surgical resection. In previous studies on the long-term follow-up of post-operative NSCLC, the results showed that the five-year survival rate was about 65% for stage IB and about 35% for stage IIIA diseases. Platinum-based chemotherapy with or without radiation therapy has been used as a neoadjuvant therapy or post-operative adjuvant therapy in NSCLC, but the improvement of survival is limited. Immune checkpoint inhibitors (ICIs) have effectively improved the 5-year survival of advanced NSCLC patients. Cancer vaccination has also been explored and used in the prevention of cancer or reducing disease recurrence in resected NSCLC. Here, we review studies that have focused on the use of immunotherapies (i.e., ICIs and vaccination) in surgically resectable NSCLC. We present the results of completed clinical trials that have used ICIs as neoadjuvant therapies in pre-operative NSCLC. Ongoing clinical trials investigating ICIs as neoadjuvant and adjuvant therapies are also summarized.	[Chiu, Li-Chung; Lin, Shu-Min; Lo, Yu-Lun; Kuo, Scott Chih-Hsi; Yang, Cheng-Ta; Hsu, Ping-Chih] Chang Gung Mem Hosp Linkou, Coll Med, Dept Internal Med, Div Thorac Med, Taoyuan 33305, Taiwan; [Chiu, Li-Chung] New Taipei Municipal Tu Cheng Hosp, Dept Thorac Med, New Taipei 23652, Taiwan; [Chiu, Li-Chung; Lin, Shu-Min; Lo, Yu-Lun; Kuo, Scott Chih-Hsi; Yang, Cheng-Ta; Hsu, Ping-Chih] Chang Gung Univ, Coll Med, Dept Med, Taoyuan 33302, Taiwan; [Yang, Cheng-Ta] Taoyuan Chang Gung Mem Hosp, Dept Internal Med, Taoyuan 33378, Taiwan; [Yang, Cheng-Ta] Chang Gung Univ, Coll Med, Dept Resp Therapy, Taoyuan 33302, Taiwan		Hsu, PC (通讯作者)，Chang Gung Mem Hosp Linkou, Coll Med, Dept Internal Med, Div Thorac Med, Taoyuan 33305, Taiwan.; Hsu, PC (通讯作者)，Chang Gung Univ, Coll Med, Dept Med, Taoyuan 33302, Taiwan.	pomd54@cgmh.org.tw; smlin100@gmail.com; loyulun@hotmail.com; chihhsikuo@gmail.com; yang1946@cgmh.org.tw; 8902049@adm.cgmh.org.tw	Hsu, Ping-Chih/AAS-7146-2020	Hsu, Ping-Chih/0000-0003-0173-7509; Chiu, Li-Chung/0000-0003-1660-7715; Yang, Cheng-Ta/0000-0003-1846-1027; Kuo, Chih-Hsi Scott/0000-0003-3309-937X	Taiwan Ministry of Science and Technology (MOST) [109-2628-B-182A-009]; Chang-Gung Medical Research Project [CMRPG3K1561, CMRPG3K1151]	This work was supported by the Taiwan Ministry of Science and Technology (MOST; grant no. 109-2628-B-182A-009 to P.C.H.) and the Chang-Gung Medical Research Project (grant no. CMRPG3K1561 to P.C.H.; grant nos. CMRPG3K1151 to L.C.C.).	Ahern E, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002248; Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6; Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Aredo JV, 2021, J THORAC ONCOL, V16, P1030, DOI 10.1016/j.jtho.2021.01.1628; Aurisicchio L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02228-9; Baas P, 2021, LANCET, V397, P375, DOI 10.1016/S0140-6736(20)32714-8; Baghba R, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0530-4; Bai RL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.575472; Barlesi F, 2018, LANCET ONCOL, V19, P1468, DOI 10.1016/S1470-2045(18)30673-9; Battiloro C, 2018, EXPERT OPIN PHARMACO, V19, P1403, DOI 10.1080/14656566.2018.1510915; Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; Belluomini L, 2019, ONCOL THER, V7, P83, DOI 10.1007/s40487-019-0092-z; Bersanelli M, 2020, NEW ENGL J MED, V382, P874, DOI 10.1056/NEJMc1916859; Besse B, 2020, ANN ONCOL, V31, pS794, DOI 10.1016/j.annonc.2020.08.1417; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Bondarenko I, 2018, ANN ONCOL, V29, P596; Broderick SR, 2020, THORAC SURG CLIN, V30, P215, DOI 10.1016/j.thorsurg.2020.01.001; Brunelli A., 2019, ANN ONCOL, V30, P30, DOI [10.1093/annonc/mdz064.014, DOI 10.1093/ANNONC/MDZ064.014]; Buonaguro L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040615; Califano R, 2014, LUNG CANCER, V85, P74, DOI 10.1016/j.lungcan.2014.03.010; Calles A, 2019, CLIN TRANSL ONCOL, V21, P961, DOI 10.1007/s12094-018-02011-9; Cao MM, 2019, THORAC CANCER, V10, P3, DOI 10.1111/1759-7714.12916; Carter BW, 2018, CANCER-AM CANCER SOC, V124, P2906, DOI 10.1002/cncr.31349; Cascone T, 2021, NAT MED, V27, P504, DOI 10.1038/s41591-020-01224-2; Cascone T, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-1719; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Chan HT, 2019, ONCOL THER, V7, P1, DOI 10.1007/s40487-018-0090-6; Chang WY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192161; Cheever MA, 2011, CLIN CANCER RES, V17, P3520, DOI 10.1158/1078-0432.CCR-10-3126; Chen Y, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07206-4; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Choi YJ, 2020, THORAC CANCER, V11, P2793, DOI 10.1111/1759-7714.13594; Cuzzubbo S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615240; de Looff M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01530; Donington JS, 2018, J THORAC ONCOL, V13, P767, DOI 10.1016/j.jtho.2018.04.002; Eichhorn F, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5624-2; Faivre-Finn C, 2021, J THORAC ONCOL, V16, P860, DOI 10.1016/j.jtho.2020.12.015; Falcone M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00569; Felip E, 2018, J THORAC ONCOL, V13, pS831, DOI 10.1016/j.jtho.2018.08.1478; Ferrara MG, 2020, CANCERS, V12, DOI 10.3390/cancers12051196; Finn OJ, 2018, NAT REV IMMUNOL, V18, P183, DOI 10.1038/nri.2017.140; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Gagliasso M, 2017, LUNG CANCER, V111, P124, DOI 10.1016/j.lungcan.2017.07.013; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gao SG, 2020, J THORAC ONCOL, V15, P816, DOI 10.1016/j.jtho.2020.01.017; Goldman JW, 2021, LANCET ONCOL, V22, P51, DOI 10.1016/S1470-2045(20)30539-8; Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009; Gotwals P, 2017, NAT REV CANCER, V17, P286, DOI 10.1038/nrc.2017.17; Gridelli C, 2015, NAT REV DIS PRIMERS, V1, DOI [10.1038/nrdp.2015.9, 10.1038/nrdp.2015.48]; Gubens MA, 2019, LUNG CANCER, V130, P59, DOI 10.1016/j.lungcan.2018.12.015; Guisier F, 2020, J THORAC ONCOL, V15, P628, DOI 10.1016/j.jtho.2019.12.129; Hammers HJ, 2017, J CLIN ONCOL, V35, P3851, DOI 10.1200/JCO.2016.72.1985; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Heymach J, 2019, J THORAC ONCOL, V14, pS625, DOI 10.1016/j.jtho.2019.08.1318; Hirschowitz EA, 2007, LUNG CANCER, V57, P365, DOI 10.1016/j.lungcan.2007.04.002; Hirschowitz EA, 2011, J THORAC ONCOL, V6, P169, DOI 10.1097/JTO.0b013e3181fb5c22; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Hong MH, 2021, J THORAC ONCOL, V16, pS194; Hopstaken Jana S, 2021, Cancer Treat Res Commun, V28, P100404, DOI 10.1016/j.ctarc.2021.100404; Hsu PC, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110331; Hsu PC, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8020036; Hsu PC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153821; Hsu PC, 2019, THORAC CANCER, V10, P1683, DOI 10.1111/1759-7714.13125; Inaba-Higashiyama R, 2020, THORAC CANCER, V11, P3618, DOI 10.1111/1759-7714.13713; Indini A, 2021, CANCERS, V13, DOI 10.3390/cancers13081794; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; Jia XH, 2020, LUNG CANCER, V147, P143, DOI 10.1016/j.lungcan.2020.07.001; Jou J, 2021, CLIN CANCER RES, V27, P689, DOI 10.1158/1078-0432.CCR-20-0245; Kartolo Adi, 2021, Cancer Treat Res Commun, V27, P100330, DOI 10.1016/j.ctarc.2021.100330; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim JY, 2019, CANCERS, V11, DOI 10.3390/cancers11111699; Kris Mark G, 2020, Am Soc Clin Oncol Educ Book, V40, P1, DOI 10.1200/EDBK_280807; Kris MG, 2017, J CLIN ONCOL, V35, P2960, DOI 10.1200/JCO.2017.72.4401; Labani-Motlagh A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00940; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lin CY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186567; Lorenzo-Luaces P, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07284-4; Mazieres J, 2019, ANN ONCOL, V30, P1321, DOI 10.1093/annonc/mdz167; McIntyre A, 2017, J SURG ONCOL, V115, P550, DOI 10.1002/jso.24532; Metro G, 2020, ONCOL THER, V8, P341, DOI 10.1007/s40487-020-00121-5; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Mougel A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00467; Nasser NJ, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110373; Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6; Nishino M, 2019, RADIOLOGY, V290, P9, DOI 10.1148/radiol.2018181349; Ogunleyea F., 2017, CANC TREAT RES COMMU, V12, P6, DOI [10.1016/j.ctarc.2017.05.002, DOI 10.1016/J.CTARC.2017.05.002]; Okazaki T, 2006, TRENDS IMMUNOL, V27, P195, DOI 10.1016/j.it.2006.02.001; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Owonikoko TK, 2021, J CLIN ONCOL, V39, P1349, DOI 10.1200/JCO.20.02212; Oya Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072623; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Passiglia F, 2016, ONCOTARGET, V7, P19738, DOI 10.18632/oncotarget.7582; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0; Pirker R, 2019, CLIN LUNG CANCER, V20, P1, DOI 10.1016/j.cllc.2018.09.016; Planchard D, 2020, ANN ONCOL, V31, P609, DOI 10.1016/j.annonc.2020.02.006; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Provencio M, 2020, LANCET ONCOL, V21, P1413, DOI 10.1016/S1470-2045(20)30453-8; Reck M, 2019, LANCET RESP MED, V7, P387, DOI 10.1016/S2213-2600(19)30084-0; Reck M, 2016, J CLIN ONCOL, V34, P3740, DOI 10.1200/JCO.2016.67.6601; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Reuss JE, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001282; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Ribas A, 2010, SEMIN ONCOL, V37, P450, DOI 10.1053/j.seminoncol.2010.09.010; Rizvi NA, 2020, JAMA ONCOL, V6, P661, DOI 10.1001/jamaoncol.2020.0237; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rodriguez PC, 2016, CLIN CANCER RES, V22, P3782, DOI 10.1158/1078-0432.CCR-15-0855; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Salazar MC, 2017, JAMA ONCOL, V3, P610, DOI 10.1001/jamaoncol.2016.5829; Schiavon M, 2021, ANN THORAC SURG, V112, P1805, DOI 10.1016/j.athoracsur.2020.12.029; Sezer A, 2021, LANCET, V397, P592, DOI 10.1016/S0140-6736(21)00228-2; Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Solomon BJ, 2019, J CLIN ONCOL, V37; Spigel DR, 2021, ANN ONCOL, V32, P631, DOI 10.1016/j.annonc.2021.01.071; Suh JW, 2019, THORAC CANCER, V10, P1241, DOI 10.1111/1759-7714.13074; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Tanaka I, 2020, CLIN LUNG CANCER, V21, P273, DOI 10.1016/j.cllc.2020.01.011; Tran T, 2019, SEMIN IMMUNOPATHOL, V41, P69, DOI 10.1007/s00281-018-0691-z; Uprety D, 2020, J THORAC ONCOL, V15, P1281, DOI 10.1016/j.jtho.2020.05.020; Vaddepally RK, 2020, CANCERS, V12, DOI 10.3390/cancers12030738; Vansteenkiste J, 2013, J CLIN ONCOL, V31, P2396, DOI 10.1200/JCO.2012.43.7103; Verma N, 2017, CLIN EXP IMMUNOL, V190, P1, DOI 10.1111/cei.12997; Verschraegen CF, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001064; Wang L, 2021, ONCOL REP, V45, P13, DOI 10.3892/or.2020.7851; Wei H, 2019, CANCER MED-US, V8, P5399, DOI 10.1002/cam4.2464; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Wislez M, 2020, ANN ONCOL, V31, pS794, DOI 10.1016/j.annonc.2020.08.1416; Wu YL, 2020, NEW ENGL J MED, V383, P1711, DOI 10.1056/NEJMoa2027071; Yang LT, 2020, J CELL MOL MED, V24, P11056, DOI 10.1111/jcmm.15743; You WJ, 2020, ONCOL REP, V44, P424, DOI 10.3892/or.2020.7643; Zhang HJ, 2019, J CELL MOL MED, V23, P535, DOI 10.1111/jcmm.13956; Zhang L, 2020, THORAC CANCER, V11, P1170, DOI 10.1111/1759-7714.13370; Zhao J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01184	143	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							689	10.3390/vaccines9070689			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5GX	34201650	Green Published			2022-04-29	WOS:000676941000001
J	Tifrea, DF; He, W; Pal, S; Evans, AC; Gilmore, SF; Fischer, NO; Rasley, A; Coleman, MA; de la Maza, LM				Tifrea, Delia F.; He, Wei; Pal, Sukumar; Evans, Angela C.; Gilmore, Sean F.; Fischer, Nicholas O.; Rasley, Amy; Coleman, Matthew A.; de la Maza, Luis M.			Induction of Protection in Mice against a Chlamydia muridarum Respiratory Challenge by a Vaccine Formulated with the Major Outer Membrane Protein in Nanolipoprotein Particles	VACCINES			English	Article						Chlamydia; vaccine; immunization; mice; nanolipoprotein particles; major outer membrane protein; intranasal challenge; telodisks; amphipols	UPPER GENITAL-TRACT; IMMUNE-RESPONSE; TRACHOMATIS INFECTION; RESOLUTION; IMMUNIZATION; ELICIT; PURIFICATION; INFERTILITY; ENHANCEMENT; ANTIBODIES	Chlamydia trachomatis is a sexually transmitted bacterium that infects over 130 million individuals worldwide annually. To implement a vaccine, we developed a cell-free co-translational system to express the Chlamydia muridarum major outer membrane protein (MOMP). This approach uses a nanolipoprotein particles (tNLP) made from ApoA1 protein, amphiphilic telodendrimer and lipids that self-assemble to form 10-25 nm discs. These tNLP provide a protein-encapsulated lipid support to solubilize and fold membrane proteins. The cell-free system co-translated MOMP and ApoA1 in the presence of telodendrimer mixed with lipids. The MOMP-tNLP complex was amenable to CpG and FSL-1 adjuvant addition. To investigate the ability of MOMP-tNLP+CpG+FSL-1 to induce protection against an intranasal (i.n.) C. muridarum challenge, female mice were vaccinated intramuscularly (i.m.) or i.n. and i.m. simultaneously 4 weeks apart. Following vaccination with MOMP-tNLP+CpG+FSL-1, mice mounted significant humoral and cell-mediated immune responses. Following the i.n. challenge, mice vaccinated with MOMP-tNLP+CpG+FSL-1 i.n. + i.m. group were protected as determined by the percentage change in body weight and by the number of C. muridarum inclusion forming units (IFU) recovered from the lungs. To our knowledge, this is the first time a MOMP-based vaccine formulated in tNLP has been shown to protect against C. muridarum.	[Tifrea, Delia F.; Pal, Sukumar; de la Maza, Luis M.] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA; [He, Wei; Evans, Angela C.; Gilmore, Sean F.; Fischer, Nicholas O.; Rasley, Amy; Coleman, Matthew A.] Lawrence Livermore Natl Lab, Phys & Life Sci Directorate, Livermore, CA 94551 USA; [Coleman, Matthew A.] Univ Calif Davis, Sch Med, Radiat Oncol, Sacramento, CA 95616 USA		de la Maza, LM (通讯作者)，Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.	dtifrea@uci.edu; he4@llnl.gov; spal@uci.edu; evans98@llnl.gov; gilmore24@llnl.gov; fischer29@llnl.gov; rasley2@llnl.gov; coleman16@llnl.gov; lmdelama@uci.edu	Fischer, Nicholas/AAE-2409-2019	Fischer, Nicholas/0000-0001-7575-4390; Rasley, Amy/0000-0002-4767-6628; Coleman, Matthew/0000-0003-1389-4018; He, Wei/0000-0003-2795-0324	Public Health Service grant from the National Institute of Allergy and Infectious Diseases [R21 AI20925, U19 AI144184]; U.S. Department of Energy by Lawrence Livermore National LaboratoryUnited States Department of Energy (DOE) [DE-AC52-07NA27344]	This research was funded by Public Health Service grant R21 AI20925 and U19 AI144184 from the National Institute of Allergy and Infectious Diseases. This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.	Abraham S, 2019, LANCET INFECT DIS, V19, P1091, DOI 10.1016/S1473-3099(19)30279-8; BAEHR W, 1988, P NATL ACAD SCI USA, V85, P4000, DOI 10.1073/pnas.85.11.4000; Blanchette CD, 2008, J LIPID RES, V49, P1420, DOI 10.1194/jlr.M700586-JLR200; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Brunham RC, 2005, J INFECT DIS, V192, P1836, DOI 10.1086/497341; BRUNHAM RC, 1983, INFECT IMMUN, V39, P1491, DOI 10.1128/IAI.39.3.1491-1494.1983; Brunham RC, 2020, PATHOG DIS, V78, DOI 10.1093/femspd/ftaa023; Brunham RC, 2020, PATHOG DIS, V78, DOI 10.1093/femspd/ftaa022; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; CALDWELL HD, 1982, INFECT IMMUN, V35, P1024, DOI 10.1128/IAI.35.3.1024-1031.1982; Carmichael JR, 2011, VACCINE, V29, P5276, DOI 10.1016/j.vaccine.2011.05.013; CDC, 2021, PSEUDOMONAS AERUGINO, P1; Cheng CM, 2014, MICROBES INFECT, V16, P244, DOI 10.1016/j.micinf.2013.11.009; Cheng CM, 2011, VACCINE, V29, P6641, DOI 10.1016/j.vaccine.2011.06.105; Cunha BA, 1998, DRUGS TODAY, V34, P1005, DOI 10.1358/dot.1998.34.12.487485; Darville T, 2013, ADV EXP MED BIOL, V764, P109, DOI 10.1007/978-1-4614-4726-9_8; de la Maza LM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00543-16, 10.1128/cvi.00543-16]; De La Maza Michael A., 1995, Vaccine, V13, P119, DOI 10.1016/0264-410X(95)80022-6; Donati M, 2003, VACCINE, V21, P1089, DOI 10.1016/S0264-410X(02)00631-X; Farris CM, 2011, INFECT IMMUN, V79, P986, DOI 10.1128/IAI.00881-10; Farris CM, 2010, INFECT IMMUN, V78, P4374, DOI 10.1128/IAI.00622-10; Fischer NO, 2013, J AM CHEM SOC, V135, P2044, DOI 10.1021/ja3063293; Geisler WM, 2013, J INFECT DIS, V207, P1850, DOI 10.1093/infdis/jit094; Gottlieb SL, 2016, VACCINE, V34, P2939, DOI 10.1016/j.vaccine.2016.03.111; Gotz H, 2002, SCAND J INFECT DIS, V34, P28, DOI 10.1080/00365540110077001; Haggerty CL, 2010, J INFECT DIS, V201, pS134, DOI 10.1086/652395; Harandi AM, 2009, EXPERT REV VACCINES, V8, P293, DOI 10.1586/14760584.8.3.293; Hasegawa H, 2005, J MED VIROL, V75, P130, DOI 10.1002/jmv.20247; He W, 2017, J BIOL CHEM, V292, P15121, DOI 10.1074/jbc.M117.784561; He W, 2013, PROTEIN SCI, V22, P1078, DOI 10.1002/pro.2292; Kelly KA, 2000, INFECT IMMUN, V68, P1519, DOI 10.1128/IAI.68.3.1519-1528.2000; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; Morrison SG, 2005, J IMMUNOL, V175, P7536, DOI 10.4049/jimmunol.175.11.7536; Morrison SG, 2001, INFECT IMMUN, V69, P2643, DOI 10.1128/IAI.69.4.2643-2649.2001; Murthy AK, 2007, INFECT IMMUN, V75, P666, DOI 10.1128/IAI.01280-06; Newman L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143304; Nigg Clara, 1942, SCIENCE, V95, P49, DOI 10.1126/science.95.2454.49-a; Numazaki K, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-2; Olsen AW, 2015, J INFECT DIS, V212, P978, DOI 10.1093/infdis/jiv137; Olsen AW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01652; Ortiz L, 2000, INFECT IMMUN, V68, P1719, DOI 10.1128/IAI.68.3.1719-1723.2000; PAL S, 1994, INFECT IMMUN, V62, P3354, DOI 10.1128/IAI.62.8.3354-3362.1994; Pal S, 2005, INFECT IMMUN, V73, P8153, DOI 10.1128/IAI.73.12.8153-8160.2005; Pal S, 2001, INFECT IMMUN, V69, P6240, DOI 10.1128/IAI.69.10.6240-6247.2001; Pal S., 2020, NPJ VACCINES, V5, P90, DOI [10.1038/s41541-020-00239-7, DOI 10.1038/s41541-020-00239-7]; Pal S, 2020, HUM VACC IMMUNOTHER, V16, P2537, DOI 10.1080/21645515.2020.1717183; PETERSON EM, 1988, INFECT IMMUN, V56, P885, DOI 10.1128/IAI.56.4.885-891.1988; Phillips S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00070; Ralli-Jain P, 2010, VACCINE, V28, P7659, DOI 10.1016/j.vaccine.2010.09.040; SCHACHTER J, 1978, NEW ENGL J MED, V298, P428, DOI 10.1056/NEJM197802232980805; Stamm W., 2008, SEX TRANSM DIS, P575; STEPHENS RS, 1988, J EXP MED, V167, P817, DOI 10.1084/jem.167.3.817; Sun GF, 2009, VACCINE, V27, P5020, DOI 10.1016/j.vaccine.2009.05.008; Tifrea DF, 2020, J INFECT DIS, V221, P191, DOI 10.1093/infdis/jiz438; Tifrea DF, 2014, J IMMUNOL, V192, P5201, DOI 10.4049/jimmunol.1303392; Tifrea DF, 2011, VACCINE, V29, P4623, DOI 10.1016/j.vaccine.2011.04.065; Weilhammer D, 2017, VACCINE, V35, P1475, DOI 10.1016/j.vaccine.2017.02.004; Weilhammer DR, 2013, BIOMATERIALS, V34, P10305, DOI 10.1016/j.biomaterials.2013.09.038; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; Yu H, 2016, EXPERT REV VACCINES, V15, P977, DOI 10.1586/14760584.2016.1161510; Yu H, 2014, VACCINE, V32, P4672, DOI 10.1016/j.vaccine.2014.06.002; Zhong GM, 2019, VACCINE, V37, P7346, DOI 10.1016/j.vaccine.2017.10.075	62	1	1	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							755	10.3390/vaccines9070755			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6HH	34358171	Green Published, gold			2022-04-29	WOS:000677009600001
J	Cheng, HY; Peng, ZC; Luo, WL; Si, ST; Mo, MJ; Zhou, HB; Xin, X; Liu, H; Yu, YX				Cheng, Haoyue; Peng, Zhicheng; Luo, Wenliang; Si, Shuting; Mo, Minjia; Zhou, Haibo; Xin, Xing; Liu, Hui; Yu, Yunxian			Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis	VACCINES			English	Article						COVID-19; vaccine; efficacy; safety; meta-analysis	IMMUNOGENICITY	Nowadays, the vaccination with COVID-19 vaccines is being promoted worldwide, professionals and common people are very concerned about the efficacy and safety of COVID-19 vaccines. No published systematic review and meta-analysis has assessed the efficacy and safety of the COVID-19 vaccines based on data from phase III clinical trials. Therefore, this study has estimated the efficacy and safety of COVID-19 vaccines and the differences between vaccine types. PubMed, Embase, the Cochrane Library, CNKI, Wanfang, medRxiv databases and two websites were used to retrieve the studies. Random-effects models were used to estimate the pooled efficacy and safety with risk ratio (RR). A total of eight studies, seven COVID-19 vaccines and 158,204 subjects were included in the meta-analysis. All the vaccines had a good preventive effect on COVID-19 (RR = 0.17, 95% CI: 0.09-0.32), and the mRNA vaccine (RR = 0.05, 95% CI: 0.03-0.09) was the most effective against COVID-19, while the inactivated vaccine (RR = 0.32, 95% CI: 0.19-0.54) was the least. In terms of safety, the risk of overall adverse events showed an increase in the vaccine group after the first (RR = 1.46, 95% CI: 1.03-2.05) or second (RR = 1.52, 95% CI: 1.04-2.20) injection. However, compared with the first injection, the risk of local (RR = 2.64, 95% CI: 1.02-6.83 vs. RR = 2.25, 95% CI: 0.52-9.75) and systemic (RR = 1.33, 95% CI: 1.21-1.46 vs. RR = 1.59, 95% CI: 0.84-3.01) adverse events decreased after the second injection. As for the mRNA vaccine, the risk of overall adverse events increased significantly, compared with the placebo, no matter whether it was the first (RR = 1.83, 95% CI = 1.80-1.86) or the second (RR = 2.16, 95% CI = 2.11-2.20) injection. All the COVID-19 vaccines that have published the data of phase III clinical trials have excellent efficacy, and the risk of adverse events is acceptable. The mRNA vaccines were the most effective against COVID-19, meanwhile the risk and grade of adverse events was minimal, compared to that of severe symptoms induced by COVID-19.	[Cheng, Haoyue; Peng, Zhicheng; Luo, Wenliang; Si, Shuting; Mo, Minjia; Zhou, Haibo; Xin, Xing; Yu, Yunxian] Zhejiang Univ, Dept Publ Hlth, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Peoples R China; [Cheng, Haoyue; Peng, Zhicheng; Luo, Wenliang; Si, Shuting; Mo, Minjia; Zhou, Haibo; Xin, Xing; Yu, Yunxian] Zhejiang Univ, Dept Anesthesiol, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Peoples R China; [Cheng, Haoyue; Peng, Zhicheng; Luo, Wenliang; Si, Shuting; Mo, Minjia; Zhou, Haibo; Xin, Xing; Yu, Yunxian] Zhejiang Univ, Sch Publ Hlth, Sch Med, Dept Epidemiol & Hlth Stat, Hangzhou 310058, Peoples R China; [Liu, Hui] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310016, Peoples R China		Yu, YX (通讯作者)，Zhejiang Univ, Dept Publ Hlth, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Peoples R China.; Yu, YX (通讯作者)，Zhejiang Univ, Dept Anesthesiol, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Peoples R China.; Yu, YX (通讯作者)，Zhejiang Univ, Sch Publ Hlth, Sch Med, Dept Epidemiol & Hlth Stat, Hangzhou 310058, Peoples R China.	3150101365@zju.edu.cn; 22018678@zju.edu.cn; 21918155@zju.edu.cn; 21818499@zju.edu.cn; minjiamo@zju.edu.cn; 11918158@zju.edu.cn; 21818488@zju.edu.cn; lhui2010@zju.edu.cn; yunxianyu@zju.edu.cn		mo, minjia/0000-0002-1932-8423	Chinese National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81973055]; Major research and development projects of Zhejiang science and Technology Department [2018C03010]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities	This study was funded by Chinese National Natural Science Foundation, grant number 81973055; Major research and development projects of Zhejiang science and Technology Department, grant number 2018C03010 and the Fundamental Research Funds for the Central Universities.	Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Alturki SO, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01880; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Chen YY, 2021, AGEING RES REV, V65, DOI 10.1016/j.arr.2020.101205; Chung YH, 2020, ACS NANO, V14, P12522, DOI 10.1021/acsnano.0c07197; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Higgins J.P.T., 2011, COCHRANE HDB SYSTEMA; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Kirby T, 2021, LANCET RESP MED, V9, pE20, DOI 10.1016/S2213-2600(21)00005-9; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Luyten J, 2016, HEALTH AFFAIR, V35, P212, DOI 10.1377/hlthaff.2015.1088; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Narayanan D.K.L., 2021, INT J PHARM RES, V13, P4588, DOI 10.31838/ijpr/2021.13.01.666; Novelli G, 2020, HUM GENOMICS, V14, DOI 10.1186/s40246-020-00298-w; Palacios R., 2021, SSRN, P66, DOI [10.2139/ssrn.3822780, DOI 10.2139/SSRN.3822780]; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Parker EPK, 2020, NAT REV IMMUNOL, V20, P650, DOI 10.1038/s41577-020-00455-1; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rogliani P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030227; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Soleimanpour S, 2021, EXPERT REV VACCINES, V20, P23, DOI [10.1080/14760584.2021.1875824, 10.1080/14760584.2021.1875824CrossMarkLogo]; Stone CA, 2019, BRIT J CLIN PHARMACO, V85, P2694, DOI 10.1111/bcp.14112; Stone PW, 2002, APPL NURS RES, V15, P197, DOI 10.1053/apnr.2002.34181; Tang JLW, 2021, J INFECTION, V82, pE8, DOI 10.1016/j.jinf.2021.01.007; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang FZ, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.924700; World Health Organization, DRAFT LANDSC COVID 1; Yuan Ping, 2020, medRxiv, DOI 10.1101/2020.11.03.20224998	39	13	13	22	49	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							582	10.3390/vaccines9060582			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ8EY	34206032	Green Published, gold			2022-04-29	WOS:000666792500001
J	Nunez, N; Reot, L; Menu, E				Nunez, Natalia; Reot, Louis; Menu, Elisabeth			Neonatal Immune System Ontogeny: The Role of Maternal Microbiota and Associated Factors. How Might the Non-Human Primate Model Enlighten the Path?	VACCINES			English	Review						microbiota; immune system maturation; colonization; non-human primate; pregnancy; birth; breastfeeding; weaning; vaccination; probiotics	INFLAMMATORY-BOWEL-DISEASE; HUMAN-MILK MICROBIOME; REGULATORY T-CELLS; GUT MICROBIOTA; EARLY-LIFE; INTESTINAL MICROBIOTA; VAGINAL MICROBIOTA; AMNIOTIC-FLUID; CESAREAN DELIVERY; PRETERM LABOR	Interactions between the immune system and the microbiome play a crucial role on the human health. These interactions start in the prenatal period and are critical for the maturation of the immune system in newborns and infants. Several factors influence the composition of the infant's microbiota and subsequently the development of the immune system. They include maternal infection, antibiotic treatment, environmental exposure, mode of delivery, breastfeeding, and food introduction. In this review, we focus on the ontogeny of the immune system and its association to microbial colonization from conception to food diversification. In this context, we give an overview of the mother-fetus interactions during pregnancy, the impact of the time of birth and the mode of delivery, the neonate gastrointestinal colonization and the role of breastfeeding, weaning, and food diversification. We further review the impact of the vaccination on the infant's microbiota and the reciprocal case. Finally, we discuss several potential therapeutic interventions that might help to improve the newborn and infant's health and their responses to vaccination. Throughout the review, we underline the main scientific questions that are left to be answered and how the non-human primate model could help enlighten the path.	[Nunez, Natalia; Reot, Louis; Menu, Elisabeth] Univ Paris Sud, IDMIT Dept, CEA,Inserm, IBFJ,Immunol Viral Infect & Autoimmune Dis IMVA H, F-92265 Fontenay Aux Roses, France; [Menu, Elisabeth] Inst Pasteur, Dept Virol, MISTIC Grp, F-75015 Paris, France; [Nunez, Natalia] Life & Soft, F-92060 Plessis Robinso, France		Menu, E (通讯作者)，Univ Paris Sud, IDMIT Dept, CEA,Inserm, IBFJ,Immunol Viral Infect & Autoimmune Dis IMVA H, F-92265 Fontenay Aux Roses, France.; Menu, E (通讯作者)，Inst Pasteur, Dept Virol, MISTIC Grp, F-75015 Paris, France.	nnunez@lifeandsoft.com; louis.reot@cea.fr; elisabeth.menu@cea.fr	Menu, Elisabeth/B-2886-2010	Menu, Elisabeth/0000-0001-8844-9328; Reot, Louis/0000-0003-1786-369X; NUNEZ, Natalia/0000-0003-1494-3205			Aagaard K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008599; Aagaard K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036466; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Adlerberth I, 2006, PEDIATR RES, V59, P96, DOI 10.1203/01.pdr.0000191137.12774.b2; Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969; Al Nabhani Z, 2020, MUCOSAL IMMUNOL, V13, P183, DOI 10.1038/s41385-020-0257-y; Al Nabhani Z, 2019, IMMUNITY, V50, P1276, DOI 10.1016/j.immuni.2019.02.014; Andrade SE, 2004, AM J OBSTET GYNECOL, V191, P398, DOI 10.1016/j.ajog.2004.04.025; Apostol AC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00123; Ardeshir A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008791; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Backhed F, 2015, CELL HOST MICROBE, V17, P690, DOI [10.1016/j.chom.2015.04.004, 10.1016/j.chom.2015.05.012]; Bailey MT, 2004, J PEDIATR GASTR NUTR, V38, P414, DOI 10.1097/00005176-200404000-00009; Baldwin EA, 2015, PEERJ, V3, DOI 10.7717/peerj.1398; Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288; Batchelder CA, 2014, ANAT REC, V297, P1392, DOI 10.1002/ar.22943; Belkaid Y, 2017, IMMUNITY, V46, P562, DOI 10.1016/j.immuni.2017.04.008; Bergstrom A, 2014, APPL ENVIRON MICROB, V80, P2889, DOI 10.1128/AEM.00342-14; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Bjorksten B, 2012, VACCINE, V30, P4336, DOI 10.1016/j.vaccine.2011.10.074; Brace RA, 1997, CLIN OBSTET GYNECOL, V40, P280, DOI 10.1097/00003081-199706000-00005; Brantsaeter AL, 2011, AM J EPIDEMIOL, V174, P807, DOI 10.1093/aje/kwr168; Brown RG, 2018, BMC MED, V16, DOI 10.1186/s12916-017-0999-x; Burbacher TM, 2013, AM J PRIMATOL, V75, P1063, DOI 10.1002/ajp.22175; Cabrera-Rubio R, 2012, AM J CLIN NUTR, V96, P544, DOI 10.3945/ajcn.112.037382; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Calder PC, 2006, BRIT J NUTR, V96, P1, DOI [10.1079/BJN20061917, 10.1079/BJN20061881]; Collado MC, 2016, SCI REP-UK, V6, DOI 10.1038/srep23129; Castellote C, 2011, J NUTR, V141, P1181, DOI 10.3945/jn.110.133652; CATASSI C, 1995, J PEDIATR GASTR NUTR, V21, P383, DOI 10.1097/00005176-199511000-00003; Chassin C, 2010, CELL HOST MICROBE, V8, P358, DOI 10.1016/j.chom.2010.09.005; Christilaw JE, 2006, INT J GYNECOL OBSTET, V94, P262, DOI 10.1016/j.ijgo.2006.04.006; Clemente JC, 2012, CELL, V148, P1258, DOI 10.1016/j.cell.2012.01.035; Coe CL, 2013, RES VET SCI, V94, P549, DOI 10.1016/j.rvsc.2012.11.017; Contractor N, 2007, J IMMUNOL, V179, P2690, DOI 10.4049/jimmunol.179.5.2690; Dauby N, 2012, LANCET INFECT DIS, V12, P330, DOI 10.1016/S1473-3099(11)70341-3; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; Dettmer AM, 2019, AM J PRIMATOL, V81, DOI 10.1002/ajp.22969; Dierikx TH, 2020, J INFECTION, V81, P190, DOI 10.1016/j.jinf.2020.05.002; Dominguez-Bello MG, 2016, NAT MED, V22, P250, DOI 10.1038/nm.4039; Ebersole JL, 2014, CLIN VACCINE IMMUNOL, V21, P21, DOI 10.1128/CVI.00291-13; Edwards SM, 2017, MCN-AM J MATERN-CHIL, V42, P310, DOI 10.1097/NMC.0000000000000372; Elizaldi SR, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00824-19; Fernandez L, 2013, PHARMACOL RES, V69, P1, DOI 10.1016/j.phrs.2012.09.001; Fettweis JM, 2019, NAT MED, V25, P1012, DOI 10.1038/s41591-019-0450-2; Freitas AC, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0502-8; Freitas AR, 2009, APPL ENVIRON MICROB, V75, P4904, DOI 10.1128/AEM.02945-08; Garcia-Lopez R, 2012, PEDIATR INFECT DIS J, V31, P1300, DOI 10.1097/INF.0b013e318269e3ec; Gardner MB, 2008, ILAR J, V49, P220, DOI 10.1093/ilar.49.2.220; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Gibbons D, 2014, NAT MED, V20, P1206, DOI 10.1038/nm.3670; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Goksor E, 2013, PEDIAT ALLERG IMM-UK, V24, P339, DOI 10.1111/pai.12078; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Golos Thaddeus G, 2004, Reprod Biol Endocrinol, V2, P35, DOI 10.1186/1477-7827-2-35; Gomez-Gallego C, 2016, SEMIN FETAL NEONAT M, V21, P400, DOI 10.1016/j.siny.2016.05.003; Gopalakrishna KP, 2019, NAT MED, V25, P1110, DOI 10.1038/s41591-019-0480-9; Gopinath B, 2012, PUBLIC HEALTH NUTR, V15, P1639, DOI 10.1017/S1368980011003569; Gosalbes MJ, 2013, CLIN EXP ALLERGY, V43, P198, DOI 10.1111/cea.12063; Grier A., 2020, BIORXIV 736090, DOI [10.1101/736090, DOI 10.1101/736090]; Gronlund MM, 2011, GUT MICROBES, V2, P227, DOI 10.4161/gmic.2.4.16799; Han QF, 2020, CELL REP, V30, P1553, DOI 10.1016/j.celrep.2019.12.091; Harris VC, 2017, J INFECT DIS, V215, P34, DOI 10.1093/infdis/jiw518; Hasegawa Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34019-0; He X, 2016, MSYSTEMS, V1, DOI 10.1128/mSystems.00128-16; Hobbs Amy J, 2016, BMC Pregnancy Childbirth, V16, P90, DOI 10.1186/s12884-016-0876-1; HOBBS JR, 1967, LANCET, V1, P757, DOI 10.1016/S0140-6736(67)91369-4; Hornef MW, 2020, IMMUNOLOGY, V159, P15, DOI 10.1111/imm.13149; Huda MN, 2014, PEDIATRICS, V134, pE362, DOI 10.1542/peds.2013-3937; ISOLAURI E, 1995, VACCINE, V13, P310, DOI 10.1016/0264-410X(95)93319-5; Ivarsson A, 2000, ACTA PAEDIATR, V89, P165, DOI 10.1080/080352500750028771; Ivarsson A, 2013, PEDIATRICS, V131, pE687, DOI 10.1542/peds.2012-1015; Jacobsson B, 2003, ACTA OBSTET GYN SCAN, V82, P423, DOI 10.1034/j.1600-0412.2003.00157.x; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Janiak MC, 2021, MICROBIOME, V9, DOI 10.1186/s40168-021-01009-w; Jarde A, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-017-1629-5; Jarrett P, 2019, EARLY HUM DEV, V135, P51, DOI 10.1016/j.earlhumdev.2019.05.015; Jeurink PV, 2013, BENEF MICROBES, V4, P17, DOI 10.3920/BM2012.0040; Jimenez E, 2005, CURR MICROBIOL, V51, P270, DOI 10.1007/s00284-005-0020-3; Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51; Knoop KA, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aao1314; Koch S, 2004, VACCINE, V22, P822, DOI 10.1016/j.vaccine.2003.11.027; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Kollmann T, 2017, SEMIN IMMUNOPATHOL, V39, P575, DOI 10.1007/s00281-017-0657-6; Koren O, 2012, CELL, V150, P470, DOI 10.1016/j.cell.2012.07.008; KROHN MA, 1995, J INFECT DIS, V171, P1475, DOI 10.1093/infdis/171.6.1475; Krusche J, 2020, SEMIN IMMUNOPATHOL, V42, P29, DOI 10.1007/s00281-019-00774-z; Kuhle S, 2015, OBES REV, V16, P295, DOI 10.1111/obr.12267; Lacroix I, 2009, EUR J CLIN PHARMACOL, V65, P839, DOI 10.1007/s00228-009-0647-2; Laimighofer M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42750-5; Laouar A, 2020, TRENDS IMMUNOL, V41, P225, DOI 10.1016/j.it.2020.01.005; Laursen MF, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00356; Lee CI, 2001, PEDIATR RES, V49, P379, DOI 10.1203/00006450-200103000-00012; Li A, 2014, SCI REP-UK, V4, DOI 10.1038/srep07417; Liao SL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07894-2; Liao ZJ, 2020, ARCH DIS CHILD, V105, P664, DOI 10.1136/archdischild-2019-317485; Lindsay KL, 2014, AM J CLIN NUTR, V99, P1432, DOI 10.3945/ajcn.113.079723; Lluis A, 2014, J ALLERGY CLIN IMMUN, V133, P551, DOI 10.1016/j.jaci.2013.06.034; Lonnerdal B, 2010, J PEDIATR-US, V156, pS26, DOI 10.1016/j.jpeds.2009.11.017; Lotz M, 2006, J EXP MED, V203, P973, DOI 10.1084/jem.20050625; Ma JR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72635-x; Ma J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4889; Magne F, 2006, FEMS MICROBIOL ECOL, V58, P563, DOI 10.1111/j.1574-6941.2006.00182.x; Magwira CA, 2018, VACCINE, V36, P3427, DOI 10.1016/j.vaccine.2018.04.091; Malek A, 1997, AM J REPROD IMMUNOL, V38, P263; Mao KR, 2018, NATURE, V554, P255, DOI 10.1038/nature25437; Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470; Mazzola G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157527; Melville JM, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00079; Menjoge AR, 2010, BIOMATERIALS, V31, P5007, DOI 10.1016/j.biomaterials.2010.02.075; Miller JE, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003429; Miyoshi J, 2017, CELL REP, V20, P491, DOI 10.1016/j.celrep.2017.06.060; Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511; Mold JE, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000383; Moles JP, 2018, PEDIAT ALLERG IMM-UK, V29, P133, DOI 10.1111/pai.12841; Muletz-Wolz CR, 2019, AM J PRIMATOL, V81, DOI 10.1002/ajp.22994; Mullie C, 2004, PEDIATR RES, V56, P791, DOI 10.1203/01.PDR.0000141955.47550.A0; Murphy K, 2017, SCI REP-UK, V7, DOI 10.1038/srep40597; Musich T, 2020, J VIROL, V94, DOI 10.1128/JVI.01225-20; Myhre R, 2011, AM J CLIN NUTR, V93, P151, DOI 10.3945/ajcn.110.004085; Narayan NR, 2015, GUT MICROBES, V6, P284, DOI 10.1080/19490976.2015.1067743; Novy MJ, 2009, REPROD SCI, V16, P56, DOI 10.1177/1933719108325508; Nugeyre MT, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00188; O'Neill I, 2017, EMERG TOP LIFE SCI, V1, P333, DOI 10.1042/ETLS20170058; Oikonomou G, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00060; Olin A, 2018, CELL, V174, P1277, DOI 10.1016/j.cell.2018.06.045; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Park HK, 2005, J MICROBIOL, V43, P345; Parnanen K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06393-w; Perez PF, 2007, PEDIATRICS, V119, pE724, DOI 10.1542/peds.2006-1649; Petersen I, 2010, J ANTIMICROB CHEMOTH, V65, P2238, DOI 10.1093/jac/dkq307; Petrova MI, 2017, TRENDS MICROBIOL, V25, P182, DOI 10.1016/j.tim.2016.11.007; Pichler K, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02484; Postler TS, 2017, CELL METAB, V26, P110, DOI 10.1016/j.cmet.2017.05.008; Pott J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002670; Prior E, 2012, AM J CLIN NUTR, V95, P1113, DOI 10.3945/ajcn.111.030254; Quan CP, 1999, AM J REPROD IMMUNOL, V42, P219; Rastogi D, 2007, J CLIN INVEST, V117, P1637, DOI 10.1172/JCI29466; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Rendina DN, 2019, J PEDIATR GASTR NUTR, V69, P363, DOI 10.1097/MPG.0000000000002394; Rhoades N, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1789-x; Richards M, 2020, ANN ALLERG ASTHMA IM, V125, P280, DOI 10.1016/j.anai.2020.04.028; Richards M, 2020, CLIN EXP ALLERGY, V50, P805, DOI 10.1111/cea.13668; Ritz N, 2013, VACCINE, V31, P3098, DOI 10.1016/j.vaccine.2013.03.059; Rodriguez JM, 2014, ADV NUTR, V5, P779, DOI 10.3945/an.114.007229; Romero R, 2001, PAEDIATR PERINAT EP, V15, P41, DOI 10.1046/j.1365-3016.2001.00007.x; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P817, DOI 10.1016/0002-9378(89)90409-2; Romero R, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-18; Romero R, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-4; Russell SL, 2013, GUT MICROBES, V4, P158, DOI 10.4161/gmic.23567; Rutayisire E, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0498-0; Scharschmidt TC, 2015, IMMUNITY, V43, P1011, DOI 10.1016/j.immuni.2015.10.016; SCHNEIDER ML, 1992, INFANT BEHAV DEV, V15, P389, DOI 10.1016/0163-6383(92)80009-J; Schulfer AF, 2018, NAT MICROBIOL, V3, P234, DOI 10.1038/s41564-017-0075-5; Seedat F, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1432-3; Selma-Royo M, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-00940-8; Sevelsted A, 2015, PEDIATRICS, V135, pE92, DOI 10.1542/peds.2014-0596; Sherer DM, 2002, AM J PERINAT, V19, P253, DOI 10.1055/s-2002-33084; Sibley CP, 2018, PLACENTA, V64, pS9, DOI 10.1016/j.placenta.2018.01.006; Sidener HM, 2017, COMPARATIVE MED, V67, P270; Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Smith K, 2007, SEMIN IMMUNOL, V19, P59, DOI 10.1016/j.smim.2006.10.002; Sohn K, 2017, SEMIN FETAL NEONAT M, V22, P284, DOI 10.1016/j.siny.2017.07.002; Stammen RL, 2018, J AM ASSOC LAB ANIM, V57, P357, DOI [10.30802/aalas-jaalas-17-000102, 10.30802/AALAS-JAALAS-17-000102]; Stencel-Gabriel K, 2009, AM J REPROD IMMUNOL, V61, P246, DOI 10.1111/j.1600-0897.2009.00687.x; Stokholm J, 2014, CLIN MICROBIOL INFEC, V20, P629, DOI 10.1111/1469-0691.12411; Stokholm J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082932; Stout MJ, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.01.018; Strunk T, 2004, PEDIATR RES, V56, P219, DOI 10.1203/01.PDR.0000132664.66975.79; Surlis C, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1310-2; Swartwout B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02840; Tamarelle J, 2020, J INFECT DIS, V221, P627, DOI 10.1093/infdis/jiz499; Tamburini S, 2016, NAT MED, V22, P713, DOI 10.1038/nm.4142; Tanaka M, 2017, ALLERGOL INT, V66, P515, DOI 10.1016/j.alit.2017.07.010; Theis KR, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00210-20; Torow N, 2015, GENOM DATA, V5, P371, DOI 10.1016/j.gdata.2015.07.009; Toscano M, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02100; Ulas T, 2017, NAT IMMUNOL, V18, P622, DOI 10.1038/ni.3745; UMESAKI Y, 1995, MICROBIOL IMMUNOL, V39, P555, DOI 10.1111/j.1348-0421.1995.tb02242.x; UMESAKI Y, 1993, IMMUNOLOGY, V79, P32; Underwood Mark A, 2005, J Perinatol, V25, P341, DOI 10.1038/sj.jp.7211290; Urushiyama D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11699-8; van Elburg R. M., 2003, Archives of Disease in Childhood, V88, pF52, DOI 10.1136/fn.88.1.F52; Vatanen T, 2016, CELL, V165, P842, DOI 10.1016/j.cell.2016.04.007; Vescicik P, 2020, CES GYNEKOL, V85, P67; Vitali B, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-236; Vlasova AN, 2019, CURR OPIN VIROL, V37, P16, DOI 10.1016/j.coviro.2019.05.001; Wang W, 2014, J CLIN MICROBIOL, V52, P398, DOI 10.1128/JCM.01500-13; Williams WB, 2018, CURR OPIN HIV AIDS, V13, P9, DOI [10.1097/COH.0000000000000423, 10.1097/coh.0000000000000423]; Wolfsberger CH, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00401; Wu BB, 2016, WORLD J PEDIATR, V12, P177, DOI 10.1007/s12519-015-0025-3; Yan J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1267; Yang ZY, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091235; Yuan YQ, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080448; Zhang XM, 2017, NAT REV IMMUNOL, V17, P495, DOI 10.1038/nri.2017.54; Zhao T, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0194-5; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18; Zimmermann P, 2018, VACCINE, V36, P207, DOI 10.1016/j.vaccine.2017.08.069	201	2	2	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							584	10.3390/vaccines9060584			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY9GE	34206053	Green Published, gold			2022-04-29	WOS:000666186700001
J	Bogogiannidou, Z; Speletas, M; Vontas, A; Nikoulis, DJ; Dadouli, K; Kyritsi, MA; Mouchtouri, VA; Mina, P; Anagnostopoulos, L; Koureas, M; Karavasilis, V; Nikou, O; Pinaka, O; Thomaidis, PC; Kadoglou, K; Bedevis, K; Spyrou, N; Eleftheriou, AA; Papaevangelou, V; Gikas, A; Vatopoulos, A; Ntzani, EE; Prezerakos, P; Tsiodras, S; Hadjichristodoulou, C				Bogogiannidou, Zacharoula; Speletas, Matthaios; Vontas, Alexandros; Nikoulis, Dimitrios J.; Dadouli, Katerina; Kyritsi, Maria A.; Mouchtouri, Varvara A.; Mina, Paraskevi; Anagnostopoulos, Lemonia; Koureas, Michalis; Karavasilis, Vasileios; Nikou, Olga; Pinaka, Ourania; Thomaidis, Pavlos C.; Kadoglou, Kornilia; Bedevis, Konstantinos; Spyrou, Natalia; Eleftheriou, Alexandros A.; Papaevangelou, Vassiliki; Gikas, Achilleas; Vatopoulos, Alkiviadis; Ntzani, Evangelia E.; Prezerakos, Panagiotis; Tsiodras, Sotirios; Hadjichristodoulou, Christos			Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020	VACCINES			English	Article						SARS-CoV-2; COVID-19; antibodies; IgG; seroepidemiology; long-term immune response		A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between May and August 2020. It was designed as a cross-sectional survey and was repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Of 20,110 serum samples collected, 89 (0.44%) were found to be positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (0.35%) observed in May 2020. The highest seroprevalence was primarily observed in the "30-49" year age group. Females presented higher seroprevalence compared to males in May 2020 (females: 0.58% VS males: 0.10%). This difference reversed during the study period and males presented a higher proportion in August 2020 (females: 0.12% VS males: 0.58%). Differences in the rate of seropositivity between urban areas and the rest of the country were also observed during the study period. The four-month infection fatality rate (IFR) was estimated to be 0.47%, while the respective case fatality rate (CFR) was at 1.89%. Our findings confirm low seroprevalence of COVID-19 in Greece during the study period. The young adults are presented as the most affected age group. The loss of the cumulative effect of seropositivity in a proportion of previous SARS-CoV-2 infections was indicated.	[Bogogiannidou, Zacharoula; Vontas, Alexandros; Nikoulis, Dimitrios J.; Dadouli, Katerina; Kyritsi, Maria A.; Mouchtouri, Varvara A.; Mina, Paraskevi; Anagnostopoulos, Lemonia; Koureas, Michalis; Karavasilis, Vasileios; Nikou, Olga; Pinaka, Ourania; Hadjichristodoulou, Christos] Univ Thessaly, Fac Med, Lab Hyg & Epidemiol, Larisa 41222, Greece; [Speletas, Matthaios] Univ Thessaly, Fac Med, Dept Immunol & Histocompatibil, Larisa 41500, Greece; [Thomaidis, Pavlos C.] Microbiol Lab Thomaidis, Korinthos 20131, Greece; [Kadoglou, Kornilia] Gen Hosp Kalamata, Biochem Lab, Kalamata 24150, Greece; [Bedevis, Konstantinos] Microbiol Lab Bedevis Konstantinos, Tripoli 22100, Greece; [Spyrou, Natalia] Microbiol Lab Bioiatriki, Athens 11524, Greece; [Eleftheriou, Alexandros A.; Ntzani, Evangelia E.] Univ Ioannina, Fac Med, Dept Hyg & Epidemiol, Ioannina 45110, Greece; [Papaevangelou, Vassiliki] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sch Med, Dept Paediat 3, Athens 12462, Greece; [Gikas, Achilleas] Univ Crete, Univ Hosp Heraklion, Sch Med, Internal Med Dept,Infect Dis Unit, Iraklion 71500, Greece; [Vatopoulos, Alkiviadis] Univ West Attica, Sch Publ Hlth, Dept Publ Hlth Policy, Athens 11521, Greece; [Ntzani, Evangelia E.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Ctr Evidence Synth Hlth, Providence, RI 02903 USA; [Ntzani, Evangelia E.] Univ Res Ctr loannina, Inst Biosci, Ioannina 45110, Greece; [Prezerakos, Panagiotis] Univ Peloponnese, Dept Nursing, Tripoli 22100, Greece; [Tsiodras, Sotirios] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sch Med, Dept Internal Med 4, Athens 12462, Greece		Hadjichristodoulou, C (通讯作者)，Univ Thessaly, Fac Med, Lab Hyg & Epidemiol, Larisa 41222, Greece.	xara.16.01@gmail.com; maspel@med.uth.gr; avontas@uth.gr; dnikoulis@uth.gr; katerina1dad@gmail.com; mkiritsi@med.uth.gr; mouchtourib@med.uth.gr; pmina@med.uth.gr; lanagnost@uth.gr; mihaliskoureas@gmail.com; karavassilis_v@yahoo.gr; onikou@med.uth.gr; rpinaka@gmail.com; thomaidispavlos@gmail.com; kadkoveroia@gmail.com; kkbed@me.com; nataspyrou@gmail.com; alexandroseleftheriou4@gmail.com; vpapaev@gmail.com; gikas.achilles@uoc.gr; avatopoulos@uniwa.gr; entzani@uoi.gr; prezerpot@gmail.com; tsiodras@med.uoa.gr; xhatzi@med.uth.gr	Vatopoulos, Alkiviadis/AAZ-6443-2021; Kyritsi, Maria/ABA-6260-2021	Kyritsi, Maria/0000-0002-4689-4623; Speletas, Matthaios/0000-0003-1287-7734; Mouchtouri, Varvara/0000-0002-2535-3596; Hadjichristodoulou, Christos/0000-0002-4769-8376; Anagnostopoulos, Lemonia/0000-0002-0654-1620; Ntzani, Evangelia/0000-0003-3712-4181; Tsiodras, Sotirios/0000-0002-0463-4321	Greek Ministry of HealthGreek Ministry of Development-GSRT	The study was funded by the Greek Ministry of Health.	[Anonymous], WHO Director-General's opening remarks at the media briefing on COVID-19: 11 March 2020; [Anonymous], POLICY RESPONSES COR; [Anonymous], GREECE CORONAVIRUS P; Atchison CJ, 2020, MEDRXIV, DOI [DOI 10.1101/2020.10.26.20219725, 10.1101/2020.10.26.20219725]; Bajema KL, 2021, JAMA INTERN MED, V181, P450, DOI 10.1001/jamainternmed.2020.7976; Bendavid E., 2020, MEDRXIV, DOI [DOI 10.1101/2020.04.14.20062463, 10.1101/2020.04.14.20062463]; Bogogiannidou Z, 2020, EUROSURVEILLANCE, V25, P8, DOI 10.2807/1560-7917.ES.2020.25.31.2001369; Buss LF, 2021, SCIENCE, V371, P288, DOI 10.1126/science.abe9728; Campbell I, 2007, STAT MED, V26, P3661, DOI 10.1002/sim.2832; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Diggle P.J., 2011, EPIDEMIOL RES INT, V2011, P1, DOI DOI 10.1155/2011/608719; Hansen CB, 2021, J IMMUNOL, V206, P109, DOI 10.4049/jimmunol.2000898; Naing N N, 2000, Malays J Med Sci, V7, P10; Nardone A, 2004, Euro Surveill, V9, P5; Rostami A, 2021, CLIN MICROBIOL INFEC, V27, P331, DOI 10.1016/j.cmi.2020.10.020; Self WH, 2020, MMWR-MORBID MORTAL W, V69, P1762, DOI 10.15585/mmwr.mm6947a2; Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259; To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149	18	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							504	10.3390/vaccines9050504			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1MW	34068100	gold, Green Published			2022-04-29	WOS:000654591300001
J	Guaraldi, F; Montalti, M; Di Valerio, Z; Mannucci, E; Nreu, B; Monami, M; Gori, D				Guaraldi, Federica; Montalti, Marco; Di Valerio, Zeno; Mannucci, Edoardo; Nreu, Besmir; Monami, Matteo; Gori, Davide			Rate and Predictors of Hesitancy toward SARS-CoV-2 Vaccine among Type 2 Diabetic Patients: Results from an Italian Survey	VACCINES			English	Article						vaccine hesitancy; SARS-CoV-2 vaccine; type 2 diabetes; COVID-19	ATTITUDES	Vaccine hesitancy (VH) has been identified as one of the major health concerns of our time by theWorld Health Organization. It may prove especially detrimental in the light of the ongoing SARS-CoV-2 pandemic, as vaccination campaigns still represent the primary strategy against the detrimental consequences of the pandemic. Among patients suffering from type 2 diabetes mellitus (DB), who are particularly vulnerable to COVID-19, VH might represent an even more serious threat. Therefore, our study focuses on identifying potential determinants of VH among patients with type 2 diabetes. Study participants (n = 1176) filled in a two-section online self-administered questionnaire, answering questions regarding demographic and anamnestic data, as well as their intention to accept any vaccination against COVID-19. Some possible reasons underlying VH were investigated as well. An overall hesitancy rate of 14.2% was registered. Data showed how older age, male gender, higher education level, and having been vaccinated for seasonal influenza in 2020-2021 were associated with a significantly higher propensity to receive the COVID-19 vaccine. On the contrary, having experienced adverse effects following past vaccinations was a negative predictor. In addition to confirming an array of predictors of VH, we found a worryingly high prevalence of VH among diabetics, who have been shown to be particularly exposed to severe COVID-19 and death. These findings may be useful in planning targeted action toward acceptance improvement and enhancing the efficacy of vaccination campaigns.	[Guaraldi, Federica] IRCCS Ist Sci Neurol Bologna, Pituitary Unit, I-40139 Bologna, Italy; [Montalti, Marco; Di Valerio, Zeno; Gori, Davide] Univ Bologna, Dept Biomed & Neuromotor Sci DIBINEM, I-40126 Bologna, Italy; [Mannucci, Edoardo; Nreu, Besmir; Monami, Matteo] Careggi Hosp, Diabet Unit, I-50139 Florence, Italy; [Mannucci, Edoardo; Nreu, Besmir; Monami, Matteo] Univ Florence, I-50139 Florence, Italy		Di Valerio, Z (通讯作者)，Univ Bologna, Dept Biomed & Neuromotor Sci DIBINEM, I-40126 Bologna, Italy.	federica.guaraldi@yahoo.it; marco.montalti7@studio.unibo.it; zeno.divalerio@studio.unibo.it; edoardo.mannucci@unifi.it; dbnreu@gmail.com; matteo.monami@unifi.it; davide.gori4@unibo.it	Gori, Davide/AAC-3486-2022; Montalti, Marco/AAQ-2494-2021	Gori, Davide/0000-0003-4954-9419; Montalti, Marco/0000-0001-7276-0277; Guaraldi, Federica/0000-0001-8416-1669			Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; [Anonymous], 10 THREATS GLOBAL HL; Billah MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242128; Bocquier A, 2020, HUM VACC IMMUNOTHER, V16, P2565, DOI 10.1080/21645515.2020.1729628; Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810; Cheng SX, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000024971; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; Gazzaz ZJ, 2021, OPEN LIFE SCI, V16, P297, DOI 10.1515/biol-2021-0034; Giacomelli A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040669; Green MS, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00458-w; Li Y, 2021, J GLOB HEALTH, V11, DOI 10.7189/jogh.11.10001; Lim S, 2021, NAT REV ENDOCRINOL, V17, P11, DOI 10.1038/s41574-020-00435-4; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Saha S, 2021, J DIABETES METAB DIS, V20, P939, DOI 10.1007/s40200-021-00779-2; Verger P, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5441-6; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	18	12	12	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							460	10.3390/vaccines9050460			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1MQ	34064486	gold, Green Published			2022-04-29	WOS:000654590700001
J	Jelsma, T; Post, J; van den Born, E; Segers, R; Kortekaas, J				Jelsma, Tinka; Post, Jacob; van den Born, Erwin; Segers, Ruud; Kortekaas, Jeroen			Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever	VACCINES			English	Article						classical swine fever virus; pestivirus; swine; vaccine; DIVA	LINKED-IMMUNOSORBENT-ASSAY; E-RNS; MARKER VACCINE; VIRUS; DIFFERENTIATION; ANTIBODY; INFECTION; PIGS; TRANSMISSION; PESTIVIRUS	Classical swine fever is a highly contagious and deadly disease in swine. The disease can be controlled effectively by vaccination with an attenuated virus known as the "Chinese" (C)-strain. A single vaccination with the C-strain provides complete protection against highly virulent isolates within days after vaccination, making it one of the most efficacious veterinary vaccines ever developed. A disadvantage of the C-strain is that vaccinated animals cannot be serologically differentiated from animals that are infected with wild-type Classical swine fever virus. Previously, a C-strain-based vaccine with a stable deletion in the E2 structural glycoprotein was developed, which allows for differentiation between infected and vaccinated animals (DIVA). The resulting vaccine, which we named C-DIVA, is compatible with a commercial E2 ELISA, modified to render it suitable as a DIVA test. In the present work, three groups of eight piglets were vaccinated with escalating doses of the C-DIVA vaccine and challenged two weeks after vaccination. One group of four unvaccinated piglets served as controls. Piglets were monitored for clinical signs until three weeks after challenge and blood samples were collected to monitor viremia, leukocyte and thrombocyte levels, and antibody responses. The presence of challenge virus RNA in oropharyngeal swabs was investigated to first gain insight into the potential of C-DIVA to prevent shedding. The results demonstrate that a single vaccination with 70 infectious virus particles of C-DIVA protects pigs from the highly virulent Brescia strain.	[Jelsma, Tinka; Post, Jacob; Kortekaas, Jeroen] Wageningen Biovet Res, NL-8221 RA Lelystad, Netherlands; [van den Born, Erwin; Segers, Ruud] MSD Anim Hlth, NL-5830 AA Boxmeer, Netherlands; [Kortekaas, Jeroen] Wageningen Univ, Lab Virol, NL-6708 PB Wageningen, Netherlands		Kortekaas, J (通讯作者)，Wageningen Biovet Res, NL-8221 RA Lelystad, Netherlands.; Kortekaas, J (通讯作者)，Wageningen Univ, Lab Virol, NL-6708 PB Wageningen, Netherlands.	tinka.jelsma@wur.nl; jacob.post@wur.nl; erwin.van.den.born@merck.com; ruud.segers@merck.com; jeroen.kortekaas@wur.nl		Kortekaas, Jeroen/0000-0002-0329-0176; Jelsma, Tinka/0000-0002-1836-3649			Blome S, 2017, VET RES, V48, DOI 10.1186/s13567-017-0457-y; Blome S, 2017, VET MICROBIOL, V206, P10, DOI 10.1016/j.vetmic.2017.01.001; Blome S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040086; Bruderer U, 2015, J IMMUNOL METHODS, V420, P18, DOI 10.1016/j.jim.2015.03.009; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Kortekaas J, 2011, VET MICROBIOL, V147, P11, DOI 10.1016/j.vetmic.2010.05.038; Kortekaas J, 2010, J VIROL METHODS, V163, P175, DOI 10.1016/j.jviromet.2009.09.012; Leifer I, 2009, VACCINE, V27, P6522, DOI 10.1016/j.vaccine.2009.08.057; Luo YZ, 2015, J VIROL METHODS, V222, P22, DOI 10.1016/j.jviromet.2015.05.006; Mittelholzer C, 2000, VET MICROBIOL, V74, P293, DOI 10.1016/S0378-1135(00)00195-4; Pannhorst K, 2015, J VET DIAGN INVEST, V27, P449, DOI 10.1177/1040638715592446; Reimann I, 2004, VIROLOGY, V322, P143, DOI 10.1016/j.virol.2004.01.028; Ribbens S, 2004, VET QUART, V26, P146, DOI 10.1080/01652176.2004.9695177; Schroeder S, 2012, REV SCI TECH OIE, V31, P997; Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x; Summerfield A, 2015, FRONT VET SCI, V2, DOI 10.3389/fvets.2015.00010; TERPSTRA C, 1984, VET MICROBIOL, V9, P113, DOI 10.1016/0378-1135(84)90026-9; van Gennip HGP, 2000, VACCINE, V19, P447, DOI 10.1016/S0264-410X(00)00198-5; van Gennip HGP, 1999, J VIROL METHODS, V78, P117, DOI 10.1016/S0166-0934(98)00171-2; Van Oirschot J.T., 1999, DIS SWINE, P159; van Oirschot JT, 2003, VET MICROBIOL, V96, P367, DOI 10.1016/j.vetmic.2003.09.008; van Rijn PA, 2004, J VIROL METHODS, V120, P151, DOI 10.1016/j.jviromet.2004.04.014; van Rijn PA, 1999, VACCINE, V17, P433, DOI 10.1016/S0264-410X(98)00215-1; Wang LH, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9080658; Weesendorp E, 2011, VET MICROBIOL, V147, P262, DOI 10.1016/j.vetmic.2010.06.032; WENSVOORT G, 1989, VET MICROBIOL, V21, P9, DOI 10.1016/0378-1135(89)90014-X	26	2	2	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							483	10.3390/vaccines9050483			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1IS	34068610	Green Published, gold			2022-04-29	WOS:000654580400001
J	Kalucka, S; Grzegorczyk-Karolak, I				Kalucka, Sylwia; Grzegorczyk-Karolak, Izabela			Barriers Associated with the Uptake Ratio of Seasonal Flu Vaccine and Ways to Improve Influenza Vaccination Coverage among Young Health Care Workers in Poland	VACCINES			English	Article						barrier; influenza; influenza vaccine; midwifery; nursing; pharmacy; public health; vaccination coverage	MEDICAL-STUDENTS ATTITUDE; PUBLIC-HEALTH; UNIVERSITY; KNOWLEDGE; RATES; HOSPITALS; AWARENESS	Despite not being full-time health care workers, annual flu vaccination is nevertheless an important consideration for medical students. This study examined the reasons for refusing flu vaccination among medical students, a group characterized by low vaccination coverage, despite the fact that the flu vaccine is arguably the most effective way of preventing serious flu complications. A cross-sectional survey was performed of 1313 students at the Medical University of Lodz. The findings indicate that the main sites of vaccination were primary care centers, and main source of information about influenza vaccination (about 90% of cases) was the general practitioner (GP). The most common motivations for vaccination were a recommendation by the family doctor or the belief that it was an important factor for protection against influenza. Most students reported various adverse effects after vaccination, usually mild pain at the site of vaccination, malaise, or fever. The main reasons for rejecting influenza vaccination were the apparent low risk of disease, the need for annual vaccination, the need to pay for it, lack of time or opportunity, lack of vaccination promotion, negative attitudes toward the flu vaccine, or the belief that there are other methods of preventing flu. To increase long-term vaccine acceptance and increase the vaccination rate among medical students and qualified health care workers, there is a need to adapt the health system and to initiate ongoing promotion programs at university to raise consciousness, promote vaccinations, and develop clinical skills for immunization.	[Kalucka, Sylwia] Med Univ Lodz, Dept Coordinated Care, PL-90251 Lodz, Poland; [Grzegorczyk-Karolak, Izabela] Med Univ Lodz, Dept Biol & Pharmaceut Bot, PL-90151 Lodz, Poland		Kalucka, S (通讯作者)，Med Univ Lodz, Dept Coordinated Care, PL-90251 Lodz, Poland.	sylwia.kalucka@umed.lodz.pl; izabela.grzegorczyk@umed.lodz.pl		Grzegorczyk-Karolak, Izabela/0000-0003-4793-4604; Kalucka, Sylwia/0000-0002-0747-9427			Abalkhail MS, 2017, J INFECT PUBLIC HEAL, V10, P644, DOI 10.1016/j.jiph.2017.05.001; Advisory Committee on Immunization Practices, 2006, MMWR Recomm Rep, V55, P1; Anastasiou Olympia E., 2021, Vaccines, V9, P169, DOI 10.3390/vaccines9020169; Babenko-Mould Y, 2015, PUBLIC HEALTH NURS, V32, P277, DOI 10.1111/phn.12151; Banaszkiewicz A, 2016, ADV EXP MED BIOL, V934, P83, DOI 10.1007/5584_2016_20; Blank PR, 2009, J INFECTION, V58, P446, DOI 10.1016/j.jinf.2009.04.001; Carman WF, 2000, LANCET, V355, P93, DOI 10.1016/S0140-6736(99)05190-9; Christini AB, 2007, INFECT CONT HOSP EP, V28, P171, DOI 10.1086/511796; Edge R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140085; European Food Safety Authority, 2019, EFSA J, V17, DOI 10.2903/j.efsa.2019.5926; Faresjo T, 2012, SCAND J INFECT DIS, V44, P237, DOI 10.3109/00365548.2011.620000; FOY HM, 1987, AM J EPIDEMIOL, V126, P506, DOI 10.1093/oxfordjournals.aje.a114683; Gallone MS, 2017, HUM VACC IMMUNOTHER, V13, P1937, DOI 10.1080/21645515.2017.1320462; Ghandora H, 2019, HUM VACC IMMUNOTHER, V15, P700, DOI 10.1080/21645515.2018.1543523; Ghendon Y., 1992, World Health Statistics Quarterly, V45, P306; Gierszon P., 2018, J ED HLTH SPORT, V8, P43; Grohskopf LA, 2013, MMWR RECOMM REP, V62, P1; Hannoun C, 2013, EXPERT REV VACCINES, V12, P1085, DOI 10.1586/14760584.2013.824709; Hernandez-Garcia I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020238; Hernández-García Ignacio, 2015, Rev. Esp. Salud Publica, V89, P615, DOI 10.4321/S1135-57272015000600009; Immunization Action Coalition Immunization Action Coalition, STAT ALL PHARM VACC; Kalucka S, 2020, GERIATRIA, V14, P72; Kalucka S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18042105; Kalucka S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030516; Kang J, 2014, INFECT CONT HOSP EP, V35, P1316, DOI 10.1086/678076; Kelly DA, 2014, HUM VACC IMMUNOTHER, V10, P1930, DOI 10.4161/hv.29071; Kennedy Erin D., 2011, Morbidity and Mortality Weekly Report, V60, P781; Kin C, 2017, VACCINE, V35, P1482, DOI 10.1016/j.vaccine.2017.02.001; Knapp K K, 1999, J Am Pharm Assoc (Wash), V39, P127; Lai E, 2020, VACCINE, V38, P1968, DOI 10.1016/j.vaccine.2020.01.004; Lambert LC, 2010, NEW ENGL J MED, V363, P2036, DOI 10.1056/NEJMra1002842; Lehmann BA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0929-5; Madar R, 2003, Bratisl Lek Listy, V104, P232; Marentette T, 2011, CLIN NURS RES, V20, P422, DOI 10.1177/1054773811409032; Martinello RA, 2003, INFECT CONT HOSP EP, V24, P845, DOI 10.1086/502147; Massot E, 2018, VACCINE, V36, P5204, DOI 10.1016/j.vaccine.2018.06.050; Metcalfe SE, 2014, PUBLIC HEALTH NURS, V31, P175, DOI 10.1111/phn.12088; Mitchell T, 2011, CLIN INFECT DIS, V52, pS138, DOI 10.1093/cid/ciq056; Muller D, 2007, INFECTION, V35, P308, DOI 10.1007/s15010-007-6218-5; Nafziger AN, 2014, J CLIN PHARMACOL, V54, P719, DOI 10.1002/jcph.299; Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1; Rebmann T, 2012, INFECT CONT HOSP EP, V33, P243, DOI 10.1086/664057; Rogers CJ, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6041-1; Sato APS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123840; Seale H, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-307; Sowada C, 2019, HEALT SYST TRANSIT, V21, P1; Stasiak A, 2014, FAM MED PRIM CARE RE, V16, P166; Taubenberger JK, 2010, PUBLIC HEALTH REP, V125, P16, DOI 10.1177/00333549101250S305; Tuohetamu S, 2017, HUM VACC IMMUNOTHER, V13, P1688, DOI 10.1080/21645515.2017.1293769; Uhart M, 2016, HUM VACC IMMUNOTHER, V12, P2259, DOI 10.1080/21645515.2016.1180490; Walker L, 2016, VACCINE, V34, P6193, DOI 10.1016/j.vaccine.2016.10.074; Walker TA, 2020, J INFECT DIS, V221, P183, DOI 10.1093/infdis/jiz570; WEINGARTEN S, 1989, AM J INFECT CONTROL, V17, P202, DOI 10.1016/0196-6553(89)90129-6; World Health Organization, REC COMP INFL VIR VA; Zielonka TM, 2009, MED PR, V60, P369	55	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							530	10.3390/vaccines9050530			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1ZC	34065371	Green Published, gold			2022-04-29	WOS:000654623100001
J	Pardi, N				Pardi, Norbert			mRNA Innovates the Vaccine Field	VACCINES			English	Editorial Material									[Pardi, Norbert] Univ Penn, Dept Med, Philadelphia, PA 19104 USA		Pardi, N (通讯作者)，Univ Penn, Dept Med, Philadelphia, PA 19104 USA.	pnorbert@pennmedicine.upenn.edu		Pardi, Norbert/0000-0003-1008-6242			Bettini E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020147; Blakney AK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020097; Buschmann MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010065; Cagigi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010061; Deal CE, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020108; Esprit A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040776; Kis Z, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010003; Knezevic I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020081; Mu ZK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020134; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Wollner CJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020148	11	2	2	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							486	10.3390/vaccines9050486			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1JD	34064557	gold, Green Published			2022-04-29	WOS:000654581500001
J	Root-Bernstein, R				Root-Bernstein, Robert			Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths	VACCINES			English	Article						COVID-19; SARS-CoV-2; invasive pneumococcal disease; lower respiratory infections; pneumococcal vaccines; PCV13; PPV23; influenza vaccine; measles-mumps-rubella vaccine; BCG	SEASONAL INFLUENZA; CONJUGATE VACCINES; CLINICAL CHARACTERISTICS; POLYSACCHARIDE VACCINE; RESPIRATORY PATHOGENS; BACTERIAL PNEUMONIA; ELDERLY-PATIENTS; OLDER-ADULTS; NURSING-HOME; SARS-COV-2	This study examines the relationship of pneumococcal vaccination rates, influenza, measles-mumps-rubella (MMR) diphtheria-tetanus-pertussis vaccinations (DTP), polio, Haemophilus influenzae type B (Hib), and Bacillus Calmette-Guerin (tuberculosis) vaccination rates to COVID-19 case and death rates for 51 nations that have high rates of COVID-19 testing and for which nearly complete childhood, at-risk adult and elderly pneumococcal vaccination data were available. The study is unique in a large number of nations examined, the range of vaccine controls, in testing effects of combinations of vaccinations, and in examining the relationship of COVID-19 and vaccination rates to invasive pneumococcal disease (IPD). Analysis of Italian regions and the states of the United States were also performed. Significant positive correlations were found between IPD (but not lower respiratory infections) and COVID-19 rates, while significant negative correlations were found between pneumococcal vaccination and COVID-19 rates. Influenza and MMR vaccination rates were negatively correlated with lower respiratory infection (LRI) rates and may synergize with pneumococcal vaccination rates to protect against COVID-19. Pneumococcal and influenza vaccination rates were independent of other vaccination rates. These results suggest that endemic rates of bacterial pneumonias, for which pneumococci are a sentinel, may set regional and national susceptibility to severe COVID-19 disease and death.	[Root-Bernstein, Robert] Michigan State Univ, Dept Physiol, 567 Wilson Rd,Room 1104,Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA		Root-Bernstein, R (通讯作者)，Michigan State Univ, Dept Physiol, 567 Wilson Rd,Room 1104,Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	rootbern@msu.edu		Root-Bernstein, Robert/0000-0002-3298-9306			Afonso ET, 2013, EMERG INFECT DIS, V19, P589, DOI 10.3201/eid1904.121198; Aimone F., 2013, J VIROL ANTIVIR RES, V2, P1, DOI [10.4172/2324-8955.1000104, DOI 10.4172/2324-8955.1000104]; Akin L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157657; Al-Tawfiq JA, 2016, HUM VACC IMMUNOTHER, V12, P326, DOI 10.1080/21645515.2015.1058456; Alkholy UM, 2020, J GLOB ANTIMICROB RE, V22, P803, DOI 10.1016/j.jgar.2020.07.005; Allam Mohamed F, 2020, Open Respir Med J, V14, P45, DOI 10.2174/1874306402014010045; Alqahtani AS, 2017, WORLD J CLIN CASES, V5, P212, DOI 10.12998/wjcc.v5.i6.212; Amato M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030535; Amin-Chowdhury Z, 2021, CLIN INFECT DIS, V72, pE65, DOI 10.1093/cid/ciaa1728; [Anonymous], 2018, INFECT AGENT SURVEIL, V39, P107; [Anonymous], 2019, HUMAN PAPILLOMAVIRUS; Augustovski FA, 2009, REV PANAM SALUD PUBL, V25, P423, DOI 10.1590/S1020-49892009000500007; Arokiaraj MC, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00444; Ashford JW, 2021, AM J MED, V134, P153, DOI 10.1016/j.amjmed.2020.10.003; Bacher P, 2020, IMMUNITY, V53, P1258, DOI 10.1016/j.immuni.2020.11.016; Badertscher N, 2012, INT J GEN MED, V5, P967, DOI 10.2147/IJGM.S38472; Baldo V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166637; Belingheri M, 2020, OCCUP MED-OXFORD, V70, P665, DOI 10.1093/occmed/kqaa197; Bellino S, 2020, HUM VACC IMMUNOTHER, V16, P301, DOI 10.1080/21645515.2019.1661754; Bengoechea JA, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012560; Benin AL, 2003, J INFECT DIS, V188, P81, DOI 10.1086/375782; Bluhm R., 2020, 926 FED RES BANK NEW, V5, P926, DOI [10.2139/ssrn.3604314, DOI 10.2139/SSRN.3604314]; Boccalini S, 2017, HUM VACC IMMUNOTHER, V13, P428, DOI 10.1080/21645515.2017.1264796; Boccalini S, 2013, HUM VACC IMMUNOTHER, V9, P699, DOI 10.4161/hv.23268; Boey L, 2020, HUM VACC IMMUNOTHER, V16, P2136, DOI 10.1080/21645515.2020.1763739; Bonnave C, 2019, EUR J CLIN MICROBIOL, V38, P785, DOI 10.1007/s10096-019-03485-3; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Brundage JF, 2006, LANCET INFECT DIS, V6, P303, DOI 10.1016/S1473-3099(06)70466-2; Brundage JF, 2008, EMERG INFECT DIS, V14, P1193, DOI 10.3201/eid1408.071313; Centers for Disease Control, 2017, CHILDHOOD PNEUMOCOCC; Centers for Disease Control, SURVEILLANCE REPORTI; Centers for Disease Control, 2016, VACCINATION COVERAGE; Centers for Disease Control, RISK COVID 19 INFECT; Centers for Disease Control, 2017, PNEUMOCOCCAL VACCINA; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P1065; Ceyhan M, 2016, HUM VACC IMMUNOTHER, V12, P2124, DOI 10.1080/21645515.2016.1159363; Chen CH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009773; Chen X, 2020, APPL MICROBIOL BIOT, V104, P7777, DOI 10.1007/s00253-020-10814-6; Chimoyi L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243707; Chiou WY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018380; Choe YJ, 2020, INT J INFECT DIS, V92, P261, DOI 10.1016/j.ijid.2019.12.021; Christenson B, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-52; Chun B.C., 2016, OPEN FORUM INFECT DI, V3, DOI [10.1093/ofid/ofw172.1136, DOI 10.1093/OFID/OFW172.1136]; Cocco P, 2021, PREV MED, V143, DOI 10.1016/j.ypmed.2020.106351; Contou D, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00736-x; Costello R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153848; Cuadrado-Payan E, 2020, LANCET, V395, pE84, DOI 10.1016/S0140-6736(20)31052-7; Cucchiari D, 2020, MED CLIN-BARCELONA, V155, P502, DOI [10.1016/j.medcli.2020.05.022, 10.1016/j.medcle.2020.05.028]; Curtin F, 1998, BIOL PSYCHIAT, V44, P775, DOI 10.1016/S0006-3223(98)00043-2; de Chaisemartin C, 2021, CLIN INFECT DIS, V72, pE501, DOI 10.1093/cid/ciaa1223; de Oliveira LH, 2016, EXPERT REV VACCINES, V15, P1295, DOI 10.1586/14760584.2016.1166961; de St Maurice A, 2015, PEDIATRICS, V136, pE1186, DOI 10.1542/peds.2015-1773; Del Riccio M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217870; Della Salute M., PIANO NAZL PREVENZIO; Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781; Draz IH, 2015, J EGYPT PUBLIC HEAL, V90, P52, DOI 10.1097/01.EPX.0000465234.31794.b1; Einarsdottir HM, 2005, CLIN MICROBIOL INFEC, V11, P744, DOI 10.1111/j.1469-0691.2005.01221.x; Ejstrud P, 1997, EUR J SURG, V163, P733; European Centre for Disease Prevention and Control, 2020, INV PNEUM DIS SURV D; Feldman C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227945; Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC; Fidel PL, 2020, MBIO, V11, DOI 10.1128/mBio.00907-20; Filia A, 2011, EUROSURVEILLANCE, V16, P18; Fink G., 2020, INACTIVATED TRIVALEN, DOI 10.1136/bmjebm-2020-111549; Fischer L, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0663-9; Garcia-Vidal C, 2021, CLIN MICROBIOL INFEC, V27, P83, DOI 10.1016/j.cmi.2020.07.041; Giese C, 2016, VACCINE, V34, P3657, DOI 10.1016/j.vaccine.2016.05.028; Giuffrida S, 2019, AGING CLIN EXP RES, V31, P421, DOI 10.1007/s40520-019-01145-2; Gold JE, 2020, MBIO, V11, DOI 10.1128/mBio.02628-20; Gopalaswamy R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040612; Goren A, 2014, EXPERT REV VACCINES, V13, P175, DOI 10.1586/14760584.2014.863714; Gorska-Ciebiada M, 2015, POSTEP HIG MED DOSW, V69, P1182; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hamidi AA, 2018, HUM VACC IMMUNOTHER, V14, P2649, DOI 10.1080/21645515.2018.1489187; Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189; Hanquet G, 2019, THORAX, V74, P473, DOI 10.1136/thoraxjnl-2018-211767; Happe M, 2019, VACCINE, V37, P1622, DOI 10.1016/j.vaccine.2019.01.084; Hashemi SA, 2020, J MED VIROL, V92, P2319, DOI 10.1002/jmv.26014; He F, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115199; Herrera AL, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00342; Hmamouchi I, 2015, VACCINE, V33, P1446, DOI 10.1016/j.vaccine.2015.01.065; Houseman C, 2017, EMERG INFECT DIS, V23, P122, DOI 10.3201/eid2301.160897; Hsu K, 2005, PEDIATR INFECT DIS J, V24, P17, DOI 10.1097/01.inf.0000148891.32134.36; Hughes S, 2020, CLIN MICROBIOL INFEC, V26, P1395, DOI 10.1016/j.cmi.2020.06.025; Huttner BD, 2020, CLIN MICROBIOL INFEC, V26, P808, DOI 10.1016/j.cmi.2020.04.024; Ietto G, 2020, MED HYPOTHESES, V141, DOI 10.1016/j.mehy.2020.109779; Intra J, 2020, AM J INFECT CONTROL, V48, P1130, DOI 10.1016/j.ajic.2020.06.185; Intra J, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00169; Isaacman DJ, 2010, INT J INFECT DIS, V14, pE197, DOI 10.1016/j.ijid.2009.05.010; Ismail MB, 2020, MED HYPOTHESES, V145, DOI 10.1016/j.mehy.2020.110305; Jacques M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010003; Jehi L, 2020, CHEST, V158, P1364, DOI 10.1016/j.chest.2020.05.580; Katz N., 2016, OPEN FORUM INFECT DI, V3, P739, DOI [10.1093/ofid/ofw172.602, DOI 10.1093/OFID/OFW172.602]; King JA, 2021, CAN MED ASSOC J, V193, pE1, DOI 10.1503/cmaj.202065; Klein EY, 2016, INFLUENZA OTHER RESP, V10, P394, DOI 10.1111/irv.12398; Klinger D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030378; Knoll MD, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9040742; Kolsek-Sustersic M, 2017, ZDRAV VARST, V56, P172, DOI 10.1515/sjph-2017-0023; Lagos R, 2002, PEDIATR INFECT DIS J, V21, P1115, DOI 10.1097/00006454-200212000-00006; Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P505, DOI 10.1016/j.jmii.2020.05.013; Langford BJ, 2020, CLIN MICROBIOL INFEC, V26, P1622, DOI 10.1016/j.cmi.2020.07.016; Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046; Lewnard JA, 2021, J INFECT DIS, DOI 10.1093/infdis/jiab128; Lopez L., 2016, FW190193 CLIENT; Lu CY, 2019, CLIN INFECT DIS, V69, P1581, DOI 10.1093/cid/ciy1127; Lu PJ, 2015, VACCINE, V33, pD83, DOI 10.1016/j.vaccine.2015.09.031; Luna CM, 2018, PNEUMONIA, V10, DOI 10.1186/s41479-018-0053-6; Lv ZH, 2020, MICROBES INFECT, V22, P195, DOI 10.1016/j.micinf.2020.05.007; Ma L, 2020, INFECT DRUG RESIST, V13, P3045, DOI 10.2147/IDR.S267238; Ma SM, 2020, INT J INFECT DIS, V96, P683, DOI 10.1016/j.ijid.2020.05.068; Marin-Hernandez D, 2021, J MED VIROL, V93, P64, DOI 10.1002/jmv.26120; Martinelli D, 2010, AM J INFECT CONTROL, V38, pE8, DOI 10.1016/j.ajic.2009.09.019; Martinez-Baz I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040611; Massoudi N, 2021, J CLIN IMMUNOL, V41, P324, DOI 10.1007/s10875-020-00925-0; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Miellet WR, 2021, CLIN INFECT DIS, V73, pE2680, DOI 10.1093/cid/ciaa1551; Mitchell S, 2020, NEW ZEAL MED J, V133, P14; Monali R, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001077; Moorlag SJCFM, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100073; Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708; Morrill HJ, 2014, INFECT DIS THER, V3, P19, DOI 10.1007/s40121-014-0025-y; Mudd PA, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abe3024; Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042; Ng Oon Tek, 2021, Lancet Infect Dis, V21, P333, DOI 10.1016/S1473-3099(20)30833-1; Nguyen MTT, 2017, SCAND J RHEUMATOL, V46, P446, DOI 10.1080/03009742.2016.1242774; Noale M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030471; Nunes MC, 2021, MBIO, V12, DOI 10.1128/mBio.02347-20; Ogimi C, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821000571; Omlin AG, 2005, EUR J CANCER, V41, P1731, DOI 10.1016/j.ejca.2005.04.027; Orsi A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071140; Ozaras R, 2020, J MED VIROL, V92, P2657, DOI 10.1002/jmv.26125; Ozdemir H, 2017, ARCH ARGENT PEDIATR, V115, P316, DOI [10.5546/aap.2017.316, 10.5546/aap.2017.eng.316]; Cruz-Hervert LP, 2013, SALUD PUBLICA MEXICO, V55, pS300; Pawlowski C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83641-y; Pennington K, 2019, ENHANCED INVASIVE PN; Peter V, 2015, ORVOSI HETILAP, V156, P186, DOI 10.1556/OH.2015.30054; Poscia A, 2017, EUR J PUBLIC HEALTH, V27, P1016, DOI 10.1093/eurpub/ckx150; Quattrone F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207581; Radaelli G., 2012, WORLD J VACCINES, V2, P143, DOI [10.4236/wjv.2012.23018, DOI 10.4236/WJV.2012.23018]; Ragni P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040675; Rawson TM, 2020, CLIN INFECT DIS, V71, P2459, DOI 10.1093/cid/ciaa530; Reche PA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586984; Regev-Yochay G, 2018, EMERG INFECT DIS, V24, P1275, DOI 10.3201/eid2407.170721; Regev-Yochay G, 2013, VACCINE, V31, P2387, DOI 10.1016/j.vaccine.2013.02.059; Renzi S, 2021, BRAZ J ANESTHESIOL, V71, P92, DOI 10.1016/j.bjane.2020.09.008; Ricco Matteo, 2020, Acta Biomed, V91, P207, DOI 10.23750/abm.v91i2.9700; Rivas MN, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145157; Root-Bernstein R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040559; Root-Bernstein R, 2020, BIOESSAYS, V42, DOI 10.1002/bies.202000076; Rothe K, 2021, EUR J CLIN MICROBIOL, V40, P859, DOI 10.1007/s10096-020-04063-8; Said MA, 2011, VACCINE, V29, P5355, DOI 10.1016/j.vaccine.2011.05.086; Satman I, 2013, HUM VACC IMMUNOTHER, V9, P2618, DOI 10.4161/hv.25826; Savulescu C, 2017, LANCET RESP MED, V5, P648, DOI [10.1016/S2213-2600(17)30110-8, 10.1016/s2213-2600(17)30110-8]; SETIA S, 2014, INT J GEN MED, V7, P179, DOI DOI 10.2147/IJGM.S54963; Sevilla JP, 2020, HUM VACC IMMUNOTHER, V16, P1923, DOI 10.1080/21645515.2019.1708668; Cepeda-Perez AS, 2021, REUMATOL CLIN, V17, P155, DOI 10.1016/j.reuma.2019.04.004; Soto K, 2011, PUBLIC HEALTH REP, V126, P81, DOI 10.1177/00333549111260S313; Stervbo U, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75972-z; Sumbul B, 2021, PEERJ, V9, DOI 10.7717/peerj.10910; Tawfik Hassan, 2015, BMJ Qual Improv Rep, V4, DOI 10.1136/bmjquality.u208497.w3388; Tempia S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1198-z; Theidel U, 2013, DTSCH ARZTEBL INT, V110, P743, DOI 10.3238/arztebl.2013.0743; Thindwa D, 2020, VACCINE, V38, P5398, DOI 10.1016/j.vaccine.2020.06.047; Torres A, 2018, RESP MED, V137, P6, DOI 10.1016/j.rmed.2018.02.007; Townsend L, 2020, JAC-ANTIMICROB RESIS, V2, DOI 10.1093/jacamr/dlaa071; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Troeger CE, 2020, LANCET INFECT DIS, V20, P60, DOI 10.1016/S1473-3099(19)30410-4; Vadlamudi NK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239848; Vaillancourt M, 2020, MBIO, V11, DOI 10.1128/mBio.01806-20; van Aalst M, 2018, TRAVEL MED INFECT DI, V24, P89, DOI 10.1016/j.tmaid.2018.05.016; Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019; Wang ZX, 2021, HUM VACC IMMUNOTHER, V17, P1455, DOI 10.1080/21645515.2020.1814653; Wasserman M, 2019, HUM VACC IMMUNOTHER, V15, P560, DOI 10.1080/21645515.2018.1516491; Woldemeskel BA, 2020, J CLIN INVEST, V130, P6631, DOI 10.1172/JCI143120; Wolff GG, 2020, VACCINE, V38, P350, DOI 10.1016/j.vaccine.2019.10.005; Zanettini Claudio, 2020, medRxiv, DOI 10.1101/2020.06.24.20129817; Zhang GQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104364; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou H, 2021, J INFECTION, V82, pE44, DOI 10.1016/j.jinf.2020.12.004; Zhu XJ, 2020, VIRUS RES, V285, DOI 10.1016/j.virusres.2020.198005	180	5	5	7	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							474	10.3390/vaccines9050474			38	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI3BJ	34066697	Green Published, gold			2022-04-29	WOS:000654700300001
J	Chiozzini, C; Manfredi, F; Ferrantelli, F; Leone, P; Giovannelli, A; Olivetta, E; Federico, M				Chiozzini, Chiara; Manfredi, Francesco; Ferrantelli, Flavia; Leone, Patrizia; Giovannelli, Andrea; Olivetta, Eleonora; Federico, Maurizio			The C-Terminal Domain of Nef(mut) Is Dispensable for the CD8(+) T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles	VACCINES			English	Article						extracellular vesicles; HIV-1 Nef; DNA immunization; CD8(+) T cell immunity; HPV vaccines; SARS-CoV-2 vaccines		Intramuscular injection of DNA vectors expressing the extracellular vesicle (EV)-anchoring protein Nef(mut) fused at its C-terminus to viral and tumor antigens elicit a potent, effective, and anti-tolerogenic CD8(+) T cell immunity against the heterologous antigen. The immune response is induced through the production of EVs incorporating Nef(mut)-derivatives released by muscle cells. In the perspective of a possible translation into the clinic of the Nef(mut)-based vaccine platform, we aimed at increasing its safety profile by identifying the minimal part of Nef(mut) retaining the EV-anchoring protein property. We found that a C-terminal deletion of 29-amino acids did not affect the ability of Nef(mut) to associate with EVs. The EV-anchoring function was also preserved when antigens from both HPV16 (i.e., E6 and E7) and SARS-CoV-2 (i.e., S1 and S2) were fused to its C-terminus. Most important, the Nef(mut) C-terminal deletion did not affect levels, quality, and diffusion at distal sites of the antigen-specific CD8(+) T immunity. We concluded that the C-terminal Nef(mut) truncation does not influence stability, EV-anchoring, and CD8(+) T cell immunogenicity of the fused antigen. Hence, the C-terminal deleted Nef(mut) may represent a safer alternative to the full-length isoform for vaccines in humans.	[Chiozzini, Chiara; Manfredi, Francesco; Ferrantelli, Flavia; Leone, Patrizia; Olivetta, Eleonora; Federico, Maurizio] Ist Super Sanita, Natl Ctr Global Hlth, Viale Regina Elena 299, I-00161 Rome, Italy; [Giovannelli, Andrea] Ist Super Sanita, Natl Ctr Anim Expt & Welf, Viale Regina Elena 299, I-00161 Rome, Italy		Federico, M (通讯作者)，Ist Super Sanita, Natl Ctr Global Hlth, Viale Regina Elena 299, I-00161 Rome, Italy.	chiara.chiozzini@iss.it; francesco.manfredi@iss.it; flavia.ferrantelli@iss.it; patrizia.leone@iss.it; andrea.giovannelli@iss.it; eleonora.olivetta@iss.it; maurizio.federico@iss.it	Manfredi, Francesco/ABA-7166-2021; Olivetta, Eleonora/N-5736-2017; Federico, Maurizio/J-5867-2016; Ferrantelli, Flavia/J-7794-2016	Leone, Patrizia/0000-0002-5281-4917; Chiozzini, Chiara/0000-0002-4153-0927; Federico, Maurizio/0000-0003-4154-1025; Ferrantelli, Flavia/0000-0002-0768-1078	Ministero degli Affari Esteri e della Cooperazione Internazionale, Italy [PGR00810]	This work was supported by the grant PGR00810 from Ministero degli Affari Esteri e della Cooperazione Internazionale, Italy.	Anticoli S., 2016, Trials in Vaccinology, V5, P105, DOI 10.1016/j.trivac.2016.05.001; Anticoli S, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700443; Anticoli S, 2018, J MOL MED, V96, P211, DOI 10.1007/s00109-017-1617-2; Arenaccio C, 2017, ADV EXP MED BIOL, V998, P3, DOI 10.1007/978-981-10-4397-0_1; BAUER S, 1995, SCAND J IMMUNOL, V42, P317, DOI 10.1111/j.1365-3083.1995.tb03662.x; Buffalo CZ, 2019, J VIROL, V93, DOI 10.1128/JVI.01322-19; Cai CY, 2011, J IMMUNOL, V186, P5807, DOI 10.4049/jimmunol.1003506; Chiozzini C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020243; Cid-Arregui A, 2003, J VIROL, V77, P4928, DOI 10.1128/JVI.77.8.4928-4937.2003; D'Aloja P, 2001, J GEN VIROL, V82, P2735, DOI 10.1099/0022-1317-82-11-2735; Di Bonito P, 2017, INT J NANOMED, V12, P4579, DOI 10.2147/IJN.S131309; Di Bonito P, 2015, VIRUSES-BASEL, V7, P1079, DOI 10.3390/v7031079; FEDERICO M, 1989, AIDS RES HUM RETROV, V5, P385, DOI 10.1089/aid.1989.5.385; Fenrich M, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00229; de Oliveira LMF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138686; Ferrantelli F, 2018, MOL BIOTECHNOL, V60, P773, DOI 10.1007/s12033-018-0114-3; Ferretti AP, 2020, IMMUNITY, V53, P1095, DOI 10.1016/j.immuni.2020.10.006; Gaspar V, 2015, EXPERT OPIN BIOL TH, V15, P353, DOI 10.1517/14712598.2015.996544; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Huang J, 2007, VACCINE, V25, P6981, DOI 10.1016/j.vaccine.2007.06.047; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P273, DOI 10.1038/nrclinonc.2016.25; Kohlmeier JE, 2009, ANNU REV IMMUNOL, V27, P61, DOI 10.1146/annurev.immunol.021908.132625; Lattanzi L, 2012, VACCINE, V30, P7229, DOI 10.1016/j.vaccine.2012.10.010; Manfredi F, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040042; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Schorey JS, 2015, EMBO REP, V16, P24, DOI 10.15252/embr.201439363; Shamanin VA, 2008, J VIROL, V82, P3912, DOI 10.1128/JVI.02466-07; Takamura S, 2019, J EXP MED, V216, P2736, DOI 10.1084/jem.20190557; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Zheng YH, 2003, P NATL ACAD SCI USA, V100, P8460, DOI 10.1073/pnas.1437453100; Zhi Y, 2005, VIROLOGY, V335, P34, DOI 10.1016/j.virol.2005.01.050	34	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							373	10.3390/vaccines9040373			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4YW	33921215	Green Published, gold			2022-04-29	WOS:000643787600001
J	De-Simone, SG; Gomes, LR; Napoleao-Pego, P; Lechuga, GC; de Pina, JS; da Silva, FR				De-Simone, Salvatore Giovanni; Gomes, Larissa Rodrigues; Napoleao-Pego, Paloma; Lechuga, Guilherme Curty; de Pina, Jorge Soares; da Silva, Flavio Rocha			Epitope Mapping of the Diphtheria Toxin and Development of an ELISA-Specific Diagnostic Assay	VACCINES			English	Article						diphtheria toxin; B epitopes; epitope mapping; bi-specific peptides; ELISA; diagnostic performance	NONTOXIGENIC CORYNEBACTERIUM-DIPHTHERIAE; CRYSTAL-STRUCTURE; ULCERANS STRAINS; RAPID DETECTION; ANTIBODIES; ANTITOXIN; FRAGMENT; PCR; IDENTIFICATION; NUCLEOTIDE	Background: The diphtheria toxoid antigen is a major component in pediatric and booster combination vaccines and is known to raise a protective humoral immune response upon vaccination. Although antibodies are considered critical for diphtheria protection, little is known about the antigenic determinants that maintain humoral immunity. Methods: One-hundred and twelve 15 mer peptides covering the entire sequence of diphtheria toxin (DTx) protein were prepared by SPOT synthesis. The immunoreactivity of membrane-bound peptides with sera from mice immunized with a triple DTP vaccine allowed mapping of continuous B-cell epitopes, topological studies, multiantigen peptide (MAP) synthesis, and Enzyme-Linked Immunosorbent Assay (ELISA) development. Results: Twenty epitopes were identified, with two being in the signal peptide, five in the catalytic domain (CD), seven in the HBFT domain, and five in the receptor-binding domain (RBD). Two 17 mer (CB/Tx-2/12 and CB/DTx-4-13) derived biepitope peptides linked by a Gly-Gly spacer were chemically synthesized. The peptides were used as antigens to coat ELISA plates and assayed with human (huVS) and mice vaccinated sera (miVS) for in vitro diagnosis of diphtheria. The assay proved to be highly sensitive (99.96%) and specific (100%) for huVS and miVS and, when compared with a commercial ELISA test, demonstrated a high performance. Conclusions: Our work displayed the complete picture of the linear B cell IgG response epitope of the DTx responsible for the protective effect and demonstrated sufficient specificity and eligibility for phase IIB studies of some epitopes to develop new and fast diagnostic assays.	[De-Simone, Salvatore Giovanni; Gomes, Larissa Rodrigues; Napoleao-Pego, Paloma; Lechuga, Guilherme Curty; de Pina, Jorge Soares; da Silva, Flavio Rocha] Fundacao Oswaldo Cruz, Ctr Technol Dev Hlth CDTS, FIOCRUZ, Natl Inst Sci & Technol Innovat Neglected Dis Pop, BR-21040900 Rio De Janeiro, Brazil; [De-Simone, Salvatore Giovanni] Fed Fluminense Univ, Biol Inst, Mol & Cellular Biol Dept, BR-24020141 Niteroi, RJ, Brazil		De-Simone, SG (通讯作者)，Fundacao Oswaldo Cruz, Ctr Technol Dev Hlth CDTS, FIOCRUZ, Natl Inst Sci & Technol Innovat Neglected Dis Pop, BR-21040900 Rio De Janeiro, Brazil.; De-Simone, SG (通讯作者)，Fed Fluminense Univ, Biol Inst, Mol & Cellular Biol Dept, BR-24020141 Niteroi, RJ, Brazil.	dsimone@cdts.fiocruz.br; larissa.gomesr@cdts.fiocruz.br; paloma.pego@cdts.fiocruz.br; guilherme.lechuga@cdts.fiocruz.br; jorge.pina@cdts.fiocruz.br; flavio.rocha@cdts.fiocruz.br	Gomes, Larissa/AFZ-0438-2022; De-Simone, Salvatore/I-2989-2013	Gomes, Larissa/0000-0001-7194-0858; De-Simone, Salvatore/0000-0002-2172-656X	FIOCRUZ-INOVA [VPPCB-007FIO-18-2-27 21, VPPIS005FIO-20-2-51]	This research was funded by FIOCRUZ-INOVA (#VPPCB-007FIO-18-2-27 21, #VPPIS005FIO-20-2-51, to SGS.	Aggerbeck H, 1996, J IMMUNOL METHODS, V190, P171, DOI 10.1016/0022-1759(95)00270-7; Alsarraf H, 2017, VIRULENCE, V8, P1880, DOI 10.1080/21505594.2017.1321726; Bell CE, 1997, BIOCHEMISTRY-US, V36, P481, DOI 10.1021/bi962214s; Bonmarin I, 2009, VACCINE, V27, P4196, DOI 10.1016/j.vaccine.2009.04.048; Both L, 2014, EUROSURVEILLANCE, V19, P19, DOI 10.2807/1560-7917.ES2014.19.24.20830; Cassiday PK, 2008, J CLIN MICROBIOL, V46, P331, DOI 10.1128/JCM.01251-07; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Clarke KEN, 2019, EMERG INFECT DIS, V25, P1834, DOI 10.3201/eid2510.190271; Colli A, 2014, HEPATOLOGY, V60, P408, DOI 10.1002/hep.26948; COLLIER RJ, 1969, SCIENCE, V164, P1179, DOI 10.1126/science.164.3884.1179; da Silva FR, 2014, VACCINE, V32, P6251, DOI 10.1016/j.vaccine.2014.09.019; De-Simone SG, 2016, METHODS MOL BIOL, V1352, P263, DOI 10.1007/978-1-4939-3037-1_20; De-Simone SG, 2017, TOXICON, V138, P37, DOI 10.1016/j.toxicon.2017.08.012; DeWinter LM, 2005, J CLIN MICROBIOL, V43, P3447, DOI 10.1128/JCM.43.7.3447-3449.2005; Di Giovine P, 2013, EPIDEMIOL INFECT, V141, P132, DOI 10.1017/S0950268812000210; Efstratiou A, 1999, Commun Dis Public Health, V2, P250; Elden S., 2007, EURO SURVEILL, V29, P12; Engler KH, 1997, J CLIN MICROBIOL, V35, P495, DOI 10.1128/JCM.35.2.495-498.1997; European Centre for Disease Prevention Control, 2015, CUTANEOUS DIPHTHERIA; Funke G, 1999, EMERG INFECT DIS, V5, P477, DOI 10.3201/eid0503.990326; Ghaderi S, 2021, Arch Razi Inst, V75, P427, DOI 10.22092/ari.2019.127251.1377; Glenny AT, 1923, BRIT J EXP PATHOL, V4, P283; Griffith J, 2019, MMWR-MORBID MORTAL W, V68, P281, DOI 10.15585/mmwr.mm6812a2; Grundy J, 2019, INT J HEALTH POLICY, V8, P211, DOI 10.15171/ijhpm.2018.127; Gubler J, 1998, CLIN INFECT DIS, V27, P1295, DOI 10.1086/514997; Khrustaleva TA, 2015, MOL IMMUNOL, V63, P235, DOI 10.1016/j.molimm.2014.07.008; Kim D, 2018, J MICROBIOL BIOTECHN, V28, P2113, DOI 10.4014/jmb.1810.10009; Konrad R, 2010, EUROSURVEILLANCE, V15, P9; Kristiansen M, 1997, APMIS, V105, P843, DOI 10.1111/j.1699-0463.1997.tb05093.x; Lakzaei M, 2019, J CELL PHYSIOL, V234, P9486, DOI 10.1002/jcp.27636; Lechuga GC, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111564; Lobeck K, 1998, INFECT IMMUN, V66, P418, DOI 10.1128/IAI.66.2.418-423.1998; Louie GV, 1997, MOL CELL, V1, P67, DOI 10.1016/S1097-2765(00)80008-8; Meinel DM, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.08.010; Metz B, 2020, J PHARM SCI-US, V109, P543, DOI 10.1016/j.xphs.2019.10.047; MIYAMURA K, 1974, J BIOL STAND, V2, P189, DOI 10.1016/0092-1157(74)90015-8; Nakao H, 1997, RES MICROBIOL, V148, P45, DOI 10.1016/S0923-2508(97)81899-2; Napoleao-Pego P., 2021, SCI REP-UK; Nascimento DV, 2010, BRAZ J MED BIOL RES, V43, P460, DOI 10.1590/S0100-879X2010007500032; Neal SE, 2009, J CLIN MICROBIOL, V47, P4037, DOI 10.1128/JCM.00473-09; Pacheco LGC, 2007, J MED MICROBIOL, V56, P480, DOI 10.1099/jmm.0.46997-0; Paniz-Mondolfi AE, 2019, EMERG INFECT DIS, V25, P625, DOI 10.3201/eid2504.181305; Patey O, 1997, J CLIN MICROBIOL, V35, P441, DOI 10.1128/JCM.35.2.441-445.1997; Pimenta FP, 2008, MOL CELL PROBE, V22, P189, DOI 10.1016/j.mcp.2008.01.001; Puliti M, 2006, J MED MICROBIOL, V55, P229, DOI 10.1099/jmm.0.46135-0; Reacher M, 2000, EMERG INFECT DIS, V6, P640; Rodnin MV, 2020, TOXINS, V12, DOI 10.3390/toxins12110704; Romney MG, 2006, J CLIN MICROBIOL, V44, P1625, DOI 10.1128/JCM.44.5.1625-1629.2006; Sane J, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.2.30105; Scheifer C, 2019, MED MALADIES INFECT, V49, P463, DOI 10.1016/j.medmal.2018.12.001; Schuhegger R, 2008, CLIN INFECT DIS, V47, P288, DOI 10.1086/589575; SESARDIC D, 1992, J GEN MICROBIOL, V138, P2197, DOI 10.1099/00221287-138-10-2197; Sevigny LM, 2013, INFECT IMMUN, V81, P3992, DOI 10.1128/IAI.00462-13; Sharma NC, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0131-y; Sing A, 2005, CLIN INFECT DIS, V40, P325, DOI 10.1086/426687; Sing A, 2003, J CLIN MICROBIOL, V41, P4848, DOI 10.1128/JCM.41.10.4848-4851.2003; Sing A, 2011, J CLIN MICROBIOL, V49, P2485, DOI 10.1128/JCM.00452-11; Tiwari TSP, 2008, CLIN INFECT DIS, V46, P395, DOI 10.1086/525262; Usuwanthim K, 2008, ASIAN PAC J ALLERGY, V26, P47; von Hunolstein C, 2003, J MED MICROBIOL, V52, P181, DOI 10.1099/jmm.0.04864-0; von Hunolstein Christina, 1999, Giornale Italiano di Malattie Infettive, V5, P299; Wenzel EV, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57103-5; Winkler DFH, 2020, METHODS MOL BIOL, V2103, P151, DOI 10.1007/978-1-0716-0227-0_10; Zhu SL, 2019, BIOCHEMISTRY-US, V58, P646, DOI 10.1021/acs.biochem.8b01123	64	6	6	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							313	10.3390/vaccines9040313			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4VZ	33810325	Green Submitted, gold, Green Published			2022-04-29	WOS:000643780100001
J	Eklundh, A; Rhedin, S; Ryd-Rinder, M; Andersson, M; Gantelius, J; Gaudenzi, G; Lindh, M; Peltola, V; Waris, M; Naucler, P; Martensson, A; Alfven, T				Eklundh, Annika; Rhedin, Samuel; Ryd-Rinder, Malin; Andersson, Maria; Gantelius, Jesper; Gaudenzi, Giulia; Lindh, Magnus; Peltola, Ville; Waris, Matti; Naucler, Pontus; Martensson, Andreas; Alfven, Tobias			Etiology of Clinical Community-Acquired Pneumonia in Swedish Children Aged 1-59 Months with High Pneumococcal Vaccine Coverage-The TREND Study	VACCINES			English	Article						pneumococcal conjugate vaccines; bacterial pneumonia; viral pneumonia; respiratory infection; etiology; children; World Health Organization	STREPTOCOCCUS-PNEUMONIAE; INFECTION; DIAGNOSIS	(1) Immunization with pneumococcal conjugate vaccines has decreased the burden of community-acquired pneumonia (CAP) in children and likely led to a shift in CAP etiology. (2) The Trial of Respiratory infections in children for ENhanced Diagnostics (TREND) enrolled children 1-59 months with clinical CAP according to the World Health Organization (WHO) criteria at Sachs' Children and Youth Hospital, Stockholm, Sweden. Children with rhonchi and indrawing underwent "bronchodilator challenge". C-reactive protein and nasopharyngeal PCR detecting 20 respiratory pathogens, were collected from all children. Etiology was defined according to an a priori defined algorithm based on microbiological, biochemical, and radiological findings. (3) Of 327 enrolled children, 107 (32%) required hospitalization; 91 (28%) received antibiotic treatment; 77 (24%) had a chest X-ray performed; and 60 (18%) responded to bronchodilator challenge. 243 (74%) episodes were classified as viral, 11 (3%) as mixed viral-bacterial, five (2%) as bacterial, two (0.6%) as atypical bacterial and 66 (20%) as undetermined etiology. After exclusion of children responding to bronchodilator challenge, the proportion of bacterial and mixed viral-bacterial etiology was 1% and 4%, respectively. (4) The novel TREND etiology algorithm classified the majority of clinical CAP episodes as of viral etiology, whereas bacterial etiology was uncommon. Defining CAP in children <5 years is challenging, and the WHO definition of clinical CAP is not suitable for use in children immunized with pneumococcal conjugate vaccines.	[Eklundh, Annika; Rhedin, Samuel; Alfven, Tobias] Sachs Children & Youth Hosp, Pediat Emergency Dept, S-11883 Stockholm, Sweden; [Eklundh, Annika; Gaudenzi, Giulia; Alfven, Tobias] Karolinska Inst, Dept Global Publ Hlth, S-17177 Stockholm, Sweden; [Rhedin, Samuel] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden; [Ryd-Rinder, Malin] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Pediat Emergency Dept, S-17164 Solna, Sweden; [Ryd-Rinder, Malin] Karolinska Inst, Dept Womens & Childrens Hlth, S-17177 Stockholm, Sweden; [Andersson, Maria; Lindh, Magnus] Univ Gothenburg, Dept Infect Dis, S-40530 Gothenburg, Sweden; [Gantelius, Jesper; Gaudenzi, Giulia] KTH Royal Inst Technol, Dept Prot Sci, Div Nanobiotechnol, SciLifeLab, S-17165 65 Solna, Sweden; [Peltola, Ville] Univ Turku, Turku Univ Hosp, Dept Paediat & Adolescent Med, FI-20521 Turku, Finland; [Waris, Matti] Univ Turku, Inst Biomed, FI-20521 Turku, Finland; [Waris, Matti] Turku Univ Hosp, Clin Microbiol, FI-20521 Turku, Finland; [Naucler, Pontus] Dept Med, Div Infect Dis, S-17176 Stockholm, Sweden; [Naucler, Pontus] Karolinska Inst, S-17164 Solna, Sweden; [Naucler, Pontus] Karolinska Univ Hosp, Dept Infect Dis, S-17164 Solna, Sweden; [Martensson, Andreas] Uppsala Univ, Dept Womens & Childrens Hlth, Int Maternal & Child Hlth IMCH, S-75237 Uppsala, Sweden		Eklundh, A (通讯作者)，Sachs Children & Youth Hosp, Pediat Emergency Dept, S-11883 Stockholm, Sweden.; Eklundh, A (通讯作者)，Karolinska Inst, Dept Global Publ Hlth, S-17177 Stockholm, Sweden.	annika.eklundh@ki.se; samuel.rhedin@ki.se; malin.ryd-rinder@sll.se; maria.andersson.3@gu.se; jesper.gantelius@gmail.com; giulia.gaudenzi@ki.se; magnus.lindh@microbio.gu.se; vilpel@utu.fi; mwaris@utu.fi; pontus.naucler@ki.se; andreas.martensson@kbh.uu.se; tobias.alfven@ki.se		Ryd Rinder, Malin/0000-0002-2947-4117; Alfven, Tobias/0000-0002-2328-3512; Eklundh, Annika/0000-0003-0482-4851; Rhedin, Samuel Arthur/0000-0001-5798-2875	European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013)/ERCEuropean Research Council (ERC) [615458]; Stiftelsen Frimurare Barnhuset in Stockholm; Martin Rind's Foundation; VetenskapsradetSwedish Research Council [2019-05170];  [ALF-20150503];  [HMT-20150818]	This research was funded by (grant number: ALF-20150503, HMT-20150818, European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement No. 615458, Stiftelsen Frimurare Barnhuset in Stockholm, Martin Rind's Foundation and Vetenskapsradet postdoc grant 2019-05170.	Andersson ME, 2014, SCAND J INFECT DIS, V46, P897, DOI 10.3109/00365548.2014.951681; Benet T, 2017, CLIN INFECT DIS, V65, P604, DOI 10.1093/cid/cix378; Berg AS, 2016, PEDIATR INFECT DIS J, V35, pE69, DOI 10.1097/INF.0000000000001009; Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353; Chochua S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167725; Elemraid MA, 2013, EUR RESPIR J, V42, P1595, DOI 10.1183/09031936.00199112; Elfving K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146054; Fathima P, 2018, CLIN INFECT DIS, V66, P1075, DOI 10.1093/cid/cix923; Ginsburg AS, 2019, JAMA PEDIATR, V173, P21, DOI 10.1001/jamapediatrics.2018.3407; Herberg JA, 2016, JAMA-J AM MED ASSOC, V316, P835, DOI 10.1001/jama.2016.11236; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Jehan F, 2020, NEW ENGL J MED, V383, P24, DOI 10.1056/NEJMoa1911998; Karppinen S, 2019, VACCINE, V37, P2935, DOI 10.1016/j.vaccine.2019.04.026; Karppinen S, 2017, AM J RESP CRIT CARE, V196, P1172, DOI 10.1164/rccm.201702-0357OC; Keitel K, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002411; Knoll MD, 2017, CLIN INFECT DIS, V64, pS213, DOI 10.1093/cid/cix144; Lewnard JA, 2016, J INFECT DIS, V214, P1411, DOI 10.1093/infdis/jiw381; Lindstrand A, 2016, VACCINE, V34, P4565, DOI 10.1016/j.vaccine.2016.07.031; Lindstrand A, 2014, PEDIATRICS, V134, pE1528, DOI 10.1542/peds.2013-4177; O'Brien KL, 2019, LANCET, V394, P757, DOI 10.1016/S0140-6736(19)30721-4; Piters WAAD, 2016, AM J RESP CRIT CARE, V194, P1104, DOI 10.1164/rccm.201602-0220OC; Rambaud-Althaus C, 2015, LANCET INFECT DIS, V15, P439, DOI 10.1016/S1473-3099(15)70017-4; Rhedin S, 2016, LANCET RESP MED, V4, P423, DOI 10.1016/S2213-2600(16)30067-4; Rhedin S, 2015, THORAX, V70, P847, DOI 10.1136/thoraxjnl-2015-206933; Rhedin S, 2014, PEDIATRICS, V133, pE538, DOI 10.1542/peds.2013-3042; Rhedin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051491; Rhedin SA, 2019, JMIR RES PROTOC, V8, DOI 10.2196/12705; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; WHO, 2020 GLOB SUMM; Wingerter SL, 2012, PEDIATR INFECT DIS J, V31, P561, DOI 10.1097/INF.0b013e31824da716; Zar HJ, 2016, LANCET RESP MED, V4, P463, DOI 10.1016/S2213-2600(16)00096-5	31	3	3	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							384	10.3390/vaccines9040384			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4TI	33919904	Green Published, gold			2022-04-29	WOS:000643773100001
J	Pires, C				Pires, Carla			What Is the State-of-the-Art in Clinical Trials on Vaccine Hesitancy 2015-2020?	VACCINES			English	Review						vaccine hesitancy; vaccination; vaccine refusal; hesitancy determinants; immunization; randomized controlled trial; clinical trial	VIRTUAL-REALITY; COMMUNICATION; PARENTS; MOTHERS; INTERVENTIONS; BELIEFS	Background: Vaccine hesitancy is related to a delay in acceptance or refusal of vaccination. Aim: to perform a systematic review of clinical trials on vaccine hesitancy (2015-2020). Methods: a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria (PRISMA). Five databases were screened-PubMed, Cochrane Library, DOAJ, SciELO and b-on-which comprise multiple resources. Keywords: "Vaccine hesitancy" and ("randomized controlled trial" or "clinical trial"). Inclusion criteria: trials about "vaccine hesitancy" enrolling patients and/or health professionals (2015-2020). Exclusion criteria: studies about other topics, repeated and qualitative studies, reviews and papers written in languages other than English, Portuguese, French or Spanish. Results: a total of 35 trials out of 90 were selected (19 PubMed, 14 Cochrane Library, 0 DOAJ, 0 SciELO and 2 b-on). Selected trials were classified into five topics: children/pediatric (n = 5); online or electronic information (n = 5); vaccination against a specific disease (n = 15) (e.g., influenza or COVID-2019); miscellaneous (n = 4); and educational strategies (n = 6). Conclusion: the provision of online or electronic information (e.g., through virtual reality, social websites of experts, or apps), communication-based interventions and training of health professionals, residents or subjects seemed to improve vaccine hesitancy.	[Pires, Carla] Univ Lusofona Humanidades & Tecnol, CBIOS, Res Ctr Biosci & Hlth Technol, Escola Ciencias & Tecnol Saude, Campo Grande 376, P-1740024 Lisbon, Portugal		Pires, C (通讯作者)，Univ Lusofona Humanidades & Tecnol, CBIOS, Res Ctr Biosci & Hlth Technol, Escola Ciencias & Tecnol Saude, Campo Grande 376, P-1740024 Lisbon, Portugal.	p5558@ulusofona.pt	Pires, Carla/P-2608-2016	Pires, Carla/0000-0003-4526-0271			Abd H.B., 2017, MED J MALAYS, V72, P64; Abukhaled M, 2021, J PEDIATR HEALTH CAR, V35, P180, DOI 10.1016/j.pedhc.2020.09.006; Ashfield S, 2020, J MED INTERNET RES, V22, DOI 10.2196/20002; Baxter AL, 2017, VACCINE, V35, P4213, DOI 10.1016/j.vaccine.2017.06.029; Betsch C, 2016, EUR J PUBLIC HEALTH, V26, P378, DOI 10.1093/eurpub/ckv154; Bocquier A, 2017, EXPERT REV VACCINES, V16, P1107, DOI 10.1080/14760584.2017.1381020; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Chapman D, 2009, J CAN ACAD CHILD ADO, V18, P148; Cochrane Library, 2020, COCHRANE DB SYST REV; Crescitelli MED, 2020, PUBLIC HEALTH, V180, P38, DOI 10.1016/j.puhe.2019.10.027; Daley MF, 2018, AM J PREV MED, V55, P44, DOI 10.1016/j.amepre.2018.04.010; Delgado-Rodriguez M, 2004, J EPIDEMIOL COMMUN H, V58, P635, DOI 10.1136/jech.2003.008466; Dempsey A., 2017, OPEN FORUM INFECT DI, V4, pS61, DOI [10.1093/ofid/ofx162.144, DOI 10.1093/OFID/OFX162.144]; Dempsey AF, 2019, VACCINE, V37, P1307, DOI 10.1016/j.vaccine.2019.01.051; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dyda A, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09327-8; Facciola A, 2019, J PUBLIC HEALTH RES, V8, P13, DOI 10.4081/jphr.2019.1436; Frascella B, 2020, VACCINE, V38, P433, DOI 10.1016/j.vaccine.2019.10.089; Gagneur A, 2019, EUROSURVEILLANCE, V24, P15, DOI 10.2807/1560-7917.ES.2019.24.36.1800641; Gagneur A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5724-y; Giese H, 2020, VACCINE, V38, P2070, DOI 10.1016/j.vaccine.2019.11.038; Glanz JM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1117; Gopalakrishnan S, 2013, J Family Med Prim Care, V2, P9, DOI 10.4103/2249-4863.109934; Gualano MR, 2019, HUM VACC IMMUNOTHER, V15, P918, DOI 10.1080/21645515.2018.1564437; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Henrikson NB, 2018, CLIN PEDIATR, V57, P1523, DOI 10.1177/0009922818787868; Henrikson NB, 2017, PUBLIC HEALTH REP, V132, P451, DOI 10.1177/0033354917711175; Henrikson NB, 2015, PEDIATRICS, V136, P70, DOI 10.1542/peds.2014-3199; Jakovljevic M, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-020-00590-3; Jakovljevic M, 2019, J MED ECON, V22, P722, DOI 10.1080/13696998.2019.1600523; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Karafillakis E, 2019, HUM VACC IMMUNOTHER, V15, P1615, DOI 10.1080/21645515.2018.1564436; Kaufman J, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010038.pub3; Kestenbaum LA, 2015, PEDIATR ANN, V44, pE71, DOI 10.3928/00904481-20150410-07; Khodadadi AB, 2020, ETHNIC DIS, V30, P661, DOI 10.18865/ed.30.4.661; Kornides ML, 2019, J WOMENS HEALTH, V28, P1586; Lambert J, 2011, CLIN ORTHOP RELAT R, V469, P1794, DOI 10.1007/s11999-010-1538-7; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lawes-Wickwar S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020072; Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loubet P, 2017, REV MED INTERNE, V38, P749, DOI 10.1016/j.revmed.2017.01.007; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Nagar R, 2018, VACCINE, V36, P6567, DOI 10.1016/j.vaccine.2017.11.023; Nekrasova E, 2020, HUM VACC IMMUNOTHER, V16, P1070, DOI 10.1080/21645515.2019.1707006; Nowak GJ, 2020, VACCINE, V38, P1225, DOI 10.1016/j.vaccine.2019.11.009; O'Leary ST, 2019, AM J PREV MED, V57, pE125, DOI 10.1016/j.amepre.2019.05.018; Olson O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040590; Opel DJ, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0802; Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3; Pahud B, 2020, VACCINE, V38, P7299, DOI 10.1016/j.vaccine.2020.09.043; Panozzo CA, 2020, J ADOLESCENT HEALTH, V67, P253, DOI 10.1016/j.jadohealth.2020.01.024; Philpott SE, 2017, PATIENT EDUC COUNS, V100, P1701, DOI 10.1016/j.pec.2017.05.002; PRISMA, 2020, PREFERRED REPORTING; Real FJ, 2017, ACAD PEDIATR, V17, P431, DOI 10.1016/j.acap.2017.01.010; Reno JE, 2019, HUM VACC IMMUNOTHER, V15, P1592, DOI 10.1080/21645515.2018.1547607; Reno JE, 2018, J HEALTH COMMUN, V23, P313, DOI 10.1080/10810730.2018.1442530; Salmon DA, 2019, VACCINE, V37, P6478, DOI 10.1016/j.vaccine.2019.08.080; Sanguino S., 2019, ACAD PEDIATR, V19, DOI [10.1016/j.acap.2019.05.012, DOI 10.1016/J.ACAP.2019.05.012]; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Shoup JA, 2019, HEALTH EDUC BEHAV, V46, P454, DOI 10.1177/1090198118818253; Taddio A, 2017, CAN MED ASSOC J, V189, pE227, DOI 10.1503/cmaj.160542; Uman LS, 2011, J CAN ACAD CHILD ADO, V20, P57; Van Hooste WLC, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16203981; Xiao XZ, 2020, VACCINE, V38, P5131, DOI 10.1016/j.vaccine.2020.04.076; Xu YW, 2021, HEALTH COMMUN, V36, P1354, DOI 10.1080/10410236.2020.1751400; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	70	2	2	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							348	10.3390/vaccines9040348			31	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS5LC	33916427	Green Published, gold			2022-04-29	WOS:000643819500001
J	Waite, NM; Pereira, JA; Houle, SKD; Gilca, V; Andrew, MK				Waite, Nancy M.; Pereira, Jennifer A.; Houle, Sherilyn K. D.; Gilca, Vladimir; Andrew, Melissa K.			COVID-19's Impact on Willingness to Be Vaccinated against Influenza and COVID-19 during the 2020/2021 Season: Results from an Online Survey of Canadian Adults 50 Years and Older	VACCINES			English	Article						influenza; COVID; older adults; decision-making; survey		There is considerable overlap in age-related risk factors for influenza and COVID-19. We explored the impact of the pandemic on anticipated influenza and COVID-19 vaccination behaviour in the 2020/2021 season. In May 2020, we conducted online surveys of Canadian adults 50 years and older via a market research panel platform, as part of a series of annual surveys to understand experiences with influenza. Given the current pandemic, respondents were also asked about COVID-19's impact on their vaccination decision-making for the 2020/2021 season. Of 1001 respondents aged 50-64 years, 470 (47.0%) originally intended on receiving the influenza vaccine and still planned to do so, while 200 (20%) respondents who had planned to abstain now reported willingness to receive the vaccine due to COVID-19. In the 65+ age group, 2525 (72.1%) reported that they had planned to be vaccinated and that COVID-19 had not changed their mind, while 285 individuals (8.1%) reported that they had initially planned to forgo the vaccine but now intended to receive it. Reasons for this change included COVID-19's demonstration of the devastating potential of viruses; and to protect against influenza, and decrease vulnerability to COVID-19. If the COVID-19 vaccine was available, 69.1% of 50-64 year olds and 79.5% of those 65 years and older reported they would opt to receive it. The COVID-19 pandemic has been a sobering demonstration of the dangers of infectious disease, and the value of vaccines, with implications for influenza and COVID-19 immunization programs.	[Waite, Nancy M.; Houle, Sherilyn K. D.] Univ Waterloo, Sch Pharm, Kitchener, ON N2G 1C5, Canada; [Pereira, Jennifer A.] JRL Res & Consulting Inc, Mississauga, ON L5G 0A3, Canada; [Gilca, Vladimir] Laval Univ, Inst Natl Sante Publ Quebec, Quebec City, PQ G1E 7G9, Canada; [Andrew, Melissa K.] Dalhousie Univ, Dept Med Geriatr, Halifax, NS B3H 2E1, Canada		Waite, NM (通讯作者)，Univ Waterloo, Sch Pharm, Kitchener, ON N2G 1C5, Canada.	nancy.waite@uwaterloo.ca; jennifer.pereira@jrlresearch.com; sherilyn.houle@uwaterloo.ca; vladimir.gilca@inspq.qc.ca; mandrew@dal.ca	Andrew, Melissa/AAR-7052-2021	Andrew, Melissa/0000-0001-7514-8972	Sanofi Pasteur	This research was funded by Sanofi Pasteur. The authors of the study had full control of study design, data collection and analysis, decision to publish, and preparation of the manuscript.	Andrew MK, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1180-5; Biggerstaff M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-480; Buchan SA, 2017, CAN MED ASSOC J, V189, pE146, DOI 10.1503/cmaj.151027; Canadian Community Health Survey, 2008, HLTH AG 2008 2009; Jiang C, 2020, MICROBES INFECT, V22, P236, DOI 10.1016/j.micinf.2020.05.005; John Hopkins University and Medicine Coronavirus Resource Centre, COVID DAT REG; Killingley B, 2013, INFLUENZA OTHER RESP, V7, P42, DOI 10.1111/irv.12080; Mertz D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5061; Paguio JA, 2020, VACCINE, V38, P5430, DOI 10.1016/j.vaccine.2020.06.069; Pereira JA, 2019, HUM VACC IMMUNOTHER, V15, P487, DOI 10.1080/21645515.2018.1520580; Pollara Strategic Insights, COVID 19 COM FLU SHO; Pormohammad A, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2179; Public Health Agency of Canada, 2019, VACCINATION COVERAGE; Public Health Agency of Canada, VACC UPD CAN AD 2019; Schanzer DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080481; Statistics Canada, TABLE 13 10 0788 01; Statistics Canada, TABLE 17 10 0005 01; Statistics Canada, INFL IMM 12 MONTHS A; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Zayet S, 2020, MICROBES INFECT, V22, P481, DOI 10.1016/j.micinf.2020.05.016; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021	21	5	5	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							346	10.3390/vaccines9040346			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS6LE	33916364	Green Published, gold			2022-04-29	WOS:000643887400001
J	Carvalho, VL; Long, MT				Carvalho, Valeria L.; Long, Maureen T.			Perspectives on New Vaccines against Arboviruses Using Insect-Specific Viruses as Platforms	VACCINES			English	Review						vaccines; insect-specific virus; arbovirus	FLAVIVIRUS; INFECTION	Arthropod-borne viruses (arboviruses) are global pathogens circulating endemically with local explosive outbreaks and constant encroachment into new locations. Few vaccines against arboviruses exist; most for humans are in development or clinical trials. Insect-specific viruses (ISVs) offer a unique platform for expression of arbovirus proteins, through the creation of ISV/arbovirus chimeras. Studies have shown promising results of these vaccines with several advantages over their wild-type counterparts. In this review, we discuss the current status of these potential vaccines using ISVs.	[Carvalho, Valeria L.; Long, Maureen T.] Univ Florida, Coll Vet Med, Dept Comparat Diagnost & Populat Med, 1945 SW 16th Ave, Gainesville, FL 32608 USA; [Carvalho, Valeria L.] Minist Hlth, Evandro Chagas Inst, Dept Arbovirol & Hemorrhag Fevers, Rodovia BR 316,Km 7,S-N, BR-67030000 Ananindeua, Para, Brazil		Carvalho, VL; Long, MT (通讯作者)，Univ Florida, Coll Vet Med, Dept Comparat Diagnost & Populat Med, 1945 SW 16th Ave, Gainesville, FL 32608 USA.; Carvalho, VL (通讯作者)，Minist Hlth, Evandro Chagas Inst, Dept Arbovirol & Hemorrhag Fevers, Rodovia BR 316,Km 7,S-N, BR-67030000 Ananindeua, Para, Brazil.	valeriacarvalho@iec.gov.br; longm@ufl.edu	CARVALHO, VALERIA/AAX-9296-2021	Long, Maureen/0000-0001-5337-9024; CARVALHO, VALERIA/0000-0001-8385-8253	Brazilian Federal Foundation for Support and Evaluation of Graduate Education (Capes)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [88881.369357/2019-01]; University of FloridaUniversity of Florida; Fern-Audette Endowment	This review is supported in part by the scholarship granted by the Brazilian Federal Foundation for Support and Evaluation of Graduate Education (Capes), in the scope of ProcadAmazonia-DRI, process number: 88881.369357/2019-01 as well as by the Fern-Audette Endowment and University of Florida.	Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Bolling BG, 2015, VIRUSES-BASEL, V7, P4911, DOI 10.3390/v7092851; Brady OJ, 2019, LANCET, V394, P1991, DOI 10.1016/S0140-6736(19)32790-4; Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760; Chen GL, 2020, JAMA-J AM MED ASSOC, V323, P1369, DOI 10.1001/jama.2020.2477; Collins MH, 2017, CLIN THER, V39, P1519, DOI 10.1016/j.clinthera.2017.07.001; da Silveira LTC, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4369-5; Erasmus JH, 2018, J VIROL, V92, DOI 10.1128/JVI.01274-17; Erasmus JH, 2017, DNA CELL BIOL, V36, P1045, DOI 10.1089/dna.2017.4019; Erasmus JH, 2017, NAT MED, V23, P192, DOI 10.1038/nm.4253; Erasmus JH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004119; FDA, VACCINES LICENSED US; Gao S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02881; Gerke C, 2019, EXPERT REV VACCINES, V18, P393, DOI 10.1080/14760584.2019.1562908; Goenaga S, 2015, VIRUSES-BASEL, V7, P5801, DOI 10.3390/v7112911; Guy B, 2015, VACCINE, V33, P7100, DOI 10.1016/j.vaccine.2015.09.108; Hobson-Peters J, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax7888; Kenney JL, 2014, J GEN VIROL, V95, P2796, DOI 10.1099/vir.0.068031-0; Manning JE, 2018, J INFECT DIS, V218, P7, DOI 10.1093/infdis/jiy179; Musso D, 2019, NEW ENGL J MED, V381, P1444, DOI 10.1056/NEJMra1808246; Nasar F, 2015, VIROLOGY, V484, P51, DOI 10.1016/j.virol.2015.05.009; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pingen M, 2016, IMMUNITY, V44, P1455, DOI 10.1016/j.immuni.2016.06.002; Poland GA, 2019, MAYO CLIN PROC, V94, P2572, DOI 10.1016/j.mayocp.2019.05.016; SCOTT RM, 1984, J ALLERGY CLIN IMMUN, V74, P808, DOI 10.1016/0091-6749(84)90183-0; Stapleford KA, 2020, JAMA-J AM MED ASSOC, V323, P1351, DOI 10.1001/jama.2020.2070; Vasconcelos PFC, 2016, VECTOR-BORNE ZOONOT, V16, P295, DOI 10.1089/vbz.2016.1952; Vasilakis N, 2015, CURR OPIN VIROL, V15, P69, DOI 10.1016/j.coviro.2015.08.007; Vetter V, 2018, ANN MED, V50, P110, DOI 10.1080/07853890.2017.1407035; Wallis J, 2019, CLIN EXP IMMUNOL, V196, P189, DOI 10.1111/cei.13287; Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008; WHO, W NILE VIRUS; WHO, CHIKUNGUNYA FACT SHE; WHO, DENG SEV DENG; WHO, ZIKA VIRUS; WHO Immunization, VACCINES BIOLOGICALS	36	1	1	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							263	10.3390/vaccines9030263			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5KS	33809576	gold, Green Published			2022-04-29	WOS:000634193400001
J	Locht, C				Locht, Camille			The Path to New Pediatric Vaccines against Pertussis	VACCINES			English	Review						whooping cough; acellular vaccines; whole-cell vaccines; cocoon vaccination; maternal immunization; nasal vaccination; live attenuated vaccines	OUTER-MEMBRANE VESICLES; BORDETELLA-PERTUSSIS; WHOLE-CELL; T-CELLS; NEONATAL VACCINATION; PROTECTIVE IMMUNITY; MUCOSAL IMMUNITY; TLR7 AGONIST; INFECTION; DISEASE	Whooping cough, or pertussis, mostly caused by Bordetella pertussis, is a respiratory disease that affects all age groups, but severe and fatal pertussis occurs almost exclusively in young children. The widespread use of whole-cell and, more recently, of acellular vaccines has substantially reduced the disease incidence. However, it has not been eliminated in any part of the world and has made a worrisome rebound in several areas. Cocoon and maternal immunization have been implemented in several countries but have their intrinsic limitations. To effectively control pertussis, novel vaccines are needed that protect against disease and prevent B. pertussis infection and transmission, which is not the case for current vaccines. Several approaches are contemplated, including alternative administration routes, such as nasal immunization, improvement of acellular vaccines by adding more antigens and T-cell-promoting adjuvants, and the development of novel vaccines, such as outer membrane vesicles and live attenuated vaccines. Among them, only a live attenuated vaccine has so far been assessed for safety and immunogenicity in preclinical models other than mice and is in clinical development. Before any of these vaccines can be used in neonates, extensive safety and immunogenicity assessment in pre-clinical neonatal models and in carefully designed clinical trials is necessary. The aim of this review is to discuss the current pertussis problem, implemented strategies to resolve it, the value of animal models and novel vaccine approaches.	[Locht, Camille] Univ Lille, CIIL Ctr Infect & Immun Lille, Inst Pasteur Lille, CHU Lille,CNRS,UMR 8204,INSERM,U1019, F-59000 Lille, France		Locht, C (通讯作者)，Univ Lille, CIIL Ctr Infect & Immun Lille, Inst Pasteur Lille, CHU Lille,CNRS,UMR 8204,INSERM,U1019, F-59000 Lille, France.	camille.locht@pasteur-lille.fr					Allen AC, 2018, MUCOSAL IMMUNOL, V11, P1763, DOI 10.1038/s41385-018-0080-x; Althouse BM, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0382-8; ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; Antunes RD, 2018, J CLIN INVEST, V128, P3853, DOI 10.1172/JCI121309; Asensio CJA, 2011, VACCINE, V29, P1649, DOI 10.1016/j.vaccine.2010.12.068; Belloni C, 2003, PEDIATRICS, V111, P1042, DOI 10.1542/peds.111.5.1042; Berstad AKH, 2000, J MED MICROBIOL, V49, P157, DOI 10.1099/0022-1317-49-2-157; Boehm DT, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0136-2; Boehm DT, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00857-17; Bruno C, 2016, EUR J PHARM BIOPHARM, V105, P1, DOI 10.1016/j.ejpb.2016.05.013; BUNNEY WE, 1965, AM J PUBLIC HEALTH N, V55, P1451, DOI 10.2105/AJPH.55.9.1451; Burns DL, 2014, J INFECT DIS, V209, pS32, DOI 10.1093/infdis/jit491; Cauchi S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02872; Chasaide CN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040621; Chen Q, 2019, CURR OPIN MICROBIOL, V47, P74, DOI 10.1016/j.mib.2019.01.002; Cherry JD, 1999, CLIN INFECT DIS, V28, pS107, DOI 10.1086/515057; Chiappini E, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-151; Collins SD, 1929, PUBLIC HEALTH REP, V44, P763, DOI 10.2307/4579202; Cornford-Nairns R, 2012, J MICROBIOL BIOTECHN, V22, P856, DOI 10.4014/jmb.1108.08003; Couch RB, 2004, NEW ENGL J MED, V350, P860, DOI 10.1056/NEJMp048006; Debrie AS, 2019, J IMMUNOL, V203, P3293, DOI 10.4049/jimmunol.1901102; Dewan KK, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020217; Drezner D, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03243-w; Dubois V, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00270-8; Elahi S, 2007, TRENDS MICROBIOL, V15, P462, DOI 10.1016/j.tim.2007.09.003; Elizagaray ML, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01879; Gaillard ME, 2014, VACCINE, V32, P931, DOI 10.1016/j.vaccine.2013.12.048; ENGLUND JA, 1995, PEDIATRICS, V96, P580; Esposito S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01344; Zurita ME, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00125; Fedele G, 2017, TOXINS, V9, DOI 10.3390/toxins9100293; Feunou PF, 2008, VACCINE, V26, P5722, DOI 10.1016/j.vaccine.2008.08.018; FINE PEM, 1982, LANCET, V1, P666; Gavillet BM, 2015, VACCINE, V33, P3450, DOI 10.1016/j.vaccine.2015.05.089; Geurtsen J, 2008, VACCINE, V26, P899, DOI 10.1016/j.vaccine.2007.12.012; Halasa NB, 2008, J PEDIATR-US, V153, P327, DOI 10.1016/j.jpeds.2008.03.011; Healy CM, 2015, PEDIATR INFECT DIS J, V34, P22, DOI 10.1097/INF.0000000000000486; Hewlett EL, 2005, NEW ENGL J MED, V352, P1215, DOI 10.1056/NEJMcp041025; Higgs R, 2012, MUCOSAL IMMUNOL, V5, P485, DOI 10.1038/mi.2012.54; Holubova J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040695; Hozbor D, 2019, ADV EXP MED BIOL, V1183, P115, DOI 10.1007/5584_2019_407; Jahnmatz M, 2020, LANCET INFECT DIS, V20, P1290, DOI 10.1016/S1473-3099(20)30274-7; JANDA WM, 1994, J CLIN MICROBIOL, V32, P2851, DOI 10.1128/JCM.32.11.2851-2853.1994; Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3; Kanojia G, 2018, J CONTROL RELEASE, V286, P167, DOI 10.1016/j.jconrel.2018.07.035; Kapil P, 2018, J INFECT DIS, V217, P1231, DOI 10.1093/infdis/jiy022; KENDRICK P. L., 1947, American Journal of Public Health, V37, P803, DOI 10.2105/AJPH.37.7.803-b; KENDRICK PL, 1975, J INFECT DIS, V132, P707, DOI 10.1093/infdis/132.6.707; Kilgore PE, 2016, CLIN MICROBIOL REV, V29, P449, DOI 10.1128/CMR.00083-15; Knuf M, 2008, J PEDIATR-US, V152, P655, DOI 10.1016/j.jpeds.2007.09.034; Li P, 2016, INT J PHARMACEUT, V513, P183, DOI 10.1016/j.ijpharm.2016.08.059; Li R, 2010, J VIROL, V84, P7105, DOI 10.1128/JVI.02542-09; Lin A, 2020, J CLIN INVEST, V130, P2332, DOI 10.1172/JCI135020; Locht C, 2018, VACCINE, V36, P5460, DOI 10.1016/j.vaccine.2017.11.055; Locht C, 2017, J INFECT DIS, V216, P117, DOI 10.1093/infdis/jix254; Maertens K, 2020, EUR J PEDIATR, V179, P235, DOI 10.1007/s00431-019-03563-w; Mahon BP, 1997, J EXP MED, V186, P1843, DOI 10.1084/jem.186.11.1843; Mannerstedt G, 1934, J PEDIATR-US, V5, P596, DOI 10.1016/S0022-3476(34)80039-X; Marr N, 2008, VACCINE, V26, P4306, DOI 10.1016/j.vaccine.2008.06.017; Mascart F, 2003, J IMMUNOL, V170, P1504, DOI 10.4049/jimmunol.170.3.1504; Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005; Medkova A.Y., 2020, J MICROBIOL EPIDEMIO, V97, P312, DOI [10.36233/0372-9311-2020-97-4-3, DOI 10.36233/0372-9311-2020-97-4-3]; Merkel TJ, 2020, CLIN INFECT DIS, V71, P412, DOI 10.1093/cid/ciz842; Mielcarek N, 2006, PLOS PATHOG, V2, P662, DOI 10.1371/journal.ppat.0020065; Mills KHG, 1998, INFECT IMMUN, V66, P594, DOI 10.1128/IAI.66.2.594-602.1998; Misiak A, 2017, VACCINE, V35, P5256, DOI 10.1016/j.vaccine.2017.08.009; MORTIMER EA, 1979, REV INFECT DIS, V1, P927; Nguyen AW, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay9258; Olin P, 1997, PEDIATR INFECT DIS J, V16, P517, DOI 10.1097/00006454-199705000-00012; PROVENZANO RW, 1965, NEW ENGL J MED, V273, P959, DOI 10.1056/NEJM196510282731804; Queenan AM, 2019, VACCINE, V37, P80, DOI 10.1016/j.vaccine.2018.11.028; Raeven RHM, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030429; Raeven RHM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63998-2; Raeven RHM, 2016, SCI REP-UK, V6, DOI 10.1038/srep38240; Reither K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114602; ROBERTS M, 1990, INFECT IMMUN, V58, P732, DOI 10.1128/IAI.58.3.732-739.1990; Roberts R, 2008, VACCINE, V26, P4639, DOI 10.1016/j.vaccine.2008.07.004; Ross PJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003264; Rowe SL, 2015, VACCINE, V33, P1791, DOI 10.1016/j.vaccine.2015.02.051; Ryan EJ, 1999, INFECT IMMUN, V67, P6270; Schnoeller C, 2014, AM J RESP CRIT CARE, V189, P194, DOI [10.1164/rccm.201307-227OC, 10.1164/rccm.201307-1227OC]; Shi W, 2018, IMMUNOL LETT, V198, P26, DOI 10.1016/j.imlet.2018.03.012; Skerry CM, 2009, CLIN VACCINE IMMUNOL, V16, P1344, DOI 10.1128/CVI.00082-09; Solans L, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03068; Solans L, 2018, MUCOSAL IMMUNOL, V11, P1753, DOI 10.1038/s41385-018-0073-9; Suzuki K, 2017, MICROBIOL IMMUNOL, V61, P371, DOI 10.1111/1348-0421.12504; Thalen M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030523; THOMAS G, 1975, J HYG-CAMBRIDGE, V74, P233, DOI 10.1017/S0022172400024293; Thorstensson R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083449; Troseid Marius, 2006, J Infect, V52, pe11, DOI 10.1016/j.jinf.2005.04.014; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Urwyler P, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-397; von Konig CHW, 2002, LANCET INFECT DIS, V2, P744, DOI 10.1016/S1473-3099(02)00452-8; Wanlapakorn N, 2020, CLIN INFECT DIS, V71, P72, DOI 10.1093/cid/ciz778; Warfel JM, 2013, MUCOSAL IMMUNOL, V6, P787, DOI 10.1038/mi.2012.117; Warfel JM, 2015, CURR OPIN IMMUNOL, V35, P48, DOI 10.1016/j.coi.2015.05.008; Warfel JM, 2014, J INFECT DIS, V210, P604, DOI 10.1093/infdis/jiu090; Warfel JM, 2014, P NATL ACAD SCI USA, V111, P787, DOI 10.1073/pnas.1314688110; Warfel JM, 2012, J INFECT DIS, V206, P902, DOI 10.1093/infdis/jis443; Warfel JM, 2012, INFECT IMMUN, V80, P1530, DOI 10.1128/IAI.06310-11; Wearing HJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000647; Wendelboe AM, 2007, PEDIATR INFECT DIS J, V26, P293, DOI 10.1097/01.inf.0000258699.64164.6d; Wilk MM, 2019, EMERG MICROBES INFEC, V8, P169, DOI 10.1080/22221751.2018.1564630; Wilk MM, 2017, J IMMUNOL, V199, P233, DOI 10.4049/jimmunol.1602051; Wood N, 2018, JAMA PEDIATR, V172, P1045, DOI 10.1001/jamapediatrics.2018.2349; World Health Organization, 2016, IMM COV DTP3 VACC IN; Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0	107	5	5	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							228	10.3390/vaccines9030228			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE6BJ	33807962	Green Published, gold			2022-04-29	WOS:000634236700001
J	Petry, M; Palus, M; Leitzen, E; Mitterreiter, JG; Huang, B; Kroger, A; Verjans, GMGM; Baumgartner, W; Rimmelzwaan, GF; Ruzek, D; Osterhaus, A; Prajeeth, CK				Petry, Monique; Palus, Martin; Leitzen, Eva; Mitterreiter, Johanna Gracia; Huang, Bei; Kroeger, Andrea; Verjans, Georges M. G. M.; Baumgartner, Wolfgang; Rimmelzwaan, Guus F.; Ruzek, Daniel; Osterhaus, Albert; Prajeeth, Chittappen Kandiyil			Immunity to TBEV Related Flaviviruses with Reduced Pathogenicity Protects Mice from Disease but Not from TBEV Entry into the CNS	VACCINES			English	Article						tick-borne encephalitis virus; Langat virus; CNS; neuronal damage; virus induced immunity		Tick-borne encephalitis virus (TBEV) is a leading cause of vector-borne viral encephalitis with expanding endemic regions across Europe. In this study we tested in mice the efficacy of preinfection with a closely related low-virulent flavivirus, Langat virus (LGTV strain TP21), or a naturally avirulent TBEV strain (TBEV-280) in providing protection against lethal infection with the highly virulent TBEV strain (referred to as TBEV-Hypr). We show that prior infection with TP21 or TBEV-280 is efficient in protecting mice from lethal TBEV-Hypr challenge. Histopathological analysis of brains from nonimmunized mice revealed neuronal TBEV infection and necrosis. Neuroinflammation, gliosis, and neuronal necrosis was however also observed in some of the TP21 and TBEV-280 preinfected mice although at reduced frequency as compared to the nonimmunized TBEV-Hypr infected mice. qPCR detected the presence of viral RNA in the CNS of both TP21 and TBEV-280 immunized mice after TBEV-Hypr challenge, but significantly reduced compared to mock-immunized mice. Our results indicate that although TBEV-Hypr infection is effectively controlled in the periphery upon immunization with low-virulent LGTV or naturally avirulent TBEV 280, it may still enter the CNS of these animals. These findings contribute to our understanding of causes for vaccine failure in individuals vaccinated with TBE vaccines.	[Petry, Monique; Rimmelzwaan, Guus F.; Osterhaus, Albert; Prajeeth, Chittappen Kandiyil] Univ Vet Med Hannover, Res Ctr Emerging Infect & Zoonoses, Bunteweg 17, D-30559 Hannover, Germany; [Palus, Martin; Ruzek, Daniel] Vet Res Inst, Hudcova 70, CZ-62100 Brno, Czech Republic; [Palus, Martin; Ruzek, Daniel] Czech Acad Sci, Inst Parasitol, Biol Ctr, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic; [Leitzen, Eva; Huang, Bei; Baumgartner, Wolfgang] Univ Vet Med Hannover, Dept Pathol, Bunteweg 17, D-30559 Hannover, Germany; [Mitterreiter, Johanna Gracia] Paul Ehrlich Inst, Dept Virol, D-63225 Langen, Germany; [Kroeger, Andrea] Helmholtz Ctr Infect Res, Innate Immun & Infect, D-38124 Braunschweig, Germany; [Kroeger, Andrea] Otto von Guericke Univ, Inst Med Microbiol & Hosp Hyg, Leipziger Str 44, D-39120 Magdeburg, Germany; [Kroeger, Andrea] Otto von Guericke Univ, Ctr Behav Brain Sci, D-39120 Magdeburg, Germany; [Verjans, Georges M. G. M.] Erasmus MC, Dept Virosci, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands		Prajeeth, CK (通讯作者)，Univ Vet Med Hannover, Res Ctr Emerging Infect & Zoonoses, Bunteweg 17, D-30559 Hannover, Germany.	Monique.petry@tiho-hannover.de; Palus@paru.cas.cz; Eva.Leitzen@tiho-hannover.de; johanna.mitterreiter@pei.de; Bei.huang@tiho-hannover.de; andrea.kroeger@med.ovgu.de; g.verjans@erasmusmc.nl; wolfgang.baumgaertner@tiho-hannover.de; guus.rimmelzwaan@tiho-hannover.de; ruzekd@paru.cas.cz; albert.osterhaus@tiho-hannover.de; prajeeth.chittappen.kandiyil@tiho-hannover.de	Růžek, Daniel/G-9275-2014; Palus, Martin/N-1263-2017; Rimmelzwaan, Guus/F-9677-2016	Růžek, Daniel/0000-0003-4655-2380; Petry, Monique/0000-0002-8482-8977; Palus, Martin/0000-0002-4279-7092; Rimmelzwaan, Guus/0000-0002-1921-4581; Leitzen, Eva/0000-0002-3818-9246; Verjans, Georges/0000-0002-2465-2674; Prajeeth, Chittappen K/0000-0002-6631-2096	Federal Ministry of Education and Research within the TBENAGER grant; Alexander von Humboldt Foundation by the German Federal Ministry of Education and ResearchAlexander von Humboldt Foundation; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)German Research Foundation (DFG) [-398066876/GRK 2485/1]; Czech Science FoundationGrant Agency of the Czech Republic [20-14325S, 20-30500S]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG); University of Veterinary Medicine Hannover, Foundation	We thank the Federal Ministry of Education and Research for funding this study within the TBENAGER grant for A.O. This work was funded in part by the Alexander von Humboldt Foundation in the framework of the Alexander von Humboldt Professorship endowed by the German Federal Ministry of Education and Research to G.F.R. We thank the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)-398066876/GRK 2485/1, VIPER for funding parts of the study. We thank the Czech Science Foundation for support (grant No. 20-14325S to DR and No. 20-30500S to Ma.P. (Martin Palus)). This publication was supported by Deutsche Forschungsgemeinschaft and University of Veterinary Medicine Hannover, Foundation within the funding programme Open Access Publishing.	Andersson CR, 2010, VACCINE, V28, P2827, DOI 10.1016/j.vaccine.2010.02.001; Attig F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133217; Beran J, 2019, VACCINE, V37, P4623, DOI 10.1016/j.vaccine.2017.12.081; Blom K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02174; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Chen CJ, 2010, J GEN VIROL, V91, P1028, DOI 10.1099/vir.0.013565-0; Chen Z, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1280-8; Cornelius ADA, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01951-w; Dai XY, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0081-6; Detje CN, 2015, J VIROL, V89, P2731, DOI 10.1128/JVI.02044-14; Fares M, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01756-x; Formanova PP, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1596-z; Garber C, 2019, NAT NEUROSCI, V22, P1276, DOI 10.1038/s41593-019-0427-y; Gelpi E, 2006, J NEUROVIROL, V12, P322, DOI 10.1080/13550280600848746; Ghoshal A, 2007, GLIA, V55, P483, DOI 10.1002/glia.20474; Gritsun TS, 2003, ANTIVIR RES, V57, P129, DOI 10.1016/S0166-3542(02)00206-1; GRITSUN TS, 1993, VIRUS RES, V27, P201, DOI 10.1016/0168-1702(93)90082-X; Heinz FX, 2007, VACCINE, V25, P7559, DOI 10.1016/j.vaccine.2007.08.024; Ho CY, 2017, ANN NEUROL, V82, P121, DOI 10.1002/ana.24968; Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]; Kovalev SY, 2017, INFECT GENET EVOL, V55, P159, DOI 10.1016/j.meegid.2017.09.014; Kubinski M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030451; Kurhade C, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0487-9; Leyssen P, 2003, J NEUROVIROL, V9, P69, DOI 10.1080/13550280390173319; Mandl CW, 1997, J GEN VIROL, V78, P1049, DOI 10.1099/0022-1317-78-5-1049; Maximova OA, 2009, J HISTOCHEM CYTOCHEM, V57, P973, DOI 10.1369/jhc.2009.954180; MAYER V, 1975, ACTA VIROL, V19, P229; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; MITROVA E, 1975, ACTA VIROL, V19, P219; Myint KSA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002980; Ngono AE, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007474; Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010; NIEDRIG M, 1994, ACTA VIROL, V38, P141; Palus M, 2014, J GEN VIROL, V95, P2411, DOI 10.1099/vir.0.068411-0; Palus M, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-77; Potokar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086219; Prajeeth CK, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0978-3; Prikhod'ko GG, 2001, VIROLOGY, V286, P328, DOI 10.1006/viro.2001.0980; Rumyantsev AA, 2006, J VIROL, V80, P1427, DOI 10.1128/JVI.80.3.1427-1439.2006; Ruzek D, 2009, VIROLOGY, V384, P1, DOI 10.1016/j.virol.2008.11.023; Ruzek D, 2008, VIROLOGY, V374, P249, DOI 10.1016/j.virol.2008.01.010; Ruzek D, 2010, TRAVEL MED INFECT DI, V8, P223, DOI 10.1016/j.tmaid.2010.06.004; Ruzek D, 2009, J GEN VIROL, V90, P1649, DOI 10.1099/vir.0.010058-0; Schwaiger M, 2003, J CLIN VIROL, V27, P136, DOI 10.1016/S1386-6532(02)00168-3; Seligman SJ, 2004, LANCET, V363, P2073, DOI 10.1016/S0140-6736(04)16459-3; Sendi P, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00119; Shrestha B, 2006, J VIROL, V80, P119, DOI 10.1128/JVI.80.1.119-129.2006; SMITH CEG, 1956, NATURE, V178, P581, DOI 10.1038/178581a0; Turtle L, 2016, J EXP MED, V213, P1331, DOI 10.1084/jem.20151517; Wang QR, 2019, J VIROL, V93, DOI 10.1128/JVI.00887-19; Weber E, 2014, J VIROL, V88, P12202, DOI 10.1128/JVI.01215-14	51	1	1	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							196	10.3390/vaccines9030196			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5IP	33652698	Green Published, gold			2022-04-29	WOS:000634187900001
J	Soares, P; Rocha, JV; Moniz, M; Gama, A; Laires, PA; Pedro, AR; Dias, S; Leite, A; Nunes, C				Soares, Patricia; Rocha, Joao Victor; Moniz, Marta; Gama, Ana; Laires, Pedro Almeida; Pedro, Ana Rita; Dias, Sonia; Leite, Andreia; Nunes, Carla			Factors Associated with COVID-19 Vaccine Hesitancy	VACCINES			English	Article						COVID-19; vaccination; vaccine hesitancy	INFLUENZA VACCINATION	It is critical to develop tailored strategies to increase acceptability of the COVID-19 vaccine and decrease hesitancy. Hence, this study aims to assess and identify factors associated with COVID-19 vaccine hesitancy in Portugal. We used data from a community-based survey, "COVID-19 Barometer: Social Opinion", which includes data regarding intention to take COVID-19 vaccines, health status, and risk perception in Portugal from September 2020 to January 2021. We used multinomial regression to identify factors associated with intention to delay or refuse to take COVID-19 vaccines. COVID-19 vaccine hesitancy in Portugal was high: 56% would wait and 9% refuse. Several factors were associated with both refusal and delay: being younger, loss of income during the pandemic, no intention of taking the flu vaccine, low confidence in the COVID-19 vaccine and the health service response during the pandemic, worse perception of government measures, perception of the information provided as inconsistent and contradictory, and answering the questionnaire before the release of information regarding the safety and efficacy of COVID-19 vaccines. It is crucial to build confidence in the COVID-19 vaccine as its perceived safety and efficacy were strongly associated with intention to take the vaccine. Governments and health authorities should improve communication and increase trust.	[Soares, Patricia; Rocha, Joao Victor; Moniz, Marta; Gama, Ana; Laires, Pedro Almeida; Pedro, Ana Rita; Dias, Sonia; Leite, Andreia; Nunes, Carla] Univ Nova Lisboa, Comprehens Hlth Res Ctr, Campo Martires Patria 130, P-1169056 Lisbon, Portugal; [Soares, Patricia; Moniz, Marta; Gama, Ana; Laires, Pedro Almeida; Pedro, Ana Rita; Dias, Sonia; Leite, Andreia; Nunes, Carla] Univ Nova Lisboa, NOVA Natl Sch Publ Hlth, Publ Hlth Res Ctr, Av Padre Cruz, P-1600560 Lisbon, Portugal		Soares, P (通讯作者)，Univ Nova Lisboa, Comprehens Hlth Res Ctr, Campo Martires Patria 130, P-1169056 Lisbon, Portugal.; Soares, P (通讯作者)，Univ Nova Lisboa, NOVA Natl Sch Publ Hlth, Publ Hlth Res Ctr, Av Padre Cruz, P-1600560 Lisbon, Portugal.	patseraos@gmail.com; jv.rocha@ensp.unl.pt; am.moniz@ensp.unl.pt; ana.gama@ensp.unl.pt; laires.pedro@gmail.com; rita.pedro@ensp.unl.pt; sonia.dias@ensp.unl.pt; andreia.leite@ensp.unl.pt; CNunes@ensp.unl.pt	Leite, Andreia/AAF-9112-2019; Soares, Patricia/J-7143-2019; GAMA, ANA FILIPA/I-6520-2012	Leite, Andreia/0000-0003-0843-0630; Soares, Patricia/0000-0001-5033-9115; Pedro, Ana Rita/0000-0002-9197-7129; GAMA, ANA FILIPA/0000-0001-6958-6159; Muniz Rocha, Joao Victor/0000-0002-8660-490X; Moniz, Marta/0000-0001-5902-9113	Fundacao Ciencia e Tecnologia, IP national support through CHRC [UIDP/04923/2020]	The present publication was funded by Fundacao Ciencia e Tecnologia, IP national support through CHRC (UIDP/04923/2020).	Comission E, 2021, UNITED FRONT BEAT CO; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Direu║ao-Geral da SauCde (DGS), 2020, AV PROGR NAC VAC; ECDC, 2021, COVID 19 SIT UPD WOR; European Centre for Disease Prevention and Control (ECDC), 2020, KEY ASP REG INTR PRI; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Hagemeister MH, 2018, PUBLIC HEALTH, V154, P102, DOI 10.1016/j.puhe.2017.10.027; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Instituto Nacional de Estatistica, 2016, INQ NAC SAUD 2014; Laires P.A., 2020, JMIR PUBLIC HLTH SUR, V7; Lazarus JV, 2020, NAT MED, V26, P1005, DOI 10.1038/s41591-020-0950-0; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mercadante AR, 2021, RES SOC ADMIN PHARM, V17, P1596, DOI 10.1016/j.sapharm.2020.12.012; Moderna, 2020, MOD COVID 19 VACC CA; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Pecorelli S., 2020, HUM VACC IMMUNOTHER, P1, DOI [10.20944/preprints202007.0295.v1, DOI 10.20944/PREPRINTS202007.0295.V1, 10.1080/21645515.2020.1829315]; Pfizer, 2020, PFIZ BIONT ANN VACC; Pichon M, 2019, J CLIN VIROL, V116, P29, DOI 10.1016/j.jcv.2019.04.008; Portuguesa R., 2020, VACINAAO COVID19 FAQ; R DEVELOPMENT CORE TEAM, 2008, R LANGUAGE ENV STAT; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Rechel B., 2019, EUR J PUBLIC HEALTH, V29, P375, DOI [10.1093/eurpub/ckz185.375, DOI 10.1093/EURPUB/CKZ185.375]; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Venables W.N., 2002, MODERN APPL STAT S, V4th; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Williams L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010017; World Health Organization, 2020, GLOBAL TUBERCULOSIS	33	84	84	78	125	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							300	10.3390/vaccines9030300			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5EF	33810131	gold, Green Published	Y	N	2022-04-29	WOS:000634176500001
J	Wang, JH; Lu, XR; Lai, XZ; Lyu, Y; Zhang, HJ; Fenghuang, YF; Jing, RZ; Li, L; Yu, WZ; Fang, H				Wang, Jiahao; Lu, Xinran; Lai, Xiaozhen; Lyu, Yun; Zhang, Haijun; Fenghuang, Yufei; Jing, Rize; Li, Li; Yu, Wenzhou; Fang, Hai			The Changing Acceptance of COVID-19 Vaccination in Different Epidemic Phases in China: A Longitudinal Study	VACCINES			English	Article						COVID-19; vaccine acceptance; change; China; phase	INFLUENZA VACCINATION; POPULATION; INTENTION; VACCINES	COVID-19 vaccines have been conditionally used in a few countries, including China since December 2020. The present study aimed to examine whether the acceptance of COVID-19 vaccination changed in different COVID-19 epidemic phases in China. Two consecutive surveys were conducted among Chinese adults in March (n = 2058) (severe epidemic phase) and November-December (n = 2013) (well-contained phase, right before the COVID-19 vaccine was conditionally approved) 2020, and 791 respondents were longitudinally followed-up. The attitude, acceptance, and preferences for future COVID-19 vaccination were compared between two epidemic phases. Multivariate logistic regression was used to identify influencing factors of acceptance. Among the 791 respondents longitudinally followed, 91.9% in March and 88.6% of them in November-December 2020 would like to get COVID-19 vaccination in China. In March 58.3% wished to get vaccinated immediately, but the proportion declined to 23.0% in November-December 2020, because more respondents wanted to delay vaccination until the vaccine's safety was confirmed. Similar results were found by comparing all respondents from the two cross-sectional surveys in different epidemic phases. The risk perception, attitude for the importance of vaccination against COVID-19, vaccination history, valuing doctor's recommendations, vaccination convenience, or vaccine price in decision-making had impacts on respondents' intention for immediate vaccination. The public acceptance for COVID-19 vaccination in China sustained at a high level in different COVID-19 epidemic phases. However, the intention of immediate vaccination declined substantially due to concerns about the vaccine's safety. Information about vaccination safety from authoritative sources, doctor's recommendations, and vaccination convenience were important in addressing vaccine hesitancy and promoting successful herd immunity for the general population in China.	[Wang, Jiahao; Lu, Xinran; Lai, Xiaozhen; Lyu, Yun; Zhang, Haijun; Fenghuang, Yufei; Jing, Rize] Peking Univ, Sch Publ Hlth, Beijing 100083, Peoples R China; [Wang, Jiahao; Lai, Xiaozhen; Lyu, Yun; Zhang, Haijun; Fenghuang, Yufei; Jing, Rize; Fang, Hai] Peking Univ, China Ctr Hlth Dev Studies, Beijing 100083, Peoples R China; [Li, Li; Yu, Wenzhou] Chinese Ctr Dis Control & Prevent, Natl Immunizat Program, Beijing 102206, Peoples R China; [Fang, Hai] Peking Univ Hlth Sci Ctr Chinese Ctr Dis Control, Beijing 100083, Peoples R China; [Fang, Hai] Natl Hlth Commiss Peoples Republ China, Key Lab Reprod Hlth, Beijing 100083, Peoples R China		Fang, H (通讯作者)，Peking Univ, China Ctr Hlth Dev Studies, Beijing 100083, Peoples R China.; Fang, H (通讯作者)，Peking Univ Hlth Sci Ctr Chinese Ctr Dis Control, Beijing 100083, Peoples R China.; Fang, H (通讯作者)，Natl Hlth Commiss Peoples Republ China, Key Lab Reprod Hlth, Beijing 100083, Peoples R China.	jiahaowang@pku.edu.cn; luxr@pku.edu.cn; laixiaozhen@pku.edu.cn; yun.lyu@bjmu.edu.cn; haijunzhang@pku.edu.cn; yffenghuang@pku.edu.cn; rzjing2015@hsc.pku.edu.cn; lili@chinacdc.cn; yuwenzhou2012@163.com; hfang@hsc.pku.edu.cn	Wang, Jiahao/ABA-3280-2021; Lu, Xinran/AGX-4952-2022	Lu, Xinran/0000-0002-9989-1573; Jing, Rize/0000-0002-1469-909X; Wang, Jiahao/0000-0001-7575-6580	Special Research Fund of Peking University (PKU) for the Prevention and Control of COVID-19; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities	This research was funded by the Special Research Fund of Peking University (PKU) for the Prevention and Control of COVID-19 and the Fundamental Research Funds for the Central Universities.	Brown KF, 2012, VACCINE, V30, P1855, DOI 10.1016/j.vaccine.2011.12.127; Burki T, 2020, LANCET INFECT DIS, V20, P292, DOI 10.1016/S1473-3099(20)30076-1; Chen SM, 2020, LANCET, V395, P764, DOI 10.1016/S0140-6736(20)30421-9; Costantino C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030545; Cottrell S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3724; Daly Michael, 2020, medRxiv, DOI 10.1101/2020.11.27.20239970; Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Dube E, 2016, VACCINE BOOK, 2ND EDITION, P507, DOI 10.1016/B978-0-12-802174-3.00026-6; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Eastwood K, 2010, MED J AUSTRALIA, V192, P33, DOI 10.5694/j.1326-5377.2010.tb03399.x; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fridman, 2020, COVID 19 VACCINE HES, DOI [10.2139/ssrn.3644775, DOI 10.2139/SSRN.3644775]; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Henrich N, 2009, Emerg Health Threats J, V2, pe8, DOI 10.3134/ehtj.09.008; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jansen VAA, 2003, SCIENCE, V301, P804, DOI 10.1126/science.1086726; Johansen K, 2009, EUROSURVEILLANCE, V14, P12; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kwok KO, 2020, J INFECTION, V80, pE32, DOI 10.1016/j.jinf.2020.03.027; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Lazarus JV, 2020, NAT MED, V26, P1005, DOI 10.1038/s41591-020-0950-0; Lee GM, 2020, JAMA-J AM MED ASSOC, V324, P1937, DOI 10.1001/jama.2020.19692; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Liu W, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072304; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9; Maurer J, 2009, VACCINE, V27, P5732, DOI 10.1016/j.vaccine.2009.07.080; National Medical Products Administration, GUID CLIN EV COVID 1; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Piot P, 2019, NATURE, V575, P119, DOI 10.1038/s41586-019-1656-7; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Sypsa V, 2009, EUROSURVEILLANCE, V14, P2; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; U.S. Food and Drug Administration, DEV LIC VACC PREV CO; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; WHO, COR DIS COVID 19 DAS; WHO, OV COVID 19 PAND; WHO, WHO TARG PROD PROF C; WHO, UPD COVID 19 VACC DE; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, VACCINE; World Health Organization, DRAFT LANDSC TRACK C; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Xu TL, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00716-0; Zhang SX, 2020, FRONT MED-PRC, V14, P215, DOI 10.1007/s11684-020-0766-9	58	15	18	18	33	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							191	10.3390/vaccines9030191			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5FD	33668923	gold, Green Published			2022-04-29	WOS:000634178900001
J	Bergmann, M; Freisl, M; Hartmann, K; Speck, S; Truyen, U; Zablotski, Y; Mayr, M; Wehner, A				Bergmann, Michele; Freisl, Monika; Hartmann, Katrin; Speck, Stephanie; Truyen, Uwe; Zablotski, Yury; Mayr, Matthias; Wehner, Astrid			Antibody Response to Canine Parvovirus Vaccination in Dogs with Hypothyroidism Treated with Levothyroxine	VACCINES			English	Article						CPV; levothyroxine; T4; protection; immunosuppression; MLV; titer	LYMPHOCYTIC THYROIDITIS; IMMUNE-RESPONSES; AUTOANTIBODIES; THYROXINE; TRIIODOTHYRONINE; HYPERTHYROIDISM; PREVALENCE; PATHOLOGY; PITUITARY; DISEASES	(1) Background: No information is available on how dogs with hypothyroidism (HypoT) respond to vaccination. This study measured pre- and post-vaccination anti-canine parvovirus (CPV) antibodies in dogs with HypoT treated with levothyroxine and compared the results to those of healthy dogs. (2) Methods: Six dogs with HypoT and healthy age-matched control dogs (n = 23) were vaccinated against CPV with a modified-live vaccine. Hemagglutination inhibition was used to measure antibodies on days 0, 7, and 28. The comparison of the vaccination response of dogs with HypoT and healthy dogs were performed with univariate analysis. (3) Results: Pre-vaccination antibodies (>= 10) were detected in 100% of dogs with HypoT (6/6; 95% CI: 55.7-100) and in 100% of healthy dogs (23/23; 95% CI: 83.1-100.0). A >= 4-fold titer increase was observed in none of the dogs with HypoT and in 4.3% of the healthy dogs (1/23; CI95%: <0.01-22.7). Mild vaccine-associated adverse events (VAAEs) were detected in 33.3% of the dogs with HypoT (2/6; 95% CI: 9.3-70.4) and in 43.5% (10/23; 95% CI: 25.6-63.2) of the healthy dogs. (4) Conclusions: There was neither a significant difference in the dogs' pre-vaccination antibodies (p = 1.000), or vaccination response (p = 0.735), nor in the occurrence of post-vaccination VAAEs (p = 0.798). The vaccination response in dogs with levothyroxine-treated HypoT seems to be similar to that of healthy dogs.	[Bergmann, Michele; Freisl, Monika; Hartmann, Katrin; Zablotski, Yury; Mayr, Matthias; Wehner, Astrid] Ludwig Maximilians Univ Munchen, Clin Small Anim Med, Vet Str 13, D-80539 Munich, Germany; [Speck, Stephanie; Truyen, Uwe] Univ Leipzig, Inst Anim Hyg & Vet Publ Hlth, Tierklin 1, D-04103 Leipzig, Germany		Bergmann, M (通讯作者)，Ludwig Maximilians Univ Munchen, Clin Small Anim Med, Vet Str 13, D-80539 Munich, Germany.	n.bergmann@medizinische-kleintierklinik.de; mireisl@medizinische-kleintierklinik.de; hartmann@lmu.de; stephanie@speck-kaysser.de; truyen@vetmed.uni-leipzig.de; Y.Zablotski@med.vetmed.uni-muenchen.de; M.mayr@medizinische-kleintierklinik.de; A.wehner@medizinische-kleintierklinik.de					American Animal Hospital Association (AAHA) Canine Vaccination Task Force, 2011, J Am Anim Hosp Assoc, V47, P1; BEALE KM, 1990, J AM VET MED ASSOC, V196, P745; Bergmann M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030547; Boretti FS, 2003, SCHWEIZ ARCH TIERH, V145, P149, DOI 10.1024/0036-7281.145.4.149; Caturegli P, 2014, AUTOIMMUN REV, V13, P391, DOI 10.1016/j.autrev.2014.01.007; CHANDEL AS, 1989, INDIAN J EXP BIOL, V27, P1013; CHASTAIN CB, 1989, J AM VET MED ASSOC, V194, P531; Chiovato L, 1997, BAILLIERE CLIN ENDOC, V11, P251, DOI 10.1016/S0950-351X(97)80272-8; Day M J, 2016, J Small Anim Pract, V57, P4, DOI 10.1111/jsap.12431; Day M.J., 2014, VET IMMUNOLOGY PRINC, V2nd ed., P221; De Amici D, 1999, BIOL NEONATE, V76, P348, DOI 10.1159/000014178; Diaz-Espineira MM, 2008, DOMEST ANIM ENDOCRIN, V35, P98, DOI 10.1016/j.domaniend.2008.03.001; Dixon R M, 1999, Vet Rec, V145, P481; Dodds WJ, 2001, J AM ANIM HOSP ASSOC, V37, P211, DOI 10.5326/15473317-37-3-211; Dodds WJ, 2002, CLIN TECH SMALL AN P, V17, P58, DOI 10.1053/svms.2002.30835; Espineira MMD, 2007, J VET INTERN MED, V21, P25, DOI 10.1892/0891-6640(2007)21[25:AOTFID]2.0.CO;2; Ferguson DC, 2007, VET CLIN N AM-SMALL, V37, P647, DOI 10.1016/j.cvsm.2007.05.015; FRITZ TE, 1970, EXP MOL PATHOL, V12, P14, DOI 10.1016/0014-4800(70)90071-7; Gershwin LJ, 2018, VET CLIN N AM-SMALL, V48, P279, DOI 10.1016/j.cvsm.2017.10.005; Goddard A, 2010, VET CLIN N AM-SMALL, V40, P1041, DOI 10.1016/j.cvsm.2010.07.007; GOSSELIN SJ, 1981, VET PATHOL, V18, P299, DOI 10.1177/030098588101800302; GOSSELIN SJ, 1982, VET IMMUNOL IMMUNOP, V3, P185, DOI 10.1016/0165-2427(82)90035-6; Graham PA, 2001, VET CLIN N AM-SMALL, V31, P915, DOI 10.1016/S0195-5616(01)50005-4; Graham PA, 2007, VET CLIN N AM-SMALL, V37, P617, DOI 10.1016/j.cvsm.2007.05.002; GRECO DS, 1994, VET CLIN N AM-SMALL, V24, P765, DOI 10.1016/S0195-5616(94)50083-4; Greene C.E., 2012, IMMUNOPROPHYLAXIS, V4th ed., P1163; Happ GM, 1995, ADV VET SCI COMP MED, V39, P97, DOI 10.1016/S0065-3519(06)80018-2; HASSMAN R, 1985, ENDOCRINOLOGY, V116, P1253, DOI 10.1210/endo-116-4-1253; Hiromatsu Y, 2013, HORM-INT J ENDOCRINO, V12, P12, DOI 10.1007/BF03401282; Hodkinson CF, 2009, J ENDOCRINOL, V202, P55, DOI 10.1677/JOE-08-0488; Hogenesch H, 1999, ADV VETER MED AP, V41, P733; Huang L, 1990, Sheng Li Xue Bao, V42, P469; Kemppainen RJ, 2001, VET CLIN N AM-SMALL, V31, P951, DOI 10.1016/S0195-5616(01)50007-8; Kemppainen RJ, 1996, J AM ANIM HOSP ASSOC, V32, P195, DOI 10.5326/15473317-32-3-195; Klecha AJ, 2000, INT J IMMUNOPHARMACO, V22, P491, DOI 10.1016/S0192-0561(00)00012-6; Kohler B, 2012, J SMALL ANIM PRACT, V53, P182, DOI [10.1111/j.1748-5827.2011.01189.x, 10.1111/j.1748-5827.2012.01189.x]; LEHANE DE, 1974, ONCOLOGY, V30, P458, DOI 10.1159/000224989; Lo JC, 1998, CLIN ENDOCRINOL, V48, P815, DOI 10.1046/j.1365-2265.1998.00449.x; LUCKE VM, 1983, J COMP PATHOL, V93, P415, DOI 10.1016/0021-9975(83)90028-2; MARIOTTI S, 1995, ENDOCR REV, V16, P686, DOI 10.1210/er.16.6.686; Mooney CT, 2011, NEW ZEAL VET J, V59, P105, DOI 10.1080/00480169.2011.563729; MOORE GE, 1992, AM J VET RES, V53, P716; Moore GE, 2010, VET CLIN N AM-SMALL, V40, P393, DOI 10.1016/j.cvsm.2010.02.002; Ohmori K, 2005, VET IMMUNOL IMMUNOP, V104, P249, DOI 10.1016/j.vetimm.2004.12.003; PANCIERA DL, 1994, J AM VET MED ASSOC, V204, P761; Reichardt HM, 2004, CURR PHARM DESIGN, V10, P2797, DOI 10.2174/1381612043383575; Riedl M, 2015, VET REC, V177, DOI 10.1136/vr.103271; Schaer M, P 33 C WORLD SMALL A; Schultz R.D., 2014, VET IMMUNOLOGY PRINC, V2nd ed., P139; Schultz R.D., 2014, VET IMMUNOLOGY PRINC, V2nd ed., P113; Scott-Moncrieff JC, 2007, VET CLIN N AM-SMALL, V37, P709, DOI 10.1016/j.cvsm.2007.03.003; Scott-Moncrieff JC, 2006, J VET INTERN MED, V20, P818, DOI 10.1892/0891-6640(2006)20[818:LOABRV]2.0.CO;2; SMITH CA, 1995, J AM VET MED ASSOC, V207, P421; Sutter NB, 2004, NAT REV GENET, V5, P900, DOI 10.1038/nrg1492; THACKER EL, 1992, AM J VET RES, V53, P449; THACKER EL, 1995, AM J VET RES, V56, P34; Tizard I.R., 2018, USW VACCINES, V10th ed., P274; Tizard I.R., 2018, VET IMMUNOLOGY, V10th ed., P401; WALL JR, 1981, J ENDOCRINOL, V91, P61, DOI 10.1677/joe.0.0910061; Walter CU, 2006, J VET INTERN MED, V20, P342, DOI 10.1892/0891-6640(2006)20[342:EOCOIR]2.0.CO;2; WILLIAMSON RA, 1990, DEV COMP IMMUNOL, V14, P305, DOI 10.1016/0145-305X(90)90021-6; YOUNG DW, 1991, AUTOIMMUNITY, V9, P41, DOI 10.3109/08916939108997122	62	2	2	1	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							180	10.3390/vaccines9020180			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6ZR	33672564	gold, Green Published			2022-04-29	WOS:000623290400001
J	Ditekemena, JD; Nkamba, DM; Mutwadi, A; Mavoko, HM; Fodjo, JNS; Luhata, C; Obimpeh, M; Van Hees, S; Nachega, JB; Colebunders, R				Ditekemena, John D.; Nkamba, Dalau M.; Mutwadi, Armand; Mavoko, Hypolite M.; Fodjo, Joseph Nelson Siewe; Luhata, Christophe; Obimpeh, Michael; Van Hees, Stijn; Nachega, Jean B.; Colebunders, Robert			COVID-19 Vaccine Acceptance in the Democratic Republic of Congo: A Cross-Sectional Survey	VACCINES			English	Article						COVID-19; vaccine acceptance; determinants and infectious diseases		We investigated the level of willingness for COVID-19 vaccination in the Democratic Republic of Congo (DRC). Data were collected between 24 August 2020 and 8 September 2020 through an online survey. A total of 4131 responses were included; mean age of respondents was 35 years (standard deviation: 11.5); 68.4% were females; 71% had elementary or secondary school education. One fourth (24.1%) were convinced that COVID-19 did not exist. Overall, 2310 (55.9%) indicated they were willing to be vaccinated. In a multivariable regression model, belonging to the middle and high-income category (OR = 1.85, CI: 1.46-2.35 and OR = 2.91, CI: 2.15-3.93, respectively), being tested for COVID-19 (OR = 4.71, CI: 3.62-6.12; p < 0.001), COVID-19 community vaccine acceptance (OR = 14.45, CI: 2.91-71.65; p = 0.001) and acknowledging the existence of COVID-19 (OR = 6.04, CI: 4.42-8.23; p < 0.001) were associated with an increased willingness to be vaccinated. Being a healthcare worker was associated with a decreased willingness for vaccination (OR = 0.46, CI: 0.36-0.58; p < 0.001). In conclusion, the current willingness for COVID-19 vaccination among citizens of the DRC is too low to dramatically decrease community transmission. Of great concern is the low intention of immunization among healthcare workers. A large sensitization campaign will be needed to increase COVID-19 vaccine acceptance.	[Ditekemena, John D.; Nkamba, Dalau M.; Mutwadi, Armand; Luhata, Christophe] Univ Kinshasa, Kinshasa Sch Publ Hlth, Kinshasa 7948, DEM REP CONGO; [Nkamba, Dalau M.] Univ Catholique Louvain UCLouvain, Inst Rech Expt & Clin IREC, Pole Epidemiol & Biostat, B-1348 Brussels, Belgium; [Mavoko, Hypolite M.] Univ Kinshasa, Dept Trop Med, Kinshasa 7948, DEM REP CONGO; [Fodjo, Joseph Nelson Siewe; Obimpeh, Michael; Van Hees, Stijn; Colebunders, Robert] Univ Antwerp, Global Hlth Inst, B-2000 Antwerp, Belgium; [Nachega, Jean B.] Univ Pittsburgh, Dept Epidemiol Infect Dis & Microbiol, Pittsburgh, PA 15260 USA; [Nachega, Jean B.] Univ Pittsburgh, Ctr Global Hlth, Pittsburgh, PA 15260 USA; [Nachega, Jean B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Nachega, Jean B.] Stellenbosch Univ, Dept Med, Fac Med & Hlth Sci, ZA-7505 Cape Town, South Africa; [Nachega, Jean B.] Stellenbosch Univ, Ctr Infect Dis, Fac Med & Hlth Sci, ZA-7505 Cape Town, South Africa		Ditekemena, JD (通讯作者)，Univ Kinshasa, Kinshasa Sch Publ Hlth, Kinshasa 7948, DEM REP CONGO.	john.ditekemena@unikin.ac.cd; dalau.nkamba@unikin.ac.cd; armand.mutwadi@unikin.ac.cd; hypolite.muhindo@unikin.ac.cd; josephnelson.siewefodjo@uantwerpen.be; christophe.luhata@pevrdcongo.cd; michael.obimpeh@student.uantwerpen.be; stijn.vanhees@uantwerpen.be; jbn16@pitt.edu; robert.colebunders@uantwerpen.be	Fodjo, Joseph Nelson Siewe/AAM-7239-2021	Fodjo, Joseph Nelson Siewe/0000-0003-3544-1239; Muhindo Mavoko, Hypolite/0000-0002-3307-3324; nkamba Mukadi, dalau/0000-0002-5379-0507; Colebunders, Robert/0000-0002-1919-1340; Mutwadi, Armand/0000-0002-9742-8091; Obimpeh, Michael/0000-0001-7140-4932; Van Hees, Stijn/0000-0003-4296-8493	European Research CouncilEuropean Research Council (ERC)European Commission [ERC 671055]; VLIRUOS (Flemish University development aid)	This research was funded by the European Research Council (ERC 671055) and the APC was funded by VLIRUOS (Flemish University development aid).	Astivia OLO, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0742-8; Austin PC, 2017, STAT MED, V36, P3257, DOI 10.1002/sim.7336; Banerjee D, 2020, INDIAN J PSYCHIAT, V62, P343, DOI 10.4103/psychiatry.IndianJPsychiatry_1002_20; Democratic Republic of Congo, 2019, DEM REP CONG MICS SN; Democratic Republic of Congo, COVID 19 ESS VACC RD; Ditekemena JD, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-043356; European Centre for Disease Prevention and Control, VACC HES HEALTHC WOR; European Centre for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR; European Parliament European Parliament, 2018, RES 19 APR 2018 VACC; Jain S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040649; Jang WM, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e220; Kabamba, 2020, PRAGMATIC OBS RES, V11, P103, DOI [10.2147/POR.S271096, DOI 10.2147/POR.S271096]; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Li BY, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-77; Lynch D, 2020, Ir Med J, V113, P100; Munoz DC, 2015, INT J PUBLIC HEALTH, V60, P767, DOI 10.1007/s00038-015-0715-6; Noh JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e182; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Programme Elargie de Vaccination Rupublique Dumocratique du Congo, 2020, PROGRAMME ELARGIE VA; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Spassiani I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040766; Tobaiqy M, 2020, Infect Prev Pract, V2, P100061, DOI 10.1016/j.infpip.2020.100061; Universitu Catholique de Louvain, MOD TEMPS COVID 19; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang Q, 2020, INFECT CONT HOSP EP, V41, P746, DOI 10.1017/ice.2020.83; Wang W, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4704; WHO, WHO TARG PROD PROF C; Wicker S, 2010, INFECT CONT HOSP EP, V31, P1066, DOI 10.1086/656242; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; World Health Organization, DRAFT LANDSC COVID 1; World Health Organization, 2019, VACC HES; World Health Organization and UNICEF, 2020, DEM REP CONG WHO UNI	34	35	35	4	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							153	10.3390/vaccines9020153			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7DA	33672938	Green Published, gold			2022-04-29	WOS:000623299300001
J	Gliga, S; Fiedler, M; Dornieden, T; Achterfeld, A; Paul, A; Horn, PA; Herzer, K; Lindemann, M				Gliga, Smaranda; Fiedler, Melanie; Dornieden, Theresa; Achterfeld, Anne; Paul, Andreas; Horn, Peter A.; Herzer, Kerstin; Lindemann, Monika			Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients	VACCINES			English	Article						human cytomegalovirus; reactivation; ELISpot; ELISA; interferon-gamma; liver transplantation; prediction		To estimate protection from cytomegalovirus (CMV) replication after solid organ transplantation, CMV serology has been considered insufficient and thus CMV immunity is increasingly assessed by cellular in vitro methods. We compared two commercially available IFN-gamma ELISpot assays (T-Track CMV and T-SPOT.CMV) and an IFN-gamma ELISA (QuantiFERON-CMV). Currently, there is no study comparing these three assays. The assays were performed in 56 liver transplant recipients at the end of antiviral prophylaxis and one month thereafter. In CMV high- or intermediate-risk patients the two ELISpot assays showed significant correlation (p < 0.0001, r > 0.6) but the correlation of the ELISpot assays with QuantiFERON-CMV was weaker. Results of both ELISpot assays were similarly predictive of protection from CMV-DNAemia >= 500 copies/mL [CMV pp65 T-SPOT.CMV at the end of prophylaxis: area under curve (AUC) = 0.744, cut-off 142 spot forming units (SFU), sensitivity set to 100%, specificity 46%; CMV IE-1 T-Track CMV at month 1: AUC = 0.762, cut-off 3.5 SFU, sensitivity set to 100%, specificity 59%]. The QuantiFERON-CMV assay was inferior, reaching a specificity of 23% when setting the sensitivity to 100%. In conclusion, both CMV-specific ELISpot assays appear suitable to assess protection from CMV infection/reactivation in liver transplant recipients.	[Gliga, Smaranda; Dornieden, Theresa; Horn, Peter A.; Lindemann, Monika] Univ Hosp Essen, Inst Transfus Med, Virchowstr 179, D-45147 Essen, Germany; [Gliga, Smaranda; Fiedler, Melanie] Univ Essen Duisburg, Univ Hosp Essen, Inst Virol, D-45147 Essen, Germany; [Achterfeld, Anne; Herzer, Kerstin] Univ Essen Duisburg, Univ Hosp Essen, Dept Gastroenterol & Hepatol, D-45147 Essen, Germany; [Achterfeld, Anne; Paul, Andreas; Herzer, Kerstin] Univ Essen Duisburg, Univ Hosp Essen, Dept Gen Visceral & Transplantat Surg, D-45147 Essen, Germany; [Herzer, Kerstin] Knappschaftsklin Bad Neuenahr, D-53474 Bad Neuenahr Ahrweiler, Germany		Lindemann, M (通讯作者)，Univ Hosp Essen, Inst Transfus Med, Virchowstr 179, D-45147 Essen, Germany.	smaranda.gliga@gmail.com; melanie.fiedler@uk-essen.de; theresa.dornieden@outlook.de; anne.achterfeld@uk-essen.de; andreas.paul@uk-essen.de; peter.horn@uk-essen.de; kerstin.herzer@uk-essen.de; monika.lindemann@uk-essen.de		Lindemann, Monika/0000-0001-6708-4390	Open Access Publication Fund of the University of Duisburg-Essen	We acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.	Azevedo LS, 2015, CLINICS, V70, P515, DOI 10.6061/clinics/2015(07)09; Banas B, 2018, TRANSPL INT, V31, P436, DOI 10.1111/tri.13110; Banas B, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0194-z; Barabas S, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0195-y; Barabas S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000198; Barshes NR, 2004, FRONT BIOSCI-LANDMRK, V9, P411, DOI 10.2741/1249; Bruminhent J, 2014, WORLD J HEPATOL, V6, P370, DOI 10.4254/wjh.v6.i6.370; Cannon MJ, 2010, REV MED VIROL, V20, P202, DOI 10.1002/rmv.655; Chanouzas D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193968; Chiereghin A, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/JCM.01040-17, 10.1128/jcm.01040-17]; CZERKINSKY C, 1988, J IMMUNOL METHODS, V110, P29, DOI 10.1016/0022-1759(88)90079-8; Egli A, 2012, CLIN INFECT DIS, V55, P1678, DOI 10.1093/cid/cis818; Fishman JA, 2007, CLIN TRANSPLANT, V21, P149, DOI 10.1111/j.1399-0012.2006.00618.x; Fletcher JM, 2005, J IMMUNOL, V175, P8218, DOI 10.4049/jimmunol.175.12.8218; Giulieri S, 2011, EXPERT REV MOL DIAGN, V11, P17, DOI [10.1586/erm.10.109, 10.1586/ERM.10.109]; Gliga S, 2018, J CLIN VIROL, V105, P91, DOI 10.1016/j.jcv.2018.06.009; Halme L, 2003, TRANSPLANTATION, V75, P1853, DOI 10.1097/01.TP.0000064620.08328.E5; Jackson SE, 2017, J VIROL, V91, DOI 10.1128/JVI.02128-16; Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984; Kotton CN, 2018, TRANSPLANTATION, V102, P900, DOI 10.1097/TP.0000000000002191; Kumar D, 2017, AM J TRANSPLANT, V17, P2468, DOI 10.1111/ajt.14347; Kumar D, 2019, AM J TRANSPLANT, V19, P2505, DOI 10.1111/ajt.15315; Lindemann M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123945; Lisboa LF, 2012, TRANSPLANTATION, V93, P195, DOI 10.1097/TP.0b013e31823c1cd4; Manuel O, 2013, CLIN INFECT DIS, V56, P817, DOI 10.1093/cid/cis993; Marcelin JR, 2014, WORLD J GASTROENTERO, V20, P10658, DOI 10.3748/wjg.v20.i31.10658; Martin-Gandul C, 2015, AM J TRANSPLANT, V15, P3024, DOI 10.1111/ajt.13486; Pourgheysari B, 2007, J VIROL, V81, P7759, DOI 10.1128/JVI.01262-06; Redeker A, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01953; Rogers R, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4787-4; Ruan YS, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015228; Sester U, 2005, AM J TRANSPLANT, V5, P1483, DOI 10.1111/j.1600-6143.2005.00871.x; Shin KH, 2018, TRANSPL IMMUNOL, V51, P62, DOI 10.1016/j.trim.2018.09.004; Sood S, 2015, LIVER TRANSPLANT, V21, P1478, DOI 10.1002/lt.24216; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Thompson G, 2018, PATHOLOGY, V50, P554, DOI 10.1016/j.pathol.2018.04.002; Varani Stefania, 2011, Herpesviridae, V2, P6, DOI 10.1186/2042-4280-2-6; Villacres MC, 2004, HUM IMMUNOL, V65, P476, DOI 10.1016/j.humimm.2004.02.021	38	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							88	10.3390/vaccines9020088			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UA	33504093	Green Published, gold			2022-04-29	WOS:000623275400001
J	Knezevic, I; Liu, MA; Peden, K; Zhou, TQ; Kang, HN				Knezevic, Ivana; Liu, Margaret A.; Peden, Keith; Zhou, Tiequn; Kang, Hye-Na			Development of mRNA Vaccines: Scientific and Regulatory Issues	VACCINES			English	Article						WHO standards; mRNA vaccines; prophylactic vaccines; vaccine development; regulatory considerations	SYSTEM	The global research and development of mRNA vaccines have been prodigious over the past decade, and the work in this field has been stimulated by the urgent need for rapid development of vaccines in response to an emergent disease such as the current COVID-19 pandemic. Nevertheless, there remain gaps in our understanding of the mechanism of action of mRNA vaccines, as well as their long-term performance in areas such as safety and efficacy. This paper reviews the technologies and processes used for developing mRNA prophylactic vaccines, the current status of vaccine development, and discusses the immune responses induced by mRNA vaccines. It also discusses important issues with regard to the evaluation of mRNA vaccines from regulatory perspectives. Setting global norms and standards for biologicals including vaccines to assure their quality, safety and efficacy has been a WHO mandate and a core function for more than 70 years. New initiatives are ongoing at WHO to arrive at a broad consensus to formulate international guidance on the manufacture and quality control, as well as nonclinical and clinical evaluation of mRNA vaccines, which is deemed necessary to facilitate international convergence of manufacturing and regulatory practices and provide support to National Regulatory Authorities in WHO member states.	[Knezevic, Ivana; Zhou, Tiequn; Kang, Hye-Na] WHO, Dept Hlth Prod Policy & Stand, Ave Appia 20, CH-1211 Geneva, Switzerland; [Liu, Margaret A.] ProTherImmune, 3656 Happy Valley Rd, Lafayette, CA 94549 USA; [Peden, Keith] US FDA, Off Vaccines Res & Review, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA		Knezevic, I (通讯作者)，WHO, Dept Hlth Prod Policy & Stand, Ave Appia 20, CH-1211 Geneva, Switzerland.; Liu, MA (通讯作者)，ProTherImmune, 3656 Happy Valley Rd, Lafayette, CA 94549 USA.	knezevici@who.int; Liu@ProTherImmune.com; keith.peden@fda.hhs.gov; zhout@who.int; kangh@who.int			Center for Biologics Evaluation and Research (CBER)-U.S. Food and Drug Administration [U01 FD005959]	This project was funded by the Center for Biologics Evaluation and Research (CBER)-U.S. Food and Drug Administration (grant number U01 FD005959).	Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Chen NH, 2017, IUBMB LIFE, V69, P297, DOI 10.1002/iub.1625; Hinz T, 2017, METHODS MOL BIOL, V1499, P203, DOI 10.1007/978-1-4939-6481-9_13; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Naik Ramachandra, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_220; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594	20	14	14	30	48	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							81	10.3390/vaccines9020081			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6ZH	33498787	Green Published, gold			2022-04-29	WOS:000623289400001
J	Lee, YH; Harris, RC; Oh, HW; Oh, Y; Vargas-Zambrano, JC; Choe, YJ				Lee, Young Hwa; Harris, Rebecca C.; Oh, Hong Won; Oh, Yongho; Vargas-Zambrano, Juan C.; Choe, Young June			Vaccine-Related Errors in Reconstitution in South Korea: A National Physicians' and Nurses' Survey	VACCINES			English	Article						vaccine; vaccination error; reconstitution; prefilled syringe		Vaccine-related errors (VREs) result from mistakes in vaccine preparation, handling, storage, or administration. We aimed to assess physicians' and nurses' experiences of VREs in South Korea, focusing on reconstitution issues, and to understand the barriers to and facilitators of preventing them. This was a cross-sectional study using an internet-based survey to examine experiences of reconstitution-related errors, and experience or preference with regard to ready-to-use vaccines (RTU) by physicians and nurses. A total of 700 participants, including 250 physicians and 450 nurses, responded to the questionnaire. In total, 76.4% and 41.5% of the physicians and nurses, respectively, reported an error related to reconstituted vaccines. All errors had been reported as experienced by between 4.9% and 52.0% of physicians or nurses. The errors were reported to occur in more than one in 100 vaccinations for inadequate shaking of vaccines by 28.0% of physicians and 6.9% of nurses, incomplete aspiration of reconstitution vials by 28.0% of physicians and 6.4% of nurses, and spillage or leakage during reconstitution by 20.8% of physicians and 6.9% of nurses. A total of 94.8% of physicians had experience with RTU vaccines, and all preferred RTU formulations. In conclusion, this study highlights the high frequency and types of reconstitution-related errors in South Korea. RTU vaccines could help reduce the time needed for preparation and reduce the risk of errors in South Korea.	[Lee, Young Hwa; Choe, Young June] Hallym Univ, Coll Med, Chunchon 24252, South Korea; [Harris, Rebecca C.; Oh, Hong Won; Oh, Yongho; Vargas-Zambrano, Juan C.] Sanofi Pasteur, F-69007 Lyon, France; [Harris, Rebecca C.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England		Choe, YJ (通讯作者)，Hallym Univ, Coll Med, Chunchon 24252, South Korea.	lkjin728@naver.com; Rebecca.Harris@sanofi.com; HongWon.Oh@sanofi.com; YongHo.Oh@sanofi.com; Juan.Vargas@sanofi.com; ychoe@hallym.ac.kr		Oh, Hong Won/0000-0002-6138-5595; Choe, Young June/0000-0003-2733-0715; Vargas-Zambrano, Juan Camilo/0000-0002-5609-7046	Sanofi Pasteur	This research was funded by Sanofi Pasteur.	[Anonymous], Average Age of Doctors, Nurses, and Pharmacists; Bakhache P, 2019, EUR J PEDIATR, V178, P533, DOI 10.1007/s00431-018-03314-3; Butte AJ, 2001, PEDIATR INFECT DIS J, V20, P561, DOI 10.1097/00006454-200106000-00003; Centers for Disease Control and Prevention, 2004, JAMA-J AM MED ASSOC, V292, P1171, DOI [10.1001/jama.292.10.1171, DOI 10.1001/JAMA.292.10.1171]; Choe YJ, 2013, J KOREAN MED SCI, V28, P1283, DOI 10.3346/jkms.2013.28.9.1283; Corrigan J.M., 2000, COMM QUAL HEALTHC AM; De Coster I, 2015, VACCINE, V33, P3976, DOI 10.1016/j.vaccine.2015.06.030; Feikema SM, 2000, JAMA-J AM MED ASSOC, V283, P1311, DOI 10.1001/jama.283.10.1311; Hall SN, 2008, HEALTH CARE MANAG SC, V11, P339, DOI 10.1007/s10729-008-9068-5; Hibbs BF, 2014, MMWR-MORBID MORTAL W, V63, P81; Icardi Giancarlo, 2020, J Prev Med Hyg, V61, pE424, DOI 10.15167/2421-4248/jpmh2020.61.3.1535; Korea Institute for Health and Social Affairs, 2018, CURR SIT HEALTHC WOR; Lloyd AJ, 2015, PATIENT PREFER ADHER, V9, P1517, DOI 10.2147/PPA.S87229; Lyabis O., P 37 ANN M EUR SOC P; Neuspiel DR, 2011, PEDIATRICS, V128, pE1608, DOI 10.1542/peds.2011-0477; Samad F, 2021, PHARM MED, V35, P1, DOI 10.1007/s40290-020-00362-9; Shadomy S., 2006, Morbidity and Mortality Weekly Report, V55, P1016; Shin HY, 2020, HUM RESOUR HEALTH, V18, DOI 10.1186/s12960-020-00513-8; Stokley S, 2004, AM J PREV MED, V26, P34, DOI 10.1016/j.amepre.2003.09.002	19	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							117	10.3390/vaccines9020117			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7GJ	33540949	Green Published			2022-04-29	WOS:000623308000001
J	Lenogue, K; Walencik, A; Laulagnier, K; Molens, JP; Benlalam, H; Dreno, B; Coulie, P; Pule, M; Chaperot, L; Plumas, J				Lenogue, Kevin; Walencik, Alexandre; Laulagnier, Karine; Molens, Jean-Paul; Benlalam, Houssem; Dreno, Brigitte; Coulie, Pierre; Pule, Martin; Chaperot, Laurence; Plumas, Joel			Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells	VACCINES			English	Article						plasmacytoid dendritic cells; vaccination; immunotherapy; infectious diseases; cancer diseases		Because dendritic cells are crucial to prime and expand antigen-specific CD8(+) T-cells, several strategies are designed to use them in therapeutic vaccines against infectious diseases or cancer. In this context, off-the-shelf allogeneic dendritic cell-based platforms are more attractive than individualized autologous vaccines tailored to each patient. In the present study, a unique dendritic cell line (PDC*line) platform of plasmacytoid origin, already used to prime and expand antitumor immunity in melanoma patients, was improved thanks to retroviral engineering. We demonstrated that the clinical-grade PDC*line, transduced with genes encoding viral or tumoral whole proteins, efficiently processed and stably presented the transduced antigens in different human leukocyte antigen (HLA) class I contexts. Moreover, the use of polyepitope constructs allowed the presentation of immunogenic peptides and the expansion of specific cytotoxic effectors. We also demonstrated that the addition of the Lysosome-associated membrane protein-1 (LAMP-1) sequence greatly improved the presentation of some peptides. Lastly, thanks to transduction of new HLA molecules, the PDC platform can benefit many patients through the easy addition of matched HLA-I molecules. The demonstration of the effective retroviral transduction of PDC*line cells strengthens and broadens the scope of the PDC*line platform, which can be used in adoptive or active immunotherapy for the treatment of infectious diseases or cancer.	[Lenogue, Kevin; Walencik, Alexandre; Molens, Jean-Paul; Chaperot, Laurence; Plumas, Joel] Univ Grenoble Alpes, Inst Adv Biosci, INSERM U1209, Immunobiol & Immunotherapy Chron Dis,CNRS UMR 530, F-38700 La Tronche, France; [Lenogue, Kevin; Laulagnier, Karine; Plumas, Joel] PDC Line Pharma, F-38701 Grenoble, France; [Lenogue, Kevin; Molens, Jean-Paul; Chaperot, Laurence; Plumas, Joel] Etab Francais Sang Auvergne Rhone Alpes, Res & Dev Lab, F-38701 Grenoble, France; [Walencik, Alexandre] Etab Francais Sang Ctr Pays Loire, HLA Lab, F-44011 Nantes, France; [Benlalam, Houssem] Univ Angers, Univ Nantes, INSERM, CRCINA, F-44011 Nantes, France; [Dreno, Brigitte] Univ Nantes, Oncodermatol Dept, CRCINA, CHU Nantes,CIC 1413, F-44093 Nantes, France; [Coulie, Pierre] Catholic Univ Louvain, De Duve Inst, B-1200 Brussels, Belgium; [Pule, Martin; Plumas, Joel] UCL, Canc Inst, London WC1E 6BT, England		Plumas, J (通讯作者)，Univ Grenoble Alpes, Inst Adv Biosci, INSERM U1209, Immunobiol & Immunotherapy Chron Dis,CNRS UMR 530, F-38700 La Tronche, France.; Plumas, J (通讯作者)，PDC Line Pharma, F-38701 Grenoble, France.; Plumas, J (通讯作者)，Etab Francais Sang Auvergne Rhone Alpes, Res & Dev Lab, F-38701 Grenoble, France.; Plumas, J (通讯作者)，UCL, Canc Inst, London WC1E 6BT, England.	k.lenogue@free.fr; alexandre.Walencik@efs.sante.fr; k.laulagnier@pdc-line-pharma.com; jean-paul.molens@efs.sante.fr; Houssem.Benlalam@univ-nantes.fr; brigitte.dreno@atlanmed.fr; pierre.coulie@uclouvain.be; martin.pule@ucl.ac.uk; laurence.chaperot@efs.sante.fr; j.plumas@pdc-line-pharma.com	chaperot, laurence/N-2927-2013; Benlalam, Houssem/K-7448-2015	chaperot, laurence/0000-0002-1479-9410; Benlalam, Houssem/0000-0001-8386-2025; Pule, Martin/0000-0002-8347-9867	Senior Marie Curie Research Fellowship of the European Union Framework 7 [251033]; Etablissement Francais du Sang (EFS APR GenAdopt); PDC*line Pharma SAS	This research was funded by a Senior Marie Curie Research Fellowship (J.P.) of the European Union Framework 7 (FP7-PEOPLE-2009-IEF Proposal nffi 251033-Acronym: PDC Therapy), by the Etablissement Francais du Sang (EFS APR GenAdopt), and by PDC*line Pharma SAS.	Akhavan D, 2019, IMMUNOL REV, V290, P60, DOI 10.1111/imr.12773; Appay V, 2008, NAT MED, V14, P623, DOI 10.1038/nm.f.1774; Aspord C, 2011, AM J TRANSPLANT, V11, P2613, DOI 10.1111/j.1600-6143.2011.03722.x; Aspord C, 2012, J INVEST DERMATOL, V132, P2395, DOI 10.1038/jid.2012.152; Aspord C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010458; Benlalam H, 2003, J IMMUNOL, V171, P6283, DOI 10.4049/jimmunol.171.11.6283; Biasco L, 2012, MOL THER, V20, P709, DOI 10.1038/mt.2011.289; Bol KF, 2016, CLIN CANCER RES, V22, P1897, DOI 10.1158/1078-0432.CCR-15-1399; Bonehill A, 2004, J IMMUNOL, V172, P6649, DOI 10.4049/jimmunol.172.11.6649; Brewin J, 2009, BLOOD, V114, P4792, DOI 10.1182/blood-2009-07-228387; Chaperot L, 2001, BLOOD, V97, P3210, DOI 10.1182/blood.V97.10.3210; Charles J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1738812; Cheever MA, 2011, CLIN CANCER RES, V17, P3520, DOI 10.1158/1078-0432.CCR-10-3126; Field AC, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.14; Freitas-Silva Rafael, 2014, Front Immunol, V5, P78, DOI 10.3389/fimmu.2014.00078; Guillaume B, 2010, P NATL ACAD SCI USA, V107, P18599, DOI 10.1073/pnas.1009778107; Heckman KL, 2007, NAT PROTOC, V2, P924, DOI 10.1038/nprot.2007.132; Keller M, 2015, EUR J IMMUNOL, V45, P3257, DOI 10.1002/eji.201445243; Lui G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007111; Marin V, 2012, HUM GENE THER METHOD, V23, P376, DOI 10.1089/hgtb.2012.050; Martinet J, 2012, GASTROENTEROLOGY, V143, P1586, DOI 10.1053/j.gastro.2012.08.046; Mathan TSM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00372; Melero I, 2015, NAT REV CANCER, V15, P457, DOI 10.1038/nrc3973; Pittet MJ, 1999, J EXP MED, V190, P705, DOI 10.1084/jem.190.5.705; Quintarelli C, 2007, BLOOD, V110, P2793, DOI 10.1182/blood-2007-02-072843; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Saudemont A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00153; Saxena M, 2018, NAT BIOMED ENG, V2, P341, DOI 10.1038/s41551-018-0250-x; Schatz MM, 2008, J IMMUNOL, V180, P3210, DOI 10.4049/jimmunol.180.5.3210; Sprooten J, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1638212; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; van de Loosdrecht AA, 2018, CANCER IMMUNOL IMMUN, V67, P1505, DOI 10.1007/s00262-018-2198-9; Veron P, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-10; Wu L, 2018, P NATL ACAD SCI USA, V115, pE4453, DOI 10.1073/pnas.1800550115; WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671	35	1	1	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							141	10.3390/vaccines9020141			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7CZ	33578850	Green Published, gold			2022-04-29	WOS:000623299200001
J	Mayor, A; Chesnay, A; Desoubeaux, G; Ternant, D; Heuze-Vourc'h, N; Secher, T				Mayor, Alexie; Chesnay, Adelaide; Desoubeaux, Guillaume; Ternant, David; Heuze-Vourc'h, Nathalie; Secher, Thomas			Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives	VACCINES			English	Review						therapeutic antibodies; respiratory tract infection; pharmacodynamics (PD); pharmacokinetics (PK); clinical development	MONOCLONAL-ANTIBODIES; DISEASES; COMBINATION; PREVENTION; PNEUMONIA; TOURS	Respiratorytract infections (RTIs) are frequent and life-threatening diseases, accounting for several millions of deaths worldwide. RTIs implicate microorganisms, including viruses (influenza virus, coronavirus, respiratory syncytial virus (RSV)), bacteria (Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus and Bacillus anthracis) and fungi (Pneumocystis spp., Aspergillus spp. and very occasionally Candida spp.). The emergence of new pathogens, like the coronavirus SARS-CoV-2, and the substantial increase in drug resistance have highlighted the critical necessity to develop novel anti-infective molecules. In this context, antibodies (Abs) are becoming increasingly important in respiratory medicine and may fulfill the unmet medical needs of RTIs. However, development of Abs for treating infectious diseases is less advanced than for cancer and inflammatory diseases. Currently, only three Abs have been marketed for RTIs, namely, against pulmonary anthrax and RSV infection, while several clinical and preclinical studies are in progress. This article gives an overview of the advances in the use of Abs for the treatment of RTIs, based on the analysis of clinical studies in this field. It describes the Ab structure, function and pharmacokinetics, and discusses the opportunities offered by the various Ab formats, Ab engineering and co-treatment strategies. Including the most recent literature, it finally highlights the strengths, weaknesses and likely future trends of a novel anti-RTI Ab armamentarium.	[Mayor, Alexie; Chesnay, Adelaide; Desoubeaux, Guillaume; Heuze-Vourc'h, Nathalie; Secher, Thomas] INSERM, U1100, Ctr Etud Pathol Resp, F-37032 Tours, France; [Mayor, Alexie; Chesnay, Adelaide; Desoubeaux, Guillaume; Ternant, David; Heuze-Vourc'h, Nathalie; Secher, Thomas] Univ Tours, Fac Med, F-37032 Tours, France; [Chesnay, Adelaide; Desoubeaux, Guillaume] CHRU Tours, Parasitol Mycol Med Trop, F-37044 Tours, France; [Ternant, David] CHRU Tours, Pharmacol Med, Pole Biol Med, F-37044 Tours, France; [Ternant, David] CHRU Tours, Ctr Pilote Suivi Biol Traitements Anticorps CePiB, F-37044 Tours, France; [Ternant, David] EA 7501 GICC Patch, F-37032 Tours, France		Secher, T (通讯作者)，INSERM, U1100, Ctr Etud Pathol Resp, F-37032 Tours, France.; Secher, T (通讯作者)，Univ Tours, Fac Med, F-37032 Tours, France.	alexie.mayor@uniy-tours.fr; adelaide.chesnay@univ-tours.fr; guillaume.desoubeaux@univ-tours.fr; david.ternant@univ-tours.fr; nathalie.yourch@univ-tours.fr; thomas.secher@univ-tours.fr	HEUZE-VOURC'H, Nathalie/P-8081-2016	Mayor, Alexie/0000-0001-5700-6196; Heuze-Vourc'h, Nathalie/0000-0003-4929-5068	Region Centre-Val de LoireRegion Centre-Val de Loire [ANR10-LABX -53-01]	The authors thank the laboratory of excellence Mab Improve (Tours-Montpellier, ANR10-LABX -53-01) and the Region Centre-Val de Loire (Novantinh and Infinhitim programs) for their support.	AHN J, 2018, RESP MED, V128, pE27, DOI DOI 10.1002/LARY.26847; Allen CT, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0603-3; ALONZO F, 2012, CPT-PHARMACOMET SYST, V83, P423, DOI DOI 10.1111/J.1365-2958.2011.07942.X; [Anonymous], US FOOD DRUG ADM EME; BENSALEM A, 2020, MOL IMMUNOL, V59, P857, DOI DOI 10.1007/S40262-020-00874-2; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; BOYERINAS B, 2015, LARYNGOSCOPE, V3, P1148, DOI DOI 10.1158/2326-6066.CIR-15-0059; BUYEL JF, 2017, CURR OPIN MICROBIOL, V35, P458, DOI DOI 10.1016/J.BIOTECHADV.2017.03.011; Caro, 2018, DEV OPEN FORUM IN S1, V5, pS424, DOI [10.1093/ofid/ofy210.1215, DOI 10.1093/ofid/ofy210.1215]; CARTER PJ, 2006, MICROBIOL SPECTR, V6, P343, DOI DOI 10.1038/NRI1837; CASADEVALL A, 2002, FRONT BIOSCI, V20, P114, DOI DOI 10.1038/NBT0202-114; Cecil RL, 1922, J AMER MED ASSOC, V79, P343, DOI 10.1001/jama.1922.02640050005003; Dagan R, 2011, PEDIATR INFECT DIS J, V30, P1, DOI 10.1097/INF.0b013e3182005389; Dasaraju PV, 1996, MED MICROBIOLOGY, V4th; Desoubeaux G, 2020, M S-MED SCI, V35, P1008, DOI 10.1051/medsci/2019200; Desoubeaux G, 2016, MABS-AUSTIN, V8, P999, DOI 10.1080/19420862.2016.1196521; Desoubeaux G, 2013, MABS-AUSTIN, V5, P626, DOI 10.4161/mabs.25300; Diep BA, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02456-16; DIGIOMENICO A, 2015, MOL MICROBIOL, V27, P78, DOI DOI 10.1016/J.MIB.2015.07.014; DOMACHOWSKE JB, 2018, LANCET, V37, P886, DOI DOI 10.1097/INF.0000000000001916; Domenech M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02700; Drumm J.E, 2017, P SEV PNEUM CAUS STA; Eggimann P., P 28 ECCMID MADR SPA; FORTES HR, 2017, PEDIATR INFECT DIS J, V126, P116, DOI DOI 10.1016/J.RMED.2017.03.030; Foundation W.L, 2010, ACUTE RESP INFECT AT; FRANKEL AE, 2009, LANCET, V14, P4516, DOI DOI 10.2741/3544; Glanville J, 2009, P NATL ACAD SCI USA, V106, P20216, DOI 10.1073/pnas.0909775106; GREENBERGER PA, 2014, CURR OPIN MICROBIOL, V2, P703, DOI DOI 10.1016/J.JAIP.2014.08.007; GRGURICH PE, 2012, CLIN MICROBIOL REV, V6, P533, DOI DOI 10.1586/ERS.12.45; GRIFFIN MP, 2017, J ALLER CL IMM-PRACT, V61, DOI DOI 10.1128/AAC.01714-16; Griffiths C, 2017, CLIN MICROBIOL REV, V30, P277, DOI 10.1128/CMR.00010-16; Gritti G., 2020, IL 6 SIGNALLING PATH, p04.01.20048561, DOI [10.1101/2020.04.01.20048561v4, DOI 10.1101/2020.04.01.20048561, 10.1101/2020.04.01.20048561]; GUARALI G, 2020, CELL SIGNAL, V2, P474, DOI DOI 10.1016/S2665-9913(20)30173-9; Hershberger E, 2019, EBIOMEDICINE, V40, P574, DOI 10.1016/j.ebiom.2018.12.051; Hey A., 2015, J MOL BIOL, V3, pAID, DOI DOI 10.1128/MICROBIOLSPEC.AID-0026-2014; Hilliard JJ, 2015, ANTIMICROB AGENTS CH, V59, P299, DOI 10.1128/AAC.03918-14; HUA L, 2015, NAT REV MICROBIOL, V59, P4526, DOI DOI 10.1128/AAC.00510-15; Irani V, 2015, MOL IMMUNOL, V67, P171, DOI 10.1016/j.molimm.2015.03.255; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEGA S, 2020, CELL, V8, P224, DOI DOI 10.3390/VACCINES8020224; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; MACKENZIE G, 2016, LANCET RHEUMATOL, V8, P14, DOI DOI 10.1186/S41479-016-0012-Z; MARKS JD, 1991, P NATL ACAD SCI USA, V222, P581, DOI DOI 10.1016/0022-2836(91)90498-U; MENG J, 2016, CLIN MICROBIOL REV, V90, P245, DOI DOI 10.1128/JVI.02140-15; Migone TS, 2009, NEW ENGL J MED, V361, P135, DOI 10.1056/NEJMoa0810603; MOULD DR, 2013, ANTIMICROB AGENTS CH, V2, DOI DOI 10.1038/PSP.2013.14; NAGY CF, 2018, ANTIMICROB AGENTS CH, V7, P652, DOI DOI 10.1002/CPDD.410; NAIR H, 2010, PEDIATRICS, V375, P1545, DOI DOI 10.1016/S0140-6736(10)60206-1; O'Neill J., 2016, Tackling drug-resistant infections globally: final report and recommendations; Park Matthew D, 2020, Nat Rev Immunol, V20, P351, DOI 10.1038/s41577-020-0317-2; Pelegrin M, 2015, TRENDS MICROBIOL, V23, P653, DOI 10.1016/j.tim.2015.07.005; PODURI R, 2020, VACCINES-BASEL, DOI DOI 10.1016/J.CELLSIG.2020.109721; POLIDORO RB, 2020, ANTIVIR RES, V11, P1626, DOI DOI 10.3389/FIMMU.2020.01626; Pugin, P AM THOR SOC 2019 I; QUE YA, 2014, AM J RESP CRIT CARE, V33, P1861, DOI DOI 10.1007/S10096-014-2156-1; REYESROBLES T, 2017, EXPERT REV RESP MED, V409, P121, DOI DOI 10.1007/82_2016_16; ROBBIE GJ, 2012, CLIN PHARMACOKINET, V56, P4927, DOI DOI 10.1128/AAC.06446-11; Ryder C, 2007, CURR OPIN MICROBIOL, V10, P644, DOI 10.1016/j.mib.2007.09.010; Sadikot RT, 2005, AM J RESP CRIT CARE, V171, P1209, DOI 10.1164/rccm.200408-1044SO; Salazar G, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0019-3; SARIOL A, 2020, FRONT IMMUNOL, DOI DOI 10.1016/J.IMMUNI.2020.07.005; Schluger Neil W, 2014, Ann Am Thorac Soc, V11, P407, DOI 10.1513/AnnalsATS.201312-420PS; SECHER T, 2018, NATURE, V189, P149, DOI DOI 10.1016/J.PHARMTHERA.2018.05.003; Secher T, 2019, J CONTROL RELEASE, V303, P24, DOI 10.1016/j.jconrel.2019.04.005; SEDEYN K, 2019, EBIOMEDICINE, V170, P4562, DOI DOI 10.1016/J.ANTIVIRAL.2019.104562; SIMON MS, 2019, B WORLD HEALTH ORGAN, V63, DOI DOI 10.1128/AAC.00897-19; Soeda S, 2019, J ALLER CL IMM-PRACT, V7, P1633, DOI 10.1016/j.jaip.2018.11.024; Spaan AN, 2017, NAT REV MICROBIOL, V15, P435, DOI 10.1038/nrmicro.2017.27; Sparrow E, 2017, B WORLD HEALTH ORGAN, V95, P235, DOI [10.2471/BLT.16.178061, 10.2471/blt.16.178061]; TANG A, 2019, J VIROL, V10, P4153, DOI DOI 10.1038/S41467-019-12137-1; TERNANT D, 2019, ANTIMICROB AGENTS CH, V58, P169, DOI DOI 10.1007/S40262-018-0680-3; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; TOOTS M, 2020, CURR OPIN IMMUNOL, V220, P33, DOI DOI 10.1016/J.TRSL.2020.01.005; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; VANDERPOLL T, 2009, PNEUMONIA, V374, P1543, DOI DOI 10.1016/S0140-6736(09)61114-4; Wang C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15001-9; WOLLACOTT AM, 2016, TRANSL RES, V5, P147, DOI DOI 10.1016/J.EBIOM.2016.02.021; World Health Organization, GLOB INFL STRAT 2019; YAMAMOTO BJ, 2016, NEW ENGL J MED, V60, P5796, DOI DOI 10.1128/AAC.01102-16; ZHOU F, 2018, NATURE, V53, P88, DOI DOI 10.1016/J.COI.2018.04.010; 2006, NAT COMMUN, V118, P1774, DOI DOI 10.1542/PEDS.2006-2223	82	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							151	10.3390/vaccines9020151			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6YW	33668613	gold, Green Published			2022-04-29	WOS:000623288300001
J	Penrith, ML; Bastos, A; Chenais, E				Penrith, Mary-Louise; Bastos, Armanda; Chenais, Erika			With or without a Vaccine-A Review of Complementary and Alternative Approaches to Managing African Swine Fever in Resource-Constrained Smallholder Settings	VACCINES			English	Review						biosecurity; disease control; disease prevention; genetic resistance; livelihoods; subsistence pig farming	PIG PRODUCTION SYSTEMS; RISK-FACTORS; ONE HEALTH; PARTICIPATORY EPIDEMIOLOGY; ANIMAL HEALTH; MOUTH-DISEASE; NO EVIDENCE; FOOD-WASTE; VIRUS; BIOSECURITY	The spectacular recent spread of African swine fever (ASF) in Eastern Europe and Asia has been strongly associated, as it is in the endemic areas in Africa, with free-ranging pig populations and low-biosecurity backyard pig farming. Managing the disease in wild boar populations and in circumstances where the disease in domestic pigs is largely driven by poverty is particularly challenging and may remain so even in the presence of effective vaccines. The only option currently available to prevent ASF is strict biosecurity. Among small-scale pig farmers biosecurity measures are often considered unaffordable or impossible to implement. However, as outbreaks of ASF are also unaffordable, the adoption of basic biosecurity measures is imperative to achieve control and prevent losses. Biosecurity measures can be adapted to fit smallholder contexts, culture and costs. A longer-term approach that could prove valuable particularly for free-ranging pig populations would be exploitation of innate resistance to the virus, which is fully effective in wild African suids and has been observed in some domestic pig populations in areas of prolonged endemicity. We explore available options for preventing ASF in terms of feasibility, practicality and affordability among domestic pig populations that are at greatest risk of exposure to ASF.	[Penrith, Mary-Louise] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Pretoria, South Africa; [Bastos, Armanda] Univ Pretoria, Fac Nat & Agr Sci, Dept Zool & Entomol, ZA-0028 Pretoria, South Africa; [Chenais, Erika] Natl Vet Inst, Dept Dis Control & Epidemiol, S-75189 Uppsala, Sweden		Penrith, ML (通讯作者)，Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Pretoria, South Africa.	marylouise@vodamail.co.za; adbastos@zoology.up.ac.za; erika.chenais@sva.se	Bastos, Armanda/B-6357-2009	Bastos, Armanda/0000-0002-9223-4204			Abramowitz SA, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003706; Alawneh JI, 2014, PREV VET MED, V114, P73, DOI 10.1016/j.prevetmed.2014.01.020; Albina E, 2013, VET MICROBIOL, V165, P38, DOI 10.1016/j.vetmic.2012.12.013; Anderson EC, 1998, VET MICROBIOL, V62, P1, DOI 10.1016/S0378-1135(98)00187-4; Arias M, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040035; Atherstone C, 2019, TROP ANIM HEALTH PRO, V51, P137, DOI 10.1007/s11250-018-1668-6; Babalobi OO, 2007, TROP ANIM HEALTH PRO, V39, P533, DOI 10.1007/s11250-007-9038-9; Barnes TS, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100151; Barnes TS, 2020, PREV VET MED, V178, DOI 10.1016/j.prevetmed.2020.104987; Barnett T, 2020, PREV VET MED, V177, DOI 10.1016/j.prevetmed.2020.104949; Barongo MB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158658; Barongo MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125842; Bastos ADS, 2004, VET MICROBIOL, V103, P169, DOI 10.1016/j.vetmic.2004.09.003; Beltran-Alcrudo D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202800; Bengis RG, 2002, REV SCI TECH OIE, V21, P53; Boinas FS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020383; Boklund A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66381-3; Boshoff CI, 2007, VET MICROBIOL, V121, P45, DOI 10.1016/j.vetmic.2006.11.007; Braae UC, 2016, ANIM WELFARE, V25, P439, DOI 10.7120/09627286.25.4.439; Brown AA, 2018, TRANSBOUND EMERG DIS, V65, P64, DOI 10.1111/tbed.12673; Burkard C, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006206; Chen JY, 2019, INT J BIOL SCI, V15, P481, DOI 10.7150/ijbs.25862; Chen T, 2015, WASTE MANAGE, V45, P42, DOI 10.1016/j.wasman.2015.06.041; Chenais E, 2017, TRANSBOUND EMERG DIS, V64, P101, DOI 10.1111/tbed.12347; Chenais E, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2005-7; Chenais E, 2019, PORCINE HEALTH MANAG, V5, DOI 10.1186/s40813-018-0109-2; Chenais E, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00119; Chenais E, 2018, EMERG INFECT DIS, V24, P810, DOI 10.3201/eid2404.172127; Chilundo AG, 2020, TROP ANIM HEALTH PRO, V52, P1447, DOI 10.1007/s11250-019-02148-x; Coffin JL, 2015, SOC SCI MED, V129, P44, DOI 10.1016/j.socscimed.2014.07.037; Costard S, 2015, SCI REP-UK, V5, DOI 10.1038/srep17074; Costard S, 2009, PHILOS T R SOC B, V364, P2683, DOI 10.1098/rstb.2009.0098; Couacy-Hymann E, 2019, TRANSBOUND EMERG DIS, V66, P882, DOI 10.1111/tbed.13098; CUNLIFFE HR, 1979, APPL ENVIRON MICROB, V37, P1044, DOI 10.1128/AEM.37.5.1044-1046.1979; Cwynar P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040310; de Balogh K, 2013, REV SCI TECH OIE, V32, P539; Dione MM, 2017, TRANSBOUND EMERG DIS, V64, P872, DOI 10.1111/tbed.12452; Dione M.M., 2018, ILRI MANUAL 28; Dione MM, 2020, TRANSBOUND EMERG DIS, V67, P2482, DOI 10.1111/tbed.13587; Dixon LK, 2020, ANNU REV ANIM BIOSCI, V8, P221, DOI 10.1146/annurev-animal-021419-083741; Ebata A, 2020, PREV VET MED, V177, DOI 10.1016/j.prevetmed.2020.104940; Ermgassen EKHJZ, 2016, FOOD POLICY, V58, P35, DOI 10.1016/j.foodpol.2015.11.001; Fasina FO, 2012, PREV VET MED, V107, P65, DOI 10.1016/j.prevetmed.2012.05.011; Fasina FO, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030155; Ferreira HCD, 2013, VET MICROBIOL, V165, P243, DOI 10.1016/j.vetmic.2013.03.007; Ferreira HCD, 2014, TICKS TICK-BORNE DIS, V5, P582, DOI 10.1016/j.ttbdis.2013.12.012; Fischer K, 2020, PREV VET MED, V180, DOI 10.1016/j.prevetmed.2020.104991; Fischer M, 2020, TRANSBOUND EMERG DIS, V67, P2318, DOI 10.1111/tbed.13650; Food and Agriculture Organization of the United Nations, 2009, FAO ANIMAL PRODUCTIO; Food and Agriculture Organization of the United Nations, 2012, PIG SECT KEN FAO AN; Food and Agriculture Organization of the United Nations, 2012, SECT PORC BURK FAS R; Food and Agriculture Organization of the United Nations, 2011, AN PROD HLTH GUID NO; Food and Agriculture Organization of the United Nations, 2012, SECT PORC REP DEM; Forth JH, 2018, TRANSBOUND EMERG DIS, V65, pe210, DOI 10.1111/tbed.12688; Frant M, 2017, J VET RES, V61, P375, DOI 10.1515/jvetres-2017-0055; Frantz L, 2016, ANNU REV ANIM BIOSCI, V4, P61, DOI 10.1146/annurev-animal-021815-111155; Gallardo C, 2017, TRANSBOUND EMERG DIS, V64, P300, DOI 10.1111/tbed.12346; Garcia AJ, 2005, WASTE MANAGE, V25, P780, DOI 10.1016/j.wasman.2005.01.006; Gogin A, 2013, VIRUS RES, V173, P198, DOI 10.1016/j.virusres.2012.12.007; Grace D, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0166; GREIG A, 1970, Journal of Hygiene, V68, P673; Guinat C, 2016, VET REC, V178, DOI 10.1136/vr.103593; Halimani TE, 2010, ECOL ECON, V69, P944, DOI 10.1016/j.ecolecon.2010.01.005; HARESNAPE JM, 1985, J HYG-CAMBRIDGE, V95, P309, DOI 10.1017/S0022172400062732; HARESNAPE JM, 1987, EPIDEMIOL INFECT, V99, P723, DOI 10.1017/S0950268800066589; HARESNAPE JM, 1988, EPIDEMIOL INFECT, V101, P173, DOI 10.1017/S0950268800029332; Heilmann M, 2020, VET SCI, V7, DOI 10.3390/vetsci7010024; Huttner K, 2000, J S AFR VET ASSOC, V71, P160; Jurado C, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00077; Juszkiewicz M, 2019, J VET RES, V63, P17, DOI 10.2478/jvetres-2019-0006; Kabuuka T, 2014, RES VET SCI, V97, P218, DOI 10.1016/j.rvsc.2014.07.001; Kagira JM, 2010, TROP ANIM HEALTH PRO, V42, P865, DOI 10.1007/s11250-009-9500-y; Kim HJ, 2020, TRANSBOUND EMERG DIS, V67, P473, DOI 10.1111/tbed.13483; Kimbi E., 2016, J AGR SCI TECHNOL A, V5, P47, DOI [10.17265/2161-6256-/2015.01.007, DOI 10.17265/2161-6256-/2015.01.007]; Koblentz GD, 2010, INT SECURITY, V34, P96, DOI 10.1162/isec.2010.34.4.96; Korennoy FI, 2017, TRANSBOUND EMERG DIS, V64, P1858, DOI 10.1111/tbed.12583; Laddomada A, 2019, TRANSBOUND EMERG DIS, V66, P1114, DOI 10.1111/tbed.13138; Lekule FP, 2003, ACTA TROP, V87, P111, DOI 10.1016/S0001-706X(03)00026-3; Leslie EEC, 2016, ACTA TROP, V155, P95, DOI 10.1016/j.actatropica.2015.12.014; Leslie EEC, 2015, PREV VET MED, V118, P319, DOI 10.1016/j.prevetmed.2014.12.006; Li XD, 2018, VET REC, V183, P300, DOI 10.1136/vr.k3774; Li Y, 2020, TRANSBOUND EMERG DIS, V67, P2564, DOI 10.1111/tbed.13603; Lichoti JK, 2016, PREV VET MED, V126, P1, DOI 10.1016/j.prevetmed.2016.01.019; Lillico SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep21645; Lubisi BA, 2009, TRANSBOUND EMERG DIS, V56, P178, DOI 10.1111/j.1865-1682.2009.01078.x; Lubisi BA, 2005, ARCH VIROL, V150, P2439, DOI 10.1007/s00705-005-0602-1; Lysholm S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233611; Malogolovkin A, 2015, EMERG INFECT DIS, V21, P312, DOI 10.3201/eid2102.140649; Mashatise E., 2005, Bunda Journal of Agriculture, Environmental Science and Technology, V3, P97; McCleary S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65808-1; MCKERCHER PD, 1987, CAN I FOOD SC TECH J, V20, P267, DOI 10.1016/S0315-5463(87)71198-5; Mebus C, 1997, FOOD CHEM, V59, P555, DOI 10.1016/S0308-8146(97)00006-X; MEBUS CA, 1993, FOOD MICROBIOL, V10, P133, DOI 10.1006/fmic.1993.1014; MELLOR PS, 1987, RES VET SCI, V43, P109, DOI 10.1016/S0034-5288(18)30753-7; MONTGOMERY R. Eustace, 1921, Journal of Comparative Pathology and Therapeutics, V34, P159; Moura JA, 2010, REV SCI TECH OIE, V29, P549, DOI 10.20506/rst.29.3.1992; Mujibi FD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190080; Mulumba-Mfumu LK, 2019, TRANSBOUND EMERG DIS, V66, P1462, DOI 10.1111/tbed.13187; Mur L, 2012, TRANSBOUND EMERG DIS, V59, P526, DOI 10.1111/j.1865-1682.2012.01308.x; Mutua FK, 2011, LIVESTOCK RES RURAL, V23, P7; Nantima N, 2015, TROP ANIM HEALTH PRO, V47, P589, DOI 10.1007/s11250-015-0768-9; Ndebi G., 2009, Tropicultura, V27, P70; Netherton CL, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00402; Nidup K., 2011, ANIMAL GENETIC RESOU, V48, P37, DOI [https://doi.org/10.1017/S2078633611000026, DOI 10.1017/S2078633611000026, 10.1017/S2078633611000026]; Niederwerder MC, 2019, EMERG INFECT DIS, V25, P891, DOI 10.3201/eid2505.181495; Nsoso S.J., 2006, LIVEST RES RURAL DEV, V18, P9; Nurmoja I, 2017, TRANSBOUND EMERG DIS, V64, P2034, DOI 10.1111/tbed.12614; Nurmoja I, 2020, PREV VET MED, V181, DOI 10.1016/j.prevetmed.2018.10.001; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Olesen AS, 2018, TRANSBOUND EMERG DIS, V65, P1024, DOI 10.1111/tbed.12837; Olesen AS, 2018, TRANSBOUND EMERG DIS, V65, P1152, DOI 10.1111/tbed.12918; Olsevskis E, 2020, TRANSBOUND EMERG DIS, V67, P2615, DOI 10.1111/tbed.13611; Olsevskis E, 2016, RES VET SCI, V105, P28, DOI 10.1016/j.rvsc.2016.01.006; Omowon A. A., 2019, Sokoto Journal of Veterinary Sciences, V17, P14, DOI 10.4314/sokjvs.v17i4.3; Osbjer K, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1811-5; Osofsky SA, 2019, J WILDLIFE DIS, V55, P755, DOI 10.7589/2019-01-024; Ouma E, 2018, PREV VET MED, V151, P29, DOI 10.1016/j.prevetmed.2017.12.010; Oura CAL, 1998, J GEN VIROL, V79, P1439, DOI 10.1099/0022-1317-79-6-1439; Park HS, 2017, ASIAN AUSTRAL J ANIM, V30, P1207, DOI 10.5713/ajas.17.0330; Penrith ML, 2007, ONDERSTEPOORT J VET, V74, P149; Penrith ML, 2009, J S AFR VET ASSOC, V80, P58; Penrith ML, 2019, TRANSBOUND EMERG DIS, V66, P672, DOI 10.1111/tbed.13117; Penrith ML, 2013, VIRUS RES, V173, P228, DOI 10.1016/j.virusres.2012.10.011; Penrith ML, 2004, REV SCI TECH OIE, V23, P965, DOI 10.20506/rst.23.3.1533; PEREZSANCHEZ R, 1994, VET REC, V135, P207, DOI 10.1136/vr.135.9.207; Petrini S, 2019, PREV VET MED, V162, P126, DOI 10.1016/j.prevetmed.2018.11.013; PLOWRIGHT W, 1969, NATURE, V221, P1071, DOI 10.1038/2211071a0; Popescu L, 2017, VIROLOGY, V501, P102, DOI 10.1016/j.virol.2016.11.012; Quembo CJ, 2016, TRANSBOUND EMERG DIS, V63, P443, DOI 10.1111/tbed.12289; Rischkowsky B, 2007, STATE WORLDS ANIMAL; Roca A, 2015, J ALLERGY CLIN IMMUN, V135, P856, DOI 10.1016/j.jaci.2015.02.015; Rock DL, 2017, VET MICROBIOL, V206, P52, DOI 10.1016/j.vetmic.2016.10.003; Rodriguez-Estevez V, 2009, LIVEST SCI, V120, P135, DOI 10.1016/j.livsci.2008.05.006; Roeder P, 2011, VET REC, V169, P671, DOI 10.1136/vr.d8253; Rowlands RJ, 2008, EMERG INFECT DIS, V14, P1870, DOI 10.3201/eid1412.080591; Sanchez Botija C., 1982, REV SCI TECH, V1, P1065, DOI [10.20506/rst.1.4.91, DOI 10.20506/RST.1.4.91]; Sanchez-Vizcaino JM, 2012, TRANSBOUND EMERG DIS, V59, P27, DOI 10.1111/j.1865-1682.2011.01293.x; Sasaki K, 2011, ANIM SCI J, V82, P175, DOI 10.1111/j.1740-0929.2010.00817.x; Schulz K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020336; Schulz K, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090866; Shyam J., 2017, INT J LIVEST RES, V7, P135, DOI [10.5455/ijlr.20170208124713, DOI 10.5455/IJLR.20170208124713]; Smith D, 2019, ONE HEALTH-AMSTERDAM, V8, DOI 10.1016/j.onehlt.2019.100109; Stahl K, 2019, VIRUS RES, V272, DOI 10.1016/j.virusres.2019.197725; Thomas LF, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-46; Thomson G., 1983, African swine fever., P85; THOMSON GR, 1980, ONDERSTEPOORT J VET, V47, P19; Thys S, 2016, VET PARASITOL, V225, P33, DOI 10.1016/j.vetpar.2016.05.029; Tummeleht L, 2020, VET SCI, V7, DOI 10.3390/vetsci7010013; Tustin R.C, 1994, AFRICAN SWINE FEVER, VVolume 1, P598; Le VP, 2019, EMERG INFECT DIS, V25, P1433, DOI 10.3201/eid2507.190303; van Rensburg LJ, 2020, J S AFR VET ASSOC, V91, DOI 10.4102/jsava.v91i0.1997; VASCO S G, 1991, Revista Portuguesa de Ciencias Veterinarias, V86, P76; Wagstaff A, 2014, HEALTH ECON, V23, P706, DOI 10.1002/hec.2944; Weaver GV, 2013, J WILDLIFE DIS, V49, P759, DOI 10.7589/2012-11-276; WILKINSON PJ, 1984, PREV VET MED, V2, P71, DOI 10.1016/0167-5877(84)90050-3; WILKINSON PJ, 1977, J COMP PATHOL, V87, P487, DOI 10.1016/0021-9975(77)90037-8; Wolff C, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1306-y; Wolff C, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1961-2; World Organisation for Animal Health, 2020, SELF DECL BELG SWIN; World Organisation for Animal Health, SELF DECL REC FREED; World Organisation for Animal Health Food and Agriculture Organization of the United Nations, 2015, GLOB STRAT CONT ER; Young JR, 2015, TRANSBOUND EMERG DIS, V62, P491, DOI 10.1111/tbed.12181; Youssao A. K. I., 2008, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V61, P235; Zani L, 2020, TRANSBOUND EMERG DIS, V67, P2086, DOI 10.1111/tbed.13554; Zani L, 2019, VET SCI, V6, DOI 10.3390/vetsci6040094; Zhou XT, 2018, TRANSBOUND EMERG DIS, V65, P1482, DOI 10.1111/tbed.12989; zu Ermgassen EKHJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196288	167	9	9	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							116	10.3390/vaccines9020116			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6QJ	33540948	Green Published			2022-04-29	WOS:000623265900001
J	Schneider, CG; Taylor, JA; Sibilo, MQ; Miura, K; Mallory, KL; Mann, C; Karch, C; Beck, Z; Matyas, GR; Long, CA; Bergmann-Leitner, E; Burkhard, P; Angov, E				Schneider, Cosette G.; Taylor, Justin A.; Sibilo, Michael Q.; Miura, Kazutoyo; Mallory, Katherine L.; Mann, Christopher; Karch, Christopher; Beck, Zoltan; Matyas, Gary R.; Long, Carole A.; Bergmann-Leitner, Elke; Burkhard, Peter; Angov, Evelina			Orientation of Antigen Display on Self-Assembling Protein Nanoparticles Influences Immunogenicity	VACCINES			English	Article						self-assembling protein nanoparticles; PfCelTOS; PfMSP1(19); vaccine; multi-stage; display	MEROZOITE SURFACE PROTEIN-1; PLASMODIUM-FALCIPARUM INFECTION; CARBOXY-TERMINAL FRAGMENT; MONOPHOSPHORYL-LIPID-A; PEPTIDE NANOPARTICLES; STERILE PROTECTION; IMMUNE-RESPONSES; ANTIBODY TITER; PFSPZ VACCINE; HUMAN MALARIA	Self-assembling protein nanoparticles (SAPN) serve as a repetitive antigen delivery platform with high-density epitope display; however, antigen characteristics such as size and epitope presentation can influence the immunogenicity of the assembled particle and are aspects to consider for a rationally designed effective vaccine. Here, we characterize the folding and immunogenicity of heterogeneous antigen display by integrating (a) dual-stage antigen SAPN presenting the P. falciparum (Pf) merozoite surface protein 1 subunit, PfMSP1(19), and Pf cell-traversal protein for ookinetes and sporozoites, PfCelTOS, in addition to (b) a homogenous antigen SAPN displaying two copies of PfCelTOS. Mice and rabbits were utilized to evaluate antigen-specific humoral and cellular induction as well as functional antibodies via growth inhibition of the blood-stage parasite. We demonstrate that antigen orientation and folding influence the elicited immune response, and when appropriately designed, SAPN can serve as an adaptable platform for an effective multi-antigen display.	[Schneider, Cosette G.; Taylor, Justin A.; Sibilo, Michael Q.; Mallory, Katherine L.; Mann, Christopher; Bergmann-Leitner, Elke; Angov, Evelina] Walter Reed Army Inst Res, Malaria Biol Branch, Silver Spring, MD 20910 USA; [Schneider, Cosette G.; Taylor, Justin A.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37831 USA; [Sibilo, Michael Q.; Mallory, Katherine L.; Mann, Christopher] Parsons Corp, Centreville, VA 20120 USA; [Miura, Kazutoyo; Long, Carole A.] NIAID, Lab Malaria & Vector Res, Rockville, MD 20892 USA; [Karch, Christopher; Beck, Zoltan; Matyas, Gary R.] Walter Reed Army Inst Res, Lab Antigen & Adjuvants, US Mil HIV Res Program, Silver Spring, MD 20910 USA; [Karch, Christopher; Beck, Zoltan] Henry Jackson Fdn, Bethesda, MD 20817 USA; [Burkhard, Peter] Alpha O Peptides AG, CH-4125 Riehen, Switzerland		Angov, E (通讯作者)，Walter Reed Army Inst Res, Malaria Biol Branch, Silver Spring, MD 20910 USA.	cosette.g.schneider.ctr@mail.mil; justin.a.taylor62.ctr@mail.mil; michael.q.sibilo.ctr@mail.mil; kmiura@niaid.nih.gov; ktmallory@gmail.com; cmann98@gmail.com; christopher.p.karch.ctr@mail.mil; zoltan.beck@gmail.com; gary.r.matyas.civ@mail.mil; clong@niaid.nih.gov; elke.s.bergmann-leitner.civ@mail.mil; peter.burkhard@aopeptides.ch; evelina.angov.civ@mail.mil	Matyas, Gary/AAK-6785-2021; Bergmann-Leitner, Elke S./B-3548-2011	Bergmann-Leitner, Elke S./0000-0002-8571-8956; Schneider, Cosette/0000-0001-5825-7640; Matyas, Gary/0000-0002-2074-2373; Miura, Kazutoyo/0000-0003-4455-2432	U.S. Military Infectious Diseases Research Program (MIDRP); Intramural Research Program of NIAID, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID); USAIDUnited States Agency for International Development (USAID)	This research was funded by the U.S. Military Infectious Diseases Research Program (MIDRP). The GIA activity was supported by the Intramural Research Program of NIAID, NIH and USAID.	Minsoko PA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001685; Ahlborg N, 2002, INFECT IMMUN, V70, P820, DOI 10.1128/IAI.70.2.820-825.2002; Alving CR, 2020, EXPERT REV VACCINES, V19, P279, DOI 10.1080/14760584.2020.1745636; Angov E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002189; Augustin T, 2015, ACTA VIROL, V59, P103, DOI 10.4149/av_2015_02_103; Babapoor Sankhiros, 2011, Influenza Res Treat, V2011, P126794, DOI 10.1155/2011/126794; Beck Z, 2015, VACCINE, V33, P5578, DOI 10.1016/j.vaccine.2015.09.001; Bergmann-Leitner ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071610; Bergmann-Leitner ES, 2011, VACCINE, V29, P5940, DOI 10.1016/j.vaccine.2011.06.053; Bergmann-Leitner ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012294; Bergmann-Leitner ES, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-183; Bhatt S, 2015, NATURE, V526, P207, DOI 10.1038/nature15535; BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P29, DOI 10.1016/0166-6851(91)90127-R; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; Burkhard P, 2015, EXPERT REV VACCINES, V14, P1525, DOI 10.1586/14760584.2015.1096781; CHAI SK, 1992, J IMMUNOL, V149, P2385; Deng L, 2017, VIROLOGY, V509, P82, DOI 10.1016/j.virol.2017.06.001; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; Doll TAPF, 2015, NANOMED-NANOTECHNOL, V11, P1705, DOI 10.1016/j.nano.2015.05.003; Egan AF, 1999, PARASITE IMMUNOL, V21, P133, DOI 10.1046/j.1365-3024.1999.00209.x; El Bissati K, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0024-6; Epstein JE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89154; Espinosa DA, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00498-16; Ferraro B, 2013, INFECT IMMUN, V81, P3709, DOI 10.1128/IAI.00180-13; Genito CJ, 2017, VACCINE, V35, P3865, DOI 10.1016/j.vaccine.2017.05.070; Gerold P, 1996, MOL BIOCHEM PARASIT, V75, P131, DOI 10.1016/0166-6851(95)02518-9; Hamley IW, 2019, BIOMACROMOLECULES, V20, P1829, DOI 10.1021/acs.biomac.9b00228; Hickey BW, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1435-y; Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400; Holder AA, 2009, PARASITOLOGY, V136, P1445, DOI 10.1017/S0031182009990515; Hui G, 2007, VACCINE, V25, P948, DOI 10.1016/j.vaccine.2006.08.041; Hume HKC, 2019, BIOTECHNOL BIOENG, V116, P919, DOI 10.1002/bit.26890; Indelicato G, 2016, BIOPHYS J, V110, P646, DOI 10.1016/j.bpj.2015.10.057; Jeamwattanalert P, 2007, CLIN VACCINE IMMUNOL, V14, P342, DOI 10.1128/CVI.00397-06; Jimah JR, 2016, ELIFE, V5, DOI 10.7554/eLife.20621; John CC, 2004, J IMMUNOL, V173, P666, DOI 10.4049/jimmunol.173.1.666; Kaba SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048304; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Karch CP, 2019, NANOMED-NANOTECHNOL, V16, P206, DOI 10.1016/j.nano.2018.12.001; Karch CP, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0295-0; Karch CP, 2017, NANOMED-NANOTECHNOL, V13, P241, DOI 10.1016/j.nano.2016.08.030; Kariu T, 2006, MOL MICROBIOL, V59, P1369, DOI 10.1111/j.1365-2958.2005.05024.x; Keitel WA, 1999, VACCINE, V18, P531, DOI 10.1016/S0264-410X(99)00221-2; Kenangalem E, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002815; Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120; KUMAR S, 1995, MOL MED, V1, P325, DOI 10.1007/BF03401557; Lee SM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57384-w; Li ZP, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-019-0446-6; Longley RJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11820; Lyke KE, 2017, P NATL ACAD SCI USA, V114, P2711, DOI 10.1073/pnas.1615324114; Lynn GM, 2020, NAT BIOTECHNOL, V38, P320, DOI 10.1038/s41587-019-0390-x; Lyon JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002830; Ma XC, 2020, IMMUNITY, V53, P1315, DOI 10.1016/j.immuni.2020.11.015; Mahajan B, 2010, INFECT IMMUN, V78, P4613, DOI 10.1128/IAI.00533-10; Mahl D, 2011, COLLOID SURFACE A, V377, P386, DOI 10.1016/j.colsurfa.2011.01.031; Malkin Elissa, 2007, PLoS Clin Trials, V2, pe12, DOI 10.1371/journal.pctr.0020012; Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; Molino NM, 2016, BIOMATERIALS, V86, P83, DOI 10.1016/j.biomaterials.2016.01.056; Mordmuller B, 2017, NATURE, V542, P445, DOI 10.1038/nature21060; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; Mudalige T, 2019, MICRO NANO TECHNOL, P313, DOI 10.1016/B978-0-12-814130-4.00011-7; Ockenhouse CF, 2006, VACCINE, V24, P3009, DOI 10.1016/j.vaccine.2005.11.028; Ogutu BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004708; Otsyula N, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-29; PERKINS ME, 1988, J IMMUNOL, V141, P3190; Pimentel TAPF, 2009, CHEM BIOL DRUG DES, V73, P53, DOI 10.1111/j.1747-0285.2008.00746.x; Pirahmadi S, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2773-3; Plassmeyer ML, 2009, J BIOL CHEM, V284, P26951, DOI 10.1074/jbc.M109.013706; Pusic KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024782; Raman S, 2006, NANOMED-NANOTECHNOL, V2, P95, DOI 10.1016/j.nano.2006.04.007; Richie TL, 2015, VACCINE, V33, P7452, DOI 10.1016/j.vaccine.2015.09.096; Schroeder U, 2009, J MOL BIOL, V386, P1368, DOI 10.1016/j.jmb.2008.11.023; Sehgal D, 1999, IMMUNOGENETICS, V50, P31, DOI 10.1007/s002510050683; Seth L, 2017, VACCINE, V35, P5448, DOI 10.1016/j.vaccine.2017.02.040; Singh S, 2006, INFECT IMMUN, V74, P4573, DOI 10.1128/IAI.01679-05; Sissoko MS, 2017, LANCET INFECT DIS, V17, P498, DOI [10.1016/S1473-3099(17)30104-4, 10.1016/s1473-3099(17)30104-4]; Steiert E, 2018, MACROMOL RAPID COMM, V39, DOI 10.1002/marc.201800186; Taylor KM, 2000, J MOL RECOGNIT, V13, P71; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Tossavainen H, 2006, PROTEIN SCI, V15, P1760, DOI 10.1110/ps.052068506; Uthaipibull C, 2001, J MOL BIOL, V307, P1381, DOI 10.1006/jmbi.2001.4574; Utterstrom J, 2021, ADV DRUG DELIVER REV, V170, P26, DOI 10.1016/j.addr.2020.12.012; Wahome N, 2012, CHEM BIOL DRUG DES, V80, P349, DOI 10.1111/j.1747-0285.2012.01423.x; Wang WJ, 2020, NAT NANOTECHNOL, V15, P406, DOI 10.1038/s41565-020-0648-y; Weiss DJ, 2019, LANCET, V394, P322, DOI 10.1016/S0140-6736(19)31097-9; WHO, 2013, WORLD MALARIA REPORT 2013, P1; Wilson DW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027705; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Zinszer K, 2020, J INFECT DIS, V221, P304, DOI 10.1093/infdis/jiz453	92	1	1	1	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							103	10.3390/vaccines9020103			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6RA	33572803	Green Published			2022-04-29	WOS:000623267600001
J	Wang, YL; Jiang, N; Fan, LJ; Gao, L; Li, K; Gao, YL; Niu, XX; Zhang, WY; Cui, HY; Liu, AJ; Pan, Q; Liu, CJ; Zhang, YP; Wang, XM; Qi, XL				Wang, Yulong; Jiang, Nan; Fan, Linjin; Gao, Li; Li, Kai; Gao, Yulong; Niu, Xinxin; Zhang, Wenying; Cui, Hongyu; Liu, Aijing; Pan, Qing; Liu, Changjun; Zhang, Yanping; Wang, Xiaomei; Qi, Xiaole			Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus	VACCINES			English	Article						novel variant infectious bursal disease virus; vaccine; viral-like particle	CAPSID PROTEIN; STRUCTURAL POLYMORPHISM; NEWCASTLE-DISEASE; CLEAVAGE SITES; CHICKENS; VP2; EFFICIENT	Infectious bursal disease (IBD), an immunosuppressive disease of young chickens, is caused by infectious bursal disease virus (IBDV). Novel variant IBDV (nVarIBDV), a virus that can evade immune protection against very virulent IBDV (vvIBDV), is becoming a threat to the poultry industry. Therefore, nVarIBDV-specific vaccine is much needed for nVarIBDV control. In this study, the VP2 protein of SHG19 (a representative strain of nVarIBDV) was successfully expressed using an Escherichia coli expression system and further purified via ammonium sulfate precipitation and size-exclusion chromatography. The purified protein SHG19-VP2-466 could self-assemble into 25-nm virus-like particle (VLP). Subsequently, the immunogenicity and protective effect of the SHG19-VLP vaccine were evaluated using animal experiments, which indicated that the SHG19-VLP vaccine elicited neutralization antibodies and provided 100% protection against the nVarIBDV. Furthermore, the protective efficacy of the SHG19-VLP vaccine against the vvIBDV was evaluated. Although the SHG19-VLP vaccine induced a comparatively lower vvIBDV-specific neutralization antibody titer, it provided good protection against the lethal vvIBDV. In summary, the SHG19-VLP candidate vaccine could provide complete immune protection against the homologous nVarIBDV as well as the heterologous vvIBDV. This study is of significance to the comprehensive prevention and control of the recent atypical IBD epidemic.	[Wang, Yulong; Jiang, Nan; Fan, Linjin; Gao, Li; Li, Kai; Gao, Yulong; Niu, Xinxin; Zhang, Wenying; Cui, Hongyu; Liu, Aijing; Pan, Qing; Liu, Changjun; Zhang, Yanping; Wang, Xiaomei; Qi, Xiaole] Chinese Acad Agr Sci, Harbin Vet Res Inst, Avian Immunosuppress Dis Div, State Key Lab Vet Biotechnol, Harbin 150069, Peoples R China; [Wang, Yulong; Jiang, Nan; Fan, Linjin; Gao, Li; Gao, Yulong; Niu, Xinxin; Zhang, Wenying; Cui, Hongyu; Liu, Aijing; Wang, Xiaomei; Qi, Xiaole] Chinese Acad Agr Sci, Harbin Vet Res Inst, OIE Reference Lab Infect Bursal Dis, Harbin 150069, Peoples R China; [Wang, Xiaomei] Yangzhou Univ, Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China		Wang, XM; Qi, XL (通讯作者)，Chinese Acad Agr Sci, Harbin Vet Res Inst, Avian Immunosuppress Dis Div, State Key Lab Vet Biotechnol, Harbin 150069, Peoples R China.; Wang, XM; Qi, XL (通讯作者)，Chinese Acad Agr Sci, Harbin Vet Res Inst, OIE Reference Lab Infect Bursal Dis, Harbin 150069, Peoples R China.; Wang, XM (通讯作者)，Yangzhou Univ, Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.	xyylong@126.com; jiangnan3596@163.com; 18346080676@163.com; gaoli@caas.cn; likai@caas.cn; gaoyulong@caas.cn; Nqct17@163.com; unstoppable0402@outlook.com; cuihongyu@caas.cn; Liuaijing@caas.cn; panqing@caas.cn; liuchangjun@caas.cn; zhangyanping@caas.cn; wangxiaomei@caas.cn; qixiaole@caas.cn	Pan, Qing/AAA-9611-2022	Gao, Li/0000-0002-4916-5346; Wang, Yulong/0000-0002-6295-4999; GAO, YULONG/0000-0002-0448-8467	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [C180202]; Heilongjiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Heilongjiang Province [ZD2020C006]; National Key Research andDevelopment Programof China [2016YFE0203200, 2017YFD0500704]; Heilongjiang Province Foundation for the National Key Research and Development Program of China [GX18B011]; China Agriculture Research System [CARS-41-G15]	This study was funded by National Natural Science Foundation of China (No. C180202); the Heilongjiang Provincial Natural Science Foundation of China (No. ZD2020C006, No.TD2019C003); the National Key Research andDevelopment Programof China (No. 2016YFE0203200, No. 2017YFD0500704); the Heilongjiang Province Foundation for the National Key Research and Development Program of China (GX18B011) and China Agriculture Research System (CARS-41-G15).	Arnold M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042870; Boudaoud A, 2016, REV SCI TECH OIE, V35, P875, DOI 10.20506/rst.35.3.2576; Brandt M, 2001, J VIROL, V75, P11974, DOI 10.1128/JVI.75.24.11974-11982.2001; Brown MD, 1996, VIRUS RES, V40, P1, DOI 10.1016/0168-1702(95)01253-2; CHETTLE N, 1989, VET REC, V125, P271, DOI 10.1136/vr.125.10.271; Chevalier C, 2002, J VIROL, V76, P2384, DOI 10.1128/JVI.76.5.2384-2392.2002; COSGROVE AS, 1962, AVIAN DIS, V6, P385, DOI 10.2307/1587909; Dey S, 2019, VET MED-RES REP, V10, P85, DOI 10.2147/VMRR.S185159; Dey S, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040031; Fan LJ, 2020, VET MICROBIOL, V251, DOI 10.1016/j.vetmic.2020.108905; Fan LJ, 2020, VET MICROBIOL, V240, DOI 10.1016/j.vetmic.2019.108507; Fan LJ, 2019, VET MICROBIOL, V230, P212, DOI 10.1016/j.vetmic.2019.01.023; Feodorova VA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020036; Gao L, 2011, VACCINE, V29, P5550, DOI 10.1016/j.vaccine.2011.04.106; He XM, 2019, VET MICROBIOL, V239, DOI 10.1016/j.vetmic.2019.108458; Huo SS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050476; Irigoyen N, 2012, J BIOL CHEM, V287, P24473, DOI 10.1074/jbc.M112.356113; ISMAIL NM, 1991, AVIAN DIS, V35, P460, DOI 10.2307/1591208; Jackwood DJ, 2008, VIROLOGY, V377, P110, DOI 10.1016/j.virol.2008.04.018; Jackwood DJ, 2017, VET MICROBIOL, V206, P121, DOI 10.1016/j.vetmic.2016.11.022; Jackwood DJ, 2013, AVIAN DIS, V57, P41, DOI 10.1637/10312-080212-Reg.1; JACKWOOD DH, 1987, AVIAN DIS, V31, P766, DOI 10.2307/1591028; Jiang DW, 2016, BIOTECHNOL LETT, V38, P901, DOI 10.1007/s10529-016-2073-8; Letzel T, 2007, J VIROL, V81, P12827, DOI 10.1128/JVI.01501-07; Li GP, 2020, AVIAN PATHOL, V49, P557, DOI 10.1080/03079457.2020.1791314; Lombardo E, 1999, J VIROL, V73, P6973, DOI 10.1128/JVI.73.8.6973-6983.1999; Lombardo E, 2000, VIROLOGY, V277, P345, DOI 10.1006/viro.2000.0595; Lucero MS, 2019, VACCINE, V37, P5203, DOI 10.1016/j.vaccine.2019.07.069; Muller H, 2012, AVIAN PATHOL, V41, P133, DOI 10.1080/03079457.2012.661403; Muller H, 2003, VET MICROBIOL, V97, P153, DOI 10.1016/j.vetmic.2003.08.005; Mustafa S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040742; Petit S, 2000, J VIROL, V74, P2057, DOI 10.1128/JVI.74.5.2057-2066.2000; Prabhu SN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040627; Qi XiaoLe, 2011, Agricultural Science & Technology - Hunan, V12, P1946; Rage E, 2019, APPL MICROBIOL BIOT, V103, P7491, DOI 10.1007/s00253-019-09992-9; Sanchez AB, 1999, VIROLOGY, V262, P190, DOI 10.1006/viro.1999.9910; Saugar I, 2005, STRUCTURE, V13, P1007, DOI 10.1016/j.str.2005.04.012; Saugar I, 2010, J BIOL CHEM, V285, P3643, DOI 10.1074/jbc.M109.075994; Suarez D.L., 2020, DIS POULTRY, VI, P257, DOI [DOI 10.1002/9781119371199.CH7, 10.1002/9781119371199.ch7]; Wang M, 2016, VACCINE, V34, P3508, DOI 10.1016/j.vaccine.2016.02.072; Wu HS, 2019, J VIROL, V93, DOI 10.1128/JVI.01899-18; Wu TT, 2020, VET MICROBIOL, V245, DOI 10.1016/j.vetmic.2020.108700; Xu AH, 2020, VIRUS RES, V276, DOI 10.1016/j.virusres.2019.197833; Le XTK, 2019, ARCH VIROL, V164, P2137, DOI 10.1007/s00705-019-04287-w; Yang H, 2020, J VIROL, V94, DOI 10.1128/JVI.01569-19; Ye CJ, 2018, J VIROL, V92, DOI 10.1128/JVI.01345-17; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	47	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							142	10.3390/vaccines9020142			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7AG	33579020	gold, Green Published			2022-04-29	WOS:000623292000001
J	Cianci, R; Franza, L				Cianci, Rossella; Franza, Laura			Genomic Medicine and Advances in Vaccine Technology and Development in the Developing and Developed World	VACCINES			English	Editorial Material									[Cianci, Rossella] Univ Cattolica Sacro Cuore, Internal Med, Fdn Policlin Univ A Gemelli IRCCS, I-00168 Rome, Italy; [Franza, Laura] Univ Cattolica Sacro Cuore, Emergency Med, Fdn Policlin Univ A Gemelli IRCCS, I-00168 Rome, Italy		Cianci, R (通讯作者)，Univ Cattolica Sacro Cuore, Internal Med, Fdn Policlin Univ A Gemelli IRCCS, I-00168 Rome, Italy.	rossellacianci@gmail.com; cliodnaghfranza@gmail.com	Cianci, Rossella/AAH-7896-2021; Franza, Laura/W-6071-2018	Cianci, Rossella/0000-0001-5378-8442; 			Hafid SRA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040198; Agallou M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030350; Amonov M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020187; Anderson EJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010069; Antenucci F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010040; Atukorale VN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010137; Bello MB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020270; Buonaguro L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040615; Burton DR, 2019, NAT REV IMMUNOL, V19, P77, DOI 10.1038/s41577-018-0103-6; Calado R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020171; Chinnakannan SK, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020184; Chiozzini C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020243; Cianci R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040636; De Brito RCF, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020252; de Sousa TR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030436; Farnos O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020338; Gerna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020194; Graham BS, 2018, NAT IMMUNOL, V19, P20, DOI 10.1038/s41590-017-0007-9; Hoang HTT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020159; Hardt K, 2016, VACCINE, V34, P6691, DOI 10.1016/j.vaccine.2016.10.078; Heaton PM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.517290; Hettinga J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030534; Johnson DM, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010114; Koriyama H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010083; Kubinski M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030451; Lemoine C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020304; Li YY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010144; Manjunathachar HV, 2020, INDIAN J MED MICROBI, V38, P379, DOI 10.4103/ijmm.IJMM_20_136; Manukyan H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010120; Matchett WE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010064; Matias J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020286; Natrajan MS, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010004; Pandolfi F, 2018, CURR MED CHEM, V25, P6070, DOI 10.2174/0929867325666180518072730; Pereiro P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020199; Roesti ES, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010116; Song CP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030399; Stojan G, 2018, CURR OPIN RHEUMATOL, V30, P144, DOI 10.1097/BOR.0000000000000480; Stromberg ZR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020273; ul Qamar MT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020288; Tang N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010097; Villani ER, 2017, J GERONTOL GERIATR, V65, P154; Wang LY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010016; Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153; Zhang ZC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020158	44	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							9	10.3390/vaccines9010009			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6UW	33374343	gold, Green Published			2022-04-29	WOS:000610808200001
J	Nasrin, S; Fuche, FJ; Sears, KT; Jones, JA; Levine, MM; Simon, R; Tennant, SM				Nasrin, Shamima; Fuche, Fabien J.; Sears, Khandra T.; Jones, Jennifer A.; Levine, Myron M.; Simon, Raphael; Tennant, Sharon M.			Refinement of a Live Attenuated Salmonella enterica Serovar Newport Vaccine with Improved Safety	VACCINES			English	Article						Salmonella; vaccine; live; attenuated; Newport; Muenchen		Non-typhoidal Salmonella (NTS) is a major cause of gastroenteritis and is responsible for approximately 93 million cases annually. In healthy individuals, gastroenteritis caused by NTS is usually self-limiting, however, NTS can cause severe invasive disease in immunocompromised patients. Very little research has been directed towards development of vaccines against Salmonella serogroups O:6,7 or O:8. We have constructed a live attenuated serogroup O:8 vaccine, CVD 1979, by deleting guaBA, htrA, and aroA from the genome of S. Newport. We have shown that the candidate vaccine is well tolerated in mice and elicits serum immunoglobulin G (IgG) antibodies against core O-polysaccharide (COPS) when administered orally. Immunized mice were challenged intraperitoneally with wild-type S. Newport and bacterial burden in the liver and spleen was found to be significantly reduced in the livers of immunized mice compared to control mice. We also observed moderate vaccine efficacy (45%) against lethal challenge with the serogroup O:8 serovar, S. Muenchen, but low vaccine efficacy (28%) following lethal challenge with a serogroup O:6,7 serovar, S. Virchow. In vitro, we have shown that antibodies generated by CVD 1979 only recognize lipopolysaccharide (LPS) from serogroup O:8 but not serogroup O:6,7 serovars, and that they mediate opsonophagocytic antibody (OPA) activity against serogroup O:8 but not serogroup O:6,7 serovars. We also showed that OPA activity can be blocked by pre-incubating the antisera with serogroup O:8 lipopolysaccharide. Taken together, our data demonstrate that we have constructed a well-tolerated, effective live attenuated S. Newport vaccine which elicits functional antibodies against serogroup O:8 but not O:6,7 serovars.	[Nasrin, Shamima; Fuche, Fabien J.; Sears, Khandra T.; Jones, Jennifer A.; Levine, Myron M.; Simon, Raphael; Tennant, Sharon M.] Univ Maryland, Sch Med, Dept Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA		Tennant, SM (通讯作者)，Univ Maryland, Sch Med, Dept Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.	snasrin@som.umaryland.edu; fabien.fuche@gmail.com; ksears@som.umaryland.edu; jennifer.jones@crisphealth.org; mlevine@som.umaryland.edu; rsimon@som.umaryland.edu; stennant@som.umaryland.edu			National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [4]; NIH/NIAID Centers for Excellence in Translation Research [U19 AI109776-01]; NIH T32 research training in Gastroenterology grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32DK067872-15]	This work was funded by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) under Project 4: Vaccine strategy for broad spectrum protection against non-typhoidal Salmonella (project leaders: Sharon M. Tennant and Raphael Simon) NIH/NIAID Centers for Excellence in Translation Research grant U19 AI109776-01 awarded to Myron M. Levine. Additionally, Shamima Nasrin was funded by NIH T32 research training in Gastroenterology grant 5T32DK067872-15.	Baliban SM, 2020, CLIN INFECT DIS, V71, pS151, DOI 10.1093/cid/ciaa514; Beyene G, 2011, J INFECT DEV COUNTR, V5, P23, DOI 10.3855/jidc.906; Boore AL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145416; CHATFIELD SN, 1992, MICROB PATHOGENESIS, V12, P145, DOI 10.1016/0882-4010(92)90117-7; Cheng RA, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01368; Chiu CH, 2004, CLIN MICROBIOL REV, V17, P311, DOI 10.1128/CMR.17.2.311-322.2004; Crim SM, 2018, FOODBORNE PATHOG DIS, V15, P612, DOI 10.1089/fpd.2018.2450; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; European Food Safety Authority, 2018, EFSA J, V16, DOI 10.2903/j.efsa.2018.5500; Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2; Fuche FJ, 2019, HUM VACC IMMUNOTHER, V15, P1427, DOI 10.1080/21645515.2018.1491499; Fuche FJ, 2018, AM J TROP MED HYG, V98, P589, DOI 10.4269/ajtmh.17-0508; Fuche FJ, 2016, CLIN VACCINE IMMUNOL, V23, P737, DOI 10.1128/CVI.00243-16; Gal-Mor O, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00391; Galen JE, 2014, VACCINE, V32, P4376, DOI 10.1016/j.vaccine.2013.12.026; Gilchrist James J, 2019, EcoSal Plus, V8, DOI 10.1128/ecosalplus.ESP-0007-2018; Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146; Hendriksen RS, 2009, FOODBORNE PATHOG DIS, V6, P1009, DOI 10.1089/fpd.2008.0245; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; HORMAECHE CE, 1991, J IMMUNOL METHODS, V142, P113, DOI 10.1016/0022-1759(91)90298-T; Huang KY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37642; Jones TF, 2008, J INFECT DIS, V198, P109, DOI 10.1086/588823; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; LEVINE MM, 1987, LANCET, V1, P1049; MacLennan CA, 2014, HUM VACC IMMUNOTHER, V10, P1478, DOI 10.4161/hv.29054; Majowicz SE, 2010, CLIN INFECT DIS, V50, P882, DOI 10.1086/650733; MUKKUR TKS, 1991, J MED MICROBIOL, V34, P57, DOI 10.1099/00222615-34-1-57; NNALUE NA, 1987, INFECT IMMUN, V55, P955, DOI 10.1128/IAI.55.4.955-962.1987; Scallan E, 2011, EMERG INFECT DIS, V17, P7, DOI 10.3201/eid1701.P11101; Schuster O, 2019, HUM VACC IMMUNOTHER, V15, P1436, DOI 10.1080/21645515.2018.1483808; Simon R, 2011, INFECT IMMUN, V79, P4240, DOI 10.1128/IAI.05484-11; Tennant SM, 2011, INFECT IMMUN, V79, P4175, DOI 10.1128/IAI.05278-11; Vugia DJ, 2004, CLIN INFECT DIS, V38, pS149, DOI 10.1086/381581	33	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							57	10.3390/vaccines9010057			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6WD	33467190	Green Published, gold			2022-04-29	WOS:000610811500001
J	Astengo, M; Paganino, C; Amicizia, D; Trucchi, C; Tassinari, F; Sticchi, C; Sticchi, L; Orsi, A; Icardi, G; Piazza, MF; Di Silverio, B; Deb, A; Senese, F; Prandi, GM; Ansaldi, F				Astengo, Matteo; Paganino, Chiara; Amicizia, Daniela; Trucchi, Cecilia; Tassinari, Federico; Sticchi, Camilla; Sticchi, Laura; Orsi, Andrea; Icardi, Giancarlo; Piazza, Maria Francesca; Di Silverio, Bruno; Deb, Arijita; Senese, Francesca; Prandi, Gian Marco; Ansaldi, Filippo			Economic Burden of Pneumococcal Disease in Individuals Aged 15 Years and Older in the Liguria Region of Italy	VACCINES			English	Article						pneumonia; pneumococcal disease; pneumococcal infections; health resources; comorbidity; healthcare costs; economic burden	PNEUMONIA; ADULTS; HOSPITALIZATIONS; OTITIS; CODES	Despite the availability of vaccines against Streptococcus pneumoniae, the global incidence and economic cost of pneumococcal disease (PD) among adults is still high. This retrospective cohort analysis estimated the cost of emergency department (ED) visits/hospitalizations associated with non-invasive pneumonia and invasive pneumococcal disease among individuals >= 15 years of age in the Liguria region of Italy during 2012-2018. Data from the Liguria Region Administrative Health Databases and the Ligurian Chronic Condition Data Warehouse were used, including hospital admission date, length of stay, discharge date, outpatient visits, and laboratory/imaging procedures. A >= 30-day gap between two events defined a new episode, and patients with >= 1 ED or inpatient claim for PD were identified. The total mean annual number of hospitalizations for PD was 13,450, costing ~euro49 million per year. Pneumonia accounted for the majority of hospitalization costs. The median annual cost of hospitalization for all-cause pneumonia was euro38,416,440 (per-capita cost: euro26.78) and was euro30,353,928 (per-capita cost: euro20.88) for pneumococcal and unspecified pneumonia. The total number and associated costs of ED visits/hospitalizations generally increased over the study period. PD still incurs high economic costs in adults in the Liguria region of Italy.	[Astengo, Matteo; Paganino, Chiara; Amicizia, Daniela; Trucchi, Cecilia; Tassinari, Federico; Sticchi, Camilla; Piazza, Maria Francesca; Di Silverio, Bruno; Ansaldi, Filippo] Reg Hlth Agcy Liguria ALiSa, I-16121 Genoa, Italy; [Trucchi, Cecilia; Sticchi, Laura; Orsi, Andrea; Icardi, Giancarlo; Ansaldi, Filippo] Univ Genoa, Dept Hlth Sci DiSSal, I-16132 Genoa, Italy; [Deb, Arijita] Merck & Co Inc, Kenilworth, NJ 07033 USA; [Senese, Francesca; Prandi, Gian Marco] MSD Italy, I-00189 Rome, Italy		Astengo, M (通讯作者)，Reg Hlth Agcy Liguria ALiSa, I-16121 Genoa, Italy.	Matteo.astengo@regione.liguria.it; Chiara.paganino@regione.liguria.it; Daniela.amicizia@unige.it; Cecilia.trucchi@regione.liguria.it; fedetassi@ymail.com; Camilla.sticchi@regione.liguria.it; Laura.sticchi@unige.it; Andrea.orsi@unige.it; icardi@unige.it; mariafrancesca.piazza@regione.liguria.it; bruno.disilverio@regione.liguria.it; arijitadeb88@gmail.com; Francesca.senese@merck.com; gian.marco.prandi@merck.com; filippo.ansaldi@unige.it	Orsi, Andrea/AAC-7431-2022; Piazza, Maria Francesca/ABG-4059-2021	Orsi, Andrea/0000-0002-2433-9610; Piazza, Maria Francesca/0000-0002-2404-3609; Tassinari, Federico/0000-0003-3114-8043; Amicizia, Daniela/0000-0002-9707-5214			[Anonymous], 2013, MINISTERO SALUTE SUP; [Anonymous], 2021, AGENZIA ITALIA DIGIT; Ansaldi F, 2008, J INT MED RES, V36, P1255, DOI 10.1177/147323000803600612; Ansaldi F, 2011, HUM VACCINES, V7, P211, DOI 10.4161/hv.7.0.14602; Boccalini S, 2017, HUM VACC IMMUNOTHER, V13, P428, DOI 10.1080/21645515.2017.1264796; Centers for Disease Control and Prevention, 2017, PNEUM DIS TYP INF; Chalmers J, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0039-9; de Garde MDBV, 2020, INTERD T GERONT GERI, V43, P113, DOI 10.1159/000504490; Durando P, 2009, VACCINE, V27, P3459, DOI 10.1016/j.vaccine.2009.01.052; EpiCentro Epidemiology for Public Health, VACC IT; Georgalis L, 2017, EUR J CLIN MICROBIOL, V36, P575, DOI 10.1007/s10096-016-2834-2; Gil-Prieto R, 2016, HUM VACC IMMUNOTHER, V12, P1900, DOI 10.1080/21645515.2016.1143577; Guevara RE, 1999, AM J EPIDEMIOL, V149, P282, DOI 10.1093/oxfordjournals.aje.a009804; Huang SS, 2011, VACCINE, V29, P3398, DOI 10.1016/j.vaccine.2011.02.088; Ministero della Salute DGPRV 0024720-P-27/05/2010, 0024720P27052010 DGP; Monali R, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001077; Navarro-Torne A, 2021, HUM VACC IMMUNOTHER, V17, P3670, DOI 10.1080/21645515.2021.1923348; Orsi A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071140; Orsi Andrea, 2014, Epidemiol Prev, V38, P66; Ozawa S, 2016, HEALTH AFFAIR, V35, P2124, DOI 10.1377/hlthaff.2016.0462; Song JY, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-202; Tan TQ, 2012, CLIN MICROBIOL REV, V25, P409, DOI 10.1128/CMR.00018-12; Torres A, 2018, RESP MED, V137, P6, DOI 10.1016/j.rmed.2018.02.007; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Trucchi C, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4412-7; van De Garde EMW, 2007, J CLIN EPIDEMIOL, V60, P834, DOI 10.1016/j.jclinepi.2006.10.018; Weinberger DM, 2017, JAMA INTERN MED, V177, P303, DOI 10.1001/jamainternmed.2016.8289; Weinberger DM, 2016, AM J EPIDEMIOL, V183, P1055, DOI 10.1093/aje/kwv283; Weycker D, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1432-4	29	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1380	10.3390/vaccines9121380			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9SJ	34960127	gold, Green Published			2022-04-29	WOS:000737304400001
J	Bekele, Y; Berzofsky, JA; Chiodi, F				Bekele, Yonas; Berzofsky, Jay A.; Chiodi, Francesca			Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals	VACCINES			English	Article						HBV; HBV vaccine; anti-HBs antibodies; HIV-1; booster dose; B cells; Tfh cells; HIV-HBV co-infection	HEPATITIS-B-VIRUS; HIV-INFECTED CHILDREN; IMMUNOLOGICAL RESPONSE; VACCINATION; IMMUNOGENICITY; COINFECTION; ADULTS; REVACCINATION; BREAKTHROUGH; HEMODIALYSIS	HBV vaccination effectively prevents HBV transmission and the development of liver cancer. Disease progression and liver-related complications are more common in HIV-1/HBV co-infected than HBV mono-infected individuals. A considerable body of literature, which will be reviewed here, indicates that response to HBV vaccine is suboptimal in HIV-1-infected individuals and that the poor maintenance of protective immunity to HBV vaccines in these individuals is an important medical issue. Several factors affect HBV vaccine response during HIV-1 infection including CD4+ T cell counts, B cell response, vaccine formulation, schedules, and timing of antiretroviral therapy (ART). The initial response to HBV vaccination also plays a critical role in the sustainability of antibody responses in both HIV-1-infected and uninfected vaccinees. Thus, regular follow-up for antibody titer and a booster dose is warranted to prevent HBV transmission in HIV-1 infected people.	[Bekele, Yonas; Berzofsky, Jay A.] NCI, Vaccine Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Chiodi, Francesca] Karolinska Inst, Biomedicum, Dept Microbiol Tumor & Cell Biol, Solnavagen 9, S-17165 Solna, Sweden		Bekele, Y (通讯作者)，NCI, Vaccine Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	yonas.feyissa@nih.gov; berzofsj@mail.nih.gov; francesca.chiodi@ki.se		Berzofsky, Jay/0000-0002-0342-3194; Chiodi, Francesca/0000-0002-1385-8343	Center for Cancer Research, National Cancer Institute, National Institutes of Health, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [ZIA-C-004020, ZIA-BC-012054]; Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [2019-01169]	The work was supported by intramural funding under project ZIA-C-004020 and project ZIA-BC-012054 from the Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA; and Swedish Medical Research Council (grant number 2019-01169), Sweden.	Abushady EAE, 2011, WORLD J HEPATOL, V3, P147, DOI 10.4254/wjh.v3.i6.147; Abzug MJ, 2009, J INFECT DIS, V200, P935, DOI 10.1086/605448; Amu S, 2013, AIDS, V27, P2323, DOI 10.1097/QAD.0b013e328361a427; Bagheri-Jamebozorgi M, 2014, HUM VACC IMMUNOTHER, V10, P3731, DOI 10.4161/hv.34393; Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6; Bekele Y, 2019, VACCINE, V37, P2348, DOI 10.1016/j.vaccine.2019.03.027; Bekele Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09165-6; Bianchi FP, 2019, J VIRAL HEPATITIS, V26, P136, DOI 10.1111/jvh.13001; Bianco E, 2003, DIGEST LIVER DIS, V35, P404, DOI 10.1016/S1590-8658(03)00157-9; Bini C, 2018, HUM VACC IMMUNOTHER, V14, P450, DOI 10.1080/21645515.2017.1398297; Burton AR, 2018, J CLIN INVEST, V128, P4588, DOI [10.1172/JCI121960, 10.1172/jci121960]; Cagigi A, 2010, LANCET INFECT DIS, V10, P499, DOI 10.1016/S1473-3099(10)70117-1; Chaves SS, 2011, VACCINE, V29, P9618, DOI 10.1016/j.vaccine.2011.10.057; Cheng ZM, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.713981; Cocchio S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040323; De Clercq E, 2010, VIRUSES-BASEL, V2, P1279, DOI 10.3390/v2061279; Fourati S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10369; Gerlich WH, 2006, J CLIN VIROL, V36, pS18, DOI 10.1016/S1386-6532(06)80004-1; Giacomet V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192638; Gilbert CL, 2014, VACCINE, V32, P6521, DOI 10.1016/j.vaccine.2014.09.015; Haban H, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4776-8; Herrero-Fernandez I, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.02050-17; Irungu E, 2013, J INFECT DIS, V207, P402, DOI 10.1093/infdis/jis695; Jahagirdar D, 2021, LANCET HIV, V8, pE633, DOI 10.1016/S2352-3018(21)00152-1; Jin H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133464; Kerneis S, 2014, CLIN INFECT DIS, V58, P1130, DOI 10.1093/cid/cit937; Kim HN, 2009, INT J STD AIDS, V20, P595, DOI 10.1258/ijsa.2009.009126; Klinger G, 2018, VACCINE, V36, P2288, DOI 10.1016/j.vaccine.2018.03.028; Kourtis AP, 2012, NEW ENGL J MED, V366, P1749, DOI 10.1056/NEJMp1201796; Lao-araya M, 2011, VACCINE, V29, P3977, DOI 10.1016/j.vaccine.2011.03.077; Lapphra K, 2017, PEDIATR INFECT DIS J, V36, P863, DOI 10.1097/INF.0000000000001613; Leuridan E, 2011, CLIN INFECT DIS, V53, P68, DOI 10.1093/cid/cir270; Levy V, 2006, CLIN INFECT DIS, V43, P904, DOI 10.1086/507532; Lopes VB, 2013, VACCINE, V31, P1040, DOI 10.1016/j.vaccine.2012.12.047; Mancinelli S, 2018, J MED VIROL, V90, P1172, DOI 10.1002/jmv.25049; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; Mendy M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058029; Mizusawa M, 2014, INT J STD AIDS, V25, P201, DOI 10.1177/0956462413495820; Mutwa PR, 2013, PEDIATR INFECT DIS J, V32, P246, DOI 10.1097/INF.0b013e318271b93d; Nlend AEN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161714; Paitoonpong L, 2008, SCAND J INFECT DIS, V40, P54, DOI 10.1080/00365540701522975; Papadopoli R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020227; Parvez MK, 2015, WORLD J HEPATOL, V7, P121, DOI 10.4254/wjh.v7.i1.121; Pensieroso S, 2013, AIDS, V27, P1209, DOI 10.1097/QAD.0b013e32835edc47; Pippi F, 2008, HIV MED, V9, P519, DOI 10.1111/j.1468-1293.2008.00598.x; Poonia B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33719-x; Poorolajal J, 2010, VACCINE, V28, P623, DOI 10.1016/j.vaccine.2009.10.068; Powell EA, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.34758; Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; Salama II, 2018, VACCINE, V36, P2005, DOI 10.1016/j.vaccine.2018.02.103; Schwarz TF, 2019, HUM VACC IMMUNOTHER, V15, P235, DOI 10.1080/21645515.2018.1509658; Singh KP, 2017, AIDS, V31, P2035, DOI 10.1097/QAD.0000000000001574; Sit D, 2015, WORLD J HEPATOL, V7, P761, DOI 10.4254/wjh.v7.i5.761; Tajiri K, 2015, WORLD J GASTROENTERO, V21, P7074, DOI 10.3748/wjg.v21.i23.7074; Van Damme P., 2013, VACCINES-BASEL, VVolume 205, P234; Van Damme P, 2019, J VIRAL HEPATITIS, V26, P1066, DOI 10.1111/jvh.13125; Van Herck K, 2007, SEX TRANSM INFECT, V83, P426, DOI 10.1136/sti.2006.022111; Whitaker JA, 2012, LANCET INFECT DIS, V12, P966, DOI 10.1016/S1473-3099(12)70243-8; WHO, 2002, HEP B; World Health Organization, 2021, GLOB PROGR REP HIV V; Wu ZK, 2018, HUM VACC IMMUNOTHER, V14, P1251, DOI 10.1080/21645515.2018.1426419; Zhao YL, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4134-9	62	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1484	10.3390/vaccines9121484			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YK5NY	34960230	Green Published, gold			2022-04-29	WOS:000745260400001
J	Hirobe, S; Kawakita, T; Yamasaki, T; Ito, S; Tachibana, M; Okada, N				Hirobe, Sachiko; Kawakita, Takuto; Yamasaki, Taki; Ito, Sayami; Tachibana, Masashi; Okada, Naoki			Adjuvant Activity of CpG-Oligonucleotide Administered Transcutaneously in Combination with Vaccination Using a Self-Dissolving Microneedle Patch in Mice	VACCINES			English	Article						transcutaneous immunization; microneedle; TLR9 ligand; adjuvant; CpG-oligonucleotide	INNATE LYMPHOID-CELLS; GERMINAL CENTER; B-CELLS; PATHWAY; ACTS; DNA	In this study, we investigated the mechanism of transcutaneous adjuvant activity of the CpG-oligonucleotide (K3) in mice. Transcutaneous immunization (TCI) with an ovalbumin-loaded self-dissolving microneedle patch (OVA-sdMN) and K3-loaded hydrophilic gel patch (HG) increased OVA-specific Th2- and Th1-type IgG subclass antibody titers more rapidly and strongly than those after only OVA-sdMN administration. However, the antigen-specific proliferation of OVA-specific CD4(+) T cells was similar between the OVA-only and the OVA+K3 groups. Population analysis of various immune cells in draining lymph nodes (dLNs) in the primary immune response revealed that the OVA+K3 combination doubled the number of dLN cells, with the most significant increase in B cells. Phenotypic analysis by flow cytometry revealed that B-cell activation and maturation were promoted in the OVA+K3 group, suggesting that direct B-cell activation by K3 largely contributed to the rapid increase in antigen-specific antibody titer in TCI. In the secondary immune response, a significant increase in effector T cells and effector memory T cells, and an increase in memory B cells were observed in the OVA+K3 group compared with that in the OVA-only group. Thus, K3, as a transcutaneous adjuvant, can promote the memory differentiation of T and B cells.	[Hirobe, Sachiko; Ito, Sayami; Okada, Naoki] Osaka Univ, Grad Sch Pharmaceut Sci, Lab Biotechnol & Therapeut, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan; [Hirobe, Sachiko] Osaka Univ, Grad Sch Pharmaceut Sci, Lab Clin Pharmacol & Therapeut, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan; [Hirobe, Sachiko] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Mol Pharmaceut Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan; [Hirobe, Sachiko] Osaka Univ Hosp, Dept Pharm, 2-15 Yamadaoka, Suita, Osaka 5650871, Japan; [Kawakita, Takuto; Yamasaki, Taki; Ito, Sayami; Tachibana, Masashi; Okada, Naoki] Osaka Univ, Grad Sch Pharmaceut Sci, Project Vaccine & Immune Regulat, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan; [Kawakita, Takuto; Yamasaki, Taki; Tachibana, Masashi; Okada, Naoki] Osaka Univ, Grad Sch Pharmaceut Sci, Lab Vaccine & Immune Regulat BIKEN, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan		Okada, N (通讯作者)，Osaka Univ, Grad Sch Pharmaceut Sci, Lab Biotechnol & Therapeut, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.; Okada, N (通讯作者)，Osaka Univ, Grad Sch Pharmaceut Sci, Project Vaccine & Immune Regulat, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.; Okada, N (通讯作者)，Osaka Univ, Grad Sch Pharmaceut Sci, Lab Vaccine & Immune Regulat BIKEN, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.	hirobe-s@phs.osaka-u.ac.jp; kawakitatakuto@gmail.com; nthngsthsmsmn@gmail.com; q8v383@gmail.com; tacci@phs.osaka-u.ac.jp; okada@phs.osaka-u.ac.jp	OKADA, NAOKI/AAP-4851-2020	OKADA, NAOKI/0000-0001-8414-0622; Tachibana, Masashi/0000-0002-0376-508X; Hirobe, Sachiko/0000-0001-8218-8809			Busch DH, 2016, SEMIN IMMUNOL, V28, P28, DOI 10.1016/j.smim.2016.02.001; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x; Ezoe S, 2020, VACCINE, V38, P7246, DOI 10.1016/j.vaccine.2020.09.056; He B, 2004, J IMMUNOL, V173, P4479, DOI 10.4049/jimmunol.173.7.4479; Hirobe S, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120563; Hirobe S, 2015, BIOMATERIALS, V57, P50, DOI 10.1016/j.biomaterials.2015.04.007; Hirobe S, 2013, PHARM RES-DORDR, V30, P2664, DOI 10.1007/s11095-013-1092-6; Ishii Y, 2008, J CONTROL RELEASE, V131, P113, DOI 10.1016/j.jconrel.2008.07.025; Ito S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030267; Kallies A, 2004, J EXP MED, V200, P967, DOI 10.1084/jem.20040973; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Koyama S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000759; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; Marafini I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126291; Memish ZA, 2019, LANCET, V393, P2073, DOI 10.1016/S0140-6736(19)30501-X; Oracki SA, 2010, IMMUNOL REV, V237, P140, DOI 10.1111/j.1600-065X.2010.00940.x; Rookhuizen DC, 2014, P NATL ACAD SCI USA, V111, pE3224, DOI 10.1073/pnas.1323985111; Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065; Seo SU, 2010, J VIROL, V84, P12713, DOI 10.1128/JVI.01675-10; Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Tozuka M, 2016, J DERMATOL SCI, V82, P38, DOI 10.1016/j.jdermsci.2015.11.008; Verthelyi D, 2001, J IMMUNOL, V166, P2372, DOI 10.4049/jimmunol.166.4.2372; Wang CJ, 2015, P NATL ACAD SCI USA, V112, P524, DOI 10.1073/pnas.1414576112; Xu L, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0214-5	27	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1480	10.3390/vaccines9121480			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0NJ	34960226	Green Published, gold			2022-04-29	WOS:000737359200001
J	Morimoto, H; Hayano, S; Ozawa, N; Ogura, Y; Usui, H; Usami, T; Ohse, A; Otsuka, M; Miyachi, M; Tokura, Y				Morimoto, Hiroki; Hayano, Satoshi; Ozawa, Naoya; Ogura, Yasuaki; Usui, Hiroaki; Usami, Takahiro; Ohse, Ayako; Otsuka, Masaki; Miyachi, Masahiko; Tokura, Yoshiki			Questionnaire Survey of Possible Association of Allergic Diseases with Adverse Reactions to SARS-CoV-2 Vaccination	VACCINES			English	Article						adverse effect; asthma; atopic dermatitis; food allergy; SARS-CoV-2 vaccine	COVID-19 VACCINES; ASTHMA	To protect against COVID-19, SARS-CoV-2 vaccines have been widely used. Besides anaphylaxis, some less severe adverse effects may occur at higher frequencies. It remains unclear whether present or past histories of allergic diseases exert effects on local and systemic reactions. We conducted a questionnaire survey among workers in our hospital. We analyzed the adverse effects occurring after the first and second doses of the Pfizer-BioNTech vaccine in 955 subjects. The presence or absence of local injection reactions and systemic reactions (headache, fatigability, fever, muscle pain, and joint pain) was questioned. The intensities of these reactions were graded on a scale of 0-4 (except fever) or 0-2 (fever). The allergic diseases that we focused on were bronchial asthma, atopic dermatitis, food allergy, pollinosis, and hand eczema. For the systemic reactions, fatigability after the first dose tended to be more severe in the bronchial asthma than in the non-allergic group. Headache, joint pain, and fever tended to be more severe in the food allergy than in the non-allergic group after the second dose. For the local skin reactions, atopic dermatitis subjects tended to show rather less severe local skin reactions after the second dose. The results contribute to the guidelines for the care of individuals with different allergy histories, so that they may safely receive their vaccine.	[Morimoto, Hiroki; Ogura, Yasuaki; Otsuka, Masaki; Tokura, Yoshiki] Chutoen Gen Med Ctr, Dept Dermatol & Skin Oncol, Kakegawa 4360040, Japan; [Hayano, Satoshi; Ozawa, Naoya; Ogura, Yasuaki; Usui, Hiroaki; Usami, Takahiro; Ohse, Ayako; Tokura, Yoshiki] Chutoen Gen Med Ctr, Allerg Dis Res Ctr, Kakegawa 4360040, Japan; [Hayano, Satoshi] Chutoen Gen Med Ctr, Dept Pediat, Kakegawa 4360040, Japan; [Ozawa, Naoya] Chutoen Gen Med Ctr, Dept Resp Internal Med, Kakegawa 4360040, Japan; [Usui, Hiroaki] Chutoen Gen Med Ctr, Dept Otolaryngol, Kakegawa 4360040, Japan; [Usami, Takahiro] Chutoen Gen Med Ctr, Dept Ophthalmol, Kakegawa 4360040, Japan; [Ohse, Ayako] Chutoen Gen Med Ctr, Dept Gen Practice, Kakegawa 4360040, Japan; [Miyachi, Masahiko] Chutoen Gen Med Ctr, Kakegawa 4360040, Japan		Morimoto, H; Tokura, Y (通讯作者)，Chutoen Gen Med Ctr, Dept Dermatol & Skin Oncol, Kakegawa 4360040, Japan.; Tokura, Y (通讯作者)，Chutoen Gen Med Ctr, Allerg Dis Res Ctr, Kakegawa 4360040, Japan.	h.morimoto.0703@gmail.com; jacafeva@gmail.com; naoya0909@med.nagoya-u.ac.jp; y.ogura523@gmail.com; h-usui777fever@yc4.so-net.ne.jp; usataka3808@yahoo.co.jp; BXU03326@nifty.com; masaki-o@chutoen-hp.shizuoka.jp; mmiyachi@chutoen-hp.shizuoka.jp; tokura@chutoen-hp.shizuoka.jp		Tokura, Yoshiki/0000-0001-7452-6919; Ozawa, Naoya/0000-0002-2833-2125; Morimoto, Hiroki/0000-0002-0657-8394			Akdis CA, 2020, ALLERGY, V75, P1582, DOI 10.1111/all.14318; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Balz K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84320-8; Balz K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00513; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Bradding P, 2020, J ALLERGY CLIN IMMUN, V146, P208, DOI 10.1016/j.jaci.2020.05.013; Cabanillas B, 2021, ALLERGOL INT, V70, P313, DOI 10.1016/j.alit.2021.04.003; Caminati M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080853; Carli G, 2021, ALLERGY, V76, P866, DOI 10.1111/all.14426; Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Liu S, 2020, CLIN REV ALLERG IMMU, V59, P78, DOI 10.1007/s12016-020-08797-3; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Patrick MT, 2021, J ALLERGY CLIN IMMUN, V147, P857, DOI 10.1016/j.jaci.2021.01.006; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Thomas WR, 2015, ALLERGOL INT, V64, P304, DOI 10.1016/j.alit.2015.05.004; Tokura Y, 2018, J CUTAN IMMUNOL ALL, V1, DOI 10.1002/cia2.12033; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V146, P327, DOI 10.1016/j.jaci.2020.06.001	21	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1421	10.3390/vaccines9121421			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	0G9TI	34960167	Green Published, gold			2022-04-29	WOS:000778383600001
J	Nasti, TH; Eberhardt, CS				Nasti, Tahseen H.; Eberhardt, Christiane S.			Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy	VACCINES			English	Article						cancer vaccines; COVID vaccines; preventive vaccines; therapeutic vaccines; influenza	DENDRITIC CELL VACCINES; T-CELLS; COMBINATION IMMUNOTHERAPY; PROSTATE-CANCER; DOSE-ESCALATION; IPILIMUMAB; BLOCKADE; PD-1; SAFETY; TRIAL	The use of immune checkpoint inhibitors (ICI) has substantially increased the overall survival of cancer patients and has revolutionized the therapeutic situation in oncology. However, not all patients and cancer types respond to ICI, or become resistant over time. Combining ICIs with therapeutic cancer vaccines is a promising option as vaccination may help to overcome resistance to immunotherapies while immunotherapies may increase immune responses to the particular cancer vaccine by reinvigorating exhausted T cells. Thus, it would be possible to reprogram a response with appropriate vaccines, using a particular cancer antigen and a corresponding ICI. Target populations include currently untreatable cancer patients or those who receive treatment regimens with high risk of serious side effects. In addition, with the increased use of ICI in clinical practice, questions arise regarding safety and efficacy of administration of conventional vaccines, such as influenza or COVID-19 vaccines, during active ICI treatment. This review discusses the main principles of prophylactic and therapeutic cancer vaccines, the potential impact on combining therapeutic cancer vaccines with ICI, and briefly summarizes the current knowledge of safety and effectiveness of influenza and COVID-19 vaccines in ICI-treated patients.	[Nasti, Tahseen H.; Eberhardt, Christiane S.] Emory Univ, Emory Vaccine Ctr, Dept Immunol & Microbiol, Atlanta, GA 30322 USA; [Eberhardt, Christiane S.] Univ Hosp Geneva, Ctr Vaccinol, CH-1211 Geneva, Switzerland; [Eberhardt, Christiane S.] Univ Geneva, Fac Med, Ctr Vaccinol, Dept Pathol & Immunol, CH-1211 Geneva, Switzerland; [Eberhardt, Christiane S.] Univ Geneva, Fac Med, Ctr Vaccinol, Dept Gen Pediat, CH-1211 Geneva, Switzerland		Nasti, TH (通讯作者)，Emory Univ, Emory Vaccine Ctr, Dept Immunol & Microbiol, Atlanta, GA 30322 USA.	tah.nasti@emory.edu; Christiane.Eberhardt@unige.ch		Nasti, Tahseen/0000-0002-5650-1563			Ahmadzadeh M, 2009, CLIN IMMUNOL, V131, pS38, DOI 10.1016/j.clim.2009.03.108; Antonios JP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87059; Ariza-Heredia EJ, 2015, HUM VACC IMMUNOTHER, V11, P2606, DOI 10.1080/21645515.2015.1062189; Awadalla M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0535-y; Baxter AG, 2002, NAT REV IMMUNOL, V2, P439, DOI 10.1038/nri823; Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584; Bersanelli M, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002619; Brossart P, 2020, CLIN CANCER RES, V26, P4442, DOI 10.1158/1078-0432.CCR-20-0305; Castle JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01856; Chang MH, 2011, RECENT RESULTS CANC, V188, P75, DOI 10.1007/978-3-642-10858-7_6; Chao MP, 2012, NAT REV CANCER, V12, P58, DOI 10.1038/nrc3171; Corulli LR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.729809; Curran MA, 2019, ANNU REV MED, V70, P409, DOI 10.1146/annurev-med-050217-121900; De Velasco G, 2017, CANCER IMMUNOL RES, V5, P312, DOI 10.1158/2326-6066.CIR-16-0237; Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3; Faiena I, 2020, J IMMUNOTHER, V43, P273, DOI 10.1097/CJI.0000000000000336; Fong L, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju268; Ford K, 2020, CANCER RES, V80, P1846, DOI 10.1158/0008-5472.CAN-19-3158; Gao T, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110888; Goldman B, 2009, NAT BIOTECHNOL, V27, P129, DOI 10.1038/nbt0209-129; Gopalakrishnan R, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3053; Guallar-Garrido S, 2020, IMMUNOTARGETS THER, V9, P1, DOI 10.2147/ITT.S202006; Gulley JL, 2014, CANCER IMMUNOL RES, V2, P133, DOI 10.1158/2326-6066.CIR-13-0108; Haen SP, 2020, NAT REV CLIN ONCOL, V17, P595, DOI 10.1038/s41571-020-0387-x; Harrington KJ, 2020, CLIN CANCER RES, V26, P5153, DOI 10.1158/1078-0432.CCR-20-1170; Hau M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-269; Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011; Herrero R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068329; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Hu ZT, 2021, NAT MED, V27, P515, DOI 10.1038/s41591-020-01206-4; Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330; Jou J, 2021, CLIN CANCER RES, V27, P689, DOI 10.1158/1078-0432.CCR-20-0245; Kavanagh K, 2017, LANCET INFECT DIS, V17, P1293, DOI 10.1016/S1473-3099(17)30468-1; Khoja L, 2017, ANN ONCOL, V28, P2377, DOI 10.1093/annonc/mdx286; Kim CG, 2021, J HEPATOL, V74, DOI 10.1016/j.jhep.2020.08.010; Kim CG, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aay0555; Kim CG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158035; Kim MH, 2018, CANCER IMMUNOL RES, V6, P255, DOI 10.1158/2326-6066.CIR-17-0320; Kreimer AR, 2011, LANCET ONCOL, V12, P862, DOI 10.1016/S1470-2045(11)70213-3; Ku J, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.368; Laubli H, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0353-7; Lasagna A, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100272; Le DT, 2010, CANCER J, V16, P304, DOI 10.1097/PPO.0b013e3181eb33d7; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Leroux-Roels G, 2015, MED MICROBIOL IMMUN, V204, P69, DOI 10.1007/s00430-014-0375-9; Li CX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01234-1; Liau LM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1507-6; Liu KJ, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0279-7; Lorenzo-Luaces P, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07284-4; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mitchell DA, 2015, NATURE, V519, P366, DOI 10.1038/nature14320; Nasti Tahseen H, 2021, Cancer Prev Res (Phila), V14, P165, DOI 10.1158/1940-6207.CAPR-20-0360; Nasti TH, 2016, MOL CARCINOGEN, V55, P646, DOI 10.1002/mc.22310; Nasti TH, 2015, J IMMUNOL, V194, P2683, DOI 10.4049/jimmunol.1402125; Obara W, 2017, CANCER IMMUNOL IMMUN, V66, P17, DOI 10.1007/s00262-016-1915-5; Ott PA, 2020, CELL, V183, P347, DOI 10.1016/j.cell.2020.08.053; Pallerla S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020779; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pergam Steven A, 2019, Biol Blood Marrow Transplant, V25, pe321, DOI 10.1016/j.bbmt.2019.07.034; Platten M, 2021, NATURE, V592, P463, DOI 10.1038/s41586-021-03363-z; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Puzanov I, 2016, J CLIN ONCOL, V34, P2619, DOI 10.1200/JCO.2016.67.1529; Pyeon D, 2020, PLOS PATHOG, V16, P8814, DOI 10.1371/journal.ppat.1008814; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Rice AE, 2015, CANCER GENE THER, V22, P454, DOI 10.1038/cgt.2015.40; Rini BI, 2006, CANCER-AM CANCER SOC, V107, P67, DOI 10.1002/cncr.21956; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Sankaranarayanan R, 2018, VACCINE, V36, P4783, DOI 10.1016/j.vaccine.2018.02.087; Saslow D, 2020, CA-CANCER J CLIN, V70, P274, DOI 10.3322/caac.21616; Saxena M, 2021, NAT REV CANCER, V21, P360, DOI 10.1038/s41568-021-00346-0; Saxena M, 2018, TRENDS CANCER, V4, P119, DOI 10.1016/j.trecan.2017.12.007; Seidel JA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00086; Sharma A, 2012, CANCER-AM CANCER SOC, V118, P4354, DOI 10.1002/cncr.26734; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shekarian T, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5025; Soares KC, 2015, J IMMUNOTHER, V38, P1, DOI 10.1097/CJI.0000000000000062; Spagnolo F, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13604; Srivatsan S, 2014, HUM VACC IMMUNOTHER, V10, P52, DOI 10.4161/hv.26568; Tamma Pranita, 2010, Pediatr Rev, V31, P38, DOI 10.1542/pir.31-1-38; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Terpos E, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01099-x; Thakkar A, 2021, CANCER CELL, V39, P1081, DOI 10.1016/j.ccell.2021.06.002; Thommen DS, 2018, CANCER CELL, V33, P547, DOI 10.1016/j.ccell.2018.03.012; Thompson RH, 2007, CLIN CANCER RES, V13, P1757, DOI 10.1158/1078-0432.CCR-06-2599; van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4; Vareki SM, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0479-7; Wada S, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-89; Waissengrin B, 2021, LANCET ONCOL, V22, P581, DOI 10.1016/S1470-2045(21)00155-8; Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648; Wang WS, 2009, INT IMMUNOL, V21, P1065, DOI 10.1093/intimm/dxp072; Wargowski E, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0333-y; Weber JS, 2013, J CLIN ONCOL, V31, P4311, DOI 10.1200/JCO.2013.51.4802; Welters MJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8307; Wieland A, 2021, NATURE, V597, P274, DOI 10.1038/s41586-020-2931-3; Yoshimura K, 2013, INT J UROL, V20, P744, DOI 10.1111/iju.12147; Zhao J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01184; Zhivaki D, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108381	101	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1396	10.3390/vaccines9121396			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9ZG	34960142	gold, Green Published			2022-04-29	WOS:000737322400001
J	Okubo, T; Inoue, A; Sekijima, K				Okubo, Toshihiro; Inoue, Atsushi; Sekijima, Kozue			Who Got Vaccinated for COVID-19? Evidence from Japan	VACCINES			English	Article						COVID-19; vaccination behavior; socioeconomic factors; Japan		Vaccination has been critical to reducing infections and deaths during the coronavirus disease 2019 (COVID-19) pandemic. While previous studies have investigated attitudes toward taking a vaccine, studies on the determinants of COVID-19 vaccination behavior are scant. We examine what characteristics, including socioeconomic and non-economic factors, are associated with vaccination behavior for COVID-19 in Japan. We use a large nationwide online survey with approximately 10,000 participants. As of September 2021, 85% of the respondents said that they had received or would receive a COVID-19 vaccine. Employing logistic regression analysis on vaccination behavior, we found that vaccination rates are higher among those who are older, married, educated, and/or work in a large company. On the other hand, vaccination rates tend to be lower among the self-employed, younger women, and those with poor mental health. Income did not significantly correlate with vaccination. Medical workers were found to have a relatively high rate of vaccination. Although attitude towards risk and time preference were not crucial factors for vaccination, fear of infection, infection prevention behavior, and agreement with government policies on behavioral restrictions in crisis situations positively correlated with vaccination.	[Okubo, Toshihiro] Keio Univ, Fac Econ, Tokyo 1088345, Japan; [Inoue, Atsushi; Sekijima, Kozue] Nippon Inst Res Adv, Tokyo 1506034, Japan		Okubo, T (通讯作者)，Keio Univ, Fac Econ, Tokyo 1088345, Japan.	okubo@econ.keio.ac.jp; ainoue@nira.or.jp; skozue@nira.or.jp		Okubo, Toshihiro/0000-0003-2795-1706			Al-Amer R, 2022, J CLIN NURS, V31, P62, DOI 10.1111/jocn.15951; [Anonymous], 2009, MINISTRY INTERNAL AF; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Chung H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1943; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Furukawa TA, 2008, INT J METH PSYCH RES, V17, P152, DOI 10.1002/mpr.257; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Government CIOs' Portal, JAP COVID 19 VACC JA; Guo N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030527; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Kadoya Y, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094864; Kantar Public, 2021, SOEP COR 2020 IND A; Kessler RC, 2003, ARCH GEN PSYCHIAT, V60, P184, DOI 10.1001/archpsyc.60.2.184; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; Kwok KO, 2021, J INFECTION, V83, P390, DOI 10.1016/j.jinf.2021.06.007; Lazarus JV, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240011; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; Nehal KR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101071; Nomura S, 2021, LANCET REG HEALTH-W, V14, DOI 10.1016/j.lanwpc.2021.100223; Okubo T, 2021, REPORT RESULTS 5 QUE; Okubo T., 2020, COVID EC, V32, P1; Okubo T, 2021, ASIAN ECON PAP, V20, P175, DOI 10.1162/asep_a_00807; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Trueblood JS, 2022, SOC PSYCHOL PERS SCI, V13, P311, DOI 10.1177/1948550621999622; Wake AD, 2021, RISK MANAG HEALTHC P, V14, P2609, DOI 10.2147/RMHP.S311074; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	33	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1505	10.3390/vaccines9121505			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	YI7DD	34960251	gold, Green Published			2022-04-29	WOS:000744004500001
J	Fulber, JPC; Farnos, O; Kiesslich, S; Yang, ZY; Dash, S; Susta, L; Wootton, SK; Kamen, AA				Fulber, Julia Puppin Chaves; Farnos, Omar; Kiesslich, Sascha; Yang, Zeyu; Dash, Shantoshini; Susta, Leonardo; Wootton, Sarah K.; Kamen, Amine A.			Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures	VACCINES			English	Article						Newcastle Disease Virus; Vero suspension culture; viral vaccine bioprocess; bioreactor production; vaccine production platform; COVID-19; SARS-CoV-2	INFLUENZA-VIRUS; ALAMAR BLUE; VACCINATION	The ongoing COVID-19 pandemic drew global attention to infectious diseases, attracting numerous resources for development of pandemic preparedness plans and vaccine platforms-technologies with robust manufacturing processes that can quickly be pivoted to target emerging diseases. Newcastle Disease Virus (NDV) has been studied as a viral vector for human and veterinary vaccines, but its production relies heavily on embryonated chicken eggs, with very few studies producing NDV in cell culture. Here, NDV is produced in suspension Vero cells, and analytical assays (TCID50 and ddPCR) are developed to quantify infectious and total viral titer. NDV-GFP and NDV-FLS (SARS-CoV-2 full-length spike protein) constructs were adapted to replicate in Vero and HEK293 suspension cultures using serum-free media, while fine-tuning parameters such as MOI, temperature, and trypsin concentration. Shake flask productions with Vero cells resulted in infectious titers of 1.07 x 10(8) TCID50/mL for NDV-GFP and 1.33 x 10(8) TCID50/mL for NDV-FLS. Production in 1 L batch bioreactors also resulted in high titers in culture supernatants, reaching 2.37 x 10(8) TCID50/mL for NDV-GFP and 3.16 x 10(7) TCID50/mL for NDV-FLS. This shows effective NDV production in cell culture, building the basis for a scalable vectored-vaccine manufacturing process that can be applied to different targets.	[Fulber, Julia Puppin Chaves; Farnos, Omar; Kiesslich, Sascha; Yang, Zeyu; Dash, Shantoshini; Kamen, Amine A.] McGill Univ, Dept Bioengn, Viral Vectors & Vaccines Bioproc Grp, Montreal, PQ H3A 0G4, Canada; [Susta, Leonardo; Wootton, Sarah K.] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada		Kamen, AA (通讯作者)，McGill Univ, Dept Bioengn, Viral Vectors & Vaccines Bioproc Grp, Montreal, PQ H3A 0G4, Canada.	julia.puppinchavesfulber@mail.mcgill.ca; omar.farnosvillar@mcgill.ca; sascha.kiesslich@mail.mcgill.ca; zeyu.yang2@mcgill.ca; shantoshini.dash@mail.mcgill.ca; lsusta@uoguelph.ca; kwootton@uoguelph.ca; amine.kamen@mcgill.ca		Wootton, Sarah/0000-0002-5985-2406; Kamen, Amine/0000-0001-9110-8815; Puppin Chaves Fulber, Julia/0000-0003-4272-0519; Farnos, Omar/0000-0003-1295-8323; , Zeyu/0000-0002-6780-7293	National Research Council of Canada (NRC) [PR-013.1]; Canada Research ChairNatural Resources CanadaCanadian Forest ServiceCanada Research Chairs [CRC-240394]; Mitacs Globalink Graduate Fellowship	This research was funded by the National Research Council of Canada (NRC), grant number PR-013.1 for Priority Research on COVID-19. A.A.K. is funded through a Canada Research Chair (CRC-240394). J.P.C.F. received funding from a Mitacs Globalink Graduate Fellowship.	Adalja AA, 2019, VACCINE PLATFORMS ST; Al-Ziaydi A.G., 2020, J PHYS C SERIES; Bukreyev A, 2005, J VIROL, V79, P13275, DOI 10.1128/JVI.79.21.13275-13284.2005; Christie A, 2021, MMWR-MORBID MORTAL W, V70, P858, DOI 10.15585/mmwr.mm7023e2externalicon; Cote J, 1998, BIOTECHNOL BIOENG, V59, P567, DOI 10.1002/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.0.CO;2-8; Crommelin DJA, 2021, J PHARM SCI-US, V110, P627, DOI 10.1016/j.xphs.2020.11.015; European Medicines Agency (EMA), ZABD SUMM PROD CHAR; European Medicines Agency (EMA), MVAB SUMM PROD CHAR; Fernandez-Sainz I, 2017, VIROLOGY, V502, P123, DOI 10.1016/j.virol.2016.12.021; Gelinas JF, 2020, METHODSX, V7, DOI 10.1016/j.mex.2020.100806; Genzel Y, 2015, BIOTECHNOL J, V10, P728, DOI 10.1002/biot.201400388; Genzel Y, 2010, APPL MICROBIOL BIOT, V88, P461, DOI 10.1007/s00253-010-2742-9; Ginting TE, 2017, ONCOLYTIC VIROTHER, V6, P21, DOI 10.2147/OV.S123292; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Hierholzer J. C., 1996, P25, DOI 10.1016/B978-012465330-6/50003-8; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; KAVERIN NV, 1995, J VIROL, V69, P2700, DOI 10.1128/JVI.69.4.2700-2703.1995; Khalfaoui R, 2021, PUBLIC HEALTH, V198, P177, DOI 10.1016/j.puhe.2021.07.026; Kiesslich S, 2021, BIOTECHNOL BIOENG, V118, P2649, DOI 10.1002/bit.27785; Kiesslich S, 2020, BIOTECHNOL ADV, V44, DOI 10.1016/j.biotechadv.2020.107608; Kim SH, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070183; Ru A, 2010, VACCINE, V28, P3661, DOI 10.1016/j.vaccine.2010.03.029; Liu T, 2019, VET MICROBIOL, V228, P53, DOI 10.1016/j.vetmic.2018.11.013; Mebatsion T., 2021, VIRAL VECTORS VET VA, P3, DOI [10.1007/978-3-030-51927-8, DOI 10.1007/978-3-030-51927-8]; Milian E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/504831; Mo C, 2008, J VIROL METHODS, V150, P63, DOI 10.1016/j.jviromet.2008.03.006; Nan FL, 2021, VET MICROBIOL, V261, DOI 10.1016/j.vetmic.2021.109181; Ndwandwe D, 2021, CURR OPIN IMMUNOL, V71, P111, DOI 10.1016/j.coi.2021.07.003; Orenstein WA, 2017, P NATL ACAD SCI USA, V114, P4031, DOI 10.1073/pnas.1704507114; Pedersen LE, 2016, VET IMMUNOL IMMUNOP, V181, P62, DOI 10.1016/j.vetimm.2016.07.012; Petiot E, 2015, VACCINE, V33, P5974, DOI 10.1016/j.vaccine.2015.05.097; Rambhia KJ, 2010, BIOSECUR BIOTERROR, V8, P321, DOI 10.1089/bsp.2010.0043; Rampersad SN, 2012, SENSORS-BASEL, V12, P12347, DOI 10.3390/s120912347; Samaranayake LP, 2021, ORAL DIS, DOI 10.1111/odi.13916; Schirrmacher V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051103; Sene MA, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00358-9; Shen CF, 2019, VACCINE, V37, P6996, DOI 10.1016/j.vaccine.2019.07.003; Silva CAT, 2021, CAN J CHEM ENG, V99, P2525, DOI 10.1002/cjce.24197; Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x; Sun WN, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103132; Thompson CM, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-141; Tomori O, 2021, CURR OPIN IMMUNOL, V71, P27, DOI 10.1016/j.coi.2021.03.008; Vijayakumar G, 2020, METHODS MOL BIOL, V2058, P133, DOI 10.1007/978-1-4939-9794-7_9; Warner BM, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103219; Wen ZY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-331; WHO, COVID 19 VACC TRACK; Yurchenko KS, 2019, ACTA NATURAE, V11, P66, DOI 10.32607/20758251-2019-11-1-66-73	48	0	0	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1335	10.3390/vaccines9111335			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF5MK	34835266	Green Published, gold			2022-04-29	WOS:000724114000001
J	Gong, LB; Zhang, X; Qu, ZQ; Francis, MR; Han, KY; Xu, CL; Cai, EM; Shi, HL; Hou, ZY				Gong, Liubing; Zhang, Xu; Qu, Zhiqiang; Francis, Mark R.; Han, Kaiyi; Xu, Cuilin; Cai, Enmao; Shi, Huilin; Hou, Zhiyuan			Public Interest in Distribution and Determinants of Influenza and Pneumonia Vaccination during the COVID-19 Pandemic: An Infodemiology and Cross-Sectional Study from China	VACCINES			English	Article						COVID-19; public attention; influenza vaccine; pneumonia vaccine; vaccination; determinant	SEASONAL INFLUENZA; PNEUMOCOCCAL VACCINATION; VACCINES; POLICY; BEHAVIOR; RECEIVE; ADULTS; IMPACT	Background: Following the COVID-19 pandemic, global interest in influenza vaccines and pneumonia vaccines has increased significantly. We aimed to examine public interest in and actual market circulation of influenza and pneumonia vaccines before and after the initial outbreak of COVID-19 and estimate the coverage and determinants of influenza and pneumonia vaccination uptake following the COVID-19 pandemic. Methods: We obtained search volume data for vaccines using the Baidu search index and collected the numbers of vaccines issued from the National Institutes for Food and Drug Control. We also conducted a cross-sectional survey among 3346 adult residents to evaluate the coverage and determinants of influenza and pneumonia vaccination uptake in the Yangtze River delta, China, from 29 January to 4 February 2021. Results: Public searches and the number of vaccines issued for the influenza vaccines and pneumonia vaccines obviously increased after the initial outbreak of COVID-19. In the total sample, 12.5% were vaccinated against influenza, and 21.5% had at least one family member vaccinated against pneumonia. A minority of participants perceived that they were highly or very highly susceptible to influenza (15.9%) and COVID-19 (6.7%). A range of socio-economic factors and perceived susceptibility to COVID-19 were associated with influenza and pneumonia vaccination uptake. Conclusions: Public interest in and issued volumes of influenza and pneumonia vaccines increased nationally following the COVID-19 pandemic. Perceptions of high susceptibility to COVID-19 were associated with the uptake of the influenza and pneumonia vaccines. Targeted interventions were needed to improve vaccination coverage.	[Gong, Liubing] Chizhou Ctr Dis Prevent & Control, Chizhou 247100, Peoples R China; [Zhang, Xu; Qu, Zhiqiang; Han, Kaiyi; Hou, Zhiyuan] Fudan Univ, Sch Publ Hlth, NHC Key Lab Hlth Technol Assessment, Shanghai 200032, Peoples R China; [Francis, Mark R.] Tampere Univ, Hlth Sci Unit, Fac Social Sci, Tampere 33014, Finland; [Han, Kaiyi] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England; [Xu, Cuilin] Yuhuatai Ctr Dis Prevent & Control, Nanjing 210012, Peoples R China; [Cai, Enmao] Changning Ctr Dis Prevent & Control, Shanghai 200051, Peoples R China; [Shi, Huilin] Fudan Univ, Minist Educ, Key Lab Publ Hlth Safety, Sch Publ Hlth, Shanghai 200032, Peoples R China		Hou, ZY (通讯作者)，Fudan Univ, Sch Publ Hlth, NHC Key Lab Hlth Technol Assessment, Shanghai 200032, Peoples R China.	chzcpdcxf@126.com; 21211020162@m.fudan.edu.cn; 21211020181@m.fudan.edu.cn; mark.francis@tuni.fi; kaiyi.han@lshtm.ac.uk; czjmk2014@163.com; caienmao@126.com; 19211020057@fudan.edu.cn; zyhou@fudan.edu.cn		Hou, Zhiyuan/0000-0003-3413-0076; Zhang, Xu/0000-0003-1109-6880; Qu, Zhiqiang/0000-0003-0259-8467	Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai [2020-2022, GWV-10.1-XK23]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71874034]	FundingThis research was funded by the Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022) (GWV-10.1-XK23) and the National Natural Science Foundation of China (No. 71874034).	[Anonymous], INTERNET SEARCH TREN; Assi TM, 2012, VACCINE, V30, P4517, DOI 10.1016/j.vaccine.2012.04.041; Beard F, 2021, COMMUN DIS INTELL, V45, DOI 10.33321/cdi.2021.45.10; Chu A, 2021, PREV MED REP, V23, DOI 10.1016/j.pmedr.2021.101417; Danis K, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.22.2000956; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Gazibara T, 2019, J HEALTH POPUL NUTR, V38, DOI 10.1186/s41043-018-0159-8; Gostin LO, 2020, JAMA-J AM MED ASSOC, V324, P335, DOI 10.1001/jama.2020.10802; Grohskopf LA, 2020, JAMA-J AM MED ASSOC, V324, P1029, DOI 10.1001/jama.2020.15845; Guzman-Holst A, 2020, VACCINE, V38, P470, DOI 10.1016/j.vaccine.2019.10.088; Hashemi SA, 2020, J MED VIROL, V92, P2319, DOI 10.1002/jmv.26014; Hasoksuz M, 2020, TURK J MED SCI, V50, P549, DOI 10.3906/sag-2004-127; Hou ZY, 2014, VACCINE, V32, P4471, DOI 10.1016/j.vaccine.2014.06.047; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jaklevic MC, 2020, JAMA-J AM MED ASSOC, V324, P926, DOI 10.1001/jama.2020.15444; Jiang XW, 2021, VACCINE, V39, P846, DOI 10.1016/j.vaccine.2020.12.040; Jung J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e378; Komori A, 2021, HUM VACC IMMUNOTHER, V17, P4673, DOI 10.1080/21645515.2021.1958612; Leung KC, 2017, HEALTH EDUC RES, V32, P455, DOI 10.1093/her/cyx053; Li Q, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108378; Liu SJ, 2014, HUM VACC IMMUNOTHER, V10, P2994, DOI 10.4161/21645515.2014.972155; Liu Y, 2021, HUM VACC IMMUNOTHER, V17, P157, DOI 10.1080/21645515.2020.1765620; Ma SM, 2020, INT J INFECT DIS, V96, P683, DOI 10.1016/j.ijid.2020.05.068; Maltezou HC, 2020, VACCINE, V38, P6078, DOI 10.1016/j.vaccine.2020.07.058; Marcus RE, 2022, J COMMUN HEALTH, V47, P226, DOI 10.1007/s10900-021-01036-6; Ng Sophia, 2015, Curr Epidemiol Rep, V2, P89; Paguio JA, 2020, VACCINE, V38, P5430, DOI 10.1016/j.vaccine.2020.06.069; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Piroth L, 2021, LANCET RESP MED, V9, P251, DOI 10.1016/S2213-2600(20)30527-0; Rastegar M, 2021, VACCINE, V39, P495, DOI 10.1016/j.vaccine.2020.12.022; Redondo E, 2016, Semergen, V42, P464, DOI 10.1016/j.semerg.2016.07.009; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Sokol RL, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-022871; Stowe J, 2021, INT J EPIDEMIOL, V50, P1124, DOI 10.1093/ije/dyab081; Stroffolini T, 2021, J MED VIROL, V93, P2446, DOI 10.1002/jmv.26763; Thindwa D, 2020, VACCINE, V38, P5398, DOI 10.1016/j.vaccine.2020.06.047; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1; Wang Q, 2018, VACCINE, V36, P7262, DOI 10.1016/j.vaccine.2018.10.045; Wang X, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.021102; Wu SS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017459; Yang J, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01545-6; Yang J, 2016, VACCINE, V34, P5724, DOI 10.1016/j.vaccine.2016.10.013; Yang L, 2015, VACCINE, V33, P6525, DOI 10.1016/j.vaccine.2015.10.012; Ye CC, 2018, HUM VACC IMMUNOTHER, V14, P2715, DOI 10.1080/21645515.2018.1491246; Zhang MY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030212; Zhou YH, 2021, HUM VACC IMMUNOTHER, V17, P2289, DOI 10.1080/21645515.2020.1871571	47	1	1	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1329	10.3390/vaccines9111329			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH4TF	34835258	Green Published, gold			2022-04-29	WOS:000725428200001
J	Jugler, C; Sun, HY; Chen, Q				Jugler, Collin; Sun, Haiyan; Chen, Qiang			SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody	VACCINES			English	Article						SARS-CoV-2; monoclonal antibody (mAb); COVID-19; interleukin 6 (IL-6); IL-6 receptor (IL-6R); cytokine storm; spike protein (S); sarilumab; plant-made therapeutics; plant-made antibody	NILE VIRUS-INFECTION; SARILUMAB; PARTICLES; CYTOKINE; COVID-19; VACCINES; VECTORS; SYSTEM; TRIAL; IL-6	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the current COVID-19 pandemic, has caused more than 4.5 million deaths worldwide. Severe and fatal cases of COVID-19 are often associated with increased proinflammatory cytokine levels including interleukin 6 (IL-6) and acute respiratory distress syndrome. In this study, we explored the feasibility of using plants to produce an anti-IL-6 receptor (IL-6R) monoclonal antibody (mAb) and examined its utility in reducing IL-6 signaling in an in vitro model, which simulates IL-6 induction during SARS-CoV-2 infection. The anti-IL6R mAb (IL6RmAb) was quickly expressed and correctly assembled in Nicotiana benthamiana leaves. Plant-produced IL6RmAb (pIL6RmAb) could be enriched to homogeneity by a simple purification scheme. Furthermore, pIL6RmAb was shown to effectively inhibit IL-6 signaling in a cell-based model system. Notably, pIL6RmAb also suppressed IL-6 signaling that was induced by the exposure of human peripheral blood mononuclear cells to the spike protein of SARS-CoV-2. This is the first report of a plant-made anti-IL-6R mAb and its activity against SARS-CoV-2-related cytokine signaling. This study demonstrates the capacity of plants for producing functionally active mAbs that block cytokine signaling and implies their potential efficacy to curb cytokine storm in COVID-19 patients.	[Jugler, Collin; Sun, Haiyan; Chen, Qiang] Arizona State Univ, Biodesign Inst, Tempe, AZ 85287 USA; [Jugler, Collin; Sun, Haiyan; Chen, Qiang] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA		Chen, Q (通讯作者)，Arizona State Univ, Biodesign Inst, Tempe, AZ 85287 USA.; Chen, Q (通讯作者)，Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.	Collin.Jugler@asu.edu; haiyan.sun@asu.edu; qiang.chen.4@asu.edu		chen, qiang/0000-0003-1498-7013			Bendandi M, 2006, REV RECENT CLIN TRIA, V1, P67, DOI 10.2174/157488706775246120; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen N., 2020, The Lancet, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chen Qiang, 2016, F1000Res, V5, DOI 10.12688/f1000research.8010.1; Chen Q, 2016, P NATL ACAD SCI USA, V113, P9404, DOI 10.1073/pnas.1610803113; Chen Q, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/932161; Chen Qiang, 2013, Adv Tech Biol Med, V1; Chen Q, 2011, HUM VACCINES, V7, P331, DOI 10.4161/hv.7.3.14262; Choudhury A, 2021, J MED VIROL, V93, P2476, DOI 10.1002/jmv.26776; Choudhury A, 2020, J MED VIROL, V92, P2105, DOI 10.1002/jmv.25987; Costela-Ruiz VJ, 2020, CYTOKINE GROWTH F R, V54, P62, DOI 10.1016/j.cytogfr.2020.06.001; Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330; Dent M, 2016, J GEN VIROL, V97, P3280, DOI 10.1099/jgv.0.000635; Diamos AG, 2020, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00472; Esqued A, 2021, METHOD ENZYMOL, V660, P223, DOI 10.1016/bs.mie.2021.05.003; Esqueda A, 2021, METHODS MOL BIOL, V2225, P25, DOI 10.1007/978-1-0716-1012-1_2; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI 10.1056/NEJMoa2100433; He JY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010060; He JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093541; He JY, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/106783; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Huang Z, 2009, BIOTECHNOL BIOENG, V103, P706, DOI 10.1002/bit.22299; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Hurtado J, 2020, PLANT BIOTECHNOL J, V18, P266, DOI 10.1111/pbi.13194; Jugler C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062140; Kallolimath S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2107249118; Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026; Karwaciak I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010054; Lai HF, 2018, VACCINE, V36, P1846, DOI 10.1016/j.vaccine.2018.02.073; Lai HF, 2014, PLANT BIOTECHNOL J, V12, P1098, DOI 10.1111/pbi.12217; Lai HF, 2012, PLANT CELL REP, V31, P573, DOI 10.1007/s00299-011-1196-6; Lai HF, 2012, PLANT BIOTECHNOL J, V10, P95, DOI 10.1111/j.1467-7652.2011.00649.x; Lai HF, 2010, P NATL ACAD SCI USA, V107, P2419, DOI 10.1073/pnas.0914503107; Leisman DE, 2020, LANCET RESP MED, V8, P1233, DOI 10.1016/S2213-2600(20)30404-5; Leuzinger K, 2013, JOVE-J VIS EXP, DOI 10.3791/50521; Ma JKC, 2015, PLANT BIOTECHNOL J, V13, P1106, DOI 10.1111/pbi.12416; Margolin E, 2020, PLANT BIOTECHNOL J, V18, P2109, DOI 10.1111/pbi.13369; Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340; Moravec R., 2020, REPRODUCIBLE MOA REF; Moreno-Eutimio MA, 2020, MICROBES INFECT, V22, P226, DOI 10.1016/j.micinf.2020.04.009; Nandi S, 2016, MABS-AUSTIN, V8, P1456, DOI 10.1080/19420862.2016.1227901; Rafique A, 2013, ANN RHEUM DIS, V72, P797; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Sabaka P, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05945-8; Schultze JL, 2021, CELL, V184, P1671, DOI 10.1016/j.cell.2021.02.029; Scott AM, 1997, LANCET, V349, pS19, DOI 10.1016/S0140-6736(97)90016-7; Shanmugaraj B, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.589995; Somanchi Srinivas S, 2011, J Vis Exp, DOI 10.3791/2540; Strasser R, 2008, PLANT BIOTECHNOL J, V6, P392, DOI 10.1111/j.1467-7652.2008.00330.x; Sun HY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010054; Teh AYH, 2014, PLANT BIOTECHNOL J, V12, P300, DOI 10.1111/pbi.12137; Traynor K, 2012, AM J HEALTH-SYST PH, V69, P1009, DOI 10.2146/news120041; Tuse D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/256135; Whittington MD, 2019, J MANAG CARE SPEC PH, V25, P80, DOI 10.18553/jmcp.2019.25.1.080; WHO, 2021, COVID 19 DASHB; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xu C, 2021, J CLIN PHARMACOL, V61, P714, DOI 10.1002/jcph.1795; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Yu CF, 2018, ANAL BIOANAL CHEM, V410, P7067, DOI 10.1007/s00216-018-1307-0; Zhao YC, 2021, CELL RES, V31, P818, DOI 10.1038/s41422-021-00495-9	61	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1365	10.3390/vaccines9111365			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI3LY	34835296	gold, Green Published			2022-04-29	WOS:000726018800001
J	Poon, PKM; Zhou, WJ; Chan, DCC; Kwok, KO; Wong, SYS				Poon, Paul Kwok Ming; Zhou, Weiju; Chan, Dicken Cheong Chun; Kwok, Kin On; Wong, Samuel Yeung Shan			Recommending COVID-19 Vaccines to Patients: Practice and Concerns of Frontline Family Doctors	VACCINES			English	Article						COVID-19; COVID-19 vaccine recommendations; family doctors; primary care	INFLUENZA VACCINATION; DISEASE; NURSES	Background: Recommendation from doctors is a well-recognized motivator toward vaccine uptake. Family doctors are in the prime position to advise the public on COVID-19 vaccination. We studied the practice and concerns of frontline family doctors concerning COVID-19 vaccination recommendations to patients. Methods: We conducted a cross-sectional online survey of all family doctors in the Hong Kong College of Family Physicians between June and July 2021. Their practice of making COVID-19 recommendation to patients was assessed. Based on the Health Belief Model, factors associated with doctors' recommendation practices were explored and examined. Multivariate logistic regression models were used to investigate the factors, including COVID-19 vaccine attributes, associated with doctors' practices in making recommendations. Their own vaccination status and psychological antecedents to vaccine hesitancy were measured. Results: A total of 312 family doctors responded (a 17.6% response rate). The proportion of doctors who had received COVID-19 vaccines was 90.1%. The proportion of doctors who would recommend all patients without contraindications for the vaccination was 64.4%. The proportion of doctors who would proactively discuss COVID-19 vaccines with patients was 52.9%. Multivariate logistic regression analysis showed that doctors' own COVID-19 vaccination status was the strongest predictor of family doctors making a recommendation to patients (aOR 12.23 95% CI 3.45-43.33). Longer duration of practice, willingness to initiate the relevant discussion with patients and less worry about vaccine side effects on chronic illness patients were the other factors associated with making a COVID-19 vaccination recommendation. Conclusions: Family doctors should be encouraged to get vaccinated themselves and initiate discussions with patients about COVID-19 vaccines. Vaccine safety data on patients with chronic illness, training and guidelines for junior doctors may facilitate the COVID-19 vaccination recommendation practices of family doctors.	[Poon, Paul Kwok Ming; Zhou, Weiju; Chan, Dicken Cheong Chun; Kwok, Kin On; Wong, Samuel Yeung Shan] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Shatin, 2-F Prince Wales Hosp, Hong Kong, Peoples R China; [Kwok, Kin On] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Peoples R China; [Kwok, Kin On] Chinese Univ Hong Kong, Hong Kong Inst Asia Pacific Studies, Hong Kong, Peoples R China; [Kwok, Kin On] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen 518057, Peoples R China		Wong, SYS (通讯作者)，Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Shatin, 2-F Prince Wales Hosp, Hong Kong, Peoples R China.	kwokmingpoon@cuhk.edu.hk; joewjzhou@cuhk.edu.hk; dicken@cuhk.edu.hk; kkokwok@cuhk.edu.hk; yeungshanwong@cuhk.edu.hk	Kwok, Kin On/A-5074-2018; WONG, Samuel Yeung Shan/D-7311-2013	Kwok, Kin On/0000-0002-2804-5433; WONG, Samuel Yeung Shan/0000-0003-0934-6385; Poon, Kwok Ming/0000-0003-4252-0656	JC School of Public Health and Primary Care; Chinese University of Hong KongChinese University of Hong Kong	The staff working on this study received funding from the JC School of Public Health and Primary Care, The Chinese University of Hong Kong. The funder had no role in the study design and collection, analysis and interpretation of data, nor in writing the manuscript.	Bandyopadhyay S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003097; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Ebert JF, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8353; HKSARG, INT GUID NOT COMM ME, V2; Hyder AA, 2021, B WORLD HEALTH ORGAN, V99, P406, DOI 10.2471/BLT.21.285616; Kelkar AH, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9030351; Kwok K.O., 2021, CLIN MICROBIOL INFEC, DOI [10.1016/j.cmi.2021.09.029, DOI 10.1016/J.CMI.2021.09.029]; Kwok KO, 2021, EMERG INFECT DIS, V27, P1802, DOI 10.3201/eid2707.210054; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lam RPK, 2018, DISASTER MED PUBLIC, V12, P329, DOI 10.1017/dmp.2017.71; Lee JT, 2021, MMWR-MORBID MORTAL W, V70, P1036, DOI [10.15585/mmwr.mm7030a2externalicon, 10.15585/mmwr.mm7030a2, 10.1101/2021.05.14.21257224v1]; Li M, 2021, POSTGRAD MED J, DOI 10.1136/postgradmedj-2021-140195; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Liu TR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060649; Loheswaran G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124402; Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016; McPhillips HA, 2001, ARCH PEDIAT ADOL MED, V155, P1051, DOI 10.1001/archpedi.155.9.1051; Mercadante AR, 2021, RES SOC ADMIN PHARM, V17, P1596, DOI 10.1016/j.sapharm.2020.12.012; Our World in Data, COR COVID 19 VACC ST; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; The Governement of the Hong Kong Special Adminsitrative Region, HEALTHC PROF CORN; Torjesen I, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1445; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; World Health Organization, TRACK SARS COV 2 VAR; Yates T, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06466-0	28	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1319	10.3390/vaccines9111319			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH3GR	34835250	gold, Green Published			2022-04-29	WOS:000725327600001
J	Arnoux, S; Bidan, F; Damman, A; Petit, E; Assie, S; Ezanno, P				Arnoux, Sandie; Bidan, Fabrice; Damman, Alix; Petit, Etienne; Assie, Sebastien; Ezanno, Pauline			To Vaccinate or Not: Impact of Bovine Viral Diarrhoea in French Cow-Calf Herds	VACCINES			English	Article						epidemiology; model; endemic disease; control strategy; vaccination; economic impact; cattle; BVD	VIRUS BVDV SEROPOSITIVITY; MUCOSAL DISEASE VIRUS; INFECTION; MODEL; SPREAD; BEEF; ASSOCIATIONS; PATHOGENESIS; BIOSECURITY; PROGRAM	Bovine viral diarrhoea (BVD) remains an issue despite control programs implemented worldwide. Virus introduction can occur through contacts with neighbouring herds. Vaccination can locally protect exposed herds. However, virus spread depends on herd characteristics, which may impair vaccination efficiency. Using a within-herd epidemiological model, we compared three French cow-calf farming systems named by their main breed: Charolaise, Limousine, and Blonde d'Aquitaine. We assessed vaccination strategies of breeding females assuming two possible protections: against infection or against vertical transmission. Four commercial vaccines were considered: Bovilis(R), Bovela(R), Rispoval(R), and Mucosiffa(R). We tested various virus introduction frequency in a naive herd. We calculated BVD economic impact and vaccination reward. In Charolaise, BVD economic impact was 113euro per cow over 5 years after virus introduction. Irrespective of the vaccine and for a high enough risk of introduction, the yearly expected reward was 0.80euro per invested euro per cow. Vaccination should not be stopped before herd exposure has been decreased. In contrast, the reward was almost nil in Blonde d'Aquitaine and Limousine. This highlights the importance of accounting for herd specificities to assess BVD impact and vaccination efficiency. To guide farmers' vaccination decisions against BVD, we transformed this model into a French decision support tool.	[Arnoux, Sandie; Damman, Alix; Assie, Sebastien; Ezanno, Pauline] INRAE, Oniris, BIOEPAR, F-44300 Nantes, France; [Bidan, Fabrice] Inst Lelevage, 42 Rue Georges Morel, F-49070 Beaucouze, France; [Petit, Etienne] GDS BFC, F-21110 Breteniere, France; [Damman, Alix] Bur Fed Plan, Rue Belliard 14-18, B-1040 Brussels, Belgium		Ezanno, P (通讯作者)，INRAE, Oniris, BIOEPAR, F-44300 Nantes, France.	sandie.arnoux@inrae.fr; fabrice.bidan@idele.fr; alix.damman@gmail.com; etienne.petit.gdsbfc@reseaugds.com; sebastien.assie@oniris-nantes.fr; pauline.ezanno@inrae.fr	Ezanno, Pauline/A-4699-2009	Ezanno, Pauline/0000-0002-0034-8950	French Research Agency (ANR), Program Investments for the FutureFrench National Research Agency (ANR) [ANR-10-BINF-07]; European fund for the regional development (FEDER Pays-de-la-Loire); European Union's Horizon 2020 research and innovation programme [101000494]; INRAE; GENCI-[CINES/IDRIS/TGCC] [2021-[A0100312468]]	The French Research Agency (ANR), Program Investments for the Future, project ANR-10-BINF-07 (MIHMES), the European fund for the regional development (FEDER Pays-de-la-Loire), the European Union's Horizon 2020 research and innovation programme under grant agreement No. 101000494 (DECIDE), and INRAE are acknowledged for providing financial support. This work was performed using HPC resources from GENCI-[CINES/IDRIS/TGCC](Grant 2021-[A0100312468]).	BAKER JC, 1987, J AM VET MED ASSOC, V190, P1449; BROWNLIE J, 1987, ANN RECH VET, V18, P157; CARLSSON U, 1989, J VET MED A, V36, P15, DOI 10.1111/j.1439-0442.1989.tb00697.x; Cherry BR, 1998, PREV VET MED, V33, P91, DOI 10.1016/S0167-5877(97)00050-0; Damman A, 2015, VET RES, V46, DOI 10.1186/s13567-015-0145-8; DONE JT, 1980, VET REC, V106, P473, DOI 10.1136/vr.106.23.473; DUFFELL SJ, 1985, VET REC, V117, P240, DOI 10.1136/vr.117.10.240; Evans CA, 2019, TRANSBOUND EMERG DIS, V66, P640, DOI 10.1111/tbed.13068; Fajardo LC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88471-6; Fray MD, 2000, ANIM REPROD SCI, V60, P615, DOI 10.1016/S0378-4320(00)00082-8; Gates MC, 2013, VET J, V198, P631, DOI 10.1016/j.tvjl.2013.09.017; Gates MC, 2013, PREV VET MED, V112, P285, DOI 10.1016/j.prevetmed.2013.07.017; Gethmann J, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00406; Graham DA, 2016, PREV VET MED, V126, P30, DOI 10.1016/j.prevetmed.2016.01.017; Gunn GJ, 2004, VET J, V167, P143, DOI 10.1016/S1090-0233(03)00112-6; Hasler B, 2012, PREV VET MED, V106, P162, DOI 10.1016/j.prevetmed.2012.01.022; Han JH, 2020, PREV VET MED, V182, DOI 10.1016/j.prevetmed.2020.105092; HOUE H, 1993, PREV VET MED, V15, P275, DOI 10.1016/0167-5877(93)90099-F; Iott B, 2019, PREV VET MED, V165, P23, DOI 10.1016/j.prevetmed.2019.02.001; Jackova A, 2008, VET RES COMMUN, V32, P7, DOI 10.1007/s11259-007-9012-z; KENDRICK JW, 1971, AM J VET RES, V32, P533; KENDRICK JW, 1974, AM J VET RES, V35, P589; Lanyon SR, 2014, VET J, V199, P201, DOI 10.1016/j.tvjl.2013.07.024; Lindberg ALE, 2003, VET QUART, V25, P1; MCCLURKIN AW, 1984, CAN J COMP MED, V48, P156; MCGOWAN MR, 1993, VET REC, V133, P39, DOI 10.1136/vr.133.2.39; Metcalfe L., 2019, J VET SCI MED, V7, P4, DOI DOI 10.13188/2325-4645.1000041; Moennig V, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7010029; MOERMAN A, 1993, VET REC, V132, P622, DOI 10.1136/vr.132.25.622; Pinior B, 2017, PREV VET MED, V137, P77, DOI 10.1016/j.prevetmed.2016.12.014; Richter V, 2019, VET REC, V184, DOI 10.1136/vr.105354; Ridpath JF, 2013, BIOLOGICALS, V41, P14, DOI 10.1016/j.biologicals.2012.07.003; Saltelli A., 2000, SENSITIVITY ANAL; Sayers RG, 2015, VET J, V205, P56, DOI 10.1016/j.tvjl.2015.03.025; Smith RL, 2014, PREV VET MED, V113, P492, DOI 10.1016/j.prevetmed.2013.11.013; Smith RL, 2010, PREV VET MED, V95, P86, DOI 10.1016/j.prevetmed.2010.02.009; Sozzi E, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030374; Stott AW, 2003, PREV VET MED, V59, P51, DOI 10.1016/S0167-5877(03)00062-X; Thulke HH, 2018, PREV VET MED, V150, P151, DOI 10.1016/j.prevetmed.2017.11.017; Viet AF, 2007, EPIDEMIOL INFECT, V135, P706, DOI 10.1017/S095026880600745X; Yesilbag K, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060128	41	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1137	10.3390/vaccines9101137			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS8WU	34696246	Green Published			2022-04-29	WOS:000715459000001
J	Balkrishna, A; Arya, V; Rohela, A; Kumar, A; Verma, R; Kumar, D; Nepovimova, E; Kuca, K; Thakur, N; Thakur, N; Kumar, P				Balkrishna, Acharya; Arya, Vedpriya; Rohela, Akansha; Kumar, Ashwani; Verma, Rachna; Kumar, Dinesh; Nepovimova, Eugenie; Kuca, Kamil; Thakur, Naveen; Thakur, Nikesh; Kumar, Pankaj			Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines	VACCINES			English	Review						SARS-CoV-2; COVID-19; diagnosis; virus-like particle vaccines; prevention	SOLID LIPID NANOPARTICLES; TARGETED DRUG-DELIVERY; GOLD NANOPARTICLES; QUANTUM DOTS; PROTECT MICE; FORMULATION; SARS-COV-2; HIV; ANTIBACTERIAL; OPPORTUNITIES	SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat COVID-19. In this context, using databases such as PubMed, Google Scholar, and Science Direct, we gathered information about nanotechnology's involvement in the prevention, diagnosis and virus-like particle vaccine development. This review revealed that various nanomaterials like gold, polymeric, graphene and poly amino ester with carboxyl group coated magnetic nanoparticles have been explored for the fast detection of SARS-CoV-2. Personal protective equipment fabricated with nanoparticles, such as gloves, masks, clothes, surfactants, and Ag, TiO2 based disinfectants played an essential role in halting COVID-19 transmission. Nanoparticles are used not only in vaccine delivery, such as lipid nanoparticles mediated transport of mRNA-based Pfizer and Moderna vaccines, but also in the development of vaccine as the virus-like particles elicit an immune response. There are now 18 virus-like particle vaccines in pre-clinical development, with one of them, developed by Novavax, reported being in phase 3 trials. Due to the probability of upcoming COVID-19 waves, and the rise of new diseases, the future relevance of virus-like particles is imperative. Furthermore, psychosocial variables linked to vaccine reluctance constitute a critical problem that must be addressed immediately to avert pandemic.	[Balkrishna, Acharya; Arya, Vedpriya; Rohela, Akansha; Kumar, Ashwani] Patanjali Res Inst, Patanjali Herbal Res Dept, Haridwar 249405, India; [Balkrishna, Acharya; Arya, Vedpriya] Univ Patanjali, Dept Allied Sci, Haridwar 249405, India; [Verma, Rachna] Shoolini Univ Biotechnol & Management Sci, Sch Biol & Environm Sci, Solan 173229, India; [Kumar, Dinesh] Shoolini Univ Biotechnol & Management Sci, Sch Bioengn & Food Technol, Solan 173229, India; [Nepovimova, Eugenie; Kuca, Kamil] Univ Hradec Kralove, Fac Sci, Dept Chem, Hradec Kralove 50003, Czech Republic; [Kuca, Kamil] Univ Hosp Hradec Kralove, Biomed Res Ctr, Sokolska 581, Hradec Kralove 50005, Czech Republic; [Thakur, Naveen; Thakur, Nikesh; Kumar, Pankaj] Career Point Univ, Dept Phys, Hamirpur 177001, India		Kumar, A (通讯作者)，Patanjali Res Inst, Patanjali Herbal Res Dept, Haridwar 249405, India.; Verma, R (通讯作者)，Shoolini Univ Biotechnol & Management Sci, Sch Biol & Environm Sci, Solan 173229, India.; Kuca, K (通讯作者)，Univ Hradec Kralove, Fac Sci, Dept Chem, Hradec Kralove 50003, Czech Republic.; Kuca, K (通讯作者)，Univ Hosp Hradec Kralove, Biomed Res Ctr, Sokolska 581, Hradec Kralove 50005, Czech Republic.	vedpriya.arya@prft.in; akansha.rohela@prft.co.in; rachnaverma@shooliniuniversity.com; dineshkumar@shooliniuniversity.com; eugenie.nepovimova@uhk.cz; kamil.kuca@uhk.cz	Verma, Rachna/AAA-6251-2021; Kumar, Dinesh/AAA-7914-2021; Kuca, Kamil/D-1396-2011	Verma, Rachna/0000-0001-5321-9450; Kumar, Dinesh/0000-0003-3485-6408; Balkrishna, Acharya/0000-0003-4749-6317; Kuca, Kamil/0000-0001-9664-1109	Excellence project PrF UHK 2011/2021-2022; MH CZ-DRO (UHHK) [00179906]	This research was supported by the Excellence project PrF UHK 2011/2021-2022 and MH CZ-DRO (UHHK, 00179906).	Adams JG, 2020, JAMA-J AM MED ASSOC, V323, P1439, DOI 10.1001/jama.2020.3972; Alidori S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12343; Alpdagtas S, 2020, APL BIOENG, V4, DOI 10.1063/5.0021554; [Anonymous], 2021, FIND FIND EVALUATION; Anselmo AC, 2019, BIOENG TRANSL MED, V4, DOI 10.1002/btm2.10143; Anu, 2020, INORG NANO-MET CHEM, V50, P933, DOI 10.1080/24701556.2020.1728554; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020; Bai BK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002685; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565; Balagna C., 2020, OPEN CERAMICS, V1, DOI DOI 10.1016/J.OCERAM.2020.100006; Balasubramaniam B, 2021, ACS PHARMACOL TRANSL, V4, P8, DOI 10.1021/acsptsci.0c00174; Balke I, 2019, ADV DRUG DELIVER REV, V145, P119, DOI 10.1016/j.addr.2018.08.007; BAYER ME, 1968, NATURE, V218, P1057, DOI 10.1038/2181057a0; Block P, 2020, NAT HUM BEHAV, V4, P588, DOI 10.1038/s41562-020-0898-6; Campos EVR, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00685-4; Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647; CDC, 2020, COR DIS 2019 COVID 1; CEPI (Coalition for Epidemic Preparedness Innovations), 2020, CEPI SURV GLOB DRUG; Chaimayo C, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01452-5; Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chauhan G, 2020, ACS NANO, V14, P7760, DOI 10.1021/acsnano.0c04006; Chen L, 2020, MAT SCI ENG C-MATER, V112, DOI 10.1016/j.msec.2020.110924; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chen XF, 2014, J MED VIROL, V86, P1705, DOI 10.1002/jmv.24013; Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90; Chroboczek J, 2014, ACTA BIOCHIM POL, V61, P531; Comparetti EJ, 2018, BIOCONJUGATE CHEM, V29, P709, DOI 10.1021/acs.bioconjchem.7b00563; Datta, 2021, WORLD ACAD SCI J, V3, P1, DOI [10.3892/wasj.2021.86, DOI 10.3892/WASJ.2021.86]; Davis MM, 2011, VACCINE, V29, P9414, DOI 10.1016/j.vaccine.2011.09.128; Demento SL, 2012, BIOMATERIALS, V33, P4957, DOI 10.1016/j.biomaterials.2012.03.041; Durocher S, 2009, J AM CHEM SOC, V131, P2475, DOI 10.1021/ja808548x; Ebrahimi OV, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.700213; Elston DM, 2020, J AM ACAD DERMATOL, V82, P1085, DOI 10.1016/j.jaad.2020.03.012; Espeseth AS, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0163-z; European Medicines Agency, 2021, COVID 19 VACC ASTRAZ; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; Florindo HF, 2020, NAT NANOTECHNOL, V15, P630, DOI 10.1038/s41565-020-0732-3; Francois, 2016, US Patent, Patent No. [US9446547B2, 9446547]; Galaway FA, 2013, MOL PHARMACEUT, V10, P59, DOI 10.1021/mp3003368; Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Hanney SR, 2020, HEALTH RES POLICY SY, V18, DOI 10.1186/s12961-020-00571-3; Hill BD, 2018, CURR PROTEIN PEPT SC, V19, P112, DOI 10.2174/1389203718666161122113041; Hua J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113973; Huang C, 2020, ACS OMEGA, V5, P12550, DOI 10.1021/acsomega.0c01554; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang HY, 2020, ACS NANO, V14, P3747, DOI 10.1021/acsnano.0c02618; Jain NK, 2015, ADV DRUG DELIVER REV, V93, P42, DOI 10.1016/j.addr.2014.10.023; Jamieson T, 2007, BIOMATERIALS, V28, P4717, DOI 10.1016/j.biomaterials.2007.07.014; Jeong H, 2017, J MICROBIOL, V55, P220, DOI 10.1007/s12275-017-7058-3; JHA N, 2021, IMMUNO, V1, P30, DOI [10.3390/immuno1010004, DOI 10.3390/IMMUNO1010004]; Jia HY, 2009, J AM CHEM SOC, V131, P40, DOI 10.1021/ja808033w; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Joe CCD, 2020, VACCINE, V38, P3892, DOI 10.1016/j.vaccine.2020.03.007; Joe YH, 2014, J HAZARD MATER, V280, P356, DOI 10.1016/j.jhazmat.2014.08.013; Kato T, 2015, PHARM RES-DORDR, V32, P3699, DOI 10.1007/s11095-015-1730-2; Kerry RG, 2019, NANOMED-NANOTECHNOL, V18, P196, DOI 10.1016/j.nano.2019.03.004; Khamsi R, 2020, NATURE, V580, P578, DOI 10.1038/d41586-020-01063-8; Khan S, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00310; Kim MG, 2014, ASIAN J PHARM SCI, V9, P227, DOI 10.1016/j.ajps.2014.06.002; Kircher MF, 2003, CANCER RES, V63, P8122; Kirchner C, 2005, NANO LETT, V5, P331, DOI 10.1021/nl047996m; Kumar, 2014, INT J PHARM SCI REV, V24, P202; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Latham T, 2001, J VIROL, V75, P6154, DOI 10.1128/JVI.75.13.6154-6165.2001; Layqah LA, 2019, MICROCHIM ACTA, V186, DOI 10.1007/s00604-019-3345-5; Le DT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54928-y; Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951; Li Q, 2010, EUR J PHARM SCI, V41, P498, DOI 10.1016/j.ejps.2010.08.004; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Liu IL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092216; Liu J, 2012, ACS SYM SER, V1119, P129; Liu R, 2020, CLIN CHIM ACTA, V505, P172, DOI 10.1016/j.cca.2020.03.009; Liu YV, 2011, VACCINE, V29, P6606, DOI 10.1016/j.vaccine.2011.06.111; Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021; Liu Z, 2020, NANOTECHNOLOGY, V31, DOI 10.1088/1361-6528/ab776d; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lokugamage KG, 2008, VACCINE, V26, P797, DOI 10.1016/j.vaccine.2007.11.092; Lovato A, 2020, ENT-EAR NOSE THROAT, V99, P569, DOI 10.1177/0145561320920762; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Lung PS, 2020, NANOSCALE, V12, P5746, DOI 10.1039/c9nr08958f; Mainardes RM, 2020, THER DELIV, V11, P411, DOI 10.4155/tde-2020-0069; Makwana V, 2015, INT J PHARMACEUT, V495, P439, DOI 10.1016/j.ijpharm.2015.09.014; Malik JA, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111254; Mansuriya BD, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20041072; Matthew, 2014, European Patent, Patent No. [WO2014143039A1, 2014143039]; Mechael, 2016, European Patent, Patent No. [WO2016125173A1, 2016125173]; Medhi R, 2020, ACS APPL NANO MATER, V3, P8557, DOI 10.1021/acsanm.0c01978; Mejia-Salazar JR, 2018, CHEM REV, V118, P10617, DOI 10.1021/acs.chemrev.8b00359; Mohsen MO, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030037; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Moitra P, 2020, ACS NANO, V14, P7617, DOI 10.1021/acsnano.0c03822; Mokhtarzadeh A, 2017, TRAC-TREND ANAL CHEM, V97, P445, DOI 10.1016/j.trac.2017.10.005; Mukherjee S, 2009, INDIAN J PHARM SCI, V71, P349, DOI 10.4103/0250-474X.57282; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+; Neuwelt EA, 2004, NEUROPATH APPL NEURO, V30, P456, DOI 10.1111/j.1365-2990.2004.00557.x; Nikaeen G, 2020, NANOMEDICINE-UK, V15, P1501, DOI 10.2217/nnm-2020-0117; Nooraei S, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00806-7; Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010; Pang HH, 2019, THERANOSTICS, V9, P1752, DOI 10.7150/thno.30977; Park JE, 2016, CHEMNANOMAT, V2, P927, DOI 10.1002/cnma.201600165; Pelaz B, 2017, ACS NANO, V11, P2313, DOI 10.1021/acsnano.6b06040; Pomares TD, 2020, HUM VACC IMMUNOTHER, V16, P1018, DOI 10.1080/21645515.2019.1698243; Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755; Pushko P, 2013, INTERVIROLOGY, V56, P141, DOI 10.1159/000346773; Qian CY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010139; Qiu GG, 2020, ACS NANO, V14, P5268, DOI 10.1021/acsnano.0c02439; Ramdas K, 2020, NAT MED, V26, P810, DOI 10.1038/s41591-020-0891-7; Roh C, 2011, J CHEM TECHNOL BIOT, V86, P1475, DOI 10.1002/jctb.2721; Rupp R, 2007, INT J NANOMED, V2, P561; Sailaja G, 2007, VIROLOGY, V362, P331, DOI 10.1016/j.virol.2006.12.014; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sampat BN, 2021, HEALTH AFFAIR, V40, P400, DOI 10.1377/hlthaff.2020.02097; Sarkar Bishajit, 2019, [Korean Journal of Microbiology, 미생물학회지], V55, P327, DOI 10.7845/kjm.2019.9089; Seo G, 2020, ACS NANO, V14, P12257, DOI [10.1021/acsnano.0c02823, 10.1021/acsnano.0c06726]; Sharif R., 2018, BACTERIAL PATHOGENES, V51, DOI [10.5772/intechopen.72526, DOI 10.5772/INTECHOPEN.72526]; Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005; Sheridan C, 2020, NAT BIOTECHNOL, V38, P515, DOI 10.1038/d41587-020-00010-2; Shiri F, 2020, ANAL BIOANAL CHEM, V412, P1563, DOI 10.1007/s00216-019-02383-z; Silva AL, 2017, SEMIN IMMUNOL, V34, P3, DOI 10.1016/j.smim.2017.09.003; Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/s0168-3659(00)00339-4; Sportelli MC, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10040802; Stringer RC, 2008, SENSOR ACTUAT B-CHEM, V134, P427, DOI 10.1016/j.snb.2008.05.018; Struck MM, 1996, NAT BIOTECHNOL, V14, P591, DOI 10.1038/nbt0596-591; Talebian S, 2020, NAT NANOTECHNOL, V15, P618, DOI 10.1038/s41565-020-0751-0; Teengam P, 2017, ANAL CHEM, V89, P5428, DOI 10.1021/acs.analchem.7b00255; Thakur BK, 2019, S AFR J BOT, V124, P223, DOI 10.1016/j.sajb.2019.05.024; Thakur N, 2021, DALTON T, V50, P6188, DOI 10.1039/d0dt04405a; Le TS, 2015, ADV NAT SCI-NANOSCI, V6, DOI 10.1088/2043-6262/6/1/015016; Tyo KM, 2020, J CONTROL RELEASE, V321, P84, DOI 10.1016/j.jconrel.2020.02.006; USFDA, 2021, USFDA FACT SHEET REC; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; Varshosaz J, 2018, J DRUG DELIV SCI TEC, V48, P9, DOI 10.1016/j.jddst.2018.08.020; VBI VACCINES, 2020, VBI2901; Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277; Vijayan V, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11100534; Vyas TK, 2008, INT J PHARMACEUT, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; Wang J, 2020, ENVIRON POLLUT, V262, DOI 10.1016/j.envpol.2020.114665; Wang M, 2020, SMALL, V16, DOI 10.1002/smll.202002169; Wani TU, 2020, POLYM BULL, V77, P3865, DOI 10.1007/s00289-019-02924-7; Watanabe Yasunori, 2021, ACS Cent Sci, V7, P594, DOI 10.1021/acscentsci.1c00080; WHO, 2021, COVID 19 VAC VER CEL; WHO, 2021, WHO STAND Q COV 19 A; WHO, 2021, WHO DRAFT LANDSC COV; Widdowson, NEW MASK MAT CAN REM; Wismans A, 2021, PLOS ONE, V16, DOI [10.1371/journal.pone.0255382, 10.25397/eur.14356229.v1]; World Health Organization(WHO), 2021, STAT COVID 19 VACC W; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001; Xiang J., 2020, EVALUATION ENZYME LI, V02, P27, DOI [10.1101/2020.02.27.20028787, DOI 10.1101/2020.02.27.20028787]; Xiao QY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090967; Zeng QH, 2008, P NATL ACAD SCI USA, V105, P9065, DOI 10.1073/pnas.0800502105; Zhai LK, 2019, ANTIVIR RES, V166, P56, DOI 10.1016/j.antiviral.2019.03.012; Zhao ZX, 2020, MATH PROBL ENG, V2020, DOI 10.1155/2020/9864935; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zhu X, 2020, BIOSENS BIOELECTRON, V166, DOI 10.1016/j.bios.2020.112437; Zielinska A, 2020, MOLECULES, V25, DOI 10.3390/molecules25163731; Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6	165	0	0	16	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1129	10.3390/vaccines9101129			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN1FY	34696237	Green Published, gold			2022-04-29	WOS:000711522400001
J	Cadeddu, C; Sapienza, M; Castagna, C; Regazzi, L; Paladini, A; Ricciardi, W; Rosano, A				Cadeddu, Chiara; Sapienza, Martina; Castagna, Carolina; Regazzi, Luca; Paladini, Andrea; Ricciardi, Walter; Rosano, Aldo			Vaccine Hesitancy and Trust in the Scientific Community in Italy: Comparative Analysis from Two Recent Surveys	VACCINES			English	Article						vaccine hesitancy; European Social Survey; scientific community; trust; vaccination; public opinion	CONFIDENCE	Vaccination rates in Italy fell until 2015 because of unfounded safety concerns. Public education and a 2017 law on mandatory vaccination have boosted rates since then. The aim of our study is to explore how trust in the scientific community and attitudes towards vaccines have changed in the period of 2017-2019 in Italy. Data were extracted from the Italian section of the 2017 and 2019 editions of the European Social Survey (ESS). We compared the two surveys highlighting changes in public opinion on vaccines. A descriptive analysis of the socio-cultural variables according to the answers provided to key questions on the harmfulness of vaccines was conducted. Differences between percentages were tested by using the chi(2) test. The association between the opinion about the harmfulness of vaccines and trust in the scientific community was analyzed through a logistic regression model. Compared to ESS8, ESS9 showed an increase in the percentage of respondents disagreeing with the harmfulness of vaccines. Trust in the scientific community raised in the period from 2017 to 2019 (59% vs. 69.6%). Higher education was significantly associated with disagreement regarding the harmfulness of vaccines (odds ratio (OR) = 2.41; 95% confidence interval (95%CI) 1.75-3.31), the strongest predictor was trust in the scientific community (OR = 10.47; 95% CI 7.55-14.52). In Italy, trust in the scientific community and in vaccinations has grown significantly in recent years, indicating a paradigm shift in public opinion compared to the past. Central actions and effective public communication strategies might reduce vaccine hesitancy and could be essential to garner public trust.	[Cadeddu, Chiara; Sapienza, Martina; Castagna, Carolina; Regazzi, Luca; Paladini, Andrea; Ricciardi, Walter] Univ Cattolica Sacro Cuore, Dept Life Sci & Publ Hlth, Largo Francesco Vito 1, I-00168 Rome, Italy; [Rosano, Aldo] Natl Inst Publ Policies Anal INAPP, Unit Stat, Corso Italia 33, I-00198 Rome, Italy		Sapienza, M (通讯作者)，Univ Cattolica Sacro Cuore, Dept Life Sci & Publ Hlth, Largo Francesco Vito 1, I-00168 Rome, Italy.	chiara.cadeddu@unicatt.it; martina.sapienza93@gmail.com; carolina.castagna01@icatt.it; luca.regazzi01@icatt.it; andrea.paladiniO3@icatt.it; walter.ricciardi@unicatt.it; rosano244@gmail.com	Cadeddu, Chiara/K-3089-2018; rosano, Aldo/G-6525-2012	Cadeddu, Chiara/0000-0003-0149-1078; Regazzi, Luca/0000-0002-0189-7687; rosano, Aldo/0000-0002-5453-2294			Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; [Anonymous], COUNCIL RECOMMENDATI; [Anonymous], 2018, PORT I FAK NEWS QUOT; Baumgaertner B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191728; Cadeddu C, 2021, HUM VACC IMMUNOTHER, V17, P4470, DOI 10.1080/21645515.2021.1961466; Cadeddu C, 2020, VACCINE, V38, P6609, DOI 10.1016/j.vaccine.2020.07.076; Chiffi D., 2021, CLIN REASONING KNOWL, V58, DOI [10.1007/978-3-030-59094-9, DOI 10.1007/978-3-030-59094-9]; D'Ancona F, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.22.1800238; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; ECDC Communication on Immunisation-Building Trust, ECDC COMMUNICATION I; European Centre for Disease Prevention and Control, 2015, VACC HES HEALTHC WOR; Germinario Cinzia, 2014, Epidemiol Prev, V38, P120; Han Q., 2020, CULT SCI, V3, P223, DOI [10.1177/20966083211003343, DOI 10.1177/20966083211003343]; Kantar, 2019, EUR ATT VACC, DOI [10.2875/685461, DOI 10.2875/685461]; Kaufman J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010038.pub2; Kieslich K, 2018, EUR J PUBLIC HEALTH, V28, P30, DOI 10.1093/eurpub/cky155; Kuru O, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248328; Lalumera E, 2018, RIV ESTET, P105, DOI 10.4000/estetica.3553; Ministero della Salute, FACC SQUADR NOSTR SA; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Sabbatucci M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122540; Sangalang A, 2019, J COMMUN, V69, P298, DOI 10.1093/joc/jqz014; Siani A, 2019, PREV MED, V121, P99, DOI 10.1016/j.ypmed.2019.02.011; Sturgis P, 2021, NAT HUM BEHAV, V5, P1528, DOI 10.1038/s41562-021-01115-7; VaccinarSi, INF VACC; WHO, HIGHL EUR IMM WEEK 2; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	28	2	2	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1206	10.3390/vaccines9101206			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI9KF	34696314	gold, Green Published			2022-04-29	WOS:000726420100001
J	Kosarkova, A; Malinakova, K; van Dijk, JP; Tavel, P				Kosarkova, Alice; Malinakova, Klara; van Dijk, Jitse P.; Tavel, Peter			Vaccine Refusal in the Czech Republic Is Associated with Being Spiritual but Not Religiously Affiliated	VACCINES			English	Article						religious conspiracy beliefs; COVID-19 vaccine; vaccination; spirituality; religiosity	CONSPIRACY THEORIES; BELIEF; FUNDAMENTALISM; RELIGIOSITY; HESITANCY	A strong reduction in the deleterious effects of the COVID-19 pandemic can be achieved by vaccination. Religiosity and spirituality (R/S) may play an important role in vaccine acceptance. However, evidence is lacking for the associations with religious conspiracy theories (RCT) in a non-religious environment. This study investigated the associations between R/S and RCT about COVID-19 vaccination and the links of R/S with vaccine refusal and hesitancy. A sample of Czech adults (n = 459) participated in the survey. We measured R/S, RCT, religious fundamentalism, and COVID-19 vaccination intentions. We found spirituality to be significantly associated with RCT belief, with odds ratios (OR) of 2.12 (95% confidence interval [CI] 1.42-3.19). A combination of R/S groups revealed that spirituality with non-religious affiliation was associated with higher beliefs in RCT, with ORs from 3.51 to 7.17. Moreover, associations were found between spirituality with non-religious affiliation [OR 2.22(1.33-7.76)] with vaccine refusal. Our findings showed associations of spirituality and religious fundamentalism with RCT about COVID-19 vaccination. Furthermore, spirituality was linked to a higher possibility of vaccine refusal. Understanding these associations may help prevent the development of RCT and negative impact of spirituality on vaccine intentions and contribute to the effectiveness of the vaccination process.	[Kosarkova, Alice; Malinakova, Klara; van Dijk, Jitse P.; Tavel, Peter] Palacky Univ Olomouc, Olomouc Univ Social Hlth Inst, Olomouc 77111, Czech Republic; [Kosarkova, Alice; van Dijk, Jitse P.] Univ Groningen, Univ Med Ctr Groningen, Dept Community & Occupat Med, NL-9713 GZ Groningen, Netherlands; [van Dijk, Jitse P.] PJ Safarik Univ Kosice, Grad Sch Kosice, Inst Soc & Hlth, Kosice 04011, Slovakia		Kosarkova, A (通讯作者)，Palacky Univ Olomouc, Olomouc Univ Social Hlth Inst, Olomouc 77111, Czech Republic.; Kosarkova, A (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Community & Occupat Med, NL-9713 GZ Groningen, Netherlands.	alice.kosarkova@oushi.upol.cz; klara.malinakova@oushi.upol.cz; j.p.van.dijk@umcg.nl; peter.tavel@oushi.upol.cz		van Dijk, Jitse P/0000-0003-0225-6811; Malinakova, Klara/0000-0001-6939-1204; Kosarkova, Alice/0000-0001-6422-9021	Grant Agency of the Czech RepublicGrant Agency of the Czech Republic [19-19526S]; Sts Cyril and Methodius Faculty of Theology of Palacky University Olomouc [IGA-CMTF-2021-005]	This study was supported by the Grant Agency of the Czech Republic, project: Biological and psychological aspects of spiritual experience and their associations with health (Contract No. 19-19526S), and by the Sts Cyril and Methodius Faculty of Theology of Palacky University Olomouc, internal project: Spiritual and social determinants of health with a focus on the COVID-19 pandemic situation (Grant number IGA-CMTF-2021-005).	Abaido G.M., 2020, AM J BIOMEDICAL SCI, V8, P122, DOI [10.34297/AJBSR.2020.08.001252, DOI 10.34297/AJBSR.2020.08.001252]; Allington D, 2021, PSYCHOL MED, V51, P1763, DOI [10.1017/S0033291721000593, 10.1017/S003329172000224X]; Altemeyer B., 2004, INT J PSYCHOL RELIG, V14, P47, DOI DOI 10.1207/S15327582IJPR1401_4; [Anonymous], 2019, LINACRE Q, V86, P182, DOI 10.1177/0024363919855896; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Beller J, 2017, PEACE CONFL, V23, P179, DOI 10.1037/pac0000250; Bertin P, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.565128; Best AL, 2019, J RELIG HEALTH, V58, P2196, DOI 10.1007/s10943-019-00890-y; Bezalel GY, 2021, EPISTEME-J INDIV SOC, V18, P674, DOI 10.1017/epi.2019.46; Browne M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132562; Buchtova M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249372; Cichocka A, 2016, EUR REV SOC PSYCHOL, V27, P283, DOI 10.1080/10463283.2016.1252530; Costa JC, 2020, VACCINE, V38, P1160, DOI 10.1016/j.vaccine.2019.11.024; Douglas KM, 2016, THINK REASONING, V22, P57, DOI 10.1080/13546783.2015.1051586; Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041; Furstova J, 2021, INT J PSYCHOL RELIG, V31, P288, DOI 10.1080/10508619.2020.1844967; Grabenstein JD, 2013, VACCINE, V31, P2011, DOI 10.1016/j.vaccine.2013.02.026; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Hogan CA, 2020, JAMA-J AM MED ASSOC, V323, P1967, DOI 10.1001/jama.2020.5445; Howard RG, 2006, J MEDIA RELIG, V5, P25, DOI 10.1207/s15328415jmr0501_2; Hunsberger B.E., 1992, INT J PSYCHOL RELIG, V2, DOI [10.1207/s15327582ijpr0202_5, DOI 10.1207/S15327582IJPR0202_5]; Imhoff R, 2018, EUR J SOC PSYCHOL, V48, P909, DOI 10.1002/ejsp.2494; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Kim S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18010266; Koenig Harold G, 2012, ISRN Psychiatry, V2012, P278730, DOI 10.5402/2012/278730; Kosarkova A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041268; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Larson H, 2014, B WORLD HEALTH ORGAN, V92, P84, DOI 10.2471/BLT.14.030214; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Liht J, 2011, ARCH PSYCHOL RELIG, V33, P299, DOI 10.1163/157361211X594159; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lisowski B, 2019, BIOSYSTEMS, V177, P16, DOI 10.1016/j.biosystems.2019.01.003; Malinakova K, 2018, CESK PSYCHOL, V62, P100; Malinakova K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198314; Marchlewska M, 2019, J SOC PSYCHOL, V159, P766, DOI 10.1080/00224545.2019.1586637; McDuffie DC, 2021, J PUBLIC HEALTH-HEID, V29, P1365, DOI 10.1007/s10389-020-01254-7; Ministry of Health of the Czech Republic, 2021, AKT KOR COVID 19 EP; Nagata J, 2001, AM ANTHROPOL, V103, P481, DOI 10.1525/aa.2001.103.2.481; Pargament K, 2011, RELIGIONS, V2, P51, DOI 10.3390/rel2010051; Pargament KI, 2002, PSYCHOL INQ, V13, P168, DOI 10.1207/S15327965PLI1303_02; Pelcic G, 2016, CROAT MED J, V57, P516, DOI 10.3325/cmj.2016.57.516; Roberts DH, 2018, HANDBOOK OF INTERNATIONAL FOOD AND AGRICULTURAL POLICIES, VOL 2: POLICIES FOR FOOD SAFETY AND QUALITY, IMPROVED NUTRITION, AND FOOD SECURITY, P1; Ruijs WLM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-408; Rumetta J, 2020, J INFECT PUBLIC HEAL, V13, P199, DOI 10.1016/j.jiph.2019.07.027; Saad-Roy CM, 2020, SCIENCE, V370, P811, DOI 10.1126/science.abd7343; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sallam M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144915; Savage S., 2008, ARCH PSYCHOL RELIG, V30, P75, DOI [10.1163/157361208X316971, DOI 10.1163/157361208X316971]; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shelton RC, 2013, J RELIG HEALTH, V52, P1120, DOI 10.1007/s10943-011-9553-x; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; Soral, 2015, PSYCHOL CONSPIRACY, P183; Sturm T, 2021, ANTHROPOL MED, V28, P122, DOI 10.1080/13648470.2020.1833684; Thomas T, 2015, ADV NURS SCI, V38, pE1, DOI 10.1097/ANS.0000000000000094; Underwood LynnG., 2006, ARCH PSYCHOL RELIG, V28, P181, DOI [DOI 10.1163/008467206777832562, 10.1163/008467206777832562]; van Prooijen JW, 2018, EUR J SOC PSYCHOL, V48, P897, DOI 10.1002/ejsp.2530; Vatican COVID-19 Commission in collaboration with the Pontifical Academy for Life, 2020, VACC 20 POINTS FAIR; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Whitehead AndrewL., 2020, SOCIUS, V6, P1, DOI [10.1177/2378023120977727, DOI 10.1177/2378023120977727]; Wood MJ, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00836; World Health Organization, COVID 19 WEEKL EP UP; Yin FL, 2021, J MED INTERNET RES, V23, DOI 10.2196/26089; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zinnbauer BJ, 1997, J SCI STUD RELIG, V36, P549, DOI 10.2307/1387689	65	4	4	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1157	10.3390/vaccines9101157			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WO7SD	34696265	gold, Green Published			2022-04-29	WOS:000712648600001
J	Kotey, EN; Ampofo, WK; Daines, R; Sadeyen, JR; Iqbal, M; Quaye, O				Kotey, Erasmus Nikoi; Ampofo, William Kwabena; Daines, Rebecca; Sadeyen, Jean-Remy; Iqbal, Munir; Quaye, Osbourne			Immune Response in Mice Immunized with Chimeric H1 Antigens	VACCINES			English	Article						universal influenza vaccine; broad-reactive antibodies; chimeric haemagglutinin; cross-reactivity; seasonal influenza; therapeutic; prophylactic	INFLUENZA VACCINE; SECRETION; PROTEIN; SOLUBILITY; MORTALITY; CHAPERONE; ALIGNMENT; DATABASE; VIRUSES; DESIGN	Identification of a universal influenza vaccine candidate has remained a global challenge for both humans and animals. This study describes an approach that uses consensus sequence building to generate chimeric HAs (cHAs): two resultant H1 HA-based chimeras comprising of conserved sequences (within several areas spanning the head and stalk regions) of H1 and H5 or H9 HAs. These cHAs expressed in Drosophila cells (S2) were used to immunize mice. All immunized mice were protected from an infectious H1 virus challenge. Seroconverted mice sera to the H1 cHAs inhibited both the challenge virus and an H5 virus isolate by haemagglutination inhibition (HI) assay. These findings further emphasize that cHAs induce cross-reactive antibodies against conserved areas of both head and stalk regions of the seasonal influenza A (H1N1) pdm09 virus' HA and holds potential for further development of a universal influenza vaccine.</p>	[Kotey, Erasmus Nikoi; Quaye, Osbourne] Univ Ghana, West African Ctr Cell Biol Infect Pathogens WACCB, Legon 23321, Accra, Ghana; [Kotey, Erasmus Nikoi; Quaye, Osbourne] Univ Ghana, Dept Biochem Cell & Mol Biol, Legon 23321, Accra, Ghana; [Kotey, Erasmus Nikoi; Ampofo, William Kwabena] Univ Ghana, Noguchi Mem Inst Med Res, Legon 23321, Accra, Ghana; [Daines, Rebecca; Sadeyen, Jean-Remy; Iqbal, Munir] Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England; [Daines, Rebecca] Royal Vet Coll, Dept Pathobiol & Populat Sci, Hawkshead Lane, Hatfield AL9 7TA, Herts, England		Quaye, O (通讯作者)，Univ Ghana, West African Ctr Cell Biol Infect Pathogens WACCB, Legon 23321, Accra, Ghana.; Quaye, O (通讯作者)，Univ Ghana, Dept Biochem Cell & Mol Biol, Legon 23321, Accra, Ghana.	rebecca.daines@pirbright.ac.uk; munir.iqbal@pirbright.ac.uk		Iqbal, Munir/0000-0001-5165-5339; Quaye, Osbourne/0000-0002-0621-876X	WACCBIP-World Bank ACE PhD fellowship [ACE02-WACCBIP]; William Kwabena Ampofo through the United States Naval Medical Research Unit 3 via the Globe Project at the National Influenza Centre; Virology Department of Noguchi Memorial Institute for Medical Research; University of Ghana; Pirbright InstituteUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC); British Council (Newton-Mosharafa Fund) [261,727,271]; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/L018853/1, BB/S013792/1, BB/N002571/1, BBS/E/I/00007030, BBS/E/I/00007031, BBS/E/I/00007035]	Erasmus Nikoi Kotey was supported by a WACCBIP-World Bank ACE PhD fellowship grant (ACE02-WACCBIP: Awandare). Erasmus Nikoi Kotey was also supported by William Kwabena Ampofo through the United States Naval Medical Research Unit 3 via the Globe Project at the National Influenza Centre, Virology Department of Noguchi Memorial Institute for Medical Research, University of Ghana, Legon. Munir Iqbal was supported by the Pirbright Institute and the British Council (Newton-Mosharafa Fund) Institutional link grant number 261,727,271 and BBSRC grants numbers BB/L018853/1, BB/S013792/1, BB/N002571/1, BBS/E/I/00007030, BBS/E/I/00007031, BBS/E/I/00007035. The views expressed in this publication are solely those of the authors and not necessarily those of the funders.	Ailor E, 1998, BIOTECHNOL BIOENG, V58, P196, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<196::AID-BIT12>3.3.CO;2-0; Ailor E, 1999, CURR OPIN BIOTECH, V10, P142, DOI 10.1016/S0958-1669(99)80024-X; Alan H, 2017, VACCINE, V35, P1104, DOI 10.1016/j.vaccine.2017.01.018; Allen JD, 2019, J VIROL, V93, DOI 10.1128/JVI.00946-18; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Armenteros JJA, 2019, NAT BIOTECHNOL, V37, P420, DOI 10.1038/s41587-019-0036-z; Bernstein DI, 2020, LANCET INFECT DIS, V20, P80, DOI 10.1016/S1473-3099(19)30393-7; Broecker F, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0126-4; Budd A., 2017, MANUAL SURVEILLANCE; Carter DM, 2016, J VIROL, V90, P4720, DOI 10.1128/JVI.03152-15; Chan MCW, 2018, EMERG INFECT DIS, V24, P1825, DOI 10.3201/eid2410.180652; Cock PJA, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0080-7; Crevar CJ, 2015, HUM VACC IMMUNOTHER, V11, P572, DOI 10.1080/21645515.2015.1012013; Dawood FS, 2012, LANCET INFECT DIS, V12, P687, DOI 10.1016/S1473-3099(12)70121-4; DeLano W.L., 2002, CCP4 NEWSL PROTEIN C, V40, P82; Dhanda SK, 2019, NUCLEIC ACIDS RES, V47, pW502, DOI 10.1093/nar/gkz452; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Gautam A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01160; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95; Han MV, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-356; Hsu TA, 1997, BIOTECHNOL PROGR, V13, P96, DOI 10.1021/bp960088d; Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jegaskanda S, 2014, J IMMUNOL, V193, P469, DOI 10.4049/jimmunol.1400432; Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Kotey E, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020053; Krammer F, 2019, J INFECT DIS, V219, pS62, DOI 10.1093/infdis/jiy711; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529; Marchi J, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8030115; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nachbagauer R, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0026-4; Nachbagauer R, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.15; Paules CI, 2017, IMMUNITY, V47, P599, DOI 10.1016/j.immuni.2017.09.007; Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118; Schrodinger L.L.C., PYMOL MOL GRAPHICS S; Shu B, 2011, J CLIN MICROBIOL, V49, P2614, DOI 10.1128/JCM.02636-10; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; Valkenburg SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01479; Whiteley EM, 1997, BIOTECHNOL BIOENG, V56, P106, DOI 10.1002/(SICI)1097-0290(19971005)56:1<106::AID-BIT12>3.0.CO;2-I; Wu NC, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a038778; Zhang Y, 2017, NUCLEIC ACIDS RES, V45, pD466, DOI 10.1093/nar/gkw857; Zheng W, 2019, FUTURE GENER COMP SY, V99, P73, DOI 10.1016/j.future.2019.04.011	46	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1182	10.3390/vaccines9101182			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS8DC	34696290	gold, Green Published			2022-04-29	WOS:000715406700001
J	Nguyen, V; Hilsky, Y; Mould-Quevedo, J				Nguyen, Van Hung; Hilsky, Yvonne; Mould-Quevedo, Joaquin			The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach	VACCINES			English	Article						influenza 2; cost-effectiveness 3; quadrivalent influenza vaccine 4; cell-based influenza vaccine 5; United States	SEASONAL INFLUENZA; COST-EFFECTIVENESS; HEALTH; PROGRAM	Mutations of the H3N2 vaccine strain during the egg-based vaccine manufacturing process partly explain the suboptimal effectiveness of traditional seasonal influenza vaccines. Cell-based influenza vaccines improve antigenic match and vaccine effectiveness by avoiding such egg-adaptation. This study evaluated the public health and economic impact of a cell-based quadrivalent influenza vaccine (QIVc) in adults (18-64 years) compared to the standard egg-based quadrivalent influenza vaccine (QIVe) in the US. The impact of QIVc over QIVe in public health and cost outcomes was estimated using a dynamic age-structured SEIR transmission model, which accounted for four circulating influenza strains [A/H1N1pdm9, A/H3N2, B(Victoria), and B(Yamagata)] and was calibrated on the 2013-2018 influenza seasons. The robustness of the results was assessed in univariate and probabilistic sensitivity analyses. Switching from QIVe to QIVc in 18- to 64-year-olds may prevent 5.7 million symptomatic cases, 1.8 million outpatient visits, 50,000 hospitalizations, and 5453 deaths annually. The switch could save 128,000 Quality-Adjusted Life Years (QALYs) and US $ 845 M in direct costs, resulting in cost-savings in a three-year time horizon analysis. Probabilistic sensitivity analyses confirmed the robustness of the cost-saving result. The analysis shows that QIVc is expected to prevent hospitalizations and deaths, and result in substantial savings in healthcare costs.</p>	[Nguyen, Van Hung] VHN Consulting Inc, 95 McCulloch, Montreal, PQ H2V 3L8, Canada; [Hilsky, Yvonne; Mould-Quevedo, Joaquin] Seqirus USA Inc, 25 Deforest Ave, Summit, NJ 07901 USA		Mould-Quevedo, J (通讯作者)，Seqirus USA Inc, 25 Deforest Ave, Summit, NJ 07901 USA.	vhnguyen@vhnconsulting.com; yvonne.hilsky@seqirus.com; Joaquin.Mould-Quevedo@seqirus.com			Seqirus USA Inc.	This research was funded by Seqirus USA Inc.	[Anonymous], 2016, GUID EC EV INFL VACC, DOI WHO/IVB/16.05 2016; Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527; Baguelin M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0452-y; Baguelin M, 2012, VACCINE, V30, P3459, DOI 10.1016/j.vaccine.2012.03.019; Belongia EA, 2019, CLIN INFECT DIS, V69, P1817, DOI 10.1093/cid/ciz411; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Boikos C, 2020, CLIN INFECT DIS, V71, pE665, DOI 10.1093/cid/ciaa371; Bruxvoort KJ, 2019, VACCINE, V37, P5807, DOI 10.1016/j.vaccine.2019.08.024; Cai R, 2021, J MED ECON, V24, P490, DOI 10.1080/13696998.2021.1908000; Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375; Centers for Disease Control and Prevention, ESTIMATED INFLUENZA; Centers for Disease Control and Prevention, ARCH CDC VACC PRIC L; Centers for Disease Control and Prevention, FLU VACCINATION COVE; Centers for Disease Control and Prevention, WEEKL US INFL SURV R; Crepey P, 2015, INFLUENZA OTHER RESP, V9, P39, DOI 10.1111/irv.12318; de Boer PT, 2017, EXPERT REV PHARM OUT, V17, P249, DOI 10.1080/14737167.2017.1343145; de Boer PT, 2016, VALUE HEALTH, V19, P964, DOI 10.1016/j.jval.2016.05.012; DeMarcus L, 2019, VACCINE, V37, P4015, DOI 10.1016/j.vaccine.2019.06.004; Esposito S, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-349; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Fleming DM, 2008, PEDIATR INFECT DIS J, V27, pS154, DOI 10.1097/INF.0b013e31818a5443; Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1; Grosse Scott D, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P165, DOI 10.1586/14737167.8.2.165; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; Nguyen V., 2019, OPTIONS CONTROL INFL, V16, P2238; Ortega-Sanchez IR, 2012, VACCINE, V30, P4175, DOI 10.1016/j.vaccine.2012.04.057; Rajaram S., 2018, OPEN FORUM INFECT DI, V5, pX69, DOI [10.1093/ofid/ofy209.164, DOI 10.1093/OFID/OFY209.164]; Rizzo CTF, 2019, ITAL J PUBLIC HLTH, V8, P5; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Ruf BR, 2014, EUR J PEDIATR, V173, P265, DOI 10.1007/s00431-013-2023-6; Thommes EW, 2014, VACCINE, V32, P5098, DOI 10.1016/j.vaccine.2014.06.005; Viboud C, 2004, INT CONGR SER, V1263, P291, DOI 10.1016/j.ics.2004.01.013; World Health Organization, FLUNET GLOB INFL SUR; Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682; Zagheni E, 2008, AM J EPIDEMIOL, V168, P1082, DOI 10.1093/aje/kwn220; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	39	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1095	10.3390/vaccines9101095			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO2NB	34696203	Green Published, gold			2022-04-29	WOS:000712295300001
J	Shiri, T; Evans, M; Talarico, CA; Morgan, AR; Mussad, M; Buck, PO; McEwan, P; Strain, WD				Shiri, Tinevimbo; Evans, Marc; Talarico, Carla A.; Morgan, Angharad R.; Mussad, Maaz; Buck, Philip O.; McEwan, Phil; Strain, William David			Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example	VACCINES			English	Article						adolescent; coronavirus; disease transmission model; COVID-19; SARS-CoV-2; vaccination		Debate persists around the risk-benefit balance of vaccinating adolescents and children against COVID-19. Central to this debate is quantifying the contribution of adolescents and children to the transmission of SARS-CoV-2, and the potential impact of vaccinating these age groups. In this study, we present a novel SEIR mathematical disease transmission model that quantifies the impact of different vaccination strategies on population-level SARS-CoV-2 infections and clinical outcomes. The model employs both age- and time-dependent social mixing patterns to capture the impact of changes in restrictions. The model was used to assess the impact of vaccinating adolescents and children on the natural history of the COVID-19 pandemic across all age groups, using the UK as an example. The base case model demonstrates significant increases in COVID-19 disease burden in the UK following a relaxation of restrictions, if vaccines are limited to those >= 18 years and vulnerable adolescents (>= 12 years). Including adolescents and children in the vaccination program could reduce overall COVID-related mortality by 57%, and reduce cases of long COVID by 75%. This study demonstrates that vaccinating adolescents and children has the potential to play a vital role in reducing SARS-CoV-2 infections, and subsequent COVID-19 morbidity and mortality, across all ages. Our results have major global public health implications and provide valuable information to inform a potential pandemic exit strategy.	[Shiri, Tinevimbo; Morgan, Angharad R.; McEwan, Phil] Hlth Econ & Outcomes Res Ltd, Cardiff CF23 8RB, Wales; [Evans, Marc] Univ Hosp Llandough, Diabet Resource Ctr, Cardiff CF64 2XX, Wales; [Talarico, Carla A.; Buck, Philip O.] Moderna Inc, Cambridge, MA 02139 USA; [Mussad, Maaz] Ashfield Healthcare Behalf Moderna, Ashby De La Zouch LE65 1HW, England; [Strain, William David] Univ Exeter, Diabet & Vasc Res Ctr, Sch Med, Exeter EX1 2HZ, Devon, England; [Strain, William David] Royal Devon & Exeter Hosp, Acad Dept Healthcare Older Adults, Exeter EX2 5DW, Devon, England		Strain, WD (通讯作者)，Univ Exeter, Diabet & Vasc Res Ctr, Sch Med, Exeter EX1 2HZ, Devon, England.; Strain, WD (通讯作者)，Royal Devon & Exeter Hosp, Acad Dept Healthcare Older Adults, Exeter EX2 5DW, Devon, England.	tinevimbo.shiri@heor.co.uk; marclyndon1@hotmail.com; Maaz.Mussad@modernatx.com; phil.mcewan@heor.co.uk; d.strain@exeter.ac.uk		Strain, William/0000-0002-6826-418X	Moderna, Inc.	Funding for this study was provided by Moderna, Inc. who provided support for model development, data analysis and medical writing for this study.	Ali K, 2021, NEW ENGL J MED, V385, P2241, DOI 10.1056/NEJMoa2109522; Ashikkali Loucia, 2020, Paediatr Child Health (Oxford), V30, P430, DOI 10.1016/j.paed.2020.09.004; Brackel CLH, 2021, PEDIATR PULM, V56, P2495, DOI 10.1002/ppul.25521; Buonsenso Danilo, 2021, Acta Paediatr, V110, P2208, DOI 10.1111/apa.15870; ClinicalTrials.Gov, 2021, STUD EV SAF EFF MRNA; ClinicalTrials.gov, 2021, STUD EV SAF TOL IMM; Daley DJ, 2001, EPIDEMIC MODELLING I; Dietz K, 2002, MATH BIOSCI, V180, P1, DOI 10.1016/S0025-5564(02)00122-0; European Medicines Agency, 1 COVID 19 VACC APPR; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2; Gurdasani D, 2021, LANCET, V398, P297, DOI 10.1016/S0140-6736(21)01589-0; Havers FP, 2021, MMWR-MORBID MORTAL W, V70, P851, DOI 10.15585/mmwr.mm7023e1; Kaushik A, 2020, PEDIATR INFECT DIS J, V39, pE340, DOI 10.1097/INF.0000000000002888; KERMACK WO, 1991, B MATH BIOL, V53, P57, DOI 10.1007/BF02464424; Ludvigsson JF, 2021, ACTA PAEDIATR, V110, P914, DOI 10.1111/apa.15673; Mahase E, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1710; Medicines and Healthcare Products Regulatory Agency, 2021, MHRA CONCL POS SAF P; Milman O, 2021, NAT MED, V27, P1367, DOI 10.1038/s41591-021-01407-5; Milne G., 2021, RELIANCE VACCINE ONL; Moderna, 2021, EMA COMM MED PROD HU; Odd D, 2022, ARCH DIS CHILD, V107, P14, DOI 10.1136/archdischild-2020-320899; Office for National Statistics, 2021, PREV ONG SYMPT FOLL; U.S. Food and Drug Administration, COR COVID 19 UPD FDA; Wise J, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1635; World Health Organisation, WHO COR DIS COVID 19; World Health Organization, 2021, POL BRIEF 39 WAK PAN	28	6	6	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1180	10.3390/vaccines9101180			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR9EP	34696288	Green Published, gold			2022-04-29	WOS:000714796300001
J	Hosseiniporgham, S; Biet, F; Ganneau, C; Bannantine, JP; Bay, S; Sechi, LA				Hosseiniporgham, Sepideh; Biet, Franck; Ganneau, Christelle; Bannantine, John P.; Bay, Sylvie; Sechi, Leonardo A.			A Comparative Study on the Efficiency of Two Mycobacterium avium subsp. paratuberculosis (MAP)-Derived Lipopeptides of L3P and L5P as Capture Antigens in an In-House Milk ELISA Test	VACCINES			English	Article						Mycobacterium paratuberculosis; antibodies; ELISA; L3P; L5P; sheep; milk; bovine	LINKED IMMUNOSORBENT ASSAYS; RISK-FACTORS; DAIRY-HERD; DIAGNOSIS; POLYMORPHISMS; CULTURE; GOATS; INFECTION; INSERTION; ACCURACY	Mycobacterium avium subsp. paratuberculosis (MAP) surface-exposed lipopeptides could be specific capture-antigen molecules targeting antibodies against MAP, in milk, through ELISA. Previous studies have revealed that MAP strains, isolated from sheep (S) or cow (C), could produce specific lipopeptides, L3P or L5P, respectively. In this study, we used L3P and L5P as capture antigens in an in-house milk ELISA (H-MELISA) to assess how these antigens perform, in comparison with other ELISA tests, on well-defined milk samples from MAP-infected sheep. The overall positivity rates of H-MELISA via L3P and L5P varied by the source of milk samples, in which, at bulk-tank-milk (BTM) level, the majority of positive cases (63.83%) reacted more against L5P, whereas a predominant number (69.14%) of milk samples were more responsive against L3P at the individual level. To clarify whether the positivity status of milk samples in H-MELISA L3P/L5P were predictive of MAP strain-types (S/C), strain-typing was carried out using PCR IS1311-restriction enzyme analysis. Although the presence of three MAP strains (S/C/bison types) was detected among the milk samples, the C-type (46.67%) and S-type (75%) MAP strains were detected with higher incidence among BTMs and individual milk samples, respectively. However, further examination on the H-MELISA L3P/L5P-positivity pattern of each C/S-type-MAP sample revealed that some samples had a reverse reactivity against both L3P and L5P. These results could be the consequence of either cross-reactivity between L3P and L5P (due to the similarity in the structures of the two epitopes) or simply a within-herd mixed infection with MAP strains of C and S types. These findings suggest that lipopeptide antigens could contribute a diagnostic test with optimal performance, considering the diversity of MAP strains.	[Hosseiniporgham, Sepideh; Sechi, Leonardo A.] Univ Sassari, Dipartimento Sci Biomed, I-07100 Sassari, Italy; [Biet, Franck] INRAE Ctr Val Loire, UMR1282, Infectiol & Sante Publ ISP311, F-37380 Nouzilly, France; [Ganneau, Christelle; Bay, Sylvie] Inst Pasteur, Dept Biol Struct & Chim, Unite Chim Biomol, F-75015 Paris, France; [Ganneau, Christelle; Bay, Sylvie] CNRS, UMR 3523, F-75015 Paris, France; [Bannantine, John P.] USDA Agr Res Serv, Natl Anim Dis Ctr, Ames, IA 50010 USA; [Sechi, Leonardo A.] Azienda Osped Univ, SC Microbiol & Virol, I-07100 Sassari, Italy; [Sechi, Leonardo A.] Mediterraneam Ctr Dis Control, I-07100 Sassari, Italy		Sechi, LA (通讯作者)，Univ Sassari, Dipartimento Sci Biomed, I-07100 Sassari, Italy.; Sechi, LA (通讯作者)，Azienda Osped Univ, SC Microbiol & Virol, I-07100 Sassari, Italy.; Sechi, LA (通讯作者)，Mediterraneam Ctr Dis Control, I-07100 Sassari, Italy.	s.hosseiniporgham@studenti.uniss.it; franck.biet@inrae.fr; christelle.ganneau@pasteur.fr; john.bannantine@usda.gov; sylvie.bay@pasteur.fr; sechila@uniss.it	Hosseiniporgham, Sepideh/ABE-5406-2021; Biet, Franck/ABA-4151-2021	Hosseiniporgham, Sepideh/0000-0001-6410-5272; Biet, Franck/0000-0001-8425-6158; sechi, leonardo antonio/0000-0003-0566-2049; Bannantine, John/0000-0002-5692-7898	PON2017 [DOT13299071, CUP: j85D17000190001]; UNISS fondo per la ricerca 2020	This research was funded by PON2017, grant code: DOT13299071 and CUP: j85D17000190001, and UNISS fondo per la ricerca 2020 to L.A.S.	Alexander DC, 2009, J BACTERIOL, V191, P1018, DOI 10.1128/JB.01340-08; Angelidou E, 2014, J DAIRY SCI, V97, P819, DOI 10.3168/jds.2013-7218; Ayele WY, 2005, APPL ENVIRON MICROB, V71, P1210, DOI 10.1128/AEM.71.3.1210-1214.2005; Bannantine JP, 2008, INFECT IMMUN, V76, P739, DOI 10.1128/IAI.00915-07; Bannantine JP, 2017, MOL MICROBIOL, V105, P525, DOI 10.1111/mmi.13717; Bay S, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.637841; Biet F, 2008, VACCINE, V26, P257, DOI 10.1016/j.vaccine.2007.10.059; Biet F, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-264; Bradner L, 2013, J CLIN MICROBIOL, V51, P1575, DOI 10.1128/JCM.00333-13; Bryant JM, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-015-2234-5; Caldow G., 2002, ASSESSMENT SURVEILLA, P1; Castellanos E, 2007, J CLIN MICROBIOL, V45, P3439, DOI 10.1128/JCM.01411-07; Castellanos E., 2007, P 9 INT C PAR TSUK J, P6; Chaitanya R. K., 2015, Advances in Animal and Veterinary Sciences, V3, P289, DOI 10.14737/journal.aavs/2015/3.5.289.294; COLLINS DM, 1990, J CLIN MICROBIOL, V28, P1591, DOI 10.1128/JCM.28.7.1591-1596.1990; Collins MT, 2005, CLIN DIAGN LAB IMMUN, V12, P685, DOI 10.1128/CDLI.12.6.685-692.2005; Conde C, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.660002; Costanzo G, 2012, VET MICROBIOL, V156, P183, DOI 10.1016/j.vetmic.2011.10.029; Cox K. L., 2004, ASSAY GUIDANCE MANUA; de Juan L, 2005, VET MICROBIOL, V106, P249, DOI 10.1016/j.vetmic.2004.12.013; Dore E, 2012, J VET INTERN MED, V26, P32, DOI 10.1111/j.1939-1676.2011.00854.x; Ellingson JLE, 2005, J FOOD PROTECT, V68, P966, DOI 10.4315/0362-028X-68.5.966; de Albuquerque PPF, 2017, BRAZ J MICROBIOL, V48, P113, DOI 10.1016/j.bjm.2016.10.010; Fry MP, 2008, J VET DIAGN INVEST, V20, P329, DOI 10.1177/104063870802000311; Gamberale F, 2019, MICROBIOLOGYOPEN, V8, DOI 10.1002/mbo3.875; Gao A, 2007, J MICROBIOL METH, V69, P417, DOI 10.1016/j.mimet.2006.10.019; Garcia AB, 2015, J DAIRY SCI, V98, P5019, DOI 10.3168/jds.2014-9241; Gardner IA, 2011, PREV VET MED, V101, P18, DOI 10.1016/j.prevetmed.2011.04.002; Hosseiniporgham S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8091264; Lavers CJ, 2014, J DAIRY SCI, V97, P299, DOI 10.3168/jds.2013-7101; Lombard JE, 2006, J VET DIAGN INVEST, V18, P448, DOI 10.1177/104063870601800504; Mameli G, 2016, SCI REP-UK, V6, DOI 10.1038/srep29268; Masala S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097621; McKenna SLB, 2006, CAN VET J, V47, P1089; Nielsen SS, 2008, VET MICROBIOL, V129, P217, DOI 10.1016/j.vetmic.2007.12.011; Okuni JB, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-99; Sechi LA, 2005, AM J GASTROENTEROL, V100, P1529, DOI 10.1111/j.1572-0241.2005.41415.x; Sechi LA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00096; Sevilla I, 2005, REV SCI TECH OIE, V24, P1061, DOI 10.20506/rst.24.3.1634; Sohal JS, 2019, CAN J VET RES, V83, P160; Stevenson K, 2015, VET RES, V46, DOI 10.1186/s13567-015-0203-2; Stevenson K, 2010, PARATUBERCULOSIS: ORGANISM, DISEASE, CONTROL, P126, DOI 10.1079/9781845936136.0126; Sugden EA, 1997, J VET DIAGN INVEST, V9, P413, DOI 10.1177/104063879700900413; Vansnick E, 2004, VET MICROBIOL, V100, P197, DOI 10.1016/j.vetmic.2004.02.006; Whittington R, 1998, MOL CELL PROBE, V12, P349, DOI 10.1006/mcpr.1998.0194; Whittington RJ, 2001, MOL CELL PROBE, V15, P139, DOI 10.1006/mcpr.2001.0346	47	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							997	10.3390/vaccines9090997			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW1MT	34579234	Green Published, gold			2022-04-29	WOS:000699929800001
J	Noseda, R; Ripellino, P; Ghidossi, S; Bertoli, R; Ceschi, A				Noseda, Roberta; Ripellino, Paolo; Ghidossi, Sara; Bertoli, Raffaela; Ceschi, Alessandro			Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase	VACCINES			English	Article						acute inflammatory neuropathy; COVID-19 vaccines; VigiBase; safety; disproportionality	BELLS-PALSY	Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell's palsy (FP/BP), and Guillain-Barre syndrome (GBS) were reported with COVID-19 vaccines of different technologies. This study aimed to assess whether NA, FP/BP, and GBS were more frequently reported in VigiBase with COVID-19 vaccines (of any technologies) than with other viral vaccines, over the full database and across potential risk groups by sex and age. The reporting odds ratio (ROR) with 95% confidence interval (95% CI) was used as the measure of disproportionality and subgroup disproportionality analyses were performed by sex and age. Out of 808,906 safety reports with COVID-19 vaccines, 57 (0.01%) reported NA, 3320 (0.4%) FP/BP, and 632 (0.1%) GBS. There were not signals of disproportionate reporting for NA and GBS with COVID-19 vaccines against other viral vaccines. FP/BP was disproportionately more frequently reported with COVID-19 vaccines than with other viral vaccines over the full database (ROR 1.12, 95%CI 1.07-1.17), in males (ROR 1.65, 95%CI 1.54-1.78) and in age subgroups 65-74 years (ROR 1.21, 95%CI 1.05-1.39) and >= 75 years (ROR 1.84, 95%CI 1.52-2.22). Albeit not proving causation, these findings might support clinicians in decision-making for patients potentially at risk for developing an acute inflammatory neuropathy with COVID-19 vaccines.	[Noseda, Roberta; Ghidossi, Sara; Bertoli, Raffaela; Ceschi, Alessandro] Ente Osped Cantonale, Inst Pharmacol Sci Southern Switzerland, Div Clin Pharmacol & Toxicol, CH-6900 Lugano, Switzerland; [Ripellino, Paolo] Ente Osped Cantonale, Neurol Dept, Neuroctr Southern Switzerland, CH-6900 Lugano, Switzerland; [Ceschi, Alessandro] Ente Osped Cantonale, Clin Trial Unit, CH-6900 Lugano, Switzerland; [Ceschi, Alessandro] Univ Svizzera Italiana, Fac Biomed Sci, CH-6900 Lugano, Switzerland; [Ceschi, Alessandro] Univ Hosp Zurich, Dept Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland		Ceschi, A (通讯作者)，Ente Osped Cantonale, Inst Pharmacol Sci Southern Switzerland, Div Clin Pharmacol & Toxicol, CH-6900 Lugano, Switzerland.; Ceschi, A (通讯作者)，Ente Osped Cantonale, Clin Trial Unit, CH-6900 Lugano, Switzerland.; Ceschi, A (通讯作者)，Univ Svizzera Italiana, Fac Biomed Sci, CH-6900 Lugano, Switzerland.; Ceschi, A (通讯作者)，Univ Hosp Zurich, Dept Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland.	Roberta.noseda@eoc.ch; Paolo.ripellino@eoc.ch; Sara.ghidossi@eoc.ch; raffaela.bertoli@eoc.ch; alessandro.ceschi@eoc.ch		Ceschi, Alessandro/0000-0002-4308-0405; Noseda, Roberta/0000-0002-4946-7926; RIPELLINO, PAOLO/0000-0002-8662-9656			Allen CM, 2021, ANN NEUROL, V90, P315, DOI 10.1002/ana.26144; Colella G, 2021, J NEUROL, V268, P3589, DOI 10.1007/s00415-021-10462-4; Diaz-Segarra N, 2021, PM&R, DOI 10.1002/pmrj.12619; Hasan T, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-243629; Mahajan S, 2021, MUSCLE NERVE, V64, pE3, DOI 10.1002/mus.27255; Mahase E, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1046; Martin-Villares C, 2022, J NEUROL, V269, P47, DOI 10.1007/s00415-021-10617-3; Nishizawa Y, 2021, QJM-INT J MED, V114, P657, DOI 10.1093/qjmed/hcab143; Ozonoff A, 2021, LANCET INFECT DIS, V21, P450, DOI 10.1016/S1473-3099(21)00076-1; Rath B, 2017, VACCINE, V35, P1972, DOI 10.1016/j.vaccine.2016.05.023; Renoud L, 2021, JAMA INTERN MED, V181, P1243, DOI 10.1001/jamainternmed.2021.2219; Sandberg L, 2020, DRUG SAFETY, V43, P999, DOI 10.1007/s40264-020-00957-w; Seabroke S, 2016, DRUG SAFETY, V39, P355, DOI 10.1007/s40264-015-0388-3; Van Eijk JJJ, 2016, MUSCLE NERVE, V53, P337, DOI 10.1002/mus.25008; Waheed S, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.13426; Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1	16	3	3	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1022	10.3390/vaccines9091022			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2WG	34579259	gold, Green Published			2022-04-29	WOS:000702070000001
J	Nuwarda, RF; Alharbi, AA; Kayser, V				Nuwarda, Rina Fajri; Alharbi, Abdulsalam Abdullah; Kayser, Veysel			An Overview of Influenza Viruses and Vaccines	VACCINES			English	Review						influenza virus; influenza vaccine; neuraminidase; hemagglutinin; vaccine manufacturing; vaccine characterization; recombinant vaccine; universal influenza vaccine	H1N1 2009 VACCINE; A VIRUS; SEASONAL INFLUENZA; ANALYTICAL ULTRACENTRIFUGATION; MASS-SPECTROMETRY; GLOBAL MORTALITY; IMMUNE-RESPONSE; PROTECTS MICE; HEMAGGLUTININ; GLYCOSYLATION	Influenza remains one of the major public health concerns because it causes annual epidemics and can potentially instigate a global pandemic. Numerous countermeasures, including vaccines and antiviral treatments, are in use against seasonal influenza infection; however, their effectiveness has always been discussed due to the ongoing resistance to antivirals and relatively low and unpredictable efficiency of influenza vaccines compared to other vaccines. The growing interest in vaccines as a promising approach to prevent and control influenza may provide alternative vaccine development options with potentially increased efficiency. In addition to currently available inactivated, live-attenuated, and recombinant influenza vaccines on the market, novel platforms such as virus-like particles (VLPs) and nanoparticles, and new vaccine formulations are presently being explored. These platforms provide the opportunity to design influenza vaccines with improved properties to maximize quality, efficacy, and safety. The influenza vaccine manufacturing process is also moving forward with advancements relating to egg- and cell-based production, purification processes, and studies into the physicochemical attributes and vaccine degradation pathways. These will contribute to the design of more stable, optimized vaccine formulations guided by contemporary analytical testing methods and via the implementation of the latest advances in the field.	[Nuwarda, Rina Fajri; Alharbi, Abdulsalam Abdullah; Kayser, Veysel] Univ Sydney, Sydney Pharm Sch, Fac Med & Hlth, Sydney, NSW 2006, Australia		Kayser, V (通讯作者)，Univ Sydney, Sydney Pharm Sch, Fac Med & Hlth, Sydney, NSW 2006, Australia.	rnuw0385@uni.sydney.edu.au; aalh0429@uni.sydney.edu.au; veysel.kayser@sydney.edu.au		Nuwarda, Rina Fajri/0000-0001-7868-0075; Kayser, Veysel/0000-0003-1310-9534	Indonesia Endowment Fund for Education (LPDP); University of Umm Al-Qura, Saudi Arabia	R.E.N. acknowledges the Indonesia Endowment Fund for Education (LPDP) and A.A.A. acknowledges the University of Umm Al-Qura, Saudi Arabia for the postgraduate scholarship.	Abdel-Motal UM, 2007, J VIROL, V81, P9131, DOI 10.1128/JVI.00647-07; Al-Halifa S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00022; ALMAZROU A, 1991, CAN MED ASSOC J, V145, P213; An YM, 2013, J PROTEOME RES, V12, P3707, DOI 10.1021/pr400329k; Arnou R, 2009, VACCINE, V27, P7304, DOI 10.1016/j.vaccine.2009.10.033; Asaduzzaman SM, 2015, MATH BIOSCI, V270, P1, DOI 10.1016/j.mbs.2015.09.006; Asha K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020192; Atsmon J, 2012, J CLIN IMMUNOL, V32, P595, DOI 10.1007/s10875-011-9632-5; Baldwin MA, 2001, ANAL CHEM, V73, P1707, DOI 10.1021/ac0011080; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bao DQ, 2021, J VIROL, V95, DOI 10.1128/JVI.02042-20; Barr IG, 2010, VACCINE, V28, P1156, DOI 10.1016/j.vaccine.2009.11.043; Baxter R, 2017, VACCINE, V35, P1254, DOI 10.1016/j.vaccine.2017.01.062; Bekkat-Berkani R, 2016, EXPERT REV VACCINES, V15, P201, DOI 10.1586/14760584.2016.1113878; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Beyer WEP, 2002, VACCINE, V20, P1340, DOI 10.1016/S0264-410X(01)00471-6; Boni MF, 2008, VACCINE, V26, pC8, DOI 10.1016/j.vaccine.2008.04.011; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Byrd-Leotis L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071541; CDC, CDC SEAS FLU VACC EF; CDC, TYP INFL VIR; CDC, 1968, PAND H3N2 VIR; Centers for Disease Control and Prevention, HIGHL PATH AS AV INF; Centers for Disease Control and Prevention (CDC), CELL BAS FLU VACC; Chang D, 2019, MOL CELL PROTEOMICS, V18, P2348, DOI 10.1074/mcp.R119.001491; Chowdhury S, 2019, TROP MED INFECT DIS, V4, DOI 10.3390/tropicalmed4040138; Chung EH, 2014, CLIN EXP VACCINE RES, V3, P50, DOI 10.7774/cevr.2014.3.1.50; Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Couch RB, 2008, VACCINE, V26, pD5, DOI 10.1016/j.vaccine.2008.05.076; Cox MMJ, 2008, INFLUENZA OTHER RESP, V2, P211, DOI 10.1111/j.1750-2659.2008.00053.x; Cox MMJ, 2009, BIOLOGICALS, V37, P182, DOI 10.1016/j.biologicals.2009.02.014; Cruz E, 2018, HUM VACC IMMUNOTHER, V14, P508, DOI 10.1080/21645515.2017.1377871; Dawson WK, 2018, BRIEF FUNCT GENOMICS, V17, P402, DOI 10.1093/bfgp/elx028; de Vries RD, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030046; de Wit E, 2008, J CLIN VIROL, V41, P1, DOI 10.1016/j.jcv.2007.10.017; Defang GN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048229; DeMarcus L, 2019, VACCINE, V37, P4015, DOI 10.1016/j.vaccine.2019.06.004; Dey AK, 2014, EXPERT REV VACCINES, V13, P671, DOI 10.1586/14760584.2014.907528; Dhakal S, 2019, J VIROL, V93, DOI 10.1128/JVI.00797-19; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Downard KM, 2009, MASS SPECTROM REV, V28, P35, DOI 10.1002/mas.20194; Dunkle L., 2015, EC MICROBIOL, V2, P224; Engelhardt OG, 2005, J VIROL, V79, P5812, DOI 10.1128/JVI.79.9.5812-5818.2005; Engelhardt OG, 2018, VACCINE, V36, P4339, DOI 10.1016/j.vaccine.2018.05.076; Essink B, 2020, VACCINE, V38, P242, DOI 10.1016/j.vaccine.2019.10.021; Filipe V, 2013, TRAC-TREND ANAL CHEM, V49, P118, DOI 10.1016/j.trac.2013.05.005; Nuorti J. Pekka, 2010, Morbidity and Mortality Weekly Report, V59, P1; Fleming DM, 1999, EUR J EPIDEMIOL, V15, P467, DOI 10.1023/A:1007525402861; Fonteneau JF, 2003, BLOOD, V101, P3520, DOI 10.1182/blood-2002-10-3063; Frahm GE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150229; Gamblin SJ, 2010, J BIOL CHEM, V285, P28403, DOI 10.1074/jbc.R110.129809; Gao X, 2013, ANTIVIR RES, V98, P4, DOI 10.1016/j.antiviral.2013.01.010; Gaymard A, 2016, CLIN MICROBIOL INFEC, V22, P975, DOI 10.1016/j.cmi.2016.07.007; Geisler C, 2018, PROTEIN EXPRES PURIF, V144, P25, DOI 10.1016/j.pep.2017.11.002; Giurgea LT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030409; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; Grodeland G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080008; Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1; Gutierrez AF, 2015, FUTURE VIROL, V10, P1057, DOI 10.2217/fvl.15.75; Hai R, 2012, J VIROL, V86, P5774, DOI 10.1128/JVI.00137-12; Harris A, 2006, P NATL ACAD SCI USA, V103, P19123, DOI 10.1073/pnas.0607614103; Hegde NR, 2015, HUM VACC IMMUNOTHER, V11, P1223, DOI 10.1080/21645515.2015.1016666; Hiremath J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151922; Hoft DF, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00414-16, 10.1128/cvi.00414-16]; Hutter J, 2013, J IMMUNOL, V190, P220, DOI 10.4049/jimmunol.1201060; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jester B, 2019, VIROLOGY, V527, P32, DOI 10.1016/j.virol.2018.10.019; Job ER, 2013, J IMMUNOL, V190, P2169, DOI 10.4049/jimmunol.1202433; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Kang HJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216871; Karch CP, 2017, NANOMED-NANOTECHNOL, V13, P241, DOI 10.1016/j.nano.2016.08.030; Kaufmann L, 2017, JOVE-J VIS EXP, DOI 10.3791/55833; Kayser V, 2021, HUM VACC IMMUNOTHER, V17, P5255, DOI 10.1080/21645515.2021.1977057; KEITEL WA, 1994, J INFECT DIS, V169, P477, DOI 10.1093/infdis/169.2.477; Khalaj-Hedayati A, 2020, INFLUENZA OTHER RESP, V14, P92, DOI 10.1111/irv.12697; Kim H, 2018, VIRAL IMMUNOL, V31, P174, DOI 10.1089/vim.2017.0141; Kim P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040183; King JC, 2000, J INFECT DIS, V181, P725, DOI 10.1086/315246; Klimov AI, 2012, VACCINE, V30, P6461, DOI 10.1016/j.vaccine.2012.07.089; Kobayashi Y, 2012, J VIROL, V86, P3446, DOI 10.1128/JVI.06147-11; Kon TC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150700; Krause JC, 2015, ANTIBODIES FOR INFECTIOUS DISEASES, P209, DOI 10.1128/microbiolspec.AID-0021-2014; Kuchipudi SV, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020262; Kumar A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00600; Lamb YN, 2019, DRUGS, V79, P1337, DOI [10.1007/s40265-019-01176-z, 10.1007/s40265-019-01237-3]; Lancaster C, 2016, METHODS MOL BIOL, V1476, P279, DOI 10.1007/978-1-4939-6361-4_21; Lee KKH, 2016, HUM VACC IMMUNOTHER, V12, P1757, DOI 10.1080/21645515.2016.1141846; Lewnard JA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020028; Lin YP, 2017, INFLUENZA OTHER RESP, V11, P263, DOI 10.1111/irv.12447; Liu J, 2006, AAPS J, V8, pE580, DOI 10.1208/aapsj080367; Lopez-Macias C, 2011, VACCINE, V29, P7826, DOI 10.1016/j.vaccine.2011.07.099; Low JGH, 2014, VACCINE, V32, P5041, DOI 10.1016/j.vaccine.2014.07.011; Luo Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22874-w; MAASSAB HF, 1967, NATURE, V213, P612, DOI 10.1038/213612a0; McCaughey Conall, 2010, Ulster Med J, V79, P46; McKeage K, 2013, DRUGS, V73, P1587, DOI 10.1007/s40265-013-0114-3; Mena I, 2016, ELIFE, V5, DOI 10.7554/eLife.16777; Milian E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/504831; Minor PD, 2015, VACCINES-BASEL, V3, P90, DOI 10.3390/vaccines3010090; Mochalova L, 2003, VIROLOGY, V313, P473, DOI 10.1016/S0042-6822(03)00377-5; Montomoli E, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010014; Moules V, 2011, VIROLOGY, V414, P51, DOI 10.1016/j.virol.2011.03.011; Muszkat M, 2003, VACCINE, V21, P1180, DOI 10.1016/S0264-410X(02)00481-4; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nakayama T, 2011, YAKUGAKU ZASSHI, V131, P1723, DOI 10.1248/yakushi.131.1723; Nayak DP, 2009, VIRUS RES, V143, P147, DOI 10.1016/j.virusres.2009.05.010; Nguyen-Van-Tam JS, 2003, VACCINE, V21, P1762, DOI 10.1016/S0264-410X(03)00069-0; Noble JE, 2009, METHOD ENZYMOL, V463, P73, DOI 10.1016/S0076-6879(09)63008-1; Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661; Oxford JS, 2000, REV MED VIROL, V10, P119, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;119::AID-RMV272&gt;3.0.CO;2-O; Palese P., 2007, ORTHOMYXOVIRDAE VIRU, V5th ed., P1647; Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0; Paules CI, 2018, NEW ENGL J MED, V378, P7, DOI 10.1056/NEJMp1714916; Pedersen JC, 2014, METHODS MOL BIOL, V1161, P11, DOI 10.1007/978-1-4939-0758-8_2; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Pelliccia M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13520; Petric M, 2006, J INFECT DIS, V194, pS98, DOI 10.1086/507554; Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008; Pillet S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216533; Ping JH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9148; Potter CW, 2001, J APPL MICROBIOL, V91, P572, DOI 10.1046/j.1365-2672.2001.01492.x; Preiss S, 2016, VACCINE, V34, P6665, DOI 10.1016/j.vaccine.2016.10.079; Rajao DS, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00123; Ramirez A, 2018, VACCINE, V36, P873, DOI 10.1016/j.vaccine.2017.12.053; Ren ZG, 2018, INT IMMUNOPHARMACOL, V58, P109, DOI 10.1016/j.intimp.2017.12.020; Rhodes DG, 2009, METHOD ENZYMOL, V463, P691, DOI 10.1016/S0076-6879(09)63039-1; Rioux G, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-19; Robertson CA, 2016, EXPERT REV VACCINES, V15, P1495, DOI 10.1080/14760584.2016.1254044; Rustandi RR, 2016, METHODS MOL BIOL, V1476, P269, DOI 10.1007/978-1-4939-6361-4_20; Sabbaghi A, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2074; Sahin Z, 2019, VACCINE, V37, P1073, DOI 10.1016/j.vaccine.2018.12.069; Sahin Z, 2017, VACCINE, V35, P3026, DOI 10.1016/j.vaccine.2017.04.066; SAITO T, 1995, J VIROL, V69, P5011, DOI 10.1128/JVI.69.8.5011-5017.1995; Samji Tasleem, 2009, Yale Journal of Biology and Medicine, V82, P153; Saunders-Hastings PR, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5040066; Sautto GA, 2020, J IMMUNOL, V204, P375, DOI 10.4049/jimmunol.1900379; SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8; Seladi-Schulman J, 2013, J VIROL, V87, P13343, DOI 10.1128/JVI.02004-13; Shytuhina A, 2014, J CHROMATOGR A, V1364, P192, DOI 10.1016/j.chroma.2014.05.087; Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153; Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023; Spreeuwenberg P, 2018, AM J EPIDEMIOL, V187, P2561, DOI 10.1093/aje/kwy191; Squarcione S, 2003, VACCINE, V21, P1268, DOI 10.1016/S0264-410X(02)00401-2; Statler VA, 2019, VACCINE, V37, P343, DOI 10.1016/j.vaccine.2018.07.036; Stohr Klaus, 2012, Methods Mol Biol, V865, P147, DOI 10.1007/978-1-61779-621-0_9; Su F, 2016, HUM VACC IMMUNOTHER, V12, P1070, DOI 10.1080/21645515.2015.1114195; Sullivan SG, 2019, EUROSURVEILLANCE, V24, P6, DOI 10.2807/1560-7917.ES.2019.24.45.1900645; Sullivan Sheena G, 2019, Ther Adv Vaccines Immunother, V7, p2515135519826481, DOI 10.1177/2515135519826481; Suryadevara M, 2014, HUM VACC IMMUNOTHER, V10, P596, DOI 10.4161/hv.27115; Suzuki T, 2015, P NATL ACAD SCI USA, V112, P7809, DOI 10.1073/pnas.1503885112; Tarasov M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030488; Tate MD, 2014, VIRUSES-BASEL, V6, P1294, DOI 10.3390/v6031294; Taubenberger JK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5485; Taubenberger JK, 2010, PUBLIC HEALTH REP, V125, P16, DOI 10.1177/00333549101250S305; Tay T, 2015, HUM VACC IMMUNOTHER, V11, P1673, DOI 10.1080/21645515.2015.1034914; Tong SX, 2012, P NATL ACAD SCI USA, V109, P4269, DOI 10.1073/pnas.1116200109; Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; Tsai TF, 2013, INFECT CHEMOTHER, V45, P159, DOI 10.3947/ic.2013.45.2.159; Vajda J, 2016, J CHROMATOGR A, V1465, P117, DOI 10.1016/j.chroma.2016.08.056; van Doorn E, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006339, 10.1097/md.0000000000006339]; Velkov T, 2013, MOL IMMUNOL, V56, P705, DOI 10.1016/j.molimm.2013.07.010; Viboud C, 2016, J INFECT DIS, V213, P738, DOI 10.1093/infdis/jiv534; Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003; von Itzstein Mark, 2009, V189, P111, DOI 10.1007/978-3-540-79086-0_5; Wang N, 2008, J BIOL CHEM, V283, P33826, DOI 10.1074/jbc.M806897200; Wanzeck K, 2011, AM J RESP CRIT CARE, V183, P767, DOI 10.1164/rccm.201007-1184OC; Weigel T, 2019, J CHROMATOGR B, V1117, P103, DOI 10.1016/j.jchromb.2019.03.037; Weir JP, 2016, INFLUENZA OTHER RESP, V10, P354, DOI 10.1111/irv.12383; WHO, AV INFL WEEKL UPD NU; WHO, INFL SEAS; WHO, WHAT IS PAND H1N1 20; Wohlbold TJ, 2014, VIRUSES-BASEL, V6, P2465, DOI 10.3390/v6062465; Wolff T, 2021, ENCY VIROL, P561; Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12; Wood JM, 2018, INFLUENZA OTHER RESP, V12, P195, DOI 10.1111/irv.12543; World Health Organization, INFL AV OTH ZOON; Xie H, 2015, SCI REP-UK, V5, DOI 10.1038/srep15279; Yamayoshi S, 2019, NAT MED, V25, P212, DOI 10.1038/s41591-018-0340-z; York IA, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20171505; Young B, 2018, J INFECT DIS, V217, P731, DOI 10.1093/infdis/jix632; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; Zhao L, 2019, Can Commun Dis Rep, V45, P149, DOI 10.14745/ccdr.v45i06a01; Zhao MC, 2019, VACCINE, V37, P5491, DOI 10.1016/j.vaccine.2018.02.090; Zhao QJ, 2013, TRENDS BIOTECHNOL, V31, P654, DOI 10.1016/j.tibtech.2013.09.002; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	187	6	6	34	41	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1032	10.3390/vaccines9091032			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW4XS	34579269	Green Published, gold			2022-04-29	WOS:000700161300001
J	Vollmann, M; Salewski, C				Vollmann, Manja; Salewski, Christel			To Get Vaccinated, or Not to Get Vaccinated, That Is the Question: Illness Representations about COVID-19 and Perceptions about COVID-19 Vaccination as Predictors of COVID-19 Vaccination Willingness among Young Adults in The Netherlands	VACCINES			English	Article						Common Sense Model (CSM) of self-regulation; illness representations; Necessity-Concerns Framework (NCF); treatment perceptions; vaccination willingness	SELF-REGULATION; STRONGER BELIEFS; HERD-IMMUNITY; IPQ-R; NECESSITY; MEDICATION; ADHERENCE; BEHAVIOR; HEALTH; INTERVENTION	Mass vaccination is considered necessary to reduce the spread of COVID-19; however, vaccination willingness was found to be especially low among young adults. Therefore, based on the extended Common Sense Model, the unique effects and the interplay of illness representations about COVID-19 and perceptions about COVID-19 vaccination in explaining COVID-19 vaccination willingness was investigated using a cross-sectional design. An online survey measuring the relevant variables was filled in by 584 participants (69.9% female) between 18 and 34 years. Correlation analyses showed that all illness representation dimensions except from timeline and both dimensions of vaccination perceptions were related to vaccination willingness. The mediation analysis revealed that less personal control, more prevention control, more concerns about COVID-19 as well as more perceived necessity of and fewer concerns about the vaccination were directly related to higher vaccination willingness. Additionally, prevention control was indirectly related to higher vaccination willingness through stronger perceptions of necessity of the vaccination. The extended Common Sense Model proved to be useful in the context of illness prevention. Campaigns to improve vaccination rates should aim at increasing the perception that COVID-19 is preventable through vaccination and the personal need of the vaccination as well as at decreasing concerns about the vaccination.	[Vollmann, Manja] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Dept Sociomed Sci, NL-3000 DR Rotterdam, Netherlands; [Salewski, Christel] Univ Hagen, Fac Psychol, Dept Hlth Psychol, D-58097 Hagen, Germany		Vollmann, M (通讯作者)，Erasmus Univ, Erasmus Sch Hlth Policy & Management, Dept Sociomed Sci, NL-3000 DR Rotterdam, Netherlands.	vollmann@eshpm.eur.nl; christel.salewski@fernuni-hagen.de		Vollmann, Manja/0000-0001-6464-775X			Al-Amer R, 2022, J CLIN NURS, V31, P62, DOI 10.1111/jocn.15951; Andela CD, 2015, GROWTH HORM IGF RES, V25, P219, DOI 10.1016/j.ghir.2015.06.008; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], WHO CORONAVIRUS COVI; [Anonymous], 2021, ACTUELE INFORM COVID; [Anonymous], Verandering in Vaccinatiebereidheid; Aw J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080900; Bartholomew L, 2011, PLANNING HLTH PROMOT PLANNING HLTH PROMOT, V3rd; Berglund E, 2013, PATIENT EDUC COUNS, V91, P105, DOI 10.1016/j.pec.2012.11.001; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826; Bolin JH, 2014, J EDUC MEAS, V51, P335, DOI 10.1111/jedm.12050; Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020; Cameron LD, 2008, PSYCHOL HEALTH, V23, P91, DOI 10.1080/14768320701342383; Chilcot J, 2013, BEHAV RES THER, V51, P690, DOI 10.1016/j.brat.2013.07.007; Clatworthy J, 2009, J AFFECT DISORDERS, V116, P51, DOI 10.1016/j.jad.2008.11.004; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; de Raaij EJ, 2012, MANUAL THER, V17, P330, DOI 10.1016/j.math.2012.03.001; Neto DD, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.640955; Figueiras MJ, 2007, PSYCHOL HEALTH, V22, P143, DOI 10.1080/14768320600774462; Fishbein M, 2008, MED DECIS MAKING, V28, P834, DOI 10.1177/0272989X08326092; Foot H, 2016, PATIENT EDUC COUNS, V99, P706, DOI 10.1016/j.pec.2015.11.004; Garg R, 2018, MATERN CHILD HLTH J, V22, P137, DOI 10.1007/s10995-017-2363-3; Granger BB, 2015, AM HEART J, V169, P539, DOI 10.1016/j.ahj.2015.01.006; Horne R, 2002, PSYCHOL HEALTH, V17, P17, DOI 10.1080/08870440290001502; Horne R., 2010, HEALTH PSYCHOL, V2nd, P175; Horne R., 2003, SELF REGULATION HLTH, P138; Horne R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080633; Horne R, 2007, JAIDS-J ACQ IMM DEF, V45, P334; IPSOS NOS, 2021, NED COR; Karademas EC, 2013, J HEALTH PSYCHOL, V18, P419, DOI 10.1177/1359105312436765; Karamanidou C, 2008, BRIT J HEALTH PSYCH, V13, P205, DOI 10.1348/135910708X288792; Kok G, 2018, HEALTH PSYCHOL REV, V12, P111, DOI 10.1080/17437199.2017.1415767; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lau JTF, 2010, AM J INFECT CONTROL, V38, P374, DOI 10.1016/j.ajic.2010.03.002; Lau JTF, 2006, VACCINE, V24, P5526, DOI 10.1016/j.vaccine.2006.04.014; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lehmann BA, 2014, VACCINE, V32, P6986, DOI 10.1016/j.vaccine.2014.10.034; Leventhal H, 1998, PSYCHOL HEALTH, V13, P717, DOI 10.1080/08870449808407425; Leventhal H., 2003, SELF REGULATION HLTH, P42; Leventhal H, 2016, J BEHAV MED, V39, P935, DOI 10.1007/s10865-016-9782-2; Marmara D, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4324-6; Martin LR, 2017, ANN BEHAV MED, V51, P652, DOI 10.1007/s12160-017-9888-y; McGrath A, 2017, SOC PERSONAL PSYCHOL, V11, DOI 10.1111/spc3.12362; Michie S, 2008, APPL PSYCHOL-INT REV, V57, P660, DOI 10.1111/j.1464-0597.2008.00341.x; Moon Z, 2017, PSYCHOL HEALTH, V32, P439, DOI 10.1080/08870446.2016.1275629; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Myers LB, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-15; National Institute for Public Health and the Environment, 2020, IMP 1 COVID 19 GOLF, DOI [10.21945/RIVM-2020-0183, DOI 10.21945/RIVM-2020-0183]; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Pot M, 2017, PREV MED, V100, P41, DOI 10.1016/j.ypmed.2017.04.005; Rademakers J, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09963-0; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Renner B, 2012, VACCINE, V30, P7019, DOI 10.1016/j.vaccine.2012.09.064; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Rowlands G, 2014, HUM VACC IMMUNOTHER, V10, P2130, DOI 10.4161/hv.29603; Salewski C., 2017, P 31 C EUR HLTH PSYC, DOI [10.25397/eur.14605383, DOI 10.25397/EUR.14605383]; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schwarzer R, 2016, ACTUAL PSICOL, V30, P119, DOI 10.15517/ap.v30i121.23458; Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054; Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043; Sheeran P, 2016, SOC PERSONAL PSYCHOL, V10, P503, DOI 10.1111/spc3.12265; Shen MW, 2021, VACCINE, V39, P2295, DOI 10.1016/j.vaccine.2021.02.056; Taylor EC, 2018, PSYCHOL HEALTH, V33, P499, DOI 10.1080/08870446.2017.1373113; Teslya A, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003166; Tiemensma J, 2014, J CLIN ENDOCR METAB, V99, P3668, DOI 10.1210/jc.2014-1527; Tomczyk S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01821; Varga TV, 2021, LANCET REG HEALTH-EU, V2, DOI 10.1016/j.lanepe.2020.100020; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Vasilevska M, 2014, INFECT CONT HOSP EP, V35, P699, DOI 10.1086/676427; Vestergaard LS, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.26.2001214; Vollmann M, 2021, PSYCHOL HEALTH, V36, P253, DOI 10.1080/08870446.2020.1775831; Wang Q, 2021, PREV MED, V150, DOI 10.1016/j.ypmed.2021.106694; Wang ZX, 2021, HUM VACC IMMUNOTHER, V17, P1455, DOI 10.1080/21645515.2020.1814653; Wilhelm M, 2018, PATIENT EDUC COUNS, V101, P497, DOI 10.1016/j.pec.2017.09.007; Winer ES, 2016, J CLIN PSYCHOL, V72, P947, DOI 10.1002/jclp.22298	76	2	2	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							941	10.3390/vaccines9090941			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ3KX	34579178	gold, Green Published			2022-04-29	WOS:000702108400001
J	Albrecht, L; Bishop, E; Jay, B; Lafoux, B; Minoves, M; Passaes, C				Albrecht, Laure; Bishop, Elodie; Jay, Basile; Lafoux, Blaise; Minoves, Marie; Passaes, Caroline			COVID-19 Research: Lessons from Non-Human Primate Models	VACCINES			English	Review						COVID-19; SARS-CoV-2; non-human primates; pathogenesis; drug discovery; vaccine	RESPIRATORY SYNDROME CORONAVIRUS; SARS CORONAVIRUS; RHESUS MACAQUES; ANIMAL-MODEL; SARS-COV-2; INFECTION; MERS; REPLICATION; IMMUNITY; PROTEIN	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19). It emerged from China in December 2019 and rapidly spread across the globe, causing a pandemic with unprecedented impacts on public health and economy. Therefore, there is an urgent need for the development of curative treatments and vaccines. In humans, COVID-19 pathogenesis shows a wide range of symptoms, from asymptomatic to severe pneumonia. Identifying animal models of SARS-CoV-2 infection that reflect the clinical symptoms of COVID-19 is of critical importance. Nonhuman primates (NHPss) correspond to relevant models to assess vaccine and antiviral effectiveness. This review discusses the use of NHPs as models for COVID-19 research, with focus on the pathogenesis of SARS-CoV-2 infection, drug discovery and pre-clinical evaluation of vaccine candidates.	[Albrecht, Laure; Bishop, Elodie; Jay, Basile; Lafoux, Blaise; Minoves, Marie] Inst Pasteur, Ctr Enseignement, Cours Virol Fondamentale, F-75015 Paris, France; [Albrecht, Laure; Bishop, Elodie; Minoves, Marie] Sorbonne Univ, Dept Sci Vie, F-75006 Paris, France; [Albrecht, Laure; Bishop, Elodie; Jay, Basile] Ecole Normale Super Paris Saclay, F-91190 Gif Sur Yvette, France; [Jay, Basile; Lafoux, Blaise] Ecole Normale Super, Dept Biol, F-75005 Paris, France; [Passaes, Caroline] Univ Paris, Dept Sci Vivant, F-75006 Paris, France		Passaes, C (通讯作者)，Univ Paris, Dept Sci Vivant, F-75006 Paris, France.	laure.albrecht@ens-paris-saclay.fr; elodie.bishop@ens.fr; basile.jay@ens-paris-saclay.fr; blaiselafoux@gmail.com; marie.minoves@agroparistech.fr; caroline.pereira-bittencourt@pasteur.fr		BISHOP, Elodie/0000-0002-1310-2239	"Programme Medecine Sciences ENS-PSL" fellowship	We thank Ana Luiza Chaves ValadAo, Anais Chapel and Federico Perdomo Celis for comments on the manuscript. We thank Institut Pasteur's Education Center, and Pierre-Emmanuel Ceccaldi, Jean-Pierre Vartanian and Nolwenn Jouvenet, directors of the Fundamental Virology Course. E.B. was supported by a "Programme Medecine Sciences ENS-PSL" fellowship.	[Anonymous], SARS COV 2 POTENTIAL; [Anonymous], CORONAVIRUS COVID 19; Bartoli A, 2021, INTERN EMERG MED, V16, P281, DOI 10.1007/s11739-020-02569-9; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Blair RV, 2021, AM J PATHOL, V191, P274, DOI 10.1016/j.ajpath.2020.10.016; Brooke GN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72528-z; Brouwer PJM, 2021, CELL, V184, P1188, DOI 10.1016/j.cell.2021.01.035; Cento V, 2020, J INFECTION, V81, pE90, DOI 10.1016/j.jinf.2020.06.024; Chakraborty I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138882; Chakraborty R, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114184; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Che Y., 2020, IN PRESS, DOI [10.1093/cid/ciaa1703, DOI 10.1093/CID/CIAA1703]; Chen H, 2020, VALID PROTECTIVE IMM, DOI [10.1101/2020.08.04.235747., DOI 10.1101/2020.08.04.235747]; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Corbett Kizzmekia S, 2021, bioRxiv, DOI 10.1101/2021.05.21.445189; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; de Wit E, 2013, P NATL ACAD SCI USA, V110, P16598, DOI 10.1073/pnas.1310744110; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Docea AO, 2020, INT J MOL MED, V45, P1631, DOI 10.3892/ijmm.2020.4555; Elizabeth G., 2020, COMPLETE PROTECTION, DOI [10.1101/2020.12.08.416297, DOI 10.1101/2020.12.08.416297]; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Estes JD, 2018, NAT REV IMMUNOL, V18, P390, DOI 10.1038/s41577-018-0005-7; Fahlberg MD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19967-4; Falzarano D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004250; FDA, APPR 1 TREATM COVID; Finch Courtney L, 2020, bioRxiv, DOI 10.1101/2020.05.14.096727; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fontanet A, 2021, LANCET, V397, P952, DOI 10.1016/S0140-6736(21)00370-6; Gabor, 2020, PHASE 1 ASSESSMENT S, DOI [10.1101/2020.11.09.20228551, DOI 10.1101/2020.11.09.20228551]; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gobeil SMC, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108630; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Grobler JA, 2020, CELL HOST MICROBE, V28, P638, DOI 10.1016/j.chom.2020.09.017; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Han L, 2020, SINGLE CELL ATLAS NO, DOI [10.1101/2020.04.10.022103, DOI 10.1101/2020.04.10.022103(2020]; Hartman AL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008903; Hasenkrug KJ, 2021, MBIO, V12, DOI [10.1101/2021.04.02.438262, 10.1128/mBio.01503-21]; Hoang TN, 2021, CELL, V184, P460, DOI 10.1016/j.cell.2020.11.007; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Ishigaki H, 2021, VIROLOGY, V554, DOI 10.1016/j.virol.2020.12.013; Iwasaki A, 2021, LANCET INFECT DIS, V21, P3, DOI 10.1016/S1473-3099(20)30783-0; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jiao L, 2021, GASTROENTEROLOGY, V160, P1647, DOI 10.1053/j.gastro.2020.12.001; Johnston SC, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246366; Jones BE, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1906; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kele B, 2021, CLIN INFECT DIS PUBL, V2021, pCIAB014, DOI DOI 10.1093/CID/CIAB014; Khoury DS, 2020, NAT REV IMMUNOL, V20, P727, DOI 10.1038/s41577-020-00471-1; Klasse PJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe8065; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Lakshmanappa YS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20642-x; Lawler JV, 2006, PLOS MED, V3, P677, DOI 10.1371/journal.pmed.0030149; Lee JS, 2021, CLIN INFECT DIS, V73, pE3002, DOI 10.1093/cid/ciaa1421; Leisman DE, 2020, LANCET RESP MED, V8, P1233, DOI 10.1016/S2213-2600(20)30404-5; Li S., 2021, TANDEM REPEAT DIMERI, DOI [10.1101/2021.03.11.434928, DOI 10.1101/2021.03.11.434928]; Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004; Liang JG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21634-1; Lu SY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00269-6; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Maisonnasse P, 2021, Res Sq, DOI 10.21203/rs.3.rs-235272/v1; Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4; Malin JJ, 2021, CLIN MICROBIOL REV, V34, DOI 10.1128/CMR.00162-20; McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Medema G, 2020, ENVIRON SCI TECH LET, V7, P511, DOI 10.1021/acs.estlett.0c00357; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; Munster VJ, 2020, NATURE, V585, P268, DOI 10.1038/s41586-020-2324-7; MUNSTER VJ, 2021, SUBTLE DIFFERENCES P, DOI DOI 10.1101/2021.05.07.443115; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002; Patel A, 2020, INTRADERMAL DELIVERE, DOI [10.1101/2020.07.28.225649., DOI 10.1101/2020.07.28.225649]; Patil S, 2020, REMARKABLE IMMUNOGEN, DOI [10.21203/rs.3.rs-65715/v1, DOI 10.21203/RS.3.RS-65715/V1]; Peccia J, 2020, NAT BIOTECHNOL, V38, P1164, DOI 10.1038/s41587-020-0684-z; Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prado-Vivar B, 2020, LANCET INFECT DIS, V21, pE142, DOI 10.1016/S1473-3099(20)30910-5; Qin C, 2005, J PATHOL, V206, P251, DOI 10.1002/path.1769; Rauch S., 2020, MRNA VACCINE CVNCOV, DOI [10.1101/2020.12.23.424138, DOI 10.1101/2020.12.23.424138]; Richmond P, 2021, LANCET, V397, P682, DOI 10.1016/S0140-6736(21)00241-5; Rockx Barry, 2020, Science, V368, P1012, DOI 10.1126/science.abb7314; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843, 10.21203/rs.3.rs-57112/v1]; Rosa Bruce A, 2020, bioRxiv, DOI 10.1101/2020.08.06.239798; Rosenke K, 2021, bioRxiv, DOI 10.1101/2021.06.11.448134; Rowe T, 2004, J VIROL, V78, P11401, DOI 10.1128/JVI.78.20.11401-11404.2004; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Salguero FJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21389-9; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Shan C, 2020, CELL RES, V30, P670, DOI 10.1038/s41422-020-0364-z; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Singh D.K., 2020, SARS COV 2 INFECT LE, DOI [10.1101/2020.06.05.136481, DOI 10.1101/2020.06.05.136481V1]; Singh DK, 2021, NAT MICROBIOL, V6, P73, DOI 10.1038/s41564-020-00841-4; Song TZ, 2020, ZOOL RES, V41, P503, DOI 10.24272/j.issn.2095-8137.2020.202; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Tebas P, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100689; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149; van Doremalen Neeltje, 2021, bioRxiv, DOI 10.1101/2021.01.09.426058; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Van Elslande J, 2021, CLIN INFECT DIS, V73, P354, DOI 10.1093/cid/ciaa1330; Vaneman J., 2021, IMMUNOGENICITY PROT, DOI [10.1101/2020.11.17.368258, DOI 10.1101/2020.11.17.368258]; Nonaka CKV, 2021, EMERG INFECT DIS, V27, P1522, DOI 10.3201/eid2705.210191; Vogel A.B., 2020, BIORXIV, V370, P1022, DOI 10.1101/2020.09.08.280818; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Wang G, 2021, CELL RES, V31, P17, DOI 10.1038/s41422-020-00450-0; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19568-1; Wang Zijun, 2021, bioRxiv, DOI 10.1101/2021.05.07.443175; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163; WHO, COR DIS COVID 19 DAS; Williamson BN, 2020, NATURE, V585, P273, DOI [10.1038/s41586-020-2423-5, 10.1101/2020.04.15.043166]; Woolsey C, 2021, NAT IMMUNOL, V22, P86, DOI 10.1038/s41590-020-00835-8; World Health Organization, DRAFT LANDSC TRACK C; Wu Fuqing, 2020, medRxiv, DOI 10.1101/2020.06.15.20117747; Wu K, 2021, NEW ENGL J MED, V384, P1468, DOI 10.1056/NEJMc2102179; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Wurtzer S, 2020, EUROSURVEILLANCE, V25, P38, DOI 10.2807/1560-7917.ES.2020.25.50.2000776; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Yao YF, 2014, J INFECT DIS, V209, P236, DOI 10.1093/infdis/jit590; Yoshida, 2020, PRECLINICAL STUDY DN, DOI [10.1101/2020.10.21.347799, DOI 10.1101/2020.10.21.347799]; Yu P, 2020, ANIM MODEL EXP MED, V3, P93, DOI 10.1002/ame2.12108; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zheng HW, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008949; Zucman N, 2021, CLIN INFECT DIS, V73, P1945, DOI 10.1093/cid/ciab129	134	2	2	1	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							886	10.3390/vaccines9080886			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3UE	34452011	gold, Green Published			2022-04-29	WOS:000689859600001
J	Cheng, ZJ; Xue, MS; Zheng, PY; Lyu, JL; Zhan, ZQ; Hu, HS; Zhang, Y; Zhang, XD; Sun, BQ				Cheng, Zhangkai Jason; Xue, Mingshan; Zheng, Peiyan; Lyu, Jiali; Zhan, Zhiqing; Hu, Haisheng; Zhang, Yong; Zhang, Xiaohua Douglas; Sun, Baoqing			Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review	VACCINES			English	Review						COVID-19; vaccines; neutralizing antibody; variants; ADE	NEUTRALIZING ANTIBODIES; COVID-19; SPIKE; PATHOGENESIS; CORONAVIRUS; INFECTIVITY; RESPONSES	Vaccines are a crucial part of the global anti-pandemic effort against COVID-19. The effects of vaccines, as well as their common influencing factors, are the most important issues that we should focus on at this time. To this end, we review statistics on immunogenicity after vaccination, using neutralizing antibodies as the main reference index. Age, infection history, and virus variants are compared, and vaccination program recommendations are made accordingly. Suggestions are made to address concerns raised by the vaccines' shortened development cycle, as well as the emergence of immunity escape of viral variants. Finally, a brief description and future prospects are provided based on the principle of the ADE effect and previous experience with similar viruses.	[Cheng, Zhangkai Jason; Xue, Mingshan; Zheng, Peiyan; Lyu, Jiali; Hu, Haisheng; Zhang, Yong; Sun, Baoqing] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth,State Key Lab Resp Dis, Natl Clin Res,Ctr Resp Dis,Dept Allergy & Clin Im, Guangzhou 510623, Peoples R China; [Zhan, Zhiqing] Guangzhou Med Univ, Clin Sch 3, Dept Clin Med, Guangzhou 510182, Peoples R China; [Zhang, Xiaohua Douglas] Univ Macau, Fac Hlth Sci, Taipa 999078, Macau, Peoples R China		Sun, BQ (通讯作者)，Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth,State Key Lab Resp Dis, Natl Clin Res,Ctr Resp Dis,Dept Allergy & Clin Im, Guangzhou 510623, Peoples R China.	jasontable@gmail.com; limorconder@gmail.com; gdmcslxx@126.com; lvjialiii@163.com; zhanzhiqing@foxmail.com; 13544377529@163.com; zhangy@hhgene.cn; douglaszhang@um.edu.mo; sunbaoqing@vip.163.com	Hu, Haisheng/J-9469-2019	Hu, Haisheng/0000-0001-7873-6956; Zheng, Peiyan/0000-0002-8795-4899; Zhang, Yong/0000-0002-3664-1040; Cheng, Zhangkai/0000-0002-8621-4119	Guangzhou Institute of Respiratory Health Open Project; (China Evergrande Group) [2020GIRHHMS04]; Zhongnanshan Medical Foundation of Guangdong Province [ZNSA-2021005, ZNSA-2020001]	This project was supported by the Guangzhou Institute of Respiratory Health Open Project (Funds provided by China Evergrande Group) (Project No: 2020GIRHHMS04), and the Zhongnanshan Medical Foundation of Guangdong Province (Project No: ZNSA-2021005 and Project No: ZNSA-2020001).	Alshoabi Sultan A, 2021, J Taibah Univ Med Sci, V16, P637, DOI 10.1016/j.jtumed.2021.01.014; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Anichini G, 2021, NEW ENGL J MED, V385, P90, DOI 10.1056/NEJMc2103825; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525; Bubar Kate M, 2021, medRxiv, DOI [10.1101/2020.09.08.20190629, 10.1126/science.abe6959]; Buckner JH, 2020, OPTIMAL DYNAMIC PRIO, DOI [10.1101/2020.09.22.20199174, DOI 10.1101/2020.09.22.20199174]; Callaway E, 2021, NATURE, V593, P491, DOI 10.1038/d41586-021-01359-3; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Chen Xinhua, 2021, medRxiv, DOI 10.1101/2021.05.03.21256506; Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y; Chowdhury MA, 2020, J INFECT PUBLIC HEAL, V13, P1619, DOI 10.1016/j.jiph.2020.07.001; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; Diamond Michael, 2021, Res Sq, DOI 10.21203/rs.3.rs-228079/v1; Diamond MS, 2015, CELL, V162, P488, DOI 10.1016/j.cell.2015.07.005; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Edara VV, 2021, JAMA-J AM MED ASSOC, V325, P1896, DOI 10.1001/jama.2021.4388; Edara Venkata-Viswanadh, 2021, bioRxiv, DOI 10.1101/2021.05.09.443299; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Gao GF., 2021, BIORXIV; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Huang BY, 2021, LANCET MICROBE, V2, pE285, DOI 10.1016/S2666-5247(21)00082-3; Huang Yang, 2020, Antib Ther, V3, P285, DOI 10.1093/abt/tbaa028; Jarjour NN, 2021, IMMUNITY, V54, P14, DOI 10.1016/j.immuni.2020.12.009; Karthik K, 2020, HUM VACC IMMUNOTHER, V16, P3055, DOI 10.1080/21645515.2020.1796425; Khan M, 2020, J MED MICROBIOL, V69, P1114, DOI 10.1099/jmm.0.001231; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lewis D, 2021, NATURE, V595, P344, DOI 10.1038/d41586-021-01805-2; Li Dapeng, 2021, bioRxiv, DOI 10.1101/2020.12.31.424729; Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Liu YF, 2021, CELL, V184, P3452, DOI 10.1016/j.cell.2021.05.032; Liu Yang, 2021, N Engl J Med, DOI 10.1056/NEJMc2102017; Lotfi R, 2021, IMMUNOL RES, V69, P213, DOI 10.1007/s12026-021-09198-0; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Ngono AE, 2018, ANNU REV IMMUNOL, V36, P279, DOI 10.1146/annurev-immunol-042617-053142; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rey FA, 2018, EMBO REP, V19, P206, DOI 10.15252/embr.201745302; Robbiani Davide F, 2020, bioRxiv, DOI 10.1101/2020.05.13.092619; Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Shah VK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01949; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; SUN BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI [DOI 10.1080/22221751.2020.1762515, 10.1080/22221751.2020.1762515]; Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367; Turner JS, 2021, NATURE, V595, P421, DOI 10.1038/s41586-021-03647-4; Wall EC, 2021, LANCET, V397, P2331, DOI 10.1016/S0140-6736(21)01290-3; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang GL, 2021, NEW ENGL J MED, V384, P2354, DOI 10.1056/NEJMc2103022; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Winkler ES, 2021, CELL, V184, P1804, DOI 10.1016/j.cell.2021.02.026; World Health Organization, TRACK SARS COV 2 VAR; Wu K, 2021, VACCINE, V39, P7394, DOI [10.1101/2021.04.13.439482, 10.1016/j.vaccine.2021.11.001]; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461; Xie JJ, 2020, J MED VIROL, V92, P2004, DOI 10.1002/jmv.25930; Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08; Yurkovetskiy Leonid, 2020, bioRxiv, DOI 10.1101/2020.07.04.187757; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	67	5	5	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							869	10.3390/vaccines9080869			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7ZY	34451994	gold, Green Published			2022-04-29	WOS:000690145000001
J	Do Minh, A; Kamen, AA				Do Minh, Aline; Kamen, Amine A.			Critical Assessment of Purification and Analytical Technologies for Enveloped Viral Vector and Vaccine Processing and Their Current Limitations in Resolving Co-Expressed Extracellular Vesicles	VACCINES			English	Review						extracellular vesicles; enveloped viruses; lentiviral vectors; viral vaccines; purification process; analytical technologies	GENE-THERAPY VECTORS; DROPLET DIGITAL PCR; INFLUENZA-VIRUS; AFFINITY-CHROMATOGRAPHY; RETROVIRAL VECTORS; PARTICLES; MEMBRANE; EXOSOMES; PROTEINS; MICROVESICLES	Viral vectors and viral vaccines are invaluable tools in prevention and treatment of diseases. Many infectious diseases are controlled using vaccines designed from subunits or whole viral structures, whereas other genetic diseases and cancers are being treated by viruses used as vehicles for delivering genetic material in gene therapy or as therapeutic agents in virotherapy protocols. Viral vectors and vaccines are produced in different platforms, from traditional embryonated chicken eggs to more advanced cell cultures. All these expression systems, like most cells and cellular tissues, are known to spontaneously release extracellular vesicles (EVs). EVs share similar sizes, biophysical characteristics and even biogenesis pathways with enveloped viruses, which are currently used as key ingredients in a number of viral vectors and licensed vaccine products. Herein, we review distinctive features and similarities between EVs and enveloped viruses as we revisit the downstream processing steps and analytical technologies currently implemented to produce and document viral vector and vaccine products. Within a context of well-established viral vector and vaccine safety profiles, this review provides insights on the likely presence of EVs in the final formulation of enveloped virus products and discusses the potential to further resolve and document these components.	[Do Minh, Aline; Kamen, Amine A.] McGill Univ, Dept Bioengn, Montreal, PQ H3A 0E9, Canada		Kamen, AA (通讯作者)，McGill Univ, Dept Bioengn, Montreal, PQ H3A 0E9, Canada.	aline.dominh@mail.mcgill.ca; amine.kamen@mcgill.ca		Kamen, Amine/0000-0001-9110-8815	Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Research Chair of the government of Canada [CRC/240394]	A.D.M. is funded by a Natural Sciences and Engineering Research Council of Canada (NSERC) doctoral scholarship. A.A.K. is a recipient of a Canada Research Chair (CRC/240394) of the government of Canada.	Americo JL, 2017, VIROLOGY, V511, P19, DOI 10.1016/j.virol.2017.08.005; Andreu Z, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00442; Batrakova EV, 2015, J CONTROL RELEASE, V219, P396, DOI 10.1016/j.jconrel.2015.07.030; Besnard L, 2016, BIOTECHNOL ADV, V34, P1, DOI 10.1016/j.biotechadv.2015.11.005; Blom H, 2014, VACCINE, V32, P3721, DOI 10.1016/j.vaccine.2014.04.033; Boudeffa D, 2019, HUM GENE THER METHOD, V30, P153, DOI 10.1089/hgtb.2019.076; Bousse T, 2013, J VIROL METHODS, V193, P589, DOI 10.1016/j.jviromet.2013.07.026; Brgles M, 2016, J CHROMATOGR A, V1447, P107, DOI 10.1016/j.chroma.2016.04.022; Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007; Cheeks MC, 2009, J CHROMATOGR A, V1216, P2705, DOI 10.1016/j.chroma.2008.08.029; Corso G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10646-x; DeMarino C, 2019, JOVE-J VIS EXP, DOI 10.3791/59876; Do Minh A, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050797; El Bilali N, 2017, J VIROL, V91, DOI 10.1128/JVI.00320-17; Feng Zhaomin, 2017, Bing Du Xue Bao, V33, P1; Forcic D, 2011, J CHROMATOGR B, V879, P981, DOI 10.1016/j.jchromb.2011.03.012; Gelinas JF, 2020, METHODSX, V7, DOI 10.1016/j.mex.2020.100806; Geraerts M, 2005, J GENE MED, V7, P1299, DOI 10.1002/jgm.778; Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.1831413100; GOYAL SM, 1980, APPL ENVIRON MICROB, V39, P500, DOI 10.1128/AEM.39.3.500-504.1980; Heath N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24163-y; Jiang CP, 2004, J VIROL, V78, P8994, DOI 10.1128/JVI.78.17.8994-9006.2004; Joshi PRH, 2021, MOL THER-METH CLIN D, V21, P341, DOI 10.1016/j.omtm.2021.03.016; Joshi PRH, 2021, HUM GENE THER, V32, P1390, DOI 10.1089/hum.2020.317; Kishishita N, 2013, J CLIN MICROBIOL, V51, P1389, DOI 10.1128/JCM.03109-12; Konadu KA, 2016, JOVE-J VIS EXP, DOI 10.3791/53495; Kotrbova A, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2018.1560808; Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004; Kramberger P, 2015, HUM VACC IMMUNOTHER, V11, P1010, DOI 10.1080/21645515.2015.1009817; Kuiper M, 2002, BIOTECHNOL BIOENG, V80, P445, DOI 10.1002/bit.10388; Liangsupree T, 2021, J CHROMATOGR A, V1636, DOI 10.1016/j.chroma.2020.461773; Lippe R, 2018, J VIROL, V92, DOI 10.1128/JVI.01765-17; Lobb RJ, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27031; Lorbetskie B, 2011, VACCINE, V29, P3377, DOI 10.1016/j.vaccine.2011.02.090; Lynch KB, 2019, ANAL CHIM ACTA, V1046, P48, DOI 10.1016/j.aca.2018.09.021; McNamara RP, 2018, MBIO, V9, DOI 10.1128/mBio.02344-17; Michael W., 2011, U.S. Patent, Patent No. [US20110306114A1, 20110306114]; Mol EA, 2017, NANOMED-NANOTECHNOL, V13, P2061, DOI 10.1016/j.nano.2017.03.011; Moleirinho MG, 2020, EXPERT OPIN BIOL TH, V20, P451, DOI 10.1080/14712598.2020.1693541; Moreira AS, 2021, BIOTECHNOL J, V16, DOI 10.1002/biot.202000019; Nabhan JF, 2012, P NATL ACAD SCI USA, V109, P4146, DOI 10.1073/pnas.1200448109; NJAYOU M, 1991, J VIROL METHODS, V32, P67, DOI 10.1016/0166-0934(91)90186-4; Nolan JP, 2018, METHODS MOL BIOL, V1678, P79, DOI 10.1007/978-1-4939-7346-0_5; Nolte-'t Hoen E, 2016, P NATL ACAD SCI USA, V113, P9155, DOI 10.1073/pnas.1605146113; Olgun Hazal Banu, 2019, Methods Mol Biol, V1879, P347, DOI 10.1007/7651_2018_154; OLOFSSON S, 1981, J VIROL, V38, P564, DOI 10.1128/JVI.38.2.564-570.1981; Opitz L, 2007, VACCINE, V25, P939, DOI 10.1016/j.vaccine.2006.08.043; Opitz L, 2009, J VIROL METHODS, V161, P312, DOI 10.1016/j.jviromet.2009.06.025; Orr V, 2013, BIOTECHNOL ADV, V31, P450, DOI 10.1016/j.biotechadv.2013.01.007; Perry C, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020268; Phillips W, 2021, PROTEOMICS, V21, DOI 10.1002/pmic.202000118; Raposo G, 2019, NAT REV MOL CELL BIO, V20, P509, DOI 10.1038/s41580-019-0158-7; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rikkert LG, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2018.1555419; Rodrigues T, 2007, J GENE MED, V9, P233, DOI 10.1002/jgm.1021; Rodrigues T, 2007, J BIOTECHNOL, V127, P520, DOI 10.1016/j.jbiotec.2006.07.028; Rossi CA, 2015, VIRUSES-BASEL, V7, P857, DOI 10.3390/v7030857; Sampey GC, 2016, J BIOL CHEM, V291, P1251, DOI 10.1074/jbc.M115.662171; Schmidt S.R., 2017, BIOPROCESS INT, V16, P6; Segura MM, 2008, J VIROL, V82, P1107, DOI 10.1128/JVI.01909-07; Segura MD, 2005, BIOTECHNOL BIOENG, V90, P391; SUNI J I, 1984, Vaccine, V2, P281, DOI 10.1016/0264-410X(84)90045-8; Sviben D, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1073-9; Tang VA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18227-8; Tang VA, 2016, VACCINE, V34, P5082, DOI 10.1016/j.vaccine.2016.08.074; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Transfiguracion J, 2004, J CHROMATOGR B, V813, P167, DOI 10.1016/j.jchromb.2004.09.034; Transfiguracion J, 2020, MOL THER-METH CLIN D, V18, P803, DOI 10.1016/j.omtm.2020.08.005; U.S. Food and Drug Administration, APPR CELL GEN THER P; U.S. Food and Drug Administration, VACC LIC US US; U.S. Food Drug Administration, 2018, PACK INS PAT INF IXI; U.S. Food Drug Administration, 2019, PACK INS JYNNEOS; van der Pol E, 2010, J THROMB HAEMOST, V8, P2596, DOI 10.1111/j.1538-7836.2010.04074.x; Van Deun J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24858; Wang FZ, 2019, J GENE MED, V21, DOI 10.1002/jgm.3108; Wang Y, 2018, HUM GENE THER METHOD, V29, P96, DOI 10.1089/hgtb.2017.198; Wolff MW, 2008, CHEM ENG TECHNOL, V31, P846, DOI 10.1002/ceat.200800118; Yang L, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01500; Ye KM, 2004, J VIROL, V78, P9820, DOI 10.1128/JVI.78.18.9820-9827.2004; Zhao MC, 2019, VACCINE, V37, P5491, DOI 10.1016/j.vaccine.2018.02.090; Zimmermann K, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-55	82	2	2	7	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							823	10.3390/vaccines9080823			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8OO	34451948	Green Published			2022-04-29	WOS:000690183000001
J	Zheng, BW; Suleman, M; Zafar, Z; Ali, SS; Nasir, SN; Namra; Hussain, Z; Waseem, M; Khan, A; Hassan, F; Wang, YJ; Wei, DQ				Zheng, Bowen; Suleman, Muhammad; Zafar, Zonara; Ali, Syed Shujait; Nasir, Syed Nouman; Namra; Hussain, Zahid; Waseem, Muhammad; Khan, Abbas; Hassan, Fakhrul; Wang, Yanjing; Wei, Dongqing			Towards an Ensemble Vaccine against the Pegivirus Using Computational Modelling Approaches and Its Validation through In Silico Cloning and Immune Simulation	VACCINES			English	Article						Pegivirus; epitopes; vaccine designing; in silico cloning; immune simulation	NON-HODGKIN-LYMPHOMA; PROTEIN-STRUCTURE PREDICTION; EPITOPES; RISK; INFECTION; DIAGNOSIS; SERVER; AMBER; CELL; WEB	Pegivirus, HPgV, which was earlier known as Gb virus and hepatitis G virus, is an enveloped, positive-stranded RNA and lymphotropic virus classified into the Flaviviridae family. The transmission routes primarily involve blood products, and infections are worldwide, leading up to 25% of persistent infections. To date, no effective therapeutic means are available to clear Pegivirus infections. Effective vaccine therapeutics is the best alternative to manage this disease and any associated potential pandemic. Thus, whole proteome-based mining of immunogenic peptides, i.e., CTL (cytotoxic T lymphocytes), HTL (helper T lymphocytes), and B cell epitopes, was mapped to design a vaccine ensemble. Our investigation revealed that 29 different epitopes impart a critical role in immune response induction, which was also validated by exploring its physiochemical properties and experimental feasibility. In silico expression and host immune simulation were examined using an agent-based modeling approach and confirmed the induction of both primary and secondary immune factors such as IL, cytokines, and antibodies. The current study warrants further lab experiments to demonstrate its efficacy and safety.	[Zheng, Bowen] Shanxi Univ, Sch Life Sci, Taiyuan 030006, Peoples R China; [Suleman, Muhammad; Ali, Syed Shujait; Hussain, Zahid] Univ Swat, Ctr Biotechnol & Microbiol, Swat 01923, Pakistan; [Zafar, Zonara] Univ Agr Faisalabad, Ctr Agr Biochem & Biotechnol, Faisalabad 38000, Pakistan; [Nasir, Syed Nouman] Quaid I Azam Univ, Natl Ctr Bioinformat, Islamabad 45320, Pakistan; [Namra; Khan, Abbas; Wang, Yanjing; Wei, Dongqing] Riphah Int Univ, Fac Rehabil & Allied Hlth Sci, Islamabad 46000, Pakistan; [Waseem, Muhammad] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biol Stat, Shanghai 200240, Peoples R China; [Hassan, Fakhrul] Univ Elect Sci & Technol China, Sch Life Sci & Technol, Chengdu 610054, Peoples R China; [Wei, Dongqing] Peng Cheng Lab, Shenzhen 518055, Peoples R China; [Wei, Dongqing] Shanghai Jiao Tong Univ, Minist Educ, State Key Lab Microbial Metab, Shanghai Islamabad Belgrade Joint Innovat Ctr Ant, Shanghai 200030, Peoples R China; [Wei, Dongqing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China		Khan, A (通讯作者)，Riphah Int Univ, Fac Rehabil & Allied Hlth Sci, Islamabad 46000, Pakistan.	bowen0513@foxmail.com; suleman@uswat.edu.pk; zony_bbt@yahoo.com; shujaitswati@uswat.edu.pk; nnasir@bs.qau.edu.pk; namraahmad444@icloud.com; zahid@uswat.edu.pk; m.waseem@riphah.edu.pk; abbaskhan@sjtu.edu.cn; fakhar_ibneadam@yahoo.com; wangyanjing@sjtu.edu.cn; dqwei@sjtu.edu.cn	Hassan, Fakhrul/AAK-4965-2021; Khan, Abbas/AAF-2409-2020; Hussain, Zahid/ABB-5830-2021	Hassan, Fakhrul/0000-0001-7540-9888; Wang, Yanjing/0000-0001-6826-1635	Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2016YFA0501703]; National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32070662, 61832019, 32030063]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [19430750600]; SJTU JiRLMDS Joint Research Fund; Joint Research Funds for Medical and Engineering and Scientific Research at Shanghai Jiao Tong University [YG2021ZD02]	D.W. is supported by grants from the Key Research Area Grant 2016YFA0501703 of the Ministry of Science and Technology of China, the National Science Foundation of China (Grant No. 32070662, 61832019, 32030063), the Science and Technology Commission of Shanghai Municipality (Grant No.: 19430750600), as well as SJTU JiRLMDS Joint Research Fund and Joint Research Funds for Medical and Engineering and Scientific Research at Shanghai Jiao Tong University (YG2021ZD02).	Ansell SM, 2005, MAYO CLIN PROC, V80, P1087, DOI 10.4065/80.8.1087; Ansell SM, 2015, MAYO CLIN PROC, V90, P1152, DOI 10.1016/j.mayocp.2015.04.025; Arroyave-Ospina JC, 2018, REV CHIL INFECTOL, V35, P164, DOI 10.4067/s0716-10182018000200164; Balcom EF, 2018, ANN NEUROL, V84, P781, DOI 10.1002/ana.25343; Bonilla FA, 2010, J ALLERGY CLIN IMMUN, V125, pS33, DOI 10.1016/j.jaci.2009.09.017; Chang CM, 2014, CANCER RES, V74, P5553, DOI 10.1158/0008-5472.CAN-14-0209; Chen ZW, 2021, J CELL MOL MED, V25, P1274, DOI 10.1111/jcmm.16200; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893; Fama A, 2020, CLIN INFECT DIS, V71, P1221, DOI 10.1093/cid/ciz940; Fatoba AJ, 2021, VACCINE, V39, P1111, DOI 10.1016/j.vaccine.2021.01.003; Feng Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021151; Gasteiger E., 2005, PROTEOM PROTOC HDB, P571, DOI [10.1385/1-59259-890-0:571, 10.1385/1-59259-890, DOI 10.1385/1592598900]; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Hennessy BT, 2004, LANCET ONCOL, V5, P341, DOI 10.1016/S1470-2045(04)01490-1; Horemheb-Rubio G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184494; Izumi T, 2019, J MED VIROL, V91, P2093, DOI 10.1002/jmv.25555; Keith RobertsPW., 2018, MOL BIOL CELL; Khan A, 2021, CHEMBIOCHEM, V22, P2641, DOI 10.1002/cbic.202100191; Khan A, 2021, COMPUT BIOL MED, V133, DOI 10.1016/j.compbiomed.2021.104420; Khan A, 2021, J CELL PHYSIOL, V236, P7045, DOI 10.1002/jcp.30367; Khan A, 2020, INTERDISCIP SCI, V12, P335, DOI 10.1007/s12539-020-00381-9; Khan A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196484; Khan M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49354-z; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493; Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424; Laskowski RA, 2005, NUCLEIC ACIDS RES, V33, pD266, DOI 10.1093/nar/gki001; Lee H, 2018, CANCER RES TREAT, V50, P222, DOI 10.4143/crt.2017.093; Liu WP, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0706-9; Marano G, 2017, ACTA VIROL, V61, P401, DOI 10.4149/av_2017_402; Maurer-Stroh S, 2019, BIOINFORMATICS, V35, P3020, DOI 10.1093/bioinformatics/btz029; Mokdad AH, 2017, JAMA-J AM MED ASSOC, V317, P388, DOI 10.1001/jama.2016.20324; Mukherjee S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020290; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Polgreen PM, 2003, MICROBES INFECT, V5, P1255, DOI 10.1016/j.micinf.2003.08.006; Rapin N, 2011, BIOINFORMATICS, V27, P2013, DOI 10.1093/bioinformatics/btr335; Ravichandran L, 2019, J CELL BIOCHEM, V120, P7082, DOI 10.1002/jcb.27979; Salles Gilles A, 2007, Hematology Am Soc Hematol Educ Program, P216; Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121; Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0; UNICEF, 2007, GLOB IMM DAT; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Vitrenko Y, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0837-y; Wang W, 2016, DATA BRIEF, V9, P345, DOI 10.1016/j.dib.2016.05.025; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Yan YM, 2017, NUCLEIC ACIDS RES, V45, pW365, DOI 10.1093/nar/gkx407; Zaharieva N., 2017, J PROTEOM BIOINFORM, V10, P11, DOI [10.4172/jpb.1000454, DOI 10.4172/JPB.1000454]; Zheng LN, 2011, FOOD CHEM TOXICOL, V49, P2954, DOI 10.1016/j.fct.2011.07.043; Zintzaras E, 2005, ARCH INTERN MED, V165, P2337, DOI 10.1001/archinte.165.20.2337	52	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							818	10.3390/vaccines9080818			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9GO	34451943	Green Published			2022-04-29	WOS:000690229800001
J	Aartse, A; Eggink, D; Claireaux, M; van Leeuwen, S; Mooij, P; Bogers, WM; Sanders, RW; Koopman, G; van Gils, MJ				Aartse, Aafke; Eggink, Dirk; Claireaux, Mathieu; van Leeuwen, Sarah; Mooij, Petra; Bogers, Willy M.; Sanders, Rogier W.; Koopman, Gerrit; van Gils, Marit J.			Influenza A Virus Hemagglutinin Trimer, Head and Stem Proteins Identify and Quantify Different Hemagglutinin-Specific B Cell Subsets in Humans	VACCINES			English	Article						antibody responses; influenza A virus; hemagglutinin; trimer specific; head; stem	GLOBULAR HEAD; MONOCLONAL-ANTIBODIES; NEUTRALIZING ANTIBODY; RECEPTOR-BINDING; SINGLE HUMAN; EPITOPE; SITE; IMMUNODOMINANCE; RECOGNITION; VACCINATION	Antibody responses against the influenza A virus hemagglutinin (HA)-protein are studied intensively because they can protect against (re)infection. Previous studies have focused on antibodies targeting the head or stem domains, while other possible specificities are often not taken into account. To study such specificities, we developed a diverse set of HA-domain proteins based on an H1N1(pdm2009)-like influenza virus strain, including monomeric head and trimeric stem domain, as well as the full HA-trimer. These proteins were used to study the B cell and antibody responses in six healthy human donors. A large proportion of HA-trimer B cells bound exclusively to HA-trimer probe (54-77%), while only 8-18% and 9-23% were able to recognize the stem or head probe, respectively. Monoclonal antibodies (mAbs) were isolated and three of these mAbs, targeting the different domains, were characterized in-depth to confirm the binding profile observed in flow cytometry. The head-directed mAb, targeting an epitope distinct from known head-specific mAbs, showed relatively broad H1N1 neutralization and the stem-directed mAb was able to broadly neutralize diverse H1N1 viruses. Moreover, we identified a trimer-directed mAb that did not compete with known head or stem domain specific mAbs, suggesting that it targets an unknown epitope or conformation of influenza virus' HA. These observations indicate that the described method can characterize the diverse antibody response to HA and might be able to identify HA-specific B cells and antibodies with previously unknown specificities that could be relevant for vaccine design.	[Aartse, Aafke; Mooij, Petra; Bogers, Willy M.; Koopman, Gerrit] Biomed Primate Res Ctr, Dept Virol, NL-2288 GJ Rijswijk, Netherlands; [Aartse, Aafke; Eggink, Dirk; Claireaux, Mathieu; van Leeuwen, Sarah; Sanders, Rogier W.; van Gils, Marit J.] Univ Amsterdam, Amsterdam UMC, Dept Med Microbiol, Amsterdam Infect & Immun Inst, NL-1105 AZ Amsterdam, Netherlands; [Sanders, Rogier W.] Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA		Koopman, G (通讯作者)，Biomed Primate Res Ctr, Dept Virol, NL-2288 GJ Rijswijk, Netherlands.; van Gils, MJ (通讯作者)，Univ Amsterdam, Amsterdam UMC, Dept Med Microbiol, Amsterdam Infect & Immun Inst, NL-1105 AZ Amsterdam, Netherlands.	a.aartse@amsterdamumc.nl; w.d.eggink@amsterdamumc.nl; m.a.claireaux@amsterdamumc.nl; s.vanleeuwenl@amsterdamumc.nl; mooij@bprc.nl; bogers@bprc.nl; r.w.sanders@amsterdamumc.nl; koopman@bprc.nl; m.j.vangils@amsterdamumc.nl		Mooij, Petra/0000-0001-8608-8629; van Gils, Marit J./0000-0003-3422-8161; Bogers, Willy/0000-0002-4563-8513; Koopman, Gerrit/0000-0002-3428-5978	Netherlands Organization for Scientific Research (NWO) Vici grantNetherlands Organization for Scientific Research (NWO); AMC Fellowship, Amsterdam UMC	This study was supported by The Netherlands Organization for Scientific Research (NWO) Vici grant (to R.W.S.); M.J.v.G. is a recipient of an AMC Fellowship, Amsterdam UMC.	Altman MO, 2018, VIRAL IMMUNOL, V31, P142, DOI 10.1089/vim.2017.0129; Altman MO, 2015, ELIFE, V4, DOI 10.7554/eLife.07467; Andrews SF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0522; Angeletti D, 2019, P NATL ACAD SCI USA, V116, P13474, DOI 10.1073/pnas.1816300116; Bangaru S, 2019, CELL, V177, P1136, DOI 10.1016/j.cell.2019.04.011; Bangaru S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04704-9; Benckert J, 2011, J CLIN INVEST, V121, P1946, DOI 10.1172/JCI44447; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Brandenburg B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080034; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Burke DF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112302; Cao LW, 2018, NAT PROTOC, V13, P1196, DOI 10.1038/nprot.2018.024; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; De Jong NMC, 2020, EXPERT REV VACCINES, V19, P563, DOI 10.1080/14760584.2020.1777861; Dong JH, 2020, J CLIN INVEST, V130, P4734, DOI 10.1172/JCI136032; Dugan HL, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abd3601; Eggink D, 2020, J VIROL, V94, DOI 10.1128/JVI.00195-20; Eggink D, 2014, J VIROL, V88, P699, DOI 10.1128/JVI.02608-13; Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Friesen RHE, 2014, P NATL ACAD SCI USA, V111, P445, DOI 10.1073/pnas.1319058110; Fu Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12780; Garten RJ, 2009, SCIENCE, V325, P197, DOI 10.1126/science.1176225; GERHARD W, 1981, NATURE, V290, P713, DOI 10.1038/290713a0; Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/nmeth.1318, 10.1038/NMETH.1318]; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Guthmiller JJ, 2018, CURR OPIN IMMUNOL, V53, P187, DOI 10.1016/j.coi.2018.05.010; Hai R, 2012, J VIROL, V86, P5774, DOI 10.1128/JVI.00137-12; Heaton NS, 2013, J VIROL, V87, P8272, DOI 10.1128/JVI.00969-13; Henry C, 2019, J VIROL, V93, DOI 10.1128/JVI.01150-19; Ho IY, 2016, J IMMUNOL METHODS, V438, P67, DOI 10.1016/j.jim.2016.09.001; Hong MS, 2013, J VIROL, V87, P12471, DOI 10.1128/JVI.01388-13; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Knight M, 2020, IMMUNOL REV, V296, P191, DOI 10.1111/imr.12900; Kosik I, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040346; Koutsakos M, 2021, IMMUNOL CELL BIOL, V99, P97, DOI 10.1111/imcb.12383; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Krause J.C., 2015, ANTIBODIES INFECT DI, V2, P209; Krause JC, 2011, J VIROL, V85, P10905, DOI 10.1128/JVI.00700-11; Kuraoka M, 2020, INT IMMUNOL, V32, P605, DOI 10.1093/intimm/dxaa028; Lee J, 2016, NAT MED, V22, P1456, DOI 10.1038/nm.4224; Lewnard JA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020028; Martin J, 1998, VIROLOGY, V241, P101, DOI 10.1006/viro.1997.8958; McCarthy KR, 2018, IMMUNITY, V48, P174, DOI 10.1016/j.immuni.2017.12.009; OKUNO Y, 1993, J VIROL, V67, P2552, DOI 10.1128/JVI.67.5.2552-2558.1993; Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sangster MY, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040167; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Sliepen K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10262-5; Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211; Tan GS, 2012, J VIROL, V86, P6179, DOI 10.1128/JVI.00469-12; Tan HX, 2019, J CLIN INVEST, V129, P850, DOI 10.1172/JCI123366; Thompson AJ, 2020, CELL HOST MICROBE, V27, P725, DOI 10.1016/j.chom.2020.03.009; Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Turner HL, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000139; van Gils MJ, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.199; Vanderen HA, 2018, J INFECT DIS, V218, P1383, DOI 10.1093/infdis/jiy328; Watanabe A, 2019, CELL, V177, P1124, DOI 10.1016/j.cell.2019.03.048; Whittle JRR, 2014, J VIROL, V88, P4047, DOI 10.1128/JVI.03422-13; Wu NC, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a038778; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Zhuang QY, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1188-7	64	1	1	1	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							717	10.3390/vaccines9070717			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6LJ	34358138	Green Published, gold			2022-04-29	WOS:000677020200001
J	Fayed, AA; Al Shahrani, AS; Almanea, LT; Alsweed, NI; Almarzoug, LM; Almuwallad, RI; Almugren, WF				Fayed, Amel Ahmed; Al Shahrani, Abeer Salem; Almanea, Leenah Tawfiq; Alsweed, Nardeen Ibrahim; Almarzoug, Layla Mohammed; Almuwallad, Reham Ibrahim; Almugren, Waad Fahad			Willingness to Receive the COVID-19 and Seasonal Influenza Vaccines among the Saudi Population and Vaccine Uptake during the Initial Stage of the National Vaccination Campaign: A Cross-Sectional Survey	VACCINES			English	Article						COVID-19; seasonal influenza; vaccine; uptake; pandemic; Saudi Arabia	INFORMATION	This study aimed to assess the willingness to receive the coronavirus disease 2019 (COVID-19) and seasonal influenza vaccines and vaccine uptake during the early stage of the national vaccination campaign in Saudi Arabia. A cross-sectional online survey was conducted among adult Saudis between 20 January and 20 March 2021. The questionnaire addressed vaccine hesitancy, perceived risk, willingness, and vaccine uptake. Approximately 39% of the participants expressed vaccine hesitancy, and 29.8% and 24% felt highly vulnerable to contracting COVID-19 and seasonal influenza, respectively. The majority (59.5%) were willing to receive the COVID-19 vaccine, although only 31.7% were willing to receive the flu vaccine. Adjusted analysis showed that vaccine hesitancy (OR 0.34, 95% CI 0.27-0.43) and the perception of being at high risk (OR 2.78, 95% CI 1.68-4.60) independently affected the intention to be vaccinated. Vaccine hesitancy was similar among those who were willing to be vaccinated (29.8%) and those who had already been vaccinated (33.1%). The perceived risk was significantly higher among those who had been vaccinated (48.1%) than among those who were willing to be vaccinated but had not yet been vaccinated (29.1%). In conclusion, the acceptance of the COVID-19 vaccine in Saudi Arabia is high. Saudis who received the vaccine had a similar level of vaccine hesitancy and a higher level of perceived risk.	[Fayed, Amel Ahmed; Al Shahrani, Abeer Salem; Almanea, Leenah Tawfiq; Alsweed, Nardeen Ibrahim; Almarzoug, Layla Mohammed; Almuwallad, Reham Ibrahim; Almugren, Waad Fahad] Princess Nourah Bint Abdulrahman Univ, Coll Med, Dept Clin Sci, Riyadh 13412, Saudi Arabia		Al Shahrani, AS (通讯作者)，Princess Nourah Bint Abdulrahman Univ, Coll Med, Dept Clin Sci, Riyadh 13412, Saudi Arabia.	aafayed@pnu.edu.sa; asalshahran@pnu.edu.sa; Almanea.l.t77@gmail.com; Harnard222@gmail.com; Almarzouq.layla@gmail.com; Rihamsaeed4444@gmail.com; Waadfahadl@hotmail.com	Fayed, Amel A/H-8588-2016; Shahrani, Abeer S Al/N-3413-2018	Fayed, Amel A/0000-0003-3395-0486; 	Deanship of Scientific Research at Princess Nourah bint; Abdulrahman University through the Fast-track Research Funding Program [42-FTTJ-48]	This research was funded by the Deanship of Scientific Research at Princess Nourah bint. Abdulrahman University through the Fast-track Research Funding Program to support publication in the top journal (Grant no. 42-FTTJ-48).	Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alfageeh EI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030226; Ali SH, 2020, JMIR PUBLIC HLTH SUR, V6, P154, DOI 10.2196/21071; [Anonymous], 2020, LANCET INFECT DIS, V20, P875, DOI 10.1016/S1473-3099(20)30565-X; [Anonymous], COVID 19 DASHBOARD; [Anonymous], ARAB NEWS; [Anonymous], CORONAVIRUS COVID 19; [Anonymous], Individuals Using the Internet (% of Population)-Saudi Arabia; [Anonymous], MOH CONSIDERING MAKI; [Anonymous], EMBASSY KINGDOM SAUD; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Centers for Disease Control and Prevention, POL VACC INF HEALTHC POL VACC INF HEALTHC; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Commodari E, 2017, SAGE OPEN, V7, DOI 10.1177/2158244017718890; Elhadad MK, 2020, IEEE ACCESS, V8, P165201, DOI 10.1109/ACCESS.2020.3022867; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; General Authority for Statistics, KINGDOM SAUDI ARABIA; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Jackson SE, 2021, NICOTINE TOB RES, V23, P1623, DOI 10.1093/ntr/ntab039; Jacobson RM, 2015, MAYO CLIN PROC, V90, P1562, DOI 10.1016/j.mayocp.2015.09.006; Jiang C, 2020, MICROBES INFECT, V22, P236, DOI 10.1016/j.micinf.2020.05.005; Johns Hopkins University & Medicine, COR RES CTR COVID 19; Karlsson LC, 2021, PERS INDIV DIFFER, V172, DOI 10.1016/j.paid.2020.110590; Konala Venu Madhav, 2020, Eur J Case Rep Intern Med, V7, P001656, DOI 10.12890/2020_001656; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mameli C, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00317; Mello MM, 2020, NEW ENGL J MED, V383, P1296, DOI 10.1056/NEJMp2020926; Ozaras R, 2020, J MED VIROL, V92, P2657, DOI 10.1002/jmv.26125; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Rey D, 2018, EUROSURVEILLANCE, V23, P30, DOI [10.2807/1560-7917.ES.23.17.17-00816, 10.2807/1560-7917.ES.2018.23.17.17-00816]; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Rossi R, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10185; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Saudi Press Agency, SAUD PRESS HLTH MIN SAUD PRESS HLTH MIN; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; WHO, EP PAND PRON DIS; WHO, COVID 19 VACC; WHO, INFL SEAS; WHO SAGE, SEASONAL INFLUENZA V	40	5	5	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							765	10.3390/vaccines9070765			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8JW	34358181	gold, Green Published			2022-04-29	WOS:000677151500001
J	Ferrara, G; Ivaldi, F; Mancardi, G; de Rosbo, NK; Uccelli, A				Ferrara, Giovanni; Ivaldi, Federico; Mancardi, Gianluigi; de Rosbo, Nicole Kerlero; Uccelli, Antonio			Bone Marrow Transfer in Relapsing-Remitting EAE Ameliorates Disease at First Remission, with No Synergistic Effect upon Co-Transplantation with Mesenchymal Stem Cells	VACCINES			English	Article						stem cell therapy; multiple sclerosis; intensive immunosuppression; experimental autoimmune encephalomyelitis; bone-marrow cells; mesenchymal stem cells	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; INDUCTION; EPITOPE; PREVENTION; TOLERANCE; RECOVERY	Multiple sclerosis (MS) is a neurological disorder characterized by an autoimmune response, demyelinating plaques and axonal damage. Intense immunosuppression (II) followed by autologous hematopoietic stem cell transplantation has been proposed as a treatment in severe forms of MS. We have used murine relapsing-remitting (RR) experimental autoimmune encephalomyelitis (RR-EAE) to evaluate the transplantation of syngeneic bone marrow cells (BMC) after II, in combination with mesenchymal stem cells (MSCs) as a new therapeutic adjunct capable of improving immune reconstitution. In EAE-affected mice treated with BMC alone, we observed a drastic reduction in the clinical course only during the early RR phase of the disease. There was no difference in the RR-EAE clinical course between mice treated with BMC alone and co-transplanted mice. To analyze the immune reconstitution, we quantified the circulating immune cells in naive and RR-EAE-affected mice after II, with BMC alone or in combination with MSC. Although II resulted in reduced numbers of circulating immune cells, reconstitution did not differ in co-transplanted mice. During the early phase of the disease, IL-4 was significantly elevated in co-transplanted mice, as compared to those treated with BMC alone. These data suggest that BMC transplantation after II transiently ameliorates the clinical symptoms of RR-EAE, but that co-transplantation with MSC has no synergistic effect.	[Ferrara, Giovanni; Ivaldi, Federico; Uccelli, Antonio] Osped Policlin San Martino IRCCS, I-16132 Genoa, Italy; [Ivaldi, Federico; Mancardi, Gianluigi; de Rosbo, Nicole Kerlero; Uccelli, Antonio] Univ Genoa, Dept Neurol Rehabil Ophthalmol Genet Maternal & C, I-16132 Genoa, Italy; [Mancardi, Gianluigi] IRCCS, ICS Maugeri, I-27100 Pavia, Italy		Ferrara, G (通讯作者)，Osped Policlin San Martino IRCCS, I-16132 Genoa, Italy.	Giovanni.Ferrara@hsanmartino.it; ivaldi@email.it; glmancardi@neurologia.unige.it; nicole.kerleroderosbo@unige.it; auccelli@neurologia.unige.it	Mancardi, Giovanni Luigi/K-8656-2016; Ferrara, Giovanni/D-8550-2015; UCCELLI, Antonio/E-7343-2012	Mancardi, Giovanni Luigi/0000-0001-8427-118X; Ferrara, Giovanni/0000-0002-4442-8864; UCCELLI, Antonio/0000-0002-2008-6038			Al Jumah MA, 2012, INT J MOL SCI, V13, P9298, DOI 10.3390/ijms13079298; Baecher-Allan C, 2018, NEURON, V97, P742, DOI 10.1016/j.neuron.2018.01.021; Bai L, 2012, NAT NEUROSCI, V15, P862, DOI 10.1038/nn.3109; Chiesa S, 2011, P NATL ACAD SCI USA, V108, P17384, DOI 10.1073/pnas.1103650108; Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871; Derdelinckx J, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1541-1; Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076; Guenova E, 2015, P NATL ACAD SCI USA, V112, P2163, DOI 10.1073/pnas.1416922112; Gutcher I, 2007, J CLIN INVEST, V117, P1119, DOI 10.1172/JCI31720; Hemmer B, 2015, LANCET NEUROL, V14, P406, DOI 10.1016/S1474-4422(14)70305-9; Jitschin R, 2013, STEM CELLS, V31, P1715, DOI 10.1002/stem.1386; Karussis D, 1999, MULT SCLER, V5, P17, DOI 10.1177/135245859900500104; Karussis D, 2004, J NEUROL SCI, V223, P59, DOI 10.1016/j.jns.2004.04.021; KARUSSIS DM, 1993, J CLIN INVEST, V92, P765, DOI 10.1172/JCI116648; KARUSSIS DM, 1992, J IMMUNOL, V148, P1693; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Lazarus HM, 2005, BIOL BLOOD MARROW TR, V11, P389, DOI 10.1016/j.bbmt.2005.02.001; Le Blanc K, 2007, LEUKEMIA, V21, P1733, DOI 10.1038/sj.leu.2404777; MCRAE BL, 1992, J NEUROIMMUNOL, V38, P229, DOI 10.1016/0165-5728(92)90016-E; MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75; Mills SY, 2007, COMPLEMENT THER MED, V15, P1, DOI [10.1016/j.ctim.2007.01.003, 10.1002/0471142735.im1501s88, 10.1002/0471142735.im1501s77]; Mitchell RE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11803-y; MIURA N, 1993, EXP HEMATOL, V21, P143; Morando S, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt94; Muraro PA, 2005, J EXP MED, V201, P805, DOI 10.1084/jem.20041679; Muraro PA, 2017, JAMA NEUROL, V74, P459, DOI 10.1001/jamaneurol.2016.5867; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Saccardi R, 2012, MULT SCLER J, V18, P825, DOI 10.1177/1352458512438454; Sormani MP, 2017, NEUROLOGY, V88, P2115, DOI 10.1212/WNL.0000000000003987; Steinman L, 2006, ANN NEUROL, V60, P12, DOI 10.1002/ana.20913; Thompson AJ, 2017, CURR OPIN NEUROL, V30, P237, DOI 10.1097/WCO.0000000000000453; Tintore M, 2019, NAT REV NEUROL, V15, P53, DOI 10.1038/s41582-018-0082-z; Tuohy VK, 1998, IMMUNOL REV, V164, P93, DOI 10.1111/j.1600-065X.1998.tb01211.x; van Bekkum DW, 2004, BEST PRACT RES CL HA, V17, P201, DOI 10.1016/j.beha.2004.04.003; VANGELDER M, 1993, BONE MARROW TRANSPL, V11, P233; vanGelder M, 1996, BONE MARROW TRANSPL, V18, P1029; Wang Y, 2006, BLOOD, V107, P358, DOI 10.1182/blood-2005-04-1418; Wei QZ, 2018, IMMUNITY, V48, P632, DOI 10.1016/j.immuni.2018.03.024; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Zhao K, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0276-z	40	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							736	10.3390/vaccines9070736			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7DE	34358152	Green Published, gold			2022-04-29	WOS:000677066500001
J	Gonzaga, ZJC; Merakou, C; DiGiandomenico, A; Priebe, GP; Rehm, BHA				Gonzaga, Zennia Jean C.; Merakou, Christina; DiGiandomenico, Antonio; Priebe, Gregory P.; Rehm, Bernd H. A.			A Pseudomonas aeruginosa-Derived Particulate Vaccine Protects against P. aeruginosa Infection	VACCINES			English	Article						Pseudomonas aeruginosa; polyhydroxyalkanoate; vaccine; protective immunity	OUTER-MEMBRANE PROTEIN; POLYHYDROXYALKANOATE BIOSYNTHESIS; DENDRITIC CELLS; LUNG INFECTION; PARTICLE-SIZE; OPRF-OPRI; T-CELL; ALGINATE; ANTIBODY; EXOPOLYSACCHARIDE	Despite numerous efforts to develop an effective vaccine against Pseudomonas aeruginosa, no vaccine has yet been approved for human use. This study investigates the utility of the P. aeruginosa inherently produced polyhydroxyalkanaote (PHA) inclusions and associated host-cell proteins (HCP) as a particulate vaccine platform. We further engineered PHA inclusions to display epitopes derived from the outer membrane proteins OprF/OprI/AlgE (Ag) or the type III secretion system translocator PopB. PHA and engineered PHA beads induced antigen-specific humoral, cell-mediated immune responses, anti-HCP and anti-polysaccharide Psl responses in mice. Antibodies mediated opsonophagocytic killing and serotype-independent protective immunity as shown by 100% survival upon challenge with P. aeruginosa in an acute pneumonia murine model. Vaccines were stable at 4 degrees C for at least one year. Overall, our data suggest that vaccination with subcellular empty PHA beads was sufficient to elicit multiple immune effectors that can prevent P. aeruginosa infection.	[Gonzaga, Zennia Jean C.; Rehm, Bernd H. A.] Griffith Univ, Ctr Cell Factories & Biopolymers CCFB, Griffith Inst Drug Discovery, Don Young Rd, Nathan, Qld 4111, Australia; [Merakou, Christina; Priebe, Gregory P.] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Div Crit Care Med, Boston, MA 02115 USA; [Merakou, Christina; Priebe, Gregory P.] Harvard Med Sch, Dept Anaesthesia, Boston, MA 02115 USA; [DiGiandomenico, Antonio] AstraZeneca, Biopharmaceut R&D, Microbial Sci, Discovery Microbiome, Gaithersburg, MD USA; [Priebe, Gregory P.] Boston Childrens Hosp, Dept Pediat, Div Infect Dis, Boston, MA 02115 USA; [Rehm, Bernd H. A.] Griffith Univ, Menzies Hlth Inst Queensland MHIQ, Gold Coast, Qld 4222, Australia		Rehm, BHA (通讯作者)，Griffith Univ, Ctr Cell Factories & Biopolymers CCFB, Griffith Inst Drug Discovery, Don Young Rd, Nathan, Qld 4111, Australia.; Rehm, BHA (通讯作者)，Griffith Univ, Menzies Hlth Inst Queensland MHIQ, Gold Coast, Qld 4222, Australia.	jean.gonzaga@griffithuni.edu.au; christina.merakou@gmail.com; antonio.digiandomenico@astrazeneca.com; gregory.priebe@childrens.harvard.edu; b.rehm@griffith.edu.au	Priebe, Gregory/AAG-4027-2021	Priebe, Gregory/0000-0001-9831-0354; Merakou, Christina/0000-0002-2098-599X; DiGiandomenico, Antonio/0000-0003-1745-647X; Rehm, Bernd/0000-0003-3908-8903	Australian Research Council (ARC)Australian Research Council [DP200100874, LE20010014]	B.H.A.R. acknowledges the support from the Australian Research Council (ARC) Discovery Project (DP200100874) and the ARC Linkage Infrastructure, Equipment and Facilities (LE20010014).	Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Baumann U, 2004, VACCINE, V22, P840, DOI 10.1016/j.vaccine.2003.11.029; Bayes HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090263; BRANDL H, 1988, APPL ENVIRON MICROB, V54, P1977, DOI 10.1128/AEM.54.8.1977-1982.1988; Brooun A, 2000, ANTIMICROB AGENTS CH, V44, P640, DOI 10.1128/AAC.44.3.640-646.2000; Chen K, 2011, IMMUNITY, V35, P997, DOI 10.1016/j.immuni.2011.10.018; Chen SX, 2019, FASEB J, V33, P7505, DOI 10.1096/fj.201802501RR; Choi KH, 2006, J MICROBIOL METH, V64, P391, DOI 10.1016/j.mimet.2005.06.001; Choi KH, 2005, NAT METHODS, V2, P443, DOI 10.1038/NMETH765; Cui ZY, 2015, APPL MICROBIOL BIOT, V99, P667, DOI 10.1007/s00253-014-6147-z; Das S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583008; De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006; Dey S, 2012, PROTEIN J, V31, P401, DOI 10.1007/s10930-012-9416-7; DiGiandomenico A, 2004, INFECT IMMUN, V72, P7012, DOI 10.1128/IAI.72.12.7012-7021.2004; DiGiandomenico A, 2012, J EXP MED, V209, P1273, DOI 10.1084/jem.20120033; Discola KF, 2014, J BIOL CHEM, V289, P3591, DOI 10.1074/jbc.M113.517920; Draper JL, 2012, BIOENGINEERED, V3, P203, DOI 10.4161/bioe.19567; Evert B, 2020, ACS APPL BIO MATER, V3, P8911, DOI 10.1021/acsabm.0c01195; FISHER MW, 1969, J BACTERIOL, V98, P835, DOI 10.1128/JB.98.2.835-836.1969; Foged C, 2005, INT J PHARMACEUT, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035; Gellatly SL, 2013, PATHOG DIS, V67, P159, DOI 10.1111/2049-632X.12033; Ghafoor A, 2011, APPL ENVIRON MICROB, V77, P5238, DOI 10.1128/AEM.00637-11; Gonzalez-Miro M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20205-7; Gonzalez-Miro M, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00291; Grage K, 2009, BIOMACROMOLECULES, V10, P660, DOI 10.1021/bm801394s; Grimwood K, 2015, HUM VACC IMMUNOTHER, V11, P14, DOI 10.4161/hv.34296; HATANO K, 1994, INFECT IMMUN, V62, P3608, DOI 10.1128/IAI.62.9.3608-3616.1994; Hay I.D., 2014, HYDROCARBON LIPID MI, P71; Hoffmann N, 2004, FEMS MICROBIOL LETT, V237, P1, DOI 10.1111/j.1574-6968.2004.tb09671.x; Huang M, 2014, INT J PHARMACEUT, V466, P139, DOI 10.1016/j.ijpharm.2014.03.015; KNIREL YA, 1990, CRIT REV MICROBIOL, V17, P273, DOI 10.3109/10408419009105729; Koh AY, 2009, INFECT IMMUN, V77, P5300, DOI 10.1128/IAI.00501-09; Kolls JK, 2003, AM J RESP CELL MOL, V28, P9, DOI 10.1165/rcmb.2002-0255PS; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Lee JW, 2017, SCI REP-UK, V7, DOI 10.1038/srep41607; Limbach LK, 2005, ENVIRON SCI TECHNOL, V39, P9370, DOI 10.1021/es051043o; Martinez-Donato G, 2016, CLIN VACCINE IMMUNOL, V23, P370, DOI 10.1128/CVI.00687-15; Merakou C, 2018, SURG INFECT, V19, P757, DOI 10.1089/sur.2018.233; MIZUNO T, 1978, J BIOCHEM, V84, P179, DOI 10.1093/oxfordjournals.jbchem.a132106; Moradali MF, 2020, NAT REV MICROBIOL, V18, P195, DOI 10.1038/s41579-019-0313-3; Moradali MF, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00039; Moser C, 2002, CLIN EXP IMMUNOL, V127, P206, DOI 10.1046/j.1365-2249.2002.01731.x; Parlane NA, 2012, CLIN VACCINE IMMUNOL, V19, P37, DOI 10.1128/CVI.05505-11; Parlane NA, 2009, APPL ENVIRON MICROB, V75, P7739, DOI 10.1128/AEM.01965-09; Peters V, 2006, APPL ENVIRON MICROB, V72, P1777, DOI 10.1128/AEM.72.3.1777-1783.2006; Pham TH, 2004, MICROBIOL-SGM, V150, P3405, DOI 10.1099/mic.0.27357-0; Pier GB, 2004, J IMMUNOL, V173, P5671, DOI 10.4049/jimmunol.173.9.5671; PIER GB, 1987, NEW ENGL J MED, V317, P793, DOI 10.1056/NEJM198709243171303; Priebe GP, 2002, INFECT IMMUN, V70, P1507, DOI 10.1128/IAI.70.3.1507-1517.2002; Priebe GP, 2008, J IMMUNOL, V181, P4965, DOI 10.4049/jimmunol.181.7.4965; Priebe GP, 2014, EXPERT REV VACCINES, V13, P507, DOI 10.1586/14760584.2014.890053; Rehm BHA, 2017, CURR OPIN BIOTECH, V48, P42, DOI 10.1016/j.copbio.2017.03.018; Rehm BHA, 2010, NAT REV MICROBIOL, V8, P578, DOI 10.1038/nrmicro2354; REHM BHA, 1994, MICROB PATHOGENESIS, V16, P43, DOI 10.1006/mpat.1994.1004; Rehm BHA, 2003, BIOCHEM J, V376, P15, DOI 10.1042/BJ20031254; REHM BHA, 1994, J BACTERIOL, V176, P5639, DOI 10.1128/JB.176.18.5639-5647.1994; Reyes PR, 2016, INT J MED MICROBIOL, V306, P624, DOI 10.1016/j.ijmm.2016.10.002; Roux D, 2009, CRIT CARE MED, V37, P1062, DOI 10.1097/CCM.0b013e31819629d2; Rubio-Reyes P, 2017, MICROB BIOTECHNOL, V10, P1434, DOI 10.1111/1751-7915.12754; Sainz-Mejias M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122617; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schaefers MM, 2018, VACCINE, V36, P6926, DOI 10.1016/j.vaccine.2018.10.010; Sharma A, 2011, HUM VACCINES, V7, P999, DOI 10.4161/hv.7.10.16369; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Spiekermann P, 1999, ARCH MICROBIOL, V171, P73, DOI 10.1007/s002030050681; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Thi MTT, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228671; Wan C, 2021, VACCINE, V39, P2386, DOI 10.1016/j.vaccine.2021.03.051; Weimer ET, 2009, INFECT IMMUN, V77, P2356, DOI 10.1128/IAI.00054-09; Westritschnig K, 2014, HUM VACC IMMUNOTHER, V10, P170, DOI 10.4161/hv.26565; Wibowo D, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120597; Wu WH, 2012, AM J RESP CRIT CARE, V186, P420, DOI 10.1164/rccm.201202-0182OC; Yang F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04029-5; Zhang XL, 2018, VACCINE, V36, P1047, DOI 10.1016/j.vaccine.2018.01.034	74	2	3	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							803	10.3390/vaccines9070803			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO4ZI	34358220	gold, Green Published			2022-04-29	WOS:000676921300001
J	Mavundza, EJ; Iwu-Jaja, CJ; Wiyeh, AB; Gausi, B; Abdullahi, LH; Halle-Ekane, G; Wiysonge, CS				Mavundza, Edison J.; Iwu-Jaja, Chinwe J.; Wiyeh, Alison B.; Gausi, Blessings; Abdullahi, Leila H.; Halle-Ekane, Gregory; Wiysonge, Charles S.			A Systematic Review of Interventions to Improve HPV Vaccination Coverage	VACCINES			English	Review						human papillomavirus; vaccination coverage; recipient-oriented interventions; provider-oriented interventions; systematic review	HUMAN-PAPILLOMAVIRUS VACCINATION; TEXT MESSAGE REMINDERS; ONLINE EDUCATIONAL INTERVENTION; SERIES COMPLETION; RANDOMIZED INTERVENTION; MISSED OPPORTUNITIES; DECISION-SUPPORT; PRIMARY-CARE; ADOLESCENTS; TRIAL	Human papillomavirus (HPV) infection is the most common sexually transmitted infection worldwide. Although most HPV infections are transient and asymptomatic, persistent infection with high-risk HPV types may results in diseases. Although there are currently three effective and safe prophylactic HPV vaccines that are used across the world, HPV vaccination coverage remains low. This review evaluates the effects of the interventions to improve HPV vaccination coverage. We searched the Cochrane Central Register of Controlled Trials, PubMed, Web of Science, Scopus, and the World Health Organization International Clinical Trials Registry Platform and checked the reference lists of relevant articles for eligible studies. Thirty-five studies met inclusion criteria. Our review found that various evaluated interventions have improved HPV vaccination coverage, including narrative education, outreach plus reminders, reminders, financial incentives plus reminders, brief motivational behavioral interventions, provider prompts, training, training plus assessment and feedback, consultation, funding, and multicomponent interventions. However, the evaluation of these intervention was conducted in high-income countries, mainly the United States of America. There is, therefore, a need for studies to evaluate the effect of these interventions in low-and middle-income countries, where there is a high burden of HPV and limited HPV vaccination programs.	[Mavundza, Edison J.; Wiysonge, Charles S.] South African Med Res Council, Cochrane South Africa, Francie van Zijl Dr, ZA-7501 Cape Town, South Africa; [Iwu-Jaja, Chinwe J.] Stellenbosch Univ, Dept Nursing & Midwifery, Francie van Zijl Dr, ZA-7505 Cape Town, South Africa; [Wiyeh, Alison B.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Gausi, Blessings; Wiysonge, Charles S.] Univ Cape Town, Div Epidemiol & Biostat, Anzio Rd, ZA-7925 Cape Town, South Africa; [Abdullahi, Leila H.] African Inst Dev Policy, POB 14688-00800, Nairobi, Kenya; [Halle-Ekane, Gregory] Univ Buea, Fac Hlth Sci, POB 63, Buea, Cameroon; [Wiysonge, Charles S.] Stellenbosch Univ, Dept Global Hlth, Div Epidemiol & Biostat, Francie van Zijl Dr, ZA-7505 Cape Town, South Africa		Mavundza, EJ (通讯作者)，South African Med Res Council, Cochrane South Africa, Francie van Zijl Dr, ZA-7501 Cape Town, South Africa.	Edison.mavundza@mrc.ac.za; chinwelolo@gmail.com; wberiliy@yahoo.co.uk; sibusiso.gausi@alumni.uct.ac.za; leylaz@live.co.za; halle-ekane.edie@ubuea.cm; Charles.Wiysonge@mrc.ac.za		Abdullahi, Leyla/0000-0002-7198-0558; Mavundza, Edison Johannes/0000-0002-0890-0164; Wiysonge, Charles/0000-0002-1273-4779; Juliana Iwu, Chinwe/0000-0003-0765-7497	South African Medical Research CouncilSouth African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	This research was funded by the South African Medical Research Council.	Acampora A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217997; [Anonymous], EPOC RES REV AUTH; Barnard M, 2019, PREV MED REP, V14, DOI 10.1016/j.pmedr.2019.100884; Bennett A, 2014, J WOMENS HEALTH, V23, P22; Bennett AT, 2015, J WOMENS HEALTH, V24, P950, DOI 10.1089/jwh.2015.5251; Brandt HM, 2016, HUM VACC IMMUNOTHER, V12, P1623, DOI 10.1080/21645515.2015.1122145; Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764; Carney PA, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-019-0871-9; Chabeda A, 2018, PAPILLOMAVIRUS RES, V5, P46, DOI 10.1016/j.pvr.2017.12.006; Chao C, 2015, J ADOLESCENT HEALTH, V56, P85, DOI 10.1016/j.jadohealth.2014.08.014; Chigbu CO, 2017, INT J GYNECOL OBSTET, V137, P319, DOI 10.1002/ijgo.12150; Coley S, 2018, VACCINE, V36, P4904, DOI 10.1016/j.vaccine.2018.06.056; Cory L, 2019, OBSTET GYNECOL, V134, P376, DOI 10.1097/AOG.0000000000003379; Daley MF, 2014, J ADOLESCENT HEALTH, V54, P282, DOI 10.1016/j.jadohealth.2013.12.011; Davies C, 2017, SEX EDUC-SEX SOC LEA, V17, P256, DOI 10.1080/14681811.2017.1300770; Dempsey A., 2017, OPEN FORUM INFECT DI, V4, pS61, DOI [10.1093/ofid/ofx162.144, DOI 10.1093/OFID/OFX162.144]; Dempsey AF, 2019, HUM VACC IMMUNOTHER, V15, P1577, DOI 10.1080/21645515.2018.1559685; Dempsey AF, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.0016; Deshmukh U, 2018, VACCINE, V36, P3599, DOI 10.1016/j.vaccine.2018.05.039; DiClemente RJ, 2015, HUM VACC IMMUNOTHER, V11, P2883, DOI 10.1080/21645515.2015.1070996; Dixon B, 2016, SEX TRANSM DIS, V43, pS199; Dixon BE, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1457; Egawa N, 2017, VIRUS RES, V231, P119, DOI 10.1016/j.virusres.2016.12.017; Fiks AG, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-0675; Fiks AG, 2013, PEDIATRICS, V131, P1114, DOI 10.1542/peds.2012-3122; Fisher-Borne M, 2018, ACAD PEDIATR, V18, pS79, DOI 10.1016/j.acap.2017.11.001; Fontes A, 2016, PAPILLOMAVIRUS RES, V2, P17, DOI 10.1016/j.pvr.2016.01.001; Forster AS, 2017, BRIT J CANCER, V117, P1121, DOI 10.1038/bjc.2017.284; Francis DB, 2017, PATIENT EDUC COUNS, V100, P1280, DOI 10.1016/j.pec.2017.02.004; Gallagher KE, 2017, PAPILLOMAVIRUS RES, V4, P72, DOI 10.1016/j.pvr.2017.09.001; Gilkey MB, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2018-2500; Gilkey MB, 2014, PEDIATRICS, V134, pE346, DOI 10.1542/peds.2013-4257; Grandahl M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009875; Henrikson N, 2017, CANCER EPIDEM BIOMAR, V26, P435, DOI 10.1158/1055-9965.EPI-17-0031; Henrikson NB, 2018, CLIN PEDIATR, V57, P1523, DOI 10.1177/0009922818787868; Herbert N, 2014, J ADOLESCENT HEALTH, V54, pS82, DOI 10.1016/j.jadohealth.2013.10.177; Higgins J.P.T., 2011, COCHRANE HDB SYSTEMA; Hofstetter AM, 2017, VACCINE, V35, P4554, DOI 10.1016/j.vaccine.2017.07.022; Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752; Hopfer S, 2012, PREV SCI, V13, P173, DOI 10.1007/s11121-011-0254-1; Irving SA, 2018, ACAD PEDIATR, V18, pS85, DOI 10.1016/j.acap.2017.09.002; Jacobs-Wingo JL, 2017, AM J PREV MED, V53, P162, DOI 10.1016/j.amepre.2017.01.024; Joseph NP, 2016, CLIN PEDIATR, V55, P851, DOI 10.1177/0009922815616244; Keeshin Susana Williams, 2017, J Int Assoc Provid AIDS Care, V16, P110, DOI 10.1177/2325957416682302; Kempe A, 2012, PEDIATRICS, V129, pE1446, DOI 10.1542/peds.2011-2921; Kim M, 2018, CANCER EPIDEM BIOMAR, V27, P187; Lee H, 2018, APPL NURS RES, V40, P51, DOI 10.1016/j.apnr.2017.12.008; Lee HY, 2016, AM J HEALTH BEHAV, V40, P67, DOI 10.5993/AJHB.40.1.8; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Loke AY, 2017, J PRIM CARE COMMUNIT, V8, P349, DOI 10.1177/2150131917742299; Lu PJ, 2015, PEDIATRICS, V136, P839, DOI 10.1542/peds.2015-1631; Mantzari E, 2015, HEALTH PSYCHOL, V34, P160, DOI 10.1037/hea0000088; Jimenez-Quinones EM, 2017, P R HEALTH SCI J, V36, P67; Mayne SL, 2014, AM J PREV MED, V47, P734, DOI 10.1016/j.amepre.2014.08.010; McLean HQ, 2017, J ADOLESCENT HEALTH, V61, P252, DOI 10.1016/j.jadohealth.2017.02.019; McRee AL, 2018, VACCINE, V36, P8158, DOI 10.1016/j.vaccine.2018.01.009; Mehta P, 2014, INT Q COMMUNITY HEAL, V34, P101, DOI 10.2190/IQ.34.1.h; Niccolai LM, 2015, JAMA PEDIATR, V169, P686, DOI 10.1001/jamapediatrics.2015.0310; O'Leary ST, 2019, VACCINE, V37, P3409, DOI 10.1016/j.vaccine.2019.05.034; Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313; Parra-Medina D, 2015, J CANCER EDUC, V30, P353, DOI 10.1007/s13187-014-0680-4; Patel A, 2014, VACCINE, V32, P2428, DOI 10.1016/j.vaccine.2014.02.095; Patel DA, 2012, J AM COLL HEALTH, V60, P151, DOI 10.1080/07448481.2011.580028; Perez GK, 2016, PSYCHOL RES BEHAV MA, V9, P285, DOI 10.2147/PRBM.S112504; Perkins RB, 2015, VACCINE, V33, P1223, DOI 10.1016/j.vaccine.2014.11.021; Pot M, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7449; Rahman M, 2013, VACCINE, V31, P5544, DOI 10.1016/j.vaccine.2013.09.017; Rand CM, 2017, J ADOLESCENT HEALTH, V60, P113, DOI 10.1016/j.jadohealth.2016.09.011; Rand CM, 2015, J ADOLESCENT HEALTH, V56, pS17, DOI 10.1016/j.jadohealth.2014.10.273; Reiter PL, 2018, LGBT HEALTH, V5, P325, DOI 10.1089/lgbt.2018.0059; Richman AR, 2019, J HEALTH CARE POOR U, V30, P1499, DOI 10.1353/hpu.2019.0090; Richman AR, 2016, J AM COLL HEALTH, V64, P269, DOI 10.1080/07448481.2015.1117466; Rickert VI, 2015, HUM VACC IMMUNOTHER, V11, P315, DOI 10.1080/21645515.2014.1004022; Rickert VI, 2014, VACCINE, V32, P1982, DOI 10.1016/j.vaccine.2014.01.049; Roblin DW, 2014, J ADOLESCENT HEALTH, V54, P275, DOI 10.1016/j.jadohealth.2013.12.001; Ruffin MT, 2015, J AM BOARD FAM MED, V28, P324, DOI 10.3122/jabfm.2015.03.140082; Russell SL, 2012, VALUE HEALTH, V15, pA248, DOI 10.1016/j.jval.2012.03.1337; Sanderson M, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4094-1; Skinner SR, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2168-5; Smulian EA, 2016, HUM VACC IMMUNOTHER, V12, P1566, DOI 10.1080/21645515.2015.1125055; Spleen AM, 2012, J CANCER EDUC, V27, P312, DOI 10.1007/s13187-011-0294-z; Suh CA, 2012, PEDIATRICS, V129, pE1437, DOI 10.1542/peds.2011-1714; Szilagyi PG, 2015, ACAD PEDIATR, V15, P149, DOI 10.1016/j.acap.2014.10.006; Szilagyi PG, 2013, ACAD PEDIATR, V13, P204, DOI 10.1016/j.acap.2013.01.002; Tiro JA, 2015, PEDIATRICS, V136, P850, DOI 10.1542/peds.2015-1563; Tull F, 2019, J ADOLESCENT HEALTH, V65, P116, DOI 10.1016/j.jadohealth.2018.12.026; Underwood NL, 2019, J SCHOOL HEALTH, V89, P603, DOI 10.1111/josh.12786; Valdez Armando, 2015, J Commun Healthc, V8, P106, DOI 10.1179/1753807615Y.0000000015; Vanderpool RC, 2013, J COMMUN, V63, P95, DOI 10.1111/jcom.12001; Wadhera P, 2015, INT J STD AIDS, V26, P893, DOI 10.1177/0956462414563626; Walling EB, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3863; Wedel S, 2016, MIL MED, V181, P1224, DOI 10.7205/MILMED-D-15-00477; Wegwarth O, 2014, VACCINE, V32, P1388, DOI 10.1016/j.vaccine.2013.12.038; Whelan NW, 2014, VACCINE, V32, P4665, DOI 10.1016/j.vaccine.2014.06.026; Wilkinson TA, 2019, VACCINE, V37, P4414, DOI 10.1016/j.vaccine.2019.05.004; Winer RL, 2016, J COMMUN HEALTH, V41, P274, DOI 10.1007/s10900-015-0093-2; Zimet G, 2018, ACAD PEDIATR, V18, pS66, DOI 10.1016/j.acap.2017.11.002; Zimet G, 2016, SEX TRANSM DIS, V43, pS158; Zimmerman RK, 2017, VACCINE, V35, P6180, DOI 10.1016/j.vaccine.2017.09.039; Zimmerman RK, 2017, VACCINE, V35, P109, DOI 10.1016/j.vaccine.2016.11.018	100	1	1	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							687	10.3390/vaccines9070687			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TO5WS	34201421	Green Published, gold			2022-04-29	WOS:000676982100001
J	Nagaoka, F; Yamazaki, T; Akashi-Takamura, S; Itoh, M				Nagaoka, Fumiaki; Yamazaki, Tatsuya; Akashi-Takamura, Sachiko; Itoh, Makoto			Detection of Urinary Antibodies and Its Application in Epidemiological Studies for Parasitic Diseases	VACCINES			English	Review						noninvasive test; urine diagnosis; urine ELISA; parasite infection; neglected tropical diseases (NTDs); mass drug administration (MDA)	LINKED-IMMUNOSORBENT-ASSAY; WUCHERERIA-BANCROFTI INFECTION; OPISTHORCHIS-VIVERRINI; VISCERAL LEISHMANIASIS; HELICOBACTER-PYLORI; IMMUNOGLOBULIN-G; IGG ANTIBODY; ENDEMIC AREA; DIAGNOSIS; ELISA	For epidemiological studies of infectious diseases, pathogen-specific antibody levels in an area give us essential and appropriate information. The antibodies against pathogens are usually detected in blood, the drawing of which inconveniences people. Collection of blood increases the risk of accidental infections through blood, and it is difficult to obtain the participation of the target populations, especially the younger generation. On the other hand, urine samples, which contain a high enough level of antibodies for ELISA, can be harmlessly and easily collected and therefore have been used for epidemiological studies for diseases. The antibody examination of urine has been used for the epidemiology of parasitic diseases with a high sensitivity and specificity of serum samples. In this paper, we reviewed antibody assays with urine for seven parasitic diseases that urine diagnostic methods have reported in the past, and these are important infections included in NTDs, caused, for example, by Leishmania donovani, Wuchereria bancrofti, Schistosoma japonicum, Paragonimus westermani, Echinococcus granulosus, Echinococcus multilocularis, Strongyloides stercoralis, and Opisthorchis viverrini. The easy and safe urine surveillance system might be an admirable tool for future epidemiological studies for infectious diseases.	[Nagaoka, Fumiaki; Yamazaki, Tatsuya; Akashi-Takamura, Sachiko; Itoh, Makoto] Aichi Med Univ, Sch Med, Dept Microbiol & Immunol, Nagakute, Aichi 4801195, Japan		Itoh, M (通讯作者)，Aichi Med Univ, Sch Med, Dept Microbiol & Immunol, Nagakute, Aichi 4801195, Japan.	fnagaoka@aichi-med-u.ac.jp; yamazaki13@aichi-med-u.ac.jp; sachiko@aichi-med-u.ac.jp; macitoh@aichi-med-u.ac.jp		Yamazaki, Tatsuya/0000-0002-2645-6490; Akashi-Takamura, Sachiko/0000-0003-4890-3172			Adachi K, 2002, J GASTROENTEROL, V37, P703, DOI 10.1007/s005350200115; ALEMOHAMMAD MM, 1993, J CLIN MICROBIOL, V31, P2174, DOI 10.1128/JCM.31.8.2174-2177.1993; Bergquist R, 2009, TRENDS PARASITOL, V25, P151, DOI 10.1016/j.pt.2009.01.004; Brunetti E, 2010, ACTA TROP, V114, P1, DOI 10.1016/j.actatropica.2009.11.001; CAO YZ, 1988, LANCET, V1, P831; CHANTEAU S, 1994, T ROY SOC TROP MED H, V88, P661, DOI 10.1016/0035-9203(94)90217-8; Chirag S, 2015, J HELMINTHOL, V89, P232, DOI 10.1017/S0022149X13000837; Eamudomkarn C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192598; Ejazi SA, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005035; Elsana S, 1998, J MED VIROL, V55, P24, DOI 10.1002/(SICI)1096-9071(199805)55:1&lt;24::AID-JMV5&gt;3.0.CO;2-Q; Gedda MR, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008221; Ghosh P, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1667-2; Gryseels B, 2012, INFECT DIS CLIN N AM, V26, P383, DOI 10.1016/j.idc.2012.03.004; HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5; Ikeda T, 1996, AM J TROP MED HYG, V55, P434, DOI 10.4269/ajtmh.1996.55.434; IMAI J, 1987, T ROY SOC TROP MED H, V81, P3, DOI 10.1016/0035-9203(87)90267-7; ISHII A, 1982, Z PARASITENKD, V67, P279, DOI 10.1007/BF00927663; Islam MZ, 2008, AM J TROP MED HYG, V79, P599, DOI 10.4269/ajtmh.2008.79.599; Islam MZ, 2002, CLIN DIAGN LAB IMMUN, V9, P789, DOI 10.1128/CDLI.9.4.789-794.2002; Itoh M, 2001, AM J TROP MED HYG, V65, P362, DOI 10.4269/ajtmh.2001.65.362; Itoh Makoto, 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P469; Itoh M, 2013, PARASITOL INT, V62, P514, DOI 10.1016/j.parint.2013.07.007; Itoh M, 2011, PARASITOL INT, V60, P393, DOI 10.1016/j.parint.2011.06.019; Kaewkes S, 2003, ACTA TROP, V88, P177, DOI 10.1016/j.actatropica.2003.05.001; Katsuragi K, 1998, HELICOBACTER, V3, P289, DOI 10.1046/j.1523-5378.1998.08045.x; Kuriyama M, 1979, Nihon Hinyokika Gakkai Zasshi, V70, P228; Lichstein HC, 1944, J BACTERIOL, V47, P221, DOI 10.1128/JB.47.3.221-230.1944; Lin DD, 2008, ACTA TROP, V107, P128, DOI 10.1016/j.actatropica.2008.05.005; MOHAMMED EAE, 1985, T ROY SOC TROP MED H, V79, P344, DOI 10.1016/0035-9203(85)90376-1; Nutman TB, 2013, LYMPHAT RES BIOL, V11, P144, DOI 10.1089/lrb.2013.0021; Olsen A, 2009, T ROY SOC TROP MED H, V103, P967, DOI 10.1016/j.trstmh.2009.02.013; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; Pinlaor P, 2012, PARASITOL INT, V61, P212, DOI 10.1016/j.parint.2011.06.014; Qiu Xu Guang, 2016, Trop Med Health, V44, P19, DOI 10.1186/s41182-016-0019-4; Requena-Mendez A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002002; Romig T, 2017, ADV PARASIT, V95, P213, DOI 10.1016/bs.apar.2016.11.002; Samad MS, 2013, PARASITOL INT, V62, P564, DOI 10.1016/j.parint.2013.08.007; Santra A, 2001, T ROY SOC TROP MED H, V95, P289, DOI 10.1016/S0035-9203(01)90236-6; Simonsen PE, 1997, TROP MED INT HEALTH, V2, P153, DOI 10.1046/j.1365-3156.1997.d01-237.x; Singh S, 2011, INT J DERMATOL, V50, P1099, DOI 10.1111/j.1365-4632.2011.04925.x; Sripa B, 2012, TRENDS PARASITOL, V28, P395, DOI 10.1016/j.pt.2012.07.006; Sunita T, 2007, ACTA TROP, V101, P187, DOI 10.1016/j.actatropica.2006.07.014; Takagi Atsushi, 2003, Nihon Rinsho, V61, P88; Takahashi S, 1998, CLIN DIAGN LAB IMMUN, V5, P24, DOI 10.1128/CDLI.5.1.24-27.1998; Terada K, 2000, PEDIATR INFECT DIS J, V19, P104, DOI 10.1097/00006454-200002000-00003; Tesana S, 2007, ANN TROP MED PARASIT, V101, P585, DOI 10.1179/136485907X229068; THAMAVIT W, 1993, CARCINOGENESIS, V14, P2415, DOI 10.1093/carcin/14.11.2415; van Griensven J, 2019, INFECT DIS CLIN N AM, V33, P79, DOI 10.1016/j.idc.2018.10.005; Vazquez S, 2007, INT J INFECT DIS, V11, P256, DOI 10.1016/j.ijid.2006.05.005; Weerasooriya MV, 2003, ANN TROP MED PARASIT, V97, P179, DOI 10.1179/000349803235001624; WEIL GJ, 1990, J INFECT DIS, V161, P549, DOI 10.1093/infdis/161.3.549; Weil GJ, 1997, PARASITOL TODAY, V13, P401, DOI 10.1016/S0169-4758(97)01130-7; World Health Organization, 2020, Weekly Epidemiological Record, V95, P509; World Health Organization, 2020, END NEGL ATT SUST DE; Yoshida A, 2019, ACTA TROP, V199, DOI 10.1016/j.actatropica.2019.105074; Zhao MD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03226-6; Zijlstra EE, 1998, CLIN DIAGN LAB IMMUN, V5, P717, DOI 10.1128/CDLI.5.5.717-720.1998	57	0	0	4	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							778	10.3390/vaccines9070778			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7ZS	34358194	Green Published, gold			2022-04-29	WOS:000677125100001
J	Rzymski, P; Pazgan-Simon, M; Simon, K; Lapinski, T; Zarebska-Michaluk, D; Szczepanska, B; Chojnicki, M; Mozer-Lisewska, I; Flisiak, R				Rzymski, Piotr; Pazgan-Simon, Monika; Simon, Krzysztof; Lapinski, Tadeusz; Zarebska-Michaluk, Dorota; Szczepanska, Barbara; Chojnicki, Michal; Mozer-Lisewska, Iwona; Flisiak, Robert			Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine	VACCINES			English	Article						vaccination; breakthrough infection; severe COVID-19; SARS-CoV-2	SURVEILLANCE; CHALLENGES; VARIANTS	The clinical trials of the COVID-19 vaccines that are authorized in the European Union have revealed high efficacy in preventing symptomatic infections. However, during vaccination campaigns, some vaccine recipients, including those partially and fully vaccinated, will experience severe COVID-19, requiring hospitalization. This may particularly concern patients with a diminished immune response to the vaccine, as well as non-responders. This work has retrospectively analyzed the 92 cases of patients who were hospitalized between 27 December 2020 and 31 May 2021 in four Polish healthcare units due to COVID-19, and who have previously received the COVID-19 vaccine (54.3% <= 14 days after the first dose, 26.1% > 14 days after the first dose, 7.6% <= 14 days after the second dose, and 12% > 14 days after the second dose). These patients represented a minute fraction (1.2%) of all the COVID-19 patients who were hospitalized during the same period in the same healthcare institutions. No significant differences in white blood count, absolute lymphocyte count nadir, C-reactive protein, interleukin-6, procalcitonin, oxygen saturation, lung involvement, and fever frequency were found between the recipients of the first and second vaccine dose. A total of 15 deaths were noted (1.1% of all fatal COVID-19 cases in the considered period and healthcare units), including six in patients who received the second dose (five > 14 days after the second dose)-three of these subjects were using immunosuppressive medicines, and two were confirmed to be vaccine non-responders. The study reassures that severe COVID-19 and deaths are not common in vaccinated individuals, highlights that the clinical course in such patients may not reveal any distinctive features, and advocates for close monitoring of those at a higher risk of vaccine failure.	[Rzymski, Piotr] Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland; [Rzymski, Piotr] Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland; [Pazgan-Simon, Monika] Gromkowski Reg Specialist Hosp, Infect Dis Ward 1, PL-50149 Wroclaw, Poland; [Pazgan-Simon, Monika; Simon, Krzysztof] Wroclaw Med Univ, Dept Infect Dis & Hepatol, PL-51149 Wroclaw, Poland; [Lapinski, Tadeusz; Flisiak, Robert] Med Univ Bialystok, Dept Infect Dis & Hepatol, PL-15540 Bialystok, Poland; [Zarebska-Michaluk, Dorota] Jan Kochanowski Univ Humanities & Sci, Dept Infect Dis, PL-25369 Kielce, Poland; [Szczepanska, Barbara] Jan Kochanowski Univ Humanities & Sci, Dept Childrens Dis, Infect Neurol Subdiv, PL-25369 Kielce, Poland; [Chojnicki, Michal] Poznan Univ Med Sci, Dept Immunobiol, PL-60806 Poznan, Poland; [Chojnicki, Michal; Mozer-Lisewska, Iwona] Jozef Strus Hosp, Dept Infect Dis, PL-61285 Poznan, Poland		Rzymski, P (通讯作者)，Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland.; Rzymski, P (通讯作者)，Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland.; Flisiak, R (通讯作者)，Med Univ Bialystok, Dept Infect Dis & Hepatol, PL-15540 Bialystok, Poland.	rzymskipiotr@ump.edu.pl; monikapazgansimon@gmail.com; krzysimon@gmail.com; twlapinski@gmail.com; dorota.zarebska-michaluk@ujk.edu.pl; barbara.szczepanska@ujk.edu.pl; michalc@ump.edu.pl; iwonalisewska@ump.edu.pl; robert.flisiak1@gmail.com	Zarębska-Michaluk, Dorota/R-1325-2019; Rzymski, Piotr/I-2240-2012; Flisiak, Robert/S-5356-2018	Zarębska-Michaluk, Dorota/0000-0003-0938-1084; Rzymski, Piotr/0000-0002-4713-0801; Szczepanska, Barbara/0000-0002-3334-039X; Simon, Krzysztof/0000-0002-8040-0412; Flisiak, Robert/0000-0003-3394-1635	Medical Research Agency in Poland [2020/ABM/COVID19/PTEILCHZ]	This research was supported by the Medical Research Agency in Poland, grant number 2020/ABM/COVID19/PTEILCHZ.	Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Agha Mounzer, 2021, medRxiv, DOI 10.1101/2021.04.06.21254949; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Booth A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247461; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; CDC COVID-19 Vaccine Breakthrough Case Investigations Team, 2021, MMWR MORB MORTAL WKL, V70, P792, DOI [10.15585/mmwr.mm7021e3, DOI 10.15585/MMWR.MM7021-3]; Charkiewicz R, 2021, ADV MED SCI-POLAND, V66, P237, DOI 10.1016/j.advms.2021.03.005; Chen J, 2021, BIOSCI TRENDS, V15, P126, DOI 10.5582/bst.2021.01092; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Flisiak R, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081583; Flisiak R, 2020, POL ARCH INTERN MED, V130, P352, DOI 10.20452/pamw.15270; Forman R, 2021, HEALTH POLICY, V125, P553, DOI 10.1016/j.healthpol.2021.03.013; Geers D, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1750; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Hobbs ALV, 2021, INFECT CONT HOSP EP, V42, P1464, DOI 10.1017/ice.2020.1435; Iacobucci G, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1346; Kashte S, 2021, HUM CELL, V34, P711, DOI 10.1007/s13577-021-00512-4; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Leung C, 2021, ADV EXP MED BIOL, V1318, P81, DOI 10.1007/978-3-030-63761-3_5; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n852; McEwen AE, 2022, CLIN INFECT DIS, V74, P1089, DOI 10.1093/cid/ciab581; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pritchard E, 2021, NAT MED, V27, P1370, DOI 10.1038/s41591-021-01410-w; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060559; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; SARS-CoV-2 w Polsce, MAPA WARIANT W MAP V; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037	37	12	12	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							781	10.3390/vaccines9070781			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7JX	34358197	gold, Green Published			2022-04-29	WOS:000677084000001
J	Venkataraman, S; Hefferon, K; Makhzoum, A; Abouhaidar, M				Venkataraman, Srividhya; Hefferon, Kathleen; Makhzoum, Abdullah; Abouhaidar, Mounir			Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?	VACCINES			English	Review						vaccines; VLPs; genetic engineering; epitopes; transgenic; agroinfiltration	VIRUS-LIKE PARTICLES; ANTIBODY-DEPENDENT ENHANCEMENT; HEPATITIS-B-VIRUS; INFLUENZA-A VIRUS; PROTECTIVE IMMUNE-RESPONSE; CARBOXYL-TERMINAL FRAGMENT; CUCUMBER-MOSAIC-VIRUS; HIGH-LEVEL EXPRESSION; MONOCLONAL-ANTIBODIES; NEUTRALIZING ANTIBODIES	Molecular pharming or the technology of application of plants and plant cell culture to manufacture high-value recombinant proteins has progressed a long way over the last three decades. Whether generated in transgenic plants by stable expression or in plant virus-based transient expression systems, biopharmaceuticals have been produced to combat several human viral diseases that have impacted the world in pandemic proportions. Plants have been variously employed in expressing a host of viral antigens as well as monoclonal antibodies. Many of these biopharmaceuticals have shown great promise in animal models and several of them have performed successfully in clinical trials. The current review elaborates the strategies and successes achieved in generating plant-derived vaccines to target several virus-induced health concerns including highly communicable infectious viral diseases. Importantly, plant-made biopharmaceuticals against hepatitis B virus (HBV), hepatitis C virus (HCV), the cancer-causing virus human papillomavirus (HPV), human immunodeficiency virus (HIV), influenza virus, zika virus, and the emerging respiratory virus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been discussed. The use of plant virus-derived nanoparticles (VNPs) and virus-like particles (VLPs) in generating plant-based vaccines are extensively addressed. The review closes with a critical look at the caveats of plant-based molecular pharming and future prospects towards further advancements in this technology. The use of biopharmed viral vaccines in human medicine and as part of emergency response vaccines and therapeutics in humans looks promising for the near future.	[Venkataraman, Srividhya; Hefferon, Kathleen; Abouhaidar, Mounir] Univ Toronto, Dept Cell & Syst Biol, Virol Lab, Toronto, ON M5S 3B2, Canada; [Makhzoum, Abdullah] Botswana Int Univ Sci & Technol, Dept Biol Sci & Biotechnol, Palapye, Botswana		Venkataraman, S (通讯作者)，Univ Toronto, Dept Cell & Syst Biol, Virol Lab, Toronto, ON M5S 3B2, Canada.	byokem@hotmail.com; kathleen.hefferon@alumni.utoronto.ca; makhzouma@biust.ac.bw; mounir.abouhaidar@utoronto.ca					Aggarwal S, 2009, NAT BIOTECHNOL, V27, P987, DOI 10.1038/nbt1109-987; Alam A, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00102; Ameghi A, 2016, VIRAL IMMUNOL, V29, P228, DOI 10.1089/vim.2015.0050; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; [Anonymous], 2012, DARPA MAKES 10 MILLI; Armbruster N, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040132; Attar N., 2016, NAT REV MICROBIOL, V14, P62, DOI DOI 10.1038/NRMICR0.2015.28; Babin C, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-10; Barahimipour R, 2016, PLANT MOL BIOL, V90, P403, DOI 10.1007/s11103-015-0425-8; Biemelt S, 2003, J VIROL, V77, P9211, DOI 10.1128/JVI.77.17.9211-9220.2003; Blanchard E, 2006, J VIROL, V80, P6964, DOI 10.1128/JVI.00024-06; Blokhina EA, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9020162; Bock R, 2001, J MOL BIOL, V312, P425, DOI 10.1006/jmbi.2001.4960; Bock R, 2015, ANNU REV PLANT BIOL, V66, P211, DOI 10.1146/annurev-arplant-050213-040212; Bock R, 2014, METHODS MOL BIOL, V1132, P93, DOI 10.1007/978-1-62703-995-6_5; Boes A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131456; Bolduc M, 2018, NANOMED-NANOTECHNOL, V14, P2563, DOI 10.1016/j.nano.2018.08.010; BREITBURD F, 1995, J VIROL, V69, P3959, DOI 10.1128/JVI.69.6.3959-3963.1995; Bruss V, 2007, WORLD J GASTROENTERO, V13, P65, DOI 10.3748/wjg.v13.i1.65; Buratti E, 1998, J GEN VIROL, V79, P2709, DOI 10.1099/0022-1317-79-11-2709; Butkovich N, 2021, WIRES NANOMED NANOBI, V13, DOI 10.1002/wnan.1681; Cabral-Miranda G, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030072; Cabral-Miranda G, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5020010; Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6; Capell T, 2020, TRENDS PLANT SCI, V25, P635, DOI 10.1016/j.tplants.2020.04.009; Carignan D, 2015, VACCINE, V33, P7245, DOI 10.1016/j.vaccine.2015.10.123; Castilho A, 2012, J BIOL CHEM, V287, P36518, DOI 10.1074/jbc.M112.402685; Castilho A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026040; Castilho A, 2010, J BIOL CHEM, V285, P15923, DOI 10.1074/jbc.M109.088401; Cervera L, 2019, APPL MICROBIOL BIOT, V103, P7367, DOI 10.1007/s00253-019-10038-3; Chabeda M, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00779; Chen Qiang, 2016, F1000Res, V5, DOI 10.12688/f1000research.8010.1; Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681; Chevaliez S, 2012, BEST PRACT RES CL GA, V26, P381, DOI 10.1016/j.bpg.2012.09.006; Chichester JA, 2018, VACCINE, V36, P5865, DOI 10.1016/j.vaccine.2018.08.033; Chitnis CE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117820; Chung YH, 2020, ADV DRUG DELIVER REV, V156, P214, DOI 10.1016/j.addr.2020.06.024; Clarke JL, 2017, PLANT BIOTECHNOL J, V15, P1611, DOI 10.1111/pbi.12743; Clemente V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103492; Crewther PE, 1996, INFECT IMMUN, V64, P3310, DOI 10.1128/IAI.64.8.3310-3317.1996; D'Aoust MA, 2010, PLANT BIOTECHNOL J, V8, P607, DOI 10.1111/j.1467-7652.2009.00496.x; DALY TM, 1993, INFECT IMMUN, V61, P2462, DOI 10.1128/IAI.61.6.2462-2467.1993; Daniell Henry, 2006, Biotechnology Journal, V1, P1071, DOI 10.1002/biot.200600145; Dellorto, 2014, 9 QUESTIONS THIS NEW; Deng L, 2017, VIROLOGY, V509, P82, DOI 10.1016/j.virol.2017.06.001; Denis J, 2008, VACCINE, V26, P3395, DOI 10.1016/j.vaccine.2008.04.052; Denis J, 2007, VIROLOGY, V363, P59, DOI 10.1016/j.virol.2007.01.011; Dent M, 2016, J GEN VIROL, V97, P3280, DOI 10.1099/jgv.0.000635; Diamos AG, 2020, VACCINE, V38, P3455, DOI 10.1016/j.vaccine.2020.02.089; Diamos AG, 2020, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00472; Diamos AG, 2019, VACCINE, V37, P137, DOI 10.1016/j.vaccine.2018.11.021; Diamos AG, 2018, PROTEIN EXPRES PURIF, V151, P86, DOI 10.1016/j.pep.2018.06.011; Diamos AG, 2018, PLANT BIOTECHNOL J, V16, P1971, DOI 10.1111/pbi.12931; Dobrica MO, 2018, VACCINE, V36, P5789, DOI 10.1016/j.vaccine.2018.07.072; Dobrica MO, 2017, ANTIVIR RES, V144, P256, DOI 10.1016/j.antiviral.2017.06.017; Draper SJ, 2018, CELL HOST MICROBE, V24, P43, DOI 10.1016/j.chom.2018.06.008; Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090; Duan K, 2020, P NATL ACAD SCI USA, V117, P9490, DOI 10.1073/pnas.2004168117; Durbin A, 2017, EXPERT REV VACCINES, V16, P781, DOI 10.1080/14760584.2017.1345309; Durrani Z, 1998, J IMMUNOL METHODS, V220, P93, DOI 10.1016/S0022-1759(98)00145-8; EDDLESTON A, 1990, LANCET, V335, P1142, DOI 10.1016/0140-6736(90)91138-Z; Fauvelle C, 2013, MICROB PATHOGENESIS, V58, P66, DOI 10.1016/j.micpath.2013.02.005; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fischer R, 2004, CURR OPIN PLANT BIOL, V7, P152, DOI 10.1016/j.pbi.2004.01.007; Fletcher EAK, 2018, J IMMUNOL, V201, P87, DOI 10.4049/jimmunol.1700911; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Friebe P, 2001, J VIROL, V75, P12047, DOI 10.1128/JVI.75.24.12047-12057.2001; Fuqua JL, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0120-5; Gamblin SJ, 2010, J BIOL CHEM, V285, P28403, DOI 10.1074/jbc.R110.129809; Gantz S., BALTIM BUS J; Ghosh S, 2002, PLANT SCI, V162, P335, DOI 10.1016/S0168-9452(01)00555-6; Girard MP, 2007, VACCINE, V25, P1567, DOI 10.1016/j.vaccine.2006.09.074; Gomez-Puertas P, 2000, J VIROL, V74, P11538, DOI 10.1128/JVI.74.24.11538-11547.2000; Govea-Alonso D.O., 2014, GENETICALLY ENGINEER, P1; Govea-Alonso DO, 2013, PLANT CELL TISS ORG, V113, P73, DOI 10.1007/s11240-012-0252-4; Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135; Greenberg MR, 2009, AM J EMERG MED, V27, P1154, DOI 10.1016/j.ajem.2009.04.003; Gretler, 2020, TOBACCO BASED CORONA; Grilo AL, 2019, TRENDS BIOTECHNOL, V37, P9, DOI 10.1016/j.tibtech.2018.05.014; Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656; Haddox HK, 2018, ELIFE, V7, DOI 10.7554/eLife.34420; Hamid MMA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020547; Han T, 2011, ANN NY ACAD SCI, V1217, P178, DOI 10.1111/j.1749-6632.2010.05829.x; Hanafi LA, 2010, VACCINE, V28, P5617, DOI 10.1016/j.vaccine.2010.06.024; Hayden CA, 2015, VACCINE, V33, P2881, DOI 10.1016/j.vaccine.2015.04.080; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; Hefferon KL, 2019, EXPERT REV VACCINES, V18, P1301, DOI 10.1080/14760584.2019.1704264; Hefferon KL, 2014, VACCINES, V2, P642, DOI 10.3390/vaccines2030642; Hernandez M, 2014, EXPERT REV VACCINES, V13, P1523, DOI 10.1586/14760584.2014.953064; Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400; Ho NI, 2017, J IMMUNOL, V198, P4235, DOI 10.4049/jimmunol.1602169; Hoelscher M, 2018, PLANT MOL BIOL, V97, P357, DOI 10.1007/s11103-018-0744-7; Hopper JTS, 2017, STRUCTURE, V25, P773, DOI 10.1016/j.str.2017.03.015; Howley PM, 2001, FIELDS VIROLOGY, V2, P2197; Huang Z, 2006, VACCINE, V24, P2506, DOI 10.1016/j.vaccine.2005.12.024; Huang Z, 2005, VACCINE, V23, P1851, DOI 10.1016/j.vaccine.2004.11.017; Huang Z, 2008, PLANT BIOTECHNOL J, V6, P202, DOI 10.1111/j.1467-7652.2007.00316.x; Huang Z, 2010, BIOTECHNOL BIOENG, V106, P9, DOI 10.1002/bit.22652; Huang Z, 2009, BIOTECHNOL BIOENG, V103, P706, DOI 10.1002/bit.22299; Hunter JGL, 2019, PEERJ, V7, DOI 10.7717/peerj.6600; Hurtado J, 2020, PLANT BIOTECHNOL J, V18, P266, DOI 10.1111/pbi.13194; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219; Joelson T, 1997, J GEN VIROL, V78, P1213, DOI 10.1099/0022-1317-78-6-1213; Joung YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101715; Kapusta J, 1999, FASEB J, V13, P1796, DOI 10.1096/fasebj.13.13.1796; Karasev AV, 2005, VACCINE, V23, P1875, DOI 10.1016/j.vaccine.2004.11.021; Kasinger LES, 2019, PLANT BIOTECHNOL J, V17, P1646, DOI 10.1111/pbi.13090; Keitel WA, 2008, J INFECT DIS, V198, P1309, DOI 10.1086/592172; Keith J., 2004, BIOTECHNOL, V3, P7; Kessans SA, 2013, PLANT BIOTECHNOL J, V11, P681, DOI 10.1111/pbi.12058; Kim H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020189; Kirk DD, 2005, TRANSGENIC RES, V14, P449, DOI 10.1007/s11248-005-5697-3; Kobinger GP, 2007, VACCINE, V25, P5220, DOI 10.1016/j.vaccine.2007.04.065; Kotomina T, 2019, ANTIVIR RES, V168, P9, DOI [10.1016/j.antivira.2019.05.001, 10.1016/j.antiviral.2019.05.001]; Krenek P, 2015, BIOTECHNOL ADV, V33, P1024, DOI 10.1016/j.biotechadv.2015.03.012; Krokhin O, 2003, MOL CELL PROTEOMICS, V2, P346, DOI 10.1074/mcp.M300048-MCP200; Kurup VM, 2020, MOL BIOTECHNOL, V62, P79, DOI 10.1007/s12033-019-00222-1; Lai HF, 2018, VACCINE, V36, P1846, DOI 10.1016/j.vaccine.2018.02.073; Laliberte-Gagne ME, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020049; Lamb RA, 2001, FIELDS VIROLOGY, V4, P1487, DOI DOI 10.1038/CR.2017.129; Landry N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015559; Latif S, 2021, BIOTECHNOL APPL BIOC, DOI 10.1002/bab.2136; Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16; Leclerc D, 2007, J VIROL, V81, P1319, DOI 10.1128/JVI.01720-06; Li Qun, 2020, N Engl J Med, V382, P1199, DOI 10.1056/NEJMoa2001316; Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727; Liang XF, 2010, LANCET, V375, P56, DOI 10.1016/S0140-6736(09)62003-1; Lico C, 2009, VACCINE, V27, P5069, DOI 10.1016/j.vaccine.2009.06.045; Lindenbach BD, 2013, CURR TOP MICROBIOL, V369, P199, DOI 10.1007/978-3-642-27340-7_8; Lindsay BJ, 2018, VACCINE, V36, P2147, DOI 10.1016/j.vaccine.2018.02.106; Loh HS, 2017, CURR OPIN VIROL, V26, P81, DOI 10.1016/j.coviro.2017.07.019; Lopez-Ramirez MA, 2020, ADV MATER, V32, DOI 10.1002/adma.201905740; Lotter-Stark HCT, 2012, BIOTECHNOL ADV, V30, P1614, DOI 10.1016/j.biotechadv.2012.06.002; Lyon GM, 2014, NEW ENGL J MED, V371, P2402, DOI 10.1056/NEJMoa1409838; Ma JKC, 2015, PLANT BIOTECHNOL J, V13, P1106, DOI 10.1111/pbi.12416; Ma JKC, 2013, PLANT BIOTECHNOL J, V11, P1029, DOI 10.1111/pbi.12127; Madesis P, 2010, J BIOTECHNOL, V145, P377, DOI 10.1016/j.jbiotec.2009.12.001; Mahmood N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010015; Makarkov AI, 2017, VACCINE, V35, P4629, DOI 10.1016/j.vaccine.2017.07.012; Makay, 2020, ALGAE TASKED MAKING; Mallajosyula JK, 2014, HUM VACC IMMUNOTHER, V10, P586, DOI 10.4161/hv.27567; Mardanova ES, 2018, CURR PHARM DESIGN, V24, P1317, DOI 10.2174/1381612824666180309125344; Mardanova ES, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0164-6; Margolin E, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.01378; Marquez-Escobar VA, 2017, EXPERT REV VACCINES, V16, P137, DOI 10.1080/14760584.2017.1232167; Marsian J, 2016, CURR OPIN BIOTECH, V37, P201, DOI 10.1016/j.copbio.2015.12.007; Marusic C, 2001, J VIROL, V75, P8434, DOI 10.1128/JVI.75.18.8434-8439.2001; Marusic C, 2018, BIOTECHNOL BIOENG, V115, P565, DOI 10.1002/bit.26503; Marusic C, 2009, TRANSGENIC RES, V18, P499, DOI 10.1007/s11248-009-9244-5; Masavuli MG, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02413; Mason HS, 2016, HUM VACC IMMUNOTHER, V12, P988, DOI 10.1080/21645515.2015.1116655; Massa S, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00452; Mastrangeli R, 2019, GLYCOBIOLOGY, V29, P199, DOI 10.1093/glycob/cwy092; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; McCarthy M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5488; McInerney TL, 1999, VACCINE, V17, P1359, DOI 10.1016/S0264-410X(98)00388-0; McKee SJ, 2015, REV MED VIROL, V25, P54, DOI 10.1002/rmv.1824; MCLAIN L, 1995, AIDS RES HUM RETROV, V11, P327, DOI 10.1089/aid.1995.11.327; McLain L, 1996, VACCINE, V14, P799, DOI 10.1016/0264-410X(95)00229-T; Menachery VD, 2018, J VIROL, V92, DOI 10.1128/JVI.00710-18; Mendoza, 2014, GENETICALLY ENG PLAN, P79; Michiels B, 2011, VACCINE, V29, P9159, DOI 10.1016/j.vaccine.2011.08.008; Milan-Noris EM, 2020, MOL BIOTECHNOL, V62, P534, DOI 10.1007/s12033-020-00271-x; Mir-Artigues P, 2019, BIOTECHNOL BIOENG, V116, P2526, DOI 10.1002/bit.27093; Mobini S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02074; Mohammadzadeh S, 2020, APMIS, V128, P593, DOI 10.1111/apm.13074; Mohammadzadeh S, 2016, PHARM BIOL, V54, P465, DOI 10.3109/13880209.2015.1048371; Mohammadzadeh S, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.20524; Monreal-Escalante E, 2017, PLANTA, V246, P123, DOI 10.1007/s00425-017-2689-5; Montero-Morales L, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00081; Moradpour D, 2013, CURR TOP MICROBIOL, V369, P113, DOI 10.1007/978-3-642-27340-7_5; Mullan K., TOBACCO GIANT BAT SA; Muller M, 1997, VIROLOGY, V234, P93, DOI 10.1006/viro.1997.8591; Mulligan MJ, 2020, PHASE 1 2 STUDY DESC, DOI [10.1101/2020.06.30. 20142570., DOI 10.1101/2020.06.30.20142570, 10.1038/s41586-020-2639-4]; Murakami K, 2001, ARCH VIROL, V146, P729, DOI 10.1007/s007050170142; Nandi S, 2016, MABS-AUSTIN, V8, P1456, DOI 10.1080/19420862.2016.1227901; Natilla A, 2004, ARCH VIROL, V149, P137, DOI 10.1007/s00705-003-0190-x; Naupu PN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040740; Nayak DP, 2009, VIRUS RES, V143, P147, DOI 10.1016/j.virusres.2009.05.010; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Nemchinov LG, 2000, ARCH VIROL, V145, P2557, DOI 10.1007/s007050070008; Pham NB, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0305-2; (NIAID) NI of A and ID, VRC 705 ZIKA VIRUS D; Nochi T, 2009, J IMMUNOL, V183, P6538, DOI 10.4049/jimmunol.0901480; Noda T, 2006, NATURE, V439, P490, DOI 10.1038/nature04378; Nogrady, SCIENTIST; Nolan TM, 2008, VACCINE, V26, P4160, DOI 10.1016/j.vaccine.2008.05.077; Novavax.com, 2021, CLIN STAGE PIPELINE; Nuzzaci M, 2007, ARCH VIROL, V152, P915, DOI 10.1007/s00705-006-0916-7; Nuzzaci M, 2010, J VIROL METHODS, V165, P211, DOI 10.1016/j.jviromet.2010.01.021; Olinger GG, 2012, P NATL ACAD SCI USA, V109, P18030, DOI 10.1073/pnas.1213709109; Opdensteinen P, 2019, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00206; Orellana-Escobedo L, 2015, PLANT CELL REP, V34, P425, DOI 10.1007/s00299-014-1720-6; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Palca J., 2020, TOBACCO PLANTS CONTR; Pan WQ, 2004, J IMMUNOL, V172, P6167, DOI 10.4049/jimmunol.172.10.6167; Patient R, 2009, NEW BIOTECHNOL, V25, P226, DOI 10.1016/j.nbt.2009.01.001; Paul G, 2018, BIOCHEM J, V475, P1197, DOI 10.1042/BCJ20180017; Pellerin C., 2010, AM FORCES PRESS SERV; Petrosky E, 2015, MMWR-MORBID MORTAL W, V64, P300; Phoolcharoen W, 2011, P NATL ACAD SCI USA, V108, P20695, DOI 10.1073/pnas.1117715108; Piazzolla G, 2005, J CLIN IMMUNOL, V25, P142, DOI 10.1007/s10875-005-2820-4; Pielak RM, 2011, BBA-BIOMEMBRANES, V1808, P522, DOI 10.1016/j.bbamem.2010.04.015; Pillet S, 2015, VACCINE, V33, P6282, DOI 10.1016/j.vaccine.2015.09.065; Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008; Pillet S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216533; Pillet S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0043-3; Plennevaux E, 2010, LANCET, V375, P41, DOI 10.1016/S0140-6736(09)62026-2; Ponndorf D, 2021, PLANT BIOTECHNOL J, V19, P745, DOI 10.1111/pbi.13501; PORTA C, 1994, VIROLOGY, V202, P949, DOI 10.1006/viro.1994.1417; Pushko P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050518; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; Rademacher T, 2008, PLANT BIOTECHNOL J, V6, P189, DOI 10.1111/j.1467-7652.2007.00306.x; Ramessar K, 2008, P NATL ACAD SCI USA, V105, P3727, DOI 10.1073/pnas.0708841104; Rathore U, 2018, J BIOL CHEM, V293, P15002, DOI 10.1074/jbc.RA118.005006; Rattanapisit K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74904-1; Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14; Remarque EJ, 2008, TRENDS PARASITOL, V24, P74, DOI 10.1016/j.pt.2007.12.002; Revill PA, 2019, LANCET GASTROENTEROL, V4, P545, DOI 10.1016/S2468-1253(19)30119-0; Rolland S, 2015, CAN MED ASSOC J, V187, P203, DOI 10.1503/cmaj.140151; Rosales-Mendoza S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020183; Rosales-Mendoza S, 2020, EXPERT OPIN BIOL TH, V20, P545, DOI 10.1080/14712598.2020.1752177; Rosales-Mendoza S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00252; Rosales-Mendoza S, 2015, MOL BIOTECHNOL, V57, P219, DOI 10.1007/s12033-014-9837-y; Rosales-Mendoza S, 2014, EXPERT REV VACCINES, V13, P203, DOI 10.1586/14760584.2014.872987; Rosales-Mendoza S, 2014, PLANT CELL TISS ORG, V116, P111, DOI 10.1007/s11240-013-0387-y; Rosales-Mendoza S, 2012, PLANT CELL REP, V31, P495, DOI 10.1007/s00299-011-1194-8; Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433; Rubio-Infante N, 2015, MOL BIOTECHNOL, V57, P662, DOI 10.1007/s12033-015-9856-3; Ruhl C, 2018, J CHROMATOGR A, V1571, P55, DOI 10.1016/j.chroma.2018.08.014; Rupp D, 2014, SEMIN LIVER DIS, V34, P9, DOI 10.1055/s-0034-1371006; Rybicki EP, 2014, VIROL J, V11, DOI 10.1186/s12985-014-0205-0; Rybicki EP, 2010, PLANT BIOTECHNOL J, V8, P620, DOI 10.1111/j.1467-7652.2010.00507.x; Rybicki EP, 2017, HUM VACC IMMUNOTHER, V13, P2912, DOI 10.1080/21645515.2017.1356497; Saba K, 2020, BIOTECHNOL APPL BIOC, V67, P148, DOI 10.1002/bab.1867; Saba K, 2019, J BIOTECHNOL, V305, P1, DOI 10.1016/j.jbiotec.2019.08.016; Salazar-Gonzalez JA, 2015, PLANT MOL BIOL, V87, P203, DOI 10.1007/s11103-014-0279-5; Salyaev RK, 2019, DOKL BIOCHEM BIOPHYS, V484, P52, DOI 10.1134/S1607672919010150; Schiller JT, 2008, VACCINE, V26, pK53, DOI 10.1016/j.vaccine.2008.06.002; Schultz-Cherry S, 2010, ADV VIRUS RES, V77, P63, DOI 10.1016/S0065-3527(10)77003-2; Scotti N, 2009, PLANTA, V229, P1109, DOI 10.1007/s00425-009-0898-2; Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783; Simmonds P, 2013, CURR TOP MICROBIOL, V369, P1, DOI 10.1007/978-3-642-27340-7_1; Singh AA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63052-1; Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316; Smith T, 2020, PLANT BIOTECHNOL J, V18, P502, DOI 10.1111/pbi.13219; Stepanova LA, 2018, ACTA NATURAE, V10, P85, DOI 10.32607/20758251-2018-10-1-85-94; Stepanova LA, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0433-5; Stephenson KE, 2015, J IMMUNOL METHODS, V416, P105, DOI 10.1016/j.jim.2014.11.006; STIRK HJ, 1992, INTERVIROLOGY, V33, P148, DOI 10.1159/000150244; Su J, 2015, BIOMATERIALS, V70, P84, DOI 10.1016/j.biomaterials.2015.08.004; Sun HY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010054; SUZICH JA, 1995, P NATL ACAD SCI USA, V92, P11553, DOI 10.1073/pnas.92.25.11553; Swanson MD, 2010, J BIOL CHEM, V285, P8646, DOI 10.1074/jbc.M109.034926; Tabll A, 2015, WORLD J HEPATOL, V7, P2369, DOI 10.4254/wjh.v7.i22.2369; Tacket CO, 2000, J INFECT DIS, V182, P302, DOI 10.1086/315653; Takano T, 2019, J VET MED SCI, V81, P911, DOI 10.1292/jvms.18-0702; Targett GA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S10; Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367; Thanavala Y, 2005, P NATL ACAD SCI USA, V102, P3378, DOI 10.1073/pnas.0409899102; Therien A, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0289-y; Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069; Tregoning JS, 2020, LANCET, V396, P1464, DOI 10.1016/S0140-6736(20)32010-9; Tremouillaux-Guiller J, 2020, CURR OPIN BIOTECH, V61, P209, DOI 10.1016/j.copbio.2020.01.004; Tuse D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/256135; Uhde-Holzem K, 2010, J VIROL METHODS, V166, P12, DOI 10.1016/j.jviromet.2010.01.017; Vamvaka E, 2018, P NATL ACAD SCI USA, V115, pE7854, DOI 10.1073/pnas.1806022115; Vamvaka E, 2016, PLANT BIOTECHNOL J, V14, P97, DOI 10.1111/pbi.12360; van Dolleweerd CJ, 2014, J INFECT DIS, V210, P200, DOI 10.1093/infdis/jiu085; Vezina L.P., 2012, Patent number, Patent No. [WO2012083445 (A1), 20120834451]; Villa LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469; Virdi V, 2013, INT J DEV BIOL, V57, P587, DOI 10.1387/ijdb.130266ad; Waheed MT, 2012, HUM VACC IMMUNOTHER, V8, DOI 10.4161/hv.8.3.18568; Walwyn DR, 2015, APPL BIOCHEM BIOTECH, V175, P841, DOI 10.1007/s12010-014-1320-5; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang BZ, 2007, J VIROL, V81, P10869, DOI 10.1128/JVI.00542-07; Wang L, 2008, INT J PARASITOL, V38, P103, DOI 10.1016/j.ijpara.2007.06.005; Ward B.J., 2020, PHASE 1 TRIAL CANDID, DOI [DOI 10.1101/2020.11.04.20226282, 10.1101/2020.11.04.20226282]; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Ward BJ, 2014, VACCINE, V32, P6098, DOI [10.1016/j.vaccine.2014.08.079, 10.10]; Wen YM, 2016, EMBO MOL MED, V8, P1120, DOI 10.15252/emmm.201606593; Wilder-Smith A, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1067-x; WILLIAMS MG, 1961, NATURE, V189, P895, DOI 10.1038/189895a0; Won SY, 2018, VACCINE, V36, P8028, DOI 10.1016/j.vaccine.2018.10.099; Wu T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10661-8; Xisto MF, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.581100; Xu JF, 2012, BIOTECHNOL ADV, V30, P1171, DOI 10.1016/j.biotechadv.2011.08.020; Yang M, 2018, PLANT BIOTECHNOL J, V16, P572, DOI 10.1111/pbi.12796; Yang M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08247-9; Yazdani R, 2019, BMC BIOTECHNOL, V19, DOI 10.1186/s12896-019-0566-y; Yuki Y, 2013, PLANT BIOTECHNOL J, V11, P799, DOI 10.1111/pbi.12071; Yusibov V, 2005, VACCINE, V23, P2261, DOI 10.1016/j.vaccine.2005.01.039; Yusibov V, 2002, VACCINE, V20, P3155, DOI 10.1016/S0264-410X(02)00260-8; Yusibov V, 2015, EXPERT REV VACCINES, V14, P519, DOI 10.1586/14760584.2015.989988; Zahmanova G, 2021, LIFE-BASEL, V11, DOI 10.3390/life11010064; Zahmanova GG, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9010029; Zeisel MB, 2013, CURR TOP MICROBIOL, V369, P87, DOI 10.1007/978-3-642-27340-7_4; Zeitlin L, 2011, P NATL ACAD SCI USA, V108, P20690, DOI 10.1073/pnas.1108360108; Zhang GG, 2002, MOL BIOTECHNOL, V20, P131, DOI 10.1385/MB:20:2:131; Zhang W, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006372; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	304	3	3	4	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							761	10.3390/vaccines9070761			35	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7ZL	34358177	gold, Green Published			2022-04-29	WOS:000677124400001
J	Gianfredi, V; Pennisi, F; Lume, A; Ricciardi, GE; Minerva, M; Ricco, M; Odone, A; Signorelli, C				Gianfredi, Vincenza; Pennisi, Flavia; Lume, Alessandra; Ricciardi, Giovanni Emanuele; Minerva, Massimo; Ricco, Matteo; Odone, Anna; Signorelli, Carlo			Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature	VACCINES			English	Review						health planning organizations; mass vaccination; vaccines; COVID-19; rapid review	INFLUENZA VACCINATION; UNITED-STATES; LOCAL HEALTH; MODEL; LESSONS; CLINICS; PREPAREDNESS; SIMULATION; EXPERIENCE; POINTS	A mass vaccination center is a location, normally used for nonhealthcare activities, set up for high-volume and high-speed vaccinations during infectious disease emergencies. The high contagiousness and mortality of COVID-19 and the complete lack of population immunity posed an extraordinary threat for global health. The aim of our research was to collect and review previous experiences on mass vaccination centers. On 4 April 2021, we developed a rapid review searching four electronic databases: PubMed/Medline, Scopus, EMBASE, Google Scholar and medRxiv. From a total of 2312 papers, 15 of them were included in the current review. Among them, only one article described a COVID-19 vaccination center; all of the others referred to other vaccinations, in particular influenza. The majority were conducted in the United States, and were simulations or single-day experiences to practice a mass vaccination after bioterrorist attacks. Indeed, all of them were published after September 11 attacks. Regarding staff, timing and performance, the data were highly heterogenous. Several studies used as a model the Center for Disease Control and Prevention guidelines. Results highlighted the differences around the definition, layout and management of a mass vaccination center, but some aspects can be considered as a core aspect. In light of this, we suggested a potential definition. The current review answers to the urgency of organizing a mass vaccination center during the COVID-19 pandemic, highlighting the most important organizational aspects that should be considered in the planning.	[Gianfredi, Vincenza; Pennisi, Flavia; Lume, Alessandra; Ricciardi, Giovanni Emanuele; Minerva, Massimo; Signorelli, Carlo] Univ Vita Salute San Raffaele, Sch Med, I-20132 Milan, Italy; [Gianfredi, Vincenza] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, NL-6211 Maastricht, Netherlands; [Ricco, Matteo] AUSL IRCCS Reggio Emilia, Serv Prevenz & Sicurezza Negli Ambienti Lavoro SP, Via Amendola 2, I-42122 Reggio Emilia, Italy; [Odone, Anna] Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy		Gianfredi, V (通讯作者)，Univ Vita Salute San Raffaele, Sch Med, I-20132 Milan, Italy.; Gianfredi, V (通讯作者)，Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, NL-6211 Maastricht, Netherlands.	gianfredi.vincenza@hsr.it; pennisi.flavia@hsr.it; lume.alessandra@hsr.it; ricciardi.giovanni@hsr.it; minerva.massimo@hsr.it; matteo.ricco@ausl.re.it; anna.odone@unipr.it; signorelli.carlo@hsr.it	Gianfredi, Vincenza/W-1408-2017; Signorelli, Carlo/AAC-7630-2022; Riccò, Matteo/T-8078-2019; Odone, Anna/AAC-4715-2022	Gianfredi, Vincenza/0000-0003-3848-981X; Riccò, Matteo/0000-0002-6525-2159; SIGNORELLI, Carlo/0000-0002-0960-9563; Ricciardi, Giovanni Emanuele/0000-0002-6903-655X			Andress Knox, 2003, Disaster Manag Response, V1, P54, DOI 10.1016/S1540-2487(03)00004-X; Arthur BC, 2015, J HEALTHC MANAG, V60, P429, DOI 10.1097/00115514-201511000-00009; Asllani A, 2007, J MED SYST, V31, P453, DOI 10.1007/s10916-007-9084-x; Azienda UnituSS Sanitaria Locale di Parma, VACC ANT 19 B 26 05; Bass SB, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.665724; Bull S, 2021, J MED ETHICS, V47, DOI 10.1136/medethics-2020-106504; Bundesanstalt fuar Arbeitsschutz und Arbeitsmedizin, EMPF AUSSCH BIOL ARB; Caum J, 2013, BIOSECUR BIOTERROR, V11, P262, DOI 10.1089/bsp.2013.0064; Cella Paola, 2020, J Prev Med Hyg, V61, pE340, DOI 10.15167/2421-4248/jpmh2020.61.3.1448; Centers for Disease Control and Prevention, 2009, GUID LARG SCAL NOV H; Cho BH, 2011, J PUBLIC HEALTH MAN, V17, pE22, DOI 10.1097/PHH.0b013e3181f87952; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Dervaux B, 2003, Int J Health Care Finance Econ, V3, P287, DOI 10.1023/A:1026021407108; Direction Gunurale de Santu Publique, 2021, ORG CTR VACC MASS CO; Ettkin, 2007, ACAD HLTH CARE MANAG, V3, P51; Fontanesi John, 2006, J Med Pract Manage, V21, P288; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; France24, 2021, FRANCE24; Garske T, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001638; Gerber R, 2007, J LAW MED ETHICS, V35, P495, DOI 10.1111/j.1748-720X.2007.00173.x; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Gianfredi V., 2019, J PREV MED HYG, V60, pE108; Gianfredi V, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00378; Gianfredi V, 2019, ANN I SUPER SANITA, V55, P209, DOI 10.4415/ANN_19_03_03; Gianfredi V, 2019, HUM VACC IMMUNOTHER, V15, P2508, DOI 10.1080/21645515.2019.1599675; Gianfredi Vincenza, 2018, Recenti Prog Med, V109, P374, DOI 10.1701/2955.29706; Gianfredi Vincenza, 2017, Recenti Progressi in Medicina, V108, P433, DOI 10.1701/2802.28356; Giot JL, 2003, ACTA GASTRO-ENT BELG, V66, P241; Goralnick E, 2021, NEW ENGL J MED, V384, pE67, DOI 10.1056/NEJMp2102535; Government of Canada, 2021, PLANN GUID IMM CLIN; Gupta A, 2013, SIMUL MODEL PRACT TH, V37, P99, DOI 10.1016/j.simpat.2013.06.004; Ha C, 2016, HEALTH SECUR, V14, P382, DOI 10.1089/hs.2016.0030; Ha C, 2016, MIL MED, V181, P582, DOI 10.7205/MILMED-D-15-00247; Iacobucci G, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4555; Jarrett S W, 1985, Assignment Child, V69-72, P243; Jenlink CH, 2010, J SCH NURS, V26, p14S, DOI 10.1177/1059840510372345; Jenlink CH, 2010, J SCH NURS, V26, p7S, DOI 10.1177/1059840510368960; Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629; Kuehnert P, 2010, J SCH NURS, V26, p27S, DOI 10.1177/1059840510368525; Lee TH, 2021, NEW ENGL J MED, V384, P685, DOI 10.1056/NEJMp2100574; Matteson LM, 2006, AM J NURS, V106, P28, DOI 10.1097/00000446-200610000-00023; Meyer D, 2018, AM J PUBLIC HEALTH, V108, pS188, DOI 10.2105/AJPH.2018.304527; Moher D, 2015, SYST REV, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; National Health Service, 2021, 001559 NAT HLTH SERV; Nicoll A, 2010, BUNDESGESUNDHEITSBLA, V53, P1267, DOI 10.1007/s00103-010-1163-3; Nolan Patricia, 2004, Med Health R I, V87, P65; Odone A., 2020, ACTA BIOMED, V91; Odone A, 2020, LANCET PUBLIC HEALTH, V5, pE310, DOI 10.1016/S2468-2667(20)30099-2; Olmsted SS, 2006, HEALTH EXPECT, V9, P110, DOI 10.1111/j.1369-7625.2006.00378.x; Paciullo F, 2021, ANN IG MED PREV COMU, V33, P198, DOI 10.7416/ai.2020.2392; Phillips FB, 2005, J PUBLIC HEALTH MAN, V11, P269; Porco TC, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-34; Porter D, 2011, J PUBLIC HEALTH MAN, V17, P530, DOI 10.1097/PHH.0b013e31822146eb; Privor-Dumm L, 2020, VACCINE, V38, P4170, DOI 10.1016/j.vaccine.2020.04.027; Rambhia KJ, 2010, BIOSECUR BIOTERROR, V8, P321, DOI 10.1089/bsp.2010.0043; Razai MS, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1138; Rebmann T, 2015, HEALTH SECUR, V13, P96, DOI 10.1089/hs.2014.0080; Rebmann T, 2015, AM J INFECT CONTROL, V43, P222, DOI 10.1016/j.ajic.2014.11.012; Ricco M, 2017, J Prev Med Hyg, V58, pE266, DOI 10.15167/2421-4248/jpmh2017.58.4.673; Ricco M, 2021, INFECT DIS NOW, V51, P402, DOI 10.1016/j.idnow.2021.03.001; Ricco Matteo, 2018, Minerva Pediatr, DOI 10.23736/S0026-4946.18.05206-4; Sarma H, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7176-4; Savitz S, 2007, MIL MED, V172, P353, DOI 10.7205/MILMED.172.4.353; Schindler Jay V, 2008, AMIA Annu Symp Proc, P1124; SCHWARTZ B, 2006, CURR TOP MICROBIOL, P131; Signorelli C, 2021, ANN IG MED PREV COMU, V33, P499, DOI 10.7416/ai.2021.2456; Signorelli Carlo, 2020, Acta Biomed, V91, P7, DOI [10.23750/abm.v91i3-S.9507, 10.23750/abm.v91i9-S.10134]; Signorelli Carlo, 2020, Acta Biomed, V91, P23, DOI 10.23750/abm.v91i2.9600; Signorelli Carlo, 2020, Acta Biomed, V91, P175, DOI 10.23750/abm.v91i3-S.9511; Sim F, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00451-3; Sutter RW, 2006, CURR TOP MICROBIOL, V304, P195; Swift MD, 2017, AM J PUBLIC HEALTH, V107, pS168, DOI [10.2105/AJPH.2017.303953, 10.2105/ajph.2017.303953]; Szilagyi PG, 2003, ARCH PEDIAT ADOL MED, V157, P191, DOI 10.1001/archpedi.157.2.191; Tricco AC., 2017, RAPID REV STRENGTHEN; Velimirovic B, 1981, Ric Clin Lab, V11 Suppl 2, P73; Wallace M, 2021, MMWR-MORBID MORTAL W, V70, P749, DOI 10.15585/mmwr.mm7020e1; Wood K., P INT C HLTH SCI SIM; World Health Organization, 2021, SPEC FEAT IMM COVID; Yang J, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-49	80	7	7	7	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							574	10.3390/vaccines9060574			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SY7CZ	34205891	Green Published, gold			2022-04-29	WOS:000666042700001
J	Herrera-Peco, I; Jimenez-Gomez, B; Magdalena, CSR; Deudero, JJ; Garcia-Puente, M; De Gracia, EB; Nunez, CR				Herrera-Peco, Ivan; Jimenez-Gomez, Beatriz; Romero Magdalena, Carlos Santiago; Jose Deudero, Juan; Garcia-Puente, Maria; Benitez De Gracia, Elvira; Ruiz Nunez, Carlos			Antivaccine Movement and COVID-19 Negationism: A Content Analysis of Spanish-Written Messages on Twitter	VACCINES			English	Article						COVID-19; fake news; misinformation; public health; Twitter; vaccines	SOCIAL MEDIA; VACCINATION; MISINFORMATION	During the COVID-19 pandemic, different conspiracies have risen, with the most dangerous being those focusing on vaccines. Today, there exists a social media movement focused on destroying the credibility of vaccines and trying to convince people to ignore the advice of governments and health organizations on vaccination. Our aim was to analyze a COVID-19 antivaccination message campaign on Twitter that uses Spanish as the main language, to find the key elements in their communication strategy. Twitter data were retrieved from 14 to 28 December using NodeXL software. We analyzed tweets in Spanish, focusing on influential users, most influential tweets, and content analysis of tweets. The results revealed ordinary citizens who 'offer the truth' as the most important profile in this network. The content analysis showed antivaccine tweets (31.05%) as the most frequent. The analysis of anti-COVID19 tweets showed that attacks against vaccine safety were the most important (79.87%) but we detected a new kind of message presenting the vaccine as a means of manipulating the human genetic code (8.1%). We concluded that the antivaccine movement and its tenets have great influence in the COVID-19 negationist movement. We observed a new topic in COVID-19 vaccine hoaxes that must be considered in our fight against misinformation.	[Herrera-Peco, Ivan; Jimenez-Gomez, Beatriz] Alfonso X El Sabio Univ, Fac Med, Nursing Dept, 28691 Villanueva de la Canada, Madrid 28040, Spain; [Romero Magdalena, Carlos Santiago; Jose Deudero, Juan; Benitez De Gracia, Elvira] Alfonso X El Sabio Univ, Fac Hlth Sci, Avda Univ 1,28691 Villanueva de la Canada, Madrid 28040, Spain; [Garcia-Puente, Maria] Fdn Jimenez Diaz, AlterBiblio, Avda Reyes Catolics 2, Madrid 28040, Spain; [Ruiz Nunez, Carlos] Loja High Resolut Hosp, APS Poniente, Av Tierno Galvan, Granada 18300, Spain		Herrera-Peco, I (通讯作者)，Alfonso X El Sabio Univ, Fac Med, Nursing Dept, 28691 Villanueva de la Canada, Madrid 28040, Spain.	iherrpec@uax.es; bgomejim@uax.es; cromemag@uax.es; jpenadeu@uax.es; maria@alterbiblio.com; eben@uax.es; cruiznu@gmail.com	Ruiz-Nuñez, Carlos/AAR-1147-2021; García-Puente, María/AAU-1008-2021; Herrera-Peco, Ivan/N-5569-2019	Ruiz-Nuñez, Carlos/0000-0003-2872-1494; García-Puente, María/0000-0002-6521-665X; Pena Deudero, Juan Jose/0000-0002-0203-2247; Benitez De Gracia, Elvira/0000-0002-7630-9624; Herrera-Peco, Ivan/0000-0002-5183-5679; Romero Magdalena, Carlos Santiago/0000-0002-3642-3422			Adil MT, 2021, POSTGRAD MED J, V97, P110, DOI 10.1136/postgradmedj-2020-138386; Ahmed W., 2017, ETHICS ONLINE RES; Ahmed W, 2020, J MED INTERNET RES, V22, DOI 10.2196/22374; Ahmed W, 2020, J MED INTERNET RES, V22, DOI 10.2196/19458; Allcott H, 2017, J ECON PERSPECT, V31, P211, DOI 10.1257/jep.31.2.211; [Anonymous], MERRIAM WEBSTER; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4; Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3; Bello-Orgaz G, 2017, FUTURE GENER COMP SY, V66, P125, DOI 10.1016/j.future.2016.06.032; Benecke Olivia, 2019, Glob Pediatr Health, V6, p2333794X19862949, DOI 10.1177/2333794X19862949; Bennett WL, 2018, EUR J COMMUN, V33, P122, DOI 10.1177/0267323118760317; Bora K, 2018, PATHOG GLOB HEALTH, V112, P320, DOI 10.1080/20477724.2018.1507784; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Garcinuno MIC, 2020, REV ESP SALUD PUBLIC, V94; Center for Countering Digital Hate, 2020, FAIL ACT; Centro Virtual Cervantes, INF 2019; Chou WYS, 2018, JAMA-J AM MED ASSOC, V320, P2417, DOI 10.1001/jama.2018.16865; Clauset A, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.066111; Cori L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093114; Evrony A, 2017, HUM VACC IMMUNOTHER, V13, P1475, DOI 10.1080/21645515.2017.1283467; Fournet N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5103-8; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Fung ICH, 2016, PUBLIC HEALTH REP, V131, P461, DOI 10.1177/003335491613100312; Gunaratne K, 2019, VACCINE, V37, P4867, DOI 10.1016/j.vaccine.2019.06.086; Herrera-Peco I., 2021, REV ESP SALUD PUBLIC, V95; Jamison A, 2020, AM J PUBLIC HEALTH, V110, pS331, DOI 10.2105/AJPH.2020.305940; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Jonnalagadda S, 2012, J BIOMED SEMANT, V3, DOI 10.1186/2041-1480-3-2; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Kirby T, 2021, LANCET RESP MED, V9, pE20, DOI 10.1016/S2213-2600(21)00005-9; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Larson HJ, 2018, NATURE, V562, P309, DOI 10.1038/d41586-018-07034-4; Lopez Santamaria M.A., 2015, REV ENE ENFERMERIA, V9, DOI [10.4321/S1988-348X2015000300011, DOI 10.4321/S1988-348X2015000300011]; McStay A, 2016, BIG DATA SOC, V3, DOI 10.1177/2053951716666868; Park HW, 2020, J MED INTERNET RES, V22, DOI 10.2196/18897; Perez-Fuentes MD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040692; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rosselli R, 2016, J Prev Med Hyg, V57, pE47; Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433; Rubin GJ, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m313; Ruiz C, 2021, RADIOGRAPHY, V27, P414, DOI 10.1016/j.radi.2020.10.001; Saha K, 2019, TRANSL BEHAV MED, V9, P1197, DOI 10.1093/tbm/ibz028; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Santillan A., 2018, TIEMPOS ENFERMERIA S, V5, P50; Sarwar Z, 2020, MOL BIOL REP, V47, P9939, DOI 10.1007/s11033-020-05988-1; Schwenk ES, 2020, ANESTH ANALG, V130, P333, DOI 10.1213/ANE.0000000000004036; Smith N, 2019, INFORM COMMUN SOC, V22, P1310, DOI 10.1080/1369118X.2017.1418406; Steffens MS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7659-3; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430	52	5	5	8	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							656	10.3390/vaccines9060656			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6NK	34203946	Green Published, gold			2022-04-29	WOS:000666679300001
J	Kim, T; Park, SY; Yu, S; Park, JW; Lee, E; Jeon, MH; Kim, TH; Choo, EJ				Kim, Tark; Park, Se Yoon; Yu, Shinae; Park, Jung Wan; Lee, Eunjung; Jeon, Min Hyok; Kim, Tae Hyong; Choo, Eun Ju			Impacts of Side Effects to BNT162b2 and the First Dose of ChAdOx1 Anti-SARS-CoV-2 Vaccination on Work Productivity, the Need for Medical Attention, and Vaccine Acceptance: A Multicenter Survey on Healthcare Workers in Referral Teaching Hospitals in the Republic of Korea	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccination; side effect	SAFETY	To establish a successful anti-SARS-CoV-2 vaccination strategy, it is necessary to take possible tradeoffs into account. We conducted a survey on vaccinated healthcare workers (HCWs) inthree referral teaching hospitals in the Republic of Korea. We investigated the frequency of vaccination side effects (SEs), the impact on their work productivity, the need for medical attention, and vaccine acceptance. Three groups of HCWs were surveyed: 1406 who had received the first dose of BNT162b2 (BNT162b2#1), 1168 who had received the second dose of BNT162b2 (BNT162b2#2), and 1679 who had received the first dose of ChAdOx1 (ChAdOx1#1). More SEs and impact on work productivity were reported in ChAdOx1#1 than in the other two groups. However, among individuals aged >= 40 years, no significant difference of absence from work was found between ChAdOx1#1 and BN162b2#2 (4.4%, 31/699 vs. 3.0%, 12/405; p = 0.26), and none were hospitalized. Older HCWs in ChAdOx1#1 showed intention to receive the second dose of the vaccine. Although the incidence of SEs and their impacts were greater after the first dose of ChAdOx1 than BNT162b2 in young people, significant impact of SEs seemed to be rare in individuals aged >= 40 years, regardless of the vaccine they received.	[Kim, Tark; Choo, Eun Ju] Soonchunhyang Univ, Coll Med, Dept Internal Med, Div Infect Dis,Bucheon Hosp, Bucheon 14584, South Korea; [Park, Se Yoon; Lee, Eunjung; Kim, Tae Hyong] Soonchunhyang Univ, Coll Med, Dept Internal Med, Div Infect Dis,Seoul Hosp, Seoul 04401, South Korea; [Yu, Shinae; Park, Jung Wan; Jeon, Min Hyok] Soonchunhyang Univ, Coll Med, Dept Internal Med, Div Infect Dis,Cheonan Hosp, Cheonan 31151, South Korea		Choo, EJ (通讯作者)，Soonchunhyang Univ, Coll Med, Dept Internal Med, Div Infect Dis,Bucheon Hosp, Bucheon 14584, South Korea.	ktocc@schmc.ac.kr; sypark@schmc.ac.kr; zolzoly@schmc.ac.kr; splendidmagic@schmc.ac.kr; shegets@schmc.ac.kr; yacsog@schmc.ac.kr; geuncom@schmc.ac.kr; mdchoo@schmc.ac.kr	Kim, Tae Hyong/L-7336-2015	Kim, Tae Hyong/0000-0003-2920-9038	Soonchunhyang University	This study was supported by Soonchunhyang University Research Fund (2021).	Bae S, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e115; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; European Medicines Agency, ASTRAZENECAS COVID 1; Kadali RAK, 2021, INT J INFECT DIS, V106, P376, DOI 10.1016/j.ijid.2021.04.047; Kadali RAK, 2021, J MED VIROL, V93, P4420, DOI 10.1002/jmv.26996; Kim SH, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e107; Mathioudakis AG, 2021, LIFE-BASEL, V11, DOI 10.3390/life11030249; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; O'Driscoll M, 2020, NATURE, DOI 10.1038/s41586-020-2918-0; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rief W, 2021, JAMA HLTH FORUM, DOI [10.1001/jamahealthforum.2021.0804, DOI 10.1001/JAMAHEALTHFORUM.2021.0804]; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Shimabukuro T, COVID 19 VACCINE SAF; Song JY, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e110; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; WHO, WHO COR COVID 19 DAS; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zimmer C., NEW YORK TIMES	20	6	6	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							648	10.3390/vaccines9060648			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3HQ	34198562	Green Published, gold			2022-04-29	WOS:000666461000001
J	Knorr, S; Reissert-Oppermann, S; Tomas-Cortazar, J; Barriales, D; Azkargorta, M; Iloro, I; Elortza, F; Pinecki-Socias, S; Anguita, J; Hovius, JW; Nijhof, AM				Knorr, Sarah; Reissert-Oppermann, Sophia; Tomas-Cortazar, Julen; Barriales, Diego; Azkargorta, Mikel; Iloro, Ibon; Elortza, Felix; Pinecki-Socias, Sophia; Anguita, Juan; Hovius, Joppe W.; Nijhof, Ard M.			Identification and Characterization of Immunodominant Proteins from Tick Tissue Extracts Inducing a Protective Immune Response against Ixodes ricinus in Cattle	VACCINES			English	Article						Ixodes ricinus; immunoprecipitation; anti-tick vaccines; midgut; salivary glands	BOOPHILUS-MICROPLUS; RNA INTERFERENCE; BINDING-SITE; RHIPICEPHALUS; METALLOPROTEASES; DETOXIFICATION; INFESTATIONS; VACCINATION; SUBUNIT; ANTIGEN	Ixodes ricinus is the main vector of tick-borne diseases in Europe. An immunization trial of calves with soluble extracts of I. ricinus salivary glands (SGE) or midgut (ME) previously showed a strong response against subsequent tick challenge, resulting in diminished tick feeding success. Immune sera from these trials were used for the co-immunoprecipitation of tick tissue extracts, followed by LC-MS/MS analyses. This resulted in the identification of 46 immunodominant proteins that were differentially recognized by the serum of immunized calves. Some of these proteins had previously also drawn attention as potential anti-tick vaccine candidates using other approaches. Selected proteins were studied in more detail by measuring their relative expression in tick tissues and RNA interference (RNAi) studies. The strongest RNAi phenotypes were observed for MG6 (A0A147BXB7), a protein containing eight fibronectin type III domains predominantly expressed in tick midgut and ovaries of feeding females, and SG2 (A0A0K8RKT7), a glutathione-S-transferase that was found to be upregulated in all investigated tissues upon feeding. The results demonstrated that co-immunoprecipitation of tick proteins with host immune sera followed by protein identification using LC-MS/MS is a valid approach to identify antigen-antibody interactions, and could be integrated into anti-tick vaccine discovery pipelines.	[Knorr, Sarah; Reissert-Oppermann, Sophia; Pinecki-Socias, Sophia; Nijhof, Ard M.] Free Univ Berlin, Inst Parasitol & Trop Vet Med, D-14163 Berlin, Germany; [Tomas-Cortazar, Julen] Univ Coll Dublin, Sch Biomol & Biomed Sci, Dublin D04 V1W8 4, Ireland; [Barriales, Diego; Azkargorta, Mikel; Iloro, Ibon; Elortza, Felix; Anguita, Juan] CIC BioGUNE BRTA Basque Res & Technol Alliance, Derio 48162, Spain; [Anguita, Juan] Basque Fdn Sci, Ikerbasque, Bilbao 48009, Spain; [Hovius, Joppe W.] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, NL-1105 AZ Amsterdam, Netherlands		Nijhof, AM (通讯作者)，Free Univ Berlin, Inst Parasitol & Trop Vet Med, D-14163 Berlin, Germany.	knorr.sarah.j@gmail.com; sophia.reissert@googlemail.com; julen.tomascortazar@ucd.ie; dbarriales@cicbiogune.es; mazkargorta@cicbiogune.es; iiloro@cicbiogune.es; felortza@cicbiogune.es; Sophia.Pinecki@fu-berlin.de; janguita@cicbiogune.es; lyme@amc.uva.nl; ard.nijhof@fu-berlin.de	Barriales, Diego/AAE-3261-2019; Anguita, Juan/D-5432-2011	Barriales, Diego/0000-0002-6433-3379; Anguita, Juan/0000-0003-2061-7182; Elortza, Felix/0000-0001-8839-5438; Tomas Cortazar, Julen/0000-0002-0812-0395	European Community's Seventh Framework ProgramEuropean Commission [602272]; Federal Ministry of Education and Research (BMBF), 'Research Network Zoonotic Infectious Diseases'Federal Ministry of Education & Research (BMBF) [01KI1720]; MCI predoctoral fellowship; Basque GovernmentBasque Government; Jesus de Gangoiti Barrera Foundation; Spanish Ministry of Science and Innovation (MCI)Spanish Government [SEV-2016-0644]	This research was funded by the European Community's Seventh Framework Program under grant agreement 602272. A.M.N. and S.P.-S. received financial support from the Federal Ministry of Education and Research (BMBF) under project number 01KI1720 as part of the `Research Network Zoonotic Infectious Diseases'. CIC bioGUNE is accredited as a Severo Ochoa Center of Excellence by the Spanish Ministry of Science and Innovation (MCI, SEV-2016-0644). D.B. is supported by an MCI predoctoral fellowship. J.T.-C. is a recipient of a postdoctoral award from the Basque Government. J.A. and D.B. acknowledge the support of the Jesus de Gangoiti Barrera Foundation.	Almazan C, 2012, VACCINE, V30, P265, DOI 10.1016/j.vaccine.2011.10.102; Almazan C, 2010, PARASITOL RES, V106, P471, DOI 10.1007/s00436-009-1689-1; Apostolovic D, 2020, ALLERGY, V75, P217, DOI 10.1111/all.13978; Apostolovic D, 2016, ALLERGO J, V25, P29, DOI 10.1007/s15007-016-1044-7; Barry G, 2013, EXP APPL ACAROL, V59, P319, DOI 10.1007/s10493-012-9598-x; Cooper AM, 2019, PEST MANAG SCI, V75, P18, DOI 10.1002/ps.5126; de la Fuente Jose, 2007, Animal Health Research Reviews, V8, P23, DOI 10.1017/S1466252307001193; Debalke S, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3414-y; Decrem Y, 2008, INT J PARASITOL, V38, P549, DOI 10.1016/j.ijpara.2007.09.003; Decrem Y, 2008, FEBS J, V275, P1485, DOI 10.1111/j.1742-4658.2008.06308.x; Diaz-Martin V, 2013, VET PARASITOL, V191, P301, DOI 10.1016/j.vetpar.2012.09.019; Duscher GG, 2014, TICKS TICK-BORNE DIS, V5, P225, DOI 10.1016/j.ttbdis.2013.11.006; Embers ME, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00006; Gao JL, 2007, VET PARASITOL, V147, P140, DOI 10.1016/j.vetpar.2007.03.007; Henderson B, 2011, FEMS MICROBIOL REV, V35, P147, DOI 10.1111/j.1574-6976.2010.00243.x; Hernandez EP, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3044-9; Heyman P, 2010, EXPERT REV ANTI-INFE, V8, P33, DOI [10.1586/eri.09.118, 10.1586/ERI.09.118]; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; Hu E, 2020, EXP APPL ACAROL, V82, P295, DOI 10.1007/s10493-020-00546-7; Huercha, 2020, VET PARASITOL, V279, DOI 10.1016/j.vetpar.2020.109043; KEMP DH, 1986, INT J PARASITOL, V16, P115, DOI 10.1016/0020-7519(86)90096-2; Knorr S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01696; Koci J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85624-5; Kumar B, 2017, VACCINE, V35, P5682, DOI 10.1016/j.vaccine.2017.08.049; Manjunathachar HV, 2019, TRANSBOUND EMERG DIS, V66, P422, DOI 10.1111/tbed.13038; Mans BJ, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.574405; Narasimhan S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004278; Ndawula C, 2019, VACCINE, V37, P1918, DOI 10.1016/j.vaccine.2019.02.039; Nijhof AM, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-112; Park Y, 2014, DEV COMP IMMUNOL, V47, P59, DOI 10.1016/j.dci.2014.06.017; Rego ROM, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3468-x; Renne T, 1999, J BIOL CHEM, V274, P25777, DOI 10.1074/jbc.274.36.25777; Sigrist CJA, 2013, NUCLEIC ACIDS RES, V41, pE344, DOI 10.1093/nar/gks1067; Sprong H, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2744-5; Sugahara R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119429; Surakasi VP, 2011, J INSECT PHYSIOL, V57, P1537, DOI 10.1016/j.jinsphys.2011.08.006; Tian MY, 2015, VET PARASITOL, V207, P318, DOI 10.1016/j.vetpar.2014.10.007; Tian ZC, 2011, VET PARASITOL, V181, P282, DOI 10.1016/j.vetpar.2011.04.026; Trentelman JJA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76268-y; Trentelman JJA, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3616-3; Vaca DJ, 2020, MED MICROBIOL IMMUN, V209, P277, DOI 10.1007/s00430-019-00644-3; Willadsen P, 2004, PARASITOLOGY, V129, pS367, DOI 10.1017/S0031182003004657; WILLADSEN P, 1989, J IMMUNOL, V143, P1346; Willadsen P., 2008, DEV NEW IMPROVED VAC; Xu L, 2019, J MED ENTOMOL, V56, P569, DOI 10.1093/jme/tjy200	45	0	0	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							636	10.3390/vaccines9060636			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ4IT	34200738	Green Published, gold			2022-04-29	WOS:000666531500001
J	Stephens, LM; Varga, SM				Stephens, Laura M.; Varga, Steven M.			Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population	VACCINES			English	Review						respiratory syncytial virus; RSV; vaccine; elderly; immune senescence; aged; defect	T-CELL RESPONSES; TRIVALENT INFLUENZA VACCINE; RECOMBINANT BCG VACCINE; ADULTS 65 YEARS; IMMUNE-RESPONSES; DENDRITIC CELLS; RISK-FACTORS; CYTOKINE PRODUCTION; RELATIVE EFFICACY; SUBUNIT VACCINE	Respiratory syncytial virus (RSV) is most commonly associated with acute lower respiratory tract infections in infants and children. However, RSV also causes a high disease burden in the elderly that is often under recognized. Adults >65 years of age account for an estimated 80,000 RSV-associated hospitalizations and 14,000 deaths in the United States annually. RSV infection in aged individuals can result in more severe disease symptoms including pneumonia and bronchiolitis. Given the large disease burden caused by RSV in the aged, this population remains an important target for vaccine development. Aging results in lowered immune responsiveness characterized by impairments in both innate and adaptive immunity. This immune senescence poses a challenge when developing a vaccine targeting elderly individuals. An RSV vaccine tailored towards an elderly population will need to maximize the immune response elicited in order to overcome age-related defects in the immune system. In this article, we review the hurdles that must be overcome to successfully develop an RSV vaccine for use in the elderly, and discuss the vaccine candidates currently being tested in this highly susceptible population.	[Stephens, Laura M.; Varga, Steven M.] Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA; [Varga, Steven M.] Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA; [Varga, Steven M.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA		Varga, SM (通讯作者)，Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA.; Varga, SM (通讯作者)，Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA.; Varga, SM (通讯作者)，Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA.	laura-stephens@uiowa.edu; steven-varga@uiowa.edu		Varga, Steven/0000-0001-7332-4290	National Institute of Allergy and Infectious Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI124093, T32CA078586]	This work was supported by funds by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI124093 (to S.M.V.) and T32CA078586 (to L.M.S.).	Abarca K, 2020, ECLINICALMEDICINE, V27, DOI 10.1016/j.eclinm.2020.100517; Ackerson B, 2020, J INFECT DIS, V222, P962, DOI 10.1093/infdis/jiaa183; Ackerson B, 2019, CLIN INFECT DIS, V69, P197, DOI 10.1093/cid/ciy991; Alansari K, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-2308; Aliprantis AO, 2021, HUM VACC IMMUNOTHER, V17, P1248, DOI 10.1080/21645515.2020.1829899; Alsaleh G, 2020, ELIFE, V9, DOI 10.7554/eLife.57950; Ambrose CS, 2011, INFLUENZA OTHER RESP, V5, P67, DOI 10.1111/j.1750-2659.2010.00183.x; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Anderson EJ, 2017, PEDIATR INFECT DIS J, V36, P699, DOI [10.1097/INF.0000000000001533, 10.1097/inf.0000000000001533]; Aoshiba K, 2007, FEBS LETT, V581, P3512, DOI 10.1016/j.febslet.2007.06.075; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Behzad H, 2012, J INFECT DIS, V205, P466, DOI 10.1093/infdis/jir769; Boraschi D, 2014, IMMUNOL LETT, V162, P346, DOI 10.1016/j.imlet.2014.06.006; Boukhvalova MS, 2007, J INFECT DIS, V195, P511, DOI 10.1086/510628; Briceno O, 2016, AGING CELL, V15, P14, DOI 10.1111/acel.12384; Bulati M, 2011, AGEING RES REV, V10, P274, DOI 10.1016/j.arr.2010.12.002; Caproni E, 2012, J IMMUNOL, V188, P3088, DOI 10.4049/jimmunol.1101764; Cayatte C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188708; Cespedes PF, 2017, VACCINE, V35, P757, DOI 10.1016/j.vaccine.2016.12.048; Chen L, 2021, EXPERT REV ANTI-INFE, V19, P787, DOI 10.1080/14787210.2021.1846520; Chen M, 2014, NAT MED, V20, P507, DOI 10.1038/nm.3521; Cherukuri A, 2013, CLIN VACCINE IMMUNOL, V20, P239, DOI 10.1128/CVI.00580-12; Cicconi P, 2020, CLIN INFECT DIS, V70, P2073, DOI 10.1093/cid/ciz653; Couch RB, 2007, VACCINE, V25, P7656, DOI 10.1016/j.vaccine.2007.08.042; Cullen LM, 2017, HUM VACC IMMUNOTHER, V13, P2814, DOI 10.1080/21645515.2017.1329069; Cusi Maria Grazia, 2010, Immun Ageing, V7, P14, DOI 10.1186/1742-4933-7-14; de Bree GJ, 2005, J INFECT DIS, V191, P1710, DOI 10.1086/429695; den Braber I, 2012, IMMUNITY, V36, P288, DOI 10.1016/j.immuni.2012.02.006; DiazGranados CA, 2013, VACCINE, V31, P861, DOI 10.1016/j.vaccine.2012.12.013; Dock J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182498; Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011; Duncan CB, 2009, J INFECT DIS, V200, P1242, DOI 10.1086/605948; Eichinger KM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01673; Falloon J, 2017, J INFECT DIS, V216, P1362, DOI 10.1093/infdis/jix503; Falloon J, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/cvi.00157-17, 10.1128/CVI.00157-17]; Falsey AR, 2006, J MED VIROL, V78, P1493, DOI 10.1002/jmv.20724; Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790; Falsey AR, 1998, J INFECT DIS, V177, P463, DOI 10.1086/517376; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; Fink PJ, 2013, ANNU REV IMMUNOL, V31, P31, DOI 10.1146/annurev-immunol-032712-100010; Fleming DM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1218-z; Frasca D, 2004, J IMMUNOL, V172, P2155, DOI 10.4049/jimmunol.172.4.2155; Fries L, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0090-7; Fulton RB, 2013, J VIROL, V87, P12694, DOI 10.1128/JVI.02282-12; Gibson KL, 2009, AGING CELL, V8, P18, DOI 10.1111/j.1474-9726.2008.00443.x; Gordon A, 2018, CURR EPIDEMIOL REP, V5, P1, DOI 10.1007/s40471-018-0136-1; Goritzka M, 2014, J VIROL, V88, P6128, DOI 10.1128/JVI.00333-14; Green CA, 2019, J INFECTION, V78, P382, DOI 10.1016/j.jinf.2019.02.003; Griffiths CD, 2020, NATURE, V583, P615, DOI 10.1038/s41586-020-2369-7; GSK, 2020, GSK PRES POS CLIN DA; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; Han LL, 1999, J INFECT DIS, V179, P25, DOI 10.1086/314567; Haynes BF, 2000, IMMUNOL RES, V22, P253, DOI 10.1385/IR:22:2-3:253; Hearps AC, 2012, AGING CELL, V11, P867, DOI 10.1111/j.1474-9726.2012.00851.x; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; Hijano DR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00566; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245; Jing Y, 2009, HUM IMMUNOL, V70, P777, DOI 10.1016/j.humimm.2009.07.005; Jordan E, 2021, J INFECT DIS, V223, P1062, DOI 10.1093/infdis/jiaa460; Joyce C, 2018, VACCINE, V36, P4265, DOI 10.1016/j.vaccine.2018.05.112; Jozwik A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10224; Kaneko M, 2001, PEDIATR INT, V43, P489, DOI 10.1046/j.1442-200X.2001.01438.x; Khurana S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002920; Kinnear E, 2018, MUCOSAL IMMUNOL, V11, P249, DOI [10.1038/mi.2017.46, 10.1038/mi.2017.79]; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Le Page A, 2018, EXP GERONTOL, V105, P128, DOI 10.1016/j.exger.2018.01.005; Lee N, 2013, CLIN INFECT DIS, V57, P1069, DOI 10.1093/cid/cit471; Levin MJ, 2018, J CLIN INVEST, V128, P4429, DOI [10.1172/JCI121484, 10.1172/jci121484]; Li G, 2012, AGING CELL, V11, P968, DOI 10.1111/j.1474-9726.2012.00867.x; Looney RJ, 2002, J INFECT DIS, V185, P682, DOI 10.1086/339008; Luangrath Mitchell A, 2021, Immunohorizons, V5, P59, DOI 10.4049/immunohorizons.2000067; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; Magro M, 2012, P NATL ACAD SCI USA, V109, P3089, DOI 10.1073/pnas.1115941109; McCoy K, 2007, J VIROL, V81, P6594, DOI 10.1128/JVI.02497-06; McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914; MEROLLA R, 1995, AM J RESP CRIT CARE, V152, P1358, DOI 10.1164/ajrccm.152.4.7551395; Meyer KC, 1996, AM J RESP CRIT CARE, V153, P1072, DOI 10.1164/ajrccm.153.3.8630547; Narbona-Lopez E, 2018, MINERVA PEDIATR, V70, P513, DOI [10.23736/s0026-4946.16.04630-2, 10.23736/S0026-4946.16.04630-2]; Ng TWY, 2019, J INFECT DIS, V219, P1525, DOI 10.1093/infdis/jiy720; Ngwuta JO, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4241; Novavax, 2016, NOV ANN TOPLRSV F VA; Novavax, 2017, NOV ANN POS TOPL DAT; O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061; Panda A, 2010, J IMMUNOL, V184, P2518, DOI 10.4049/jimmunol.0901022; Parrish AR, 2017, TISSUE BARRIERS, V5, DOI 10.1080/21688370.2017.1343172; Pennings JLA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35180-2; Phadwal K, 2012, AUTOPHAGY, V8, P677, DOI 10.4161/auto.18935; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prakash S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/436438; Puleston DJ, 2014, ELIFE, V3, DOI 10.7554/eLife.03706; Qian F, 2011, J INFECT DIS, V203, P1415, DOI 10.1093/infdis/jir048; Quinn KM, 2018, CELL REP, V23, P3512, DOI 10.1016/j.celrep.2018.05.057; Renkema KR, 2014, J IMMUNOL, V192, P151, DOI 10.4049/jimmunol.1301453; Rodriguez R, 2014, J INFECTION, V68, pS115, DOI 10.1016/j.jinf.2013.09.021; Roos-van Eijndhoven DG, 2001, J MED VIROL, V63, P293, DOI 10.1002/1096-9071(200104)63:4&lt;293::AID-JMV1004&gt;3.0.CO;2-C; Roumanes D, 2018, J INFECT DIS, V218, P418, DOI 10.1093/infdis/jiy016; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Sadoff Jerald, 2021, J Infect Dis, DOI 10.1093/infdis/jiab003; Sadoff J, 2021, J INFECT DIS, V223, P699, DOI 10.1093/infdis/jiaa409; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Samy N, 2020, VACCINE, V38, P2608, DOI 10.1016/j.vaccine.2020.01.055; Schmidt ME, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006810; Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402; Shi T, 2020, J INFECT DIS, V222, pS577, DOI 10.1093/infdis/jiz059; Sommer Constanze, 2011, Open Microbiol J, V5, P144, DOI 10.2174/1874285801105010144; Sridharan A, 2011, AGE, V33, P363, DOI 10.1007/s11357-010-9191-3; Steger MM, 1996, CLIN EXP IMMUNOL, V105, P544, DOI 10.1046/j.1365-2249.1996.d01-790.x; Stranks AJ, 2015, J INNATE IMMUN, V7, P375, DOI 10.1159/000370112; Tatsis N, 2006, GENE THER, V13, P421, DOI 10.1038/sj.gt.3302675; Tayyari F, 2011, NAT MED, V17, P1132, DOI 10.1038/nm.2444; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Toapanta FR, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-112; Tricco AC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4029; Van Epps P, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00498-16; Walsh EE, 2013, J INFECT DIS, V207, P1424, DOI 10.1093/infdis/jit038; Walsh EE, 2004, J INFECT DIS, V190, P373, DOI 10.1086/421524; Walsh EE, 2004, J INFECT DIS, V189, P233, DOI 10.1086/380907; WARE JH, 1990, AM J EPIDEMIOL, V132, P685, DOI 10.1093/oxfordjournals.aje.a115710; Weinberger B, 2016, BIOGERONTOLOGY, V17, P177, DOI 10.1007/s10522-015-9576-x; Widjojoatmodjo MN, 2015, VACCINE, V33, P5406, DOI 10.1016/j.vaccine.2015.08.056; Williams K, 2020, J INFECT DIS, V222, P979, DOI 10.1093/infdis/jiaa193; Wong TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088764; Wroe PC, 2012, J INFECT DIS, V205, P1589, DOI 10.1093/infdis/jis240; Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025; Zacca ER, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140672; Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777	129	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							624	10.3390/vaccines9060624			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY4WW	34207770	Green Published, gold			2022-04-29	WOS:000665891300001
J	Van Tilbeurgh, M; Lemdani, K; Beignon, AS; Chapon, C; Tchitchek, N; Cheraitia, L; Lopez, EM; Pascal, Q; Le Grand, R; Maisonnasse, P; Manet, C				Van Tilbeurgh, Matthieu; Lemdani, Katia; Beignon, Anne-Sophie; Chapon, Catherine; Tchitchek, Nicolas; Cheraitia, Lina; Marcos Lopez, Ernesto; Pascal, Quentin; Le Grand, Roger; Maisonnasse, Pauline; Manet, Caroline			Predictive Markers of Immunogenicity and Efficacy for Human Vaccines	VACCINES			English	Review						vaccines; systems immunology; predictive biomarkers; vaccine signatures; preclinical models; high-throughput technologies; in vivo imaging; unsupervised analyses; machine learning	NEUTRALIZING ANTIBODY-RESPONSES; MACROPHAGE MANNOSE RECEPTOR; IMAGING MASS-SPECTROMETRY; HUMORAL IMMUNE-RESPONSES; HEPATITIS-B VACCINATION; T-CELL RESPONSES; IN-VIVO; DENDRITIC CELLS; FLOW-CYTOMETRY; SYSTEMS VACCINOLOGY	Vaccines represent one of the major advances of modern medicine. Despite the many successes of vaccination, continuous efforts to design new vaccines are needed to fight "old" pandemics, such as tuberculosis and malaria, as well as emerging pathogens, such as Zika virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccination aims at reaching sterilizing immunity, however assessing vaccine efficacy is still challenging and underscores the need for a better understanding of immune protective responses. Identifying reliable predictive markers of immunogenicity can help to select and develop promising vaccine candidates during early preclinical studies and can lead to improved, personalized, vaccination strategies. A systems biology approach is increasingly being adopted to address these major challenges using multiple high-dimensional technologies combined with in silico models. Although the goal is to develop predictive models of vaccine efficacy in humans, applying this approach to animal models empowers basic and translational vaccine research. In this review, we provide an overview of vaccine immune signatures in preclinical models, as well as in target human populations. We also discuss high-throughput technologies used to probe vaccine-induced responses, along with data analysis and computational methodologies applied to the predictive modeling of vaccine efficacy.	[Van Tilbeurgh, Matthieu; Lemdani, Katia; Beignon, Anne-Sophie; Chapon, Catherine; Cheraitia, Lina; Marcos Lopez, Ernesto; Pascal, Quentin; Le Grand, Roger; Maisonnasse, Pauline; Manet, Caroline] Univ Paris Sud INSERM U1184, Immunol Viral Infect & Autoimmune Dis IMVA, IDMIT Dept, Inst Biol Francois Jacob IBJF,CEA, F-92265 Fontenay Aux Roses, France; [Tchitchek, Nicolas] Hop La Pitie Salpetriere, Unite Rech i3, Inserm UMR S 959, Batiment CERVI, F-75013 Paris, France		Manet, C (通讯作者)，Univ Paris Sud INSERM U1184, Immunol Viral Infect & Autoimmune Dis IMVA, IDMIT Dept, Inst Biol Francois Jacob IBJF,CEA, F-92265 Fontenay Aux Roses, France.	matthieu.van-tilbeurgh@cea.fr; lemdani.katia@gmail.com; anne-sophie.beignon@cea.fr; catherine.chapon@cea.fr; nicolas.tchitchek@sorbonne-universite.fr; lina.cheraitia@yahoo.com; ernesto.marcos-lopez@cea.fr; quentin.pascal@cea.fr; roger.le-grand@cea.fr; pauline.maisonnasse@cea.fr; caroline.manet@cea.fr		Tchitchek, Nicolas/0000-0003-3307-0446; Manet, Caroline/0000-0002-7730-8818; Le Grand, Roger/0000-0002-4928-4484; Maisonnasse, Pauline/0000-0002-0555-207X; Chapon, Catherine/0000-0002-3210-8468; PASCAL, Quentin/0000-0001-5842-7080	ANRFrench National Research Agency (ANR) [ANR-11-INBS-0008]	The Infectious Disease Models and Innovative Therapies (IDMIT) research infrastructure is supported by the `Programme Investissements d'Avenir', managed by the ANR (ANR-11-INBS-0008). The Fondation Bettencourt Schueller and the Region Ile-de-France contributed to the implementation of IDMIT's facilities and imaging technologies.	Aarntzen EHJG, 2011, P NATL ACAD SCI USA, V108, P18396, DOI 10.1073/pnas.1113045108; Abel K, 2009, CURR HIV RES, V7, P2, DOI 10.2174/157016209787048528; Ackerman ME, 2017, IMMUNOL REV, V275, P262, DOI 10.1111/imr.12503; Adam L, 2020, J IMMUNOL, V204, P3375, DOI 10.4049/jimmunol.1900517; Afik S, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx615; Ahrens ET, 2013, NAT REV IMMUNOL, V13, P755, DOI 10.1038/nri3531; Al-Gubory KH, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201900146; Alcorn JF, 2020, HUM VACC IMMUNOTHER, V16, P1782, DOI 10.1080/21645515.2020.1711677; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Anbarasu D, 2013, CYTOKINE, V61, P747, DOI 10.1016/j.cyto.2012.12.031; [Anonymous], 2021, NUCLEIC ACIDS RES, V49, pD325, DOI [10.1093/nar/gkaa1113, DOI 10.1093/NAR/GKAA1113]; Antia R, 2005, NAT REV IMMUNOL, V5, P101, DOI 10.1038/nri1550; Arrode-Bruses G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110883; Arunachalam PS, 2020, NAT MED, V26, P932, DOI 10.1038/s41591-020-0858-8; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Avey S, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal4656; Avey S, 2017, BIOINFORMATICS, V33, pI208, DOI 10.1093/bioinformatics/btx260; Babji S, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0178-5; Baharlou H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02657; Baker RE, 2018, BIOL LETTERS, V14, DOI 10.1098/rsbl.2017.0660; Bandura DR, 2009, ANAL CHEM, V81, P6813, DOI 10.1021/ac901049w; Barre-Sinoussi F, 2015, FUTUR SCI OA, V1, DOI [10.4155/FSO.15.63, 10.4155/fso.15.63]; Ben-Othman R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580373; Bhaumik SK, 2018, CLIN INFECT DIS, V67, pS66, DOI 10.1093/cid/ciy634; Blykers A, 2015, J NUCL MED, V56, P1265, DOI 10.2967/jnumed.115.156828; Boesch M, 2018, J IMMUNOL, V201, P1813, DOI 10.4049/jimmunol.1801037; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Bousso P, 2002, SCIENCE, V296, P1876, DOI 10.1126/science.1070945; Brewer KD, 2014, VACCINE, V32, P6956, DOI 10.1016/j.vaccine.2014.10.058; Bricker KM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008954; Buchberger AR, 2018, ANAL CHEM, V90, P240, DOI 10.1021/acs.analchem.7b04733; Campbell-Tofte J, 2019, CELL MOL LIFE SCI, V76, P67, DOI 10.1007/s00018-018-2925-6; Cao QZ, 2019, J NUCL MED, V60, P1317, DOI 10.2967/jnumed.118.220350; Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i; Center for Viral Systems Biology CViSB, SARS COV 2 HCOV 19 M; Chandrupatla DMSH, 2019, DRUG DELIV TRANSL RE, V9, P366, DOI 10.1007/s13346-018-0589-2; Chanier T, 2019, ANTIBODIES, V8, DOI 10.3390/antib8010013; Chapman SJ, 2012, NAT REV GENET, V13, P175, DOI 10.1038/nrg3114; Chaudhury S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35452-x; Chauvat A, 2014, HUM VACC IMMUNOTHER, V10, P104, DOI 10.4161/hv.26593; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen ZY, 2020, BIOINFORMATICS, V36, P819, DOI 10.1093/bioinformatics/btz672; Ciabattini A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00380; Cirelli KM, 2020, CELL, V180, P206, DOI 10.1016/j.cell.2019.12.027; Coates EE, 2017, CLIN NUCL MED, V42, P329, DOI 10.1097/RLU.0000000000001603; Costa-Silva J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190152; Cotugno N, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/8732191; Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806; Cruz LJ, 2011, MOL PHARMACEUT, V8, P520, DOI 10.1021/mp100356k; Curtis AD, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00162-20; Daldrup-Link HE, 2011, CLIN CANCER RES, V17, P5695, DOI 10.1158/1078-0432.CCR-10-3420; Damond N, 2019, CELL METAB, V29, P755, DOI 10.1016/j.cmet.2018.11.014; Darrah PA, 2020, NATURE, V577, P95, DOI 10.1038/s41586-019-1817-8; Davila S, 2010, GENES IMMUN, V11, P232, DOI 10.1038/gene.2010.1; de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002; De Rosa SC, 2001, CLIN LAB MED, V21, P697; de Vries IJM, 2005, NAT BIOTECHNOL, V23, P1407, DOI 10.1038/nbt1154; DeGottardi Q, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72610-6; Deguine J, 2013, IMMUNOL REV, V251, P154, DOI 10.1111/imr.12015; Dekkers JF, 2019, NAT PROTOC, V14, P1756, DOI 10.1038/s41596-019-0160-8; Derian N, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004801; Durand M, 2019, J EXP MED, V216, P1561, DOI 10.1084/jem.20181994; Elhmouzi-Younes J, 2017, CYTOM PART A, V91A, P969, DOI 10.1002/cyto.a.23107; Elsner RA, 2020, IMMUNITY, V53, P1136, DOI 10.1016/j.immuni.2020.11.006; Epaulard O, 2014, J IMMUNOL, V193, P2416, DOI 10.4049/jimmunol.1303339; Ermann J, 2012, CURR OPIN IMMUNOL, V24, P564, DOI 10.1016/j.coi.2012.09.005; Eslamizar L, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00277-1; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Faye N, 2015, AM J ROENTGENOL, V205, pW11, DOI 10.2214/AJR.14.13680; Ferguson PM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065318; Floris S, 2004, BRAIN, V127, P616, DOI 10.1093/brain/awh068; Fourati S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10369; Freise AC, 2015, MOL IMMUNOL, V67, P142, DOI 10.1016/j.molimm.2015.04.001; Fruhwirth GO, 2018, MOL IMAGING BIOL, V20, P696, DOI 10.1007/s11307-018-1254-3; Fu RS, 2018, CHEMMEDCHEM, V13, P2466, DOI 10.1002/cmdc.201800624; Furman D, 2015, VACCINE, V33, P5271, DOI 10.1016/j.vaccine.2015.06.117; Furman D, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.15; Futamura K, 2015, CYTOM PART A, V87A, P830, DOI 10.1002/cyto.a.22725; Gabrielson K, 2018, ILAR J, V59, P80, DOI 10.1093/ilar/ily010; Galassie AC, 2015, PROTEOM CLIN APPL, V9, P972, DOI 10.1002/prca.201500054; Galson JD, 2014, TRENDS IMMUNOL, V35, P319, DOI 10.1016/j.it.2014.04.005; Germain RN, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspecta033308; Gerner MY, 2015, IMMUNITY, V42, P172, DOI 10.1016/j.immuni.2014.12.024; Gerner MY, 2012, IMMUNITY, V37, P364, DOI 10.1016/j.immuni.2012.07.011; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/NMETH.2869, 10.1038/nmeth.2869]; Goncalves E, 2019, J CLIN INVEST, V129, P1960, DOI 10.1172/JCI125372; Gonnet J, 2020, J PROTEOMICS, V216, DOI 10.1016/j.jprot.2020.103670; Gonzalez-Dias P, 2020, HUM VACC IMMUNOTHER, V16, P269, DOI 10.1080/21645515.2019.1697110; Gourley TS, 2004, SEMIN IMMUNOL, V16, P323, DOI 10.1016/j.smim.2004.08.013; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Han QF, 2020, CELL REP, V30, P1553, DOI 10.1016/j.celrep.2019.12.091; Hansen SG, 2018, NAT MED, V24, P130, DOI 10.1038/nm.4473; Hao Yuhan, 2021, GEO, DOI 10.1016/j.cell.2021.04.048; Heaton PM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.517290; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Heskamp S, 2017, BIOCONJUGATE CHEM, V28, P2211, DOI 10.1021/acs.bioconjchem.7b00325; Horns F, 2020, CELL REP, V30, P905, DOI 10.1016/j.celrep.2019.12.063; Hou J, 2017, J IMMUNOL, V199, P1476, DOI 10.4049/jimmunol.1700083; Huang YD, 2017, VACCINE, V35, P1184, DOI 10.1016/j.vaccine.2016.09.053; Huttner A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj1701; Idoko OT, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00197; James ML, 2012, PHYSIOL REV, V92, P897, DOI 10.1152/physrev.00049.2010; Janes HE, 2017, J INFECT DIS, V215, P1376, DOI 10.1093/infdis/jix086; Johnson N, 2010, VACCINE, V28, P3896, DOI 10.1016/j.vaccine.2010.03.039; Kasturi SP, 2017, J VIROL, V91, DOI 10.1128/JVI.01844-16; Kazmin D, 2017, P NATL ACAD SCI USA, V114, P2425, DOI 10.1073/pnas.1621489114; Kennedy RB, 2009, VACCINE, V27, P3319, DOI 10.1016/j.vaccine.2009.01.086; Kesarwani A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82614-5; Kiros TG, 2012, INNOVATION VACCINOLO, V29, P251, DOI DOI 10.1007/978-94-007-4543-8_11; Klasse PJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe8065; Klein SL, 2013, VACCINE, V31, P2599, DOI 10.1016/j.vaccine.2013.02.070; Klein SL, 2012, J LEUKOCYTE BIOL, V92, P67, DOI 10.1189/jlb.0811427; Kotliarov Y, 2020, NAT MED, V26, P618, DOI 10.1038/s41591-020-0769-8; Kotov DI, 2019, J IMMUNOL, V202, P300, DOI 10.4049/jimmunol.1801202; Kriegsmann K, 2019, PROTEOM CLIN APPL, V13, DOI 10.1002/prca.201800035; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Le D, 2015, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00177; Levast B, 2013, VACCINE, V31, P2489, DOI 10.1016/j.vaccine.2012.11.089; Lewis DJM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/909406; Li SZ, 2017, CELL, V169, P862, DOI 10.1016/j.cell.2017.04.026; Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789; Li WZ, 2019, NAT PROTOC, V14, P1708, DOI 10.1038/s41596-019-0156-4; Li WZ, 2017, P NATL ACAD SCI USA, V114, pE7321, DOI 10.1073/pnas.1708981114; Liao WH, 2017, J IMMUNOL, V198, P3846, DOI 10.4049/jimmunol.1601852; Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080; Lindsay KE, 2019, NAT BIOMED ENG, V3, P371, DOI 10.1038/s41551-019-0378-3; Lingblom CMD, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1528-1; Luo W, 2021, IMMUNOL INVEST, V50, P780, DOI 10.1080/08820139.2021.1903033; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Mahe B, 2009, J INVEST DERMATOL, V129, P1156, DOI 10.1038/jid.2008.356; Mahnke YD, 2007, CLIN LAB MED, V27, P469, DOI 10.1016/j.cII.2007.05.002; Makela AV, 2017, SCI REP-UK, V7, DOI 10.1038/srep42109; Mall S, 2016, CANCER RES, V76, P4113, DOI 10.1158/0008-5472.CAN-15-2784; McCarthy CE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01067; McInnes L., 2018, UMAP UNIFORM MANIFOL; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Meller B, 2004, EUR J NUCL MED MOL I, V31, P403, DOI 10.1007/s00259-003-1398-4; Mentzer AJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0341; Merino KM, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00388; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Mingos M, 2016, NUCL MED MOLEC IMAG, V50, P358, DOI 10.1007/s13139-015-0385-6; Mitchell TM, 1997, MACH LEARN; Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0; Zurbia-Flores GM, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1895644; Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105; Moss B, 2011, IMMUNOL REV, V239, P8, DOI 10.1111/j.1600-065X.2010.00975.x; Movahedi K, 2012, CANCER RES, V72, P4165, DOI 10.1158/0008-5472.CAN-11-2994; Muntifering Michael, 2018, Curr Protoc Cytom, V86, pe38, DOI 10.1002/cpcy.38; Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429; Nakaya HI, 2016, P NATL ACAD SCI USA, V113, P1853, DOI 10.1073/pnas.1519690113; Nakaya HI, 2015, IMMUNITY, V43, P1186, DOI 10.1016/j.immuni.2015.11.012; Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067; Natrajan MS, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010004; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Ng'uni T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.590780; Nigam S, 2020, MOL IMAGING BIOL, V22, P685, DOI 10.1007/s11307-019-01427-1; Nishida N, 2018, HEPATOLOGY, V68, P848, DOI 10.1002/hep.29876; Noll KE, 2019, CELL HOST MICROBE, V25, P484, DOI 10.1016/j.chom.2019.03.009; O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y; Oetjen J, 2013, J PROTEOMICS, V90, P52, DOI 10.1016/j.jprot.2013.03.013; Olafsdottir TA, 2016, SCI REP-UK, V6, DOI 10.1038/srep39097; Ols S, 2020, CELL REP, V30, P3964, DOI 10.1016/j.celrep.2020.02.111; Olsen LR, 2019, CYTOM PART A, V95A, P156, DOI 10.1002/cyto.a.23621; Omersel J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113561; Ottobrini L, 2011, EUR J NUCL MED MOL I, V38, P949, DOI 10.1007/s00259-010-1687-7; Palgen JL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.612747; Palgen JL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0175-8; Palgen JL, 2019, J LEUKOCYTE BIOL, V105, P1055, DOI 10.1002/JLB.4A1018-391RR; Palgen JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21222-2; Pan LP, 2014, HUM MOL GENET, V23, P2210, DOI 10.1093/hmg/ddt586; Panchanathan V, 2006, J VIROL, V80, P6333, DOI 10.1128/JVI.00115-06; Parvandeh S, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7030079; Patel H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85877-0; Pattyn J, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100185; Pauthner M, 2017, IMMUNITY, V46, P1073, DOI 10.1016/j.immuni.2017.05.007; Pejoski D, 2016, J IMMUNOL, V196, P4814, DOI 10.4049/jimmunol.1502005; Pektor S, 2018, EJNMMI RES, V8, DOI 10.1186/s13550-018-0435-z; PETERS AM, 1983, J NUCL MED, V24, P39; Petrovas C, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2285; Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Pogorelyy MV, 2018, P NATL ACAD SCI USA, V115, P12704, DOI 10.1073/pnas.1809642115; Poland GA, 2009, PHARMACOGENOMICS, V10, P837, DOI [10.2217/pgs.09.25, 10.2217/PGS.09.25]; Pulendran B, 2014, P NATL ACAD SCI USA, V111, P12300, DOI 10.1073/pnas.1400476111; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Ramos L, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.045740; Rappuoli R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2888; Rashidian M, 2019, P NATL ACAD SCI USA, V116, P16971, DOI 10.1073/pnas.1905005116; Rashidian M, 2017, J EXP MED, V214, P2243, DOI 10.1084/jem.20161950; Rashidian M, 2015, P NATL ACAD SCI USA, V112, P6146, DOI 10.1073/pnas.1502609112; Rattanapak T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089503; Ravindran R, 2016, NATURE, V531, P523, DOI 10.1038/nature17186; Ravindran R, 2014, SCIENCE, V343, P313, DOI 10.1126/science.1246829; Rechtien A, 2017, CELL REP, V20, P2251, DOI 10.1016/j.celrep.2017.08.023; Reeves PM, 2018, FASEB J, V32, P5, DOI 10.1096/fj.201700325R; Romain G, 2012, EUR J IMMUNOL, V42, P2019, DOI 10.1002/eji.201242478; Rosario M, 2010, J VIROL, V84, P7815, DOI 10.1128/JVI.00726-10; Rosenbaum P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.645210; Rosenbaum P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00870; Routhu NK, 2021, IMMUNITY, V54, P542, DOI 10.1016/j.immuni.2021.02.001; Ryan NM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00276-2; Saeys Y, 2016, NAT REV IMMUNOL, V16, P449, DOI 10.1038/nri.2016.56; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Salabert N, 2016, EUR J IMMUNOL, V46, P689, DOI 10.1002/eji.201545465; Sarkar S, 2019, CLIN THER, V41, P1912, DOI 10.1016/j.clinthera.2019.08.010; Scepanovic P, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0568-8; Shen CJ, 2014, VACCINE, V32, P5337, DOI 10.1016/j.vaccine.2014.07.036; Shinoda K, 2012, P NATL ACAD SCI USA, V109, P7409, DOI 10.1073/pnas.1118539109; Shirone N, 2012, ANN NUCL MED, V26, P248, DOI 10.1007/s12149-011-0568-x; Siegel TP, 2018, MOL IMAGING BIOL, V20, P888, DOI 10.1007/s11307-018-1267-y; Spitzer MH, 2016, CELL, V165, P780, DOI 10.1016/j.cell.2016.04.019; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Subrahmanyam Priyanka B, 2020, Immunohorizons, V4, P774, DOI 10.4049/immunohorizons.1900097; Tan WCC, 2020, CANCER COMMUN, V40, P135, DOI 10.1002/cac2.12023; Tavare R, 2016, CANCER RES, V76, P73, DOI 10.1158/0008-5472.CAN-15-1707; Tavare R, 2014, P NATL ACAD SCI USA, V111, P1108, DOI 10.1073/pnas.1316922111; Teraguchi S, 2020, COMPUT STRUCT BIOTEC, V18, P2000, DOI 10.1016/j.csbj.2020.07.008; Terao K, 2009, J TOXICOL SCI, V34, pSP321, DOI 10.2131/jts.34.SP321; Thakur A, 2012, VACCINE, V30, P4907, DOI 10.1016/j.vaccine.2012.05.049; Thompson EA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120692; Todorova B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04547-2; Todorova B, 2017, CONTRAST MEDIA MOL I, DOI 10.1155/2017/3127908; Tomic A, 2019, J IMMUNOL, V203, P749, DOI 10.4049/jimmunol.1900033; Torcellan T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00309; Tremblay ML, 2018, MAGN RESON MED, V80, P304, DOI 10.1002/mrm.27018; Trovato M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02130; Trtica-Majnaric L, 2010, J BIOMED INFORM, V43, P774, DOI 10.1016/j.jbi.2010.04.011; Tsang JS, 2014, CELL, V157, P499, DOI 10.1016/j.cell.2014.03.031; Turner JS, 2020, NATURE, V586, P127, DOI 10.1038/s41586-020-2711-0; Vadala M, 2020, NUCL MED COMMUN, V41, P1275, DOI 10.1097/MNM.0000000000001280; Van Damme Pierre, 2007, Travel Med Infect Dis, V5, P79, DOI 10.1016/j.tmaid.2006.04.004; van der Heiden M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01962; Van Elssen CHMJ, 2017, J NUCL MED, V58, P1003, DOI 10.2967/jnumed.116.186007; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004; Varasteh Z, 2019, EJNMMI RES, V9, DOI 10.1186/s13550-019-0474-0; Waickman AT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11634-7; Walch A, 2008, HISTOCHEM CELL BIOL, V130, P421, DOI 10.1007/s00418-008-0469-9; Wall N, 2021, CLIN INFECT DIS, V73, pE880, DOI 10.1093/cid/ciab078; Wang DX, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188503; Warram JM, 2014, CANCER METAST REV, V33, P809, DOI 10.1007/s10555-014-9505-5; Watson HA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01321; Weinberg A, 2019, J VIROL, V93, DOI 10.1128/JVI.00305-19; Weinberg A, 2009, J INFECT DIS, V200, P1068, DOI 10.1086/605611; WHO, GLOB VACC ACT PLAN 2; Wieten RW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149871; Wilkinson MD, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.18; Wimmers F, 2020, CURR OPIN IMMUNOL, V65, P57, DOI 10.1016/j.coi.2020.05.001; Wong MT, 2016, IMMUNITY, V45, P442, DOI 10.1016/j.immuni.2016.07.007; Woodham AW, 2020, NAT METHODS, V17, P1025, DOI 10.1038/s41592-020-0934-5; Wu CX, 2013, THERANOSTICS, V3, P448, DOI 10.7150/thno.6592; Wu TW, 2015, J GASTROEN HEPATOL, V30, P891, DOI 10.1111/jgh.12845; Yagnik G, 2021, J AM SOC MASS SPECTR, V32, P977, DOI 10.1021/jasms.0c00473; Yuki Y, 2010, J IMMUNOL, V185, P5436, DOI 10.4049/jimmunol.1001789; Zhang YY, 2014, MAGN RESON IMAGING, V32, P168, DOI 10.1016/j.mri.2013.10.006; Zhao Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06089-1; Zimmermann MT, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00445; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	259	4	4	4	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							579	10.3390/vaccines9060579			36	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TB3US	34205932	gold, Green Published			2022-04-29	WOS:000667872900001
J	Seephetdee, C; Buasri, N; Bhukhai, K; Srisanga, K; Manopwisedjaroen, S; Lertjintanakit, S; Phueakphud, N; Pakiranay, C; Kangwanrangsan, N; Srichatrapimuk, S; Kirdlarp, S; Sungkanuparph, S; Chutipongtanate, S; Thitithanyanont, A; Hongeng, S; Wongtrakoongate, P				Seephetdee, Chotiwat; Buasri, Nattawut; Bhukhai, Kanit; Srisanga, Kitima; Manopwisedjaroen, Suwimon; Lertjintanakit, Sarat; Phueakphud, Nut; Pakiranay, Chatbenja; Kangwanrangsan, Niwat; Srichatrapimuk, Sirawat; Kirdlarp, Suppachok; Sungkanuparph, Somnuek; Chutipongtanate, Somchai; Thitithanyanont, Arunee; Hongeng, Suradej; Wongtrakoongate, Patompon			Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2	VACCINES			English	Article						HexaPro; spike; SARS-CoV-2; vaccine	IMMUNOGENICITY	Updated and revised versions of COVID-19 vaccines are vital due to genetic variations of the SARS-CoV-2 spike antigen. Furthermore, vaccines that are safe, cost-effective, and logistic-friendly are critically needed for global equity, especially for middle- to low-income countries. Recombinant protein-based subunit vaccines against SARS-CoV-2 have been reported using the receptor-binding domain (RBD) and the prefusion spike trimers (S-2P). Recently, a new version of prefusion spike trimers, named HexaPro, has been shown to possess two RBD in the "up" conformation, due to its physical property, as opposed to just one exposed RBD found in S-2P. Importantly, this HexaPro spike antigen is more stable than S-2P, raising its feasibility for global logistics and supply chain. Here, we report that the spike protein HexaPro offers a promising candidate for the SARS-CoV-2 vaccine. Mice immunized by the recombinant HexaPro adjuvanted with aluminum hydroxide using a prime-boost regimen produced high-titer neutralizing antibodies for up to 56 days after initial immunization against live SARS-CoV-2 infection. Also, the level of neutralization activity is comparable to that of convalescence sera. Our results indicate that the HexaPro subunit vaccine confers neutralization activity in sera collected from mice receiving the prime-boost regimen.	[Seephetdee, Chotiwat; Buasri, Nattawut; Srisanga, Kitima; Lertjintanakit, Sarat; Phueakphud, Nut; Pakiranay, Chatbenja; Wongtrakoongate, Patompon] Mahidol Univ, Fac Sci, Dept Biochem, Bangkok 10400, Thailand; [Bhukhai, Kanit] Mahidol Univ, Dept Physiol, Fac Sci, Bangkok 10400, Thailand; [Manopwisedjaroen, Suwimon; Thitithanyanont, Arunee] Mahidol Univ, Dept Microbiol, Fac Sci, Bangkok 10400, Thailand; [Kangwanrangsan, Niwat] Mahidol Univ, Dept Pathobiol, Fac Sci, Bangkok 10400, Thailand; [Srichatrapimuk, Sirawat; Kirdlarp, Suppachok; Sungkanuparph, Somnuek; Chutipongtanate, Somchai] Mahidol Univ, Chakri Naruebodindra Med Inst, Fac Med, Ramathibodi Hosp, Samut Prakan 10540, Thailand; [Chutipongtanate, Somchai; Hongeng, Suradej] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pediat, Bangkok 10400, Thailand; [Chutipongtanate, Somchai] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Clin Epidemiol & Biostat, Bangkok 10400, Thailand; [Wongtrakoongate, Patompon] Mahidol Univ, Ctr Neurosci, Fac Sci, Bangkok 10400, Thailand		Wongtrakoongate, P (通讯作者)，Mahidol Univ, Fac Sci, Dept Biochem, Bangkok 10400, Thailand.; Wongtrakoongate, P (通讯作者)，Mahidol Univ, Ctr Neurosci, Fac Sci, Bangkok 10400, Thailand.	chotiwat.see@student.mahidol.ac.th; nattawut.bua@alumni.mahidol.ac.th; kanit.bhu@mahidol.ac.th; kitima.sri@mahidol.ac.th; swiboonut@gmail.com; sarat.lej@student.mahidol.ac.th; nut.phe@alumni.mahidol.ac.th; chatbenja.pai@student.mahidol.ac.th; niwat.kan@mahidol.ac.th; sirawat.sri@mahidol.ac.th; suppachok.kir@mahidol.ac.th; somnuek.sun@mahidol.ac.th; schuti.rama@gmail.com; arunee.thi@mahidol.edu; suradej.hon@mahidol.ac.th; patompon.won@mahidol.ac.th	Thitithanyanont, Arunee/AAN-4383-2021; Chutipongtanate, Somchai/H-6936-2019	Thitithanyanont, Arunee/0000-0002-9756-4763; Chutipongtanate, Somchai/0000-0001-6398-5626; Wongtrakoongate, Patompon/0000-0001-6070-1843; Seephetdee, Chotiwat/0000-0001-7266-4744; Manopwisedjaroen, Suwimon/0000-0002-7571-8733; Kirdlarp, Suppachok/0000-0003-3444-4796	Faculty of Medicine Ramathibodi Hospital, Mahidol University; CIF Grant, Faculty of Science, Mahidol University; Science Achievement Scholarship of Thailand; Mahidol University [NDFR 11/2563]; Office of National Higher Education Science Research and Innovation Policy Council by Program Management Unit for Human Resources and Institutional Development, Research and Innovation (PMU-B) [B05F630081]; Research Cluster Grant of Faculty of Medicine Ramathibodi Hospital, Mahidol University [CF63010]	This research project was supported by the Faculty of Medicine Ramathibodi Hospital, Mahidol University, and CIF Grant, Faculty of Science, Mahidol University. C.S., S.L., and C.P. were supported by the Science Achievement Scholarship of Thailand. P.W. was supported by Mahidol University (New Discovery and Frontier Research Grant; grant number NDFR 11/2563) and the Office of National Higher Education Science Research and Innovation Policy Council by Program Management Unit for Human Resources and Institutional Development, Research and Innovation (PMU-B; grant number B05F630081). This research was funded by the Research Cluster Grant of Faculty of Medicine Ramathibodi Hospital, Mahidol University, grant number CF63010 (P.W. and S.C.). The APC was funded by Mahidol University.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Edwards RJ, 2021, NAT STRUCT MOL BIOL, V28, P128, DOI 10.1038/s41594-020-00547-5; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x; Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826; Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062; Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; Nitayaphan S, 2004, J INFECT DIS, V190, P702, DOI 10.1086/422258; Ozono S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21118-2; Pace D, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1554; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sandstrom E, 2008, J INFECT DIS, V198, P1482, DOI 10.1086/592507; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762	23	2	2	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							498	10.3390/vaccines9050498			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1EW	34066016	Green Published, gold, Green Submitted			2022-04-29	WOS:000654570300001
J	Spinewine, A; Petein, C; Evrard, P; Vastrade, C; Laurent, C; Delaere, B; Henrard, S				Spinewine, Anne; Petein, Catherine; Evrard, Perrine; Vastrade, Christelle; Laurent, Christine; Delaere, Benedicte; Henrard, Severine			Attitudes towards COVID-19 Vaccination among Hospital Staff-Understanding What Matters to Hesitant People	VACCINES			English	Article						COVID-19; vaccination; hospital staff; attitudes; vaccine hesitancy; survey	HEALTH-CARE WORKERS; INFLUENZA VACCINATION; UNITED-STATES	Hospital staff are a priority target group in the European COVID-19 vaccination strategy. Measuring the extent of COVID-19 vaccination hesitancy and understanding the reasons behind it are essential to be able to tailor effective communication campaigns. Using the Health Belief Model (HBM) as a theoretical framework, a survey was conducted among staff members of a Belgian three-site hospital center between 6 and 20 January 2021. Multivariable logistic ordinal regression was performed to assess determinants of the attitude towards COVID-19 vaccination. Reasons for and against COVID-19 vaccination and the need for information were explored among hesitant staff members. Among the respondents (N = 1132), 58% and 4.9% said that they would certainly and certainly not get vaccinated, respectively; 37.1% were hesitant, with different degrees of certainty. A positive attitude towards COVID-19 vaccination was associated with being older, being a physician, being vaccinated against seasonal flu, and with several HBM factors (including perceived benefits and cues to actions). Among hesitant staff, concerns about potential side effects and the impression that the vaccine was developed too quickly were the main reasons against COVID-19 vaccination. The key factors in the decision process were data on vaccine efficacy and safety, and knowing that vaccination went well in others. These data are helpful to further tailor the communication campaign and ensure sufficient vaccination coverage among hospital staff.	[Spinewine, Anne; Petein, Catherine; Evrard, Perrine; Henrard, Severine] Catholic Univ Louvain, Louvain Drug Res Inst, Clin Pharm Res Grp, B-1200 Brussels, Belgium; [Spinewine, Anne] Catholic Univ Louvain, Pharm Dept, CHU UCL Namur, B-5530 Yvoir, Belgium; [Vastrade, Christelle] Catholic Univ Louvain, Nursing Dept, CHU UCL Namur, B-5530 Yvoir, Belgium; [Vastrade, Christelle] Catholic Univ Louvain, Infect Control Unit, CHU UCL Namur, B-5530 Yvoir, Belgium; [Laurent, Christine] Catholic Univ Louvain, Infect Control Unit, CHU UCL Namur, B-5530 Yvoir, Belgium; [Delaere, Benedicte] Catholic Univ Louvain, Infect Dis Dept, CHU UCL Namur, B-5530 Yvoir, Belgium; [Henrard, Severine] Catholic Univ Louvain, Inst Hlth & Soc IRSS, B-1200 Brussels, Belgium		Spinewine, A (通讯作者)，Catholic Univ Louvain, Louvain Drug Res Inst, Clin Pharm Res Grp, B-1200 Brussels, Belgium.; Spinewine, A (通讯作者)，Catholic Univ Louvain, Pharm Dept, CHU UCL Namur, B-5530 Yvoir, Belgium.	anne.spinewine@uclouvain.be; catherine.petein@uclouvain.be; perrine.evrard@uclouvain.be; christelle.vastrade@uclouvain.be; christine.laurent@uclouvain.be; benedicte.delaere@uclouvain.be; severine.henrard@uclouvain.be		Henrard, Severine/0000-0002-0389-8093; Petein, Catherine/0000-0002-7480-0014			Blasi F, 2011, CLIN MICROBIOL INFEC, V17, P1223, DOI 10.1111/j.1469-0691.2011.03501.x; Bruyneel A, 2021, INTENS CRIT CARE NUR, V62, DOI 10.1016/j.iccn.2020.102967; Bults M, 2011, BMC PUBLIC HEALTH, V11, DOI [10.1186/1471-2458-11-2, 10.1186/1471-2458-11-165]; Centers for Disease Control and Prevention (CDC), BUILD HEALTHC PERS C; Chou W.-Y.S., COVID 19 VACCINATION; Crowe S, 2021, INTENS CRIT CARE NUR, V63, DOI 10.1016/j.iccn.2020.102999; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Eskola J, 2015, VACCINE, V33, P4215, DOI 10.1016/j.vaccine.2015.04.043; European Commission, EU VACC STRAT SPEED; Fagerland MW, 2016, J STAT COMPUT SIM, V86, P3398, DOI 10.1080/00949655.2016.1156682; Federal Public Service Health Food Chain Safety and Environment, COR COVID 19 VACC; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Germani F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247642; Gharpure R, 2021, MMWR-MORBID MORTAL W, V70, P178, DOI 10.15585/mmwr.mm7005e2; Glanz JM, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002227; Kociolek LK, 2021, INFECT CONT HOSP EP, V42, P775, DOI [10.1017/ice.2021.58, 10.1017/ice.2021.415]; Lee K, 2009, GLOB INST, P1; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018; R Core Team, 2020, R LANGUAGE ENV STAT; ROSENSTOCK IM, 1966, MILBANK FUND Q, V44, P94, DOI 10.2307/3348967; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sciensano, 2020, COVID 19 B EP 5 DEC; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018; Zampetakis LA, 2021, APPL PSYCHOL-HLTH WE, V13, P469, DOI 10.1111/aphw.12262; Zheng RJ, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103809	32	8	9	3	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							469	10.3390/vaccines9050469			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1SB	34066476	Green Published, gold			2022-04-29	WOS:000654604800001
J	Ragan, IK; Hartson, LM; Dutt, TS; Obregon-Henao, A; Maison, RM; Gordy, P; Fox, A; Karger, BR; Cross, ST; Kapuscinski, ML; Cooper, SK; Podell, BK; Stenglein, MD; Bowen, RA; Henao-Tamayo, M; Goodrich, RP				Ragan, Izabela K.; Hartson, Lindsay M.; Dutt, Taru S.; Obregon-Henao, Andres; Maison, Rachel M.; Gordy, Paul; Fox, Amy; Karger, Burton R.; Cross, Shaun T.; Kapuscinski, Marylee L.; Cooper, Sarah K.; Podell, Brendan K.; Stenglein, Mark D.; Bowen, Richard A.; Henao-Tamayo, Marcela; Goodrich, Raymond P.			A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model	VACCINES			English	Article						SARS-CoV-2; vaccination; hamster; inactivated virus vaccine; riboflavin; UV light	PATHOGEN REDUCTION; VIRUS-VACCINES; RIBOFLAVIN; BLOOD; TECHNOLOGY; DAMAGE	The COVID-19 pandemic has generated intense interest in the rapid development and evaluation of vaccine candidates for this disease and other emerging diseases. Several novel methods for preparing vaccine candidates are currently undergoing clinical evaluation in response to the urgent need to prevent the spread of COVID-19. In many cases, these methods rely on new approaches for vaccine production and immune stimulation. We report on the use of a novel method (SolaVAX) for production of an inactivated vaccine candidate and the testing of that candidate in a hamster animal model for its ability to prevent infection upon challenge with SARS-CoV-2 virus. The studies employed in this work included an evaluation of the levels of neutralizing antibody produced post-vaccination, levels of specific antibody sub-types to RBD and spike protein that were generated, evaluation of viral shedding post-challenge, flow cytometric and single cell sequencing data on cellular fractions and histopathological evaluation of tissues post-challenge. The results from this preliminary evaluation provide insight into the immunological responses occurring as a result of vaccination with the proposed vaccine candidate and the impact that adjuvant formulations, specifically developed to promote Th1 type immune responses, have on vaccine efficacy and protection against infection following challenge with live SARS-CoV-2. This data may have utility in the development of effective vaccine candidates broadly. Furthermore, the results of this preliminary evaluation suggest that preparation of a whole virion vaccine for COVID-19 using this specific photochemical method may have potential utility in the preparation of one such vaccine candidate.	[Ragan, Izabela K.; Maison, Rachel M.; Gordy, Paul; Bowen, Richard A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA; [Hartson, Lindsay M.; Goodrich, Raymond P.] Colorado State Univ, Infect Dis Res Ctr, Ft Collins, CO 80523 USA; [Dutt, Taru S.; Obregon-Henao, Andres; Fox, Amy; Karger, Burton R.; Cross, Shaun T.; Kapuscinski, Marylee L.; Cooper, Sarah K.; Podell, Brendan K.; Stenglein, Mark D.; Henao-Tamayo, Marcela; Goodrich, Raymond P.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA		Goodrich, RP (通讯作者)，Colorado State Univ, Infect Dis Res Ctr, Ft Collins, CO 80523 USA.; Goodrich, RP (通讯作者)，Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	izabela.ragan@colostate.edu; lindsay.hartson@colostate.edu; taru.dutt@colostate.edu; andres.obregon@colostate.edu; rachel.maison@colostate.edu; paul.gordy@colostate.edu; amy.fox@colostate.edu; burton.karger@colostate.edu; shaun.cross1992@gmail.com; marylee.layton@colostate.edu; sarah.cooper@rams.colostate.edu; brendan.podell@colostate.edu; mark.stenglein@colostate.edu; richard.bowen@colostate.edu; marcela_henao_tamayo@colostate.edu; ray.goodrich@colostate.edu	Dutt, Taru S./AAN-1183-2021; Stenglein, Mark/E-3541-2017; Goodrich, Raymond/D-7014-2019	Dutt, Taru S./0000-0002-5101-1311; Bowen, Richard/0000-0002-7576-2881; Cooper, Sarah/0000-0001-9656-2283; Hartson, Lindsay/0000-0002-3131-3507; Maison, Rachel/0000-0002-4003-2643; Stenglein, Mark/0000-0002-0993-813X; Fox, Amy/0000-0002-2321-5499; Obregon-Henao, Andres/0000-0002-6496-6790; Goodrich, Raymond/0000-0002-5945-4571	NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32 AI162691] Funding Source: Medline		Allain JP, 2016, LANCET, V387, P1753, DOI 10.1016/S0140-6736(16)00581-X; Barrett PN, 2017, EXPERT REV VACCINES, V16, P883, DOI 10.1080/14760584.2017.1357471; Bost P, 2020, CELL, V181, P1475, DOI 10.1016/j.cell.2020.05.006; Chan JFW, 2020, CLIN INFECT DIS, V71, P2428, DOI 10.1093/cid/ciaa325; Delrue I, 2012, EXPERT REV VACCINES, V11, P695, DOI [10.1586/erv.12.38, 10.1586/ERV.12.38]; Eng NF, 2013, HUM VACC IMMUNOTHER, V9, P1661, DOI 10.4161/hv.24715; Fox A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64516-0; Frederiksen LSF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01817; Goodrich RP, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/7142375; GOODRICH RP, 2006, FLAVINS PHOTOCHEMIST, P83; Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516; Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI 10.1073/pnas.2009799117; Kumar V, 2004, PHOTOCHEM PHOTOBIOL, V80, P15, DOI 10.1562/2003-12-23-RA-036.1; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Liu Z, 2020, J VIROL, V94, DOI 10.1128/JVI.00790-20; MacLennan CA, 2013, SEMIN IMMUNOL, V25, P114, DOI 10.1016/j.smim.2013.05.004; Martin CB, 2005, PHOTOCHEM PHOTOBIOL, V81, P474, DOI 10.1562/2004-08-25-RA-292.1; McKay B., 2020, WALL STREET J; Monchatre-Leroy E, 2021, J GEN VIROL, V102, DOI 10.1099/jgv.0.001567; Mundt JM, 2014, PHOTOCHEM PHOTOBIOL, V90, P957, DOI 10.1111/php.12311; Ogando NS, 2020, J GEN VIROL, V101, P925, DOI 10.1099/jgv.0.001453; Park H, 2020, VOX SANG, V115, P525, DOI 10.1111/vox.12935; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Reddy HL, 2008, TRANSFUS MED REV, V22, P133, DOI 10.1016/j.tmrv.2007.12.003; RHEE Y, 1995, NUCLEIC ACIDS RES, V23, P3275, DOI 10.1093/nar/23.16.3275; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Rosenke K, 2020, EMERG MICROBES INFEC, V9, P2673, DOI 10.1080/22221751.2020.1858177; Ruane PH, 2004, TRANSFUSION, V44, P877, DOI 10.1111/j.1537-2995.2004.03355.x; Schmitt K, 2017, VIROLOGY, V510, P175, DOI 10.1016/j.virol.2017.07.005; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; van der Meer PF, 2018, BLOOD, V132, P223, DOI 10.1182/blood-2018-02-831289; Yonemura S, 2017, BLOOD TRANSFUS-ITALY, V15, P357, DOI 10.2450/2017.0320-16; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	35	5	5	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							340	10.3390/vaccines9040340			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5GP	33916180	gold, Green Published			2022-04-29	WOS:000643807800001
J	Alvarado-Socarras, JL; Vesga-Varela, AL; Quintero-Lesmes, DC; Fama-Pereira, MM; Serrano-Diaz, NC; Vasco, M; Carballo-Zarate, V; Zambrano, LI; Paniz-Mondolfi, A; Rodriguez-Morales, AJ				Alvarado-Socarras, Jorge L.; Vesga-Varela, Andrea Liliana; Quintero-Lesmes, Doris Cristina; Fama-Pereira, Marcela M.; Serrano-Diaz, Norma C.; Vasco, Mauricio; Carballo-Zarate, Virgil; Zambrano, Lysien I.; Paniz-Mondolfi, Alberto; Rodriguez-Morales, Alfonso J.			Perception of COVID-19 Vaccination Amongst Physicians in Colombia	VACCINES			English	Article						COVID-19; SARS-CoV-2; pandemic; medical staff; vaccine	MORTALITY	Introduction: The SARS-CoV-2/COVID-19 pandemic has triggered the need to develop rapidly effective and safe vaccines to prevent infection, particularly in those at-risk populations such as medical personnel. This study's objective was to assess the perception of COVID-19 vaccination amongst Colombian physicians featuring two different scenarios of COVID-19 vaccination. Methods: A cross-sectional analytical study was carried out through an online survey directed at medical staff in several cities in Colombia. The percentage of physicians who have a positive perception to be vaccinated and the associated factors that determine that decision were determined. A binomial regression analysis adjusted for age and sex was carried out, taking as a dependent variable the acceptance of free vaccination with an effectiveness of 60 and 80%. The most significant factors were determined in the non-acceptance of vaccination. Results: Between 77.0% and 90.7% of physicians in Colombia accept COVID-19 vaccination, according to the scenario evaluated where the vaccine's effectiveness was 60 or 80%, respectively. Medical specialty, having never paid for a vaccine, recommending the administration of the vaccine to their parents or people over 70 years, and dispensing the vaccine to their children, were the factors to consider to be vaccinated for free with an effectiveness of 60% and 80%. Conclusions: There is a high perception of the intention to vaccinate physicians in Colombia against COVID-19, and this is very similar to that of the general population.	[Alvarado-Socarras, Jorge L.; Quintero-Lesmes, Doris Cristina; Serrano-Diaz, Norma C.] Fdn Cardiovasc Colombia, Calle 155A 23-58, Floridablanca 681003, Colombia; [Vesga-Varela, Andrea Liliana] Univ Sao Paulo, R Reitoria 374, BR-3550308 Sao Paulo, SP, Brazil; [Fama-Pereira, Marcela M.] Univ Quindio, Hosp Dept Quindio, Armenia 630004, Quindio, Colombia; [Vasco, Mauricio] Soc Colombiana Anestesiol & Reanimac, Bogota 110911, Colombia; [Carballo-Zarate, Virgil] Asociac Colombiana Med Interna, Bogota 110911, Colombia; [Zambrano, Lysien I.] Univ Nacl Autonoma Honduras UNAH, Fac Med Sci, Sch Med, Unit Sci Res, Tegucigalpa 11101, Honduras; [Zambrano, Lysien I.; Paniz-Mondolfi, Alberto; Rodriguez-Morales, Alfonso J.] Latin Amer Network Coronavirus Dis 2019 Res LANCO, Pereira 660003, Risaralda, Colombia; [Paniz-Mondolfi, Alberto] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based Med, Lab Microbiol, New York, NY 10029 USA; [Paniz-Mondolfi, Alberto] Inst Inves Biomed IDB Incubadora Venezolana Cienc, Barquisimeto 3001, Venezuela; [Rodriguez-Morales, Alfonso J.] Fdn Univ Autonoma Amer, Grp Invest Biomed, Fac Med, Pereira 660003, Risaralda, Colombia; [Rodriguez-Morales, Alfonso J.] Univ Privada Franz Tamayo, Sch Med, Cochabamba 4780, Bolivia		Rodriguez-Morales, AJ (通讯作者)，Latin Amer Network Coronavirus Dis 2019 Res LANCO, Pereira 660003, Risaralda, Colombia.; Rodriguez-Morales, AJ (通讯作者)，Fdn Univ Autonoma Amer, Grp Invest Biomed, Fac Med, Pereira 660003, Risaralda, Colombia.; Rodriguez-Morales, AJ (通讯作者)，Univ Privada Franz Tamayo, Sch Med, Cochabamba 4780, Bolivia.	jorgealvarado@fcv.org; alilianavesga@usp.br; dorisquintero@fcv.org; mfama@uniquindio.edu.co; normaserrano@fcv.org; presidentescare@scare.org.co; vircaza@hotmail.com; lysien.zambrano@unah.edu.hn; Alberto.Paniz-mondolfi@mountsinai.org; alfonso.rodriguez@uam.edu.co	Rodriguez-Morales, Alfonso J./R-9765-2016; vesga varela, andrea liliana/AAA-5280-2022; Zambrano, Lysien Ivania/R-5628-2019; Quintero-Lesmes, Doris Cristina/AGP-5258-2022	Rodriguez-Morales, Alfonso J./0000-0001-9773-2192; vesga varela, andrea liliana/0000-0001-7165-9791; Zambrano, Lysien Ivania/0000-0001-9002-5807; Quintero-Lesmes, Doris Cristina/0000-0001-8875-0110	Direccion de Investigacion Cientifica, Humanistica y Tecnologica, National Autonomous University of Honduras, Tegucigalpa, MDC, Honduras, Central America [2-05-01-01]	From the Direccion de Investigacion Cientifica, Humanistica y Tecnologica (2-05-01-01), National Autonomous University of Honduras, Tegucigalpa, MDC, Honduras, Central America.	Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Arda B, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-87; Asma S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1528-9; Bhagavathula AS, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.8342; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Eguia H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020170; Fisher D, 2020, LANCET, V396, P653, DOI 10.1016/S0140-6736(20)31601-9; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Goldman RD, 2020, CLIN THER, V42, P2124, DOI 10.1016/j.clinthera.2020.09.012; Henriquez-Marquez KI, 2021, J MED VIROL, V93, P1885, DOI 10.1002/jmv.26702; Hernandez, 2021, SCIELO PREPR, DOI [10.1590/SciELOPreprints.1879, DOI 10.1590/SCIELOPREPRINTS.1879]; HernuYn M.A., 2017, CONCAPAN 37 2017 IEE, P1; Hossain MF, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.563478; Hussain A, 2018, CUREUS, V10, DOI 10.7759/cureus.2919; Iyengar KP, 2020, DIABETES METAB SYND, V14, P1743, DOI 10.1016/j.dsx.2020.09.003; Kluytmans-van Den Bergh MFQ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.9673; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; Labetoulle R, 2020, EXPERT REV VACCINES, V19, P937, DOI 10.1080/14760584.2020.1843432; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n372; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n296; Malik YS, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9070519; Mehraeen E, 2020, EUR J INTEGR MED, V40, DOI 10.1016/j.eujim.2020.101226; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Patel SK, 2020, J INFECT DEV COUNTR, V14, P450, DOI 10.3855/jidc.12744; Petersen E, 2021, INT J INFECT DIS, V104, P175, DOI 10.1016/j.ijid.2021.01.039; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Schlagenhauf P, 2021, TRAVEL MED INFECT DI, V40, DOI 10.1016/j.tmaid.2021.101996; Schwarzinger M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010199; Valenzuela-Rodriguez G, 2020, INT J INFECT DIS, V101, P226, DOI 10.1016/j.ijid.2020.09.018; Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Xu P, 2020, EUR REV MED PHARMACO, V24, P5797, DOI 10.26355/eurrev_202005_21374	38	10	10	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							287	10.3390/vaccines9030287			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5DY	33808918	Green Submitted, Green Published, gold			2022-04-29	WOS:000634175800001
J	Tejada-Perez, JJ; Vazquez-Vicente, JJ; Herrera-Burgos, MR; Martin-Martin, FG; Parron-Carreno, T; Alarcon-Rodriguez, R				Jose Tejada-Perez, Juan; Jose Vazquez-Vicente, Juan; Renee Herrera-Burgos, Maria; Gabriel Martin-Martin, Francisco; Parron-Carreno, Tesifon; Alarcon-Rodriguez, Raquel			Fendrix(R) Vaccine Effectiveness in Healthcare Workers Who Are Non-Responsive to Engerix B(R) Vaccination	VACCINES			English	Article						Hepatitis B; vaccination; fendrix; healthcare workers; occupational health	HEPATITIS-B-VACCINE; SPAIN.; IMPACT	Hepatitis B (HBV) is a pathogen virus with transmission mechanisms that include contact with the infected blood or bodily fluids of the infected organism. Nowadays, healthcare workers are one of the most exposed groups to HBV. Conventionally, completing a vaccine series dosage with Engerix B(R) lowers this risk by providing workers with immunity to the virus. However, through the years, we have encountered nonresponsive health personnel to the Engerix B(R) vaccine; hence, the Occupational Health Service of Poniente Hospital studied the Fendrix(R) adjuvanted vaccine as an alternative vaccine to develop immunological responses in healthcare workers who do not respond to vaccination with Engerix B(R). In our study, we employed a vaccination schedule with the Fendrix(R) vaccine, performing serology tests on the cases after the application of each dose. The results obtained showed humoral immunity in 92.3% of the cases, with a remarkable increase in antibody titer after the first doses. These encouraging results support the future inclusion of this vaccine as one possible alternative for the immunization to HBV for healthcare workers nonresponsive to Engerix B(R).	[Jose Tejada-Perez, Juan; Parron-Carreno, Tesifon; Alarcon-Rodriguez, Raquel] Univ Almeria, Fac Hlth Sci, Carr Sacramento S-N, Almeria 04120, Spain; [Jose Vazquez-Vicente, Juan; Renee Herrera-Burgos, Maria; Gabriel Martin-Martin, Francisco] Poniente Hosp Entrepreneurial Publ Hlth Agcy, Risk Prevent Serv, Ctra Almerimar 31, Almeria 04700, Spain		Tejada-Perez, JJ (通讯作者)，Univ Almeria, Fac Hlth Sci, Carr Sacramento S-N, Almeria 04120, Spain.	jtp119@inlumine.ual.es; juanjose.vazquez@ephpo.es; marenee_dc@hotmail.com; franspreven@gmail.com; tpc468@ual.es; ralarcon@ual.es	alarcon rodriguez, raquel/N-8571-2015	alarcon rodriguez, raquel/0000-0002-2220-6128; Martin Martin, Francisco Gabriel/0000-0001-8400-6001; Tejada-Perez, Juan Jose/0000-0001-7489-9483			[Anonymous], FICHA TECNICA ENGERI; [Anonymous], FICHA TECNICA FENDRI; [Anonymous], 2013, IBM SPSS STAT; [Anonymous], Generalidades de las Vacunas|Comite Asesor de Vacunas de la AEP; [Anonymous], POSTEXPOSURE PROPHYL; Fernandez JA, 2015, ENFERM INFEC MICR CL, V33, P113, DOI 10.1016/j.eimc.2014.12.010; Martinez MPA, 2015, ENFERM INFEC MICR CL, V33, P58, DOI 10.1016/j.eimc.2014.12.001; Batista-Duharte A, 2014, ENFERM INFEC MICR CL, V32, P106, DOI 10.1016/j.eimc.2012.11.012; Iturbe EB, 2009, AN PEDIATR, V70, P72, DOI 10.1016/j.anpedi.2008.10.001; Bravo-Grande JL, 2021, VACCINE, V39, P554, DOI 10.1016/j.vaccine.2020.12.006; Brown CM, 2011, RENAL FAILURE, V33, P276, DOI 10.3109/0886022X.2011.559300; Elmiyeh B, 2004, J ROY SOC MED, V97, P326, DOI 10.1258/jrsm.97.7.326; Fabrizi F, 2015, INT J ARTIF ORGANS, V38, P625, DOI 10.5301/ijao.5000458; Fink AL, 2018, CURR OPIN PHYSIOL, V6, P16, DOI 10.1016/j.cophys.2018.03.010; Fisman DN, 2002, CLIN INFECT DIS, V35, P1368, DOI 10.1086/344271; FORCE L, 1992, CLIN INFECT DIS, V15, P473, DOI 10.1093/clind/15.3.473; Hoebe CJPA, 2012, VACCINE, V30, P6734, DOI 10.1016/j.vaccine.2012.08.074; Tejada-Perez JJ, 2020, REV ESP COMUN SALUD, V11, P44, DOI 10.20318/recs.2020.5083; Keating GM, 2003, DRUGS, V63, P1021, DOI 10.2165/00003495-200363100-00006; Liaw YF, 2009, LANCET, V373, P582, DOI 10.1016/S0140-6736(09)60207-5; Limia Sanchez A., VACUNACION TRABAJADO; Limia Sanchez A., VACUNACION POBLACION; Limia Sanchez A., VACUNACION GRUPOS RI; Lindemann M, 2017, SCAND J IMMUNOL, V85, P51, DOI 10.1111/sji.12497; Loubet P, 2020, LANCET INFECT DIS, V20, P7, DOI 10.1016/S1473-3099(19)30582-1; Mateo Otero L., 2019, INMUNOGENICIDAD VACU; Nayagam S, 2016, LANCET GLOB HEALTH, V4, pE568, DOI 10.1016/S2214-109X(16)30101-2; Raven SFH, 2020, LANCET INFECT DIS, V20, P92, DOI 10.1016/S1473-3099(19)30417-7; Chavarri GS, 2020, ATEN PRIM, V52, P70, DOI 10.1016/j.aprim.2020.08.001; Uberos Fernandez J., ADYUVANTES VACUNAS	30	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							279	10.3390/vaccines9030279			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5MB	33808589	Green Published, gold			2022-04-29	WOS:000634196900001
J	Thompson, EE				Thompson, Esi E.			Botched Ebola Vaccine Trials in Ghana: An Analysis of Discourses in the Media	VACCINES			English	Article						moral panic; risk society; Ebola vaccine trials; Ghana		In June 2015, proposed Ebola vaccine trials were suspended by the Ministry of Health of Ghana amid protests from members of parliament and the general public. Scholarship has often focused on the design, development, and administration of vaccines. Of equal importance are the social issues surrounding challenges with vaccine trials and their implementation. The purpose of this study was to analyze discourses in the media that led to the suspension of the 2015 Ebola vaccine trials in Ghana. I use a sociological lens drawing on moral panic and risk society theories. The study qualitatively analyzed discourses in 18 semi-structured interviews with media workers, selected online publications, and user comments about the Ebola vaccine trials. The findings show that discourses surrounding the Ebola vaccine trials drew on cultural, biomedical, historical, and even contextual knowledge and circumstances to concretize risk discourses and garner support for their positions. Historical, political, and cultural underpinnings have a strong influence on biomedical practices and how they are (not) accepted. This study highlights the complexity and challenges of undertaking much needed vaccine tests in societies where the notion of drug trials has underlying historical and sociological baggage that determine whether (or not) the trials proceed.	[Thompson, Esi E.] Indiana Univ, Media Sch, Commun Sci Unit, Bloomington, IN 47405 USA		Thompson, EE (通讯作者)，Indiana Univ, Media Sch, Commun Sci Unit, Bloomington, IN 47405 USA.	Esiethom@iu.edu			Indiana University's Open Access Article Publishing Fund	I would like to thank God for the grace to complete this paper. I am also indebted to the reviewers who provided valuable feedback to improve the paper. The publication of this paper was made possible by Indiana University's Open Access Article Publishing Fund.	Alenichev A, 2020, GLOB PUBLIC HEALTH, V15, P13, DOI 10.1080/17441692.2019.1632368; [Anonymous], 2014, WHO REPORT SAGE WORK; Asante Kwaku Poku, 2019, Ghana Med J, V53, P90, DOI 10.4314/gmj.v53i2.2; Barnes R, 2015, NEW MEDIA SOC, V17, P810, DOI 10.1177/1461444813511039; Beck U., 2015, ECOLOGICAL POLITICS; Beck U, 1992, RISK SOC NEW MODERNI, V17; Beck U., 2012, WILEY BLACKWELL ENCY, DOI [10.1002/9780470670590.wbeog242, DOI 10.1002/9780470670590.WBEOG242]; Beland Daniel, 2011, MORAL PANIC POLITICS, P224; Busari S., 2020, THE CNN; Cherubini F., 2013, ONLINE COMMENT MODER; Cohen S., 1972, FOLK DEVILS MORAL PA; Cohen S, 2011, CRIME MEDIA CULT, V7, P237, DOI 10.1177/1741659011417603; Critcher C, 2008, SOCIOL COMPASS, V2, P1127, DOI 10.1111/j.1751-9020.2008.00122.x; Critcher C, 2009, BRIT J CRIMINOL, V49, P17, DOI 10.1093/bjc/azn040; Darko SA, 2020, COGENT SOC SCI, V6, DOI 10.1080/23311886.2020.1772444; Durodie B., 2005, NUFFIELD TRUST GLOBA; Essack Z, 2010, DEV WORLD BIOETH, V10, P11, DOI 10.1111/j.1471-8847.2009.00254.x; Fraser S, 2010, SOC THEOR HEALTH, V8, P192, DOI 10.1057/sth.2009.28; Fredrickson A., 2019, CONTEMP DRUG PROBL, V46, P105, DOI [10.1177/0091450918823340, DOI 10.1177/0091450918823340]; Garland D, 2008, CRIME MEDIA CULT, V4, P9, DOI 10.1177/1741659007087270; Gearhart S, 2018, JOURNAL PRACT, V12, P1183, DOI 10.1080/17512786.2017.1363658; GOODE E, 1994, ANNU REV SOCIOL, V20, P149, DOI 10.1146/annurev.so.20.080194.001053; Hier SP, 2003, BRIT J SOCIOL, V54, P3, DOI 10.1080/0007131032000045879; Howarth A, 2013, HEALTH RISK SOC, V15, P681, DOI 10.1080/13698575.2013.851180; Jegede AS, 2007, PLOS MED, V4, P417, DOI 10.1371/journal.pmed.0040073; Lacy S, 2013, J MASS COMMUN Q, V90, P457, DOI 10.1177/1077699013493790; Lazcano-Ponce E, 2001, ARCH MED RES, V32, P243, DOI 10.1016/S0188-4409(01)00277-6; Lee EJ, 2012, J COMPUT-MEDIAT COMM, V18, P32, DOI 10.1111/j.1083-6101.2012.01597.x; Lindegger G, 2007, HEALTH EDUC BEHAV, V34, P108, DOI 10.1177/1090198105277852; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; Miller T., 2006, CULTURAL POLITICS IN, V2, P299, DOI [https://doi.org/10.2752/174321906778531682, DOI 10.2752/174321906778531682, 10.2752/174321906778531682]; Nyarko J, 2016, SAGE OPEN, V6, DOI 10.1177/2158244016654952; Romano A., 2017, AUST J REV, V39, P79; Segbefia A., 2015, STATEMENT PARLIAMENT; Strauss Anselm, 1990, BASICS QUALITATIVE R; Thompson E.E., 2019, SAGE INT ENCY MASS M; Thompson EE, 2021, JOURNAL PRACT, V15, P1441, DOI 10.1080/17512786.2020.1784775; Thompson EE, 2019, SCI COMMUN, V41, P707, DOI 10.1177/1075547019878875; Thompson EE, 2013, CRIT ARTS, V27, P370, DOI 10.1080/02560046.2013.800669; Ungar S, 2001, BRIT J SOCIOL, V52, P271, DOI 10.1080/00071310120044980; Wong W., 2020, NBC NEWS	41	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							177	10.3390/vaccines9020177			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO7BJ	33669759	gold, Green Published			2022-04-29	WOS:000623295000001
J	Mellet, J; Pepper, MS				Mellet, Juanita; Pepper, Michael S.			A COVID-19 Vaccine: Big Strides Come with Big Challenges	VACCINES			English	Review						COVID-19; SARS-CoV-2; vaccine; vaccine development; vaccine platforms; immune response	IMMUNE-RESPONSES; ADENOVIRUS; ANTIBODIES; DESIGN	As of 8 January 2021, there were 86,749,940 confirmed coronavirus disease 2019 (COVID-19) cases and 1,890,342 COVID-19-related deaths worldwide, as reported by the World Health Organization (WHO). In order to address the COVID-19 pandemic by limiting transmission, an intense global effort is underway to develop a vaccine against SARS-CoV-2. The development of a safe and effective vaccine usually requires several years of pre-clinical and clinical stages of evaluation and requires strict regulatory approvals before it can be manufactured in bulk and distributed. Since the global impact of COVID-19 is unprecedented in the modern era, the development and testing of a new vaccine are being expedited. Given the high-level of attrition during vaccine development, simultaneous testing of multiple candidates increases the probability of finding one that is effective. Over 200 vaccines are currently in development, with over 60 candidate vaccines being tested in clinical trials. These make use of various platforms and are at different stages of development. This review discusses the different phases of vaccine development and the various platforms in use for candidate COVID-19 vaccines, including their progress to date. The potential challenges once a vaccine becomes available are also addressed.	[Mellet, Juanita; Pepper, Michael S.] Univ Pretoria, Inst Cellular & Mol Med, SAMRC Extramural Unit Stem Cell Res & Therapy, Dept Immunol,Fac Hlth Sci, ZA-0001 Pretoria, South Africa		Pepper, MS (通讯作者)，Univ Pretoria, Inst Cellular & Mol Med, SAMRC Extramural Unit Stem Cell Res & Therapy, Dept Immunol,Fac Hlth Sci, ZA-0001 Pretoria, South Africa.	juanitamellet@yahoo.co.uk; michael.pepper@up.ac.za	Pepper, Michael/M-6143-2014	Pepper, Michael/0000-0001-6406-2380	South African Medical Research CouncilSouth African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	South African Medical Research Council and theUniversity of Pretoria (to Michael S Pepper).	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], EYE WITNESS NEWS; [Anonymous], BBC NEWS; [Anonymous], SCI NEWS; [Anonymous], REUTERS; [Anonymous], THE CNN; [Anonymous], FDA NEWS; [Anonymous], PHARM TECHNOL; [Anonymous], CONVERSATION; [Anonymous], NEWS 24; [Anonymous], STAT NEWS; [Anonymous], GUARDIAN; [Anonymous], NEW YORK TIMES; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025; Bassett MT, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003402; Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004; Braciale TJ, 2013, IMMUNOL REV, V255, P5, DOI 10.1111/imr.12109; Burki TK, 2020, LANCET RESP MED, V8, pE85, DOI 10.1016/S2213-2600(20)30402-1; Calcedo R, 2009, J VIROL, V83, P2623, DOI 10.1128/JVI.02160-08; Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Centre for Disease Control and Prevention, COVID 19 HOSPITALIZA; Chirmule N, 1999, GENE THER, V6, P1574, DOI 10.1038/sj.gt.3300994; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; Davis CW, 2020, SCIENCE, V370, P237, DOI 10.1126/science.aaz8432; De Gregorio E, 2014, NAT REV IMMUNOL, V14, P505, DOI 10.1038/nri3694; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; E.U, WASH POST; Edwards K.M., 2018, PLOTKINS VACCINES, P7, DOI [10.1016/B978-0-323-35761-6.00002-X, DOI 10.1016/B978-0-323-35761-6.00002-X]; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Graham BS, 2013, IMMUNOL REV, V255, P230, DOI 10.1111/imr.12098; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jain S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040649; Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Lesser, 2020, EFFECT CONVALESCENT, DOI [10.1101/2020.08.12.20169359v1, DOI 10.1101/2020.08.12.20169359, 10.1101/2020.08.12.20169359]; Liu AD, 2020, CLIN MICROBIOL INFEC, V26, P1703, DOI 10.1016/j.cmi.2020.07.009; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3967; McCoy K, 2007, J VIROL, V81, P6594, DOI 10.1128/JVI.02497-06; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843, 10.21203/rs.3.rs-57112/v1]; Sarkar S, 2021, J MED VIROL, V93, P1111, DOI 10.1002/jmv.26408; Singh K, 2016, J POSTGRAD MED, V62, P4, DOI 10.4103/0022-3859.173187; Sumida SM, 2004, J VIROL, V78, P2666, DOI 10.1128/JVI.78.6.2666-2673.2004; Truyers, 2020, SAFETY IMMUNOGENICIT, DOI [10.1101/2020.09.23.20199604, DOI 10.1101/2020.09.23.20199604, 10.1101/2020.09.23.20199604v1]; University of Oxford, UNIVERSITY OF OXFORD; University of the Witwatersrand, 1 COVID 19 VACCINE T; US Food and Drug Association, 2019, DRUG TRIALS SNAPSHOT; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; World Health Organization, 2019, NOVEL CORONAVIRUS; World Health Organization, 2021, DRAFT LANDSCAPE COVI; Xiang ZQ, 2006, EMERG INFECT DIS, V12, P1596, DOI 10.3201/eid1210.060078; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Yang L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00243-2; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	66	37	38	18	30	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							39	10.3390/vaccines9010039			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VC	33440895	gold, Green Published	Y	N	2022-04-29	WOS:000610808800001
J	Pogan, R; Weiss, VU; Bond, K; Dulfer, J; Krisp, C; Lyktey, N; Muller-Guhl, J; Zoratto, S; Allmaier, G; Jarrold, MF; Munoz-Fontela, C; Schluter, H; Uetrecht, C				Pogan, Ronja; Weiss, Victor U.; Bond, Kevin; Duelfer, Jasmin; Krisp, Christoph; Lyktey, Nicholas; Mueller-Guhl, Jurgen; Zoratto, Samuele; Allmaier, Gunter; Jarrold, Martin F.; Muneoz-Fontela, Cesar; Schlueter, Hartmut; Uetrecht, Charlotte			N-terminal VP1 Truncations Favor T = 1 Norovirus-Like Particles	VACCINES			English	Article						norovirus; capsid assembly; native mass spectrometry; nES GEMMA; differential mobility analysis; CDMS		Noroviruses cause immense sporadic gastroenteritis outbreaks worldwide. Emerging genotypes, which are divided based on the sequence of the major capsid protein VP1, further enhance this public threat. Self-assembling properties of the human norovirus major capsid protein VP1 are crucial for using virus-like particles (VLPs) for vaccine development. However, there is no vaccine available yet. Here, VLPs from different variants produced in insect cells were characterized in detail using a set of biophysical and structural tools. We used native mass spectrometry, gas-phase electrophoretic mobility molecular analysis, and proteomics to get clear insights into particle size, structure, and composition, as well as stability. Generally, noroviruses have been known to form mainly T = 3 particles. Importantly, we identified a major truncation in the capsid proteins as a likely cause for the formation of T = 1 particles. For vaccine development, particle production needs to be a reproducible, reliable process. Understanding the underlying processes in capsid size variation will help to produce particles of a defined capsid size presenting antigens consistent with intact virions. Next to vaccine production itself, this would be immensely beneficial for bio-/nano-technological approaches using viral particles as carriers or triggers for immunological reactions.	[Pogan, Ronja; Duelfer, Jasmin; Mueller-Guhl, Jurgen; Uetrecht, Charlotte] Leibniz Inst Expt Virol, Heinrich Pette Inst, D-20251 Hamburg, Germany; [Pogan, Ronja; Uetrecht, Charlotte] European XFEL GmbH, D-22869 Schenefeld, Germany; [Weiss, Victor U.; Zoratto, Samuele; Allmaier, Gunter] TU Wien, Inst Chem Technol & Analyt, A-1060 Vienna, Austria; [Bond, Kevin; Lyktey, Nicholas; Jarrold, Martin F.] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; [Krisp, Christoph; Schlueter, Hartmut] Univ Med Ctr Hamburg Eppendorf, Inst Clin Chem & Lab Med, Mass Spectrometr Prote Grp, D-20246 Hamburg, Germany; [Mueller-Guhl, Jurgen; Muneoz-Fontela, Cesar] Bernhard Nocht Inst Trop Med, Partner Site Hamburg Lubeck Borstel Riems, D-20359 Hamburg, Germany; [Mueller-Guhl, Jurgen; Muneoz-Fontela, Cesar] German Ctr Infect Res DZIF, D-20359 Hamburg, Germany		Uetrecht, C (通讯作者)，Leibniz Inst Expt Virol, Heinrich Pette Inst, D-20251 Hamburg, Germany.; Uetrecht, C (通讯作者)，European XFEL GmbH, D-22869 Schenefeld, Germany.	ronja.pogan@leibniz-hpi.de; victor.weiss@tuwien.ac.at; kmbond@iu.edu; jasmin.duelfer@leibniz-hpi.de; c.krisp@uke.de; nalyktey@iu.edu; juergen.mueller@leibniz-hpi.de; samuele.zoratto@tuwien.ac.at; guenter.allmaier@tuwien.ac.at; mfj@indiana.edu; munoz-fontela@bnitm.de; hschluet@uke.de; charlotte.uetrecht@xfel.eu	Uetrecht, Charlotte/D-1883-2010	Uetrecht, Charlotte/0000-0002-1991-7922; Dulfer, Jasmin/0000-0001-9614-7645; Weiss, Victor/0000-0002-0056-6819; Munoz-Fontela, Cesar/0000-0002-7725-2586; Zoratto, Samuele/0000-0002-1491-3404	Free and Hanseatic City Hamburg; Federal Ministry of Health (Bundesministerium fur Gesundheit); Leibniz Association [SAW-2014-HPI-4]; EU Horizon 2020 project [VIRUSCAN 731868]; MIN Graduate School Universitat Hamburg; Austrian Theodor Korner Fonds; COST Action Native Mass Spectrometry and Related Methods for Structural Biology [BM1403]; DFGGerman Research Foundation (DFG)European Commission [FOR2327]	The Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology is supported by the Free and Hanseatic City Hamburg and the Federal Ministry of Health (Bundesministerium fur Gesundheit, BMG). C.U. acknowledges funding from the Leibniz Association through SAW-2014-HPI-4 grant. R.P., J.M.-G., C.U., and C.M.-F. acknowledge funding from EU Horizon 2020 project VIRUSCAN 731868. R.P. further acknowledges funding from MIN Graduate School Universitat Hamburg. J.D. was funded by DFG FOR2327 Virocarb. V.U.W. acknowledges funding of the Austrian Theodor Korner Fonds. V.U.W. and R.P. both acknowledge funding of COST Action BM1403 Native Mass Spectrometry and Related Methods for Structural Biology.	Ahmed SM, 2014, LANCET INFECT DIS, V14, P725, DOI 10.1016/S1473-3099(14)70767-4; Bacher G, 2001, J MASS SPECTROM, V36, P1038, DOI 10.1002/jms.208; Baker TS, 1999, MICROBIOL MOL BIOL R, V63, P862, DOI 10.1128/MMBR.63.4.862-922.1999; Bertolotti-Ciarlet A, 2002, J VIROL, V76, P4044, DOI 10.1128/JVI.76.8.4044-4055.2002; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Chhabra P, 2019, J GEN VIROL, V100, P1393, DOI 10.1099/jgv.0.001318; Contino NC, 2013, J AM SOC MASS SPECTR, V24, P101, DOI 10.1007/s13361-012-0525-5; de Graaf M, 2015, EUROSURVEILLANCE, V20, P8, DOI 10.2807/1560-7917.ES2015.20.26.21178; Devant JM, 2019, ANTIVIR RES, V168, P175, DOI 10.1016/j.antiviral.2019.05.010; Diamos AG, 2018, PROTEIN EXPRES PURIF, V151, P86, DOI 10.1016/j.pep.2018.06.011; Dulfer J, 2019, ADV VIRUS RES, V105, P189, DOI 10.1016/bs.aivir.2019.07.003; Eden JS, 2013, J VIROL, V87, P6270, DOI 10.1128/JVI.03464-12; Ettayebi K, 2016, SCIENCE, V353, P1387, DOI 10.1126/science.aaf5211; Gotoh T, 2001, APPL MICROBIOL BIOT, V56, P742, DOI 10.1007/s002530100602; Gotoh T, 2010, BIOSCI BIOTECH BIOCH, V74, P2154, DOI 10.1271/bbb.100476; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Hansman GS, 2007, J CLIN MICROBIOL, V45, P1347, DOI 10.1128/JCM.01854-06; Hansman GS, 2005, ARCH VIROL, V150, P21, DOI 10.1007/s00705-004-0406-8; Hasegawa K, 2017, ACTA CRYSTALLOGR F, V73, P568, DOI 10.1107/S2053230X17013759; Huo YQ, 2015, VIRUS RES, V204, P1, DOI 10.1016/j.virusres.2015.04.009; JIANG X, 1990, Science (Washington D C), V250, P1580; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; Jung J, 2019, P NATL ACAD SCI USA, V116, P12828, DOI 10.1073/pnas.1903562116; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; Kaufman SL, 1996, ANAL CHEM, V68, P1895, DOI 10.1021/ac951128f; Krol MA, 1999, P NATL ACAD SCI USA, V96, P13650, DOI 10.1073/pnas.96.24.13650; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorenzen K, 2007, INT J MASS SPECTROM, V268, P198, DOI 10.1016/j.ijms.2007.06.012; Lutomski CA, 2017, J AM CHEM SOC, V139, P16932, DOI 10.1021/jacs.7b09932; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; Morgner N, 2012, ANAL CHEM, V84, P2939, DOI 10.1021/ac300056a; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Pierson EE, 2016, J MOL BIOL, V428, P292, DOI 10.1016/j.jmb.2015.06.019; Pogan R, 2018, CURR OPIN VIROL, V31, P59, DOI 10.1016/j.coviro.2018.05.003; Pogan R, 2018, J PHYS-CONDENS MAT, V30, DOI 10.1088/1361-648X/aaa43b; Prasad BVV, 1999, SCIENCE, V286, P287, DOI 10.1126/science.286.5438.287; PRASAD BVV, 1994, J VIROL, V68, P5117, DOI 10.1128/JVI.68.8.5117-5125.1994; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Shoemaker GK, 2010, MOL CELL PROTEOMICS, V9, P1742, DOI 10.1074/mcp.M900620-MCP200; Someya Y, 2011, J GEN VIROL, V92, P2320, DOI 10.1099/vir.0.033985-0; Tan M, 2005, J VIROL, V79, P14017, DOI 10.1128/JVI.79.22.14017-14030.2005; Tan M, 2008, VIROLOGY, V382, P115, DOI 10.1016/j.virol.2008.08.047; Tan M, 2012, NANOMEDICINE-UK, V7, P889, DOI [10.2217/NNM.12.62, 10.2217/nnm.12.62]; TANIGUCHI K, 1981, J MED MICROBIOL, V14, P107, DOI 10.1099/00222615-14-1-107; Taube S, 2005, ARCH VIROL, V150, P1425, DOI 10.1007/s00705-005-0517-x; Teunis PFM, 2008, J MED VIROL, V80, P1468, DOI 10.1002/jmv.21237; Tome-Amat J, 2014, MICROB CELL FACT, V13, DOI 10.1186/s12934-014-0134-z; Tycova A, 2016, ELECTROPHORESIS, V37, P924, DOI 10.1002/elps.201500467; Uetrecht C, 2011, NAT CHEM, V3, P126, DOI [10.1038/nchem.947, 10.1038/NCHEM.947]; van den Heuvel RHH, 2006, ANAL CHEM, V78, P7473, DOI 10.1021/ac061039a; Weiss VU, 2019, ANAL BIOANAL CHEM, V411, P5951, DOI 10.1007/s00216-019-01998-6; Weiss VU, 2015, ANAL CHEM, V87, P8709, DOI 10.1021/acs.analchem.5b01450; White LJ, 1997, J VIROL, V71, P8066, DOI 10.1128/JVI.71.10.8066-8072.1997; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992	55	5	5	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							8	10.3390/vaccines9010008			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6WJ	33374273	Green Submitted, Green Published, gold			2022-04-29	WOS:000610812100001
J	Tsilibary, EP; Charonis, SA; Georgopoulos, AP				Tsilibary, Effie-Photini; Charonis, Spyros A.; Georgopoulos, Apostolos P.			Vaccines for Influenza	VACCINES			English	Editorial Material									[Tsilibary, Effie-Photini; Charonis, Spyros A.; Georgopoulos, Apostolos P.] Dept Vet Affairs Hlth Care Syst, Brain Sci Ctr, Minneapolis, MN 55417 USA; [Tsilibary, Effie-Photini; Charonis, Spyros A.; Georgopoulos, Apostolos P.] Univ Minnesota, Sch Med, Dept Neurosci, Minneapolis, MN 55455 USA		Georgopoulos, AP (通讯作者)，Dept Vet Affairs Hlth Care Syst, Brain Sci Ctr, Minneapolis, MN 55417 USA.; Georgopoulos, AP (通讯作者)，Univ Minnesota, Sch Med, Dept Neurosci, Minneapolis, MN 55455 USA.	tsili001@umn.edu; scharoni@umn.edu; omega@umn.edu					Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Charonis S., 2020, J IMMUNOLOGICAL SCI, V4, P12; Chen JR, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0626-6; Dawood FS, 2020, MMWR-MORBID MORTAL W, V69, P177, DOI 10.15585/mmwr.mm6907a1; Harding AT, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020019; James L. M, 2018, J NEUROL NEUROMED, V3, P27, DOI DOI 10.29245/2572.942X/2018/6.1235; Lewnard JA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020028; Mohammed AA, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/2567957; Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Posteraro B, 2014, VACCINE, V32, P1661, DOI 10.1016/j.vaccine.2014.01.057; Rose A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.10.2000153; Tsilibary EPC, 2020, NEUROSCI INSIGHTS, V15, DOI 10.1177/2633105520931966; Tsilibary EPC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020232; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Yung AD, 2019, US PHARM, V44, P18	17	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							47	10.3390/vaccines9010047			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6TD	33466608	Green Published, gold			2022-04-29	WOS:000610803600001
J	Dubov, A; Distelberg, BJ; Abdul-Mutakabbir, JC; Beeson, WL; Loo, LK; Montgomery, SB; Oyoyo, UE; Patel, P; Peteet, B; Shoptaw, S; Tavakoli, S; Chrissian, AA				Dubov, Alex; Distelberg, Brian J.; Abdul-Mutakabbir, Jacinda C.; Beeson, W. Lawrence; Loo, Lawrence K.; Montgomery, Susanne B.; Oyoyo, Udochukwu E.; Patel, Pranjal; Peteet, Bridgette; Shoptaw, Steven; Tavakoli, Shahriyar; Chrissian, Ara A.			Predictors of COVID-19 Vaccine Acceptance and Hesitancy among Healthcare Workers in Southern California: Not Just "Anti" vs. "Pro" Vaccine	VACCINES			English	Article						COVID-19 pandemic; SARS-CoV-2; COVID-19 vaccine; vaccine hesitancy; vaccine acceptance; healthcare professionals	CRITERION; CLUSTERS; NUMBER	In this study, we evaluated the status of and attitudes toward COVID-19 vaccination of healthcare workers in two major hospital systems (academic and private) in Southern California. Responses were collected via an anonymous and voluntary survey from a total of 2491 participants, including nurses, physicians, other allied health professionals, and administrators. Among the 2491 participants that had been offered the vaccine at the time of the study, 2103 (84%) were vaccinated. The bulk of the participants were middle-aged college-educated White (73%), non-Hispanic women (77%), and nursing was the most represented medical occupation (35%). Political affiliation, education level, and income were shown to be significant factors associated with vaccination status. Our data suggest that the current allocation of healthcare workers into dichotomous groups such as "anti-vaccine vs. pro-vaccine" may be inadequate in accurately tailoring vaccine uptake interventions. We found that healthcare workers that have yet to receive the COVID-19 vaccine likely belong to one of four categories: the misinformed, the undecided, the uninformed, or the unconcerned. This diversity in vaccine hesitancy among healthcare workers highlights the importance of targeted intervention to increase vaccine confidence. Regardless of governmental vaccine mandates, addressing the root causes contributing to vaccine hesitancy continues to be of utmost importance.	[Dubov, Alex; Distelberg, Brian J.; Montgomery, Susanne B.; Peteet, Bridgette] Loma Linda Univ, Sch Behav Hlth, Loma Linda, CA 92350 USA; [Abdul-Mutakabbir, Jacinda C.] Loma Linda Univ, Sch Pharm, Loma Linda, CA 92350 USA; [Beeson, W. Lawrence] Loma Linda Univ, Sch Publ Hlth, Loma Linda, CA 92350 USA; [Loo, Lawrence K.; Patel, Pranjal; Tavakoli, Shahriyar; Chrissian, Ara A.] Loma Linda Univ, Sch Med, Loma Linda, CA 92350 USA; [Oyoyo, Udochukwu E.] Loma Linda Univ, Sch Dent, Loma Linda, CA 92350 USA; [Shoptaw, Steven] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90032 USA		Dubov, A (通讯作者)，Loma Linda Univ, Sch Behav Hlth, Loma Linda, CA 92350 USA.	adubov@llu.edu; bdistelberg@llu.edu; JAbdulmutakabbir@llu.edu; lbeeson@llu.edu; lkloo@llu.edu; smontgomery@llu.edu; UOyoyo@llu.edu; PRAPatel@llu.edu; bpeteet@llu.edu; SShoptaw@mednet.ucla.edu; STavakoli@llu.edu; AChrissian@llu.edu		Abdul-Mutakabbir, Jacinda/0000-0003-4162-6408; Dubov, Alex/0000-0003-2940-0254; Peteet, Bridgette/0000-0003-2429-3445; Patel, Pranjal/0000-0003-4031-9545; Montgomery, Susanne/0000-0003-1269-9034; Shoptaw, Steven/0000-0002-3583-0026	Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) NIMH [MH58107]	This work was supported by the Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) NIMH grant MH58107. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH.	Allen JD, 2009, PREV MED, V48, P420, DOI 10.1016/j.ypmed.2008.12.005; Ball P, 2020, NATURE, V581, P371, DOI 10.1038/d41586-020-01452-z; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Burden S, 2021, J ADV NURS, V77, pE16, DOI 10.1111/jan.14854; Centers for Disease Control, BUILDING CONFIDENCE; Chevallier C, 2021, TRENDS COGN SCI, V25, P331, DOI 10.1016/j.tics.2021.02.002; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Ciardi F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050516; de Bruin WB, 2019, HEALTH PSYCHOL, V38, P975, DOI 10.1037/hea0000771; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dzieciolowska S, 2021, AM J INFECT CONTROL, V49, P1152, DOI 10.1016/j.ajic.2021.04.079; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Food and Drug Administration, COVID 19 VACC; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Gharpure R, 2021, MMWR-MORBID MORTAL W, V70, P178, DOI 10.15585/mmwr.mm7005e2; Grochowska M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050475; Hamel Liz, KFF COVID 19 VACCINE; Hudson A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18158054; Islam MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251605; Jamieson K. H., 2020, HARVARD KENNEDY SCH, DOI [10.37016/mr-2020-012, DOI 10.37016/MR-2020-012]; Kirzinger A, VACCINE HESITANCY RU; Klompas M, 2021, ANN INTERN MED, V174, P1305, DOI 10.7326/M21-2366; Korn L, 2020, P NATL ACAD SCI USA, V117, P14890, DOI 10.1073/pnas.1919666117; KROLAKSCHWERDT S, 1992, MULTIVAR BEHAV RES, V27, P541, DOI 10.1207/s15327906mbr2704_3; Latkin C, 2021, VACCINE, V39, P2237, DOI 10.1016/j.vaccine.2021.02.058; Li M, 2021, POSTGRAD MED J, DOI 10.1136/postgradmedj-2021-140195; MILLIGAN GW, 1981, PSYCHOMETRIKA, V46, P187, DOI 10.1007/BF02293899; MILLIGAN GW, 1985, PSYCHOMETRIKA, V50, P159, DOI 10.1007/BF02294245; Milligan MA, 2021, PSYCHOL HEALTH MED, DOI 10.1080/13548506.2021.1969026; Moniz M.H., 2021, COVID 19 VACCINE ACC, DOI [10.1101/2021.04.29.21256186, DOI 10.1101/2021.04.29.21256186]; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oliver K., 2021, FACTORS ASS COVID 19, DOI [10.1101/2021.03.24.21253489, DOI 10.1101/2021.03.24.21253489]; Palm R., 2021, FRONTIERS POLITICAL, V3, DOI DOI 10.3389/FPOS.2021.661257; Pan WJ, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.630268; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Pennycook G, 2020, PSYCHOL SCI, V31, P770, DOI 10.1177/0956797620939054; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; SteelFisher GK, 2021, NEW ENGL J MED, V384, P1483, DOI 10.1056/NEJMp2100351; Stolle LB, 2020, ADV THER, V37, P4481, DOI 10.1007/s12325-020-01502-y; Strickland J.C., 2021, INTEGRATING OPERANT, DOI [10.1101/2021.01.20.21250195, DOI 10.1101/2021.01.20.21250195]; Tabachnick B. G., 2007, USING MULTIVARIATE S, V5, P481; Weisel O, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026745118; World Health Organization Conversations to Build Trust in Vaccination, TRAIN MOD; World Health Organization (WHO), Coronavirus disease 2019 (COVID-19) weekly epidemiological update-5 October 2021; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Yang Y, 2021, J COMMUN HEALTH, V46, P1090, DOI 10.1007/s10900-021-00993-2; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	51	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1428	10.3390/vaccines9121428			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9QX	34960171	Green Submitted, Green Published, gold			2022-04-29	WOS:000737300200001
J	Gianfredi, V; Filia, A; Rota, MC; Croci, R; Bellini, L; Odone, A; Signorelli, C				Gianfredi, Vincenza; Filia, Antonietta; Rota, Maria Cristina; Croci, Roberto; Bellini, Lorenzo; Odone, Anna; Signorelli, Carlo			Vaccine Procurement: A Conceptual Framework Based on Literature Review	VACCINES			English	Article						vaccine procurement; Europe; review; vaccine; immunization	QUALITY; PROGRESS; FUTURE; WORLD	Ensuring timely access to affordable vaccines has been acknowledged as a global public health priority, as also recently testified by the debate sparked during the COVID-19 pandemic. Effective vaccine procurement strategies are essential to reach this goal. Nevertheless, this is still a neglected research topic. A narrative literature review on vaccine procurement was conducted, by retrieving articles from four academic databases (PubMed/MEDLINE, Scopus, Embase, WebOfScience), 'grey' literature reports, and institutional websites. The aim was to clarify key concepts and definitions relating to vaccine procurement, describe main vaccine procurement methods, and identify knowledge gaps and future perspectives. A theoretical conceptual framework was developed of the key factors involved in vaccine procurement, which include quality and safety of the product, forecasting and budgeting, procurement legislation, financial sustainability, and plurality of manufacture, contracting, investment in training, storage and service delivery, monitoring and evaluation. This information can be useful to support policymakers during planning, implementation, and evaluation of regional and national vaccine procurement strategies and policies.	[Gianfredi, Vincenza; Croci, Roberto; Bellini, Lorenzo; Signorelli, Carlo] Univ Vita Salute San Raffaele, Sch Med, Via Olgettina 58, I-20132 Milan, Italy; [Filia, Antonietta; Rota, Maria Cristina] Italian Natl Hlth Inst, Dept Infect Dis, Viale Regina Elena Rome 299, I-00161 Rome, Italy; [Odone, Anna] Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy		Gianfredi, V (通讯作者)，Univ Vita Salute San Raffaele, Sch Med, Via Olgettina 58, I-20132 Milan, Italy.	gianfredi.vincenza@hsr.it; antonietta.filia@iss.it; mariacristina.rota@iss.it; croci.roberto@hsr.it; bellini.lorenzo@hsr.it; anna.odone@unipv.it; signorelli.carlo@hsr.it	Signorelli, Carlo/AAC-7630-2022; Gianfredi, Vincenza/W-1408-2017; Odone, Anna/AAC-4715-2022; Filia, Antonietta/M-7919-2017	Gianfredi, Vincenza/0000-0003-3848-981X; SIGNORELLI, Carlo/0000-0002-0960-9563; Odone, Anna/0000-0002-5657-9774; rota, maria cristina/0000-0002-9861-446X; Croci, Roberto/0000-0001-5496-7493; Filia, Antonietta/0000-0002-9909-6422	European Union's Health Programme [801495]	This project has received co-funding from the European Union's Health Programme under Grant Agreement no. 801495.	Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Andrus JK, 2007, PUBLIC HEALTH REP, V122, P811; [Anonymous], 2011, OP PROC PAHO REV FUN; [Anonymous], 2020, TERMS OGOS CARTEL; [Anonymous], 2019, CTR DIS CONTROL PREV; [Anonymous], 2019, DRUG SHORTAGES CANAD; [Anonymous], 2020, PREV CONTR INFL RACC; [Anonymous], 2001, 54 WORLD HLTH ASS WH; Australian Governement Department of Health, 2020, MED SHORT INF IN; Baethge C, 2019, RES INTEGR PEER REV, V4, DOI 10.1186/s41073-019-0064-8; Barrett ADT, 2016, NEW ENGL J MED, V375, P301, DOI 10.1056/NEJMp1606997; Bernd E.R., 2018, ORG DEL VACC SERV EU; Bumpas J., 2008, STUDY COMP EFFICIENC; Burgess RA, 2021, LANCET, V397, P8, DOI 10.1016/S0140-6736(20)32642-8; Burioni R, 2018, NATURE, V555, P27, DOI 10.1038/d41586-018-02267-9; Centers for Disease Control and Prevention, CURR VACC SHORT DEL; Coyne PE, 2019, INT HEALTH, V11, P79, DOI 10.1093/inthealth/ihy095; Dellepiane N, 2015, VACCINE, V33, P52, DOI 10.1016/j.vaccine.2013.11.066; DeRoeck D., 2003, GROUP PROCUREMENT VA; Dimitri N, 2006, HANDBOOK OF PROCUREMENT, P1, DOI 10.1017/CBO9780511492556; Duclos P, 2013, VACCINE, V31, P5314, DOI 10.1016/j.vaccine.2013.08.084; Ethgen O, 2016, HUM VACC IMMUNOTHER, V12, P2038, DOI 10.1080/21645515.2016.1155013; European Commission, 2014, WORLD TRENDS R D PRI; Fadeyi I, 2017, VALUE HEALTH, V20, pA411, DOI 10.1016/j.jval.2017.08.080; Filia A., 2019, REPORT PREVIOUS EXPE; GAVI Board, 2019, MEN OUTBR RESP SUPPL; GAVI Board, 2002, LESS LEARN NEW PROC; GAVI the Vaccine Alliance, 2016, SUPPL PROC STRAT 201; Hinsch M, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/1744-8603-10-34; Huff-Rousselle M, 2012, SOC SCI MED, V75, P1572, DOI 10.1016/j.socscimed.2012.05.044; Johansen K., 2019, REPORT UNDERSTANDING; Kartoglu U, 2014, EXPERT REV VACCINES, V13, P843, DOI 10.1586/14760584.2014.923761; Lee BY, 2016, VACCINE, V34, P4998, DOI 10.1016/j.vaccine.2016.08.036; Lopalco PL, 2015, VACCINE, V33, P1541, DOI 10.1016/j.vaccine.2014.10.047; Lydon P, 2017, VACCINE, V35, P2121, DOI 10.1016/j.vaccine.2016.12.071; Malhame M, 2019, VACCINE-X, V2, DOI 10.1016/j.jvacx.2019.100033; McCue C.P., 2000, J PUBLIC BUDGETING A, V12, DOI [10.1108/jpbafm-12-03-2000-b003, DOI 10.1108/JPBAFM-12-03-2000-B003]; McCurry Justin, 2004, Lancet, V363, P134, DOI 10.1016/S0140-6736(03)15314-7; Milstien J, 2002, VACCINE, V20, P1000, DOI 10.1016/S0264-410X(01)00422-4; Nelson EAS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089593; New Zealand Ministry of Health, BCG VACC VACC END 20; Odone A, 2017, VACCINE, V35, P1209, DOI 10.1016/j.vaccine.2015.11.051; Pagliusi S, 2019, VACCINE, V37, P5909, DOI 10.1016/j.vaccine.2019.07.088; Pubmed, NAT LIB MED PUBL CHA; Rey-Jurado E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00026; Saitoh A, 2018, VACCINE, V36, P4582, DOI 10.1016/j.vaccine.2018.01.092; Shamsi GN, 2018, INT SER OPER RES MAN, V262, P267, DOI 10.1007/978-3-319-65455-3_11; Stuurman AL, 2018, EUR J PUBLIC HEALTH, V28, P82; Tafuri S, 2020, ANN IG MED PREV COMU, V32, P430, DOI 10.7416/ai.2020.2366; Thompson KM, 2016, RISK ANAL, V36, P1487, DOI 10.1111/risa.12265; Vaccines Europe, 2016, EU VACC IND FIG; Wilsdon T, 2020, EXPERT REV VACCINES, V19, P123, DOI 10.1080/14760584.2020.1717952; World Health Organization, 2015, MYTHS FACTS VACC PRO; World Health Organization, 2003, PROC VACC PUBL SECT; World Health Organization, 2016, WHO EXP COMM SPEC PH, V5th; World Health Organization, 2019, SEV 2 WORLD HLTH ASS; World Health Organization, 2020, PROC MECH SYST; World Health Organization, 2007, MULT REG POOL PROC M; World Health Organization, 2013, REV VACC PRIC DAT; World Health Organization, 2019, FACT CONS COMP VACC; World Health Organization, 2016, VACC PROD PRIC PROC; World Health Organization, 2019, WHO UNICEF JOINT REP; World Health Organization Immunization Programmes, PROC MECH 2018; World Health Organization MI4A, MARK INF ACC VACC 20; Zaffran M, 2013, VACCINE, V31, pB73, DOI 10.1016/j.vaccine.2012.11.036; Zerhouni E, 2019, CELL, V179, P13, DOI 10.1016/j.cell.2019.08.026	66	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1434	10.3390/vaccines9121434			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2DE	34960180	gold, Green Published			2022-04-29	WOS:000737467900001
J	Nazaruk, P; Monticolo, M; Jedrzejczak, AM; Krata, N; Moszczuk, B; Sanko-Resmer, J; Pilecki, T; Urbanowicz, A; Florczak, M; Paczek, L; Foroncewicz, B; Mucha, K				Nazaruk, Paulina; Monticolo, Marta; Jedrzejczak, Anna Maria; Krata, Natalia; Moszczuk, Barbara; Sanko-Resmer, Joanna; Pilecki, Tomasz; Urbanowicz, Arkadiusz; Florczak, Michal; Paczek, Leszek; Foroncewicz, Bartosz; Mucha, Krzysztof			Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients-Is It Related to Immunosuppression Only?	VACCINES			English	Article						BNT162b2 mRNA; COVID-19; kidney transplantation; liver transplantation; SARS-CoV-2; SOT; vaccination	COVID-19 VACCINE; H1N1 VACCINE	The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant recipients (LTRs). In this retrospective cohort study, we included randomly 65 KTRs and 65 LTRs, who received two 30 mu g doses of BNT162b2 vaccine in 3-to6-week intervals. We analyzed the anti-SARS-CoV-2 spike protein IgG antibody (anti-S1 Ab) titer, biochemical liver and renal tests, immunosuppressive drug trough level, and clinical follow up 4-6 weeks after the first dose and 4-8 weeks after the second dose. The level of protective antibodies was 57.1% in KTRs and 88.9% in LTRs after the second dose. The anti-S1 Ab response was significantly associated with sex, age, and history of COVID-19. A tacrolimus dose at vaccination but not its trough level was significantly correlated with the increase in anti-S1 Ab titer after the second vaccine dose in LTRs. Rejection episodes did not occur after vaccination. Our results showed a higher than previously reported humoral response to the BNT162b2 vaccine in KTRs and LTRs, which was dependent upon age, type of transplanted organ, and immunosuppression.	[Nazaruk, Paulina; Monticolo, Marta; Jedrzejczak, Anna Maria; Krata, Natalia; Pilecki, Tomasz; Urbanowicz, Arkadiusz; Florczak, Michal; Paczek, Leszek; Foroncewicz, Bartosz; Mucha, Krzysztof] Med Univ Warsaw, Dept Immunol Transplantol & Internal Dis, PL-02006 Warsaw, Poland; [Moszczuk, Barbara] Med Univ Warsaw, Dept Clin Immunol, PL-02006 Warsaw, Poland; [Sanko-Resmer, Joanna] Med Univ Warsaw, Dept Nephrol Nursing, PL-02007 Warsaw, Poland; [Paczek, Leszek; Mucha, Krzysztof] Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland		Mucha, K (通讯作者)，Med Univ Warsaw, Dept Immunol Transplantol & Internal Dis, PL-02006 Warsaw, Poland.; Mucha, K (通讯作者)，Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland.	tapaulla@wp.pl; marta.monticolo@gmail.com; nkrata@wum.edu.pl; bmoszczuk@gmail.com; bmoszczuk@gmail.com; joannnaresmer@poczta.onet.pl; tomaszpilecki@wp.pl; arcurbi@gmail.com; mflorek1983@gmail.com; leszek.paczek@wum.edu.pl; bartosz.foroncewicz@wum.edu.pl; kmucha@wum.edu.pl		Krata, Natalia/0000-0003-0564-0819; Paczek, Leszek/0000-0003-0160-3009			Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Barda N, 2021, LANCET, V398, P2093, DOI 10.1016/S0140-6736(21)02249-2; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Boyarsky BJ, 2021, TRANSPLANTATION, V105, pE56, DOI 10.1097/TP.0000000000003654; Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases (NCIRD), NAT CTR IMM RESP DIS; Cornberg M, 2021, J HEPATOL, V75, P265, DOI 10.1016/j.jhep.2021.05.007; Deepak P, 2021, ANN INTERN MED, V174, P1572, DOI 10.7326/M21-1757; Eckerle I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056974; Fairhead T, 2012, TRANSPL INFECT DIS, V14, P575, DOI 10.1111/tid.12006; Galli C., ANTIBODY TESTING SAR; Gobbi F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030422; Grupper A, 2021, AM J TRANSPLANT, V21, P2719, DOI 10.1111/ajt.16615; Jalkanen P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24285-4; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Katerinis I, 2011, AM J TRANSPLANT, V11, P1727, DOI 10.1111/j.1600-6143.2011.03604.x; Kohmer N, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104480; Korth J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050756; Krause PR, 2021, LANCET, V398, P1377, DOI 10.1016/S0140-6736(21)02046-8; Masset C, 2021, KIDNEY INT, V100, P1132, DOI 10.1016/j.kint.2021.08.017; Phadke VK, 2021, CURR TRANSPLANT REP, V8, P127, DOI 10.1007/s40472-021-00322-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rabets A, 2021, ARCH IMMUNOL THER EX, V69, DOI 10.1007/s00005-021-00607-8; Rabinowich L, 2021, J HEPATOL, V75, P435, DOI 10.1016/j.jhep.2021.04.020; Rashidi-Alavijeh J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070738; Rivas-Santiago B, 2021, ARCH IMMUNOL THER EX, V69, DOI 10.1007/s00005-021-00630-9; Rusk DS, 2021, J MED VIROL, V93, P5623, DOI 10.1002/jmv.27044; Schaffer SA, 2011, AM J TRANSPLANT, V11, P2751, DOI 10.1111/j.1600-6143.2011.03743.x; Subesinghe S, 2018, J RHEUMATOL, V45, P733, DOI 10.3899/jrheum.170710; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; Vassilaki N, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9081725; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3; Werbel WA, 2021, ANN INTERN MED, V174, P1330, DOI 10.7326/L21-0282; Wheeler SE, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.00341-21; Wise J, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2160; World Health Organisation, EST WHO INT STAND RE; Yan SJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00912	38	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1454	10.3390/vaccines9121454			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YH0SE	34960200	gold, Green Published			2022-04-29	WOS:000742885800001
J	Pedersen, ESL; Mallet, MC; Lam, YT; Bellu, S; Cizeau, I; Copeland, F; Fernandez, TL; Manion, M; Harris, AL; Lucas, JS; Santamaria, F; Goutaki, M; Kuehni, CE				Pedersen, Eva S. L.; Mallet, Maria Christina; Lam, Yin Ting; Bellu, Sara; Cizeau, Isabelle; Copeland, Fiona; Fernandez, Trini Lopez; Manion, Michele; Harris, Amanda L.; Lucas, Jane S.; Santamaria, Francesca; Goutaki, Myrofora; Kuehni, Claudia E.		COVID PCD Patient Advisory Grp	COVID-19 Vaccinations: Perceptions and Behaviours in People with Primary Ciliary Dyskinesia	VACCINES			English	Article						SARS-CoV-2; COVID-19; PCD; primary ciliary dyskinesia; vaccine; vaccinations; pandemic		Primary ciliary dyskinesia (PCD) is a rare genetic disease that causes recurrent respiratory infections. People with PCD may be at higher risk of severe coronavirus disease 2019 (COVID-19), and therefore vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important. We studied vaccination willingness, speed of vaccination uptake, side effects, and changes in social contact behaviour after vaccination in people with PCD. We used data from COVID-PCD, an international participatory cohort study. A COVID-19 vaccination questionnaire was emailed to participants in May 2021 and 423 participants from 31 countries replied (median age: 30 years, range 1-85 years; 261 (62%) female). Vaccination uptake and willingness were high, with 273 of 287 adults (96%) being vaccinated or willing to be in June 2021; only 4% were hesitant. The most common reason for hesitancy was fear of side effects, reported by 88%. Mild side effects were common, but no participant reported severe side effects. Half of the participants changed their social behaviour after vaccination by seeing friends and family more often. The high vaccination willingness in the study population might reflect the extraordinary effort taken by PCD support groups to inform people about COVID-19 vaccination. Clear and specific information and involvement of representatives is important for high vaccine uptake.	[Pedersen, Eva S. L.; Mallet, Maria Christina; Lam, Yin Ting; Goutaki, Myrofora; Kuehni, Claudia E.] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Mallet, Maria Christina] Univ Bern, Grad Sch Hlth Sci, CH-3012 Bern, Switzerland; [Bellu, Sara] Assoc Italiana Discinesia Ciliare Primaria Sindro, I-70124 Bari, Italy; [Cizeau, Isabelle] Assoc ADCP, F-42218 St Etienne, France; [Copeland, Fiona] PCD Support UK, London MK18 9DX, England; [Fernandez, Trini Lopez] Asociac Espanola Pacientes Discinesia Ciliar Prim, Santo Angel 30151, Philippines; [Manion, Michele] PCD Fdn, Minneapolis, MN 55420 USA; [Harris, Amanda L.; Lucas, Jane S.] Univ Hosp Southampton NHS Fdn Trust, NIHR Biomed Res Ctr, Primary Ciliary Dyskinesia Ctr, Southampton SO16 6YD, Hants, England; [Lucas, Jane S.] Univ Southampton, Sch Clin & Expt Med, Fac Med, Southampton SO17 1BJ, Hants, England; [Santamaria, Francesca] Univ Naples Federico II, Dept Translat Med Sci, I-80138 Naples, Italy; [Goutaki, Myrofora; Kuehni, Claudia E.] Univ Bern, Div Paediat Resp Med & Allergol, Dept Paediat, Inselspital,Bern Univ Hosp, CH-3010 Bern, Switzerland		Kuehni, CE (通讯作者)，Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland.; Kuehni, CE (通讯作者)，Univ Bern, Div Paediat Resp Med & Allergol, Dept Paediat, Inselspital,Bern Univ Hosp, CH-3010 Bern, Switzerland.	eva.pedersen@ispm.unibe.ch; maria.mallet@ispm.unibe.ch; yin.lam@ispm.unibe.ch; saradcp@virgilio.it; icizeau@cegetel.net; fiona.copeland@stonac.co.uk; asociaciondcpes@gmail.com; michelemanion@gmail.com; Amanda-lea.harris@uhs.nhs.uk; jlucas1@soton.ac.uk; santamar@unina.it; myrofora.goutaki@ispm.unibe.ch; Claudia.kuehni@ispm.unibe.ch	Santamaria, Francesca/AAC-3503-2022	Harris, Amanda/0000-0002-6953-7370; Lucas, Jane/0000-0001-8701-9975; Goutaki, Myrofora/0000-0001-8036-2092; Kuehni, Claudia E./0000-0001-8957-2002; Pedersen, Eva Sophie Lunde/0000-0003-0293-9954; Mallet, Maria Christina/0000-0002-3633-8017; Lam, Yin Ting/0000-0002-2380-834X	Swiss National Foundation (SNF) , Switzerland [320030B_192804/1, PZ00P3_185923]; Swiss Lung Association, Switzerland; PCD Foundation, United States; Verein Kartagener Syndrom und Primaere Ciliaere Dyskinesie, Germany; PCD Family Support Group, UK; PCD Australia, Australia; European Respiratory Society	This research was funded by the Swiss National Foundation (SNF 320030B_192804/1, PZ00P3_185923), Switzerland; the Swiss Lung Association, Switzerland (2021-08_Pedersen); the PCD Foundation, United States; the Verein Kartagener Syndrom und Primaere Ciliaere Dyskinesie, Germany; the PCD Family Support Group, UK; and PCD Australia, Australia. Study authors participated in the BEAT-PCD Clinical Research Collaboration, supported by the European Respiratory Society.	Al-Jayyousi GF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060548; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bequignon E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050619; Boon M, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-11; Caminati M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080853; Cuschieri S, 2021, J PUBLIC HEALTH-HEID, DOI 10.1007/s10389-021-01585-z; Davis SD, 2019, AM J RESP CRIT CARE, V199, P190, DOI 10.1164/rccm.201803-0548OC; EMA European Medicines Agency, COVID 19 VACC AUTH 2; FDA US Food and Drug Administration, COVID 19 VACC COVID; Flanagan KL, 2021, J ALLER CL IMM-PRACT, V9, P3535, DOI 10.1016/j.jaip.2021.07.016; Galanis P., 2021, PREDICTORS COVID 19, DOI [10.1101/2021.07.28.21261261v1, DOI 10.1101/2021.07.28.21261261V1]; Glampson B, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/30010; Goutaki M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092871; Goutaki M, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00237-2019; Goutaki M, 2016, EUR RESPIR J, V48, P1081, DOI 10.1183/13993003.00736-2016; Halbeisen FS, 2019, ERJ OPEN RES, V5, DOI 10.1183/23120541.00231-2018; Halbeisen FS, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01040-2018; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Hosie PH, 2015, J PAEDIATR CHILD H, V51, P722, DOI 10.1111/jpc.12791; Jain V, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073483; Janssen C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060547; Jeskowiak I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050502; Kuehni CE, 2010, EUR RESPIR J, V36, P1248, DOI 10.1183/09031936.00001010; Lucas JSA, 2011, EUR RESPIR MONOGR, P201, DOI 10.1183/1025448x.10008310; Marthin JK, 2010, AM J RESP CRIT CARE, V181, P1262, DOI 10.1164/rccm.200811-1731OC; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Nachimuthu S, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.102190; Nguyen KH, 2021, ANN MED, V53, P1419, DOI 10.1080/07853890.2021.1957998; Pedersen ESL, 2021, INT J PUBLIC HEALTH, V66, DOI 10.3389/ijph.2021.1604277; Pedersen ESL, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.04548-2020; Pedersen ESL, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00843-2020; Pifferi M, 2021, ANN AM THORAC SOC, V18, P963, DOI 10.1513/AnnalsATS.202007-816OC; Revon-Riviere G, 2021, EUR J CANCER, V154, P30, DOI 10.1016/j.ejca.2021.06.002; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Rotondo JC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13091687; Rubbo B, 2020, ARCH DIS CHILD, V105, P724, DOI 10.1136/archdischild-2019-317687; Shapiro AJ, 2014, CHEST, V146, P1176, DOI 10.1378/chest.13-1704; Sprent J, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj9256; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120, 10.1371/journal.pmed.0040296]; Woolf K, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100180; Wright L., 2021, DO PEOPLE REDUCE COM, DOI [10.1136/jech-2021-217179, DOI 10.1136/JECH-2021-217179]	42	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1496	10.3390/vaccines9121496			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1XG	34960242	gold, Green Submitted, Green Accepted, Green Published			2022-04-29	WOS:000737452500001
J	Prates-Syed, WA; Chaves, LCS; Crema, KP; Vuitika, L; Lira, A; Cortes, N; Kersten, V; Guimaraes, FEG; Sadraeian, M; da Silva, FBL; Cabral-Marques, O; Barbuto, JAM; Russo, M; Camara, NOS; Cabral-Miranda, G				Prates-Syed, Wasim A.; Chaves, Lorena C. S.; Crema, Karin P.; Vuitika, Larissa; Lira, Aline; Cortes, Nelson; Kersten, Victor; Guimaraes, Francisco E. G.; Sadraeian, Mohammad; Barroso da Silva, Fernando L.; Cabral-Marques, Otavio; Barbuto, Jose A. M.; Russo, Momtchilo; Camara, Niels O. S.; Cabral-Miranda, Gustavo			VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants	VACCINES			English	Article						virus-like particles; vaccines; COVID-19; SARS-CoV-2	INFECTIOUS-BRONCHITIS VIRUS; NEUTRALIZING ANTIBODY-RESPONSES; HUMAN-PAPILLOMAVIRUS TYPE-16; CORONAVIRUS MEMBRANE-FUSION; E-PROTEIN; NUCLEOCAPSID PROTEIN; PARTICLE VACCINE; ENVELOPE PROTEIN; TERMINAL DOMAIN; SPIKE PROTEIN	Virus-like particles (VLPs) are a versatile, safe, and highly immunogenic vaccine platform. Recently, there are developmental vaccines targeting SARS-CoV-2, the causative agent of COVID-19. The COVID-19 pandemic affected humanity worldwide, bringing out incomputable human and financial losses. The race for better, more efficacious vaccines is happening almost simultaneously as the virus increasingly produces variants of concern (VOCs). The VOCs Alpha, Beta, Gamma, and Delta share common mutations mainly in the spike receptor-binding domain (RBD), demonstrating convergent evolution, associated with increased transmissibility and immune evasion. Thus, the identification and understanding of these mutations is crucial for the production of new, optimized vaccines. The use of a very flexible vaccine platform in COVID-19 vaccine development is an important feature that cannot be ignored. Incorporating the spike protein and its variations into VLP vaccines is a desirable strategy as the morphology and size of VLPs allows for better presentation of several different antigens. Furthermore, VLPs elicit robust humoral and cellular immune responses, which are safe, and have been studied not only against SARS-CoV-2 but against other coronaviruses as well. Here, we describe the recent advances and improvements in vaccine development using VLP technology.	[Prates-Syed, Wasim A.; Crema, Karin P.; Vuitika, Larissa; Lira, Aline; Cortes, Nelson; Kersten, Victor; Cabral-Marques, Otavio; Barbuto, Jose A. M.; Russo, Momtchilo; Camara, Niels O. S.; Cabral-Miranda, Gustavo] Univ Sao Paulo ICB USP, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, SP, Brazil; [Prates-Syed, Wasim A.; Crema, Karin P.; Lira, Aline; Cortes, Nelson; Cabral-Miranda, Gustavo] Inst Res & Educ Child Hlth PENSI, BR-01228200 Sao Paulo, SP, Brazil; [Chaves, Lorena C. S.] Emory Univ, Sch Med, Dept Microbiol & Immunol, Claudia Nance Rollins Bldg, Atlanta, GA 30329 USA; [Guimaraes, Francisco E. G.; Sadraeian, Mohammad] IFSC USP, Sao Carlos Inst Phys, BR-13566590 Sao Carlos, SP, Brazil; [Sadraeian, Mohammad] Univ Technol, Inst Biomed Mat & Devices IBMD, Fac Sci, Sydney, NSW 2007, Australia; [Barroso da Silva, Fernando L.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Biomol Sci, BR-14040903 Ribeirao Preto, SP, Brazil; [Barroso da Silva, Fernando L.] North Carolina State Univ, Dept Chem & Biomol Engeneering, Raleigh, NC 27695 USA; [Cabral-Marques, Otavio] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05508000 Sao Paulo, SP, Brazil; [Cabral-Marques, Otavio] Univ Sci Educ & Res Network USERN, Childrens Med Ctr, Network Immun Infect, Malignancy & Autoimmun NIIMA, Tehran 1419733151, Iran; [Barbuto, Jose A. M.] Univ Sao Paulo, Hosp Clin HCFMUSP, Dept Hematol, Lab Med Invest Pathogenesis & Targeted Therap Onc, BR-0124690 Sao Paulo, SP, Brazil		Cabral-Miranda, G (通讯作者)，Univ Sao Paulo ICB USP, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, SP, Brazil.; Cabral-Miranda, G (通讯作者)，Inst Res & Educ Child Hlth PENSI, BR-01228200 Sao Paulo, SP, Brazil.	wasim.syed@usp.br; lorenachaves@emory.edu; Karincrema@usp.br; vuitika@usp.br; aline.llira@usp.br; nelson.cortes@usp.br; vkersten@biof.ufrj.br; guimarae@ifsc.usp.br; msadraeian@usp.br; flbarroso@usp.br; otavio.cmarques@usp.br; jbarbuto@icb.usp.br; momrusso@usp.br; niels@icb.usp.br; gcabral.miranda@usp.br	Chaves, Lorena/AFK-2070-2022; camara, niels/AAX-3269-2020	camara, niels/0000-0001-5436-1248; Cabral Marques, Otavio/0000-0002-3183-6236; Sadraeian, Mohammad/0000-0002-7384-2247; Barroso da Silva, Fernando Luis/0000-0003-2526-2085; Gontijo Guimaraes, Francisco Eduardo/0000-0002-2504-7812; Assis Kersten, Victor/0000-0001-9401-5702; Syed, Wasim/0000-0002-2032-3902; Marzagao Barbuto, Jose Alexandre/0000-0001-9526-6781	Sao Paulo Research Foundation, FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/10910-5, 2019/14526-0, 2020/07158-2, 2020/05146-7]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]; Conselho Nacional de Desenvolvimento Cientifico e TecnologicoConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [CNPq 305393/2020-0]	This research group is funded by The Sao Paulo Research Foundation, FAPESP-Grants 2017/10910-5, 2019/14526-0, 2020/07158-2 and 2020/05146-7. This study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES)-Finance Code 001 and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq 305393/2020-0).	Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], Tracking SARS-CoV-2 variants [Internet]; [Anonymous], ZHANG MODELING SARS; [Anonymous], CTR DIS CONTROL PREV; [Anonymous], WEEKLY EPIDEMIOLOGIC; [Anonymous], WHO ISSUES EMERGENCY; [Anonymous], COVID-19 Vaccines; [Anonymous], SCHRODINGER PYMOL MO; Arunachalam PS, 2021, NATURE, V594, P253, DOI 10.1038/s41586-021-03530-2; Atcheson E, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00242-y; Azizgolshani O, 2013, VIROLOGY, V441, P12, DOI 10.1016/j.virol.2013.03.001; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bale JB, 2016, SCIENCE, V353, P389, DOI 10.1126/science.aaf8818; Bangaru S, 2020, SCIENCE, V370, P1089, DOI 10.1126/science.abe1502; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Block SL, 2006, PEDIATRICS, V118, P2135, DOI 10.1542/peds.2006-0461; Bos R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00243-x; Boscarino JA, 2008, J VIROL, V82, P2989, DOI 10.1128/JVI.01906-07; Braun M, 2012, EUR J IMMUNOL, V42, P330, DOI 10.1002/eji.201142064; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Brown CM, 2021, MMWR-MORBID MORTAL W, V70, P1059, DOI 10.15585/mmwr.mm7031e2; Bueno SM., 2021, INTERIM REPORT SAFET, DOI [10.1101/2021.03.31.21254494, DOI 10.1101/2021.03.31.21254494V1, DOI 10.1101/2021.03.31.21254494]; Caldas LA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73162-5; Campbell F, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100509; Chang CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065045; Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9; Chaves LCS, 2018, J GEN VIROL, V99, P265, DOI 10.1099/jgv.0.001002; Cherian S., 2021, BIORXIV; Cohen AA, 2021, SCIENCE, V371, P735, DOI 10.1126/science.abf6840; Costello DA, 2013, BIOMATERIALS, V34, P7895, DOI 10.1016/j.biomaterials.2013.06.034; Coutinho R.M., 2021, MODEL BASED EVALUATI, DOI [10.1038/s43856-021-00048-6, DOI 10.1038/S43856-021-00048-6]; Crooke SN, 2019, MOL PHARMACEUT, V16, P2947, DOI 10.1021/acs.molpharmaceut.9b00180; Cubas R, 2009, J IMMUNOTHER, V32, P118, DOI 10.1097/CJI.0b013e31818f13c4; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; Dashti NH, 2018, ACS NANO, V12, P4615, DOI 10.1021/acsnano.8b01059; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; de Haan CAM, 2000, J VIROL, V74, P4967, DOI 10.1128/JVI.74.11.4967-4978.2000; DeDiego ML, 2008, VIROLOGY, V376, P379, DOI 10.1016/j.virol.2008.03.005; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; Dormitzer PR, 2008, TRENDS BIOTECHNOL, V26, P659, DOI 10.1016/j.tibtech.2008.08.002; Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Emary KRW, 2021, EFFICACY CHADOX1 NCO; Falsey AR, 2021, NEW ENGL J MED, V385, P2348, DOI 10.1056/NEJMoa2105290; Fan H, 2005, STRUCTURE, V13, P1859, DOI 10.1016/j.str.2005.08.021; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1126/science.abh2644Article, 10.1101/2021.02.26.21252554]; Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1; Fischman S, 2018, CURR OPIN STRUC BIOL, V51, P156, DOI 10.1016/j.sbi.2018.04.007; Flood A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164692; Fluckiger A.-C., 2021, ENVELOPED VIRUS LIKE, DOI [10.1101/2021.04.28.441832, DOI 10.1101/2021.04.28.441832]; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fougeroux C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20251-8; Frost SDW, 2018, MOL BIOL EVOL, V35, P1348, DOI 10.1093/molbev/msy088; Gallagher TM, 1996, J VIROL, V70, P4683, DOI 10.1128/JVI.70.7.4683-4690.1996; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]; Gardner A, 2018, IEEE COMPUT GRAPH, V38, P51, DOI 10.1109/MCG.2018.2877076; Giannini SL, 2006, VACCINE, V24, P5937, DOI 10.1016/j.vaccine.2006.06.005; Giron Carolina Correa, 2021, Front Med Technol, V3, P694347, DOI 10.3389/fmedt.2021.694347; Godeke GJ, 2000, J VIROL, V74, P1566, DOI 10.1128/JVI.74.3.1566-1571.2000; GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022; Hou YXJ, 2020, SCIENCE, V370, P1464, DOI 10.1126/science.abe8499; Hurst KR, 2010, J VIROL, V84, P10276, DOI 10.1128/JVI.01287-10; Kang SS, 2020, ACTA PHARM SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009; Keating GM, 2003, DRUGS, V63, P1021, DOI 10.2165/00003495-200363100-00006; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Koyani R, 2017, NANOTECHNOL REV, V6, P405, DOI 10.1515/ntrev-2016-0071; Kumar Swatantra, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00571-5; Kuo L, 2014, J VIROL, V88, P4451, DOI 10.1128/JVI.03866-13; Lam P, 2019, BIOMATER SCI-UK, V7, P3138, DOI 10.1039/c9bm00785g; Lavillette D, 2006, J BIOL CHEM, V281, P9200, DOI 10.1074/jbc.M512529200; Lee EB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38533-7; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI 10.1038/s41564-020-0688-y; Li FQS, 2005, FEBS LETT, V579, P2387, DOI 10.1016/j.febslet.2005.03.039; Li ML, 1997, J VIROL, V71, P2988, DOI 10.1128/JVI.71.4.2988-2995.1997; Li WT, 2015, J VIROL, V89, P8077, DOI 10.1128/JVI.00356-15; Li YZ, 2021, ACS CENTRAL SCI, V7, P512, DOI 10.1021/acscentsci.1c00120; Liao Y, 2004, BIOCHEM BIOPH RES CO, V325, P374, DOI 10.1016/j.bbrc.2004.10.050; LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Liu ZD, 2014, SCI REP-UK, V4, DOI 10.1038/srep07266; Lopez Bernal J, 2021, EARLY EFFECTIVENESS, V2021, DOI 10.1101/2021.03.01.21252652; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Lustig Y, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.26.2100557; Machamer CE, 2006, ADV EXP MED BIOL, V581, P193; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Mercurio I, 2021, CELL MOL LIFE SCI, V78, P1501, DOI 10.1007/s00018-020-03580-1; Mlcochova P., 2021, BIORXIV, DOI [10.1101/2021.05.08.443253, DOI 10.1101/2021.05.08.443253]; Mohsen MO, 2020, IMMUNOL REV, V296, P155, DOI 10.1111/imr.12863; Mohsen MO, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030037; Monie A, 2008, BIOL-TARGETS THER, V2, P107; Muus C, 2021, NAT MED, V27, P546, DOI 10.1038/s41591-020-01227-z; Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07; Nezafat N, 2015, BIOLOGICALS, V43, P11, DOI 10.1016/j.biologicals.2014.11.001; Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010; Nooraei S, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00806-7; Oli AN, 2020, IMMUNOTARGETS THER, V9, P13, DOI 10.2147/ITT.S241064; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pang HH, 2019, THERANOSTICS, V9, P1752, DOI 10.7150/thno.30977; Peng, 2020, NOVEL SARS COV 2 MUL; Pervushin K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000511; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Plescia CB, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016148; Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poveda-Cuevas SA, 2020, J CHEM INF MODEL, V60, P944, DOI 10.1021/acs.jcim.9b00895; Powell AE, 2021, ACS CENTRAL SCI, V7, P183, DOI 10.1021/acscentsci.0c01405; Pritchard E, 2021, NAT MED, V27, P1370, DOI 10.1038/s41591-021-01410-w; Qian CY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010139; Rappazzo CG, 2021, SCIENCE, V371, P823, DOI 10.1126/science.abf4830; Robson B, 2021, COMPUT BIOL MED, V128, DOI 10.1016/j.compbiomed.2020.104124; Ruch TR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002674; Ruch TR, 2011, J VIROL, V85, P675, DOI 10.1128/JVI.01570-10; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sanchez-Sanchez L, 2014, ENZYME MICROB TECH, V60, P24, DOI 10.1016/j.enzmictec.2014.04.003; Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Sormanni P, 2018, CHEM SOC REV, V47, P9137, DOI 10.1039/c8cs00523k; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Teoh KT, 2010, MOL BIOL CELL, V21, P3838, DOI 10.1091/mbc.E10-04-0338; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tomar PPS, 2020, BIOCHEM BIOPH RES CO, V530, P10, DOI 10.1016/j.bbrc.2020.05.206; Tomasello G, 2020, BIOINFORMATICS, V36, P2909, DOI 10.1093/bioinformatics/btaa009; Vicente T, 2011, J INVERTEBR PATHOL, V107, pS42, DOI 10.1016/j.jip.2011.05.004; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walls AC, 2020, CELL, V183, P1367, DOI 10.1016/j.cell.2020.10.043; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang PF, 2021, CELL HOST MICROBE, V29, P747, DOI 10.1016/j.chom.2021.04.007; Ward BJ, 2021, NAT MED, V27, P1071, DOI 10.1038/s41591-021-01370-1; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424; White TC, 2007, VIRUS RES, V126, P139, DOI 10.1016/j.virusres.2007.02.008; Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033; Win SJ, 2011, IMMUNOL CELL BIOL, V89, P681, DOI 10.1038/icb.2010.161; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Xu RD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.01026; Yacoby I, 2006, ANTIMICROB AGENTS CH, V50, P2087, DOI 10.1128/AAC.00169-06; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yang YP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020073; Yao HP, 2020, CELL, V183, P730, DOI 10.1016/j.cell.2020.09.018; Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhao J, 2018, ANTIBODIES, V7, DOI 10.3390/antib7030022; Zhao P, 2020, CELL HOST MICROBE, V28, P586, DOI [10.1016/j.chom.2020.08.004, 10.1101/2020.06.25.172403]; Zhou H, 2021, CELL, V184, P4380, DOI 10.1016/j.cell.2021.06.008; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	163	2	2	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1409	10.3390/vaccines9121409			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2EQ	34960155	gold, Green Published, Green Submitted			2022-04-29	WOS:000737471700001
J	Sabir, MJ; Low, R; Hall, N; Kamli, MR; Malik, MZ				Sabir, Mumdooh J.; Low, Ross; Hall, Neil; Kamli, Majid Rasool; Malik, Md. Zubbair			A Bioinformatics Approach to Identifying Potential Biomarkers for Cryptosporidium parvum: A Coccidian Parasite Associated with Fetal Diarrhea	VACCINES			English	Article						Cryptosporidium parvum infection; Differentially Expressed Genes (DEGs); key protein; miRNA; gene ontology	LONG NONCODING RNAS; GENE-EXPRESSION; TARGET GENES; APOPTOSIS; REGULATORS; INFECTION; RESPONSES; CHILDREN; DISEASE; ILLNESS	Cryptosporidium parvum (C. parvum) is a protozoan parasite known for cryptosporidiosis in pre-weaned calves. Animals and patients with immunosuppression are at risk of developing the disease, which can cause potentially fatal diarrhoea. The present study aimed to construct a network biology framework based on the differentially expressed genes (DEGs) of C. parvum infected subjects. In this way, the gene expression profiling analysis of C. parvum infected individuals can give us a snapshot of actively expressed genes and transcripts under infection conditions. In the present study, we have analyzed microarray data sets and compared the gene expression profiles of the patients with the different data sets of the healthy control. Using a network medicine approach to identify the most influential genes in the gene interaction network, we uncovered essential genes and pathways related to C. parvum infection. We identified 164 differentially expressed genes (109 up- and 54 down-regulated DEGs) and allocated them to pathway and gene set enrichment analysis. The results underpin the identification of seven significant hub genes with high centrality values: ISG15, MX1, IFI44L, STAT1, IFIT1, OAS1, IFIT3, RSAD2, IFITM1, and IFI44. These genes are associated with diverse biological processes not limited to host interaction, type 1 interferon production, or response to IL-gamma. Furthermore, four genes (IFI44, IFIT3, IFITM1, and MX1) were also discovered to be involved in innate immunity, inflammation, apoptosis, phosphorylation, cell proliferation, and cell signaling. In conclusion, these results reinforce the development and implementation of tools based on gene profiles to identify and treat Cryptosporidium parvum-related diseases at an early stage.	[Sabir, Mumdooh J.] Univ East Anglia, Fac Med & Hlth Sci, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England; [Sabir, Mumdooh J.] King Abdulaziz Univ, Fac Comp & Informat Technol, Dept Comp Sci, Jeddah 21589, Saudi Arabia; [Sabir, Mumdooh J.; Low, Ross; Hall, Neil] Earlham Inst, Norwich Res Pk, Norwich NR4 7UZ, Norfolk, England; [Kamli, Majid Rasool] King Abdulaziz Univ, Ctr Excellence Bionanosci Res, Jeddah 21589, Saudi Arabia; [Kamli, Majid Rasool] King Abdulaziz Univ, Dept Biol Sci, Jeddah 21589, Saudi Arabia; [Malik, Md. Zubbair] Jawaharlal Nehru Univ, Sch Computat & Integrat Sci, New Delhi 110067, India		Kamli, MR (通讯作者)，King Abdulaziz Univ, Ctr Excellence Bionanosci Res, Jeddah 21589, Saudi Arabia.; Kamli, MR (通讯作者)，King Abdulaziz Univ, Dept Biol Sci, Jeddah 21589, Saudi Arabia.; Malik, MZ (通讯作者)，Jawaharlal Nehru Univ, Sch Computat & Integrat Sci, New Delhi 110067, India.	mumdooh-jamal-s.sabir@uea.ac.uk; ross.low@earlham.ac.uk; neil.hall@earlham.ac.uk; mkamli@kau.edu.sa; zubbairmalik@jnu.ac.in	kamli, majid/AFS-7216-2022	Malik, Md Zubbair/0000-0001-6693-0401; kamli, majid/0000-0003-0553-0046			Abrahamsen MS, 2004, SCIENCE, V304, P441, DOI 10.1126/science.1094786; Alam A, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00932; Ali S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198525; Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554; Atianand MK, 2014, TRENDS MOL MED, V20, P623, DOI 10.1016/j.molmed.2014.09.002; Baldursson S, 2011, WATER RES, V45, P6603, DOI 10.1016/j.watres.2011.10.013; Banaganapalli B, 2021, COMPUT BIOL MED, V135, DOI 10.1016/j.compbiomed.2021.104570; Bandettini WP, 2012, J CARDIOVASC MAGN R, V14, DOI 10.1186/1532-429X-14-83; Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184; Bouzid M, 2013, CLIN MICROBIOL REV, V26, P115, DOI 10.1128/CMR.00076-12; Brandes U, 2001, J MATH SOCIOL, V25, P163, DOI 10.1080/0022250X.2001.9990249; Burnet JB, 2014, SCI TOTAL ENVIRON, V472, P1023, DOI 10.1016/j.scitotenv.2013.10.083; Chappell CL, 2015, AM J TROP MED HYG, V92, P50, DOI 10.4269/ajtmh.14-0525; Chen XM, 2007, J BIOL CHEM, V282, P28929, DOI 10.1074/jbc.M702633200; Chen XM, 1999, AM J PHYSIOL-GASTR L, V277, pG599, DOI 10.1152/ajpgi.1999.277.3.G599; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Curtale G, 2013, P NATL ACAD SCI USA, V110, P11499, DOI 10.1073/pnas.1219852110; Estrada E, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.056103; Farooqui A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28375-0; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gupta V, 2021, MSYSTEMS, V6, DOI 10.1128/mSystems.00030-21; Ishrat R, 2021, BIOINFORM BIOL INSIG, V15, DOI 10.1177/11779322211027396; Janssen B., 2017, CRYPTOSPORIDIOSIS; Khan A, 2018, ACTA TROP, V184, P1, DOI 10.1016/j.actatropica.2017.10.023; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Lee I, 2011, GENOME RES, V21, P1109, DOI 10.1101/gr.118992.110; Lee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185906; Li JB, 2014, CHEM SOC REV, V43, P506, DOI 10.1039/c3cs60312a; Liao Q, 2014, PARASITOL RES, V113, P1269, DOI 10.1007/s00436-014-3765-4; Licursi V, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3105-x; Liu XY, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-722; Malik MZ, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6309-6; Malik MZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40596; Mangangcha IR, 2020, GENOMICS, V112, P5227, DOI 10.1016/j.ygeno.2020.09.033; Mangangcha IR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52896-x; McCole DF, 2000, INFECT IMMUN, V68, P1710, DOI 10.1128/IAI.68.3.1710-1713.2000; McDonald AC, 2001, J INFECT DIS, V183, P1373, DOI 10.1086/319862; Ming ZP, 2018, PARASITOL RES, V117, P831, DOI 10.1007/s00436-018-5759-0; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; Norman FF, 2015, FUTURE MICROBIOL, V10, P69, DOI 10.2217/fmb.14.105; O'Connor RM, 2007, MOL BIOCHEM PARASIT, V152, P149, DOI 10.1016/j.molbiopara.2007.01.003; Ojcius DM, 1999, MICROBES INFECT, V1, P1163, DOI 10.1016/S1286-4579(99)00246-4; Prasad K, 2021, MOL NEUROBIOL, V58, P1875, DOI 10.1007/s12035-020-02266-w; Prasanth KV, 2007, GENE DEV, V21, P11, DOI 10.1101/gad.1484207; Puiu D, 2004, NUCLEIC ACIDS RES, V32, pD329, DOI 10.1093/nar/gkh050; Robertson L.J., 2014, CRYPTOSPORIDIUM PARA, P149, DOI 10.1007/978-3-7091-1562-6_4; Sato Y, 2017, MICROBIOL IMMUNOL, V61, P159, DOI 10.1111/1348-0421.12483; Scallan E, 2011, EMERG INFECT DIS, V17, P16, DOI [10.3201/eid1701.P21101, 10.3201/eid1701.091101p2]; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Shtrichman R, 2002, INFECT IMMUN, V70, P5579, DOI 10.1128/IAI.70.10.5579-5588.2002; Sibley LD, 2004, SCIENCE, V304, P248, DOI 10.1126/science.1094717; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Thomson S, 2017, VET RES, V48, DOI 10.1186/s13567-017-0447-0; Tomazic ML, 2013, VET PARASITOL, V198, P382, DOI 10.1016/j.vetpar.2013.09.022; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Vembar SS, 2014, CURR OPIN MICROBIOL, V20, P153, DOI 10.1016/j.mib.2014.06.013; Wang Y, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12760; Wang Y, 2017, J INFECT DIS, V215, P636, DOI 10.1093/infdis/jiw607; Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537; West K.O., 2021, GLOBAL TRANSCRIPTOMI, DOI [10.3389/fimmu.2021.656885, DOI 10.3389/FIMMU.2021.656885]; Xiao Lihua, 2017, Food Waterborne Parasitol, V8-9, P14, DOI 10.1016/j.fawpar.2017.09.002; Yamagishi J, 2011, PARASITOL INT, V60, P199, DOI 10.1016/j.parint.2011.03.001; Yang YL, 2010, INFECT IMMUN, V78, P1040, DOI 10.1128/IAI.01009-09; Yanta CA, 2021, FOOD WATERB PARASIT, V23, DOI 10.1016/j.fawpar.2021.e00115; Zhou R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002702; Zhou R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000681; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	68	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1427	10.3390/vaccines9121427			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YG3YZ	34960172	gold, Green Accepted, Green Published			2022-04-29	WOS:000742429800001
J	Zhang, RQ; Khong, KW; Leung, KY; Liu, DL; Fan, YJ; Lu, L; Chan, PC; Chen, LL; To, KKW; Chen, HL; Yuen, KY; Chan, KH; Hung, IFN				Zhang, Ruiqi; Khong, Ka-Wa; Leung, Ka-Yi; Liu, Danlei; Fan, Yujing; Lu, Lu; Chan, Pui-Chun; Chen, Linlei; To, Kelvin Kai-Wang; Chen, Honglin; Yuen, Kwok-Yung; Chan, Kwok-Hung; Hung, Ivan Fan-Ngai			Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant	VACCINES			English	Article						COVID-19; vaccines; Delta variants	MESSENGER-RNA	Vaccinating recovered patients previously infected by COVID-19 with mRNA vaccines to boost their immune response against wild-type viruses (WT), we aimed to investigate whether vaccine platform and time of vaccination affect immunogenicity against the SARS-CoV-2 WT and Delta variant (DV). Convalescent patients infected by COVID-19 were recruited and received one booster dose of the BNT162b2 (PC-B) or CoronaVac (PC-C) vaccines, while SARS-CoV-2 naive subjects received two doses of the BNT162b2 (CN-B) or CoronaVac (CN-C) vaccines. The neutralizing antibody in sera against the WT and DV was determined with live virus neutralization assay (vMN). The vMN geometric mean titre (GMT) against WT in recovered individuals previously infected by COVID-19 reduced significantly from 60.0 (95% confidence interval (CI), 46.5-77.4) to 33.9 (95% CI, 26.3-43.7) at 6 months post recovery. In the PC-B group, the BNT162b2 vaccine enhanced antibody response against WT and DV, with 22.3-fold and 20.4-fold increases, respectively. The PC-C group also showed 1.8-fold and 2.2-fold increases for WT and DV, respectively, after receiving the CoronaVac vaccine. There was a 10.6-fold increase in GMT in the CN-B group and a 1.3-fold increase in the CN-C group against DV after full vaccination. In both the PC-B and PC-C groups, there was no difference between GMT against WT and DV after vaccination. Subjects in the CN-B and CN-C groups showed inferior GMT against DV compared with GMT against WT after vaccination. In this study, one booster shot effectively enhanced the pre-existing neutralizing activity against WT and DV in recovered subjects.	[Zhang, Ruiqi; Khong, Ka-Wa; Liu, Danlei; Fan, Yujing; Hung, Ivan Fan-Ngai] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China; [Leung, Ka-Yi; Lu, Lu; Chan, Pui-Chun; Chen, Linlei; To, Kelvin Kai-Wang; Chen, Honglin; Yuen, Kwok-Yung; Chan, Kwok-Hung] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Peoples R China; [To, Kelvin Kai-Wang; Chen, Honglin; Yuen, Kwok-Yung; Chan, Kwok-Hung; Hung, Ivan Fan-Ngai] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China; [To, Kelvin Kai-Wang; Chen, Honglin; Yuen, Kwok-Yung; Chan, Kwok-Hung; Hung, Ivan Fan-Ngai] Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect, Hong Kong, Peoples R China		Hung, IFN (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China.; Hung, IFN (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.; Hung, IFN (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect, Hong Kong, Peoples R China.	zhangrq@hku.hk; kwkhong@connect.hku.hk; joy2u@connect.hku.hk; danlei6@connect.hku.hk; jyjfan@connect.hku.hk; u3003963@connect.hku.hk; bcpc@hku.hk; u3006707@connect.hku.hk; kelvinto@hku.hk; hlchen@hku.hk; kyyuen@hku.hk; chankh2@hku.hk; ivanhung@hku.hk	; Chen, Honglin/C-4224-2009	/0000-0003-1771-8249; Zhang, Ruiqi/0000-0002-4859-3445; Hung, Ivan Fan Ngai/0000-0002-1556-2538; Chen, Honglin/0000-0001-5108-8338			Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Cerutti G, 2021, CELL HOST MICROBE, V29, P819, DOI 10.1016/j.chom.2021.03.005; Chan KH, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11101757; Charitos IA, 2020, WORLD J CLIN CASES, V8, P3920, DOI 10.12998/wjcc.v8.i18.3920; Chen LL, 2021, CLIN INFECT DIS, DOI 10.1093/cid/ciab656; Chen YZ, 2020, CELL, V183, P1496, DOI 10.1016/j.cell.2020.10.051; Chia Po Ying, 2022, Clin Microbiol Infect, V28, DOI 10.1016/j.cmi.2021.11.010; Chu H, 2020, LANCET MICROBE, V1, pE14, DOI 10.1016/S2666-5247(20)30004-5; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Falzone L, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4933; Gabriella D, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106519; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Greaney AJ, 2021, CELL HOST MICROBE, V29, P463, DOI 10.1016/j.chom.2021.02.003; Hansen CH, 2021, LANCET, V397, P1204, DOI 10.1016/S0140-6736(21)00575-4; Hanson Quinlin M, 2020, bioRxiv, DOI 10.1101/2020.06.16.154708; Havenar-Daughton C, 2016, CELL REP, V17, P2195, DOI 10.1016/j.celrep.2016.10.085; Ip JD, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2020.10.030; Jalkanen P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24285-4; Kruttgen A, 2022, J VIROL METHODS, V299, DOI 10.1016/j.jviromet.2021.114297; Li XN, 2021, EMERG MICROBES INFEC, V10, P1751, DOI 10.1080/22221751.2021.1969291; Lim WW, 2021, LANCET MICROBE, V2, pE423, DOI 10.1016/S2666-5247(21)00177-4; Lucas C, 2021, NATURE, V600, P523, DOI 10.1038/s41586-021-04085-y; Michel M, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.597529; Mok DZL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050520; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Quast I, 2021, IMMUNITY, V54, P205, DOI 10.1016/j.immuni.2021.01.014; Reynolds CJ, 2021, SCIENCE, V372, P1418, DOI 10.1126/science.abh1282; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843, 10.21203/rs.3.rs-57112/v1]; Shurin MR, 2020, IMMUNOTARGETS THER, V9, P111, DOI 10.2147/ITT.S264138; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; To K.K., 2021, CLIN INFECT DIS, V73, pe2946, DOI [10.1093/cid/ciaa1275, DOI 10.1093/cid/ciaa1275]; To KKW, 2021, CLIN INFECT DIS, V72, pE659, DOI 10.1093/cid/ciaa1368; Tregoning JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/s41577-021-00592-1; Turner JS, 2021, NATURE, V596, P109, DOI 10.1038/s41586-021-03738-2; Wall EC, 2021, LANCET, V397, P2331, DOI 10.1016/S0140-6736(21)01290-3; Zhou L, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06222-4	38	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1442	10.3390/vaccines9121442			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YI6BH	34960189	Green Published, gold			2022-04-29	WOS:000743930900001
J	Zhou, Q; Tian, T; Ni, J; Zhao, XH; Li, H; Yang, YL; Zhang, YM; Pan, JY				Zhou, Qian; Tian, Tian; Ni, Jie; Zhao, Xiaoheng; Li, Hong; Yang, Yili; Zhang, Yumeng; Pan, Jay			COVID-19 Vaccination Acceptance in China after It Becomes Available: A Cross-Sectional Study	VACCINES			English	Article						COVID-19; vaccine acceptance; SARS-CoV-2; China; health belief model	PANDEMIC INFLUENZA; INTENTION; WORKERS	The outbreak of coronavirus disease 2019 (COVID-19) has led to numerous tragic deaths all over the world. Great efforts have been made by worldwide nations for COVID-19 targeted vaccine development since the disease outbreak. In January 2021, the Chinese government started to provide free vaccination among nationwide communities, which was optional for citizens. As no evidence has been provided so far regarding COVID-19 vaccination acceptance since the initiation of nationwide vaccination, this study aims to investigate COVID-19 vaccination acceptance among Chinese citizens as well as its associated factors as an attempt to bridge such gap embedded in the current literature. An anonymous cross-sectional study was conducted online in March and April 2021 among adults, with the survey questionnaire designed based on the framework of the health belief model (HBM). Information on socio-demographics, risk perception, past pandemic-related experience, awareness of vaccination as well as acceptance of COVID-19 vaccination were collected. Chi-squared test and multi-level regression were performed to distinguish the acceptance between different groups as well as to identify the significant predictors. A total of 3940 participants completed the survey, with 90.6% of the participants reporting strong willingness to get vaccinated. A list of factors were found to be significantly associated with individuals' acceptance of vaccination, including the region of residence, ethnicity, annual income, whether or not they had experienced a major pandemic event in the past, risk perception of the COVID-19 as well as the awareness of receiving vaccination. Safety concerns about the vaccine (27.7%), concerns about receiving vaccination immediately after newly developed vaccines were released into the market (22.4%) as well as concerns about the potential side effects induced by vaccination (22.1%) were identified as the primary reasons of residents' resistance against vaccination. Overall, residents demonstrated strong willingness to receive vaccination against COVID-19 in China. However, the improvement of vaccination-related knowledge among Chinese residents should be highlighted as a critical strategy to facilitate the penetration of nationwide vaccination in order to ultimately achieve the establishment of herd immunity in China.	[Zhou, Qian; Zhang, Yumeng; Pan, Jay] Sichuan Univ, West China Sch Publ Hlth, HEOA Grp, Chengdu 610041, Peoples R China; [Zhou, Qian; Zhang, Yumeng; Pan, Jay] Sichuan Univ, West China Hosp 4, Chengdu 610041, Peoples R China; [Zhou, Qian; Tian, Tian; Ni, Jie; Zhao, Xiaoheng] Sichuan Hlth Dev Res Ctr, Chengdu 610041, Peoples R China; [Li, Hong] Sichuan Univ, West China Hosp, Chengdu 610041, Peoples R China; [Yang, Yili; Zhang, Yumeng; Pan, Jay] Sichuan Univ, Inst Hlth Cities, Chengdu 610041, Peoples R China; [Yang, Yili; Zhang, Yumeng; Pan, Jay] Sichuan Univ, West China Res Ctr Rural Hlth Dev, Chengdu 610041, Peoples R China		Zhang, YM; Pan, JY (通讯作者)，Sichuan Univ, West China Sch Publ Hlth, HEOA Grp, Chengdu 610041, Peoples R China.; Zhang, YM; Pan, JY (通讯作者)，Sichuan Univ, West China Hosp 4, Chengdu 610041, Peoples R China.; Zhang, YM; Pan, JY (通讯作者)，Sichuan Univ, Inst Hlth Cities, Chengdu 610041, Peoples R China.; Zhang, YM; Pan, JY (通讯作者)，Sichuan Univ, West China Res Ctr Rural Hlth Dev, Chengdu 610041, Peoples R China.	zhouqian_97@163.com; tiantiant77@126.com; Jieni82@126.com; xiaohengzhao@yeah.net; lihonghxhx@scu.edu.cn; yyl115@hotmail.com; yumengzhang@scu.edu.cn; panjie.jay@scu.edu.cn					Al-Hanawi MK, 2020, RISK MANAG HEALTHC P, V13, P733, DOI 10.2147/RMHP.S264037; Barakat A.M., 2020, MIDDLE E CURR PSYCHI, V27, P1, DOI [10.1186/s43045-020-00051-y, DOI 10.1186/S43045-020-00051-Y]; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Champion V., 2008, HLTH BEHAV HLTH ED T, V4th, P45; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dimaschko J., 2021, SciMedicine Journal, V3, P88, DOI 10.28991/SciMedJ-2021-0302-2; Ding ZQ, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.011005; Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dryhurst S, 2020, J RISK RES, V23, P994, DOI 10.1080/13669877.2020.1758193; Eguia H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020170; Fougeroux C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040686; Frank K., CANADIANS WILLINGNES; Frederiksen LSF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01817; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Guo Y, 2020, INFECT CONT HOSP EP, V41, P1363, DOI 10.1017/ice.2020.172; Hotez P, 2019, PEDIATR RES, V85, P912, DOI 10.1038/s41390-019-0354-3; Hotez PJ, 2020, CURR OPIN VIROL, V41, P1, DOI 10.1016/j.coviro.2020.01.001; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jang WM, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e220; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jin H, 2021, INT J QUAL HEALTH C, V33, DOI 10.1093/intqhc/mzaa143; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Li YZ, 2021, ACS CENTRAL SCI, V7, P512, DOI 10.1021/acscentsci.1c00120; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Liu W, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072304; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Mello MM, 2020, NEW ENGL J MED, V383, P1296, DOI 10.1056/NEJMp2020926; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Noh JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e182; Opel DJ, 2021, JAMA PEDIATR, V175, P125, DOI 10.1001/jamapediatrics.2020.3019; Qualls N, 2017, MMWR RECOMM REP, V66, P1, DOI 10.15585/mmwr.rr6601a1; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405; Sharpe HR, 2020, IMMUNOLOGY, V160, P223, DOI 10.1111/imm.13222; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Tian W, 2021, ASIAN ECON PAP, V20, P75, DOI 10.1162/asep_a_00800; Tobaiqy M, 2020, Infect Prev Pract, V2, P100061, DOI 10.1016/j.infpip.2020.100061; Trogen B, 2020, JAMA-J AM MED ASSOC, V323, P2460, DOI 10.1001/jama.2020.8917; Vasquez WF, 2021, VALUE HEALTH, V24, P1543, DOI 10.1016/j.jval.2021.05.007; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang Q, 2020, INFECT CONT HOSP EP, V41, P746, DOI 10.1017/ice.2020.83; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434; Yin FL, 2021, J MED INTERNET RES, V23, DOI 10.2196/26089; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	59	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1398	10.3390/vaccines9121398			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9PQ	34960144	gold, Green Published			2022-04-29	WOS:000737296800001
J	Antonelli-Incalzi, R; Blasi, F; Conversano, M; Gabutti, G; Giuffrida, S; Maggi, S; Marano, C; Rossi, A; Vicentini, M				Antonelli-Incalzi, Raffaele; Blasi, Francesco; Conversano, Michele; Gabutti, Giovanni; Giuffrida, Sandro; Maggi, Stefania; Marano, Cinzia; Rossi, Alessandro; Vicentini, Marta			Manifesto on the Value of Adult Immunization: "We Know, We Intend, We Advocate"	VACCINES			English	Article						adults; aging; inflammaging; immunosenescence; Italy; recommendations; vaccination; vaccines	VACCINATION CALENDAR; INFLUENZA VACCINE; OLDER-ADULTS; INFECTION; DISEASE; HOSPITALIZATIONS; IMMUNOSENESCENCE; CHILDREN; PEOPLE; STROKE	Immunization through vaccination is a milestone achievement that has made a tremendous contribution to public health. Historically, immunization programs aimed firstly to protect children, who were disproportionally affected by infectious diseases. However, vaccine-preventable diseases can have significant impacts on adult mortality, health, and quality of life. Despite this, adult vaccinations have historically been overlooked in favor of other health priorities, because their benefits to society were not well recognized. As the general population is aging, the issue of vaccination in older adults is gaining importance. In high-income countries, recommendations for the routine vaccination of older adults have been gradually introduced. The Italian National Immunization Plan is considered to be among the most advanced adult vaccination plans in Europe. However, available data indicate there is low adherence to vaccination recommendations in Italy. The COVID-19 pandemic has exposed the damage that can be caused by an infectious disease, especially among adults and individuals with comorbidities. The aim of this "Manifesto", therefore, is to provide an overview of the existing evidence on the value of adult vaccination, in the Italian context, with a call to action to healthcare providers and health authorities.	[Antonelli-Incalzi, Raffaele] Campus Biomed Univ, Geriatr Unit, I-00128 Rome, Italy; [Antonelli-Incalzi, Raffaele] Italian Soc Gerontol & Geriatr, I-50129 Florence, Italy; [Blasi, Francesco] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy; [Blasi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Resp Unit, Dept Internal Med, I-20122 Milan, Italy; [Blasi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Adult Cyst Fibrosis Ctr, Dept Internal Med, I-20122 Milan, Italy; [Conversano, Michele] Local Hlth Unit Taranto, Dept Publ Hlth, I-74121 Taranto, Italy; [Gabutti, Giovanni] Univ Ferrara, Dept Med Sci, I-44121 Ferrara, Italy; [Giuffrida, Sandro] Local Hlth Unit Reggio Calabria, Dept Prevent, I-89124 Reggio Di Calabria, Italy; [Maggi, Stefania] CNR, Inst Neurosci, Aging Branch, I-35128 Padua, Italy; [Marano, Cinzia] GSK, Med Affairs, B-1300 Wavre, Belgium; [Rossi, Alessandro] Italian Soc Gen Med & Primary Care, I-50142 Florence, Italy; [Vicentini, Marta] GSK, Med Affairs, I-37135 Verona, Italy		Vicentini, M (通讯作者)，GSK, Med Affairs, I-37135 Verona, Italy.	R.Antonelli@unicampus.it; francesco.blasi@unimi.it; michele.conversano@asl.taranto.it; giovanni.gabutti@unife.it; sandrogiuffrida@gmail.com; stefania.maggi@in.cnr.it; cinzia.x.marano@gsk.com; rossi.alessandro@simg.it; marta.a.vicentini@gsk.com	; Blasi, Francesco/O-5885-2017	Antonelli Incalzi, Raffaele/0000-0003-2100-2075; Gabutti, Giovanni/0000-0002-7259-4923; Blasi, Francesco/0000-0002-2285-9970; Maggi, Stefania/0000-0002-0453-8663; Giuffrida, Sandro/0000-0003-3183-0421			Aguado MT, 2018, VACCINE, V36, P921, DOI 10.1016/j.vaccine.2017.12.029; Amato G, CORTILE GENTILI PAND; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; [Anonymous], 2017, PNEUMOLOGIE, V71, P9; [Anonymous], POSITION PAPER NUOVE; [Anonymous], MINISTERO SALUTE VAC; [Anonymous], 2017, MINISTERO SALUTE DIS; [Anonymous], 2020, MED HEALTHCARE PRODU; Aris E, 2021, COPD, V18, P157, DOI 10.1080/15412555.2021.1899155; Atti MLCD, 2002, PEDIATR INFECT DIS J, V21, P763, DOI [10.1097/00006454-200208000-00013, 10.1097/01.inf.0000023961.12041.2b]; Badur S, 2020, HUM VACC IMMUNOTHER, V16, P1007, DOI 10.1080/21645515.2020.1740559; Bechini A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020263; Ben Ari Z, 2015, CLIN LIVER DIS, V19, P341, DOI 10.1016/j.cld.2015.01.006; Beretta V., 2019, EC AZIEND ONLINE, V10, P585, DOI [10.13132/2038-5498/10.4.1965, DOI 10.13132/2038-5498/10.4.1965]; Blasi F, 2020, HUM VACC IMMUNOTHER, V16, P340, DOI 10.1080/21645515.2019.1652517; Boersma P, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.200130; Bonanni P, 2021, VACCINE, V39, P1183, DOI 10.1016/j.vaccine.2021.01.019; Bonanni P, 2021, VACCINE, V39, P1187, DOI 10.1016/j.vaccine.2020.10.024; Bonanni P, 2018, EXPERT REV VACCINES, V17, P103, DOI 10.1080/14760584.2018.1419069; Bonanni Paolo, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.26964; Brayne C, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002275; Buchy P, 2020, INT J INFECT DIS, V90, P188, DOI 10.1016/j.ijid.2019.10.005; Cassimos DC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010034; CDC, EPIDEMIOLOGY PREVENT; Centers for Disease Control and Prevention (CDC), REC VACC AD; Chen YY, 2021, AGEING RES REV, V65, DOI 10.1016/j.arr.2020.101205; Choi BCK, 2007, J EPIDEMIOL COMMUN H, V61, P832, DOI 10.1136/jech.2006.057752; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; de Gomensoro E, 2018, ANN MED, V50, P181, DOI 10.1080/07853890.2017.1417632; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Del Giudice G, 2017, NPJ AGING MECH DIS, V4, DOI 10.1038/s41514-017-0020-0; Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025; Doherty TM, 2019, ANN MED, V51, P128, DOI 10.1080/07853890.2019.1588470; Doherty TM, 2018, EUR GERIATR MED, V9, P289, DOI 10.1007/s41999-018-0040-8; Ecarnot F, 2020, VACCINE, V38, P1535, DOI 10.1016/j.vaccine.2019.11.065; El Chakhtoura NG, 2017, INFECT DIS CLIN N AM, V31, P593, DOI 10.1016/j.idc.2017.07.017; Esposito S, 2018, VACCINE, V36, P5819, DOI 10.1016/j.vaccine.2018.08.041; Ethgen O, 2018, HUM VACC IMMUNOTHER, V14, P2911, DOI 10.1080/21645515.2018.1504528; European Centre for Disease Prevention and Control (ECDC), 2017, MISS REP ECDC COUNTR; European Centre for Disease Prevention and Control (ECDC), SEAS INFL VACC ANT U; European Centre for Disease Prevention and Control (ECDC), VACC SCHED ALL COUNT; Fauci AS, 2014, CLIN INFECT DIS, V59, pS80, DOI 10.1093/cid/ciu420; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Fulop T, 2018, SEMIN IMMUNOL, V40, P17, DOI 10.1016/j.smim.2018.09.003; Fulop T, 2016, REV INVEST CLIN, V68, P84; Gao YD, 2021, ALLERGY, V76, P428, DOI 10.1111/all.14657; Giacomelli A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040669; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Icardi G, 2018, J Prev Med Hyg, V59, pE249, DOI 10.15167/2421-4248/jpmh2018.59.4.1124; Istituto Superiore di Sanita, 2 SIST SORV ROUT MAL; Istituto Superiore di Sanita Epicentro Le Vaccinazioni in Italia, COP VACC IT; Italian National Institute of Health, SORV MAL BATT INV IT; Jansen KU, 2018, HUM VACC IMMUNOTHER, V14, P2142, DOI 10.1080/21645515.2018.1476814; Jenkins VA, 2020, HUM VACC IMMUNOTHER, V16, P2609, DOI 10.1080/21645515.2020.1738168; Jevtic S, 2017, AGEING RES REV, V40, P84, DOI 10.1016/j.arr.2017.08.005; Jiang YW, 2020, EMERG MICROBES INFEC, V9, P2578, DOI 10.1080/22221751.2020.1854624; Jillella DV, 2019, CURR OPIN INFECT DIS, V32, P285, DOI 10.1097/QCO.0000000000000547; Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198; Kandeil W, 2019, EXPERT REV VACCINES, V18, P439, DOI 10.1080/14760584.2019.1588727; Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371; Kim SY, 2020, ALLERGY ASTHMA CL IM, V16, DOI 10.1186/s13223-020-00453-x; Klugman KP, 2018, P NATL ACAD SCI USA, V115, P12896, DOI 10.1073/pnas.1721095115; Kwon SU, 2016, CLIN MICROBIOL INFEC, V22, P542, DOI 10.1016/j.cmi.2016.03.003; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; Li CK, 2006, PUBLIC HEALTH, V120, P517, DOI 10.1016/j.puhe.2006.03.004; Lipsitch M, 2016, MBIO, V7, DOI 10.1128/mBio.00428-16; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Maggi S, 2010, EXPERT REV VACCINES, V9, P3, DOI [10.1586/erv.10.26, 10.1586/ERV.10.26]; Mallapaty S, 2021, NATURE, V590, P197, DOI 10.1038/d41586-021-00316-4; Marchisio P, 2009, PEDIATR INFECT DIS J, V28, P855, DOI 10.1097/INF.0b013e3181a487b4; Mazzola P, 2016, GERONTOLOGIST, V56, P383, DOI 10.1093/geront/gnv152; Micoli F, 2021, NAT REV MICROBIOL, V19, P287, DOI 10.1038/s41579-020-00506-3; Ministero della Salute, CIRC PREV CONTR MAL; Monali R, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001077; Monasta L, 2019, LANCET PUBLIC HEALTH, V4, pE645, DOI 10.1016/S2468-2667(19)30189-6; Nichol KL, 2007, NEW ENGL J MED, V357, P1373, DOI 10.1056/NEJMoa070844; O'Connor SM, 2006, EMERG INFECT DIS, V12, P1051; Organisation for Economic Co-operation and Development (OECD) and European Centre for Disease Prevention and Control (ECDC), ANTIMICROBIAL RESIST; Panatto D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010119; Parkins Michael D, 2009, Can J Infect Dis Med Microbiol, V20, pe81; Patterson BJ, 2019, MAYO CLIN PROC, V94, P763, DOI 10.1016/j.mayocp.2018.12.025; Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004; Pietrobon AJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.579220; Piot P, 2019, NATURE, V575, P119, DOI 10.1038/s41586-019-1656-7; Poole PJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002733.pub2; Prevenzione e Controllo dell'Influenza, RACC STAG 2021 2022; Privor-Dumm LA, 2021, VACCINE, V39, P5240, DOI 10.1016/j.vaccine.2020.06.082; Quattrone F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207581; Quilici Sibilia, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27044; Rodgers JL, 2019, J CARDIOVASC DEV DIS, V6, DOI 10.3390/jcdd6020019; Rodgers LR, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246156; Rodrigues CMC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01526; Ronchetti F, RICERCA SCI; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Societa Italiana di Medicina Generale e delle Cure Primarie (SIMG), VACC AD AI TEMP COVI; Societa Italiana di Pediatria (SIP) Societa Italiana di Igiene Medicina Preventiva e Sanita Pubblica (SITI) Federazione Italiana Medici Pediatri (FIMP), 2019, FEDERAZIONE ITALIANA, V4th; Thomas-Crusells Judith, 2012, Vaccine, V30, P6007, DOI 10.1016/j.vaccine.2012.07.025; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Topol E.J., FAUCI MEDSCAPE WE RE; United Nations Department of Economic and Social Affairs Population Division, 2019, STESASERA444; WHO, POL KEY FACTS; WHO, 10 PRIOR DEC HLTH AG; Word Health Organization, REG OFF EUR EUR VACC; World Health Organization, GLOB ACT PLAN ANT RE; World Health Organization (WHO, SMALLPOX; World Health Organization (WHO), FACT SHEET HUM PAP H; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Xu WL, 2020, SEMIN IMMUNOPATHOL, V42, P559, DOI 10.1007/s00281-020-00824-x; Yawn BP, 2016, MAYO CLIN PROC, V91, P33, DOI 10.1016/j.mayocp.2015.09.015; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021; Zinger A, 2017, AGING DIS, V8, P611, DOI 10.14336/AD.2016.1230	112	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1232	10.3390/vaccines9111232			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI5ML	34835163	Green Published, gold			2022-04-29	WOS:000726155400001
J	DeMarco, JK; Royal, JM; Severson, WE; Gabbard, JD; Hume, S; Morton, J; Swope, K; Simpson, CA; Shepherd, JW; Bratcher, B; Palmer, KE; Pogue, GP				DeMarco, Jennifer K.; Royal, Joshua M.; Severson, William E.; Gabbard, Jon D.; Hume, Steve; Morton, Josh; Swope, Kelsi; Simpson, Carrie A.; Shepherd, John W.; Bratcher, Barry; Palmer, Kenneth E.; Pogue, Gregory P.			CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology	VACCINES			English	Article						SARS-CoV-2; COVID-19; betacoronavirus; vaccine; betacoronaviridae; TMV	INFECTION	We developed a SARS-CoV-2 vaccine candidate (CoV-RBD121-NP) comprised of a tobacco mosaic virus-like nanoparticle conjugated to the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 fused to a human IgG1 Fc domain. CoV-RBD121-NP elicits strong antibody responses in C57BL/6 mice and is stable for up to 12 months at 2-8 or 22-28 & DEG;C. Here, we showed that this vaccine induces a strong neutralizing antibody response in K18-hACE2 mice. Furthermore, we demonstrated that immunization protects mice from virus-associated mortality and symptomatic disease. Our data indicated that a sufficient pre-existing pool of neutralizing antibodies is required to restrict SARS-CoV-2 replication upon exposure and prevent induction of inflammatory mediators associated with severe disease. Finally, we identified a potential role for CXCL5 as a protective cytokine in SARS-CoV-2 infection. Our results suggested that disruption of the CXCL5 and CXCL1/2 axis may be important early components of the inflammatory dysregulation that is characteristic of severe cases of COVID-19.	[DeMarco, Jennifer K.; Severson, William E.; Gabbard, Jon D.; Palmer, Kenneth E.] Univ Louisville, Ctr Predict Med Biodef & Emerging Infect Dis, Louisville, KY 40202 USA; [DeMarco, Jennifer K.] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40202 USA; [Royal, Joshua M.; Hume, Steve; Morton, Josh; Swope, Kelsi; Simpson, Carrie A.; Shepherd, John W.; Bratcher, Barry; Pogue, Gregory P.] Kentucky BioProc Inc, Owensboro, KY 42301 USA; [Palmer, Kenneth E.] Univ Louisville, James Brown Canc Ctr, Louisville, KY 40202 USA; [Palmer, Kenneth E.] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; [Pogue, Gregory P.] Univ Texas Austin, IC2 Inst, Austin, TX 78805 USA		Royal, JM (通讯作者)，Kentucky BioProc Inc, Owensboro, KY 42301 USA.	jennifer.wolf.2@louisville.edu; royalj@kentuckybioprocessing.com; william.severson@louisville.edu; jon.gabbard@louisville.edu; humes@kentuckybioprocessing.com; mortonj2@kentuckybioprocessing.com; swopek@kentuckybioprocessing.com; simpsoc3@kentuckybioprocessing.com; shephej@KentuckyBioProcessing.com; bratchbl@rjrt.com; kenneth.palmer@louisville.edu; gppogue@ymail.com		Palmer, Kenneth Edward/0000-0002-2811-1111; Royal, Joshua/0000-0002-4243-2667	British American Tobacco (BAT)	This work was funded by British American Tobacco (BAT).	Anand P, 2021, PATIENT SAF SURG, V15, DOI 10.1186/s13037-021-00291-9; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Boechat JL, 2021, PULMONOLOGY, V27, P423, DOI 10.1016/j.pulmoe.2021.03.008; Brown CM, 2021, MMWR-MORBID MORTAL W, V70, P1059, DOI 10.15585/mmwr.mm7031e2; Burger M.I., REUTERS; Costela-Ruiz VJ, 2020, CYTOKINE GROWTH F R, V54, P62, DOI 10.1016/j.cytogfr.2020.06.001; Dhama K, 2021, HUM VACC IMMUNOTHER, V17, P3495, DOI 10.1080/21645515.2021.1926183; Hamorsky KT, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97423-z; Harrison J, 2021, J AM MED DIR ASSOC, V22, P1133, DOI [10.1016/j.jamda.2021.03.0121525-8610/, 10.1016/j.jamda.2021.03.012]; Karki R, 2021, CELL, V184, P149, DOI 10.1016/j.cell.2020.11.025; Lu J., 2021, VIRAL INFECT TRANSMI, DOI [10.1101/2021.07.07.21260122, DOI 10.1101/2021.07.07.21260122]; Martinez-Flores D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.701501; McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06; McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537; Mittal A, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008762; Moreau GB, 2020, AM J TROP MED HYG, V103, P1215, DOI 10.4269/ajtmh.20-0762; Nouailles G, 2014, J CLIN INVEST, V124, P1268, DOI 10.1172/JCI72030; O'donnell C., REUTERS; Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026; Pogue GP, 2002, ANNU REV PHYTOPATHOL, V40, P45, DOI 10.1146/annurev.phyto.40.021102.150133; Pouwels KB, 2021, NAT MED, V27, P2127, DOI 10.1038/s41591-021-01548-7; Rodriguez Y, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102506; Royal JM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111347; Shastri J, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.737007; Steele JFC, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1447; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; van Eijk LE, 2021, J PATHOL, V254, P307, DOI 10.1002/path.5642; Wang J, 2020, J LEUKOCYTE BIOL, V108, P17, DOI 10.1002/JLB.3COVR0520-272R; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Wruck W, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78402-2; Xu ZS, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0211-1; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yinda CK, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009195; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zhu ZL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78703-6	37	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1346	10.3390/vaccines9111346			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG5VN	34835277	Green Published, gold			2022-04-29	WOS:000724820500001
J	Hu, F; Gong, RJ; Chen, YX; Zhang, JX; Hu, T; Chen, YQ; Zhang, KC; Shang, ML; Cai, Y				Hu, Fan; Gong, Ruijie; Chen, Yexin; Zhang, Jinxin; Hu, Tian; Chen, Yaqi; Zhang, Kechun; Shang, Meili; Cai, Yong			Prediction Model for COVID-19 Vaccination Intention among the Mobile Population in China: Validation and Stability	VACCINES			English	Article						COVID-19; vaccination intention; nomogram; prediction model; model validation	UNITED-STATES; HESITANCY	Since China's launch of the COVID-19 vaccination, the situation of the public, especially the mobile population, has not been optimistic. We investigated 782 factory workers for whether they would get a COVID-19 vaccine within the next 6 months. The participants were divided into a training set and a testing set for external validation conformed to a ratio of 3:1 with R software. The variables were screened by the Lead Absolute Shrinkage and Selection Operator (LASSO) regression analysis. Then, the prediction model, including important variables, used a multivariate logistic regression analysis and presented as a nomogram. The Receiver Operating Characteristic (ROC) curve, Kolmogorov-Smirnov (K-S) test, Lift test and Population Stability Index (PSI) were performed to test the validity and stability of the model and summarize the validation results. Only 45.54% of the participants had vaccination intentions, while 339 (43.35%) were unsure. Four of the 16 screened variables-self-efficacy, risk perception, perceived support and capability-were included in the prediction model. The results indicated that the model has a high predictive power and is highly stable. The government should be in the leading position, and the whole society should be mobilized and also make full use of peer education during vaccination initiatives.	[Hu, Fan; Gong, Ruijie; Chen, Yexin; Zhang, Jinxin; Cai, Yong] Shanghai Jiao Tong Univ, Sch Publ Hlth, Sch Med, Shanghai 200025, Peoples R China; [Gong, Ruijie] Xuhui Ctr Dis Control & Prevent, Shanghai 200237, Peoples R China; [Hu, Tian; Chen, Yaqi; Zhang, Kechun] Longhua Ctr Dis Control & Prevent, Shenzhen 518100, Peoples R China; [Shang, Meili] Sanlin Community Hlth Serv Ctr, Shanghai 200124, Peoples R China		Cai, Y (通讯作者)，Shanghai Jiao Tong Univ, Sch Publ Hlth, Sch Med, Shanghai 200025, Peoples R China.; Zhang, KC (通讯作者)，Longhua Ctr Dis Control & Prevent, Shenzhen 518100, Peoples R China.; Shang, ML (通讯作者)，Sanlin Community Hlth Serv Ctr, Shanghai 200124, Peoples R China.	hufan@sjtu.edu.cn; cynthia-dt@sjtu.edu.cn; chenyexin888@sjtu.edu.cn; jjjxxzhang@sjtu.edu.cn; ht1137571641@126.com; chloe4697@163.com; zkc1317@yeah.net; lilyshang1984@outlook.com; caiyong@shsmu.edu.cn		Gong, Ruijie/0000-0002-4971-1802; Chen, Yexin/0000-0002-7638-6662	Shanghai Three-year Action Plan for Public Health [GWV-10.1-XK15, GWV-10.2-XD13, GWV-10.1-XK18]; Science and Technology Commission Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [20JC1410200, 20JC1410204]; Strategic Collaborative Innovation Team [SSMU-ZLCX20180601]; High Level Project of Medicine in Longhua, Shenzhen [HLPM201907020105]; scientific research project of Longhua District Medical Institution, [2020207]	This research was funded by the Shanghai Three-year Action Plan for Public Health under grant numbers GWV-10.1-XK15, GWV-10.2-XD13 and GWV-10.1-XK18; a grant from the Science and Technology Commission Shanghai Municipality, numbers 20JC1410200 and 20JC1410204; the Strategic Collaborative Innovation Team, grant number SSMU-ZLCX20180601; the High Level Project of Medicine in Longhua, Shenzhen, grant number HLPM201907020105 and the 2020 district-level scientific research project of Longhua District Medical Institution, grant number 2020207.	Alabdulla M, 2021, INFLUENZA OTHER RESP, V15, P361, DOI 10.1111/irv.12847; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Cherian V, 2022, J PUBLIC HEALTH-UK, V44, P70, DOI 10.1093/pubmed/fdab007; Corace KM, 2016, VACCINE, V34, P3235, DOI 10.1016/j.vaccine.2016.04.071; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Crawshaw AF, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab048; DeStefano F, 2019, ANNU REV VIROL, V6, P585, DOI 10.1146/annurev-virology-092818-015515; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Fishbein M, 2011, PREDICTING AND CHANGING BEHAVIOR: THE REASONED ACTION APPROACH, P1; Funk CD, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030418; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; [李晓敏 Li Xiaomin], 2015, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V23, P590; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Liu RG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030292; Min B.Q., 2013, J NEUROSCIENCE MENTA, V13, P569, DOI [10.3969/j.issn.1009-6574.2013.06.009, DOI 10.3969/J.ISSN.1009-6574.2013.06.009]; National Health Commission of the People's Republic of China, 2021, GUID COVID 19 VACC, V1st; National Health Commission of the People's Republic of China, 2021, COVID 19 VACC; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Sekine M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030362; Visser O, 2018, VACCINE, V36, P736, DOI 10.1016/j.vaccine.2017.12.021; Word Health Organization, 2021, COR DIS COVID 19 WEE; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; [曾庆枝 Zeng Qingzhi], 2013, [中国心理卫生杂志, Chinese Mental Health Journal], V27, P163; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2	27	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1221	10.3390/vaccines9111221			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG0EP	34835154	gold, Green Published			2022-04-29	WOS:000724435400001
J	Liu, ZH; Bai, W; Cai, H; Liu, S; Chen, X; Qi, H; Liu, R; Cheung, T; Su, ZH; Jackson, T; Sha, S; Xiang, YT				Liu, Zi-Han; Bai, Wei; Cai, Hong; Liu, Shou; Chen, Xu; Qi, Han; Liu, Rui; Cheung, Teris; Su, Zhaohui; Jackson, Todd; Sha, Sha; Xiang, Yu-Tao			Body Appreciation as a Factor Associated with College Students' Willingness to Receive Future COVID-19 Vaccines	VACCINES			English	Article						body appreciation; COVID-19 vaccine; vaccination intentions; college student	IMAGE; ATTITUDES; HEALTH	Background: Following the initial manufacture of COVID-19 vaccines, numerous studies have investigated factors that influence people's vaccination intentions. However, no studies have examined links of vaccination attitudes with body-related attitudes, especially body appreciation. To address this gap in the literature, we conducted this study to disentangle the relationship between college students' COVID-19 vaccination intentions and body appreciation. Method: A cross-sectional study was conducted among Chinese college students. Participants completed the Body Appreciation Scale-2 (BAS-2) and other questionnaire measures of demographics, intentions to be vaccinated, and attitudes toward COVID-19 vaccination programs. Results: A total of 2058 college students participated in this study. Students who were willing to get COVID-19 vaccines had significantly higher BAS-2 scores than did those who were unwilling to receive a vaccine (3.61 & PLUSMN; 0.84 vs. 3.34 & PLUSMN; 0.92, p < 0.001). A hierarchical multiple logistic regression analysis was performed to test the association between body appreciation and COVID-19 vaccine intentions when controlling for other covariates; elevated BAS-2 scores were associated with greater willingness to receive COVID-19 vaccines (OR = 1.250, 95%CI: 1.112-1.406, p < 0.001), independent of other significant influences. Conclusion: Our study was the first to reveal that body appreciation is a significant factor related to college students' COVID-19 vaccination intentions. Public health interventions designed to improve people's body-appreciation levels may help in efforts to promote universal immunization.	[Liu, Zi-Han; Bai, Wei; Cai, Hong; Xiang, Yu-Tao] Univ Macau, Fac Hlth Sci, Unit Psychiat, Dept Publ Hlth & Med Adm, Macau 999078, Peoples R China; [Liu, Zi-Han; Bai, Wei; Cai, Hong; Xiang, Yu-Tao] Univ Macau, Fac Hlth Sci, Inst Translat Med, Macau 999078, Peoples R China; [Liu, Zi-Han; Bai, Wei; Cai, Hong; Xiang, Yu-Tao] Univ Macau, Ctr Cognit & Brain Sci, Macau 999078, Peoples R China; [Liu, Zi-Han; Bai, Wei; Cai, Hong; Xiang, Yu-Tao] Univ Macau, Inst Adv Studies Humanities & Social Sci, Macao Sar 999078, Macao, Peoples R China; [Liu, Shou] Qinghai Univ, Med Coll, Dept Publ Hlth, Xining 810000, Peoples R China; [Chen, Xu; Qi, Han; Liu, Rui; Sha, Sha] Capital Med Univ, Natl Clin Res Ctr Mental Disorders, Sch Mental Hlth, Beijing Anding Hosp, Beijing 100069, Peoples R China; [Chen, Xu; Qi, Han; Liu, Rui; Sha, Sha] Capital Med Univ, Sch Mental Hlth, Beijing Anding Hosp, Beijing Key Lab Mental Disorders, Beijing 100069, Peoples R China; [Chen, Xu; Qi, Han; Liu, Rui; Sha, Sha] Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Sch Mental Hlth, Beijing 100069, Peoples R China; [Cheung, Teris] Hong Kong Polytech Univ, Sch Nursing, Hong Kong 999077, Peoples R China; [Su, Zhaohui] UT Hlth San Antonio, Mays Canc Ctr, Sch Nursing, Ctr Smart & Connected Hlth Technol, San Antonio, TX 73301 USA; [Jackson, Todd] Univ Macau, Dept Psychol, Macau 999078, Peoples R China		Sha, S (通讯作者)，Capital Med Univ, Natl Clin Res Ctr Mental Disorders, Sch Mental Hlth, Beijing Anding Hosp, Beijing 100069, Peoples R China.	yb97603@umac.mo; yc07611@connectum.edu.mo; yc07640@umac.mo; liushou@qhu.edu.cn; chenxuadyy@ccmu.edu.cn; qihan@carrmedu.cn; ruiliu@ccmu.edu.cn; teris.cheung@polyu.edu.hk; szh@utexas.edu; toddjackson@um.edu.mo; shasha@mail.ccmu.edu.cn; ytxiang@um.edu.mo	cheung, teris/G-3179-2017	cheung, teris/0000-0002-5878-9193; Su, Zhaohui/0000-0003-2005-9504	Beijing Municipal Science & Technology CommissionBeijing Municipal Science & Technology Commission [Z181100001718124]; Beijing Talents Foundation [2017000021469G222]; University of Macau [MYRG2019-00066-FHS]; Beijing Municipal Administration of Hospitals Incubating Program [PX2018063]	FundingThe study was supported by the Beijing Municipal Science & Technology Commission (Grant No.: Z181100001718124), Beijing Talents Foundation (Grant No.: 2017000021469G222), and the University of Macau (MYRG2019-00066-FHS), Beijing Municipal Administration of Hospitals Incubating Program (Grant Number PX2018063).	Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Andrew R, 2016, J HEALTH PSYCHOL, V21, P28, DOI 10.1177/1359105314520814; Asdaq SMB, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040542; Baceviciene M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030752; Bai W, 2021, INT J BIOL SCI, V17, P1469, DOI 10.7150/ijbs.58835; Bazargan M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2160894; Bock JO, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0597-y; Burnette CB, 2019, HEALTH EQUITY, V3, P238, DOI 10.1089/heq.2019.0003; Burychka D, 2021, PSYCHOL BELG, V61, P248, DOI 10.5334/pb.1057; Cook M, 2020, HEALTH SOC WORK, V45, P47, DOI 10.1093/hsw/hlz036; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dharini, 2020, INDIAN J PLAST SURG, V53, P273, DOI 10.1055/s-0040-1716458; Drury Christine Aramburu Alegria, 2002, J Am Acad Nurse Pract, V14, P554; Dumitrescu Alexandrina L, 2008, Rom J Intern Med, V46, P343; Eissazade N, 2021, ASIA-PAC PSYCHIAT, V13, DOI 10.1111/appy.12434; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gillen MM, 2015, BODY IMAGE, V13, P67, DOI 10.1016/j.bodyim.2015.01.002; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Hartman-Munick SM, 2020, CURR OPIN PEDIATR, V32, P455, DOI 10.1097/MOP.0000000000000910; Kaushik, 2017, INT J PSYCHOL PSYCH, V5, P63, DOI [10.5958/2320-6233.2017.00011.6, DOI 10.5958/2320-6233.2017.00011.6]; Kelly BJ, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06023-9; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Laine C, 2021, ANN INTERN MED, V174, P252, DOI 10.7326/M20-8008; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Ma Y, 2018, HUM VACC IMMUNOTHER, V14, P1283, DOI 10.1080/21645515.2017.1423157; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; McLESTER Cherilyn N, 2018, Int J Exerc Sci, V11, P957; Mercadante AR, 2021, RES SOC ADMIN PHARM, V17, P1596, DOI 10.1016/j.sapharm.2020.12.012; Naderifar M, 2017, STRIDES DEV MED ED, V14, DOI [DOI 10.5812/SDME.67670, 10.5812/sdme.67670]; Ning LW, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09892-y; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Rosenbaum DL, 2020, APPETITE, V154, DOI 10.1016/j.appet.2020.104756; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sediri S, 2020, ARCH WOMEN MENT HLTH, V23, P749, DOI 10.1007/s00737-020-01082-4; Swami V, 2016, BODY IMAGE, V18, P23, DOI 10.1016/j.bodyim.2016.04.005; Tylka TL, 2015, BODY IMAGE, V12, P53, DOI 10.1016/j.bodyim.2014.09.006; Wang K, 2018, PSYCH J, V7, P31, DOI 10.1002/pchj.200; Wang X, 2020, STROKE VASC NEUROL, V5, P323, DOI 10.1136/svn-2020-000514; Wibawa T, 2021, TROP MED INT HEALTH, V26, P14, DOI 10.1111/tmi.13503; Winter VR, 2019, J HEALTH PSYCHOL, V24, P1517, DOI 10.1177/1359105317728575; Xiang YT, 2008, SCHIZOPHR RES, V102, P270, DOI 10.1016/j.schres.2008.04.009	44	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1285	10.3390/vaccines9111285			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XE4GF	34835216	Green Published, gold			2022-04-29	WOS:000723347300001
J	Mamedov, T; Yuksel, D; Ilgin, M; Guerbuezaslan, I; Gulec, B; Mammadova, G; Ozdarendeli, A; Yetiskin, H; Kaplan, B; Pavel, STI; Uygut, MA; Hasanova, G				Mamedov, Tarlan; Yuksel, Damla; Ilgin, Merve; Guerbuezaslan, Irem; Gulec, Burcu; Mammadova, Gulshan; Ozdarendeli, Aykut; Yetiskin, Hazel; Kaplan, Busra; Islam Pavel, Shaikh Terkis; Uygut, Muhammet Ali; Hasanova, Gulnara			Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in Nicotiana benthamiana Plant as a Vaccine Candidate against COVID-19	VACCINES			English	Article						COVID-19; SARS-CoV-2; nucleocapsid protein; RBD of SARS-CoV-2; plant; transient expression system	RECEPTOR-BINDING DOMAIN; SPIKE PROTEIN; CORONAVIRUS; ANAPHYLAXIS; EXPRESSION; RESPONSES; TARGETS; VIVO	The COVID-19 pandemic has put global public health at high risk, rapidly spreading around the world. Although several COVID-19 vaccines are available for mass immunization, the world still urgently needs highly effective, reliable, cost-effective, and safe SARS-CoV-2 coronavirus vaccines, as well as antiviral and therapeutic drugs, to control the COVID-19 pandemic given the emerging variant strains of the virus. Recently, we successfully produced receptor-binding domain (RBD) variants in the Nicotiana benthamiana plant as promising vaccine candidates against COVID-19 and demonstrated that mice immunized with these antigens elicited a high titer of RBD-specific antibodies with potent neutralizing activity against SARS-CoV-2. In this study, we engineered the nucleocapsid (N) protein and co-expressed it with RBD of SARS-CoV-2 in Nicotiana benthamiana plant to produce an antigen cocktail. The purification yields were about 22 or 24 mg of pure protein/kg of plant biomass for N or N+RBD antigens, respectively. The purified plant produced N protein was recognized by N protein-specific monoclonal and polyclonal antibodies demonstrating specific reactivity of mAb to plant-produced N protein. In this study, for the first time, we report the co-expression of RBD with N protein to produce a cocktail antigen of SARS-CoV-2, which elicited high-titer antibodies with potent neutralizing activity against SARS-CoV-2. Thus, obtained data support that a plant-produced antigen cocktail, developed in this study, is a promising vaccine candidate against COVID-19.	[Mamedov, Tarlan; Yuksel, Damla; Ilgin, Merve; Guerbuezaslan, Irem; Gulec, Burcu; Mammadova, Gulshan; Hasanova, Gulnara] Akdeniz Univ, Dept Agr Biotechnol, TR-07058 Antalya, Turkey; [Ozdarendeli, Aykut; Yetiskin, Hazel; Kaplan, Busra; Islam Pavel, Shaikh Terkis; Uygut, Muhammet Ali] Erciyes Univ, Fac Med, Dept Microbiol, TR-38280 Kayseri, Turkey; [Ozdarendeli, Aykut; Yetiskin, Hazel; Kaplan, Busra; Islam Pavel, Shaikh Terkis] Erciyes Univ, Vaccine Res Dev & Applicat Ctr, TR-38280 Kayseri, Turkey		Mamedov, T (通讯作者)，Akdeniz Univ, Dept Agr Biotechnol, TR-07058 Antalya, Turkey.	tmammedov@gmail.com; dmlyuksel07@gmail.com; merveilgin.akd@gmail.com; irem.gurbuzaslan@gmail.com; burcudogusoy@gmail.com; gulka2878@gmail.com; aozdarendeli@erciyes.edu.tr; hazelyetiskin@gmail.com; busra.kaplan.3@gmail.com; biotech.pavel@outlook.com; mauygut@gmail.com; gulnarahasanova@yahoo.com	PAVEL, TERKIS ISLAM/AAL-7889-2021	PAVEL, TERKIS ISLAM/0000-0002-7178-0943; KAPLAN, BUSRA/0000-0002-2029-6270; Ozdarendeli, Aykut/0000-0002-6950-8545	Akdeniz UniversityAkdeniz University	This study was funded by Akdeniz University to Tarlan Mamedov.	Bellomo RG, 2021, J BIOL REG HOMEOS AG, V35, P839, DOI 10.23812/BELLOMO_EDIT_3_21; Chong P, 2015, ADV PROTEIN CHEM STR, V99, P55, DOI 10.1016/bs.apcsb.2015.03.003; Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Duchene S, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa061; Dutta NK, 2020, J VIROL, V94, DOI 10.1128/JVI.00647-20; Edara Venkata Viswanadh, 2021, bioRxiv, DOI 10.1101/2021.02.20.432046; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fratev F., 2020, SARS COV 2 S1 SPIKE, DOI [10.1101/ 2020.12.23.424283, 10.1101/2020.12.23.424283, DOI 10.1101/2020.12.23.424283]; Gangemi S, 2021, J BIOL REG HOMEOS AG, V35, P843, DOI 10.23812/21-20-E; Gao TY, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02107-3; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06; Holmes KV, 2003, SCIENCE, V300, P1377, DOI 10.1126/science.1086418; Hou YXJ, 2020, SCIENCE, V370, P1464, DOI 10.1126/science.abe8499; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kang SS, 2020, ACTA PHARM SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040; Liu WB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00461-20; Maharjan PM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090992; Mamedov T., 2020, ENG PRODUCTION CHARA, DOI [10.1101/2020.12.29.424779, DOI 10.1101/2020.12.29.424779]; Mamedov T., 2020, SEQUENCE ANALYSIS AM, V2020050026, DOI [10.20944/preprints202005.0026.v1, DOI 10.20944/PREPRINTS202005.0026.V1]; Mamedov T, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081595; Mamedov T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46375-6; Mamedov T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213438; Mamedov T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183589; Mamedov T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153956; Nelson G., 2021, BIORXIV, DOI [10.1101/2021.01.13.426558, DOI 10.1101/2021.01.13.426558]; Pavel STI, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238614; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Prokhnevsky A, 2015, MOL BIOTECHNOL, V57, P101, DOI 10.1007/s12033-014-9806-5; Rattanapisit K, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8120560; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Sainsbury F, 2009, PLANT BIOTECHNOL J, V7, P682, DOI 10.1111/j.1467-7652.2009.00434.x; Shanmugaraj B, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9070842; Shin YJ, 2021, FRONT PLANT SCI, V12, DOI 10.3389/fpls.2021.689104; Siriwattananon K, 2021, FRONT PLANT SCI, V12, DOI 10.3389/fpls.2021.682953; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Starr TN, 2021, SCIENCE, V371, P850, DOI 10.1126/science.abf9302; Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012; Streatfield SJ, 2015, PLANT BIOTECHNOL J, V13, P1136, DOI 10.1111/pbi.12475; van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y; Walensky RP, 2021, JAMA-J AM MED ASSOC, V325, P1037, DOI 10.1001/jama.2021.2294; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20; Weissman D., 2021, CELL HOST MICROBE, V29, P23, DOI [10.1016/j.chom.2020.11.012, DOI 10.1016/j.chom.2020.11.012]; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Worobey M, 2020, SCIENCE, V370, P564, DOI 10.1126/science.abc8169; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu Kai, 2021, bioRxiv, DOI 10.1101/2021.01.25.427948; Yurkovetskiy L, 2020, CELL, V183, P739, DOI 10.1016/j.cell.2020.09.032; Zheng NY, 2009, VACCINE, V27, P5001, DOI 10.1016/j.vaccine.2009.05.073; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	56	1	1	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1337	10.3390/vaccines9111337			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG4KE	34835268	Green Published, gold			2022-04-29	WOS:000724722500001
J	Trofimova, O; Korotkaja, K; Skrastina, D; Jansons, J; Spunde, K; Isaguliants, M; Zajakina, A				Trofimova, Olga; Korotkaja, Ksenija; Skrastina, Dace; Jansons, Juris; Spunde, Karina; Isaguliants, Maria; Zajakina, Anna			Alphavirus-Driven Interferon Gamma (IFNg) Expression Inhibits Tumor Growth in Orthotopic 4T1 Breast Cancer Model	VACCINES			English	Article						interferon gamma; cancer immunotherapy; viral vectors; alphavirus; bone-marrow-derived macrophages; spheroids; CD38; Pam3CSK4	EFFECTOR T-CELLS; STIMULATED GENES; VIRUS; DELIVERY; MACROPHAGES; THERAPY; IMMUNE; MICROENVIRONMENT; RESPONSES; VECTORS	Interferon gamma (IFNg) is a pleiotropic cytokine that can potentially reprogram the tumor microenvironment; however, the antitumor immunomodulatory properties of IFNg still need to be validated due to variable therapeutic outcomes in preclinical and clinical studies. We developed a replication-deficient Semliki Forest virus vector expressing IFNg (SFV/IFNg) and evaluated its immunomodulatory antitumor potential in vitro in a model of 3D spheroids and in vivo in an immunocompetent 4T1 mouse breast cancer model. We demonstrated that SFV-derived, IFN-g-stimulated bone marrow macrophages can be used to acquire the tumoricidal M1 phenotype in 3D nonattached conditions. Coculturing SFV/IFNg-infected 4T1 spheroids with BMDMs inhibited spheroid growth. In the orthotopic 4T1 mouse model, intratumoral administration of SFV/IFNg virus particles alone or in combination with the Pam3CSK4 TLR2/1 ligand led to significant inhibition of tumor growth compared to the administration of the control SFV/Luc virus particles. Analysis of the composition of intratumoral lymphoid cells isolated from tumors after SFV/IFNg treatment revealed increased CD4(+) and CD8(+) and decreased T-reg (CD4(+)/CD25(+)/FoxP3(+)) cell populations. Furthermore, a significant decrease in the populations of cells bearing myeloid cell markers CD11b, CD38, and CD206 was observed. In conclusion, the SFV/IFNg vector induces a therapeutic antitumor T-cell response and inhibits myeloid cell infiltration in treated tumors.	[Trofimova, Olga; Korotkaja, Ksenija; Skrastina, Dace; Jansons, Juris; Spunde, Karina; Zajakina, Anna] Latvian Biomed Res & Study Ctr, Ratsupites Str 1 K1, LV-1067 Riga, Latvia; [Isaguliants, Maria] Riga Stradins Univ, Inst Microbiol & Virol, LV-1007 Riga, Latvia; [Isaguliants, Maria] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden; [Isaguliants, Maria] NF Gamaleya Natl Res Ctr Epidemiol & Microbiol, Moscow 123098, Russia		Zajakina, A (通讯作者)，Latvian Biomed Res & Study Ctr, Ratsupites Str 1 K1, LV-1067 Riga, Latvia.	olj.trofimova@gmail.com; ksenjakorotkaja@gmail.com; dace.skrastina@biomed.lu.lv; jansons@biomed.lu.lv; spunde.carina@gmail.com; maria.issagouliantis@rsu.lv; anna.zajakina@gmail.com	, ISSAGOULIANTIS/AAI-3148-2021; Spunde, Karina/G-3296-2019	, ISSAGOULIANTIS/0000-0001-9382-2254; Spunde, Karina/0000-0002-1383-0156; Jansons, Juris/0000-0003-0845-4392; Zajakina, Anna/0000-0002-4753-1103	Latvian Council of ScienceLatvian Ministry of Education and Science [lzp-2018/1-0208]	This research was funded by the Latvian Council of Science, project title "Functional Programming of Tumor-Associated Macrophages with Viral Immunotherapy Vectors in Breast Cancer Model", project number lzp-2018/1-0208.	Abdel-Aal AM, 2014, CHEMBIOCHEM, V15, P1508, DOI 10.1002/cbic.201402077; ALEXANDER P, 1971, NATURE-NEW BIOL, V232, P76, DOI 10.1038/newbio232076a0; Alspach E, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a028480; Amici SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01593; Amiset L, 2012, ONCOIMMUNOLOGY, V1, P1271, DOI 10.4161/onci.21479; Baklaushev VP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07851-z; Bayurova E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6016278; Berg DR, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006773; Berraondo P, 2019, BRIT J CANCER, V120, P6, DOI 10.1038/s41416-018-0328-y; Bialkowska K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176225; Bourgeois-Daigneault MC, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.1; Brown MC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22088-1; Castro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00847; Chaicharoenaudomrung N, 2019, WORLD J STEM CELLS, V11, P1065, DOI 10.4252/wjsc.v11.i12.1065; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chen LM, 2018, CANCER DISCOV, V8, P1156, DOI 10.1158/2159-8290.CD-17-1033; Cheon H, 2014, SEMIN ONCOL, V41, P156, DOI 10.1053/j.seminoncol.2014.02.002; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Cho HJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3195; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Davies John Q, 2005, Methods Mol Biol, V290, P91; Deligne C, 2015, LEUKEMIA, V29, P947, DOI 10.1038/leu.2014.275; Delprat V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57677-5; Denton NL, 2016, BIOMEDICINES, V4, DOI 10.3390/biomedicines4030013; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; Ding GP, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6145-8; Dreno B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083670; Dupre SA, 2008, EXP MOL PATHOL, V85, P174, DOI 10.1016/j.yexmp.2008.05.002; El Kasmi KC, 2008, NAT IMMUNOL, V9, P1399, DOI 10.1038/ni.1671; Engblom C, 2016, NAT REV CANCER, V16, P447, DOI 10.1038/nrc.2016.54; Esquivel-Velazquez M, 2015, J INTERF CYTOK RES, V35, P1, DOI 10.1089/jir.2014.0026; Fathallah-Shaykh HM, 2000, J IMMUNOL, V164, P217, DOI 10.4049/jimmunol.164.1.217; Feng XY, 2017, CLIN CANCER RES, V23, P4290, DOI 10.1158/1078-0432.CCR-16-3192; Frolov I, 2012, J VIROL, V86, P5055, DOI 10.1128/JVI.07223-11; Garner H, 2020, NAT REV IMMUNOL, V20, P483, DOI 10.1038/s41577-019-0271-z; Gheytanchi E, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01898-9; Giese MA, 2019, BLOOD, V133, P2159, DOI 10.1182/blood-2018-11-844548; Gocher AM, 2022, NAT REV IMMUNOL, V22, P158, DOI 10.1038/s41577-021-00566-3; Gorczyca W., 2014, ATLAS DIFFERENTIAL D, Ved 3; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Granot T, 2012, CANCER GENE THER, V19, P588, DOI 10.1038/cgt.2012.33; Grasselly C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02100; Hanze J, 2020, TARGET ONCOL, V15, P377, DOI 10.1007/s11523-020-00728-8; Hu HG, 2020, BIOCONJUGATE CHEM, V31, P2499, DOI 10.1021/acs.bioconjchem.0c00522; Hutornojs V., 2012, ENVIRON EXP BIOL, V10, P117; Ivashkiv LB, 2018, NAT REV IMMUNOL, V18, P545, DOI 10.1038/s41577-018-0029-z; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Jorgovanovic D, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00228-x; Kalanjeri S, 2012, CURR PULMONOL REP, V1, P54, DOI 10.1007/s13665-011-0008-3; Kanno H, 1999, CANCER GENE THER, V6, P147, DOI 10.1038/sj.cgt.7700008; Karakasheva TA, 2015, CANCER RES, V75, P4074, DOI 10.1158/0008-5472.CAN-14-3639; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kloker LD, 2018, ONCOLYTIC VIROTHER, V7, P79, DOI 10.2147/OV.S165479; Kurena B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01667; Kurena B, 2017, J VIROL METHODS, V245, P28, DOI 10.1016/j.jviromet.2017.03.008; Kuwada K, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0981-2; Levy A, 2012, NEURO-ONCOLOGY, V14, P1037, DOI 10.1093/neuonc/nos121; Li LY, 2011, J CANCER, V2, P458, DOI 10.7150/jca.2.458; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Liu CQ, 2019, ONCOL RES, V27, P965, DOI 10.3727/096504019X15498329881440; Liu SX, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68766-w; Lv Q, 2018, BIOACT MATER, V3, P118, DOI 10.1016/j.bioactmat.2017.08.003; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; Melissaridou S, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0733-1; Mojic M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010089; Muller E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01383; Nemunaitis J, 1999, HUM GENE THER, V10, P1289, DOI 10.1089/10430349950017978; Neophytou CM, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00899; Ni L, 2018, CANCER MED-US, V7, P4509, DOI 10.1002/cam4.1700; Okita Y, 2014, J SURG RES, V186, P192, DOI 10.1016/j.jss.2013.08.024; Oldford SA, 2010, J IMMUNOL, V185, P7067, DOI 10.4049/jimmunol.1001137; Overacre-Delgoffe AE, 2018, CANCER IMMUNOL RES, V6, P882, DOI 10.1158/2326-6066.CIR-18-0066; Overacre-Delgoffe AE, 2017, CELL, V169, P1130, DOI 10.1016/j.cell.2017.05.005; Paston SJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627932; Patton DT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017359; Pyeon D, 2020, PLOS PATHOG, V16, P8814, DOI 10.1371/journal.ppat.1008814; Quetglas JI, 2015, CANCER IMMUNOL RES, V3, P449, DOI 10.1158/2326-6066.CIR-14-0216; Quetglas JI, 2012, MOL THER, V20, P1664, DOI 10.1038/mt.2012.56; Rama-Esendagli D, 2014, MOL BIOL REP, V41, P2885, DOI 10.1007/s11033-014-3144-3; Reed JM, 2008, J INTERF CYTOK RES, V28, P611, DOI 10.1089/jir.2007.0145; Reid GSD, 2009, CLIN CANCER RES, V15, P6602, DOI 10.1158/1078-0432.CCR-09-0829; Relation T, 2018, STEM CELLS, V36, P915, DOI 10.1002/stem.2801; Ryman KD, 2008, IMMUNOL REV, V225, P27, DOI 10.1111/j.1600-065X.2008.00670.x; Salerno F, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1532762; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; SCHREIBER RD, 1983, J IMMUNOL, V131, P826; Singh A, 2019, CANCER IMMUNOL IMMUN, V68, P849, DOI 10.1007/s00262-018-2276-z; SRISKANDAN K, 1986, CANCER CHEMOTH PHARM, V18, P63, DOI 10.1007/BF00253067; Takahashi K, 2015, CANCER SCI, V106, P867, DOI 10.1111/cas.12685; Upreti M, 2011, TRANSL ONCOL, V4, P365, DOI 10.1593/tlo.11187; Vasilevska J, 2012, CANCER GENE THER, V19, P579, DOI 10.1038/cgt.2012.37; Wang FL, 2018, EBIOMEDICINE, V30, P303, DOI 10.1016/j.ebiom.2018.02.009; Wang J, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07234-0; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; Wu C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01126; Xu Q, 2021, FRONT MED-PRC, V15, P333, DOI 10.1007/s11684-020-0776-7; Yamashita M, 2021, MOL THER-ONCOLYTICS, V20, P422, DOI 10.1016/j.omto.2021.01.016; Yuan A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14273; Zaidi MR, 2019, J INTERF CYTOK RES, V39, P30, DOI 10.1089/jir.2018.0087; Zajakina A, 2017, CURR PHARM DESIGN, V23, P4906, DOI 10.2174/1381612823666170622094715; Zeytin H, 2008, J INTERF CYTOK RES, V28, P73, DOI 10.1089/jir.2007.0063; Zhang Y, 2018, ONCOL LETT, V15, P6233, DOI 10.3892/ol.2018.8113; Zhang Y, 2011, J IMMUNOL, V186, P1963, DOI 10.4049/jimmunol.1002320; Zhao P, 2007, LIFE SCI, V81, P695, DOI 10.1016/j.lfs.2007.05.028; Zhou ZH, 2021, AM J CANCER RES, V11, P1503; Zibelman M., COMBINATION INTERFER	106	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1247	10.3390/vaccines9111247			31	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF9OO	34835178	Green Published, gold			2022-04-29	WOS:000724393700001
J	Kamal, A; Hodson, A; Pearce, JM				Kamal, Atiya; Hodson, Ava; Pearce, Julia M.			A Rapid Systematic Review of Factors Influencing COVID-19 Vaccination Uptake in Minority Ethnic Groups in the UK	VACCINES			English	Review						vaccine uptake; minority ethnicity; facilitator; barrier; COVID-19		COVID-19 has disproportionately affected minority ethnic groups in the United Kingdom. To maximise the effectiveness of the vaccination programme, it is important to understand and address disparities in vaccine uptake. The aim of this review was to identify factors influencing COVID-19 vaccination uptake between minority ethnic groups in the UK. A search was undertaken in peer-reviewed databases, polling websites and grey literature from January 2020-May 2021. Studies were included if they reported data on vaccine uptake or the reasons for or against accepting the COVID-19 vaccination for minority ethnic groups in the UK. Twenty-one papers met the inclusion criteria, all of which were rated as either good or moderate quality. Ethnic minority status was associated with higher vaccine hesitancy and lower vaccine uptake compared with White British groups. Barriers included pre-existing mistrust of formal services, lack of information about the vaccine's safety, misinformation, inaccessible communications, and logistical issues. Facilitators included inclusive communications which address vaccine concerns via trusted communicators and increased visibility of minority ethnic groups in the media. Community engagement to address the concerns and informational needs of minority ethnic groups using trusted and collaborative community and healthcare networks is likely to increase vaccine equity and uptake.	[Kamal, Atiya] Birmingham City Univ, Dept Psychol, Birmingham B4 7BD, W Midlands, England; [Hodson, Ava; Pearce, Julia M.] Kings Coll London, Dept War Studies, Strand Campus, London WC2R 2LS, England		Kamal, A (通讯作者)，Birmingham City Univ, Dept Psychol, Birmingham B4 7BD, W Midlands, England.	atiya.kamal@bcu.ac.uk; ava.hodson@kcl.ac.uk; julia.pearce@kcl.ac.uk		Pearce, Julia/0000-0001-5422-3283; Kamal, Atiya/0000-0002-6651-6400	Economic and Social Research Council (ESRC), as part of UK Research and Innovations rapid response to Covid-19 [ES/W001721/1]	This systematic review was funded by the Economic and Social Research Council (ESRC), as part of UK Research and Innovations rapid response to Covid-19 [grant number ES/W001721/1].	Allington D, 2021, VACCINE, V39, P2595, DOI 10.1016/j.vaccine.2021.02.054; Allington D, 2021, PSYCHOL MED, DOI 10.1017/S0033291721001434; Barts Health NHS Trust, 2021, STAFF SHAR COVID 19; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; British Red Cross, 2021, NEW RES COVID 19 VAC; Caribbean and African Health Network, 2021, COVID 19 VACC CAR AF; CDC Centers for Disease Control and Prevention, 2021, COVID DAT TRACK; Curtis H.J., 2021, TRENDS CLIN CHARACTE, DOI [10.1101/2021.01.25.21250356v3, DOI 10.1101/2021.01.25.21250356]; Department of Health and Social Care, 2021, COMM CHAMP GIV COVID; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gov.UK, 2018, UK POP ETHN; Gov.UK, JCVI ISS UPD ADV COV; Hanif W, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4845; Healthwatch, 2021, GETT VACC CENTR MOR; Healthwatch Camden, 2021, BLACK AS MIN ETHN VI; Hodson, RAPID SYSTEMATIC REV; Hong QN, 2018, EDUC INFORM, V34, P285, DOI 10.3233/EFI-180221; Knights F, 2021, BRIT J GEN PRACT, V71, pE583, DOI 10.3399/BJGP.2021.0028; Lockyer B, 2021, HEALTH EXPECT, V24, P1158, DOI 10.1111/hex.13240; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; MacKenna B., TRENDS REGIONAL VARI, DOI [10.1101/2021.01.25.21250356, DOI 10.1101/2021.01.25.21250356V3, DOI 10.1101/2021.01.25.21250356]; National Health Service, 2021, COVID 19 VACC; Nguyen Long H, 2021, medRxiv, DOI 10.1101/2021.02.25.21252402; Office for National Statistics, 2021, COR VACC HES GREAT B; Office for National Statistics, 2021, COR VACC RAT PEOPL A; Osama T, 2021, J ROY SOC MED, V114, P240, DOI 10.1177/01410768211001581; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Rogers, 2021, PSYARXIV, DOI [10.31234/osf.io/6qtc2, DOI 10.31234/OSF.IO/6QTC2]; Royal Society for Public Health, 2020, NEW POLL FINDS ETHN; SAGE Ethnicity Group, 2020, FACTORS INFLUENCING; Scientific Advisory Group for Emergencies, EV SUMM IMP DAT PUBL; Scientific Advisory Group for Emergencies, ROL COMM CHAMP NETW; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Shand, 2021, EVALUATION REPORT; Smith LE, 2021, VACCINE, V39, P4046, DOI 10.1016/j.vaccine.2021.06.018; Sze S, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100630; The Finance Info, 2021, VACC UPT RIS ENGL ET; Williams L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010017; Woolf K, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100180	39	4	4	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1121	10.3390/vaccines9101121			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI9BU	34696228	Green Accepted, gold, Green Published			2022-04-29	WOS:000726398200001
J	Wittner, J; Schuh, W				Wittner, Jens; Schuh, Wolfgang			Kruppel-like Factor 2 (KLF2) in Immune Cell Migration	VACCINES			English	Review						Kruppel-like factor 2; KLF2; migration; S1PR1; B cells; T cells; plasma cells; monocytes; neutrophils; NK cells	HOMING T-CELLS; TRANSCRIPTION-FACTOR; UP-REGULATION; GENE-EXPRESSION; L-SELECTIN; B-CELLS; TRAFFICKING; ACTIVATION; QUIESCENCE; RECEPTOR	Kruppel-like factor 2 (KLF2), a transcription factor of the kruppel-like family, is a key regulator of activation, differentiation, and migration processes in various cell types. In this review, we focus on the functional relevance of KLF2 in immune cell migration and homing. We summarize the key functions of KLF2 in the regulation of chemokine receptors and adhesion molecules and discuss the relevance of the KLF2-mediated control of immune cell migration in the context of immune responses, infections, and diseases.</p>	[Wittner, Jens; Schuh, Wolfgang] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Nikolaus Fiebiger Ctr, Div Mol Immunol,Dept Internal Med 3, D-91054 Erlangen, Germany		Schuh, W (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Nikolaus Fiebiger Ctr, Div Mol Immunol,Dept Internal Med 3, D-91054 Erlangen, Germany.	wolfgang.schuh@uk-erlangen.de		Wittner, Jens/0000-0002-9729-9111	Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [TRR130/P09]	FundingThis work was in part supported by research grant TRR130/P09 provided by the Deutsche Forschungsgemeinschaft (DFG) to W.S.	Ahrendt M, 2008, J IMMUNOL, V181, P1898, DOI 10.4049/jimmunol.181.3.1898; Aira LE, 2021, J INVEST DERMATOL, V141, P1995, DOI 10.1016/j.jid.2021.01.013; Alberts-Grill N, 2016, J IMMUNOL, V197, P4651, DOI 10.4049/jimmunol.1600206; Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Alles M, 2014, J IMMUNOL, V193, P1737, DOI 10.4049/jimmunol.1302613; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Anderson Luke R, 2014, Biophys Rev, V6, P203, DOI 10.1007/s12551-013-0124-0; Ariotti S, 2012, P NATL ACAD SCI USA, V109, P19739, DOI 10.1073/pnas.1208927109; Atkins GB, 2008, CIRC RES, V103, P690, DOI 10.1161/CIRCRESAHA.108.184663; Bhattacharya D, 2007, J IMMUNOL, V179, P6808, DOI 10.4049/jimmunol.179.10.6808; Bixel MG, 2017, CELL REP, V18, P1804, DOI 10.1016/j.celrep.2017.01.042; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Chen J, 2010, EUR J IMMUNOL, V40, P1890, DOI 10.1002/eji.200939817; Chien YH, 2014, ANNU REV IMMUNOL, V32, P121, DOI 10.1146/annurev-immunol-032713-120216; Cinamon G, 2008, NAT IMMUNOL, V9, P54, DOI 10.1038/ni1542; Clipson A, 2015, LEUKEMIA, V29, P1177, DOI 10.1038/leu.2014.330; Crinier A, 2018, IMMUNITY, V49, P971, DOI 10.1016/j.immuni.2018.09.009; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Dang XT, 2009, BBA-GENE REGUL MECH, V1789, P146, DOI 10.1016/j.bbagrm.2008.10.004; Das H, 2006, P NATL ACAD SCI USA, V103, P6653, DOI 10.1073/pnas.0508235103; Das M, 2012, CURR MOL MED, V12, P113, DOI 10.2174/156652412798889090; Deng YC, 2015, IMMUNITY, V42, P457, DOI 10.1016/j.immuni.2015.02.006; Fabre S, 2008, J IMMUNOL, V181, P2980, DOI 10.4049/jimmunol.181.5.2980; Fischer A, 2016, GUT, V65, P1642, DOI 10.1136/gutjnl-2015-310022; Gaylo-Moynihan A, 2019, IMMUNITY, V51, P298, DOI 10.1016/j.immuni.2019.06.026; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; Glynne R, 2000, IMMUNOL REV, V176, P216; Groenendijk BCW, 2007, PHYSIOLOGY, V22, P380, DOI 10.1152/physiol.00023.2007; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Habtezion A, 2016, GASTROENTEROLOGY, V150, P340, DOI 10.1053/j.gastro.2015.10.046; Haddad W, 2003, J EXP MED, V198, P369, DOI 10.1084/jem.20020691; Hammerschmidt SI, 2008, J EXP MED, V205, P2483, DOI 10.1084/jem.20080039; Hart GT, 2012, J IMMUNOL, V189, P3293, DOI 10.4049/jimmunol.1201439; Hart GT, 2012, J IMMUNOL, V188, P521, DOI 10.4049/jimmunol.1101530; Hart GT, 2011, P NATL ACAD SCI USA, V108, P716, DOI 10.1073/pnas.1013168108; Herglotz J, 2016, BLOOD, V127, P572, DOI 10.1182/blood-2015-04-643270; Hewavisenti RV, 2021, IMMUNOL CELL BIOL, V99, P894, DOI 10.1111/imcb.12481; Hoek KL, 2010, IMMUNITY, V33, P254, DOI 10.1016/j.immuni.2010.07.016; Iijima N, 2015, TRENDS IMMUNOL, V36, P556, DOI 10.1016/j.it.2015.07.002; Itkin T, 2016, NATURE, V532, P323, DOI 10.1038/nature17624; Jaigirdar SA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01627; Jha P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112383; Kabashima K, 2006, J EXP MED, V203, P2683, DOI 10.1084/jem.20061289; Komano Y, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2046; Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145; Lee JY, 2015, IMMUNITY, V42, P252, DOI 10.1016/j.immuni.2015.01.013; Lindquist RL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00788; Lingrel JB, 2012, CIRC RES, V110, P1294, DOI 10.1161/CIRCRESAHA.112.267310; Mahabeleshwar GH, 2011, IMMUNITY, V34, P715, DOI 10.1016/j.immuni.2011.04.014; Manoharan P, 2019, ISCIENCE, V17, P334, DOI 10.1016/j.isci.2019.07.009; Manoharan P, 2014, J BIOL CHEM, V289, P31638, DOI 10.1074/jbc.M114.579763; Marquardt N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11632-9; Marschall JS, 2012, CELL SIGNAL, V24, P879, DOI 10.1016/j.cellsig.2011.12.007; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; McHeyzer-Williams M, 2012, NAT REV IMMUNOL, V12, P24, DOI 10.1038/nri3128; Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669; Mizuguchi M, 2021, BIOCHEM BIOPHYS REP, V26, DOI 10.1016/j.bbrep.2021.100984; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Morteau O, 2008, J IMMUNOL, V181, P6309, DOI 10.4049/jimmunol.181.9.6309; Mueller SN, 2016, NAT REV IMMUNOL, V16, P79, DOI 10.1038/nri.2015.3; Nanki T, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2823; Nayak LV, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-113719; O'Sullivan C, 2013, TRENDS PHARMACOL SCI, V34, P401, DOI 10.1016/j.tips.2013.05.002; Odumade OA, 2010, J IMMUNOL, V184, P6060, DOI 10.4049/jimmunol.1000511; Pabbisetty SK, 2016, P NATL ACAD SCI USA, V113, pE4662, DOI 10.1073/pnas.1605849113; Pabbisetty SK, 2014, P NATL ACAD SCI USA, V111, P9579, DOI 10.1073/pnas.1323493111; Pereira JP, 2010, INT IMMUNOL, V22, P413, DOI 10.1093/intimm/dxq047; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; Preston GC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077537; Rabacal W, 2016, P NATL ACAD SCI USA, V113, P5370, DOI 10.1073/pnas.1521491113; Richardson MW, 2012, J IMMUNOL, V189, P3815, DOI 10.4049/jimmunol.1201431; Riedel R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16464-6; Roberts AW, 2017, IMMUNITY, V47, P913, DOI 10.1016/j.immuni.2017.10.006; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Rott LS, 2000, J LEUKOCYTE BIOL, V68, P807; Rupprecht TA, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-42; Salazar-Gonzalez RM, 2006, IMMUNITY, V24, P623, DOI 10.1016/j.immuni.2006.02.015; Schuh W, 2008, MOL IMMUNOL, V45, P362, DOI 10.1016/j.molimm.2007.06.154; Sebzda E, 2008, NAT IMMUNOL, V9, P292, DOI 10.1038/ni1565; Serr I, 2016, P NATL ACAD SCI USA, V113, pE6659, DOI 10.1073/pnas.1606646113; Shevyrev D, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03100; Skon CN, 2013, NAT IMMUNOL, V14, P1285, DOI 10.1038/ni.2745; Spina V., 2021, ANN LYMPHOMA, V5, DOI [10.21037/aol-20-38, DOI 10.21037/AOL-20-38]; Sweet DR, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00006; Takada K, 2011, J IMMUNOL, V186, P775, DOI 10.4049/jimmunol.1000094; Thomas SY, 2003, J IMMUNOL, V171, P2571, DOI 10.4049/jimmunol.171.5.2571; Tindemans I, 2020, J CLIN INVEST, V130, P3576, DOI 10.1172/JCI128310; Trinite B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110719; Tuomisto TT, 2008, CARDIOVASC RES, V78, P175, DOI 10.1093/cvr/cvn007; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Weber JP, 2015, J EXP MED, V212, P217, DOI 10.1084/jem.20141432; Weinreich MA, 2009, IMMUNITY, V31, P122, DOI 10.1016/j.immuni.2009.05.011; Winkelmann R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097953; Winkelmann R, 2011, P NATL ACAD SCI USA, V108, P710, DOI 10.1073/pnas.1012858108; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Wu ZN, 2013, DEV BIOL, V373, P235, DOI 10.1016/j.ydbio.2012.10.031; Zajac AJ, 2014, CELL MOL IMMUNOL, V11, P221, DOI 10.1038/cmi.2014.7; Zhu LM, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165920; Zuccarino-Catania GV, 2014, NAT IMMUNOL, V15, P631, DOI 10.1038/ni.2914	104	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1171	10.3390/vaccines9101171			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR9ZM	34696279	Green Published			2022-04-29	WOS:000714850600001
J	Kateeb, E; Danadneh, M; Pokorna, A; Klugarova, J; Abdulqader, H; Klugar, M; Riad, A				Kateeb, Elham; Danadneh, Mayar; Pokorna, Andrea; Klugarova, Jitka; Abdulqader, Huthaifa; Klugar, Miloslav; Riad, Abanoub			Predictors of Willingness to Receive COVID-19 Vaccine: Cross-Sectional Study of Palestinian Dental Students	VACCINES			English	Article						COVID-19 vaccines; cross-sectional studies; decision making; education; dental; students; dental; mass vaccination; social determinants of health	HESITANCY	The overarching aim of this study was to assess the predictors related to the willingness of Palestinian dental students to receive the COVID-19 vaccine when it becomes available. A cross-sectional study was conducted among a universal sample of dental students in the Palestinian territories. Willingness to get the COVID-19 vaccine was related to the following factors: Demographic characteristics, COVID-19-related experiences, beliefs and knowledge about the vaccine, attitudes toward vaccinations in general, and other factors outlined by the WHO SAGE Vaccination Hesitancy Questionnaire. Four hundred and seventeen students completed the questionnaire (response rate = 41.7%). In general, 57.8% (n = 241) were willing to take the COVID-19 vaccine when it became available to them, 27% (n = 114) were hesitant, and 14.9% (n = 62) were not willing to get vaccinated. The final regression model explained 46% of the variation in the willingness to receive the COVID-19 vaccine as follows: Attitudes towards new vaccines (beta = 6.23, p < 0.001), believing in a favorable risk-benefit ratio (beta = 5.64, p < 0.001), trust in the pharmaceutical industry (beta = 5.92, p = 0.001), believing that natural immunity is better than being vaccinated (beta = -4.24, p < 0.001), and having enough information about the vaccine (beta = 4.12, p < 0.001). Adequate information about vaccines, their risk-benefit ratios, and natural and acquired immunity are important to build trust and favorable attitudes towards vaccines among future dentists.	[Kateeb, Elham; Danadneh, Mayar] Al Quds Univ, Oral Hlth Res & Promot Unit, Jerusalem 51000, Palestine; [Kateeb, Elham] World Dent Federat FDI, Publ Hlth Comm, CH-1216 Geneva, Switzerland; [Kateeb, Elham] Univ Iowa, Publ Policy Ctr, Iowa City, IA 52242 USA; [Pokorna, Andrea; Klugarova, Jitka; Klugar, Miloslav; Riad, Abanoub] Masaryk Univ, Czech Natl Ctr Evidence Based Healthcare & Knowle, Cochrane Czech Republ,GRADE Ctr,Fac Med, Inst Biostat & Anal,Czech EBHC JBI Ctr Excellence, Brno 62500, Czech Republic; [Pokorna, Andrea; Klugarova, Jitka; Klugar, Miloslav] Masaryk Univ, Dept Nursing & Midwifery, Brno 62500, Czech Republic; [Klugarova, Jitka; Klugar, Miloslav; Riad, Abanoub] Masaryk Univ, Dept Publ Hlth, Brno 62500, Czech Republic; [Abdulqader, Huthaifa; Riad, Abanoub] Int Assoc Dent Students IADS, CH-1216 Geneva, Switzerland		Klugar, M (通讯作者)，Masaryk Univ, Czech Natl Ctr Evidence Based Healthcare & Knowle, Cochrane Czech Republ,GRADE Ctr,Fac Med, Inst Biostat & Anal,Czech EBHC JBI Ctr Excellence, Brno 62500, Czech Republic.; Klugar, M (通讯作者)，Masaryk Univ, Dept Nursing & Midwifery, Brno 62500, Czech Republic.; Klugar, M (通讯作者)，Masaryk Univ, Dept Publ Hlth, Brno 62500, Czech Republic.	ekateeb@staff.alquds.edu; mayar.danadneh@students.alquds.edu; apokorna@med.muni.cz; klugarova@med.muni.cz; vpsr@iads-web.org; klugar@med.muni.cz; abanoub.riad@med.muni.cz	Kateeb, Elham/Q-5207-2018; Klugarova, Jitka/V-1108-2019; Pokorna, Andrea/E-5483-2019; Riad, Abanoub/AAU-7046-2020; Klugar, Miloslav/E-5748-2018	Kateeb, Elham/0000-0003-2077-3257; Klugarova, Jitka/0000-0001-7254-9586; Pokorna, Andrea/0000-0002-1305-6455; Riad, Abanoub/0000-0001-5918-8966; Klugar, Miloslav/0000-0002-2804-7295; AbdulQader, Huthaifa/0000-0001-6677-0276	Masaryk University [MUNI/IGA/1543/2020, MUNI/A/1608/2020]; INTEREXCELLENCE "Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic" [LTC20031]	This study was funded by Masaryk University, grant numbers MUNI/IGA/1543/2020 and MUNI/A/1608/2020. The work of A.P., J.K., M.K. and A.R. was supported by the INTEREXCELLENCE grant number LTC20031-"Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic".	Al-Khanati N.M., 2020, BRAZ J ORAL SCI, V19, pE201354, DOI [10.20396/bjos.v19i0.8661354, DOI 10.20396/BJOS.V19I0.8661354]; Al-Qerem WA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.632914; Alawia R., 2021, J ORAL MED ORAL SURG, V27, P17, DOI [10.1051/mbcb/2020056, DOI 10.1051/MBCB/2020056]; Alawia R, 2022, ORAL DIS, V28, P975, DOI 10.1111/odi.13593; Ali SN, 2021, LANCET, V397, P1443, DOI 10.1016/S0140-6736(21)00779-0; AlMarzooqi LM, 2018, HUM VACC IMMUNOTHER, V14, P2999, DOI 10.1080/21645515.2018.1507667; dos Santos JA, 2021, J DENT RES, V100, P1321, DOI 10.1177/00220345211029637; [Anonymous], Ten Health Issues WHO Will Tackle This Year-World Health Organization; [Anonymous], 2020, GUID PREP WORKPL COV; [Anonymous], 2021, WHO COR DIS COVID 19; [Anonymous], GDPR GEN DATA PROTEC; Argyris YA, 2021, SOC SCI MED, V282, DOI 10.1016/j.socscimed.2021.114043; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Belingheri M, 2021, J AM DENT ASSOC, V152, P740, DOI 10.1016/j.adaj.2021.04.020; BENTLEY CD, 1994, J AM DENT ASSOC, V125, P579, DOI 10.14219/jada.archive.1994.0093; Bloomberg, COV 19 VACC TRACK; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Centers for Disease Control and Prevention (CDC), 2020, EP INFOTM WIND; Checchi V, 2021, INT DENT J, V71, P21, DOI 10.1111/idj.12601; Dzieciolowska S, 2021, AM J INFECT CONTROL, V49, P1152, DOI 10.1016/j.ajic.2021.04.079; Godin G, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-36; Gottlieb S., WALL STREET J; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Hockova B, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040581; International Association of Dental Students (IADS), DEL LIST GOV; Iranmanesh B, 2021, DERMATOL THER, V34, DOI 10.1111/dth.14578; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kateeb E., 2021, INT J DENT ORAL SCI, V8, P1560, DOI [10.19070/2377-8075-21000310, DOI 10.19070/2377-8075-21000310]; Kateeb ET, 2022, INT DENT J, V72, P83, DOI 10.1016/j.identj.2021.01.017; Kelekar AK, 2021, J AM DENT ASSOC, V152, P596, DOI 10.1016/j.adaj.2021.03.006; Kelly BJ, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06023-9; Klugar M, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10080752; KoBoToolbox.org, 2020, KOBOTOOLBOX; Kun E, 2019, ORVOSI HETILAP, V160, P1904, DOI 10.1556/650.2019.31538; Lau M, 2012, VACCINE, V30, P3112, DOI 10.1016/j.vaccine.2012.02.034; Lazarus J.V., 2020, HESITANT NOT GLOBAL, DOI 10.1101/2020.08.23.20180307; Luo C., 2021, AM J INFECT CONTROL, DOI [10.1016/j.ajic.2021.06.020, DOI 10.1016/J.AJIC.2021.06.020]; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; McKee Chephra, 2016, J Pediatr Pharmacol Ther, V21, P104, DOI 10.5863/1551-6776-21.2.104; Motta M., 2021, FRONTIERS POLITICAL, V3, P1, DOI [DOI 10.3389/FPOS.2021.630133, 10.3389/fpos.2021.630133]; Olagoke AA, 2021, J RELIG HEALTH, V60, P65, DOI 10.1007/s10943-020-01090-9; Palestine Chronicle, PAL HLTH MIN START M; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122629; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060673; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060566; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Riad A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.14479; Riad A, 2022, ORAL DIS, V28, P999, DOI 10.1111/odi.13675; Riad A, 2022, ORAL DIS, V28, P988, DOI 10.1111/odi.13635; Roller-Wirnsberger R, 2021, AGING CLIN EXP RES, V33, P2123, DOI 10.1007/s40520-021-01793-3; Rosenbaum L, 2021, NEW ENGL J MED, V384, P1367, DOI 10.1056/NEJMms2101220; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; SPSS Inc, IBM SPSS STAT 27; Stellefson M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041153; Strategic Advisory Group of Experts on Immunization (SAGE), VACC HES SURV QUEST; Trent Mallory, 2022, Vaccine, V40, P2498, DOI 10.1016/j.vaccine.2021.06.048; Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018; WHO, COVID 19 VACC; World Health Organization, WHO DIR GEN OP REM M	61	16	17	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							954	10.3390/vaccines9090954			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3OB	34579190	Green Published, gold			2022-04-29	WOS:000702116600001
J	Rathogwa, NM; Scott, KA; Opperman, P; Theron, J; Maree, FF				Rathogwa, Ntungufhadzeni M.; Scott, Katherine A.; Opperman, Pamela; Theron, Jacques; Maree, Francois F.			Efficacy of SAT2 Foot-and-Mouth Disease Vaccines Formulated with Montanide ISA 206B and Quil-A Saponin Adjuvants	VACCINES			English	Article						foot-and-mouth disease virus; stabilized antigen; adjuvant; vaccine; SAT2	IMMUNE-RESPONSES; EMERGENCY VACCINATION; INTERNATIONAL BANK; VIRUS FMDV; CATTLE; ASSAY; PROTECTION; ANTIGENS; PIGS; QUANTIFICATION	The effective control of foot-and-mouth disease (FMD) relies strongly on the separation of susceptible and infected livestock or susceptible livestock and persistently infected wildlife, vaccination, and veterinary sanitary measures. Vaccines affording protection against multiple serotypes for longer than six months and that are less reliant on the cold chain during handling are urgently needed for the effective control of FMD in endemic regions. Although much effort has been devoted to improving the immune responses elicited through the use of modern adjuvants, their efficacy is dependent on the formulation recipe, target species and administration route. Here we compared and evaluated the efficacy of two adjuvant formulations in combination with a structurally stabilized SAT2 vaccine antigen, designed to have improved thermostability, antigen shelf-life and longevity of antibody response. Protection mediated by the Montanide ISA 206B-adjuvanted or Quil-A Saponin-adjuvanted SAT2 vaccines were comparable. The Montanide ISA 206B-adjuvanted vaccine elicited a higher SAT2 neutralizing antibody response and three times higher levels of systemic IFN-gamma responses at 14- and 28-days post-vaccination (dpv) were observed compared to the Quil-A Saponin-adjuvanted vaccine group. Interestingly, serum antibodies from the immunized animals reacted similarly to the parental vaccine virus and viruses containing mutations in the VP2 protein that simulate antigenic drift in nature.	[Rathogwa, Ntungufhadzeni M.; Scott, Katherine A.; Opperman, Pamela; Maree, Francois F.] Agr Res Council, Onderstepoort Vet Res, Vaccines & Diagnost Dev, ZA-0110 Onderstepoort, South Africa; [Rathogwa, Ntungufhadzeni M.; Theron, Jacques; Maree, Francois F.] Univ Pretoria, Fac Nat & Agr Sci, Dept Biochem Genet & Microbiol, ZA-0002 Pretoria, South Africa; [Opperman, Pamela] Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, ZA-0110 Pretoria, South Africa; [Maree, Francois F.] Clinglobal Ltd, B03-04 Tamarin Commercial Hub,Jacaranda Ave, Tamarin 90903, Mauritius		Maree, FF (通讯作者)，Agr Res Council, Onderstepoort Vet Res, Vaccines & Diagnost Dev, ZA-0110 Onderstepoort, South Africa.; Maree, FF (通讯作者)，Univ Pretoria, Fac Nat & Agr Sci, Dept Biochem Genet & Microbiol, ZA-0002 Pretoria, South Africa.; Maree, FF (通讯作者)，Clinglobal Ltd, B03-04 Tamarin Commercial Hub,Jacaranda Ave, Tamarin 90903, Mauritius.	mactungu@gmail.com; katherineanne.scott@astrazeneca.com; StoreyP@arc.agric.za; jacques.theron@up.ac.za; francois.maree@clinglobal.com		Opperman, Pamela/0000-0003-2313-520X	Animal Health Cluster, Technology Innovation Agency, South Africa (ESCP)	This work was supported by funding from the Animal Health Cluster, Technology Innovation Agency, South Africa (ESCP).	BAHNEMANN HG, 1975, ARCH VIROL, V47, P47, DOI 10.1007/BF01315592; BAHNEMANN HG, 1990, VACCINE, V8, P299, DOI 10.1016/0264-410X(90)90083-X; Barnard AL, 2005, VACCINE, V23, P1037, DOI 10.1016/j.vaccine.2004.07.034; Barnett PV, 2003, VACCINE, V21, P3240, DOI 10.1016/S0264-410X(03)00219-6; Barnett PV, 1996, VACCINE, V14, P1187, DOI 10.1016/S0264-410X(96)00055-2; BARTELING SJ, 1974, ARCH GES VIRUSFORSCH, V45, P362, DOI 10.1007/BF01242879; Bazid AHI, 2021, ARCH VIROL, V166, P1977, DOI 10.1007/s00705-021-05043-9; Blignaut B, 2011, J GEN VIROL, V92, P849, DOI 10.1099/vir.0.027151-0; Bruckner GK, 2002, REV SCI TECH OIE, V21, P751, DOI 10.20506/rst.21.3.1368; Bucafusco D, 2015, VIROLOGY, V476, P11, DOI 10.1016/j.virol.2014.11.023; Callahan JD, 2002, J AM VET MED ASSOC, V220, P1636, DOI 10.2460/javma.2002.220.1636; Capozzo AVE, 1997, VACCINE, V15, P624, DOI 10.1016/S0264-410X(96)00284-8; Carr BV, 2013, J GEN VIROL, V94, P97, DOI 10.1099/vir.0.045732-0; Cloete M, 2008, ONDERSTEPOORT J VET, V75, P17; Coulter A, 1998, VACCINE, V16, P1243, DOI 10.1016/S0264-410X(98)80125-4; Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1; Cox SJ, 1999, VACCINE, V17, P1858, DOI 10.1016/S0264-410X(98)00486-1; DALSGAARD K, 1977, ACTA VET SCAND, V18, P367; Dar P, 2013, VACCINE, V31, P3327, DOI 10.1016/j.vaccine.2013.05.078; DOEL TR, 1985, J BIOL STAND, V13, P335, DOI 10.1016/S0092-1157(85)80048-2; DOEL TR, 1981, ARCH VIROL, V70, P21, DOI 10.1007/BF01320790; DOEL TR, 1990, VACCINE, V8, P473, DOI 10.1016/0264-410X(90)90249-L; Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7; Doherty R, 2013, VET IMMUNOL IMMUNOP, V154, P102, DOI 10.1016/j.vetimm.2013.05.004; Ferguson KJ, 2013, ECOHEALTH, V10, P314, DOI 10.1007/s10393-013-0850-6; Ferris N P, 1992, Rev Sci Tech, V11, P657; Hunter P, 1998, VACCINE, V16, P261, DOI 10.1016/S0264-410X(97)00170-9; Hunter P, 1996, REV SCI TECH OIE, V15, P913, DOI 10.20506/rst.15.3.954; Ibrahim EES, 2015, VET WORLD, V8, P1189, DOI 10.14202/vetworld.2015.1189-1198; Jori F, 2016, TRANSBOUND EMERG DIS, V63, pE58, DOI 10.1111/tbed.12231; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Kotecha A, 2015, NAT STRUCT MOL BIOL, V22, P788, DOI 10.1038/nsmb.3096; Liu, 2013, J BIOSCI MED, V1, P22, DOI DOI 10.4236/jbm.2013.13005; Maree FF, 2011, J GEN VIROL, V92, P2297, DOI 10.1099/vir.0.032839-0; Maree FF, 2015, VACCINE, V33, P2909, DOI 10.1016/j.vaccine.2015.04.058; Maree FF, 2010, VIRUS RES, V153, P82, DOI 10.1016/j.virusres.2010.07.010; MCCULLOUGH KC, 1992, J VIROL, V66, P1835, DOI 10.1128/JVI.66.4.1835-1840.1992; Oh Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044365; Opperman PA, 2014, J VIROL, V88, P8307, DOI 10.1128/JVI.00470-14; Park ME, 2014, VACCINE, V32, P5221, DOI 10.1016/j.vaccine.2014.07.040; Patch JR, 2011, CLIN VACCINE IMMUNOL, V18, P280, DOI 10.1128/CVI.00417-10; Patil PK, 2002, VACCINE, V20, P2781, DOI 10.1016/S0264-410X(02)00184-6; PAY TWF, 1987, VACCINE, V5, P60, DOI 10.1016/0264-410X(87)90011-9; RIEDER E, 1994, J VIROL, V68, P7092, DOI 10.1128/JVI.68.11.7092-7098.1994; ROEDER PL, 1987, RES VET SCI, V43, P225, DOI 10.1016/S0034-5288(18)30778-1; SALT JS, 1993, BRIT VET J, V149, P207, DOI 10.1016/S0007-1935(05)80168-X; Schiller I, 2009, CLIN VACCINE IMMUNOL, V16, P1196, DOI 10.1128/CVI.00150-09; Scott KA, 2017, VACCINE, V35, P5426, DOI 10.1016/j.vaccine.2017.02.003; Scott KA, 2017, J VIROL, V91, DOI [10.1128/jvi.02312-16, 10.1128/JVI.02312-16]; Sorensen KJ, 1998, ARCH VIROL, V143, P1461, DOI 10.1007/s007050050390; Storey P, 2007, VIRUS RES, V124, P184, DOI 10.1016/j.virusres.2006.11.003; Sutmoller P, 2003, VIRUS RES, V91, P101, DOI 10.1016/S0168-1702(02)00262-9; Vosloo W, 2002, REV SCI TECH OIE, V21, P437, DOI 10.20506/rst.21.3.1349; World Organization for Animal Health (OIE), 2018, MANUAL DIAGNOSTIC TE; World Organization for Animal Health (OIE), 2016, TERR AN HLTH COD	55	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							996	10.3390/vaccines9090996			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3WJ	34579233	Green Published, gold			2022-04-29	WOS:000702138600001
J	Wahyuningtyas, R; Lai, YS; Wu, ML; Chen, HW; Chung, WB; Chaung, HC; Chang, KT				Wahyuningtyas, Rika; Lai, Yin-Siew; Wu, Mei-Li; Chen, Hsin-Wei; Chung, Wen-Bin; Chaung, Hso-Chi; Chang, Ko-Tung			Recombinant Antigen of Type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV-2) Promotes M1 Repolarization of Porcine Alveolar Macrophages and Th1 Type Response	VACCINES			English	Article						PAMs; CD163; PRRSV; M1; M2; Th1	T-CELL; VACCINE; CD163; POLARIZATION; RECEPTORS; STRAIN; SUPPRESSION; ACTIVATION; CHALLENGES; PHENOTYPE	The polarization status of porcine alveolar macrophages (PAMs) determines the infectivity of porcine reproductive and respiratory syndrome virus (PRRSV). PRRSV infection skews macrophage polarization toward an M2 phenotype, followed by T-cells inactivation. CD163, one of the scavenger receptors of M2 macrophages, has been described as a putative receptor for PRRSV. In this study, we examined two types of PRRSV-2-derived recombinant antigens, A1 (g6Ld10T) and A2 (lipo-M5Nt), for their ability to mediate PAM polarization and T helper (Th1) response. A1 and A2 were composed of different combination of ORF5, ORF6, and ORF7 in full or partial length. To enhance the adaptive immunity, they were conjugated with T cells epitopes or lipidated elements, respectively. Our results showed that CD163(+) expression on PAMs significantly decreased after being challenged with A1 but not A2, followed by a significant increase in pro-inflammatory genes (TNF-alpha, IL-6, and IL-12). In addition, next generation sequencing (NGS) data show an increase in T-cell receptor signaling in PAMs challenged with A1. Using a co-culture system, PAMs challenged with A1 can induce Th1 activation by boosting IFN-gamma and IL-12 secretion and TNF-alpha expression. In terms of innate and T-cell-mediated immunity, we conclude that A1 is regarded as a potential vaccine for immunization against PRRSV infection due to its ability to reverse the polarization status of PAMs toward pro-inflammatory phenotypes, which in turn reduces CD163 expression for viral entry and increases immunomodulation for Th1-type response.	[Wahyuningtyas, Rika; Lai, Yin-Siew; Wu, Mei-Li; Chaung, Hso-Chi; Chang, Ko-Tung] Natl Pingtung Univ Sci & Technol, Res Ctr Anim Biol, Pingtung 912, Taiwan; [Wahyuningtyas, Rika; Chung, Wen-Bin; Chaung, Hso-Chi] Natl Pingtung Univ Sci & Technol, Dept Vet Med, Pingtung 912, Taiwan; [Wu, Mei-Li] Natl Pingtung Univ Sci & Technol, Dept Food Sci, Pingtung 912, Taiwan; [Chen, Hsin-Wei] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Miaoli 350, Taiwan; [Chen, Hsin-Wei] China Med Univ, Grad Inst Biomed Sci, Taichung 400, Taiwan; [Chen, Hsin-Wei] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 800, Taiwan; [Chaung, Hso-Chi; Chang, Ko-Tung] Natl Pingtung Univ Sci & Technol, Flow Cytometry Ctr, Precis Instruments Ctr, Pingtung 912, Taiwan; [Chang, Ko-Tung] Natl Pingtung Univ Sci & Technol, Dept Biol Sci & Technol, Pingtung 912, Taiwan		Chaung, HC; Chang, KT (通讯作者)，Natl Pingtung Univ Sci & Technol, Res Ctr Anim Biol, Pingtung 912, Taiwan.; Chaung, HC (通讯作者)，Natl Pingtung Univ Sci & Technol, Dept Vet Med, Pingtung 912, Taiwan.; Chaung, HC; Chang, KT (通讯作者)，Natl Pingtung Univ Sci & Technol, Flow Cytometry Ctr, Precis Instruments Ctr, Pingtung 912, Taiwan.; Chang, KT (通讯作者)，Natl Pingtung Univ Sci & Technol, Dept Biol Sci & Technol, Pingtung 912, Taiwan.	rikawahyurizky@gmail.com; rindy.0802@gmail.com; mlwu@mail.npustedu.tw; chenhw@nhri.org.tw; wbchung@mail.npust.edu.tw; hcchaung@mail.npust.edu.tw; kotungc@mail.npust.edu.tw	Chen, Hsin-Wei/ABA-7436-2021	Chen, Hsin-Wei/0000-0002-3207-2397; Chang, Ko-Tung/0000-0001-9383-831X; Lai, Yin Siew/0000-0003-2963-9038; Wahyuningtyas, Rika/0000-0002-4150-266X	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST 107-3017-F-020-001-, MOST 108-3017-F-020 -001-, MOST 109-2634-F-020-001-, MOST 110-2634-F-020-001-, MOST 109-2314-B-020-002, MOST 110-2314-B-020-003]; Research Center for Animal Biologics; Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education	This study was financially supported by the Research Center for Animal Biologics, from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education and the Ministry of Science and Technology (MOST 107-3017-F-020-001-, MOST 108-3017-F-020 -001-, MOST 109-2634-F-020-001-, MOST 110-2634-F-020-001-, MOST 109-2314-B-020-002, MOST 110-2314-B-020-003), Taiwan.	Alvarado-Vazquez PA, 2017, IMMUNOBIOLOGY, V222, P900, DOI 10.1016/j.imbio.2017.05.011; Aramburu J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00535; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brinton MA, 2021, J GEN VIROL, V102, DOI 10.1099/jgv.0.001632; Burks J, 2019, CANCER IMMUNOL IMMUN, V68, P2029, DOI 10.1007/s00262-019-02422-9; Buxade M, 2012, J EXP MED, V209, P379, DOI 10.1084/jem.20111569; Calvert JG, 2007, J VIROL, V81, P7371, DOI 10.1128/JVI.00513-07; Campbell L, 2014, J INVEST DERMATOL, V134, P2447, DOI 10.1038/jid.2014.175; Carty SA, 2018, HEMATOLOGY BASIC PRI, VSeventh, P221, DOI 10.1016/B978-0-323-35762-3.00021-4; Chen NH, 2016, INFECT GENET EVOL, V40, P167, DOI 10.1016/j.meegid.2016.03.002; Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299; Conley JM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00076; Cox M.M., 2009, DEV INFLUENZA VIRUS; Crisci E, 2019, VET SCI, V6, DOI 10.3390/vetsci6010026; Das PB, 2010, J VIROL, V84, P1731, DOI 10.1128/JVI.01774-09; Ezquerra A, 2009, DEV COMP IMMUNOL, V33, P284, DOI 10.1016/j.dci.2008.06.002; Fang LR, 2006, VIRUS GENES, V32, P5, DOI 10.1007/s11262-005-5839-y; Friederichs K, 2001, EUR J BIOCHEM, V268, P6401, DOI 10.1046/j.0014-2956.2001.02586.x; Furiati SC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43899-9; Duran MG, 2016, J VIROL METHODS, V236, P77, DOI 10.1016/j.jviromet.2016.03.021; Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569; Gilbert SC, 2012, IMMUNOLOGY, V135, P19, DOI 10.1111/j.1365-2567.2011.03517.x; Gujer C, 2011, J LEUKOCYTE BIOL, V89, P811, DOI 10.1189/jlb.0810460; Han K, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-12; Han QL, 2016, INT IMMUNOPHARMACOL, V34, P101, DOI 10.1016/j.intimp.2016.01.023; Han YW, 2011, COMP IMMUNOL MICROB, V34, P335, DOI 10.1016/j.cimid.2011.04.001; Hu JM, 2017, ONCOTARGET, V8, P21526, DOI 10.18632/oncotarget.15630; Hwang JR, 2020, EXP MOL MED, V52, P750, DOI 10.1038/s12276-020-0435-8; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kang H, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1480-6; Kappes MA, 2015, VIROLOGY, V479, P475, DOI 10.1016/j.virol.2015.02.012; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Kimman TG, 2009, VACCINE, V27, P3704, DOI 10.1016/j.vaccine.2009.04.022; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lee Kun Yeong, 2019, Medical Bilogical Science and Engineering, V2, P1, DOI 10.30579/mbse.2019.2.1.1; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li X, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/416727; Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Meng XJ, 2000, VET MICROBIOL, V74, P309, DOI 10.1016/S0378-1135(00)00196-6; Mengeling WL, 2003, VET MICROBIOL, V93, P13, DOI 10.1016/S0378-1135(02)00427-3; Mills CD, 2016, CANCER RES, V76, P513, DOI 10.1158/0008-5472.CAN-15-1737; Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10; Muraille E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00603; Murtaugh M.P., 2004, ANN M AM ASS SWIN VE, V359, P367; Nakanishi K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00763; Nascimento IP, 2012, BRAZ J MED BIOL RES, V45, P1102, DOI 10.1590/S0100-879X2012007500142; Nazimek K, 2015, IMMUNOLOGY, V146, P23, DOI 10.1111/imm.12466; Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001; Novakovic P, 2016, VET RES, V47, DOI 10.1186/s13567-016-0364-7; Nygard AB, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-67; Opriessnig T, 2002, J VIROL, V76, P11837, DOI 10.1128/JVI.76.23.11837-11844.2002; Parida R., 2012, CELL MEDIATED IMMUNI; Pesente P, 2006, VET MICROBIOL, V114, P214, DOI 10.1016/j.vetmic.2005.11.061; Rayees S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02091; Rodriguez-Gomez IM, 2019, VET MICROBIOL, V235, P101, DOI 10.1016/j.vetmic.2019.06.011; Rompato G, 2006, VET IMMUNOL IMMUNOP, V109, P151, DOI 10.1016/j.vetimm.2005.08.015; Salerno-Goncalves R, 2006, TRENDS MICROBIOL, V14, P536, DOI 10.1016/j.tim.2006.10.004; Sanchez EG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09948-x; Schmidt A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00051; Secombes CJ, 2012, WOODHEAD PUBL FOOD S, P3; Sewell HF, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4838; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Skapenko A, 2005, ARTHRITIS RES THER, V7, pS4, DOI 10.1186/ar1703; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tellechea M, 2018, J IMMUNOL, V200, P305, DOI 10.4049/jimmunol.1601942; Tripathi NK, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00420; Van Gucht S, 2004, VET IMMUNOL IMMUNOP, V102, P165, DOI 10.1016/j.vetimm.2004.09.006; Veloso P, 2020, CLIN ORAL INVEST, V24, P4571, DOI 10.1007/s00784-020-03324-2; Voss F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020310; Wang LT, 2017, J VET MED SCI, V79, P1906, DOI 10.1292/jvms.17-0258; Wang XL, 2009, VIRUS RES, V143, P24, DOI 10.1016/j.virusres.2009.02.017; Wei CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47239-9; Wissink EHJ, 2005, J VIROL, V79, P12495, DOI 10.1128/JVI.79.19.12495-12506.2005; Wood L, 2015, J IMMUNOL, V194; Yao YL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00792; Zhang C, 2018, ONCOTARGET, V9, P2175, DOI [10.18632/oncotarget.23299, 10.18632/oncotarget.25667]; Zhang QZ, 2015, VET MICROBIOL, V177, P229, DOI 10.1016/j.vetmic.2015.04.002; Zhu ZB, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00501	81	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1009	10.3390/vaccines9091009			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2XO	34579246	Green Published, gold			2022-04-29	WOS:000702073400001
J	Araujo, OC; de Paula, VS; do O, KM; Villela-Nogueira, CA; Araujo, NM				Araujo, Oscar C.; de Paula, Vanessa S.; do O, Kycia M.; Villela-Nogueira, Cristiane A.; Araujo, Natalia M.			Association of Polymorphisms in the Glutathione S-Transferase Theta-1 Gene with Cirrhosis and Hepatocellular Carcinoma in Brazilian Patients with Chronic Hepatitis C	VACCINES			English	Article						hepatitis C virus; glutathione S-transferases; cirrhosis; hepatocellular carcinoma; polymorphisms	VIRUS-INFECTION; RISK-FACTORS; GSTM1; M1; SUSCEPTIBILITY; LOCUS; GSTT1	Oxidative stress contributes to hepatitis C virus (HCV)-induced liver damage. Host genetic factors may be involved in progression of HCV infection. The present study was conducted to determine the influence of glutathione S-transferase (GST)-M1 and T1 gene polymorphisms during different stages of HCV infection, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). The study population comprised 190 patients (47 with chronic hepatitis, 83 with cirrhosis (without HCC), and 60 with HCC). GSTM1 and GSTT1 gene polymorphisms were analyzed via multiplex polymerase chain reaction. The GSTT1-null genotype was more commonly detected in patients with cirrhosis (n = 17; 20.5%) and HCC (n = 13; 21.7%) than those with chronic hepatitis (n = 3; 6.4%). The differences in GSTT1-null genotype frequencies were significant for cirrhosis vs. chronic hepatitis (odds ratio, OR, 3.778 (95% confidence interval, CI, 1.045-13.659); p = 0.043) and HCC vs. chronic hepatitis (OR, 4.057 (95% CI, 1.083-15.201); p = 0.038) groups. However, the incidence of individual GSTM1-null or combined GSTM1/GSTT1 double-null genotypes did not vary significantly between the groups. Our collective findings support the utility of the GSTT1-null genotype as a useful biomarker for liver disease progression in Brazilian patients with chronic hepatitis C.	[Araujo, Oscar C.; de Paula, Vanessa S.; Araujo, Natalia M.] Fiocruz MS, Oswaldo Cruz Inst, Lab Mol Virol, BR-21040360 Rio De Janeiro, Brazil; [do O, Kycia M.] Sao Lucas Hosp, BR-25660290 Petropolis, RJ, Brazil; [Villela-Nogueira, Cristiane A.] Univ Fed Rio de Janeiro, Clementino Fraga Filho Univ Hosp, Sch Med, Hepatol Div, BR-21941617 Rio De Janeiro, Brazil		Araujo, NM (通讯作者)，Fiocruz MS, Oswaldo Cruz Inst, Lab Mol Virol, BR-21040360 Rio De Janeiro, Brazil.	araujo.orc@gmail.com; vdepaula@ioc.fiocruz.br; kyciadoo@gmail.com; crisvillelanog@gmail.com; nmaraujo@ioc.fiocruz.br	Araujo, Natalia M/B-6596-2013	Motta de Araujo, Natalia/0000-0001-9037-1304; de Paula, Vanessa/0000-0002-6314-754X	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [428676/2018-9]; Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ) [E-26/210.450/2019]	This research was funded by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), grant number 428676/2018-9, and Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), grant number E-26/210.450/2019.	AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; Caruso S, 2021, HEPATOLOGY, V73, P14, DOI 10.1002/hep.31394; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Ferreira GD, 2021, XENOBIOTICA, V51, P737, DOI 10.1080/00498254.2021.1893408; Fujiwara N, 2018, J HEPATOL, V68, P526, DOI 10.1016/j.jhep.2017.09.016; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; IARC International Agency for Research on Cancer, GLOB 2020; Ibrahim AM, 2016, ANN HUM GENET, V80, P32, DOI 10.1111/ahg.12138; INCA, TIP CANC CANC FIG; Kanda T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061358; Koike K, 2006, HEPATOL RES, V34, P65, DOI 10.1016/j.hepres.2005.11.001; Kumar V, 2011, NAT GENET, V43, P455, DOI 10.1038/ng.809; Li SL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0792-3; Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057043; Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3; Martinez C, 2007, J INFECT DIS, V195, P1320, DOI 10.1086/513569; McIlwain CC, 2006, ONCOGENE, V25, P1639, DOI 10.1038/sj.onc.1209373; Miki D, 2011, NAT GENET, V43, P797, DOI 10.1038/ng.876; Nahon P, 2012, J HEPATOL, V57, P663, DOI 10.1016/j.jhep.2012.02.035; Paranagua-Vezozzo DC, 2014, ANN HEPATOL, V13, P386, DOI 10.1016/S1665-2681(19)30845-2; Pena SDJ, 2020, AM J MED GENET C, V184, P928, DOI 10.1002/ajmg.c.31853; Ravi S, 2017, GASTROENTEROLOGY, V152, P911, DOI 10.1053/j.gastro.2016.12.021; Roche B, 2018, LIVER INT, V38, P139, DOI 10.1111/liv.13659; Shen YH, 2014, TUMOR BIOL, V35, P4007, DOI 10.1007/s13277-013-1524-2; Sherratt PJ, 1997, BIOCHEM J, V326, P837, DOI 10.1042/bj3260837; Sun FC, 2014, J MED BIOCHEM, V33, P259, DOI 10.2478/jomb-2013-0028; Unal M, 2007, BRIT J OPHTHALMOL, V91, P527, DOI 10.1136/bjo.2006.102418; WHO The World Health Organization, FACT SHEETS HEP C; Zhang C, 2020, GENE, V735, DOI 10.1016/j.gene.2020.144365	30	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							831	10.3390/vaccines9080831			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3ZZ	34451956	Green Published, gold			2022-04-29	WOS:000689874700001
J	Faggiano, F; Rossi, MA; Cena, T; Milano, F; Barale, A; Ristagno, Q; Silano, V				Faggiano, Fabrizio; Rossi, Maicol Andrea; Cena, Tiziana; Milano, Fulvia; Barale, Antonella; Ristagno, Quenya; Silano, Virginia			An Outbreak of COVID-19 among mRNA-Vaccinated Nursing Home Residents	VACCINES			English	Article						COVID-19; SARS-CoV-2; nursing home; long-term care; COVID-19 vaccines	ILLNESS RATING-SCALE; VALIDATION; BURDEN	An outbreak was described among the guests of a Long-Term Care Facility in the North of Italy. Among 23 guests, 20 of whom were fully vaccinated with BNT162b2 vaccine, the outbreak led to a final count of 11 positive guests, 9 of whom were vaccinated, and 4 positive healthcare workers, of whom only 1 was vaccinated. Eight of the positive guests (six vaccinated and two unvaccinated) had symptoms that in five cases (three vaccinated and two unvaccinated) led to death. The risk of infection and the risk of death appeared not to be correlated with the health status neither with the serological titer, but only with age.	[Faggiano, Fabrizio; Rossi, Maicol Andrea] Univ Piemonte Orientale, Dept Translat Med, I-28100 Novara, Italy; [Faggiano, Fabrizio; Cena, Tiziana; Barale, Antonella] ASL Vercelli, Epidemiol Unit, I-13100 Vercelli, Italy; [Milano, Fulvia] ASL Vercelli, Lab Unit, I-13100 Vercelli, Italy; [Ristagno, Quenya; Silano, Virginia] ASL Vercelli, Publ Hlth Unit, I-13100 Vercelli, Italy		Rossi, MA (通讯作者)，Univ Piemonte Orientale, Dept Translat Med, I-28100 Novara, Italy.	fabrizio.faggiano@uniupo.it; 20034828@studenti.uniupo.it; tiziana.cena@aslvc.piemonte.it; fulvia.milano@aslvc.piemonte.it; antonella.barale@aslvc.piemonte.it; quenya.ristagno@aslvc.piemonte.it; virginia.silano@aslvc.piemonte.it					Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; CONWELL Y, 1993, J AM GERIATR SOC, V41, P38, DOI 10.1111/j.1532-5415.1993.tb05945.x; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Fisher MJ, 2021, AM J INFECT CONTROL, V49, P1210, DOI [10.1016/j.ajic.2021.06.010, 10.1016/j.ajic.2021.06.0100196-6553/]; Harboun M, 2001, REV EPIDEMIOL SANTE, V49, P287; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Istituto Superiore di Sanita, 2021, SORV STRUTT RES SOC; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x; MAHONEY F I, 1965, Md State Med J, V14, P61; Mazagatos C, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100452; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Ministero della Salute, VACC ANTISARS COV 2; Mistry R, 2004, J GERONTOL A-BIOL, V59, P1068; PARMELEE PA, 1995, J AM GERIATR SOC, V43, P130, DOI 10.1111/j.1532-5415.1995.tb06377.x; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Salvi F, 2008, J AM GERIATR SOC, V56, P1926, DOI 10.1111/j.1532-5415.2008.01935.x; Shrotri M, 2021, LANCET INFECT DIS, V21, P1529, DOI 10.1016/S1473-3099(21)00289-9; White EM, 2021, NEW ENGL J MED, V385, P474, DOI 10.1056/NEJMc2104849	21	3	3	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							859	10.3390/vaccines9080859			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3PJ	34451984	Green Published, gold			2022-04-29	WOS:000689847100001
J	Garcia-Toledano, E; Palomares-Ruiz, A; Cebrian-Martinez, A; Lopez-Parra, E				Garcia-Toledano, Eduardo; Palomares-Ruiz, Ascension; Cebrian-Martinez, Antonio; Lopez-Parra, Emilio			Health Education and Vaccination for the Construction of Inclusive Societies	VACCINES			English	Article						vaccines; public health; vaccine reluctance; education; inclusive societies; COVID-19; immunization; bootstrap; gender		Globalization has led to what has happened in a certain part of the world having a significant and rapid impact on other places, causing significant changes in health problems. In the last quarter of the 18th century, the history of vaccination began, becoming an effective tool to prevent and control communicable diseases. This paper proposes an observational research with a cross-sectional design to study the importance of health education and vaccination in building inclusive societies. With a sample of 1000 participants from 76 countries, vaccine awareness and regulation were analyzed, considering the following variables: gender, age, sector, Human Development Index (HDI), and continent. The instrument used was a questionnaire (VACUNASEDUCA) developed for this research and timely validated. As a result, it is highlighted that the profiles of women, people under 30 years of age, education sector, high Human Development Index, and European continent are those that most value the importance of raising awareness in society and the regulation of actions for vaccination compliance. The consequences of "vaccine reluctance" are of concern in every country on the planet. Therefore, it is concluded that effective and evidence-based communication is key to allaying fears and promoting acceptance of vaccination around the world, building inclusive societies in which all citizens enjoy the health benefits.	[Garcia-Toledano, Eduardo] Childhood Canc Fdn, Dept Publ Hlth, Madrid 28029, Spain; [Palomares-Ruiz, Ascension; Cebrian-Martinez, Antonio; Lopez-Parra, Emilio] Univ Castilla La Mancha, Dept Pedag, Albacete 02071, Spain		Palomares-Ruiz, A (通讯作者)，Univ Castilla La Mancha, Dept Pedag, Albacete 02071, Spain.	Toledanoeg@gmail.com; Ascension.Palomares@uclm.es; Antonio.Cebrian@uclm.es; Emilio.LopezParra@uclm.es	Cebrián, Antonio/AAW-7944-2020; PALOMARES RUIZ, ASCENSION/V-4788-2017	Cebrián, Antonio/0000-0001-6946-5488; PALOMARES RUIZ, ASCENSION/0000-0003-3350-2341; LOPEZ PARRA, EMILIO/0000-0002-9785-0815; GARCIA-TOLEDANO, EDUARDO/0000-0003-4924-8122	Ministry of Education, Culture and Sports of Castilla-La Mancha [SBPLY/000149]; European Regional Development Funds (ERDF)European Commission [SBPLY/000149]	This research has received assistance from the Scientific Research and Technology Transfer Project (SBPLY/000149) funded by the Ministry of Education, Culture and Sports of Castilla-La Mancha and European Regional Development Funds (ERDF).	Aquino-Canchari. C., 2020, REV CUBA INVESTIG BI, V39, P1; Cabero-Almenara J., 2013, EDUWEB REV TECNOL IN, V7, P11; Casino G., 2018, VACUNAS ESPANA SITUA, P1; Piqueras MC, 2019, GAC SANIT, V33, P53, DOI 10.1016/j.gaceta.2017.07.004; Escobar Jasmine., 2008, AV MED, V6, P27, DOI DOI 10.1016/0032-3861(78)90049-6; European Union, 2010, CARTA DERECHOS FUNDA, P15; Fernandez-Nino J., 2019, SALUD UIS, V51, P103, DOI [10.18273/revsal.v51n2-2019002, DOI 10.18273/REVSAL.V51N2-2019002]; Perales RG, 2020, REV ESP ORIENTAC PSI, V31, P78, DOI 10.5944/reop.vol.31.num.2.2020.27987; Garcia-Toledano E., 2020, THESIS U CASTILLA MA; Garcia-Toledano E., 2021, ABC; Gil C.G., 2018, PAP RELAC ECOSOCIALE, V140, P107; Gil-Flores J., 2005, REV ED, V33, P251; Global Alliance for Vaccines and Immunization, 2019, IMM SUST DEV GOALS; Gonzalez Garcia R, 2021, REV ESP CIR ORAL MAX, V43, P1, DOI [10.20986/recom.2021.1279/2021, DOI 10.20986/RECOM.2021.1279/2021]; International Vaccine Access Center (IVAC), 2019, METH REP DEC VACC EC, P1; Jasarevic T., 2015, VACCINE HESITANCY GR; Jenner E., 1798, INQUIRY CAUSES EFFEC; Kerlinger F, 2002, INVESTIGACION COMPOR; LAWSHE CH, 1975, PERS PSYCHOL, V28, P563, DOI 10.1111/j.1744-6570.1975.tb01393.x; Méndez Martínez Carolina, 2012, rev.colomb.psiquiatr., V41, P197, DOI 10.1016/S0034-7450(14)60077-9; Matesanz R, 2021, RED MED; Olmedo M.C., 2008, REV ADM SANIT SIGLO, V6, P729; Patel M, 2019, MMWR-MORBID MORTAL W, V68, P893, DOI 10.15585/mmwr.mm6840e2; Pead PJ, 2003, LANCET, V362, P2104, DOI 10.1016/S0140-6736(03)15111-2; Perez Pelea Leneidy, 2018, Revista del Jardin Botanico Nacional, V39, P1; Scholz N., 2020, NUEVO PROGRAMA SALUD; Schwab K., 2016, CUARTA REVOLUCION IN; Benedicto AS, 2012, GAC SANIT, V26, P366, DOI 10.1016/j.gaceta.2011.11.018; Simon J.L., 1991, CHANCE, V4, P22; Simon J.L., 1997, RESAMPLING NEW STAT; Swaminathan S., 2021, BBC NEWS MUNDO; United Nations Educational Scientific and Cultural Organization, 2020, INF SEG ED MUND 2020; Urbiztondo L, 2020, Vacunas, V21, P69, DOI 10.1016/j.vacun.2020.04.002; WHO, 2020, IMM AG 2030 GLOB STR; WHO, 2013, GLOB VACC ACT PLAN 2; Willis NJ, 1997, SCOT MED J, V42, P118, DOI 10.1177/003693309704200407	36	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							813	10.3390/vaccines9080813			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4DM	34451938	Green Published			2022-04-29	WOS:000689883800001
J	Guo, MN; Li, JJ; Teng, ZD; Ren, M; Dong, H; Zhang, Y; Ru, JX; Du, P; Sun, SQ; Guo, HC				Guo, Mengnan; Li, Jiajun; Teng, Zhidong; Ren, Mei; Dong, Hu; Zhang, Yun; Ru, Jiaxi; Du, Ping; Sun, Shiqi; Guo, Huichen			Four Simple Biomimetic Mineralization Methods to Improve the Thermostability and Immunogenicity of Virus-like Particles as a Vaccine against Foot-and-Mouth Disease	VACCINES			English	Article						foot-and-mouth disease; virus-like particles; biomineralization; thermal stability; biomimetic	BIOMINERALIZATION; SILICIFICATION	The need for a cold chain system during storage and transport substantially increases the cost of vaccines. Virus-like particles (VLPs) are among the best countermeasures against foot and mouth disease virus (FMDV). However, VLPs are composed of pure proteins, and thus, are susceptible to heat. To address this problem, four simple biomimetic mineralization methods with the use of calcium phosphate were developed to improve heat tolerance via biomineralization. The results showed that biomineralization can significantly improve the heat resistance of VLPs. The biomineralized VLPs can be stored at low as 25 degrees C for eight days, and 37 degrees C for four days. Animal experiments showed that biomineralization had no effect on the immunogenicity of VLPs or the expression of specific antibodies (Abs) and neutralizing Abs. Even after heat treatment at 37 degrees C for four days, the biomineralized VLPs remained immunogenic and produced highly specific and neutralizing Abs with a high rate of protection. These results suggest that these biomineralization approaches can promote the thermal stability of VLPs against and significantly reduce dependence on cold storage and delivery systems.	[Guo, Mengnan; Li, Jiajun; Teng, Zhidong; Ren, Mei; Dong, Hu; Zhang, Yun; Ru, Jiaxi; Du, Ping; Sun, Shiqi; Guo, Huichen] Chinese Acad Agr Sci, State Key Lab Vet Etiol Biol, Natl Foot & Mouth Dis Reference Lab, Lanzhou Vet Res Inst, Lanzhou 730030, Peoples R China; [Sun, Shiqi; Guo, Huichen] Yangtze Univ, Coll Anim Sci, Jingzhou 434025, Peoples R China; [Guo, Huichen] Yunnan Anim Sci & Vet Inst, Yunnan Trop & Subtrop Anim Virus Dis Lab, Kunming 650000, Yunnan, Peoples R China		Guo, HC (通讯作者)，Chinese Acad Agr Sci, State Key Lab Vet Etiol Biol, Natl Foot & Mouth Dis Reference Lab, Lanzhou Vet Res Inst, Lanzhou 730030, Peoples R China.; Guo, HC (通讯作者)，Yangtze Univ, Coll Anim Sci, Jingzhou 434025, Peoples R China.; Guo, HC (通讯作者)，Yunnan Anim Sci & Vet Inst, Yunnan Trop & Subtrop Anim Virus Dis Lab, Kunming 650000, Yunnan, Peoples R China.	guomengnan2021@163.com; jiajunlii@163.com; tengzhidong163@163.com; Mei.Ren@student.uliege.be; donghu.0608@163.com; zhangyun03@caas.cn; rujiaxi@caas.cn; westernboydp555@163.com; sunshiqi@caas.cn; guohuichen@caas.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31672592]; National Key Research and Development Program [2017YFD0500900, 2017YFD0501100, 2016YFE0204100]; Central Public-interest Scientific Institution Basal Research Fund [Y2020XK22]; Central Public-Interest Scientific Institution Basal Research Fund [1610312016002, 1610312018003, Y2017JC57]	This work was supported by grants from the National Natural Science Foundation of China (31672592), the National Key Research and Development Program (2017YFD0500900, 2017YFD0501100, 2016YFE0204100), the Central Public-interest Scientific Institution Basal Research Fund (Y2020XK22), and the Central Public-Interest Scientific Institution Basal Research Fund (1610312016002, 1610312018003, Y2017JC57).	Brandau DT, 2003, J PHARM SCI-US, V92, P218, DOI 10.1002/jps.10296; Buonaguro L, 2010, CURR HIV RES, V8, P299, DOI 10.2174/157016210791208659; Cai YR, 2008, J MATER CHEM, V18, P3775, DOI 10.1039/b805407j; Chu XB, 2011, J PHYS CHEM B, V115, P1151, DOI 10.1021/jp106863q; Combes C, 2010, ACTA BIOMATER, V6, P3362, DOI 10.1016/j.actbio.2010.02.017; Cox SJ, 2009, VET RES, V40, DOI 10.1051/vetres:2008051; David V, 2011, AM J PHYSIOL-RENAL, V300, pF783, DOI 10.1152/ajprenal.00304.2010; Domingo E, 2003, VIRUS RES, V91, P47, DOI 10.1016/S0168-1702(02)00259-9; Dong H, 2021, PROTEIN CELL, DOI 10.1007/s13238-021-00828-9; Du P, 2019, NANOSCALE, V11, P22748, DOI 10.1039/c9nr05549e; George A, 2008, CHEM REV, V108, P4670, DOI 10.1021/cr0782729; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; Guo HC, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-48; Hill AB, 2016, CURR OPIN BIOTECH, V42, P67, DOI 10.1016/j.copbio.2016.03.002; Jamal SM, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-116; Jegerlehner A, 2002, EUR J IMMUNOL, V32, P3305, DOI 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J; Khalifehzadeh R, 2020, ADV COLLOID INTERFAC, V279, DOI 10.1016/j.cis.2020.102157; Laidler JR, 2010, ASTROBIOLOGY, V10, P569, DOI 10.1089/ast.2010.0463; Li J, 2010, J CONTROL RELEASE, V142, P416, DOI 10.1016/j.jconrel.2009.11.008; Liu YQ, 2015, VET RES, V46, DOI 10.1186/s13567-015-0273-1; Michel ML, 2010, PATHOL BIOL, V58, P288, DOI 10.1016/j.patbio.2010.01.006; Middelberg APJ, 2011, VACCINE, V29, P7154, DOI 10.1016/j.vaccine.2011.05.075; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; Mitragotri S, 2009, NAT MATER, V8, P15, DOI [10.1038/NMAT2344, 10.1038/nmat2344]; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Nudelman F, 2012, ANGEW CHEM INT EDIT, V51, P6582, DOI 10.1002/anie.201106715; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Pagnotta SE, 2010, J PHYS CHEM B, V114, P4904, DOI 10.1021/jp911940h; Parida S, 2009, EXPERT REV VACCINES, V8, P347, DOI 10.1586/14760584.8.3.347; Park K, 2011, J CONTROL RELEASE, V152, P329, DOI 10.1016/j.jconrel.2011.05.015; Qian CY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010139; Ribeiro-Muller L, 2014, CLIN DERMATOL, V32, P235, DOI 10.1016/j.clindermatol.2013.08.008; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Rowe PSN, 2004, BONE, V34, P303, DOI 10.1016/j.bone.2003.10.005; Tavafoghi M, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0462; Wahid AA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47657-9; Wang G., 2012, ANGEW CHEM, V124, P10728, DOI DOI 10.1002/ANGE.201206154; Wang GC, 2015, ACS NANO, V9, P799, DOI 10.1021/nn5063276; Wang GC, 2013, P NATL ACAD SCI USA, V110, P7619, DOI 10.1073/pnas.1300233110; Yoon H, 2012, TRANSBOUND EMERG DIS, V59, P517, DOI 10.1111/j.1865-1682.2011.01304.x; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zhang S, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-333	42	0	0	2	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							891	10.3390/vaccines9080891			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3BC	34452016	Green Published, gold			2022-04-29	WOS:000689810000001
J	Hanna, J; Tipparaju, P; Mulherkar, T; Lin, E; Mischley, V; Kulkarni, R; Bolton, A; Byrareddy, SN; Jain, P				Hanna, John; Tipparaju, Padmavathi; Mulherkar, Tania; Lin, Edward; Mischley, Victoria; Kulkarni, Ratuja; Bolton, Aliyah; Byrareddy, Siddappa N.; Jain, Pooja			Risk Factors Associated with the Clinical Outcomes of COVID-19 and Its Variants in the Context of Cytokine Storm and Therapeutics/Vaccine Development Challenges	VACCINES			English	Review						SARS-CoV-1; SARS-CoV-2; COVID-19; IL-6; cytokine storm	ACUTE RESPIRATORY SYNDROME; TOLL-LIKE RECEPTORS; DC-SIGN; VITAMIN-D; SYNDROME CORONAVIRUS; BLOOD-GROUP; SARS-COV; SUSCEPTIBILITY; EXPRESSION; INTERLEUKIN-6	The recent appearance of SARS-CoV-2 is responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic and has brought to light the importance of understanding this highly pathogenic agent to prevent future pandemics. This virus is from the same single-stranded positive-sense RNA family, Coronaviridae, as two other epidemic-causing viruses, SARS-CoV-1 and MERS-CoV. During this pandemic, one crucial focus highlighted by WHO has been to understand the risk factors that may contribute to disease severity and predict COVID-19 outcomes. In doing so, it is imperative to understand the virology of SARS-CoV-2 and the immunological response eliciting the clinical manifestation and progression of COVID-19. In this review, we provide clinical data-based analyses of how multiple risk factors (such as sex, race, HLA genotypes, blood groups, vitamin D deficiency, obesity, smoking, and asthma) contribute to the inflammatory overactivation and cytokine storm (frequently seen in COVID-19 patients) with a focus on the IL-6 pathway. We also draw comparisons to the virulence and pathophysiology of SARS and MERS to establish parallels in immune response and discuss the potential for therapeutic approaches that may limit disease progression in patients with higher risk profiles than others. Moreover, we cover the latest information on approved or upcoming COVID-19 vaccines. This paper also provides perspective on emerging variants and associated opportunistic infections such as black molds and fungus that have added to mortality in some parts of the world, such as India. This compilation of existing COVID-19 studies and data will provide an excellent referencing tool for the research, clinical, and public health communities.	[Hanna, John; Tipparaju, Padmavathi; Mulherkar, Tania; Lin, Edward; Mischley, Victoria; Kulkarni, Ratuja; Bolton, Aliyah; Jain, Pooja] Drexel Univ, Dept Microbiol & Immunol, Coll Med Philadelphia, 2900 Queen Lane, Philadelphia, PA 19129 USA; [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA		Jain, P (通讯作者)，Drexel Univ, Dept Microbiol & Immunol, Coll Med Philadelphia, 2900 Queen Lane, Philadelphia, PA 19129 USA.	jh3743@drexel.edu; pvt24@drexel.edu; thm35@drexel.edu; ewl35@drexel.edu; vmm75@drexel.edu; ratujak@gmail; arb432@drexel.edu; sid.byrareddy@unmc.edu; pj27@drexel.edu		Jain, Pooja/0000-0001-8057-7835; Byrareddy, Siddappa/0000-0002-6889-4640	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS097147]	These studies are fully supported by the funding from NIH/NINDS via R01 NS097147 to P.J.	Abduljalil JM, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100672; Amaral WZ, 2015, BRAIN BEHAV IMMUN, V49, P171, DOI 10.1016/j.bbi.2015.05.010; Amraei Razie, 2021, bioRxiv, DOI [10.1021/acscentsci.0c01537, 10.1101/2020.06.22.165803]; Anderluh M, 2012, CURR MED CHEM, V19, P992, DOI 10.2174/092986712799320664; Aranow C, 2011, J INVEST MED, V59, P881, DOI 10.2310/JIM.0b013e31821b8755; Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4; Aygun H, 2020, N-S ARCH PHARMACOL, V393, P1157, DOI 10.1007/s00210-020-01911-4; Barquera R, 2020, HLA, V96, P277, DOI 10.1111/tan.13956; Beigel JH, 2018, LANCET INFECT DIS, V18, P410, DOI 10.1016/S1473-3099(18)30002-1; Brosbol-Ravnborg A, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/807971; Castiblanco J, 2013, AUTOIMMUNITY BENCH B; CDCgov, 2021, COVID 19 RAC ETHN MI; Centers for Disease Control and Prevention, FUNG DIS MUC; Centers for Disease Control and Prevention COVID Data Tracker, 2021, US DEP HLTH HUM SERV; Chen X, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.40; Cheng YF, 2005, JAMA-J AM MED ASSOC, V293, P1450, DOI 10.1001/jama.293.12.1450-c; Cherian S., 2021, BIORXIV; Cunningham AL, 2007, NAT IMMUNOL, V8, P556, DOI 10.1038/ni0607-556; Dankers W, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00697; Della-Torre E, 2020, ANN RHEUM DIS, V79, P1277, DOI [10.1136/annrheumdis-2020-218122, 10.1136/annrheumdis-2020-218724, 10.1136/annrheumdis-2020-218759]; Dyall Julie, 2017, Drugs, V77, P1935, DOI 10.1007/s40265-017-0830-1; Fani M, 2020, FUTURE VIROL, V15, P317, DOI 10.2217/fvl-2020-0050; Farsalinos K, 2020, TOXICOL REP, V7, P658, DOI 10.1016/j.toxrep.2020.04.012; Folegatti PM, 2020, LANCET INFECT DIS, V20, P816, DOI 10.1016/S1473-3099(20)30160-2; Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001; Ganji A, 2020, BLOOD CELL MOL DIS, V83, DOI 10.1016/j.bcmd.2020.102437; Gauthier AG, 2021, J IMMUNOTOXICOL, V18, P23, DOI 10.1080/1547691X.2021.1875085; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Gillespie L, 2016, SCI REP-UK, V6, DOI 10.1038/srep19428; Gonzalez-Galarza F, ALLELE FREQUENCY NET; Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gubernatorova EO, 2020, CYTOKINE GROWTH F R, V53, P13, DOI 10.1016/j.cytogfr.2020.05.009; Guillon P, 2008, GLYCOBIOLOGY, V18, P1085, DOI 10.1093/glycob/cwn093; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Hilton HG, 2017, CELL REP, V19, P1394, DOI 10.1016/j.celrep.2017.04.059; Holmes L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124322; Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0; Hui DS, 2017, CLIN CHEST MED, V38, P71, DOI 10.1016/j.ccm.2016.11.007; Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Jain P, 2009, J VIROL, V83, P10908, DOI 10.1128/JVI.01054-09; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jensen S, 2012, J VIROL, V86, P2900, DOI 10.1128/JVI.05738-11; Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Khoo US, 2008, J MOL MED, V86, P861, DOI 10.1007/s00109-008-0350-2; Kitamura H, 2017, CANCER SCI, V108, P1947, DOI 10.1111/cas.13332; Koch T, 2020, LANCET INFECT DIS, V20, P827, DOI 10.1016/S1473-3099(20)30248-6; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Lange NE, 2012, AM J RESP CRIT CARE, V186, P616, DOI 10.1164/rccm.201110-1868OC; Latz CA, 2020, ANN HEMATOL, V99, P2113, DOI 10.1007/s00277-020-04169-1; Laurencin CT, 2020, J RACIAL ETHN HEALTH, V7, P398, DOI 10.1007/s40615-020-00756-0; Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024; Levin AM, 2015, AM J RESP CELL MOL, V53, P206, DOI 10.1165/rcmb.2014-0227OC; Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9; Liu J, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1072-4; Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8; McMullan CJ, 2017, J HYPERTENS, V35, P822, DOI 10.1097/HJH.0000000000001220; Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200; Meyerholz DK, 2016, AM J PATHOL, V186, P78, DOI 10.1016/j.ajpath.2015.09.014; Mitchell F, 2020, LANCET DIABETES ENDO, V8, P570, DOI 10.1016/S2213-8587(20)30183-2; Monneret G, 2006, INTENS CARE MED, V32, P1175, DOI 10.1007/s00134-006-0204-8; Moreno-Eutimio MA, 2020, MICROBES INFECT, V22, P226, DOI 10.1016/j.micinf.2020.04.009; Narayanan K, 2015, VIRUS RES, V202, P89, DOI 10.1016/j.virusres.2014.11.019; Narazaki M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113528; Neogi U, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050320; Ng MHL, 2004, J INFECT DIS, V190, P515, DOI 10.1086/421523; Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20; Nurden AT, 2008, FRONT BIOSCI-LANDMRK, V13, DOI 10.2741/2947; O'Donovan A, 2012, BRAIN BEHAV IMMUN, V26, P642, DOI 10.1016/j.bbi.2012.02.003; Ohno Y, 2016, CANCER IMMUNOL IMMUN, V65, P193, DOI 10.1007/s00262-015-1791-4; Olwenyi OA, 2020, J MOL MED, V98, P1369, DOI 10.1007/s00109-020-01961-4; Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623; Patel RH, 2021, J MED VIROL, V93, P641, DOI 10.1002/jmv.26416; Plaze M, 2020, ENCEPHALE, V46, P169, DOI 10.1016/j.encep.2020.05.006; Preece AF, 2002, BLOOD, V99, P2477, DOI 10.1182/blood.V99.7.2477; Pustylnikov S, 2016, AIDS RES HUM RETROV, V32, P93, DOI 10.1089/aid.2015.0184; Raut A, 2021, LANCET RESP MED, V9, pE77, DOI 10.1016/S2213-2600(21)00265-4; Reference G.H., HIST COMPL; Rodriguez-Diaz CE, 2020, ANN EPIDEMIOL, V52, P46, DOI 10.1016/j.annepidem.2020.07.007; Rothan HA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9070538; Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433; Scherberich JE, 2005, EUR J MED RES, V10, P179; Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y; Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831; Singh AK, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.05.019; Singu S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00406; Souyris M, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8855; Spinola H., 2016, J RESP RES, V2, P56, DOI DOI 10.17554/; Spratt Austin N, 2021, bioRxiv, DOI 10.1101/2021.03.24.436850; Stepanikova I, 2017, AM J PREV MED, V52, pS63, DOI 10.1016/j.amepre.2016.09.026; Tai DBG, 2021, CLIN INFECT DIS, V72, P703, DOI 10.1093/cid/ciaa815; Tanaka T, 2012, INT J BIOL SCI, V8, P1227, DOI 10.7150/ijbs.4666; Tse LV, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00658; van den Brand JMA, 2015, J PATHOL, V235, P175, DOI 10.1002/path.4458; van Paassen J, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03400-9; Vepa A, 2020, DIABETES METAB SYND, V14, P1043, DOI 10.1016/j.dsx.2020.06.056; Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4; Wang W, 2020, HLA, V96, P194, DOI 10.1111/tan.13941; White SR, 2019, J ALLERGY CLIN IMMUN, V144, P304, DOI 10.1016/j.jaci.2019.04.007; Wortsman J, 2000, AM J CLIN NUTR, V72, P690, DOI 10.1093/ajcn/72.3.690; Yang ML, 2017, SCI REP-UK, V7, DOI 10.1038/srep43829; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004; Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729; Zhao J, 2021, CLIN INFECT DIS, V73, P328, DOI 10.1093/cid/ciaa1150; Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V146, P327, DOI 10.1016/j.jaci.2020.06.001; Zietz Michael, 2020, medRxiv, DOI 10.1101/2020.04.08.20058073; Zisi D, 2019, HORM-INT J ENDOCRINO, V18, P353, DOI 10.1007/s42000-019-00155-z	111	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							938	10.3390/vaccines9080938			29	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4QE	34452063	gold, Green Published			2022-04-29	WOS:000689916800001
J	Peroni, DG; Morelli, L				Peroni, Diego Giampietro; Morelli, Lorenzo			Probiotics as Adjuvants in Vaccine Strategy: Is There More Room for Improvement?	VACCINES			English	Review						adjuvant; COVID-19; immune system; infant; LGG; microbiota; nutrition; probiotics; supplementation; vaccine	1ST 6 MONTHS; ANTIBODY-RESPONSES; DOUBLE-BLIND; LACTOBACILLUS-RHAMNOSUS; ROTAVIRUS VACCINE; LIFE; GG; SUPPLEMENTATION; PROTECTION; MICROBIOTA	Background. It has been recognized that microbiota plays a key role in shaping immune system maturation and activity. Since probiotic administration influences the microbiota composition and acts as a biological response modifier, the efficacy of an adjuvant for boosting vaccine-specific immunity is investigated. Methods. A review of the literature was performed, starting from the mechanisms to laboratory and clinical evidence. Results. The mechanisms, and in vitro and animal models provide biological plausibility for microbiota use. Probiotics have been investigated as adjuvants in farm conditions and as models to understand their potential in human vaccinations with promising results. In human studies, although probiotics were effective in ameliorating seroconversion to vaccines for influenza, rotavirus and other micro-organisms, the results for clinical use are still controversial, especially in particular settings, such as during the last trimester of pregnancy. Conclusion. Although this topic remains controversial, the use of probiotics as adjuvant factors in vaccination represents a strategic key for different applications. The available data are deeply influenced by heterogeneity among studies in terms of strains, timing and duration of administration, and patients. Although these do not allow us to draw definitive conclusions, probiotics as adjuvants in vaccination should be considered in future studies, especially in the elderly and in children, where vaccine effectiveness and duration of immunization really matter.	[Peroni, Diego Giampietro] Univ Pisa, Sect Pediat, Dept Clin & Expt Med, I-56126 Pisa, Italy; [Morelli, Lorenzo] Univ Cattolica Sacro Cuore, Dept Sustainable Food Proc DiSTAS, I-29122 Piacenza, Italy		Peroni, DG (通讯作者)，Univ Pisa, Sect Pediat, Dept Clin & Expt Med, I-56126 Pisa, Italy.	diego.peroni@unipi.it; lorenzo.morelli@unicatt.it	Peroni, Diego G/K-4002-2018; Peroni, Diego/K-8795-2016	Peroni, Diego/0000-0002-0234-1373	FONDAZIONE CARIPLOFondazione Cariplo [2018/2757]; Regione LombardiaRegione Lombardia [XI/953]; Cremona FOOD-LAB: Cremona AGRI-FOOD TechnologiesCRAFT [CUP J16J16001240003]	The manuscript was funded by ID 2018/2757-FONDAZIONE CARIPLO. Delibera Regionale n. XI/953-Regione Lombardia. Cremona FOOD-LAB: Cremona AGRI-FOOD TechnologiesCRAFT. CUP J16J16001240003.	Akatsu H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020136; Alqazlan N, 2021, VIRAL IMMUNOL, V34, P86, DOI 10.1089/vim.2020.0209; Bavananthasivam J, 2021, VACCINE, V39, P2424, DOI 10.1016/j.vaccine.2021.03.046; Belkacem N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184976; Bianchini S, 2020, HUM VACC IMMUNOTHER, V16, P86, DOI 10.1080/21645515.2019.1633877; Boge T, 2009, VACCINE, V27, P5677, DOI 10.1016/j.vaccine.2009.06.094; Boyle RJ, 2011, ALLERGY, V66, P509, DOI 10.1111/j.1398-9995.2010.02507.x; Bron PA, 2012, NAT REV MICROBIOL, V10, P66, DOI 10.1038/nrmicro2690; Chattha KS, 2013, J IMMUNOL, V191, P2446, DOI 10.4049/jimmunol.1300678; Chen Y, 2019, J AGR FOOD CHEM, V67, P13282, DOI 10.1021/acs.jafc.9b05744; Costagliola G, 2021, ITAL J PEDIATR, V47, DOI 10.1186/s13052-021-00990-0; Daliri EBM, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.655705; Davidson LE, 2011, EUR J CLIN NUTR, V65, P501, DOI 10.1038/ejcn.2010.289; Eloe-Fadrosh EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062026; Gao J, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00477; Gharajalar SN, 2020, COMP IMMUNOL MICROB, V72, DOI 10.1016/j.cimid.2020.101520; Harris VC, 2017, J INFECT DIS, V215, P34, DOI 10.1093/infdis/jiw518; Huda MN, 2014, PEDIATRICS, V134, pE362, DOI 10.1542/peds.2013-3937; Ismail IH, 2012, PEDIAT ALLERG IMM-UK, V23, P255, DOI 10.1111/j.1399-3038.2011.01239.x; ISOLAURI E, 1995, VACCINE, V13, P310, DOI 10.1016/0264-410X(95)93319-5; Kandasamy S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00334; Kukkonen K, 2006, PEDIAT ALLERG IMM-UK, V17, P416, DOI 10.1111/j.1399-3038.2006.00420.x; Lee JE, 2020, VET RES, V51, DOI 10.1186/s13567-020-00788-8; Lehtoranta L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103163; Lei WT, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111175; Licciardi PV, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00381; LINKAMSTER H, 1994, FEMS IMMUNOL MED MIC, V10, P55, DOI 10.1111/j.1574-695X.1994.tb00011.x; Liu JK, 2014, RES VET SCI, V96, P283, DOI 10.1016/j.rvsc.2014.01.010; Lynn DJ, 2022, NAT REV IMMUNOL, V22, P33, DOI 10.1038/s41577-021-00554-7; Lynn MA, 2018, CELL HOST MICROBE, V23, P653, DOI 10.1016/j.chom.2018.04.009; Mahooti M, 2019, WORLD J MICROB BIOT, V35, DOI 10.1007/s11274-019-2667-0; Mullie C, 2004, PEDIATR RES, V56, P791, DOI 10.1203/01.PDR.0000141955.47550.A0; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Olivares M, 2007, NUTRITION, V23, P254, DOI 10.1016/j.nut.2007.01.004; Peroni DG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00700; Rockel C, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00056; Ruck CE, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.565368; Soh SE, 2010, VACCINE, V28, P2577, DOI 10.1016/j.vaccine.2010.01.020; Taylor AL, 2006, CLIN EXP ALLERGY, V36, P1227, DOI 10.1111/j.1365-2222.2006.02553.x; Vitetta L, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040050; Vivarelli S., 2019, WORLD ACAD SCI J, V1, P125; Vlasova AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076962; Wang HF, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0727-2; Wen K, 2015, J PEDIATR GASTR NUTR, V60, P834, DOI 10.1097/MPG.0000000000000694; Wen K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094504; West CE, 2008, PEDIAT ALLERG IMM-UK, V19, P53, DOI 10.1111/j.1399-3038.2007.00583.x; Yadav R, 2018, CRIT REV FOOD SCI, V58, P1735, DOI 10.1080/10408398.2016.1274877; Yakabe K, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020163; Zhang HS, 2014, GUT PATHOG, V6, DOI 10.1186/s13099-014-0039-8; Zheng JS, 2020, INT J SYST EVOL MICR, V70, P2782, DOI 10.1099/ijsem.0.004107; Zimmermann P, 2018, VACCINE, V36, P207, DOI 10.1016/j.vaccine.2017.08.069; Zolkiewicz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082189	52	2	2	3	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							811	10.3390/vaccines9080811			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2GL	34451936	Green Published			2022-04-29	WOS:000689756300001
J	Schmidt, S; Kreutzmann, H; Stadler, M; Mair, KH; Stas, MR; Koch, M; Vatzia, E; Durlinger, S; Knecht, C; Spergser, J; Dolezal, M; Springer, S; Theuss, T; Fachinger, V; Ladinig, A; Saalmuller, A; Gerner, W				Schmidt, Selma; Kreutzmann, Heinrich; Stadler, Maria; Mair, Kerstin H.; Stas, Melissa R.; Koch, Michaela; Vatzia, Eleni; Duerlinger, Sophie; Knecht, Christian; Spergser, Joachim; Dolezal, Marlies; Springer, Sven; Theuss, Tobias; Fachinger, Vicky; Ladinig, Andrea; Saalmueler, Armin; Gerner, Wilhelm			T-Cell Cytokine Response in Salmonella Typhimurium-Vaccinated versus Infected Pigs	VACCINES			English	Article						Salmonella Typhimurium; pig; multifunctional T cells; interferon-gamma; tumor necrosis factor-alpha; Interleukin-17A; lamina propria lymphocytes	NONTYPHOIDAL SALMONELLA; PROTECTIVE IMMUNITY; TYPHOID VACCINE; IFN-GAMMA; IMMUNIZATION; DISEASE; LYMPHOCYTES; RESISTANCE; EFFICACY; ANTIBODY	Vaccination with the live attenuated vaccine Salmoporc is an effective measure to control Salmonella Typhimurium (STM) in affected swine populations. However, the cellular immune response evoked by the Salmoporc vaccine including differences in vaccinated pigs versus non-vaccinated pigs upon STM infection have not been characterized yet. To investigate this, tissue-derived porcine lymphocytes from different treatment groups (vaccination-only, vaccination and infection, infection-only, untreated controls) were stimulated in vitro with heat-inactivated STM and abundances of IFN-gamma, TNF-alpha and/or IL-17A-producing T-cell subsets were compared across organs and treatment groups. Overall, our results show the induction of a strong CD4(+) T-cell response after STM infection, both locally and systemically. Low-level induction of STM-specific cytokine-producing CD4(+) T cells, notably for the IFN-gamma/TNF-alpha co-producing phenotype, was detected after vaccination-only. Numerous significant contrasts in cytokine-producing T-cell phenotypes were observed after infection in vaccinated and infected versus infected-only animals. These results suggest that vaccine-induced STM-specific cytokine-producing CD4(+) T cells contribute to local immunity in the gut and may limit the spread of STM to lymph nodes and systemic organs. Hence, our study provides insights into the underlying immune mechanisms that account for the efficacy of the Salmoporc vaccine.	[Schmidt, Selma; Stadler, Maria; Mair, Kerstin H.; Vatzia, Eleni; Saalmueler, Armin; Gerner, Wilhelm] Univ Vet Med, Inst Immunol, Dept Pathobiol, A-1210 Vienna, Austria; [Kreutzmann, Heinrich; Stas, Melissa R.; Koch, Michaela; Duerlinger, Sophie; Knecht, Christian; Ladinig, Andrea] Univ Clin Swine, Univ Vet Med, Dept Farm Animals & Vet Publ Hlth, A-1210 Vienna, Austria; [Spergser, Joachim] Univ Vet Med, Inst Microbiol, Dept Pathobiol, A-1210 Vienna, Austria; [Dolezal, Marlies] Univ Vet Med, Dept Biomed Sci, Platformfor Bioinformat & Biostat, A-1210 Vienna, Austria; [Springer, Sven; Theuss, Tobias; Fachinger, Vicky] Ceva Innovat Ctr GmbH, D-06861 Dessau Rosslau, Germany		Gerner, W (通讯作者)，Univ Vet Med, Inst Immunol, Dept Pathobiol, A-1210 Vienna, Austria.	selma.schmidt@pirbright.ac.uk; heinrich.kreutzmann@vetmeduni.ac.at; maria.stadler@vetmeduni.ac.at; kerstin.mair@vetmeduni.ac.at; melissa.stas@vetmeduni.ac.at; michaela.koch@vetmeduni.ac.at; eleni.vatzia@pirbright.ac.uk; sophie.duerlinger@vetmeduni.ac.at; christian.knecht@vetmeduni.ac.at; joachim.spergser@vetmeduni.ac.at; marlies.dolezal@vetmeduni.ac.at; sven.springer@ceva.com; tobias.theuss@ceva.com; vicky.fachinger@ceva.com; andrea.ladinig@vetmeduni.ac.at; armin.saalmueller@vetmeduni.ac.at; wilhelm.gerner@vetmeduni.ac.at			Ceva Innovation Center GmbH, Dessau-Rosslau, Germany	This project was funded by Ceva Innovation Center GmbH (formerly part of IDT Biologika GmbH), Dessau-Ro ss lau, Germany.	Abusleme L, 2017, ORAL DIS, V23, P854, DOI 10.1111/odi.12598; Arguello H, 2013, COMP IMMUNOL MICROB, V36, P489, DOI 10.1016/j.cimid.2013.05.002; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bearson BL, 2017, J MED MICROBIOL, V66, P651, DOI 10.1099/jmm.0.000482; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.200737504; Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6; Bonardi S, 2017, EPIDEMIOL INFECT, V145, P1513, DOI 10.1017/S095026881700036X; Booth JS, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02263-6; Booth JS, 2017, CELL MOL GASTROENTER, V4, P419, DOI 10.1016/j.jcmgh.2017.08.002; Campos J, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8010019; Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107; Cote S, 2004, CAN J VET RES, V68, P241; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; Davies R, 2016, COMP IMMUNOL MICROB, V46, P7, DOI 10.1016/j.cimid.2016.03.005; Edelblum KL, 2015, GASTROENTEROLOGY, V148, P1417, DOI 10.1053/j.gastro.2015.02.053; European Food Safety Authority, 2019, EFSA J, V17, DOI 10.2903/j.efsa.2019.5926; European Food Safety Authority, 2018, EFSA J, V16, DOI 10.2903/j.efsa.2018.5500; Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2; FOX J, 1992, J AM STAT ASSOC, V87, P178, DOI 10.2307/2290467; Fox J., 2019, R COMPANION APPL REG, V3rd; Fresnay S, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0819-7; Gal-Mor O, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00391; Gil C, 2020, VET RES, V51, DOI 10.1186/s13567-019-0730-3; Godinez I, 2009, INFECT IMMUN, V77, P387, DOI 10.1128/IAI.00933-08; Gradassi M, 2013, VACCINE, V31, P3695, DOI 10.1016/j.vaccine.2013.05.105; Haesebrouck F, 2004, VET MICROBIOL, V100, P255, DOI 10.1016/j.vetmic.2004.03.002; Hess J, 1996, J IMMUNOL, V156, P3321; International Organization for Standardization, 2017, MICR FOOD CHAIN HOR; Johanns TM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001043; Kassambara A.; Kurtz JR, 2017, IMMUNOL LETT, V190, P42, DOI 10.1016/j.imlet.2017.07.006; Lee JY, 2020, CELL, V180, P79, DOI 10.1016/j.cell.2019.11.026; Lee SJ, 2012, IMMUNOL LETT, V148, P138, DOI 10.1016/j.imlet.2012.10.009; Lee SJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002499; Lee Y, 2012, NAT IMMUNOL, V13, P991, DOI 10.1038/ni.2416; Lenth R.; Leyman B, 2012, VET J, V194, P250, DOI 10.1016/j.tvjl.2012.04.011; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; MacLennan CA, 2008, J CLIN INVEST, V118, P1553, DOI 10.1172/JCI33998; Manne C, 2019, P NATL ACAD SCI USA, V116, P7425, DOI 10.1073/pnas.1818242116; Majowicz SE, 2010, CLIN INFECT DIS, V50, P882, DOI 10.1086/650733; McSorley SJ, 2000, INFECT IMMUN, V68, P3344, DOI 10.1128/IAI.68.6.3344-3348.2000; Meurens F, 2009, VET RES, V40, DOI 10.1051/vetres:2008043; Michael GB, 2016, CLIN MICROBIOL INFEC, V22, P968, DOI 10.1016/j.cmi.2016.07.033; MICHETTI P, 1992, INFECT IMMUN, V60, P1786, DOI 10.1128/IAI.60.5.1786-1792.1992; Mittrucker HW, 2000, J IMMUNOL, V164, P1648, DOI 10.4049/jimmunol.164.4.1648; MIXTER PF, 1994, INFECT IMMUN, V62, P4618, DOI 10.1128/IAI.62.10.4618-4621.1994; Monack DM, 2004, J EXP MED, V199, P231, DOI 10.1084/jem.20031319; Nelson RW, 2013, J IMMUNOL, V190, P2828, DOI 10.4049/jimmunol.1202183; Patterson SK, 2016, ANIM HEALTH RES REV, V17, P159, DOI 10.1017/S1466252316000165; Peeters L, 2020, PREV VET MED, V182, DOI 10.1016/j.prevetmed.2019.04.016; Pham OH, 2015, FUTURE MICROBIOL, V10, P101, DOI 10.2217/fmb.14.98; Pieper J, 2011, INFECT IMMUN, V79, P822, DOI 10.1128/IAI.00788-10; Martins RP, 2013, DEV COMP IMMUNOL, V41, P100, DOI 10.1016/j.dci.2013.04.020; Proietti M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08156-z; Ravindran R, 2005, J IMMUNOL, V175, P4603, DOI 10.4049/jimmunol.175.7.4603; Reutner K, 2012, DEV COMP IMMUNOL, V38, P321, DOI 10.1016/j.dci.2012.06.011; Roesler U, 2006, J VET MED B, V53, P224, DOI 10.1111/j.1439-0450.2006.00951.x; Salerno-Goncalves R, 2002, J IMMUNOL, V169, P2196, DOI 10.4049/jimmunol.169.4.2196; Schmidt S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.603089; Schulz SM, 2008, INT IMMUNOL, V20, P1129, DOI 10.1093/intimm/dxn069; Selke M, 2007, INFECT IMMUN, V75, P2476, DOI 10.1128/IAI.01908-06; Smith RP, 2018, J APPL MICROBIOL, V124, P274, DOI 10.1111/jam.13609; Springer S, 2001, BERL MUNCH TIERARZTL, V114, P342; Stanaway JD, 2019, LANCET INFECT DIS, V19, P1312, DOI 10.1016/S1473-3099(19)30418-9; Theuss T, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1271-5; Trepnau D, 2008, BERL MUNCH TIERARZTL, V121, P334, DOI 10.2376/0005-9366-121-334; Trupschuch S, 2010, INT J MED MICROBIOL, V300, P279, DOI 10.1016/j.ijmm.2010.02.001; Uche Ifeanyi Valentine, 2017, PLoS Negl Trop Dis, V11, pe0005118, DOI 10.1371/journal.pntd.0005118; Ugolini M, 2018, NAT IMMUNOL, V19, P386, DOI 10.1038/s41590-018-0068-4; Wahid R, 2016, CLIN IMMUNOL, V173, P87, DOI 10.1016/j.clim.2016.09.006; Wales AD, 2017, ZOONOSES PUBLIC HLTH, V64, P1, DOI 10.1111/zph.12256; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	74	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							845	10.3390/vaccines9080845			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9ME	34451970	Green Published, gold			2022-04-29	WOS:000690244400001
J	Dallagiacoma, G; Allora, A; Salvati, S; Cocciolo, G; Capraro, M; Lamberti, A; Senatore, S; Gentile, L; Gianfredi, V; Laurenzi, A; Molinari, C; Caretto, A; Faccini, M; Signorelli, C; Scavini, M; Odone, A				Dallagiacoma, Giulia; Allora, Agnese; Salvati, Stefano; Cocciolo, Giulia; Capraro, Michele; Lamberti, Anna; Senatore, Sabrina; Gentile, Leandro; Gianfredi, Vincenza; Laurenzi, Andrea; Molinari, Chiara; Caretto, Amelia; Faccini, Marino; Signorelli, Carlo; Scavini, Marina; Odone, Anna			Type 1 Diabetes Patients' Practice, Knowledge and Attitudes towards Influenza Immunization	VACCINES			English	Article						vaccination; influenza; diabetes; type 1 diabetes mellitus	ADDRESSING VACCINE HESITANCY; GLOBAL ECONOMIC BURDEN; SEASONAL INFLUENZA; POPULATION; COVERAGE; ADULTS; WEB; WORKING	Diabetic patients are at higher risk of developing infectious diseases and severe complications, compared to the general population. Almost no data is available in the literature on influenza immunization in people with type 1 diabetes mellitus (T1DM). As part of a broader project on immunization in diabetic patients, we conducted a cross-sectional study to: (i) report on seasonal influenza coverage rates in T1DM patients, (ii) explore knowledge, attitudes, and practices (KAPs) towards seasonal influenza in this population, and (iii) identify factors associated with vaccine uptake, including the role of family doctors and diabetologists. A survey was administered to 251 T1DM patients attending the Diabetes Clinic at San Raffaele Research Hospital in Milan, Italy and individual-level coverage data were retrieved from immunization registries. Self-reported seasonal influenza immunization coverage was 36%, which decreased to 21.7% when considering regional immunization registries, far below coverage target of 75%. More than a third (36.2%) of T1DM patients were classified as pro-vaccine, 30.7% as hesitant, 17.9% as uninformed, and 15.1% as anti-vaccine. Diabetologists resulted to be the most trusted source of information on vaccines' benefits and risks (85.3%) and should be more actively involved in preventive interventions. Our study highlights the importance of developing tailored vaccination campaigns for people with diabetes, including hospital-based programs involving diabetes specialists.	[Dallagiacoma, Giulia; Gentile, Leandro; Odone, Anna] Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy; [Allora, Agnese; Salvati, Stefano; Cocciolo, Giulia; Capraro, Michele; Gianfredi, Vincenza; Signorelli, Carlo] Univ Vita Salute San Raffaele, Sch Med, I-20132 Milan, Italy; [Lamberti, Anna; Senatore, Sabrina; Faccini, Marino] Agcy Hlth Protect Metropolitan Area Milan ATS, I-20121 Milan, Italy; [Laurenzi, Andrea; Molinari, Chiara; Caretto, Amelia; Scavini, Marina] Osped San Raffaele, Diabet Res Inst, I-20132 Milan, Italy		Odone, A (通讯作者)，Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy.	giulia.dallagiacoma01@universitadipavia.it; allora.agnese@hsr.it; salvati.stefano@hsr.it; cocciolo.giulia@hsr.it; Capraro.Michele@hsr.it; alamberti@ats-milano.it; Ssenatore@ats-milano.it; leandro.gentile01@universitadipavia.it; gianfredi.vincenza@hsr.it; laurenzi.andrea@hsr.it; molinari.chiara@hsr.it; caretto.amelia@hsr.it; MFaccini@ats-milano.it; signorelli.carlo@hsr.it; scavini.marina@hsr.it; anna.odone@unipv.it	Gianfredi, Vincenza/W-1408-2017; Signorelli, Carlo/AAC-7630-2022; Odone, Anna/AAC-4715-2022; Caretto, Amelia/AAG-8695-2020; Gentile, Leandro/AAX-7299-2021	Gianfredi, Vincenza/0000-0003-3848-981X; Caretto, Amelia/0000-0003-1153-6700; Gentile, Leandro/0000-0003-2375-7287; Capraro, Michele/0000-0002-8115-2377; Odone, Anna/0000-0002-5657-9774; SIGNORELLI, Carlo/0000-0002-0960-9563			Abu-Ashour W, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2975-2; Alvarez CE, 2017, J CLIN TRANSL ENDOCR, V9, P15, DOI 10.1016/j.jcte.2017.06.002; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc12-s064, 10.2337/dc13-S067, 10.2337/dc10-S062, 10.2337/dc11-S062]; Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI 10.2337/dc11-S011; [Anonymous], 2020, DIABETES CARE, V43, pS1, DOI [10.2337/dc20-Sint, 10.2337/dc20-SINT]; [Anonymous], CDC PINKBOOK COURSE; [Anonymous], MINISTERO SALUTE PIA; [Anonymous], Internation Diabetes Federation Diabetes Atlas, V9th; Basevi V, 2011, DIABETES CARE, V34, P1887, DOI 10.2337/dc11-s011; Bocquier A, 2020, HUM VACC IMMUNOTHER, V16, P2565, DOI 10.1080/21645515.2020.1729628; Bommer C, 2018, DIABETES CARE, V41, P963, DOI 10.2337/dc17-1962; Bommer C, 2017, LANCET DIABETES ENDO, V5, P423, DOI 10.1016/S2213-8587(17)30097-9; Bragazzi NL, 2017, HUM VACC IMMUNOTHER, V13, P464, DOI 10.1080/21645515.2017.1264742; Burioni R, 2018, NATURE, V555, P27, DOI 10.1038/d41586-018-02267-9; Carey IM, 2018, DIABETES CARE, V41, P513, DOI 10.2337/dc17-2131; Casqueiro Juliana, 2012, Indian J Endocrinol Metab, V16 Suppl 1, pS27, DOI 10.4103/2230-8210.94253; Censis Indagine Censis, 2017, VACC ANT NUOV ASS DE VACC ANT NUOV ASS DE; Centers for Disease Control and Prevention, FLU PEOPL DIAB; Cheloni R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022188; Clancy U, 2012, Ir Med J, V105, P298; Di Bartolo P., 2018, DIABETE, V30, DOI [10.30682/ildia1804i, DOI 10.30682/ILDIA1804I]; Dos Santos G, 2018, HUM VACC IMMUNOTHER, V14, P1853, DOI 10.1080/21645515.2018.1446719; Durant W, 2019, PERSPECT PUBLIC HEAL, V139, P280, DOI 10.1177/1757913919878655; EpiCentro Istituto Superiore di Sanita, SANIT VACC ANT DAT S SANIT VACC ANT DAT S; EpiCentro Istituto Superiore di Sanita, PROGR AZ SAN SAL IT PROGR AZ SAN SAL IT; Ferro A, 2015, EPIDEMIOL PREV, V39, P88; Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074; Gianfredi V., 2019, J PREV MED HYG, V60, pE108; Gianfredi V, 2019, HUM VACC IMMUNOTHER, V15, P2508, DOI 10.1080/21645515.2019.1599675; Gianfredi Vincenza, 2018, Recenti Prog Med, V109, P374, DOI 10.1701/2955.29706; Goeijenbier M, 2017, VACCINE, V35, P5095, DOI 10.1016/j.vaccine.2017.07.095; Guthrie Richard A, 2004, Crit Care Nurs Q, V27, P113; Hung MC, 2020, VACCINE, V38, P6545, DOI 10.1016/j.vaccine.2020.08.008; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Lau D, 2014, DIABETOLOGIA, V57, P690, DOI 10.1007/s00125-013-3158-8; Maahs DM, 2010, ENDOCRIN METAB CLIN, V39, P481, DOI 10.1016/j.ecl.2010.05.011; Mangtani P, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-249; Mobasseri M, 2020, HEALTH PROMOT PERSPE, V10, P98, DOI 10.34172/hpp.2020.18; Moreno-Fernandez J, 2020, PRIM CARE DIABETES, V14, P343, DOI 10.1016/j.pcd.2019.09.004; Odone A, 2018, HUM VACC IMMUNOTHER, V14, P2533, DOI 10.1080/21645515.2018.1486156; Odone A, 2017, VACCINE, V35, P1209, DOI 10.1016/j.vaccine.2015.11.051; Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313; Olatunbosun OD, 2017, VACCINE, V35, P6375, DOI 10.1016/j.vaccine.2017.10.006; Pluviano S, 2019, COGN PROCESS, V20, P325, DOI 10.1007/s10339-019-00919-w; Schmidt AM, 2018, ARTERIOSCL THROM VAS, V38, pE1, DOI 10.1161/ATVBAHA.117.310221; Shen SX, 2019, CAN FAM PHYSICIAN, V65, P175; Shin HY, 2018, VACCINE, V36, P91, DOI 10.1016/j.vaccine.2017.11.035; Signorelli C, 2019, EUR J PUBLIC HEALTH, V29, P1003, DOI 10.1093/eurpub/ckz135; SIMG, 2018, JAMD, V21, P232; Stahl JP, 2016, MED MALADIES INFECT, V46, P117, DOI 10.1016/j.medmal.2016.02.002; Szucs TD, 2006, MED KLIN, V101, P537, DOI 10.1007/s00063-006-1076-y; Tacken MAJB, 2015, VACCINE, V33, P4886, DOI 10.1016/j.vaccine.2015.07.052; Tan EK, 2010, SINGAP MED J, V51, P623; Tuomi T, 2005, DIABETES, V54, pS40, DOI 10.2337/diabetes.54.suppl_2.S40; Verger P, 2015, Clin Microbiol Infect, V21, DOI 10.1016/j.cmi.2015.06.017; World Health Organization, GLOBAL REPORT DIABET; Ye LX, 2021, HUM VACC IMMUNOTHER, V17, P106, DOI 10.1080/21645515.2020.1761201; Yu MC, 2014, HUM VACC IMMUNOTHER, V10, P1028, DOI 10.4161/hv.27816	58	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							707	10.3390/vaccines9070707			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7YW	34210044	Green Published, gold			2022-04-29	WOS:000677122900001
J	Jachowicz, E; Gebicka, M; Plakhtyr, D; Shynkarenko, M; Urbanowicz, J; Mach, M; Czepiel, J; Marchewka, J; Wojkowska-Mach, J				Jachowicz, Estera; Gebicka, Magdalena; Plakhtyr, Daria; Shynkarenko, Myroslav; Urbanowicz, Juri; Mach, Maciej; Czepiel, Jacek; Marchewka, Jakub; Wojkowska-Mach, Jadwiga			Incidence of Vaccine-Preventable Childhood Diseases in the European Union and in the European Free Trade Association Countries	VACCINES			English	Article						vaccine-preventable childhood diseases; incidence rate; vaccine schedules; mumps; rubella; measles; Streptococcus pneumoniae; Neisseria meningitidis	MEASLES ELIMINATION; SEROLOGICAL SURVEY; MUMPS	Introduction: Despite the widespread availability of vaccines, the incidence of vaccine-preventable childhood diseases (VPCD) started to grow in recent years. The aim of the study was to compare the annual incidence of selected VPCDs in the EU (European Union) and EFTA (European Free Trade Association) countries in the period of the last 5 years (2014-2019 or other intervals, depending on data availability), and the country-specific vaccine schedules. Methods: VPCD incidence rates in Europe were based on "The Surveillance Atlas of Infectious Diseases" by the ECDC (European Centre for Disease Prevention and Control); vaccination schedules were based on ECDC reports. Results: The obligation to vaccinate was not universal, and it generally only applied to two preparations: the MMR (measles, mumps, rubella) vaccine and the one against polio. During the study, the situation associated with mumps did not change or improve in individual countries; the median incidence amounted to 30 cases. The median incidence associated with rubella amounted to 1 case, but in a few countries, it grew very rapidly, i.e., in Germany, Italy, and Romania; in Poland, the incidence was clearly decreasing, from 5923 to 1532 cases. The most dynamic situation concerned measles. The total median was 2.4 cases per 100,000 population; the only one country with falling incidence was Germany. The diseases associated with Streptococcus pneumoniae and Neisseria meningitidis remained at a stable level in all analyzed countries. Conclusion: Vaccine schedules differ among the countries, so does the epidemiological situation of selected diseases. Morbidity on measles was the most disturbing phenomenon: the incidence rate increased in almost 40% of all countries, regardless of the obligation to vaccinate. The increasing incidence of VPCD may be due to anti-vaccine movements, the activity of which is often caused by mistrust and spreading misinformation. In order to better prevent the increase in morbidity, standardization of vaccine schedules and documentation should be considered in the EU countries.	[Jachowicz, Estera; Wojkowska-Mach, Jadwiga] Jagiellonian Univ Med Coll, Fac Med, Dept Microbiol, PL-31121 Krakow, Poland; [Gebicka, Magdalena] Jagiellonian Univ Med Coll, Fac Med, Dept Immunol, PL-31121 Krakow, Poland; [Plakhtyr, Daria; Shynkarenko, Myroslav; Urbanowicz, Juri] Jagiellonian Univ Med Coll, Fac Med, PL-31121 Krakow, Poland; [Mach, Maciej] SGH Warsaw Sch Econ, Quantitat Methods Econ, PL-02554 Warsaw, Poland; [Czepiel, Jacek] Jagiellonian Univ Med Coll, Dept Infect & Trop Dis, PL-30688 Krakow, Poland; [Marchewka, Jakub] Univ Phys Educ, Dept Physiotherapy, PL-31571 Krakow, Poland		Wojkowska-Mach, J (通讯作者)，Jagiellonian Univ Med Coll, Fac Med, Dept Microbiol, PL-31121 Krakow, Poland.	estera.jachowicz@doctoral.uj.edu.pl; magdalena.gebicka@doctoral.uj.edu.pl; daria.plakhtyr@student.uj.edu.pl; myroslav.shynkarenko@student.uj.edu.pl; yuriy.urbanovych@student.uj.edu.pl; mach-maciej@wp.pl; jacek.czepiel@uj.edu.pl; jakub.marchewka@awf.krakow.pl; mbmach@cyf-kr.edu.pl	; Wojkowska-Mach, Jadwiga/U-1186-2018	Czepiel, Jacek/0000-0002-9997-8417; Wojkowska-Mach, Jadwiga/0000-0003-0756-1639; Jachowicz, Estera/0000-0002-1067-9964; Marchewka, Jakub/0000-0002-7316-2380	Faculty of Medicine, Jagiellonian University Medical College	This research received no external funding. The APC was funded by Faculty of Medicine, Jagiellonian University Medical College.	Booy R, 2019, HUM VACC IMMUNOTHER, V15, P470, DOI 10.1080/21645515.2018.1532248; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Bustreo F, 2015, ARCH DIS CHILD, V100, pS34, DOI 10.1136/archdischild-2013-305693; Chovatiya R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231329; Cizman M, 2021, ANTIBIOTICS-BASEL, V10, DOI 10.3390/antibiotics10070758; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Deolalikar A.B., 2000, RESOUR FUTURE, V10695, P32, DOI [10.22004/ag.econ.10695, DOI 10.22004/AG.ECON.10695]; Diana Alessandro, 2019, Rev Med Suisse, V15, P1521; ECDC, DIS FACTSH ROT DIS FACTSH ROT; ECDC, VACC SCHED DAT VACC SCHED DAT; European Centre for Disease Prevention and Control, 2020, ANN EPIDEMIOLOGICAL; European Centre for Disease Prevention and Control, 2019, ANN EPIDEMIOLOGICAL; European Centre for Disease Prevention and Control (ECDC), SURV ATL INF DIS; European Centre for Disease Prevention and Control (ECDC), 2017, CAT INT ADDR VACC HE; Fajfr M, 2017, CENT EUR J PUBL HEAL, V25, P152, DOI 10.21101/cejph.a4408; Hamilton JL, 2020, PRIMARY CARE, V47, P467, DOI 10.1016/j.pop.2020.05.003; Kavalari ID, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41983-8; Kowalzik F, 2018, VACCINE, V36, P5402, DOI 10.1016/j.vaccine.2017.07.051; Lassi ZS, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18030988; Loenenbach AD, 2020, CLIN INFECT DIS, V70, P2036, DOI 10.1093/cid/ciz578; Matulyte E, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05462-0; NATHANSON N, 1982, REV INFECT DIS, V4, P940; Patel MK, 2020, MMWR-MORBID MORTAL W, V69, P1700, DOI 10.15585/mmwr.mm6945a6; Pebody R G, 2005, Euro Surveill, V10, P11, DOI 10.2807/esm.10.09.00564-en; Rao T S Sathyanarayana, 2011, Indian J Psychiatry, V53, P95, DOI 10.4103/0019-5545.82529; Smetana J, 2018, HUM VACC IMMUNOTHER, V14, P887, DOI 10.1080/21645515.2017.1412021; Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2; Strebel PM, 2004, J INFECT DIS, V189, pS251, DOI 10.1086/378092; Udden F, 2021, J INFECTION, V83, P190, DOI 10.1016/j.jinf.2021.05.031; University of Wisconsin Population Health Institute, COUNT HLTH RANK MOD; Vaz OM, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0620; Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430; World Health Organization (WHO), 2018, ORG DEL VACC SERV EU	33	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							796	10.3390/vaccines9070796			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8CJ	34358212	Green Published			2022-04-29	WOS:000677132000001
J	Xu, BY; Gao, XL; Zhang, XY; Hu, YL; Yang, HX; Zhou, YH				Xu, Biyun; Gao, Xuelian; Zhang, Xinyue; Hu, Yali; Yang, Huixia; Zhou, Yi-Hua			Real-World Acceptance of COVID-19 Vaccines among Healthcare Workers in Perinatal Medicine in China	VACCINES			English	Article						coronavirus disease 2019 (COVID-19); vaccine acceptance; healthcare workers; China	INACTIVATED SARS-COV-2 VACCINE; SAFETY; ACCEPTABILITY; PERSPECTIVES; INTENTION; ADULTS	Surveys showed that vaccine hesitancy may influence the acceptance of COVID-19 vaccines in healthcare workers (HCWs) and the general population. Currently, the actual acceptance of COVID-19 vaccination in HCWs has rarely been reported. In the present survey, we investigated the real-world acceptance of COVID-19 vaccination in HCWs in perinatal medicine during the first three-month period of vaccination in China and to identify the main reason for the decline of vaccination. HCWs (1087) who participated in a Chinese national symposium on perinatal medicine during 16-18 April 2021 were invited to answer a 27-question questionnaire online. A total of 1051 HCWs completed the questionnaire. Of them, 86.2% (906/1051) accepted the COVID-19 vaccination and 13.8% (145/1051) declined the vaccination. Because of the vaccine hesitancy, one-fourth of the vaccinated participants did not accept the vaccination until consulted with others or requested by employers. The main reason for the decline of vaccination in 145 unvaccinated HCWs was the concern about vaccine safety. The results indicate that vaccination request by employers may promote vaccine acceptance. More convincing data on the safety of COVID-19 vaccines appears to be important to increase the acceptance of vaccination.	[Xu, Biyun; Zhou, Yi-Hua] Nanjing Univ, Dept Lab Med, Med Sch, Nanjing Drum Tower Hosp, Nanjing 210008, Peoples R China; [Xu, Biyun; Zhou, Yi-Hua] Nanjing Univ, Dept Biomed Stat, Med Sch, Nanjing Drum Tower Hosp, Nanjing 210008, Peoples R China; [Gao, Xuelian; Zhang, Xinyue; Yang, Huixia] Peking Univ First Hosp, Dept Obstet & Gynecol, Beijing 100034, Peoples R China; [Hu, Yali] Nanjing Univ, Dept Obstet & Gynecol, Nanjing Drum Tower Hosp, Med Sch, Nanjing 210008, Peoples R China; [Zhou, Yi-Hua] Nanjing Univ, Dept Infect Dis, Nanjing Drum Tower Hosp, Med Sch, Nanjing 210008, Peoples R China		Zhou, YH (通讯作者)，Nanjing Univ, Dept Lab Med, Med Sch, Nanjing Drum Tower Hosp, Nanjing 210008, Peoples R China.; Zhou, YH (通讯作者)，Nanjing Univ, Dept Biomed Stat, Med Sch, Nanjing Drum Tower Hosp, Nanjing 210008, Peoples R China.; Yang, HX (通讯作者)，Peking Univ First Hosp, Dept Obstet & Gynecol, Beijing 100034, Peoples R China.; Zhou, YH (通讯作者)，Nanjing Univ, Dept Infect Dis, Nanjing Drum Tower Hosp, Med Sch, Nanjing 210008, Peoples R China.	biyunxu@163.com; gaoxuelian@163.com; zhwc_zhangxinyue@163.com; dtylhu@126.com; yanghuixia@bjmu.edu.cn; zgr03summer@126.com		Xu, Biyun/0000-0002-5610-2677; Zhang, Xinyue/0000-0002-7949-2153			Advisory Committee on Immunization Practices (ACIP), 2016, GUID VACC PREGN WOM GUID VACC PREGN WOM; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Butter S, 2022, BRIT J HEALTH PSYCH, V27, P13, DOI 10.1111/bjhp.12530; Carbone L, 2021, AM J OBST GYNEC MFM, V3, DOI 10.1016/j.ajogmf.2021.100352; Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563; Couto A. Mallmann, 2010, Morbidity and Mortality Weekly Report, V59, P130; Gadoth A, 2021, ANN INTERN MED, V174, P882, DOI 10.7326/M20-7580; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gharpure R, 2021, JAMA-J AM MED ASSOC, V325, P1670, DOI 10.1001/jama.2021.2352; Gray K.J., 2021, AM J OBSTET GYNECOL; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Jaca A, 2021, HUM VACC IMMUNOTHER, V17, P3016, DOI 10.1080/21645515.2021.1903294; Kukreti S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030246; Kuter BJ, 2021, VACCINE, V39, P1693, DOI 10.1016/j.vaccine.2021.02.029; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Leong DP, 2021, CAN J CARDIOL, V37, P1112, DOI 10.1016/j.cjca.2021.04.012; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lokken EM, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.02.011; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Maltezou HC, 2021, INFECT DIS HEALTH, V26, P189, DOI 10.1016/j.idh.2021.03.002; Meyer MN, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.5344; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nazli SB, 2022, IRISH J MED SCI, V191, P71, DOI 10.1007/s11845-021-02640-0; Pal R, 2021, DIABETES METAB SYND, V15, P505, DOI 10.1016/j.dsx.2021.02.026; Panagiotakopoulos L, 2020, MMWR-MORBID MORTAL W, V69, P1355, DOI [10.15585/mmwr.mm6938e2, 10.15585/mmwr.mm6938e1, 10.15585/mmwr.mm6938e2externalicon]; Pu J, 2021, VACCINE, V39, P2746, DOI 10.1016/j.vaccine.2021.04.006; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Raftopoulos V, 2021, HUM VACC IMMUNOTHER, V17, P2397, DOI 10.1080/21645515.2021.1896907; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Shaw J, 2021, CLIN INFECT DIS, V73, P1776, DOI 10.1093/cid/ciab054; Stephenson KE, 2021, JAMA-J AM MED ASSOC, V325, P1535, DOI 10.1001/jama.2021.3645; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang J, 2021, HUM VACC IMMUNOTHER, V17, P2926, DOI 10.1080/21645515.2021.1909328; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wiysonge CS, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1893062; World Health Organization, 2021, COVID 19 WEEKL EP; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Yan J, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.014; Zhang MX, 2021, EXPERT REV VACCINES, V20, P891, DOI 10.1080/14760584.2021.1925112	44	9	10	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							704	10.3390/vaccines9070704			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5VO	34199143	gold, Green Published			2022-04-29	WOS:000676979100001
J	Cuspoca, AF; Diaz, LL; Acosta, AF; Penaloza, MK; Mendez, YR; Clavijo, DC; Reyes, JY				Cuspoca, Andres Felipe; Diaz, Laura Lorena; Acosta, Alvaro Fernando; Penaloza, Marcela Katherine; Mendez, Yardany Rafael; Clavijo, Diana Carolina; Yosa Reyes, Juvenal			An Immunoinformatics Approach for SARS-CoV-2 in Latam Populations and Multi-Epitope Vaccine Candidate Directed towards the World's Population	VACCINES			English	Article						SARS-CoV-2; vaccine; LATAM; in silico	RESPIRATORY SYNDROME SARS; BETA-DEFENSIN 3; MOLECULAR-DYNAMICS; IMMUNE-RESPONSES; WEB SERVER; HUMAN BETA-DEFENSIN-3; STRUCTURAL PROTEINS; COVID-19 PNEUMONIA; SUBUNIT VACCINE; DENDRITIC CELLS	The coronavirus pandemic is a major public health crisis affecting global health systems with dire socioeconomic consequences, especially in vulnerable regions such as Latin America (LATAM). There is an urgent need for a vaccine to help control contagion, reduce mortality and alleviate social costs. In this study, we propose a rational multi-epitope candidate vaccine against SARS-CoV-2. Using bioinformatics, we constructed a library of potential vaccine peptides, based on the affinity of the most common major human histocompatibility complex (HLA) I and II molecules in the LATAM population to predict immunological complexes among antigenic, non-toxic and non-allergenic peptides extracted from the conserved regions of 92 proteomes. Although HLA-C, had the greatest antigenic peptide capacity from SARS-CoV-2, HLA-B and HLA-A, could be more relevant based on COVID-19 risk of infection in LATAM countries. We also used three-dimensional structures of SARS-CoV-2 proteins to identify potential regions for antibody production. The best HLA-I and II predictions (with increased coverage in common alleles and regions evoking B lymphocyte responses) were grouped into an optimized final multi-epitope construct containing the adjuvants Beta defensin-3, TpD, and PADRE, which are recognized for invoking a safe and specific immune response. Finally, we used Molecular Dynamics to identify the multi-epitope construct which may be a stable target for TLR-4/MD-2. This would prove to be safe and provide the physicochemical requirements for conducting experimental tests around the world.	[Cuspoca, Andres Felipe; Diaz, Laura Lorena; Acosta, Alvaro Fernando; Penaloza, Marcela Katherine; Mendez, Yardany Rafael] Univ Pedag & Tecnol Colombia, Grp Invest Epidemiol Clin Colombia GRECO, Tunja 150003, Colombia; [Clavijo, Diana Carolina] Pontificia Univ Javeriana Cali, Fac Ingn & Ciencias, Santiago De Cali 760031, Colombia; [Yosa Reyes, Juvenal] Univ Simon Bolivar, Fac Ciencias Basicas & Biomed, Lab Simulac Mol, Barranquilla 080002, Colombia		Reyes, JY (通讯作者)，Univ Simon Bolivar, Fac Ciencias Basicas & Biomed, Lab Simulac Mol, Barranquilla 080002, Colombia.	diana.clavijo@javerianacali.edu.co; juvenal.yosa@unisimonbolivar.edu.co		Acosta Costilla, Alvaro Fernando/0000-0003-0849-8248; Clavijo Buritica, Diana Carolina/0000-0003-0941-4552; Mendez Fandino, Yardany Rafael/0000-0003-1528-2672; Penaloza, Marcela/0000-0002-2736-0538; Yosa, Juvenal/0000-0002-6492-2640; Diaz Lache, Laura Lorena/0000-0001-9030-6043			Peele KA, 2021, J BIOMOL STRUCT DYN, V39, P3793, DOI 10.1080/07391102.2020.1770127; Addetia Amin, 2020, medRxiv, DOI 10.1101/2020.08.13.20173161; Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Agarwal A, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3939; Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011; Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w; Almofti Y., 2018, AM J MICROBIOL RES, V6, P94, DOI 10.12691/ajmr-6-3-5; Anderson SK, 2018, HLA, V92, P271, DOI 10.1111/tan.13396; [Anonymous], 2019, LANCET, V394, P1966, DOI 10.1016/S0140-6736(19)32935-6; Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529; Ascarateil S., 2015, J IMMUNOTHER CANCER, V3, pP428, DOI [10.1186/2051-1426-3-S2-P428, DOI 10.1186/2051-1426-3-S2-P428]; Banerjee AK, 2020, CELL, V183, P1325, DOI 10.1016/j.cell.2020.10.004; Bazhan SI, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020034; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Beltrame MH, 2015, MOL IMMUNOL, V67, P85, DOI 10.1016/j.molimm.2015.03.245; Ben Haij N, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-123; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336; Blais ME, 2011, IMMUNOLOGY, V133, P1, DOI 10.1111/j.1365-2567.2011.03422.x; Blander JM, 2007, TRENDS IMMUNOL, V28, P19, DOI 10.1016/j.it.2006.11.001; Blum JS, 2013, ANNU REV IMMUNOL, V31, P443, DOI 10.1146/annurev-immunol-032712-095910; Buchan DWA, 2019, NUCLEIC ACIDS RES, V47, pW402, DOI 10.1093/nar/gkz297; Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Case D. A., 2016, AMBERTOOLS 16; Chakradhar S, 2015, NAT MED, V21, P540, DOI 10.1038/nm0615-540; Chan VSF, 2006, NAT GENET, V38, P38, DOI 10.1038/ng1698; Chauhan V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39299-8; Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Choudhury A, 2020, J MED VIROL, V92, P2105, DOI 10.1002/jmv.25987; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Dar HA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030088; De Diego ML, 2014, VIRUS RES, V194, P124, DOI 10.1016/j.virusres.2014.07.024; Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Dorosti H, 2019, J BIOMOL STRUCT DYN, V37, P3524, DOI 10.1080/07391102.2018.1519460; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Durfee LA, 2010, MOL CELL, V38, P722, DOI 10.1016/j.molcel.2010.05.002; Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018; Elizondo V, 2021, EMERG MICROBES INFEC, V10, P51, DOI 10.1080/22221751.2020.1863747; Enayatkhani M, 2021, J BIOMOL STRUCT DYN, V39, P2857, DOI [10.1080/07391102.2020.1756411, 10.1080/07391102.2020.1857843]; Fast E, 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]; de Oliveira LMF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138686; Ferris LK, 2013, J INVEST DERMATOL, V133, P460, DOI 10.1038/jid.2012.319; Fievez V, 2010, INT J PHARMACEUT, V394, P35, DOI 10.1016/j.ijpharm.2010.04.023; Food and Drug Administration, 2020, TEMP POL COMP CERT D; Fraser CC, 2014, VACCINE, V32, P2896, DOI 10.1016/j.vaccine.2014.02.024; Funderburg N, 2007, P NATL ACAD SCI USA, V104, P18631, DOI 10.1073/PNAS.0702130104; Gao G.F, 2011, ELS, DOI 10.1038/npg.els.0000922; Gauttier V., 2020, TISSUE RESIDENT MEMO, DOI [10.1101/2020.08.14, DOI 10.1101/2020.08.14.240093]; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0; Gupta R., 2004, PREDICTION N GLYCOSY; Gupta S., 2013, PLOS ONE, V8, pE73597, DOI 10.1371/journal.pone.0073957; Hanisch FG, 2006, CURR PROTEIN PEPT SC, V7, P307, DOI 10.2174/138920306778018034; Harvey MJ, 2009, J CHEM THEORY COMPUT, V5, P1632, DOI 10.1021/ct9000685; Hasanzadeh S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73179-w; Hegde NR, 2003, TRENDS IMMUNOL, V24, P278, DOI 10.1016/S1471-4906(03)00099-1; Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Howell MD, 2007, J ALLERGY CLIN IMMUN, V119, P1022, DOI 10.1016/j.jaci.2007.01.044; Idicula-Thomas S, 2005, PROTEIN SCI, V14, P582, DOI 10.1110/ps.041009005; Italian Medicine Agency, 2020, COVID 19 TSUN STUD P; Iturrieta-Zuazo I, 2020, CLIN IMMUNOL, V219, DOI 10.1016/j.clim.2020.108572; Iyer AS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0367; Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889; Jiang Hongbing, 2011, Antiviral Chemistry & Chemotherapy, V22, P119, DOI 10.3851/IMP1902; Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Joshi Amit, 2020, Inform Med Unlocked, V19, P100338, DOI 10.1016/j.imu.2020.100338; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kamthania M, 2019, INT J PEPT RES THER, V25, P1627, DOI 10.1007/s10989-018-09805-z; Kanduc D, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108426; Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108; Khan MAA, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04064-8; Koyama T, 2020, B WORLD HEALTH ORGAN, V98, P495, DOI 10.2471/BLT.20.253591; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829; Kurcinski M, 2019, BIOINFORMATICS, V35, P4170, DOI 10.1093/bioinformatics/btz185; Landi L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78492-y; Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Le Grand S, 2013, COMPUT PHYS COMMUN, V184, P374, DOI 10.1016/j.cpc.2012.09.022; Lescure FX, 2021, LANCET RESP MED, V9, P522, DOI 10.1016/S2213-2600(21)00099-0; Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685; Li L, 2020, JAMA-J AM MED ASSOC, V324, P519, DOI 10.1001/jama.2020.13216; Liang MF, 2005, BIOMED ENVIRON SCI, V18, P363; Lipinski T, 2013, J IMMUNOL, V190, P4116, DOI 10.4049/jimmunol.1202937; Liu L, 2022, IEEE T KNOWL DATA EN, V34, P2293, DOI [10.1101/2020.06.17.153486, 10.1109/TKDE.2020.3004939]; Liu YY, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000012706, 10.1097/md.0000000000012706]; Mackenzie-Dyck S, 2014, CLIN VACCINE IMMUNOL, V21, P463, DOI 10.1128/CVI.00696-13; Maeshima N, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00003; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Manczinger M, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000131; Mellan TA., 2020, REPORT 21 ESTIMATING, DOI [10.1101/2020.05.09.20096701, DOI 10.1101/2020.05.09.20096701]; Meng FP, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00286-5; Millan-Onate J, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00358-y; Mitra D., 2020, MULTIEPITOPE BASED P, DOI [10.1101/2020.04.23.055467, DOI 10.1101/2020.04.23.055467]; Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863; Narayanan K, 2008, VIRUS RES, V133, P113, DOI 10.1016/j.virusres.2007.10.009; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07; Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Niehrs A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00055; O'Donnell TJ, 2018, CELL SYST, V7, P129, DOI 10.1016/j.cels.2018.05.014; OCHOA YC, 2020, INT J INFECT DIS, DOI DOI 10.1016/J.IJID.2020.04.069; Ojha R, 2019, ACS OMEGA, V4, P13069, DOI 10.1021/acsomega.9b00944; Olejnik J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007390; Oliveira SC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587615; Ong Edison, 2020, bioRxiv, DOI 10.1101/2020.03.20.000141; Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1; Park BS, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.97; Peng P, 2014, MOL THER, V22, P881, DOI 10.1038/mt.2013.287; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Piccinini AM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/672395; Pisanti S, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02515-5; Pridgen EM, 2015, EXPERT OPIN DRUG DEL, V12, P1459, DOI 10.1517/17425247.2015.1018175; Rakib A, 2020, COMPUT BIOL MED, V124, DOI 10.1016/j.compbiomed.2020.103967; Rallabhandi P, 2012, MBIO, V3, DOI 10.1128/mBio.00218-12; Renu K, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117839; Rilinger J, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04447-3; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Rodriguez-Morales Alfonso J, 2020, Curr Trop Med Rep, V7, P75, DOI 10.1007/s40475-020-00205-2; RODRIGUEZMORALE.AJ, 2020, TRAVEL MED INFECT DI, V35, DOI DOI 10.1016/J.TMAID.2020.101613; Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p; Romeli S, 2020, MALAYS J MED SCI, V27, P10, DOI 10.21315/mjms2020.27.2.2; Rosano GL, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00172; Roulois D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/871936; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Sanchez-Duque JA, 2020, ATEN PRIM, V52, P369, DOI 10.1016/j.aprim.2020.04.001; Sariol A, 2020, IMMUNITY, V53, P248, DOI 10.1016/j.immuni.2020.07.005; Shin D, 2020, NATURE, V587, P657, DOI 10.1038/s41586-020-2601-5; Solanki V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41496-4; Song YF, 2013, STRUCTURE, V21, P1735, DOI 10.1016/j.str.2013.08.005; Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059; Su QD, 2020, VACCINE, V38, P5071, DOI 10.1016/j.vaccine.2020.04.070; Tableu, 2020, AC PROGR TABL SOFTW; TAMALIKA K, 2020, SCI REP-UK, V10, P10895; Tavasolian F, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601886; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237; Tey SK, 2012, BLOOD, V120, P994, DOI 10.1182/blood-2012-01-402404; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002; Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004; Vajda S, 2017, PROTEINS, V85, P435, DOI 10.1002/prot.25219; Vina MAF, 2012, PHILOS T R SOC B, V367, P820, DOI 10.1098/rstb.2011.0320; Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069; Walker JM, 2005, PROTEOMICS PROTOCOLS; Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000; Wang H, 2011, VACCINE, V29, P2328, DOI 10.1016/j.vaccine.2010.12.124; Wang JQ, 2003, CLIN CHEM, V49, P1989, DOI 10.1373/clinchem.2003.023184; Wang M, 2014, HUM VACC IMMUNOTHER, V10, P3544, DOI 10.4161/hv.36174; Wang Rui, 2020, Res Sq, DOI 10.21203/rs.3.rs-49671/v1; Wang SF, 2011, VIRAL IMMUNOL, V24, P421, DOI 10.1089/vim.2011.0024; Wang YD, 2004, J VIROL, V78, P5612, DOI 10.1128/JVI.78.11.5612-5618.2004; Wang Y, 2016, P NATL ACAD SCI USA, V113, pE884, DOI 10.1073/pnas.1525639113; Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983; Wei JX, 2020, BIOCONJUGATE CHEM, V31, P1948, DOI 10.1021/acs.bioconjchem.0c00308; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Williams TC, 2021, LANCET RESP MED, V9, P333, DOI 10.1016/S2213-2600(21)00075-8; Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/nchembio.1403, 10.1038/NCHEMBIO.1403]; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001; Wu CY, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-88; Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514; Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337; Zhang, 2020, HIGHLY PATHOGENIC CO, DOI [10.1101/2020.03.29.20041962, DOI 10.1101/2020.03.29.20041962]; Zhang W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15030-4; Zhao LX, 2013, HUM VACC IMMUNOTHER, V9, P2566, DOI 10.4161/hv.26088	177	2	2	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							581	10.3390/vaccines9060581			36	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY7FZ	34205992	Green Published, Green Submitted, gold			2022-04-29	WOS:000666050500001
J	Hatmal, MM; Al-Hatamleh, MAI; Olaimat, AN; Hatmal, M; Alhaj-Qasem, DM; Olaimat, TM; Mohamud, R				Hatmal, Ma'mon M.; Al-Hatamleh, Mohammad A. I.; Olaimat, Amin N.; Hatmal, Malik; Alhaj-Qasem, Dina M.; Olaimat, Tamadur M.; Mohamud, Rohimah			Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects	VACCINES			English	Article						SARS-CoV-2 vaccine; COVID-19 vaccine; post-vaccination symptoms; vaccine acceptance; vaccine hesitancy; vaccine anxiety; thrombocytopenia; thrombosis; blood clot; machine learning	PERSPECTIVES; WILLINGNESS; SARS-COV-2; INFECTION; VACCINES	Background: Since the coronavirus disease 2019 (COVID-19) was declared a pandemic, there was no doubt that vaccination is the ideal protocol to tackle it. Within a year, a few COVID-19 vaccines have been developed and authorized. This unparalleled initiative in developing vaccines created many uncertainties looming around the efficacy and safety of these vaccines. This study aimed to assess the side effects and perceptions following COVID-19 vaccination in Jordan. Methods: A cross-sectional study was conducted by distributing an online survey targeted toward Jordan inhabitants who received any COVID-19 vaccines. Data were statistically analyzed and certain machine learning (ML) tools, including multilayer perceptron (MLP), eXtreme gradient boosting (XGBoost), random forest (RF), and K-star were used to predict the severity of side effects. Results: A total of 2213 participants were involved in the study after receiving Sinopharm, AstraZeneca, Pfizer-BioNTech, and other vaccines (38.2%, 31%, 27.3%, and 3.5%, respectively). Generally, most of the post-vaccination side effects were common and non-life-threatening (e.g., fatigue, chills, dizziness, fever, headache, joint pain, and myalgia). Only 10% of participants suffered from severe side effects; while 39% and 21% of participants had moderate and mild side effects, respectively. Despite the substantial variations between these vaccines in the presence and severity of side effects, the statistical analysis indicated that these vaccines might provide the same protection against COVID-19 infection. Finally, around 52.9% of participants suffered before vaccination from vaccine hesitancy and anxiety; while after vaccination, 95.5% of participants have advised others to get vaccinated, 80% felt more reassured, and 67% believed that COVID-19 vaccines are safe in the long term. Furthermore, based on the type of vaccine, demographic data, and side effects, the RF, XGBoost, and MLP gave both high accuracies (0.80, 0.79, and 0.70, respectively) and Cohen's kappa values (0.71, 0.70, and 0.56, respectively). Conclusions: The present study confirmed that the authorized COVID-19 vaccines are safe and getting vaccinated makes people more reassured. Most of the post-vaccination side effects are mild to moderate, which are signs that body's immune system is building protection. ML can also be used to predict the severity of side effects based on the input data; predicted severe cases may require more medical attention or even hospitalization.	[Hatmal, Ma'mon M.] Hashemite Univ, Fac Appl Med Sci, Dept Med Lab Sci, Zarqa 13133, Jordan; [Al-Hatamleh, Mohammad A. I.; Mohamud, Rohimah] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian 16150, Kelantan, Malaysia; [Olaimat, Amin N.] Hashemite Univ, Fac Appl Med Sci, Dept Clin Nutr & Dietet, Zarqa 13133, Jordan; [Hatmal, Malik] Prince Hamza Hosp, Amman 11947, Jordan; [Alhaj-Qasem, Dina M.] Precis Med Lab, Amman 11954, Jordan; [Olaimat, Tamadur M.] Zarqa Univ, Fac Pharm, Zarqa 13132, Jordan		Hatmal, MM (通讯作者)，Hashemite Univ, Fac Appl Med Sci, Dept Med Lab Sci, Zarqa 13133, Jordan.; Mohamud, R (通讯作者)，Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian 16150, Kelantan, Malaysia.	mamon@hu.edu.jo; alhatamleh@student.usm.my; aminolaimat@hu.edu.jo; hatmal.malik@yahoo.com; dina.dq96@gmail.com; tamadurmhmd@gmail.com; rohimahm@usm.my	Olaimat, Amin/AAP-5004-2020; Al-Hatamleh, Mohammad A. I./AAH-3451-2019; Mohamud, Rohimah/C-8790-2016	Olaimat, Amin/0000-0001-7202-5440; Al-Hatamleh, Mohammad A. I./0000-0001-8249-9519; Alhaj-Qasem, Dina/0000-0002-6079-483X; Mohamud, Rohimah/0000-0002-2465-6421; M. Hatmal, Ma'mon/0000-0003-1745-8985	Universiti Sains Malayisa (USM) Fellowship Scheme	The authors would like to thank all the participants and people who helped in survey distribution. M.A.I.A.-H. would like to acknowledge the Universiti Sains Malayisa (USM) Fellowship Scheme for providing financial support.	Abu-Farha RK, 2020, PATIENT PREFER ADHER, V14, P2451, DOI 10.2147/PPA.S284385; Al-Hatamleh MAI, 2021, EUR J PHARMACOL, V896, DOI 10.1016/j.ejphar.2021.173930; Al-Hatamleh MAI, 2020, MOLECULES, V25, DOI 10.3390/molecules25215017; Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; [Anonymous], NTR; Bhattacharjee Sukrita, 2020, SN Compr Clin Med, V2, P2048, DOI 10.1007/s42399-020-00521-8; Carli G, 2021, INTERN EMERG MED, V16, P803, DOI 10.1007/s11739-021-02685-0; Chapin-Bardales J, 2021, JAMA-J AM MED ASSOC, V325, P2201, DOI 10.1001/jama.2021.5374; Chew NWS, 2021, INT J INFECT DIS, V106, P52, DOI 10.1016/j.ijid.2021.03.069; Chung YH, 2020, ACS NANO, V14, P12522, DOI 10.1021/acsnano.0c07197; El-Shitany NA, 2021, INT J GEN MED, V14, P1389, DOI 10.2147/IJGM.S310497; Fleiss JL, 2003, STAT METHODS RATES P, V3rd; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Haidere MF, 2021, BIOMOL THER, V29, P1, DOI 10.4062/biomolther.2020.178; Hatmal MM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122638; Hatmal MM, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9080222; Jayadevan R, SURVEY SYMPTOMS FOLL, V2021, DOI [10.1101/2021.02.08.21251366, DOI 10.1101/2021.02.08.21251366]; Kadali RAK, 2021, INT J INFECT DIS, V106, P376, DOI 10.1016/j.ijid.2021.04.047; Kadali RAK, 2021, J MED VIROL, V93, P4420, DOI 10.1002/jmv.26996; Kappel BA, 2020, MOL METAB, V36, DOI 10.1016/j.molmet.2020.100976; Kashte S, 2021, HUM CELL, V34, P711, DOI 10.1007/s13577-021-00512-4; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lopez YON, 2019, MOL METAB, V20, P63, DOI 10.1016/j.molmet.2018.11.003; Mahmood DY., 2013, INT ORG SCI RES J CO, V15, P107; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Mustapha IB, 2016, MOLECULES, V21, DOI 10.3390/molecules21080983; Othman M, 2007, BLOOD, V109, P2832, DOI 10.1182/blood-2006-06-032524; Petousis-Harris H, 2020, DRUG SAFETY, V43, P1205, DOI 10.1007/s40264-020-01002-6; Purdy S, 2013, J ROY COLL PHYS EDIN, V43, P340, DOI 10.4997/JRCPE.2013.415; Ren XD, 2017, LECT NOTES COMPUT SC, V10431, P378, DOI 10.1007/978-3-319-64185-0_28; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; RIEDMILLER M, 1993, 1993 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS, VOLS 1-3, P586, DOI 10.1109/ICNN.1993.298623; Rozinajova V., 2018, COMPUTATIONAL INTELL, P23; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Silveira MM, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118919; Swetha G., 2020, DRUG INVENTION TODAY, V14, P3; Tao C, 2015, IEEE GEOSCI REMOTE S, V12, P2438, DOI 10.1109/LGRS.2015.2482520; Tripathi R, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00482; van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071818; Wang YX, 2010, PREV MED, V51, P445, DOI 10.1016/j.ypmed.2010.08.019; Wiharto W, 2016, HEALTHC INFORM RES, V22, P30, DOI 10.4258/hir.2016.22.1.30; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Wold WSM, 2013, CURR GENE THER, V13, P421; Wool GD, 2021, PATHOBIOLOGY, V88, P15, DOI 10.1159/000512007; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8	50	30	30	9	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							556	10.3390/vaccines9060556			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5NC	34073382	Green Published, gold			2022-04-29	WOS:000665933500001
J	Xie, JX; Vereecke, N; Theuns, S; Oh, D; Vanderheijden, N; Trus, I; Sauer, J; Vyt, P; Bonckaert, C; Lalonde, C; Provost, C; Gagnon, CA; Nauwynck, H				Xie, Jiexiong; Vereecke, Nick; Theuns, Sebastiaan; Oh, Dayoung; Vanderheijden, Nathalie; Trus, Ivan; Sauer, Jannes; Vyt, Philip; Bonckaert, Caroline; Lalonde, Christian; Provost, Chantale; Gagnon, Carl A.; Nauwynck, Hans			Comparison of Primary Virus Isolation in Pulmonary Alveolar Macrophages and Four Different Continuous Cell Lines for Type 1 and Type 2 Porcine Reproductive and Respiratory Syndrome Virus	VACCINES			English	Article						PRRSV; virus isolation; production; macrophages; MARC-145; PK15(Sn-CD163); PK15(S10-CD163)	SYNDROME PRRS VIRUS; NUCLEOCAPSID PROTEIN; DENDRITIC CELLS; NORTH-AMERICAN; IDENTIFICATION; SIALOADHESIN; REPLICATION; INFECTION; EFFICACY; INVOLVEMENT	Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) has a highly restricted cellular tropism. In vivo, the virus primarily infects tissue-specific macrophages in the nose, lungs, tonsils, and pharyngeal lymphoid tissues. In vitro however, the MARC-145 cell line is one of the few PRRSV susceptible cell lines that are routinely used for in vitro propagation. Previously, several PRRSV non-permissive cell lines were shown to become susceptible to PRRSV infection upon expression of recombinant entry receptors (e.g., PK15(Sn-CD163), PK15(S10-CD163)). In the present study, we examined the suitability of different cell lines as a possible replacement of primary pulmonary alveolar macrophages (PAM) cells for isolation and growth of PRRSV. The susceptibility of four different cell lines (PK15(Sn-CD163), PK15(S10-CD163), MARC-145, and MARC-145(Sn)) for the primary isolation of PRRSV from PCR positive sera (both PRRSV1 and PRRSV2) was compared with that of PAM. To find possible correlations between the cell tropism and the viral genotype, 54 field samples were sequenced, and amino acid residues potentially associated with the cell tropism were identified. Regarding the virus titers obtained with the five different cell types, PAM gave the highest mean virus titers followed by PK15(Sn-CD163), PK15(S10-CD163), MARC-145(Sn), and MARC-145. The titers in PK15(Sn-CD163) and PK15(S10-CD163) cells were significantly correlated with virus titers in PAM for both PRRSV1 (p < 0.001) and PRRSV2 (p < 0.001) compared with MARC-145(Sn) (PRRSV1: p = 0.22 and PRRSV2: p = 0.03) and MARC-145 (PRRSV1: p = 0.04 and PRRSV2: p = 0.12). Further, a possible correlation between cell tropism and viral genotype was assessed using PRRSV whole genome sequences in a Genome-Wide-Association Study (GWAS). The structural protein residues GP2:187L and N:28R within PRRSV2 sequences were associated with their growth in MARC-145. The GP5:78I residue for PRRSV2 and the Nsp11:155F residue for PRRSV1 was linked to a higher replication on PAM. In conclusion, PK15(Sn-CD163) and PK15(S10-CD163) cells are phenotypically closely related to the in vivo target macrophages and are more suitable for virus isolation and titration than MARC-145/MARC-145(Sn) cells. The residues of PRRSV proteins that are potentially related with cell tropism will be further investigated in the future.	[Xie, Jiexiong; Vereecke, Nick; Oh, Dayoung; Vanderheijden, Nathalie; Nauwynck, Hans] Univ Ghent, Virol Lab, Fac Vet Med, B-9820 Merelbeke, Belgium; [Vereecke, Nick; Theuns, Sebastiaan; Sauer, Jannes; Nauwynck, Hans] PathoSense BV, B-2500 Lier, Belgium; [Trus, Ivan] Univ Saskatchewan, Int Vaccine Ctr, Vaccine & Infect Dis Org VIDO, Saskatoon, SK S7N 5E3, Canada; [Vyt, Philip] Belsele, Dialab, B-9111 St Niklaas, Belgium; [Bonckaert, Caroline] Anim Hlth Care Flanders DGZ, B-8820 Torhout, Belgium; [Lalonde, Christian; Provost, Chantale; Gagnon, Carl A.] Univ Montreal, Swine & Poultry Infect Dis Res Ctr CRIPA, Fonds Rech Quebec, Fac Med Vet, St Hyacinthe, PQ J2S 2M2, Canada		Nauwynck, H (通讯作者)，Univ Ghent, Virol Lab, Fac Vet Med, B-9820 Merelbeke, Belgium.; Nauwynck, H (通讯作者)，PathoSense BV, B-2500 Lier, Belgium.	xjx297@gmail.com; nick.vereecke@ugent.be; sebastiaan.theuns@pathosense.com; Dayoung.oh@ugent.be; Nathalie.Vanderheijden@ugent.be; ivan.trus@gmail.com; jannes.sauer@pathosense.com; philip.vyt@gmail.com; caroline.bonckaert@dgz.be; christian.lalonde@umontreal.ca; chantale.provost@umontreal.ca; carl.a.gagnon@umontreal.ca; hans.nauwynck@ugent.be		Provost, Chantale/0000-0002-6674-1157; Nauwynck, Hans/0000-0001-5470-0713; Oh, Dayoung/0000-0002-1694-2620; Trus, Ivan/0000-0003-2849-5140; Vanderheijden, Nathalie/0000-0002-7899-1161; Gagnon, Carl A./0000-0003-4528-541X; Vereecke, Nick/0000-0001-5367-9756; Xie, Jiexiong/0000-0002-3374-6605	Ministere de l'Agriculture, des Pecheries et de l'Alimentation du Quebec (MAPAQ) Innov'Action program; Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Canadian Swine Research and Development Cluster (CSRDC); CRIPA; Fonds de recherche du Quebec-Nature et technologies (FRQNT)	The sequencing of the Canadian PRRSV2 isolates was financially supported by the Ministere de l'Agriculture, des Pecheries et de l'Alimentation du Quebec (MAPAQ) Innov'Action program. C.A.G. was financially supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) discovery grant and a Canadian Swine Research and Development Cluster (CSRDC) grant. C.L. was a recipient of a scholarship from the CRIPA, a research network financially supported by the Fonds de recherche du Quebec-Nature et technologies (FRQNT).	BAUTISTA EM, 1993, J VET DIAGN INVEST, V5, P163, DOI 10.1177/104063879300500204; Calzada-Nova G, 2012, VET IMMUNOL IMMUNOP, V148, P116, DOI 10.1016/j.vetimm.2012.05.008; Chang HC, 2008, VET MICROBIOL, V129, P281, DOI 10.1016/j.vetmic.2007.12.002; COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201; de Abin MF, 2009, CAN J VET RES, V73, P200; De Coster W, 2018, BIOINFORMATICS, V34, P2666, DOI 10.1093/bioinformatics/bty149; Dea S, 2000, ARCH VIROL, V145, P659, DOI 10.1007/s007050050662; Delputte PL, 2004, J VIROL, V78, P8094, DOI 10.1128/JVI.78.15.8094-8101.2004; Delputte PL, 2002, J VIROL, V76, P4312, DOI 10.1128/JVI.76.9.4312-4320.2002; Delrue I, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-48; Doan DNP, 2003, STRUCTURE, V11, P1445, DOI 10.1016/j.str.2003.09.018; Dokland T, 2010, VIRUS RES, V154, P86, DOI 10.1016/j.virusres.2010.07.029; Duan X, 1997, ARCH VIROL, V142, P2483, DOI 10.1007/s007050050256; Duan X, 1997, VET MICROBIOL, V56, P9, DOI 10.1016/S0378-1135(96)01347-8; Frydas IS, 2015, VET RES, V46, DOI 10.1186/s13567-015-0166-3; Gagnon CA, 2021, J VET DIAGN INVEST, V33, P216, DOI 10.1177/1040638720952411; Gao JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep25120; Geldhof MF, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-182; Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101; Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108; KIM HS, 1993, ARCH VIROL, V133, P477, DOI 10.1007/BF01313785; King AMQ, 2018, ARCH VIROL, V163, P2601, DOI 10.1007/s00705-018-3847-1; Koren S, 2017, GENOME RES, V27, P722, DOI 10.1101/gr.215087.116; Labarque GG, 2000, J GEN VIROL, V81, P1327, DOI 10.1099/0022-1317-81-5-1327; Lalonde C, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00097-20; Liu L, 2016, J VIROL, V90, P5384, DOI 10.1128/JVI.03216-15; Lu ZH, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-42; Posthuma CC, 2006, J VIROL, V80, P1653, DOI 10.1128/JVI.80.4.1653-1661.2006; Provost C, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-267; Reed LJ., 1938, AM J HYG, V27, P493, DOI [10.1093/oxfordjournals.aje.a118408, DOI 10.1093/OXFORDJOURNALS.AJE.A118408]; Shanmukhappa K, 2001, ADV EXP MED BIOL, V494, P641; Shanmukhappa K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-62; Shi M, 2010, J VIROL, V84, P8700, DOI 10.1128/JVI.02551-09; Shi XB, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0717-5; Sovic I, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11307; Stadejek T, 2008, ARCH VIROL, V153, P1479, DOI 10.1007/s00705-008-0146-2; Van Breedam W, 2011, VET IMMUNOL IMMUNOP, V141, P246, DOI 10.1016/j.vetimm.2011.03.008; Van Breedam W, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000730; Van Gorp H, 2008, J GEN VIROL, V89, P2943, DOI 10.1099/vir.0.2008/005009-0; Vanderheijden N, 2003, J VIROL, V77, P8207, DOI 10.1128/JVI.77.15.8207-8215.2003; Verheije MH, 2003, VACCINE, V21, P2556, DOI 10.1016/S0264-410X(03)00047-1; Wang X, 2007, ARCH VIROL, V152, P289, DOI 10.1007/s00705-006-0857-1; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Wootton SK, 2003, J VIROL, V77, P4546, DOI 10.1128/JVI.77.8.4546-4557.2003; Xie JX, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010036; Xie JX, 2018, VET RES, V49, DOI 10.1186/s13567-018-0569-z; Xie JX, 2017, J GEN VIROL, V98, P2030, DOI 10.1099/jgv.0.000859; Yim-Im W, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.01757-20; Zhang HL, 2018, VET MICROBIOL, V222, P46, DOI 10.1016/j.vetmic.2018.06.021	49	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							594	10.3390/vaccines9060594			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY7DB	34205087	Green Published, gold			2022-04-29	WOS:000666042900001
J	Lemoine, CH; Nidom, RV; Ventura, R; Indrasari, S; Normalina, I; Santoso, KP; Derouet, F; Barnier-Quer, C; Borchard, G; Collin, N; Nidom, CA				Lemoine, Celine H.; Nidom, Reviany V.; Ventura, Roland; Indrasari, Setyarina; Normalina, Irine; Santoso, Kuncoro Puguh; Derouet, Francis; Barnier-Quer, Christophe; Borchard, Gerrit; Collin, Nicolas; Nidom, Chairul A.			Better Pandemic Influenza Preparedness through Adjuvant Technology Transfer: Challenges and Lessons Learned	VACCINES			English	Review						pandemic preparedness; technology transfer; adjuvanted vaccines; influenza; lessons learned; global health	VACCINE PRODUCTION CAPACITY; WATER EMULSION ADJUVANT; GLOBAL PRODUCTION; RESPONSES; PLATFORM; ACCESS	Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. The use of adjuvants is one approach to augment the number of available vaccine doses and to overcome potential vaccine shortages. Appropriately selected adjuvant technologies can decrease the amount of vaccine antigen required per dose, may broaden or lengthen the conferred protection against disease, and may even allow protective single-dose vaccination. Here we describe a technology transfer collaboration between Switzerland and Indonesia that led to the establishment of a vaccine formulation platform in Surabaya which involved the transfer of equipment and expertise to enable research and development of adjuvanted vaccine formulations and delivery systems. This new Indonesian capability aims to facilitate local and regional access to know-how relating to adjuvanted vaccine formulations, thus promoting their application to local vaccine developers. In this review, we aim to share the "lessons learned" from this project to both support and inspire future scientific collaborations of a similar nature.	[Lemoine, Celine H.; Borchard, Gerrit] Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Rue Michel Servet 1, CH-1221 Geneva, Switzerland; [Lemoine, Celine H.; Ventura, Roland; Collin, Nicolas] Vaccine Formulat Inst, Chemin Aulx 14, CH-1228 Plan Les Ouates, Switzerland; [Nidom, Reviany V.; Indrasari, Setyarina; Normalina, Irine; Santoso, Kuncoro Puguh; Nidom, Chairul A.] Prof Nidom Fdn, Surabaya 60298, Indonesia; [Santoso, Kuncoro Puguh; Nidom, Chairul A.] Univ Airlangga, Fac Vet Med, Surabaya 60115, Indonesia; [Derouet, Francis] Univ Lausanne, Ctr Lab Epalinges, Ch Boveresses 155, CH-1011 Epalinges, Switzerland; [Barnier-Quer, Christophe] Univ Lausanne, Vaccine Formulat Lab, Ch Boveresses 155, CH-1011 Epalinges, Switzerland; [Barnier-Quer, Christophe] GALVmed, Doherty Bldg,Pentlands Sci Pk, Edinburgh EH26 0PZ, Midlothian, Scotland		Lemoine, CH (通讯作者)，Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Rue Michel Servet 1, CH-1221 Geneva, Switzerland.; Lemoine, CH (通讯作者)，Vaccine Formulat Inst, Chemin Aulx 14, CH-1228 Plan Les Ouates, Switzerland.	celine.lemoine@vformulation.org; reviany@pnfinstitute.org; roland.ventura@vformulation.org; setyarina_ire@pnfinstitute.org; irine_normalina@pnfinstitute.org; kuncoropuguhsantoso@pnfinstitute.org; francis.derouet@unil.ch; christophe.barnier-quer@galvmed.org; gerrit.borchard@unige.ch; nicolas.collin@vformulation.org; nidomca@fkh.unair.ac.id			Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF) [IZ07Z0_160923]; Swiss Agency for Development and Cooperation (SDC) [IZ07Z0_160923]	This research was funded by the Swiss National Science Foundation (SNF) and Swiss Agency for Development and Cooperation (SDC) as a joint funding initiative called The Swiss Programme for Research on Global Issues for Development (r4d programme), grant number IZ07Z0_160923.	Akamatsu MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233632; [Anonymous], IFPMA Technology Transfer: A Collaborative Approach to Improve Global Health; [Anonymous], BIOFARMA ANN REPORT; [Anonymous], Bill and Melinda Gates Foundation BMGF-Vaccine Development and Surveillance Strategy Overview; Atmar RL, 2009, CURR TOP MICROBIOL, V333, P323, DOI 10.1007/978-3-540-92165-3_16; Ben Oppenheim, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001157; Berkley S., COVAX EXPLAINED GAVI; Bhide Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00646; Bihari I, 2012, CLIN VACCINE IMMUNOL, V19, P1943, DOI 10.1128/CVI.00373-12; Brende B, 2017, LANCET, V389, P233, DOI 10.1016/S0140-6736(17)30131-9; Budimir N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063163; Castellacci F, 2013, RES POLICY, V42, P579, DOI 10.1016/j.respol.2012.10.006; Centers for Disease Control and Prevention (CDC) Food and Drug Administration (FDA) U.S Department of Health and Human Services (HHS), VACC ADV EV REP SYST; Collin N, 2011, VACCINE, V29, pA37, DOI 10.1016/j.vaccine.2011.04.125; Collin N, 2009, VACCINE, V27, P5184, DOI 10.1016/j.vaccine.2009.06.034; Crager SE, 2014, AM J PUBLIC HEALTH, V104, pE85, DOI 10.2105/AJPH.2014.302236; de Jonge J, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0187-4; de Vries RD, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030046; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; El Sahlyt HM, 2008, EXPERT REV VACCINES, V7, P241, DOI 10.1586/14760584.7.2.241; European Centre for Disease Prevention and Control (ECDC), MON VACC SAF REP SID; Fox Christopher B, 2017, Ther Adv Vaccines Immunother, V5, P111, DOI 10.1177/2051013617733259; Fox CB, 2013, VACCINE, V31, P1633, DOI 10.1016/j.vaccine.2012.10.048; Friede M, 2011, VACCINE, V29, pA2, DOI 10.1016/j.vaccine.2011.02.079; Geeraedts F, 2008, INFLUENZA OTHER RESP, V2, P41, DOI 10.1111/j.1750-2659.2008.00038.x; Halabi S, 2020, ANN HLTH L, V28, P27; Hendriks J, 2011, VACCINE, V29, pA8, DOI 10.1016/j.vaccine.2011.04.124; Henning J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216984; Hoa LK, 2011, VACCINE, V29, pA34, DOI 10.1016/j.vaccine.2011.04.118; Jakob U., 2020, NORM CONFLICTS GLOBA; Kaswandani N., 2004, PAEDIATR INDONES, V44, P153, DOI [10.14238/pi44.4.2004.153-9, DOI 10.14238/PI44.4.2004.153-9]; Kristensen D, 2013, VACCINE, V31, pB157, DOI 10.1016/j.vaccine.2012.10.113; Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5; Lowe C, 2010, CORNELL U PRESS SE A, V90, P24; Luke CJ, 2014, EXPERT REV VACCINES, V13, P873, DOI 10.1586/14760584.2014.922416; McHugh KJ, 2015, J CONTROL RELEASE, V219, P596, DOI 10.1016/j.jconrel.2015.07.029; Menristek, ID VAKS IND HAR TUMB; Miyaki C, 2011, VACCINE, V29, pA12, DOI 10.1016/j.vaccine.2011.04.127; Newland M, 2021, EXPERT REV VACCINES, V20, P235, DOI 10.1080/14760584.2021.1886931; Nidom CA, 2010, EMERG INFECT DIS, V16, P1515, DOI 10.3201/eid1610.100508; O'Hagan DT, 2007, CLIN PHARMACOL THER, V82, P740, DOI 10.1038/sj.clpt.6100402; Partridge J, 2010, VACCINE, V28, P4709, DOI 10.1016/j.vaccine.2010.04.083; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755; Rockman S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020211; Schwartz J, 2017, J MICROBIOL IMMUNOL, V50, P125, DOI 10.1016/j.jmii.2016.08.010; Scorza FB, 2017, VACCINE, V35, P5397, DOI 10.1016/j.vaccine.2017.03.094; Secretariat of the Convention on Biological Diversity Montreal United Nations, NAG PROT ACC GEN RES; Sedyaningsih ER, 2007, J INFECT DIS, V196, P522, DOI 10.1086/519692; Sell TK, 2021, VACCINE, V39, P1667, DOI 10.1016/j.vaccine.2021.02.017; Slifka MK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00956; Sparrow E, 2021, VACCINE, V39, P512, DOI 10.1016/j.vaccine.2020.12.018; Stavaru C, 2016, HUM VACC IMMUNOTHER, V12, P1009, DOI 10.1080/21645515.2015.1111495; Stoel M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125228; Suhardono M, 2011, VACCINE, V29, pA22, DOI 10.1016/j.vaccine.2011.04.123; The Gavi Alliance, GOV LEG STRUCT; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; Trombetta CM, 2019, EXPERT REV VACCINES, V18, P737, DOI 10.1080/14760584.2019.1639503; United Nations UNCTAD, TRANSFER TECHNOLOGY; van der Heiden P, 2016, J ENG TECHNOL MANAGE, V41, P65, DOI 10.1016/j.jengtecman.2016.07.001; Ventura R, 2013, VACCINE, V31, P1641, DOI 10.1016/j.vaccine.2012.07.074; Vesikari T, 2012, VACCINE, V30, P1388, DOI 10.1016/j.vaccine.2011.12.009; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Wijesinghe Pushpa R, 2020, WHO South East Asia J Public Health, V9, P43, DOI 10.4103/2224-3151.282995; World Health Organisation, CUM NUMB CONF HUM CA; World Health Organisation, KEY EL SUST INFL VAC; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	70	3	3	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							461	10.3390/vaccines9050461			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1RJ	34063131	gold, Green Published			2022-04-29	WOS:000654603000001
J	Rangel, G; Barcena, J; Moreno, N; Mata, CP; Caston, JR; Alejo, A; Blanco, E				Rangel, Giselle; Barcena, Juan; Moreno, Noelia; Mata, Carlos P.; Caston, Jose R.; Alejo, Ali; Blanco, Esther			Chimeric RHDV Virus-Like Particles Displaying Foot-and-Mouth Disease Virus Epitopes Elicit Neutralizing Antibodies and Confer Partial Protection in Pigs	VACCINES			English	Article						virus-like particles (VLPs); chimeric VLPs; nanoparticles; vaccine platform; RHDV; FMDV; B-cell epitope; T-cell epitope; immune response; pig	CAPSID PROTEIN; MOLECULAR SWITCH; IMMUNE-RESPONSE; RESEARCH UPDATE; VACCINE; SWINE; INDUCE	Currently there is a clear trend towards the establishment of virus-like particles (VLPs) as a powerful tool for vaccine development. VLPs are tunable nanoparticles that can be engineered to be used as platforms for multimeric display of foreign antigens. We have previously reported that VLPs derived from rabbit hemorrhagic disease virus (RHDV) constitute an excellent vaccine vector, capable of inducing specific protective immune responses against inserted heterologous T-cytotoxic and B-cell epitopes. Here, we evaluate the ability of chimeric RHDV VLPs to elicit immune response and protection against Foot-and-Mouth disease virus (FMDV), one of the most devastating livestock diseases. For this purpose, we generated a set of chimeric VLPs containing two FMDV-derived epitopes: a neutralizing B-cell epitope (VP1 (140-158)) and a T-cell epitope [3A (21-35)]. The epitopes were inserted joined or individually at two different locations within the RHDV capsid protein. The immunogenicity and protection potential of the chimeric VLPs were analyzed in the mouse and pig models. Herein we show that the RHDV engineered VLPs displaying FMDV-derived epitopes elicit a robust neutralizing immune response in mice and pigs, affording partial clinical protection against an FMDV challenge in pigs.	[Rangel, Giselle; Barcena, Juan; Moreno, Noelia; Alejo, Ali; Blanco, Esther] CSIC, INIA, CISA, Madrid 28130, Spain; [Mata, Carlos P.; Caston, Jose R.] CSIC, Ctr Nacl Biotecnol, Dept Struct Macromol, Madrid 28049, Spain; [Rangel, Giselle] Inst Invest Cient & Serv Alta Tecnol INDICASAT AI, City Of Knowledge 084301103, Panama; [Moreno, Noelia] Consejeria Agr, CFMR Moraleja, Junta De Extremadura 10840, Caceres, Spain; [Mata, Carlos P.] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England		Blanco, E (通讯作者)，CSIC, INIA, CISA, Madrid 28130, Spain.	grangel@indicasat.org.pa; barcena@inia.es; noeliamorm@gmail.com; c.perezmata@leeds.ac.uk; jrcaston@cnb.csic.es; alejo@inia.es; blanco@inia.es	Barcena, Juan/B-8855-2013; Blanco, Esther/C-1245-2013; Caston, Jose/L-5896-2014	Barcena, Juan/0000-0001-6050-0654; Blanco, Esther/0000-0001-8413-4222; Mata, Carlos P./0000-0003-3381-7431; Alejo, Ali/0000-0002-1613-6063; Rangel Tapia, Giselle Angeline/0000-0001-6825-3803; Caston, Jose/0000-0003-2350-9048	Spanish Ministry of Science and InnovationSpanish Government [AGL201676445-R, PID2019-107145RB-I00, BFU2017-88736]; Comunidad de MadridComunidad de Madrid; ECFEDER fundsEuropean Commission [P2018/BAA-4370 PLATESA 2, P2018/NMT-4389]; Spanish Ministry of Science and Innovation (FPI programme)	This work was supported by Spanish Ministry of Science and Innovation (grants AGL201676445-R to EB and AA; PID2019-107145RB-I00 to EB and BFU2017-88736-to JRC) and Comunidad de Madrid co-financed with ECFEDER funds (P2018/BAA-4370 PLATESA 2 to EB and P2018/NMT-4389 to JRC). GR and NM were holders of a PhD fellowship from the Spanish Ministry of Science and Innovation (FPI programme) and CPM was a PhD fellow of the La Caixa Foundation International Fellowship Program (La Caixa/CNB).	ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; Almanza H, 2008, J CLIN MICROBIOL, V46, P3971, DOI 10.1128/JCM.01204-08; Alves MP, 2009, CLIN VACCINE IMMUNOL, V16, P1151, DOI 10.1128/CVI.00018-09; Bachmann MF, 2011, PHILOS T R SOC B, V366, P2815, DOI 10.1098/rstb.2011.0103; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Barcena J, 2004, VIROLOGY, V322, P118, DOI 10.1016/j.virol.2004.01.021; Barcena Juan, 2013, Subcell Biochem, V68, P631, DOI 10.1007/978-94-007-6552-8_21; Barcena J, 2015, VET RES, V46, DOI 10.1186/s13567-015-0245-5; Blanco E, 2001, J VIROL, V75, P3164, DOI 10.1128/JVI.75.7.3164-3174.2001; Blanco E, 2016, ANTIVIR RES, V129, P74, DOI 10.1016/j.antiviral.2016.03.005; Blanco E, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/475960; Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234; Canas-Arranz R, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00498; Canas-Arranz R, 2020, TRANSBOUND EMERG DIS, V67, P1614, DOI 10.1111/tbed.13497; Mansilla FC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232782; Chang JT, 2019, J GEN VIROL, V100, P187, DOI 10.1099/jgv.0.001194; Crisci E, 2009, VIROLOGY, V387, P303, DOI 10.1016/j.virol.2009.02.045; Crisci E, 2015, MOL IMMUNOL, V63, P343, DOI 10.1016/j.molimm.2014.08.006; Crisci E, 2012, VET IMMUNOL IMMUNOP, V148, P211, DOI 10.1016/j.vetimm.2012.04.026; Cubillos C, 2008, J VIROL, V82, P7223, DOI 10.1128/JVI.00401-08; Cubillos C, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-66; Cubillos-Zapata C, 2020, VET RES, V51, DOI 10.1186/s13567-020-00785-x; Donaldson B, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0270-1; FRANCIS MJ, 1986, RES VET SCI, V41, P33, DOI 10.1016/S0034-5288(18)30568-X; GOLDING SM, 1976, RES VET SCI, V20, P142, DOI 10.1016/S0034-5288(18)33445-3; Hume HKC, 2019, BIOTECHNOL BIOENG, V116, P919, DOI 10.1002/bit.26890; Johnson JE, 2000, CURR OPIN STRUC BIOL, V10, P229, DOI 10.1016/S0959-440X(00)00073-7; Kelly HG, 2019, EXPERT REV VACCINES, V18, P269, DOI 10.1080/14760584.2019.1578216; Knight-Jones TJD, 2016, TRANSBOUND EMERG DIS, V63, P14, DOI 10.1111/tbed.12522; Kramer K, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/5364632; LAURENT S, 1994, J VIROL, V68, P6794, DOI 10.1128/JVI.68.10.6794-6798.1994; Le Pendu J, 2017, J GEN VIROL, V98, P1658, DOI 10.1099/jgv.0.000840; Lee KL, 2016, WIRES NANOMED NANOBI, V8, P554, DOI 10.1002/wnan.1383; Leuthold MM, 2015, J VIROL, V89, P2378, DOI 10.1128/JVI.02832-14; Li KY, 2013, J IMMUNOTHER, V36, P11, DOI 10.1097/CJI.0b013e3182787f5e; Li X, 2018, APPL MICROBIOL BIOT, V102, P10541, DOI 10.1007/s00253-018-9361-2; Lua LHL, 2014, BIOTECHNOL BIOENG, V111, P425, DOI 10.1002/bit.25159; Luque D, 2012, J VIROL, V86, P6470, DOI 10.1128/JVI.07050-11; Mateu MG, 2016, ADV EXP MED BIOL, V940, P83, DOI 10.1007/978-3-319-39196-0_5; Mateu MG, 2011, PROTEIN ENG DES SEL, V24, P53, DOI 10.1093/protein/gzq069; MCCULLOUGH KC, 1992, J VIROL, V66, P1835, DOI 10.1128/JVI.66.4.1835-1840.1992; Mohsen MO, 2020, IMMUNOL REV, V296, P155, DOI 10.1111/imr.12863; Mohsen MO, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030037; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Moreno N, 2016, SCI REP-UK, V6, DOI 10.1038/srep31844; OIE, MANUAL DIAGNOSTIC TE; Peacey M, 2008, VACCINE, V26, P5334, DOI 10.1016/j.vaccine.2008.07.074; Perez-Filgueira DM, 2007, VIROLOGY, V364, P422, DOI 10.1016/j.virol.2007.03.016; PFAFF E, 1982, EMBO J, V1, P869, DOI 10.1002/j.1460-2075.1982.tb01262.x; Pushko P, 2013, INTERVIROLOGY, V56, P141, DOI 10.1159/000346773; Robinson L, 2016, TRANSBOUND EMERG DIS, V63, P30, DOI 10.1111/tbed.12521; Rouco C, 2018, TRANSBOUND EMERG DIS, V65, pe373, DOI 10.1111/tbed.12767; Rueda P, 2004, J GEN VIROL, V85, P563, DOI 10.1099/vir.0.19525-0; Singanallur NB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010080; VALICEK L, 1990, ARCH VIROL, V112, P271, DOI 10.1007/BF01323171; Wang X, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003132; Win SJ, 2011, IMMUNOL CELL BIOL, V89, P681, DOI 10.1038/icb.2010.161; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zhang YL, 2007, SCAND J IMMUNOL, V65, P320, DOI 10.1111/j.1365-3083.2007.01900.x	59	3	3	3	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							470	10.3390/vaccines9050470			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1LW	34066934	gold, Green Published			2022-04-29	WOS:000654588600001
J	Cao, YM; Li, K; Xing, XC; Bao, HF; Huang, NN; Zhu, GQ; Bai, XW; Sun, P; Fu, YF; Li, PH; Zhang, J; Ma, XQ; Li, D; Liu, ZX; Lu, ZJ				Cao, Yimei; Li, Kun; Xing, Xiangchuan; Bao, Huifang; Huang, Nana; Zhu, Guoqiang; Bai, Xingwen; Sun, Pu; Fu, Yuanfang; Li, Pinghua; Zhang, Jing; Ma, Xueqing; Li, Dong; Liu, Zaixin; Lu, Zengjun			Selection of Vaccine Candidate for Foot-and-Mouth Disease Virus Serotype O Using a Blocking Enzyme-Linked Immunosorbent Assay	VACCINES			English	Article						foot-and-mouth disease; serotype O; NA-ELISA; VNT; vaccine selecting		Foot-and-mouth disease (FMD) is a highly contagious disease and one of the most economically important diseases of livestock. Vaccination is an important measure to control FMD and selection of appropriate vaccine strains is crucial. The objective of this study was to select a vaccine candidate and to evaluate the potential of a blocking ELISA for detecting neutralizing antibodies (NA-ELISA) in vaccine strain selection. Binary ethylenimine inactivated vaccines, prepared from four representative circulating strains (FMDV O/Mya/98, SCGH/CHA/2016, O/Tibet/99, and O/XJ/CHA/2017) belonging to four lineages within three different topotypes of FMD virus (FMDV) serotype O in China, were used to vaccinate cattle (12-13 animals for each strain), sheep (12-13 animals for each strain), and pigs (10 animals for each strain). The results of immunogenicity comparison showed that O/XJ/CHA/2017 exhibited the highest immunogenicity among the four strains in pigs, cattle, and sheep both by NA-ELISA and virus neutralizing test (VNT). Cross-neutralization analysis indicated that O/XJ/CHA/2017 displayed broad antigen spectrum and was antigenically matched with other three representative strains both by NA-ELISA and VNT. In addition, A significant correlation (p < 0.0001) was observed between the NA-ELISA titers and the VNT titers for four representative strains. The results showed that O/XJ/CHA/2017 was a promising vaccine strain candidate and NA-ELISA was comparable to VNT in neutralizing antibodies detection and could be used as the reference test system for vaccine strain selection.	[Cao, Yimei; Li, Kun; Xing, Xiangchuan; Bao, Huifang; Huang, Nana; Zhu, Guoqiang; Bai, Xingwen; Sun, Pu; Fu, Yuanfang; Li, Pinghua; Zhang, Jing; Ma, Xueqing; Li, Dong; Liu, Zaixin; Lu, Zengjun] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, OIE Natl Foot & Mouth Dis Reference Lab China, Lanzhou 730046, Peoples R China; [Xing, Xiangchuan; Huang, Nana] Tianjin Weite Biol Med Co Ltd, Tianjin 300301, Peoples R China		Lu, ZJ (通讯作者)，Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, OIE Natl Foot & Mouth Dis Reference Lab China, Lanzhou 730046, Peoples R China.	caoyimei@caas.cn; likun02@caas.cn; xxc15232058169@163.com; baohuifang@caas.cn; h1540414396@163.com; zhuguoqiang1998@126.com; baixingwen@caas.cn; sunpu@caas.cn; fuyuanfang@caas.cn; lipinghua@caas.cn; zhangjing@caas.cn; maxueqing@caas.cn; lidong@caas.cn; liuzaixin@caas.cn; luzengjun@caas.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31902288, 32072873]	This work was supported by grants from the National Natural Science Foundation of China (Nos. 31902288; 32072873).	[Anonymous], 2012, MANUAL DIAGNOSTIC TE, VVolume 2, P145; BROOKSBY J B, 1958, Adv Virus Res, V5, P1, DOI 10.1016/S0065-3527(08)60670-3; Cao YM, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01030-19; Cao YM, 2009, VET MICROBIOL, V137, P10, DOI 10.1016/j.vetmic.2008.12.007; Domingo E, 2003, VIRUS RES, V91, P47, DOI 10.1016/S0168-1702(02)00259-9; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Haas B., 1994, APPL FMD LIQUID PHAS, P124; HINGLEY PJ, 1987, J BIOL STAND, V15, P127, DOI 10.1016/0092-1157(87)90036-9; Knight-Jones TJD, 2013, PREV VET MED, V112, P161, DOI 10.1016/j.prevetmed.2013.07.013; Knowles NJ, 2016, REV SCI TECH OIE, V35, P741, DOI 10.20506/rst.35.3.2565; Li D, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-215; Li D, 2010, VET RES COMMUN, V34, P445, DOI 10.1007/s11259-010-9419-9; Li KB, 2012, ADV MATER RES-SWITZ, V468-471, P365, DOI 10.4028/www.scientific.net/AMR.468-471.365; Mackay DKJ, 2001, J VIROL METHODS, V97, P33, DOI 10.1016/S0166-0934(01)00333-0; Mattion N, 2009, VACCINE, V27, P741, DOI 10.1016/j.vaccine.2008.11.026; MCCULLOUGH KC, 1992, J VIROL, V66, P1835, DOI 10.1128/JVI.66.4.1835-1840.1992; MCCULLOUGH KC, 1992, VET MICROBIOL, V30, P99, DOI 10.1016/0378-1135(92)90106-4; MCCULLOUGH KC, 1986, IMMUNOLOGY, V58, P421; Paton DJ, 2005, REV SCI TECH OIE, V24, P981, DOI 10.20506/rst.24.3.1632; Brito BP, 2014, VACCINE, V32, P433, DOI 10.1016/j.vaccine.2013.12.007; Robiolo B, 2010, VACCINE, V28, P6235, DOI 10.1016/j.vaccine.2010.07.012; RWEYEMAMU MM, 1978, J HYG-CAMBRIDGE, V81, P107, DOI 10.1017/S002217240005381X; VANMAANEN C, 1989, J IMMUNOL METHODS, V124, P111, DOI 10.1016/0022-1759(89)90192-0; W O for A H (OIE), 2018, TERR MAN ONL ACC OIE, P433; Zheng HX, 2012, VIRUS GENES, V44, P80, DOI 10.1007/s11262-011-0670-0; Zhu Z, 2018, TRANSBOUND EMERG DIS, V65, P2027, DOI 10.1111/tbed.12895	26	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							387	10.3390/vaccines9040387			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4OA	33920779	Green Published, gold			2022-04-29	WOS:000643759200001
J	Choe, S; Kim, KS; Shin, J; Song, S; Park, GN; Cha, RM; Choi, SH; Jung, BI; Lee, KW; Hyun, BH; Park, BK; An, DJ				Choe, Seeun; Kim, Ki-Sun; Shin, Jihye; Song, Sok; Park, Gyu-Nam; Cha, Ra Mi; Choi, Sung-Hyun; Jung, Byung-Il; Lee, Kyung-Won; Hyun, Bang-Hun; Park, Bong-Kyun; An, Dong-Jun			Comparative Analysis of the Productivity and Immunogenicity of an Attenuated Classical Swine Fever Vaccine (LOM) and an Attenuated Live Marker Classical Swine Fever Vaccine (Flc-LOM-BErns) from Laboratory to Pig Farm	VACCINES			English	Article						CSFV; LOM; Flc-LOM-BErns; SE; DIVA; pig		Herein, we compared the productivity of pigs inoculated with one of two classical swine fever (CSF) vaccines (low virulent of Miyagi (LOM) or Flc-LOM-BErns) plus the swine erysipelothrix rhusiopathiae (SE) vaccine. The feed intake and weight increase of the pigs inoculated with Flc-LOM-BErns + SE were normal. However, the feed intake of the pigs inoculated with LOM + SE dropped sharply from four days post-vaccination (dpv). In addition, the slaughter date was an average of eight days later than that of the pigs inoculated with Flc-LOM-BErns + SE. All pigs inoculated with the Flc-LOM-BErns + SE vaccine were completely differentiated at 14 days against CSF E-rns antibody and at approximately 45 days against the bovine viral diarrhea virus (BVDV) E-rns antibody; the titers were maintained until slaughter. Leucopenia occurred temporarily in the LOM + SE group, but not in the Flc-LOM-BErns + SE group. Expression of tumor necrosis factor (TNF)-alpha and IFN-gamma was significantly (p < 0.05) higher in the LOM + SE group than in the mock (no vaccine) group. When conducting the same experiment on a breeding farm, the results were similar to those of the laboratory experiments. In conclusion, the biggest advantage of replacing the CSF LOM vaccine with the Flc-LOM-BErns vaccine is improved productivity.	[Choe, Seeun; Kim, Ki-Sun; Shin, Jihye; Song, Sok; Park, Gyu-Nam; Cha, Ra Mi; Hyun, Bang-Hun; Park, Bong-Kyun; An, Dong-Jun] Anim & Plant Quarantine Agcy, Virus Dis Div, Gimchen 39660, Gyeongbuk Do, South Korea; [Choi, Sung-Hyun; Jung, Byung-Il] Korea Pork Producers Assoc, Seoul 06643, South Korea; [Lee, Kyung-Won] Pig Integrated Control Ctr PICC, Cheonan 31008, South Korea; [Park, Bong-Kyun] Seoul Univ, Coll Vet Med, Seoul 08826, South Korea		An, DJ (通讯作者)，Anim & Plant Quarantine Agcy, Virus Dis Div, Gimchen 39660, Gyeongbuk Do, South Korea.	ivvi59@korea.kr; kisunkim@korea.kr; shinjibong227@gmail.com; ssoboro@naver.com; changep0418@gmail.com; rami.cha01@korea.kr; heechan9@hanmail.net; exksa001@daum.net; dukelee72@hanmail.net; hyunbh@korea.kr; parkx026@korea.kr; andj67@korea.kr			Animal and Plant Quarantine Agency [B-1543083-2019-20-01]; Ministry of Agriculture Food and Rural Affairs, Republic of Korea	This project was supported by grants (project code no. B-1543083-2019-20-01) from the Animal and Plant Quarantine Agency and Ministry of Agriculture Food and Rural Affairs, Republic of Korea.	Becher P, 2003, VIROLOGY, V311, P96, DOI 10.1016/S0042-6822(03)00192-2; Blackburn SD, 2007, TRENDS MICROBIOL, V15, P143, DOI 10.1016/j.tim.2007.02.006; Blome S, 2017, VET RES, V48, DOI 10.1186/s13567-017-0457-y; Choe S, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9080608; Choe S, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9010018; Choe S, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040251; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Drew T., 2008, MANUAL DIAGNOSTIC TE, V6th ed., P1092; Duvigneau JC, 2005, J IMMUNOL METHODS, V306, P16, DOI 10.1016/j.jim.2005.06.021; Gabriel C, 2012, VACCINE, V30, P2928, DOI 10.1016/j.vaccine.2012.02.065; Ganges L, 2020, VIRUS RES, V289, DOI 10.1016/j.virusres.2020.198151; Graham SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029310; Khatoon E, 2019, ACTA VIROL, V63, P60, DOI 10.4149/av_2019_105; Koenig P, 2007, VET MICROBIOL, V120, P343, DOI 10.1016/j.vetmic.2006.10.034; Kristensen CS, 2011, PREV VET MED, V98, P250, DOI 10.1016/j.prevetmed.2010.11.015; Lim SI, 2019, VACCINE, V37, P3598, DOI 10.1016/j.vaccine.2019.04.076; Lim SI, 2016, VET MICROBIOL, V193, P36, DOI 10.1016/j.vetmic.2016.07.027; Lim SI, 2016, VACCINE, V34, P2021, DOI 10.1016/j.vaccine.2016.02.062; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Park S, 2013, CLIN EXP VACCINE RES, V2, P135, DOI 10.7774/cevr.2013.2.2.135; Peiponen KS, 2018, ACTA VET SCAND, V60, DOI 10.1186/s13028-018-0374-8; Petrov A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108910; Renson P, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-9; Sanchez-Cordon PJ, 2005, J COMP PATHOL, V132, P249, DOI 10.1016/j.jcpa.2004.10.002; Song JY, 2013, TRANSBOUND EMERG DIS, V60, P546, DOI 10.1111/j.1865-1682.2012.01371.x; Suradhat S, 2001, VET IMMUNOL IMMUNOP, V83, P177, DOI 10.1016/S0165-2427(01)00389-0; Tarradas J, 2010, VET MICROBIOL, V142, P51, DOI 10.1016/j.vetmic.2009.09.043	27	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							381	10.3390/vaccines9040381			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5AO	33924647	gold, Green Published			2022-04-29	WOS:000643792000001
J	Rzymski, P; Zeyland, J; Poniedzialek, B; Malecka, I; Wysocki, J				Rzymski, Piotr; Zeyland, Joanna; Poniedzialek, Barbara; Malecka, Ilona; Wysocki, Jacek			The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland	VACCINES			English	Article						COVID-19; vaccinations; vaccine hesitancy; mRNA vaccines; vector vaccines; SARS-CoV-2	INFLUENZA VACCINATION; KNOWLEDGE; HESITANCY; WOMEN	Vaccine hesitancy is a major threat to the success of COVID-19 vaccination programs. The present cross-sectional online survey of adult Poles (n = 1020) expressing a willingness to receive the COVID-19 vaccine was conducted between February and March 2021 and aimed to assess (i) the general trust in different types of vaccines, (ii) the level of acceptance of the COVID-19 vaccines already in use in Poland (BNT162b2 by BioNTech/Pfizer, mRNA-1273 by Moderna and AZD1222 by Oxford/AstraZeneca) as well as eight vaccines approved outside European Union (EU) or in advanced stages of clinical trials, (iii) level of fear of vaccination against COVID-19, and (iv) main sources of information on COVID-19 vaccination. Among all major vaccine technology, the highest level of trust was observed for the mRNA platform, with a considerable number of surveyed (>20%) not aware of the existence of vaccines produced using the traditional approach (inactivated and live attenuated vaccines). The age of participants was the main factor differentiating the level of trust in a particular vaccine type. Both BNT162b and mRNA-1273 received a high level of acceptance, contrary to AZD1222. From eight vaccines unauthorized in the EU at the moment of study, the CVnCoV (mRNA; CureVac) was met with the highest level of trust, followed by Ad26.COV2.S (vector; Janssen/Johnson&Johnson) and NVX-CoV2373 (protein; Novavax). Sputnik V (vector; Gamaleya Research Institute) was decidedly the least trusted vaccine. The median level of fear (measured by the 10-point Likert-type scale) in the studied group was 4.0, mostly related to the risk of serious allergic reactions, other severe adverse events and unknown long-term effects of vaccination. Female, individuals with a lower level of education and those not seeking any information on the COVID-19 vaccines revealed a higher fear of vaccination. Experts' materials were the major source of information on COVID-19 vaccines in the studied group. The study shows the level of trust in COVID-19 vaccines can vary much across the producers while the mRNA vaccines are received with a high level of acceptance. It also emphasizes the need for effective and continuous science communication when fighting the pandemic as it may be an ideal time to increase the general awareness of vaccines.	[Rzymski, Piotr; Poniedzialek, Barbara] Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland; [Rzymski, Piotr] Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland; [Zeyland, Joanna] Poznan Univ Life Sci, Dept Biochem & Biotechnol, PL-60632 Poznan, Poland; [Malecka, Ilona; Wysocki, Jacek] Poznan Univ Med Sci, Dept Prevent Med, PL-60179 Poznan, Poland		Rzymski, P (通讯作者)，Poznan Univ Med Sci, Dept Environm Med, PL-60806 Poznan, Poland.; Rzymski, P (通讯作者)，Universal Sci Educ & Res Network USERN, Integrated Sci Assoc ISA, PL-60806 Poznan, Poland.	rzymskipiotr@ump.edu.pl; joanna.zeyland@up.poznan.pl; bpon@ump.edu.pl; imalecka@ump.edu.pl; jawysocki@pro.onet.pl	; Rzymski, Piotr/I-2240-2012	Zeyland, Joanna/0000-0002-1208-3291; Poniedzialek, Barbara/0000-0002-1601-1703; Rzymski, Piotr/0000-0002-4713-0801			Albano L, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-208; Alholm Z., 2017, OPEN FORUM INFECT DI, V4, pS458, DOI [10.1093/ofid/ofx163.1167, DOI 10.1093/OFID/OFX163.1167]; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Balakrishnan VS, 2020, LANCET INFECT DIS, V20, P1128, DOI 10.1016/S1473-3099(20)30709-X; Baldo V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010021; Bazan D, 2021, INT J DISAST RISK RE, V55, DOI 10.1016/j.ijdrr.2021.102109; Betancourt JA, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040380; Boytchev H, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n414; Brownlie J, 2006, SOC SCI MED, V62, P433, DOI 10.1016/j.socscimed.2005.05.033; Bucci E, 2020, LANCET, V396, pE53, DOI 10.1016/S0140-6736(20)31960-7; Burgos Rodrigo M, 2021, Drugs Context, V10, DOI 10.7573/dic.2020-12-2; Burki TK, 2020, LANCET RESP MED, V8, pE85, DOI 10.1016/S2213-2600(20)30402-1; CBOS, ATTITUDES VACCINATIO; CBOS, RES REPORTS; Cochran WG, 1977, SAMPLING TECHNIQUES; Costantino C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155362; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Di Giuseppe G, 2008, BRIT J CANCER, V99, P225, DOI 10.1038/sj.bjc.6604454; Dolgin E, 2021, NATURE, V589, P189, DOI 10.1038/d41586-021-00019-w; Dube E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156118; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; European Medicines Agency, EMA STARTS ROLLING R; Ferdinand KC, 2020, J NATL MED ASSOC, V112, P681, DOI 10.1016/j.jnma.2020.11.001; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Geldsetzer P, 2020, J MED INTERNET RES, V22, DOI 10.2196/18790; Gianola S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240123; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Kar-Gupta S., EU MUST BE UNITED RU; Krasnicka J, 2018, HUM VACC IMMUNOTHER, V14, P2884, DOI 10.1080/21645515.2018.1496766; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Lenzen M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235654; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Male V, 2021, NAT REV IMMUNOL, V21, P200, DOI 10.1038/s41577-021-00525-y; McLean CP, 2009, CLIN PSYCHOL REV, V29, P496, DOI 10.1016/j.cpr.2009.05.003; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; Napolitano CL, 1999, SOC INDIC RES, V46, P191, DOI 10.1023/A:1006845025370; Napolitano F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2138-2; Nitsch-Osuch A, 2017, ADV EXP MED BIOL, V968, P19, DOI 10.1007/5584_2016_193; Nowakowska J, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110451; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Persad G, 2020, JAMA-J AM MED ASSOC, V324, P1601, DOI 10.1001/jama.2020.18513; Pew Research Center, RUSSIAS GLOBAL IMAGE; Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prati G, 2021, PSYCHOL MED, V51, P201, DOI 10.1017/S0033291721000015; Quinn SC, 2021, AM J PUBLIC HEALTH, V111, P355, DOI 10.2105/AJPH.2020.306036; Rapanta C., 2020, POSTDIGIT SCI ED, V2, P923, DOI [10.1007/s42438-020-00155-y, DOI 10.1007/S42438-020-00155-Y]; Ribas A, 2021, CANCER DISCOV, V11, P233, DOI 10.1158/2159-8290.CD-20-1817; Rimoin A.W., 2020, ASSESSMENT COVID 19, DOI [10.1101/2020.11.18.20234468, DOI 10.1101/2020.11.18.20234468]; Ring S., EUROPE RESTARTS ASTR; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Rzymski P, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106711; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Schiavo R., 2020, J COMMUNICATION HEAL, V13, P73, DOI [https://doi.org/10.1080/17538068.2020.1778959, DOI 10.1080/17538068.2020.1778959, 10.1080/17538068.2020.1778959]; Sidor A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061657; Simon RM, 2010, PUBLIC UNDERST SCI, V19, P642, DOI 10.1177/0963662509335449; Thorp HH, 2020, SCIENCE, V369, P885, DOI 10.1126/science.abe3147; Defendi HGT, 2021, J PHARM INNOV, DOI 10.1007/s12247-021-09535-8; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Zarobkiewicz MK, 2017, HUM VACC IMMUNOTHER, V13, P2654, DOI 10.1080/21645515.2017.1365994	66	31	32	8	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							382	10.3390/vaccines9040382			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS4VE	33919672	Green Published, gold			2022-04-29	WOS:000643777900001
J	Valenzuela-Munoz, V; Benavente, BP; Casuso, A; Leal, Y; Gallardo-Escarate, C				Valenzuela-Munoz, Valentina; Benavente, Barbara P.; Casuso, Antonio; Leal, Yeny; Gallardo-Escarate, Cristian			Chimeric Protein IPath(R) with Chelating Activity Improves Atlantic Salmon's Immunity against Infectious Diseases	VACCINES			English	Article						iron transport; chimeric protein; chelating activity; Salmo salar; Aeromonas salmonicida; Caligus rogercresseyi; Piscirickettsia salmonis	PISCIRICKETTSIA-SALMONIS; IRON OVERLOAD; CALIGUS-ROGERCRESSEYI; LEPEOPHTHEIRUS-SALMONIS; GENE-EXPRESSION; SEA LICE; HEPCIDIN; FERRITIN; SALAR; BACTERIAL	Infection processes displayed by pathogens require the acquisition of essential inorganic nutrients and trace elements from the host to survive and proliferate. Without a doubt, iron is a crucial trace metal for all living organisms and also a pivotal component in the host-parasite interactions. In particular, the host reduces the iron available to face the infectious disease, increasing iron transport proteins' expression and activating the heme synthesis and degradation pathways. Moreover, recent findings have suggested that iron metabolism modulation in fish promotes the immune response by reducing cellular iron toxicity. We hypothesized that recombinant proteins related to iron metabolism could modulate the fish's immune system through iron metabolism and iron-responsive genes. Here a chimeric iron transport protein (IPath(R)) was bioinformatically designed and then expressed in a recombinant bacterial system. The IPath(R) protein showed a significant chelating activity under in vitro conditions and biological activity. Taking this evidence, a vaccine candidate based on IPath(R) was evaluated in Atlantic salmon challenged with three different fish pathogens. Experimental trials were conducted using two fish groups: one immunized with IPath(R) and another injected with adjutant as the control group. After 400 accumulated thermal units (ATUs), two different infection trials were performed. In the first one, fish were infected with the bacterium Aeromonas salmonicida, and in a second trial, fish were exposed to the ectoparasite Caligus rogercresseyi and subsequently infected with the intracellular bacterium Piscirickettsia salmonis. Fish immunized with IPath(R) showed a significant delay in the mortality curve in response to A. salmonicida and P. salmonis infections. However, no significant differences between infected and control fish groups were observed at the end of the experiment. Notably, sea lice burden reduction was observed in vaccinated Atlantic salmon. Transcriptional analysis evidenced a high modulation of iron-homeostasis-related genes in fish vaccinated with IPath(R) compared to the control group during the infection. Moreover, increasing expression of Atlantic salmon IgT was associated with IPath(R) immunization. This study provides evidence that the IPath(R) protein could be used as an antigen or booster in commercial fish vaccines, improving the immune response against relevant pathogens for salmon aquaculture.	[Valenzuela-Munoz, Valentina; Benavente, Barbara P.; Casuso, Antonio; Leal, Yeny; Gallardo-Escarate, Cristian] Univ Concepcion, Interdisciplinary Ctr Aquaculture Res INCAR, Concepcion 4030000, Chile; [Valenzuela-Munoz, Valentina; Benavente, Barbara P.; Casuso, Antonio; Leal, Yeny; Gallardo-Escarate, Cristian] Univ Concepcion, Dept Oceanog, Lab Biotechnol & Aquat Genom, Concepcion 4030000, Chile		Gallardo-Escarate, C (通讯作者)，Univ Concepcion, Interdisciplinary Ctr Aquaculture Res INCAR, Concepcion 4030000, Chile.; Gallardo-Escarate, C (通讯作者)，Univ Concepcion, Dept Oceanog, Lab Biotechnol & Aquat Genom, Concepcion 4030000, Chile.	valevalenzuela@udec.cl; bbenaventec@gmail.com; acasuso@udec.cl; yleal@udec.cl; crisgallardo@udec.cl	Gallardo-Escárate, Cristian/AAE-8980-2022	Gallardo-Escárate, Cristian/0000-0002-7094-6702	CONICYT-Chile through the grant FONDAP [1510027]; CONICYT-Chile through the grant FONDECYT [1180867]; CONICYT-Chile through the Postdoctoral grant FONDECYT [3190320]	CONICYT-Chile funded this study through the grants FONDAP (1510027) and FONDECYT (1180867), and Postdoctoral grant FONDECYT (3190320).	Almarza O, 2016, INT MICROBIOL, V19, P49, DOI 10.2436/20.1501.01.263; Anderson GJ, 2009, CELL MOL LIFE SCI, V66, P3241, DOI 10.1007/s00018-009-0051-1; Arriagada G, 2019, PREV VET MED, V171, DOI 10.1016/j.prevetmed.2019.104771; Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Barragan G., 2016, REV MED HOSP GEN, V79, P88; CHART H, 1983, J BACTERIOL, V156, P758, DOI 10.1128/JB.156.2.758-764.1983; Chifman J, 2014, ADV EXP MED BIOL, V844, P201, DOI 10.1007/978-1-4939-2095-2_10; Cuesta A, 2008, MOL IMMUNOL, V45, P2333, DOI 10.1016/j.molimm.2007.11.007; Dallaire-Dufresne S, 2014, VET MICROBIOL, V169, P1, DOI 10.1016/j.vetmic.2013.06.025; De Zoysa M, 2007, FISH SHELLFISH IMMUN, V23, P624, DOI 10.1016/j.fsi.2007.01.013; DECKER EA, 1990, J AGR FOOD CHEM, V38, P674, DOI 10.1021/jf00093a019; DESOUSA M, 1989, CLIN EXP IMMUNOL, V75, P1; Ewart KV, 2005, DEV COMP IMMUNOL, V29, P333, DOI [10.1016/j.dci.2004.08.084, 10.1016/j.dci.2004.08.004]; Feng CY, 2009, PHYSIOL GENOMICS, V37, P149, DOI 10.1152/physiolgenomics.90373.2008; Galay RL, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0482-x; Gallardo-Escarate C, 2019, REV AQUACULT, V11, P325, DOI 10.1111/raq.12334; Gallardo-Escarate C, 2019, FISH SHELLFISH IMMUN, V90, P199, DOI 10.1016/j.fsi.2019.04.065; Ganz T, 2005, BEST PRACT RES CL HA, V18, P171, DOI 10.1016/j.beha.2004.08.020; Ganz T, 2007, J AM SOC NEPHROL, V18, P394, DOI 10.1681/ASN.2006070802; Garcia N., 2010, HAEMATOLOGIA, V<bold>14</bold>, P48; Gkouvatsos K, 2012, BBA-GEN SUBJECTS, V1820, P188, DOI 10.1016/j.bbagen.2011.10.013; Hajdusek O, 2016, TICKS TICK-BORNE DIS, V7, P565, DOI 10.1016/j.ttbdis.2016.01.006; He DD, 2015, NEW BIOTECHNOL, V32, P651, DOI 10.1016/j.nbt.2014.12.006; Hood MI, 2012, NAT REV MICROBIOL, V10, P525, DOI 10.1038/nrmicro2836; Johnson EE, 2012, MICROBES INFECT, V14, P207, DOI 10.1016/j.micinf.2011.10.001; Kvingedal Ane M., 1993, Molecular Marine Biology and Biotechnology, V2, P233; Lee JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103729; Martin SAM, 2006, MOL IMMUNOL, V43, P1900, DOI 10.1016/j.molimm.2005.10.007; Montosi G, 2005, HEPATOLOGY, V41, P545, DOI 10.1002/hep.20620; Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303; Neves JV, 2009, DEV COMP IMMUNOL, V33, P848, DOI 10.1016/j.dci.2009.02.001; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Nunez G, 2018, J IMMUNOL, V201, P11, DOI 10.4049/jimmunol.1800325; OMARA FO, 1994, BRIT J NUTR, V72, P899, DOI 10.1079/BJN19940094; Pan X, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-64; Perner J, 2016, ELIFE, V5, DOI [10.7754/eLife.12318, 10.7554/eLife.12318]; Pontigo JP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.602689; Pulgar R, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1716-9; Rauta PR, 2012, IMMUNOL LETT, V148, P23, DOI 10.1016/j.imlet.2012.08.003; Rodrigues PNS, 2006, DEV COMP IMMUNOL, V30, P1156, DOI 10.1016/j.dci.2006.02.005; Rorvik KA, 2003, J FISH DIS, V26, P477, DOI 10.1046/j.1365-2761.2003.00482.x; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; Rozas M, 2014, J FISH DIS, V37, P163, DOI 10.1111/jfd.12211; Rozas-Serri M, 2019, FISH SHELLFISH IMMUN, V93, P789, DOI 10.1016/j.fsi.2019.08.031; Singh M, 2019, ECOTOX ENVIRON SAFE, V170, P87, DOI 10.1016/j.ecoenv.2018.11.129; Standal H, 1997, BIOL TRACE ELEM RES, V59, P13, DOI 10.1007/BF02783225; Tadiso TM, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-141; THORSON JA, 1991, CELL IMMUNOL, V134, P126, DOI 10.1016/0008-8749(91)90336-A; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Valderrama K, 2019, J FISH DIS, V42, P1601, DOI 10.1111/jfd.13077; Valdes N, 2015, FEMS MICROBIOL LETT, V362, DOI 10.1093/femsle/fnu062; Valenzuela-Miranda D, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02877; Valenzuela-Miranda D, 2017, DEV COMP IMMUNOL, V77, P287, DOI 10.1016/j.dci.2017.08.016; Valenzuela-Miranda D, 2016, FISH SHELLFISH IMMUN, V59, P427, DOI 10.1016/j.fsi.2016.11.001; Valenzuela-Munoz V, 2017, J FISH DIS, V40, P1169, DOI 10.1111/jfd.12592; Valenzuela-Munoz V, 2017, FISH SHELLFISH IMMUN, V60, P97, DOI 10.1016/j.fsi.2016.11.045; Valenzuela-Munoz V, 2016, FISH SHELLFISH IMMUN, V59, P276, DOI 10.1016/j.fsi.2016.10.046; Vera-Bizama F, 2015, FISH SHELLFISH IMMUN, V47, P725, DOI 10.1016/j.fsi.2015.10.022; Wessling-Resnick M, 2010, ANNU REV NUTR, V30, P105, DOI 10.1146/annurev.nutr.012809.104804; Yaacob EN, 2018, VET IMMUNOL IMMUNOP, V204, P19, DOI 10.1016/j.vetimm.2018.09.001; Yamashita M, 2014, IMMUNOBIOLOGY, V219, P149, DOI 10.1016/j.imbio.2013.08.011; Yang H, 2019, FISH SHELLFISH IMMUN, V86, P882, DOI 10.1016/j.fsi.2018.12.022; Yang M, 2007, FISH SHELLFISH IMMUN, V23, P1060, DOI 10.1016/j.fsi.2007.04.011; Ye T, 2015, FISH SHELLFISH IMMUN, V42, P138, DOI 10.1016/j.fsi.2014.10.039; Zhang J, 2014, FISH SHELLFISH IMMUN, V38, P127, DOI 10.1016/j.fsi.2014.03.011; Zhang ZB, 2011, FISH SHELLFISH IMMUN, V31, P1, DOI 10.1016/j.fsi.2010.12.019; Zheng WJ, 2010, COMP BIOCHEM PHYS B, V156, P222, DOI 10.1016/j.cbpb.2010.03.012; Zheng WJ, 2010, FISH SHELLFISH IMMUN, V28, P829, DOI 10.1016/j.fsi.2010.01.013	68	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							361	10.3390/vaccines9040361			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4PI		gold, Green Published			2022-04-29	WOS:000643762600001
J	Asare, M; Popelsky, B; Akowuah, E; Lanning, BA; Montealegre, JR				Asare, Matthew; Popelsky, Braden; Akowuah, Emmanuel; Lanning, Beth A.; Montealegre, Jane R.			Internal and External Validity of Social Media and Mobile Technology-Driven HPV Vaccination Interventions: Systematic Review Using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) Framework	VACCINES			English	Review						HPV; HPV vaccine; social media; mobile phone; HPV vaccine intervention; RE-AIM Framework	PHYSICAL-ACTIVITY INTERVENTIONS; BEHAVIOR-CHANGE RESEARCH; RANDOMIZED INTERVENTION; OBESITY PREVENTION; IMPROVE TRANSLATION; UNITED-STATES; IMPACT; ADOLESCENTS; COMPLETION; INTENTION	Social media human papillomavirus (HPV) vaccination interventions show promise for increasing HPV vaccination rates. An important consideration for the implementation of effective interventions into real-world practice is the translation potential, or external validity, of the intervention. To this end, we conducted a systematic literature review to describe the current body of evidence regarding the external validity of social media HPV vaccination-related interventions. Constructs related to external validity were based on the reach, effectiveness, adoption, implementation, maintenance (RE-AIM) framework. Seventeen articles published between 2006 and 2020 met the inclusion criteria. Three researchers independently coded each article using a validated RE-AIM framework. Discrepant codes were discussed with a fourth reviewer to gain consensus. Of these 17 studies, 3 were pilot efficacy studies, 10 were randomized controlled trials (RCTs) to evaluate effectiveness, 1 was a population-based study, and 3 did not explicitly state which type of study was conducted. Reflecting this distribution of study types, across all studies the mean level of reporting RE-AIM dimensions varied with reach recording 90.8%, effectiveness (72.1%), adoption (40.3%), implementation (45.6%), and maintenance (26.5%). This review suggests that while the current HPV vaccination social media-driven interventions provide sufficient information on internal validity (reach and effectiveness), few have aimed to gather data on external validity needed to translate the interventions into real world implementation. Our data suggest that implementation research is needed to move HPV vaccination-related interventions into practice. Included in this review are recommendations for enhancing the design and reporting of these HPV vaccination social media-related interventions.	[Asare, Matthew; Popelsky, Braden; Akowuah, Emmanuel; Lanning, Beth A.] Baylor Univ, Dept Publ Hlth, Waco, TX 76708 USA; [Montealegre, Jane R.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA		Asare, M (通讯作者)，Baylor Univ, Dept Publ Hlth, Waco, TX 76708 USA.	matt_asare@baylor.edu; braden_popelsky@baylor.edu; emmanuel_akowuah@baylor.edu; Beth_Lanning@baylor.edu; jrmontea@bcm.edu	; Lanning, Beth/E-3673-2013	Asare, Matthew/0000-0002-6831-3586; Lanning, Beth/0000-0002-2505-4799			Akers JD, 2010, J AM DIET ASSOC, V110, P1511, DOI 10.1016/j.jada.2010.07.005; Allen K, 2011, J HEALTH COMMUN, V16, P55, DOI 10.1080/10810730.2011.604381; Barden C, 2021, INT J SPORTS MED, V42, P112, DOI 10.1055/a-1212-0649; Bastos PD, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155558; Brazil K, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-1; Bull SS, 2003, HEALTH EDUC BEHAV, V30, P537, DOI 10.1177/1090198103254340; Chao C, 2015, J ADOLESCENT HEALTH, V56, P85, DOI 10.1016/j.jadohealth.2014.08.014; Chodick G, 2021, GYNECOL ONCOL, V160, P106, DOI 10.1016/j.ygyno.2020.10.037; Craike M, 2017, BJOG-INT J OBSTET GY, V124, P573, DOI 10.1111/1471-0528.14276; Dempsey AF, 2006, PEDIATRICS, V117, P1486, DOI 10.1542/peds.2005-1381; Deshmukh AA, 2020, JNCI-J NATL CANCER I, V112, P829, DOI 10.1093/jnci/djz219; Dixon BE, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1457; Duggan Maeve, 2015, PARENTS SOCIAL MEDIA, V16; Dumville JC, 2006, BMJ-BRIT MED J, V332, P969, DOI 10.1136/bmj.332.7547.969; Dzewaltowski DA, 2004, HEALTH PROMOT INT, V19, P235, DOI 10.1093/heapro/dah211; Dzewaltowski DA, 2004, EXERC SPORT SCI REV, V32, P57, DOI 10.1097/00003677-200404000-00004; Economos CD, 2019, PREV MED, V119, P37, DOI 10.1016/j.ypmed.2018.12.007; Elam-Evans LD, 2020, MMWR-MORBID MORTAL W, V69, P1109, DOI 10.15585/mmwr.mm6933a1; Ellington TD, 2020, MMWR-MORBID MORTAL W, V69, P433, DOI 10.15585/mmwr.mm6915a1; Estabrooks P, 2003, J SCHOOL HEALTH, V73, P21, DOI 10.1111/j.1746-1561.2003.tb06554.x; Fishman J, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-2048; Fontenot HB, 2020, J MED INTERNET RES, V22, DOI 10.2196/22878; Francis DB, 2017, PATIENT EDUC COUNS, V100, P1280, DOI 10.1016/j.pec.2017.02.004; Friedman L.M., 2015, FUNDAMENTALS CLIN TR, V5th ed.; Gaglio B, 2013, AM J PUBLIC HEALTH, V103, pE38, DOI 10.2105/AJPH.2013.301299; Gerend MA, 2021, ANN BEHAV MED, V55, P321, DOI 10.1093/abm/kaaa056; Gerend MA, 2020, VACCINE, V38, P725, DOI 10.1016/j.vaccine.2019.11.028; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Glasgow RE, 2004, ANN BEHAV MED, V27, P3, DOI 10.1207/s15324796abm2701_2; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752; Isaacs SA, 2018, CHILD FAM SOC WORK, V23, P122, DOI 10.1111/cfs.12380; Iwelunmor Juliet, 2020, Implement Sci Commun, V1, P53, DOI 10.1186/s43058-020-00042-4; Kang HS, 2018, J PEDIATR NURS, V39, P7, DOI 10.1016/j.pedn.2017.12.003; Kempe A, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2857; Kim M, 2020, HEALTH EDUC BEHAV, V47, P258, DOI 10.1177/1090198119894589; Klesges LM, 2008, AM J PREV MED, V34, P216, DOI 10.1016/j.amepre.2007.11.019; Lee HY, 2016, AM J HEALTH BEHAV, V40, P67, DOI 10.5993/AJHB.40.1.8; Leung SOA, 2019, VACCINE-X, V3, DOI 10.1016/j.jvacx.2019.100037; Lipsey M., 1990, CANCER CAUSE CONTROL, V1, P196; Matheson EC, 2014, J PEDIATR HEALTH CAR, V28, pE35, DOI 10.1016/j.pedhc.2013.09.001; Mccoy CE, 2017, WEST J EMERG MED, V18, P1075, DOI 10.5811/westjem.2017.8.35985; McGoey T, 2016, PREV MED, V82, P8, DOI 10.1016/j.ypmed.2015.11.004; Mohanty S, 2018, VACCINE, V36, P5955, DOI 10.1016/j.vaccine.2018.08.060; Ortiz Rebecca R, 2018, Glob Pediatr Health, V5, p2333794X18777918, DOI 10.1177/2333794X18777918; Palmer J, 2015, J VAC, P2015, DOI DOI 10.1155/2015/869468; Patel A, 2014, VACCINE, V32, P2428, DOI 10.1016/j.vaccine.2014.02.095; Peterson CE, 2016, TRANSL BEHAV MED, V6, P672, DOI 10.1007/s13142-016-0441-5; Piedimonte S, 2018, J OBSTET GYNAECOL CA, V40, P440, DOI 10.1016/j.jogc.2017.07.028; Rand CM, 2017, J ADOLESCENT HEALTH, V60, P113, DOI 10.1016/j.jadohealth.2016.09.011; Rand CM, 2015, J ADOLESCENT HEALTH, V56, pS17, DOI 10.1016/j.jadohealth.2014.10.273; Richman AR, 2019, J HEALTH CARE POOR U, V30, P1499, DOI 10.1353/hpu.2019.0090; Richman AR, 2016, J AM COLL HEALTH, V64, P269, DOI 10.1080/07448481.2015.1117466; Rodriguez SA, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00164; Sanchez-Flack JC, 2020, TRANSL BEHAV MED, V10, P1168, DOI 10.1093/tbm/ibz179; Schlechter CR, 2016, PREV MED, V91, P233, DOI 10.1016/j.ypmed.2016.08.030; Shanks CB, 2016, AM J HEALTH PROMOT, V30, P511, DOI 10.4278/ajhp.140116-QUAL-28; Steckler A, 2008, AM J PUBLIC HEALTH, V98, P9, DOI 10.2105/AJPH.2007.126847; Tull F, 2019, J ADOLESCENT HEALTH, V65, P116, DOI 10.1016/j.jadohealth.2018.12.026; U.S. Food and Drug Administration, FDA APPROVES EXPANDE; Watts LA, 2009, GYNECOL ONCOL, V112, P577, DOI 10.1016/j.ygyno.2008.12.010; Weiss C., 1998, EVALUATION METHODS S; White SM, 2009, ANN BEHAV MED, V37, P10, DOI 10.1007/s12160-009-9084-9; Wilson AR, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0323-5; World Health Organization, CERV CANC; Yoshida Y, 2020, J AM MED INFORM ASSN, V27, P946, DOI 10.1093/jamia/ocaa041	66	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							197	10.3390/vaccines9030197			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE5VR	33652809	Green Submitted, Green Published, gold			2022-04-29	WOS:000634221900001
